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Personalizing therapy of lung cancer: a paradigm 
shift from empiric to integrated decision-making
Gandara, David R.
UC Davis Cancer Center, Sacramento, CA, USA
Current practice for selection of therapy in patients with advanced 
stage NSCLC, and many other tumor types as well, is largely 
empiric. However, new basic and clinical research findings in non-
small cell lung cancer (NSCLC) are revolutionizing both biologic 
concepts about this malignancy and our clinical practice patterns. In 
general, each time a treating Oncologist selects therapy, four differ-
ent dimensions (see figure) are considered in the decision-making 
process: 1) evidence from the literature [i.e. therapeutic ratio of 
different regimens], 2) individual patient characteristics [i.e. age, 
gender, performance status, smoking status], 3) patient preference 
[i.e. desire for longer life versus quality of life], and 4) physician 
experience and preference. While this empiric process serves most 
patients well, in 2009 a paradigm shift has begun in which decision-
making is beginning to move from “empiric” to what can be called an 
“integrated” approach. As summarized in the table below, a variety of 
emerging selection factors now make it possible to consider custom-
izing therapy in individual NSCLC patients by integrating clinical, 
histologic and molecular factors. Since possible selection factors 
now list in the hundreds, only representative examples for which data 
appear most robust are listed in the table. 
Figure. Empiric Approach to Selection of Therapy for NSCLC
Category Drug Class Factor
Clinical EGFR TKIs Female, Never-smoker, Asian
 Bevacizumab No Hemoptysis or brain metastasis, age < 70 years (?)
Tumor Histology EGFR TKIs Adenocarcinoma
 Bevacizumab No SCCA due to risk of hemoptysis
 Pemetrexed Non-SCCA
Molecular Pemetrexed Thymidylate Synthase
 Platinums ERCC1/RRM1
 Gemcitabine RRM1
 EGFR TKIs (+) EGFR Mutation and FISH
 Cetuximab EGFR IHC; EGFR FISH (?)
 Anti-Angiogenic Undetermined
SCCA: Squamous cell
First and foremost, previous studies have documented that clinical 
factors such as female gender, never-smoking status and east-Asian 
ethnicity are associated with response to epidermal growth factor 
receptor (EGFR) tyrosine kinase inhibitors (TKIs). Despite this clear 
association, the recently reported IPASS trial, performed entirely in 
east-Asian adenocarcinoma patients, 94% never smoking and about 
80% female, strikingly demonstrates that a molecular selection factor 
(EGFR TK domain mutation) “trumps” clinical features in predict-
ing benefit from the EGFR TKI gefitinib. (1) In this study, in which 
East-Asian patients with advanced NSCLC were randomized to 
gefitinib or chemotherapy, response and progression-free survival 
were highly associated with EGFR mutation status. Those patients 
with tumors harboring EGFR TK domain mutations did much bet-
ter with gefitinib, while those with wild type EGFR tumors fared 
better with chemotherapy, despite near uniformity in clinical factors 
which would have suggested superior outcomes with gefitinib. Since 
approximately 85% of North American NSCLC tumors are wild type 
for EGFR, this finding has significant implications for individual-
izing therapy. As discussed further below, other molecular factors 
(e.g. KRAS mutation, EGFR gene copy number by fluorescence in 
situ hybridization [FISH], have also recently been reported to have 
predictive value in selection of EGFR-directed therapies. 
Additional clinical factors are now being utilized in day-to-day prac-
tice to select patients for various treatment approaches. For example, 
while chemotherapy plus bevacizumab is generally accepted in North 
America as a standard of care for advanced NSCLC, bevacizumab-
containing regimens are contraindicated in patients with NSCLC of 
the squamous cell subtype (SCCA), due to an increased risk of induc-
ing life-threatening hemoptysis. (2) Recent data from the E4599 trial 
also suggested reduced benefit and more toxicity in patients older 
than age 70, approximating 50% of all NSCLC patients in the USA. 
(3)
Regarding tumor histology, research findings confirm that NSCLC 
represents a heterogeneous group of malignancies, linked primar-
ily by site of origin. From the standpoint of pathologic subtyping, 
NSCLC can be differentiated into adenocarcinoma (which can be 
further sub-classified) squamous cell carcinoma, large cell carcinoma 
(neuroendocrine and non-neuroendocrine) and a variable group 
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classified by pathologists as non-otherwise specified (NOS). While 
adenocarcinoma histology is known to correlate with a higher likeli-
hood of response to EGFR TKIs, this association does not necessar-
ily translate into superior survival. For example, in the BR.21 trial 
testing the EGFR TKI erlotinib, the hazard ratios for survival were 
virtually identical for adenocarcinomas versus squamous cell histol-
ogy. (4) For the first time in recent history, randomized clinical trials 
in NSCLC now suggest that histologic subtyping can also be used 
as a chemotherapy selection factor. (5) In the randomized trial of 
Scagliotti et al, comparing pemetrexed-cisplatin versus gemcitabine-
cisplatin, survival was superior in those patients with non-squamous 
histology receiving the pemetrexed-based regimen. Conversely, 
gemcitabine-cisplatin resulted in superior survival in patients with 
squamous histology tumors. These data, combined with retrospective 
analyses of other pemetrexed trials in NSCLC, suggest that histo-
logic subtype can now be used to select individual patients who may 
benefit more or less from different chemotherapy regimens. From a 
practical standpoint, these findings have led the FDA to limit pem-
etrexed therapy to NSCLC patients with non-squamous histology. 
Although this regulatory direction seems reasonable in the short run, 
it is quite likely that underlying molecular factors are responsible 
for these findings. In fact, recent data suggest that to histology is at 
best a crude method of molecular selection, and that tumor molecu-
lar profiling will supplant histology in the near future for selecting 
chemotherapy in individual NSCLC patients. For example, for pem-
etrexed a number of possible predictive molecular biomarkers have 
been described. The largest body of evidence relates to thymidylate 
synthase (TS), an enzyme important in DNA biosynthesis and a 
molecular target of fluropyrimidine- and pemetrexed-based therapies. 
(6) Lower TS expression levels have been associated with a greater 
likelihood of response to fluoruracil (5FU)-containing therapies in 
gastrointestinal cancers, and to pemetrexed in NSCLC and breast 
cancer. (7) Although TS mRNA expression is statistically lower 
in groups of patients with NSCLC of adenocarcionoma or large 
cell subtypes, compared with those of squamous histology, there 
is tremendous overlap of expression ranges in individual patient 
tumors. Conversely, it should be also noted that pemetrexed shows 
limited activity in small cell lung cancer, a histiology associated with 
characteristically high levels of TS expression. (8,9) Thus, assuming 
the validity of TS expression as a predictive factor for pemetrexed 
benefit, there is rationale for TS testing in individual patients as the 
basis for selection of chemotherapy. In view of these data, a pharma-
cogenomic-driven adjuvant phase III study (ITACA trial) in stage II 
and IIIA NSCLC which selects chemotherapy on the basis of TS and 
ERCC1 RT-PCR expression is currently ongoing in Europe.
Similarly, sufficient data now exist to consider ERCC1 and RRM1 
as possible molecular selection factors for platinum compounds and 
gemcitabine, respectively. (10-13) Although a variety of different 
methodologies have been employed to measure protein or mRNA 
expression of these genes, cross-study results are consistent in 
demonstrating both prognostic and predictive value. A number of 
clinical trials are in progress worldwide attempting to validate these 
biomarkers. While the issue of how to integrate these data into clini-
cal decision-making outside of a clinical trial remains “in flux”, the 
presence of commercially available assays demands that Oncologists 
be up-to-date on relevant literature and ready to answer patient ques-
tions about use in day-to-day practice.
Perhaps more relevant in 2009 is KRAS mutation as a molecular pre-
dictor of reduced efficacy of EGFR TKIs. (14-15) KRAS mutation 
is typically associated with a positive smoking history in NSCLC. 
As might be expected, finding both KRAS and EGFR activating 
mutations in the same NSCLC specimen is rare. KRAS mutation 
status has recently come to light as an important negative predic-
tor for benefit of cetuximab-containing therapy in colorectal cancer. 
(16) In contrast, preliminary reports suggest that KRAS mutation 
does not adversely affect the efficacy of cetuximab-based therapy 
in advanced NSCLC. (17,18) EGFR gene copy number by FISH 
has been reported to predict favorable outcome from both EGFR 
TKI and cetuximab-containing therapies in patients with advanced 
NSCLC (19, 20), and is the subject of phase III biomarker validation 
trials for erlotinib (N0723) and cetuximab-based therapy (S0819). 
Lastly, molecular selection factors for anti-angiogenic therapies are 
undetermined at present, but are the subject of numerous clinical 
research studies.
Will the paradigm shift discussed here toward integrated decision-
making occur within the foreseeable future, and if so, when will the 
transition be complete? Some would say it is already in process, 
with the finding that EGFR TKD mutation is highly predictive of 
benefit from EGFR TKIs, independent of clinical factors. It is worth 
recalling that in decision-making for therapy of breast cancer, HER2 
testing transitioned into clinical practice in a rapid fashion, driven 
by the availability of a new targeted therapy, trastuzumab. We have 
similar targeted therapies in NSCLC. Shouldn’t we be using them in 
a targeted fashion, rather than continuing empiric patient selection. 
Further, we are now realizing that even chemotherapy is “targeted 
therapy”, and the tools to begin appropriately targeting it are now 
available. In Summary, integrated decision-making, incorporating 
clinical, histologic and molecular factors is now feasible. The next 
few years will determine the pace of transition from empiricism (21). 
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Biomarker development: muddy waters
Pass, Harvey I.
NYU Langone Medical Center, New York, NY, USA
The ideal biomarker would be one that requires minimal invasion of 
the patient and has a high sensitivity and specificity for the job it is 
supposed to do. These jobs can be either trying to classify whether 
one has a lung cancer or some other disease; whether the biomarker 
is going to prognosticate whether you have a lung cancer that is more 
agressive than other types of lung cancers; or whether the biomarker 
can predict whether you are going to respond to a given treatment. 
The holy grail for such a biomarker would be to be able to find it 
reproducibly from a minimal amount of fluid: either blood, urine, 
sputum, pleural effusion or ascites. In the literature, there are a lot 
of papers (over 2000) that deal with this subject using a multitude of 
technologies for discovery. Unfortunately 99.9% of the papers have 
no formal validation of the biomarker(s) that were presented. The 
Early Detection Research Network has outlined specific methodolo-
gies for the discovery and validation of biomarkers, and this involves 
four distinct phases, including prospective validation as the final test. 
This lecture will deal with the difficulties in producing robust, fluid 
based biomarkers for lung cancer, and will cover the known literature 
as well as novel platforms in development. Biomarkers of historical 
interest including CEA and the cytokeratins, as well as a potpouri 
of ELISA markers which are awaiting validation will be discussed. 
Newer technologies including the analysis of circulating tumor cells, 
carrying out mutation specific PCR on circulating DNA, probing 
for methylated species of DNA in the serum, as well as proteomic 
approaches and the newer autoantibody technologies will be covered. 
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Personalized therapy: emerging methodologies
Hirsch, Fred R.
University of Colorado Denver, Denver, CO, USA
Personalized therapy has arrived to lung cancer! 
Within the last years we have learned that histology is important for 
treatment decisions, either for efficacy (i.e. pemetrexed) or toxic-
ity (i.e. bevacizumab). Most recently we also learned that EGFR 
mutation analysis is critical for treatment choice of 1st line therapy 
(EGFR TKI versus chemotherapy + targeted therapy). Gene copy 
number might be important for EGFR-directed therapy or new 
targeted therapies (i.e. ALK/EML4 inhibition). Protein expression for 
several markers has also been associated with therapy response and 
outcome. However, the current challenges are to identify the most 
optimal assays and determine how best to integrate newer techni-
cal developments while “old” methodologies undergo validation 
processes.
1. Mutation analyses: Tissue-based DNA sequencing remains 
the most commonly used technique, and should be coupled with 
pathology-guided microdissection. However, within the last few 
years, more sensitive PCR-based methodologies have emerged (i.e. 
high resolution melt curve analysis; Scorpion-ARMS using the DXS 
system) and multigene high- throughput approaches such as the 
Sequenom technique (Thomas et al, 2007, Gabriel et al, 2009). Large 
scale sequencing as done in the Tumor Sequencing Project (TSP) for 
lung adenocarcinomas by integrating different methods has given 
important information in the search for personalized therapy (Ding 
et al, 2008). Mutation-specific antibodies for immunohistochemis-
try have recently been developed (i.e. EGFR antibodies) with very 
encouraging results for eventual patient screening (Yu et al, 2009).
Mutation analysis from peripheral blood-based platforms is rapidly 
evolving. Several approaches have been taken, either by using tumor 
DNA shed into patient plasma (Bai et al. 2009) or by isolating cir-
culating tumor cells (Maheswaran et al 2008). The latter technology, 
based on a novel microfluidic platform for isolating the circulating 
tumor cells, seems to be very encouraging. While some of these 
technologies have already undergone extensive evaluation and are in 
clinical practice at limited institutions, others require further clinical 
validation before they are ready for routine use for patient treatment 
assignment.
2. Gene copy number: Based on experience with HER2 in breast 
cancer, the FISH technology has been the most prevalent method, 
and has shown promising predictive results for lung cancer in 
retrospective- and prospective studies, particularly related to EGFR 
inhibitors,. However, new technologies have emerged, among them 
the non-fluorescence Silver in situ Hybridization (SISH) technique 
(Ventana, Tucson AZ.US), assessable in bright-light microscopy with 
preservation of the cell morphology. Thus, the specimens are stable 
and can be revisited for years. The technology has been introduced 
for HER2 determination in breast cancer, but clinical validation for 
other markers (i.e IGF-1R) in lung cancer has just been initiated 
(Wynes et al. 2009). More genome wide copy number assessment by 
SNP chip analysis will likely in the future be of significant value in 
identifying relevant targets and planning of therapy for the individual 
patient (Weir et al, 2007).
3. Immunohistochemistry (IHC): IHC has traditionally been used 
for many years, but for most of the markers, no objective standard-
ized assessment methods have been established. This might contrib-
ute to the fact that the methodology has not been given much credit 
for predictive performance. However, new platforms have been 
developed for more objective, automated staining and interpretation. 
Among these is the AQUA-system, which generates a quantitative, 
objective score for protein expression, and can differentiate cellular 
compartmental (i.e. cytoplasmic versus nuclear). The system has 
undergone extensive evaluation and validation in lung cancer for 
ERCC1 (platinum-based chemotherapy) and for RRM1 (gemcit-
abine) and its utility for patient assignment is currently being tested 
in a Southwest Oncology Group trial. Studies are undergoing for 
validation of EGFR expression and other proteins related to targeted 
therapies in lung cancer.
4. Proteomics: While tissue based assays have several limitations for 
clinical use, i.e. tissue availability, tumor heterogeneity etc, serum/
plasma based platforms have emerged for more optimal clinical 
applicability. For prediction of outcome to EGFR TKIs a serum/
plasma proteomic classifier was developed and later commercial-
ized as the Veristrat® (Biodesix, Broomfield, CO. USA) ( Taguchi 
2007). This technology has later been found to predict sensitivity to 
other EGFR inhibitors and in also other types of cancer (Chung et al. 
2009). Clinical validation in prospective studies is ongoing.
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Genomic strategies for personalized cancer therapy
Nevins, Joseph R.1, 2
1 Duke Institute for Genome Sciences & Policy, Durham, NC, USA;  
2 Duke University Medical Center, Durham, NC, USA
The ability to tailor cancer therapy to characteristics of the individual 
patient is key in achieving a successful outcome. We have made use 
of genomic data to develop predictors that assess risk and sensitivity 
to potential therapeutic options. The current standard of care for the 
majority of Stage 1 patients is surgery and observation. Nevertheless, 
a substantial fraction of these patients will have a disease recurrence 
suggesting the need to identify individuals in this subgroup for more 
effective therapy. We developed gene expression profiles that could 
predict risk of recurrence, performing significantly better than previ-
ously described clinical prognostic factors. Importantly, we show that 
this provides an opportunity to re-classify Stage 1 patients to identify 
a subset of higher risk patients that might be appropriate for adjuvant 
chemotherapy. This can be coupled with gene expression signatures 
that have the capacity to predict sensitivity to cytotoxic chemothera-
peutics, including those used in the treatment of lung cancer, to guide 
the most effective chemotherapy for these patients. This concept 
is being tested in further prospective trials. Finally, the capacity 
to direct the use of new investigational drugs, particularly those 
that target oncogenic signaling activities, is critical to allow more 
efficient use of these agents and to develop strategies for rational 
combinational therapy. We have made use of expression signatures 
that predict pathway deregulation in cancer cell lines as a basis to 
guide the use of therapeutic agents that target components of the 
pathway. This approach, when combined with the capacity to predict 
chemotherapy use, has the potential to identify therapeutic strategies 
that make use of all available drugs, matched to the characteristics of 
the individual patient and thus an approach towards the development 
of personalized treatment options for the individual patient
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Personalized therapy: pharmacogenomic approaches
Scagliotti, Giorgio
University of Turin, S. Luigi Hospital, Orbassano, Italy
In 2009 lung cancer continues to be the leading cause of cancer death 
among both men and women being the death toll from lung cancer 
higher than from colon, breast, and prostate cancers combined, with 
an expected one third of all deaths from malignancy attributable to 
lung cancer (1). Non-Small Cell Lung Cancer (NSCLC) represents 
approximately 80% of all lung cancers. 
Although the use of chemotherapy impacts on survival of almost 
every stage of NSCLC, the survival improvement is still modest and 
despite advances in multimodality approach the five-year survival 
rate for NSCLC across all stages remains around 15%. 
Randomised trials performed in good performance status patients 
with advanced NSCLC have confirmed survival and quality of life 
benefits with platinum-based doublets chemotherapy (2-5) with 
overall response rates are ranging 25-30%, median survival times 
between 9-12 months and one-year survival rates between 30 and 
40%. 
There is evidence that therapeutic plateau benefit has been reached 
using cytotoxic chemotherapy, and it appears unlikely that simply 
replacing with new cytotoxic agents into combinations with platinum 
compounds will lead to significant advances in outcome. 
Although the average benefit of cytotoxic chemotherapy is generally 
modest, survival can vary significantly, from weeks to years, among 
individual patients. These considerable differences in survival and 
differences in response to treatment have led researchers to investi-
gate biomarkers that may identify factors that predict response and 
survival to chemotherapy. Therefore, predictive factors for response 
to anticancer therapies could be used prospectively to identify 
subgroups of patients that can achieve a response when treated with 
either standard chemotherapy regimens or targeted therapies. Unfor-
tunately, most of the genetic predictive factors already identified 
are at the same time prognostic indicators, indicating that they are 
providing information regardless of which treatment is used. Clinical 
studies designed to test the impact of a treatment when driven by 
tumor genetic profile represent the next step of integration of clinical 
and basic research. 
DNA is one of the key targets for cancer chemotherapy and although 
cellular resistance is multifactorial it is well known that chemosensi-
tivity is individually predetermined, and the upregulation of mRNA 
transcripts has been linked to differential response to cytotoxic drugs.
The potential role of molecular markers such as the DNA repair 
genes ERCC1 (excision repair cross complementing 1), RRM1 (the 
regulatory subunit of ribonucleotide reductase) and BRCA1 (breast 
cancer 1) as well the oligonucleotide-based gene expression profiles 
as predictor of response to chemotherapy in NSCLC has been 
already investigated. Several retrospective studies already suggested 
the possibility to use these molecular markers to tailor therapy for 
individual patients but the differences in the methods for the evalu-
ation of gene versus protein expression (RT-PCR versus protein 
expression through immunohistochemistry), the use of snap-frozen 
versus formalin-fixed tissues as well as of different house-keeping 
genes do not allow cross-comparison of the results from one study 
to another. Standardization represents a mandatory priority to make 
pharmacogenomic approaches ready for prime-time. 
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ERCC1 is a component of the nucleotide excision repair pathway 
(NER), responsible for removing platinum-induced DNA adducts (6), 
as those generated by the interaction of cisplatin with cellular DNA.
In patients with advanced NSCLC treated with cisplatin and gem-
citabine median overall survival was significantly longer in patients 
with low ERCC1 level expression, as evaluated by real time RT-
PCR, compared to patients with high ERCC1 expression (15 months 
versus 5 months) (7). 
A phase III trial of customized cisplatin according to ERCC1 mRNA 
levels in stage IV NSCLC was carried out. Patients in the control 
arm received cisplatin plus docetaxel, while in the genotypic arm, 
patients with low ERCC1 levels received cisplatin plus docetaxel 
and those with high levels received gemcitabine plus docetaxel 
(8). Although objective response was higher in the genotypic arm 
than in the control arm (50.7% vs 39.3%), this did not translate to 
improved survival. In a retrospective analysis of a phase III study in 
advanced NSSLC conducted by British Thoracic Oncology Group, 
66 formalin-fixed paraffin embedded tumor samples were analyzed 
by real-time RT-PCR and no association was found. between ERCC1 
levels and survival in patients treated with docetaxel plus carboplatin 
(9). 
A large cohort large of tumors (n=761) from a phase III cisplatin-
based adjuvant study was retrospectively assessed for tumoral 
ERCC1 protein expression and patients were dichotomized into 
highand low ERCC1 expressors by using the median level as the 
cut-off (10). Positive ERCC1 expression was correlated with better 
prognosis in the control group of patients, who did not received adju-
vant chemotherapy indicating that an intact DNA repair mechanism 
may reduce the accumulation of genetic aberrations contributing to 
malignant potential of cells. In patients treated with cisplatin-based 
chemotherapy, an inverse correlation was identified. Therefore 
NSCLC patients with completely resected ERCC1-negative tumors 
seem to be better candidates for adjuvant cisplatin-based chemother-
apy than those with resected ERCC1-positive tumors.
Based on these results a phase II randomised clinical study in the 
adjuvant setting for patients with completely resected non-squamous 
NSCLC, stage II-IIIA is currently ongoing in France. Patients in 
the control arm will receive cisplatin-pemetrexed while those in the 
experimental arm will be screened for EGFR mutation and, if posi-
tive treated with erlotinib. All the patients with EGFR gene wild-type 
will be allocated to the adjuvant treatment according to ERCC1 
protein expression : if high will receive observation only, if low 
cisplatin-pemetrexed (TASTE trial).
Another enzyme involved in the DNA synthesis and repair is ribonu-
cleotide reductase, which catalyzes the biosynthesis of deoxyribonu-
cleotides from corresponding ribonucleotides (11). It is the molecular 
target of gemcitabine and in NSCLC patients the loss of one copy of 
RRM1 gene ,the regulatory subunit of ribonucleotide reductase, was 
associated with reduced survival. (12) 
Lower expression of RRM1 predicted longer survival in gemcitabi-
ne-treated NSCLC patients (13). Moreover, low levels of RRM1 
improved the prognosis in NSCLC, especially if coupled with low 
ERCC1 levels (14). 
In a retrospective study formalin-fixed paraffin-embedded (FFPE) 
bronchoscopic/fine needle aspiration biopsies obtained from 70 
patients with advanced NSCLC were retrospectively collected to 
investigate the expression level of ERCC1, RRM1 and EGFR by 
real-time PCR. Sufficient amounts of mRNA were successfully 
extracted from 61 (87%) specimens, reverse transcribed and ampli-
fied with intron-spanning primers. Forty-one patients had stage 
IV disease and 43 received cisplatin/gemcitabine chemotherapy. 
A strong correlation between ERCC1 and RRM1 mRNA levels 
(rs=0.624, p<0.0001) was found. Median survival time in patients 
with low ERCC1 significantly longer (17.3 vs. 10.9 months, 
p=0.0032 ) as well as in patients with low RRM1 (13.9 vs. 10.9 
months, p=0.04). Concomitant low expression levels of ERCC1 and 
RRM1 (n=33) were predictive of a better outcome (14.9 vs. 10.0 
months, p=0.0345 log-rank test). Among cisplatin-treated patients, 
a low ERCC1 level was highly predictive of a longer survival (23.0 
vs. 12.4 months, p=0.0001). No correlation between gene expression 
levels and histology was reported. At multivariate analysis perfor-
mance status, response to chemotherapy, presence of weight loss and 
ERCC1 were independent prognostic factors for survival. (15)
A phase II trial suggested that therapeutic decision-making based 
on RRM1 and ERCC1 gene expression is a promising strategy to 
improve outcome (16). Overall response rate was 44%, 1 year-sur-
vival was 59%, and median survival was 13 months. 
Currently a proof of concept study from Southwestern Oncology 
Group (SWOG) is looking at completely resected patients with stage 
I NSCLC and assessing in resected tumoral samples ERCC1 and 
RRM1 through quantitative IHC. Patients with high levels of both 
RRM1 and ERCC1 genes will be monitored with observation only 
while those with low RRM1 and/or low ERCC1 levels will receive 
cisplatin-based chemotherapy. 
Another hypothesis to be tested is whether ERCC1 expression could 
be up-regulated in vivo upon platinum-based therapy. Monitoring 
of ERCC1 levels during chemotherapy to separate early responders 
from non-responders could be a new approach, as well as the devel-
opment of inhibitors of ERCC1 (17). 
BRCA1 is another component of multiple DNA repair pathways 
and functions as a differential regulator of chemotherapy-induced 
apoptosis. BRCA1 abrogates the apoptotic phenotype induced by a 
range of DNA-damaging agents, including cisplatin and etoposide, 
while inducing dramatic responses to a range of antimicrotubule 
agents, including paclitaxel and vinorelbine (18). A low expression 
of BRCA1 mRNA closely correlates with ERCC1 mRNA expression 
and predicts a more favorable outcome in locally advanced NSCLC 
patients treated with cisplatin and gemcitabine followed by surgery. 
It was recently found that low levels of BRCA1 are associated 
with longer survival in completely resected NSCLC patients, while 
patients with high tumoral BRCA1 expression had a shorter survival 
(19). Since BRCA1 mRNA expression has been previously linked 
to differential sensitivity to cisplatin and antimicrotubule drugs, 
BRCA1 mRNA expression may provide additional information for 
customizing adjuvant antimicrotubule-based chemotherapy. This 
hypothesis has been already tested in a phase II adjuvant study in 
completely resected NSCLC (20) and a phase III study is underway.
Recent data seem to make possible to choose cytotoxic drugs based 
on clinico-pathological parameters rather than on more complicated 
biological parameters that are not easily accessible to all oncology 
units. The bulk of available data from large randomized trials failed 
so far to show a prognostic role for different histologic types of 
NSCLC. However, differences in biological behaviour and response 
to anticancer therapies are now emerging between squamous cell 
carcinomas and adenocarcinomas or non-squamous carcinomas of 
the lung and the superior efficacy of pemetrexed in non-squamous 
histology has been consistently reported (21).
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In surgically resected NSCLC thymidylate synthase (TS), the main 
target of pemetrexed, is over-expressed at a higher level in squamous 
cell carcinomas than in adenocarcinomas (22). Therefore, differ-
ential expression of TS could be a factor to modulate sensitivity to 
pemetrexed. In fact, over-expression of TS correlates with reduced 
sensitivity to pemetrexed in antifolate-resistant cell lines. In a 
preclinical study low levels of TS, dihydrofolate reductase (DHFR), 
glycinamide ribonucleotide formyl transferase (GARFT) and mrp4 
gene expression significantly correlated with chemosensitivity to 
pemetrexed (23). These data provide a molecular background for 
the improved efficacy for pemetrexed among patients with non-
squamous histology.
The above mentioned findings supporting the preferential activ-
ity of pemetrexed in NSCLC with non-squamous histology are 
strongly hypotheses-generating, but they require a robust prospective 
validation.
Expression of ERCC1, a putative marker of sensitivity to cisplatin, 
and TS will be determined using real time RT-PCR on paraffin-
embedded tumor specimens in completely resected stage II and IIIA 
NSCLC and then patients randomized to receive standard adjuvant 
chemotherapy (control arm) selected according to the investiga-
tor choice (cisplatin/vinorelbine, cisplatin/docetaxel or cisplatin/
gemcitabine) or an experimental treatment (tailored chemotherapy 
arm). The primary end point of study is the assessment of the overall 
survival. 
Gene microarrays allow to analyze thousands of genes at a time, all 
on a single glass slide and to find gene expression patterns of specific 
tumor types, to categorize unique characteristics of a particular tumor 
and to tailor treatments on an individual basis. On the other side such 
studies produce an amount of data that could easily be misinterpreted 
and difficult to replicate. Laser capture microdissection and RNA 
preserving solutions are among modern techniques to overcome 
standardization problems. One major drawback is arrays measure 
only messenger RNA levels and results do not always correlate with 
protein expression levels as well as they cannot show post-transla-
tional changes of proteins. 
Gene expression profiling and correlation with clinical outcome have 
been extensively studied in NSCLC (24-29).
Genomic signatures of cisplatin and pemetrexed sensitivity were 
shown to predict in vitro response to cisplatin and in 59 NSCLC 
patients. The accuracy was 83% as compared with only 62% of 
ERCC1 measurement by IHC (30). In NSCLC cell lines a provoca-
tive result is the inverse correlation of the likelihood of sensitivity 
to cisplatin and pemetrexed. In vitro sensitivity of NSCLC cell lines 
must be interpreted cautiously: in cisplatin-refractory tumours prior 
treatment with docetaxel or paclitaxel before pemetrexed may induce 
resistance to subsequent therapy with pemetrexed. 
The therapeutic window of anticancer drugs is usually narrow. It is 
therefore difficult to separate toxicity from suboptimal treatment. 
Inter-individual variations in drug response stem from different drug 
metabolizing capacity and complicate the evaluation of a treatment 
even within a group of individuals in the same stage of disease. As 
discussed above, the genetic profile of each tumour may affect the 
activity of anticancer therapies but it is the genetic background of 
each patient with respect to metabolizing enzymes and drug trans-
porters that has a direct impact on the therapeutic effect.
A good example is represented by the relationship between phar-
macokinetic parameters and irinotecan-related neutropenia and 
diarrhoea. Differential inheritance of variant alleles, encoding drug 
metabolizing enzymes or drug transporters represents the basis for 
intrinsic differences between individual patients. Genetic polymor-
phisms, occurring in >1% of the population, are the variation in the 
UDP-glucuronosyl transferase 1A1 (UGT1A1) gene with respect 
to irinotecan treatment (31) and the thiopurine methyltransferase 
(TPMT) gene with respect to 6-mercaptopurine treatment (32). Also 
genetic variability in cytochrome P450 enzymes plays a fundamen-
tal role in response to anticancer agents (33). A report showed that 
polymorphisms in the drug target of camptothecins, topoisomerase 
I (TOP1) and haplotype-tagging single nucleotide polymorphisms 
(htSNP) downstream effectors may influence patient outcomes to 
irinotecan therapy in colorectal cancer patients. TOP1 and TDP1 
htSNPs were related to grade 3-4 neutropenia and response. Patients 
homozygous for an XRCC1 haplotype were more likely to show 
an objective response to therapy (34). In NSCLC data indicate that 
in patients with polymorphisms of the UGT1A1, UGT1A7, and 
UGT1A9 genes irinotecan toxicity is extremely severe, especially 
in homozygous patients (35). An improved genetic-based therapeu-
tic strategy for NSCLC patients treated with irinotecan should be 
developed. 
Prospective clinical trials are still necessary to assess if expression of 
RRM1, ERCC1, TS and other markers remains the same through all 
stages of disease. Other key issues for the near future include better 
definitions of cutoff levels for such markers, the feasibility of core 
needle biopsies with immediate freezing to perform gene expression 
analysis, and the research for newer molecular pathways that modu-
late response to anticancer agents.
The development of gene expression profiles that can predict 
response to commonly used cytotoxic agents is the key to maximize 
efficacy of chemotherapy and to find the right way to use them in 
combination with targeted therapies. Studies on NSCLC cell lines 
could identify pathways to define the most effective cytotoxic drugs 
(36). 
Ultimately, introduction of widely applicable methodologies based 
on technologies easily accessible to clinical laboratories and patholo-
gists of most facilities is mandatory. As of today such tests are still 
far from entering clinical practice on a routine basis. 
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Lung cancer remains the one of the largest causes of cancer-related 
death in the world. Approximately 80% of lung cancer patients will 
have non-small cell lung cancer and of those 40% (32% of the total) 
will have locally advanced disease which is normally not amenable 
to surgical resection. Radiotherapy plays a key role in the treatment 
of these patients whether it be part of a curative treatment plan or 
indicated for the palliation and prompt relief of symptoms including 
hemoptysis, dyspnea due to bronchial obstruction or persistant pain. 
The involvement of the radiation oncologist in the treatment of lung 
cancer is certainly standard practice and requires close consultation 
with both medical oncologists as well as thoracic surgeons to deter-
mine optimal treatment.
There has certainly been a progression in the approach to locally 
advanced non-small cell lung cancer over the last two decades. 
Radiotherapy alone was the traditional standard therapy for stage III 
disease however it was associated with poor survivals. A progression 
of randomized trials have shown that survivals can be improved with 
the addition of chemotherapy in either a sequential or concurrent 
fashion. While concurrent therapies are associated with a improved 
outcomes in patients who have a good performance status they are 
also associated with increased toxicities. The goal of all cancer 
therapies is to increase the therapeutic ratio; that is, to increase the 
probability of cure while minimizing the toxicity. Theoretically, all 
cancers can be cured if a sufficient dose of radiation can be delivered 
to all clonogens without causing undue toxicity to the patient. Obvi-
ously, this is not the case in most instances. Precise target localiza-
tion, in theory, can improve the therapeutic ratio by allowing more 
conformal radiation delivery, enabling one to escalate the tumor dose 
while sparing surrounding normal tissue. In the last decade, conven-
tional 2-dimensional (2-D) radiotherapy, based on surface anatomy 
and bony landmarks, has given way to the computed tomography 
(CT)-based 3-D radiotherapy, which allowed for the use of internal 
anatomy. Great interests are now emerging in the field of radia-
tion oncology in tracking the motion of the tumor and surrounding 
normal tissue, either from day to day or during each treatment ses-
sion, and in delivering treatments that adapt to the detected motion. 
Commercially available 4-D CT imaging capabilities and various 
strategies to deliver the radiation dose to the moving target made the 
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implementation of this new paradigm possible. In this review presen-
tation, we will discuss the concept of 4-D radiotherapy, particularly 
as it applies to lung cancer, and elaborate on the technical advances 
that made it possible.
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Over the last two decades the use of chemotherapy in non-small 
cell lung cancer has evolved dramatically. Currently, it is used both 
in the palliative as well as the curative-intent treatment setting is 
well-established. Regimens with acceptable toxicity profiles and risk-
benefit rations have been identified and novel approaches continue 
to be integrated. Increasingly, these are based on the integration of 
sophisticated biomarkers and genomic analyses.
Chemotherapy in the palliative care setting has evolved sequen-
tially through the use of randomized clinical trials many of which 
were conducted within the cooperative group system. Historically, 
first generation regimens, frequently using doxorubicin and vinca 
alkaloids, were tested in phase II settings. With the emergence of 
cisplatin and etoposide, or cisplatin and vinblastine, second genera-
tion regimens were shown to have consistent activity as well as a 
possible impact on survival. Studies directly comparing the use of 
these chemotherapy regimens vs. “best supportive care” established a 
small but consistent and significant survival benefit favoring the use 
of chemotherapy. Furthermore, cost and quality of life analyses also 
supported its use. 
During the 1990s the integration of third generation agents with 
increased single-agent active such as the taxanes, gemcitabine and 
vinorelbine led to a variety of randomized trials that collectively 
established a standard of two drug (doublet) platinum-based third 
generation chemotherapy as superior to earlier regimens. Studies 
comparing single agents vs. doublet chemotherapy in aggregate also 
supported the use of two third generation drugs over one single-
agent. While toxicity profiles between these regimens differ, there 
was apparent equivalence in response and survival activity allowing 
for physician or patient preference-based choice of an individuals 
specific regimen. Overall median survival rates of approximately 10 
months were established. When investigators studied three-drug regi-
ments versus two-drug chemotherapy no further survival advantage 
was established while toxicities were increased.
Over the last decade the administration and integration of tar-
geted therapies have been studied. In the first-line palliative intent 
care setting, large randomized trials were conducted but failed to 
demonstrate a benefit from the addition of such agents including 
matrix metalloproteinase inhibitors, farnesyl transferase inhibitors, 
antisense molecules, EGFR directed tyrosine kinase inhibitors and 
others. To date, the only positive randomized trials published have 
investigated the monoclonal antibodies cetuximab and bevacizumab. 
However, even for these drugs positive trials are counterbalanced by 
similar studies that failed to achieve a survival endpoint. Thus, while 
the addition of cetuximab or bevacizumab can be justified on an 
evidence-based analysis, the counterpoint could also be argued. 
Additional recent first-line chemotherapy developments have been 
based on enrichment designs using molecular analyses or tumor 
histology. For example, a large randomized study comparing cis-
platin, gemcitabine with cisplatin, pemetrexed demonstrated similar 
progression-free and overall survival rates for the entire study popu-
lations. However, planned subset analysis comparing patients with 
squamous cell carcinoma vs. non-squamous cell carcinomas estab-
lished a survival benefit favoring the latter group of patients when 
treated with cisplatin and pemetrexed. It is likely that this effect is 
due to a differential expression of potential therapeutic targets, such 
as thymidylate synthase, in patients with adenocarcinomas, although 
a precise molecular explanation remains to be identified.
Finally, targeted agents such as small molecular EGFR inhibitors 
have been directly compared in clinically enriched populations of 
patients with standard doublet chemotherapy. In the recent “IPASS” 
trial, patients with history of light or never smoking and adenocarci-
noma were randomized to be treated with gefitinib or vs. carboplatin 
and paclitaxel. Overall, progression-free survival was superior in 
patients treated with gefitinib. Molecular analysis revealed that 
patients with EGFR mutation benefited from early use of gefitinib 
while those with wild-type EGFR did poorly when treated with 
gefitinib alone. This study is the first to suggest that patient selection 
based on molecular biomarkers in the first line setting may be of use. 
Chemotherapy is now also firmly established in the second and 
potentially third line treatment setting. Specifically docetaxel was 
shown in a randomized study to be superior to supportive care. 
Subsequently, pemetrexed in direct comparison with docetaxel was 
found to be of similar clinical activity and was established as the 
second cytotoxic standard therapeutic agent for second line therapy. 
More recently erlotinib was directly compared vs. best supportive 
care in the third line (and second line setting for patients not eligible 
for second line chemotherapy). Erlotinib was shown to be superior 
to best supportive care thus establishing for the first time that third 
line therapy could further prolong survival. Clearly first- second- and 
third-line therapies are now established for broad groups of patients. 
However, strategies for sequencing such therapies in individual 
patients are not yet clearly established and will be the focus of cur-
rent and future investigations. 
Chemotherapy has also been established in the curative-intent 
treatment setting and is an important component of such combined 
modality approaches. In patients with locoregionally advanced 
disease, chemotherapy given as induction or concomitantly with 
radiotherapy has been shown to prolong survival. Current investiga-
tions are focused on establishing newer and potentially more effec-
tive regimens. Furthermore, the integration of cetuximab as added 
radiation enhancer is being studied. The latter is of interest given the 
favorable outcome demonstrated when adding cetuximab to radio-
therapy in patients with regionally advanced head and neck cancer. 
In early stage disease, adjuvant chemotherapy is similarly firmly 
established in patients with stage II and IIIA resected tumors. Current 
standard regimens consist of cisplatin-based doublet chemotherapy 
regimens. A study of carboplatin and paclitaxel in patients with stage 
IB disease showed increased progression-free survival but its effect 
on survival was not statistically significant. Therefore, carboplatin 
is not currently accepted as a substitute for cisplatin in the adjuvant 
therapy setting. Current investigations here are focused on the inte-
gration of bevacizumab as an antiangiogenic therapy as well as small 
molecule tyrosine kinase inhibitors and immune modulators. 
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In summary, great progress in defining standard indications for sys-
temic therapies of non-small cell lung cancer have been made. The 
careful use of sophisticated biomarker analysis and genomic-based 
choice of chemotherapy is likely to further refine and modify our 
choice of specific therapies and allow for the first time individualized 
therapy approaches in the near future. 
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Molecularly target therapy is an area of active investigation in treat-
ment of non-small cell lung cancer (NSCLC). However, the past 
decade has seen the approval of only two classes of agents – inhibi-
tors of the epidermal growth factor receptor (EGFR) and inhibitors of 
angiogenesis. 
Erlotinib has established second and third-line efficacy following 
the BR.21 study. Gefitinib has also been shown to benefit certain 
subgroups of patients including life-time non-smokers and patients 
of Asian ethnicity as second and third-line therapy. Recently the 
INTEREST trial and three other smaller trials have shown gefitinib 
to have an equivalent outcome to docetaxel in the second line setting. 
In the first-line setting, the addition of EGFR TKIs to chemotherapy 
does not add to response rate or overall survival. In contrast, four 
trials suggest that the addition of the EGFR monoclonal antibody 
cetuximab to chemotherapy may improve response rates and perhaps 
add to overall survival as well, although the additional benefit is 
modest. 
Both erlotinib and gefitinib have been evaluated as first-line single 
agent therapy in selected populations including the elderly, those 
with poor performance status and patients with bronchalveolar carci-
noma. None of these studies suggests that EGFR TKI therapy would 
be superior to standard chemotherapy. Phase II trials suggest that 
patients with EGFR mutations have high response rated to EGFR 
TKI therapy. The results of the IPASS trial comparing gefitinib to 
paclitaxel/carboplatin in Asian patients with adenocarcinoma provide 
the first evidence that an EGFR inhibitor may be an alternative to 
combination chemotherapy in patients with EGFR mutations. The 
TORCH trial comparing erlotinib to gemcitabine/cisplatin is still 
open to accrual and will not report results for some years.
Numerous other TKI drugs and monoclonal antibodies have dem-
onstrated clinical activity in phase I and phase II trials. Novel TKIs 
may have the ability to overcome resistance to first generation TKI 
therapy. Furthermore there are encouraging studies combining EGFR 
inhibitors and anti-angiogenesis drugs such as bevacizumab.
Several studies have shown that the presence of somatic mutations 
in EGFR exons 19 and 21 are associated with higher response rates 
to chemotherapy. However, in the trials with placebo control arms, 
although hazard ratios have been lower for patients with mutations, 
significant interaction has not yet been shown, perhaps due to the low 
numbers of patients with mutations in studies with predominately 
Caucasian patients. Response and survival benefit also seem to be 
higher in patients who express EGFR protein on their tumors, and in 
some studies the interaction has been significant. Similarly, EGFR 
gene copy number is associated with higher response rates and 
greater survival benefit compared to placebo with significant interac-
tion seen in some trials. 
Both KRAS and EGFR T790M mutations are associated with resis-
tance to EGFR TKI therapy. Similarly MET amplification has also 
been shown to confer resistance to EGFR TKIs, and inhibitors of 
MET are under study both as single agents and in combination with 
EGFR TKIs.
Inhibition of angiogenesis now plays a central role in the manage-
ment of many malignancies including lung cancer. The monoclo-
nal antibody, bevacizumab, has demonstrated efficacy (improved 
response rates and overall survival) in phase II and III trials in 
combination with standard first-line chemotherapy in NSCLC. The 
large North American trial that evaluated bevacizumab 15 mg/kg in 
combination with paclitaxel and carboplatin demonstrated positive 
results with improvement in response rate, progression-free and over-
all survival. However, a global study that evaluated bevacizumab, 7 
or 15 mg/kg in combination with gemcitabine and cisplatin showed 
higher response rates and progression-free survival, but no differ-
ence in overall survival. Furthermore, there was no apparent benefit 
for the 15 mg dose over the 7.5 mg dose. Patients in both of these 
large phase III studies were highly selected in order to reduce the risk 
of fatal hemoptysis. Those with squamous cell histology, cavitat-
ing lesions or a history of brain metastases, thrombosis, bleeding or 
hemoptysis were all excluded. In the North American Intergroup, a 
trial evaluating the addition of bevacizumab to cisplatin-based che-
motherapy in the post-operative adjuvant setting is open for patients 
of all histologic subtypes.
VEGF-trap, a fusion protein has demonstrated activity as a single 
agent, is being evaluated in combination with docetaxel in the 
second-line setting and with combination chemotherapy in the first-
line setting in NSCLC.
Many small molecule tyrosine kinase inhibitors, including vande-
tanib, sorafenib, sunitinib, and cediranib, are under investigation 
in phase III trials as monotherapy or in combination with standard 
therapy. 
Vandetanib targets both the VEGF receptor and the EGFR receptor. 
Randomized Phase II trials suggested that the addition of vandetanib 
to single agent chemotherapy might improve response rates and 
survival, and so numerous Phase III trials were launched. A random-
ized trial comparing vandetanib to erlotinib has completed accrual. 
Similarly, two trials in the second-line setting evaluating the addition 
of vandetanib or placebo to docetaxel in one trial and pemetrexed in 
the other have both completed accrual and results will be available 
shortly. Finally, in the third and fourth-line setting, vandetanib is 
being compared to placebo. If this trial is positive, it will be the first 
to demonstrate a role for any treatment in the forth-line setting in 
NSCLC. 
Sorafenib in combination with paclitaxel and carboplatin was evalu-
ated in a large Phase III trial. Overall, no survival benefit was seen 
with the addition of sorafenib, and survival was actually shorter in 
patients with squamous cell cancer treated with sorafenib compared 
to placebo. A similar trial of sorafenib in combination with gemcit-
abine and cisplatin remains open, but patients with squamous cell 
cancer are no longer eligible.
Cediranib, was evaluated in a randomized Phase II trial in combina-
tion with paclitaxel and carboplatin. The addition of cediranib result-
ed in a significantly higher response rate and longer progression-free 
survival. However, doses of cediranib at 45 and 30 mg daily were 
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found not to be tolerable when administered with chemotherapy, and 
so this trial did not proceed to Phase III. A new trial of similar design 
with cediranib 20 mg daily is now open.
A randomized trial of erlotinib with or without sunitinib in the 
second-line setting has almost completed accrual, but results are not 
yet available. Of interest, however, a trial of similar design in the 
same setting that compared erlotinib to erlotinib and bevacizumab 
was negative with no survival benefit seen despite some improve-
ment in progression-free survival. Results are also awaited for trials 
of chemotherapy the first-line setting with or without AMG706 and 
sunitinib. Also in the first-line setting CALGB30707 will evaluate 
the role of maintenance sunitinib in stable and responding patients 
who have completed four cycles of platinum-based chemotherapy.
Other targets under study include MET, IGF1r, mTOR, the prote-
osome to name but a few. Only Phase I and II data are available to 
date, but numerous studies are either open or planned. 
In summary, targeting the EGFR pathway and angiogenesis are 
exciting and attractive areas in the treatment of lung cancer, and the 
results of ongoing trials are eagerly awaited. More work is required 
to identify sub-groups of patients most likely to benefit from these 
drugs. 
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Implementation of the IASLC revised 
staging system: overview
Goldstraw, Peter
Royal Brompton Hospital, London, UK
The recommendations of the IASLC Staging Project have now 
been accepted by the American Joint Committee on Cancer (AJCC) 
and the International Union Against Cancer (UICC)) and will be 
incorporated into the 7th edition of TNM due to be published in May 
2009. All of the data supporting these changes and other aspects of 
the staging system have been published in the Journal of Thoracic 
Oncology. These articles are available, without subscription, on their 
web site at www.jto.org . Those interested are encouraged to study 
the details in these publications, which also records the valuable 
contribution made by those who collaborated in this project.
Changes to the T descriptors are: 
• Subclassify:
• T1 as
– T1a ( ≤ 2 cm) or
– T1b (> 2 cm to ≤ 3 cm); and
• T2 as 
– T2a (>3 to ≤ 5 cm or T2 by other factor and ≤ 5 cm) or
– T2b (>5 to ≤ 7 cm).
• Reclassify T2 tumours > 7 cm as T3.
• Reclassify T4 tumours by additional nodule/s in the lung (primary 
lobe) as T3.
• Reclassify M1 by additional nodule/s in the ipsilateral lung (dif-
ferent lobe) as T4.
• Reclassify pleural dissemination (malignant pleural or pericardial 
effusions, pleural nodules) as M1.
There will be no changes to the N descriptors as these, for the first 
time, have been validated in an International data base of patients 
treated with all modalities of care.
Changes to the M descriptors are:
• Reclassify pleural dissemination (malignant pleural effusions, 
pleural nodules) from T4 to M1a. 
• Subclassify M1 by additional nodules in the contralateral lung as 
M1a.
• Subclassify M1 by distant metastases (outside the lung/pleura) as 
M1b.
The resultant TNM stage groupings are summarised as: 
Occult Carcinoma TX N0 M0
Stage 0 Tis N0 M0
Stage IA
T1b N0 M0 T1a N0 M0
Stage IB T2a N0 M0
Stage IIA 
T1b N1 M0 
T2a N1 M0 
T2b N0 M0 T1a N1 M0
Stage IIB  
T3 N0 M0 T2b N1 M0
Stage IIIA  
T1b N2 M0 
T2a N2 M0 
T2b N2 M0 
T3 N1 M0 
T3 N2 M0 
T4 N0 M0 
T4 N1 N0 T1a N2 M0
Stage IIIB 
Any T N3 M0 T4 N2 M0
Stage IV 
Any T Any N M1b Any T Any N M1a 
The table below summarises the descriptors, proposed T and M 
categories, and proposed stage groupings. Shaded cells indicate a 
proposed change from the 6th Edition of the TNM Classification for 
lung cancer for a particular TNM category.
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UICC6 T/M and Descriptor Proposed T/M N0 N1 N2 N3
T1 (<=2cm) T1a IA IIA IIIA IIIB
T1 (>2 – 3 cm) T1b IA IIA IIIA IIIB
T2(<=5cm) T2a IB IIA IIIA IIIB
T2 (>5-7cm) T2b IIA IIB IIIA IIIB
T2 (>7cm) T3 IIB IIIA IIIA IIIB
T3 invasion  IIB IIIA IIIA IIIB
T4 (same lobe nodules)  IIB IIIA IIIA IIIB
T4 (extension) T4 IIIA IIIA IIIB IIIB
M1 (ipsilateral lung)  IIIA IIIA IIIB IIIB
T4 (pleural effusion) M1a IV IV IV IV
M1 (contralateral lung)  IV IV IV IV
M1 (distant) M1b IV IV IV IV
In addition the IASLC Staging Project has confirmed the value of 
TNM in the clinical staging of small-cell lung cancer (7) and the 
use of TNM for SCLC cases will be strongly encouraged in the 
7th edition of TNM, especially for stratification in trials of chemo/
radiotherapy and for those cases treated by surgery. We have pro-
vided evidence for the inclusion of carcinoid tumours of the lung 
and tracheobronchiial tree in the 7th edition of TNM, developed an 
IASLC Nodal Chart to reconcile the Japanese and Mountain/Dressler 
Nodal Charts and developed a precise definition of “visceral pleural 
invasion”. We have analysed the prognostic value of those additional 
prognostic factors for which we had data, re-affirmed the dominant 
role of the anatomical extent of disease as described by the TNM 
system and undertaken a meta-analysis of the place of additional 
prognostic factors in patient evaluation. We have reported a meta-
analysis of the prognostic value of the Standardised Uptake Value on 
pre-treatment PET scans and have reviewed the prognostic value of 
biological markers in lung cancer as they stand today. The IASLC 
Staging Project is now recruiting Institutions to collaborate in the 
prospective collection of data for the 8th edition. This will be facili-
tated by a web-based data collection process, and will incorporate 
selected neuroendocrine tumours and cases of mesothelioma treated 
by all modalities of care. We hope that colleagues in the global Tho-
racic Oncology Community will support this initiative and ensure 
global relevance to future proposals for the TNM system.
PL3.2 Implementation of IASLC Revised Staging System, Tue, Aug 4, 08:30 - 10:00
Implementation of staging: pathologic implications
Brambilla, Elisabeth1; Travis, William D.2; Chu, Albert Michallon1
1 Grenoble Hospital, Department of Pathology, INSERM U823, 
Grenable, France; 2 Memorial Sloan Kettering Cancer Center, 
Department of Pathology, New York, NY, USA
The histopathological classification of lung cancer has been provided 
in his full development with clinical and molecular characteristics 
through WHO pathology and genetics in 2004 (1). Despite remark-
able advances in the classification in adenocarcinoma, there remains 
a widely divergent clinical, radiologic, molecular, and pathologic 
spectrum with lung adenocarcinoma which has staging issues. 
Because the term of BAC was applied by pathologist to small soli-
tary peripheral tumors with 100 % 5-year survival, and by the medi-
cal oncology community to a widespread advanced disease (extend-
ed-BAC ?) with a 10 % 3-5 year survival, a new multidisciplinary 
classification of lung adenocarcinoma has been engaged and spon-
sored by the International Association for the Study of Lung Cancer 
(IASLC), the American Thoracic Society (ATS), and the European 
Repsiratory Society (ERS) which gathered together oncologists, 
pathologists, molecular biologists, thoracic surgeons, and thoracic 
radiologists. This new classification proposal has several implica-
tions for the implementation of the TNM data bases and cancer 
registries : the term BAC has been discarded from the classification 
because its clinical use covered three different diseases : the small 
solitary BACs of non mucinous type with 100 % 5-year survival and 
low stage at presentation ; the mucinous BAC with extended local 
regional diseases with high stage at presentation ; the extended BAC 
for cases with mixed adenocarcinoma BAC component.
This new classification defines first the preinvasive lesions under 
the term of AAH (Atypical Adenomatous Hyperplasia) which is 
a preneoplastic alveolar lesion, and adenocarcinoma in situ (AIS) 
(formerly pure BAC). These two proliferations have a spectrum of 
criteria and histological pattern, the first being equivalent to an alveo-
lar dysplasia, the second being considered as T is (as is CIS). How-
ever, since adenocarcinoma in situ with lepidic growth pattern are 
rarely larger than 2 cm, the specimen should be sampled extensively 
to exclude the presence of invasion. Consequently the size of the 
lesion should be specified in contrast with other in situ carcinomas 
and diagnosis is possible only on resection (even wedge resection). 
Tumors larger than 2 cm are likely to have areas of invasive growth 
and the diagnosis of AIS should be made with caution. 
The second category proposed is minimal invasive adenocarcinoma 
which is classified T1 (or T2). Clinical evidence has been provided 
that a lesion with less than 5 mm invasion of less than 10 % inva-
sion has the same excellent prognosis with 100 % 5-year survival 
than adenocarcinoma in situ (formerly BAC) (2-7). In all Japanese 
or Caucasian series so far examined, a group of patients with tumor 
with less than 5 mm invasion beneficiated of long term survival after 
resection (100 % 5-years). The definition of invasion is thus critical 
: invasive growth into stroma with myofibroblastic proliferation, 
destruction of alveolar architecture, invasion into vessels or pleura, 
and more importantly invasive adenocarcinomatous patterns (acinar, 
papillary, solid). 
The second consideration with implication in TNM implementation 
of staging is that of tumor diameter in cases of tumors with BAC 
(lepidic growth pattern) predominant or not. The size of the non 
lepidic (non BAC) growth (acinar, papillary, or solid) in otherwise 
invasive adenocarcinoma impacts the prognosis even for lesions 
sized 2 cm or smaller (7). The size of non lepidic components is 
an independent adverse prognostic factor, whereas total size of the 
tumor including lepidic growth at the periphery is not significant 
(6). We may have to consider that the real pT is the size of invasive 
growth as a better determinant of prognosis than the total diameter of 
the tumor including the lepidic growth pattern.
The third pathologic implication in implementation of staging is the 
re-assignments of multiple synchronous nodules to the right T stage 
category, which requires the distinction between multiple synchro-
nous or metachronous primary tumors and intrapulmonary metas-
tases. The new TNM classification has promoted the re-assignment 
of the multiple nodules (considered as metastatic) if histologically 
similar to another T/stage category with better survival. The down-
staging has been done for intra-pulmonary metastases presenting as 
same lobe nodules as T3, ipsilateral lobes multiple nodules as T4, 
controlateral nodules as M1A. Since multiple nodules being synchro-
nous primaries would be T1 or T2 according to the larger nodule, 
the distinction between independent primaries and metastases is 
critical for TNM implementation prognostic and therapeutic strategy. 
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This is specifically true for adenocarcinoma since adenocarcinoma 
presents more often with multiple nodules than other categories. In 
the IASLC/TNM database 72 % of cases with multiple ipsilateral 
nodules (T4) were adenocarcinoma.
Using the Martini-Melamed criterias for synchronous multiple 
primaries versus metastases (8, 9), (histologically different, presence 
of carcinoma in situ, absence of lymphatic invasion …) is the source 
of difficulties considering the huge intra-tumoral heterogeneity of 
adenocarcinoma. To go further on this differential diagnosis, molecu-
lar profile had been applied with different results and no obvious 
consensus about which of these molecular abnormalities should be 
taken into account. It has been shown that there is a strong hetero-
geneous distribution of EGFR mutation of KRAS mutation between 
several primary tumors and/or the primary and the metastatic tumors 
(10-13).
Due to the concept of field cancerization, the synchronous mul-
tiple primary lung cancer could be either multifocal with different 
clonality or look like metastatic with same clonality if they develop 
in the same cancerization field. This applies also to CGH and SNP’s 
molecular profiles. A recent study showed that a comprehensive 
histological subtyping of adenocarcinoma or squamous cell carci-
noma using the new classification details about the predominance 
and percentage of each pattern inside adenocarcinoma as well as 
additive morphological criteria showed a strong correlation of 90 % 
with molecular characterization (an array of mutation and CGH) and 
was more powerful in predicting multiple primaries versus metas-
tases in a large series of patients with long term survival allowing a 
posteriori clinical classification of the two processes (WD. Travis et 
al. Am J Surg Pathol 2009, in press). This study is a first demonstra-
tion of adenocarcinoma heterogeinity taken as an advantage in the 
comparison of tumors with multiple nodules and assessment of their 
clonal differences or similarities. 
Given its high correlation with molecular characterization and clini-
cal course, histological assessment has great clinical implication for 
staging and therapeutic management of lung tumors.
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Implementation of IASLC revised staging 
system: imaging implications
Patz, Jr, Edward F.
Duke University Medical Center, Durham, NC, USA
Background
The TNM staging system has evolved over the past 50 years, and 
enables a standardized description of the anatomic extent of disease. 
Imaging plays an essential role in determining the clinical stage, 
which dictates further intervention, provides prognostic information, 
and helps to optimize therapy. 
In 1998, the IASLC established a Lung Cancer Staging project 
in order to recommend evidence based changes to the next ver-
sion of the TNM Classification of Malignant Tumors. The current 
discussion will focus on the imaging implications of the suggested 
modifications.
IASLC Revision of the TNM Descriptors
The recommended changes were based on extensive analysis of 
a multi-national database that included over 67,000 lung cancer 
cases. These data were published in a recent series of articles (see 
References). 
Given these data, changes to the T and M descriptors were proposed. 
The T descriptors modifications include a refinement in the size 
criteria and location of additional nodules (i.e. same lobe, ipsilateral 
lobe, contralateral lobe). The M descriptors modifications suggest 
stratification based on distribution of metastatic disease (local or 
distant). The IASLC data validated the current N descriptors, and no 
changes were suggested.
The standard imaging approach for TNM staging NSCLC has typi-
cally included a combination of the following studies, 
• Chest radiographs,
• Thoracic CT,
• PET-CT,
• Brain imaging,
• Bone scans.
With the new IASLC proposal, advances in imaging technology, and 
a better understanding of tumor biology, not all of these studies are 
required in each patient. The appropriate combination of radiologi-
cal studies will be discussed, so that an efficient and accurate staging 
approach can be used to guide patient management. 
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Implementation of IASLC revised staging system: 
taking the new staging system into the clinic
Rusch, Valerie W.
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Acceptance of the IASLC revised staging system by both the 
International Union Against Cancer (UICC) and the American Joint 
Commission on Cancer (AJCC) for the 7th editions of their staging 
manuals offers important new opportunities with respect to the treat-
ment and clinical trials for patients with lung cancer and carcinoid 
tumors. Importantly, for the first time, the staging system is based on 
international data on patients with advanced as well as early stage 
disease and is both internally and externally validated. 
The IASLC revisions to the staging system include major changes 
in the T stage categories and the stage groupings for non-small 
cell lung cancer (NSCLC) and raise questions about the N stage 
categories that warrant further study. The revisions define many of 
the T stage categories more clearly than did the previous version 
of the international staging system thereby facilitating day-to-day 
patient care and clarifying eligibility for clinical trials. For instance, 
malignant pleural effusions are now classified as M1a rather T4 
which eliminates the need for oncologists to use the informal distinc-
tion between “wet” and “dry” stage IIIb disease. This change clearly 
designates malignant effusions as belonging to a disease category 
for which chemotherapy is the primary treatment. Another example 
is the division of the T1 stage into T1a and T1b. Tumors that are 2 
cm or less in size are now thought potentially to be appropriately 
treated by sublobar resection. Indeed, two multicenter trials, one in 
Japan and one in North America are studying the validity of sublobar 
resection for these small cancers. The distinction between T1a and 
T1b will also facilitate the study of these tumors within prospec-
tive tumor registries and should help clarify the influence of T stage 
versus tumor histology and molecular features in very early NSCLC. 
Recent trials testing the use of adjuvant therapy in Stage Ib NSCLC 
(T2N0) have yielded equivocal results. The subcategorization of 
T2 tumors according to size in the IASLC revised staging system 
and the reclassification of “very large T2” tumors as T3 should now 
allow more focused trials of multimodality therapy for this group of 
tumors that will resolve the dilemma of when to offer chemotherapy 
to these patients.
Additional related work by the IASLC staging committee has led to 
important recommendations for the classification of visceral pleural 
involvement within the T2 category. These include the use of elastic 
staining to identify tumor involvement of the visceral pleura and 
nomenclature to specify the depth of pleural invasion. Uniform 
application of elastic staining by pathologists and of the proposed 
nomenclature should clarify in the future whether visceral pleural 
involvement is associated with a poor prognosis. 
Close coordination between the UICC and the AJCC in revisions of 
their staging manuals has also eliminated previous discrepancies in T 
stage definitions which have important implications for tumor regis-
tries and for eligibility criteria in clinical trials. For instance, the term 
“satellite nodules”, previously suggested by Mountain and widely 
used in North America but not elsewhere, has been eliminated in 
favor of the term “additional tumor nodules in the same lobe” which 
is now classified as T3. Another example is the definition of synchro-
nous primary NSCLC which has now been harmonized between the 
UICC and AJCC staging manuals. Subtle differences in stage defini-
tions make it difficult to compare treatment results around the world, 
and hopefully most of these differences have now been resolved.
Another important result of the IASLC revisions is the evidence-
based demonstration that this system should also be applied to both 
small cell lung cancer (SCLC) and to carcinoid tumors. Both the 
UICC and AJCC previously recommended using the staging system 
for SCLC as well as NSCLC but oncologists continued to use the 
shorthand classification of “limited” versus “extensive” disease for 
SCLC. The staging system was often informally applied to carcino-
ids without any real evidence for doing so. The application of the 
revised staging system across the entire spectrum of neuroendocrine 
lung tumors will now permit studies correlating the clinical, patho-
logical and molecular features of these tumors. Such studies will 
hopefully enhance our understanding of atypical carcinoids and large 
cell neuroendocrine carcinomas which to date, have defied efforts at 
effective multimodality therapy.
The IASLC revisions did not recommend any changes to the N stage 
categories. However, analyses of the IASLC database suggested 
that future changes might be appropriate with subclassification of N 
stages into N1a, N1b, N2a and N2b based on the number of involved 
lymph node stations. These potential changes do not influence cur-
rent clinical care but warrant future study in the planned prospective 
IASLC database, in tumor registries and within clinical trials. Inter-
ested investigators may wish to evaluate further the validity of such 
subclassifications. A related effort by the IASLC staging committee 
has been the revision and harmonization of lymph nodes “maps” 
between Western and Eastern countries. Specifically, the Japanese 
have used the Naruke lymph node map to describe the anatomical 
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location of involved lymph nodes while North Americans have used 
the Mountain-Dresler modification of the American Thoracic Society 
map. Usage in Europe has varied between these two maps which 
have important discrepancies in definitions. In fact, these discrepan-
cies are so substantial that nodes designated as N1 (stage II) in one 
map would be labeled as N2 (stage IIIa) in the other map, making it 
impossible to compare treatment results worldwide. Refinement and 
harmonization of anatomical definitions for lymph node location will 
facilitate international standardization of clinical care, of entry crite-
ria for clinical trials and of future studies of potential revisions to N 
stage classification. As part of the development of a revised lymph 
node map, the IASLC staging committee proposed that individual 
lymph node stations could be grouped together into “zones” which 
describe larger anatomical regions. This approach to N classification 
may prove helpful to medical and radiation oncologists who often 
have to rely on clinical staging for patients with advanced disease 
without benefit of the precise information provided by the surgi-
cal staging. Again, while the proposal of lymph node zones does 
not immediately affect clinical care, it merits further study with an 
eye towards future revisions of the international staging system and 
IASLC lymph node map. 
In summary the IASLC revised staging system has numerous direct 
implications for current clinical care but also offers opportunities 
for future studies and should facilitate correlations of clinical patient 
characteristics with tumor stage, histology and molecular features.
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SRC as a Target
Fennell, Dean A.
Queen’s University Belfast, Belfast, UK
Overview
SRC family kinases (SFKs) are a family of conserved proto-onco-
gene, non-receptor tyrosine kinases comprising 9 homologous mem-
bers. They are activated by C-terminal de-phosphorylation (tyrosine 
527), leading to catalytic activity and downstream regulation of cell 
survival, growth, and invasion. Due to the role of SFKs in mediating 
drug resistance and tumour cell invasiveness, targeting SFKs repre-
sents a new and promising therapeutic strategy.
Regulation of Cell survival by SFKs
SFKs regulate cell survival, stabilizing the anti-apoptotic BCL-2 
family proteins including BCL-XL and MCL-1. The multidomain 
proapoptotic BCL-2 family protein BAX induces detatchment 
induced cell death (anoikis), but is antagonised by MCL-1 which 
must be degraded before anoikis occurs. SFKs stabilize MCL-1 via 
STAT3 and prevents its degradation, effectively blocking anoikis and 
promoting metastasis. FAK mediates integrin associated, anchor-
age dependent and independent growth, and is regulated by SFKs. 
Accordingly preclinical inhibition of SFKs leads to promotion of 
anoikis, as well as suppression of tumour invasiveness and growth. 
SFKs regulate cisplatin sensitivity via 
regulation cell-cell communication
Cisplatin is the cornerstone of chemotherapy for non-small cell lung 
cancer (NSCLC), small cell lung cancer (SCLC) and malignant 
pleural mesothelioma (MPM). Resistance to this agent is therefore 
a major problem which limits its efficacy. SFKs mediate cisplatin 
resistance. Recent evidence suggests that SFKs can block cisplatin 
induced cell death mediated through cell-to-cell communication. 
This trans-acting survival signalling is to-date, unique for SFKs and 
is achieved via tyrosine phosphorylation of the gap junction protein 
connexion 43. Importantly, this survival mechanism is blocked by 
inhibition of SFKs or upregulation of connexion 43, and suggests a 
potential cisplatin sensitising mechanism for SFK inhibitors. 
Expression of SFKs in non-small cell lung cancer (NSCLC)
NSCLCs exhibit a high level of SFK activation, greater in adeno-
carcinoma compared with squamous carcinomas. EGFR and SFKs 
cooperate to promote an aggressive phenotype. SFKs promote EGF 
signalling by ligand dependent and independent mechanisms. Direct 
phosphorylation of EGFR occurs at several sites, promoting EGF 
signalling. Accordingly, simultaneous inhibition of EGFR and SFK 
promotes apoptosis in preclinical models, in particular, in NSCLCs 
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exhibiting EGFR dependence. Accordingly SFK inhibition may 
overcome acquired resistance to EGFR inhibitors. 
SFKs regulate an ADAM17 dependent survival pathway 
In response to certain apoptotic stimuli, such as the activation of cell 
surface death receptors such by TRAIL, SFKs regulate shedding 
of TGF alpha. This leads to paracrine activation of EGFR ligand. 
Accordingly, inhibition of EGFR signalling or ADAM17 synergizes 
with TRAIL to potentiate apoptotic cell death, and this is recapitu-
lated by either SFK inhibition. Based on this finding, a randomized 
phase II has been approved by the EORTC to test the hypothesis that 
combined EGFR inhibition (by panitumumab) and DR5 agonism 
by AMG655 are synergistic in relapsed non-small cell lung cancer 
(EORTC 08071). This trial will randomise panitumumab with or 
without AMG655 against docetaxel (endpoint, progression free 
survival). 
SFK activation in mesothelioma
The carcinogen asbestos plays a major aetiological role in mesothe-
lioma and is also a potent activator of SFKs, implicating its involve-
ment in tumorigenesis. Preclinical inhibition of SFK in mesothelioma 
by the multi-targeted dual BCR/Abl and SFK inhibitor dasatinib, has 
been shown to induce both apoptosis, cell cycle arrest, and inhibition 
of invasion in mesothelioma. The activity of dasatinib is being evalu-
ated in an NCI sponsored phase II clinical trial, which is currently 
enrolling in the relapsed setting. The primary endpoint for this study 
is 24 week (5.5 month) PFS, and translational endpoints will include 
correlation of SFK phosphorylation in peripheral blood mononuclear 
cells with PFS, and confirm SKF inhibition in mesothelioma tissue. 
Summary
SFKs are involved in resistance to chemotherapy and promote anti-
apoptosis, proliferation and invasion. Approaches to target SFKs 
directly or SFK dependent resistance mechanisms are therefore 
attractive and are currently under evaluation in the clinic. Other 
small molecule inhibitors of SFK are currently at different stages of 
clinical development and will be discussed.
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m-TOR inhibitors
Crinò, Lucio
Medical Oncology Azienda Ospedaliera, Perugia, Italy
TOR, target of rapamycin a serine/threonine kinase, is a member 
of the phosphoinositide-kinase-related kinase (PIKK) family, and 
appears to be a central controller of eukaryotic cell growth and 
proliferation in mammalian cells and allowing progression from G1 
to S phase.
TOR directly or indirectly controls several cellular events, such as 
translational initiation transcription and protein stability, and it has a 
crucial role in the control of cell proliferation, neoangiogenesis and 
metastasis.
In this way, signalling pathways regulating TOR, are potential selec-
tive targets for cancer therapy.
RAD001 (everolimus) is a novel derivative of rapamycin, a mac-
rolide antibiotic identified as a potent antifungal agent and a potent 
suppressor of immune system. Antitumor activity has been shown 
against several tumor models in the N.C.I. screening programme. 
RAD001 is active directly on the tumor cells by inhibiting tumor cell 
growth and proliferation and indirectly by inhibiting angiogenesis 
through a potent negative effect on tumor cell VEGF production.
At molecular level, RAD001 acts as a signal transductional inhibitor 
by down regulation of m-TOR, a key protein kinase crucial in cell 
growth, proliferation and survival. In phase I/II trials, RASD001 has 
shown promising activity in NSCLC, renal and breast cancer.
Phase II trials in combinations with chemotherapy and tyrosine-
kinase inhibitors are currently ongoing.
Everolimus has been evaluated as single agent in phase II study in 
advanced non small cell lung cancer, in patients previously treated 
with platinum based chemotherapy and EGFR tyrosine-kinase 
inhibitors.
The trial was performed in eighty five patients with an overall 
response rate of 4.7% and a disease control rate of 47%. In this expe-
rience everolimus was administered orally at 10 mg/day and it was 
well tolerated with a modest activity in heavily pre-treated NSCLC 
patients.
In a phase II trial performed at Memorial Sloan Kettering Cancer 
Center everolimus was evaluated in combination with gefitinib in 35 
advanced unselected NSCLC patients either pre-treated (18) or not 
with platinum based chemotherapy (17).
All the patients were current or former smokers and adenocarcinoma 
was the predominant histology (88%). In this experience the overall 
response rate was 16% (95% C.I. 5-33%) with a median survival of 
12 months in the pre-treated group. It is note worthy that response 
were observed independently from EGFR mutations and in one 
patient harbouring KRAS mutation.
On the basis of these experience m-TOR inhibitors are currently 
investigated in combination with chemotherapy and biological drugs 
in advanced lung cancer.
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Novel targets beyond EGFR and VEGFR: HSP inhibitors
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Heat shock proteins (HSPs) are derived from several distinct gene 
families that play a vital role in cell survival following exposure 
to stress including heat shock, physical and chemical stressors. 
They function as molecular chaperones involved in holding and 
folding proteins resulting in their stabilisation or facilitating their 
degradation. The proteins are named according to their approximate 
molecular mass e.g. HSP90, HSP70 and HSP27. Some HSPs are 
constitutively expressed such as HSP90 whilst others are induced 
by stress factors such as HSP70 and HSP27. Whilst each HSP has 
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specific functions the different members often work in concert, in 
large multi-protein complexes that contain other proteins. HSPs are 
found predominantly in the cytoplasm and nucleus of cells apart 
from HSP60 which is present in mitochondria. HSPs may, however, 
be present on plasma membranes and in the extracellular space. 
HSPs, if overexpressed, have a number of functions that may 
enhance the malignant potential of a cell. For example HSP90 
accounts for 1-2% of all protein in the cytosol under non-stress con-
ditions but may be overexpressed in cancer cells. The chaperone’s 
principal role is to stabilise the fragile structure of many transcription 
factors, growth factor receptors and signalling molecules involved 
with normal cellular growth. HSP90 may also stabilise the structure 
of aberrant proteins such as bcr-abl. Through these stabilising effects 
HSP90 may enhance tumour growth by inhibiting apoptosis (akt), 
promoting angiogenesis (HIF-1a; VEGFR), inducing tissue inva-
sion and metastasis (met; MMP-2) and increasing proliferation by 
enhancing autocrine and cell signalling growth pathways (HER2; 
raf), overcoming limited replication potential (telomerase) and block-
ing of anti-growth signalling (CDK4; cyclin D). 
These observations have led to the development of HSP inhibi-
tors particularly against HSP90. Geldanamycin, a benzoquinone 
ansamysin, is a natural product that was found to bind to HSP90 and 
compete with ATP at the nucleotide binding site in the NH2-terminal 
domain. Resultant inhibition of the ATPase activity leads to degrada-
tion of several client proteins by the ubiquitin-proteasome pathway 
but, although showing promising anti-tumour activity in pre-clinical 
models, the agent is hepatotoxic. AAG (17-allylamino-17-demethox-
ygeldanamycin) has a better therapeutic index. A number of phase I 
and II studies have been conducted in solid tumours either alone or 
in combination with cytotoxic agents with anti-tumour efficacy being 
seen when used with the taxanes. 17-AAG has also been demonstrat-
ed to enhance the anti-tumour activity of EGFR and HER2 targeted 
agents in pre-clinical and clinical studies. In a phase I study of 
17-AAG combined with trastuzumab (Herceptin) in 29 patients with 
herceptin resistant breast cancer, 5 patients had objective responses 
and 5 stable disease. Formulation difficulties have led to the develop-
ment of new analogues of AAG including CNF101, a lipid formula-
tion of 17-AAG, 17-DMAG, a more water soluble geldanamycin 
analogue and IPI-504, a C-11 modifed analogue all of which have 
been evaluated in phase I studies the latter showing evidence of 
anti-tumour activity in relapsed GIST tumours. Toxicities observed 
with 17-AAG and its analogues include hepatotoxicity and gastroin-
testinal side-effects such as abdominal pain, vomiting and diarrhoea, 
haematological toxicities such as anaemia and thrombocytopenia and 
proteinuria and peripheral oedema.
In order to overcome the bioavailability and hepatotoxicity issues 
around AAG based compounds, several new synthetic HSP90 inhibi-
tors have been developed including BIIB021 that binds competitively 
with geldanamycin in the ATP-binding pocket of HSP90. BIIB021 
has been demonstrated to induce the degradation of HSP90 client 
proteins such as raf-1, akt, and HER2 whilst upregulating HSP70 
and HSP27 expression, common effects of HSP90 inhibition, in 
cancer cells in vitro at nanomolar concentrations. This correlates with 
inhibition of cell proliferation. The agent can be administered orally 
and has been demonstrated to have anti-tumour efficacy in animal 
models. The agent is now in clinical development alone and in com-
bination with cytotoxic chemotherapeutic agents. 
Tumour-derived HSP-peptide complexes (HSPPCs) can be used for 
vaccination against malignancies. The autologous, tumour-derived 
heat-shock protein (glycoprotein 96)-peptide complex (HSPPC-96; 
oncophage; vitespen) has recently been granted orphan status for the 
potential treatment of glioma. The results of 2 phase III studies in 
solid tumours have recently been published. In patients at high risk 
of recurrence after resection of renal cell carcinoma, adjuvant treat-
ment with HSPPC-96 vaccine had no effect on overall recurrence 
rate. However in predefined exploratory analyses by AJCC stage, a 
trend towards a reduction in recurrence in patients with stage I or II 
disease was found. In a study comparing HSPPC-96 vaccine with 
standard physician’s choice anti-cancer therapy in melanoma, no 
significant improvement in overall survival was seen. A suggestion 
of a survival benefit, however, was seen in M1a and M1b substage 
patients receiving a larger number of vitespen immunizations. Stud-
ies are ongoing in NSCLC.
In conclusion HSPs, in particular HSP90, are novel targets for 
therapy in NSCLC. The availability of relatively well tolerated anti-
HSP90 oral agents is attractive. The encouraging data suggesting 
that these agents may enhance the anti-tumour activity of established 
cytotoxic and targeted anti-cancer therapies opens up novel areas for 
therapeutic research in the future.
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HDAC inhibitors
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Histone deacetylases regulate gene expression and cell cycle progres-
sion through post-translational modification of chromatin proteins. 
HDACs also act through acetylation of non-histone proteins such 
as hsp-90, AKT, and erb-B2. Through these epigenetic effects, 
inhibitors of HDAC have been shown to induce cell cycle arrest 
and differentiation in preclinical models of several solid tumors, 
including NSCLC (Gridelli et al, Crit Rev Oncol Hematol, 2008). 
A number of structurally different classes of HDAC inhibitors have 
been developed including aliphatic acids (valproic acid, phenylbu-
tyrate, pivanex); benzamides (MS-275 and CI-994); cyclic peptides 
(depsipeptide); and hydroxamates (vorinostat and PXD-101). Vor-
inostat has been the most extensively tested agent among these, and 
it is currently FDA approved for the treatment of cutaneous T-cell 
lymphoma. 
Over the last several years, a number of studies with vorinostat 
have been conducted in thoracic malignancies. In a phase II study 
of single agent vorinostat for NSCLC, no objective responses were 
observed, but 8/14 had stable disease for a median of 3.7 months 
(Traynor et al, J Thorac Oncol, 2009). Ramalingam et al conducted 
a phase I study combining vorinostat with paclitaxel and carbo-
platin in advanced malignancies (Clin Cancer Res, 2007). Dosing 
vorinostat 400 mg daily x 14 days, or 300 mg twice daily for 7 days 
was tolerable in combination with the chemotherapy. Ten out of the 
18 chemo-naïve patients with NSCLC had partial responses and 4 
had stable disease. These encouraging results led to two phase III 
trials randomizing patients to treatment with paclitaxel/carboplatin 
with or without vorinostat. Trials combining vorinostat with other 
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chemotherapy combinations or erlotinib are also ongoing. Vorinostat 
showed evidence of single agent activity in patients with malignant 
pleural mesothelioma who were enrolled on the original phase I 
study (Kelly et al, JCO 200, Krug et al, Clin Lung Cancer 2006). 
Two of the thirteen patients with mesothelioma had responses and 4 
received more than six cycles of treatment. This observation led to 
the ongoing phase III trial comparing vorinostat to placebo as second 
line therapy in that disease. The trial has passed two interim analyses, 
and continues enrollment to a planned 660 patients.
During this session, we will discuss the mechanism of action, pro-
vide an overview of the preclinical data, and update the results on the 
clinical trials for the HDAC inhibitors.
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Pro-apoptotic agents
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The ability of a tumor cell population to expand in number is 
determined not only by the rate of cell proliferation but also by the 
rate of cell loss. Programmed cell death or apoptosis is the major 
component of the negative regulatory process. In order to survive the 
cellular stress imposed by multiple DNA changes ultimately leading 
to the development of cancer, cancer cells depend on the inhibition of 
apoptotic pathways for their survival. 
There are two major signalling pathways that lead to apoptosis by 
activating the effector caspases: the intrinsic and the extrinsic path-
way. The intrinisic pathway or mitochondrial pathway is activated 
by a wide range of signals, including cytotoxic agents, radiation and 
withdrawal of growth factors. It involves the release of cytochrome 
C and other proteins from the mitochondria. The intrinsic pathway 
is controlled by the pro-and anti-apoptotic Bcl-2 family of proteins. 
High levels of the anti-apoptotic Bcl-2 family members are associ-
ated with resistance of tumor cells to chemotherapy. Among solid 
tumors, increased expression of Bcl-2 has been reported in small cell 
lung cancer and of Bcl-xL in non-small cell lung cancer. Inhibition 
of Bcl-2 expression by antisense oligonucleotides induces apoptosis 
and sensitizes small cell lung cancer cells to the effect of chemo-
therapeutic agents. However, clinical trials failed to demonstrate 
a beneficial effect of the addition of antisense oligonucleotides to 
standard chemotherapy, most likely due to insufficient suppression of 
Bcl-2 in vivo. Because of this the hope of targeting Bcl-2 and other 
anti-apoptotic family members resides in the development of small 
molecules. A series of molecules directly interacting with the anti-
apoptotic Bcl-2 proteins have been developed. ABT-737 or its oral 
version ABT-263 binds with high affinity Bcl-2, Bcl-xL and Bcl-w. 
Both agents sensitize small cell lung cancer cells to cytotoxic agents 
and to radiation and are active as single agents in small cell lung can-
cer xenografts. ABT-263 is currently undergoing phase I/IIA testing 
in small cell lung cancer and haematological malignacies. Obatoclax 
is another Bcl-2 inhibitors is undergoing clinical testing in relapsed 
small cell lung cancer in combination with topotecan and in relapsed 
non-small cell lung cancer in combination with docetaxel. 
In contrast to the intrinsic pathway, the extrinsic pathway is initi-
ated by apoptotic signalling cascades mediated by members of the 
tumor necrosis factor (TNF) superfamily. The pathway constitutes 
of the TNF-related apoptosis-inducing ligand (TRAIL) and related 
proteins and TRAIL receptors also called death receptors. The 
TRAIL receptors TRAILR1 and TRAILR2 are promising targets for 
inducing apoptosis in cancer cells. Upon ligand binding the TRAIL 
receptors oligomerize on the cell membrane and initiate apoptosis by 
recruiting the FAS-associated protein with death domain (FADD) to 
activate caspase 8 and the effector caspases. Several agents activat-
ing the death receptor pathway are under development. These include 
the ligand recombinant Apo2L/TRAIL and agonistic monoclonal 
antibodies to TRAIL receptors. While these agents have in general 
demonstrated good tolerance in phase I studies, clinical responses 
have seldom been observed. A phase II study with Apo2L/TRAIL in 
previously untreated patients with non-small cell lung cancer in com-
bination with carboplatin and paclitaxel is currently ongoing. At least 
five antagonistic antibodies to TRAIL receptor 2 (also called DR5) 
are under investigation, these include lexatumumab, apomab, AMG 
655, LBY135 and CS-1008. Current clinical trials in non-small cell 
lung cancer include a phase I/II study of carboplatin and paclitaxel 
with AMG 655 and a randomized phase II study of carboplatin and 
paclitaxel with or without apomab. An agonistic antibody to TRAIL 
receptor 1 (also called DR4) is also under investigation in non-small 
cell lung cancer in a phase II trial in combination with chemotherapy. 
A family of inhibitor of apoptosis proteins (IAPs) are responsible for 
inhibiting distinct caspases. Prominent members are surviving and 
x-linked inhibitor of apoptosis (XIAP). Increased levels of surviv-
ing have been observed in many tumors, including lung cancer. 
Antisense oligonucleotides against survivin and XIAP have demon-
strated activity against lung cancer in vitro and in xenograft models. 
Ly-2181308, a survivin antisense compound and AEG35156, a XIAP 
antisense compound are currently being evaluated clinically. 
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Angiogenesis in lung cancer: predictive 
plasma biomarker profiles
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Angiogenesis is a critical event for tumor growth and metastasis. The 
vascular endothelial growth factor (VEGF) is an important mediator 
of angiogenesis in both physiological circumstances and the tumor 
milieu (1). Direct inhibition of VEGF or the receptor results in tumor 
regression and improved survival in preclinical models. Bevaci-
zumab, a monoclonal antibody against VEGF, has been approved for 
first-line therapy of advanced non-squamous NSCLC based on the 
positive results of two randomized phase III studies. In the ECOG 
4599 study, the addition of bevacizumab to the combination of carbo-
platin and paclitaxel resulted in an improved overall survival (2). In 
the AVAiL study, there was an improvement in median progression-
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
Copyright © 2009 by the International Association for the Study of Lung CancerS22
free survival with bevacizumab in combination with cisplatin-gem-
citabine, though overall survival was not affected (3). The results of 
these two studies have prompted the evaluation of a variety of agents 
that target the VEGF receptor. Investigations are also underway to 
identify predictive biomarkers that would select patients for treat-
ment with these agents. This would help maximize the therapeutic 
benefit in a selected sub-group while avoiding unnecessary exposure 
and toxicity in the rest of the patients. 
In the ECOG 4599 study, a variety of plasma biomarkers relevant to 
the angiogenesis were measured at baseline and after therapy with 
bevacizumab. Patients with low baseline levels of intracellular adhe-
sion molecule (ICAM) had a higher response rate (32% versus 14%; 
P = 0.02), better overall survival (P = 0.00005), and better 1-year 
survival (65% versus 25%) than those with high ICAM, respectively, 
regardless of treatment arm (4). Patients with high VEGF levels were 
more likely to respond to bevacizumab-based regimen compared 
with chemotherapy alone, but this was not predictive of survival. 
The baseline VEGF concentration has also been linked to a favor-
able progression-free survival advantage upon therapy with vande-
tanib, a small molecule VEGFR inhibitor (5). This was noted in two 
randomized studies that compared vandetanib to either gefitinib or 
chemotherapy. In both studies, the median PFS was favorable with 
vandetanib compared to other therapies in patients with low baseline 
VEGF. To the contrary, several other studies have failed to establish a 
correlation between baseline VEGF concentration and outcome with 
anti-angiogenic therapy. 
Heymach and colleagues have evaluated circulating endothelial 
cells as a predictive marker (6). In animal models, they noted two 
sub-types of circulating endothelial cells (CEC); the mature and the 
progenitor types. In response to vandetanib, there was an increase in 
the mature cells in the peripheral blood, but the progenitor cells were 
not affected. The CEC is now being evaluated in ongoing clinical 
trials of VEGF inhibitors as a potential predictive marker based on 
early changes in concentrations with treatment. Assessment of the 
phosphorylation status of the VEGF receptor in CECs is another pre-
dictive marker currently under investigation (7). It is hypothesized 
that a reduction in VEGFR phosphorylation in response to treatment 
with a VEGF inhibitor would predict for higher degree of anti-cancer 
effect. 
Recently, Schneider and colleagues reported on the impact of single 
nucleotide polymorphism in VEGF and VEGFR on the outcome in 
a study of bevacizumab and paclitaxel for patients with metastatic 
breast cancer (8). Patients with the VEGF-2578 AA genotype expe-
rienced an improved overall survival with the bevacizumab-combi-
nation regimen. Polymorphisms in the relevant genes were noted in 
approximately 30-50% of the Caucasian patients. Interestingly, two 
additional genotypes, VEGF-634 CC and VEGF-1498 TT, were asso-
ciated with significantly less grade 3 or 4 hypertension. These excit-
ing results have prompted the ECOG investigators to study the link 
between SNPs in VEGF with outcome for patients who participate in 
the ECOG 4599 study. The results of these experiments are awaited.
Circulating levels of certain pro-angiogenic factors might also be 
useful to follow patients during therapy with anti-angiogenic agents. 
In a phase II clinical trial for patients with metastatic colorectal can-
cer, elevation in the concentration of bFGF and PlGF preceded overt 
tumor progression (9). This raises the possibility that circulating 
markers could be used to predict the emergence of resistance to anti-
angiogenic therapy. Serum proteomics is another promising avenue 
that is currently under investigation for patient selection.
Taken together, the progress achieved in identifying biomarkers for 
angiogenic therapy has been minimal, though a number of promising 
leads have been identified. Validation of these markers in prospective 
trials and larger data sets will be the next step before moving these to 
routine practice setting.
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Therapeutic combinations with bevacizumab
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Vascular endothelial growth factor (VEGF) is a potent specific 
endothelial mitogen and an important mediator of angiogenesis. 
It has been implicated in tumorgenesis and represents a target for 
novel agents designed to interfere with angiogenesis. Bevacizumab 
is a humanized monoclonal antibody directed against VEGF and is 
commonly used in the treatment of colon, lung, and breast cancers. A 
randomized phase II trial, combining becvacizumab with carboplatin/
paclitaxel in the treatment of chemo-naïve patients with non-small 
cell lung cancer (NSCLC) indicated that there might be a therapeutic 
benefit with this combination.1 Because of incidents of severe pulmo-
nary hemorrhage associated with primarily squamous histology; the 
following phase III trial excluded these patients. E4599 was a phase 
III trial that randomized patients with predominantly non-squamous 
histology to receive carboplatin/paclitaxel ± bevacizumab. Patients 
who received carboplatin/paclitaxel/bevacizumab had a significantly 
better median survival of 12.3 months compared to 10.3 months for 
patients who received carboplatin/paclitaxel alone.2 For the first time, 
the one year survival surpassed 50% on the bevacizumab-containing 
study arm. The AVAil trial is another phase III study that evaluated 
gemcitabine/cisplatin plus low dose (7.5 mg/kg), high dose (15 mg/
kg) bevacizumab or placebo.3 Progression-free survival and response 
rate was significantly improved for the bevacizumab + cisplatin/
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gemcitabine study arms. Interestingly, overall survival was not sig-
nificantly different between the study arms. This however was not the 
primary study endpoint. Based on the results from these trials, there 
has been an interest in combining bevacizumab with other agents. 
In a phase II trial patients with advanced NSCLC were treated with 
carboplatin, pemetrexed, and bevacizumab followed by bevacizumab 
and pemetrexed maintenance.4 Median progression-free survival was 
a promising 9.3 months. A phase III trial is planned that will random-
ize patients to receive carboplatin/pemetrexed/bevacizumab followed 
by bevacizumab or bevacizumab and pemetrexed as maintenance 
therapy. The outcome of these studies is particularly important as 
pemetrexed moves into front-line treatment for advanced NSCLC.
Bevacizumab has also been utilized in the second-line treatment set-
ting. A randomized phase II trial compared chemotherapy (docetaxel 
or pemetrexed), chemotherapy (docetaxel or pemetrexed) plus beva-
cizumab, and erlotinib plus bevacizumab.5 The progression-free sur-
vival and overall survival favored bevacizumab plus chemotherapy 
or erlotinib over chemotherapy alone. The bevacizumab and erlotinib 
combination had the best toxicity profile. The outcome of this study 
led to the BeTa phase III trial.6 Patients were randomized to receive 
erlotinib plus bevacizumab or placebo. The primary endpoint of this 
trial was not met with no significant improvement in overall survival 
for bevacizumab and erlotinib.
Currently, bevacizumab has a role in the treatment of advanced 
disease so it makes sense to consider its use in earlier stage NSCLC. 
Adjuvant platinum-based chemotherapy has become the standard of 
care after surgical resection for stages II and IIIA NSCLC. Benefits 
from adjuvant chemotherapy are still very modest so different treat-
ment strategies are still needed. ECOG 1505 is an ongoing phase III 
trial that randomizes patients with resected stages IB ( tumors ≥ 4 
cm), II, and IIIA NSCLC of all histologies to receive platinum-based 
chemotherapy ± bevacizumab. 
The treatment of unresectable stage III NSCLC involves the integra-
tion of platinum-based chemotherapy with radiation. There is a lot 
of variability in the chemotherapy and radiation regimens that are 
employed making the integration of targeted agents somewhat dif-
ficult. It makes sense that based on its activity in advanced NSCLC, 
attempts would be made to incorporate bevacizumab in the treat-
ment of locally advanced unresectable NSCLC. When the trials 
were developed it was also theorized that by delivering radiation 
to the primary tumor, it might be possible to incorporate bevaci-
zumab in the treatment of lung cancers of all histologies including 
those that had features that might ordinarily put patients at risk for 
pulmonary hemorrhage. A trial in metastatic NSCLC led by the 
California Consortium explored the feasibility of delivering 30 Gy to 
the primary tumor of patients perceived to be at risk for pulmonary 
hemorrhage, in order to subsequently treat with chemotherapy plus 
bevacizumab. The trial was aborted early when a patient developed 
a fatal pulmonary hemorrhage despite receiving radiotherapy to the 
primary lesion. A current ongoing trial in North Carolina is treat-
ing patients with induction carboplatin/paclitaxel plus bevacizumab 
followed by weekly chemotherapy and bevacizumab given concur-
rently with radiotherapy. In subsequent phases of the trial erlotinib 
was also added to the treatment. Preliminary results were reported at 
ASCO 2008.7 About a third of the patients had significant esophagi-
tis and there was one late incidence of fatal pulmonary hemorrhage 
in a patient with squamous cell carcinoma. Another phase II trial 
from Sarah Cannon employed carboplatin/pemetrexed and bevaci-
zumab concurrent with radiation. Patients received consolidation 
chemotherapy and bevacizumab after the concurrent chemoradiation. 
The trial was designed in a stepwise fashion to allow adequate obser-
vation of patients for toxicity. Two episodes of tracheoesophageal fis-
tulas developed after the completion of all treatment. This resulted in 
early termination of the trial. (Personal Communication, D. Spigel) 
SWOG 0533 is another trial that is attempting to incorporate beva-
cizumab in the treatment of locally advanced NSCLC. Patients are 
divided into low risk and high risk strata. High risk patients have 
characteristics that might put them at risk for pulmonary hemorrhage 
such as hemoptysis, tumor cavitation, proximity of tumor to a major 
vessel, and/or predominantly squamous histology. Patients were 
accrued separately to each stratum. All patients receive concurrent 
cisplatin/etoposide and radiation followed by docetaxel consolida-
tion. In the first cohort of patients bevacizumab is given with the 
consolidation docetaxel. In the second cohort bevacizumab would 
be introduced on day 15 during the concurrent phase of treatment 
and if the treatment is determined to be safe a third cohort would 
commence with the bevacizumab being delivered on day one along 
with concurrent chemotherapy and radiation. This trial is currently 
accruing patients to the low risk stratum. The high risk stratum was 
recently closed during the first treatment cohort due to two episodes 
of fatal pulmonary hemorrhage. 
Bevacizumab has been evaluated in the treatment of small cell lung 
cancer (SCLC). In 2 separate phase II trials bevacizumab was com-
bined with irinotecan/carboplatin and cisplatin/etoposide (E3501).8,9 
In both studies the combinations were safe and the median surviv-
als were a little over 11 months. It is difficult to determine based on 
these 2 trials whether bevacizumab adds any benefit to the treatment 
of extensive stage SCLC. The results of 2 phase II studies have been 
reported that incorporate bevacizumab in the treatment of limited 
stage SCLC. In the first trial 60 patients were treated with concurrent 
carboplatin/ irinotecan and radiation followed by maintenance beva-
cizumab.10 The median survival was 17.5 months and there was one 
episode of tracheoesophageal fistula complicated by hemorrhage. In 
the second trial carboplatin/irinotecan and bevacizumab were given 
concurrently with radiation.11 The radiation started with the third 
treatment cycle. The trial was closed early for safety reasons. There 
were 2 episodes of tracheoesophageal fistula and another death from 
an aerodigestive hemorrhage.
Currently, bevacizumab plays an important role in combination with 
chemotherapy for the first-line treatment of advanced NSCLC. There 
are many questions remaining including its value in earlier stage dis-
ease, as maintenance therapy, and in patients who have failed initial 
treatment. Its utility in SCLC is still unknown. Combinations with 
radiation should only be considered in the context of a clinical trial. 
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The dependency of solid tumor growth and metastases on develop-
ment of new vasculature (neo-vascularization) was hypothesized 
decades ago. The utility of blocking angiogenesis as an anti-tumor 
therapy was initially realized with the anti-vascular endothelial 
growth factor (VEGF) antibody bevacizumab, but many other VEGF 
pathway targeted drugs, including multiple VEGFR-tyrosine kinase 
inhibitors (TKI) are also active in NSCLC. The VEGF family plays 
a key pro-angiogenic role in vascular development and VEGF is 
expressed in up to 75% of NSCLC, with a clear association between 
high tumoral VEGF expression and a worse prognosis. Direct block-
ade of VEGF with the anti-VEGF antibody bevacizumab has proven 
benefit in colon, breast and lung cancer and the agent is approved for 
use in combination with first-line chemotherapy for NSCLC patients 
in North America, Europe and parts of Asia.
There are 3 key receptors for VEGF. VEGFR-2 is the most important 
receptor in this pathway, and activation leads to induction of endothe-
lial cell proliferation, survival, and migration [1]. VEGFR-1 plays a 
regulatory role by VEGF sequestration or stimulation of hematopoi-
etic stem cell migration, while VEGFR-3 mediates lymphangiogen-
esis, and has been associated with lymph node metastasis [16]. The 
tyrosine kinase inhibitors that block VEGFR2, among other targets 
include Vandetanib (ZD6474/Zactima), Cediranib (AZD2171), 
Sorafenib (BAY43-9006, Nexavar), Sunitinib (SU11248, Sutent), 
Axitinib (AG-013736), Vatalanib (PTK787,ZK-222584), Pazopanib 
(GW786034), Motesanib (AMG 706), and multiple others less far 
along in development [2]. They are all small molecules, which bind 
to the adenosine triphosphate pocket of the tyrosine kinase (TK) resi-
dues of the internal domain of the receptor, thus inhibiting activation, 
and downstream signalling. In addition to VEGFR-2, they all have 
multiple other targets, which lead to the variable toxicity and efficacy 
results seen to date. All are oral agents. While many have single 
agent activity, the results of chemotherapy combination trials with 
them to date have been disappointing due to toxicity.
Vandetanib (ZD6474 /Zactima): is an oral anilinoquinazoline, and 
inhibits VEGFR-1, VEGFR-2, VEGFR-3, RET, and EGFR [3]. A 
phase I study included 49 patients, with a maximum dose tolerated 
of 300 mg daily. Hypertension, and QTc prolongation were the most 
important adverse events [3]. No unexpected toxicities were seen in 
phase I/II combination trials with pemetrexed or docetaxel [4, 5]. In 
a randomized phase II study versus gefitinib in 168 patients the PFS 
was 11 weeks vs 8.1 weeks for vandetanib vs gefitinib, respec-
tively. Grade 3/4 Adverse events were diarrhea (8.4%), and rash 
(4.8%) [6]. Another phase II tested 3 arms (arm A: vandetanib 100 
mg+docetaxel, arm B: vandetanib 300 mg+docetaxel, and arm C: 
docetaxel alone) in 127 NSCLC previously treated by chemotherapy 
with platinum. The median PFS was 18.7 weeks, 17 weeks, and 12 
weeks for arms A, B, and C, respectively. [4]. These results led to 
4 recently completed phase III trials, ZODIAC, ZEAL, ZEST, and 
ZEPHYR. The ZODIAC and ZEAL trials were second line trials of 
docetaxel or pemetrexed with or without vandetinib and preliminar-
ily the docetaxel (ZODIAC) study, but not the pemetrexed (ZEAL) 
met its PFS primary endpoint and both showed a trend in favor of OS 
with the addition of vandetanib. A direct comparison of vandetinib to 
erlotinib (ZEST) found equivalent PFS and OS with the compounds. 
Results are not yet known for the. ZEPHYR study which randomized 
patients to vandetinib versus placebo. More details of at least 3 of 
these trials are expected at the ASCO 2009 meeting.
Cediranib (AZD2171) (Cediranib): inhibits VEGFR-1, VEGFR-2, 
VEGFR-3, PDGFR-Beta, and c-Kit [7]. As a single agent, the drug is 
well tolerated at doses up to 45mg daily with toxicities of hyperten-
sion, headache, diarrhea, and voice hoarseness. In phase II chemo-
therapy combination trials in previously untreated advanced stage 
NSCLC patients, response rates were high and toxicities included 
fatigue, diarrhea, febrile neutropenia, mucositis, anorexia, and hyper-
tension [8]. Doses of 45 mg daily and above were associated with 
increased toxicity. A phase II/III trial of carboplatin/paclitaxel with 
or without cediranib, run by the NCI-Canada Clinical Trials Group 
found the combination active, but too toxic at a 30 mg dose and there 
are plans to restart the trial with 20 mg dosing of cediranib.
Sorafenib (BAY43-9006, Nexavar): inhibits raf-kinase, VEGFR-1, 
VEGFR-2, VEGFR-3, PDGFR-Beta, Flt-3, c-kit, and p38-alpha [9] 
and has proven activity in renal cell carcinoma, and hepatocellular 
carcinoma. The usual dose is 400 mg twice daily with common tox-
icities including diarrhea, and skin toxicities (hand-foot syndrome). 
Single agent activity in NSCLC is limited, though prolongation of 
disease stability has been seen. In a monotherapy trial in untreated 
stage IIIB/IV NSCLC (n=20), the ORR was 12%, the disease control 
rate was 40%, and the median survival was 8.8 months. Adverse 
events included grade significant fatigue, diarrhea in about 10% of 
patients and 1 patient with a grade 4 pulmonary hemorrhage [10]. 
Trials of the drug in NSCLC patients who had received prior therapy 
reported similar toxicity profiles with response rates of 0-13%, 
disease stability over 50% and PFS around 5 months. Most recently 
a large phase II trial, employing a randomized discontinuation 
design provided more definitive evidence for single agent activity 
of sorafenib. E2501 enrolled 342 patients and compared sorafenib 
vs placebo in NSCLC patients after failure with 2 prior regimens of 
chemotherapy. After a 2 month lead-in period in which all patients 
received active drug, eligible patients with stable disease (n=83) 
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were randomized to sorafenib versus placebo with a median PFS of 
3.6 months and 2 months (p.009) and median survival of 11.9 and 
9.0 months (NS) in the sorafenib and in the placebo arms respec-
tively. Grade 5 Adverse events were one renal failure and two with 
pulmonary hemorrhage and there were 4 patients with significant 
(grade 4) cerebrovascular ischemia events. The other toxicities were 
fatigue, hand foot reaction, and rash [11]. These encouraging results 
have led to a randomized phase III trial currently in development 
looking at the drug versus placebo in patients who have had prior 
chemotherapy. 
Combination trials with the drug have been less encouraging. In 
a phase III trial of 926 chemotherapy-naïve patients with stage 
IIIB/IV NSCLC patients who received carboplatin/paclitaxel +/- 
sorafenib, the drug failed to show an improvement in survival and 
greater toxicities were observed in the sorafenib arm, in particular 
in patients with squamous histology. Thirteen patients had a fatal 
pulmonary hemorrhage [12]. A similar phase III trial, NEXUS uti-
lized cisplatin+gemcitabine with or without sorafenib and completed 
accrual in February 2009, with a restriction to patients with non-
squamous histology. 
Sunitinib (SU11248, Sutent): is an oral multi-target TKI against 
VEGFR-1, VEGFR-2, PDGFR, c-KIT, and FLT-3 [13] approved for 
the treatment of renal cell carcinoma and refractory gastrointestinal 
stromal tumors (GIST). Dose limiting toxicities observed in phase 
I and II trials were asthenia, hypertension, and bullous skin toxicity 
with pulmonary hemorrhage seen in NSCLC specific studies [13]. 
Single agent activity in NSCLC with a 9.5% ORR was seen with 
an intermittent dosing schedule (4 weeks on/2 weeks off) [14]. In a 
randomized phase II study including non-squamous NSCLC patients 
treated with the combination of carboplatin+paclitaxel+bevacizumab 
with or without sunitinib 5 grade 5 adverse events occurred in a total 
of 56 patients. Though the toxicity in combination with first-line che-
motherapy is concerning, the single agent activity of the compound 
is very encouraging and the Cancer and Leukemia Group B is plan-
ning a large maintenance trial using the drug after completion of first 
line chemotherapy. In the phase III trial patients will be randomized 
to receive sunitinib, pemetrexed or both sunitinib and pemetrexed 
after completion of first line chemotherapy. Combination trials with 
erlotinib are also ongoing. 
Axitinib (AG-013736): is a small molecule that inhibits VEGFR1, 
VEGFR2, VEGFR3, PDGFR, and c-Kit. The maximum tolerated 
dose is 5 mg twice daily and reported adverse events include hyper-
tension, seizure, elevation of liver tests, fatigue and diarrhea. A phase 
II trial in 32 advanced NSCLC found 3 responses (9.4%), a median 
survival of 12.8 months, and PFS of 5.8 months [15], which led to an 
ongoing phase III trial of axitinib in advanced NSCLC.
Vatalanib (PTK787, ZK-222584): inhibits VEGFR-1, VEGFR-2, 
VEGFR-3, PDGFR, c-Kit, and c-Fms with adverse events including 
fatigue, dizziness, and vomiting, hypertension, ataxia, and dyspnea. 
In a phase II monotherapy trial in previously treated NSCLC the 
agent had a moderate efficacy with a RR of 10%, and an OS of 7 
months, but 3 fatalities occurred (2 pulmonary hemorrhages, 1 pul-
monary embolism) [16]. Another phase II trial in pre-treated NSCLC 
using dynamic contrast-enhanced magnetic resonance measure-
ments showed a statistically significant reduction in tumor vascular 
parameters. 
Pazopanib (GW786034) was tested in stage I/II NSCLC patients 
treated for 2-6 weeks before surgery and in twenty-three evalu-
able, 20 (87%) had reduction of the tumor volume and 3 had partial 
response and treatment was associated with decreases in sVEGFR-2, 
and a strong correlation existed between sVEGFR-2 changes and 
tumor shrinkage [17]. Development of this drug, with detailed cor-
relative studies is ongoing.
Motesanib (AMG 706): is an oral multi-kinase inhibitor against 
VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, RET, and Kit. This mol-
ecule was analyzed in a phase I study in patients with advanced solid 
tumor with a maximum tolerated dose of 125 mg daily. Combination 
trials of the drug with panitumumab, and carboplatin+paclitaxel or 
panitumumab with cisplatin and gemcitabine have been conducted 
with grade 3/4 adverse events of fatigue (45%), hypertension (27%), 
dyspnea (9%), sinusitis (9%), and pulmonary embolism (9%) [18]. 
Currently, a phase III with carboplatin+paclitaxel is ongoing.
Other VEGFR-TKIs in early stages of development include BIBF 
1120, XL647 (which has more EGFR-TKI activity), CP-547,632, 
E7080, AEE788, KRN951, ABT-869, OSI-930 and BMS-690514 
among others. Many of the compounds are also under exploration in 
small cell lung cancer.
Conclusions
The therapeutic benefit of anti-angiogenic agents in lung cancer and 
other malignancies has been proven with the anti-VEGF antibody 
bevacizumab, with growing data in support of other strategies such 
as inhibition of the VEGF-receptor. The VEGFR-TKIs as a class 
have expected VEGF target toxicities such as hypertension and 
proteinuria, but given various off-target inhibition some also have 
unique toxicities such as hair discoloration, and mental status chang-
es (table 1). Many have proven single agent activity, but combination 
chemotherapy trials have been fraught with toxicity, particularly 
in patients with squamous cell histology. How best to utilize these 
agents, in which patients and in combination with which other drugs 
remains an area of active investigation with considerable promise.
Table 1: Toxicities of VEGFR-TKIs
Inhibitor Company Toxicity
Vandetanib-ZD6474 AstraZeneca Diarrhea, rash, hypertension (mild), proteinuria, 
  ↑ QTc interval
Cediranib-AZD2171 AstraZeneca Fatigue, nausea/vomiting, diarrhea 
Sunitinib-SU11248 Pfizer Asthenia, rash, skin discoloration (yellow), 
  hair depigmentation, neutropenia, hypertension 
  stomatitis, diarrhea, nausea/vomiting
Sorafenib-BAY43-9006 Bayer Diarrhea, fatigue, pancreatitis, hypertension, 
  hand/foot syndrome
Axitinib- AG013736 Pfizer Fatigue, Hypertension, transaminitis, seizure, 
  stomatitis, diarrhea, nausea/vomiting, anorexia 
  arthralgia, rare epistaxis/hemoptysis
Valatanib-PTK787 Novartis Fatigue, nausea/vomiting, dizziness, 
  ataxia, transaminitis
Pazopanib-GW786034 GlazoSmithKline Fatigue, hypertension, nausea/vomiting,  
  anorexia, diarrhea, hair depigmentation,  
  extrapyramidal disorder, transaminases
Motesanib- AMG-706 Amgen Hypertension, diarrhea, fatigue, cholecystitis
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Histopathological diagnosis on frozen examination
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An accurate histopathological intraoperative diagnosis by frozen sec-
tion examination is essential for (1) providing gross or microscopic 
diagnoses to guide intra- or perioperative patient management to 
establish the type and extent of the surgery; (2) optimally process-
ing tissue for special studies to be used for diagnosis, treatment 
or research; and for (3) confirming that lesional tissue is present 
for diagnosis on permanent sections and/or after special studies. 
The most common diagnoses requested are: (a) identification of an 
unknown pathologic process, (b) evaluation of margins, (c) identi-
fication of mediastinal lymph node metastases, and (d) identifica-
tion of tissue types. The diagnostic information provided by frozen 
section analysis is limited compared to the information that can be 
provided in the final sign-out of a case based on permanent sections. 
For these reasons, the goals of intraoperative consultations must be 
limited to what is feasible under these conditions. In most cases, the 
pathologist is able to provide the information needed by the surgeon 
to perform the surgical resection. 
1. Patients with mediastinal staging of lung carcinomas are often 
required a frozen examination to determine if a lung carcinoma is 
resectable or to terminate lymph node sampling once a positive 
node is found. 
2. Patients with pulmonary resections for lung masses are required 
a frozen section examination to identify if the malignant or 
benign nature of the mass. If the mass is identified as malignant, 
additional surgery may be indicated to ensure that the margins 
are uninvolved and to establish a thorough pathologic staging. 
The final surgical resection specimen is evaluated by frozen sec-
tion examination for the presence of malignancy at the surgical 
resection margin. In wedge resection specimens perpendicular or 
en face sections of lung tissue in areas closest to lung tumor are 
sampled to evaluate the relationship of the tumor to margins. In 
lobectomy and/or pneumonectomy specimens, the distance to the 
bronchial margin is assessed, the bronchial margin sectioned en 
face, and assessed by microscopic evaluation for the presence of 
tumor. 
3. Frozen sections for open lung biopsies are usually performed in 
critically-ill patients with a wide differential diagnosis, to provide 
a preliminary diagnosis (infection or tumor) and to guide the 
distribution of tissue for ancillary studies. 
In each of these clinical scenarios, the potential pitfalls are discussed, 
as well as the negative and false positive rates for each type of frozen 
section examination.
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Introduction
Cytology obtained by bronchoscopy and fine-needle aspiration 
(FNA) is a cornerstone in the diagnosis of lung cancer [1]. In our 
institution, more than one third of all lung carcinomas are diagnosed 
by cytology alone. In particular, transbronchial FNA is often very 
helpful in diagnosing carcinomas that are poorly accessible by bron-
chial biopsy. In addition, transbronchial FNA guided by endobron-
chial ultrasound (EBUS) has become a standard method for mediasti-
nal staging. Nevertheless, lung cytology including FNA faces several 
challenges. 
Diagnostic reliability of FNA cytology
There is no doubt that FNA cytology often allows for an unequivocal 
diagnosis of lung cancer provided sufficient education and exper-
tise in cytology. However, as in many fields of pathology, there is a 
challenging and difficult area of uncertain morphological findings. 
In our institution, approximately 2% of all patients who undergo 
bronchoscopical evaluation are left with an unsatisfactory diagnosis 
of equivocal cytology. In an international online study on equivocal 
lung cytology, we found that many of these difficult cases are refrac-
tory even to experts in the field (http://www.unibas.ch/patho/lungen-
zyto/loesung/) [2]. Since chromosomal alterations are a hallmark of 
cancer, chromosomal analysis could help in differentiating reactive 
from malignant changes. In fact, a multi-target fluorescence in situ 
hybridization (FISH) assay (LA Vysion™, Abbott Molecular) for the 
simultaneous analysis of Chromosome 6 and the 5p15, 7p12 (EGFR 
gene), and 8q24 (MYC gene) loci, respectively, was designed to 
improve the sensitivity in lung cytology. If combined with automated 
relocation of the cells in question, this assay is a powerful tool to 
clarify equivocal lung cytology, reaching a sensitivity of 79% and 
a specificity of close to 100%. Thus, lack of a negative FISH result 
in atypical cells is in favor of reactive changes, and an expectant 
strategy with clinical controls can be considered in these patients. In 
contrast, presence of chromosomal aberrations is strongly in favor 
of cancer and warrants further actions for morphological proof of 
cancer without delay.
Primary lung cancer or metastasis?
Immunocytochemistry has grown to an indispensable tool for a 
precise classification tumor cells and infiltrates. This technique is not 
restricted to histology but also amenable to cytological routine speci-
mens. Due to the increasing number of lung patients with a history 
of previously treated cancer of other body sites, we are often asked 
to differentiate a primary lung carcinoma from lung metastasis of a 
known or suspected non-pulmonary cancer. While a distinction can 
sometimes be assumed safely based on characteristic cytomorpho-
logical features, immunocytochemical proof is usually mandatory. 
Several well-established antibodies allow for a definitive decision 
on the type and primary site of the tumor, or greatly narrow down 
the number of possible primary sites. The most commonly used 
antibodies include thyroid transcription factor (TTF-1), cytokeratins 
7 and 20, (CK 7 and 20), and caudal-type homeobox transcription 
factor 2 (CDX2). E.g., TTF-1 is almost specific for lung and thyroid 
adenocarcinoma, while CDX2 is typically expressed in colorectal 
adenocarcinoma but only exceptionally in pulmonary adenocarci-
noma. Specialized online databases such as Immunoquery (www.
immunoquery.com) aid in interpreting the increasing complexity of 
marker combinations and expression patterns. 
Squamous or non-squamous?
The specific subtypes of a non-small cell lung cancer (NSCLC) can 
often be determined even in small biopsies and cytological speci-
mens based on unequivocal morphological features. However, in up 
to 30% of such specimens, a reliable subtyping beyond the umbrella 
diagnosis of NSCLC remains impossible. This problem of imperfect 
classification in small diagnostic biopsies and cytology is relevant, 
since the majority of all patients with NSCLC are no candidates for 
surgical treatment by surgery. Until recently, the specific subtype 
of NSCLC was of no particular interest to the clinicians, as this 
information did not influence treatment decisions. This has changed. 
There is now compelling evidence that the histological subtype mat-
ters. Recent data suggest that pemetrexed (Alimta®) is only active 
in non-squamous cell carcinoma, and that bevacizumab (Avastin®) 
should not be given to patients with squamous cell carcinoma due 
to increased risk of bleeding. In addition, good response to tyrosine 
kinase inhibitors such as erlotinib (Tarceva®) is much more likely in 
adenocarcinoma than in the other subtypes. Immunocytochemistry 
can successfully enforce subtyping by combination of markers that 
are typically expressed in squamous cell carcinoma (CK5/6 and p63) 
or in adenocarcinoma (CK7 and TTF-1), respectively. E.g. we calcu-
lated that the accuracy of combined analysis of CK5/6, p63 and CK7 
for differentiation of SCC from AC reaches up to 97% with only 3% 
miss classifications. These markers do also reliably work on cyto-
logical specimens. Despite this progress, it is important to note that 
solely histological features define the classification of lung cancer by 
the WHO with no reference to immunocytochemical phenotype. This 
is also true for previous clinical trials, where immunocytochemi-
cal typing was usually not done. Therefore, it remains to be proven 
whether or not immunocytochemical distinction between squamous 
and non-squamous phenotype is superior to morphology alone for 
patient selection [3].
Predictive molecular analyses
Selection of individual patients for therapies with new drugs that 
are directed against specific molecular targets becomes increasingly 
important. Since the diagnosis of malignant primary tumors or dis-
tant metastases is often based on cytology alone, molecular analyses 
of therapeutic targets that are performed from histological material 
must also be amenable to cytological specimens, which often contain 
a high number of excellently preserved cancer cells. Epidermal 
growth factor receptor gene (EGFR) analysis in lung cancer is cur-
rently one of the most prominent examples. 
EGFR mutations, increased copy numbers, and EGFR protein 
expression are considered as predictors of response to EGFR 
tyrosine kinase inhibitors (EGFR-TKI) in non-small cell lung cancer 
(NSCLC) [4]. The relative predictive importance of these markers 
has been controversial across different studies [5]. However, pres-
ence of an activating mutation of the exons 19 and 21 is generally 
regarded as highly important as it can predict dramatic clinical 
response to TKI therapy. The technical challenge of EGFR and 
KRAS mutation analysis lies in the isolation of a pure tumor cell 
population from small biopsies and cytological specimens in order to 
avoid dilution of tumor cell DNA with DNA from benign cells. This 
can be well achieved by using laser-assisted microdissection (LMD). 
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LMD allows isolating single cells or small groups of cells out of 
routinely processed cytological specimens [6, 7].
Increased copy numbers of the EGFR gene might also independently 
predict therapy response [5]. The criteria for a positive EGFR FISH 
status defined by Cappuzzo et al. include high-level amplification 
(at least two times more gene signals than centromeric signals or 
≥15 EGFR signals in at least 10% of the cells) or a “high polysomy” 
defined as (≥4 EGFR signals in ≥40% of the cells) [8]. However, 
these criteria were established on histological specimens and cannot 
readily be translated to cytological specimens. The nuclei in cyto-
logical specimens are intact and always contain the true number of 
gene signals. In contrast, a fraction of the nuclei including chromo-
somal material on histological sections is truncated. Therefore, the 
prevalence of “high polysomy” is at least twice as high in cytological 
specimens as compared to histological specimens, leading to “false 
positive” results when the criteria that were established on tissue sec-
tions are considered as the gold standard [6]. Interestingly, we found 
the interobserver concordance of the Cappuzzo criteria was only 
moderate in histological specimens (k=0.5) but excellent in cytology 
(k=0.94). Other than the Cappuzzo criteria, the mean copy number 
(MCN) showed excellent interobserver concordance both in cytology 
and histology (Zlobec et al, unpublished). This suggests that MCN is 
superior to the Cappuzzo criteria for the analysis of the EGFR gene 
copy number status by FISH. Furthermore, we calculated a formula 
that can reliably predict the histology MCN based on the cytology 
MCN, allowing using the same thresholds for treatment decisions 
irrespective of the type of tumor material. 
In recent recommendations by a Non-Small-Cell Lung Cancer 
Working Group the use of cytological specimens for EGFR analysis 
was discouraged, especially in clinical trials [9]. This was based on 
the assumption that there are no established and validated IHC or 
FISH assays in cytology. It was also believed that cytology smears 
are not amenable to standardized FISH analysis due to non-uniform 
thickness and three-dimensional clusters. In addition laser cap-
ture microdissection of cytological specimens was considered as 
extremely laborious. We agree that it might be reasonable to enforce 
the collection of biopsy tumor tissue in clinical trials n order to 
enable multiple marker analyses on serial sections. However, consid-
ering that approximately 40% of all lung cancers are diagnosed by 
cytology alone, such an apodictic rule would require rebronchoscopy 
in a sizeable fraction of patients (with no guarantee of a representa-
tive biopsy). There is no reason to believe that EGFR gene analysis is 
more problematic from cytological than from histological specimens. 
LMD technology is not a fancy research tool any more but has 
become a standard method in laboratories offering advanced molecu-
lar analysis from small diagnostic specimens. In addition, EGFR 
FISH analysis is technically straightforward in, as outlined above. In 
diagnostic routine, the decision on whether to use biopsy or cytology 
material for EGFR mutation analysis should be made individually, 
depending the availability, quantity and quality of tumor cells in the 
specimens.
Conclusion
Cytology including FNA is a well-established method for the diag-
nosis of lung cancer. While cytomorphology remains the diagnostic 
cornerstone, is must meet new demands such as prognostic and pre-
dictive information. As in histology, this can be achieved by molecu-
lar technologies. It is clear that advanced molecular analysis on small 
biopsies and cytological specimens is not trivial and requires special 
expertise and equipment such as automated relocation and laser 
microdissection. Institutions that cannot keep pace with this develop-
ment should consider collaborating with specialized centers.
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Assessment of invasion before surgery
Borczuk, Alain C.
Columbia University Medical Center, New York, NY, USA
The definition of bronchioloalveolar carcinoma, non-mucinous type 
as a noninvasive adenocarcinoma (adenocarcinoma in situ) by the 
WHO in 1999 as well as data both prior to 1999 and after 1999 indi-
cating a favorable prognosis for this subtype has led to an interest in 
recognizing this entity prior to surgical intervention. This interest has 
been bolstered by the fact that screening approaches for lung cancer 
increases detection of adenocarcinoma when compared to other sub-
types. It is possible that “lung sparing” wedge resections of the lung 
rather than anatomic lobectomy may be adequate for indolent bron-
chioloalveolar carcinomas. The decision tree for surgical intervention 
when a lung nodule is encountered depends on clinical features of 
the patient and radiologic features of the nodule for risk assessment 
into low, intermediate, and high probability of malignancy groups. 
Specifically focusing on the intermediate group, tissue sampling 
either by fine needle aspiration or biopsy is an option to determine 
a diagnosis of malignancy. In the high risk group, frozen section 
confirmation of a malignant diagnosis prior to a definitive anatomic 
resection (lobectomy versus pneumonectomy) is often performed.
Fine needle aspiration or core biopsy sampling can both be used to 
assess malignancy preoperatively. These techniques yield differ-
ent sample preparations that in the case of cytologic preparations 
emphasize cytomorphology with some residual intercellular tumor 
cell architecture. Tissue biopsies are better at preserving architec-
tural structure of tumor especially in relation to pre-existing lung 
architecture as well as tumor induced stromal changes. In fine needle 
aspiration specimens, cell block samples can sometimes bridge 
the cytomorphology with some of the features of tissue biopsy 
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architectural preservation. These two sample types can provide infor-
mation regarding histologic classification of tumors, and in doing so 
can recognize patterns of small cell carcinoma, squamous carcinoma, 
and subtypes of adenocarcinoma. If there is a recognized subtype of 
invasive adenocarcinoma (such as papillary, micropapillary, acinar 
or solid), then the diagnosis of an invasive adenocarcinoma can be 
rendered.
The difficulty with this approach occurs when the tumor has a 
predominant or exclusive bronchioloalveolar carcinoma pattern. 
While this can be commented on in both aspiration and tissue biopsy 
samples, quantitation of microscopic invasion and exclusion of inva-
sion in the unsampled portions of the tumor cannot be performed. 
Therefore based on morphologic assessment of biopsy type samples, 
a preoperative decision to perform a sub-anatomic resection such 
as a wedge resection cannot be made with absolute certainty based 
on a biopsy sample alone, but potentially the integration of clinical, 
radiologic, and pathologic parameters could improve the predic-
tion of what will be an exclusively non-invasive bronchioloalveolar 
carcinoma on resection.
Frozen section diagnosis offers the same problem of sampling for 
the certain exclusion of invasion. Frozen section diagnoses can offer 
a diagnosis of unequivocal invasion using parameters of histologic 
subtype, stromal invasion and invasion of other structures such as 
vessels or pleura, but with predominant or exclusive bronchioloal-
veolar carcinoma the issue of complete sampling and the technical 
limitations of frozen sections limit the certainty of that diagnosis. 
This could be aided by the observation that small foci of invasion, 
perhaps up to 5 mm, do not appear to impart significant reductions 
in survival and do not appear to be associated with lymph node 
metastasis. However since such studies were conducted in situa-
tions in which anatomic resections were performed in the majority 
of patients, information on the impact on survival of micro-invasive 
lung adenocarcinoma when compared to exclusively in situ carci-
noma remains very limited.
Therefore current methodologies allow for greater certainty when 
invasion is present then when it is absent or focal on a tissue speci-
men. Based on this observation, a definitive classification histologi-
cally of bronchioloalveolar carcinoma or predominant bronchi-
oloalveolar carcinoma with microscopic foci of invasion requires 
extensive examination of a nodule in a fashion that is not conducive 
to small biopsies or cytologic samplings.
This observation highlights a potential role for molecular studies on 
small samples that may guide pre-surgical assessment. Such a test 
may play a role in both the intermediate and high risk category lung 
nodule. While this is still speculation for the future, testing for gene 
expression, mutations, or allelic imbalance/copy number alteration 
are all potential platforms for investigation. It is clear, however, that 
once such a test is formulated, that its ability to predict invasiveness 
needs to be validated both on retrospective data sets to associate 
the result with invasion and lymph node/distant metastasis and on 
prospective data sets that may include patients that been randomized 
to different surgical options (e.g. wedge or sub anatomic resections 
versus anatomic resections).
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Challenges of tobacco control in the 
US and around the world
Glantz, Stanton A.
University of California San Francisco, San Francisco, CA, USA
This is a time of transition for tobacco control, both in the United 
States and globally.
Smokefree policies are spreading rapidly around the USA and the 
world, and these policies both protect people from the carcinogens 
and other toxins in secondhand smoke and create an environment 
that encourages people to stop smoking or not to start. The evidence 
that large scale state tobacco control programs can not only reduce 
smoking, but also smoking-induced disease (including lung cancer) 
continues to accumulate. Despite this evidence of proven efficacy, 
these programs continue to struggle for the funding necessary to 
sustain them.
At the federal level, as of this writing (April, 2009), the House of 
Representatives had passed a bill giving the Food and Drug Adminis-
tration jurisdiction over tobacco products and action was anticipated 
in the Senate. This bill, while widely supported by health advocates, 
represents a compromise with Philip Morris Tobacco Company, and 
it contains several provisions which may affect its effectiveness in 
reducing tobacco-induced disease.
At the same time, the tobacco industry is responding to the declining 
social acceptability of smoking by developing and test-marketing a 
new generation of “smokeless” products. These products, which are 
often cobranded with cigarettes, my promote “dual use which has the 
effect of keeping people smoking cigarettes.
At the international level, 164 countries had ratified (not including 
the USA) the Framework Convention on Tobacco Control, the first 
global public health treaty, which is stimulating tobacco control 
efforts around the world. At the same time, the tobacco industry is 
working to undermine effective implementation of the FCTC. 
All these developments make 2009 a time of opportunity for reduc-
ing tobacco use and the associated lung and other cancer burden.
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Tobacco control strategies in Europe
Britton, John
University of Nottingham, Nottingham, Great Britain
Tobacco smoking is the largest avoidable cause of cancer and other 
major morbidity and mortality in Europe, and is also the biggest 
avoidable cause of social inequalities in health. Currently there are 
about 100 million smokers living in European Union (EU) countries, 
in which about 650,000 people die each year as a consequence of 
their own smoking and about 19,000 non-smokers from exposure to 
others’ smoke. Over 40% of deaths from smoking (285,000) are due 
to cancer, particularly lung cancer (190,000); the majority of the rest 
are due to heart disease (183,000) and chronic obstructive pulmonary 
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disease (113,000). About 13 million people in the EU are currently 
living with a serious disease caused by smoking. 
The overall prevalence of smoking in the EU in 2006 was about 27% 
and falling in most, but not all, countries. The country with the low-
est prevalence, at 18%, was Sweden. The extent to which different 
EU countries have implemented tobacco control measures is highly 
variable, both between countries and in relation to specific policy. 
Advertising and promotion, for example, is now banned in all EU 
countries, whilst others, such as price and smoke-free policy imple-
mentation, vary substantially. 
In this presentation I will review progress across the EU in relation to 
implementation of the main components of tobacco control policies 
of proven efficacy, relating to: 
• Price
• Prevention of tobacco advertising, promotion and product 
placement
• Health promotion campaigns
• Health warnings on packs
• Smoke-free policy
• Cessation services
I will also review the emerging debate on the potential role of harm 
reduction in tobacco control, summarising the potential for more 
widespread use of medicinal nicotine as a smoking substitute, 
and reviewing the controversy over the contribution of smokeless 
tobacco products to the especially low prevalence of both smoking 
and lung cancer in Sweden. 
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Tobacco epidemic and tobacco control in China
Zhi, Xiuyi
Beijing Lung Cancer Center, CMU, Beijing, China
The Chinese government pays a great deal of attention to tobacco 
control and actively participates in the international tobacco control 
movement. From 2000 to 2003, a State Council-approved intergov-
ernmental negotiation entity consisting of twelve ministries (com-
missions and administrations), including the National Development 
and Reform Commission, the Ministry of Health, and the Ministry of 
Foreign Affairs, actively supported and participated in the negotia-
tion and development of the Framework Convention on Tobacco 
Control (the Convention).
On May 21, 2003, the 56th World Health Assembly Session unani-
mously passed the Convention. China signed the Convention on 
November 10, 2003. On August 28, 2005, the 17th Session of the 
Standing Committee of the 10th National Peoples Congress formally 
ratified the Convention, making China the 89th ratifying country. 
On October 13, 2005, the Chinese government held a launching 
ceremony for the Convention, which became effective in China on 
January 9, 2006.
In January 2007, the State Council approved the establishment of 
the China Convention Inter-Ministerial Coordination Mechanism, 
consisting of eight ministries (commissions and administrations) 
including the National Development and Reform Commission and 
the Ministry of Health, to actively and effectively implement the 
Convention. This mechanism is based on the former Chinese inter-
governmental negotiation entity, and is tasked with the coordination 
of Convention implementation in China.
These steps and measures underline the importance China gives 
to tobacco control and highlight Chinas serious commitment to 
strengthening international cooperation under the framework of 
the Convention to strengthen public health and protect the citizens 
health. The Convention poses new opportunities and challenges for 
China in tobacco control.
Article Eight of the Convention, Protection from Exposure to 
Tobacco Smoke, states:
1.  Parties recognize that scientific evidence has unequivocally estab-
lished that exposure to tobacco smoke causes death, disease, and 
disability.
2.  Each Party shall adopt and implement the Convention in areas of 
existing national jurisdiction, as determined by national law, and 
actively promote at other jurisdictional levels the adoption and 
implementation of effective legislative, executive, administrative 
and/or other measures, providing for protection from exposure 
to tobacco smoke in indoor workplaces, public transport, indoor 
public places and, as appropriate, other public places.
It is estimated that each year, more than 100,000 people die from 
passive smoking in China. Each fallen life testifies against passive 
smoking. However, a significant proportion of the public is not 
clear about the health hazards caused by passive smoking. In indoor 
workplaces, public transport, and indoor public places, exposure to 
passive smoking remains high. There is a significant gap in China 
from what the Convention mandates.
Smoke-Free Environments was the theme for 2007’s World No 
Tobacco Day. The Office for Tobacco Control and Convention 
Implementation at the Ministry of Health organized experts to 
compile and publish the 2007 China Tobacco Control Report: Create 
a Smoke-Free Environment, Enjoy a Healthy Life to publicize the 
hazards of passive smoking and to take concrete steps to implement 
the Convention in China,.
Many Chinese people currently lack a deep understanding of the 
hazards caused by passive smoking. The Report lists the scientific 
evidence on health hazards caused by passive smoking, elaborates on 
the seriousness of the Chinese peoples exposure to passive smok-
ing hazards, analyzes key impacts of passive smoking and studies 
the public attitude towards prohibiting smoking in public places and 
current legislation. In addition to these, it proposes related challenges 
and recommendations.
It is intended that the Report will support government at various lev-
els to promulgate and to effectively implement such laws or regula-
tions to protect the public from exposure to passive smoking hazards 
in indoor workplaces, public transport and indoor public places.
Law enactment for banning smoking in public places in China
1) National laws and regulations 
Today China does not have a national law or regulation specifically 
banning smoking in public places. Related stipulations appear in 
some provisions or detailed rules of relevant laws and regulations. 
For example, the Ministry of Healths 1991 Detailed Implementation 
Rules for the Public Place Hygiene Management Regulation, enacted 
by the State Council in 1987, stipulates that smoking is banned in 
thirteen types of public places: cinemas and theaters, video theaters, 
music halls, ballrooms, music tea rooms, recreational halls, sports 
arenas, libraries, museums, fine art galleries, shops, bookstores, and 
waiting rooms for public transport.
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In 1991, the 20th plenary session of the Standing Committee of the 
7th National Peoples Congress passed the Tobacco Monopoly Law 
of the Peoples Republic of China. The General Principles of this law 
stipulate that the State and society shall strengthen the publicity and 
education of the health hazards of smoking, and prohibit or restrict 
smoking in public transport and public places.
In 1991, the 21st plenary session of the Standing Committee of the 
7th National Peoples Congress passed the Law on the Protection of 
Minors of the Peoples Republic of China. Its 27th article stipulates 
that no one should smoke in the classrooms, sleeping and activity 
rooms of primary and middle schools, kindergartens, and childcare 
centers, as well as other rooms where minors convene.
In 1997, the National Patriotic Public Health Campaign Committee, 
Ministry of Health, Ministry of Railroads, Ministry of Communica-
tions, Ministry of Construction, and Civil Aviation Administration 
enacted the Regulations on Prohibiting Smoking in Public Transport 
and Waiting Rooms, setting out further requirements on banning 
smoking in public transport and waiting rooms.
2) Local regulations
Local law enactment to ban smoking in public places first began in 
1993. By the end of October 2006, 154 cities across mainland China 
had enacted regulations to ban smoking in public places. During 
those thirteen years local regulations to ban smoking in public places 
were implemented and developed, playing some role in controlling 
smoking in public places of the areas covered. However, deficiencies 
remain, including:
A At present, only 45.7% of prefecture and above level cities have 
tobacco control regulations in China, while the remainder lack 
any regulations concerning tobacco control.
B There are only a limited number of places where smoking is 
banned. Most local regulations set bans at medical entities, 
cinemas and theaters, music halls, video halls, childcare centers 
and kindergartens, schools, conference rooms, libraries, exhibi-
tion halls, public transport, as well as postal, telecommunications, 
and banking offices. Only Guangzhou and Shenzhen set bans on 
smoking at air-conditioned restaurants. None of the local regula-
tions include workplaces such as offices.
C The restrictions are vague and difficult to implement, and law 
enforcement is unclear. For example, some articles stipulate that 
those who violate will be given administrative penalties or will be 
penalized according to related regulations, but no detailed penalty 
is described and there is no law enforcement body.
3) Industry regulations
As early as 1983, the Civil Aviation Administration of China enacted 
a ban on smoking on domestic flights. Starting in 2003, it enacted 
a complete smoking ban on all domestic and international flights, 
which was the first ban on smoking across an entire industry.
On March 1, 1987, Beijing Railway Station was declared to have 
a non-smoking waiting area. Most express trains to Beijing have 
become smoke-free, a prelude to a smoking ban for the railway 
industry. In April 2007 express trains began enforcing comprehensive 
smoking bans, following modernization of trains.
In 2005, the Chinese Center for Disease Control and Prevention 
(China CDC) surveyed the tobacco control situation in fourteen 
provincial CDCs, and found that only four (28%) had partial or com-
plete bans on smoking[23]. CDCs should be the model for tobacco 
control, but less than one third of the organizations have regulations 
for their own premises.
It is safe to conclude that while this is the case with CDCs it is even 
more challenging to control tobacco in other industries.
4) Learning from tobacco control law enactment in the Hong Kong 
Special Administrative Region
On January 1, 2007, Chinas Hong Kong Special Administrative 
Region began to implement a complete ban on smoking in public 
places and workplaces. There is a clear law enforcement entity- the 
Hong Kong Tobacco Control Office, with 100 staff members. The 
efforts on enforcement and publicity are strong, and the maximum 
fine for smoking in public places is HK$5,000.
Challenges and Responses V
1. Action by the government
The Ministry of Health established and set up an office for the 
Leadership Team for Implementing the Convention to effectively 
implement the Convention with concrete measures,. As entrusted by 
the State Council, the Ministry of Health is revising the Public Place 
Hygiene Management Regulation, which will strengthen provisions 
on banning smoking in public places.
A designated budget for tobacco control was provided in 2006 and 
2007 central government subsidies to local projects to create a sup-
portive environment for tobacco control across China, improve local 
competence to implement the Convention, and facilitate the effective 
implementation of local tobacco control activities. The capability of a 
tobacco control network in China is also being strengthened. Priority 
is being given to surveillance and intervention measures for tobacco 
control in public places such as government agencies, hospitals, 
schools, shopping centers, and public transport waiting rooms.
2. Implementation of smoking bans in public places
Over the last decade China has been making continuous progress on 
smoking bans for public places.
China began creating smoke-free Schools in 1992, and 12,094 
schools had been named smoke-free by 2004.
Under the leadership of the Ministry of Health, the China Association 
for Tobacco Control and China Association for Hospital Manage-
ment organized the formulation of smoke-free Hospital Standards. 
Since 1999, many smoke-free hospitals have reached the standards 
in Beijing, Shanghai, Guangzhou, Fuzhou, Dalian, and Shenzhen. In 
Beijing alone, forty-four hospitals meet the Standards.
3. A Smoke-free Olympics
Smoke-free Olympics originated in 1988 at the Canadian Winter 
Olympics, and in 1992, the Barcelona Olympic Games completely 
banned smoking. Each Olympic Games thereafter has been smoke-
free. The host countries implemented a complete ban on smoking 
in all indoor areas and most public places, such as Olympic venues 
during events, and prohibited tobacco sales and all tobacco related 
advertising.
China is the first country to host the Olympic Games since the 
Convention came into effect. Premier Wen Jiabao instructed that 
a Smoke-free Olympics should be a part of the Green Olympics 
campaign.
In the Notice on the 20th World No Tobacco Day issued by the Min-
istry of Health and the China Patriotic Public Health Campaign Com-
mittee, the Ministry and Committee called on the host cities of the 
Olympic Games to formulate action plans on a Smoke-free Olympics 
as soon as possible and to implement them using concrete measures. 
The Smoke-free Olympics action will help to promote the creation of 
smoke-free and clean work and public environments.
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On February 8, 2007, the Beijing Chamber of Commerce, Beijing 
Food Service Trade Association, Beijing Cuisine Association, and 
Beijing Western Food Association jointly issued the Initiative to 
Advocate the Creation or Addition of Smoke-free Dining Areas 
in Food Service Enterprises. On April 25, the Beijing Municipal 
Government convened a launch meeting for implementing tobacco 
control in the Beijing food service industry.
The Beijing Health Administration, Beijing Chamber of Commerce, 
Beijing Tourism Administration and other agencies jointly issued 
a notice requiring the food service industry to implement tobacco 
control. Contracted hotels for the Olympics, Olympic premises, and 
restaurants in the Olympic Village must completely ban smoking 
before June 2008. Furthermore, food service outlets of medium and 
large sizes should advocate a complete ban on smoking; if, however, 
they cannot become 100% smoke-free, 75% of the area of the prem-
ises should be smoke-free.
The Framework Convention on Tobacco Control has become effec-
tive in China. However, with 300 million smokers and 540 million 
passive smokers there is a long way to go to protect people from 
passive smoking and achieve a smoke-free China.
We hope that every smoker, if addicted to smoking and as yet unable 
to quit, will not smoke in front of their child, spouse, colleagues, 
or friends, and that other people will have the courage and sense of 
responsibility to ask smokers to please go outdoors to smoke.
Let us work together to create a smoke-free environment, and enjoy 
a healthy life.
M4.4 Tobacco Control, Sat, Aug 1, 10:30 - 12:00
Tobacco control in South America
Sandoval, Rosa1; Blanco, Adriana1; Yamaguchi, Nise H.2, 3;  
Costa e Silva, Vera1
1 PAHO, Brazil; 2 University of Sao Paulo-Cancer Institute ICESP, 
Sao Paulo, Brazil; 3 Health Ministry, Sao Paulo, Brazil
Introduction: Tobacco is the single greatest preventable cause of 
death in the world today killing up to half the people who use it regu-
larly, currently more than five million people worldwide each year, 
one million in the Americas region.1 Tobacco use continues to grow 
in developing countries and despite progress in some countries, the 
Americas region makes no exception to this trend. 
The prevalence of smoking ranges widely globally and was recently 
published by WHO.2 Among adults, the highest prevalence rates 
available are observed in the Southern Cone, e.g., Argentina, Chile, 
and Uruguay. Gender differences also vary by countries with a 
significantly higher prevalence in men than women in most coun-
tries. Among youth (aged 13–15) the highest current tobacco use 
prevalence rates are also observed in Chile (29.9 % boys and 40.2% 
girls); Colombia (31.6 % boys and 34.0% girls); and Uruguay (27.2 
% boys and 31.4 % girls). As of 2004, tobacco consumption among 
girls was increasing and girls smoked more than boys in the Southern 
Cone countries – Argentina, Uruguay and Chile. 
Similarly to adult and youth smoking prevalence rates, the high-
est exposure to SHS at home and in public places among students 
13–15 years old, was found in the Southern Cone (86.7% in public 
places, Buenos Aires 2000).3 
Tobacco consumption is largely influenced by a number of factors 
including the global dissemination of products promoting availability 
and increasing affordability to consumers especially vulnerable 
groups as young people, women and the poor. The aggressive 
marketing strategies of the tobacco industry associated to the social 
acceptance of this lethal product are responsible for the high burden 
of tobacco related diseases and deaths on families, governments and 
societies.
Due to the global nature of the tobacco epidemic and related cross-
border aspects including illicit trade and cross-border advertising of 
tobacco products it became clear that the tobacco epidemic cannot be 
tackled by countries in isolation. In consequence, the World Health 
Organization Member States engaged in a negotiation of its first ever 
treaty, the WHO Framework Convention on Tobacco Control.
The WHO Framework Convention on Tobacco Control:4 The WHO 
FCTC contains guidelines and requirements for the implementation 
of the most cost-effective tobacco control measures available. Key 
provisions that parties to the WHO FCTC will be required to imple-
ment and are legally bound to include:
• A comprehensive ban on tobacco advertising, promotion and 
sponsorship by the tobacco industry to be implemented within five 
years;
• Strong health warnings on tobacco packaging that cover at least 
30% (and ideally 50%) of the principal display areas within three 
years and banning of misleading descriptors as “low tar”, “light”, 
“ultra light” or “mild”;
• Protection from secondhand smoke in all indoor workplaces and 
public places and in public transportation; 
• Offering cessation treatment to smokers who want to quit tobacco 
use; and
• Increasing tobacco taxes and prices along with measures to reduce 
the illicit trade of tobacco products. 
These measures are part of the package of tobacco control measures 
recently released by WHO, the MPOWER package. Other mea-
sures are included as treaty provisions: regulation of the contents of 
tobacco products and disclosures, sales to and by minors, provision 
of support for economically viable alternative activities, protection of 
the environment and the health of persons and litigation.
Status of tobacco control policies in the South America sub-
region: The treaty has globally 163 Parties including the European 
Community. Twenty-six countries in the Americas region (74%) are 
currently Parties to the WHO Framework Convention on Tobacco 
Control. Albeit the efforts undertaken globally and in the America’s 
region, progress in implementing the treaty is still irregular.
Parties and observers to the WHOFCTC in South America: Elev-
en out of twelve South American countries are Parties to the treaty 
(92% of the South American countries). Argentina is the only country 
from the South-American region that has not yet become a Party to 
the WHO FCTC. Countries like Uruguay and Brazil are setting the 
example with higher implementation rates for key provisions than 
other countries in South America. 
The Conference of the Parties, the governing body of the WHO 
Framework Convention on Tobacco Control (WHO FCTC) is com-
prised of all Parties to the Convention and also allows for observers 
participation. From the South America region, the Southern Common 
Market (MERCOSUR) has recently been accredited as an intergov-
ernmental organization observer to the WHO FCTC showing the 
political commitment of governments in this sub-region. Many inter-
national non-governmental organizations have also been accredited 
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as observers and under their umbrella include several Central and 
South American NGOs representing the organized civil society. 
Table 1. Status of the WHOFCTC in South America5
South America Country Signature Date Ratification, Accession (a)
1. Argentina 25 September 2003 —
2. Bolivia 27 February 2004  15 September 2005
3. Brazil 16 June 2003 3 November 2005
4. Chile 25 September 2003 13 June 2005
5. Colombia — 10 April 2008(a)
6. Ecuador 22 March 2004 25 July 2006
7. Guyana — 15 September 2005(a)
8. Paraguay 16 June 2003 26 September 2006
9. Peru 21 April 2004 30 November 2004
10. Suriname 24 June 2004 16 December 2008
11. Uruguay 24 June 2004 9 September 2004
12. Venezuela 22 September 2003 27 June 2006
Map 1: Parties to the WHO FCTC in the South America sub-region6
Examples on implementing with the treaty provisions in South-
America sub-region: Uruguay is the country not only in this region 
but also in the world that has made the most remarkable progress in 
fully implementing and enforcing some of the more relevant treaty 
provisions. 
Some examples on implementing the WHOFCTC provisions were 
recently mapped out by the Pan-American Health Organization and 
despite existing progress, much still need to be done.7
Article 6: Tobacco taxes and Prices
Raising the price of tobacco and tobacco products through tax 
increases is the most effective way to reduce smoking. Higher 
cigarette prices reduce the number of smokers and induce those who 
continue to smoke to consume fewer cigarettes per day. Taxes and 
prices increases are the most cost-effective tobacco control policy 
in the short and medium term especially impacting on youth and the 
poor. Only one country in South America (Uruguay) applies tobacco 
taxes (70%) that correspond to more than 66% of the final price to 
consumer. Other countries with relatively high tobacco taxes as a 
percentage of final prices are: Argentina (61%) where legislation has 
been passed recently which might translate into a higher percentage 
once regulations are approved; Chile ( 60%) and Brazil (between 50 
and 60% depending on the IVA tax applied at the State level), which 
has also recently increased tobacco taxes. 
Map 2. Taxes in the South America sub-region
Article 11: Packaging and Labeling of tobacco products
Warning labels on tobacco packs are a cost-effective method of 
informing the population about the dangers of tobacco use, providing 
direct health messages to tobacco users as well as to non-users who 
see the packs. This intervention can be implemented at virtually no 
cost to the government.8
Comprehensive regulation of packaging and labeling in accordance 
with the FCTC Article 11 includes key measures like banning mis-
leading descriptors (including but not limited to “low tar”, “light”, 
“ultra light” or “mild”) or mandated covering of at least 30% percent 
of the principal display areas with health warnings. 
• Five countries (42%) implement comprehensive regulation WITH 
picture warnings. Although, one of them, Peru’s regulation does 
not establish health warnings to cover at least 30% of the principal 
display areas.
• Some countries are moving towards comprehensive regulation, 
like Ecuador, where regulation does not include the banning of 
deceitful terms and have not yet picture warnings and Bolivia 
which is in process of regulating a comprehensive law. 
• Five countries have minimal regulations in place.
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Map 3. Packaging and labeling regulations in the South America sub-
region
Article 8: Protection from exposure to tobacco 
smoke (Smoke-Free Environments)
Second-hand smoke causes a wide range of diseases, including 
heart disease, lung cancer and other respiratory problems. There is 
no known safe level of second-hand smoke exposure. Completely 
smoke-free environments are the only proven way to protect people 
adequately from the harmful effects of second-hand smoke. Smoke-
free environments not only protect non-smokers, they also help 
smokers who want to quit.9
• Two countries in South America have a comprehensive smoke-
free law: Uruguay bans smoking in all public places and work-
places including bars and restaurants at the federal/national level 
by National Law while Colombia addresses the issue through a 
Ministerial Resolution.
• Six countries (50%) have banned smoking in at least two of the 
following categories: Health care facilities (public and private), 
educational facilities except universities (public and private) and 
governmental facilities.
• Argentina has made significant progress through sub-national 
legislation
• Three countries have minimal legislation
Map 4: Smoke-free environments in the South America sub-region
Article 13: Ban on advertisement and promotion of tobacco 
products and sponsorship by the tobacco industry
The tobacco industry spends tens of billions of dollars worldwide 
each year on advertising, promotion and sponsorship. A key compo-
nent of tobacco control, therefore, is a comprehensive ban on every 
form of marketing of tobacco products. Comprehensive advertising, 
promotion and sponsorship bans are highly effective in reducing 
smoking among people of all income and educational levels. Partial 
advertising bans have little or no effect on smoking prevalence.10
• No country in South America has a complete ban on advertise-
ment and promotion of tobacco products and sponsorship by the 
tobacco industry.
• Four countries have significant restrictions, including a ban on 
advertising through certain means (national TV and radio) and 
some promotion activities (free distribution by mail or other 
means)
• The majority of countries (seven) has no or minimal regulations
Map 5: Advertising, promotion and sponsorship bans in the South 
America sub-region
Other developments in the sub region:
Other provisions of the treaty have been addressed by some countries 
in South America. The treatment of the tobacco dependence is 
essential in supporting smokers to quit. Toll-free lines are available 
in three out of the 12 countries in South American: Argentina, Brazil 
and Uruguay and nicotine replacement therapies is available for pur-
chase in almost all countries in the sub-region (except Ecuador and 
Paraguay). Initiatives for diversification of tobacco crops (article 17) 
are underway in Brazil and measures to combat illicit trade are under 
discussion in the MERCOSUR countries (article 15). 
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Smoking cessation in Asia
Park, Jae Gahb
Seoul National University Hospital, Seoul, Korea
Over the course of the last several decades, the prevalence of 
smoking among adult males has decreased in many high-resource 
countries of Europe, North America, and Australia. International 
and national level efforts to reduce tobacco consumption have 
significantly contributed to this decrease. In particular, global anti-
smoking activities have been greatly strengthened by building upon 
the first-ever global public health treaty: the Framework Conven-
tion on Tobacco Control (FCTC) and by taking action to implement 
MPOWER.
Yet much more remains to be accomplished, since serious and wide-
spread problems remain. According to the report issued by the WHO 
(FCTC) on this global epidemic, only 5% of the world’s population 
is fully protected by any one of the MPOWER interventions, and no 
country implements all of them. Furthermore, many Asian countries 
show an usually high rate of smoking among adult males. Russian 
and India each have a rate exceeding 60%. China also has one of the 
highest rates among Asian countries, over 50% of adult males. China 
is also the largest market for cigarettes, representing 37% of estimat-
ed global consumption. Japan is also included in the top five counties 
which have the highest consumption of cigarettes. The pattern of 
tobacco use in Asian countries is characterized by a high prevalence 
of tobacco use among men, and very low use among women. The 
rate of tobacco use among men reaches between 50% and 80%, but 
is only between 3%-5% among women in China, Taiwan, Vietnam, 
Korea, and Malaysia. But recently in several countries, the rate of 
tobacco use among women has been increasing. Exposure of youth 
to second hand smoke is also a serious problem in Asian countries. 
For instance, 56% and 65% of youth in the Philippines and Korea, 
respectively, are exposed to second hand smoke at home and outside 
of the home.
The economic factors associated with widespread smoking should 
also be considered. The price of a single pack of cigarettes in Japan 
or Indonesia is higher than 1 kg of rice, which would presumably 
take a significant toll upon the economic situation of a frequent 
smoker of average income. From a different perspective, some Asian 
countries including China and India are leading producers of tobacco 
leaves, as there is a lack of policy instituting or enforcing tobacco 
control measures including ‘Tobacco Control Acts’. In these coun-
tries, cigarettes are relatively affordable and thus easily accessible. 
The exceptionally high prevalence of smoking among Asian nations 
described above clearly represents a serious public health issue, 
and requires the implementation of effective public tobacco control 
strategies and measures. In formulating these public policies and 
measures, it would be informative and instructional to review those 
tobacco control strategies which have already been shown to be 
effective in Asia. Effective tobacco control strategies have been suc-
cessfully instituted in the countries of Bhutan, Thailand, Singapore, 
and Korea. These effective policies have focused on direct interven-
tion aimed at the cessation of smoking, and the designation of smoke 
free environments. Bhutan completely bans the sale of tobacco and 
smoking in public places as part of the king’s plan for gross national 
happiness. Nepal and Sri Lanka ban tobacco advertising and promo-
tion. Thailand has substantially reduced smoking rates with com-
prehensive tobacco control acts, warning labels on cigarette packs, 
and organized campaign and education. Singapore has implemented 
nationwide campaigns directed towards young women, and require 
the “Quit Line” number and pictorial warnings to be displayed on 
cigarette packs.
Korea is one of the countries that has had a high prevalence of smok-
ing among adult males. It is estimated that tobacco smoking incurs 
social and economic costs worth over 10 billion US dollar per year 
(1 US dollar ≈ 1000 Korean Won). The smoking rate of adult males 
peaked at 79.3% in the 1980s and steadily declined reaching 67.6% 
in 2000. However, it has rapidly fallen to 43.4% over a recent period 
of 7 years.
The first president of the National Cancer Center (NCC) in Korea, 
Jae-Gahb Park, has introduced several anti-smoking policies since 
his inauguration in 2000. As one of the non-smoking policy proc-
lamations, he announced and instituted the policy that the NCC 
must visibly stand as an exemplary model of anti-smoking activity. 
This proclamation was universally accepted among the staff of the 
NCC, and culminated in the non-smoking declaration ceremony in 
December 2002, in which the staff of the NCC pledged to abstain 
from smoking. In 2004, Jae-Gahb Park’s recommendation that scenes 
depicting smoking on television or in newspapers be prohibited was 
accepted by three major broadcasting companies and twelve news-
paper companies. As part of his crusade to promote anti-smoking 
initiatives, Jae-Gahb Park also instituted and oversaw numerous 
other achievements: the Federation of Korean Trade Unions and 
Korean Confederation of Trade Unions, and six major Korean medi-
cal organizations were persuaded to sign on to the non-smoking 
resolution. These activities, and their expansion to the National 
Police Agency and the Ministry of National Defense, were overseen 
by Jae-Gahb Park. In 2008, the National Police Agency terminated 
the sale of duty-free cigarettes to the police, and in 2009 the Ministry 
of National Defense did the same for the army. As president of 
the NCC, Jae-Gahb Park recommended the designation of a non-
smoking area in government buildings; this recommendation was 
subsequently accepted and instituted. With these experiences, he filed 
a petition to the National Assembly of Korea, along with the former 
National Assembly Speaker, K. Y. Park and the former President 
and 2000 winner of the Nobel Peace Prize winner, D. J. Kim. In the 
petition, a complete ban on the manufacture and sales of tobacco 
products was called for in next ten years. The petition was continu-
ally joined by other petitioners, including 155 leading figures in vari-
ous social areas. Because a new term of Congress started in 2008, the 
petition was filed again in November 2008. The purpose of this bill is 
to protect the people from the harmful effects of tobacco use through 
prohibitions on the manufacture, import, export, and sale of tobacco. 
To support this petition, a book containing 542 pages of text entitled, 
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“Banning the Manufacture and Sale of Tobacco Products: The 
Problems and Answers’ with 8 co-authors was published in Korean 
on January 2006. On November 2008, this book was translated into 
English and published under the title, “Banning Tobacco”.
The Tobacco Free World Alliance (ToFWA) was formed by the first 
president of NCC Korea, Jae-Gahb Park, and Dr. Zatonski on 11 
November 2004 to promote a law which bans the manufacture and 
sales of tobacco products in every country within the next 10-15 
years. To promote such antismoking activities in Asian countries, 
the presidents of cancer centers from 9 Asian nations (Korea, China, 
Japan, Singapore, Thailand, Bangladesh, Mongol, Pakistan, Vietnam) 
gathered at the NCC Korea on September 2005 to establish the Asian 
National Cancer Center Alliance (ANCCA) in NCC Korea on Sep-
tember 2005, and took an oath to work for the eventual prohibition 
of the cultivation, import, export, and sale of cigarettes. This meeting 
was held subsequently in Tokyo, Japan in 2007. Furthermore, on 
April 2009 in Manila, Philippines, Dr. Young-soo Shin, the Regional 
Director of the Western Pacific, WHO, convened the Consultative 
Meeting, for the purpose of the Draft Regional Action Plan 2010-
2014 for the tobacco free initiative. 
At the International Agency for Research on Cancer (IARC) meeting 
held in Lyon, France on September 2004, prohibition of the manu-
facture and sale of tobacco products in every country encouraged 
the Lyon Declaration. It was made on October 2005, which included 
pledges of the directors of Cancer Centers to persuade governments 
to reduce the consumption of tobacco products in their countries, and 
ultimately to reach the complete ban on tobacco products. 
As mentioned above, there has been widespread recognition of the 
negative effects of smoking in Korea within a relatively short period 
of time, brought about by continuous efforts directed towards foster-
ing understanding of the need for control of tobacco, and garner-
ing support for anti-tobacco activities. These achievements have 
expanded with the effort that expert institutions, including the NCC, 
have constantly put into promoting anti-smoking activity. And these 
achievements will be a good model and reference for other countries.
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Mucositis and lung cancer
Keefe, Dorothy M.
University of Adelaide, Adelaide, SA, Australia
Mucositis is one of the most distressing toxicities of cancer treat-
ment, and can affect all mucosal surfaces of the body. It causes ulcer-
ation, pain, abdominal bloating, and diarrhoea, depending on the area 
involved. Lung cancer patients are at risk of oral, oesophageal and 
lower gastrointestinal mucositis depending on the type of chemother-
apy they receive, with radiotherapy adding to the risk of oesophageal 
mucositis, and targeted therapies increasing diarrhoea.
Measurement of mucositis is problematic due to the relative inacces-
sibility of some areas of the gastrointestinal tract as well as the differ-
ence in patient and clinician perceptions. Increasing work in “patient 
reported outcomes” is being reported, although overall reporting of 
mucositis in the literature is still poor.
The mechanisms of toxicity in the various areas are linked, but 
radiotherapy induced mucositis has the added complication of daily 
dosing leading to escalating damage. The duration of mucositis is 
longer following radiotherapy than previously thought, and full 
recovery is not guaranteed either post radiotherapy or chemotherapy. 
Targeted therapy induced diarrhoea has not been well studied and the 
mechanism is not fully understood. Work is ongoing in this area. 
Mucositis contributes to reduction of quality of life, nutritional 
deficiency, analgesic requirements and mortality. Prevention and 
treatment are in developmental phases but there are measures that 
can be taken to alleviate symptoms.
It is now known that chemotherapy toxicities can occur in clusters, 
and the development of mechanism based treatments is a prior-
ity research area. There is a cluster of respiratory toxicities which 
includes pain, cough, palpitation, infection and dyspnoea, all of 
which are particularly problematic in lung cancer patients, and the 
prevention of which could have major implications for quality of life.
M5.2 Controlling Adverse Effects of Treatment in Lung Cancer, Sat, Aug 1, 10:30 - 12:00
Emesis
Grunberg, Steven M.
University of Vermont, Burlington, VT, USA
Nausea and vomiting are the toxicities of chemotherapy most 
feared by cancer patients and have been said to account for half of 
the total impact of chemotherapy on patient quality of life. How-
ever the history of the development of effective antiemetic therapy 
is closely linked to the history of the development of effective 
chemotherapy for lung cancer. The introduction of cisplatin in the 
late 1970’s revolutionized lung cancer care by allowing the develop-
ment of combination chemotherapeutic regimens that could cause 
tumor shrinkage in a significant percentage of patients and also 
increase duration of survival. However it was soon recognized that 
chemotherapeutic agents were not all equally emetogenic. Chemo-
therapeutic agents ranged from those that were non-emetogenic to 
those that would cause emesis in virtually all patients not receiving 
antiemetic therapy. On such a scale, cisplatin ranked at the top for 
both frequency and severity of emesis and thus became the target and 
the gold standard for development of new antiemetics. Standard dose 
phenothiazines had virtually no effect in decreasing emesis. However 
high dose metoclopramide was found to be significantly effective, 
with prevention of emesis improved even more by the addition of a 
corticosteroid. About 20 years ago, it was recognized that high dose 
metoclopramide had both antidopaminergic and antiserotonergic 
properties, and that use of specific serotonin receptor antagonists 
could maintain antiemetic efficacy while eliminating antidopamiergic 
toxicities. Agents such as ondansetron, granisetron, and palonosetron 
(with or without dexamethasone) thus became the mainstays of acute 
antiemetic therapy.
Improved control of acute emesis led to the realization that certain 
agents, such as cisplatin and cyclophosphamide, caused a second 
wave of emesis (delayed emesis) that could last for up to 5 days and 
was not as responsive to standard antiemetics. More recent work has 
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shown that the incidence of delayed nausea and vomiting is under-
estimated even by experienced oncologists and oncology nurses by 
about 50%. Although effective acute antiemetic protection is impor-
tant in decreasing delayed emesis, different neurotransmitter recep-
tors, such as the NK-1 receptor, are important in maintaining this 
phenomenon. Several NK-1 receptor antagonists have been devel-
oped that, when used in combination with a serotonin antagonist and 
a corticosteroid, will further reduce the incidence of delayed emesis. 
Recent work has also suggested that multiple day administration 
of these agents to prevent delayed emesis may not be necessary if 
appropriate preventive doses are administered before chemotherapy.
Although there has been marked success in improving antiemetic 
control, numerous challenges remain. Different routes of administra-
tion for standard antiemetic agents, such as the transdermal route, are 
being developed, and differences in mechanism and physical proper-
ties even of agents in the same family are coming to be appreciated. 
Question has been raised as to whether a single dose of an appropri-
ate antiemetic regimen may be sufficient for protection against both 
acute and delayed emesis. On the other hand, new strategies for the 
control of emesis from extended chemotherapy administration (mul-
tiple day intravenous chemotherapy or oral chemotherapy) and from 
high-dose chemotherapy administration are still needed.
Of particular interest is the growing emphasis on nausea, which is 
being recognized as distinct from vomiting and has become perhaps 
an even greater residual problem. Although standard antiemetics will 
have some effect on nausea in proportion to their effect on vomiting, 
the goal of complete protection from nausea is certainly not achieved 
to a similar extent. Interest has therefore turned to whether more 
traditional remedies may have a role in controlling this phenomenon. 
Data on the antiemetic properties of acupuncture is mixed. However 
recent work has suggested that herbal remedies that have a long-
standing reputation for relieving nausea and stimulating appetite, 
such as ginger or cannabinoids, may indeed have a role in antineo-
plastic therapy. Carefully designed trials with well-defined endpoints 
will be necessary to evaluate this early suggestive data.
The field of antiemetic control has set a benchmark for other areas of 
supportive care in cancer. However better understanding of mecha-
nisms of action and drug-drug interactions are now needed. The 
ability to look outside of the boundaries of this field and to detect 
similarities and synergisms with other areas of supportive care, such 
as prevention of mucositis and anorexia, may lead to the next genera-
tion of advances in antiemetic control. The ultimate goal will be to 
remove nausea and vomiting from the list of toxicities most feared 
by the cancer patient.
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Fatigue in NSCLC: etiology, impact and treatment options
Eckardt, John R.
DAVA Oncology, Dallas, TX, USA
Fatigue is the most common symptom patients with cancer experi-
ence, with a prevalence rate that exceeds 60% in many studies. 
Cancer-related fatigue is a common complication of both advanced 
lung cancer and the treatment required for lung cancer patients. The 
U.S. National Institutes of Health has identified the treatment of 
cancer-related fatigue as a priority for advancing the care of cancer 
patients. The idea of palliative care arose because of the great need 
to provide compassionate care for patients at the end of life. There 
is little need greater for the lung cancer patient then the treatment of 
cancer-related fatigue. In addition to cancer related fatigue the cancer 
patient often experiences additional symptoms, including sleep dis-
turbance, pain, and depression. Cancer-related fatigue may arise as a 
result of the cancer itself or it can be a frequently reported side effect 
of cancer treatment(s) such as chemotherapy, radiotherapy, surgery, 
and immunotherapy. The impact of treatment related fatigue is dif-
ficult to assess due to the confounding influence of disease related 
fatigue. In a randomized study in second-line NSCLC evaluating the 
use of docetaxel vs. best supportive care, the incidence of fatigue 
was 50% less in the treatment arm then in the best supportive care 
arm. This suggests that even though treatments can cause fatigue, 
in the advance NSCLC setting the disease has a much larger impact 
on fatigue and treating the cancer can reduce cancer related fatigue. 
Typically, cancer-related fatigue is more severe than the usual fatigue 
experienced by healthy people in that it is associated with a higher 
level of distress, is disproportionate to the activity or exertion level, 
and is not relieved by sleep or rest. Cancer-related fatigue can com-
promise quality of life and a patient’s ability to function optimally 
on a daily basis. Many patients report that cancer-related fatigue is 
more distressing and has a greater impact on activities of daily living 
and quality of life than other cancer-related symptoms such as pain, 
nausea, and depression. Evaluation and treatment of cancer-related 
fatigue require a broad initial approach because of the multiple eti-
ologies and possible contributing factors. Current therapeutic options 
include the assessment and treatment of any underlying causes 
(e.g., the cancer itself, anemia, depression). Several pharmacologic 
approaches have the potential to provide relief for patients suffering 
from cancer-related fatigue. The most numerous rigorously designed 
clinical trials to date have been conducted with erythropoietin and 
darbepoetin alfa; several studies have shown their efficacy in treat-
ing cancer-related fatigue in patients with anemia. However, recent 
studies have suggested a negative impact of these drugs on cancer 
outcomes. Other classes of medications, such as psycho-stimulants 
and CNS stimulants, have shown promise in open-label prospective 
designs, but evidence is lacking from placebo-controlled random-
ized trials. Future research regarding pharmacologic treatment of 
fatigue needs to confirm the effects of promising open-label studies 
via a double-blind randomized design. In particular, the relative 
benefits and side-effect profiles should be evaluated via head-to-head 
randomized studies comparing different classes of medications, as 
well as medications as single agents versus medications in combina-
tion with promising behavioral and non-pharmacologic interventions, 
such as exercise and nutrition.
M5.4 Controlling Adverse Effects of Treatment in Lung Cancer, Sat, Aug 1, 10:30 - 12:00
Cutaneous toxicities
Lacouture, Mario E.
Northwestern University, Chicago, IL, USA
The range of activity of drugs used against lung cancer is not limited 
to tumor cells. Most notably, epidermal growth factor receptor inhibi-
tors (EGFRIs) result in dermatologic toxicities. These agents are able 
to affect the function of cells in the skin and appendages, leading 
to serious dermatologic adverse events, reported in more than 45%, 
and up to 100% of patients. The most common and clinically evident 
cutaneous side effect includes a papulopustular eruption, often 
described in the literature as an acneiform eruption. A correlation has 
been suggested between this cutaneous event and clinical efficacy. 
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Other events reported consist of periungual and nail changes, hair 
alterations, xerosis and pruritus, telangiectasias and ophthalmologic 
side effects. These events are believed to result as a consequence of 
EGFR inhibition in receptor bearing cells in the epidermis and outer 
root sheath of the hair follicle. 
The most frequently reported side effect of EGFRIs is a papulo-
pustular rash that has been described in the literature as acneiform 
eruption. Data from trials of the various EGFRIs show that the 
eruption commonly occurs within the first 2 weeks of treatment and 
reaches maximum intensity after 2-3 weeks of starting therapy. The 
papulopustular reaction involves primarily the face, neck, and upper 
torso. Staphylococcus aureus is frequently cultured in long-standing 
rashes or in patients that have recurrent flares. In addition, S Aureus 
septicemia has been reported secondary to severe skin toxicity to 
erlotinib. When in doubt, swab cultures and sensitivities of pustules 
or affected skin should be obtained in order to determine adequate 
antibiotic therapy.
A periungual inflammation is another typical side effect that is seen 
in 12-16% of patients and usually starts at least after 4-8 weeks of 
EGFR inhibitor treatment. The inflammation usually starts as ery-
thema of the proximal and lateral nail folds, and is more common in 
the thumbs or great toes. Treatment usually consists of topical anti-
biotics or chemical cauterization with silver nitrate application. Hair 
anomalies are apparent after approximately 2-3 months, including 
alopecia of scalp and increased hair growth in the face and eyelashes. 
Ophthalmologic evaluation is advisable for ocular symptoms. Diffuse 
non-scarring alopecia may eventually develop in 4-11% of patients, 
although this may be underreported. Xerosis affecting the upper 
trunk and extremities is very common (7-35%) in patients receiving 
EGFR inhibitors, and usually respond to topical moisturizers with 
keratolytic activity (ammonium lactate 12%). Often, patients find 
pruritus (8-35%) a disabling symptom, although topical corticoster-
oids (in a foam or shampoo formulation for the scalp) or oral agents 
may be beneficial (gabapentin, pregabalin or antihistamines).
Controlled studies have been conducted for management of rash (see 
table). A multidisciplinary approach with frequent follow-ups (every 
2-4 weeks until resolution) as a general measure, so that clinical 
outcome can be maximized. 
Population/Patients Treatment Impact of Preventative Treatment
mCRC patients  6 weeks pre-emptive vs. • Significantly reduced incidence of ≥ 
preparing to initiate  reactive treatment with  grade 2 skin toxicities 
panitumumab (n=95) moisturizer, sunscreen,  • Significantly delayed time to severe 
 hydrocortisone 1% cream   skin toxicity 
 and doxycycline 100mg bid • Significantly improved event-free 
   probability for ≥ grade 2 skin toxicity
mCRC patients  8 weeks prophylactic • Significantly fewer total facial lesion 
preparing to initiate  minocycline 100mg qd vs.  counts 
cetuximab (n=48) placebo • Significantly reduced moderate to 
   severe itch 
  • Topical tazarotene associated with 
   significant irritation and no improvement
Patients starting any  4 weeks prophylactic • Significant reduction in ≥ grade 2  rash 
EGFR Inhibitor therapy  tetracycline 500 mg bid vs. • Improved patient-reported SKINDEX-
16(n=61) placebo   measures of skin pruritus
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Multi-kinase inhibitors for NSCLC: what is 
the rationale and the clinical evidence? 
Belani, Chandra P.
Penn State Hershey Cancer Institute, Hershey, PA, USA
Non-small cell lung cancer is a disease characterized by wide 
molecular heterogeneity. In recent years, several novel agents that 
target specific, aberrant molecular pathways in NSCLC have been 
under rigorous evaluation. Formation of new blood vessels is a rate-
limiting step for cancer progression. Therefore, inhibition of neovas-
cularization has been pursued as a treatment strategy for lung cancer 
and other malignancies during the past three decades. Vascular 
endothelial growth factor (VEGF), secreted by the cancer cells, and 
is an important mediator of angiogenesis. Direct or indirect targeting 
of the ligand (VEGF) at the mRNA or protein level, direct target-
ing of its receptors, VEGFR1, VEGFR2, and neuropilin 1 (NP1), or 
by blocking downstream signaling pathway components can lead 
to angiogenesis inhibition representing a promising new targeted 
therapeutic treatment strategy for a variety of malignant disorders 
including lung cancer. 
Bevacizumab, a humanized monoclonal antibody that binds with 
high affinity to VEGF-A, has demonstrated a survival advantage 
when added to chemotherapy for patients with nonsquamous 
advanced NSCLC (E4599). This triplet regimen has been adopted as 
the new ‘standard of care’ in the treatment of patients with non-
squamous NSCLC. However, 30-40 % of all NSCLC patients with 
squamous histology, brain metastasis and those on chronic antico-
agulation have been excluded from treatment with bevacizumab due 
to potential complications. The early results from the PASSPORT 
trial which enrolled patients with treated and stable brain metastasis 
are encouraging but not conclusive. The increase in toxicity noted 
with the addition of bevacizumab with chemotherapy calls for cau-
tion in selecting patients for therapy with the novel regimen. A recent 
unplanned subset analysis of E4599 demonstrated higher toxicity 
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and treatment-related deaths in elderly patients (age > 70 years) 
with bevacizumab-carboplatin-paclitaxel. Surprisingly, despite an 
improved PFS, survival was not superior with the three-drug combi-
nation in elderly patients.
Clinical trials are also underway to evaluate the utility of various 
small-molecule inhibitors that target the VEGF receptor and other 
kinases in both endothelial and cancer cells and agents that cause 
regression of existing tumor vasculature (vascular targeting agents). 
Inhibitors of the VEGF tyrosine kinase that may have incremental 
benefits in lung cancer include Vatalanib (PTK 787), sorafenib (BAY 
43-9006), AZD 2171, Sunitinib (SU 11248), Axitinib, ABT-869 
etc. Though there is evidence of single agent activity with these 
agents in advanced NSCLC, sorafenib and AZD 2171 have failed to 
demonstrate a benefit when used in combination with chemotherapy 
(ESCAPE and BR 24). Possible benefits of oral VEGFR TKI’s 
include oral dosing and feasibility of targeting multiple kinases. 
Agents that target multiple pathways or multiple levels of the same 
pathway have the potential for enhanced anti-tumor activity, but it 
makes it difficult to develop predictors of response because of mul-
tiplicity of targets. Fatigue is a more-common side effect across the 
multitargeted TKIs than for monoclonal antibodies and hypertension 
(class effect) which presents a unique challenge, is usually manage-
able with medical treatment. 
Other antiangiogenic strategies in development include VEGF 
Trap, thalidomide and its analogs, synthetic ribozyme that cleaves 
VEGFR-1 specific mRNA, IMC-1121B - fully human antibody to 
VEGFR-2, SDF-1 inhibitor and Spectrum Selective Kinase Inhibi-
tors (SSKIs) such as XL-647 (targets VEGFR- 2,EGFR, HER2 and 
EphB4) and XL 999 (VEGFR-1, VEGFR-2 ,VEGFR-3, PDGFR, 
FGFR, c-kit, and Flt-3). VEGF Trap belongs to the class of VEG-
FR-1/VEGFR-2 fusion protein and targets VEGF-A., preventing 
VEGF from binding to its receptors. Involvement of the SDF-1/
CXCR4 pathway in cancer related angiogenesis has prompted the 
development of a novel SDF-1 inhibitor to evaluate its mechanistic 
and therapeutic potential. Standard chemotherapeutic drugs such as 
taxanes, when modified by the frequency and dose of administra-
tion, can also target angiogenesis, and have led to the development 
of metronomic therapies. Antiangiogenic agents seem to have a 
great potential but their use has to be optimized. It seems that their 
use may be limited to certain defined subgroups based on histology, 
biomarkers or imaging characteristics.
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The IGF1R pathway – rationale and inhibitors
Camidge, D. Ross
University of Colorado, Aurora, CO, USA
In 1987, the terms insulin-like growth factor-1 (IGF-1) and insulin-
like growth factor-2 (IGF-2), describing two related growth factors 
with significant sequence homology to insulin became officially 
adopted. The Insulin-like Growth Factor (IGF) axis is now recog-
nized to involve elements of endocrine, paracrine and autocrine 
control. Growth hormone (GH) acting on GH-Receptors in the liver 
liberates IGF-1 into the bloodstream, accounting for approximately 
80% of the circulating levels of IGF-1. IGF-1 is also produced by 
a number of other large volume tissues, including skeletal muscle 
and cartilage. In addition to its endocrine role, peripheral connec-
tive tissue cells such as fibroblasts release IGF-1 in response to GH 
where it performs both autocrine and paracrine stimulatory roles 
and is a major determinant of somatic growth. IGF-1 is also released 
locally by a variety of tissues, including blood vessels and the brain, 
in response to damage, either directly or through the action of other 
factors associated with tissue responses to damage, including Epider-
mal Growth Factor, Fibroblast Growth Factor and Platelet-Derived 
Growth Factor (EGF, FGF and PDGF, respectively). 
In contrast to IGF-1, IGF-2 is minimally affected by GH levels. The 
normal serum levels of IGF-2 are approximately three times those of 
IGF-1, with the liver also contributing most to these levels. Tissue 
specific control of IGF-2 effects are thought to be very important, 
through binding proteins, degradation through clearance receptors 
and additional local production. IGF-2 is one of the best examples of 
an imprinted, or monoallelically expressed gene. In normal physiol-
ogy only the paternally-inherited allele is usually expressed. The 
basis of IGF-2 imprinting relies on separate epigenetic events: one 
that actively turns on the paternal gene and another that turns off the 
maternal gene. These methylation and expression patterns persist 
during cell division and are passed to each new generation of cells. 
The tight regulation of IGF-2 expression through these mechanisms 
suggests that gene dosage effects are particularly important for this 
ligand. 
While insulin circulates freely in the blood, concentrations of IGF-1 
and IGF-2 are affected by the levels of several IGF-binding proteins 
(IGF-BPs), with normally only a very small percentage of the total 
ligand being free in the circulation. There are six known IGFBPs. All 
the IGFBPs have a greater affinity than the IGF-receptors for their 
ligands. In general it is difficult to ascribe simple roles to the IGFBPs 
as their effects – modulating the kinetics of free IGF exposure -could 
in theory both increase and decrease IGF related signaling depend-
ing on the time frame considered. IGFBP3 is the dominant circulat-
ing binding partner for both IGFs, accounting for 70-80% of their 
blood levels. A third protein, acid labile subunit (ALS) also binds 
the IGF-IGFBP3 complex, together increasing the plasma half-life 
of the ligands. Proteolytic cleavage of IGFBP3 in catabolic states 
may initially increase free IGF-1, but ultimately decreases the total 
circulating IGF pool. IGFBP2 is the second most abundant IGFBP. 
IGFBP2 is unsaturated in the blood and represents a sink for binding 
additional ligand. IGFBP1 is the third most abundant IGFBP, which 
is also not saturated under normal physiological conditions. As it 
drops rapidly on feeding, this may be a means to quickly elevate 
free IGF levels. IGFBPs 4, 5 and 6 are only present at low levels in 
the circulation and appear to have more of a role in the periphery 
as general inhibitors/ regulators of IGF action, some of which may 
be tissue specific. Most bind both ligands, but IGFBP6 is IGF-2 
specific. Some of the IGFBPs may also have direct signaling roles, 
independent from their effects on the IGFs, through effects on as yet 
unspecified cell surface receptors that induce anti-proliferative and 
pro-apoptotic effects. 
The pure IGF-1R is a tetramer, of two ligand-binding alpha sub-
units and two transmembrane/kinase domain beta subunits, that is 
expressed in almost all cell types. The highly homologous insu-
lin receptor exists as two splice variants, IR-A and IR-B. IR-B is 
responsible for most of the classical metabolic responses to insulin. 
The homology is such that in the same cell, in addition to hybrid-
izing with each other in homo- or heteromeric complexes, IR-A or 
IR-B chains can also polymerize with IGF-1R chains to form IR-A/
IGF-1R and IR-B/IGF-1R hybrid receptors. The relative numbers of 
different receptor chains determines the proportions of the different 
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pure and hybrid receptors formed and may influence tissue specific 
effects of the different ligands. Both IR and IGF-1R are often concur-
rently expressed in cells, however exceptions exist. For example 
hepatocytes almost exclusively express the IR, whereas fibroblasts 
very dominantly express the IGF-1R. Of the three ligands, insulin, 
IGF-1 and IGF-2, each has a different binding potential. The IGF-1R 
has a 15-20 fold higher affinity for IGF-1 than IGF-II, consistent 
with its name. However, the greater binding potential of IGF-2 
across different receptors may give it a broader range of biologi-
cal functions than IGF-1. The IGF-2R receptor (also known as the 
mannose-6 phosphate receptor) is structurally distinct from the IR 
and IGF-1R and has no known signaling role, but rather is perceived 
to act as a specific sink, internalizing and reducing the local levels of 
IGF-2. Binding of IGF-1 or IGF-2 to the IGF-1R leads to autophos-
phorylation of the intracellular domains of the receptor complex and 
initiation of multiple signaling cascades. Signaling in the absence of 
ligand does not appear to occur under physiological conditions. The 
two dominant pathways downstream of the IGF-1R are the ras-raf-
MEK-ERK pathway, which, depending on cell type can mediate cell 
growth, survival and differentiation; and the phosphatidylinositol 
3-kinase (PI3K-AKT) pathway, which is involved in cell survival, 
cell-cycle progression, growth and metabolism. The initial step in the 
recruitment of the P13K pathway involves activation through IRS1, 
one of several mammalian insulin receptor substrates (IRS), which 
represent the most prominent initial mediators of signaling from both 
the IGF-1R and IR. The expression of different IRS molecules may 
be associated with different downstream phenotypes, and be both 
tissue and disease specific. Numerous other intracellular adaptor 
proteins are also associated with downstream signaling from the 
IGF-1R.
A number of different lines of evidence – beyond the simple associa-
tion of the pathway in normal somatic growth – link aspects of the 
IGF axis to the development and/or maintenance of neoplasia in 
humans. Epidemiologically, individuals with circulating IGF-1 levels 
in the upper quartile have a higher risk of pre-menopausal breast can-
cer, prostate, lung, colorectal, endometrial and bladder cancers than 
those in the lowest quartile. A known somatic polymorphism in the 
IGF-1 promoter region that may influence circulating levels of IGF-1 
has been noted to be more frequent in those with prostate cancer than 
in controls. Similar IGF-1 polymorphisms have been associated with 
breast, lung, colorectal cancer and sarcoma. In addition to systemic 
effects, IGF-1 expression has been noted in many common solid 
tumors. IGF-1 (and IGF-2) expression is common across a range of 
tumor cell lines including both NSCLC and SCLC, consistent with 
roles in autocrine stimulation. Loss of IGF-2 imprinting has been 
noted in hepatoblastoma, NSCLC, SCLC, cervical cancer, breast 
cancer, rhabdomyosarcoma, neuroblastoma, choriosarcoma and tes-
ticular cancer. Transgenic mice over-expressing IGF-2 develop lung 
adenocarcinomas in nearly 70% of animals by 18 months of age. 
Decreased expression of IGFBP3 has been noted in both SCLC and 
NSCLC cell lines, with hypermethylation of the IGFBP3 promoter 
noted in approximately 60% of NSCLC clinical cases, and associated 
with poorer prognosis. Preclinically, over-expression of wildtype 
IGF-1R in several cell types results in transformation. Deletion of the 
receptor can also abrogate the transforming potential of other growth 
factors, such as PDGF, the Ewing’s sarcoma fusion protein, and 
transforming viruses, such as SV40. Gene expression levels of the 
IGF-1R are also known to be reduced by wildtype p53 and BRCA1. 
However, although IGF-1R expression has been noted in many 
common solid tumors, gene copy number or protein levels are rarely 
dramatically exaggerated, and activating mutations have not yet 
been convincingly reported in clinical specimens. Ligand dependent 
activation is currently assumed to be the major driving force in both 
host and tumor cells. 
In theory, local reduction in the levels of the IGF-2R should reduce 
IGF-2 clearance, leaving more available for signaling, and genetic 
aberrations at the IGF-2R locus have been reported in several dif-
ferent lung cancer cell lines and clinical specimens, particularly 
squamous cancers.
Downstream of the receptors, IRS variability may influence pheno-
typic outcomes, for example IRS1 has been associated with prolifera-
tion, whereas IRS2 has been associated with metastatic behaviour. 
Signaling through hybrid receptors and through IGFs binding to 
IR-A may also impact on malignant transformation. A fetal splice-
variant of the insulin receptor that binds IGF-1 and IGF-2 with 
higher affinity than the adult IR-A and IR-B forms has been noted in 
breast, colon and lung cancers, resulting in preclinical augmentation 
of the mitogenic responses to IGF-2.
The strong signaling through IGF-1R into the PI3K-AKT pathway, 
associated with the delivery of pro-survival signals within the cell, 
also implicates the IGF axis as a possible mechanism of innate 
or acquired resistance to anti-cancer treatment in neoplastic cells. 
Survivin, a molecule involved in the control of cell proliferation and 
apoptosis, is known to be tightly regulated by the IGF axis through 
mammalian target of rapamycin (mTOR) mediated protein synthesis 
in a number of experimental systems. Co-administration of IGF-
1 is known to reduce the apoptosis induced by chemotherapy or 
radiotherapy in a range of different cancer cell lines and xenografts. 
IGF1-R inhibition is associated with increased sensitivity to ionizing 
radiation in NSCLC cell lines and xenograft models. Several lines 
of evidence implicate expression of IGF1-R with reduced efficacy 
of anti-EGFR targeting. AKT activity has, for some time, been 
associated with EGFR TKI resistance and in some cell lines, IGF1-R 
inhibition in addition to EGFR inhibition is required to reduce AKT 
pathway activity. Resistance to EGFR TKIs may be manifest through 
EGFR:IGF-1R heterodimerization and ultimately the induction of 
survivin as a pro-survival strategy. In small cell lung cancer cell lines 
c-kit targeting together with IGF-1R inhibition produces synergistic 
apoptosis.
A large number of different anti-cancer strategies directed against 
the IGF axis are being developed. Monoclonal antibodies are the 
furthest advanced, although small molecule inhibitors are now also in 
early phase clinical studies. Antibodies directed against the extracel-
lular domain of the IGF-1R may perform any or all of the follow-
ing beneficial activities, in part depending on the specific isotype 
of the antibodies used: block ligand binding, induction of receptor 
internalization and degradation, direction of antibody-dependent cell-
mediated cytotoxicity (ADCC) to cells expressing surface IGF-1Rs. 
The difference in the number of active receptors needed for turning 
on a mitogenic response to ligand may be as little as between 15 and 
22,000 per cell. Consequently, small differences in receptor num-
ber affected by therapeutic antibodies may be clinically significant. 
Many different drug companies are in the process of developing 
monoclonals directed against the IGF-1R. The furthest advanced 
monoclonal is CP-75,871 (Pfizer). CP-751,871 is a fully human IgG2 
monoclonal antibody that preclinically abolishes ligand-dependent 
signaling through the IGF-1R within minutes and reduces overall 
cell expression of IGF-1R within 24 hours. CP-751,871 appears to 
combine well with cytotoxic chemotherapy. Both 10 and 20mg/kg 
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CP-751,871 are compatible with full dose carboplatin and paclitaxel, 
at the expense of producing additional grade 3 neutropenia and 
hyperglycemia. Hyperglycemia appears to be a class effect. In a ran-
domized phase II study of up to 6 cycles of carboplatin and paclitaxel 
plus/minus CP-751,871 (including maintenance post-chemotherapy) 
in the first line treatment of advanced NSCLC, dramatic response 
rate increases have been reported from the addition of the anti-
IGF-1R antibody, with some suggestion of a dose response to the 
CP-751,871. Both adenocarcinomas and squamous cancers appeared 
to benefit from the addition of CP-751,871 although the highest 
response rates for the IGF-1R inhibitor-chemotherapy combination 
were in patients with squamous cancer. Due to the design of the 
study, cross-over to CP-751,871 monotherapy after progression on 
chemotherapy alone was permissible and at least one patient demon-
strated tumor shrinkage to single agent CP-751,871 in this setting. 
To date, the major difference between the antibodies used in clinical 
trials seems to be their plasma half-lives, leading to a number of dif-
ferent administration regimens being taken forward. 
With regard to the small molecule inhibitors of the IGF-1R, XL228 
is an intravenously administered multi-targeted kinase inhibitor with 
preclinical activity against IGF1-R, Src, FGFR and BCR-Abl. It is 
being explored as a weekly 1-hour intravenous infusion in phase I 
studies in both solid tumors and in CML or Philadelphia chromo-
some positive ALL. No clinical results have yet been released. 
OSI has developed a potent and relatively specific inhibitor of the 
IGF1R kinase, with approximately 14-fold selectivity over the 
Insulin Receptor and minimal activity against other kinases tested in 
vitro. It reduces signaling through the IGF1-R but, in contrast to the 
anti-IGF1-R monoclonal antibodies, achieves this without produc-
ing down-regulation of the receptor. A form suitable for human 
exploration, OSI-906, is currently being explored in two ongoing 
phase I studies using once or twice daily continuous oral dosing, and 
intermittent oral dosing for between 3 and 7 days every 14 days. No 
clinical results have yet been released
Explorations of aspects of ligands, binding proteins, receptors and 
receptor substrates are all ongoing to identify potential biomarkers 
predictive of benefit from IGF axis intervention.
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ASA404, a novel tumor vascular disrupting agent (VDA): 
rationale for advanced non-small cell lung cancer therapy
Lara, Primo N.
University of California Davis Cancer Center, Sacramento, CA, USA
ASA404 (formerly DMXAA or ASA1404) is a flavone-8-acetic 
acid analogue that possesses anti-cancer activity through a unique 
mechanism termed vascular disruption. This mechanism of action 
is related to induction of apoptosis in tumor vascular endothelial 
cells as well as cytokine production that causes irreversible tumor 
vasculature collapse, subsequently resulting in hemorrhagic tumor 
necrosis.1, 2Additionally, preclinical data have shown that ASA404 
can yield necrosis within a tumor mass while leaving a viable rim 
of surviving cells, providing a rationale for combination therapy 
with cytotoxic therapy.3 When given in combination with paclitaxel, 
cisplatin/carboplatin or gemcitabine, ASA404 has been demon-
strated to have potent activity against lung cancer xenografts. It has 
been hypothesized that ASA404’s antineoplastic activity is greatest 
in poorly-perfused regions of the tumor typically inaccessible to 
chemotherapeutic agents or have relative chemo-resistance due to 
tumor hypoxia. A randomized phase I/II clinical trial (AS1404-201) 
of ASA404 in combination with paclitaxel and carboplatin in patients 
with locally advanced or metastatic non-small cell lung cancer 
(NSCLC) was reported to demonstrate evidence of activity. Specifi-
cally, 84 patients were randomized, with 76 patients included in the 
efficacy population. In the phase I portion of the trial, three incre-
mental doses of ASA404 (600, 1200 and 1800 mg/m2) were tested in 
combination with paclitaxel (175 mg/m2) and carboplatin (AUC 6). 
The dose of 1200 mg/m2 of ASA404 was subsequently used for the 
randomized phase II portion of the trial. To explore the potential for 
enhanced activity with a higher ASA404 dose, an additional cohort 
of 25 patients was treated at 1800 mg/m2 during the phase II portion, 
with a total of 31 patients treated at that dose. At the end of the study, 
47.1% (ASA404 1200 mg/m2 treatment group), 46.7% (ASA404 
1800 mg/m2 treatment group) and 41.7% (standard therapy group) 
remained alive. The median survival time was 14.0 months in the 
1200 mg/m2 arm and 14.9 months in the 1800 mg/m2 arm, while the 
median survival time in the chemotherapy-only control arm was 8.8 
months. This difference was clinically and statistically significant. 
These encouraging data have subsequently led to the development 
of ATTRACT-1, a prospective, global, multi-center, double-blind, 
placebo-controlled, randomized Phase III trial in patients with 
advanced NSCLC. This trial is presently open and accruing, with an 
accrual goal of 1,200 patients. Patients are randomized into one of 
the following two treatment arms: ASA404 plus paclitaxel/carbopla-
tin or placebo plus paclitaxel/carboplatin. The results of ATTRACT-1 
will validate the role of vascular disruption as a novel strategy in the 
management of advanced NSCLC.
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EGFR Based Therapies:  
Emerging Predictive Markers
Lynch, Thomas J.1, 2
1 Yale Cancer Center, New Haven, CT, USA; 2 Smilow Cancer 
Hospital, New Haven, CT, USA
The treatment of lung cancer has undergone a remarkable transfor-
mation over the past five years. Previously a simple diagnosis of 
“non-small cell lung cancer” was sufficient to determine appropriate 
treatment. Histology now plays a larger role in determining optimal 
therapy for metastatic disease. And while we continue to optimize 
treatment based on histology, the future of treating lung cancer will 
be based on molecular staging strategies. This will allow us to select 
more effective and less toxic treatments in the initial treatment of 
metastatic disease. It will also permit informed selection of patients 
for adjuvant treatment. Finally aggressive molecular staging will 
hopefully uncover new targets that will result in new drugs that may 
one day transform lung cancer into a chronic disease with long-term 
survival the rule and not the exception.
Agents that target the epidermal growth factor receptor (EGFR) 
tyrosine kinase are among the most important new drugs in use to 
treat non-small cell lung cancer. Both gefitinib and erlotinib are 
capable of producing remarkable tumor responses as single agents 
that are durable. These dramatic responses are often associated with 
mutations in the EGFR tyrosine kinase domain. In 2008 we learned 
that that EGFR mutation testing selects patients who benefit from 
first line tyrosine kinase inhibitor therapy with lung cancer in the 
IPASS study. Most importantly from IPASS we learned that for 
patients who are EGFR wild type combination chemotherapy is the 
optimal approach. 
For patients with EGFR mutations we are learning of drugs that may 
have activity when used in the setting of EGFR exon 20 resistance 
mutations—further highlighting the role of mutation testing. Com-
binations of drugs that target c-Met and EGFR are now in clini-
cal trial in order to target a second key mechanism of EGFR-TKI 
resistance—c-Met amplification. 
In addition when used in second and third line treatment of lung 
cancer erlotinib has been shown to prolong survival in this setting. 
This clinical benefit, at least when compared to best supported care, 
may be predicted by increased EGFR gene copy number as measured 
by FISH. Measurement of gene copy number by FISH is being used 
to select patients for treatment with EGFR-TKI treatment in several 
clinical scenarios. Patients who are FISH positive are being entered 
onto trials of erlotinib plus chemotherapy as first line treatment. 
Adjuvant studies of chemotherapy plus erlotinib given as sequential 
therapy are under review. 
New predictive markers that are under development include studying 
the tumor proteome to identify patterns that predict responsiveness. 
Novel molecular markers are also under development as is a better 
understanding of how patient pharmacogenomic features predict 
response. Finally the integration of knowledge from molecular stag-
ing plus clinical features allow the optimal selection of treatment for 
patients. 
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DNA repair mechanisms to tailor therapy in NSCLC
Olaussen, Ken A.1; Soria, Jean-Charles1, 2
1 Institut Gustave Roussy, Villejuif Cedex, France; 2 Université Paris-
Sud XI, Kremlin-Bicêtre, France
Novel therapeutic strategies need to be developed and existing 
therapies optimized in order to raise the survival rate of lung cancer 
patients. In this regard, rational treatment decision-making based on 
an analysis of biomarkers of response and resistance to cytotoxic 
drugs and novel molecular targeted agents appears to be a promising 
approach. 
Alkylating agents such as platinum components interfere in the 
cancer-cell DNA replication process by inducing DNA-adducts. 
The induction of DNA lesions by the covalent binding of platinum 
DNA adducts is responsible for the cytotoxicity of cisplatin. The 
DNA repair mechanism is one of the crucial molecular pathways 
potentially involved in resistance to platinum-based chemotherapy. 
Indeed, many cancer cells have the ability to increase their capacity 
of DNA-repair, in particular through the activation of the Nucleotide 
Excision Repair (NER) pathway. NER functions by a “cut-and-paste” 
mechanism in which cisplatin damage recognition, local opening 
of the DNA helix around the lesion, damage lesion and gap-filling 
occur in successive steps. The excision repair cross-complementation 
group 1 (ERCC1) is a highly conserved nuclease that performs an 
essential DNA excision step during the NER process.
Numerous studies have reported the role of ERCC1 expression in 
the repair mechanism of cisplatin-induced DNA adducts in many 
human carcinomas, particularly in NSCLC. We have previously 
studied ERCC1 protein expression in resected NSCLC tumors from 
761 patients who had participated in the International Adjuvant 
Lung Trial (IALT). Patients with ERCC1 negative tumors who were 
randomized to chemotherapy had significantly prolonged survival 
compared to those who were randomized to observation (test for 
interaction, P<0.009; HR=0.65; 95% CI [0.50-0.86]). In contrast, 
there was no survival difference between treated and none-treated 
patients among ERCC1 positive patients (HR=1.14; 95% CI [0.84-
1.55]). It was concluded that NSCLC patients with completely 
resected ERCC1 negative tumors seem to be stronger candidates 
for adjuvant cisplatin-based chemotherapy than those with resected 
ERCC1 positive tumors.
More recently, we investigated other DNA repair proteins as new 
potential markers able to predict efficacy to chemotherapy. In this 
aim, we investigated the expression of the human MutS homolog 2 
(MSH2) protein (PI: Pr. Pierre Fouret, University of Pierre et Marie 
Curie, Paris, France), which binds to cisplatin-induced DNA cross-
links (ICLs), initiating their excision and repair (a pathway called 
ICL-repair). Studies in vitro have shown that MSH2 is required, 
together with critical components of other DNA damage repair 
pathways, such as ERCC1, to repair cisplatin-induced DNA inter-
strand cross-links. By using immunohistochemistry to determine 
MSH2 expression in tumors from IALT patients, the data suggest 
that long-term survival benefit (7.5 years median follow-up) derived 
from chemotherapy is different according to MSH2 expression (test 
for interaction, P=0.06) : chemotherapy prolonged survival in the 
MSH2-negative group compared to observation (adjusted hazard 
ratio for death, 0.76; 95%CI, 0.59 to 0.97; P=0.03), but not in the 
MSH2-positive group (adjusted hazard ratio for death, 1.12; 95%CI, 
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0.81 to 1.55; P=0.48). Interestingly, chemotherapy strongly pro-
longed long-term survival in the combined MSH2-negative/ERCC1-
negative subgroup compared to observation (adjusted hazard ratio for 
death, 0.65; 95%CI, 0.47 to 0.91; P=0.01).
We concluded that MSH2 may be combined with ERCC1 to predict 
long-term benefit from adjuvant cisplatin-based chemotherapy in 
patients with non-small cell lung cancer.
Based on these results, two areas of development can be envisioned. 
First, future platinum-based chemotherapy (or even radiotherapy) 
could be chosen according to individual pharmacogenomic criteria 
such as expression of DNA repair proteins in a tumor tissue. Second, 
pharmacological blocking of DNA repair proteins may allow increas-
ing the therapeutic efficacy of platinum-derivatives.
Other proteins implicated in DNA repair might also be potential 
indicators to help selecting the patients with the highest probability 
of response to cisplatine and/or gemcitabine. Two important candi-
dates are RRM1 (allows synthesis of nucleotides necessary for DNA 
repair) and BRCA1, the latter being implicated in several DNA repair 
pathways such as non-homologous end joining, homology-directed 
repair, mismatch repair, and ICL-repair. The ICL-repair pathway 
seems again promising with a growing body of evidence linking 
BRCA1 with the Fanconi anemia pathway for ICL-repair. More gen-
erally, other markers have been suggested as potential predictors of 
the efficacy or toxicity of pemetrexed (eg TS, homocysteine levels), 
paclitaxel (eg Map-tau), or docetaxel (eg bcl2).
Preclinical and clinical data clearly show that DNA repair markers 
are not only promising markers in future algorithms paving the way 
for personalized therapy, but also potential anti-cancer drug targets. 
However pharmacological modulation of these targets clearly pres-
ents major challenges for drug discovery.
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Development of image processing tools 
for drug response evaluation
Avila, Ricardo S.
Kitware, Inc., Clifton Park, NY, USA
Computed tomography scanners have advanced rapidly over the 
last two decades and this is enabling new opportunities to improve 
lung cancer therapy assessment through the use of quantitative 
image processing methods. The isotropic, sub-millimeter resolution 
data that is now routinely available from current day CT scanners 
provides a large amount of detailed anatomical information that is 
of significant value when assessing a patient’s response to therapy. 
The main focus of research in this area has been on the development 
of quantitative image analysis methods that are able to accurately 
identify the boundary of lung cancer lesions and determine their 
volumetric change in size within a time series of CT scans. While 
many research groups have demonstrated promising initial results, a 
significant number of technical challenges must be overcome before 
these tools are routinely utilized in clinical trials. First, most lesion 
sizing methods have been designed to operate on sub-centimeter lung 
nodules and have great difficulty handling the larger lung cancer 
lesions present in the late stage disease that is a characteristic of cur-
rent lung cancer clinical trials. This is being addressed by exploring 
alternatives to image processing methods that identify the boundary 
of a lesion, referred to here as segmentation-based methods. Alterna-
tives include (a) the investigation of methods that apply deformable 
registration algorithms to serial studies and analyze image deforma-
tions over time (registration-based methods) and (b) the tracking of 
lesion surfaces over time, leveraging both registration and bound-
ary segmentation algorithms (hybrid methods). Another important 
technical challenge that quantitative methods must address is the 
ability to robustly support the wide range of scanners and protocols 
that are used in stage II and stage III clinical trials. This requires that 
algorithms attain fundamental characteristics of the imaging system, 
such as the point spread function (PSF) and noise characteristics of a 
scan, and are further able to algorithmically adapt to this information 
in order to maintain high measurement accuracy. Finally, it is impor-
tant to recognize that acceptance of a new methodology for assess-
ing lung cancer drug therapies will require the building of scientific 
consensus on the design and utility of new methods. To help achieve 
this goal an open source lesion sizing toolkit has been developed that 
provides a general framework for implementing lesion sizing algo-
rithms and also contains a specific set of methods for the volumetric 
measurement of lung cancer lesions. This new resource, combined 
with the growing number of publicly available lung cancer imag-
ing archives offers a path toward accelerating the development and 
acceptance of quantitative therapy assessment methods.
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Induction trial of RAD001 in operable lung cancer
Khuri, Fadlo R.; Ramalingam, Suresh; Fu, Haian; Sun, Shi-Yong
Emory University School of Medicine, Winship Cancer Institute, 
Atlanta, Georgia, USA
Lung cancer is by far the most devastating cause of cancer death, 
leading to more than 1 million deaths worldwide in 2009. Despite 
substantial progress in the surgical and oncologic care of lung cancer 
patients, 5 year survival has only improved from 7% to 16% over 
the last 2 decades, with the magnitude of that survival improvement 
evident only in the most developed countries. Recent progress in the 
development of chemotherapeutic and targeted agents has led to the 
approval of 6 novel chemotherapy agents, small molecule tyrosine 
kinase inhibitors and 2 monoclonal antibodies in lung cancer over 
the last 15 years. However, most lung cancers ultimately become 
refractory to therapy with shifts in metabolic dependence that are 
difficult to detect with conventional imaging. The mammalian target 
of rapamycin (mTOR) represents a plausible therapeutic target for 
development of novel approaches to lung cancer. 
To date, mTOR inhibitors have been developed for the treatment 
of advanced refractory or poor prognosis renal-cell cancer with 
evidence of prolongation of survival and disease free-survival. Data 
from our group showed that targeting the AKT-mTOR axis presents 
substantial therapeutic opportunities for the treatment of lung cancer. 
In cancer cells, mTOR is often dysregulated through a number of 
different means, including excessive growth factor signaling, gain-
of-function mutation in upstream kinases, loss of function of the 
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
Copyright © 2009 by the International Association for the Study of Lung CancerS44
negative regulators PTEN, TSC1-2 and LKB1 and through increased 
activity of kinases that stimulate the PI3-K/Akt pathway, such as 
Ras/Raf, Abl, and ER. Further evidence indicates that the PI3-K/Akt 
pathway is dysregulated in cancer, with frequent AKT activation / 
mTOR phosphorylation found in NSCLCs. Thus, mTOR is involved 
in invasion and in tobacco carcinogen-induced cellular transforma-
tion with more than 70% of cells have active AKT specifically in 
tumor (both S473 & T303 phosphorylation sites). This activation of 
AKT appears to be associated with shorter overall survival. Finally, 
dysregulated signal transduction through the PI3K/AKT/mTOR 
pathway is involved in upregulation of CXCR4 (CXC chemokine 
receptor 4 which is involved in metastases). 
We have developed a targeted collaborative approach with col-
leagues from the Spanish Lung Cancer Study Group led by Dr. 
Rafael Rossell to evaluate the prognostic significance the mTOR /
AKT axis proteins in lung cancer. Today, we have analyzed over 
a 160 samples with evidence that phospho-AKT expression dif-
fers significantly between normal tissue, surrounding hypoplastic 
tissue, and the NSCLCs. We are conducting a phase Ib trial to assay 
preoperative everolimus(RAD001) in patients with resectable lung 
cancer. Patients eligible for the study were those who have resectable 
disease, and are willing to participate in a study in which they would 
receive 3 weeks of pre-operative RAD001 (everolimus/toricell) at 
5mg/day prior to surgery. Patient response to the RAD001 treatment 
was evaluated by metabolic assessment, with a PET Scan obtained 
prior to therapy and another one obtained the day before surgery. 
Patients were to discontinue the RAD001 within 24 hours prior to 
definitive surgical resection. Baseline tumor biopsies were paired 
with the resection material for each patient in order to correlate meta-
bolic changes with modulation in activity of AKT, mTOR, and other 
phospho-proteins of the AKT-mTOR axis. This was based on the pre-
vious discovery by our group that treatment of lung cancer cell lines 
and xenografts with mTOR inhibitors such as rapamycin or everoli-
mus leads to a paradoxical upregulation of phospho-AKT. Eight 
patients have been treated to date, with 1 patient experiencing grade 
3 nausea and another patient experiencing grade 2 GI toxicities. All 
patients were treated with 5 mg of everolimus per day, with 6 of the 8 
patients completing the 3 weeks of preoperative RAD001. The other 
2 patients voluntarily discontinued their medications, due to either 
toxicity or poor patient tolerance. Six of the eight patients (all of the 
patients that completed three weeks of the RAD001) had significant 
reductions in the metabolic signaling as assessed by serial FDG-PET 
scan. Significant modulation of phospho-AKT and phospho-mTOR 
was seen in the samples. The feasibility of this window of opportu-
nity study suggests that novel metabolic modulators, such as mTOR 
inhibitors, can be safely given in the pre-operative setting and their 
metabolic and biochemical activity in lung cancer can be assessed by 
obtaining serial biopsies and by correlating these biopsies with PET 
and CT findings.
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Challenges of Neoadjuvant Window of Opportunity Trials
Parikh, Purvish M.
Tata Memorial Hospital, Mumbai, India
Lung Cancer remains the most common cancer globally. Diagnosis in 
early stage is currently possible only in a small fraction. This makes 
potentially curative surgical therapy unavailable to the majority. Neo-
adjuvant therapies are an attractive option to increase operability, and 
ultimately cure rates. The current knowledge (or lack of it) should 
make neoadjuvant studies an attractive proposition. Unfortunately 
there are challenges while designing and implementing neoadjuvant 
trials. This window of opportunity really seems smaller and more 
jagged than expected. I will present data of a survey of lung cancer 
specialists from varying geographies that provide insight into why 
such challenges really exist and how they can be surmounted. This 
data will be discussed in the light of ongoing neoajduvant trials and 
how future trials can be optimised.
Session M8:  
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Early detection of lung cancer using an electronic nose
McWilliams, Annette
British Columbia Cancer Research Centre/University of British 
Columbia, Vancouver, British Columbia, Canada
Background
Due to the enormity of the worldwide clinical problem of lung cancer 
there has been increased interest in the development of a screening 
program for early lung cancer. Over the last decade, thoracic CT scan 
and other modalities such as autofluorescence bronchoscopy appear 
promising as tools to detect small lung cancers. However, broad 
implementation of these techniques in a community screening pro-
gram are limited by factors such as cost, invasive nature, high false 
positive rate and radiation dosage. The development of a screening 
program would be enhanced by the availability of a non-invasive 
tool to target the group that requires further investigation with these 
diagnostic technologies. 
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Volatile Organic Compounds
One technique that is stimulating research interest is the identifica-
tion of volatile organic compounds (VOCs) in exhaled breath that 
may aid in the detection of pre-symptomatic lung cancer.1-7 It is 
hypothesised that these compounds are markers of oxidative stress.6 
The detection of volatile organic compounds (VOCs) in exhaled 
breath analysis of lung cancer patients by gas chromatography/
mass spectrometry (GC/MS) was initially reported in the 1970s and 
1980s.1,2  More recently published series have characterized a number 
of VOCs by GC/MS and some have developed classification models 
to predict the presence of lung cancer.3-7 (Table 1) These prediction 
models resulted in sensitivity >70% and specificity >80%. Although 
these results are encouraging, the use of GC/MS to analyse exhaled 
breath is expensive and the results are not rapidly available.
Electronic Nose
The more recent development of odour sensing technology has 
created devices called “electronic noses”.8-12 These devices rely on 
chemical vapour sensor arrays that respond to specific stereochemi-
cal characteristics of an odorant molecule, particularly VOCs. Small 
published studies in patients with and without lung cancer using 
pattern recognition of exhaled VOCs suggest a sensitivity >70% and 
specificity of >90%8 ,9 ,11 ,12 (Table 1). The analysis of exhaled breath 
by the electronic nose is much simpler and cheaper than analysis by 
GC/MS, thereby making the electronic nose more useful for large 
scale screening applications and the test results are immediately 
available. This method deserves further in-depth study in a large 
study population with well matched cancer and control subjects.
Conclusion
The detection of volatile organic compounds (VOCs) in exhaled 
breath analysis with an “electronic nose” is an interesting technique 
that shows promise. Further prospective investigation in large 
numbers of subjects in a screening setting is required to explore this 
technique and its possible role in the detection of pre-symptomatic 
early lung cancer. If proven effective, it offers the possibility of a first 
step screening test with a sensitivity and specificity of ≥ 80 % that is 
relatively cheap and easy to use.
Table 1. Exhaled Breath Analysis for Detection of Lung Cancer
Study Method Subjects Sensitivity Specificity
Phillips M et al. 20034 GC/MS 108 85% 81%
Phillips M et al. 20076 GC/MS 404 85% 80%
Poli D et al. 20055 GC/MS 146 72% 94%
Di Natale C et al. 20038 Electronic Nose 60 100% 94%
Machado R et al. 20059 Electronic Nose 135 71% 92%
Blatt R et al. 200811 Electronic Nose 101 95% 91%
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Optical coherence tomography
Lam, Stephen
British Columbia Cancer Agency, Vancouver, BC, Canada
Although autofluorescence bronchoscopy improves the detection rate 
of high grade dysplasia and carcinoma in-situ compares to white-
light examination, the natural history of preneoplastic bronchial 
lesions is still poorly understood because the biopsy procedure for 
histological confirmation can mechanically remove these small 
lesions. The lack of accurate information regarding the spontane-
ous progression and regression rates of preneoplastic lesions make 
if difficult to assess the effect of chemoprevention agents. When 
carcinoma in-situ is encountered, there is always the uncertainty 
that micro-invasion has occurred in the lesion that is not part of the 
biopsy. The presence and depth of tumor invasion can influence the 
outcome after endobronchial treatment. It is therefore important to 
develop non-biopsy methods that can characterize preneoplastic 
lesions in the bronchial epithelium. 
Optical coherence tomography (OCT) is an optical imaging method 
that can visualize cellular and extra-cellular structures at and below 
tissue surface. OCT is a non-invasive imaging technique that can 
image tissue structures up to 3 millimeters below the surface [1-3]. 
In principle, it is similar to B-type ultrasound. Instead of using sound 
waves, a low coherence near infra-red light such as from a 1300 nm 
superluminescent diode source is passed into the tissue. By detecting 
the reflected light as it interacts with tissue structures as a function of 
depth, a cross sectional image is created through optical interferom-
etry. Its contrast is the backscattered light from interfaces at different 
depths in the tissue, due to the heterogeneity of optical refractive 
indices from different tissue compositions and densities. Changes in 
the extracellular matrix can be readily seen due to the strong back-
scattering properties of collagen and elastin. OCT provides cross-
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sectional tomographic images about anatomic layered structures of 
tissues with a field-of-view of a few millimeters, a spatial resolution 
of 3 to 16 microns and a depth penetration of 2–3 mm to provide 
near-histological images. The imaging procedure is performed using 
fiberoptic probes that can be miniaturized to enable imaging of 
airways down to the terminal bronchiole. Unlike ultrasound, light 
waves do not require liquid based coupling medium and thus are 
more compatible with airway imaging. There are no associated risks 
from the weak near infrared light. OCT has distinct advantages over 
CT and MRI for imaging small airways in-vivo in that it has superior 
resolution approaching near-microscopic resolution and requires no 
ionizing radiation. It has advantages over confocal microscopy in 
that it can pentrate tissue three times deeper, does not require contact 
with the tissue surface and is less susceptible to motion artifacts 
due to cardiac pulsation and respiratory movements. It can be done 
within minutes as part of a standard bronchoscopic examination 
under local anesthesia and conscious sedation. 
In addition to morphometric information, functional OCT, such as 
spectral domain OCT and Doppler OCT, can also provide quantita-
tive information on blood flow of blood vessels and micro-vascula-
ture [4, 5]. To obtain molecular and biochemical information, OCT 
can be combined with multi-photon microscopy (MPM). MPM per-
mits imaging and measurement of specific tissue components such as 
collagen, elastin, NADH, and flavins (6-8). Integration of MPM and 
OCT will allow simultaneous structural and functional imaging as 
well as biochemical or molecular analysis of the extracellular matrix, 
cellular and vascular elements. Alternatively, using a sheath catheter, 
OCT can be integrated with spectroscopic measurements such as 
Raman (9) or fluorescence spectroscopy to study the biochemical 
composition of bronchial tissues. OCT imaging has been applied to 
study bronchial and lung tissues and has been shown to be promising 
in detecting tumor invasion through the basement membrane, dif-
ferentiating high grade dysplasia from metaplasia or hyperplasia and 
localization of small peripheral tumors [10-13].
Supported in part by NIH grant 1PO1-CA96964, U01CA96109 and 
the BC Cancer Foundation.
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Autofluorescence-reflectance imaging
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Introduction
Early detection of central type lesions, especially intraepithelial 
stage, is a challenge for bronchoscopists. Last decade has witnessed 
several advances in both technical and clinical aspects of bronchol-
ogy. These advances have led to better diagnostic yield from bron-
choscopy. Fiberoptic bronchoscope has been replaced by videoendo-
scope, so bronchoscopists can capture more detailed images of the 
bronchus. Inhaled carcinogens may cause cumulative genetic damage 
to the entire bronchial surface resulting in genetic disorder. The 
multicentric nature of central type lung cancer may be the result of 
field cancerization. This theory also supports the concept of multistep 
carcinogenesis: lung cancer developing through a series of morpho-
logical changes from dysplasia to carcinoma in situ and then invasive 
cancer. However, dysplasias are generally a few cell layers thick and 
are detected only by chance. Autofluorescence bronchoscopy (AFB) 
has widely spread since early 1990’s. Several studies have shown 
that AFB improved the sensitivity of cancer and dysplastic lesions of 
the airway, especially those in intraepithelial stage (1-6). Recently, 
videoendoscopy-based autofluorescence systems have come into 
clinical use (7, 8). Synchronous dual images with white light and 
AFB with better resolution than that of fiberscopy-based AFB could 
be obtained (8).
AFB is also useful in the objective evaluation of the margin of 
the tumor before surgery or endoscopic treatment as well as in the 
localization of the lesions of cases with abnormal sputum cytology 
findings. It is well understood that the combination of bronchofibers-
copy and AFB increased the sensitivity of dysplasia and carcinoma in 
situ (CIS). We postulate that comprehensive diagnostic bronchoscopy 
including AFB and reflectance imaging might show better images 
with higher resolution, which result in accurate evaluation of intra-
epithelial lesions. 
Patients
There is as yet no universally accepted indication as to who should 
undergo AFB. Indications need to be established based on the consid-
eration of benefit and risk of this procedure.
Usually, cases for AFB are classified into 4 groups as described 
below.
•  Patients with known or suspected lung cancer who were sched-
uled for bronchoscopy as a part of standard examination
•  Patients with abnormal sputum cytology findings (moderate atypia 
or worse) with a normal chest radiograph
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•  Patients after curative surgery of stage I lung cancer who were 
scheduled for bronchoscopy as a part of follow up
•  Heavy smokers with respiratory symptom
A total of 440 consecutive patients were studied using the videoen-
doscopy-based AFB system. A total of 550 sites were biopsied to 
evaluate the relationship between endoscopic findings and pathology 
results. The sensitivity of the system for CIS+dysplasia was 68% in 
white light and 94% in videoendoscopy-based AFB. The new AFB 
system had significantly higher sensitivity for intraepithelial lesions 
than videoendoscopy alone.
Discussion
Most studies in the past reported increased sensitivity of dysplasia 
or cancer in patients at high risk by autofluorescence bronchoscopy 
compared to white light alone.
However, morphological classification of grades of dysplasias in 
objective way as well as the follow up protocol of high grade dyspla-
sia should be discussed (9). Genetic anaysis and quantitative pathol-
ogy may bring a clue of this problem. Also, reflectance imaging 
would improve the endoscopic evaluation of intraepithelial lesions, 
especially oprtical coherence tomography (OCT) and confocal imag-
ing would be promising.
Our diagnostic strategy for central type early stage lung cancer using 
AFB as well as endoscopic ultrasonography (EBUS) and OCT for 
depth diagnosis will also be also explained. 
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Introduction: 
Narrow band imaging (NBI) is a new optical technology that can 
clearly visualize the microvascular structure in the mucosal layer. 
Since the development of NBI, some investigator reported that this 
new technology can provide clear vascular structure image in some 
organ especially GI tract. Moreover, in the field of bronchovideosco-
py we have also reported that high magnification bronchovideoscopy 
combined with NBI was useful in the detection of capillary blood 
vessels in angiogenic squamous dysplasia lesions.
In the present study, we investigated the ability of a high resolu-
tion bronchovideoscopy system with narrow band imaging (NBI) 
to detect blood vessels structure in the squamous cell carcinoma of 
bronchi including carcinoma in situ and micro invasive carcinoma in 
addition to the dysplastic bronchial epithelium. 
Methods: 
Narrow band imaging
The conventional RGB sequential videoscope system has a xenon 
lamp and rotation disk with 3 RGB optical filters. The rotation disk 
and monochrome CCD are synchronized and 3 band images are 
generated sequentially. Color images can be synthesized using 3 
band images by the video processor. Narrow band imaging, devel-
oped in conjunction with the Olympus Optical Corp., Tokyo, Japan, 
is a novel system that can be used to observe microvessels structure 
using a new narrow banding filter on an RGB sequential videoscope 
system instead of the conventional RGB broadband filter. In the 
current study, wavelength ranges of the new NBI filter were 400–430 
nm (Blue), 400–430 nm (Green), and 520–560 nm (Red). In contrast, 
the range of wavelengths in the conventional RGB broadband filter 
were 400–500 nm (Blue), 500–600 nm (Green), and 600–700 nm 
(Red). The main chromosphere in bronchial tissues in the visible 
wavelength range is haemoglobin, which has a maximum absorp-
tive wavelength near 415 nm, and is within the wavelength range 
for NBI-Blue and Green (400–430 nm). When conventional RGB 
broadband light is delivered through an endoscope onto a tissue sur-
face, some of the light is reflected from the tissue, some is scattered 
or absorbed within the tissue, and little light is detected to form an 
image on the television monitors. However, narrow band light deliv-
ered onto the same surface shows less scattering and makes it pos-
sible to show clearer television monitor images. One-hundred eighty 
six patients with sputum cytology specimens suspicious or positive 
for malignancy and lung cancer patients seen at the Department of 
Thoracic Surgery, Graduate School of Medicine, Chiba University 
in Chiba patients were entered into the study. White light examina-
tion using high resolution bronchovideoscopy was first performed 
under local anesthesia with sedation by intravenous midazolam 
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injection and O2 inhalation. Observations were repeated with NBI 
light to examine microvascular networks in the bronchial mucosa. 
The images can be changed from WL to NBI with a single touch of a 
switch and vice versa. 
Results: 
Biopsy specimens from abnormal NBI images were 79 squamous 
dysplasia including 31 angiogenic squamous dysplasia, 11 carcinoma 
in situ, 12 micro invasive squamous cell carcinoma and 41 invasive 
squamous cell carcinoma. Increased vessel growth and complex 
networks of tortuous vessels of various sizes in squamous dysplasia, 
some dotted vessels in addition to complex networks of tortuous ves-
sels of various sizes in angiogenic squamous dysplasia and several 
dotted vessels, spiral type vessels and screw type vessels of vari-
ous sizes and various grades in squamous cell carcinoma including 
carcinoma in situ were clearly observed in NBI with high resolution 
bronchovideoscopy. The sensitivity of the NBI Images was 100% 
of squamous cell carcinoma and 86% of squamous dysplasia and 
specificity was 84%, respectively.
Conclusion: 
NBI with high resolution bronchovideoscopy was useful in the detec-
tion of tortuous vessel networks, several dotted and spiral or screw 
type vessels of various sizes and grades in squamous cell carcinoma 
of bronchi in addition to dysplastic bronchial epithelium. This may 
enable detect the onset of angiogenesis during multi-step carcinogen-
esis of the lung. 
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Summary : 
With recent advances in computer and optics engineering, diagnostic 
endoscopy of the respiratory tract has now entered the era of micro-
scopic imaging.
Fibered confocal fluorescence microscopy (FCFM) is based on the 
principle of confocal microscopy, where the microscope objective 
has been replaced by a thin fiberoptic probe. FCFM has a lateral 
resolution of 3µm, a field of view of 600 µm and produces real-
time imaging at 9 frames per second in contact with the probe tip. 
FCFM has the capability to image in real time the epithelial and 
subepithelial layers of the proximal bronchial tree, as well as the 
more distal parts of the lungs, from the terminal bronchioles down to 
the alveolar ducts and sacs. Potential applications of FCFM include 
« optical biopsy » assessment of early bronchial cancers, bron-
chial wall remodelling evaluation, diffuse peripheral lung disease 
exploration as well as in-vivo diagnosis of peripheral lung nodules. 
The technique has also the potential to be coupled with fluorescence 
molecular imaging. This strategy may help in the future to enable 
early diagnosis, rapid typing of molecular markers and assessment 
of therapeutic outcome in many lung diseases. This paper reviews 
the capabilities and possible limitations of confocal microendoscopy 
for proximal and distal lung exploration with special focus on lung 
cancer imaging in-vivo. 
Introduction : 
Confocal microscopy allows in-vivo optical sectionning of cells and 
tissue with enhanced lateral and axial resolutions (1, 2). Translating 
the principles of confocal microscopy into the clinic for endomicros-
copy is currently the subject of significant scientific efforts (1, 2), 
which recently ended in the availability of commercial systems for 
both animal (3-5) and human in vivo explorations (6-8).
Confocal endomicroscopes aim at providing to the clinician « optical 
biopsies », i.e. in vivo microscopic imaging, of a living tissue during 
endoscopy (9, 10). Such systems have recently been applied to the 
in-vivo microscopic imaging of both the proximal (7) and distal 
respiratory systems (8). 
Current commercially available confocal endomicroscopy system 
for lung exploration (Cellvizio®, Mauna Kea Technologies, Paris, 
France) uses the principle of proximal scanning in which the illu-
mination light scans the proximal part of a coherent fiber bundle or 
miniprobe. This bundle conducts the light back and forth from the 
imaged area at the tip of the miniprobe (11). 
This fiber bundle or catheter based system, also described as « 
fibered confocal fluorescent microscopy (FCFM) » uses very thin and 
flexible miniprobes (300µm to 2 mm in diameter) that can contain up 
to 30,000 compacted microfibers. Similar to conventional confocal 
microscopes, FCFM uses two rapidly moving mirrors to scan the 
microfibers across the coherent fiber bundle in a raster fashion. Each 
microfiber, which is scanned one at a time by the laser light, acts 
as a light delivery and collection system and is, in essence, its own 
pinhole. The main advantages of this design is the very small size 
and the flexibility of the probe that can reach the more distal part of 
the lungs (8), as well as the fast image collection speed that helps to 
avoid artifacts due to tissue movement. 
Specific miniprobes for bronchial and alveolar imaging have a 
diameter of 1mm that can enter the working channel of any adult 
bronchoscope. These miniprobes are devoid of distal optics and have 
a depth of focus of 0-50 µm, a lateral resolution of 3µm for a field of 
view of 600 x 600 µm. The system produces endomicroscopic imag-
ing in real time at 9 to 12 frames / second. 
Two different wave lengths are currently available. The Cellvizio 
488 nm is used for autofluorescence imaging of the respiratory tract 
as well as for fluorescein induced imaging of the GI tract (7, 8, 12). 
Another device at 660 nm excitation can be used for epithelial cell 
imaging after topical application of exogenous fluorophores such as 
methylene blue (13-15). 
The main limitations are related to the maximal imaging capabili-
ties (30,000 pixels) which restrict the lateral resolution to the fiber 
intercore distance (3µm), and the fact that the focus point of the 
system cannot be adjusted. Interpretation of the data also relies on 
the fluorescence properties of the imaged tissue. 
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Human In-vivo confocal microimaging of 
the normal lung using FCFM. 
FCFM imaging of the proximal bronchi. 
FCFM can easily be performed during a fiberoptic bronchoscopy 
under local anesthesia (7, 8). The technique of in-vivo bronchial 
FCFM imaging is simple : the miniprobe is introduced into the 2mm 
working channel of the bronchoscope and the probe tip applied onto 
the bronchial mucosae under sight control. The depth of focus being 
50 µm below the contact surface, the system can image the first lay-
ers of the bronchial subepithelial connective tissue, presumably the 
lamina densa and the lamina reticularis (7).
At 488 nm excitation, FCFM produces very precise microscopic 
fluorescent images of the bronchial basement membrane zone 
(Figure 1). FCFM bronchial microimaging reveals a mat of large 
fibers mainly oriented along the longitudinal axis of the airways with 
crosslinked smaller fibers, as well as larger openings – 100µm to 
200 µm - corresponding to the bronchial glands origins. In vivo, the 
technique also makes it possible to record high resolution images of 
small airways such as terminal bronchioles, which are recognizable 
by the presence of the helicoidal imprint of the smooth muscle on the 
inner part of the bronchiole. (7)
Figure 1 . Bronchial confocal microendoscopy imaging :
A.  Normal elastic fibered network of the basement membrane zone. 
B.  Disorganized basement membrane zone elastic network at the vicinity of a bronchial CIS
C. Regular normal bronchial epithelium 660 nm excitation FCFM after topical application of methylene 
blue (0,1%).
D. CIS imaging, FCFM at 660 nm and topical methylene blue. 
Fluorescence properties of the bronchial mucosae at 488 nm excita-
tion are determined by the concentration of various cellular and 
extracellular fluorophores, including the intracellular flavins, that 
could originate from the epithelial cells, and specific crosslinks of 
collagens and elastin present in the subepithelial areas (1, 16, 17). 
Microspectrometer experiments coupled with FCFM imaging, have 
clearly demonstrated that the main fluorescence signal emitted after 
488nm excitation from both bronchial and alveolar human system 
originates from the elastin component of the tissue (7, 8, 18). Indead, 
flavin cellular autofluorescence appears too weak to allow imaging of 
the epithelial layer using 488nm FCFM without exogenous fluoro-
phore (19). Similarly, the collagen fluorescence does not significantly 
affect the FCFM image produced at 488nm, the fluorescence yield 
of collagen at this wave length being at least one order of magnitude 
smaller than that of elastin. 
As a result, 488nm excitation FCFM specifically images the elastin 
respiratory network that is contained in the basement membrane of 
the proximal airways and participates to the axial backbone of the 
peripheral interstitial respiratory system. In the future, it is possible 
that a modified FCFM device using several wavelengths (20), or 
devices based on a multiphoton approach (2) may enable imaging of 
collagen, elastin and flavins simultaneously. 
Distal lung FCFM imaging in-vivo : from the 
distal bronchioles down to the lung acini. 
In the acinus, elastin is present in the axial backbone of the alveolar 
ducts and alveolar entrances, as well as in the external sheath of the 
extra-alveolar microvessels (21, 22). FCFM acinar imaging is easily 
obtained by pushing forward the probe a few centimeters after the 
endoscope is distally blocked into a sub-segmental bronchi. When 
progressing towards the more distal parts of the lungs, the entry into 
the alveolar space is obtained by penetration through the bronchiolar 
wall. Alveolar fluorescence imaging in active smokers dramatically 
differs from imaging in non-smokers. The alveolar areas of smok-
ers are usually filled with highly fluorescent cells corresponding to 
alveolar fluorescent macrophages, the presence of which appears 
very specific of active smoking. (8). In situ alveolar microspectro-
metric measurements have been performed in active smokers, which 
evidenced that the main fluorophore contributing to the FCFM 
alveolar signal corresponds to the tobacco tar by itself, explaining 
this difference (8, 18).
Potential clinical applications of 
bronchoalveolar confocal imaging. 
Preliminary studies have shown that per endoscopic FCFM could 
be used to study specific basement membrane remodeling altera-
tions in benign or malignant / premalignant bronchial alterations 
(7). The FCFM microstructure of the bronchial walls underlying 
premalignant epithelia is significantly altered. In these precancer-
ous conditions, the elastic fibered pattern of the lamina reticularis is 
absent or disorganized in almost every preinvasive lesions (Figure 1). 
This supports the hypothesis of an early degradation of the basement 
membrane components in preinvasive bronchial lesions. However, 
while this observation shed some light on the origin of the autofluo-
rescence defect in precancerous bronchial lesions, the absence of 
epithelial cell visualisation does not allow the technique to differenti-
ate between the different grades of progression of the precancerous 
bronchial lesions such as metaplasia / dysplasia / carcinoma in situ. 
In order to be successfully applied to the exploration of precancerous 
/ cancerous bronchial epithelial layer, the FCFM technique would 
need to be coupled with the use of an exogenous non toxic fluoro-
phore. Ex-vivo studies have shown that the resolution of the system 
is not a limitation for nuclear or cellular imaging (7, 8). Exogenous 
fluorophores that could be activated at 488 nm such as Acriflavin - a 
putative mutagen agent - or fluorescein solution, which does not stain 
the nuclei (23) are not approved for intrabronchial use. Recently, 
Lane et al. have used a confocal microendoscope prototype at 488 
nm excitation and topical physiological PH cresyl violet to provide 
cellular contrast in the bronchial epithelium both in-vitro and in-vivo 
(24). 
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Methylene blue is a non toxic agent which is commonly used during 
bronchoscopy for the diagnostic of broncho-pleural fistulae. MB 
is also used in gastroenterology for chromo-endoscopic detection 
of precancerous lesions (25-27), as well as for in-vivo microscopic 
examination of the GI tract and bronchus using a novel endocyto-
scopic system (28, 29). MB is a potent fluorophore which enters the 
nuclei and reversibelly binds to the DNA, before being reabsorbed 
by the lymphatics. In order to give a fluorescent signal, MB needs 
to be excited around 660 nm, and is therefore accessible to FCFM 
intravital imaging using this excitation wave length. 
Preliminary study has demonstrated that Cellvizio 660 / topical 
methylene blue makes it possible to reproducibly image the epithelial 
layer of the main bronchi. Future studies using this technique could 
make it possible to differentiate normal, premalignant and malignant 
alterations at the microscopic level. If this strategy is successful, 
FCFM may become a very powerful technique for in vivo diagnostic 
of early malignant and premalignant conditions of the bronchial tree, 
allowing the analysis of both the epithelial and subepithelial layers 
during the same procedure. 
Coupled to electromagnetic navigation or radial EBUS, FCFM could 
also image microstructural and cellular patterns of peripheral solide 
lung nodules in-vivo at both 448nm and 660 nm (14, 15) (figure 2).
Figure 2. FCFM imaging of normal distal lung and peripheral lung nodule 
:
A.  FCFM imaging of normal distal lung 
B.  Interstitial fiber network disorganisation in a peripheral lung adenocarcinoma (488 nm excitation 
wave length)
C. FCFM cellular imaging of a peripheral lung adenocarcinoma (660 nm excitation and topical 
methylene blue)
Until now, confocal microendoscopy of the airways has only used 
endogenous autofluorescence or simple fluorescent contrast agents 
to visualize the in-vivo cellular and interstitial organization of the 
airways and distal lung parenchyma. In the future, using molecu-
lar contrast coumponds, it will be possible to extend the range of 
biomarkers that may be imaged. Pilot studies exploring this strat-
egy have recently been published, that provided specific confocal 
imaging of molecular probes in precancerous conditions of the oral 
cavity ex-vivo (30) and of colonic dysplasia in-vivo (31). Coupled 
to FCFM, molecular imaging may help in the future to enable early 
diagnosis, rapid typing of molecular markers and assessment of 
therapeutic outcome in many lung diseases. 
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ERCC1 and RRM1 – predictive vs. prognostic 
roles in non-small cell lung cancer (NSCLC)
Simon, George R.
Fox Chase Cancer Center, Philadelphia, PA, USA
Introduction: 
Despite recent advances in treatment, only 16% of patients diag-
nosed with NSCLC will survive five years. Molecular analyses based 
rational selection of therapy may improve response rates and survival 
and this is made possible by identifying molecular markers with 
prognostic and predictive function. The term “prognostic” refers to 
a marker that is useful for estimating patients’ prognosis or outcome 
independent of therapeutic decisions; i.e., survival is different in 
marker positive and negative patients. The term “predictive” refers to 
a marker that is useful to make therapeutic decisions, i.e., the effect 
of treatment is different in marker positive and negative patients (1). 
Some markers like ERCC1 and RRM1 have both prognostic and pre-
dictive functions. The prognostic and predictive functions of molecu-
lar determinants are generally utilized to individualize treatment in 
the adjuvant setting, whereas the predictive function of a molecular 
marker are used in individualize therapy in the advanced setting. 
Using the prognositic and predictive function of ERCC1 
and RRM1 to tailor treatment in the adjuvant setting. 
ERCC1 
Excision repair cross complementing gene 1 (ERCC1) is a DNA 
damage repair gene that encodes the 5’ endonuclease of the nuclear 
excision repair complex (NER) and plays an important role in DNA 
damage repair. Impaired NER may result in genomic instability with 
an increased malignant phenotype and therefore explains the prog-
nostic function of ERCC1 (2) (1). Thus, ERCC1 could be interpreted 
to be an intermediate biomarker of the extent of intratumoral DNA 
damage. 
We evaluated the effect of intratumoral ERCC1 expression on 
survival in 51 NSCLC patients who underwent surgical resection for 
cure(3). ERCC1 mRNA expression was a continuous parameter, and 
the value of 50 (cohort median) was used to dichotomize patients 
into high and low ERCC1 expressers. A statistically significant dif-
ference (p=0.01) in median survival was seen in patients with high 
ERCC1 expression (94.6 months) when compared to patients with 
low ERCC1 expression (35.5 months) (Figure 1A). A significant rela-
tionship was also observed between ERCC1 and survival when the 
levels of ERCC1 were categorized into <30, 30-100, and >100. The 
median survival in these groups was 35.5, 62.1, and 94.6 months, 
respectively (Figure 1B).
Figure 1A. Median survival of patients with ERCC1 of > 50 (94.6 months) 
vs < 50 (35.5 months) (p = 0.01). 
Figure 1B - Median survival of patients with ERCC1 of < 30 (35.5 months), 
30 to 100 (62.1 months), and > 100 (94.6 months) (p = 0.03, two-sided 
log-rank test). (Adapted from Simon et al with permission (3)).
These findings were confirmed by Olaussen et al. in a cohort of 
patients from whom specimens were available from the International 
Adjuvant Cancer Trial (IALT) (4). In this ‘IALT-Bio’ study, immuno-
histochemical (IHC) staining was used to determine the expression of 
ERCC1 protein in 761 resected NSCLC tumors. These patients had 
been randomized to treatment with cisplatin-based chemotherapy or 
observation. Among 761 tumors, ERCC1 expression was positive in 
335 (44%) and negative in 426 (56%). Patients in the control group, 
who had not received adjuvant chemotherapy, with ERCC1 posi-
tive tumors had longer survival compared to patients with ERCC1 
negative tumors (adjusted HR 0.66; 95% CI, 0.49 to 0.90; p=.009). 
Among patients who received adjuvant chemotherapy a significantly 
prolonged survival was observed in ERCC1-negative tumors (adjust-
ed HR, 0.65; 95% CI, 0.50 to 0.86; p=.002) but not among patients 
with ERCC1 positive tumors (adjusted HR 1.14; 95% CI, 0.84 to 
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1.55; p= .40). The study concluded that low ERCC1 expression was 
associated with a survival benefit from cisplatin-based adjuvant 
chemotherapy for resected NSCLC. Patients with high ERCC1 in 
the control group had a better outcome than those with low ERCC1 
and did not derive additional benefit from adjuvant platinum-based 
chemotherapy. This identifies a group of patients (those with low 
ERCC1) that are likely to derive maximal benefit from platinum-
based adjuvant chemotherapy.
RRM1
RRM1 (Ribonucleotide Reductase M Subunit 1) is an enzyme that is 
involved in DNA synthesis by catalyzing the biosynthesis of deoxy-
ribonucleotides from corresponding ribonucleotides (5). It is the 
molecular target of gemcitabine, an antimetabolite with activity in 
several malignancies including NSCLC. RRM1, the regulatory sub-
unit of ribonucleotide reductase, plays an important role in suppress-
ing tumor cell migration and metastasis formation likely through 
PTEN, which is involved in the attenuation of growth factor signal-
ing through its lipid and protein phosphatase activity (6). Decreased 
survival has been observed in NSCLC patients with loss of one copy 
of the RRM1 gene compared to those with two copies (7). 
We had previously assessed the prognostic importance of RRM1 
expression at the mRNA level in patients with NSCLC (8). In this 
study of surgically resected patients (n = 40) with NSCLC, RRM1 
expression in tumor tissue was prognostic of overall (p=.011) and 
disease-free survival (p=.002). Patients with high levels of expres-
sion lived longer and had delayed disease recurrence as compared to 
patients with low levels of expression. The authors concluded that 
high RRM1 expression was indicative of long term survival indepen-
dent of stage, performance status, and weight loss.
Our group then confirmed this at the protein level in a subsequent 
study. An automated and quantitative estimation of RRM1 and 
ERCC1 protein levels were performed in tumor specimens (9). 
Overall survival in patients with completely resected stage I NSCLC 
with high RRM1 expression (>40.5) was reported to be 120 months 
as compared to 60.2 months in patients with low RRM1 expression 
(<40.5) (HR, 0.61; p=.02). A statistically significant difference in 
disease free survival was also observed (p=.004). RRM1 expression 
correlated with the expression of ERCC1, and the combination of 
both genes improved the prognostic utility 
Currently a proof of concept study, to be initiated soon by the 
Southwestern Oncology Group (SWOG), is looking at completely 
resected patients with stage I NSCLC and assessing ERCC1 and 
RRM1 expression in resected tumor samples through quantitative 
IHC. Patients with high levels of both RRM1 and ERCC1 genes 
will be monitored while those with low RRM1 and/or low ERCC1 
levels will receive cisplatin and gemcitabine adjuvantly for 4 cycles. 
This is a feasibility study and the primary endpoint is demonstrat-
ing the feasibility of doing a genomically based study. Feasibility is 
defined as the percentage of patients in whom treatment assignment 
can be made (>75%=success). A total of 90 patients is planned to be 
accrued. 
Using the predictive function of ERCC1 and RRM1 
to tailor treatment in the advanced NSCLC. 
Doublet chemotherapy currently forms the back bone of chemo-
therapy for advanced disease. In an unselected population of patients, 
most doublet chemotherapy combinations are equivalent to each 
other in efficacy with minor variations in toxicity (10). Recently 
reported and published trials have shown modest benefits in response 
and survival by adding either bevacizumab to carboplatin/paclitaxel 
(11) or cetuximab to cisplatin/vinorelbine. However the chemother-
apy backbone could be optimized by its rational selection by the use 
of ERCC1 and RRM1. 
Platinum compounds are heavy metal complexes that form adducts 
with and cross-links between DNA molecules and thus effectively 
block DNA replication and transcription. Repair of these adducts and 
cross-links are dependent on ERCC1. The NER complex recognizes 
and removes these adducts, and thus triggers resistance to platinum 
agents. 
Several in vitro studies have demonstrated that RRM1 is a molecu-
lar target of gemcitabine and thus a key cellular determinant of its 
therapeutic efficacy. To evaluate the impact of intratumoral RRM1 
expression on the efficacy of gemcitabine and carboplatin in previ-
ously untreated NSCLC patients, we conducted a prospective phase 
II clinical trial to confirm the in vitro data (8). Findings of this study 
confirmed that tumoral levels of RRM1 expression were significantly 
and inversely correlated with the magnitude of tumor shrinkage  
(r = -0.498, p=.002). In addition, NSCLC lines with differing levels 
of RRM1 expression was generated through genetic modification. In 
vitro cytotoxicity of gemcitabine was found to be directly associated 
with the level of RRM1 expression.
Lord et al. (12), correlated response and survival with the level of 
ERCC1 expression in 56 patients with advanced NSCLC treated 
with gemcitabine and cisplatin. mRNA was isolated from formalin-
fixed tumor specimens prior to therapy, and relative expression 
levels of ERCC1 were determined by real-time RT-PCR. The overall 
response rate was 44.7%. Median overall survival was significantly 
longer in patients with low ERCC1 expression (61.6 weeks; 95% CI, 
42.4–80.7) compared to patients with high expression (20.4 weeks, 
95% CI, 6.9–33.9 weeks), (p= .046). We had studied prospectively if 
an association between ERCC1 mRNA levels as determined by real-
time RT-PCR in fresh-frozen tumor specimens and response to two 
cycles of gemcitabine/carboplatin exists. In a group of 35 patients, 
we found an inverse correlation between ERCC1 levels and tumor 
shrinkage (r = -0.283, p=.099) (8). 
We also recently reported results from a prospective phase II 
clinical trial that was designed to test the feasibility and efficacy 
of molecular analysis-directed individualized therapy in patients 
with advanced NSCLC (13). ERCC1 and RRM1 mRNA expres-
sion levels were determined by real-time RT-PCR in fresh-frozen 
tumor specimens from 53 eligible patients. Predetermined values 
for ERCC1 and RRM1 were used for decisions regarding usage of 
the drugs gemcitabine and carboplatin. Gemcitabine was used in 
the treatment doublet if RRM1 was ≤16.5 and carboplatin was used 
in the doublet if ERCC1 was ≤ 8.7. This strategy resulted in four 
gene expression groups. The low RRM1 and low ERCC1 group was 
treated with gemcitabine and carboplatin (GC group), the low RRM1 
and high ERCC1 group was treated with gemcitabine and docetaxel 
(GD group), the high RRM1 and low ERCC1 group was treated 
with docetaxel and carboplatin (DC group), and the high RRM1 and 
high ERCC1 group was treated with vinorelbine and docetaxel (DV 
group). Disease response was 42%. Overall and progression-free 
survivals were 59% and 14% at 12 months with medians of 13.3 and 
6.6 months, respectively (Figure 2(A)). There were no significant dif-
ferences in Overall Survival of the individual groups (GC vs. GD vs. 
DC vs. DV) (Figure 2(B)). The conclusion from this trial is that gene 
expression analysis for treatment decisions of individual patients 
with advanced NSCLC is feasible and safe; and that it has produced 
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favorable response and survival data, which require confirmation in a 
randomized phase III trial. Such a phase III randomized multi-center 
confirmatory trial is currently underway comparing the customized 
approach to the standard arm of carboplatin and gemcitabine. 
Figure 2(A). Overall survival (OS) and progression-free survival (PFS) of 
53 patients with advanced non–small-cell lung cancer treated with che-
motherapy based on expression of the genes ribonucleotide reductase 
subunit 1 (RRM1) and excision repair cross-complementing group 1 gene 
(ERCC1). 
Figure 2(B). Overall survival (OS) by assigned chemotherapy. DC, doc-
etaxel and carboplatin; GC, gemcitabine and carboplatin; DV, docetaxel 
and vinorelbine; GD, gemcitabine and docetaxel. Adapted with permis-
sion from Simon et al(15). 
In a prospective phase III trial, conducted by the Spanish lung 
cancer study group, patients in the control arm received docetaxel 
plus cisplatin while patients in the test arm (genotypic arm) were 
treated according to ERCC1 levels and received cisplatin/docetaxel if 
ERCC1 mRNA levels were low or gemcitabine/docetaxel if ERCC1 
levels were high. Overall of 346 patients assessable for response, 
response rate was 39% in the control arm and 51% in the genotypic 
arm (p= 0.02). In the control arm, response rate was 47% in patients 
with low ERCC1 levels and 26% in patients with high ERCC1 
levels. Survival was also significantly better in the group with low 
ERCC1 levels in the control arm (14). This study further adds to the 
mounting evidence that ERCC1 is reliable biomarker for cisplatin 
sensitivity. 
In conclusion: Phase III randomized trials, that compare individual-
ized therapy approaches versus standard approaches are currently 
underway and these studies will be helpful in discerning the predic-
tive and prognostic functions of ERCC1. Once validated, these mark-
ers will need to be measured as part of the initial histologic diagnosis 
and their expression levels factored into treatment decision making. 
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BRCA1 gene and sensitivity to lung cancer chemotherapy
Rosell, Rafael
Institut Catala d’Oncologia- Hospital Germans Trias i Pujol, 
Badalona, Ctra Canyet s/n, Spain
The vast majority of clinical trials combining chemotherapy plus 
targeted agents are based on empirical criteria and in general yield 
short-lived responses and no substantial benefit in prolonging sur-
vival in a meaningful way for the patient. Moreover, some chemo-
therapy drugs may well be antagonistic when combined with others 
and even with targeted drugs. Therefore, the first endeavor should 
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focus on the correct choice of chemotherapy drugs and combinations. 
If further validated, the assessment of BRCA1 together with RAP80 
mRNA expression levels could become a bona fide predictive marker 
for customizing chemotherapy, based on the appealing differential 
modulating effect of BRCA1 on platinums and antimicrotubule drugs 
(docetaxel, paclitaxel or vinorelbine). In the Spanish Lung Cancer 
Group (SLCG) prospective customized study based on the baseline 
analysis of BRCA1 mRNA expression in advanced NSCLC (non-
squamous histology), a record time to progression of 14 months was 
observed in the subgroup of patients expressing low levels of both 
BRCA1 and RAP80 mRNA (lowest tercile). The length of this time 
to progression is three times that attained in trials with docetaxel plus 
cisplatin [1], with pemetrexed (a potent inhibitor of thymidylate syn-
thase) plus cisplatin [2], or with customized docetaxel plus cisplatin 
based on ERCC1 mRNA levels [3]. Interestingly, time to progression 
was only 5.2 months in NSCLC (non-squamous histology) treated 
with pemetrexed plus cisplatin [2]. A time to progression of 14 
months in patients receiving gemcitabine plus cisplatin based on low 
expression of BRCA1 in conjunction with low expression of RAP80 
is a milestone in NSCLC chemotherapy. In the only prospective 
study reported of gefitinib, time to progression was 9.2 months in a 
subgroup of 31 NSCLC (non-squamous histology) patients harboring 
EGFR TK mutations [4]. In the customized SLCG phase II study, 
time to progression for 217 patients with EGFR mutations treated 
with erlotinib was 14 months, and in the SLCG prospective trial of 
erlotinib in NSCLC patients with EGFR mutations, time to progres-
sion was 13 months.
A crucial clinical discovery emerging from this BRCA1 mRNA 
phase II customized study, which concurs with preclinical findings, 
is that time to progression and survival decline abruptly in patients in 
the lowest tercile of BRCA1 mRNA expression treated with cisplatin 
plus gemcitabine when RAP80 mRNA is elevated (intermediate or in 
the highest expression tercile. This concurs with the observation that 
the UIM-containing protein RAP80 plays a key role in the recruit-
ment of BRCA1 protein complexes to DNA DSBs [5-8]. Conversely, 
since RAP80 by itself is able to translocate to IRIF in HCC1937 cells 
which express a truncated BRCA1 unable to migrate to IRIF, RAP 
80 alone could replace the BRCA1 function in cells lacking BRCA1 
[8]. This can explain the fact that patients with high levels of both 
BRCA1 and RAP80 mRNA show significant benefit when treated 
with single-agent docetaxel, which showed no significant benefit 
in spite of high levels of BRCA1 when RAP80 levels were low. 
Similarly, the best time to progression and survival were attained 
in patients in the intermediate terciles of both BRCA1 and RAP80 
treated with docetaxel plus cisplatin. The BRCA1 Expression Cus-
tomization (BREC) is an international phase III trial of customized 
chemotherapy for NSCLC, sponsored by the SLCG. Patients with 
the lowest levels of RAP80, regardless of BRCA1 levels, receive 
gemcitabine plus cisplatin. Patients with intermediate or high levels 
of RAP80 receive docetaxel plus cisplatin or, when BRCA1 levels 
are high, docetaxel alone. 
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Thymidylate synthase as a marker 
of sensitivity to antifolates
Scagliotti, Giorgio; Papotti, Mauro; Ceppi, Paolo; Monica, Valentina
University of Turin, S. Luigi Hospital, Orbassano, Italy
Translational research is aiming to characterize patients and tumours 
on a molecular basis and, by the identification of patients who 
may benefit from a certain therapy. Pharmacogenomic diagnostic 
techniques could be able to accurately predict patients outcome and 
to tailor the treatment strategy according to the genotype and the 
phenotype of the tumour.
Thymidylate synthase (TS) is an enzyme which plays an important 
role in the DNA biosynthesis, catalyzing the methylation of fluo-
rodeoxyuridine monophosphate (dUMP) to deoxythimidine mono-
phosphate (dTMP), and is a target enzyme for antimetabolite agents. 
Several studies clearly showed the efficacy of the evaluation of the 
intratumoral expression of TS mRNA in predicting the response to 
5-fluorouracil (5-FU) therapy in breast (1), colorectal (2), head and 
neck (3), pancreatic (4) and NSCLC (5) cancer patients. This asso-
ciation was not invariably reported (6,7) but in most of these studies 
an adverse effect of higher TS levels on the survival was documented 
in different types of human cancer (1-5). In colorectal cancer, it 
was shown that low microsatellite instability, the genotype 2R/2R 
of the 5’UTR enhancer region of TS gene and lower intratumoral 
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expression levels were associated with a good response to chemo-
therapy (8).
A potential prognostic role of TS in NSCLC has been suggested in 
some studies (9-12) but results are conflicting. Nakagawa et al. (11) 
showed that TS expression as assessed by immunohistochemistry is 
an important prognostic indicator, whereas Higashiyama et al. failed 
to demonstrate a significant relation between TS expression and 
survival (12). 
In a retrospective study in 160 patients with completely resected 
NSCLC not treated with adjuvant therapies, cytoplasmic TS protein 
expression evaluated by automated in situ protein quantification was 
a clinically relevant determinant of survival (9). The optimal cut-
point for protein expression was determined by the maximal log-rank 
method with adjustment of the p-values for multiple looks and it was 
found at the 25% percentile. TS protein expression was significantly 
associated with patient survival (P value =.0013, adjusted P value 
=.034). The group with low expression had a median overall survival 
of 51.7 months, and the high expression group had a median overall 
survival of 81.3 months. In a multivariate analysis adjusting for 
tumour stage, TS protein expression remained significantly prognos-
tic for survival (adjusted P value=.032). TS mRNA expression was 
also determined by reverse-transcriptase polymerase chain reaction 
(RT-PCR) in 85 patients. In this study differently from others (11) 
TS mRNA expression was not significantly associated with patient 
survival or TS protein expression.
Pemetrexed, a multitargeted antifolate, is reported to be a potent TS, 
but also, even if less intensely, a dihydrofolate reductase (DHFR) and 
a glycinamide ribonucleotide formyltransferase (GARFT) inhibitor 
(13). Pemetrexed has been approved for the treatment of malignant 
mesothelioma (14), for both second- (15) and front- line NSCLC 
(16) with predominantly non-squamous histology. The superior effi-
cacy of pemetrexed in non-squamous histology has been consistently 
reported (17).
Messenger RNA expression of genes involved in the mechanism of 
action of pemetrexed was correlated with in vitro chemosensitivity 
of 61 freshly explanted human tumor specimens (18). Multiplex RT-
PCR experiments for reduced folate carrier (RFC), folate receptor-α 
(FR-α), folylpolyglutamate synthetase (FPGS), TS, DHFR, glycin-
amide ribonucleotide formyl transferase (GARFT), mrp4 and mrp5 
(both transporters of multiple drugs) were performed in parallel. 
Correlations, threshold optimization, sensitivity, specificity, and 
efficiency were analyzed using the appropriate statistical method-
ologies. Low levels of TS, GARFT, DHFR, and mrp4 gene expres-
sion significantly correlated with chemo-sensitivity to pemetrexed. 
Similarly, in breast cancer low TS levels were predictive of sensitiv-
ity to pemetrexed (19) and in NSCLC cell lines high pre-treatment 
TS, GARFT, and DHFR levels of expression conferred resistance to 
pemetrexed (20). 
A retrospective study in surgically resected, chemotherapy naive 
patients with adenocarcinoma or squamous cell carcinoma of the 
lung demonstrated that the baseline expression of the TS gene 
and protein were significantly higher in squamous cell carcinoma 
compared with adenocarcinoma (p <0.0001) (21). These data have 
been recently confirmed in a Japanese series of completely resected 
NSCLC in which a similar differential expression has been also doc-
umented for two other antifolate–related genes, thymidine phospho-
rylase and orotate phosphoribosyl transferase, while the expression 
of dihydropyrimidine dehydrogenase, was higher in adenocarcinoma 
than in squamous cell carcinoma (22). This pattern of differential 
gene-expression may provide a molecular explaination why a combi-
nation of tegafur and uracil (UFT) as adjuvant chemotherapy showed 
selective activity in adenocarcinoma as demonstrated by a large 
randomised clinical study (23) and a meta-analysis (24).
An immunohistochemical study in 151 resected NSCLC patients 
postoperatively treated with UFT assessed the TS protein expression. 
Eighty-two NSCLC were TS-positive and the 5-year survival rate of 
patients with TS-negative tumours was significantly higher than that 
with TS-positive tumours (P=0.0133) (25).
TS and Skp2 (S-phase kinase associated protein) are two genes that 
are transcriptionally regulated in the S-phase of the cell cycle by the 
transcription factor E2F-1 (26,27). Like TS, elevated expression of 
Skp2 has been more commonly detected in patients with squamous 
carcinoma of the lung than in those with adenocarcinoma (28).
While only baseline expression and preliminary, non conclusive data 
on the predictive value for response and survival of TS expression in 
different histotypes of NSCLC are available, the marginal activity of 
pemetrexed as single agent (29,30) and in combination with carbo-
platin (31,32) in extensive SCLC may be related to higher baseline 
TS expression levels in this histotype. 
In one hundred and sixteen neuroendocrine tumours, including 58 
gastroenteropancreatic and 58 lung tumours total messenger RNA 
was extracted from micro-dissected paraffin blocks and TS mRNA 
quantification performed by RT-PCR, whereas protein expression 
was evaluated by immunohistochemistry (33). Both diagnostic 
techniques showed higher TS expression levels in large cell and 
SCLC compared with typical and atypical carcinoids (P < 0.01). 
Similarly, in gastroenteropancreatic tumors, a higher TS expres-
sion in poorly differentiated carcinomas than both well differenti-
ated neuroendocrine carcinomas and benign tumors (P < 0.01) was 
detected. In patients with gastroenteropancreatic well differentiated 
neuroendocrine carcinomas treated with 5-FU, high TS mRNA levels 
were associated with shorter time to progression (P value = 0.002) 
and overall survival (P value= 0.04). This negative prognostic role 
was confirmed in multivariate analysis adjusting for major prognostic 
variables (P value = 0.01). No association between TS mRNA and 
survival was observed in patients with gastroenteropancreatic well 
differentiated neuroendocrine carcinomas not receiving 5-FU.
The above mentioned findings supporting the preferential activ-
ity of pemetrexed in NSCLC with non-squamous histology are 
strongly hypotheses-generating, but they require a robust prospective 
validation.
A phase III multicenter randomized study denominated ITACA 
(International TAilored Chemotherapy Adjuvant) conducted in Italy, 
Germany and Poland will compare adjuvant pharmacogenomic-driv-
en versus standard adjuvant chemotherapy in completely resected 
stage II-IIIa NSCLC. Expression of Excision Repair Cross-Comple-
menting gene-1 (ERCC1), a putative marker of sensitivity to cispla-
tin, and TS will be determined using RT-PCR on paraffin-embedded 
tumor specimens. Ribonucleotide reductase subunit M1 (RRM1) 
mRNA expression will be assessed, but it will not be considered in 
the assignment of the tailored treatment. Within 30-45 days post-
surgery patients in each genetic profile will be randomized to receive 
standard adjuvant chemotherapy (control arm) selected according to 
the investigator choice (cisplatin/vinorelbine, cisplatin/docetaxel or 
cisplatin/gemcitabine) or an experimental treatment (tailored chemo-
therapy arm). The primary end point of study is the assessment of the 
overall survival. 
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Conclusion
Results from prospective studies and from retrospective subset analy-
ses clearly indicate in NSCLC with predominantly non-squamous 
histology a superior activity of pemetrexed alone or in combination 
with platinum agents and initial studies in the preclinical and clinical 
setting indicate low TS expression, as evaluated through quantita-
tive RT-PCR and immunohistochemistry, as a candidate marker 
of chemo-sensitivity to pemetrexed. Further studies are needed to 
prospectively validate this hypothesis. 
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M9.4 Predictive or Prognostic Factors in Chemotherapy, Sat, Aug 1, 16:30 - 18:00
KRAS as a marker of chemoresistance in lung cancer
Tsao, Ming S.
Princess Margaret Hospital, Toronto, ON, Canada
Non-small cell lung cancer (NSCLC) constitutes approximately 
80% of all lung cancers, and tumor stage is currently the primary 
determinant of prognosis for these patients (1). Early stage NSCLC 
refers to mainly stage I-IIIA patients, who remain potentially curable 
by complete surgical resection. Advanced stage patients are treated 
by chemotherapy and/or radiotherapy. The overall prognosis of early 
stage patients remains relatively poor with 5-year survival rates of 
30-60% (2). Variation in survival largely reflects heterogeneity in the 
tumor biology, with some tumors having more aggressive growth and 
greater metastatic potential than others. While histology subtypes 
and grades demonstrate some impact on the prognosis of NSCLC 
patients, the overall differences are not sufficiently great to impact 
on treatment decision (3). Identification of tumor characteristics that 
Copyright © 2009 by the International Association for the Study of Lung Cancer S57
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
are associates with poor survival outcome for the patients would 
provide potentially important method for selecting patients to receive 
adjuvant chemotherapy.
The first evidence that molecular aberrations in lung cancer can be 
prognostic markers involved the KRAS oncogene. Slebos et al (4) 
reported that oncogenic KRAS mutations occurred in approximately 
30% of lung adenocarcinoma and its presence defined a subgroup of 
patients with poorer prognosis. Since then, more than fifty retrospec-
tive and mostly institutional based studies have been conducted to 
validate the finding, but have provided contradicting results. A meta-
analysis on 23 PCR-based studies involving 2632 NSCLC patients 
and 11 studies involving 1170 lung adenocarcinoma only patients 
recorded RAS mutation hazard ratio (HR) of 1.39 [95% confidence 
interval (CI) 1.22–1.58, p=0.03] and 1.50 (95% CI 1.26-1.80, p=0.1), 
respectively (5). These results strongly suggest that RAS mutation 
was a poor prognostic marker for NSCLC patients. However, the 
only two studies that involved large number of patients in phase 
III randomized adjuvant clinical trials, E4592 (6) and JBR.10 (7) 
failed to show a prognostic value for RAS mutation. These results 
emphasize the importance of validating prognostic markers in large 
randomized clinical trial samples, as institutional studies even when 
analyzed by meta-analyses, could be plagued by patient selection and 
publication biases. 
While KRAS mutation may not be a poor prognostic marker, its 
biological role in activating constitutively the AKT survival pathway 
suggests a potential role as a predictive marker for resistance to 
chemotherapy. Rosell et al (8) evaluated KRAS mutation status in 
60 stage IIIA NSCLC patients treated in a randomized phase III trial 
that compared surgical resection followed by radiotherapy with or 
without induction chemotherapy. While chemotherapy improved 
survival, KRAS mutation [detected in 13 of 44 (30%) tumors 
assessable for KRAS) was not predictive of outcome. However the 
treatment arms were not balanced for KRAS mutations (42% of 
patients who did not receive chemotherapy versus 15% treated with 
chemotherapy, p=0.05), which limits the conclusion of this study. In 
the randomized phase III (E3590) trial of adjuvant radiotherapy plus 
or minus chemotherapy after surgical resection involving 488 stage II 
and IIIA NSCLC patients, there was no difference in overall survival 
between the treatments (6). In its ancillary laboratory correlative 
study (E4592) of this trial, KRAS genotype was obtained in 184 of 
217 patients with tumor available for analysis; 44 (24%) were found 
to have mutation. The median survival of patients with mutated 
KRAS was 30 months, which was not significantly different from 
the 42 months for wild-type KRAS patients [risk ratio (RR) 0.82, 
95% confidence interval (CI) 0.52 - 1.27, p=0.38). There was also 
no difference in survival for patients with KRAS mutation who were 
treated by chemo and radiotherapy compared to radiotherapy alone. 
However, on the chemotherapy arm, there was a trend to worse sur-
vival for 20 mutated KRAS patients (median survival 24.7 months) 
compared to 70 wild-type patients (median survival 41.8 months; 
RR 0.59, 95% CI 0.32-1.08, p=0.09), suggesting that chemotherapy 
might impact on chemotherapy. However, there was no statistically 
significant survival difference in treatment arms in both KRAS wild 
type and KRAS mutant patients, although interaction of KRAS and 
treatment arm was showed a trend bordering on statistical signifi-
cance (p=0.07). 
In contrast to the above studies that evaluated KRAS retrospectively, 
the phase III placebo controlled JBR.10 trial that compared adjuvant 
chemotherapy with cisplatin and vinorelbine to no chemotherapy 
after resection of stage IB and II NSCLC included a prospective 
evaluation of RAS status, with patients stratified for RAS muta-
tion, wild-type or unknown. This trial demonstrated an absolute 
survival advantage of 15% at five years in favor of chemotherapy [5 
year survival 69 % versus 54% for surgery alone (p=0.03); hazard 
ratio (HR) 0.71, 95% confidence interval (CI) 0.54-0.94, p=0.01] 
(7). RAS genotype was determined in 450 out of 482 patients and 
117 (26%) had mutation. While all RAS family genes (K, H and N) 
were analyzed, 117 of 119 mutations found were on KRAS gene 
(111 on codon 12, 6 on codon 13). RAS mutation was not a prog-
nostic marker for survival but the survival benefit of chemotherapy 
appeared less for patients with RAS mutation. Among 333 patients 
with wild-type RAS there was a survival benefit with adjuvant che-
motherapy [HR=0.69, 95% CI 0.49-0.97, p=0.03]. In contrast among 
117 patients with mutated RAS, there was no demonstrable benefit 
[HR 0.95, 95% CI 0.53-1.71, p=0.87]. However, the interaction test 
of the chemotherapy effect in patients with wild-type versus mutant 
RAS was not significant (p=0.29) (9). 
In advanced NSCLC patients, data on the impact of KRAS on 
chemotherapy is very limited. Rodenhuis et al. (10) detected KRAS 
mutations in 26% (16/62) patients with advanced, inoperable stage 
III and IV adenocarcinoma patients treated with ifosfamide, car-
boplatin and etoposide chemotherapy. The objective response rate 
was 19% in KRAS mutant patients compared to 26% in wild type 
patients (p=0.49). No differences were seen in either overall survival 
or progression free survivals. Camps et al (11) demonstrated KRAS 
codon 12 mutations in serum DNA from 20 out of 67 patients (30%) 
who were subsequently treated with gemcitabine and platinum 
chemotherapy. There was no significant difference in response rate or 
survival for patients with KRAS mutations versus wild-type. These 
studies are all underpowered and were not performed in randomized 
patient populations controlled for potential confounding factors, thus 
the results were insufficient to derive any conclusion for use at clini-
cal practice.
Small molecule EGFR tyrosine kinase inhibitor (EGFR-TKI), 
erlotinib is effective in improving the survival of advanced NSCLC 
patients that has progressed after treatment with chemotherapy (12), 
but was not effective when given together with chemotherapy (13). 
Eberhard et al (14) conducted a retrospective mutational analysis of 
KRAS in a subgroup of 274 (out of 1079) patients with advanced 
NSCLC who were randomized to receive chemotherapy (carbo-
platin and paclitaxel) with erlotinib or placebo in TRIBUTE trial. 
KRAS mutations were identified in tumors of 21% of patients and 
were associated with decreased survival in patients who received 
erlotinib plus chemotherapy compared to other patient groups, 
including KRAS mutant patients who received chemotherapy alone 
and patients with wild-type KRAS who received chemotherapy 
alone or chemotherapy plus erlotinib (p = 0.02). Among the patients 
with mutant KRAS, the hazard ratio for survival of erlotinib plus 
chemotherapy versus chemotherapy alone was 2.1 (95% CI 1.1-3.8). 
However these data need to be interpreted with caution because 
of the small number of patients (n=25 treated with erlotinib and 
chemotherapy; n=30 treated with chemotherapy alone) and there is 
unclear scientific rationale to explain why the addition of erlotinib 
to chemotherapy should lead to an inferior outcome in patients with 
mutated KRAS compared to chemotherapy alone.
Taken together, there is as yet limited data to make a conclusion on 
the predictive role of KRAS for chemotherapy response. However, 
there is an ongoing effort to further validate the prognostic and 
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predictive significance of KRAS in the Lung Adjuvant Cisplatin 
Evaluation (LACE) biomarker project involving the five large 
adjuvant chemotherapy trials: IALT, JBR.10, ANITA, NATCH and 
CALGB9633 (15). The results of this meta-analysis should provide a 
clearer answer on the value of best candidate prognostic and predic-
tive markers including KRAS for selection of patients to receive 
adjuvant chemotherapy. 
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Genomic strategies to guide standard chemotherapy
Nevins, Joseph R.
Duke Institute for Genome Sciences & Policy, Durham, NC, USA
Perhaps the major challenge in developing more effective therapeutic 
strategies for the treatment of most major cancers is confronting the 
heterogeneity of the disease, recognizing that breast cancer or lung 
cancer is not one disease but multiple disorders with distinct underly-
ing mechanisms. Gene expression profiling studies have been used to 
dissect this complexity, identifying multiple subtypes of the disease 
with distinct clinical properties and outcomes. We have developed a 
series of gene expression signatures that have the capacity to predict 
sensitivity to various standard-of-care cytotoxic chemotherapeutics, 
including those used in the treatment of lung cancer. Many of these 
predictors have been validated with chemotherapeutic response data 
from patient samples, including a prospective breast neoadjuvant 
study, demonstrating a capacity to identify those patients most likely 
to respond to a given drug. These signatures have formed the basis 
for a series of prospective clinical trials that are evaluating the ability 
of these predictors of response to more efficiently guide the selection 
of agents that will be of most benefit to the individual lung cancer 
patient. Importantly, these predictions also accurately identify those 
patients likely to be resistant to current standard of care regimens 
emphasizing the importance of developing strategies for effective 
therapy of these individuals. One approach will make use of other 
potential cytotoxic chemotherapies, not necessarily standard of 
care for lung cancer but nevertheless potentially effective for the 
individual patient. A second strategy makes use of predictions of 
pathway deregulation in cancer cell lines that are shown to coincide 
with sensitivity to therapeutic agents that target components of the 
pathway, underscoring the potential for such pathway prediction to 
guide the use of targeted therapeutics. Finally, we have combined the 
chemotherapy predictive signatures with the signatures of oncogenic 
pathway deregulation to identify therapeutic strategies that make use 
of all available drugs, matched to the characteristics of the individual 
patient. We suggest that this approach provides a strategy, and an ini-
tial step, towards the development of personalized treatment options 
for the individual patient.
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M10.1 Emerging Operative Techniques in Early Stage Lung Cancer, Sat, Aug 1, 16:30 - 18:00
Techniques of VATS resections for lobectomy, 
segmentectomies, and lymph node dissections 
and their results in 2009: who are the 
candidates, when do you not do this?
D’Amico, Thomas A.
Duke University Medical Center, Durham, NC, USA
Improving outcomes with early stage lung 
cancer: thoracoscopic lobectomy
Strategy for Thoracoscopic Lobectomy
After bronchoscopy and mediastinoscopy (when indicated), single-
lung anesthesia is established using a dual lumen endotracheal tube 
or bronchial blocker. The patient is positioned in full lateral decu-
bitus position with slight flexion of the table at the level of the hip, 
which provides splaying of the ribs to improve thoracoscopic access 
and exposure. Port placement is a matter of surgeon preference. Most 
surgeons use 3 or 4 incisions, although lobectomy can usually be 
accomplished using only 2 incisions. The first incision, a 10 mm port 
access used predominantly for the thoracoscope, is placed in the 7th 
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or 8th intercostal space in the midaxillary line. The second incision, 
an anterior access incision (4.5-6.0 cm) for dissection and specimen 
retrieval, is placed in the 5th or 6th intercostal space. 
Instrumentation for thoracoscopic lobectomy is critical to success-
ful completion of the procedure. The thoracoscope should be a 
30-degree angled scope, to optimize the ability to achieve panoramic 
visualization during dissection and to minimize competition with 
the operative instruments. A spectrum of surgical instruments may 
be employed for dissection, including conventional instruments and 
dedicated thoracoscopic or laparoscopic instruments. It is especially 
beneficial to use curved instruments for retraction during dissection, 
as it will minimize the tendency for instruments to compete or col-
lide with each other. Thoracoscopic (linear) mechanical staplers are 
employed for control of the vessels (2.0 or 2.5 mm staples), bronchus 
(3.5 or 4.8 mm staples) and fissure. 
Individual vessel dissection is not performed through the fissure; 
rather, dissection is performed beginning with the anterior hilum, and 
continuing posteriorly. For any anatomic thoracoscopic lobectomy, 
hilar dissection is begun with mobilization of the pulmonary vein. 
For upper lobectomy, the lung is reflected posteriorly and inferiorly 
to facilitate dissection. For lower lobectomy, the lung is retracted 
superiorly. Moving the thoracoscope to the anterior incision may 
improve visualization of the superior hilum and may facilitate place-
ment of the linear stapler for upper lobectomy, if introduced through 
the midaxillary port. 
Results
The safety and efficacy of thoracoscopic lobectomy for patients with 
early-stage lung cancer has been established. Although there are no 
prospective, randomized series that compare thoracoscopic lobec-
tomy to conventional approaches, a sufficient number of series have 
been published, both single-institution and multi-institution experi-
ences, to conclude that thoracoscopic lobectomy is a reasonable 
strategy for patients with clinical stage I lung cancer.
The Cancer and Leukemia Group B (CALGB) reported on the results 
of a multi-institutional series of 97 patients who underwent thoraco-
scopic lobectomy. In this series, the mortality was 2%, the operative 
time was 130 minutes, and the median length of stay was 3 days. 
Daniels and colleagues reported the results of thoracoscopic lobec-
tomy in 170 consecutive patients. The 30-day mortality was 2%, 
with no intraoperative deaths. The conversion rate was 1.8%, and 
none were emergent. The median chest tube duration was 3 days and 
median length of stay was 3 days. Follow-up review of 500 patients 
in that series demonstrates a mortality of 1% and chest tube duration 
of 2 days. In that series, atrial fibrillation occurred in only 10% of 
patients post-operatively.
Demmy and colleagues reported on their results in a series of 
patients, who underwent either thoracoscopic lobectomy or conven-
tional thoracotomy. In this series, the percentage of patients reporting 
severe pain was 6% in those patients after thoracoscopic lobectomy 
and 65% after thoracotomy. Moreover, the percentage of patients 
reporting minimal or no pain was 63% in those patients after thoraco-
scopic lobectomy and 6% after thoracotomy. Other studies analyzing 
acute pain have concluded that VATS either causes less pain or lower 
analgesia requirement in the early postoperative period. 
In addition, several studies have recently demonstrated that the 
incidence of postoperative complications is lower after thoraco-
scopic lobectomy, as compared to thoracotomy. In one study, 283 
patients who underwent open lobectomy were compared with 300 
patients who underwent thoracoscopic lobectomy. Using a propen-
sity matched analysis, thoracoscopic lobectomy was associated with 
fewer overall complications, including atrial fibrillation. In a second 
study, using a case-matched strategy, 122 patients undergoing tho-
racoscopic surgery and 122 patients undergoing thoracotomy were 
compared. Overall, complications were lower in the thoracoscopic 
group (17.2% vs 27.9%, P = .046). In another study, focusing on 
elderly patients (age 70 years), a retrospective, matched case-control 
study was performed evaluating the perioperative outcomes after 
lobectomy by thoracoscopy and thoracotomy. After matching based 
on age, gender, presence of co-morbid conditions, and preoperative 
clinical stage, there were 82 patients in each group. Thoracoscopic 
lobectomy resulted in a significantly lower rate of complications 
compared with thoracotomy (28% vs 45%, p = 0.04). No patients 
undergoing thoracoscopic lobectomy had higher than grade 2 
complications, whereas 7% of complications in the open lobectomy 
group were grade 3 or higher. There were no perioperative deaths in 
the thoracoscopic lobectomy patients compared with an in-hospital 
mortality rate of 3.6% for thoracotomy patients. 
Thoracoscopic lobectomy has recently been demonstrated to be 
effective in selected patients after induction therapy. Finally, the use 
of thoracoscopic lobectomy may improve compliance with adjuvant 
chemotherapy, allowing a greater fraction of patients to undergo the 
combination of surgery and adjuvant therapy.
Thoracoscopic Segmentectomy
General Strategy for Thoracoscopic Segmentectomy
The standard segmentectomies performed with this technique include 
lingula-sparing left upper lobectomy, lingulectomy, superior seg-
mentectomy, and basilar segmentectomy. Other individual segmental 
resections, such has posterior or anterior upper lobe segmentectomy, 
are feasible but less commonly performed. 
The technique for thoracoscopic segmentectomy utilizes the funda-
mentals of thoracoscopic lobectomy previously reported. In brief, 
this technique utilizes only 2 incisions: a 1-cm incision (“camera 
port”) in the 7th or 8th intercostal space in the posterior axillary line 
and a 4-cm incision (“access incision”) in the 5th or 6th intercostal 
space anteriorly. This approach is suitable for any lobar or sub-lobar 
thoracoscopic resection, despite anatomic variations from patient to 
patient, as well as differential location of the various anatomic area 
of interest. Using this technique for thoracoscopic lobectomy, the 
conversion rate is less than 2%.
For each anatomic sub-lobar resection, the segmental pulmonary vein 
of interest is the first hilar structure of interest. In order to improve 
access to the hilum, division of the pleura at the pleural-parenchymal 
reflection is performed, adding length to the hilum and exposing the 
vein for staple ligation, using a linear endoscopic stapler. Subse-
quent dissection is dependent on the specific segment(s) of interest. 
Parenchymal resection is then performed with the stapling device. 
Identification of the segmental borders for parenchymal division may 
be enhanced with temporary pulmonary re-inflation; however, the 
visible venous anatomy of the exposed segments, including the seg-
ment being removed and the adjacent segment being preserved, will 
also guide this process. 
Experience with Thoracoscopic Segmentectomy
Although thoracoscopic lobectomy has achieved increased utilization 
over the past several years, there are few references to thoracoscopic 
segmentectomy in the literature. Houck and colleagues reported the 
technical issues involved with the performance of lingular-sparing 
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left upper lobectomy in a series of 11 patients. A retrospective 
review of prospectively collected data for 77 consecutive segmen-
tectomy patients was recently reported. In this study, preoperative, 
intraoperative, and postoperative variables for patients undergoing 
thoracoscopic segmentectomy (TS; n=48) were compared with those 
undergoing open segmentectomy (OS; n=29). Baseline demograph-
ics were similar between groups. Indications for pulmonary resec-
tion included non-small cell lung cancer (NSCLC; n=39), central 
pulmonary metastases (n=30), and benign diagnoses, including bron-
chiectasis (and other infectious processes), congenital abnormalities, 
and bronchial adenoma (n=8). 
In this series, no thoracoscopic cases required conversion to open 
procedures. Operative times, estimated blood loss, and chest tube 
duration were similar between groups. Outcomes were also similar, 
except that hospital length of stay was significantly shorter among 
TS patients (6.8 ± 6 days vs. 4.3 ± 3 days; p = 0.03). Thirty-day 
mortality was 6.9% (2/29) for the OS group compared with 0% for 
the TS group. 
The experience of Atkins and colleagues and by Houck and col-
leagues demonstrate that thoracoscopic lobectomy is safe and 
feasible. Also demonstrated is an acceptable rate of postoperative 
complications for thoracoscopic segmentectomy, similar to the com-
plication profile of the open segmentectomy group in this study, and 
consistent with other published data for open segmentectomy. 
It remains to be established whether thoracoscopic segmentectomy 
is an appropriate procedure for patients with NSCLC who would 
tolerate lobectomy. This concept may be addressed by a study 
conducted by the Cancer and Leukemia Group B (CALGB 14053), 
a phase III randomized trial of lobectomy versus sub-lobar resection 
(either thoracoscopic or open) for small (< 2 cm) NSCLC. As lung 
cancer screening becomes more prevalent, the identification of small 
tumors, including sub-centimeter lesions, may lead to increased per-
formance of segmentectomy, and the thoracoscopic approach should 
be considered.
Summary
Minimally invasive approaches to lung cancer treatment have been 
demonstrated to be safe and effective for patients with early-stage 
lung cancer. Thoracoscopic lobectomy is designed to achieve the 
same oncologic result as conventional lobectomy: complete hilar 
dissection and individual vessel control. The recognized advantages 
of thoracoscopic anatomic resection include less short-term postop-
erative pain, shorter hospital stay, faster return to full activity, and 
preserved pulmonary function. In addition, thoracoscopic lobectomy 
may preserve immunologic response and may improve compliance 
with adjuvant therapy. Although there are no prospective random-
ized studies comparing the thoracoscopic approach to conventional 
thoracotomy, there is no data from published series to suggest any 
difference in oncologic efficacy. 
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Evidence for the use of sublobar vs lobar resection for 
the medically operable lung cancer patient: a complete 
review of the literature with most recent results
Watanabe, Shun-ichi; Asamura, Hisao
Division of Thoracic Surgery, National Cancer Center, Tokyo, Japan
Standard surgical procedure for lung cancer
In 1933, Graham reported the first successful pneumonectomy for 
a lung cancer patient, who survived for 18 years after surgery. In 
1951, Cahan suggested that pneumonectomy with regional lymph 
node dissection should be a routine procedure for lung cancer in 
1951. Then in 1960, Cahan reported the first 48 cases that success-
fully underwent lobectomy with regional lymph node dissection, 
which was called “radical lobectomy.” The descriptions of lobectomy 
with lymph node dissection in Cahan’s reports were very similar to 
our routine procedure. Since then, this procedure was universally 
accepted and has remained a standard surgery for lung cancer. 
Histrical perspective of sublobar resection
Segmentectomy was initially used for the resection of localized 
bronchiectasis as reported by Churchill and Belsey (1939). Jensik 
(1973) reported their 15-year successful experience of segmentec-
tomy for lung cancer patients. However, the use of sublobar resection 
as definitive management of NSCLC has been a controversial issue. 
Lung Cancer Study Group (LCSG) (1995) conducted the only ran-
domized trial comparing sublobar resection with lobectomy for stage 
IA NSCLC patients. They observed a 75% increase in recurrence and 
a 50% increase in cancer death in the patients undergoing sublobar 
resection, compared to those in the patients undergoing lobectomy. 
This is the reason lobectomy has remained a standard surgery for 
lung cancer.
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Problems and controversies in sublobar 
resection for lung cancer patients
Sublobar resection is a lung parenchyma-preserving surgery with 
limited nodal dissection. Regarding the limited nodal dissection, it 
is difficult to select candidate patients for limited resection, because 
even cT1N0 lung cancer patients diagnosed on CT scan show nodal 
disease with a 15 to 25% incidence. Although positron emission 
tomography (PET) is considered to be the most sensitive and accu-
rate investigation for screening of lymph node involvement, with a 
sensitivity of 79 to 85% and specificity of 90 to 91% in a meta-anal-
ysis, the assessment of nodal status by PET is not reliable in patients 
with microscopic nodal metastasis. Therefore, the intrathoracic 
evaluation of nodal involvement at the mediastinal and hilar levels 
during lobectomy is considered to be an important component of the 
staging process.
However, with the recent development of the CT scanner, the number 
of very early-stage lung cancer showing ground-grass opacity (GGO) 
on CT is rising as well, and a new therapeutic strategy for nodal 
dissection has been required. Lobectomy with mediastinal dissection 
could be an excessive resection for selected patients with such early 
lesion. Proposals of sublobar resection for small-size lung cancer 
less than 2 cm have been undertaken in some previous reports. Many 
retrospective studies of sublobar resection have already been under-
taken for stage IA NSCLC patients. Regarding surgery for com-
promised stage IA patients, Hoffmann (1980), Landreneau (1997) 
and Campione (2004) showed no significant survival difference 
between sublobar resection and lobectomy group. Okada (2001) and 
Koike (2003) conducted the comparative study between intentional 
sublobar resection and standard lobectomy in patients with tumors 
20mm or less in diameter. They showed no significant difference in 
survival between two groups and suggested that sublobar resection 
was acceptable operation for small-sized lung cancer. 
Clinical trials regarding the use of sublobar 
resection and future perspective
Cancer and Leukemia Group B (CALGB) and Japan Clinical Oncol-
ogy Group (JCOG) are conducting similar randomized investigations 
for small-sized (<=2 cm) lung cancer patients. The American College 
of Surgeon Oncology Group (ACOSOG) is conducting a random-
ized trial comparing sublobar resection alone with sublobar resection 
with intraoperative brachytherapy for stage IA NSCLC. Although 
clear evidence regarding the survival benefit of sublobar resection for 
lung cancer patient is lacking so far, sublobar resection could be an 
appropriate therapy for medically operable early-stage lung cancer 
patient based on the retrospective studies. Abovementioned random-
ized trials will more clearly define the role of sublobar resection in 
patients with stage I patients. 
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Intraoperative techniques for the 
prevention of positive margins
Yom, Sue
UCSF, San Francisco, CA, USA
Margin status is important for prognosis and in the determination of 
subsequent adjuvant therapy. Intraoperative techniques offered by 
the non-surgical disciplines can be of great utility for the surgeon in 
achieving the objective of diagnosing and addressing microscopic 
disease. These techniques may include recognition of tumor charac-
teristics and patterns which can guide the selection of an operative 
strategy, intraoperative pleural lavage and touch cytology which can 
provide diagnostic and prognostic information guiding the operation 
and selection of adjuvant therapies, and intraoperative brachytherapy 
and/or intraoperative radiation therapy which can be used to address 
specifically defined areas of residual disease posing concern to the 
surgeon. Real-time incorporation of complex clinical information 
obtained in a cross-disciplinary fashion has become feasible. As a 
result, intraoperative decision-making may become increasingly 
challenging and complex but also offers the opportunity for greater 
individualization and the adaptation of the surgical approach to rap-
idly evolving clinical conditions.
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Genetic susceptibility to lung cancer in women
Brahmer, Julie R.
Johns Hopkins University, Baltimore, MD, USA
Differences in risk of developing lung cancer between the sexes may 
exist but this remains controversial. Several studies provide support 
for and against this notion. Some studies suggest that female smokers 
may be at higher risk of developing lung cancer than male smokers 
when controlling for the amount smoked.1, 2 Inherited factors may 
affect individual susceptibility to carcinogens, as demonstrated by a 
family history of lung cancer increasing the risk of developing lung 
cancer particularly in nonsmokers.3 Potential genetic reasons that 
might increase a female’s risk for the development of lung cancer 
may exist in differences in carcinogen metabolism and detoxification 
as well as DNA repair capacity. Different polymorphisms in genes 
involved in the pathways of carcinogen metabolism and detoxifica-
tion as well as DNA repair genes exist and may contribute to the risk 
of developing lung cancer. Enzymes are involved in the two phases 
of carcinogen metabolism. Enzymes in phase I activate carcinogens 
to reactive intermediates. In phase I, specific polymorphisms of 
the cytochrome P450 CYP1A1 gene are associated with increased 
development of DNA adducts.4, 5, 6 CYP1A1 activates polycyclic 
aromatic hydrocarbons in smoke to reactive epoxides. These reactive 
epoxides can cause DNA damage. Mollerup and colleagues found 
that increased CYP1A1 expression significantly correlated with 
increased levels of DNA adducts per pack-year smoking history. 
Female smokers in this study had a significantly higher amount of 
DNA adducts than male smokers. Phase II of carcinogen metabolism 
is when reactive intermediates formed in phase I are inactivated to 
conjugates that are more water soluble and excreted easier. Gluta-
thione S-transferase M1 (GSTM1) gene is important in phase II of 
carcinogen metabolism. The GSTM1 (null) phenotype has been asso-
ciated with a greater risk of lung cancer.7,8 These two polymorphisms 
together, CYP1A1 and GSTM1, may contribute to lung cancer risk 
particularly in non-smokers.9 In one study, the combination of these 
two polymorphisms was associated with a fourfold increase in risk of 
lung cancer compared with normal genotypes. Another study found 
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that the combined variant genotypes conferred an odds ratio of 6.54 
for lung cancer in females versus 2.36 in males.6 Individual differ-
ences in DNA repair, once DNA damage has occurred, also contrib-
utes to an increased risk of lung cancer in some studies.10, 11 Using 
a nonspecific mutagen sensitivity assay to measure a DNA repair 
capacity phenotype, some studies have associated a less proficient 
DNA repair capacity phenotype with an increased risk for lung 
cancer. Murine double minute 2 (MDM2), a central regulator of p53 
activity, SNP309 may also be associated with increased lung cancer 
risk. Lind and colleagues found that females homozygous for SNP 
309 G/G had associated odds ratio of 4.06 for lung cancer compared 
to males with the same (associated odds ratio of 1.25).12 All of these 
genetic polymorphisms, DNA repair capacity, or SNPs may influ-
ence the risk of developing lung cancer in both males and females. 
Potential sex differences in the susceptibility to lung cancer remain 
an important area of research.
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Estrogen and progesterone receptors in lung cancer
Siegfried, Jill M.
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USA
Classical steroid hormone pathways have been successfully targeted 
in the treatment of breast and prostate cancer. Estrogen receptors 
(ERs) are known to be expressed in tissues outside the reproductive 
tract, and to have biological effects in non-reproductive tumors, such 
as the lung. These effects include induction of gene transcription 
via estrogen response elements and AP-1 sites, and activation of 
non-genomic signaling through MAPK. The ERβ is the most highly 
expressed and most actively signaling ER in non-small cell lung 
cancers (NSCLCs). 96.6% of tumors from 183 lung cancer patients 
were positive for ERβ; tumors expressed significantly higher ERβ 
compared to matched normal lung tissue. Total and nuclear ERβ 
expression were both identified to be negative prognostic predictors 
of progression free survival in all patients. Furthermore, elevated 
ERβ nuclear expression was predictive of PFS in Stage III and IV 
patients (p=0.0459) but not Stage I and II patients (p=0.5787), sug-
gesting ERβ pathway may be involved in progression of late-stage 
disease. Some of the signaling effects occurring through ERβ are ini-
tiated by the ligand estrogen, while others appear to be independent 
of estrogen, and result from activation of ERβ by phosphorylation. 
Estrogen receptors could have biological activity in lung tumors via 
estrogen-induced signaling or even in the absence of estrogen. ER-
Epidermal Growth Factor Receptor (EGFR) interactions also occur. 
NSCLCs also appear to contain an autocrine system for synthesis 
of estrogen via the enzyme aromatase and response to estrogen via 
ERs. The progesterone receptor (PR) is also frequently expressed 
(90.9% of 183 tumors) and may play a role in lung cancer biology 
as well, although we did not see an effect on survival of PR expres-
sion. No differences were observed in marker expression with sex or 
histology, suggesting men as well as women with lung cancer have 
ER involvement. Based on our current understanding of the biology 
of estrogen receptor (ER) signaling pathways in non-small cell lung 
cancer, the ER is a promising target for lung cancer therapy. Clini-
cal trials that are underway to examine ER or estrogen targeting in 
NSCLC wil be discussed. 
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Sex as a prognostic and predictive factor
Novello, Silvia
University of Turin, Orbassano (Turin), Italy
In the early 1900s lung cancer was reported to be rare in women, 
but from 1990 to 2003 there was a 60% increase in the number of 
new cases of lung cancer in American women, while the number of 
men diagnosed with lung cancer remained stable. This increase was 
reflected in clinical trial participation by women, causing a survival 
improvement and suggesting the need of stratification by sex in 
future studies. 
Gender differences in terms of susceptibility to carcinogens and 
natural history of the disease have been observed. When compared 
with male sex, women are more likely to develop adenocarcinoma 
and small-cell carcinoma than squamous cell carcinoma, are more 
likely to be younger at diagnosis, a positive smoking history is less 
frequently documented and, in any stage of the disease, they have a 
better survival [1,2,3,4].
The 5-year survival rate for women who have lung cancer is 15.6% 
compared with 12.5% for men and this improved survival has impor-
tant implications in the design and interpretation of lung cancer trials. 
Prognostic role of sex in early disease
Population-based studies support this hypothesis, including an 
analysis of more than 20.000 lung cancer cases from Poland that 
found a relative risk of death for men of 1.5 (p=0.001) in multivariate 
analysis [2]. In a French cohort of 208 patients, when the data was 
adjusted for stage, women lived significantly more at each stage[5]. 
In a retrospective review of 7553 patients treated for NSCLC 
between 1974 and 1998 there is an overall median survival of 12.4 
months for women and 10.3 for men (p<0.001) and the advantage 
is present for all stages (p<0.001)[6]. In the evaluation of the above 
mentioned three studies, two factors have to be taken into account: 
the lack of information about smoking habit and lack of data about 
cause-specific mortality. However there is a prospective trial which 
confirm the female sex as an independent predictor of survival 
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including in the multivariate analysis age at diagnosis, histology, 
stage, smoking attitude and treatment and, despite the greater number 
of comorbidities in the male cohort, the survival was not negatively 
impacted for men [7].
These data have been confirmed in others prospective cohorts. Cerfo-
lio and colleagues analyzed a cohort of 1085 patients and detected an 
overall age-adjusted and stage-adjusted 5-year survival rate favour-
ing women (60% versus 50%, respectively; p < 0.001). Furthermore, 
women who received neo-adjuvant chemotherapy were more likely 
to be a complete or partial responder than men (p=0.025) [8]. 
In a single institution cohort it was tested whether patient gender 
affects the outlook following lung resection for NSCLC and it was 
found that pathological stage, female gender and squamous cell type 
were independent predictors of survival. Regarding the stage, women 
had a significant survival advantage at pathological stage I (P=0.01) 
and a relatively better survival at stage II and stage III disease 
(P=0.3) [9]. A similar survival trend according to stage with a more 
pronounced survival difference in stage I and II was also observed in 
two other studies [3,10]. 
The positive impact of gender on survival has also been confirmed 
in a large Japanese cohort (n=12.703) of resected NSCLC patients 
independently from the smoking status [11].
Similar results are reported in elderly patient population: in a popu-
lation-based analysis from the Surveillance, Epidemiology, and End 
Results database 18,967 elderly patients (> 65 years old) with stage 
I and II NSCLC, diagnosed between 1991 and 1999 were evaluated. 
Patients were grouped into three categories according to the treat-
ment received: surgery, radiation or chemotherapy but no surgery, 
and untreated cases. Survival data were controlled for competing 
risks including lung cancer-specific survival, overall survival adjust-
ing for comorbidities, and relative survival. Women in all treatment 
groups had better lung cancer-specific, overall, and relative survival 
than did men (p < .0001). Sex differences were also observed among 
untreated patients and this suggests that lung cancer in women may 
have a different natural history [12].
An ongoing SWOG (South Western Oncology Group) trial is investi-
gating molecular epidemiology of NSCLC in smoking and non-
smoking men and women, evaluating the influence of hormonal and 
reproductive factors in 720 stage I, II and III lung cancer patients. 
Female sex is an independent positive prognostic factor also in the 
SWOG study with multimodality therapy (chemotherapy, radiother-
apy, surgery): the median survival for women was 21 months versus 
12 months for men (p=0.08) [13]. 
The epidemiological findings from population-based studies show 
more women diagnosed at earlier stages and the observation of an 
higher adhesion rate among women in ongoing early detection stud-
ies in high-risk subjects raises the issue to be ruled out if the gender 
survival advantage may be attributable only to a more frequent 
medical consultation and radiological assessments other than related 
to differences in genetic predisposition and natural history of the 
neoplastic disease.
In the International Early Lung Cancer Action Program (I-ELCAP) 
14,435 asymptomatic volunteers with no history of cancer and fit 
to undergo thoracic surgery (6296 women), at least 40 years of 
age, and past or current cigarette smokers underwent baseline CT 
screening for lung cancer. Lung cancer was diagnosed in 111 of 6296 
women and 93 of 8139 men: the women versus men prevalence odd 
ratio was 1.6 (p=.001). Women with diagnosis of lung cancer had a 
comparable age with men (67 versus 68 years) but had a significantly 
reduced tobacco exposure (47 versus 64 pack-years, respectively). 
Additionally, women were more frequently diagnosed in clinical 
stage I disease (89 versus 80%), but resection rate in stage I was 
only slightly superior than men (90 versus 88%). The proportion of 
adenocarcinoma subtype among women and men was 73% and 59%, 
respectively [14].
Prognostic/predictive role of sex in advanced disease
In advanced disease gender seems to be either prognostic and predic-
tive of an higher effectiveness of chemotherapy. There is evidence 
of survival advantage for women described in a large review of 
13 SWOG trials with a database of 2531 women enrolled between 
1974 and 1988. Median survival ratio for females/males was 5.7/4.8 
with 1-year survival rates of 19% vs 14% (p<0.01) [15]. Similar 
results were reported by the European Lung Cancer Working Party 
(ELCWP) among 1052 patients evaluating 23 pretreatment variables: 
female sex was one of eight variable significantly associated with 
superior survival with a relative risk of death of 0.7 (p=0.003) in 
multivariate analysis [16]. 
O’Connell and colleagues also showed female sex to be one of four 
predictors of improved survival among 378 patients with advanced 
NSCLC treated with chemotherapy from 1978 to 1986 at a single 
institution. At the multivariate analysis, the median survival time for 
women was 12.4 months versus 8.8 months for men (p=0.001) [17]. 
Most of the published randomized trials cannot be pooled because 
of survival differences in the arms, but in the ECOG 1594 study this 
evaluation was possible considering the lack of survival differ-
ence among the four arms [18]. Patients were grouped together and 
divided into female/male (726/431) cohorts. Men were more likely to 
have weight loss (65% for men versus 58% for women, p=0.02) and 
be slightly older (mean age 61.9 years versus 60.5 years for women, 
p=0.02). Women were more likely to have adenocarcinoma histology 
(63% of women versus 53% of men, p= 0.003). There was no differ-
ence in relative risk by sex (19% in both cohorts, p=0.15). Median 
progression-free and median survival times were different by sex: 
median progression-free survival for women was 3.8 months versus 
3.5 months for men (p=0.022) and median survival 9.2 months for 
women and 7.3 months for men (p=0.004). Survival was also better 
at 1, 2 and 3 years being for women 38%, 14% and 7% versus 31%, 
11% and 5%, for men. This survival difference remained statistically 
significant after adjusting for performance status, weight loss > 10%, 
presence of brain metastases and stage (IIIB versus IV). No differ-
ence in survival was found by regimen of chemotherapy for either of 
the sex cohorts: median survival time ranged from 6.7 months on cis-
platin/docetaxel to 7.7 months with carboplatin/paclitaxel and when 
survival by sex was calculated separately for each arm of the trial, 
the trend for improved survival in women versus men was seen in all 
four arms, but statistical significance was lost. Toxicity differences 
were identified between the gender cohorts: in general women tended 
to have more nausea, vomiting, alopecia, neurosensory deficits and 
neuropsychiatric deficits.
The role of female sex on survival for NSCLC was not supported 
in a recent study by the North Central Cancer Treatment Group 
(NCCTG), which considered nine trials (six phase II and three phase 
III) conducted from 1985 and 2001. At the multivariate analysis for 
overall survival and time to progression, sex was not a significant 
factor. However, a difference in toxicity was observed: both grade ≥3 
hematologic and non-hematologic toxicities were higher in women 
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than in men with odds ratios of 1.60 (p=0.0007) and 1.71 (p<0.001), 
respectively [19].
Sex as a predictor of survival has also been evaluated in the cisplatin 
or carboplatin in combination with docetaxel versus the standard 
therapy of cisplatin and vinorelbine in the first line treatment of 
advanced NSCLC[20]. Being the three arms not equivalent in terms 
of efficacy, the authors were unable to group all patients together 
into female and male cohorts to evaluate survival, but within each 
arm of the study they reported a trend favouring a survival advantage 
for women [21]. Similarly to ECOG 1594 sex differences in toxicity 
were also noted: women were more likely than men to develop grade 
≥ 3 nausea and vomiting and neurotoxicity across all three treatment 
arms, while the other haematological and non-haematological toxic-
ity was similar for both sexes. 
In the ECOG 4599 study the benefit on survival of adding beva-
cizumab to the doublet of carboplatin/paclitaxel was consistently 
reported in all subgroups of patients (measurable versus non-measur-
able disease, prior radiation therapy versus no prior radiation therapy, 
prior weight loss of less than 5% versus 5% or more, stage IIIB with 
pleural effusion versus stage IV), but not in women and in the elderly 
patient population. Among men the median overall survival was 8.7 
months in the standard arm and 11.7 months in the experimental arm, 
while in women 13.1 and 13.3 months, respectively. This unexpected 
finding may be attributable to imbalances between the two groups 
related to known or unknown baseline prognostic factors, to the use 
of second and third-line therapies may be related to statistical chance 
or a true sex-based difference [22]. Further analyses about these data, 
adding informations about different ages of patients, are ongoing.
Some interesting data according to a differential activity by gen-
der are emerging for paclitaxel poliglumex, a drug that combines 
paclitaxel with poly-L-glutamic acid, a biodegradable polymer that is 
broken down to the active form by cathepsin B, which is modulated 
by estrogens. In two phase III studies paclitaxel poliglumex did not 
show any advantage over standard chemotherapy but in the subgroup 
of 198 women from these two studies, it was found that it produced 
a better survival in younger pre-menopausal women, especially those 
with higher circulating levels of estrogens [23]. On the bases of 
these results a phase III study comparing paclitaxel poliglumex plus 
carboplatin versus paclitaxel plus carboplatin was designed, recruit-
ing only female patients with advanced lung cancer patients, who are 
premenopausal or taking estrogen replacement therapy. 
Data reported from several phase II and III clinical trials evaluat-
ing the role of epidermal growth factor receptor tyrosine kinase 
inhibitors in the setting of second and third line NSCLC claim for 
an higher responsiveness to these agent in women. In the IDEAL 1 
and 2 studies gefitinib was tested in patients with advanced NSCLC 
previously treated with one or two lines of chemotherapy and female 
gender was associated with improved outcomes [24,25]. In the 
IDEAL 2 study 50% of women had an symptom improvement of 
compared with 31% in men and 82% of partial responses occurred in 
women. 
In a randomized double-blind, placebo-controlled phase III trial 
in second-line and third-line advanced NSCLC [26] those patients 
treated with daily erlotinib had a response rate of 8.9% with a 
median survival of 6.7 months, resulting in a 42% improvement in 
median survival compared with patients receiving placebo that had 
a median survival of 4.7 months. The response rate in women was 
14.4% compared to 6.0% in males and univariate analysis revealed 
that female sex was one of the factors significantly associated with 
responsiveness, but this association was not maintained in the multi-
variate analysis. 
In another large randomized study a statistically significant higher 
response rate was observed for gefitinib-treated patients compared 
with placebo and it was significantly higher in women than in 
men, 14.7% versus 5.1%, respectively. This study overall included 
1,692 patients and failed to demonstrate an improvement of median 
survival with gefitinib in either overall population (5.6 versus 5.1 
months) or in adenocarcinomas (6.3 versus 5.4 months).
In a large phase II study 138 patient with a diagnosis of broncho-
alveolar carcinoma were treated with gefitinib as first or second 
line treatment. An exploratory subset analysis found gefitinib more 
significantly active in women, who experienced prolonged survival 
with a statistical significance in the previously untreated population 
(p=0.04) [27].
The improved survival observed in women may be due to differences 
in frequency of mutations in tyrosine kinase domain of the epidermal 
growth factor receptor (20% in women versus 9% in men) [28], an 
increased percentage of high EGFR copy number by FISH or an 
higher EGFR expression by immunohistochemistry. Moreover cross-
talk among different molecular pathways has critical importance in 
cancers and the interaction between estrogen receptors (ERs) and 
growth factors is one example. Polypeptide growth factors, such as 
EGF and insulin-like growth factor-I, stimulate the transcriptional 
activity of ERs in an estrogen-independent manner. There is evidence 
that EGF can directly phosphorylate nuclear ER by phospho-p44/p42 
MAPK [29]. Recent studies suggest that there is also a non-nuclear 
ER that can activate phosphatidylinositol 3’-kinase and the EGFR 
family of receptors. This suggests that in cells that express both 
EGFR and ER estrogen may stimulate cell proliferation and survival 
through these alternate pathways and that bidirectional signalling 
between these two receptors is a potent method of augmenting both 
estrogen and growth factor action. In a study performed in NSCLC 
cell lines it has been shown that EGFR protein expression is down-
regulated in response to estrogen and up-regulated in response to ful-
vestrant, an ER antagonist with no agonist effects in vitro, suggest-
ing that the EGFR pathway is activated when estrogen is depleted. 
NSCLC cell lines exposed to gefitinib, fulvestrant or the combination 
of these two agents showed up to 90% decrease in cell proliferation 
and 2-fold increase in apoptosis. In an in vivo lung tumor xenograft 
model, the drug combination decreased tumor volume in severe 
combined immunodeficient mice by approximately 60% compared 
with 49% and 32% for gefitinib and fulvestrant treatment alone, 
respectively. A study in recurrent NSCLC in postmenopausal women 
evaluating the efficacy of the combination of gefitinib plus fulves-
trant as second or third line treatment is currently ongoing. 
Similarly sex-related differences in survival outcome have been 
documented in small cell lung cancer: the analysis of four consecu-
tive prospective trials showed the superior survival for women 
compared with men [30]. A total of 2580 patients from 10 SWOG 
trials with limited (LD) and extensive disease (ED) were analyzed 
for prognostic factors and, only for LD, female sex (p=<0.0.001) was 
significant favourable independent predictor [31].
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     MST  MST 
Author N  Female Stage of  female male 
 patients % Disease Therapy (months) (months) HR p value
O’Connel 378 30 III-IV Chemotherapy 12.4 8.8 0.71 0.001
Mitsudomi 492 27 I-III Surgery 60 38 0.63 0.00036
Ferguson 299 45 I-IV All modalities 12.1 9.1 0.75 0.044
Sorensen 259 46 III-IV Chemotherapy 6.8 6.8 1.0 0.5
Albain 2531 23 III-IV Chemotherapy —  0.77 
<0.00005
Paesman 1052 10 III-IV Chemotherapy —  0.70 0.003
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M11.5 Women and Lung Cancer, Sat, Aug 1, 16:30 - 18:00
Clinical and epidemiologic features of 
lung cancer in Asian females
Thongprasert, Sumitra
Chiangmai University, Chiangmai, Thailand
Patterns of female lung cancer incidence and mortality in Asia are 
difference from the West. The incidence rate of female lung cancer in 
China is rather high: age-standardized incidence rate (ASR) is 19.0 
per 100,000, ASR in Japan is 12.3 per 100,000 and in South Eastern 
Asia is 8.9 per 100,000. Most of lung cancer cases in the West were 
related to tobacco, however several factors were noted as a causative 
factors in Asia i.e. low fruit and vegetable intake, history of chronic 
respiratory disease, cooking fumes, exposure to indoor random, high 
level of particular matter ( PM10 and PM2.5) etc.
Outcome of Asian female lung cancer with Adenocarcinoma treated 
with chemotherapy are better than Western population, which may 
be related to high incidence of EGFR mutation in Asian population. 
In Asian female non-smoker with Adenocarcinoma, treatment with 
EGFR tyrosine kinase inhibitor achieved higher response rate and 
longer progression free survival as compared to chemotherapy.
Clinical characteristics of Asian female lung cancer will be discussed 
in detail.
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Debate - stereotactic radiotherapy for Stage I NSCLC: 
should it be regarded as the standard of care – No 
Ball, David
Peter MacCallum Cancer Centre, Melbourne, Australia
The gold standard by which a new treatment is established as the 
standard of care for a common disease is the randomized phase III 
trial. This is especially important when the new treatment is revolu-
tionary in concept and a major departure from established practice. 
In patients with stage I non-small cell lung cancer (NSCLC) who are 
inoperable for medical reasons, or who refuse surgery, the standard 
of care is conventionally fractionated radiotherapy (CF RT), 60 Gy in 
30 fractions or greater, administered over 6 weeks. The local failure 
rate using this approach is approximately 40%,(1) but may vary 
according to tumor size.(2) CF RT however is very safe, with negli-
gible mortality.(2) Hypofractionated stereotactic body radiotherapy 
(HF SBRT), using 3 or 4 large fractions, appears to result in superior 
local control compared with CF RT based on retrospective and phase 
II studies, but has also been the cause of treatment related deaths.
(3) HF SBRT has not been demonstrated to be superior to CF RT 
in a randomized trial, and so cannot be regarded as the standard of 
care. Further, there are sufficient concerns about the arbitrary choice 
of the dose fractionation schemes in use in HF SBRT, the toxicity of 
treatment, and the reliability of normal tissue constraints, to argue 
that much more work needs to be done to determine if it is a safe 
replacement for CF RT.(4)
Is it more effective? Most studies of HF SBRT report local control 
in the range of 85-100%. Impressive as these results are, we need to 
ask the questions that can only be answered by a randomized study: 
are the patient groups and tumors comparable? Is the follow up the 
same? Is there publication bias in favour of the best outcomes? In 
one of the few explicitly titled phase II studies, the local control for 
T2 tumors at 2 years was only 40%.(5)
Is it safe? CF RT has been used for many years because its safety 
in relation to normal tissue toxicity is well established. On the other 
hand, there is abundant historical evidence that hypofractionation 
causes irreversible damage to normal tissues including brachial 
plexus, spinal cord, bone and cartilage.(6) There is also now emerg-
ing evidence of the dangers of HF SBRT especially for chest wall 
and central tumors. Although the BED of a 54 Gy in 3 fractions regi-
men is 151 Gy10 for early effects using the linear quadratic model, 
for late reacting tissues it is 378 Gy3.(7) It should surprise nobody 
that doses of this order given to bone, cartilage and mediastinal soft 
tissues can result in chest wall pain, irreversible necrosis, vacular 
rupture and fistulisation. Even if a “gentler” fractionation is used for 
centrally located tumors, it is likely, based on what we already know, 
that some patients may die as result of HF SBRT.
Conclusion
There are sufficient questions about the efficacy, ideal dose-fraction-
ation schedule and safety of HD SBRT that its apparent superiority 
over CF RT requires confirmation by a randomized phase III trial. 
Two trials have been designed to address this question: SPACE in 
Scandinavia, and CHISEL in Australia and New Zealand. Until the 
results of these trials are available, HD SBRT should be regarded as 
investigational for the treatment of stage I NSCLC. 
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Debate: For stereotactic radiotherapy 
in operable stage I tumors 
Senan, Suresh
Department of Radiation Oncology, VU University Medical Center, 
Amsterdam, Netherlands
Surgery is currently the treatment of choice in patients presenting 
with a Stage I non-small cell lung cancer (NSCLC). However, the 
mortality and morbidity associated with surgery, as well as the fact 
that 35% or more will experience disease relapse (predominantly 
distant metastases) has led to the evaluation of alternative treat-
ment strategies. Stereotactic radiotherapy (SRT) is a non-invasive 
technique which can achieve local control rates in excess of 90% 
for patients with stage IA peripheral tumors [Haasbeek C, 2008]. 
SRT is characterized by the use of accurate image-guided patient 
repositioning during treatment simulation and delivery, and with the 
use of ablative doses of radiation delivered typically in 3-5 frac-
tions. Despite the use of very high radiation doses, a literature review 
revealed that major toxicity is limited to approximately 5-6% of 
patients who were treated for peripheral tumors. However, the over-
all survival observed in the patients undergoing SRT is poor as most 
treated patients have had extensive co-morbidities. Consequently, the 
SRT literature may mask the true incidence of late local and regional 
recurrences. 
These findings have led to interest in initiating trials comparing 
surgery with primary stereotactic radiotherapy for operable stage I 
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NSCLC. In order to limit the risk of unsuspected nodal or distant 
metastases, the Dutch ROSEL trial will include only FDG-PET posi-
tive peripheral stage IA NSCLC [Hurkmans C, 2009]. A comprehen-
sive quality assurance program for SRT has been implemented, and 
doses to normal tissues will be more restricted than has been the case 
in medically-inoperable patients who were treated using SRT.
The lack of significant acute and sub-acute toxicity with SRT is in 
marked contrast with the known morbidity associated with sur-
gery for stage IA NSCLC [Allen M, 2006; Whitson BA, 2008]. 
The growing interest in evaluating SRT in patients who are fit to 
undergo primary surgery has generated controversy in some quarters. 
However, an open discussion can only take place when some of the 
limitations of both SRT and conventional surgery are recognized and 
acknowledged: 
1. Post surgical survival is poor. The 5-year survival in pathologi-
cally-staged T1 tumors is 71% for tumors measuring 2-3 cm, and 
58% for lesions of 3-5 cm [Rami-Porta R, 2007].
2. Surgical morality is age-related and the average post-operative 
mortality is in lung cancer is 4.2% [Damhuis R, 2006]. Mortality 
increases from 1.7% in patients aged younger than 60 years, to 
9.4% for octogenarians. This is of concern as the median age of 
patients presenting with lung cancer is nearly 70 years.
3. The quality of life of patients is significantly impaired for 24 
months or longer after surgery for early-stage NSCLC [Kenny L, 
2008; Schulte T, 2008].
4. Variations in mortality and long-term survival are seen when 
operations are performed by board-certified general thoracic sur-
geons (GTS) versus general surgeons (GS). Only 32% of patients 
are operated upon by GTS, but this subgroup had an 11% lower 
hazard of death compared with those who underwent resection 
by GS (hazard ratio, 0.89; 99% confidence interval, 0.82 to 0.97). 
[Farjah F, 2009].
5. Video-assisted thoracoscopic surgery (VATS) is considered a less 
morbid procedure but it is currently performed in only between 
8-10% of patients undergoing lung surgery [Farjah F, 2009; Allen 
2006]. However, the acute morbidity and mortality associated 
with VATS [Swanson S, 2007] is far greater than that reported 
after SRT [Lagerwaard FJ, 2008]. 
6. A key drawback of SRT is that surgical staging is far more 
accurate, even in patients who are staged to have IA NSCLC 
using CT scans and FDG-PET. In 266 pts with clinical stage IA 
NSCLC, only 65% had the same pathological stage [Stiles BM, 
2009]. Nodal metastases were found in 11.7%, with 6.8% having 
N1 disease and 4.9% N2 disease. The final pathologic stages also 
included IIB (4.1%), IIIA (4.9%) and IIIB (7.5%). Although the 
final T-stage was T2 in 20%, this subgroup can achieve high local 
control rates with SRT [Lagerwaard F, 2008]. Of the 7.5% who 
had stage pT4, all had satellite nodules within the resected lobe. 
The latter has implications for target volume definition in SRT. 
7. Delayed detection of N1 and N2 disease in patients undergoing 
SRT may be offset by (i) the fact that staging nodal dissections 
were performed in only 23% of operated patients in a SEER 
analysis [Farjah F, 2009], and (ii) routine follow-up CT scans can 
identify patients with regional recurrence for salvage treatment, 
without having all patients subjected to the mortality and morbid-
ity of surgery.
There is a clear need for less toxic and tailored therapy for patients 
who present with a stage I NSCLC. SRT for operable stage I NSCLC 
should be evaluated in the context of prospective clinical trials, and 
the thoracic oncology community must acknowledge that current 
surgical results are not optimal.
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Against SRT in operable tumors
Van Schil, Paul E.
Department of Thoracic and Vascular Surgery Antwerp University 
Hospital, Edegem (Antwerp), Belgium
Surgical treatment for stage I lung cancer
Although no large randomized phase III studies exist comparing 
surgical resection to present-day radiotherapy, surgery is considered 
the treatment of choice for patients with resectable stage I non-small 
cell lung cancer (NSCLC) [1,2]. Lobectomy with systematic nodal 
dissection is the standard treatment offering the best chance of long-
term survival on the condition that a complete resection has been 
performed. Recently, specific definitions of complete, incomplete and 
uncertain resection have been published by a subcommittee of the 
International Association for the Study of Lung Cancer (IASLC) [3]. 
When there are no distant metastases prognosis of a bronchogenic 
carcinoma depends on specific lymph node involvement. In a recent 
meta-analysis mediastinal lymph node dissection was associated with 
improved survival compared to nodal sampling in patients undergo-
ing resection for early stage NSCLC [1]. As clinical staging is not 
always reliable, even with the recently introduced diagnostic pro-
cedures, adequate peroperative evaluation to determine a “surgical 
stage” is of paramount importance to guide further strategy[4]. 
Regarding the extent of resection, lobectomy became the standard 
intervention after a randomized trial of the Lung Cancer Study Group 
comparing limited resection to lobectomy for patients with cT1N0 
NSCLC [5]. Randomization was performed at the time of thoraco-
tomy. After peroperative verification of the clinical stage, more than 
50% of patients had a contra-indication to randomization because of 
benign disease, T2 status or unsuspected nodal involvement discov-
ered at thoracotomy. Although overall survival differences were only 
significant at the 0.10 level, there was a tripling in local recurrence 
rate in patients undergoing limited resection. The importance of 
careful peroperative evaluation is demonstrated by a study from the 
Brompton Hospital in London in 240 patients showing that even after 
careful preoperative staging including mediastinoscopy, unexpected 
N2 involvement is found in 20% of patients [6]. No subgroup had 
a 0% incidence of N2 disease. Even in patients with tumors < 2 cm 
nodal involvement was present in 24%.
There is currently an ongoing discussion whether limited resec-
tion (anatomical segmentectomy or wedge resection) may provide 
similar local control and survival results as lobectomy. This specifi-
cally focuses on early lesions < 2cm with predominant ground glass 
characteristics on chest computed tomography (CT). In specific 
subgroups excellent long-term survival is obtained after limited 
resection [7]. 
So, in functionally operable and resectable patients with NSCLC, 
treatment guidelines are well established to obtain the best postop-
erative results and long-term survival.
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Stereotactic radiotherapy as new treatment modality
For patients with compromised pulmonary or cardiac function, 
alternative strategies to thoracotomy have been developed. These 
include stereotactic radiotherapy (SRT), sometimes called stereotac-
tic radiosurgery (SRS), and radiofrequency ablation. 
In compromised patients standard radiotherapy does not provide 
long-term local control and survival results are disappointing. In a 
meta-analysis of medically inoperable patients with stage I NSCLC 
treated by classical radiotherapy, local recurrence was the most com-
mon reason for treatment failure and estimated overall 5-year surviv-
al rate was only 21% [8]. Recently, new radiotherapeutic strategies 
have been developed allowing administration of a very high dose 
of radiation to localized lung lesions. Some recent, non-randomized 
studies claim a local control rate similar to surgical resection [9]. For 
this reason SRT is also considered for patients with operable early 
stage NSCLC who functionally tolerate a lobectomy. At the present 
time, major concerns with this treatment strategy are:
1.  How to obtain a pathological diagnosis? 
Peroperative frozen section analysis provides the diagnosis when 
this is not known preoperatively. In some studies on SRT a precise 
histological diagnosis was not present in 70% of patients [10]. In 
the planned ROSEL (Radiotherapy Or Surgery for operable Early 
stage non-small cell Lung cancer) trial a pathological diagnosis 
is not required and patients with a new or growing lesion with 
isotope uptake on positron emission tomographic (PET) scan are 
eligible. In this way, lesions are treated by SRT without knowing 
the precise type. What exactly is irradiated will remain an open 
question! 
2.  How to determine nodal staging?  
When there are no distant metastases prognosis of a NSCLC 
depends mainly on nodal involvement. However, as demonstrated 
in carefully conducted surgical studies, clinical staging is not reli-
able which induces a survival difference when comparing clinical 
to pathological TNM staging [6,11]. When applying SRT to lung 
cancer precise information on nodal involvement will never be 
available.
3.  How to evaluate response and local recurrence rate? 
As fibrosis and radiopneumonitis may occur at a variable degree 
after SRT, evaluation of response is difficult to perform, even 
with PET scanning [11]. Some authors have introduced modified 
RECIST criteria incorporating CT and PET data, but no uniform 
agreement exists [12]. 
4.  How to select patients for adjuvant therapy? 
Currently, carefully staged patients with pN1 or pN2 involvement 
discovered at thoracotomy are treated with adjuvant chemothera-
py or in some specific cases even with postoperative chemoradio-
therapy [13]. How will these patients be selected after SRT?
5.  Radiotherapy issues. 
At the present time there are no clear guidelines for SRT and 
precise selection of lesions for SRT has not been established yet. 
SRT applied to central lesions may give rise to excessive toxicity 
and increased mortality [14]. How to determine primary endpoint 
in randomized studies with SRT? Local control is not sufficient 
as progressive regional and distant disease may occur rapidly in 
these patients in whom no adequate staging is performed. How to 
determine the exact dose? There is clearly a steep dose-response 
relationship and even in recent studies applying SRT, local 
failures up to 42% have been reported [12]. How to adjust for 
movement of the target lesion? Unlike brain or prostate, the lung 
is constantly moving and several techniques have been devel-
oped to adjust for this, but none has been universally accepted 
[15]. Long-term safety of SRT has not been clearly established 
but radiation pneumonitis, rib fractures and chronic pain have 
been reported [9]. So, many concerns and questions remain when 
applying SRT to operable patients. Thoracic surgeons should 
be involved as principal investigators from the beginning when 
designing trials comparing surgery to SRT. 
When applying SRT to operable lung cancer a lot of compromises 
are being made regarding specific diagnosis, staging, response and 
long-term evaluation. These issues should be clearly investigated 
by carefully conducted studies not driven by industry, before SRT 
can be more widely applied to resectable lesions. Otherwise, this 
technique may disappear as rapidly as it has arisen on the horizon... 
Anyway, let’s abandon the term “radiosurgery” as at the present time, 
these two treatment modalities cannot be considered to provide equal 
results for resectable, early stage lung cancer.
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Conventional imaging (CT, MR)
Leung, Ann
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In the context of the TNM classification for staging of non-small 
cell lung cancer, the major indication for conventional imaging is to 
accurately differentiate Stage I – IIIA (potentially resectable) from 
Stage IIIB – IV (unresectable) disease. Evidence-based guidelines 
published separately by the American Society of Clinical Oncology 
and the American College of Chest Physicians both recommend that 
diagnostic evaluation of a patient with suspected non-small cell lung 
cancer should begin with performance of a contrast-enhanced CT 
scan that extends to the level of the liver and adrenals (1,2).
Assessment of the T descriptor requires determination of the size and 
anatomic extent of tumor and its relation to a number of intrathoracic 
structures. In the TNM system, T4 or unresectable primary tumors 
invade the mediastinum, heart, great vessels, trachea, recurrent laryn-
geal nerve, esophagus, vertebral body, or carina; or are associated 
with separate tumor nodule(s) in a different ipsilateral lobe. CT and 
MR are roughly equivalent in their accuracy of T staging in patients 
with lung cancer (3); MR has been show to be slightly superior in the 
assessment of chest wall invasion and mediastinal invasion and in 
determining the superior extent of Pancoast tumors (4-6).
Assessment of the N descriptor requires determination of the extent 
of regional lymph node involvement. In the regional lymph node 
classification system (7) adopted by the American Joint Commit-
tee on Cancer in 1997, 14 numbered stations are used to designate 
the status of mediastinal, hilar, and intrapulmonary nodes. N3 or 
unresectable nodal disease consists of metastasis to contralateral 
mediastinal, contralateral hilar, ipsilateral or contralateral scalene, 
or supraclavicular nodes. In a meta-analysis of 39 studies by Gould 
et al (8), CT was found to have a median sensitivity and specific-
ity of 61% and 79%, respectively for identification of mediastinal 
lymph node involvement. Prior studies (4, 9, 10) have shown CT and 
MR to be similar in sensitivity and accuracy in detection of nodal 
metastasis.
The presence of distant metastases in a patient with NSCLC is clas-
sified as M1 (Stage IV), unresectable disease. Patients with clinical 
stage I or II NSCLC and a normal clinical examination require no 
further imaging because of the low yield for extrathoracic metastases 
(2, 11). As asymptomatic metastases occur more frequently with 
later stage disease, patients with clinical Stage IIIA and IIIB disease 
are recommended to undergo a standard imaging evaluation (CT or 
MR of brain, whole body PET or bone scan, and CT of abdomen) for 
metastatic disease (2, 3, 11). 
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Update in Staging of Lung Cancer
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Introduction 
Imaging, usually with CT and more recently with positron emis-
sion tomography (PET) using 18F-2-deoxy-D-glucose (FDG), a 
D-glucose analog labeled with fluorine-18, has an important role in 
the tumor node metastasis (TNM) clinical staging of patients with 
non-small cell lung cancer (NSCLC). CT is the optimal modality 
for evaluating the primary tumor (T descriptor) while PET is useful 
in improving the accuracy of staging by detecting occult nodal (N 
descriptor) and distant metastases (M descriptor). This talk will 
review the use of CT and PET-CT in staging patients with NSCLC. 
Staging
Contrast-enhanced chest CT that includes the adrenals is typically 
used in the clinical staging of patients with NSCLC and the mani-
festations of disease are usually described using a traditional tumor 
(T), node (N) and metastasis (M) system. The differentiation of T1-3 
from T4 NSCLC and the detection of contra-lateral nodal (N3) and 
or extrathoracic metastases (M1) are important as these typically 
preclude surgical resection or require additional chemotherapy or 
radiotherapy. The use of whole-body FDG-PET, in addition to CT in 
the clinical staging evaluation of patients with NSCLC, improves the 
detection of occult nodal and distant metastases. FDG-PET is usually 
used together with CT because the relatively poor spatial resolution 
of FDG-PET limits its utility in the evaluation of the primary tumor 
(T descriptor) and in the determination of the precise anatomic loca-
tion of regions of focal increased FDG-uptake. In this regard, the use 
of integrated PET-CT with co-registration of PET and CT images 
improves the accuracy of clinical staging when compared with visual 
correlation of PET and CT performed separately. 
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Primary Tumor (T Descriptor)
The T descriptor defines the size, location, and extent of the primary 
tumor. The poor spatial resolution of FDG-PET is a limitation in 
this assessment and accordingly CT is used to detect and localize 
additional nodules. The International Association for the Study of 
Lung Cancer (IASLC) has proposed a revision of the T descriptors in 
the forthcoming staging system that will result in a greater emphasis 
on the size of the primary tumor. For instance, T1 and T2 will be sub-
classified on size and tumors >7-cm in diameter will be reclassified 
as T3, rather than T2. In addition, primary tumors associated with 
malignant satellite nodule(s) in the same lobe, currently classified as 
non-resectable (T4 disease) will be re-classified to T3. Furthermore 
the proposal is to reclassify M1 by additional nodule(s) in the ipsilat-
eral lung (different lobe) as T4; and to reclassify T4 pleural dissemi-
nation (malignant pleural effusions, pleural nodules) as M1. 
Invasion of the pleura, chest wall, and mediastinum by the primary 
tumor can affect patient management and accordingly imaging, 
usually with CT, is typically performed to assess the extent of loco-
regional invasion. CT is useful in confirming gross chest wall and 
mediastinal invasion but is inaccurate in differentiating between 
anatomic contiguity and subtle invasion and this limitation is not sig-
nificantly improved by MR imaging. However, MR is useful in the 
evaluation of superior sulcus tumors. MR is the optimal modality in 
the assessment of the degree of involvement of the brachial plexus, 
subclavian vessels, and vertebral bodies. Importantly, absolute con-
traindications to surgery, including invasion of the brachial plexus 
roots or trunks above the level of T1, are often more accurately 
assessed by MR than CT. 
The diagnosis of a malignant pleural effusion is important as this is 
currently classified as non-resectable (T4 disease) and the IASLC 
Lung Cancer Staging Project proposal is to reclassify pleural dis-
semination (malignant pleural effusions, pleural nodules) as M1 
disease. A malignant pleural effusion typically manifests on CT as 
pleural thickening and nodularity. However, a diagnostic limitation 
of CT is that the pleura is often normal in appearance in patients with 
NSCLC and a malignant pleural effusion. 
Regional Lymph Nodes (N Descriptor)
The detection and location of nodal metastases are important in 
determining patient management i.e. surgical resection, the use of 
adjuvant therapy and radiation are dependent on the N descriptor. 
The IASLC Lung Cancer Staging Project has proposed that the cur-
rent N descriptors should be maintained as there were no significant 
survival differences in analysis by station. Nodal metastases are 
diagnosed on CT when hilar and or mediastinal nodes have a short-
axis diameter greater than 1-cm. However, lymph node size is not 
a reliable parameter for the evaluation of nodal metastatic disease 
in patients with NSCLC. In a meta-analysis of 20 studies evaluat-
ing the accuracy of CT for staging mediastinal nodes, the pooled 
sensitivity and specificity values were 57% and 82%, respectively. 
The limitations of CT in nodal staging are high-lighted by Prenzel et 
al., who reported that 77% of 139 patients with NSCLC and no nodal 
metastases had at least one node greater than 1-cm in diameter and 
that 12% of 127 patients with nodal metastases had no nodes greater 
than 1-cm.
To overcome the limitations of CT in the detection of nodal metas-
tases, patients with NSCLC are often imaged with FDG-PET. In 
a recent meta-analysis of patients with NSCLC, the sensitivity 
and specificity of FDG-PET for detecting mediastinal lymph node 
metastases ranged from 66% to 100% and 81% to 100%. Although 
FDG-PET for nodal staging is cost-effective and can reduce the 
likelihood that a patient with non-resectable disease due to N3 nodal 
metastases will undergo surgery, the number of false-positive results 
due to infectious or inflammatory etiologies are too high to preclude 
invasive sampling. In this regard, invasive sampling of FDG-avid 
nodes should be performed to confirm nodal metastatic disease when 
this will affect patient management. 
Metastatic Disease (M Descriptor) Patients with NSCLC commonly 
have metastases to the lung, adrenals, liver, brain, bones and extra-
thoracic lymph nodes at presentation. The IASLC Lung Cancer Stag-
ing Project has proposed that the M1 descriptor should be subclassi-
fied into M1a (additional nodules in the contralateral lung) and M1b 
(distant metastases outside the lung and pleura). Additionally, based 
on survival analysis, the current M descriptor should be modified to 
reclassify pleural metastases (malignant pleural effusions, pleural 
nodules) from T4 to M1a. 
CT (and occasionally MR) are typically performed to detect these 
metastases. However, because clinical staging using CT can be 
inaccurate in patients with NSCLC, whole-body FDG-PET is often 
performed to improve the accuracy of staging. Whole-body FDG-
PET has a higher sensitivity and specificity than CT in detecting 
metastases to the adrenals, bones and extrathoracic lymph nodes and 
a recent study reported a sensitivity, specificity, positive predictive 
value and negative predictive value of 83%, 90%, 36% and 99%, 
respectively for M1 disease in patients with potentially operable 
NSCLC. The incidence of detection of occult metastases increases as 
the T and N descriptors increase and has been reported to be 7.5% in 
early stage disease and 24% in advanced disease. Importantly, whole-
body FDG-PET detects occult extrathoracic metastases in up to 24% 
of patients selected for curative resection. 
It is important to emphasize that although whole-body FDG-PET 
improves the accuracy of staging, false-positive uptake of FDG in 
infection and inflammation can mimic distant metastases. Because 
false-positive uptake of FDG is common in PET, all focal lesions 
with increased FDG-uptake should be biopsied if they potentially 
would alter patient management. 
Conclusion 
Clinical staging of NSCLC lung cancer is important in determining 
therapeutic management and prognosis. CT, MR and FDG-PET are 
an integral component of this evaluation. However, invasive sam-
pling is often required to clarify the imaging findings in patients with 
NSCLC and is advocated if these findings will alter management. 
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Endoscopic ultrasound (EBUS-EUS) for 
staging and follow up of lung cancer
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Despite the advances in surgical treatment and multimodality treat-
ment, lung cancer is still the leading cause of death from malignant 
disease worldwide. Accurate staging of the disease is important not 
only to determine the prognosis but also to decide the most suitable 
treatment plan. During the staging process, mediastinal lymph node 
staging is one of the most important factors that affect the patient 
outcome. Non-invasive staging such as computed tomography (CT) 
and positron emission tomography (PET) indicate size and meta-
bolic activity, respectively. However imaging alone is inaccurate and 
therefore tissue sampling is the preferred and most reliable. Surgical 
staging by mediastinoscopy is still the gold standard for mediastinal 
lymph node staging. However for some parts of the mediastinum 
not assessable by mediastinoscopy, video-assisted thoracoscopic 
surgery (VATS) is necessary. However, surgical staging requires 
general anesthesia and complications cannot be ignored. Endoscopic 
ultrasound techniques provide a minimally invasive alternative for 
surgical staging.
The current available endoscopic ultrasound techniques for mediasti-
nal staging include transesophageal endoscopic ultrasound guided 
fine needle aspiration (EUS-FNA) and endobronchial ultrasound 
guided transbronchial needle aspiration (EBUS-TBNA). Both 
procedures can be performed in an outpatient setting under local 
anesthesia. EUS-FNA is a sensitive and safe method of evaluat-
ing the inferior mediastinal nodes (stations 7, 8, and 9) and some 
parts of the anterior mediastinal nodes (station 4L) if the lymph 
nodes are enlarged. However, in spite of the strength of EUS-FNA 
for evaluating the inferior mediastinal nodes, its ability to evaluate 
lesions anterior to the trachea is limited. On the other hand, EBUS-
TBNA is an accurate bronchoscopic method for lymph node staging 
which has reach to the anterior mediastinum (stations 1, 2, 3 and 
4) and subcarinal lymph node (station 7), as well as the N1 lymph 
nodes (hilar, interlobar and lobar). Thus, EUS-FNA and EBUS-
TBNA are complementary methods for lymph node staging in lung 
cancer and most of the mediastinum and the hilum can be evaluated 
with these endoscopic procedures. Aortic nodes (stations 5 and 6) 
are exceptions and must be evaluated by surgical methods (VATS, 
thoracotomy).
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The asbestos threat: a world-wide overview 
of the epidemiology of asbestos exposure
Takahashi, Ken
Department of Environmental Epidemiology, University of 
Occupational and Environmental Health Japan, Kitakyushu City, 
Japan
For almost a century, asbestos has been utilized as a valuable 
industrial commodity for a wide range of applications. For almost 
half a century, the health hazards of asbestos exposure, including its 
carcinogenicity, have been known to mankind. These two facts com-
bined underlie the fact that, today, 2.0 million metric tons of asbestos 
are still being used, but this number has decreased by 57% from the 
historical peak of 4.7 million tons recorded in 1980. However, is the 
world really “retreating from dependence on asbestos (1)”? To firmly 
address this question, it is advantageous to take the standpoint of 
global public health.
Chrysotile, the predominant type of asbestos in use today, was 
precluded from the Prior Informed Consent (PIC) list under the Rot-
terdam Convention. The decision in late 2008 for chrysotile preclu-
sion was a result of a veto of a few countries, while the majority was 
voting for inclusion on the list. As other types of asbestos are already 
on the PIC list, the decision discredited the recommendations by 
the WHO and ILO which explicitly called to stop using all types of 
asbestos. In effect, exporting countries are exempted from the need 
to obtain consent from the importing countries, the majority of which 
is now economically developing.
Indeed national situations regarding asbestos use and asbestos dis-
eases exhibit a diverse panorama across countries. Many industrial-
ized countries have already felt and expect to see more of the burden 
of asbestos diseases. Industrializing countries, many of which are 
still spared from the manifestation of asbestos diseases, continue to 
depend on or even increase the use of asbestos. To exemplify, Asia 
has increased its global share of asbestos use in the raw form from 
19% (i.e. 840 of 4,350 thousand metric tons) in 1985 to 47% (i.e. 
950 of 2,040 thousand metric tons) in the year 2000.(2) On the other 
hand, societal responses to asbestos hazards (ultimately bans) have 
been embraced by many industrialized countries but notably less so 
by industrializing countries.
A macroscopic perspective in the framework of ecological analyses 
is useful to examine, and, to an extent, forecast national and global 
situations on asbestos diseases. The premises for this somewhat mun-
dane approach are as follows: asbestos diseases (not only by defini-
tion) demonstrate high etiologic fraction; the mesothelioma epidemic 
is already a reality in many industrialized countries; epidemic curves 
closely follow the historic consumption curve of asbestos; and coun-
tries are provided with numeric reference points. Per capita use (unit 
in kg/capita/year) is a useful indicator to compare the state of asbes-
tos use between countries. Recently, we and others demonstrated the 
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potential of this simple indicator to serve as a surrogate measure for 
the general exposure level of a population which can also be used to 
estimate subsequent disease burdens at national levels.
In an ecological study of all (albeit mostly developed) countries with 
mortality statistics reported to WHO, we found that recent mortality 
levels of four categories of asbestos diseases (all, pleural and perito-
neal mesothelioma and asbestosis) are strongly correlated with per 
capita asbestos use of 1960-1969.(3) The relationship was deemed 
plausible in view of the postulated lag time (37.5 yr) and the stronger 
relationship shown for all mesothelioma in both sexes and asbestosis 
in men. As this relationship held between the absolute levels of mor-
tality and use, we subsequently demonstrated the correlation between 
change (Δ) in the level of historical use and change (Δ) in the level 
of mortality of pleural mesothelioma.(1)
The aforementioned relationship can be further utilized to estimate 
rates of asbestos diseases, especially for mesothelioma, in industrial-
izing countries which have no relevant statistics but may actually 
be “missing cases” in view of the known historical dependence on 
asbestos. We estimated an annual total of 14,960 mesothelioma 
deaths in the world. Our estimate is considerably less than that of 
the WHO (43,000), but has the advantage of providing estimates by 
country.(4)
Our most recent work to probe the relationship between dependence 
on asbestos use and economic development (5) suggests that indus-
trializing countries are, in fact, closely following paths once traced 
by the industrialized countries. Our findings indicated that industrial-
izing countries are at a critical crossroad toward asbestos non-depen-
dence or toward the contrary. The scientific community thus has a 
vital role to assist transitions in industrializing countries as well as to 
transfer technologies for the prevention of asbestos diseases.
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SV40 and mesothelioma
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Strianese, Oriana1; Zhang, Lei2
1 University of Hawaii, Honolulu, HI, USA; 2 University of Hawaii, 
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SV40 is a DNA tumor virus that has been detected in human 
mesotheliomas. Although over 50 different laboratories detected 
SV40 in human specimens, the rate of detection varied from about 
4% to 80% of the specimens that were tested. These discrepancies 
can be attributed to the technologies used in different laboratories, 
geographical differences to SV40 exposure – see below – laboratory 
contamination, or random differences within small samples tested, or 
all of the above. In the USA and most of the Western world, we were 
exposed to infectious SV40 through contaminated polio-vaccines 
from 1954 until 1963, and until at least 1978 in countries under the 
influence of USSR. The possible consequences of this exposure to 
human health have been scarcely investigated. SV40 oncogenicity 
has been studied mostly in hamsters. In these animals SV40 causes 
mesothelioma in 100% of animals injected intrapleurally and in 60% 
of those injected intracardially. Transfection of the early region of 
SV40 that codes for Tag and t antigen causes malignant transforma-
tion of human fibroblasts and other cell types. Instead, SV40 infec-
tion of human fibroblasts does not cause malignant transformation 
because the virus replicates and lyses these cells. These experiments 
demonstrated that although SV40 T antigens are capable of caus-
ing malignant transformation of human cells, the whole virus is not, 
because it replicates and lyses the cells. In contrast to this dogma, 
we found that human mesothelial cells are very susceptible to SV40 
infection and transformation. SV40-transformed human mesothe-
lial cell lines can be easily derived and these cells are oncogenic in 
nudes. We recently elucidated the mechanisms responsible for the 
unusual susceptibility of human mesothelial cells to SV40 mediated 
transformation. We found that in human mesothelial cells, a mes-
sanger RNA originating from the early region of SV40 (that codes 
for T and t antigens) fails to detach at the polyadenylathion site and 
continues running in antisense orientation along the circular SV40 
genome giving rise to double stranded mRNA in the late SV40 DNA 
region that codes for the capsid proteins. Double stranded RNA is 
rapidly degraded, thus SV40 viral particles are not formed and meso-
thelial cells are not lysed. At the same time, the early genes (T and 
t antigens) are produced and the mesothelial cells are transformed. 
The mechanisms of transformation are linked mostly to the ability 
of SV40 T antigen to bind to and inactivate p53, and pRB-related 
proteins, and to activate Notch-1, c-met and IGF-1. We found that 
in human mesothelial cells Tag forms a multi-protein complex with 
p53-pRb and p300 that binds to and activates the IGF-1 promoter 
directly stimulating tumor cell growth. Thus on one hand by binding 
p53, pRB and p300 Tag, inactivates the tumor suppressor activities 
of these proteins, on the other, this multiprotein complex acquires its 
own “oncogenic” activity and promotes IGF-1 secretion and tumor 
cell growth. 
In summary, SV40 is fully capable of causing malignant transforma-
tion of human mesothelial cells and preferentially causes mesothe-
lioma in hamsters. Although the marked increase in the incidence 
of mesothelioma during the past 50 years can be mostly attributed 
to asbestos exposure, it is possible that SV40 contributed to this 
increase. We and others found that SV40 and asbestos are co-car-
cinogens in causing mesothelioma in animals and in transforming 
human mesothelial cells in culture. As observed in lung cancer where 
asbestos and smoke act synergistically, it appears possible that SV40 
and asbestos together cause some human mesotheliomas.
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Current MM lab studies and their possible translation
Kratzke, Robert
University of Minnesota, Minneapolis, MN, USA
Mesothelioma remains a largely untreatable disease except in some 
early stages. The best hope for improved therapy of mesothelioma 
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is the targeting of novel molecular markers and pathways. These 
include pathways of angiogenesis, proliferation, and motility 
among others that will be discussed. In addition, new applications 
of genomic technology can provide new prognsotic and predictive 
markers. Discussion will be made of several clinical studies currently 
are in development that will exploit laboratory insights gained over 
the past decade in mesothelioma.
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Gene therapy/immunotherapy and 
mesothelioma: where are we?
Albelda, Steven M.; Vachani, A; Haas, A; Sterman, D H.
Thoracic Oncology Gene Therapy Program, University of 
Pennsylvania Medical Center, Philadelphia, PA, USA
Malignant Mesothelioma has been a target of immunotherapy for 
decades. Early studies used cytokines. In the early 1990’s, the French 
group led by Boutin showed interesting responses in early stage 
tumors to intrapleural administration of interferon-gamma. Subcuta-
neous Interferon-alpha (a Type 1 interferon) had some activity and 
was used fairly widely ten years ago. Immunotherapy trials using 
IL-2 have also been conducted. 
Vaccines have also been studied in clinical trials. Approaches include 
autologous tumor cells (with and without adjuvants such as GM-
CSF) and a vaccine containing peptides from the Wilms tumor-1 
(WT-1) gene product. Anecdotal responses have been noted. A SV40 
large T-antigen vaccine trial was planned, but never conducted. More 
recently, a trial is being conducted in the Netherlands using tumor-
loaded dendritic cells, although results have not yet been published. 
Based on strong preclinical data, a study using an agonistic CD40 
antibody to stimulate immune responses will be started soon in Perth, 
Australia.
The protein mesothelin, which is highly upregulated on mesothe-
lioma, has been indentified as a potentially good tumor antigen and 
thus a target for immunotherapy. Clinical trials initiated at the NCI 
using a high affinity antibody alone (MORAB-009) or a fusion 
protein between an anti-mesothelin antibody and pseudomonas 
exotoxin (SS1P) are being conducted. Two Phase I studies showed 
SSP1 was relatively well tolerated and resulted in some interesting 
clinical effects, including partial responses and stable disease. A new 
trial, combining SS1P with chemotherapy is underway. A trial using 
a modified listeria bacterial vector encoding mesothelin is also being 
conducted, however preliminary results have not shown genera-
tion of good cellular immune response. Finally, at least two groups 
(including our own) are generating “designer chimeric T cells” in 
which a single chain antibody fragment is linked to the transmem-
brane and cytoplasmic regions of the T-cell receptor. This artificial 
T-cell receptor is then transduced into T-cells that are then rein-
fused. The T-cells are then activated by cells expressing mesothelin. 
Preclinical data show striking activity against mesothelin-expressing 
tumors in mice. 
Mesothelioma has several characteristics that make it an attractive 
target for direct gene therapy, including: (1) the absence of stan-
dard, effective therapy; (2) the accessibility of the pleural space for 
biopsy, vector delivery, and analysis of treatment effects; and (3) the 
availability of therapeutic strategies that require only transient gene 
expression. Malignant mesothelioma is an especially attractive target 
since local extension of disease, rather than distant metastases, is 
responsible for much of its morbidity and mortality. 
There have been a number of small clinical trials using gene therapy 
for mesothelioma and metastatic pleural disease. A cell-transfer trial 
was conducted by Schwarzenberger and colleagues at the Louisiana 
State University (LSU) Medical Center in New Orleans using intra-
pleural instillation via an indwelling pleural catheter of an irradiated 
ovarian carcinoma cell line retrovirally transfected with a “suicide 
gene”, herpes simplex thymidine kinase (HSVtk). Our group at the 
University of Pennsylvania conducted a series of Phase 1 clinical 
trials of a replication-incompetent adenoviral vector encoding HSVtk 
(Ad.HSVtk) delivered intrapleurally (followed by Ganciclovir) into 
34 patients with pleural mesothelioma. Dose limiting toxicity was 
not reached, side effects were minimal and gene transfer was con-
firmed in a dose-related fashion with clearly detectable gene transfer 
(evidenced by immunostaining) at tumor surfaces and up to 30-50 
cell layers deep. Anti-tumor antibodies and strong anti-adenoviral 
immune responses, including high titers of neutralizing antibody 
and proliferative T-cell responses were generated, however, with 
no obvious adverse side effects. Interestingly, a number of clinical 
responses were seen at the higher dose levels, including two patients 
that remained alive (one without disease) for more than 10 years after 
vector instillation. 
The first human clinical trial of direct intra-tumoral delivery of 
cytokine genes in malignant pleural mesothelioma was conducted by 
investigators at Queen Elizabeth II Hospital in Perth, Australia using 
a recombinant vaccinia virus (VV) expressing the human interleu-
kin-2 (IL-2) gene. Toxicities were minimal, and there was no clinical 
or serological evidence of spread of vaccinia virus to patient con-
tacts. No significant tumor regression was seen in any of the patients, 
and only modest intra-tumoral T-cell infiltration was detected.
Based on a series of preclinical experiments, our group has com-
pleted a series of Phase 1 dose escalation studies evaluating the 
safety and feasibility of intrapleural interferon-beta gene transfer 
using an adenoviral vector (Ad.IFNβ) in patients with malignant 
pleural mesothelioma (MM) and metastatic pleural effusions (MPE). 
Ad.IFNβ was administered through an indwelling pleural catheter in 
doses ranging from 9 x 1011 to 3 x 1012 viral particles (vp). A total 
of 27 patients in 3 trials have been dosed since 2005 and include 17 
with malignant mesotheliomas, 5 with advanced lung cancer, 3 with 
metastatic ovarian cancer, and 2 with metastatic breast cancer. In 
the first trial, we used one dose of vector; later trials used two doses 
spaced at 14 or 7 days apart. Subjects were evaluated for toxicity, 
gene transfer, humoral, cellular, and cytokine-mediated immune 
responses, and tumor responses via 18-fluorodeoxyglucose (18FDG) 
positron-emission tomography (PET) scans and chest CT scans. 
Intrapleural Ad.INF-β was generally well tolerated with transient 
lymphopenia the most common side effect. The presence of the 
vector did not elicit a marked cellular infiltrate in the pleural space. 
Good gene transfer seen after first dose with high IFN beta levels 
measured in the pleural fluid after vector installation. However, only 
very low gene transfer seen after a second dose- with either 14 day 
and 7 day spacing. We attribute this to rapid upregulation of neutral-
izing antibodies against adenovirus. Anti-tumor humoral immune 
responses were seen almost all patients with reactions seen against 
known Meso tumor antigens (SV40 large T antigen and mesothelin) 
and against unknown proteins in cell lysates. Given the caveats of 
Phase 1 trials (small numbers, different doses, heavily pretreated 
patients), we still saw clinical responses (defined as prolonged stable 
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disease, prolonged survival, partial or complete responses by modi-
fied RESIST criteria, decreased metabolic tumor activity by PET 
scanning, or “mixed” responses) in about 1/3 of the patients. We are 
currently administering two doses spaced only three days apart. This 
appears to be well tolerated. Based on strong preclinical data sup-
porting the combination of gene therapy and chemotherapy, we are 
planning to integrate Ad.INF instillation into the first treatment cycle 
of first line (Cisplatin/Pemetrexed) or second line chemotherapy 
(Gemcitabine).
Finally, another emerging approach has been the use of replicating 
viral vectors that selectively target mesothelioma tumors. Preclinical 
work has shown efficacy animal models using herpes virus and with 
vesicular stomatitis virus. 
In summary, immuno- and immuno-gene therapies are being actively 
studied in mesothelioma and have shown some promising results. 
Future trials are focusing on combining these approaches with che-
motherapy and surgery. Given the relatively mild and non-overlap-
ping toxicities, we believe these, or other immunologic approaches 
will soon become part of the therapeutic armamentarium. 
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Phase I and II strategies for choosing a 
good dose with targeted agents
Crowley, John J.
CRAB, Seattle, WA, USA
The main goal in Phase I trials for traditional cytotoxic agents is to 
determine the maximal tolerated dose (MTD). The underlying prem-
ise is that both efficacy and toxicity increase monotonically with 
increasing dose levels. Only toxicity, not efficacy, is monitored dur-
ing a traditional phase I trial. The standard 3+3 design accrues three 
patients at a time to a given dose level and then increases the dose 
level until dose limiting toxicity (DLT) is observed. If two or more 
DLTs are observed in a group of six patients at that dose level, dose 
escalations ceases and the MTD has been exceeded. The highest dose 
where no more than one DLT in six subjects is observed is the MTD. 
The premise for phase I trials for cytostatic or targeted agents is 
different. Since the agent is designed to specifically interfere with a 
molecular pathway directly related to specific characteristics of the 
tumor it is hypothesized to be less toxic than a traditional cytotoxic 
agent. Toxicity does not necessarily increase with increasing dose 
levels. Efficacy also does not necessarily increase monotonically 
with increasing dose levels, but likely plateaus after it reaches a 
maximal efficacy.
Thus the goal for dose-finding trials for targeted agents should be to 
determine the lowest dose level that provides highest efficacy while 
assuring the safety of that dose level. We call this dose the maximally 
efficacious dose (MED). A variety of continual reassessment models 
(CRM) have been proposed for this purpose. Here we propose a two-
step dose-finding trial for assessing both toxicity and efficacy for a 
new targeted agent. For the first step we use a traditional Phase I trial 
design, such as the 3+3, the accelerated titration or the CRM model. 
This step only assesses toxicity and finds the MTD. This step insures 
that the dose levels at and below the MTD are safe in humans. 
The goal of the second step is to determine the MED as a dose level 
no larger than the MTD. For this second step we propose a phase 
II trial design for two or three dose levels at and below the MTD to 
determine efficacy. We assume that a binary endpoint for efficacy has 
been determined. Such an endpoint could be a traditional CR rate, 
percent patients alive and progression free at a specific time point, 
or if a biologic response has been determined, the percent of patients 
achieving the biologic response. 
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Phase I designs for identifying a biologically optimal dose
Mandrekar, Sumithra J.; Qin, Rui; Sargent, Daniel J.
Mayo Clinic, Rochester, MN, USA
Phase I clinical trials are first-in-man studies that historically have 
primarily focused on the safety profile of a regimen. Traditionally the 
primary aim of a phase I clinical trial has been to establish the Maxi-
mum Tolerated Dose (MTD) and characterize the toxicity profile of 
the tested agent(s). Consequently, many phase I clinical trial designs, 
such as the standard cohorts of 3+3 design [1], the accelerated titra-
tion design [2], the two-stage design [3], and the Continual Reassess-
ment Method (CRM) [4] do not utilize any efficacy information in 
the dose-finding process. The inherent assumption in such a design 
is that there is a monotonically non-decreasing relationship between 
dose and efficacy. While this is true for cytotoxic agents, it is not 
always appropriate for molecularly-targeted therapies, vaccines and 
immunotherapy. The dose-efficacy curves for these novel therapies 
may follow a non-monotone pattern such as a quadratic curve or an 
increasing curve with a plateau, hence the focus of a phase I trial for 
these agents is more appropriately to identify a Biologically Optimal 
Dose (BOD), instead of the MTD. This is particularly relevant for 
many novel therapies which have a limited toxicity profile. 
The BOD is quantified by a measure of efficacy, for example, a mini-
mum effective blood concentration level of the agent, percent target 
inhibition of a marker, or minimum expression level of a molecular 
target (targeted biologic response). Of course, this requires 1) the 
presence of sufficient preclinical evidence demonstrating a relation-
ship between the biomarker based endpoint and the ultimate clinical 
outcome, 2) the biomarker endpoint can be assessed relatively easily 
and quickly, and 3) the assay methodology to assess the biomarker is 
validated and reproducible. Novel designs that incorporate a measure 
of efficacy (in addition to toxicity) into phase I clinical trials are 
becoming increasingly popular. 
In the setting of combination therapies, the goal of the phase I trial is 
to establish either the MTD or BOD of the combination. Designs for 
dose-finding studies to establish the BOD utilizing both toxicity and 
efficacy are limited, as the dose-toxicity and dose-efficacy surfaces 
for combination therapies are more complex. We review model based 
designs to identify an optimal dose of a single or dual agent combi-
nations in a Phase I setting utilizing both toxicity and efficacy data. 
The model based trivariate CRM (TriCRM) designs, specifically the 
proportional odds model-based design [5] and the continuation ratio 
model-based designs [6, 7], as well as the independent logistic model 
and the bivariate probit model will be discussed [8]. A continual 
reassessment method with straightforward dose selection criterion 
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using accumulated data from all patients treated until that time point 
is employed. The methods explicitly allow for separate toxicity and 
efficacy curves for each drug in a two-drug combination setting. The 
observed clinical outcomes are assumed to follow a sequential order 
in the TRiCRM designs: no dose-limiting toxicity and no efficacy, no 
dose-limiting toxicity but with efficacy, or severe dose-limiting toxic-
ity which renders any efficacy irrelevant. For the independent logistic 
and bivariate probit models, all 4 combinations of outcomes are 
considered. The conduct of a trial using these model based designs 
follows a modified CRM approach as outlined below:
1) Treat a cohort of three patients at a time, starting from the lowest 
dose level, or a subset of the lowest levels for the dual agent case. 
2) Doses can be escalated only by one level (or within a pre-defined 
dose neighborhood) at a time but dose de-escalation is not 
restricted.
3) At each interim point, the accumulated toxicity and efficacy data 
is evaluated using formal rules to allow a recommendation of dose 
escalation or de-escalation.
4) If the toxicity at a dose level is considered acceptable, then the 
dose of one or both agents is escalated until the optimal dose level 
is attained based on the pre-specified decision rules. 
5) If the current dose level is deemed too toxic, and the current dose 
level is not the lowest dose level, then the dose is de-escalated to 
either a lower dose level or the lowest dose level, whichever is 
appropriate. 
6) If the current dose level is deemed too toxic, and the current dose 
level is the lowest dose level, then the trial is terminated. 
7) The trial is terminated after the maximum allowable number of 
patient is treated, provided a pre-specified number of patients are 
already treated at the recommended dose level.
Figure 1 depicts three possible dose-efficacy scenarios in a phase I 
setting, specifically, a monotonically increasing dose-efficacy curve, 
an increasing dose-efficacy curve with a plateau, and a unimodal or 
parabolic dose-efficacy curve. For combination therapy, the dose is 
a combination of dual agents based on the model adopted. Simula-
tion studies have demonstrated satisfactory performance in terms 
of recommendation rates and experimentation rates with reasonable 
sample size for the designs considered above. The true optimal dose 
or dose combination are selected a higher proportion of the times 
with some variation across the scenarios considered for a single and 
dual agent combination. 
Figure 1. Examples of dose-efficacy curves for targeted agents and novel 
therapies
Despite the favorable operating characteristics (primarily demon-
strated through simulation studies), in our experience, there has been 
reluctance among the clinical community to adopt novel model based 
phase I designs similar to those presented here [5-7]. While model 
based designs are not appropriate for every dose finding study, they 
provide an attractive alternative compared to the traditional algo-
rithm-based up and down methods when one or both of the following 
is true: 1) number of dose levels for escalation/de-escalation is large, 
i.e. 5 or higher for example, and 2) agent(s) being tested are expected 
to have unknown dose efficacy outcomes. In the first case, the tra-
ditional designs would typically require a larger number of patients 
to be treated if indeed the optimal dose level is near the highest dose 
level. In the second case, the dose escalation / de-escalation decisions 
are based not only on safety but also a measure of efficacy that is 
quick and reliable to assess. 
The challenge of determining an optimal dose for biologic and 
molecularly targeted agents is considerable from both a clinical and 
statistical standpoint in early phase trials. The model based designs 
we present have been shown to have considerable promise, at least 
from a theoretical standpoint, in improving the ability to identify 
an optimal dose levels. In the case of combination therapy, a better 
understanding of the underlying biologic rationale can help improve 
the statistical designs. For example, are the toxicity profiles of the 
agents overlapping, or additive? Is the efficacy of the two agents’ 
additive, complementary, or synergistic? If statistical designs are 
developed in concert with a clinical paradigm, then the acceptance of 
these designs may be quicker and easier. It is essential to engage and 
educate clinical investigators as these new designs are developed. 
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Dose escalation trials based on a 
molecularly targeted endpoint
Hunsberger, Sally
National Cancer Institute, Rockville, MD, USA
Traditional phase I dose-finding studies for chemotoxic agents 
base dose escalation on toxicity, with escalation continuing until 
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unacceptable toxicity is observed. When it is of interest to dose esca-
late based on an endpoint other than toxicity, traditional phase I study 
designs may not be best.
In this presentation we discuss assumptions that are important to 
consider in phase I study designs with molecularly targeted agents. 
We discuss and compare two designs for dose escalation with a 
molecular target.
In these designs, escalation is based on a binary response that 
indicates whether or not the agent has had the desired effect on the 
molecular target. In one design the goal is to ensure that if the target 
response rate is low there will be a high probability of escalating 
and if the target response rate is high there will be a low probability 
of escalating. In the other design the goal is to continue to escalate 
as long as the true response rate is increasing and to stop escalating 
when the response rate plateaus or decreases. 
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What should be the ideal design of phase I clinical trials?
Lau, Derick
University of California, Davis, Sacramento, CA, USA
Phase I clinical trials of anticancer drugs have traditionally been 
conducted according to a modified Fibonacci design. This design 
requires enrollment of sequential cohorts of 3 patients with escalated 
doses of a drug to reach dose-limiting toxicity (DLT). The dose 
associated with DLT is used to determine the maximum tolerated 
dose (MTD) for subsequent phase II trials. However, this design may 
not be optimal for conducting phase I trials of molecular targeting 
agents. Most of these agents, as compared to cytotoxic drugs, have 
a much higher therapeutic index, i.e. the ratio of the dose associated 
with DLT to the dose inducing a therapeutic effect. Therefore, the 
DLT and MTD may not be readily reachable despite a multitude of 
dose escalation.
There are potentially promising target-driven designs for conducting 
phase I trials with the targeting agents. Instead of toxicity endpoints 
used in the toxicity-driven design, one may consider employing 
pharmacodynamic and pharmacokinetic endpoints which may be 
more relevant for these agents in phase I studies (1). Theoretically, 
these endpoints may include the measurements of direct effects 
on the target, a surrogate biomarker or the blood level of the drug. 
Unfortunately, these endpoints have not yet been proven practical to 
be routinely employed to determine a therapeutically effective dose. 
As an alternative to the modified Fibonacci design, we have devel-
oped a population-based method for conducting phase I trials of 
anticancer drugs including the targeting agents. This population-
based design takes into account of individual pharmacodynamic and 
pharmacokinetic variations. Dose escalation of a drug is performed 
in each individual subject according to a pre-determined schema to 
reach either DLT or target effect. The individual doses associated 
with DLTs are subsequently used to determine a population-based 
MTD (pMTD). On the other hand, the individual doses associated 
with target effect can be subsequently used to determine a popula-
tion-based target-effective dose (pTED). Either the pMTD or the 
pTED can be applied for subsequent phase II trials. We have demon-
strated the feasibility of determining pMTD for cytotoxic drugs (2). 
A population-based phase I study is being conducted for a targeting 
agent, sorafenib. 
References
1.  Morabito A, et al. Methodology of clinical trials with new molecular-targeted agents: 
where do we stand? Annals of Oncology 17 (Suppl 7):128–131, 2006.
2.  Lau D, Huynh M and Johl J. A Population-Based Clinical Trial of Irinotecan and 
Carboplatin. 2009 (In press, Journal of Oncology).
Session M16: Clinical Trial Designs with  
Biomarkers to Incorporate or Validate 
Clinical or Lab Selection 
Sunday, August 2
M16.1 Clinical Trial Designs with Biomarkers to Incorporate or  
 Validate Clinical or Lab Selection, Sun, Aug 2, 10:30 - 12:00
Front line studies using clinical parameters for EGFR-TKI
Mok, Tony
Department of Clinical Oncology, Chinese University of Hong Kong, 
Shatin, Hong Kong SAR, China
The human epidermal growth factor receptor (EGFR) is overex-
pressed in 40–80% of primary NSCLC tumours and was proposed as 
a target for NSCLC treatment based on its important role in cellular 
growth and proliferation. EGFR tyrosine kinase inhibitors compete 
with ATP to bind the EGFR TK domain and prevent downstream 
signalling. Phase III studies comparing EGFR TKI to placebo as 
2nd/3rd line therapy showed evidence of improvement in survival 
outcome. Overall benefit is small while clinical subgroups including 
female gender, Asian ethnicity, never smoker and adenocarcinoma 
histology was associated with higher tumor response rate and sur-
vival. The finding suggested that the commonly overexpressed EGFR 
may not be the genuine target for EGFR TKI. Patients with these 
clinical parameters have a higher incidence of activated mutation at 
EGFR, which is the real reason for the better treatment outcomes. 
The challenge is to apply these clinical parameters for patient selec-
tion in first line setting. Somatic mutations in the kinase domain of 
EGFR are responsible for the dramatic and durable tumor response to 
EGFR TKIs. Multiple phase II studies conducted in Asia showed that 
clinically selected population with high incidence of EGFR mutation 
benefit from EGFR TKI as first line therapy. Lee et al reported tumor 
response rate of 69% to gefitinib in a population of non-smoking 
Korean women with adenocarcinoma. Similar results in clinical 
efficacy were noted in a Spanish Lung Cancer group trial with EGFR 
mutation-positive patients who received erlotinib monotherapy. 
Tumour biopsies were obtained from 2312 patients and a total of 
307 patients had EGFR mutations. A median survival of 24 months 
and an ORR of 73% was noted in 165 patients with EGFR mutation-
positive tumours who received erlotinib as either first- or second-line 
therapy. 
When planning for the IPASS study, we asked the following 
questions:
1. What is the EGFR mutation rate in each clinical subgroups? 
2. What is the definition of light ex-smoker and what is the antici-
pated mutation rate?
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3. What is the expected tumor response rate to EGFR TKI in EGFR 
mutation + and EGFR mutation – patients. 
4. How to estimate sample size according to clinical parameter?
The primary objective of IPASS is to test for noninferiority of 
gefitinib compared to carboplatin/paclitaxel. Only if they hypothesis 
for non-inferiority was accepted, then we perform the same analysis 
looking for superiority between the two groups. We randomized 1217 
patients from 9 countries in Asia to gefitinib (n=609) or carboplatin/
taxol (n=608). Gefitinib demonstrated superior PFS compared with 
C/P (HR 0.74; 95% CI 0.65-0.85; p<0.0001). We were able to analy-
sis EGFR mutation in 36% of the enrolled patients. We processed 
437 tumor samples and found 261 EGFR mutations (59.7%). Tumor 
response rate was significantly higher (43% vs 32.2%; odds ratio 
[OR] 1.59; 95% CI 1.25-2.01 p=0.0001). PFS in EGFR mutation + 
pts was longer for geftinib than chemotherapy (HR 0.48: 95% CI 
0.36-0.64; p<0.0001); in EGFR mutation pts PFS was longer with 
chemotherapy than geftinib (HR 2.85: 95% CI 2.05-3.98; p<0.0001). 
Conclusion is that EGFR mutation is a potent predictor of treatment 
outcome to EGFR TKI. 
In summary, it is feasible to use clinical parameter to select patients 
with EGFR mutation in clinical trail. For proper planning we needed 
extensive background information on the EGFR mutation rate in spe-
cific clinical subgroups. Significant proportion of tumor samples has 
to be available for validation of clinical findings. However, patients 
without EGFR mutation did quite poorly on first line EGFR TKI. 
Investigator must be aware of the potential ethical issue of subject-
ing patients with EGFR wild type to ineffective medication. Patients 
should be monitored very closely for disease progression and salvage 
therapy to be offered promptly. 
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Epidermal growth factor receptor 
assessment in prospective studies
Dziadziuszko, Rafal
Medical University of Gdansk, Gdansk, Poland
Several epidermal growth factor inhibitors, including small molecule 
tyrosine kinase inhibitors and monoclonal antibodies, are currently 
evaluated in clinical trials in non-small cell lung cancer (NSCLC). 
Available data suggest that these agents are effective in the subsets 
of patients with particular molecular characteristics. The molecular 
assays currently evaluated and validated for prediction of the benefit 
from EGFR antagonists include EGFR protein expression by immu-
nohistochemistry (IHC), EGFR gene copy number by fluorescence 
in situ hybridization (FISH), EGFR gene mutations, the absence 
of K-ras mutations, and serum proteomic profiling based on mass 
spectrometry (1). 
Clinical trial designs that incorporate prospective biomarker testing 
include “all comers’ design” (biomarker is tested, all patients are 
randomized and the treatment is stratified based on biomarker status), 
“enrichment design” (only biomarker positive or negative patients 
are enrolled and randomized) or “randomized strategy design” 
(patients are randomized based on traditional strategy vs. on strategy 
using biomarker status). Efficient biomarker testing before random-
ization is essential to ensure validity of prospective evaluation. The 
most important features of a laboratory test include high intra- and 
inter-laboratory reproducibility, short turn-over time, low proportion 
of samples with indeterminate results, and low cost. 
Examples of clinical trials with “all comers’ design” include phase III 
clinical study of maintenance erlotinib vs. placebo after four cycles 
of platinum-based chemotherapy (SATURN trial). In this study, 889 
non-progressing patients were randomly allocated to erlotinib versus 
placebo, with progression-free survival as primary endpoint. EGFR 
protein expression was determined prior to randomization and used 
as stratification factor with adequate power for comparisons in both 
overall and EGFR IHC positive co-primary populations. 
“Enrichment strategy design” is often used in clinical trials with 
targeted therapies. Examples of this strategy include studies with 
anti-EGFR monoclonal antibodies and chemotherapy performed in 
patients with EGFR IHC-positive tumors (approximately 70-90% of 
unselected NSCLC patients) (2) ongoing trials with EGFR tyrosine 
kinase inhibitors in patients with tumors harboring EGFR mutations 
(10-20% of unselected NSCLC Caucasian patients) or high EGFR 
gene copy number by FISH (30-40% of unselected patients). For 
example, Spanish Lung Cancer Study Group is conducting a clinical 
trial with first-line erlotinib vs. chemotherapy in patients with tumors 
showing EGFR gene mutations, using progression-free survival as a 
primary end-point (3). Central and East European Oncology Group 
is conducting a phase II trial in patients with EGFR FISH positive 
tumors (FLIKER trial). These trials have the potential to include 
patients with the maximal clinical benefit, which otherwise may be 
“diluted” by the patients without benefit from the treatment. Trials 
with this design will not determine the treatment efficacy in marker 
negative subset of patients. 
Clinical trails that enrich patients with two markers, one of which is a 
stratification factor, were designed with erlotinib. In a two-arm study 
evaluating the efficacy of erlotinib monotherapy or combination of 
erlotinib and paclitaxel/carboplatin with pharmocodynamic separa-
tion, patients were selected with EGFR IHC or FISH and stratified by 
FISH result. Similar design with adequate power for subset compari-
sons is used in an ongoing phase III trial with adjuvant postoperative 
erlotinib in early stage NSCLC (RADIANT trial). These two trials 
may serve as an example of “hybrid design” with some elements of 
enrichment and prospective stratification by biomarker as used in “all 
comers’ design”. 
“Randomized strategy design” is used primarily in clinical trials 
assessing novel prognostic assays, as for example MINDACT study 
testing the applicability of prognostic gene signature in breast cancer 
(4). In the area of predictive markers for targeted therapies, one may 
envision a study comparing traditional clinical criteria (for example 
never-smoking history) and molecular criteria (for example the pres-
ence of EGFR mutations) for selection of patients to EGFR tyrosine 
kinase inhibitor therapy. Such trial is unlikely to be performed ever, 
because other studies demonstrate that never-smoking history may 
serve as a surrogate for the presence of activating EGFR mutations 
and the latter explains the sensitivity to EGFR inhibitors in vitro and 
in preclinical models. 
In summary, incorporation of biomarker assessment early in the 
clinical development is essential for successful determination of 
patient subsets deriving the benefit from targeted therapies. The 
development of EGFR inhibitors serves as an example of biomarker 
discovery in retrospective analyses and subsequent validation in pro-
spective trials. It is hoped that this process will be accelerated in the 
future to bring more efficiently new targeted therapies from bench to 
bedside. 
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How to design a meta-analysis in biomarkers
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Background
There is widespread research in the field of oncology into biomark-
ers that may be prognostic for disease outcome or predictive for 
treatment effect. Identification of such biomarkers needs to be valid 
and robust as they will ultimately be used in clinical practice to target 
different treatment approaches to different subgroups of patients. 
One way to reduce the uncertainty regarding potential biomarkers 
is to synthesise the evidence from a series of studies addressing the 
same question. 
Systematic reviews and meta-analysis are recognised approaches to 
evidence synthesis regarding a treatment effect. Systematic reviews 
are used to identify, evaluate and combine the evidence base within 
a transparent framework. Meta-analysis is a statistical method to 
combine the quantitative results across studies to produce an overall 
summary measure of the treatment effect and thereby reduce uncer-
tainty. Meta-analysis methods use either published aggregate data or 
individual patient data. Interpretation of the results from a meta-
analysis requires consideration of heterogeneity between studies and 
publication bias. This paper considers the application of meta-analy-
sis for evidence synthesis regarding biomarkers.
Methods
A planned meta-analysis requires a protocol. This will state the 
research question of interest, provide details of the systematic review 
that will be used to identify the relevant studies and eligibility criteria 
for inclusion in the meta-analysis, list the data elements that will be 
extracted from the studies and provide the statistical analysis plan for 
the meta-analysis. 
In general, the aim of the meta-analysis will be to assess the relation-
ship between the presence of a biomarker and either patient outcome 
or patient response to treatment. Examples of research questions in 
lung cancer that have been addressed by meta-analysis are: (i) is the 
k-ras oncogene mutation a prognostic marker in non-small cell lung 
cancer (Huncharek et al 1999) and (ii) is k-ras mutation a predictive 
biomarker for anti-EGFR-targeted therapeutic strategies in non-small 
cell lung cancer and metastatic colorectal cancer (Linardou et al 
2008). 
The systematic review should aim to identify all relevant published 
studies and where possible attempt to discover unpublished studies. 
Eligibility criteria are specified to clarify which studies revealed by 
the review should actually be included in the meta–analysis. These 
criteria may relate to the patient population, the biomarker measure-
ment, the treatment involved and the study design (e.g. randomised).
Meta-analysis assessing whether different levels of a biomarker are 
prognostic of a binary outcome such as dead or alive at 2 years will 
combine odds ratios across studies whilst those relating to a time-
to-event outcome such as survival time will combine hazard ratios. 
Meta-analysis assessing predictive biomarkers may combine mea-
sures of treatment-biomarker interaction. Measures will be combined 
in a meta-analysis using either aggregate data obtainable from the 
publications or individual patient data.
Results
There is a plethora of studies assessing prognostic and predictive 
biomarkers, but the size of studies is generally small and often the 
quality is questionable (Riley at al 2009). A systematic review in 
non-small cell lung cancer found that over 100 different prognostic 
markers have been investigated in the field but the median number of 
articles per marker was only one (Brundage et al 2002). Systematic 
reviews of the literature on specific biomarkers generally result in 
a large number of potential studies with only a few being eligible 
for the meta-analysis. The literature review of studies investigating 
k-ras mutation as a prognostic factor in non-small cell lung cancer 
revealed 1080 publications but only 8 studies were deemed eligible 
for inclusion in the meta-analysis (Huncharek 1999).
One of the key problems with meta-analysis of biomarker studies 
is the inter-study heterogeneity. Key sources of variation specific 
to prognostic and predictive biomarker studies include selection of 
patients for tissue donation, type of tissue selected for biomarker 
extraction, laboratory techniques used to measure the biomarker and 
approaches used to categorise the biomarker. Extracting consistent 
measures of prognostic or predictive effects from published aggre-
gate data for the meta-analysis is difficult because studies vary in the 
type of clinical outcome measure, the type of statistical analysis and 
the adjustment for treatment effects, other key prognostic markers 
and post-treatment factors. Individual patient data meta-analysis 
is recommended as it can overcome some of these difficulties but 
requires considerably more resources (Riley et al 2009).
Conclusions
Meta-analysis to assess prognostic and predictive biomarkers is prob-
lematic due to the quality and heterogeneity of individual studies. 
These difficulties result in inability to integrate studies in a way that 
provides robust conclusions about the true prognostic or predictive 
effect of the biomarker. Research groups need to work collaborative-
ly at a multi-disciplinary and international level to reach consensus 
on key biomarkers of interest and optimal laboratory techniques 
for their measurement. The research community need to strive to 
produce quality primary studies with consistent designs that enable 
prospectively planned pooled analysis.
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Proteomics is the study of proteome which is the entire complement 
of proteins, including the modifications made to a particular set of 
proteins, produced by an organism or systemproteins. The serum 
proteome is considered to be a rich source of undiscovered biomark-
ers and protein expression profiles by looking at the expression of 
the entire proteome. Direct evaluation of the proteome expressed in 
tumor cells offers information that can not be obtained by study of 
DNA alterations or RNA expression patterns. Within several methods 
that have been applied 2DIGE and Mass Spectrometry have been 
identified as the most helpful in clinical practice for the purpose of 
patients’ population selection.
So far the proteomic research in cancer has been focused on protein 
identification cell lines and mouse model studies. However none of 
them identified strong surrogate biomarkers that directly or indirectly 
contributed to the physiological, and therapeutic target discovery. 
The very first clinical proteomic study which identified a surrogate 
biomarker was conducted on NSCLC patients In this study we built 
and validated an algorithm, based on the serum and plasma pro-
teomic analysis of NSCLC patients treated with EGFR TKIs able to 
predict clinical benefit. The importance of this study is related also 
to the simple blood test availability, the high reproducibility and easy 
technique applied. In this previous intercontinental study a predictive 
approach was evaluated based on MALDI MS analysis of unfraction-
ated serum that identified patients with better outcome when treated 
with EGFR TKIs independently from other factors. Two hundred and 
six samples (the training set and the Italian B validation set) were 
labelled as good and poor with an overall observed concordance of 
97.1 % between two different laboratories (Vanderbilt and Colorado, 
USA). Good labelled patients EGFR TKIs treated had a statistically 
significantly longer time to progression than poor labelled patients 
(119 days vs. 62 days) with an hazard ratio of 0.52 (95% CI 0.25 - 
0.82, p = 0.004). The analysis resulted statistically significant also 
in terms of overall survival (192.5 days vs. 73 days; good vs poor 
respectively) with an hazard ratio of 0.52 (95% CI 0.25 - 0.83, p = 
0.008). 
Despite these clinically relevant observations, the study has limits 
of a retrospective analysis that needed a prospective validation. The 
prospective PROSE study was design based on data obtained from 
the retrospective study and the hypothesis was built to prospectively 
validate that clinical decision may be guided by proteomic analy-
ses. In this, ongoing prospective second-line setting clinical study 
patients previously treated with one non-EGFR TKIs therapy for 
advanced NSCLC are included. All patients are stratified by pro-
teomic profile, histology, smoking status, and response to first-line 
chemotherapy, and than randomized to receive standard chemothera-
py (pemetrexed or docetaxel) versus EGFR TKI therapy (erlotinib).
The sample size is primarily calculated to have a 90% power to 
detect, with a type I error of 2.5% (one-tailed), the presence of a dif-
ferent effect between erlotinib and chemotherapy in the two different 
groups defined on the basis of good and poor proteomic profile (Ver-
istrat+ and Veristrat-). Assuming a 35%:65% distribution of patients 
in Veristrat- and Veristrat+ groups, a median survival time in patients 
treated with chemotherapy of 7 months, irrespectively of proteomic 
profile, a median OS in patients treated with erlotinib expected to be 
approximately 4.2 (Veristrat-) and 9.9 (Veristrat+), the expected dif-
ference of efficacy of erlotinib vs chemotherapy in these subgroups 
should translate in a HR of 1.7 and 0.71. According to the approach 
of Peterson and George, with a recruitment period of 18 months and 
a further 12 month period of follow-up, the number of patients to 
randomize is approximately 275.
The presence of a different effect of treatments in the Veristrat- and 
Veristrat+ groups, thus evaluating the predictive value of proteomic 
profile, will be assessed. Statistical significance of difference will 
be tested in a Cox’s model including group categories (+ vs -), 
treatment, first order interaction term between treatment and group 
category, as well as stratification factor. 
In case of statistical significant interaction, the hypothes that the 
effect of erlotinib is dependend by biological factors determined by 
proteomic analysis will be accepted. 
In conclusion, the identification of predictive markers may be the 
way to optimize individual patient treatment, and improve limited 
survival benefit of patients with advanced NSCLC. The rigorously 
designed prospective studies are needed to confirm the clinical 
relevance of data obtained from retrospective analysis. The PROSE 
study is a very first prospective randomized study to explore the 
potential use of blood proteomic analysis for treatment selection in 
patients with advanced NSCLC. 
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Introduction
Histological subtypes of lung cancer are recognized for many years. 
Thus lung cancer has been divided into Small Cell Lung Cancer 
(SCLC) and Non-Small Cell Lung Cancer (NSCLC) and NSCLC is 
further divided into three major histological sub-types squamous cell 
carcinoma, adenocarcinoma and large cell carcinoma. Differences in 
epidemiologic and clinical features among the different histological 
subtypes of lung cancer are also recognized for many years. Patients 
with squamous cell carcinomas and small cell lung cancer are more 
likely to be heavy smokers than patients with adenocarcinomas. 
Almost always a lung cancer patient who is a never smoker has ade-
nocarcinomas. Both squamous cell and small cell lung cancers tend 
to be located in the central portion of the chest. These epidemiologic 
and clinical differences have raised the possibility that important bio-
logic differences exist among these histological subtypes of lung can-
cer and that these biologic differences may have therapeutic implica-
tions. It is also well recognized that there has been an epidemiologic 
shift from a decline in the incidence of squamous cell and small cell 
carcinomas to a rise in the incidence of adenocarcinomas(1). 
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Systemic therapy plays a major role in the management of lung 
cancer patients since a large majority of patients have regional or 
systemic metastases at diagnosis. Until recently the only pathological 
information that influenced choice of systemic therapy was the dis-
tinction between SCLC and NSCLC. All subtypes of NSCLC were 
treated with platinum based two drug combinations since studies did 
not demonstrate a difference in efficacy and outcomes based on the 
different subtypes for any of the regimens. Recent trials have chal-
lenged this paradigm of platinum based two drug combination for all 
subtypes of NSCLC.
Histology and Pemetrexed therapy
Pemetrexed is a multi-targeted anti-folate that has shown clinical 
efficacy in NSCLC patients with excellent tolerability. Recent data 
has shown that the benefits of pemetrexed are restricted to non-
squamous NSCLC patients. This first became evident in a retro-
spective analysis of a phase III trial evaluating pemetrexed versus 
docetaxel in recurrent NSCLC patients(2). While survival was not 
statistically different between the 2 groups (8.3 vs 7.9 months), 
among patients with nonsquamous histology, median survival was 
9.3 months with pemetrexed vs 8.0 months with docetaxel (P = .048). 
However, in patients with squamous cell histology, median survival 
with pemetrexed was 6.2 months vs 7.4 months with docetaxel (P = 
.018). 
This difference in efficacy based on histology was confirmed in a 
large phase III study evaluating cisplatin/pemetrexed and cisplatin/
gemcitabine as front line treatments for advanced NSCLC(3). The 
primary objective of the trial was to demonstrate non-inferiority of 
cisplatin/pemetrexed to cisplatin/gemcitabine and this endpoint was 
met. However a pre-specified subgroup analysis showed significant 
differences according to histology. Among the patients with non-
squamous histology, survival was significantly better when treated 
with cisplatin/pemetrexed as compared with cisplatin/gemcitabine 
(11.8 vs 10.4 months, P = .005). However, among the patients with 
squamous cell histology, survival favored cisplatin/gemcitabine 
rather than cisplatin/pemetrexed (OS 10.8 months v 9.4 months, 
respectively, P = .05). Based on these results, the combination of 
cisplatin/pemetrexed received approval for the treatment of advanced 
NSCLC patients with non-squamous histology. This is the first 
instance of a chemotherapy agent receiving approval for only certain 
subtypes of NSCLC. 
The precise reason for this differential activity of pemetrexed 
remains to be defined. Recent data has suggested that levels of 
thymidylate synthase, a primary target of pemetrexed, are higher in 
squamous cell carcinomas(4).
Histology and Anti-VEGF (Vascular 
Endothelial Growth Factor) therapy
Angiogenesis plays a crucial role in progression of NSCLC and has 
prognostic relevance(5, 6). VEGF has a central role in tumor angio-
genesis and therefore this was considered an attractive therapeutic 
target. Bevacizumab, a recombinant humanized monoclonal antibody 
targeting VEGF was the first anti-angiogenic drug evaluated for the 
treatment of NSCLC. In a randomized phase II study conducted 
to evaluate the efficacy and tolerability of bevacizumab added to 
carboplatin and paclitaxel in advanced NSCLC patients promising 
survival results were observed(7). However the study also showed 
that patients with squamous cell lung cancer had a high rate (31%) of 
severe hemoptysis. Based on these observations, a randomized phase 
III study evaluating the addition of bevacizumab to carboplatin and 
paclitaxel for the treatment of patients with advanced non-squamous 
NSCLC was conducted by the Eastern Co-operative Oncology 
Group (ECOG 4599)(8). A significant improvement in survival was 
observed in patients who received bevacizumab along with chemo-
therapy (median 12.3 mo vs. 10.3 mo, p=0.003). In this study 2% 
of the patients experienced Grade 3-5 hemoptysis. Based on these 
results bevacizumab combined with carboplatin and paclitaxel is 
approved for the treatment of advanced stage non-squamous NSCLC 
patients in the United States. Subsequently the AVAIL study evalu-
ated the addition of bevacizumab at two different dose levels (7.5 
mg/kg and 15 mg/kg) to a combination of cisplatin and gemcitabine 
in patients with advanced non-squamous NSCLC(9). This study 
demonstrated a significant improvement in progression free survival 
(PFS), the primary endpoint, with both dose levels of bevacizumab 
(median PFS control- 6.1 mo, median PFS bevacizumab at 7.5 mg/
kg- 6.7 mo and bevacizumab at 15 mg/kg- 6.5 mo; p). Improvement 
in overall survival was not observed in this study. There is currently 
an ongoing study evaluating the safety of delayed bevacizumab in 
patients with squamous cell NSCLC. 
VEGF receptor tyrosine kinase inhibitors (VEGFR-TKIs) have 
also been evaluated for the treatment of lung cancer patients. Many 
exploratory phase II trials conducted did not exclude NSCLC 
patients with squamous cell histology(10, 11). However in a random-
ized study evaluating the addition sorafenib, a multikinase inhibitor 
including VEGFR-TK to carboplatin and paclitaxel inferior survival 
was observed in patients with squamous cell NSCLC who received 
sorafenib and chemotherapy. In current clinical practice bevacizumab 
should be only considered in non-squamous NSCLC patients due to 
significant safety concerns in squamous cell patients.
Histology and Anti-EGFR (epidermal 
growth factor receptor) therapy
EGFR is a transmembrane receptor belonging to a family of four 
related proteins. Activation of the receptor through ligand binding 
results in phosphorylation of tyrosine residues in the intra-cellular 
domain of EGFR. The phosphorylated intra-cellular domain subse-
quently activates downstream molecules resulting in signal transduc-
tion that activates cellular proliferation, anti-apoptosis and angiogen-
esis. EGFR is overexpressed in 40-80% of NSCLCs. Some studies 
have found a correlation between EGFR overexpression in NSCLCs 
and poor outcomes(12, 13). Based on these data two EGFR-TKIs, 
gefitnib and erlotinib were evaluated for the treatment of patients 
with recurrent NSCLC. The response rates with these agents were 
about 10%(14, 15). However the clinical data suggested that the 
probability of benefit was higher in patients with adenocarcinoma 
histology, female gender, Asian ethnicity and never-smoker status. 
Based on these data many carried the impression that EGFR-TKIs 
have no benefit in NSCLC patients with squamous histology. How-
ever randomized studies have shown that EGFR-TKIs can provide 
clinical benefit in NSCLC patients with squamous cell histology and 
that this benefit is similar to cytotoxic agents in patients with recur-
rent NSCLC(14, 16). 
Based on the observation that the extent of benefit from EGFR-TKIs 
is highly variable, retrospective analyses of tumors were conducted 
by several investigators to identify tumor factors that can predict 
for clinical benefit from these agents. Among the tumor factors 
identified by such analyses is the presence of activating mutations 
in intra-cellular domain of EGFR(17, 18). Presence of these muta-
tions predicts for a high likelihood of response from EGFR-TKIs. 
The presence of EGFR mutations differs based on the histological 
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subtype of NSCLC. Thus EGFR mutations were not observed in any 
of the squamous cell tumors analyzed by Marchetti et al(19). These 
same investigators found that the mutation rate was 26% among 
patients with BAC tumors and 6% among patients with adenocarci-
noma without BAC features. In a similar analysis by Finberg et al, 
EGFR mutation rate of 35% was detected among patients with BAC 
and adenocarcinoma with BAC features (AWBF)(20). However the 
EGFR mutation rate differed based on mucinous histology. The rate 
of EGFR mutations with non-mucinous BAC/AWBF was 47% but 
among mucinous BAC/AWBF the rate was 0. These data suggest 
that the probability of benefit from EGFR-TKIs may differ among 
NSCLC patients with BAC or AWBF based on presence of mucinous 
or non-mucinous histology.
Cetuximab is a monoclonal antibody that binds to the extra-cellular 
domain of EGFR. The addition of cetuximab to cisplatin and vinore-
lbine for the treatment of advanced NSCLC patients was evalu-
ated in the FLEX study(21). This study showed that patients who 
received cetuximab with chemotherapy had a superior survival and 
response rate. In addition in a pre-specified analysis of the Caucasian 
population there was significant improvement in survival across all 
histological subtypes. 
Conclusion
The only information from a pathology report that medical oncolo-
gists concerned themselves with, while treating lung cancer patients, 
was the distinction between SCLC and NSCLC. Recent data has 
clearly shown that defining the subtypes of NSCLC is very important 
since choice of therapy is influenced by the specific histology of 
NSCLC. Treatment of ‘unspecified’ NSCLC may deny the patient the 
opportunity to be treated by the most effective therapy and expose 
the patient to treatments that may have significant adverse effects. 
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Wnt pathway in lung cancer
You, Liang
UCSF, San Francisco, CA, USA
Lung cancer is the leading cause of cancer deaths in the US and 
worldwide, with >170,000 newly diagnosed cases each year in the 
US and nearly million cases worldwide. Despite progresses made 
in the past decades, the 5-year survival rate for lung cancer remains 
under 15%. Lung cancers are divided into two main groups: non-
small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). 
NSCLC consists of three major types: adenocarcinoma, squamous 
cell carcinoma, and large-cell carcinoma. Lung adenocarcinomas 
and squamous cell carcinomas represent 60–70% of all lung cancers. 
Surgery, radiation, and chemotherapy have been used with generally 
unsatisfactory results in advanced lung cancers. A better understand-
ing of molecular mechanisms for lung cancer pathogenesis may offer 
more targets for the therapeutics of patients with lung cancer.
Wnt pathway is one of the key stem-cell pathways that regulate cell 
self-renewal and differentiation. Wnt canonical pathway (beta-
catenin dependent) has been extensively studied and linked with 
human cancers. In the absence of Wnt (e.g., normal cells), adenoma-
tous polyposis coli (APC) and axin form a phosphorylation complex 
with glycogen synthase kinase 3 (GSK3). Glycogen synthase kinase 
3 then phosphorylates beta-catenin. This marks beta-catenin for 
ubiquitin mediated degradation, maintaining relatively low levels of 
beta-catenin in the cytoplasm. Most of beta-catenin is attached to the 
plasma membrane and associated with E-cadherin. In the presence 
of Wnt, Wnt binding to frizzled (Fz) leads to signal transduction 
through Dishevelled (Dvl). The downstream signal decreases beta-
catenin phosphorylation. This results in beta-catenin stabilization and 
accumulation in the cytoplasm. Beta-catenin then translocates to the 
nucleus and binds to Tcf/Lef transcription factors and activates the 
transcription of multiple Wnt target genes, e.g., c-myc and cyclin D1. 
Aberrant activation of downstream components in the Wnt pathway 
has been described in multiple human cancers and in greatest detail 
in colon cancer. Familial adenomatous polyposis is caused by a 
mutation in the APC gene. Moreover, the majority of sporadic colon 
cancer tumors and adenomas also contain mutations in the APC gene. 
Mutations in beta-catenin and axin have been found in colon cancer. 
These genetic changes cause beta-catenin stabilization and accumu-
lation in the cytoplasm. 
The genetic changes in Wnt pathway have been rare in most human 
cancers including lung cancer. We have recently described the activa-
tion of upstream Wnt pathway (e.g., Wnt, Fz, and Dvl overexpres-
sion) in non-small cell lung cancer and mesothelioma. Epigenetic 
silencing of Wnt antagonists appears to be one of the mechanisms 
responsible for the upstream Wnt pathway activation. It is becom-
ing increasingly clear that the activation of Wnt pathway drives the 
formation of a variety of human cancers. 
With the purpose of developing potential cancer therapeutics that 
inhibits Wnt signaling, we and others have been exploring different 
approaches to block these protein-protein interactions (e.g., Wnt/Fz,  
Fz/Dvl, etc). For instance, several recombinant proteins (e.g., Wnt 
inhibitory factor-1) that binds directly to Wnt ligands have been 
evaluated. Several proof-of-principle small-molecule inhibitors of 
Wnt pathway have also been reported. We have recently rationally 
designed a small-molecule antagonist of Dvl/Fz interactions that per-
meate cells and exert effects attributable to their targeted biochemical 
antagonism.
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The Hedgehog signaling pathway in lung cancer: 
moving beyond inhibition of cell growth
Rohatgi, Rajat
Stanford University School of Medicine, Stanford, CA, USA
The link between developmental signaling pathways, such as Hedge-
hog and Wnt, and cancer development has been recognized for many 
years. These pathways clearly play important roles in adults by regu-
lating tissue specific stem cells and by coordinating repair processes. 
Cancer cells often hijack these pathways to acquire the capacity 
for unlimited self-renewal, invasiveness, metastasis and the ability 
to interact with the stroma. Since these properties are some of the 
most intractable features of epithelial tumors, the inhibition of these 
developmental pathways is a major goal of drug development efforts. 
The Hedgehog signaling pathway plays a key role in lung develop-
ment by coordinating interactions between the branching airways 
and the surrounding stroma and has also been shown to be active in 
stem cell niches in the adult lung epithelium. The unchecked activa-
tion of Hedgehog signaling has been implicated in both small cell 
and non-small cell lung cancer, largely through studies in cultured 
tumor cell lines and xenograft models. Inhibitors of the Hedgehog 
pathway protein Smoothened have now entered clinical trial for 
various malignancies. These inhibitors are some of the most exciting 
investigational agents for lung cancer trials because they may allow 
the inhibition of tumor stem cells, invasion programs, and tumor-
stroma interactions.
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Identifying cancer stem cells prognostic markers: Notch
Reguart, Noemi
Hospital Clinic Barcelona, Barcelona, Spain
Hedgehog (Hh), Notch and Wingless-Int (Wnt) are signalling 
pathways highly conserved among species, essential for embryonic 
development and progenitor cell fates. All three of these pathways 
participate in lung development as well as airway epithelial repair 
processes. Interestingly, aberrant activation of these pathways is 
observed in a large variety of cancers, suggesting its potential contri-
bution in the evolution and maintenance of a malignant phenotype. 
Notch is a cell-cell contact depending pathway crucial in develop-
ing lung morphogenesis (1) and the canonical pathway is comprised 
of 5 membrane-associated ligands (Jagged 1 and 2: Delta-like (Dll) 
1, 3 and 4) and 4 transmembrane receptors (Notch 1 to 4) (2). The 
interaction between them leads intramembranous cleavage of Notch 
receptors by metalloprotease and γ-secretase to induce nucleus 
activation of transcriptional regulatory factors (HES1, HES5, HES7, 
HEY1, HEY2 and HEYL) that determine the cell fate. Notch signal-
ling is essential to modulate branching (3) and neuroendocrine (NE) 
cell differentiation (4) during murine lung development. In adults 
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Notch has an essential role in vascular differentiation and homeosta-
sis by repressing endothelial cell proliferation in normal tissue (5).
In cancer, the effects of Notch are context dependent. Whereas in 
several tumors Notch acts as a pro-oncogene resulting in tumor 
growth and differentiation (6-8), in other tumors such as skin cancer 
Notch act as a tumor suppressor (9, 10). High expression levels of 
Notch receptors, Jagged1 and transcriptional target genes have been 
found in non-small-cell lung cancer (NSCLC) and malignant meso-
thelioma (MMS) cell lines as well as in frozen tumor samples (11, 
12). Furthermore, blockade of Notch receptors inhibits lung tumor 
growth in vivo using mouse xenograft models (11). In addition, 
Notch-3 over-expression in NSCLC cell lines has been associated 
with a specific somatic acquired chromosomal translocation at 19p 
(15;19) (12), giving more insight into the importance of Notch fam-
ily members in lung tumorigenesis.
In cancer, Notch signalling can transmit bidirectional signals not only 
among cancer cells that express both ligands and receptors, but also 
with endothelia and stroma. In endothelial tumor cells there is over-
expression of Notch ligands (13) which also correlates with VEGF 
levels (14). Inhibition of Notch induces a chaotic overgrowth of the 
tumor vasculature affecting the efficient delivery of blood therefore 
affecting tumor growth (15). In NSCLC, angiogenesis is a target for 
therapeutic intervention and molecular antibodies have been vali-
dated as standard treatment of advanced disease with chemotherapy, 
consequently Notch ligand inhibition could represent an alternative 
to VEGF inhibitors in NSCLC treatment. 
Notch signalling is also crucial for the epithelial-mesenchymal tran-
sition (EMT), which is associated with increased tumor cell mobility 
and invasiveness (16, 17). In NSCLC, EMT phenotype has been 
related with sensitivity to epidermal growth factor receptor (EGFR) 
inhibitors. Preliminary data indicates that inhibiting Notch by using 
γ-secretase inhibitor (MRK003) reduces tumor growth in vivo and 
enhances tumor sensitivity to EGFR inhibitors (18). Consequently, 
the development of new molecules targeting Notch could be a new 
strategy to overcome the resistance to tyrosine kinase inhibitors.
On the other hand, Notch signalling pathway is one of the main 
transcriptional regulators of Hes proteins and hASH1 (mammalian 
achaete-scute homolog-1) silencing in lung is mediated by Hes-1. 
Mammalian achaete-scute homolog-1 is highly expressed in NE 
tumors such as carcinoid tumors and small cell lung carcinomas 
(SCLC) among others. It is known that disruption of hASH1 tran-
scripts affects NE differentiation, resulting in a reduced expression of 
classic NE markers in cultured SCLC cells (19). Moreover, overex-
pression of hASH1 in mice airway epithelium induce aggressive lung 
tumors with NE phenotype (20). However little is known about the 
transcriptional targets of hASH1 and their relationship to lung cancer 
pathogenesis. Several reports show no activity of Notch signalling 
in NE tumors which could be related with the characteristic high 
expression levels of hASH1 (21). In fact reactivation of Notch1 
and Notch2, but not HES1, causes a potent G1 arrest in SCLC 
cells, accompanied by repression of hASH1 (22). Taken together, 
the results support a hypothetical model for lung development and 
tumorigenesis in which Notch pathway activity could be the switch 
suppressing NE differentiation in immature lung precursors.
Selective strategies to inhibit Notch are being tested in tumors, such 
as antisense, monoclonal antibodies and RNA interference. It is yet 
to be determined which patients are most likely to benefit from these 
treatments.
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Upcoming therapeutics: preclinical to clinical
He, Biao
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Lung cancer is an extraordinarily challenging and difficult disease 
to treat with a high incidence in the U.S. and a staggering death 
rate that closely parallels the annual tally of new cases. Five year 
survival is poor at 15% and most patients experience only modest 
benefit from the armamentarium of conventional therapies, includ-
ing chemotherapy, radiation and surgery. To the extent clinically 
meaningful responses occur, they are usually short lived and for 
many, a diagnosis of lung cancer is seen as a virtual death sentence, 
a view unfortunately shared by some physicians treating the disease. 
Research funding on a per death basis lags far behind the other com-
mon major cancers, fueled by a perception, at least among some, that 
lung cancer is a self inflicted disease. 
Traditional drug development approaches for lung cancers were 
optimized for cytotoxic therapies involving radiation and chemo-
therapy. Although these treatments do show some efficacy, the 
drawbacks are the severe and life-long side effects. One of the major 
obstacles in drug development is that testing new drugs relies on 
tissue culture and xenograft models, which recapitulate some but not 
all the features of malignancy. Another consideration is that drugs 
are often tested in heterogeneous populations of cancer cells that are 
not genetically profiled results in impeding development of targeted 
therapies that are specific for a molecular pathway and that may only 
be disrupted in a subset of cancers. Some of these considerations 
may explain why traditional strategies for drug development have 
brought only modest improvements to the treatment of lung cancers. 
Currently most advances in the clinic are still based on the stratifica-
tion of patients into risk groups and optimizing the dose of radia-
tion and chemotherapy accordingly. Therefore, new more effective 
targeted therapies are still in great need. The advent of targeted, 
biological therapies offers the most promising avenue for develop-
ing effective treatments. One such approach is the development of 
molecularly targeted therapies that block cell signaling pathways 
central to lung carcinogenesis. Clinical trials of new agents using this 
research paradigm have been encouraging. Currently strategies of 
development of cancer therapies largely depend on targets identified 
from studying the genetics of human cancers. Investigation of the 
molecular pathways and their interactions in human cancers should 
yield a better understanding of molecular targets for therapy and thus 
lead to more specific and therefore less toxic treatments. This inves-
tigation could include multiple steps such as identification of the 
control pathways driving lung cancer growth; development of a more 
genetically equivalent, high-incidence lung cancer model for new 
drug testing; and Design of specific inhibitors of the growth control 
pathways of lung cancer, etc.
Stem cells are rare within any given cell population, However, sev-
eral factors make them a likely culprit in the development of cancers. 
First is their capacity for self-renewal and replication. Second is 
their long-lived potential as undifferentiated cells, creating a larger 
window of opportunity for molecular alterations accumulate over 
time. Thus, it is not surprising that the Hedgehog and Wnt pathways, 
regulatory mechanisms for stem cell renewal, tissue repair and tissue 
regeneration, are implicated in the development of cancers when 
aberrantly activated. A large amount of data from various research 
groups have demonstrated, corroborated and reinforced the role of 
the Wnt signaling pathway throughout development and later in 
tissue homeostasis and cancer in adulthood. We have been steadily 
accumulating data that is allowing us to dissect in detail the Wnt 
signaling pathway, a complex yet strictly regulated transduction 
apparatus with numerous roles. However, the precise mechanisms 
of the individual, precise events during Wnt transduction processes 
still need to be resolved. Examples of this include but are not limited 
to understanding the mechanisms of Wnt secretion and presentation 
to cells; how Wnt binds to the Fz/LRP complex and signals to Dvl; 
the mechanisms by which proteins within the beta-catenin degra-
dation complex are regulated and how positive and negative Wnt 
regulators are integrated in the nucleus to initiate the transcriptional 
machinery to execute the events that will lead to downstream cellular 
physiological or pathological events. The functional ‘modularity’ of 
Wnt in controlling important cellular processes is also enriched and 
consequently complicated by its interaction with other developmen-
tal signaling pathways such as Hedgehog and Notch. Understanding 
the complex crosstalk between Wnt and these other pathways, is 
undoubtedly important, and will improve our understanding of their 
mechanisms of action during stem cell-fate decision, renewal and 
malignant conversion. We know that the Wnt pathway is strongly 
associated with cell fate and self-renewal, and with the many novel 
available research tools such as purified Wnt ligands, stimulatory of 
inhibitory small molecules and RNAis we will be able to tackle the 
challenging task of translating knowledge about the Wnt machinery 
into significant, pharmacologically relevant strategies to intervene 
in the diseases that its anomalous function causes. Additionally and 
paramount to the functionality of Wnt and its role in stem cell fate 
and renewal are their microenvironment or niches. Furthermore, 
tumor initiation and progression is increasingly being linked to the 
microenvironment, and therefore a better understanding of how its 
regulated affecting proliferation and self-renewal of homeostatic and 
cancer stem cells is a growing field in both science and medicine. 
The concept of cancer stem cells originated from findings in the 
haematopoietic system and acute myelogenous leukaemia and 
describes a cancer cell that has the power to self-renew resulting in 
another cancerous stem cell as well as a cell that will give rise to the 
phenotypically diverse cancer cell populations. There is consider-
able evidence demonstrating that only a subset of cells in a particular 
cancer displays characteristics of self-renewal. Cancer stem cells and 
normal stem cells share numerous properties, including the expres-
sion of common cell-surface markers, capacity to self-renew, and 
unlimited replication potential and the quality of being long-lived, 
allowing the accrual of multiple mutations over time to increase 
the rate of cell proliferation and produce cancer cells. These cancer 
cells are thought to represent the bulk-tumor proliferative cell pool 
that responds to chemoradiotherapies, leaving the cancer stem cell 
population unaffected. Eventually this results in tumor repopulation 
and disease recurrence. There is accumulating and robust scientific 
proof supporting that lung stem cells may be some of the culprits in 
lung carcinogenesis. For example, clinical specimens from SCLC 
and adenocarcinoma patients were found to contain a small subpopu-
lation of cells (<1.5%) that possessed the ability to form colonies 
when grown on agar. Upon their intracranial injection into athymic 
nude mice, they yielded cancers with features identical to those of 
the original specimens. This supports the notion of cancer stem cell 
populations within some lung cancers. Many experiments have also 
shown that certain malignant lung cancers contain specific subpopu-
lations of putative cancer stem cells that are resistant to chemotoxic 
agents. Therefore, identifying and characterizing cancer stem cells 
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should accelerate the development of novel targeted therapeutic 
drugs that target them, which may also sensitize cancer stem cells 
to traditional chemotoxic agents and possibly prevent cancer from 
recurrence. 
Our lab was among the first to discover the fundamental role that 
the Wnt signaling pathway plays in the development of lung cancer 
which likely develops from stem cell population. For example, we 
previously reported that aberrant activation of the Wnt pathway is a 
crucial step in the development of lung cancer. We validated the Wnt 
pathway activation in NSCLC by demonstrating over-expression of 
upstream components (Wnt ligands and Dishevelled (Dvl) proteins), 
and hypermethylation silencing of secreted antagonists (secreted 
Frizzled Related Proteins (SFRPs) and Wnt Inhibitory Factor 1 
(WIF1)). Re-awakening of the Wnt signaling pathway was recently 
found to be a critical element in lung cancer cell survival, mak-
ing them ideal targets for highly potent and safe molecular cancer 
therapies. The Wnt activation is thought to arm normal stem cells 
with proliferative and anti apoptotic armor, setting the stage for lung 
carcinogenesis with its hallmark of destructive processes: invasion, 
progression and distant micrometastatic spread. Targeted inhibition 
of aberrantly activated Wnt signaling may lead to the suppression 
or killing of cancer stem cells awakened from biological dormancy 
by aberrant Wnt activation and propelled forward by deranged Wnt 
signaling. In addition, targeted inhibition at cell membrane level of 
the Hedgehog pathway has shown promising preclinical and clinical 
anti-cancer activity in basal-cell carcinoma (BCC) suggesting its 
potential clinical applications in the treatment of multiple cancers 
through possible suppression of cancer stem cells. In conclusion, one 
of the most important future drug development strategies seeks to 
identify compounds that will kill cancer stem cells. Although there 
are no specific in vivo trials with treatments targeting lung cancer 
stem cells, one could postulate that blocking components of the Wnt 
and/or Hedgehog pathways could be an important way to inhibit 
the signalling required for lung cancer stem cells. This represents a 
paradigm shift in lung cancer pathogenesis and may translate into 
meaningful and effective novel lung cancer treatments. 
M17.6 Identifying Cancer Stem Cells, Sun, Aug 2, 10:30 - 12:00
Lung cancer stem cells and their application to 
future therapy and prevention research
Minna, John D.
Hamon Center for Therapeutic Oncology Research, University of 
Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
The emergence of the cancer stem cell (CSC) hypothesis and initial 
studies identifying a subpopulation of cells within lung cancers with 
“stem cell like” (“cancer initiating”) properties indicates they are 
important new targets for early detection, prevention and therapeutic 
targeting [1, 2]. The primary tenant of this hypothesis is that a subset 
of cells within the tumor behave like stem cells including using stem 
cell signaling pathways and that it is this subset of cells (rather than 
the remainder of the cells in the tumors – “progenitor cells” ) which 
initiate tumor formation and drive tumor progression and metastatic 
disease through aberrant self-renewal and differentiation [3, 4]. In 
essence, cancers have hijacked stem cell physiology to maintain 
tumor growth beyond normal developmental boundaries. In conjunc-
tion with their enhanced tumor initiating capacity, it is believed 
that CSCs are responsible for generating distant metastases, and are 
more resistant than the “progenitors” to radio and chemotherapy [5]. 
Another important aspect is that the microenvironment (referred to 
as “stem cell niche”) can play an important role in regulating not 
only normal but also cancer stem cell growth. Taken together these 
attributes highlight the CSC population and their “niche” as prime 
cellular components that drives tumor progression. From a clini-
cal perspective, monitoring and managing the lung CSC popula-
tion presents new opportunities and challenges. Because CSCs are 
thought to be derived from transformed stem cells, it is possible that 
the prevalence of lung epithelial stem cells that have acquired genetic 
and epigenetic changes may be the most important “field defect” 
linked with increased lung cancer risk. Furthermore, there could be 
both inherited and acquired genetic/epigenetic changes that elevate 
stem cell numbers in the lung that may also lead to and be predictors 
for increased cancer risk [6, 7]. These same pathways and factors 
may be targets for both chemoprevention of lung cancer and for 
targeting therapy to clinical evident lung cancers (Figure 1). To this 
end, a better understanding of the stem cell pathways expressed in 
normal, premalignant, and clinically evident lung cancers may yield 
valuable information on lung cancer risk, the prognosis of individual 
cancers, and what would be the best pathways to target in individual 
patient’s tumors. Managing and eliminating lung CSCs hinges on our 
ability to identify lung CSCs and dissect the molecular characteris-
tics of lung CSCs. Currently few lung CSC specific markers have 
been described. Recently the stem cell marker, ALDH1 leading to 
increased ALDH activity, was found to identify CSCs and provide 
prognostic information for breast and lung cancers [8, 9]. Our studies 
of a large number of non-small cell lung cancers (NSCLCs) have 
found ALDH(+) cells in 0.1-20% of cells while small cell lung 
cancers (SCLCs) show significantly higher levels of >50%. Thus, 
SCLCs appear to be greatly enriched in an ALDH(+) population. 
We have found that lung cancer ALDH(+) populations are more 
tumorigenic in NOD/SCID mice than the ALDH(-) population. We 
have investigated the expression of stem cell pathway genes in lung 
cancers of all histologic types and in immortalized human bronchial 
epithelial cells (HBECs) with and without defined oncogenic chang-
es. In studies of a panel of 40 stem cell signaling pathway genes we 
find large differences in expression between the ALDH(+) and (-) 
lung cancer subpopulations. Like normal stem cells, CSCs utilize 
developmental signaling pathways to undergo self-renewal. The Wnt, 
SHH and Notch signaling pathways have been implicated in normal 
stem cell development as well as in CSCs from a variety of tumor 
types [10, 11]. The blockade of SHH signaling by agents such as 
cyclopamine has been shown to be effective in killing some SCLCs 
[12]. By capitalizing on the differential expression of self-renewal 
signaling pathways in lung CSCs, new therapies may be employed 
to selectively inhibit the self-renewing cancer population (Figure 
1). Our preliminary results indicate Notch transcripts are elevated 
in highly tumorigenic ALDH(+) lung cancer cells and that blockade 
of Notch with gamma-secretase inhibitors reduces ALDH(+) cells. 
In conclusion, by identifying lung CSCs and targeting the stem cell 
pathways in this subset of cells, new diagnostic, prognostic, preven-
tion and therapeutic approaches are possible. 
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Figure 1. Cancer stem cell–specific therapeutic approaches. 
Hedgehog (HH), Notch, and Wnt signaling are key stem cell 
selfrenewal pathways that are deregulated in lung cancer and thus 
represent potential therapeutic targets (i). Agents inhibiting the 
hedgehog pathway include monoclonal antibodies against HH ligand 
and cyclopamine, which is a small molecule inhibitor of smoothened 
(SMO). Monoclonal antibodies against Wnt ligand and frizzled 
(FZD) receptor and inhibitors of protein complexes mediating Wnt 
signaling, such as Wnt-FZD or β-catenin–transcription factor (β-Cat-
TCF), are examples of ways of targeting the Wnt pathway. Strate-
gies of blocking or silencing Notch signaling can be either selective, 
such as the targeting of individual Notch receptors with antisense or 
monoclonal antibodies, or nonselective, such as the use of soluble 
receptor decoys that sequester Notch ligands or γ-secretase inhibi-
tors. Solid and dashed arrows represent multiple components of these 
pathways that, for simplicity, are not detailed here. These compo-
nents also represent potential therapeutic targets. Other methods of 
targeting cancer stem cells include immunotherapy-based approaches 
against antigens present on cancer stem cells (ii); targeting cancer 
stem cell mechanisms of resistance to cytotoxic therapy by inhibit-
ing DNA repair enzymes such as the checkpoint kinases (Chk1, 
Chk2) (iii); targeting stem cell–specific survival mechanisms with 
telomerase inhibitors (GRN163L) (iv); and inducing stem cell dif-
ferentiation with soluble factors such as bone morphogenetic proteins 
(BMPs) (v). GLI, glioma-associated oncogene; GLIACT, active form 
of GLI; GLIREP, repressor form of GLI; NICD, Notch intracellular 
domain; CSL, CBF1, suppressor of hairless, Lag-1; TACE, TNF-
α–converting enzyme; ADAM10, a disintegrin and metalloprotease 
domain 10; PTCH, patched homolog; GSK3β, glycogen synthase 
kinase 3β; CSK1α, cyclin-suppressing kinase 1; DSH, dishevelled. 
(From Chapter by Sun et al. in Lung Cancer: Prevention, Manage-
ment, and Emerging TherapiesAdapted, Humana Press edited by 
D. Stewart, 2009 In Press, and adapted from Sun, S., Schiller, J.H., 
Spinola, M. & Minna, J.D. New molecularly targeted therapies for 
lung cancer. J Clin Invest 117, 2740-50 (2007).) 
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Lung cancer is the most common cause of major cancer incidence 
and mortality worldwide. Adenocarcinoma is the most common 
histologic subtype of lung cancer in most countries. There is a widely 
divergent clinical, radiologic, molecular and pathologic spectrum 
within lung adenocarcinoma. Despite remarkable advances in 
understanding of this tumor in the past decade; there remains a need 
for a universally accepted criteria for adenocarcinoma subtypes, in 
particular bronchioloalveolar carcinoma (BAC). The use of the term 
BAC is currently applied for a broad spectrum of tumors ranging 
from solitary small peripheral lung tumors with a 100% 5-year sur-
vival to widespread advanced disease with a 10% 3-5 year survival. 
There are also clinical, immunohistochemical, and molecular differ-
ences that can be distinguished among the subsets of mucinous and 
non-mucinous types of BAC. There continue to be widely varying 
interpretations and use of terminology even after publication of the 
1999 and 2004 World Health Organization (WHO) Classification 
criteria for diagnosis of adenocarcinoma and BAC. As a result there 
is continued confusion in the literature and it is often difficult to 
compare studies. 
For this reason we have initiated a new multidisciplinary classifica-
tion of lung adenocarcinoma that is being sponsored by the Interna-
tional Association for the Study of Lung Cancer (IASLC), American 
Thoracic Society (ATS), and the European Respiratory Society 
(ERS). We have assembled an international panel of 13 oncologists, 
10 pathologists, 7 molecular biologists, 5 thoracic radiologists and 6 
thoracic surgeons. Each of these individuals represent world experts 
in the field of lung adenocarcinoma. In addition there is a larger 
panel of reviewers who are participating in the project although they 
have not participated in the meetings as part of the core panel. These 
core and reviewer panels have broad international representation 
from North America, Europe and Asia. A series of meetings have 
been held in 2008 and 2009 with the following purpose:
Specific aims and project objectives 
1)  To develop a multidisciplinary subclassification of lung 
adenocarcinoma 
a)  To resolve the ongoing discrepancy in the pathologic vs clini-
cal use of the term BAC - which currently defines 100% vs 
5-20% 5-year survival, respectively 
b)  To achieve an international standard for histologic subclassifi-
cation of lung adenocarcinoma 
c)  To define clinical/histologic/radiologic/molecular subtypes of 
lung adenocarcinoma and to define clinical, radiologic, patho-
logic and molecular terminology and criteria. 
2)  To achieve an international consensus by involving a broad 
international group of respected leaders from the beginning of the 
project to increase the acceptance of the final proposal 
All previous WHO classifications of lung tumors, including lung ade-
nocarcinoma have been purely pathology based with little or no input 
by other specialties such as surgery, oncology, molecular biology and 
radiology. One of the unique aspects of this classification effort is 
how from the very beginning, the project has had a multidisciplinary 
approach. Although the foundation of the final classification will 
still be pathology, the classification will integrate clinical, radiologic 
and molecular information. It is intended that this classification will 
ultimately be adopted by the next WHO classification, which needs 
to be applicable throughout the world even in settings where special 
molecular or even immunohistochemical techniques are not avail-
able. So guidance will be provided for adenocarcinoma diagnosis and 
classification without special techniques. 
In recent years the field of lung adenocarcinoma diagnosis and man-
agement has been transformed because of the remarkable advances in 
not only in pathology, but in molecular biology, radiology, oncology 
and thoracic surgery. With the rapid progress in molecular biology, 
particularly the recognition of responsiveness to tyrosine kinase 
inhibitors in patients with EGFR mutations, there has been a wave 
of new drug development based on molecular targets. In addition to 
the EGFR and KRAS pathways which account for 30-50% of the 
molecular abnormalities in lung adenocarcinoma, activating muta-
tions have been demonstrated in HER2, PIK3CA, BRAF and EML4-
ALK genes in small percentages of lung adenocarcinomas. This 
leaves a large percentage of tumors where the major molecular path-
way remains unknown. Other comprehensive molecular techniques 
including gene expression profiling have identified subsets of lung 
adenocarcinomas that generally correlate with different histologic 
subtypes, smoking histories, EGFR mutation status and prognosis. 
The concept of developing personalized treatment for patients based 
on molecular characteristics has also led to new strategies for medi-
cal and surgical therapy. 
The availability of molecular data provides a new and potentially 
very informative way to evaluate histologic classification according 
to biologic properties beyond the traditional clinical and epidemio-
logic characteristics. This makes the need for a uniform classification 
all the more important to allow for standardized reporting of patho-
logic diagnoses so data can be compared between different studies. 
Radiologists have also recognized that solitary lung adenocarcinomas 
with a predominant ground glass pattern correlate with a bronchi-
oloalveolar carcinoma (BAC) pattern, those with a predominant solid 
pattern are invasive adenocarcinomas and part solid tumors with a 
ground glass component are mixed subtype adenocarcinomas with 
both a BAC and an invasive component. One of the hopes of this 
effort is to evaluate the existing literature whether a subset of lung 
adenocarcinoma patients can be defined that only need a limited lung 
resection, short of the standard lobectomy used for lung cancers. The 
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pathology group is trying to determine if criteria can be established 
to define a “minimally invasive” lung adenocarcinoma for small soli-
tary tumors that may have the same 100% survival seen in patients 
with BAC histology. 
This classification will make recommendations regarding the diag-
nosis of adenocarcinoma versus other non-small cell carcinomas in 
small biopsies and cytology. This has not been addressed in previ-
ous WHO classifications which have focused on histologic patterns 
primarily seen in surgical specimens. However, this classification 
will address criteria for adenocarcinoma diagnosis in small biopsies 
and cytology since approximately 70% of lung cancers are diag-
nosed based on these types of specimens. This is now very important 
because of the contraindication of using bevicizumab in patients with 
squamous cell carcinoma due to potential life threatening hemor-
rhage and the reported responsiveness to pemetrexed in patients 
with adenocarcinoma or large cell carcinoma rather than squamous 
cell carcinoma. Because of the newly recognized importance of 
distinguishing squamous cell from large cell and adenocarcinoma, 
a panel of special stains including mucin stains as well as immuno-
histochemistry for TTF-1, P63, 34BE12 are now being utilized in 
tumors that are difficult to classify by light microscopy. An algorithm 
for use of these stains will be presented in this classification. An 
important caveat is that all of the existing studies of bevicizumab and 
pemetrexed were based on light microscopy alone and the introduc-
tion of immunohistochemistry could change the results in future 
studies. Whether the clinical significance of toxicity or efficacy for 
these drugs is altered by introduction of immunohistochemistry will 
require pathologists to record their initial light microscopic impres-
sion and then document if this impression is altered by the use of 
immunohistochemistry. 
This project also involves a systematic review of the published 
literature on the subject of lung adenocarcinoma from January 1990 
through February 2009. So there will be an evidence based founda-
tion to the classification.
A tentative proposed classification is listed in the following tables 
but this is only the proposal being considered after the most recent 
March 12-16, 2009 meeting at Memorial Sloan Kettering Cancer 
Center in New York and it is still subject to revision. 
The major changes in this classification include:
1) Cessation of the use of the term BAC. This tumor now appears in 
three places in the classification: a) Adenocarcinoma in situ (AIS) 
which can be non-mucinous and rarely mucinous; b) Minimally 
invasive adenocarcinoma and c) Invasive adenocarcinoma with 
lepidic pattern. With AIS the size of the lesion should be specified 
and the specimen should be sampled extensively to exclude the 
presence of invasion, particularly in larger tumors. Tumors larger 
than 2 cm are likely to have areas of invasive growth and the 
diagnosis of AIS should be made with caution. 
2) Addition of a category of minimally invasive adenocarcinoma 
(MIA). The definition of MIA is still being refined at the time of 
writing this abstract, but this is a tumor that has a lepidic predomi-
nant pattern with either ≤5mm or <10% invasion. The basis for 
this category is a series of papers that demonstrate that patients 
with small solitary minimally invasive adenocarcinomas can have 
100% 5-year survival
3) For the group of invasive adenocarcinomas, the category of mixed 
subtype is dropped, because it is recognized that over 80-90% 
of lung adenocarcinomas fell into this category according to the 
1999 and 2004 WHO classifications. Therefore a tumor should 
be classified according to its predominant subtype and compre-
hensive histologic subtyping with semiquantitative assessment of 
each of the histologic subtypes in increments of 5-10% is suggest-
ed. This will allow the reader of a pathology report to appreciate 
whether the histologic subtype of a tumor is pure or if it is mixed. 
If it is a tumor with mixtures of patterns, the extent of the other 
subtypes will be recorded. The micropapillary pattern character-
ized by small papillae without a fibrovascular core is added as one 
of the major subtypes as it is now accepted to be associated with 
poor prognosis. 
4) The former mucinous BAC now appears in two places in the 
classification: a) the very rare event of a non-invasive tumor that 
is now called AIS - mucinous type and b) Mucinous adenocar-
cinoma with lepidic pattern is under the category of variants. 
Here it is also situated with mucinous cystadenocarcinoma and 
colloid carcinoma where there may be some overlap and mixtures. 
Similar to the non-mucinous lepidic predominant (former non-
mucinous BAC’s), most mucinous adenocarcinomas with lepidic 
pattern (former mucinous BAC’s) have mixtures of invasive pat-
terns such as acinar or solid growth. It was felt that the invasive 
adenocarcinomas previously classified as non-mucinous BAC and 
mucinous BAC are very different tumors, so they are now listed in 
completely different categories. In particular the mucinous tumors 
with lepidic patterns are more often associated with K-Ras muta-
tions and multicentric growth. For these tumors comprehensive 
histologic subtyping is also suggested.
5) Clear cell and signet ring adenocarcinoma are deleted since these 
are cytologic changes both of which can occur in a variety of the 
histologic patterns including acinar, papillary and solid. Clear cell 
changes also occur in lepidic tumors. Furthermore tumors with 
predominant clear cell and/or signet ring features are very rare 
and most often they are seen as a focal finding. The presence of 
clear cell and/or signet ring features should be recorded as a com-
ment in a diagnosis that primarily focuses on the major histologic 
subtypes identified. One important issue in recognizing tumors 
with clear cells and signet ring cells is the exclusion of metasta-
ses from other sites such as the kidney or gastrointestinal tract, 
respectively.
6) The category of enteric adenocarcinoma is added, recognizing that 
rare primary lung adenocarcinomas may have morphologic and or 
immunohistochemical properties (CK20+, CDX2+, TTF1-) identi-
cal to colorectal adenocarcinomas. In such cases, careful examina-
tion of the gastrointestinal tract is needed to exclude an metastasis 
from an extrapulmonary primary.
For the purpose of this classification the term “lepidic” pattern means 
growth of type II pneumocytes and/or Clara cells along the surface 
of alveolar walls. In the context of mucinous adenocarcinoma with 
lepidic pattern the cell type lining the alveolar walls is the goblet cell 
with abundant apical mucin. If the term mucinous is not used, it is 
understood that the term “lepidic” refers to type II pneumocytes and/
or Clara cells.
A grading system for lung adenocarcinoma is being developed in 
parallel with this classification. At our first meeting, three patholo-
gists made presentations on grading. This highlighted that unlike 
other major cancers such as prostate, breast and ovary, there are 
no precise criteria for lung adenocarcinoma grading. It is generally 
appreciated that patients with predominantly lepidic tumors do better 
and those with predominantly solid and micropapillary tumors do 
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worse, but a grading system that incorporates all histologic types 
remains to be defined. Several projects have been performed over the 
past year and data presented at recent meetings. It is hoped that these 
will be published or in press by the time this classification document 
is completed and some recommendations can be made on this topic.
The multidisciplinary integration of this classification remains to 
be built upon the backbone of this tentative proposal. At the time of 
this writing the proposal is primarily based on pathology, although 
the oncologists, molecular biologists, radiologists and surgeons have 
participated in all major decisions. A major point of this classification 
will to emphasize that lung adenocarcinoma diagnosis and classifica-
tion should be viewed as a multidisciplinary problem. 
Table 1. Tentative proposed IASLC/ATS/ERS classification of lung 
adenocarcinoma
PREINVASIVE LESIONS
Atypical adenomatous hyperplasia
Adenocarcinoma in situ (formerly BAC)
• nonmucinous
• mucinous
MINIMALLY INVASIVE ADENOCARCINOMA  
(a lepidic predominant tumor with ≤5 mm or >10% invasion)
Table 2. Invasive Adenocarcinoma
Lepidic predominant (formerly non-mucinous BAC pattern)
Acinar predominant
Papillary predominant
Micropapillary predominant
Solid predominant
Table 3. Variants
Mucinous adenocarcinoma with lepidic pattern (formerly mucinous BAC)
Mucinous cystadenocarcinoma
Colloid
Fetal (low and high grade)
Enteric
M18.2 Adenocarcinoma: Multidisciplinary Classification, Sun, Aug 2, 10:30 - 12:00
Compartment concept for lung cancer pathogenesis
Tang, Ximing; Wistuba, Ignacio I.
UT-MD Anderson Cancer Center, Houston, TN, USA
From biological, histopathologic and clinical perspectives, lung 
cancer is a highly complex neoplasm, having multiple preneoplastic 
pathways (1). Lung cancer consists of several histological types, 
including small cell lung carcinoma (SCLC) and the non-small 
cell lung carcinoma (NSCLC) types of squamous cell carcinoma, 
adenocarcinoma (including the non-invasive type of bronchioloal-
veolar carcinoma), and large cell carcinoma. Lung cancers may arise 
from the major bronchi (central tumors) or from the small bronchi, 
bronchioles or alveoli (peripheral tumors) of the distant airway of the 
lung. Squamous cell carcinomas and SCLCs usually arise centrally, 
while adenocarcinomas and large cell carcinomas usually arise 
peripherally. The population of normal respiratory epithelial cells 
varies along different compartments of the respiratory tree, and the 
specific respiratory epithelial cell type from which each lung cancer 
type develops has not been established with certainty. The sequence 
of histopathologic changes in the bronchial mucosa that precedes the 
development of squamous carcinomas of the lung has been identi-
fied. However, for the other major forms of lung cancers they have 
been poorly documented. Although many molecular abnormalities 
have been described in clinically evident lung cancers, relatively 
little is known about the molecular events preceding the develop-
ment of lung carcinomas and the underlying molecular basis of lung 
carcinogenesis. Although several studies have provided relevant 
information regarding the molecular characterization of the premalig-
nant changes involved in the pathogenesis of lung cancer, especially 
for squamous cell carcinoma, that information has demonstrated 
to be insufficient to identify with certainty molecular pathogenetic 
pathways or molecular markers useful for risks assessment, targeted 
chemoprevention or treatment, and early detection of lung premalig-
nant lesions (2). 
In this presentation we will summarize the current information on 
lung cancer molecular and histopathologic pathogenesis and discuss 
the complexity of the identification of novel molecular mechanisms 
involved in the development of the lung premalignant disease, 
and their relevance to the development of new strategies for early 
detection and chemoprevention. During the recent years, there are 
several important lessons learnt on the molecular pathogenesis of 
lung cancer, including the following: a) there are several histopatho-
logic and molecular pathways associated to the development of the 
major types of NSCLC; b) although there is field effect phenomenon 
for lung preneoplastic lesions, recent data suggest that there are at 
least two distinct lung airways compartments (central and periph-
eral) for lung cancer pathogenesis, and “localized” field effect can 
be detected (e.g., EGFR mutations in lung adenocarcinomas) (3, 4); 
c) inflammation may play an important role in lung cancer devel-
opment and it could be an important component of the field effect 
phenomenon; and, d) for lung adenocarcinoma, at least two smok-
ing and nonsmoking-related pathways have been identified (5). The 
identification of deregulated molecular signaling pathways in lung 
respiratory field at different compartments may provide rationale for 
designing novel strategies for lung cancer early detection and tar-
geted chemoprevention (Supported by grant Department of Defense 
W81XWH-04-1-0142). 
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Expression profiling-based approaches for a better 
understanding of human lung cancer biology
Takahashi, Takashi
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Nagoya, Japan
Adenocarcinomas exhibit the highest degree of morphologic and 
clinical diversities among the various types of lung cancers, and it 
is well recognized that their current pathologic classification and 
the ability to predict postsurgical prognosis are quite inadequate. 
Although the existence of marked heterogeneity including their 
expression profiles is well appreciated, virtually all adenocarcino-
mas are currently treated similarly under the diagnosis of non-small 
cell lung cancer. Along this line, better understanding of molecular 
heterogeneities is considered to be one of the major factors that 
has significantly improved cure rates of certain types of neoplasia, 
such as hematological malignancies and breast cancer. Thus, a bet-
ter understanding of the underlying molecular mechanisms of the 
heterogeneities among lung adenocarcinomas is greatly anticipated 
to contribute to reducing the unbearably large number of deaths by 
establishing a foundation for rational individualized treatment strate-
gies as well as development of novel therapeutic methods. 
Microarray analysis has made it possible to analyze global expres-
sion profiles on a genome-wide basis in order to better understand 
molecular pathogenesis of human cancers as well as to search for 
molecular markers and targets for diagnosis and treatment, respec-
tively. The expression profile in a given tumor can be regarded as the 
outcome of complex influences resulting from accumulated genetic 
and epigenetic changes important for pathogenesis, as well as from 
the differentiation-commitment status of the progenitor cells. Our 
previous comprehensive study of lung cancer transcriptome signa-
tures allowed us to establish an expression profile-defined, highly 
robust classification of adenocarcinomas (1). Adenocarcinomas 
were consequently shown to consist of two major types based on the 
expression profiles, and we found that they corresponded well to the 
terminal respiratory unit (TRU) and non-TRU types (2). We noted 
that TRU-type adenocarcinomas exhibited characteristic high expres-
sion of TTF-1, which was occasionally accompanied with increase in 
the gene copy (3). Furthermore, we also found that TTF-1 mediates 
lineage-specific survival signals in this type of adenocarcinomas. 
Interestingly, three other groups also reached similar conclusions 
through searches for genomic regions with non-random gene-copy 
changes, while TTF-1 appeared to reside within a shortest region of 
overlap among those studies (4-6). 
Realization of individualized patient outcome prediction is another 
important and much needed application of global expression profiling 
analysis. We have identified a molecular signature, termed RRS-82, 
which allowed us to construct a highly accurate prognosis prediction 
classifier for surgically treated adenocarcinoma patients (7). Notably, 
the RRS-82-based classifier clearly distinguished patients with very 
poor prognosis from those with favorable outcome, including the 
duration of relapse-free survival, even in stage I cases. There are, 
however, criticisms stating that such models are based on grounds 
that do not provide biological insight, but it should be recognized 
that prognosis prediction classifiers including our own are not aimed 
at identifying functionally relevant gene sets or pathways. In this 
connection, we employed two independent bioinformatics approach-
es, gene set enrichment analysis and connectivity map analysis, in 
combination with biologic and biochemical experiments for valida-
tion, in order to elucidate the underlying molecular basis for the 
link of poor prognosis with particular pathways and/or functions of 
the gene sets involved (8). Consequently, deregulations of multiple 
signaling converging onto mTOR were identified as associated with 
fatal outcome. In addition, multivariate Cox regression analysis 
showed that deregulation of mTOR-converging signaling was an 
independent prognostic factor in addition to disease stage, whereas 
such statistical significance was not observed with various other 
parameters, including mutations of EGFR, K-ras, and p53, as well 
as BAC features and TRU/non-TRU classification. Also interest-
ing is that our in silico search using C-MAP analysis for drugs with 
activities that potentially revert a fatal prognosis-associated signature 
to a favorable prognosis-associated one resulted in identification of 
not only well-known inhibitors of PI3K or mTOR, but also several 
unexpected ones, such as those with antitumor activities in vitro.
Rapid proliferation of cancer cells causes an insufficient blood 
supply, which elicits a variety of environmental stresses, such as 
deprivation of growth factors, nutrients, and/or oxygen. However, 
cancer cells are thought to be capable of surviving in spite of such 
constraints, which conceivably leads to disease progression and 
ultimately confers poor prognosis in affected patients. Activation 
of the PI3K-AKT-mTOR axis plays a key role in growth factor 
receptor-mediated signaling for cancer cell growth and survival, 
while LKB1, which is inactivated in a fraction of lung adenocarcino-
mas, activates AMPK in micro-environmental conditions including 
insufficient nutrients and leads to inhibition of mTOR activity in an 
AKT-independent manner. In addition, amino acids such as leucine 
regulate mTOR signaling, which involves raptor and an ras homolog 
enriched in the brain (Rheb), and a GTPase that activates mTOR, 
each of which are directly associated with mTOR. Taken together, 
these findings suggest that adaptation to an insufficient availability of 
growth factors, glucose and amino acids may be a prerequisite for the 
progression of lung adenocarcinomas. 
In conclusion, we identified a significant association between 
deregulation of signaling converging onto mTOR and poor prog-
nosis in lung adenocarcinomas, suggesting the existence of gene 
set-definable, intrinsic heterogeneities in this devastating tumor type. 
In addition, our results lend support to the notion that compounds 
identified by in silico screening as having potential activities to alter 
signatures associated with relapse and death to favorable ones can 
be anticipated to show antitumor activities and inhibitory effects on 
pathways converging onto mTOR. 
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In situ status, invasion, and extension as 
prognostic factors in adenocarcinoma
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In the histological classification of adenocarcinoma, bronchioloal-
veolar carcinoma (BAC) showing lepidic growth is considered 
to represent a very early stage (in situ adenocarcinoma). Atypical 
adenomatous hyperplasia (AAH) is preinvasive lesion of adenocar-
cinoma. Therefore, both BAC and AAH are thought to represent the 
very early stages of adenocarcinoma. In 1995, my group showed 
that small lung adenocarcinomas (2 cm in diameter or less) could be 
divided into two major groups, each of which was further subdivis-
ible into three types (the so-called Noguchi classification) (Cancer 
1995;75:2844). One of these two major groups is the lepidic growth 
type that shows replacement growth along the pre-existing alveolar 
framework. The other is the non-lepidic growth type, which shows 
destruction of the original alveolar framework. The three subtypes 
in the former group include localized bronchioloalveolar carcinoma 
(LBAC) without active fibroblastic proliferation (types A and B) and 
LBAC with active fibroblastic proliferation (type C). These three 
replacement-type adenocarcinoma entities show more favorable 
prognosis than non-replacement-type adenocarcinomas, which are 
subdivided into solid adenocarcinoma (type D), tubular adenocarci-
noma (type E) and papillary adenocarcinoma (type F). In fact, type A 
and B tumors are associated with a 100% 5-year survival rate, indi-
cating that they are indeed in situ adenocarcinomas. Subsequently, 
many histological criteria that define in situ adenocarcinoma or early 
invasive adenocarcinoma have been reported. For example, Suzuki 
et al. examined the size of central fibrosis in adenocarcinomas and 
showed that those having an area of fibrosis 5 mm or smaller in 
maximum dimension were associated with a 5-year survival rate of 
100% (Ann Thorac Surg 2000;69:893). They concluded that the size 
of central fibrosis is an independent prognostic factor in peripheral 
lung adenocarcinoma, and that a fibrotic area measuring 5 mm or 
less indicates in situ or minimally invasive carcinoma. On the other 
hand, Sakurai et al. classified the degree of invasive growth accord-
ing to structural deformity and its location in Grade 0 to Grade 4 
adenocarcinomas (Am J Surg Pathol 2004;28:198). They concluded 
that tumors with grade 1 and 2 invasion, like tumors with grade 0 
invasion (bronchioloalveolar carcinoma), had an excellent prognosis, 
and therefore could be considered “minimally invasive” or “early” 
adenocarcinomas. 
On the other hand, in order to define in situ adenocarcinoma or early 
invasive adenocarcinoma immunohistochemically, many factors 
that can be predictive of patient survival have been reported for lung 
cancer. However, no comparative studies have attempted to deter-
mine those that are most significant for practical medicine. My group 
conducted a retrospective review of 139 patients who underwent 
complete resection of adenocarcinomas less than 2 cm in diameter 
between 1993 and 2000 at the National Cancer Center Hospital 
(Tokyo, Japan). The MIB-1 labeling index (LI), immunohistochemi-
cal staining for CEA, p53, p27, EGFR, phosphorylated EGFR 
(pEGFR), Cox-2, neuronatin, gH2AX, and TTF-1, the prevalence of 
a micropapillary pattern and the ratio of the bronchioloalveolar cell 
carcinoma (BAC) or lepidic growth (LG) component were deter-
mined, and their significance as prognostic factors for lung adenocar-
cinoma was compared. Kaplan-Meier analysis indicated that patients 
who had a BAC/LG ratio of >50% had a significantly more favor-
able outcome than the others (p<0.001). On the other hand, patients 
who were positive for pEGFR and CEA, and had a high MIB-1 LI, 
showed significantly worse survival rates than those who were nega-
tive for those factors, respectively (pEGFR: p=0.018, MIB-1 index: 
p=0.019, CEA: p=0.044). None of the other factors was correlated 
with prognosis. As various reports have indicated that pure BAC/
LG has an extremely favorable prognosis whereas adenocarcinoma 
without BAC/LG (solid, acinar, and papillary) has an unfavorable 
prognosis, we focused on the 70 patients who had adenocarcinoma 
mixed subtypes with a BAC/LG component (type C). Kaplan-Meier 
analysis indicated that patients with a BAC/LG ratio of >50% and 
positivity for TTF-1 had a markedly more favorable outcome than 
the others. None of the other factors was correlated with prognosis. 
On the other hand, univariate analysis showed that lymph node 
metastasis (p-N status), BAC/LG component, vascular invasion (p-V 
status), MIB-1 LI, pEGFR and CEA were prognostically significant 
(p-N status: p<0.0001, BAC/LG: p=0.0005, p-V status: 0.002, MIB-1 
LI: p=0.005, pEGFR: p=0.024, CEA: p=0.049). Multivariate analysis 
showed that only p-N status (p= 0.013) was of prognostic signifi-
cance. However, BAC/LG component (p=0.051) was a more reliably 
prognostic factor than p-N status in mixed adenocarcinoma with a 
BAC/LG component (Table 1). In comparison with other immuno-
histochemical and histopathological factors, BAC/LG component is 
independently and reliably prognostic for small adenocarcinomas of 
the lung, and particularly for the major histologic subtype (adeno-
carcinoma mixed subtype with BAC/LG), BAC/LG component is 
more reliably prognostic than lymph node metastasis. This analysis 
indicated that although various immunohistochemical markers are 
potentially useful for estimating the malignancy of adenocarcinoma, 
none have yet been shown to be of value for diagnosis of in situ or 
microinvasive adenocarcinoma.
Table 1
Parameter  Hazard Ratio (95% CI) P-value
BAC/LG ≥ 50% 4.084 (0.992-16.813) 0.051
p-N status 0.513 (0.193-1.362) 0.180
Gender 0.662 (0.276-1.589) 0.356
Age ≥ 60 1.283 (0.276-1.589) 0.584
p-V status 1.037 (0.312-3.451) 0.953
Many investigators have tried to derive criteria for defining in situ 
adenocarcinoma or minimally invasive adenocarcinoma based 
purely on histology and/or immunohistochemistry. On the other 
hand, in the current World Health Organization Classification of 
Tumors, the prognostic value of morphometrically assessed cyto-
logic atypia has not been verified for pulmonary adenocarcinoma. 
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Nuclear morphometry is a method for quantitative measurement 
of histopathologic changes in the appearance of stained cell nuclei. 
Some studies have indicated that these assessments may provide 
clinically relevant information related to the degree of progression 
and malignant potential of various cancers, such as breast carcinoma, 
urinary bladder carcinoma, and renal cell carcinoma. For example, 
after Zajdela et al. reported the relationship between the morpho-
logical characteristics and outcome of mammary cancer based on 
a study of cytological materials, several studies demonstrated the 
prognostic value of nuclear morphometry in cases of invasive ductal 
carcinoma of the breast. Thereafter, nuclear morphology began to be 
applied for histological grading of invasive breast carcinoma in the 
World Health Organization Classification. The WHO recommends 
that nuclear grade should be included in the surgical report for each 
case of invasive ducal carcinoma of the breast. Focusing on nuclear 
morphometry, my group attempted to use it for extracting cases of 
minimally invasive adenocarcinoma of the lung. One hundred and 
thirty-three pulmonary adenocarcinomas 2 cm or less in diameter 
were analyzed for the following nuclear size features using an 
image processor designed for analytical pathology: area, major axis 
diameter. The results were then evaluated using receiver operator 
characteristic (ROC) analysis, and survival curves were obtained 
by the Kaplan-Meier method. On the basis of nuclear area (NA) 
and nuclear major axis diameter (ND), lung adenocarcinomas were 
separable into two groups showing an extremely favorable prognosis 
and a fairly favorable prognosis without having to consider histologi-
cal features or classification. The ROC curve analysis showed that 
a cut-off NA level of 67μm2 had a sensitivity and specificity of 75% 
and 70% for separating the two groups. A ND level of 10.7μm had a 
sensitivity and specificity of 75% and 65% for separating them, and 
a NA level of 67 μm2 or higher was correlated with shorter survival 
(p<0.0001). The 5-year survival rate was 90.4% (Figure 1a). Simi-
larly, a ND level of 10.7μm or higher was correlated with shorter 
survival (p=0.0002), and the 5-year survival rate was 88.6% (Figure 
1b). Thus, nuclear area and nuclear major diameter are two useful 
markers indicating a favorable prognosis of lung adenocarcinoma, 
and can be applied to select minimally invasive adenocarcinomas 
without histological findings. Nuclear markers and histological mark-
ers are independent, and the former are useful prognostic factors for 
evaluating the biological characteristics of lung adenocarcinomas. 
Histologically and cytologically, a lepidic growth pattern and nuclear 
markers (nuclear area and size) are the most important factors for 
estimating the malignancy of peripheral-type adenocarcinoma of 
the lung, and are useful for classification of in situ and/or minimally 
invasive adenocarcinoma. 
Figure 1a
 
Figure 1b
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Bringing quality of life assessment into the 
mainstream of lung cancer management
Theodore, Pierre R.
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USA
Quality of life measurement in all domains of critical illness has been 
controversial.
Clinically useful metrics of the adequacy of life do have bearing on 
interventions proposed, medical therapies delivered and the response 
to complications following treatment. Thus a thorough and honest 
apraisal of the known literature regarding QOL metrics is crticical to 
guide decision making in lung cancer involving often elderly patients 
with significant comorbidity. Treatment in the elderly may differ 
quite significantly versus that of younger patients due to perceived 
treatment related morbidty and mortality. In addition some gender 
disparities have been identified in QOL assesment after therapies for 
lung cancer. However it is important that customized treatment strat-
egies be based on data confirmatory of risk/benfit analyses performed 
in clinical reasoning. The most common form of analysis of QOL 
involves self-reporting of metrics of physiological and emotional 
well being. Since qulaity of life is inherently determined by the 
patient and family, objective metrics of QOL outcomes may fail to 
properly represent response to therapy.
Recently applied measures of assesment of outcome such as the 
Functional Assessment of Cancer Therapy-Lung (FACT-L) and the 
Functional Living Index-Cancer (FLIC) will be discussed. The use 
of current day validated qulaity of life measures will be compared to 
older versions in terms of overall influence on pre treatment decision 
strategy. Bearing in mind the broad spectrum of stages of disease and 
comorbidities facing the lung cancer clinician, consensus opinion 
regarding integrating quality of life metrics with decision making 
algorithms will be sought.
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Lung cancer advocacy – the European approach
Fox, Jesme W.
The Roy Castle Lung Cancer Foundation, Glasgow, UK
Cancer Patient Advocacy
There are many areas in which cancer patient advocates can impact 
on patient care and outcomes of treatment. They can ensure an 
increase in research funding, speed access to novel drugs, lobby for 
equal access to treatment, challenge discrimination and enhance 
recruitment into clinical trials. There are a number of “tools by which 
advocates can effect such change:
• Strategic use of mass media, by mobilising large numbers of “like 
minded” patients and high profile celebrities
• By raising public awareness on disease issues, through public 
meetings and petitions, through position statements, advertising 
and mass leafleting. 
• Political lobbying, arranging meetings, letter and on-line type 
campaigns
• By providing a uniquely informed “patient” perspective by mem-
bership on key policy making committees and presentation at key 
meetings 
Patient advocates in the US (in particular, in Breast Cancer and HIV/
AIDS) have many years of experience in showing that this “patient 
power” can make a real difference. In Europe we have many differ-
ent issues, but, have learned much from the experience of our US 
advocacy colleagues. 
Issues in Lung Cancer 
Lung cancer, though globally the commonest cause of cancer death, 
has many negative associations, which makes it devastating for those 
affected by it. 
• Poor outcomes of treatment 
Only around 1 in 10 patients diagnosed with lung cancer will 
survive ten years. There are few long term survivors. In the UK of 
the estimated 2 million people living with cancer, only 60,000 are 
lung cancer survivors. 
• Majority diagnosed when disease too advanced for  
curative treatment 
The multiple and non-specific nature of many of the symptoms 
associated with this disease, make it difficult for patients to spot 
(1). General public awareness of this disease is poor. 
• Multiple symptoms, often difficult to control 
Many lung cancer patients, being smokers or ex-smokers, often 
have problems with other medical conditions. These may make 
anti-cancer treatment difficult. Also, those diagnosed with this 
disease commonly have multiple symptoms, Symptoms such as 
breathlessness, weight loss and fatigue are often difficult to man-
age. They are often not well enough to advocate on behalf of the 
disease. 
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• Lung cancer is stigmatised by its association with tobacco.  
Patients are often blamed for having inflicted the disease upon 
themselves. A MORI Poll of over 2000 people in the UK showed 
that 7 out of 10 people felt that people with lung cancer had 
brought the disease on themselves and only three-quarters of those 
surveyed said that patients with lung cancer had as much right to a 
hospital bed as those who develop other forms of cancer (2). The 
stigma caused by a tobacco-related disease can create hardship 
for patients, many of whom suffer in silence, remain isolated and 
experience a sense of hopelessness and helplessness about their 
condition (3). Such feelings are compounded by personal guilt 
for having smoked and demoralization, resulting from the lack of 
public support and empathy towards their plight. 
• There are few lung cancer “voices” 
Globally, there are few lung cancer patient organizations and 
few celebrity supporters, despite some high profile celebrities 
dying of the disease. Unfortunately, few lung cancer patients are 
well enough, or survive long enough, to create a “voice” for this 
disease. 
• Little media interest in lung cancer 
The media has contributed significantly to the fatalistic attitudes 
members of the public hold about lung cancer and has helped to 
fuel misconceptions about the disease. 
Cancer Patient Advocacy in Europe 
Historically cancer patient organisations in Europe have been con-
cerned mainly with initiatives in patient information and support. 
The picture is very variable, but until recently, relatively few were 
involved in campaigning or lobbying for changes in service provi-
sion, either locally or nationally. This remains the case, particularly 
in Central and Eastern European countries. There are many reasons 
for this – lack of resources, cultural taboos, and complicated politi-
cal systems. However, with increasing awareness of inequalities in 
access to treatment, dissatisfaction with cancer services and a grow-
ing number of cancer survivors, things are changing. 
At a pan–European level, we have three established cancer patient 
coalitions – Europa Donna (breast cancer), Europa Uomo (prostate 
cancer) and the European Cancer Patient Coalition (ECPC). Estab-
lishing such coalitions is a massive challenge. Language is a major 
barrier. Major differences in healthcare systems, political systems 
and expectations make the creation of coalition policy on key issues 
extremely difficult. 
ECPC was launched in September 2003 and currently has more than 
250 members from all EU countries. Its members are all national 
cancer patient organisations – many are pan-cancer charities, with 
only 5 lung cancer specific members. Over the past 5 years it has 
established itself by networking and sharing good practice between 
its members, by developing a presence in the EU policy arena and 
by living up to its slogan, “Nothing about us, without us” – ensuring 
involvement in patient seminars at many meetings.
In Europe, as with the rest of the world, there are few lung cancer 
specific, advocacy organisations. There are many reasons for this, not 
least the short survival of potential advocates, the lack of celebrity 
and media interest and the relatively small amount of public aware-
ness campaigning for this disease.
Patients are starting to Fight Back 
Emergence of a Lung Cancer Patient Advocacy movement – lung 
cancer patients and advocates are coming together to campaign on 
key issues, in a number of countries. Examples are the Lung Cancer 
Patient’s Charter and the Report Card initiatives of the Roy Castle 
Lung Cancer Foundation in the UK – The Report Card (6) is a 
publication of key criteria, on which the UK governments will be 
benchmarked in the coming years. It mirrors a similar initiative from 
the National Lung Cancer Alliance in the US. 
In an attempt to create a more global “voice” for lung cancer 
patients, the Global Lung Cancer Coalition came into being in 2001. 
In the same year, November was designated “Global Lung Cancer 
Awareness Month”. Though national campaigns have been small, 
compared with other common disease areas, GLCC members are 
making a start. An example of this is the general public and media 
campaign, organized in the UK by the Roy Castle Lung Cancer 
Foundation and Macmillan Cancer Support (5). The GLCC now has 
23 members from 16 countries.
Ultimately, patient advocates and professionals share many com-
mon goals. Elsewhere, we have seen patient groups working with 
researchers and clinicians, to massively impact the care agenda. Why 
not in lung cancer? 
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M20.4 Advocacy and Survivorship in Lung Cancer, Sun, Aug 2, 10:30 - 12:00
Bonnie J. Addario Lung Cancer 
Foundation: bridging to the future
Addario, Bonnie
Bonnie J. Addario Lung Cancer Foundation.USA
Lung Cancer kills over 450 people a day in the United States alone. 
1.3 million annually worldwide. Sixty percent of those diagnosed 
with Lung Cancer are former or never smokers. Lung Cancer kills 
more people than breast, prostate, colon, liver, melanoma, and kidney 
cancers combined. Lung Cancer surpassed breast cancer as the #1 
cancer killer of women in 1987. That was 22 years ago. The Bonnie 
J. Addario Lung Cancer Foundation (BJALCF) exists to eradicate 
Lung Cancer with our patients, survivors, and their families through 
research, early detection, awareness, education, prevention, and 
treatment. The Addario Lung Cancer Medical Institute (ALCMI) is 
dedicated to catalyzing and accelerating the discovery, development 
and deliver of new and more effective treatment options for Lung 
Cancer patients.
Together, both foundations are bridging to the future.
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M20.5 Advocacy and Survivorship in Lung Cancer, Sun, Aug 2, 10:30 - 12:00
Advocacy and survivorship in lung cancer: the role of 
media in increasing the awareness of lung cancer 
Seng, John J.
Spectrum, Washington, DC, USA
Presentation Overview: In his presentation titled “The Role of Media 
in Increasing the Awareness of Lung Cancer John J. Seng will exam-
ine the public’s perception and knowledge of lung cancer and how 
the media has impacted this view over the years. Forty-five years ago 
people began talking about the negative effects of tobacco use. While 
scientific evidence points toward its contribution to lung cancer, the 
media’s coverage of the disease has added to the stigma the disease 
currently carries. Now, as the media is continuously changing and 
moving to digital forums, bloggers, online journalists and tradi-
tional media have the opportunity to educate the public about the 
people suffering from lung cancer and the disease’s true severity and 
prevalence. 
Session M21: Implementing Radiation and Systemic 
 Therapy for Stage III Non-Small Cell Lung Cancers 
Sunday, August 2
M21.2 Implementing Radiation and Systemic Therapy for Stage III  
 Non-Small Cell Lung Cancers, Sun, Aug 2, 10:30 - 12:00
Radiation dose and volume considerations 
in combined modality therapy
Gaspar, Laurie E.
University of Colorado Denver, Aurora, CO, USA
Combined modality therapy for both locally advanced non-small cell 
lung cancer (NSCLC) limited small cell lung cancer (LSCLC) has 
lead to improvements in local control and survival. However, there is 
controversy regarding the appropriate dose and volume of radiation 
therapy in order to maximize the therapeutic ratio. The objectives of 
this talk are to (1) discuss the rationale for increasing radiation dose 
intensity, (2) review ongoing studies that address radiation dose/vol-
ume, and (3) discuss potential ways to improve the benefits and risks 
associated with combined modality therapy.
M21.3 Implementing Radiation and Systemic Therapy for Stage III  
 Non-Small Cell Lung Cancers, Sun, Aug 2, 10:30 - 12:00
When is concurrent CT-RT not the treatment 
of choice in inoperable Stage III disease?
MacBeth, Fergus Robert1; O’Rourke, Noelle2
1 National Institute for Health and Clinical Excellence, London, UK;  
2 Beatson Oncology Centre, Glasgow, UK
The short and heretical answer to this question is ‘Always’. In our 
view there is no good evidence to support the widely held belief that 
the ‘standard of care’ for patients with Stage III non small cell lung 
cancer (NSCLC) is concurrent chemotherapy and radical radiothera-
py (CT-RT).
First, many patients will be too unwell or have too many co-morbid-
ities to consider either chemotherapy or radical radiotherapy alone, 
let alone given concurrently. The study by de Ruysscher et al showed 
that 59% of patients in a population-based study were considered 
ineligible for concurrent CT-RT either because aged over 75 or 
because of significant co-morbidity. 
Secondly there will be many patients whose known disease in the 
lung and mediastinum will be too bulky to include in a sensible and 
safe volume for radical radiotherapy. Stage III is a category that 
can embrace patients with a small (less than 5cm diameter) primary 
tumour and mediastinal lymph nodes discovered on PET scan and/ 
or mediastinsocopy, as well as those with a large primary tumour 
and bulky bilateral mediastinal lymphadenopathy. The total volume 
which is considered to be the upper limit of what is ‘suitable’ for 
radical radiotherapy depends on many factors: technical planning 
considerations, lung function, spinal cord dose as well as the less 
definable, personal belief in what is potentially beneficial and what 
may be futile. The enthusiasts may happily treat a tumour volume 
of 2L, especially with IMRT, while the cautious may settle for a 
maximum of 0.5L.
So, if the patient is fit enough to receive platinum-based chemo-
therapy and the tumour volume is thought appropriate for radical RT. 
What evidence is there to help us decide what is the most effective 
approach?
The 1995 NSCLC meta-analysis showed that giving adjuvant plati-
num-based chemotherapy after radical RT increased 2 year survival 
by 4%. An individual patient data meta-analysis published in 2006 
showed an identical improvement in 2 year survival for concurrent 
CT-RT compared to RT alone.
A Cochrane review confirmed the benefit of concurrent CT-RT 
compared to RT alone. It also looked at sequential (chemotherapy 
first) CT-RT compared to concurrent CT-RT. Only 3 eligible RCTs 
were found, all only in abstract and came to cautious conclusions. 
An update of this review will be presented at the conference but, in 
essence, there are now 6 eligible RCTs which confirm that concur-
rent CT-RT is more effective than giving chemotherapy first. This is 
not surprising for a variety of clinical and biological reasons and it 
could be that giving chemotherapy first is actually detrimental. But 
this survival benefit (ranging from 0% at 3 years to 8% at 4 years) is 
at the expense of considerably more toxicity, especially oesophagitis 
and a doubling of risk of treatment related death.
So how does concurrent CT-RT, compare with radical RT followed 
by adjuvant CT? We do not know, because the trials have not been 
done. But given that evidence from two large meta-analyses based 
on individual patient data shows that the benefit of each compared 
to radical RT alone is of the same order, it seems unlikely that there 
would be a major and clinically relevant difference.
On current evidence accelerated, hyperfractionated RT (CHART) 
appears to give greater survival benefit (9% at 2 years) compared 
to RT alone, than concurrent chemoRT does. So the most effective 
(and probably cost-effective) way of treating patients fit enough to 
receive both radical RT and chemotherapy may be CHART followed 
by adjuvant chemotherapy. Concurrent CT-RT should not be the 
‘standard of care’.
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M21.4 Implementing Radiation and Systemic Therapy for Stage III  
 Non-Small Cell Lung Cancers, Sun, Aug 2, 10:30 - 12:00
Integrating Novel Targeted Therapy to 
Concurrent Chemoradiotherapy in Lung 
Cancers – What Agents and What Setting?
Le, Quynh-Thu
Stanford University, Stanford, CA, USA
Lung cancer is the leading cause of cancer-related death in the west-
ern world. Standard treatment for locally advanced non-small cell 
lung cancer (NSCLC), namely stage III tumors, is concurrent chemo-
radiotherapy (CRT). In a small subset of patients with low-volume 
mediastinal nodal disease, the addition of surgery may improve 
local control and disease free survival. Despite recent advances in 
chemotherapeutic development, improvement in radiation delivery 
approaches and modern surgical techniques, the long-term survival 
of patients with locally advanced NSCLC remains poor. The addition 
of induction or consolidation chemotherapy to a backbone of CRT 
has not resulted in improved survival; therefore, there is a strong 
interest in integrating biologic or targeted therapy with CRT in these 
patients. 
The two classes of targeted drugs that have been tested in pilot trials 
with concurrent CRT in stage III NSCLC are anti-EGFR and anti-
angiogenic agents because these have been shown to have promising 
activities in the advanced/metastatic setting. SWOG 0023 was the 
first randomized trial that evaluated a targeted therapy, gefitinib, in 
patients with stage III tumors. In this study, patients who did not 
progress after CRT and consolidation docetaxel, was randomized to 
either maintenance gefitinib or placebo. The study showed unex-
pected inferior survival for the gefitinib arm and the reason for the 
worse survival with the targeted drug remains unclear at this point.
(1) In contrast, RTOG 0324, which was a phase II study evaluat-
ing cetuximab in combination with CRT in patients with stage III 
NSCLC, reported a highly promising median survival of 23 months 
and a 2 year overall survival of 49%.(2) These survival outcomes far 
exceeded any previously reported results by the RTOG, prompting 
an on-going phase III trial, comparing CRT with high dose thoracic 
radiation (TRT) to the same regimen plus cetuximab. The Cancer 
and Leukemia Group B (CALGB) conducted a randomized phase II 
trial (CALGB 30407), comparing CRT with pemetrexate/carboplatin 
and high dose TRT (70 Gy) with the same regimen plus cetuximab. 
All patients received consolidation pemetrexate chemotherapy. A 
preliminary report showed that the addition of cetuximab to this 
regimen is feasible and fairly well tolerated.(3) SWOG is also testing 
the addition of cetuximab to TRT and weekly docetaxel in poor-risk 
stage III patients.(4) Due to concern of pulmonary hemorrhage and 
fistula development with anti-angiogenic agents, there are fewer 
trials evaluating them with CRT. SWOG-S-0533 is a pilot phase I/II 
feasibility study, which tests CRT with or without bevacizumab, fol-
lowed by consolidation docetaxel plus bevacizumab in patients with 
unresectable stage III tumors.(4) Data is not yet available regarding 
the regimen toxicity profile.
Emerging laboratory evidence indicates that inhibiting a single aber-
rant pathway may not be sufficient for tumor control in NSCLC due 
to their efficiency in compensating for such inhibition, and targeting 
a combination of pathways may be necessary to improve the cure 
rate. This leads to a strong interest in combining both the EGFR and 
the VEGF targeting agents together with standard therapy. Socinski 
et al reported on a pilot study, in which patients were treated with 
induction carboplatin, paclitaxel and bevacizumab followed by 
weekly carboplatin, paclitaxel, high dose thoracic RT (74 Gy) plus 
bevacizumab and dose escalating erlotinib. Phase I data showed that 
incorporating both targeted agents into a backbone of CRT is feasible 
with the maximal tolerated dose of 100 mg/day for erlotinib and that 
esophagitis is main primary acute toxicity for this regimen.(5) A 
phase II trial testing its efficacy is on going.
As new data emerge regarding the feasibility and the toxicity of 
incorporating targeted agents to CRT in NSCLC, several questions 
remain to be addressed. What is the optimal radiation dose and 
delivery approach to be tested with targeted agents? What is the best 
sequence of integrating these agents with CRT? What are the best 
agents or combination of agents to use? What is the best chemo-
therapy regimen and schedule to use with these agents? What is the 
late toxicity profile that may arise from these treatments? And more 
importantly, which patient group would most benefit from such an 
aggressive treatment and how do we select for these patients? Hope-
fully some of these questions will be addressed by ongoing clinical 
trials and their companion translational research. Realization of these 
aims can be best accomplished via clinical trials that incorporate 
serial novel, non-invasive surrogate endpoints such as molecular 
makers or imaging methods. As oncologists, our responsibility is 
to develop and support such trials in order to improve efficacy and 
reduce toxicity in our patients. 
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M22.1 Open Challenges in the Management of Advanced NSCLC, Sun, Aug 2, 16:30 - 18:00
Mechanisms of drug resistance with cytotoxics
Taron, Miquel1, 2; Benlloch, Susana2; Chaib, Imane1; Mendez, Pedro1; 
Rosell, Rafael1, 2
1 Medical Oncology Service-Catalan Institute of Oncology, Hospital 
Germans Trias i Pujol, Badalona, Spain; 2 Medical Oncology 
Service, USP University Institute Dexeus, Barcelona, Spain
In the last few years, we have witnessed many changes in the biology 
and treatment of lung cancer. It is clear that two different diseases 
scenarios can be drawn in non-small cell lung cancer (NSCLC): 
those patients with EGFR mutations, that confer sensitivity to tirosin-
kinase inhibitors (TKIs); and those patients without EGFR muta-
tions. Although patients carrying the sensitive mutations in EGFR 
gene have shown dramatic responses to TKIs, the frequency of these 
mutations accounts for 10% of the total NSCLC population. This 
means that there are still many patients with advanced NSCLC for 
whom chemotherapy is the first choice for treatment. The challenge 
now is how to treat these patients. Although individualized treatment 
involves patient care and multidisciplinary collaboration at multiple 
levels, molecular biology has evolved into the most promising tool 
for chemotherapy selection. 
One of the most important questions in cancer is why some patients 
with apparently similar tumors respond and others progress to stan-
dard chemotherapy/radiotherapy and targeted therapies. In spite of 
a plethora of knowledge at the research level, in daily practice, the 
physician is still challenged by the lack of both prognostic markers to 
identify patients with a high risk of relapse, and predictive markers 
for customizing chemotherapy and targeted therapy. 
High levels of ERCC1 and RRM1 mRNA expression (Lord et al 
2002, Taron et al 2004, Boukovinas et al 2008) analyzed by real 
time quantitative PCR are shown to be involved in chemotherapy 
resistance to cisplatin-based and gemcitabine-based chemotherapy 
treatment. In our experience, BRCA1 and Rap80 expression levels 
can be a strong signature with which to select chemotherapy. These 
two genes are involved in DNA repair, mainly via the homologous 
recombination repair pathway (Wang et al 2007, Sobhian et al 2007, 
Kim et al 2007, Yan et al 2007). The assessment of BRCA1 and 
RAP80 mRNA expression levels could become a predictive marker 
for customizing chemotherapy, based on the differential modulat-
ing effect of BRCA1 on platinums and antimicrotubule drugs: 
low BRCA1 expression levels have shown to confer sensitivity to 
platinum compounds and resistance to antimicrotubule agents, and 
vice versa. In the Spanish Lung Cancer Group (SLCG) prospective 
customized study (Rosell et al 2009) based on the baseline analysis 
of BRCA1 mRNA expression in advanced NSCLC (non-squamous 
histology), a record time to progression of 14 months was observed 
in the subgroup of patients expressing low levels of both BRCA1 and 
RAP80 mRNA (lowest tercile). The length of this time to progression 
is three times that attained in trials with docetaxel plus cisplatin (Fos-
ella et al 2003), with pemetrexed (a potent inhibitor of thymidylate 
synthase) plus cisplatin (Scaglioti et al, JCO 2008), or with custom-
ized docetaxel plus cisplatin, based on ERCC1 mRNA levels (Cobo 
et al 2007). 
The BRCA1 Expression Customization (BREC) trial is an inter-
national phase III trial of customized chemotherapy for NSCLC, 
sponsored by the SLCG. Patients are randomized to a control arm 
(docetaxel/cisplatin) or to a genotypic arm, where patients with the 
lowest levels of RAP80, regardless of BRCA1 levels, receive gem-
citabine plus cisplatin. Patients with intermediate or high levels of 
RAP80 receive docetaxel plus cisplatin or, when BRCA1 levels are 
high, docetaxel alone. 
BRCA1 and Rap80 mRNA expression levels are assessed in a central 
laboratory (Medical Oncology Service-ICO, Hospital Germans Trias 
i Pujol, Spain) in paraffin-embedded tumour biopsies. Expression 
level data from both genes, analyzed by real time quantitative PCR, 
are provided to physicians within one week. This is a crucial point to 
bear in mind when designing clinical trials based on genetic analysis 
in advanced NSCLC patients. The time span from patient enrolment 
to treatment obviously cannot exceed 1–2 weeks, thus a reproducible 
and easy-to-use technique and platform is crucial.
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M22.2 Open Challenges in the Management of Advanced NSCLC, Sun, Aug 2, 16:30 - 18:00
Maintenance therapy with cytotoxics
Kelly, Karen
The University of Kansas Medical Center, Kansas City, Kansas, USA
Evidence-based medicine supports the use of 4-6 cycles of chemo-
therapy as the standard of care for patients with advanced non-small 
cell lung cancer. Previous evaluation of longer durations of treatment 
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has not yielded a survival benefit. As new active agents with toler-
able toxicity profiles have emerged, reinvestigation of additional 
treatment beyond 4-6 cycles was launched. Of particular interest is 
the evaluation of two cytotoxic agents approved for the second line 
treatment of NSCLC: docetaxel and pemetrexed. Their proven record 
in this setting suggests they could be active earlier in the disease 
process to slow subclinical disease progression and/or maintain non-
progressing disease.
Docetaxel
Fidas and colleagues conducted a phase III trial to determine the effi-
cacy of administering docetaxel immediately after standard frontline 
treatment with gemcitabine and carboplatin versus administering 
docetaxel in the traditional setting of disease progression (Fidas PM 
et al J Clin Oncol 27:591-598, 2009). A total of 309 non-progressing 
patients were randomized to immediate or delayed docetaxel. Doc-
etaxel was administered at 75 mg/m2 for a maximum of 6 cycles. 
Overall survival (OS) was the primary endpoint. Median OS was 
12.3 months for immediate docetaxel and 9.7 months for delayed 
docetaxel (P=.0853). Median progression free survival (PFS) favored 
the immediate arm at 5.7 months versus 2.7 months (P=.0001). 
Toxicity profiles were similar in the docetaxel arms except there was 
a higher rate of grade 3 and 4 diarrhea in the delayed docetaxel arm. 
Quality of life (QOL) data was similar between the arms. Of concern 
was the imbalance in the number of patients actually receiving treat-
ment with only 63% of patients on the delayed arm receiving at least 
one cycle of docetaxel versus 95% in the immediate docetaxel arm. 
Furthermore, patients who received docetaxel in both arms had an 
identical median survival of 12.5 months.
Pemetrexed
A larger randomized phase III trial was conducted with pemetrexed. 
In this trial, 663 patients who had completed four cycles of a plati-
num-based doublet were randomized in a 2:1 manner to pemetrexed 
500 mg/m2 or placebo until disease progression (Belani CP, et al. J 
Clin Oncol 27:806s, 2009). The trial meet its primary endpoint of 
a prolonged PFS with a hazard ratio (HR) of 0.60 (CI: 0.49-0.73; 
P<0.00001). Overall, survival was also significantly prolonged with a 
HR of .79 (CI: 0.65-0.95; P=0.012). Efficacy by histology showed a 
significant PFS and OS for pemetrexed in patients with tumors bear-
ing non-squamous histology and no benefit for patients with tumors 
of squamous histology. Pemetrexed was well tolerated. Grade 3 or 
greater adverse events were infrequent however more patients on the 
pemetrexed arm developed neutropenia (3% versus 0, P<.05) and 
fatigue (5% versus 1%, P<.05). A concern of this study is that only 
19% of patients in the placebo arm received pemetrexed at the time 
of disease progression. Overall 67% of patients in the placebo arm 
received post study treatment. 
The limited number of patients receiving active second line therapy 
in both of these studies suggests that the favorable survival benefit 
with immediate therapy may be misleading and due to the poorer 
than expected survival result in the control arm due to the lack of 
treatment in one third of the patients. Further support for this pos-
sibility is the identical survival times in the patients who received 
docetaxel. 
Meta-analysis of the Duration of Chemotherapy
To gain a comprehensive perspective on the role of additional upfront 
treatment, Soon et al recently published a meta-analysis of random-
ized trials evaluating treatment beyond the standard 4-6 cycles (Soon 
YY, et al. J Clin Oncol 27:epublished 5/2009). Three trial designs 
were included: 1) trials comparing a defined number of cycles versus 
the continuation of the identical chemotherapy until progressive dis-
ease, 2) a set number of cycles versus a larger set number of cycles, 
and 3) a defined number of cycles in both arms versus continuation 
in one arm with an alternative regimen. Thirteen trials were selected 
involving 3027 patients. Not surprisingly, extended chemotherapy 
substantially improved PFS with a HR of 0.75 (CI: 0.69-0.81; 
P<.00001) but overall survival was only modestly improved with a 
HR of .92 (CI: 0.86-0.99; P=.03). The significant overall survival 
benefit was due to the inclusion of the recent pemetrexed versus 
placebo trial. A subset analysis revealed that the effect on PFS was 
greater with third generation regimens (P=.003). Toxicity and QOL 
was not statistically analyzed due to marked differences in reporting 
but was judged to be more frequent in the extended treatment arms 
and QOL declined in two of seven trials. 
Future Directions
Two randomized trials building on the pemetrexed data are planned. 
ECOG 5508 will enroll 1236 patients to receive paclitaxel, carbopla-
tin and bevacizumab. Eight hundred sixty four (864) non-progressors 
will be randomized to one of three maintenance arms: bevacizumab, 
pemetrexed or the combination of bevacizumab plus pemetrexed. 
The Pointbreak Study will randomize 900 patients to pemetrexed, 
carboplatin and bevacizumab followed by bevacizumab versus the 
same treatment followed by bevacizumab plus pemetrexed. Overall 
survival is the primary endpoint. This trial will also provide insight 
into whether pemetrexed maintenance therapy after upfront pem-
etrexed is valuable. One hypothesis for the favorable outcome with 
docetaxel and pemetrexed is the early use of a non-cross resistant 
agent.
Summary
Maintenance chemotherapy with pemetrexed is a reasonable option 
for patients with nonsquamous tumors following a standard plati-
num-based doublet. The decision to administer pemetrexed early 
or wait until tumor progression is controversial. Currently there are 
no clinical or molecular predictors that can guide treatment selec-
tion. Physicians must carefully discuss the risks and benefits of each 
option with their patients to determine the right care for the right 
patient at the right time. 
M22.3 Open Challenges in the Management of Advanced NSCLC, Sun, Aug 2, 16:30 - 18:00
Maintenance with EGFR agents
Jassem, Jacek
Medical University of Gdansk, Gdansk, Poland
Lung cancer is the leading cause of cancer-related death worldwide. 
More than 80% of lung cancers are of non-small-cell (NSCLC) his-
tology. Most NSCLC patients have advanced disease at presentation 
or will relapse after primary local therapy. Despite the introduction 
of platinum-based combination chemotherapy with third generation 
cytotoxic agents, the prognosis in advanced NSCLC remains poor 
and further improvements are sorely needed. Growing knowledge 
of cancer cell biology has led to the identification of new targets in 
cancer cells. Owing to the therapeutic plateau having been reached 
with conventional treatment strategies, strong interest is now focused 
on the development of targeted therapies. 
The EGFR pathway has emerged as a key target in NSCLC and 
its inhibition may be achieved via small molecular tyrosine kinase 
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inhibitors (TKIs), such as erlotinib or gefitinib, or monoclonal 
antibodies. 
TKIs have been shown to be effective in a second- or third-line 
treatment of advanced NSCLC [1] and are currently being used in 
this setting. The benefits of EGFR TKIs in salvage therapy have 
propelled them into evaluation as a maintenance treatment. They are 
theoretically attractive in this setting, owing to their oral route of 
administration and relatively mild toxicity profile. 
A series of randomized studies evaluated the role of maintenance 
EGFR-TKIs in patients with inoperable stage III or IV NSCLC 
(Table 1). In all these studies, TKI maintenance therapy was 
introduced after the completion of chemotherapy or, in the case of 
locally advanced NSCLC, after completion of chemoradiotherapy 
and consolidation chemotherapy. Most studies included molecu-
larly unselected populations of patients, one used tumor EGFR IHC 
assessment as a stratification factor (SATURN), and one was revised 
to require EGFR IHC positivity (EORTC 08021). In three studies, 
the primary endpoint was overall survival (OS), in three progression-
free survival (PFS) and in one non-progression rate (NPR) after the 
predefined period of time. At the time this manuscript was being 
prepared, 6 studies had been terminated (two prematurely owing 
to poor accrual or an apparent superiority of the experimental arm 
each). Only three studies were published as full articles or presented 
as abstracts, and one is still ongoing.
Table 1. Phase III studies of maintenance EGFR TKIs in advanced NSCLC
Study Stage Initial treatment Maintenance Primary No. of Effect of TKI 
    endpoint pts.
SATURN IIIB/IV Chemotherapy E vs. placebo PFS 889 Met primary 
      endpoint
EORTC 08021 IIIB/IV* Chemotherapy G vs. placebo OS 172 Closed due to 
      poor accrual
INFORM IIIB/IV Chemotherapy G vs. placebo PFS 296† Ongoing
FAST-ACT IIIB/IV Chemotherapy E vs. no further NPR at 154 NPR: NS; 
   therapy 8 weeks  Increased PFS
WJTOG 0203 IIIB/IV Chemotherapy G vs. no further OS 598 OS: NS; 
   therapy    Increased PFS
ATLAS IIIB/IV Chemotherapy Bevacizumab  PFS 768 Increased PFS 
   plus placebo vs.  
   bevacizumab  
   plus E
SWOG 0023 IIIA/IIIB Radiochemotherapy  G vs. placebo OS 243^ Decreased OS 
  followed by  
  docetaxel
*Revised to require EGFR IHC positivity; †planned number; ^randomized to G or placebo; E, erlotinib; 
G, gefitinib; OS, overall survival; PFS, progression-free survival; NPR, non-progression rate; NS, not 
significant; PD, progressive disease
The largest single-agent EGFR TKI maintenance study performed 
thus far is SATURN. This placebo-controlled, randomized, double-
blind, industry-sponsored phase III trial enrolled 889 patients with 
advanced NSCLC at approximately 160 sites worldwide. After at 
least four cycles of standard first-line platinum-based chemotherapy, 
patients were randomized to erlotinib or placebo. Therapy was 
continued until disease progression or unacceptable toxicity. The pri-
mary endpoint was PFS, with the assumption of a 25% increase with 
the maintenance therapy, whereas the secondary endpoints included 
OS, safety and exploratory biomarker analysis. Prospective tissue 
collection was performed allowing for the future correlative studies. 
The study met its primary endpoint and preliminary results sug-
gested that patients who were applied maintenance therapy may have 
significantly longer time to progression compared to placebo [http://
osip.client.shareholder.com/releasedetail.cfm?ReleaseID=370630]. 
The study results are being fully analyzed and the final data are 
announced to be presented in June 2009.
Two other smaller studies with similar design have been launched. In 
the EORTC 08021 study, stage IIIB or IV NSCLC patients who did 
not progress after completion of 2-6 cycles of a platinum-based stan-
dard first-line chemotherapy were randomized to maintenance gefi-
tinib or placebo. The primary endpoint was OS. This study was later 
revised to require strong EGFR expression in the tumor cells. Owing 
to poor accrual, the trial was prematurely terminated in July 2008, 
after the enrolment of 172 patients of the planned 598 [Van Meer-
beeck, personal communication]. The INFORM study is an ongoing 
double-blind, multicenter, randomized, placebo-controlled trial. The 
locally advanced or metastatic NSCLC patients are randomized to 
receive gefitinib or placebo following 4 cycles of platinum-based first 
line chemotherapy. The study is designed to recruit 296 patients.
In the FAST-ACT randomized phase II study, patients with chemo-
therapy-naïve, advanced NSCLC were administered chemotherapy 
(cisplatin and gemcitabine) every 4 weeks, with either erlotinib 150 
mg daily (n = 76) or placebo (n = 78) on days 15 to 28 of each cycle 
[2]. Responding patients continued to receive erlotinib or placebo 
until progression or unacceptable toxicity. The primary endpoint was 
non-progression rate (NPR: CR+PR+SD) at 8 weeks using RECIST 
criteria. All patients were of Asian origin and, unlike in the USA or 
Europe, 34% of them were never-smokers and 67% had adenocarci-
nomas. Preliminary results demonstrated a significant PFS advantage 
for the experimental arm (7.2 vs. 5.5 months), but no OS benefit. 
In the 0203 study of the West Japan Thoracic Oncology Group 
(WJTOG), 603 chemotherapy-naïve patients with advanced NSCLC 
were randomized to either platinum-doublet chemotherapy up to 6 
cycles or platinum-doublet chemotherapy for 3 cycles followed by 
maintenance gefitinib therapy (250 mg orally once daily) [3]. The 
primary endpoint was OS; secondary endpoints included PFS, RR, 
safety and quality of life. Similarly to the previous study, 31% of the 
patients in this trial were never-smokers and about 78% had adeno-
carcinomas. There was a significant improvement in PFS (HR, 0.68; 
95% CI, 0.57-0.80; P<0.001) in patients randomized to erlotinib; 
however, the difference in OS did not reach statistical significance 
(P=0.10). In a pre-specified analysis by pathology subtypes, OS was 
significantly better with gefitinib in adenocarcinoma patients (n=467; 
HR, 0.79; 95% CI, 0.65-0.98; P=0.03). 
In the ATLAS study, 1,157 patients with locally advanced, recurrent 
or metastatic NSCLC were initially given first-line treatment of 4 
cycles of monoclonal antibody bevacizumab in combination with 
investigators’ choice of platinum-based chemotherapy regimens. 
Patients (n=768) with no tumor progression or significant toxicity 
were then randomized to receive maintenance therapy with beva-
cizumab plus erlotinib or bevacizumab plus placebo until disease 
progression. The study’s primary efficacy endpoint was post-chemo-
therapy PFS, and the secondary endpoints included OS, toxicity and 
incidence of treatment discontinuation. The study was stopped early 
after the interim data analysis showed that the addition of erlotinib to 
bevacizumab extends the PFS compared to maintenance therapy with 
bevacizumab plus placebo [http://www.pharmanews.eu/roche/106-
roche-announces-interim-results-from-a-phase-iii-atlas-study].
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In the only study involving locally advanced inoperable NSCLC 
patients (SWOG 0023), previously untreated patients with stage 
III NSCLC were applied thoracic radiation at the dose of 61 Gy 
concurrently with cisplatin plus etoposide, followed by 3 cycles of 
docetaxel [4]. Three to six weeks after the last dose of docetaxel, 
patients were again restaged, reregistered, and randomly assigned 
to receive gefitinib 500 mg or placebo orally, once a day for 5 years 
or until disease progression or intolerable toxicity. The study was 
activated in June 2001 and was later amended to the gefitinib daily 
dose of 250 mg. The patients receiving the 500 mg daily dose were 
then switched to the lower dose. The planned sample size was 840 
patients and the primary endpoint was OS. The study was prema-
turely closed after accruing of 620 (74%) patients, as an unplanned 
interim analysis conducted in April 2005 showed unexpectedly 
inferior one- and two-year OS rates in the gefitinib arm. In October 
2006, with a median follow-up time of 27 months, median OS in the 
patients randomized to the maintenance therapy was 23 months for 
gefitinib (n = 118) and 35 months for placebo (n = 125; two-sided P 
= 0.013). One- and two-year survival rates were 73% and 46% for 
the gefitinib arm, and 81% and 59% for the placebo arm, respective-
ly. The median PFS from randomization was 8.3 months for gefitinib 
and 11.7 months for placebo (P = 0.17; HR = 0.80; 95% CI, 0.58 to 
1.10). Decreased survival did not seem to be a result of toxicity, with 
only a 2% toxicity death rate reported for gefitinib. These results 
were in striking contrast to the expected 33% increase in median 
survival with gefitinib. 
As expected, in all these studies the salient toxicities of TKIs 
included acneiform rash and diarrhea, though grades 3 to 4 toxicity 
occurred in less than 10% of patients.
Two studies (FLEX, BMS099) investigated the role of cetuximab, 
an anti-EGFR antibody, in addition to standard chemotherapy in 
advanced NSCLC. In both studies, patients who received cetuximab 
during chemotherapy continued on maintenance after its completion. 
The FLEX study included 1,125 previously-untreated patients whose 
tumors expressed EGFR by immunohistochemistry. The primary 
endpoint, OS favored the addition of cetuximab to cisplatin plus 
vinorelbine (p=0.04), but the difference was modest (median 11.3 
vs. 10.1 months, respectively) [5]. In the BMS099, 676 patients were 
randomized to carboplatin plus a taxane (docetaxel or paclitaxel), 
with or without cetuximab. No significant difference was demonstrat-
ed in terms of both PFS (the primary endpoint) and OS [6]. 
In summary, current clinical experience does not provide solid end-
point data on the role of maintenance EGFR therapy in advanced 
NSCLC. Some studies suggested a possible efficacy of this strategy; 
however, they typically included populations sensitive to EGFR, and 
their results cannot be generalized. Other studies have been inconclu-
sive or have even demonstrated a detrimental effect. Clearly, further 
clinical research is required to clarify the role of EGFR therapy in 
this setting. The utility of these compounds can likely be enhanced 
by appropriate selection of patients. Future clinical trials should 
include prospective collection of biological material to allow correla-
tive studies.
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Background
Although there have been improvements in the curative treatment 
of lung cancer, most patients will ultimately die of this disease. As 
a consequence, palliation of symptoms, prolongation of life and 
improving or maintaining quality of life (QoL) is the main goal in the 
majority of our patients at some stage in their life. 
A major problem is that many symptoms such as breathlessness 
or fatigue as well as QoL are subjective in their nature and should 
therefore be scored by the patients themselves using validated scor-
ing systems. Moreover, as the majority of these patients suffer from 
more than one symptom of which some may be better palliated than 
others and because any treatment may also induce toxicity, the meth-
odology to investigate the interplay between these and many more 
factors is complex. Most trials have focused on one major endpoint 
such as pain control, but neither provides patient self assessments nor 
multifactorial symptom, performance status and QoL data. Obvi-
ously, performing such a study in a large trial is a very challenging 
and costly exercise. 
These methodological issues are not specific for radiotherapy trials, 
but they are obviously to be kept in mind. 
What should be palliated?
In a large study conducted in the 1990’s in 700 patients with lung 
cancer, treated with palliative intention, the commonest symptoms at 
baseline were: psychological (worry, anxiety), general (fatigue, loss 
of appetite), and chest symptoms (shortness of breath, cough). Inter-
estingly, pain was not on the 10 most frequent symptoms. The most 
severe symptoms were decreased sex interest, lack of energy, and 
shortness of breath. Most patients reported multiple symptoms: the 
mean number of symptoms per patient was 14; the mean number of 
symptoms rated as severe was 2.3. Ranking of the top four symptoms 
remained unchanged in long-term follow-up, up to a month prior to 
death. 
Role of radiotherapy 
Radiotherapy has a major role to play in the palliation of chest symp-
toms of lung cancer, such as dyspnea, cough, hemoptysis and pain. 
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The focus of the presentation will nevertheless be on the role of 
radiotherapy of two major metastatic sites, being bone and brain. 
Bone Metastases
Radiotherapy remains the gold standard for palliation of painful bone 
metastases. 
A lot of emphasis has been placed on the optimal fractionation sched-
ule, but data on technical aspects are very scarce. This is nevertheless 
an important issue, as with older, mostly non-CT scan bases radiation 
techniques, there is a high likelihood for missing parts of metastatic 
lesions that cause symptoms because of the reliance on plain X-rays. 
This is especially the case when besides bone destruction, extensive 
soft tissue invasion is present. Underdosage may also arise from clas-
sical techniques in which one posterior radiation field with a “one-fits 
it all” dose specification at 5 cm depth is used to treat vertebral 
metastases. Moreover, the application of basic 3D conformal radia-
tion techniques may spare adjacent normal tissues, hence decreasing 
side effects that may induced by radiotherapy, even when delivered 
at low total palliative doses, but at high doses per fraction. 
Total radiation doses and fractionation schedules vary widely, from 
single fractions, in doses usually of 8 Gy, to shorter fractionation 
schedules (20 Gy for 5 fractions, 30 Gy for 10 fractions) to more 
prolonged fractionation schemes such as 50 Gy over 5 weeks. 
Multiple randomized phase III trials have nevertheless shown that 
the overall response rate was 9.5 % (95 % CI 57.2-61.8; n=1779) for 
single-fraction regimen (e.g. 8 Gy/ 1 fraction) and 58.7 % (95 % CI 
56.4-61.0, n=1769) for multiple-fraction regimen (e.g. 20 Gy/ 5 frac-
tions, 30 Gy/ 10 fractions), p=0.70 (adapted from ref. 2). Complete 
pain response rates were 34.5 % (95 % CI 32.1-36.9; n=1441) for 
single-fraction regimen (e.g. 8 Gy/ 1 fraction) and 32.3 % (95 % CI 
29.9-34.7, n=1435) for multiple-fraction regimen (e.g. 20 Gy/ 5 frac-
tions, 30 Gy/ 10 fractions) p=0.20. 
Single fraction radiotherapy is thus as good as more prolonged frac-
tionation schedules to treat bone pain from cancer. 
Nevertheless, concerns may be the higher re-treatment rate with 
single-fraction regimen, being 21.5 % (95 % CI 19.2-23.4; n=1240) 
for single-fraction regimen (e.g. 8 Gy/ 1 fraction) and 7.4 % (95 % 
CI 5.9-8.9, n=1236) for multiple-fraction regimen (e.g. 20 Gy/ 5 
fractions, 30 Gy/ 10 fractions) p<0.00004 (adapted from ref. 2). The 
differences may also reflect the reluctance of physicians to re-irradi-
ate lesions that were already exposed to moderately radiation doses.
Also the pathological fracture rate of 3 % (95 % CI 2.7-3.3; n=1240) 
for single-fraction regimen (e.g. 8 Gy/ 1 fraction) is higher than for 
multiple-fraction schedules, i.e. 1.6 % (95 % CI 1.2-2.2, n=1236) for 
multiple-fraction regimen (e.g. 20 Gy/ 5 fractions, 30 Gy/ 10 frac-
tions) p=0.03, but in both circumstances, the absolute differences are 
small, questioning the usefulness of protracted radiation schedules. 
Importantly, the spinal cord compression rate was similar after single 
vs. multiple fractions: 1.9 % (95 % CI 1.1-2.7; n=1102) for single-
fraction regimen (e.g. 8 Gy/ 1 fraction) vs. 1.4 % (95 % CI 0.7-2.1, 
n=1104) for multiple-fraction regimen (e.g. 20 Gy/ 5 fractions, 30 
Gy/ 10 fractions) p=0.30. 
Obviously, the methodological shortcomings mentioned earlier, 
apply to these phase III trials.
In general, most patients with painful bone metastases can be suc-
cessfully palliated with single-fraction schedules (typically 8 Gy/ 1 
fraction). More research is needed for appropriate patient selection, 
the influence of the type of cancer, the integration with systemic 
treatment and other methods to treat bone metastases such as bispho-
sphonates, the type of pain, the influence of radiation techniques on 
patients’ outcome, the appropriate use of pain assessment systems 
and quality of life and cost analyses. 
Brain Metastases
Brain metastases are extremely common in lung cancer. 
Solitary brain metastases can be treated by surgical resection or by 
stereotactic radiotherapy, also known as radiosurgery, or ‘‘gamma-
knife,’’ i.e., external beam radiation with multiple beam from mul-
tiple directions, so as to concentrate the radiation dose to a limited 
area of the brain.
Randomized phase III trials (reviewed in 3), have established a 
superior survival for surgery or stereotactic radiosurgery (SRS) vs. 
whole brain radiotherapy (WBRT). The addition of SRS to WBRT 
also improved survival, the performance status and decreased steroid 
dependence. 
Even when adequate MRI scans of the brain were used, the addi-
tion of WBRT after surgical resection of solitary brain metastases 
improved significantly the overall survival and recurrence-free 
survival. 
The ongoing EORTC (European Organisation for Research and 
Treatment of Cancer) study 22952 is designed to answer the ques-
tion whether surgery and SRS are really comparable/equivalent and 
whether WBRT is needed in addition to SRS/resection. 
However, the majority of patients with brain metastases presents 
with multiple metastases and are not candidates for surgery or SRS. 
WBRT is usually recommended, although steroids alone may be 
an option in patients with very limited life expectancy, since some 
patients may not live long enough to benefit from WBRT (4). It has 
also not been clearly established whether radiotherapy is beneficial in 
asymptomatic patients, although prevention of neurological deterio-
ration has been often used as an argument for nevertheless treating 
these patients with WBRT. 
Several randomized studies compared various fractionation sched-
ules including 40 Gy in 20 fractions, 30 Gy in 10 fractions, 20 Gy 
in 5 fractions, and 17 Gy in 2 fractions for WBRT (reviewed in 3). 
No difference was observed in response rate and survival, although a 
faster response was often seen with shorter fractionation schedules. 
About 50% to 90% of patients reported relief of neurological symp-
toms. Fifty percent of patients had functional improvement. It was 
not possible to draw conclusions what the effect of WBRT was on 
steroid dependence. The median survival in these trials ranged from 
15 - 20 weeks. Side effects were usually mild and transient, with 
approximately 10 - 15 % of patients experiencing nausea, vomiting 
and headache that responded to steroids. It is reassuring that tumor 
progression adversely affects neuro-cognitive function more than 
WBRT does (5). 
The importance of patient selection is illustrated in a large study 
with 533 patients of the Royal College of Radiologists in the United 
Kingdom, comparing WBRT with 12 Gy in 2 fractions to 30 Gy in 
10 fractions (6). One third of the patients randomized were too ill or 
were dead at the 1-month follow-up assessment. 
Patient selection systems are therefore of great clinical useful-
ness, for these may allow the rational selection of patients for no 
WBRT, WBRT or more aggressive approaches. Established methods 
include the recursive partitioning analysis (RPA) (7) and the Graded 
Prognostic Assessment (GPA) (8), the former being widely used. 
The RPA model was derived from analyzing outcomes of patients in 
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the RTOG studies, which have identified three prognostic strata on 
the basis of patients’ age, performance status, and the presence or 
absence of extracranial cancer (7). The model parameters are age, 
Karnofsky performance status, and the presence of cancer elsewhere 
in the body. The best prognosis is achieved in RPA group I, being 
less than 60 years, a Karnofsky performance status of 80 - 100 % and 
no cancer elsewhere, with a median survival of 7.7 months. Patients 
lacking one of the above criteria fall into an intermediate prognosis 
group (group II, with a median survival of 4.5 months), and those 
not satisfying two or more criteria fall in the worst prognosis group 
III (median survival 2.3 months). The latter group are the least 
likely to benefit from treatment, but if therapy is indicated, a short 
course of palliative radiotherapy (e.g. 20 Gy in 5 fractions) is usually 
employed. For groups I and II, more aggressive treatments are given 
including higher dose WBRT and combining WBRT with a stereot-
actic boost. 
Conclusions and future prospects
Radiotherapy plays a major role to palliate symptoms of metastatic 
cancer, with mild side effects. As it is delivered in one or a few frac-
tions, the burden for patients can be minimized. Still, future research 
is needed in the optimal combination of palliative radiotherapy with 
systemic treatment and other drugs used for palliation such as bis-
phosphonates, the optimal radiation schedule according to individual 
patient, tumor and pain characteristics and assessment systems that 
can be implemented on large patient numbers with throughout the 
world. Prospective economic evaluation is needed.
Finally, in daily clinical practice, palliation should be discussed early 
in multidisciplinary teams. 
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Small cell lung cancer (SCLC) accounts for about 15% of all lung 
cancer histology. SCLC has aggressive clinical course, with median 
survival time of only 2 to 4 months without treatment. Ninety-seven 
percent of patients with SCLC have history of tobacco smoking. 
Although the incidence of SCLC has been declining, it remains 
serious public health problem especially in countries where smoking 
control is poor. 
Two-stage staging system has more often been utilized than the TNM 
staging system. Limited disease (LD) is defined as disease confined 
to one hemithorax, the mediastinum, or the supraclavicular lymph 
nodes. Tumors that have spread beyond LD are defined as extensive 
disease (ED). In both stages, combination chemotherapy is corner-
stone of treatment for SCLC.
Extensive disease (ED-SCLC)
Chemotherapy sensitivity to SCLC has been reported since 1940s. 
Based on several randomized trials, combination chemotherapy, 
especially CAV (cyclophosphamide, doxorubicin, vincristine), 
became standard of care for SCLC in 1970s. Etoposide plus cisplatin 
(EP) regimen is active not only in untreated patients with SCLC, 
but also in patients previously treated with CAV. Although random-
ized trials comparing CAV versus EP failed to demonstrate overall 
survival differences, meta-analyses published in 2000 demonstrated 
the superiority of cisplatin-containing regimens. Myelotoxicity is less 
severe in EP. EP has been the standard first-line chemotherapy regi-
men for SCLC. Carboplatin is active for SCLC and nausea, vomit-
ing, nephrotoxicity were less severe than cisplatin. Japan Clinical 
Oncology Group (JCOG) compared etoposide 80mg/m2 on day 1 to 
3, plus carboplatin AUC 5, to divided doses of cisplatin 25mg/m2 on 
day 1 to 3 plus same doses of etoposide in elderly or poor PS patients 
with ED-SCLC. Response rate, progression free survival, overall 
survival and symptom palliation score were similar between both 
arms. In a large randomized trial compared etoposide plus carbopla-
tin (EC) to pemetrexed plus carboplatin, response rate, progression 
free survival and overall survival were significantly better in EC arm. 
Based on these data, carboplatin can be substituted for cisplatin par-
ticularly in elderly or poor PS patients with ED-SCLC or in patients 
who cannot tolerate cisplatin. A JCOG randomized trial for ED-
SCLC demonstrated that overall survival was significantly better in 
patients treated with irinotecan plus cisplatin (IP) than EP. Although 
subsequent confirmatory studies failed to demonstrate significant 
survival advantage of IP over EP, IP shows at least similar efficacy to 
EP and less myelotoxicity. Thus, IP is a standard of care for patients 
with ED-SCLC who can tolerate irinotecan diarrhea. Another evi-
dence of irinotecan activity was demonstrated in a North European 
trial in which irinotecan plus carboplatin was compared to etoposide 
plus carboplatin. Complete response rate and overall survival were 
significantly better in the group treated irinotecan plus carboplatin. 
Irinotecan plus carboplatin is also a standard regimen for ED-SCLC.
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Limited Disease (LD-SCLC)
Meta-analyses of randomized trials compared chemotherapy with or 
without thoracic radiotherapy (TRT) revealed survival advantage of 
chemotherapy plus TRT over chemotherapy alone. Several random-
ized trials evaluated timing of TRT demonstrated conflicting results. 
Three meta-analyses of these trials also resulted in different conclu-
sions. This would be due to inclusion of cyclophosphamide-based 
old regimens. Platinum plus etoposide and early concurrent TRT 
showed best results, and should be considered the standard of care in 
patients with LD-SCLC who deemed tolerable to early TRT. 
Recurrent SCLC
Randomized trial compared oral topotecan to supportive care in pre-
viously treated patients with relapsed SCLC showed significant sur-
vival advantage of topotecan over supportive care alone. Single agent 
chemotherapy, as topotecan, is standard treatment for this group of 
patients. Two randomized phase II studies of topotecan or amrubicin 
demonstrated significantly higher response rate of amrubicin. Amru-
bicin is also a standard regimen for patients with relapsed SCLC. 
Conclusion
Etoposide plus cisplatin, etoposide plus carboplatin, irinotecan plus 
cisplatin, or irinotecan plus carboplatin are standard regimens for 
ED-SCLC. In patients with LD-SCLC, early concurrent EP plus 
TRT is the standard. Standard of care for relapsed SCLC is single 
agent, topotecan or amrubicin. Although many targeted agents or 
immunotherapy failed to demonstrate benefit for patients with SCLC, 
continued clinical research is needed. 
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Introduction: Small cell lung cancer – in need of new ideas
Small cell lung cancer (SCLC) is a common and nearly always fatal 
disease (1). SCLC represents approximately 15% of all lung cancers, 
or about 26,000 cases annually in the United States (2). This disease 
is strongly associated with tobacco exposure, and is expected to be 
an increasingly prevalent concern, particularly in Asia and the devel-
oping world, mirroring smoking trends worldwide (3).
SCLC has a marked predilection for early, distant metastasis: 
approximately two thirds of the cases of SCLC are advanced stage at 
the time of diagnosis. Advanced stage SCLC patients are considered 
incurable, and with current standard of care treatment have a median 
survival time of approximately 9 – 10 months from the time of 
diagnosis (4). Five-year survival is exceedingly rare. Limited stage 
SCLC, functionally defined as disease confined to one hemitho-
rax and which can be encompassed in a single radiation port, also 
carries a dismal prognosis, with median survival of approximately 
18 months from diagnosis. In contrast to extensive stage disease, 
limited stage SCLC is potentially curable using current multimodal-
ity therapy, with long-term disease free survival in approximately 20 
– 25% of cases (5).
Standard therapy for advanced and limited stage SCLC differs 
primarily in the addition of concomitant radiation for limited stage 
disease. Typical first line chemotherapy, regardless of stage, consists 
of a platinum agent (cisplatin or carboplatin) paired with a second 
agent, in the U.S. usually the topoisomerase II inhibitor etoposide. 
This essential treatment paradigm was initiated in the early 1980s, 
and has undergone only minor subsequent modifications, primarily 
limited to improvements in supportive care medications, and in the 
timing, focus, and intensity of radiation (6-8).
Clinical barriers to progress in SCLC
With the advent of platinum-based chemotherapy, there was consid-
erable optimism among lung cancer clinical researchers regarding 
the potential for further rapid progress against SCLC (9). SCLC, in 
contrast to non-small cell lung cancer (NSCLC), is a remarkably 
chemosensitive tumor, with objective response rates of 60 – 80% to 
standard chemotherapy. A number of newer chemotherapeutic agents, 
including topotecan, paclitaxel, and gemcitabine were found to have 
promising activity (10). However, throughout the 80s and 90s, none 
of the newer agents tested, as single agents, as combinations, or 
added to cisplatin and etoposide, appeared to offer any significant 
improvement over standard therapy. Despite initial chemosensitiv-
ity, extensive stage SCLC recurs universally, and recurrent disease 
is relatively resistant to further therapy. Attempts at post-induction 
“maintenance” chemotherapy have been universally unsuccessful 
(11). These failures promoted a climate of nihilism regarding further 
clinical investigation in SCLC.
The development and testing of high potency inhibitors of cell 
surface receptor tyrosine kinases has been a predominant focus of 
solid tumor clinical research over the past decade. SCLC, in contrast 
to NSCLC and several other common solid tumors, does not appear 
to depend on EGFR family receptor tyrosine kinases for survival or 
proliferation (12). These key oncogenic factors are frequently unde-
tectable in SCLC. Targeted inhibition of c-Kit, an alternative receptor 
tyrosine kinase that appears to be upregulated in a subset of SCLC, 
demonstrated no clinical activity in SCLC (13). The oncogenic fac-
tors most strongly implicated in malignant transformation of SCLC, 
p53 and Rb, are not kinases, and are notoriously difficult targets for 
selective pharmacologic intervention (14).
Preclinical barriers to progress in SCLC
Another barrier to progress has been a relative absence of predic-
tive preclinical models of human SCLC. Tobacco smoke-exposed 
mice do not typically develop lung tumors similar to SCLC. This 
issue was partially addressed by Meuwissen et al. in 2003, with the 
demonstration that targeted somatic inactivation of both p53 and Rb 
led to the development of murine lung neuroendocrine tumors that 
were phenotypically similar to human SCLC (15). However, the 
utility of this two-hit transgenic approach as a therapeutic model is 
unclear. Clinical SCLC, induced by tobacco carcinogens, is marked 
by a diversity of genetic alterations, is biologically heterogeneous, 
and most notably demonstrates severe chromosomal instability (16). 
None of these features, key contributors to the emergence of thera-
peutic resistance, are reflected in extant transgenic models of SCLC.
The most common in vivo model for anti-cancer drug development 
is based on the use of human cancer cell lines implanted as tumor 
xenografts in recipient animals. Although allowing response analysis 
of actual human tumors, this model also has clear limitations. Both 
genetic and epigenetic characteristics of cancer cells are influenced 
by culture conditions, and these changes may lead to misleading 
results in preclinical drug studies (17-19). Features of a cancer cell 
line that favor preferential selection ex vivo include rapid growth as a 
monolayer on plastic, growth in fetal calf serum and synthetic media, 
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growth in high pO2 and high glucose conditions, survival through 
trypsin passaging, and low mutagenicity resulting in a stable and 
consistent phenotype. Tumor features irrelevant to cell line derivation 
include angiogenic drive, metastatic potential, and survival in states 
of hypoxia, nutrient limitation, and high oncotic pressure. Implanted 
subcutaneously, most standard xenografts grow as localized, non-
invasive, non-metastatic nodules, in marked contrast to human 
cancers and in particular in contrast to the aggressive behavior of 
clinical SCLC.
Primary xenografts: an emerging model
Our laboratories have begun to explore an alternative approach 
to preclinical drug testing in SCLC, using primary xenografts or 
heterotransplants (20). This model depends on immediate transfer of 
human SCLC from patients into recipient mice, without intervening 
tissue culture or cell line derivation ex vivo. This avoids the selective 
pressures associated with ex vivo cell survival and proliferation by 
maintaining tumors in a biologically relevant context. Tumors pas-
saged from animal to animal in this model maintain stable histologic 
and immunophenotypic characteristics. To validate this model, cell 
lines were derived from a series of primary SCLC xenografts, and 
reimplanted as secondary (standard cell-line based) xenografts. Com-
parison of gene expression profiles between human tumors, primary 
xenografts, cell lines, and secondary xenografts suggests that primary 
xenografts maintain gene expression patterns closer to the human 
disease than either cell lines or cell line-based xenografts. We were 
able to identify a group of tumor-specific genes expressed in human 
tumors and primary xenografts that are lost during transition to cell 
culture, and that are not reexpressed when tumors are reimplanted as 
secondary xenografts (20). Taken together these observations suggest 
that primary xenograft models may represent a better platform for 
preclinical therapeutic testing, one that may be more predictive of 
ultimate clinical efficacy.
SCLC and apoptotic sensitivity: Bcl-2 as a target
Dysregulation of apoptotic signaling pathways is one of the fun-
damental hallmarks of cancer (21). Two features of SCLC have 
made targeting apoptosis in this tumor type a particularly attractive 
strategy. First, in contrast with most other solid tumors, SCLC dem-
onstrates remarkable sensitivity to multiple apoptotic triggers (22). 
The apoptotic threshold of SCLC cell lines to standard cytotoxics 
is similar to that of many hematologic malignancies; this sensitivity 
may in part explain the exceptional clinical response rates of SCLC. 
Second, a central contributor to the apoptotic dysregulation in SCLC 
appears to be a well-characterized factor amenable to therapeutic 
targeting, Bcl-2. Bcl-2 is a central apoptotic regulator implicated in 
cell survival, tumorigenesis, and chemotherapeutic resistance (23). 
Bcl-2 has been reported to be upregulated in 73–90% of human 
SCLC tumors (24-26). Suppression of Bcl-2 levels through use of 
an antisense oligonucleotide targeting the bcl-2 mRNA increases the 
sensitivity of SCLC cell lines and xenografts to standard cytotoxics 
including cisplatin and etoposide (27). Finally, and most notably, tar-
geted inhibition of Bcl-2 using ABT-737 or ABT-263, high potency, 
high specificity, small molecule inhibitors, has dramatic single agent 
and combinatorial activity against SCLC cell lines treated both in 
vitro and in xenograft models (28-30). Notably, in contrast to data 
from in standard cell line based xenografts in the primary xenograft 
model of SCLC, ABT-737 appears to have modest single agent activ-
ity, but can augment the efficacy of standard cytotoxics (30).
Initial clinical translation of Bcl-2 inhibitor therapy for SCLC, 
through intravenous administration of a Bcl-2 antisense oligonucle-
otide, are disappointing. Oblimersen is a phosphorothioate 18-mer 
oligonucleotide complementary to the first 6 codons of the bcl-2 
mRNA (31). Two phase I studies and a randomized phase II study of 
oblimersen with cytotoxic chemotherapy in patients with SCLC have 
been reported (32-35).
The first of these phase I studies combined oblimersen with pacli-
taxel in patients with chemorefractory relapsed SCLC, based on 
observations that Bcl-2 and related family members contribute to 
paclitaxel resistance. Two patients among this very poor prognosis 
cohort experienced stable disease, one remaining without progres-
sion for over six months, but there were no objective responses (32). 
The second study evaluated oblimersen, carboplatin and etoposide in 
patients with newly diagnosed extensive stage SCLC (33). This small 
phase I study reported a response rate of 83% (10 of 12 evaluable 
patients) for the combination, and led directly to a randomized phase 
II study in the Cancer and Leukemia Group B consortium comparing 
carboplatin and etoposide with or without oblimersen. In this larger 
study oblimersen did not improve response rate or survival (34, 35).
One explanation for the lack of evident enhancement of chemothera-
peutic efficacy with oblimersen may have been inadequate intracel-
lular delivery of the oligonucleotide. Indeed, our correlative analyses 
of peripheral blood mononuclear cells of patients receiving oblimers-
en suggested no consistent effect on Bcl-2 protein level in vivo (33). 
Recent generation small molecule inhibitors of Bcl-2, in contrast to 
Bcl-2 antisense oligonucleotides, demonstrate high level single agent 
activity in SCLC xenograft models. These observations have led to 
a shift in research in this area from oligonucleotide vectors to small 
molecule inhibitors.
Clinical studies of at least 3 small molecule inhibitors of Bcl-2 and 
related Bcl-2 family members in patients with SCLC are ongoing. 
ABT-263 is an orally bioavailable high potency Bcl-2/Bcl-xL inhibi-
tor, currently being evaluated in a multicenter phase I/II study in pat-
ents with recurrent SCLC. Obatoclax and AT-101 are Bcl-2 inhibitors 
with lower affinity but differing and possibly complementary patterns 
of selective inhibition across the Bcl-2 family. A two-institution NCI-
supported phase I/II study of obatoclax with topotecan in recurrent, 
chemosensitive SCLC is ongoing. An NCI-supported study involving 
multiple phase II consortia is evaluating the efficacy of AT-101 as a 
single agent in patients with recurrent SCLC. The outcome of these 
studies is eagerly awaited.
SCLC and embryonic differentiation 
pathways: Hedgehog as a target
The Hedgehog (Hh) pathway is an essential embryonic signal-
ing cascade that regulates of stem/progenitor cell differentiation 
pathways is a critical factor in organismal morphogenesis, includ-
ing mammalian lung development (36, 37). Smoothened (Smo) is a 
transmembrane protein that is absolutely required for activating the 
downstream Hedgehog signaling pathway. Patched, an inhibitory cell 
surface receptor, constitutively suppresses Hedgehog pathway activa-
tion through inhibition of Smo. Any of three Patched ligands (Sonic, 
Indian, and Desert Hedgehog) can bind to and inactivate Patched, 
derepressing Smo and promoting pathway activation. Remarkably, 
evolution from flies to man has not resulted in the development of 
Smoothened paralogs. By contrast, there are perhaps as many as 7 
Frizzled receptors, which are close relatives of Smo in the Wnt path-
way. The discovery that the plant-derived alkaloid cyclopamine is a 
potent Smo antagonist has propelled efforts to develop high potency 
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and specificity Hedghog inhibitors, and make Smo one of the most 
attractive pharmacologic targets for cancer drug discovery (38).
The Hedgehog pathway has been implicated as a key oncogenic 
factor for multiple tumor types, which fall into at least 2 fundamen-
tally different classes. One class, including medulloblastoma and 
basal cell carcinomas, demonstrate inactivating PATCHED muta-
tions, leading to constitutive ligand-independent pathway activation. 
Preclinical models of tumors with this phenotype are exquisitely 
sensitive to treatment with Smo inhibitors. A second class, typified 
by SCLC (39), appears to retain pathway integrity but demonstrates 
ligand-dependent pathway upregulation, and activation via a para-
crine pathway involving tumor-associated stroma (40). Tumors of 
this class are also inhibited by Smo inhibitors in multiple preclinical 
models. A high proportion of SCLC demonstrate constitutive ligand-
dependent activation of the Hedgehog pathway and are growth-inhib-
ited by Smo inhibitors (39, 41). 
Several orally bioavailable highly selective Hedgehog pathway 
inhibitors are now in early phase clinical development in patients 
with advanced solid tumors. The first of these to reach the clinic, 
GDC-0449, has been reported to have potent antitumor activity in 
patients with advanced or metastatic basal cell carcinoma in the 
initial phase I study (42). A recommended phase II dose of 150mg 
daily has been defined, and multiple phase II studies are currently 
in progress or planned. Two other inhibitors, IPI-926 and XL139 
(BMS-33923), are now in similar phase I dose-escalation studies in 
patients with advanced solid tumors. One of these, IPI-926, inhibits 
tumor transplantation and delays tumor recurrence after cytotoxic 
chemotherapy in the primary xenograft model of small cell lung 
cancer (43).
SCLC and a virus targeting neuroendocrine 
cancers: fighting biology with biology
Over the past decade there have been several attempts to develop 
live, replication-competent anti-cancer viruses. Agents tested have 
included retrovirus and adenoviral constructs. A novel, naturally 
derived picornavirus was discovered as a contaminant of a labora-
tory adenoviral preparation. This picornavirus, Seneca Valley Virus 
or SVV-001, has selective tropism for cancer cells of neuroendocrine 
differentiation, and demonstrates remarkable activity in SCLC xeno-
grafts (44). A phase I dose escalation study of SVV-001 in patients 
with tumors having neuroendocrine features was recently completed. 
Intratumoral viral replication following intravenous administration 
has been documented. The essential biologic characteristics of this 
virus, including definition of its cellular receptor and mechanisms of 
selective tropism for neuroendocrine tumors, are areas of ongoing 
research in our laboratory.
Summary: a time of renewed hope for SCLC
SCLC remains a nearly universally fatal malignancy, marked by 
rapid disease recurrence and short survival times. Developments over 
the past several years suggest that there is reason for renewed hope 
in SCLC. Improved in vivo laboratory models of disease, based on 
transgenic modification of key oncogenic factors leading to murine 
SCLC, and based on primary xenografting of human SCLC, have 
generated new, and possibly more predictive, platforms for rapid 
assessment of therapeutic strategies. An improved understanding of 
the determinants of malignant transformation, clonogenic potential, 
tumor growth, and metastatic spread has led to the identification 
of novel targets for drug development in SCLC, several of which 
are currently being translated into the earliest phases of clinical 
development. These include concurrent first-in-human, first-in-class 
phase I studies of a novel anticancer virus with tropism for neuroen-
docrine tumors, of a high potency Hedgehog pathway inhibitor, and 
of multiple selective Bcl-2 family inhibitors. Other targeted thera-
peutics of relevance to SCLC are likely to follow in the next several 
years from emerging insights into the SCLC kinome: the set of 
somatically activated kinases characteristic of SCLC. Combinations 
of these novel therapeutics with the standard regimens, remarkably 
effective against the bulk of SCLC tumor cells, has the potential to 
change the prognosis for patients with this disease. It’s about time.
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In Japan, lung cancer is usually diagnosed by a pulmonologist. Pres-
ently, the most useful tool for detecting lung cancer is high-resolution 
computed tomography (HRCT). In this mini-symposium, I would 
like to focus on HRCT diagnoses and differential diagnoses of lung 
cancer. As you know, HRCT findings of lung cancer vary by histol-
ogy. First, I will describe nonmucinous bronchioloalveolar carcinoma 
(BAC), then miscellaneous pulmonary diseases mimicking lung can-
cer, and finally, I will discuss lung cancer associated with idiopathic 
pulmonary fibrosis (IPF) because chest physicians often detect lung 
cancer during follow-up of IPF. 
Recently, focal ground-glass opacities (GGOs) have been frequently 
detected because of the widespread use of computed tomography 
(CT) in daily practice or low-dose CT screening for lung cancer. 
GGO is a radiological term indicating an area of increased hazy lung 
opacity in which vessels and bronchial structures can still be seen. 
Focal GGOs are further classified into pure GGOs (nonsolid nodules) 
and mixed solid/GGOs (part-solid nodules). 
Pure GGOs are associated with BAC or atypical adenomatous 
hyperplasia, while mixed GGOs are more likely to represent invasive 
adenocarcinomas. Well-demarcated, rounded or lobulated GGOs 
strongly indicate a malignant histology. On the other hand, ill-
defined, polygonal GGOs are associated with inflammatory lesions. 
It is not, however, possible to reliably discriminate malignant from 
benign GGOs based on HRCT findings alone, since some benign 
lesions closely resemble their malignant counterparts. 
Some studies have recommended a course of antibiotics followed 
by another HRCT within two months for evaluating focal GGOs. 
Patients who show good response to antibiotics can be excluded from 
further work-up. 
There are various kinds of pulmonary diseases resembling lung 
cancer on HRCT, such as pulmonary cryptococcosis, nontuberculous 
mycobacterial pulmonary disease, postinflammatory lesions, bacte-
rial pneumonia, and inflammatory pseudotumor (IPT) of the lung. 
Pulmonary cryptococcosis is caused by inhalation of Cryptococcus 
neoformans. Cryptococcal infection can occur in individuals with 
normal immunity, but is most common in the immunocompromised 
host. The typical HRCT findings are solitary or multiple nodules 
in the subpleural area. Spiculation, lobulation, and convergence of 
peripheral vessels are often observed. Such nodules make it difficult 
to distinguish pulmonary cryptococcosis from lung cancer. Video-
assisted thoracoscopic surgery is recommended for both diagnosis 
and treatment of solitary pulmonary cryptococcosis. 
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Nontuberculous mycobacteria are ubiquitous organisms that are 
increasingly being recognized as important causes of chronic pulmo-
nary infection in immunocompetent individuals. The most common 
HRCT finding of nontuberculous mycobacterial pulmonary disease 
is a combination of small nodules and bronchiectasis. Patients with 
nontuberculous mycobacterial pulmonary disease rarely show a soli-
tary mass without nodules or bronchiectasis, which is indistinguish-
able from lung cancer. 
On the other hand, very slow growing adenocarcinomas are fre-
quently diagnosed as old inflammatory lesions. Some of these adeno-
carcinomas show a characteristic bubble-like appearance on HRCT. 
This bubble-like appearance is characterized by an irregular shape 
with straight margins, peripheral GGO, dilated air bronchogram, and 
prominent pleural indentation, as reported by Kojima and colleagues 
in 2008 (Haigan 48: 801-806). The average doubling time of adeno-
carcinomas was reportedly 1167 days. These types of lesions require 
careful attention in order to avoid misdiagnosing lung cancer.
Mucinous BAC often has the appearance of bacterial pneumonia and 
is characterized by the presence of a bubble-like low attenuation area 
within the tumor (pseudocavitation). In contrast, infectious pneu-
monia is distinguished by bronchial wall thickening proximal to the 
lesion and pleural thickening associated with the lesion. 
IPT of the lung is rare and mostly affects children and young adults. 
It consists of a spectrum of fibroblastic or myofibrotic proliferation 
with varying infiltrate of inflammatory cells. The lesions are usually 
solitary and well-circumscribed masses, but some of them invade 
local mediastinal structures or the chest wall. The reported HRCT 
findings include notch formation, spiculation, and pleural indenta-
tion. It is sometimes difficult to differentiate lung cancer from IPT 
based on HRCT findings alone. Surgical excision is usually required 
to make a definitive diagnosis of IPT. 
IPF, on the other hand, is known to be associated with an increased 
risk of lung cancer. Chest radiographic findings of lung cancer 
developing with IPF have been described as a nodular shadow or a 
mass and a diffuse reticular infiltrate with honeycombing. However, 
the radiographic detection of lung cancer may prove difficult with 
a pulmonary fibrosis background. At present, HRCT plays a central 
role in the diagnostic approach to nodules as well as diffuse lung 
diseases. The typical HRCT findings of lung cancer are well-defined 
nodular lesions with lobulation in the peripheral areas of the lung. 
However, some patients show an unusual pattern on HRCT, such as 
diffuse GGO resembling acute exacerbation of IPF. Because it is dif-
ficult to detect small-sized lung cancer associated with IPF by chest 
radiography, annual HRCT is recommended for the early detection of 
lung cancer as well as for evaluating serial changes in IPF.
In summary, well-defined, rounded GGOs are the characteristic 
HRCT findings of BAC, whereas ill-defined, polygonal GGOs are 
considered to be inflammatory lesions. HRCT findings of solitary 
pulmonary cyptococcosis and nontuberculous mycobacterial pulmo-
nary disease include a spiculated nodule or a mass mimicking lung 
cancer. Special caution must be observed for a very slowly progres-
sive adenocarcinoma with a bubble-like appearance. Routine HRCT 
is recommended for following up patients with IPF in order to detect 
early stage lung cancer. 
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Positron emission tomography with 18F-Fluoro-2-Deoxy-Glucose 
(FDG-PET) has become an important imaging modality in lung can-
cer patients. Its role in diagnosis and staging of non-small cell lung 
cancer (NSCLC) has been implemented in many clinical guidelines. 
Other applications – beyond the scope of this text – such as its role 
in assessment of prognosis, in radiotherapy planning, in assessment 
of response to chemotherapy or targeted agents, in small cell lung 
cancer, are in exciting development as well.
Diagnosis
Solitary pulmonary nodules (SPNs) are a common problem in clini-
cal practice, and a diagnostic challenge, if there is no typical calcifi-
cation or comparison with previous X-ray findings. The problem also 
arises in studies on early lung cancer detection with low-dose spiral 
computed tomography (CT), where the problem of coincidentally 
detected nodules is very common.
In most studies, a cut-off value for maximum Standardized Uptake 
Value (SUVmax) of >2.5 was used to diagnose malignancy. In a 
meta-analysis, the sensitivity, specificity, positive and negative pre-
dictive values were 96%, 78%, 91% and 92%, respectively 1. Impor-
tant to note is that this meta-analysis was based on studies where the 
number of patients with SPNs of 1 cm or less, or with ground-glass 
like SPNs was very small.
In respect to sensitivity – and thus possible false negative findings – 
three important and interrelated remarks have to be made: 1/ choice 
of SUVmax cut-off value; 2/ size of the lesion; 3/ ground glass 
aspect of the lesion. Sensitivity for detection on PET decreases if 
the number of metabolic active cells is low. Therefore, exclusion of 
malignancy is more hazardous in small lesions, or in lesions with low 
metabolic activity such as carcinoid tumors 2. With evolving data, 
it became that – for the sake of sensitivity – the use of the SUVmax 
threshold of >2.5 might perhaps better be abandoned, as quite some 
lesions with SUVmax <2.5 are malignant 3. A large prospective 
series (n=585) looked at the accuracy of integrated PET/CT scan in 
SPNs <2.5 cm 4. If the SUVmax was between 0 and 2.5 there was a 
24% chance of malignancy, if between 2.6 and 4.0 it was 80%, and if 
>4 it was 96%. Likewise, the accuracy of PET is also challenged in 
small nodules detected in lung cancer screening studies 5. Nonethe-
less, selective use of PET was reported to be useful in some series 
6-8, but with more limitations than in the daily practice population 
presenting with SPNs. In studies, several coming from Japan, false 
negative findings were reported in ground glass lesions up to a size 
of 3 cm 9. These lesions often have an important component of bron-
chioloalveolar cell carcinoma, where metabolic activity is low due 
to significantly lower expression of the glucose transporter Glut-1 
compared to other NSCLC subtypes 10.
In respect to sensitivity – and thus possible false positive findings – 
one should be aware of the different inflammatory conditions, where 
FDG uptake is due to activated granulocytes and/or macrophages, 
such as sarcoidosis, tuberculosis, Wegener granulomatosis, coal 
miner disease, etc. This results in variable specificity (50-100%) in 
different series, determined by the prevalence of certain inflamma-
tory or infectious diseases, such as tuberculosis or histoplasmosis. 
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In special situations, specificity can be improved by looking at the 
FDG uptake kinetics using dual time point imaging at 1 and 2 hours 
(FDG continued uptake in malignant versus rapid uptake followed by 
washout in benign lesions) 11.
Staging
T-factor. With the excellent anatomic of modern spiral CT scans, this 
tool remains the method of choice to assess the extent of the primary 
tumor in relation to lung fissures, mediastinal structures, pleura or 
chest wall. PET on its own has little to add to the accuracy of CT, 
because of its lower spatial resolution 12. This changed with the 
introduction of PET-CT in more recent studies. In truly integrated 
PET-CT, a combined scanner creates both datasets, that are subse-
quently merged to a single image, to create the best combination 
of morphologic and metabolic information. Comparisons are often 
made with either PET alone or with PET images in visual correla-
tion with CT-images. While the first comparison may be of scientific 
interest, it is of little clinical relevance. Papers in the late 90-ies 
already pointed out that interpretation of PET-images in visual cor-
relation with CT-images was the minimum standard 13, 14. Three 
studies reported better results with PET-CT in comparison to PET 
alone 15-17. This superiority can be assigned to the CT component 
of this examination, because of poor performance of PET alone in 
measuring tumor size or assessing potential infiltration of adjacent 
structures. The integrated images allow more precise evaluation of 
chest wall and mediastinal infiltration in some patients, and better 
differentiation between tumor and accompanying inflammation or 
atelectasis in others. In the Zurich group report, there was a benefit in 
comparison to side-by-side reading of PET- and CT-images as well, 
which was not in the place in the Leuven experience 18.
N-factor. One of the main limitations of CT here is that it only uses 
a size criterion, known to be of low accuracy in differentiating 
benign from malignant lymph nodes 19, 20. Since about a decade, 
the metabolic information from PET imaging (added to CT imaging) 
was proven to be superior to CT alone 13, 21, a finding confirmed in 
different meta-analyses based on a multitude of prospective studies 
22-24. Because of the lack of anatomical detail on PET images, read-
ing indeed always should be in visual correlation with CT images, 
but even then it sometimes remains difficult to distinguish hilar from 
mediastinal nodes, or to exclude lymph node metastasis in patients 
with a large centrally located tumor. Better anatomic correlation on 
integrated PET-CT images allows better distinction between N1, N2 
and N3. Furthermore the role of PET-CT in identifying supraclavicu-
lar N3 nodes and in the distinction between FDG-avid brown fat and 
a metastatic lymph node is indisputable 15-17. Here again, in the 
study of the Zurich group PET-CT was superior to visual comparison 
of PET and CT, but the accuracy of the latter in this study was unex-
pectedly low at 59% 15. In the Leuven experience, there was little 
difference between integrated and visually compared imaging 18. 
As a whole, it seems that visual side-by-side comparison of images 
remains a reasonable approach, even if technological evolution will 
lead to widespread availability of integrated PET-CT machines, that 
will replace the previous generation of stand-alone PET cameras.
M-factor. Many well designed prospective studies also demon-
strated a gain in accuracy here, mainly because PET is able to detect 
additional metastatic lesions in 5 to 25% of the patients 25. There is 
a substantial variation in the proportion of patients with additional 
lesions, because authors differ in the definitions of ‘unexpected’ 
lesions: in most series, an equivocal lesion on conventional imaging, 
found to be metastatic on PET, was not regarded as ‘unexpected’, 
while this was the case in some series. PET also helps to character-
ize equivocal lesions, this usually is for adrenal lesions, contralat-
eral lung nodules, or bone scintigraphy abnormalities 25. In a large 
retrospective study on integrated PET-CT in lung cancer, there was a 
significant superiority of PET/CT versus PET alone or CT alone, but 
not versus side to side correlation 12. Similarly, in a large retrospec-
tive survey on patients with different tumors, there was significant 
advantage of integrated PET-CT versus PET or CT alone, but not 
versus side-to-side correlated images 26.
Based on the above findings, PET or PET-CT now is an important 
staging tool in all NSCLC patients with a potential for radical treat-
ment. Its use in clinical studies resulted in stage shift from the one 
determined by conventional imaging in 27% to as high as 62% of the 
patients with NSCLC, and a change in patient management in 25% 
to even 52% of the patients 27-29. Multiple intense abnormal foci 
in different organs usually point at disseminated disease. Patients 
should however not be excluded from potentially radical treatment 
based on isolated abnormal finding on PET suggestive for distant 
metastasis. In these instances, additional confirmation by other imag-
ing procedures or by tissue confirmation should be sought, in order 
to rule out a false positive finding,, or a second primary tumor not 
affecting the stage of the lung cancer 30.
The additive value of PET was also investigated through comparing 
implementation of PET added to conventional staging compared to 
the conventional process alone in randomized controlled trials. One 
trial randomly allocated 188 clinical stage I-III NSCLC patients to 
either conventional work-up or conventional work-up plus PET 31. 
A clear reduction in the number of futile surgical procedures in the 
latter arm was found: 5 patients needed a PET in order to prevent one 
futile surgery. A similar trial in clinical stage I-II patients revealed 
no difference between a PET guided or conventional strategy 32. As 
with therapeutic interventions, multiple trials should be performed to 
provide a valid estimation of the effect.
An other prospective randomized study compared staging with 
upfront PET (i.e. directly after first presentation) versus routine clini-
cal staging in 465 patients 33. In this study, patients with FDG-avid, 
non-centrally located tumors without signs of mediastinal or distant 
spread on PET proceeded directly to surgical resection, without con-
ventional staging tests. Quality of staging was measured by compari-
son of the clinical stage to the final stage, and was similarly good in 
both arms. Non-invasive tests to reach a clinical TNM were similar 
in both arms, but invasive tests (i.e. mainly mediastinoscopy) were 
significantly less needed in the upfront PET group.
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Preoperative evaluation of pulmonary function
Fong, Kwun M.
The Prince Charles Hospital, Brisbane, QLD, Australia
For most lung cancers, i.e. non-small cell lung cancers (NSCLC), 
curative intent surgery remains the most effective major therapeu-
tic modality for cure. However, as most lung cancers are found in 
smokers or former smokers, clinicians assessing patients for possible 
surgery also have to address the other lung diseases and abnormal 
physiology that results from tobacco smoke. In addition, other condi-
tions in particular cardiovascular disease in the form of coronary 
artery disease, is often found in smokers with lung cancer and can 
impact on surgical outcomes.
Thus the evaluation of the patient pre-operatively for potential sur-
gery involves several steps, before a clinician and patient are able to 
make an informed decision as to whether to undergo curative intent 
resection. The aim is to undertake sufficient evaluative testing so as 
to allow a careful consideration and weighing up of the benefits and 
risks of surgery. 
The benefits to be considered include: 
• likelihood of enhanced survival outcomes following curative 
surgery with or without adjuvant treatments 
The direct risks include:
• immediate peri-operative risk from co-morbid cardiopulmonary 
and other diseases 
• the interaction with neo-adjuvant or adjuvant therapies 
• medium and long-term risks of pulmonary dysfunction and 
impairment
Given the subsequent small but significant risk of future lung 
cancers in patients who have had successfully resected lung cancer, 
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evaluation should also reflect potential downstream implications of 
surgical management on potential future lung cancer issues. Evalu-
ation should also consider the possibility of co-interventions such 
as lung volume reduction surgery in a subset of patients with severe 
emphysema and lung cancer, who may not otherwise be considered 
suitable surgical candidates.
Evaluation involves:
• Clinical assessment - history, examination
• Physiological testing - respiratory function tests (ranging simple 
eg FEV1.0 to complex eg cardiopulmonary exercise testing)
• Imaging - CT scan, differential ventilation or perfusion scans
• Multi-disciplinary interaction
The ultimate aim is to perform an effective and cost-effective pul-
monary evaluation to carefully inform the clinicians and patients on 
the likely risk-benefit ratio for surgery for their lung cancer. This will 
enable sensible decision making and help identify those at high risk 
of or unlikely to benefit in the medium and long term from surgery.
M24.4 The Role of the Chest Physician in a Multidisciplinary Lung Cancer Clinic,  
 Sun, Aug 2, 16:30 - 18:00
Pulmonary complications in the treatment of lung cancer
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Treatment of lung cancer can induce pulmonary complications. 
The incidence of lung cancer, the development of multimodality 
strategies and the emergence of new targeted drug is associated 
with an increase in pulmonary complications especially in a fragile 
population. 
Thoracic surgery is associated with infectious complications, 
atelectasis, prolonged air leak, fistula, pneumonia and acute respi-
ratory distress syndrome. Alternative procedure such as thermo 
ablation therapy may also lead to pneumothoraces, hemorrhage 
and infectious complications. Radiotherapy can induce early or late 
radiation pneumonitis and less frequently cryptogenetic organiz-
ing pneumonia. Chemotherapy is associated with infectious events 
including febrile neutropenia and specific lung toxicity for drugs 
such as bleomycine, ifosfamide, gemcitabine. New targeted drugs 
also displayed unexpected pulmonary complications. EGFR tyrosine 
kinase inhibitors can induce rare but severe acute interstitial pneumo-
nia. Angiogenesis inhibitors are associated with severe hemoptysis. 
One aspect of lung cancer research is to improve treatment strategies 
in order to minimize side effects. We recently observed the develop-
ment of new surgical procedures, of new techniques of radiation 
therapy, of new drugs and of new supportive treatment that decrease 
pulmonary complications. Moreover, biological markers are cur-
rently studied to predict radiation or chemotherapy-induced toxicity 
in order to optimize treatment of lung cancer. 
Prediction, prevention and management of pulmonary complica-
tions in the treatment of lung cancer require a strong collaboration 
between oncologist, chest physicians and researchers.
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Lung cancer is the most common cause of cancer death worldwide 
with mortality exceeding that of colon, breast and prostate cancers 
combined. For non-small lung cancer, surgery provides the best 
chance of cure if the tumor can be completely resected in the absence 
of lymph node and distant metastases however, cure rate remains 
dismal at < 15% due to the advanced stage of disease at presentation.
The flexible bronchoscope has become an essential tool for the diag-
nosis, staging and palliation of lung cancer. By allowing access into 
the bronchial tree, bronchoscopy facilitates acquisition of specimens 
through bronchial washing, brushing, endobronchial and transbron-
chial biopsies in patients suspected of lung cancer. Moreover, the 
incorporation of transbronchial needle aspiration of enlarged medi-
astinal lymph nodes allows clinicians to increase its diagnostic yield 
as well as stage the disease. 
Since most lung cancers are advanced at diagnosis, another important 
goal of interventional bronchoscopy is in palliation when central 
airway obstruction is encountered. Approximately 30% of patients 
with lung cancer will present with airway obstruction, and 35% will 
die from local intrathoracic complications such as hemoptysis, post-
obstuctive pneumonia and asphyxia. Emergent restoration of airway 
patency not only confers symptom relief and improved quality of 
life importantly it obviates mechanical ventilation and provides the 
time window necessary for institution of adjuvant therapy. Selec-
tion of treatment modality depends on acuity of presentation, type of 
lesion, patient’s general, cardiac and pulmonary status, and physi-
cian’s expertise (figure). These procedures can be performed with the 
flexible or rigid bronchoscope with the patient under local or general 
anesthesia.
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The last decade witnessed huge technological advances in bron-
choscopic imaging for early lung cancer detection such as auto-
fluorescence bronchoscopy; high magnification and narrow band 
imaging; spectroscopy; optical computed tomography and confocal 
microendoscopy that may allow optical biopsy and facilitate in-depth 
understanding of the carcinogenesis process; precise targeting of 
pulmonary nodules and accurate staging of the mediastinum. 
Indeed the millennium spells an exciting time for interventional 
pulmonologists, thoracic surgeons and oncologists who manage 
lung cancer. Therefore this lecture is prepared in acknowledgement 
of the complementary and rapidly expanding role of interventional 
bronchoscopy in the area of thoracic oncology.
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Lung Carcinogenesis Detected by 
Exhaled Breath Approaches
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Lung cancer screening technologies have inherently limited diag-
nostic specificity as currently applied [Bach 2007]. Therefore, a con-
certed effort at identifying particularly high risk individuals for appli-
cation of candidate early disease detection strategies could be crucial 
in leveraging the performance of imperfect disease-detection tools 
such as CT scanning. So far, purely clinico-demographic models 
have not been able to identify those at risk with sufficient certainty to 
offer this leverage [Bach, 2003].
An airway-based biochemical marker of risk offers several attrac-
tions. However, sampling the target visceral epithelia non-invasively 
for risk assessment in asymptomatic subjects poses anatomic chal-
lenges. Expectorated sputum has been intensively studied for this 
reason, although up to 30% of current or former smokers do not 
produce sputum, even after induction with nebulized saline [Har-
tung, 2002, Belinsky 2005, 2006]. Nonetheless, the study of sputum, 
presumably derived solely from lung epithelia, has been well-
demonstrated in suggestive studies by the New Mexico/Colorado 
consortium where Belinsky, et al. have demonstrated the promise of 
multiple gene promoter hypermethylation for identifying people at 
high risk for cancer incidence [Belinsky, 2006]. 
Exhaled breath is another biomatrix that might be considered for 
such purposes, as it contains gas aerosols and vapors that can be 
collected for non-invasive analysis of physiologic and pathologic 
processes in the lung. There is a considerable recent literature on the 
use of the gas phase of exhaled breath to identify individual volatile 
components, or complex volatile mixtures, that correlate with the 
presence of lung cancer. Study design has typically been case-
control, such that predictive capacity for incident disease is largely 
unknown. 
In some of the initial studies on volatile compounds in the gas 
phase that correlate to lung cancer, in a case-control context, Philips 
[Philips 1999, 2003] reported significant correlations of gas-chro-
matography-coupled-mass spectrometry (GC-MS) patterns, and the 
likelihood of having lung cancer. In one study, the approach yielded 
a training set sensitivity of 90%, and specificity of 85% for lung can-
cer. In the test set, 83% sensitivity and 80% specificity was obtained 
[Philips 2003]. Distinction from the exhaled volatile patterns of 
active or former cigarette smokers without apparent lung cancer was 
made [Philips 2003]. Another group reported 71% sensitivity, and 
92% specificity for lung cancer detection in a case-control setting, 
using a commercialized sensor array “electronic nose” [Machado, 
2005]. In the sensor array method, the actual volatile components 
of the unique signal are not directly evaluated, although additional 
work-up has revealed them to be predominantly volatile hydrocar-
bons. Corroborative later reports simplifying the sensor array have 
been reported [Mazzone, 2007], although these patterns do not 
directly identify the responsible biomarker compounds. A recent 
uncorroborated study on training dogs, the ultimate biosensors, 
in study-blinded fashion, reports an extraordinary performance in 
distinguishing exhaled breath from those with lung cancer versus 
healthy controls (sensitivity and specificity both 99%) [McCulloch, 
2006]. A recent report that lung cancer cells in vitro evolve unique 
volatile metabolites in the gas phase above the culture dish, lends 
some credence to the cancer-specificity of the evolved exhaled gas 
detection approach [Chen 2007]. 
For example, in one of many carefully executed studies, [Wehinger 
2007] collected tidal volume breathing mixed expiratory gas 
samples, prior to any subject diagnostic or therapeutic interventions. 
They used a proton transfer mass spectrometry (PTR-MS) approach 
to exhaled gas analysis, which avoids pre-concentration steps other-
wise required for gas chromatography-based techniques, but cannot 
distinguish compounds of the same mass. Among 17 predominantly 
early-stage lung cancer cases, and 170 controls, m/z=31 or VOC-31 
(tentatively protonated formaldehyde), and VOC-43 (tentatively a 
protonated fragment of isopropanol) were the most discriminatory; 
impressive 2-3-fold differences of cases versus smoker controls, with 
some overlap, were found. Overall test performance, in simulations, 
showed sensitivity for detecting lung cancer was 54%, accuracy was 
96%, specificity was 99%, PPV (given 5% prevalence) was 90%, 
and NPV was 96%. ROC curves showed AUCs for those aged >50 
y.o. of 0.82, and 0.95, respectively. If one were to see these numbers 
in a marker of risk, as opposed to a marker of disease diagnosis, this 
marker would be considered promising. 
To capture the aqueous fraction for dissolved molecules in breath 
condensate for assay, exhaled air is passed through a cooled, 
condensing apparatus, which in it’s simplest form is available as a 
handheld, disposable device. The resulting exhaled breath conden-
sate (EBC) is predominantly derived from water vapor, but EBC has 
dissolved within it aqueous-soluble, nonvolatile compounds. The 
technique has attracted broad research interest, and there is a signifi-
cant literature describing its utility in procuring small metabolites for 
the investigation of inflammatory lung diseases [Kharitonov, 2006, 
Barnes, 2006]. Several investigative groups, including our own, have 
detected macromolecules in EBC, such as genomic DNA [Gessner, 
2004, Carpagnano 2005, 2008]. This suggests the possibility of 
DNA-based analyses of lung processes. 
Gene promoter hypermethylation is known to cause stable gene 
silencing and plays an important role for both normal develop-
ment [Reik 2007] and disease [Feinberg 2007], and recognized as a 
crucial component in lung cancer initiation and progression [Herman 
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
Copyright © 2009 by the International Association for the Study of Lung CancerS112
2003]. We recently reported a method for the facile annotation of 
larger expanses of gene sequence for CpG methylation at single base 
resolution, using a tag-modification of bisulfite genomic sequenc-
ing (tBGS) [Han 2006]. Because of consistent reports as a relevant 
biomarker class in carcinogenesis, we pursued the appearance of 
promoter hypermethylation of tumor suppressor genes in the exhaled 
matrix putatively representing lung-derived material. 
In our pilot study, we analyzed promoter methylation patterns in 
DAPK, RASSF1A and PAX5β promoters in EBC samples from 54 
individuals, comprised of 34 controls including current-smokers 
(n=19), former-smokers (n=10), never-smokers (n=8); and 17 
lung cancer cases (five current, 11 former smokers and one never 
smoker)]. We found: (1) Wide inter-individual variability in methyla-
tion density and spatial distribution for DAPK, PAX5β and RASSF1A. 
(2) Methylation patterns from paired exhaled breath condensate and 
mouth rinse specimens were completely divergent. (3) For smok-
ing status comparisons, for the methylation density of RASSF1A, 
there was statistical differences among smoking groups (p=0.0285); 
pair-wise comparisons showed that the former smokers had higher 
methylation density versus never smokers and current smokers 
(p=0.019 and p=0.031). There was no significant difference in the 
overall methylation densities for DAPK and PAX5β. (4) In case-con-
trol comparisons, CpG at -63 of DAPK promoter and +52 of PAX5β 
promoter were significantly associated with lung cancer status (p= 
0.0042 and 0.0093, respectively). After adjusting for multiple testing, 
both loci were of borderline significance (p
adj
=0.054 and 0.031). (5) 
The DAPK gene had a regional methylation pattern with two blocks 
(1)~ -215~ -113 and (2) -84 ~+26), lung cancer cases and non-cancer 
controls had similar methylation density in block 1, but was signifi-
cantly different in methylation density in block 2 (p=0.045); (6) the 
results of a second method, quantitative methylation-specific PCR 
applied to EBC, correlated with the corresponding sequencing map 
loci. Our results show that DNA methylation in exhaled breath con-
densate is detectable and likely of lung origin. Suggested correlations 
with smoking and lung cancer case-control status depend on the gene 
set and individual CpG sites chosen for examination. We are follow-
ing up this pilot study in several dimensions, both to verify anatomic 
origin and relevant genes in directly sampled lung epithelium, and to 
expand our EBC multiplexing capacity, to better capture informative 
gene sets in this matrix.
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Novel genomic applications in lung cancer: 
what are the latest SNPs and CHIPs?
Geraci, Mark W.
University of Colorado Denver, Aurora, CO, USA
This lecture proceeds in addressing six important questions in the use 
of genomic technologies to the study of lung cancer. The six ques-
tions are: 
1) What is lung cancer and can we classify tumors on a molecular 
basis? 
One of the first studies to use gene expression arrays to sub-classi-
fy adenocarcinoma was performed by Dr. Matt Meyerson and his 
group and published in PNAS in 2001.(1) This group discovered 
that unsupervised cluster analysis demonstrated the four classic 
types of non-small cell lung cancer. Moreover, in a supervised 
analysis, the group was able to define five sub groups of adeno-
carcinoma of the lung. The most differentiated of these groups 
demonstrated markers of classic type II cell lineage specific gene 
expression. This group tended to have a better prognosis. One 
group, the C-2 group, was characterized by over expression of 
neuroendocrine markers. This group tended to have the worst 
prognosis. 
 Our group has performed an extensive analysis of adenocarci-
noma using orthologous gene expression comparisons between 
human adenocarcinoma and a carcinogen induced murine model.
(2) This study proved useful in determining the similarities 
between an animal model and the human condition. Moreover, 
this analysis also included an extensive comparison of surround-
ing unaffected lung in comparison to the tumor. By this method, 
one is able to distinguish changes between non tumorous and 
tumorous lung. 
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2)  Can “signatures” be used for prognosis? 
Several studies have been used to show that gene expression 
signatures can indeed predict survival in patients with lung cancer. 
One of the first to accomplish this was published by Dr. David 
Beer in Nature Medicine in 2002.(3) More recent studies have 
focused on early stage non-small cell lung cancer. The work by 
Drs. Anil Potti and Joe Nevins published in the New England 
Journal of Medicine in 2006 demonstrated that even early stage 
tumors can demonstrate signatures which predict aggressive 
behavior of the tumors and may require further treatment other 
than conventional early stage treatment.(4) Dr. Yang published 
a minimal five gene signature portending clinical outcome in 
non-small cell lung cancer published in the New England Journal 
of Medicine in January 2007.(5) This work was important in its 
utilization of training and testing cohorts. Dr. David Christiani 
has demonstrated that genetic variation among individuals with 
polymorphisms of either MDM-2 or VEGF may assist in predict-
ing survival.(6, 7) 
3) Can we diagnose lung cancer or can we predict who will get lung 
cancer? 
Dr. Avi Spira demonstrated that gene expression patterns in 
airway brush samples of smokers are useful in predicting a gene 
signature for lung cancer. This work was published in Nature 
Medicine in March 2007.(8) Our group has utilized further animal 
modeling to demonstrate that bronchoalveolar lavage gene expres-
sion profiles from a murine model of adenocarcinoma can predict 
the resident tumors in the lung parenchyma.(9) More importantly, 
cell free bronchoalveolar lavage fluid contains elevated levels of 
some of the proteins in tumor bearing animals.
4) Can we personalize treatment for lung cancer? 
The quest to personalize treatment for lung cancer has been given 
significant importance with the finding that a small percentage 
of individuals are highly responsive to EGFR (epidermal growth 
factor receptor) tyrosine kinase inhibition. Several sentinel papers 
by Lynch, New England Journal of Medicine 2004, Peaz, Science 
2004 and Pao, PNAS 2004 all demonstrate that activating muta-
tions in the EGFR are responsible for sensitivity to this com-
pound. Our group has utilized gene expression profiling of lung 
cancer cell lines to define a gene expression signature for EGFR 
TKI sensitivity or resistance.(10) Importantly, this signature 
also correctly predicts sensitivity or resistance to head and neck 
squamous cell carcinoma cell lines.(11) The group from Vander-
bilt, including Drs. David Carbone and Pierre Massion, utilized 
a proteomics approach to define signatures in serum or plasma 
which correctly predict sensitivity and resistance to treatment with 
EGFR TKIs.(12) These works formed the basis for the SPECS 
(Strategic Partnership to Evaluate Cancer Signatures) trial. In this 
study, patients will be enrolled in a prospective fashion to deter-
mine whether conventional chemotherapy or guided therapies 
improve outcome. 
5) Can we prevent lung cancer? 
Prevention of lung cancer has become a significant focus of many 
laboratories. Our group has utilized transgenic animal modeling 
to over express the prostacyclin synthase gene in a lung specific 
fashion. By this approach, we have demonstrated protection in 
three distinct carcinogenesis protocols.(13, 14) Moreover, prosta-
cyclin synthase is nearly universally lost in most lung cancer spec-
imens.(2) Retention of expression of prostacyclin synthase is a 
marker of dramatically improved survival. Given this background, 
there is currently a large randomized placebo control trial ongoing 
for the use of iloprost, a prostacyclin animal log, in the chemopre-
vention of lung cancer for patients at high risk. Outcomes for this 
study include endobronchial histology. 
6) What’s new on the horizon? 
The newest technologies utilize sophisticated tiling strategies for 
either DNA or RNA measurements. Furthermore, there exists the 
ability to measure exon level expression arrays. DNA based arrays 
(SNP arrays) can be utilized for large scale genome wide associa-
tion studies. Moreover, fine mapping of genetic copy number can 
be utilized. Array-based approaches to determine methylation 
status across the genome have recently been published. Dr. Tycko 
performed evaluation of methylation status utilizing SNP arrays 
in work published in Cancer Research in 2006.(15) High resolu-
tion mapping of DNA hyper- and hypo-methylation states has 
been performed and published in the PNAS January 2008.(16) In 
terms of copy number analysis relevant to lung cancer one of the 
more important findings was published by Dr. Janne and his col-
leagues in Science 2007.(17) This work utilized cell lines initially 
sensitive to EGFR inhibition. By repeated treatments with EGFR 
TKIs, a resistance pattern emerged. The group was able to then 
demonstrate, using copy number analysis that samples becoming 
resistant to EGFR TKI showed a concombinant amplification of 
the MET oncogene. 
 More recently, Dr. Matt Meyerson’s group published in Nature in 
2007 a significant analysis of copy number variation across 371 
distinct lung cancers.(18) The group demonstrated that 26 of 39 
autosomal arms of chromosomes show large scale gains or losses, 
many of which had not previously been described. Importantly, 
the group was able to demonstrate 31 recurrently local events. 
These local events involve 24 instances of amplification and 7 
instances of homozygous deletions. In terms of discovery, the 
group demonstrated that only 6 previously know regions of ampli-
fication or deletion had been documented in lung cancer. 
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Development of gene methylation as a 
biomarker for lung cancer detection
Belinsky, Steven A.
Lovelace Respiratory Research Institute, Albuquerque, NM, USA
The involvement of gene methylation in carcinogenesis has led 
to studies focused on establishing the utility of methylation as a 
biomarker in screening for cancer risk, prevention, treatment, and 
prognosis. Our group was the first to establish that gene-specific 
methylation could be detected in sputum from lung cancer patients 
prior to clinical diagnosis of lung cancer. This observation led to 
the initiation of studies focused on identifying a panel of genes 
whose methylation in sputum would predict the presence of early 
lung cancer. Those studies conducted through the Johns Hopkins 
Lung SPORE and in collaboration with the Colorado Lung SPORE 
initially identified a panel of six genes whose concomitant methyla-
tion in sputum was associated with a 6.5-fold increased risk for lung 
cancer. Those studies have been extended to evaluate an additional 
46 genes for their association to lung cancer using the case-control 
design within the Colorado Cohort. We have now identified 14 genes 
associated with a 2-fold or more increased lung cancer risk. Prior to 
selecting gene panels and determining their combined sensitivity and 
specificity for cancer detection, we are evaluating other cohorts to 
determine the reproducibility of our individual gene associations to 
cancer. A diagnostic test for lung cancer should have high specific-
ity and sensitivity for identifying early-stage disease where curative 
resection and possibly adjuvant therapy could reduce mortality. 
Thus, sputum obtained from patients with Stage I lung cancer and 
who are generally asymptomatic for disease should be an appropri-
ate specimen for refining our gene panel for prospective studies. The 
sensitivity and specificity of this gene panel for cancer detection are 
being assessed in prevalent Stage I and incident lung cancer patients 
identified from our cancer registry and smoker cohorts. Cases (n = 
67) were matched 1:2 with controls by age (± 5 yr), gender, smok-
ing status, and enrollment site. These and other planned studies on 
our SPORE grant will evaluate additional lung cancer cases and 
control being recruited in Baltimore, MD, and lead to the final selec-
tion of a gene panel for validation in a nested, case-control study 
in the American College of Radiology Imaging Network (ACRIN) 
Cohort. Finally, studies are underway to determine whether integrat-
ing validated SNPs and haplotypes identified through GWAS or 
resequencing and associated with methylation and/or lung cancer can 
improve the positive and negative predictive value of gene methyla-
tion detection in sputum for early lung cancer diagnosis. (Supported 
by P50 CA58184 and U01 CA097356)
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Recent developments in proteomic strategies addressing 
lung cancer biomarkers discovery and validation
Massion, Pierre P.
Division of Allergy, Pulmonary and Critical Care Medicine, Thoracic 
Oncology Center, Vanderbilt Ingram Comprehensive Cancer Center, 
Vanderbilt University Medical Center, Nashville, TN, USA
Cancer biomarkers are measurable products of tumors which can 
assist in the diagnosis (identification of cases), prognosis (correlation 
with outcome independent of interventions) or prediction (associated 
with outcome after a specific intervention). It is clear that lung cancer 
outcomes could be improved by high quality biomarkers address-
ing each of these steps in lung cancer management. Unfortunately 
very few candidates have been identified, and even fewer have been 
validated. 
Biomarkers are needed to identify patients at high risk for lung 
cancer and to identify surrogate endpoints for response to chemopre-
vention strategies. The discovery of biomarkers for lung cancer is 
hampered by the slow onset of lung cancer and the lack of screening 
tests to identify early disease. The assumption underlying the concept 
of biomarkers is that certain molecular characteristics of the lesions 
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are highly correlated with specific clinically relevant biological 
states. These characteristics include changes in expression levels of 
genes and proteins and their posttranslational modifications. Detec-
tion of cancers at early stages maximizes survival, and identification 
of blood-borne markers would lead to minimally invasive tests. The 
best biomarkers are those that are reproducibly measured, related to 
the disease process and that trigger a clinical decision resulting in 
improved clinical outcomes. Despite an intense search for such bio-
markers, there are none currently validated for the early diagnosis of 
lung cancer (1). Early detection by low dose computed tomography 
scanning is being evaluated prospectively with the National Lung 
Cancer Screening Trial in 50,000 smokers. The addition of molecular 
studies may significantly increase the sensitivity and specificity of 
this new strategy for early detection.
Changes in DNA and in RNA may not be reflected in changes in 
protein expression. In fact, recent advances in protein profiling have 
suggested a poor correlation between gene expression and protein 
expression. It is now well established that protein activity is often 
highly regulated by post-translational modifications such as prote-
olysis and phosphorylation. Neither protein expression levels nor 
post-translational modification can be assessed by genomic or cDNA 
microarray technologies, prompting interest in evaluation of protein 
expression, commonly referred to as “proteomics”.
Lung cancer has been studied by several proteomic methods includ-
ing two-dimensional gel electrophoresis, mass spectrometry (MS) 
and immunohistochemistry to identify biomarkers in tumors (2-4) 
or in body fluids such as bronchoalveolar lavage (5) of patients with 
or without cancer. MALDI profiling is rapid, high throughput, but 
detects only the most abundant proteins of relatively low molecular 
weight, and does not enable direct identification when applied to 
complex proteomes. Two dimensional gel-based analysis suffers 
problems of inter-laboratory reproducibility and throughput. Shotgun 
proteomics is lower throughput, but yields confident identification of 
large numbers of proteins from every cellular compartment.
Matrix assisted laser desorption ionisation time-of-flight mass spec-
trometry (MALDI-TOF MS) is capable of very high throughput in 
which a sample can be analyzed in seconds and with a higher toler-
ance for salts, buffers, and other biological contaminants. Because 
of these qualities, MALDI MS has been utilized to study proteins/
peptides in serum (6-8), urine (9), tissue extracts (10, 11), whole cells 
(12), and laser-captured microdissected cells (13). These profiling 
experiments have been applied to a series of biological specimens. 
In one MALDI MS study from our group, hierarchical clustering of 
data from lung cancers and normal tissues allowed the identifica-
tion of patterns distinguishing between tumor and normal as well as 
histological subgroups (14).
In an effort to further our understanding of lung cancer biology and 
to identify new candidate biomarkers to be used in the management 
of lung cancer, we need to probe these tissues and biological fluids 
with tools that address the biology of lung cancer directly at the pro-
tein level. Cancer cells express proteins that distinguish them from 
normal cells. New technologies are being developed to allow the 
rapid and systematic analysis of thousands of proteins. The analytical 
advantages of MS, including sensitivity and high throughput, prom-
ises to make it a mainstay of novel biomarker discovery to differenti-
ate cancer from normal cells and predict individuals likely to develop 
or recur with lung cancer. In general, however, because of a lack of 
reproducibility between platforms and institutions, profiling has not 
yet made a significant impact in clinical medicine. This is in contrast 
with greater early steps in the translation of genomic signatures to 
the clinic (15, 16). Profiling using this technology in biological fluids 
or tissue samples is not without challenges. The complexity of the 
sample composition, the large predominance of few proteins in the 
sample and their ability to mask lower abundance limits the informa-
tivity of this approach. 
In this presentation, we will summarize the progress made in clini-
cal proteomics as it applies to lung cancer biomarker discovery and 
validation. We will focus our discussion on how MS approaches 
may advance the areas of early detection, response to therapy and 
prognostic evaluation. 
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Plasma DNA as biomarker for lung 
cancer detection and prognosis
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Increased knowledge of molecular pathogenesis of lung cancer 
offers a basis for the use of molecular markers in biological fluids for 
early detection as well as identification of higher-risk smokers. The 
identification of useful molecular biomarkers is strictly linked to the 
knowledge of the genomic, genetic and epigenetic changes that drive 
lung cancer formation and progression. Many molecular changes 
have been described, the most common being genomic instabili-
ties involving chromosome 3p, 9p and 17p, mutations of oncogenes 
(K-ras) and inactivation of tumour suppressor genes through muta-
tion (p53), promoter hypermethylation (p16) or genomic rearrange-
ments (FHIT)1. All these changes represent possible targets for early 
detection strategies that have sparked from the finding that tumours 
are capable of shedding nucleic acids (DNA or RNA) into the blood 
stream 2.3. Free circulating DNA in lung cancer patients has been 
used as a surrogate source of tumour DNA, but the search for specific 
molecular changes in plasma or serum DNA is hampered by several 
difficulties. To begin with, it is unlikely that any single marker will 
have the adequate specificity and sensitivity to be clinically useful on 
its own and it appears therefore necessary to envision strategies that 
combine the use of a panel of markers. Furthermore it has been dem-
onstrated that not all (and possibly just a small fraction) of the free 
circulating DNA detectable in cancer patients is of tumour origin, 
implying that any specific molecular change has to be detected in a 
high background of normal DNA4. Although advances in analyti-
cal methods and in molecular screening technology will improve 
our current methodologies, the use of individual tumour-associated 
markers is not yet ready for clinical development of early detection 
strategies.
An attractive possibility is instead that free circulating DNA concen-
tration could by itself be related to disease status. In the past, several 
studies reported increased levels of free DNA in the serum of patients 
with various types of cancer as determined by indirect radio immu-
nological methods, by direct nick translation DNA labelling, or by 
spectrophotometry (reviewed in Pathak et al.4). The data suggested 
that increased amount of circulating DNA in advanced-stage disease 
correlated with prognosis and response to treatment. However, these 
studies used either radioactive or low sensitivity, time-consuming 
techniques, did not perform subsequent determinations during the 
course of the disease in patients, and the tumour origin of serum/
plasma DNA was not proven.
In our studies we evaluated whether the amount of circulating DNA 
in plasma could discriminate between lung cancer patients and 
healthy individuals acting as a novel diagnostic marker for an early 
detection of lung carcinoma.
Colorimetric Assay
Initially we evaluated the diagnostic potential of plasma DNA 
analysis by using both a DNA quantification assay and the molecu-
lar characterization of tumour plasma DNA through the analysis of 
microsatellite alterations5. We also assessed whether the presence 
and quantity of tumour DNA in plasma have any relationship with 
stage, histological subtype and recurrence of disease during follow-
up; and, finally, we analysed the kinetics of circulating plasma DNA 
in surgically treated patients. This study included 84 patients with 
non-small cell lung cancer, 38 of whom were also studied during 
follow-up, and 43 healthy controls.
Quantification of the circulating plasma DNA was performed using 
DNA DipStick™ Kit (Invitrogen). This colorimetric assay provides 
linear results from 0.1 to 10 ng of nucleic acid and for data analysis 
the DNA values were categorized into different classes: 0–5, 6–25, 
26–125, 126–250, 251–500, and >500 ng/ml. The analysis of loss of 
heterozygosity (LOH) and microsatellite instability was performed 
by studying microsatellite alterations at loci located at 3p14.2 
(D3S1300, FHIT locus), 3p21 (D3S1289), 3p23 (D3S1266), 3p24.2 
(D3S2338), and 3p25–26 (D3S1304), which are hot-spots of dele-
tions in lung cancer.
DNA levels were measurable in 81 (96%) of 84 patients and in 32 
(74%) of 43 controls. In patients, the mean value of plasma DNA 
concentration was 318 ng/ml, and significantly differed from the 
mean amount of 18 ng/ml observed in controls. Age and sex did not 
correlate with plasma DNA values in either group. Among tumour 
patients, no significant association was observed among plasma DNA 
values and sex, age, histotype, and tumour stage. It is interesting 
to note that DNA levels were already high even in the 14 stage Ia 
patients (320 ng/ml) when compared with control individuals. Higher 
levels of circulating DNA did not correlate with patients prognosis, 
in terms of relapse-free survival (P = 0.675) or overall survival (P = 
0.548).
A ROC curve was used to evaluate the accuracy of the DNA quanti-
fication assay and the test discriminated between the two groups; the 
best results were obtained with the classes 6–25 ng/ml and 26–125 
ng/ml plasma DNA concentration, for which a sensitivity of 75 and 
54% and a specificity of 86 and 100% were recorded, respectively. 
Overall the value of the AUC-ROC was 0.844 (95% confidence inter-
val, 0.767–0.898), indicating a good discrimination power of the test.
We also evaluated whether plasma DNA analysis could be useful in 
the follow-up of lung cancer patients in a subgroup of 38 patients. 
In 35 clinically relapse-free individuals, DNA concentrations in the 
follow-up plasma sample (34 ng/ml on average) were significantly 
lower than those recorded in the sample at the time of surgery 
(345 ng/ml on average; P < 0.001) and comparable with the value 
observed in the control group (P = 0.929 for the test for trend). Circu-
lating tumour DNA levels in relapse-free individuals showed a trend 
toward reduction with time but were already low in the 1–6-month 
interval. Conversely, four individuals showed a 2- to 20-fold increase 
in the amount of plasma DNA in the samples collected during fol-
low-up and were found to cancer carriers (two had liver metastases, 
one a local recurrence of carcinoma and the fourth patient displayed 
a new primary tumour of the liver).
The analysis of microsatellite alterations indicated the presence of 
the same allelic imbalance observed in the tumour also in the cor-
responding plasma sample taken at the time of surgery in 45% of the 
assessable patients (9 out of the 20 patients whose tumour had an 
alteration). Interestingly, the only two patients with persistent genetic 
alterations in the follow-up samples belonged to the group with 
recurrent neoplastic disease (one with liver metastasis, and the other 
with local recurrence).
The quantification of DNA amounts in the plasma of lung cancer 
patients, once a cut-off value is established, is a valuable tool to dis-
criminate between patients with disease and unaffected individuals 
and may be proposed as an early detection test as well as a comple-
mentary, non-invasive assay to follow up patients and high-risk 
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individuals such as symptomatic chronic smokers. Increased tumour 
DNA in the plasma of these subjects might prompt more accurate and 
specific clinical examinations. It is of particular interest that during 
the follow-up, both variations in DNA level and the persistence of 
genetic changes correlated with the clinical status of the patients.
Real-Time PCR Assay
To measure with greater accuracy the amount of free circulating 
DNA, a quantification approach based on real-time quantitative poly-
merase chain reaction (PCR) was developed6. Using Epstein-Barr 
virus DNA as the target genome, real-time PCR has proven effec-
tive to monitor the progress of nasopharyngeal cancer and assess 
the effects of treatment7. A single copy gene, the amplification of 
which is specific and robust, represents the ideal target for DNA-
based quantitative real-time PCR assay. For this study, we selected 
a fluorescent probe based assay designed for the human telomerase 
reverse transcriptase (hTERT) genomic sequence that performed 
consistently in preliminary experiments. Absolute quantification 
of DNA is obtained by interpolation of the experimental data on a 
standard curve generated with reference genomic DNA. Amplifica-
tion of hTERT was therefore used as a marker of the total amount of 
DNA present in plasma samples. We considered that hTERT expres-
sion and telomerase activity have been reported as prognostic factors 
in stage I non–small-cell lung cancer (NSCLC) patients. However, 
our working hypothesis was not based on the evaluation of hTERT 
expression at the transcriptional level as a tumour-associated marker, 
but was based instead on the use of a single copy gene such as 
hTERT as an indicator of the global amount of circulating DNA.
The sensitivity and the specificity of the test were validated in a large 
case-control study of 100 consecutive cases of NSCLC and 100 
controls matched by sex, age, and smoking habits.
Median concentration in patients (24.3 ng/mL) was almost eight 
times the value detected in controls (3.1 ng/mL). High concentrations 
were observed only in patients, whereas at the other end of the distri-
bution there were few patients with low concentrations of DNA (ie, 
0.5 ng/mL). The area under the ROC curve was 0.94 (95% CI, 0.907 
to 0.973), suggesting a strong discrimination power of the molecular 
assay. Although the highest sum of sensitivity (90%), specificity 
(86%), positive predictive value (90%), and negative predictive value 
(90%) was obtained with a DNA concentration value of 9 ng/mL, the 
CIs around these diagnostic indicators overlap with those of adjacent 
concentrations. The selection of the optimal cut point will therefore 
have to acknowledge this variability.
An elevated concentration of circulating plasma DNA was associ-
ated with a higher risk of NSCLC. Tertile stratification showed that 
the risk increased exponentially when study participants with plasma 
concentrations in the second and third tertile were compared with 
those in the first tertile using conditional logistic regression (up to 
85-fold). When analyzed as a continuous distribution, a unit increase 
in plasma DNA (ng/ml) was associated with a 21% increase in 
NSCLC risk (OR, 1.21; 95% CI, 1.11 to 1.31).
Analysis of the correlation of plasma DNA levels with clinicopatho-
logical data indicated that plasma DNA was significantly associated 
with age while no association was observed between plasma DNA 
levels and smoking intensity or duration, cell type, pathologic stage, 
or other features such as necrosis, lymphoid infiltration, or growth 
patterns. 
There was an association between plasma DNA and microves-
sel density that was modified by the age of the patient (significant 
interaction): plasma DNA increased with increasing microvessel 
density in younger and not in older patients.
In a subset of 35 cancer patients, a second plasma sample was col-
lected, 3 to 15 months after surgery (median elapsed time, 8 months), 
and analyzed to monitor changes in DNA levels during clinical 
follow-up. The overall median DNA concentration in follow-up plas-
ma samples was 8.4 ng/ml, showing a clear trend toward reduction, 
compared with median baseline levels of 24.5 ng/ml (P < .0001). 
When these patients were tested according to their clinical status, 
median DNA concentration at follow-up was significantly lower in 
30 disease-free individuals as compared with the five cancer patients 
with proven cancer relapse (7.1 v 24.7 ng/ml; P = .002). Examples of 
the use of DNA quantification in follow-up of patients are presented 
in Figure 1.
Of particular interest, we found increased amounts of circulating 
plasma DNA in samples from any stage and tumour size. This is par-
ticularly relevant for small lesions, the systematic detection of which 
could help reduce lung cancer morbidity and mortality. 
Storage effect
Although many studies have investigated the concentration of free 
circulating DNA, little is known about the effect of specimen stor-
age. This is particularly relevant in the context of large screening 
trials where samples are collected over a long period of time and 
analyses of biological markers are often performed at the end of the 
study when most of the clinical information has been gathered.
We therefore investigated the effects of prolonged storage of whole 
plasma or isolated plasma DNA aliquots on the plasma DNA quan-
tification assay by hTERT qPCR by comparing results of measure-
ments performed after many months of storage8. 
The results indicated that prolonged storage of both isolated DNA 
and whole plasma samples leads to substantial DNA degradation as 
measured by real-time PCR-based assays. Whether similar storage-
related degradation also occurs for other molecules (e.g., RNA and 
protein) circulating in the bloodstream remains to be determined. 
In the light of our findings, we suggest that future studies of plasma 
DNA biomarkers should involve quality control programs to deter-
mine the influence of both pre-analytic factors (i.e., factors related to 
blood sampling and processing) and analytic factors (i.e., the use of 
different procedures to quantify circulating DNA) on the variability 
of quantitative assays. 
Plasma DNA quantification in lung cancer 
computed tomography screening
Circulating DNA in plasma has been proposed as a useful marker 
for clinical management of symptomatic lung cancer patients but 
so far no studies have evaluated the impact of biomarkers and DNA 
quantification in plasma in prospective spiral-CT lung cancer screen-
ing trials.
Our prospective pilot trial of early lung cancer detection that was 
launched in Milan in 2000, applying yearly low-dose spiral CT and 
selective use of positron emission tomography (PET) to a cohort of 
1035 high-risk heavy smoker volunteers (minimum pack/year index 
of 20) aged 50 or older, also included systematic plasma sampling for 
DNA testing. 
We tested the methodology of plasma DNA quantification in a prior 
case-control study which demonstrated higher levels of plasma DNA 
in 69% of 100 lung cancer patients versus only 2% of 100 matched 
controls20 with a strong diagnostic power and a receiver operating 
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characteristic (ROC) curve of 0.94. Given the high sensitivity and 
specificity of the qPCR test, that proved to be independent from 
tumor size, we decided to test the value plasma DNA quantification 
in combination with spiral CT for early lung cancer detection. 
We performed plasma DNA quantification by hTERTqPCR in the 
entire cohort of 1035 volunteers enrolled in the early detection trial, 
based on a minimum follow-up of five years9. Statistical analysis 
was carried out to investigate the diagnostic performance and the 
prognostic value of plasma DNA levels in a lung cancer screening 
setting. 
Plasma samples were collected at first year of screening (baseline) 
and at the second year of annual screening (first spiral CT repeat) 
for all the 1035. Additional blood samples were collected from the 
screened individuals when CT was indicative of lung cancer, as well 
as at the time of lung cancer resection throughout the study. Screen-
ing performance of the assay was calculated through the area under 
the receiver-operating characteristic curve (AUC–ROC). Kaplan-
Meier analyses were computed for association with prognosis. 
Of the 1035 subjects 956 remained cancer free over the 5 years of the 
study, 38 developed lung cancer, 2 developed a lung carcinoid and 
41 developed other tumors. Clinical outcome of lung cancer patients 
was evaluated for a median follow-up period of 62 months.
Median baseline DNA levels of lung cancer patients were not differ-
ent from those of cancer-free controls, nor from the levels detected 
in patients with other tumors (AUC-ROC 0.496 (P=0.93) and 0.492 
(P=0.87), respectively) A significant result was instead achieved by 
considering DNA levels at surgery in lung cancer patients, in which 
the AUC ROC for the discrimination versus controls was equal to 
0.607 (P=0.0369). DNA levels at surgery were much higher for 
tumors detected in the first year of screening (median 10.1 ng/ml), 
with a trend toward a reduction in year 2 (4.9 ng/ml) and year 3 5 
(3.3 ng/ml, P=0.0141 for the overall comparison) and tended to be 
higher for tumors in stage II IV. In terms of diagnostic performance, 
these patterns translated into relatively high AUC ROC figures when 
considering plasma DNA at surgery in tumors detected in the first 
year of screening (AUC–ROC 0.802, P<0.0001), or Stage II-IV 
tumors detected during the first 2 years of screening (AUC–ROC 
0.866, P<0.0001).
Thirty-three patients had 2 to 4 plasma samples collected at differ-
ent time points during the 5 years of the screening up to the time 
of surgery, for a total of 93 measurements. A significant differ-
ence (p=0.0010) was observed in the amount of circulating DNA 
in plasma samples taken at all time points before surgery (n= 60; 
median 2.9 ng/ml) and those at the time surgery (n= 33; median 4.7 
ng/ml). The difference was still significant (P=0.0071) when compar-
ing DNA values in plasma samples collected within 12 months from 
surgery (n=57; median 4.6 ng/ml) versus >12 months preceding 
lung cancer diagnosis (n= 36; median 2.4 ng/ml), thus showing that 
plasma DNA tends to increase as the time to lung cancer diagnosis 
decreases.
An elevated concentration of circulating plasma DNA at surgery was 
associated with a shorter 5-years survival in resected patients. Tertile 
stratification showed that patients survival decreased for increasing 
plasma DNA at surgery ( p=0.0066). The worsening in survival ( 
33% at 5 years) was evident in patients with DNA concentrations in 
the third tertile (≥6.3 ng/ml). Because of the small overall number of 
deaths (n=11), it was not possible to estimate the adjusted prognostic 
effect of plasma DNA with multivariable analysis. However, patterns 
similar to that described above were observed in the subgroups of 
patients with tumors detected in year 1-2, year 3-5, or Stage IB-IV.
In conclusion this study showed an overall limited discrimina-
tory power of plasma DNA levels for identification of lung cancer 
patients in a CT-screening setting, with better performance in particu-
lar subsets. Interestingly, 5-year survival analysis, based on extended 
follow-up, demonstrates that a higher amount of plasma DNA at 
surgery is indicative of a poorer prognosis, and can provide clinically 
relevant information. 
To our knowledge, this study is the first attempt to investigate circu-
lating DNA in a large cohort of volunteers undergoing annual chest 
CT screening for 5 years.
Future studies, testing larger numbers of patients, will clarify if 
quantitative or qualitative analysis of circulating DNA can provide a 
fingerprint of different metastastic behaviour, and improve the clini-
cal management of CT detected lung cancer.
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In 2004, it was found that activating mutations of the epidermal 
growth factor receptor (EGFR) gene are present in a subset of non-
small cell lung cancer (NSCLC) and that tumors with EGFR muta-
tions are highly sensitive to EGFR tyrosine kinase inhibitors (TKI) 
(1-3). EGFR mutations are mainly present in the first 4 exons of 
the tyrosine kinase domain. About 90% of the EGFR mutations are 
either small deletions encompassing five amino acids from codons 
746 through 750 (ELREA) or missense mutations resulting in leucine 
to arginine substitution at codon 858 (L858R) (4). There are over 
20 variant types of deletion, e.g. larger deletion, deletion plus point 
mutation, deletion plus insertion, etc. About 3% of EGFR muta-
tions occur at codon 719 resulting in substitution of glycine to either 
cysteine, alanine or serine (G719X) (4). Also, about 3% are in-frame 
insertion mutations in exon 20. These four types of mutations seldom 
occur simultaneously. There are many rare point mutations, some of 
which occur with L858R.
EGFR mutations are predominantly found in female, non-smoking 
patients with adenocarcinoma of East Asian origin. According to the 
data of 2880 patients complied from the literature, EGFR mutations 
are highly dependent on ethnicity (East Asians, 32% compared with 
Caucasians, 7%), sex (male, 10% compared with female, 38%), 
smoking history (never smoked, 47% compared with smoked, 7%), 
and histologic type (adenocarcinoma, 30% compared with other 
types of lung cancer, 2%) (5). One of the authors (AG) performed 
the international multivariate analysis (N=3533) that involved Japan 
(N=1177), Taiwan (N=194), Hong Kong (N=215), Korea (N=203), 
Australia (N=101), Italy (N=860) and USA (N=783). Odds ratios for 
EGFR mutations were as follows; histology Adeno vs. non-adeno 
6.41 P<0.001, Smoking never vs. ever 3.03 P<0.001, Ethnicity, 
East Asians vs. other, 3.34 P<0.001; Gender, female vs. male 1.90, 
P<0.001 (Gazdar et al., unpublished observations).
It is of particular interest that EGFR mutations are the first molecu-
lar aberrations found in lung cancer that are more frequent among 
never-smoking patients than smoking patients. EGFR mutation 
frequency is inversely associated with cumulative smoking dos-
age. When we divided patients with adenocarcinomas into four 
categories depending on smoke exposure (pack year (PY) 0, <20, 
20~50, 50<), incidence of EGFR mutations decreased as smoking 
dose increased (68%, 55%, 27%, 22.5, respectively) (6). However, 
it should be noted that EGFR mutations were detected in more than 
20% of patients with a heavy smoking history. These findings should 
not be construed to mean that smoking has a preventive effect on 
EGFR mutations, rather, they suggest that EGFR mutations are 
caused by carcinogen(s) other than those contained in tobacco smoke 
and that the apparent negative correlation with smoking dose is a 
result of diluting the number of tumors with EGFR mutations with 
an increased number of tumors with wild-type EGFR as smoking 
dose increases. Indeed, this was suggested in our case-control study. 
We enrolled 152 lung patients with cancer with EGFR mutations, 
283 lung patients with cancer with wild-type EGFR, and 2,175 
age- and sex matched controls. When cumulative smoking expo-
sure was classed into three groups, cumulative exposure to smok-
ing showed a linear increased risk for lung cancer without EGFR 
mutation only (trend P < 0.001). The odds ratios (OR) for pack-year 
(PY) 1–40 and > 40 were 2.72 (1.79–4.14; P < 0.001) and 10.0 
(6.33–15.8; P < 0.001), respectively (7). In contrast, no significant 
risk changes were observed for patients with EGFR mutations (0.68 
(0.42-1.12, P=0.134) for PY1-40, 0.79 (0.42-1.46, P=0.45) for 
PY > 40) (7). These results suggest that EGFR mutations are caused 
by carcinogen(s) other than those contained in tobacco smoke and 
that the apparent negative correlation with smoking dose is a result 
of diluting the number of tumors with EGFR mutations with an 
increased number of tumors with wild-type EGFR as smoking dose 
increases. Mutations of the TP53 tumor suppressor gene caused by 
tobacco carcinogens are known to occur at codons 157, 248, or 273 
and to be predominantly a G to a T transversions. In our analysis of 
79 adenocarcinomas with TP53 mutations, six of seven mutations at 
codons 157, 248, or 273 occurred in tumors without EGFR mutations 
(6). Furthermore, of 16 mutations caused by a G to a T transversions 
occurred in tumors without EGFR mutations, again suggesting that 
a strong inverse relationship exists between EGFR mutations and 
tobacco carcinogens (6).
The KRAS gene encodes a small GTP binding protein and activat-
ing missense mutation of the KRAS gene was originally found from 
a lung cancer cell line in 1982 (8). KRAS mutations have been 
reported in various types of human cancers including pancreas, 
colorectal, thyroid, and melanoma (9). Although EGFR and KRAS 
are both oncogenes that are utilized by lung adenocarcinoma, lung 
cancer with EGFR mutations and that with KRAS mutations makes a 
distinct contrast. We were the first to report that occurrence of EGFR 
and KRAS mutations are strictly mutually exclusive (6, 10). This 
finding may be explained by the fact that the KRAS–MAP kinase 
pathway is one of the downstream signaling pathways of EGFR. 
Interestingly, KRAS mutations predominantly occur in Caucasian 
patients with smoke exposure. KRAS mutation is present ~30% of 
adenocarcinoma of Caucasian patients, while it is present in ~10% 
of Asian patients (10, 11). In above-mentioned categorization of 
patients by smoke exposure (PY 0, <20, 20~50, 50<), incidence of 
KRAS mutations increased as smoking dose increased (6, 5, 18, 18, 
respectively) (6). This trend was similar to TP53 mutations (29, 40, 
65, 66%, respectively).
The authors proposed a terminal respiratory unit (TRU) type of 
adenocarcinoma. This type of cancer is characterized by distinct 
cellular features (expression of thyroid transcription factor 1 (TTF-1) 
and surfactant proteins, and replacement type growth in the periph-
ery) which resembles those of adenocarcinomas with non-mucinous 
bronchioloalveolar cell carcinoma (BAC) features (12). Although 
mucinous BAC is a subsetof BAC according to the WHO classifica-
tion, this type of BAC does not express TTF-1 or surfactant apopro-
tein, and is thus not a TRU-type adenocarcinoma. KRAS mutations 
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are more frequent in mucinous BAC than in non-mucinous BAC (13, 
14). In our series of 195 Japanese adenocarcinomas, 149 were of the 
TRU type and 46 were of other types. Nineteen TRU-type adenocar-
cinomas associated with a significantly higher incidence of women, 
never-smokers, and EGFR mutations, but fewer KRAS and TP53 
mutations than other type of adenocarcinoma (14). EGFR mutation 
was detected in 97 of 195 adenocarcinomas, 91 of 149 TRU type 
adenocarcinomas, and six of 46 tumors of othertypes. Conversely, 91 
of 97 EGFR-mutated adenocarcinomas were categorized as TRU-
type adenocarcinomas (14).
Activating mutations of the EGFR gene result in increased and 
sustained phosphorylation of EGFR and other HER family proteins 
without ligand stimulation. It is shown that mutant EGFR selectively 
activates AKT and STAT signaling pathway that promote cell sur-
vival (15). These cells become highly dependent on these pathways, 
therefore when this pathway is inhibited by siRNA or EGFR-TKI, 
they will undergo apoptosis. Clinically, about 70% of NSCLCs with 
EGFR mutations respond to EGFR-TKIs, whereas 10% of tumors 
without EGFR mutations do so (4). Furthermore, progression free 
survival (PFS) for patients with EGFR mutations was ~10 months, 
while PFS for those treated with cytotoxic chemotherapy was ~6 
months as shown by recent pooled analysis of seven prospective 
evaluation of EGFR mutations (I-CAMP) (16) or subset analysis of 
IPASS (randomized control study for Asian, non- or light smokers 
with adenocarcinoma of the lung comparing gefitinib with chemo-
therapy) (17). On the other hand, lung cancers with KRAS mutations 
are resistant to EGFR-TKI. Many investigators including us reported 
that response rate of patients with KRAS mutations to EGFR-TKI 
is zero (18, 19). However, it is not very clear whether there is a 
difference in response to EGFR-TKI between tumors with KRAS 
mutations and tumors with neither KRAS nor EGFR mutations. 
Miller et al., showed that in their study of adenocarcinoma with 
BAC feature treated with erlotinib, some of the tumors with KRAS 
mutations showed minor tumor shrinkage, although there was no 
response by RECIST (20). Thus, it is not clear whether we should 
exclude patients with KRAS mutations from the list of patients with 
potential clinical benefit from EGFR-TKI therapy. In addition, role of 
KRAS mutations as a negative predictor of treatment by anti-EGFR 
antibody, cetuximab for the treatment of lung cancer is not clear (21), 
in contrast to established role in the treatment of colorectal cancer.
In conclusion, EGFR mutations make a sharp contrast with KRAS 
mutations in epidemiological, pathological, biological and clinical 
aspects in lung cancer. While EGFR mutation testing becomes a must 
for selecting patients that would be most benefited by EGFR-TKI, a 
role of KRAS for clinical applications is still not clear. Specific treat-
ment strategies that target activated KRAS are eagerly awaited.
Table. Comparison of EGFR and KRAS mutations in adenocarcinoma of 
the lung
Mutation KRAS EGFR
Discovery 1982 2004
Hot spots G12, G13, G61 X19 del, L858R
Mutations in other cancers Pancreas, colon and many None
Incidence in Westerns ~30% ~15%
Incidence in Asians ~10% ~50%
Smoking S>NS NS>S
Sex M>F F>M
Histology mucinous BAC non-mucinous BAC(TRU)
Prognosis poorer better
Response for EGFR-TKI poor ~ 0% good ~70%
NS, non-smokers; S, smokers; F, female; M, male.
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M26.2 Molecular Predictors of Response and Resistance to EGFR  
 Tyrosine Kinsase Inhibitors (TKI’s), Sun, Aug 2, 16:30 - 18:00
Resistance factors to EGFR TKIs
Pao, William
Vanderbilt Ingram Cancer Center, Nashville, TN, USA
Gefitinib (Iressa) and erlotinib (Tarceva) are small molecules that 
inhibit the tyrosine kinase activity of the epidermal growth factor 
receptor (EGFR). They induce dramatic responses in patients with 
non-small cell lung cancer (NSCLC) whose tumors harbor somatic 
drug-sensitizing EGFR kinase domain mutations. Unfortunately, 
~90% of patients’ tumors display primary resistance to these agents, 
and all patients whose tumors initially respond to therapy eventually 
develop progressive disease. We will review mechanisms of both 
primary and secondary resistance to EGFR tyrosine kinase inhibi-
tors (TKIs) in lung cancer. A greater understanding of these mecha-
nisms could lead to ways to overcome both primary and secondary 
resistance.
M26.3 Molecular Predictors of Response and Resistance to EGFR  
 Tyrosine Kinsase Inhibitors (TKI’s), Sun, Aug 2, 16:30 - 18:00
Second-generation EGFR inhibitors and combinations
Gatzemeier, Ulrich
Hospital Grosshansdorf, Grosshansdorf, Germany
Epidermial growth factor (EGF) receptor (EGFR) is a major target of 
molecular anticancer therapy.
Two treatment approaches involving the use of monoclonal antibod-
ies and receptor tyrosine kinase inhibitors (TKI) have been devel-
oped, and both of these approaches have shown benefits in clinical 
trials.
Although anti-EGFR therapies are active in some patients, in nearly 
all patients, the disease eventually become resistant to therapy.
Eludication of the molecular mechanism leading gefitinib or erlotinib 
resistance has led to the development of alternative strategies that 
can circumvent resistance to EGFR TKIs. These strategies have 
included development of a second generation of EGFR TKIs that 
include:
• BIBW2992
• PF-299804
• CI-1033 (canertinib)
• GW-572016 (Tykerb/Lapatinib)
• HKI-272
• EKB-569
• CL-387,785
• AE788
• BIBW2992: This compound is a novel,potent,combined EGFR/
HER2 receptor tyrosine kinase inhibitor that displays anti-tumour 
efficacy both in vitro and in vivo. The evaluable efficacy data for 
BIBW2992 is based on phase I and phase II studies and indi-
cate that patients with advanced solid tumors may benefit from 
BIBW2992. Efficacy has been seen esp. in patients with advanced 
NSCLC. A large phase III program has been initiated and started.
• PF-299804 is a highly selective,irreversible small molecule 
inhibitor of the HER family of tyrosine kinases (Pan-HER1,2,+4). 
Early signs of efficacy have been observed in highly refractory 
NSCLC in phase I. Most common AEs are typical of EGFR inhi-
bition, including skin rash,diarrhea and mucositis. Clinical trials 
are ongoing and planned in all lines of NSCLC.
• CI-1033 (canertinib) acts as a highly selective irreversible ATP 
binding site-directed inhibitor of erB-1,erB-2, and erB-4 tyrosine 
kinases. There is evidence of antitumor efficacy reported in phase 
I in NSCLC patients. The most commonly reported AEs have 
been rash, diarrhea, nausea, vomiting and asthenia.
• GW-572016 (Lapatinib) is a small molecule that is administered 
orally and functions as a dual reversible inhibitor of EGFR and 
HER2 tyrosine kinases.Lapatinib has been shown to significantly 
inhibit the proliferation of cancer cells showing EGFR and/
or HER2 overexpression both in vitro and in vivo. It`s efficacy 
in breast cancer is proven. However, the effects of lapatinib in 
NSCLC are unclear. A phase II trial comparing two schedules 
as first or second line monotherapy in patients with advanced or 
metastatic NSCLC with either BAC differentiation or no smoking 
history was negative.
Overall there are some new second generation EGFR-Inhibitors 
under development with a broader spectrum of efficacy in compari-
son to the actual evaluable drugs erlotinib and gefitinib. 
M26.4 Molecular Predictors of Response and Resistance to EGFR  
 Tyrosine Kinsase Inhibitors (TKI’s), Sun, Aug 2, 16:30 - 18:00
Prediction of Benefit from EGFR TKIs by 
Proteomic Analysis of Pre-treatment Serum
Carbone, David P.
Vanderbilt Cancer Center, Nashville, TN, USA
Unlike some tumor types, the majority of the common solid tumors 
appear not to be driven by single dominant targetable pathways. 
Instead, diseases such as lung cancer are likely to be much more 
complex and heterogeneous, with many distinct and overlapping 
subsets of tumors within the class, each of which will demand an 
in depth analysis to define the optimal therapeutic approach. These 
groups are starting to be defined by multiple technologies, and 
the simplest example is the small subset of patients with tumors 
expressing mutant EGFR, who achieve substantial clinical benefit 
from minimally toxic targeted therapy. Even for this small subset of 
patients with mutant epidermal growth factor receptors (EGFR), mul-
tiple resistance mechanisms have emerged requiring different salvage 
strategies. Ras gene mutations define a subset of patients resistant to 
these and other therapies. DNA sequence analysis will likely yield 
other small subgroups with direct therapeutic implications. 
Using the simple, inexpensive, and rapid technology of matrix-
assisted laser desorption/ionization time-of-flight mass spectrom-
etry (MALDI MS) we studied unfractionated, pretreatment sera to 
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identify NSCLC patients with improved survival after treatment with 
the EGFR TKIs gefitinib and erlotinib. Mass spectra, independently 
acquired at two institutions, gave highly concordant results, and were 
used to generate an algorithm predictive of time to progression and 
survival. This prediction algorithm was then validated in a blinded 
manner in two independent cohorts of NSCLC patients treated with 
EGFR TKIs. This classification algorithm did not predict outcome 
in three independent cohorts of patients who did not receive treat-
ment with EGFR TKIs. It also predicts survival after therapy with 
the combination of erlotinib and bevacizumab. Thus, if upheld in 
prospective clinical trials, this analysis of pre-treatment peripheral 
blood might be useful in selecting therapy for advanced non-small 
cell lung cancer patients. We are currently in the process of testing 
this signature in sample sets from past randomized clinical trials, and 
a prospective trial is underway.
M26.5 Molecular Predictors of Response and Resistance to EGFR  
 Tyrosine Kinsase Inhibitors (TKI’s), Sun, Aug 2, 16:30 - 18:00
EGFR immunohistochemistry: prediction 
of benefit from gefitinib
Cappuzzo, Federico
Istituto Clinico Humanitas IRCCS, Rozzano, Italy
In 2008, lung cancer continued to lead cancer-related death world-
wide. Although it has been recently registered a slight decline in the 
overall incidence of this disease in western countries, its incidence 
in developing countries is rising. Despite therapeutic advances, the 
prognosis of lung cancer remains poor, and the overall cure rate 
is less than 15%. Chemotherapy and radiation therapy, used in the 
management of advanced non-small cell lung cancer (NSCLC), are 
associated with significant therapeutic and safety limitations. These 
limitations can cause poor outcome in terms of disease control and 
overall survival, thus emphasizing the need for treatment approaches 
that demonstrate efficacy in targeting tumor cells. Given the rapid 
advances in the molecular and biological understanding of the 
disease process, carcinogenesis, angiogenesis, and cell growth 
regulation, several new strategies have emerged for the treatment 
of NSCLC. During the last 5 years, agents targeting the epidermal 
growth factor receptor (EGFR), or the vascular endothelial growth 
factor (VEGF) have significantly prolonged survival when used 
alone or in combination with chemotherapy. Although these agents 
are offering new hopes for NSCLC patients, definitive cure is not 
achievable in case of metastatic disease, and survival outcome is still 
disappointing, thus highlighting the urgent need for more effective 
strategies. 
Since its identification, EGFR has emerged as a crucial factor in 
the development and growth of human malignancies. EGFR signal 
transduction network plays an important role in multiple tumorigenic 
processes, contributing to proliferation of cancer cells, angiogenesis, 
and metastasis. The EGFR family includes four distinct receptors: 
EGFR/erbB-1, HER2/erbB-2, HER3/erbB-3 and HER4/erbB-4. Each 
extracellular domain of EGFR, HER3, and HER4 interacts with a 
specific set of soluble ligands, whereas no ligand has been identified 
for the orphan HER2 receptor. Binding of ligands to the extracellular 
domain of EGFR, HER3, and HER4 leads to the formation of homo-
dimeric and hetero-dimeric complexes, activation of the intracellular 
intrinsic tyrosine-kinase activity with subsequent recruitment of 
second messengers, eventually leading to intensification of the anti-
apoptotic signaling. The main strategy aimed at inhibiting the EGFR 
pathway includes agents directed against the extracellular domain 
of the receptor, such as monoclonal antibodies, or small molecules 
interfering with the tyrosine kinase activity of the intracellular 
domain, such as tyrosine kinase inhibitors (TKIs). 
Gefitinib and erlotinib are selective EGFR-TKIs that, in early phase I 
and II trials, demonstrated activity in pretreated NSCLC. Two phase 
III studies comparing erlotinib or gefitinib to placebo in pretreated 
NSCLC showed a survival improvement for individuals receiving the 
EGFR-TKI, statistically significant for patients with certain clini-
cal or biological characteristics. When compared to chemotherapy 
in a large phase III study, gefitinib demonstrated non-inferiority 
versus docetaxel in the second-line setting. On the other hand, four 
large phase III trials failed to show an improvement in survival 
when an EGFR-TKI was administered concomitantly with first-line 
chemotherapy. The INTACT 1 & 2, TRIBUTE and TALENT trials 
randomly assigned more than 4.000 chemonaïve NSCLC patients 
to standard chemotherapy (cisplatin plus gemcitabine or carboplatin 
plus paclitaxel) versus the same combination plus gefitinib (INTACT 
1 & 2) or erlotinib (TALENT and TRIBUTE). Although no differ-
ences in survival were observed between the two arms of treatment, 
some benefit was noted at the end of chemotherapy, particularly for 
never smokers, suggesting that a sequential approach could be more 
effective than a concomitant strategy. Three recent phase III studies 
strongly supported the use of an EGFR-TKI as maintenance treat-
ment after chemotherapy. The West Japan Thoracic Oncology Group 
randomly assigned 598 chemonaïve NSCLCs to platinum-based 
chemotherapy up to six cycles versus 3 cycles of chemotherapy 
followed by gefitinib. Although the primary end point of survival 
was not reached, Progression Free Survival (PFS) was significantly 
prolonged in the gefitinib arm (4.6 versus 4.2 months, p<0.001), 
with a modest but statistically significant survival improvement in 
the adenocarcinoma population (15.4 versus 14.3 months, p=0.03, 
Hazard Ratio=0.79). The SATURN trial was a large phase III study 
of erlotinib as maintenance therapy in non-progressing NSCLC 
patients treated with 4 cycles of platinum-based chemotherapy. This 
study met its primary end point showing a significant PFS prolon-
gation in the erlotinib arm. On the other hand, Mok et al. recently 
presented the results of a large phase III study (IPASS) of gefitinib 
versus carboplatin-paclitaxel in chemonaïve Asiatic NSCLC patients 
with adenocarcinoma histology. The study showed that in a selected 
patient population in which female and never smokers were over-
represented, gefitinib prolongs significantly PFS versus chemothera-
py (Hazard Ratio=0.74). Importantly in the whole population as well 
as in patients harboring an EGFR mutation, PFS improvement was 
observed after 4-5 months of treatment, further supporting a sequen-
tial approach. Another important aspect of the IPASS trial was the 
lack of efficacy in terms of response rate and PFS in patients without 
EGFR mutations. In this group of patients both response and PFS 
resulted significantly better in the chemotherapy arm, clearly indicat-
ing that even in a population enriched with clinical characteristics 
predicting sensitivity to EGFR-TKIs (Asiatic race, adenocarcinoma 
histology, female gender, never smoking status) the targeted agent is 
ineffective when the disease is not EGFR dependent, thus highlight-
ing the importance of biological as opposed to clinical selection. 
Since their identification in 2004, activating EGFR gene mutations 
have emerged as the most important predictor of response to gefitinib 
or erlotinib. Several retrospective and prospective studies confirmed 
that patients carrying an EGFR mutation were particularly sensi-
tive to EGFR-TKIs, with responses observed in up to 90%. Since 
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these early reports, it clearly emerged that a significant fraction of 
patients with EGFR mutations do not respond to EGFR-TKIs, thus 
suggesting that other mechanisms are involved in drug sensitivity. 
Importantly, increased EGFR gene copy number as assessed by Fluo-
rescence in situ hybridization (FISH) emerged as another relevant 
method for patient selection. However, although indirect comparison 
indicates that EGFR mutations could be better than EGFR gene copy 
number in predicting response to treatment, no direct comparison 
has ever been made between the two methods. Nevertheless, in 
clinical practice, particularly for patients with limited therapeutic 
options, such as those with pretreated NSCLC, response to therapy 
may not the best end point, since improvement in survival is not only 
confined to patients with tumor shrinkage. Therefore, the question 
whether mutation analysis is better than FISH for patient selection 
should be investigated in prospective randomized clinical trials with 
a control arm, which is the only way to assess the impact of such 
biomarkers on patient survival. Three randomized studies compar-
ing gefitinib (ISEL, INSTEP) or erlotinib (BR21) versus placebo 
showed that EGFR FISH positive patients treated with an EGFR-TKI 
have a significant improvement in survival when compared to EGFR 
FISH positive treated with placebo. The impact on survival of EGFR 
gene mutations was explored only in the BR21 study where erlotinib 
produced a substantial survival improvement in both EGFR mutated 
and wild type patients. 
The role of EGFR expression detected by immunohistochemistry 
(IHC) for selection of patients candidate for EGFR-TKI therapy was 
investigated in several studies with conflicting results. The first study, 
conducted among participating to the IDEAL trials, showed no asso-
ciation between EGFR expression and response to gefitinib therapy. 
Similarly, two small retrospective studies from Italy and from Korea 
showed no predictive value for EGFR expression. In the Italian 
study, involving 43 NSCLC patients treated with gefitinib, we found 
no association between EGFR protein status and gefitinib activity 
in terms of response, time to progression or survival. Similarly, no 
association with response was observed for EGFR expression in 
other retrospective analyses of patients exposed to either gefitinib 
or erlotinib. The impact of EGFR expression detected by IHC on 
survival of patients exposed to erlotinib or gefitinib has been inves-
tigated among participating to the BR21 and ISEL trials. Tsao et al. 
reported improved survival for EGFR positive patients included onto 
the BR21 trial receiving erlotinib over placebo (HR 0.68, p=0.02), 
with no difference in EGFR negative patients regardless of the treat-
ment (HR 0.93, p=0.70). However, the interaction test to compare the 
two hazard ratios was not statistically significant. In the ISEL trial, 
EGFR expressing patients treated with gefitinib had better survival 
than EGFR positive individuals treated with placebo (HR=0.77), 
with a statistically significant interaction test (p=0.049). More 
recently, a significant improvement in PFS was observed among 
erlotinib treated EGFR IHC positive patients included onto the 
SATURN trial. Nevertheless, a consisten PFS benefit with erlotinib 
was also observed in EGFR IHC negative patients. All together these 
data indicate that IHC is probably not the best method for selection 
of patients candidate for EGFR-TKI therapy. Although it is now 
clear that EGFR FISH or mutation analyses are useful for patient 
selection, with FISH that is the best predictor for survival, in clini-
cal practice it is not possible to deny an EGFR-TKI to EGFR FISH 
negative or EGFR wild type individuals. Results from the BR21 trial 
suggest that some survival benefit cannot be excluded in any patient 
subgroup, and there is no single EGFR test able to detect patients 
with no benefit at all from EGFR-TKIs, even if the expected survival 
improvement is minimal. Therefore, in the absence of any other valid 
therapeutic option, the treatment should be considered also for EGFR 
negative NSCLC. Probably, additional biomarkers or combination of 
multiple tests might allow us to identify the 30% of NSCLC patients 
in whom a TKI should not be offered.
Section M27: Emerging Field of 
Lung Cancer Research 
Sunday, August 2
M27.1 Emerging Field of Lung Cancer Research, Sun, Aug 2, 16:30 - 18:00
Molecular prognosticators of lung cancer outcome: 
lung cancer staging for the 21st century
Jablons, David M.1, 2
1 Department of Surgery, University of California San Francisco, San 
Francisco, CA, USA; 2 Helen Diller Comprehensive Cancer Center, 
University of California San Francisco, San Francisco, CA, USA
Lung cancer survivals across all stages remains at a relatively 
abysmal 15% at five years. Discouragingly, despite slow but real 
progress in the development and clinical testing of third generation 
cytotoxic therapies and new targeted treatments, survival for patients 
with advanced stage disease remains poor. Even early stage patients 
(Stage I-III) tend to have worse outcomes than similar staged other 
solid organ cancers (i.e. breast and colon). The reasons for this are 
multi-focal and unclear but relate to the complexity and heterogene-
ity of non-small cell lung cancer and its intrinsic genomic instability. 
That being said, however, there is a movement in the lung cancer 
world to embrace a new way of both staging and analyzing for both 
prognosis and prediction of response to therapeutic agents for lung 
cancer. 
Recent work dedicated to improving clinical and pathologic staging 
has produced a more accurate and validated new staging system due 
to implement fall 2009. While this staging system predicts outcome 
significantly more accurately based on TNM staging than prior stag-
ing paradigms (as it is based on vastly greater numbers of patients 
and diverse, world-wide collection), it is still predicated on old, tried 
and true, pathological criteria, i.e. tumor size and extent of regional 
and distant metastasis. 
Yet even in this new and improved staging system there will be a 
percentage of truly early stage I patients who ultimately succumb to 
their disease and thus were initially understaged by standard TNM 
criteria. Does this mean that the staging system as such is inaccurate 
or just limited by relatively crude parameters such as tumor size 
and regional metastasis? More likely the later. While many would 
argue that classic parameters of clinical and pathologic staging are 
excellent surrogates of tumor biology and outcome, we now have 
the technology and the burgeoning knowledge to better define tumor 
biology and predict outcome based not solely on physical criteria but 
on intrinsic tumor biology.
In the recent decade, investigators have been exploring the use of 
molecular predicators of outcomes in addition to classical staging. In 
almost all cases, the maximum prognostic ability of molecular assays 
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to predict outcome was best realized in earliest stages of disease i.e. 
stage I-II and, occasionally, stage III patients. This has been seen 
across multiple independent sets of analyses, patient cohorts, gene 
sets and investigators and, again, speaks to the heterogeneity and 
biologic complexity of lung cancer and especially the comparatively 
short survival times in advanced stages of the disease.
In early stage disease, especially stage I, molecular analysis of 
resected tumors has been able to separate “good’ biology patients 
with survival exceeding 80-90% from “bad” biology patients whose 
disease specific survivals are less than 30-40% despite classical TNM 
staging predicting survivals of a T1N0M0 patient of 65-70%. 
This observation has now been replicated by numerous groups of 
investigators and despite disparate gene sets and patient cohorts, 
have come up with comparatively similar results. While these early 
pioneering efforts and studies are novel and exciting they await 
further validation in larger patient cohorts either through larger retro-
spective analyses and/or prospective trials. In other words, the use of 
molecular prognostic markers allows investigators to not just identify 
patients with “bad/vs. good” biology but to more accurately identify 
those patients who by all standard criteria (TNM and PET) are early 
stage but, in fact, are really stage IV micro metastatic patients whose 
survivals are much worse. These patients might then be treated with 
systemic therapy sooner (i.e. adjuvant therapy) or closer observation. 
These new concepts of molecular staging need prospective valida-
tion and testing and prospective randomized phase III trials using the 
“metagene” microarray analysis tool are about to commence.
Because of a revolution in molecular biology and bio-informatics, it 
is hoped that the burgeoning field of lung cancer biology and the use 
of high thorough put analytic tools (such as micro arrays, multiplex 
PCR and the like) will allow rapid and reliable biologic predictors 
of lung cancer to be further tested and to emerge as standard tools 
for staging. When this occurs and it is this author’s prediction that it 
is coming quickly to the forefront of clinical management both for 
molecular staging and implementing a more “personalized’ medicine 
therapeutic strategy, then the relatively stagnant 15% 5 year survivals 
will finally begin to improve. 
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Cyclooxygenase-2 in lung cancer
Reckamp, Karen L.
City of Hope, Duarte, CA, USA
Cyclooxygenase (COX) is the rate-limiting enzyme in the conversion 
of arachidonic acid to prostaglandins (PGE) and thromboxanes. Two 
isoforms of COX have been identified, COX-1 which is a consti-
tutive enzyme produced in most cells, and an inducible enzyme, 
COX-2. COX-2 can be up regulated in response to growth factors, 
cytokines, tumor promoters, and other stimuli (1). Multiple studies 
have suggested that overexpression of COX-2 plays a significant 
role in tumor development, angiogenesis, tumor invasion, resistance 
to apoptosis, and suppression of host immunity (2-6). It has been 
reported to be constitutively overexpressed in a variety of malignan-
cies, including NSCLC (7). In murine lung cancer models, inhibi-
tion of COX-2 resulted in reduction in tumor growth and prolonged 
survival (3). Taxane chemotherapy has been shown to induce COX-2 
and PGE2 overexpression by stimulating transcription and mRNA 
stability to decrease sensitivity to chemotherapy (8, 9). Studies 
have used COX-2 inhibition to improve tumor sensitivity to both 
chemotherapy and radiation (10-13). Furthermore, additional studies 
suggest that tumor COX-2 expression promotes epidermal growth 
factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance and 
combined inhibition may improve efficacy (14, 15). 
Most trials using the COX-2 inhibitor, celecoxib for chemopreven-
tion and treatment of cancer have used an oral dose of 400 mg b.i.d. 
or less. This is based on the published studies of celecoxib in familial 
adenomatous polyposis (FAP) in which the 400 mg b.i.d. dose led to 
a significant reduction in the number of polyps compared with 100 
mg b.i.d. (16). Recently, the importance of urinary 11α-hydroxy-
9,15-dioxo-2,3,4,5-tetranor-prostane-1,20-dioic acid (PGE-M, the 
major urinary metabolite of PGE2) has been identified as a marker to 
determine the degree of COX-2 inhibition in cancer patients (10, 12, 
15). The dose of COX-2 inhibitors required to significantly reduce 
COX-2 levels in the plasma, and subsequently in the tumor, may be 
higher than previously thought (15).
COX-2 inhibition has been investigated in combination with both 
chemotherapy and chemoradiation in NSCLC (10-13). Celecoxib 
has been studied in combination with taxane-based chemotherapy 
resectable NSCLC as neoadjuvant therapy, and in advanced NSCLC. 
The combination of paclitaxel and carboplatin with celecoxib in 
the neoadjuvant setting in Stage IB-IIIA NSCLC demonstrated an 
increased pathologic and clinical response rate in comparison to 
historical controls (11). Celecoxib was also combined with docetaxel 
in recurrent NSCLC(10). Csiki et al examined the pre- and post-
treatment levels of intratumoral PGE2 and urinary PGE-M. They 
found that intratumoral levels showed a marked decline, but expres-
sion was not completely eliminated (10). The overall response rate 
was 11% and median survival was 6 months, similar to that observed 
with docetaxel alone. They also found that survival was prolonged in 
this study in patients with the greatest proportional decline in urine 
PGE-M levels. Thus, providing evidence that urinary PGE-M may 
serve as a useful biomarker to evaluate COX-2 activity in NSCLC. 
Edelman et al evaluated carboplatin and gemcitabine in combination 
with zileuton 600 mg q.i.d., celecoxib 400 mg b.i.d., or celecoxib and 
zileuton at the same doses (13). They did not find a survival differ-
ence between the treatment arms, but found that COX-2 expression 
was a negative prognostic marker for overall survival for patients 
who did not receive celecoxib. Moreover, patients with increased 
COX-2 expression (index 4) who received celecoxib had improved 
survival over COX-2–expressing patients who did not receive 
celecoxib. In a recent study, Mutter et al evaluated treatment with 
celecoxib combined with chemoradiation (carboplatin and paclitaxel)
(12). Patients who experienced complete or partial response had a 
signi ficant decrease in the level of urinary PGE-M. This data further 
suggests that selection for a population of patients who overexpress 
COX-2 or demonstrate a decline in urinary PGE-M to COX-2 inhibi-
tor therapy, may predict for improved outcomes when evaluated 
COX inhibition in combinations with chemotherapy, radiation or 
targeted agents. 
Evidence that EGFR and COX-2 have related signaling pathways 
that can interact to regulate cellular proliferation, migration and inva-
sion (14, 17-19) has triggered interest in evaluating the combination 
of COX-2 inhibition and EGFR inhibition in NSCLC. The overex-
pression of COX-2 in lung cancer stimulates the activation of Erk/
MAPK signaling in an EGFR tyrosine TKI-resistant manner through 
the COX-2 metabolite PGE2. This data strongly suggests the poten-
tial for COX-2 inhibition to augment the efficacy of EGFR inhibition 
(14). The combination of COX-2 inhibition with either celecoxib 
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or rofecoxib and EGFR celecoxib and EGFR TKI therapy with 
gefitinib or erlotinib have been investigated in multiple studies (15, 
20-22). Results demonstrate that the combinations are generally well 
tolerated, but response rates have been variable. The studies suggest 
that selecting for tumors that overexpress COX-2 may improve the 
efficacy of the combination (22). In addition, the COX-2 inhibition 
may have been ineffective in some studies due to an inadequate dose. 
Utilizing urinary PGE-M as a marker for determining the appropri-
ate dose of COX-2 inhibition may be an important strategy for the 
continued use of these agents in cancer therapy (10, 12, 15). 
A novel COX-2 inhibitor, apricoxib, is now being studied for the 
treatment of NSCLC. Apricoxib is a once-daily oral, potent and 
selective inhibitor of COX-2. Preclinical studies of apricoxib show 
in vitro and in vivo activity in human lung cancer xenograft models. 
Initial investigations focused on the combination with erlotinib in 
patients with metastatic disease (23). The combination has been 
shown to be well tolerated and demonstrated responses in patients 
who were EGFR TKI naïve. Patients who had received prior EGFR 
TKI therapy were also eligible, and 50% experienced prolonged 
stable disease. The recommended phase II dose was based on decline 
in urinary PGE-M and maximum tolerated dose. 
COX-2 is plays an important role in the tumorigenesis of NSCLC 
and in chemotherapy, radiation and EGFR resistance. Effectively 
combining COX-2 inhibition with therapeutic modalities will require 
patient selection, likely by COX-2 expression or evaluation of uri-
nary PEG-M. In selected patients, COX-2 remains a viable target for 
improving therapies for lung cancer. 
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Advances in mouse models of lung cancer 
Linnoila, Ilona
National Cancer Institute, NIH, Bethesda, Maryland, USA
Differences between mice and humans
Human lung cancers are divided into four major histological types 
that impact the clinicopathologic behavior: adenocarcinoma, 
squamous cell carcinoma, small cell (SCLC) and large cell lung 
cancer. Spontaneous lung tumors in laboratory animals other than 
the mouse are rare. Mouse tumors, both induced and spontaneous, 
are typically Type II cell adenomas, which are very infrequent in 
humans, and adenocarcinomas, which is the most common histologic 
type of human lung cancers in many countries. Another difference 
is that mouse tumors seldom metastasize. All this is changing with 
genetically engineered mouse models (GEMMs). For instance, 
conditional deletion of the tumor suppressors p53 and Rb1, which 
are altered in nearly all human SCLCs, resulted in aggressive mouse 
tumors that closely mimicked human SCLC by histology, expression 
of neuroendocrine markers and dissemination to typical metastatic 
sites (1). Likewise, inactivating somatic mutations of LKB1 are 
present in primary human lung tumors and cell lines, and LKB1 inac-
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tivation in K-ras-induced lung tumorigenesis resulted in squamous or 
mixed histology and metastases in 60% of the mice (2). 
Well-characterized human preneoplastic changes such as squamous 
metaplasia/dysplasia and carcinoma in situ have been difficult to 
replicate. Basal cells, which are thought to give rise to squamous 
metaplasia in the human lung, are exceedingly rare in mice. How-
ever, constitutive expression of the basal cell marker keratin 14 in the 
airways resulted in squamous metaplasia and dysplasia in the mouse 
lung (3). Together with pulmonary adenomas, atypical adenomatous 
hyperplasia (AAH), which is less common in humans, is the most 
prevalent preneoplastic lesion in mice. Notably, the expression of the 
achaete-scute homolog-1 transcription factor (hASH1) in Clara cells 
led to bronchiolization of alveoli (BOA), a candidate precursor lesion 
also found in human lung cancer resections (4). 
While most lung cancers in humans are derived from the epithelium 
lining bronchi and bronchioles, such neoplasms remain rare in mice. 
Many GEMMs are associated with bronchiolar or Clara cell hyper-
plasia, but emerging tumors typically show Type II cell differentia-
tion, which is implicated by the expression of surfactant-associated 
protein C (SPC) (5). One exception is inducible expression of the 
most common HER2 mutant [HER2(YVMA)] in mouse lung, which 
resulted in invasive adenosquamous carcinomas restricted to bron-
chioles (6). Interestingly, the best characterized mouse lung cancer 
stem cells (BASCs), do share the expression of alveolar SPC and 
bronchiolar Clara cell protein (CCSP or CC10) (7).
Smoking-related and chemical lung carcinogenesis 
The typical alveolar lung tumor in mouse was first recognized more 
than a century ago. For many decades, the credibility of mouse 
models suffered because of the lack of evidence that tobacco smoke, 
the main cause of human lung cancers, would lead to tumors in mice. 
The incidence of spontaneous lung tumors among the commonly 
used inbred mouse strains varies markedly from high 61% in A/J to 
low 6% in C57B16 males at 2 years that is also reflected in suscep-
tibility to induction of tumors by chemical compounds. Eventually, 
exposing mice to cigarette smoke yielded lung tumors reproducibly 
in various strains when different regimens were defined (8, 9). 
In contrast, components of cigarette smoke such as the tobacco-
specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
(NNK) and benzo[a]pyrene (B[a]P) readily cause lung tumors 
in mice, which are mainly adenomas and adenocarcinomas. The 
application of these carcinogens is simple and well-characterized and 
continues to be widely used in studies on pathogenesis, chemopre-
vention and novel therapies either as a main venue or an adjunct to 
GEMMs (10-13). Exposures to urethane and vinyl carbamate have 
been used to mimic the inflammatory changes and AAH associated 
with smoking, respectively (14, 15). Notably, treatment of mice with 
N-nitroso-tris-chloroethylurea (NTCU) by skin painting resulted in 
premalignant and invasive squamous cell carcinoma in the lungs of 
several mouse strains resembling the clinical spectrum in human 
smokers (16).
K-ras and other genetically engineered lung cancer models
Approximately one third of human lung cancers harbor K-ras muta-
tions and are resistant to standard therapies. Three main strategies 
have been used to express a mutant K-ras allele for inducing lung 
tumors in mice. In addition, it has been shown that tumors are actu-
ally dependent on this oncogene. First, a “hit and run” strategy relied 
on somatic recombination of the engineered K-rasG12D allele mim-
icking the spontaneous mutations happening under the endogenous 
promoter in humans. Second, the expression of an engineered 
K-rasG12D allele was accomplished by Cre-mediated removal of a 
stop codon sequence from LSL-K-rasG12D by lung infections with 
adenoviral vectors carrying a Cre-expressing transgene. Finally, 
using rat or mouse CCSP promoters a doxycycline-regulated and 
transgenic approach has been used to express mutant K-ras in the 
lung, respectively (17, 5). Tumors in most of the models developed 
rapidly thru bronchiolar and alveolar hyperplasias into Type II cell 
adenomas and adenocarcinomas, but rarely resulted into metastases. 
Notably, substituting adenoviral with lentiviral vectors for Cre-medi-
ated activation of the K-ras yielded slower tumor progression and 
significantly higher metastatic rate The lentiviral insertion site also 
provided a molecular identification and allowed the study of paired 
tumors and metastases revealing similar gene-expression patterns 
(18).
The reproducibility of K-ras-induced lung tumors has resulted in 
extensive literature reporting the impact of different oncogenes, 
tumor suppressor genes, various signaling pathways, microRNAs 
and other effectors as well as novel therapies on carcinogenesis (2, 
19-23). For instance, tumor growth and formation of metastases 
in mice were accelerated by ablation of p53, PTEN, Rb1 and p130 
(24-26). Histologically these modifications led to increased cellular 
atypia, desmoplasia and vascularization, which are all hallmarks of 
aggressive human lung adenocarcinomas, but rarely seen in spon-
tanous or chemically induced mouse lung tumors. 
Most non-small cell lung cancers (NSCLCs) are characterized by 
overexpression of the tyrosine kinase receptor EGFR, which is 
important to cell growth. Ten-20% of patients have somatic EGFR 
mutations that are sensitive to tyrosine kinase inhibitors such as 
gefitinib or erlotinib, but rapidly develop resistant mutations. EGFR 
mutations appear to be mutually exclusive with K-ras ones. Doxycy-
cline-regulated expression of drug sensitive human EGFR (deletion) 
mutations using lung specific CCSP or SP-C promoters led to rapid 
development of lung adenocarcinomas in several mouse lines. The 
tumors were shown to be dependent on this oncogene and sensi-
tive for the clinically used inhibitors (27-29). Additional GEMMs 
with the EGFR resistant T790M mutation alone or in combination 
with the drug-sensitive L858R mutation revealed resistance to these 
kinase inhibitors, but were potentially sensitive for combination or 
other therapies (30-32).
EML4-ALK is a protein kinase of unknown significance (33) found 
in NSCLCs as a result of a recurrent chromosomal inversion. Trans-
genic mice that expressed EML4-ALK in alveolar epithelial cells 
developed hundreds of adenocarcinoma nodules in a few weeks after 
birth suggesting that the fusion kinase has potent oncogenic activity 
(34). Oral administration of a small molecule inhibitor of the kinase 
activity of ALK resulted in their rapid disappearance.
The role of inflammation and immunosuppression in lung cancer
Chronic inflammation can predispose an individual to cancer and 
patients with chronic obstructive pulmonary disease (COPD) have an 
increased risk of lung cancer (35). Mouse models of lung carcino-
genesis and inflammation have involved two main approaches. 
In the first one, existing or newly developed tumor models were 
analyzed for the inflammatory pathways, and in the second one the 
lung’s inflammatory environment has been genetically altered and its 
impact on carcinogenesis was studied.
Activation of K-ras in the mouse lung generates an inflammatory 
process (36). In addition, a recent study was able to show over 
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3-fold increase in the promotion of carcinogenesis by COPD-like 
airway inflammation. In this model, mice carrying G12D-activated 
K-ras-allele in airway secretory cells were exposed to Haemophilus 
influenzae (5). While a great deal of attention has been devoted to the 
critical impact that macrophages may have on mouse lung carcino-
genesis (37, 38), modulation of immune function in general may 
also be an important determinant of lung tumorigenesis. Evidence 
for the central role of regulatory T cells in lung tumorigenesis was 
obtained using three complementary murine models that depended 
on mutant K-ras: a chemical NNK-driven, a syngeneic inocula-
tion and a transgenic model (39). Mice lacking Foxp3+ regulatory 
T cells demonstrated a 75-90% reduction in lung tumorigenesis. 
The results support clinical testing of rapamycin, known also for its 
anti-Akt activity, or other agents that may target regulatory T cells in 
K-ras-driven human lung cancer. In a study exploring the potential 
of immunotherapy for lung cancer, a novel system was established in 
which a well-chracterized T-cell tumor antigen was overexpressed in 
autochthonous, Cre-Lox-regulatable mouse model (40). The analysis 
revealed multiple levels of immune tolerance that limit an effective 
T-cell response against a tumor-associated antigen. 
The significance of these models is that they are able to address and 
manipulate the complex interactions of inflammatory process one 
component at a time, which is a hallmark of good modeling. There 
are an increasing number of examples how expressing cytokines, 
chemokines and activating inflammatory pathways in the lung will 
modify the local environment thus providing models to analyze 
tumorigenesis as well (41). Not surprisingly, NF-κB has emerged as 
a central effector of inflammatory responses in the lung. For instance, 
following urethane treatment, tumor formation was only observed 
in strains of mice with early NF-κB activation and inflammation in 
the lungs. Using an inducible transgenic mouse model to express 
a dominant inhibitor of NF-κB in airway cells, it was shown that 
urethane-induced inflammation was blocked and tumor formation cut 
in half (42).
Translation of mouse models
In many cases mouse models have already become an integral part 
of lung cancer research. Multifaceted experimental approaches using 
mouse models have incorporated also cDNA microarray analyses, 
isogenic cell-based assays, well characterized cancer cell lines and 
xenografts (39,43, 44, 45).
While the strength of GEMMs is the ability to effectively test in vivo 
both clinical and in vitro observations as well as to elucidate signal-
ing pathways regarding lung carcinogenesis, an important goal of the 
research on mouse models remains to perform preclinical experi-
ments and to prepare for the emerging personalized cancer therapy 
(30, 46-48).
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Isolation and expansion of the tumorigenic 
lung cancer stem cell population
De Maria, Ruggero
Istituto Superiore di Sanità, Rome, Italy
Cancer stem cells are the population of undifferentiated cells 
responsible for tumor initiation, maintenance and spreading. In the 
last decade, the existence of such a minute population of tumorigenic 
cells has been demonstrated in a number of tumors. The intense 
efforts on discovery and characterization of cancer stem cells lay in 
the assumption that this cell population should represent the target of 
effective therapies aimed at eradicating tumors.
Recently, our group demonstrated the existence of a tumorigenic cell 
population that sustains lung carcinomas, and this discovery may 
contribute significantly to the development of effective therapies 
to eradicate this leading cancer killer. The tumorigenic cells are 
included in the high-density CD133+ population, which accounts for 
less than 1% in the majority of the small cell and non-small cell lung 
carcinomas examined. The injection of 104 CD133+ cells is able to 
reproduce the original patient tumor in immunocompromized mice, 
while a 10-fold higher number of CD133- cells are not tumorigenic. 
We developed serum-free culture conditions that allowed the unlim-
ited expansion of undifferentiated CD133+ cells as tumor spheres, 
which differentiate into mature tumor cells upon growth factor 
removal and exposure to serum. Upon differentiation, lung cancer 
CD133+ cells acquire the specific lineage markers, while losing the 
tumorigenic potential together with CD133 expression. 
The availability of exponentially growing cancer stem cells rep-
resents a powerful tool for the development of new therapeutic 
compounds targeting specific survival pathways of the tumorigenic 
population. Moreover, the use of cancer stem cell-based xenografts 
which reproduce the parental tumor, as assessed by morphologi-
cal and molecular analysis, offers a unique opportunity to test new 
anticancer treatments and potentially optimize future individualized 
therapies. 
We are currently characterizing the lung cancer stem cells at different 
levels, including drug screening, genome-wide expression of mRNA, 
microRNA and proteome profiling. Such extensive characteriza-
tion may allow the identification of more specific markers of the 
tumorigenic cell population, while providing key information on the 
relevant pathways to be targeted for successful therapies. 
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What is the definition of resectable N2 disease?
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Switzerland
N2 disease in non-small cell lung cancer (NSCLC) is defined as lung 
cancer with metastasis to the ipsilateral mediastinal lymph nodes 
in absence of distant metastasis. This stage is relatively frequent as 
it occurs in about 30% of newly diagnosed NSCLC. However, N2 
disease is a heterogeneous entity and encompasses a broad spec-
trum of metastatic lymph node involvement. On one side includes 
microscopic disease found unexpectedly at surgery despite careful 
preoperative evaluation and on the other side a multilevel bulky 
lymph node involvement of the ipsilateral mediastinum. Furthermore 
other factors such as histology, T-stage, performance status, and other 
patient related criteria will have an impact on the prognosis. 
None of the other stages of NSCLC lead to a more controversial 
discussion regarding the overall management than the situation of 
N2 disease. Depending on the experience of the team responsible for 
treatment decisions, different algorithms are applied. Due to the lack 
of fully convincing randomized trials the diversity of phase II studies 
and especially the inhomogeneity of the study population, it is not 
surprising that the available evidence is interpreted differently and 
discussed controversially. Survival data may differ widely between 
studies and an explanation is often elusive. Patient selection is among 
other factors the key for differences in outcome. Unfortunately N2 
disease is often imprecisely described. Several authors have proposed 
that N2 disease should be divided into subgroups. For example Rob-
inson proposed 4 subgroups (1. Incidental nodal metastasis found on 
final pathology, 2. Nodal metastasis recognized intraoperatively, 3. 
Nodal metastasis recognized by prethoracotomy staging, 4. Bulky or 
fixed multistation N2 disease).
The question, whether N2 disease can be considered resectable can-
not be answered easily since several co-founding factors play a role. 
The question includes at least for different aspects. The first aspect is 
regarding the technical resectability. The surgeon has to answer if the 
affected lymph nodes are completely removable from a macroscopic 
standpoint. This question is a prerequisite and is typically answered 
by analysing images especially the CT or PET/CT by an experienced 
surgeon. Further tests such as mediastinoscopy may be needed for 
final evaluation. The second and even more critical aspect relates to 
the question if local resection is useful for the patient since N2 dis-
ease may be the tip of an iceberg and indicate more than just locally 
advanced disease, a disease with systemic spread of tumor cells to 
other organs. The third aspect regarding the usefulness of resection is 
the response rate of the tumor and mediastinal lymph nodes to neo-
adjuvant chemo- or chemoradiotherapy. Finally the fourth aspect has 
to take into account the risk benefit ratio for the patient regarding the 
treatment. It is relevant for the decision making to evaluate to what 
risk the patient is exposed when a lobectomy or pneumonectomy is 
performed after neoadjuvant therapy.
When the question has to be answered if N2 disease is resectable or 
in other words when surgery is indicated or not, subgroups can be 
defined which allow a clear answer and most oncologists, surgeons 
and radiotherapists might agree. One subgroup is N2 metastasis 
found unexpectedly during surgery. If a radical resection of the tumor 
as well of the lymph nodes is possible and tolerated by the patient, 
surgery should be completed and adjuvant therapy is recommended. 
On the other hand in cases of bulky multistation N2 at initial diagno-
sis and especially after neoadjuvant therapy, surgery is not indicated 
since the patient will not experience a profit. The main controversy 
occurs in cases with initially diagnosed N2 disease at either a single 
or in some adjacent stations but surgically resectable. These patients 
are recommended either to undergo neoadjuvant chemo- or chemo-
radiotherapy followed by surgery or definitive chemo-radiotherapy 
without surgery. However the term resectable is not clearly defined 
by authors and depends from the expertise and subjective judgement 
of the surgeon.
Despite the fact that two randomized trials did not show a survival 
benefit in the arm which included surgery after chemo-radiotherapy 
in comparison to chemo-radiotherapy alone there remain some open 
questions. The North American intergroup 0196 trial reported a 
treatment related mortality of 7.9% in the surgical arm in comparison 
to 2.1% in the medical arm. The mortality was especially high in 
pneumonectomies with 26%. Despite this unusually high mortality 
the 5 year survival in the surgical arm in those patients with complete 
clearance of the mediastinal lymph nodes was 41% and significantly 
higher. Furthermore patients who underwent a lobectomy experi-
enced a significantly better survival than non-surgical patients. Taken 
into account that other centres report a much lower perioperive mor-
tality even in pneumonectomies after neoadjuvant therapy the role of 
surgery has to be considered at least in centres with a high expertise. 
We reported recently a 3% mortality rate in 172 pneumonectomies 
after chemoradiotherapy for stage III disease treated in two different 
centers.
In the EORTC trial reported by van Meerbeck there was also no 
survival benefit in the surgical arm in comparison to the chemoradio-
therapy alone arm and the overall 5-year survival was 16.4months. 
However 50% of the patients had an incomplete resection and the 
patients which were included had irresectable N2 at study entry. In 
the multicenter phase II SAKK study reported by Betticher patients 
with N2 disease and treated by neoadjuvant chemotherapy and 
surgery the 5-year overall survival was superior with 27.6 months. 
This outcome was even better in those patients who experienced a 
complete remission of the mediastinal nodes and underwent surgery. 
It is of importance that patients who present with N2 disease should 
be evaluated by a multidisciplinary team including an experienced 
surgeon in thoracic oncology in order to select patients for the 
appropriate treatment either in a study protocol or an individualised 
regimen which respects the local expertise.
Further aspects and other data will be discussed in detail during the 
conference.
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What is the definition of “resectable N2 
disease”? - Medical oncologist’s view
Eberhardt, Wilfried E.; Gauler, Thomas C.
Department of Medicine (Cancer Research), West German Tumor 
Centre, University Hospital of University Duisburg-Essen, Essen, 
Germany
Introduction
Stage III A(N2) non-small-cell lung cancer (NSCLC) represents 
a heterogenous group of lung cancer patients (pts). It includes pts 
with one lymph node involved within one lymph node station up 
to diffuse lymphangiogenic infiltration of multiple nodes in mul-
tiple lymph node stations/zones of the ipsilateral mediastinum and/
or bulky mediastinal nodes. Besides this loco-regional pattern of 
disease spread there are a number of clinical, medical and prognos-
tic factors that have to be taken into account when discussing the 
overall treatment strategy for these pts groups. Moreover, it cannot 
be overlooked, that differences in the pretherapeutic staging methods 
involved in the individual study even more lead to different pts selec-
tions and overall treatment results. It is therefore necessary to strictly 
base clinical data analysis on these staging factors. Newer methods 
besides mediastinoscopy – such as PET/CT or EUS/EBUS – even 
more complicate the overall picture of this issue and have led to pos-
sible new algorithms of management in these pts. A more evidence 
based standardization seems to be clearly warranted for future data 
comparisons and for the development of new treatment paradigms in 
this setting.
Material and Methods
A systematic review has been undertaken looking at the literature 
for “resectable N2-disease“ in NSCLC and at “prognostic factors“ 
in “stage III(N2) NSCLC“ within PUBMED. The investigations 
were grouped according to their results and the identified prognos-
tic factors and their relevance on treatment descisions and survival 
prognosis. Whenever available, findings from multivariate analysis 
were included into the evaluation. A specific impact of factors on 
resectability of the pts was analysed besides. Methods of pretreat-
ment staging were taken into account for the individual investiga-
tions. Prospective investigations were clearly separated from strictly 
retrospectively gathered datasets and marked as such.
Results
The largest database on the prognosis of stage III NSCLC pts has 
been gathered by the IASLC staging project. Preliminary data 
from this analysis show that there are considerable differences in 
long-term survival between pts with single zone N2-disease versus 
multiple zone N2-disease [1]. Unfortunately, this dataset has not been 
large enough to give definitive clear prospective recommendations. 
Only recently, there has been a prospective validation of this classifi-
cation in a South Korean population [2]. These data can be compared 
to the retrospective data analysis by the French group on resected 
stage III(N2) disease [3]. Single node metastases not preoperatively 
known turned out to have the best prognosis. These patients can be 
considered to be prognostically resectable as the long-term survival 
data are found to be encouraging following surgery. These findings 
have already been subsummed within a classification published by 
Robinson et al in the ACCP-guidelines [4]. Generally, four cathe-
gories of N2-involvement are differentiated. Two cathegories can 
only been identified and grouped following surgery. IIIA1 is only 
incidentally found at pathological investigation of resected specimen 
and lymph nodes. IIIA2 is single node metastases again only noticed/
detected intraoperatively. These two groups have an adequate long-
term prognosis with the inclusion of resection/surgery. However, the 
problem is, that with current methods these pts cannot be identified 
preoperatively. Management of these pts would typically include 
both surgery as well as adjuvant chemotherapy [5]. If staging or 
new imaging methods such as PET/CT or EBUS reveal some pts 
to have single or multiple node metastasis: IIIA3 cathegory, these 
patients are typically candidates for multidisciplinary approaches of 
chemotherapy or chemoradiotherapy plus/minus definitive surgery 
[6]. Patients with bulky N2-disease –IIIA4 are usually handled with 
concurrent chemoradiation without surgery. It is not clear whether 
surgery has any role in selected pts of this subset. However, there 
are individual series of pts that have been published showing an 
excellent response to induction chemotherapy or chemoradiation 
protocols and these were then considered for thoracotomy. On the 
other hand, these pts would be the typical pt selection for concurrent 
chemoradiation protocols or clinical studies. Further prognostic or 
clinical factors that have been investigated and identified in this set-
ting of N2-disease are: pretreatment weight loss, performance status, 
pretreatment serum LDH, gender, age, T-factor, histopathology, 
proliferative index, microvessel density, bulky mediastinal lymph 
nodes (eg. >2.5 cm), extracapsular spread for mediastinal nodes. Up 
to now, the majority of publications have only looked at selected 
subsets of these factors. No clear picture can currently be drawn 
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concerning the overall value of these parameters in the pretherapeutic 
staging and the treatment descision planning. The whole issue is even 
more complicated as comorbidity factors have not been prospectively 
analysed in this setting. Nevertheless, these important factors clearly 
determine medical operability as well as the intensity of combined-
modality approaches let it be concurrent chemoradiotherapy proto-
cols or induction protocols followed by surgery. 
Conclusions
As long as prospectively validated pretreatment prognostic factors 
are missing in this setting of stage III(N2)-disease, no clear and 
definite recommendation can be made for the guidance of treatment 
descisions. Most of the groups have accepted that single node/zone 
involvement versus multiple nodes/zones involvement of N2-nodes 
has a considerable impact on overall prognosis and could be used at 
least for stratification within clinical studies. It is generally accepted 
that it is necessary to rule out N3-disease with adequate investiga-
tions. Prospective evaluation or validation of treatment principles 
in pts with stage III(N2) should be strongly encouraged to generate 
more evidence in this clinical setting. Multicenter databases or joint 
databases from cooperative trials/groups would be an important first 
step to move forward in this curative treatment situation.
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Role of pneumonectomy in the management 
of resectable non-small cell lung 
Landreneau, Rodney J.
The University of Pittsburgh Medical Center, Pittsburgh, PA, USA
There is growing concern with the role of pneumonectomy as a 
surgical option for the management of non-small cell lung cancer. Of 
course, the patient’s cardiopulmonary physiologic limitations can be 
a primary determinant leading away from pneumonectomy mandat-
ing a careful physiologic assessment prior to surgery if this extent of 
resection is required. 
This concern is even greater when pneumonectomy is required fol-
lowing induction chemotherapy / radiation therapy for resectable but 
regionally advanced lung cancer. Indeed, some recent investigations 
have identified a detrimental overall effect on survival compared to 
chemo-radiation therapy alone when pneumonectomy is required 
(North American Inter Group Study 0139).
Many oncologists, pulmonary specialists, and thoracic surgeons are 
now avoiding the recommendation for surgery following induction 
therapy for stage III when the likelihood of pneumonectomy is high 
if surgery is performed. As an extension of this philosophy, other 
surgeons and medical oncologists are tempering their enthusiasm 
for surgical resection, particularly pneumonectomy, when clinical 
evidence of any residual viable tumor exists in the mediastinal nodes 
following induction therapy.
Pneumonectomy is associated with significant alterations in the 
patients cardiopulmonary physiology. Anatomic distortion and 
the involvement of vital pulmonary hilar structures (vascular and 
airway) associated with tumors requiring pneumonectomy for surgi-
cal extirpation lead to a potential increased possibility of important 
complications during and after surgery. Certainly, sleeve lobectomhy 
with bronchoplasty resection should be considered as an alternative 
to pneumonectomy when technically feasible.
In spite of these limitations, there are many patients who can benefit 
from pneumonectomy when lesser resections are not feasible. Further 
investigation into the role of pneumonectomy for the management of 
regionally advanced non-small cell lung cancer is warranted.
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Surgical complications for pre-operative therapy
Grunenwald, Dominique H.; Assouad, Jalal; Gounant, Valerie
University of Paris, Hopital Tenon, Paris, France
Surgical resection is a potentially curative treatment for resectable 
non-small cell lung cancers (NSCLC). Induction therapy became 
popular among oncologists since 1994, when two small (120 patients 
in all) phase III trials of preoperative chemotherapy in stage IIIA 
NSCLC began to transform the treatment of these patients [1, 2]. 
Then, several phase III trials had started, all of which concentrated 
on stage III disease except for one study which included earlier stag-
es [3]. This induction chemotherapy trial was widely criticised at the 
time, particularly because surgeons had little confidence in treating 
the cancers medically, suggesting that it made surgery more difficult 
and dangerous. Despite the overall results of this French study were 
considered to be negative, trials on the early stages of the disease 
using newer drugs, known to be much more effective and much less 
toxic, were initiated on the basis of fragmentary results. The attitude 
of surgeons had changed considerably in the meantime and most of 
thoracic surgeons collaborated with oncologists to improve overall 
outcomes through multimodal strategies. Thoracic radiation therapy 
was added to preoperative treatment in several groups for locally 
advanced diseases, in an attempt to offer surgery to patients with 
marginally resectable tumors [4].
As soon as a preoperative therapy was given to the patients, the 
issue of its consequences on the postoperative course was adressed. 
When the postoperative lethal toxicity rate was not different in both 
arms in the spanish historical randomized trial comparing preopera-
tive chemotherapy plus surgery with surgery alone (2 deaths in each 
arm), by contrast the french study showed a nonsignificant excess of 
morbidity in the preoerative chemotherapy arm [1,3]. The postopera-
tive mortality rate in both studies (6.6% and 7,8%, respectively) was 
similar to that reported in phase II studies [5]. The most frequently 
observed complications in the French trial were empyemas and 
broncho-pleural fistulae. Authors suggested that a better surgical 
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management could prevent this postoperative morbidity, and new 
chemotherapy regimens might be less toxic than the triplet (mitomy-
cine, ifosfamide, cisplatin) utilized in the trial. Using a more modern 
association, a group from Switzerland reported a lower 30-day 
mortality rate (3% of patients with tumor resection) [6]. In this study, 
surgical resection after neoadjuvant docetaxel-cisplatin treatment 
was also well tolerated after right pneumonectomy (49% of patients 
with tumor resection), which was previously been associated with 
unacceptable morbidity and mortality [7]. Yet, right pneumonectomy 
is generally considered as a predictor of postoperative mortality, in 
patients treated preoperatively with chemotherapy alone or chemo-
radiotherapy [8]. Moreover pneumonectomy per se is worldwidely 
associated with a higher rate of postoperative mortality compared 
to lesser resections [9]. Indeed the surgical mortality after thoracic 
operation without chemotherapy ranges from 0.5% to 4% after lobec-
tomy, and from 2% to 12% after pneumonectomy, respectively [10]. 
On the other hand, a retrospective analysis in 380 NSCLC patients 
found no significant difference in the overall incidence of postopera-
tive morbidity and mortality in patients who received neoadjuvant 
chemotherapy plus surgery versus surgery alone [11]. Besides, results 
from the Bimodality Lung Oncology Team phase II multicenter trial 
also demonstrated good tolerability for induction chemotherapy in 
a multicenter setting [12]. Nevertheless, high rates of perioperative 
morbidity and mortality have been reported elsewhere, preventing 
definitive conclusions [10]. Addition of radiotherapy to neoadjuvant 
treatment seems to increase substantially the rate of postoperative 
complications especially following pneumonectomy [13]. A retro-
spective analysis of 350 patients who underwent thoracotomy after 
chemotherapy followed by concurrent chemoradiotherapy showed 
a 44% rate of early or late complications [14]. The hospital mortal-
ity rate was 4.9%. The causes of death were sepsis, pneumonia and 
respiratory failure, acute respiratory distress syndrome (ARDS), car-
diac failure and lung embolism. Age, performance status, abnormal 
echocardiographic findings and no bronchial stump covering tech-
nique were significant predictors for perioperative morbidity. Lower 
Karnofsky status and increased age were significant risk factors for 
postoperative mortality. Among the surgical complications observed 
after neoadjuvant therapy, the most frequently reported are arrhyt-
mia, hemorrhage, pulmonary embolism, pneumonitis, pulmonary 
edema, respiratory infection, empyema, and bronchopleural fistula. 
Interestingly, when induction chemotherapy has become a paradigm, 
actually supported by a recent meta-analysis, pre-operative chemo-
radiation, including high doses protocols, continues to be proposed 
by several groups of investigators, who consider it as well tolerated 
[15,16]. 
Conclusions : Wether pre-operative therapy increases post-operative 
morbidity in patients with NSCLC remains controversial. Improve-
ments of surgical and peri-operative care are likely to decrease the 
rate of technical complications. Other morbidities like pneumoni-
tis, or ARDS are remaining unexpected adverse events. A better 
knowledge of pejorative predictive factors should lead to an adequate 
selection of patients who would be candidates for surgical resection 
following induction treatments. 
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Involvement of the T-Spine, including Pancoast tumors
Walsh, Garrett L.
The University of Texas MD Anderson Cancer Center, Houston, TX, 
USA
Introduction 
Lung cancers that involve the thoracic spine, including superior 
sulcus tumors, represent some of the more technically challenging 
resections for the General Thoracic surgeon, based on the complex 
neurovascular and boney relationships of the thoracic inlet. While 
many centers would consider a lung cancer with spine extension to 
be unresectable, recent advances in multidisciplinary neoadjuvant 
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and adjuvant regimens combined with surgery can result in cure. 
Therefore, aggressive resections, including vascular grafting and 
vertebral body resections are justified in selected patients. 
Patient Selection
A patient can often present in a debilitated state, secondary to severe 
and chronic pain from bone (rib or vertebral body) or nerve root 
invasion. While a clinical first impression of such a patient might 
suggest “medical inoperability”, optimal pain control with narcot-
ics can quickly improve a patient’s well being and nutritional status 
and make them eligible for a “curative intent” surgical treatment 
protocol. While neoadjuvant regimens have been most widely imple-
mented, our combined modality approach at the University of Texas, 
M.D. Anderson Cancer Center is to perform the resection first and 
give concurrent chemotherapy (cisplatin and etoposide)and radiation 
therapy (65Gy) in the post-operative period. This permits an uninter-
rupted course of high dose radiation therapy. Some key points in our 
selection of patients for resection include:
1. The physical examination is of paramount importance. Patients 
who present with ipsilateral motor loss in the hand and arm often 
have frank invasion of the brachial plexus more cephalad than 
the T1 root and usually cannot be helped surgically. 
2. Confirmation of histology is essential. There can be infectious 
etiologies (fungal and bacterial) and other non-bronchogenic 
malignancies which can present with similar clinical (Horner’s 
syndrome) and radiographic findings which can mimic a Pan-
coast tumor
3. Patients are evaluated with CT/PET scans, as is standard for all 
lung cancer patients. Additionally, MRI’s are routinely employed 
in all patients with superior sulcus tumors to better evaluate the 
subclavian vessels, brachial plexus, vertebral body and neural 
foramina. Tumor location, by MRI, will dictate the surgical 
approach as posterior only (the tumor is behind the vessels), 
anterior only or a combined anterior and posterior resection. 
4. Prior to resection, the mediastinum is evaluated for nodal disease 
(Endoscopic bronchial ultrasound (EBUS) or video-mediasti-
noscopy). The finding of N2 disease portends a poor prognosis 
and such a patient would be treated in a non-surgical manner. 
A patient with ipsilateral N3 (supraclavicular disease) behaves 
biologically more in an N1 fashion and would be considered for 
resection. 
Surgical Approaches:
Posterior (with or without vertebral body involvement):
This is a standard approach for posteriorly situated tumors which 
based on MRI are posterior to the subclavian vessels. These tumors 
at minimum will require resection of the first rib. If it does not 
involve the first rib, I do not consider them true superior sulcus 
tumors but merely upper lobe tumors with extension to the lung 
apex. Most superior sulcus tumors will require additional resection of 
the second and often third and even forth ribs. Preoperative review of 
the MRI with a spine surgeon is important to assess involvement of 
any elements of the spinal column, including the transverse process, 
vertebral body proper, pedicle, neural foramen with or without epi-
dural extension. This may extend over several levels. If the spine is 
involved, a midline posterior approach with laminectomy and stabili-
zation may be required prior to entering the chest. Some key points:
1. If anticipated spinal involvement, the patient is positioned with 
the head immobilized in cervical tongs. A bean bag stabilization 
is required in the lateral positioning to avoid rotation of the torso 
during the chest wall resection and to maintain alignment of the 
spine if rodding is required. 
2. If posterior stabilizing hardware is anticipated (because of ver-
tebral body involvement), appropriate skin incision placement is 
critical to avoid angles with ischemic skin islands
3. Muscle advancements or rotations may be required if spinal 
hardware is anticipated. This must be well thought out prior to 
the skin incision.
4. If there is no spine involvement, then a standard, high postero-
lateral thoracotomy is performed with division of the latissimus, 
trapezius, rhomboids and reflection of the serratus anterior
5. The chest is entered a rib below the lesion. Palpation is used to 
guide the extent of chest wall resection
6. The scapula is elevated from the chest wall with one blade of a 
Finochietto retractor or an internal mammary retractor
7. The scalene posterior muscle insertion into the second rib is 
divided. 
8. A subperiosteal resection of the first rib anterior to the tumor is 
performed. 
9. The subclavian vessels course vertically in the lateral decubitus 
position and must be gently dissected away from the first rib
10. A Gigli saw or a notched, first rib cutter are used to divide the rib 
anterior to the tumor
11. Posterior rib disarticulation is performed in a caudal to cephalad 
manner. The direction of disarticulation is always away from 
the neural foramina to avoid inadvertent spinal cord injury. The 
nerves are ligated as they exit their respective foramen. 
12. The T1 root exits below the neck of the first rib and courses at an 
angle to join the C8 root. The T1 root usually requires resection. 
Every effort through neurolysis should be made to preserve the 
C8 root. The stellate ganglion is resected during the extrapleural 
dissection once the chest wall has been freed
13. Partial or complete vertebral body resection can be performed 
from a lateral approach. An endo lesional resection can be 
performed of the vertebral body once the specimen is removed. 
While counter thoracic oncologic principles, this has not been 
associated with a higher local recurrence rate and permits a more 
rapid resection and reconstruction from a lateral approach. 
14. Once the chest wall component is mobile, a standard lobectomy 
and mediastinal dissection is performed. For bulky tumors, the 
lung parenchyma is divided with a GIA stapler to remove the 
specimen for pathologic frozen section review and to facilitate 
dissection of the pulmonary hilum for the completion lobectomy
15. The chest wall defect if small is not reconstructed. If three or 
more ribs have been removed, then the defect is reconstructed 
with polypropylene mesh or PTFE to avoid scapular tip entrap-
ment and perhaps to improvement post-operative chest wall 
mechanics.
Anterior approach
For tumors, based on MRI imaging, that may abut or involve the 
subclavian vessels, involve the anterior portion of first rib, have 
documented or suspected supraclavicular nodes or a tumor in which 
the proximal involvement of the brachial plexus is unknown, the 
anterior surgical approach either alone or in combination with a 
posterior approach is preferred as the initial approach. This permits a 
safe dissection with proximal control of the vasculature and grafting 
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if necessary. Complete, en-bloc dissections can be performed from an 
anterior approach including upper lobectomies, and vertebral body 
resections. Key points include:
1. Initial positioning of the patient by rotating the neck away from 
the tumor. 
2. If an EBUS has not been performed, then the mediastinoscopy 
incision should be placed in such a manner that it can be incor-
porated into the full incision if N2 disease is ruled out at frozen 
section. 
3. Incisions can include a transverse incision over the clavicle or an 
L-shaped incision along the anterior border of the sternocleido-
mastoid extending along the inferior border of the clavicle or 
lower if a anterior lobectomy is anticipated (trap door)
4. The medial half of the clavicle can be excised which permits 
excellent exposure however the post-operative functional and 
cosmetic results (arm drooping and rotation) can be problematic
5. The Grunenwald modification with division of the manubrium 
and maintenance of sternoclavicular joint is preferred pres-
ently. The first rib is divided medially to permit the clavicle and 
attached manubrium to rotate laterally
6. A standard dissection of the scalene fat pad is first performed 
with ligation of internal jugular vein. 
7. If the subclavian vein is involved, it is resected en-bloc without 
reconstruction
8. Care is taken on the left to ligate the thoracic duct
9. The scalene anterior muscle is divided either at the tubercle of 
the first rib or superiorly if involved by tumor
10. Care is taken to preserve the phrenic nerve and proximal vagus 
nerve and its branch the recurrent nerve, if possible
11. A subadventitial dissection is next performed along the subcla-
vian artery
12. One must ligate the internal mammary artery carefully, especially 
in a heavily radiated field
13. If a short segment of the subclavian artery is involved, it is 
grafted with a 6mm or 8 mm graft. For tumors on the left, which 
extend more proximally along the subclavian artery, the graft 
can be placed to the aortic arch from the front. More extensive 
involvement can be addressed with a carotid-subclavian graft 
anteriorly and subsequent proximal ligation of the subclavian 
from the aortic arch at the time of the posterolateral thoracotomy.
14. The brachial plexus exits just lateral to the scalene anterior mus-
cle. Neurolysis under direct vision is optimal from an outward to 
inward fashion. 
15. The first rib and the T1 root can be cut posteriorly from the ante-
rior approach
16. For en-bloc vertebrectomies, the anterior approach can be used to 
perform the initial vertebral body dissection medial to the carotid 
sheath. The trachea and esophagus can be gently retracted as 
a unit away from the vertebral body. The prevertebral fascia is 
scored with electrocautery. An osteotomy is performed from the 
front medial to the tumor. The lobectomy, chest wall resection 
and nodal dissection can also be completed from the anterior 
approach. The patient is then repositioned prone. From a pos-
terior midline approach, contralateral spine stabilization is first 
performed, followed by several level laminectomies, intraspinal 
(extradural) ligation of the T1, T2 and possibly T3 roots can be 
performed followed by completion of the hemicorporectomy by 
osteotome to connect to the previously placed vertebral body cut. 
The specimen can now be rotated away from the dural sac and 
spinal cord, avoiding the need for a thoracotomy. 
Summary:
Through multidisciplinary approaches and detailed preoperative 
radiographic planning, the unique anatomic challenge of broncho-
genic malignancies that invade the spine, can be broken down into 
component parts based on the involvement of the vessels, nerves or 
boney structures. The surgical approach is selected based on safety, 
the need for proximal vascular control, and optimal bone resection 
and reconstruction that is required. Complete surgical resection in 
combination with neoadjuvant or adjuvant chemotherapy and radia-
tion therapy can result in dramatic improvement in a patient’s quality 
of life and can result in long-term cures. 
M29.3 Specialized Surgical Expertise: Indications, Results, Sun, Aug 2, 16:30 - 18:00
Guidelines for intraoperative lymph node staging
Passlick, Bernward
University of Freiburg, Freiburg, Germany
Defining the stage of a malignant disease is the key for planning 
therapy, estimating prognosis, and for comparison of studies. The 
extent of lymph node involvement in patients with non-small cell 
lung cancer is the most important prognostic factor and it influences 
therapeutic strategies. There are internationally accepted definitions 
for lymph node staging in lung cancer. However, there are some 
unanswered questions regarding the extent, the nomenclature, and 
the surgical procedure of intraoperative lymph node evaluation. 
The evolution of lymph node mapping began in 1978 when the first 
lymph node map was reported by Naruke. In 1983 the American 
Thoracic Society produced a system in which the vague terms ‘hilär’ 
and ‘mediastinal’ were replaced by definitions of nodal levels based 
on constant anatomical landmarks which could be identified in the 
operating theatre. In 1997 the latest Revised International Staging 
System was released by Mountain. In 2006 the guidelines of the 
ESTS (European Society of Thoracic Surgeons) released different 
ways to describe the intraoperative surgical assessment of lymph 
nodes:
Selected lymph node biopsy: In this procedure one or multiple suspi-
cious lymph nodes are biopsied. This method is used only to prove 
N1or N2-disease.
Lymph node sampling: Lymph node sampling means the removal 
of one or more lymph nodes guided by preoperative or intraopera-
tive findings. Systematic sampling means that predetermined lymph 
nodes are dissected.
Systematic nodal dissection: This means that all mediastinal tissue 
containing the lymph nodes is dissected and removed systematically 
within anatomical landmarks.
Nowadays, for the complete resection of non-small cell lung cancer 
a systematic nodal dissection is recommended in all cases. Ideally, 
this should be done as en-bloc resection, when possible of the upper 
mediastinal nodes on the right side and en-bloc resection of the lower 
mediastinum starting from the fatty tissue or from the diaphragm to 
the subcarinal space. On the left side, the removal of the subaortic 
lymph nodes and fatty tissue as well as the inferior paratracheal 
lymph nodes is minimally required. For complete nodal dissection of 
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the left upper mediastinal division of the ligamentum arteriosum is 
required.
It is important that the nodal stations are excised and put in different 
vials with separate labelings. The highest mediastinal node removed 
should be separately identified. 
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Extent of surgery for synchronous/metachronous 
pulmonary lesions: prognostic implications and 
importance of CT appearance in the decision making
Asamura, Hisao; Tsushima, Yukio; Watanabe, Shun-ichi
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
The therapeutic decision making for synchronous/metachnorous 
multiple pulmonary lesions with proven/unproven histology is one of 
the most difficult situations in the practice, since both of two extreme 
situations, multiple primary lung cancers (possibly curable) and 
disseminated lung cancer with many intrapulmonary metastases (not 
curable), are essentially included despite their similar presentations 
on chest X-ray and CT images. Here, we strictly divide the term, 
multiple lung cancer lesions (MLCs), into multiple primary lung can-
cers (MPLCs) and multiple intrapulmonary metastases (PMs), where 
MLC=MPLC + PM. Despite these definitions, however, the actual 
discrimination between MPLC and PM is being made by Martini and 
Melamed’s criteria (Martini N, Malamed R. Multiple primary lung 
cancers. J Thorac Cardiovasc Surg 1975;70:606-12) and by histologi-
cal comparison of multiple lesions. Although the genetic profiling is 
recently being used in various purposes, it is not practically appli-
cable for the differential diagnosis of MLCs.
1. A retrospective analysis of multiple lung cancers 
at the National Cancer Center Hospital, Tokyo 
To figure out the clinical profiles and prognosis, we retrospec-
tively reviewed 173 patients with MLC among 2,544 patients who 
underwent resection from 1999 to 2005. There were 89 men and 84 
women with the average age of 65 years (30-81 years). The num-
ber of resected lesions ranged from 2 to 8 (median), Histologically, 
MPLCs and PMs were defined based on the histological findings 
such as structure, cellular subtype, in situ component, and replace-
ment growth of tumor cells. According to these definitions, tumors 
in 90 patients (52%) were MPLCs, and those of 83 patients (48%) 
were PMs. The 5-year survival rate (5YSR) after the initial resection 
for the entire group was 60% (Figure 1). The 5YSRs of MPLCs and 
PMs were 74% and 39%, respectively, and the difference of survival 
was statistically significant (p=0.0000, Figure 2). The survival of the 
MLCs, which showed the ground glass opacity (GGO) appearance of 
CT in the main lesion, also had the better survival than those without. 
This retrospective analysis indicated that the histologically-diag-
nosed MPLCs had the better survival and, therefore, despite the need 
for multiple (or repeated) lung resections, the surgical intervention 
might be reasonably justified. Furthermore, considering the fact that 
the main lesion of MPLCs with GGO appearance on CT images was 
more likely to have better prognosis, the preoperative assessment 
of roentgenological features might enable the better selection of the 
surgical candidates as well as the exclusion of those with dissemi-
nated disease.
Figure 1
Figure 2
2. Factors in selecting the candidate patients for local treatment
Despite the suggestion of better prognosis for the patients with 
MPLCs by a retrospective, histological study, the actual selection of 
the patients with MLCLs who might benefit from the local modality 
is indeed difficult only by the preoperative indicators. The assess-
ment by the following diagnostic modality might provide the hint to 
select the proper candidates.
•  CT scan. The CT appearance of the lesions might provide the 
hint about the nature of the disease. As is shown in the present 
retrospective study, the principal and satellite lesion with GGO 
features tend to be multicentric, since such appearance histologi-
cally reflects the replacement growth of the alveolus-lining cells 
with tumor cells (histological indicator of primary tumor) and, 
therefore, good prognosis.
•  PET scan. The assessment of whole body by PET is indispensable 
to exclude the extrathoracic metastasis (M1) and extensive lymph 
node metastasis (N2-3). The use of max SUV of the primary 
Copyright © 2009 by the International Association for the Study of Lung Cancer S135
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
(principal) and other lesions in the discrimination between 
MPLCs and PMs is yet to be defined. 
•  Serum CEA level. The higher level of the serum CEA is more 
likely to indicate the dissemination of the cancer cells. Those 
patients should be eliminated for the local treatment.
3. Surgical consideratons for performing pulmonary resection for 
multiple sites and use of alternative local treatment modalities
If we try to manage the patients with MPLCs by the surgery, the 
resection of the multiple sites is inevitable. The appropriate combina-
tion of surgical mode needs to be chosen on the basis of factors such 
as the number and distribution of the lesions, depth from the pleural 
surface, pulmonary reserve, and age. In some occasions, the alterna-
tive modality other than surgery might be used by themselves alone 
or in combination with surgery. AS the local therapeutic modal-
ity, RFA (Radiofrequency ablation) and SBRT (stereotactic body 
radiation therapy) are the candidates. While the surgical resection 
inevitably sacrifices the large, healthy lung parenchyma for tumors 
which are located deeply in the lung parenchyma, these two modali-
ties are more likely to provide the better outcome compared with the 
surgery. Both of these two modalities, however, are not feasible in 
the management of lesions which are located close to the pulmonary 
hilum and vessels/bronchi of large size for fear of fatal bleeding 
(hemoptysis) and bronchial fistula. The definition of the optimal 
combination of surgery, RFA, SBRT might be an important issue for 
the future management of MPLCs.
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Oral iloprost for the chemoprevention of lung cancer
Keith, Robert L.1, 2, 3
1 Denver Veterans Affairs Medical Center, Denver, CO, USA;  
2 University of Colorado Comprehensive Cancer Center, Denver, CO, 
USA; 3 Division of Pulmonary Sciences and Critical Care Medicine, 
University of Colorado Denver, Anschutz Medical Campus, Denver, 
CO, USA
Background: Alterations in prostaglandin metabolism are found 
in a significant portion of non-small lung cancers (NSCLC). Tissue 
microarray studies have shown that the majority of NSCLC have 
decreased expression of prostacyclin synthase (PGIS). Our group has 
focused PGI2 (prostacyclin) manipulation for lung cancer chemo-
prevention. Prostacyclin supplementation (either with selective 
pulmonary overexpression of prostacyclin synthase or administration 
of the oral prostacyclin analogue iloprost) prevents development of 
lung cancer in multiple murine models, including cigarette smoke 
exposure and an initiator-promoter model. Based on these promising 
results, a multi-center, double-blind, placebo-controlled phase II trial 
of iloprost in subjects at increased risk for lung cancer was designed 
and recently completed.
Methods: Study subjects were selected for the trial if they met the 
following criteria: current or former smoker (> 20 pack years, former 
smokers had to have quit at least 6 months prior to study entry); at 
least mild cytologic atypia on sputum cytology or mild dysplasia or 
worse on previous endobronchial biopsy; and no previous history 
of cancer. Fluorescent and/or white light bronchoscopy was per-
formed at study entry on all subjects with 6 standard endobronchial 
sites biopsied in all subjects (RUL, RML, RB6, LUL, LUDB, and 
LB6). All other abnormally appearing endobronchial areas were 
also biopsied during each of the bronchoscopies. Subjects were then 
randomized to oral iloprost (starting with 50 mcg po BID and dose 
escalating monthly to a maximum dose of 150 mcg BID) or placebo 
for 6 months and then a repeat fluorescent/white light bronchoscopy 
with biopsy of all the central airway areas sampled during the first 
bronchoscopy. The primary endpoints for the study are bronchial 
histology and Ki-67 labeling index. H & E slides were prepared from 
all endobronchial biopsies and all were reviewed by a single study 
pathologist. Ki-67 immunostaining was performed using the mib-1 
monoclonal antibody (Dako) and 400 cells within the specific lesion 
were counted and scored as the percentage of Ki-67 positive cells. 
The clinical trial data was reviewed biannually by an independent 
data and safely monitoring committee. 
Results: The enrollment goal of 152 subjects was met, of which 125 
completed two bronchoscopies. Baseline characteristics showed the 
subjects to be matched in terms of age, gender, and tobacco expo-
sure. All evaluable endobronchial biopsies were reviewed by the 
study pathologist scored on a 1-8 (ranging from normal epithelium 
(scored a 1) to invasive cancer (scored an 8)) scale based on standard 
WHO criteria. Endobronchial histology was summarized within 
subjects using three distinct measures: worst biopsy score (Max); 
dysplasia index (DI - defined as the percentage of biopsies with a 
score of at least 4 (mild dysplasia) or worse); and the average of 
all biopsy scores (Avg). The averages of these measures for all trial 
subjects are: Max = 4.0 (SD = 1.6), DI = 32.9% (SD = 30.1), and 
Avg = 2.6 (SD = 1.1). The average number of baseline biopsies was 
7.0 (SD = 1.7). When stratified by smoking status, Avg for current 
smokers was 3.0 (SD = 1.1) and Avg for former smokers was 2.1 (SD 
= 1.0), a statistically significant difference (Diff = 0.9, SE = 0.17, t 
= 5.46, df = 150, p< 0.001) that confirms smokers exhibit more dys-
plasia in their central airways. There were no statistically significant 
differences between treatment groups in any of the baseline histo-
logic measures. The follow-up bronchoscopy was completed in 125 
subjects, 60 in the iloprost group and 65 in the placebo group. The 
average of the three summary measures for each treatment group are: 
Max histology was 3.8 for iloprost and 4.2 for placebo; DI was 27% 
for iloprost and 33% for placebo; and Avg histology was 2.4 for ilo-
prost and 2.5 for placebo. Subjects tolerated the treatment well, with 
the major adverse events being headache, flushing, myalgias and 
dysgeusia. This is consistent with previous studies of oral iloprost in 
subjects with peripheral vascular disease. Biopsies are also currently 
being evaluated for Ki-67 labeling index and other markers in the 
eicosanoid pathway.
Conclusions: The iloprost chemoprevention trial has been com-
pleted, and our recruitment model was able to identify subjects with 
endobronchial dysplasia. Fluorescent bronchoscopy assisted in the 
identification of dysplastic airway lesions, and current smokers (on 
average) had more histologically advanced lesions. The treatment has 
been well tolerated and histologic changes were observed in many 
of the subjects. Analysis of endobronchial biopsies for treatment 
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response is ongoing and will be updated during the meeting. Future 
directions in lung cancer chemoprevention will also be discussed.
M30.2 Novel Agents in Clinical Trials for Prevention, Sun, Aug 2, 16:30 - 18:00
Targeting mTOR for lung cancer prevention
Dennis, Phillip
NCI, Bethesda, MD, USA
Smoking is responsible for approximately 30% of all cancer deaths 
and is the most common cause of malignancies of the upper aerodi-
gestive tract, including lung and head and neck cancers. Tobacco-
related cancers are often genetically complex and highly resistant to 
chemotherapy, which underlies the high mortality rates associated 
with late stage of diagnosis of these cancers. These poor outcomes, 
combined with the ability to examine epithelial surfaces of the oral 
cavity and proximal airways, led to clinical testing of many agents 
to prevent tobacco-related cancers. Unfortunately, several large, 
expensive phase III cancer chemoprevention trials in the lung were 
negative or even harmful, and the findings of these trials still rever-
berate throughout the cancer prevention community. These outcomes 
helped change the design and emphasis of clinical prevention trials, 
which now are generally smaller and designed to inhibit molecular 
targets and/or treat pathologic, preinvasive lesions rather than pre-
venting cancer development in higher-risk populations. Such changes 
have placed increasing importance on the identification of relevant 
molecular targets and the development of mouse models to validate 
these targets.
The serine/threonine kinase called mammalian target of rapamycin 
(mTOR) is an emerging target for lung cancer prevention. It is a 
critical component of the phosphoinositide 3-kinase/Akt pathway, 
and its phosphorylation and activation promotes protein translation, 
cell cycle progression, and cellular survival. The prototypical mTOR 
inhibitor is rapamycin (sirolimus). 
Several studies have linked mTOR to tobacco-related lung tumori-
genesis. Tobacco components such as nicotine or the tobacco-specific 
carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) 
can activate Akt and mTOR in human bronchial or alveolar airway 
epithelial cells and cause a partially transformed phenotype in vitro. 
In A/J mice, NNK induces a full spectrum of lung lesions including 
adenocarcinomas, and phenotypic progression of NNK-induced lung 
lesions correlates with activation of Akt and mTOR but not other Akt 
substrates. Activation of mTOR is critical for NNK-induced tumori-
genesis, because rapamycin can inhibit lung tumorigenesis by 90% 
when administered at physiologic doses. 
These studies, combined with other studies showing that rapamycin 
or rapamycin analogues can prevent tumor development in geneti-
cally engineered mouse models of lung cancer as well as carcinogen-
driven models of head and neck cancer, provide a strong rationale 
to test rapamycin as a preventive agent in tobacco-related cancers 
such as lung cancer. Practical advantages of rapamycin include the 
fact that it is an FDA-approved, oral drug that is readily available, 
it is relatively inexpensive, and commercial assays are available to 
measure rapamycin levels.
Enthusiasm for clinical testing of rapamycin must be tempered by 
very important safety and efficacy issues. The two major safety 
issues are the risk of immunosuppression and risk of feedback activa-
tion of Akt that could lead to increased tumorigenesis. Rapamycin 
is FDA-approved as an immunosuppressant to prevent rejection of 
renal allografts. The FDA has issued a black-box warning about 
rapamycin, stating that increased risks of infection, lymphoma, and 
nonmelanoma skin cancers have been observed in renal transplant 
patients taking the drug. All of the renal-transplant patients tak-
ing rapamycin, however, were also taking cyclosporine and corti-
costeroids, raising the possibility that rapamycin may be safe as a 
single agent. Indeed, no increased incidence of immunosuppression 
has been observed in multiple trials of single-agent rapamycin or 
rapamycin analogues in cancer patients or in a large trial of tuberous 
sclerosis patients who received single-agent rapamycin for 1 year 
and had serum drug levels equal to or exceeding those in transplant 
patients on rapamycin. Furthermore, epidemiologic data suggest that 
transplant patients maintained on rapamycin are at a lower risk of 
cancer.
The second rapamycin safety concern—feedback activation of Akt 
and increased tumorigenesis—is based on the ability of rapamycin 
to de-repress inhibition of the Akt/mTOR pathway mediated by con-
stitutive phosphorylation of insulin receptor substrate 1 by S6 kinase 
and to increase phosphorylation of Akt by TOR complex 2. Either 
mechanism could lead to increased phosphorylation of Akt at S473, 
increased Akt activity, and possible promotion of tumor growth 
through propagation of the Akt signal to substrates other than mTOR. 
Although such feedback phosphorylation of Akt has been observed 
in some cancer patients that were treated with rapamycin or one of its 
analogues, it has not been observed in multiple mouse studies where 
rapamycin or rapamycin analogues were administered for prolonged 
periods (up to 10% of the mouse life span). These long-term admin-
istration data are consistent with in vitro data showing that TOR 
complex 2 is inhibited by prolonged exposure to rapamycin.
The principal efficacy issue with rapamycin involves its pharma-
codynamics and tissue penetration. Inhibition of mTOR is readily 
detected in peripheral blood, but this effect does not accurately 
reflect inhibition of mTOR in target tissues. Analysis of mTOR 
activity in oral or bronchial tissues in prevention studies will allow 
correlations to be made between rapamycin levels, mTOR inhibition, 
and regression of premalignant lesions. Importantly, it is not clear 
that the levels of rapamycin required for transplant patients will be 
required for mTOR inhibition in prevention studies. To its advan-
tage, rapamycin has greater efficacy in vivo than in vitro, probably 
because rapamycin exerts anti-tumor effects through direct effects on 
tumor cells but also through other cell types such as endothelial cells, 
lymphocytes, and macrophages. 
Despite concerns over efficacy and safety, it is possible that carefully 
designed prevention trials of rapamycin could be conducted safely 
and meet focused end points such as inhibition of mTOR. Smaller, 
early-phase trials that establish the safety and efficacy of rapamycin 
in inhibiting mTOR in epithelial tissues and in regressing premalig-
nant lesions might prompt investment in larger phase III prevention 
trials designed to establish whether rapamycin can prevent upper 
aerodigestive tract cancers. Consequently, we will implement a pro-
tocol using rapamycin in subjects at high risk to develop lung cancer, 
where the end points will include inhibition of mTOR in bronchial 
tissues and peripheral blood, regression of premalignant lesions, and 
assessment of immune function and overall safety.
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Phase II clinical trial of zileuton in 
persons with bronchial dysplasia
Kucuk, Omer; Pass, Harvey; Lonardo, F.; Gazdar, Adi; Madan, S.; 
Abrams, J.; Maddipati, K. R.; Upfal, M.; Soubani, Ayman O.;  
Honn, K. V.; Szabo, E.
Karmanos Cancer Institute, Wayne State University, Detroit, MI, 
USA; NYU School of Medicine and Cancer Center, New York, NY, 
USA; UT Southwestern Hamon Cancer Center, Dallas, TX, USA; 
Division of Cancer Prevention, National Cancer Institute, NIH, 
Bethesda, MD, USA 
Eicosanoids derived from the arachidonic acid cascade have been 
implicated in the pathogenesis of lung cancer. The most compelling 
data involve the 5-lipoxygenase (5-LO) pathway. Animal studies 
found that LO inhibitors have chemopreventive activity in lung 
carcinogenesis. Therefore, we have conducted a placebo controlled, 
double-blind, randomized, two-arm phase II chemoprevention trial 
with zileuton, an asthma drug which inhibits 5-LO, in humans with 
biopsy proven bronchial dysplasia. Our primary hypothesis was 
that treatment with zileuton would be associated with regression of 
bronchial dysplastic lesions and, therefore, with reduced risk of lung 
cancer. Our secondary hypothesis was that zileuton would modulate 
biomarkers of cell proliferation and apoptosis, Ki67, Cyclin D1, 
Bcl-2, Bax and Caspase 3, and lipoxygenase metabolites, 5-HETE 
and LTB4 in bronchial biopsies, bronchoalveolar lavage (BAL) fluid, 
brushings and sputum and these changes would be associated with 
regression of bronchial dysplasia. Study population included current 
or former smokers who have smoked >30 pack-years and who were 
over the age of 35. A total of 1041 subjects were screened for study 
entry. Eighty-six laser induced fluorescence endoscopy (LIFE) bron-
choscopies were performed; 47 were negative for dysplasia, 39 had 
dysplasia. Thirty-eight eligible subjects were entered on the study 
and 8 subjects dropped out. Thirty-seven subjects were randomly 
assigned to receive zileuton (n=20) 600 mg or placebo (n=17) po 
4 times daily for 6 months, after which they were switched to the 
opposite arm for 6 months. LIFE bronchoscopies were performed 
at baseline, 6 months and 12 months and biopsies were taken from 
pre-designated and abnormal appearing areas and BAL and blood 
specimens were collected for biomarker studies. Bronchial biopsy 
readings were consensus opinions of two experienced lung patholo-
gists (LF and AG) and Ki67, Cyclin D1, Bcl-2, Bax and Caspase 3, 
were evaluated with immunohistochemistry. Serum and BAL levels 
of 5-HETE and LTB-4 were measured by LC-MS-MS. There were 
no statistically significant differences between the groups with regard 
to number and severity of bronchial dysplastic lesions at baseline, 6 
months and 12 months. There were no significant differences in any 
of the immunohistochemical or metabolic biomarkers measured. The 
study shows that zileuton is inactive in this population of subjects. 
However the study is underpowered due to small number of subjects. 
Most adverse events (AE) were mild and did not require interruption 
of the study drug. There were 174 grade 1, 43 grade 2, 5 grade 3, 4 
grade 4 and 2 grade 5 AEs. Most of the grade 1-2 events and all of 
the grade 3-5 events were felt to be unrelated or unlikely to be related 
to the study drug. Supported by NCI contract NO1-CN-05022.
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Individuals who quit smoking continue to have an elevated risk of 
lung cancer that may not return to baseline risk for more than 20 
years following smoking cessation. As a result, 60% of new lung 
cancer diagnoses in the U.S. now occur in former or never smokers. 
Thus, there are more than 50 million former smokers in this country 
have varying degrees of elevated risk for lung cancer.
How can we help this population at risk? Chemoprevention refers to 
“the use of agents that can cause regression of existing preneoplastic 
lesions, prevent the progression of these lesions to cancer, or prevent 
the development of new lesions.” The underlying concept of risk 
reduction is similar to the use of statins to lower cholesterol to reduce 
the risk of coronary heart disease. But how can we determine which 
agents to evaluate in lung cancer chemoprevention? Up to now there 
has been no systematic approach for chemoprevention agent selec-
tion and the absence of rigorous pre-clinical studies has led to clini-
cal prevention trials that have failed and, in some cases, increased 
the risk for lung cancer. One possible solution is the development 
of high throughput systems that create an “individualized medicine” 
approach to select combinations of chemoprevention agents targeted 
to the specific molecular abnormalities in the individual at risk. Lung 
cancer develops through a stepwise process that forms a continuum 
from normal lung epithelial cells towards frank malignancy. Detailed 
molecular genetic investigations of lung cancer reveal that clinically 
evident lung cancers have multiple epigenetic and genetic abnor-
malities, including DNA sequence alterations, copy number changes 
and aberrant promoter hypermethylation. For example, years of 
smoking-related tobacco exposure results in specific proto-oncogene 
(such as Ras) and tumor suppressor (such as p53) gene alterations 
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and amplification and/or mutation of certain kinase receptors (such 
as epidermal growth factor receptor [EGFR]) in lung epithelial 
cells. Because the molecular pathogenesis of lung cancer may vary 
within histological type and even between subjects, an individualized 
approach to prevention will be required.
We are addressing a major problem in lung cancer chemoprevention 
by developing a novel system for the optimization of drug combi-
nations for personalized targeted prevention utilizing an artificial 
neural network modeling algorithm. We are first determining optimal 
combinations of multiple drugs against a panel of well characterized 
human bronchial epithelial cell (HBEC) lines. Isogenic HBEC lines 
will bear mutations relevant to the pathogenesis of lung cancer. To 
determine the desired combinations, we are utilizing both the system-
level data driven models of the combination drug proliferation 
response of different cell lines and multi- objective optimization. The 
proliferation assays using the optimal drug combinations are being 
performed using the Luminesence ATP detection Assay System. We 
have begun by selection of 2-drug combinations assessed from librar-
ies of 10 agents. In the second phase of these studies the defined drug 
combinations are being evaluated for efficacy, synergy and toxic-
ity in transgenic murine lung cancer models in which lung cancer 
develops as a result of mutations evaluated in the HBEC lines. Our 
long-term goals include utilization of this system for translational 
clinical investigations in patients at risk for lung cancer. This system 
has several advantages for the prevention of lung cancer. First, we 
are assessing combination chemoprevention tailored to gene array 
profiles and sensitivities of individual mutational events in a rapid 
manner. This will allow for a personalized medicine approach that 
targets susceptible pathways in individual patients at risk for lung 
cancer. Second, because the system includes simultaneous evaluation 
of normal cells to derive optimal drug combinations, we anticipate 
that effective chemoprevention can be achieved with significant limi-
tation of drug toxicities. Finally, using search and systems optimiza-
tion algorithms, we are combining and integrating the mathematic 
approaches for tailoring drug combination therapies that will enable 
clinical translation of these investigations.
In order to initiate targeted chemoprevention for lung cancer, we are 
developing a pre-clinical system to assess potential chemopreventive 
agents against mutated HBECs. Normal HBECs were immortalized 
with telomerase and Cdk4 to generate normal immortalized HBECs. 
Such an immortalized HBEC (HBEC3) was subsequently manipulat-
ed to express oncogenic K-Ras (HBEC3 KRAS), knockdown of p53 
(HBEC3 p53), or mutant EGFR (HBEC3 EGFR), that are relevant 
in the pathogenesis of human lung cancer. These manipulated HBEC 
cells have acquired gene, protein and phenotypic characteristics con-
sistent with these mutations but do not evidence the full malignant 
phenotype of lung cancer; the mutated HBECs under consideration 
here do not grow in immunodeficient mice and are therefore models 
of pre-malignancy.
The above diagram maps our overall strategy for the development of 
targeted personalized combination chemoprevention for lung cancer. 
Our current research covers the portion of studies in boxes 1-4. 
Based on these results, the clinical studies encompassed in sections 
5-6 will be performed in future studies. These studies are addressing 
the problem of chemoprevention selection by including targeting to 
specific mutational events and encompassing multiple endpoints to 
be evaluated in a systems approach. The development of lung cancer 
is complex and combination chemoprevention selection in this para-
digm affords the advantage of addressing this complexity in a high 
throughput manner. Importantly, whenever a chemopreventive agent 
is delivered to attack a particular endpoint, multiple other pathways 
may be targeted leading to unanticipated deleterious effects. Our 
system addresses this problem by assessing systems-based endpoints 
including growth in 3D culture platforms as well as gene, microRNA 
and protein expression. In addition, another advantage of a sys-
tems- based selection of agents targeted to key mutational events is 
the potential for decreased toxicity as well as greater efficacy. For 
example, we have found that the application of agent combinations 
allows for a significant decrease in the concentration of individual 
agents.
In the current research we are examining the relationships between 
input pairwise agent combinations and measured output cellular 
responses such as proliferation and gene expression. Given the num-
ber of agents considered and the number of pairwise combinations 
to test, we are utilizing mathematical tools to enable quantitative 
characterization of the cellular responses given a “relatively small” 
number of tested input combinations. The mathematical tools are 
being used to construct predictive models that can predict the cellular 
outputs to any pairwise input combination. To that end, experiments 
are providing response data for a number of combinations of the two 
inputs. This is important because testing a larger number of combina-
tions adds time and cost constraints and may not be feasible when 
there are several inputs. Furthermore, mathematical tools enable 
determination of the response function without the need to test more 
combinations. Several methods to construct models of input-output 
data artificial neural networks are under evaluation in the context of 
these studies. We are indentifying a mathematical representation of 
the data such that the prediction error, the difference between mea-
sured and predicted data, is minimized.
Although proliferation is one of our main endpoints to select drug 
combinations that are most effective for HBECs bearing mutations, 
we are exploring the optimal efficacy of those drug combinations by 
multiparameter assessments utilizing a systems approach. Protein 
profiles, gene expression and micro RNA profiles are being tested to 
define (a) potential biomarkers, (b) adverse effects, (c) downstream 
mechanisms of prevention by the selected drug combinations and (d) 
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optimal gene and protein expression for chemoprevention. Findings 
thus far indicate that a single agent has its own pattern of effects 
on various protein and micro-RNA expression profiles. In addition, 
each individual mutation has a distinct drug response profile. We 
are performing gene array analysis of each agent using Affymetrix 
Human Genome U133 Plus 2.0 GeneChip. The same RNA samples 
are being utilized in parallel for Taqman MicroRNA Array to analyze 
over 700 micro-RNAs. The protein assays are being performed using 
a high throughput multiplex immuno-assay for analyzing 60 related 
proteins. 
Currently, investigators are assessing individual chemoprevention 
agents in individual preclinical assay models in which a paucity 
of endpoints are determined in conventional carcinogenic models. 
These systems in current research fail to incorporate high throughput 
testing and 3-dimensional endpoints. Current research in chemopre-
vention for lung cancer does not include a systematic assessment of 
unanticipated drug induced gene and protein alterations. Whenever 
a drug is administered in the chemoprevention setting, investigators 
are embarking on an effort to target certain pathways relevant in car-
cinogenesis. However, inevitably, multiple pathways may be altered 
in this attempt, which in certain cases may be deleterious. This is 
especially the case when investigative systems do not incorporate 
the heterogeneity of underlying mutational risk. We anticipate that 
a full evaluation of the events downstream of drug administration in 
the chemoprevention setting can only be assessed in a biosystems 
approach that is structured to encompass the broad possibilities of 
outcomes in combination therapy directed at specific mutational 
events in the subjects at risk. We are utilizing a system designed to 
select agent combinations that both increase efficacy and reduce 
potential toxicity; the development of this systems approach will 
allow for selection of agent combinations that utilize lower, non-tox-
ic concentrations of each agent. These studies will allow for future 
application of a targeted, personalized chemoprevention strategy for 
lung cancer.
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More than 25% of patients presenting with lung cancer will be diag-
nosed with locally advanced disease, with spread to regional lymph 
nodes but not yet to distant metastatic sites. Most of these patients 
are approached with curative intent, commonly with surgery and 
mediastinal node dissection. Adjuvant chemotherapy is now standard 
treatment following resection of advanced primary stage or node 
positive disease, resulting in improved survival. Despite this, disease 
recurrence following optimal surgery and adjuvant systemic therapy 
is as high as 60% in randomized trials. For patients with nodal 
disease at the time of surgery, the majority will have a recurrence 
within the chest, most commonly at the bronchial stump or in hilar 
or mediastinal lymphatics(ref 1,2). Postoperative radiation therapy 
(PORT) has been used to attempt to decrease this risk, with mixed 
results. PORT decreases recurrence at the surgical bed and regional 
lymph nodes, an effect noted most clearly in stage N2 patients and 
those with positive surgical margins. An improvement in survival has 
not been consistently noted, however, presumably due to treatment-
related normal tissue toxicity. Improvements in radiation technique 
have decreased the toxicity of therapy, presumably increasing the 
potential benefit of PORT.
Nine randomized trials currently examined the impact of PORT on 
disease-free and overall survival in patients with resected stage I, II, 
and III NSCLC. These data from more than 2,000 patients were indi-
vidually analyzed by the PORT Meta-analysis Trialists Group (ref 3). 
Collectively, PORT decreased overall survival by 7% at 2 years but 
the subgroup analysis is instructive. In patients without nodal disease 
(stage N0), PORT resulted in the greatest survival detriment. There 
was a lesser detriment in patients with hilar lymph nodes (N1), and in 
patients with mediastinal lymph nodes there was neither a detriment 
nor a benefit to PORT in terms of survival. Specific endpoints related 
to treatment-related toxicity following PORT were not universally 
available for meta-analysis, nor were data concerning the efficacy of 
radiation in decreasing local or regional recurrences analyzed. Nota-
bly, in all the included trials that reported crude or actuarial local 
control, it was improved with PORT (ref 4). The clear implication is 
that significant toxicity, specifically related to the PORT, outweighed 
any potential benefit in the early stage patients. In patients with 
N2 disease, the effect of PORT in reducing recurrence was greater, 
although still not sufficient to out-weigh the morbidity of the therapy. 
The meta-analysis has been subject to criticism on several accounts. 
The data reflect radiotherapy techniques now considered out of date. 
Importantly, of the nine trials included in the 1998 meta-analysis, 
two trials have not been published yet. The utilization of PORT 
decreased following publication of the meta-analysis.
In 2006, Lally and coworkers published a similar analysis using the 
Surveillance, Epidemiology, and End Results (SEER) database (ref 
5) The data include clinicopathologic and demographic informa-
tion on 7,465 incident NSCLC lung cancer patients, stage II or III, 
treated with lobectomy and pneumonectomy between 1998 and 2002 
(in contrast, the meta-analysis included patients treated between 
1966 and 1995). Forty-seven percent of patients received PORT. On 
multivariable analysis of the entire cohort, the use of PORT had no 
impact on survival. Similar to the finding of the metaanalysis, the use 
of PORT in stage N0 and N1 patients was associated with decreased 
survival. In contrast, in patients with N2 disease, the use of PORT 
was associated with improved overall survival and disease-specific 
survival. Five-year overall survival in this subgroup was 27% in 
patients who received PORT and 20% in patients who were observed 
after resection, despite the fact that patients receiving PORT had 
significantly larger tumor size and significantly more nodes positive 
(without a significant difference in the number of nodes examined). 
This is a retrospective analysis and thus subject to selection bias, and 
the SEER data lacks critical information on both the surgical margin 
status and the details of the radiotherapy dose and technique. But the 
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fact that, in comparison to the PORT meta-analysis, the benefit of 
PORT is increased in a more recently treated cohort and the survival 
detriment in early stage patients similarly diminished strongly 
implies that the toxicity of therapy has decreased over time. This 
large study suggests a benefit in stage N2 patients and calls for fur-
ther evaluation in patients known to be at high risk. The indications 
for PORT in current practice remain controversial. Trials examining 
the effect of PORT on survival in patients with Stage N2 disease will 
be presented and discussed, with a special focus for the presentation 
of the international Lung Art trial(ref 6).
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Historical Perspective
The treatment of stage IIIA (pN2) non-small cell lung cancer 
(NSCLC) has continued to evolve from surgery only to combined 
multi-modality therapy for the best possible results. 
Surgery with adjuvant postoperative radiation therapy for unforeseen 
stage IIIA (pN2) and marginally resectable stage IIIA (pN2) disease 
were the mainstay of therapy in the 1970s and early 1980s before the 
era of effective chemotherapy (1). 
However, the distinction between unresectable and marginally resect-
able N2 diseases still remains to be clearly defined (2). 
Since the advent of more effective chemotherapy, i.e., cisplatin-based 
regimen in the 1980s (3), the potential of cisplatin-based chemother-
apy has been explored in a setting of postoperative adjuvant therapy 
in patients with completely resected stage I-II and stage III (N2) 
NSCLC in the 1990s. It was a logical step because the main cause of 
death for these patients remains distant metastatic disease. 
Six large multinational trials have been conducted. In some of these 
studies, postoperative radiation therapy was also allowed in both 
control and study groups. 
Postoperative Radiation Therapy before 
the Era of Modern Chemotherapy
Radiation therapy is capable of sterilizing cancer cells at the primary 
site and the regional lymph nodes when adequate radiation dose is 
applied. 
The Lung Cancer Study Group 773 study (LCSG) found a significant 
reduction of local recurrence for patients who received postoperative 
radiation therapy (PORT) with first site of relapse, 1% vs. 20% (p 
< 0.001); overall recurrence, 37% vs. 47% (p = 0.188); recurrence 
in pN2 29% vs. 57% (p = 0.03, but survival was not different (4). 
In a study by the Medical Research Council Lung Cancer Working 
Party, the local recurrence rate was 41% vs. 29%; the distant failure 
rate was not significantly different between groups in the pN1 but 
was much higher in the pN2 subsets (46% vs. 70%, p = 0.03), with a 
3-year survival benefit in the radiotherapy group (5).
The PORT meta-analysis that is published in 1998 included nine 
studies (2,128 patients) in which PORT was compared with sur-
gery alone (6). The meta-analysis concluded that PORT produced a 
significant detrimental effect on survival: 21% increase in the relative 
risk of death and 2-year survival rates of 48% for PORT and 55% 
for the control group. The survival curves diverged approximately at 
4 months from randomization. The detrimental effect of PORT was 
marked for patients with pN0 or pN1 disease whereas in patients 
with Stage III and pN2 survival was slightly better with PORT, but 
the effect was not statistically significant. Detailed information on 
causes of death was not presented; 15% of deaths with PORT vs. 9% 
in the control were coded as “intercurrent and respectively 4% and 
2% were coded as treatment related. The data have been interpreted 
as potentially indicative of toxic effects of PORT.
Trials of Adjuvant Chemotherapy 
Six major phase III trials have been conducted since 1990s to evalu-
ate the role of adjuvant chemotherapy in completely resected stage 
I – III NSCLC. 
These trials included ALPI (Adjuvant Lung Project Italy), BLT 
(Big Lung Trial), IALT (International Adjuvant Lung Cancer Trial), 
ANITA (Adjuvant Navelbine International Trialists Association), 
JBR.10 and CALGB 9633 (7-12). JBR.10 entered patients with stage 
IB-II only and CALGB 9633 limited accrual of patients with stage 
IB NSCLC. 
This was a necessary step for a progress in searching for better 
adjuvant treatment since PORT does not offer gain in survival benefit 
according to the PORT meta-analysis. 
ALPI, BLT, IALT and ANITA trials entered patients with completely 
resected stage I–III (pN2) NSCLC. However, both ALPI and BLT 
showed no survival gain with adjuvant chemotherapy (7, 8).
Thus, it is pertinent to review the long-term follow-up data of IALT 
(13) and the survival data of exploratory analysis for the subgroups 
of patients who were given PORT as per the investigator choice 
within the ANITA trial (14). In addition, it is also pertinent to include 
a recent retrospective study conducted based on the Surveillance, 
Epidemiology, and End Results (SEER) database by selecting 
patients with stage II or III NSCLC who underwent a lobectomy or 
pneumonectomy. In this study, only those patients coded as receiving 
PORT or observation were included (15).
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Lung Adjuvant Cisplatin Evaluation (LACE):  
A Pooled Analysis by the LACE Collaborative Group
This study was conducted to identify treatment options associated 
with a higher benefit or groups of patients who particularly benefit 
from postoperative chemotherapy (16).
Individual patient data were collected and pooled from the five 
largest trials (4,584 patients) of cisplatin-based chemotherapy in 
completely resected patients that were conducted after the 1995 
NSCLC meta-analysis. The interactions between patient subgroups 
or treatment types and chemotherapy effect on overall survival were 
analyzed using hazard ratios (HRs) and log-rank tests stratified by 
trial.
With a median follow-up time of 5.2 years, the overall HR of death 
was 0.89 (P= .005), corresponding to a 5-year absolute benefit of 
5.4% from chemotherapy. 
There was no heterogeneity of chemotherapy effect among trials. The 
benefit varied with stage (HR for stage IA = 1.40; HR for stage IB = 
0.93; HR for stage II = 0.83; HR for stage III = 0.83). The effect of 
chemotherapy did not vary significantly (test for interaction, P = .11) 
with the associated drugs, including vinorelbine, etoposide or vinca 
alkaloid or others.
Chemotherapy effect was higher in patients with better performance 
status. There was no interaction between chemotherapy effect and 
sex, age, histology, type of surgery, planned radiotherapy or planned 
total dose of cisplatin.
Postoperative cisplatin-based chemotherapy significantly improves 
survival in patients with NSCLC.
Long Term Results of IALT
IALT study accrued patients with completely resected NSCLC were 
randomly assigned to three or four cycles of cisplatin-based chemo-
therapy or to observation. The dose of cisplatin (total 300-400 mg/
m2), the drug to be combined with cisplatin (etoposide or vinorelbine 
or vindesine or vinblastin) and the use of adjuvant radiotherapy were 
predefined at each center. Cox models were used to evaluate treat-
ment effect according to follow-up duration (9). 
Between February 1995 and December 2000, there were 1,867 
patients included. Median follow-up was 7.5 years at the cut-off date 
of September 1, 2005 (13). 
Results showed a beneficial effect of adjuvant chemotherapy on 
disease-free survival (HR: 0.88; p= 0.02) only and not in overall 
survival (HR: 0.91; p= 0.10). 
There was a significant difference between the results of overall 
survival within the first 5 years (HR: 0.86; p = 0.01) versus beyond 
5 years (HR: 1.45; p =0.04). Disease-free survival benefit was also 
changed according to the follow-up duration (first 5 years, HR=0.85, 
p=0.006; beyond 5 years, HR=1.33, p=0.16). The analysis of 
non-lung cancer deaths for the whole period showed a HR of 1.34 
(p=0.06). 
These results confirm the efficacy of chemotherapy in improving 
survival for the first 5 years after surgery. However, the gain in 
survival with adjuvant chemotherapy disappears beyond 5 years of 
follow-up suggesting late adjuvant chemotherapy-related mortality. 
This potential long-term adverse effect of adjuvant chemotherapy 
underscores the need for the long-term follow-up of the adjuvant 
lung cancer trials in order to validate the long term findings of IALT: 
The survival gain in the first 5 years was offset by increased death 
from likely treatment related toxicities beyond 5 years. 
Subgroup Analysis of ANITA
ANITA is a randomized phase III trial of adjuvant cisplatin and 
vinorelbine chemotherapy to compare with observation in completely 
resected non–small-cell lung carcinoma (NSCLC) Stages IB to IIIA 
(11). Use of PORT was recommended for pN+ disease but was not 
randomized or mandatory. Each center decided whether to use PORT 
before initiation of the study. An unplanned subgroup analysis was 
performed for a difference in survival among patients who did or 
did not receive PORT within each treatment group of ANITA. No 
statistical comparison of survival was performed because this was an 
exploratory subgroup analysis.
Overall, 232 of 840 patients received PORT (33.3% in the observa-
tion arm and 21.6% in the chemotherapy arm). In univariate analysis, 
PORT had a deleterious effect on the overall population survival. 
Patients with pN1 disease had an improved survival from PORT in 
the observation arm (median survival (MS) 25.9 vs. 50.2 months), 
whereas PORT had a detrimental effect in the chemotherapy group 
(MS 93.6 months and 46.6 months). In contrast, survival was 
improved in patients with pN2 disease who received PORT, both in 
the chemotherapy (MS 23.8 vs. 47.4 months) and observation arm 
(median 12.7 vs. 22.7 months).
This retrospective subgroup analysis suggests a positive effect of 
PORT in pN2 disease and a negative effect on pN1 disease in a set-
ting of postoperative adjuvant chemotherapy (14). 
Results of SEER Study
This study was performed to investigate the association between 
survival and postoperative radiotherapy (PORT) in patients with 
resected non–small-cell lung cancer (NSCLC).
Within the Surveillance, Epidemiology, and End Results (SEER) 
database, patients with stage II or III NSCLC who underwent a 
lobectomy or pneumonectomy were selected. Only those patients 
coded as receiving PORT or observation were included. To account 
for perioperative mortality, patients who survived less than 4 months 
were excluded. 
A total of 7,465 patients, with a median follow-up time of 3.5 years 
for patients still alive, were selected (15).
Factors for the use of PORT included younger age group (< 50 
years), higher American Joint Committee on Cancer stage, T3-4 
tumor stage, larger tumor size, advanced node stage, greater number 
of lymph nodes involved, and a ratio of lymph nodes involved 
to lymph nodes sampled approaching 1.00. Multivariate analysis 
showed older age, T3-4 tumor stage, N2 node stage, male sex, fewer 
sampled lymph nodes, and greater number of involved lymph nodes 
had a negative impact on survival. 
The use of PORT did not have a significant impact on survival. How-
ever, in subset analysis for patients with N2 nodal disease, PORT was 
associated with a significant increase in survival. For patients with 
N0 and N1 nodal disease, PORT was associated with a significant 
decrease in survival.
In a population-based cohort, PORT use is associated with an 
increase in survival in patients with N2 nodal disease but not in 
patients with N1 and N0 nodal disease.
Prognostic Factors Capable for Guiding 
Personalized Adjuvant Therapy
It is highly desirable to offer PORT to patients who need such 
therapy. However, we do not have such biomarkers or prognostic fac-
tors for use in developing individualized therapy (17). 
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However, there are on-going intensive research in molecular bio-
markers and it is hoped that we can use such biomarkers in future to 
tailor caner therapy for individual patients.
Conclusion 
Radiation oncology is now given opportunity to demonstrate that 
adjuvant PORT is safe and effective in offering survival gain for 
patient with completed resected stage IIIA (pN2) NSCLC. Two 
recent retrospective studies support a hypothesis that PORT may pro-
vide a gain in survival in combination with cisplatin-based chemo-
therapy for patients with completely resected pN2 NSCLC. 
Patients with completely resected pN2 NSCLC should not be offered 
PORT as a standard of care. In the meantime, it is important to 
conduct phase III clinical trials to test the hypothesis that PORT 
may result in gain in survival. This is particularly significant given 
the finding that cisplatin-based adjuvant chemotherapy can cause 
increased death from long-term toxicities even after 5 years and that 
such long-term toxicity can offset the survival gain achieved within 
the first 5 years. 
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Recent Advances in Antiemetics
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Center of Boston, Boston, Massachusetts, USA
From a patient’s standpoint, chemotherapy-induced nausea and 
vomiting (CINV) represent two of the most feared adverse effects 
of cancer treatment. Three emetic syndromes have been described in 
association with chemotherapy: acute (within 24 hours of chemo-
therapy); delayed (24–120 hours after chemotherapy); and anticipa-
tory (a conditioned response linked to stimuli associated with a prior 
chemotherapy experience associated with uncontrolled emesis). (1)
Our ability to anticipate the likelihood of CINV developing in any 
given clinical setting has been improved by the identification of a 
number of predictive factors. Patient-related factors associated with 
an a greater likelihood of CINV include: younger age, female gender, 
emesis with prior chemotherapy, non-user of ethanol and certain 
polymorphisms in genes involved in the metabolism of antiemet-
ics and neurotransmitter receptor genes. (1) The most important 
predictive factor, however, is the intrinsic emetogenicity of the 
chemotherapy agents. This factor is the primary determinant utilized 
in assessing risk for emesis and appropriate prophylactic treatment. A 
useful classification schema defining chemotherapy emetogenicity is 
available for use in guiding antiemetic treatment.(1)
Considerable progress has been made in better understanding the 
pathophysiology of CINV. A number of neurotransmitters includ-
ing dopamine, cannabinoids, serotonin (5-hydroxytrpytamine) 
and Substance P have been identified as having important roles in 
CINV. (1)The introduction of the first generation selective antago-
nists of the type three 5-hydroxytrptamine (5-HT3) receptor in the 
early 1990’s revolutionized antiemetic treatment providing a more 
effective and better tolerated class of antiemetics compared to older 
agents. Despite the improvement in CINV control noted with the 
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introduction of this class of drugs, a significant minority of patients 
continued to have suboptimal control of emesis and delayed emesis 
remained a troublesome problem.
Newer Agents
Over the last several years, a number of new antiemetic options have 
been introduced including a second-generation 5-HT3 antagonist 
(palonosetron), the first representative of a new class of antiemetics 
targeting the NK1 receptor (aprepitant) and a new formulation of an 
older 5-HT3 antagonist (Sancuso®).
Palonosetron is a second generation 5-HT3 antagonist that differs 
from first generation agents in its prolonged half-life (~ 40 hours) 
and enhanced receptor binding affinity. The agent received FDA 
approval in July 2003 based upon the results of three phase III trials 
conducted in patients receiving moderately or highly emetogenic 
chemotherapy. In single agent comparative trials with moderately 
emetogenic chemotherapy, it demonstrated superior control of 
acute and delayed emesis compared to ondansetron (2) and delayed 
emesis compared to dolasetron. (3) In the third trial with highly 
emetogenic chemotherapy, it resulted in comparable control to the 
comparator ondansetron.(4) In a recently reported trial conducted in 
patients receiving cisplatin or anthracycline/cyclophosphamide based 
chemotherapy, the combination of palonosetron/dexamethasone was 
comparable to granisetron combined with dexamethasone in the 
control of acute emesis, but displayed superior control of delayed 
emesis. (5)The approved palonosetron regimen is 0.25 mg IV or 0.50 
mg PO prior to chemotherapy. Properly designed trials to definitively 
determine whether palonosetron is superior to older 5-HT3 antago-
nists when employed according to standard guidelines are awaited 
with interest.
Aprepitant is the first approved member of a new class of antiemet-
ics, the neurokinin 1 antagonists. Substance P is the preferred ligand 
for the NK1 receptor. Selective NK1 antagonists have demonstrated 
potent inhibition of emesis resulting from a wide range of emetic 
stimuli in preclinical models. Aprepitant received FDA approval in 
March 2003 based upon the results of two phase III trials conducted 
in patients receiving cisplatin-based chemotherapy. (6,7) In each 
trial, the addition of aprepitant to ondansetron and dexamethasone 
was associated with significantly better control of acute and delayed 
emesis when compared to ondansetron and dexamethasone alone. 
Results from a large phase III trial in patients with breast cancer 
receiving cyclophosphamide combined with an anthracycline also 
demonstrated superior antiemetic control with the addition of 
aprepitant compared to ondansetron and dexamethsone alone. (8) 
The approved aprepitant regimen is 125 mg PO or 115 mg IV prior 
to chemotherapy and 80 mg PO on the second and third days after 
chemotherapy. At the 2008 meeting of the American Society of 
Clinical Oncology, the results of two phase three trials with another 
NK1 antagonist, casopitant were presented. (9,10) In both the setting 
of moderately emetogenic and highly emetogenic chemotherapy, 
the addition of casopitant to the combination of ondansetron and 
dexanethasone resulted in better control of emesis than ondansetron 
and dexamethasone alone. 
In 2008, a new formulation of an older 5-HT3 antagonist received 
regulatory approval for prevention of CINV with multi-day chemo-
therapy regimens of moderate to high emetic potential. Sancuso® 
is a transdermal formulation of granisetron. In a phase III trial, 
Sancuso® was found to be non-inferior in emesis control to oral 
granisetron in patients receiving 3-5 consecutive day chemotherapy 
regimens. (11)
Guidelines for the Management of CINV 
in Patients with Lung Cancer
The risk of emesis in patients with lung cancer receiving che-
motherapy varies widely depending upon the treatment regimen 
being employed. Without prophylaxis, nearly all patients receiving 
cisplatin will have severe emesis, whereas, virtually no patients 
receiving vinca agents such as vinorelbine will have emesis. Under 
the leadership of the Multinational Association of Supportive Care 
in Cancer (MASCC) a set of management guidelines have been 
published which represent a consensus proposal from nearly all the 
major oncology groups who have previously put forth their own 
individual guidelines. (12) Table 1 summarizes these consensus 
guidelines. Determining the need for antiemetic prophylaxis should 
take into account the potential of a given chemotherapy agent to 
produce both acute and delayed emesis. With agents such as cisplatin 
that are strongly associated with both emetic syndromes, patients 
should receive prophylaxis for acute emesis with a combination of 
aprepitant, dexamethasone and a 5-HT3 receptor antagonist prior 
to chemotherapy and delayed emesis with aprepitant (days 2-3) and 
dexamethasone(days 2-4). Carboplatin-based regimens are moderate-
ly emetogenic with the potential for acute and delayed emesis. The 
role of the NK1 antagonists has not yet been defined in this setting. 
Appropriate acute and delayed prophylaxis would include a 5-HT3 
receptor antagonist and dexamethasone (day 1) and dexamethasone 
alone (days 2-3) respectively. Finally agents such as pemetrexed and 
the taxanes have low emetic potential and should receive prophylaxis 
for acute emesis only with a corticosteroid or prochloperazine.
Table 1. Recommended Antiemetic Therapy for Single Day Intravenous 
Chemotherapy
 Prevention of acute emesis 
Emetic Risk Category (Day 1 prior to chemotherapy) Prevention of delayed 
emesis
High 5-HT3 receptor antagonist plus  Dexamethasone Days 2-4 plus 
 Dexamethasone plus Aprepitant Days 2 and 3 
 Aprepitant 
Moderate 
AC* 5-HT3, receptor antagonist plus  Aprepitant Days 2 and 3 or 
 Dexamethasone plus Dexamethasone Days 2 and 3 
 Aprepitant
Non-AC 5-HT3 receptor antagonist plus  5-HT3 receptor antagonist or 
 Dexamethasone  Dexamethasone Days 2 and 3
Low Dexamethasone or Prochlorperazine No preventive measures
Minimal As needed No preventive measures
*anthracydine and cydophosphamide
Summary
Nausea and vomiting can be completely prevented in the majority 
of patients receiving current chemotherapy treatments if clinicians 
follow evidence-based antiemetic treatment guidelines. Despite the 
significant progress realized in the last 20 years, nausea and vomiting 
control remains suboptimal in a significant minority of patients. The 
majority of lung cancer patients receiving chemotherapy require 
antiemetic prophylaxis which should be guided by the intrinsic 
emetogenicity of the chemotherapy and the potential for acute and 
delayed emesis.
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Managing anemia in lung cancer
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Anemia is highly prevalent in patients with lung cancer, often 
occurring at baseline and frequently exacerbated as a result of treat-
ment with platinum-based chemotherapy. Between 30 and 60% of 
individuals receiving cytotoxic chemotherapy will develop grade > 
2 anemia, and a substantive percentage will develop grade 3 and 4 
anemia, requiring repeated transfusions. Cisplatin, carboplatin and 
gemcitabine are amongst the most commonly implicated agents. 
Anemia has also been shown to have a negative effect on quality 
of life in patients with lung cancer, and additional data indicate that 
decreases in hemoglobin (Hb), either at baseline or during the course 
of treatment, are associated with impaired survival, both in the local-
ly advanced and metastatic setting. Multiple clinical studies have 
demonstrated that treatment of anemia with erythropoietic agents in 
patients with lung cancer results in a significant increase in hemoglo-
bins (Hgb), decrease in transfusions, and potential improvement in 
quality of life. Recent meta-analyses, however, have also shown that 
these agents are associated with an increased risk of thromboembolic 
events and a trend toward impaired survival, particularly in the cura-
tive setting and in patients not receiving concurrent chemotherapy; 
these observations appear to be due to a class effect extending to both 
recombinant erythropoetin and darbepoetin, and are clearly worse 
in those who start these agents at higher hemoglobin levels or who 
“overshoot” to Hgb levels of 13.5 or higher. Consequently, the FDA 
has recently altered its approval to prohibit initiation of these agents 
in the adjuvant setting, in patients with anemia of cancer who are not 
receiving cytotoxics and for those with basal Hgb above 10 g/dl; and 
the NCCN guidelines have followed suit, although they allow a bit 
more leeway with regard to acceptable Hgb levels. Ongoing research 
is evaluating whether tumor cells harbor EPO receptors, and whether 
recent changes in the guidelines have translated into increased use of 
transfusions and other sequelae.  
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Supportive care optimization as a target: bone metastasis
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Introduction:
Bone is a frequent site of metastatic involvement in lung cancer 
patients (1). Skeletal involvement has a significant impact in quality 
of life and is associated with a median survival of only 7 months 
(2). Bone pain, fractures and spinal cord compression are frequent 
and sometimes devastating symptoms resulting form direct bone 
involvement.
Mechanism of Bone Metastasis:
Bone metastasis can be either osteolytic or osteoblastic depending 
on the predominant mechanisms by which tumor cells interfere with 
normal bone cell physiology and bone remodeling processes (3). In 
lung cancer lesions are more frequently osteolytic with increased 
bone destruction, however it is important to recognize that both 
osteoclast and osteoblast activation are significant elements of the 
bone metastatic process and both occur to a certain degree in all 
metastatic bone lesions.
Recent developments on the understanding of the complexity of the 
metastatic process suggest that there is a biologically determined 
interaction between tumor cells, extra-cellular microenvironment and 
local bone marrow cells that accounts for the development or not of 
metastasis on a specific site (4). Cancer cells do express and produce 
different receptors and molecules, which bind to receptors on stromal 
cells of the bone marrow and bone matrix. This interaction is what 
finally determines the occurrence of metastasis. 
Within the heterogeneity of gene expression profiles encountered in 
a primary tumor, there is increasing evidence of the existence of a 
metastatic genotype that enables tumor cells to complete the different 
steps of the complex physiologic processes required to generate a 
metastatic tumor. Recent work has uncovered a significant role of 
single stranded small RNA molecules (21-23 nucleotides in length) 
which regulate gene expression (microRNAs) in this process. These 
are non-coding nucleotide molecules whose primary function is to 
down regulate gene expression (4). At least in pre-clinical models of 
breast cancer miRNA-335 and miRNA-126 have been found to sup-
press the expression of genes that give the tumor cell specific meta-
static capabilities. Accordingly, lack of expression of these miRNAs 
has been associated with higher chances of metastases. The potential 
of expanding these concepts to the clinic may enable us in the future 
to predict who are the patients determined to develop metastasis and 
where these metastasis will develop (bone, brain, liver, lung, etc).
Preferential Homing of tumor cells to the bone:
The interaction of all these elements (tumor cells, microenviron-
ment and local tissue cells) explains why certain tumors manifest a 
clear propensity to metastasize to certain organs. In the case of bone 
metastasis, some examples of molecules expressed by the cancer 
cell and/or bone cell that may be responsible for this interaction 
and have been studied include: chemokine receptor CXCR4, SDF-1 
(5, 6) RANKL and RANK (7), bone sialoprotein (8, 9) Annexin II 
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and its receptor (10). In addition, a number of local bone factors are 
released as consequence of the presence of the cancer cell in the bone 
microenvironment and actively participate in the process: IGF 1 and 
2, FGF, PDGF, TGF-beta among others (11, 12). 
Improving the understanding of this complex interaction that results 
in the development of bone metastasis is essential to identify patients 
at increase risk of skeletal involvement, to design preventive strate-
gies and to treat established metastasis.
Treatment of Bone Metastasis:
Prevention of bone metastasis, pain relief, prevention and treatment 
of related complications and preservation of quality of life remain 
the primary objectives of treatment. A multidisciplinary approach 
including radiation, surgery and systemic treatments (analgesia and 
bisphosphonates) should lead to the selection of the best approach for 
each patient presentation.
Radiation therapy and surgical procedures to palliate pain and com-
plications of bone metastasis have been important in the management 
of lung cancer patients with bone involvement. While most patients 
with bone metastasis will receive radiotherapy during their course, 
less than 10% will require surgical interventions (13). Both modali-
ties address localized complications and require a careful evaluation 
of the general extension of the metastatic involvement (both in bone 
and other sites) for an appropriate indication.
In cases with limited and painful bone involvement, radiation therapy 
offers excellent analgesic results. Protocols with single fraction 
radiation administration have been shown safe, effective and practi-
cal although with higher re-treatment rates (14). Surgical fixation of 
metastasis involving long or weight bearing bones may be indicated 
prior to radiation to prevent or to treat pathological fractures. A mul-
tidisciplinary approach is essential to offer each individual patient 
with the best possible alternative according to his specific symptom 
presentation. It is worth noting a randomized clinical trial showing 
that surgical intervention followed by radiation therapy was signifi-
cantly better that radiation alone for patient presenting with spinal 
cord compression (15). In cases of disseminated painful metastasis, 
strategies of hemi-body radiation or even the indication of radiophar-
maceuticals have been used with some success (16).
Bisphosphonates have been the mainstay of the treatment of wide-
spread bone metastasis in a number of malignancies like breast can-
cer, prostate cancer and multiple myeloma among other tumors (17). 
Clinical trial experience with these agents in patients with skeletal 
metastasis form lung cancer has been limited. However, as most 
bone metastasis in lung cancer are predominantly osteolytic, the 
osteoclast inhibitory activity of bisphosphonates make their indica-
tion particularly attractive. A phase III trial has been conducted in 
patients with bone metastasis from solid tumors other than breast 
and prostate cancer (18). Patients were treated with zoledronic acid 
or placebo. Approximately 50% of the 773 patients in this study 
had advanced NSCLC with bone involvement. There was a non-
significant numerical reduction on the SREs in the group treated with 
the bisphosphonate compared with placebo as well a delayed time to 
the first SRE. According to the Anderson-Gill analysis (accounting 
for both number of events and time between events) there was a 31% 
reduction in the risk of SREs compared to placebo (p=.003).
Perspectives: 
There are two ongoing studies exploring Zoledronic Acid in NSCLC 
patients. Both studies are exploring patients with advanced disease 
with no bone metastasis. Besides the time to occurrence of the first 
bone metastasis, a number of other clinical endpoints are being fol-
lowed (19, 20). 
One other approach in clinical trials explores the humanized anti-
body Denosumab directed to RANKL therefore inhibiting osteoclast 
mediated bone resorption. A 1690 patient phase III trial will address 
the non-inferiority of this antibody to zoledronic acid in patients with 
solid tumors other than prostate and breast cancer. This trial will 
include MM patients with lytic bone lesions (21). 
Other investigational approaches include suppression of osteoclast 
activity through c-Src proto-oncogene inhibition. This oncogene 
has been found to be important in regulation not only of tumor cell 
growth, migration and survival but has also showed a significant role 
in bone metabolism promoting osteoclast bone resorption. Herbimy-
cin A, AZD0530 and Dasatinib are some of the molecules that target 
this kinase and are being studied in clinical trials (22, 23, 24, 25). 
Conclusions:
Bone metastases represent a significant problem for cancer patients 
in general and for lung cancer patients in particular. As we improve 
survival rates in different tumor types the risk of complications relat-
ed to skeletal involvement increases. So far, our approach has been 
one of palliation of metastatic bone related symptoms. Radiation 
therapy for bone pain, surgical procedures to prevent or to treat frac-
tures and analgesics remain important therapeutic alternatives. The 
increasing understanding of bone remodeling and a clearer character-
ization of the complexity of bone directed metastases are leading us 
to design more appropriate and hopefully individualized therapies. A 
number of different strategies target inhibition of bone resorption. At 
least with bisphosphonates, there is evidence for a clinical effect in 
a number of tumor types. Even though the randomized clinical trial 
experience is limited in lung cancer patients with this approach there 
is suggestive evidence for benefit. New pharmacological strategies 
addressing some of the critical players in the metastatic process to 
bone hopefully will confirm and expand our ability to help patients 
with this very debilitating situation.
More importantly, within the well recognized cell heterogeneity of 
most tumors, gene expression profiles that predict for the develop-
ment of a metastatic phenotype in general and for a bone metastatic 
variant specifically have been recently suggested. Detailed under-
standing of these processes will undoubtedly lead to a more elegant 
approach to patient management allowing us to identify different 
populations with diverse risks. This will improve not only thera-
peutic approaches but hopefully will allow us to address preventive 
strategies that may result in significant survival benefits.
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M32.5 Supportive Care Optimization as a Target, Tue, Aug 4, 10:30 - 12:00
Dyspnea: evaluation and management strategies
Leard, Lorriana E.
University of California San Francisco, San Francisco, CA, USA
Dyspnea is the sensation of uncomfortable breathing. Unfortunately, 
dyspnea is a frequent and distressing symptom in patients with 
advanced lung cancer. Multiple potential etiologies must be consid-
ered in order to identify the causative factor and to attempt to allevi-
ate patient symptoms.
This presentation will address:
1. The differential diagnosis of dyspnea in patients with thoracic 
malignancies: directly related to cancer invasion, complications 
related to chemotherapy and radiation therapy, infections, pulmo-
nary embolism, central airway obstruction, pleural effusions, or 
other co-morbidities. 
2. Interventional procedures that may be performed to alleviate 
symptoms from (a) bronchial obstruction (bronchial stenting, laser 
therapy, cryoprobe therapy) and (b) Management of malignant 
pleural effusions. 
3. Medical therapeutic interventions and symptom management.
4. Nonpharmacologic symptom management strategies.
Session M33: Cutting Edge in  
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M33.1 Cutting Edge in OMICS Research for Lung Cancer, Tue, Aug 4, 10:30 - 12:00
Oncogene discovery in lung adenocarcinoma
Meyerson, Matthew and colleagues
Dana-Farber Cancer Institute; Department of Pathology, Harvard 
Medical School; and Broad Institute of Harvard and MIT, 
Cambridge, MA, USA
Cancer is a disease of the genome. High-throughput genome analysis 
tools now enable the detection of somatic alterations in cancer cells 
including point mutations, copy number alterations, translocations, 
and infections.
To find copy number alterations, we have now analyzed over 2,600 
cancer samples with arrays representing 250,000 mapped single 
nucleotide polymorphisms (SNPs), or most recently, over 1.8 million 
mapped probe sets. Major discoveries include the identification of 
lineage-specific amplification of the NKX2-1 gene in human lung 
adenocarcinoma (Weir et al., 2007). Most recently, we have identi-
fied a counterpart amplified gene in squamous cell carcinomas.
To find mutations, we are performing systematic sequencing of 
selected gene families. Here, major discoveries include activation 
mutations of the epidermal growth factor receptor tyrosine kinase 
gene, EGFR, in human lung adenocarcinomas (Paez et al., 2004) and 
glioblastoma. Furthermore, we have identified a total of 26 genes that 
are recurrently mutated in lung adenocarcinoma (Ding et al., 2008).
I will describe these studies and several ongoing studies.
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M33.2 Cutting Edge in Omics Research for Lung Cancer, Tue, Aug 4, 10:30 - 12:00
Mining the Proteome for Clinically 
Useful Lung Cancer Signatures
Carbone, David P.
Vanderbilt Cancer Center, Nashville, TN, USA
Unlike some tumor types, the majority of the common solid tumors 
appear not to be driven by single dominant targetable pathways. 
Instead, diseases such as lung cancer are likely to be much more 
complex and heterogeneous, with many distinct and overlapping 
subsets of tumors within the class, each of which will demand an 
in depth analysis to define the optimal therapeutic approach. These 
groups are starting to be defined by multiple technologies, and 
the simplest example is the small subset of patients with tumors 
expressing mutant EGFR, who achieve substantial clinical benefit 
from minimally toxic targeted therapy. Even for this small subset 
of patients with mutant EGFR (in Western countries), multiple 
resistance mechanisms have emerged requiring different salvage 
strategies. DNA sequence analysis will likely yield other small sub-
groups with direct therapeutic implications, and expression arrays are 
beginning to identify others, but analysis of the proteome has many 
theoretical advantages, for a complete knowledge of the proteome 
would encompass all known mechanisms of functional dysregula-
tion associated with the development of cancer, including DNA 
mutations, rearrangements, transcriptional alterations and promoter 
methylation, but also post-translational modifications. This depth of 
information is still far from reality, however, and the true information 
content of today’s technologies leaves a lot to be desired. 
Using the simple, inexpensive, and rapid technology of matrix-
assisted laser desorption/ionization time-of-flight mass spectrom-
etry (MALDI MS) we studied unfractionated, pretreatment sera to 
identify NSCLC patients with improved survival after treatment with 
the EGFR TKIs gefitinib and erlotinib. Mass spectra, independently 
acquired at two institutions, gave highly concordant results, and were 
used to generate an algorithm predictive of time to progression and 
survival. This prediction algorithm was then validated in a blinded 
manner in two independent cohorts of NSCLC patients treated with 
EGFR TKIs. This classification algorithm did not predict outcome in 
three independent cohorts of patients who did not receive treatment 
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with EGFR TKIs. Thus, if upheld in prospective clinical trials, this 
analysis of pre-treatment peripheral blood might be useful in select-
ing therapy for advanced non-small cell lung cancer patients. We are 
currently in the process of testing this signature in sample sets from 
past randomized clinical trials, and a prospective trial is underway.
We have also used this technology to develop signatures predicted 
of response to chemotherapy in lung cancer cell lines and applied 
the resulting signatures to tumors resected with curative intent. This 
signature accurately classified survival for patients who received 
adjuvant chemotherapy, and not for those who did not, suggesting 
that it might be predictive of benefit from adjuvant chemotherapy, 
and not merely prognostic. 
New technologies, such as shotgun proteomics, that give far more 
detailed information have also been far more cumbersome and 
less reproducible. However, we are now able to achieve a depth of 
information comparable to expression microarray analysis using 
shotgun proteomics of tumor and normal samples, with improving 
reproducibility. This is allowing for the more practical analysis of 
single samples, and definition of activated pathways in tumor cells in 
real-time. Direct quantitation of specific peptides of interest can also 
be achieved. It is likely that as the technology improves, proteomic 
signatures of cancer will be a significant source of information 
enabling the development of clinically useful individualized of risk 
assessments and therapeutic decision-making.
M33.3 Cutting Edge in Omics Research for Lung Cancer, Tue, Aug 4, 10:30 - 12:00
MicroRNA signatures for outcome 
prediction of lung cancer patients
Yang, Pan-Chyr
National Taiwan University College of Medicine, Taipei, Taiwan
Cancer is the most serious health problem word-wide. The recent 
advances in genomics and proteomics have greatly improved our 
understanding the molecular mechanisms of cancer progression. The 
new genomic technologies have enabled us to analyze the genetic 
alterations in a genome-wide scale. Novel candidate biomarkers and 
pathways have been identified for potential clinical application in 
disease risk stratification and management of cancer patients. These 
biomarkers, signaling pathways and new targets can be translated 
to clinical practice for personalized therapy of cancer patients and 
improve treatment outcome. 
MicroRNAs are a class of small non-protein-coding RNAs that can 
act as endogenous RNA interference. MicroRNAs can post-transcrip-
tionally regulate the expression of hundreds of their target genes, 
thereby controlling a wide range of biological functions such as 
cellular proliferation, differentiation, and apoptosis. Recent evidence 
indicates that microRNAs may function as tumor suppressors or 
oncogenes, and alteration in microRNA expression may play a criti-
cal role in tumorigenesis and cancer progression. Our understanding 
of microRNA expression patterns as potential biomarkers for diagno-
sis, prognosis, personalized therapy, and disease management is just 
starting to emerge. We identified a unique microRNA signature that 
can predict clinical outcome of lung cancer patients. The microRNA 
signature consisted of three risk microRNAs (miR-137, miR-182*, 
miR-372) and two protective microRNA (miR-221 and let-7a). Based 
on the relative expression levels of these 5 microRNAs and the risk 
score analysis, we developed an algorithm to predict the survival 
and relapse of non-small cell lung cancer (NSCLC) patients. The 
results were re-confirmed by an independent cohort. The microRNA 
signature can distinguish high or low-risk patients with significantly 
different survival within stage I, II, III, as well as the adenocarci-
noma or squamous cell carcinoma subgroups of NSCLC patients. 
Combination of gene expression signature we previously described 
and microRNA signature, we can further improve the prediction 
of the outcome of lung cancer patients. Currently we are working 
on the identification of specific targets of these microRNAs. These 
microRNA signatures need further validations by prospective clinical 
trials and may be potentially useful for personalized therapy of lung 
cancer patients. 
M33.4 Cutting Edge in Omics Research for Lung Cancer, Tue, Aug 4, 10:30 - 12:00
Genomic Signatures
Potti, Anil
Division of Medical Oncology,
Institute for Genome Sciences and Policy, Duke University, Chapel 
Hill, NC, USA
Gene expression profiles reflect unique aspects of individual tumors 
and may provide precise prognostic information (Potti A, NEJM 
2006 and Bild A, Nature 2006). In this study of patients with non-
small cell lung carcinoma (NSCLC), we use gene expression patterns 
that reflect the deregulation of major oncogenic signaling pathways 
including Ras, PI3 kinase, Akt, Src, ß-catenin, E2F, and Myc path-
ways, and applied this ability to identify the state of critical regulato-
ry pathways to several hundred samples from patients with recurrent 
NSCLC and metastatic disease. These individuals, in particular, the 
patients with metastatic disease are likely to be resistant to standard 
chemotherapy pointing to the need for alternative therapeutic options 
(Potti, A Nature Medicine 2007). As one approach to this challenge, 
we have exploited gene expression data generated in patients with 
recurrence and metastasis. Briefly, the methods involved extracting 
RNA from NSCLC tumor samples and gene expression data gener-
ated using the Affymetrix arrays and then analyzed by hierarchical 
clustering to identify patterns of pathway deregulation. Results from 
binary regression analyses are expressed as a probability of pathway 
activation by tumor sample, and Kaplan-Meier survival analysis per-
formed stratifying by pathway status revealed that patient subgroups 
defined by distinct patterns of pathway deregulation exhibited statis-
tically significant differences in disease-free survival. Further, using 
cell proliferation assays, we have shown that the predicted deregula-
tion of Ras, Src and PI3 kinase pathways was directly proportional 
to the sensitivity of lung cancer cell lines to agents that specifically 
target these pathways, suggesting that an ability to profile the status 
of oncogenic pathways in a patient tumor sample provides a unique 
opportunity to better characterize the oncogenic process in patients 
with recurrent and advanced NSCLC, and could provide a mecha-
nism to guide the appropriate use of pathway specific inhibitors – a 
novel approach to targeted therapeutics. In addition, we describe a 
novel strategy to guide choices of cisplatin-based chemotherapy.
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The airway transcriptome as a biomarker for lung cancer
Spira, Avrum
The Pulmonary Center, Boston University Medical Center, Boston, 
Massachusetts, USA
While cigarette smoking is the major cause of lung cancer, only 
10-20% of smokers develop lung cancer. Because of the lack of 
effective diagnostic biomarkers and the inability to identify which 
current and former smokers are at greatest risk, lung cancer is most 
often diagnosed at a late stage where current therapies are largely 
ineffective. We have been exploring how cigarette smoking affects 
airway epithelial cell gene expression and defining lung-cancer-
specific alterations in airway gene expression that can identify that 
subset of smokers who have, or are at risk for developing, lung can-
cer. The approach is based on the concept that inhaled toxins create 
a “field of injury” in all exposed airway epithelial cells, and that by 
measuring gene expression in these cells, one can develop a profile 
that reflects physiologic response to exposure1,2. Using this approach, 
we have developed a gene expression biomarker from histologically-
normal bronchial airway epithelial cell brushings that distinguishes 
smokers with and without lung cancer and can serve as an early diag-
nostic biomarker3,4. We have also begun to explore how a smoker’s 
pattern of airway gene-expression reflects perturbation of specific 
oncogenic pathways, potentially allowing for personalized chemo-
prophylaxis and therapy. Additionally, we have recently character-
ized the impact of smoking on whole-genome miRNA expression in 
the bronchial airway, and demonstrated how changes in these short 
non-coding regulatory RNAs modulate the gene expression response 
to smoking5. Finally, we have begun to extend this molecular field 
of injury to epithelial cells that can be obtained non-invasively from 
nose and mouth and have demonstrated that smoking-related changes 
in bronchial airway gene expression are largely recapitulated in oral 
and nasal mucosa6. If cancer-specific gene-expression changes extend 
to the epithelial cells lining the nose and mouth, genomic analysis of 
specimens at these sites could serve as the basis for screening tools to 
identify smokers at highest risk for lung cancer. 
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Signal transduction overview
Bunn, Jr, Paul A.
University of Colorado Cancer Center, Aurora, CO, USA
Activation of cell surface receptors accomplish their biologic activ-
ity through intracellular cell signal networks. These networks may 
signal a cancer cell to develop one or more of the hallmarks of 
cancer described by Weinberg in 2000 including evading apoptosis, 
insensitivity to auto growth signals, tissue invasion and metastases, 
sustained angiogenesis, limitless replicative potential, self-sufficien-
cy in growth signals. 
While these intracellular signal pathways are interconnected and 
seem indecipherably complex, recent studies have suggested that 
as few as 12 central pathways hold the key to the development of 
cancer. These 12 pathways are controlled by many genes that can 
be altered by activation through mutation, amplification, epigenetic 
regulation and loss of function by mutation, gene loss, epigenetic 
regulation and so forth. To date, the signal transduction pathways 
that have received the most attention in lung cancer are the pathways 
involved in growth factor activation by tyrosine kinase receptors 
especially in the EGFR family of receptors. We know that EGFR 
activation occurs by mutation in 5-40% of patients with NSCLC 
varying by race and ethnicity. In these patients, EGFR TKIs produce 
outcomes that are superior to those achieved with chemotherapy. 
Resistance can develop by several mechanisms that allow intracel-
lular signaling through related pathways. Amplification of MET, and 
use of related pathways are two such mechanisms of action. Recent 
studies show that the downstream target ALK can also activated by 
a fusion gene EML4/ALK. Interestingly, mutations in EGFK, KRAS 
and the EML4/ALK are largely mutually exclusive.
MET/ALK TKI termed PF 0234 1066 can inhibit both MET and 
ALK and was shown to be highly active in NSCLC patients with the 
EML4/ALK fusion. Other inhibitors of downstream targets such as 
P13K, mTOR, MEK, and ERK are now being studied and may play 
a role alone or in combination when there are pathway alterations. 
Other signal pathways such as Hedgehog and apoptosis pathways 
are also under investigation and will be discussed elsewhere at this 
meeting. Signal transduction inhibitors are here to stay and will play 
an increasing role in lung cancer therapy.
M34.3 Signal Transduction Inhibitors – Biology and Activity, Tue, Aug 4, 10:30 - 12:00
Src inhibitors
Gautschi, Oliver
University Hospital Bern, Medical Oncology, Bern, Switzerland
The majority of cancer deaths are directly associated with the con-
sequences of metastasis. Currently, there is no effective treatment 
available to block cancer cell invasion and metastasis in patients. 
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Src was discovered based on the seminal work by Francis Peyton 
Rous in 1911 on the viral transmission of chicken sarcoma, and the 
subsequent discovery of the Rous Sarcoma Virus (RSV) carrying 
the v-Src oncogene. Today, the human c-Src family of non-receptor 
tyrosine kinases contains several members, including Src, Yes, 
Fyn, Lyn, Lck, Hck, Fgr, Blk, and Yrk. Src kinases are activated by 
growth factor receptors, cytokine receptors, protein tyrosine phos-
phatase 1B, CAS, and focal adhesion kinase (FAK). Src kinases can 
interact with a broad network of intracellular signalling pathways, 
including the integrin/FAK pathway, beta-catenin/Wnt, RAS-MEK, 
PI3K-AKT, and JAK-STAT. This explains the implication of Src 
kinases in a wide range of cellular functions, including adhesion, 
migration, invasion, survival, proliferation, differentiation, inflamma-
tion and angiogenesis. Constitutively active Src induces transforma-
tion of human fibroblasts in vitro, and Src is overexpressed in many 
tumors. 
In non-small cell lung cancer (NSCLC), Src expression levels were 
elevated in 50-80% of the reported cases, and high Src expression 
was correlated with poor differentiation. The levels of activated Src, 
determined by enolase-assays, were higher in lung cancer com-
pared with normal lung. Src kinase activity appeared to be higher 
in primary NSCLC compared with small cell lung cancer (SCLC). 
Activating mutations of Src have not been described in primary lung 
cancer so far. Aberrant EGFR signaling appears to be the dominant 
mechanism of Src activation in NSCLC. This view is strongly sup-
ported by studies reporting induction of apoptosis by Src inhibition 
in EGFR-dependent lung cancer cell lines.
Several small-molecule inhibitors of Src are currently in phase I and 
II clinical trials. These include dasatinib (Bristol-Myers Squibb), 
AZD0530 (AstraZeneca), SKI-606 (Wyeth), SU6656 (Sugen), 
XL999 (Exelixis), AP23846 (Ariad Pharmaceuticals), and others. 
Dasatinib, based on its affinity for Abl and PDGFR kinases, has 
shown clinical activity in leukaemia and in gastro-intestinal stromal 
tumors, respectively. For all other Src inhibitors, it is presently not 
known which types of cancer may respond best, and which markers 
may predict treatment outcome in individual patients. New clinical 
trials are combining Src inhibitors with chemotherapy and/or other 
molecular targeted agents. At the WCLC 2009, the speaker will dis-
cuss the present status of Src inhibitors in patients with lung cancer 
and other solid malignancies. 
M34.5 Signal Transduction Inhibitors – Biology and Activity, Tue, Aug 4, 10:30 - 12:00
IGF-1R inhibitors
Paz-Ares, Luis
Hospital Universitario Virgen del Rocio, Seville, Spain
Recently, significant progress has been made towards understanding 
the pathogenesis of lung cancer from the molecular standpoint. To 
this end, a growing number of approaches are being exploited for the 
identification and validation of new therapeutic targets suitable for 
potent and specific intervention. The type 1 insulin-like growth factor 
receptor (IGF-1R) system has recently become the focus of major 
attention in the arena of cancer research. The involvement of the 
receptor and its downstream signaling cascades in the carcinogenesis 
process makes this system an excellent target for potential cancer 
therapy. Indeed, advances in the understanding of the molecular 
mechanisms behind IGF-1R activation have led to the discovery 
of agents designed selectively for targeting IGF-1R. The potential 
application of these inhibitors is currently under intense clinical 
investigation. In this lecture we will review the relevance of the 
biology of the IGF/IGF-1R pathway in lung cancer and the attempts 
to develop effective IGF-1R antagonists, with special emphasis on 
antibodies and small tyrosine kinase inhibitors.
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M35.1 Lights and Shadows in the Staging of Lung Cancer, Tue, Aug 4, 10:30 - 12:00
Lung cancer staging: latest revision
Detterbeck, Frank 
Yale University School of Medicine, New Haven, CT, USA
The 7th edition of the Lung Cancer Stage Classification represents a 
major advance and is unique among cancer types in that it is statisti-
cally sound, internally and externally validated, and based on a large 
worldwide detailed database. The work was performed by the IASLC 
Staging Committee in conjunction with an extensive international 
collaboration. This presentation reviews the new stage classification 
and the scientific basis underlying it, as well as nuances that could 
not be fully defined and will require future work. 
M35.2 Lights and Shadows in the Staging of Lung Cancer, Tue, Aug 4, 10:30 - 12:00
How new staging affects surgical perspectives
Rami-Porta, Ramón
Hospital Universitario Mutua de Terrassa, Terrassa, Spain
Introduction
The new tumour, node and metastasis (TNM) classification and stag-
ing system for lung cancer is based on the proposals of the Inter-
national Association for the Study of Lung Cancer (IASLC). The 
International Staging Committee (ISC) (1) of the IASLC collected 
100,869 patients from around the world with the objective to validate 
and update the previous revision of the TNM classification for lung 
cancer, that was published in its fifth edition (1997) and remained 
unchanged in the sixth (2002). The changes proposed by the IASLC 
were published in the Journal of Thoracic Oncology (2, 3, 4, 5, 6, 7). 
They were both internally and externally validated (8). The modifica-
tions proposed are summarised in the table (9). 
Non-small cell lung cancer
In the new TNM classification for lung cancer, tumour size has 
much more relevance than it had in the previous editions. From a 
dichotomous system where the 3-cm landmark separated T1 from 
T2 tumours, we have advanced into a system with five tumour size 
groups of significantly different prognosis: two groups in T1, two 
groups in T2 and one group in T3 (Table). 
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Changes in the new TNM classification of lung cancer  
proposed by the IASLC
T
• Subclassification of T1 according to tumour size in: T1a: equal to or less than 2 cm, and T1b: 
more than 2 but equal to or less than 3 cm. 
• Subclassification of T2 according to tumour size in: T2a: more than 3 cm but equal to or less 
than 5 cm (or tumour with any other T2 descriptors, but equal to or less than 5) and T2b: more 
than 5 cm but equal to or less than 7 cm.
• Reclassification of T2 tumours larger than 7 cm as T3.
• Reclassification of T4 tumours by additional nodule/s in the same lobe of the primary tumour 
as T3.
• Reclassification of M1 tumours by additional nodule/s in another ipsilateral lobe as T4.
• Reclassification of T4 tumours by malignant pleural effusion as M1a.
N
• No changes.
M
• Subclassification of M1 in: M1a: separated tumour nodule/s in the contralateral lung; 
tumour with pleural nodules or malignant pleural (or pericardial) effusion; and M1b: distant 
metastasis.
Undiagnosed small lung nodules raise diagnostic discussions and 
controversies, and many systems have been developed to predict 
their nature based on clinical, radiographic and metabolic features. 
Those that are not clearly deemed malignant may be observed over a 
variable period of time. The new TNM classification has shown that 
a difference in a few millimetres matters: when a tumour grows from 
2 cm to more than 2 cm but less than 3 cm, 5-year survival is signifi-
cantly reduced by 6% both in the clinically and pathologically staged 
tumours with no nodal disease (2). Reduction of survival is greater if 
the tumour grows more than 3 cm. This evidence should be brought 
forward when discussing the indication for invasive diagnosis and 
resection of small lung nodules, and the patients must be aware of it: 
resection of the earliest lung cancer, from the macroscopic point of 
view, (T1a), is associated with the highest probability of long term 
remission and survival. 
The new TNM staging system reconciles the classification of 
additional tumour nodules with their real prognosis. The former T4 
category so defined by the presence of additional tumour nodules 
in the same lobe of the primary tumour was found to have a similar 
prognosis to that of T3 tumours, and has, therefore, been downstaged 
from T4 to T3. For the same reason, tumours with additional nodules 
in a different ipsilateral lobe have been downstaged from M1 to T4 
(Table). This downstaging is likely to increase the indication for 
resection in these patients, because their 5-year survival is 45% or 
greater for completely resected tumours with no nodal disease (2).
There was no change in the N component, but the N categories in use 
were all validated both in the clinical and pathologic classifications. 
None of the N1 or N2 stations had a significantly worse prognosis. 
Then, the traditional nodal stations were amalgamated into nodal 
zones comprising groups of neighbouring nodal stations. The analy-
sis of part of the population of patients who had undergone lung 
resection and systematic nodal dissection and had detailed informa-
tion on the extension of N disease revealed that the magnitude of the 
nodal involvement, in terms of number of nodal zones involved, had 
prognostic impact. Three prognostic categories were found: involve-
ment of single N1 zone (N1a); involvement of multiple N1 zones 
(N1b) or single N2 zone (N2a); and involvement of multiple N2 
zones (N2b). Their 5-year survival rates were 48%, 35%, 34%, and 
20%, respectively. Differences between multiple N1 zones and single 
N2 zone were not significant (3). These findings could not be vali-
dated by geographic areas or type of databases and, therefore, could 
not be used to modify the present N categories, but they have clinical 
importance. In contrast with N2 disease, the surgical indication of N1 
disease has never been challenged. The above results show that there 
is a subgroup of N2 disease (involvement of a single N2 zone) that 
has the same prognosis of multiple N1 zones. Could this subgroup 
of N2 be considered a good candidate for surgical resection upfront? 
Maybe, but it is important to bear in mind that this survival analysis 
was done in the population of patients who underwent resection 
and systematic nodal dissection; that means that their tumours were 
pathologically staged. Indications for surgery are based on the clini-
cal staging. Transferring the results of pathologically staged tumours 
to those clinically staged may be misleading. In order to indicate 
initial resection for single zone N2 disease, we must be sure that the 
patient has single zone N2 disease. This raises the question of how 
clinical staging has to be done. No doubt, it has to be very thorough 
to prove that it is single zone N2. This means that all mediastinal 
nodal stations have to be evaluated and the certainty of this evalua-
tion depends on the procedure. Imaging and metabolic scanning have 
lower accuracy that invasive procedures. Endobronchial and oesoph-
ageal fine-needle aspirations guided by ultrasounds are unlikely to 
explore all possible mediastinal locations. Standard mediastinoscopy 
may miss small nodes that may be involved. The recently developed 
video-assisted mediastinoscopic lymphadenectomy (VAMLA) (10, 
11, 12) and transcervical extended mediastinal lymphadenectomy 
(TEMLA) (13, 14) can be aligned with systematic nodal dissection 
of the upper mediastinum and para-oesophageal nodal station. With 
these procedures, the nodes of the pulmonary ligament are the only 
ones that remain unexplored, but are unlikely to be involved if the 
others are negative. If primary resection is considered for single N2 
zone tumours, these types of lymphadenectomy will have to be seri-
ously considered to rule out multiple N2 zone involvement. 
Contralateral tumour nodules are now classified as M1a. This indi-
cates a better prognosis within the M category. In most clinical situa-
tions it will be difficult or impossible to know whether these nodules 
are metastasis or second primaries. The fact that they have a better 
prognosis may increase the indications for resection.
Small cell lung cancer
The classic dichotomous classification of small cell lung cancer (lim-
ited and extensive disease) groups tumours with different anatomic 
extension and prognosis. The analyses of the IASLC have shown 
that the TNM classification and staging system separate groups of 
significantly different prognosis. This has led to recommend the 
use of the TNM classification to stage small cell lung cancer and to 
stratify future clinical trials by tumour stage (6). The more precise 
TNM classification will separate early tumours from the old ‘limited 
disease’ category that may be amenable to resection. Recent evidence 
has also shown that resection may have an important role in the man-
agement of selected patients with small cell lung cancer (15).
Conclusion
The new edition of the TNM classification for lung cancer better sep-
arates tumours with significantly different prognosis and, therefore, it 
is likely to expand the indications for resection in some subgroups. 
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Pleural invasion 
Roggli, Victor L.
Duke Univ Med Ctr, Durham, NC, USA
The American Joint Committee on Cancer TNM staging system 
recognizes the prognostic significance of visceral pleural invasion, 
and tumors that are otherwise T1 are classified as T2 when visceral 
pleural invasion is present. In some centers, adjuvant chemotherapy 
is offered for patients with this finding. (1) Hence the assessment of 
visceral pleural invasion is critical to the pathological evaluation of 
lung cancer, in particular those peripheral tumors extending to the 
pleura.
Evaluation of invasion of the visceral pleura can be challenging due 
to the complexity of this structure. The visceral pleura consists of 
five layers, which include the outer mesothelial layer, a submeso-
thelial layer of loose connective tissue, the external elastic lamina, 
another layer of loose connective tissue (containing lymphatics, 
capillaries, and collagen), and the internal elastic lamina and fibrous 
tissue layer that merges with the subjacent lung. (2)
Assessment of visceral pleural invasion can be further complicated 
by distortion of the visceral pleura or reduplication of the elastic 
layer in response to a peripheral carcinoma. Furthermore, fibrous 
tissue may be deposited on the surface of the pleura, giving the 
mistaken impression that the tumor does not extend to the pleural 
surface. In such cases, elastic stains are very helpful in sorting out 
the anatomy and may demonstrate invasion of the visceral pleura 
that is inapparent on routine hematoxylin and eosin (H&E)-stained 
sections.
Taube et al (3) reported on a study of 100 consecutive peripheral 
non-small cell carcinomas that had been classified as Stage 1A based 
on evaluation of H&E stains alone. The authors found that when 
elastic stains were applied to these cases, there was upgrading to 
Stage 1B in nineteen cases (19%). Furthermore, in a survey of heads 
of departments of anatomical pathology, 59% stated that they never 
used elastic stains in the evaluation of peripheral non-small cell car-
cinomas abutting the pleura, whereas 20% stated that they always do. 
The authors concluded that elastic stains should be part of the routine 
evaluation of peripheral lung carcinomas.
Travis et al (4) reviewed the literature regarding the use of elastic 
stains in the evaluation of peripheral carcinomas and suggested that 
they should be used whenever the findings on H&E were ambiguous. 
They further recommended that the new classification system include 
four levels of pleural invasion. PL0 (T1) applies to cases where there 
is lack of invasion of the elastic layer of the visceral pleura. PL1 (T2) 
includes cases with invasion beyond the elastic layer but not to the 
pleural surface. PL2 (T2) refers to cases where there is invasion to 
the visceral pleural surface. Finally, PL3 (T3) includes cases with 
invasion of the parietal pleura. The committee also recommended 
that the abbreviation PL should be used to designate pleural involve-
ment in order to avoid confusion with p (for pathologic) as opposed 
to c (for clinical) staging.
In the evaluation of elastic stains for visceral pleural invasion, 
the presence of tumor cells (individually or in clusters) above the 
internal elastic lamina constitutes invasion. This may or may not 
be accompanied by discontinuities in the elastic layer. Tumors in 
this location have access to the visceral pleural lymphatics, which 
probably contributes to their poorer prognosis. In cases with pleural 
puckering, the elastic layer is drawn inward so that elastic stains can 
be very useful for detecting invasion of visceral pleura by tumor 
cells that are a considerable distance from the visceral pleural surface 
(Figure 1). The elastic stain has the further advantage of facilitating 
the identification of intravascular invasion (Figure 2).
Desmoplastic responses to invasive tumors may result in redupli-
cation of the elastic layers or fusion of the internal and external 
elastic layers. In this circumstance, it may be difficult to evaluate the 
presence or absence of visceral pleural invasion. (5) In such cases, 
the pathologist may have to report invasion of the visceral pleura as 
being indeterminate. 
An additional problem area in the staging of lung cancer is the clas-
sification of cases with visceral pleural invasion that extends into an 
adjacent lung lobe (interlobar pleural invasion). Under the current 
system, such tumors are classified as T2.
In summary, elastic stains are a valuable aid to the pathologist in the 
assessment of visceral pleural invasion. In cases where the interpre-
tation of H&E stains is ambiguous, it is recommended that elastic 
stains be employed in lung cancers that extend to the pleura. (4) 
However, the interpretation of H&E stained sections alone can be 
misleading. Therefore, elastic stains are employed in all cases of non-
small cell carcinoma that abut the pleura at the author’s institution.
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Figure 1
Figure 2
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Multiple tumor nodules: characteristics of 
lung cancers with multiple nodules from 
BAC to ALK fusion gene carcinoma
Ishikawa, Yuchi
The Cancer Institute, Jpn Foundation Cancer Res., Tokyo, Japan
We often encounter multiple tumors of lung cancer, including mul-
tiple BAC and obviously metastatic lesions. For staging purposes, it 
is important to determine whether multiple tumors are all primaries 
or include metastases. But pathologically, is it possible to dif-
ferentiate primary lung cancer from metastasis, in particular, with 
squamous histology? In this talk, I’ll present (1) some cases of mul-
tiple BAC, including MMPH (multifocal micronodular pneumocyte 
hyperplasia), (2) how to distinguish primary tumors from metastases, 
employing methods of histology, mutation and LOH analyses, (3) 
how to practically diagnose such tumors without aids of molecular 
techniques, and additionally (4) cases of multiple cancer with ALK 
fusion.
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Growth Factors in Lung Cancer Management 
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Clinical use of erythropoiesis-stimulating 
agents: defining the benefits
Pirker, Robert
Department of Medicine I, Medical University of Vienna, Vienna, 
Austria
Anemia is common among patients with lung cancer and affects 
50-70% of lung cancer patients (1). Factors contributing to ane-
mia are myelosuppressive chemotherapy and radiotherapy, tumor 
infiltration of the bone marrow, relative deficiency of erythropoietin, 
inappropriate response of the bone marrow, functional iron defi-
ciency, nutritional deficiencies, bleeding, hemolysis, cytokines and 
other factors (2-4). A special type of cancer-related anemia is the 
anemia of chronic disease which is due to mainly an impaired bone 
marrow response to eythropoietin and partly a relative inadequacy of 
erythropoietin production. 
Anemia virtually affects all organs and, therefore, can lead to many 
symptoms (5). In particular, anemia is one of the most relevant 
causes of cancer-related fatigue (6). In patients with lung cancer, the 
symptoms of anemia are often enhanced by diminished pulmonary 
function and other co-morbidities. The severity of symptoms depends 
on the absolute Hb level, the rapidity of onset, compensatory mecha-
nisms, co-morbidity and other factors. Anemia is also associated 
with a 19% relative increase in the risk of death in patients with 
lung cancer (7). Adequate assessment of anemia should focus on its 
symptoms, laboratory findings including storage iron as well as vita-
min levels, impact on activities of daily living, and potential causes. 
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Multidimensional instruments such as the Functional Assessment 
of Cancer Therapy-Anemia (FACT-Anemia) scales allow a more 
detailed assessment of the impact of anemia on quality of life (8). 
Treatment of anemia focuses on the correction of its cause, red blood 
cell transfusions and the administration of erythropoiesis-stimulating 
agents (ESAs). Red blood cell transfusions result in immediate but 
often only transient improvement of anemia-related symptoms. 
Transfusions are usually only given when the hemoglobin (Hb) lev-
els drops near to 8 g/dl and also carry several risks. 
The therapeutic development of ESAs (epoetin alfa, epoetin beta 
and darbepoetin alfa) has had a major impact on the management of 
cancer-related anemia (9). These agents are administered subcutane-
ously once weekly or at higher doses with extended dosing intervals. 
ESAs increase Hb levels and decrease RBC transfusions in patients 
receiving chemotherapy, chemoradiotherapy or radiotherapy (for 
review see ref. 4 & 9). Approximately 30% to 80% of patients 
respond to treatment with ESAs. Response to ESAs is dependent on 
the dose, frequency as well as route of administration, duration of 
therapy, presence of other or additional causes of anemia, functional 
iron deficiency, presence of infection and other factors. Response is 
usually not affected by age, sex, type of cancer, type of chemothera-
py (platinum versus non-platinum) and chemotherapy response. ESA 
decrease the relative odds of receiving a RBC transfusion by an aver-
age of 62% (10). Thus 4 to 5 patients have to be treated with ESAs in 
order to benefit one patient (10). ESAs also improve anemia-related 
symptoms as well as quality of life (11). In particular, energy levels, 
daily activities and overall quality of life increase during treatment 
with ESAs. These improvements correlate with an increase in the Hb 
levels (12). 
In patients with lung cancer, the clinical benefits of ESAs have been 
demonstrated for patients undergoing chemotherapy or chemoradio-
therapy (for review see ref. 4-5). These trials either included lung 
cancer patients among patients with other cancers or were performed 
exclusively in patients with lung cancer. Most trials included patients 
with pre-existing anemia, but few studies also assessed the prophy-
lactic use of ESAs for the prevention of anemia in patients receiving 
myelosuppressive therapy. Based on the results of these trials, ESAs 
are currently indicated in patients with lung cancer and chemothera-
py-induced anemia.
In the 3 large community-based trials that demonstrated the benefit 
of epoetin alfa in cancer patients (13-15), about one quarter of the 
patients had lung cancer. An analysis of these lung cancer patients 
confirmed that epoetin alfa treatment increased Hb levels, decreased 
RBC transfusion rates and improved quality of life (16). Epoetin beta 
was also shown to effective in patients with lung cancer receiving 
palliative chemotherapy (17).
The clinical efficacy of darbepoetin alfa compared to placebo was 
proven in patients with lung cancer (29% SCLC, 71% NSCLC) and 
chemotherapy-induced anemia in a phase III trial (18). The median 
Hb level at the time of inclusion was 10 g/dl. Patients receiving 
darbepoetin alfa required fewer transfusions (27% versus 52%) and 
had more hematopoietic responses (66% versus 24%) than those 
receiving placebo. Patients receiving darbepoetin alfa had better 
improvement in health-related quality of life as assessed by the 
FACT-Fatigue score. Improvements correlated with increases in Hb 
levels. Both patients with baseline Hb levels >10 g/dl and those with 
levels <10 g/dl benefited from darbepoetin alfa treatment (19). The 
proportion of patients with milder anemia experiencing a hematopoi-
etic response was similar to that observed in patients with moderate 
to severe anemia indicating that response to darbepoetin alfa is inde-
pendent of baseline Hb. However, the proportion of patients who still 
required red blood cell transfusions when darbepoetin alfa treatment 
was initiated at Hb levels between 10-11 g/dl was approximately 
halved relative to the proportion of patients requiring a transfusion 
when therapy was initiated at Hb levels below 10 g/dl. Darbepoetin 
alfa was well tolerated. Adverse events were similar between patients 
receiving darbepoetin alfa and those receiving placebo. In the 
subgroup of patients with SCLC, progression-free survival was pro-
longed in the darbepoetin alfa group when compared to the placebo 
group but no such difference was seen for patients with NSCLC (18). 
Although ESAs were studied in patients undergoing concurrent 
chemoradiotherapy or radiotherapy and for the prevention of anemia 
during cisplatin-based chemotherapy (for review see ref. 3-4), more 
information on the impact of ESAs is required before these agents 
can be recommended in these settings. In patients with active cancer 
and anemia but not receiving chemotherapy or radiotherapy, darbe-
poetin alfa did not significantly decrease the rate of transfusions and 
was associated with shorter survival of the patients (20). Thus ESAs 
are currently not indicated in these patients.
Because anemia leads to the development of tumor hypoxia which is 
linked to treatment resistance and poor prognosis, epoetin-mediated 
improvement or correction of anemia may increase response to 
chemotherapy or radiotherapy. This then could result in improved 
survival. To test this hypothesis, several trials were performed. A 
phase III trial in patients with extensive disease of small-cell lung 
cancer undergoing platinum-based chemotherapy aimed to demon-
strate a survival benefit by using darbepotin alfa in patients with Hb 
levels below 13 g/dl (21). This trial did not find a difference in sur-
vival between patients receiving darbepoetin alfa and those receiving 
placebo but clearly demonstrated the safety of darbepoetin alfa in 
these patients. Another trial also found no impact of epoetin alfa on 
survival in patients with SCLC (22). A trial in patients with advanced 
NSCLC unsuitable for curative treatment was terminated prema-
turely after an unplanned safety analysis found a shorter survival in 
the epoetin alfa group compared to the placebo group (23). This trial 
and a few other trials which included patients with cancers other 
than lung cancer raised concerns that ESAs might decrease survival 
of patients. Thus several meta-analyses were performed in order to 
determine the association between the use of ESAs and survival in 
patients with cancer (24-26). The most recent meta-analysis used 
data from 13933 cancer patients enrolled into 53 studies (26). This 
patient population included 10441 patients from 38 studies receiving 
mainly chemotherapy. Including all cancer patients in the analysis, 
ESAs increased on-study mortality by 10% (HR 1.1; 95% CI 0.98-
1.24) and overall survival by 6% (HR 1.06; 95% CI 1.00-1.12). In 
patients receiving mainly chemotherapy, ESAs had no statistically 
significant impact on on-study mortality (HR 1.10; 95% CI 0.98-
1.24) or overall survival (HR 1.04; 95% CI 0.97-1.11). 
Treatment with ESAs is usually well tolerated. Important side effects 
are hypertension and thrombo-embolic events. The risk of hyperten-
sion is increased by 1.25-fold and the one of thrombo-embolic events 
by 1.67-fold (24, 25). Other occasional side effects are skin reac-
tions, cephalea and influenza-like symptoms. 
ESAs should be used according to practice guidelines such as those 
of the American Society of Clinical Oncology and the American 
Society of Hematology (27) or the EORTC (28). In addition, recom-
mendations by both the FDA and the European Agencies have to be 
considered. Currently, treatment with ESAs is indicated in anemic 
Copyright © 2009 by the International Association for the Study of Lung Cancer S155
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
patients undergoing non-curative chemotherapy when Hb levels drop 
below 10 g/dl. According to the updated EORTC guidelines, initia-
tion of treatment with ESAs is recommended at Hb levels of 9-11 g/
dl based on anemia-related symptoms in patients with chemotherapy. 
The target Hb level should be between 10-12 g/dl and should not 
exceed 12 g/dl. Dose escalation of ESAs in non-responders is not 
recommended. ESAs are not indicated in non-anemic cancer patients 
and anemic patients not receiving chemotherapy. 
In summary, anemia is of major clinical relevance in patients with 
lung cancer. ESAs benefit patients with chemotherapy-induced ane-
mia and are safe when used within their current label. 
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Clinical use of the erythropoietin 
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Kosmidis, Paris A.
Head of 2nd Med Onc Dept of HYGEIA Hospital, Athens, Greece
Anaemia is a common complication in cancer patients and can be 
disease and/or treatment related. For a long time anaemia was not 
considered to be a major problem. Now both the incidence as well as 
the consequences of anaemia for the patient’s well being have been 
recognized. The usual treatment of anaemia consisted of red blood 
cell (RBC) transfusions. Erythropoiesis-stimulating agents (ESAs) 
became an adjunct to the traditional approach of anaemia, as they 
are effective in increasing haemoblobin (Hb) levels, reducing the 
need for RBC transfusions. They had a positive effect on QoL in 
many studies in patients with chemotherapy-induced anaemia (CIA). 
Recently, this significant progress in the supportive care of patients 
having chemotherapy was challenged by safety concerns. 
The first safety signals were observed in two studies with non-
anaemic cancer patients. In a head and neck cancer study, patients 
underwent curative treatment with radiotherapy or postoperative 
radiotherapy. They received epoetin beta or placebo to maintain nor-
mal Hb values. Locoregional progression-free survival was poorer in 
the group treated with epoetin beta (adjusted relative risk 1.62, 95% 
CI 1.22–2.14). In the Breast cancer Erythropoietin Survival Trial 
study, patients with metastatic breast cancer and planned chemother-
apy were treated with epoetin alfa versus placebo once Hb fell below 
13 g/dl, and with a target Hb of 12–14 g/dl, for 12 month overall 
survival of 70% in the epoetin alfa group versus 76% in the placebo 
arm (p=0.01). Other studies also raised concerns about decreased 
survival related to ESAs. Specifically for lung cancer, the results in 
the literature are conflicting. A small study, designed to look at the 
effect of epoetin alfa therapy on QoL, was initiated in patients with 
advanced non-small-cell lung cancer. An unplanned safety analysis, 
when only 70 patients had been included, led to discontinuation of 
the trial, because median survival was significantly worse in the 
active-treatment arm (HR=1.84, p=0.04). On the contrary two other 
studies with small cell lung cancer failed to show any negative effect 
on PFS or overall survival in the group treated with ESA.
The first was a double blind, placebo-controlled, trial with adminis-
tration of epoetin alfa or placebo when Hb fell below 14.5 g/dl. The 
primary endpoint was non-inferiority of response rate (complete or 
partial) after three chemotherapy cycles, and it was reached with 
response rate of 72.5% in the epoetin alfa arm versus 67% in the 
placebo arm. Median overall survival was similar across arms (10.5 
versus 10.4 months). The other study was a placebo controlled, dou-
ble-blind, Phase III trial with survival as primary endpoint in patients 
receiving platinum-based therapy plus darbepoetin alfa or placebo. 
Despite the high target Hb level of 13–14 g/dl, there was no statisti-
cally significant difference in progression free or overall survival.
Therefore, the major concern for the safety of ESAs is their negative 
impact on disease outcome which recently was raised by some trials. 
The thrombo-embolic side effects were more or less well known 
from previous studies.
Because of these concerns generated by different studies regarding 
survival and thrombo-embolic events, guidelines were formulated 
by EORTC ASCO/ASH and FDA. The later are the more strict and 
recommend the following: 
 FDA label
Recommended initiating Hb/aim Non-myeloid malignancies –anaemia due to  
 concomitantly administered chemotherapy
Mild anaemia Hb ≤ g/dl
Target Hb If Hb exceeds a level needed to avoid transfusion
Non-responders Discontinue after 8 weeks if no response in Hb levels or if  
 transfusions are still required
Iron Iron therapy recommended when serum ferritin is  
 < 100μg/l or serum transferring saturation < 20%
Anaemia of cancer patients Not indicated for patients without myelosuppressive  
 chemotherapy or when anticipated outcome is cure
Thrombo-embolic events Overall, the incidence of thrombotic events was 6.2% for  
 Aranesp® and 4.1% for placebo
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In conclusion, when ESAs are used according to the guidelines no 
significant harm to patients has been documented in the treatment of 
CIA, except for a significant increase in the risk of venous thrombo-
embolic events. Also according to the strict FDA guidelines treat-
ment must be limited to patients with moderate to severe anaemia 
and symptomatic CIA.
M36.3 Update on Hematopoietic Growth Factors in Lung Cancer Management,  
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Management of myelosuppression 
in the lung cancer patient
Crawford, Jeffrey
Department of Medicine, Duke University Medical Center, Durham, 
NC, USA
The most common life threatening complication of myelosuppres-
sive chemotherapy is the development of neutropenia. The two major 
complications of neutropenia are the associated risk of development 
of febrile neutropenia which can lead to complicated life threatening 
infection, prolonged hospitalization and increased risk of mortality. 
Because of this complication, the other major outcome from neutro-
penia is the common necessity for either chemotherapy dose delays 
or dose reductions, resulting in decreased relative dose intensity 
(RDI) of the planned myelosuppressive chemotherapy. The impor-
tance of RDI has been best studied in curative settings, particularly in 
patients with lymphoma and early stage breast cancer. In prospective 
studies in both these settings, relative modest reductions of RDI to 
85% or less have been associated with significant reductions in over-
all survival. From these studies, the importance of maintenance of 
chemotherapy in the curative and adjuvant setting has been extrapo-
lated to many other tumor types, but has not been formally tested in 
lung cancer. However, with increasing use of chemotherapy in both 
the adjuvant setting in non-small cell lung cancer and in conjunction 
with radiation in both limited small cell and stage III non-small cell 
lung cancer patients, the evaluation of chemotherapy dose delivery in 
these settings is needed.
Since neutropenia is the most common limitation in the development 
of combination chemotherapy regimens, it can also be viewed as 
a surrogate biomarker for chemotherapy delivery in the individual 
patient. For example, studies in Hodgkin’s lymphoma patients on 
German Hodgkin’s disease study group trials demonstrated a clear 
association of the frequency of grade 3 and grade 4 leucopenia 
and the failure free survival in those patients (Klimm, JCO 2005; 
23:8003-8011). Interestingly, a similar relationship exists with the 
development of neutropenia with the association of neutropenia and 
survival in patients with advanced NSCLC. In the study by DiMaio 
(Lancet Oncology 2005; 6:669), patients who developed mild or 
severe neutropenia had a significantly longer survival compared to 
those patients who did not develop neutropenia. While all patients 
were initially treated with the same doses of chemotherapy in the 
clinical trials evaluated, clearly pharmacogenomic differences and 
perhaps other host factors led to a variation in the degree of neutro-
penia and the likewise result of differences in systemic chemotherapy 
exposure. While this is not a test of relative dose intensity per se, it 
does suggest that even in the palliative setting of advanced lung can-
cer, chemotherapy dose delivery may be an important determinant of 
outcome.
On the other hand, the complications of neutropenia are well 
established. From the initial randomized placebo controlled trials 
of G-CSF in patients with small cell lung cancer receiving CAE 
chemotherapy, there was an approximate 50% reduction in the dura-
tion of neutropenia in the G-CSF treated patients. This was associ-
ated with a similar reduction in the rate of febrile neutropenia and 
hospitalization. Importantly, the general relationship between days of 
severe neutropenia and risk of febrile neutropenia was similar in both 
groups. For every one day of severe neutropenia, there is approxi-
mately a 10% risk of developing febrile neutropenia. This relation-
ship has been consistent across multiple chemotherapy regimens and 
tumor types. In small cell lung cancer, because of the longer duration 
of neutropenia with etoposide based therapies, febrile neutropenia is 
more common than in non-small cell regimens where most che-
motherapy regimens tend to be less myelosuppressive (Crawford 
JNCCN 2008; 6:109-118). However, even in this setting, febrile 
neutropenia occurs particularly in older patients with co-morbid 
disease. A recent prospective registry study involving more than 
100 US practices, demonstrated that the rate of febrile neutropenia 
was approximately 15% in small cell lung cancer patients receiving 
planned relative dose intensity of greater than 85%. By contrast, the 
rate of febrile neutropenia was less than 10% in the non-small cell 
lung cancer population. Interestingly, with reduction in the planned 
relative dose intensity, this rate of febrile neutropenia was reduced 
to less than 5% in the non-small cell population. However, similar 
dose reductions in the small cell population were not associated with 
a reduction in febrile neutropenia. This paradox is likely due to the 
advanced nature of the disease in those patients and co-morbidities 
which even with the planned dose reductions may not always miti-
gate the risk of febrile neutropenia.
The other important distinction of neutropenia from many other tox-
icities is that it is most prevalent in the first cycle of chemotherapy. 
This most likely relates to the inability to accurately determine the 
optimum systemic delivery of chemotherapy based on our current 
techniques of body surface calculation coupled with an inadequate 
understanding of both the pharmacokinetics and pharmacodynamics 
of chemotherapy in individual patients with multiple co-morbidities 
and variations in organ function, as well as disease extent. As a 
result, without proactive management, febrile neutropenia occurs and 
can lead to prolonged hospitalization and risk of mortality. In a study 
by Kuderer (Cancer 2006; 106:2258-2266), the overall mortality 
following hospital admission for adult cancer patients with febrile 
neutropenia, including both solid tumor patients and hematologic 
malignancies, was 9.5%. In patients with no major co-morbidities, 
the risk was 2.6%, but with multiple co-morbidities, the risk rose to 
above 20%. While the risk is higher in the hematologic malignancy, 
the solid tumor type with highest risk of mortality was lung cancer.
The potential impact on survival both in terms of acute complications 
and infection from neutropenia, as well as the longer term impact of 
reduced chemotherapy dose delivery requires a proactive approach 
to management. Options for prevention include chemotherapy dose 
reduction and delay which may be appropriate in certain settings, but 
as noted above, even in the palliative setting of advanced non-small 
cell lung cancer, chemotherapy dose delivery may be an important 
determinant outcome. Alternative strategies include the use of pro-
phylactic antibiotics. This has been best tested in the setting of high 
dose chemotherapy regimens of hematologic malignancies and/or 
transplantation. In these settings, prophylaxis with fluoroquinolones 
is well established to reduce the risk of fever and infection, as well as 
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infection related death and all cause mortality. However, the develop-
ment of resistant bacteria remains a concern and this approach is not 
recommended for routine use in support of chemotherapy in patients 
with solid tumors. The other approach is the use of prophylactic 
myeloid growth factors. Those best established in this setting are 
the granulocyte colony stimulating factors, filgrastim, lenograstim, 
and pegfilgrastim. Pegfilgrastim has the additional advantage of 
being a single dose administration rather than daily dosing, required 
with either filgrastim or lenograstim. A meta-analysis of trials using 
primary prophylaxis with one of the G-CSFs demonstrated a 46% 
reduction in febrile neutropenia, as well as a 45% reduction in the 
risk of infection related mortality and a 40% reduction in the risk 
of early mortality from primary prophylaxis (Kuderer, JCO 2007; 
25:3158-3167). What is not clear is whether the early mortality 
is related strictly to improvement in infection related mortality or 
whether subsequent dose delays and dose reductions in the patients 
who had prior febrile neutropenia ultimately impacts overall tumor 
response and survival.
Currently, the major guidelines groups of ASCO, NCCN and 
EORTC all recommend first cycle use of prophylactic CSFs when 
the predicted risk of an event from neutropenia is 20% or greater. 
Unfortunately, most of our risk assessment in this setting is limited 
to clinical trial reporting of rates of febrile neutropenia which are 
often under-reported and stem from clinical trial populations often 
healthier with less co-morbidity and at lower risk of development of 
febrile neutropenia than those patients treated in normal community 
settings.
To better define the risk and appropriate use of first cycle prophylaxis 
with myeloid growth factors, risk factor assessment is needed. A 
model has been developed by Dr. Gary Lyman that may help refine 
the risk to be based on chemotherapy regimen, but also age, organ 
function and other co-morbidities. Studies further validating this 
model in the lung cancer population would be of significant value. 
In the interim, oncologists are encouraged to apply the guidelines as 
outlined in their individual patients, noting in particular the NCCN 
guidelines which further support a decision making model that incor-
porates the goals of chemotherapy in terms of curative and adjuvant 
therapy versus life prolonging and/or palliative treatment. Further-
more, with the advent of targeted therapies added to myelosuppres-
sive chemotherapy, the risk of neutropenia and febrile neutropenia 
may increase as has been seen with the addition of bevacizumab to 
combination chemotherapy regimens. As new treatments emerge in 
management of patients with lung cancer, continued evaluation of the 
toxicities and their management will be vital in optimizing outcomes 
for our patients.
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Chemoprevention of high risk patient populations
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Netherlands Cancer Institute, Amsterdam, The Netherlands
Introduction
Lung cancer is the leading cause of cancer-related mortality and 
around 3000 people are dying every day as a consequence of this 
disease. More than 85% of this enormous toll is due to cigarette 
smoking (1).
Although the prevalence of smoking is declining, the risk of lung 
cancer after smoking cessation persists and remains elevated com-
pared with never-smokers (2).
It has been estimated that 42% of the adult population in the United 
States has an increased risk of lung cancer because of current or 
former smoking practice (3) and this percentage is expected to be 
significantly higher in many other countries. In addition it has been 
noted that despite the initial success of smoking cessation programs 
there seems to remain a population of hardcore smokers that are 
either unwilling or unable to quit (4). Thus, the addicted smoker and 
the ex-smokers are at high risk for lung cancer and it is obvious that 
we must elaborate a cost-effective strategy to prevent this devastating 
disease in those individuals, who are at greatest risk. Chemopreven-
tion of lung carcinogenesis is one way forward. So far the efforts to 
prevent lung cancer by natural or synthetic agents have not been suc-
cessful and we have neither been able to accurately identify high-risk 
individuals. 
Carcinogenesis
It is generally accepted that lung cancers are a result of complex 
interactions between genetic, environmental and life style factors. 
Molecular epidemiological studies have revealed a large number of 
genes involved in lung carcinogenesis (5). At he same time associa-
tions between antioxidant enzyme polymorphisms, food constituents 
and lung cancer risk have been noted (6). The bronchial epithelium 
is one of the major sites to undergo changes in response to inhaled 
toxic substances such as cigarette smoke. Whole genome gene 
expression studies, using brush-derived epithelial cells have shown 
large differences between ‘healthy’ smokers and non-smokers. These 
changes seem to revert after smoking cessation (7). Elevated expres-
sion of genes related to oxidative stress response is an important 
characteristic of the epithelium of smokers and lung cancer patients. 
In a recent study the down-regulation of genes, including a number 
of tumor suppressor genes, seemed to be more expressed in cancer 
patients, when compared with ‘healthy’ smokers (8). A genome-wide 
association study in chronic obstructive pulmonary disease (COPD) 
has identified the association between two polymorphisms in the 
alpha-nicotinic acetylcholine receptor 3/5 locus and COPD, a locus 
previously been implicated in smoking behavior and risk of lung 
cancer (9,10).
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Unfortunately most of the molecular markers studied so far seem to 
be expressed in specimens of lung cancer patients as well as in those 
of heavy smokers and our increased insight in pulmonary carcino-
genesis has not been helpful in designing a more accurate risk profile 
than may be calculated on the basis of pack-years, concomitant 
COPD and sputum atypia score (11). 
Biomarkers
Promoter hypermethylation has shown to be responsible for the inac-
tivation of key regulatory genes as detected in non-small lung cancer 
and its precursor lesions (12). This finding suggested that methyla-
tion when detected in exfoliated cells within sputum, could serve 
as a biomarker for the early stages of lung carcinogenesis. More 
recent studies have demonstrated that sputum can indeed be used 
effectively as a surrogate for tumor tissue to predict the methylation 
status and that a link seems to exist between double-strand breaks in 
DNA, reduced DNA repair capacity and gene methylation in smok-
ers (13,14). Thus gene promoter methylation in biological fluids is 
emerging as a biomarker that could be important for early detection 
of lung cancer and monitoring prevention and intervention.
Also the new class of non-protein coding small RNAs (MicroRNAs) 
have attracted attention and was proposed as a biomarker for lung 
cancer. In a large case-control study a functional genetic variant in 
microRNA-196a2 was found to be associated with increased sus-
ceptibility of lung cancer in a Chinese population (15). At he same 
time the simple determination of C-reactive protein CRP) has been 
proposed as a means to identify a high risk population as elevation of 
CRP levels were found to be associated with increased risk (HR 2.2; 
95%CI,1.0-4.6) of lung cancer (16). 
It is expected that the current rapid progress in (high-throughput) 
laboratory technology will lead to the identification of other novel 
biomarkers associated with high lung cancer risk and we must be 
prepared to investigate panels of the most promising markers. The 
current trend to invest in bio-banks of considerable size will hope-
fully allow the research community to perform the necessary valida-
tion studies. 
Chemoprevention
In chemoprevention the focus is on the treatment of lung carcinogen-
esis and not lung cancer. Lung cancer is the end result of carcinogen-
esis. Since more than 85% of lung carcinogenesis is caused by tobac-
co smoke there is a good reason to target on the carcinogenic activity 
of tobacco smoke. The carcinogens in tobacco smoke are well-
defined with at least 20 credible carcinogens (17). Pro-inflammatory 
changes have been identified in smokers and inflammation is closely 
associated with tumor promotion and COPD (18). At the same time 
genetic polymorphisms of detoxifying/anti-oxidant enzymes seem 
to play a role in determining individual susceptibility while certain 
food constituents have shown to be able to modulate individual risk 
(6). Consequently it can be argued that a combination of agents 
blocking different steps of carcinogenesis is expected to be more 
effective in blocking carcinogenesis than a single agent. The unfavor-
able outcome of the large chemoprevention studies of the previous 
century has been followed by a structured stepwise approach to test 
new preventive agents (19). This approach is still valid and may be 
enriched by the accurate identification of high-risk populations. It is 
expected that increasing insight in carcinogenesis and more accurate 
identification of high-risk individuals will eventually translate into 
effective chemoprevention strategies for lung cancer. 
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Development of molecular risk models for lung cancer
Spitz, Margaret R.; Amos, Chris I.; D’Amelio, Anthony M.;  
Dong, Qiong; Etzel, Carol J.
Department of Epidemiology, The University of Texas M.D. Anderson 
Cancer Center, Houston, TX, USA
Background: 
Reliable risk prediction tools for estimating the probability of cancer 
over a defined time period have substantial public health implica-
tions and could be of value in early detection, and clinical decision 
making. Further, risk prediction tools could be incorporated into the 
design of smaller, more powerful, and “smarter” prevention trials. 
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Such tools hold promise, but their interpretation is complex. Cardio-
vascular risk profiles using epidemiologic data have been effectively 
used for nearly two decades. Likewise there are well validated and 
easily measured risk factors that are powerful predictors of type 2 
diabetes. In the cancer arena, risk prediction models for breast cancer 
have the longest history, although prognostic models have also been 
generated for prostate, lung, melanoma, ovary, colorectal, and blad-
der cancers. 
The advent of genome-wide association studies to identify low-
penetrance common susceptibility alleles now heralds the possibil-
ity of incorporating panels of gene variants into existing models 
and to assess improvement in model performance. However, to 
date the updated models have shown only modest improvements in 
discrimination. 
It has been suggested that the ROC curve may not be sensitive to dif-
ferences in probabilities between models, and therefore insufficient 
to assess the impact of adding a new predictor. A substantial gain in 
performance may not yield a substantial increase in AUC, and only a 
very large independent association of the new marker with risk will 
yield a meaningful larger AUC. As an example, the Framingham 
Risk Score that is widely applied has an AUC of about 0.80. Adding 
another very sensitive marker of coronary artery disease, i.e. coro-
nary artery calcification, yields an AUC of about 0.84. 
One suggested statistic for comparing nested models is the Net 
Reclassification Index (NRI) that is useful when risk categories are 
defined, and there is a consensus as to clinically meaningful cut 
points or thresholds. This statistic quantifies overall improvement 
in sensitivity and specificity of the model. The expanded model is 
considered to reflect a net improvement in risk classification when 
there is evidence of upward reclassification of cases and downward 
reclassification for the controls.
Lung Cancer Risk Models: 
We have explored these various approaches for lung cancer predic-
tion. There are an estimated 45 million current smokers in the United 
States and 49 million former smokers. The challenge is to identify 
that subset of ever smokers at higher risk for developing lung cancer. 
Such high-risk individuals could undergo a program of screening 
surveillance that might not be appropriate for a lower risk population 
and receive the most intensive smoking cessation interventions. The 
few lung-specific models that have been developed include the vari-
ables of sex, age, smoking phenotype, and in one instance, a limited 
occupational exposure assessment.
Baseline Model: We have constructed and internally validated clini-
cal tools for lung cancer risk prediction for current, former and never 
smokers, based on epidemiologic and clinical data derived from an 
ongoing lung cancer case control study. Variables included were 
environmental tobacco smoke (for never and former smokers only), 
family cancer history, asbestos and dust exposures, prior respiratory 
disease, history of hay fever, and smoking history variables (pack 
years for current smokers and age stopped smoking for former smok-
ers). All variables have strong biologically plausible etiologic roles, 
and are relatively easy to ascertain through patient interview. The 
validated area under the curve (AUC) statistics for the former and 
current smoker models were modest (0.63, and 0.58, respectively), 
although consistent with those from other risk prediction models. If 
age and smoking status (that were case-control matching variables) 
had been included in the models, the models would likely have 
performed far better.
Extended Risk Model: Our baseline model is comprehensive in terms 
of epidemiologic and clinical variables, but its relatively low sensi-
tivity and specificity limit its widespread use. We have estimated the 
improvement in model performance, using the AUC, by incorporat-
ing two markers of DNA repair capacity that have been shown in 
case-control analyses to be associated with increased lung cancer 
risk. Addition of the biomarker assays does improve the sensitivity 
of the models over epidemiologic and clinical data alone. These in 
vitro lymphocyte culture assays, however, are time-consuming and 
require some level of technical expertise. Therefore while feasible in 
a controlled academic setting, they are not applicable for widespread 
population-based implementation. 
Multi-genic Risk Model: The next step in lung cancer risk model 
refinement is to include genetic data that are stable, inexpensive to 
ascertain, accurate and amenable to high-throughput analysis. We 
recently completed a genome-wide association analysis of 315,450 
tagging SNPs in 1,154 current and former smoking lung cancer cases 
of European ancestry and 1,137 frequency-matched controls. Two 
SNPs, rs1051730 and rs8034191, mapping to a region of strong 
linkage disequilibrium within 15q25.1 were strongly associated with 
risk; the overall odds ratio was 1.32 (P < 1 × 10–17) and this finding 
was replicated in two additional study sets. This region encom-
passes the nicotinic acetylcholine receptor subunit genes CHRNA3 
and CHRNA5, that have a defined role in nicotine dependence, and 
a hypothesized direct role in downstream signaling pathways that 
promote carcinogenesis.
We have also participated in a meta-analysis pooling study with data 
from the UK and IARC (summary data from which are publicly 
available). As expected, the strongest associations were obtained for 
SNPs mapping to 15q25.1. Aside from 15q25, there was consistent 
evidence for a new disease locus at 5p15.33 (rs401681; P = 4.40 
X 10_6). The 5p15.33 locus contains two known genes: the TERT 
(human telomerase reverse transcriptase) gene and the CLPTM1L 
(alias CRR9; cleft lip and palate transmembrane 1 like) gene. TERT 
is an especially plausible candidate. TERT is the reverse transcriptase 
component of telomerase, making it essential for telomerase enzyme 
production and maintenance of telomeres. Up to 90% of human 
tumor samples, including lung cancer, exhibit telomerase activity, 
suggesting that telomere regeneration is inherent to the carcinogenic 
process.
We therefore added three SNPS that were most significant in our own 
data on univariate analysis – rs1051730 from 15q25 and two SNPs 
from the 5p15.33 locus (rs2736100 and rs401681 that were not in 
strong LD) to the baseline model and assessed whether the enriched 
multimarker model gave better discrimination.
Using the three SNPs, we constructed a genetic risk score (GRS) 
by summing the number of adverse alleles (range from zero to six). 
Our AUC for the baseline epidemiologic/clinical model including 
1016 cases and 1111 controls (all ever smokers) was 0.59. There was 
evidence of a gene dosage effect with an odds ratio over threefold 
elevated in the highest GRS stratum. With addition of the GRS to 
the model, the AUC showed modest improvement, to 0.61, although 
this was significantly improved over the baseline model, (P< 0.001). 
Comparing the baseline and genetic models, we estimated the Net 
Reclassification Index to be 0.33 overall, 0.19 for cases, and 0.14 
for controls. All of these increases in the Net Reclassification Index 
were statistically significant. This could imply that the genetic fac-
tors modestly improve sensitivity and specificity. Larger numbers 
of cases and controls with identification of additional susceptibility 
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alleles is required to achieve any substantive improvement in model 
performance that is necessary for clinical applicability. 
Models of Outcome: 
The unifying premise of Integrative epidemiology is that the same 
genes and pathways that are implicated in cancer risk may also be 
involved in a prognosis, response to therapy, and outcome. We are 
therefore taking the same approach to constructing risk prediction 
models for prediction of outcome, toxicity and response to therapy 
by exploiting the depth and diversity of GWA data for pharmacoge-
netic research.
M37.3 Risk Stratified Approaches to Prevention of Lung Cancer, Tue, Aug 4, 10:30 - 12:00
Convergence between adjuvant and 
prevention approaches
Lippman, Scott
University of Texas M.D. Anderson Cancer Center, Houston, TX, 
USA
Our understanding of molecular events within multistep and field 
carcinogenesis is evolving rapidly, and this evolution is making 
it increasingly difficult to draw a distinct biological line between 
intraepithelial neoplasia and cancer. A recent comprehensive analysis 
of single nucleotide polymorphisms in the context of a phase III trial 
of adjuvant treatment and second-primary-tumor prevention led to 
the development of a novel model of cancer risk in this convergent 
setting. This work exemplifies advances in the ability to define a 
very high risk of cancer, which is leading to more and more shared 
features between cancer prevention and cancer therapy, features such 
as potential prognostic/predictive markers, agents and side effects 
that patients would be willing to tolerate, and the logistics of defini-
tive trials. New opportunities for clinical trial designs that integrate 
therapy and prevention endpoints are growing out of work with 
promising new molecular-targeted agents and new technologies for 
screening and early detection. Convergent trials with these integrated 
designs promise to facilitate and streamline targeted drug develop-
ment by helping to identify strategies for application both in cancer 
prevention and advanced-cancer therapy. These several advances in 
a convergent approach to cancer therapy and cancer prevention ulti-
mately promise to hasten the achievement of substantial reductions 
in the burden of cancer to patients, families and the public health.
M37.4 Risk Stratified Approaches to Prevention of Lung Cancer, Tue, Aug 4, 10:30 - 12:00
Gene promoter methylation as a biomarker to assess 
selenium chemoprevention for lung cancer
Belinsky, Steven A.
Lovelace Respiratory Research Institute, Albuquerque, NM, USA
Lung cancer is the leading cause of cancer-related death in the U.S. 
and will soon reach epidemic levels worldwide. Mortality from 
this disease could be reduced through the identification of high-risk 
individuals and the implementation of chemopreventive strate-
gies that can reverse or impede the progression of pre-malignant 
disease. Therefore, it is essential to develop biomarkers that can 
predict the efficacy of promising chemopreventive agents. In 1996, 
Dr. Larry Clark reported a study on skin cancer chemoprevention 
using L-selenomethionine. Although the primary endpoint of skin 
cancer prevention was negative, the rate of expected lung cancer in 
the group taking selenium decreased by approximately 50%. This 
finding has led to the implementation of ECOG 5597, “A Phase III 
Chemoprevention Trial of Selenium Supplementation in Persons 
with Resected Stage I Non-Small Cell Lung Cancer.” This trial is 
testing the hypothesis that 200 µg of L-selenomethionine given as 
selenized yeast can decrease the rate of second primary tumors in 
patients who have undergone curative surgery for stages Ia (T1N0) 
or Ib (T2N0) non-small cell lung cancer (NSCLC). Our studies have 
identified genes inactivated by aberrant cytosine-guanosine (CpG) 
island methylation as candidate biomarkers for early detection of 
lung cancer. A nested, case-control study of high-risk smokers with 
chronic obstructive pulmonary disease revealed that a panel of genes 
could predict incident lung cancer 3–18 months prior to clinical diag-
nosis. We are currently evaluating methylation of a panel of 8 genes 
in sputum and blood collected at entry onto the clinical trial, and at 
6, 12, 24, and 48 months for predicting response to selenium and 
tumor recurrence. Through comparison of selenium trial participants 
to cancer-free smokers and never smokers, we first demonstrated that 
the prevalence of gene methylation in plasma and sputum increased 
with lung cancer risk. These findings further support gene methyla-
tion as a biomarker for assessing response to selenium and predicting 
cancer recurrence. Second, a preliminary analysis of the initial 283 
persons enrolled onto our correlative trial demonstrated a signifi-
cant association between gene methylation in sputum collected at 
entrance onto the clinical trial and the development of lung cancer 
(second primary or recurrence) or mortality. Studies are continuing 
to evaluate methylation longitudinally and in new trial participants. 
(Supported by CA 095568)
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M38.1 Implementing IGRT in Clinical Practice, Tue, Aug 4, 10:30 - 12:00
PET to assess treatment response, and guide radiation 
planning and individualized adaptive radiation 
therapy in patients with non-small cell lung cancer
Kong, Feng-Ming
University of Michigan and Veterans Administration Hospitals,  
Ann Arbor, MI, USA
[18F] Fluorodeoxyglucose positron emission tomography (FDG-PET) 
has been used for staging, restaging, assessing treatment response 
after completion of neoadjuvant or definitive chemoradiation, and 
guiding guide target delineation for individualized radiation treat-
ment planning in patients with non-small cell lung cancer (NSCLC). 
Most interestingly, FDG-PET/CT is now acquired during the course 
of radiation therapy, and can be used as a predictor for post treatment 
response for both tumor and normal tissues and as a guide for individ-
ualized adaptive radiation therapy. The primary objective of this talk 
is to review the value of FDG-PET/CT for assessing treat response 
and guiding treatment planning and adaptive radiation therapy for 
NSCLC. In addition to reviewing the value of FDG-PET in staging, 
restaging and treatment planning, I will focus the presentation on 1) 
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the feasibility of acquiring PET scans during the course of fraction-
ated radiation therapy and the optimal timing of scanning, 2) tumor 
response assessment during treatment. investigating the predictive 
value of during-treatment response for the ultimate response post-
treatment, local tumor control and long term survival, and 3) normal 
tissue (lung and esophagus) response assessment during the course of 
fractionated RT and their correlation with treatment toxicity. Discus-
sion will also be addressed to the possibility of using the PET scan 
during treatment to individualize adaptive radiation therapy. 
After this lecture, the audience should be able to: 
1.  Provide an overview of FDG-PET/CT in management of NSCLC 
including staging, restaging, treatment response assessment and 
radiation therapy planning 
2.  Learn the promises and challenges of using FDG-PET for target 
delineation in primary tumor and nodal diseases 
3.  Understand the potential value of FDG-PET acquired during the 
course of treatment for adaptive radiation therapy 
4.  Exam the future prospect of using more tumor-specific tracers, 
such as 18F-fluoroazomycin arabinoside (FAZA) for hypoxia and 
fluoro-L-thymidine (FLT) for DNA proliferation. 
M38.2 Implementing IGRT in Clinical Practice, Tue, Aug 4, 10:30 - 12:00
Pitfalls of motion management strategies 
in 4-D radiation therapy
Loo, Bill W.
Stanford University, Stanford, CA, USA
One of the challenges of radiation therapy for thoracic tumors is 
managing breathing induced motion of the tumor and normal organs. 
Historically, motion has been managed by adding a population based 
margin for motion around the target volume, which for individual 
patients is likely to over- or under-treat the tumor.
Advances in imaging both during the treatment planning step and at 
the time of treatment delivery have made it possible to characterize 
and compensate for breathing induced motion on a per patient basis. 
This includes 4-D CT, 4-D PET, optical imaging, and fluoroscopy, as 
well as devices to position and immobilize the patient and control or 
modify breathing patterns.
When using such complex technologies, it is important to under-
stand the limitations of the information provided by these tools, 
what artifacts can affect the quality of the information, and how 
the information can potentially be misused. In this session, we will 
cover common pitfalls of motion management strategies, and ways to 
improve the quality of the information and optimize its use.
M38.3 Implementing IGRT in Clinical Practice, Tue, Aug 4, 10:30 - 12:00
Intensity-modulated related radiation therapy (IMRT) in 
patients with locally advanced non-small-cell lung cancer 
treated with concurrent chemotherapy: good or bad
Komaki, Ritsuko; Liao, Zhongxing; Chang, Joe Y.; Sejpal, Samir V.; 
Wei, Xiong; Mohan; Allen, Pamela; Tucker, Susan; Cox, James D.
Departments of Radiation Oncology, Radiation Physics and 
Biostatistics, The University of Texas M. D. Anderson Cancer Center, 
Houston, TX, USA
Background/Purpose: According to Eric Hall ( Int. J. Radia-
tion Oncology Biol. Phys., Vol. 65, No. 1, pp. 1–7, 2006 ) IMRT 
allows dose to be concentrated in the tumor volume while sparing 
normal tissues. However, the downside to IMRT is the potential to 
increase the number of radiation-induced second cancers especially 
for children. The reasons for this potential are more monitor units 
and, therefore, a larger total-body dose because of leakage radiation 
and, because IMRT involves more fields, a bigger volume of normal 
tissue is exposed to lower radiation doses. Intensity-modulated radia-
tion therapy may double the incidence of solid cancers in long-term 
survivors. 
Radiotherapy is one of the most effective treatment modalities for 
solid malignancies especially the tumor is unresectable or patients 
are not medically fitted for radical surgery, including lung cancer. 
About 50% of patients diagnosed with locally advanced lung cancer 
receive radiotherapy. Treatment of these patients with concomitant 
chemoradiotherapy is constrained, however, by the sensitivity of lung 
tissue to radiation, manifested in dose-limiting radiation pneumonitis 
(RP).
In the past 5 years, important technological advances have changed 
radiotherapy treatment planning and delivery. These advances have 
included imaging technologies such as functional imaging, three-
dimensional conformal radiotherapy (3DCRT), respiratory gating 
or four-dimensional computed tomography (4DCT) simulation, 
intensity-modulated radiotherapy (IMRT), image-guided radiothera-
py, stereotactic body irradiation, tomotherapy, image-guided adaptive 
radiotherapy, and proton beam therapy. 
In addition, the popularity of IMRT has rapidly increased, and its use 
among radiation oncologists in the United States has grown substan-
tially without the availability of standardized guidelines or careful 
prospective analyses evaluating its risks and benefits. In theory, 
a therapeutic gain could be realized by implementing advanced 
technologies because the conformal radiotherapeutic approach, used 
in 3DCRT and IMRT, ensures a high dose distribution conforming 
to the target volume and tailored to the limits of healthy tissues. 
However, there are concerns about using IMRT for lung cancer with 
respiratory motion, because IMRT, unlike 3DCRT, only irradiate a 
portion of the target volume at a particular time. Therefore, there is 
a potential for significant dosimetric missing in target volume which 
may unfavorablely influence locoregional control of the tumor. 
Furthermore, there is concern that IMRT may be used excessively 
without evidence of real clinical benefit because of its higher reim-
bursement from Medicare.
Our initial evaluation of treatment related pneumonitis (TRP) in 
patients with locally advanced non-small cell lung cancer (NSCLC) 
treated with concurrent chemotherapy and Intensity-modulated radio-
therapy (IMRT) showed a significant reduction in TRP when com-
pared to three-dimensional conformal radiation therapy (3D-CRT). 
On dosimetric analysis, proton beam radiotherapy (PBT) appears 
to reduce dose to normal tissues significantly, when compared to 
3D-CRT or IMRT. The purpose of this study was to clinically evalu-
ate the frequency of TRP in patients with locally advanced NSCLC 
who received concurrent chemotherapy with PBT or IMRT.
Patients and Methods: A total of 496 NSCLC patients have been 
treated at the MDACC between 1999 and 2006 with concomitant 
chemoradiotherapy. Among these, 318 were treated with CT/3DCRT 
and 91 with 4DCT/IMRT. Both groups received a median dose of 63 
Gy. Disease end points were locoregional progression, distant metas-
tasis (DM), and overall survival (OS), with covariates gross tumor 
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volume (GTV), nodal status, and histology. The toxicity endpoint 
was grade ≥3 radiation pneumonitis with covariates GTV, smoking 
status, and dosimetric factors. From 1/2003 to 9/ 2007, 108 patients 
with locally advanced NSCLC were treated with chemotherapy and 
PBT (31 patients) or IMRT (75 patients) with the following criteria: 
concurrent chemotherapy, no prior thoracic RT, and dose of >=60 
Gy (or cobalt-60 Gy Equivalent (CGE) for protons). Patients who 
had IMRT + 3D-CRT or PBT were excluded. Common Terminology 
Criteria (CTC) for adverse Events version 3.0 was utilized to grade 
toxicities. 
Results: When 4DCT/IMRT group was compared to CT/CRT group, 
mean follow-up times were 1.3 (range 0.1 - 3.2) and 2.1 (range 0.1 - 
7.9) years, respectively. The hazard ratios for 4DCT/IMRT were <1 
for all disease end points; the difference was significant for OS. Tox-
icity rate was significantly lower in the IMRT/4DCT group. V20 was 
significantly higher in 3DCRT group and was a significant factor in 
determining toxicity. Freedom from DM was nearly identical in two 
groups. On the other hand, median follow up time for PBT and IMRT 
patients were 9.5 months (range, 1.6 – 16.1 months) and 9.8 months 
(range, 1.4 – 32.3 months), respectively. Median gross tumor volume 
was 93.6 ml (range, 13 - 431 ml) and 247.7 ml (range, 21-818 ml) 
(p <0.0001) between PBT and IMRT, respectively. Median dose 
in the PBT group was 74 (CGE) (range, 63-74 CGE) vs. 63 Gy 
(range, 60-76 Gy) in the IMRT group. The most common concurrent 
chemotherapy regimen in both arms was carboplatin with taxol (PBT 
= 61% and IMRT = 56%). Some patients also received induction 
(PBT = 42%, IMRT = 49%) and adjuvant chemotherapy (PBT = 
26%, IMRT = 25%). The median values for rV5, rV10 and rV20 for 
the PBT group were 32%, 29%, 24% compared to IMRT where they 
were 59%, 45% and 31%. PBT significantly reduced amount of nor-
mal lung receiving 5Gy (rV5) (p<0.0001), 10 Gy (rV10) (p<0.0001) 
and 20 Gy (rV20) (p =0.005) compared to IMRT. The incidence of 
Grade 2-5 TRP with PBT and IMRT was 19.4% and 33% (p = 0.15) 
respectively. When tumor volume was taken into account (see table 
below), PBT still reduced >=G2 TRP when compared to IMRT. No 
patients treated with PBT experienced Grade >= 3 TRP compared to 
9.3% with IMRT (p=0.07). 
Conclusions: In patients with locally advanced NSCLC treated 
with combination chemotherapy and radiotherapy, our 4DCT/IMRT 
reduced TRP compared to 3DCRT. However our preliminary evalu-
ation suggests that PBT appears to reduce frequency of TRP in spite 
of higher total cumulative dose when compared to IMRT. We have 
some concern about lower dose scattering by IMRT to the lung as 
well as whole body which might cause secondary malignancy as 
other researchers suggested. We are going to compare toxicity and 
outcome of patients with stage III NSCLC patients treated by IMRT 
vs. PBRT and concurrent chemotherapy on a prospective randomized 
trial. 
M38.4 Implementing IGRT in Clinical Practice, Tue, Aug 4, 10:30 - 12:00
Status of particle beam therapy for lung cancer
Tsujii, Hirohiko; Baba, Masayuki; Yamamoto, Naoyoshi;  
Nakajima, Mio
National Institute of Radiological Sciences, Chiba-shi, Japan
In radiotherapy of non-small cell lung cancer (NSCLC), particle 
beams offer improved dose distributions as compared to photon 
beams and thus enable dose escalation within the tumor while 
sparing normal tissues. While protons have a biological effectiveness 
comparable to photons, carbon ions being heavier than protons pro-
vide a higher biological effectiveness. This paper describes clinical 
aspects of particle beam therapy for NSCLC. 
Methods and materials 
For Stage I NSCLC, the results of treatment with carbon ions at 
NIRS are reviewed, using 9 and 4 fractions, as well as preliminary 
results of single fraction irradiation is described. Also, results of 
proton beam RT reported in the literature are compared. 
Results of treatment with particle beams
1) Carbon ion radiotherapy
Only at NIRS, Japan, NSCLC has been treated with carbon ions. 
For peripheral tumor, we have been conducting clinical studies to 
establish a short-course, hypofractionated radiotherapy. We first 
performed a dose-escalation study using 18 fractions/6 weeks. The 
number of fractions and treatment times were subsequently reduced 
to 9 fractions over 3 weeks, 4 fractions over one week, and eventu-
ally to a single fraction treatment. 
In the current analysis, a total of 129 patients with stage I NSCLC 
treated with 9 fractions/3 weeks (50 patients) and 4 fractions/1 week 
(79 patients) were evaluated. The total dose was fixed at 72GyE in 9 
fractions and at 52.8GyE for stage IA and at 60GyE for stage 1B in 
4 fractions. All the patients were treated more than 5 years ago and 
none of them developed severe toxicities. The 5-year local control 
rates were 98.6% for stage-IA cases and 89.7% for stage-IB cases, 
and the 5-year survival rates were 63.1% for stage-IA cases and 
50.0% for stage-IB cases. 
Since 2003, a dose-escalation study using single fraction treatment 
has been underway for peripheral-type NSCLC. The total dose has 
been escalated from 28.0 to 44.0 GyE at increments of 5%. So far, no 
serious adverse events have been observed, and local control appears 
to be improving with increases in total dose.
C-ion RT has also been applied to locally advanced lung cancers 
and hilar-type cancers, and case studies are being accumulated. 
The locally advanced lung cancers included Pancoast tumors and 
mediastinal-type tumors in stages II–IIIA. The overall local control 
rate was 92.7%, and the cause-specific survival rate at 46 months was 
52.7%. The superficial lesions arising at the hilar region have been 
successfully treated with acceptable toxicities.
2) Proton beam radiotherapy
On protons, four prospective studies were identified, mainly includ-
ing stage I patients. The 2–5 year overall local tumor control rates 
varied between 57% and 87%, and for 2-3 year/5 year overall sur-
vival and 2-3 year/5 year cause specific survival were 44-84%/30% 
and 72%/40%, respectively. Radiation induced pneumonitis was 
observed in about 10%. Equivalent outcomes were achieved using 
STR.
Discussion
In C-ion RT of Stage I peripheral-type NSCLC, no patients devel-
oped severe toxicities, and a local control rate of >90% was obtained. 
C-ion RT, which is an excellent new modality in terms of high QOL 
and superior local control, was proven to be a valid alternative to sur-
gery for stage I cancer, especially for elderly and inoperable patients. 
Considering that the average age of the patients receiving C-ion RT 
was about 75 years, about 10 years older than that of 65 years in the 
operated patients, the results of C-ion RT for stage-I lung cancer 
may be comparable to surgical results. Furthermore, short-course 
Copyright © 2009 by the International Association for the Study of Lung Cancer S163
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
irradiation with 9 and 4 fractions was confirmed as a safe treatment 
for the peripheral-type stage-I lung cancer, for which surgery was 
not indicated or refused. A clinical study on a single fraction treat-
ment is being conducted at NIRS, and the preliminary results appear 
favorable.
Proton therapy has been used in NSCLC using longer fractionations 
than C-ion RT. For T1 cases, improved results have been obtained 
in terms of local control and survival, but for T2 tumors further 
improvement may be needed. 
M38.5 Implementing IGRT in Clinical Practice, Tue, Aug 4, 10:30 - 12:00
Beyond IGRT – a look to the future
Werner-Wasik, Maria
Thomas Jefferson University Hospital, Philadlphia, PA, USA
FDG-PET scan imaging has established its place in staging of non-
small cell lung cancer and its role is evolving as an ancillary tool in 
radiation therapy planning. However, several issues remain unre-
solved as how to best incorporate PET in planning. First, PET helps 
define areas of tumor involvement by simple visual comparison of 
PET images and planning CT scan images. Second, PET images can 
be fused (through rigid or deformable registration) with planning 
CT images. The most optimal way of contouring tumor border on 
PET scan is not defined (% threshold vs. minimum SUV vs. manual 
contouring). Recently, gradient based-methods became available 
and seem in preliminary reports to have less interobserver variabil-
ity and result in higher concordance with the known PET phantom 
tumor volumes than the previous methods. In one meticulous study 
of patients with resected pharyngo-laryngeal cancers, such gradi-
ent method demonstrated a better volumetric correlation with the 
resected specimen than the correlation obtained with tumor volumes 
based on CT or MRI scans (Daisne JF, 2004).
Acquisition time of PET images is much longer than those of fast 
CT scanners, which leads to potential artifacts in defining PET-
based tumor border and volume. Newest PET technologies account 
for organ and tumor motion, which should allow for more precise 
fusion with the 4D-CT-derived tumor images. In addition, through 
minimizing of the blurring of the image, a better quantification of the 
tracer uptake is possible, therefore improving the evaluation of tumor 
response after therapy. High-definition PET enables improved delin-
eation of small lesions, especially lesions without very high tracer 
uptake, which should be important for RT target definition. Before 
“dose-painting” based on PET is widely adopted, a consensus needs 
to emerge whether high-uptake areas of the tumor represent the least 
radioresponsive portions of the tumor. We also need to demonstrate 
unequivocally that those areas do not migrate during the course of 
prolonged radiotherapy. 
Biologically targeted therapies have been extensively studied in 
combination with cytotoxic chemotherapy, but clinical trials testing 
concurrent administration of those agents with radiation therapy are 
few. In the current RTOG 0825 Phase III randomized trial bevaci-
zumab will be combined with cranial RT and temozolomide. Assess-
ment of response to treatment with anti-angiogenic agents, such as 
bevacizumab, may be potentially facilitated in the future with newer 
types of functional imaging, such as three- dimensional DCE MRI, 
which can study the pathophysiology of tumors by evaluating micro-
vascular density and vascular permeability, parameters affected by 
anti-angiogenic therapy. Several studies have shown that successful 
therapies can result in changes in DCE-MRI contrast-enhancement 
parameters, which may prove to be an early indication of tumor 
response. Mid-RT course dose adjustment of the ionizing radiation 
(or “dose-painting” again) and decision on continuing or discontinu-
ing anti-angiogenic drug could be potentially made based on such 
imaging.
Radiation oncologists are not formally trained in diagnostic radiol-
ogy, yet as part of their daily responsibilities they interpret plain 
X-rays, CT scans, MRI scans or PET scans in order to define target 
volumes and organs at risk. In order to improve the quality of target 
delineation and to decrease interobserver variability, a major educa-
tional effort, starting at the resident level, is necessary. IGRT is only 
as good as the target definition. Atlases for delineating volumes are 
gaining in popularity (head and neck atlas; mediastinal lymph nodes 
atlas for lung cancer etc) and may be expected to become a manda-
tory tool in radiation therapy clinic. Patients treated according to 
such atlases will need to be followed closely and patterns of potential 
locoregional failure recorded meticulously in order to prospectively 
validate the merit of those atlases.
Delivery of complex IGRT plans will require standardized evalua-
tion tools of their quality, as illustrated by the fact that one-third of 
participating top institutions failed at first attempt to deliver an IMRT 
treatment in the anthropomorphic phantom according to the specifi-
cations during the Radiation Therapy Oncology Group’s credential-
ing process (Vikram B et al, 2009).
In summary, advances in imaging for RT planning and adaptive RT, 
as well as molecular imaging to visualize in vivo response to RT and 
biologic agents will be at the forefront of advancements in IGRT 
in the near future. Standardized assessment of the quality of IGRT 
will require a major educational and organizational effort in order to 
assure patient safety and delivery of the optimal RT. 
Session M39: Molecular  
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Tuesday, August 4
M39.1 Molecular Epidemiology of Lung Cancer, Tue, Aug 4, 10:30 - 12:00
Molecular epidemiology of lung cancer
Ambrosone, Christine B.
Roswell Park Cancer Institute, Buffalo, NY, USA
While cancer rates have decreased overall since 1992, a major excep-
tion to this trend has been the increase in lung cancer in both smok-
ing and non-smoking women. To some extent the higher prevalence 
of smoking may account for some of this increased incidence among 
women, but there is also suggestive evidence that, dose for dose, 
women are more susceptible to tobacco smoke carcinogens than 
men. Furthermore, there are no facile reasons to explain the increas-
ing lung cancer incidence in non-smoking women. To address these 
questions, we are conducting a molecular epidemiologic case-series 
study of non-small cell lung cancer in smoking and non-smoking 
women and men. To optimize our capabilities to enroll non-smoking 
men and women with lung cancer, this study is being conducted 
with the NCI Lung Cancer Intergroup and the Lung Committee 
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investigators of the Southwest Oncology Group. We are recruiting 
360 women newly diagnosed with histologically confirmed non-met-
astatic, non-small cell lung cancer (NSCLC) (240 ever smokers and 
120 non-smokers), and an equal number of men, similarly distrib-
uted, for a total of 720 cases. 
Because studies indicate that there is a role for steroid hormones in 
lung carcinogenesis, we are exploring pathways by which women 
may be differentially affected by carcinogenic exposures, and exam-
ining the role of estrogens in lung cancer etiology, using biomarkers 
of exposure, effect and susceptibility in lung tissue and in blood. We 
hypothesize that lung cancer in women, particularly non-smoking 
women, is influenced by hormonal factors and endogenous estro-
gens, mediated by variability in their metabolism. To address this 
hypothesis we are collecting questionnaire data regarding hormonal 
(oral contraceptive use, hormone replacement therapy) and reproduc-
tive (age at menarche, age at menopause, number of children, etc.) 
factors and will analyze in relation to lung cancer risk in smokers 
and non-smokers, and in relation to tumor characteristics. We have 
made tissue microarrays from blocks collected from lung cancer 
patients, and have immunostained for estrogen receptors α and β, as 
well as overexpression of HER2 in tumor tissue. We expect that these 
markers, commonly seen in breast cancer, will be more prevalent in 
women than in men, in non-smokers than in smokers, and are related 
to reproductive and hormonal factors or “higher-risk” genotypes. 
Preliminary results will be presented.
M39.2 Molecular Epidemiology of Lung Cancer, Tue, Aug 4, 10:30 - 12:00
Biomarkers of polycyclic aromatic hydrocarbon-
DNA damage and cigarette smoke exposure 
Santella, Regina M.1; Zhang, Yu-Jing1; Wang, Qiao1; Redman, Mary 
2; Chansky, Kari2; Reid, Mary3; Davis, Warren3; Gandara, David4;  
Powell, Charles A.1; Albain, Kathy5; Ambrosone, Christine3
1 Columbia University, New York, NY, USA; 2 Soutwest Oncology 
Group Statistical Center, Seattle, WA, USA; 3 Roswell Park Cancer 
Institute, Buffalo, NY, USA; 4 University of California Davis Cancer 
Center, Davis, CA, USA; 5 Loyola University Chicago Stritch School 
of Medicine, Chicago, IL, USA
To investigate differences in lung cancer among male and female 
smokers and nonsmokers, we are conducting case-series study of 
non-small cell lung cancer. This study is being conducted with the 
NCI Lung Cancer Intergroup and the Lung Committee investigators 
of the Southwest Oncology Group (SWOG). The plan was to recruit 
360 women newly diagnosed with histologically confirmed non-met-
astatic, non-small cell lung cancer (NSCLC) (240 ever smokers and 
120 non-smokers), and an equal number of men, similarly distrib-
uted, for a total of 720 cases. Biomarkers of exposure, susceptibility, 
and effect would be assayed in the blood and tumor tissue of these 
women and men and evaluated in relation to questionnaire data. 
One of the two primary hypotheses is that increased risk of lung 
cancer among women is due to their greater susceptibility to tobacco 
smoke carcinogens, based on variability in carcinogen metabolism. 
To address this hypothesis we are collecting questionnaire data on 
active and passive smoking and other carcinogenic exposures. Blood 
samples and paraffin blocks of tumor tissue are also being collected 
for all subjects. 
Across the country approximately 70 sites are enrolling newly identi-
fied cases within 3 months of diagnosis. Recruitment of smokers is 
completed with 355 eligible male and 314 eligible female smok-
ers enrolled. Recruitment of nonsmokers is ongoing with 30 male 
and 119 female enrolled to date (4/1/09). Bloods are shipped from 
all sites to the Biomarkers Laboratory at Columbia University for 
processing into plasma, mononuclear cells and granulocyte fractions. 
Tissue blocks are sent to Roswell Park Cancer Institute for prepara-
tion of sections or tissue arrays. Sites that would do not release tissue 
blocks sent unstained slides.
At Columbia, polycyclic aromatic hydrocarbon (PAH)-DNA adducts 
are being measured in tumor and adjacent lung tissue of paraffin 
sections and peripheral blood mononuclear cells. Tissue adducts are 
being measured with monoclonal antibody 5D11, generated against 
the DNA adduct produced by benzo(a)pyrene diol epoxide (BPDE), 
the reactive metabolite of BP, a common environmental pollutant. BP 
is produced in the burning of any organic material and is thus present 
in cigarette smoke and charbroiled foods as well as in air pollution. 
The antibody cross-reacts with the diol epoxide adducts of several 
other PAH. Immunoperoxidase staining of sections or tissue microar-
rays is ongoing. Mononuclear cell DNA adducts are being measured 
with a chemiluminescence competitive enzyme-linked immunosor-
bent assay (ELISA) using a polyclonal antibody generated against 
BPDE-DNA that also recognizes other PAH adducts. Thus both assay 
provide a relative measure of PAH exposure. The ELISA can detect 
one DNA adduct in 108 normal nucleotides. Batched samples of 
male and female smokers and nonsmokers are run blinded to gender 
and smoking status. Preliminary results will be presented.
M39.3 Molecular Epidemiology of Lung Cancer, Tue, Aug 4, 10:30 - 12:00
Role of EGFR pathway activation in never 
smoking patients with lung cancer
Mack, Philip C.
UC Davis Cancer Center, Sacramento, CA, USA
Starting in the mid 1960’s, there has been a dramatic increase in the 
incidence of lung cancer in women, such that it is now the leading 
cause of cancer-related death. Cigarette smoking is the primary risk 
factor associated with this disease and there is mounting evidence 
that women are more susceptible than men to tobacco carcinogens 
(1-4). Risch and colleagues found that, at 40 pack-years of smoking, 
the odds ratio of developing lung cancer was 27.9 for women com-
pared to 9.6 for men relative to nonsmokers (p=0.01) (2). However, 
at least 15,000 USA patients who never smoked die from lung cancer 
each year, and the proportion of never-smoking women with lung 
cancer is more than twice that of men (5). World-wide, estimates 
from the year 2000 suggest that 53% of lung cancer in women occur 
independently of tobacco use; whereas in men it is only 15% (6). 
Epidemiology studies suggest that never-smoking women with lung 
cancer are more likely to be younger, to have a family history of lung 
cancer and have adenocarcinoma histology (7-13). In general, once 
women are diagnosed with lung cancer, stage for stage they have bet-
ter survival then men (14-16). These observations have led research-
ers to postulate that lung cancer in never-smokers may be an inher-
ently different disease than that of smokers (17). Several studies have 
reported divergent gene signatures and chromosomal aberrations 
between smokers and never-smokers, albeit with significant overlap 
(18, 19). A key example is the frequency and type of mutations 
found in the p53 gene. In smokers, p53 mutations are more common 
and tend to be transversions rather than transitions (17). Toyooka 
et al. noted that this disproportion of G→T transversions was most 
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prevalent in women (20). More recently, EGFR activating mutations 
have been associated with never-smokers, whereas KRAS mutations 
are more common to smokers. Percentages of EGFR mutations in 
never-smokers have ranged in clinical trials from 42% to 83% (21). 
In 2004, several groups, investigating the relatively small subset of 
patients with excellent responses to the EGFR TKI gefitinib, cor-
related their outcome with somatic activating mutations in the EGFR 
kinase domain (22, 23). EGFR kinase domain mutations result in 
ligand-independent signaling and may alter the binding kinetics of 
EGFR TKIs (24-26). The frequency of EGFR mutations in West-
ern populations is approximately 10%; however, they are far more 
frequent in Asian patients, estimated at over 40% (27). Regardless of 
ethnicity, mutations occur more commonly in women, never-smokers 
and patients with adenocarcinoma histology (28). In NSCLC, KRAS 
mutations are generally exclusive of EGFR mutations, rarely occur-
ring together in the same patient (29, 30). 
Cooperative Signaling between EGFR and ER: The concept 
that estrogen signaling contributes to lung tumorigenesis has been 
in consideration for decades. In 1994, Taioli and Wynder reported 
that the use of estrogen replacement therapy was associated with 
development of lung adenocarcinoma, particularly in patients who 
smoke. These data drew a link between carcinogen exposure and 
hormone signaling in the etiology of lung cancer. Recently, several 
pivotal reports have demonstrated convincingly that ER isoforms are 
expressed and active in lung tumor cells (31-35). ER expression pat-
terns are strikingly different between genders, with ER α expressed 
in 85% of women versus 15% of men, and ER β expressed in 92% of 
women and 69% of men (36). Gender differences were also observed 
in ER α promoter hypermethylation (37), and in the activity of ER 
α and β (38). In the case of men, these observations were prognostic 
(37). In laboratory models, estrogen can stimulate cell proliferation 
and tumor progression. Enhanced estrogen synthesis by aromatases 
has also been documented in lung cancers (33, 39). These data 
suggest that estrogens produced either intrinsically or extrinsically 
relative to the tumor can promote malignant growth. NSCLC cells 
are equipped to respond to estrogen signaling, expressing functional 
ER variants as well as steroid receptor coactivators. These complexes 
are often localized to tumor nuclei but are also found in caveolae 
and lipid rafts where they may enhance activity of receptor tyrosine 
kinases such as EGFR (40, 41). Several lines of research have sug-
gested that estrogen signaling can cooperate with EGFR pathway 
activation to promote tumor growth (42, 43). Marquez-Garban et 
al studied NSCLC cell lines that are ER-dependent, demonstrating 
that silencing of either ER α or β by RNA interference reduced cell 
growth. They found that the addition of exogenous EGF and estradiol 
resulted in activation of the ER coactivator SRC-3, and conversely, 
that the ER antagonist fluvestrant plus erlotinib synergistically 
blocked NSCLC growth in xenograft models (44). Taken together, 
these data suggest that estrogen signaling can cooperate with EGFR 
abnormalities in never-smoking populations to initiate or promote 
lung cancer growth, and that gender may influence the degree to 
which ERs impact growth. The Southwest Oncology Group-led 
molecular epidemiology study S0424, nearing final accrual, was 
designed to investigate relationships between tumor biology with 
tobacco carcinogen exposure and gender in a cohort of early stage 
NSCLC patients enriched for never-smokers. This study provides a 
unique resource in which to enhance our understanding of the rela-
tionship between ER- and EGFR-dependency.
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Polymorphisms of DNA repair genes and 
tobacco-related carcinogenesis
Christiani, David C.
Harvard School of Public Health, Boston, MA, USA
Although smoking is the primary risk factor for most lung cancers, 
genetic predisposition may play an important role. Familial aggre-
gation studies suggest a greater genetic component in the risk for 
younger individuals developing lung cancer, for lifetime nonsmok-
ers, and possibly for women. Low-penetrance, high-prevalence poly-
morphic genes may explain part of this genetic predisposition. Subtle 
alterations in the DNA repair, among other pathways, may alter lung 
cancer susceptibility. DNA repair genes such as XPD (nucleotide 
excision pathway), XRCC1 (base excision pathway), and MGMT 
affect lung cancer risk and show evidence for gene-environment 
interactions. Moreover, although in a later phase of the carcinogen-
esis process, tumor recurrence and patient survival are affected by 
polymorphisms in DNA repair.
Gene-environment interaction for the ERCC2 polymorphisms 
and cumulative cigarette smoking exposure in lung cancer
Excision repair cross-complementing group 2 (ERCC2), a major 
DNA repair protein, is involved in nucleotide excision repair and 
basal transcription. The ERCC2 polymorphisms have been associ-
ated with altered DNA repair capacity. We investigated two ERCC2 
polymorphisms, Asp312Asn and Lys751Gln, in 1092 Caucasian lung 
cancer patients and 1240 spouse and friend controls. The results were 
analyzed using generalized additive models and logistic regression, 
adjusting for relevant covariates. The overall adjusted odds ratios 
(ORs) and 95% confidence intervals (CIs) were 1.47 (95% CI, 1.1-
2.0) for the Asp312Asn polymorphism (Asn/Asn versus Asp/Asp) 
and 1.06 (95% CI, 0.8-1.4) for the Lys751Gln polymorphism (Gln/
Gln versus Lys/Lys). Gene-smoking interaction analyses revealed 
that the adjusted ORs for each of the two polymorphisms decreased 
significantly as pack-years increased. When comparing individuals 
with Asn/Asn + Gln/Gln versus individuals with Asp/Asp + Lys/Lys, 
the fitted ORs (95% CIs) were 2.56 (95% CI, 1.3-5.0) in nonsmok-
ers and 0.69 (95% CI, 0.4-1.2) in heavy smokers (80 pack-years; P 
< 0.01 for the interaction term). Consistent and robust results were 
found when models incorporated different definitions of cumula-
tive cigarette smoking. A stronger gene-smoking interaction was 
observed for the Asp312Asn polymorphism than for the Lys751Gln 
polymorphism. In conclusion, cumulative cigarette smoking modifies 
the associations between ERCC2 polymorphisms and lung cancer 
risk.
Polymorphisms in the DNA repair genes XRCC1 
and ERCC2, smoking, and lung cancer risk:
XRCC1 (X-ray cross-complementing group 1) and ERCC2 (excision 
repair cross-complementing group 2) are two major DNA repair pro-
teins. Polymorphisms of these two genes have been associated with 
altered DNA repair capacity and cancer risk. We have described sta-
tistically significant interactions between the ERCC2 polymorphisms 
(Asp312Asn and Lys751Gln) and smoking in lung cancer risk. In this 
case-control study of 1091 Caucasian lung cancer patients and 1240 
controls, we explored the gene-environment interactions between 
the XRCC1 Arg399Gln polymorphism, alone or in combination with 
the two ERCC2 polymorphisms, and cumulative smoking exposure 
in the development of lung cancer. The results were analyzed using 
logistic regression models, adjusting for relevant covariates. Overall, 
the adjusted odds ratio (OR) of XRCC1 Arg399Gln polymorphism 
(Gln/Gln versus Arg/Arg) was 1.3 [95% confidence interval (CI), 
1.0-1.8]. Stratified analyses revealed that the ORs decreased as pack-
years increased. For nonsmokers, the adjusted OR was 2.4 (95% CI, 
1.2-5.0), whereas for heavy smokers (>/=55 pack-years), the OR 
decreased to 0.5 (95% CI, 0.3-1.0). When the three polymorphisms 
were evaluated together, the adjusted ORs of the extreme genotype 
combinations of variant alleles (individuals with 5 or 6 variant 
alleles) versus wild genotype (individuals with 0 variant alleles) were 
5.2 (95% CI, 1.7-16.6) for nonsmokers and 0.3 (95% CI, 0.1-0.8) 
for heavy smokers, respectively. Similar gene-smoking interaction 
associations were found when pack-years of smoking (or smoking 
duration and smoking intensity) were fitted as a continuous variable. 
In conclusion, cumulative cigarette smoking plays an important role 
in altering the direction and magnitude of the associations between 
the XRCC1 and ERCC2 polymorphisms and lung cancer risk.
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DNA repair polymorphisms predict overall survival 
in advanced non-small cell lung cancer patients 
treated with platinum-based chemotherapy:
Platinum agents cause DNA cross-linking and oxidative damage. 
Genetic polymorphisms of DNA repair genes are associated with 
differential DNA repair activity and may explain interindividual 
differences in overall survival after therapy with platinum agents 
for non-small-cell lung cancer (NSCLC). We evaluated genetic 
polymorphisms of the XPD (Asp312Asn) and XRCC1 (Arg399Gln) 
DNA repair genes in 103 patients with stage III (54%) and IV (46%) 
NSCLC treated with platinum-based chemotherapy. Median age was 
58 years (range, 32 to 77 years), 49% were females, and there were 
86 deaths. Median follow-up period was 61.9 months. Median sur-
vival time (MST) was 14.9 months; by stage, MST was 28.6 months 
(IIIA), 16.0 months (IIIB), and 9.3 months (IV). Genotypes were not 
associated with stage. Increasing numbers of either XPD or XRCC1 
variant alleles were associated with shorter overall survival (P =.003 
and P =.07, respectively, by log-rank test). Similarly, when we com-
pared combinations of variant alleles across both polymorphisms, 
we found that a greater number of variant alleles was associated with 
decreasing overall survival (P =.009, log-rank test). These polymor-
phisms independently predicted overall survival even after taking 
into account stage, performance status, and chemotherapy regimen. 
Genetic polymorphisms in XPD and XRCC1 may be important prog-
nostic factors in platinum-treated patients with advanced NSCLC. 
We also examined ERCC1. DNA repair is a critical mechanism of 
resistance to platinum-based chemotherapy. Excision repair cross-
complementation group 1 (ERCC1) is the lead enzyme in the nucle-
otide excision repair process. Increased ERCC1 mRNA levels are 
related directly to platinum resistance in various cancers. We exam-
ined the association between two polymorphisms of ERCC1, codon 
118 C/T and C8092A, which are associated with altered ERCC1 
mRNA levels and mRNA stability, and overall survival (OS) in 128 
advanced non-small cell lung cancer patients treated with platinum-
based chemotherapy. The two polymorphisms were in linkage dis-
equilibrium. There was a statistically significant association between 
the C8092A polymorphism and OS (P = 0.006, by log-rank test), 
with median survival times of 22.3 (C/C) and 13.4 (C/A or A/A) 
months, respectively, suggesting that any copies of the A allele were 
associated with poor outcome. No statistically significant association 
was found for the codon 118 polymorphism and OS (P = 0.41, by 
log-rank test), with median survival times of 19.9 (T/T), 16.1 (C/T), 
and 13.3 (C/C) months, respectively. The ERCC1 C8092A poly-
morphism may be a useful predictor of OS in advanced non-small 
cell lung cancer patients treated with platinum-based chemotherapy. 
Finally, decreased overall survival was associated with increasing 
number of variant polymorphisms associated with decreased DNA 
repair in late stage lung cancer, whereas the opposite is true for early 
stage disease.
These data add to the growing knowledge base that will inform per-
sonalized medicine choices for lung cancer in the future.
Session M40: Statistical Designs in 
the Bioinformatics Age 
Tuesday, August 4
M40.1 Statistical Designs in the Bioinformatics Age, Tue, Aug 4, 10:30 - 12:00
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Many targeted agents have been developed for lung cancer therapy 
in recent years. These targeted agents, however, may work only in 
a subset of patients. The identification and use of predictive mark-
ers, which are associated with the treatment outcome, is imperative 
for the success of the development of target agents. The challenge 
is that, often times, we don’t know how well the treatments work 
and what are the predictive markers which can predict the treatment 
success or failure. The goal is to come up with efficient, flexible, 
and ethical designs that can (1) identify or validate prognostic and 
predictive markers, (2) estimate the treatment effect accurately, and 
(3) provide better treatments to patients enrolled in the trial. 
Randomized controlled trials (RCTs) have been the gold standard 
for evaluating and comparing treatments for the past 60+ years. By 
applying proper design features such as including a control group, 
randomization, blinded patient assignment and outcome evaluation, 
intent-to-treat principles etc., the results of RCTs are sound and cred-
ible. The drawback, however, is that the framework of standard RCTs 
tends to be fixed, rigid, requiring long study duration, and not giving 
patients with best treatments during the trials. 
On the other hand, adaptive designs which allow adjusting trial 
conduct based on the interim data are ideally suited for drug develop-
ment. In contrast to the frequentist equal randomization designs, 
we propose novel Bayesian adaptive randomization (AR) designs 
to allow treating more patients with effective treatments, stopping 
ineffective treatments early, and increasing efficiency by using less 
patients or shortening the study duration while controlling type I and 
type II errors. The new design incorporates rational learning from 
the interim data to guide the study conduct in terms of randomiza-
tion and early stopping. Important biomarkers can be identified and 
validated during the trial. 
We use the BATTLE-1 (Biomarker-integrated approaches of targeted 
therapy of lung cancer elimination) study to illustrate the use of 
adaptive designs. BATTLE-1 study employs a randomized phase II 
design in patients with refractory, advanced staged non-small cell 
lung cancer (NSCLC). The four targeted therapies are erlotinib, 
sorafenib, vandetanib, and the combination of erlotinib and bexaro-
tene. A total of 11 biomarkers including EGFR mutation / amplifica-
tion, K-ras and/or B-raf mutation, VEGF and/or VEGFR expression, 
and RXR and/or cyclin D1 expression are selected based on prior 
reports. It is assumed that each treatment may be more efficacious 
in patients with a certain biomarker profile matching the agent’s 
mechanism of action. All patients have baseline biopsy samples 
taken for biomarker assessment prior to randomization to treatments. 
The primary endpoint of this study is the disease control rate at 8 
weeks after randomization. The Bayesian probit model is used to 
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characterize the disease control rate. The first half of the patients are 
equally randomized and the second half of patients are adaptively 
randomized to one of four treatments with the randomization rate 
based on the updated disease control rate from the accumulated data 
in the trial. For each biomarker profile, high-performing treatments 
have higher randomization rates, and vice versa. An early stopping 
rule is implemented to suspend low-performing treatments from 
randomization. Based on extensive simulation studies, with a total of 
200 evaluable patients with 20% type I error rate and 80% power, the 
trial has desirable operating characteristics to: (1) identify effective 
agents with a high probability; (2) suspend ineffective agents; and 
(3) treat more patients with effective agents that correspond to their 
biomarker profiles. The trial design allows the continuing update 
and refinement of the estimates as the trial progresses. By comparing 
with previously published designs, the proposed design can be more 
efficient and ethical and is also more flexible in the study conduct. 
Based on what we learn from the BATTLE-1 study, we design the 
next generation study called BATTLE-2 to study the combination of 
targeted agents in the same patient population. The primary endpoint 
is still the 8-week disease control rate but we adapt the Bayesian 
logistic regression model as the statistical framework. BATTLE-2 
trial can also be divided into two stages. The first stage is the “Initial 
AR phase” in which patients will be randomized into one of the four 
treatment groups based on two “Group 1 Markers” – EGFR muta-
tion and K-ras mutation. During the first stage, we will also collect 
the information on the “Group 2 Markers” which are pre-identified 
putative markers and the “Group 3 Markers” which are genomic 
discovery markers. At the end of stage 1, all marker information will 
be used to refine the statistical model. By applying variable selection 
and model building methods, best prognostic and predictive mark-
ers are identified to form the refined model. The second stage is the 
“Refined AR phase” where patients will be adaptively randomized 
based on the refined model. At the end of the study, all marker and 
outcome information will be used to derive the final model for mak-
ing statistical inference. 
During the drug development process, the efficacy and toxicity of 
new agents and/or their combinations under investigation are often 
unknown before the study. The roles of markers on treatments are 
also unclear. As the trials progress, adaptive designs can use the 
observed information to guide the study conduct. The resulting 
designs are often more efficient in terms of requiring less patients to 
achieve the study objective and can be more ethically appealing by 
treating more patients with safe and efficacious regimens. In order to 
adapt based on the interim data, study endpoints need to be observed 
within a reasonably short period of time. Additional infrastructure 
support is required. This includes a robust mechanism for endpoint 
evaluation during the trial, timely data entry into a centralized 
database, and the development of specialized software for imple-
menting the adaptive randomization. Drug development is all about 
learning. Adaptive designs provide a sensible and flexible approach 
to facilitate such learning. Other novel trial designs will be shown to 
illustrate the applications of adaptive designs.
Bayesian adaptive trial designs are smart, novel, efficient, and ethi-
cal. In conjunction with early stopping rules, they can be used to 
efficiently identify effective agents, eliminate ineffective ones, and 
match effective treatments with patients’ biomarker profiles. The pro-
posed designs are suitable for the development of targeted therapies 
and provide a rational basis for personalized medicine.
(This work was supported in part by a US Department of Defense 
grant W81XWH-06-1-303 and a National Cancer Institute grant CA 
16672.)
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Phase III trial designs for targeted agents
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Targeted agents with mechanisms of action which are very different 
from the more conventional chemotherapeutic agents are increasing-
ly being developed. Appropriately, concurrent with the development 
of these agents, there has been discussion of Phase III trial design for 
targeted agents. New clinical trial designs have been proposed, but 
trial design is not a “one-size fits all” situation. Often there are either 
many different pathways of action for a new agent or multiple pos-
sible assays to measure the target. Trial designs should be dependent 
on the level of knowledge about the target’s role in the mechanism of 
action of the agent and the performance characteristics of the assay 
used to measure the target. In this talk we will discuss the relative 
merit of various phase III designs, for targeted agents such as the 
randomize-all design, the targeted design, and the strategy design.
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Statistical designs in the bioinformatics age: 
a clinical researcher’s perspective
Kunitoh, Hideo
Mitsui Memorial Hospital, Tokyo, Japan
Tyrosine kinase inhibitors of epidermal growth factor receptor 
(EGFR-TKI), gefitinib and erlotinib, have been shown to be active 
against non-small cell lung cancer (NSCLC). Activating mutation of 
the EGFR on the tumor cells has been reported to be a strong predic-
tive factor for response to, and probably for survival benefit from, 
EGFR-TKI therapy. There is a huge ethnic difference in the propor-
tion of the NSCLC with EGFR mutation: approximately 30% in the 
Asian and 10% in the Western population. 
Recently, a series of randomized clinical trials directly comparing an 
EGFR-TKI and a cytotoxic chemotherapy have been conducted. The 
results of the trials published so far, which used gefitinib as EGFR-
TKI, strongly suggested the difference in the “nature” of efficacy 
between a target-based therapy and a cytotoxic chemotherapy. 
The Japanese study V15-32 compared efficacy of gefitinib and 
docetaxel in patients with platinum-pretreated patients with NSCLC. 
The trial was initiated intended to show non-inferiority of gefitinib 
in overall survival to docetaxel, with the non-inferiority thresh-
old of 1.25. With the ITT analysis of the 489 accrued patients, the 
hazard ratio was 1.12 (95% confidence interval: 0.89 to 1.40), and 
non-inferiority was not demonstrated. One notable characteristic 
of the survival curves was that they crossed with each other at 
approximately 18-months point, initially favoring docetaxel and later 
favoring gefitinib. That strongly suggested that the hazard ratio was 
not constant over passage of time. Additional analysis did show that 
the hazred ration changed with time, initially significantly favoring 
docetaxel arm and later tended to favor gefitinib.
Although the overall survival tended to favor docetaxel, the objec-
tive tumor response rates by RECIST significantly favored gefitinib, 
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with overall response rates of 22.5% in gefitinib arm and 12.8% in 
docetaxel arm (p=0.009), compatible with prior Japanese data with 
docetaxel and gefitinib as second-line chemotherapy in NSCLC. The 
initial fall of the overall survival in gefitinib arm was unlikely to 
be due to excessive toxicity, because causes of death in the initial 3 
months of treatment, more frequently observed in the gefitinib arm, 
were mainly tumor-related, with only a few patients dead of toxicity 
such as peumonitis.
What caused the results of discrepancy of tumor response and sur-
vival (without excessive toxicity) and crossing survival curves? One 
could account for that with the “difference in the nature of efficacy” 
theory.
The cytotoxic chemotherapy should work, more or less, against 
virtually all tumors. However, since the current chemotherapy fails 
to bring a long-lasting effect in NSCLC, the survival curves as 
compared to the natural history would look like Image 1, initially 
improving the outcomes but without long-term survivors. On the 
other hand, a “target-based” drug would work only if it hits the 
target, and would be utterly powerless when it misses the target. 
Whether or not the drug “hits” the target would depend on the 
existence/nonexistence, richness/paucity or characteristics (such as 
mutation) of the target on the tumor cells. But when it does hit the 
target, a good target-based drug should hit hard, drastically working 
against the tumor. Therefore, the survival curves as compared to no 
active treatment would look like Image 2, implying very effective 
in a specific population and not at all in the others. Since the clinical 
response to the therapy is defined as the proportion of the patients 
who achieved tumor shrinkage of more than an arbitrarily pre-set 
criterion (30% in RECIST), the response rate would be affected by 
much in cytotoxic chemotherapy (Image 1) and by little in target-
based therapy (Image 2). Numerical comparison of the response rates 
would thus be meaningless. 
Image 1
Image 2
Image 3
Combining the curves of Image 1 and 2 would give makes Image 3, 
with crossing of the survival curves, initially favoring the cytotoxic 
chemotherapy and later favoring the target-based therapy. This per-
fectly simulates the survival curves of the V15-32 study. 
The interpretation of the V15-32 trial has been validated by the 
results of another trial named iPASS (iressa Pan Asian study), which 
compared first-line gefitinib with the standard carboplatin-paclitaxel 
doublet chemotherapy in NSCLC. In this trial, patients were clini-
cally “enriched” for efficacy of gefitinib: Asian patients with adeno-
carcinoma, with light or no smoking history. Those factors have been 
known to be positively predictive for clinical response to the drug, 
probably via EGFR mutation. Although the overall survival data 
remain premature, the progression-free survival curves were impres-
sive enough and reproduced the “crossing curves phenomenon” 
observed in the prior V15-32 study; they favored platinum-based 
therapy during the first 6 months, when they crossed with each other, 
and favored gefitinib thereafter. The overall hazard ratio was reported 
to be 0.741, favoring gefitinib. 
What was even more remarkable was that the therapeutic benefits of 
gefitinib as opposed to the cytotoxic chemotherapy have been clearly 
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separated by a biomarker, the EGFR mutation status of the tumor. 
Among the one-third of the total patients evaluated for the EGFR 
mutation status, 60% were positive and 40% negative for muta-
tion, reflecting the enrichment of the patient population by clinical 
selection. For those with EGFR mutation, progression-free survival 
favored gefitinib arm (hazard ratio: 0.48), and for those without, it 
favored carboplatin-paclitaxel (hazard ratio: 2.85). It is thus clear that 
the “crossing” of the progression-free survival curves in the whole 
population in fact reflects the mixture of two different populations. No 
other biomarkers could predict the therapeutic effect so accurately.
Therefore, in this trial, the clinical hypothesis from the observation 
of the V15-32 study, that difference in the nature of efficacy between 
a cytotoxic therapy and target-based therapy led to the time-depen-
dent hazard ratio and crossing survival curves, has been validated, 
with sound biological basis. 
Before the results of the IPASS trial was available, the results of 
another phase III trial with unselected NSCLC patients who had 
received prior platinum-based chemotherapy in Western population 
were published. In this trial named INTEREST (Iressa NSCLC Trial 
Evaluating Response versus Taxotere), non-inferiority of gefitinib in 
the overall survival as compared to docetaxel was demonstrated, with 
the hazard ratio of 1.020 (95% confidence interval: 0.905 to 1.150). 
The positive result was apparently due to its larger sample size than 
that of V15-32 study (more than 1400 versus less than 500).
Although the overall survival curves of the gefitinib arm and the doc-
etaxel arm in the INTEREST trial overlapped with each other, those 
of the Asian subset, known to be enriched for the EGFR mutation-
positive population, did sow the tendency similar to the V15-32 
study, initially favoring docetaxel and later favoring gefitinib. In fact, 
the median progression-free survival time of the EGFR-wild type 
subset in the gefitinib arm was only 1.7 months and not different 
from that of historical data of patients with best supportive care, 
casting doubt on any efficacy, if at all, of gefitinib in the subset. The 
apparent survival benefit of the gefitinib arm could be ascribed to 
post-protocol chemotherapy such as docetaxel.
The implication of the results of direct comparison of gefitinib, a 
target-based drug, and cytotoxic chemotherapy should be that they 
could not be amenable to Cox regression analysis, which calculates 
the hazard ratio with a presumption that it remains constant over 
time. In a situation where the hazard ratio changes with time, calcu-
lation of the p-value loses its significance. In fact, it has long been 
pointed out that when survival curves cross with each other, neither 
the medicine nor the biostatistics could judge which is “better”. It 
would be a social or philosophical decision to choose initial benefit 
or later advantage.
These “cross-of-survival-curves” phenomena were not noticed in 
previous trials with target-based drugs, probably because of differ-
ence in the trial designs. Samples of prior trials were as follows:
1) Comparison of a target-based drug versus best supportive care, in 
which any beneficial effect, if at all, of the drug could be easily 
detected with adequate number of patients (i.e., statistical power).
2) Comparison of conventional chemotherapy with or without a 
target-based drug. Again, any additional benefit of the drug would 
be detected in a properly powered trial. Subset analysis could 
demonstrate a sub-population without any additional benefit (such 
as colon cancer with K-ras mutation to cetuximab), but this would 
appear as “no improvement” of the outcomes rather than deterio-
ration of survival.
3) The “unselected” study subject was, in fact, properly selected, 
such as the case of imatinib in patients with CML; the disease 
itself is caused by fusion of BCR-ABL, which exactly is the target 
of imatinib.
In each of the example above, there appeared no problem associated 
with the comparison of the one which works to all subjects to some 
extent (cytotoxic chemotherapy), and the other which works greatly 
to selected population only and not at all to others (target-based 
drug).
There are several on-going trials comparing an EGFR-TKI and 
cytotoxic chemotherapy in advanced NSCLC. One of which is called 
TORCH trial, in which untreated patients (not selected by biomark-
ers or clinical factors) are randomized to receive either erlotinib or 
cisplatin-gemcitabine combnation chemotherapy. Although this trial 
would not be justified with gefitinib for the reasons above, TORCH 
trial might be able to identify biomarkers for erlotinib, for which, 
unlike gefitinib, no reliable marker for efficacy has been established. 
For gefitinib, two Japanese trials are comparing the target-based drug 
and first-line cytotoxic chemotherapy in properly selected (those with 
mutated EGFR) patients. 
Even when the trials are conducted in optimally selected patients, 
the question of how to evaluate the efficacy of the treatment remains, 
due to post-protocol crossover to the other arm. In a comparison of 
two platinum-based combination chemotherapy, in which the choice 
of one arm virtually excludes the use of the other arm, difference in 
the PFS would lead to that in the OS. On the other hand, the majority 
of the patients enrolled in a trial of chemotherapy and EGFR-TKI 
would receive the other arm as post-protocol therapy without major 
compromise of the 2nd line efficacy (Image 4), the OS would not 
reflect the PFS. The difference in OS would be very small due to 
crossover, and it would require a huge number of patients to detect a 
difference.
In conclusion, direct comparison of a target-based therapy and con-
ventional cytotoxic chemotherapy in unselected population would be 
just like a match between a sumo yokozuna and a boxing champion, 
and is unlikely to clinically relevant conclusions. Search for bio-
markers to identify predictive factors, which might be different from 
originally assumed ones, is necessary. Validating trials should be then 
conducted in properly selected populations. 
Image 4
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GR1.1 Stage IIIA N2: 2003 vs 2009, Sat, Aug 1, 10:30 - 12:00
Stage III A: 2003 vs 2009
VanHoutte, Paul J.
Institut Bordet, Brussels, Belgium
The management of stage IIIA disease remains a controversial issue 
both in term of optimal staging or treatment. Questions include the 
role of PET, echoendoscopy, the pathological or not confirmation 
of an enlarged node; the place of initial brain evaluation… The best 
treatment approach is still debate in spite of the recent randomized 
trials. There are tenants of induction chemotherapy or radiochemo-
therapy before surgery. In contrast, other would favour in concurrent 
definitive radiochemotherapy approach. Furthermore, for selected 
cases, an initial surgery followed by adjuvant chemotherapy may 
be a valid approach. Two large scale randomized trials have been 
presented or published (the American Intergroup and the EORTC 
trial) but there were not able to solve the debate between surgery 
and radiotherapy for the local treatment modality. The only common 
observation was the positive impact of a mediastinal downstaging 
stressing the needs for a new mediastinal staging by mediastinos-
copy, echoendoscopy or PET-CT. This has then changed the algo-
rithm for the initial evaluation as repeated mediastinoscopy may be 
difficult due to the fibrosis. Recent metaanalysis have also outlined 
the superiority of a combined chemoradiotherapy approach for 
patients not candidate for a surgical resection, especially a concurrent 
approach with a platinum based chemotherapy. There are still many 
unsolved questions such as the place of an induction or adjuvant 
chemotherapy to be added to the concurrent chemoradiotherapy, the 
place of maintenance chemotherapy, the role of targeted agents. Tri-
als are on-going to answer some of those questions. During the last 
IASLC meeting held in Vancouver in 2003, a case presentation of a 
stage IIIA disease was presented asking the audience their advice. 
We planned to repeat the case to see if the opinions have changed 
over this 6 years period and to see the impact of the published trials 
on the daily practice. 
GR2.2 Adjuvant Chemotherapy: Stage Specific Discussion, Sat, Aug 1, 16:30 - 18:00
Adjuvant chemotherapy: stage specific discussion
Abratt, Raymond P.
Univeristy of Cape Town, Cape Town, South Africa
Introduction:
Surgery is the mainstay of curative treatment in patients with resect-
able non-small cell lung cancer (NSCLC) Failure to achieve cure for 
this group of patients is largely due to the presence of micro metas-
tases at presentation. The incidence of micro metastases varies with 
stage of disease, as well as other factors such as biological character-
istics of the tumor. 
Cisplatin based Adjuvant Chemotherapy has been shown to increase 
both overall survival (OS) and disease free survival (DFS). Chemo-
therapy also has associated morbidity and indeed mortality. The gain 
/ cost ratio in patients receiving adjuvant chemotherapy will therefore 
depend on the likelihood of micro metastases in addition to the indi-
vidual sensitivity of the micro-metastases to adjuvant chemotherapy.
Effect Of Adjuvant Cisplatin Based 
Chemotherapy On OS And DFS:
The 1995 Non-small Cell Lung Cancer Collaborative Group 
landmark meta-analysis of adjuvant chemotherapy in 1394 patients 
(individual patients data from 8 trials), reported a 13% reduction in 
risk of death1. The HR was 0.87, the absolute benefit in survival at 5 
yrs =5% and p=0.08 
The subsequent Lung Cisplatin Adjuvant Evaluation (LACE) meta- 
analysis of 2008 looked at individual patient data from subsequent 
trials with more than 300 patients who also had received cisplatin 
based chemotherapy2. There were 5 trials with 4584 patients. The 
hazard ratio was (HR) for cisplatin based chemo = 0.89 (0.82 -0.96). 
The absolute benefit in survival at 5 yrs = 5.3% +/- 1.6% with a p 
=0.004. 
Stage and Cisplatin Based Chemotherapy:
The influence of Stage was included as a subset analysis in adjuvant 
chemotherapy trials preformed after the 1995 meta-ananlysis. The 
findings are presented below for the Hazard Ratio in cisplatin doublet 
studies with more than 300 patients 
Table 1
Study Overall IB II IIIA
IIALT3 (1867) 0.86 P<0.03 0.95 (0.74-1.23) 0.93 (0.72-1.20) 0.79 (0.66-0.95)
ANITA4(829) 0.79 P=0.013 1.10 (0.76-1.57) 0.71 (0.49-0.94) 0.69 (0.53-0.90)
NCI-C5 (482) 0.69 P=0.04 0.79 (0.52-1.95) 0.59 (0.42-0.85)  Not included
 
The LACE meta-analysis finding of the influence of Stage is 
presented 
Table 2
Stage Deaths/Patients HR (95% CI)
IA 102 / 347 1.41 (0.96;2.09)
IB 509 / 1371 0.92 (0.78;1.10)
II 880 / 1616 0.83 0.73;0.95)
III 865 / 1247 0.83 (0.73;0.95)
 
The HR was statistically significantly favourable in patients with 
Stage II and Stage III disease. The HR tended towards indicating a 
more modest beneficial effect in patients with Stage IB disease; the 
findings in Stage I B disease are however compatible with the find-
ings in patients with more advanced Stage because of overlapping 
confidence Intervals. Further studies are underway to clarify the role 
of chemotherapy in patients with Stage I B disease. There was a ten-
dency towards a detrimental effect in patients with Stage IA disease. 
Stage and Non-Cisplatin Based Chemotherapy:
The CALGB Study was limited to patients with Stage I B disease6. 
Patients were treated with carboplatin and paclitaxel based che-
motherapy. The HR for patients was .80 (0.6-1.07). However, for 
patients with tumours larger than 4 cm, the HR was .69; 90% CI 
0.48-0.99; p=0.43.
Japanese Studies In Japan, the oral antimetabolite UFT, either alone 
or combined with other intravenous agents, has been evaluated in 
several studies. In a meta-analysis7 of UFT chemotherapy that pooled 
individual patient data from six trials, (96% stage I disease), survival 
rates at 5 years were significantly higher in the surgery plus UFT 
group (81.5%) than in the surgery-alone group (77.2%); P = 0.011.
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The Toxicity Of Chemotherapy:
The LACE Study collected data on the maximum grade of toxic-
ity only2. The overall rate of grade 4 toxicity was 32%; Grade 4 
neutropenia occurred in 28%. There was great variability between 
trials which was most probably related to methods of testing and data 
collection. 
There were 19 chemotherapy-related deaths reported for a treatment 
related mortality = 0.9%.
Micro Metastases: Tumour Stage, Size and Molecular Predictors:
Loco regional disease includes both evaluation of T and N stage. The 
T Stage has traditionally focused on potential resectability rather than 
tumour size of volume. 
However, the incidence of micro metastases relates to tumour size. 
This may be inferred from outcome of in patients with N0 disease, 
who have had complete resection as failure is largely due to metastat-
ic disease. A study of this group in 1020 patients (Table 3) showed a 
decrease of survival in such patients with an increase in size8.
Table 3
Tumour Size in cm Patients 5 yr Survival rate (95%CI)
0-2  147 0.63  (0.58 to 0.68)
2.1-4  448 0.56 (0.53 to 0.59)
4,1-7 336 0.49 (0.46 to 0.52) 
7+  89 0.38 (0.32 to 0.44)
An earlier series of patients with resected tumours found a decrease 
in survival of 23.8% for each tumour volume doubling9. There would 
thus be a stronger indication for adjuvant therapy with increasing 
tumour size. This is also compatible with the findings of a beneficial 
effect from adjuvant chemotherapy for patients with tumours larger 
than 4 cm, as in the CALGB study.
In addition the molecular biology of staging is currently being evalu-
ated, both to determine prognosis as well as identifying targets for 
therapy10.
Conclusion:
Adjuvant chemotherapy will be beneficial after resection in appropri-
ate patients with Stage II and IIIA Lung Cancer. It is likely to also be 
of benefit in patients with Stage IB disease although further clarifica-
tion of this will take place from current studies. It is not indicated in 
patients with Stage IA disease.
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GR3.3 Testing for Biomarker driven Therapy (ERCC1 and EGFR), Sun, Aug 2, 10:30 - 12:00
Testing for biomarker driven therapy (ERCC1 and EGFR)
Dancey, Janet Ellen
NCIC CTG, Kingston, ON, Canada
A biomarker is a substance used as an indicator of a biologic state. 
It is a characteristic that is objectively measured and evaluated as 
an indicator of normal biologic processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention. A clinically 
useful biomarker provides a result that assist treatment decisions. 
Other features of useful biomarkers and tests are that they provide 
reliable results from small tumor samples, the biomarker expression 
within the sample is uniform or the observed result may be mislead-
ing, the assay method is robust and gives a result that is not unduly 
influenced by tumor collection, processing, storage conditions and 
the interpretation of the results can be consistent and correlates well 
to clinical outcome. Given the number of scientific and methodologi-
cal steps required, validating a biomarker is a resource-intensive 
undertaking. However, a biomarker that wins “known validated” 
status is positioned for regulatory approval, reimbursement, and 
incorporation into personalized medicine approaches with compan-
ion therapeutics. Both the DNA repair gene excision repair cross-
complementing 1 (ERCC1) and the epidermal growth factor receptor 
(EGFR) are biomarkers that correlate with treatment outcomes of 
non-small cell lung cancer patients but are they “validated” biomark-
ers? Do these biomarkers have clinical utility? Should they routinely 
be assessed prior to recommending specific treatments to lung cancer 
patients? 
Multiple studies have evaluated ERCC1 expression and outcome of 
patients treated with platinum chemotherapy. Laboratory methods 
were mainly RT-PCR (reverse transcriptase polymerase chain reac-
tion) or immunohistochemistry (IHC). A few have evaluated ERCC1 
polymorphisms. The literature is dominated by small and heteroge-
neous patient populations and yielded different results. A few larger, 
randomized studies have reported benefit in outcome among NSCLC 
patients, who received adjuvant platinium combination treatment, 
and had low-ERCC1 expression. However, before ERCC1 should be 
routinely used to determine treatment, several technical and practical 
issues need to be addressed. It remains to be seen whether ERCC1 be 
reliably measured in small tumor samples, and whether its expres-
sion is consistent in the primary or the metastatic sites. To date most 
studies have measured ERCC1 from RNA or DNA thus a method 
and standardized cut-points for interpretation that can be used in 
clinical laboratories remain to be defined. Other genes products 
have also been linked to chemo-sensitivity including p-glycoprotein 
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expression, glutathione s-transferase pi expression and tumor sup-
pressor p53 mutation. Optimal individual therapy likely requires 
evaluating markers of sensitivity for platinum (ERCC1 is only one 
mechanism of resistance) as well as other drugs. No firm conclusions 
can be drawn on the value of measuring ERCC1 based on the current 
literature. Research on the development of a reliable methodology 
is warranted followed by validation in large, prospective, random-
ized trials as ERCC1 may possibly play an important role as tumor 
marker in tailored chemotherapy for NSCLC. 
Analysis EGFR as a marker of sensitivity to EGFR inhibitors has 
been conducted in numerous trials testing EGFR targeting small 
molecules and antibodies. EGFR protein expression, copy number, 
mutations and polymorphisms have all been assessed using a variety 
of test methods. Of interest is that EGFR biomarkers correlate with 
differing degrees of benefit to EGFR directed therapies in certain dis-
ease settings. Although protein expression by (IHC) has been shown 
to correlate with patient outcome in some trials, the results are not 
sufficiently robust to use IHC as a means of selecting treatment for 
individual patients. Both gene mutations (by sequencing or rtPCR) 
and copy number (by fluorescent in-situ hybridization (FISH)) have 
correlated with patient benefit to an EGFR small molecule inhibi-
tor in some trials. Patients with EGFR mutations may benefit to a 
greater degree from a small molecule inhibitor than to an EGFR 
antibody. Patients with either increased copy number or mutations 
may benefit from chemotherapy in addition to EGFR inhibitor. The 
lack of consistency across trials may reflect patient heterogene-
ity, line of therapy, control group, the endpoints used as primary or 
heterogeneity in samples or assays. The most compelling evidence 
of benefit from EGFR small molecule inhibitor is for patients with 
EGFR mutations who appear to benefit similarly to EGFR inhibi-
tors as first-line combination chemotherapy. Patients with increased 
copy number may benefit equally from EGFR inhibitor or secondline 
chemotherapy. Patients unselected for EGFR biomarkers or selected 
by IHC, mutation or copy number may benefit compared to best 
supportive case. Thus, the data supporting biomarker testing in part 
depends of the magnitude of anticipate benefit of an EGFR inhibitor 
versus other available treatment.
The development of clinically useful biomarkers to aid clinical 
treatment decisions has been challenging. Trials designed to evaluate 
treatments have not been optimally designed to test hypothesis driven 
biomarker questions. Often biomarker studies are done on limited 
samples that are conveniently available using assays that are not 
optimized for the sample conditions. Such suboptimal approaches 
may lead to misleading results. Prospective studies to validate bio-
markers to aid in treatment decisions should be adequately sized and 
use an assay system that can perform well on the samples collected 
during the course of the study. Because of the resources required for 
such studies, evaluating more than one potential predictive marker 
strategy would be advantageous. Trial design, assay, patient popula-
tion and specimen collection should be optimized to yield a definitive 
answer.
GR4.1 Debate: MoAbs versus TKIs: Pros and Cons, Sun, Aug 2, 16:30 - 18:00
Monoclonal antibodies
Boyer, Michael
Sydney Cancer Centre, Camperdown, NSW, Australia
Advances in the treatment of malignancy in general, and lung cancer 
in particular will require the introduction of effective new agents. In 
recent years, an understanding of the molecular pathways that are 
involved with the development and maintenance of malignancy has 
resulted in the development of novel anti-cancer treatments. Many 
of these pathways involve trans-membrane receptors, which are 
activated as a consequence of ligand binding to their external surface. 
Two broad approaches have been used to interrupt signal transduc-
tion. Small molecules which enter cells and target enzymes involved 
in signal transduction have been developed. Most commonly, these 
molecules inhibit tyrosine kinases, which are part of the intracellular 
component of the trans-membrane receptors. This inhibition results 
in interruption of signal transduction. The second major approach has 
been to use monoclonal antibodies directed against the extracellular 
component of the receptor, or against the ligand.
The use of monoclonal antibodies in the treatment of illness became 
a reality in the 1970’s with the use of hybridoma technology to 
produce large amounts of specific molecules. Early monoclonal 
antibodies were of murine origin, which hampered their clinical 
use, because of their immunogenicity and limited ability to activate 
human immune effector mechanisms. Chimeric and humanized anti-
bodies have been developed which overcome these problems and the 
antibodies in clinical use today are of these types. 
Monoclonal antibodies have several advantages over small molecule 
approaches for the treatment of cancer. These agents are highly 
specific for their target, with little effect on other pathways. Antibod-
ies that target receptors can act by blocking ligand binding, inducing 
receptor internalization, inhibiting receptor dimerization, and by 
preventing receptor phosphorylation (which is required for down-
stream signal transduction). An alternate approach is to use agonistic 
antibodies which mimic the effects of ligand binding to receptor and 
activate processes that can lead to cell death (for example, antibodies 
to TRAIL receptors). The long half-life of many monoclonal antibod-
ies is also an advantage as it results in prolonged receptor inhibition / 
activation, with relatively infrequent dosing.
Additionally, antibodies that are constructed using a human IgG1 
structure are also capable of recruiting immune effector cells and 
producing antibody-dependent cellular cytotoxicity (ADCC), which 
is a direct method of cell killing mediated by NK cells. However, it 
is unclear to what extent the clinical effects of monoclonal antibodies 
on solid tumours rely on ADCC. An additional advantage of mono-
clonal antibodies is the ability to use them to target ligands, rather 
than receptors. Bevacizumab is an example of an agent targeted 
against a ligand rather than a receptor.
Antibody approaches to cancer treatment also offer the possibility of 
utilizing antibodies to deliver cytotoxic payloads (for example immu-
noconjugates with radioisotopes, enzymes or drugs). In addition, 
new monoclonal antibodies are being developed that only bind to 
activated forms of receptors. These developments offer the potential 
of making therapy even more specific and thereby reducing toxicity 
though no such molecules have been tested specifically for the treat-
ment of lung cancer.
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In general, the toxicities of antibody-based therapies are mechanism 
based and correspond to the same toxicities observed when pathways 
are inhibited by other mechanisms such as tyrosine kinase inhibitors. 
The major exception to this is the occurrence of infusion reactions. 
However, these are usually mild and easily controllable.
The first monoclonal antibody to be approved for use in the treatment 
of NSCLC was bevacizumab, which is a chimeric antibody which 
binds to vascular endothelial growth factor (VEGF) -A, and thus 
prevents activation of the VEGF receptor. It was initially evaluated in 
a randomized phase 2 study where it was shown to improve response 
rates, progression free and overall survival. However, an increased 
rate of death due to severe pulmonary hemorrhage was noted in 
patients with squamous cell histology, and further trials were restrict-
ed to non-squamous tumours. Two randomized phase 3 trials have 
demonstrated the efficacy of this agent. The first trial, E4599, carried 
out in the USA, compared chemotherapy with carboplatin and pacli-
taxel alone or with the addition of bevacizumab at a dose of 15mg/
kg q 3 weeks. The addition of bevacizumab resulted in an increase 
in response rate and a two month improvement in median survival 
from 10.3 to 12.3 months, with a hazard ratio of 0.79 (p = 0.003). 
However, it was also associated with a higher rate of toxic deaths 
(14 vs 2). A second study, AVAIL, compared the addition of two dif-
ferent doses of bevacizumab (7.5 mg / kg and 15 mg / kg q 3 weeks) 
to combination chemotherapy with gemcitabine and cisplatin. The 
primary endpoint of this study was progression-free survival, which 
was modestly, but significantly, improved in the bevacizumab arms 
(6.1 vs 6.7 and 6.5 months on the placebo, 7.5 mg/kg and 15 mg/
kg arms respectively). Overall survival data were immature, at the 
time of initial reporting. The addition of bevacizumab also improved 
response rates. Although some toxicities were increased with the 
additional agent, there was no increase in toxic deaths. As a result of 
these two phase 3 trials, first line treatment of non-squamous NSCLC 
now includes bevacizumab in many parts of the world, though ques-
tions remain over the cost-effectiveness of this approach.
The other monoclonal antibody for which phase 3 data exist in 
NSCLC is cetuximab. This is a human IgG1 chimeric antibody 
targeting the epidermal growth factor receptor (EGFR). Based on 
promising results in phase 2 trials, two large randomized phase 3 
studies have been conducted, evaluating the effect of the addition of 
cetuximab to chemotherapy. The first of these, BMS CA225099, add-
ed cetuximab to standard therapy with carboplatin and a taxane. The 
addition of cetuximab increased response rates (from 17.2 to 25.7%), 
but had no impact on progression free survival. Overall survival has 
not been reported. The second study, FLEX, was of a similar design 
but used a different chemotherapy base, cisplatin and vinorelbine. In 
addition, this trial selected patients on the basis of EGFR positivity 
within their tumour. The addition of cetuximab modestly improved 
survival (HR 0.87, median 11.3 vs. 10.1 months, p = 0.04), although 
in a pre-specified sub-group analysis including only Caucasians, the 
effects were somewhat larger.
Other monoclonal antibodies directed against EGFR have been 
evaluated in NSCLC. These include panitumumab and matuzumab as 
well as trastuzumab (targeting Her2). In general, however, the results 
of these agents have been disappointing.
Monoclonal antibodies represent an important addition to the treat-
ment options for NSCLC and other malignancies. Further refinement 
in their use, by identifying additional targets, and identifying the 
optimal ways of combining them with chemotherapy should continue 
to enhance their clinical utility.
GR5.1 Therapy for Early Stage NSCLC with Poor Lung Function:  
 Surgical vs. Non-Surgical, Mon, Aug 3, 10:30 - 12:00
Brachytherapy
Nakayama, Yuko
Division of Radiation Oncology, Kanagawa Cancer Center, 
Yokohama, Japan
Intraluminal irradiation using high-dose-rate (HDR) iridium as the 
source is becoming standard treatment worldwide. This technique 
is generally used for curative treatment of uterine cervical cancer. 
Brachytherapy has the advantage of delivering a high dose to the 
tumor while sparing the surrounding normal tissues. The use of HDR 
brachytherapy is well established for palliative treatment in patients 
with advanced or metastatic lung cancer. Endobronchial brachyther-
apy with curative intent is indicated in early stage patients who are 
medically inoperable because of poor lung function, advanced age, or 
refusal of surgery. Early endobronchial cancer has characteristics of 
synchronicity and metachronicity, so it is the best choice for minimal 
invasive treatment, especially for patients with poor lung function.
Methods of endobronchial brachytherapy
An initial bronchoscopy is performed to evaluate the airway and to 
locate the site of the tumor. A catheter is inserted through the brush 
channel of the bronchoscope, passed through the tumor, and lodged 
in one of the smaller bronchi. The use of fluoroscopy assists in keep-
ing the catheter in place during the bronchoscope removal. The use 
of an applicator with wings is recommended to keep the position 
of the catheter in the center of the bronchus and deliver a homog-
enous dose to the surface of the bronchial mucosa. Endobronchial 
brachytherapy is performed at a dose of 5 Gy per fraction, one to 
two times per week. To deliver the dose theoretically to the surface 
of the bronchial mucosa, the reference dose point should ,be set at 
9mm-10mm point from the source in the trachea, 7mm in the main 
bronchus, 5mm in the lobar to segmental bronchi, and 3mm in the 
subsegmental bronchi. The length to be irradiated usually includes 
the endobronchial tumor and 2.0-cm proximal and distal margins. 
Treatment results of endobronchial brachytherapy
Endobronchial brachytherapy with curative intent is indicated 
in early stage patients who are medically inoperable because of 
poor lung function, advanced age, or refusal of surgery. Fuwa et 
al. reported long-term observation of 64 patients with roentgeno-
graphically occult lung cancer treated with external irradiation and 
intraluminal irradiation (1). The therapeutic effect was complete 
response in 63 patients and partial response in 1; the 5-year overall 
and relapse-free survival rates were 56% and 55%, respectively. On 
multivariate analysis, clearness of peripheral visibility of the tumor 
lesion was found to have a significant impact on local control. Saito 
et al. also reported long-term observation of 64 patients with roent-
genographically occult lung cancer treated with external irradiation 
and intraluminal irradiation (2). The 5-year overall and relapse-free 
survival rates were 72.3% and 87.3%, respectively.
The definition of endoscopic early stage lung cancer according to the 
Japan Lung Cancer Society (JLCS) in 1999 is as follows: a radiog-
raphycally occult carcinoma had no metastasis to lymph nodes and 
distant organs by clinical definition, and was located between the tra-
chea and subsegmental bronchus with length < 2 cm, has clearly vis-
ible margins with squamous cell carcinoma histology in endoscopic 
definition. In our experience, all of the patients fitting this definition 
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(profile) were locally controlled, so they were good candidates for 
endobronchial brachytherapy. 
Toxicity of brachytherapy
Bronchial hemorrhage was reported as a complication after endo-
bronchial brachytherapy (1). Recently overdosing of the bronchial 
mucosa has been avoided by using a winged applicator, which holds 
the radiation source in the center of the bronchus and minimizes the 
radiation dose per fraction. Stenosis of peripheral bronchus is often 
apparent, but clinical symptoms seldom occur (2). For patients with 
poor lung function, endobronchial brachytherapy alone is safer than 
a combination of external beam radiotherapy and brachytherapy, 
from the standpoint of the possible complications of radiation 
pneumonitia.
Which is better, brachytherapy alone or brachytherapy 
plus external beam radiation therapy? 
In Japanese studies of brachytherapy in early lung cancer, combina-
tion therapy was generally used (1-2). One of the reasons for the use 
of additional external beam radiation therapy might be conclusive 
irradiation to the tumor using a localized limited field. Another 
reason is prophylactic irradiation to the lymph nodes of the hilus and 
mediastinum using a large mediastinal field. In a surgical study (3), 
there was no evidence of nodal metastasis with lesions <10 mm. For 
lesions >10 mm, however, the incidence was 11%. Thus, lesion size 
could be used to determine which patients had little probability of 
having metastasis to the lymphatic system. It is recommended that 
among patients diagnosed with endoscopic early stage lung cancer 
according to JLCS, lesions < 10mm might be treated by brachythera-
py alone and others by a combination of brachytherapy and prophy-
lactic external radiotherapy.
Synchronicity and metachronicity
This group of patients is selected for having minimal disease, but 
also for their history of prior lung cancer or moderate to severe medi-
cal problems.
It isn’t uncommon that some have undergone treatment for a previ-
ous lung carcinoma, pneumonectomy or mediastinal irradiation. 
Their entire bronchial mucosa is at risk and has a high probability 
of developing more than one lesion (synchronous or metachronous 
lesions). While a pneumonectomy will cure a certain percentage of 
patients, the remaining lung would continue to be at risk. Therefore, 
properly selected lesions should be considered for therapies designed 
to preserve pulmonary function.
Conclusion
The recommendation level of brachytherapy for early lung cancer is 
not high. ACCP guidelines point out that for patients with superfi-
cial squamous cell carcinoma who are not surgical candidates, PDT, 
electrocautery, cryotherapy, and brachytherapy are recommended as 
treatment options (4).
According to the guideline of JLCS, surgery is first choice for early 
endobronchial cancer. And PDT is recommended for endobronchial 
cancer with length < 1cm, no evidence of invasion over submucosal 
layer.
There is still controversy concerning the use of brachytherapy for 
early endobronchial cancer. Indication for brachytherapy would 
be broader than PDT, for example, hilar lung cancer with length < 
2cm, infiltrative depth < 1cm. More importantly, early endobron-
chial cancer has characteristics of synchronicity and metachronicity, 
so brachytherapy is generally the best choice for minimal invasive 
treatment modality, especially for patients with poor lung function.
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Stereotactic radiotherapy early stage 
NSCLC with poor lung function
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Nearly 25% of patients with stage I NSCLC will not undergo surgery 
due to patient refusal, or because of coexisting illnesses that preclude 
surgery. Survival in untreated stage I NSCLC is poor, with 5-year 
survivals at between 6 and 14% [Wisnivesky J, 2005; Raz D, 2007]. 
When surgery is not possible, treatment with conventional radio-
therapy can be delivered over a 5–7 week period. Analysis of SEER 
data showed lung cancer-specific survival rates after conventional 
radiotherapy to range from 69% at 1 year, 29% at 3 years and 15% at 
5 years [Wisnivesky J, 2005]. More recent data from single-institu-
tion studies show improved local control rates using 3-dimensional 
conformal radiotherapy and, when corrected for higher rates of co-
morbidity, the data suggests that that survival rates after radiotherapy 
approach those seen in contemporaneous surgical cohorts treated at 
the same institution [Graham P, 2006; Yendamuri S, 2007].
Recent technological advances in radiation oncology, the so-called 
‘Image-Guided radiotherapy / IGRT’ approaches, allow for greater 
precision in planning and treatment delivery [Haasbeek C, 2008]. 
IGRT techniques have been widely applied for stereotactic radio-
therapy (SRT), which is a non-invasive technique characterized 
by accurate patient repositioning during treatment simulation and 
delivery, and by use of ablative doses of radiation that are typically 
delivered in 3-5 fractions. SRT can achieve 2 year local control rates 
in excess of 90% [Onishi H, 2007; Lagerwaard F, 2008]. For patients 
with peripheral lung tumors, high-grade toxicity is limited to less 
than 6% of patients. In non-randomized studies, the reported local 
control with SRT is far higher than that reported with conventional 
radiotherapy in 6-7 weeks. Prospective study of quality of life and 
pulmonary function reveals that these are generally well preserved in 
patients treated using SRT [Lagerwaard F, 2007]. 
In 193 consecutive frail elderly patients with medically inoperable 
stage I NSCLC, curative SBRT achieved actuarial local-, regional- 
and distant failure rates at 3 years of 11%, 8% and 21%, respectively 
[Senan S, pASCO 2009]. The median age of patients was 79 years, 
25% had chronic obstructive pulmonary disease GOLD Class III 
or higher, median age-adjusted Charlson co-morbidity score was 
7 (range 2-12), and minimal toxicity was observed. The favorable 
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toxicity profile of SRT is confirmed by outcomes in patients treated 
curatively for stage I lung tumors arising after prior pneumonectomy 
[Haasbeek C, 2009].
Despite the lack of randomized data comparing SRT with conven-
tionally fractionated radiotherapy, a majority of members of the 
European Society for Therapeutic Radiology and Oncology consider 
SRT to be their treatment of choice for a patient with medically-
inoperable stage I NSCLC [Widder J, pESTRO 2008]. 
Very long-term follow up data is limited and data on the following 
areas are awaited:
1. A potential underestimate of late toxicity as follow-up in most 
reports is less than 5 years. Recent reports on the incidence of late 
rib fractures, which are occasionally asymptomatic, and symptom-
atic lesions of the brachial plexus when apical tumors have been 
treated indicate a need for careful follow-up of treated patients. 
2. There is a lack of consensus on optimal doses to be used for 
centrally located tumors, although data using ‘risk-adapted’ 
fractionation schemes from some institutions suggest that SRT is 
a feasible option [Lagerwaard F, 2008; Chang J 2008]. However, 
other reports suggest that significant late bronchial stenosis can 
develop after SRT to mediastinal targets [Song SY 2009].
3. Normal tissue dose constraints are not well established as plan-
ning algorithms used in some previous reported are likely to have 
incorrectly estimated the doses received by critical organs. New 
guidelines for the delivery of SRT have been formulated so as to 
collect such planning data, and national groups have implemented 
programs to ensure safe implementation of SRT [Hurkmans C, 
2009].
In summary, the available data on treatment-related toxicity, local 
control and quality of life suggests that outcomes of SRT in patients 
with poor lung function compare favorably to that using other local 
treatments.
GR6.1 Pre-operative vs. Post-operative Chemotherapy for Early Stage NSCLC,  
 Tue, Aug 4, 10:30 - 12:00
Induction chemotherapy for operable 
non-small cell lung cancer 
Le Chevalier, Thierry
Institut Gustave Roussy, Villejuif, France
Despite optimal surgical management, five-year survival rate of 
patients with resectable Non-Small Cell Lung Cancer (NSCLC) 
remains poor, ranging from 70% for stage IA to 25 % for stage IIIA. 
Preoperative staging often underestimates the extent of the disease 
(particularly if positron-emission tomography and mediastinoscopy 
are not used) and the estimated survival rates for a given clinical 
stage are substantially lower than the corresponding postoperative 
pathological stage. Adjuvant chemotherapy, combined or not with 
thoracic radiation, marginally - even if significantly - improves sur-
vival (by 4% at 5 years in the recently updated individual data-based 
meta-analysis). It is clear that other therapeutic strategies are to be 
explored if one wants to improve these results.
Giving chemotherapy preoperatively offers several advantages. 
Among those, downstaging is observed in about 50% of cases, 
sometimes permitting a complete resection. Induction chemotherapy 
also allows a front-line attack of micro-metastases. In addition, 
compliance of chemotherapy is around 90% compared to 60-70% for 
post-operative chemotherapy.
A number of phase II trials have been carried out in the 80’s to evalu-
ate the benefit of induction chemotherapy in stage I–III NSCLC. The 
radiological response rates in these trials ranged from 39 to 79 %. 
Secondary surgical resection was generally feasible and a complete 
pathologic response was observed in some patients. The first ran-
domized phase II trial comparing induction chemotherapy followed 
by surgery to front-line surgery was prematurely stopped after inclu-
sion of 26 patients due to disease progression in four cases (leading 
to cancellation of the surgical resection in 2 patients). However, two 
subsequent randomized phase III trials had a significant impact on 
the medical community due to their impressive results. Both trials 
randomized 60 stage IIIA patients and were interrupted after positive 
interim results were observed. The first (by Roth et al.) compared 
surgery alone to three cycles of cyclophosphamide/etoposide/cispla-
tin followed by surgery. No adjuvant radiotherapy was planned. The 
response rate to induction chemotherapy was 35%. After 37 months 
of follow-up, the median survival was 64 months for the group 
receiving induction chemotherapy vs 11 months for the control group 
(p = 0.008); after 82 months of follow-up, median survival was 21 
and 14 months respectively (p = 0.056). The second study (by Rosell 
et al) concerned cN2 patients treated by either front line surgery or 
three cycles of mitomycin/ifosfamide/cisplatin (MIP) followed by 
surgery. Post-operative radiotherapy was given in both arms. The 
objective response rate following induction chemotherapy was 60 
%. Median survival was 22 months for the induction therapy group 
and 10 months for the control group (p = 0.005). The unusually poor 
survival in the control arm (0% at five years) suggested a possible 
bias of the study. A NCI study included only 28 randomized patients 
with histologically proven N2. It offers only limited insight into the 
potential value of induction chemotherapy due to the small number 
of patients. In fact, only two published randomized phase III studies 
accrued the number of patients that were initially planned: A French 
study included 373 patients with disease stage IB-IIIA. In the experi-
mental arm, patients received 2 induction cycles of MIP. In addition, 
responders (64% of the cohort) received 2 additional post-operative 
cycles of the same combination. Adjuvant radiotherapy was planned 
for pT3 and pN2 patients, or for patients with incomplete resection. 
Thirty-seven percent of the patients had stage I NSCLC, 16% stage II 
and 47% stage IIIA. The statistical hypothesis of a 15% survival ben-
efit at 2 years was not confirmed in the experimental arm. (HR=0.78 
[0.60 to 1.02]). Median survival was 37 months in the pre-operative 
chemotherapy arm and 26 months in the surgery alone arm (p = 
0.15). An unplanned posthoc analysis suggested a potential benefit 
in the pN0/pN1 subgroup. The second study was led by the Medical 
Research Council (LU22/NVALT2/EORTC 08012 trial). It included 
519 patients who were randomized to either surgery alone or three 
cycles of chemotherapy including vinorelbine/cisplatin or gemcitabi-
ne/cisplatin or mitomycin/vinblastine/cisplatin or docetaxel/carbopla-
tin followed by surgery. Most patients had stage I disease (61%), and 
only 7% had stage III. The response rate to initial chemotherapy was 
49% [95% CI 43%–55%]) but there was no overall survival benefit 
(HR: 1.02, 95% CI 0.80–1.31, p=0.86). 
Among other studies that are either unpublished or that ended pre-
maturely due to insufficient accrual (mostly related to the positive 
results of adjuvant studies), the SWOG (S9900) trial evaluated the 
benefit of three cycles of paclitaxel/carboplatin in 354 patients (out 
of 600 planned) with stage IB-IIIA disease (without N2). Two third 
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of patients had stage IB-IIA disease and a third were stage IIB or 
IIIA. The response rate to induction chemotherapy was 38 %. After 
31 months of follow up, the ratio for death was 0.84 (CI 95% 0.63-
1.18, p=0.32), favoring the chemotherapy arm. After 53 months of 
follow-up, the HR was 0.81 (CI 95% 0.60-1.10, p=0.19). The same 
population was eligible in the Ch.E.S.T. study, comparing surgery 
alone to three cycles of gemcitabine/cisplatin followed by surgery. A 
total of 270 (out of 700 planned) patients with stage IB/IIIA disease 
(excluding N2) were included. Response rate after initial chemother-
apy was 35% (CI 95%, 26-44%) and 5.5% of patients experienced 
progression. The overall 3-year-survival rate was 60% after surgery 
alone (CI 95% 51-68%) compared to 67% in the experimental arm 
(CI 95%, 58-75%) with a p value of 0.053.
No individual patient data-based meta-analysis of neoadjuvant 
therapy trials have been realized up to now and the only available 
analyses are based on abstracts and literature data. The first pooled 
analysis, published in 2005 and based on six randomized trials (for 
a total of 590 patients), found a benefit of cisplatin-based induction 
chemotherapy (HR = 0.66, CI 95% 0.48-0.93). When the effect of 
induction chemotherapy was analyzed in the subgroup of patients 
with clinical stage III disease, the HR was 0.65 (CI95% 0.41-1.04); 
despite a strong trend in favor of the use of chemotherapy in stage 
III disease, this value did not reach statistical significance (possibly 
due to the number of patients included). A second meta-analysis by 
Burdett et al. included seven of the 12 eligible randomized trials (five 
trials were excluded as the data that could be extracted from the pub-
lications were insufficient). Two trials used carboplatin-based chemo-
therapy, while all other trials used cisplatin-based regimens. Among 
the 988 patients, authors found that preoperative chemotherapy 
improved survival, with a HR of 0.82 (CI 95% 0.69-0.97, p=0.02). 
This is equivalent to an absolute benefit of 6% at five years. This 
pooled analysis was recently updated, incorporating the MRC LU22/
NVALT2/EORTC 08012 trial. A total of 1507 patients were included 
and a HR of 0.88 (CI 95% 0.76–1.01, p=0.07) was observed, equiva-
lent to an absolute improvement in survival of 5% at five years. 
Data from all these randomized studies are summarized in the table 
seen below.
Randomized platin-based induction trials and pooled analyses
 No. of    Complete Hazard Ratio 
Trial Patients Stage Chemotherapy ORR Resection  [95% CI] P
Rosell 60 IIIA MIP 60% 90/77 — 0.005
Roth 60 IIIA CEP 35% 31/39 — 0.056
Depierre 373 IB-IIIA MIP 64% 26/37 0.78 [0.60-1.02] 0.15
LU22 519 I-IIIA VnrP, GemP, MVdP,  49% 80/82 1.02 [0.80-1.31] 0.86 
   Doc/carbo
Ch.E.S.T 344 IB-IIIA GemP 35% — 0.63 [0.42-0.93] 0.053
Berghmans 590 I-IIIA Cisplatin-based — NR/NR 0.66 [0.48-0.93] n.a.
Gilligan 4,584 I-IIIA Cisplatin-based — NR/NR 0.88 [0.76-1.01] 0.07
Abbreviations: ORR, objective response rate; MIP, mitomycin/ifosfamide/cisplatin; CEP, etoposide/
cisplatin/cyclophosphamide; VnrP, vinorelbine/cisplatin; GemP, gemcitabine/cisplatin; MVdP, 
mitomycin/vindesine/cisplatin; Doc/carbo, docetaxel/carboplatin.
Various chemotherapy regimens have been evaluated in phase II 
and III trials. Comparisons of phase II trials are difficult to inter-
pret, due to the heterogeneity of study populations (stage of disease 
and staging procedures at inclusion, smoking status, histological 
features, etc…) and the type of treatment modalities (i.e. surgery and 
radiotherapy) following induction chemotherapy. Optimizing chemo-
therapy with one or two new agents or with a triplet has not proved 
superiority to date. In one trial, a docetaxel/cisplatin/gemcitabin 
combination was associated with a response rate of 48%; whereas, 
in another randomized phase II trial, response rates of 61% and 65% 
were reported with gemcitabin/cisplatin/vinorelbine and gemcitabin/
cisplatin combinations, respectively. 
Whatever the cisplatin based regimen used, the optimal number 
of cycles is also unkown. A striking result comes from the French 
intergroup IFCT0002 study, in which two pre-operative + two post-
operative cycles were compared to four preoperative chemotherapy 
cycles. Clinical responses to treatment did not differ between the two 
or four cycle regimens (50.6% and 50.9%, respectively), using either 
gemcitabin/ciplatin or paclitaxel/carboplatin. In the LACE analysis, 
the effect of adjuvant chemotherapy did not differ significantly (test 
for interaction, p=0.10) for the drugs used even if the vinorelbine-
cisplatin combination (HR=0.80 [0.70-0.91]) appeared superior 
to etoposide/vinca-alcaloide-cisplatin (HR=0.93 [0.80-1.07]) or 
other combinations (HR=0.98 [0.84-1.14]). To improve the efficacy 
of cytotoxic agents, selected new targeted agents, such as anti-
angiogenic drugs, are currently being evaluated in the peri-operative 
setting. Nevertheless, it is too early to determine whether or not they 
will improve the results obtained with standard cytotoxic agents. 
Finally, rather than asking whether neoadjuvant or adjuvant chemo-
therapy should be preferred, the key issue may be to determine which 
patients should be treated with adjuvant and/or neo-adjuvant therapy. 
The neo-adjuvant approach offers a unique opportunity to test new 
drugs and compare the tumour characteristics prior to and following 
induction therapy. Developing molecular based therapeutic strategies 
will certainly be one of the major challenges over the next few years. 
A number of trials, including the TASTE (IFCT 0801) trial, examin-
ing the use of personalized regimens for adjuvant chemotherapy, are 
therefore underway. 
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Biology of the EGF pathway
Yarden, Yosef
Weizmann Institute, Rehovot, Israel
Growth factors and their transmembrane receptors contribute to all 
steps of tumor progression, from the initial phase of clonal expan-
sion, through angiogenesis to metastasis. An important example com-
prises the epidermal growth factor (EGF) and the respective receptor 
tyrosine kinase, namely ErbB-1/EGFR, which belongs to a prototype 
signaling module that drives carcinoma development. The extended 
module includes two autonomous receptors, EGFR and ErbB-4, and 
two non-autonomous receptors, namely: a ligand-less oncogenic 
receptor, HER2/ErbB-2, and a kinase-dead receptor (ErbB-3). This 
signaling module is richly involved in human cancer and already 
serves as a target for several cancer drugs.
Due to inherent complexity and a large amount of experimental data, 
we propose a systemic approach to understanding ErbB signaling in 
mammals. EGF - to - ErbB signaling is envisioned as a bow-tie con-
figured network, sharing modularity, redundancy and control circuits 
with robust biological and engineered systems. Our work concen-
trates on system controls, a plethora of positive and negative feed-
back loops, which include rapidly synthesized ligands of ErbBs (e.g., 
transforming growth factor alpha), E3 ubiquitin ligases (e.g., Cbl and 
Nedd4), receptor endocytosis and newly transcribed genes. Because 
network fragility is an inevitable tradeoff of robustness, systems 
level understanding is expected to identify therapeutic opportunities 
for targeting aberrant activation of the network in human pathologies. 
Specific examples include anti-receptor monoclonal antibodies, such 
as Trastuzumab, as well as dual-specificity kinase inhibitors, such as 
Lapatinib, drugs targeting essential network hubs. Combinations of 
targeted therapies and chemo- or radio-therapy are relatively effec-
tive in clinical settings, but the underlying molecular mechanisms 
remain incompletely understood. Another fragile aspect of oncogenic 
networks, especially those incorporating protein kinases, comprises 
reliance on chaperones. Accordingly, chaperone inhibitors, such as 
blockers of the nucleotide binding site of heat shock protein 90, may 
develop into effective drugs. Mechanisms underlying response to 
approved, as well as experimental drugs, and evolvement of second-
ary patient resistance will be discussed.
E1.2 EGFR Pathway, Sat, Aug 1, 10:30 - 12:00
Using Biomarkers to Predict Response to EGFR Inhibitors
Kris, Mark G.
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Despite the near universal presence of EGFR protein in lung cancer 
specimens and the demonstration that agents targeting EGFR 
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effectively block signaling through that receptor, most patients with 
lung cancer fail to derive significant benefit from gefitinib, erlotinib, 
and cetuximab. However, early in the development of both gefi-
tinib and erlotinib, clinicians recognized that some patients experi-
ence substantial benefit with dramatic symptomatic improvement, 
radiographic regressions, and long response durations achieved with 
minimal toxicity compared to other approaches. Accurately iden-
tifying these individuals quickly became an active research area. 
Several centers collected the tumor specimens from their patients 
with dramatic regressions and focused on the EGFR gene, sequenc-
ing the exons encoding the tyrosine kinase domain which is the 
target of gefitinib and erlotinib. This effort led to the discovery of 
somatic activating mutations in EGFR exons 19 and 21. Cancer cells 
with these mutations are addicted to EGFR signaling and undergo 
rapid cell death if the EGFR pathway is disrupted. Cells with EGFR 
mutations are much more sensitive to EGFR blockade with gefitinib 
and erlotinib than cells with wild type EGFR. Based on these labora-
tory findings, treating patients whose tumors harbor these muta-
tions should result in dramatic shrinkage. Cells addicted to EGFR 
signaling demonstrate additional characteristics demonstrating EGFR 
dependence including increases in EGFR copy number, amplification 
of EGFR, and overexpression of EGFR protein. Conversely, if a lung 
adenocarcinoma cell is addicted to another oncogene, like KRAS, 
it is unlikely to be affected by EGFR blockade. Clinical experience 
has demonstrated that patients with lung adenocarcinomas harboring 
KRAS mutations almost never experience regressions with gefitinib 
and erlotinib. Mutations in EGFR and KRAS are never found in the 
same adenocarcinoma cell. 
Although cetuximab binds to the extracellular domain of EGFR and 
it effectively abrogates EGFR signaling, its exact mechanism of 
action is unknown. Dramatic responses like those seen with gefitinib 
and erlotinib have not been observed, even in patients with EGFR 
mutations. Available data fails to confirm that cells with EGFR muta-
tions are more sensitive to cetuximab or that lung adenocarcinomas 
that harbor KRAS mutations do not benefit from cetuximab treatment 
as has been demonstrated in colorectal cancer.
The practical consequences of these biological and clinical observa-
tions are clear. The best way to predict response to gefitinib or erlo-
tinib is to test for the presence of EGFR mutations. At present, tumor 
tissues must be analyzed for the presence of the activating mutations 
in exons 19 and 21. Cell blocks from effusions or ascites can also 
be used for this purpose. Because this is a DNA-based test, archival 
specimens can be used. There are few false positives and most false 
negatives result from variabilities in tissue sampling or poor sensitiv-
ity of the test. The use of EGFR copy number by fluorescent in situ 
hybridization (FISH) is less accurate in predicting which patients 
will have dramatic clinical responses to treatment with gefitinib or 
erlotinib. Major responses are seen in about one-third of patients 
whose tumors have increased EGFR copy number compared with 
~70% of patients whose tumors have EGFR mutations. Testing for 
the presence of EGFR protein by immunohistochemistry has even 
less ability to discriminate between individuals likely and unlikely 
to benefit. KRAS mutation testing and blood proteomic testing can 
identify individuals very unlikely to benefit from gefitinib and erlo-
tinib. No biomarker has been identified to select individuals likely to 
benefit from cetuximab.
Clinical characteristics do not provide adequate discrimination to 
select therapy with gefitinib and erlotinib. While never smoking 
status is the strongest clinical predictor of response, it’s predictive 
ability is quite limited. In the IPASS study, a large study conducted 
in East Asia which randomly assigned patients with adenocarcinoma 
who never smoked or had smoked <10 pack years to initial treatment 
with gefitinib or conventional chemotherapy, nearly 40% of East 
Asian never smokers did not have tumors with an EGFR mutation. In 
these individuals, gefitinib had a response rate of only 1% and those 
randomized to initial chemotherapy had superior progression free 
survival compared to those given gefitinib. In North America, half of 
individuals with tumors with EGFR mutations are current or former 
smokers. In a Memorial Sloan-Kettering induction trial where we 
used a clinical enrichment strategy to increase the number of patients 
with tumors with EGFR mutations by enrolling only individuals 
with minimal tobacco exposure and/or bronchioloalveolar histol-
ogy, only 42% of patients had tumors with EGFR mutations when 
genotyped. The ability to select individuals likely to have clinical and 
radiographic improvement with gefitinib and erlotinib by testing for 
EGFR mutations far surpasses any clinical selection criteria.
Testing tumor specimens for EGFR mutations should be done at 
diagnosis for patients with lung adenocarcinoma. Consideration 
should be given for rebiopsy if necessary. Squamous cell carcinomas 
very rarely harbor KRAS or EGFR mutations and are unlikely to 
benefit from routine testing for these mutations. Based on data from 
IPASS and other prospective trials giving gefitinib or erlotinib alone 
as initial therapy, major responses can be expected in more than 
two-thirds of patients with EGFR mutations. While some benefit 
with gefitinib and erlotinib has been documented in individuals with 
tumors with wild type EGFR, objective radiographic response is 
extremely rare. Therefore, treatment with gefitinib or erlotinib in 
these individuals is warranted only after therapies with a higher like-
lihood of benefit are exhausted. If a KRAS mutation is detected, the 
response rate with gefitinib or erlotinib is less than 1% in reported 
series. There is no data to support the use of gefitinib or erlotinib 
in patients with tumors harboring KRAS mutations. Cetuximab 
has been tested as initial treatment in combination with cisplatin or 
carboplatin and vinorelbine, gemcitabine, or paclitaxel. Based on 
this data, cetuximab in combination with other chemotherapies is an 
option for initial treatment of patients with tumors that do not harbor 
EGFR mutations. There is insufficient evidence to confirm that 
KRAS mutations are not a contraindication to cetuximab in patients 
with lung adenocarcinoma.
Advances in technology have the potential to make mutation testing 
quicker, cheaper, and possible even if histologic material is not avail-
able. For example, the mass spectrometry based sequencing systems 
and other deep sequencing technologies can detect mutations when 
present in less than 5% of tumor cells and allow the simultaneous 
detection of all “known” mutations in the same testing run. Investi-
gational immunohistochemical testing can detect sensitizing muta-
tions, potentially even in cytology specimens. Mutations can also be 
detected in blood DNA or circulating tumor cells as well. Not only 
will these newer analytic techniques make the detection of EGFR 
and KRAS mutations faster and more accurate to permit the optimal 
use of gefitinib and erlotinib in all patients with adenocarcinoma, 
but they will also provide a platform for the testing for other genetic 
abnormalities that lead to oncogene addiction and specific therapy 
such as EML4-ALK.
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State of the art of clinical research 
with monoclonal antibodies
Douillard, Jean-Yves
Centre R Gauducheau, St-Herblain, France
Monoclonal antibodies have emerged in the past 10 years as potential 
therapeutic agents for various tumors. In Non-Small-Cell Lung Can-
cer, two antibodies have demonstrated activity:
• Bevacizumab is a humanized IgG 1 monoclonal antibody target-
ing all isotypes of the Vascular Endothelial Growth Factor VEGF. 
Its mode of action, by depleting tumor from VEGF is directed 
against neo-angiogenesis. 
• Cetuximab is an IgG 1 chimeric monoclonal antibody targeting 
the Epidermal Growth Factor Receptor EGFR. Binding of Cetux-
imab to EGFR induces receptor dimerization, internalization and 
blockade of signaling for cell division.
Bevacizumab, has been initially evaluated in a small randomized 
ECOG phase II trial for 1st line treatment of advanced NSCLC. An 
improved efficacy was demonstrated at the dose of 15 mg/kg in com-
bination with Paclitaxel-Carboplatin. Toxicity in term of cardiovas-
cular and respiratory events was reported including fatal hemoptysis, 
mainly in proximal squamous cell carcinoma. Further studies were 
therefore conducted in non-squamous histologies. Based on this 
initial phase II, ECOG 4599 was performed: a randomized phase III 
trial comparing Paclitaxel-Carboplatin with or without Bevacizumab 
(15 mg/kg) in first-line treatment of advanced NSCLC. Eligibility 
criteria were restricted to non-squamous histology and absence of 
hemoptysis. On a total of 878 patients, 850 were included in the 
primary analysis. Median survival as a primary end-point showed a 
significant benefit in favor of Bevacizumab as well as Progression-
free Survival (PFS) and response rate (RR). In subgroup analysis, all 
patients benefited from the addition of Bevacizumab except women 
on overall survival (OS). In terms of safety, Bevacizumab increased 
significantly the incidence of grade IV neutropenia, hypertension and 
bleeding mainly hemoptysis despite restrictive inclusion criteria. A 
better selection of patients at baseline, excluding patients with pre-
existing tumor cavitation may reduce the risk if hemoptysis accord-
ing to a recent retrospective analysis of the ECOG trials patient 
population. A second study was performed outside the US comparing 
Gemcitabine-Cisplatin with or without Bevacizumab (AVAIL). Two 
doses of Bevacizumab were explored 7.5 and 15 mg/kg. Inclusion 
criteria were restricted as in the ECOG trial. The results of this study 
showed an improved PFS (primary end-point) and RR, but OS was 
not significantly different among the experimental and the control 
arms. Main toxicities were similar to ECOG with an increased risk of 
neutropenia, hypertension and hemoptysis including fatal hemop-
tysis. Regarding the effect of dose, 7.5mg/kg provided a more signifi-
cant benefit. From the analysis of these 2 trials, the contribution of 
Bevacizumab remains unclear, seems to depend upon the combined 
chemotherapy and should be carefully considered, taking under con-
sideration the added toxicity and extra cost. In addition, the real need 
for maintenance therapy with Bevacizumab single agent, as done in 
the randomized trials requires to be further evaluated. Bevacizumab 
has also been used in combination with Erlotinib, an EGFR-Tyrosine 
Kinase Inhibitor (TKI) in the Beta lung trial in the setting of 2nd line 
therapy and showed an improved RR and PFS, but not OS. Bevaci-
zumab is presently tested in the adjuvant setting (ECOG 1505) and 
plans to accrue 1500 patients over 4 years.
Cetuximab is not as advanced in term of development but random-
ized data are available. Initial small phase II (Lucas) compared 
Vinorelbine-Cisplatin with and without Cetuximab. Adding Cetux-
imab showed a trend of better efficacy on RR, PFS and OS with 
an acceptable tolerance profile. Similarly, Cetuximab was added to 
a Gemcitabine-Platinum backbone chemotherapy (BMS-100) and 
showed an improved outcome on RR, PFS and OS. The contribution 
of Cetuximab was further tested in a phase III trial (FLEX) reported 
at ASCO 2008 in combination with Vinorelbine–Cisplatin. Overall, 
on 1125 patients: Median Survival was significantly improved, as 
well as RR, Time to Treatment Failure, but not PFS. As regard to 
ethnicity, Asian did not benefit from Cetuximab on any parameter. 
The magnitude was larger on Caucasian for all histologies. Toler-
ance was acceptable with however an unexpected high rate of febrile 
neutropenia. Finally an additional phase III (BMS-099) evaluated the 
adjunction of Cetuximab to a Taxane-Carboplatin chemotherapy. The 
primary end-point (PFS) was not met, RR was improved, survival 
is not yet reported. The outcome according to various biomarkers 
including EGFR gene copy number or amplification, EGFR gene 
mutations and Kras mutation have not yet been fully reported but 
preliminary data do not seem to show any difference.
In summary, the contribution of monoclonal antibodies in the treat-
ment of NSCLC remains controversial for Bevacizumab, data on 
Cetuximab seem encouraging but additional data are needed to con-
vince. Interestingly, as opposed to colorectal cancer, the combination 
of both Bevacizumab and Cetuximab with chemotherapy in first-line 
seems feasible in term of safety and the initial results of SWOG 0536 
phase II non-randomized trial are encouraging.
Other monoclonal antibodies are presently evaluated in Non-
Small-Cell Lung Cancer. Panitumumab is a fully human anti EGFR 
monoclonal antibody, so far tested in small non randomized phase II. 
Insulin-Growth Factor1 Receptor is another potential target for treat-
ment and several phase III are on-going with IGF1-R monoclonal 
antibodies. Several of those anti IGF1-R antibodies are under investi-
gation after randomized phase II trials showing an improved outcome 
on RR and PFS. Another, less advanced field of investigation with 
monoclonal antibodies is targeting the death receptor pro-apoptotic 
pathway Trail. In the very early phase of development (phase I) some 
signals were noticed and such antibodies (Apomab, AMG-655) are 
evaluated in randomized phase II trails.
In conclusion, several pathways may be targeted with monoclonal 
antibodies: anti-angiogenesis with Bevacizumab, anti EGFR with 
Cetuximab and Panitumumab, anti IGF1-R and the Trail pro-apop-
totic pathway. These antibodies are most often used in combination 
with chemotherapy, possibly with oral TKI or in combination among 
themselves and offer a new field of investigation at various stages 
for Non-Small-Cell Lung Cancer. Better selection of patients to use 
the appropriate target is needed and search for predictive markers of 
efficacy is mandatory. 
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The merits of traditional bronchoscopic 
transbronchial needle aspiration
Gasparini, Stefano
Azienda Ospedaliera “Ospedali Riuniti”, Ancona, Italy
Transbronchial needle aspiration (TBNA) can be used for medi-
astinal staging of lung cancer and for diagnosis of hilar-medi-
astinal pathologies without evidence of tracheobronchial mucosa 
involvement.
TBNA sensitivity is dependent on several factors as: LN location 
(most of the authors agree that sensitivity is better for right para-
tracheal and subcarinal LNs compared to left paratracheal and high 
paratracheal stations), LN size (the percentage of positive aspirates 
increases linearly with increasing LNs size from 1 cm to 2-2.5 cm), 
number of aspirates performed, presence of rapid on site cytological 
evaluation, nature of the lesions (results are better with carcinoma 
than with benign lesions and lymphoma), prevalence of LNs metasta-
ses, the operator experience and ability.
Two meta-analyses of TBNA have recently been published, report-
ing a sensitivity of 78% (1,2). Considering this sensitivity value, all 
negative or nondiagnostic TBNAs should be considered potentially 
false negatives, and should be further verified.
Despite its variable and non optimal sensitivity, blind TBNA presents 
several advantages.
First of all, there is uniform agreement that the technique has a very 
high specificity (approaching 100%) with very rare cases of false 
positives. This high specificity suggests that a positive TBNA may 
preclude the need for additional surgical staging of the mediasti-
num, with consequent saving of time and reduction of cost and risk. 
Secondly, TBNA can and should be performed at the time of the 
initial routine diagnostic bronchoscopy. In this way, TBNA provides 
the unique opportunity to efficiently diagnose and stage lung cancer 
with one procedure, avoiding the need for supplemental investiga-
tions. Thirdly, multiple lymph node stations can be sampled during 
one procedure, including contralateral LNs and low subcarinal, 
retrotracheal and hilar LN that may be difficult to access surgically. 
Furthermore, TBNA is more cost-effective than surgical staging and 
can be performed in every bronchoscopic suite, without the need of 
expensive technologies.
Numerous publications confirm the safety of TBNA. No case reports 
of mortality related to TBNA have been described. The rare compli-
cations that have been reported are: pneumothorax, pneumomediasti-
num, hemomediastinum, bacteremia and pericarditis. None of these 
complications were determined to be of major clinical consequence.
In addition to lung cancer staging, TBNA can be used also for diag-
nostic purposes both, in lung cancer and in other pathological condi-
tions of the hilar-mediastinal area. In diagnosis of lung cancer TBNA 
is the exclusively diagnostic mean in 18%-38% of patients (3,4).
Other hilar-mediastinal pathological processes that have been diag-
nosed using TBNA are: sarcoidosis, lymphoma, tuberculus adenitis, 
posttransplantation lymphoproliferative disorders, criptococcal infec-
tions, histoplasmosis, goiter, thymoma, mesothelioma, carcinoid, 
metastatic adenopathies.
With the aim of improving TBNA sensitivity, different systems of 
guidance have been developed. CT fluoroscopy, virtual bronchosco-
py, electromagnetic navigation system and bronchoscopic ultrasound 
have all been proposed (5). Among these, ultrasound guidance 
appears to be the most promising tool for improving TBNA accuracy, 
and not surprisingly it is receiving great interest in this clinical field. 
Despite its great value and its capability to improve TBNA sensitiv-
ity, the ultrasound guided TBNA cannot replace traditional TBNA for 
several reasons. The echoendoscope is not suited for performing a 
routine diagnostic bronchoscopy. Conversely conventional TBNA, as 
already mentioned, can be performed during the initial bronchoscop-
ic exploration that is already being performed to establish a diagnosis 
and to examine the airways. In addition, the echoendoscope needles 
are more expensive than traditional needles for TBNA. Furthermore, 
the use of endobronchial ultrasound is not easy and in any case the 
bronchoscopist should be proficient and skilled with traditional 
TBNA before starting to use ultrasound (5). 
Taking into account these considerations, we propose an algorithm 
for optimizing the mediastinal staging of lung cancer (6). In cases 
where mediastinal LNs are enlarged on CT and/or are avid on PET, 
bronchoscopy with traditional TBNA for concurrent diagnosis, 
airway assessment and staging should be performed. If TBNA is 
positive (this happens in more than 70% of cases) there is no need for 
further investigations. If TBNA is negative or equivocal an alterna-
tive mediastinal staging procedure should be considered. 
If available, ultrasound guided TBNA is the alternative staging pro-
cedure of choice. It may be particularly useful when LNs are smaller 
than 1 cm or when there is involvement of high paratracheal LNs 
(stations 2R and 2L: in these locations the trachea has no landmarks 
to help identify the correct point of puncture), where traditional 
TBNA has a low yield. Transesophageal ultrasound guided fine nee-
dle aspiration (EUS-FNA) may also be considered and is particularly 
useful for accessing low subcarinal LN and lower para-esophageal 
LN. If these image-guided techniques are not available, the tradition-
al surgical procedures (mediastinoscopy, anterior mediastinotomy 
or VATS) should be considered as alternative mediastinal staging 
procedures in cases of negative or equivocal TBNA.
In recent years, the continued development of TBNA has changed 
the concept of bronchoscopy. With these advances, the interventional 
pulmonologists’ role in staging lung cancer has greatly expanded. 
Bronchoscopy should now be considered both a diagnostic and medi-
astinal staging procedure (7). Furthermore, for optimal efficiency, 
“blind” TBNA should be performed at the time of initial bronchos-
copy, potentially obviating the need for an additional and perhaps 
more invasive staging procedure. Failure to perform TBNA in this 
fashion is a lost opportunity to stage lung cancer in the most cost-
effectiveness manner possible. Traditional “blind” TBNA should be 
considered as a routine tool and its great value remains unaffected by 
newer techniques such as ultrasound-guided TBNA. These “old” and 
“new” techniques should be considered not alternative but comple-
mentary to optimize the mediastinal staging of lung cancer and the 
diagnostic process of mediastinal pathologies.
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The advantages of endobronchial ultrasound 
guided needle aspiration (EBUS/EUS-TBNA) 
in staging of non-small cell lung cancer
Becker, Heinrich D.
Thoraxklinik at Heidelberg University, Heidelberg, Germany
The decision for appropriate treatment of lung cancer essentially 
depends on the extent of the disease. This comprises evaluation of 
the primary tumor, lymph node inolvement and distant metastasis. 
In localized lung cancer lymph node involvement is decisive for 
the prognosis. Thus exact mediastinal staging is the prerequisite for 
treatment.
For imaging of mediastinal lymph nodes CT has become state of the 
art, where size is the criterion for assumption of involvement. How-
ever, in large studies, size is reliable in only 50%. 25% are underesti-
mated and 25% are overstaged. Thus for exact staging pathomorpho-
logical diagnosis has to be performed.
Staging by mediastinoscopy has been state of the art for decades, 
although bronchoscopic needle biopsy of mediastinal lymph nodes 
(TBNA) was described already 50 years ago. Only after introduc-
tion of TBNA via flexible bronchoscopes the method gained some 
acceptance. Correct staging could be performed in up to 70%, based 
on localization of lymph nodes by CT. Yet, TBNA has been widely 
underused. 
After introducing endobronchial ultrasound (EBUS) for localiza-
tion of mediastinal lymph nodes TBNA results could be improved 
to 85%. Especially development of the dedicated ultrasonic bron-
choscope, enabling real time control of the biopsy needle promoted 
the widespread application of TBNA and increase of results to over 
90%. As lower mediastinal paraesophageal lymph nodes and those at 
the pulmonary ligament are out of reach for EBUS TBNA, recently 
endoesophageal (EUS) TBNA has been combined for staging. By 
these methods today accurracy of 95% can be achieved and as lymph 
nodes out of reach for mediastinoscopy can be approached, in many 
institutions endoscopic ultrasound guided needle aspiration is begin-
ning to replace mediastinoscopy.
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Endoscopic ultrasound guided needle 
biopsy: complementary or first line?
Irving, Louis1, 2
1 Dept Respiratory Medicine, Royal Melbourne Hospital, Melbourne, 
VIC, Australia; 2 Peter MacCallum Cancer Institute, Melbourne, 
VIC, Australia
Summary
Until recently, the diagnosis and staging of non small cell lung can-
cer (NSCLC) have been performed as step-wise, discrete processes. 
Staging of the mediastinum has involved a combination of imaging 
(CT and PET) and surgical (cervical mediastinoscopy and anterior 
mediastinotomy) techniques.
Endoscopic ultrasound guided needle aspiration via the esophagus 
(EUS-FNA) or airways (EBUS-TBNA) have now been shown to 
have similar sensitivity to surgical techniques for detecting malignant 
mediastinal lymph nodes. EUS-FNA and EBUS-TBNA can also be 
used to establish the diagnosis of NSCLC and stage the mediastinum 
in the same procedure. Initially EUS-FNA and EBUS-TBNA were 
seen as competing techniques, but there is now evidence for their 
combined use.
More research is required but it is possible that EUS-FNA and 
EBUS-TBNA will be increasingly used as combined first line tech-
niques during the one procedure, for the simultaneous diagnosis and 
mediastinal staging of NSCLC.
Technique of EUS-FNA
EUS-FNA uses a dedicated endoscope with an ultrasound transducer 
in its tip that allows real-time visualization of lymph node sampling. 
It is usually performed as a day-case with the patient under conscious 
sedation. The procedure takes 20-30 minutes and allows visualization 
of those mediastinal nodes accessible from the esophagus as well as 
the left adrenal gland and left lobe of the liver (1). Patients are dis-
charged after a short period of observation. Complications are very 
uncommon and many series have reported no morbidity (2).
EUS-FNA for mediastinal lymph node staging in lung cancer
More than a decade of experience indicates that EUS-FNA is a 
valuable technique for mediastinal lymph node staging in lung 
cancer. Multiple studies of EUS-FNA in people with lung cancer and 
enlarged mediastinal lymph nodes on CT scanning have demonstrat-
ed a positive predictive value (PPV) greater than 99% and a negative 
predictive value (NPV) of 81% (3). Similar findings occur when 
EUS-FNA is used to assess PET positive mediastinal adenopathy in 
lung cancer patients (4).
False negatives are mainly due to lymph node metastases in regions 
that are difficult to visualize or access using EUS in the esopha-
gus, especially the anterior mediastinum (lymph node stations 3 
and 6) and more distant lymph node sites such as lobar (station 12) 
and interlobar sites (station11). When used to evaluate CT or PET 
positive nodes in the posterior and lower mediastinum (stations 5, 
7, 8 and 9) the PPV, NPV and accuracy are 100%, 94% and 97% 
respectively (5).
These studies show that EUS-FNA alone cannot exclude mediastinal 
lymph node metastases in all cases. However, EUS-FNA combined 
with mediastinoscopy improves intrathoracic staging compared to 
EUS-FNA alone, and this combination has been shown to reduce the 
rate of futile thoracotomies (6,7).
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If EUS-FNA is used as the initial invasive staging modality it can 
reduce the rate of surgical staging procedures by up to 70% with 
significant cost savings (8,9,10). 
Combined EUS-FNA and EBUS-TBNA
A direct comparison of EUS-FNA versus EBUS-TBNA to estab-
lish a tissue diagnosis in enlarged lymph nodes accessible to both 
techniques (2R, 2L, 3, 4R, 4L, 7, 10R and 10L) showed that the EUS 
and EBUS approaches were equal except for the 2R, 4R and 10R 
nodes, where the diagnostic yield of EBUS-TBNA was superior (11). 
Combining both procedures provided a diagnosis in 94% of cases. 
A more recent study combining EUS-FNA and EBUS-TBNA at the 
same procedure also showed that the two procedures had a higher 
estimated sensitivity and NPV compared with either alone (12). 
These and other studies raise the possibility that combined EUS-FNA 
and EBUS-TBNA might completely replace surgical staging of the 
mediastinum, however there is no randomized, controlled data to 
support this.
EUS-FNA and EBUS-TBNA to diagnose lung cancer
Confirming the diagnosis of a peripheral lung cancer can be prob-
lematic because standard bronchoscopy fails to establish a tissue 
diagnosis in up to 30% of cases and CT guided transthoracic needle 
aspiration is not feasible in all cases and is complicated by a pneu-
mothorax in 5-30% of cases. A number of reports have shown that 
EUS-FNA and EBUS-TBNA can be used to diagnose lung cancer, 
by sampling mediastinal nodes, primary tumour directly invading 
the mediastinum or, in the case of EUS-FNA, obtaining cells from 
involved celiac axis lymph nodes and the left adrenal gland (6,8,13). 
A prospective study of EUS as the first test after CT in consecutive 
patients found to have a lung mass showed a diagnostic yield for 
EUS-FNA of 70% overall and higher if there was CT evidence of 
mediastinal or celiac axis metastases (14).
Further studies are being performed to determine the utility of com-
bined EBUS-TBNA and EUS-FNA as the initial invasive diagnostic 
and staging tests for lung cancer. If these studies are successful the 
initial assessment of lung cancer might be simplified, quicker and 
less expensive. 
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Electromagnetic navigation guided biopsy of 
mediastinal lymph nodes – the latest technology
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Abstract: 
Staging of the mediastinum either by invasive or non-invasive tech-
niques should efficiently and accurately determine whether patients 
are candidates for a potentially curative surgical resection, or for 
protocols involving multimodality approaches prior to or instead of 
attempted surgical resection. Newer techniques to stage the medi-
astinum are rapidly evolving, and older techniques, instead of being 
replaced by newer technologies, are being supplemented with infor-
mation that hopefully stratifies patients into categories for the most 
appropriate therapy based on their prognosis. The latest technology 
in this field, electromagnetic navigated lymphnode biopsy will be 
discussed 
Introduction
Lung cancer is one of the most common cancers. Despite the 
advances in surgical treatment and multimodality treatment, lung 
cancer is still the leading cause of death from malignant disease 
worldwide (1).
Accurate staging of the disease is important not only to determine the 
prognosis but also to decide the most suitable treatment plan. During 
the staging process, mediastinal lymph node staging is one of the 
most important factors that affect the patient outcome. Mediastinal 
staging can be divided into noninvasive staging (imaging) and inva-
sive staging (sampling).
Computed tomography (CT), magnetic resonance imaging (MRI), 
positron emission tomography (PET) and PET-CT are used for non-
invasive imaging (2-5).
Other imaging modalities include the use of esophageal ultrasound 
(EUS) and endobronchial ultrasound (EBUS) using a radial probe for 
detecting even small mediastinal lymph nodes (6-7). Invasive staging 
provides a definitive tissue diagnosis by surgical biopsy or needle 
biopsy. Mediastinoscopy is still the gold standard for mediastinal 
lymphnode staging (8-9).
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However, it requires general anesthesia, and complications cannot be 
ignored. Various needle biopsy techniques exist, including conven-
tional bronchoscopic transbronchial needle aspiration (TBNA), EUS-
guided fine-needle aspiration (EUS-FNA), CT fluoroscopy-guided 
TBNA, and EBUS-guided TBNA using the radial probe (10-14). 
Each of these methods has its limitations.
There has been a need for a new modality with a high yield, enabling 
pulmonologists and thoracic surgeons to assess the mediastinum 
easily and safely. In 2003 a new endoscope with built-in linear probe 
ultrasound (US) on the tip enables real-time guidance during TBNA 
was available. 
The newest technique in the possibilities of mediastinal staging is 
electromagnetic navigation and guidance. Advances in technol-
ogy have led to the recent development of a new type of real-time 
guidance for sampling of peripheral lung lesions and lymph node 
tissue. Electromagnetic registration and guidance combines virtual 
bronchoscopy, three-dimensional CT images, and a steerable probe 
to aid in the biopsy of lung lesions.
Electromagnetic Guidance: Technique
An electromagnetic location board is placed under the bronchoscopy 
table. It emits a low frequency electromagnetic field. A sensor probe, 
when within the electromagnetic field and connected to a navigating 
computer, provides data to the computer so that the x, y, and z axis 
coordinates of the tip of the probe are always tracked.
The probe is steerable using cables attached to a rotating knob and 
a lever on the handle. The procedure requires the patient to have a 
spiral CT with thin cuts, usually about 1mm. The CT information is 
uploaded into the navigating computer and a virtual bronchoscopy 
image is created. Prominent anatomical landmarks, such as the main 
carina, are used as ‘fiducial points’, and are located on the CT images 
and on the virtual bronchoscopic images. These are selected by the 
bronchoscopist using a mouse. Bronchoscopy is then performed 
using moderate sedation or general anesthesia.
The sensor probe is fed through an extended working channel of the 
flexible bronchoscope. Endobronchial mapping is next performed 
by touching the probe to an anatomical landmark that corresponds to 
one of the fiducial points previously selected. Usually the first one 
selected is the main carina. When the probe is in contact with the 
main carina, a pedal is stepped on, effectively registering that point 
in the electromagnetic field (x, y, and z coordinate) with the point on 
the CT scan that was selected as a fiducial point (main carina on CT 
image).
Then the probe is piloted to the next fiducial point, and that point is 
registered. Once enough points are mapped in this way, the navigat-
ing computer can effectively map any point in the electromagnetic 
field to its corresponding point on the CT image. This effectively 
synchronizes the real-time bronchoscopy with the 3D radiographic 
images.
Clinical results:
The accuracy of ENB navigation has been proven in animal studies 
(10) and against fluoroscopically verified reference points in humans 
(11). Eberhardt et al. (12) examine the yield of ENB without fluoros-
copy in the diagnosis of peripheral lung lesions and solitary pulmo-
nary nodules. He concluded that ENB can be used as a stand-alone 
bronchoscopic technique without compromising diagnostic yield or 
increasing pneumothorax risk. This may result in sizable timesaving 
and avoids radiation exposure. Marquette et al. (13) confirmed these 
results. Also the French group summarized, that Electromagnetic 
navigation guided bronchoscopy has the potential to improve the 
diagnostic yield of transbronchial biopsies without additional fluoro-
scopic guidance and may be useful in early diagnosis of lung cancer, 
particularly in nonoperable patients.
Until now, only one trial is published about the yield in using the 
technique for lymph node staging. Gilead et al. (14) conducted 
a prospective, open label, single-center, pilot study to determine 
the ability of electromagnetic navigation bronchoscopy to sample 
peripheral lung lesions and mediastinal lymph nodes with standard 
bronchoscopic instruments and demonstrate safety. He enrolled 
60 subjects. Mean navigation times were 7.6 min and 2.2 min for 
peripheral lesions and lymph nodes, respectively. The steerable 
probe tip was navigated to the target lung area in all cases. The mean 
peripheral lesions and lymph nodes size was 22.8 mm and 28.1 mm. 
The yield/procedure was 74% and 100% for peripheral lesions and 
lymph nodes, respectively. A diagnosis was obtained in 80.3% of 
bronchoscopic procedures. A definitive diagnosis of lung malignancy 
was made in 74.4% of subjects. 
The group was able to demonstrate, that Electromagnetic navigated 
lymph node biospy is a safe and effective method for sampling 
mediastinal lesions with high diagnostic yield independent of lesion 
size and location.
Conclusion
Staging of the mediastinal lymph nodes is particularly important 
because it guides treatment decisions and determines prognosis. 
Options for mediastinal nodal staging include CT scanning, PET, 
bronchoscopy with transbronchial needle aspiration (TBNA), elec-
tromagnetic guided lymphnode biopsy, CT guided needle aspiration, 
and mediastinoscopy. Clinical staging with CT and PET offer the 
advantages of being relatively noninvasive. Because of the num-
ber of false positives involved, however, a tissue diagnosis is often 
required before deciding that a patient is not a surgical candidate.
Accurate diagnosis and staging of lung carcinomas is vital for prog-
nostic and therapeutic decision-making. Endobronchial ultrasound 
and electromagnetic navigation are innovations that are safe, mini-
mally invasive, and highly accurate. They may be able to increase 
the diagnostic sensitivity of bronchoscopy for both the diagnosis 
and staging of lung cancer. The body of evidence supporting these 
technologies is growing rapidly. 
Electromagnetic navigation also has potential to improve the sen-
sitivity of lung cancer diagnosis and staging, although the body of 
evidence supporting this technology is much smaller than that for 
EBUS. Preliminary studies have demonstrated its safety and feasibil-
ity. No studies have been performed comparing electromagnetic 
navigation and guidance to EBUS. Initial findings, however, suggest 
that the diagnostic yield may be superior to that of conventional 
bronchoscopy for peripheral nodules and lymph nodes.
The body of evidence is small, however, and there have been 
no direct comparisons between conventional bronchoscopy and 
electromagnetic registration and guidance systems to determine the 
incremental value of this technology.
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The balance between cell survival and cell 
death in lung cancer chemoprevention
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The goals of chemoprevention of cancer are to inhibit the initiation 
or suppress the promotion and progression of preneoplastic lesions to 
invasive cancer through the use specific natural or synthetic agents. 
Therefore, a more desirable and aggressive approach is to eliminate 
aberrant clones by facilitating their death rather than merely slowing 
down their proliferation. Apoptosis represents a genetically well-
controlled programmed death mechanism that plays a crucial role in 
maintenance of tissue homeostasis by eliminating unwanted cells. 
Thus, it represents a universal and exquisitely efficient endogenous 
or induced cellular suicide pathway and can be induced in many 
cell types via numerous physiological, biochemical and/or noxious 
stimuli. Because defects in apoptotic pathways or the inhibition of 
apoptosis play important roles in cancer development or carcinogen-
esis, targeting the induction of apoptosis in premalignant or malig-
nant lesions may selectively eliminate aberrant precancerous clones 
or cancer cells while sparing normal cells. Therefore, the induction 
of apoptosis should be efficient not only for cancer therapy but also 
for cancer chemoprevention. Compared with other strategies that 
merely slow down proliferation, the induction of apoptosis appears 
to be a more desirable and aggressive chemopreventive approach 
to eliminate aberrant clones (1). In this way, some chemopreven-
tive agents with apoptosis-inducing activity can be administered for 
shorter periods of time and at higher doses, which would allow the 
inclusion of agents with some reversible or moderate side effects for 
the prevention of premalignant lesions. 
There are two well characterized apoptotic pathways: the death 
receptor-mediated extrinsic apoptotic pathway and the mitochondia-
mediated intrinsic apoptotic pathway. Both pathways involve the 
activation of a set of caspases, which in turn cleave cellular sub-
strates and result in the characteristic morphological and biochemical 
changes constituting the process of apoptosis (2, 3). The extrinsic 
pathway is characterized by the oligomerization of cell surface death 
receptors and activation of caspase-8, while the intrinsic pathway 
involves the disruption of mitochondrial membranes, the release of 
cytochrome c and the activation of caspase-9. Through caspase-8-
mediated cleavage or truncation of Bid, the extrinsic death receptor 
apoptotic pathway is linked to the intrinsic mitochondrial apoptotic 
pathway (2, 3). These apoptotic pathways are tightly regulated 
by multiple pro-apoptotic (e.g., DR5 and Bax) and anti-apoptotic 
proteins [e.g., cellular FLICE-inhibitory protein (c-FLIP) and Bcl-2]. 
Manipulation of the levels or activity of these proteins will drive 
cells to die or to survive. An increasing number of previously identi-
fied chemopreventive agents were found to induce apoptosis in a 
variety of premalignant and malignant cell types in vitro and in a few 
animal models in vivo (4).
The extrinsic apoptotic pathway plays a critical role in tumor immu-
nosurveillance and thus represents a suitable and attractive target 
for cancer chemoprevention (4). The major components involved 
in the extrinsic apoptotic pathway are death ligands (e.g., TRAIL), 
death receptors (e.g., Fas, DR4 and DR5), FADD, caspase-8 and 
c-FLIP. Ligation of a death ligand with its correspondent death 
receptor or induction of death receptor clustering on the cell surface 
activates the extrinsic apoptotic pathway, leading to cell death. The 
major molecule that blocks the activation of the extrinsic apoptotic 
pathway is c-FLIP, which prevents caspase-8 activation by death 
receptors. There are two major isoforms of c-FLIP: FLIPL consists 
of two N-terminal death effector domains and a C-terminal caspase 
homology domain devoid of enzymatic activity, whereas FLIPS is 
only composed of the N-terminal death effector domains and a short 
C-terminal stretch of amino acids not found in FLIPL (5). It has been 
shown that c-FLIP expression correlates with resistance to death 
receptor-induced apoptosis in a variety of cancer cells, and c-FLIP-
transfected tumor cell lines develop more aggressive tumors in vivo 
(1). In addition, many studies have shown that downregulation of 
c-FLIP is sufficient to confer sensitivity to death receptor-induced 
apoptosis.
Our data show that DR4 and DR5 are universally expressed in both 
normal and malignant human bronchial epithelial (HBE) cells; 
however, c-FLIP levels are low in normal HBE cells and become 
high in premaligant and malignant HBE cells. Enforced downregula-
tion of c-FLIP by small interfering RNA (siRNA) effectively induces 
apoptosis in the malignant HBE cells, but minimally in normal HBE 
cells. These finding suggest that c-FLIP is a good target not only 
for lung cancer therapy, but also for lung cancer chemoprevention. 
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Moreover, we have shown that some chemopreventive agents such 
as non-steroidal anti-inflammatory drugs, triterpenoids, PPARgamma 
ligands and the natural product honokiol effectively downregulate 
c-FLIP levels in addition to increasing the expression of death recep-
tors (e.g., DR5). Accordingly, these agents are able to augment death 
receptor-induced apoptosis (4, 6). 
In summary, understanding the modulation of the death receptor-
mediated extrinsic apoptotic pathway by chemopreventive agents 
and their implications in chemoprevention may provide a rational 
approach for using such agents alone or in combination with other 
agents to enhance death receptor-mediated apoptosis as a strategy for 
effective chemoprevention of lung and other cancers. 
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Emerging models in lung carcinogenesis
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Lung cancer is the leading cause of cancer death worldwide. Primary 
prevention, early diagnosis and development of new therapies are the 
three major avenues for the reduction of mortality from lung cancer. 
One of the main challenges in the field of lung cancer is the design 
of successful strategies to prevent or inhibit the progression of the 
disease in high risk individuals. Chemoprevention for lung cancer 
in high risk populations has been the object of several studies in 
the past, but have not yet rendered the expected outcome. Recently, 
several independent groups have reported lung cancer susceptibil-
ity loci using SNP genome-wide association studies (Amos et al 
2008). Susceptibility-associated SNPs could be used together with 
environmental (tobacco exposure) and clinical parameters to build a 
quantitative lung cancer risk model. Several groups, including ours 
at the University of Navarra, have shown that airway obstruction 
(COPD), chronic inflammation and/or emphysema may be also used 
as a risk indicator for lung cancer (De Torres et al Chest 2007). These 
recent data have raised hopes for a more successful risk stratification 
of smokers in the future, which could lead to a more effective imple-
mentation of lung cancer screening and chemopreventive protocols. 
In our presentation we will focus on the available and newly emerg-
ing tools for the development of new chemopreventive interventions 
for lung cancer. These interventions are based on agents which are 
generally evaluated both in vitro (by means of cell lines), and in vivo 
(using animal models). The in vitro cell models are always the first 
step of the process to assess the efficacy of a given chemotherapeutic 
or chemopreventive intervention. The in vitro models most frequent-
ly used are based on standard cell cultures. However, protocols are 
being established to culture these cells in 3D multi-cellular spheroids 
and to develop new 3D models of differentiation of immortalized 
human bronchial epithelial cells (Vaughan et al Differentiation 2006), 
which may be good reagents for research in cancer progression. The 
in vivo analysis in animal models is an invariable recommendation of 
regulatory agencies prior to human trials for any agent. Either chemi-
cally induced or genetically generated lung cancer rodent models, but 
rarely human lung cancer xenografted mice, are used for the in vivo 
assessment of chemoprevention strategies. 
In our presentation we will briefly summarize the classical lung 
cancer models induced by chemical carcinogens on susceptible mice 
strains and rats, as well as the genetically modified mouse models. 
There are a number of well established chemically induced lung 
cancer models using several carcinogens, such as urethane, NNK, 
BaP, or vinyl carbamate, that give mainly adenomas but also some 
adenonarcinomas. All of them have been used to assess the preven-
tive potential of a variety of agents (Pereira et al Int J Cancer, 2006; 
Orita et al Clin Cancer Res 2008, Yan et al Neoplasia 2007, Anderson 
et al Carcinogenesis 2008, etc.). NCTU is one of the few carcinogens 
that give rise to squamous cell carcinomas in susceptible mice (Wang 
et al Cancer Res 2004). On the other hand, genetically modified 
mouse models for lung carcinogenesis are now available carry-
ing single or combined alterations in lung cancer key genes, either 
oncogenes or tumor suppressors. Among the first genetically modi-
fied mouse models for lung cancer are those based on the regulated 
expression of mutated k-Ras (Jackson et al Genes and Development 
2001). Some years ago a mouse model for SCLC was developed by 
conditional inactivation of Rb1 and Trp53 in mouse lung epithelial 
cells (Meuvissen et al Cancer Cell Sept 2003). More recently, geneti-
cally engineered mice with EGFR (Ji et al Cancer Cell 2006, Politi et 
al Genes Dev 2006), b-Raf mutations (Ji et al Can Res 2007), LKB1 
inactivation (Ji et al Nature 2007) or EML4-ALK gene fusion (Soda 
et al PNAs 2008) have been shown to develop lung carcinomas. 
Several models of lung cancer metastasis recapitulating local (to the 
thoracic cavity) or distant dissemination to brain, bone and adrenal 
medulla are also available and have helped in the identification of 
key mediators of the metastatic cascade (Vicent et al Can Res 2008) 
Finally, the role of smoking induced inflammation in lung carcino-
genesis is being unveiled thanks to newly available animals models 
for inflammation-driven lung carcinogenesis (Malkinson, Exp Lung 
Res 2005, Blanco et al 2007, Walser et al Proc Am Thor Soc. 2008, 
Moghaddam et al Am J Respir Cell Mol Biol 2009). 
Although some of these elegant models may be extremely useful to 
understand the biological mechanisms linking these gene alterations 
to lung cancer, their potential relevance in the context of chemo-
prevention is still being explored (Abate-Shen et al. Can Prev Res 
2008). A critical aspect for the importance of these models in chemo-
prevention is the extent to which they recapitulate the actual multi-
step carcinogenesis process present in human lung cancer, and the 
degree of similarity at the cellular and molecular level between the 
carcinogenic mechanism in a given animal model and the long and 
multi-factorial process which very likely drives human lung carcino-
genesis. Human bronchial and bronchioloalveolar carcinogenesis is a 
multicentric and multistep process, leading to a sequential accumula-
tion of molecular and genetic abnormalities, mainly due to exposure 
to tobacco carcinogens. Concomitantly, a series of morphological 
alterations of normal bronchial or bronchioloalveolar epithelium 
occur, resulting in preneoplastic and then neoplastic lesions (Lan-
tuejoul et al 2009). The pathological and molecular similarities and 
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differences of the available animal models as compared to human 
lung cancer will be discussed.
Finally, in addition to showing reasonable similarity to the human 
counterpart, the best murine models for chemoprevention testing 
should allow for ready determination of tumor progression. Assess-
ing progression is relatively easy for tumors or preneoplastic lesions 
that are superficial (for example, breast or skin), but is more difficult 
for tumors of internal organs such the lung. Serial measurements of 
progression, however, may allow for the determination of impor-
tant features with regard to the efficacy of the chemopreventive or 
therapeutic agents that are complex to analyze longitudinally in 
human patients. New imaging technologies such as micro computer-
ized tomography (CT) scans for small animals are currently being 
developed to perform longitudinal studies on animal models of 
lung cancer. Micro CT has been mainly used for the assessment of 
tumor response to therapeutic drugs. Standardization of protocols, 
better resolution, more robust image acquisition and interpretation 
algorithms and criteria are still required if microCT imaging is to be 
incorporated to the chemoprevention armamentarium.
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Aurorakinase inhibitor + radiation for NSCLC
Lu, Bo
Vanderbilt University, Nashville, TN, USA
Aurora kinases are key modulators for cell division. Elevated levels 
of these molecules were observed in lung cancer tissues and were 
associated with poor clinical outcomes. Lung cancers also harbor 
stem cells that are responsible for therapeutic resistance and distant 
metastases. We found that cancer stem cells are enriched following 
cisplatin or radiation treatment. These cells are more resistant to radi-
ation and failed to undergo radiation-mediated apoptosis. However, 
these stem cells exhibit higher levels and activities of aurora kinases. 
In addition, these resistant stem cells were effectively sensitized to 
radiation by aurora kinase inhibitors. Our data provide preclinical 
rationale for integrating aurora kinase inhibitors into current chemo-
radiation regimens for treating locally advanced lung cancer.
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PARP inhibition and tumour radio sensitivity
Stratford, Ian1; Senra, Joana1; Telfer, Brian1; Wedge, Steve2
1 University of Manchester, Manchester, UK; 2 Astra Zeneca Plc, 
Alderley Park, UK
It has long been known that DNA repair deficiencies can have a 
major impact on radiation sensitivity. However, exploiting this for 
potentially improving radiotherapy has not yet made any major 
impact.
The enzyme Poly (ADP) ribosyl transferase (PARP) is an important 
component of the base excision repair (BER) pathway. The enzyme 
is recruited to sites of single strand breakage where its activity 
stimulates the assembly of proteins which together facilitate repair of 
DNA damage. Inhibition of PARP activity increases the sensitivity 
of cells to treatment with mono-functional alkylating agents, such as 
temazolomide, and to treatment with ionizing radiation.
More recently inhibition of PARP has been used to develop the 
concept of synthetic lethality. This is based on the fact that cells not 
only engage the BER pathway to repair DNA strand breaks but also 
can utilize Homologous Repair (HR) which is the process but which 
DNA double strand breaks arising at replication are repaired during 
S-phase. Thus, HR deficient cells can be exquisite sensitive to PARP 
inhibition.
In the context of the relationship between PARP inhibition, HR defi-
ciency and radiotherapy, a number of important observations have 
been made. The first of these is that inhibition of PARP can substan-
tionally increase the radiosensitivity of xenografted human tumours 
in mice (Calabrese etal, PNAS, 2004, 96, 56-67). A contributory, 
radiobiological mechanism for this is the ability of PARP inhibi-
tors to inhibit repair of potentially lethal radiation damage (PLD). 
However, a physiological effect of PARP inhibition may make an 
even greater contribution to overall tumour radiosensitivity. Here the 
underlying mechanism is to increase overall tumour oxygenation. We 
have demonstrated this, using the dorsal window chamber in mice, to 
be due to inhibitor-induced changes in tumour vascular dynamics.
A second relevant observation was made by Sprong etal (Int J Radiat 
Oncol Biol Phys, 2006, 64,562-572) who showed that cells lacking 
HR capability not only showed greater sensitivity to radiation but 
also showed a much reduced Oxygen Enhancement Ration (OER) 
when compared to cells with an intact HR system. Our contention 
is combining PARP inhibitors with radiation to treat HR deficient 
tumours will reduce the OER further and potentially eliminate it 
altogether.
HR deficiency can predispose to tumour formation in a wide variety 
of sites including lung. However, this may be a repair deficiency that 
is potentially exploitable. We therefore hypothesize that PARP inhibi-
tion when combined with radiotherapy may provide real therapeutic 
benefit, particularly in tumours lacking HR. This will be due to the 
dual effects on oxygen delivery and a much reduced OER. Evidence 
supporting this hypothesis will be presented. 
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Imaging with 18F-3-deoxy-3-fluoro-l-thymidine (FLT) 
positron emission tomography in patients with lung cancer 
MacManus, Michael P.
Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia
Structural imaging, in the form of CT scanning, has long been a 
cornerstone of non-invasive lung cancer staging and has been the 
primary means of assessment of clinical response to treatment with 
radiation therapy (RT) and chemotherapy. CT imaging has well-
known drawbacks in lung cancer imaging, including poor sensitivity 
and specificity for the detection of intrathoracic lymph node (LN) 
metastasis, relatively poor sensitivity for detecting distant metastasis 
and a relatively slow imaging response to therapy, often confounded 
by the presence of atelectasis and/or radiation-induced pneumonitis 
and fibrosis. Residual fibrotic masses may remain after RT even in 
cured patients. CT imaging during and after chemotherapy or RT 
provides no information on the effects of RT on tumor metabolism 
or cellular proliferation. Because tumors consist of inflammatory and 
supportive tissues as well as tumor cells, imaging studies that only 
allow measurement of tumor volume provide only partial informa-
tion on the response of a tumor to therapy.
Molecular imaging with 18F-fluoro-2'-deoxy-d-glucose (FDG) PET 
scans is becoming increasingly widely-used for the staging of lung 
cancer, especially for non-small cell lung cancer (NSCLC). FDG-
PET has been proven to be more accurate for primary staging of 
lung cancer and is superior to PET for the assessment of response to 
definitive chemoradiation. It can also provide a very early indication 
of response to chemotherapy. Preliminary data suggest that serial 
FDG-PET imaging performed during a course of RT can give useful 
prognostic information and could potentially be used to modify treat-
ment delivery in a response-adapted fashion. Despite its excellent 
sensitivity and specificity, FDG is not a highly selective tracer for 
cancer imaging, as it is also taken up by activated macrophages and 
other cells involved in inflammatory processes. 
A newer radiopharmaceutical, 18F-3'-deoxy-3'-fluoro-l-thymidine 
(18F-FLT), was developed with the intention of imaging prolifera-
tion in tumors. This molecule is phosphorylated by thymidine kinase 
1 (TK1), after which it becomes trapped within the cell. Because 
TK1 concentration increases almost tenfold during the S phase of 
the cell cycle at the time of DNA synthesis, 18F-FLT uptake reflects 
the proliferation rate of cells. In NSCLC there is a close correlation 
between the uptake of 18F-FLT and immunohistochemical measures 
of cellular proliferation. Preliminary studies have suggested that 
18F-FLT can detect dose-dependent changes in tumors and surround-
ing organs in patients receiving chemo-RT for colorectal cancer. In a 
study of murine breast cancer, changes in FLT uptake occurred soon 
after irradiation. 
At our center, a clinical trial was initiated to investigate changes in 
18F-FLT during chemoRT for NSCLC using serial PET/CT imaging. 
The aims of the study were to investigate the possibility that cellular 
proliferation of lung tumors could be imaged during a course of radi-
ation therapy and to explore the possibility that personalized changes 
in therapy could potentially be made in future, based on the prolifera-
tive response to chemoRT. We also considered the possibility that, if 
accelerated repopulation occurred during RT, it could influence the 
measured uptake of FLT serial PET scans during therapy.
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In an initial pilot study, five patients with locally-advanced NSCLC 
underwent serial F-FLT PET/CT scans during chemoRT. Baseline 
18F-FLT PET/CT scans were compared to routine staging 18F-FDG-
PET/CT scans. Each patient subsequently had two FLT-PET scans 
during therapy. These scans were performed on days 2, 8, 15 or 
29, providing a range of time-points for response assessment. In 
all five patients, baseline lesional uptake of 18F-FLT on PET/CT 
corresponded to staging 18F-FDG PET/CT abnormalities in the 
primary tumor, although tumor to background ratios were lower 
with FLT than with FDG. Tumor FLT uptake was observed on five 
of nine (55%) on-treatment scans, on day 2, 8 and 29, but not day 
15. A ‘flare’ of 18F-FLT uptake in the primary tumor of one case 
was observed following 2 Gy of radiation. The remaining eight on-
treatment scans demonstrated a mean reduction in 18F-FLT tumor 
uptake of 0.58 x baseline. A marked reduction of 18F-FLT uptake in 
irradiated bone marrow was observed for all cases and was appar-
ent after only 2 Gy. All patients demonstrated a complete absence of 
detectable proliferation in bone marrow after 10 Gy, suggesting that 
FLT imaging is a sensitive marker of radiation associated bone mar-
row toxicity. This pilot study has led to the development of a larger 
study, currently under way, in which patients will undergo serial 
imaging during therapy with both FDG and FLT. Early experience 
with FLT-PET suggests that important information on the biology 
of tumor response to chemoradiation may be obtained, but it is too 
early to tell if this imaging modality will be clinically useful during a 
course of therapy.
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Targeting the IGF-1R in lung cancer 
prevention and therapy
Owonikoko, Taofeek K.; Ramalingam, Suresh ; Sun, Shi-Yong;  
Khuri, Fadlo R.
Emory University School of Medicine, Winship Cancer Institute, 
Atlanta, GA, USA
The insulin-like growth factor receptor is an exciting new target for 
lung cancer. Insulin-like growth factor-1 receptor (IGF-1R) expres-
sion is widespread in lung carcinogenesis and appears to peak after 
the development of lung cancer. The IGF-1R is a transmembrane 
heterotetrameric protein, encoded by the IGF-1R gene located on 
chromosome 15q25-q26. IGF-1R promotes oncogenic transforma-
tion, growth and survival of cancer cells. The binding of insulin-like 
growth factor (IGF) I and IGF-II to the extracellular subunit domain 
of IGF-1R activates the tyrosine kinase activity of IGF-1R and trig-
gers a cascade involving several critical signal transduction path-
ways, including Ras/Raf, met-kinase and PI3-kinase/AKT/mTOR.1 
Evidence to date indicates that high co-expression of IGF-1R with 
the epidermal growth factor receptor (EGFR) is associated with a 
shorter disease-free survival in resected non-small cell lung cancer 
(NSCLC) patients,2 and high expression levels of IGF-1R interfere 
with the anti-tumor activity of erlotinib, an EGFR tyrosine kinase 
inhibitor (TKI).3 
With the increase in the number of EGFR mutant lung cancers 
detected, particularly in Eastern Asia, and also in Europe, the Middle 
East, and North America, the use of erlotinib and gefitinib, the two 
first generation EGFR-TKIs has increased significantly. Several stud-
ies are currently underway to evaluate combinations of EGFR and 
IGFR inhibitors for the therapy of advanced NSCLC. 
To date, several new approaches targeting IGFR have been devel-
oped. Both small molecule TKIs and monoclonal antibodies have 
been brought forward, with the most advanced of these an anti-
IGF-1R antibody, CP-751,871 which was used in combination with 
paclitaxel and carboplatin in patients with NSCLC.4 This trial treated 
a total of 156 on a randomized portion with safety and efficacy data 
available on 151 patients. Fifty-four percent of patients treated with 
the combination of paclitaxel, carboplatin, and anti-IGFR therapy in 
this trial had objective responses with the response rate notably, very 
high in squamous cell tumors. Given the evidence to date that IGFR 
represents an important resistance pathway for EGFR inhibitors5 and 
the importance of both IGFR signaling and EGFR signaling in lung 
carcinogenesis,6-8 approaches considering combinations of IGFR and 
EGFR inhibitors in cancer chemoprevention as well as therapy have 
begun to develop.
Our data to date indicate that prolonged treatment with inhibitors of 
the mammalian target of rapamycin (mTOR) leads to an increase in 
signaling through PI3-kinase/AKT,9 and we and other investigators 
have proposed combining PI3-kinase/AKT/mTOR inhibitors with 
IGFR inhibitors. The purpose here is to develop enhanced pathway 
blockade through the targeting of pharmacologically-enhanced 
oncogene addiction. The theory of oncogene addiction developed by 
Bernard Weinstein, suggests that cancer cells are disproportionately 
dependent on a discreet number of signaling pathways.10 Evidence 
to date suggests that blockade of the distal end of the PI3K/AKT/
mTOR axis leads to increased dependence on AKT signaling,9 and 
that this can be therapeutically exploited through combinations of 
mTOR inhibitors with PI3K/AKT inhibitors or with growth factor 
receptor inhibitors including IGF-1R and EGFR inhibitors.11 Data 
showing progress in this area will be presented at the meeting.
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Chemoprevention: EGFR targeted agents
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Beyond smoking cessation, there are no currently proven strategies 
for reducing risk of developing lung cancer. The development of 
chemopreventive agents for lung cancer would have a significant 
impact on lung cancer morbidity and mortaliy. For effective chemo-
prevention, a high risk population must be defined and effective and 
well-tolerated chemoprevention agents identified. High risk popula-
tions for lung cancer include current and ex-smokers, especially 
those with obstructive lung disease, and survivors of a tobacco 
induced malignancy. No effective chemoprevention agents have been 
described. Prior to choosing agents for phase III chemoprevention 
studies, evidence from epidemiologic, biologic ,preclinical and phase 
II intermediate biomarker investigations must be carefully evaluated.
EGFR tyrosine kinase inhibitors (TKI) are attractive chemopreven-
tive agents. NSCLC tumors frequently express EGF receptors and 
ligands. Premalignant dysplasias also express EGF receptors, with 
increasing expression with higher grades of dysplasia. Tumors with 
activating EGFR mutations or gene amplification often display 
dramatic responses to EGFR TKIs. Both EGFR mutation and 
gene amplification have been described in premalignant airway 
epithelium.
Several groups, including ours, have described preclinical chemo-
prevention experiments using EGFR TKIs. Most of the models have 
been based on activating K-ras mutations, which may bias against 
EGFR TKI efficacy. The majority of these reports have described 
fairly minor chemopreventive activity. One group has developed a 
genetic model based on SPC promoter driven expression of an acti-
vated K-ras gene with impressive results.
To date, no phase II trials of EGFR TKIs have been reported. We 
have developed a trial of EGFR TKI with endobronchial histology 
as the endpoint in patients receiving these agents for therapy of 
advanced NSCLC. Accrual has been poor to date, but one patient was 
enrolled and showed no improvement in extensive airway dysplasia 
after 6 weeks of erlotinib. 
To assess EGFR TKIs further for chemoprevention, creative study 
designs must be developed. Endobronchial histology may not be the 
best endpoint; CT detected ground-glass opacities in patients with a 
previous adenocarcinoma or bronchioloalveolar carcinoma may be 
more productive.
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COX/LOX inhibition
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Lung cancer is the leading cause of cancer death in the world. Close 
to 90% of lung cancer cases are caused by tobacco smoking. Unfor-
tunately, smoking cessation does not completely eliminate the risk of 
lung cancer. In fact, more lung cancers are being diagnosed in former 
smokers than active smokers in recent years. The lack of effective 
therapy has intensified research efforts toward chemoprevention. 
Chemoprevention refers to the use of specific agents to reverse, sup-
press, or prevent the process of carcinogenesis, thereby preventing 
the development of cancer. 
It has become increasingly clear that ongoing, chronic inflammation 
contributes to lung carcinogenesis, as many inflammatory-mediated 
events share similar mechanisms that are known to occur during 
multi-step carcinogenesis. Eicosanoids are key mediators of the 
inflammatory response and aberrant productions of eicosanoids have 
been implicated as major driving forces in malignant transformation. 
Eicosanoids are lipid metabolites that derive their names from their 
common origin, the eicosaenoic acids, which are C20 polyunsatu-
rated fatty acids. The major precursor Arachidonic acid (all-cis-
5,8,11,14-eicosatetraenoic acid) is metabolized to prostaglandins 
(PG) by the cyclooxygenase (COX) pathway, while leukotrienes are 
formed via the lipoxygenase (LOX) pathway. These down stream 
lipid metabolites are thought to be involved in carcinogenesis, and 
ample preclinical findings support modulations of arachidonic acid 
pathways for inhibition of carcinogenesis. 
There are two main isoforms of COX: COX-1 and COX-2. COX-1 
exists in most cells and is constitutively active. In contrast, COX-2 
is an inducible enzyme that is upregulated by carcinogens such as 
tobacco smoke, as well as other inflammatory and mitogenic stimuli. 
COX-2 is primarily responsible for the overproduction of PG in 
inflamed, as well as neoplastic tissues. Overproduction of PGE2 
is associated with a variety of carcinogenic mechanism, including 
abnormal expression of epithelial growth factors, epithelial and 
microvascular proliferation, resistance to apoptosis and inhibition of 
antitumor immunity.
COX-2 expression has been demonstrated in premalignant bronchial 
tissue and lung cancer. Patients with higher levels of COX-2 expres-
sion in their tumors have a poorer prognosis. In murine models, 
COX-2 inhibition impedes lung tumorigenesis, decreases the rate of 
growth of lung cancer and number and size of metastasis. Expression 
of COX-2 has been shown to enhance tumorigenesis by regulation 
of angiogenesis via CXC chemokines and EGFR, invasion via CD44 
and matrix metalloproteinases, apoptosis via survivin and insulin like 
growth factor, and anti-tumor immunity via IL-10 and IL-12. 
Recently, several clinical trials addressing the use of Celecoxib, 
a COX-2 inhibitor, for lung cancer chemoprevention have been 
conducted. Results from a pilot, phase IIa trial in high-risk smokers 
performed at UCLA suggest that Celecoxib is capable of modulat-
ing surrogate endpoint biomarker (SEBM) with reduction of PGE2 
production, restoration of anti-tumor immunity and reduction of 
proliferation indices (Ki-67 labeling index). A follow-up larger phase 
IIb trial focusing on heavy former smokers is evaluating the effect 
of Celecoxib on cellular and molecular events associated with lung 
carcinogenesis. Another phase IIb trial of Celecoxib in current and 
former smokers has been completed at MD Anderson Cancer Center. 
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Preliminary findings indicate a favorable reduction of Ki-67 expres-
sion, the primary endpoint in bronchial epithelium. Moreover, a 
multi-center study using Sulindac, a nonspecific COX inhibitor, with 
Mayo Clinic as the lead center is ongoing.
5-lipooxygenase (5-LOX) is the enzyme involved in the conver-
sion of arachidonic acid to leukotrienes. Leukotrienes have been 
implicated to play a prominent inductive role in lung carcinogenesis. 
This is based on data demonstrating that 5-LOX is expressed in lung 
cancers and 5-LOX inhibitors reduced the multiplicity and incidence 
of lung tumors in mice. A Phase II Clinical trial of the 5-LOX inhibi-
tor Zileuton has been conducted at the Karmanos Cancer Institute 
addressing the effect of Zileuton on bronchial dysplasia and multiple 
SEBM in at-risk smokers or patients with curatively treated aerodi-
gestive cancers.
Numerous phase II clinical studies evaluating promising agents in 
lung cancer chemoprevention are underway. Data from lung cancer 
chemoprevention trials with Celecoxib are emerging. Findings from 
these trials will undoubtedly influence the next generation of lung 
cancer chemoprevention trials. Some of the important goals for 
future chemoprevention trials include devising strategies to improve 
the selection of high risk participants, minimize toxicity, identify 
and validate appropriate SEBM. To this end, integration of diagnos-
tic technologies such as fluorescence bronchoscopy and spiral CT, 
molecular profiling of risks, using high-throughput technology such 
as genomics microarray, gene expression profiling and proteomics, 
for therapeutic stratification and monitoring, will collectively facili-
tate the development of effective paradigms for prevention, early 
detection and management of lung cancer. 
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Adjuvant chemotherapy
Hanna, Nasser
Indiana University, Indianapolis, Indiana, USA
Surgery continues to provide the best hope for cure for patients with 
stage I, II and select patients with stage III non-small cell lung cancer 
(NSCLC). Five-year survival rates for stage I and II disease vary 
from 57-67% and 39-55%, respectively. Patients with completely 
resected stage III disease have 5 year survival rates of approximately 
25% [1]. While surgery remains the cornerstone of treatment for 
early stage NSCLC, many patients suffer a relapse and subsequently 
succumb to metastatic disease months or years after surgery. There 
is a growing body of evidence that adjuvant chemotherapy results 
in prolonged survival and improved cure rates compared to surgery 
alone. As a result of these trial results, adjuvant chemotherapy with 4 
cycles of a platinum-containing regimen is standard of care treatment 
for patients with resected stage II and III NSCLC and select patients 
with resected stage IB disease. The relative risk reduction for relapse 
observed with adjuvant chemotherapy in lung cancer appear similar 
to that seen in breast and colon cancer clinical trials.
Trials from the 1970’s and 80’s evaluating adjuvant chemotherapy 
in NSCLC failed to consistently demonstrate a survival benefit over 
surgery alone. Most of these trials evaluated alkylating agents and 
biological response modifiers that have little efficacy in NSCLC. A 
meta-analysis published in 1995 containing 4,357 patients exam-
ined 14 trials using adjuvant chemotherapy [2]. The authors found 
decreased survival with older regimens utilizing alkylating agents 
and a trend towards improved survival with platinum-based chemo-
therapy. Eight of these trials (1,394 patients) contained cisplatin-
based regimens. Six of the eight trials favored the use of adjuvant 
cisplatin-based therapy with an overall hazard ratio of 0.87 (p=0.08). 
Five year overall survival was increased by 5% (p=0.08). While this 
data was provocative, routine use of adjuvant platinum chemother-
apy could not be recommended based upon a subgroup analysis of 
a meta-analysis. Furthermore, the majority of these trials examined 
a small number of patients in an era when preoperative staging was 
often inadequate and platinum-based chemotherapy was associ-
ated with substantial toxicity, especially in the lung cancer popula-
tion treated with surgery. In 2002 results from the Adjuvant Lung 
Project Italy (ALPI) trial underscored the difficulty in delivering 
adjuvant chemotherapy to patients with lung cancer [3]. In this study, 
patients (n=1209) with completely resected stage I, II, IIIA disease 
were randomized to receive adjuvant treatment with three cycles of 
mitomycin C, vindesine, and cisplatin or a control group. Patients 
were allowed to receive radiation beginning 3-5 weeks following 
chemotherapy at the discretion of the treating center (43% received 
radiation). There was no significant difference in overall survival 
between the groups (hazard ratio 0.96, p=0.589). These data sup-
ported the continued use of observation as a control arm for future 
studies in this disease setting.
The largest trial to date of adjuvant chemotherapy in NSCLC was 
published in 2004 and represented a paradigm shift in the manage-
ment of patients with resected NSCLC. The International Adjuvant 
Lung Trial (IALT) enrolled 1,867 patients from 1995-1999 [4]. 
Patients with completed resected stage I, II, or III disease were 
eligible for randomization. The study design allowed flexibility in the 
selection of which stages of disease to include, the dose of cisplatin 
given per cycle, and the agent to be combine with cisplatin. Choices 
of doublet agent included etoposide (56%), vinorelbine (27%), 
vinblastine (11%), or vindesine (6%). Adjuvant radiation given 
sequentially to chemotherapy was planned for approximately 31% of 
the study population. The hazard ratio for death was 0.86 (p<0.03) 
favoring the chemotherapy group. Five-year survival rates for the 
chemotherapy group and the control group were 44.5% and 40.4%, 
respectively. The positive results from this trial were consistent with 
the small survival advantage suggested in the meta-analysis with 
cisplatin-based adjuvant chemotherapy. 
Shortly after the results from the IALT were reported, 2 North 
American trials were completed, each of which supported the use 
of adjuvant chemotherapy in early stage disease. The Cancer and 
Leukemia Group B (CALGB) 9633 study randomized 344 patients 
with completely resected stage IB (T2) disease to receive 4 cycles of 
adjuvant paclitaxel and carboplatin or observation from 1996-2003 
[5]. The goal of this trial was to treat “higher risk” stage I patients 
(approximately 30% develop distant disease) that would be more 
likely to benefit from adjuvant chemotherapy. Compared to previous 
trials, compliance was high with 85% of patients completing all four 
cycles of chemotherapy and 65% received no dose reductions. There 
were no chemotherapy related deaths. The study was terminated after 
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an interim analysis showed a statistically significant benefit favoring 
treatment, although 90% of the accrual goal had been reached. With 
further follow-up time, however, overall survival was not significant-
ly different (HR 0.83, p=12). However, an unplanned subset analysis 
from this trial suggested that patients with larger tumors (>4cm) 
experienced a survival advantage with adjuvant chemotherapy (HR 
0.69, p=0.043).
The U.S. Intergroup JBR.10 study was led by the National Cancer 
Institute of Canada (NCIC) [6]. From 1994-2001 a total of 482 
patients with completely resected (68% underwent lobectomy) stage 
IB or II (excluding T3N0) disease were randomized to receive either 
four cycles of adjuvant cisplatin and vinorelbine or no treatment. 
Sixty-five percent of the patients received 3 or 4 cycles of chemo-
therapy. Despite the relatively high risk of delivering adjuvant che-
motherapy following thoracotomy, only two deaths were attributed 
to treatment. Overall survival in the treatment group was 94 months 
compared to 73 months in the observation group (p=0.012). Five-
year survival also improved from 54% to 69% (p=0.0022). 
Further evidence supporting the use of post-operative chemotherapy 
was presented in 2005. The ANITA trial reported by Douillard et 
al randomized 840 patients with resected stages IB-IIIA non-small 
cell lung cancer to receive adjuvant cisplatin and vinorelbine versus 
observation [7]. Overall compliance in this adjuvant trial was rela-
tively low with 75% and 56% of planned cisplatin and vinorelbine 
given, respectively. Despite this, the final analysis showed a benefit 
for those receiving adjuvant therapy in stage II and IIIA disease. 
Collectively taken, these trials consistently demonstrate a small, but 
statistically significant and clinically important survival gain with the 
use of cisplatin-based adjuvant chemotherapy. The LACE Collabora-
tive Group performed a pooled analysis on data from the 5 largest 
trials utilizing cisplatin-based therapy [8]. The overall HR of death 
was 0.89 (p=0.005) which corresponded to a 5.4% survival benefit at 
5 years with cisplatin-based chemotherapy. The benefit was not seen 
in stage IA or IB disease, but was for stage II and III disease. There 
was no interaction between chemotherapy effect and sex, age, histol-
ogy, type of surgery, or cisplatin dose.
Non-platinum based adjuvant chemotherapy has also been studied. 
Uracil/Tegafur (UFT) is an oral 5-FU derivative plus uracil mixed 
in a 1:4 ratio. Based upon a favorable side effect profile, ease of 
administration, and the hypothetical benefit of continued adminis-
tration of chemotherapy against the cancer growth cycle, several 
studies from Japan have tested this agent in the adjuvant setting. Four 
initial studies produced conflicting results with modest benefits seen 
in stage I patients with adenocarcinoma [9-12]. In 2004, Kato et al. 
published the largest trial to date comparing UFT vs. placebo [13]. 
A total of 979 patients were enrolled from 1994-1997 and random-
ized to receive either oral uracil-tegafur for two years or observation. 
Patients that had undergone complete resection of a pathologically 
documented stage I (T1 or T2) adenocarcinoma of the lung were eli-
gible for randomization. The five-year overall survival rate was 88% 
in the UFT group and 85% in the observation group (p=0.047). This 
survival benefit was seen almost exclusively among patients with 
T2 disease (five year survival rates of 85% vs. 74% favoring UFT). 
Despite its ease of administration, compliance with UFT was poor in 
that only 61% completed two years of therapy. 
Hamada et al. presented a meta-analysis of six UFT trials [14]. A 
total of 2,003 patients were enrolled from 1985-1997 and random-
ized to surgery alone or surgery followed by adjuvant UFT. The use 
of UFT was associated with a hazard ratio of 0.74 (p=0.001) favoring 
adjuvant UFT. Five and seven year overall survival rates were 81.8% 
and 76.5% for the UFT group and 77.2% and 69.5% for the con-
trol group, respectively. Experience with UFT in North America is 
extremely limited because this agent has not been approved for use. 
While adjuvant chemotherapy is considered standard of care for 
patients with resected stage II and III NSCLC (and select patients 
with stage IB disease), the overall survival gains are modest (5% 
at 5 years) in the general patient population. Efforts to determine 
who is at high risk for relapse based upon molecular characteristics 
are being actively pursued. Olaussen et al conducted an analysis of 
patients treated on the IALT trial to determine whether immunohis-
tochemical analysis of the expression of the excision repair cross-
complementation (ERCC1) protein could predict for tumor recur-
rence and/or benefits with adjuvant cisplatin-based chemotherapy 
[15]. In this analysis of 761 tumors, ERCC1 expression was positive 
in 44% of patients. The benefit from cisplatin-based adjuvant chemo-
therapy was only associated with the absence of ERCC1 (p=0.009). 
Validation of this result in prospective trials is warranted. Other 
investigators have evaluated gene expression profiles and their asso-
ciation with survival in patients with resected lung cancer [16,17]. 
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Among completely resected NSCLC patients, 40% of stage I, 66% 
of stage II and 75% of stage IIIA patients die within five years of 
resection[1], mainly due to the development of distant metastases. 
The benefit of adjuvant chemotherapy is negligible in stage IB[2, 3]. 
Although at present there are no reliable clinical predictors of relapse 
after surgery in early-stage NSCLC, transcriptional analysis of pri-
mary tumors has identified gene expression profiles strongly related 
to disease recurrence in adenocarcinoma[4-10] and, to a lesser extent, 
in SCC[7-10]. The lung metagene model is a gene expression profile 
that predicts recurrence in early NSCLC (including stage IA) with 
an overall accuracy of 72%[10]. A meta-analysis[9] of data sets from 
seven microarray studies[4, 6, 11, 12] identified a 64-gene-expres-
sion signature that predicted survival with 85% accuracy. A study 
including 51 stage I-III lung SCCs identified a 111-gene signature 
with a 72% predictive accuracy for disease recurrence[13]. However, 
despite the lack of commonality of many genes identified between 
the published prognostic signatures, numerous gene-expression 
signatures occupy overlapping prognostic space[14] and may be able 
to predict outcome in early NSCLC[15]. 
The RT-QPCR assay is convenient in terms of laboratory work-
load and applicable for large-scale routine use, making it a viable 
alternative to more complex microarrays. RT-QPCR also allows for 
accurate and reproducible RNA quantification. The expression pat-
tern of eight genes determined by RT-QPCR correlated with survival 
in lung adenocarcinoma[16]. Similarly, RT-QPCR-based three-[17, 
18], four-[19] and five-[20]gene signatures and a five-miRNA signa-
ture[21] correlated with metastasis-free survival and overall survival 
in early NSCLC. A three-gene prognostic model[17] includes a key 
gene, hypoxia-inducible factor 1 alpha (HIF1alpha). The construc-
tion of the small gene signatures developed with RT-QPCR is based 
on the prognostic value of each gene as determined in a multivariate 
analysis. Each gene that is significant according to the multivariate 
analysis is then included in a risk score model, generated by adding 
the z-scores of the expression levels of each of the genes multiplied 
by its corresponding coefficient. The risk score is used to clas-
sify patients into high or low risk of metastasis and death[20]. The 
five-gene signature[20] is comprised of dual-specificity phosphatase 
6 (DUSP6), monocyte-to-macrophage differentiation-associated 
protein (MMD), signal transducer and activator of transcription 
1 (STAT1), HER3/neu receptor tyrosine kinase (ERBB3), and 
lymphocyte-specific protein tyrosine kinase (LCK). 
Intriguingly, in vitro studies have shown that BRCA1 can regu-
late differential sensitivity to different classes of chemotherapy 
agents[22, 23]. The absence of BRCA1 results in high sensitivity to 
cisplatin, whereas its presence increases sensitivity to antimicrotu-
bule agents[22, 23]. Therefore, it is plausible that patients with the 
highest expression levels would receive more benefit from antimi-
crotubule, non-platinum-based chemotherapy. Along these lines, we 
have carried out a pilot study of customized adjuvant chemotherapy 
based on BRCA1 mRNA levels in 88 completely resected stage 
II-IIIA NSCLC patients, where those with the highest expression 
levels received adjuvant docetaxel and those with the lowest levels 
received cisplatin-based chemotherapy. The interim analysis shows 
that recurrence-free survival is similar in both groups. These data 
support previous findings in stage II-IIIA patients who received 
neoadjuvant gemcitabine plus cisplatin, where those with the highest 
BRCA1 levels had a dismal survival of 12 months[24]. The fact that 
high levels of ERCC1 or RRM1 transcripts conferred a higher risk of 
relapse[25] provides further evidence for the role of the loss of let-7 
in upregulation of ERCC1 and RRM1, as well as BRCA1[26] and 
for the upregulation of BRCA1 and RRM1 in the SV40 T/t-antigen 
signature[27]. Paradoxically, contradictory findings[28, 29], leading 
to opposed strategies of customizing adjuvant chemotherapy, have 
reported that the lack of ERCC1 protein implies a higher risk of 
relapse and a greater sensitivity to cisplatin-based chemotherapy[28]. 
Nevertheless, the clinical evidence that overexpression of ERCC1, 
RRM1 and especially BRCA1 confers poor survival in early NSCLC 
patients indicates the high risk involved in adjuvant chemotherapy. 
Against the current standard of cisplatin-based chemotherapy, non-
cisplatin-based chemotherapy, including antimicrotubule drugs, may 
be the proper treatment for the majority of patients with a high risk 
of relapse [25].
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Reports from CT screening trials have demonstrated the ability of 
chest CT to detect lesions that are missed by chest radiographs. 
Available data suggests that a screening chest x-ray will miss 
70-80% of cancers detected by screening CT. The National Cancer 
Institute pilot trial of screening randomized approximately 1600 
participants each to CXR and spiral CT and detected 7 lung cancers 
in the CXR arm versus 30 lung cancers in the CT arm. Other small 
randomized pilot studies have also detected more cancers in the CT 
screening arm. CT is clearly more sensitive than chest radiographs 
for detection of small lung cancers. Disease specific mortality is the 
most appropriate outcome measure in the evaluation of screening 
effectiveness. Effectiveness of screening is determined by the reduc-
tion of deaths from lung cancer in the screened group versus the 
control group in a randomized controlled trial [RCT]. Some authors 
suggest that improved survival in a non-randomized, observational 
study, demonstrates the effectiveness of screening. Screening will 
improve survival whether or not it leads to fewer people dying of 
lung cancer and is therefore an inadequate measure of effectiveness. 
The International Early Lung Cancer Action Program (I-ELCAP) 
investigators reported the results of a large collaborative observa-
tional non-randomized CT screening program. They screened over 
31,000 asymptomatic individuals at baseline and had repeat scans at 
7-18 months in 27,000 plus participants. They detected a total of 484 
lung cancers of which 412 (85%) had clinical stage I lung cancer. In 
other non-randomized CT screening studies such as the Mayo CT 
screening trial, 39 of 66 lung cancers (59%) were stage I. Novello et 
al (Italy) observed 73% stage I cancers and Diederich and associ-
ates (Germany) reported 54% stage I cancers. Similarly three small 
randomized CT screening trials also reported lower rates of stage I 
disease detection than in I-ELCAP Study. In the CT screening arm 
of LSS, Depiscan, and the DANTE trials there were 48%, 37.5%, 
and 57% stage I lung cancers detected respectively. The I-ELCAP 
report calculated an 80% 10-year survival rate based on a median 
follow-up of 40 months. While survival has been excellent in this 
and other nonrandomized screening trials, the trials all suffer from 
the three potential biases of screening; lead-time, length-time, and 
over diagnosis. The need for an RCT was highlighted by the results 
of pooled data from 3 CT non-randomized screening trials. In this 
report Bachetal screened a cohort of over 3000 participants and they 
were compared to a validated prediction model. CT screening found 
3 times the number of expected cancers and resulted in 10 times the 
expected number of resections. Despite having a 94% actual 4-year 
survival for participants with clinical stage I cancers who underwent 
surgery, there was not an observed decrease in advanced stage lung 
cancers or lung cancer deaths as compared to the validated prediction 
model control group. To determine if CT screening can reduce lung 
cancer mortality, we will need the results of the two large RCT from 
North America (NLST) and Netherlands-Belgium (NELSON). 
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Noncalcified nodules (NCN) detected by CT screening have the 
potential to be early cancers. The difficulty is determining which 
NCN are malignant and which are benign. Initial reports from Japan 
and New York suggested a modest rate of NCN of 17-26%. However, 
these screening trials were conducted with single detector CT scan-
ners and used 1 cm thick CT slices. More recent trials with newer CT 
scanners have detected a much higher rate of NCN. The Fleischner 
Society has published guidelines for recommended follow-up and 
management of NCN detected incidentally at the time of a CT. The 
frequency of recommended follow-up is based on a low risk or high 
risk category determined by the individuals smoking history and 
presence or absence of a prior malignancy. 
Pastorino and colleagues enrolled 1035 individuals in a CT screen-
ing trial in Milan, Italy. After two yearly CT screening scans, they 
diagnosed 22 lung cancers but 6 additional patients (21%) underwent 
surgical biopsy for benign disease. In the first 3 years (1999-2002) 
of the Mayo CT screening trial, a total of 55 participants underwent 
a thoracic surgical procedure. Benign disease was present in 10 
patients (18%), and lung cancer was identified in 45 (82%). Investi-
gators from the University of Pittsburgh CT screening trial reported 
that 34% (28 of 82) thoracotomies or VATS procedures were per-
formed for benign disease in their CT screening trial. 
Overdiagnosis is defined as a lung cancer that will not lead to an 
individual’s death because of slow growth and age related competing 
risks of death. Some authors have opined that a doubling time of > 
400 days would be consistent with overdiagnosis. With a doubling 
time of 400 days, it would take a 3 mm lesion a total of 7.7 years 
to increase to the size of 15 mm lesion (diameter) based on the 
exponential growth mathematical model doubling time. In a Japanese 
CT screening trial by Hasegawa and colleagues at least 27 of 82 CT 
detected lung cancers had volume doubling time (VDT) of 400 days 
or more and would be potential cases of overdiagnoses. In the Mayo 
Clinic CT screening trial, thirteen lung cancers (27%) had VDT of 
greater than 400 days. Eleven of the 13 lung cancers with VDT over 
400 days were in females. 
An issue of heightened concern is the risk of cancer associated with 
diagnostic x-rays. A report from the United Kingdom estimated that 
the attributed risk percentage of cancer due to diagnostic x-rays 
ranges from 0.6% to 1.8% of all cancers in the developed countries. 
It is estimated that 62 million CT scans were performed in the United 
States in 2006. Based on the estimate of CT use in the United States, 
and the estimates of diagnostic radiation risk from the United King-
dom study, current CT usage may account for as much as 1.5-2.0% 
of all cancers in the United States. 
Currently, there are two large randomized screening trials that are 
nearing completion. The National Lung Screening Trial (NLST) is a 
multicenter trial that randomized over 53,000 high risk participants 
(2002–2004) to low dose CT screening or chest radiograph. Results 
of the trial are anticipated in 2011. The NELSON trial (Netherlands, 
Belgium, and Denmark) was launched in 2003, one year after the 
NLST. High risk participants were randomized to low dose CT 
screening or no screening of any type. Almost 20,000 participants 
have been enrolled, and the study will have an 80% power to detect 
a mortality reduction of 25%. Mortality results are to be available in 
2015. Until these results are available, routine CT screening of high 
risk individuals is not recommended by major medical organizations. 
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Learning objectives
1.  Understand the variability of prognosis of pulmonary nodule by 
CT findings of the solid nodule, partly solid nodule or pure GGO. 
2. Familiarize key CT findings rather than the density of the nodule 
such as the margin, shape and growth pattern according to lobular 
structure. 
3.  Understand radiological approach beyond HRCT for indetermi-
nate pulmonary nodule. The radiological approach depends on 
the CT findings and its size. In case with solid nodule without 
calcification, contrast enhanced CT or MRI is useful for differen-
tial diagnosis. In case with partly solid nodule, HRCT findings of 
the size and the ratio of GGO is most important factor because no 
recommended modality has been reported so far. Relatively short 
interval follow up by HRCT is acceptable management. 
Abstract
There are number of diseases showing pulmonary nodule mimicking 
lung cancer. Pulmonary nodule in plain chest X-ray as well as CT is 
the most common abnormal finding in asymptomatic population. 
Pulmonary solid nodule
The likelihood of lung cancer in the case with solid nodule signifi-
cantly depends on the size. If the lesion is larger than 2 cm in diam-
eter, the likelihood of malignancy is extremely high. If the lesion is 
smaller than 5 mm, the likelihood of malignancy is extremely low. 
Also interval size change is a widely-used standard practice that 
any non-calcified pulmonary nodules with stability over 2 years 
could be of a benign nature. There are number of pathology showing 
solid nodule, and most of them are benign in asymptomatic popula-
tion. Granulomas, focal fibrosis, Intra-pulmonary lymphnode and 
organized pneumonia are common cause of benign nature of solid 
nodule. Intra-pulmonary lymphnode is located along the interlobular 
septa, usually several mm inside from the pleural surface. Organized 
pneumonia is usually separated by secondary pulmonary lobule. 
Bronchial or bronchiolar thickening is also additional findings sug-
gestive of trans-bronchial infectious process. These HRCT findings 
rather than the density of size is another key findings for differential 
diagnosis. 
Management of solid pulmonary nodule
In general, malignant solid nodules grow more rapidly than the 
malignant nodule with GGO, and short interval follow-up or addi-
tional radiological examination is required if the nodule is larger 
than 1 cm in diameter. The contrast CT is useful to differentiate 
malignancy if the lesion is not enhanced. The ring like enhancement 
is reported as characteristic findings of tuberculoma. MRI and FDG-
PET sometimes gives us the useful information, but not always be 
a recommended procedure if we consider their cost and diagnostic 
reliability.
Pulmonary nodule with GGO
Pulmonary nodule with GGO is relatively rare occasion in case with 
pulmonary nodule, and adenocarcinoma is one of the most concern-
ing differential diagnosis. Any diseases showing a preservation of 
partial air in the alveolar space can be presented as GGO. Lung 
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metastasis sometimes shows nodules with GGO. Especially when the 
primary lesions are hypervascular such as melanoma, angiosarcoma 
and chorio-carcinoma, a hemorrhage may occur and spill out into the 
surrounding air-space producing surrounding GGO ; this CT finding 
is the so-called “halo sign”. Benign processes such as a mycotic 
infection invading vascular structures can also show as halo sign by 
the same reason. Sclerosing hemangioma (pneumocytoma) was also 
reported as having the same features. 
In general, a nodule with GGO is a significantly higher incidence of 
malignancy than a solid nodule. However, almost all benign nodules 
with GGO had partially or completely resolved within 3 months. The 
persistent GGO after several months of observation was an indicator 
of early adenocarcinoma or its precursor. 
CT feature of GGO nodules have a spectrum from pure GGO to 
GGO nodule with relatively large solid component. In 1995, Noguchi 
et al. reported a new pathological classification of adenocarcinoma 
less than 2 cm in diameter. He reviewed more than 200 cases, and 
more than two-third were classified as localized replacement adeno-
carcinoma for type A to C, representing the spectrum of progression 
from BAC to invasive adenocarcinoma. These tumors are called 
“replacement tumors because the tumor cells progressively replace 
the alveolar lining cells and progress from A and B to C. The remain-
ing types, D,E,F, were non-replacement tumors, poorly differentiated 
adenocarcinomas, which were thought to be de novo adenocarcino-
mas with a worse prognosis.
The positive correlation between the ratio of GGO and histological 
classification were reported from Japanese researchers. They also 
suggested that the internal solid component as a significant indicator 
of prognosis. This table is from the current review article by Fukui 
et al. and summarized current data of the percentage of GGO area 
and histological classification. From the data of Matsuguma, GGO 
smaller than 25 % shows that almost all are adenocarcinoma. A 
26-50 % shows adenocarcinoma in two-third.The larger than 50 % 
shows more than half is pure BAC, and the larger than 75% is BAC 
mostly. The increased GGO ratio increased pure BAC ratio. 
In contrast to the mixed nodular GGO, pure GGO type nodules are 
thought to be a favorable prognosis without a significant invasive 
nature, even though the size is more than 10 mm in diameter.
Management of pulmonary nodule with GGO
The management decision should not be decided by CT findings 
alone. The serial size change is still the only reliable indicator from 
the CT findings that helps decide the management. There has been 
no documentation the management recommendation of pulmonary 
nodules on the basis of CT characterization officially. 
The Fleischner Society published the current guidelines for the adults 
with nodules that are incidental in the sense in 2005. The nodule size 
is still the main reason to discriminate the management planning. 
Only the documentation in a supplementary note described that 
“Nonsolid (GGO) or partially solid nodules may require a longer 
follow-up to exclude indolent adenocarcinoma”. These guidelines 
do not mention the difference between non-solid (pure GGO) and 
partially solid nodules. However, a number of ongoing projects using 
MDCT are currently running. The characterization of the GGO com-
ponent may, in the near future, affect the management for patients 
whose pulmonary nodules were incidentally discovered.
E7.3 Early Detection of Lung Cancer, Sat, Aug 1, 10:30 - 12:00
Ancillary findings on screening studies
Swensen, Stephen J.
Mayo Clinic, Rochester, MN, USA
Ancillary findings are frequently encountered on screening exams 
performed both inappropriately and appropriately. Overuse of imag-
ing services compounds issues related to ancillary findings and is an 
important and serious public health issue. Many exams, including 
some for screening promoted today, do not meet appropriateness cri-
teria or are not recommended by professional societies (e.g., whole 
body or lung cancer CT screening). There are ethical issues raised 
by promotion to the public of imaging to screen for clinically occult 
disease. A central issue is managing the financial conflict of interest 
that is inherent in a physician’s relationship with an imaging center.
The consequences of ancillary findings on screening exams are pre-
dominantly negative. They include the following:
• False positive findings
• Exposure to incremental ionizing radiation
• Additional cost to patient
• Additional cost to society
• Anxiety from undiagnosed conditions
• Risk of additional interventions
In determining the cost effectiveness of any CT screening program, 
the entire cost of diagnostic and therapeutic follow-up of all ancillary 
findings is necessary. It is requisite to understand the frequency and 
spectrum of imaging findings in a screened asymptomatic population. 
A summary of findings from a literature review will be presented 
with recommendations for consideration of a reasonable and ethical 
way forward.
The ancillary findings on screening examinations have important 
financial ramifications both for the health care system and the 
individual. In a fee-for-service environment, this presents owners of 
imaging equipment with a financial conflict of interest to refer more 
or to accept requests that fall outside of accepted appropriateness 
criteria. For the individual involved, there are economic issues driven 
by co-payments, deductibles, etc. Furthermore, some findings dis-
covered at screening may alter a patient’s ability to obtain disability, 
life, or medical insurance. 
Approximately 10% of patients undergoing CT colonography screen-
ing for colon cancer will have an ancillary finding that will require 
additional testing. This could lead to hundreds of millions of dollars 
of new costs for hundreds of thousands of patients. At least one study 
suggests that the cost of managing incidental findings may actually 
exceed the cost of CT colonography itself.
There is potential harm beyond financial concerns. Studies of 
CT screening show that a majority of patients have one or more 
abnormalities. A large portion of these findings require additional 
diagnostic work. In the end, the vast majority of actionable abnor-
malities on CT screening are false positive findings. Once identified, 
many of these ancillary findings require further evaluation ranging 
from physical exam, more imaging studies, endoscopy, image-guided 
biopsies and surgical intervention. Patients are put at further risk 
of exposure to ionizing radiation and contrast material reactions or 
complications related to renal function. 
There are also psychosocial considerations related to the anxiety a 
patient may have in regard to the unknown diagnosis of an imaging 
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finding. It may take years to resolve an indeterminate nodule with 
follow-up examinations, for instance. 
On the other hand, it is possible that the absence of findings at 
screening may reassure a patient that they are “disease-free” when 
that is not an appropriate conclusion from a negative screening exam. 
Conversely, it is also possible that the false assurance of a negative 
screening exam may allow a patient to justify a risk-taking behavior 
such as cigarette smoking.
If the intended outcome of a screening exam is to identify a cancer 
at a stage at which treatment will decrease mortality, then over-diag-
nosis cancers could be considered an “ancillary” non-value-added 
finding. Over-diagnosis cancers, or pseudo-disease, are cancers that 
do not contribute to mortality. They are “die with” cancers. They are 
the worst form of false positive finding in that they often result in the 
most aggressive and risky intervention, surgical resection.
There are many potentially positive ancillary screening findings 
ranging from detection of renal calculi to lymphoma. The great-
est benefit may be in added life years from detecting and treating 
abdominal aortic aneurysms. 
Ancillary findings detected on screening exams have measurable sig-
nificant and in part negative public health consequences. Their social 
and financial ramifications must be part of the efficacy considerations 
in assessing the validity of population-based screening programs and 
recommendations. 
Session E8: VEGF Pathway 
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VEGF pathway: state of the art of clinical 
research with monoclonal antibodies
Johnson, David H.
Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
Angiogenesis is a fundamental event in the process of tumor growth 
and metastatic dissemination (1, 2). The vascular endothelial growth 
factor (VEGF) pathway is a key regulator of angiogenesis. VEGF 
was originally identified as an endothelial cell specific growth factor 
stimulating angiogenesis and vascular permeability (3). The VEGF/
VEGF-receptor axis is composed of multiple ligands and receptors 
with overlapping and distinct ligand-receptor binding specificities, 
cell-type expression, and function (3). Activation of the VEGF-recep-
tor pathway triggers a network of signaling processes that promote 
endothelial cell growth, migration, and survival from pre-existing 
vasculature. More recently, an important role for VEGF has emerged 
in mobilization of endothelial progenitor cells from the bone marrow 
to distant sites of neovascularization (4). The well-established role 
of VEGF in promoting tumor angiogenesis and the pathogenesis of 
human cancers has led to the rational design and development of 
agents that selectively target this pathway (5). 
Bevacizumab is a neutralizing humanized monoclonal antibody to 
VEGF (6). Phase I and II trial results found that bevacizumab was 
well tolerated and could be combined with standard regimens in vari-
ous solid tumors. The first evidence that this agent might be useful in 
the treatment of non-small cell lung cancer (NSCLC) emerged from 
a randomized phase II trial that employed bevacizumab in combina-
tion with carboplatin and paclitaxel in patients with advanced disease 
(7). The phase II trial also provided an important safety signal in 
that patients with squamous histology appeared to have a higher rate 
of serious and potentially life-threatening pulmonary hemorrhage. 
In subsequent pivotal phase III trials patients with predominantly 
squamous histology were excluded, as were patients with brain 
metastases and a history of significant hemoptysis (8, 9). These 
exclusion parameters may have played a critical factor in the success 
of these trials. Eastern Cooperative Oncology Group trial E4599 
compared carboplatin and paclitaxel ± bevacizumab in patients 
with advanced NSCLC (8). When combined with carboplatin and 
paclitaxel, bevacizumab was associated with an improved overall 
response, progression-free survival and overall survival benefit. 
However, the survival benefit came at a cost of increased toxicities 
including increased neutropenia, febrile neutropenia, thrombocytope-
nia, pulmonary hemorrhage, hypertension and proteinuria. Nonethe-
less, bevacizumab proved to be the first targeted therapeutic agent 
to improve survival in advanced NSCLC when added to standard 
chemotherapeutic regimens (10). As a result the U.S. Food and Drug 
Administration granted approval for bevacizumab on October 11, 
2006 (11). Of note, Sandler et al recently conducted a retrospective 
case-control and cohort analyses to identify associated radiographic 
and clinical risk factors for sever pulmonary hemorrhage (PH) (12). 
Among patients enrolled in the aforementioned phase II (N = 99) 
and phase III (N = 878) trials of bevacizumab plus carboplatin and 
paclitaxel, there were 22 cases of proven or potential cases of sever 
PH. When compared to matched controls form the study, baseline 
tumor cavitation appeared to be a potential risk factor for PH. No 
other baseline clinical variables were predictive for PH although the 
number of events was small.
In the so-called AVAiL trial, bevacizumab at two dose levels was 
combined with cisplatin and gemcitabine (9). The primary endpoint 
of this trial, after modification of the original design, was progression 
free survival. Both progression-free survival and overall response 
rate were improved; however, there was no improvement in overall 
survival. There also was no difference in outcome with respect to 
bevacizumab dose (7.5 vs. 15 mg/kg). The lack of survival benefit 
in AVAiL is not easily explained although a possible explanation has 
emerged from the studies of Kerbel et al (4, 13). These investigators 
found that certain chemotherapy drugs, e.g., paclitaxel, can rapidly 
induce proangiogenic bone marrow-derived circulating endothe-
lial progenitor (CEP) mobilization and subsequent tumor homing, 
whereas others, e.g., gemcitabine, do not. Acute CEP mobilization 
was mediated, at least in part, by systemic induction of SDF-1α and 
could be prevented by various procedures such as treatment with 
anti-VEGFR2 blocking antibodies or paclitaxel treatment in CEP-
deficient Id mutant mice, both of which resulted in enhanced anti-
tumor effects mediated by paclitaxel, but not by gemcitabine (13). 
In short, the data of Shaked et al. suggest that some chemotherapy 
agents offer potential mechanistic synergy that others lack (14). 
Notably only about half of NSCLC patients are candidates for beva-
cizumab therapy either because they have squamous histology, brain 
metastases, or because they are on anti-coagulation therapy. Ongo-
ing trials are exploring the safety of bevacizumab in these patient 
populations, as well as in combination with other cytotoxic regimens 
(15, 16). Exploration of other applications of bevacizumab in the 
second-line and adjuvant setting are ongoing as well. The largest 
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class of drugs that block angiogenesis are the multi-targeted tyrosine 
kinase inhibitors that target the VEGF receptor. These drugs are still 
in development, and though sunitinib and sorafenib are now on the 
market for treating other malignancies, their role in NSCLC is under 
investigation (17). 
Despite the success of bevacizumab in multiple cancers, the mecha-
nism of action of antivascular endothelial growth factor therapy in 
general and bevacizumab in particular is not fully understood. Pre-
dictive markers have not yet been identified and questions regarding 
bevacizumab’s usefulness in the adjuvant setting as well as its value 
as continued therapy beyond progression are still unanswered (16). 
It is indisputable, though, that antiangiogenesis has greatly enhanced 
the therapeutic arsenal of anticancer therapies and has substantially 
altered the management of advanced NSCLC.
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E9.1 Neoadjuvant Chemotherapy Trials in Lung Cancer, Sat, Aug 1, 16:30 - 18:00
Neoadjuvant chemotherapy: past and present US trials
Edelman, Martin J.
University of Maryland Greenebaum Cancer Center, Baltimore, 
Maryland, USA
Though localized lung cancer (defined as stages Ia-IIIa) is a poten-
tially curable entity with surgical therapy alone, the majority of 
patients will relapse and die from their disease. Most of these relaps-
es are systemic and therefore a systemic approach, i.e. chemotherapy, 
has been advocated. Chemotherapy can be administered either prior 
to or after surgical resection. The majority of studies, and the cur-
rent standard to care, is to administer chemotherapy after resection 
(adjuvant chemotherapy). Beginning in 2003 with the results of 
International Adjuvant Lung Trial (IALT ), a number of trials have 
demonstrated improved survival with this approach.1 Meta-analysis 
indicates that platinum based therapy administered to patients with 
resected stages IIa-IIIa results in an approximately 5% improvement 
in overall survival. 2 Perhaps an even more accurate assessment of 
the potential impact are the results of two studies that employed a 
modern regimen (i.e. cisplatin/vinorelbine) and resulted in a 10-15% 
improvement in OS. 3 4
The alternative approach to adjuvant chemotherapy is to administer 
chemotherapy prior to surgical resection. This has several theoreti-
cal advantages: immediate treatment of systemic disease, greater 
potential to deliver full doses of therapy with less toxicity than will 
be seen postoperatively and an in vivo assessment of chemotherapy 
activity. Large single institutional experiences demonstrated that 
preoperative chemotherapy can be delivered without an increase 
in surgical morbidity or mortality. 5 6 An early randomized trial at 
the US NCI by Pass et al. in pathologically documented N2 disease 
randomized 27 patients between cisplatin/etoposide and surgery vs. 
surgery and postoperative irradiation. Despite the small number, 
there was a strong trend towards improved disease free survival for 
the chemotherapy group (12.7 mo vs. 5.8 mo). 7 Roth et al random-
ized 60 patients in a study of IIIA (N2) patients and demonstrated 
a significant advantage for patients who received three cycles of 
preoperative and three cycles of postoperative chemotherapy (cyclo-
phosphamide, etoposide, and cisplatin). 8 The trial was halted after 
an interim analysis met the criteria for early termination for efficacy. 
Though positive, the study, along with a very similar Spanish trial 
published in the same time frame, did not change the standard of 
care. Furthermore, the study was restricted to patients with N2 dis-
ease, and therefore the results would not necessarily be applicable to 
lower stages. The multicenter bimodality lung oncology trial (BLOT) 
demonstrated considerable promise of preoperative carboplatin/
paclitaxel in stage I and II disease and ultimately led to a large 
randomized trial by the Southwest Oncology Group (SWOG 9900). 9 
This study was halted after the results of the IALT became available. 
10 However, 354 of a planned 600 patients had been accrued. This 
study demonstrated a level of benefit similar to that adjuvant therapy, 
though not quite achieving statistical significance. 
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Currently the issue of neoadjuvant therapy remains unsettled. The 
overall results from both North American as well as European studies 
indicate that the approach is safe. The degree of effectiveness is dif-
ficult to ascertain as studies were either halted early or may not have 
had optimal patient selection. It is becoming increasingly clear from 
the adjuvant and neoadjuvant approaches that the benefits of chemo-
therapy tend to accrue primarily to patients with N1 or N2 disease 
and that unselected patients with N0 disease may be harmed. Future 
trials will need to focus on these patients.The neoadjuvant approach 
is particularly attractive in the research setting as a method to assess 
the activity of new agents as tissue will routinely be obtained prior to 
and after therapy. 
E9.2 Neoadjuvant Chemotherapy Trials in Lung Cancer, Sat, Aug 1, 16:30 - 18:00
Neoadjuvant chemotherapy past and 
present European trials
Milleron, Bernard1, 2
1 University Tenon Hospital, Paris, France; 2 IFCT.France
Many phase 2 and some phase 3 trials on neoadjuvant chemotherapy 
in non small cell lung cancer (NSCLC) have been conducted in 
Europe during the past 20 years with two very distinct aims : 1) early 
treatment of distant micrometastatic disease for all stages and 2) 
reduction of local tumor with potential increase in resectabitity rates 
for stages III patients.
Phase 2 trials :
Despite the variability of these trials, they have demonstrated that 
with several regimens of chemotherapy in stage I-III or chemo-
radiotherapy in stage IIIA and/or IIIB patients several points : 1) The 
response rates to chemotherapy are greater than a 50%, significantly 
higher than those observed in patients with stage IV disease, 2) the 
neoajuvant chemotherapy is feasible and generally well tolerated, 3) 
surgery after chemotherapy is feasible.
More recentlly one phase 2 prospective trial in patients with stage 
IIIA-N2 NSCLC 1 had demonstrated that downstaging of mediasti-
nal lymph nodes is a predictor of long-term survival in the postopera-
tive period. Furthermore the complete surgical resection is also a pre-
dictor of long-term survival and consequently the surgical resection 
has been proposed for the patients with mediastinal downstaging.
Phase 3 trials :
Eight european phase III studies include the neoadjuvant chemo-
therapy arm (table I) 2-10. 
Five of them include patients with all stages (I-III) NSCLC, two 
include patients with stage IIIA-N2 and one trial, patients with early 
stages I and II. 
These 8 studies have different goals : 
• in six studies 2,4-7,10,11 the control-arm is the surgery randomly 
compared with preoperative chemotherapy and surgery.Thus 
the aim of these 6 studies is to evaluate whether preoperative 
chemotherapy could improve the survival in those with resectable 
NSCLC
• in one study 8 the comparison is between pre-operative chemo-
therapy and peri-operative chemotherapy in non small cell lung 
cancer stage I and 2.
• the last trial 9 evalueted the benefits of surgery compared to 
radiochemotherapy in stage IIIA-N2 non small cell lung cancer 
after neoadjuvant chemotherapy. 
Table I : The European Randomized Phase III trials
Authors Name N Question Stage Reference
Rosell  60 Preoperative CT IIIA-N2 2,3
Depierre MIP91 355 Preoperative CT IB, II, IIIA 4
Sorensen Scandinavian  44 Preoperative CT IB, II, IIIA 5 
 Phase III
Gilligan MRCLU22 519 Preoperative CT I-III 6
Felip NATCH 623 Pre or postoperative  IB, II, IIIA 7 
   CT or alone surgery
Depierre IFCT 0002 528 Preoperative or  I, II 8 
   perioperative CT
Van Meerbeck  579 Surgery IIIA-N2 9
Scagliotti ChEST 236 Preoperative CT IB, II, IIIA 10
Trials with surgery as the control arm :
The first trial comparing neoadjuvant chemotherapy and surgery 
with surgery alone is the Spanish trial from Rosell 2,3 : 60 patients 
with non-small cell lung cancer stage IIIA were randomly assigned 
to undergo either immediate surgery or surgery preceded by three 
courses of chemotherapy of MIP (mitomycin, ifosfamide and cis-
platin). The response rate was 60 % (partial response (PR) 53% and 
complete response (CR) 7%). After 24 months an analysis showed 
a significant difference in survival, and enrollment was stopped. At 
this time, the mediane time of survival was 26 months in the patients 
treated with chemotherapy plus surgery, as opposed to 8 months in 
the patients treated with surgery alone (P<0.001). Subsequently the 
results were updated at seven years : overall median survival was 
22 months (95% CI, 13.4 – 30.6) for the chemotherapy group vs 10 
months (95% CI, 7.4 – 12.6; P = 0.005 by the log rank test) for the 
surgery alone group. 
In a major French study 4 355 patients with resectable (IB – IIIA) 
NSCLC were randomized : half of patients received two cycles of 
MIP (2 cycles before surgery and two after surgery and the other 
half surgery alone. The overall response rate was 64% with 11% CR. 
Although there was a 12% excess of N2 disease in the combined 
treatment arm, the median survival was 26 months in the surgical 
arm vs 37 months in the combined treatment arm. The survival dif-
ferences between both arms was 8.6% at 4 years. Unfortunately, this 
difference was not statistically significant. Nevertheless a favorable 
effect of the chemotherapy was noted among patients in the earliest 
stages: RRs of 0.68 (95% CI, 0.49 to 0.96; P = .027) in patients with 
N0 to N1 disease. Sixteen post-operative deaths were observed in 
the combined treatment arm and nine in the surgery arm, but the 
difference was not significant. Similarly there was a nonsignificant 
increase of morbidity in the combined treatment arm during the 30 
postoperative days. 
A Scandinavian trial 5 was conducted in NSCLC stages IB, IIA, IIB, 
and IIIA/T3 with negative mediastinoscopy. The patients were ran-
domized to 3 courses of Paclitaxel 225 mg/m2 and Carboplatin AUC 
6 day 1 q 3 weeks followed by surgery vs surgery alone. Unfortu-
nately, because of slow patients recruitment, this study was prema-
turely closed : 280 patiens were necessary but only 90 patients were 
randomized. No statistically significant differences were noted, but 
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median survival was increased and the 5-year survival rate increased 
by 12% for patients receiving neoadjuvant chemotherapy.
In another trial 6 (UK, Netherlands, Germany, and Belgium) 519 
patients received either surgery alone, or three cycles of platinum-
based chemotherapy followed by surgery (CT-S). Clinicians had 
to chose the chemotherapy that would be given from a list of six 
standard regimens. Neo-adjuvant chemotherapy was feasible with a 
response rate at 49%. There was no increase of complications in the 
chemotherapy group, and no impairment in the quality of life was 
observed. However, there was no evidence of a benefit in terms of 
overall survival (hazard ratio [HR] 1.02, 95% CI 0.80-1.31, p=0.86). 
The Italian phase III Randomized study ChEST 10 compared surgery 
alone or surgery plus perioperative gemcitabine-cisplatin in early-
stage non-small cell lung cancer IB, II or IIIA except N2) : 712 
patients were scheduled to participate but this trial was terminated 
early when the positive results from adjuvant studies were released. 
Investigators judged it to be unethical to have patients complete the 
study with surgery alone. Thus only 270 patients were randomized. 
The response rate was 45 %. The 3-yr overall survival was 67% for 
the combined arm vs 60 % for the surgery arm (p= 0.053). In stage 
IIB-IIIA, the 3-yr overall survival was 70% for the combined arm vs 
47 % for the surgery arm. 
Were are still waiting for the results of the Spanish trial NATCH. 
This trial had three arms of treatment : neoadjuvant chemotherapy or 
adjuvant chemotherapy with paclitaxel and carboplatin compared to 
surgery alone in clinical stages I (>2cm), II and T3N1. Between april 
2000 and march 2007, 625 patients participated. The first results on 
chemotherapy toxicity and reponse in the neoadjuvant chemotherapy 
arm were presented during the last WCLC meeting 7 : chemotherapy 
was feasible with response rate at 59% and a good resectability rate. 
Comparison between pre-operative chemotherapy 
and peri-operative chemotherapy 
The preliminary results of the french IFCT 0002 trial were presented 
in 2007 8. The main objective was to determine the best time to 
administer chemotherapy, either before surgery or both before and 
after surgery. Two regimens of chemotherapy were also compared 
cisplatin-gemcitabine or carboplatin and paclitaxel. Five hundred 
twenty eight patients were included. Administration of 4 cycles of 
chemotherapy was feasible and post operative mortality was low. The 
responses rate was 52.3% for the Gemcitabine arm and 49.2 for the 
Paclitaxel arm. The compliance after 2 cycles to 2 additional cycles 
was better before than after surgery. 
The definitive results will be in at the next ASCO meeting. 
Trial evaluating the advantages of surgery versus 
radiochemotherapy in stage IIIA-N2
The trial of the European Organisation for Research and Treatment of 
Cancer-Lung Cancer Group (EORTC) 9 had compared surgery with 
radiotherapy in patients with stage IIIA-N2 NSCLC who showed a 
response to induction chemotherapy. 
The patients with proven histologic or cytologic stage IIIA-N2 
NSCLC were given three cycles of platinum- based induction che-
motherapy. The response rate was 61% for the 579 eligible patients. 
Responding patients were randomly assigned to surgical resection 
(n = 167) or radiotherapy (n = 165). In the arm surgery, 154 (92%) 
patients were operated and 14% had an exploratory thoracotomy. 
Only 50% had a radical resection, 42% a pathologic downstaging, 
and 5% a pathologic complete response; 4% died after surgery. Sur-
gical resection did not improve overall or progression-free survival 
compared with radiotherapy. Median and 5-year overall survival for 
patients randomly assigned to resection versus radiotherapy were 
16.4 versus 17.5 months and 15.7% versus 14%, respectively (hazard 
ratio = 1.06, 95% CI = 0.84 to 1.35). Rates of progression-free sur-
vival were also similar in both groups. 
In conclusion, the number of trials and the number of included 
patients is lower for the neoadjuvant chemotherapy than for adjuvant 
chemotherapy. Nevertheless these trials and systematic review and 
meta-analysis of these 12,13 suggests : 1) the neoadjuvant chemo-
therapy is feasible, 2) compliance is most probably higher than adju-
vant chemotherapy, 3) there is a significant survival benefit of around 
6% for patients with NSCLC who receive preoperative chemo-
therapy compared with those who do not. Some important questions 
remain and an individual patient data meta-analysis is required
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S9900 trial update, mature analysis
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Prior to the findings of a survival benefit for postoperative chemo-
therapy in early stage NSCLC, phase III trials were designed to 
evaluate the role of preoperative chemotherapy. A large phase II 
trial of preoperative paclitaxel and carboplatin found this approach 
feasible and improved survival over historical controls. The phase III 
intergroup S9900 study was undertaken to determine whether preop-
erative paclitaxel/carboplatin chemotherapy could improve survival 
compared to surgery alone. 
Consenting pts with clinical stage T2N0, T1-2N1, and T3N0-1 
NSCLC (excluding superior sulcus tumors) were stratified by clinical 
stage (IB/IIA vs. IIB/IIIA) and randomized to preoperative paclitaxel 
and carboplatin (P:225 mg/m2 over 3 hours, C:AUC=6) on day 1, 
every 3 weeks x 3 or surgery alone. Eligible pts had performance 
status 0-1, age >/= 18 years (yrs), predicted post-resection FEV1 >/= 
1.0L. Surgery was at least a lobectomy and mediastinal nodal sam-
pling. The primary endpoint was an increase in median survival by 
33% over expected 2.7 yrs for surgery. Planned sample size of this 
prospective, randomized trial was 600 pts, giving 81% power using a 
one-sided test with a 0.025 significance level. 
S9900 closed to new pt entry in 07/04 based on the positive adjuvant 
data. 354 pts were accrued, 17 were ineligible. Median age 64 yrs, 
66% male, 36% PS 1, 63% T2N0, 5% T1N1, 19% T2N1, 10% T3N0, 
4% T3N1. With a median of 64 months followup, 5 year overall 
survival rates favored the combined arm (50% vs 41%, p=0.11). 
Survival differences observed in this and other randomized trials of 
preoperative chemotherapy lend further support to the role of sys-
temic therapy in the management of early stage NSCLC patients.
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Medical thoracoscopy for malignant pleural effusion
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Malignant Pleural Effusion (MPE) is a sign of advanced, dissemi-
nated malignancy and has a major impact on the life expectancy 
and quality of life of cancer patients. Lung cancer remains the most 
common cause of malignant pleural effusion accounting for one 
third of cases (1). Dyspnea, cough, chest discomfort and pain are the 
most common symptoms of MPE. Since MPE by definition implies 
inoperable and incurable disease the main goal of therapy for MPE is 
palliation. A number of therapeutic options are now available includ-
ing: treatment of the underlying disease (possibly successful in breast 
cancer and lymphoma but rarely successful in lung cancer), repeated 
thoracentesis, pleural-peritoneal shunt, surgical pleurectomy, tube 
thoracoscopy with sclerotherapy, thorascopic surgery (VATS or 
medical thoracoscopy) with sclerotherapy and tunneled pleural cath-
eters (1-3). The effectiveness of therapy depends on the agent chosen 
for pleurodesis and on the route of administration. Talc is a pleural 
sclerosing agent that appears to be the agent most likely to achieve 
pleurodesis and palliation of the symptoms of MPE. 
Thoracoscopy is an invasive procedure, but generally it is well toler-
ated. Medical thoracoscopy usually takes place in a procedure room 
using moderate sedation and local anesthesia. Patients breathe spon-
taneously during the procedure. Thoracoscopy allows for complete 
drainage of the pleural fluid, pleural biopsy if needed for diagnosis 
or tissue sampling for generic studies, lysis of adhesions and for 
ideal chest tube placement. Powdered sterile talc can be insufflated 
using a simple hand pump or by spray from an aerosol can. General 
anesthesia and VATS are rarely required for thorascopic treatment 
of MPE. Although tube thoracoscopy is considered a less invasive 
procedure it is often preformed at the bedside with less than adequate 
local anesthesia and sedation and can be quite uncomfortable for the 
patient. Distribution of the talc slurry through a chest tube is often 
problematic especially if adhesions are present.
Dresler et. al (4) recently reported on a CALGB corporative study 
comparing tube throacoscopy with talc slurry (TS) to surgical thora-
coscopy with talc insufflation (TTI). In this randomized multi center 
trial efficacy was assessed at thirty days and quality of life and safety 
were evaluated. Five hundred and one patients were randomized; 
and it was concluded that there was no difference in the ability of 
talc to prevent recurrence at thirty days whether instilled by slurry or 
by insufflation. A subset analysis however did suggest that TTI was 
more advantageous for patients with lung and breast cancer. 
Stefani et. al (5) reported on a prospective comparison study of talc 
poudrage versus talc slurry in the treatment of malignant pleural 
effusion. Thoracoscopy was preformed under general anesthesia with 
selective one lung ventilation using typical VATS technique. The 
authors felt that pleurodesis by thoracoscopy led to a higher success 
rate and therefore should be preformed whenever possible. Patients 
eligible for thoracoscopy must have an acceptable performance 
status, life expectancy greater than three months and the ability to 
undergo general anesthesia. This study was prospective but not ran-
domized. A recent Cochrane database review confirmed the superior-
ity of talc as a sclerosing agent and that “thorascopic pleurodesis as 
the preferred technique for pleurodesis based on efficacy” (6).
Talc pleuradeiss by thoracoscopy is a safe procedure. Long-term 
studies of talc pleurodesis for benign conditions have shown that 
there is no long-term affect on lung function using talc (7). Acute 
lung injury from talc pleruodesis is the main concern with this tech-
nique. Kuzniar et. al suggest that the pre procedure need of oxygen 
supplementation, recent chemotherapy and the presence of periph-
eral edema are predictors of acute lung injury or severe hypoxemia 
after VATS talc pleurodesis (8). It appears that talc particle size is an 
important predictor of the development of post procedure acute lung 
injury. Janssen et. al (9) in a multi-center European study of over five 
hundred patients saw no evidence of acute lung injury in patients 
treated with the French large particle talc. A recent review of Lahey 
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Clinic patients undergoing talc pelruadesis by thoracoscopy showed 
a twelve percent incidence of hypoxemia and pulmonary infiltrates. 
All patients had received the only available America talc, which 
contains both small and large particles. 
In summary, thorascopic talc pleurodesis for malignant pleural 
effusion appears to be the therapy most likely to achieve adequate 
control of the pleural fluid and palliation of the patient’s symptoms. 
It is a more invasive procedure than other techniques such as the use 
of indwelling pleural catheters and bedside tube thoracoscopy but in 
patients with adequate performance status it is a well-tolerated, safe 
procedure. 
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Management of malignant pleural effusions 
- PleurX catheter placement
Tremblay, Alain
University of Calgary, Calgary, AB, Canada
Malignant pleural effusion (MPE) is a common complication in 
advanced malignancy that causes debilitating symptoms. The stan-
dard treatment options can require hospitalization, the use of surgical 
or procedure suites as well as - administration of anesthesia. Many 
patients with poor performance status or trapped lung may not be 
candidates for these therapies, and significant concerns about side 
effects and complications have been raised. In the past years, the use 
of indwelling tunneled pleural catheters (TPC) on an outpatient basis 
for chronic drainage of these effusions have been found to represent 
a safe and effective treatment option for many of these patients(1-4).
Patient selection
One of the main advantages of this technique is its broad applicabil-
ity. Few contraindications exist for the placement of these catheters 
and patients who may not be good candidates for traditional treat-
ment options, such as those with trapped lung or poor performance 
status may still benefit from this approach. 
Insertion technique and catheter care
Tunneled catheters can be inserted with local anesthetic in an 
adequately equipped procedure room on an outpatient basis. A full 
barrier sterile technique is used and bedside ultrasound guidance is 
favored. IV access is not required. We typically insert the catheter at 
the anterior axillary line and tunnel the catheter caudally towards the 
upper quadrant of the abdomen. Occasionally, a posterior approach 
is used as well. Details on insertion technique and catheter care have 
been published(5). Following placement, the catheter is drained and 
a chest x-ray obtained. The patient can be discharged home once the 
chest radiograph has been reviewed.
The catheter is drained at home every other day by the patient and 
caregiver, and in our experience these patients benefit from regular 
visits of a palliative home care nurse who can assist with catheter 
drainage as well as other palliative issues frequent in these patients. 
Specific plastic vacuum bottles (500 or 1000 mL size) with a needle-
less access system for the catheter are utilized. In our center, all 
patients are seen for a 2 week follow-up visit in clinic with a repeat 
chest radiograph. Following his visit, patients are seen every 12 
weeks or sooner if problems arise or pleurodesis occurs.
Published results
We have found that approximately 90% of patients treated with this 
technique experience relief of dyspnea, which is the primary goal 
of treatment for such patients(2). In addition, TPC’s appear to be a 
definite treatment approach as fewer than 10% of patients require 
additional ipsilateral pleural procedures.
Spontaneous pleurodesis occurs between 40 and 70% of patients but 
this can take an average of 2 months to occur(2;3). This pleurodesis 
appears to be long lasting with very few patients requiring additional 
pleural treatments following catheter removal.
Only one trial has compared this approach to chemical pleurodesis. 
In this study, symptom relief with TPC’s was similar to that achieved 
with doxycycline pleurodesis, with hospitalization time decreased 
from 6.5 to 1 day(1).
Complications
The most severe complication associated with the use of TPC use 
is that of empyema. The incidence of this complication has been 
reported to be between 0.3 and 3.2% of cases(2;3). Patients can be 
treated with intravenous antibiotics, continuous pleural drainage 
through the TPC and intrapleural thrombolytics. Surgical decortica-
tion has not been required in our experience to date.
Cellulitis is occasionally seen in the first 2 weeks post placement. 
This can usually be treated with oral antibiotics targeted towards 
normal skin flora without catheter removal. 
Symptomatic loculated pleural fluid can be a problem in a minority 
of patients. This can be addressed by instilling thrombolytics through 
the catheter, performing a thoracentesis or rarely inserting a new 
catheter. Asymptomatic loculations are best ignored.
Cons of TPC
Although reports of safety and efficacy of TPC use in MPE are grow-
ing, no study has yet compared this technique with talc pleurodesis, 
arguably the current gold standard. 
A theoretical concern regarding the potential negative impact of 
chronic drainage of proteinaceous fluid on nutritional status has been 
raised, but has not been well described or documented. 
Copyright © 2009 by the International Association for the Study of Lung Cancer S203
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
Length of drainage of 2-3 months is often seen as an undue burden 
imposed on patients and families by detractors of this approach, 
although in our experience patients accept this with ease. Neverthe-
less, strategies to reduce the length of TPC drainage while minimiz-
ing side effects could be of benefit.
A TPC insertion program requires specific resources such as ade-
quate home care support and catheter supplies, as well as a dedicated 
team of health care providers. While the cost of the initial catheter 
insertion is low(6), the cost of supplies is not insignificant and a 
long-term cost effectiveness study has not been performed. 
Conclusion
A growing body of evidence is confirming that long-term pallia-
tion of MPE can be achieved by using TPCs in relatively unselected 
patients on an outpatient basis. While the high success rates, low 
complication rates and efficacy in patients with a wide range of per-
formance status support the use of TPCs as a first line treatment for 
symptomatic MPE, there is still a need for cost effectiveness studies 
with talc pleurodesis as the benchmark, and for the development of 
further treatment modalities for this condition. 
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Implanted port reservoir for pleural drainage
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The major goal in the management of malignant pleural effusions 
is symptom control. Commonly employed strategies are thora-
coscopy with talc poudrage, chest tube thoracostomy with talc (or 
other chemical) pleurodesis, an indwelling pleural catheter with 
an externalized access for periodic drainage (PleurX catheter) and 
serial thoracentesis. A more recent management strategy has been to 
place a small gauge catheter into the pleural space and to tunnel it 
to a subcutaneously implanted port reservoir for intermittent access. 
Limited experience with this pleural drainage system suggests that 
a subgroup of patients with malignant pleural effusions may be best 
managed with this system. 
The management of malignant pleural effusions is often complex and 
no single strategy is universally effective. The major goal in the man-
agement of malignant pleural effusions is symptom control, and the 
interventional approach is heavily influenced by patient preference 
and performance status. For nonsmall cell lung cancer, a malignant 
pleural effusion is generally regarded as having an extremely poor 
prognosis with a median survival of 7.5 months. These patients are 
therefore generally considered end stage and curative strategies are 
not usually employed. However, survival of patients with malignant 
pleural effusions is highly variable, with performance score being 
the most important predictor. Patients with a good performance score 
(Karnofsky score > 70) have a median survival of 395 day. Although 
an unproven strategy, it makes sense to offer these more fit patients 
with a longer predicted survival, more aggressive treatment such as 
chest tube thoracostomy with chemical pleurodesis or thoracoscopy 
with talc poudrage. These procedures are invasive, generally require 
hospitalization for 3-7 days (a substantial amount of time for patients 
with a limited life expectancy) and prone to complications, some 
life threatening. Therefore, patients with a poor performance score 
(Karnofsky score < 30) who have a median survival of 34 days, in 
general do not tolerate these aggressive procedures. These patients 
and patients who fail or are predicted to fail pleurodesis (e.g. trapped 
lung) are therefore best managed with a less invasive management 
strategy, e.g. serial thoracentesis, PleurX catheter or implanted port 
reservoir. 
Experience with implanted port reservoirs for pleural drainage has 
been limited and a commercially available product and drainage 
system has not been readily available. The largest published series to 
date from a single center (Institut Curie, France) reported on thirty-
four port reservoirs implanted in twenty-nine patients. Twenty-eight 
patients received partial or complete relief of their dyspnea and six 
(17%) patients achieved pleurodesis. Fifteen patients were receiving 
chemotherapy at the time of placement. Complications included 1) 
pneumonia and empyema responding to antibiotics, 2) cellulitis over 
the port site requiring removal of the port, 3) extrusion of the port 
and 4) disconnection of the port. An update from the same group will 
be presented at this conference. They report their experience with 
117 ports implanted in 95 patients. In brief they report an equivalent 
dyspnea control, improved pleurodesis rate and a reduced complica-
tion rate. We have reported our experience with eight patients, all had 
symptom control, two achieved spontaneous pleurodesis and no com-
plications were encountered. Scattered case reports of successful use 
of this system have also been published over the past several years.
The implanted port reservoir system and the PleurX catheter have 
advantages over serial thoracentesis in that they eliminate the need 
and risk involved in repeated needle insertion into the thorax. In 
general, expert opinion discourages the use of serial thoracentesis 
to manage malignant pleural effusions in all but the most end stage 
patients or to patients who have malignancies that are expected to 
dramatically respond to chemotherapy, such as small cell lung cancer 
or lymphoma.
The implanted port reservoir system has potential advantages over 
the PleurX catheter:
1) While unproven, the implanted port reservoir may have a lower 
infection rate. The PleurX is reported to have an empyema rate 
of 3% and a cellulitis rate of 2%. The implanted port reservoir 
is completely implanted under the skin and should theoretically 
be less susceptible to infection. Limited data suggests this to be 
true. We and other investigators have implanted this catheter in 
immunocompromised patients receiving chemotherapy with a low 
infection rate. 
2) Patients are less encumbered by the device, as it is subcutaneously 
implanted. They are no externalized parts to ensnare, dislodge or 
to be concerned with during bathing, exercise and other activities 
of daily living.
The implanted port reservoir system has distinct advantages over 
chest tube thoracostomy and thoracoscopy. 
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1) It can be placed the outpatient setting and patients with a poor 
performance score are not forced to spend a potentially significant 
portion of their limited life expectancy in the hospital. 
2) The outpatient nature of the procedure minimizes interruption of 
chemotherapy or radiation therapy. 
3) Patient comfort and complication rates are likely superior.
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DNA methylation markers in lung cancer
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The prognosis of lung cancer patients, especially in advanced stages, 
is bad. A better understanding of the pathogenesis of this disease is 
essential for the development of more effective treatment strategies, 
might also be helpful for risk assessment and early detection and 
finally could improve the prognosis of lung cancer patients. So far, 
enormous progress has been made in understanding the molecular 
and cellular biology of lung cancer. In recent years it has been shown 
that aberrant DNA methylation (referred to as methylation) is of 
important significance in the pathogenesis of lung cancer. 
The addition of methyl groups to the 5-position of cytosines alters 
the appearance of the major groove of DNA to which DNA binding 
proteins bind leading to prevention of transcriptional initiation and 
gene silencing. Important for methylation of cytosine residues are 
DNA methyltransferases. Cancer can be caused and impacted by 
de novo methylation of CpG islands of cancer-related genes. CpG 
islands are clusters of CpG sites and are often found in promoter 
regions and first exons of genes and are ~500-2000 bp in length. 
Besides other tumor entities, methylation plays a crucial role in the 
pathogenesis of lung carcinomas leading to inactivation of cancer-
related genes. Interestingly, methylation can be reversed by methyla-
tion inhibitors such as 5-aza- 
2'-deoxycytidine (5-aza-dC) resulting in gene re-expression. More-
over, it has been demonstrated that DNA methylation is linked to 
chromatin modifications and that DNA methylation and histone 
deacetylation work together in gene silencing. This explains the syn-
ergistic effect of methylation inhibitors and HDAC inhibitors such as 
trichostatin A on re-expression of silenced genes in tumors.
Numerous studies investigating methylation in lung cancer have been 
published in the last few years. Initial studies focused mainly on 
investigating methylation of single genes or a small number of genes 
in primary lung tumors. Examples of genes which are of relevance in 
the pathogenesis of lung cancers and which are frequently methylat-
ed in this tumor entity include p16, RASSF1A, CDH13 and TSLC1.
The p16INK4a (p16) gene, located at chromosome 9p21, func-
tions by binding to cyclin-dependent protein kinase 4 (CDK4) and 
inhibits the ability of CDK4 to interact with cyclin D1. Methylation 
of p16 was found in up to 40% of primary NSCLC samples and a 
strong correlation between loss of expression and methylation was 
observed. Interestingly, methylation of p16 was linked to an early 
stage in the pathogenesis of lung cancer, was associated with pack-
years smoked, duration of smoking and negatively with the time 
since quitting smoking and was associated with significantly poorer 
survival in non-small cell lung cancer (NSCLC) patients. 
The RAS association domain family 1 (RASSF1) gene is a tumor 
suppressor gene located at the chromosomal region 3p21.3 and 
acts in the level of G1/S-phase cell cycle progression. RASSF1A is 
frequently lost in various malignant tumors including lung carcino-
mas and methylation has been identified as the major mechanism for 
inactivating this gene. The frequency of RASSF1A methylation in 
primary NSCLC ranges between 30-40% and in small cell lung can-
cers (SCLC) between 72-85%. It has been reported that RASSF1A 
methylation is associated with a poor prognosis in NSCLC patients, 
occurs more frequently in poorly differentiated tumors and that 
RASSF1A methylation is associated with starting cigarette smoking 
at an early age.
CDH13 (H-cadherin) belongs to the cadherin-family which are cell 
surface glycoproteins responsible for homophilic cell recognition and 
adhesion. CDH13 expression is frequently absent in lung carcinomas 
and methylation has been identified as the major mechanism for gene 
silencing. Methylation of CDH13 has been observed in up to 45% in 
primary NSCLCs.
The tumor suppressor in lung cancer-1 (TSLC1, IGSF4) was cloned 
from the chromosomal region 11q23.2. This gene encodes a member 
of the immunoglobulin superfamily molecules which is involved in 
cell-cell adhesion. Recent data demonstrated that methylation is an 
important mechanism for TSLC1 inactivation in primary NSCLCs. 
Interestingly, the frequencies of methylation of certain genes differ 
between NSCLCs and SCLCs. Moreover, the methylation pattern 
also differs between NSCLCs from smokers and never smokers. 
A very recent study investigated whether methylation of the genes 
p16, CDH13, RASSF1A, adenomatous polyposis coli gene (APC), 
O6-methylguanine-DNA methyltransferase gene (MGMT), death-
associated protein kinase 1 gene (DAPK) and the PYD and CARD 
domain-containing gene ASC in tumor and lymph nodes of stage I 
NSCLC patients was associated with tumor recurrence after surgery 
in these patients. Methylation of the genes p16, CDH13, RASSF1A 
and APC were found to be associated with early recurrence in these 
patients. Recently, methylation of certain genes was investigated 
in atypical adenomatous hyperplasia of the lung (AAH), a precur-
sor lesion from which lung adenocarcinomas arise, as well as in 
normal-adjacent lung and in adenocarcinomas of the same patients. 
Interestingly, a progressive increase in methylation with each step 
from normal-adjacent lung to low-grade AAH to high-grade AAH to 
adenocarcinoma was observed.
Methylation analysis of single genes or a small number of genes 
was mainly done by methylation-specific PCR or genomic bisulfite 
sequencing. However, strategies for genome-wide screening for 
methylated genes were developed recently. Overall the aim of these 
studies is to identify genes whose epigenetic silencing is unknown 
so far. One approach compared expression of genes which contain 
5`CpG islands and are expressed in immortalized human bronchial 
epithelial cells before and after treatment of lung cancer cells with 
the methylation inhibitor 5-aza-dC. Gene re-expression after drug 
treatment suggests that methylation is the underlying mechanism for 
gene silencing. Using this method about 130 genes were identified 
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in lung cancer cell lines. Another approach is the methylated-CpG 
island recovery assay (MIRA) which were used to identify a large 
number of CpG islands methylated in the majority of the samples 
analysed. We are currently working on a genome-wide methylation 
profiling approach in primary NSCLCs and matching non-malignant 
lung tissue specimens. The methylation status of >15000 genes will 
be determined using a methylated DNA immunoprecipitation com-
bined microarray approach (MeDIP-chip).
However, methylation cannot only be detected in primary tumors but 
also in serum, plasma, sputum, bronchoalveolar lavage (BAL) and 
bronchial brushing samples from lung cancer patients. While serum, 
plasma and sputum can be obtained in a minimally/non-invasive 
way, BAL and bronchial brushing sample can only be obtained by 
an invasive procedure. In general, despite a higher frequency of 
methylation of certain genes in primary lung tumors a relatively 
high concordance of methylation between primary tumor samples 
and serum/plasma samples were observed in most of the studies. 
Methylation of certain genes in serum/plasma was only detected 
when also the primary tumor was methylated for a specific gene. 
However, one concern is that for efficient detection there may be not 
enough methylated DNA in blood samples from lung cancer patients 
at an very early stage and that therefore the use of serum and plasma 
samples are questionable for early detection of lung cancer. 
Since methylation of certain genes was frequently detected in lung 
carcinomas researchers started to investigate if methylation occurs 
already in aerodigestive tract samples from cancer-free smokers. The 
frequency of methylation of p16 and DAPK in bronchial epithelium 
was compared between former and current smokers. Methylation of 
genes was seen as frequently in bronchial epithelium from current 
smokers as from former smokers suggesting that methylation chang-
es persist. Moreover, it has been demonstrated that methylation of 
p16 and/or MGMT in DNA from sputum of patients with squamous 
cell lung carcinomas was already observed up to 3 years prior to the 
clinical diagnosis of lung cancer. Recently, we performed a study 
investigating methylation of the genes p16, RASSF1A, retinoic acid 
receptor beta-2 (RARbeta-2) and CDH13 in different types of speci-
mens (oropharyngeal brushes, sputum samples, bronchial brushes 
and BAL samples) of the upper aerodigestive tract epithelium from 
heavy smokers without evidence of cancer but with morphometric 
evidence of sputum atypia. At least one gene was methylated in one 
or more specimens from 48% of the smokers. Methylation occurred 
more frequently in samples from the central airways (sputum, 
bronchial brushes) compared to the peripheral airways (BAL), and 
only occasionally in the oropharynx. These results demonstrate that 
methylation of certain genes can be an early event in the pathogen-
esis of lung cancer. 
Finally, I want to discuss some aspects for the potential use of methy-
lation markers in the clinic. So far, several authors reported a prog-
nostic impact of methylation of certain genes detected in primary 
tumors from lung cancer patients. This finding may influence future 
treatment strategies for lung cancer patients. Finding genes of prog-
nostic impact methylated in tumors could allow one to “individual-
ize“ therapy for those lung cancer patients. These patients potentially 
might benefit from a more aggressive treatment strategy or new 
treatment options. Methylation could also be used in lung cancer risk 
assessment and early lung cancer detection. Sputum samples would 
be the ideal medium for this kind of studies. A panel of genes could 
be used to predict an increased lung cancer risk. This subgroup of 
people could then undergo other, more costly procedures for early 
detection of lung cancer such as spiral computer tomography scan. In 
addition, these methylated genes could be used as surrogate markers 
to test the efficacy of chemopreventive agents. In addition, methyla-
tion of certain genes might also be useful for monitoring the occur-
rence of disease recurrence. 
In conclusion, in recent years it has become increasingly apparent 
that epigenetic changes play a critical role in gene silencing in lung 
cancer. A large number of genes were found which are frequently 
methylated in lung carcinomas and currently genome-wide strate-
gies are used to identify genes whose epigenetic silencing is still 
unknown. Moreover, it has been demonstrated that methylation of 
certain genes is an early change in the pathogenesis of lung cancer 
suggesting that it may be a useful marker for lung cancer risk assess-
ment and early detection. 
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Somatic mutations in lung cancer
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Current efforts are focusing towards the development of drugs that 
specifically target abnormal regulatory pathways of cancer cells. 
Therefore, it is becoming increasingly important to identify the 
set of genes altered in cancer and to discriminate tumors by their 
genetic background. Lung tumors carry alterations at known genes, 
some of them highly specific to their histology. Most lung tumors 
feature inactivation at TP53 and CDKN2A or RB1, whereas BRAF, 
MET, ERBB2, and NRAS alterations are infrequent. A preferential 
accumulation of alterations among histopathological types and a 
mutually exclusive occurrence of alterations of CDKN2A and RB1 
as well as of KRAS, EGFR, NRAS, and ERBB2 were seen. Wide 
screening for chromosomal deletions allowed us to unveil that LKB1 
located at chromosome 19p13.3 was somatically mutated in one 
third of lung tumors. Through impairing the AMPK/mTOR pathway, 
LKB1 inactivation abrogates the cell energetic checkpoint control, 
an obligatory step for cancer development. In addition to LKB1, we 
recently observed that chromosome 19p13 targets the tumor suppres-
sor BRG1, which encodes the ATPase of the SWI/SNF chromatin-
remodelling complex. BRG1 inactivating mutations were identified 
in one third of the cancer cells tested and did not coexist with MYC 
amplification. Our data strongly supports that BRG1 is a bona fide 
tumor suppressor and a major factor in lung tumorigenesis. Inactiva-
tion of LKB1 in cancer cells frequently coexisted with alterations 
at other indirect modulators of mTOR such as PIK3CA and KRAS. 
This proves that multiple pathways that control mTOR activity are 
simultaneously altered in cancer and thus have independent roles in 
its development. In addition, it may help explain why neither LKB1 
status nor alterations in other genes such as KRAS, ERBB2 or EGFR 
predict sensitivity to the mTOR inhibitor rapamycin. To identify 
novel oncogenes, we performed combined Comparative Genome 
Hybridization microarrays and cDNA microarrays. Following this 
approach we identified several amplicons with increase in gene 
expression. We mapped the boundaries and measured gene expres-
sion levels within an amplicon at chromosome 6p. The SOX4 gene, 
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encoding a transcription factor involved in cell differentiation, was 
over-expressed relative to normal cells. SOX4 levels were also high 
in a fraction of primary tumors and associated with increased in gene 
copy number, supporting that SOX4 is a candidate oncogene in lung 
cancer. In conclusion, we provide novel genes altered in lung tumors 
and amplified regions that may contain oncogenes relevant for lung 
carcinogenesis.
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Molecular changes in invasion, tumor 
progression and metastasis
Franklin, Wilbur A.
UCDenver, Aurora, CO, USA
Two critical events are largely responsible for the lethality of 
pulmonary tumors: invasion of benign tissues, and metastasis. The 
molecular events responsible for these two properties are incomplete-
ly understood for several reasons. First, the airways are large and 
complex and prediction of where an invasive tumor is likely to occur 
has not been possible to date. What we do know about the molecu-
lar changes that lead to invasion of normal tissues and metastases 
are that they begin many years prior to acquisition of invasive and 
metastatic properties. Molecular changes associated with invasion 
of the central airways appear to be different than those associated 
with invasion in the peripheral airways. Also, molecular progres-
sion associated with cigarette smoking is significantly different than 
that in nonsmokers. Each of these subcategories will be considered 
separately.
Central airway lesions in smokers
A variety of molecular changes in the central airways that occur 
before the development of lung carcinoma have been described. 
Genetic damage most likely begins with direct damage to DNA by 
reactive metabolites in tobacco smoke and industrial pollutants. The 
most potent of the carcinogens generating these metabolites are poly-
cyclic aromatic hydrocarbons, aromatic amines, and metals. Most of 
the carcinogens are metabolized by cytochrome p450 and glutathione 
transferase to unreactive compounds. However, a small fraction of 
highly reactive intermediates may form bulky adducts on cellular 
DNA. Adducts may be repaired by complex DNA repair mecha-
nisms, but residual unrepaired bases may cause replication errors 
that can be transmitted to daughter cells. The accumulation of these 
mutations and epigenetic changes are thought to be responsible for 
the ultimate transformation of preneoplastic epithelium into invasive 
carcinoma. 
Precisely which individual and combination of molecular changes 
are responsible for the acquisition of invasive properties by pre-
malignant epithelial cells is a central challenge in central airway 
carcinogenesis. To date, virtually all molecular changes including 
mutations, methylation, loss of heterozygosity and cytogenetic 
abnormalities that are present in invasive tumors have been described 
in pre-neoplastic epithelium. It appears that malignancy is associated 
with increasing numbers of mutations, copy number imbalances, 
cytogenetic and epigenetic changes in comparison to pre-malignant 
epithelium. A critical event in the development of invasive carcinoma 
may be clonal expansion of aneuploid cells. The detailed molecular 
mechanisms responsible for the development of aneuploidy remain 
unclear. At least a proportion of aneuploid changes are associated 
with p53 mutation. In relevant studies of Barrett’s esophagus, it 
appears that reduction to homozygosity of mutant p53 is critically 
associated with the progression to invasive carcinoma in the esopha-
gus. The level of precision in identifying premalignant anatomical 
sites, that is possible in the esophagus, has not yet been achievable in 
lung. However, it has been shown that aneuploidy is associated with 
invasive carcinoma at a cytogenetic level. Because of the central 
role of p53 in the development of aneuploidy, it seems likely that 
homozygous p53 mutation may also be a critical event in a large 
proportion of invasive lung cancers as well. 
A central challenge, therefore, in predicting and intervening in the 
natural history of central lung neoplasia is to identify molecular 
changes that are accessible and can therefore be tested in screening 
studies. To date, biomarkers of this type, while in many cases prom-
ising, have not been validated at a clinical level. Bronchial mapping 
of pre-neoplastic lesions in the central airways is one approach to 
studying the molecular events that precede invasive carcinoma at 
specific bronchial sites, but the logistics of this type of study will 
require large numbers of subjects probably in collaborative stud-
ies for an extended period of time. Ongoing studies of candidate 
biomarkers will be essential if mortality from lung cancer is to be 
reduced in the future.
Peripheral airway lesions in smokers
The molecular configuration of peripheral airway tumors (adenocar-
cinomas) in smokers is significantly different than that in the central 
airways. Notably, KRAS is much more frequently mutated in adeno-
carcinoma associated with smoking than the central airway lesions 
of squamous and small-cell carcinoma. The reason for this is not 
entirely clear at the present time. The leading candidate pre-neoplas-
tic lesion in the peripheral airways is atypical adenomatous hyperpla-
sia (AAH). KRAS mutation has been described in a large proportion 
of these lesions. KRAS mutation appears to be a marker of smoking, 
since it is rarely associated with malignancy in nonsmokers or AAH. 
Unfortunately, AAH is rarely identified outside the setting of surgical 
resection for lung cancer. One reason is the lack of visibility of these 
lesions and, even on pathological examination, they are frequently 
invisible. Thus, the progression from benign to malignant epithelium 
in the peripheral airways is even less well defined than in the central 
airways and, in many ways, the central airway epithelium can be 
considered as surrogate, albeit a limited one, for events occurring in 
the less accessible peripheral bronchiolar and alveolar epithelium. 
It seems likely that the pre-malignant loss of heterozygosity, DNA 
methylation, gene copy number changes, cytogenetic abnormalities 
and mutations that occurs in the central airways is likely to be pres-
ent in the peripheral lung as well. 
Central and peripheral changes in nonsmokers
The central and peripheral airways of nonsmokers rarely harbor 
significant cellular abnormalities detectable at a light microscopic 
level and data on the frequency of genetic and epigenetic abnor-
malities in non-malignant epithelium of never-smokers is virtually 
non-existent. However, the presence of EGFR mutations in a large 
proportion of never-smoker tumors has generated considerable 
interest in the pathogenesis of this neoplasm. The EGFR mutation 
can be demonstrated in benign epithelium from patients who harbor 
EGFR mutations lung tumors elsewhere in the lung. In fact, EGFR 
mutation has been noted in AAH lesions, in patients who have no 
EGFR mutation in tumors for which surgery has been performed. It 
therefore appears that EGFR mutation may be an early event in the 
development of lung carcinoma. The EGFR mutation is frequently 
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associated with high copy number of the EGFR gene, and it seems 
likely that duplication of the mutant gene may be a further step lead-
ing to progression to invasive carcinoma in patients without smoking 
history. There are other factors that may predispose to the develop-
ment of tyrosine kinase mutations in the peripheral airways, notably 
p53 mutation associated with Li Fraumeni syndrome. It appears that 
the genetic instability imparted by loss of mitotic checkpoint may be 
responsible for EGFR mutation. 
Progression and metastases
It is frequently noted that relatively low-grade tumors may progress 
to higher grade in the same tumor with increased invasiveness and 
capacity to metastasize. However, this is not an inevitable event and, 
in many cases, tumors that appear relatively low-grade may have the 
capacity to metastasize widely. The molecular events responsible 
for metastases and progression have not been completely identi-
fied. One phenomenon of interest that appears to be associated with 
higher metastatic rate is loss of E-cadherin and the development of 
epithelial mesenchymal transformation (EMT) in a subset of non-
small-cell carcinomas. In this phenomenon, tumor cells may take on 
sarcomatous properties and this transformation is regulated by the 
expression of snail and ZEB transcription factors. It appears that this 
transformation occurs in approximately 10% to 20% of lung cancers 
and its general applicability has not yet been clarified.
Finally, the introduction of deep genetic sequencing to the study 
of lung cancer has provided an opportunity to globally evaluate 
genomic changes at sites of malignant transformation and in the 
transition from local to metastatic disease. However, it will be critical 
in interpreting large scale genomic changes to be able to access pre-
malignant epithelium in order to determine which molecular events 
are critical for invasion and metastasis. This will require accessing 
of pre-malignant epithelium and more thorough sequencing and 
epigenetic analysis in critical airway sites than has heretofore been 
possible. The possibility of identifying molecular changes in the air-
ways before the development of invasive carcinoma in patients who 
are at risk remains a hope for reducing the morbidity and mortality 
from lung cancer in the 21st century.
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Introduction
Malignant mesothelioma (MM) is an asbestos-induced aggressive 
tumour of serosa which is increasing in incidence worldwide (1). 
MM tends to present at advanced stages with a broad range of fea-
tures, often including serous effusions and/or localised masses. MM 
diagnosis is generally clinically challenging with immunophenotyp-
ing of cytological and histological samples being required. The need 
for complementary biomarkers for MM diagnosis is well described 
(2). 
Early publications on biomarkers for the management of MM 
involved small patient numbers but several biomarkers, includ-
ing hyaluronic acid, tissue polypeptide antigen (TPA) and ferritin 
were found in serum and/or in effusions and were shown to help 
distinguish MM from either healthy controls or patients with benign 
disease. 
Mesothelin
Mesothelin is a GPI-linked surface protein on mesothelial cells 
(3). A mesothelin assay has been commercialised by Fujirebio Inc 
(‘MESOMARK’). In addition to mesothelin, the MESOMARK 
assay detects the related glycoprotein SMRP. SMRP and mesothelin 
are both products of the MSLN gene on chromosome 16p13.3 and 
alternative splicing of the gene results in the production of the two 
glycoproteins which have identical N-terminal regions and unique 
C-terminals. SMRP is 40kDa, has a hydrophobic tail, and thus is 
soluble; whereas mesothelin is a glycophoshatidylinositol-linked 
cell-surface glycoprotein which can be released from the cell surface. 
Mesothelin appears to be the predominant isoform produced by MM 
and ovarian cancers.
As MM is a mesothelin positive tumour it seemed logical to assess 
whether MM patients had elevated levels of mesothelin in their 
serum. Of 44 MM patients 37 (84%) had elevated mesothelin in their 
serum, compared to apparently healthy asbestos-exposed and non 
asbestos-exposed controls. 
The mesothelin assay is analytically robust, with no observed 
analytical interferences and mesothelin in stable inpatient samples. 
Notably, soluble mesothelin levels are not elevated in patients with 
benign asbestos related diseases, eg. pleural thickening and asbes-
tosis. Soluble mesothelin levels can be elevated in other non-MM 
malignancies such as ovarian cancer and in some lung cancer 
patients. Serum mesothelin clearly could form a component of the 
clinician’s repertoire of diagnostic tools for this difficult to diagnose 
disease (4).
Soluble mesothelin has also been elevated in pleural and peritoneal 
fluid from MM patients relative to levels in benign effusions (5). 
Effusion mesothelin appears to have greater sensitivity for MM 
and other malignancies, than does serum levels. Elevated effusion 
mesothelin levels can predate definitive cytological and/or histologi-
cal diagnosis. As the majority of MM patients present with effusions, 
elevated fluid mesothelin levels could suggest the need for active 
invasive investigations such as thoracoscopy and facilitate earlier 
diagnosis.
Osteopontin
Osteopontin has been proposed as a biomarker for various condi-
tions, including MM. Whilst serum osteopontin levels can distin-
guish between individuals with MM and healthy asbestos-exposed 
individuals, those with benign asbestos-related disease also show 
elevations. At a specificity of 95% relative to healthy controls and 
patients with benign asbestos related disease, osteopontin has a 
sensitivity of 47% for MM, limiting the utility of osteopontin as a 
diagnostic tool (6). 
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CA125
CA125 is a well characterised tumour marker which has problems 
with specificity, so serum CA125 levels has little value as a tool for 
differential diagnosis in patients with suspected MM. There is a role 
of CA125 in monitoring disease. 
Biomarkers and Screening
MM is strongly associated with asbestos exposure, mostly occu-
pational exposure and the risk of developing MM in an individual 
with substantial occupational asbestos-exposure can be over 20%. 
Potential biomarkers for screening for early diagnosis of MM have 
been published but none have proven to be useful clinically. 
Mesothelin can be elevated in serum up to several years prior to 
presentation with MM. In a prospective analysis of 538 occupation-
ally asbestos exposed individuals, 15 individuals (~3%) had elevated 
soluble mesothelin levels (7). When further evaluated by positron 
emission tomography (PET) and computed tomography (CT), one 
individual had chronic renal failure and was on dialysis but had no 
malignancy, another individual had early stage lung adenocarcinoma 
and a third patient had a suspected cardiac tumour. No malignancy 
was noted in the remaining 12 patients. Of note, during the period of 
the study two other individuals died, one from lung cancer and the 
other from pancreatic cancer but both had low soluble mesothelin 
levels. 
It should be noted that the relative risk of developing asbestos-
induced malignancy, which includes lung cancer as well as MM, 
depends upon the level and length of exposure to asbestos. One of 
15 in the above study with elevated soluble mesothelin was found to 
have a potentially curable, (possibly asbestos-induced) lung cancer. 
Soluble mesothelin will not be sufficient for screening for asbestos-
related malignancy Although there is no curative treatment for MM, 
further studies to evaluate screening of asbestos exposed individuals 
should not be discouraged.
Combinations of biomarkers
In a study of 66 MM patients we compared three markers, osteopon-
tin, MPF and soluble mesothelin in serum and found that at a 95% 
level of specificity, the sensitivity of these markers for MM was 34% 
for MPF, 47% for osteopontin and 73% for soluble mesothelin (6). 
When these markers were combined either by discriminant analysis 
or using a logistic regression model the sensitivity for detecting MM 
was not improved over that of mesothelin alone. 
Conclusion
An ideal biomarker for pleural MM has not been identified (8, 9). 
Soluble mesothelin has a role in diagnosis and monitoring of MM 
patients. Screening for asbestos-related malignancy has been under-
taken but none of the currently available biomarkers are sufficiently 
sensitive for this task. 
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Introduction
Malignant mesothelioma (MM) is a nearly invariably lethal tumor 
of the pleura or peritoneum for which the search of an active treat-
ment is still ongoing. If only given active supportive care the median 
survival is around 7.6 months (1) and when treated with single 
agent or combination therapy the median survival increases to 9-12 
months. Prognostic factors like histological subtype, performance 
score, thrombocyte count and extent of disease at time of diagnosis 
influence outcome of survival (2) and occasionally some long-term 
survivors have been reported. 
MM is notoriously refractory to the different treatment modalities 
available. Neither surgery nor radiotherapy alone has resulted in 
increased survival. Only in patients with a very limited stage long-
term survivors have been found. 
Second line therapy
Chemotherapy treatments have mostly been tested in phase 2 setting, 
either as single agents or in combination. Response rates of 14 to 40 
% with a small improvement in median survival have been reported 
in most phase 2 trials (3,4). Unfortunately most of these studies were 
small in size and non-balanced for prognostic figures.
Although some chemotherapy regimens like high dose methotrex-
ate, adriamycine, gemcitabine or cisplatin give a hint of improved 
survival and response rate, nearly all tumors recur within a year. A 
meta-analysis of clinical trials in the last century identified cisplatin 
as one of the most active agent (5). It is not often used as single agent 
nowadays but served as comparator in larger randomized studies 
and is still considered to be the backbone for combination therapy. 
One of the most recent improvements in the therapy of patients with 
mesothelioma is the use of pemetrexed. Pemetrexed is a multi-
target antifolate, which exerts its action by blocking three different 
enzymes that are involved in the folate metabolism (GARFT, TS 
and DHFR). Although its action as single agent is limited to 14% (6) 
it is active in combination with a platinum compound. Pemetrexed 
can be safely combined with cisplatin or carboplatin, with the latter 
being more acceptable in the elderly population. In 2003 the first 
large randomized phase 3 study in patients with mesothelioma was 
performed. It compared single agent cisplatin vs. cisplatin with 
pemetrexed and showed a significant improvement in response rate, 
median survival and quality of life (7). A comparable study tested 
the efficacy of raltitrexed plus cisplatin versus cisplatin alone and 
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showed nearly similar results (8). Close analysis of these data reveal 
that the achieved advantage in overall survival of 2-3 months cannot 
be maintained for two years or longer. Therefore it is imperative that 
new therapeutic approaches are explored in order to maintain an 
improved response and survival. This has lead to the development of 
combination of standard chemotherapy with targeted agents of which 
many studies are now ongoing in first line (Sunitinib, Bevacizumab, 
Axitinib, Erlotinib etc). Other studies address the question whether 
maintenance therapy is indicted for patients who showed clinical 
benefit of the initial treatment. As example a randomized phase 3 
study in The Netherlands examines the effect of Thalidomide in this 
group of patients versus observation based on data from a phase 2 
study (9). 
One of the important targets in cancer therapy and also in malignant 
mesothelioma is the vasculature. It is well understood that inhibition 
of vascular growth factors and angiogenetic compounds could play 
an important role in further management of this disease. Although it 
is not expected that the use of these factors will completely eradicate 
tumors, we hope they can inhibit progression of growth. Malignant 
mesothelioma cells often express vascular endothelial growth factor 
(VEGF) and to some extent basic fibroblast growth factor (b-FGF). 
The combination with the anti angiogenic drug bevacizumab has 
been studied in a large randomized phase 2 setting. It indicated that 
by proper selection the median overall survival was improved in both 
arms when bevacizumab was added to a standard regimen of cispla-
tin and gemcitabine (10).
Second line therapy
In second line treatment of mesothelioma only a few studies have 
been published so far. One of the first was a study published in 
2002, which tested the experimental platinum compound ZD0473. 
Although no objective responses were observed it became clear 
that with proper patient selection, drugs could be tested in a second 
line setting in patients with mesothelioma. Since then a number of 
studies in phase 2 setting have reported combination therapies of 
gemcitabine with oxaliplatin; gemcitabine with vinorelbine; cisplatin 
with irinotecan and mitomycin or single agents like vinorelbine; 
pemetrexed or bortezomib. In phase 3 setting only one study has cur-
rently been published in second line. The use of pemetrexed versus 
best supportive care was tested and showed a significantly better time 
to progression in the active treatment arm but no improvement in 
overall survival was observed. Currently a large randomized double 
blind study in mesothelioma is exploring the effects of Vorinos-
tat. Vorinostat is an oral agent which inhibits class I and II histone 
deacetylases, is a potent inhibitor of mesothelioma growth in vitro. 
In a phase I trial of vorinostat, 2 partial responses were observed in 
patients with mesothelioma and was the reason for further develop-
ment of this drug. Quality of life increased in patients treated with 
vorinostat and a decrease in dyspnea or pain was observed in all 
patients who did not show signs of clinical progression. The phase 3 
study is ongoing and has accrued 285 of the 660 patients required in 
second or third line.
In conclusion for first line treatment most schedules are platin based 
and combined with an anti-folate. New, targeted, drugs are tested 
with this combination to improve survival and time to progression. 
For second line treatment no standard of care has yet been defined. 
Best supportive care, local radiation therapy and pain treatment 
should be given to patients when required. Testing of new drugs in 
second line is only indicated as part of a study protocol.
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The challenges of new drug development for mesothelioma
Kindler, Hedy L.
Medical Oncology, Mesotheliona Program, University of Chicago, 
Chicago, IL, USA
Modest, but genuine progress has been made in recent years in the 
systemic treatment of malignant mesothelioma. Cytotoxic drugs with 
single-agent activity include pemetrexed, raltitrexed, vinorelbine, 
and vinflunine. Unfortunately, response rates are still no greater than 
25%. Adding pemetrexed or raltitrexed to cisplatin prolongs survival, 
but only by 3 months or less. Adding a platinum to pemetrexed, 
raltitrexed, irinotecan, vinorelbine, or gemcitabine increases the 
response rate, but only by 10 to 20%. In preclinical models, many 
novel agents have appeared ‘promising’, but few have activity in 
clinical trials.
Why can’t we do better? Several factors have hampered the develop-
ment of effective regimens for mesothelioma. What are they, and 
how might we overcome them?
Mesothelioma is uncommon, thus most clinical trials are small. This 
can result in false positive and false negative results. The low inci-
dence of this cancer also makes it challenging to perform adequately 
powered randomized studies. Response assessment is difficult. The 
disease is hard to measure, and assessment criteria vary between 
trials. Mesothelioma is heterogeneous disease, with many prognostic 
factors, and three pathologic subtypes that produce very differ-
ent outcomes. Since staging is unreliable, there is no approach that 
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can accurately select non-surgical patients with similar prognoses. 
Patients with stages I-IV may therefore participate in the same trial.
How are new agents selected for clinical trials in this disease? Pre-
clinical data that suggests activity is often a starting point, although 
promising preclinical data has led to many disappointing results in 
patients, and there is limited information about many targets in this 
disease. The choice of drug is usually based on the availability of 
agents for clinical testing against a target of interest, phase I single-
agent and combination safety data, and most importantly, the willing-
ness of a pharmaceutical company to test an agent in mesothelioma.
There certainly are several advantages to developing new drugs 
for mesothelioma. It should be relatively easy to get a new agent 
approved, because there is only one drug currently approved by the 
FDA and EMEA for mesothelioma. Once a drug is approved for this 
uncommon indication, it may be more readily licensed for a second, 
more lucrative indication, as occurred for pemetrexed in non-small 
cell lung cancer. Survival is relatively short, so trials complete 
quickly. Trials are small, so they require less of a financial invest-
ment. Due to the epidemiology of asbestos exposure, the incidence is 
regionalized, as are the centers of excellence. 
But there are even more challenges in developing new agents for 
mesothelioma. Most importantly, many drugs don’t work. While 
much exciting preclinical research is ongoing in this disease, we 
still understand less about mesothelioma biology than many other 
cancers, hence we may be less well-equipped to select appropriate 
targets. Mesothelioma is uncommon, therefore it is not profitable. 
The potential market is small, so it is a major challenge to inter-
est drug companies and grant funding agencies. Large trials can be 
difficult to accrue, requiring many centers in many countries over 
many years. The same drugs may produce very different outcomes in 
different trials, because it is difficult to accurately measure response, 
there is significant variability in prognostic factors, and it is difficult 
to accurately stage. 
Once the new drug is chosen, how should it be studied? We will 
discuss several possibilities, each with its pros and cons: first-line, 
single-agent; first-line, in combination with pemetrexed-cisplatin or 
other cytotoxic chemotherapy; and maintenance, adjuvant, neo-
adjuvant, or second-line approaches. We will also address different 
trial designs.
The bottom line is that there are a limited number of agents that will 
be available to study in this disease, and a limited pool of patients to 
test them in. To move forward, we certainly need better drugs, and 
we need to be appropriately selective about the ‘promising’ drugs 
we move from the bench to the clinic. Finally, we need to focus on 
designing the proper trials, or we may miss an active agent, or con-
clude erroneously that an inactive regimen merits further study, only 
to be disappointed later. 
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Cost studies in lung cancer – what is the purpose?
Bishop, Jim F.; Tracey, Elizabeth A.
Cancer Institute NSW, Eveleigh, NSW, Australia
Background: A number of lung cancer patterns of care studies have 
been conducted in New South Wales (NSW).This study provides 
a comprehensive overview of the cost of lung cancer in NSW and 
projects future costs. 
Methods: The cost model used in this study used unit costs for each 
stage along the care pathway by considering the identified types of 
care the patients receive along the pathway (consultations, diagnosis 
and staging, treatment, MDT management, follow up and supportive 
care) and applies these to the estimated proportions of lung cancer 
patients actually receiving treatment based on the patterns of care 
studies. Direct costs were based on official costs provided by the 
Australian Institute of Health and Welfare data. Indirect costs were 
based on mortality and survival estimates obtained from the NSW 
Central Cancer Registry applied to obtain disability adjusted life 
years and were adjusted for co morbidities using the Human Capital 
approach. The willingness to pay method was also used to estimate 
indirect costs. Other indirect costs include out of pocket expenses 
born by lung cancer patients as classified by Kirschstein. Further 
modelling of projected costs was calculated. 
Results: The direct health care cost per case of lung cancer in NSW 
in 2005 was $23,282. Treatment costs were the largest component 
accounting for 35 per cent of costs followed by supportive care 32 
per cent, diagnosis and staging 11 per cent and 10 per cent of other 
costs. Costs varied by stage with localised lung cancer incurring the 
highest direct costs of $25,332 per case. Regardless of stage patients 
who received surgery, chemotherapy and radiotherapy incurred 
direct costs of $55,099 exceeding or over $100,000 if patients had 
complications. Patients without active treatment incurred the lowest 
direct costs of $8,224. Indirect costs per case varied depending on 
the method but increased with stage. Overall stage IV lung cancer 
patients had direct and indirect costs that were 19 per cent higher 
than the average. If earlier detection and diagnosis could reduce the 
incidence of stage IV lung cancer and increase stage I then each case 
detected earlier would reduce the cost by between $151,985 and 
$321,242. 
Conclusion: This study clearly shows that stage shift due to early 
detection leads to a reduction in costs overall. It is not known 
whether chest X rays or CT scanning are effective for early detec-
tion of a population. A modification of best practice, early detection 
or screening in the future will allow future costs of lung cancer to be 
considered.
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The use, cost, and cost-effectiveness of 
chemotherapy for nonsmall cell lung cancer
Ramsey, Scott David
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Background: Lung cancer is the most common non-skin cancer in 
the developed world, and a major source of cancer-related morbidity 
and mortality. Because most patients present with advanced stage 
disease, adjuvant or palliative chemotherapy is commonly indicated. 
Following regulatory approval of several novel agents for advanced 
nonsmall cell lung cancer (NSCLC), the costs of treating this condi-
tion has increased markedly in developed countries with public and 
private health insurance plans that cover these drugs 
Methods: First, the presentation will review the budget impact and 
cost-effectiveness of chemotherapy and novel agents used to treat 
advanced NSCLC, focusing on erlotinib, pemetrexed, bevacizumab, 
and cetuximab. Second, the use of cost-effectiveness analysis and 
other strategies to guide reimbursement policies for cancer chemo-
therapy in the United States, Canada, United Kingdom, and Aus-
tralia, and the implications for use of costly novel agents in those 
countries is reviewed. 
Results: The cost effectiveness of newer agents varies widely, 
ranging from relatively cost-effective to modest or poor cost-
effectiveness as gauged by country-specific standards of value for 
expenditure. Most US insurers have relatively open policies regard-
ing coverage of chemotherapy for cancer, although patient access is 
being increasingly threatened by placing costly agents into “4th tiers” 
with copays that can reach 50% of purchase price. In contrast, in the 
UK, Australia, and Canada, patient cost-sharing for costly drugs is 
minimal, yet these national health systems are adopting policies that 
are increasingly restrictive, largely based on internal and external 
analyses that show poor value for money. In response to rising costs 
of drugs throughout these health systems, payers and manufacturers 
are entering into novel funding schemes, such as “pay for perfor-
mance” programs, for some drug as a way to allow access to novel 
agents under flexible reimbursement systems. Whether such schemes 
will be applied to therapies for NSCLC is unclear.
Conclusion: The rapid rise in the cost of treating lung cancer, 
combined with the burden of this disease in society, is forcing health 
systems throughout the world to establish reimbursement schemes 
that consider value for money. Therapies that show poor value (e.g., 
minimal improvements in survival, quality of life, or both) are lead-
ing to “hard choices” in some systems, although not without some 
political resistance. The United States has been resistant to adopting 
cost-effectiveness as a means for restricting access to costly cancer 
therapies, yet the degree of cost sharing now being imposed on many 
patients for novel lung cancer agents may be creating other access 
issues. The best hope for improving access to costly cancer therapies 
likely lies in researcher’s ability to find targets that predict differen-
tial response. The cost-effectiveness of such ‘personalized medicine’ 
approaches may be superior to current care. 
E13.3 Cost Effectiveness of Lung Cancer Care, Sun, Aug 2, 10:30 - 12:00
Molecular Targeted Therapy – Can We Afford it?
Evans, William K.
McMaster University and Juravinski Cancer Centre, Hamilton, 
Ontario, Canada
The total cost of cancer is greatest in high income industrialized 
countries where there is a high incidence of lung and other cancers 
and adequate resources to enable state-of-the-art care to be given. 
However, even wealthy nations are under pressure to contain health 
care costs and the economic burden resultant from new health care 
technologies will exceed the capacity of most, if not all developing 
countries to provide evidence-based care. Governments, insurers 
and health care institutions alike are critically examining the value 
of health care interventions and the efficiency of health care delivery 
systems. The cost of drugs is rising faster than other health care costs 
and so the cost-effectiveness of new drugs such as the molecular 
targeted therapies is of keen interest to funders.
Data on drugs may be presented in many forms – as the cost to 
treat an individual (cost per case), as the economic impact to the 
funder (government in a publicly funded system; insurer in a private 
coverage system) of the total number of treated cases over a defined 
period, or as the costs in relation to the consequences in compari-
son to an alternative drug therapy. Many governments now review 
information on cost-effectiveness as part of the decision-making for 
funding approval as it provides an estimate of the value of the inter-
vention relative to the money expended on it. 
A cost-effectiveness analysis is the most common form of economic 
analyses that can be performed and it provides information on the 
incremental cost of the intervention compared to the standard therapy 
over the incremental benefit measured in life years gained. The 
incremental cost per case (ICER) can then be used by decision mak-
ers to determine if a new therapy represents good value for money 
or is “cost-effective”. A value less than $50,000 per life year gained 
(LYG) is generally considered “cost-effective” but there is little to 
recommend this specific number as a threshold of cost-effectiveness. 
A range from $20,000-100,000/LYG is more realistic. The weak-
ness of cost effectiveness analysis is that it does not take account of 
the morbidity of a disease state like lung cancer and its treatment. 
A quality adjusted life year (QALY) incorporates morbidity into a 
single multi-dimensional measure (i.e. the quantity of life gained 
by treatment weighted by the quality of that life). The quality of life 
is approximated by a utility which is a measure of preference for a 
given health state rated on a scale where 0 equals death and 1 equals 
perfect health. “Standard gamble” exercises, time trade off and direct 
rating on a visual analogue scale can be used, as well as specific 
instruments such as the Health Utilities Index and Euro QoL.
In interpreting the results of an economic analysis, it is important 
to be aware of issues such as the differences in health care systems, 
costs versus charges, the transparency of the analysis, the use of dis-
counting and sensitivity analysis and the methodologies for assess-
ing effectiveness. The interested reader is directed to guidelines for 
reporting economic studies (1) and strategies to critically appraise 
economic analyses (2,3).
Most of the new molecular targeted therapies cost more per average 
treated case than the cytotoxic agents that preceded them. Agents 
such as gemcitabine, paclitaxel and taxotere were considered to 
be very expensive when introduced at roughly $3,000, $4,750 and 
$5,320 Cdn respectively per average treated case, but now appear 
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inexpensive relative to the cost of molecular targeted therapies 
(MTTs) such as the monoclonal antibodies targeted to specific recep-
tors (erlotinib $16,500 per case (5) need cost per case and beva-
cizamab at $40,000 per case). As the survival gain is measured in 
mere months, it is not surprising that these agents push the limits of 
generally accepted cost-effectiveness. 
Other molecular targeted therapies are also at or above the level that 
funding agencies commonly accept for cost-effectiveness or cost-
utility.
Trastuzumab in adjuvant breast cancer $40,000 per QALY (4)
Sorafinib in renal cell carcinoma $89,000 per QALY (6)
Bevacizamab with 5FU/LV in stage IV CRC $114,000 per QALY (7)
Cetuximab + irinotecan in CRC $127,000 per QALY (8)
Sunitinib in second-line GIST $143,000 per QALY (9)
Bortezomib in refractory multiple myeloma $275,500 per QALY(10)
The consequence of this has been that a number of national review 
bodies have recommended against funding some of these agents: 
NICE in the United Kingdom recommended against funding beva-
cizamab with 5FU/LV in stage IV colorectal cancer (CRC), second-
line cetuximab in stage IV CRC, sunitinib and sorafenib in renal cell 
and erlotinib in NSCLC; the Pharmaceutical Benefits Advisory Com-
mittee (PBAC) in Australia recommended against funding cetuximab 
in CRC and the Common Drug Review in Canada has recommended 
against sunitinib and sorafenib.
The high drug costs and the refusal to fund them in some jurisdic-
tions has had negative consequences for consumers and led to a 
variety of responses from industry and governments. Canada’s 
attempt to regulate the price of cetuximab through its usual pro-
cesses resulted in the manufacturer refusing to launch the drug and 
resulted in patients being unable to access a potentially useful agent. 
In the United States, the high cost of drugs has hurt Medicare/Medi-
cade patients because of the high co-pay, which can be as much as 
$10,000 for bevacizamab.
One US jurisdiction (DC) passed legislation to reduce drug prices 
but was successfully sued by two major pharmaceutical companies 
and the law was ruled unconstitutional by the US Supreme Court. 
A more innovative approach to managing the cost of the MTTs has 
been attempted in the UK where Johnson and Johnson offered to 
forgo charges for patients who did not have an adequate response to 
the drug. An adequate criterion for response had to be negotiated; 
NICE and Johnson and Johnson agreed on the indicator (monoclonal 
protein level) but had difficulty agreeing on the degree of reduction 
(25% versus 50%) (11)
A possible new way of selecting those most likely to benefit may be 
to use a combination of clinical and molecular markers to identify 
the patients with the greatest probability of response and an accept-
able cost-effectiveness ratio. The NCIC CTG trial of erlotinib versus 
placebo in metastatic NSCLC patients who had failed two prior lines 
of chemotherapy demonstrated improved progression free and over-
all survival. Clinical predictors of a better outcome included female 
gender, adenocarcinoma histology, never smoker and Asian origin. 
Molecular predictors included EGFR protein expression, EGFR gene 
amplification and Kras gene mutations. The incremental cost-effec-
tiveness ratio was $95,868/LYG (95% CI $52,399 - $429,149). The 
ICER is more favorable for never smokers ($39,486/LYG) and for 
EGFR gene amplification ($33,353/LYG). Combinations of clinical 
and molecular markers might define those patient populations most 
likely to benefit at an acceptable level of cost-effectiveness. This type 
of approach may be even more relevant as combinations of MTTs are 
identified to be effective. (12)
Finally an innovative new approach to rewarding innovation has 
been suggested by Joseph Stiglitz, a Nobel prize-winning econo-
mist (13). He argues that the current system of intellectual property 
protection and the creation of a monopoly for drug production and 
distribution leads to higher prices and more limited access in the 
developing world. As an alternative, he has suggested a global fund, 
paid for by the industrialized nations that would award large prizes 
for curative drugs or vaccines that prevent diseases and that affect 
many people. Me-too drugs that do no better than existing ones 
would get a small prize, if anything. Awarding prizes would be both 
more efficient and more equitable and would provide a strong incen-
tive for research.
The current situation is increasingly intolerable to patients and physi-
cians alike and new approaches are clearly needed. The molecular 
targeted therapies have pushed us to the brink where new innovative 
strategies for drug funding will be required. 
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E14.1 Emerging Options for Therapy in Early Stage NSCLC, Sun, Aug 2, 10:30 - 12:00
Current status of stereotactic body 
radiation therapy (SBRT)
Nagata, Yasushi
Hiroshima University Hospital, Dept. of Radiation Oncology, 
Hiroshima, Japan
Stereotactic body radiation therapy (SBRT) is a new technique, 
introduced in the late 1990s. SBRT is a method of using single 
10-20Gy of high dose and hypofractionated radiotherapy using three-
dimensional conformal technique. Recently, many papers have been 
published on its clinical results, especially in early stage lung cancer. 
The purpose of this presentation is to evaluate the past clinical results 
and introduce the current status of SBRT for lung cancer.
The key issues for SBRT are fixing apparatus, respiratory regula-
tion, treatment planning and verification. A few types of stereotactic 
body frames are available. For regulation of respiratory movement, 
abdominal wall compression, breath-holding, respiratory gating and 
tumor chasing methods were used. For irradiation technique, 6 to 
10 non-coplanar beams or multiple arc beams were adopted. Daily 
verification before radiotherapy is mandatory for SBRT. Portal films, 
EPID and CT on rails were used. Frequently used radiation regi-
mens were 48 to 60 Gy in 3 to 5 fractions. Single dose radiosurgery 
technique is still pursued in a few institutes. The local relapse-free 
rates were almost always between 85 to 95 % for lung cancer. Long 
term follow-up results have also been reported. The number of seri-
ous complications was very low. The patient accrual for RTOG 0236, 
60 Gy in 3 fractions, was complete, and for JCOG 0403, 48 Gy in 
4 fractions, was also finished. The other currently ongoing multi-
institutional protocols will be introduced and several unanswered 
questions will be discussed in this presentation.
E14.2 Emerging Options for Therapy in Early Stage NSCLC, Sun, Aug 2, 10:30 - 12:00
Radiofrequency ablation for lung cancer
Fernando, Hiran Chrishantha
Department of Cardiothoracic Surgery, Boston, MA, USA
Radiofrequency ablation (RFA) has been used in many centers for 
patients with liver tumors. RFA is now being used increasingly to 
treat lung tumors, with several reports with intermediate follow-
up appearing in the literature. RF energy consists of an alternating 
current that moves from an active electrode that is placed within the 
tumor to dispersive electrodes that are placed on the patient. As the 
RF energy is applied, frictional heating of tissues results with cell 
death occurring at temperatures beyond 60ºC. In most cases RFA is 
performed using a percutaneous approach with CT guidance.
RFA can be used for patients with primary lung cancer and limited 
pulmonary metastases. RFA is most effective for smaller tumors 
(3cm or less), although tumors up to 5cm can be effectively ablated. 
Unlike resection, lymph nodes are not removed, and occult nodal 
disease may be missed, leading to local failure as well as understag-
ing of disease. It is also not guaranteed that 100% tumor destruction 
with an adequate therapeutic margin will be achieved when ablation 
is used, although this is more likely for smaller tumors and may 
be improved with new ablation technologies such as microwave or 
irreversible electroporation. Surgical (lobectomy or sublobar) resec-
tion should continue to be the preferred therapy for patients with 
early stage lung cancer. RFA is a good option for those patients who 
are felt to be at increased risk for resection, or refuse resection, when 
operation would otherwise be appropriate therapy. Additionally RFA 
may be used for local control of peripheral tumors in patients with 
more advanced cancers in combination with other therapies.
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Stage specific therapy for NSCLC: 
choosing the right operation
Krasna, Mark J.
St Joseph Cancer Institute, Towson, MD, USA
The role of surgery in NSCLC is key to curative therapy. A stage 
specific approach, however, must be employed in ascertaining the 
place and type of surgery in the armamentarium. Without surgery the 
Prognosis is dismal with 95% Mortality.
Operable Treatment is possible in about 50% of patients. Of these 
approximately 50% are resectable. The Overall Survival (5 year) for 
NSCLC patients is 25- 35%. For those who are LN (-) : 49% whereas 
those who are LN (+) : 31% even for T1 tumors.
This underscores the importance of Lung Cancer Staging. This can 
include all or some of the following Surgical Procedures: Mediasti-
noscopy, Scalene Lymph Node Exploration, Chamberlain Procedure, 
and Video-assisted Thoracoscopy (Left side lesions especially).
The surgical approach to these lesions may involve the following 
operations: Lobectomy, Anatomical Segmentectomy, Wedge Resec-
tion, VATS Lobectomy, and pneumonectomy (rare for early stage 
lesions!).
The role of VATS lobectomy is currently being assessed. Using Rou-
tine staging, Anatomical lobectomy other than Technical concerns the 
procedure should have the same oncologic impact. There are some 
potential Disadvantages including a steep learning curve. In a review 
of 13 Studies (>25 pts) with over 580 patients, there was Comparable 
Morbidity/Mortality, Equivalent Survival. There were some obvious 
differences in some Intrinsic issues related to a minimally invasive 
procedure such as Conversions, Pain, OR Time, Port Mets.
Another challenge is the role of chemotherapy in early stage NSCLC. 
There has been much progress in this area over the last 5-10 years. 
The use of neoadjuvant chemotherapy as described by the BLOT 
trial were recently reviewed in Stage I on protocol 0111. This was 
a Phase II for Stages I and II where they received Neoadjuvant 
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Chemotherapy using either Gemcitabine + Carboplatin vs. Gemcit-
abine + Cisplatin. Adjuvant therapy for stages I and II was studied in 
several recent reports including CALGB 9633. Patients with Stage 
I- T2N0 underwent Surgery first and were then randomized to obser-
vation vs Chemotherapy with Taxol + Carboplatin. In patients with 
stage IB and stage II disease there was a mean 5% improvement on 
overall and disease free survival.
The role of chemoradiotherapy followed by surgery is well described 
for patients with stage IIIA disease as well as those with Pancoast 
tumors. In general combined modality therapy is superior to radio-
therapy alone in Stage III disease. Recent studies have defined the 
role of concurrent vs sequential chemoradiation. In general a plati-
num based regimen with a second drug is utilized in the neoadjuvant 
setting. Radiation doses from 4500-7200 have been employed with 
a mean dose of about 60cGy used at most institutions at present. 
What the role for consolidative chemotherapy is remains unclear. 
Whether or not PCI adds to survival or recurrence free survival will 
soon be known after the results of rtog 0214 are analyzed. The role 
of surgery in Stage III disease is better local control and resection of 
patients who have had mediatinal nodal clearance by chemoradiation. 
Some authors still advocate chemotherapy followed by surgery but 
the response rate is much lower in these series. There is a growing 
consensus among thoracic surgeons that there is a role for trimodality 
therapy.
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Chemoprevention: past, present and future
Kim, Edward S.
Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, 
USA
Chemoprevention is defined as the use of specific natural, synthetic 
or biological agents to reverse, suppress, or prevent the carcinogenic 
progression into invasive cancer. Chemoprevention is a rational 
approach to treating patients with medical conditions. Examples 
include cardiac patients who take low dose aspirin do so in hopes 
of preventing a future ischemic event, breast cancer patients where 
the use of hormonal agents to prevent recurrence and contralateral 
disease in hormone-receptor positive tumors, and vaccines targeting 
hepatitis B virus (leading to hepatocellular cancer) and human papil-
lomavirus (leading to cervical cancer) are major clinical chemopre-
vention successes. 
Lung cancer is a worldwide epidemic, with an estimated annual 
incidence of over 1.2 million cases and over 1.1 million deaths. In 
advanced disease, multiple drugs have been approved for therapy 
including traditional cytotoxic and molecularly targeted therapy. 
However, large-scale lung cancer chemoprevention trials (Alpha-
Tocopherol, Beta-Carotene [ATBC] trial, Beta-Carotene and Retinol 
Efficacy Trial [CARET], Lung Intergroup Trial [LIT]), have yet to 
show that any agent can reduce lung-cancer risk. Like therapy, early 
detection, and smoking cessation before them, these lung preven-
tion trials demonstrate the tremendous obstacle that extremely 
complex lung-cancer biology poses for any approach to control the 
burden of this disease. Identifying molecular mechanisms involved 
in carcinogenesis provides strong rationale for developing strategies 
for cancer treatment and prevention. The few molecular-targeted 
drugs that have been evaluated extensively in cancer prevention 
trials include cyclooxygenase-2 (COX-2) inhibitors (colon cancer 
prevention), selective estrogen receptor modulators (SERMs; breast 
cancer prevention), and 5-alpha reductase inhibitors (prostate cancer 
prevention). These approaches have provided the proof of principle 
of feasible, effective molecular-targeted cancer chemoprevention.
If we are to improve survival in lung cancer through therapy and 
prevention, we must focus on incorporating high risk populations 
and reliable biomarkers. Clinical trials must be tissue-based in order 
to study which drugs are best for individual patients. Risk model 
development is essential for chemoprevention strategies to be suc-
cessful. Lung cancer chemoprevention for the 21st century must be 
able to effectively translate clinical factors, targeted therapies, and 
basic science research.
E15.2 Chemoprevention: Past, Present and Future, Sun, Aug 2, 10:30 - 12:00
High throughput screening and the discovery of natural 
product-derived compounds for cancer prevention
Fu, Haian1, 2
1 Departments of Pharmacology, Hematology and Medical Oncology, 
Emory University School of Medicine, Atlanta, GA, USA;  
2 Emory Chemical Biology Discovery Center, Emory University 
School of Medicine, Atlanta, GA, USA
Recent developments in genomics research, molecular oncology, 
and laboratory automation provide unprecedented opportunities for 
breakthrough discoveries leading to critical new insights into the 
pathological conditions that trigger human cancers. However, trans-
ferring this knowledge into practical gains in cancer prevention has 
moved slowly. Traditionally, chemoprevention agents are identified 
by empirical means and tested in individual bioassays one at a time. 
The establishment of academic high throughput screening centers 
has now changed the way that we discover new anti cancer agents. 
This talk will introduce high throughput screening (HTS) and high 
content screening (HCS) technologies available at the Emory Chemi-
cal Biology Discovery Center. Three case studies will be presented 
to illustrate the discovery of anticancer agents through HTS and 
HCS. The first case study focuses on 14-3-3 proteins to demonstrate 
the strategy for identifying small molecule inhibitors for promising 
molecular targets. 14-3-3 proteins have been shown to promote tum-
origenesis in part through their role in sustaining tumor cell survival 
and avoidance of anoikis. Upregulation of 14-3-3 has been correlated 
with poor survival of patients of lung cancer, breast cancer, and 
pancreatic cancers. Therefore, targeting 14-3-3 may identify agents 
for chemoprevention and chemotherapy. An HTS assay using fluores-
cence polarization technology was established for mornitoring 14-3-
3/ligand interactions, and was subsequently used to screen several 
compound libraries. Candidate 14-3-3 inhibitors have been identified 
and are now under vigorous testing in various bioassays. The second 
case study will highlight the use of HCS to characterize the activity 
of a natural product, curcumin, and its derivatives. An HCS assay 
was established to monitor the cytoplasmic to nuclear translocation 
of the p65 subunit of NF-κB in response to NF-κB activation signals 
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such as TNFα. NF-kB is a well characterized chemoprevention tar-
get, which is used here to identify potent curcumin derivatives with 
improved pharmacological properties. Through this assay, a number 
of promising compounds were identified. Two were selected for fur-
ther examination with the goal of moving forward to a human phase 
0 clinical trial as a component of a Head and Neck Cancer SPORE 
project. The third example will illustrate the use of transgenic 
zebrafish for the identification of angiogenesis inhibitors in an HCS 
format. This study has led to the discovery of new anti-angiogenesis 
agents for future development. These studies demonstrate the power 
of HTS and HCS for rapid discovery of mechanism- and natural 
product- based chemoprevention agents.
E15.3 Chemoprevention: Past, Present and Future, Sun, Aug 2, 10:30 - 12:00
Transgenic mouse models as tools for 
lung cancer chemoprevention
Dmitrovsky, Ethan1; Liu, Xi1; Galimberti, Fabrizio1; Ma, Tian1;  
Guo, Yongli1; Dragnev, Konstantin H.1; Memoli, Vincent A.2; 
Freemantle, Sarah J.1; Sempere, Lorenzo1
1 Dartmouth Medical School, Hanover, NH, USA; 2 Dartmouth 
Medical School, Lebanon, NH, USA
There is need for innovative strategies to treat or chemoprevent lung 
cancers. One way to achieve this is to engineer genetically defined 
mouse models that recapitulate key features of lung carcinogenesis 
found in patients. Ideally, a murine lung carcinogenesis model would 
be generated by the same genetic alterations as found in human lung 
carcinogenesis. For this reason, we chose to independently target to 
the lung with the human surfactant C promoter (hSP-C) expression 
of wild-type and proteasome-degradation-resistant cyclin E species. 
Cyclin E is a key regulator of the G1-S cell cycle transition and is 
a negative prognostic factor in lung cancer. Cyclin E is frequently 
aberrantly expressed in pre-malignant and malignant lung lesions. 
Two independent hSP-C-driven wild-type human cyclin E and two 
independent hSP-C-driven proteasome-degradation resistant human 
cyclin E lines were engineered. Three of these lines had comparable 
levels of exogenous cyclin E expression, allowing comparisons 
between them. These lines developed chromosome instability, 
pulmonary dysplasia, hedgehog pathway activation, as well as single 
and multiple lung adenocarcinomas and even metastases, as reported 
(Ma Y, et al. Proceedings of the National Academy of Sciences 
(USA) 104:4089-4094, 2007). To learn whether these lines are tools 
to predict genetic abnormalities found in human lung carcinogen-
esis, microRNA (miRNA) microarray analyses were performed to 
search for growth suppressive miRNAs in these transgenic lines 
and in a well-characterized paired human normal/malignant lung 
tissue bank (Liu X, et al. Clinical Cancer Research 15:1177-1183, 
2009). Novel lung cancer cell lines were independently derived from 
wild-type (ED-1 cells) and proteasome-degradation-resistant (ED-2 
cells) transgenic cyclin E expressing murine lung cancers. Notably, 
miR-34c, miR-145, and miR-142-5p were each repressed in murine 
and human lung cancers (by real-time reverse transcription poly-
merase chain reaction and in situ hybridization assays) as well as in 
ED-1 and ED-2 cells. When each of these species was engineered as 
over-expressed individually in ED-1 and ED-2 cells, this markedly 
suppressed lung cancer cell growth. Intriguingly, cyclin E was identi-
fied as a bioinformatic target of miR-34c and engineered miR-34c 
over-expression triggered cyclin E repression. Currently, oncogenic 
miRNAs are under study in these same models and in human lung 
cancer cell lines to learn whether these miRNAs aberrantly expressed 
in murine lung cancers are also altered in human lung carcinogen-
esis. Since ED-1 and ED-2 cells are syngeneic with FVB mice from 
which these transgenic lung cancer cells were derived, we took 
advantage of this and found that tail vein injections of each of these 
cells rapidly leads to lung adenocarcinoma formation in mice. These 
murine transgenic transplantable lung cancer models are currently 
being used to explore anti-neoplastic activities of targeting the cyclin 
E-CDK-2 complex as well as other pathways, as will be presented. 
Taken together, these models are useful tools to expedite translational 
lung cancer research by using these transgenic mice and derived 
lung cancer cell lines as well as a large panel of human lung cancer 
cell lines to rapidly assess anti-neoplastic effects at the bench before 
launching hypotheses driven clinical trials. This would test activities 
of novel agents that target cyclin E or other oncogenic species.
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Outcome measures in the national lung screening trial
Pastorino, Ugo
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Lung cancer is the first cause of cancer mortality in developed coun-
tries. Metastatic disease at diagnosis is the main reason of failure, 
and low-dose spiral CT has shown its ability to detect early lung can-
cer, with higher resectability and better long term survival. However, 
the capacity of annual CT screening to reduce lung cancer mortality 
in heavy smokers has still to be demonstrated. 
Screeniing trials with chest radiography were unable to decrease lung 
cancer mortality, despite the higher proportion of early stage cancers, 
and 25 years follow-up showed a higher mortality in the screening 
arm.
The International ELCAP study group reported a 92% 10-years sur-
vival in screening detected clinical stage I lung cancers, claiming that 
spiral CT could prevent 80% of all lung cancer deaths in smokers. At 
the same time, a meta-analysis of three single-arms studies showed 
that CT screening resulted in a 3.5-fold increase of lung cancer 
diagnoses, a 10-fold increase of surgical resections, but no decrease 
of the number of advanced lung cancers or lung cancer deaths. The 
most obvious explanation of such a discrepancy is that spiral CT 
can detect slow-growing or “indolent” lung cancer at a much earlier 
stage, but is unable to intercept the fast-growing or “most aggres-
sive” disease before the onset of metastases, throughout the trial. 
Prospective randomized controlled trials remain the most adequate 
instrument to test the efficacy of annual CT screening in heavy smok-
ers, and the National Lung Screening Trial (NLST) is the largest 
randomized controlled trial comparing CT screening vs. chest radiog-
raphy, with lung cancer mortality as the end point. More than 50,000 
participants were enrolled across the United States. Screening ended 
in 2006, and subjects are currently in follow-up, with final results 
expected in 2010.
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Lung cancer specific mortality represents the main outcome measure 
of NLST trial, and this study has the appropriate design and size to 
assess even modest differences between the two arms. 
Frequency of locally advanced or metastatic lung cancer is the other 
major issue, to understand the ultimate results of chest monitoring 
on mortality. In particular, it will be crucial to assess the incidence of 
subcentimetric lesion presenting with metastases, and the frequency 
and stage of second primary cancers.
Prevalence of overdiagnosis, represented by well-differentiated stage 
Ia adenocarcinomas with major bronchiolo-alveolar (BAC) compo-
nent, in the other side of potential screening failure. Proportion of 
subjects undergoing lung biopsy or anatomical resection for benign 
diasease, as well as morbidity and mortality for all screening-related 
surgical procedures, is an important measure of short term screening 
toxicity.
Quality and quantity of smoking in the two arms, attempts to quit 
and use of pharmacological support, should bre carefully monitored 
throughout the trial.
Overall mortality for all causes in the two arms is another impor-
tant outcome measure for NLST trial. In fact, when compared with 
other common neoplasms, lung cancer shows a major environmental 
etiology, where a number of different cancers are associated with a 
large spectrum of chronic tobacco-related diseases, each representing 
a major competing risk of death. All these concurrent diseases, and 
mainly cardiovascular and COPD, may cut the benefit of early detec-
tion, and increase the cost and damage of systematic screening. 
E16.3 Modeling Approaches to Mortality Reduction Benefit, Sun, Aug 2, 16:30 - 18:00
Defining the high risk cohort for lung cancer screening
van Klaveren, Rob J.
Erasmus MC, Rotterdam, Netherlands
There is real potential for environmental and genetic factors to 
improve on risk prediction and targeting of susceptible individuals 
beyond the traditional models based only on smoking and age. The 
development of a molecular-epidemiological risk model for lung 
cancer will inform the development of effective surveillance, early 
detection and chemoprevention strategies. Several population-based 
case-control and prospective cohort studies are in progress to identify 
these molecular and epidemiological risk factors to define popula-
tions and individuals most at risk for developing lung cancer. One of 
the models is from the Liverpool Lung project. Data from the case-
control study have been analysed to define a high-risk population. 
Detailed lifestyle and occupational information were collected during 
structured interviews. Models were constructed using conditional 
logistic regression and included terms for age, tobacco consumption 
and previous respiratory disease. Histories of bronchitis, emphysema 
or pneumonia appeared to be most significant for the prediction of 
lung cancer. 
Even in a molecular-epidemiological high risk cohort, approxi-
mately 50% of the participants will have at least one pulmonary 
nodule. Challenge is find out which nodules are benign and which 
are malignant. During this lecture we will discuss how to deal with 
these nodules in an non-invasive way based on the Dutch –Belgian 
(NELSON) lung cancer CT screening strategy. This strategy allows 
us to narrow down the population at risk for lung cancer to only 2% 
of the initial high risk population which was based on epidemiologi-
cal risk factors alone.
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Percutaneous biopsies
Moore, Elizabeth
University of California Davis.CA, USA
Upon the discovery of a new pulmonary nodule, percutaneous lung 
biopsy is only one of many tools for evaluation. Serial followup 
(preferably with tumor volumetrics) may be appropriate if the lesion 
does not have an appearance suggestive of malignancy. If the lesion 
is highly suggestive of malignancy, such as a spiculated appearance 
and/or activity on PET scan, and the patient is a surgical candidate, 
proceeding directly to surgery is most cost effective. Biopsy has the 
greatest role in lesions in which there is some discordance between 
clinical, CT, and PET findings, or in cases in which advanced 
stage disease is suspected or the patient is medically inoperable. 
Any planned biopsy should have the potential to change therapeu-
tic approach. Biopsy of hilar nodes, mediastinal nodes, or distant 
metastases can be performed and the biopsy site should be selected 
to “stage up” the lesion as much as possible.
Feasibility of a lung biopsy is based on a combination of size and 
location. If favorably located, lesions as small as 4 mm can be 
biopsied with high degrees of success. Biopsy under CT guidance 
using thin section imaging assures the appropriate placement of the 
sampling needle even in small lesions. Small nodules are difficult 
targets when they abut the pleura, but are easy targets when located 
in deeper portions of the lung. Core biopsy specimens are useful in 
establishing a specific benign diagnosis and for non-carcinomatous 
malignancies, but fine needle aspirates for cytology are usually ade-
quate for diagnosing carcinomas. Modern techniques of lung biopsy 
use a coaxial needle system, allowing multiple fine needle aspirates, 
cultures, or core specimens to be obtained through a thin walled 
guide needle with a single pleural puncture. Accuracy of lung biopsy 
is a function of needle placement, lesion size, skill of pathologist, as 
well as the type and quality of the specimens obtained. Sensitivity for 
diagnosis of lung cancer is in the range of 90%. There is a low false 
positive rate of about 1%.
Biopsy of hilar and mediastinal lymph nodes also can be performed 
under CT guidance. The pre-carinal and paratracheal nodal stations 
are difficult to access percutaneously because of the great vessels 
and the trachea and these nodal stations are better approached with 
transbronchial biopsy or mediastinoscopy.
Contraindications to lung biopsy include clotting abnormalities, 
thrombocytopenia, pulmonary hypertension, and lack of patient 
cooperation. Risk of pneumothorax is exaggerated in patients with 
underlying emphysema, and in smaller, deeper lesions. Pneumotho-
rax only occurs when aerated lung is punctured. Approximately 
10-20% of patients have some air leakage after the procedure, and 
approximately 1% require chest tube drainage for ongoing or marked 
air leakage. Various techniques such as blood patching of the sub-
pleural lung and the puncture site and puncture site dependent posi-
tioning can reduce the occurrence of significant air leakage. Pulmo-
nary hemorrhage, though rare, is the most common cause of death in 
lung biopsy. Air embolism, another potentially fatal complication, is 
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usually caused by damage to a pulmonary vein causing hemorrhage 
and coughing, forcing air into the vein and systemic circulation.
E17.2 Image Guided Procedures, Sun, Aug 2, 16:30 - 18:00
Evolving concepts in lung cancer: radiofrequency 
ablation for inoperable lung cancers
Suh, Robert
Ronald Reagan-UCLA Medical Center, Los Angeles, CA, USA
Only about 15% of patients diagnosed with lung carcinoma each year 
are surgical candidates, either due to advanced disease or comorbidi-
ties. The past decade has seen the emergence of minimally invasive 
therapies using thermal energy sources: radiofrequency, cryoablation, 
focused ultrasound, laser, and microwave: radiofrequency ablation 
(RFA) is the best developed of these.
Radiofrequency ablation is safe and technically highly successful 
in terms of initial ablation. Long-term local control or complete 
necrosis rates drop considerably when tumors are larger than 3 
cm, although repeat ablations can be performed. Patients with lung 
metastases tend to fare better with RF lung ablation than those with 
primary lung carcinoma in terms of local control, but it is unclear if 
this is related to smaller tumor size at time of treatment, lesion size 
uniformity, and sphericity with lung metastases, or to differences in 
patterns of pathologic spread of disease. 
The effects of RFA on quality of life, particularly dyspnea and pain, 
as well as long-term outcome studies are generally lacking. Even so, 
the results regarding RF lung ablation are comparable to other thera-
pies currently available, particularly for the conventionally unresect-
able or high-risk lung cancer population.
With refinements in technology, patient selection, clinical applica-
tions, and methods of follow-up, RFA will continue to flourish as a 
potentially viable stand-alone or complementary therapy for both 
primary and secondary lung malignancies in standard and high-risk 
populations.
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Stenting and embolization
Kerlan Jr, Robert K.
University of California, San Francisco, San Francisco, CA, USA
Tracheal and Bronchial Stenting
Though the presence or absence of airway obstruction does not 
appear to significantly influence the survival of patients with non-
small cell lung cancer(1), compression of the tracheobronchial tree 
from an unresectable malignant tumor can result in dyspnea, stridor 
or post-obstructive pneumonia. Patients with severe or recurrent 
symptoms can be treated in a variety of ways including radiation, 
endoscopic coring, laser ablation or placement of a stent. 
Structures that are amenable to stenting include the trachea, main-
stem bronchi, and segmental bronchi. More peripheral airways are 
generally too small and have too many branches to accommodate 
stent placement. 
When a patient is being considered for palliative stent placement, 
both diagnositic bronchoscopy and computed tomography are 
performed. 
Spiral CT is of particular value in the evaluation of patients with 
airway compression. It allows the acquisition of volumetric data and 
enables two-dimensional or three-dimensional reconstructions that 
can be instrumental in understanding airway anatomy at a site of 
airway stenosis. Accurate measurements of the normal uninvolved 
airway size can be made electronically, avoiding the necessity of 
estimating the stent size needed by more cumbersome methods. The 
diameter of the trachea varies considerably but generally ranges from 
14-20 mm. The normal diameter of the mainstem bronchi vary from 
8-12 mm. 
Stents can be divided into two main groups: silicone and metal-
lic. The original silicone stent is the Dumon (Endoxane, Novatech, 
Abayone, France) that is designed to exit a trecheostomy site. A 
bifurcated silicone stent, the Freitag (Dynamic Y-stent, Rusch, 
Kernan, Germany) is also available. Silicone stents have been used 
for palliation of airway obstruction with acceptable outcomes. Wood 
et al.(2) reported a series of 143 patients with malignant and benign 
stenoses in which 87% of patients received silicone stents placed by 
rigid endoscopy. 95% of patients in this series reported a significant 
improvement in symptoms. However, complications occurred in 42% 
of the procedures including retained secretions, granulation tissue 
formation and stent migration.
Because of these limitations, recent interest has been focused on the 
placement of metallic stents that can be placed with a combination of 
flexible bronchoscopy and fluoroscopy.
Unlike silicone stents, uncovered metallic stents can be placed 
across the origin of substabtial airways, such as the right upper lobe 
bronchus. Ventilation is possible through the stent intersticies, though 
clearing of secretions may be suboptimal.
One of the first stents to be used clinically was the Gianturco Z stent 
(3). It is made of .018 inch stainless steel monofilament, bent into a 
zigzag configuration and formed into a cylinder. Several cylinders 
can be linked together into series, yielding devices of increasing 
length. The stents are typically available with diameters of 6 mm to 
35 mm. The stent is deployed by pushing it through a delivery sheath 
of 8.5 to 16.5 French size. When the stent is in a suitable position, 
the sheath is retracted and the self-expanding stent springs open 
within the airway. This stent is self-expanding, exerts good radial 
force, is readily visible on fluoroscopy, is non-shortening, is easy to 
deploy and has large spaces between the stent wires. However, com-
plications due to erosion have been reported, and this stent is rarely 
used at his time.
A commonly used self-expanding stent is the Wallstent(4), which is 
woven in crisscross fashion from thin stainless steel alloy wires to 
form a flexible cylinder. The stent is concentrically constrained onto 
the shaft of a flexible delivery catheter by a membrane. When this 
membrane is retracted, the stent deploys. Wallstents are available 
in diameters ranging from 6 mm to 30 mm and in lengths from 20 
mm to 100 mm. The woven structure of the stent mandates that the 
stents of diameters of 12 mm and larger are at least 40 mm in length. 
Delivery systems are 7-to 12-Fr in diameter. Wallstents are self-
expanding, exert moderate radial force, have good flexibility, and are 
well seen on fluoroscopy. The main disadvantage of the Wallstent is 
that it shortens considerably upon deployment requiring a high level 
of experience for accurate positioning. 
Because of the tendency of Wallstents to stimulate a fibrotic hyper-
plastic response at the stent ends as well as the foreshortening of 
the stent during deployment, many other types of self-expanding 
metallic stents have been used to treat airway obstruction. These 
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stents are constructed of nitinol. Nitinol shortens minimally during 
deployment, compared to the stainless steel alloy that composes the 
Wallstent. These nitinol stents include Ultraflex (Boston Scientific), 
Luminexx (Bard), Zilver (Cook), Smart (Johnson and Johnson), and 
Symphony (Boston Scientific). The Symphony stent is somewhat 
unique in having the minimal amount of metal creating the best 
opportunity for through stent ventilation when a major bronchi is 
“caged” by the device. Metal stents are designed to be permanently 
within the airway, though there are reports of removing both the 
Wallstent (in piecemeal fashion) and the Ultraflex stent (via attached 
sutures) after placement. Uncovered stents, however, become incor-
porated into the tissue 4 to 6 weeks following placement. This tissue 
incorporation makes stent removal very problematic.
Several of these stents are available with plastic (PTFE) or silicone 
coating. Covered versions of both the Wallstent and Ultraflex stents 
are available. A recently developed dedicated tracheobronchial stent, 
the Aero Advantage (Alveolus), is a silicone covered nitinol stent 
that has been designed to be repositionable and removable. Covered 
stents appear to diminish problems with tumor ingrowth but are more 
likely to migrate.
The Palmaz stent(5) differs from the previously described stents, 
because it is balloon expandable rather than self-expandable. Prior 
to deployment the stent is “crimped” onto a dilating balloon that is 
then positioned across the narrowed area. The balloon is then inflated 
expanding the stent. The stent remains expanded after the balloon 
is deflated. Delivery is via a 7-Fr introducer sheath. The stent is 
available in lengths ranging from 10 mm to 40 mm and its diameter 
depends on the diameter of the deployment balloon typically in the 
range of 8 to 12 mm. 
The Palmaz stent exerts the strongest radial force. Unfortunately, 
the stent is non-elastic and may collapse under pressure. The stent is 
highly visible by fluoroscopy, exhibits little shortening on deploy-
ment, but is inflexible. This device is available in short lengths from 
10 mm to 40 mm, and small diameters, and facilitating placement 
in small airways. This stent is only suitable for segmental bronchi 
as dynamic forces deform the stent when it is deployed in a more 
proximal location.
The technical success of stent placement exceeds 90% and in some 
series approaches 100%.
Tracheobronchial stents rapidly improve dyspnea related to large air-
way obstruction. For patients with malignant disease, dyspnea scores 
(Hugh-Jones or Medical Research Council) and Karnofsky perfor-
mance scores improve in 82% to 97% of patients(6-10). Interestingly, 
up to one-third of patients will experience symptomatic relief despite 
no improvement in the appearance of their chest radiograph. Though 
the improvement is noted almost immediately in the majority of 
patients, up to 10% of individuals may not notice improve for a one 
to two-week period.
Embolization
Transcatheter embolic therapy has also proven to be useful in 
selected patients with complications of bronchogenic carcinoma and 
pulmonary metastases.
The most widely accepted indication for this form of therapy is 
recurrent or massive hemoptysis. In the majority of patients this 
procedure can be accomplished under local or conscious sedation. If 
bleeding is brisk, endotracheal intubation with a dual channel endo-
tracheal tube and adjunctive management with a bronchoscopically 
directed occlusion balloon may be necessary.
The majority of bleeding tumors are supplied by branches of the 
bronchial artery, therefore, a femoral arterial approach is used for 
the procedure. Selective catheterization of normal sized bronchial 
arteries can be technically demanding and physicians experienced in 
bronchial arteriography are best equipped to perform this procedure. 
A pre-procedural computed tomographic angiogram (CTA) can 
provide valuable information with regard to the number and location 
of bronchial arterial supplies.
Following successful engagement of the bronchial arterial branch 
with a 5 or 6-French catheter, a 3-French co-axial microcatheter is 
inserted to achieve a secure position within the artery beyond medi-
astinal or intercostal arteries. Subsequently, a permanent embolic 
agent such as tris-acryl microspheres or polyvinyl alcohol ranging in 
size from 150 microns to 600 microns is injected through the catheter 
until the artery is occluded.
Using this technique Park et al.(11) reported technical success in 
100% and clinical success in 79% of 15 patients treated for signifi-
cant hemoptysis due to primary lung cancer. The recurrence rate 
was 33%. In another study of 30 patients who underwent bronchial 
artery embolization with platinum coils for tumor related hemoptysis 
(12), control of recurrent hemoptysis was significantly higher (0% 
vs 27%) and survival significantly longer (139 days vs 62 days) in 
patients who were embolized compared to 15 matched patients who 
were managed conservatively.
Trans-catheter embolotherapy combined with chemotherapeutic 
agents has also undergone preliminary evaluation as a therapy for 
unresectable primary and metastatic pulmonary malignancies. When 
a chemotherapeutic agent is combined with an embolic agent, both 
the concentration and dwell time of the chemotherapeutic agent in 
the tumor are increased. Moreover, as lower overall doses are used 
and the majority of the material is retained in the treated vascular 
bed, systemic toxicities are significantly reduced.
In a prospective study of 52 patients with unresectable pulmonary 
metastases performed by Vogl et al. (13) using selective pulmonary 
arterial chemoembolization with mitomycin C, a partial response 
was achieved in 16 cases and stable disease in 11 cases by RECIST 
criteria. No significant complications were encountered. Preliminary 
evaluation also suggests that chemoembolization of central lesions 
supplied predominantly by systemic bronchial artery branches is also 
feasible, though controlled studies of this technique have not been 
performed.
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Systemic therapy: the current evidence
West, Howard (Jack)
Swedish Cancer Institute, Seattle, WA, USA
Conventional chemotherapy has been demonstrated in several 
large prospective randomized phase III trials in the last few years 
to confer a significant improvement in overall survival for patients 
who have undergone complete surgical resection for a stage II or 
IIIA non-small cell lung cancer (NSCLC). In addition, the role for 
adjuvant chemotherapy remains controversial but with some support 
for standard platinum-based chemotherapy for patients with stage 
IB disease. Emerging data, however, also suggest the potential for 
long-term adverse effects of chemotherapy, as well as the possibility 
that subgroups identified by biomarker and/or molecular signature 
patterns may receive much greater or lesser benefit than other sub-
groups. Certain clinically-defined subgroups, such as elderly and/or 
patients with a marginal performance status, remain understudied but 
may receive significant benefit from systemic therapy in the adjuvant 
setting. Finally, targeted therapies as well as immunotherapy-based 
treatments are being explored in clinical trials that will be highlight-
ed as additional or alternative strategies that may improve long-term 
survival outcomes for patients with early stage resected NSCLC.
E18.2 Adjuvant Therapies in Early Disease Management, Tue, Aug 4, 10:30 - 12:00
Is there still a role for adjuvant radiotherapy?
Arriagada, Rodrigo1, 2, 3
1 Karolinska Institutet and University Hospital Solna, Stockholm, 
Sweden; 2 Institut Gustave-Roussy (IGR), Villejuif, France; 3 Faculty 
of Medicine, University of Paris South, Paris, France
Background
Adjuvant or post-operative radiotherapy has been a largely practiced 
treatment after complete surgical resection of non-small cell lung 
cancer (NSCLC). The rationale has been to decrease the thoracic 
recurrence rate and then to have a potential beneficial effect on over-
all survival. However, despite that hundreds of thousands of patients 
have been treated worldwide, the number of patients included in 
randomised trials to evaluate this treatment effect has been limited to 
about 3,000 patients [1]. This contrasts with the number of patients 
randomised until now to evaluate the role of adjuvant chemotherapy 
in lung cancer (almost 11,000, excluding the trials treating with 
long-term alkylant agents [2, 3]). And also contrasts with the number 
of more than 23,000 breast cancer patients randomised to evaluate 
postoperative radiotherapy [4].
The need to irradiate lymph nodes in patients with involved but 
resected mediastinal stations (N2) is highly debatable, as the irradia-
tion of the mediastinum may induce late lung and vascular toxicity 
in already previously damaged normal tissues in heavy smokers. The 
rationale to perform this treatment yields only in retrospective stud-
ies that are well known to introduce major biases in the evaluation of 
treatment effects [5, 6]. We will discuss some of these issues mostly 
based on the knowledge given by the randomised evidence. 
Results and discussion
The most comprehensive randomised evidence that is available at 
the present time is the individual-patient based PORT meta-analysis, 
conducted by the Institut Gustave-Roussy (IGR) and the Medical 
Research Council [7]. In summary, it included 2,128 patients from 
nine randomised trials. The analysis showed an increase relative 
risk of death of 21% with the use of post-operative radiotherapy 
(P=0.001).The absolute survival detriment at 5 years was 7%.This 
deleterious effect was concentrated in patients with N0 and N1 
disease. No effect was detected in patients with N2 disease (relative 
risk of death: 0.96, p=0.72). The addition of a more recent small 
trial including 103 patients did not change significantly these results 
[8]. The indication of post-operative radiotherapy in N2 disease 
still remains frequent in several countries. For instance, in a pool 
performed in many Latin American centres, it was shown that this 
treatment was indicated in 26% of N1 and in all N2 stage [9]. How-
ever, the rationale to indicate the treatment in N2 disease relay only 
on the results of small retrospective studies (summary in [1]), some 
of them showing implausible differences in favour of the treatment. 
The possibility of side effects, such as cardiovascular, pulmonary 
toxicity and second cancers remains an important subject of research, 
as it has been largely demonstrated in the case of breast cancer [4] in 
which the mediastinal doses remain much lower than in lung cancer. 
Despite that the PORT meta-analysis was published in 1998, there 
has been no further large randomised trials to test this treatment that 
it is widely performed based on soft data and tradition. This is in 
contrast with the effect of the first meta-analysis evaluating the role 
of chemotherapy in the adjuvant setting, published in 1995 [2], that 
was followed in the Western countries by several large randomised 
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trials testing mainly platinum-based chemotherapy [3]. Despite 
the criticisms awaken by the PORT meta-analysis (old fashioned 
techniques, inappropriate radiation dose or fraction size), the created 
challenge did not meet active specialists and the question has not 
been investigated through a large-scale trial using high technology 
radiotherapy (CT-scan based planning, conformal radiotherapy with 
three-dimensional dosimetry). Only some months ago, the Lung 
Adjuvant Radiotherapy trial (LungART), organised by the IGR, was 
initiated in France and then should spread in Europe. The trial has 
been also adopted by the European Organisation for Research and 
Treatment of Cancer (EORTC) and some further national groups 
are planning to join it. If this trial is not successful in recruiting the 
needed 700 patients, this will represent a lost opportunity to evaluate 
the role of post-operative radiotherapy in N2 completed surgically 
resected lung cancer, and it will certainly be a failure of academic-
based research. And at the end, our patients would continue to be 
treated on the bases of only traditional and unsound knowledge. 
Conclusion
Post-operative radiotherapy in patients with complete surgically 
resected lung cancer remains a wide practiced treatment despite that 
its value has been insufficiently evaluated in randomised trials. Hyp-
pocrates of Kos (460-370 BC) was maybe right when he proposed 
the statement “Primum non nocere”.
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Vaccines as adjuvant therapy for  
non-small cell lung cancer (NSCLC)
Butts, Charles
Cross Cancer Institute, Edmonton, Alberta, Canada
The demonstration that a brief course of adjuvant chemotherapy 
improves survival in resected, early stage non-small cell lung cancer 
(NSCLC) represents a major advance in the management of these 
patients. However, many of these patients will still suffer relapse and 
die of their cancer. Clearly, new therapeutic modalities are needed to 
build on these recent advances.
The use of adjuvant systemic therapy is based on the principle 
that systemic micrometastases exist at the time of surgery. These 
micrometastases may be dormant, but after a period of time may 
reactivate and present as clinical recurrence. That adjuvant systemic 
chemotherapy improves survival suggests that these micrometastases 
are susceptible to therapeutic intervention, but the impact is small. In 
NSCLC the absolute improvement in survival is in the order of 5%.1 
The fact that cancer micrometastases exist, can survive adjuvant 
therapy, and subsequently emerge as clinically evident disease, 
suggests that these cells can exist and survive in a dormant state. 
Excellent reviews of tumor dormancy have been published.2, 3 This 
abstract will briefly review the potential role of the immune response 
in maintaining tumor dormancy and the implications of this for adju-
vant immunotherapy to potentially improve outcomes in NSCLC.
The existence of bone marrow micrometastases (BMM) and their 
effect on prognosis has best been described best in breast cancer. 
Braun et al4 performed a pooled analysis from individual patient data 
of more than 4700 patients with stage I-III breast cancer from 9 stud-
ies. Bone marrow micrometastases were found in 30% of patients. 
BMM were a significant prognostic factor even after controlling for 
tumor size, grade, lymph node status, and hormone receptor status. 
BMM have been detected in 40%–70% of patients with localized 
NSCLC and were associated with a higher risk of recurrence, espe-
cially blood-borne recurrence.5 
In a study of 36 breast cancer patients with no evidence of clinical 
disease, 36% of patients were found to have circulating tumor cells 
(CTC) 7–22 years post mastectomy.6 These CTC’s were found to 
have a short half life measured in hours. Presumably a source of 
these CTC’s must exist as micrometastases that can survive for many 
years but not appear as clinical recurrence. 
The capacity of the immune system to control and shape cancer is 
engendered in the concept of cancer immuno-editing.7 There are 
three potential outcomes of immuno-editing: elimination of cancers 
cells, an equilibrium whereby cancer cell immune destruction bal-
ances tumor cell expansion, leading to selection of less immunogenic 
tumor cells which eventually escape.
The evidence to support this model comes from mouse models and 
clinical observation.8, 9 A case report documented the development 
of melanoma in two separate recipients of renal transplants from the 
same donor.10 Neither recipient had a history or evidence of melano-
ma. The donor, who died of subarachnoid hemorrhage, had a 2.6 mm 
thick primary melanoma excised 16 years prior to her death. This 
suggests that dormant melanoma cells were present in the donor. In 
the face of immune suppression in the recipients these dormant cells 
were able to progress and manifest as clinically evident melanoma. 
In general, use of newer immunosuppressive regimens has resulted in 
reduction in transplant rejection, but have also resulted in an increase 
in post-transplant malignancies as a cause of death in transplant 
recipients.11 It is estimated that 20% of transplant recipients will 
develop malignancy after 10 years. Although skin cancers and post 
transplant lympho-proliferative disorders are most common, solid 
tumors are also increased. 
Further evidence for an interaction between the immune system and 
solid tumors comes from the study of tumor infiltration by lympho-
cytes. Studies have correlated a prominent infiltration of cytotoxic 
T-lymphocytes with favorable prognosis in colon cancer.12 In 
Copyright © 2009 by the International Association for the Study of Lung Cancer S221
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
NSCLC, Kerr et al13 studied 28 primary lung cancers with histologi-
cal features characteristic of regressing melanomas. They found 
the immuno-phenotype of cells infiltrating these lung cancers to be 
similar to that in regressing melanoma, and to be associated with 
better prognosis. 
Tertiary lymphoid structures composed of mature dendritic cells/T-
cell clusters and B-cell follicles have been described in some early 
stage NSCLC cancers but not in lung distant from the tumour.14 The 
density of mature dendritic cells was highly predictive of overall, 
disease free, and disease specific survival. 
There is also evidence that the innate immune response to NSCLC 
predicts survival. Welsh et al15 reviewed surgical specimens from 
175 resected NSCLC patients. They found the micro anatomic 
localization of tumor infiltrating macrophages to be strongly predic-
tive of survival, even in patients with positive resection margins. 
Macrophage and mast cell infiltration of tumor islets were strongly 
associated with better survival, independent of other prognostic fac-
tors. Conversely, stromal macrophage density was strongly associ-
ated with reduced survival
Attempts to actively enhance an anti-tumor immune response using 
specifically designed therapeutic vaccine strategies has shown prom-
ise in the adjuvant setting in NSCLC. A randomized phase II trial 
reported at ASCO 2007,16 compared patients with resected stage IB/
II NSCLC with MAGE-A3 positive tumors who were randomized 
to receive a MAGE-A3 vaccine or observation. No patient received 
adjuvant chemotherapy. Patients randomized to the vaccine had 
a strong trend toward improved disease free and overall survival. 
Based on this promising result, a large randomized phase III trial 
testing this MAGE-A3 vaccine in the adjuvant setting in resected 
NSCLC is currently enrolling patients. 
Further support for a potential role for cancer vaccines as adjuvant 
therapy in NSCLC comes from a randomized phase II trial with 
the MUC-1 vaccine, BLP-25. In a subgroup analysis, patients with 
stage IIIB local/ regional disease receiving maintenance vaccine had 
improved median and three year survival, although the difference 
was not statistically significant.17 A subsequent small phase I/II trial 
assessed adjuvant/maintenance BLP-25 vaccine in stage III NSCLC 
cancer patients having completed concurrent chemoradiaton. A very 
promising 64% 2 year survival was seen.18 
A randomized phase III trial testing the BLP-25 vaccine as mainte-
nance/adjuvant therapy in patients treated with combined modality 
therapy for stage III NSCLC is expected to complete accrual some-
time in 2010.
In conclusion, there is evidence for a role of the immune response 
in modifying the natural history of malignancy. While much of 
this evidence comes from mouse models and clinical observation, 
recent clinical trials suggest a promising role for therapeutic cancer 
vaccines as adjuvant therapy in NSCLC. Definitive evidence for 
vaccines in this setting awaits the results of ongoing phase III clinical 
trials.
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Antifolate in the adjuvant setting
Ichinose, Yukito
National Kyushu Cancer Center, Fukuoka, Japan
Methotrexate, a synthetic analog of folic acid, is a potent inhibitor of 
dihydrofolate reductase (DHFR), a key enzyme in the folate metabo-
lism. DHFR maintains the intracellular folate pool in a fully reduced 
form as tetrahydrofolates which are required for the synthesis of 
pyrimidines and purines, and thus also for DNA synthesis. After no 
benefit was observed in postoperative adjuvant chemotherapy trials 
combined with methotrexate was observed in the 1970’s, no further 
clinical trials using antifolate in an adjuvant setting were conducted 
up until pemetrexed was recently developed. Pemetrexed is a novel, 
multitarget antifolate chemotherapy agent that is active in multiple 
tumor types, including non-small cell lung cancer (NSCLC). The 
anti-tumor effect of pemetrexed is thought to inhibit DHFR, glyci-
namide ribonucleotide formyl transferase for purine synthesis and 
thymidylate synthase (TS) for thymidine synthesis. Several adjuvant 
trials with combination chemotherapy using pemetrexed and plati-
num compound are now ongoing. If the combination chemotherapy 
using pemetrexed in an adjuvant setting is found to be as effective 
as it was observed to be in a treatment setting for advanced non-
squamous NSCLC, especially for adenocarinoma of the lung whose 
gene and protein expression of TS was significantly lower than that 
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of squamous cell carcinoma of the lung, then the primary mechanism 
of action by pemetrexed in an adjuvant setting may also be ascribed 
to the inhibition of TS. These results will also be intriguing since 
adjuvant chemotherapy with uracil-tegafur, whose main anti-tumor 
activity is thought to inhibit TS, has proven to be effective in patients 
with resected adenocarcinoma of the lung.
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Virtual bronchoscopic navigation
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Bronchoscopic diagnosis of peripheral pulmonary lesions 
There has been a rise in the number of peripheral pulmonary lesions 
due to the increased availability of CT. It is particularly important to 
identify early lung cancers within these lesions. Methods to collect 
samples for pathological diagnosis include transbronchial biopsy 
under bronchoscopy, CT-guided percutaneous biopsy, and biopsy by 
surgery. Although surgery is the most reliable method, it is highly 
invasive. In addition, smaller lesions are likely to be benign. Percu-
taneous biopsy relatively frequently causes complications such as 
pneumothorax and hemorrhage, and lethal complications including 
dissemination and air embolism have also been reported. In contrast, 
transbronchial biopsy has few complications and is less invasive. 
However, the yield of diagnosing peripheral pulmonary lesions by 
bronchoscopy is unsatisfactory, partly due to the insufficient skill and 
experience of bronchoscopists. The 2007 Guidelines of the American 
College of Chest Physicians (ACCP) showed a diagnostic yield of 
57% for all lesions, and 34% for lesions < 2 cm in diameter. Pres-
ently, many bronchoscopists perform bronchoscopic path selection 
by mentally reconstructing 3D images from a CT scan-based 2D road 
map. This method, however, is inaccurate and inapplicable to the 
distal bronchi, the examination of which has become possible with a 
thin or ultrathin bronchoscope.
Ultrathin bronchoscopy
Smaller diameter bronchoscopes have recently become available, and 
special ultrathin bronchoscopes can be inserted into more distal bron-
chi. Furthermore, ultrathin bronchoscopes that can be used for biopsy 
(2.8 mm in external diameter, 1.2 mm in forceps channel diameter) 
have also been developed and marketed. Ultrathin bronchoscopes 
can be inserted to a level near the lesion, facilitating the guidance 
of biopsy devices and contributing to the diagnosis of peripheral 
pulmonary lesions. Even lesions at sites difficult to examine with 
ordinary bronchoscopes such as the mediastinal side of the lung apex 
can be examined. With ultrathin bronchoscopes 2.8 mm in external 
diameter, examination to a mean of the 6th-7th bronchial level is pos-
sible. It is impossible to guide a bronchoscope to this level with a CT 
scan-based 2D road map.
Virtual bronchoscopy (VB)
Virtual bronchoscopy is a method to 3-dimensionally visualize the 
bronchial lumen as observed by actual bronchoscopy. The images, 
which reflect the distance to the target structure or lesion and its size, 
mimic true bronchoscopic images. It has recently become possible to 
scan the thoracic region quickly and in detail during one breath-hold 
by multi-detector CT. This has suppressed artifacts due to respira-
tion and the pulse and improved the temporal and spatial resolutions. 
An advantage of virtual bronchoscopy is that it can be performed 
as many times as necessary non-invasively, without additional 
exposure, through the use of CT volume data sets. VB is presently 
used for the evaluation of airway stenosis, preoperative planning of 
stenting, detection of foreign bodies in the airway, training in bron-
choscopic techniques, etc. It has not, however, been used to examine 
peripheral bronchial lesions.
Virtual bronchoscopic navigation (VBN)
Virtual bronchoscopic navigation (VBN) is a method for guiding the 
bronchoscope to peripheral lesions using VB images of the bronchial 
path. In the case we first reported, virtual images up to the 10th-gen-
eration bronchus comprising the bronchial pathway to the target were 
displayed simultaneously with real images, and an ultrathin broncho-
scope could be advanced along the path to the target. 
VBN can be performed using software attached to the CT system 
in each institution, but there are some issues that must be taken into 
consideration. VB findings depend on the threshold value selected 
to differentiate between the airway wall and lumen. Therefore, 
inappropriate thresholds may cause the bronchoscope to be guided 
to the wrong bronchi. It is important to select appropriate threshold 
values while confirming the presence or absence of branchings on 
axial, sagittal, and coronal MPR images, and this requires experi-
ence. In actual bronchoscopy, unlike in VB, the bronchoscope tip can 
be moved only up or down, and the bronchoscope should therefore 
be appropriately rotated at the time of its insertion. Therefore, the 
virtual images differ from the real images based on the angle of this 
rotation. Unless the bronchoscope is advanced while both images 
are synchronized with each other at each branching, the risk of 
disorientation is high. A system that, by simply determining a target, 
automatically finds the bronchoscopic path to the target and prepares 
and presents virtual images along with corresponding real images has 
been developed and applied clinically.
VBN has been used concomitantly with CT-guided ultrathin 
bronchoscopy and endobronchial ultrasonography with a guide-
sheath (EBUS-GS), and satisfactory results have been reported. The 
diagnostic yield was 65.4-86% by CT-guided ultrathin bronchoscopy, 
63.3-84.4% by EBUS-GS, 62.5% by fluoroscopy, and 73.6% by all 
techniques combined. Moreover, randomized studies have shown 
that the use of VBN under EBUS-GS improves the diagnostic yield 
and shortens the time until the arrival of the bronchoscope to the 
target, and thus the total examination time. Two-hundred patients 
with peripheral pulmonary lesions 3 cm or less in diameter were ran-
domized to VBN and no-VBN groups, and biopsy was performed by 
EBUS-GS. The thin bronchoscope was guided using the VBN system 
in the VBN group, but according to axial CT images in the non-VBN 
group. In the VBN group, virtual images could be prepared to a 
median of the 6th-generation bronchi, and the rate of agreement with 
the real images was 98%. The diagnostic yield in the VBN group 
(78%) was significantly higher than in the non-VBN group (67%,) at 
p<0.05. The time until the initiation of the biopsy and examination 
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time (median, 8.1 and 24 minutes, respectively) were significantly 
shortened in the VBN compared with the non-VBN group p<0.05.
Advantages of VBN
VBN facilitates the guidance of the bronchoscope. As a result, a high 
diagnostic yield may be achieved irrespective of the skill or experi-
ence of the bronchoscopist. VBN is a safe method in which the bron-
choscope is guided by looking at both the real image and virtual one, 
and no complications of VBN itself have been reported. In addition, 
since VBN requires no special apparatus except software, the cost is 
generally not prohibitive. Its wider use is thus anticipated.
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Electromagnetic navigation bronchoscopy
Arenberg, Douglas
University of Michigan, Ann Arbor, MI, USA
A variety of sampling techniques are now available to provide 
options for clinicians and patients who require biopsy of a lung 
nodule or nodules. These range from CT guided percutaneous biopsy, 
to video assisted thoracoscopic surgery (VATS) and, more recently, 
the development of a system that combines three dimension chest CT 
reconstruction of a virtual bronchoscopic image, with electromag-
netic guidance. The latter, electromagnetic navigation bronchoscopy 
(ENB), uses a steerable probe, combined with a narrow “extended 
working channel” which are coupled together. This combined probe 
and working channel fit through the working channel of a standard 
therapeutic fiberoptic bronchoscope, and this system is the subject of 
this review. 
The utility of ENB must be considered in the context of a multidisci-
plinary approach to the care of patients with lung cancer or suspected 
lung cancer. Many patients with lung nodules either require no 
biopsy because they are considered at very low risk for lung cancer 
and a more conservative approach (serial observation) may be more 
reasonable, while others are at such high risk that biopsy (other than 
at the time of surgical exploration) is not useful. However, there are 
patients for whom surgery is not an option, in whom a tissue diag-
nosis is required to guide treatment decisions. These include patients 
who have significant co-morbid illnesses that preclude surgery, and 
those with suspected metastatic disease. Once a decision has been 
made to attempt to biopsy a lung nodule, the options should be 
discussed with the patient in the context of local expertise, and the 
relative risks and benefits of each option. In general, choosing among 
options for biopsy comes down to a trade-off between certainty 
(sensitivity of the technique) and risk (degree of invasiveness). The 
most invasive “biopsy” is a surgical exploration; video assisted 
thoracoscopic surgery (VATS) or thoracotomy, which provides the 
most definitive tissue sample for the pathologist. Until recently, the 
CT guided percutaneous biopsy was the preferred choice for biopsy 
of peripheral nodules in non-surgical patients, due to the lack of 
sensitivity of transbronchial biopsy. The development of ENB allows 
patients another option for biopsy of peripheral nodules, one with a 
lower risk of pneumothorax, and also gives clinicians a tool for locat-
ing nodules with fiducial markers (for stereotactic radiation therapy) 
and pleural tattoos to guide surgeons resecting small nodules that 
are not palpable ENB increases the yield of bronchoscopic biopsy of 
peripheral lung nodules. Experienced users of this newer technique 
report a 69-80% sensitivity for the diagnosis of small peripheral lung 
nodules (as small as 7 mm, ranging up to 8 cm, and average size less 
than 2 cm) (3, 4). The ENB system is divided into three phases, pre-
planning, registration, and navigation.
Preplanning. The process used for ENB starts with the software. 
DICOM formatted data from the patent’s CT scan are loaded from 
a disc onto a planning computer (SuperDimension, Minneapolis, 
MN), allowing the software to reconstruct axial, sagittal, and coronal 
images of the chest from the CT data. The software also displays a 
three-dimensional virtual bronchoscopic view, through which the 
user navigates using an intuitive interface with a standard computer 
mouse (Figure 1). The quality of the 3D virtual bronchoscopic imag-
es (and consequently of the planning process) is highly dependent 
upon the CT scan parameters. At a maximum, the slice thickness of 
the scan should be 3.0 mm, with 50% overlap between the slices. In 
general, the thinner the slices, the better for planning purposes. One 
exception to this is that the software cannot process a data file con-
taining more than approximately 650 images. Thinner slices result 
in excellent detail of bronchi down to a few mm in diameter in the 
virtual model of the airway. As the user navigates through the virtual 
airway, the view is displayed as it would appear through the bron-
choscope. The operator selects and marks well recognized anatomic 
landmarks in the planning phase using the mouse by “touching” each 
spot; usually the main carina, and the carinae delineating the right 
upper lobe, middle lobe, a basilar segment from the right lower lobe, 
the left upper lobe, and one of the left lower lobe basilar segments. 
Any easily recognizable landmark is appropriate, as long as it can 
be seen through the bronchoscope. During the pre-planning phase 
the target(s) to be biopsied are also marked. The ability to biopsy 
multiple nodules in one procedure without an appreciable increase in 
the risk of pneumothorax must be considered one of the advantages 
of ENB. The size and location of each target nodule are marked, and 
the planning software can save a compressed version of the data to a 
removable USB drive, which is then inserted into the USB slot of the 
computer located in the procedure room. In the procedure room, the 
location board, a flat plate located under the patient, generates a mag-
netic field. This location board is connected to the location processor, 
and from that to a computer which also has the ENB software. The 
location board and processor generate a sensing volume, and when 
the patient is positioned properly on the table, the patient’s chest is 
encompassed by this volume. Three motions-sensors are also placed 
on the patient’s chest within the sensing volume, and these allow for 
tracking of lung motion during spontaneous respiration. The proce-
dure can be done with conscious sedation or with deeper sedation 
given with an endotracheal tube in place. The operator performs the 
procedure with a steerable probe (the locatable guide; “LG”) inserted 
into an extended working channel (EWC: a hollow plastic catheter, 
see figure 2C), both of which fit in the working channel of a thera-
peutic bronchoscope. The three-dimensional position of the tip of 
the LG within the chest (x, y, and z coordinates as well as roll, pitch, 
and yaw) is detected by the location processor and displayed on the 
screen during the procedure in real-time. 
Registration. Once the patient is adequately sedated, the operator 
advances the scope and locatable guide to each of the anatomic reg-
istration points entered during the planning phase, and registers them 
within the patient by touching the same spots with the probe, and 
“entering” the point with a foot-pedal or handheld remote control. 
Once the landmarks have been registered in the patient, the computer 
will report an average fiducial target registration error (AFTRE) 
which gives an estimation of the divergence between the CT 
anatomy, and the patient’s anatomy. The ideal AFTRE is less than 5 
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mm, but error rates less than 4 mm are achievable. It is not necessary 
to use all the registration points entered during the planning phase if 
one proves particularly difficult to accurately register. The software 
may suggest particular points to “re-register”, or the user may select 
problematic points to delete from the registration. It is critical to 
have at least four accurately marked registration points that are well 
separated in space, with at least one on each side of the thorax, and 
one registration point should always be the main carina. 
Navigation. The navigation is achieved initially by approaching the 
proper segment containing the target with the scope. The locatable 
guide-EWC is advanced through the working channel and steered 
to the target using the four views displayed on the computer. Axial, 
sagittal, and coronal views of the chest move along with the tip of 
the locatable guide, and the “tip-view” is displayed alongside the 
planar views of the CT scan. The tip-view displays the distance to the 
nodule, as well as an arrow indicating the direction of turn required 
to reach the nodule. On the proximal end of the locatable guide in 
the operators hand, is a click-wheel with an identical arrow, and the 
operator steers the distal end of the guide to the lesion by matching 
the clock position of the arrows on the guide with that suggested on 
the tip view, and squeezing the trigger to deflect the tip in the direc-
tion of the target. The tip is advanced toward the nodule until it is in 
sufficiently close proximity to allow biopsy tools to reach the lesion. 
Once in position, the operator locks the EWC in place at the entrance 
to the scope’s working channel, and removes the LG is, leaving the 
extended working channel in place near the nodule. Various tech-
niques can be used for real time confirmation of the location of the 
EWC near or within the nodule as suggested by the virtual images 
generated by the location processor. Fluoroscopy, as well as a radial 
probe ultrasound catheter which is fits through the working channel 
are useful. There is also a confocal laser micro-endoscopic catheter 
which passes easily through the EWC, and displays real time video 
on a microscopic level. 
Once the EWC position is confirmed to the satisfaction if the bron-
choscopist, biopsy tools can be advanced to the nodule through the 
EWC to take samples. Prior to the procedure, it is standard practice 
to mark the tools at their proximal end, so the operator knows how 
far to advance the tool prior to its emergence from the distal end of 
the EWC. The choice of biopsy tool is up to the operator, but any 
standard needle, cytology brush, or transbronchial forceps can be 
used to obtain either cytologic, or histopathologic material from the 
nodule. 
Other uses.  While ENB is now gaining wide use as a tool for 
diagnosis of peripheral lung nodules, there have been other uses pub-
lished for this system. These include placement of fiducial markers in 
and around nodules to guide stereotactic radiotherapy (5). Addition-
ally, ENB permits the bronchoscopist to navigate the overlying pleu-
ra of a small nodule, and deliver a tattoo (usually indigo-carmine), 
allowing the surgeon then visualize the tattoo through the thoraco-
scope and eliminating the need to palpate the nodule. This approach 
can reduce the duration of the procedure, and reduce the likelihood 
of conversion to thoracotomy (6). Some users have developed the 
technique for delivering brachytherapy by a transbronchial route for 
patients who cannot tolerate external beam radiotherapy. 
References
1. Gould MK, Fletcher J, Iannettoni MD, Lynch WR, Midthun DE, Naidich DP, et al. 
Evaluation of patients with pulmonary nodules: when is it lung cancer?: ACCP evi-
dence-based clinical practice guidelines (2nd edition). Chest 2007; 132:108S-130S.
2. Baaklini WA, Reinoso MA, Gorin AB, Sharafkaneh A, Manian P. Diagnostic yield 
of fiberoptic bronchoscopy in evaluating solitary pulmonary nodules. Chest 2000; 
117:1049-1054.
3. Gildea TR, Mazzone PJ, Karnak D, Meziane M, Mehta AC. Electromagnetic naviga-
tion diagnostic bronchoscopy: a prospective study. Am J Respir Crit Care Med 2006; 
174:982-989.
4. Schwarz Y, Mehta A, Ernst A, Herth F, Engel A, Besser D, et al. Electromagnetic 
Navigation during Flexible Bronchoscopy. Respiration 2003; 70:516.
5. Anantham D, Feller-Kopman D, Shanmugham LN, Berman SM, DeCamp MM, 
Gangadharan SP, et al. Electromagnetic Navigation Bronchoscopy-Guided Fiducial 
Placement for Robotic Stereotactic Radiosurgery of Lung Tumors: A Feasibility 
Study. In, 2007; 930-935.
6. Seymour CW, Krimsky WS, Sager J, Kruklitis RJ, Lund ME, Musani AI, et al. 
Transbronchial needle injection: a systematic review of a new diagnostic and thera-
peutic paradigm. Respiration 2006; 73:78-89.
E19.3 Image Guided Biopsy/ Novel Technologies, Tue, Aug 4, 10:30 - 12:00
Endobronchial ultrasonography for 
peripheral lung lesions
Kurimoto, Noriaki; Nakamura, Haruhiko; Shirakawa, Taeko; 
Miyazawa, Teruomi; Osada, Hiroaki
St. Marianna University School of Medicine, Kawasaki, Japan
Internal structures of peripheral pulmonary lesions by EBUS
Endoscopic ultrasonography (EUS) has been used to examine the 
internal structure of pancreatic, and the results have been correlated 
with histopathology in cases of cystic tumour, calcifications, and 
pancreatic stones. Internal structures of peripheral pulmonary lesions 
as visualized by EBUS were correlated these findings with the 
histopathology. The lesions in well-differentiated adenocarcinoma 
had homogeneous internal echoes overall, but some hyperechoic 
dots (less than 1 mm in size) also were observed reflecting residual 
air in invaded alveoli. The distribution of the hyperechoic dots was 
irregular, and the margins of the lesions also were irregular. Blood 
vessels could be seen coursing through the lesion. In most cases of 
moderately differentiated adenocarcinoma and squamous cell carci-
noma, the EBUS images showed obstruction of blood vessels within 
the lesion, obstruction of bronchi, heterogeneous internal echoes, 
and irregular margins. In several cases of squamous cell carcinoma, 
numerous echo-free areas of various sizes were noted, and their 
distribution corresponded to areas of necrosis. In cases of poorly dif-
ferentiated adenocarcinoma, EBUS revealed few patent blood vessels 
or bronchi, heterogeneous internal echoes, and irregular margins. In 
some cases of small cell carcinoma, the tumour had directly invaded 
the pulmonary artery adjacent to the affected bronchus, resulting 
in stenosis of the pulmonary artery within the lesion. Comparing 
EBUS images and histopathological findings, EBUS shows bronchi-
oles, vessels, calcifications, bleeding, mucus plug in the bronchus, 
necrosis, and air in well differentiated adenocarcinoma. Hürter et al. 
reported successful visualization of peripheral lung lesions in 19 of 
26 cases, and Goldberg et al. reported that EBUS provided unique 
information that exceeded other diagnostic modalities in 18 of 25 
cases (including 6 peripheral lesions and 19 hilar tumours). 
Hosokawa and colleagues reported a typical EBUS pattern of neo-
plastic disease was 1) continuous marginal echo, 2) rough internal 
echo, 3) no hyperechoic spots standing for bronchi, or if there 
were any, there was no longitudinal continuity. Kuo and colleagues 
assessed the feasibility of EBUS in differential diagnosis between 
malignant and benign lesions by the following three characteristic 
echoic features indicating malignancy: continuous margin; absence 
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of a linear-discrete air bronchogram; and heterogenous echogenic-
ity. The negative predictive value for malignancy of a lesion with 
none of three echoic features is 93.7%. The positive predictive value 
for malignancy of a lesion with any two of three echoic features 
is 89.2%. Kurimoto and colleagues reported a classification sys-
tem with the aim of distinguishing between benign and malignant 
diseases, identifying the type of lung carcinoma and determining the 
degree of differentiation. The lesions were typed based on the inter-
nal echoes (whether homogenous or heterogenous), vascular patency, 
and the morphology of the hyperechoic areas (reflecting the presence 
of air and the state of the bronchi). Factors indicating malignancy 
were heterogenous internal echo, obstructive vessels, and obstructive 
bronchi. A homogenous pattern (Type I) was overwhelmingly benign 
(92%), whereas hyperechoic dots or a heterogenous pattern (Type II 
and III, respectively) portended malignancy in 98 of 99 cases (99%). 
Detection of the location of peripheral pulmonary lesion
EBUS can be used to assist TBB of peripheral pulmonary lesions. 
Because the air content of the lung parenchyma completely reflects 
the ultrasound signal, pulmonary masses can be precisely located 
by EBUS. EBUS-guided TBB of peripheral pulmonary lesions has 
been shown to yield a similar success rate as fluoroscopy guidance. A 
large-scale, prospective, randomized study to compare EBUS-guided 
TBB with TBB in patients with lesions <3 cm has been performed 
with good results. In lesions >3 cm, there were no significant differ-
ences in the diagnostic ability between the two procedures. However, 
in lesions <3 cm and <2 cm, a considerable decrease in TBB sensitiv-
ity (31% and 23%) was seen, whereas EBUS-guided TBB provided 
its sensitivity (75% and 71%).
More recently, studies have shown the efficacy of a new proce-
dure, EBUS using a Guide Sheath (EBUS-GS), for sampling of 
peripheral lesions to increase the diagnostic yield of TBB under 
EBUS guidance. A guide sheath covered the miniature radial probe 
is then advanced through the working channel of a therapeutic 
bronchoscope with the probe tip outside the sheath until the lesion is 
visualized. Under fluoroscopy, the sheath is held in place while the 
EBUS probe is withdrawn. An instrument such as a brush, needle, or 
biopsy forceps is then inserted through the sheath and the lesion is 
sampled. EBUS-GS increases the reliability of specimen collection 
via bronchoscopy. Diagnostic yields of bronchoscopy for peripheral 
pulmonary lesions less than 2 cm in published reports have been 
varied from 5 to 28%. When an undetectable lesion under fluoros-
copy is contact to the probe inserted inside the bronchus, the lesion is 
visualized by EBUS, and EBUS-GS is particularly useful for lesions 
≤20 mm that are undetectable by fluoroscopy. EBUS-GS was most 
successful when the probe could be placed within the lesion. The 
yield of TBB when the probe was adjacent to the lesion was very 
low. These suggest that the lesions visualized as adjacent to the probe 
may only be in contact with the outer surface of the bronchus, and 
therefore sampling is unlikely to be diagnostic. 
At the first approach to the target lesion, the probe did not reach to 
the target lesion in about 10% of all cases of EBUS-GS. To resolve 
this problem, the bronchoscopist withdrawn the probe and inserted 
the curettage into the guide sheath. The tip of the curettage is able to 
be angulated and search the correct bronchus.
One advantage of EBUS-GS lies in the repeatability of access to the 
bronchial lesion for sampling. Without a guide sheath, it can be dif-
ficult at times to be certain that the forceps are being inserted into the 
same bronchial branch for the second biopsy. Further, the bronchial 
mucosa becomes edematous after several attempts at manipulation, 
and it can be difficult to insert the forceps into the bronchus. Another 
advantage of EBUS-GS lies in its ability to protect against bleed-
ing into proximal bronchus from the biopsy site. Although massive 
hemorrhage following TBB is not frequent (<2%) into the bronchus, 
excessive bleeding may require hemostasis by wedging the tip of the 
bronchoscope. If bleeding occurs during EBUS-GS, blood drains 
through the sheath, because the outer surface of the sheath is snug 
against the internal surface of the bronchus. Our method of EBUS 
using a 20 MHz probe allowed visualization of the inner structures of 
peripheral lesions, including vessels, bronchi, calcifications, necrosis, 
hemorrhage, and bronchial dilatation. 
Many reports were published in these days. Yang evaluated whether 
EBUS may improve the diagnostic yield of transbronchial biopsy 
in peripheral lung cancer. The diagnostic accuracy of TBLB was 
significantly increased under EBUS guidance for small cell carci-
noma (88.9%) and for non-small cell ca. (67.7%) than without EBUS 
for small cell carcinoma (22.2%) and for non-small cell ca. (50.0%). 
Under EBUS guidance, the diagnostic yield of TBLB in peripheral 
lung cancer was significantly improved without EBUS. 
Yoshikawa evaluated the feasibility and efficacy of transbronchial 
biopsy (TBB) and bronchial brushing by EBUS with a guide sheath 
(GS) as a guide for diagnosing peripheral pulmonary lesions (PPLs) 
without radiographic fluoroscopy. Seventy-six of 123 PPLs (61.8%) 
were diagnosed by EBUS-GS guidance without fluoroscopy. The 
diagnostic yield for PPLs > 20 mm in diameter (75.6%) was sig-
nificantly higher than that for those ≤ 20 mm in diameter. The PPLs 
located in the middle lobe and the lingular segment had significantly 
higher diagnostic yields (p < 0.05). Multivariate analysis revealed 
that the diameter and location of the PPL were independent predic-
tors of diagnostic sensitivity by EBUS-GS-guided bronchoscopy.
Fielding and colleagues compared the diagnostic yields and pneu-
mothorax rate of EBUS GS and CT FNA in terms of the location 
of the lesion needing biopsy, in particular, whether the lesion is 
touching the pleura. For EBUS GS 140 cases were carried out with 
mean lesion size 29 mm. Over all diagnostic sensitivity was 66%. 
For lesions not touching visceral pleura it was 74% compared with 
35% where it was on the pleura. For CT FNA 121 cases were carried 
out with mean size 37 mm. Over all diagnostic sensitivity was 64%. 
Rate of pneumothorax and inter costal catheter placement in EBUS 
GS was 1 and 0% and in CTFNA was 28 and 6%, with P < 0.001 for 
both. Lesion location, in particular, connection to the visceral pleura, 
can improve decision-making in referral for either CT FNA or EBUS 
GS to maximize diagnostic yield and minimize pneumothorax rate.
In recent years, two methods of navigation for peripheral pulmonary 
lesions have been developed. The electromagnetic navigation system 
is a localization device that assists in placing endobronchial accesso-
ries in the desired areas of the lung. This system uses low-frequency 
electromagnetic waves, which are emitted from an electromagnetic 
board placed under the bronchoscopy table mattress. Harms and 
colleagues reported the technical note introduced a new approach 
for the treatment of inoperable peripheral lung tumors by combining 
the electromagnetic navigation system and EBUS with 3-D-planned 
endobronchial brachytherapy. Asano and colleagues developed a 
bronchoscope insertion guidance system that produces virtual images 
by extracting the bronchi by automatic threshold adjustment, and 
searching for the bronchial route to determined target. They used this 
system in combination with a thin bronchoscope and EBUS-GS. The 
system automatically produced virtual images to median of fifth-
order bronchi. EBUS visualized 93.8% of cases successfully, and 
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84.4% could be pathologically diagnosed. Using the bronchoscope 
insertion guidance system, virtual images can be readily produced, 
and the bronchoscope can be successfully guided to the target. This 
method is promising as a routine examination method in the biopsy 
of peripheral pulmonary lesions.
Comparison diagnostic yields of Endobronchial 
Ultrasonography using the thick guide sheath with the 
thin guide sheath for peripheral pulmonary lesions
We devised the technique of Endobronchial ultrasonography using a 
guide sheath (EBUS-GS) for the diagnosis of peripheral pulmonary 
lesions. We compared diagnostic yields of EBUS-GS using two types 
of the guide sheath.
1st method (EBUS-thick GS): EBUS using a thick guide sheath (2.5 
mm in diameter) covering a miniature probe, and 150 lesions were 
evaluated.
2nd method (EBUS-thin GS): EBUS using a thin guide sheath (2.0 
mm in diameter) covering a miniature probe, and 189 lesions were 
evaluated.
The total diagnostic yield with thin GS (88%) was significantly 
higher than that with thick GS (77%) (P=0.005). 
The total diagnostic yield of malignant lesions with thin GS (92%) 
was significantly higher than that with thick GS (81%) (P=0.008). 
The diagnostic yield by brushing cytology for malignant lesions 
with thin GS (85%) was significantly higher than that with thick GS 
(71%) (P=0.005). 
The diagnostic yield by transbronchial biopsy (TBB) for malignant 
lesions with thin GS (75%) was significantly lower than that with 
thick GS (87%) (P=0.03). 
Lesions which the probe was located within, had a significantly 
higher diagnostic yield (thick: 87%, thin: 92%) than that which the 
probe was located adjacent to (thick: 42%, thin: 66%).
The diagnostic yield at left B1+2 with thin GS (92%) was signifi-
cantly higher than the diagnostic yield at left B1+2 that with thick 
GS (40%) (P=0.0007). 
EBUS-thin GS increases the diagnostic yield of peripheral malignant 
lesions. EBUS-thin GS is useful for diagnosis of lesions in the left 
upper segment.
Techniques of Endobronchial Ultrasonography using a guide 
sheath (EBUS-GS) for peripheral pulmonary lesions
I will show some knacks as follows: 
1)  To confirm of the location of the guide sheath; after you get ultra-
sonic image of the lesion, you should pull back the probe slowly. 
While the transducer locates inside the sheath, the brightness 
of the ultrasonic image decreases. We can confirm the tip of the 
guide sheath is located in the lesion.
When you get the ultrasonic image as adjacent to the lesion
2)  To select the better bronchial branch lead into the lesion under 
bronchoscopic findings, 
3)  To change the direction of the probe for leading to the lesion using 
up and down of the bronchoscope,
4)  To change the direction the probe for leading the lesion using a 
curettage,
5)  To open the obstracted bronchus by inserting the curretage into 
the lesion.
Clinical application of Endobronchial Ultrasonography 
guided Transbronchial Needle Aspiration at the 
lobar, segmental, or sub-segmental bronchus 
Endobronchial Ultrasonography guided Transbronchial Needle 
Aspiration (EBUS-TBNA) is used for the lesions around the trachea, 
main bronchus, or intermediate trunk. We assessed the feasibility of 
EBUS-TBNA at the lobar, segmental, or sub-segmental bronchus. 
EBUS was performed for nine lesions around the lobar, segmental, 
or sub-segmental bronchus. Before bronchoscopy, we measured the 
mean diameter of the bronchus just beside the target lesion by ZAIO 
workstation. In the procedure of EBUS-TBNA, we inserted BF-
UC260F (diameter: 6.9 mm, 7.5 MHz, convex type, Olympus) into 
the lobar, segmental, or sub-segmental bronchus around the target 
lesion. While scanning the lesion by EBUS, TBNA was performed. 
Specimens were evaluated cytologically and histopathology. 
Case 1 (diagnosis; signet ring cell carcinoma): target lesion; #12 
lymph node (LN), location of the convex probe; right middle bron-
chus (mean diameter; 5.5 mm)
Case 2 (squamous cell carcinoma): #13 LN, right B10 (mean diam-
eter; 4.5 mm)
Case 3 (capillary hemangioma): tumor, right B9+10 (mean diameter; 
4.5 mm)
Case 4 (tuberculosis): lung lesion, right B7 (mean diameter; 4.9 mm)
Case 5 (metastatic tumor from renal cell carcinoma): lung tumor, 
right B3 (mean diameter; 4.7 mm)
Case 6 (adenocarcinoma): lung tumor, right B3 (mean diameter; 4.6 
mm)
Case 7 (adenocarcinoma): lung tumor, right B10 (mean diameter; 4.6 
mm)
Case 8 (small cell carcinoma): lung tumor, left B8a (mean diameter; 
5.0 mm)
Case 9 (adenocarcinoma): #12 LN, right middle bronchus (mean 
diameter; 5.7 mm)
In all lesions, EBUS visualized the target lesion. In 8 out of 9 lesions, 
EBUS-TBNA provided histopathological diagnosis.
While the mean diameter of the bronchus just beside the target lesion 
is greater than or equal to 4.5 mm, EBUS-TBNA may be performed 
at the bronchus beside the target lesion. 
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EBUS-TBNA: a safe and accurate modality 
for mediastinal staging in lung cancer
Fujisawa, Takehiko1, 2, 3; Yasufuku, Kazuhiro1, 2, 3;  
Nakajima, Takahiro1, 2, 3
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Lung cancer is still leading cause of death among malignant dis-
eases worldwide. Accurate staging of the disease whether hilar or 
mediastinal lymph nodes were involved is crucial to determine the 
prognosis, as well as to decide the most suitable treatment plan, 
because prognosis and treatment strategies are completely dependent 
on lymph node involvement. Non-invasive staging mainly consist-
ing of conventional imaging methods available for the assessment 
of mediastinum includes chest CT, positron emission tomography 
(PET), transesophageal ultrasonography (EUS) and endobronchial 
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ultrasound (EBUS) using the radial probe. Imaging alone is inac-
curate and, therefore, tissue sampling is the preferred and most 
reliable. On the other hand, invasive staging offers tissue proof of the 
mediastinum. Mediastinoscopy is a standard method for diagnosis of 
mediastinal lymph node staging by histology in lung cancer patients, 
however, it is invasive, carried out under general anesthesia and the 
complications can not be ignored. Other invasive staging modalities 
of the mediastinum include conventional bronchoscopic transbron-
chial needle aspiration (TBNA), EUS-guided fine needle aspiration 
(EUS-FNA), CT fluoroscopy guided TBNA, and EBUS-guided 
TBNA using the radial probe. Each of these methods, however, has 
its limitations. 
Therefore, less invasive method with high diagnostic yield which 
enables pulmonologists and thoracic surgeons to assess the medi-
astinum easily and safely was awaited to be developed. In 2002, we 
started to develop a new convex probe endobronchial ultrasound 
(CP-EBUS) with ability to perform earl-time EBUS guided TBNA 
(EBUS-TBNA) in collaboration with Olympus Optical Co1,2. The 
basic structure is a flexible bronchoscope with a convex type probe 
attached on the tip. The outer diameter is 6.9mm, angle of view is 
90 degrees, the direction of view is 30 degrees forward oblique and 
the instrument channel is 2.0mm. On the tip there is a linear curved 
array transducer with a frequency of 7.5 MHz. It is equipped with 
a B-mode as well as the Doppler mode. In clinical practice, guide 
sheeth, 22G TBNA needle and internal stylet is set, of which tip 
is near the orifice of the instrument channel. EBUS-TBNA was 
performed on an outpatient basis under conscious sedation. Local 
anesthesia was achieved with nebulized 1% lidocaine sodium (5 ml) 
in the pharynx. A bolus dose of 2 ml of 2% lidocainewas used during 
the procedure. The bronchoscope was inserted oyally with conscious 
sedation by 2 mg midazolam, patients are monitored for electrocar-
diogram, pulse oxymetry, and blood pressure without the presence 
of anesthegiologists. Conventional white light bronchovideoscopy is 
first performed in standard fashion to examine the tracheobronchial 
tree, followed by examination of the mediastinum using the CP-
EBUS. CP-EBUS is inserted through vocal cord to near the target. 
Near the target, the balloon attached on the probe is inflated with 
saline and is gently attached against the bronchial wall. A dedicated 
22G needle is punctured into the target under real-time ultrasound 
guidance. The depth of imaging can be adjusted from 2cm to 9cm 
with 1cm intervals. The ultrasound images can be frozen and the 
size of lesions can be measured in two dimensions by the placement 
of cursors. A dedicated 22-gauge needle was developed to perform 
transbronchial aspiration. The inner diameter of the needle is equal 
to a 21-gauge needle. The needle is also equipped with an internal 
stylet. The internel stylet is used to clear the bronchial membrane and 
debris stuffed on the tip of the needle after passing through the air-
way wall. This helps to obtain histological cores from lymph nodes 
as well as cytological specimens. 
EBUS-TBNA can be used for 1) lymph node staging in patients with 
lung cancers, 2) diagnosis of intrapulmonary tumors adjacent to tra-
chea or bronchus, 3) diagnosis of unknown hilar and/or mediastinal 
lymphadenopathy, and 4) diagnosis of mediastinal tumors. From our 
7 year experience, we have not experienced any major complications. 
To evaluate the usefulness of EBUS-TBNA for staging and diagnosis 
of lung cancer in patients with mediastinal lymph nodes suspected of 
malignancy and to assess the impact of this method in patient man-
agement, a total of 108 patients with known or suspected lung cancer 
were included3. Final diagnosis was based on cytology, surgical 
results, and/or clinical follow-up. In 105 patients, EBUS-TBNA was 
successfully performed to obtain samples from 163 lymph nodes. 
With respect to the correct prediction of lymph node stage, EBUS-
TBNA had a sensitivity of 94.6%, specificity of 100%, positive pre-
dictive value of 100%, negative predictive value of 89.5%, and diag-
nostic accuracy rate of 96.3%. In the 20 suspected lung cancer cases, 
mediastinal lymph node was used for tissue diagnosis of malignancy 
as well as staging. As a result of EBUS-TBNA, 29 mediastinosco-
pies, 8 thoracotomies, and 9 CT-guided PCNB was avoided. 
A comparison between EBUS-TBNA and CT, PET has shown favor-
able results for EBUS-TBNA in the lymph node staging of lung 
cancer4. One hundred two potentially operable patients with proven 
(n=96) or radiologically suspected (n=6) lung cancer underwent 
CT,PET, and EBUS-TBNA prior to surgery for the evaluation of 
mediastinal and hilar lymph node metastasis. Surgical histology is 
used as the gold standard to confirm lymph node metastasis unless 
patients were found inoperable for N3 or extensive N2 disease 
proven by EBUS-TBNA. EBUS-TBNA was successfully performed 
in all 102 patients (mean age 67.8 years) from 147 mediastinal and 
53 hilar lymph nodes. EBUS-TBNA proved malignancy in 37 lymph 
node stations in 24 patients. CT identified 92 positive lymph nodes 
and PET identified 89 lymph nodes. The sensitivities of CT, PET 
and EBUS-TBNA for the correct diagnosis of mediastinal and hilar 
lymph node staging were 76.9%, 80.0%, and 92.3%, respectively. 
Specificities were 55.3%, 70.1% and 100%. The diagnostic accura-
cies were 60.8%, 72.5%, and 98.0%. Compared to CT and PET, 
EBUS-TBNA had a high sensitivity as well as specificity for medi-
astinal and hilar lymph node staging in patients with lung cancer.
We have already reported that the size of histological cores obtained 
by EBUS-TBNA is sufficient not only for cytological and histo-
logical diagnosis but also for immunohistochemical and genetical 
studies. The presence of somatic mutations in epidermal growth 
factor (EGFR) predicts the effectiveness of EGFR tyrosine kinase 
inhibitors (TKIs). It would be ideal if an EGFR mutation could be 
detected in biopsy samples, since the majority of non-small cell 
lung cancer patients are inoperable at the time of presentation. To 
develop and analyze the feasibility of detecting EGFR mutations 
in samples obtained by EBUS-TBNA, a total of 46 patients with 
primary lung cancer in whom metastatic adenocarcinoma in the hilar 
and/or mediastinal lymph node was diagnosed by EBUS-TBNA were 
enrolled in this study6. DNA was extracted from paraffin-embedded 
samples, and the EGFR mutation was analyzed in exon 19 and 21 
using a newly developed loop-hybrid mobility shift assay. The results 
were confirmed by direct sequencing. EGFR mutation was detected 
in 11 of 46 cases (25.6%). One case was an inframe deletion (E746-
A750del) of exon 19, nine cases were point mutations (L858R) of 
exon 21, and 1 case was a double point mutation
(L858R+L861V). EGFR mutation can easily be detected in metas-
tinal lymph nodes sampled by EBUS-TBNA. EBUS-TBNA allows 
genetic evaluations of tumor cells within the lymph node and provide 
us with indication for EGFR-TKI therapy in near future.
Immunohistochemical study (IHC) using EBUS-TBNA samples clar-
ified the usefulness of IHC in lung cancer patients with inoperable 
N3 and extensive N2 disease6. Antibodies against cell-cycle proteins 
included activation of oncogene;Ki67,CD1, inactivation of tumor 
suppressor gene (TSG); RB, p16, p21, mutations of TSG;p53. Posi-
tiveness to at least one of these proteins is considered to be predic-
tive value for chemotherapy (CTH) response. A total of 36 patients 
with inoperable N3 or extensive N2 disease were used for this study. 
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Univariate analysis showed significant correlation with IHC of p21 
and p53 to CTH response, but did not show any correlation in IHC 
of Ki67, CD1, RB, p16. Multivariate analysis revealed that only p53 
is an independent parameter for predicting CTH response. There-
fore, patients with negative p53 IHC in metastatic lymph node are 
candidates for Cisplatin-based CTH in lung cancer with inoperable 
N2/3(+) disease. 
Several different invasive and non-invasive modalities exist for 
mediastinal staging. Invasive tests include mediastinoscopy, tho-
racoscopy, transbronchial needle aspiration, transthoracic needle 
aspiration, endoscopic ultrasound-guided fine-needle aspiration and 
EBUS-TBNA. Each of the invasive tests has limitations for par-
ticular locations, has particular risks and require specific skills. We 
reviewed7,8 and emphasized that EBUS-TBNA is a novel approach 
that has a good diagnostic yield with excellent potential in assisting 
safe and accurate diagnostic interventional bronchoscopy. Meta-anal-
ysis on EBUS-TBNA9 revealed that EBUS-TBNA is an accurate, 
safe and cost-effective tool in lung cancer staging. The selection of 
patients who had positive results of suspected lymph node metastasis 
in CT or PET may improve the sensitivity of EBUS-TBNA. High-
quality prospective studies regarding EBUS-TBNA in lung cancer 
staging are still needed to be conducted.
Reference:
1. Yasufuku K, Chhajed PN, Sekine Y, Nakajima T, Chiyo M, Shibuya K, Fujisawa T. 
Endobronchial ultrasound using a new convex probe – a preliminary study on surgi-
cally resected specimens. Onclo Rep 2004;11:293-296.
2. Yasufuku K, Chiyo M, Sekine Y, Chhajed PN, Shibuya K, Iizasa T, and Fujisawa 
T. Real-time ultrasound-guided transbronchial needle aspiration of mediastinal and 
hilar lymph nodes. Chest 2004;126:122-128.
3. Yasufuku K, Chiyo M, Koh E, Moriya Y, Iyada A, Sekine Y, Shibuya K, Iizasa T, 
Fujisawa T. Endobronchial ultrasound guided transbronchial needle aspiration for 
staging of lung cancer. Lung Cancer 2005;50:347-354.
4. Yasufuku K, Nakajima T, Motoori K, Sekine Y, Shibuya K, Hiroshima K, Fujisawa 
T. Comparison of endobronchial ultrasound, positron emission tomography, and 
computed tomography 
5. Nakajima T, Yasufuku K, Suzuki M, Hiroshima K, Kubo R, Mohammed S, Miyagi 
Y, Matsukuma S, Sekine Y, Fujisawa T. Chest 2007;132:597-602.
6. Mohamed S, Yasufuku K, Nakajima T, Hiroshima K, Kubo R, Iyoda A, Yoshida S, 
Suzuki M, Sekine Y, Shibuya K, Farouk A, Fujisawa T. Analysis of cell-cycle related 
proteins in mediastinal lymph nodes of N2-NSCLCpatients obtained by EBUS-
TBNA: Relevance to chemotherapy response. Thorax 2009 (in press).
7. Yasufuku K, Nakajima T, Chiyo M, Sekine Y, Shibuya K, Fujisawa T. Endobronchial 
ultrasonography: current status and future directions. J Thorac Oncol 2007;2:970-
979.
8. Yasufuku K, Fujisawa T. Staging and diagnosis of non-small cell lung cancer: Inva-
sive modalities. Respirol 2007;12:173-183.
9. Gu P, Zhao YZ, Jiang LY, Zhang W, Xin Y, Han BH. Endobronchial ultrasound-guid-
ed trasbronchial needele aspiration for staging of lung cancer: A systematic review 
and mata-analysis. Eur J Cancer 2009 (in press).
Session E20: Mediastinal Restaging 
Tuesday, August 4
E20.1 Mediastinal Restaging, Tue, Aug 4, 10:30 - 12:00
Imaging of the mediastinum after induction therapy
De Leyn, Paul
University Hospitals Leuven, Leuven, Belgium
Introduction 
Patients with proven N2 disease do not benefit from surgical resec-
tion. Although the optimal treatment of patients with stage IIIa (N2 
disease) is still under investigation, there seems to be a role for 
surgery in patients with potentially resectable N2 disease. Important 
prognostic factors after neo-adjuvant therapy are complete surgi-
cal resection, downstaging of the mediastinal lymph nodes and the 
degree of pathologic response in the primary tumour (1). Downstag-
ing of mediastinal lymph nodes is important but some patients with a 
very good response in the primary tumour but persistant N2 disease 
have a promising survival. The advantage of PET or PET-CT over 
mediastinoscopy and fine needle aspiration is the additional informa-
tion on pathologic response in the primary tumour.
Different restaging techniques 
The mediastinum can be restaged by CT-scan, remediastinoscopy, 
fine needle aspiration, PET scan, PET/CT-scan and fine needle 
aspiration. 
In primary staging, CT-scan has proved to have a low accuracy. It is 
not surprising that the accuracy of CT-scan in restaging the mediasti-
num is also low. In a Spanisch study of 24 patients who underwent 
neoadjuvant chemotherapy for N2 non-small cell lung cancer, restag-
ing was performed by CT-scan and remediastinoscopy (2). CT-scan 
had a sensitivity of 41%, a specificity of 75% and an accuracy of 
58%. 
Restaging by mediastinoscopy or fine needle aspiration has the 
advantage that histology/cytology is available. Repeat mediastinos-
copy has been propagated as a tool for restaging of the mediastinum 
after induction therapy in patients with N2-disease, as it may offer 
histological evidence of mediastinal LN status. Retrospective studies 
from a few centres have reported that repeat mediastinoscopy after 
induction treatment has a fairly good accuracy (2, 3). In other centres 
with ample experience, repeat mediastinoscopy was disappointing. 
In a prospective study in 30 patients who had a thorough baseline 
staging mediastinoscopy to establish IIIA-N2, followed by induction 
chemotherapy, the sensitivity of repeat mediastinoscopy to detect 
residual mediastinal LN disease was only 29% with a negative pre-
dictive value (NPV) of 52% (4). Poor results were due to fibrosis and 
dense adhesions caused by initial thorough mediastinoscopy. Similar 
findings were reported by other groups (5). It is very unlikely that a 
scenario with two mediastinoscopies (one baseline and one post-
induction) will be the best one in future multimodality treatment. 
There are a few reports suggesting that EUS-FNA can be used for 
mediastinal restaging after induction therapy, however these were 
small studies reporting a suboptimal sensitivity and NPV (6). The 
same comment can be made for the only study using EBUS-TBNA 
after induction chemotherapy reporting a NPV of 20% (7). This NPV 
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is far too low to advise these echo-endoscopic techniques in a post-
induction setting.
PET-scan has proved to be very accurate in primary staging of the 
mediastinum mainly due to its high negative predictive value. In 
the restaging of mediastinal lymph nodes after induction therapy, 
PET-scan is more accurate than CT but is clearly not as accurate as 
in untreated patients. In most studies, the sensitivity is reported to be 
50%-60% with a good specificity of 85%-90%. So in a high propor-
tion of patients, PET-scan is false negative on the mediastinal nodes 
after induction therapy. The reason for this poor sensitivity is not 
clear. A very small mass of tumor, such as posttreatment microscopic 
foci surrounded by fibrosis may be more difficult to detect. Changes 
in the microenvironment of the tumor such as altered perfusion due 
to postchemotherapy changes may also impair presentation of FDG 
to the metastatic lymph nodes. 
The use of PET-CT for mediastinal restaging improved the accuracy 
mainly by increasing the sensitivity without loosing specificity. The 
first prospective study evaluating the role of PET-CT on restaging 
mediastinal lymph nodes after induction chemotherapy showed 
a sensitivity of 77%, a specificity of 92% and a NPV of 75% (4). 
Use of PET-CT fusion images significantly increases the specificity 
through better localisation of focal FDG update in mediastinal lymph 
nodes or other vascular-mediastinal structures. We found a very 
high positive predictive value of PET-CT (92%) and found a high 
rate of incomplete resection (46%) in case of residual mediastinal 
involvement on PET-CT. It is the impression from our study, that 
patients with persistent mediastinal disease on PET-CT should not 
undergo resection. Many studies many studies have addressed the 
value of PET and PET-CT in assessment of LN downstaging. These 
studies differ in methodological aspects, such as type of induction 
(chemotherapy or chemoradiotherapy), timing of imaging (interval 
3-4 weeks, straight after, or at a variable interval 4-10 weeks after 
neo-adjuvant therapy, respectively), interpretation of imaging (visual 
correlation with CT or integrated PET-CT). Nonetheless, it is clear 
that the sensitivity and specificity are lower than for baseline lymph 
node staging, but better if studies with PET-CT are considered. 
The earliest studies on response in the primary tumour reported a 
sensitivity of 81%-97% and a specificity of 64%-67% to predict a 
pathological complete response on PET after neo-adjuvant therapy. 
Other studies used the percentage change in the SUVmax on PET 
before and after neo-adjuvant therapy, and described a strong but 
imperfect correlation between this decrease and the residual amount 
of viable tumour in the resection specimen. 
The combination of lymph node downstaging on PET and a SUVmax 
decrease of >50% in the primary tumour predicted a better outcome 
(9). Since then, many studies have addressed the value of PET and 
PET-CT in assessment of LN downstaging, estimation of pathologic 
response, and relation of these findings with survival outcome. In one 
study, a cut-off value of 60% decrease in SUVmax after induction 
chemotherapy was a significant predictor of 5-year survival (60% 
versus 15%, P=0.0007) (10).
Conclusion
Restaging of the mediastinum after induction treatment for N2 
disease is of paramount importance. CT is by far not accurate enough 
in restaging. Remediastinoscopy has proven to be feasible but due 
to adhesions and fibrosis, the intervention is technically challeng-
ing and in a prospective study it has shown to have a low sensitivity 
and accuracy. Less invasive techniques, such as EUS fine needle 
aspiration seems to obtain similar results as remediastinoscopy. The 
accuracy op PET in mediastinal restaging is far from optimal, mainly 
due to its low sensitivity. PET-CT seems to improve very much the 
results with a very favourable sensitivity, specificity and accuracy. 
As for imaging, a unique feature of repeat PET after induction is that 
it not only assesses mediastinal nodes, but response in the primary 
tumor as well. In this context, fusion PET-CT images are likely to be 
superior to side-by-side comparison of PET and CT images.
For the invasive tests to be used after induction, the choice will be 
determined by the tools used at initial staging. As repeat medias-
tinoscopy after induction is in general disappointing and difficult 
to achieve, the use of endoscopic techniques for baseline staging 
becomes very attractive. In that scenario, a first mediastinoscopy 
can be performed in optimal conditions after the induction treat-
ment, thereby giving maximum information on LN status. A recent 
paper explored how the use of different tools for reassessment after 
induction might be optimised if one works in a scenario with upfront 
endoscopic staging. It described that the combination of patho-
logic response in mediastinal LNs and primary tumour response 
as assessed on serial PET, might be a very powerful tool to predict 
outcome after multimodality therapy for stage IIIA-N2 NSCLC (11).
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The surgical exploration of the mediastinum (mediastinoscopy, 
parasternal mediastinotomy, and extended cervical mediastinoscopy) 
provides the possibility of a pathologic diagnosis, which yields 
the maximum clinical classification certainty. Its sensitivity ranges 
between 66% and 81% depending on the histologic type and tumor 
location, with a specificity of 100%.
In 2004, 170,000 Americans were diagnosed with non-small cell lung 
cancer (NSCLC), and almost 1 in 5 patients presented with N2 or 
stage IIIa disease. Mediastinal downstaging after induction therapy 
for locally advanced NSCLC is an important prognostic factor for 
long-term survival. Patients with persisting mediastinal involvement 
have a poor prognosis and a majority will not benefit from surgical 
resection. Recent studies have shown that patients whose tumors are 
downstaged after neoadjuvant therapy and then undergo resection 
have a significant longer 5-year survival of 40% to 50% than those 
who have residual N2 disease. Betticher et al. showed that persist-
ing N2 after induction therapy is associated with a poor prognosis. 
Albain et al. reported a 5- year overall survival after induction 
chemoradiotherapy and surgery of 41% if ypN0 at surgery, 24% if 
ypN1—3 and 8% when no surgical resection was performed.
So, precise restaging after induction chemo or chemoradiotherapy is 
of great importance to determine subsequent treatment and progno-
sis. Different restaging methods are available: Non invasive: comput-
ed tomography (CT), magnetic resonance imaging (MRI), positron 
emission tomography (PET) and integrated PET-CT. Invasive: repeat 
mediastinoscopy (reMS) and video-assisted thoracic surgery (VATS). 
Minimally invasive: transthoracic fine-needle aspiration biopsy 
(FNAB), transbronchial needle aspiration (TBNA), endobronchial 
ultrasound with FNAB (EBUS) and endoscopic esophageal ultra-
sound with FNAB (EEUS)
Repeat mediastinoscopy is an invasive technique providing patholog-
ical evidence of response. However, it is technically more demanding 
resulting in a lower accuracy compared to a first procedure. Shortly 
after the introduction of mediastinoscopy, redo procedures were con-
sidered to be technically impossible due to the scar tissue developing 
after the first intervention. However, in subsequent years reMS was 
found to be technically feasible, also after induction therapy and can 
be performed even as an outpatient procedure. Difficulties posed by 
peritracheal adhesions are relative. With patience and dedication, the 
trachea can be freed from adhesions and the nodes reached and rebi-
opsied. Recently in an experimental study in rats, the adhesions caus-
ing technical difficulty during re-mediastinoscopy were reduced with 
the application of anti-adhesive agents during the primary procedure. 
As for the increased adhesions caused by radiotherapy, the key factor 
here is timing. Remediastinoscopy should be performed within three 
weeks after completing radiotherapy. The longer the time between 
radiotherapy and remediastinoscopy, the harder the adhesions.
The main purpose of this repeat mediastinoscopy is to obtain an 
objective assessment of the effect that the neoadjuvant chemo-
therapy has had and also to rule out the presence of conditions that 
could render any future operation incomplete, namely extracapsular 
involvement and presence of N3 not apparent by radiologic criteria. 
This allows the selection of patients with a higher probability to 
undergo complete operation, which appears to be the most significant 
prognostic factor associated with patients who present long-term 
survival. Remediastinoscopy has been performed for various indica-
tions: assessment of second primary tumors or recurrent tumors; in 
patients where the first mediastinoscopy was incomplete; in patients 
with a delayed commencement of the treatment; in lung cancer 
occurring after unrelated disease (e.g. lymphoma, sarcoidosis, tuber-
culosis) and in patients after neoadjuvant chemotherapy. In all these 
patients, it was technically possible to perform remediastinoscopy. 
Results of recent series of reMS after induction therapy show a sen-
sitivity of 70% or higher (up to 83%), except in a prospective study 
comparing reMS to integrated CT-PET scanning with a sensitivity of 
29%. This low sensitivity could be explained by the existence of firm 
adhesions and fibrosis in 67% of patients without adequate biopsies 
of the subcarinal lymph node station. The specificity of reMS is 
100% in all published series and diagnostic accuracy between 80% 
and 93%, except in the two studies with less number of explorations 
(50% and 60%). 
The largest series of reMS was reported by Stamatis et al. in 2005, 
which described a total of 279 reMS, of which 165 were performed 
after induction chemoradiotherapy.
Results were very similar to other series with sensitivity of 74%, 
specificity of 100% and accuracy of 93%; so, even combined induc-
tion chemo and radiotherapy does not give rise to increased difficul-
ties or a lower accuracy of reMS compared to chemotherapy alone. 
In this study patients with a positive reMS also had a poor survival 
rate of only 5% after 5 years compared with 36.6% for N0. In the 
study of De Wale et al including 104 patients from two institutions, 
sensitivity, specificity and accuracy were 70%, 100% and 80% 
respectively. Median survival time of patients with a positive and/or 
false-negative remediastinoscopy was significantly lower than that 
of patients with a negative repeat mediastinoscopy (14 months vs 28 
months). With a positive remediastinoscopy, the relative risk of dying 
was 1.99, compared to that of patients who had a negative repeat 
mediastinoscopy
The learning curve can influence the results as usually happen with 
the use of new techniques. Rami-Porta et al found a difference 
between the first 24 reMS and the subsequent 24 in sensitivity (70% 
vs 83%), accuracy (80% vs 91%) and negative predictive value (60% 
vs 85%). Morbidity and mortality is the main cause of criticism of 
repeat mediastinoscopy with one perioperative death in a serie of 104 
reMS due to haemopericardium and heart arrest after a haemorrhage 
from the origin of the innominate artery that was controlled. Morbid-
ity is around 0%-3.9% due mainly to superficial wound infections 
and haemorrhage controlled by packing. 
Video-assisted thoracic surgery (VATS) has been used for restaging 
but experience is limited. In a phase II study by the Cancer and Leu-
kemia group B (CALGB), 70 patients with stage IIIA-N2 NSCLC 
underwent restaging by VATS. Sensitivity in this series was 75%, 
specificity 100% and negative predictive value 76%.
Non invasive imaging techniques such as computed tomography 
(CT) and also magnetic resonance imaging are not accurate enough 
for mediastinal restaging with a sensitivity of chest CT of 41% and 
an accuracy of 58%.
Positron emission tomography (PET) provides additional metabolic 
information and has been shown to be more accurate in predicting 
the T factor than the N status. Port et al. reported, in a prospective 
study including 25 patients with NSCLC treated by induction chemo-
therapy, a positive predictive value of PET to detect persisting nodal 
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disease of 73%, but less than 20% for residual N2 disease. On the 
other hand, integrated PET-CT, combining anatomical and functional 
information has shown to be more promising. In a prospective study 
of 30 patients the accuracy of PET-CT was 83% that was significant-
ly better than reMS. However, sensitivity of reMS in this study was 
much lower than reported in other series. 
In a larger prospective study of 93 patients who were restaged by 
chest CT and integrated PET-CT after induction chemoradiotherapy, 
repeat PET-CT was found to be superior to repeat CT alone. This dif-
ference achieved statistical significance for those patients with patho-
logical stages 0 –complete responders- (92% versus 39%) and I (89% 
versus 36%) disease. However, there were 20% false-negative and 
25% false positive cases with repeat CT-PET. The percent decrease 
in the maximum standardized uptake value (SUVmax) of the primary 
tumor and the involved lymph node was predictive of pathology but 
a persistently high SUVmax should not be perceived as evidence of 
residual disease and nodal biopsies are required.
Several other minimally invasive techniques for restaging the medi-
astinum have shown to be promising but they only provide cytologi-
cal proof of mediastinal involvement.
These include endoscopic oesophageal and endobronchial ultrasound 
(EEUS and EBUS) and transbronchial needle aspiration (TBNA). 
Although high false-negative rates (between 20 and 30%) have been 
reported, accuracy is similar to that of a repeat mediastinoscopy 
(75—83%).
The European Society of Thoracic Surgeons (ESTS) guidelines for 
preoperative lymph node staging in NSCLC recommend an invasive 
technique for cytohistological information for restaging after induc-
tion therapy. Endoscopic or surgical invasive procedures may be 
utilized, the precise choice depending on the availability of the tech-
nique and expertise of the centre. Repeat mediastinoscopy remains a 
valuable restaging tool as it provides pathological proof of downstag-
ing or persisting mediastinal involvement but is difficult to integrate 
in the surgical practice of those who rarely perform mediastinoscopy. 
However, those who perform it routinely obtain the best results and 
consider it the best restaging method. A possible alternative to the 
mediastinoscopy—remediastinoscopy staging sequence could be to 
perform a minimally invasive technique (EEUS, EBUS, TBNA) for 
initial cytological proof of mediastinal involvement, in which case a 
first mediastinoscopy would be done after induction therapy, avoid-
ing a technically more demanding remediastinoscopy.
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Novel therapies improving toxicities and 
side effects in thoracic radiation
Ricardi, Umberto; Mantovani, Cristina; Filippi, Andrea Riccardo
Department of Surgical and Medical Sciences, University of Turin, 
Torino, Italy
Several dose-escalation studies (1,2,3) clearly suggest that local 
tumor control is a function of the radiation dose delivered, with 
higher radiation doses resulting in a higher probability of local con-
trol and hence prolonged survival in patients affected with non small 
cell lung cancer (NSCLC). 
Stereotactic radiotherapy series (4,5) using very high dose of radia-
tion report local control rates greater than 85% in stage I disease. 
According to the currently available evidence, the standard of care 
for the treatment of locally advanced disease is concurrent chemo-
radiotherapy; however, in a concomitant approach, dose escalation 
programs are limited by concerns about the potential toxicity on 
surrounding healthy tissues. 
Radiation Induced Lung Injury (RILI) is the main dose-limiting 
toxicity for patients receiving thoracic irradiation. Pneumonitis rep-
resents the acute injury to the lung, an early inflammatory reaction 
concerning alveolar cell depletion and inflammatory cell accumula-
tion in the interstitial space. Lung fibrosis occurs late and is caused 
by an abnormal fibrobast proliferation, collagen accumulation and 
consequently destruction of the normal lung architecture.
The incidence of RILI varies widely among reports; this variability is 
mainly due to differences in methods of scoring and reporting radia-
tion toxicities. 
Kocak et al. (6) performed a prospective study to assess the complex-
ity of assigning a definitive clinical diagnosis of radiation induced 
lung injury in 318 patients irradiated for lung cancer. The authors 
found that scoring of radiation pneumonitis was challenging in 28% 
of patients for the presence of confounding medical conditions, such 
as pre-existing lung disease and poor pulmonary function. 
The pathogenetic mechanism underlying RILI depends on treatment 
related factors (radiation dose and fractionation, volume of lung 
receiving radiation dose above thresholds levels), use of concomitant 
chemotherapy and patients related factors. 
Radiation induced oxidative stress and free radical generation results 
in DNA damage of lung cells inducing mRNA translation of a 
variety of genes involved in epithelial/connective tissue and vascular 
regeneration. This event leads to collagen accumulation, changes in 
the quality of the extracellular matrix and destruction of normal lung 
architecture resulting in fibrosis. 
Many authors have attempted to define the predictive factors of RILI, 
finding out some dosimetric parameters, including values of normal 
lung volumes receiving more than doses like 20 Gy (V20) or 30 Gy 
(V
30
), MLD and NTCP models. 
As a consequence of increasing use of concurrent chemo-radio-
therapy in advanced disease, esophagitis has emerged as another 
significant dose-limiting toxicity. However, clinical and dosimetric 
predictors of acute esophagitis are not well characterized. 
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Traditionally, esophageal length included in radiotherapy field was 
considered a predictive factor of radiation toxicity, but there are con-
troversial data at this regard. Ball et al. (7) and Choy et al (8) did not 
find any correlation between esophageal length and the severity of 
esophagitis. However, Langer et al. observed a correlation between 
length of irradiated esopaghus and severity of esophagitis. 
Rodriguez et al. (9) evaluated prospectively esophageal toxicity in 
100 lung cancer patients treated with concurrent chemo-radiotherapy 
with a mean dose of 62 Gy, analyzing a series of dosimetric param-
eters. They found that the 30% of esophageal volume receiving >50 
Gy was the most statistically significant factor associated with acute 
esophagitis grade >1 (RTOG score system). 
The implementation of new sophisticated radiation therapy tech-
niques, allowed by several recent advances both in planning (4D-CT 
for respiratory gating, image-fusion with functional imaging, IMRT) 
and in treatment delivery (IMRT, respiratory-gated radiotherapy, 
Image Guided radiotherapy) might improve local control with com-
parable or reduced toxicities. 
Intensity Modulated Radiation Therapy (IMRT) improves target cov-
erage and reduces the volume of normal lung irradiated; however the 
dosimetric benefits of IMRT for advanced disease must be evaluated 
further in clinical trials. 
The introduction of modern dose calculation algorithm in planning 
process might improve estimation of dose distribution; this aspect is 
more pronounced in inhomogeneous tissues such as the lungs (pencil 
beam vs collapsed cone algorithms). 
Radiation therapy conformal techniques require high level of accura-
cy in defining and localizing target volume; in lung cancer one of the 
potential challenge is tumor motion, which can lead to a geographi-
cal miss and consequent tumor underdosage, or, alternatively, to the 
inclusion of a useless huge amount of normal lung in the planning 
target volume. 
Traditionally, the planning target volume is defined by applying a 
uniform standard margin to the target, taking into account set up 
errors and organ motion. However, tumor motion can vary substan-
tially among lung patients suggesting that individualized margins 
must be defined to optimize tumor coverage and sparing of healthy 
tissues. 
Four dimensional CT (4D-CT) scans enable registration and assess-
ment of the respiratory motion of the primary lung tumor and medi-
astinal lymphnodes. 
Target delineation based on imaging with 4DCT improves treat-
ment accuracy, and have the potential to reduce treatment morbility, 
allowing radiation oncologist to reduce margins from clinical target 
volume to planning target volume. 
The introduction of multimodality imaging and modern planning 
techniques to rigorously delineate and irradiate tumors using very 
small safety margins makes mandatory Image Guided Radiation 
Therapy (IGRT) approaches to monitor patients and tumor position 
during treatment. 
Tumor position can be verified using high-quality imaging systems 
and automatic images registration integrated into the linear accel-
erator, with different technical solutions including active implanted 
markers, megavoltage (MV) single slice CT (tomotherapy) and KV 
or MV cone-beam CT. 
Another important aspect of IGRT relies on the possibility to identify 
any changes in tumor volume and shape, or in patient’s anatomy due 
to excessive weight loss during the treatment, allowing interactive 
adaptation of the treatment plan based on daily assessment (Adaptive 
Radiotherapy).
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in the treatment of lung cancer
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Within the field of Interventional Pulmonology, the use of various 
interventional bronchoscopic techniques (IBT) has become indis-
pensable by virtue of its minimally invasive nature, thus optimizing 
quality of life of our patients. These techniques are less morbid for 
the individuals at risk as many of them also suffer from smoking 
related co-morbidities such as COPD and poor cardiovascular health. 
Therefore IBT can provide elegant alternative strategies even for 
patients with poor performance status.(1,2)
IBTs encompass a vast array of activities: early diagnosis, accurate 
staging, treatment and close surveillance of individuals with or at risk 
for developing – subsequent lung cancer.(3-5) Targeting the region 
of interest with virtual bronchoscopy navigation,(6) localizing early 
preneoplastic changes in the bronchial mucosa with autofluorescence 
bronchoscopy,(7) nodal staging with endobronchial ultrasound,(8) 
applying various local bronchoscopic treatments for intraluminal 
early stage squamous cell cancer e.g. carcinoma in situ,(1,3-5) as 
well as dynamic monitoring with emerging technologies e.g. optical 
computed tomography, near infrared Raman spectroscopy and confo-
cal endoscopy.(9-11) 
IBTs not only provide cost effective strategies for immediate relief of 
imminent suffocation, but offer potential curative treatment alter-
natives for N0M0 cancer lesion.(4,5) Its minimal invasive nature 
obviously preserves quality of life much better than the application 
of conventional surgical modalities, especially when dealing with 
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asymptomatic individuals. Current understanding about different 
clonal processes and the issue of overdiagnosis do warrant a more 
differentiated thinking rather than persistent adherence to standard 
strategies.(12,13) 
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Preneoplasia of lung cancer
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The lung and it tumors represent a complex topic as the lung may be 
divided into central and peripheral compartments, and distinct tumor 
types arise from each compartment.
The development of the lung
The lung develops as an anterior outgrowth from the embryonic 
foregut, as does the thyroid. The location of both buds is marked 
by expression of the master transcription factor thyroid transcrip-
tion factor or TITF1 (also called TTF1) (1). As the lung develops, it 
forms a series of closed buds, lined by a single epithelial cell, a tall 
columnar glycogen rich cell with apical located nuclei. As no other 
cells enter the developing epithelium, we can presume that these cells 
represent the primordial stem cell of the lung, and that all epithelial 
including neuroendocrine cells are derived from this primordial 
stem cell. The branching developing lung becomes enveloped in 
mesenchyme, and epithelial-mesenchymal interaction is essential for 
further development and maturation. Full maturation does not occur 
until shortly before birth.
The concept of central and peripheral lung compartments
The lung is one of a few organs in which distinct anatomic and 
functional compartments have been recognized, and these compart-
ments give rise to specific tumor types (2). The central compart-
ment consists of the large and medium sized bronchi, involved in 
air conduction. The peripheral compartment consists of smaller 
airway bronchioles and alveoli. The histological structures of these 
compartments are very different. The central airways are lined by 
pseudostratified epithelium having basally located basal cells and 
neuroendocrine cells, and luminal tall ciliated cells and mucous 
secreting cells. In the terminal (respiratory) bronchioles are located 
short stubby ciliated cells and secretory Clara cells. The alveoli are 
lined by flattened type I alveolar pneumocytes (through which gas 
exchange occurs) and type II pneumocytes which secrete surfactant. 
The only cells capable of sustained division are the Clara cells and 
the type II cells. Both of these cell types are believed to be derived 
from a common bronchiolo-alveolar stem cell. Thus the primordial 
lung stem cell is believed to give rise to the secondary stem cells of 
the central and peripheral compartments.
Most squamous and small cell carcinomas (SCLC) arise from the 
central airways, while many if not most adenocarcinomas arise from 
the peripheral airways. The peripheral adenocarcinomas often have a 
prominent bronchiolo-alveolar component, although true bronchiole-
alveolar carcinomas (BAC), as defined by the WHO classification, 
are non invasive carcinomas. Some adenocarcinomas arise centrally 
from the surface epithelium or occasionally from the bronchial 
glands. 
Premalignant changes in the central and peripheral airways
As with most epithelial tumors, lung cancers are preceded by a series 
of premalignant changes. Because of the compartmentalization of the 
lung and the multiple histological tumors, these differ for individual 
tumor types and compartment location. In the large bronchi (which 
can be serially sampled via endoscopy), a series of squamous ori-
ented changes leading from metaplasia, different degrees of dysplasia 
to carcinoma in situ and invasive cancer have been described. While 
conventional belief is that lesions progress along the sequential path 
described above, actual observations indicate that the natural history 
and progression of lesions is highly variable, and that the sequen-
tial pathway is not always followed. Sequential biopsies of specific 
sites may demonstrate progression to CIS or cancer without all the 
intermediate stages (parallel theory of progression). Another change 
described in the bronchial mucosa is angiogenic squamous dysplasia, 
which results in vascular thickenings or protrusions of the bronchial 
mucosa, usually accompanied by overlying squamous dysplastic 
changes (3). They are regarded as evidence that neoangiogenesis of 
the bronchial mucosa is an early premalignant change. 
Many of the premalignant lesions cannot be detected by white light 
bronchoscopy, and fluorescence bronchosopy is much more efficient 
at detecting such lesions (4). A lesson learnt from fluorescence bron-
choscopy is the small size of many of these lesions (one to three mm 
in longest length). The small size of the premalignant lesions com-
plicates studies of the natural history of such lesions, as bronchial 
biopsy may remove the lesions either directly or by the subsequent 
fibrotic reaction. 
The development of peripheral adenocarcinomas is less well defined 
as sequential biopsies cannot be obtained. Our current belief is that 
focal lesions of type 2 alveloar cells (atypical adenomatous hyperpla-
sias, AAH), precede the onset of non-mucionous bronchiole-alveolar 
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carcinomas (BAC). BACs (by definition, strictly a non-invasive 
lesion) eventually lead to invasive carcinoma (often starting in a cen-
tral scar focus). Molecular studies support the concept of AAH being 
a premalignant lesion and BAC being a preinvasive lesion. However, 
because BAC can potentially occupy much of the lung and spread 
bilaterally via aeroginous dissemination, it is preinvasive cancer that 
can kill the host. 
A wide variety of molecular lesions are present in the smoke dam-
aged lungs of smokers. These lesions are very small, and molecular 
changes precede the onset of pathologically recognizable changes (5, 
6). The number of lesions, their size and the complexity and the num-
ber of their molecular changes increase with increasing histological 
severity of the lesions. The order of appearance of such changes is 
not random but follows certain general guidelines (7, 8). 
In smoke damaged lungs there are numerous foci of molecularly 
damaged and histologically abnormal foci. They tend to be larger and 
more advanced in the vicinity of the tumors. Thus smoke associated 
lung cancers demonstrate large field effects. In the lungs of never 
smokers with lung cancers, the field of damage is usually much less 
limited, to he region surrounding the tumor. Field effects in cancers 
also result in multiple synchronous and metachronous tumors. These 
tumors present a dilemma – are they multiple primary tumors arising 
as a result of field cancerization or are they intra-pulmonary metasta-
ses? Molecular studies indicate that they arise by both mechanisms, 
but that the origin has little effect on prognosis, as aggressive surgi-
cal resection of these lesions results in a surprisingly good prognosis 
(9). 
No precursor lesions have been identified with certainty for the 
development of small cell carcinoma of the lung (SCLC). However, 
microdissection studies indicate that extensive genetic damage in 
the accompanying normal and hyperplastic bronchial epithelium is 
characteristic of SCLC tumors and suggest major differences in the 
pathogenesis of the three major lung cancer types (10).
Model systems for the study of lung preneoplasia
Understanding lung preneoplasia has been limited by a shortage of 
adequate sequential samples. Our group has immortalized human 
bronchial epithelial cells (HBECs) which can be manipulated by 
the introduction of oncogenes or by inactivating tumor suppressor 
genes (11). By using combinations of such molecular manipulations, 
models for the premalignant, preinvasive, and invasive stages of lung 
cancer can be obtained and studied. Because the cells have stem cell 
like properties, they are pluripotential and can form squamous, adeno 
or undifferentiated (large cell) carcinomas. More recently we have 
immortalized human small airway cells (HSAECs). These cells also 
have stem cell like properties and can be made to differentiate along 
the lines of peripheral airway cells – Clara cells, type 1 and type 2 
pneumocytes. 
Summary
Recent advances in molecular biology, imaging techniques, patholo-
gy have greatly advanced our knowledge of the pathogenesis of lung 
cancers via a study of the multistage pathogenesis of lung cancers 
and have provided evidence for the concept of central and peripheral 
compartments of the lung and the tumors derived from them. 
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Lung cancer is the leading cause of cancer death across the world. 
However there are universal challenges with building advocacy to 
support enhancements of research and therepeutic efforts for this 
cancer. At the last World Conference, the remarkable success of 
the Korean government in supporting national smoking cessation 
measures was a model for academic leaders to adaptively engage the 
political leadership to align efforts to improve lung cancer outcomes. 
Prof Jae-Gahb Park in his presentation at the 12th World Conference 
shared key elements of his strategic communications to galvanize the 
public to create a political environment to support improved health 
policy.
Recently, advocates in the United States have been successful in sup-
porting new legislation to allow the Department of Defense to fund 
lung cancer research using an approach pioneered by breast cancer 
advocates. This funding mechanisim has led to cummulative support 
of breast cancer research in excess of a billion dollars in the years 
since the initial Congressional approval. 
What are the characteristics of political efforts which are successful 
in leading to new support for lung cancer research and care? In this 
forum, these issues will be analyzed and a strategy proposed for sup-
porting coordinated national and international efforts to improve lung 
cancer outcomes. 
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Large cell carcinoma
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In the WHO 2004 classification of lung cancer, large cell carcinoma 
is defined as ‘an undifferentiated non-small cell carcinoma that lacks 
the cytological and architectural features of small cell carcinoma and 
glandular or squamous differentiation’. This heterogeneous collec-
tion of tumours accounts for approximately 9% of all lung cancers. 
Clinically and radiologically they are similar to other lung cancers. 
They are commoner in males, are mostly smoking-related and often 
present as large peripheral masses; pleural and chest wall invasion 
are not uncommon. Patterns of spread are also indistinguishable from 
other non-small cell carcinomas with hilar and mediastinal lymph 
nodes, liver, bone, brain, adrenal glands and pericardium being 
favoured sites. 
Apart from what might be considered large cell carcinoma, not oth-
erwise specified (NOS), there are several described variants in this 
category, some of which are exceptionally rare. Large cell neuroen-
docrine carcinoma (LCNEC), either in pure form or combined with 
another tumour type is probably the most frequently encountered, 
followed by basaloid carcinoma. Lymphoepithelioma-like carcinoma, 
clear cell carcinoma and large cell carcinoma with rhabdoid pheno-
type are extremely uncommon. These variants are discussed first.
Large cell neuroendocrine carcinoma
By definition, this tumour shows either immunohistochemical or 
ultrastructural evidence of neuroendocrine differentiation. In prac-
tice at least two of the three most commonly used neuroendocrine 
markers; chromogranin, synaptophysin and CD56 will be strongly 
positive in tumour cells. On H&E stained sections this tumour also 
has a neuroendocrine morphology. Tumour cells are generally larger 
than three adjacent resting lymphocytes, and there is abundant, often 
eosinophilic cytoplasm. Nuclei are large, with vesicular chromatin, a 
well defined nuclear membrane and have prominent nucleoli which 
may be multiple. Mitotic figures are abundant; a mitotic count of 
over 10 per 10 high power fields (hpf) or 2 mm sq sets LCNEC apart 
from atypical carcinoid tumour but in practice, the mitotic count in 
LCNEC is usually extremely high, exceeding 50 per 10 hpf. Apop-
tosis is also widespread and sheets of eosinophilic necrosis stand out 
in contrast to the basophilia of viable tumour. The architecture of 
this tumour is important in diagnosis and reflects the neuroendocrine 
nature of the lesion; organoid nesting with trabeculae, peripheral 
palisading of cells and rosettes are characteristic. 
These tumours may be centrally located or, more often, peripheral 
but are strongly associated with smoking. Clinically these tumours 
share some features with small cell lung carcinomas (SCLC); they 
are aggressive tumours exhibiting poorer prognosis than adeno or 
squamous cell carcinomas with an outcome akin to, stage for stage, 
that of SCLC. They tend to be large, are commoner in males and 
the brain and liver appear to be preferred metastatic sites. Ectopic 
hormone syndromes are not reported with LCNEC. There is evidence 
that they respond to the same platinum / etoposide chemotherapeutic 
regimens used in SCLC. 
Differential diagnosis of LCNEC includes atypical carcinoid tumours 
and SCLC. The context is important. In the case of surgically resect-
ed tumours, atypical carcinoid (AC) is mostly easy to distinguish 
from LCNEC due to the former’s lower mitotic rate (2-10 per hpf) 
and clear carcinoid-like features of a relatively low grade tumour. 
Apart from occasional foci of punctuate necrosis, AC lacks the 
appearance of a high grade malignant tumour exhibited by LCNEC. 
LCNEC may be difficult to separate from the unusual occurrence 
of a resectable SCLC but attention to the cell size, plus the lack of 
cytoplasm, prominent nuclear moulding and frequent DNA smearing 
(Azzopardi effect) in SCLC all help. LCNEC with prominent rosette 
formation may be misdiagnosed as cribriform-pattern adenocarci-
noma. With this in mind, TTF1 is expressed in 50-70% of LCNEC 
but mucin is not found. Greater problems may arise in the context 
of small biopsy samples or cytology. LCNEC is generally not a 
diagnosis which can be made with confidence in such samples, 
though occasionally sufficient features are present to at least suggest 
the diagnosis. Neuroendocrine markers are, of course, useful, and 
proliferation markers have been suggested as an adjunct to discrimi-
nate LCNEC, which would have a high Ki67 index, from carcinoid 
tumours for which a low Ki67 index would be expected. Distinguish-
ing LCNEC from SCLC may not be possible in some cases. Both 
show neuroendocrine markers and TTF1 but lack staining for high 
molecular weight cytokeratins; 34betaE12 (CK 1,5,10 &14). 
About 20% of LCNEC occur in combination with another form 
of lung carcinoma, most commonly adenocarcinoma (so-called 
combined large cell neuroendocrine carcinoma). Tumours showing 
LCNEC in combination with SCLC are classified as combined small 
cell carcinoma of the lung.
LCNEC has both neuroendocrine morphology on H&E stained 
sections and evidence of neuroendocrine differentiation, most often 
demonstrated by immunohistochemistry. Occasionally, tumours 
will be encountered which have neuroendocrine morphology but 
neuroendocrine marker immunohistochemistry is negative; so-called 
large cell carcinoma with neuroendocrine morphology. Too little is 
published on these tumours to draw any definite conclusion regarding 
their relationship with LCNEC. Furthermore, large cell carcinomas 
lacking neuroendocrine morphology may express neuroendocrine 
markers by immunohistochemistry (so-called large cell carcinoma 
with neuroendocrine differentiation). There has been speculation 
in the past that such tumours may be more aggressive than other 
non-small cell carcinomas and that they may be particularly chemo-
sensitive. Recent evidence, however, suggests that this is probably 
not the case.
Basaloid carcinoma
Basaloid carcinoma is well described in the upper aerodigestive tract, 
oesophagus, anal canal, cervix and thymus, but has only recently 
been recognised as a separate entity in the lung. Previously these 
tumours would have been considered poorly differentiated squamous 
cell carcinomas. The poor prognosis of basaloid carcinoma and its 
distinctive histological features led to its inclusion in the 1999 WHO 
classification.
Basaloid carcinoma is a rare tumour, especially in pure form, 
accounting for 2-4% of primary lung cancers and about one third of 
‘undifferentiated’ carcinomas in resected case series. These tumours 
are associated with smoking tobacco and are usually centrally 
located. Prognosis is generally poor; median survival is around 20 
months and for Stage I-II disease, 5-year survival is about 15%. 
Brain metastases seem to be particularly frequent.
Tumours are often large; lesions up to 7cm in diameter have been 
described and 85% show endobronchial growth of tumour as well as 
extrabronchial invasion. One third of cases show direct invasion of 
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mediastinal pleura or perihilar fat. Around 40% of resected tumours 
are stage I while 30% are stage II. 
The main histologic characteristics of this tumour are a growth pat-
tern in lobules or anastamosing trabeculae with peripheral nuclear 
palisading. Cells are small (12-15 um), cuboidal or fusiform with 
scant cytoplasm. Nuclei are moderately hyperchromatic with 
granular chromatin and inconspicuous or absent nucleoli. Nuclear 
moulding is absent. Mitotic rate is high; 15-50 per 10 hpf / 2mm sq. 
Other features include centrilobular comedo-type necrosis (60% of 
cases), small cystic spaces (30%) which may contain AB/PAS posi-
tive mucin, papillary architecture in any endobronchial component, 
rosettes (30%), stromal hyaline basement membrane-like material 
(30%), myxoid change (20%), osseous or chondroid metaplasia 
(rare). 
True, pure basaloid carcinoma shows the above features in at 
least 90% of the lesion; around half of all tumours exhibiting this 
morphology fall into this category. In the other half, another non-
small cell carcinoma type accounts for a proportion of the tumour: 
mostly (in over 80% of cases) this is well-moderately differentiated 
squamous cell carcinoma, in which case the appropriate diagnosis is 
basaloid variant of squamous cell carcinoma. When, rarely, the non-
basaloid component is undifferentiated large cell-type carcinoma, 
basaloid carcinoma may be diagnosed if the latter accounts for more 
than half the tumour. Lesser amounts of basaloid tumour, in practice, 
merit a descriptor of ‘basaloid features’ but in such cases tumour 
classification should be determined by the dominant non-basaloid 
component.
Basaloid carcinoma lacks evidence of keratinisation (inter-cellular 
bridges or true individual cell keratinisation) but, in around 25% 
of cases, a rather abrupt form of hair follicle-like squamous ‘pearl’ 
may be seen. This is acceptable within the basaloid component and 
does not warrant a diagnosis of squamous cell carcinoma. About one 
quarter of cases are associated with bronchial squamous carcinoma-
in-situ which is rich in basal cells. 
Cytokeratin expression commensurate with bronchial basal/reserve 
cell differentiation is evident; CKs 7,8,18 and 19 are consistently 
expressed in well fixed cases while CKs 5,6,13,14 and 16 are 
found in up to half of cases. Expression may be weak and heterog-
enous. CKs 4, 10 and 11, characteristic of squamous epithelium 
and squamous cell carcinoma are not found. All cases stain with 
34betaE12 (CK 1, 5, 10 &14). Basaloid carcinoma is consistently 
negative for TTF-1. Neuroendocrine markers are rarely found; 
usually only one marker is positive in relatively few (<20%) cells. 
Around 10% of basaloid carcinomas express CD56 (NCAM), 3% 
express synaptophysin and none show chromogranin. 
Definitive diagnosis is generally only made after examination of the 
whole, or a substantial part of the tumour and is mostly, therefore, 
only made in surgical resection specimens. Basaloid features may be 
recognised in biopsy specimens but, as with large cell carcinomas 
in general, the diagnosis can at best only be suggestive since small 
samples may not be representative of the whole lesion. Differential 
diagnosis from poorly differentiated or basaloid variants of squamous 
cell carcinoma have been addressed above. Criteria for diagnos-
ing squamous cell carcinoma (inter-cellular bridges, individual cell 
keratinisation) are robust if strictly applied. A tumour with definite 
squamous cell carcinoma but a clear basaloid component should be 
classified as a basaloid variant of squamous cell carcinoma. There 
are no clear rules regarding the relative proportions of each required 
for this diagnosis. Following the WHO ‘rule’ that components 
comprising <10% of mixed tumours do not, with the exception of 
SCLC, influence tumour classification, it would be reasonable to 
regard a tumour with 90% or more basaloid carcinoma as a ‘true’ 
basaloid carcinoma. Similarly, a basaloid tumour with between 10% 
and 90% of its mass showing definite squamous cell carcinoma could 
reasonably be called basaloid variant of squamous cell carcinoma. 
Current knowledge suggests there is no clinical difference between 
pure basaloid carcinoma and the basaloid variant of squamous cell 
carcinoma.
Large cell neuroendocrine carcinoma is an important differential 
diagnosis, especially if rosettes and peripheral nuclear palisad-
ing are present. LCNEC generally shows more cytoplasm and 
prominent nucleoli, and strong and usually widespread expression 
of at least two neuroendocrine markers (chromogranin, synapto-
physin, CD56-NCAM), frequent TTF-1 expression and absent high 
molecular weight cytokeratins (34betaE12) help separate LCNEC 
from basaloid carcinoma. While the chromatin patterns in basaloid 
carcinoma and SCLC are similar, the absence of nuclear moulding, 
the stromal features and the distinctive lobulated growth pattern of 
basaloid carcinoma help distinguish the two, as will neuroendocrine 
marker immunohistochemistry. A basaloid tumour component can 
be difficult to distinguish from SCLC in cytological preparations or 
small crushed biopsy samples.
Lymphoepithelioma-like carcinoma (LELC)
This is a rare but distinctive tumour characteristically seen in Asian 
patients when the tumour is more closely associated with Epstein 
Barr virus (EBV) infection than with smoking; in Western cases, 
EBV is not involved. 
Tumours are often well circumscribed, firm with a white cut surface. 
Histologically a syncytial growth pattern of sheets or nests of large 
cells with abundant eosinophilic cytoplasm are characteristic, there 
are large vesicular nuclei with prominent nuclei and abundant mito-
ses. The tumour shows a pushing border and a heavy admixture of 
lymphocytes (CD8+), plasma cells, macrophages and even neutro-
phils and eosinophils. Squamous or adenocarcinomatous differentia-
tion is never found. Stromal sclerosis or even amyloid deposition 
has been described. Large tumour cells in EBV-associated cases may 
show EBV-encoded RNA-1 (EBER-1) by in-situ hybridisation but 
LMP-1 protein is not present. 
Differential diagnosis includes large cell carcinoma with a heavy 
lymphoid infiltrate (see below), lymphoma, metastatic tumours, 
inflammatory pseudotumour and even thymoma. Appropriate immu-
nohistochemistry and clinico-pathological correlation are important 
in reaching the correct diagnosis. Good data on clinical outcome are 
lacking; stage for stage prognosis is probably no different from other 
large cell carcinomas.
Clear cell carcinoma
Clear cell change is common in both squamous and adenocarcinomas 
as a morphological feature worthy of description but of no known 
clinical significance. In the absence of such differentiation and when 
clear cell change is notable in an otherwise undifferentiated large cell 
carcinoma, a diagnosis of clear cell carcinoma may be made; this is 
an extremely rare tumour. Large polygonal cells with distinct cell 
borders, clear or foamy cytoplasm rich in glycogen and relatively 
small nuclei are found. 
The most important differential diagnosis is metastatic renal cell car-
cinoma, a much more common occurrence than primary lung disease.
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Large cell carcinoma with rhabdoid phenotype
This tumour is exceptionally rare and is diagnosed when an other-
wise undifferentiated large cell carcinoma shows at least 10% of 
the lesion comprising rhabdoid cells with eosinophilic cytoplasmic 
globules. Cells are polygonal, round or pleomorphic, and eosino-
philic cytoplasm is frequent. Tumours often grow by filling alveoli at 
the tumour edge.
TTF1 and muscle markers are negative but some neuroendocrine 
markers may be positive. Melanoma and lymphoma are the major 
differential diagnoses.
Large cell carcinoma, ‘NOS’ 
A majority of large cell carcinomas fall into this ‘NOS’ category 
which has been considered something of a ‘wastebasket’ diagnosis. 
Gross features of these tumours include large lobulated masses, 
which may or may not involve a cartilaginous airway, with exten-
sive necrosis. The viable areas of tumour range from cream or tan 
coloured to a grayish ‘fish-flesh’ appearance. Cavitation is uncom-
mon but some tumours are haemorrhagic.
Histologically, these cases comprise large pleomorphic malignant 
cells often with vesicular nuclei and prominent nucleoli, though 
irregular nuclei with coarse, clumped chromatin may be encountered. 
Mitotic activity is often brisk. Cytoplasm is generally abundant and 
eosinophilic, but can show basophilia. Some cases show tumour 
giant cells, severe pleomorphism, or multinucleate cells; occasionally 
polylobated nuclei are seen. In such cases, distinction must be made 
between large cell carcinoma and sarcomatoid carcinoma, if the 
pleomorphic elements comprise over 10% of the lesion. A diagnosis 
of large cell or anaplastic lymphoma, melanoma or other metastatic 
tumours may require consideration, depending on the individual 
case.
The tumour may grow in a destructive fashion and interstitial infiltra-
tion is described. Occasionally cases grow within the alveolar air-
spaces, preserving alveolar walls, mimicking a macrophage (desqua-
mative interstitial) pneumonia. A heavy lymphoplasmacytic infiltrate 
is common, not only within tumour stroma but also infiltrating 
amongst and sometimes obscuring the tumour cells. Neutrophils and/
or eosinophils may be present and some cases may show a degree of 
emperipolesis of neutrophils by tumour cells. The author has seen 
several cases of primary lung carcinoma in which large swathes of 
the tumour are replaced by fibrosis, macrophages and chronic inflam-
mation, where intratumoural CD8+ lymphocytes, macrophages and 
S100+ Langerhans cells are common, where granulomas may be 
seen and where viable tumour may be hard to identify. The impres-
sion is one of immunological regression of tumour and the common-
est underlying tumour type was large cell carcinoma. Prognosis was 
good.
Some tumours show a rather ‘squamoid’ architecture with promi-
nent intercellular gaps but by definition, intercellular bridges and 
keratinisation are absent. Equally, occasional mucin vacuoles 
may be identified but, provided these fall short of the 5 cells with 
mucin in each of at least two hpf required to diagnose solid-pattern 
adenocarcinoma, the diagnosis of large cell carcinoma still stands. 
It is of interest that ultrastructural studies of non-variant large cell 
carcinomas have shown squamous differentiation in 14% of cases, 
adenocarcinomatous features in 56% of cases, both patterns in 12%, 
neuroendocrine features in 8% and a complete lack of even ultra-
structural differentiation in only 10% of cases. Evidence of ‘molecu-
lar’ differentiation may be found using immunohistochemistry. The 
presence of neuroendocrine markers in some cases has already been 
mentioned. Around 40 -60% of cases express TTF1 and a ‘squamous’ 
immunophenotype (high level p63 and/or CK5/6 expression) may 
be found in a similar proportion of cases. Desmocollin 3, a potential 
squamous lineage marker has been found in a proportion of large 
cell carcinomas and always mutually exclusive with TTF1 (Prof M 
Papotti, Turin; personal communication). This raises the possibil-
ity that a proportion, perhaps a majority of large cell carcinomas 
represent dedifferentiation of other non-small cell tumours; some 
representing progression of squamous carcinomas while retaining 
ultrastructural features and an appropriate immunophenotype, others 
dedifferentiated adenocarcinomas, retaining occasional mucin vacu-
oles and TTF1 expression. The preponderance of ‘occult’ adenocar-
cinomatous differentiation in large cell carcinomas and the frequent 
peripheral location and large size of a majority of cases is commen-
surate with this hypothesis. Equally, large cell carcinomas may arise 
de novo from pulmonary epithelium, with or without a recognizable 
pre-invasive precursor stage, retaining a limited similarity, at an 
ultrastructural or molecular level, with the epithelium from which the 
invasive tumour arose. In practice, however, small sized (sub-2cm) 
large cell carcinomas are proportionately less common in surgically 
resected tumour series than small squamous cell or adenocarcinomas. 
It is also of interest that in gene expression array studies, some differ-
entiated squamous cell or adenocarcinomas show expression profiles 
‘typical’ of large cell carcinoma, whilst some large cell carcinomas 
‘cluster’ with squamous or adenocarcinomas. 
While substantial proportions of primary non-small cell carcinomas 
may be undifferentiated using standard H&E stains and light micros-
copy, and thus resemble large cell carcinoma, other area may show 
squamous or glandular differentiation, which determines a specific 
subtype diagnosis. Consequently, the presence of undifferentiated 
non-small cell carcinoma on a small biopsy sample or in a cytology 
preparation does not warrant a diagnosis of large cell carcinoma. 
In such circumstances, a diagnosis of ‘non-small cell carcinoma, 
not otherwise specified’ (NSCLC, NOS) is appropriate. A diagnosis 
of large cell carcinoma can only be made after examination of the 
whole tumour; it cannot be made on small, possibly unrepresentative 
samples. In cases where NSCLC, NOS is diagnosed and the tumour 
is subsequently resected, a majority of tumours prove to be adenocar-
cinomas, some are squamous cell carcinoma, and relatively few are 
true large cell carcinomas as defined under the WHO classification.
Conclusion
Large cell carcinomas are a rather heterogeneous collection of 
tumours, undifferentiated by H&E stains and light microscopy but 
demonstrating differentiation at an ultrastructural or molecular level 
which may provide insight into their origins. Although relatively 
uncommon, they are generally quite aggressive and their molecular 
characteristics may in the future allow more effective therapeutic 
choices for their management.
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Maximizing perioperative outcome 
after neoadjuvant therapy
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Locally advanced non-small cell lung cancer (Stage IIIA and IIIB) 
is composed of a very heterogenous population of patients. Overall 
survival for this group of patients is poor (5 to 30%) because of the 
high risk of both locoregional and metastatic recurrence. Neverthe-
less, some patients are cured and a multidisciplinary approach with 
surgery, chemotherapy and radiation therapy for selected subsets 
of patients offers the best chance for cure. Surgical resection can 
provide increased locoregional control over radiation therapy but 
this improved locoregional control must be balanced by the often 
increased morbidity of treatment in patients whose survival is often 
dictated by systemic rather than locoregional disease. Chemotherapy 
serves to target micrometastic disease and enhance locoregional 
modalities of treatment (surgery and/or radiation therapy) but it is 
associated with significant toxicity with unclear benefits in certain 
subsets of patients. This presentation will try to define the subsets 
of patients in this heterogenous group of patients (Stage III) who 
are benefited by an aggressive locoregional approach (surgery) and 
the strategies to optimize perioperative outcome after neoadjuvant 
therapy. 
Initial assessment for surgery includes an assessment of the patient’s 
physiologic reserves with a thorough physical examination, history, 
cardiac evaluation and pulmonary assessment. Surgical resection is 
beneficial in subsets of locally advanced non-small cell lung cancer 
patients in which improved locoregional control is balanced by the 
potential increased morbidity of surgery. 
Subsets of non-Pancoast tumors which may be benefited by an 
aggressive locoregional approach with surgery include:
• T3N1 (Stage IIIA) - Surgery alone in physiologically fit patients.
• T1-3N2 (Stage IIIA) - Induction chemotherapy followed by 
surgery in patients who are physiologically fit, do not have bulky 
adenopathy, or have responded well to chemotherapy (radiograph-
ic or histologic response).
• T4N0-1 (Stage IIIB) - Surgery after induction chemotherapy may 
help a subset of patients with locoregionally aggressive disease.
• T4N2 (Stage IIIB), T1-4N3 (Stage IIIB) or T4 malignant pleural 
effusions Non-Pancoast tumors are best treated non-operatively 
because of the poor long-term survival.
Subsets of Pancoast tumors which may be benefited by an aggressive 
locoregional approach with surgery include:
• T3N1 (Stage IIIA), T4N0-1 (Stage IIIB) - Surgery followed by 
postoperative chemoradiation to minimize the chance of locore-
gional recurrences.
• T1-4N2-3 (Stage IIIA and IIIB) or T4 malignant pleural effusions 
Pancoast tumors are best treated non-operatively because of the 
poor long-term survival.
In summary, locoregionally advanced non-small cell lung cancer 
(Stage IIIA and IIIB) is composed of a very heterogenous population 
of patients. Surgical resection can provide increased locoregional 
control. This improved locoregional control may be able to impact 
on a subset of these difficult patients. It is important to be able to 
define the subsets of patients in which aggressive surgical resection 
is warranted. This decision is best made in a multidisciplinary setting 
in which oncologists, radiation therapists and surgeons discuss each 
patient individually so as to maximize the chance for long-term cure 
while minimizing the chance of treatment related morbidity. In the 
future, the advent of novel biologic agents may provide additional 
therapeutic treatment options and molecular diagnostic markers 
may allow more accurate means of assessing those locally advanced 
non-small cell lung cancer patients best benefited by surgery or other 
forms of treatment.
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cell lung cancer (SCLC)
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Background:
A very good landscape overview of small cell lung cancer [SCLC] 
was published in 2006 the JTO (1). It points to the decreasing in fre-
quency of SCLC from about 20-25% in 1970’s to as low as 13.8% in 
recent years. It expands the issues I will discuss. While SCLC tempts 
investigators with high response rates and illusions of systemic and 
local control, there have been few advances in systemic treatment. 
With the now dated meta-analyses of thoracic radiotherapy [TRT] (2) 
and prophylactic cranial irradiation PCI (3) each producing indepen-
dent 5% increases in survival, the trials that comprise these studies 
were largely alkylator and anthracycline based, so we perhaps need 
to adjust to the newer cisplatin-etoposide (PE) trials and tackle the 
issues of dose, volume, fractionation and timing to reprise what I 
first did for the Australian World conference 20 years ago, and leave 
PCI issues to others. We can speak of these factors in isolation, but in 
practice they overlap.
Limited Disease Thoracic Radiotherapy Issues: 
Dose and Volume: While the Intergroup study (4) set the standard 
for survival in LSCLC, today’s readers and young investigators 
puzzle at why the dose of “only” 45 Gy was used in the once-daily 
control. The trial was conceived in 1989 and completed in 1993, a 
time when even the use of thoracic radiotherapy was questioned. 
The toxicity of 45-50Gy to the esophagus in concurrent therapy was 
serious. Cisplatin-Etoposide (PE) was new then, and many used 
alkylator and anthracycline based regimens that were incompatible 
with thoracic radiotherapy, a key regimen was “CAV” ( Cytoxan 
[cyclophosphamide], adriamycin [doxorubicin] and vincristine). An 
attribute of (PE) is the ability to be used in full dose with full doses 
of TRT. A maximal dose of 60 Gy, then the standard in non-small 
cell lung cancer (NSCLC), but was never thought of for SCLC. 
Three-dimensional treatment planning was in its infancy, available 
not widely available. Many used a posterior “spinal cord” shield 
after 2-3 weeks of treatment to limit spinal cord dose despite the 
shielding delivered to central and subcarinal nodal disease. An added 
benefit protected the esophagus. “Shrinking fields” tracked ebbing 
tumor bulk with weekly re-simulations, but this tactic could not be 
standardized this for a multi-institutional study and it was forbidden 
on the Intergroup trial. Elective nodal irradiation was common; I was 
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considered a Philistine for forbidding prophylactic elective treatment 
of supraclavicular (SC) fossae and the contralateral hilar disease con-
ferred ineligibility. We could not encompass the target into the simple 
opposed oblique fields used with the primitive targeting methods we 
had. There are no studies looking at volume of irradiation in the post-
CT-based treatment planning era. My practice is to treat only evident 
disease, not elective nodal irradiation. Esophageal toxicity once 
problematic; now is unusual. Pulmonary toxicity remains uncom-
mon. These are dose limiting. The spinal cord can tolerate 39 Gy 
in 3 weeks when the 1.5Gy BID fractionation scheme is used to 45 
Gy. Spinal cord issues return to concerns as the once daily and twice 
daily doses ascend beyond 60 Gy.
Recently some have expressed that the Intergroup trial used the 
wrong “control” for the comparative arm, because one arm was 
“biologically more active” than the other, and a larger once daily 
dose should have been employed. This is either a misunderstanding 
of history or a revisionist invention. When one calculates the differ-
ence using alpha to beta ratios and seeks biologic equivalent doses, 
one is hard pressed even in retrospect to show clear or compelling 
differences. The equipoise that allowed the trial was that each treat-
ment had performed rather well as pilots within ECOG (Eastern 
Cooperative Oncology Group) for the twice daily and SWOG( 
Southwestern Oncology Group) for the once daily, and many forecast 
that this twice daily idea was daft, and the results would fail in a 
large national trial. That did not prove to be the case. Early reports 
were remarkable because of how similar outcomes were with median 
follow up of 24 months. 
Fractionation and Time: Today, while doses of 60–70 Gy now can be 
achieved with 3-D treatment systems, these are no prospective com-
parative trials proving relative safety or benefit when compared to 
standard. The assumption is: higher doses have to be better; however, 
there are no compelling data to support this belief. Since protraction 
of radiotherapy dose involves 6 to 7 weeks or longer, it will overlap 
with 3 cycles of chemotherapy, and may lead to dose reductions in 
chemotherapy and treatment breaks in the radiotherapy – both can be 
the cause of inferior local control and poorer survival. More may in 
fact prove to be worse, as well as more costly.
My 1998 ASCO abstract first reported survival benefit after a suf-
ficient number of events occurred (5). Moreover, the focus of this 
abstract concerned local failure, which was scored for all partial 
response (PR) patients. PR was scored in about one-third of each 
group. The five year survival within the BID arm was nearly identi-
cal (23%) to the overall group, but only 8% of the QD patients 
survived for five years. This means that local failure was over-called, 
and some of patients scored as local failure on the BID arm were 
actually cured, surviving 5 years or longer, and the residual radio-
graphic abnormality likely represented fibrotic scar. I estimate that 
true local failure may be 10-15% on this trial in the twice-daily arm, 
not the 30% reported errantly in New England journal (4). It is the 
errant higher local failure rate that continues to spur interest in “more 
dose” or ways to achieve better local control. Adding to this mis-
characterization of true local failure was the fact that the cases were 
not planned 3-D, and there were major protocol failures in treatment 
delivery, significantly more common in the BID patients. Waggishly I 
have remarked that it is indeed better to hit the target once daily than 
to miss it twice! Local failure is of interest, but can be rather difficult 
to discern, and depends on what studies are done and when they are 
declared as controlled, failed or stable. The North Central [NCCTG] 
study unfortunately used two daily fractions with a planned a 2 week 
gap in treatment (6) and compared it to a continuous daily treat-
ment. Both methods protracted treatment time in sharp contrast the 
accelerated scheme of the Intergroup Trial. Two daily treatments are 
only worthwhile if there are no treatment interruptions. The NCCTG 
total treatment time of the once daily and twice daily treatments was 
just about identical (6). As done this study actually provides evidence 
that by decreasing the intensity of the treatment and protracting 
overall radiotherapy treatment time, the desired effect (improved 
survival) is lost. Protracting treatment time, either by planned breaks, 
as in this study, or unplanned breaks in practice, and increasing dose 
by a small amount leads to no significant survival benefit, and might 
be a cause of resistance and local failure. Two new trials will test 
this: CONVERT, which uses concurrent therapy with cycle two and 
66Gy, and a new US trial that employs a 5 week and 7 week course 
concurrent with cycle 1.
The argument about early versus late use of thoracic radiotherapy 
arises in studies that continue to use cyclophosphamide and/or an 
anthracycline chemotherapy. In many ways the framing of the ques-
tion about radiotherapy timing in the chest is more about the chemo-
therapy than the radiotherapy. Similarly, the agents that added to the 
intrathoracic toxicity caused problems with accepting thoracic radio-
therapy. While this is a throw-back to the days when this is debated, 
evidence points to four cycles of cisplatin etoposide is sufficient as 
standard therapy, and the attribute of the cisplatin etoposide combi-
nation is that it can be used in full doses with full doses of thoracic 
radiotherapy. The same cannot be said about CAV-like chemotherapy 
– it’s their toxicity and incompatibility with the thoracic radiotherapy 
that raises this red herring. Prolonged chemotherapy not only is of 
unproven benefit, it may select for resistant clones, allow for distant 
metastasis, and change the frequency of neurocognitive effects. The 
use of irinotecan may be an advance in Asian populations, but does 
not outdistance PE in western populations. An issue with irinotecan 
is its compatibility with TRT. Actual reports of pulmonary toxicity 
are sketchy, but have hampered investigation in LD-SCLC
Delaying TRT in order to “get all the chemotherapy in” may be based 
on the desire to see response, or on theory that reducing bulk may 
make combined modality less toxic, or more crassly on the econom-
ics of wanting to deliver 4-6 cycles without the toxic interference of 
thoracic radiotherapy. Similarly, planning a gap, break or interruption 
in the delivery of thoracic radiotherapy may diminish effectiveness 
as seen in the Mayo/NCCTG study (6). DeRuysscher introduced 
the concept of “Start to End of Radiotherapy” (SER) to analyze the 
empiric data using meta-analytic techniques (7). It claims that start-
ing chemotherapy or any treatment stimulates proliferation of surviv-
ing tumor cells, especially those that resisted the first cycle. Survival 
is superior when radiotherapy treatment is completed in 30 days – a 
little more than 4 weeks. Obviously if correct, this would eliminate 
induction chemotherapy unless used to reduce bulk. I find this analy-
sis quite appealing, and data from Convert or the new US trial may 
provide contemporary data to the point: short accelerated treatment 
versus protraction. We shall see. While Pignon (2) and Auperin (3) 
meta-analyze data from the CAV era, there are a plethora of modern, 
less quoted meta-analyses referenced below (8-11) 
The Role of TRT in Extensive Disease (ED) Small Cell: Since most 
at least two-thirds of patients with SCLC have ED and five year 
survival is anecdotal, the focus rightly is on improvement in systemic 
disease. Quality of life remains of paramount importance to these 
patients. Systemic treatment produces complete or partial response 
in more than 50% of patients. Commonly, thoracic disease persists. 
Copyright © 2009 by the International Association for the Study of Lung Cancer S241
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
Jeremic and colleagues (12) studied over 200 patients, and random-
ized patients after 3 cycles of chemotherapy: those with complete 
systemic response, with or without residual disease randomized 
between more chemotherapy or a rather intensive concurrent che-
motherapy schedule. They report a significant benefit in the subset 
receiving TRT including more than 10% 5-year survival. In the 
European PCI trial (13), 75% of patients had residual chest disease 
after 4-6 cycles of chemotherapy. Despite this, the PCI produced an 
astounding improvement in overall and a doubling of one-year post 
intervention survival.
While certainly there is a need for more information, there appears to 
be considerable preliminary information supporting the use of TRT 
(as well as PCI) in ED responders, and trials are either underway in 
the EORTC or under consideration, as well as in Canada.
My personal bias is that the treatment needs to be as least toxic as 
possible given the poor prospect for greater than 2-year survival.
Prophylactic Cranial Irradiation (PCI): There really is no question 
about the benefit of PCI; its role is established by the meta-analysis 
published by Auperin (3), who reported a reduction in brain relapse 
and a 5% improvement in survival. Others will focus this subject in 
detail, but PCI seems indicated at standard doses 2.0 to 2.5 Gy/frac-
tion to total doses of 25 to 30 Gy. Clarifying studies are underway 
and long term cognitive data are desirable; however, the best way to 
preserve cognitive function is to prevent brain metastasis.
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After pemetrexed and cisplatin, what is the way forward?
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Historically, the treatment of unresectable pleural mesothelioma 
began with single agent chemotherapy. A good example of these are 
the single agent trials of the Cancer and Leukemia Group B which 
has completed over 15 studies of single agents or doublets (1, 2). The 
studies began to be published in 1993 and showed that the agents 
with the highest response rate and the longest median survivals were 
the antifolates, either edatrexate or trimetrexate. The edatrexate 
response rate was 25% with a median survival of 9.6 months (2); 
the trimetrexate at a dose of 10mg/m2 had a response rate of 12% 
and survival of 9.8 months. Addition of leucovorin to edatrexate 
appeared to reduce its effectiveness. Reduction of the trimetrexate 
dose likewise appeared to reduce its effectiveness (3, 4). These clues 
of activity of the antifolates presaged the later development of pem-
etrexed for the treatment of malignant pleural mesothelioma.
In 1999, however, Byrne, et al, (5), and subsequently confirmed in a 
number of other studies (6-8), found that the combination of gemcit-
abine and cisplatin induced response rates of 20-25%, with median 
survival rates ranging from 9.5 up to 20 months. Thus, the regime of 
gemcitabine and cisplatin became the standard of care beginning in 
1999 and continuing through until the mid 2000s.
Also in a 1999 Phase I study, pemetrexed and cisplatin was reported 
to induce responses in 5 of 11 mesothelioma patients. Thödtmann, 
et al, (9), recommended a phase II dose of pemetrexed 500mg/m2 
plus cisplatin 75mg/m2. Neutropenia was a dose limiting toxicity. 
Scagliotti, et al, (10) reported on 64 mesothelioma patients treated 
with single agent pemetrexed, 43 of whom had full vitamin supple-
mentation and 21 of whom had no vitamin supplementation. A 14% 
response rate was noted but more importantly a median survival of 
10.7 months was achieved with a one year survival of 48%. These 
data suggested that, like previous antifolates, pemetrexed impacted 
the natural history of malignant pleural mesothelioma.
Thus, in 2003, there were substantial Phase II data but no Phase III 
data to guide treatment of mesothelioma. The consensus standard of 
care was gemcitabine and cisplatin. Cisplatin and antifolates were 
considered to be the best single active agents. In 2003 the interna-
tional randomized Phase III trial of cisplatin +/- pemetrexed was 
reported (11). This study of 448 patients reported a median survival 
time of 13 months for the 2-drug arm, versus just under 10 months 
for the 1-drug arm, and rapidly became the standard of care.
In 2005 the EORTC (12), reported that cisplatin plus raltitrexed 
(another antifolate) had a median survival of 11 months compared 
to 9 months for cisplatin alone P=0.048) in a 250 patient trial. Both 
trials also reported improvement in response rates, quality of life, and 
in one year survival rates. However, grade 3/4 neutropenia was more 
common but there was no increase in the drug related deaths in the 
two drug regimens. No other trials of single agent versus a doublet 
have been conducted.
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In 2004, Muers, et al, compared active symptom control (ASC) 
to ASC with either vinorelbine or the three drug combination of 
mitomycin C, vinblastine and cisplatin-MVP (13). That trial had 
initially been designed to achieve a survival endpoint with a target 
of 840 patients. With the data of pemetrexed and cisplatin, the trial 
began to slow to accrual. Thus in February of 2005 the study was 
changed from a 3-arm to a 2-arm study comparing ASC to ASC plus 
chemotherapy. This reduced the target number of patients required 
to 420 patients. It was a 2 to 1 randomization to no chemotherapy 
versus chemotherapy, where 140 ASC patients were compared to 
280 ASC patients plus chemotherapy. The median survival was 8.5 
months for the ASC plus chemotherapy versus 7.6 months for ASC 
alone. (P= 0.32, HR= .89). The median survival of the vinorelbine 
arm (9.4 months) was slightly better than ASC but the hazard ratio 
was insignificant (14). That trial suggests that vinorelbine or MVP 
chemotherapy was roughly equivalent to cisplatin alone (used as 
the control arm in the pemetrexed cisplatin study). Thus, there does 
not appear to be a major role for vinorelbine or MVP chemotherapy 
in the treatment of malignant pleural mesothelioma. The standard 
of care for malignant pleural mesothelioma remained cisplatin and 
pemetrexed (15).
Since 2007, the question has been asked repeatedly, what is the way 
to advance the treatment of malignant pleural mesothelioma? Most 
importantly, new active agents must be discovered and developed 
mesothelioma. There are a number of possible study designs; for 
example a “window of opportunity” design using cisplatin and 
pemetrexed as salvage or back-up, or standard phase II new drug 
trials as second or third line therapy. A second way forward, which is 
complimentary to the new agent strategy, would be to study Phase II 
trials of triplets, i.e. pemetrexed/cisplatin and new agent. If the phase 
II results exceed the expected median survival of pemetrexed/cispla-
tin, a, Phase III trial could be performed.
Unfortunately the number of new agents that have shown effective-
ness in mesothelioma is rather limited. In spite of aggressive efforts 
to identify novel and unique agents, no agents have had a response 
rate substantially over 10% (16). The exception may be the suni-
tunib trial from Australia of 38 patients in which the response rate 
was 15% and a median survival rate of 9 months was achieved (17). 
Phase I mesothelioma specific studies such as those with SSP1 
Immunotoxin (18) or the anti-mesothelin-MORab 009 (19), although 
promising, are still in need of phase II testing. The major coopera-
tive groups such as SWOG and CALGB are conducting trials with 
new agents such as everolimus, cediranib and other TKI agents (20). 
There are many new agents worthy of study, such as AKT inhibitors, 
proteosome inhibitors, aurora kinase inhibitors, hedgehog pathway 
inhibitors etc. Thus these Phase I and II trials in mesothelioma need 
to continue.
One promising class of agents are the deacetylase-inhibiting agents 
(DAC), otherwise known as histone DACs or HDACs (21). A num-
ber of preclinical trials have shown activity of this class of agents in 
mesothelioma call lines (22). Symanowski et al showed that LBH, a 
potent HDAC inhibitor, was also a potent inhibitor of mesothelioma 
cell line growth. SAHA or vorinostat, is another histone deacetylase 
inhibitor and it is approved by the FDA for the treatment of cutane-
ous T-Cell lymphoma. In a preliminary report of 13 patients with 
mesothelioma enrolled in a Phase I study of SAHA, there were two 
unconfirmed partial responses and four patients with prolonged 
stable disease (23). These and other data (24) lead to a very large 
phase III trial being conducted by Merck in which patients with 
unresectable pleural mesothelioma and one or two prior chemother-
apy regimens (the most recent of which had to include pemetrexed) 
are randomized to either vorinostat 300mg bid for 3 out of 7 days 
each week or placebo (25). The first interim analysis of 50 patients 
revealed that the study was meeting its endpoints and the study is 
ongoing and active. It is expected to require 660 patients however. 
A trial of pemetrexed/cisplatin and SAHA was terminated due to 
unexpected and excess toxicity (26).
In 2007 a randomized phase II study of a new agent bevacizumab 
added to gemcitabine and cisplatin was reported by Karrison et al 
(27). This study of 108 patients was a multi-center, double blind 
placebo-controlled randomized Phase II. Although there was a 
statistically significant increase in grade 1 and 2 toxicities in the 3 
drug regimen, there was not any increase in the grade 3/4 toxici-
ties. The overall one year survival rate was 57% and an excellent 
median survival rate was achieved of 15 months. Unfortunately there 
was no difference in the two arms between the bevacizumab arm 
(15.6 months) and placebo (14.7 months). When baseline VEGF 
levels were measured, there was a difference in the median survival. 
Those patients with a lower plasma VEGF level had a statistically 
significant improvement in survival compared to those with higher 
VEGF levels. When stratified by bevacizumab treatment, the high 
VEGF level patients did not show any benefit but the low VEGF 
patients, when treated with bevacizumab appeared to show a survival 
advantage. This subset analysis of course can only be hypothesis-
generating and a Phase III trial is still needed.
A number of triplet phase II trials have been reported, but no regi-
men has reported an apparent improvement in median survival over 
the original doublet regimen. For example, Hillardal et al reported 
a median survival of 12 months with liposomal doxorubicin added 
to the gemcitabine and carboplatin doublet (28). There are Phase 
II studies underway of pemetrexed plus cisplatin plus CBP 501, a 
checkpoint inhibitor and sensitizing agent for cisplatin (29), pem-
etrexed cisplatin plus an anti-mesothelin antibody from Morphotek 
(30), and pemetrexed/cisplatin plus bevacizumab (31).
In non-small cell lung cancer, the Phase III doublet versus doublet 
studies of non-small cell almost always show equivalence (32). To 
date only the addition of bevacizumab or cetuximab to a doublet has 
improved median survivals (33, 34). This paradigm may also apply 
to mesothelioma. Many alternative doublet regimens show activ-
ity in mesothelioma. Pemetrexed/carboplatin (35), oxaliplatin and 
gemcitabine (36), irinotecan/gemcitabine, bevacizumab/erlotinib, and 
epirubicin/gemcitabine (37) have not shown major improvements 
in response rate or median survival over that expected from peme-
trexed/cisplatin. A number of other doublet trials such as pemetrexed/ 
oxaliplatin are underway but it is likely that most doublets studied in 
mesothelioma will be equivalent. Of note, pemetrexed plus gemcit-
abine was not apparently better than single agent pemetrexed (38).
Following the paradigm of non-small cell lung cancer, an internation-
al phase III trial of pemetrexed/cisplatin plus bevacizumab is needed. 
There are no single agent data yet in mesothelioma with cetuximab.
To conclude, pemetrexed and cisplatin with folic acid B12 remains 
the standard of care for unresectable mesothelioma and has been so 
since 2003. Other doublets such as gemcitabine and cisplatin or pem-
etrexed and carboplatin appear to equivalent to pemetrexed/cisplatin, 
and thus a phase III trial comparing two doublets would be relatively 
un-interesting. By far the largest need is for trials of new agents. The 
early data with the newer agents, except for DACs and sunitunib are 
not particularly promising. Phase II trials will need to be conducted 
Copyright © 2009 by the International Association for the Study of Lung Cancer S243
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
with the promising new single agents added to pemetrexed and 
cisplatin. 
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Background
VEGF, the key mediator of tumor angiogenesis
Angiogenesis is a key process throughout tumor development, and 
vascular endothelial growth factor (VEGF) is the key mediator of 
this process. VEGF directly stimulates angiogenesis through receptor 
binding, which activates a series of intracellular signaling pathways 
that lead to the proliferation of vascular endothelial cells. It also acts 
as a survival factor through inhibition of apoptosis, and promotes 
degradation of the basement membrane, ultimately facilitating the 
migration and sprouting of endothelial cells.1 In addition, VEGF 
plays an important role in the recruitment of circulating endothelial 
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progenitor cells to sites of neovascularization, where they comple-
ment the process of angiogenesis. VEGF is produced continuously 
in a variety of solid tumors, including lung, breast and colorectal 
cancers, the majority of renal cell carcinomas as well as bladder, 
ovarian, gastrointestinal tract and brain cancer.1,2
Bevacizumab and VEGF inhibition – mode of action
Bevacizumab, a humanized monoclonal antibody, was the first 
labeled biologic agent designed to specifically target VEGF and 
inhibit tumor angiogenesis, and opened the path to a new approach 
to cancer treatment. Unlike chemotherapy, which kills any rapidly 
dividing cell, bevacizumab starves a tumor of its blood supply by 
shrinking existing tumor vessels and preventing angiogenesis. This 
selective targeting offers the important additional benefit of reduced 
cancer mutations, since unlike cancer cells, which can mutate and 
develop resistance to treatments like chemotherapy, blood vessel 
cells do not mutate. Thus, VEGF is a stable target for treatment 
throughout the course of therapy.3
Using preclinical models, researchers have shown that bevacizumab 
works by
• shrinking existing tumor blood vessels to reduce the supply of 
oxygen and nutrients, thus reducing tumor size and arresting 
growth 
• normalizing the surviving tumor blood vessels (less leaky and 
more organized), which facilitates the delivery of anti-cancer 
therapy to the tumor
• inhibiting new and recurrent blood vessel growth.
Although advanced tumors tend to use multiple pathways to support 
vessel growth, the VEGF pathway plays a life-long key role in their 
growth and survival. Therefore, continuous VEGF inhibition is vital 
for arresting tumor growth and spread. From a therapeutic safety 
perspective, precise VEGF inhibition with bevacizumab has limited 
impact on the side effects of chemotherapy, which is supported by 
data from several bevacizumab clinical trials.
Bevacizumab regulatory approvals
Bevacizumab has been investigated in a comprehensive clinical trial 
program in several tumor types and different settings, and has been 
used for the treatment of more than 570,000 patients worldwide.4 
Accordingly, bevacizumab has already gained regulatory approval 
for multiple indications as first- and second-line therapy. It is 
noteworthy that throughout the clinical trial program, patients who 
received bevacizumab-based therapy continued to receive beva-
cizumab monotherapy until disease progression, since continuous 
inhibition of the VEGF pathway is known to control tumor growth.
In 2006, the FDA approved bevacizumab in combination with 
paclitaxel/carboplatin (PC) chemotherapy for first-line treatment of 
patients with inoperable, locally advanced, recurrent or metastatic 
non-squamous NSCLC, the most common type of lung cancer. 
Approval was based on results from the pivotal randomized, con-
trolled, multicenter phase III ECOG 4599 trial.5 This trial showed 
that patients receiving bevacizumab plus PC had a significant 
improvement in overall survival, the primary endpoint, compared 
with patients who received chemotherapy alone. In August 2007, 
bevacizumab gained regulatory approval in Europe for first-line 
treatment of patients with advanced NSCLC, in combination with 
platinum-based chemotherapy. This approval was based on both 
E4599 and the phase III AVAiL trial. The AVAiL trial also met its pri-
mary endpoint of PFS, which was significantly prolonged compared 
with chemotherapy alone. 
Table 1
  Line of treatment (and)  
Indication  Dosing regimen chemotherapy regimen
Metastatic colorectal  • 5 mg/kg or 10 mg/kg q2w •  First- and second-line, in combination with 
cancer (mCRC)  • 7.5 mg/kg or 15 mg/kg q3w   IV 5-fluorouracil-containing chemotherapy
Metastatic NSCLC 7.5mg/kg or 15mg/kg q3w •  First-line, in combination with platinum- 
   doublet chemotherapy
Metastatic breast cancer 10 mg/kg q2w •  First-line, in combination with paclitaxel 
Metastatic renal  10mg/kg q2w •  First-line, in combination with interferon-
cell cancer (RCC)
Dosing 
Pharmacokinetics
The pharmacokinetic profile of bevacizumab has been assessed using 
an assay that measured total serum bevacizumab concentrations. 
Based on a pharmacokinetic analysis of 491 patients who received 
1 to 20 mg/kg of bevacizumab weekly, every 2 weeks (q2w) or 
every 3 weeks (q3w), the estimated half-life of bevacizumab was 
approximately 20 days. The predicted time to reach steady state was 
100 days. The accumulation ratio following a dose of 10 mg/kg of 
bevacizumab q2w was 2.8.
Key clinical evidence
In NSCLC, two different doses of bevacizumab were assessed for 
efficacy and safety in a number of clinical trials. AVF0757g was a 
phase II randomized, controlled trial of bevacizumab 7.5mg/kg and 
15mg/kg q3w plus PC versus PC alone. The 15 mg/kg dosing regi-
men of bevacizumab-based therapy provided a 76% increase in time 
to progression versus the control arm. Based on these results, ECOG 
selected this dosing regimen for the phase III E4599 trial.5 
E4599 investigated bevacizumab plus PC versus PC alone for up to 
6 cycles, followed by bevacizumab monotherapy (15 mg/kg q3w) 
until disease progression. Importantly, bevacizumab-based therapy 
increased overall survival (primary endpoint) beyond the historical 
benchmark of 1 year: overall survival in the bevacizumab arm was 
extended to 12.3 months, compared with 10.3 months for patients 
treated with chemotherapy alone (hazard ratio [HR] 0.79, p=0.003). 
As a result, bevacizumab became the ECOG reference standard for 
the first-line treatment of patients with advanced (predominantly 
non-squamous) NSCLC. Moreover, in a preplanned analysis of the 
adenocarcinoma sub-population of patients in E4599, bevacizumab-
based therapy provided an unprecedented OS of 14.2 months, a 
4-month improvement in survival compared to PC alone, correspond-
ing to a 31% reduction in the risk of death (HR 0.69).6 
Building on the proven efficacy and safety of bevacizumab, AVAiL, 
a multicenter, randomized, placebo-controlled, phase III trial, 
examined bevacizumab at a dose of 7.5mg/kg or 15mg/kg q3w in 
combination with cisplatin/gemcitabine in patients with previously 
untreated advanced or recurrent non-squamous NSCLC. Both doses 
of bevacizumab provided a significant increase in PFS (primary 
endpoint) versus the control arms (HR 0.75 and 0.82, p=0.0003 and 
0.0456, for both the low- and high-dose arms respectively, versus 
placebo). The safety profile of bevacizumab-based therapy was 
consistent with that observed in the E4599 trial, with no new safety 
signals reported.5,7 The majority of adverse events reported during 
the study were of grade 1 or 2 severity, and the overall incidence of 
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grade ≥3 adverse events was similar across all arms, further support-
ing the favorable safety profile of bevacizumab.
Duration
The central importance of tumor neovascularization throughout the 
tumor’s lifecycle has been highlighted by clinical trials using antian-
giogenic therapy in several types of cancer. The fact that angiogen-
esis is highly restricted in the normal adult means that a tumor must 
switch to an neoangiogenic phenotype in order to initiate revascu-
larization. This acquisition happens early in tumor development 
and it is rate limiting with regards to tumor progression. As a result, 
early tumors are very responsive to anti-VEGF treatment and early 
administration of bevacizumab has a significant effect in arresting 
cancer growth. Furthermore, the combination of bevacizumab with 
chemotherapeutic agents allows the delivery of therapy to the site of 
cancer via the normalized vasculature, and facilitates oxygen enter-
ing the tumor, which is necessary for effective radiotherapy. 
The continued use of bevacizumab-based therapy, from first-line 
until disease progression, as examined in all bevacizumab clinical 
trials, is a much more feasible option than continuous chemotherapy 
for several reasons. Firstly, its well-established and clinically proven 
safety profile across multiple lines and indications makes it suitable 
for prolonged treatment, which contrasts with the cumulative toxici-
ties associated with extended numbers of cycles of chemotherapy. 
Secondly, the lack of cumulative toxicity of bevacizumab has been 
demonstrated through clinical trials, where patients received several 
cycles of bevacizumab until disease progression. Specifically, in the 
E4599 trial, 53% of patients in the bevacizumab arm received more 
than 6 cycles of treatment and 21% received more than 13 cycles. 
Similar findings came from the AVAiL trial, where 49% of patients 
in the bevacizumab arm received 7–10 cycles of bevacizumab-
based therapy. Furthermore, the maximum duration of bevacizumab 
therapy in AVAiL was 28.5 months. In both trials, bevacizumab-
based therapy was well tolerated with a similar incidence of grade ≥3 
adverse events across all arms.
Drug resistance issues are worth highlighting since they are currently 
believed to cause treatment failure in more than 90% of patients with 
metastatic cancer.8 This problem of cytotoxic drug resistance renders 
mutant cancer cells insensitive to chemotherapeutic agents. How-
ever, the mechanisms of resistance towards biologic agents, such 
as bevacizumab, are not well understood and there is a hypothesis 
that persistent VEGF suppression along with secondary and tertiary 
cytotoxic regimens may give continuous clinical benefit. A large 
observational cohort study of bevacizumab in metastatic colorectal 
cancer (BRiTE) found a significant and independent association 
between survival and the use of bevacizumab beyond progression.9 
The median overall survival for patients receiving bevacizumab post 
progression (44%) was 31.8 months compared with 19.9 months for 
those receiving non-bevacizumab-containing therapy post progres-
sion. These results support the hypothesis that continuous VEGF 
inhibition is important to maximize the clinical benefit of bevacizum-
ab. The potential role of bevacizumab beyond progression in NSCLC 
warrants investigation in clinical trials.
Conclusions
VEGF is a key mediator of the angiogenic pathway, which is impor-
tant throughout tumor development. VEGF is a stable therapeutic 
target and is continually expressed throughout the development of 
several tumor types, including NSCLC. Bevacizumab, a humanized 
monoclonal antibody, specifically inhibits VEGF, thus blocking the 
angiogenic cascade. Bevacizumab is approved for first-line use in 
several tumor types, including non-squamous NSCLC. Two large 
phase III trials, E4599 and AVAiL, demonstrated the significant 
clinical benefit and favorable safety profile of first-line bevacizumab 
in combination with platinum-doublet chemotherapy in NSCLC. Sig-
nificantly, bevacizumab provided an unprecedented overall survival 
benefit of 14.2 months in patients with adenocarcinoma histology in 
E4599. Both E4599 and AVAiL provided evidence that precise VEGF 
inhibition with bevacizumab until disease progression is a rational 
approach to optimizing benefit in NSCLC. Likewise, clinical evi-
dence supports the use of 7.5 mg/kg or 15 mg/kg bevacizumab every 
3 weeks until disease progression in NSCLC. Furthermore, due to the 
limited impact of bevacizumab on the side effects of chemotherapy, 
a high proportion of patients in clinical trials received bevacizumab 
until disease progression as planned. Finally, clinical trial evidence 
from metastatic CRC suggests the potential of bevacizumab-based 
therapy as post-progression treatment. This evidence, together with 
the proven survival benefit of bevacizumab until progression in 
NSCLC, supports its further investigation across multiple lines.
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MTP12.1 Novel Cytotoxics in Small Cell, Sun, Aug 2, 07:00 - 08:00
Novel cytotoxics in small cell lung cancer (SCLC)
Hirsh, Vera
McGill University Health Centre, Montreal, QC, Canada
Small cell lung cancer (SCLC) accounts for approximately 10-15% 
of all lung cancer. Majority of the patients (pts) present with exten-
sive disease (ED), only 30-40% of patients with limited disease 
(LD). 
In the limited-stage disease, treated with chemotherapy and radio-
therapy, overall response rates are 85-95%, 50-60% are complete 
responses, median survival is about 20 months with a two-year 
disease-free survival of about 40%. In extensive-stage disease treated 
with chemotherapy, complete response rates are ≤ 20 %, median 
survival 8-10 months, and almost all pts are dead within two years. 
Standard chemotherapy has not changed for limited or extensive-
stage disease in last 20 years. It remains to be platinum and etoposide 
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
Copyright © 2009 by the International Association for the Study of Lung CancerS246
in first-line treatment. High dose chemotherapy, alternating regimens, 
or three-drug combinations did not improve the treatment efficacy. 
The third generation chemotherapeutic agents, such as irinotecan, 
topotecan, paclitaxel, gemcitabine, vinorelbine, and docetaxel have 
response rates from 8-50%, but when added to platinum/etoposide 
i.e., paclitaxel, efficacy is not improved, but toxicity is increased.
In Japanese trial, irinotecan and cisplatin (IP) showed better efficacy 
in ED SCLC as first-line treatment but two North American trials 
showed similar efficacy with etoposide/platinum (EP). IP had lower 
rates of neutropenia and neutropenic fever, anemia, and thrombocy-
topenia while diarrhea, vomiting, and dehydration were higher with 
IP. The differences could be due to pharmacogenomic disparities, 
different patient characteristics, and differences in platinum dose and 
schedule changes. 
Randomized trial comparing EP to topotecan and cisplatin (TP) 
showed advantage for TP in TTP 7 vs. 6 months, p = 0.004, but no 
advantage for median survival (MS) or one-year survival. The grade 
3-4 thrombocytopenia and anemia were worse with TP. Oral topo-
tecan with cisplatin in ED SCLC randomized phase III trial did not 
demonstrate higher efficacy than EP.
Phase III trial of pemetrexed/carboplatin compared to etoposide/car-
boplatin showed inferior efficacy of pemetrexed combination in ED 
SCLC. There is an ongoing E5501 trial in ED SCLC with random-
ization between T followed by EP vs. IP followed by E, attempting to 
modulate Topo I and II levels. 
Amrubicin is a third generation, synthetic anthracycline (analogue of 
doxorubicin). Phase II study of amrubicin and cisplatin in first-line 
ED SCLC pts with amrubicin 40 mg/m2 days 1-3 and cisplatin 60 
mg/m2 day 1 every three weeks, 44 pts, showed response rate of 
87.8%, CR = 10%, MS = 13.6 months, one-year survival 56.1%. 
Main (grade 4) toxicity was neutropenia 78% (ASCO 2004). 
Relapsed SCLC can be non-refractory (relapse ≥ 3 months after 
completing front-line therapy) and treatment can be re-induction with 
front-line therapy, oral etoposide, CAV (cyclophosphamide, doxoru-
bicin, vincristine), topotecan or investigational agents, or refractory 
(no response to or relapse ≤ 3 months after completing front-line 
therapy) in which case pts are offered supportive care or investiga-
tional agents.
Phase II trials of platinum-sensitive 36 pts, and platinum refractory 
38 pts, with topotecan showed CR of 8% and 0%, MS 6.5 and 5.7 
months respectively. Topotecan was compared with CAV in chemo-
sensitive relapsed pts and the efficacy was the same, but when topo-
tecan was compared to best supportive care (BSC), median survival 
was 26 weeks vs. 14 weeks (p = 0.01) and quality of life (QOL) was 
better on topotecan. 
Topotecan 1.5 mg/m2 i.v. daily x 5 days (25 pts) was compared to 
amrubicin 40 mg/m2 i.v. daily x 3 days (50 pts) in randomized phase 
II trial of second-line chemosensitive SCLC pts. Response rate was 
34% on amrubicin vs. 4% on topotecan (p ≤ 0.004), amrubicin was 
better tolerated except for higher incidence of pneumonia (10% vs. 
0%). Sixty-three pts entered phase II trials in second-line refractory 
SCLC with amrubicin 40 mg/m2 i.v. daily x 3 every three weeks. 
Primary endpoint was response rate of 17.4%, and CR of 1.4%. 
Median PFS was 3.2 months, OS data are still immature. Mean 
number of treatment cycles was 4.4. Amrubicin was well tolerated, 
with myelosuppression as the main dose-limiting toxicity. There was 
no evidence of cardiotoxicity. A phase III trial in second-line SCLC 
pts is under way.
Future investigations will include new targeted agents in combina-
tion with chemotherapy.
MTP13.1 Systemic Treatment of Brain Metastasis in Lung Cancer, Sun, Aug 2, 07:00 - 08:00
Systemic and local therapy of brain metastases 
from lung cancer: pitfalls and promises
Langer, Corey J.
Abramson Cancer Center, University of Pennsylvania, Philadelphia, 
PA, USA
Brain metastases are the most frequent neurologic complication 
related to cancer. In the US, approximately 170,000 cancer patients 
develop brain metastases each year. Lung cancer accounts for the 
highest number of brain metastases; more than 25% of patients 
develop brain metastases at some point in their disease. Other com-
mon sources of brain metastases include breast cancer, melanoma, 
colorectal cancer, renal cell carcinoma, and adenocarcinoma of 
unknown primary site. The incidence of brain metastases appears to 
be increasing as new systemic treatment options become available 
that consistently increase the longevity of patients with advanced dis-
ease, but which do not cross the blood-brain barrier (BBB) well. For 
instance, in the setting of locally advanced NSCLC, the incidence of 
brain metastases after aggressive combined modality therapy may 
be as high as 33% to 50%; and brain metastases are often the first or 
only site of recurrence in lung cancer patients. 
The prognosis for patients with brain metastases is poor. Overall, 
median survival of patients with brain metastases is about 4 months 
after whole-brain radiation therapy (WBRT), but it varies based on 
several prognostic variables. For example, in a study of 740 brain 
metastases patients, the actuarial 2-year survival rate was 8.1%, but it 
ranged from 1.7% for brain metastases patients with small-cell lung 
cancer (SCLC) to 23.9% for those with ovarian cancer. Factors that 
predict for better survival include good performance status, age <65 
years, successful control of the primary tumor, absence of extracra-
nial metastases, favorable tumor histology, and presence of a solitary 
brain metastasis. Using recursive partitioning analysis (RPA) to iden-
tify prognostic variables to group patients into prognostic categories, 
Gaspar et al. identified a three-tier classification scheme using a 
database of several Radiation Therapy Oncology Group (RTOG) tri-
als. Median survival ranged from 7.1 months for RPA class 1 patients 
(all favorable prognostic factors) to 2.3 months for class 3 patients 
(Karnofsky performance status [KPS] <70). 
Improvements in median survival beyond that provided by WBRT 
have been difficult to demonstrate in randomized clinical trials. 
Because of competing risks from the primary tumor or extracranial 
metastatic disease, survival may not be the optimal measure of treat-
ment effectiveness for brain metastases. Other outcomes may be just 
as important to consider, particularly if they lead to improvement 
in quality of life. Brain metastases often trigger a serious deteriora-
tion in neurologic and neurocognitive function. Despite receiving 
WBRT, approximately half of patients die from brain metastases 
progression particularly as extracranial disease control improves. In 
a recent survey of 315 medical and radiation oncologists, the vast 
majority (87%) indicated that improving neurologic and neurocogni-
tive function or preventing its deterioration is more important than 
prolonging survival. Only 11% of the respondents indicated that 
extending survival was their sole reason for providing treatment of 
brain metastases. 
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Patients with brain metastases exhibit significant neurologic and 
neurocognitive deficits. In a recent study of 401 brain metastases 
patients by Meyers et al. that included careful neurocognitive test-
ing of memory, verbal fluency, executive function, and fine motor 
control, 90.5% of patients were impaired in at least one neurocogni-
tive domain at the time of diagnosis. In particular, memory, executive 
function, and fine motor control were compromised. The degree of 
impairment correlated with tumor volume but not with the number of 
lesions, and it was an independent predictor of survival.14
Work by Sperduto et al has shown that the addition of stereotac-
tic radiosurgery to WBRT in patients with solitary or oligo-brain 
metastases in the setting of metastatic lung cancer is superior to 
WBRT alone. Historically, from the standpoint of ongoing research, 
this therapeutic arena has been neglected, but interest in this area is 
now burgeoning as new agents with innovative mechanisms of action 
undergo development. Separate phase III trials in NSCLC and other 
primary cancer sites have attempted, but failed, to show a consis-
tent survival advantage for a variety of systemic agents, including 
temozolomide, motexafin gadolinium, and efaproxiral; yet much has 
been learned about the natural progression of brain metastases from 
these trials. These trials have also highlighted the potential pitfalls 
to be avoided in future research. More recently, data for PARP 
inhibitors and EGFr tyrosine kinase inhibitors in this setting appear 
promising. As follow-up of the results of prior studies, The RTOG 
is currently conducting a randomized prospective, phase III trial in 
NSCLC patients with oligo- and solitary brain metastases and intact 
performance status, comparing WBRT and SRS alone to WBRT and 
SRS combined with either erlotinib or temozolomide. In the future, 
treatment of brain metastases will likely involve a multimodality 
approach that combines new systemic therapies, standard WBRT and 
more focal radiotherapeutic approaches, including SRS and gamma 
knife. 
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Management of malignant pleural effusions
Astoul, Philippe
Institute of Thoracic and Cardio-Vascular Diseases, Department of 
Thoracic Oncology, Sainte-Marguerite Hospital, Marseille, France
Malignant pleural effusions (MPE), malignant cells identified 
in pleural fluid or pleural tissue, are a common consequence of 
malignancy and result in a debilitating situation for patients. With 
the virtual epidemic of lung cancer and breast cancer which are the 
most common cause of malignant effusions, clinicians will face the 
challenge of managing such patients. Moreover with the incidence 
of MPE in lymphoma and the contribution from non lung primaries, 
the number of cases of MPE is increasing dramatically. Usually, the 
management of MPE is a palliative treatment and the main objective 
will be the relief of breathlessness (3). The decision in managing this 
situation has to be considered after global evaluation of the patient 
and should not be based on a single factor (2).
They are various mechanisms for pleural metastases which are not 
clearly defined. It could be pulmonary vascular invasion with tumour 
emboli to the visceral pleural surface with subsequent seeding of the 
parietal pleura, direct tumour invasion, haematogenous metastases 
to the parietal pleura from extra pulmonary primaries, and lymphatic 
involvement. The process leading for tumour to metastasize to a 
distant site is a sequence of events incluiding adhesion, migration, 
propagation, and angiogenesis mediated by the interaction of meso-
thelial and neoplastic cells through different systems influencing the 
remodelling with the stroma of neoplasms and growth of the tumour 
in the pleural space (1). Also tumour produces specific growth, 
permeability, and adhesion-related factors (11). The effusion per se 
is mainly formed by increased capillary permeability and impaired 
lymphatic drainage from the pleural space (16). However sometimes, 
pleural effusion in patient with known malignancy does not reveal 
malignant cells in pleural fluid or pleural tissue. These effusions 
are termed ‘paramalignant’ and are not the direct result of pleural 
involvement with tumour but related to local (lymphatic obstruction, 
bronchial obstruction with pneumonia or atelectasis, trapped lung, 
chylothorax, superior vena cava syndrome, …) or general (pulmo-
nary embolism, hypoalbuminemia) effect of the primary tumour). 
In some situations they can be due to complications of radiotherapy 
or chemotherapy. In these situations it is important to establish the 
cause of effusion as it will relate to the management.
Dyspnoea, cough, weight loss, and chest pain are the most frequent 
symptoms in patients with MPE. Radiologic findings easily lead to 
the diagnosis. Moderate to important pleural effusion usually results 
in contralateral mediastinal shift and diaphragm depression. When 
there is an absence of contralateral mediastinal shift with an apparent 
large pleural effusion, lung cancer involving the ipsilateral mainstem 
bronchus or fixation of the mediastinum due to malignant lymph 
nodes should be suspected (2). CT scan of the chest may be helpful 
in the evaluation of patients with a malignant effusion by demon-
strating mediastinal lymph node involvement, parenchymal disease, 
and airway involvement as well as pleural abnormalities and distant 
metastases. Ultrasound can be useful in case of small pleural effusion 
(14). If MRI may be helpful in evaluating chest wall involvement, 
the place of PET scan to analyze the pleura has to be defined.
Diagnostic options
Thoracentesis for pleural fluid analysis is the first step for the thera-
peutic management of MPE. Besides relieving the breathlessness, 
which will be a prerequisite for a potential pleural symphysis in case 
of recurrence, it allows pleural fluid biochemical analysis (usually 
pleural exudates) and cytology. The diagnostic rate of cytology in 
MPE is low but depends on the primary cancer (higher for MPE 
from breast cancer) and the metastatic pleural involvement. The later 
explains the variety of the results concerning percutaneous pleural 
biopsy in MPE (usually poor).
Medical thoracoscopy, which can be performed using local anaes-
thesia, and video-assisted thoracic surgery (VATS), which requires 
general anaesthesia and single lung ventilation, are the most sensitive 
diagnostic procedure approaching 100% with experienced operator 
(15). These two procedures also lead to a careful examination of the 
entire pleural cavity in checking the spreading of the disease on the 
parietal pleura, the visceral pleura, the pericardium, the mediastinum, 
and the diaphragm with a prognostic relevance. On the same time a 
therapeutic procedure as pleural symphysis for instance can be done.
Therapeutic options
• Therapeutic thoracentesis should be performed in all dyspnoeic 
patients with a MPE to determine its effect on breathlessness 
and the rate and degree of recurrence. When dyspnoea is not 
relieved by thoracentesis, other causes of breathlessness should 
be considered (lymphangitic carcinomatosis, atelectasis, tumour 
embolism, thomboembolism). The volume of fluid that can be 
removed safely from the pleural space is unknown. Monitoring of 
the pleural fluid pressure during thoracentesis would be optimal. 
If the pressure does not decrease to < -20 cmH2O with removal of 
several hundred cc, fluid removal can be continued safely (4, 8). 
In practical situation it is recommended to remove no more than 
one and a half liters of fluid at a single setting. Reexpansion pul-
monary edema is not related to level of negative pleural pressure 
but is a consequence of rapid removal of fluid from the pleural 
space (6, 7.
• Talc pleurodesis is recommended for pleural symphysis. Com-
pared with other agents for chemical pleurodesis, talc seemed to 
give the best results in terms of effectiveness, with least recur-
rence of effusion, after both talc poudrage, and instillation of talc 
slurry through a chest tube (5). The effectiveness of talc pleur-
odesis compared with other forms of pleurodesis has also been 
supported by animal studies. Additionally, talc is inexpensive and 
widely available. However, the safety of intrapleural applica-
tion of talc has been debated since cases of respiratory failure 
and acute respiratory distress syndrome after talc pleurodesis 
were reported. Other authors noted no complications at all, even 
in large series of patients. The occurrence of acute respiratory 
distress syndrome in some series and its absence in others was 
independent of the underlying disease (malignant pulmonary 
effusion or pneumothorax), the quantity of talc used (2–10 g), 
or the technique of talc instillation (slurry or poudrage). Several 
researchers have reported results that suggest that acute respira-
tory distress syndrome after talc pleurodesis is mainly related to 
the particle size of the talc used (9, 10). However in a recent large 
prospective multicenter study, the absence of acute respiratory 
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distress syndrome in patients with recurrent malignant pleural 
effusion undergoing pleural talc poudrage for pleurodesis using 
non-asbestos calibrated talc supports the fact that pleurodesis with 
large-particle talc is safe (12). 
 Briefly, the data available on talc pleurodesis lead to the following 
conclusions:
- Poudrage and slurry are effective for treating recurrent malig-
nant pleural effusions
- From recent studies, talc poudrage is superior to talc slurry in 
malignant pleural effusions due to primary breast cancer and 
lung cancer
- Long-term safety has been documented, in particular with the 
use of calibrated, asbestos-free, sterile talc. Indeed respira-
tory failure induced by talc for pleurodesis could be caused by 
contaminants in talc, endotoxin, non-sterile talc, or small talc 
particle.
• Chronic indwelling catheters can be effective in the relief of 
dyspnoea and successful for pleurodesis. However, no prospective 
comparative studies have been done to find the best procedure. 
This approach offers several key benefits, in particular more 
liberal patient selection including patients with trapped lungs, 
outpatient placement and management without sedation or general 
anaesthesia, cost-effectiveness, and low complication rates. 
Small-bore drains are safe to insert with a low rate of insertion or 
infective complications that is at least comparable to that of large-
bore chest drains (13). The procedure is particularly well tolerated 
by patients and offers effective treatment for malignant pleural 
effusions with 83% (17, 20). 
Patients with recurrent pleural effusions, especially when caused by 
malignant disease, should be treated with thoracoscopic talc pleurod-
esis to improve symptoms and preserve quality of life. The procedure 
should be performed as early as possible, when the patient’s general 
condition is more favourable, because the aforementioned variables 
are associated with higher hospital mortality rates and shorter sur-
vival rates after pleurodesis. In case of trapped-lung or short predic-
tive survival the best option is represented by the use of indwelling 
pleural catheter. All these therapeutic options after brief presentation 
of epidemiology, physiopathology, and diagnostic work-up will be 
developed and discussed (18, 19).
References
1.  Antony VB, Hott JW, Kunkel SL, Godbey SW, Burdick MD, Strieter RM. Pleural 
mesothelial cell expression of C-C (monocyte chemotactic peptide) and C-X-C 
(interleukin 8) chemokines. Am J Respir Cell Mol Biol. 1995; 12: 581-8 
2.  Antony VB, Loddenkemper R, Astoul P, Boutin C, Goldstraw P, Hott J, Rodriguez 
Panadero F, Sahn SA. Management of malignant pleural effusions. Eur Respir J. 
2001; 18: 402-19.Review. 
3.  Burrows CM, Mathews WC, Colt HG. Predicting survival in patients with recurrent 
symptomatic malignant pleural effusions: an assessment of the prognostic values of 
physiologic, morphologic, and quality of life measures of extent of disease. Chest 
2000; 117: 73–8.                 
4.  Doelken P, Huggins JT, Pastis NJ, et al. Pleural manometry: technique and clinical 
implications. Chest 2004; 126: 1764 –9.
5.  Dresler CM, Olak J, herndon JE, et al. Phase III Intergroup study of talc poudrage vs 
talc slurry sclerosis for malignant pleural effusion. Chest 2005; 127: 909-15
6.  Feller-Kopman D, Walkey A, Berkowitz D, Ernst A. The relationship of pleural pres-
sure to symptom development during therapeutic thoracentesis. Chest 2006; 129: 
1556-1560.
7.  Feller-Kopman D, Berkowitz D, Boiselle P, Ernst A. Large-volume thoracentesis and 
the risk of reexpansion pulmonary edema. Ann Thorac Surg 2007; 84: 1656-1662. 
8.  Feller-Kopman D, Parker MJ, Schwartzstein RM. Assessment of pleural pressure in 
the evaluation of pleural effusions. Chest. 2009; 135: 201-9.
9.  Ferrer J, Villarino MA, Tura JM, Traveria A, Light RW. Talc preparations used 
for pleurodesis vary markedly from one preparation to another. Chest 2001; 119: 
1901–1905.
10.  Fraticelli A, Robaglia–Schlupp A, Riera H, Cau P, Astoul P. Distribution of cali-
brated talc after intrapleural administration: an experimental study in rats. Chest 
2002; 122: 1737–41.
11.  Hott KW, Yu L, Antony VB. Role of VEGF in the formation of malignant pleural 
effusions. Am J Respir Crit Care Med 1999; 159: 12-22.
12.  Janssen JP, Collier G, Astoul P, Tassi GF, Noppen M, Rodriguez-Panadero F, Lod-
denkemper R, Herth FJF, gasparini S, Marquette CH, Becke B, Froudarakis M, 
Driesen P, Bolliger CT, Tschopp JM. Safety of pleurodesis with talc poudrage in 
malignant pleural effusion: a prospective cohort study. Lancet 2007; 369: 1535-39.
13.  Musani AI. Treatment options for malignant pleural effusion. Curr Opin Pulm Med. 
2009;15: 380-7
14.  Qureshi NR, Rahman NM, Gleeson FV. Thoracic ultrasound in the diagnosis of 
malignant pleural effusion. Thorax. 2009 Feb;64(2):139-43
15.  Rodriguez-Panadero F, Janssen JP, Astoul P. Thoracoscopy: general overview and 
place in the diagnosis and management of pleural effusion. Eur Respir J 2006; 28: 
409-422.
16.  Shetty S, Kumar A, Johnson A, Idell S. Expression of the urokinase-type plasmi-
nogen activator receptor in human malignant mesothelial cells: role in tumor cell 
mitogenesis and proteolysis. Am J Physiol lung Cell Mol Physiol 1995; 12: 972-982. 
17.  Schneider T, Reimer P, Storz K, Klopp M, Pfannschmidt J, Dienemann H, Hoffmann 
H. Recurrent pleural effusion: who benefits from a tunneled pleural catheter? Thorac 
Cardiovasc Surg. 2009; 57: 42-6.
18. Steger V, Mika U, Toomes H, Walker T, Engel C, Kyriss T, Ziemer G, Friedel G. 
Who gains most? A 10-year experience with 611 thoracoscopic talc pleurodesis. Ann 
Thorac Surg 2007; 83: 1940-5.
19.  Tan C, Sedrakyan A, Browne J, Swift S, Treasure T. The evidence on the effective-
ness of management for malignant pleural effusion: a systematic review. Eur J 
Cardiothorac Surg 2006; 29: 829 –38.
20.  Tremblay A, Michaud G. Prise en charge des pleurésies néoplasiques par insertion 
d’un cathéter pleural tunnellisé. Une approche ambulatoire exclusive? Single-center 
experience with 250 tunnelled pleural catheter insertions for malignant pleural effu-
sion. Chest 2006 ; 129 : 362-368
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Mesothelioma
Jones, Kirk D.
University of California, San Francisco, San Francisco, CA, USA
In this session we will discuss the factors involved in making the 
diagnosis of epithelioid and sarcomatous mesotheliomas. Informa-
tion regarding histochemical and immunohistochemical stains used 
to distinguish mesothelioma from other tumor types will be pre-
sented. Histological features characteristics of benign and malignant 
mesothelial processes will be discussed.
MTP17.1 Molecular Biology and Pathology of Lung Adenocarcinomas, Sun, Aug 2, 
07:00 - 08:00
An Emerging Concept of Lung Adenocarcinoma: 
What can we learn from EGFR, KRAS, BRAF, 
HER2 and EML4-ALK gene alterations?
Yatabe, Yasushi
Dept. of Pathology and Molecular Diagnosis, Aichi Cancer Center, 
Nagoya, Japan
The KRAS mutation is a classical genetic mutation in lung adeno-
carcinomas, while several additional genes have been identified in 
the last decade, including mutations of the EGFR tyrosine kinase 
domain, BRAF, and HER2, and a novel EML4-ALK translocation 
(1, 2). Interestingly, these five genes are involved in a mutually 
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exclusive fashion, suggesting some association of their roles in 
molecular pathogenesis. However, the morphological features of 
lung adenocarcinomas are relatively characteristic according to the 
involved genes. For example, adenocarcinomas with the KRAS 
mutation are characterized by goblet cell morphology (3, 4). These 
include mucinous bronchioloalveolar carcinoma (BAC) and invasive 
adenocarcinomas with mucinous BAC features, which constitute a 
spectrum of the cancer with a different progression stage. Adenocar-
cinomas with the EGFR mutation frequently have bronchioloalveolar 
features in the tumor periphery (5), though those are not an absolute 
determinant, because a poorly-differentiated solid carcinoma can also 
harbor this mutation (6). The adenocarcinomas with either a BRAF 
or HER2 mutation show morphological characteristics similar to 
those with the EGFR mutation (7, 8), and they are difficult to distin-
guish morphologically. Although chromosomal translocation is rare 
in solid cancer, EML4-ALK translocation was recently revealed to 
be a member of genetic alterations involved in lung adenocarcinomas 
(9). Those with this alteration have quite characteristic morphologi-
cal features, i.e., high grade, solid or cribriform-tubular growth pat-
tern, and mucin production with convoluted nulcei (10). Therefore, 
KRAS mutation and EML4-ALK translocation lead to distinctively 
peculiar morphologies, while the others show only characteristic 
features.
An important question is whether these different adenocarcinomas 
are separate tumor entities with unique genetic changes. Alterna-
tively, do the individual gene mutations occur under the control that 
can be elucidated? Recent advances in genome-wide expression 
analysis may help to answer these questions (11, 12). Unsupervised 
hierarchical clustering in expression profiling analysis is considered 
to represent the molecular classification of a tumor, based on the 
similarity of its genome-wide expression pattern. This new molecu-
lar based classification shares the current pathological classification 
in part, although it provides additional clues to identify cancers by 
their biological groups. The clustering schema of the lung cancers 
published so far, has a shared configuration as shown in Fig. 1, 
although the proportion of each cluster varies among the reports 
(13-18). Lung cancers can be divided into two distinct branches. One 
includes adenocarcinomas alone, and is associated with a normal 
expression profile. The other branch consists of all four other histo-
logical subtypes. The former, an adenocarcinoma subset of the left 
branch, is characterized by frequent development in female subjects 
and non-smokers, and expression of TTF-1 and surfactant proteins. 
As expected, EGFR mutations are associated with this cluster, and a 
majority of adenocarcinomas with EGFR, BRAF, HER2, and EML4-
ALK alterations express the markers of this cluster. 
Next question is what biological significance of the distinction in the 
molecular classification is. Anatomically, the lung is composed of the 
bronchial tree and the lung parenchyma, which carry out air conduc-
tion and oxygen exchange, respectively. This distinction is also seen 
in the development of the lung. After the generation of the two lung 
buds, branching morphogenesis generates the bronchial systems, and 
subsequently the peripheral parenchyma, namely the terminal sac 
and then alveolar space, mature. During the latter phase, develop-
ment is regulated by TTF-1. This molecule is constantly expressed 
in the peripheral lung epithelial cells, such as pneumocytes, whereas 
the epithelium lining the bronchial system lacks this expression. 
Mice deficient in the gene for TTF-1 die just after birth: although 
branching morphogenesis is maintained, maturation of the peripheral 
parenchyma is severely impaired, leading to aplasia (19). Further-
more, recent study identified bronchioloalveolar stem cells, which 
supply the cells in the peripheral parenchyma (20). The stem cells 
are located in bronchioalveolar duct junction, and express Clara cell 
antigen and surfactant protein C, both of which are transcriptionally 
regulated by TTF-1. Therefore, TTF-1 is indispensable to develop 
the normal lung parenchyma, and to maintain normal function of the 
lung, indicating that TTF-1 is a master key regulator of the peripheral 
lung. We refer to a series of the peripheral lung cells that this master 
regulator regulates, as a cellular lineage of the “terminal respira-
tory unit (TRU)” (Fig 2) (21). This novel concept of cellular lineage 
implies that diverse adenocarcinoma types with various acquired 
genes can be integrated into a simple schema.
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Management of oligometastases: should patients with 
limited sites of metastases be treated aggressively?
Bezjak, Andrea
Princess Margaret Hospital/University Health Network, University 
of Toronto, Toronto, ON, Canada
Traditionally, the approach to patients with lung cancer has been 
very dependent on whether there is clinical-radiological evidence of 
metastases. Patients with no obvious extra-thoracic (or contralateral 
lung) metastases are considered for aggressive treatment, typically 
multi-modality, with the hope of eradication or at least control of 
local disease, despite the awareness that that risk of metastases is 
high and that patients may not cured, even if local disease is suc-
cessfully treated. In contrast to this approach, patients with known 
metastatic disease are treated with palliative intent, typically with 
chemotherapy, and/or palliative radiation, and the intent is not to 
eradicate or control local disease, but to prevent or manage symp-
toms and attempt to prolong survival, while maintaining quality of 
life.
Several facts and arguments suggest that this “black and white” type 
of thinking needs to be revisited. They include the following:
• Survival is influenced by many other factors, beyond stage. Many 
patients with stage IV lung cancer live longer than some patients 
with no known metastases at presentation. Despite advances in 
treatment, less than a third of patients with stage III lung cancer 
live beyond 2 years. Thus, presence of metastases doesn’t reliably 
distinguish survivors from those who we can only hope to palliate.
• It has long been recognized that some patients with solitary brain 
metastases at presentation of their lung cancer can be cured with 
aggressive treatment of both thoracic and cerebral disease – they 
can have decades of survival without further metastatic disease, 
even in the absence of chemotherapy. Thus, one clinically appar-
ent hematogenous metastasis need not predict for further develop-
ment of metastases.
• Aggressive management of metastases, including lung and 
liver metastases, in other cancer primaries, such as colo-rectal, 
sarcoma, renal cell, thyroid cancer and others, has been well docu-
mented to lead to cures in well-selected patients.
• Modern imaging, including high quality CT scans, MRI scans 
and FDG PET scans, allows for detection of metastases at a much 
lower burden of disease than previously, meaning that many of 
such patients would have been treated radically previously, and 
may have enjoyed longer survival and less cancer-related prob-
lems, and now, with progress in imaging, may end up without the 
benefit of local treatment. 
• Some patients with a known history of cancer and what appears 
to be metastases may have a new synchronous or metachronous 
primary tumor, that may have a better prognosis or may even 
be curable; thus, a palliative approach is not appropriate for all 
patients with new malignant lesions.
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• Although we are far from fully understanding the biology of 
metastases, we do know that immune factors may module the pro-
gression of metastases, and that the burden of disease and other 
as-yet poorly understood factors affect the rate of progression and 
symptoms from metastatic disease. In that context, uncontrolled 
thoracic disease is a likely source of further metastases, as proven 
by trials of more effective radiotherapy, where better local control 
resulted in fewer metastases, even in the absence of any systemic 
treatment (e.g. CHART).
• Uncontrolled thoracic disease can cause a lot of morbidity as 
well as mortality. Although palliative radiotherapy is effective in 
symptom relief, high doses may be needed to control the tumor 
in patients who have prolonged survival expectations. In patients 
with good performance status, no significant weight loss and low 
bulk/limited site metastatic disease, the morbidity of a more radi-
cal approach to local disease, and their metastatic disease, may 
prove worthwhile.
• Although increasing cure rate is the most compelling argument 
to justify a new treatment approach, prolongation of disease-free 
survival is worthwhile goal for most cancer patients, if achieved 
with acceptable morbidity and resulting in good quality of life.
• Advances in systemic therapy, including targeted agents, are 
improving the survival of patients with metastases, which in turns 
puts an increasing emphasis on long-term local control of known 
disease, ie argues for a more radical approach to thoracic disease 
and/or the known metastatic disease. The targeted agents may be 
more effective in patients with limited burden of disease, and their 
combination with effective local agents may be lead to both local 
and metastatic disease control with relatively favourable toxicity 
profile. 
• Improvements in radiotherapy planning, including image guid-
ance, intensity-modulated radiation (IMRT) and stereotactic body 
radiotherapy (SBRT) have improved the likelihood of local con-
trol and have favourably tilted the therapeutic ratio, with greater 
chances of benefit with less toxicity, from high dose radiotherapy. 
Thus, local control in the thorax, brain (gamma-knife) and 
selected other sites, including liver, has become a more attainable 
goal for more patients.
Examples of patients with oligo-metastatic disease from clinical 
practice will be used to illustrate a more tailored patient-centered 
approach to management of selected stage IV patients with good 
performance status and few metastases. This approach needs to 
include a realistic enunciation of goals of treatment, frank discussion 
of likely side-effects and quality of life impact of a more aggressive 
approach to the thoracic disease and/or metastases and a true multi-
modality and multi-professional approach, including incorporation 
of patient preferences and careful monitoring of the outcomes of that 
approach, to guide patient selection. The challenges of study design 
to test the viability of such an aggressive approach will be discussed.
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Current status of prophylactic cranial irradiation in SCLC
Le Pechoux, Cecile
Institut Gustave Roussy, Villejuif, France
Small cell lung cancer (SCLC) has several features that distinguish 
it from other tumor types such as an early propensity to disseminate 
and most particularly in the brain. Chemotherapy is therefore the 
cornerstone treatment in both limited and extensive disease. Radio-
therapy has also a role in the therapeutic strategy, and 2 meta-analy-
ses have contributed to establish “the standard treatment”: thoracic 
radiotherapy should be combined to chemotherapy in limited disease 
and prophylactic cranial irradiation (PCI) should be also part of 
treatment among complete responders [Pignon et al (1993), Aupérin 
et al (1999)]. Even in patients who achieve a complete response, 
the incidence of cerebral metastasis as the sole site of initial relapse 
varies between 14 and 45% at 2 years [Arriagada et al (1995), Ball et 
al (1995)]. Historically, chemotherapeutic agents have had a limited 
role in the treatment of cerebral metastases because of the inability 
of cytostatic drugs to cross the blood brain barrier. However, even if 
the symptomatic relief is of some benefit, quality of life is poor and 
overall survival after development of brain metastases is low with 
median survival times ranging from 1.5 to 4.5 months. 
PCI has thus been developed as a strategy to prevent dissemina-
tion to the uninvolved brain, as systemic agents do not cross the 
blood-brain-barrier effectively [Hansen (1973)]. However, even if 
several retrospective and prospective studies have shown that PCI 
significantly reduced the incidence of a CNS relapse compared with 
patients who did not receive PCI, the utility of PCI has been a con-
troversial issue for several years due to the lack of improvement in 
survival in individual trials and a possible risk of neurotoxicity and 
cognitive deficits in long-term survivors. PCI is now less contro-
versial because of the results of the meta-analysis on PCI in SCLC 
complete responders [Aupérin et al (1999)]. It has become part of 
the standard treatment in complete responders, after the publication 
of the individual-patient-data-based metaanalysis, showing both 
a reduction in the risk of total brain metastases (59% vs 33% at 3 
years) and a 5.4% increase in 3-year survival (from 15 to 21%) in the 
treatment group compared with no treatment. 
Even in extensive disease, PCI reduces the risk of brain metastases 
and significantly improves overall survival as shown in the meta-
analysis for complete responders and confirmed in all responders in 
a recent EORTC trial [Slotman et al (2007)]. The 1-year cumulative 
risk of symptomatic brain metastases was 14.6% in the irradiation 
group and 40.4% in the control group. Irradiation was associated 
with an increase in median overall survival and 1-year survival rate, 
from 5.4 months to 6.7 months, and from 13.3% to 27.1% in the 
irradiation group (p=0.003). 
However, about a third of patients still develop brain relapses after 
PCI, and there is no wholly effective treatment: the response rate 
to whole-brain irradiation is only 50%, and median survival ranges 
from 4 to 6 months [Arriagada et al (1995), Castrucci et al (2008)]. 
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The meta-analysis, through an indirect comparison of the trials, sug-
gested an effect of PCI dose and of PCI timing on the incidence of 
brain metastases. An intergroup trial was thus designed to compare 
a standard dose of 25 Gy with a higher dose of 36 Gy, to assess the 
effect of PCI dose escalation on the incidence of brain metastases 
among limited disease SCLC patients [Le Péchoux (2009)]. The 
results did not confirm the data suggested by the meta-analysis. 
Thus PCI is now fully part of SCLC treatment. The data of these 
different studies will be developed, as well as the “pros and cons” of 
this treatment that has been so controversial. However, it should be 
outlined that as the incidence of brain metastases seems to increase 
in other tumor types, PCI is also being considered. Further research 
is warranted as the development of brain metastases becomes a real 
issue in several solid tumors.
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Translational research and mesothelioma
Pass, Harvey I.
NYU Langone Medical Center, New York, NY, USA
Malignant pleural mesothelioma (MPM) is a locally aggressive can-
cer that arises from the multipotential mesothelial cells of the pleura. 
MPM has a uniformly poor prognosis with a median survival from 
diagnosis of 9-12 months. Limited treatment options are available 
for those diagnosed with MPM or at risk for developing MPM from 
past or ongoing asbestos exposure. While rare, MPM is responsible 
for approximately 0.6% of all cancer related deaths, MPM poses an 
increasing public health, medical, and economic problem. This is due 
to the peak commercial use of asbestos in industrialized countries 
from the 1930’s to the 1960’s and the latency in developing MPM 
from the time of first exposure that ranges from 15-40 years. In addi-
tion, asbestos continues to pose a public health hazard throughout the 
world due to the need for its disposal and its current and increasing 
use in industrializing nations. Recent estimates report an expected 
incidence of 2000-3000 cases per year in the United States, 1950-
2450 cases per year in Great Britain, and 250,000 deaths caused 
by MPM in Western Europe over the next few decades. In addition 
to the direct costs to the health care system, defendant companies 
in the United States have already paid 54 billion dollars in legal 
claims and are expected to face upwards of 200 billion dollars in 
future liabilities, thus representing a significant socio-economic 
burden. Interestingly, only 5% of asbestos mine workers who have 
experienced heavy exposure to asbestos go on to develop malignant 
pleural mesothelioma, a fact that illustrates the complex relationship 
between environment, biology, and genetics in MPM. In addition, the 
characteristically long latency time for developing malignant pleural 
mesothelioma suggests that the multiple chromosomal abnormalities 
common in MPM accumulate within the mesothelial cells over time 
and contribute substantially to the pathogenesis of MPM. 
Recent research has implicated multiple molecular pathways and 
genetic loci that are abnormal in MPM and has increased our under-
standing of the pathogenesis of MPM. These insights may provide 
possible therapeutic targets for treatment and prevention.
Genomic and molecular analyses have elucidated multiple cytoge-
netic and molecular abnormalities that contribute to the develop-
ment of MPM. Repeated episodes of inflammation and healing, 
oxygen free radical production from inflammatory cells and the iron 
moiety within asbestos, and direct damage to DNA by the fibers 
are generally accepted pathogenic features of asbestos exposure. 
Karyotype and comparative genomic hybridization (CGH) analyses 
of primary MPM tumors and cell lines detected frequent deletions, 
duplications, and translocations with genomic losses more common 
than gains. Deletions within chromosomes 1p, 3p, 4p, 4q, 6q, 9p, 
13q, 14q, and 22q are common and notable for the loss of the tumor 
suppressor genes p16/CDKN2A, p53, and NF2 located within these 
loci. Heterozygous Nf2 (+/-) mice exposed to asbestos exhibited fre-
quent homozygous deletions of the Cdkn2a/Arf and Cdkn2b loci and 
activation of Akt with rapid development of MPM, suggesting that 
these molecular events may be critical to tumorigenesis. In addition, 
the Wilms’ tumor gene (WT1), which encodes a transcription factor 
that represses the transcription of a number of growth factors and 
proto-oncogenes, is often mutated in both MPM primary tumors and 
cell lines. Loss of tumor suppressor gene activity may be a key to the 
transformation into malignant mesothelioma. Moreover, they may be 
important in designing new clinical trials for novel therapeutics.
Many cytokines and growth factors produced by malignant mesothe-
lial cells are associated with asbestos carcinogenesis. Platelet derived 
growth factor-A chain and, C-sis, an oncogene which encodes for 
the platelet derived growth factor beta chain (PDGF-β), are over-
expressed in cell lines derived from primary and metastatic MPM 
whereas C-sis expression is virtually nonexistent in normal meso-
thelial cells. In addition, transforming growth factor beta (TGF- β) 
is a growth-regulatory and immunomodulatory cytokine expressed 
in high levels in MMP cell lines. TGF- β may play a role in PDGF 
receptor expression in MMP. Pleural fluid from MPM patients also 
shows increased levels of IL-6 and IL-8, both important cytokines 
involved in angiogenesis. It has been shown that increased expres-
sion of IL-6 results in higher levels of vascular endothelial growth 
factor (VEGF) and a greater degree of thrombocytosis in MPM 
patients. The HGF/met pathway is also key to the regulation of 
mesothelioma growth. Most importantly, new trials of agents which 
impact on these cytokine loops are in progress. 
Asbestos also causes direct activation of cell-signaling pathways. 
Crocidolite fibers can stimulate autophosphorylation of the epidermal 
growth factor receptor (EGFR) which activates extracellular regu-
lated kinase 1 and 2 (ERK1 and ERK2). ERK1/2 activation in turn 
increases activator protein (AP)-1 activity with subsequent increased 
mitosis of the mesothelial cells. Recent work has implicated the Wnt 
pathway in the development of MPM and have recently shown that 
promoter hypermethylation of Wif-1 results in constitutive activa-
tion of Wnt signaling, suggesting a mechanism for the inhibition of 
apoptosis in abnormal mesothelial cells.
New biomarkers including SMRP and osteopontin are moving 
towards validation for the early detection of mesothelioma, and mul-
tiple platforms are being used to discover prognostic and predictive 
biomarkers for the disease. 
This “Meet the Professor” session will attempt to put all of the recent 
molecular pathway findings into the context of clinical utility, both 
for early detection, pathogenesis and diagnosis, as well for justifica-
tion of novel therapeutics. 
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cancer and its treatment
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Neurological complications of lung cancer are common, affecting as 
many as half of patients with advanced lung cancer and perhaps 10% 
with early lung cancer. Table one classifies those complications
Table 1: Neurologic complications of lung cancer
Metastases Nonmetastatic (Paraneoplastic)
• Intracranial (usually to brain parenchyma) • Side effects of therapy
• Spinal (usually epidural from vertebral metastases)  - Chemotherapy
• Leptomeningeal  - Cranial radiation (prophylactic or therapeutic)
• Cranial nerve, peripheral nerve, nerve plexus   - Targeted therapy
 (e.g. brachial plexus) • Vascular disorders (hemorrhage or infarction)
• Muscle • Infections
  • Metabolic/nutritional disorders
  • “Paraneoplastic disorders”
   - Endocrine Paraneoplastic syndromes  
    (e.g. SIADH)
   - Neurologic paraneoplastic syndromes  
    (e.g. limbic encephalopathy)
   - Vascular paraneoplastic syndromes  
    (Trousseau’s syndrome)  
   - Metabolic/nutritional disorders
Metastases
The most common nervous system site of metastases from both 
small cell and non-small cell lung cancer is the brain. Brain metas-
tases may be the presenting symptom in as many as 10% of patients 
or may occur at any time after the diagnosis of the primary cancer. 
Brain metastases may be single or multiple and symptomatic or 
asymptomatic. Perhaps as many as 5% of patients with newly diag-
nosed lung cancer have occult brain metastases at presentation. When 
symptoms are present, headache is the most common symptom. 
Treatment depends on the number, location and size of metastatic 
lesions. Single metastatic lesions are probably best treated surgically, 
although radiosurgery for small lesions is also effective. Sometimes, 
2 or 3 metastases can be treated surgically or with radiosurgery. 
Patients presenting with synchronous lung and brain lesions are prob-
ably best treated first by surgery to the brain, preceding the thoraco-
tomy. Prophylactic cranial irradiation is prescribed for patients with 
small cell lung cancer who have responded to chemotherapy and has 
been considered for patients with non-small cell lung cancer.
Metastases to vertebral bodies compressing the spinal cord and caus-
ing paralysis are also common, usually occurring late in the course of 
the disease, but rarely the presenting complaint. Back pain precedes 
neurologic symptoms and should lead to rapid investigation of its 
cause. In appropriate patients surgical treatment should be considered 
to be followed by radiation therapy.
Nonmetastatic complications
Perhaps the most common nonmetastatic complication of cancer 
results from chemotherapeutic treatment of the tumor. Peripheral 
neuropathy is a common and often dose-limiting complication 
particularly of platinum-containing drugs. As new agents, doses and 
combinations of agents are developed, new neurologic complications 
are identified. An example is the complication of headache occurring 
with anti-angiogenesis agents.
Among the nonmetastatic complications of cancer, perhaps the 
most challenging and interesting are the paraneoplastic syndromes. 
Endocrine syndromes such as SIADH and Cushing’s disease may be 
the presenting complaint in patients with lung cancer. Trousseau’s 
syndrome may also precede diagnosis of the cancer. Neurologic 
paraneoplastic syndromes including limbic encephalopathy, cerebel-
lar degeneration and sensory neuronopathy usually precede identifi-
cation of the cancer. Small cell lung cancer is a much more frequent 
offender than non-small cell lung cancer. Paraneoplastic antibodies 
are often identifiable in his is in no is is well he doesn’t seem to his 
elbow he is the serum. Early diagnosis and aggressive treatment of 
lung cancer may lead to stabilization or even amelioration of the 
neurologic symptomatology. 
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Management of thymoma 
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Surgery is the therapeutic cornerstone in the curative management of 
early stage thymomas. Even so, thymomas are highly responsive to 
both chemotherapy and radiation, and these modalities are critically 
important in the palliative management of advanced thymoma. Che-
motherapy and radiation are also important adjuncts to surgery in the 
treatment of locally advanced disease, where the outcomes with sur-
gery alone are suboptimal. In addition, chemoradiation can produce 
durable control in inoperable, locally-advanced disease. Therefore, a 
multimodality team approach provides the best care for patients with 
this rare neoplasm. 
Background
Thymoma is the most common tumor of the thymus and the most 
common cause of an anterior mediastinal mass in an adult. Nev-
ertheless, thymic tumors in general are quite rare. The National 
Cancer Institute’s Surveillance, Epidemiology, and End Results 
(SEER) tumor registry estimates the incidence of thymoma to be 
0.15/100,000 person-years.1 Because of the rarity of thymoma, ran-
domized studies are not possible and the management, and therefore 
many management recommendations necessarily derive from retro-
spective series or phase II studies. 
By definition, thymomas have a bland, non-malignant appearance 
under the microscope. However, in spite of this histologic appear-
ance, all thymomas (even, albeit rarely, the completely encapsulated 
stage I thymoma) have the capacity to invade and metastasize. Thy-
mic carcinoma, in constrast, appears malignant histologically and in 
general follows a more aggressive clinical course than thymoma. 
Thymic epithelial cells make up the neoplastic cells of thymomas. 
The mature thymus consists of the cortex, the medulla, and perivas-
cular spaces divided by fibrous septae. Similar to the normal thymus, 
thymomas consist of a combination of epithelial cells and lymphoid 
cells (thymocytes) separated by fibrous bands. The thymus reaches 
its maximum size during puberty and then undergoes involution and 
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replacement with adipose tissue, such that in the normal adult, only a 
small remnant structure remains. 
The purpose of the thymus is to allow for appropriate maturation of 
T lymphocytes. This critical role the thymus plays in the immune 
system likely accounts for the association between thymoma and 
autoimmune paraneoplastic syndromes. The most common of these 
is myasthenia gravis, an antibody-mediated, T-cell dependent, 
autoimmune attack against the acetylcholine receptors of the post-
synaptic neuromuscular junction. Patients experience weakness the 
ocular, bulbar, limb, and respiratory muscles. Surgery on patients 
with myasthenia can precipitate a myasthenic crisis with respiratory 
failure. 
Other paraneoplastic syndromes associated with thymoma include 
pure red cell aplasia (5% of pts with thymoma), hypogammaglobu-
linemia (5-10%), systemic lupus erythematosis, polymyositis, 
agranulocytosis, and pemphigus vulgaris. Thymic carcinomas are not 
associated with autoimmune conditions. 
On presentation with thymoma, one-third of patients are asymp-
tomatic, and the thymoma is detected incidentally. In one-third of 
patients, there are local symptoms such as cough, chest-pain, SVC 
syndrome, or dysphagia. One-third of patients present with myasthe-
nia gravis. Conversely, 10-15% of patients with myasthenia gravis 
have thymoma. 
Histologic Classification
While the original Bernatz classification system categorized thymo-
mas based upon the proportion of non-neoplastic lymphoid cells to 
neoplastic epithelial cells2, this system did not correlate well with 
prognosis. The WHO (World Health Orgaization) classification 
system, established in 19993 and updated in 20034, sought to remedy 
this. In this system, thymomas are classified as either A, AB, B1, B2, 
B3, or C, and the characteristics (along with corresponding terminol-
ogy from older classification systems) are shown in Table 1:
Table 1: WHO Thymoma Classification
A (medullary, spindle cell, epithelial-predominant) 
• epithelial cells are spindle-shaped/oval, lack nuclear atypia, have dispersed nuclear chromatin 
and indistinct nucloeli, and few if any lymphocytes are present, are mostly encapsulated
• make up about 5% of thymomas 
• long-term survival ~100%
AB (mixed) 
• features of type A with lymphocyte rich foci
• make up about 30% of thymomas 
• long-term survival >90%
B1 (lymphocyte-rich, lymphocytic, predominantly cortical) 
• dendritic/epithelioid epithelial cells which appear like normal thymic cortex (epithelial cells are 
widely separated with slightly vesicular chromatin and small nucleoli) with medullary areas, 
rich in lymphocytes
• make up about 15% of thymomas 
• long-term survival ~90%
B2 (cortical, polygonal cell)
• resembles B1 but foci of medulla less or absent 
• about 30% of thymomas 
• long-term survival ~60%
B3 (epithelial, atypical, squamoid, well-differentiated thymic carcinoma) 
• sheet-like growth of epithelial cells, mild or no atypia, sparse lymphocytes 
• about 10% of thymomas 
• long-term survival ~40%
C: thymic carcinoma
• appear histologically malignant
• Multiple sub-types: basaloid squamous carcinoma, squamous cell carcinoma, 
lymphoepithelioma-like carcinoma, mucoepidermoid carcinoma, clear cell carcinoma, papillary 
carcinoma, sarcomatoid carcinoma, neuroendocrine carcinoma, undifferentiated carcinoma
• The majority express CD5 (unlike other thymomas and mediastinal tumors including germ cell 
tumors and lymphomas)
• make up about 5% of thymic epithelial tumors
• long-term survival ~30% 
Staging
The most commonly used staging categorization for thymoma is the 
Masaoka staging system, initially proposed in 19815 and shown in 
Table 2. Modifications to this staging system have been proposed to 
accommodate the facts that capsular invasion does not affect survival 
and therefore the prognoses for stage I and II disease is quite similar, 
and that great vessel invasion carries a worse prognosis than pericar-
dial invasion even though both circumstances would be classified as 
stage III disease6,7. 
Table 2: Masaoka staging system 
Stage I: macroscopically and microscopically completely encapsulated
Stage II: Microscopic transcapsular invasion or macroscopic invasion into surrounding fatty 
tissue or grossly adherent to but not through the mediastinal pleura or pericardium
Stage III: Macroscopic invasion into neighboring organs
Stage IV: Pleural dissemination or lymphangitic/hematologic metastases
Treatment
Complete surgical resection is the optimal treatment for thymoma, 
and the prognosis is excellent for early stage disease. If a mass in 
the anterior mediastinum is completely encapsulated and diagno-
sis of thymoma is likely, immediate en bloc surgical resection is 
appropriate. If upfront surgery is not feasible, making a diagnosis of 
an anterior mediastinal mass can be complicated, but is necessary 
prior to instituting treatment. Fine needle aspiration can establish the 
diagnosis in 90% of cases8. Larger biopsies, however, are frequently 
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required in order to establish with certainty some forms of lymphoma 
versus thymoma. 
Median sternotomy is the preferred surgical approach as it avoids 
the risk of seeding the pleural space. Complete en bloc resection 
with negative margins is the ideal, and care must be taken to avoid 
the phrenic nerve. If the tumor does project into the pleural space, 
the entire pleural space should be explored and any drop metasta-
ses resected. In a study of surgical outcomes for 241 patients with 
thymoma, the survival rates at seven years 82%, 71%, and 26% in 
patients undergoing complete resection, subtotal resection, and biop-
sy alone, respectively9. Recurrences of thymoma may occur several 
years later, so prolonged follow-up is necessary. Repeat resection of 
recurrences in selected patients can be beneficial10. 
The prognosis for completely resected stage I thymoma is excellent 
with one series showing only 2 relapses out of 133 patients with 
completely resected, completely encapsulated thymoma9. It is clear 
for these patients, no further treatment other than surgery is required. 
Recurrences are more likely for higher stages of disease. Neverthe-
less, complete surgical resection still gives the best chance of cure. 
The role of post-operative radiation is somewhat controversial. 
A review of 115 patients in eight series with resected stage II or 
III thymoma demonstrated 20/72 (28%) recurred who did not get 
adjuvant radiation therapy while in those that did, only 2/43 (5%) 
recurred11. In another large series, however, there were no differ-
ences in the rates of recurrence for Stage II and III thymoma treated 
with or without radiation post-operatively (in stage II patients, 4.1% 
of 122 patients treated with surgery alone recurred compared with 
4.7% of the 86 patients who received post-operative radiation while 
in the stage III patients, 26% out of the 31 treated with surgery alone 
recurred compared with 23% of the 78 patients treated with surgery 
and radiation).12 Mediastinal radiation following surgery reduces the 
risk of mediastinal recurrence, but does not seem to impact upon the 
risk of pleural dissemination.13 Some authors advocate radiation for 
resected stage III disease, but not for stage II14, while others believe 
radiation should be reserved for those patients with stage II disease 
who have a close margin or higher risk histology.15
In the University of Pennsylvania experience, in a review of 62 
patients with stage Masaoka stage II thymoma underwent complete 
resection. The decision to deliver post operative radiation was made 
based upon the surgeon’s perception of whether a complete resec-
tion had been attained, with the higher risk patients being referred 
for post operative radiation. Two out of 24 patients (8.3%) who did 
not receive radiation experienced local recurrence versus 0 out of 38 
patients who did receive adjuvant radiation (p=0.81)16. Our experi-
ence confirms the low risk of recurrence for patients with stage II 
disease. 
Thymomas are generally responsive to chemotherapy. Single agent 
chemotherapeutic agents demonstrate response rates from 10-50% 
with the most active agents being cisplatin, ifosfamide, and doxoru-
bicin17-19. Response rates are better for combination chemotherapy, 
with response rates in the 50 to 90% range, as shown in Table 3. 
Re-treatment with chemotherapy following a treatment hiatus can 
also be successful.20
Table 3: Efficacy of chemotherapy regimens in thymoma
Author Regimen Stage N RR MST (years)
Loehrer37 PAC IV 30 50% 3.1
Forniasiero38 ADOC III/IV 32 90% 1.3
Giaccone39 PE IV 16 56% 4.3
Loehrer40 VIP III/IV 28 32% 2.6
P: CisPlatin, A: Doxorubicin(Adriamycin), C: Cyclophosphamide, O: Vincristine(Oncovin),  
E/V: Etoposide(VP-16), I: Ifosfamide
RR: response rate
MST: median survival time
Chemotherapy is the obvious choice for patients with diffuse 
metastatic disease, and surgery for localized disease, but what about 
locally advanced disease which does not appear approachable with a 
complete surgical resection? In these patients, induction chemother-
apy can make complete resection possible, and increase the chance 
of a complete surgical resection21-23. On retrospective analysis using 
historical controls, it does appear that a multimodality approach is 
superior to surgery alone for patients with high risk/locally advanced 
disease24,25. Therefore, if a patient’s resectability is in doubt, a reason-
able and likely beneficial approach is to start with chemotherapy and 
then perform surgery following tumor response, reserving radiation 
therapy if there is evidence of invasion post-operatively. 
For patients who do not have distant metastatic disease and yet are 
not surgical candidates in spite of induction chemotherapy, or for 
patients who undergo incomplete resections, definitive radiation can 
result in prolonged progression-free survival. In a phase II intergroup 
study of 26 patients with locally-advanced, unresectable thymoma 
treated with 2 to 4 cycles of cisplatin/doxorubicin/cyclophosphamide 
followed by 54 Gy of radiation, the response rate to chemotherapy 
was 70%, and the 5-year failure-free survival was 54%26. Some 
centers advocate preoperative radiation27 or chemoradiation (with 
cisplatin/etoposide) for patients for whom immediate surgery is 
unlikely to produce a complete resection15. 
The chemotherapy regimens shown in table 3 are generally regimens 
which were prior standards for non-small cell lung cancer before 
newer, better tolerated and more convenient regimens were found to 
be equally effective or superior. The hope was certainly that some of 
these more user-friendly regimens would also be useful in thymoma. 
However, in a phase II study of 46 treatment-naïve patients with 
unresectable thymoma or thymic carcinoma treated with carboplatin 
and paclitaxel, the response rates were disappointing, with 33% of 
the 25 patients with thymoma achieving at least a partial response, 
and 24% of the patients with thymic carcinoma28 
Pemetrexed has shown promise in previously treated thymoma. Pem-
etrexed is a relatively new chemotherapeutic agent, a multi-targeted 
anti-folate approved for use in non-squamous non-small cell lung 
cancer as well as mesothelioma. In a phase II trial in 27 previously-
treated thymoma, out of 23 fully evaluable patients, there were two 
complete and two partial responses for an overall response rate of 
17%29. 
Responses for thymoma have been noted to steroids18,30. However, 
this is likely a lympholytic effect of the steroids rather than a true 
effect on the neoplastic cells. Octreotide, however, does seem effec-
tive with a response rate of 32% in patients with octreotide-positive 
disease31. In another study of octreotide in patients with evidence of 
uptake on octreoscan showed a response rate of 28.5%32
Thymomas have been shown to exhibit expression of the epidermal 
growth factor receptor (EGFR). However, gefitinib, an oral EGFR 
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tyrosine kinase inhibitor, produced only 1 partial response in 26 
patients with previously treated metastatic thymoma or thymic 
carcinoma33, although there is a recent case report of a response of 
thymoma to erlotinib34 and cetuximab.35
In general, thymic carcinomas are managed in a similar fashion to 
thymomas, though the clinical course is generally more aggressive 
and prognosis is worse. Interestingly, however, one study found 
that 80% of thymic carcinomas stained positive for KIT (CD117) 
as opposed to only 5% of thymomas36, thereby making inhibitors of 
c-kit a potentially attractive therapy for thymic carcinoma. 
Conclusion
Thymic tumors are rare neoplasms that respond well to chemothera-
py and radiation, but are best managed with complete surgical resec-
tion whenever this can be achieved. Induction strategies followed by 
surgery in selected patients can improve complete resection rates and 
therefore patient outcomes. 
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Elderly
Gridelli, Cesare
Division of Medical Oncology “S.G. Moscati” Hospital, Avellino, 
Italy
Non small cell lung cancer (NSCLC) may be considered typical of 
advanced age. More than 50% of lung cancer patients are diagnosed 
over the age of 65 and about 30% over the age of 70. More than 
two-thirds of patients dying of lung cancer in the United States are 
over 65 years old. Elderly patients tolerate chemotherapy poorly 
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because of comorbidity and organ failure. Prospective phase II tri-
als have demonstrated suitable toxicity profile and good antitumor 
activity for single agent chemotherapy with vinorelbine, gemcitabine 
and taxanes in the treatment of advanced NSCLC elderly patients. 
Vinorelbine, in a phase III randomized trial named ELVIS (Elderly 
Lung Cancer Vinorelbine Italian Study), compared to best sup-
portive care, has proven to improve survival and quality of life of 
advanced NSCLC patients. In order to improve results obtained 
with monochemotherapy, the development of non cisplatin-based 
combinations is an interesting issue in the treatment of advanced 
NSCLC elderly patients. In fact the possibility of having active and 
well-tolerated chemotherapy while preserving patient quality of 
life is more attractive in the elderly. The most studied non platin-
based regimen is the combination of gemcitabine plus vinorelbine, 
resulted active and well-tolerated in several phase II trials. How-
ever, a large phase III randomized trial (MILES-Multicenter Italian 
Lung cancer in the Elderly Study), enrolling about 700 patients, 
showed that polychemotherapy with gemcitabine and vinorelbine 
does not improve any outcome (response rate, time to progression, 
survival or quality of life) as compared to single agent chemotherapy 
with vinorelbine or gemcitabine. In clinical practice, single agent 
chemotherapy should remain the standard treatment. Feasibility of 
cisplatin-based polychemotherapy remains an open issue and has 
been recently addressed by some retrospective analyses of random-
ized trials without age limits, suggesting that advanced age alone 
should not preclude aggressive cisplatin-based treatment to fit 
NSCLC elderly patients. The evidences from these analyses could 
however suffer from selection bias, because their target population 
may not be representative of the whole elderly population but only 
of a small subgroup thought to be eligible for aggressive treatments 
by investigators. Prospective clinical trials with inclusion criteria 
selective for elderly population are to be considered the unique tool 
for investigating cisplatin-based chemotherapy in this clinical setting. 
More recently some prospective phase II trials have explored innova-
tive schedules of cisplatin delivering that could be more suitable to 
elderly population. 
Among new biologic agents, the Epidermal Growth Factor Recep-
tor tyrosine-kinase inhibitor erlotinib, characterized by a favourable 
toxicity profile, potentially suitable to elderly population, is being 
investigated. Erlotinib has been tested as first-line treatment in unse-
lected elderly patients showing good tolerability and activity with 
11% response rate and a median survival of 10.5 months. Among 
antiangigenetic agents bevacizumab, in a retrospective analysis of 
the ECOG 4599 study of carboplatin+paclitaxel vs carboplatin+pa
clitaxel+bevacizumab, showed no survival advantage in the elderly 
subgroup, differently from results observed in general patients popu-
lation. This was mainly explaned by greater toxicity in the elderly as 
compared to their younger counterpart. However bevacizumab in this 
setting should be furtherly investigated combined with single agents 
or modified regimens with lower cisplatin doses. Drugs with multiple 
target are the new frontiers of biologic therapy. ZD6474, a small 
molecule that inhibits VEGF and EGFR, a merit to be investigated in 
elderly NSCLC patients. A phase II randomized trial of gemcitabine 
vs gemcitabibe+ZD6474 is ongoing in Italy. 
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Special populations: PS2
Lilenbaum, Rogerio C.
none 
Patients with advanced NSCLC and a poor performance status com-
prise approximately 30% of patients seen in clinical practice. Yet, 
despite their prevalence, these patients have been largely excluded 
from the clinical research due to a perception that chemotherapy was 
too toxic and of no benefit. 
More recently, several trials have either included a subset of patients 
with PS of 2, often designed to compare single agent versus combi-
nation chemotherapy, or in some cases, were specifically designed 
for this population, as testing grounds for new agents. In general, 
carboplatin-based or non-platinum based regimens proved tolerable 
in PS 2 patients, and appear to increase response rates and prolong 
progression-free survival compared to single agent therapy. How-
ever, an improvement in overall survival has not been demonstrated 
and experts do not always agree on the optimal management of these 
patients. 
None of the new chemotherapeutic agents have shown superiority 
over more traditional regimens. Furthermore, research in the use 
of targeted agents in PS 2 patients has lacked behind the wave of 
clinical trials in patients with better PS. For instance, the use of anti-
angiogenesis agents, such as bevacizumab, has not shown to be safe 
or efficacious in PS 2 patients. The same applies to the many multi-
targeted tyrosine kinase inhibitors currently under evaluation. As far 
as EGFR inhibitors, the use of TKIs alone tends to lead to inferior 
outcomes compared to standard chemotherapy in unselected patients. 
On the other hand, the monoclonal antibody cetuximab, in its pivotal 
trial, in combination with chemotherapy, showed a similar magnitude 
of benefit in the small subset of PS 2 patients enrolled in the trial as 
in the PS 0-1 population. 
Lest we accept that innovations in the treatment of advanced NSCLC 
may not or will not apply to a large segment of the patients seen in 
practice, we ought to design trials that address the needs of patients 
with a compromised PS. Moreover, a better understanding of the 
characteristics of these patients, including disease-related symptoms 
and co-morbidities, will go hand in hand with the pursuit of therapies 
with an improved therapeutic index. 
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Evaluation of solitary pulmonary nodules
Midthun, David E.
Mayo Clinic, Rochester, MN, USA
An SPN is defined as a focal opacity in the lung < 3 cm in size and 
surrounded by aerated lung. The finding of a solitary nodule on a 
chest radiograph presents a dilemma for the patient and physician. 
The majority of such nodules are benign; however the presence of a 
nodule may be the first and only point in time of a chance of cure in 
the patient with lung cancer. In the absence of a completely sensi-
tive and specific non-invasive test for malignancy, the physician 
and patient must weigh the options for management. The recently 
published update of the nodule evaluation guidelines by the Ameri-
can college of Chest physicians (ACCP) can help in the decision 
making.1 
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Detection: Change in the availability and use of computed tomogra-
phy (CT) has led to unprecedented numbers of CTs being performed; 
one estimate is that over 60 million CT scans are performed annually 
in the US. CT is being used to diagnose a variety of symptoms as 
well as to diagnose pulmonary embolism, assess for coronary calci-
fication and to look for colon cancer. Use of CT has resulted in the 
detection of incidental pulmonary nodules; many of these nodules 
would be too small to have been seen on CXR. At this point single 
arm (all participants received screening) observational studies have 
found that CT greatly increases detection of lung cancer in early 
stage.2-4 These studies have also shown that CT screening leads to 
a high rate of detection of small parenchymal nodules. The rate of 
nodule detection is a function of how the CT slice thickness (collima-
tion) used. The majority of the nodules identified are 5 mm in diam-
eter or less; the participants in these studies were current or former 
smokers above age 50, yet the likelihood of malignancy in nodules of 
this size was less than 1%. 
Risk factors of Malignancy: Studies have shown that the indepen-
dent risk factors for malignancy include nodule size, age, smoking 
history, upper lobe location and a history of prior malignancy.5 Cal-
culators of likelihood of malignancy can be found on line.6 Estimat-
ing risk is critical in deciding on the appropriate nodule evaluation 
whether it be to observe or pursue resection. Size of the nodule is of 
the utmost importance. Reviewing the data from 8 CT studies in high 
risk patients (current or former smokers, age 50 or above), Wahidi 
reported that likelihood of malignancy was 0 to 1% for nodules < 
5 mm, 6 to 28% for nodules 5 to 10 mm, 33 to 60% for nodules > 
11-20 mm, and 64 to 82% for nodules > 20-30 mm.7 
Age of the patient is important as approximately only 10% of all lung 
cancers occur in people less than age 45 and only 1% in those < age 
35. There is a gradually increasing risk for lung cancer with age and 
the highest above age 70 years. A history of smoking is certainly the 
greatest recognized risk for lung cancer. Risk increase with the dura-
tion of smoking, number of cigarettes per day, tar content and earlier 
age at onset of smoking. A prior history of malignancy is another 
indicator to alert the physician regarding the possibility that a nodule 
is malignant. The lung is a frequent site of metastasis from a variety 
of malignancies; the most common of these include breast, head and 
neck, colon, thyroid and renal. 
Radiology: Imaging not only identifies the presence of an SPN but is 
also the cornerstone of its evaluation. The finding of an SPN should 
first prompt review of any available old images that might include 
the nodule for comparison. The old images may be prior chest imag-
ing or sometimes may even be a coronary CT or abdominal CT that 
contains part of the lung fields. The review of old images may show 
that the nodule is growing or establish that it has been stable for 2 or 
more years. The finding of nodule stability in size over a two-year 
period has been established as an excellent indicator of benignancy. 
An exception to this rule is the pure ground glass opacity that may be 
a slow growing bronchoalveolar cell carcinoma and further follow up 
is recommended.
Evidence for nodule growth is a hallmark for malignancy and should 
lead to a staging PET-CT scan (in those who are candidates for 
surgery) and consideration of prompt resection. Additional radiologic 
features may be helpful in establishing benign or malignant disease. 
Calcification in a benign pattern is an excellent indicator that a 
nodule is a granuloma and needs no further pursuit. Eccentric calci-
fication should maintain concern for the presence of malignancy. If 
review of old films does not settle the concern of a definite SPN, CT 
of the chest with thin section cuts through the nodule is the next step 
in evaluation. Thin-section CT (1-3 mm collimation) allows for more 
sensitive and specific detection of calcification when compared to 
chest x-ray or standard CT (5-10 mm collimation). Thin-section CT 
may identify fat indicating the lesions a hamartoma, and establishes 
it as benign. CT of the chest may also detect presence of additional 
nodules or adenopathy and help determine appropriate management. 
Additional radiologic imaging may be appropriate if available for a 
nodule 8-30 mm at time of detection. 
Techniques of nodule enhancement utilizing CT, and positron emis-
sion tomography (PET) have been shown to be helpful in distin-
guishing benign nodules form malignant ones. Nodules enhancing 
> 15 HU are indeterminate and suspicious for malignancy; those 
enhancing < 15 HU are highly likely benign. Non-enhancing nod-
ules should still be followed radiologically for a two-year period. 
Those nodules which enhance (> 15 HU) call for a decision of PET 
scanning, biopsy or removal. A multicenter prospective study was 
conducted using the CT enhancement protocol evaluated 356 nod-
ules and found a sensitivity of 98% and a specificity of 58%.8 The 
negative predictive value was 96%; in other words, a negative CT 
enhancement study is a strong predictor that a nodule is benign. 
PET scanning uses the injection of the glucose analog 18F-2-fluo-
rodeoxyglucose (FDG) and identifies nodules with high metabolic 
activity. Nodule enhancement is an indication that a nodule is more 
likely malignant than benign, and absence of enhancement is a strong 
predictor that a nodule is benign. In a multicenter prospective study 
of 89 patients with SPNs, Lowe et al reported that FDG-PET had 
an overall sensitivity of 92% and a specificity of 90% for detecting 
malignant nodules, yet the sensitivity fell to only 80% when nodules 
of 15 mm or smaller were analyzed.9 In a meta-analysis, Gould et 
al showed that in the evaluation of a solitary pulmonary nodule that 
PET had a sensitivity of 94% and a specificity of 86%.10 Within this 
meta-analysis, there were only eight cases in which the nodule was 
< 1 cm in size. The lower limit of nodule size for PET applicability 
using current techniques is about 8-10 mm. A growing nodule that is 
shows no enhancement on PET should still be considered suspicious 
for malignancy and prompt needle biopsy or resection. 
Observation: Nodules that are < 8-10 mm and not benign by thin-
section CT or enhancement study, if available, are generally too 
small for PET evaluation and call for a decision between observation, 
biopsy or removal. In the young non-smoking patient the likelihood 
of malignancy is low and observation may be the best option. Obser-
vation should be approached as an active process with the specific 
goal of either establishing a nodule is benign by showing shrinkage 
or lack of growth over two years, or identifying need for removal by 
nodule growth. The danger inherent in observation is that the lesion 
is malignant and the opportunity for cure may pass – this risk is felt 
to be low for the subcentimeter nodule. The Fleischner Society has 
published recommendations regarding the appropriate interval for 
follow-up of small nodules bases on patient risk factors.11
Biopsy: Whether or not an indeterminate nodule should be biopsied 
is the subject of considerable debate and practices vary. As biopsy 
finding showing malignancy leads to surgery in the operable patient, 
the question comes down to one of what will be done with a benign 
biopsy result? If the answer to that is to remove the nodule anyway 
due to high concern for malignancy, then it would appear that biopsy 
would be unnecessary. If a negative or non-specifically benign 
biopsy finding would lead to avoidance of surgery then it may be 
warranted to pursue biopsy. 
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The two biopsy techniques for assessment of SPNs are bronchoscopy 
and transthoracic needle aspiration (TTNA). Bronchoscopy is a val-
ued tool in the diagnosis and staging of lung cancer particularly when 
endobronchial disease is present or sampling of mediastinal nodes 
is desired. The role of bronchoscopy in the evaluation of the SPN 
remains limited. A number of series have shown that bronchoscopy 
with fluoroscopy has a yield is a function of nodule size and may be 
as less than 20% in the setting of malignant nodules less than 2 cen-
timeters and in the range of 40-60% when the nodule is 3 cm. Yield 
rises with increasing nodule size, however, preoperative diagnosis is 
generally not needed for lesions greater than 3 centimeters due to the 
high likelihood of malignancy in nodules of this size. Bronchoscopic 
yield increases if the CT shows that a bronchus is present within the 
nodule. Studies using CT, or endobronchial ultrasound, or electro-
magnetic guidance have shown improvements in diagnostic yield 
over standard fluoroscopic guidance. Electromagnetic navigation 
combines CT virtual bronchoscopy simultaneously with real time 
bronchoscopy and Makris et al showed a yield of 63% of peripheral 
nodules of a mean diameter of 24 mm.12 Although new bronchoscop-
ic methods show improvement in yield over fluoroscopic guidance, 
results do not favorably comparable to TTNA. 
A meta-analysis of 47 studies evaluating small peripheral nodules 
with TTNA reported yields of approximately over 90% for nod-
ules < 2 cm and 95% for nodules > 2 cm (figure 7).13 Likelihood 
of obtaining a specific diagnosis in the setting of a benign lesion is 
greater than with bronchoscopy but is still problematic. Pneumotho-
rax is the most frequent complication of TTNA. 
Resection: Resection is the ultimate fate of many lesions that 
remain indeterminate after imaging evaluation especially in a high 
risk individual. Unfortunately there are currently too many benign 
nodules removed surgically. Recent series of video assisted thoracos-
copy have reported benign nodules representing 50-86% of nodules 
resected.14-16 When a wedge resection reveals a malignant nodule, a 
lobectomy should be performed as the best cancer resection, unless 
reduced pulmonary function will only allow a limited resection. 
Lobectomy with formal mediastinal lymph node dissection is the 
appropriate operation for resection and staging; this may be accom-
plished via thoracotomy or VATS. 
Summary: The finding of a solitary pulmonary nodule raises 
concern for malignancy. Careful evaluation can speed resection of 
a curable lung cancer, or alternatively avoid unnecessary removal 
of the benign nodule. Old images can be invaluable in establishing 
that a nodule is smaller, stable or growing and direct appropriate 
management. Contrast enhanced CT and FDG-PET have put added 
noninvasive measures to improved identification of which nodules > 
8-10 mm are highly likely to be benign. Nodules, which are shown 
to enhance by the advanced imaging techniques, are more likely to 
be malignant and it may be appropriate to proceed to PET or biopsy. 
Non-enhancing nodules by CT or PET are highly likely benign; 
resection may be avoided and the lesion observed. The improved 
imaging techniques may be a means to ease the decision making and 
reduce the incision making. The patient ultimately accepts the risks 
involved and a careful discussion between physician and patient is a 
necessary part of a successful nodule evaluation.
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“Early Lung Cancer” represents a collection of different cancer cell 
types that are of a bronchogenic origin. Beyond pathology however, 
there is a wide constellation of radiologic findings, clinical presenta-
tions, biologic behavior and ultimately varying prognosis. In this 
presentation, we shall review early cancer as it relates to relatively 
“central” airway lung cancers, with a focus on the Intraepithelial 
Neoplasias that affect the normally columnar bronchial epithelium. 
As such, this usually relates to the precursor lesions leading to 
invasive squamous cell carcinomas (SCCA) of the central airways. 
A discussion of the peripheral atypical adenomatous hyperplasias 
(AAH) arising from the parenchymal type II pneumocytes lead-
ing in a step wise progression to bronchioloalveolar cell carcinoma 
(BAC) and eventually to adenocarcinomas is beyond the scope of 
this abstract. For Small Cell Lung Cancers (SCLC), even though it is 
most often located centrally, including presenting as endobronchial 
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obstructing lesions, so little is known about its precursor lesion and 
step-wise carcinogenesis that it will also be omitted from the present 
discussion.
Most lung cancers, be they central or peripheral in location, and 
across cell types, continue to be diagnosed at a relatively late stage 
when local invasion beyond the basement membrane has occurred, 
and most often with spread to regional lymph nodes if not with 
spread to distant metastatic sites. Given the relatively small improve-
ments in overall survival of lung cancers with inclusion of multimo-
dality treatment including the current generation of cytotoxic and 
targeted therapies, there is rightfully interest in early detection of pre-
invasive bronchial intraepithelial lesions when treatment may be both 
local and more effective. Of the challenges posed to realizing this 
goal for central airway cancers, some of the less obvious but more 
important impediments have to do with lack of a uniform nomencla-
ture in describing the pathology seen in the step-wise progression of 
carcinogenesis and disagreement over which findings constitute early 
pre-cancerous lesions that will progress towards a deadly disease.
The “Early Pre-invasive” Lung Cancer Pathology
Panels of expert lung cancer pathologists have provided periodic 
updates to the World Health Organization (WHO) Lung Cancer 
Classifications. Bronchial biopsies should henceforth be classified 
across eight categories from 1) normal, 2) bronchial or reserve cell 
hyperplasia, 3) squamous metaplasia, 4) mild squamous dysplasia, 
5) moderate squamous dysplasia, 6) severe squamous dysplasia, 7) 
carcinoma-in-situ and 8) invasive carcinoma. Accepting histology 
as the “gold standard” for defining pathologic states, the stipu-
lated lesions nevertheless represent a continuum and there is often 
discordance in the reading of a biopsy by different pathologists, and 
indeed intra-pathologists reading of the same slide on different days. 
Adding to the confusion is the incomplete adherence to the WHO 
classification as individual pathologists may employ descriptors 
such as “inflamed”, “thickened”, “abnormal”, “reactive”, “atypia” or 
“atypical” that has different meaning to different pathologists and the 
clinicians who are supposed to be informed by the readings and are 
expected to act on the information. 
Assuming a uniform system of pathology classification is adopted 
by all pathologists and reproducible reading can be achieved, the 
next area of disagreement is which lesions should be regarded as 
definitely pre-invasive in nature deserving of ablative therapies. 
There is general agreement that a carcinoma-in-situ (CIS) confirmed 
on a bronchial biopsy is not a lesion that will spontaneously regress, 
and hence should be treated by proven modalities that will prevent it 
continued growth into a locally invasive and eventually more dissem-
inated disease. Case reports of sites of CIS revisited with repeat biop-
sies on follow-up bronchoscopies that show lower grade lesions or 
normal bronchial mucosa likely represent small foci of CIS that were 
completed debrided by the biopsy process. Next in severity would 
be moderate and severe dysplasias, often regarded as the “high-
grade” pre-invasive lesion. Whether such lesions if left untreated will 
invariably progress towards CIS and invasive carcinoma is uncertain 
because of the relative paucity of such lesions in single center reports 
and even more lacking are longitudinal observational studies. Again 
assuming uniform pathology classification criteria, the risk of a par-
ticular site’s progression appear to perhaps correlate with the number 
of poor prognostic molecular, genetic and epigenetic markers that are 
associated with lung carcinogensis. Continued exposure to tobacco 
adducts and other lung cancer carcinogens, presence and degree of 
airflow obstruction may confer further risks for disease progression. 
Mild dysplasia and squamous metaplasia have occupied even more 
nebulous positions as squamous metaplasia has in the past often been 
associated with a non-specific injury state to the bronchial epithelium 
due to infections, aspiration or other mechanical trauma, with the 
assumption that recovery to normal bronchial epithelium may be 
complete if recurring insult avoided. However given the generally 
accepted step-wise progression of carcinogenesis, and that these are 
histological milestones along the path towards invasive lung cancer, 
investigators employing molecular techniques have also demon-
strated the presence of various mutations and abnormal expression 
of proto-oncogenes and tumor suppressor genes in these “low grade” 
lesions, and those lesions that harbor more of these signals (e.g. 
hTERT, Loss of Heterozygosity-LOH, epigenetic signals) are more 
likely to progress while those lesions without or with fewer such 
abnormal signatures are more likely to regress or remain arrested 
in an “abnormal” but benign state. Continued investigations at the 
molecular level may identify ever more “normal” appearing mucosa 
to be at risk for carcinogenesis. For now however, the first goal is for 
the multidisciplinary lung cancer community to recognize the need 
to adhere to the established lung cancer classifications, including 
for pre-invasive lesions, and to promulgate the widespread use of a 
common nomenclature such that on-going and future studies may 
be more comparable and perhaps combined in larger longitudinal 
diagnostic and interventional studies.
Prevention by Screening 
Primary prevention of lung cancer by reducing carcinogen exposure 
remains the most cost-effective and potentially efficient means of 
reducing lung cancer mortality and morbidity. Secondary prevention 
means the identification of disease before it has becomes estab-
lished, invasive in the case of lung cancer. Secondary prevention 
also includes chemoprevention if effective therapies can be found 
that result in pre-cancerous lesion regression and again prevention of 
the ill effects of invasive lung cancer. Screening for cancers that are 
present but that has not yet become invasive has been a standard goal 
for common cancers that is a significant burden to the community. 
Various modalities including radiologic (breast cancer screening by 
mammography), cytologic (cervical cancer screening by pap smear), 
endoscopic (colon cancer screening by colonoscopy), and blood 
marker (prostate cancer screening by prostate specific antigen) have 
been established but usually only after large numbers of individuals 
at risk have been screened in prospective studies that almost always 
require huge monetary and time commitment. Over the past decade 
there has been a lot of interest in the potential of spiral CT scans 
in the detection of early lung cancer. While it has been effective in 
detecting smaller lung cancers, with between 60–85% of CT screen-
ing detected cancers being in stage Ia (less than 3 cm and no nodal 
involvement), its role in screening for early central airways cancer 
is essentially nil. It is important to remember that stage Ia cancers 
represent an invasive cancer, and it is much less frequent that spiral 
CT scans will detect a ground glass opacity (GGO) that represents 
a truly pre-invasive lesion such as an AAH. As pre-invasive central 
airway cancers such as moderate to severe dysplasias and CIS are 
almost by definition less than 5 mm in depth, and usually much less, 
low-dose spiral CTs at even 2 mm slice thickness that are used for 
lung cancer screening does not have the resolution to detect such 
lesions. In fact in screening studies where CT scans are combined 
with another modality such as sputum to look for cancer or dysplasia 
by cytology, or cytometric features of malignant potential, the spiral 
CT scans miss between 3 to 10% of invasive cancers that are most 
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often central airways SCCA. A few studies have included broncho-
scopic examination as part of a multi-modal lung cancer screening, 
including tri-modality screening of “high-risk” patients by spiral CT, 
sputum cytology/cytometry and bronchoscopy. While bronchoscopy 
always add to the number of dysplasias, CIS and invasive central car-
cinomas detected, it is much more invasive and unlike colonoscopy, 
there is no established criteria as to who will benefit from bronchos-
copy screening, at what interval such procedures should be repeated, 
and which bronchoscopy instrument should be employed. The “Holy 
Grail” remains a low-cost, non or minimally invasive and highly 
effective screening method that is at least similar to PSA in efficacy, 
but to date, none has been proven effective for lung cancer. Much 
work remains to be done on such “early blood markers for cancers as 
it is also not known whether such tests should apply to peripheral or 
to central tumors, and if effective in pointing to much greater likeli-
hood of a pre-invasive squamous cell carcinoma, whether it could 
be specific for SCCA of lung origin versus that of head and neck 
or esophagus, the other “upper aero-digestive tract malignancies”. 
Measurements of breath and exhaled respiratory contents have also 
generated much interest as it is a logical route to sample the respira-
tory tract milieu. Measurement of Carbon-26 or smaller volatile 
organic compounds (VOC) and larger compounds including peptides 
and other biomarkers is possible by exhaled breath condensate. There 
are competing devices and competing claims of what profile of VOC 
and compounds may best identify subjects for further discriminatory 
tests that will eventually lead some to invasive biopsies. 
Diagnosis
Tissue showing the varying grades of dysplasia remains the gold-
standard in diagnosis at the present time. Bronchoscopy with 
bronchial forceps biopsies is the major tool for this purpose, because 
even though sputum cytology, bronchial brushings, bronchoalveolar 
lavage and washings may demonstrate cancer or cells suspicious for 
dysplasia, bronchial architecture is needed to provide an assessment 
of the extent of mucosal and submucosal involvement. There remain 
limitations as a particular biopsy read as severe dysplasia or CIS may 
be on the border of a truly invasive carcinoma. Endoscopic imag-
ing provide guidance as to the extent of mucosal abnormalities, and 
where best to biopsy. From the original rigid bronchoscopes with 
direct naked eye visualization to glass rod telescopes, bronchoscopic 
examination today is mostly in the realm of the flexible fiberoptic 
instruments. The first generation of fiber-optic flexible broncho-
scopes has further largely given way to Charged Couple Device 
(CCD-“chip”) video bronchoscopes of increasing “chip” resolution 
coupled with higher definition displays on monitors. In the hands of 
bronchoscopists experienced in the detection and biopsies of lung 
cancers, the sensitivity of finding invasive central airway lung can-
cers is high (> 80 – 90%), however for “early pre-invasive lesions”, 
the sensitivity is generally much lower. One major advance in the 
1990s has been the development of Autofluorescence (AF) bronchos-
copy technology. Normal living tissue exhibit autofluorescence in 
response to tissue illumination by photons of various wavelengths, 
and this relatively weak signal may be magnified and imaged through 
special filters and detectors. Recognition that dysplastic and malig-
nant tissue loses autofluorescence led to the testing and validation 
of a number of autofluorescent endoscopes. The general findings is 
that compared with white light bronchoscopy, the addition of AF 
bronchoscopy increases the diagnostic sensitivity for the detection 
of dysplastic lesions, usually moderate dysplasia or worse, but at the 
price of decreased specificity, that is more biopsies are taken from 
potentially pre-malignant lesions that are then read as “normal” or 
only with hyperplasia and metaplasia. While the use of AF bron-
choscopy did increase the detection of moderate to severe dysplasias 
by three to six fold, it’s sensitivity is far from 100%. In the North 
American validation of two of the AF bronchoscopy systems where 
investigators had to take biopsies of two “normal” sites as seen by 
both White-light and AF, such “random-site control biopsies” yielded 
one-third of the low grade pre-malignant lesions. Since these afore-
mentioned studies were performed with fiber-optic AF systems and 
they were completed in the late 1990s and early 2000s, newer gen-
eration of video-AF bronchoscopes have been developed although 
none of the systems have yet undergone multi-center, multi-national 
studies with control site biopsies that will provide a better estimate 
for the true sensitivity of the technologies. Non-AF techniques using 
other filtered imaging such as Narrow Band Imaging (NBI-Olym-
pus) and post image capture processing through various Spectral 
Estimation Technologies (SET; e.g. Fujinon’s FICE Intelligent 
Chromo-endoscopy) also hold promise for additional delinearation of 
abnormal pre-invasive or invasive cancer lesions, either by enhanced 
visibility of tumor associated angiogenesis at a macroscopic level, 
but data from rigorous prospective studies are lacking. Parallel 
developments in improved resolution and magnification of video-
bronchoscopes lead some bronchoscopists to consider AF and similar 
systems unnecessary. One model of endoscopic detection and visual 
classification of early mucosal cancers is what gastroenterologists 
have done for esophageal and gastric carcinomas by the combined 
use of high-resolution, high-magnification and NBI in developing 
the Intra-papillary capillary loop (IPCL) system. The limitation 
for bronchoscopes at the present time being a physical one, that is 
the difficulty of outfitting the roughly 7mm diameter of the largest 
“therapeutic” bronchoscope with the latest generation of high-resolu-
tion “chip” and a magnification system. Also with an eye towards the 
gastroenterology flexible endoscopy experience in “In-Vivo” biop-
sies, nascent studies are being conducted in the areas of con-focal 
microendoscopy (CFME) and optical-coherence tomography (OCT) 
as means of characterizing suspicious bronchial mucosa at a near-
histology resolution as an adjunct to identifying sites for biopsies if 
not actually obviating the need for tissue biopsies after appropriate 
validation of these systems. There is still a long distance to travel 
down this path before these systems can be declared effective. In the 
case of CFME, although there are natural fluoro-phores in natural tis-
sue, benign and malignant that responds to the laser light source used 
in CFME, these provide only a cytoskeletal outline, and some form 
of exogenous chromophore will likely have to be applied to visualize 
the surface mucosa. Because of the high resolution nature of these 
imaging systems, it is not practical to use them for a low-powered 
“screening” of the visible central airway mucosa. Instead they shall 
be used as an adjunct to further characterize in greater detail areas of 
interest, especially those suspicious but not obviously of an invasive 
malignant nature. Indeed practitioners with several of these advanced 
systems have proposed a multi-step approach for the detection of 
pre-malignant or early invasive central lung cancers. This include 
initial visualization with some form of auto-fluorescence system, fol-
lowed by NBI or a higher-resolution / higher magnification system to 
assess vascular growth pattern, and finally if available very close-up 
examination with CFME or OCT. The ability to make all biopsies 
obsolete is however unlikely to be realized as there is now growing 
emphasis to not only identify cancerous and pre-cancerous mucosa, 
but to provide tissue suitable for the study of biomarkers involved in 
the carcinogenesis and disease progression.
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Disease Management
When to intervene depends on histology that is dependent on pathol-
ogy reading, and a prediction of disease progression. In invasive car-
cinoma, the treatment paradigm has been reviewed and there is gen-
eral agreement based on consensus statements developed by several 
multi-disciplinary association with an interest in Thoracic Oncology, 
these include the American College of Chest Physicians (ACCP) and 
the National Cancer Care Networks (NCCN)’s Lung Cancer Guide-
lines. The evidence-based practice (EBP) recommendations become 
less robust when it comes to carcinoma-in situ (CIS) and micro-inva-
sive disease, and the evidence become individual “expert-opinions” 
when it comes to high-grade and low-grade dysplasias. 
Invasive carcinoma of a central type should be considered for cura-
tive resection provided it is anatomically feasible and the patient has 
sufficient physiologic reserve and do not have other contraindications 
for resection. Truly central lesions involving the trachea, main-carina 
and proximal bronchi can be technically challenging as sleeve resec-
tions including carinal sleeve with end to tracheal-side to bronchial-
end anastamosis may have to be considered, and such cases should 
be presented to experienced thoracic surgeons and discussed at a 
multi-disciplinary tumor board for consideration of pre-surgical 
induction therapy and post-operative adjuvant therapies.
With regards to CIS, this represents an established malignant lesion 
with growth and metastatic potential, although it is true that the pace 
of growth and rapidity of dissemination may be difficult to predict as 
a group and even harder for a specific lesion in the individual patient. 
Much focus has been on the modes of tumor ablation that include the 
range of heat therapies (LASER, argon-plasma coagulation, electro-
cautery), direct-contact cryotherapies, high-dose rate brachytherapy 
delivered via endobronchially placed catheters, photo-dynamic ther-
apy (PDT) and mechanical debridement by forceps or by mechanical 
micro-debrider. While there have been some multi-center studies of 
single modalities such as PDT, the available data represents much 
more single center experience encompassing a range of pathologies 
and depth of invasion, collected over years to decades, and there are 
no good comparator studies of randomizing ablation techniques spe-
cifically for CIS. More important than the specific techniques is the 
pre-procedural assessment of curability by such local therapies, and 
follow-up monitoring. Different parameters have been considered 
in predicting long term disease-free recurrence in CIS, these include 
estimated size of the central lesion, visibility of the distal end of CIS 
extension, and depth of invasion. It is difficult to be exact in the mea-
surement of the surface size of CIS, because it is difficult to exactly 
tell the border edges of a focus of CIS, of the visual distortion of 
the magnified bronchoscopic image, and lack of accurate measuring 
instruments. Airway pathology measurements are often performed by 
placing the bronchoscope at the “distal” end of a lesion, slowly pull-
ing the bronchoscope backwards until the proximal edge of a lesion 
is seen, and then looking at the movement of the bronchoscope rela-
tive to a “static” reference point such as the opening to the nares or 
an endotracheal tube. With this uncertainty in measurements in mind, 
it is recommended that only CIS smaller than 1 to 2 cm in diam-
eter should be considered for local therapies for curative intent. A 
non-visible distal end of the CIS makes cure less likely is logical as 
it difficult to treat and control what one cannot see. Some practitio-
ners have recommended PDT or brachy-therapy for such lesions as 
it is more possible to extend the treatment zone distally using these 
modalities with lesser risk of airway or vascular perforation. It is in 
general sound advice that laser or APC should not be fired blindly 
into more distal and more likely distorted airways. The importance 
of estimating the depth of tumor invasion in CIS have been nicely 
documented by the use of Endo-bronchial Ultrasound (EBUS) using 
a 20 MHz relatively high resolution radial balloon ultrasound probe. 
Invasion to the bronchial cartilage layer usually precludes long term 
cure either because of microscopic tumor spread that is already pres-
ent, or because this depth of about 5 mm may represent the limit of 
treatment effectiveness by local therapies. One alternate to the use of 
radial-probe EBUS would be the use of high-resolution CT scans that 
in some radiologists’ opinion may yield tissue thickness information, 
however they will need to be informed of the area corresponding 
to the bronchoscopic finding, and to date, there has not been direct 
comparative study of the two techniques. In only the investigational 
phase but holding biologic promise is the study of tumor biology, in 
that CIS and surrounding pre-invasive mucosa with a larger number 
of tumor aggressive markers are less likely to remain disease free and 
may deserve more aggressive treatment and certainly more intense 
follow-up.
How best to manage high-grade and lower-grade dysplasias are 
unknown. As with established CIS post-treatment, bronchoscopic 
follow-ups with or without high-resolution CT scans to look at the 
airway mucosa and lung parenchyma for possible synchronous 
lesions as these patients are usually smokers subject to multi-focal 
lung cancer development under field- carcinogenesis theory. Whether 
patients should be followed up initially at one or three months, and 
thereafter at what interval is also unknown. 
Current and Future Developments
As outlined in this presentation, there are challenges through all 
stages of the classification, definition, diagnosis and diagnosis of ear-
ly-stage and pre-invasive central bronchial cancers. The most urgent 
needs include the agreement to use standardized classification and 
nomenclature by pathologists, bronchoscopists, surgeons, oncolo-
gists and cancer researchers working in this field. Such a process is 
on-going such as through the ACCP Thoracic Oncology Network’s 
development of a consensus statement regarding bronchial epithelial 
neoplasia. The next urgent step is for interested investigators, be 
they clinicians or researchers to agree on general guidelines in the 
identification of such lesions, and to develop an expanded reference, 
teaching and research database that may be pooled to increase the 
number of patients and lesions that are uniformly graded and that can 
be prospectively followed. A truly multi-disciplinary project is under 
development with the involvement of the US National Aero-space 
Administration (NASA) and the Jet Propulsion Lab (JPL)’s hosting 
of a web-accessible site for the uploading of a reference Lung Map 
site where multi-modality images of radiology, bronchoscopy and 
pathology can be aggregated and updated. This effort may be paired 
with an evolving multi-center effort at capturing cases studied by 
AF and other advanced lung cancer imaging bronchoscopy systems 
into a prospective early lung cancer database (Roswell Park Cancer 
Center ABREIN project). Looking ahead, in the planning stages is a 
multi-national multi-modality prospective randomized study for the 
follow-up of patients with previously resected stage I Non-small cell 
lung cancers, with regular screening by bronchoscopy and low-dose 
spiral CT scans for second lung cancers. Given the lack of long-term 
prospective studies, this planned minimum five years randomized 
study for intensive follow-up study will hopefully accrue sufficient 
cases of early lung cancers as to provide information about how best 
to screen, diagnose and manage these lesions, and help in address-
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ing one aspect of the spectrum of challenges presented in our overall 
goal of lowering lung cancer mortality.
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Gene therapy for lung cancer
Roth, Jack A.1; Johnson, Bud 2
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TX, USA; 2 W.M. Keck Center for Innovative Cancer Therapies, USA
Restoration of tumor suppressor gene p53 using intratumor injection 
of a p53-expressing adenovirus has been accomplished in clinical 
trials for lung and other cancers. The most common mutation seen in 
cancer is in the tumor suppressor gene p53, and the inactivation of 
this gene appears to contribute to tumorigenesis; it follows, then, that 
replacement of a copy of a “wild-type” (wt; non-mutated) gene might 
be sufficient to restore normal growth and proliferation pathways. 
The p53 gene product (p53) is a phosphoprotein consisting of 393 
amino acids and capable of complexing with viral proteins, which 
can inactivate p53. The p53 protein is multifunctional – it contains 
major domains that transactivate other genes, can bind other proteins, 
can bind sequence specific DNA and can form oligomers with other 
p53 proteins. Abnormalities in any of these critical functions has the 
potential to severely reduce the tumor-suppressor function of the 
p53 gene product. P53 is also a regulatory element for the progres-
sion of a cell from G1to G2 in the cell cycle. Normally, when DNA 
is damaged p53 will cause arrest at G1 until the DNA is repaired or 
will trigger apoptosis. Overexpression of p53 in cancer cells will 
induce either apoptosis or cell cycle arrest. Expression of high levels 
of p53 protein in normal cells will not have a detectable effect on 
cell growth. Forced p53 expression will also synergistically interact 
with ionizing radiation and DNA damaging agents in the induction 
of apoptosis. Bystander effects, (effects on non-transduced cells fol-
lowing transduction of some cells in the tumor) including release of 
pro-apoptotic mediators, antiangiogenesis, and anti-tumor immune 
responses have been documented. Phase I-II clinical trials in lung 
cancer patients have shown safety and responses. A recent random-
ized clinical trial with replication defective adenovirus p53 as a 
monotherapy in recurrent head and neck cancer showed efficacy in 
prolonging survival. The p53 mutational status and level of expres-
sion were predictive of clinical benefit. 
Recently, the development of nanoscale synthetic particles that can 
encapsulate plasmid DNA and deliver it to cells after intravenous 
injection has been reported. This has been studied in mouse xeno-
graft models of disseminated human cancer. In addition to p53, other 
tumor suppressor genes have been delivered using this technique. 
Multiple 3p21.3 genes show different degrees of tumor suppres-
sion activities in various human cancers in vitro and in preclinical 
animal models. One of the tumor suppressor genes at this locus is 
FUS1, which is not expressed in many cancers including lung. When 
wild-type FUS1 is expressed in cancer cells, apoptosis occurs. To 
translate these findings to clinical applications for molecular cancer 
therapy, we recently developed a systemic treatment strategy by 
using a novel FUS1-expressing plasmid vector complexed with 
DOTAP:cholesterol (DOTAP:Chol) liposome, termed FUS1 nano-
particle, for treating lung cancer and lung metastases Intravenous 
injections of FUS1 nanoparticles into mice bearing experimental 
A549 lung metastasis significantly decreased the number of meta-
static tumor nodules. Lung tumor-bearing animals treated with FUS1 
nanoparticles survived longer (median survival time: 80 days) than 
control animals. These results demonstrate the potent tumor suppres-
sive activity of the FUS1 gene, making it a promising therapeutic 
agent for treatment of primary and disseminated human lung cancer. 
Based on these studies, a phase I clinical trial with FUS1-mediated 
molecular therapy by systemic administration of FUS1 nanoparticles 
is now under way in stage IV lung cancer patients. 
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Cytoreductive surgery as the basis of multimodality 
therapy for malignant pleural mesothelioma
Sugarbaker, David J.
Division of Thoracic Surgery, Brigham and Women’s Hospital, 
Harvard Medical School, Boston, MA, USA
Malignant pleural mesothelioma (MPM) is an aggressive disease 
with few effective treatments and historically poor long-term results.1 
With palliative or no treatment, median survival is between 6-9 
months. 2 MPM is highly resistant to most chemotherapy regimens. 
Various single-agent chemotherapy trials have shown response rates 
between 15-20% with overall median survivals not significantly 
improved over palliative treatment. 3 Vogelzang and colleagues found 
improved survival with the combination of cisplatin and pemetrexed 
compared to cisplatin alone, but this only increased the median 
survival from 9 to 12 months. 4 Radiation therapy is generally inef-
fective as primary treatment because of the multifocal nature of 
the disease that creates a proposed treatment field (the entire chest) 
too large to allow sufficient dosage without inducing unacceptable 
cardiopulmonary toxicity. 5 Radiation and chemotherapy alone and 
in combinations have been used with some success as adjuvant and 
palliative therapy. 6
MPM is unique among thoracic malignancies in its tendency for 
frequent local spread and rare hematogenous progression, even in 
advanced disease.7 The cytoreductive success of adjuvant therapy 
is thought to depend on the tumor burden remaining after primary 
therapy. Controlling locoregional spread of disease is critical. As 
result of inadequate chemotherapy and radiation therapy options for 
local control of MPM, maximum cytoreductive surgery has evolved 
as the cornerstone of the multimodality therapeutic approach to this 
disease.
Pleurectomy/decortication and extrapleural pneumonectomy (EPP) 
are the two operations currently applied for maximum cytoreduction. 
EPP involves the en bloc resection of the lung, parietal and visceral 
pleura, pericardium and ipsilateral hemidiaphragm. Early high opera-
tive mortality with EPP in the 1970s has been reduced to 3.4% at the 
Brigham and Women’s Hospital with aggressive perioperative man-
agement of procedure-related complications. 7 Pleurectomy/decor-
tication involves resection of the parietal pleura without or without 
resection of the pericardium and/or diaphragm with decortication of 
the lung to resect the visceral pleura. Pleurectomy/decortication is 
associated with a 1.8% mortality rate, 8 but is suitable for achieving 
macroscopic complete resection (MCR) only in patients with limited 
disease not involving the fissures or in patients who are unable to tol-
erate pneumonectomy. Postoperative morbidity includes prolonged 
air leak, bleeding, empyema and hemorrhage.
Mature data from our institution’s experience with 183 patients who 
underwent extrapleural pneumonectomy (EPP) followed by adjuvant 
chemotherapy and radiation initiated 4-6 weeks after postoperative 
recovery were published in 1999. 9 The specific chemotherapeutic 
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
Copyright © 2009 by the International Association for the Study of Lung CancerS266
agents varied over the years, with doxorubicin and cyclophosph-
amide10, 11 used prior to transitioning to platin-based therapy in 1985. 
Perioperative mortality was 3.8% (7 deaths) and combined major 
and minor morbidity was 50%. Overall survival for the 176 patients 
who remained was 38% at 2 years and 15% at 5 years (median 19 
months). For patients with epithelial sub-type, negative resection 
margins, and no extrapleural nodal disease, overall survival was 68% 
at 2 years and 46% at 5 years with a median of 51 months.
Our outcomes reveal that for select individuals with favorable 
prognostic variables, surgery-based multimodality treatment of 
MPM optimizes overall and disease-free survival in comparison with 
palliation (historical controls) and chemotherapy alone. Unfortu-
nately, this effect is thwarted by a high rate of early locoregional 
recurrence, which continues to pose a barrier to extended survival. 7 
Novel methods for controlling local disease recurrence have included 
intraoperative radiotherapy and brachytherapy, intraoperative photo-
dynamic therapy, and intraoperative chemotherapy with or without 
hyperthermia. Phase I and II trials with hyperthermic intraoperative 
chemotherapy (HIOC) at our institution have shown increased over-
all and disease-free interval with this approach in comparison with 
those involving other forms of adjuvant or neoadjuvant therapy. 12, 13 
Brigham and Women’s Hospital Experience
Our experience with HIOC began with a phase I trial of EPP with 
HIOC cisplatin and intravenous sodium thiosulfate. 14 This dose-
escalation protocol established a maximum tolerated dose (MTD) of 
250 mg/m2 cisplatin. Operative mortality was 2% (1/50) and major 
morbidity, including atrial fibrillation, occurred in 60% of patients. 
Favorable pharmacokinetic conditions were created by the high lev-
els of cisplatin delivered IC with acceptable morbidity and mortality. 
The findings suggested that sodium thiosulfate may have reduced 
the effectiveness of this treatment by binding with and inactivating 
cisplatin. 
To investigate the efficacy of HIOC in patients unable to tolerate 
EPP, owing to older age and/or presence of comorbidities, we con-
ducted a phase I/II dose escalation trial of pleurectomy and decorti-
cation (P/D) with HIOC cisplatin. 12 In this study, sodium thiosulfate 
was administered after but not before completion of the lavage. The 
MTD for cisplatin was determined to be 225 mg/m2. Postoperative 
mortality was 11.4%. Major morbidity including atrial fibrillation 
occurred in 22.7% (10/44). This study revealed a survival benefit of 
18 versus 6 months (P=0.0019) in patients receiving higher doses 
(175-250 mg/m2) versus lower doses (50-150 mg/m2) of cisplatin. 
The findings supported both the safety and feasibility of HIOC after 
P/D in this cohort of older patients with comorbidities and a survival 
benefit with higher doses of hyperthermic IC cisplatin.
To minimize renal toxicity without altering the effectiveness of cis-
platin, amifostine was substituted for sodium thiosulfate in a Phase I 
dose escalation trial of EPP with HIOC. 13  Amifostine was adminis-
tered during but not before the lavage. Immediately after resection 
by EPP, amifostine was administered intravenously (910 mg/m2) in a 
15-minute infusion, to permit a 30-minute window before the admin-
istration of HIOC with cisplatin. Postoperative mortality was 3.7% 
(1/29). Postoperative morbidity included 8 patients with grade 3 or 4 
creatinine toxicity, which was reversible in all but one case. An MTD 
was not established, as the tendency to experience renal toxicity was 
not systemically related to cisplatin dose. The median survival for the 
29 patients undergoing this protocol was 20 months. While survival 
was improved relative to historical controls, amifostine alone pro-
vided inadequate protection against cisplatin-related renal toxicity.
In an effort to reduce renal cytoxicity further without dampening the 
pharmacokinetic profile of cisplatin, a phase II trial of HIOC cis-
platin after EPP was conducted with amifostine administered before 
lavage and sodium thiosulfate after lavage. 15 After EPP, patients 
had hyperthermic intracavitary cisplatin (225 mg/m2). Intravenous 
sodium thiosulfate was given immediately after resection as a bolus 
infusion to maximize renal cytoprotection. This study found that 
HIOC after EPP with renal cytoprotection consisting of amifostine 
and sodium thiosulfate could be performed with acceptable morbid-
ity and mortality and may enhance local control.
Conclusions
Maximum cytoreductive surgery-based multimodal therapy has 
revolutionized the treatment of malignant pleural mesothelioma. Pro-
spective data from our institution demonstrate promising results with 
intrapleural, intracavitary drug delivery to counteract the resistance 
of MPM to cisplatin-based chemotherapy. We have established that 
heated intraoperative chemotherapy after maximum cytoreduction 
with either EPP or pleurectomy/decortication can be performed with 
minimal mortality and acceptable morbidity. Renal and hematologic 
cytoprotection with intravenous amifostine and sodium thiosulfate 
permits high doses of cisplatin to be delivered locally with minimal 
renal toxicity. However, more investigation is needed of the measures 
used to confer renal protection, because current drugs diminish some 
of the cytotoxic benefits of HIOC with cisplatin. Finally, current 
and future trials are investigating new strategies that boost cisplatin 
sensitivity by combination with other promising drugs. 16, 17, 18 
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Surgery in Mesothelioma: NO
Pavlakis, Nick
University of Sydney, Sydney, NSW, Australia
Surgical management of cancer can be considered to have two 
distinct purposes: The first being the complete removal of the disease 
for hope of cure and the second being palliation of disease related 
symptoms. The main controversy regarding surgery in malignant 
pleural mesothelioma (MPM) centers on the use of “radical” surgery, 
either with the purpose of cure or, for the purpose of palliation by 
“debulking” the disease. This controversy is based on the fact that 
the radical procedures undertaken cannot unequivocally be certain 
to eradicate all disease. This is unlike the arguments for surgery in 
most other solid organ tumours, where complete resection (R0) can 
be obtained, and so surgery is the prime modality of treatment when 
pursuing cure, with radical radiotherapy or chemo-radiotherapy 
being the alternative curative treatment modes available for some 
diseases. 
For the purpose of palliation in MPM, the commonest role for 
surgery is in the palliation of breathlessness due to recurrent pleural 
effusion. The optimal method to achieve this is in the form of talc 
pleurodesis, preferably by video-assisted thoracoscopic surgery 
(VATS)1. VATS also provides the best opportunity to get representa-
tive tissue for a diagnosis, as well as providing more direct informa-
tion on the potential extent of the disease in the pleura, than can be 
determined by radiologic methods alone. If the debate regarding 
surgery was based on the use of VATS, there would be little to argue 
against it. More controversial however, is the use of radical surgery 
for “palliation” or “cure”. The two most commonly referred to radi-
cal surgical procedures used in MPM are extra-pleural pneumonec-
tomy (EPP) and pleurectomy/decortication (P/D). 
Mesothelioma is considered a slowly progressing tumour that might 
have been present for years before clinical presentation. Consequent-
ly, reported survival times are susceptible to lead-time bias and vary 
as a result. As there are no surgical outcome studies with an internal 
control group it is difficult to know what the expected average sur-
vival of patients by stage or histology actually should be. It is com-
mon for surgical investigators to analyse the predictors of survival 
within their study groups and to argue for surgery on the basis of 
multivariate analyses comparing outcomes according to prognostic 
factors. The strongest factors predicting for longer survival include 
early stage disease and epithelioid histological subtype. However, it 
can be argued that the most favourable patients are selected for “radi-
cal” treatments, who might otherwise have survived similar length 
of times with less morbid therapy. Further, proponents of “radical” 
treatments point to longer median survive times in their highly 
selected patient series when indirectly compared with those from 
series of patients not selected or excluded from radical treatments, 
using this argument as evidence of benefit.
A recent review of 663 patients across 3 specialist centres indicated 
an operative mortality of 7% for EPP and 4% for P/D, with serious 
post op respiratory complications described in 10% of patients under-
going EPP and in 6.4% of patients undergoing P/D2. The impact on 
quality of life was not reported in this series and therefore remains 
uncertain. Further, the median survival of all patients in this study 
was only 14 months, with the longest survival not unexpectedly 
being seen in patients with early stage disease, better prognosis his-
tology (epithelioid), and those having received multimodality therapy 
(additional radiotherapy and chemotherapy) versus surgery alone. 
In another recently reported large surgical series of 444 patients 
undergoing EPP for MPM, overall operative mortality was noted to 
be 4 %3. However, overall morbidity (major and minor) was noted 
to be 60.4% (198/328). Furthermore, additional morbidity would be 
expected from the radical radiotherapy and chemotherapy now used 
as standard additions to radical surgery in most common multimodal-
ity protocols, and this whole treatment program could take 6 months 
or longer to recover from. Overall, based on the tenant “do no harm”, 
it is hard to promote the policy of radical surgery for MPM given we 
are unsure if the degree of benefit is worth the morbidity associ-
ated with it. The truth should come from the only randomized trial 
addressing this question – the MARS (mesothelioma and radical 
surgery ) trial, if it can be successfully completed. For the moment, 
in MPM, we can still wonder whether the “pen is mightier than the 
sword”?
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Pre-neoplastic lesions
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In the last decade, there has been acceptance not only of the 
metaplasia-dysplasia-carcinoma in situ sequence for squamous 
carcinoma but also of associations between both atypical adenoma-
tous hyperplasia (AAH) and peripheral adenocarcinomas and, to a 
lesser degree, neuroendocrine cell hyperplasia with development of 
carcinoid tumors. These are all recognized within the current WHO 
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classification1 and are reviewed in sequence. Screening is also 
briefly discussed.
Squamous dysplasia and carcinoma in situ
Squamous lesions arising in the airways have been regarded as pro-
genitors of squamous carcinoma for decades2 and basal cell hyper-
plasia and squamous metaplasia may also represent earlier phases in 
the development of squamous carcinomas. The WHO classification 
tabulates methodology for such gradation, and the system appears 
sufficiently reproducible for diagnostic usage.1, 3 Squamous dysplasia 
is usually asymptomatic but there may be symptoms relating to other 
smoking related pathologies. Symptoms relating to obstruction and 
haemoptysis may also occur. Foci of carcinoma in situ usually arise 
near bifurcations in the segmental bronchi, subsequently extending 
proximally into the lobar bronchus and distally into subsegmental 
branches.4 Focal or multi-focal plaque-like greyish lesions resem-
bling leukoplakia, non-specific erythema with oedema and even 
nodular or polypoid lesions may all be seen. These can be highlight-
ed by autofluorescence bronchoscopy.5
In terms of aetiology, cigarette smoke causes a field change in the 
mucosa, with mutations demonstrable even in histologically normal 
areas. Several studies have also shown an increased incidence of 
squamous metaplasia and dysplasia in the lungs of smokers6 and the 
incidence of squamous metaplasia and dysplasia increases sequen-
tially according to degree of exposure to cigarette smoke (non-smok-
ers, those exposed to secondary smoke, ex-smokers and smokers).7 
HPV infection may also play a role.8 
On microscopy, one may see:
• Basal cell (reserve cell) hyperplasia - Expansion of the basal layer 
of bronchial epithelium, ranging from two cell layers to more than 
ten. 
• Squamous metaplasia - Progressive maturation of epithelial cells 
from the basal zone through a defined intermediate cell zone to 
a desquamating superficial zone, with minimal cellular pleomor-
phism or cytological atypia. 
• Squamous dysplasia - epithelial layer comprises architecturally 
disrupted and cytologically atypical squamous cells. The variation 
in severity of these changes reflects categorization into mild, mod-
erate and severe. Squamous dysplasia may also be accompanied 
by stromal changes, sometimes with capillary loops termed as 
angiogenic squamous dysplasia.9 
• Carcinoma in situ may be a consequence of in situ extension from 
adjacent invasive carcinoma or may arise unassociated with con-
current carcinoma. The epithelium comprises highly pleomorphic 
and mitotically active cells with no evident maturation from basal 
to superficial layers of the epithelium.
It is important to distinguish carcinoma in situ from invasive 
squamous cell carcinoma, as this will likely affect treatment. It is 
also important to recognize that squamous metaplasia, particularly 
squamous metaplasia with superimposed inflammation may show 
significant reactive atypia that histologically overlaps with dyspla-
sia. Pagetoid spread of carcinoma cells may also rarely occur in the 
bronchial epithelium. Complete resection of specific lesions is cura-
tive, although frequent multifocality means that foci of dysplasia will 
usually be present elsewhere in the airways.
Atypical adenomatous hyperplasia
Atypical adenomatous hyperplasia (AAH) is a localized proliferation 
of mild to moderately cytologically atypical epithelial cells lining 
involved alveoli and, sometimes, respiratory bronchioles, resulting 
in focal lesions in peripheral alveolar parenchyma. Incidence ranges 
from 4 to 10% in lungs removed at autopsy,10, 11 being most common 
in relation to adenocarcinomas. Lungs with very high numbers of 
AAH (over 160 in one case) have been reported. Foci rarely show 
more than one of the following features: >5 mm size, marked cellular 
stratification, high cell density/marked overlapping of nuclei, coarse 
nuclear chromatin/the presence of nucleoli, columnar cell change 
with cellular crowding and micropapillary tufting. Most cases are 
identified in resections adjacent to adenocarcinomas, although high 
resolution compute tomography (HRCT) in relation to screening 
studies may identify cases.12 Foci are sometimes visible on the cut 
surface of lung as discrete, grey to yellow foci.13 
On microscopy, AAH is a discrete parenchymal lesion arising often 
in the centriacinar region. The alveoli are lined by rounded, cuboidal, 
low columnar or ‘peg’ cells, many of which have features of Clara 
cells and/or type II pneumocytes. Most lesions are well defined with 
a sharp cut-off between abnormal and normal. The involved alveolar 
walls may rarely be thickened by fibrosis. Although separation into 
low and high grades may be useful for research, this is not recom-
mended in a diagnostic setting.1
AAH needs to be distinguished from reactive hyperplasia second-
ary to parenchymal inflammation or fibrosis. In the latter, type 2 cell 
hyperplasia is more diffusely distributed and there is not such a sharp 
demarcation between normal and abnormal lining cells. Distinction 
between pleomorphic foci of AAH and bronchioloalveolar carcinoma 
is arbitrary and based on morphologic criteria given above. Studies 
have compared post-operative survival, in groups of patients with 
and without AAH, but none have shown any difference in outcome. 
As a putative precursor of pulmonary adenocarcinoma, the risk and 
rate of progression is unknown. 
Neuroendocrine cell hyperplasia
Neuroendocrine cell hyperplasia is a localized proliferation of more 
than four neuroendocrine cells that does not infiltrate beyond the 
basement membrane, although these foci may reach the lumenal 
surface of the airway. Diffuse idiopathic neuroendocrine cell hyper-
plasia (DIPNECH) is used when there is widespread distribution of 
localized foci of neuroendocrine cell hyperplasia. When localized 
aggregates of neuroendocrine cells extend beyond the basement 
membrane into subepithelial stroma, they are termed tumourlets if 
the diameter is less than 5mm in diameter. Lesions of 5mm or greater 
in diameter are termed carcinoids. The origin of the proliferating 
neuroendocrine cells is unknown, but it is likely to be an uncommit-
ted precursor cell. 
Neuroendocrine cell hyperplasia is seen with increased frequency in 
a variety of non-neoplastic conditions, with no neoplastic potential. 
However, DIPNECH is associated with the development of periph-
eral carcinoids,14, 15 and therefore may be a precursor lesion for some 
carcinoids. DIPNECH occurs at any age, but presents typically in 
the fifth or sixth decades, and appears more common in women.14, 16 
Patients may be asymptomatic but can present with obstructive lung 
disease.14, 17 Macroscopically, tumourlets can be seen as small, gray-
white nodules. Microscopically, there are nodular aggregates of neu-
roendocrine cells confined to the bronchial or bronchiolar epithelium 
in NEH, with tumourlets showing aggregates that infiltrate subepi-
thelial stroma. Tumorlets may resemble meningothelioid nodules but 
the former stain for cytokeratins and CD56. DIPNECH is a slowly 
progressive condition with a benign course spanning many years. 
Associated carcinoid tumors are indolent, more frequently peripheral 
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and atypical features have also rarely been described, along with rare 
association with type1 MEN syndrome.17
Molecular events in preneoplasia
Underlying the morphological changes of preneoplasia, there is a 
multi-step accumulation of 10-20 alterations at the genomic level, 
leading to the development of lung cancer.18 These affect the entire 
bronchial tree which is exposed diffusely to carcinogens, mainly 
cigarette smoke, leading to so-called “field cancerisation”. In addi-
tion, Epidermal Growth Factor Receptor (EGFR) mutations have 
been found in 5-25% of AAHs, indicating that EGFR mutation, 
when it occurs, is an early event in adenocarcinoma development.19 
Transformation to malignancy comes from molecular events that 
give advantage to potential malignant cells in relation to cellular 
growth and survival, and these can be broadly subdivided into (1) 
activation of growth-signaling pathways related to proto-oncogenes 
activation, (2) inactivation of tumour suppressor pathways (3) resis-
tance to apoptosis, (4) DNA repair alteration and immortalisation, (5) 
angiogenesis, and (6) cellular migration. These have been recently 
reviewed in detail.20 
Screening for lung cancer
The goal of screening is to reduce the rate of mortality from a 
disease, using systematic testing of healthy individuals to detect 
presymptomatic stages of that disease. In this respect, no trial for 
lung cancer screening has yet been successful.21 However, advances 
in molecular biology and increased understanding of the multiple 
steps involved in carcinogenesis have renewed interest in potential 
usage. This is coupled with advances in diagnostic imaging tech-
niques, in particular the use of HRCT in the recognition of peripheral 
early adenocarcinomas as new avenue for investigation.21 However, 
although many studies are in progress for squamous lesions, none 
have been proven to reduce mortality and screening for lung cancer 
via assessment of sputum is not recommended.22 For low dose CT 
screening for early adenocarcinomas, this technique is only currently 
recommended within specialist centers dealing with ongoing trials.23 
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Comprehensive supportive care in the 
patient with mesothelioma
Clayson, Helen
Hospice of St Mary of Furness, Ulverston, UK
Mesothelioma is a potentially preventable fatal disease causing 
around 2000 deaths/year in the UK, increasing in incidence, and 
lacking effective treatments (1, 2). This paper presents findings 
from a doctoral investigation: ‘The Experience of Mesothelioma in 
Northern England’ (2). This is a community-based, mixed methods, 
case study in four parts, conducted in Barrow-in-Furness, Leeds and 
Doncaster – all industrial towns with a past history of heavy use 
of asbestos due to shipbuilding, asbestos textile manufacture and 
railway plant maintenance respectively. The study investigates the 
experience of pleural mesothelioma for patients and their families, 
and for healthcare professionals and service providers, and leads to 
determination of the supportive care needs related to mesothelioma.
Mesothelioma is experienced as a devastating disease that carries 
a severe burden in physical, psychological, and social domains. 
Breathlessness, usually due to recurrent pleural effusions, and/or pain 
occur in >90% cases and may be refractory (2). In comparison with 
lung cancer, breathlessness scores are similar, and scores for pain, 
social role and functioning are significantly higher in mesothelioma 
(3). Other symptoms are common: cough (41%), weight loss (41%), 
sweating (18%), nausea (14%), fatigue (14%), and dysphagia (11%). 
Data from hospital, GP and hospice records of 80 deceased patients 
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who died due to mesothelioma suggest that medical management of 
these symptoms is suboptimal. 
Diagnostic delay is common due to inadequate knowledge of meso-
thelioma and the lack of specific tests that identify mesothelioma. 
Disease burden is high in terms of multiple invasive investigations 
and emergency admissions and is reflected in service usage: 2 or 3 
hospital admissions, 5 outpatient appointments and 11 GP consulta-
tions, 4 of these at home, occurred on average in the last year of 
life in this study. Median survival was 294 days and 45% died in 
hospital, 30% in hospice, and 14% at home (2). In the UK around 
4% of cancer patients die in hospice; the much higher percentage of 
mesothelioma patients who die in hospice supports the findings of a 
highly symptomatic disease in which breathlessness and pain may be 
particularly difficult to manage successfully.
Psychosocial aspects relate to causation, latency, rapid decline in 
health with deterioration in body image and agency, helplessness 
regarding severe symptoms, and impending death. The erratic trajec-
tory is unusual in malignancy and living with the uncertainty of an 
unpredictable illness adds to the distress. Patients tend to react with 
stoicism and patients (and relatives) often adopt a ‘coping narrative’ 
which may prevent timely access to supportive services. 
Bereaved relatives’ emotional accounts reflect witnessing severe 
suffering, express anger and blame around the potentially avoidable 
asbestos exposure, and present the deaths due to mesothelioma as 
‘mass murder’. State benefits and civil compensation procedures, and 
the Coroner’s investigation, create additional psychosocial distress. 
Bereaved relatives recount in focus groups that these medico-legal 
processes prolonged adjustment to loss and led to a sense of ‘no clo-
sure’; severe bereavement reactions have features of ‘tragic grief’. 
National guidance suggests early referral of patients with mesothe-
lioma to palliative care services (4). However, in spite of the severe 
symptom and psychosocial burden, less than half of the patients were 
referred to palliative care and there was no systematic approach to 
care and support of either patients or their relatives.
Support groups have been set up to assist victims of asbestos-related 
diseases, coordinated in the UK by the Asbestos Victims Support 
Groups’ Forum UK. In 2005, in Barrow-in-Furness, the local hospice 
held two open public meetings to explore the wishes of the local 
community regarding support for patients with mesothelioma – Bar-
row has the highest incidence of mesothelioma in men in England 
(4). The Participatory Appraisal method was used to obtain the views 
of the public and the main requests were as follows: 
1) Easy access to understandable information about the disease, 
including treatment options, chemotherapy trials and “centres of 
excellence”.
2) Easy access to expert advice concerning State benefits.
3) Easy access to expert legal advice.
4) Support for carers
5) Bereavement support
6) Education for health care professionals
7) Access to treatments locally whenever possible
These results provided the mandate for the founding of a support 
group, BARDS – Barrow Asbestos-Related Disease Support - which 
now meets monthly. BARDS is a unique organisation as it provides 
medical, nursing, legal, welfare, family and bereavement support. 
The group is sponsored by the local Hospice of St Mary of Furness, 
legal firms and Job Centre Plus (a State benefits agency) and hospice 
volunteers run the monthly meetings with a variety of paid hos-
pice staff. The first BARDS mesothelioma nurse has recently been 
recruited and she will link with the national Mesothelioma Nurse 
Action Team. BARDS organises annual conferences (5), alternating 
between medical and social aspects of asbestos-related conditions. 
Support groups can provide valuable healthcare and psychosocial 
support alongside practical assistance and advocacy; although many, 
for a variety of reasons, do not realise their full potential.
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The role of radiotherapy in patients with mesothelioma
Price, Allan
Edinburgh Cancer Centre, Edinburgh, UK
Three indications have been described for radiotherapy in patients 
with mesothelioma: as a palliative treatment for pain or masses, as 
prophylactic treatment against the development of seedlings where 
the pleural cavity has been broached, and as adjuvant therapy after 
surgical resection.
Many retrospective series have described the use of palliative 
radiotherapy in patients with mesothelioma, but only one prospec-
tive study has examined its use for pain. This reported reduced pain 
in 13/19 patients at 1 month, but only 3/12 by 3 months. The authors 
emphasised the importance of large radiotherapy volumes; by the 
time pain can no longer be controlled with analgesics the lung is 
usually encased by mesothelioma, and the precise source of pain dif-
ficult to delineate.
Three randomised trials have examined the use of prophylactic chest 
wall radiotherapy to biopsy and drain sites. One reported a significant 
reduction in recurrences from 40 to 0%, but in the other two only 
about 10% of patients relapsed with or without radiotherapy.
No randomised trial on the use of adjuvant radiotherapy after major 
resection has been reported, but one is currently underway in Swit-
zerland. The evidence for adjuvant radiotherapy depends on series in 
which higher radiotherapy doses, or the use of intensity modulated 
radiotherapy (IMRT), resulted in fewer in-field recurrences than 
historic controls. The use of conformal radiotherapy is limited by the 
difficulty in obtaining satisfactory dose distributions because of dose-
limiting structures such as the liver, particularly in one of the highest 
areas of risk for recurrence, the diaphragmatic gutters, while IMRT 
may carry a higher risk of radiation damage to the remaining lung 
than conformal radiotherapy. Moreover, if the fashion for surgery 
moves from extra-pleural pneumonectomy to pleurectomy/decortica-
tion the role of radiotherapy will be further limited by the presence of 
underlying lung.
In summary radiotherapy does have a role in palliation, although this 
is becoming less as analgesics improve and their use becomes more 
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widespread. Randomised trials suggest it is unnecessary for the pro-
phylaxis of biopsy sites. Such trials remain to be completed in more 
radical settings, but the role of radiotherapy may depend on fashions 
in surgical practice.
MTP30.2 Radiotherapy for Malignant Pleural Mesothelioma and Thymic Tumors:  
 Where is the Evidence?, Mon, Aug 3, 07:00 - 08:00
Thymic tumors: where is the evidence?
Cameron, Robert B.
David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Thymomas are variably sensitive to ionizing radiation. Although 
radiation commonly is used to treat stage II-IV tumors as well as 
recurrent disease, the use of radiation in the treatment of invasive 
thymoma clearly warrants future prospective, multi-institutional 
clinical trials, particularly using modern imaging, three-dimensional 
treatment planning and delivery techniques that have increased 
the therapeutic overall efficacy and safety profile of thoracic 
radiotherapy.
Postoperative adjuvant radiotherapy has been administered in stage 
I thymomas but has not improved on the excellent more than 80% 
10-year survival rate obtained with surgery alone. In stage II and 
III, however, adjuvant radiation definitely decreases recurrence rates 
after complete surgical resection from 28% to 5%. In addition, an 
increase in 5-year disease-free survival has been reported. Stage II 
cortical tumors and tumors with invasion of pleura or pericardium 
are most likely to benefit. Decreased tumor burden and potential for 
tumor seeding during surgery have been reported in limited studies 
of preoperative therapy. While currently according to a preliminary 
review of 671 cases in the SEER database, most Masaoka stage 
II patients receive adjuvant (postoperative) thoracic radiotherapy, 
recent data suggests that not all may necessarily require postopera-
tive radiation.
 Radiation therapy has proven beneficial in the treatment of exten-
sive disease and after incomplete surgical resection, producing 
control rates of 35% to 74% and 5-year survival rates ranging from 
50% to 70% for stage III and 20% to 50% for stage IVa tumors. In 
addition, similar survival rates (87% 5-year and 70% 7-year) have 
been reported in patients treated with radiation alone compared with 
partial surgical resection and adjuvant radiation in small numbers 
of stage III and IV patients. Large variations in the amount of tumor 
treated and radiation delivered, however, make these results difficult. 
 Radiation is delivered in doses ranging from 30 to 60 Gy in 1.8 or 
2.0 cGy fractions over 3 to 6 weeks. Completely resected and micro-
scopic residual disease can be well controlled with only 40 to 45 Gy. 
It is not clear that doses exceeding 60 Gy offer any advantage even 
with gross tumor. Treatment portals have included single anterior 
field, unequally weighted (2:1 or 3:2) opposed anterior-posterior 
fields, wedge- pair, and multifield arrangements. The gross tumor 
volume is defined by visible tumor or surgical clips seen on a treat-
ment- planning CT scan. Areas of possible microscopic disease and 
a small border to account for daily variability and respiratory motion 
are added to define the clinical and planning target volumes. Gating 
techniques to minimize respiratory variation and intensity-modulated 
radiation therapy are new techniques that can minimize the dose het-
erogeneity, increase total dose and fraction size, and minimize toxic-
ity. Prophylactic supraclavicular and hemithorax fields have been 
used but carry increased risks of pulmonary fibrosis, pericarditis, and 
myelitis, and therefore are generally not employed.
MTP31.1 Image guided procedures for Therapy of Lung Cancer, Mon, Aug 3, 07:00 - 08:00
Image guidance in judging therapeutic response
Shelton, David K.
UCDMC, Sacramento, CA, USA
Anatomic imaging with chest x-ray, computed tomography (CT) 
and occasionally magnetic resonance imaging (MRI) have been the 
traditonal methods for staging lung cancer, restaging lung cancer 
and judging response to therapy. These anatomic techniques have 
included bi-dimensional measurements, RECIST criteria measure-
ments, volumetric measurements and dynamic contrast enhancement 
(DCE) judgements. Molecular imaging with radiotracer technology 
has more recently provided methods for judging response to therapy 
with planar, whole body, single photon emission computed tomogra-
phy (SPECT) and now positron emission tomography (PET). Even 
more recently, PET-CT has provided a combination of anatomic tech-
niques with it’s CT component, and molecular/functional techniques 
with it’s PET component. The images can be co-registered and fused 
to allow visualization of the molecular process being studied onto the 
high resolution anatomic depiction. 
Utilizing serial, simple anatomic tumor measurements might require 
months or even a year or more to know the true response of a tumor 
to radiation or chemotherapy and even then measurable disease 
or fibrous scarring may remain whether there is viable tumor or 
not. Utilizing functional or molecular methods such as PET with 
F-18 FDG (fluorodeoxyglucose) has proven it’s ability to judge a 
tumor’s response very quickly with many tumors, and can actually 
map to a different survival outcome for early responders versus 
nonresponders. In judging response to therapy, one can calculate the 
Standard Uptake Value (SUV), which has proven to provide a more 
objective method for determining changes in the metabolic rate, 
aggressiveness or viability of a mass. 
While PET with F-18 FDG has proven to be an outstanding imaging 
biomarker, there are other new tracers and molecular imaging agents 
being studied, such as F-18 FLT (fluorodeoxythymidine) which is a 
molecular biomarker for DNA proliferation in tumors, and is thought 
to be more tumor specific than F-18 FDG. Most experts agree that 
molecular imaging methods of the future will allow us to more 
quickly judge a tumor’s response to therapy and to decide whether to 
continue with that treatment or turn to a new course, thus decreasing 
morbidity, saving valuable healthcare dollars, and providing a more 
personal form of treatment with better outcomes.
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Ethnic differences in chemotherapy 
toxicities and outcomes
Chang, Alex Y.
Johns Hopkins Singapore International Medical Centre, Singapore, 
Singapore
It is a common belief that ethnic differences in chemotherapy toxici-
ties and outcomes exist in patients with advanced non-small cell lung 
cancer (NSCLC) and other malignant diseases receiving the same 
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regimen at the same dose levels and schedules. Several lines of data 
give us such an impression. Firstly, same study of Phase II clinical 
trials involving patients from both East (Singapore patients) and 
West (Australian patients) tends to report high response rates (43%) 
and higher myelosuppression (especially grade 4 neutropenia) and 
better survival in Asian patients than the same treatment in Cauca-
sians (with a response rate of 23%). Secondly, comparison between 
patients from USA (SWOG) and Japanese patients (JCOG) receiving 
same chemotherapy of paclitaxel and carboplatin of same eligibil-
ity criteria but in separately run protocols showed similar findings 
with Japanese patients having higher response rates, higher grade 4 
myelosuppression and longer survival time. Single nucleotide poly-
morphism (SNP) analysis showed significant difference sufficient 
to explain the response difference. Thirdly, etiology of NSCLC may 
not be identical among ethnic groups. Women with lung cancer in 
the Asia Pacific region are non-smokers in 80 – 90% of the cases; in 
contrast, 80% of women with lung cancer in the USA are smokers. 
The prevalence of pulmonary tuberculosis which may be related to 
the development of adenocarcinoma of the lung also varies drasti-
cally. In addition, epidermal growth factor receptor (EGFR) mutation 
rate is much higher in the East (average 30%) than in the West 
(<10%). Patients with adenocarcinoma, never smoker, female gender 
and East Asian have higher mutation rates of EGFR and respond 
better to EGFR tyrosine kinase inhibitors than their counterpart in 
the West. The significance of impact on prognosis in NSCLC patients 
by EGFR mutation and gene copy amplification is also different. 
However, there are still many unknowns and controversies. Whether 
the difference in chemotherapy outcome and toxicities can be 
explained by biological differences in diseases between the East and 
West is not 100% certain. Recently, the IPASS study showed higher 
response rates to chemotherapy in patients with EGFR mutation as 
compared to EGFR wild type (46% vs. 23%). This may explain the 
higher response rates in Asian patients to chemotherapy. In addition, 
K-ras mutation usually confers resistance to chemotherapy as its rate 
is higher in Caucasians than Asians (20% vs. <5%). The differences 
in chemotherapy toxicity and outcome may imply different treat-
ment strategies in different parts of the world such as selection of 
chemotherapy agents, schedule of administration and dose in order to 
achieve maximum therapeutic benefit and minimum toxicity which is 
the ultimate goal and art in practising oncology medicine. 
MTP34.1 Lung Cancer in Never Smokers, Tue, Aug 4, 07:00 - 08:00
Limited surgical resection and local radiation 
therapy for high risk NSCLC
Bogart, Jeffrey
Department of Radiation Oncology, SUNY Upstate Medical 
University, Syracuse, NY, USA
Due largely to medical co-morbidities related to tobacco smoke, 
many patients who present with curable lung cancer are not candi-
dates for standard surgical resection, and Surveillance, Epidemiology 
and End Results (SEER) data suggest that approximately 25% of 
patients with early stage non-small cell lung cancer (NSCLC) do not 
undergo surgery. During the past decade, several treatment alterna-
tives have been explored prospectively for this patient population and 
mature results are starting to be reported. This presentation will focus 
on retrospective and prospective reports of sublobar resection for 
poor-risk stage I NSCLC, including trials combining adjuvant exter-
nal beam radiotherapy or brachytherapy with lesser resection. Patient 
selection factors will be described in addition to toxic effects of treat-
ment, patterns of relapse, and intermediate and long-term outcomes. 
Results following thorascopic resection and open thoracotomy will 
be described. Treatment with sublobar resection will be contrasted 
to alternative treatment options including conformal radiotherapy, 
stereotactic body radiotherapy, and radiofrequency ablation.
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Ethnic considerations in EGFR biology 
and clinical parameters
Park, Keunchil
Division of Hematology/Oncology, Department of Medicine, 
Samsung Medical Center, Sungkyunkwan University School of 
Medicine, Seoul, Korea, Republic of (South Korea)
It is now widely accepted that epidermal growth factor receptor 
(EGFR) tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, 
are effective in non-small cell lung cancer (NSCLC). This session 
will focus on the ethnic difference in EGFR biology and EGFR TKI 
efficacy.
Efficacy of EGFR TKIs in Asia
A higher response rates of 25 – 60% has been observed in phase II 
trials of gefitinib as first-line treatment in East Asian NSCLC patients 
[1-5] when compared with those in non-East Asian NSCLC group (≤ 
5%)[6-7]. Several studies including ours have identified East Asian 
ethnicity, adenocarcinoma histology, never-smoker status, female 
sex, and good performance status as significant predictive factors for 
treatment response to gefitinib [8-10]. In a matched pair case-control 
study comparing overall survival of NSCLC patients between pre-
gefitinib and post-gefitinib era, the median survival was significantly 
prolonged in the post-gefitinib era (19.3 vs 11.5 months; P < 0.001) 
[11]. In particular, patients with adenocarcinoma showed 14 months 
prolongation in medial survival since gefitinib was introduced in 
Korea. Recently, the phase III IPASS (Iressa Pan-Asian Study) trial 
including 1,217 patients with stage IIIB/IV NSCLC who had either 
never smoked or were former light smokers were randomized to 
receive gefitinib versus paclitaxel/carboplatin as first-line therapy in 
7 Asian countries [12]. In a subgroup analysis, PFS in patients with 
EGFR mutations was significantly better in the gefitinib group com-
pared to those receiving chemotherapy (HR 0.48; < .0001). Given the 
potential survival benefit from EGFR TKI in NSCLC patients with 
adenocarcinoma, never smoker or female sex or EGFR mutations, 
several clinical trials testing EGFR TKI efficacy in this subpopula-
tion are currently ongoing in Asia.
EGFR mutation rates in East Asian NSCLC
A number of studies have demonstrated that EGFR mutation rates 
are exceptionally high in East Asian NSCLC when compared to 
other ethnic origin NSCLCs. The EGFR mutation rate ranges 
from 19%~61% in East Asian NSCLC patients while the rate in 
patients of other ethnic origin show only 8~15%. Among East Asian 
patients with NSCLC, EGFR mutations are even more common 
in females (33.3–72.0% vs. 9.3–53% in males) and never-smokers 
(25.6–71% vs. 12.8–42% in ever-smokers) than those in the general 
patient population [13-23]. Given the high frequency of female, 
adenocarcinoma and never smoker in East Asian NSCLC patients, 
genome-wide approach may further reveal the genetic susceptibil-
ity for NSCLC in this particular subset of patients. Intriguingly, a 
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combined analysis of a Samsung Cancer Center Registry (n=4,846) 
and a regional California Cancer Registry (n=8,565) demonstrated 
that Korean ethnicity (vs Caucasian; HR = 0.839; P < .0001) was an 
independent favorable factor for OS at multivariate analysis (Ou S-H 
et al. WCLC abstract#). HR for Korean ethnicity when compared to 
Caucasian ethnicity improved during 2002-2005 (HR = 0.795; P < 
.0001) compared to 1998-2001 (HR = 0.889; P = .0013).
Conclusion
Based on several clinicopathological studies, Asian NSCLC patients 
seem to have distinctive clinical features, which should be reflected 
in future clinical developmental processes. Further prospective stud-
ies with large numbers of patients from diverse ethnic backgrounds 
are required to define the exact roles of molecular markers to clarify 
the patients who may benefit from EGFR TKIs for NSCLC. In addi-
tion, the role of EGFR TKI should be tested in adjuvant, neoadjuvant 
settings, especially in patients with EGFR mutations.
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Emerging endoscopic staging techniques
Demmy, Todd L.
Roswell Park Cancer Institute, Buffalo, NY, USA
Despite its inconsistent use, accurate surgical thoracic lymph node 
staging is recommended in the management of lung cancer patients 
to direct therapy, demonstrate treatment response, and predict sur-
vival. One barrier to the use of mediastinoscopy or other traditional 
staging methods is PET imaging that has a negative predictive value 
that is acceptable to many clinicians. This better negative predictive 
value reduces the incentive for the patient to accept the additional 
low risk of complications or inconvenience; however, many patients 
are still understaged and some patients are overstaged by PET if 
surgical staging is not used as a confirmatory test.
Lymph nodes can be sampled for staging or removed in their entirely 
for potential therapeutic benefits. Less invasive methods are emerg-
ing for both LN sampling and lymphadenectomy. Ultrasound-guided 
FNA of lymph nodes by either the transbronchial or transesophageal 
routes offer better accuracy than “blind” FNA and, if positive, can 
avoid more costly or invasive staging operations. Furthermore, these 
procedures are useful if mediastinoscopy is impractical, dangerous 
(eg. Tracheostomy), has been performed already, or is planned for 
later (eg. after downstaging by neoadjuvant therapy). The route of 
these natural passages limits access to certain stations (See Table 1); 
however, the sizes of the targets and variations in airway/esophageal 
anatomy can make other areas accessible. In addition, combining 
these methods may increase the overall negative predictive value. 
Failure to recover malignant cells or other plausible diagnostic 
material from suspicious nodes leads to the need for larger biopsies 
afforded by procedures like mediastinoscopy. FNA guided by CT or 
transcutaneous ultrasound can also sample mediastinal or cervical 
nodes to provide staging information but generally this is in the con-
text of bulky lymphatic disease with evidence of advanced disease 
elsewhere.
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Table 1. Less Invasive Mediastinal Staging Options. 
  High  
Methodology Accessible Yield Sensitivity/  
 Stations  Stations NPV % Advantages Disadvantages
Traditional
Cervical  1, 2, 3, 4,  2, 4, 7 86/94.5  Rapid access to Incidence of RLN 
Mediastinoscopy 7, 10    multiple stations  injury or vascular 
     injury (low)
Mediastinotomy  5, 6 5, 6 55/96 AP window access Chest wall pain 
(Chamberlain)      extending hospital 
     stay 
VATS/Robotic 2, 3, 4, 5, 4, 5, 6, 7, 100/100 Lymph node Chest wall pain 
 6, 7, 8, 9,    access  approaching  
 10, 11   thoracotomy
Newer
VAMLA 2,4,7,8 2, 4, 7 100/98 Better lymph node  Incidence of RLN 
    clearance  injury or vascular  
     injury (low)
TEMLA 1, 2, 3a, 3p,  2, 3a, 4,   94/97 Highest lymph Incidence of RLN 
 4,  5, 6, 7, 8 5, 7, 8   clearance and level  injury or vascular 
    5,6 access  injury (low)
EUS 4L, 5, 7, 8, 9 7, 8, 9 69/88 No incision Limited biopsy size
EBUS 2, 4, 7, 10 2, 4, 7 69/88 No incision Limited biopsy size
EUS/EBUS  See above  93/97 See above. Multiple 
combined     disciplines may be  
    needed. 
Experimental
NOTES* — — — No incision Risk of  
     contamination  
     and bleeding
*Not performed clinically but theoretically same stations as VATS with EUS regions being higher yield. 
EUS = Esophageal Endoscopic Ultrasound, EBUS = Endobronchial Ultrasound, NOTES = Natural Orifice 
Transendoscopic Surgery; NPV = Negative predictive value, RLN = Recurrent laryngeal nerve,  
TEMLA = Transcervical Extended Mediastinal Lymphadenectomy, VAMLA = Video-assisted Mediastinal 
Lymphadenectomy, VATS = Video-Assist Thoracic Surgery
Mediastinoscopy instruments are enhanced by the addition of a video 
optics and expandible blades that provide better exposure to remove 
larger amounts of lymphatic tissue. With this enhanced scope, Video-
assisted Mediastinal Lymphadenectomy (VAMLA) is performed with 
a similar incision as mediastinoscopy and Transcervical Extended 
Mediastinal Lymphadenectomy (TEMLA) is performed through 
a larger “collar” incision similar to that used for thyroidectomy. 
In addition, TEMLA uses a sturdy sternal retractor to elevate the 
manubrium to increase exposure so that much of the case can be 
performed by direct viewing. The popularity of these “extended” 
approaches is growing and recurrence of disease in mediastinal 
lymph nodes has been unusual event for patients who have had suc-
cessful, negative initial TEMLA. Some key points are listed in Table 
1 as well. Another potential benefit to the use of more aggressive 
transcervical lymph node dissections is the reduction of dissection 
needed during subsequent thoracoscopic lobectomy operations (if 
performed before adhesions form). Thoracoscopy is an excellent 
alternative or supplement to other surgical staging methods. It may 
have a higher rate of successful recovery of lymphatic tissue from 
the level 5/6 stations than mediastinotomy and it is being used as an 
adjunct to endoscopic dissections like VAMLA.
Finally, quite a few preclinical experiments have been performed 
using Natural Orifice Transendoscopic Surgery (NOTES)with 
acceptable acute and chronic results. Using methods popular for 
esophageal submucosal resection, a mucosal flap and a submucosal 
tunnel are used to pass an upper flexible endoscope into the pleural 
spaces and central mediastinal structures to achieve lymph node 
biopsies. Afterward, endoscopic suture methods close the flap and 
most animals recover without serious complications or discernable 
esophageal scarring. While highly experimental, this methodology 
may provide options to access critical nodes in patients for whom the 
above methods are unsuccessful or potentially more hazardous.
In summary, all the current methodologies for mediastinal lymph 
node staging should be considered complementary and used in 
combination where needed to achieve assessment of all nodes at risk. 
While proficiency at any one technique can reduce the need for the 
others, none can be eliminated entirely as clinical options. 
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Proton beam therapy
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Proton beam therapy (PBT) for the treatment of cancer was first 
suggested by physicist Robert Wilson in 1946. It has actually been 
used in physics research facilities for nearly 50 years. Because of the 
restrictions on its availability in these facilities, only a few diseases 
have been treated, primarily uveal melanoma. The treatment of this 
disease can be completed in one week so the interference with nucle-
ar research was minimal. Safety and efficacy of PBT were demon-
strated in the more than 50,000 patients treated for uveal melanoma.
Copyright © 2009 by the International Association for the Study of Lung Cancer S275
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
The biologic effects of protons are quite similar to x-rays. However, 
proton beams distribute energy quite differently than x-rays. Whereas 
x-rays always have the maximum dose at or near the surface or 
entry region and then penetrate through the body to exit on the other 
side, no matter how low the energy of the beam, protons deliver the 
maximum energy where they come to stop in the body and there is 
no dose delivered beyond the high dose region. The depth of the high 
dose region can be determined by the energy of the proton beam 
delivered. It is thus possible to avoid normal tissues or limit the dose 
to them with PBT to a degree not possible with x-rays.
Loma Linda University Medical Center developed the first hospital 
based proton facility and several others have developed in recent 
years. In principle, this permits more clinically relevant beam con-
figurations with larger field sizes and higher energies than possible in 
physics research facilities.
The Proton Therapy Center at the University of Texas M. D. Ander-
son Cancer Center opened in May 2006. The vision for this facility is 
to expand the indications for proton therapy especially in the context 
of contemporary multidisciplinary patient care. Every patient treated 
at the PTC is enrolled on an IRB approved protocol for quality assur-
ance and reporting purposes.
Cancer of the lung was a major focus from the earliest days of proto-
col development at the M.D. Anderson PTC. Patients with non-small 
cell lung cancer (NSCLC) with large (T2) are treated with dose-
intensified fractionated PBT. Locally advanced (T3A/B) NSCLC is 
treated with concurrent chemotherapy and PBT. The rationale for 
this treatment is compelling as it should be possible to limit the dose 
to the esophagus and normal lung with PBT to a degree not possible 
with x-rays and thus avoid acute and subacute toxicity. It should also 
be possible to increase the radiation dose in the tumor while sparing 
normal tissues.
The first 64 patients treated with concurrent chemotherapy and 
proton therapy have been analyzed for toxicity. These patients have 
a minimum follow-up of 6 months and a median follow-up of 15 
months. Seven patients were less than stage III, 25 had stage IIIA 
tumors, 18 had stage IIIB, 5 had stage IV and 9 had tumors that had 
recurred after surgical resection. These patients received platinum-
based chemotherapy, usually carboplatin and paclitaxel administered 
weekly during radiation therapy. The median total dose of PBT was 
74 cobalt-gray equivalent (CGE).
Comparisons were made with historical patients with similar pre-
treatment characteristics: 83 patients treated with 3D conformal radi-
ation therapy (3D CRT) and chemotherapy between 2001 and 2003, 
and 67 patients treated with intensity modulated radiation therapy 
(IMRT) and concurrent chemotherapy between 2003 and 2005. The 
median total dose for these patients treated with x-rays was 63 Gy.
Thirteen patients (16%) treated with 3D CRT had severe (> grade 
3) esophagitis as did 30 (45%) of the IMRT patients. Four patients 
treated with PBT and concurrent chemotherapy had severe esophagi-
tis. Severe (> grade 3) treatment related pneumonitis (TRP) was seen 
in 25 (33%) of 3D CRT patients. IMRT was associated with severe 
TRP in 6 patients (9%). We have yet to observe a case of severe TRP 
among patients treated with proton beam therapy. 
The experience to date with PBT and concurrent chemotherapy for 
locally advanced unresectable NSCLC suggests that higher tumor 
doses are possible without an increase in normal tissue toxicity.
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Clinical implications of the new staging system: 
pulmonary and oncology perspective
Dubey, Sarita
University of California, San Francisco, San Francisco, CA, USA
The sixth edition of the AJCC TNM staging classification for 
non-small cell lung cancer is based on an analysis of 5,319 patients 
between the years 1975 and 1988 (1). Challenges of this classifica-
tion are that these are single institution data which are at present 
relatively old. Thus the IASLC (International Association for the 
Study of Lung Cancer) Staging Project was created.
Data on 100,869 patients treated for primary lung cancer from 
1990-2000 were submitted to the Cancer Research and Biostatistics 
office (CRAB) database. This database thus represented a wider 
international and temporal population. Survival was calculated by the 
Kaplan Meier method and prognostic groups were assessed by Cox 
regression analysis using SAS system. Running log-rank statistics 
were used to derive tumor size cut points. The results obtained were 
validated internally and externally. Internal validation was achieved 
by comparison of databases (consortium/surgical versus clinical 
trials versus registries) and geographic locations (North America 
versus Asia /Australia versus Europe). External validation was done 
by comparison to the Surveillance, Epidemiology and End Results 
(SEER) database (2). 
T stage analysis included size, descriptors (atelectasis, parietal pleura 
invasion, chest wall invasion, invasion of heart/mediastinum, etc), 
histologic cell type, and completeness of resection (R0,R1,R2) (3). In 
comparison of survival based on tumor size in the N0 M0 R0 popula-
tion, survival groups were differentiated at size cutpoints of 2, 3, 5, 
and 7cm. The 5 year survivals in these groups are as follows: 
pT1a <2cm  77%
pT1b 2-3cm  71% (p<0.001); 
pT2a 3-5cm  58%,
pT2b 5-7cm  49% 
pT2 >7cm  35% (p<0.0001)
When T descriptors were used the following 5 yearS results were 
obtained:
pT3  31%
pT4 additional nodule same lobe  28% (p=0.28 v pT3)
Other pT4  22% (p=0.0029 v pT4  
 additional nodule same lobe)  
M1 ipsilateral separate lobe nodule  22%
Pleural dissemination pT 4 11% 
Pleural dissemination cT4  2%
Based on these data, the recommendation is to make the following 
changes in T stage:
• Subclassify T1 into T1a (<2cm) and T1b (2-3cm), 
• Subclassify T2 into T2a (3-5cm) and T2b (5-7cm). 
• T2 >7cm as well as additional nodule in same lobe (prior T4) will 
be moved into T3
• Prior M1 due to ipsilateral separate lobe nodule will be reclassi-
fied into T4
• Prior T3 with pleural effusion will be known as M1
With regard to N classification, three survival groups were observed: 
i) single N1 (N1a), ii) multiple N1 (N1b) and single N2 (N2a) and 
iii) multiple N2 (N2B). However, the number of patients in these 
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three groups was insufficient to produce statistically significant 
results (4). Therefore, no recommendations to change the N classifi-
cation are being made at this time. It is interesting to note that there 
were some regional discrepancies in lymph node mapping. Surgical 
cases from Japan are mapped with the Naruke lymph node map, 
while those in North America are staged with the Mountain-Dresler 
modification of the American Thoracic Society map. The Naruke 
system classifies subcarinal lymph node along the inferior border of 
the main stem bronchus as a level 10 (hilar lymph node), while the 
same lymph node would be classified in the MD-ATS map as a level 
7 (mediastinal lymph node). A separate project is underway in an 
effort to reconciliate these discrepancies. 
The next classification group consists of the M descriptors (5). For 
this purpose 6596 cases in categories T4 and M1, with clinical and/
or pathologic stage were available. Clinical pleural dissemination 
(pleural effusion or nodules) cT4 in the absence of other metastatic 
disease had a 5 year S of 2% worse than that of other cT4 M0 15% 
(p<0.0001). The 5 year survival of contralateral lung nodule was 3% 
(p=0.0235 versus pleural dissemination) and that of M1 distant was 
1% (p<0.0001 versus contralateral nodule or pleural dissemination). 
Thus a worsening of survival is noted with progression of stage from 
T4 to pleural dissemination to contralateral lung nodule to distant 
metastases. Based on these observations, the recommendation is 
to remove pleural dissemination from T4 (IIIB) and reclassify it as 
M1a. Further, M1 will be subclassified as M1a (pleural dissemination 
and contralateral lung nodule) and M1b (distant metastases). 
The last classification group is that of the group stage (6). A recursive 
partitioning and amalgamation analysis generated a survival tree 
based on stage. An ordered list of groupings was created starting 
with HR 1.0 for T1aN0 and gradually increasing to HR16.44 for 
M1b. Based on survival analyses, the recommended group staging is 
described in table below.
IASLC Staging Project: Proposed Changes
AJCC 6th Edition 
Descriptor
Proposed 
T/M Stage Based on Proposed T/M Definitions
N0 N1 N2 N3
T1 (≤2cm) T1a IA IIA IIIA IIIB
T1 (2-3cm) T1b IA IIA IIIA IIIB
T2 (≤5cm) T2a IB IIA (Prior IIB) IIIA IIIB
T2 (5-7cm) T2b IIA (Prior IB) IIB IIIA IIIB
T2 (>7cm) T3 IIB (Prior IB) IIIA (Prior IIB) IIIA IIIB
T3 invasion T3 IIB IIIA IIIA IIIB
T4 (same lobe nodule) T3 IIB (Prior IIIB) IIIA (Prior IIIB) IIIA (Prior IIIB) IIIB
T4 (extension) T4 IIIA (Prior IIIB) IIIA (Prior IIIB) IIIB IIIB
M1 (ipsilateral lung) T4 IIIA (Prior IV) IIIA (Prior IV) IIIB (Prior IV) IIIB (Prior IV)
T4 (pleural 
dissemination) M1a IV (Prior IIIB) IV (Prior IIIB) IV (Prior IIIB) IV (Prior IIIB)
M1 (contralateral lung) M1a IV IV IV IV
M1 (distant) M1b IV IV IV IV
The implications of the new proposed staging classification are the 
following. First, and foremost, tumors will be placed in prognostic 
groups which are truly reflective of the associated survival. Mov-
ing malignant pleural effusion from stage IIIB to stage IV would 
correspond to the practice patterns of treatment with chemotherapy 
in this stage. In early disease, tumors that are 5-7cm T2bN0 which 
have so far been classified as IB will now move to IIA with obvious 
implication on the use of adjuvant chemotherapy. There remains the 
potential for changes in current practices in response to the staging 
reclassification. For example, reassignment of ipsilateral separate 
lobe nodule from M1 to T4 raises the issue of change in treatment 
paradigm, which this staging project was not designed to answer. An 
explanation for the prognostic difference between contralateral lung 
nodule (M1a) and distant metastases (M1b) is not apparent. It is quite 
possible that an additional nodule in the contralateral lung may rep-
resent a second primary and not true metastases thus contributing to 
a better survival in this database. In the absence of histological data 
on the additional nodule, it is impossible to confirm or refute this 
hypothesis. Thus the treatment decision of a patient with a solitary 
nodule in the contralateral lung is an individualized one. 
The limitations of the staging project were two fold. First, large 
areas of the world were not represented. Secondly, the classification 
is based on submitted data with the caveat that there are missing 
data fields from the dataset. Nevertheless, this is the largest staging 
project in lung cancer and achieves its objectives: to provide a con-
sistent and reproducible classification for lung cancer and to provide 
a prognostic tool to guide physicians.
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Thymic epithelial tumors
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The histological classification of thymoma has remained for many 
years an area of conflict. In recent years, the World Health Organi-
zation (WHO) presented a proposal for the classification of these 
tumors that has been widely adopted in many countries throughout 
the world. Two successive versions of this classification have been 
presented in recent years; however, controversy still exists regard-
ing its accuracy and usefulness in clinical practice. The histological 
classification of thymoma has been controversial for many years and 
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has been approached in the past in a variety of ways. A large number 
of classification schemes have been proposed over the years, none 
of which have managed to satisfy all the problems involved in the 
evaluation of these tumors. Historically, the most widely accepted 
histologic classification of thymoma in the United States was the 
“traditional” classification proposed by Bernatz et al from the Mayo 
Clinic. These authors divided thymomas histologically on the basis 
of their relative proportion of epithelial cells to lymphocytes as 
well as on the basis of the shape of the tumor cells. Their classifi-
cation recognized four basic types of thymoma: lymphocyte-rich, 
epithelial-rich, mixed (lymphoepithelial), and spindle cell thymoma. 
Several other classifications have also been introduced over the years 
by investigators from Japan, France, Germany and Italy, none of 
which were successful in attaining universal acceptance. Due to the 
difficulties in achieving a consensus regarding thymoma classifica-
tion, the World Health Organization (WHO) in 1999 assembled a 
panel of experts to devise a histopathologic classification of thymic 
epithelial neoplasms. The original proposal by the WHO was the first 
time an international panel of experts reached an agreement regard-
ing terminology and classification for these tumors. This original 
proposal has more recently been ratified with minor modifications in 
the latest WHO publication on the histologic classification of tumors 
of the lung, pleura, thymus and heart. A review of the current WHO 
classification of thymoma, with a discussion of some of the incon-
sistencies and limitations and the possible alternatives to the current 
approach for the histopathologic classification of these tumors will 
be presented. 
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Should the treatment of non-small cell 
lung cancer be histology-based?
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Lung cancer remains a formidable disease globally. In the United 
States, it is the number one cause of cancer death in both men and 
women, and overall, the mortality rate exceeds the number two, 
three, four, and five causes of cancer death combined. 
Modest improvement has been made in the treatment of stage IV 
non-small cell lung cancer. A platinum doublet compared to best 
supportive care improves median survival time by two months. The 
addition of bevacizumab in patients who are eligible for the ECOG 
4599 trial, improved survival by 2 months when combined with 
carboplatin + paclitaxel compared to carboplatin + paclitaxel alone. 
However, a similar study (AVAIL) performed in Europe using cis-
platin + gemcitabine with or without bevacizumab failed to show an 
improvement in survival. During the past decade, therapy with either 
pemetrexed, docetaxel, or erlotinib as second or third-line therapy 
has been demonstrated to have a slight improvement in survival. 
The patients most likely to benefit from Erlotinib clinically are never 
smokers, females, adenocarcinoma (especially BAC), and patients 
of Asian descent. In the non-inferiority study comparing docetaxel 
versus pemetrexed in second-line therapy which demonstrated 
equivalence, the pemetrexed arm was superior for adenocarcinoma, 
but not squamous carcinoma compared to docetaxel. Therefore, as 
far as therapy beyond a platinum-based combination chemotherapy 
regimen, there has been evidence for several years that treatment can 
be histology based. 
A recently completed study compared cisplatin 75 mg/M2 + peme-
trexed 500 mg/M2 versus the same cisplatin + gemcitabine 1,250 mg/
M2 (1). Over 1600 patients were randomized in this non-inferiority 
study and the primary objectives were met showing comparability in 
overall survival and progression free survival, but with less toxicity 
and more convenience with the pemetrexed arm since it is given rap-
idly IV every 3 weeks compared to the slightly longer infusion time 
with gemcitabine and the additional day 8 treatment. A pre-planned 
analysis was based upon histology and there was a statistically 
significant improvement in survival for non-squamous carcinoma 
favoring the pemetrexed arm (HR 0.81) with confidence intervals of 
0.7 to 0.94. By contrast, there was a suggestion of superiority with 
gemcitabine for the squamous cell carcinoma patient population. 
There is a molecular rationale for these results. Pemetrexate inhibits 
thymidylate synthase (TS). The baseline expression of TS gene is 
significantly higher in squamous cell carcinoma compared to adeno-
carcinoma. Preclinical data suggests reduced activity of pemetrexate 
with higher expressions of TS. 
It is felt by most investigators and regulatory agencies that histology 
can be used as an independent prognostic variable for personalizing 
first-line therapy. A platinum compound + pemetrexate (with or with-
out a molecular targeted agent such as bevacizumab) becomes a very 
attractive first-line therapy for patients with stage IV non-squamous 
cell carcinoma. Hopefully, more sophisticated molecular markers 
rather than 19th century technology with light microscopy can be 
used to better define an individualized therapy for patients with stage 
IV non-small cell lung cancer.
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The emergence of the cancer stem cell (CSC) hypothesis and initial 
studies identifying a subpopulation of cells within lung cancers with 
“stem cell like” (“cancer initiating”) properties indicates they are 
important new targets for early detection, prevention and therapeu-
tic targeting translational research [1]. The primary tenant of this 
hypothesis is that a subset of cells within the tumor behave like stem 
cells including using stem cell signaling pathways and that it is this 
subset of cells (rather than the remainder of the cells in the tumors – 
“progenitor cells” ) which initiate tumor formation and drive tumor 
progression and metastatic disease through aberrant self-renewal 
and differentiation [2, 3]. In essence, cancers have hijacked stem cell 
physiology to maintain tumor growth beyond normal developmen-
tal boundaries. In conjunction with their enhanced tumor initiating 
capacity, it is believed that CSCs have the capability of generating 
distant metastatic lesions and that CSCs are responsible for resis-
tance to radio and chemotherapy [4]. Another important aspect is that 
the microenvironment (referred to as “stem cell niche”) can play an 
important role in regulating not only normal but also cancer stem cell 
growth. Taken together these attributes highlight the CSC population 
and their “niche” as prime cellular components that drives tumor 
progression. The CSC model was first established in acute myeloid 
leukemia where only rare, undifferentiated cells isolated from patient 
samples were capable of reconstituting tumors in immunodeprived 
mice. Since then, the argument for cancer stem cells in solid tumors 
has been gaining significant traction, due in large part to the opti-
mization and implementation of stem cell purification techniques 
based on identifying stem cell markers. Here, the identification and 
characterization of lung CSCs has lagged due in large part to the 
relative lack of information on normal lung epithelial stem cells 
[5]. Major evidence for the existence of lung cancer stem cells was 
reported by Kim et al in 2005, where they observed the expansion of 
bronchoalveolar stem cells (BASCs) in lung adenocarcinomas driven 
by oncogenic K-ras in transgenic mouse models of lung cancer 
[6]. In human lung however, effective isolation and purification of 
BASCs has not been realized. Therefore, in lieu of well documented 
methods for purifying lung stem cells, the hunt for human lung 
cancer stem cells in multiple laboratories including our own has 
borrowed heavily from other tissue stem cell studies including the 
use of “side populations”, stem cell antigenic markers (like CD133), 
and aldehyde dehydrogenase activity [7-9]. The predominant method 
for isolating cancer stem cells from solid tumors has been the use of 
fluorescence activated cell sorting (FACS) to isolate sub-populations 
of tumor cells based on their expression of extracellular stem cell 
markers. CD133 (a.k.a Prominin-1) has been a successful marker 
in selecting for CSCs in breast, brain, and colon cancers [10-12]. 
Recently CD133+ cells isolated from patient lung tumors were 
observed to be highly tumorigenic, clonogenic and drug resistant, 
indicating the enrichment of human lung CSCs [13]. Also ALDH 
activity has been used to identify a stem like population in small cell 
lung cancers (SCLCs) and Non-small cell lung cancers (NSCLCs) 
and in the case of SCLCs ALDH activity appears to be regulated by a 
neuroendocrine transcription factor Achaete-scute complex homo-
logue 1 (ASCL1) [14]. In studies on lung cancer cell lines and patient 
tumor samples we discovered the limitations of cell surface markers 
like CD133 as a sole method for purifying potential rare lung CSCs. 
Often markers such as CD133 were not detected in samples, or their 
expression was not confined to a rare population. Furthermore, the 
fidelity of cell surface markers may be compromised by the method 
in which samples are prepared. Likewise use of the “side population” 
methodology identifying cells that possess the ability to efflux fluo-
rescent Hoechst dye by virtue of their enhanced multi-drug resistance 
protein(s) expression poses problems related to the cytotoxicity of 
Hoechst dye limiting this assay as a reliable enrichment method. By 
contrast, we have found that the approach based on enriching for 
cells with increased aldehyde dehydrogenase activity (ALDH) is a 
reproducible and easily applicable technique. Recent reports in breast 
and colon have revealed ALDH(+) tumor cells retain stem/progenitor 
properties [15, 16]. We have found ALDH(+) cells are found in 0.1-
20% of NSCLCs and in >50% of SCLCs. Important aspects to char-
acterize in putative cancer stem cells are their expression of stem cell 
pathway signaling programs, self renewal, and tumorigenic capacity. 
Using a panel of 40 stem cell pathway genes, renewal assays, and 
tumorigenicity tests of small numbers of lung cancer cells in NOD/
SCID mice we have found that ALDH(+) selected cells compared 
to the bulk population of lung tumor cells, are more tumorigenic, 
clonogenic, can undergo self-renewal and express elevated levels of 
stem cell signaling transcripts, all hallmarks of a CSC population. We 
have also studied the effect of small molecule inhibitor of telomerase 
on this subpopulation and the expression of ALDH1 by immunohis-
tochemistry in tissue microarrays as a marker of clinical behavior 
and survival. Study of this ALDH(+) subpopulations of cells for 
response to chemo and radiation therapy and targeting the stem cell 
pathways (such as the Notch pathway) in such subpopulations offers 
new approaches for personalizing therapy for lung cancer patients 
and development of new lung cancer targeted therapy.
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Improvements in early detection
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CT screening trials have demonstrated the ability of chest CT to 
detect lesions that are missed by chest radiographs. Available data 
suggests that a screening chest x-ray will miss 70-80% of cancers 
detected by screening CT. The National Cancer Institute pilot trial of 
screening randomized approximately 1600 participants each to CXR 
and spiral CT and detected 7 lung cancers in the CXR arm versus 
30 lung cancers in the CT arm. Other small randomized pilot studies 
have also detected more cancers in the CT screening arm. Data from 
CT screening trials suggest that 3 times more cases of lung cancer 
would be diagnosed as compared to control groups not undergoing 
CT screening. CT is clearly more sensitive than chest radiographs 
for detection of small lung cancers. Disease specific mortality is the 
most appropriate outcome measure in the evaluation of screening 
effectiveness. Effectiveness of screening is determined by the reduc-
tion of deaths from lung cancer in the screened group versus the 
control group in a randomized controlled trial [RCT]. Some authors 
suggest that improved survival in a non-randomized, observational 
study, demonstrates the effectiveness of screening. Screening will 
improve survival whether or not it leads to fewer people dying of 
lung cancer and is therefore an inadequate measure of effectiveness. 
The International Early Lung Cancer Action Program (I-ELCAP) 
investigators reported the results of a large collaborative observa-
tional non-randomized CT screening program. They screened over 
31,000 asymptomatic individuals at baseline and had repeat scans at 
7-18 months in 27,000 plus participants. They detected a total of 484 
lung cancers of which 412 (85%) had clinical stage I lung cancer. In 
other non-randomized CT screening studies such as the Mayo CT 
screening trial, 39 of 66 lung cancers (59%) were stage I. Novello et 
al (Italy) observed 73% stage I cancers and Diederich and associ-
ates (Germany) reported 54% stage I cancers. Similarly three small 
randomized CT screening trials also reported lower rates of stage I 
disease detection than in I-ELCAP Study. In the CT screening arm of 
LSS, Depiscan, and the DANTE trials there were 48%, 37.5%, and 
57% stage I lung cancers detected respectively. The I-ELCAP report 
calculated an 80% 10-year survival rate based on a median follow-
up of 40 months. While survival has been excellent in this and other 
nonrandomized screening trials, the trials all suffer from the three 
potential biases of screening; lead-time, length-time, and over diag-
nosis. The need for an RCT was highlighted by the results of pooled 
data from 3 CT non-randomized screening trials. In this report Bach 
et al, screened a cohort of over 3000 participants and they were com-
pared to a validated prediction model. CT screening found 3 times 
the number of expected cancers and resulted in 10 times the expected 
number of resections. Despite having a 94% actual 4-year survival 
for participants with clinical stage I cancers who underwent surgery, 
there was not an observed decrease in advanced stage lung cancers 
or lung cancer deaths as compared to the validated prediction model 
control group. To determine if CT screening can reduce lung cancer 
mortality, we will need the results of the two large RCT from North 
America (NLST) and Netherlands-Belgium-Denmark (NELSON). 
Noncalcified nodules (NCN) detected by CT screening have the 
potential to be early cancers. The difficulty is determining which 
NCN are malignant and which are benign. Initial reports from Japan 
and New York suggested a modest rate of NCN of 17-26%. However, 
these screening trials were conducted with single detector CT scan-
ners and used 1 cm thick CT slices. More recent trials with newer CT 
scanners have detected a much higher rate of NCN. The Fleischner 
Society has published guidelines for recommended follow-up and 
management of NCN detected incidentally at the time of a CT. The 
frequency of recommended follow-up is based on a low risk or high 
risk category determined by the individuals smoking history and 
presence or absence of a prior malignancy. 
Pastorino and colleagues enrolled 1035 individuals in a CT screen-
ing trial in Milan, Italy. After two yearly CT screening scans, they 
diagnosed 22 lung cancers but 6 additional patients (21%) underwent 
surgical biopsy for benign disease. In the first 3 years (1999-2002) 
of the Mayo CT screening trial, a total of 55 participants underwent 
a thoracic surgical procedure. Benign disease was present in 10 
patients (18%), and lung cancer was identified in 45 (82%). Investi-
gators from the University of Pittsburgh CT screening trial reported 
that 34% (28 of 82) thoracotomies or VATS procedures were per-
formed for benign disease in their CT screening trial. 
Overdiagnosis is defined as a lung cancer that will not lead to an 
individual’s death because of slow growth and age related competing 
risks of death. Some authors have opined that a doubling time of > 
400 days would be consistent with overdiagnosis. With a doubling 
time of 400 days, it would take a 3 mm lesion a total of 7.7 years 
to increase to the size of 15 mm lesion (diameter) based on the 
exponential growth mathematical model doubling time. In a Japanese 
CT screening trial by Hasegawa and colleagues at least 27 of 82 CT 
detected lung cancers had volume doubling time (VDT) of 400 days 
or more and would be potential cases of overdiagnoses. In the Mayo 
Clinic CT screening trial, thirteen lung cancers (27%) had VDT of 
greater than 400 days. Eleven of the 13 lung cancers with VDT over 
400 days were in females. 
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An issue of heightened concern is the risk of cancer associated with 
diagnostic x-rays. A report from the United Kingdom estimated that 
the attributed risk percentage of cancer due to diagnostic x-rays 
ranges from 0.6% to 1.8% of all cancers in the developed countries. 
It is estimated that 62 million CT scans were performed in the United 
States in 2006. Based on the estimate of CT use in the United States, 
and the estimates of diagnostic radiation risk from the United King-
dom study, current CT usage may account for as much as 1.5-2.0% 
of all cancers in the United States. 
Currently, there are two large randomized screening trials that are 
nearing completion. The National Lung Screening Trial (NLST) is a 
multicenter trial that randomized over 53,000 high risk participants 
(2002-2004) to low dose CT screening or chest radiograph. Results 
of the trial are anticipated in 2011. The NELSON trial (Netherlands, 
Belgium, and Denmark) was launched in 2003, one year after the 
NLST. High risk participants were randomized to low dose CT 
screening or no screening of any type. Almost 20,000 participants 
have been enrolled, and the study will have an 80% power to detect 
a mortality reduction of 25%. Mortality results are to be available in 
2015. Until these results are available, routine CT screening of high 
risk individuals is not recommended by major medical organizations. 
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Non/invasive mediastinal staging
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Mediastinal lymph nodes (LN) involvement is present in 26-38% of 
patients with non-small cell lung cancer at the time of diagnosis and 
it is often the most significant factor in determining surgical resect-
ability. Complete and accurate mediastinal staging of lung cancer is 
essential for determining prognosis and for guiding optimal treat-
ment strategies. Computed tomography (CT) and positron emission 
tomography (PET) are the most widely used non-invasive means for 
the mediastinal staging in lung cancer. Based on their reported speci-
ficities, CT and PET findings should be verified by cytohistological 
sampling. In recent decades, the technique of transbronchial needle 
aspiration (TBNA) has been developed, permitting the bronchosco-
pist to obtain cytohistological material from the hilar and mediastinal 
lymphnodes adjacent to the tracheobronchial wall 
The technique of TBNA has a great specificity, is safe and cost-
effective compared to surgical methods and can be performed during 
the initial diagnostic bronchoscopy. TBNA sensitivity is 76-78% and 
is influenced by several factors. Endobronchial ultrasound has been 
proposed as a means for improving TBNA sensitivity. Recently, a 
new type of bronchoscope with a built in convex ultrasound probe 
directly attached to the tip, has been developed to guide TBNA under 
real time imaging. The initial reports on this innovative technique 
reveal a sensitivity of 94.6-95.7%, which is superior to the reported 
sensitivity of surgical methods. However, echoendoscopic guided 
TBNA and traditional TBNA should be considered complementary 
techniques. Their integrated use could become the optimal staging 
strategy for lung cancer patients.
Session Y2: Better Targeting 
Friday, July 31
Y2.1 Better Targeting, Fri, Jul 31, 07:00 - 11:00
Gene expression profiling for diagnosis and therapy
Potti, Anil
Division of Medical Oncology, Institute for Genome Sciences and 
Policy, Duke University, Chapel Hill, NC, USA
Gene expression profiles reflect unique aspects of individual tumors 
and may provide precise prognostic information (Potti A, NEJM 
2006 and Bild A, Nature 2006). In this study of patients with non-
small cell lung carcinoma (NSCLC), we use gene expression patterns 
that reflect the deregulation of major oncogenic signaling pathways 
including Ras, PI3 kinase, Akt, Src, ß-catenin, E2F, and Myc path-
ways, and applied this ability to identify the state of critical regulato-
ry pathways to several hundred samples from patients with recurrent 
NSCLC and metastatic disease. These individuals, in particular, the 
patients with metastatic disease are likely to be resistant to standard 
chemotherapy pointing to the need for alternative therapeutic options 
(Potti, A Nature Medicine 2007). As one approach to this challenge, 
we have exploited gene expression data generated in patients with 
recurrence and metastasis. Briefly, the methods involved extracting 
RNA from NSCLC tumor samples and gene expression data gener-
ated using the Affymetrix arrays and then analyzed by hierarchical 
clustering to identify patterns of pathway deregulation. Results from 
binary regression analyses are expressed as a probability of pathway 
activation by tumor sample, and Kaplan-Meier survival analysis per-
formed stratifying by pathway status revealed that patient subgroups 
defined by distinct patterns of pathway deregulation exhibited statis-
tically significant differences in disease-free survival. Further, using 
cell proliferation assays, we have shown that the predicted deregula-
tion of Ras, Src and PI3 kinase pathways was directly proportional 
to the sensitivity of lung cancer cell lines to agents that specifically 
target these pathways, suggesting that an ability to profile the status 
of oncogenic pathways in a patient tumor sample provides a unique 
opportunity to better characterize the oncogenic process in patients 
with recurrent and advanced NSCLC, and could provide a mecha-
nism to guide the appropriate use of pathway specific inhibitors – a 
novel approach to targeted therapeutics. In addition, we describe a 
novel strategy to guide choices of cisplatin-based chemotherapy.
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Pharmacogenomic based strategies 
for diagnosis and therapy
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Although notable progress has been made in the treatment of non-
small-cell lung cancer (NSCLC) in recent years, this disease is still 
associated with a poor prognosis for most patients. Modern tech-
niques have facilitated the identification of specific genetic factors 
that may play a role in disease progression and patient response to 
therapy, prompting research efforts to identify the clinical predic-
tors of outcome for NSCLC. Recent evidence suggests that the 
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application of a pharmacogenomic approach has the potential to 
greatly improve survival in certain subpopulations of patients with 
NSCLC, which could profoundly influence the decision-making 
process used in evolving treatment strategies for this malignancy. 
Genomic signatures may improve the currently used prognostic clas-
sification based on clinical characteristics. Impressive responses are 
observed in patients with epidermal growth factor receptor (EGFR) 
tyrosine kinase mutations following treatment with gefitinib and erlo-
tinib; and methylation of the mitotic checkpoint gene 14-3-3sigma in 
circulating tumour serum DNA predicts response to cisplatin/gemcit-
abine therapy. Expression of markers of DNA repair, ERCC1, RRM1 
and BRCA1 are also determinants of response to cisplatin/gemcit-
abine, with low levels of mRNA predicting improved survival.
The future challenge of chemotherapy of NSCLC relies on the iden-
tification and validation of molecular markers that are predictive of 
drug sensitivity and are helpful in the selection of chemotherapeutic 
agents best suited to the individual patient. Other relevant issues will 
be the identification of the optimal drug sequence in combination 
regimens and the pharmacogenetics of clinically important toxici-
ties. In addition, due to the developments of novel technologies to 
discover genetic alterations involved in tumor progression, new 
therapeutic strategies are awaited. 
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Trial designs for biomarker assessment
Billingham, Lucinda
Cancer Research UK Clinical Trials Unit, Birmingham, UK
Background
There is widespread research in the field of oncology to discover bio-
markers that may be prognostic for disease outcome or predictive for 
response to treatment. The research pathway starts with the identifi-
cation of potential biomarkers through biological studies. Classifiers 
are then developed using one or more of the identified biomarkers. 
A classifier is a mathematical function that translates values from the 
biomarkers to a set of predictive categories; here positive and nega-
tive indicate good and poor outcome respectively. In some cases the 
classifier may be a multiple genomic signature where identification 
of the individual biomarkers is not necessary. Validation of any clas-
sifier requires testing it on an independent set of patients to assess 
predictive accuracy. Finally formal evaluation of the classifier in a 
randomised trial is required to provide reliable evidence of benefits 
when used in clinical practice. Various trial designs for this purpose 
have been proposed (Simon et al 2008, Sargent et al 2005) and 
choosing the most appropriate is crucial. The choice of design must 
consider two possible scenarios; one in which a developing treatment 
is targeted at a subgroup predicted to benefit and one in which an 
established treatment is withdrawn from a subgroup predicted not to 
benefit. This paper will illustrate the advantages and disadvantages of 
different designs.
Methods
Four designs are considered. The marker-based strategy design 
randomises patients to a marker-based treatment strategy or stan-
dard care. The targeted trial design randomises only those patients 
who are classifier positive to receive either experimental or control 
treatment and excludes classifier negative patients from the trial. 
The stratified trial design and the marker by treatment interaction 
design both stratify patients prior to randomisation according to a 
positive or negative classifier and then randomise to experimental 
or control treatment. The aim of the former is to compare treatments 
within each stratum whilst the latter tests for a treatment-classifier 
interaction. 
Results
The marker-based strategy design is optimal for assessing the effect 
of introducing the marker-based treatment into clinical practice. The 
design is appropriate for assessing the use of both prognostic and 
predictive markers in clinical practice but can be inefficient in terms 
of sample size when the prevalence of the classifier positives is low. 
Treatment for classifier negative patients will generally be standard 
care, thus a large proportion of the patients on the marker-based 
treatment arm will be receiving the same treatment as those on the 
standard care arm. This will therefore dilute the difference between 
the randomised arms, especially if the prevalence of classifier posi-
tives is low and thus large numbers of patients will be needed to 
test the hypothesis of a difference between the arms. Patients with 
immeasurable markers must be included to ensure intention-to-treat 
analysis.
The targeted trial design only enables the experimental treatment 
to be tested in the classifier positive patients i.e. in those that are 
expected to benefit. There may be some benefit in classifier nega-
tive patient but this design does not test this hypothesis thus denying 
such patients the opportunity of the treatment. However, this may be 
a valid approach if there is strong biological rationale. The resulting 
design is extremely efficient although all patients have to be screened 
for the biomarker as part of the design.
The stratified trial design allows two separate trials to be run concur-
rently. Each can be powered to test to effect of treatment in the spe-
cific classifier group or a statistical analysis plan can be devised such 
that treatment effect is assessed in classifier positive group first and 
the plan for the classifier negative group will be dependent on these 
results. This design will not test whether the treatment effect is dif-
ferent in the two groups. The marker by treatment interaction design 
is powered to test a single research hypothesis that the treatment 
effect in classifier positives is different to that for classifier negative 
patients. Large numbers of patients are generally required to test for 
an interaction, typically four times the number required for assessing 
a prognostic biomarker (Schmoor et al 2000).
Conclusions
Prognostic and predictive classifiers developed from biomarkers need 
to be tested in a prospective randomised setting before use in clinical 
practice. For any classifier to be practical the measurements need to 
be quick, cheap, reliable, reproducible and have high sensitivity and 
specificity. There is an escalation in the use of randomised trials to 
assess the value of biomarkers. Trialists need to be aware of the dif-
ferent designs and their advantages and disadvantages to ensure the 
research question is answered in the most effective and efficient way. 
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Mutations and copy number gains of KRAS gene correlate 
with biological activity of ras and clinical outcome in lung 
adenocarcinomas
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Background: Oncogenes can be activated by 1) mutations, 2) copy 
number gains (CNG), and/or 3) translocations. The KRAS gene is 
frequently mutated (~30% of all solid tumors including non-small-
cell lung cancers, NSCLC). Here we analyzed mutational status and 
copy number of KRAS gene to investigate the association between 
these genetic alterations and biological ras activity as well as clinical 
outcome in a large panel of NSCLC cell lines and tumors.
Methods: We analyzed KRAS mutational status (direct sequencing) 
and copy number (qPCR) in 86 NSCLC lines and 293 lung adeno-
carcinomas including Non-Asian and Asian populations. Cell lines 
with KRAS CNGs detected by qPCR were confirmed by array com-
parative genomic hybridization and fluorescence in situ hybridiza-
tion. Relative mRNA expression of KRAS gene was quantitated by 
qPCR assay. Ras GTPase activity was determined in 36 cell lines by 
ELISA. We also evaluated the effect of KRAS mutations and CNGs 
on clinical outcome. 
Results: We identified 30% and 21% KRAS mutations and 10% and 
7% KRAS CNGs in NSCLC lines and tumors, respectively. KRAS 
CNGs were significantly correlated with KRAS mutation (P = 0.04, 
table1). KRAS mutations or CNGs were significantly frequent in 
smokers (P = 0.0016 or 0.003, respectively) and Non-Asian popu-
lations (P = 0.008 or 0.003, respectively). The copy number was 
consistent with mRNA level of KRAS, indicating that the gene dos-
age of KRAS was preserved after transcription. While mutations (P 
<0.0001) and CNGs (P <0.0001) were associated with increased ras 
activity, cell lines with both alterations also had significantly higher 
activity than all others (P <0.0001, table1). While tumors with muta-
tions (P = 0.2) or CNGs (P = 0.1) alone had a trend to be associated 
with poor prognosis, tumors having both alterations had significantly 
worse prognosis (Stage I – lll, n = 240, P = 0.04).
Conclusions: KRAS mutations and/or CNGs are present in 25% 
of lung adenocarcinomas. Both mutations and copy number gains 
are associated with increased the ras GTPase activity. However, the 
combination of mutation and CNG, while present in a small subpopu-
lation, is associated with greatly increased activity and poor survival. 
PRS.2 Presidential Symposium, Mon Aug 3, 8:30 - 10:00
Evolution of gene expression and biological pathways 
involved at successive steps of lung squamous 
carcinogenesis
Mascaux, Céline1; Haibe-Kains, Benjamin1; Anthoine, Geraldine1; 
Rothe, Francoise1; Stamatopoulos, Basile1; Desmedt, Christine1; 
Laes, Jean-François2; Haller, Annick1; Ninane, Vincent3;  
Burny, Arsène4; Sculier, Jean-Paul1
1 Institut Jules Bordet, ULB, Brussels, Belgium; 2 DNA Vision, 
Gosselies, Belgium; 3 CHU Saint-Pierre, Brussels, Belgium; 4 Faculty 
of Agronomic Sciences (FUSAGX), Gembloux, Belgium
Introduction: The molecular biology study of lung carcinogenesis 
would help understanding this process and finding candidate targets 
for early diagnosis. Only 60 markers have been studied at successive 
steps of lung squamous carcinogenesis, mainly by immunohistochem-
istry. Using high throughput techniques allow studying, on a small 
amount of tissue, thousands of markers and their biological pathways 
during lung carcinogenesis. We aimed to characterize gene expression 
profiles across successive steps of lung squamous carcinogenesis and 
thereby to identify candidate targets for early detection of lung cancer.
Methods: A total of 122 human bronchial biopsies at all stages of 
lung squamous carcinogenesis obtained by fluorescence bronchos-
copy were analyzed by gene expression microarrays. Genes and 
biological pathways involved at each step were identified: 1) from 
normal bronchial of smokers (group A) to morphologically modi-
fied tissue at low risk of progression or low-grade lesions (group B), 
2) from group B to pre-invasive tissue at high risk of progression 
or high-grade lesions (group C1) and 3) from group C1 to invasive 
carcinoma (group C2).
Results: Analysis of the 3966, 2547 and 2267 differentially ex-
pressed genes (filter 1.5 fold change, false discovery rate 0.05) 
Peer Reviewed Abstracts
Copyright © 2009 by the International Association for the Study of Lung Cancer S283
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
between groups A and B, B and C1 and C1 and C2 showed the bio-
logical pathways involved at each step. Some modifications occurring 
at the first step were reversed at next steps, while those occurring at 
step 2 were almost never reversed, but maintained or amplified. All 
molecular and cellular functions, the main five ones being cell growth 
and proliferation, cell-to-cell signaling and interaction, cellular de-
velopment, cellular movement and cell death, were already moder-
ately affected at step 1, extremely modified at step 2 and finally only 
changed in a very small proportion at the last step from pre-invasive 
to invasive lesions. The genes of cancer pathways were mainly 
modified at the step 1 and less and less at steps 2 and then 3. The 
predominant phenomenon at step 2 was a large increase of immune 
response, reflecting, at least as a part, infiltration by T and B lympho-
cytes and by natural killer cells. Canonical pathways described in 
invasive lung carcinomas (Weiss, J Thor. Oncol. 2008) were also 
already activated in pre-invasive lesions, eg hepatic fibrosis/hepatic 
stellate cell activation, leukocyte extravasation signaling, comple-
ment system, acute phase responding. Finally, a list of 1090 genes, al-
tered from severe dysplasia and CIS, allowed segregating high-grade 
and invasive lesions from low-grade ones and normal tissue. 
Conclusions: These data show that the main biological pathways of 
cancer are affected from the first morphological modifications of bron-
chial epithelium during lung squamous carcinogenesis. The largest 
modifications occur in lesions at high risk of progression to invasive 
carcinoma and are not reversible, suggesting that these lesions possess 
a high tumorigenic potential and induce an intense immune response 
and that switching from pre-invasive to invasive stage would only 
require a modified expression level of a smaller number of genes. 
Moreover, a signature, segregating high grade and invasive lesions 
from lower grade ones, provides candidate targets to test for early 
detection of lung cancer.
PRS.3 Presidential Symposium, Mon Aug 3, 8:30 - 10:00
A phase III randomized  trial of surgery (S) alone, 
or preoperative (preop) paclitaxel/carboplatin (PC) 
chemotherapy followed by S, or S followed by adjuvant 
(adj) PC chemotherapy in early stage non-small cell lung 
cancer (NSCLC): NATCH follow-up data 
Felip, Enriqueta 1 Massuti, Bartomeu 2 Maestre, José Antonio 1 
Alonso, Guillermo 4 Paniagua, José Manuel R. 2 González-Larriba, 
José Luis  5  Camps, Carlos 6 Isla, Dolores 7 Overbeck, Tobias 9 
Costas, Emma 3  Sánchez, José Javier 10 Rosell, Rafael 3
1 Vall d’Hebron University Hospital, Barcelona, Spain; 2 Hospital 
General Universitario de Alicante, Alicante, Spain; 3 Hospital 
Germans Trias i Pujol, Barcelona, Spain; 4 Hospital Juan Canalejo, 
La Coruña, Spain; 5 Hospital Clínico San Carlos, Madrid, Spain;  
6 Hospital General de Valencia, Valencia, Spain; 7 Hospital Clínico 
Universitario Lozano Blesa, Zaragoza, Spain; 8 Hospital Arnau de 
Vilanova, Valencia, Spain; 9 Georg-August-Universität, Göttingen, 
Germany; 10 Universidad Autónoma de Madrid, Madrid, Spain
Background: This phase III trial was designed to address whether 
preop or adj PC improves disease-free survival (DFS) compared to S 
alone in early-stage NSCLC.
Methods: Chemotherapy-naïve pts with clinical stage IA (tumor size 
> 2 cm), IB, II and T3N1 were randomized to S alone, or 3 cycles of 
preop PC (P:200 mg/m2/ C AUC:6 on day 1 every 3wks) followed by 
S, or S followed by 3 cycles of adj PC at the same schedule. Eligible 
pts had to have a PS>70%, age > 18 yrs, and a tumor considered 
resectable. The study was designed to determine whether preop or 
adj PC resulted in a 15% absolute improvement in 5-year DSF (from 
30% to 45%). Planned sample size was 624 pts, 80% power, 2-sided 
test, 0.05 significance. Current median follow-up is 50 months (mo).
Results: Between April 2000 and May 2007, 624 pts were random-
ized, 212 in S alone arm, 201 in preop arm, and 211 in adj arm. 
Groups were well-balanced: median age 64 yrs; 87% male; 30% 
adenocarcinoma; 11% T1N0 (>2 cm), 64% T2N0, 21% II, 2% 
T3N1. In the preop arm 90% of pts received 3 chemotherapy cycles, 
response rate was 52% and progression 5%; 8.5% of pts had pCR. In 
the adj arm 61% of pts received 3 chemotherapy cycles. The 3-year 
DFS rate is 42% in the S alone arm, 45% in the adj arm, and 48% in 
the preop arm. The 5-year DFS is 34% in the S alone arm, 37% in the 
adj arm, and 38% in the preop arm. Five-year overall survival is 44% 
in S arm, 45.5% mo in adj arm, and 46.6% in preop arm.
Conclusions: More pts in the preop arm receive the planned chemo-
therapy treatment. 5-year DFS is not significantly different among 
arms.
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A randomized phase III study of gefitinib (IRESSATM) 
versus standard chemotherapy (gemcitabine plus cisplatin) 
as a first-line treatment for never-smokers with advanced 
or metastatic adenocarcinoma of the lung
Lee, Jin S.1; Park, Keunchil 3; Kim, Sang-We 2; Lee, Dae Ho 2;  
Kim, Heung Tae 1; Han, Ji-Youn1; Yun, Tak1; Ahn, Myung-Ju3;  
Ahn, Jin Seok3; Suh, Cheolwon2; Lee, Jung-Shin2; Han, Jong Hee1; 
Yu, Sun Young 1; Lee, Jae Won4; Jo, SookJung4
1 National Cancer Center Korea, Goyang, Korea; 2 Asan Medical 
Center, Seoul, Korea; 3 Samsung Medical Center, Seoul, Korea;  
4 Department of Statistics, Korea University., Seoul, Korea
Background: Gefitinib has shown high response rate and extended 
survival in never smoker lung adenocarcinoma patients. A random-
ized phase III trial was conducted to compare the efficacy of gefitinib 
as a first-line treatment with standard chemotherapy in this patient 
population. (ClinicalTrials.gov, NCT00455936)
Methods: From Oct 2005 to Nov 2007, a total of 313 never-smokers 
with chemonaïve stage IIIB/IV lung adenocarcinoma, ECOG PS 0-2 
and adequate organ functions were randomly assigned to receive 
either gefitinib (250 mg/p.o. daily) or GP chemotherapy (G: Gem-
citabine 1,250 mg/m2 on day1 & 8; P: Cisplatin 80 mg/m2 on day1 
every 3 weeks, up to 9 courses). Primary endpoint was overall sur-
vival (OS); secondary endpoints were objective response rate (ORR), 
progression-free survival (PFS), and toxicity. After initial disease 
progression, further treatment was at the discretion of the treating 
physicians.
Results: Of 309 patients who received actual treatment, 88.7% were 
female, 90.0% had stage IV disease, and 9.1% had PS2, with no 
difference between the two arms. The median(range) was 57(19-74) 
years. The gefitinib arm had a numerically higher ORR than the GP 
arm (85/159 [53.5%] vs. 63/150 [42.0%], p=0.0811) and significantly 
better PFS (HR=0.737 [95% CI, 0.580-0.938], p=0.0063 by log-rank 
test) with the median of 5.9 vs. 5.8 months (mo) while the curve 
crosses over around the median time. This crossing-over of the PFS 
curve was in part due to the difference in PFS by the EGFR muta-
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tion status. In the gefitinib arm with known EGFR mutation status, 
the PFS was significantly shorter in the mutation-negative subgroup 
(N=26) than the mutation-positive subgroup (N=27) with median of 
2.1 vs. 7.9 mo (HR=0.385 [95% CI, 0.208-0.711], p=0.0090) while 
there was no such difference in the GP arm (median 5.5 vs. 5.8 mo; 
HR=1.223 [95% CI, 0.650-2.305], p=0.2657) 
OS was similar between the two arms (HR=1.029 [95% CI, 0.756-
1.401], p=0.4278 by log-rank test). The median and 1-year survival 
rate were 20.3 mo and 73.7% for the gefitinib arm, and 23.1 mo and 
76.2% for the GP arm, respectively. Of note, 121 (80.7%) of the 150 
GP arm patients received EGFR-TKI during their disease course. 
Grade 3/4 toxicity was less common in the gefitinib arm (28.3% vs. 
67.3%, p<0.0001) while no unusual toxicity was noted in both arms. 
Conclusion: While gefitinib did not improve OS over the standard 
GP chemotherapy, unprecedented survival outcome along with high 
ORR and better toxicity profile suggests that gefitinib might be a 
reasonable first-line therapy for this group of never–smoker lung 
adenocarcinoma patients.
(This study was in part supported by AstraZeneca)
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Phase II study comparing paclitaxel-carboplatin alone 
with paclitaxel-carboplatin plus bevacizumab in previously 
untreated Japanese patients with advanced-stage non-
squamous non-small cell lung cancer (NSCLC)
Asahina, Hajime1; Kunitoh, Hideo1; Ichinose, Yukito2; Horai, 
Takeshi3; Nishiwaki, Yutaka4; Hida, Toyoaki5; Yamamoto, 
Nobuyuki6; Kawahara, Masaaki7; Saijo, Nagahiro4; Fukuoka, 
Masahiro8
1 National Cancer Center Hospital, Tokyo, Japan; 2 National Kyushu 
Cancer Center, Fukuoka, Jamaica; 3 Cancer Institute Hospital, 
Japanese Foundation for Cancer Research, Tokyo, Japan; 4 National 
Cancer Center Hospital East, Chiba, Japan; 5 Aichi Cancer Center 
Hospital, Nagoya, Japan; 6 Shizuoka Cancer Center, Naga-izumi, 
Japan; 7 National Hospital Organization Kinki-Chuo Chest Medical 
Center, Osaka, Japan; 8 Kinki University School of Medicine, Osaka, 
Japan
Background: Bevacizumab, a monoclonal antibody against vas-
cular endothelial growth factor, has shown to benefit patients with 
advanced-stage non-squamous NSCLC in two phase III trials (ECOG 
4599 and BO17704) [Sandler et al. NEJM 2006 and Manegold et al. 
ESMO2008]. 
This randomized, open-label, multicenter, phase II trial evaluated the 
efficacy and safety of bevacizumab in combination with paclitaxel 
and carboplatin as first-line treatment for Japanese patients with 
advanced or recurrent non-squamous NSCLC.
Methods: A total of 180 patients were planned to be randomly as-
signed to receive either bevacizumab(Bev) plus pacltaxel/ carboplatin 
(PC), P 200mg/m2 and C AUC=6 q3 wks for up to 6 cycles plus Bev 
continued to disease progression at 15mg/kg q3 wks, or PC alone, P 
200mg/m2 and C AUC=6 q3 wks for up to 6 cycles with observation 
till progression. The randomization ratio of PC+Bev: PC was 2:1. 
The primary endpoint was progression free survival (PFS); second-
ary endpoints included overall survival (OS), objective response rate 
(RR) and safety. This study was designed to observe a 20% reduction 
in the risk of a PFS event in the PC+Bev arm compared with PC. 
Eligibility criteria: histologically or cytologically documented previ-
ously untreated advanced or recurrent non-squamous NSCLC; ECOG 
PS 0-1; no brain metastases; no episode of hemoptysis; no cavitation 
in or invasion into major vessels by tumor. 
Results: One hundred eighty (180) patients were enrolled; 121 on 
PC+Bev and 59 on PC. Baseline patient demographics were well 
balanced between both treatment arms. Three patients of them 
were ineligible and not dosed at all. As of the data-cutoff date, 
Aug/14/2008, 120 PFS events (PD or death) were reported. With the 
addition of Bev, PFS and RR were significantly improved as assessed 
by investigators. OS data was not obtained due to short duration of 
follow up. Updated PFS results as assessed by the central review 
committee and OS data will be provided. Whereas one Grade 5 event 
of hemoptysis occurred in PC+Bev arm, no new safety signals for 
Bev were detected. PK profile was comparable to data obtained from 
US/EU studies.
Conclusions: In combination of Bev with PC, clinical benefits simi-
lar to those reported in ECOG 4599 were obtained from this Japanese 
trial with NSCLC. Safety of Bev was within a range already reported. 
This study confirms the efficacy and safety of Bev in Japanese pa-
tients with NSCLC. 
 Treatment duration CP + Bev (N=119) CP alone (N=58)
 CP (median no. of cycles) 6.0 4.5
 Bev (median no. of cycles) 7.0 -
 Efficacy (ITT population) CP + Bev (N=121) CP alone (N=59)
 PFS Hazard ratio (95%CI) 0.55 (0.37,0.82) 
 Median PFS (months)  6.6 5.4
 Response rate (%) 56 34
 Safety CP + Bev (N=119) CP alone (N=58)
 Grade ≥3 AEs (%) 97.5 93.1
 Grade ≥3 Febrile Neutropenia (patients) 10 4
 Grade ≥3 hypertension(patients) 11 0
 Grade ≥3 hemoptysis (patients) 1 (Grade 5) 0
A1.2 Improving on Platinum based Chemotherapy, Sat Aug 1, 14:30 - 16:00
Final report of a randomized phase II study of docetaxel/
oxaliplatin vs docetaxel in previously treated non-small cell 
lung cancer (NSCLC) patients: a novel design, Alpe-Adria 
Thoracic Oncology Multidisciplinary group study (ATOM 
019)
Grossi, Francesco3; Rossetto, Ciro2; Follador, Alessandro2; Sibau, 
Angela2; Brianti, Annalisa3; Defferrari, Carlotta3; Aita, Marianna2; 
Gaiardo, Marica2; Pronzato, Paolo3; Fasola, Gianpiero2; Ceschia, 
Tino2; Belvedere, Ornella1, 2
1 Leeds Institute of Molecular Medicine, Leeds, UK; 2 S. Maria 
Misericordia University Hospital, Udine, Italy; 3 National Institute 
for Cancer Research, Genoa, Italy
Background: No combination regimen has proven superior to 
single agent chemotherapy as second-line treatment for NSCLC. The 
absence of cross-resistance with cisplatin/carboplatin, the favorable 
toxicity profile, along with both pre-clinical and clinical evidence of 
activity in NSCLC, make oxaliplatin a good candidate for combina-
tion with docetaxel as second-line chemotherapy in this setting. In 
this study we evaluated the activity of docetaxel plus oxaliplatin in 
second-line NSCLC using a novel phase II trial design.
Methods: This multicenter, non-comparative randomized phase 
II trial evaluated the activity of docetaxel (75 mg/m2 day 1) plus 
oxaliplatin (70 mg/m2 day 2) every 3 weeks in previously treated 
NSCLC patients; the comparator arm was single agent docetaxel (75 
mg/m2 day 1 every 3 weeks). This one-stage, three-outcome phase II 
trial design (Sargent et al, Control Clin Trials 2001) had 21 evaluable 
patients per arm. Main eligibility criteria included: stage wIIIB or IV, 
histologically confirmed, NSCLC that had progressed during or after 
platinum-based chemotherapy; age ≥ 18 and < 70 years; ECOG PS 
0-1; peripheral neuropathy < grade 2. Primary endpoint was response 
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rate according to RECIST; secondary endpoints were toxicity, time to 
progression (TTP), and 1-year survival.
Results: Fifty patients were enrolled. Patients characteristics: males/
females, 76/24%; median age 62 yrs (range 43-69); ECOG PS 0/1, 
36/64%; adenocarcinoma/other, 36/64%. With 48 patients evaluable, 
partial response was seen in 20% and 8% of patients, stable disease 
in 52% and 32% and progressive disease in 24% and 56% in the do-
cetaxel/oxaliplatin and docetaxel arm, respectively. One patient was 
inevaluable for response due to early death (docetaxel arm). Main 
grade 3-4 toxicities were: neutropenia 56% and 64%; febrile neutro-
penia 4% and 8%; diarrhea 12% and 4% for docetaxel/oxaliplatin and 
docetaxel, respectively. Median TTP was 4.9 and 1.8 months, median 
survival was 10.9 and 6.9 months, and 1-year survival was 41% and 
16% for docetaxel/oxaliplatin and docetaxel, respectively.
Conclusions: This study shows how novel phase II trial designs 
enrolling a limited number of patients may help identify promising 
regimens for subsequent study in large phase III trials. The level 
of activity for the combination docetaxel/oxaliplatin we observed 
satisfied the pre-defined study primary endpoint and warrants further 
evaluation of this combination as second-line therapy for NSCLC.
The protocol of this study was developed at the 6th FECS/AACR/
ASCO Workshop on Methods in Clinical Cancer Research held in 
Flims, Switzerland, in 2004, with the contribution of Professor Marc 
Buyse and Professor Chris Twelves.
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Gemcitabine/vinorelbine followed by paclitaxel versus 
cisplatin/gemcitabine/vinorelbine versus cisplatin/
paclitaxel in advanced non-small cell lung cancer: final 
results of the AASLC-AIO-3 phase III trial
Pirker, Robert1; Fischer, Berthold6; Eberhardt, Wilfried2; Niederle, 
Norbert 3; Mohn-Staudner, Andrea4; Ewert, Ralf8; Benisch, Peter5; 
Pfeifer, Wolfgang7; Gauler, Thomas2; Griesinger, Frank9; Minar, 
Wilma1; Buhl, Roland6
1 Department of Medicine I, Medical University of Vienna, Vienna, 
Austria; 2 Universitätsklinikum, West German Cancer Center, 
Essen, Germany; 3 Klinikum Leverkusen, Leverkusen, Germany; 4 
Sozialmedizinisches Zentrum Baumgartner Höhe, Vienna, Austria; 
5 Hanusch-Krankenhaus, Vienna, Austria; 6 Universitätsmedizin der 
Johannes Gutenberg-Universität Mainz, Mainz, Germany; 7 AKH 
Linz, Linz, Austria; 8 Universitätsklinikum Greifswald, Greifswald, 
Germany; 9 Pius-Hospital, Oldenburg, Germany
Background: Platinum-based doublets are considered as standard 
treatment in patients with advanced non-small-cell lung cancer 
(NSCLC). Triplets might result in improved outcome at the expense 
of increased toxicity, while non-platinum-based chemotherapy might 
result in inferior outcome but better tolerance. The AASCL-AIO-3 
phase III trial compared a cisplatin-based doublet with a cisplatin-
based triplet and a non-platinum-based combination in patients with 
advanced NSCLC. 
Methods: Patients with newly diagnosed stage IV or relapsed 
NSCLC and adequate performance status were randomized into one 
of 3 arms. Patients in arm A received 3-week cycles of gemcitabine 
1000 mg/m2 daily on days 1 and 8 and vinorelbine 25 mg/m2 daily 
on days 1 and 8 up to 4 cycles followed by paclitaxel 200 mg/m2 on 
day 1 of 3-week cycles up to 4 cycles. Treatment of arm B consisted 
of 3-week cycles with cisplatin 40 mg/m2 daily on days 1 and 8, gem-
citabine 1000 mg/m2 daily on days 1 and 8, and vinorelbine 20 mg/
m2 daily on days 1 and 8. Patients in arm C received 3-week cycles 
with paclitaxel 200 mg/m2 on day 1 followed by cisplatin 80 mg/m2 
on day 2. Up to 6 cycles were given in arms B and C. Re-staging by 
adequate imaging techniques was performed every other cycle. The 
primary endpoint was overall survival. Secondary endpoints included 
response rates, quality of life and safety.
Results: Between January 2000 and April 2005, 444 patients from 
17 centers in Austria and Germany were randomized into arm A 
(n=147), arm B (n=148) or arm C (n=149). The patients had the fol-
lowing baseline characteristics: median age 60 (range 31-79); 68% 
males; 85% de novo NSCLC, 15% relapsed NSCLC. The baseline 
characteristics were well balanced between the 3 arms. Overall 
survival was not significantly different between the 3 treatment arms. 
Median overall survival times were 8.5, 8.2 and 8.3 months and one-
year overall survival rates were 34%, 44% and 35% for arm A, arm B 
and arm C, respectively. In patients who received at least 2 cycles of 
chemotherapy, median overall survival times were 9.1, 10.0 and 9.2 
months, respectively. Median progression-free survival times were 
3.6, 4.6 and 4.6 months for arm A, arm B and arm C, respectively. 
In patients evaluable for response to chemotherapy (n=397), the 
response rates were 27%, 39% and 40% in arm A, arm B and arm C, 
respectively. Toxicity was as expected and acceptable in all 3 arms. 
Conclusion: This phase III trial did not demonstrate significant sur-
vival differences between a cisplatin-based doublet, a cisplatin-based 
triplet and a non-platinum-based protocol in patients with advanced 
NSCLC. However, the statistical power of the trial did not allow 
detecting small differences in survival. Progression-free survival and 
response rates favored the cisplatin-based protocols over the non-
platinum-based protocol. Thus platinum-based doublets remain the 
standard for most patients, while platinum-based triplets or non-plat-
inum-based protocols might be treatment options for selected patients 
with advanced NSCLC. 
(Supported by grants from Bristol-Myers Squibb, Eli Lilly, 
Boehringer Ingelheim, Pierre Fabre and Asta Medica)
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The influence of sex and histology on outcomes in non-
small cell lung cancer: a pooled analysis of 5 randomized 
trials
Wheatley-Price, Paul1; Blackhall, Fiona2; Lee, Siow-Ming3; Ma, 
Clement1; Ashcroft, Linda2; Jitlal, Mark3; Qian, Wendi4; Hackshaw, 
Allan3; Rudd, Robin5; Booton, Richard2; Danson, Sarah6; Lorigan, 
Paul2; Thatcher, Nick2; Shepherd, Frances A.1
1 Princess Margaret Hospital, Toronto, ON, Canada; 2 Christie 
Hospital, Manchester, UK; 3 University College Hospital, London, 
UK; 4 Medical Research Council Clinical Trials Unit, London, UK; 
5 St Bartholomew's Hospital, London, UK; 6 Weston Park Hospital, 
Sheffield, UK
Background: Female sex is a modest positive prognostic factor in 
non-small cell lung cancer (NSCLC), in both early and late-stage 
disease. Some surgical series have suggested this benefit is limited to 
adenocarcinoma patients. We performed a retrospective analysis to 
investigate the role of sex and histology on efficacy, toxicity and dose 
delivery.
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Methods: Individual patient data from five randomized phase III 
NSCLC trials, investigating platinum-based first-line chemotherapy 
regimens, were pooled in a single database and analyzed by patient 
sex. Primary outcomes were tumor response rate, overall survival 
(OS), hematological and non-hematological toxicity and dose deliv-
ery. To allow for the possibility that baseline co-morbidities might 
explain a difference in survival, we also report lung cancer specific 
survival (LCSS). A secondary analysis further examined survival by 
sex in histological subgroups. 
Results: Of 2349 patients included, 793 were women (34%). Base-
line demographics are shown in the Table. Overall, women had a 
higher response rate to chemotherapy (44% versus 39%, p=0.007), 
and longer survival than men (median OS 9.6 versus 8.6 months, 
one-year survival 41% versus 35%, HR 0.86 [95% CI 0.78-0.95], 
p=0.002). The HR and 95% CI for LCSS were identical to that of 
OS. The difference in OS between sexes remained significant after 
adjusting for age, stage, performance status and histology (HR 0.83, 
95% CI 0.74 – 0.92, p=0.0005). Upon further data examination, the 
longer survival in women was only seen in patients with adenocarcin-
oma histology (test for interaction p=0.006, see Figure).
There were no differences in any hematological toxicity, or rates of 
blood or platelet transfusions, between sexes. Women experienced 
more grade 3-4 nausea and vomiting than men (10% versus 5%, 
p=0.0002), and more dose delays (39% versus 32%, p=0.02) and dose 
reductions (32% versus 23%, p<0.0001. 
Conclusions: The positive prognostic effect among females is con-
firmed in this large case series of patients receiving modern platinum-
based chemotherapy, but we demonstrate that this benefit is confined 
to those with adenocarcinoma histology.
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Cetuximab in combination with either sequential 
gemcitabine followed by docetaxel or with a combination 
of carboplatin and gemcitabine in chemonaïve patients 
with advanced non-small cell lung cancer (NSCLC): 
Preliminary toxicity profile from the ongoing phase II/III 
GemTax IV trial
Eschbach, Corinna1; Cicenas, Saulius2; Kollmeier, Jens 9; Kortsik, 
Cornelius3; Schumann, Christian4; Serke, Monika 5; Steins, Martin6; 
Manegold, Christian 7; Pilz, Lothar R.8
1 ASKLEPIOS KLINIK Harburg, Hamburg, Germany; 2 University 
Medical Center, Vilinius, Lithuania; 3 Sankt Hildegardis Hospital, 
Mainz, Germany; 4 University Medical Center, Ulm, Germany; 5 
Lung Clinic Hemer, Hemer, Germany; 6 Thoraxklinik, Heidelberg, 
Germany; 7 University Medical Center, Mannheim, Germany; 8 
German Cancer Research Center, Heidelberg, Germany; 9 HELIOS 
Klinikum Emil von Behring, Berlin, Germany
Background: The epidermal growth factor receptor (EGFR) target-
ing antibody cetuximab is undergoing broad clinical investigation in 
NSCLC in combination with different chemotherapies. Our random-
ized trial assesses the safety of cetuximab in combination with two 
different chemotherapy regimens in patients with advanced NSCLC. 
Phase II results will be reported here. 
Methods: Patients with histologically confirmed stage IIIB or IV 
NSCLC, WHO performance status (PS) 0-2, and no prior chemother-
apy received cetuximab with 400 mg/m² as starting dose followed 
by 250 mg/m² weekly either combined with gemcitabine 1000 mg/
m² at days 1 and 8 for 2 cycles (3qw) followed by docetaxel 75 mg/
m² at day 1 for 2 cycles (q3w) (arm A) or carboplatin AUC5 at day 
1 combined with gemcitabine 1200 mg/m² at days 1 + 8 for 4 cycles 
(q3w) (arm B). Maintenance cetuximab therapy was administered 
weekly (also reported as 3 weekly cycle) until disease progression or 
unacceptable toxicity.
Results: 269 patients evaluable for safety received 2207 infusions 
of cetuximab combined with chemotherapy and 1486 infusions of 
maintenance cetuximab therapy. Patient characteristics were balanced 
between treatment arms with 73% male patients of median age 64 
(range 36-80), 37% of WHO PS 0 and 56% of PS 1, 84% had tumor 
stage IV, and histology was 52% adeno-, 30% squamous cell, and 
9% large cell carcinoma. 47 patients in arm A received 1-26 cycles 
(median 3) of maintenance cetuximab and 8 patients received more 
than 10 cycles; 60 patients in arm B received 1-22 cycles (median 
3) and 7 patients more than 10 cycles. Grade 1 or 2 skin reactions 
related to study medication occurred in 82% of patients in arm A and 
76% in arm B. In general, hematological toxicity was more common 
in patients receiving carboplatin; leukopenia and neutropenia in more 
than 20%; non-hematological events such as pneumonia and fever 
occurred in about 10% of patients. In arm B, thrombopenia without 
intervention developed in 40% of patients and allergic reactions in 
7% considering all measurement points. Toxicities requiring clinical 
intervention are shown below. Updated results will be presented for 
more than 300 patients.
Conclusions: Cetuximab does not increase chemotherapy toxicity in 
the induction phase and is well tolerated in the maintenance phase. 
Notably, about 80% of patients developed skin rash (grade 3/4 in 
about 8% of patients).
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TABLE: Toxicities requiring clinical intervention. 
Arm A Arm A Arm B Maintenance
Cycles
Cetuximab 
plus 
gemcitabine 
n=134
Cetuximab 
plus do-
cetaxel (2nd 
part of the 
sequence) 
n=80
Cetuximab 
plus 
gemcitabin/ 
carboplatin 
n=135
Cetuximab main-
tenance n=107
Total number of cycles 239 141 426 537
Median number of cycles 2 2 4 3
Grade 3/4 anemia + ≥ 1 
blood transfusion during 
treatment cycle (% cycles)
<1 1 3 -
Grade 3/4 thrombocyto-
penia + ≥ 1 platelet 
transfusion during treat-
ment cycle (% cycles)
<1 - 6 -
Grade 3/4 febrile neu-
tropenia + IV antibiotics 
during treatment cycle (% 
cycles)
<1 4 1 -
Skin reaction (any/severe) 
(% cycles) 55/5 31/5 37/5 9/<1
A1.6 Improving on Platinum based Chemotherapy, Sat Aug 1, 14:30 - 16:00
Quality of life (QOL) outcomes with cediranib/placebo in 
combination with carboplatin/paclitaxel (CP) in advanced 
non-small cell lung cancer (ANSCLC): results from NCIC 
CTG BR.24
Lee, Christopher W.1; Ding, Keyue2; Le Maitre, Aurelie2; Han, 
Lei2; Laurie, Scott A.3; Goss, Glen3; Shepherd, Frances A.4; Arnold, 
Andrew5; Frymire, Eliot2; Seymour, Lesley2
1 BC Cancer Agency, Surrey, British Columbia, Canada; 2 NCIC 
Clinical Trials Group, Kingston, ON, Canada; 3 The Ottawa Hospital 
Regional Cancer Centre, Ottawa, ON, Canada; 4 University Health 
Network/Princess Margaret Hospital, Toronto, ON, Canada; 5 
Juravinski Cancer Centre, Hamilton, ON, Canada
Background: NCIC CTG BR.24 was a randomized placebo-con-
trolled trial of cediranib with CP in ANSCLC. Objective response 
(OR) and progression-free survival (PFS) were improved with ce-
diranib. Patients were enrolled to either 45mg or 30mg of cediranib/
placebo. The addition of cediranib to CP resulted in incremental dose-
related gastrointestinal and hematologic toxicity, hand foot syndrome 
(HFS), hypothyroidism and hypertension.
Methods: QOL was assessed at baseline, prior to each cycle of 
treatment, then every 12 weeks until disease progression (PD) using 
the EORTC QLQ-C30 and QLQ-LC13, plus two questions on HFS 
and headache. Dyspnea is included in both questionnaires. Standard 
published NCIC CTG analyses were conducted, including change 
in mean scores from baseline and QOL response, where improved/
worsened requires ≥ 10-point change from baseline.
Results: A total of 296 patients were randomized (251 to 30mg). 
On treatment QOL compliance was high (89.1%), but lower when 
off treatment prior to PD (30%). At baseline, compared to placebo, 
cediranib patients had significantly worse scores for dyspnea (p 0.08), 
sore mouth (p 0.007), and trouble swallowing (p 0.04). On treatment, 
there was no evidence of a significant difference between the two 
treatment arms in the 5 functional domains (physical, role, emo-
tional, cognitive, social) or in global health status (GHS). Changes in 
symptom domains mirrored the clinical findings for both efficacy and 
adverse events (Table).
Conclusions: The QOL analysis demonstrates the impact of expected 
adverse effects, although there are improvements in disease-related 
symptoms with cediranib. The addition of cediranib to CP had no 
significant impact on functional and GHS scores. This combination 
of agents is undergoing further evaluation in NCIC CTG BR.29 using 
cediranib 20mg.
Table: QOL Response - Significant Findings in Symptom Domains
 Cediranib Placebo
  Better Stable Worse Better Stable Worse
 Dyspnea 50% 20% 30% 34% 31% 34%
 Dyspnea LC13 58% 7% 35% 41% 16% 43%
 Diarrhea 16% 9% 75% 13% 61% 27%
 Sore mouth 13% 28% 58% 5% 67% 28%
 Headache 24% 26% 50% 26% 46% 28%
 HFS 4% 37% 59% 11% 57% 32%
A1.7 Improving on Platinum based Chemotherapy, Sat Aug 1, 14:30 - 16:00
Known brain metastases: a valid exclusion criterion in 
non-small cell lung cancer (NSCLC) clinical trials? An 
audit of the eligibility criteria in NSCLC trials, and an 
evaluation of treatment delivery, toxicity and survival 
experienced by patients with brain metastases in NCIC 
clinical trial group (CTG) trials
Bradbury, Penelope A.1; Twumasi-Ankrah, Philip1; Ding, Keyue1; 
Shepherd, Frances A.2; Goss, Glenwood3; Leighl, Natasha B.2; 
Laurie, Scott3; Seymour, Lesley1
1 NCIC Clinical Trials Group, Kingston, ON, Canada; 2 Princess 
Margaret Hospital/ University of Toronto, Toronto, ON, Canada; 3 
The Ottawa Hospital/ University of Ottawa, Ottawa, ON, Canada
Background: A prior history of brain metastases is a common exclu-
sion criterion in NSCLC clinical trials, due to concerns regarding 
the perceived poor prognosis, potential increased toxicity and lack 
of benefit from systemic therapy for this patient group. We evaluated 
brain metastases as an exclusion criterion in NSCLC trials, and inves-
tigated the treatment delivery, toxicity and survival experienced by 
patients with brain metastases, compared to stage IV patients without 
brain metastases recruited to NCIC CTG clinical trials.
Methods: 1. Data on the eligibility criteria for patients with CNS 
metastases in stage IV NSCLC systemic therapy clinical trials listed 
on www.clinicaltrials.gov was reviewed. 2. A pooled analysis of 
BR.18 (carboplatin/ paclitaxel ± BMS275291; BR.24 carboplatin/ pa-
clitaxel ± cediranib; BR.21 (erlotinib versus placebo) was performed 
to evaluate the toxicity, treatment delivery, progression free survival 
(PFS) and overall survival (OS) of patients with brain metastases 
compared with stage IV patients without known brain metastases 
recruited to NCIC CTG clinical trials. Each study allowed patients 
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with brain metastases to be enrolled if neurologically stable, and off 
corticosteroids (BR.18 and BR.24), on a stable dose of corticosteroids 
(BR.21) and if treated (BR.24). 
Results: 1.Of the 151 trials eligible for review, 121 trials included 
CNS metastases within the eligibility criteria. Of these, patients 
with a prior history of brain metastases were excluded in 44 trials 
(36%), and 11 of 18 (61%) active phase III clinical trials. 2. In the 
pooled analysis, 131 patients were recruited with a prior history of 
brain metastases constituting 10% of the stage IV patients enrolled to 
BR18, 21 and 24 combined. The median number of cycles of treat-
ment was similar: brain metastases cohort median no. of cycles= 4 
[range 1-28]); no brain metastases cohort median =4 [range 1-33]). 
Grade 3+ toxicities were similar across both groups (brain metastases 
vs. no brain metastases: fatigue 24% vs. 28%; nausea 4% vs. 8%; 
vomiting 10% vs. 12% respectively). There were no occurrences of 
CNS haemorrhage in the brain metastases cohort. Toxicity accounted 
for 9% of patients coming off study in the brain metastases group 
compared with 11% in the no brain metastases group. 61% of patients 
with prior history of brain metastases came of study for progres-
sive disease compared with 58% for the no brain metastases cohort. 
In multivariate analysis, there was no difference in the PFS or OS 
between the brain metastases and no brain metastases cohorts: PFS: 
AHR 1.02(0.84-1.24), p=0.81; OS: AHR 1.11 (0.90-1.37), p=0.31. 
Conclusion: A significant proportion of patients with a prior history 
of brain metastases are excluded from NSCLC clinical trials. In a 
pooled analysis, patients with a prior history of brain metastases com-
pleted similar number of cycles of therapy without evidence of excess 
toxicity. No PFS and OS difference was detected between the groups. 
Neurologically stable patients with known brain metastases should 
not be excluded from NSCLC clinical trials. 
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Efficacy and safety of erlotinib as first-line maintenance 
in NSCLC following non-progression with chemotherapy: 
results from the phase III SATURN study
Cappuzzo, Federico1; Coudert, Bruno P.2; Wierzbicki, Rafal3; Wu, 
Yi-Long5; Gonzalez, Emilio E.7; Davidson, Neville6; Giaccone, 
Giuseppe 4; Chang, Jian H.8; Klingelschmitt, Gaëlle9; Ciuleanu, 
Tudor E.10; on behalf of the SATURN investigators11
1 Istituto Clinico Humanitas IRCCS, Rozzano, Italy; 2 Centre GF 
Leclerc, Dijon, France; 3 Durham Regional Cancer Center, Oshawa, 
Canada; 4 National Cancer Institute, Bethesda, USA; 5 Guangdong 
General Hospital, Guangzhou, China; 6 Broomfield Hospital, 
Chelmsford, UK; 7 Hospital Universitario Central de Asturias, 
Oviedo, Spain; 8 Tumor Hospital of Fudan University, Shanghai, 
China; 9 F-Hoffmann – La Roche Ltd, Basel, Switzerland; 10 Institure 
of Oncology, Cluj-Napoca, Romania; 11 UK
Background: The epidermal growth factor receptor (EGFR) 
tyrosine-kinase inhibitor erlotinib (Tarceva®) is an effective and well-
tolerated second-line therapy for advanced non-small-cell lung cancer 
(NSCLC). This efficacy and tolerability, combined with a convenient 
dosing regimen, make erlotinib a strong candidate for use as first-
line maintenance to extend time to progression after chemotherapy, 
ensuring patients have a chance to benefit from erlotinib. The phase 
III SATURN study was initiated to evaluate the efficacy and safety 
of erlotinib as first-line maintenance following non-progression with 
chemotherapy.
Methods: All patients who received four cycles of chemotherapy and 
had no evidence of disease progression were randomized to receive 
either erlotinib 150mg/day or placebo until progression or unaccept-
able toxicity. The co-primary endpoints were progression-free 
survival (PFS) in all patients and PFS in EGFR immunohistochem-
istry-positive (IHC+) patients. Secondary endpoints included overall 
survival (OS) in all patients and EGFR IHC+ patients, disease control 
rate and safety.
Results: 1,949 patients were enrolled and received chemother-
apy; 889 did not have progressive disease and were randomized to 
erlotinib (n=438; median age 60yrs) or placebo (n=451; median age 
60yrs). Baseline characteristics for erlotinib and placebo arms (%) 
were: male/female: 73/27 and 75/25; adenocarcinoma + bron-
choalveolar carcinoma/squamous-cell/other: 47/38/15 and 44/43/13; 
stage IIIB/IV: 26/74 and 24/76; Caucasian/Asian/other: 84/14/2 
and 83/15/2; ECOG PS 0/1: 31/69 and 32/68; current (within last 
12 months)/former/never smoker: 55/28/18 and 56/27/17; EGFR 
IHC+/–/unavailable: 70/14/16 and 69/13/18. PFS was determined 
by investigator assessment and confirmed by independent review. 
Significantly prolonged PFS was observed with erlotinib versus 
placebo in all patients (hazard ratio (HR) 0.71 [95% CI 0.62–0.82]; 
p=0.000003) and in EGFR IHC+ patients (HR 0.69 [95% CI 0.58–
0.82]; p=0.00002). This is equivalent to a 29–31% reduction in risk 
of progression with erlotinib or an increase in PFS time of 41–45%. 
Pre-planned subgroup analyses for PFS (HR) were: 0.60 for patients 
with adenocarcinoma; 0.76 for those with squamous-cell carcinoma; 
0.56 for never smokers; 0.66 for former smokers; and 0.80 for current 
smokers. Further subgroup analyses demonstrated that a PFS benefit 
was seen with erlotinib regardless of gender, PS, EGFR expression or 
ethnicity. OS data are not yet mature. Disease control rate (complete 
response + partial response + stable disease >12wks) was 40.8% with 
erlotinib versus 27.4% with placebo (p<0.0001). The most common 
reported treatment-related adverse events (AEs) were rash (60% with 
erlotinib versus 9% with placebo) and diarrhea (20% with erlotinib 
versus 5% with placebo), mostly grade 1/2. Ten patients (2.3%) in 
the erlotinib arm had a treatment-related serious AE, compared with 
one patient (0.2%) in the placebo arm. Twelve patients (2.8%) in the 
erlotinib arm and two patients (0.4%) in the placebo arm withdrew 
due to treatment-related AEs.
Conclusions: The SATURN study met its co-primary endpoints of 
statistically significantly prolonged PFS with erlotinib as first-line 
maintenance following non-progression on chemotherapy. Erlotinib 
was well tolerated in this setting and subgroup analyses confirmed 
that erlotinib is effective in a broad patient population.
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Early or late EGFR tyrosine kinase inhibitor, which is 
better for survival? - Retrospective analysis of 228 Korean 
patients with advanced or metastatic NSCLC
Kim, Min Kyoung1; Ryoo, Hun Mo2; Bae, Sung Hwa 2; Lee, Kyung 
Hee1; Hyun, Myung Soo1; Lee, Kwan-Ho3; Chung, Jin-Hong3; Shin, 
Kyung-Chul3; Lee, Sun Ah2; Lee, Sang Chae3; Hyun, Dae Sung3
1 Division of Oncology, Department of Internal Medicine, 
Yeungnam University College of Medicine, Daegu, Korea; 2 
Division of Oncology, Department of Internal Medicine, Catholic 
University of Daegu School of Medicine, Daegu, Korea; 3 Division 
of Pulmonology, Department of Internal Medicine, Yeungnam 
University College of Medicine, Daegu, Korea
Background: Despite the results of ISEL trial, we have observed 
gefitinib is active in treatment of selected patients with NSCLC. 
The proper timing of EGFR-TKI therapy in NSCLC has yet to be 
determined. We therefore evaluated whether the timing of gefitinib 
administration affect clinical outcomes.
Methods: From 2001 to 2006, 228 patients with advanced or meta-
static NSCLC received gefitinib at our institution. First, we analyzed 
the impact of timing of gefitinib on survival. Overall survival from 
the first diagnosis of advanced/metastatic or recurrent disease (OSd) 
was the primary endpoint. We then sought to identify variables affect-
ing resistance to gefitinib. PFS following gefitinib treatment was the 
primary endpoint.
Results: At a median follow-up of 27.1 months for surviving pa-
tients, the median OSd was 18.2 months. For the 111 patients treated 
with gefitinib as first or second line therapy (early gefitinib group), 
median OSd was 14.1 months (95% CI, 11.4-16.7 months); whereas 
for the 84 patients treated with gefitinib as third or higher line treat-
ment (delayed gefitinib group), median OSd was 23.9 months (95% 
CI, 18.2-19.5 months) (P=0.016). Cox proportional hazard models 
showed that history of surgery, smoking status, maximal response 
of first line treatment, timing of gefitinib therapy (early vs delayed), 
and ECOG PS (0, 1 vs ≥ 2) were independent predictors of OSd 
(P=0.001, P=0.003, P=0.004, P=0.021, and P=0.035, respectively). 
For the overall population, median OS following gefitinib treatment 
(OSg) was 6.7 months and median PFS was 2.7 months. The timing 
of gefitinib therapy did not affect OSg or PFS. In multivariate an-
alysis, Hb ≥ 10 g/dl (p<0.001), having never-smoked (p=0.003), and 
ECOG PS ≤1 (p=0.04) were associated with better PFS. Among the 
75 patients with adenocarcinoma histology who had never-smoked, 
there were no significant differences in OSd or OSg according to tim-
ing of gefitinib therapy.
Conclusions: The present findings suggest that it may be better 
to defer gefitinib therapy in patients with advanced or metastatic 
NSCLC. After treated with gefitinib, non-smokers with good PS and 
Hb level over 10 g/dL had the best prognosis. This finding requires 
confirmation in large prospective clinical trials.
A2.3 Sequencing of EGFR Inhibitors, Sat Aug 1, 14:30 - 16:00
Open-label, single arm, multicenter, phase II study on 
the efficacy and safety of cetuximab in combination with 
cisplatin and gemcitabine as 1st-line therapy in patients 
with advanced non-small cell lung cancer
Barata, Fernando1; Parente, Bárbara2; Teixeira, Encarnação 3; Costa, 
Agostinho4; Fernandes, Ana 5; Pimentel, Francisco L.6, 7; Andrade, 
Sofia8
1 Centro Hospitalar de Coimbra, Coimbra, Portugal; 2 Centro 
Hospitalar de Vila Nova de Gaia, Vila Nova de Gaia, Portugal; 
3 Hospital de Santa Maria, Lisbon, Portugal; 4 Hospital Pulido 
Valente, Lisbon, Portugal; 5 Centro Hospitalar Vila Real, Vila Real, 
Portugal; 6 Hospital São Sebastião, Santa Maria da Feira, Portugal; 
7 Secção Autónoma de Ciências da Saúde da Universidade de 
Aveiro, Aveiro, Portugal; 8 KeyPoint, Scientific Consultancy, Lisbon, 
Portugal
Background: Phase II and III studies have demonstrated that ce-
tuximab, an EGFR-targeting antibody, improves survival and overall 
response rate (ORR), when combined with any standard 1st-line 
regimen: platinum plus gemcitabine, cisplatin plus vinorelbine, and 
paclitaxel or docetaxel plus carboplatin.
This study assessed the efficacy and tolerability of cetuximab in 
combination with cisplatin and gemcitabine, in the 1st-line treatment 
of advanced non-small cell lung cancer (NSCLC). 
Methods: Multicenter, single-arm, phase II clinical trial. Patients 
received cetuximab (400 mg/m2 initial dose then 250 mg/m2 weekly 
in combination with cisplatin (40 mg/m2 day 1 & 8) and gemcitabine 
(1200 mg/m2 day 1 & 8) each 21 days for 4 cycles, maximum of 6 
cycles for patients achieving an objective response. Main eligibil-
ity criteria included metastatic NSCLC of any histological subtype, 
ECOG PS 0/1, and measurable disease. Patients with brain metasta-
ses were excluded. The primary endpoint was the ORR, according to 
RECIST criteria. Secondary endpoints included overall survival (OS), 
time to progression (TTP), and safety. Statistical analyses were per-
formed in intention to treat (ITT) and per protocol (PP) populations. 
ORRs and the corresponding 95% confidence intervals (CIs) were 
estimated. Kaplan–Meier curves were computed for TTP and OS.
Results: Between December 2006 and March 2008, a total of 48 
patients were enrolled. Seventy five percent of the patients were 
men and the median age was 62.5 years (range 34–75). Best ORR 
were 35.4% (95% CI 22.2–50.5%) and 38.1% (95% CI 23.6–54.4%) 
for the ITT and PP populations, respectively. Median TTP was 5.0 
months (95% CI 3.9–6.1). Median overall survival in the ITT popula-
tion was 12.0 months (95% CI 8.53–15.47).
In a post-hoc analysis (including all the patients who were alive on 
day 21), OS in patients who had any grade rash within the 1st cycle 
of treatment was 16 months (95% CI 13.05–18.96), patients who did 
not develop rash during this time had an OS of 6 months (95% CI 
1.73–10.27). This difference was statistically significant (p=0.007). 
Best ORR in EGFR positive patients (determined by FISH) was 
26.9% and 53.8% in EGFR negative patients (p=0.5). 
During the treatment 96 grade III to V adverse events were reported 
in 77% of the patients. Of these, 36 were considered to be probably 
or highly probably related to the study treatment (combination of 
chemotherapy with cetuximab). The most common grade III to V 
adverse events were neutropenia and thrombocytopenia (36 and 18 
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events, respectively). Grade III skin rashes occurred in 4 cases and 
there was no grade IV rash.
Conclusions: Cetuximab in combination with platinum-based 
chemotherapy had an acceptable safety profile and resulted in an 
increase in all efficacy parameters when compared with chemother-
apy alone. 
OS was significantly higher in patients who developed any grade 
rash within the 1st cycle of treatment. This is consistent with earlier 
results which suggested 1st-cycle rash is a clinical indicator for better 
outcome.
A2.4 Sequencing of EGFR Inhibitors, Sat Aug 1, 14:30 - 16:00
Gefitinib versus docetaxel in patients with pretreated 
advanced non-small-cell lung cancer (NSCLC): meta-
analysis from four randomized clinical trials
Shepherd, Frances A.1; Douillard, Jean-Yves 2; Fukuoka, Masahiro 3; 
Saijo, Nagahiro 4; Kim, Sang-We 5; Čufer, Tanja 6; Sellers, Mark V.7; 
Armour, Alison A.7; Kim, Edward S.8
1 Princess Margaret Hospital, Toronto, ON, Canada; 2 Centre 
René Gauducheau, Nantes, France; 3 Kinki University School of 
Medicine, Osaka, Japan; 4 National Cancer Centre Hospital East, 
Chiba, Japan; 5 Asan Medical Center, Seoul, Korea; 6 University 
Clinic Golnik, Golnik, Slovenia; 7 AstraZeneca, Macclesfield, UK; 8 
University of Texas MD Anderson Cancer Center, Houston, TX, USA
Background: Four open-label, randomized trials evaluated gefitinib 
versus docetaxel in unselected patients with pre-treated advanced 
NSCLC; INTEREST (Iressa NSCLC Trial Evaluating REsponse and 
Survival against Taxotere; multinational), V-15-32 (Japan), SIGN 
(Second-line Indication of Gefitinib in NSCLC; multinational) and 
ISTANA (IRESSA as Second-line Therapy in Advanced NSCLC–
KoreA). In INTEREST, gefitinib demonstrated non-inferior overall 
survival (OS), and similar progression-free survival (PFS) and object-
ive response rate (ORR) versus docetaxel (Lancet 2008;372:1809). 
V-15-32 did not demonstrate non-inferiority in OS for gefitinib rela-
tive to docetaxel, but found no significant difference in OS and PFS, 
and ORR was statistically significantly improved with gefitinib (J Clin 
Oncol 2008;26:4244). SIGN demonstrated similar OS, PFS and ORR 
versus docetaxel (Anticancer Drugs 2006;17:401). ISTANA demon-
strated prolonged PFS, significantly improved ORR, and a suggestion 
of improved OS with gefitinib versus docetaxel (follow-up ongoing) (J 
Clin Oncol 2008;26:Abs8025). Meta-analyses using the data from all 
patients and data from those of Asian origin are reported here. 
Methods: The meta-analysis compared efficacy of gefitinib (250mg/
day) and docetaxel (75mg/m2 [60mg/m2 in V-15-32]) in 2257 patients 
(972 of Asian origin) from the INTEREST (1466 patients random-
ized, 323 of Asian origin,), V-15-32 (all 489 patients randomized 
were from Japan), SIGN (141 non of Asian origin, excluded for Asian 
only meta-analysis) and ISTANA (161 patients randomized from 
Korea, 160 Asian origin) studies. Meta-analyses (unadjusted and 
adjusted for covariates) were performed using individual patient data 
by Cox proportional hazards for overall survival and PFS, and by 
logistic regression for ORR. 
Results: In the meta-analysis, gefitinib demonstrated similar OS and 
PFS and superior ORR to docetaxel in the primary analyses. Second-
ary analyses demonstrated similar results. In patients of Asian origin, 
gefitinib demonstrated similar OS and superior PFS and ORR to 
docetaxel in the primary analyses. Secondary analyses demonstrated 
similar results. 
 Variable Number of Analysis Hazard ratio 95% CI p-value 
  patients/events  /Odds ratio3
 Overall survival      
  Overall  2224/1608  Unadjusted1  1.03 0.93-1.13 0.577
    Adjusted 1.00 0.91-1.10 0.991
  Asian 963/590 Unadjusted1  1.04 0.88-1.22 0.651
    Adjusted2  0.99 0.84-1.17 0.894
 PFS      
  Overall  2005/1710 Unadjusted1  0.97 0.88-1.07 0.536
    Adjusted2  0.96 0.87-1.07 0.378
  Asian 839/707 Unadjusted1  0.83 0.71-0.96 0.013
    Adjusted2  0.81 0.69-0.94 0.006
 ORR      
  Overall 2005 Unadjusted1  1.58 1.19-2.10 0.002
    Adjusted2  1.65 1.24-2.21 0.001
  Asian 839 Unadjusted1  2.52 1.71-3.72 <0.001
    Adjusted2 2.63 1.76-3.93 <0.001
1Unadjusted analyses include terms for randomized treatment and study. For overall survival the 
primary analysis was unadjusted. 2Adjusted analyses includes terms for randomized treatment, study, 
histology, smoking history, number of prior chemotherapy regimens, performance status, sex, race, 
age, time from diagnosis, and best response to prior chemotherapy (in analyses of the Asian origin 
patients race, histology and time from diagnosis were not included). For PFS and ORR the primary 
analysis was adjusted. 3Hazard ratio (for overall survival and PFS) <1 indicates a lower risk of event on 
gefitinib. Odds ratio (for ORR) >1 indicates a higher chance of response on gefitinib
Conclusions: Results of the meta-analyses of overall and Asian pa-
tient data were consistent with those of the individual studies. Given 
the similar/superior efficacy demonstrated by gefitinib, its favorable 
tolerability profile, quality-of-life benefits, and oral administration, 
gefitinib has a favorable benefit-risk profile compared with docetaxel 
in both a broad pre-treated advanced NSCLC patient population and a 
similar population of Asian origin. 
A2.5 Sequencing of EGFR Inhibitors, Sat Aug 1, 14:30 - 16:00
Randomized phase II trial of first-line gefitinib, 
gemcitabine or docetaxel, in performance status (PS) 2 or 3 
non-small cell lung cancer (NSCLC) patients (IFCT-0301): 
Elderly Patients analysis
Des Guetz, Gaetan2, 1; Westeel, Virginie3, 1; Baudrin, Laurence1; 
Gounant, Valérie6, 1; Lebeau, Bernard4, 1; Vaylet, Fabien7, 1; Barlesi, 
Fabrice9, 1; Urban, Thierry8, 1; Moro-Sibilot, Denis10, 1; Souquet, 
Pierre-Jean11, 1; Debieuvre, Didier5, 1; Morin, Franck1; Morere, Jean-
Francois2, 1
1 IFCT, Paris, France; 2 APHP - Hôpital Avicenne, Bobigny, France; 
3 CHU, Besançon, France; 4 APHP - Höpital Saint-Antoine, Paris, 
France; 5 CH, Vesoul, France; 6 APHP - Hopital Tenon, Paris, 
France; 7 HIA Percy, Clamart, France; 8 CHU, Angers, France; 
9 AP-HM Hopital Ste-Marguerite, Marseille, France; 10 CHU, 
Grenoble, France; 11 HCL - Hôpital Lyon-Sud, Pierre-Bénite, France
Background: PS 2 or 3 patients are usually excluded from clinical 
trials. Optimal treatment in this setting remains a challenge. The aim 
of this analysis was to evaluate the impact of age in a randomized 
phase II trial with 3 monotherapy modalities 
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Methods: PS 2 or 3 patients with confirmed stage IIIB or IV NSCLC 
were enrolled into a multicenter randomized phase II trial: arm A, 
gefitinib (250 mg/day), arm B gemcitabine (1250 mg/m², day 1 and 
8, every 3 weeks) and arm C docetaxel (75 mg/m², day 1, every 3 
weeks). Treatments were maintained until progression or unaccept-
able toxicity. Second-line treatment consisted of: arm A, docetaxel 
(75 mg/m², day 1, every 3 weeks) and arm B and C, gefitinib (250 
mg/day). The primary endpoint was Progression-Free Survival (PFS). 
In our present analysis we performed a multivariate analysis.
Results: Between December 2004 and June 2007, 128 patients were 
enrolled. Given the median age in eligible population (n=127) was 71 
yr, an analysis was performed between 2 populations <70 (Y n=56) 
and ≥70 (E n=71). The characteristics of the 127 eligible patients 
are the following (Y/E): adenocarcinoma (46% / 51 %), PS 2 (62% 
/ 75%), PFS (1.4 month, CI95%: [1.1;1.9] / 2.3 months, CI95%: 
[2.1;2.9]), Overall Survival (OS) (2.0 months, CI95%: [1.5;2.4]/ 3.7 
months, CI95%: [2.4;4.8]). 
 UNIVARIATE  MULTIVARIATE 
 HR, 95%CI p HR, 95%CI p
 Arm B 0.75 [0.48;1.16] 0.1938 0.71 [0.45;1.13] 0.1483
  C 0.67 [0.43;1.05] 0.0803 0.78 [0.49;1.25] 0.2979
  A 1 - 1 -
 Age code ≥ 70 yrs 0.55 [0.38;0.80] 0.0019 0.57 [0.38;0.85] 0.0067
  < 70 yrs 1 - 1 -
 PS 3 1.41 [0.96;2.06] 0.0806 1.26 [0.83;1.91] 0.2856
  2 1 - 1 -
 Histology SCC 0.92 [0.61;1.40] 0.7103 0.82 [0.53;1.28] 0.3853
  Other 1.05 [0.67;1.64] 0.8423 0.82 [0.50;1.36] 0.4503
  ADC 1 - 1 -
 Weight loss code ≥ 5 % Yes 1.30 [0.84;2.00] 0.2380 1.16 [0.73;1.83] 0.5232
  No 1 - 1 -
 Brain metastasis Yes 1.10 [0.58;2.11] 0.7665 1.10 [0.56;2.16] 0.7838
  No 1 - 1 -
There was no difference in toxicity between younger (<70yrs) and 
older patients (≥70yrs). Elderly patients were significantly bet-
ter controlled after 3 cycles of monotherapy than younger patients 
(p=0.034), with a trend in favour of docetaxel. Adjusted for stratifica-
tion criteria (PS and histology), arm, weight loss and brain metasta-
sis, age was a determinant factor to explain progression-free survival. 
Adjusted HR for PFS was 0.57, CI95%: [0.38;0.85] for patients 
of 70 and more, compared to patients aged less than 70 years old 
(p=0.0037). Patients aged 70 years and over had a decrease in their 
risk of progression/death of 34%, compared to patients aged less than 
70 years old.
Conclusion: Age is not a bad prognostic factor in PS 2-3 NSCLCC 
patients, single-agent chemotherapy could be considered for PS2 
elderly patients.
A2.6 Sequencing of EGFR Inhibitors, Sat Aug 1, 14:30 - 16:00
Comparison of erlotinib (TarcevaTM) versus gefitinib 
(Iressa®) as the second line therapy for the treatment 
of advanced non-small cell lung cancer patients: a 
randomized phase II trial
Uhm, Ji Eun; Sun, Jong Mu; Lee, Soo Hyeon; Kong, Jee Hyun; Yun, 
Jin A; Lee, Sang Mi; Lee, Jeeyun; Park, Yeon Hee; Ahn, Jin Seok; 
Park, Keunchil; Ahn, Myung-Ju
Samsung Medical Center, Seoul, Korea
Background: A single-center, randomized, phase II trial of gefitinib 
versus erlotinib as the second-line therapy for advanced non-small 
cell lung cancer patients was performed to compare the efficacy and 
toxicity between two groups. 
Methods: Patients with histologically or cytologically confirmed 
stage IIIB or IV NSCLC including recurrent or metastatic disease, 
with performance status from 0 to 2, were eligible if they had failed 
or were intolerable to first-line chemotherapy. Patients had at least 
two factors among three (female or non-smoker or adenocarcin-
oma). Enrolled patients were treated with erlotinib 150 mg daily or 
gefitinib 250mg daily after randomization until disease progression or 
development of intolerable toxicity. 
Results: A total of 96 patients were enrolled between August 2007 
and October 2008. Each forty-eight patients (50%) were random-
ized to each group. Median age of all patients was 59 years (range, 
32-83) and 82 patients (85.4%) were female. Most patients (85.4%) 
had ECOG PS1. Ninety patients (93.7%) were never-smoker. The 
clinical characteristics were well balanced between two groups. The 
overall response rate of gefitinib group was 47.9% (95% CI, 33.8-
62.0) and erlotinib group was 39.6% (95% CI, 25.7-53.4)(p=0.411). 
The median progression-free survival of gefitinib and erlotinib were 
4.9 months (95% CI, 2.7-6.9) and 3.1 months (95% CI, 0.0-6.8)
(p=0.394), respectively. Two patients of gefitinib group and a patient 
of erlotinib group died of pneumonia. The most common adverse 
event was skin rash. Thirty patients of gefitinib arm and 35 patients 
of erlotinib arm developed any grade of skin rash. However, twenty 
one patients (43.7%) with erlotinib suffered from grade 2/ 3 skin rash, 
while five patients (20.3%) with gefitinib developed grade 2/3 skin 
rash (p=0.003). Although more patients of erlotinib group showed 
grade 2/3 skin rash, patients requiring dose reduction of each was 
similar (4 of gefitinib and 6 of erlotinib). 
Conclusions: Erlotinib and gefitinib showed similar anti-tumor activ-
ity as second-line treatment for advanced NSCLC. Although more 
serious skin rash was developed in more patients with erlotinib, this 
could not be implicated in the difference of dose intensity.
Copyright © 2009 by the International Association for the Study of Lung Cancer S293
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
A2.7 Sequencing of EGFR Inhibitors, Sat Aug 1, 14:30 - 16:00
A multicenter phase II randomised study of docetaxel/
gemcitabine weekly followed by erlotinib after 
progression versus erlotinib followed by docetaxel/
gemcitabine after progression in advanced non small 
cell lung cancer (NSCLC) in fit elderly patients selected 
with a comprehensive geriatric assessment (CGA) 
(gfpc*0504): preliminary results gfpc*groupe francais de 
pneumocancerologie
Le Caer, Herve1; Barlesi, Fabrice2; Corre, Romain3; Jullian, Herve4; 
Bota, Suzanna5; Falchero, Lionel6; Vergnenegre, Alain7; Le Treut, 
Jacques8; Balas, Daniel9; Chouaid, Christos10
1 Centre Hospitalier de Dracenie, Draguignan, France; 2 Centre 
Hospitalier Universitaire de Marseille, Marseille, France; 3 Centre 
Hospitalier Universitaire de Rennes, Rennes, France; 4 Centre 
Hospitalier de Martigues, Martigues, France; 5 Centre Hospitalier 
Universitaire de Rouen, Rouen, France; 6 Centre Hospitalier de 
Villefranche, Villefranche, France; 7 Centre Hospitalier Universitaire 
de Limoges, Limoges, France; 8 Centre Hospitalier uu Pays d’Aix, 
Aix, France; 9 Centre Hospitalier Universitaire de Nice, Nice, 
France; 10 Centre Hospitalier Universitaire St Antoine, Paris, France
Background: Elderly patients represent an heterogeneous popula-
tion in which anticancer therapeutic decision is often difficult. The 
objective of this study was to evaluate the feasibility and activity of 
weekly docetaxel + gemcitabine followed by erlotinib after progres-
sion versus erlotinib following by docetaxel + gemcitabine after 
progression in fit elderly patients with advanced NSCLC selected on 
the basis of their age, general condition, and number of co-morbid 
disorders(Charlson score).
Methods: This multicenter phase 2 study randomized chemonaive 
patients with stage IV and IIIB with pleural effusion selected accord-
ing to table 1 received docetaxel 30 mg/m²weekly for 6 consecu-
tive weeks plus gemcitabine 900mg/m²(gemcitabine only on days 
1,8,22,29) followed by 2 weeks off, for a maximum of 24 weeks or 
until progression, followed by erlotinib (arm A) until progression 
versus erlotinib in first line followed by docetaxel + gemcitabine 
as second line(arm B), with for the 2 arms epoietin beta 30000 UI 
weekly if haemoglobine <11,5g/dl . For CGA we use a software 
(EGSK) adapted in oncology practice included in a palm assistant 
with 10 items: socio-economic conditions, cognitive assessment, 
emotional status and depression scale, nutritional risk, quality of life, 
ADL,IADL, incontinence, falls and mobility problems, pain.
Major endpoint was time to second progression, secondary endpoints 
were response, time to first progression (TTP1), safety, quality of life.
Results: From july 2006 to november 2008, 100 pts were enrolled 
and to date 85 pts are available. Patients characteristics: Male/Female 
50/35, median Age 75.7(67-86); PS 0/1/2:39/41/4, median co-
morbidity(CS) 0,4 (0-4)median global geriatric index: 18.5/20 . Stage 
IV/IIIB:34/5(A)40/3(B). For arm A and B were respectively: partial 
response 31.3% and 20.5%,stable disease 34.4% and 35.9%,progres-
sive disease 34.4% and 43.6%,TTP1 were 4.2 and 3.7months, median 
survival 9.9 and 8.5 months. The main WHO Grade3/4 toxicity was 
neutropenia 26.8% and thrombopenia 7.3% in arm A and fatigue 
9.1% and cutaneous 6.8% in arm B.
Conclusions: Preliminary analysis suggests that either the combina-
tion of docetaxel and gemcitabine weekly and erlotinib in first line 
following by erlotinib or docetaxel + gemcitabine appears to be 
promising with a favourable toxicity profile in fit elderly with mild 
co-morbidity pts with NSCLC. Complete analysis will be presented 
at the meeting
 Age (Charlson) dependence Co-morbidity Charlson PS GERIATRIC 
  for  ADL and IADL score score  SYNDROM
 65-69 (2) no 0-2 2-4 0-1 0 INELIGIBLE
  no 0-2 2-4 2 0 ELIGIBLE
  no 3-4 5-6 0-1 0 ELIGIBLE
  no 3-4 5-6 2 0 INELIGIBLE
 70-79 (3) no 0-1 3-4 0-1 0 ELIGIBLE
  no 0-1 3-4 2 0 INELIGIBLE
  no 2-5 5-8 0-2 0 INELIGIBLE
 80-89 (4) no 0 4 0-1 0 ELIGIBLE
  no 1-4 5-8 0-2 0 INELIGIBLE
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A phase 2 trial of PF-00299804 (PF299), an oral 
irreversible HER tyrosine kinase inhibitor (TKI), in 
patients (pts) with advanced NSCLC after failure of prior 
chemotherapy and erlotinib: preliminary efficacy and 
safety results
Janne, Pasi A.2; Reckamp, Karen3; Koczywas, Marianna3; Camidge, 
David R.5; Engelman, Jeffery A.4; Khuri, Fadlo7; Rajan, Arun6; 
Gadgeel, Shirish8; Taylor, Ian1; Liang, Jane1; O’Connell, Joseph1; 
Giaccone, Giuseppe6
1 Pfizer Global Research and Development, New London, CT, USA; 
2 DanaFarber Caner Institute, Boston, MA, USA; 3 City of Hope, 
Duarte, CA, USA; 4 Massachusetts General Hospital, Boston, MA, 
USA; 5 University of Colorado Cancer Center, Aurora, CO, USA; 6 
National Cancer Institute, Bethesda, MD, USA; 7 Winship Cancer 
Institute, Atlanta, GA, USA; 8 Karmanos Cancer Institute, Troy, MI, 
USA
Background: Treatment options are limited for pt with advanced 
NSCLC after prior chemotherapy and selective reversible EGFR TKI. 
PF299 is an oral irreversible inhibitor of the tyrosine kinase domain 
of HER-1, -2, and -4. Non-clinical data suggests broad activity 
against NSCLC cell lines. Efficacy results from Phase 1 NSCLC co-
hort have been presented (Janne, ASCO 2008). This reported Phase 2 
trial evaluates PF299 in pts with advanced NSCLC, KRAS wild type, 
who have failed 1-2 prior chemotherapy regimens and progressed 
after erlotinib (E).
Methods: Patients were enrolled by histology: adenocarcinoma 
(Arm A, N= 44), 22 non-adenocarcinoma (Arm B, N=22). Primary 
endpoint: objective response rate in Arm A; secondary endpoints 
included duration of response, PFS, OS, safety, PK and correlations 
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of pharmacokinetic parameters: tissue and blood KRAS and EGFR 
studies, and serum levels of HER 2 and EGFR extracellular domain 
on all patients. 
Results: In the first 50 patients treated there are 45 in Arm A, 5 in 
Arm B. Overall there are 34/16 F/Male; 28 are non-smokers; ethni-
city included 36 Caucasian, 10 Asian. Preliminary data are as follows.
There are 3 confirmed PR who are still active on the study with 
ongoing PR: (1) adenocarcinoma with exon 19 del, in female, non-
smoker following 9 months of E given 2 year prior PF299, (2) adeno-
carcinoma in female, ex-smoker, 2 prior chemo, 1 year E completed 
5 week prior to PF299, (EGFR n/a); and (3) non-adenoCA EGFR 
wild type/ HER-2 + in male non-smoker, progressing at 8 weeks on E 
administered 2 month prior PF299. The duration of response for the 3 
responders are 127+, 44+ and 82+ days. There are two adenocarcin-
oma with stable disease (SD) > 6 months and one non-adeno (exon 
20 insertion) with SD > 6 months. Clinical benefit rate, defined as 
CR+PR+SD beyond two cycles (i.e., 6 weeks), was seen in 24 (67%) 
out of 36 response evaluable patients in arm A and 2 out of 5 in arm B. 
Patients with known EGFR wild type status had duration of treatment 
ranging from 4 - 24 weeks.
Patients with known T790M mutation progressing after E, had dur-
ation of treatment ranging from 9-12 weeks. 
Safety data (N= 50) expressed as frequency of All Grades /Grade 
3 include: skin toxicity 77/14%, diarrhea 82/10%, fatigue 59/10% 
(no G3 treatment related), stomatitis 28/0, vomiting 23/ 3% There 
were three patients with Grade 4 pulmonary embolus in the setting 
of documented progressive disease. Analysis of serum levels of shed 
EGFR and HER-2 are ongoing and will be presented.
Conclusions: PF299, a second generation irreversible Pan-Her TKI, 
has shown encouraging activity in advanced NSCLC after failure of 
prior chemotherapy and erlotinib. Preliminary evidence of efficacy 
includes 3 confirmed PR, and SD in approximately 60% of evaluable 
patients in the combined arms. Prolonged SD was seen in patients 
with T790M and exon 20 insertion. With Arm A enrollment complete, 
and Arm B ongoing, updated efficacy, molecular and biomarker data 
will be presented.
A3.2 Targeting the Epidermal Growth Factor Receptor, Sat Aug 1, 14:30 - 16:00
First report of PF 00299804 (PF299) in Asian patients 
(pts): a Korean phase 1/2 in KRAS wild-type (WT) stage 
IIIb/IV NSCLC, refractory to chemotherapy and erlotinib 
or gefitinib 
Heo, Dag Sae2; Kim, Joo-Hang3; Cho, Byoung-Chul3; Ahn, Myung-
Ju4; Millham, Robert1; Lee, Se-Hoon2; Lee, Sang-Yoon5; Guo, Feng1; 
Liang, Jane1; Taylor, Ian1; Park, Keunchil4
1 Pfizer Oncology, New London, CT, USA; 2 Seoul National 
University College of Medicine, Seoul, Korea; 3 Yonsei Cancer 
Center, Seoul, Korea; 4 Samsung Medical Center, Seoul, Korea; 5 
Pfizer, Inc, Seoul, Korea
Background: PF299 is an orally bioavailable, potent, and irrevers-
ible panHER tyrosine kinase inhibitor which may be effective in 
tumors driven by HER1/EGFR, HER2, and HER4. Preclinical stud-
ies suggest that PF299 may have a clinical activity for erlotinib or 
gefitinib resistant pts. This is the first report from a phase 1/2 study 
in Asian pts with NSCLC enriched for KRAS WT and refractory to 
chemotherapy and erlotinib (E) or gefitinib (G). 
Methods: In phase 1, pts received PF299 30 mg QD. If <2/6 pts 
experienced a dose-limiting toxicity (DLT), 6 additional pts were 
treated with PF299 45 mg QD. Following determination of the 
recommended phase 2 dose (RP2D; phase 1 primary endpoint), 
pts enrolled into the phase 2 study with a Simon two-stage optimal 
design. The primary endpoint of phase 2 portion was objective tumor 
response (RECIST). Pharmacodynamic measures include assess-
ment of skin rash and serum levels of HER2 and EGFR extracellular 
domains. Blood samples for pharmacokinetic (PK) evaluation were 
collected after single and multiple doses.
Results: 12 pts with stage IIIb/IV NSCLC were enrolled in phase 
1. Baseline characteristics were: mean age 52.6 yrs, prior EGFR 
inhibitors (E=5, G=7), prior number of chemotherapy regimens 1–7, 
Smoking Status (Smokers 0, Former Smokers 2, Never-smokers 10). 
PK parameters (Cmax and AUC) increased with dose, with an aver-
age terminal half-life of 55–70 hours. The most frequently reported 
treatment-related adverse events (AEs) were diarrhea (83%) and rash 
(75%) and were low grade. No grade 3/4 treatment-related AEs were 
reported at either dose level. 45 mg QD was determined to be the 
RP2D. At 30 mg QD, all patients (n= ?) achieved stable disease (≥6 
weeks on study, SD) and at 45 mg QD (n=?) 3 patients achieved SD 
and 2 pts achieved a confirmed partial response (PR). To date, 18 pts 
have been enrolled in phase 2. Baseline characteristics were: mean 
age 55.3 yrs, prior EGFR inhibitors (E=7, G=11), prior number of 
chemotherapy regimens 1–7, Smoking Status (Smokers 1, Former 
Smokers 4, Never-smokers 13). Available safety data has been com-
parable to that observed in phase 1. Only 3 Grade 3 treatment-related 
AEs were reported (rash, pruritis, diarrhea). Available data reflects 
two confirmed partial responses (PR) and five Stable Disease lasting 
longer than 6 weeks, for an overall Clinical Benefit Response (CBR, 
CR + PR + SD≥6 weeks) of total 7 patients (39%) in the phase 2 
stage 1 cohort. 
Conclusions: In this first report in Asian pts, PF299 appears well 
tolerated. The PK profile is consistent with an earlier phase 1 study in 
Western pts. The RP2D is 45 mg/day and the phase 2 trial is ongoing. 
Preliminary efficacy data suggest encouraging antitumor activity 
in heavily pre-treated NSCLC pts, including 4 confirmed PRs in 
24 patients (17%) treated at 45 mg QD. Updated clinical data will 
be presented, including data on serum levels of HER2 and EGFR 
extracellular domains. PF-299 is being investigated in other phase 2 
studies in NSCLC pts.
A3.3 Targeting the Epidermal Growth Factor Receptor, Sat Aug 1, 14:30 - 16:00
BIBW 2992, a novel irreversible EGFR/HER2 
tyrosine kinase inhibitor, in chemonaïve patients with 
adenocarcinoma of the lung and activating EGFR 
mutations
Yang, Chih-Hsin1; Shih, Jin-Yuan1; Su, Wu-Chou2; Hsia, Te-Chun3; 
Ho, Ching-Liang4; Dudek, Arkadiusz Z.5; Terlizzi, Elizabeth6; Zhao, 
Yihua M.6; Shahidi, Mehdi7; Miller, Vincent A.8
1 National Taiwan University Hospital, Taipei, Taiwan; 2 National 
Cheng Kung University Hospital, Tainan, Taiwan; 3 China Medical 
University Hospital, Taichung, Taiwan; 4 Tri-Service General 
Hospital, Taipei, Taiwan; 5 Masonic Cancer Care Center, University 
of Minnesota, Minneapolis, MN, USA; 6 Boehringer Ingelheim, 
Ridgefield, CT, USA; 7 Boehringer Ingelheim, Bracknell, UK; 8 
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
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Background: EGFR mutations, found in 10–30% of patients with 
non-small cell lung cancer (NSCLC) characterize a subpopulation 
with exquisite sensitivity to epidermal growth factor receptor (EGFR) 
tyrosine kinase inhibitors (TKIs). A Phase II study of BIBW 2992 
(Tovok*), an oral, novel and potent dual and irreversible inhibitor of 
EGFR and human epidermal growth factor receptor (HER)2 is being 
conducted in Taiwan and the US.
Methods: This was a two-stage Phase II trial. Eligibility criteria 
included stage IIIB/IV lung adenocarcinoma with EGFR mutation 
present in exons 18–21 (tested by direct sequencing), no prior EGFR-
TKI, measurable disease, Eastern Cooperative Oncology Group 
(ECOG) performance status 0–2 and adequate end-organ function. 
Following informed consent and confirmation of EGFR mutation, 
patients received 50 mg BIBW 2992 once daily until disease progres-
sion. Tumor assessments were performed every course for three 
courses and every two courses thereafter. The primary endpoint was 
objective response rate. After observing a 55% response and 87.5% 
disease control rate in the first 40 second-line patients, the trial was 
expanded to accrue 120 patients, including chemonaïve patients. The 
results of the treatment in chemonaïve patients will be presented.
Results: A total of 367 patients have been sequenced and 90 have 
been treated with BIBW 2992 (including 22 chemonaive patients). 
Available data on 17 chemonaïve patients (m: 6, f: 11) shows a 
median age of 60 years (range: 47–81) (14 from Taiwan, three from 
the US) with detectable EGFR mutations including del 19 (n=10), 
L858R (n=5) and other mutations (n=2) have started treatment. 
Among 10 evaluable patients, seven (70%) had a partial response and 
three (30%) had stable disease. Three of five patients with del 19, all 
three patients with L858R and one of two patients with other muta-
tion had a PR. The most frequently occurring drug-related side effects 
included skin adverse events (Grade 3 in one patient) and diarrhea 
(Grade 3 in four patients). Eight patients (47%) had a dose reduction 
to 40 mg and three patients (18%) had a further dose reduction to 30 
mg per day due to drug-related adverse events. Updated response and 
disease control rates will be presented.
Conclusions: Oral BIBW 2992 is highly active in patients with 
adenocarcinoma of the lung and EGFR mutations with high response 
and disease control rates. Manageable cutaneous side effects and diar-
rhea are the main adverse events. Evaluation of single-agent BIBW 
2992 as a treatment option for chemonaïve patients with NSCLC and 
EGFR mutations is warranted. 
An international Phase III trial program investigating BIBW 2992 in 
NSCLC, LUX-Lung, is now recruiting patients.
*Trade name not FDA approved.
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Final results of a phase II trial of erlotinib in chemo-naive 
women with advanced pulmonary adenocarcinoma
Jackman, David M.1; Cioffredi, Leigh-Anne1; Lindeman, Neal I.2; 
Morse, Linda K.1; Lucca, Joan1; Weckstein, Doug3; Huberman, Mark 
S.5; Lynch, Thomas J.4; Johnson, Bruce E.1; Janne, Pasi A.1
1 Dana-Farber Cancer Institute, Boston, MA, USA; 2 Brigham and 
Women’s Hospital, Boston, MA, USA; 3 Dana-Farber/New Hampshire 
Oncology-Hematology, Londonderry, NH, USA; 4 Massachusetts 
General Hospital, Boston, MA, USA; 5 Beth Israel Deaconess 
Medical Center, Boston, MA, USA
Background: This single-arm phase II study explored the role of 
specific clinical characteristics (female gender, adenocarcinoma 
histology, no tobacco within 1 year) in selecting pts for 1st-line 
therapy w/ erlotinib. Available tissue for EGFR mutation analysis 
was required to assess its impact on outcomes; molecular and clinical 
predictors were compared.
Methods: Eligible pts were chemo-naïve women, stage IIIB/ IV, PS 
0-2, adenocarcinoma, and w/ available tissue for analysis of EGFR 
mutation status. Pts received erlotinib 150 mg PO daily until disease 
progression or unacceptable toxicity. Primary endpoint was response 
rate (RR). Secondary endpoints included toxicity, time to progres-
sion (TTP), overall survival (OS), and impact of EGFR genotype on 
clinical outcomes.
Results: From 11/04 - 12/08, 84 pts were treated. Median age 68 
(range 34-88); 59 PS 0, 24 PS 1, 1 PS 2; race: 79 white, 3 Asian, 2 
black; 16 pts had BAC or predominant BAC features; smoking status: 
35 never, 49 former. 
Tox: Rash (90%; 21% grade 3) and diarrhea (69%; 7% grade 3) were 
the most common toxicities. 32 pts developed toxicity grade 3+ felt 
likely related to erlotinib. 2 deaths may be treatment-related (1 DIC, 
1 hepatic failure). There were also 3 pts w/ PE’s (1 fatal).
Efficacy: Response (n=84): 0 CR, 26 PR (RR 31%), 28 SD, 23 PD. 
7 pts not evaluable (5 tox, 1 non-progression death, 1 withdrawn 
consent). Median TTP was 5.6 months (95% CI 4.1-7.4 mos), and 
median OS was 22.7 months (95% CI 15.8 – 26.0 mos). At time of 
analysis, there were 36 deaths, 16 pts on treatment w/o progression, 
and 5 pts lost to follow-up.
Compared to smokers, never-smokers trended toward improved RR 
(43% vs 22%, p=.06), w/ improved TTP (HR .59; 95%CI .36-.96) 
but no improvement OS (HR 1.15, 95%CI .58-2.27). Genotype had a 
more obvious impact on outcomes: compared w/ 37 known wild-type 
EGFR, 33 pts w/ known sensitizing mutations had a higher response 
rate (67% vs 0), and significantly improved hazard ratios for both 
TTP (.20, 95%CI .11-.36) and OS (.36, 95% CI .18 – .73). Results 
will be updated and outcomes for rarer mutations reported.
Conclusion: Clinical characteristics may help select appropriate pts 
for first-line erlotinib when EGFR mutation status is unavailable. 
However, EGFR mutation status is a better indicator for selecting pts 
for first-line erlotinib.
A3.5 Targeting the Epidermal Growth Factor Receptor, Sat Aug 1, 14:30 - 16:00
Erlotinib therapy in non small cell lung cancer patients - 
survival of patients on reduced erlotinib doses
Pesek, Milos1; Krejci, Jana1; Skrickova, Jana1; Zatloukal, Petr2; 
Kolek, Vitezslav3; Salajka, Frantisek4; Koubkova, Leona5; Sixtova, 
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Pavlik, Tomas10
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Republic; 7 Facutty Hosp., Dept. of Oncology, Praha, Czech 
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Czech Republic; 9 Masaryk Memorial Cancer Institute, Brno, 
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Background: Erlotinib is a standard treatment of recurrent/metastatic 
non-small cell lung cancer (NSCLC) in second and subsequent lines. 
Rash and diarrhea are the most common side effect of erlotinib and 
may be a reason of dose reduction from standard dose 150mg/day 
to 100mg/day. We investigated whether this dose reduction was not 
associated with decreased effect of treatment. 
Methods: All patients with NSCLC treated in nine pulmooncology 
centers by erlotinib are followed in the Czech Tarceva Registry. We 
compare patients in which the erlotinib dose was reduced to 100 
whenever during treatment with patient without dose reduction. 
Results: 394 patients with full data set needed for the analysis were 
identified in the registry. Erlotinib dose was reduced in 43 (10,9%) 
of them while 351 patient had full dose during all treatment. Rash 
was the reason of dose reduction in 27 of them (rash + diarrhea in 
6 patients), diarrhea alone in 2 patients, other toxicity in 7 patients 
and the reason is unknown in 7 patients. There were no differences 
in baseline characteristic of the patients, such as. gender, smoking 
habits or histology between both the groups. Clinical benefit rate was 
superior (CBR) in group with dose reduction: complete response 
(CR) 2,8%, partial response (PR) 14% and disease stabilization 
(SD) 53,5% gives CBR of 70,3%, while in the group without dose 
reduction CR reached 0,6%, PR 9,1% and SD 38,7%, what represents 
CBR of 48,4%, p=0,048. Also both progression free survival (PFS) 
and overall survival (OS) were significantly superior in the group 
of patients with dose reduction. Median PFS reached 3,9 versus 2,0 
months, p=0,024 and median OS 14,7 versus 4,9 months, p=0,003 in 
patients with dose reduction and without dose reduction, respectively. 
Conclusion: Patients with erlotinib dose reduction from 150mg/day 
to 100mg/day due to side effects surprisingly have superior progres-
sion free and overall survival than patients without dose reduction. 
Several analyses of patients with different cancers treated by erlotinib 
confirmed better results of treatments in patients who experienced 
rash (or higher grade of rash). This can be also explanation of our 
finding, because rash was the most common reason for dose reduc-
tion in our cohort of patients. In patients with side effect erlotinib can 
be reduced without decreasing its efficacy. 
A3.6 Targeting the Epidermal Growth Factor Receptor, Sat Aug 1, 14:30 - 16:00
Is there a relationship between increased EGFR gene copy 
number and the presence of activating EGFR mutations in 
advanced NSCLC?
Soulières, Denis1; Ciuleanu, Tudor E.2; Stelmakh, Lilia V.3; Whittom, 
Renaud4; Delmar, Paul R.5; Rohr, Kerstin5; Brugger, Wolfram6; 
Cappuzzo, Federico7; on behalf of the SATURN investigators,8
1 Centre hospitalier de l'Université de Montréal, Montreal, QC, 
Canada; 2 Institute of Oncology, Cluj-Napoca, Romania; 3 Pavlov 
Medical University, St Petersburg, Russia; 4 Hopital du Sacre-Coeur, 
Montreal, QC, Canada; 5 F. Hoffmann La Roche, Basel, Switzerland; 
6 Schwarzwald-Baar Clinic, Villingen-Schwenningen, Germany; 7 
Istituto Clinico Humanitas IRCCS, Rozzano, Italy; 8 UK
Background: Erlotinib, a potent EGFR tyrosine-kinase inhibitor 
(TKI), is an established treatment option for relapsed NSCLC. 
Increased EGFR gene copy number and the presence of activating 
EGFR mutations have been proposed as potential predictive markers 
for EGFR TKIs. Some reports indicate a possible correlation between 
EGFR gene amplification and EGFR mutation. We conducted 
exploratory analyses to investigate this association, and to determine 
whether it impacts clinical outcomes with erlotinib. These analyses 
were based on data from the phase III placebo-controlled SATURN 
study of erlotinib as maintenance therapy for advanced NSCLC.
Methods: In the SATURN study, 889 patients who attained CR/PR/
SD following four cycles of first-line platinum-doublet chemotherapy 
were randomized to erlotinib 150mg/day or placebo. Baseline tumor 
samples from 874 patients were available for molecular marker an-
alyses, including EGFR gene copy number (using fluorescent in-situ 
hybridization; FISH), and EGFR mutation status (using DNA sequen-
cing; exons 18–21). EGFR FISH-positive status was defined as high 
polysomy (≥4 gene copies in ≥40% of nuclei) and/or gene amplifica-
tion (gene/chromosome ratio ≥2, or ≥10% nuclei with EGFR clusters, 
or ≥10% of nuclei with ≥15 gene copies). Tumors were classified as 
EGFR mutation-positive if exon 19 deletions and/or L858R muta-
tions (exon 21) were identified.
Results: Pre-planned analyses of PFS according to EGFR gene 
copy number showed a benefit with erlotinib in both subgroups: HR 
0.68 in EGFR FISH+ group (n=231), and HR 0.81 in FISH– group 
(n=255). Different scores and cut-offs were tested in an exploratory 
approach, to determine whether a different classification discrimin-
ated more effectively between benefiting and non-benefiting groups. 
Patients whose tumors displayed true amplification of EGFR (n=115) 
obtained substantially greater PFS benefit with erlotinib than those 
without amplification (n=371): HR 0.46 (95% CI 0.30–0.70) versus 
0.86 (95% CI 0.69–1.08), respectively. Amplification of the EGFR 
gene was significantly more common in tumors with EGFR muta-
tions than in those with wild-type EGFR (p<0.01). Furthermore, 
a very large PFS benefit was observed with erlotinib in patients 
with EGFR mutations (HR 0.09), suggesting that the difference in 
outcomes between patients with EGFR-amplified tumors and those 
with non-amplified tumors could be driven by the presence of a high 
number of patients with EGFR mutations in the former group. In 
patients with EGFR wild-type tumors, the PFS benefit with erlotinib 
was similar regardless of EGFR amplification status: HR 0.83 in the 
EGFR-amplified group (n=49) versus 0.87 in the non-amplified group 
(n=193).
Conclusions: In the SATURN study, patients with EGFR gene ampli-
fication obtained a greater benefit from erlotinib than those without 
amplification. Moreover, there was a strong association between 
EGFR amplification and the presence of EGFR mutations, which are 
correlated with particularly good clinical outcomes on erlotinib ther-
apy. This suggests that the difference in outcomes between the ampli-
fied and non-amplified groups is explained by a higher incidence 
of EGFR mutations in the former group. When patients with EGFR 
mutations were excluded from the analysis, similar efficacy was 
observed with erlotinib between the two groups (EGFR amplification 
versus no amplification) Confirmation of these findings is required in 
future studies. 
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Cetuximab plus platinum-based chemotherapy as 1st-
line treatment in patients with non-small cell lung cancer 
(NSCLC): a meta-analysis of randomized phase II/III 
trials
Thatcher, Nick1; Lynch, Thomas J.2; Butts, Charles3; Rosell, Rafael4; 
Shepherd, Frances5; Pujol, Jean-Louis6; Vansteenkiste, Johan7; Emig, 
Michael8; Groos, Jutta8; Pirker, Robert9
1 Christie Hospital NHS Foundation Trust, Manchester, UK; 2 
Massachusetts General Hospital, Yawkey Cancer Center, Boston, 
MA, USA; 3 Cross Cancer Institute, Edmonton, Canada; 4 Catalan 
Institute of Oncology, Hospital Germans Trias i Pujol, Barcelona, 
Spain; 5 Princess Margaret Hospital, University of Toronto, Toronto, 
Canada; 6 Institut Universitaire de Recherche Clinique, Montpellier, 
France; 7 University Hospital Leuven, Leuven, Belgium; 8 Merck 
KGaA, Darmstadt, Germany; 9 Medical University of Vienna, Vienna, 
Austria
Background: Cetuximab significantly improves overall survival 
(OS) in patients with NSCLC, both squamous and nonsquamous 
subtypes, when added to 1st-line cisplatin/vinorelbine (Pirker et al. 
J Clin Oncol 2008;26(Suppl. 15):Abstract 3). Three other random-
ized controlled studies have shown consistent results with differ-
ent platinum doublets: Lynch et al. (J Thorac Oncol 2008;3(Suppl. 
4):S305), a phase III study which compared carboplatin/docetaxel or 
carboplatin/paclitaxel, with or without cetuximab; and two random-
ized phase II trials by Butts et al. (J Clin Oncol 2007;25:5777–84) 
and Rosell et al. (Ann Oncol 2008;19:362–9), which investigated cis-
platin/gemcitabine or carboplatin/gemcitabine, and cisplatin/vinorel-
bine, with or without cetuximab, respectively. In order to confirm 
the robustness of the efficacy of cetuximab added to platinum-based 
chemotherapy (CT), a meta-analysis based on individual patient data 
was performed.
Methods: The meta-analysis was performed on 2018 patients from 
the four randomized controlled phase II/III studies for OS, progres-
sion-free survival (PFS), and objective response rate (ORR). Hazard 
ratios (HRs) for the treatment effect on OS and PFS were obtained 
by applying Cox’s proportional hazards model to individual patient 
data, which was adjusted for study and the baseline covariates age, 
gender, histology, tumor stage, and ECOG performance status. Odds 
ratios for the treatment effect on ORR were obtained by performing a 
logistic regression on individual patient data using the same adjust-
ment. A test of heterogeneity of the treatment effect across studies 
was performed. Three additional models were applied as sensitivity 
analyses to the adjusted models described above.
Results: The meta-analysis based on 1003 patients treated with CT 
+ cetuximab and 1015 patients treated with CT alone demonstrated 
a significant benefit across all investigated efficacy endpoints for 
the cetuximab combination over CT alone: OS (HR=0.878, 95% 
CI 0.795–0.969, p=0.010), PFS (HR=0.899, 95% CI 0.814–0.993, 
p=0.036), and ORR (odds ratio=1.463, 95% CI 1.201–1.783, 
p<0.001). The test for heterogeneity did not indicate a difference in 
the treatment effect across studies. All three sensitivity analyses con-
firmed the results of the primary analysis in each endpoint.
Conclusions: Adding cetuximab to 1st-line chemotherapy has con-
sistently demonstrated improvements in efficacy across four random-
ized controlled studies, irrespective of which platinum doublet was 
used and in all histologic subtypes of NSCLC. This was confirmed 
in the present meta-analysis comprising 2018 patients which showed 
significant overall improvements in OS, PFS, and ORR.
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Class III beta-tubulin (βTubIII) expression is an 
independant and powerful prognostic marker in patients 
with resectable nonsmall cell lung cancer (NSCLC) treated 
by perioperative chemotherapy (CT) in the phase III trial 
IFCT-0002
Zalcman, Gerard1; Levallet, Guenaëlle1; Bergot, Emmanuel1; 
Antoine, Martine2; Creveuil, Christian1; Beau-Faller, Michèle3; 
Brambilla, Elisabeth4; Galateau-Salle, Françoise1; Dumontet, 
Charles5; Morin, Franck6; Depierre, Alain7; Milleron, Bernard2
1 Caen University Hospital, Caen, France; 2 Tenon University 
Hospital, Paris, France; 3 Strasbourg University Hospital, 
Strasbourg, France; 4 Grenoble University Hospital, Grenoble, 
France; 5 Lyon University Hospital, Lyon, France; 6 Intergroupe 
Francophone de Cancérologie Thoracique (IFCT), Paris, France; 7 
Besançon University Hospital, Besançon, France
Background: IFCT-0002 phase 3 trial compared two timings of CT 
in early lung cancer, all before surgery (PRE) versus PERIoperative, 
and two CT regimens, CDDP-Gemcitabine vs. CBDCA-Paclitaxel. 
528 patients were randomized. Paraffin embedded post-chemo patho-
logical specimens were collected in the 490 non complete responder 
patients for tissue expression of the putative biomarker beta-tubulin 
III (βTubIII) along with other putative prognostic or predictive bio-
markers such as p27, ERCC1 and p14ARF.
Methods: 423 (86%) surgical pathological specimens with enough 
remaining viable tumor tissue after neoadjuvant chemo were pro-
cessed for immunohistochemistry as published in the Bio-IALT study. 
A semi-quantitative score was attributed taking account the number 
of stained cells and the intensity of staining. Semiquantitative scores 
were studied as continuous variables, without any pre-determined 
cut-off. Multivariate analysis for progression-free (PFS) and overall 
survival (OS) were corrected with Bonferroni-Holm method for mul-
tiple analyses. Median follow-up for OS was 59 months. 
Results: 412 slides gave reliable immunostaining results. No expres-
sion of βTubIII was found in 127 specimens (30.8%) with positive 
internal controls, whereas expression of βTubIII, of any intensity 
or with any number of stained cells, was found in 285 pathological 
specimens (69.2%). βTubIII immunostaining was more frequent in 
women than in men (chi2 test, p=0.0016), in non-squamous than in 
squamous cell carcinomas (chi2 test, p=2.10-15). In the 181 speci-
mens in which the two analyses could be performed simultaneously, 
βTubIII staining was significantly more frequent in K-Ras-mutated 
than in wild-type K-Ras specimens (chi2 test, p= 0.0008). In addition, 
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βTubIII expression was significantly more frequently encountered in 
patients that only received 2 cycles of chemotherapy since they did 
not experience partial response (PR), than in patients that received 
more than 2 cycles because of a PR after the two first cycles (Chi2 
test, p=0.0003). In the same way, βTubIII expression was associated 
with non-response to chemotherapy in univariate (p<0.0001) as in 
multivariate analysis (HR= 1.3 [1.00-1.69], p=0.054), adjusted for 
histology, T and smoking. Finally, βTubIII immunostaining was the 
only IHC marker significantly associated with poor PFS in univariate 
(p=0.014) or multivariate analysis, adjusted for histology, T and stage 
(HR= 1.50 [1.07-2.10]; p=0.020). In patients with a pathological 
specimen showing a βTubIII positive immunostaining, median PFS 
was 30.6 months, versus 60.1 months (HR=1.46 [1.08-1.99] for 
βTubIII negative patients. βTubIII IHC score remained predictive 
of poor OS in univariate (p= 0.0065) as in multivariate analysis 
(p=0.019 with Bonferroni correction, HR=1.75 [1.15-2.68] ). Median 
OS was not reached for βTubIII negative patients whereas it was 71.7 
months in patients with βTubIII immunostaining of any intensity 
score (HR=1.61, [1.11-2.35] . 
Conclusions: This study showed a dramatic negative prognostic 
impact for βTubIII immunostaining in resectable early lung cancer. 
A subset of βTubIII expressing patients with poor prognosis did not 
take any advantage from perioperative chemo and expression of this 
protein was associated with non-response to CT. A possible explana-
tion could rely on the association of βTubIII expression with tumor 
hypoxia, since βTubIII synthesis has been shown to be controled by 
Hypoxia Inducible Factor-1 (HIF-1). Hence, those patients could 
rather have beneficiated from personalized adjuvant treatment with 
alternative approaches.
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Validation of the prognostic and predictive value of class 
III beta tubulin (TUBB3) for adjuvant chemotherapy 
(ACT) in completely resected non-small cell lung cancer 
(R-NSCLC): results from four randomized trials
Reiman, Tony1; Seve, Pascal2; Veillard, Anne-Sophie3; Soria, Jean-
Charles3; Rosell, Rafael4; Taron, Miquel4; Graziano, Stephen5; 
Kratzke, Robert9; Seymour, Lesley6; Shepherd, Frances8; Pignon, 
Jean-Pierre3; Lai, Raymond7
1 Saint John Regional Hospital, Saint John, NB, Canada; 2 Hopital 
de l’Hotel-Dieu, Lyon, France; 3 Institut Gustave-Roussy, Villejuif, 
France; 4 Catalan Institute of Oncology, Badalona, Spain; 5 State 
University of New York, Syracuse, NY, USA; 6 NCIC Clinical Trials 
Group, Kingston, ON, Canada; 7 Cross Cancer Institute, Edmonton, 
AB, Canada; 8 Princess Margaret Hospital, Toronto, ON, Canada; 9 
University of Minnesota, Minneapolis, MN, USA
Background: The IALT, JBR.10, ANITA and CALGB 9633 trials all 
compared modern ACT to observation for patients with R-NSCLC. 
Data from the pre-clinical and metastatic settings suggest that 
TUBB3 expression is a determinant of the anti-neoplastic effects of 
tubulin-targeting agents such as vinorelbine and paclitaxel. In 265 
patients from JBR.10, high TUBB3 was an adverse prognostic factor 
for overall survival (OS; HR = 1.42, [95% C.I. 0.97 – 2.09] p=0.07) 
but not disease-free survival (DFS; HR = 1.32, [0.90 – 1.94] p = 
0.16). Although benefit for ACT appeared higher in high TUBB3 
expressing patients, TUBB3 was not predictive for OS (interaction 
p=0.25) nor DFS (interaction p = 0.15).
Methods: Tumour tissues from 784 IALT pts, 152 ANITA pts, 212 
CALGB 9633 pts and an additional 52 JBR.10 pts were stained with 
IHC for TUBB3 (51 pt samples not assessable) for a total “valida-
tion set” of 1149 pts. A score was generated based on the intensity 
and the proportion of positive-staining tumor cells in each case. The 
same TUBB3 cutoff score for classifying tumors as TUBB3 high or 
low was used to analyze both the original JBR.10 cohort (n=265) and 
the validation set. The prognostic and predictive value of TUBB3 
on DFS and OS was assessed by Cox models stratified on trial and 
adjusted on clinical and pathological factors.
Results: In the validation set, only adenocarcinoma histology correl-
ated significantly (p<0.0001) with TUBB3 expression in multivariate 
analysis High TUBB3 expression was prognostic for OS (HR=1.27 
[1.07-1.51], p=0.008) and DFS (HR=1.30 [1.11-1.53], p=0.001). 
However, TUBB3 was not predictive of a differential treatment effect 
(interaction p=0.20 [OS] and p=0.23, [DFS]).
Exploratory subset analyses were performed in 420 patients compar-
ing vinorelbine/cisplatin to observation with similar results. TUBB3 
was prognostic (OS, HR=1.43 [1.06-1.93] p=0.02; DFS, HR=1.57 
[1.20-2.05], p=0.001) but not predictive (interaction p=0.15 for both 
DFS and OS).
Conclusion: We were able to validate our observation that high 
TUBB3 expression is prognostic in patients with R-NSCLC. We were 
unable to confirm a predictive effect for high TUBB3 in this valida-
tion study in either the overall study population, or in a subset of 
patients who received vinorelbine/cisplatin therapy. TUBB3 does not 
appear useful for selecting patients for ACT for R-NSCLC. 
Supported by LNCC, the Canadian Cancer Society, the Ontario Can-
cer Research Network, the Alberta Heritage Foundation for Medical 
Research and the Alberta Cancer Foundation. 
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Bio-ANITA project: increased BRCA1 mRNA levels 
predict favorable outcome in non-small cell lung cancer 
(NSCLC) patients receiving adjuvant cisplatin (cis)/
vinorelbine (vrb)
Wei, Jia 2; Okamoto, Tatsuro1; Sanchez-Ronco, Maria3; Chaib, 
Imane1; Perez-Roca, Laia1; Mendez, Pedro1; Taron, Miquel1; Liu, 
Baorui2; Rosell, Rafael1
1 Institut Catala d’Oncologia- Hospital Germans Trias i Pujol, 
Badalona, Ctra Canyet s/n, Spain; 2 Drum Tower Hospital, Medical 
School of Nanjing University, Nanjing, China; 3 University of Alcala 
de Henares, Alcala de Henares, Spain
Background: BRCA1 is a critical gene directly involved in DNA 
repair through the nucleotide excision repair and homologous recom-
bination repair pathways. BRCA1 is a crucial prognostic factor in 
NSCLC and has a differential modulating effect on response to cis 
and antimicrotubule drugs.
Methods: 156 tumor samples were obtained from the Adjuvant 
Navelbine International Trialist Association (ANITA) trial (IS-
RCTN95053737), which randomized stage IB-IIIA NSCLC patients 
to observation or four cycles of cis/vrb. BRCA1 mRNA expression 
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was analyzed by QPCR following microdissection, and patients were 
divided into terciles based on their BRCA1 levels.
Results: Preliminary data on 41 patients is available at this time 
(20 from the observation arm and 21 from the chemotherapy arm).
No differences in clinical characteristics were observed according to 
BRCA1 expression levels. In the chemotherapy arm, median survival 
was not reached in any of the BRCA1 subgroups but was longer in 
patients in the top tercile of BRCA1 expression (Figure). There was 
no prognostic impact of BRCA1 in the observation arm, perhaps 
due to the small number of patients. No differences in survival were 
observed according to BRCA1 expression levels in patients receiving 
post-operative radiotherapy.
Conclusion: Patients with the highest levels of BRCA1 expression 
could receive the most benefit from adjuvant cis/vrb. Complete data 
on more patients will be provided.
A4.4 Biomarkers in Adjuvant Trials and Stereotactic Body Radiation, Sat Aug 1, 
14:30 - 16:00
The pharmacogenomic approach in adjuvant setting 
of NSCLC: postoperative chemotherapy customized 
according BRCA1 levels; docetaxel single agent arm 
compared with platinum doublets; SCAT pilot trial results
Massuti, Bartomeu1; Cobo, Manuel2; Sanchez, Jose Miguel3; 
Rodriguez-Paniagua, Jose Manuel4; Jimenez, Ulpisno5; Aguiar, 
David6; Arrabal, Ricardo 7; Gonzalez-Larriba, Jose Luis8; Reguart, 
Noemí10; Astudillo, Julio9; Tarón, Miquel10; Rosell, Rafael10
1 Medical Oncology Dpt Alicante University Hospital, Alicante, 
Spain; 2 Hospital Universitario Carlos Haya, Malaga, Spain; 3 
Hospital Universitario 12 de Octubre, Madrid, Spain; 4 Thoracic 
Surgery Alicante University Hospital, Alicante, Spain; 5 Hospital 
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Dr. Negrin, Las Palmas, Spain; 7 Thoracic Surgery Hospital 
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Background: Value of postoperative platinum-based chemotherapy 
(CT) has been confirmed in completely resected non-small cell lung 
cancer with lymph nodes involvement stages II-IIIA. Improvement 
of outcome in adjuvant setting could be achieved through better risk 
selection, addition of biologicals or customizing therapy. mRNA 
BRCA1 level is prognostic in early NSCLC (Rosell et al 2007). 
Patients (p) with low BRCA1 benefit from cisplatin based doublets 
meanwhile p with high BRCA1 attained longer survival when are 
treated with taxanes 
Methods: NSCLC p with R0 surgery and with pathological lymph 
nodes involvement (N1, N2) received 4 cycles of customized CT 
according BRCA1 levels. P with low BRCA1 levels received 
Cisplatin-Gemcitabine (Cis-G), intermediate levels Cisplatin-Do-
cetaxel (Cis-D) and high levels group Docetaxel (D) single agent. 
Clinical prognostic factors, secondary effects, type of surgery, use of 
radiotherapy were assessed. Time to relapse (TTR) and survival (OS) 
are outcomes of the trial. Median follow-up 23 months. Multivariate 
analysis for survival was done. ABRAXAS and RAP80 expression 
levels were also correlated with BRCA1 and outcome. 
Results: 83 patients were prospectively included in the trial. Median 
age 63 y. M/F: 69/14. 95% were smokers.98% PS 0-1. Median 
BRCA1 levels 5.94 (0.65-40.81). 42 p Adenocarcinoma, 35 p 
Squamous cell, 6 Undifferentiated large cell. Extent of surgery: 23% 
pneumonectomy, 67% lobectomy, 10% bilobectomy. 45 (54%) N1; 
38 (46%) N2. CT: 44 p (53%) Cis-G, 28 p (34%) Cis-D and 11 p 
(13%) D. Significant differences between groups were found only 
in histology ( ADC 71% in low BRCA1 and 11% in high BRCA1 
groups) and pN status. Outcome: Overall TTR is 20.7 m; with median 
19.64 m in Cis-G and NR in Cis-D and D groups (p=0.36). Median 
OS not reached (p=0.56). Multivariate analysis for survival: HR 3.57 
if T > 4 cm. Increasing in RAP80 values correlates with BRCA1 
increase. Updated results with a planned median follow-up 36 months 
will be presented
Conclusion: BRCA1expression level could be a prognostic and pre-
dictive marker. Significant differences in histology and staging were 
found according BRCA1. Customization of CT is feasible in adjuvant 
setting. For group of patients with high-expression levels postopera-
tive CT with single agent taxane without cisplatin outcomes were 
not inferior to the groups treated with cisplatin-doublets. Customized 
adjuvant CT could improve therapeutic ratio. The results of this pilot 
trial had led to open a Phase III trial comparing customized CT arm 
with control arm non-selected cisplatin doublet; this trial is currently 
recruiting p.
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RTOG 0236: stereotactic body radiation therapy to treat 
medically inoperable early stage lung cancer patients
Timmerman, Robert D.1; Paulus, R2; Galvin, J3; Michalski, J4; 
Straube, W4; Bradley, J4; Fakiris, A5; Bezjak, A6; Videtic, G7; Choy, 
H1
1 University of Texas Southwestern Medical Center, Dallas, TX, USA; 
2 Radiation Therapy Oncology Group Headquarters, Philadelphia, 
PA, USA; 3 Thomas Jefferson University, Philadelphia, PA, USA; 4 
Washington University, St. Louis, MO, USA; 5 Indiana University, 
Indianapolis, IN, USA; 6 Princess Margaret Hospital, Toronto, ON, 
Canada; 7 Cleveland Clinic Foundation, Cleveland, OH, USA
Background: The Radiation Therapy Oncology Group (RTOG) 
protocol RTOG 0236 was a phase II trial utilizing stereotactic body 
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radiation therapy (SBRT) with ablative prescription dose to treat early 
stage medically inoperable non-small cell lung cancer patients (pts).
Methods: All pts were required to have documented severe co-mor-
bid medical conditions precluding lobectomy. Pts with biopsy proven 
peripheral (greater than 2 cm from the central bronchial tree) T1-T3, 
N0, M0 tumors were eligible. The prescription dose was 20 Gy per 
fraction times 3 fractions (60 Gy total dose) assuming all water 
density. Subsequent analysis with proper tissue heterogeneity cor-
rection showed the actual dose to be approximately 54 Gy total. The 
treatment was delivered in 1½-2 weeks. Rigorous central accredit-
ation and quality assurance assessments were used to assure pts were 
treated according to protocol guidelines. The primary endpoint was 
two-year local control with overall and disease free survival, toxicity, 
regional failure and disseminated failure as secondary endpoints. 
Local failure was defined as enlargement of at least 20% on CT and 
either biopsy confirming cancer or PET uptake similar to the patient’s 
pretreatment imaging. Marginal failures (within 1 cm of the treated 
lesion) were considered local failures for analysis.
Results: The study opened May 2004 and closed October 2006 after 
accruing a total of 59 pts. Of 55 evaluable pts, 44 had T1 and 11 
had T2 tumors. Median age was 72 years. Contouring compliance 
indicated 98% of targets and 73% of normal tissue structures were 
outlined per protocol or with only minor deviations. Protocol related 
grade 3 and 4 adverse events were reported in thirteen (24%) and 2 
(4%) patients, respectively. The most common severe adverse event 
categories were pulmonary/upper respiratory and musculoskeletal. 
No treatment related deaths have been reported. With median follow-
up of 24.8 months, 3 patients (5%) have been scored with a local 
failure giving an estimated 2-year local control rate of 93.7% (95% 
CI: 81.5%, 98.0%). No patients have experienced regional failure 
while eight patients (15%) experienced distant failure. Two year esti-
mates of disease free and overall survival are 66.6% (95% CI: 52.2%, 
77.5%) and 72.0% (95% CI: 57.9%, 82.1%), respectively.
Conclusions: SBRT using a total (heterogeneity corrected) dose of 
54 Gy in 3 fractions appears to be associated with very high rates of 
local tumor control and moderate treatment related morbidity in a 
population of medically inoperable early stage non-small cell lung 
cancer patients with peripheral lesions. Two year disease free and 
overall survival is encouraging for this frail population.
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Stereotactic radiotherapy (SRT) in patients aged 75 years 
and older with stage I NSCLC – analysis of outcomes in 
193 patients 
Senan, Suresh; Haasbeek, Cornelis J.; Antonisse, Marilisa E.; 
Slotman, Ben J.; Lagerwaard, Frank J.
Department of Radiation Oncology, VU University Medical Center, 
Amsterdam, Netherlands
Patients aged 75 years or older comprise more than 40% of new cases 
of lung cancer. SEER data show a lower compliance with guideline-
recommended therapy in such patients. Elderly patients experience 
an increase in surgical mortality and morbidity, and convalescence at 
extended-care facilities is more common. Stereotactic radiotherapy 
(SRT) involves image-guided delivery of high biological doses of 
radiotherapy in 3-8 fractions in an outpatient setting. We report on 
clinical outcomes of SRT in patients aged 75 years or older.
Materials and Methods: Since 2003, 193 consecutive patients with 
Stage I NSCLC aged 75 years or older (67% male; 32% female) were 
treated with SRT at our center. Median age was 79 years, with 47% 
of patients aged 80 years or older. 56% of patients had T1 lesions and 
44% T2 tumors. 79% of patients were considered medically inoper-
able and 21% refused surgery. All tumors measured 8 cm or less, and 
all patients underwent a staging FDG-PET scan. The median age-
adjusted Charlson co-morbidity score was 7 (range 2-12), and 25% 
had chronic obstructive pulmonary disease GOLD Class III or higher. 
Risk-adapted SRT schemes were used with the same total physical 
dose of 60 Gy in 3 (31%), 5 (53%) or 8 fractions (16%) depending 
upon risk for toxicity. Quality of life was scored prospectively using 
validated EORTC instruments.
Results: SRT was well tolerated, and all but one patient completed 
treatment. Survival rates at 1 and 3 years were 85% and 46%, re-
spectively, and survival correlated with performance score (p=0.001) 
and pre-SRT lung function (p=0.04). Actuarial local-, regional- and 
distant failure rates at 3 years were 11%, 8% and 21%, respectively. 
60% of patients reported no early side effects. Fatigue (31%), cough 
(6%), dyspnea (5%), local chest wall pain (3%) and chest wall 
erythema (2%) were observed in other pts. Severe late toxicity was 
uncommon, with RTOG Grade 3 or higher radiation pneumonitis in 
2%, radiation-induced rib fractures in 2%, chronic chest wall pain in 
3%, and non-malignant pleural effusion in 2% of cases.
Conclusion: In a population consisting of frail elderly patients, cura-
tive SRT achieved high local control rates with minimal toxicity. This 
contrasts with the morbidity and mortality reported using surgery in 
highly-selected elderly populations. In view of this treatment option, 
active diagnostic and therapeutic approaches are clearly justified in 
elderly patients presenting with a clinical stage I NSCLC.
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A5.1 Surgery Allowing Neoadjuvant Treatment of N2 NSCLC, Sat Aug 1, 14:30 - 16:00
Outcomes of lobectomy following chemoradiation for 
locally advanced non-small cell lung cancer
Farlow, Erin Corinne; Kim, Anthony W.; Liptay, Michael J.; Warren, 
William H.; Basu, Sanjib; Bonomi, Philip; Faber, L. Penfield
Rush University Medical Center, Chicago, IL, USA
Background: Resection of locally advanced non-small cell lung 
cancer (NSCLC) remains highly disputed. This study evaluates out-
comes of patients with locoregionally advanced NSCLC treated with 
neoadjuvant chemoradiation therapy (CRT) and lobectomy. 
Methods: Chart review of 144 sequential patients with locally 
advanced NSCLC who underwent neoadjuvant chemoradiation fol-
lowed by lobectomy was performed. Clinicopathologic parameters 
and follow-up information were collected. Kaplan-Meier curves were 
used to assess survival and recurrence using SPSS. 
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Results: There were 63 females and 81 males with a mean age of 
59.8 ± 9.8 years. Pre-treatment stages were: IIb (T3N0) - 35 (24.8%), 
IIIa – 87 (61.7%), IIIb - 9 (6.4%) and IV in 10 (7.1%). Pathologic 
stages were: CR (complete responders) – 39 (27.5%), Ia – 23 
(16.2%), Ib – 13 (9.2%), IIa – 6 (4.2%), IIb – 11 (7.8%), IIIa – 30 
(221.1%), IIIb – 7 (4.9%). Overall 5-year survival was 50%. The 
5-year survival for patients with N0, N1 and N2 disease was 57.7%, 
37.5%, and 33.3%, respectively. A 5-year survival benefit was seen 
for patients downstaged from N2 or N1 to N0 disease after CRT 
(p=0.0181). Female gender was associated with a 5 year survival 
benefit (p=0.0278). Pooled analysis showed survival differences 
amongst the stages (p=0.002). Pooled analysis also showed five-year 
survival correlated inversely with the pathologic T and N stages 
individually, p=0.05 and p=0.006 respectively. 30-day and 90-day 
mortality were 0/144 and 4/144 (2.8%), respectively. 
Major complications post-operatively (atrial fibrillation, reintubation, 
atelectasis, etc) correlated with poorer 5-year survival (p=0.0258). 
Specifically patients with post-operatively respiratory complications 
(reintubation, atelectasis requiring bronch, bronchopleural fistula) 
had a 27.6% 5-year survival compared to those without respiratory 
complications, 55.4% 5-year survival (p=0.0033). Significant cor-
relation with survival was not seen with presenting symptoms, side 
of operation, type of operation (including chest wall resection), or 
histopathology. 
The overall known recurrence rate was 40.9%. Patients with N0 dis-
ease had 37% recurrence (42% local, 58% distant), N1 disease 75% 
recurrence (33% local, 67% distant), N2 had 81% recurrence (34.5% 
local, 65.5% distant). No significant correlation was seen between 
positive nodal disease and local vs. distant recurrence (p=0.62). Posi-
tive nodal disease correlated with increased recurrence (p=0.00001). 
Conclusions: Surgical resection of patients with locally advanced 
disease after neoadjuvant chemoradiation is associated with satisfac-
tory survival, especially among patients with downstaging of nodal 
disease. Post-operative complications and more specifically respira-
tory complications are associated with decreased 5-year survival. 
While survival decreases with positive nodal disease, lobectomy 
after chemoradiation remains a valid treatment for loco-regionally 
advanced disease. Recurrence is more prevalent with positive nodal 
disease, but no difference in location of recurrence (local versus 
distant) was seen between the lymph node positive versus the lymph 
node negative group. 
A5.2 Surgery Allowing Neoadjuvant Treatment of N2 NSCLC, Sat Aug 1, 14:30 - 16:00
Pulmonary resection of non-small cell lung cancer 
(NSCLC) can be performed safely following definitive 
chemoradiotherapy
Page, Brandi R.; Blitz, Maurice; Vallieres, Eric; Louie, Brian E.; Aye, 
Ralph W.
Swedish Cancer Institute, Seattle, WA, USA
Background: Historically, pulmonary resection had been considered 
extremely risky in patients who had received definitive radiation ther-
apy and therefore was contraindicated. As surgeons have accumulated 
more experience in operating after induction chemotherapy alone or 
in combination with radiotherapy up to 45Gy, there has been a shift 
towards considering resection for selected patients who have been 
treated with full dose (>/= 60Gy) radiotherapy. Little has been pub-
lished regarding the safety of this approach. We have analyzed our 5 
year experience in this setting.
Methods:We retrospectively reviewed all patients with NSCLC who 
underwent surgery with curative intent following chemoradiotherapy 
at a single institution between February 2004 and March 2009. Pa-
tients receiving definitive radiotherapy (identified as 60Gy or greater) 
in combination with chemotherapy were eligible for inclusion. Clinic 
and hospital charts and all relevant clinical databases were reviewed. 
Data related to treatment and subsequent morbidity and mortality 
were collected and analyzed.
Results:In the defined study period 24 patients underwent surgical 
resection for NSCLC after having received definitive chemoradio-
therapy. This included 14 women and 10 men with a median age of 
59 years (range 38 – 72). Prior to any therapy, clinical stages were: Ia 
(1), Ib (2), IIa (1), IIb (4), IIIa (6), IIIb (8) and IV (2).
All patients were former (16) or current (8) smokers. Mean preopera-
tive FEV1 was 77% (std. dev. ± 20%) and mean DLCO 61% (std dev. 
± 19%). Pre-operatively, 1 patient was classified as ASA I, 6 as II 
and, 16 as III. 
Median pre-operative radiation dose received was 61Gy (range 60 – 
70 Gy). Sixteen (67%) patients underwent lobectomy, two (8%) had 
bilobectomies, 3 had pneumonectomies (13%) and 3 had Pancoast 
resections (13%) 2 of which included vertebral bodies. All received 
radical mediastinal (N2) node dissections.
There was one (4%) mortality in hospital or within 30-days of sur-
gery. Seventeen (71%) patients suffered 31 morbidities. Nine patients 
experienced parenchymal air leaks lasting greater than 5 days 2 of 
which were discharged with chest tubes in situ. Four had episodic 
atrial fibrillation. Median Hospital stay was 8 days (range 4-28 days).
Eight patients had complete response after chemoradiotherapy while 
16 had residual disease identified in the resection specimen.
Conclusions: In selected individuals surgical resection after defin-
itive chemoradiotherapy (>/= 6000cGy) can be performed safely. 
Although there is morbidity, this resulted in only a modest increase in 
hospital stay and acceptable mortality. Pathologic examination identi-
fied residual disease in 67% of the resected specimens.
A5.3 Surgery Allowing Neoadjuvant Treatment of N2 NSCLC, Sat Aug 1, 14:30 - 16:00
Induction chemo-radiation followed by surgical resection 
for Pancoast tumor: long-term results in a single 
Institution experience
Marulli, Giuseppe1; Breda, Cristiano1; Zuin, Andrea1; Loy, Monica1; 
Favaretto, Adolfo G.2; Loreggian, Lucio3; Sartori, Francesco1; Rea, 
Federico1
1 Thoracic Surgery-University of Padova, Padova, Italy; 2 Oncology-
Veneto Oncologic Institute, Padova, Italy; 3 Radiotherapy-Veneto 
Oncologic Institute, Padova, Italy
Background: Pancoast tumor is a rare neoplasia in which the optimal 
therapeutic management is still controversial. The traditional treat-
ment of Pancoast tumor (surgery, radiotherapy or a combination 
of both) led to an unsatisfactory outcome due to the high rate of 
incomplete resection and the lack of systemic control. Recently, a 
multimodality approach with induction chemo-radiotherapy (CT-RT) 
and surgical resection yielded interesting results.
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The aim of the present mono-institutional study was to determine 
whether a trimodality therapeutic scheme improves local control and 
survival.
Methods: Patients in stage IIB to IIIB were enrolled in the study 
during a period between 1994 and 2008. Induction therapy changed 
over years and consisted of a platinum-based CT: carboplatin AUC 5 
on days 1 and 22, with mitomicin-C 8 mg/m 2 on days 1 and 22 and 
vinblastine 4 mg/m 2 days 1, 8, 22 and 29 (MVC) from 1994 to 1999, 
or combined with vinorelbine 25 mg/m 2 days 1, 8, 22 and 29 (NC), 
from 2000 to 2008. RT was administered 5 days/week, 30 Gy in 10 
fractions from day 22 to 35 (from 1994 to 1996), or 44 Gy in 22 frac-
tions, from day 22 to 52 (from 1997 to 2008). After restaging, eligible 
patients underwent surgery 3-4 weeks post-radiation.
Results: Forty-seven patients (male/female ratio: 42/5, median age: 
62 yrs) completed the protocol. 17(36.2%) received MVC chemo-
therapy scheme and 30 (63.8%) NC. 8 (17%) patients received 30 
Gy of RT and 39 (83%) 44 Gy. 39 (82.9%) patients underwent R0 
resection and 6 (12.8%) had a complete pathologic response (CPR). 
28 (59.6% ) cases were T3 and 19 (40.4%) T4, 40 (85.1%) were N0 
and 7 (14.9%) N+. Thirty-days mortality rate was 6.4% (n=3/47), 
perioperative non fatal complications occurred in 22.8% (n=10/44). 
Overall, 5-year survival was 35%, 52% for patient with stage IIB 
R0 and 83% for the small group of CPR. Significant difference in 
survival was found between T3 and T4 tumors (5-year survival: 49% 
and 13%, respectively. p=0.007), also R0 and R1 resection had a 
different prognosis, even not significant (5-year survival 39% and 
15%, respectively. p=0.07). On multivariate analysis T status was 
an independent predictor of survival (p=0.01). At last follow-up, out 
of 39 R0 patients, 7 (17.9%) had a local recurrence and 12 (30.8%) 
distant metastasis. 
Conclusions: This combined approach is feasible and allows for a 
good rate of complete resection. Long term survival rates are accept-
able, especially for T3 tumors. Systemic control of the disease still 
remains poor with distant recurrence being the most common cause 
of death. 
A5.4 Surgery Allowing Neoadjuvant Treatment of N2 NSCLC, Sat Aug 1, 14:30 - 16:00
Comparative study of anterior and posterior approaches to 
superior sulcus tumors
Shrager, Joseph B.1, 3; Nathan, Derek2; Hoang, Chuong D.1; Kurichi, 
Jibby E.4; Kucharczuk, John C.2; Kaiser, Larry R.2
1 Stanford University School of Medicine, Stanford, CA, USA; 2 
University of Pennsylvania School of Medicine, Philadelphia, PA, 
USA; 3 VA Palo Alto Health Care System, Palo Alto, CA, USA; 4 
University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Background: Anterior approaches to Pancoast tumors have become 
more popular in recent years. No study, however, has directly com-
pared outcomes following anterior versus posterior approaches. We 
hypothesized that the anterior approach provides measurable benefits. 
Methods: Retrospective review of patients with NSCLC involving 
the first rib or higher who were operated upon between 1995 and 
2005. 
Results: Among 49 patients, there were 19 anterior approaches 
(group A) and 30 posterior approaches (group B). Anterior approach-
es included 4 thoracosternotomies and 15 cervicothoracic, modified 
“Dartevelle” incisions. The median year of surgery was 2001 in group 
A and 1999 in group B, suggesting a shift to anterior approaches 
over time. The only preoperative variables that differed significantly 
were rate of administration of neoadjuvant therapy (A=78%; B=30%) 
and age (A=54 years; B=63 years). Most patients in both groups had 
stage IIB tumors, but there were more IIIB tumors and thus extended 
resections in group A (29% vs 4%; p=0.022). Group B had more 
ribs resected (mean 3.7 vs 2.3; p<0.001). Lobectomy was performed 
in 95% in group A and 97% in group B. There were no significant 
differences in the rates of complete resection (A=79%; B=87%) or 
30 day mortality (A=5%; B=3%). Length of stay was substantially 
longer in group B (13.7 vs 8.9 days; p=0.049). In groups A and B, 
39% and 33% of followed patients remain alive without disease at 
means of 38 and 55 months, respectively. 
Conclusions: The anterior and posterior approaches to Pancoast 
tumors result in similarly acceptable morbidity/mortality rates and 
good technical outcomes. The anterior approach appears to facilitate 
complete resection of T4 tumors. The shorter length of stay despite 
a higher rate of T4 tumors and neoadjuvant therapy in the anterior 
group suggests that this approach may be less morbid. 
A5.5 Surgery Allowing Neoadjuvant Treatment of N2 NSCLC, Sat Aug 1, 14:30 - 16:00
Pre-operative and post-operative prognostic factors in 
patients with resectable N2-NSCLC
Ratto, Giovanni B.1; Costa, Roberta2; Maineri, Paola3; Alloisio, 
Antonella1; Piras, MariaTeresa1; Verna, Anna1; Lupi, Paolo3; Bruzzi, 
Paolo4; Dozin, Beatrice4
1 Unit Thoracic Surgery, Dept Surgical Oncology, Nat Cancer 
Research Inst, Genoa, Italy; 2 Dept Cardiothoracic Surgery, SS 
Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy; 3 Unit 
Thoracic Surgery, Santa Corona Hospital, Pietra Ligure, Italy; 4 
Unit Clinical Epidemiology, Dept Epidemiology and Prevention, Nat 
Cancer Research Inst, Genoa, Italy
Background: Long-term survival in patients with pre-operatively 
demonstrated N2-NSCLC remains poor. Controversy still persists 
as to which factors have greater influence on prognosis, and which 
patients may benefit from surgery. This study was planned to identify 
significant pre- and the post-surgery prognostic factors suitable for 
selecting surgical candidates and for assessing prognosis. In every 
patient a pre-established number of descriptors was prospectively 
recorded. 
Methods: Included in this study were 277 consecutive, pre-opera-
tively documented (by mediastinoscopy) N2-NSCLC patients who 
underwent surgery with systematic mediastinal lymph node dissec-
tion between February 1991 and July 2004. One hundred ninety two 
patients were treated with initial surgery and 85 with neoadjuvant 
chemotherapy (3 cycles of platinum based chemotherapy combined 
with at least 1 other drug: gemcitabine, paclitaxel or vinorelbine) 
followed by surgery. Before 1999, surgery was the initial treatment. 
From 1999, neoadjuvant chemotherapy was our first option of treat-
ment, and only patients who refused neoadjuvant chemotherapy were 
treated primarily with surgery. Among the patients who underwent 
induction chemotherapy 45.7% did not go to surgery because of 
deterioration of the health status, complications or disease progres-
sion. Kaplan-Meier curves were used to evaluate survival, and the 
statistical significance of differences between curves was assessed by 
the log-rank test. Cox’s regression was used for multivariate analyses.
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Results: In the entire group of patients, cumulative 5-year OS was 
21.3%, and median OS 1.4 years. 
In multivariate analysis, the pre-operative factors significantly associ-
ated with survival were: number of involved nodal stations (p<0.001), 
severity of symptoms (p=0.013), preoperative T (p=0.041), and 
administration of neoadjuvant chemotherapy (p=0.001). Three groups 
of patients with different prognosis were identified, based on the 
individual prognostic score. The 5-year OS in patients with the most 
favourable prognostic factors was 40%, while being below 10% in 
patients with the worst prognostic factors.
The post-operative predictors of survival were: pathological T 
(p=0.003), incomplete resection (p=0.034) and number of mediastinal 
nodes involved (p<0.001). Again, 3 groups of patients with different 
prognosis were identified: the 5-year OS was 47% in the best prog-
nostic group, and 5% in the worst, respectively.
Conclusions: Although the design of the present study does not allow 
inferences on the relative value of different treatment strategies, it 
shows that, on the basis of the significant pre-operative prognostic 
factors we have identified, it is possible to select subgroups of patients 
with different prognosis, the subset with better prognosis having a 
median survival of 29.6 months. Since pre-operatively demonstrated 
N2-NSCLC patients with the most favourable prognostic factors 
showed good long-term survival and excellent local disease control, 
surgery should still play an important role in the multimodality treat-
ment of these patients. Although our study points out the usefulness of 
the significant post-operative factors for assessing patient prognosis, 
their value for planning adjuvant treatments remains to be evaluated.
A5.6 Surgery Allowing Neoadjuvant Treatment of N2 NSCLC, Sat Aug 1, 14:30 - 16:00
Surgical resection of locally advanced non-small cell 
lung cancer following neoadjuvant chemoradiation is 
appropriate even in the presence of persistent nodal 
metastases
Kim, Anthony W.; Farlow, Erin C.; Faber, L. P.; Warren, William H.; 
Basu, Sanjib; Bonomi, Philip; Liptay, Michael J.
Rush University Medical Center, Chicago, IL, USA
Background: Surgery following chemoradiation for locoregionally 
advanced non-small cell lung cancer (NSCLC) with positive lymph 
nodes is controversial. The objective of this study was to evaluate the 
impact on survival of anatomic pulmonary resections in the pres-
ence of pathologically positive N1 and N2 disease after neoadjuvant 
chemoradiation. 
Methods: Between 1989 and 2007, 223 patients were identified 
as having locally advanced NSCLC who underwent neoadjuvant 
chemoradiation followed by pneumonectomy, sleeve lobectomy, 
bilobectomy, or lobectomy. Clinicopathologic parameters including 
age, gender, pathologic stage including individual T and N status, and 
follow-up information were collected. Univariate analysis was per-
formed with Kaplan-Meier survival curves that were generated and 
compared using log-rank analysis. Multivariate analysis with a Cox 
regression model was also performed to analyze survival.
Results: The mean age of the total population was 58.0 ± 9.7 years 
(range: 30-78). There were 105 female and 118 male patients. Post 
resection pathologic stages were: Complete Responders [CR] – 50 
(22.5%), I – 50 (22.5%), II – 38 (17%), and III – 85 (38%). The 
pathologic status of the surgically resected primary tumors were: 
T0 – 53 (24%), T1 – 62 (28%), T2 – 59 (26%), T3 – 31 (14%), and 
T4 – 18 (8%). The pathologic status of the surgically resected lymph 
nodes were: N0 – 124 (56%), N1 – 27 (12%), and N2 – 72 (32%). 
The overall survival 5-year for the entire cohort of patients was 46%. 
The 90-day mortality rate was 7% (16/223).
Univariate analysis demonstrated that there were no differences in 
survival according to gender or laterality of resection. According 
to the type of resection, 5-year survivals were 36% for pneumon-
ectomy vs. 53% for lobectomy (including conventional lobectomy, 
sleeve lobectomy, and bilobectomy), p=0.0047. According to stage, 
5-year survivals were: CR – 64%, I – 54%, II – 41%, and III – 33%. 
When stratified according to pathologic nodal status, 5-year survivals 
were: N0 – 54%, N1 – 41%, N2 – 35% (Figure 1). The difference in 
survival was not significant between N0 and N1 disease, p=0.1484 
and between N1 and N2 disease, p=0.7590. In contrast, the difference 
in survival between N0 and N2 disease was significant, p≤0.0093. A 
significant difference was found in survival between N0 and any node 
positive (N1 + N2) disease, p =0.0080. 
Multivariate analysis demonstrated that pneumonectomy was associ-
ated with a statistically significant worse 5-year survival, p=0.0117. 
On the other hand, the multivariate analysis demonstrated that the 
patients who were classified as a CR had a statistically significant 
improved 5 year survival, p=0.0214.
Conclusions: Acceptable 5-year survival can be achieved in patients 
with locally advanced disease following neoadjuvant chemoradiation 
and an anatomic pulmonary resection with total lymphadenectomy. 
Complete sterilization of NSCLC is associated with the most favor-
able long term survival. Patients with persistently positive N2 disease 
had reasonable long term survival rates and therefore, resection can 
be recommended even in this subset of patients. 
A5.7 Surgery Allowing Neoadjuvant Treatment of N2 NSCLC, Sat Aug 1, 14:30 - 16:00
Surgery versus radiosurgery for single synchronous brain 
metastasis from non-small cell lung cancer
Li, Hui; Hu, Bin; Hou, Sheng-cai
Department of Thoracic Surgery, Beijing Chaoyang Hospital, Capital 
Medical University, Beijing, China
Background: The aim of this study is to compare the effectiveness of 
surgery with that of radiosurgery for patients with a single synchron-
ous brain metastasis from successfully treated non-small cell lung 
cancer. 
Method: Between 1995 and 2002, fifty-three patients underwent 
resection of both a primary non-small cell lung cancers and the as-
sociated single brain metastasis. There were 33 men and 20 women 
with a mean age of 57 years (range, 32-85 years). At the time of 
diagnosis,forty-two patients experienced lung cancer related symp-
toms, whereas 11 patients experienced brain metastases-related symp-
toms. Forty-two patients had ungone thoracic surgery first, and 11 
patients had undergone neurosurgery or radiosurgery first. Pneumon-
ectomy was performed in 9 out of 42 patients (21.4%), lobectomies 
in 30 (71.4%), and wedge resection in 3 (7.2%). Forty-eight patients 
(90.5%) underwent complete lymphadenectomy. 35 patients under-
went brain metastasectomy. 18 underwent SRS. 
Results: There was no postoperative mortality and severe com-
plications after either lung or brain surgery. Histology showed 34 
adenocarcinomas, 16 squamous cell carcinomas, and 3 large cell 
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lung cancers. 15 patients (28.3%) had no evidence of lymph node 
mtastases (N0), 20 patients (37.7%) had hilar metastases (N1), and 
18 patients (34%) had mediastinal metastases (N2). The 1-,2-, 3- and 
5-year overall survival rates were 49%,19%, 10%, and 5%, respect-
ively. The corresponding data for neurosurgery group was 55%, 17%, 
11%, and 6%, respectively. The median survival time was 13 months. 
For SRS group the corresponding data were 44.8%, 20.9% 10.5%, 
and 2%, respectively. The median survival time was 14 months. The 
differences between the two groups were not significant (p>0.05). In 
lymph node negative patients (N0), the overall 5-year survival rate 
was 10%, as compared with a 1% survival rate in patients with lymph 
node metastases (N1-2). The difference was significant (p<0.01). For 
adenocarcinomas, the 5-year survival rate was 5%. The correspond-
ent data for squamous cell lung cancers was 3%. The difference was 
not significant (p>0.05). 
Conclusion: Although the overall survival rate for patients who have 
brain metastases from NSCLC is poor, surgical resection or radiosur-
gery may prove benificial in a select group of patients with synchron-
ous brain metastases and lung cancer without lymph node metastases.
Session A6: Novel Combination 
Regimens and Unique Pathways 
Saturday, August 1 
A6.1 Novel Combination Regimens and Unique Pathways, Sat Aug 1, 14:30 - 16:00
Improved survival in a double-blind, placebo-controlled, 
randomized phase 2 study of AT-101 plus docetaxel, in 
second-line NSCLC
Ready, Neal2; Karaseva, Nina A.3; Orlov, Sergey V.4; Luft, Alexander 
V.5; Popovych, Olexandr7; Liu, Ping-Yu6; Holmlund, Jon T.1; Wood, 
Brian A.1; Leopold, Lance1
1 Ascenta Therapeutics, Malvern, PA, USA; 2 Duke University, 
Durham, NC, USA; 3 St Petersburg City Clinical Oncology Center, 
St Petersburg, Russia; 4 St Petersburg Sate Medical University n.a. 
Ivan Pavlov, St Petersburg, Russia; 5 Leningrad Regional Clinical 
Hospital, St. Petersburg, Russia; 6 Fred Hutchinson Cancer Center, 
Seattle, WA, USA; 7 Donetsk Regional Antitumor Center, Donetsk, 
Ukraine
Background: AT-101 is an inhibitor of Bcl-2 family proteins includ-
ing Bcl-2, Bcl-xL, Mcl-1, and Bcl-w. In vivo and in vitro studies have 
exhibited broad activity of AT-101, including synergy with docetaxel 
in NSCLC tumor models.
Methods: We conducted a prospective, randomized (1:1), double-
blind, placebo-controlled phase 2 study. Eligible patients must 
have received one prior chemotherapeutic regimen for advanced 
or metastatic NSCLC and may also have received therapy with an 
EGFR inhibitor. Patients received AT-101 (40 mg b.i.d. x 3 days) or 
placebo in combination with docetaxel (75mg/m2 on day one) every 
21 days. The primary endpoint was progression-free survival (PFS) 
as determined by independent review; other endpoints include overall 
survival (OS) and PFS by investigator determination. Approximately 
102 patients were planned to provide 70 events (80% power, hazard 
ratio of 0.6, 1-sided alpha of 0.1).
Results: 106 patients were assigned to treatment and 105 patients 
received at least one dose of AT-101 or placebo. Baseline factors 
were balanced between treatment groups: median age 59 years; 
77% male, and 79% current or former smokers. 94% of patients had 
distant metastatic disease at randomization and 56% had squamous 
histology. The most frequently reported adverse events were fatigue 
(18%), anemia (18%), and dyspnea (18%). No statistically signifi-
cant differences in AEs were observed between AT-101 and placebo; 
grade 1/2 headaches appeared more frequently with AT-101 (9% vs 
0%) and neutropenia was reported more frequently in the placebo + 
docetaxel arm (17% vs 8%). Unlike trials with continuous daily dos-
ing of AT-101, no cases of non-mechanical small bowel obstruction 
were reported. IHC analysis of BCL-2 family proteins was conducted 
on tumor samples from 18 patients; 3/16 were positive for BCL-2, 
17/18 for MCL-1, 18/18 for BCL-xL, and 18/18 for p53. With 71 
events, the median investigator determined PFS was 12.6 weeks and 
10.7 weeks for the AT-101 + docetaxel and placebo + docetaxel arms 
respectively (HR 1.0, p=0.49). After 46 deaths, the median OS for 
patients on AT-101 + docetaxel was 7.3 months versus 5.6 months 
on the placebo + docetaxel arm (HR 0.60, p =0.05) (Figure 1); final 
survival data will be provided. A subgroup analysis of survival sug-
gested the benefit was primarily seen in squamous histology (HR 
0.59, p=0.09).
Conclusions: AT-101 is the first oral, pan Bcl-2 family inhibitor to 
suggest a survival benefit in a randomized study. The addition of AT-
101 was well tolerated with an AE profile indistinguishable from the 
base docetaxel regimen.
A6.2 Novel Combination Regimens and Unique Pathways, Sat Aug 1, 14:30 - 16:00
Pharmacodynamic separation (PDS) of pemetrexed and 
erlotinib versus pemetrexed monotherapy as second-line 
therapy in patients with advanced non-small cell lung 
cancer (NSCLC): first-stage analysis of a randomized 
phase II study
Li, Tianhong3; Gucalp, Rasim 3; Piperdi, Bilal1; Walsh, William V.1; 
Kim, Mimi3; Cohen, Bruce3; Shan, Jidong3; Mack, Philip C.2; Lara, 
Jr, Primo N.2; Gandara, David R.2; Perez-Soler, Roman3
1 University of Massachusetts-Memorial Campus, Worcester, MA, 
USA; 2 University of California Davis Cancer Center, Sacramento, 
CA, USA; 3 Montefiore-Einstein Cancer Center, Bronx, NY, USA
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Background: Preclinical and phase I studies support that PDS 
between the EGFR TKI erlotinib and a multi-targeted antifolate 
pemetrexed could avoid potential antagonistic effects. The primary 
objective of this ongoing, investigator-initiated, multi-center, random-
ized phase II study was to determine the progression-free survival 
(PFS) of pemetrexed monotherapy (Arm A) and PDS of pemetrexed 
and erlotinib (Arm B) as second-line therapy in patients with ad-
vanced NSCLC (stage IIIB with a malignant pleural effusion or stage 
IV disease). 
Methods: Advanced NSCLC patients who progressed after first-line 
chemotherapy for metastatic disease or recurred while receiving (or 
within 12 months of completing) adjuvant therapy and had measur-
able disease, adequate organ function and ECOG performance status 
of 0-2 were eligible. Patients were randomized in 1:2 to Arm A or B 
according to gender, prior smoking history, and performance status. 
Treatment consisted of pemetrexed 500 mg/m2 IV over 10 minutes 
on day 1 every 21 days in both arms and erlotinib 150 mg orally once 
daily on days 2-17 every 21 days in Arm B. Seventy-five evaluable 
patients are required to detect a 50% improvement in median PFS in 
Arm B compared to Arm A. Pre-specified interim analysis defines 
that the study will be terminated early if 15 or more of the first 20 
patients in Arm B have a PFS of <3 months.
Results: Twenty-eight patients have been enrolled to-date. Twenty-
seven patients are assessable (9 in Arm A and 18 in Arm B). Median 
PFS is 1.5 and 3.3 months in the Arms A and B, respectively (log-
rank p value=0.03). Disease control rate (i.e., partial response and 
stable disease for at least 3 months) was 22% (2 of 9 patients) and 
65% (11 of 17 patients) in Arms A and B, respectively. Grade 3/4 
hematologic toxicities were observed in 2 (22%) and 3 (18%) patients 
in Arms A and B, respectively. One patient in Arm A and 2 patients 
in Arm B required dose reduction of pemetrexed. Results of correla-
tive science studies, which include mutational analysis of EGFR and 
K-Ras genes using serum tumor DNA and quantitative multiplex 
immunohistochemistry assay using archival tumor specimens col-
lected from the study patients, are ongoing and will be presented. 
Conclusions: PDS of pemetrexed and erlotinib is well tolerated and 
has promising clinical activity in the first-stage analysis. These prelim-
inary results compliment other recent data in support of intermittent 
dosing schedules of EGFR TKIs and chemotherapy. Given the recent 
change in the indication of pemetrexed, the study has been amended to 
accrue only NSCLC patients with non-squamous histology.
Acknowledgement: Supported by Montefiore Medical Center, Eli 
Lilly and Company and OSI Pharmaceuticals.
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Phase II trial: effect of All-trans retinoic acid with 
chemotherapy based in paclitaxel and cisplatin as first line 
treatment of patients with advanced non-small cell lung 
cancer
Arrieta, Oscar 1, 2; De la Rosa, Claudia Haydée G.3; Ocampo, Elena 
A.2; Lizarraga, Tania L. C.2; Avitia, Miguel Angel A.1; Manríquez, 
María E. V.4; Rios Trejo, Miguel Angel 2; Rodríguez, Geraldine V.2; 
Salazar, Jaime D.1
1 Department of Medical Oncology, Instituto Nacional de 
Cancerología, México, D.F., Mexico; 2 Experimental Oncology 
Laboratory, Instituto Nacional de Cancerología (INCAN), México, 
D.F., Mexico; 3 Universidad Autónoma Metropolitana (UAM 
Cuajimalpa), México, D.F., Mexico; 4 Department of Pathology, 
Instituto Nacional de Enfermedades Respiratorias (INER), Mexico 
City, Mexico
Background: Platinum-based chemotherapy (CT) is the standard 
treatment for advanced non–small-cell lung cancer (NSCLC). 
Unfortunately, the survival and response rate (RR) to CT is poor. All 
trans retinoic acid (ATRA) has tumor-supressive capacity through 
binding and activating it´s nuclear receptors RAR and RXR. Specific-
ally ATRA acts through RAR beta (RAR β2) isoform. Loss of it´s ex-
pression is associated with human tumor progression in lung cancer. 
Previous phase I and II studies have indicated that adding ATRA to 
CT could have a synergic effect and may improve outcome in ad-
vanced NSCLC.The aim of this trial is to determine the progression-
free survival (PFS) and RR of ATRA in addition to paclitaxel and 
cisplatin in patients with advanced NSCLC.
Methods: Between April 2005 and October 2007, 107 patients with 
stage IIIB and IV NSCLC were included to receive Paclitaxel 175 
mg/m2 and Cisplatin 80 mg/m2 (PC) every 21 days for a maximum of 
6 cycles. Patients were randomized to receive ATRA 20 mg/day (RA/
PC) or placebo (P/PC) 1 week before treatment until completing two 
cycles. Imaging studies were performed prior and after two cycles of 
CT to assess response. RAR β2 expression was analyzed by immuno-
histochemistry (IHC) and RT-PCR.
Results: RR for RA/PC was 55.8% (CI 95%, 46.6% - 64.9%) and 
for P/PC of 25.4% (CI 95%, 21.3% - 29.5%, p=0.001). Median of 
PFS was 8.9 months vs 6.0 months (p=0.008) for RA/PC and P/PC, 
respectively. The multivariate analysis of PFS adjusted to stage at 
enrollment showed significant differences in favor to RA/PC group 
(HR 1.62, CI 95% 1.06-2.5, p=0.028). No significant differences 
in toxicity grade 3/4 were found between groups except for hyper-
triglyceridemia (10% vs 0%) in RA/PC (p=0.05). Only 6 tumors 
were positive for RAR β2 by IHC and RT-PCR in tumor tissue, but 
remained expressed in adjacent normal tissue.
Conclusions: Adding ATRA to CT could increase RR and PFS in ad-
vanced NSCLC patients with an acceptable toxicity profile. A phase 
III clinical trial is warranted to confirm these findings. 
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Clinical activity of the oral ALK and MET inhibitor PF-
02341066 in non-small lung cancer (NSCLC) with EML4-
ALK translocations
Shaw, Alice T.2; Costa, Daniel B.1; Iafrate, A. J.2; Dezube, Bruce J.1; 
Shapiro, Geoffrey I.4; Bang, Yung J.7; Janne, Pasi A.4; Lynch, Thomas 
J.2; Maki, Robert G.5; Camidge, D. R.3; Solomon, Benjamin 6; Kwak, 
Eunice L.2; Tan, Weiwei10; Chen, Isan 10; Christensen, Jamie 10; 
Wilner, Keith9; Clark, Jeffrey W.2; Salgia, Ravi8
1 Beth Israel Deaconess Medical Center, Harvard Medical School, 
Boston, MA, USA; 2 Massachusetts General Hospital Cancer Center, 
Harvard Medical School, Boston, MA, USA; 3 University of Colorado 
Cancer Center, Denver, CO, USA; 4 Dana-Farber Cancer Institute, 
Harvard Medical School, Boston, MA, USA; 5 Memorial Sloan 
Kettering Cancer Center, New York, NY, USA; 6 Peter MacCallum 
Cancer Centre, Melbourne, Australia; 7 Seoul National University 
Hospital, Seoul, Korea; 8 University of Chicago Medical Center, 
Chicago, IL, USA; 9 Pfizer Pharmaceuticals, La Jolla, CA, USA; 10 
Pfizer Inc., La Jolla, CA, USA
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Background: PF-02341066 (PF) is a selective, ATP-competitive, 
small molecule, orally bioavailable inhibitor of the ALK and MET/
HGF (hepatocyte growth factor) receptor tyrosine kinases. EML4-
ALK translocations have been reported in approximately 4% of 
NSCLC. NSCLC patients whose tumors harbor an EML4-ALK fusion 
oncogene were recruited into an expanded cohort at the recom-
mended phase 2 dose (RP2D) within the first-in-patient monotherapy 
trial of PF.
Methods: The RP2D of PF in the dose escalation portion of the study 
was determined to be 250 mg twice daily (BID). ALK transloca-
tions were determined by FISH using a break-apart probe to ALK. 
Responses were determined by RECIST, and radiographic studies 
repeated every 8 weeks. Disease control rate (DCR) is the sum of 
complete/partial responses and stable disease rates.
Results: To date, 13 EML4-ALK NSCLC patients have been treated 
within the expanded cohort. The median number of prior treat-
ments was 2 (range, 1- 7). All patients were either never (N=9) or 
light smokers (N=4) with adenocarcinoma histology or NSCLC 
not otherwise specified. Predicted target efficacious concentration 
inhibiting ALK phosphorylation from preclinical tumor models was 
estimated to be at least 120 ng/mL. Mean plasma Ctrough achieved at 
250 mg BID was 292 ng/mL and median terminal t1/2 was approxi-
mately 51 hours. Eight of the 13 patients were evaluable for response; 
6 achieved partial response and 1 had stable disease as the best 
response. DCR at week 8 in the evaluable patients was calculated at 
87.5% (7/8). All PRs are currently ongoing (range, 2 to 4+ months). 
Of note, 5/6 PRs demonstrated response at the time of the first sta-
ging CT scan. Mature data on time to progression and survival will be 
presented at the meeting.
Conclusions: The oral ALK and MET inhibitor PF demonstrated 
marked activity in patients whose tumors harbor the EML4-ALK 
translocation, validating ALK as a therapeutic target in this recently 
defined molecular subset of NSCLC. Future development of PF as a 
novel therapy for NSCLC is underway.
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Phase 1 dose escalation trial (ARQ 197-111) evaluating 
combination of selective c-Met inhibitor ARQ 197 and 
erlotinib
Goldman, Jonathan W.1; Rosen, Lee1; Laux, Isett1; Brady, Karen3; 
Li, Jian2; Schwartz, Brian2; Savage, Ron2; Garmey, Edward G.2; Just, 
Richard3
1 Premiere Oncology, Santa Monica, CA, USA; 2 ArQule, Inc., 
Woburn, MA, USA; 3 Pacific Oncology, San Diego, CA, USA
Background: Recent evidence suggests that c-Met amplification 
promotes resistance to EGFR-inhibition by driving ERBB3 (HER3)–
dependent PI3K activation. Dual EGFR-Met inhibition is now pro-
posed as a strategy for overcoming primary and secondary resistance 
to EGFR-inhibition. ARQ197 (A) is a selective, non-ATP competitive 
inhibitor of c-Met, a receptor tyrosine kinase implicated in tumor 
cell migration, invasion, and proliferation. Phase I data for ARQ 197 
monotherapy is previously reported. 
Methods: Patients (pts) were enrolled in a sequential-cohort dose-
escalation trial to define safety, tolerability, pharmacokinetics (PK), 
and preliminary anti-tumor activity of A in combination with 150 mg 
daily oral erlotinib (E). Oral A was administered at escalating doses 
of 120, 240, and 360 mg bid. Intra-patient dose escalation was al-
lowed in the absence of dose-limiting toxicity (DLT) through 1 cycle 
of therapy (21 days).
Results: 25 pts (10 F/15 M; mean 60.5 yrs) received EA in combina-
tion with starting A dose of 120 (8 pts), 240 (4 pts), and 360 (13 pts) 
mg bid. PK data displayed linear kinetics through 360 bid and no 
evidence of drug-drug interaction. Adverse events (AEs) considered 
related to combination therapy were reported in 13 (52%) pts incl. 
(≥ 10% of patients) sinus bradycardia (5 pts), fatigue (5 pts), rash 
(4 pts), itching (3 pts), and diarrhea (3 pts). Two pts experienced 
treatment-related serious AEs incl. neutropenia (360 bid) and sinus 
bradycardia (240 bid). One death occurring on-study was considered 
unrelated to study drug. 9/10 evaluable pts demonstrated disease 
stabilization (SD) as their best RECIST response (5.9-27.1+ wks). 
Tumor regressions (2.3%-19.4%) were observed in 4/10 evaluable 
pts. Of note, 3/3 evaluable pts with NSCLC achieved SD for dur-
ations (14-32 wks) exceeding the median PFS in BR.21 (9.7 wks). 
Conclusions: Continuous therapy with EA combination appears well 
tolerated and without drug-drug interaction. While no formal MTD 
was identified, a phase 2 combination dose (R2PD) of 360 mg bid 
A + 150 mg daily E is recommended. This RP2D is currently being 
investigated in an ongoing randomized trial comparing EA to E 
monotherapy in 2nd/3rd line NSCLC.
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A phase II trial of 5-azacitidine (5AC) and entinostat 
(SNDX-275) in relapsed advanced lung cancer (NSCLC): 
an interim analysis
Juergens, Rosalyn1; Vendetti, Frank2; Coleman, Barbara1; Sebree, 
Rosa1; Belinsky, Steven3; Rudek, Michelle1; Brock, Malcolm2; 
Herman, James1; Baylin, Stephen1; Rudin, Charles1
1 The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, 
Baltimore, MD, USA; 2 The Johns Hopkins University, Baltimore, 
MD, USA; 3 Lovelace Respiratory Research Institute, Albuquerque, 
NM, USA
Background: Epigenetics refers to heritable changes in the pattern of 
gene expression mediated by mechanisms other than alteration of the 
primary nucleotide sequence. Through epigenetic inactivation, genes 
can be silenced, promoting malignant transformation. Epigenetic 
gene silencing is mediated through aberrant DNA methylation and 
histone deacetylation. Epigenetic gene silencing is a key contributor 
in lung carcinogenesis. Pre-clinical studies suggest that combining 
inhibitors of DNA methyltransferase (DNMT) with inhibitors of his-
tone deacetylase (HDAC) synergistically induce re-expression of epi-
genetically-silenced tumor suppressor genes. Clinical studies at our 
institution combining the DNMT inhibitor, 5-azacytidine (5AC), with 
HDAC inhibitors including phenylbutyrate or entinostat in hema-
tologic malignancies have resulted in remarkable clinical activity, 
associated with evidence of re-expression of key tumor suppressor 
genes known to be epigenetically silenced in these diseases. Based on 
this research, we have explored this approach in lung cancer. A phase 
I study of 5AC and entinostat has been completed and shown this 
combination is safe and tolerable. We now report the updated results 
of the phase II study of 5AC and entinostat in refractory NSCLC.
Methods: The study is limited to patients ≥ 18 years of age with 
histologically confirmed recurrent NSCLC with progressive disease 
after at least one previous chemotherapy regimen. 40 mg/m2 of 5AC 
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is administered SQ days 1-6 and 8-10 with 7 mg of entinostat given 
days 3 and 10 of a 28 day schedule. A standard Simon two stage 
design is being used. The sample size was calculated with a power 
of 90% and a two-sided type 1 error allowance of 5%. Stage 1 will 
include 18 patients. After 1 response is documented, the total accrual 
goal expands to 32 patients.
Results: 27 patients have enrolled in this phase II trial. The demo-
graphic characteristics include: mean age (range) - 63 (46-80); Male: 
Female ratio - 1:2; 80% former smokers; 80% adenocarcinomas; 
mean number of previous therapies - 3. To date we have had two 
impressive responses. One woman had a complete response despite 
progressing previously through 2 prior therapies as well as radiation. 
She remained on therapy for 14 months before coming off therapy 
due to a new nodule which was resected. The new nodule was patho-
logically and genetically distinct from her initial tumor. She remains 
disease-free 12 months off of therapy. Another man has continued 
stabilization of disease for over 18 months with marked improvement 
in quality of life. He had progressed rapidly through 3 previous ther-
apies. Another two patients had stabilization of disease for 4 months. 
Another patient has tumor shrinkage after 2 cycles that does not yet 
meet criteria for a partial response. He remains on therapy. Two other 
patients are actively being treated and have not been evaluated for 
response. The remaining 20 patients have progressed after 2 cycles of 
therapy. The main toxicities include injection site reactions, nausea/
vomiting, constipation, fatigue, and hematologic toxicities.
Conclusions: 5AC and entinostat are safe and tolerable in advanced 
NSCLC patients. Several patients have had impressive benefit from 
treatment. This abstract reports the first documented responses to 
combined epigenetically-directed therapy in solid tumors. Further 
studies are planned for earlier stage disease. Pharmacodynamic and 
pharmacokinetic analyses are being conducted to identify optimal 
candidates for this novel therapy.
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Clinical activity of BIBW 2992, an irreversible inhibitor 
of EGFR and HER2 in adenocarcinoma of the lung with 
mutations in the kinase domain of HER2neu
De Grève, Jacques L.1; Teugels, Erik1; De Mey, Johan1; Geers, 
Caroline1; Galdermans, Danny3; Decoster, Lore1; In ‘t Veld, Peter1; 
Schallier, Denis1; Taton, Martine2; Shahidi, Mehdi2
1 Medical Oncology, Oncologisch Centrum, UZBrussel, Brussels, 
Belgium; 2 Boehringer-Ingelheim, Brussels, Belgium; 3 ZNA 
Middelheim, Antwerp, Belgium
Background: HER2neu mutations are found in 2-4 % of lung adeno-
carcinoma and like EGFR mutations are more common in female, 
non-smokers and patients with Asian background. BIBW 2992 (To-
vok™) is a potent, irreversible inhibitor of EGFR and HER2 (IC50 
0.5 and 14nM, respectively) with preclinical and clinical activity 
in NSCLC with EGFR mutations. An exploratory Phase II study in 
demographically and genetically selected NSCLC is being conducted.
Methods: Patients with stage IIIB/IV lung adenocarcinoma who are 
never or light ex-smokers and their tumors harbor EGFR or HER2 
mutations (current report) or are EGFR FISH+ are eligible. Patients 
receive 50 mg BIBW 2992 qd until disease progression. Tumor as-
sessments are performed every 8 weeks. Based on the criteria set out 
in the protocol, patients who progress may continue treatment with 
BIBW 2992 and weekly paclitaxel (80 mg/m² weekly, 3/4 weeks). 
The primary endpoint is objective response rate.
Results: To date three patients (age: 49, 62 and 72 yrs) with lung 
adenocarcinoma and HER2 mutations in exon 20 (determined by 
DGGE and nucleotide sequencing) have been included. All three pa-
tients are female, non smokers with Stage III/IV adenocarcinoma of 
the lung and had failed prior chemotherapy (up to five lines). Prelim-
inary analysis shows significant improvement of patients’ symptoms 
and performance status as well as tumor size reduction amounting to 
PR in all three patients. One patient has been on treatment >6 months. 
Diarrhea and skin rash were the predominant AEs.
Conclusions: This is the first report of the use of BIBW 2992 in three 
pretreated patients with NSCLC and activating HER2 mutations in 
exon 20, leading to significant subjective and objective benefit. The 
presence of HER2 mutation characterizes a subgroup of NSCLC 
dependent on HER2 pathway for survival. This clinical observation 
closely mimicks very recent results with BIBW 2992 in a HER2 driv-
en transgenic lung cancer model (Perera et al., Proc Natl Acad Sci U 
S A. 2009;106(2):474-9). The use of BIBW 2992, an irreversible and 
dual EGFR/HER2 inhibitor as a potential new treatment option for 
these patients warrants further investigations. An international Phase 
III trial program investigating BIBW 2992 in NSCLC, LUX-Lung, is 
now recruiting patients. 
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Smoking cessation prior to diagnosis of lung cancer
Campling, Barbara G.1; Collins, Bradley N.2; Algazy, Kenneth M.1; 
Schnoll, Robert A.3; Lam, Miu4
1 Philadelphia VA Medical Center, Philadelphia, PA, USA; 2 Temple 
University, Philadelphia, PA, USA; 3 University of Pennsylvania, 
Philadelphia, PA, USA; 4 Queen’s University, Kingston, ON, Canada
Background: Our observation that many lung cancer patients stop 
smoking prior to diagnosis, often preceding symptoms and without 
difficulty, led us speculate that, in some cases, smoking cessation may 
be a presenting symptom of lung cancer. 
Methods: Patients from the Philadelphia VA Medical Center with 
a diagnosis of lung cancer, and for comparison, prostate cancer and 
myocardial infarction underwent a structured interview about their 
smoking habits up to the time of diagnosis. Severity of nicotine ad-
diction at the time of heaviest smoking was graded using the Fager-
ström Test for Nicotine Dependence (FTND: range 0—10). Among 
former smokers, dates of smoking cessation, onset of symptoms and 
diagnosis were recorded. Difficulty quitting was rated on a scale of 
0—10. Smoking status was verified by cotinine analysis. For the lung 
cancer patients, the distribution of intervals from cessation to diag-
nosis was compared with a group of 103 former smokers with lung 
cancer from the Kingston Regional Cancer Centre (KRCC), Canada. 
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Results: Among 115 lung cancer patients, 60 (52.2%) were current 
and 55 (47.8%) were former smokers. Only 6 of the 55 former smok-
ers (11%) were symptomatic when they quit. Among 101 prostate 
cancer patients, 21 (20.8%) had never smoked, 32 (31.7%) were 
current and 48 (47.5%) were former smokers. Among 99 MI patients, 
15 (15.2%) had never smoked, 58 (58.6%) were current and 26 
(25.7%) were former smokers. The median interval from cessation to 
diagnosis was 2.7 yr for lung cancer, 24.3 yr for prostate cancer and 
10.0 yr for MI patients (p<0.0001). For prostate cancer the median 
FTND was 7.0 for current vs 3.0 for former smokers (p=0.0004), and 
for MI it was 6.5 for current vs 4.0 for former smokers (p=0.011). 
In contrast, for lung cancer, the median FTND was 7.0 for both cur-
rent and former smokers There was a positive correlation between 
difficulty quitting and FTND score for the prostate cancer patients 
(Pearson correlation coefficient 0.4, p=0.01), but not for lung cancer 
or MI patients. Seventeen of the lung cancer patients (31% of former 
smokers) rated their difficulty quitting as 0/10, and the median FTND 
score in this group was 5. Among lung cancer patients, there was no 
significant difference in stage distribution, tumor histology or sur-
vival of current vs former smokers. For lung cancer, but not the other 
groups, the hazard of smoking cessation increased at an increasing 
rate approaching diagnosis. There was no significant difference in 
the distribution of intervals from cessation to diagnosis in the KRCC 
compared to VA lung cancer patients. 
Conclusions: 48% of the lung cancer patients in this study had 
stopped smoking prior to diagnosis, and only 11% of these were 
symptomatic at quitting. Unlike prostate cancer or MI patients, lung 
cancer patients who quit smoking were as severely dependent on 
nicotine (when smoking most heavily) as those who continued to 
smoke. Despite this, many of them quit with no difficulty. The inter-
val from cessation to diagnosis was much shorter for lung cancer than 
the other two groups, and the hazard of smoking cessation increased 
approaching diagnosis, suggesting a close relationship between 
smoking cessation and future diagnosis of lung cancer. These results 
refute the notion that lung cancer patients quit smoking because of 
disease symptoms. The hypothesis that smoking cessation can be a 
presenting symptom of lung cancer warrants further investigation. 
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The impact of smoking behavior on quality of life among 
long term survivors of lung cancer
Garces, Yolanda I.1; Szydlo, Daniel W.1; Sarna, Linda2; Clark, 
Matthew M.1; Sloan, Jeff A.1; Yang, Ping1
1 Mayo Clinic, Rochester, MN, USA; 2 UCLA, Los Angeles, CA, USA
Background: To describe the changes over time among long term 
lung cancer (LTLC) survivor’s quality of life (QOL) with respect to 
their current cigarette smoking status. 
Methods: An eleven-year longitudinal study of QOL in LTLC sur-
vivors (N=869) was conducted among those who had been diagnosed 
from 1997-2003. Patients had to complete a short term (<3 years) as 
well as a long term QOL assessment (>5 years) to be eligible for this 
study. 674 completed a long term assessment (78% response rate) and 
429 completed both assessments and are the subjects of this report. 
Overall QOL was measured by a single-item numerical analogue 
validated for lung cancer survivors. The QOL scores were adjusted 
for gender, stage, cell type, age, development of a new primary, a 
second lung primary and/or recurrent disease. A 10 point differ-
ence between groups was a priori defined as clinically significant on 
transformed scales (0-100: poor to high QOL). A general repeated 
measures analysis of variance was supplemented by Srivastava’s 
profile analysis to model the longitudinal changes in QOL over time 
among the various smoking categories. 
Results: At the time of both assessments, 75.1% of the 429 patients 
who completed both assessments were former smokers, 19.1% had 
never smoked, and 5.8% were current smokers. Twenty-five patients 
were excluded because their smoking status changed over the as-
sessments. The adjusted overall QOL mean(SE) scores for the never, 
former, and current smokers were 83.7(2.0), 80.8(1.0), and 73.8(3.5) 
at the short term assessment and 76.7(2.1), 73.9(1.0) and 67.3(3.7) at 
the long term assessment, respectively (repeated measures MANOVA 
test for equal vectors, p=0.06). See Figure below. Composite profile 
analysis tests of hypothesis indicated that the QOL for all of the 
smoking groups began at significantly different levels (p<0.0001), 
declined significantly from the short term to the long term time point 
(p<0.0001), but the rate of decline was no different among the three 
smoking groups p=0.96). The remaining QOL variables that were 
studied will be reported at the meeting. 
Conclusion: These findings suggest that persistent cigarette smoking 
after lung cancer diagnosis has a continuous negative impact on QOL 
even among LTLC survivors. Unfortunately, all groups of LTLC 
survivors had declines in QOL over time necessitating targeted inter-
ventions to improve QOL; particularly, further promoting smoking 
cessation among smokers. 
This work was supported by research grants CA77118, CA80127, 
and CA84354 from the U.S. National Institutes of Health
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Long-term follow-up of nicotine replacement therapy for 
smoking cessation
Takagi, Keigo; Sasamoto, Shuichi; Hata, Yoshinobu; Tamaki, 
Kazuyoshi; Takahashi, Shoji; Sato, Fumitomo
Toho University Medical Center, Dept.of Chest Surgery, Tokyo, Japan
Introduction: Campaigns for smoking cessation are increasingly be-
ing carried out worldwide, and nicotine replacement therapy has been 
reported to show a beneficial effect. Although this therapy has been 
found to be effective for brief periods in efforts to quit smoking, its 
long-lasting effect has not yet been examined.
Subjects and Methods: One hundred and three smokers between 
2001 and 2007 who underwent replacement therapy with nicotine 
patches after a 2-week period during which they made an effort to 
minimize smoking (reduced-smoking period) were analyzed.
The replacement therapy was given for 2 months. The expired carbon 
monoxide concentration was measured at 1, 3, 6, and 12 months after 
smoking cessation to assess the smoking cessation rates at specific 
time points and thereby find out how long the subjects were able to 
abstain from smoking.
Results: The smoking cessation rates were 65, 50, 35, and 29% at 1, 
3, 6, and 12 months, respectively. Less than 30% continued to abstain 
from smoking after 12 months.
The smoking cessation rate at 12 months in the group with lung and 
cardiovascular disorders was 50%, however, the rate for the group 
with other disorders was only 20%.
Conclusions: The smoking cessation rate was initially high, but it 
decreased during a long follow-up period. The finding that a large 
number of subjects resumed smoking after the initial follow-up 
period during which they were under strict observation by physicians 
suggests that both education and motivation concerning smoking-
derived health problems were insufficient.
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Better survival in non-smokers of young females with 
primary lung adenocarcinoma after curative resection
Liu, Ming; Jiang, GeNing; Ding, JiaAn
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, 
Tongji University, Shanghai, China
Background: Adenocarcinoma of the lung is now the most common 
histologic subtype of lung cancer. Young patients under age 40 have 
an increased percentage of women, and more often have adenocarcin-
oma. With the rate of incidence of lung adenocarcinoma increasing 
in the past few decades, this retrospective study was performed to 
investigate the survival rates and risk factors between non-smokers 
and current-smokers in young females with primary lung adeno-
carcinoma.
Methods: From 1 January 1985 to 31 December 2007, 11,994 lung 
cancer cases with thoracic treatment were registered in Department 
of Thoracic Surgery, Shanghai Pulmonary Hospital. A total of 282 
females with histologically confirmed primary lung adenocarcinoma 
(or bronchioloalveolar carcinoma, BAC) were age <40 years at the 
time of diagnosis. 13 of the 282 patients were excluded from the 
study: 4 patients were lost to follow-up, 5 patients were stage IV 
(other lobe metastasis was found during operation), 3 patients were 
former smokers, and 6 patients were not performed with complete re-
section. Overall survivals were studied for two groups using Kaplan-
Meier analyses. Multivariate analyses were performed using the Cox 
regression method to identify variables with independent prognostic 
significance. 
Results: The overall survival of all patients was 22.5%.The 5-year 
survival rate of the never-smokers and the current-smokers were 
36.6% and 20% (p=0.03). In patients of stage I the 5-year sur-
vival rate of two groups were 68.8% and 50% (p=0.02). Smoking 
(RR=3.15, CI 1.726~8.786) was identified as an independent negative 
prognostic factor by multivariate analyses. There was no significant 
difference in the 5-year survival rate between two groups, whether 
the patients received platinum-based adjuvant chemotherapy or 
not. But both the non-smokers ((p=0.02) and the current-smokers 
(p=0.03) benefited from the adjuvant chemotherapy, for the long-
term survival rate of the two groups of patients were enhanced by the 
adjuvant chemotherapy.
Conclusions: Among young females with primary lung adenocarcin-
oma, non-smokers have better survival after curative treatment than 
current-smokers in China, especially in patients of stage I. Smoking 
is the main risk factor for lung adenocarcinoma in young females. 
Urgent interventions for smoking cessation in young females are 
therefore required. Once the diagnosis of lung adenocarcinoma was 
made, young females should receive adjuvant chemotherapy.
A7.5 Nicotine, Tobacco and Cancer Control and Health Services, Sat Aug 1, 14:30 - 16:00
Changes in the lung cancer epidemic in Norway
Sagerup, Camilla M.1; Johannesen, Tom B.2; Helland, Aslaug1; 
Brustugun, Odd Terje1
1 The Norwegian Radium Hospital, Oslo, Norway; 2 The Norwegian 
Cancer Registry, Oslo, Norway
Purpose: The magnitude of the lung cancer epidemic, new diagnostic 
possibilities and the advent of novel histology-dependent treatment 
regimens underscore the need of analyzing trends in incidence, sub-
group distribution and other characteristics.
Materials and Methods: In the period 1988 to 200, a total of 40,118 
cases were diagnosed with lung cancer in Norway. We utilized the 
Cancer Registry of Norway database to determine incidence, analyz-
ing the distribution of gender, age, histological subgroups, diagnos-
tics methods and stage at time of diagnosis among all reported cases. 
Results: Over the last twenty years, the lung cancer incidence in 
Norway has increased with 64 %, from 1564 cases (1149 men, 415 
women) in 1988 to 2570 cases (1480 men, 1090 women) in 2007. 
The age adjusted annual average increase in lung cancer among 
women was 4,9% (163% increase through the period), whereas 
in men it was 1,4% (29% total increase). In the first 5-year period 
observed (1988-1992), the median age at diagnosis was 68 years in 
women and 69 years in men. In the last 5-year period (2003-2008), 
median age had increased by 1 year in women and 2 years in men. 
Adenocarcinoma has been the predominant subtype among women 
throughout the period, increasing from 29% in 1988 to 35% in 2007. 
In men, squamous cell carcinoma was the predominant subtype in the 
first part of the period, and the incidence declined with an average 
age-adjusted annual rate of -2%, being responsible for 22% of male 
lung cancers in 2007. In 1988, carcinomas not otherwise specified 
(NOS) comprised 18% of all cases, by 2007 approaching 30% in both 
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genders and has surpassed adenocarcinoma as the biggest subgroup 
in men. The proportion of small cell lung carcinoma is down from 
20% in 1988 to 16% in 2007. In 1988, 83% of all cases were diag-
nosed by biopsy, and in 10% cytology was used solely for primary 
classification. In 2007, the corresponding numbers were 76% and 
13%, respectively. The stage distribution has varied throughout the 
period, and from 1993 to 2004, a decrease in the fraction of localized 
and regional disease was observed in both genders among all entities. 
However this trend seems to change in 2004, as the fraction of local 
stage lung cancer increased in both genders, most predominant in 
women, from 21% in 2004 to 35% in 2007. Small cell carcinoma had 
the highest fraction of metastatic disease of all histological subtypes, 
comprising 59% in 2007. 
Conclusion: These complete national data point to certain important 
trends in the lung cancer epidemic in Norway that presumably can be 
extrapolated to most western countries: increased number of women, 
older patients, higher proportion of adenocarcinomas, and probably 
more localized, operable disease. The rising proportion of carcinoma 
NOS is a worrisome trend in the light of increasing use of subtype-
specific treatment regimens and cannot be explained by increased use 
of cytology.
A7.6 Nicotine, Tobacco and Cancer Control and Health Services, Sat Aug 1, 14:30 - 16:00
Survival after non-small cell lung cancer in never-smoking 
Asian/Pacific Islander and Latina women
Wakelee, Heather A.1; Chang, Ellen T.2, 1; Shema, Sarah2; Reynolds, 
Peggy2; Clément-Duchêne, Christelle3, 1; Wiencke, John4; Gomez, 
Scarlett L.2, 1
1 Stanford University, Stanford, CA, USA; 2 Northern California 
Cancer Center, Fremont, CA, USA; 3 CHU Brabois, Service de 
Pneumologie, Vandoeuvre-Lès-Nancy, France; 4 University of 
California, San Francisco, San Francisco, CA, USA
Background: Lung cancer is the leading cause of cancer death 
among Asian/Pacific Islander (API) women and the second most 
common cause among Latina women, despite the low prevalence of 
tobacco smoking (<20%) in these populations. This paradox suggests 
that a high proportion of lung cancer in API and Latina women oc-
curs among never-smokers. To evaluate the disease burden of lung 
cancer in never-smokers (LCINS) in these groups, we studied pre-
dictors of survival in a population-based sample of lung cancer cases 
in the San Francisco Bay Area of California.
Methods: Women diagnosed with incident, invasive lung cancer 
between 1998 and 2002 were identified by rapid case ascertainment 
at the population-based Greater Bay Area Cancer Registry (GBACR). 
Among 3949 eligible patients, 2093 completed telephone interviews 
assessing self-reported race/ethnicity, detailed smoking history, 
demographic background, and other lung cancer risk factors. Socio-
economic status (SES) was measured by individual-level educational 
attainment and a composite residential area-level index combining 
education, employment, income, poverty, and housing information. 
Interview data were merged with updated follow-up data from the 
GBACR, yielding 1874 female patients with follow-up information. 
Among these, 334 (18%) had never smoked tobacco; 311 (93%) were 
API, Latina, or non-Latina White. Excluding six patients diagnosed 
with small-cell lung cancer and 1 patient with invalid follow-up data, 
our final sample included 149 APIs, 36 Latinas, and 119 non-Latina 
Whites. All 304 LCINS patients were followed until the date of 
death, last known contact, or December 31, 2007, whichever occurred 
earliest. The hazard ratio (HR) of all-cause or lung-cancer-specific 
mortality was estimated using multivariable Cox proportional hazards 
regression models stratified by stage at diagnosis. 
Results: Nearly 70% of API and 45% of Latina female lung cancer 
cases were never-smokers versus 10% of non-Latina Whites. API and 
Latina patients, particularly those born in the US, had poorer overall 
and lung-cancer-specific survival than non-Latina Whites. Compared 
with White women, the lung-cancer-specific HRs were 3.09 (95% 
confidence interval [CI]=1.36-7.01) for US-born Latinas, 2.22 (95% 
CI=1.21-4.09) for foreign-born Latinas, 2.24 (95% CI=1.24-4.03) for 
US-born APIs, and 1.46 (95% CI=1.01-2.09) for foreign-born APIs. 
Adjusting for stage, factors significantly associated with reduced 
overall and lung-cancer-specific survival were older age at diagnosis, 
unmarried status, and non-surgical treatment; those associated with 
reduced lung-cancer-specific survival only were lower neighborhood 
SES, radiation treatment, and squamous-cell histology; and those 
associated with reduced overall survival only were non-bronchi-
oloalveolar carcinoma histology, no family history of lung cancer, 
and private vs. public insurance.
Conclusions: Whereas API women have previously been shown to 
have better survival from lung cancer, we found that API and Latina 
women have not only a higher proportion of LCINS than non-
Latina White women, but that those with LCINS have both poorer 
all cause and lung cancer-specific survival, especially among the 
US-born. To our knowledge, this is the first study to evaluate factors 
that affect survival among API and Latina women with LCINS. The 
disproportionate burden of LCINS in these rapidly growing minority 
populations is a noteworthy public health problem requiring further 
research.
A7.7 Nicotine, Tobacco and Cancer Control and Health Services, Sat Aug 1, 14:30 - 16:00
Socioeconomic status predicts outcomes from NSCLC
Erhunmwunsee, Loretta; Stinnett, Sandra S.; Harpole, David H.
Duke University Medical Center, Durham, NC, USA
Background: Lung cancer is the leading cause of cancer death 
worldwide. It is important therefore to understand factors that may 
impact survival. In this study we examined whether differences in 
neighborhood socioeconomic characteristics, as a surrogate for socio-
economic status (SES), might affect the survival of patients with non 
small cell lung cancer (NSCLC). 
Methods: We performed a retrospective, case-only analysis of over 
4800 patients who were diagnosed with NSCLC between 1995 and 
2007 and prospectively collected in our tumor registry. We assessed 
their SES by using their address at diagnosis to determine (1) the 
percentage of residents within the census tract that have a high 
school (HS) degree or higher, (2) a bachelors degree or higher, (3) 
the median income of those that reside within that tract and (4) the 
percentage of residents within the tract that live below the poverty 
line. Each of these 4 factors was further categorized into 4 levels (see 
Table 1) and their association with survival determined. Comparisons 
of variables across various categories were performed using the Pear-
son chi-square statistic or the Fisher exact test for nominal variables. 
Survival curves were constructed using the Kaplan-Meier method and 
compared using the Log-rank test.
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 Variable Quartile 1 Quartile 2 Quartile 3 Quartile 4 
  (bottom 25%)   (top 25%)
 % graduated with HS degree or higher < 70.2 70.2-79.1 79.1-87.4 >87.4
 % graduated with bachelors or higher < 11.1 11.1-19.7 19.7-34.4 >34.4
 Median Income ($) < 32,132 32,132-40,177 40,177-49,615 > 49,615
 % below poverty line >15.9 10.5-15.9 6.5-10.5 <6.5
Results: Complete data were available for 4838 patients. Those with 
variables in the highest quartiles had longer median survival than 
those in the lowest quartiles (See Table 2). 
 Variable Median Survival p-value 
  (Highest vs. Lowest Quartiles - months)
 % graduated with HS degree or higher 13.3 vs. 11.0  0.004
 % graduated with bachelors or higher 13.0 vs. 11.4  0.037
 Median Income ($) 13.5 vs. 11.0  <0.001
 % below poverty line 13.1 vs. 10.2  <0.001
Using Cox proportional hazards models, we find that the follow-
ing are predictors of survival in patients with NSCLC: the percent-
age of residents in the patient’s tract who have graduated from HS 
(p<0.001), the median income within the tract (p<0.001) and the per-
centage of people within the tract who live below poverty (p<0.001). 
Conclusion: Our study suggests that neighborhood social character-
istics may be significant predictors of survival from NSCLC and that 
patients in the lowest class faired worse. These provocative results 
need to be validated nationally as they may have significant import-
ance in public health policy towards disparities in oncology out-
comes. Our next step includes analysis of National Cancer databases, 
such as ACS and/or SEER.
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KRAS copy number gains in non-small cell lung cancer: 
association with mutation and resistance to epidermal 
growth factor receptor inhibitors
Varella-Garcia, Marileila1; Kiatsimbul, Porntip1; Xiao, Yun1; Coldren, 
Christopher1; Soh, Junichi2; Yamamoto, Hiromasa3; Shigematsu, 
Hisayuki2; Lockwood, William4; MacAulay, Calum4; Lam, Wan4; 
Gazdar, Adi F.2
1 University of Colorado Cancer Center, Aurora, CO, USA; 2 
University of Texas Southwestern Medical Center, Dallas, TX, USA; 
3 Graduate School of Medicine, Dentistry and Pharmaceutical 
Sciences, Okayama University, Okayama, Japan; 4 British Columbia 
Cancer Research Agency, Vancouver, BC, Canada
Background: Accumulated data suggest that tyrosine kinase in-
hibitors (TKIs) of the epidermal growth factor receptor (EGFR) are 
attractive agents to treat non-small cell lung cancer (NSCLC). Acti-
vating mutations and increased copy number of EGFR are associated 
with clinical responsiveness to EGFR TKIs. The RAS-RAF-MAPK 
pathway is a major signaling network linking EGFR activation to cell 
proliferation and survival, and the major genetic mechanism respon-
sible for its deregulation is the constitutive activation of KRAS by 
mutation in codons 12, 13 and 61. In this study, we investigated the 
frequency of KRAS copy number gain (CNG) in NSCLC cell lines, 
its association with KRAS mutation and the potential role of KRAS 
activation in resistance to EGFR TKIs. 
Methods: CNG was initially tested in NSCLC cell lines by fluor-
escence in situ hybridization (FISH), using the probe set KRAS 
(RP11-1119I8) and CEP12 (Abbott Molecular) as control. KRAS 
copy number from the FISH platform was compared with recently 
published real time quantitative PCR (qPCR) data (Gandhi et al., 
PLoS One 2009,4:e4576) and with SNP array based copy number 
analysis (Wellcome Trust Sanger Institute Cancer Genome Project). 
The half maximal inhibitor concentration (IC50) for the EGFR TKIs 
gefitinib and erlotinib were measured in the lung lines.
Results: The genomic status of the KRAS gene was evaluated by 
FISH in 45 NSCLC cell lines. No or very low copy number gain 
(CNG) was found in 69% lines, while 31% showed CNG including 
11% with gene amplification. These frequencies were higher than 
detected using other platforms. By qPCR, KRAS CNG was deter-
mined in 14.3% of 77 NSCLC lines and by SNP arrays in 18.8% of 
149 lines. A comparison between NSCLC lines evaluated by multiple 
platforms showed that KRAS copy number correlated significantly 
between FISH and qPCR for all tested lines (n=37, r=0.80), as well as 
specifically for the KRAS mutant (n=10, r=0.93) and wild type (WT) 
(n=27, r=0.94) lines. KRAS copy numbers determined by FISH and 
SNPs showed no significant correlation (n=21, r=0.24) and only the 
mutant lines had significant correlation between copy numbers deter-
mined by qPCR and SNPs (n=10, r=0.74). The presence of activating 
mutations was positively associated with CNG determined by FISH 
(n=30, r=0.42) and qPCR (n=43, r=0.45) but not by SNPs (n=22, 
r=0.30). Interestingly, KRAS gene amplification was significantly 
associated with mutation (p=0.03) while CNG by chromosomal 
polysomy was not. IC50 values for TKIs gefitinib and erlotinib had 
high correlation rates with KRAS copy numbers determined by FISH 
(respectively n=29, r= 0.61 and n=28, r=0.52) and qPCR (respective-
ly n=42, r=0.26 and n=41, r=0.45) but not by SNPs. Among 30 lines 
tested for all variables, resistance to TKIs was detected in all KRAS 
mutant and 50% of KRAS WT lines, in 91% of lines with and 58% 
lines without CNG by FISH.
Conclusions: KRAS CNG is frequent in NSCLC lines and is as-
sociated with resistance to EGFR-TKIs. KRAS gene amplification 
is strongly associated with mutation. Among platforms for CNG 
evaluation, FISH and qPCR generated the closest results in terms of 
association with presence of mutations and sensitivity to EGFR-TKIs. 
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A8.2 EGFR and KRAS Mutations, Sat Aug 1, 14:30 - 16:00
Clinical implications of resistance-inducing KRAS 
mutations in minor clones detected by a highly sensitive 
method
Marchetti, Antonio2; Milella, Michele1; Felicioni, Lara2; Cappuzzo, 
Federico3; Irtelli, Luciana4; Del Grammastro, Maela2; Sciarrotta, 
Mariagrazia2; Malatesta, Sara2; Nuzzo, Carmen1; Finocchiaro, 
Giovanna3; Perrucci, Bruno4; Carlone, Donatella2; Gelibter, Alain1; 
Ceribelli, Anna1; Cognetti, Francesco1; Buttitta, Fiamma2
1 Medical Oncology A, Regina Elena National Cancer Institute, 
Rome, Italy; 2 Clinical Research Center, Center of Excellence 
on Aging, University-Foundation, Chieti, Italy; 3 Department of 
Oncology-Hematology, Istituto Clinico Humanitas IRCCS, Rozzano, 
Milan, Italy; 4 Department of Oncology, SS Annunziata Hospital, 
Chieti, Italy
Background: Genetic abnormalities affecting EGFR signaling, 
namely activating EGFR and KRAS mutations, play a major role in 
NSCLC biology, particularly in the subgroup of lung adenocarcin-
omas (ADK). In addition, the presence of KRAS and EGFR muta-
tions profoundly impacts on patients’ outcome upon treatment with 
EGFR tyrosine kinase inhibitors (TKI). However, optimal strategies 
to search for mutations and to incorporate such information into 
specific treatment algorithms are still controversial. Here we compare 
the predictive power of KRAS mutations assessed by direct (DS) 
or mutant-enriched sequencing (MES) in lung ADK patients treated 
with EGFR TKI.
Methods: KRAS and EGFR mutational status of was investigated by 
DS in 83 lung ADK patients treated with either gefitinib or erlotinib. 
In all patients, KRAS mutations were also assessed by MES. This 
method requires a first PCR reaction, using primers mismatched from 
the wt-KRAS sequence at specific codons. Such mismatch introduces 
a new restriction site that is then used to digest the CCTGG sequence 
in the amplicon of the wt allele. In contrast, KRAS mutant alleles are 
not digested, resulting in the enrichment of mutant alleles. 
Results: DS detected KRAS mutations in 16/83 (19%) tumors; 
MES correctly identified all of the mutations detected by DS and 14 
additional mutations in minor clones (total 30/83, 36%). Interest-
ingly, MES allowed the identification of KRAS mutations in 3/20 
EGFR-mutated tumors. KRAS mutations assessed by DS and MES 
significantly correlated with resistance to TKI (P=0.04 and P=0.004, 
respectively) and significantly impacted on both progression-free 
(PFS) and overall survival (OS). However, the predictive power of 
KRAS mutations assessed by MES was higher than that obtained by 
DS (HR=2.82, P=0.0001 vs HR=1.98, P=0.04, respectively for OS; 
HR=2.52, P=0.0005 vs HR=2.21, P=0.007, respectively for PFS). 
Survival outcome of patients harboring KRAS mutations in minor 
clones, detected only by MES, did not differ from that of patients 
with KRAS mutations detected by DS (Figure 1) and only KRAS 
mutations assessed by MES remained an independent predictive fac-
tor at multivariate analysis. As expected, EGFR mutations were pre-
dictive of longer PFS and OS; however, the simultaneous presence of 
MES-detected KRAS mutations significantly worsened the outcome 
of EGFR-mutated patients upon TKI treatment.
Conclusions: KRAS mutations in minor clones have an important 
impact on response and survival of patients with lung ADK treated 
with EGFR TKI. The use of sensitive KRAS detection methods, 
such as MES, could allow to more effectively identifying treatment-
resistant patients.
A8.3 EGFR and KRAS Mutations, Sat Aug 1, 14:30 - 16:00
Kras mutation and Mcl-1 over-expression cooperate with MYC 
in the genesis of advanced lung adenocarcinomas
Allen, Thaddeus D.1; Jones, Kirk D.2; Bishop, J. Michael1
1 G.W. Hooper Rsch. Fdn., UCSF, San Francisco, CA, USA; 2 
Department of Pathology and Laboratory Medicine, UCSF, San 
Francisco, CA, USA
Background: Augmented expression of MYC occurs in approxi-
mately 50% of NSCLCs where it is associated with a poor treat-
ment outcome. Exactly how MYC interacts with other genes that 
are commonly deregulated in non-small cell lung cancer is poorly 
understood. In order to investigate this issue, mouse models of MYC-
induced lung cancer where constructed.
Methods: Transgenic mouse models were constructed that over-
expressed MYC in the pulmonary epithelium in a Doxycycline-
dependent manner. Additionally, we developed a technique to direct 
retroviral integration to MYC expressing alveolar cells. This allowed 
us to introduce the expression of additional genes and measure their 
influence in the presence or absence of high MYC expression.
Results: We over-expressed MYC in the pulmonary epithelium of 
mice and discovered a MYC-induced apoptotic program that hindered 
tumor initiation. In due course, however, the animals developed both 
adenomas and adenocarcinomas that over-expressed MYC and always 
harbored mutant alleles of Kras. Mutation of Kras was therefore a 
genetic event that cooperated with MYC in the formation of lung 
tumors. Despite this apparent interdependence, we demonstrated that 
mutant Ras alone could not confer complete resistance to MYC-
induced apoptosis. Tumor progression required further anti-apoptotic 
events. One such event was the increased expression of Mcl-1, which 
we found in a subset of MYC transgenic tumors. We found that in the 
presence of activated Ras, Mcl-1 over-expression cooperated further 
with MYC in the growth of advanced adenocarcinomas with regions 
of large cell undifferentiated carcinoma.
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Conclusions: These results shed light on the events that underlie the 
development of lung adenocarcinomas that over-express MYC. MYC-
induced apoptosis, like oncogene-induced senescence, represents a 
demonstrable impediment to lung tumorigenesis that must be circum-
vented by an independent step during tumor progression.
A8.4 EGFR and KRAS Mutations, Sat Aug 1, 14:30 - 16:00
Reflex testing of lung adenocarcinomas for EGFR and 
KRAS mutations: the initial Memorial Sloan-Kettering 
Cancer Center (MSKCC) experience
Zakowski, Maureen F.; Ladanyi, Marc; Rekhtman, Natasha; Park, 
Bernard; Finley, David; Azzoli, Christopher; Kris, Mark G.; Rusch, 
Valerie; Miller, Vincent; Riely, Gregory
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Background: Primary lung adenocarcinoma, particularly those that 
are well differentiated, often with a component of bronchioloalveolar 
carcinoma, is preferentially susceptible to effects of tyrosine kinase 
inhibitors. Identification of activating mutations in EGFR TK domain 
remains the best predictor for sensitivity/response to EGFR TKIs. 
These mutations are mutually exclusive with KRAS mutations. The 
presence of a KRAS mutation is a contraindication for EGFR TKI 
therapy and points to other agents, or investigational therapies. Given 
the high rate of recurrence of adenocarcinoma, and frequent difficul-
ties or delays in obtaining archival material for molecular testing at 
time of recurrence (necessitating in some patients a second proced-
ure), we have instituted routine reflex testing for EGFR and KRAS 
mutations of all lung adenocarcinomas resected at MSKCC. 
Methods: At the time of gross prosection, a small slice of tumor, 
corresponding to a section for paraffin embedding and hematoxylin 
and eosin (H&E) staining for routine diagnosis, is snap frozen and 
retained. When microscopy examination identifies adenocarcinoma, 
frozen tissue, along with the corresponding H&E slide, is sent to the 
clinical molecular diagnostic laboratory for extraction of DNA and 
identification of EGFR exon 19 deletions and exon 21 L858R muta-
tions by mutation-specific PCR assays. In samples lacking EGFR 
mutations, KRAS analysis is done by direct sequencing of PCR 
products. If sufficient frozen tissue is unavailable, the corresponding 
paraffin block serves as an alternate source of DNA. These assays are 
batched and run at least weekly. A molecular diagnostic pathology re-
port is issued to the clinician before the patient’s post op or oncology 
visit, and becomes part of the medical record.
Results: Reflex testing started in 2006. In a one year period, over 
500 lung resections were performed. 297 adenocarcinomas, includ-
ing wedge resection, segmentectomy, lobectomy, bilobectomy, and 
pneumonectomy were successfully studied. 294 (98%) of cases were 
studied for both EGFR and KRAS. 58 (20%) EGFR mutations in 
exon 19 or 21 and 85 (28%) were found in KRAS. 
Interestingly, in this group, there were 13 Asian patients with an 
EGFR mutation rate of 53% and no KRAS mutations; 11 Black 
patients had a 9% EGFR mutation rate and 45% KRAS mutation 
rate. This high KRAS mutation rate in Black patients has not proved 
consistent in further studies targeting this population.
Conclusions: Mutations in exons 19 and 21 of EGFR and exon 2 of 
KRAS are common in resected specimens from patients with lung 
adenocarcinoma.
Reflex testing for EGFR and KRAS mutations is easily implemented 
and ensures that key molecular data are available to inform and 
expedite subsequent treatment decisions. This reflex method using 
frozen tissue also provides the opportunity to obtain dna and rna for 
further studies in adenocarcinoma patients.
A8.5 EGFR and KRAS Mutations, Sat Aug 1, 14:30 - 16:00
Intratumor heterogeneity of epidermal growth factor 
receptor mutations in lung cancer and its correlation of 
response to gefitinib
Okami, Jiro1; Taniguchi, Kazuya1; Higashiyama, Masahiko1; Maeda, 
Jun1; Oda, Kazuyuki1; Kato, Kikuya2; Kodama, Ken1
1 Department of Thoracic Surgery, Osaka Medical Center for Cancer 
and Cardiovascular Diseases, Osaka, Japan; 2 Research institute, 
Osaka Medical Center for Cancer and Cardiovascular Diseases, 
Osaka, Japan
Background and Objectives: The association between EGFR 
mutations and response to EGFR tyrosine kinase inhibitors (TKIs) 
has been consistently confirmed in a number of studies. In a clinical 
practice, the EGFR-TKIs have already become a therapeutic option in 
postoperative recurrence as well as in advanced non-small cell lung 
cancer (NSCLC) in Japan. However, there is a subset of the NSCLC 
patients with EGFR mutations that have poor response or require 
drug-resistance in a short time, suggesting that there are additional 
factors determining responsiveness to the EGFR-TKIs. Thus, an opti-
mal selection of patients who will benefit from this treatment remains 
important.
Methods: 1) EGFR mutations were analyzed in 169 surgically 
resected NSCLC by direct sequencing of multiple clones. The as-
sociation between EGFR mutation status and the clinical outcome of 
gefitinib treatment was investigated. 2) For an intratumor heterogen-
eity assay in mutation-positive cases, sixty small areas per each speci-
men were microscopically confirmed to be cancer and dissected using 
AS LMD system, and their EGFR mutation statuses were determined 
by a primer extension assay. 
Results: 1) We identified EGFR mutations in 71 out of 169 pa-
tients with NSCLC. 46 patients, including 23 patients with EGFR 
mutations, were treated with gefitinib for postoperative recurrence. 
Progression-free survival and overall survival after initial gefitinib 
were significantly longer in patients with EGFR mutation than 
with wild-type (univariate analysis, p<0.001 for both). Multivariate 
analyses identified EGFR mutation and longer disease-free interval 
after surgery as significant prognostic factors for progression-free 
survival and overall survival. 2) Following the striking difference in 
the clinical outcome after gefitinib treatment between EGFR statuses, 
we attempted to stratify patients with mutated EGFR by intratumor 
heterogeneity of the mutations. According to the result of this assay, 
cancer tissues were classified into two groups: those consisting only 
of EGFR-mutated cells (15 cases, Group I) and those with EGFR-
mutated and non-mutated cells (six cases, Group II). Progression-free 
survival (Fig.) after gefitinib treatment was significantly shorter in 
those patients with EGFR heterogeneity (P=0.026). 
Conclusions: EGFR mutation status and disease-free interval were 
associated with prolonged progression-free survival and overall sur-
vival after gefitinib treatment for postoperative recurrence of NSCLC. 
A considerable proportion of NSCLC contains a heterogeneous popu-
lation of both EGFR mutated and non-mutated cancer cells, resulting 
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in a reduced response to gefitinib. The intratumor genetic heterogen-
eity of a target molecule such as EGFR would be an important factor 
to consider when treating patients with molecular target agents.
A8.6 EGFR and KRAS Mutations, Sat Aug 1, 14:30 - 16:00
Rebiopsy of patients with “acquired resistance” to 
epidermal growth factor receptor tyrosine kinase 
inhibitors (EGFR-TKIs) in non-small cell lung cancer 
(NSCLC)
Miller, Vincent A.; Riely, Gregory J.; Arcila, Maria E.; Oxnard, 
Geoffrey; Zakowski, Maureen F.; Kris, Mark G.; Pao, William; 
Ladanyi, Marc
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Background: The EGFR-TKIs erlotinib and gefitinib produce 
dramatic regressions of in tumors of approximately 70% of NSCLC 
patients with activating mutations in the EGFR-TK domain. After a 
median time of ~1 year, patients commonly experience progression 
of disease (Mok, Proc Eur Soc Med Onc 2008). We undertook this 
study to search for mechanisms of “acquired resistance” to EGFR-
TKIs, to determine the spectrum and frequency of secondary EGFR 
mutations which arose, and to determine the feasibility of rebiopsy in 
this setting.
Methods: All patients had stage III-B (“wet”), IV or recurrent 
NSCLC, prior treatment with an EGFR-TKI and progressive disease 
while on EGFR-TKI. Pts must also have had an activating EGFR 
mutation OR radiographic response (RECIST or WHO criteria) to 
EGFR-TKI OR significant and durable improvement in cancer-relat-
ed symptoms as judged by patient’s physician. Core biopsies were 
performed and studied for EGFR mutation (exons 18-21 including 
PCR-based test for T790M) and MET amplification.
Results: From 8/04-12/08 98 patients were consented for rebi-
opsy and 85 underwent the procedure. Demographics: Female/
Male=59/39; median age 62 (range 28-88); smoking: never=59, 
former/current=39. Primary EGFR mutation was exon 19 del-39; 
exon 21 L858R-11, other/WT-28, pending-7. Median time on EGFR-
TKI before biopsy was 12 months (7-28 months). Secondary EGFR 
mutations: T790M-33, other-2, none detected-31, indeterminate-10, 
pending-9. MET amplification in 2/16 studied to date.
Conclusions and Future Directions: 1) Rebiopsy of patients with 
NSCLC and acquired resistance to EGFR TKIs is feasible and well-
received by pts. 2) Knowledge of EGFR genotype including EGFR 
T790M and MET status can inform clinical trials of targeted therapies 
in this population 3) More complete annotation of MET status and 
exploratory analyses of profiles of specimens by metastatic sites and 
prior EGFR-TKI versus chemo and EGFR-TKI is ongoing. Supported 
by the Doris Duke Foundation, the LaBrecque Foundation, Steps for 
Breath, NIH and an anonymous donor
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Evaluation of copy number changes and rearrangements 
of ALK in lung cancer and association with EGFR status 
in adenocarcinomas
Arriola, Edurne1; Salido, Marta2; Pijuan, Lara 3; Martinez-Aviles, 
Luz4; Galvan, Ana B.2; Zanui, Montserrat1; Rovira, Ana5; Sole, 
Francisco2; Bellosillo, Beatriz4; Serrano, Sergi3; Albanell, Joan1
1 Medical Oncology Department Hospital del Mar, Barcelona, 
Spain; 2 Cytogenetics Laboratory Pathology Department Hospital 
del Mar, Barcelona, Spain; 3 Pathology Department Hospital del 
Mar, Barcelona, Spain; 4 Molecular Biology Laboratory Pathology 
Department Hospital del Mar, Barcelona, Spain; 5 Molecular 
Therapeutics and Biomarkers laboratory IMIM, Barcelona, Spain
Background: A novel oncogenic gene fusion between the anaplastic 
lymphoma kinase (ALK) (2p23) and EML4 (2p21) has been recently 
described in non-small cell lung cancer. The frequency of this finding 
is invariably low (<10%) in reported series. The efficacy of ALK 
inhibitors in preclinical models with EML4-ALK rearrangement 
emphasizes the importance of the characterization of the ALK gene 
status in lung cancer. 
The aim of our work was to evaluate the copy number changes and 
rearrangements of ALK in all subtypes of lung tumours (small and 
non-small cell lung cancers) on Caucasian patients and to correlate it 
with EGFR status.
Methods: Ninety lung adenocarcinoma samples were analyzed for 
EGFR mutation (exons 18, 19, 20 and 21), gene copy number and 
protein expression status by direct sequencing, fluorescence in situ 
hybridization (FISH) and immunohistochemistry, respectively. In 
addition, 21 squamous cell carcinomas (SCC), 8 poorly differentiated 
non-small cell lung cancer (NSCLC) and 17 small cell lung cancer 
(SCLC) specimens were evaluated for ALK status by FISH. For 
studying chromosomal breaks in the ALK loci, break-apart probes 
flanking the gene were applied (Abbott Molecular Inc, Des Plaines 
IL). For the detection of chromosomal rearrangements of the EML4 
locus, a dual colour break-apart FISH assay was designed using 
bacterial artificial chromosome (BAC) clones (centromeric: pooled 
RP11804P20 and RP11413N9 labelled in Spectrum Red; telomeric: 
pooled RP11798D22 and RP1134L01 labelled in Spectrum Green) 
(http://bacpac.chori.org). These probes allowed for the assessment of 
gene translocations and copy number aberrations. A minimum of 50 
nuclei were scored. 
Results: We found EGFR protein expression in 74% of cases, FISH 
positivity (Capuzzo et al. criteria) in 35/65 (53.8%) cases, and 
mutations in 12/74 (16.2%) within the adenocarcinomas. There was 
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a direct association between EGFR FISH positive cases with those 
harboring EGFR mutations (p=0.026). Only 2 FISH negative cases, 
presented EGFR mutations. In the whole set of tumors, we observed 
2 cases (3%) with ALK translocations (both adenocarcinomas), 8 
cases (12%) with gene amplification (one SCC, 7 adenocarcinomas) 
and 40 cases (60%) with gain of the 2p region (3 to 6 copies of ALK 
gene). Interestingly, SCLC was characterized by the absence of copy 
number changes of ALK. The 2 cases with ALK translocation were 
FISH negative for EGFR and wild-type for EGFR mutation. One 
of them showed breakage of EML4 gene, but the other presented 
a normal FISH result, suggesting the existence of another fusion 
partner. Notably, out of the 8 samples with ALK amplification, 7 
were FISH positive for EGFR (one showed co-amplification and 6 
high-polysomy of EGFR) and 2 cases showed EGFR mutations on 
exon 21. 
Conclusions: ALK gene rearrangements are present in lung cancer 
but their prevalence is extremely low in Caucasian patients. However, 
ALK gene copy number changes are more frequent in NSCLC, with 
12% of patients presenting ALK amplification and 60% presenting 
gain of 2p. ALK amplified cases are often FISH positive for EGFR. 
The evaluation of the potential clinical significance of these findings 
and predictive role in response to ALK inhibitors is warranted.
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Tracking an ultrathin bronchoscope to reach peripheral 
nodules with laser-based diagnostics 
Soper, Timothy D.1; Haynor, David R.1; Chien, Jason W.2; Seibel, 
Eric J.1
1 University of Washington, Seattle, WA, USA; 2 Fred Hutchinson 
Cancer Research Center, Seattle, WA, USA
Background: Current bronchoscopes have a physical sensor for each 
display pixel. Reducing bronchoscope size reduces image resolu-
tion and quality. By placing a custom lensed microscanner (1-mm 
diameter, 8-mm length) at the bronchoscope distal tip, laser light is 
scanned to generate high-resolution (500-line) wide-field (80º) im-
ages at video rate (30Hz). With this technology, a 1.6 mm O.D. scan-
ning fiber bronchoscope (SFB) has been developed and coupled with 
an intraoperative tracking system and laser diagnostics for image-
guided biopsy of peripheral nodules.
Methods: Red, green, and blue low-power laser light is combined 
to form white-light illumination from a single optical fiber. Back-
scattered light from the tissue is acquired one-pixel-at-a-time with 
standard features of zooming, fluorescence, and enhanced spectral 
imaging (ESI), see Figure. Attached to the SFB’s distal end is a 6-de-
gree-of-freedom electromagnetic sensor (Ascension) to track the SFB 
in real-time. During bronchoscopy within a live pig, the anatomical 
position of the SFB was determined by two Methods: first, by a small 
electromagnetic tracking (EMT) sensor attached to the SFB distal tip; 
and second, using image-based tracking, where each video frame is 
registered to a CT virtual reconstruction. Tracking performance of the 
two techniques was compared during four bronchoscopic sessions, 
each beginning in the trachea and ending in peripheral airways. For 
evaluation, tracking results were compared to manual registrations 
performed every 20th frame. Tracking failure was defined as dis-
agreement in position of 10-mm or 20-degrees in orientation across 
three consecutive manually-registered frames.
Results: Image-based tracking alone resulted in premature tracking 
failure in every session. EMT, by contrast, was more robust, but less 
accurate, resulting in tracking errors greater than the airway diam-
eter, see Figure. However, using a hybrid of EMT and image-based 
tracking, tracking failures were eliminated. Furthermore, an inte-
grated means of respiratory motion compensation (RMC) reduced the 
average tracking error by 47% overall and 77% in peripheral regions 
which experienced larger relative motion from respiration.
Conclusions: The small SFB diameter permits extension of image-
guided biopsy into peripheral airways. With the SFB, image-based 
tracking was highly accurate, but experienced intermittent failures. 
EMT, by contrast, was more robust, but lacked sensitivity to deforma-
tion of the airway anatomy. The hybrid system including RMC, gar-
nered the advantages of both methods, accurately tracking the SFB to 
peripheral airways. Future embodiments will focus on computational 
optimizations for real-time implementation and incorporation of a 
steering mechanism for direct visualization of peripheral nodules dur-
ing transbronchial biopsy.
A9.2 Scientific and Technologic Advances in Pulmonary Medicine and Endoscopy, 
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Pre-operative barium marking with virtual bronchoscopic 
navigation for small peripheral pulmonary lesions
Tachihara, Motoko Y.1; Ishida, Takashi1; Sugawara, Aya1; Watanabe, 
Kana1; Kanazawa, Kenya1; Suzuki, Hiroyuki2; Miyazaki, Makoto3; 
Moriya, Hiroshi4; Shinagawa, Naofumi5; Asano, Fumihiro6; 
Munakata, Mitsuru1
1 Department of Pulmonary Medicine, Fukushima Medical University 
School of Medicine, Fukushima, Japan; 2 Department of Thoracic 
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University School of Medicine, Fukushima, Japan; 4 Department 
of Radiology, Sendai Kousei Hospital, Sendai, Japan; 5 First 
Department of Medicine, Hokkaido University Hospital, Sapporo, 
Japan; 6 Department of Pulmonary Medicine, Gifu Prefectural 
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Study objectives: Confirmation of small intrapulmonary lesions is 
not always possible during video-assisted thoracic surgery (VATS). 
Pre-operative transthoracic marking has been widely used for partial 
lung resection, and complications such as pneumothorax occasionally 
occur. In this study, we performed transbronchial barium marking 
with virtual bronchoscopic navigation (VBN) before surgery for 
small peripheral pulmonary lesions (PPLs), and evaluated the feas-
ibility and safety of this procedure.
Patients: Subjects were 26 pathologically undiagnosed patients (10 
men, 16 women; mean age, 63 years; range, 39-81 years) with 26 
PPLs ≤30 mm in diameter, who were scheduled to undergo thoraco-
scopic partial lung resection. Subjects were enrolled between July 
2004 and January 2009.
Methods: Prior to bronchoscopy, virtual bronchoscopic images were 
reconstructed from multi-detector computed tomography (CT) data. 
Following consecutive virtual images, the actual bronchoscope was 
advanced to the bronchus with a VBN system (a prototype of Bf 
NAVI®, Olympus Medical Systems, Tokyo, Japan). Under X-ray 
fluoroscopy, a thin catheter (outer diameter, 1.0 mm) filled with bar-
ium sulfate was inserted via the working channel and small amount 
of barium sulfate was placed close to the lesion.
Results: Mean ± standard deviation diameter of PPLs was 12.7 ± 
5.4 mm (range, 5-28 mm). In chest CT, lesions comprised 14 pure 
ground-glass opacities (GGOs), 4 mixed GGOs, 7 solid nodules, and 
1 cavitary lesion. Eighteen of the 26 PPLs (69.3%) were invisible 
under X-ray fluoroscopy. One marking was placed for 23 lesions and 
two markings for 3 lesions. Less than 10 min was required to achieve 
endoscopic procedure. Median distance between the marking and 
the lesion was 4 mm (range, 0-24 mm) and the median amount of 
installed barium sulfate was 0.04 ml (range, 0.01-0.4 ml). In VATS, 
17 (65.4%) of 26 PPLs were visibly unidentified from the lung sur-
face, but all barium-marked sites were confirmed on intra-operative 
X-ray fluoroscopy. All lesions were uneventfully resected. Patho-
logical examination revealed primary lung cancer in 19 lesions (10 
bronchiolo-alveolar carcinomas, 8 adenocarcinomas, and 1 squamous 
cell carcinoma), 2 metastatic tumors, 1 hamartoma, 3 inflammatory 
lesions and 1 intra-pulmonary lymph node. Barium did not influence 
the pathological diagnosis, even in cases where barium had partially 
encroached into lesions. Complications were encountered in 2 cases 
(bleeding in 1 case and barium leakage into the thoracic space in 1 
case), although neither required treatment.
Conclusions: We have demonstrated the efficacy and safety of trans-
bronchial barium marking for small lesions prior to thoracoscopic 
surgery. This method is useful to clarify lesion location and determine 
the area for excision. This precise locating technique might also be 
promising for installing metallic markers for use in extra-thoracic 
irradiation.
A9.3 Scientific and Technologic Advances in Pulmonary Medicine and Endoscopy, 
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Novel endoscopic microscopy using Endo-Cytoscopy 
system
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Kaoru1; Mohamed, Alaa1; Tamura, Hajime1; Yoshino, Mitsuru1; 
Hoshino, Hidehisa1; Moriya, Yasumitsu1; Yoshida, Shigetoshi1; 
Suzuki, Makoto1; Hiroshima, Kenzo2; Nakatani, Yukio2; Yoshino, 
Ichiro1
1 Department of Thoracic Surgery, Graduate School of Medicine, 
Chiba University, Chiba, Japan; 2 Department of Clinical Pathology, 
Graduate School of Medicine, Chiba University, Chiba, Japan; 3 
Department of Thoracic Surgery, Graduate School of Medicine, 
Chiba University, Chiba, Japan
Background: We investigated the ability of Endo-Cytoscopy system 
(ECS) that enables microscopic imaging of tracheobronchial tree 
including normal bronchial epithelium, dysplastic mucosa and squa-
mous cell carcinoma.
Methods: The newly developed probe type ECS has a 5.5m diameter, 
combines two systems- CCD for endocyto images(Endocyto mode) 
and image fiber for normal images(Normal mode). ECS has a high 
magnification of ×450 on a video monitor. Fourteen patients with one 
squamous cell carcinoma, 9 squamous dysplasia and 4 after hilar lung 
cancer therapies were entered into the study and underwent white 
light, NBI light and AFI bronchoscopy. Both abnormal area of inter-
est and normal bronchial mucosa were stained with 0.5% methyl-
ene blue and examined with ECS at high magnification of ×450. 
Histological examinations with hematoxylin and eosin stain were 
performed using the biopsied specimens. The ECS imaging were ana-
lyzed and correlated with the corresponding histological examination. 
Results: In normal bronchial mucosa, ciliated columnar epithelial 
cells with small round nuclei were observed. In bronchial squamous 
dysplasia, superficial cells with rounded nuclei and abundant cyto-
plasm are arranged minimal irregularly. In squamous cell carcinoma, 
large and polymorphic tumor cells show increased cellular density 
with irregular stratified patterns. These ECS images corresponded 
well with light-microscopic examination of conventional histology. 
Conclusion: ECS was useful in the discrimination between normal 
bronchial epithelial cells and dysplastic cells or malignant cells. This 
novel technology has an excellent potential to provide in vivo micro-
scopic diagnosis during bronchoscopic examinations.
A9.4 Scientific and Technologic Advances in Pulmonary Medicine and Endoscopy, 
 Sat Aug 1, 14:30 - 16:0
Spectroscopy of transmitted NIR during bronchoscopy 
increases yield of transbronchial biopsy 
Votruba, Jiri2; Bruha, Tomas P.1; Balaz, Theodor3
1 ENEX spol. s r.o., Praha, Czech Republic; 2 Nemocnice Na 
Homolce, Prague, Czech Republic; 3 University of Defence, Brno, 
Czech Republic
Background: Diagnosis of a lung cancer is a challenging process. 
Recently due to a widespread use of a CT there are more of smaller 
peripheral lesions being detected. Because of need for morphological 
verification new bronchoscopic methods for biopsy of such small 
peripheral lesions are needed. We present an easy and cheap method 
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by which it is possible to choose the best area for biopsy during 
bronchoscopy examination. The method of question is NIR spectros-
copy of penetrating light. We have carried out an opened randomized 
prospective study to discriminate an efficiency of two techniques 
- transbronchial biopsy under fluoroscopic guidance and a NIR spec-
troscopy guided transbronchial biopsy. 
Methods: We have designed a instrument for measurement of a 
penetrated NIR light through the lung tissue.
It consists of two fibres of 1 mm in diameter contained in one bundle 
covered with insulation sleeving. One of the fibres is a detector; the 
other is a source fibre. The indicator fibre is 1,5 cm longer than the 
source fibre and it is covered with insulation till its ending. The end-
ing is cut in the angle of 60 degrees and titan coated. The detector 
fibre is connected to NIR spectroscope and the source fibre to NIR 
source. Measurements of a normal lung tissue at various areas of a 
lung tissue show peak at 735 nm which is not present during cancer 
tissue spectroscopy. In cancer tissue in addition all spectra have got 
fixed ratio of two transmittance values at two wavelengths (773, 
823 nm)- resembling the source values with its mild modification by 
autofluorescence. By help of those findings we utilized endobronchial 
measurement of NIR spectra in attempt to improve sensitivity of 
transbronchial biopsy under fluoroscopic guidance. 
Patient population consisted of 60 patients with CT/PET finding of 
metabolically active solitary pulmonary node 2-5 cm in diameter. 
Patients have been randomized into the group of fluoroscopic TBB 
and NIR confirmed fluoroscopic TBB. With each TBB there were 3-5 
bioptic attempts
Results: From overall 60 patients there were 33 in fluoroscopy only 
group and 27 in combined NIR spectroscopy and fluoroscopy group. 
There were 21 successful biopsies in fluoroscopy only group and 23 
successful biopsies in combined approach group. Resulting sensitiv-
ity in fluoroscopy only group was 0,636 and 0,852 in combined NIR 
and fluoroscopy group.
Conclusion: We conclude that the use of NIR spectroscopy for ideal 
biopsy area confirmation has been useful in increasing the sensitiv-
ity of fluoroscopically guided TBB. Such device or its modifications 
could be included for example into the examination by electro-
magnetic navigation. 
A9.5 Scientific and Technologic Advances in Pulmonary Medicine and Endoscopy, 
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Diagnostic bronchoscopy: a window of opportunity for 
timely biomarker driven therapy in non-small cell lung 
cancer (NSCLC)
Medley, Louise1; West, Sophie1; Davies, Joanna1; Clelland, Colin1; 
Olsen, Anna2; McHugh, Peter2; Talbot, Denis1
1 Oxford Lung Cancer Group, Churchill Hospital, Oxford, UK; 2 
Weatherall Institute of Molecular Medicine, Oxford, UK
Introduction: Fibreoptic bronchoscopy (FOB), a common procedure 
in the investigation of suspected lung cancer, can provide valu-
able tissue samples for research. The Oxford Lung Cancer Group 
have shown that bronchial brushing samples yield more material 
than bronchial washings for analysis and have developed validated 
methodology for the acquisition, processing and analysis of bron-
chial brushing samples as part of early phase clinical trials[1, 2]. The 
Bronchoscopy Protein Screening Study (BPS) was initially developed 
to identify patients at the time of diagnosis, for whom trial-based 
tailored targeted therapy might be suitable. We report here the results 
of the BPS study (at 50% accrual), which has evolved to become a 
valuable resource providing tissue for other collaborative projects.
Methods: All patients over 18 years old requiring a diagnostic FOB 
as part of their standard clinical care were offered entry into the 
study. Following informed consent additional endobronchial brushing 
samples were collected during the diagnostic FOB procedure and the 
diagnostic samples were screened for EGFR protein expression. The 
methods for processing these tumour samples have been described 
previously and include Immuno-histochemistry, Western blotting, and 
Flow cytometry (FACS)[2]. 
Results: Between July 2007 and March 2009, 133 patients were 
offered entry into the study and 120 patients were enrolled (90% up-
take). Sufficient material for analysis was obtained in 111 cases (93% 
of samples) with a mean of 10,000 cells per patient sample. Tumour 
samples to date have enabled:
Quantification of EGFR over-expression, at diagnosis. This currently 
supports a Phase II Study of first-line Erlotinib in advanced NSCLC. 
Biomarker identification at the time of diagnostic bronchoscopy has 
enabled targeted treatment to commence within 10 days. 
Prospective, timely identification of EGFR/K-Ras mutations. To 
date, brushing samples have been analysed for 14 of the 19 patients 
currently enrolled in the Phase II study. Of these 6 (43%) had EGFR 
mutations (commonly Exon 20-c.[2361G>A][=]/ p.GLN787GLN) 
and 3 (21%) K-Ras mutations (commonly c.[34G>T][=] 
p.Gly12Cys).
Identification and validation of survivin protein expression.
Assessment of cell cycle progression/Histone H3 expression.
Conclusions: Most patients, undergoing diagnostic FOBs, are willing 
to consent to additional endobronchial samples being taken. These 
bronchial brushings provide sufficient material for analysis and this 
pragmatic approach to consent and sample collection provides scope 
for both individual tailored treatment as well as pharmacodynamic 
endpoints in current/future trials or collaborations. By gaining con-
sent at the time of diagnostic FOB a wider range of treatment options, 
including trial based therapy can be identified without delaying the 
initiation of treatment. Tailored treatment, using tumour molecular 
characteristics, is likely to become more important in the future and 
the methodology described here will help in identifying appropriate 
treatment options in a timely fashion. 
References: 
[1] Talbot DC et al. A randomized phase II pharmacokinetic and pharmacodynamic 
study of indisulam as second-line therapy in patients with advanced non-small cell 
lung cancer. Clin Cancer Res. 2007 Mar 15;13(6):1816-22 
[2] Bradbury P et al. Cell Cycle Regulatory Proteins as Therapeutic Targets:A validated 
method for pharmacodynamic evaluation of clinical trials. Proceedings from 
EORTC-PAMM 2002, 15, (Suppl n.1), 67
A9.6 Scientific and Technologic Advances in Pulmonary Medicine and Endoscopy, 
 Sat Aug 1, 14:30 - 16:0
Negative EBUS TBNA - a challenge to the ESTS guidelines
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Background: The guidelines for staging of lung cancer advise to 
perform medistinoscopy if EBUS TBNA is negative.
The aim of this study is to avaluate the guidelines if EBUS TBNA is 
performed with biopsy of a least 4R, 4L and 7
Methods: EBUS TBNA was performed on all patients referred to 
staging of the mediastinum either because of lung cancer or changes 
suspicious of lung cancer. If EBUS TBNA were without metastases 
in at least station 4R, 4L and 7 the patients were referred to surgery 
(VATS/thoracotomy). Station 5 can not be reach by Ebus TBNA 
Results: 69 consecutive patients (46 males, 23 females, mean 66 
years (range 40-85)) were included. The sizes of the lymph nodes 
were mean 17mm ( range 4 - 7mm) for station 7. 7mm (range 
2-30mm) for station 4R and mean 6 mm (range 2-21mm) for station 
4 L. 
The final diagnose were cancer in 62 patient and benign in 7 patients 
(Harmathoma, BOOP, infarct).
In 3 patients operation showed metastases to 3 lymph nodes, one in 
station 4 R and 2 in station 5. The NPV was 0.96.
34 PET-CT were performed. 7 PET positive. 2 of these patients were 
benign and one was false positive. 28 were negative. 2 were benign. 6 
were falce negative- 5 with N1 and 1 with N2 disease
Conclusions: EBUS TBNA is a safe procedure and can be performed 
in local anaesthesia. Following the guidelines a patient with negative 
EBUS TBNA should be reffered to mediastinoscopy. We challenge 
these guidelines with our results. 
A9.7 Scientific and Technologic Advances in Pulmonary Medicine and Endoscopy, 
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Is clinical to pathological (c to p) stage migration another 
Will Rogers phenomenon? An analysis of the IASLC 
staging database 
van Meerbeeck, Jan P.1, 4; Chansky, Kari2; Goldstraw, Peter3
1 Ghent University Hospital, Gent, Belgium; 2 CRAB, Seattle, WA, 
USA; 3 Royal Brompton Hospital, London, UK; 4 Lung Oncological 
Network Gent (LONG), Gent, Belgium
Background: The observed differences in distribution frequencies 
between clinical and pathological stages of non-small cell lung cancer 
(NSCLC) suggests the presence of a Will Rogers phenomenon with 
improved stage specific but similar overall survival [Feinstein, 1985].
Aim: To estimate the staging accuracy, the magnitude and direction 
of c to p stage migration and its impact on outcome in resected cases 
of NSCLC from the IASLC staging database [Goldstraw, 2006].
Methods: Resected NSCLC cases, paired according to clinical and 
pathological stage and classified according to the 6th edition of TNM 
(UICC 6) [Sobin, 2000], were extracted from the IASLC database. 
Cases having received preoperative chemotherapy and/or radiother-
apy were excluded from the set; postoperative deaths were included, 
as were substages A and B for stage III only. C to p stage migration 
was estimated by calculating the rate of patients classified in any 
higher (upmigrated) or lower (downmigrated) pathological stage as 
compared to their presenting clinical stage. Outcome was esti-
mated by the Kaplan-Meier method using a common zero time and 
expressed as 5-year survival rate (5-y SR) with lower and upper 95% 
confidence intervals (95%CI). 
Results: 3299 cases with full clinical and pathological data were 
retrieved (6% of the NSCLC cases), with a 5-y SR of 41% (39-43%). 
Overall clinical staging accuracy is 59%, and highest in stage I 
(64%). Migration per stage with corresponding outcome is shown in 
the table. Upmigration is observed in 29% of patients and downmi-
gration in 12%. The observed improvement in outcome between cI 
(45%(43-47)) and pI (54%(51-56)) is due to the upmigration of 738 
cI cases with worse prognosis (29%(25-32)) and the downmigra-
tion of 272 cII and cIII cases with better prognosis (54%(47-60)). 
A complex migration of cases results in a small net improvement in 
outcome between cII (34%(30-38)) and pII (38%(34-41)). The out-
come in pIIIA (23%(19-26)) and pIIIB (17%(12-23)) is worse than in 
cIII A(35%(31-40)) and cIIIB (27%(17-38)), respectively, due to the 
upmigration of 587 cI and II cases with worse prognosis (20%(17-
24)) and the downmigration of 264 cases with better prognosis 
(49%(43-55)).
Conclusion: C to p stage migration in this series of resected NSCLC 
1/ is substantial and reflects the inaccuracy of our current clinical 
staging; 2/ points in both directions, although up-migration is far 
commoner; 3/ results in a improvement in stage-specific outcome in 
stage I and a decrease in both substages IIIA and B, making the pres-
ence of a ‘Will Rogers phenomenon’ less likely. The introduction of 
new staging techniques –PET scan, E(B)US- is expected to improve 
the present inaccuracy of clinical staging. These data hence form a 
baseline for future comparison.
   Clinical  Staging (UICC 6) 
 Pathological staging Total I II IIIA IIIB
 Total (% of total) 3299 2035 (62) 664 (20) 519 (16) 81 (2)
 5-y SR (%) (95%CI) 41 (39-43) 45 (43-47) 34 (30-38) 35 (31-40) 27 (17-38)
 pI (% of column) 1569 (48) 1297 (64) 147 (23) 106 (20) 19 (23)
 5-y SR (%) (95%CI) 54 (51-56) 54 (51-57) 51 (42-59) 62 (51-70) 26 (7-50)
 pII (% of column) 793 (24) 340 (17) 314 (47) 126 (24) 13 (16)
 5-y SR (%) (95%CI) 38 (34-41) 38 (32-43) 36 (30-41) 42 (33-50) 44 (17-68)
 pIIIA (% of column) 684(21) 310 (15) 147 (22) 21 (42) 8 (10)
 5-y SR (%) (95%CI) 23 (19-26) 21 (17-26) 21 (14-28) 25 (19-32) 33 (6-66)
 pIIIB (% of column) 229 (7) 83 (4) 47 (7) 58 (11) 41 (51)
 5-y SR (%) (95%CI) 17 (12-23) 20 (11-30) 13 (5-26) 15 (7-25) 20 (8-35)
 pIV (% of column) 24 (1) 5 (0.2) 9 (1) 10 (2) 0
 5-y SR (%) (95%CI) 5 (0-19) 0 0 12 --
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B1.1 Therapeutic Strategies in Malignant Mesothelioma, Sun Aug 2, 14:30 - 16:00
Randomized, multicentre phase IIIb study of ranpirnase 
+ doxorubicin (DOX) versus DOX in patients with 
unresectable malignant mesothelioma (MM)
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Corinna4; Kozielsky, Jerzy5; Costanzy, John J.6; Gatzemeier, Ulrich1; 
Shogen, Kuslima7; von Pawel, Joachim8
1 Department of Thoracic Oncology; Hospital Grosshansdorf, 
Grosshansdorf, Germany; 2 Institute of Oncology, Warsaw, Poland; 3 
Medical University, Gdansk, Poland; 4 Asklepios Klinikum Harburg, 
Hamburg, Germany; 5 Medical University, Zabrze, Poland; 6 Lone 
Star Oncology Consultants, Austin, TX, USA; 7 Alfacell, Somerset, 
NY, USA; 8 Asklepios Klinikum Gauting, München Gauting, Germany
Background: Ranpirnase (ONCONASE), a novel ribonuclease with 
preclinical activity against various tumors, has led to a median sur-
vival of 8.3 ms (one year survival: 42%) in a multicentre phase II trial 
in chemonaive and pretreated pts whom met the Cancer and Leuk-
emia Group B (CALGB) prognostic criteria for group 1–4 (Mikulski, 
J Clin Oncol 20, 2001).
Methods: This multicenter controlled phase III trial compared effi-
cacy and safety of Dox (one of the most active single agents when the 
study was planned) with or without ranpirnase. Primary endpoint was 
overall survival (OS), secondary endpoints included response rate, 
time to progression, safety and disease related symptoms. Eligibil-
ity criteria: histologically proven unresectable MM; CALGB group 
1-4, ECOG PS 0-1, adequate organ function. Stratification was by 
CALGB group and histology (epithelioid vs. non-epithelioid). One 
line of prior therapy was permitted. Between 08/01 and 09/07 413 
eligible pts were randomized to DOX 60 mg/m2 every 3 wks with 
or without ranpirnase 240 μg/m2 weekly (cycle 1) and 480 μg/m2 if 
no severe toxicity had occurred. The study was designed to detect an 
increase of 4 ms (9 vs. 13) in median OS (MST) using a two-sided 
logrank test (α = 5%) with 90% power.
Results: Both arms were well balanced (DOX + ranpirnase / DOX: 
203/210 pts): Mean age 62.2/61.8 yrs; males 157/156; PS 0 52/60; PS 
1 151/150; prior chemo 65/65 pts (pemetrexed 35/35; other chemo 
30/30). CALGB groups 14/14 (1), 45/51 (2), 117/115 (3), 27/30 (4). 
Investigator assessed tumor regression and stabilization rate was 
in favor of the combination arm (tumor regression: 28% vs 18%, 
tumor stabilization: 47% vs 47%, p = 0.04). In the ITT there was no 
significant difference in OS (MST: 11.1 vs 10.7 ms; HR 1.02, 95% CI 
0.82-1.26) whilst in a preplanned analysis including 130 pretreated 
patients a significant advantage in survival in favor of ONC + ran-
pirnase was found (MST: 10.5 vs 9 ms; HR 1.49, 95% CI 1.02-2.17). 
The safety profile for both treatment arms was similar. Most frequent 
side effects reported for both treatment groups included nausea, 
fatigue and alopecia.
Conclusion: Combination of ranpirnase and DOX is a safe and feas-
ible treatment in unresectable MM and showed a significant impact 
on survival of pretreated patients compared to DOX alone.
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Pemetrexed, cisplatin, and bevacizumab in patients with 
advanced malignant mesothelioma: a multi-center phase II 
trial
Dowell, Jonathan E.1; Lan, Cynthia 1; Gerber, David1; Hughes, 
Randall1; Yan, Jinsheng1; Xie, Yang1; Blake, V2; Taub, Robert3; 
Dunphy, Frank4; Kindler, Hedy2
1 UT Southwestern, Dallas, TX, USA; 2 University of Chicago, 
Chicago, IL, USA; 3 Columbia University, New York, NY, USA; 4 
Duke University, Durham, NC, USA
Background: There is considerable data identifying vascular endo-
thelial growth factor (VEGF) as an important growth factor in meso-
thelioma. Anti-VEGF antibodies inhibit mesothelioma proliferation 
in vitro. In mesothelioma patients, high VEGF levels correlate with 
poor outcome. Pemetrexed plus cisplatin, the standard chemotherapy 
for mesothelioma, achieves an objective response rate of 41%, a 
progression-free survival (PFS) of 5.7 months and a median overall 
survival of 12.1 months. We are evaluating the addition of the anti-
VEGF antibody bevacizumab to pemetrexed-cisplatin in an ongoing 
multi-center phase II study in mesothelioma patients. 
Methods: Eligible patients have unresectable, histologically-con-
firmed mesothelioma, no prior chemotherapy, and ECOG perform-
ance status 0-1. Patients receive cisplatin 75 mg/m2, pemetrexed 500 
mg/m2 and bevacizumab 15 mg/kg every 21 days for 6 cycles, then 
bevacizumab every 21 days until disease progression. CT scans are 
obtained every 2 cycles. Response is assessed by modified RECIST. 
The primary endpoint is progression-free survival. Correlative studies 
include immunohistochemistry for the VEGF/KDR complex and 
PCR for simian virus 40 (sv40) T antigen. 
Results: 43 patients enrolled at 4 centers from March 2006 to Febru-
ary 2009. Forty patients are currently evaluable for efficacy and 43 
for toxicity. Patient characteristics: male 85%; median age 66 (range 
24-81); histology: epithelial 65%, sarcomatoid 12.5%, biphasic 
17.5%, unclassified 5%; site of origin: pleura 85%, peritoneum 
12.5%, tunica vaginalis 2.5%; performance status: 0 - 30%, 1 - 70%; 
thrombocytosis (>400) 33%. The median duration of follow-up is 
10 months. The median PFS is 6.9 months (95% CI: 5.3, 7.7). The 
median overall survival is 14.8 months (95% CI: 10, 18.8). Partial re-
sponse rate 43%, stable disease 38%, disease control rate 81%. Grade 
3/4 toxicity (% patients): neutropenia 7%; anemia 0%; thrombocyto-
penia 3%; venous thrombosis 14%; hypertension 7%; vomiting 5%; 
mucositis 5%; CVA 2%; proteinuria 0%; visceral perforation 0%. 
Conclusions: In this ongoing study, the combination of pemetrexed-
cisplatin plus bevacizumab achieved a PFS of 6.9 months, a dis-
ease control rate of 81%, and a median overall survival of 14.8 
months. These results compare favorably with historical controls of 
pemetrexed-cisplatin in mesothelioma patients. Accrual continues to 
a total of 65 patients. Correlative studies evaluating IHC for VEGF/
KDR and PCR for sv40 are in progress.
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Mesothelioma-avastin-pemetrexed-study (MAPS) IFCT-
GFPC-ELCWP 07-01 trial, a French Intergroup multi-
center randomized phase II-III trial of pemetrexed/
cisplatin with or without bevacizumab in patients with 
malignant pleural mesothelioma: preliminary results
Zalcman, Gerard1; Mazieres, Julien2; Creveuil, Christian1; Astoul, 
Philippe3; Ruffie, Pierre4; Margery, Jacques12; Moro-Sibilot, Denis5; 
Milleron, Bernard6; Hubscher, Philippe7; Paillotin, Dominique8; 
Robinet, Gilles9; Morin, Franck10; Lebitasy, Marie-Paule10; Barlesi, 
Fabrice3; Scherpereel, Arnaud11
1 Caen University Hospital, Caen, France; 2 Toulouse University 
Hospital, Toulouse, France; 3 Marseille University Hospital, 
Marseille, France; 4 Institut Gustave Roussy (IGR), Villejuif, 
France; 5 Grenoble University Hospital, Grenoble, France; 6 Tenon 
University Hospital, Paris, France; 7 Le Havre General Hospital, Le 
Havre, France; 8 Rouen University Hospital, Rouen, France; 9 Brest 
University Hospital, Brest, France; 10 Intergroupe Francophone de 
Cancérologie Thoracique (IFCT), Paris, France; 11 Lille University 
Hospital, Lille, France; 12 Percy Military Hospital, Clamart, France
Background: Malignant Pleural Mesothelioma (MPM) is an ag-
gressive malignancy, with median overall survival not exceeding 13 
months with modern chemotherapy doublet pemetrexed/cisplatin. 
A body of biological and clinical evidences suggest that VEGF is 
a major autocrine growth factor for MPM. A recent US Intergroup 
randomized phase II trial using gemcitabine/cisplatin, with or with-
out bevacizumab, reported an interesting median survival of 15.6 
months in the bevacizumab arm, without any difference between this 
experimental arm and the placebo arm, whereas a majority of patients 
received pemetrexed-based therapy in second-line setting. Moreover, 
an exploratory analysis showed that patients with low baseline serum 
VEGF levels had a significantly better median survival of 24 months. 
Therefore, French Intergroup IFCT aimed to test the association 
of the bona fide chemotherapy doublet pemetrexed/cisplatin with 
bevacizumab, in a randomized phase II-III design, with correlative 
biological studies of prognostic and predictive biomarkers.
Methods: Eligible patients have unresectable MPM, with a thoraco-
scopic histological centralized diagnosis, no prior chemotherapy, PS 
0-2, no thrombosis, bleeding, nor major vessel invasion. Primary end-
point: percentage of non-progressive patients at 6 months. Statistics: 
Randomization 1 :1. H0 : P ≤ 40 % versus H1 : P ≥ 60 %; binomial 
exact test requiring the inclusion of 50 evaluable patients in each arm, 
and at least 25 non-progressive patients in the bevacizumab arm to 
go further through the phase III step of the study (Power 94.3%, α 
error=9.8%). Stratification factors: PS (0/1-2), histology (epithelial/
other), center. Patients receive pemetrexed 500 mg/m2, cisplatin 75 
mg/m2 (PC), at D1, with vitaminic supplementation, with (arm B) or 
without bevacizumab (arm A) 15 mg/kg, on a 21-days schedule, for 6 
cycles. Non-progressive patients after 6 cycles receive bevacizumab 
maintenance therapy until progression or toxicity. Enrollment begun 
in February 2008 in 53 French centers and 1 Belgium center.
Results: On March, 1tst 2009, 61 patients have been enrolled and 36 
are evaluable for toxicity, 19 in arm A, 17 in arm B. Median age: 64.3 
(range 34.7-75.5), M:F = 46:15, epithelial:non epithelial = 48:13, 
WHO PS 0:1:2 = 25:32:4. 175 cycles of chemotherapy have been 
analysed in those 36 patients. 52 (8.8%) Grade 3-4 events (44 grade 
3 :8 grade 4) out of 778 adverse events related to chemotherapy are 
summarized in the Table below (maximum toxicity for each individ-
ual patient).
  Arm A  Arm A  Arm B  Arm B
  Grade 3  Grade 4  Grade 3  Grade 4
  n=19  n=19  n=17  n=17
 Anorexia 1 5.25% 0  0  0 
 Asthenia 1 5.25% 0  1 5,25% 0 
 Constipation 0  0  1 5,25% 0 
 Pulmonary Embolism 0  0  0  3 18%
 Hyperglycemia 1 5.25% 0  0  0 
 Hypertension  0  0  1 5,25% 0 
 Hypokaliemia 0  0  1 5,25% 0 
 Oral Mucositis 1 5,25% 0  0  0 
 Neutropenia 4 21% 3 16% 3 16% 1 6%
 Thrombopenia 2 10.5% 1 5.25% 0  0 
 Vomiting 2 10.5% 0  1 5,25% 0 
 Creatininemia rise 0  0  1 5,25% 0 
In addition, a grade 2 thrombophlebitis of the calf was observed in a 
patient who received bevacizumab.
Conclusions: Pemetrexed-cisplatin-bevacizumab triplet chemother-
apy for MPM was relatively well-tolerated and feasible, leading to a 
substantial increase of thrombo-embolic events as a recent meta-
analysis showed for bevacizumab-based therapies. Updated toxicity 
data, Response Rates (RR), number of non-progressive patients at 6 
months will be presented at the meeting
B1.4 Therapeutic Strategies in Malignant Mesothelioma, Sun Aug 2, 14:30 - 16:00
Mesothelioma and radical surgery trial (MARS): the 
feasibility study process
Snee, Michael1; Treasure, Tom2; Rogers, Shaun3; Bliss, Judith3; Peto, 
Julian3; O’Brien, Mary4; O’Byrne, Kenneth5; Spicer, James6; Waller, 
David7
1 St James Institute of Oncology Leeds, Leeds, UK; 2 Tom Treasure 
MD MS FRCS FRCP, London, UK; 3 Institute of Cancer Research, 
London, UK; 4 Royal Marsden Hospital, London, UK; 5 St James 
Hospital, Dublin, Ireland; 6 King’s College Hospital, London, UK; 7 
Leicester University Hospitals, Leicester, UK
Background: The incidence of malignant pleural mesothelioma 
(MPM) continues to rise worldwide, due to uncontrolled asbestos 
use. Most patients will die of their disease but extrapleuralpneu-
monectomy (EPP) has been proposed as a means of improving local 
control and prolonging survival. Patients being selected for EPP are 
generally younger, fitter and have earlier stage disease compared with 
the general population with MPM and EPP has never been the subject 
of a randomised trial. 
Methods: The Mesothelioma and Radical Surgery (MARS) trial 
randomised patients with malignant pleural mesothelioma (MPM) 
between EPP and no EPP. Patients had histological proven, resectable 
MPM based on computerised tomography and positron emission tom-
ography (PET) with no evidence of mediastinal nodal involvement 
at mediastinoscopy. Patients had to be fit to undergo chemotherapy, 
radical surgery by EPP and radical radiotherapy. 
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MARS had a two stage consent process. At 1st consent the patient 
was registered to be treated according to the MARS protocol but 
without final commitment to randomisation. After three cycles of 
platinum based chemotherapy and restaging with CT the MARS ‘vir-
tual’ multi-disciplinary team of surgeons, radiologists and oncologists 
reviewed each case and suitable patients were offered randomisa-
tion to EPP or no EPP, after further consent. The pilot phase of the 
MARS trial assessed the rate of accrual, compliance and feasibility of 
randomising patients, and treatment toxicity.
Results: Between October 2005 and November 2008, 11 UK centres 
screened over 300 patients, of whom 112 (approximately 3% of 
incident cases in the UK over the study period) were registered. 
During the first phase 27 progressed, 5 were staged inoperable, 4 
were treated off trial, 18 withdrew, 1 died and 57 (51%) consented 
for randomisation. After final review for randomisation 6 more were 
deemed inoperable, another 1 withdrew and 50 were randomised, 24 
to EPP and 26 to no EPP. 
Conclusion: The trial has been implemented through a network of 
UK centres, confirming successful collaboration for shared delivery 
of multimodality therapy within a randomised surgical trial. This 
sucess is evident from the fact that about half of those entering the 
study for evaluation were eventually randomised. We have shown 
that a substantial majority of eligible patients are willing to be ran-
domised between radical surgery and a non-surgical treatment. 
The two stage consent has proved useful in MARS. It allowed pa-
tients to enter the study without being committed to randomisation. 
The temporal separation of registration to enter the study and consent 
to being randomised helps both patients and doctors.
Our data can contribute to a meta-analysis with similar initiatives go-
ing on in other countries but more importantly can lead onto a phase 
III study with an updated research question: “is there a role for any 
surgery in mesothelioma”.
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The effect of extrapleural pneumonectomy versus radical 
pleurectomy/decortication on the pattern of disease 
progression in epithelioid malignant pleural mesothelioma
Nakas, Apostolos1; Begum, Shah Sheikh S.1; Martin-Ucar, Antonio 
E.1; Black, Edward2; Edwards, John G.3; Waller, David A.1
1 Glenfield Hospital, Leicester, UK; 2 Nottingham City Hospital, 
Nottingham, UK; 3 Northertn General Hospital, Sheffield, UK
Objective: We have tested the hypothesis that radical pleurectomy/
decortication (P/D) can be as effective as extrapleural pneumonec-
tomy (EPP) in locally advanced malignant pleural mesothelioma 
(MPM) with no difference in the pattern of disease progression.
Methods: We identified 208 consecutive patients from a prospective 
database of radical surgery for MPM over a 9 year period. In 153 
patients with epithelioid MPM:we compared the demographics, adju-
vant treatment, time to disease progression, first site of symptomatic 
progression and overall survival in 91 post EPP with 62 post P/D.
Results: Patients in the EPP group were younger (Median 57, 
range14-73 years vs Median 62, range 45-75 years, p<0.05) and had 
earlier stage disease: IMIG stage I: 9 EPP;0 P/D, stage II: 7 EPP; 14 
P/D, stage III: 52 EPP;35 P/D, stage IV: 23 EPP; 13 P/D (p=0.004). 
There was no significant difference in 30 and 90 day mortality (3.2% 
and 6.5% P/D, vs 5.5% and 13.2% EPP, p=0.4 and p=0.1 respect-
ively). 
In chemonaive patients (n=121), adjuvant chemotherapy was re-
ceived by significantly more post P/D: 60% (35 of 55 vs 35% (23 of 
66) post EPP, p=0.01.
Disease progression was recorded in more patients after EPP (62 
patients, 68%) than P/D (33 patients, 53%, p=0.04) even though there 
was no difference in follow-up; 20 months EPP vs 16 months P/D, 
p=0.5.
The pattern of first symptomatic disease progression was different be-
tween the groups. Local progression was more common after P/D: 24 
of 33 (73%) vs 31 of 62 patients (50%). Combined local and distant 
and distant only progression were more common after EPP: 14 of 62 
(23%) post EPP vs 6 of 31 (20%) post P/D and 17 of 62 (27%) post 
EPP vs 3 of 31 (10%) post P/D respectively ( p=0.03). 
The time to symptomatic disease progression was similar: EPP 11 
months (SE 1, 95% CI 10-12.5 months), vs P/D 11 months(SE 2.5 
95% CI 6-16 months), p=0.6. Overall median survival was also 
similar: EPP 19.1 months (SE 2,5, 95% CI 14-24 months), P/D 25.4 
months (SE 3, 95% CI 19-32 months), p=0.24. 
Estimated 1 year survival was 67% for EPP and 70% for P/D, 2 years 
38% and 50%, 3 years 19% and 28% and 4 years 11% and 18% 
respectively.
Conclusion: Although EPP appears to offer better local control 
than P/D this does not equate to improved overall survival in locally 
advanced epithelioid MPM.
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Toxicity of EORTC 08031: phase II feasibility trial of 
induction chemotherapy (ICT) followed by extrapleural 
pneumonectomy (EPP) and postoperative radiotherapy 
(PORT) for malignant pleural mesothelioma (MPM) 
cT3N1M0 or less
Van Schil, Paul E.1; Baas, Paul 2; Gaafar, Rabab3; Maat, Alex P.4; van 
de Pol, Marjan5; Hasan, Baktiar 6; Klomp, Houke M.2; Abdelrahman, 
Abdelrahman M.3; Welch, John6; Van Meerbeeck, Jan7
1 Antwerp University Hospital, Edegem (Antwerp), Belgium; 2 
Netherlands Cancer Institute, Amsterdam, Netherlands; 3 National 
Cancer Institute, Cairo, Egypt; 4 Erasmus University, Rotterdam, 
Netherlands; 5 Dr. Bernard Verbeeten Institution, Tilburg, 
Netherlands; 6 EORTC, Brussels, Belgium; 7 University of Ghent, 
Ghent, Belgium
Background: MPM is a highly lethal disease and optimal treatment 
has not been determined yet. The use of EPP in the treatment of early 
stage, potentially resectable MPM remains controversial. EORTC 
08031 phase II trial investigated the feasibility of trimodality therapy 
(TMT) consisting of ICT followed by EPP and PORT. 
Methods: Eligibility criteria were cT3N1M0 or less proven MPM, < 
70 years, PS 0-1, fit for TMT, no widespread chest wall invasion, no 
prior chemo- or radiotherapy. ICT consisted of 3 courses of cisplatin 
75mg/m2 and pemetrexed 500 mg/m2 q3weeks with dexamethasone 
and vitamin supplementation. Non-progressing patients (pts) under-
went EPP followed by PORT (54Gy, 30 fractions). Primary endpoint 
was “success of treatment” defined as a patient who received the full 
protocol treatment, was still alive 90 days after end of protocol treat-
ment without progression and without grade (G) 3-4 toxicity. Using a 
one step Fleming design 52 patients and 26 successes were required. 
Secondary endpoints were toxicity of TMT, overall survival (OS) and 
progression-free survival (PFS). 
Results: 59 pts were registered between 07/26/05 and 08/24/07, 1 
was ineligible. Median age 57 years (range 26-67), M/F:46/12, all 
proven MPM (31 epithelial, 18 mixed, 9 other). All pts underwent 
mediastinoscopy, cT1/T2/T3 36/16/6, cN0/N1 57/1. Fifty-five pts 
received 3 cycles of ICT. G3-4 toxicity related to ICT included 
fatigue (1.8%), infection (3.6%), pain (5.4%), dyspnea (3.6%), 
renal (1.8%), septic shock (1.8%), thromboembolism (3.6%), 
atrial fibrillation (1.8%), retinal detachment (1.8%), leucopenia 
(1.8%), anemia (1.8%), neutropenia (15.5%), hyponatremia (5.2%), 
hyperkalemia (3.4%). Forty-six pts (79.3%) were operated, 42 
(73.7%) had EPP. R0/1/2: 30/10/3, 6 were reoperated, pT0/1/2/3/4: 
2/5/19/15/4, N0/1/2/3: 34/2/6/2, 90-day mortality 6.5% (3 pts, 
pulmonary embolism, lung edema, progressive disease); in 38 pts 
(82.6%) postoperative complications (atrial fibrillation, pneumonia, 
empyema, bronchopleural fistula) occurred. PORT was initiated in 
38 pts and completed in 37 (65%). G3/4 toxicity of PORT included 
fatigue (3.5%), anorexia (3.5%), dysphagia (1.8%), nausea (3.5%), 
vomiting (1.8%), pain (1.8%), dyspnea (1.8%), pneumonitis (1.8%), 
pulmonary embolism (1.8%). After PORT 2 pts died due to infection. 
Persisting G3/4 toxicity 90 days after end of protocol treatment: 3 
pts (5.3%) due to radiation pneumonitis, bronchopleural fistula. After 
median follow-up time of 19.3 months (mos) overall median survival 
time (MST) was 18.4 mos (95% CI 14.8-NR) and progression-free 
MST 13.9 mos (95% CI 10.9-17.1). Only 24 pts (42.1%) met the 
definition of “success”(one-sided 90% CI for proportion of success is 
0.36-1.00). 
Conclusions: EORTC 08031 investigated the feasibility of TMT in 
pts with proven MPM. Primary endpoint was “success” of TMT. Due 
to the low proportion of “successes” this TMT is considered not to be 
feasible. Overall toxicity of this TMT was acceptable but adjustments 
to the protocol are necessary. 
This abstract is presented on behalf of the EORTC Lung Cancer 
Group.
This study was supported by Eli Lilly and Company.
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Initial analyses of the IASLC International Database for 
Malignant Pleural Mesothelioma (MPM)
Rusch, Valerie W.1; Giroux, Dorothy2; Edwards, John3; Waller, 
David4; Kennedy, Catherine5; Ruffini, Enrico6; Pass, Harvey7; Rice, 
David8; Flores, Raja1; de Perrot, Marc10; Crowley, John2; Goldstraw, 
Peter9
1 Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 
2 Cancer Research and Biostatistics, Seattle, WA, USA; 3 Sheffield 
Teaching Hospitals, NHS Foundation Trust, Sheffield, UK; 4 Glenfield 
Hospital, Leicester, UK; 5 University of Sydney, Strathfield Private 
Hospital, Sydney, Australia; 6 University of Torino, Torino, Italy; 7 
New York University, New York, NY, USA; 8 MD Anderson Cancer 
Center, Houston, TX, USA; 9 Royal Brompton Hospital, London, UK; 
10 University of Toronto, Toronto General Hospital, Toronto, ON, 
Canada
Background: The staging system for MPM is based on analyses of 
older small surgical series that may no longer be accurate, especially 
for clinical staging. To propose future revisions of the MPM staging 
system, the IASLC Staging Committee initiated an international 
database to analyze survival in relationship to TNM descriptors and 
prognostic factors. 
Methods: Proprietors of large MPM registries and clinical trials 
databases worldwide were solicited to participate in the IASLC MPM 
database. Core data elements established after review of data diction-
aries submitted by participating groups. Median survival calculated 
by the Kaplan-Meier method. Prognostic factors assessed by univari-
ate Cox regression analysis in this initial analysis, which was limited 
to patients treated surgically with or without multimodality therapy. 
Results: 2680 patients (81% male, median age 64 years) from 
U.S.A., Canada, Europe, Australia, treated between 1995 and 2008, 
were accrued. 1505 patients (56%) had epithelioid tumors. 1528 
patients (57%) underwent pleurectomy/decortication (P/D, n=636) or 
extrapleural pneumonectomy (EPP, n=888), and 1042 had procedures 
for palliation only. pTNM data available for 1357 patients, cTNM for 
940 and both for 578 patients. Median survivals (MS) were 
Factors associated with MS (p<.0001) included tumor histology (epi-
thelioid, 17 mos vs. non-epithelioid, 10 mos), procedure type (P/D + 
EPP, 15 mos vs. palliative, 11 mos), and adjuvant therapy (chemo/RT, 
19 mos vs. none, 10 mos). 
Conclusions: The IASLC Staging Committee has created the largest 
international MPM database reported to date. Analyses corroborate 
the importance of prognostic factors previously identified in single 
institution experiences. The current staging system creates discrep-
ancy between clinical and pathological staging and does not stratify 
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patients well within pathologic stages I-II or III-IV. Additional inter-
national datasets being added to the database to extend these analyses 
and prospective data collection beginning this year should enable 
revision of the current staging system.
Session B2: Individualizing Treatment 
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Biomarker evaluation in the phase III, placebo (P)-
controlled, randomized BeTa trial of bevacizumab (B) and 
erlotinib (E) for patients (Pts) with advanced non-small 
cell lung cancer (NSCLC) after failure of standard 1st-line 
chemotherapy: correlation with treatment outcomes
Herbst, Roy S.1; Stern, Howard2; Amler, Lukas2; Otterson, Gregory3; 
Lin, Ming2; O’Connor, Paula2; Hainsworth, John4
1 The University of Texas M. D. Anderson Cancer Center, Houston, 
TX, USA; 2 Genentech, San Francisco, USA; 3 Ohio State Univ, 
Columbus, USA; 4 Sarah Cannon Rsrch Inst, Nashville, USA
Background: Epidermal growth factor receptor (EGFR) is a tyrosine 
kinase (TK) receptor that may be expressed or mutated in NSCLC. 
E inhibits the activity of the EGFR and has demonstrated improved 
survival when used as monotherapy to treat patients with recurrent 
NSCLC. The BETA Lung study assessed the outcomes of pts with 
advanced stage NSCLC, treated with E+B or E+P in the 2nd-line. 
Clinical activity for the E+B combination was demonstrated by a 
doubling of progression free survival (median PFS 3.4 mos [B+E] 
vs. 1.7 mos [E+P]; hazard ratio [HR]=0.62). However, there was no 
improvement in overall survival (median OS 9.3 mos (B+E) vs.9.2 
mos (E+P); HR=0.97. 
EGFR immunohistochemistry (IHC), EGFR fluorescence in situ hy-
bridization (FISH), EGFR and Kras mutation status, and expression 
of the epithelial mesenchymal transition (EMT) markers were correl-
ated with treatment outcomes in accordance with the study plan.
Methods: Pts enrolled were randomized (1:1) to E+B or E+P. E 
dosing was 150 mg daily. B/P dosing was 15mg/kg intravenous every 
3 weeks. Responses were assessed every 6 weeks until week 24 and 
every 12 weeks thereafter. Treatment continued until disease progres-
sion or unacceptable toxicity. 
Archival tumor tissue was collected for biomarker analysis. EGFR 
FISH and IHC analyses were performed using the PathVysion® and 
PharmDx kits from Abbott-Vysis and DAKO, respectively. Highly 
sensitive analyses of EGFR TK mutations in exons 18-21 and Kras 
mutations in exons 2 and 3 were performed using DHPLC (denatur-
ing high-performance liquid chromatography) and mutations were 
validated by sequencing. Markers of EMT, including e-cadherin and 
vimentin expression, were assessed using established IHC protocols
Results: 477 of 636 enrolled subjects provided tissue samples.
The PFS and OS HRs for pts with an EGFR IHC result were 0.63 
(95% CI: 0.49 -0.80) and 1.03 (95% CI: 0.80 -1.34), respectively. 
They were 0.62 (95% CI: 0.46 -0.84) and 1.24 (95% CI: 0.90 -1.71) 
for subjects with an EGFR FISH result; and 0.62 (95% CI: 0.49 
-0.78) and 1.09 (95% CI: 0.85 -1.40) for those with an EGFR muta-
tion result. The PFS and OS HRs for patients with a K-ras mutation 
result were 0.63 (95% CI: 0.50 -0.79) and 1.10 (95% CI: 0.86 -1.41).
Conclusions: Tissue for biomarker analysis was collected from 75% 
of the pts enrolled in the BETA Lung study. These patients were 
representative of the overall enrolled patient population. The PFS 
and OS results for the biomarker defined sub-groups were consist-
ent with the overall results of the trial. A detailed correlation of these 
biomarkers with outcomes will be presented. 
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A phase II study of biomarker-directed treatment for 
advanced non-small cell lung cancer (NSCLC): the 
BATTLE (Biomarker-integrated Approaches of Targeted 
Therapy for Lung Cancer Elimination) clinical trial 
program
Kim, Edward S.; Herbst, Roy S.; Lee, J. Jack; Blumenschein, George; 
Tsao, Anne; Tang, Ximing; Wistuba, Ignacio I.; Alden, Christine; 
Gupta, Sanjay; Stewart, David J.; Lippman, Scott M.; Hong, Waun K.
University of Texas M. D. Anderson Cancer Center, Houston, TX, 
USA
Background: Predicting tumor response through specific biomarkers 
will help personalize therapy for individuals with cancer. Treatment 
for patients (pts) with recurrent NSCLC continues to be challenging 
because of the limited efficacy despite the use of new targeted agents. 
The feasibility of obtaining tissue at the time of treatment for pts with 
NSCLC has also been difficult in the past. The BATTLE program 
studies the integration of biomarker prediction with targeted therapies 
and the applicability of obtaining core biopsies upon enrollment.
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Methods: Eligible pts had prior chemotherapy, ECOG PS 0-2, and 
when enrolled, required 2 fresh core needle biopsy specimens to 
test 11 biomarkers related to 4 molecular pathways in NSCLC. The 
tests include 3 gene mutation analyses by PCR-based sequencing 
(EGFR; Kras; Braf), two copy number analyses by fluorescent in situ 
hybridization (FISH; EGFR and Cyclin D1), and 6 protein analyses 
by immunohistochemistry (VEGF/R and RXR receptors/Cyclin D1 
markers). Based on eligibility and tumor biomarker analyses, pts 
were then randomized into 1 of 4 possible treatments: erlotinib 150 
mg daily; sorafenib 400 mg twice daily, vandetanib 300 mg daily; er-
lotinib 150 mg + bexarotene 400 mg/m2 daily. The primary endpoint 
of the study is progression-free survival at 8 weeks. The first 97 pts 
were equally randomized, with subsequent pts adaptively randomized 
under a Bayesian framework.
Results: Since 11/2006 and as of 12/2008, 227 pts have been enrolled 
and 171 randomized and treated (median age 62 yrs, 89 males, 137 
Caucasians, 11 Asians, 107 former and 38 never smokers). Accrual 
has proceeded well (average 9 pts per month). 112 of the biopsied 
lesions were lung, with a pneumothorax rate of 12.1% (15 of 124 pts; 
grade 1-2 only; lung, mediastinal and pleural sites). 168 pts (74%) 
have complete biomarker profiles and 7 (3%) have partial. Histology: 
adenocarcinoma (75%), squamous (11%), large cell (13%). Mutation 
frequency was 19% EGFR, 15.4% Kras, and 2.9% Braf. 2 tumors 
contained both EGFR and Kras mutations, and 2 cases had both Kras 
and Braf mutations. EGFR polysomy by FISH was 36.4%, and gene 
amplification 21%. Cyclin D1 amplification was 16.3%. Treatment-
related adverse events (grade 3 or more) were 6.5%. 
Conclusions: We have demonstrated that biopsies are safe and feas-
ible for biomarker-directed studies. The study continues enrollment to 
200 evaluable pts and will be completed later this year. Updated data 
will be presented. BATTLE is one of the first studies in advanced 
lung cancer to prospectively utilize biomarker analysis of fresh biop-
sies to direct pt treatment, and is a step towards personalizing therapy 
in NSCLC. Supported by grant DoD W81XWH-6-1-0303.
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Molecular and clinical biomarkers of cetuximab efficacy: 
data from the phase III FLEX study in non-small cell lung 
cancer (NSCLC)
Gatzemeier, Ulrich1; Paz-Ares, Luis2; Rodrigues Pereira, Jose3; von 
Pawel, Joachim4; Ramlau, Rodryg5; Roh, Jae Kyung6; Yu, Chih-
Teng7; O’Byrne, Kenneth8; Stroh, Christopher9; Pirker, Robert10
1 Hospital Grosshansdorf, Grosshansdorf, Germany; 2 Hospital 12 
de Octubre, Madrid, Spain; 3 Instituto do Cancer Arnaldo Vieira de 
Carvalho, Sao Paulo, Brazil; 4 Asklepios Fachkliniken Muenchen-
Gauting, Gauting, Germany; 5 Wielkopolskie Centrum Chorob Pluc 
i Gruzlicy, Poznan, Poland; 6 Yonsei University College of Medicine, 
Seoul, Korea; 7 Chang Gung Memorial Hospital, Taoyuan, Taiwan; 
8 St James’s Hospital, Dublin, Ireland; 9 Merck KGaA, Darmstadt, 
Germany; 10 Medical University of Vienna, Vienna, Austria
Background: In the randomized, multinational FLEX study, cisplat-
in/vinorelbine (CT) plus cetuximab (an EGFR-targeting monoclonal 
antibody) was compared with CT alone for the 1st-line treatment of 
patients (pts) with advanced EGFR-expressing NSCLC. The study 
demonstrated significantly improved OS time in pts receiving CT 
plus cetuximab. This analysis tested the hypothesis that KRAS and 
EGFR mutation status are predictive for cetuximab efficacy and could 
therefore enable optimal use of this agent. In addition, the association 
between 1st-cycle rash (ie acne-like rash developing within ≤21 days 
of treatment initiation) and OS time was evaluated for pts treated 
with CT plus cetuximab.
Methods: Genomic DNA derived from formalin-fixed paraffin-
embedded tumor tissue samples was analyzed for mutations in 
codons 12/13 of the KRAS oncogene using an LNA-mediated qPCR 
clamping assay and for EGFR kinase domain mutations using a 
mutation-specific real-time PCR assay (EGFR29 mutation test kit, 
DxS, Manchester, UK). OS and PFS times were estimated using the 
Kaplan–Meier method for pts in each treatment arm. All pts treated 
with CT plus cetuximab who were alive 21 days after treatment 
initiation were included in the analysis examining the association 
between 1st-cycle rash and OS time.
Results: Of the 395/1125 pts for whom KRAS mutation status could 
be determined, 75 (19%) were found to have KRAS mutant (mt) 
tumors. OS was not markedly different between pts with KRAS wild-
type (wt) or mt tumors in both treatment groups. Of 293 patients for 
whom EGFR mutation status could be determined, 49 (17%) were 
found to have tumors with EGFR kinase domain mutations. OS was 
longer in patients with EGFR mt tumors compared with wt tumors in 
both treatment groups. These results indicate that EGFR kinase do-
main mutations are prognostic rather than predictive biomarkers for 
cetuximab in NSCLC. In total, 518 pts were included in the analysis 
of 1st-cycle rash. Pts treated with CT plus cetuximab who developed 
1st-cycle rash of any grade (grade 1–3; 56%, n=290) achieved a 
significantly longer median OS time than those who did not develop 
1st-cycle rash (n=228) (median [95% CI]: 15.0 [12.8–16.4] months 
vs 8.8 [7.6–11.1] months; HR [95% CI]: 0.63 [0.52–0.77]; p<0.001).
Conclusions: Data from the FLEX study suggest that KRAS and 
EGFR mutation status are not predictive for efficacy of cetuximab 
when combined with chemotherapy in the 1st-line treatment of 
advanced NSCLC. However, results indicate that, in this setting, 1st-
cycle rash of any grade is associated with improved outcome in pts 
treated with platinum-based chemotherapy plus cetuximab.
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Multicenter prospective study of erlotinib in advanced 
non-small-cell lung cancer (NSCLC) patients with 
epidermal growth factor receptor (EGFR) mutations
Cardenal, Felipe2; Moran, Teresa1; Queralt, Cristina1; Porta, Ruth3; 
Camps, Carlos4; Majem, Margarita5; Lopez-Vivanco, Guillermo6; 
Isla, Dolores7; Provencio, Mariano8; Sanchez, Jose Javier9; Taron, 
Miquel1; Rosell, Rafael1
1 Institut Catala d’Oncologia- Hospital Germans Trias i Pujol, 
Badalona, Ctra Canyet s/n, Spain; 2 Catalan Institute of Oncology, 
Hospital Duran i Reynals, Bellvitge, Spain; 3 Hospital Trueta, 
Girona, Spain; 4 Hospital General de Valencia, Valencia, Spain; 5 
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 6 Hospital 
de Cruces, Cruces-Baracaldo, Spain; 7 Hospital Lozano Blesa, 
Zaragoza, Spain; 8 Hospital Puerta de Hierro, Madrid, Spain; 9 
Autonomous University of Madrid, Madrid, Spain
Background: Progression-free survival (PFS) attained with tyrosine 
kinase inhibitors in NSCLC patients with EGFR mutations is dra-
matic but short-lived. We have evaluated the feasibility of large-scale 
screening for EGFR mutations in advanced NSCLC patients and the 
efficacy of customized erlotinib in these patients.
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Methods: Between April 2005 and November 2008, 2105 NSCLC 
patients from 129 institutions in Spain were prospectively screened 
for EGFR mutations. The analysis was performed in tumor and, 
when available, in paired serum DNA in a central laboratory. Patients 
harboring EGFR mutations were eligible for erlotinib treatment. The 
primary endpoint was PFS.
Results: EGFR mutations were found in 350 of 2105 patients 
(16.6%). Mutations were found more frequently in women (69.7%; 
P<0.001), in never-smokers (66%; P<0.001), and in adenocarcin-
omas (80.9%; P<0.001). Deletions in exon 19 (del 19) were found 
in 62.3% and the L858R mutation in exon 21 in 37.8% of patients. 
EGFR mutations were assessed in paired serum samples from 164 
patients for whom baseline blood samples were available; 97 (59%) 
harbored mutations: del 19 in 64 (39%) and L858R in 33 (20%). PFS 
and median survival (MS) for 217 patients receiving erlotinib was 
14 months and 27 months, respectively. The hazard ratios for shorter 
PFS were 2.35 for male gender (P<0.001); 1.72 for the L858R muta-
tion (P=0.01), and 1.68 for the presence of L858R mutation in the 
paired serum DNA (P=0.02). Based on the results of the multivariate 
Cox model for PFS, a sub-group of 164 patients were divided into 
high- and low-risk groups. The high-risk group was comprised of 
33 males harboring the L858R mutation in both tumor and serum, 
and the remaining 131 patients were considered low-risk. PFS for 
the high-risk patients was 11 months, compared to 16 months for the 
low-risk patients (P=0.02). Three-year PFS for the low-risk group 
was 25.4%.
Conclusion: Large-scale screening of patients for EGFR mutations, 
with subsequent customization of erlotinib, is feasible and leads to 
impressive outcomes, especially in low-risk patients. The assessment 
of EGFR mutations in serum DNA can help to identify patients with a 
high risk of shorter PFS.
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Impact of histology on response and survival in advanced 
non-small cell lung cancer (NSCLC) - subset analysis of a 
phase III trial comparing two platinum-based doublets: 
i.v./oral vinorelbine (NVB) vs docetaxel (DTX)
Gatzemeier, Ulrich, on behalf of the GLOB 3 (Global Lung Oncology 
Branch Trial #3) study investigators
Hospital Grosshansdorf, Grosshansdorf, Germany
Introduction: Despite the uprising of individual criteria for a tailored 
treatment in NSCLC, histology is taking an expanding place in the 
decision making attitude. The aim of this retrospective analysis was to 
evaluate the impact of histology on the efficacy parameters of a large 
patient population homogeneously treated for advanced NSCLC with 
two reference platinum-based doublets as first-line chemotherapy.
Materials and Methods: From February 2004 to January 2006, 381 
patients with unresectable or metastatic NSCLC from 42 investiga-
tional centers in 19 countries were randomly assigned and treated by 
either a cisplatin-based doublet with iv/oral NVB on day 1,8 (NVB 
Arm, 190 pts) or DTX on day 1 (DTX Arm, 191 pts), both combina-
tions delivered every 3 weeks for a maximum of 6 cycles. Time to 
Treatment Failure (TTF) was the primary endpoint. Patients char-
acteristics in both arms were balanced for age, sex, disease extent, 
and PS. Histological types at diagnosis in NVB/DTX arms (%): 
Squamous 65(34.2)/64(33.5); Adenocarcinoma 79 (41.6)/75 (39.3); 
Large cell 8 (4.2 )/18 (9.4); BAC 2 (1.1)/0 (0); Giant Cell 1 (0.5)/1 
(0.5); Unknown 35 (18.4)/33 (17.3). An exploratory analysis on OR, 
TTF and OS was performed taking into account the Squamous and 
Adenocarcinoma histology of patients included in both arms.
Results: Overall, both arms reported similar results in terms of OR 
(NVB 27.4% [95% CI 21.2-34.2]; DTX 27.2% [95% CI 21-34.2]) 
(p=0.97 ), TTF (NVB 3.22 months [95% CI 2.96-4.24]; DTX 4.11 
months [95% CI 3.45-4.50]) (p=0.20), and OS (NVB 9.9 months 
[95% CI 8.41–11.6]; DTX 9.8 months [95% CI 8.80–11.5]) (p=0.58).
Results by histology:
  NVB Arm NVB Arm DTX Arm DTX Arm 
  (n=190) (n=190) (n=191) (n=191)
  Squamous Adenocarcinoma Squamous Adenocarcinoma
 OR (%) ITT 24.6 29.1 28.1 22.7
 TTF (months) 3.22 3.05 4.22 3.94
 95% CI 2.76-4.63 2.33-4.27 3.81-4.57 2.23-6.08
 OS (months) 8.87 11.73 9.82 11.60
 95% CI 6.44-12.81 8.67-16.46 8.41-12.19 9.72-15.74
Conclusion: This retrospective analysis confirms that third genera-
tion platinum-based doublets are effective in all histological subtypes 
of advanced NSCLC. Adenocarcinoma is predictive for a better 
response to chemotherapy, as confirmed in this trial with NVBo + 
CDDP.
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Pemetrexed is more effective in patients with nonsquamous 
non-small cell lung cancer (NSCLC) histology: an analysis 
of three large, randomized, phase III trials 
Scagliotti, Giorgio1; Brodowicz, Thomas2; Shepherd, Frances3; 
Zielinski, Christoph2; Vansteenkiste, Johan5; Manegold, Christian6; 
Simms, Lorinda7; Fossella, Frank8; Sugarman, Katherine9; Belani, 
Chandra10
1 University of Turin, S. Luigi Hospital, Orbassano, Italy; 2 
University Vienna - General Hospital, Vienna, Austria; 3 Princess 
Margaret Hospital, Toronto, ON, Canada; 4 Medical University of 
Vienna, Vienna, Austria; 5 University Hospitals, Leuven, Belgium; 6 
University Medical Center Mannheim, Mannheim, Germany; 7 Eli 
Lilly Canada Inc., Toronto, ON, Canada; 8 MD Anderson Cancer 
Center, Houston, TX, USA; 9 Eli Lilly and Company, Indianapolis, IN, 
USA; 10 Penn State Cancer Institute, Hershey, PA, USA
Background: Previous clinical trials have shown that NSCLC 
histology predicts pemetrexed efficacy. This analysis reviews overall 
survival (OS) according to histology in three large, randomized, 
phase III trials in the second-line, first-line, and maintenance settings 
for advanced NSCLC. 
Methods: The three studies reported were pemetrexed (Pem) versus 
docetaxel (Doc) in previously treated patients (N=571), cisplatin 
(Cis) plus Pem versus Cis plus gemcitabine (Gem) in chemonaive 
patients (N=1725), and maintenance Pem plus best supportive care 
(BSC) versus placebo plus BSC (N=663) in patients with advanced 
NSCLC. A Cox model of OS was used to test for a significant treat-
ment-by-histology interaction. A significant treatment-by-histology 
interaction indicates that the efficacy benefit for pemetrexed relative 
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to the control arm is greater in patients with nonsquamous histology 
than in those with squamous histology. Subsequent Cox models were 
used to estimate hazard ratios (HR) for OS according to histology. 
Analyses for efficacy according to histology were prespecified in the 
first-line and maintenance studies based on the retrospective findings 
in the second-line study. 
Results: Histology was well balanced between treatment arms in 
each study (approximately 30% squamous and 70% nonsquamous). 
Across all three studies, no clinically relevant differences were 
observed for the safety profile of pemetrexed between histologic 
subgroups. Treatment-by-histology interactions were statistically 
significant in all three studies for OS (p=0.001, 0.002, and 0.033, 
respectively), indicating that patients with nonsquamous histology 
treated with pemetrexed had longer survival than those treated with 
comparators. The following table summarizes the OS results accord-
ing to histology.
NSCLC 
Histologic 
Group
Second-
line Pem 
vs Doc 
N=571
First-line 
Cis+Pem vs 
Cis+Gem 
N=1725
Mainten-
ance Pem 
vs Placebo 
N=663
Pem Doc Cis+Pem Cis+Gem Pem Placebo
Nonsquamous n=205 n=194 n=618 n=634 n=325 n=156
 Median OS 
(mos)
9.3 8.0 11.0 10.1 15.5 10.3
 Adjusted HR 
(95% CI)
0.78 
(0.61, 
1.00)
0.84 (0.74, 
0.96)
0.70* (0.56, 
0.88)
 p-value 0.048 0.011 0.002
Squamous n=78 n=94 n=244 n=229 n=116 n=66
 Median OS 
(mos)
6.2 7.4 9.4 10.8 9.9 10.8
 Adjusted HR 
(95% CI)
1.56 
(1.08, 
2.26)
1.23 (1.00, 
1.51)
1.07* (0.77, 
1.50)
 p-value 0.018 0.050 0.678
*unadjusted
Conclusions: These analyses demonstrate a statistically significant 
interaction between treatment effect and NSCLC histology. Nonsqua-
mous patients have longer survival on pemetrexed regimens whereas 
squamous patients fail to derive benefit relative to comparators. Thus, 
pemetrexed regimens are a preferred choice for NSCLC patients with 
nonsquamous histology.
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Chemotherapy outcomes by histologic subtype of non-
small cell lung cancer (NSCLC): analysis of the SWOG 
database for antimicrotubule-platinum therapy
Chansky, Kari1; Mack, Philip C.2; Crowley, John J.1; Lara, Primo N.2; 
Hirsch, Fred R.3; Franklin, Wilbur A.3; Gandara, David R.2
1 Cancer Research And Biostatistics (CRAB), Seattle, WA, USA; 2 
University of California Davis Cancer Center, Sacramento, CA, USA; 
3 University of Colorado Cancer Center, Denver, CO, USA
Background: Recent reports suggest emergence of NSCLC 
histologic subtype as a predictive factor for chemotherapy-related 
outcomes from pemetrexed-platinum and gemcitabine-platinum 
combinations in first line therapy of advanced stage disease. Data for 
antimicrotubule (AMT)-platinum combinations are limited. Here we 
describe analysis of the SWOG database for chemotherapy outcomes 
by NSCLC histologic subtype, focusing on antimicrotubule-platinum 
combinations.
Methods: SWOG trials in advanced stage NSCLC employing a 
vinca- or taxane-platinum combination (S9806 S0003 and the CDDP/
Vin arm of S9308) were included in this analysis (N= 741 patients). 
Overall survival (OS) and progression-free survival (PFS) compari-
sons were done using Cox proportional hazards regression, adjusting 
for sex. Median survival times were estimated by Kaplan-Meier.
Results: Non-SCCA patients: 613 (83%), with 424 adenocarcinoma 
(57%), 81 large cell (11%), 107 NOS (14%); SCCA: 128 (17%). 
Patient characteristics: balanced in regard to histology except SCCA 
had a significantly greater male proportion (73%) compared to all 
others (63%), P= .03. OS and PFS were not significantly different by 
histology after adjusting for sex in a multivariate model (Table 1.) 
Biomarker analysis of S0003 showed that low plasma osteopontin 
levels were associated with improved patient efficacy (Mack et al, 
JCO, 2008), but there were no differences in predictive value by 
histologic subtype. 
Conclusions: In this analysis of pooled data from 3 SWOG trials 
employing AMT/platinum combinations, no differences in patient 
outcomes were observed by histologic subtype (SCCA versus non-
SCCA). Refinement of potential predictive biomarkers is ongoing.
Table 1. OS and PFS outcomes by histologic subtype.
   Overall Survival Progression-Free Survival
 Histology N Median Adjusted HR* Median Adjusted HR*
 Adeno 424 (57%) 8.5 months 1.00 (referent) 4.3 months 1.00 (referent)
 SCCA 128 (17%) 8.4 months 0.987 (P=.89)$ 4.5 months 0.986 (P=.89)&
 Large Cell 82 (11%) 7.9 months 0.974 (P=.83) 4.2 months 1.03 (P=.81)
 NSCLC, NOS 107 (14%) 9.6 months 0.971 (P=.79) 5.0 months 0.87 (P=.20)
*Hazard ratio (HR) from Cox proportional hazards model with adenocarcinoma as referent, adjusted 
for sex. 
$HR for SCCA vs. all others combined, OS: 0.995 (95% CI 0.82-1.21, P=.96). 
&HR for SCCA vs. all others combined, PFS: 1.01 (95% CI 0.83-1.22, P=.94)
Copyright © 2009 by the International Association for the Study of Lung Cancer S327
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
Session B3: Molecular Profiling 
Sunday August 2
B3.1 Molecular Profiling, Sun Aug 2, 14:30 - 16:00
Shotgun proteomic analysis of non-small cell lung cancer 
tissue
Kikuchi, Takefumi1; Amann, Joseph M.1; Slebos, Robbert J.1, 2; 
Zhang, Bing 3; Li, Ming1; Rahman, Jamshedur S.1; Zimmerman, Lisa 
J.1, 2; Tabb, David L.3; Gonzalez, Adriana L.1; Liebler, Daniel C.1, 2, 3; 
Massion, Pierre P.1; Carbone, David P.1
1 Vanderbilt Ingram Cancer Ctr. Vanderbilt Univ., Nashville, TN, 
USA; 2 Jim Ayers Institute for Precancer Detection and Diagnosis, 
Vanderbilt Univ., Nashville, TN, USA; 3 Department of Biomedical 
Informatics, Vanderbilt Univ., Nashville, TN, USA
In-depth analysis of the cancer proteome should yield an unpreced-
ented level of insight into dysregulation of cancer pathways as well as 
clues for the identification of diagnostic and therapeutic biomarkers. 
Previous technologies have allowed the analysis of only several 
hundreds of proteins, which is insufficient to reflect the complex-
ity of the cancer proteome. We applied a novel shotgun proteomics 
approach combining peptide isoelectric focusing (IEF) and reversed 
phase liquid chromatography-tandem mass spectrometry (LC-MS-
MS) to identify proteins differentially expressed between pools of 20 
samples each from 2 lung cancer sub-types, adenocarcinoma (ADC) 
and squamous cell carcinoma (SCC) and normal lung from non-
cancer controls.
With conservative criteria for protein identification from peptide 
sequences, we have confidently identified 3688 protein groups (6651 
IPI accessions) from the 3 different tissue pools with quantitative 
information. Gene Ontology annotations indicated that 2487 intra-
cellular proteins, 925 nuclear proteins and 514 plasma membrane 
or extracellular space proteins were identified. We observed 93% of 
all identified protein in at least 2 of 4 replicate analyses in the tumor 
pool, and 80% in the normal pool, demonstrating the high repro-
ducibility of the analyses. The number of protein groups expressed 
uniquely in the ADC, SCC and normal tissue pools were 17, 117 and 
21, respectively. Using spectral count data, we identified 232 dif-
ferentially expressed proteins between the normal and tumor pools, 
and selected a subset of these known to be cell-surface or secreted 
proteins as novel biomarker candidates.
Since this dataset represents the most comprehensive analysis of the 
lung cancer proteome to date, we performed pathway and functional 
analyses of the dysregulated proteins with the greatest fold discrimin-
ation between the tumor and normal. We also were able to compare 
these data to microarray data for the same genes, which gave us 
insights into the lung cancer proteome not previously reported on this 
scale. 
We have also developed a high-throughput, label-free mass spectro-
metric method for quantitation of these candidates simultaneously 
in complex biological samples to validate our shotgun data. The 
combination of these two proteomics technologies: shotgun analysis 
as a discovery tool with the capability of identifying and approximate 
quantitation of thousands of proteins, and quantitative proteomics 
analysis with more accurate quantitative verification of the abundance 
of proteins of interest across many samples in a high-throughput 
manner, gave us a list of candidates for lung cancer early detection as 
well as clues regarding potentially novel functionally important mol-
ecules. We are currently focusing on studies of several molecules we 
identified with these technologies in the arachidonic acid metabolism 
pathway as well as cytoskeletal signaling molecules as potentially 
functionally important in lung tumor biology. 
B3.2 Molecular Profiling, Sun Aug 2, 14:30 - 16:00
Gene expression profiles in tumor and normal lung tissue 
in smoking vs. non-smoking non-small cell lung cancer 
(NSCLC) patients (pts)
Szymanowska, Amelia1; Skrzypski, Marcin2; Rosell, Rafael3; Taron, 
Miquel3; Muley, Thomas4; Dienemann, Hendrik4; Meister, Michael4; 
Rzyman, Witold5; Rzepko, Robert6; Jarzab, Michal7; Jassem, Ewa1; 
Jassem, Jacek2
1 Department of Allergology, Medical University of Gdansk, 
Gdansk, Poland; 2 Department of Oncology and Radiotherapy, 
Medical University of Gdansk, Gdansk, Poland; 3 Catalan Institute 
of Oncology, Barcelona, Spain; 4 Department of Thoracic Surgery, 
University of Heidelberg, Heidelberg, Germany; 5 Department of 
Thoracic Surgery, Medical University of Gdansk, Gdansk, Poland; 
6 Department of Pathology, Medical University of Gdansk, Gdansk, 
Poland; 7 Department of Tumor Biology, Center of Oncology Maria 
Sklodowska - Curie Memorial Institute Branch Gliwice, Gliwice, 
Poland
Background: Lung cancer is the leading cause of cancer-related 
mortality. The vast majority of cases are tobacco-related, however 
about 5-20% of all lung cancer pts have never smoked. Molecular 
characterization of NSCLC in non-smokers may allow for better 
understanding of the tumor biology in this growing population of 
pts and provide means for prevention and treatment. In this study we 
assessed the expression of genes potentially related to lung carcino-
genesis.
Methods: All 46 pts underwent pulmonary resection with curative 
intent. Tumor samples of 27 non-smoking and 19 smoking NSCLC 
pts (with corresponding normal lung tissue samples of 15 and 10 
pts, respectively) were analyzed. Expression analysis of 21 genes 
(including genes associated with smoking, kinases, growth factor 
receptors, transcription factors, genes indirectly involved in HPV 
infection pathways and others) was assessed by RT-PCR quantitation 
of mRNA copies in freshly frozen tumor tissue and in normal lung 
tissue. Reactions were carried out in microfluidic cards (TLDAs) in 
HT7900 cycler (AppliedBiosystems). Gene expression was obtained 
by 2-ΔΔCT method with the raw expression data normalized against 
the expression of 18S, POLR2A and ESD. Statistical analysis used 
parametric test with Bonferroni correction for multiple comparisons. 
Results: Five genes were significantly overexpressed in tumors from 
non-smokers vs. from smokers: aryl hydrocarbon receptor (AHR; 
p=0.001), Ras-related associated with diabetes (RRAD; p=0.0047), 
colony stimulating factor for macrophages receptor (CSF1R; p=0.01), 
receptor 2 for TGF beta (TGFBR2; p=0.014) and sex-determining 
region Y-box 9 (SOX9; p=0.038). The normal lung tissue in smok-
ers vs. in non-smokers was characterized by higher expression of 
AHR and RRAD (p=0.01 and p=0.007; not corrected). Intriguingly, 
the tumors in smokers exhibited exclusive and significant 44-fold 
overexpression of aldo-keto reductase (AKR1B10) in contrast to 
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tumors in non-smokers and normal lung tissue in both smokers and 
non-smokers (p=0.000007). Tumors in both smokers and non-smok-
ers overexpressed survivin (BIRC5; more than 7-fold; p=0.0000001) 
and nicotine receptor for acetyl-choline subunit A6 (CHRNA6; 
4-fold; p=0.0000001) compared to normal lung tissue. Expression 
of CHRNA6 in tumors was higher in non-smokers vs. in smokers 
(p=0.03; not corrected). As expected, P16 (CDKN2A) was expressed 
at a low level in normal lung tissue in both smokers and non-smokers, 
however, its expression was 5-fold higher in tumors, particularly in 
non-smokers (p=0.00067). Expression of TGFBR3 and TGFBR2 was 
lower in tumors than in normal lung tissue. TGFBR2 expression in 
tumor samples was higher in non-smokers vs. in smokers. 
Conclusions: NSCLC is characterized by a specific gene expression 
profile strongly related to smoking history. Some of the analyzed 
genes seem to play a role in adaptive response of lung tissue to 
smoking insult (RRAD, AHR, SOX9). Particular molecular distinct 
features (e.g. downregulation of RRAD, TGFR2 and TGFR3) may 
provide the grounds for new therapies for NSCLC in smokers and 
non-smokers.
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Integrating genome wide DNA copy number and mRNA 
expression analyses identifies new candidate tumour 
suppressor genes in lung cancer
Thu, Kelsie1, 2; Lockwood, William W.1, 2; Chari, Raj1, 2; Coe, Bradley 
P.1; MacAulay, Calum1; Girard, Luc3; Gazdar, Adi F.3; Minna, John 
D.3; Lam, Stephen1; Lam, Wan L.1, 2
1 BC Cancer Research Centre, Vancouver, BC, Canada; 2 University 
of British Columbia, Vancouver, BC, Canada; 3 Hamon Center for 
Therapeutic Oncology Research, University of Texas Southwestern 
Medical Center, Dallas, TX, USA
Background: Inactivation of tumour suppressor genes (TSGs) like 
p53 is characteristic of lung cancer, and leads to cellular transforma-
tion. Homozygous deletion, the loss of both alleles of a gene, is one 
genetic mechanism for inactivating TSGs. These events occur due 
to strong selection, making them excellent markers for identifying 
important TSGs that may also be silenced by other mechanisms. 
Discovery of TSGs and the consequences of their inactivation has 
revealed signalling pathways commonly disrupted in lung cancer, 
enhancing our understanding of its development. To discover novel 
TSGs we screened for homozygous deletions in lung cancer gen-
omes. Identification of these TSGs will contribute to our understand-
ing of and ability to prevent and treat lung cancer.
Objective: To use an integrative genomics approach to discover po-
tential tumour suppressor genes inactivated by DNA deletion in lung 
cancer genomes and elucidate their downstream effects on pathway 
disruption. 
Method: Copy number profiles of 86 lung cancer cell lines were 
generated by whole genome tiling path array comparative genomic 
hybridization. Regions of deletion and loss were systematically de-
termined for each sample and compiled across all genomes analyzed. 
Expression profiles were generated for 66 of the cell lines using 
the Affymetrix U133A platform for integration with genomic data. 
Identified genes were separated based on copy number status (de-
letion versus neutral) and their expression compared using the Mann 
Whitney U test to evaluate the effects of deletion on transcript levels. 
Candidate genes were validated by investigating copy number and 
expression levels in a panel of NSCLC samples. 
Results: Array CGH revealed both reported and novel regions of 
frequent deletion. 232 ‘hotspots’ of homozygous deletion were identi-
fied which were altered in >5% of the samples analyzed. Chromo-
some 18 showed a relative enrichment for deletions suggesting it may 
harbour several TSGs, while chromosomes 7 and 14 had the fewest. 
Known TSGs including SMAD4, FHIT, and CDKN2A were lost or 
homozygously deleted in a large proportion of cases validating our 
approach. Integration of copy number and expression data revealed 
significantly lower expression in samples with deletions versus those 
without for 95 genes within the deletion hotspots. Among these are 
lung candidate TSGs such as WWOX and PTPRD, which further 
validates the utility of our integrative method in TSG discovery. We 
identified homozygous deletion as a novel genetic mechanism of 
inactivation of the candidate TSG SMARCA2, which has been shown 
to be silenced by epigenetic alterations in lung cancer. In addition, 
we identified KLHL9 (9p) and MYOM2 (8p) as two novel candidate 
TSGs frequently inactivated in lung cancer. These genes require fur-
ther functional analysis to validate their tumour suppressor potential.
Conclusion: By screening lung cancer genomes for underexpressed, 
homozygously deleted genes, we have identified both reported 
and novel candidate TSGs in lung cancer, including WWOX and 
SMARCA2, and KLHL9 and MYOM2, respectively. Functional valida-
tion is required to further investigate the tumour suppressor potential 
of the candidate genes identified and these findings may provide 
novel targets for lung cancer diagnosis and treatment. 
Supported by SPORE P50CA70907, CIHR, Genome Canada 
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Integrative transcriptome analysis in patients in a phase 
II clinical trial of first-line erlotinib for clinically selected 
patients with advanced non-small cell lung cancer
Laskin, Janessa J.1; Pugh, Trevor J.2; Jackson, Cathy1; Barclay, 
Lorena2; Morin, Ryan2; Ionescu, Diana1; Melosky, Barbara1; Cheryl, 
Ho1; Sun, Sophie1; Murray, Nevin R.1; Marra, Marco A.2
1 British Columbia Cancer Agency, Vancouver, BC, Canada; 2 
Genome Sciences Centre, Vancouver, BC, Canada
Background: The purpose of this study was to clinically select a 
population of patients (pts) likely to benefit from erlotinib and to 
perform extensive genetic profiling of fresh tissue tumour to identify 
predictive biomarkers.
Methods: Treatment was erlotinib 150mg p.o. daily until disease 
progression. Eligibility criteria included: stage IIIB/IV NSCLC; no 
prior chemo; ECOG ≤2; at least 2 of the following 4 criteria: women, 
never-smokers, Southeast Asian origin, adenocarcinoma and/or BAC. 
All pts had baseline serum samples and a fresh frozen tumour biopsy. 
EGFR and KRAS were sequenced using traditional methods to 
identify known mutations of erlotinib. A next-generation sequencing 
method was used to sequence all transcribed RNAs (i.e. the transcrip-
tome) in 25 pretreatment tumours to uncover novel mutations, fusion 
genes, and viral activity. 
Results: From Sept-06 to Oct-08, 65 pts have been enrolled and 60 
completed at least 8 wks of erlotinib (or progressed before 8 wks). 
Median age is 63. 49F and 11M; 45 never smokers, 15 former/current 
smokers. PS 0/1/2: 10/39/11. Ethnicity: 18 Caucasian and 42 Asian. 
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Pathology: 44 Adenocarcinoma; 3 BAC;1 squamous carcinoma; 13 
NSCLC NOS. Toxicities as expected with rash (8 grd 3) and diarrhea 
(2 with grd 3). Responses: PR - 21 (35%); SD - 24 (DCR 75%); PD - 
10; NE - 5. 51 of 60 pts 85% did not progress at 8 weeks.
For all patients, study-specific tumour samples were collected, fresh 
frozen, and pathologist reviewed. 19 of 49 (39%) pre-treatment sam-
ples had an EGFR mutation. 10 of the 28 pts with response data (24 
pts still on drug) had a PR and 7 of these had either an LREA deletion 
or L858R point mutation. 1 of 3 post-treatment samples developed a 
T790M mutation on erlotinib. 3 of 51 pts have KRAS mutations (1 
evaluable for response had PD; 2 non-evaluable).
Analysis of over 40 gigabasepairs of aligned transcriptome sequen-
cing data from 25 tumour samples has uncovered a per tumour 
median of 21,567 genes detected, 273 putative non-synonymous 
point mutations, 6 fusions, and 1 viral sequence. The single squamous 
carcinoma in our study generated over 1700 reads (65 kbp) corres-
ponding to the Epstein-Barr viral genome; none of the other pts had 
viral transcripts. None of the fusion genes were seen in more than one 
tumour nor did any involve to EML4 or ALK as has been reported 
in other studies. Of the total 3,991 non-synonymous point mutations 
observed, 175 were seen in two samples but only EGFR was mutated 
in more than two tumours.We found that 387 mutated genes clus-
tered within 94 canonical pathways including those involved in drug 
metabolism, cellular development, and cell cycle control.
Conclusions: Clinical selection of pts enriches the EGFR muta-
tion positive and KRAS mutation negative population and leads to 
high rates of non-progression. These tumours represent a distinct 
molecular class of lung cancer and are enriched for mutations in a 
number of gene pathways in addition to EGFR and diminished for 
TKI-resistance features such as EML4-ALK fusion genes and KRAS 
mutations. Viral expression in one patient with squamous carcinoma 
is hypothesis generating. Integrative transcriptome analysis of ex-
pression, mutation, and pathway information may uncover common 
patterns of somatic alteration within these tumours that may describe 
mechanisms of erlotinib response and resistance. These data suggest 
clustering of pathway mutations rather than single point mutations 
should be the focus of further study.
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The unique “smell print” of NSCLC cell lines 
Peled, Nir1; Adams, Orna2; Yoshida, Koichi1; Bunn, Paul1; Haick, 
Hossam2; Hirsch, Fred R.1
1 University of Colorado Denver, Denver, CO, USA; 2 The 
Department of Chemical Engineering and Russell Berrie 
Nanotechnology Institute, Technion – Israel Institute of Technology, 
Haifa, Israel
Recent studies have identified specific volatile organic compounds 
(VOCs) in the breath of lung cancer patients. However, the origin of 
these VOCs still scarce and many questions have been raised whether 
those VOCs are emerging from the tumor itself, its micro-environ-
ment or produced by the human as a reaction to the tumor. In the cur-
rent study, we use Non Small Cells Lung Cancer (NSCLC) cell lines 
as a model to clarify this question.
Methods: Ten adenocarcinoma (AC) cell lines and two squamous 
carcinoma (SCC) cell lines were grown to 95% confluence using 
standard conditions (RPMI medium + 10% serum; 5% CO2 environ-
ment). Medium without cells served as a control in duplicates. Head-
space of seven cell lines was collected and analyzed by: (i) gas-chro-
matography/mass-spectrometry (GC-MS) combined with solid phase 
micro-extraction (SPME) for determining the chemical nature of the 
cancerous VOCs; and by (ii) nonmaterial-based electronic nose de-
vice, which has been developed in our (Technion) labs, for obtaining 
simple, real-time discriminations between tumour and healthy cells. 
For the latter, the electrical properties of the sensors were measured 
by a device analyzer using integration times that spanned at least two 
power line cycles. 
Results: GC-MS analysis identified 350-450 different VOCs. For-
ward stepwise discrimination analysis identified 120 common VOCs 
that appear in all tumor and control cells, with >89% confidence. The 
common compounds are mostly nonpolar C1-C13 hydrocarbons. 
Further forward stepwise discrimination analysis revealed 5 VOCs 
that appear in tumor cells but not in control states. Those compounds 
are: diphenylmethane, heptane, 3-methyl-hexane, 1-ethyl-2,4-dim-
ethyl-benzene, and 3-ethyl-benzaldehyde. Three of them (heptane, 
3-methyl-hexane, and 1-ethyl-2,4-dimethyl-benzene) were found also 
in breath of lung cancer patients (unpublished cohort). Focusing on 
85% appearance of the unique VOCs (i.e. VOCs that appear in >85% 
of tumor cells and not in control), 17 VOCs were isolated (table 1), 
where another 2 VOCs occurred in >90% of the NSCLC patients 
(2,3-dimethyl-pentane, 3-ethyl-pentane). Electronic nose analysis 
showed low distribution among the tumor cells. The control signals 
were rather different from the tumor cells, but more improvements 
should be achieved. 
Conclusion: Lung cancer cells share five unique VOCs. Three of 
them occur in the exhaled breath of >90% of NSCLC patients, thus 
indicating that the part of the VOCs transfer to the breath via a meta-
bolic pathway of the tumor cells. 
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Deciphering clonality where patients present with multiple 
lung tumors 
Buys, Timon P.1; Aviel-Ronen, Sarit2; Coe, Bradley P.1; Hwang, 
David3; Waddell, Thomas K.3; MacAulay, Calum1; English, John C.1; 
Tsao, Ming-Sound4; Lam, Wan L.1
1 BC Cancer Research Centre, Vancouver, BC, Canada; 2 The Chaim 
Sheba Medical Center, Tel-Hashomer, Israel; 3 University Health 
Network, Toronto, ON, Canada; 4 Princess Margaret Hospital, 
Toronto, ON, Canada
Background: Lung malignancies are the leading cause of cancer 
death world-wide and the routine detection of multiple lung tumours 
(MLT) is increasing. Primary lung carcinomas can give rise to 
intrapulmonary metastases and it is often difficult to determine the 
clonal relationship between lesions based on pathological methods. 
This distinction is critical given the different approaches to staging 
and clinical management for synchronous tumors and pulmonary 
metastases. Attempts to define clonality using molecular markers 
such as p53 mutation and X chromosome inactivation are limited 
in their effectiveness because they fail to account for the fact that 
similar alterations at these loci can arise independently. To improve 
molecular analysis of clonality, we have used high resolution whole 
genome DNA copy number data to decipher relationships between 
lesions from the same patient, with fine-mapped genomic alteration 
boundaries serving as signature markers for a shared progenitor.
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Methods: Tumor samples from twelve patients presenting with 
multiple lung lesions were analyzed. Following review by a lung 
pathologist, we collected and extracted DNA from cancer cells for 
each lesion. Genome profiling of tumors was undertaken using a 27k 
whole genome tiling-path comparative genomic hybridization (CGH) 
array, with DNA copy number changes precisely defined using 
multiple segmentation algorithms (aCGH-Smooth, FACADE, etc.). 
Genome alteration boundaries in MLT cases were compared to those 
defined in a large panel of unrelated lung tumors (n = 200) to define 
rare alteration events (in contrast to changes at commonly reported 
genome fragile sites, such as the FHIT gene on chromosome 3p). 
Where an alteration boundary was detected solely in lesions from a 
MLT case (and not in other cases), it was interpreted as a rare event 
and taken as evidence for a shared progenitor cell.
Results: Within approximately half of MLT cases, identical segment-
al DNA alteration boundaries were observed, suggesting a common 
origin for lesions in these patients. This finding was bolstered in each 
case when similar DNA changes were not detected in other MLT 
patients or in a large panel of unrelated lung malignancies. Genomic 
data were able to delineate a common origin for some MLT cases 
with similar morphological features, providing a means of defin-
ing clonality where histopathology left this relationship ambiguous. 
MLT cases deemed clonally-related also harboured differing genome 
changes, indicating ongoing tumor evolution (i.e. independent altera-
tions). These findings were consistent across different lung tumor 
histological subtypes.
Conclusions: Fine-mapped genome alterations are a useful tool for 
delineating clonal relationships where patients present with multiple 
lung lesions. With standardized approaches to sample handling and 
data analysis, high resolution genome profiling technologies may 
be reasonably adapted to a clinical setting where they could have a 
significant impact on diagnosis and treatment strategies.
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Profiling in pharmacologically re-expressed microRNAs by 
5-azacytidine and SAHA identified a metastasis associated 
miR-148b in malignant pleural mesothelioma cell lines 
Corvalan, Alejandro H.1; Suraokar, Milind B.1; Gazdar, Adi2; Raso, 
Maria Gabriela3; Moran, Cesar1; Mehran, Reza J.1; Tsao, Anne S.1; 
Wistuba, Ignacio I.1
1 UTMDACC, Houston, TX, USA; 2 UT Southwestern, Dallas, TX, 
USA; 3 UT Southwestern, Houston, TX, USA
Background: MicroRNAs (miRNAs) have emerged as key players 
in human carcinogenesis. Recently it has been shown that some miR-
NAs can be epigenetic up-regulated by aberrant hypermethylation in 
human cancer. Malignant pleural mesothelioma (MPM) is a highly 
malignant neoplasm with different histological subtypes. To explore 
the role of epigenetic mediated up-regulation of miRNAs in MPM we 
performed pharmacological unmasking of miRNA expression in cell 
lines. 
Methods: Five mesothelioma cell lines, including one normal 
mesothelial (Met5A) and five MPMs (epitheliod H2452, biphasic 
H211 and unclassified H28 and H2052) were treated in vitro with the 
demethylating agent 5-aza-cytidine (5-Aza;1 uM) and SAHA (2.5 
uM) for 96 hrs. After RNA extraction (Trizol), miRNA profiling was 
performed by Agilent human microRNA kit v2. 
Results: Total miRNA up-regulated (two-fold) after the treatment 
were 299 (51%) in normal mesothelial Met5A cell line, and lower 
in the malignant cell lines: 171 (29%) in H2452, 79 (13.5%) in 
H211, 55 (9.4%) in H28, and 56 (9.6%) in H2052. We detected that 
167 (55.9%) miRNAs were exclusively up-regulated in Met5A, 56 
(32.7%) in H2452, 21 (26.6%) in H211, 16 (29.1%), in H28, and 18 
(32.1%) in H2052. Among all unique miRNA, only 17 (let-7b, let-7c, 
let-7f-2, miR-302c, miR-328, miR-510, miR-125b-1, miR-16-1, miR-
223, miR-302b, miR-383, miR-551b, miR-922, miR-148a, miR-18b, 
miR-302d, miR-326) have been previously associated to human car-
cinogenesis. Interestingly, one of these miRNA (miR-148a) has been 
associated with microRNA tumor metastasis signature. 
Discussion: The number of total and unique miRNA upregulated 
after 5-Aza and SAHA was lower in MPM cell lines compared with 
normal Met5A cell line. Up-regulation of unique miRNAs was found 
associated with cell lines obtained from some specific subtypes of 
MPM. The identification of metastasis associated miR-148a sug-
gests a potential biomarker for metastasis in this highly malignant 
neoplasm. Further studies, including the analysis of tissue specimens 
are needed to validate these results. 
Grant support: PROSPECT DoD W81XWH-07-1-0306.
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Phase III study comparing preoperative and perioperative 
chemotherapy (CT) with two different regimens in 
resectable non-small cell lung cancer (NSCLC): the results 
of the IFCT-0002 study
Quoix, Elisabeth2, 1; Lavole, Armelle3; Westeel, Virginie4, 1; 
Puyraveau, Marc4; Bigay-Game, Laurence7, 1; Ozenne, Gervais5, 1; 
Gervais, Radj9, 1; Lebeau, Bernard6, 1; Debieuvre, Didier8, 1; Poudenx, 
Michel10, 1; David, Philippe11, 1; Morin, Franck1; Cadranel, Jacques1
1 IFCT, Paris, France; 2 HUS, Strasbourg, France; 3 APHP - Hôpital 
Tenon, Paris, France; 4 CHU, Besançon, France; 5 Clinique du 
Cèdre, Bois-Guillaume, France; 6 APHP - Hôpital Saint-Antoine, 
Paris, France; 7 CHU - Hôpital Larrey, Toulouse, France; 8 CH, 
Vesoul, France; 9 CRLCC Baclesse, Caen, France; 10 CRLCC - 
Lacassagne, Nice, France; 11 CHI, Elbeuf, France
Background: Adjuvant or neoadjuvant chemotherapy using platin-
based doublets is now standard for the treatment of early stage 
NSCLC. Recent metanalyses demonstrated similar results of both 
modalities. The main objective of our study was to compare survival 
of patients randomised between preoperative only CT (PRE) versus 
pre- and post-operative CT (PERI). The secondary objective was to 
compare two platin-based doublets: gemcitabine 1250 mg/m² d1,8 
and cisplatin 75 mg/m² d1 q 3 weeks (GP) versus paclitaxel (200 mg/
m²) and carboplatine AUC 6 d1 q 3 weeks (TC).
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Methods: During a 5-year period, 528 patients were randomised be-
tween the following 4 parallel arms. Arm A: 2 GP followed by 2 more 
GP in responders then surgery; arm B: 2 GP followed by surgery then 
2 more GP in responders; arm C: 2 TC followed by 2 more CT in 
responders then surgery; arm D: 2 TC followed by surgery then by 2 
more TC in responders.
Results: 501 patients could be operated on, 96.2% of the preopera-
tive CT arms (PRE: A+C) and 95.8% of the perioperative CT arms 
(PERI: B+D). The 3-month postoperative mortality was 4.9% and 
4.2% (NS), respectively. Pathological complete response rate did 
not differ according to the number of preoperative cycles (PRE: 
8.6%, PERI: 6.4%). On an intent to treat analysis, 3-year survival 
was 67.8% in the PRE arms and 68.6% in the PERI arms (p=0.96). 
There was a dramatic difference of compliance between the PRE and 
PERI arms with 90.4% and 75.2% of the responding patients having 
received the 4 scheduled cycles, respectively (p=0.001). However, 
there was no significant difference in the 3-year survival of respond-
ers (75.1% and 79.5%, p=0.82). Response rate and survival did not 
differ according to the platin-based doublet used (p=0.54 and 0.84, 
respectively). Overall survival did differ according to stage with a 
3-year survival of 72.9% for stage I patients and 59.1% for stage II 
patients. Survival was significantly improved in responders in both 
stages. There was no interaction between CT strategy and stage.
Exploratory analysis of histological subgroups, showed no significant 
difference in overall survival with a 3-year survival of 68.1% in the 
PRE arms and 77.2% in the PERI arms for squamous cell carcinoma 
(SCC) and of 67.7% and 61.6%, respectively, in the non-SCC sub-
groups. In SCC, 3-year survival was 74.6% for GP arms and 70.7% 
for TC arms whereas, it was 64.2% and 65.4% in non-SCC, respect-
ively. There was no interaction between histological subgroups and 
treatment (PRE or PERI).
Conclusions: As could be expected, compliance to chemotherapy 
was significantly greater in the PRE arms. However, there was no 
significant difference in the outcome neither according to chemother-
apy schedule nor to the regimen. There was no significant difference 
of survival according to histological subtypes and no interaction 
between CT and histology.
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Results of screening for lung cancer with low dose CT: 
surgical aspects and future perspectives
Pardolesi, Alessandro; Veronesi, Giulia; Casiraghi, Monica; Petrella, 
Francesco; Maisonneuve, Patrick; Bellomi, Massimo; Travaini, 
Laura; Brambilla, Daniela; Spaggiari, Lorenzo; Galetta, Domenico
European Institute of Oncology, Milano, Italy
Background: Annual low-dose CT (LD-CT) screening of the chest 
seems to represent a promising tool to diagnose lung malignancies 
at initial stage in high risk subjects. We analysed results of our first 
4 years prospective screening trial in 5203 individuals focusing on 
tumors characteristics and surgical aspects. 
Method: an observational study on LD-CT CT screening of lung 
cancer started in 2004 on asymptomatic actual or former smokers 
older than 50. A non-invasive diagnostic protocol has been applied to 
patients with nodules larger or equal to 5 mm. Patients with suspi-
cious nodules were candidates to minimally invasive wedge resection 
of the lesion, intraoperative frozen section and anatomical resection 
with radical lymph node dissection. Since 2007 lobectomy was per-
formed with minimally invasive robotic approach with radioguided 
intraoperative localisation in case of non palpable lesions. 
Results: a lung cancer was diagnosed in 163 cases among 5203 
(3.1%) enrolled volunteers during the first four years of study. A rad-
ical resection was obtained in 145 (88.9%) patients. Type of surgery 
was pneumonectomy in 4 (2.7%) cases, traditional lobectomy in 
100 (69.0%) cases, robotic lobectomy in 26 (17.9%) cases, sublobar 
resection in 15 (10.3%). A radioguided intraoperative localisation was 
successful in all the 20 patients with non palpable lesions approached 
with this technique (19 videothoracoscopic wedge resections). Patho-
logical exam revealed 118 (72,4%) adenocarcinoma, 20 (12,2%) 
squamous cell carcinoma, 9 (5.5%) small cell lung cancer and 16 
(16,6%) other tumor types. Multifocal tumors were 17 (10.4%). 
Postoperative complications occurred in 47 of 145 cases (32.4%). Re-
operation was necessary in 3 cases (2%). No 30 days post-operative 
mortality occurred. 
Mean diameter decreased from 20 +13.7 mm in baseline tumors to 
13,05 +1,2 mm in those detected during the subsequent screening 
rounds. Rate of p-stage I was similar after baseline CT and subsequent 
screening rounds (71.4% and 74,8%). A benign disease was diagnosed 
in 27 of 190 surgical resections (14%). Overall actuarial 4-year sur-
vival rate of lung cancer patients was 85% (77-93%) (Table 1).
 YEARS N° lung   Radical  Benign disease Stage I Mean Size Rate 
  cancers/screened (%) resection, resected   mm (SD) PET
 Baseline 56/5203 (1,08%) 51 (91,07%) 7 (12%) 40 (71,4%) 20,75 (±13,67 ) 49 (87,50%)
 1 38/4871 (0,78%) 31 (81,58%) 10 (24%) 25 (65,78%) 12,78 (±6,68) 26 (68,42%)
 2 40/4638 (0,86%) 39 (97,50%) 8 (17%) 35 (87,5%) 11,78 (±8,12) 13 (32,50%)
 3 29/4480 (0,65%) 24 (82,76%) 2 (7,7%) 20 (68,97%) 14,6 (±8,11) 21 (72,41%)
 Tot 163/5203 (3.1%) 145 (88,9%)  27 (15,7%) 120 (73,6%) 14,97+ 4,02 109 (66,8%)
Conclusions: Annual CT-screening allows detection of early stage 
lung cancer in high percentage of cases even years after baseline CT. 
Overall surgical treatment is associated to low morbidity and mortal-
ity. Minimally invasive robotic lobectomies represents a safe proced-
ure and may be offered to subjects with initial disease. The role of 
limited resection should be investigated in initial peripheral lesions 
with the aim to preserve quality of life and respiratory function. 
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MAGRIT phase III trial in adjuvant NSCLC: MAGE-A3 
gene expression frequency on the first 2150 patients 
screened and demographics of first patients randomized
De Pas, Tommaso 4; Kim, Joo-Hang1; Zarogoulidis, Konstantinos2; 
Zielinski, Marcin3; Dahabreh, Jubrail5; Vanakesa, Tonu6; Nush, 
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Nasser13; Debruyne, Channa11; Vansteenkiste, Johan14
1 Yonsei University Severance Hospital, Seoul, Korea; 2 University 
Pulmonary Clinic, G. Papanikolaou” General Hospital of 
Thessaloniki, Thessaloniki, Greece; 3 Chest Disease Hospital, 
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Westfalen, Germany; 8 Hospital Central de Asturias, Oviedo, Spain; 
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Background: The MAGE-A3 Antigen-Specific Cancer Immuno-
therapeutic (ASCI) combines a tumor-specific antigen delivered as a 
recombinant protein with a potent immunological Adjuvant System. 
Following a positive signal for clinical activity, reported in a double-
blind, placebo controlled Phase II study in patients with resected 
NSCLC[1], MAGE-A3 ASCI is now under evaluation as adjuvant 
treatment for completely resected stage IB, II and IIIA MAGE-A3(+) 
NSCLC patients in the Phase III MAGRIT trial. This is a first report 
on the frequency of MAGE-A3 gene expression and baseline demo-
graphics of randomized patients in this hitherto largest adjuvant trial.
Methods: Formalin Fixed Paraffin-Embedded (FFPE) tumor tissue 
from surgical samples are tested for MAGE-A3 by quantitative Re-
verse Transcription Polymerase Chain Reaction (RT-PCR) in central 
laboratory facilities. MAGE-A3 positivity is defined as a MAGE-A3 
mRNA level above a pre-defined control cut-off value (≥1% MAGE-
A3 expression in control cell line). Several other baseline patient and 
tumor characteristics are collected and associated with the expression 
of MAGE-A3.
Results: MAGE-A3 expression. Between Oct 4, 2007 and Feb13, 
2009, tumor samples from 2150 operable NSCLC patients have 
been screened for MAGE-A3 expression of which 33% are posi-
tive. Results were given to sites in an average of 5 working days. 
The number of invalid samples is low (2.4%). MAGE-A3 expres-
sion level obtained by FFPE in MAGRIT trial was comparable to 
the data obtained on fresh tissue in the proof of concept phase II trial 
(33 % and 35% respectively). The expression is similar across tumor 
stages: 34% in stage IB, 35% in stage II, 31% in stage IIIA. However, 
expression by histopathology is different with 46% in squamous cell 
carcinoma and 24% in adenocarcinoma. Irrespective from stage and 
histopathology, expression increases with primary tumor size: from 
24% for tumors less than 2cm to up to 41% for tumors larger than 
5cm.
Study Demographics of the first 336 patients randomized. Mean age 
is 63. Gender: 23% females. Type of surgical resection: 84% (bi-)lob-
ectomy/sleeve lobectomy, 16% pneumonectomy. Radical mediastinal 
lymphadenectomy was performed in 57%. Pathological stage: 54% 
stage IB, 34% stage II and 12% stage IIIA. Histopathological type: 
53% squamous cell carcinoma and 33% adenocarcinoma.
Adjuvant platinum-based chemotherapy was given to 46% of patients 
(26% Stage IB, 67% Stage II, 80% Stage IIIA).
Conclusions: This preliminary data confirms the feasibility and ease 
of a large scale MAGE-A3 screening by RT- PCR on FFPE tissue, 
performed by central laboratories. The present large series of samples 
confirms previously reported MAGE-A3 expression rate from smaller 
cohorts in these stages of NSCLC[2-4]. This expression is constant 
throughout stages IB, II and IIIA. Interestingly, MAGE-A3 expres-
sion differs according to i)the histological type, with a frequent 
expression in squamous tumors, ii)the tumor size, with increased 
expression in large tumors.
About half of patients randomized do not receive adjuvant chemo-
therapy, confirming a survey in 400 centers conducted prior to the 
initiation of this study. In those given adjuvant chemotherapy, these 
are mainly stages II and IIIA.
[1] Vansteenkiste, JCO,25 Suppl18:398,2007
[2] Gure et al,Clin Cancer Res,11(22):8055-62,2005
[3] Sugita et al,Cancer Res,62:3971-9,2002
[4] Grah et al,Coll Antropol,32(3):731-6,2008
B4.4 Pre versus Post-operative Chemotherapy and Prognostic Markers 
 in Adjuvant Trials, Sun Aug 2, 14:30 - 16:00
Biomarker analysis from completely resected NSCLC 
patients enrolled in an adjuvant erlotinib (Tarceva®) 
clinical trial (RADIANT)
Richardson, Frank1; Richardson, Katherine 1; Sennello, Regina1; 
Young, David 1; Choporov, Sergey 4; Gorbunova, Vera 3; Heo, Dae-
Seog 6; Milanowski, Janusz 7; Tsai, Chun Ming5; Altorki, Nasser2
1 OSI Pharmaceuticals Inc., Boulder, CO, USA; 2 The New York 
Presbyterian-Weill Medical College of Cornell University, New York, 
NY, USA; 3 Russian Academy of Medical Sciences, Moscow, Russia; 
4 State Healthcare Institution of Yaroslavl Region, Yaroslavl, Russia; 
5 Taipei Veterans General Hospital, Taipei City, Taiwan; 6 Seoul 
National University Hospital, Seoul, Korea; 7 Samodzielny Publiczny 
Szpital Kliniczny, Lublin, Poland
Background: RADIANT is a phase III trial comparing erlotinib 
150 mg daily vs. placebo (2:1) in stage IB-IIIA NSCLC patients 
with EGFR-positive tumors (IHC and/or FISH), following complete 
surgical resection. Planned accrual is 945 patients. Correlative bio-
marker studies on primary tumor tissue, whole blood, and serum are 
key components of the study.
Methods: Tumor tissue was evaluated by IHC for protein expression 
of EGFR (PharmDx Kit, Dako with + ≥ 1% positive tumor cells), by 
FISH for gene expression of EGFR (Vysis, Abbott), and by Wave HS 
for EGFR and Kras mutations. 
Results: Among 655 tissue samples analyzed, 96% were EGFR 
IHC+ and 74% EGFR FISH+. Of the 476 tissue samples analyzed 
to date for mutations (mut), 12% had activating EGFR and 19% had 
Kras mut. Preliminary comparisons suggest that EGFR mut rate 
increased while Kras mut rate decreased with tumor stage. EGFR 
mut occurred in 29/178 (16%) females (F) vs. 23/271 (8%) males 
(M), 19/57 (33%) Asians (A) vs. 33/392 (8%) non-Asians (NA), and 
29/66 (44%) never smokers (NS) vs. 23/383 (6%) current or former 
smokers (S). The differences between A vs. NA and NS vs. S were 
significantly different (P <0.0001) for all comparisons made. Kras 
mut occurred in 40/180 (22%) F vs. 48/280 (17%) M, 4/57 (7%) A 
vs. 84/403 (21%) NA, and 3/68 (4%) NS vs. 85/392 (22%) S. The 
difference between A vs. NA and NS vs. S were significantly different 
(P ≤0.0389) for all comparisons made. In adenoca, 51/254 (20%) had 
EGFR and 79/261 (30%) had Kras mut, and in SCC, 0/157 (0%) had 
EGFR and 3/162 (2%) had Kras mut. One tumor sample demonstrat-
ed both an activating EGFR and Kras mut. 
Conclusion: Ongoing comprehensive biomarker assessment in the 
RADIANT population indicates successful sample collection and 
analysis. FISH positivity rates are greater than observed in late-stage 
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tumors. Remaining results in this early-stage population are consist-
ent with those observed in advanced-stage disease. Once complete, 
this study will provide a robust biomarker dataset on which to 
evaluate predictive and prognostic response markers, which may 
help determine who may benefit from treatment with erlotinib in the 
adjuvant setting.
B4.5 Pre versus Post-operative Chemotherapy and Prognostic Markers 
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Prognostic implications of EGFR and KRAS gene 
mutations in resected lung adenocarcinoma
Janjigian, Yelena Y.; Kris, Mark G.; Pao, William; Marks, Jenifer L.; 
Zheng, Junting; Shen, Ronglai; Dycoco, Joseph P.; Park, Bernard J.; 
Riely, Greg J.
MSKCC, New York, NY, USA
Background: Somatic mutations in EGFR (exon 19 and 21) and 
KRAS (exon 2) are found in lung adenocarcinomas and are prognos-
tic in patients with advanced disease. Approximately 70% of patients 
with Stage IV lung adenocarcinoma whose tumors harbor EGFR 
mutations have a radiographic response after treatment with an EGFR 
tyrosine kinase inhibitor (TKI). More cigarette smoking, measured 
in pack years, is associated with decreased survival after diagnosis 
in patients with Stage IV non-small cell lung cancer. To evaluate the 
impact of EGFR and KRAS mutation status and smoking history on 
survival in patients with resected lung adenocarcinoma, we analyzed 
patients with resected lung adenocarcinoma in whom smoking history 
and EGFR and KRAS mutation status were available.
Methods: With Institutional Review Board approval, clinical in-
formation was obtained on all patients with Stage I-III lung adeno-
carcinoma that underwent resection at MSKCC from February 2002 
to August 2008 in whom EGFR and KRAS mutation status were 
determined. Age, gender, smoking history, type of surgery, histology, 
EGFR mutation (exon 19 deletion or exon 21 L858R), KRAS muta-
tion (exon 2), pathologic stage, perioperative therapy and survival 
were recorded. Kaplan-Meier analysis and Cox regression analy-
sis were performed adjusting for stage and perioperative therapy. 
Patients who received EGFR TKI therapy were excluded from the 
analysis.
Results: 735 patients (455 women, 280 men) with completely 
resected Stage I (533), II (86) and III (116) lung adenocarcinoma 
were studied. The median age was 69 and median follow up was 18 
months.
  n % median survival log-rank p
 EGFR mutant 113 15% Not Reached 
 KRAS mutant 163 22% 59 months 
 EGFR/KRAS wild type 459 62% 76 months 0.26
     
 Never smoker 148 20% Not Reached 
 Former/current smoker 587 80% 76 months 0.38
Conclusions: The molecular subsets of lung adenocarcinoma, 
defined by EGFR and KRAS mutation, appear to be associated with 
distinct clinical outcomes. In this surgical cohort, never smoking 
status may also impact survival. Longer follow up will help deter-
mine whether smoking history and mutation status are independent 
prognostic factors in resected, early stage lung adenocarcinoma. 
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Pathologic determinants of survival for adjuvant 
treatment of stage IB non-small cell lung cancer (NSCLC): 
an analysis of the National Cancer Institute of Canada 
(NCIC) and Intergroup Study JBR.10
Strevel, Elizabeth L.1; Ding, Keyue2; Seymour, Lesley2; Tsao, Ming 
S.3; Le Maitre, Aurelie2; Shepherd, Frances A.4; Burkes, Ronald L.5
1 Peel Regional Cancer Centre, Mississauga, ON, Canada; 2 National 
Cancer Institute of Canada, Kingston, Canada; 3 University Health 
Network, Toronto, Canada; 4 Princess Margaret Hospital, Toronto, 
Canada; 5 Mount Sinai Hospital, Toronto, Canada
Background: Adjuvant cisplatin-based chemotherapy (ACT) has 
become the standard of care with established overall survival (OS) 
benefit in resected Stages II and IIIA NSCLC. However, the utility of 
ACT in Stage IB (T2N0) NSCLC has not been proven and remains 
controversial, despite the poor prognosis IB disease portends. Factors 
which differentiate this heterogeneous population into “high” and 
“low” risk are needed. This exploratory retrospective study evalu-
ated the prognostic and predictive value of surgical and pathologic 
determinants on OS in patients with Stage IB NSCLC in the NCIC 
Clinical Trials Group study JBR.10.
Methods: Original surgical and pathology reports were reviewed 
retrospectively for the Stage IB population. Features evaluated 
included tumour size, pathologic grade, visceral pleural invasion 
(VPI), lymphatic invasion (LI), vascular invasion (VI), perineural 
invasion (PNI), tumour necrosis (TN), cavitation and extent of lymph 
node sampling. When available, a single hematoxylin and eosin 
stained section was evaluated for microscopic necrosis, degree of 
stromal fibrosis and inflammatory cell infiltrate and categorized into 
four categories: absent, mild, moderate or marked. Standard analyses 
were conducted testing potential prognostic and predictive factors. 
Multivariate analyses variables also included treatment arm, gender, 
age, histology, performance status, smoking status, extent of surgery 
as well as TMN status. 
Results: Of the 219 IB NSCLC patients in JBR.10, 108 were 
randomized to observation (OBS) and 111 to ACT with cisplatin 
and vinorelbine. Baseline characteristics were generally balanced 
between the two arms, except for VI (p=0.004) and inflammation 
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(p=0.03) which were more common for the ACT arm. Median OS 
was 11 years for OBS and 9.8 years for ACT patients (HR 1.03 (95% 
CI 0.7-1.52, p=0.87). In multivariate analyses, tumour size ≥4cm (HR 
2.45, 95% CI 1.26-4.76, p=0.009) elevated LDH (HR 3.08, 95%CI 
1.02-9.31, p=0.05), moderate fibrosis (HR 2.71, 95% CI 1.31-5.61, 
p=0.007), and moderate inflammatory infiltrate (HR 2.26, 95% CI 
1.07-4.78, p=0.03) were prognostic of poorer outcome in OBS pts. 
Factors that were predictive of treatment effect included tumour size 
≥ 4cm [interaction p 0.026; HR 0.66, 95% CI 0.39-1.14) and absence 
of LI (interaction p 0.008; HR 0.78 95% CI 0.49-1.244). 
Conclusions: Elevated LDH, moderate degree of intratumoural 
fibrosis and inflammation as well as tumour size ≥4cm are prognostic 
in stage IB, while only tumour size ≥ 4 cm and absence of lymphatic 
invasion are predictive for ACT effect. Further analyses, including 
full pathological review and pooled analyses with other ACT trials 
are indicated.
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Subgroup analysis of the phase III trial of adjuvant 
vinorelbine-cisplatin vs observation (Obs) in resected 
patients with NSCLC (ANITA): does efficacy vary by 
histology?
Douillard on behalf of the Adjuvant Navelbine International Trialist 
Association, Jean Y.
Medical Oncology Branch, St-Herblain, France
Background: Recent data questioned a possible impact of histol-
ogy on survival in patients receiving cytotoxic chemotherapy (CT) 
for advanced NSCLC. We reviewed the data issued from the ANITA 
trial which established the benefits of adjuvant Cisplatin-Vinorelbine 
in resected NSCLC: survival outcome was evaluated according to 
histology in the observation group (Obs arm) and in the adjuvant CT 
group (NVB arm). 
Methods: The ANITA trial evaluated vinorelbine (NVB) 30mg/m2 
weekly (16 doses) plus cisplatin (CDDP) 100 mg/m2 on day 1, 29, 57 
and 85 (n = 407) versus observation (n = 433) after complete tumor 
resection in patients stage IB-IIIA NSCLC. Five years (5Y) overall 
survival (OS) rates were calculated with the Kaplan-Meier method in 
both arms for the following subgroups: squamous vs. non squamous 
and adenocarcinoma (ADK) vs. other histological types. Cox models 
were performed with gender (female vs. male), disease stage (IB vs. 
II vs. IIIA) and WHO performance status (0 vs. 1-2) as cofactors: 
estimates of cofactor-adjusted hazard ratios (HR) within the above 
mentioned subgroups were obtained. 
Results: Histological subtypes were balanced between CT and Obs 
arms: 59% and 58% squamous-cell carcinoma, 40% and 41% non 
squamous-cell carcinoma (1% mixed and missing), respectively; the 
ADK accounted for 34% and 33% of patients in each arm.
The 5Y survival rate was similar in squamous and non squamous in 
each treatment arm: 51.6 vs. 50.7 % in CT arm and 43.7 vs. 41.4 % in 
Obs arm. Comparing more specifically ADK to all the other subtypes, 
5Y survival may suggest a poorer prognosis in untreated patients 
with ADK as compared to other subtypes (Obs group:: 38.2 vs 45.0 
%) which disappears with adjuvant NVB-CDDP treatment: 52.1 vs 
50.8 % in CT arm. However, the adjusted HR presented below do not 
show any statistical difference according to histological subtypes.
 Arm Histology Median OS (mo) HR (95%CI)
 CT Nonsquamous / Squamous 60.8 / 69.4 1.19 [0.89-1.60]
 Obs Nonsquamous / Squamous 39.9 / 44.3 1.08 [0.84-1.39]
 CT ADK / Other subtypes 65.7 / 66.5 0.93 [0.69-1.25]
 Obs ADK / Other subtypes 37.3 / 45.5 0.86 [0.66-1.11]
The vinorelbine-cisplatin CT lead to a benefit of 8.6 % in OS at 5 
years overall, consistent whatever the histological subtype: 7.9% in 
squamous, 9.3% in non squamous, 13.9% in the ADK vs. 5.8 % in 
the other subtypes. In ADK, the HR related to CT vs. Obs is 0.71 
[0.52-0.97] and 0.82 [0.65-1.03] in the other subtypes.
Conclusion: The efficacy of the vinorelbine-cisplatin adjuvant CT is 
constant whatever the histological subtype with similar 5YS. Patients 
with ADK in the CT group reached 5YS and median OS similar to 
other histological subtypes. In this trial, the poor outcome of ADK 
versus other subtypes found in the Obs arm was reversed by the posi-
tive impact of CT, possibly due to a higher chemo-sensitivity of this 
subtype. 
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The complex relationship of lung tumor volume to survival 
in patients with non-small cell lung cancer (NSCLC) 
treated by definitive radiotherapy (RT): (Trans Tasman 
Radiation Oncology Group Study 9905)
Ball, David1; Fisher, Richard1; Burmeister, Bryan2; Poulsen, 
Michael3; Graham, Peter4; Penniment, Michael6; Vinod, Shalini5; 
Krawitz, Hedley7; Joseph, David8; Wheeler, Greg 1; McClure, Bev1
1 Peter MacCallum Cancer Centre, Melbourne, Australia; 2 Princess 
Alexandra Hospital, Brisbane, Australia; 3 Mater Hospital, Brisbane, 
Australia; 4 St George Hospital, Sydney, Australia; 5 Liverpool 
Hospital, Sydney, Australia; 6 Royal Adelaide Hospital, Adelaide, 
Australia; 7 Auckland Hospital, Auckland, New Zealand; 8 Sir 
Charles Gairdner Hospital, Perth, Australia
Background: A number of retrospective studies have found that 
tumor size influences survival in patients with NSCLC treated by RT. 
This multicentre prospective observational study was undertaken to 
investigate the hypothesis that tumor volume is a prognostic factor 
independent of T and N stages in patients with NSCLC treated by 
definitive RT. 
Methods: Patient eligibility: pathologic diagnosis of NSCLC; 
disease confined to primary site and intrathoracic nodes; CT-based 
radiotherapy planning; planned for definitive RT (minimum 50 Gy in 
20 fractions or equivalent) with or without chemotherapy. Volumes 
were measured according to a standardised protocol and reviewed 
centrally. Survival was measured from the date of registration. 
Results: Between 9/99 and 7/07, 531 patients were registered of 
whom 509 were eligible and had volumes available for analysis. 
Patient characteristics: 69% male; median age 71 (range 40-94); 44% 
squamous histology; 89% EGOG performance status < 0-1; 75% 
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FDG PET staged; clinical stage: I 33%, II 12%, IIIA 29%, IIIB 27%. 
Treatment given: RT alone 38%, chemoradiation 62%. Survival (95% 
CI): 1 year 71% (67, 75); 2 years 42% (38, 47); 3 years 30% (26, 34); 
5 years 18% (14, 22). 
There was no evidence of an effect of (log) tumour volume on overall 
survival after adjusting for the effects of T stage and node positivity: 
HR = 1.012 (1.2% increase in hazard rate per doubling of volume), 
95% CI 0.94 to 1.09, P = 0.75. 
In univariable analyses, increasing tumour size appeared to be associ-
ated with worsening survival up to about 25 mL, but above this, the 
survival appeared to plateau, or perhaps even improve. For the upper 
third largest tumors (> 7 cm maximum diameter or > 83 mL), 5 year 
survival was 18% (se = 3%) compared with 17% for the lower third. 
On univariable analysis, the following factors were associated with 
shorter survival: male sex (HR 1.43, P = 0.002); worse ECOG 
performance status (Ptrend = 0.019); weight loss (Ptrend = 0.035); 
lymph node involvement (HR 1.35, P = 0.003); larger lymph node 
volume > 13ml (median) (HR 1.39, P = 0.030); more than 1 lymph 
node involved (HR 1.28, P = 0.036). 
On multivariable analysis, the most important prognostic factors were 
lymph node involvement (HR 1.41, P = 0.001), male sex (HR 1.37. P 
= 0.007), ECOG performance status (HR 1.24, P = 0.008), age (HR 
1.15 per 10 year increase, P = 0.018), and T stage (HR 1.13 per stage, 
P = 0.036). Among other factors, tumor volume (HR 1.02, P = 0.53) 
and weight loss (HR 1.15, P = 0.22) were not significant.
Conclusions: The hypothesis that tumor volume is an independent 
prognostic factor was not substantiated by this study. In contradis-
tinction to results from retrospective studies, our prospective study 
observed a plateauing of the relationship of tumor volume to survival, 
suggesting that tumor size alone should not influence treatment 
intent. 
Clinical Trials Registration Number: NCT 00351598
Acknowledgment: This study was supported by a grant from the 
Cancer Council Victoria. 
B5.2 Radiotherapy, Sun Aug 2, 14:30 - 16:00
Initial primary analysis of phase II for RTOG 0117: 
a phase I/II dose intensification study using three 
dimensional conformal radiation therapy and concurrent 
chemotherapy for patients with inoperable, non-small cell 
lung cancer (NSCLC)
Bradley, Jeffrey D.1; Bae, Kyounghwa 2; Graham, Mary3; Byhardt, 
Roger4; Govindan, Ramaswamy1; Fowler, Jack5; Purdy, James A.6; 
Michalski, Jeff1; Gore, Elizabeth4; Choy, Hak7
1 Washington University School of Medicine, St. Louis, MO, USA; 
2 Department of Statistics, RTOG, Philadelphia, PA, USA; 3 Phelps 
County Medical Center, Rolla, MO, USA; 4 Medical College of 
Wisconsin, Milwaukee, WI, USA; 5 University of Wisconsin, Madison, 
WI, USA; 6 University of California, Davis, CA, USA; 7 University of 
Texas Southwestern, Dallas, TX, USA
Background: Phase I portion of Radiation Therapy Oncology Group 
(RTOG) 0117 determined that 74 Gy was maximum tolerated dose 
using 3DCRT with concurrent weekly carboplatin/paclitaxel chemo-
therapy for inoperable NSCLC. Initial results for the Phase II portion 
of this study are reported here, and serve as the basis for the cur-
rent intergroup Phase III randomized trial testing high-dose (74 Gy) 
versus standard dose (60 Gy) radiation therapy. The primary endpoint 
was to determine the percentage of patients that survive at least 12 
months.
Methods: Eligibility included patients with histologically proven, 
unresectable Stages I-III NSCLC and a Zubrod performance status 
of 0-1. Weight loss eligibility was <5%. Concurrent chemotherapy 
consisted of paclitaxel 50 mg/m2 and carboplatin AUC=2 given 
weekly. The radiation dose was 74 Gy/35 fractions. Radiation therapy 
volumes consisted of gross tumor and involved nodes plus a margin. 
Elective lymph nodes were not included in the treatment fields. Tech-
nical criteria included strict dosimetric constraints on the normal lung 
(V20 <30%) and esophagus (mean dose <34 Gy and V55 < 30%) and 
water-based dose calculations prescribed to the isocenter. 
Results: 63 total patients were registered to the study; 46 patients to 
the Phase II portion. The median follow up time is 19.3 months (0.9-
57.9 months) for all patients and 25.4 months (13.1-57.9 months) for 
those still alive. 2 patients were excluded; one withdrew consent and 
the other was ineligible due to the presence of a synchronous prostate 
cancer. All patient treatment plans were centrally reviewed. 94% 
of radiotherapy plans were per protocol or acceptable and 6% were 
unacceptable deviations. The median overall survival (OS) time for 
all patients was 25.9 months and OS and progression-free surviv-
als (PFS) at 12 months were 75.5% and 50.9%, respectively. The 
median, OS, and PFS for patients with Stage III disease (n=44) were 
21.6 months, 72.7%, and 50.0%, respectively. 12 patients experi-
enced ≥grade 3 lung toxicity and 21 patients experienced ≥grade 2 
esophageal toxicity. 2 patients died of complications from treatment 
to ≥74 Gy; 1 pneumonitis and 1 hemorrhage. Lung and esophageal 
dosimetric parameters were not statistically different between patients 
with and without toxicity.
Conclusions: The median survival time and OS rate at 12 months is 
amongst the best we have seen within the RTOG trials for patients 
receiving chemoradiation therapy for NSCLC. These survival and 
toxicity results support the projection expectations for the high-dose 
radiation arms of the current intergroup trial (RTOG 0617).
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Individualized radiation dose escalation for stage I-III 
non-small cell lung cancer (NSCLC) based on normal 
tissue constraints: mature results of a phase II trial
van Baardwijk, Angela1; Reymen, Bart 1; Wanders, Rinus1; Bootsma, 
Gerben2; Pitz, Cordula3; Hochstenbag, Monique5; Geraedts, Wiel4; 
Lunde, Ragnar6; De Ruysscher, Dirk1, 7
1 Maastro Clinic, Department of Radiation Oncology, Maastricht, 
Netherlands; 2 Atrium Medical Centre, Department of Lung 
Diseases, Heerlen, Netherlands; 3 Laurentius Hospital, Department 
of Lung Diseases, Roermond, Netherlands; 4 Orbis Medical Centre, 
Department of Lung Diseases, Sittard, Netherlands; 5 University 
Medical Center Maastricht, Department of Lung Diseases, 
Maastricht, Netherlands; 6 Sint Jans Gasthuis, Department of 
Lung Diseases, Weert, Netherlands; 7 University Medical Center 
Maastricht, Department of Radiation Oncology, GROW, Maastricht, 
Netherlands
Background: Local recurrence is a major problem after (chemo-)
radiation for NSCLC. In a modeling study we showed that increasing 
the radiation dose for each individual patient to the limits of normal 
tissues results in an increase in tumor control probability with the 
same normal tissue complication probability (van Baardwijk et al, 
Int J Radiat Oncol Biol Phys 2008). We proofed the safety of this 
approach in a subsequent feasibility trial (van Baardwijk et al, Int J 
Radiat Oncol Biol Phys 2008). Here, we report the mature results of 
a phase II trial, investigating the efficacy of radical radiotherapy to an 
individualized MLD.
Methods: Patients with medically inoperable or locally advanced 
NSCLC, WHO-performance score 0-2 and a reasonable lung function 
(FEV1 and DLCO >30%) were included. All patients were irradiated 
using an individualized prescribed TTD based on normal tissue dose 
constraints (mean lung dose (MLD) 10 to 19 Gy dependent on FEV1 
and DLCO, maximal spinal cord dose 54 Gy, maximal dose plexus 
brachialis 66 Gy) up to a minimal TTD of 54 Gy and a maximal 
TTD of 79.2 Gy, in 1.8 Gy fractions twice daily. No concurrent 
chemo-radiation was administered. Patients received radiotherapy to 
the primary tumor and the initially PET-positive mediastinal lymph 
nodes. Primary endpoint was overall survival. Furthermore, toxicity 
during and after radiotherapy was scored according to CTCAE 3.0. 
The trial was approved by the required authorities, all patients gave 
informed consent. The Kaplan-Meier method was used to compute 
overall survival. 
Results: 166 patients were included (115 males and 51 females), 
irradiated between December 2004 and June 2007. The median age 
(± SD, range) was 69.0 ± 10.4 years (42-88). Stage distribution was 
as following: stage I 29 %, II 10 %, IIIA 22 %, IIIB 39 %. Fifty-five 
percent received induction chemotherapy. The median prescribed 
radiation dose was 65.9 ± 9.9 Gy (50.4-79.2) with a median MLD 
of 14.8 ± 4.6 Gy (2.4-21.7). Three patients (1.8%) did not complete 
the prescribed dose. The TTD was delivered in 36.3 ± 6.3 fractions 
(3-44) in a median overall treatment time of 25.5 ± 5.8 days (1-50). 
Median overall survival was 21 months (95 % CI 15.7-26.1) with a 
1-year survival of 68.7% and a 2-year survival of 44.9%.The median 
survival showed a trend in favor of resectable vs unresectable tumors 
(23.2 vs 14.9 months, p=0.09) and in favor of stage I-II vs stage III 
(25.6 vs 15.7 months, p=0.05). Acute toxicity during radiotherapy 
was mainly mild: dysphagia grade 0: 46%, 1: 27%, 2: 22%, 3: 5% 
and dyspnea grade 0: 30%, 1: 42%, 2: 18%, 3: 8%, 4: 2%. Regarding 
late toxicity no grade 2 or higher dysphagia was observed, while 
grade 3 or 4 dyspnea was seen in 5% of patients, mainly patients with 
grade 3 or 4 dyspnea before start of treatment. 
Conclusions: Individualized prescribed radical radiotherapy based on 
normal tissue constraints, shows in a relatively unselected group of 
patients survival rates similar to concurrent chemo-radiation sched-
ules, with acceptable acute and late toxicity.
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Survival of patients treated with high-dose radiotherapy & 
concurrent chemotherapy for unresectable non-small cell 
lung cancer
Schild, Steven E.1; Graham, David L.2; Hillman, Shauna L.3; 
Vora, Sujay A.1; Garces, Yolanda I.3; Molina, Julian R.3; Shahidi, 
Homayoon4; Kugler, John W.5; Adjei, Alex A.6
1 Mayo Clinic & NCCTG, Scottsdale, AZ, USA; 2 NCCTG & 
Carle Cancer Center, Urbana, IL, USA; 3 NCCTG & Mayo Clinic, 
Rochester, MN, USA; 4 MeritCare Clinic Bemidji & NCCTG, 
Bemidji, MN, USA; 5 NCCTG & Illinois CancerCare, Peoria, IL, 
USA; 6 NCCTG & Roswell Park Cancer Institute, Buffalo, NY, USA
Background: NCCTG N0028 was a trial performed for patients 
with unresectable non-small cell lung cancer (NSCLC). This trial 
determined the maximally tolerated dose (MTD) of radiotherapy that 
could be given with concurrent carboplatin and paclitaxel was 74 Gy 
in 34 fractions. This secondary analysis was performed to determine 
the survival of the patients treated on this trial.
Methods: Eligible patients had medically or surgically unresectable 
NSCLC, PS=0-1, weight loss <10% in the prior 3 months, no prior 
therapy, adequate laboratory & pulmonary functions. Included were 
25 patients with clinical stages I (4 patients), II (1 patient), IIIa (12 
patients), & IIIb (8 patients) tumors. Treatment included weekly I.V. 
paclitaxel (50mg/m2) and carboplatin (AUC=2) during radiotherapy. 
The radiotherapy included 2 Gy daily to an initial dose of 70 Gy. The 
total dose was increased in 4 Gy increments until the MTD was deter-
mined. Radiotherapy was delivered with 3-D treatment planning but 
no elective nodal irradiation was delivered. Three patients received 
70 Gy, 18 patients received 74 Gy, and 4 patients received 78 Gy.
Results: Patients were followed until death or from 10 to 67 months 
(median: 28 months) in those alive at last evaluation. The median 
survival of the entire cohort was 42 months. The 5 stages I-II patients 
had a median survival of 53 months and the 20 stage III patients had 
a median survival of 42 months.
Conclusions: Standard dose radiotherapy is unable to sterilize dis-
ease in the majority of patients with unresectable NSCLC. While the 
addition of chemotherapy has significantly improved survival of these 
patients, the median survival is generally reported between 15 and 24 
months. These preliminary results suggest higher than standard doses 
of radiotherapy may improve disease control and prolong survival. 
A phase III trial comparing standard-dose radiotherapy (60 Gy) to 
high-dose radiotherapy (74 Gy) is open and should more definitively 
address the issue of radiotherapy dose with concurrent chemother-
apy for unresectable NSCLC. Future technological improvements in 
imaging and targeting will provide methods to safely administer even 
greater radiotherapy doses which will likely further improve disease 
control. 
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Induction chemotherapy and continuous 
hyperfractionated accelerated radiotherapy (CHART) for 
patients with locally advanced inoperable non-small cell 
lung cancer: the MRC INCH randomised trial
Hatton, Matthew2; Nankivell, Matthew G.1; Lyn, Ethan3; Falk, 
Stephen4; Pugh, Cheryl1; Navani, Neal1, 5; Stephens, Richard1
1 Medical Research Council, London, UK; 2 Weston Park Hospital, 
Sheffield, UK; 3 Mount Vernon Hospital, London, UK; 4 Nuffield 
Heath Bristol Hospital, Bristol, UK; 5 University College London 
Hospital, London, UK
Background: Patients who present with locally advanced inoper-
able non-small cell lung cancer (NSCLC) may be suitable for 
radical radiotherapy. In the 1990s a randomised trial of 563 patients 
compared CHART (54Gy/36f, 1.5Gy TID over 12 consecutive days) 
and conventional radical radiotherapy (60Gy/30f) and showed that 
CHART resulted in a 9% improvement in 2-year survival (Saun-
ders et al, Lancet 1997, 350, 161-5). Meta-analysis suggested a 4% 
improvement in 2-year survival with the addition of chemotherapy 
prior to conventional radical radiotherapy (NSCLC Collaborators, 
BMJ 1995, 311, 899-909). A multi-centre randomised controlled trial 
(INCH) was therefore set up to assess the value of adding neo-adju-
vant chemotherapy to CHART.
Methods: Patients with WHO performance status 0/1 histologically 
confirmed, inoperable, stage I-III non-small cell lung cancer were 
randomised to ICT (Induction Chemotherapy (3 cycles of cisplatin 
(80 mg/m2 on day 1) and vinorelbine (25 mg/m2 on days 1 + 8) on a 
21 day cycle) followed by CHART) versus CHART alone.
Results: Between August 2005 and September 2007, 46 patients 
were enrolled (23 in each treatment arm) from 9 UK centres. As a 
result of this poor rate of accrual (against a planned sample size of 
500 patients), the trial was closed in December 2007. 28 patients 
were male, 28 had squamous cell and 34 were stage IIIA or IIIB. 
The median age was 64 years and baseline characteristics were well 
balanced between the two treatment arms. All ICT patients received 
at least 1 cycle of chemotherapy (17 (74%) received all 3) and 20 
went on to receive CHART. In the CHART alone arm 22/23 patients 
received CHART. At the time of analysis 29 patients have died with 
a median survival of 24 months in the ICT arm and 17 months with 
CHART, (hazard ratio of 0.70 (95% CI [0.33, 1.49]), p=0.35). Grade 
3 or 4 adverse events (mainly fatigue, dysphagia and anorexia) were 
reported for 10 (50%) ICT and 6 (26%) CHART patients. 
Conclusions: As reported in previous feasibility studies induction 
chemotherapy followed by CHART is well tolerated and appears 
to result in comparable outcomes to concurrent chemotherapy with 
conventional radiotherapy schedules (Furuse et al, JCO 1999, 17, 
2692-9, Zatloukal et al, Lung Cancer 2004, 46, 87-98, Fournel et al, 
JCO 2005, 23, 5910-7, Belderbos et al, Eur J Ca 2007, 43, 114-21). 
CHART remains an important radiotherapy schedule but moving it 
forward poses major challenges. The ECOG 2597 trial demonstrated 
a median survival of 20.3 months with chemotherapy followed by 
HART compared to 14.9 months with chemotherapy followed by 
conventional RT (Belani et al, JCO 2005, 23, 3760-3767). Therefore, 
the results from INCH together with data from ECOG 2597, suggest 
that the role of accelerated hyperfractionated radiotherapy in the 
treatment of locally advanced NSCLC deserves further study. 
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Image guided stereotactic body radiotherapy for early 
stage non-small cell lung cancer – the importance of dose
Taremi, Mojgan M.1, 2; Pearson, Shannon1, 2; Fung, Sharon3; 
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Bezjak, Andrea1, 2
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Biostatistics, Princess Margaret Hospital, Toronto, ON, Canada
Background: Lung Stereotactic Body Radiotherapy (SBRT) delivers 
high dose, hypofractionated radiation (RT) to pulmonary tumors. 
Compared to conventional RT, SBRT delivers higher biologic ef-
fective dose (BED) with potential for increased tumor control. We 
evaluated tumor control rates for different SBRT dose/fractionation 
schedules used to treat patients with early stage non-small cell lung 
cancer (NSCLC) in our single institution prospective cohort study. 
Methods: Between Dec 2004 and July 2008, ninety-six inoperable 
patients with Stage I NSCLC received SBRT (a total of 100 lesions). 
Patients had complete staging investigations, as well as pre- and 3 
months post-RT PET scan. Respiratory-sorted CT (4DCT) was used 
for RT simulation, and cone beam CT scanning was performed for 
image-guidance before treatment. Dose/fractionation schedules were 
48 Gy /4 fr for most peripheral T1 (tumors < 3 cm) and 54-60 Gy 
/3 fr for T2 (tumors >3 cm) and some T1. More centrally located 
tumors received 60 Gy/8fr or 50 Gy/10 fr. An ITV, formed by the 
fusion of GTV inhale/exhale was expanded by 5mm for setup margin 
to define the PTV. Dose was prescribed to 60-90% isodose encom-
passing the edge of PTV, and heterogeneity correction was used in 
24/100 treatment plans. Patients were reviewed for toxicity while on 
treatment and on protocol follow-up (FU) using CTCAE v.3 toxicity 
assessment criteria; tumor response was evaluated on serial (every 6 
months) CT scans using RECIST criteria. 
Results: Mean age was 72 year (48 to 89), the majority of patients 
had significant co-morbidities (61%) but good performance status 
(78% had PS < 1). There were 100 pulmonary lesions (T1: 74, T2: 
26) with mean size of 2.5 ± 1.2 cm. Median F/U was 16.4 months 
(1.3 - 47.9). Local control was 91% in 100 lesions (96 patients). 
Nine patients (pts) had local failure, most common in the 50Gy/10 fr 
cohort, with 5/12 pts failing, compared to 0/33 pts with 60 Gy/3, 1/18 
pts with 54 Gy/3, 2/33 pts with 48 Gy/4 and 1/4 pts with 60 Gy/8. 
The estimated 1 year overall survival (OS) was 83% (95% CI: 74% 
- 89%), 3 yr OS 48% (95% CI: 32% - 62%); corresponding cause 
specific survival (CSS) were 93% (95% CI: 87% - 98%) and 83% 
(95% CI: 72% - 94%) respectively. Overall, there was no significant 
difference in local control or OS between 60 Gy/3 fr, 54 Gy/3 fr or 
48 Gy/4 fr, however patients treated with 50 Gy/10 fr had higher rate 
of tumor failure and lower 1 year CSS (p < 0.01). The most common 
acute toxicities were grade 1 and 2 fatigue (42/96 patients). There 
were no grade 4 or 5 toxicities; 4 patients developed grade 3 acute 
toxicities (1 fatigue, 3 dyspnea) and 3 patients had grade 3 late toxici-
ties (2 rib fractures and 2 dyspnea). 
Conclusions: Our experience confirms high rates of local control, 
CSS and modest toxicity for patients with early stage NSCLC treated 
with lung SBRT. 50 Gy /10 fr was the only schedule associated with 
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higher rates of local failure. Thus, dose of SBRT appears to be an 
important determinant of local control.
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Stereotactic radiotherapy for centrally located stage I lung 
cancer: results of a ‘risk-adapted’ 60 Gy scheme
Haasbeek, Cornelis J.; Lagerwaard, Frank J.; Slotman, Ben J.; Senan, 
Suresh
Department of Radiation Oncology, VU University Medical Center, 
Amsterdam, The Netherlands
Background: The use of stereotactic radiation therapy (SRT) in 
centrally located early stage lung cancer has been associated with an 
increased risk of complications when fraction sizes exceeding 10 Gy 
were used. Since 2003, we consistently applied a ‘risk-adapted’ SRT 
scheme delivering 60 Gy in 8 fractions to centrally located tumors, 
and report on the clinical outcomes .
Methods: Of 49 patients presenting with a centrally located lung 
tumor, 34 were defined as central using RTOG 0236 criteria, namely 
“primary tumor within or touching the zone of the proximal bronchial 
tree defined as a volume 2 cm in all directions around the proximal 
bronchial tree (carina, right and left main bronchi, right and left up-
per lobe bronchi, intermedius bronchus, right middle lobe bronchus, 
lingular bronchus, right and left lower lobe bronchi”. A further 15 
tumors had planning target volumes (PTV) which overlapped with 
the pericardium. All patients underwent a planning 4-dimensional CT 
scan, and the PTV encompassed all observed motion. Tumors where 
the PTV overlapped the esophagus were excluded from SRT. The 8 
fraction scheme was delivered in a 2-3 week period in the majority 
of patients, and the biologically effective dose was 105 Gy. Doses 
were prescribed to the 80% PTV encompassing isodose. Follow-up 
CT scans were performed at 3, 6 and 12 months following SRT and 
yearly thereafter. The outcomes in high-risk patients were compared 
to outcomes in 357 patients who were treated at our center for non-
high risk tumors in the same period.
Results: The median follow-up was 12 months (range 3 - 55 
months), and no patients were lost to follow-up. Acute toxicity 
consisted of fatigue in 10 patients, mild hemoptysis in 2 patients, 
and increased coughing and dyspnoea in 3 patients. Late toxicity (≥3 
months) consisted of fatigue in 3 patients, pain located at the thoracic 
wall in 3 patients, and non-malignant pleural effusion in one patient. 
At the time of last follow-up, 11 patients had died. Five patients died 
of distant metastasis, and one due to local progression. One patient 
died of AIDS related complications. Only four patients died of other 
causes that could theoretically be treatment-related: one myocardial 
infarction, two cases of respiratory insufficiency and in one case the 
cause of death remained unclear.
One- and 3-year overall survival rates were 84.5% and 54.5%, 
respectively. Local-, regional-, and distant progression-free survival 
rates after 3 years were 93.9, 86.0 and 65.3%, respectively. Overall 
survival (p=0.48), as well as local control (p=0.54), regional control 
(p= 0.63) and distant control (p=0.26) were not significantly different 
from the outcomes of the 357 non-“high risk” patients.
Conclusions: Early results of SRT delivery to centrally-located stage 
I lung using 8 fractions of 7.5 Gy suggests that the toxicity of this 
scheme is acceptable. Longer follow-up will be required to assess late 
effects such as bronchial and pericardial toxicity.
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Personalized lung cancer therapy: safety and adequacy 
of image-guided small-caliber core needle biopsy for 
evaluation of multiple molecular biomarkers
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Background: With the growing trend towards personalized target-
based cancer therapies, it is important to be able to safely and reliably 
obtain tumor tissue for biomarker analysis. In this study we evaluated 
the safety and reliability of image-guided small-caliber core needle 
biopsies for multi-marker analysis in patients with advanced lung 
who were enrolled in the ongoing“Biomarker-integrated Approaches 
of Targeted Therapy for Lung Cancer Elimination” (BATTLE) trial.
Methods: Enrollment in the BATTLE trial required acquisition 
of 2 fresh core needle biopsies to test for 11 different biomarkers 
including gene mutation analyses by polymerase chain reaction-
based sequencing (EGFR exons 18-21; KRAS, codons 12, 13 and 61; 
BRAF, exons 11 and 15), two copy number analyses by fluorescent 
in situ hybridization (EGFR and Cyclin D1), and 6 protein analyses 
by immunohistochemistry (VEGF/R and RXR receptors/Cyclin 
D1 markers). We evaluated the imaging and medical records of the 
patients for the following parameters: biopsy site, imaging findings, 
needle size, image-guidance, diagnostic yield, and complications 
resulting from the biopsy procedure.
Results: A total of 212 biopsies have been performed in 194 patients. 
These included 127 transthoracic biopsies from pulmonary (n=106), 
pleural (n=14), mediastinal (n=5) or hilar (n=2) lesions. Other biopsy 
sites included lymph nodes (n=29), adrenal (n=21), liver (n=15), bone 
(n=8, lytic lesions with soft tissue component in 7 patients and scler-
otic lesion in one patient), soft tissue masses (n=6), subcutaneous 
nodules (n=4) and kidney (n=1). Biopsies were performed with CT 
(n=170) or ultrasound (n=42) guidance. 20-gauge core biopsy needles 
were used to obtain tissue samples in 93% of cases. 
One hundred and seventy seven (83.5%) of the biopsy specimens 
were found to have adequate tumor tissue for analysis of the required 
11 biomarkers. Biopsy sites in the 35 patients with inadequate 
samples included lung (n=26), lymph nodes (n=3), adrenal (n=3), 
and bone (sclerotic lesion), kidney and soft tissue in one patient each. 
Histological evaluation of slides suggested that main reasons of fail-
ure were extensive tumor necrosis and fibrosis in tissue samples. Re-
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view of imaging data in the patients with inadequate tissue samples 
showed that the tissue yield in 19 of these patients could potentially 
have been improved by sampling a different lesion, sampling a differ-
ent portion of the lesion, and performing a PET scan before biopsy to 
assess for viable tumor.
Complications occurred after 18 biopsy procedures (8.5%). Pneumo-
thorax occurred in 18 of the 127 transthoracic biopsy procedures 
(14%). Eleven of these patients (8.6%) required small-bore chest tube 
placement; most of these patients were managed on an outpatient 
basis with the tubes removed the next day. Biopsy from other sites 
did not result in any complications.
Conclusions: Image-guided 20-gauge core needle biopsy is safe and 
provides adequate tissue for analysis of multiple biomarkers in the 
majority of patients with lung cancer enrolled in clinical trials for 
personalized targeted cancer therapy. Careful appraisal of imaging 
to select the appropriate biopsy site has the potential to improve the 
diagnostic yield.
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A distributed bronchial mapping software tool for the 
tracking of cellular, molecular and imaging results in the 
central airways
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Background: The natural history of premalignant changes in the 
central airways has been difficult to decipher because of the inaccess-
ibility of the lower respiratory tract, and the long follow-up time to 
ultimate outcome. Additionally, the paucity of studies with sufficient 
statistical power, the inconsistency of clinical trial entry criteria and, 
importantly, variation in the interpretation of histological endpoints 
also contribute to the difficulty in assessing premalignant changes. 
Despite these limitations, several trials to test natural history of bron-
chial premalignancy, the effect of chemoprevention on lower airway 
epithelium and new methods for visualizing the airways are currently 
underway in industrialized countries. A pooling of data from these 
trials and a uniform interpretation of histological and molecular chan-
ges in the central airways would be highly advantageous in evaluat-
ing the outcomes of these important trials.
Methods: The EDRN Biomarker Atlas Working Group recently has 
developed a Biomarker Atlas software system that allows a re-
searcher to map the bronchi and bronchioles and to associate images 
and clinical data with specific anatomic loci. Characteristics of the 
bronchoscopic procedures including white light and fluorescence 
methods, image records of bronchoscopic findings and histology may 
be accessed using web-based Biomarker Atlas tools including the 
Bronchial Map. Patient specimen data is annotated with a common 
set of data elements that allow the system to filter through and co-
locate available data.
Advances in location-based data discovery and AJAX-based user 
interfaces, e.g., Google Maps, have allowed users to find businesses, 
restaurants and sites of interest using a few simple keywords and the 
selection of a “region” on the map. Our “Biomarker Atlas” capability 
is predicated upon the above recent technical advances and provides 
a means for lung cancer researchers to browse lung cancer specimens 
collected at sites participating in the distributed specimen sharing 
network using a location-based map of a human lung. The backend 
distributed data system is built upon the data grid middleware frame-
work called OODT, the principal enabling technology of the EDRN 
Resource Network Exchange (ERNE). 
Results: To date nearly 5000 images are on file in the Colorado data 
warehouse from 365 patients. Other images are being prepared for 
mapping at Roswell Park. The mapping tool is being used to directly 
compare specific bronchial sites at differing time points in regard to 
fluorescence and white light appearances, histology, immunohisto-
chemistry (Ki-67) FISH and other molecular features. The map has 
dramatically documented spreading of carcinoma in situ through the 
airways and the longer progression of low-grade squamous dysplasia 
to carcinoma at the same site over a 14 year time frame.
Conclusions: The Bronchial Map is a useful software tool that has 
the potential to alter perceptions about premalignant changes in the 
lower airways. The initial pilot sites for the Biomarker Atlas include 
University of Colorado Denver and Health Sciences Center (UCDH-
SC) and Roswell Park Cancer Institute (RPCI). Future work entails 
collaborating with more sites to include specimens in the distributed 
Biomarker Atlas system, and increase the chances of cancer and 
premalignancy biomarker discovery and validation.
Supported by NCI grants U01-CA85070 (EDRN) and P50-CA58187 
(SPORE) 
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Clinical impact of pathological vessel invasion on proposed 
tumor, node, metastasis (TNM) classification of the IASLC 
lung cancer staging project
Tsuchiya, Tomoshi
Department of Translational Medical Sciences, Nagasaki University 
Graduate School of Biomedical Sciences, Nagasaki, Japan
Object: Blood and lymphatic vessel invasion has been considered an 
additional prognostic factor in non-small cell lung cancer (NSCLC) 
without lymph node metastasis. However vessel invasion is not cited 
in current tumor, node, metastasis (TNM) classification system in 
case of lung cancer. We have reported clinical importance of vessel 
invasion in the patients with stage I NSCLC. Herein, according to 
D2-40 immunostaining, a specific monoclonal antibody for lymphatic 
endothelium, we divided patients into two groups by “presence (Vi)” 
and “absence (non-Vi)” of vessel invasion. We re-classified current 
pathological TNM staging of NSCLC into proposed IASLC revision 
and verified whether the factor of vessel invasion has clinical impact 
on the new TNM staging system. 
Patients and Methods: We reviewed 857 patients who received 
surgical resection of NSCLC including pathological stage IA 363, IB 
141, IIA 35, IIB 88, IIIA 120, IIIB, 89, and IV 21 patients. Lymphatic 
(ly) or blood vessel (v) invasion was pathologically classified into 
grade 0 to 3. Classification criteria of vessel invasions are follows; 
ly1: minimal (less than 2 lymphatic vessel invasions); ly2, moderate 
(more than 3 lymphatic vessel invasions); ly3: marked (in the lesion 
beyond the tumoral area); v1 ly1: minimal (barely detect destruction 
of small blood vessels); v2, moderate (detect several relatively easily 
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or invasion to big vascular endothelium ); v3: marked (obvious inva-
sion or embolism in big blood vessel). According to D2-40 immunos-
taining, we defined as ly0 /ly1 and v0 were non-Vi and ly2 or more 
and v1 or more were Vi. Specific time-to-survival curves were plotted 
using the Kaplan-Meier method, while the log-rank test was used to 
assess the statistical significance of differences between groups. The 
appropriateness each staging system was judged by regression an-
alyses using a Cox proportional hazards model, and compared using 
Akaike information criteria (AIC) statistics. A smaller AIC score 
indicated a more appropriate model for predicting outcome. 
Results and discussion: The 5-year survival rates of all patients with 
current stage IA, IB, IIA, IIB, IIIA, IIIB, and IV disease were 85.1%, 
66.9%, 57.4%, 39.4%, 35.2%, 47.6%, and 19.3%, respectively. We 
could observe statistical significance between stage IA/IB, IIIA/IIIB, 
and IIIA/IV. The prognosis of stage IIIB patients was better than 
stage IIIA patients. In the proposed IASLC revision, patients were 
re-classified; stage IA 360, IB 115, IIA 96, IIB 94, IIIA 155, IIIB, 
23, and IV 13 patients. The 5-year survival rates of all patients with 
new stage IA, IB, IIA, IIB, IIIA, IIIB, and IV disease were 86.3%, 
70.2%, 55.2%, 50.9%, 31.9%, 18.9%, and 18.5%, respectively. We 
could observe statistical significance between stage IA/IB, and IIB/
IIIA. Vi group in the proposed IASLC revision showed significantly 
poorer prognosis than non-Vi group at stage IA, Moreover, the group 
showed poorer prognosis than non-Vi group at stage IB. Upstaging 
of Vi group at stage IA uniformized patient number at stage I and 
conduced statistical significance between stage IA/IB, IB/IIA and 
IIB/IIIA. AIC score of current, IASLC proposal, and IASLC + vessel 
invasion staging systems were 2977.6, 2956.7, and 2948.9; IASLC + 
vessel invasion was the best of all the classification. 
Conclusion: The proposed IASLC revision improved current TNM 
staging system. Vessel invasion has clinical impact even on new sta-
ging system. We propose vessel invasion as a considerable prognostic 
factor for pathological TNM staging system. 
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Immunohistochemical diagnosis of ‘non-small cell 
carcinoma, not otherwise specifiable’ in bronchial biopsy 
specimens
Loo, Peh Sun; Thomas, Stuart C.; Fyfe, Margaret N.; Kerr, Keith M.
Aberdeen University Medical School, Aberdeen, UK
Background: Distinguishing small cell from other non-small cell 
lung carcinomas (NSCLC) is important for prognostic and therapeut-
ic reasons. Whilst this histological distinction can be made on small 
biopsy samples with high accuracy and consistency, discrimination 
between NSCLC subtypes (squamous, adenocarcinoma etc) is more 
difficult. In some cases a lack of diagnostic features renders subtyp-
ing impossible and a diagnosis of ‘NSCLC, not otherwise specifiable 
(NOS)’ has to be made. Emerging selective chemotherapies have 
shown differential activity in subtypes of NSCLC, increasing the 
importance of accurate subtyping in small biopsy samples. In this 
study we evaluated the ability of a panel of immunohistochemical 
markers to predict the likely subtype in cases where the bronchial 
biopsy diagnosis was NSCLC-NOS and the tumour was subsequently 
resected and definitively categorized.
Methods: Tissue sections of fifty cases of surgically-resected lung 
cancer, pre-operatively diagnosed as NSCLC-NOS were stained for 
mucin (Alcian Blue / PAS) and with a panel of antibodies (S100A7, 
p63, cytokeratins (CK) 5/6 and 34betaE12 (HMWCK), and TTF1) 
using standard immunohistochemistry methodology (heat Ag re-
trieval, Ventana Benchmark XT autostainer and Ultraview visualisa-
tion). Any intracytoplasmic mucin droplet staining in tumours cells 
was considered positive. Immuno-scoring was semi-quantitative, 
assessing intensity (light +, moderate ++, strong +++) and distribu-
tion (0, 1-10% +, 11-50% ++, 51-100% +++). Analysis of the score 
distribution for each antibody allowed overall grading into low and 
high level staining. Positive (PPV) and Negative (NPV) Predictive 
Values, Sensitivity and Specificity were calculated for each marker 
and for various combinations of markers to predict tumour histotype.
Results: Of the 50 cases, six had insufficient material for study. 
Resected tumour diagnoses were as follows: 23 squamous, 10 adeno-
carcinomas, 8 large cell, 2 adenosquamous and one combined large 
cell neuroendocrine-adenocarcinoma. To correctly predict adeno-
carcinoma, any combination of TTF1 and mucin positivity yielded 
a sensitivity of 69%, specificity 97%, PPV 90%, NPV 88%. To cor-
rectly predict a squamous histotype the individual markers showed; 
S100A7 (Sensitivity 36%, Specificity 74%, PPV 64%, NPV 47%), 
p63 (Sensitivity 92%, Specificity 74%, PPV 82%, NPV 88%), CK5/6 
(Sensitivity 84%, Specificity 79%, PPV 84%, NPV 79%), HMWCK 
(Sensitivity 88%, Specificity 74%, PPV 81%, NPV 82%). Numerous 
combinations of scores were also tested. The best positive predictive 
marker of squamous histology was p63 alone. Whilst combinations 
of ‘squamous’ markers offered no improvement over p63 alone, com-
bining p63 with ABPAS score offered the best sensitivity (78%) and 
specificity (92%) for a ‘non-squamous’ histotype.
Staining of pre-operative samples from large cell carcinomas (8 
cases) showed a ‘squamous’ profile in 4 cases, an ‘adenocarcinoma’ 
profile in 1 case and in 3 cases a profile of low-level staining sug-
gested neither squamous nor adenocarcinoma. 
Conclusion: Immunohistochemistry is a useful tool to refine the 
subtyping of non-small cell carcinomas in bronchoscopically-derived 
biopsy samples in those cases where discrimination beyond a generic 
diagnosis of NSCLC-NOS is not possible. This classification is sug-
gestive rather than definitive for cell type and the responsiveness of 
tumours subtyped in this way to histotype-specific therapies still has 
to be investigated. 
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Enriched tumor expression of folate transporters 
correlates with adenocarcinoma histology type, female 
gender and presence of EGFR mutation in non-small cell 
lung carcinoma 
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Background: Membrane bound folate receptor alpha (FOLR1) and 
transmembrane Reduced folate carrier 1 (RFC1) regulate uptake of 
folate as well as folate linked conjugates inside the cell. FOLR1 and 
RFC1 are over expressed in epithelial primary and metastatic tumors 
and are promising therapeutic targets and tumor biomarkers. Due to 
limited information on the expression of these receptors in non-small 
cell lung carcinoma (NSCLC) we studied the protein immunohisto-
chemical (IHC) expression of these receptors in a large set of tumors 
and correlate our findings with patients’ clinicopathologic features. 
Methods: IHC protein expression of FOLR1, RFC1, was examined 
in 320 surgically resected NSCLCs placed in tissue microarrays, 
including 202 adenocarcinomas and 118 squamous carcinomas, and 
correlated with patients’ clinico-pathological characteristics. A semi-
quantitative IHC score was obtained assessing intensity of immunos-
taining and percentage of positive tumor cells. Wilcoxon rank-sum 
test or Kruskal-Wallis test was used to detect the differences between 
groups. General linear model or logistic regression model was used in 
the multivariate analysis
Results: The pattern of IHC expression varied in malignant cells, 
with FOLR1 and RFC1 expressed in the membrane and cytoplasm. 
In all cases expression in tumor cells was higher than in non-malig-
nant bronchial epithelial cells. Tumor stroma IHC expression was 
frequently detected, especially in endothelial cells, lymphocytes, 
macrophages and fibroblasts. Adenocarcinomas showed significantly 
higher expression compared with squamous cell carcinoma for mem-
brane (P<0.001) and cytoplasmic (P<0.001) FOLR1. Female NSCLC 
patients had significantly higher expression of membrane (P=0.001) 
and cytoplasmic FOLR1 (P=0.01) compared with male patients. 
Ever smoker patients demonstrated significantly lower expression 
of membrane (P<0.001) and cytoplasmic FOLR1 (P=0.002), and 
higher expression of membrane RFC1 (P=0.01), compared with never 
smokers. The differences between histological groups and between 
smokers and nonsmokers remained significant or marginally signifi-
cant in the multivariate models with histology, smoking, gender, race 
and stage. However, the gender differences became non-significant. 
In adenocarcinomas, the presence of EGFR mutations correlated with 
higher expression of membrane FOLR1 (P=0.002). Finally, squamous 
carcinomas showed higher positive endothelial cell expression of 
FOLR1 (P=0.00001) than adenocarcinomas. These findings are sup-
ported by 4 published gene expression datasets, collectively profil-
ing about 400 tumor samples, which show that FOLR1 mRNA is 
expressed at higher levels in adenocarcinomas compared to squamous 
cell carcinomas.
Conclusion: 1. FOLR1 and RFC1 membrane transporters proteins 
are over expressed in NSCLC compared to normal lung bronchial 
epithelium; 2. significant differences were found between adeno-
carcinomas and squamous lung cancer in both tumor cells and the 
tumor microenvironment; 3. differences were found in tumors of 
males and females, between tumors from never and ever smokers, 
and tumors with EGFR or KRAS mutations. The different patterns of 
transporter expression may explain the superior response of NSCLC 
patients with adenocarcinoma histology to pemetrexed.
Supported by grants US DoD W81XWH-07-1-0306, and UT-Lung 
SPORE P50CA70907.
B6.6 Pathology, Sun Aug 2, 14:30 - 16:00
Comparison of CISH and FISH for detection of EGFR 
copy number in lung adenocarcinomas and correlation 
with EGFR and KRAS mutation status and EGFR 
immunohistochemistry reactivity
Varella Garcia, Marileila2; Ladanyi, Marc 1; Kris, Mark G.1; 
Rekhtman, Natasha1; Hirsch, Fred2; Miller, Vincent1; Riely, Gregory1; 
Pao, William1; Zakowski, Maureen F.1
1 Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 2 
University of Colorado Denver, Denver, CO, USA
Background: EGFR copy number has been shown to correlate with 
the presence of EGFR mutations and response to tyrosine kinase 
inhibitors (TKIs) in patients with lung adenocarcinoma. Fluorescent 
in situ hybridization (FISH) for EGFR has been more widely used 
than chromogenic in situ hybridization (CISH) but the latter offers 
some advantages in terms of equipment, ease of implementation and 
preservation of results. We compared CISH and FISH for EGFR in 
a series of lung adenocarcinomas and correlated the findings with 
EGFR and KRAS mutation status and EGFR expression by immuno-
histochemistry (IHC). 
Materials and Methods: A tissue microarray was constructed con-
taining triplicate 2 mm cores from 28 resected EGFR mutated lung 
adenocarcinomas and 31 EGFR non-mutated cases, the latter includ-
ing 8 KRAS mutated cases. For both ISH methods, nuclear counts 
of 5 or more signals were scored as positive. The criteria for FISH 
include polysomy or high copy number. EGFR IHC was scored from 
0-3 with 0 and 1 counted as negative and 2 and 3 considered positive.
Results: Overall correlation of CISH and FISH was excellent. 20 of 
59 (33%) cases were amplified by CISH and 23 of 59 (37%) were 
amplified by FISH, with 18 (30%) positive and 34 (57%) negative 
by both methods (p<0.0001). Discordant cases included 5 negative 
by CISH and positive by FISH and 2 positive by CISH and negative 
by FISH. Of 20 EGFR CISH positive cases, 15 (75%) were mutated 
(p=0.003); of the 23 FISH positive cases, 16 (70%) were mutated 
(p=0.007). One case called positive by FISH and negative by CISH 
showed a KRAS mutation. No other KRAS mutant case was scored 
as EGFR-amplified by either method. EGFR was positive by IHC in 
28 cases, of which 15 were positive by CISH (p=0.003) and 16 by 
FISH (p=0.007). There was no correlation with IHC and mutations 
status.
Conclusions: EGFR CISH and FISH show excellent concordance 
in scoring EGFR amplification, which shows a highly significant as-
sociation with EGFR mutation
B6.7 Pathology, Sun Aug 2, 14:30 - 16:00
Detecting EGFR mutations in NSCLC with specific 
antibodies
Yu, Jian1; Kane, Susan1; Benedettini, Elisa4; Li, Daiqiang3; Crosby, 
Katie1; Wetzel, Randall1; Gu, Tinglei1; Loda, Massimo4; Zhou, 
Xinmin3; Comb, Michael1
1 Cell Signaling Technology, Inc, Danver, MA, USA; 2 Department of 
Medical Oncology and Center for Molecular Oncologic Pathology, 
Boston, MA, USA; 3 2nd Xiangya Hospital, Changsha, China; 4 
Dana-Farber Cancer Institute, Boston, MA, USA
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Activating mutations within the tyrosine kinase domain of epidermal 
growth factor receptor (EGFR) are found in approximately 10-20% of 
non-small cell lung cancer (NSCLC) patients and are associated with 
response to EGFR inhibitors. We have developed an Immunohisto-
chemistry and Immunocytochemistry assay with mutation-specific 
antibodies that detects EGFR mutations at the protein level. The 
assay is capable of detecting the heterogeneity of tumor cells with 
respect to EGFR mutations, which cannot be achieved by sequencing 
and has far-reaching clinical implications. This mutation assay can 
be carried out in any pathology laboratory. Immunohistochemistry 
screening of a panel of 340 paraffin-embedded tumor samples of 
NSCLC patients shows that the sensitivity is 92%, with a specificity 
of 99% to the presence of EGFR mutations by DNA sequencing. It 
has confirmed to work with circulating tumor cells by Immunofluor-
escence. The assay shows promise as the basis of a clinically relevant 
tool in screening cancer patients for target therapy.
  DNA Sequencing DNA Sequencing DNA Sequencing DNA Sequencing
 IHC L858R (+) dEGFR (+) Wild Type Failed
 L858R (+) 24 0 2 2
 dEGFR (+) 0 23 0 1
 L858R (-) 2 0 193 25
 dEGFR (+) 0 3 196 23
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The long-term results of lobectomy or pneumonectomy 
combined with extended resection of the heart, great 
vessels, or both in the treatment of locally advanced non-
small cell lung cancer
Zhou, Qinghua; Chen, Jun; Zhu, Daxin
Tianjin Lung Cancer Institute, Tianjin, China
Purpose To summarize the results of extended resection of the heart, 
great vessels, or both in the treatment of 1049 patients with locally 
advanced lung cancer. 
Methods: From February 1983 to December 2006, lobectomy or 
pneumonectomy combined with extended resection of the heart, 
great vessels or both were carried out in 1458 patients with locally 
advanced lung cancer. The operations included bronchoplastic pro-
cedures and pulmonary artery reconstruction in 828 cases, extended 
resection of left atrium in 295 cases, superior vena cava resection 
and reconstruction in 335 cases (41 patients had carina resection and 
reconstruction simultaneously), and aorta resection and reconstruc-
tion in 5 cases respectively. 
Results: There were 15 operative death. The operative mortality was 
1.02% in the series. 103 patients had operative complications. The 
1, 3, 5 and 10-year survival rates were 73.31%, 57.93%, 31.84% and 
22.13% respectively. 
Conclusion: Extended resection of the heart, great vessels or both 
can remarkably increase the long-term survival and improve the prog-
nosis in patients with locally advanced lung cancer. 
B7.3 Surgery for Locally Advanced NSCLC, Sun Aug 2, 14:30 - 16:00
Role of surgery in chest wall invasion for NSCLC
Lequaglie, Cosimo; Giudice, Gabriella; Marasco, Rita Daniela; 
Garramone, Margherita
National Cancer Institute, Rionero in Vulture, Italy
We analyzed the same surgical team experience about 239 patients 
with primary lung tumors invading the thoracic wall from 1984 to 
2006 regarding the long term results and the prognosis after en bloc 
resection. The ribs invasion has caused the 1997-TNM revision 
with the shift of the T3N0M0 to the stage IIB from the stage IIIA 
(in which the T3N1-2M0 has remained) really for a best long term 
prognosis.
The males were 198 (83%), and 41 females (17%), 62.97+8.64 year-
old mean age (median: 64 years, range: 36-81 years). 
All the patients have been submitted to chest x-ray, CT scan, bronc-
hofiberoscopy, and a fine-needle biopsy. PET/CT scan was performed 
in the last 10 years. 
In 138 cases the tumor was located to the right (58%), in 101 to the 
left (42%). 
Twenty-eight cases (12%) have been submitted to radiotherapy and/
or neo-adjuvant chemotherapy.
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All the 239 patients have received a pulmonary resection en-bloc 
with the costal segments interested by the tumor with a ilo-mediastin-
al lymphadenectomy: 157 lobectomies (66%), 8 bilobectomies (3%), 
14 pneumonectomies (6%) and 60 sublobar resections (25%). 
Twenty-five patients have removed 1 rib segment (10%), 90 of 2 
(38%), 107 of 3 (45%), 15 of 4 (6%) and 2 of 5 (1%), with an average 
of 2.73+0.98 removed segments (median: 3 ribs, range: 1-5) always 
with macroscopically free-disease of the resection margins.
For 78 patients it is not necessary a repair; in 10 patients, with one 
only removed rib, a muscle flap has been used; the other 151 patients 
have been submitted to contemporary reconstruction of the thoracic 
wall with alloprosthesis: 103 prolene nets; 38 patches of PTFE; 10 
sandwich of acrylic-prolene net. 
There were 126 adenocarcinomas (53%), 82 squamous carcinomas 
(34%), 21 large cell carcinomas (8%), 3 mucoepidermoid carcinomas 
(1.5%), 3 SCLC (1.5%), 2 neuroendocrine tumors (1%) and 2 BACs 
(1%).
The post-operative complications have been 6% (15/239): 13 not-
fatal (4 bronchopulmonary infections, 4 arrhythmias, 1 cerebral 
ischemia and 4 infections of wound). The 2 fatal complications (1%) 
were 1 heart attack and 1 cerebral ictus. 
According to CF Mountain TNM classification, 155 patients were 
into the T3N0M0 group of the stage IIB (65%), 71 patients into the 
T3N1M0 and 9 into the T3N2M0 both in the stage IIIA (33%), and 3 
patients to the T4N0M0 and 1 to the T4N1M0 of the stage IIIB (2%). 
Obviously these last 4 subjects are resulted with multifocal disease in 
the same lobe of the primary tumor. 
The pre-operative staging results to be accurate bringing to the sur-
gery the 65% of the N0 patients. Also 3 among the tumors classified 
to the stage IIIB (for multifocal T4 in the same lobe) were N0.
Radiotherapy has been performed on the thoracic wall in the 22 
patients with microscopic disease (9%). Radiation therapy has been 
performed on the mediastinum in 48 patients with N1, and adjuvant 
chemotherapy and/or mediastinal radiation has been performed in the 
9 patients with N2. 
The overall probability of survival by Kaplan-Meier, resulted to be 
for the all cases (pT3N0-1-2M0 or 1986-stage IIIA) of 38% to 5 
years. 
To 1997 TNM-revision confirmation, the 5 year-survival of the 
T3N0M0 (stage IIB) was 44% and 21% in the T3N1 and even more 
worse in T3N2 (8%) (actually stage IIIA) (image1).
B7.4 Surgery for Locally Advanced NSCLC, Sun Aug 2, 14:30 - 16:00
Tracheal carinal reconstruction and bronchovasculoplasty 
in central type bronchogenic carcinoma
Ma, Qian li
Department of Thoracic Surgery, Chinese-Japan Friendship 
Hospital, Beijing, China
Background: Analyze the variables of successful tracheal carino-
plasty and bronchovasculoplasty to discover best practices for best 
early and long term results.
Patients and Methods: Of 1399 lung resections for primary lung 
cancer performed in our hospital from April 1985 to December 2006, 
133 underwent bronchoplastic surgeries, including 15 carinoplasty 
cases and 118 bronchoplasty cases. 
Results: Complications occurred in 18 cases, with no operative re-
lated mortality. For all patients, the 1 year, 3 year, and 5 year survival 
rates were 79.8%, 56.7% and 31.2%, respectively. The 5 year survival 
rate by cancer stage was 69.2% for IB, 40.6% for IIB, 19.6% for IIIA, 
and 16.6% for IIIA (N2). 
Conclusion: Selection of cases, clearance of lymph nodes, disposal 
of the bronchus and pulmonary vessel and replacement or restoration 
of the superior vena cava are the main factors influencing prognosis.
B7.5 Surgery for Locally Advanced NSCLC, Sun Aug 2, 14:30 - 16:00
Extended bilateral mediastinal lymph node dissection 
through a median sternotomy with non-small cell 
carcinoma of the left lung
Yokota, Toshiya; Ikeda, Shingo; Hata, Enjo
Mitsui Memorial Hospital, Tokyo, Japan
Background: Survival rate after surgical treatment for N2 Non 
Small Cell Lung Cancer (NSCLC) range from 6 to 35%. According 
to the study of regional lymphatic drainage, we considered reason-
able lymphadenectomy contributes the post-operative survival of the 
patient with N2 NSCLC. And we had devised Systemic extended 
bilateral mediastinal dissection and lung resection through a median 
sternotomy (ND3 operation) for patient with NSCLC of the left lung. 
Material and Method: The patients with NSCLC who are estimated 
to be able to conventional radical operation and aged 75 year-old 
or less becomes the adaptation of ND3 operation. From Jan.1988 
through Dec. 2007, 298 patients of the left lung primary underwent 
ND3 operation(complete resection:263pts) and we reviewed 54 cases 
with c-N2 left primary NSCLC.
Results: Postoperative survival rates calculated with Kaplan-Meier 
method. Overall 5-year survival rate in the 263 patients of left lung 
primary was 61.4%. Operative mortality in 263 patients was 3.3%. 
In these c-N2(n=54) patients, over all five-year survival was 50.8%, 
and according to post-operative pathological stages were in 3 pts of 
p-stage IA was 50%, in 6 pts p-stagIB was 66.7%, in 8 pts p-stage 
IIB was 54.7%, in 23 pts p-stageIIIA was 51.4% in 14 pts p-stageIIIB 
was 35.7%.
Conclusion: In this nonrandomized comparison, the post-operative 
survival of patients with c-N2 NSCLC of the left lung primary would 
be remarkably improved by our Systemic Bilateral Mediastinal Dis-
section. To improve survival rate, it is important to perform curative 
operation with mediastinal dissection.
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Lung cancer with invasion of the interlobar pleura and 
minimal invasion of the adjacent lobe: which is the correct 
T determinant for a correct TNM staging? 
Ruffini, Enrico1; Filosso, Pier Luigi1; Buffoni, Lucio2; Schena, 
Marina2; Asioli, Sofia3; Solidoro, Paolo4; Bruna, Maria Cristina1; 
Novello, Silvia5; Mossetti, Claudio1; Oliaro, Alberto1
1 Thoracic Surgery, University of Torino, Torino, Italy; 2 Medical 
Oncology, AOU S. Giovanni Battista, Torino, Italy; 3 Pathology, 
University of Torino, Torino, Italy; 4 Pneumology, AOU S. Giovanni 
Battista, Torino, Italy; 5 Medical Oncology, AOU S. Luigi, 
Orbassano, Orbassano, Italy
Objective: Lung tumours invading the interlobar pleura with min-
imal invasion of the adjacent lobe (IAL) have been classified as T2 
until the most recent TNM edition. Some authors questioned whether 
these tumors should be reclassified as T3. We analysed our experi-
ence of operated lung cancer patients with IAL in order to assess 
prevalence, correlations and prognostic significance in view of the 
forthcoming new TNM staging system. 
Methods: From January 1998 to October 2008 1521 lung cancer 
patients received resection at our Institution. Of these, 46 patients 
(3%) had IAL at the time of surgery requiring limited resection of the 
adjacent lobe in addition to resection of the primary lobe. There were 
38 men and 8 women with a mean age of 65 years (range 46-82). 
Histologically, there were 24 adenocarcinomas, 13 squamous cell 
carcinomas, 5 bronchiolo-alveolar carcinomas, an 4 other types. N 
status was: N0 in 32 patients, N1 in 6 and N2 in 8 patients. Mean tu-
mour dimension was 4 cm. (range 2-11). Prevalence, correlations and 
survival analysis either univariate and multivariate were performed 
in the population of patients with and without IAL at the time of sur-
gery. For survival analysis, patients with IAL were compared with pa-
tients with operated T2 (visceral pleural) and T3 (parietal pleura) M0 
stages in the same period. Patients with tumour involvement beyond 
parietal pleura were excluded. 
Results: Histology and N status were similar among the IAL patients 
as compared to the general population of operated NSCLC patients 
(p=0.1 and p=0.38 respectively). Logistic regression analysis using 
the presence/absence of IAL as dependent variable and several 
clinico-pathologic variables including grading, microscopic vascular 
invasion, tumour-infiltrating lymphocytes, tumour dimension and N 
factor revealed that the presence of IAL was significantly correlated 
with microscopic vascular invasion (OR 0.45, 95%CI 0.23-0.89, 
p=0.002). Five-year survival of patients with IAL, T1, T2 (visceral 
pleura) and T3 (parietal pleura) disease were 42%, 60%, 48% and 
28% overall (p=0.00001), and 53%, 66%, 60% and 35% in N0 dis-
ease (p=0.00001). Survival of IAL was similar to that of T2 (visceral 
pleura) (p=0.40 overall and p=0.61 in N0 disease) and significantly 
higher than that of T3 (parietal pleura) disease (p=0.04 overall and 
p=0.05 in N0 disease). In multivariate analysis, the presence of IAL 
was associated with a nonsignificant increased risk of death (HR 
1.08, 95%CI 0.66-1.76, p=0.75) as compared to visceral pleura in-
volvement (HR 1.25, 95%CI 1.06-1.47, p=0.007) and parietal pleura 
involvement (HR 1.78, 95%CI 1.40-2.25, p=0.00002). 
Conclusions: In lung cancer, invasion of the interlobar pleura and 
minimal invasion of the adjacent lobe is observed far less frequently 
than involvement of visceral or parietal pleura. IAL is associated with 
microscopic vascular invasion. Patients with IAL have a prognosis 
more similar to T2-visceral pleura disease, and significantly better 
than T3 parietal pleura disease. Maintenance of the present TNM 
classification for these patients seems justifiable.
B7.7 Surgery for Locally Advanced NSCLC, Sun Aug 2, 14:30 - 16:00
Hylar non-small cell lung cancer infiltrating mediastinal 
vessels: how often is pneumonectomy required?
Leo, Francesco; Conti, Barbara; Delledonne, Vincenzo; Tavecchio, 
Luca; Girotti, Paolo; Bellini, Roberto; Calabrò, Elisa; Pastorino, Ugo
National Cancer Institute, Milan, Italy
Background: Hylar lung cancers may infiltrate mediastinal vessels, 
such as superior vena cava, pulmonary artery or arterial great vessels. 
When feasible, these patients may be still considered for resection, 
but unfortunately pneumonectomy is often required. In order to 
avoid morbidity and adverse effect on quality of life due to pneu-
monectomy, in selected cases vascular reconstruction with or without 
bronchial sleeve resection may be performed. The present series 
report our 10-year experience in the management of non small cell 
lung cancers (NSCLC) infiltrating mediastinal vessels.
Materials and Methods: During the last 10 years, 89 consecu-
tive patients underwent surgery for NSCLC infiltrating mediastinal 
vessels, 43 of which infiltrating the Superior Vena Cava (SVC), 42 
infiltrating the pulmonary artery (PA) and 4 infiltrating the thoracic 
aorta or the subclavian artery. In case of hylar infiltration, hylar 
pulmonary vessels were isolated and clamped in order to obtain com-
plete surgical exploration and to establish feasibility of lung-sparing 
procedures. Clinical records were retrospectively reviewed in order to 
define morbidity, mortality and the rate of pneumonectomy.
Results: Out of the 43 patients with SVC infiltration, 11 had com-
plete prosthetic replacement and 32 partial reconstruction. Twenty 
of them underwent sleeve lobectomy of bilobectomy (46.5%), 14 
patients underwent standard anatomical resection (32.5%) and in 9 
cases pneumonectomy was required (20.9%).
In case of hylar PA infiltration (n=42), vascular reconstruction was 
obtained by tangential resection in 12 cases (11 of which on the left 
side), pericardial patch reconstruction in 24 cases, direct termino-
terminal anastomosis in 4 cases and circular graft replacement in 2 
cases. Lung resection was represented by sleeve lobectomy in 22 
patients (52.3%), and standard lobectomy in 20 cases (47.7%).
Three out of four cases with aortic or subclavian infiltration required 
pneumonectomy combined with prosthetic replacement.
Overall postoperative mortality was 2.2%. The two postoperative 
deaths occurred in the group of SVC resection, due to cardiac arrest 
and respiratory failure respectively. Two major postoperative compli-
cations occurred (2.2%). One patient developed AP thrombosis after 
pericardial circumferential reconstruction and required completion 
pneumonectomy. One case of postoperative ARDS was recorded fol-
lowing pneumonectomy and SVC replacement. Ten additional minor 
complications were recorded, mailnly due to atelectasis requiring 
bronchoscopy (4 cases) and minor SVC prosthesis complications (2 
cases).
Conclusions: Infiltration of mediastinal vessels does not preclude the 
possibility to obtain radical resection and pneumonectomy may be 
often avoided by the use of combined vascular and bronchial lung-
sparing procedures, with limited postoperative morbidity and mortal-
ity. Patients presenting right hylar tumor infiltrating SVC required 
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pneumonectomy in about 20% of cases. In case of left tumors, PA 
reconstruction often combined with bronchoplasty was effective in 
minimizing the rate of pneumonectomy. 
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Validation of soluble mesothelin: design and preliminary 
results of a Belgian multicentric observational study
Hollevoet, Kevin1; Kellen, Eliane 2; Nackaerts, Kristiaan 2; Thimpont, 
Joël 3; Germonpré, Paul 4; De Vuyst, Paul 5; Bosqueé, Lionel 6; 
Delanghe, Joris 7; Legrand, Catherine 8; van Meerbeeck, Jan P.1
1 Dept of Respiratory Medicine, Ghent University Hospital, Ghent, 
Belgium; 2 Dept of Respiratory Medicine, University Hospital 
Gasthuisberg, Leuven, Belgium; 3 Fund for Occupational Diseases, 
Brussels, Belgium; 4 Dept of Respiratory Medicine, Antwerp 
University Hospital, Antwerp, Belgium; 5 Respiratory Medicine, 
Erasme Hospital ULB, Brussels, Belgium; 6 Dept of Respiratory 
Medicine, CHU Sart Tilman, Liège, Belgium; 7 Dept of Clinical 
Chemistry, Ghent University Hospital, Ghent, Belgium; 8 Institut de 
statistique, Université catholique de Louvain, Louvain-la-Neuve, 
Belgium
Background:Soluble mesothelin (SM) is a biomarker for malignant 
mesothelioma (MM), an asbestos-related cancer. 
Aim:Validation of the screening, diagnostic, prognostic and monitor-
ing performance of SM in different cohorts with variable asbestos 
exposure and medical condition, enrolled in a Belgian prospective, 
observational multicentric study. 
Methods:Study design is shown in Table 1. Blood sampling of 
healthy controls, individuals with benign respiratory diseases and 
untreated lung cancer pts is done at inclusion. Asbestos-exposed 
workers (both healthy and diseased) are followed for two years with 
yearly serum SM analysis and medical follow-up. In MM pts, serum 
SM levels are determined at each therapy session and control visit. 
Serum SM (nM) was measured with FDA approved ELISA kits (ME-
SOMARKTM, Cis bio International). Diagnostic performance of SM 
was analyzed with ROC analysis, cutoff levels and sensitivity were 
determined at a high specificity (~95%).
Results: Preliminary baseline results from 384 of the intended 600 
cases showed a significant difference in mean SM values between 
MM pts and each cohort (p < 0.05, ANOVA, Tukey). Mean SM of 
healthy controls did not differ from the other cohorts, except MM pts 
(Table 1). 
With AUC’s ranging from 0.875 to 0.941, SM had a high perform-
ance in differentiating MM pts from each cohort. ROC analysis of 
MM pts versus all cohorts gave an AUC of 0.905. At a cutoff level of 
2.00 nM, a sensitivity and specificity of 73% and 96%, respectively, 
was obtained (Table 2).
Conclusion: Preliminary results confirmed SM as a specific diagnos-
tic MM marker. However, SM was not useful as a marker for asbestos 
exposure/disease as mean values did not differ between healthy 
controls and asbestos-exposed cohorts.
Updated results will be presented at the meeting.
--This study was made possible by a grant of the Belgian Foundation 
against Cancer--
B8.2  Molecular Biomarkers of Malignant Mes.and Thymoma, Sun Aug 2, 14:30 - 16:00
Changes in mesothelin levels reflect response to 
chemotherapy in mesothelioma patients
Creaney, Jenette1; Segal, Amanda2; Nowak, Anna K.1; Francis, Ros3; 
Musk, Bill1; Robinson, Bruce W.1
1 National Center for Asbestos Related Disease, Nedlands, WA, 
Australia; 2 PathWest Laboratory Medicine, Nedlands, Australia; 3 
Sir Charles Gairdner Hospital, Nedlands, Australia
Background: Numerous studies have demonstrated the sensitivity 
and specificity of the biomarker mesothelin for diagnosing malignant 
mesothelioma both in serum and in effusion samples. The current 
study examined the utility of mesothelin for monitoring of patients, 
both during the course of natural disease progression and in response 
to therapy. 
Methods: Ninety-eight patients (12F:86M) were enrolled in the study 
and longitudinal serum samples were collected during the course 
of their routine standard care, and mesothelin concentrations were 
determined using the MESOMARK™ assay (Fujirebio Diagnostic 
Incorporated, Malvern PA). Fifty-three patients received first-line 
chemotherapy and of these 20 went on to second line therapy. Re-
sponse to chemotherapy was assessed by both the modified RECIST 
criteria and by changes in the Positron Emission Tomography (PET) 
parameters, maximum standardized uptake value (SUVmax), volume 
and Total Glycolytic Volume (TGV). 
Results: Examining baseline data we observed that group mean 
mesothelin level increased with increasing tumour stage, as defined 
by the IMIG TNM staging system. There was no correlation between 
mesothelin level and the presence of metastatic disease. Using 
baseline measures, there was a positive correlation of mesothelin 
levels with PET volume (r=0.342; p=0.001) TGV (r=0.36; p<0.001) 
and SUVmax (r=0.272; p=0.01). Using the percentage change in 
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baseline mesothelin levels and an arbitrary cut-off value for the 53 
patients who received chemotherapy, we found that mesothelin levels 
decreased in 24 patients, remained stable in 19 patients and increased 
in 10 patients. Median survival for these three groups were 15.6, 10.7 
and 5.2 months respectively, with patients who had a decrease in 
mesothelin level having a significant survival advantage (log rank test 
p<0.005). There was good concordance between change in mesothel-
in level and patient response as defined by modified RECIST, with no 
patients having a partial response having an increase in mesothelin 
level and conversely no patients having progressive disease having a 
decrease in mesothelin level. There was a good correlation between 
change in mesothelin level and change in baseline PET TGV (r=0.42; 
p=0.007). 
Conclusion: These findings demonstrate the potential value of chan-
ges in mesothelin levels to provide a means of monitoring treatment 
response in mesothelioma. 
B8.3  Molecular Biomarkers of Malignant Mesothelioma and Thymoma, 
 Sun Aug 2, 14:30 - 16:00
The value of ERCC1 as a prognostic marker for malignant 
pleural mesothelioma
Opitz, Isabelle1; Soltermann, Alex2; Schramm, Alexandra1; Thies, 
Svenja2; Schaefer, Niklaus3; Moch, Holger2; Stahel, Rolf A.3; Weder, 
Walter1
1 Department of Thoracic Surgery, University Hospital, Zuerich, 
Switzerland; 2 Institute for Surgical Pathology, Department 
Pathology, University Hospital, Zuerich, Switzerland; 3 Laboratory 
for Molecular Oncology, Clinic and Polyclinic of Oncology, 
University Hospital, Zuerich, Switzerland
Background: Expression of the excision repair cross-complemen-
tation group 1 (ERCC1) protein predicts response to platinol-based 
chemotherapy and survival in lung cancer patients. The relevance of 
ERCC1 expression in MPM has not yet been studied.
Patients and Methods: Three tissue microarrays (TMA) with biop-
sies of 356 MPM patients without standardized treatment were used 
as training set for the assessment of immunohistochemical expression 
of ERCC1. Staining intensity was semi-quantitatively scored (0-3) 
and percentage of positive stained cells (0-100%) was measured. A 
final H-score was calculated and correlated to overall survival of this 
retrospective data. 
One TMA with tumour of 105 MPM patients who underwent induc-
tion chemotherapy with cisplatin/gemcitabine (cis/gem) or cisplatin/
pemetrexed (cis/pem) followed by extrapleural pneumonectomy 
(EPP) was constructed and a second one with 47 patients where 
pre-chemotherapy biopsies were available. ERCC1 expression was 
assessed and correlated to prospectively documented data. The 
influence on overall survival and response to chemotherapy were 
evaluated.
Results: ERCC1 was expressed in 80% of the cases in the training 
TMA set. Median survival of patients with ERCC1-H-score 260 was 
8.8 (95% CI 7.1; 10.5) in comparison to patients with H-score ³ 260 
15.5 months (95% CI 8.0; 22.9). Cox-regression analysis revealed 
that ERCC1 H-score was the only independent marker for overall 
survival. 
From May 1999 to January 2009, 160 were intended to treat with in-
duction chemotherapy followed by EPP (42% cis/gem; 58% cis/pem). 
Response to chemotherapy according to modified RECIST criteria 
was available for 92 patients. Partial response was documented for 30 
patients, for 34 patients stable disease and 28 patients with progres-
sive disease. Patients with a better response to chemotherapy accord-
ing to modified RECIST criteria had a significant longer survival 
(p=0.013). The median overall survival of all patients was 19 months, 
of the patients undergoing EPP 22 months. The patients undergoing 
EPP with low ERCC1 expression (dichotomized at the median value 
of 200) - assessed in the biopsy before chemotherapy - had a shorter 
survival with 13 months in comparison to 22 months survival of 
patients with a high expression of ERCC1 (p=0.06). A significant 
prognostic factor was the response to chemotherapy assessed by 
modified RECIST criteria: operated patients with progressive disease 
had a median survival of 15 months, in comparison to 23 months for 
stable disease as well as partial response (p=0.03). Modified RECIST 
criteria significantly correlated to ERCC1 expression in the operated 
EPP specimens (p=0.025). 
Conclusion: Loss of ERCC1 expression seems to be an independent 
prognostic marker for poor overall survival of mesothelioma patients 
as assessed in the retrospective data set. In a patient group under-
going multimodality treatment concept ERCC1 expression is correl-
ated to modified RECIST criteria and both measures for response to 
chemotherapy seem to influence overall survival. 
B8.4  Molecular Biomarkers of Malignant Mesothelioma and Thymoma, 
 Sun Aug 2, 14:30 - 16:00
Predicitve value of thymidylate synthase in epithelial and 
biphasic malignant pleural mesothelioma treated with 
pemetrexed
Selvaggi, Giovanni; Righi, Luisella; Billè, Andrea; Ceppi, Paolo; 
Bacillo, Elisa; Pandiscia, Saverio; Ardissone, Francesco; Papotti, 
Mauro G.; Scagliotti, Giorgio V.
Dept. of Clinical and Biological Sciences, University of Torino at San 
Luigi Hospital, Orbassano, Italy
Background: Thymidylate Synthase (TS) is the main target of Pe-
metrexed and its predicitve role has been already evaluated in several 
solid tumors. Pemetrexed is the cornerstone of first-line chemother-
apy regimens in Malignant Pleural Mesothelioma (MPM). 
Methods: study population includes 60 consecutive, chemotherapy-
naive, histologically confirmed MPM patients eligible for chemother-
apy (all from our Institution, between 2005 and 2008). Male/female: 
45/15, median age: 64 years (range 36-77), histology: 50 epithelial, 
10 biphasic, PS 0/1: 44/16, EORTC score: 58/60 good (<1.27). 
Pemetrexed was administered in combination with cisplatin or 
carboplatin (45/60) or as single agent (15/60). TS protein expression 
levels were retrospectively evaluated by immunohistochemistry and 
quantified by H-score method. In addition, mRNA extraction was per-
formed in micro-dissected tissues and TS relative levels quantified by 
RT-PCR. Survival probability was assessed by Kaplan-Meier method 
and results compared by log-rank test. Cox multivariate analysis for 
survival was performed adjusting for clinical-pathological variables. 
Results: Thirty-seven patients had progressive disease and 27 had 
died at the time of the analysis, with average follow up time of 16 
months. Overall median Time to Progression (TTP) and Median Sur-
vival Time (MST) were 9.5 and 20 months, respectively. Median TS 
H-score value was 90 (range 5-240). Patients with low TS H-score 
(<90) had longer MST (40 vs 17 months, p=0.006) and showed only 
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a trend for longer TTP (11 vs 8 months, p=0.06). When we adopted a 
TS cut-off value of 70 (1st tertile), both MST and TTP were signifi-
cantly longer in low TS patients (22/60): 40 vs 16 months (p=0.004) 
and 19 vs 8 months (p=0.01), respectively. Conversely, TS mRNA 
levels did not correlate with protein expression nor with outcome 
parameters. At multivariate analysis TS protein levels were the only 
independent prognostic factor for survival (p=0.008). 
Conclusion: In MPM patients treated with pemetrexed-based chemo-
therapy low TS protein levels are predictive of improved TTP and 
prognostic for better survival. TS role in MPM should be validated 
prospectively in order to customize chemotherapy.
B8.5 Molecular Biomarkers of Malignant Mesothelioma and Thymoma, 
 Sun Aug 2, 14:30 - 16:00
A diagnostic microRNA-based test for the diagnosis of 
mesothelioma
Benjamin, Hila2; Lebanony, Danit2; Tabak, Sarit2; Barabash, Naama2; 
Gibori, Hadas2; Morgenstern, Sara3; Meiri, Eti2; Bentwich, Zvi2; 
Rosenfeld, Nitzan1; Rosenwald, Shai2; Cohen, Dalia2
1 Bioinformatics, Rehovot, Israel; 2 Rosetta Genomics, Rehovot, 
Israel; 3 Rabin Medical Center, Beilinson Campus, Petah Tikva, USA
Background: Malignant mesothelioma is an aggressive pleural 
neoplasm, strongly linked to environmental exposures such as 
asbestos. Mesothelioma can be difficult to differentiate from other 
tumors in the lung and pleura such as primary lung adenocarcinoma 
presenting with pleural effusion or metastatic adenocarcinoma from 
different sites. To address the increasing need for accurate differential 
diagnosis of these tumors we developed a diagnostic test based on ex-
pression levels of microRNAs, a family of small, non-coding RNAs 
whose tissue-specificity has proven applicability for identification of 
cancer tissue type and histology.
Methods: Protocols were developed for extraction of high-quality 
RNA that retain the microRNA fraction from FFPE tissue samples 
and 52 MPM and 235 carcinoma (FFPE) samples were used in the 
study. Microarrays were used for initial profiling and qRT-PCR was 
used to validate results and to develop a diagnostic test. 
Results: Using microarray profiling, microRNAs were identified 
that were differentially expressed between mesothelioma and vari-
ous carcinomas. Three specific microRNAs were chosen for further 
analysis, that were over-expressed in mesothelioma, peripheral lung 
adenocarcinoma or carcinomas that frequently metastasize to the lung 
pleura. We developed a diagnostic assay based on the expression of 
these microRNAs. The assay reached sensitivity of 95% and specifi-
city of 96% in a blinded validation set of 44 samples.
Conclusions: MicroRNAs are emerging as effective cancer bio-
markers. A robust and simple assay based on the expression level of 
a few microRNA biomarkers can accurately differentiate mesotheli-
oma from other possible tumors in the lung and pleura. This assay 
provides an important new tool for diagnosing mesothelioma.
B8.6  Molecular Biomarkers of Malignant Mesothelioma and Thymoma, 
 Sun Aug 2, 14:30 - 16:00
Response to chemotherapy predicts longer survival in 
an individual patient meta-analysis of 1205 patients with 
mesothelioma
Fennell, Dean A.1; Ceresoli, Giovanni L.8; Castagneto, Bruno 14; 
Scullin, Paula12; O’Brien, Mary7; Parker, Michael6; Hasan, Baktiar11; 
Sylvester, Richard11; Rudd, Robin9; Steele, Jeremy9; Porta, Camilo13; 
Mutti, Luciano5; O’Byrne, Kenneth J.4; Gaafar, Rabab 10; Baas, Paul3; 
Van Meerbeeck, Jan2
1 Queen’s university Belfast, Belfast, UK; 2 Thoracic Oncology, 
University Hospital, Ghent, Belgium; 3 Netherlands Cancer Institute, 
Amsterdam, Netherlands; 4 St James’ Hospital, Dublin, Ireland; 5 
Lab. di Oncologia Clinica, Borgosesia, Italy; 6 Clinical Research 
Support Centre, The Royal Hospitals, Belfast, UK; 7 Royal Marsden 
Hospital, Sutton, UK; 8 Istituto Clinico Humanitas Istituto di 
Ricovero e Cura a Carattere Scientifico, Rozzano, Milan, Italy; 9 St 
Bartholomew’s Hospital, London, UK; 10 National Cancer Center, 
Cairo, Egypt; 11 EORTC Data Center, Brussels, Belgium; 12 Northern 
Ireland Cancer Center, Belfast, UK; 13 Medical Oncology IRCCS San 
Matteo, University Hospital Foundation, Piazzale C. Golgi 19, Pavia, 
Italy; 14 Department of Medical Oncology, Azienda Ospedaliera, Novi 
Ligure, Italy
Background: Recent phase III data has demonstrated an improved 
survival for anti-folate containing platinum based doublet therapy in 
patients with mesothelioma. Although this suggests that synergistic 
interactions between these agents may account for greater tumour 
cell kill and therefore disease control, robust analysis of the impact 
of tumour response on survival has not been conducted to date. Ac-
cordingly, we have undertaken an individual patient meta-analysis 
of 1205 patients, to determine whether response is associated with 
improved survival. 
Patients and Methods: Individual patient data was collected from 16 
previously published mesothelioma clinical trials including 9 EORTC 
studies. Median overall survival (OS) for 1205 patients (pts) was 9.6 
(95% CI 8.9-10.2) with a total of 230 censored pts. A total of 1086 pts 
were evaluable for analysis of response; 176 patients exhibited either 
partial or complete responses (PR or CR 16.2% measured by WHO 
or modified RECIST); stable disease (SD), 583 pts (53.7%); Progres-
sive disease (PD) 327 pts (30.1%). The OS Kaplan-Meier distribution 
was stratified according to response. OS for PR was 17.2 months 
(95% CI 15.5-18.9); SD was 10.9 months (95% 10.1-11.7); PD was 
5.3 months (95% CI 4.9-5.8). Stratification by response was statistic-
ally significant for comparisons between PR vs SD, PR vs PD and SD 
vs PD respectively (logrank for all comparisons p<0.005). Disease 
control rate (DCR) was 69.9% (759 pts) with an OS of 10.1 months 
(95% CI 9.4-10.8). Landmark analysis was conducted at +62 day fol-
lowing treatment initiation. Of the 835 pts eligible for this analysis, 
response stratified survival; PR 13 months (95% CI 11.6-14.5), SD 8 
months (95% CI 7.2-8.8), PD 3 months (95% CI 7.3-8.7); logrank p 
< 0.005 for PR/CR vs SD, PR/CR vs PD, SD vs PD. Pts with PR/CR 
were stratified by WHO vs modified RECIST, however no difference 
in OS was measured (p=0.69); stratification of this group by platinum 
versus non-platinum chemotherapy was not significant (p=0.3), how-
ever epithelioid responders lived longer than sarcomatoid responders 
(20.8 versus 13.5 months respectively, p=0.008), consistent with the 
known, worse prognosis associated with sarcomatoid mesothelioma.
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
Copyright © 2009 by the International Association for the Study of Lung CancerS348
Summary: This data, which represents one of the largest individual 
pt meta-analyses related to mesothelioma, strongly suggests that 
patients with chemoresponsive tumours live longer compared with 
tumours exhibiting disease progression or even stable disease. This 
benefit is seen irrespective of whether therapy is platinum-containing, 
the method of response assessment, or the type of histology. How-
ever, survival of pts with chemoresponsive sarcomatoid mesothelo-
mas is shorter than than for epithelioid mesotheliomas. 
B8.7  Molecular Biomarkers of Malignant Mesothelioma and Thymoma, 
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Comprehensive genomic analysis reveals clinically relevant 
molecular distinctions between thymic carcinomas and 
thymomas
Girard, Nicolas; Shen, Ronglai; Guo, Tianhua; Zakowski, Maureen 
F.; Heguy, Adriana; Riely, Gregory J.; Huang, James; Lau, 
Christopher; Lash, Alex; Ladanyi, Marc; Viale, Agnes; Antonescu, 
Cristina; Travis, William D.; Rusch, Valerie W.; Kris, Mark G.; Pao, 
William
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Background: Thymic epithelial tumors are intrathoracic malignan-
cies that can be aggressive and difficult to treat. At the pathologic 
level, these tumors are classified together as thymomas and thymic 
carcinomas. The former are further subdivided into types A, AB, B1, 
B2, B3, depending on the extent of the lymphocytic component, the 
degree of atypia, and the resemblance with normal thymus. Com-
pared to more common epithelial cancers, current knowledge about 
the biology of thymic tumors is limited, because thymic tumors are 
rare and extensive molecular studies in the disease have not yet been 
performed.
Methods: We performed comprehensive genomic analysis of previ-
ously untreated thymomas and thymic carcinomas, which were 
resected at Memorial Sloan-Kettering Center Center. Frozen tumor 
specimens were analyzed using array comparative genomic hybrid-
ization (aCGH), mRNA expression profiling, and mutational profiling 
of selected genes (EGFR, KIT, TP53, KRAS, HRAS, NRAS, BRAF, 
PIK3CA, AKT1, ERBB2, and MEK1). A tissue microarray was 
constructed using matched formalin-fixed, paraffin-embedded tumor 
tissue samples, to perform immunohistochemical (IHC) studies. 
Results: We analyzed 27 thymic tumors: 21 thymomas (type A 
n=5, type B2 n=14, type B3 n=2), and 6 thymic carcinomas. We 
first explored the EGFR signaling pathway. Moderate to high EGFR 
staining was associated with stage III-IV tumors (p=0.021, Chi-2 
test). We identified somatic RAS mutations in 2 of 27 tumors: one 
KRAS G12V mutation in a thymic carcinoma, and one HRAS G13V 
mutation in a type A thymoma. EGFR staining was moderate to high 
in these tumors. No other mutations were identified in the analyzed 
EGFR signaling pathway genes. We then assessed the status of KIT. 
Two of 27 tumors, both thymic carcinomas, displayed strong stain-
ing with an anti-KIT antibody. Only these two KIT-positive cases 
harbored somatic KIT mutations (one V560del and one H697Y). We 
generated stable Ba/F3 transfectants expressing the V560del mutant. 
The growth of these transfectants was readily inhibited by the KIT 
inhibitors imatinib and sunitinib, (GI50 values 15.0 and 13.6nM, 
respectively). Gene expression profiling was possible on 23 tumor 
specimens. Unsupervised hierarchical cluster analysis of gene expres-
sion data revealed 2 major groups: cluster 1 (n=8), associated with 
B2 histology, and cluster 2 (n=15), associated with thymoma type A 
and thymic carcinoma (p=0.023, Chi-2 test). Hierarchical clustering 
analysis of aCGH data also generated 2 distinct clusters: cluster 
1 (n=17) was associated with thymoma (type A, B2 and B3) and 
characterized by infrequent copy number alterations, whereas cluster 
2 (n=10) was associated with thymic carcinoma (p<0.001, Chi-2 test) 
and showed multiple chromosomal aberrations.
Conclusion: Thymic carcinomas are genetically distinct from thymo-
mas. Compared to thymomas, thymic carcinomas display multiple 
chromosomal aberrations and exclusively harbor KIT mutations. 
We propose that despite their rarity, future clinical trials should treat 
thymic carcinomas separately from thymomas. A trial of KIT inhib-
itors in KIT-positive thymic carcinoma is warranted. Furthermore, 
RAS mutation testing should be considered, as RAS mutations have 
therapeutic implications regarding the use of anti-EGFR therapies.
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Molecular markers and clinical outcome with erlotinib: 
results from the phase III placebo-controlled SATURN 
study of maintenance therapy for advanced NSCLC
Brugger, Wolfram1; Kim, Joo-Hang2; Hansen, Olfred3; Sullivan, 
Richard N.4; White, Shane C.5; Lee, Jung-Shin6; Klingelschmitt, 
Gaëlle7; Spleiss, Olivia7; Nagelmeier, Iris8; Cappuzzo, Federico9; on 
behalf of the SATURN investigators10
1 Schwarzwald-Baar Clinic, Villingen-Schwenningen, Germany; 
2 Yonsei Cancer Center, Seoul, Korea; 3 Odense University 
Hospital, Odense, Denmark; 4 Auckland City Hospital, Auckland, 
New Zealand; 5 Austin Hospital, Melbourne, Australia; 6 Asian 
Medical Center, Seoul, Korea; 7 F-Hoffmann – La Roche Ltd, Basel, 
Switzerland; 8 Targos Molecular Pathology GmbH, Kassel, Germany; 
9 Istituto Clinico Humanitas IRCCS, Rozzano, Italy; 10 UK
Background: Erlotinib provides significant survival, quality-of-
life and symptom benefits in relapsed advanced NSCLC. Potential 
predictive molecular markers for erlotinib have been proposed but, 
to date, none have been tested prospectively. The SATURN study 
evaluated whether erlotinib maintenance therapy prolongs PFS versus 
placebo in patients with advanced NSCLC who obtained clinical 
benefit from first-line chemotherapy. This large, randomized phase III 
study incorporated prospective molecular marker analyses.
Methods: 889 patients who obtained CR/PR/SD following four 
cycles of first-line platinum-doublet chemotherapy were random-
ized to erlotinib 150mg/day or placebo. Mandatory baseline tumor 
samples were tested for EGFR expression (using immunohistochem-
istry [IHC]), EGFR gene copy number (using fluorescent in-situ 
hybridization [FISH]), and EGFR and KRAS mutation status (using 
DNA sequencing; exons 18–21 for EGFR, and 12/13/61 for KRAS). 
Analyses were performed in this priority order; due to insufficient 
tissue, it was not possible to perform all analyses for all samples. 
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Patients were stratified according to EGFR IHC status, using a cut-off 
of ≥10% tumor cells with any membranous staining. Genotyping 
of EGFR intron 1 CA-repeat polymorphism was performed using 
baseline blood samples. The co-primary endpoints were PFS in all 
patients, and PFS in EGFR IHC+ patients.
Results: Patient and disease characteristics, including biomarker 
status, were well balanced between arms. Both co-primary endpoints 
were met, with erlotinib significantly prolonging PFS in all patients 
(HR 0.71, p=0.000003), and in the EGFR IHC+ subgroup (HR 0.69, 
p=0.00002). Details of molecular analyses are shown in the table. A 
PFS benefit was observed with erlotinib in all biomarker subgroups 
analyzed. Only EGFR mutation status predicted a differential PFS 
benefit with erlotinib, with a marked increase in PFS observed in 
patients with EGFR mutations (exon 19 deletions and/or L858R 
mutation). However, a PFS benefit was also observed with erlotinib 
in patients with wild-type EGFR. Interestingly, patients with KRAS 
mutations obtained a similar clinical benefit from erlotinib to those 
with wild-type KRAS.
Conclusions: In the context of a randomized, placebo-controlled 
study, these data provide important information on the predictive 
versus prognostic value of tumor molecular markers, and constitute 
the largest prospective biomarker analysis performed to date for er-
lotinib. The results demonstrate that erlotinib provides clinical benefit 
regardless of the status of the most commonly studied biomarkers. 
EGFR mutation status appears to be a strong positive predictor of 
PFS benefit with erlotinib. In this study, KRAS mutation status was a 
negative prognostic factor but showed no predictive value for benefit 
with erlotinib.
 Biomarker status n % (per biomarker) HR for PFS interaction p value
 EGFR IHC+ 618 84 0.69 0.6312
 EGFR IHC– 121 16 0.77 
     
 EGFR FISH+ 231 48 0.68 0.3515
 EGFR FISH– 255 52 0.81 
     
 EGFR mutation+ 40 11 0.09 0.0006
 EGFR wild-type 328 89 0.81 
     
 KRAS mutation+ 90 18 0.77 0.9480
 KRAS wild-type 403 82 0.70 
     
 Long EGFR CA-repeat* 396 51 0.75 0.6104
 Short EGFR CA-repeat 385 49 0.68 
* sum of alleles >35 for Caucasian patients and >37 for Asian patients
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Impact of EGFR and KRAS mutations on clinical 
outcomes in previously untreated patients with advanced 
NSCLC treated with gefitinib or erlotinib: results of an 
online tumor registry of clinical trials
Jackman, David M.1; Miller, Vincent A.2; Cioffredi, Leigh-Anne1; 
Yeap, Beow Y.3; Janne, Pasi A.1; Riely, Gregory J.2; Gallegos Ruiz, 
Marielle4; Giaccone, Giuseppe5; Sequist, Lecia V.3; Johnson, Bruce 
E.1
1 Dana-Farber Cancer Institute, Boston, MA, USA; 2 Memorial 
Sloan-Kettering Cancer Center, New York, NY, USA; 3 Massachusetts 
General Hospital, Boston, MA, USA; 4 Vrije Universiteit, Amsterdam, 
Netherlands; 5 National Cancer Institute, Bethesda, MD, USA
Purpose: The impact of EGFR and KRAS genotype on outcomes 
with erlotinib or gefitinib therapy continues to be debated. This study 
combines patient data from 5 trials in predominantly Western popula-
tions to assess the impact of EGFR and KRAS mutations on first-line 
therapy with an EGFR-TKI and compare clinical versus molecular 
predictors of sensitivity.
Patients and Methods: Chemotherapy-naïve patients with advanced 
NSCLC and known EGFR mutation status treated with erlotinib 
or gefitinib monotherapy as part of a clinical trial were eligible for 
inclusion. Patients received daily erlotinib (150mg) or gefitinib 
(250mg) until disease progression or unacceptable toxicity. Data were 
collected in a password-protected web database. Clinical outcomes 
were analyzed to look for differences based on EGFR and KRAS 
genotype, as well as clinical characteristics. 
Results: 223 patients from five clinical trials were included. Sensitiz-
ing EGFR mutations were associated with a 67% response rate, TTP 
of 11.8 months, and OS of 23.9 months. Exon 19 deletions were 
associated with longer median TTP (14.6 vs 9.7 months, p = .02) and 
OS (30.8 vs 14.8 months, p < .001) compared with L858R mutations. 
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
Copyright © 2009 by the International Association for the Study of Lung CancerS350
Wild-type EGFR was associated with poorer outcomes (RR 3%, TTP 
3.2 months) irrespective of KRAS status (figure 1). No difference 
in outcome was seen between patients harboring KRAS transition 
vs. transversion mutations. EGFR genotype was more effective than 
clinical characteristics at selecting appropriate patients for considera-
tion of first-line therapy with an EGFR-TKI (figure 2).
Conclusion: EGFR mutation status is associated with sensitivity to 
treatment with an EGFR-TKI in patients with advanced NSCLC. 
Patients harboring sensitizing EGFR mutations should be considered 
for first-line erlotinib or gefitinib.
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KRAS mutation analysis in non-small cell lung cancer 
(NSCLC) versus colorectal cancer (CRC): implications for 
EGFR-directed therapies 
Mack, Philip C.1; Gandara, David R.1; Omori, Akiko2; Grimminger, 
Peter P.3; Lenz, Heinz-Josef3; Joshi, Mary-Beth M.4; Harpole, David 
H.4; Danenberg, Kathleen D.2
1 University of California, Davis, Sacramento, CA, USA; 2 Response 
Genetics, Inc., Los Angeles, CA, USA; 3 University of Southern 
California, Los Angeles, CA, USA; 4 Duke University Medical Center, 
Durham, NC, USA
Background: KRAS mutations (MTs) have both prognostic and 
predictive value in NSCLC and CRC, yet little data exist comparing 
the specifics of these events in the two cancers. In CRC, benefit from 
the EGFR-targeted monoclonal antibody cetuximab is largely limited 
to patients whose tumors are KRAS wild-type. However, in NSCLC, 
preliminary SWOG data suggest that KRAS MTs do not play a pre-
dictive role for cetuximab therapy. We hypothesized that the unique 
molecular biology and etiology of NSCLC, in conjunction with the 
usage of cetuximab in front-line therapy, contribute to this diver-
gence in KRAS dependency. In NSCLC, KRAS MTs are tobacco 
carcinogen-related, occur predominantly in adenocarcinoma, and are 
associated with a poor response to EGFR tyrosine kinase inhibitors. 
In contrast, tobacco carcinogens are reported to be a minor contribu-
tor to CRC etiology (estimated at 10% of cases). Here we compare 
KRAS status in NSCLC versus CRC in the large Response Genetics 
Inc. (RGi) database. 
Methods: DNA from microdissected formalin fixed paraffin embed-
ded (FFPE) tumor samples was analyzed by PCR and direct sequen-
cing from 919 specimens: 664 CRC and 255 NSCLC. Specimens 
were acquired from multiple studies analyzed by RGi. Fisher’s Exact 
Test was used for all statistical comparisons.
Results: KRAS mutations were found in 39.6% of CRC and 20.8% 
of NSCLC specimens (p<0.001). The ratio of transversions to transi-
tions was 3.08 in NSCLC versus 0.80 in CRC (p<0.001). In NSCLC, 
KRAS MTs were identified in 28.5% (41/144) of tumors with adeno-
carcinoma/BAC phenotype versus 10% (12/120) of squamous cell 
carcinomas (p=0.0036). No statistical differences in KRAS mutation 
frequency were observed between early and late disease (NSCLC: 
p=0.48; CRC: p=0.582). The tobacco carcinogenesis-associated G>T 
transversions (codon 12 GGT>TGT plus GGT>GTT) comprised 
68% of KRAS MTs in NSCLC, but only 36% in CRC (p<0.001). The 
GGT>GAT transition was the most prevalent type of substitution in 
CRC at 33.5%. In both tumor types, KRAS MTs were more frequent 
in Asian and Hispanic patients compared to Caucasian patients. In 
Hispanic patients, the KRAS MTs were observed in 41% (n=39) 
compared to 22.3% of Caucasians (n= 157)(p=0.017). In Asian pa-
tients, KRAS MT occurred at 46% (n=26)(p=0.012 compared to the 
frequency in Caucasians). Analysis of the association between MT 
type and patient smoking status is ongoing.
Conclusions: This analysis of the RGI database demonstrates differ-
ences in KRAS status between NSCLC and CRC in regard not only to 
MT incidence but in the frequency of specific base substitutions in co-
dons 12 and 13. Of particular distinction were the increased frequen-
cies of DNA transversions, likely linked to smoking history. Differ-
ences in KRAS frequency were observed between ethnicities. These 
findings, in combination with the underlying molecular milieu of these 
two cancers, may explain prognostic and predictive differences.
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Gene copy numbers of signaling components downstream 
of EGFR identify non small cell lung cancer (NSCLC) 
patients with poor outcomes on 2nd/3rd line gefitinib 
therapy
Morrison, Larry E.1; Basu, Sanjib2, 3; Buckingham, Lela E.3; Kaiser, 
Kelly A.3; Fidler, Mary J.3; Batus, Marta3; Jacobson, Kris K.1; Jewell, 
Susan S.1; Coon, John S.3; Bonomi, Philip D.3
1 Abbott Molecular, Des Plaines, IL, USA; 2 Northern Illinois 
University, De Kalb, IL, USA; 3 Rush University Medical Center, 
Chicago, IL, USA
Background: EGFR mutations in exons 19 and 21 and high EGFR 
copy number have been associated with increased sensitivity to 
EGFR tyrosine kinase inhibitors (TKI’s) in NSCLC patients, while 
KRAS mutations, MET expression, and EGFR T790M mutation have 
been linked to resistance. In preclinical models, EGFR downstream 
markers have been important in EGFR sensitivity or resistance. In 
this study we have examined the impact of abnormal PTEN and 
PIK3CA gene copy numbers on the outcomes of patients treated with 
gefitinib.
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Methods: Formalin-fixed paraffin embedded tissues and cell pel-
lets from 81 gefitinib-treated NSCLC patients were analyzed by 
fluorescence in situ hybridization (FISH) with probes specific for 
EGFR, PTEN, PIK3CA, and centromeres (cen) 3, 7, and 10, and 72 
specimens yielded results for all 6 probes. Patients were previously 
treated with at least one chemotherapy regimen or were considered 
ineligible for chemotherapy. FISH signals were enumerated in ≥40 
cells per specimen to obtain copy numbers for each locus. Vari-
ous classifiers were derived from the genomic copy numbers and a 
range of cutoff values were applied to classify patients by objective 
response (OR), progression free survival (PFS), and overall survival 
(OS). EGFR mutation status (exons 19 & 21) was obtained for 55 of 
the specimens.
Results: Loss of PTEN (≥20% of cells with <2 copies of PTEN) 
and low cen7 copy number (average cen7 copies/cell <4) were each 
significantly associated with lower OS, and high PIK3CA copy num-
ber (≥40% of cells with >2 copies of PIK3CA) and low EGFR copy 
number (<75% cells with >2 copies of EGFR) showed trends toward 
lower OS. Combined loss of PTEN and high PIK3CA copy number, 
or 3-way combinations of high PIK3CA copy number, loss of PTEN, 
and either low EGFR copy number or low cen7 copy number, were 
significantly associated with lower OS and lower PFS. Twenty two 
patients (31%) had tumors with high PIK3CA copy number, loss of 
PTEN, and low cen7 copy number, and these patients exhibited medi-
an OS of 132 d compared to 373 d in the other 50 patients (p<0.0001 
Kaplan-Meier analysis, log rank test), median PFS of 62 d compared 
to 128 d (p=0.0007), and 0% OR compared to 22% (p=0.015, 2-tail 
Fischer’s exact test). In the 37 patients that did not harbor an EGFR 
mutation, the classifier was still significant (median OS: 128 vs 380 
d, p<0.0001; median PFS: 62 vs 102 d, p=0.019). In multivariate 
analysis, including PIK3CA, PTEN, and cen7 FISH status, gender, 
histology, and EGFR mutation status, all 3 FISH parameters remained 
significantly associated with OS.
Conclusions: These data indicate that gefitinib is relatively ineffect-
ive in tumors with relatively high PTEN loss and PIK3CA gain, 
and low levels of EGFR or cen7, in either the full study group or 
the subgroup without EGFR mutations. If confirmed in subsequent 
studies, alternative treatments, potentially including agents selected 
for combination with EGFR TKI’s, should be considered for patients 
whose tumors have this profile.
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Clinical outcomes of patients with epidermal growth factor 
receptor (EGFR) mutations (Mut) in IPASS (IRESSATM 
Pan ASia Study)
Mok, Tony S.1; To, Kai Fai1; Srimunimimit, Vichien 10; Chao, Tsu-Yi 
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Emma6; Rukazenkov, Yuri7; Saijo, Nagahiro8; Yang, Chih-Hsin3; 
Fukuoka, Masahiro5
1 The Chinese University of Hong Kong, Hong Kong, China; 2 
GuangDong Provincial People’s Hospital, Guangzhou, China; 3 
National Taiwan University Hospital, Taipei, Taiwan; 4 Maharaj 
Nakorn Chiang Mai Hospital, Chiang Mai, Thailand; 5 Kinki 
University, Osaka, Japan; 6 Astrazeneca, Alderly Park, UK; 7 
Astrazeneca, Macclesfield, UK; 8 National Cancer Center Hospital 
East, Chiba, Japan; 9 National Kyushu Cancer Center, Fukuoka, 
Japan; 10 Siriraj Hospital, Mahidol University, Bangkok, Thailand; 11 
Triservice General Hospital, Taipei, Taiwan
Introduction: Single arm studies on tyrosine kinase inhibitors (TKIs) 
have suggested that clinical outcomes in patients with EGFR muta-
tion in exon 19 (deletions), 20 (T790M) and 21 (L858R) are different. 
We performed a post-hoc analysis of efficacy by EGFR mutation type 
in IPASS, a randomized phase III study that compared oral gefitinib 
250mg/day (G) with carboplatin/paclitaxel (C/P) as first-line therapy.
Methods: Of 1217 enrolled patients, 437 (35.9%) samples were 
evaluable for EGFR mutation. We employed the Amplification Re-
fractory Mutation System (ARMS) using the DxS EGFR 29 mutation 
detection kit. EGFR mutation positivity was defined as detection of 
≥ 1 mutation. Clinical outcomes including objective response rate 
(ORR) and progression free survival (PFS) were analyzed.
Results: 261 (59.7% of evaluable samples) samples harboured EGFR 
mutation and 11 (2.5%) had >1 mutation. Distribution is summarized 
in the Table. The PFS HR (G:C/P) was 0.38 (95% CI 0.26-0.56) in 
the exon 19 deletions subgroup and 0.55 (95% CI 0.35-0.87) in the 
L858R mutation subgroup. The ORR (G vs C/P) was 84.8% vs 43.2% 
(OR 7.23, 95% CI 3.19-16.37) in the exon 19 deletions subgroup, and 
60.9% vs 53.2% (OR 1.41, 95% CI 0.65-3.05) in the L858R muta-
tion subgroup. Three out of 5 patients with T790M attained a partial 
response to G (all 3 G responders also had exon 19 deletions). Simi-
larly, 3 out of 6 patients with T790M responded to C/P (of the 3 C/P 
responders, 1 had exon 19 deletions, 1 had L858R, and 1 had T790M 
only). Further results, including PFS comparisons between mutation 
types for G and C/P, will be presented at the meeting.
Conclusions: G had longer PFS and greater ORR compared to C/P 
in both the exon 19 deletions and L858R subgroups, with a slightly 
greater advantage in the exon 19 deletions subgroup. Responses to 
both G and C/P were observed in the small group of patients with 
T790M mutations, which have previously been reported to be associ-
ated with resistance to EGFR TKIs. 
 EGFR mutation type* Gefitinib (n=132) C/P (n=129) Total (n=261)
 Exon 19 deletions 66 (50.0%) 74 (57.4%) 140 (53.5%)
 Exon 21 L858R 64 (48.5%) 47 (36.4%) 111 (42.5%)
 Exon 20 T790M 5 (3.8%) 6 (4.7%) 11 (4.2%)
 Other mutations 3 (2.3%) 7 (5.4%) 10 (3.8%)
 *11 pts had multiple mutations   
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Background: Several studies have suggested that EGFR tyrosine 
kinase domain (TKD) mutation is a favorable prognostic marker 
for NSCLC. When compared to patients with wildtype (WT) EGFR 
tumors, patients with EGFR mutant tumors demonstrate higher 
response rates to EGFR TK inhibitors and to chemotherapy. The 
potential effect of EGFR mutation and gene copy number on early 
stage NSCLC patients receiving adjuvant chemotherapy has not been 
reported. 
Methods: Tumor samples from 448 of 482 patients randomized in 
the NCIC CTG JBR.10 Phase 3 trial of adjuvant vinorelbine/cisplatin 
(ACT) versus observation (OBS) were analysed for EGFR mutation 
and gene copy number status. Mutation analyses were performed on 
exons 18-21 by direct sequencing; negative/failed results were further 
analysed by fragment analysis method or the Scorpion-Amplified 
Refractory Mutation System. EGFR gene copy was assessed by 
fluorescent in situ hybridization and scored using the previously 
published algorithm from the University of Colorado Cancer Center. 
EGFR mutation and gene copy number were correlated with clinical 
outcomes and interaction with chemotherapy. 
Results: EGFR analyses of tumor samples were successful for 445 
patients, (225 OBS and 220 ACT). Mutations were identified in 43 
patients. These included 36 with the classical exon 19 deletions and 
exon 21 L858R mutations (22 OBS and 14 ACT). There was no 
significant difference in overall survival (OS) for the 22 OBS patients 
with exon 19 or 21 mutations compared to that of the 203 patients 
with WT EGFR or other mutations patients (Hazard Ratio [HR] 0.80, 
95% CI 0.39-1.65). Multivariate analysis using the Cox regression 
model confirmed the lack of association with survival. Among the 
36 patients with exon 19 or 21 mutations, 14 received ACT. Chemo-
therapy improved OS (HR 0.44, 95% CI 0.11-1.70), but this was not 
statistically significant (p=0.22), perhaps due to the small number 
of patients with mutations. Among 409 patients with WT EGFR or 
other mutations, 206 received ACT. Chemotherapy was also associ-
ated with improved OS in this group (HR 0.80, 95% CI 0.59-1.08, 
p=0.14). There was no significant interaction between mutation status 
and ACT (p=0.49). The results from gene copy number study will be 
presented at the meeting.
Conclusions: In the JBR.10 cohort of stage IB and II NSCLC 
patients, mutations in exon 19 and 21 were neither significantly 
prognostic of overall survival nor predictive of a differential survival 
benefit from ACT, although trends towards longer survival and a 
greater benefit from chemotherapy were observed. The interpreta-
tion of the results was limited by the low EGFR mutation rate in this 
study of mainly Caucasian patients. (Supported by grants from the 
Canadian Cancer Society and Ontario Institute of Cancer Research)
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Background: Mutations in the tyrosine-kinase (TK) domain of 
EGFR occur in approximately 10% of Caucasian patients and 30% 
of Asian patients with advanced NSCLC. Perhaps uniquely, the 
survival of tumor cells with the most common activating EGFR 
mutations (exon 19 deletions or L858R point mutations in exon 21) 
may be solely dependent on anti-apoptotic signalling via the Akt 
pathway. Therefore, EGFR-mutant NSCLC may be considered as a 
distinct disease within the broader spectrum of NSCLC. Tumors with 
EGFR TK mutations appear to be highly sensitive to EGFR tyrosine-
kinase inhibitors (TKIs) such as erlotinib or gefitinib. However, the 
relatively low rate of mutations, and the limited availability of tumor 
samples from randomised trials makes it difficult to conduct large-
scale investigations of possible associations between EGFR muta-
tions and therapeutic outcomes. We sought to consolidate some of the 
existing data by pooling study results.
Methods: We identified published papers, from phase II/III studies 
or retrospective analyses, that reported PFS outcomes among patients 
with EGFR mutations who were treated with either chemotherapy or 
EGFR TKI monotherapy (erlotinib or gefitinib). Important unpub-
lished data were included where available. We used reported median 
PFS, or the percentage of progression-free survivors at a fixed time 
as the basis for our analysis. To facilitate a weighted, pooled analysis, 
we used the assumption that PFS times were exponentially distrib-
uted, as described by the survival function Sexp(t)=exp{- λt}, where 
λ is the constant hazard rate and median survival is given by ln(2)/λ. 
This is the simplest parametric assumption for a survival analysis. 
For a reported percentage (γ) of progression-free survivors at time T, 
i.e. Sexp(T)=γ, λ was estimated by –ln(γ)/T. At γ=50%, T represents 
the median PFS. The results of individual studies were pooled by 
calculating the overall mean of ln(2)/λ for each treatment, weighted 
by group size, to obtain an estimate of the pooled median PFS. Lim-
itations to this approach are that it is based on a parametric simplifi-
cation of high-level data (not individual patient data), and does not 
discriminate between specific mutation types.
Results: Data were included from 6 studies with chemotherapy (192 
patients), 8 studies with erlotinib (341 patients), and 13 studies with 
gefitinib (413 patients in total). In the first-line setting, the pooled 
median PFS was 6.4 months for chemotherapy (n=170), 13.6 months 
for erlotinib (n=185), and 9.7 months for gefitinib (n=311). In the 
second-line setting, the pooled median PFS was 4.1 months for 
chemotherapy (n=22), 13.3 months for erlotinib (n=156), and 8.8 
months for gefitinib (n=102).
Conclusions: This analysis provides a useful overview of the many 
reports on clinical outcomes in patients with EGFR mutations. These 
data support the suggestion that patients with EGFR mutations might 
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obtain a greater benefit from EGFR TKI therapy than from conven-
tional chemotherapy. The use of EGFR TKIs as first-line therapy is an 
attractive prospect in patients with EGFR-mutant advanced NSCLC, 
and ongoing prospective studies such as the phase III ‘European 
randomised trial of Tarceva vs chemotherapy’ (EURTAC) should 
provide further information on the merit of this approach.
Session C1: Advanced NSCLC - Novel Therapeutics I 
Monday August 3
C1.1 Advanced NSCLC - Novel Therapeutics I, Mon Aug 3, 10:30 - 12:00
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Group [CTG] BR.24: a randomized, double-blind trial 
of carboplatin + paclitaxel [C+P] with either daily oral 
cediranib, a potent inhibitor of all vascular endothelial 
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advanced non-small cell lung cancer [NSCLC]
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Introduction: In phase I testing at selected centres, cediranib [Ced] 
(AZD2171, Recentin, AstraZeneca) at either 45 or 30 mg / d with 
C+P was tolerable and showed encouraging antitumour activity, 
leading to the initiation of BR.24. Toxicity concerns led to an early 
amendment to reduce the dose from 45 to 30 mg and exclude pts with 
poor PS. At the interim analysis, the addition of Ced 30 mg / day 
significantly increased response rate ([RR] 38 vs 18 %, p < 0.0001) 
and progression free survival ([PFS]: HR 0.77). This met the efficacy 
endpoint for proceeding directly to phase III, but an imbalance in 
fatal serious adverse events [SAE] (any causality) led to a decision 
to halt the trial, to allow a reevaluation of dose and toxicity for this 
combination. Herein we present the final OS analysis. 
Methods: Consenting adults (stage IIIB / IV any histology; PS 0-1 
[2 for 45 mg cohort only]; no bleeding; therapeutic anticoagulation 
and stable, treated brain metastases permitted) were randomized to 
C (AUC 6) + P (200 mg/m2) q3w (up to 8 cycles) with daily Ced or 
placebo [Pla] until progression. This OS analysis was performed on 
all randomized pts (45 + 30 mg) in an intent-to-treat fashion. Survival 
distributions were estimated using the Kaplan-Meier method and 
compared with log-rank testing. An exploratory stratified Cox regres-
sion model was used to adjust for prespecified prognostic factors. 
Results: 296 pts accrued (251 at 30 mg); baseline characteristics 
generally balanced although Ced pts were more likely > 60 (52 vs 41 
%). Post-protocol systemic therapy was uncommon, but more pts on 
Pla received an angiogenesis inhibitor (21 vs 4 %). With a median 
follow-up of 17 m: MS was 10.5 vs 10.1 m (Ced vs Pla; HR 0.94, 95 
% CI 0.70 – 1.24, p = 0.65). In the Cox model, significant predictors 
of poorer survival were PS 1/2 (HR 1.84), hypoalbuminemia (HR 
2.08), high LDH (HR 2.16), and bulky disease (HR 1.83), while treat-
ment with Ced was associated with a trend to improved survival (HR 
0.78, 95 % CI 0.57-1.06, p = 0.11). Survival by histology (Ced / Pla): 
adenocarcinoma 11.0 vs 8.8 m (HR 0.97); squamous 8.9 vs 9.3 m 
(HR 0.99); the interaction term was NS. There were similar numbers 
of deaths (99 on Ced vs 105 on Pla), but more attributed at least in 
part to complications of protocol therapy (13 vs 0 %). 
Conclusion: Despite improved RR / PFS, MS was not increased, 
possibly due to the imbalance in early fatal SAE. As we found a 
dose-toxicity without a clear dose-efficacy relationship, NCIC CTG, 
in conjunction with ALTG, has initiated BR.29, a randomized trial of 
20 mg / d Ced / Pla with C+P in advanced NSCLC of any histology, 
excluding pts with poor PS and low albumin / weight loss > 5 %, as 
these latter predicted fatal SAE. 
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Background: Patients with non-small cell lung cancer are currently 
treated with concomitant or sequential chemotherapy and radiother-
apy. However, the effect of existing treatment modalities is unsatis-
factory. Progress of new strategies including more efficient therapy is 
warranted. Endostar (Rh-endostatin Injection) may have anti-tumor 
activity by against vascular endothelial growth factor for initial treat-
ment. This study was designed to evaluate the security and the valid-
ity of the combination endostatin-paclitaxel and carboplatin (TC) 
therapy in patients with nonsmall-cell lung cancer (NSCLC) seeking 
for the more effective method of treatment. 
Objective: to compare two groups time to progression (TTP); 1 
year survival; secondary evaluating indicator:objective response 
rate(ORR), clinical benefit rate(CBR), mean survival time(MST), 
quality of life(QOL). 
Methods: In this randomized, double-blind, placebo-controlled, 
multicentre trial, 126 patients between July 5 2007 and June 30 2008 
are planned to enroll in randomized into 2 groups from 10 centers: 
the experimental group and control group (1:1). The code-breaking 
time estimate is about June 2009. The leader units are Shanghai Chest 
Hospital Affiliated to Shanghai Jiao-Tong University and Shanghai 
Changzheng Hospital. Main eligibility criteria were histologically or 
cytologically proven stage III or IV NSCLC, with an age of 18-75 
years. All eligible patients received 1 cycle (21 days) of TC chemo-
therapy. After chemotherapy, patients with the curative effect reaches 
above SD or SD were randomized to receive endostar plus TC or TC 
alone for 3 cycles. Each 21-day cycle consisted of endostar 7.5mg/m2 
on days 8 to days 21, carboplatin AUC 5 on day 1, and paclitaxel 175 
mg/m on day 1
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Results: From July 5 2007 to August 2008, 126 assessable entered in 
this trial screening in 145 NSCLC patients. FAS analysis: Objective 
response A group: 39.34%, B group 22.95%, no Significant differen-
ces between two groups, P=0.0778: PPS analysis: Objective response 
rate for A group: 40.00%, B group: 25.00%, P=0.1074: NSCLC IIIB 
sub-group, ORR for group A: 33.33%, group B: 38.10%, no Signifi-
cant differences between two groups, P=1.0000; NSCLC for stage 
IV sup-group: ORR group A 41.86%, group B 11.11%. Significant 
differences between two groups, P=0.0026; Squamous carcinoma 
sub-group, ORR group A: 39.13%, group B 36.36%, no significant 
differences between two groups, P=1.0000: Adenocarcinoma sub-
group, ORR group A: 40.54%, group B 17.07%. Significant differ-
ences between two groups, P=0.0257.
Clinic benefit rate (CBR): FAS analysis: CBR for group A 90.16%, 
group B67.21%. Significant differences between two groups, 
P=0.0035; PPS analysis: CBR for group A 89.09%, group B 69.64%. 
Significant differences between two groups, P=0.0180.
FAS result analysis show: Sub-group for stage IIIB, CBR for group 
A: 88.89%, group B 76.19%, no significant differences between 
two groups, P=0.4179. Sub-group for stage IV, CBR for group 
A 90.70%, group B 63.89%. Significant differences between two 
groups, P=0.0055; or squamous carcinoma sub-group, CBP for group 
A 91.30%, group B 72.13%, P=0.2999, no Significant differences 
between two groups. For adenocarcinoma sub-group, CBR for group 
A 89.19%, group B 65.85%, P=0.0171.
Conclusions: The addition of endostar to paclitaxel plus carboplatin 
in the treatment of selected patients with non–small-cell lung cancer 
has a significant clinic benefit rate, especial for stage IV and adeno-
carcinoma of advanced NSCLC . PFS is still follow-up process.
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Background: Rh-endostatin is a new recombinant human endostatin 
Endostatin is an important endogenous inhibitor of neovasculariza-
tion, which has been widely used in anti-angiogenesis therapy for 
cancer. Rh-endostatin could inhibit tumor endothelial cell prolifera-
tion, angiogenesis and tumor growth. Phase I studies revealed that 
rh-endostatin was effective as single agent with good tolerance in 
clinical trial. 
Methods: Randomised, double-blinded and placebo-controlled 
were used to evaluated the anti-tumor efficacy of the combination of 
Rh-endostatin with NP or placebo with NP.43 cases of Stage III/IV 
NSCLC with at least one lesion of measurable disease, ECOG PS 0 
-1, must have no brain metastasis. Patients received NP(Vinorelbine 
25 mg/m2 d1&d5, Cisplatin 30 mg/m2 day2-4) and Rh-endostatin 
7.5 mg/m2 day 1-14 every 3 weeks for 4 cycles. Evaluated efficacy 
after 2 cycles of therapy. For patients of PR need conformed after one 
month, patients continued after 4 cycles until progressive disease or 
intolerable toxicity. The primary endpoint was to compare the effects, 
Secondary endpoints included response rate, clinical benefit rates, 
time to progression, survival and tolerability. 
Results: 43 patients have enrolled, Baseline demographic charac-
teristics were: male 28,female 15; median age 61;adenocarcinoma 
histology 28,squamous cell histology 13, others histology-2; 42 
patients have been evaluated for response rate was 26.9% in trial 
group and 12.4% in control group (P=0.038). The clinical benefit rate 
was 88.5% in trial group and 50.0% in control group (P=0.006).The 
median TTP was 164 days and 79.5 days for trial group and control 
group respectively (P=0.002). In treatment group and control group, 
the response rates were 35%, 18.2% (P=0.264) The median Survival 
time were 11months,( Log Rank p=0.71). There were no significantly 
differences in incidence of toxity, no have severe side effects between 
trial group and control group.
Conclusions: NP combined Rh-endostatin resulted in improvement 
in response rate, median time to tumor progression, and clinical bene-
fit rate compared with NP alone in advanced NSCLC patients. Re-
combinant rh-endostatin in combination with chemotherapy improve 
response rate and well tolerated in advanced cancer patients.
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nonsquamous non-small cell lung cancer (NSCLC)
Blumenschein, Jr, George1; Kabbinavar, Fairooz4; Menon, Hari5; 
Mok, Tony S.K.6; Stephenson, Joe J.7; Beck, J. Thaddeus8; 
Lakshmaiah, Kuntegowdanahalli9; Reckamp, Karen10; Hei, Yong-
jiang11; Kracht, Karolyn12; Sikorski, Robert11; Schwartzberg, Lee13
1 M.D. Anderson Cancer Center, Houston, TX, USA; 2 University 
of California Los Angeles Medical Center, Los Angeles, CA, USA; 
3 Translational Oncology Research International, Los Angeles, 
CA, USA; 4 University of California Los Angeles Medical Center/
Translational Oncology Research International, Los Angeles, 
CA, USA; 5 Tata Memorial Center, Mumbai, India; 6 The Chinese 
University of Hong Kong, Hong Kong, China; 7 Cancer Center of 
the Carolinas, Greenville, SC, USA; 8 Highlands Oncology Group, 
Fayetteville, AR, USA; 9 Kidwai Memorial Institute of Oncology, 
Bangalore, India; 10 City of Hope Comprehensive Cancer Center, 
Duarte, CA, USA; 11 Oncology Development, Amgen Inc., Thousand 
Oaks, CA, USA; 12 Amgen Inc., Thousand Oaks, CA, USA; 13 The 
West Clinic, Memphis, TN, USA
Background: The addition of a vascular endothelial growth factor 
(VEGF) pathway inhibitor to standard chemotherapy has been shown 
to improve clinical outcomes in NSCLC. Motesanib is an investi-
gational, highly selective inhibitor of VEGF receptors 1, 2, and 3; 
platelet-derived growth factor receptor, and Kit. The objective of this 
study is to estimate the difference in objective tumor response rates 
(ORR) between each of two cohorts receiving motesanib plus P/C 
and one cohort receiving the anti–VEGF-A antibody bevacizumab 
plus P/C.
Methods: Eligible adult patients had confirmed unresectable, 
stage IIIB with pericardial or pleural effusion or stage IV/recurrent 
nonsquamous NSCLC and ECOG 0 or 1. Patients were randomized 
(1:1:1) to receive paclitaxel (200mg/m2) and carboplatin (AUC of 
6 mg/mL/min) on day 1 of each 3-week cycle (maximum 6 cycles) 
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plus motesanib orally from day 1 of cycle 1 at either (Arm A) 125 mg 
once daily (QD) continuously or (Arm B) 75 mg twice daily (BID) 
for 5 days followed by 2 treatment-free days; or (Arm C) P/C plus 
bevacizumab 15 mg/kg once every 3 weeks on day 1 of each cycle 
until disease progression or intolerability. The primary endpoint is 
ORR (confirmed complete response or partial response) per RE-
CIST by independent central review. Secondary endpoints include 
progression-free survival (PFS), overall survival (OS), and incidence 
of treatment-emergent adverse events (AEs).
Results: 181 patients received ≥ 1 dose of treatment (Arms A/B/C, 
n=59/62/60). Baseline demographics and characteristics were similar 
with some exceptions, including adenocarcinoma histology (Arms 
A/B/C, 77/90/86%) and ECOG status (ECOG 0, 43/52/52%; ECOG 
1, 56/47/48%). In patients with measurable disease at baseline 
(Arms A/B/C, n=56/60/62) ORR in Arms A/B/C was 23/22/29%. 
No complete responses were observed on study. At the time of data 
cut-off the median PFS in months (95% CI) was 7.4 (5.3, 8.5) in 
Arm A, 5.2 (4.2, 6.8) in Arm B, and 6.8 (4.4, 8.8) in Arm C. In 
Arms A/B/C, grade 3 AEs occurred in 47/50/45%, grade 4 AEs in 
8/6/7%, and grade 5 AEs (excluding progression of NSCLC) in 
5/15/7% of patients. The most common AEs (across all grades) were 
fatigue (Arms A/B/C, 63/50/60%), diarrhea (47/44/27%), hyperten-
sion (47/21/15%), nausea (47/48/35%); and peripheral neuropathy 
in Arm C (27/24/45%). AEs of interest (across all grades) included 
cardiac toxicity (0/2/2%), cholecystitis (5/6/0%), hemorrhagic events 
(20/21/18%), deep vein thrombosis (3/0/2%), and pulmonary embol-
ism (3/0/3%). The most common grade 3, 4 or 5 AEs according to 
descending order in Arm A were diarrhea (Arms A/B/C, 19/13/3%), 
dehydration (17/8/3%), fatigue (17/5/8%), anorexia (12/2/3%), and 
nausea (10/3/2%).
Conclusions: The estimated efficacy in the motesanib 125 mg 
QD plus P/C treatment arm appears to be similar to that of the 
bevacizumab plus P/C arm. Motesanib BID dosing showed relatively 
lower efficacy than the other two arms. The data support further study 
of motesanib plus P/C in nonsquamous NSCLC. Updated data will be 
presented.
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II trial of sorafenib and erlotinib or erlotinib alone in 
previously treated advanced non-small-cell lung cancer
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Background: Sorafenib (S) is an oral multikinase inhibitor of angio-
genesis and cell proliferation which has shown preliminary activity in 
non-small-cell lung cancer (NSCLC), and safety in combination with 
erlotinib (E). We conducted a randomized phase II trial of E and S 
versus E alone in previously treated NSCLC.
Methods: Eligible patients (pts) included: stage IIIB/IV NSCLC; 
ECOG performance status 0-2; 1-2 prior chemotherapies; measurable 
disease. Pts with treated brain metastases, any NSCLC histology, 
or on stable anticoagulation were eligible. Stratification: squamous/
non-squamous histology; prior bevacizumab use; number of prior 
regimens. Pts were randomly assigned 2:1 to E 150 mg daily and S 
400 mg twice daily, or E and placebo in the Sarah Cannon Research 
Institute Oncology Consortium, a community-based research net-
work. Primary endpoint: progression-free survival (PFS). Pts were 
enrolled to demonstrate a 40% improvement in a 2.2 month PFS with 
a power ≥ 80% and one-sided alpha of 0.1. Therapeutic endpoints 
were correlated with epidermal growth factor receptor (EGFR) levels 
by FISH and EGFR and K-Ras mutations.
Results: 168 pts were enrolled from March 2008 to February 2009. 
Pt characteristics: median age 65 years; 2 prior chemotherapy regi-
mens (33%), prior bevacizumab (36%), squamous cell (29%), female 
(55%), African-American 12%. 70% of pts consented to correlative 
testing.
Conclusions: Updated PFS, estimated overall survival, toxicity, and 
correlative molecular data will be presented at the meeting.
C1.6 Advanced NSCLC - Novel Therapeutics I, Mon Aug 3, 10:30 - 12:00
A randomized discontinuation phase II study of sorafenib 
vs placebo in patients with non-small cell lung cancer 
(NSCLC) who failed at least two prior chemotherapy 
regimens: E2501
Schiller, Joan1; Lee, Ju-whei6; Hanna, Nasser H.3; Traynor, Anne M.4; 
Wakelee, Heather5; Carbone, David P.2
1 UT Southwestern, Dallas, TX, USA; 2 Vanderbilt University Cancer 
Center, Nashville, TN, USA; 3 Indiana University, Indianapolis, 
IN, USA; 4 University of Wisconsin, Madison, WI, USA; 5 Stanford 
University, Stanford, CT, USA; 6 Dana Farber Cancer Institute, 
Boston, MA, USA
Background: Sorafenib is a Raf kinase and angiogenesis inhibitor 
with activity in hepatoma and renal-cell carcinoma. Given the activity 
of other angiogenic inhibitors in NSCLC, we conducted this random-
ized, double blind, placebo-controlled, Phase II study in the third-line 
and beyond settings. We utilized a unique, randomized discontinua-
tion design in order to enrich for patients with slower-growing 
disease, who theoretically may be more likely to derive benefit.
Methods: Patients were required to have ECOG PS 0-1, at least 
two prior chemotherapy regimens, and progressive disease. All 
patients received 400 mg of sorafenib orally twice daily for 2 cycles 
(2 months) (Step 1). Patients who responded on Step 1 continued 
on sorafenib; patients who progressed were discontinued from the 
trial, and those with stable disease were randomized to receive either 
sorafenib or placebo (Step 2). Patients randomized to placebo were 
allowed to cross over to sorafenib upon progression (Step 3). The pri-
mary endpoint of the study was the proportion of patients with stable 
or responding disease 2 months after randomization. The accrual goal 
was 311 patients in order to randomize 98, giving a 91% power to 
detect a difference in stable disease at 2 mo of 25% for placebo vs 
56% for sorafenib.
Results: 342 patients were enrolled in Step 1, 333 of whom received 
sorafenib. 107 patients were subsequently randomized to Step 2, 95 
of whom were treated. 37 patients on Step 2 were crossed over to 
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sorafenib upon progression. Demographics on Step 2 were well bal-
anced. The proportion of patients having stable or responding disease 
2 months after randomization was 49% in the sorafenib group, com-
pared with 19% in the placebo group. (P=0.01). No difference was 
found between squamous and non-squamous patients in any of the 
outcome variables, although numbers are small. The most common 
grade 3 treatment-related toxicities (safety population, n=331) includ-
ed rash/hand-foot syndrome or rash (15%) and fatigue (16%). 18 and 
7 patients, respectively, experienced grade 4 or 5 treatment-related 
toxicity. Grade 5 toxicity included 1 case of pulmonary hemorrhage 
and 3 cases of pulmonary infection/pneumonitis.
Conclusions: Sorafenib prolongs PFS in heavily pretreated patients 
with slowly growing NSCLC. Although not statistically significant, 
the trend toward an improvement in median survival is encouraging 
and deserves further study.
PFS = progression-free survival; PR = partial response; PD = progressive disease
*From date of entry on study; **from date of randomization; †from date of registration on Step 3
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A phase II study of sunitinib in patients with non-small cell 
lung cancer and irradiated brain metastases
Novello, Silvia1; Abrey, Lauren2; Grossi, Francesco3; Camps, Carlos4; 
Mazieres, Julien5; Fain, Jerry6; Vernejoux, Jean-Marc7;  
de Castro Carpeño, Javier8; Selaru, Paulina9; Patyna, Shem 9;  
Torigoe, Yasuhiro10; Chao, Richard9; Scagliotti, Giorgio1
1 University of Turin, Turin, Italy; 2 Memorial Sloan-Kettering 
Cancer Center, New York, USA; 3 National Institute for Cancer 
Research, Genoa, Italy; 4 University General Hospital of Valencia, 
Valencia, Spain; 5 Höpital Larrey, Toulouse, France; 6 Texas 
Oncology, Austin, USA; 7 Höpital du Haut-Lévèque, Pessac, France; 
8 Hospital Universitario La Paz, Madrid, Spain; 9 Pfizer Oncology, 
La Jolla, USA; 10 Pfizer Global Outcomes Research, New London, 
USA
Background: Brain metastases (BrMs) occur in ≥25% of non-small 
cell lung cancer (NSCLC) patients, and the prognosis for these pa-
tients is poor. Preclinical data provide evidence that VEGF signaling 
is required for the growth of BrMs, suggesting that antiangiogenic 
agents may have activity in this setting. Sunitinib malate (SUTENT®) 
is an oral, multitargeted inhibitor of VEGFRs, PDGFRs, KIT, FLT3, 
CSF-1R, and RET that has promising single-agent antitumor activity 
in patients with previously-treated NSCLC (Socinski JCO 2008). 
This phase II study investigated the safety and preliminary efficacy of 
sunitinib in NSCLC patients with previously irradiated BrMs.
Methods: Eligible patients (male or female ≥18 years) had NSCLC 
and had received whole brain radiation therapy (WBRT) for BrMs 
and ≤2 prior systemic therapies. Patients were eligible to receive 
sunitinib at a starting dose of 37.5 mg with continuous daily dosing 
(CDD) in 4-wk cycles. Antitumor efficacy was based on overall (RE-
CIST) and intracranial bidimensional (WHO criteria) tumor assess-
ments. Intracranial disease was assessed by MRI. Safety was assessed 
by monitoring adverse events (AEs) with a focus on neurologic 
status, and health-related quality of life was assessed using FACT/
NCCN Lung Symptom Index (FLSI) and Brain Symptom Index 
(FBrSI). Study termination was to occur if 3 cases of intracranial 
hemorrhage (ICH) associated with neurologic deficit were identified. 
Results: To date 47 patients received sunitinib for a median of 2 
cycles (range: 1, 9). Tumor histology included adenocarcinoma 
(n=28), squamous cell carcinoma (n=10), large cell carcinoma (n=2), 
bronchioloalveolar (n=1) not otherwise specified/other (n=6). The 
median age of patients was 61 yrs (range: 35, 75), most were male 
(n=26, 55%) and were smokers (n=36, 77%), and all had good 
performance status (ECOG 0/1). In total, 25 patients (53%) experi-
enced non-neurologic grade 3/4 AEs; the most frequent were fatigue/
asthenia and dyspnea. Neurologic AEs occurred in 4 patients (9%) 
and included intracranial pressure increased, mental impairment, and 
gait disturbance (each n=1 and grade 1) and 1 patient with grade 3 
convulsion and peripheral motor neuropathy. Importantly, no cases of 
ICH were noted. Stable disease occurred in 7 (19%) of 36 measurable 
pts. Median PFS was 10.9 wks (95% CI: 6.4,15.4). Median OS was 
19.6 wks (95% CI:13.1, NR). Mean change from baseline in FLSI 
and FBrSI scores did not differ significantly at any time point. 
Conclusions: Oral sunitinib 37.5 mg on a CDD schedule had a man-
ageable safety profile in NSCLC patients with BrMs, and no cases of 
ICH were reported. Preliminary data are indicative of encouraging 
activity (PFS of 10.9 wks) in this population. These results support 
further investigation of sunitinib in patients with BrMs from NSCLC. 
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Vandetanib plus pemetrexed versus pemetrexed as 
2nd-line therapy in patients with advanced NSCLC: a 
randomized, double-blind phase III trial (ZEAL)
de Boer, Richard H.1; Arrieta, Oscar2; Gottfried, Maya3; Blackhall, 
Fiona H.4; Raats, Johann5; Yang, Chih-Hsin6; Langmuir, Peter7; 
Milenkova, Tsveta 8; Read, Jessica8; Vansteenkiste, Johan9
1 Western Hospital, Melbourne, VIC, Australia; 2 Instituto Nacional 
de Cancerologia, Mexico City, Mexico; 3 Meir Medical Center, 
Kfar Saba, Israel; 4 Christie Hospital NHS Trust, Manchester, UK; 
5 Panorama Medical Center, Capetown, South Africa; 6 National 
Taiwan University Hospital, Taipei, Taiwan; 7 AstraZeneca, 
Wilmington, DE, USA; 8 AstraZeneca, Macclesfield, UK; 9 University 
Hospital Leuven, Leuven, Belgium
Background: Vandetanib (ZACTIMA™) is a once-daily oral 
anticancer drug that selectively inhibits vascular endothelial growth 
factor receptor (VEGFR), epidermal growth factor receptor (EGFR) 
and RET (REarranged during Transfection) receptor tyrosine kinase 
activity. A phase I study in patients with previously treated advanced 
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non-small-cell lung cancer (NSCLC) demonstrated that vandetanib + 
pemetrexed was generally well tolerated and supported further inves-
tigation of this combination in this setting (de Boer et al, Ann Oncol 
2008). This randomized, placebo-controlled phase III study evaluated 
vandetanib + pemetrexed as a 2nd-line treatment for patients with 
advanced NSCLC.
Methods: The primary objective of this study was to determine 
whether vandetanib (100 mg/day) + pemetrexed (500 mg/m2 every 
21 days; maximum of 6 cycles) prolonged progression-free survival 
(PFS) versus placebo + pemetrexed. Overall survival, objective re-
sponse rate (ORR), time to deterioration of disease-related symptoms 
(TDS, assessed by the Lung Cancer Symptom Scale questionnaire) 
and safety were secondary assessments. Efficacy and safety were as-
sessed in females as a co-primary analysis population. Eligibility cri-
teria included stage IIIB/IV NSCLC, WHO performance status (PS) 
0–2, and previous 1st-line therapy. Patients with squamous cell histol-
ogy were eligible, and brain metastases were permitted if treated at 
least 4 weeks before study entry and clinically stable without steroid 
treatment for 10 days.
Results: A total of 534 patients (mean age 59 years; 38% female; 
21% squamous cell histology; 8% brain metastases; 84% stage IV 
NSCLC; 41%/53%/6% PS 0/1/2) were recruited from 100 centers be-
tween January 2007 and March 2008. Patients were randomized 1:1 
to receive vandetanib + pemetrexed (n=256) or placebo + pemetrexed 
(n=278). Baseline characteristics were similar in both arms. The 
median duration of follow-up was 9.0 months; 83% of patients had 
progressed and 50% had died by data cut-off (5 September 2008). 
There were positive trends observed for vandetanib + pemetrexed 
versus placebo + pemetrexed for both PFS (hazard ratio [HR] 0.86, 
97.58% CI 0.69–1.06; 2-sided P=0.108) and overall survival (HR 
0.86, 97.54% CI 0.65–1.13; 2-sided P=0.219), which did not reach 
statistical significance. Similar positive trends for PFS and overall 
survival were observed for females. There were statistically signifi-
cant advantages in ORR for vandetanib + pemetrexed versus placebo 
+ pemetrexed (19.1% vs 7.9%, 2-sided P<0.001) and TDS (HR 0.71, 
97.5% CI 0.54–0.94; 2-sided P=0.005). Exploratory analyses showed 
the effects of vandetanib + pemetrexed on PFS and overall survival 
were similar among the clinical and molecular subgroups analyzed. 
The adverse event profile was consistent with that observed in previ-
ous vandetanib studies in NSCLC. There was a higher incidence of 
some adverse events in the vandetanib arm, including rash (38% vs 
26%), diarrhea (26% vs 18%) and hypertension (12% vs 3%). There 
was evidence of reduced pemetrexed toxicity with the addition of 
vandetanib: anemia (8% vs 22%), nausea (29% vs 37%), vomiting 
(15% vs 22%), fatigue (37% vs 45%), and asthenia (11% vs 17%). 
The incidence of protocol-defined QTc prolongation was <1%. Pa-
tients receiving vandetanib did not experience an increase in bleeding 
or thrombotic events. 
Conclusions: In this randomized phase III study, the combination of 
vandetanib + pemetrexed demonstrated evidence of clinical benefit in 
patients with pretreated advanced NSCLC but the study did not meet 
the primary endpoint of statistically significant PFS prolongation 
versus placebo + pemetrexed. Vandetanib + pemetrexed was gener-
ally well tolerated.
C2.2 Anti-Angiogenics, Mon Aug 3, 10:30 - 12:00
Vandetanib plus docetaxel versus docetaxel as second-
line treatment for patients with advanced NSCLC: a 
randomized, double-blind phase III trial (ZODIAC)
Herbst, Roy S.1; Sun, Yan2; Korfee, Soenke3; Germonpre, Paul4; 
Saijo, Nagahiro5; Zhou, Caichun6; Wang, Jie7; Langmuir, Peter8; 
Tada, Hiroomi8; Kennedy, Sarah J.9; Johnson, Bruce E.10
1 MD Anderson Cancer Center, Houston, TX, USA; 2 Cancer 
Hospital, Beijing, China; 3 Department of Medicine (Cancer 
Research), West German Tumor Center, University Duisburg-Essen, 
Essen, Germany; 4 Antwerp University Hospital, Antwerp, Belgium; 
5 National Cancer Center Hospital East, Chiba, Japan; 6 Tongji 
University, Shanghai, China; 7 Beijing Institute for Cancer Research, 
Beijing, China; 8 AstraZeneca, Wilmington, USA; 9 AstraZeneca, 
Macclesfield, UK; 10 Dana-Farber Cancer Institute, Boston, MA, 
USA
Background: Vandetanib (ZACTIMA™) is a once-daily oral 
inhibitor of vascular endothelial growth factor receptor (VEGFR), 
epidermal growth factor receptor (EGFR) and RET (REarranged 
during Transfection) signaling. A randomized phase II study in 
patients with previously treated advanced non-small-cell lung cancer 
(NSCLC) demonstrated that the addition of vandetanib 100 mg/day 
to docetaxel prolonged progression-free survival (PFS) and improved 
response rate (Heymach et al, JCO, 2007); these encouraging data 
supported further evaluation of this treatment regimen in a random-
ized, placebo-controlled phase III study. 
Methods: The primary objective was to determine whether van-
detanib 100 mg/day + docetaxel 75 mg/m2 every 21 days (maximum 
6 cycles) prolonged PFS versus placebo + docetaxel. Secondary 
endpoints included overall survival, objective response rate, time to 
deterioration of symptoms (TDS) and safety. Efficacy and safety in 
females were assessed as a co-primary analysis population. Eligibil-
ity criteria included stage IIIB/IV NSCLC, performance status 0–1, 
and previous chemotherapy. Patients with squamous cell histology 
were eligible, and brain metastases were permitted if treated at least 
4 weeks before study entry and clinically stable without steroid 
treatment for 10 days. Previous treatment with bevacizumab was also 
permitted. 
Results: A total of 1391 patients (mean age, 58 years; 30% female; 
25% squamous cell histology; 10% brain metastases; 85% stage 
IV NSCLC; 35%/65% PS 0/1) were recruited between May 2006 
and April 2008. Patients were randomized to receive vandetanib + 
docetaxel (n=694) or placebo + docetaxel (n=697). Baseline char-
acteristics were similar in both arms. At the time of data cut-off (22 
August 2008), the median duration of follow-up was 12.8 months, 
87% patients had progressed and 59% had died. The addition of 
vandetanib to docetaxel showed a statistically significant improve-
ment in PFS versus docetaxel (hazard ratio [HR] 0.79, 97.58% CI 
0.70–0.90; 2-sided P<0.001), and a similar advantage in females (HR 
0.79; 97.58% CI 0.62–1.00; 2-sided P=0.024). Significant advantages 
for vandetanib + docetaxel were also seen for objective response rate 
(17% vs 10%, 2-sided P<0.001) and TDS (HR 0.77, 97.5% CI 0.65–
0.92; 2-sided P<0.001; FACT-L Lung Cancer Subscale). Overall 
survival showed a positive trend for vandetanib + docetaxel that was 
not statistically significant (HR 0.91, 97.52% CI 0.78–1.07; 2-sided 
P=0.196). Exploratory clinical and molecular subgroup analyses for 
PFS and overall survival were generally consistent with the results 
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seen in all patients. The adverse event profile was consistent with that 
previously observed for vandetanib in NSCLC. Adverse events occur-
ring more frequently in the vandetanib arm included diarrhea (42% vs 
33%), rash (42% vs 24%), neutropenia (32% vs 27%) and hyperten-
sion (6.0% vs 1.7%). Nausea (23% vs 32%), vomiting (16% vs 21%) 
and anemia (10% vs 15%) were less frequent in the vandetanib arm. 
There was no increase in hemoptysis in patients receiving vandetanib. 
The incidence of protocol-defined QTc prolongation in the van-
detanib arm was 1.9%. 
Conclusions: Vandetanib is the first and only oral targeted therapy 
to show significant clinical benefits when added to chemotherapy in 
phase III studies in second-line advanced NSCLC. This randomized 
phase III study met its primary objective of PFS prolongation with 
vandetanib + docetaxel versus placebo + docetaxel. The vandetanib 
plus docetaxel arm also showed an improvement in objective re-
sponse rate and a delay in the deterioration of symptoms. 
C2.3 Anti-Angiogenics, Mon Aug 3, 10:30 - 12:00
Vandetanib versus erlotinib in patients with previously 
treated advanced NSCLC: a randomized, double-blind 
phase III trial (ZEST)
Natale, Ronald B.1; Thongprasert, Sumitra2; Greco, F Anthony3; 
Thomas, Michael4; Tsai, Chun-Ming5; Sunpaweravong, Patrapim6; 
Ferry, David 7; Langmuir, Peter8; Gogov, Sven9; Rowbottom, Jacqui 
A.9; Goss, Glenwood D.10
1 Cedars-Sinai Cancer Center, Los Angeles, CA, USA; 2 Maharaj 
Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, 
Thailand; 3 Sarah Cannon Research Institute, Nashville, TN, USA; 
4 University of Heidelberg, Heidelberg, Germany; 5 Taipei Veterans 
General Hospital, Taipei, Taiwan; 6 Prince of Songkhla University, 
Songkhla, Thailand; 7 New Cross Hospital, Wolverhampton, UK; 8 
AstraZeneca, Wilmington, DE, USA; 9 AstraZeneca, Macclesfield, 
UK; 10 Ottawa Hospital Cancer Center, Ottawa, ON, Canada
Background: Vandetanib (ZACTIMA™) is a once-daily oral anti-
cancer drug that selectively inhibits vascular endothelial growth fac-
tor receptor (VEGFR), epidermal growth factor receptor (EGFR) and 
RET (REarranged during Transfection) receptor tyrosine kinase activ-
ity. Vandetanib demonstrated antitumor activity as a monotherapy in a 
phase II study of patients with advanced NSCLC (Natale et al, J Clin 
Oncol, in press). This phase III study assessed whether vandetanib 
monotherapy prolonged progression-free survival (PFS) compared to 
erlotinib in patients with advanced, previously treated NSCLC. 
Methods: The primary objective of this randomized, double-blind, 
multicenter study was to show superiority in PFS for vandetanib ver-
sus erlotinib. Patients were randomized 1:1 to receive vandetanib 300 
mg/day or erlotinib 150 mg/day until progressive disease, unaccept-
able toxicity or withdrawal of consent. Secondary endpoints included 
overall survival, objective response rate (ORR), time to deteriora-
tion of disease-related symptoms (TDS) of pain, dyspnea and cough 
(assessed using the EORTC-QLQ-C30 questionnaire) and safety and 
tolerability. Eligibility criteria included stage IIIB/IV NSCLC, WHO 
performance status (PS) 0–2, and 1–2 prior cytotoxic chemotherapy 
regimens. Patients with squamous cell histology were eligible, and 
brain metastases were permitted if treated at least 4 weeks before 
study entry and clinically stable without steroid treatment for 10 days.
Results: A total of 1240 patients (mean age 61 years; 38% female; 
22% squamous cell histology; 84% stage IV NSCLC; 30%/58%/11% 
PS 0/1/2) were recruited from 160 centers in 22 countries between 2 
October 2006 and 30 November 2007. Patients were randomized to 
receive vandetanib (n=623) or erlotinib (n=617); baseline characteris-
tics were similar in both arms. The median duration of follow-up was 
14.0 months; 88% of patients had progressed and 67% had died at 
data cut-off (26 September 2008). There was no difference in PFS for 
patients treated with vandetanib compared with erlotinib (hazard ratio 
[HR] 0.98, 95.22% CI 0.87–1.10; 2-sided P=0.721), and no differ-
ence in the secondary endpoints of overall survival (HR 1.01, 95.08% 
CI 0.89–1.16; 2-sided P=0.830), ORR (12% in both arms) and TDS 
(pain: HR 0.96, 95% CI 0.83–1.11; 2-sided P=0.582; dyspnea: HR 
1.08, 95% CI 0.93–1.25; 2-sided P=0.333; cough: HR 0.94, 95% CI 
0.80–1.09; 2-sided P=0.402). A preplanned non-inferiority analysis 
for PFS and overall survival demonstrated equivalent efficacy for 
vandetanib and erlotinib. Exploratory clinical and molecular sub-
group analyses for PFS and overall survival did not demonstrate dif-
ferential benefits for vandetanib compared to erlotinib. The adverse 
events observed for vandetanib were generally consistent with previ-
ous NSCLC studies with vandetanib. There was a higher incidence 
of some adverse events (any grade) in the vandetanib arm, including 
diarrhea (50% vs 38%) and hypertension (16% vs 2%), whereas rash 
was more frequently observed in patients receiving erlotinib (38% 
vs 28%). The overall incidence of CTCAE grade ≥3 adverse events 
was also higher with vandetanib (50% vs 40%). The incidence of 
protocol-defined QTc prolongation in the vandetanib arm was 5%. 
Conclusions: While vandetanib demonstrated clear evidence of anti-
tumor activity, the study did not meet its primary objective of demon-
strating PFS prolongation with vandetanib versus erlotinib in patients 
with previously treated advanced NSCLC. However, vandetanib and 
erlotinib showed equivalent efficacy for PFS and overall survival in a 
preplanned non-inferiority analysis.
C2.4 Anti-Angiogenics, Mon Aug 3, 10:30 - 12:00
MO19390 (SAiL): hypertension in patients with 
advanced or recurrent non-squamous non-small cell lung 
cancer (NSCLC) receiving first-line bevacizumab plus 
chemotherapy
Thatcher, Nicholas1; Tsai, Chun-Ming2; Laskin, Janessa 3; Crinò, 
Lucio4; Pavlakis, Nick5; Garrido, Pilar6; Dansin, Eric7; Bearz, 
Alessandra8; Hirsh, Vera9; Griesinger, Frank10; on behalf of the 
MO19390 (SAiL) study group11
1 Christie Hospital, Manchester, UK; 2 Taipei Veterans General 
Hospital, Taipei, Taiwan; 3 BC Cancer Agency, Vancouver, BC, 
Canada; 4 Perugia Hospital, Perugia, Italy; 5 Royal North Shore 
Hospital (Sydney University), Sydney, Australia; 6 Hospital Ramon y 
Cajal, Madrid, Spain; 7 Centre Oscar Lambret, Lille, France; 8 CRO-
IRCCS, Aviano, Italy; 9 McGill University Health Centre, Montreal, 
QC, Canada; 10 Pius Hospital, Oldenburg, Germany; 11 UK
Background: First-line bevacizumab in combination with standard 
chemotherapy was evaluated since 2006 in an open-label, single-arm 
study (SAiL) in 2,267 patients with advanced NSCLC. 
Methods: Eligible patients had locally advanced, metastatic non-
squamous NSCLC and received first-line bevacizumab (7.5 or 15mg/
kg every 3 weeks) plus chemotherapy for up to six cycles, followed 
by bevacizumab alone until disease progression. Eligibility criteria 
included ECOG PS 0–2, no history of gross haemoptysis, no symp-
tomatic baseline CNS metastases or evidence of tumour invading ma-
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jor blood vessels, no uncontrolled hypertension (systolic >150mmHg 
and/or diastolic >100mmHg) or active cardiovascular disease at 
baseline. The primary endpoint was the incidence of serious adverse 
events (SAEs) related to bevacizumab, and AEs of special inter-
est, including hypertension. Bevacizumab was interrupted only in 
patients with persistent or symptomatic grade 3 hypertension and 
discontinued if blood pressure remained uncontrolled by medication. 
Bevacizumab was discontinued in patients with grade 4 hypertension.
Results: This analysis was based on 2,088 patients who received 
at least one dose of study medication (data cut-off 4 August 2008): 
median age was 59 and ECOG PS 0/1/2 (%) was 38/56/6. Patients 
received a median of 6.4 cycles of bevacizumab and 4.2 cycles of 
chemotherapy. A total of 1,779 (all grades) and 315 (grade ≥3) events 
of special interest were reported. Hypertension was a common event 
(all grades, 30.1%; grade ≥3, 4.8%). Antihypertensive medications 
at baseline included ACE inhibitors (11.3%), beta-blockers (10.8%), 
diuretics (8.2%), calcium channel blockers (7.8%) and angiotensin II 
receptor blockers (6.3%). 
Conclusions: The safety profile of bevacizumab in combination with 
first-line chemotherapy is consistent with that in previous NCSLC 
trials. The incidence of grade ≥3 hypertension was low. Updated data 
will be presented showing the incidence and management of hyper-
tension during bevacizumab therapy.
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MO19390 (SAiL): first-line bevacizumab-based therapy in 
advanced non-small cell lung cancer (NSCLC) – outcome 
by chemotherapy regimen
Laskin, Janessa 1; Crinò, Lucio2; Tsai, Chun-Ming3; Pavlakis, Nick4; 
Thatcher, Nicholas5; Dansin, Eric6; Griesinger, Frank7; Isla, Dolores8; 
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1 BC Cancer Agency, Vancouver, BC, Canada; 2 Perugia Hospital, 
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Essen, Germany; 10 UK
Background: MO19390 (SAiL) is an international, multicentre, 
open-label study evaluating the safety of first-line bevacizumab in 
combination with a range of standard chemotherapy regimens in 
2,267 patients. Reported here are safety data by chemotherapy regi-
men.
Methods: Eligible patients had non-squamous NSCLC not treated 
with prior chemotherapy, ECOG PS 0–2, no uncontrolled hyperten-
sion or active cardiovascular disease at baseline, no history of grade 
>2 haemoptysis, and no evidence of tumour abutting or invading 
major blood vessels. Patients received bevacizumab (7.5 or 15mg/kg 
every 3 weeks) with chemotherapy for up to six cycles, after which, 
patients with non-progressive disease continued bevacizumab until 
disease progression. The primary endpoint was safety; secondary 
endpoints included time to disease progression and overall survival.
Results: A total of 2,088 patients were available for this analysis 
(data cut-off 4 August 2008) and had received at least one dose of 
study medication. Patient characteristics: median age 59 years; male/
female (%) 60/40; ECOG PS 0/1/2 (%) 38/56/6; adenocarcinoma/
other (%) 86/14; stage IIIB/IV (%) 20/80. Chemotherapy regimens 
used included: carboplatin doublets/cisplatin doublets/non-platinum 
doublets/monotherapy (%) 49/39/0.6/2. The mean number of treat-
ment cycles was 6.4 for bevacizumab and 4.2 for chemotherapy. 
A total of 1,166 serious adverse events (SAE) were reported, 24% 
of which were deemed to be associated with bevacizumab. The 
frequency of AEs (grade 3–5) of special interest by chemotherapy 
regimen is shown in Table 1; no significant differences were observed 
between the carboplatin doublets and cisplatin doublets treatment 
groups. Efficacy data were not mature.
Conclusions: These data from over 2,000 patients confirm the well-
characterised safety profile of bevacizumab when combined with a 
range of chemotherapy regimens for first-line treatment of NSCLC. 
Preliminary efficacy and updated safety data will be presented.
 Grade 3–5 AEs of  Carboplatin Cisplatin  Mono- Other  
 special interest n (%) doublets doublets chemotherapy combinations* 
  (Total events=132) (Total events=146) (Total events=9) OR switched 
     chemotherapy 
     (Total events=28)
 Hypertension  33 (25) 40 (27.4) 4 (44.4) 9 (32.1)
 Gastrointestinal perforations  13 (9.8) 6 (4.1) 0 (0) 1 (3.6)
 All thromboembolic events  55 (41.7) 69 (47.3) 2 (22.2) 15 (53.6)
 Congestive heart failure  4 (3.0) 2 (1.4) 2 (22.2) 0 (0)
 Any bleeding  27 (20.5) 24 (16.4) 0 (0) 2 (7.1)
 Epistaxis  12 (9.1) 9 (6.2) 0 (0) 1 (3.6)
 CNS bleeding‡ 0 (0) 1 (0.7) 0 (0) 1 (3.6)
*Including non-platinum doublets; ‡Cerebral haemorrhage
C2.6 Anti-Angiogenics, Mon Aug 3, 10:30 - 12:00
MO19390 (SAiL): safety and efficacy of first-line 
bevacizumab plus chemotherapy in elderly patients with 
advanced or recurrent non-squamous non-small cell lung 
cancer (NSCLC)
Griesinger, Frank1; Pavlakis, Nick2; Garrido, Pilar3; Dansin, Eric E.4; 
Crinò, Lucio5; Thatcher, Nicholas6; Laskin, Janessa 7; Zhou, Caicun8; 
Kohlhäufl, Martin J.9; Tsai, Chun-Ming10; on behalf of the MO19390 
(SAiL) study group11
1 Pius-Hospital, Oldenburg, Germany; 2 Royal North Shore Hospital 
(Sydney University), Sydney, Australia; 3 Hospital Ramon y Cajal, 
Madrid, Spain; 4 Centre Oscar Lambret, Lille, France; 5 Perugia 
Hospital, Perugia, Italy; 6 Christie Hospital, Manchester, UK; 7 BC 
Cancer Agency, Vancouver, Canada; 8 Shanghai Pulmonary Hospital, 
Shanghai, China; 9 Klinik Schillerhöhe, Stuttgart, Germany; 10 Taipei 
Veterans General Hospital, Taipei, Taiwan; 11 UK
Background: MO19390 (SAiL) is an international, open-label, 
single-arm study evaluating the safety of first-line bevacizumab plus 
standard chemotherapy in patients (n=2,267) with advanced NSCLC. 
Data were analysed to assess the safety and preliminary efficacy in 
elderly (>65 years) patients.
Methods: Patients with locally advanced, metastatic non-squamous 
NSCLC received up to six cycles of bevacizumab (7.5 or 15mg/kg 
every 3 weeks) plus chemotherapy. Non-progressing patients con-
tinued bevacizumab as single-agent therapy until disease progression 
or unacceptable toxicity. Key eligibility criteria included: ECOG PS 
of 0–2; no history of haemoptysis and no symptomatic baseline CNS 
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metastases or evidence of tumour invading major blood vessels. The 
primary endpoint was safety. Secondary endpoints included time to 
disease progression and overall survival.
Results: A total of 549 patients >65 years (median 70 years) and 
1,459 patients ≤65 years (median 56 years) were evaluable for safety 
analysis (data cut-off 2 July 2008). Patients >65 years were: male 
62.7%; ECOG PS 0/1/2 (%) 33/61/6; adenocarcinoma/large cell (%) 
84/8; received carboplatin doublets/cisplatin doublets/non-platinum 
doublets/monotherapy/other (%) 54/32/1/4/8. The mean number of 
cycles of bevacizumab and chemotherapy was 5.5 and 3.7 for patients 
>65 years and 6.3 and 4.2 for patients ≤65 years, respectively. 30.8% 
of patients aged ≤65 years experienced a serious adverse event (SAE) 
of any grade compared with 36.8% of patients aged >65 years. Most 
SAEs in patients >65 years (71.3%) and ≤65 years (75.8%) resolved 
or improved. A relatively low proportion of AEs (any grade) of 
special interest was observed in both age groups (Table 1). The fre-
quency of AEs of special interest in both age groups was comparable 
across all chemotherapy regimens. 
Conclusions: Patients >65 years do not appear to be at increased risk 
of experiencing an AE of special interest when treated with first-line 
bevacizumab-based therapy compared with patients ≤65 years. Ef-
ficacy and updated safety data will be presented.
   Events, n (%)  
 Patients aged >65 years  Patients aged ≤65 years 
 (n=549) (n=1,459) 
  All grades Grade ≥3 All grades Grade ≥3
 AEs of special interest*  533 (100) 255 (100) 1,443 (100) 554 (100)
 Hypertension  147 (27.6) 1 (0.4) 340 (23.6) 6 (1.1)
 Proteinuria  111 (20.8) 0 (0) 276 (18.9) 1 (0.2)
 Gastrointestinal perforation 6 (1.1) 5 (2.0) 18 (1.2) 15 (2.7)
 Wound-healing complications  6 (1.1) 0 (0) 12 (0.8) 2 (0.4)
 Embolism‡ 48 (9.0) 24 (9.4) 155 (10.7) 72 (13.0)
 Congestive heart failure 20 (3.8) 1 (0.4) 43 (3.0) 2 (0.4)
 Any bleeding  195 (36.6) 13 (5.1) 599 (41.5) 18 (3.2)
 CNS bleeding§ 2 (0.4) 2 (0.8) 2 (0.1) 1 (0.2)
 Haemoptysis** 28 (5.3) 1 (0.4) 84 (5.8) 7 (1.3)
*Patients may have experienced multiple events; ‡All thromboembolic events; §Cerebral haemor-
rhage/haematoma; **Haemoptysis and pulmonary haemorrhage
C2.7 Anti-Angiogenics, Mon Aug 3, 10:30 - 12:00
Preliminary safety and effectiveness of bevacizumab- (BV) 
based treatment in subpopulations of patients with non-
small cell lung cancer (NSCLC) from the ARIES study: a 
BV treatment observational cohort study (OCS)
Fischbach, Neal1; Spigel, David R.2; Brahmer, Julie3; Robles, 
Robert4; Teng, Siew L.5; Wang, Lisa5; Sing, Amy P.5; Lynch, 
Thomas6; ARIES Investigators, for the5
1 Oncology Associates of Bridgeport, PC, Fairfield, CT, USA; 2 Sarah 
Cannon Research Institute, Nashville, TN, USA; 3 Dept. of Oncology, 
Johns Hopkins Medical School, Baltimore, MA, USA; 4 Diablo Valley 
Oncology and Hematology Medical Group, Inc., Pleasant Hill, 
CA, USA; 5 Genentech, Inc., South San Francisco, CA, USA; 6 Yale 
Cancer Center, New Haven, CT, USA
Background: Phase III trials have shown that BV (Avastin®), an 
anti-vascular endothelial growth factor monoclonal antibody, pro-
longs progression-free and overall survival in patients with advanced 
NSCLC. These trials had strict eligibility criteria, resulting in exclu-
sion or underrepresentation of certain patient subpopulations that are 
commonly treated in the general community, making it difficult to es-
tablish BV treatment decisions in these patients. In the pivotal E4599 
study underrepresented patients included: older patients (in the BV 
arm median age was 63.0 years, and 14% of patients were ≥75 years), 
patients with brain metastases (0%), patients with ECOG PS ≥2 (0%), 
and patients on full dose therapeutic anticoagulation (0%). 
The ARIES OCS was initiated to further define clinical outcomes 
associated with BV treatment among a broad population of NSCLC 
patients in a real-world setting. ARIES will permit examination of 
treatment benefit and toxicity in patient subpopulations that could not 
be adequately studied in traditional randomized clinical trials (RCTs), 
including the elderly, patients with poor PS, patients with brain me-
tastases, and patients receiving concurrent anticoagulants (AC).
Methods: Patients with advanced NSCLC who are receiving a BV-
containing, 1st-line regimen are eligible to enroll in ARIES; 257 sites 
are enrolling patients; a total of 2000 patients is expected. There are 
no protocol-specified treatments or assessments. Data is collected at 
baseline, then quarterly, including targeted adverse events (AEs) and 
BV-related serious AEs (SAEs). Descriptive analyses will summarize 
clinical outcomes in patient subpopulations. 
Results: As of 9/15/08, 1518 NSCLC patients had enrolled; median 
follow-up time was 7.5 months. Key baseline characteristics includ-
ed: 65 years median age; 300 patients (20% ) ≥75 yrs; 10% ECOG 
PS ≥2; 8% with known brain metastasis; 5% on therapeutic AC. The 
most common 1st-line chemotherapy regimen was carboplatin/pa-
clitaxel (63.5%). 
Among the 101 patients who entered the study with brain metastases, 
no (0%) CNS hemorrhage events had been reported as of the data 
cut. Other key safety outcomes and cohort size of subpopulations are 
shown in the Table:
 Patients Experiencing All Patients 75 Years ECOG Therapeutic  
  Targeted AEs   or Older PS ≥2 AC 
  (n=1518) (n=300) (n=150) (n=77)
 Bleeding Events (Grade 3-5), n (%) 45 (3.0) 4 (1.3) 5 (3.3) 1 (1.3)
  CNS Hemorrhage, n (%) 1 (0.1) 0 0 1 (1.3)
  GI Hemorrhage, n (%) 17 (1.1) 2 (0.7) 3 (2.0) 0
  Severe Pulmonary Hemorrhage, n (%) 11 (0.7)a 1 (0.3) 2 (1.3) 0
 Serious Arterial Thromboembolic Events, n (%) 21 (1.4) 8 (2.7) 4 (2.7) 2 (2.6)
 aOne patient experienced 2 severe pulmonary hemorrhage events   
Conclusions: Based on an interim analysis of NSCLC patient 
subpopulations in ARIES that are generally excluded or under-
represented in RCTs for BV (the elderly, poor PS ≥2, known brain 
metastasis, or on therapeutic AC), the safety of BV in these patient 
subpopulations is generally consistent with previously reported safety 
results from RCTs. Updated outcomes analyses will be presented at 
the meeting for >1600 patients and specific subpopulations.
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Peptides and recombinant proteins as strategy for 
targeting Notch3 in lung cancer
Lin, Luping; Yi, Fuming; Blum, David; Mernaugh, Ray; Carbone, 
David P.; Dang, Thao P.
Vanderbilt University Medical Center, Nashville, TN, USA
Notch signaling is an important pathway for cell-fate determina-
tion during embryonic development of multi-cellular organisms. 
Moreover, Notch receptors have been implicated in many types of 
human cancer. Notch3 is expressed in about 40% of lung cancers, 
and inhibiting this pathway resulted in tumor suppression in vitro and 
in vivo. Previous mutational studies, involving deletions of several 
EGF-like repeats in the extracellular domain of Notch receptors, have 
given some insights into a potential ligand-binding site, but the exact 
domain for Notch3-ligand interaction is not well known. Using a 
library of 155 peptides representing the entire extracellular domain 
of Notch3, we screened these peptides for their ability to induce 
apoptosis. Six peptides were found to have pro-apoptotic activity. 
The sequences of the peptides were localized to two distinct regions 
within the extracellular domain of Notch3, the EGF-like repeats 7-10 
and 21-22. Several lines of evidence, including the reduced expres-
sion of Notch3-dependent gene Hey1 after peptides treatment, sug-
gested that the observed, apoptotic change was Notch3-dependent. 
We also showed direct binding of these peptides to Jagged1, a Notch 
ligand, suggesting that the affect on apoptosis by these peptides is 
through the disruption of Notch3 and Jagged1 interaction. Finally, 
similar affect on apoptosis and Notch3 signaling was observed when 
Notch3 EGF7-10:Fc-fusion and EGF21-22:Fc-fusion proteins were 
used. Furthermore, using xenograft models, we demonstrated that 
the Notch3 Fc-fusion proteins suppressed tumor growth in vivo. In 
summary, our data indicated that EGF-like repeats 7-10 and 21-22 are 
necessary for ligand binding and Notch3 activation, an observation 
that has not been made previously. This observation thus can serve as 
a basis for Notch3-targeted, therapeutic development in lung cancer.
C3.2 Cancer Pathways and Biomarkers, Mon Aug 3, 10:30 - 12:00
Frizzled 8 activation by Wnt-2 and synergistic up-
regulation in lung cancer
Bravo, Dawn T.1; You, Liang1; He, Biao 1; Xu, Zhidong1; Okamoto, 
Junichi 2; Hung, Ming-Szu 3; Yagui-Beltran, Adam 1; Clement, 
Genevieve 1; Shi, Yihui 3; Ramamoorthi, Kartik 4; Hirata, Tomomi 1; 
Jablons, David M.1
1 Thoracic Oncology Laboratory, Department of Surgery, Helen 
Diller Family Comprehensive Cancer Center University of 
California, San Francisco, San Francisco, CA, USA; 2 Department 
of Surgery, Division of Thoracic Surgery, Nippon Medical School, 
Tokyo, Japan; 3 Stanford Research Institute (SRI) International, 
Menlo Park, CA, USA; 4 McGovern Institute for Brain Research, 
Massachusetts Institute of Technology, Cambridge, MA, USA
Background: Aberrant activation of the Wnt pathway has been dem-
onstrated in numerous cancers, including lung cancer. The canonical 
Wnt signaling pathway regulates the stability of β-catenin, the key 
signaling component of the pathway. When activated, β-catenin en-
ters the nucleus and activates TCF/LEF transcription factors inducing 
the expression of target genes, many implicated in cancer. There are 
19 known mammalian Wnt genes. Receptors for the Wnt proteins 
are members of the Frizzled (Fzd) family of receptors. Currently, 
10 Fzd proteins have been identified in mammals. Transduction of 
Wnt signaling begins with Wnt ligands binding to Fzd receptors at 
the cell membrane. Knowledge regarding the regulation of specific 
Wnts and their corresponding receptors in lung cancer is lacking. It 
is not known in great detail which receptors are selectively expressed 
or the roles they play in the pathogenesis of lung cancer. Therefore, 
we sought to investigate specific Wnt/Frizzled interactions that are 
activated in lung cancer.
Methods: Cell lines 293, 293T and NSCLC cell line A549 were 
transfected with each of the Frizzled receptor constructs together 
with Wnt2. Lipofectamine 2000 was used to mediate co-transfection 
of pTOPflash or pFOPflash vectors in the TOPflash assay. Western 
blot analysis of cytosolic proteins was performed with antibodies to 
β-catenin. Lung tumor tissues and adjacent normal lung tissues from 
patients were collected and snap-frozen in liquid nitrogen. Total RNA 
from lung cancer cell lines, fresh lung cancer, and paired adjacent 
normal tissue were isolated and relative mRNA levels determined 
by quantitative and semi-quantitative reverse transcription-PCR 
respectively.
Results: Wnt-2 overexpression has been demonstrated in many can-
cers, but the specificity of the Wnt-2 interaction with its receptor(s) 
remains largely unknown. We therefore investigated Wnt-2 specifi-
city by analyzing the abilities of Frizzled receptors to induce T cell 
factor (TCF)-dependent transcription in the presence of Wnt-2. When 
Wnt-2 was coexpressed with each of the Frizzled receptors in 293T 
cells, TCF activity of Fzd8 increased by ~25 fold over that of vector 
alone. Wnt-2 activation of Fzd8 was also demonstrated in 293 and 
A549 cells. Wnt pathway activation was confirmed by western blot 
analysis. Analysis of 50 freshly resected lung cancer tumor samples 
together with their corresponding matched normal lung pairs showed 
Wnt-2 up-regulation by 70% and Fzd8 up-regulation by 42% in 
tumor samples. Furthermore, when the expression patterns of Wnt-2 
were compared with those for Fzd8, 91% of the Fzd8 lung cancer 
tumor samples demonstrating up-regulation showed concomitant up-
regulation of Wnt-2.
Conclusions: The results described here demonstrate the first re-
ported interaction between Wnt-2 and Fzd8. This interaction activates 
the Wnt/β-catenin pathway and induces TCF-dependent transcription 
in 293 cells and in NSCLC cell line A549. Analysis of 50 freshly re-
sected tumor samples with their corresponding matched normal lung 
controls demonstrated up-regulation of Fzd8 and concomitant up-
regulation in most tumor samples in which Wnt-2 was overexpressed. 
Together, our findings demonstrate a novel Fzd8/Wnt-2 interaction 
and up-regulation of Fzd8 in lung cancer tissues. The frequent inci-
dence of this apparent interaction in lung cancer samples signifies a 
potential therapeutic target in lung cancer. 
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RASSF1/hippo pathway molecular dissection in patients 
with resectable non-small cell lung cancer (NSCLC) 
treated by perioperative chemotherapy (CT) in the phase 
III trial IFCT-0002
Zalcman, Gerard1; Levallet, Guenaëlle1; Do, Hongdo2; De Fraipont, 
Florence3; Mounawar, Mounia4; Beau-Faller, Michèle5; Bergot, 
Emmanuel1; Morin, Franck6; Creveuil, Christian1; Dobrovic, 
Alexander2; Hainaut, Pierre4; Milleron, Bernard7
1 Caen University Hospital, Caen, France; 2 Peter McCallum Cancer 
Center, Melbourne, Australia; 3 Grenoble University Hospital, 
Grenoble, France; 4 International Agency for Research on Cancer 
(IARC), Lyon, France; 5 Strasbourg University Hospital, Strasbourg, 
France; 6 Intergroupe Francophone de Cancérologie Thoracique 
(IFCT), Paris, France; 7 Tenon University Hospital, Paris, France
Background: The IFCT-0002 phase 3 trial compared two timings of 
CT in resectable lung cancer, all before surgery (PRE) versus PERIo-
perative, and two platinum-based regimens, with either Gemcitabine 
or Paclitaxel. In a subset of 208/528 (42%) randomized patients with 
snap-frozen surgical specimens, we reported that RASSFIA promoter 
gene methylation on 3p21 gene was an independant prognostic factor. 
The RASSF1A pathway is a highly conserved signaling pathway 
from Drosophila to man, downstream of RTK-induced Ras activation. 
Eight RASSF genes have been described encoding proteins able to 
heterodimerize, with some of those dimers (RASSF1A/RASSF5A) 
connecting activated K-Ras with MST (hippo) kinases. Downstream 
effectors regulate death-receptor mediated apoptosis, G1/S transi-
tion, and tubulin cytoskeleton remodeling. Several of the RASSF1A 
pathway genes have been reported to be altered in human cancers. 
Therefore, we systematically looked in the Bio-IFCT 0002 NSCLC 
bio-bank, for gene alterations in this pathway. 
Methods: Molecular alterations in the RASSF1A pathway were 
evaluated in 208 patients with snap-frozen tissue collected at the 
time of surgery. EGFR mutations, gene amplification and intron 1 
polymorphism, RASSF1A gene A133S polymorphism, 3p LOH, K-
Ras mutations, RASSF2A, NORE1A/RASSF5, MST/hippo, LATS1 
& 2 promoter gene methylation, along with p53 mutations were 
analyzed. Survival rates were estimated with the use of the Kaplan-
Meier method. Only prognostic values of gene alterations showing 
a p value of less than 0.2 in univariate analysis were included in the 
adjusted Cox multivariate model. p values were corrected according 
to the Bonferroni-Holm method for multiple-hypothesis testing, and 
all reported p values were two-sided. 
Results: EGFR-mutations were detected in 7.9% of specimens. 
Q-PCR identified EGFR gene amplification in 14.8% of specimens. 
The EGFR intron 1 polymorphism was found in 47% of the analyzed 
DNAs. K-Ras codons 12 or 13 mutations were shown in 19.9% of 
patients. RASSF2A promoter gene methylation was detected in 24% 
of patients whereas the RASSF1A methylation frequency was 21.8%. 
The S allele of the A133S RASSF1A polymorphism was detected 
in 10.5% of patients. 3p21 LOH was detected in 55.7% of patients. 
NORE 1A, MST1/2 (hippo), LATS1/2 promoter gene methylation 
only involved 2.5% of specimens. The frequency of P53 mutations, 
as detected by genomic sequencing, was 27.6%. RASSF1A gene 
methylation was significantly associated with RASSF2A methylation 
(chi2 test, p= 0.018) and 3pLOH (chi2 test, p=0.0094). RASSF1A 
gene methylation and RASSF1A polymorphism were not mutually 
exclusive, since both alterations could be encountered in seven 
tumors. RASSF1A as RASSF2A gene methylation were interest-
ingly both associated with p53 mutations (respectively p=0.0068 
and p=0.032). Among all those alterations of the RASSF1A/hippo 
pathway, only RASSF1A gene methylation and 3p LOH predicted a 
significantly worse overall survival in univariate analysis, but only 
RASSF1A remained independantly associated with survival in the 
adjusted multivariate model. 
Conclusions: This is the first systematic analysis of RASSF1A/hippo 
pathway molecular alterations in early lung cancer. Association of 
RASSF1A promoter methylation and 3pLOH confirms the need for 
cancer cells to inactivate both RASSF1A alleles. The significant as-
sociation of RASSF1 and 2 methylation with p53 mutations, suggests 
the need for cancer cells to inactivate both p53-dependent and p53 in-
dependent apoptosis pathways. However, RASSF1A epigenetic silen-
cing by promoter methylation remains the only prognostic biomarker 
in this series of patients, emphazising the central role of RASSF1A, 
as a scaffold protein connecting essential signaling pathways for lung 
cancer cell survival and proliferation.
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BRF2 is a lineage specific oncogene amplified early in 
squamous cell lung cancer development
Lockwood, William W.1; Chari, Raj1; Coe, Bradley P.1; Garnis, 
Cathie1; Campbell, Jennifer1; Williams, Ariane C.1; Thu, Kelsie L.1; 
Malloff, Chad A.1; Hwang, Dorothy1; Zhu, Chang Q.2; Buys, Timon 
P.1; Yee, John3; English, John3; MacAulay, Calum1; Tsao, Ming S.2; 
Gazdar, Adi F.4; Minna, John D.4; Lam, Stephen1; Lam, Wan L.1
1 British Columbia Cancer Research Centre, Vancouver, BC, Canada; 
2 Ontario Cancer Institute/Princess Margaret Hospital, Toronto, ON, 
Canada; 3 Vancouver General Hospital, Vancouver, BC, Canada; 4 
UT Southwestern Medical Center, Dallas, TX, USA
Background: Squamous cell carcinoma (SqCC) and adenocarcin-
oma (AC) are the predominant lung cancer subtypes. Currently, they 
are regarded as a single disease entity in terms of systemic therapy. 
However, SqCC and AC display distinct development and progres-
sion characteristics probably related to the specific cell lineages 
from which they develop, which in turn affect the range of genetic 
alterations required for tumor initiation in a lineage restricted man-
ner. Identification of molecular differences between the tumor types 
will have a significant impact in designing novel therapies that can 
improve treatment outcome. 
Objective and Rationale: DNA amplification is thought to arise 
from the selection of genes that promote tumor growth. The specific 
requirements for tumorigenesis in different cell lineages may 
therefore be associated with selection of different amplicons. Copy 
number increase of 8p12-p11.21 is one of the most frequent focal 
changes in NSCLC occurring in 9-35% of cases, with amplification 
present in 3-8% of cases. These frequencies rival those of established 
NSCLC oncogenes such as MYC (~6%) and EGFR (~3%). The study 
objective is to determine the specificity of the 8p amplicon in order 
to discover novel oncogenes restricted to tumorigenesis in individual 
NSCLC cell lineages.
Methods: Tiling-path CGH array profiles of 103 AC, 58 SqCC 
tumors and 20 carcinoma in situ lesions were generated. Frequen-
cies of alteration for each locus on 8p were compared between AC 
and SqCC using Fisher’s Exact Test and regions with difference of 
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p≤0.01 were considered statistically significant. Genomic data was 
then integrated with expression data to identify genes deregulated as 
a result of copy number alterations specific to each NSCLC subtype. 
Quantitative RT-PCR and immunohistochemistry were performed to 
validate results from microarray experiments and cell models were 
utilized to confirm the functional significance of identified genes. 
Results: We discovered that 8p amplification is a SqCC specific 
genetic event in lung cancer. Copy number increase of focal regions 
at 8p12-p11.21 was found in up to 40% of SqCC tumors, while DNA 
loss was the most prevalent event in AC (~39%). In addition, high 
level amplification was present in ~12% of SqCC samples (7/58) 
demonstrating the preferential selection for this alteration in tumors 
of this cell lineage. Integrative genetic analyses of multiple independ-
ent cohorts of clinical tumor samples identified the overexpression of 
BRF2, a RNA polymerase III (Pol III) transcription initiation factor, 
as the result of increased gene dosage in SqCC. Ectopic expression 
of BRF2 in human bronchial epithelial cells induced a transformed 
phenotype and demonstrated downstream oncogenic effects, while 
siRNA mediated knockdown suppressed growth of cells overexpress-
ing BRF2. Frequent expression of BRF2 in pre-invasive bronchial 
CIS and dysplastic lesions provides evidence that BRF2 activation is 
an early event in cancer development of this cell lineage. 
Conclusions: Our data suggest that activation of BRF2 represents a 
novel mechanism of lung tumorigenesis through the increase of Pol 
III mediated transcription. Targeted activation of this gene in lung 
SqCC suggests that it may be an excellent candidate for new treat-
ment strategies tailored to this NSCLC subtype.
Support: CIHR, Genome Canada, NCI SPORE Grant P50CA70907
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Bortezomib resistance in mesothelioma is associated with 
NOXA downregulation: reversal by the MCL-1 antagonist 
obatoclax 
Chacko, Alex D.1; Busacca, Sara2; Barbone, Dario3; Crawford, 
Nyree1; Al Rashid, Shahnaz 1; Bertino, Pietro2; Mutti, Luciano4; 
Gaudino, Giovanni2; Broaddus, V. C.3; Fennell, Dean A.1
1 Queen’s University Belfast, Centre for Cancer Research and Cell 
Biology, Belfast, UK; 2 DISCAFF University of Piemonte orientale 
“A.Avogadro”, Novara, Italy; 3 Lung Biology Center, University of 
California, San Francisco, CA, USA; 4 Lab. di Oncologia Clinica, 
Borgosesia, Italy
Background: We previously reported that bortezomib (bz) shows 
promising activity in vitro and in vivo preclinical models of meso-
thelioma (1), resulting in two International multicentre clinical trials, 
ICORG 05-10 and EORTC 08052. Bz is known to induce cell death 
via regulation of the BCL-2 family (2). However, the molecular 
determinants of sensitivity and resistance to bortezomib in mesotheli-
oma are unknown warranting analysis of its proapoptotic pharmaco-
dynamics in the sensitive and resistant settings.
Results: We observed the induction of mitochondrial apoptosis in bz-
sensitive REN cells with activation of the proapoptotic BCL-2 family 
regulator BAK, mitochondrial cytochrome C release, caspase 3 (but 
not caspase 8) activation, and cell surface phosphatidylserine expos-
ure. MPP89 cells exhibited log-fold resistance to bz. Upregulation of 
the proapoptotic BH3-only protein NOXA occurred in bz-sensitive 
REN cells and xenografts but not in bz-resistant MPP89. When 
grown as 3D cultures (spheroids), REN acquired marked resistance to 
bz despite evidence of proteasome inhibition. Resistance was associ-
ated with loss of NOXA. Knockdown of NOXA using siRNA in REN 
inhibited bortezomib-induced death. Despite the lack of bz-induced 
NOXA upregulation in MPP89 cells, direct targeting of MCL-1/A1 
with either exogenous BH3NOXA domain which inhibits MCL-1, 
or obatoclax (obx) a novel small molecule MCL-1 antagonist (3), 
reduced viability of MPP89 cells and synergized with bz. REN cells 
were then selected for resistance to bz (bzR-REN). Compared to the 
parental cells, they exhibited transformation to spindle-like morphol-
ogy, failed to exhibit caspase activation or BAX oligomerization, and 
were cross-resistant with cisplatin. NOXA was not upregulated by bz 
in bzR-REN cells, however, obx potentiated bz suggesting suscept-
ibility to MCL-1 antagonism. 
Conclusion: NOXA is a critical tumour suppressor which accounts 
for bz efficacy in mesothelioma and is not upregulated in models 
of bz resistance. Antagonism of MCL-1 substitutes for this loss of 
NOXA and can be accomplished by obx. We propose that obx plus 
bz is a rational combination to overcome resistance in mesothelioma 
warranting a combination trial of these agents in the second line set-
ting. 
References: 
1. Sartore-Bianchi et al, Clin Cancer Res 2007;13(19):5942-51.
2. Fennell DA et al, Oncogene 2008;27(9):1189-97.
3. Nguyen M et al, Proc Natl Acad Sci U S A 2007;104(49):19512-7.
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Neutrophil gelatinase associated lipocalin (NGAL) 
contributes to erlotinib resistance in non-small cell lung 
cancer (NSCLC)
Cui, Xiaoyan; Li, Zhu; Krysan, Kostyantyn; Luo, Jie; Gardner, Brian; 
Sharma, Sherven; Dubinett, Steven M.
UCLA, Los Angeles, CA, USA
Background: Deregulated EGFR signaling is common in non-small 
cell lung cancer (NSCLC). This discovery has led to the develop-
ment of tyrosine kinase inhibitors (TKIs), such as erlotinib, that are 
highly effective in a subset of NSCLC. Prospective trials have shown 
a response rate of 70% to 75% for patients with tumors harboring 
activating EGFR mutations. These studies indicate, however, that 
approximately another 30% of the patients are intrinsically resist-
ant to EGFR TKI although their tumors harbor activating mutations 
in EGFR. In addition, even those patients who show a significant 
response to initial treatment also develop, almost without excep-
tion, acquired resistance to the EGFR TKI. Many but not all of these 
patients who develop resistance have secondary EGFR mutations 
leading to resistance. 
Methods and Results: We developed several erlotinib resistant 
cell lines by growing the initially moderately sensitive cells in the 
presence of increasing concentrations of erlotinib. Gene expression 
profiling analysis (Affymetrix U133 Plus 2.0 Array) was performed 
to compare the parental and erlotinib-resistant cell lines. Neutrophil 
gelatinase associated lipocalin (NGAL, also named lipocalin-2) 
was upregulated more than 200 fold in resistant cells. Western blot 
confirmed this result. To study the potential role of NGAL in erlotinib 
resistance, we established two stable NGAL overexpressing NSCLC 
cell lines, H441NGAL and H3255NGAL. Both cell lines were more 
resistant to erlotinib-induced apoptosis than control cell lines. The 
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proapoptotic protein Bim was decreased and ERK1/2 phosphoryla-
tion was increased in both NGAL overexpressing cell lines. Knock-
down of Bim expression by siRNA decreased apoptosis sensitivity, 
suggesting NGAL-mediated erlotinib resistance was Bim-dependent. 
Erlotinib treatment inhibited ERK1/2 phosphorylation and induced 
Bim expression, however, this induction was attenuated in both 
NGAL overexpressing cell lines. Treatment with a proteosome 
inhibitor increased Bim protein level, and the increase was more pro-
nounced in NGAL overexpressing cell lines, suggesting that NGAL 
may promote Bim degradation via the ubiquitin-proteosome pathway 
in an ERK1/2 phosphorylation-dependent manner. In SCID mice, 
tumors derived from H3255NGAL cells were significantly more 
resistant to erlotinib-induced growth inhibition compared to those de-
rived from control cells. In patients with late stage NSCLC receiving 
erlotinib, serum NGAL levels were higher in patients with progres-
sive disease than in patients with stable disease or partial response. 
Conclusion: Our results suggest that NGAL could contribute to 
erlotinib resistance by decreasing Bim expression and increasing 
apoptosis resistance in NSCLC. 
C3.7 Cancer Pathways and Biomarkers, Mon Aug 3, 10:30 - 12:00
Two-hit integrated screening identifies a novel tumour 
suppressor candidate in a lung cancer susceptibility locus
Wilson, Ian M.; Buys, Timon P.; Chari, Raj; Lam, Stephen; Lam, 
Wan L.
British Columbia Cancer Research Centre, Vancouver, BC, Canada
Background: Tumour suppressor genes (TSGs) involved in non-
small cell lung cancer (NSCLC) are known to be disrupted by dif-
ferent genetic alterations (e.g. deletion and mutation) and epigenetic 
alterations (e.g. CpG island hypermethylation). Although each 
tumour may harbour many genes that are deleted or hypermethylated, 
those affected by both types of alteration are most interesting as TSG 
candidates since they exhibit classic Knudsonian two-hit inactivation. 
Global approaches to analyzing these different levels of molecular 
down-regulation have recently become available and are readily 
applied to NSCLC. TSG candidates identified by this powerful ap-
proach will yield insight into disease biology and be useful for early 
disease diagnosis, particularly since DNA methylation marks may be 
detectable in sputum and bronchial cells before presentation of overt 
neoplastic disease.
Objective: The primary goal of this study is to identify novel TSGs 
in lung adenocarcinomas using a two-hit integrated screen that high-
lights genes silenced by both DNA hypermethylation and deletion.
Methods: Lung adenocarcinomas from 29 patients were obtained at 
time of resection along with matched histologically normal lung par-
enchyma. Following pathology review, tumour cells were isolated by 
microdissection. DNA and RNA were extracted from both the tumour 
and the matched lung parenchyma tissues. Copy number status was 
determined for tumours using v3.0 of the British Columbia Cancer 
Research Centre whole-genome tiling path array. DNA methylation 
status was determined for tumour and parenchyma DNA at >27000 
loci using the Illumina Infinium assay. Gene expression profiles for 
the 29 samples were generated using the Agilent 44k expression 
microarray, and additional profiles were generated for exfoliated 
bronchial epithelia using Affymetrix GeneChips. DNA deletions were 
defined using a computational smoothing and segmentation algorithm 
(aCGH Smooth). Hypermethylated genes were identified by examin-
ing the difference between tumour and normal methylation levels at 
each locus and flagging those where methylation was at least 25% 
higher in the matched tumour specimen. Combined analysis of DNA 
copy number and methylation data in each tumour flagged two-hit 
regions of alteration. The frequency of two-hit alteration was then 
calculated for each gene across all analyzed samples. Those twice-hit 
genes altered in ≥15% of samples were selected for further investi-
gation. This included analysis of mRNA expression in two separate 
gene-expression data sets and validation of DNA hypermethylation 
by methylation-specific PCR (MSPCR).
Results: Our analysis identified 38 twice-hit genes in our panel 
of lung adenocarcinomas. Of these, ten were significantly under-
expressed in matched tumour specimens (corrected p≤0.05). Further 
examination of these genes in unrelated gene-expression data 
sets showed that two genes in particular were under-expressed in 
adenocarcinomas relative to normal bronchial epithelium samples 
(corrected p≤0.05). Interestingly, one of these genes is located at 
chromosome 6q23, a region previously identified as a lung cancer 
susceptibility locus. DNA methylation of this gene was validated by 
MS-PCR in our original sample panel as well as in 16 lung cancer 
cell lines. Validation of this gene’s functional role in tumourigenesis 
is ongoing.
Conclusion: Two-hit analysis based on integration of different 
genetic and epigenetic data is a powerful means of identifying critical 
TSGs for NSCLC.
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Outcomes after repeated resection for recurrent 
pulmonary metastasis of colorectal cancer
Park, Joon Suk1; Kim, Hong Kwan 1; Choi, Yong Soo 1; Kim, 
Kwhanmien1; Shim, Young Mog 1; Kang, Won Ki 2; Park, Young Suk 
2; Chun, Ho-Kyung 3; Lee, Woo-Yong 3; Kim, Jhingook 1
1 Department of Thoracic and Cardiovascular Surgery, Samsung 
Medical Center, Sungkyunkwan University School of Medicine, Seoul, 
Korea; 2 Division of Hematology Oncology, Department of Medicine, 
Samsung Medical Center, Sungkyunkwan University School of 
Medicine, Seoul, Korea; 3 Department of Surgery, Samsung Medical 
Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Background: Metastasectomy is a standard treatment for pulmonary 
metastasis of colorectal cancer. However, it remains controversial 
whether it is still feasible and effective for patients who develop a 
pulmonary recurrence after initial metastasectomy. The aim of this 
study is to evaluate the safety and outcomes of repeated metastasec-
tomy in patients with pulmonary metastasis of colorectal cancer.
Methods: From January 1995 to December 2007, 202 patients 
received a metastasectomy for pulmonary metastasis of colorectal 
Copyright © 2009 by the International Association for the Study of Lung Cancer S365
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
cancer at our institution. With a median follow-up of 28.9 months, 98 
patients developed a pulmonary recurrence and of those, 48 patients 
received a second metastasectomy (29 wedge resections, 5 seg-
mentectomies, 13 lobectomies, and 1 completion pneumonectomy). 
The median disease-free interval between initial metastasectomy 
and pulmonary recurrence was 9.6 months. Among the 48 repeated 
metastasectomy cases, 28 patients showed a pulmonary recurrence 
and of those, 10 patients received a third metastasectomy (2 wedge 
resections, 2 segmentectomies, 4 lobectomies, and 2 completion 
pneumonectomies).
Results: There was no postoperative mortality. For the 50 patients 
who were followed up without repeated resection, overall survival 
was 49% at 5 years. For the 48 patients undergoing a second metas-
tasectomy, overall and disease-free 5-year survivals were 79% and 
49%, respectively. For the 10 patients undergoing a third metastasec-
tomy, overall survival was 78% at 5 years. 
Conclusions: Repeated resection after initial metastasectomy can be 
safely performed and offer prolonged survival in patients with recur-
rent pulmonary metastasis. Our findings suggest that vigilant follow-
up for early detection of recurrence and parenchyma-saving resection 
can enhance the chance of additional resection.
C4.2 Indications for and Outcomes of Surgery for Metastatic Disease, Primary Lung 
 Cancer and Mediastinal Nodal Involvement, Mon Aug 3, 10:30 - 12:00
Single center experience on 839 lung metastasectomies: the 
evidence of the International Registry prognostic factors
Casiraghi, Monica1; Maisonneuve, Patrick2; Ciprandi, Barbara1; 
Petrella, Francesco1; Borri, Alessandro1; Galetta, Domenico1; Veronesi, 
Giulia1; Solli, Piergiorgio1; Gasparri, Roberto1; Vannucci, Fernando1; 
Brambilla, Daniela1; De Pas, Tommaso3; Spaggiari, Lorenzo1
1 Division of Thoracic Surgery European Institute of Oncology, 
Milano, Italy; 2 Division of Epidemiology and Biostatistics European 
Institute of Oncology, Milano, Italy; 3 Clinical Pharm and New Drug 
Development European Institute of Oncology, Milano, Italy
Background: The International Registry of Lung Metastases (IRLM) 
defined a new staging system based on identified prognostic factors 
for long-term survival after metastasectomy. The aim of our study 
was to confirm the validity of the IRLM classification system in pa-
tients who underwent curative lung metastasectomy in a single center.
Methods: We retrospectively reviewed 582 patients who underwent 
a total of 839 complete curative resections for lung metastases from 
January 1998 to October 2008. Four-hundred and forty seven patients 
developed lung metastases from epithelial tumors, 90 from sarco-
mas, 33 from melanomas, and 12 from germ cell tumors. The mean 
disease free interval (DFI) between diagnosis of primary cancer and 
metastases was 47.2 months, including 12 synchronous metastases. 
Surgical resection was performed via thoracoscopy in 27 patients and 
open in 555. Two-hundred and thirty-three patients had a single lung 
metastasis and 349 multiple. Lymph nodes dissection was performed 
in 369 cases and lymph nodes metastases (N+) present in 16.3% of 
the cases. Survival estimates were calculated with Kaplan-Meier’s 
method and compared by the log rank test. Multivariate Cox propor-
tional hazard regression analysis was used to assess the independent 
prognostic factors.
Results: After a mean follow-up of 34 months 253 patients (43%) 
died. In multivariate analysis, patients with germ cell tumors 
(p=0.03) had better prognosis and patients with sarcoma (p=0.002) 
or melanoma (p<.0001) had worse prognosis than patients with 
epithelial tumors. Open surgery approach (p=0.004) and DFI≥36 
months (p=0.01) were also associated with better prognosis. Absence 
of lymph nodes metastases was an independent positive prognostic 
factor for epithelial tumors (p=0.0004). Age, sex, and number of me-
tastases did not statistically influence the long-term survival. Five and 
10-year overall survival rates were 43% and 28%, respectively. Five-
year survival was 45% for patients with no lymph nodes metastases, 
44% for patients who underwent open surgery, and 91% for patients 
with germ cell tumors.
Conclusions: In our experience we confirmed DFI≥36 months as 
an independent prognostic factor. Number of metastases, compared 
to IRLM, was not statistically significant; however, the shape of the 
Kaplan-Meier’s curve showed a positive prognostic trend that may 
be significant on a larger population. Finally, the absence of lymph 
nodes metastases was an independent positive prognostic factor for 
epithelial tumors.
C4.4 Indications for and Outcomes of Surgery for Metastatic Disease, Primary Lung 
 Cancer and Mediastinal Nodal Involvement, Mon Aug 3, 10:30 - 12:00
Long term survival and prognostic factors for pulmonary 
metastasectomy in hepatocelluar carcinoma
Yoon, Yoo Sang; Kim, Hong Kwan; Choi, Yong Soo; Shim, Young 
Mog; Kim, Jhingook; Paik, Seung Woon; Kim, Kwhanmien
Samsung Medical Center, Seoul, Korea
Background: Recent advances in early diagnostic tools and modal-
ities of surgical or nonsurgical treatment have improved the prog-
nosis of hepatocellular carcinoma (HCC) significantly. Pulmonary 
metastasis (PM) is the most common type of extrahepatic recurrence 
of HCC. The standard treatment of pulmonary metastasis has not 
been established. We analyzed patients who underwent pulmonary 
resection of metastasis from HCC to evaluate the long term survival 
and the prognostic factors. 
Methods: We retrospectively reviewed patients with pulmonary me-
tastasectomy from HCC at Samsung Medical Center between August 
1998 and May 2008. The clinico-pathologic features and prognoses 
were investigated. Long term survival rate was analyzed by Kaplan-
Meier. A logistic regression analysis was made to evaluate a rela-
tionship between the overall and disease free survival and different 
clinico-pathologic variables. 
Results: Fifty two pulmonary metastasectomies were performed in 
45 patients (38 male and 7 female) with pulmonary metastases in 
HCC. The average age of the patients was 50.9(±11.0). Forty patients 
had viral hepatitis and 20 patients had liver cirrhosis. Seventy pul-
monary nodules were resected. The average number of the resected 
pulmonary nodules was 1.3 (±0.7). Video-assisted thoracic surgery 
was applied to 24 patients. Lobectomy was performed in 8 cases, and 
wedge resection was in the others. The median survival after pulmon-
ary metastasectomy was 40.7 months. The 1-, 2- and 5-year overall 
survival rate after pulmonary metastasectomy were 86%, 62% and 37 
%, respectively. The actual disease free 1-, 3-, 5-year survivals were 
36.0%, 30.6%, 27.6%, respectively. First recurrence in liver (p=0.03), 
short disease free interval (p=0.02) and multiple pulmonary meta-
static nodules (p=0.03) were unfavorable factors for overall survival 
in univariate analysis. However, there was no independent prognostic 
factor for overall survival in multivariate analysis. First recurrence in 
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liver was identified as an unfavorable factor for PM free survival in 
multivariate analysis (p=0.022, Hazard ratio = 0.382). 
Conclusions: Pulmonary metastasectomy in selected patients with 
HCC was found to have relatively good survival rate. First recurrence 
in liver was the only poor prognostic factor in disease free survival. 
Although we couldn’t find the independent prognostic factors for 
overall survival, pulmonary metastasectomy may be effective in 
single pulmonary metastasis of HCC without hepatic recurrence. 
C4.5 Indications for and Outcomes of Surgery for Metastatic Disease, Primary Lung 
 Cancer and Mediastinal Nodal Involvement, Mon Aug 3, 10:30 - 12:00
Better survival rate of women following lung resection for 
adenocarcinoma of the lung: different tumor biology or 
different victims? 
Kim, Young T.; Han, Kook N.; Kang, Chang H.; Sung, Sook-Whan; 
Kim, Joo H.
Seoul National University Hospital, Seoul, Korea
Background: Many reports have suggested female gender is an 
important prognostic factor to predict better survival after lung cancer 
surgery. It is not certain, however, whether such gender difference 
reflects different tumor biology or not. We performed a retrospective 
study to determine how the patient’s gender affects the clinical out-
come following lung resection for adenocarcinoma of the lung. 
Methods: Among 814 patients registered for non-small cell lung 
cancer between 2000 and 2004 in our center, we selected 330 patients 
with adenocarcinoma who underwent a complete resection. Long-
term outcomes of overall survivals and cancer-specific survivals were 
analyzed according to various clinical variables including smoking 
history, preoperative pulmonary function, extent of surgical resec-
tion, presence of bronchioloalverolar cell carcinoma histology, and 
pathologic stages along with gender factor.
Results: One hundred seventy-two patients were male(mean age 
60.4±10.1 years) and 158 were female (mean age 59.4±9.5 years, 
p=0.345). Male patients were more likely to have a smoking history 
(male; 25.6, female; 1.3%, p=0.000). However, the need for pneu-
monectomy (male; 5.8, female; 4.4%, p=0.110), the frequency of 
bronchioloalveolar carcinoma histology (male; 7.0, female; 9.5%, 
p=0.405) and the distribution of the pathologic stage (p=0.853) were 
similar in two gender groups. 
The overall 5-year survival was better in female compared to that in 
male group (male; 53.7±4.0, female; 73.6±3.8%, p=0.0001). On uni-
variate analysis, earlier pathologic stage (p=0.000) and female gender 
(p=0.001) were significant favorable factors for overall survival. 
On Cox’s proportional hazard model, pathologic stage (p=0.000), 
preoperative FEV1 (p=0.001) and gender (p=0.000) were independent 
predictors of overall survival. However, for cancer-specific survival, 
only the pathologic stage (p=0.000) was an independent predictor 
whereas the gender (p=0.162) was not, which suggested the improved 
survival in females may not be attributed to the development of 
cancer recurrence. 
To clarify the mechanism of such survival discrepancy, we analyzed 
the overall survival according to the development of recurrence. 
Among the patients who experienced recurrence, there was no differ-
ence in 5-year survival between two groups (male; 37.5±5.8, female; 
49.7±6.6%, p=0.1349). However, in those who had not recurred, 
the 5-year survival was significantly better in female patients (male; 
68.2±5.0, female; 90.2±3.6%, p= 0.0002). 
Conclusions: Our result suggested that survival advantage of female 
gender could be attributed to the less occurrence of non-cancer 
related death in females compared to that in males and may not be 
related to the differences of tumor biology between two genders. 
Accordingly, an improved survival with recent treatment regimens 
for lung cancer may simply reflect the increased proportion of women 
and, thus, the gender should be well stratified in the future design of 
clinical trials for lung cancer treatment. 
C4.6 Indications for and Outcomes of Surgery for Metastatic Disease, Primary Lung 
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Objective review of surgeon reported lymph node 
dissection after resection of lung cancer in a US 
metropolitan area 
Ninan, Mathew1; Wu, James T.2; Allen, Jeffrey W.1; Farooq, Aamer1; 
Kernstine, Kemp2; Osarogiagbon, Raymond U.1
1 University of Tennessee, Memphis, TN, USA; 2 City of Hope, 
Duarte, CA, USA
Background: Complete dissection or systematic sampling of medias-
tinal lymph nodes is vital for accurate staging and design of adjuvant 
therapy. With a view to designing future studies to improve quality 
of intra-operative pathologic staging of lung cancer, we hypothesized 
that the greatest inaccuracies of pathologic staging occurred in the 
discrepancy of surgeon-specified lymph node dissection versus the 
pathology reports. 
Methods: Retrospective review of all patients who underwent 
curative-intent resection for NSCLC at all hospitals in the Memphis 
Metropolitan Area from 1/1/2004 to 12/31/2007. Patients were div-
ided into four groups a)mediastinal lymph node dissection (MLND), 
defined according to criteria for the American College of Surgeons 
Oncology Group (ACOSOG) Z0030 trial, b)systematic sampling 
(SS), defined according to the criteria for either the ACOSOG Z0030 
trial, the RADIANT Adjuvant Trial or the Eastern Cooperative Onc-
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ology Group E1505 Trial c)all other patients with mediastinal lymph 
nodes submitted or reported were categorized as random sampling 
(RS) and d) patients who had no lymph node specimens submitted or 
reported (NS). The surgeon-specified groups were then compared to 
the pathology report. Variables were compared by the chi-square test 
or the Fisher’s exact test. 
Results: 
  MLND n (%) SS n (%) RS n (%) NS n (%) p-value
 Age, years median (range) - 67 (43, 84) 66 (39, 89) 69 (37, 87) <0.008
 Gender n (%)     
 Female 0 35 (53) 176 (44) 164 (50) 0.17
 Male 0 31 (47) 222 (56) 162 (50) 
 Race     
 Black 0 20 (30) 98 (25) 60 (19) <0.05
 White 0 46 (70) 297 (75) 264 (82) 
 Histology     
 Adenocarcinoma 0 32 (49) 184 (46) 137 (42) 0.78
 Squamous  0 22 (33) 138 (35) 124 (38) 
 Other 0 12 (18) 76 (19) 65 (20) 
 T-stage     
 T1 0 27 (41) 182 (46) 190 (59) <0.008
 T2 0 31 (47) 159 (41) 101 (31) 
 T3 0 2 (3) 22 (6) 8 (3) 
 T4 0 6 (9) 30 (8) 23 (7) 
 Extent of surgery     
 Pneumonectomy  0 11 (17) 59 (15) 18 (6) <0.0001
 Lobe/bilobectomy 0 49 (74) 312 (78) 254 (78) 
 Sub-lobar 0 6 (9) 27 (7) 54 (17) 
 Surgeon specified lymph nodal dissection     
 MNLD 0 51 (77) 242 (61) 63 (19) <0.0001
 SS 0 0 0 0 
 RS 0 3 (5) 45 (11) 10 (3) 
 NS 0 12 (18) 111 (28) 253 (78) 
MNLD mediastinal lymph node dissection SS systematic sampling RS random sampling 
NS no node sampled
790 patients were eligible. Median age was 67.7 (range 36.5 to 89.4), 
there were 375 females (47%) and 415 males (53%). There were 399 
T1 tumors (51%), 291 T2 tumors (37%), 32 T3 tumors (4%) and 59 
T4 tumors (7%). 356 (45%) of the lymph node dissections were sur-
geon specified as MLND, 58 (7%) were RS and 376 (48%) were NS. 
No patient was surgeon-specified as SS. Of the 356 surgeon-specified 
MLND, 242 patients (68%) were reclassified as RS, 63 (18%) were 
reclassified NS and 51 (14%) were reclassified as SS. No case ful-
filled the ACOSOG MLND criteria. Of the 376 surgeon-specified NS, 
111 (30%) fulfilled RS criteria. Of the surgeon specified RS, 17% and 
5% fulfilled NS or SS criteria, respectively.
Conclusions: 
1. There is considerable discrepancy in surgeon-specified opera-
tive procedure for lymph node dissection when compared to the 
pathology reports during curative-intent resection for lung cancer.
2. Virtually no patients underwent MLND based on the ACOSOG 
criteria.
3. A quality improvement project educating surgeons, pathologists 
and hospital administration is necessary to improve dissection 
and reporting of lymph node dissection lung cancer, leading to 
accurate staging and better trial accrual.
Session C5: Supportive Care 
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C5.1 Supportive Care, Mon Aug 3, 10:30 - 12:00
Should there be a preferred serotonin antagonist for 
antiemetic use in chemotherapy for lung cancer? Using 
two meta-analysis methods to determine whether 
common dose differences affect efficacy with the serotonin 
antagonist palonosetron
Lesser, Martin2; Raftopoulos, Harry1; Gralla, Richard J.1; Bria, 
Emilio3; Napolitano, Barbara2; Giannarelli, Diana3
1 North Shore - LIJ Health System, Lake Success, NY, USA; 2 
Feinstein Institute for Medical Research, Manhasset, NY, USA; 3 
Regina Elena National Cancer Institute, Rome, Italy
Objectives: Serotonin antagonists (5-HT3) are the most frequently 
used antiemetics in lung cancer medical oncology and are key agents 
in guideline-recommended combination regimens. Efficacy advan-
tages for palonosetron have been reported in large double-blinded 
randomized clinical trials when compared with other 5-HT3 agents 
in single agent trials; however, only recently was a combination 
randomized clinical trial with dexamethasone published which con-
firmed treatment enhancement (Saito, Lancet Oncology 2009). In that 
this latter trial used 0.75 mg palonosetron doses (three times the gen-
erally used dose), controversy ensued as to the applicability of this 
trial in terms of recommending palonosetron as the preferred agent 
in its class. We conducted two meta-analyses to address this dosing 
issue employing both of the most frequently used meta-analysis 
Methods: individual patient data (IPD) and abstracted data (AD - 
literature based) involving all patients entered into all randomized 
clinical trials at these doses.
Methods: A literature search and colleague inquiry identified eight 
double-blinded randomized clinical trials with palonosetron 0.25mg 
and 0.75mg treatment arms. Primary endpoints were Complete Re-
sponse (CR, no vomiting and no rescue) over days 1-5 after chemo-
therapy; secondary endpoints were Complete Control (no vomiting, 
days 1-5), acute CR (day 1), delayed CR (days 2–5), and grade 3-4 
toxicities. Sensitivity analyses by setting (highly or moderately 
emetic chemotherapy), and a meta-regression analysis for predict-
ive factors were undertaken. Odds Ratios and Relative Risks with 
95% confidence intervals were derived for IPD and AD analyses, 
respectively. Interaction and Cochrane Q-Heterogeneity tests were 
performed.
Results: 1947 subjects in the 8 double-blinded randomized clinical 
trials were identified (4 trials with highly emetic chemotherapy 
“HEC” and 4 trials with moderately emetic chemotherapy “MEC.” 
6 of these trials used the IV form of palonosetron, and two used the 
oral form). No significant heterogeneity was found for Complete 
Response or Complete Control. Remarkably similar emetic outcomes 
were found for all endpoints at both doses. No significant differences 
were found between palonosetron doses, regardless of: 1) meta-
analysis approach (IPD or AD) and for either Complete Response or 
Complete Control; 2) acute or delayed emesis; 3) HEC or MEC. Re-
sults for the primary endpoint are in the table. No significant toxicity 
differences were found. 
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PALONOSETRON DOSES: 
0.25mg versus 0.75mg
IPD Meta-Analysis Method: 
Odds Ratio (95% Confidence 
Interval)
AD Meta-Analysis Method: 
Relative Risk (95% Confidence 
Interval)
Complete Response (days 1-5, 
no vomiting or rescue)
1.00 (0.83 - 1.20) 0.998 (0.909 - 1.097)
Conclusions: Both palonosetron doses provide very similar efficacy 
for all endpoints, for both HEC and MEC. Both meta-analysis meth-
ods yielded the same result, as shown in the table, and add confidence 
to the conclusion of similar efficacy for both palonosetron doses. 
These findings indicate that either dose is appropriate for antiemetic 
treatment in many lung cancer settings. In that the randomized trial 
comparing 5HT3 antagonist + dexamethasone combinations gave a 
non-standard dose of palonosetron, these meta-analyses support the 
use of palonosetron as the serotonin antagonist of choice at frequently 
used doses.
C5.2 Supportive Care, Mon Aug 3, 10:30 - 12:00
Antiemetic efficacy of casopitant, a novel NK-1 receptor 
antagonist, in patients with non-small cell lung cancer 
receiving cisplatin-based chemotherapy: subgroup analysis 
from a randomized, double-blind, placebo-controlled 
phase III trial
Grunberg, Steven M.1; Lane, Stephen R.2; Wissel, Paul S.2; Russo, 
Mark W.2
1 The University of Vermont College of Medicine, Burlington, VT, 
USA; 2 GlaxoSmithKline, Collegeville, PA, USA
Background: This phase III trial (NKV102551) evaluated the NK-1 
receptor antagonist casopitant as an adjunct to ondansetron/dexa-
methasone (OND/DEX) for the prevention of chemotherapy-induced 
nausea and vomiting (CINV) in patients receiving cisplatin-based 
highly emetogenic chemotherapy (HEC). Antiemetic efficacy in 
a subgroup of patients with non–small-cell lung cancer (NSCLC) 
receiving HEC is evaluated here. 
Methods: Patients receiving cisplatin-based HEC (>/=70 mg/m2) 
were randomized to receive OND/DEX plus one of the following 
casopitant regimens: single-dose 150-mg oral casopitant (SDO); 
3-day IV/oral casopitant (90 mg IV/50 mg oral/50 mg oral) (IV/
ORAL); or placebo. The primary endpoint was the proportion of 
subjects who achieved complete response (no vomiting/retching and 
no rescue therapy) over the first 120 hours (CR) following the initia-
tion of the first cycle of cisplatin-based HEC. Secondary endpoints 
included no significant nausea (maximum nausea score <25 mm on 
the visual analogue scale for nausea from all assessments). P values 
were not adjusted for multiplicity.
Results: Of the 810 patients in this study, 439 (334 [76%] men; 105 
[24%] women) had NSCLC. Baseline characteristics and chemo-
therapy regimens were similar across treatment groups. The most 
commonly co-administered chemotherapy agents were gemcitabine 
(40%), vinorelbine (35%), and paclitaxel (12%). Eastern Cooperative 
Oncology Group (ECOG) performance status (PS) was as follows: 
ECOG PS 0 for 33%, PS 1 for 62%, and PS 2 for 5% of patients. 
CR occurred in 87% of patients receiving SDO (P<0.001) and 82% 
of patients receiving IV/ORAL casopitant (P<0.001) compared 
with 64% of placebo patients. The percentage of patients achieving 
CR from 0-24 hours was 95% SDO (P=0.009) and 97% IV/ORAL 
(P=0.001) versus 87% placebo. Percentages of patients achieving 
CR from 24-120 hours was identical to overall CR in each group 
(P<0.001 for both casopitant groups vs placebo). More patients re-
ceiving casopitant reported no significant nausea (77% SDO [P=NS], 
80% IV/ORAL [P=0.048] versus 70% placebo). These responses 
were similar to those achieved in the population as a whole. Several 
adverse events were slightly increased in frequency in the casopitant 
arms. The incidence of neutropenia was 33% placebo, 37% SDO, and 
45% IV/ORAL, similar to expected 47% rates for cisplatin doublets 
(Bunn et al. J Clin Oncol. 2002;20:3565-67). All infections were 11% 
placebo, 12% SDO, and 14% IV/ORAL. The incidence of grade 4 
neutropenia was 9% placebo, 16% SDO, and 18% IV/ORAL. The 
incidence of hiccups was 4% placebo, 6% SDO, and 10% IV/ORAL. 
Conclusions: The addition of casopitant to a regimen of OND/DEX 
in patients with NSCLC receiving cisplatin-based HEC provided 
significant improvements in proportion of patients achieving antie-
metic CR and control of significant nausea. The CR rate in patients 
with NSCLC receiving casopitant appears consistent with that in the 
complete data set. 
C5.3 Supportive Care, Mon Aug 3, 10:30 - 12:00
Pooled analysis of efficacy and safety of palonosetron 0.75 
mg IV for prevention of chemotherapy-induced nausea 
and vomiting (CINV) in patients receiving cisplatin for 
lung cancer – Palonosetron Japanese Cooperative Study 
Group for lung cancer
Ogura, Takashi1; Segawa, Yoshihiko2; Sekine, Ikuo3; Masuda, 
Noriyuki4; Katakami, Nobuyuki5; Sakai, Hiroshi6; Kubota, Kaoru7; 
Imamura, Fumio8; Atagi, Shinji9; Yoshizawa, Hirohisa10; Kitagawa, 
Chiyoe11; Takeda, Yuichiro12
1 Kanagawa Cardiovascular and Respiratory Center, Division 
of Respiratory Medicine, Kanagawa, Japan; 2 National Hospital 
Organization Shikoku Cancer Center, Department of Medicine 
and Thoracic Oncology, Ehime, Japan; 3 National Cancer Center 
Hospital, Division of Internal Medicine and Thoracic Oncology, 
Tokyo, Japan; 4 Kitasato University School of Medicine, Department 
of Respiratory Medicine, Kanagawa, Japan; 5 Institute of Biomedical 
Research and Innovation, Division of Integrated Oncology, Hyogo, 
Japan; 6 Saitama Cancer Center, Division of Thoracic Oncology, 
Saitama, Japan; 7 National Cancer Center Hospital East, Thoracic 
Oncology Division, Kashiwa, Japan; 8 Osaka Prefectural Hospital 
Organization Osaka Medical Center for Cancer and Cardiovascular 
Diseases, Department of Pulmonary Oncology, Osaka, Japan; 
9 National Hospital Organization Kinki-Chuo Chest Medical 
Center, Department of Internal Medicine, Osaka, Japan; 10 Niigata 
University Medical and Dental Hospital, Bioscience Medical 
Research Center, Niigata, Japan; 11 National Hospital Organization 
Nagoya Medical Center, Department of Respiratory Medicine, Aichi, 
Japan; 12 International Medical Center of Japan, Department of 
Respiratory Medicine, Tokyo, Japan
Background: Cisplatin (CDDP) was reported to be effective in lung 
cancer and it is an essential drug in lung cancer treatment, used in 
many kinds of combination chemotherapy. Since cisplatin is highly 
emetogenic, when used in a dose >50 mg/m2, prevention of CINV 
is important to continue the chemotherapy and to improve quality of 
life of patients. Palonosetron, a second-generation 5-HT3 receptor 
antagonist (RA), showed non-inferior efficacy on acute (0-24 hrs) and 
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superior efficacy on delayed (24-120 hrs) CINV compared to a first-
generation 5-HT3 RA granisetron [Lancet Oncol 2009; 10: 115–24]. 
We sought to identify efficacy and safety of single and repeated dose 
of palonosetron in patients receiving cisplatin for lung cancer.
Methods: The analysis for single dose of palonosetron was based 
on pooled data from two double-blind studies: a phase III com-
parative trial and a phase II dose-ranging trial in patients receiving 
cisplatin >50 mg/m2 for lung cancer. The analysis for repeated dose 
of palonosetron in cisplatin chemotherapy was performed for selected 
patients from this phase III study subsequently enrolled in an open-
label, repeated cycles, phase III study. In these studies, palonosetron 
0.75 mg was intravenously administrated 30 min prior to cisplatin. 
Dexamethasone was prophylactically administrated on days 1-3. 
The efficacy endpoint was complete response rate (CR, no emesis 
or no rescue medication) regarding all cisplatin treatment and each 
combination agents with cisplatin. Safety was assessed according to 
CTCAE ver. 3.0.
Results: A total of 370 patients were evaluated in single dose; 
271 (73.2%) patients were male and 99 (26.8%) were female; 301 
(81.4%) were non-small cell lung cancer (NSCLC), 68 (18.4%) 
were small cell lung cancer (SCLC) and 1 (0.3%) was mixed type 
of NSCLC and SCLC; median dose of cisplatin was 80 mg/m2. CR 
rates are shown in the table below. In repeated dose analysis, 188 
patients were evaluated. CR rates in the 1st (N=188), 2nd (N=157), 
3rd (N=103), and 4th (N=44) cycles were 81.4%, 76.4%, 75.7% and 
72.7% in the acute phase; 55.3%, 49.7%, 62.1% and 59.1% in the 
delayed phase; 52.7%, 49.7%, 58.3% and 56.8% in the overall phase, 
respectively. Adverse events in repeated dose were not different from 
the adverse events in single dose.
Conclusions: Palonosetron showed efficacy in preventing CINV 
regardless of the different cisplatin combinations. Efficacy was main-
tained in the repeated cycles. Incidence and severity of adverse events 
did not arouse any concern over safety of palonosetron.
 Chemotherapy No. of patients Complete Response rates (%)
   Acute (0-24 hrs) Delayed (24-120 hrs) Overall (0-120 hrs)
 Any+CDDP 370 80.5 53.5 51.6
 Gemcitabine+CDDP 121 73.6 50.4 47.9
 Vinorelbine+CDDP 103 89.3 60.2 57.3
 Irinotecan+CDDP 58 79.3 53.4 53.4
 Docetaxel+CDDP 51 76.5 43.1 41.2
 Etoposide+CDDP 31 83.9 54.8 54.8
 S-1* +CDDP 6 100 83.3 83.3
 *S-1, an oral fluoropyrimidine derivative    
C5.4 Supportive Care, Mon Aug 3, 10:30 - 12:00
The effect of reduced ESA use on resource utilization 
related to transfusions and thrombosis rates: longitudinal 
data which may affect lung cancer practice
Raftopoulos, Harry; Gralla, Richard J.; Pelc, Kathleen; Gleason, 
Karen; Strugatz, Joshua
North Shore-LIJ Health System, Lake Success, NY, USA
Background: Prior to randomized trials and meta-analyses revealing 
significant toxicity issues with ESAs (Bohlius, JNCI, 2006; Raftop-
oulos, Proc ASCO, 2008; Bennett, JAMA 2008), ESAs were liberally 
used in patients with multiple tumor types, including lung cancer. 
The observed increased thrombosis rate and negative survival trends 
with ESAs led to restricted labeling by the FDA and reimbursement 
decisions by the Centers for Medicare and Medicaid Services (CMS). 
Despite these major safety concerns, fears surrounding increased 
use of transfusions and blood supply shortages remain, even though 
the reported benefits with ESA use have resulted in only an average 
1-1.5g/dl rise in hemoglobin. We conducted a longitudinal study 
to assess the impact of the new ESA policies on thrombosis rates, 
demand on transfusion services and ESA use.
Methods: Over a 3-year period (2006-2008), we compiled data on 
ESA use and red cell transfusions from our center, a large compre-
hensive combined hematology and oncology program with a non-
restrictive transfusion policy. During the same period, we enumerated 
unique hospital discharges including both a thrombosis and malig-
nancy diagnosis. 2006 was our baseline; 2007 was the year of initial 
FDA and CMS changes; 2008 allowed us to see if practice changes 
persisted.
Results: The table below presents our data on ESA use, transfusion 
utilization and hospital thrombosis admissions. 
  2006 2007 2008
 Total Treatment Visits 18,929 20,450 22,253
 ESA injections 4,514 2,862 1,161
 ESA as % of total visits 24% 14% 5.2%
 Transfusions as % of total visits 6.2% 6.3% 6.4%
 95% confidence intervals of transfusions (5.8-6.5%) (6.0-6.6%) (6.1-6.7%)
 Thrombosis discharges (TDs) as % of total visits  2.0% 1.61% 1.58%
 95% confidence intervals of TDs per visit (1.8-2.2%) (1.45-1.79%) (1.41-1.74%)
Conclusions: At our center marked reductions in ESA use over a 
3 year period (78% relative decrease) have occurred. These cur-
tailments have had little effect on red cell transfusion rates, and 
have been associated with significant decreases in cancer-related 
thrombosis rates (21% relative decrease, representing annually 93 
fewer thrombosis discharges) over the same period. These findings 
reinforce the unfavorable risk/benefit profile of ESAs now demon-
strated in multiple meta-analyses and indicate that a marked decrease 
in ESA need not be accompanied by increased utilization of other 
resources.
C5.5 Supportive Care, Mon Aug 3, 10:30 - 12:00
Impact of the comprehensive health enhancement support 
system (CHESS), an interactive cancer communication 
system (ICCS) on NSCLC survival: a randomized study 
comparing CHESS with the internet
Cambpell, Toby C.1; Dubenski, Lori L.1; Gustafson, David1; Buss, 
Mary K.3; Carmack-Taylor, Cindy L.2; Namkoong, Kang1; Traynor, 
Anne M.1; Govindan, R4; Bhattacharya, Abhik1; McTavish, Fiona1; 
Cleary, James F.1
1 University of Wisconsin, Madison, WI, USA; 2 MD Anderson Cancer 
Center, Houston, USA; 3 Dana Farber Cancer Center, Boston, USA; 4 
University of Washington - St Louis, St Louis, USA
Background: Advanced NSCLC patients face a rapidly progressive 
lethal illness which often burdens them with intense physical and 
emotional symptoms. The high mortality, and symptoms associated 
with both disease and treatment, impact the quality of life (QOL) of 
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
Copyright © 2009 by the International Association for the Study of Lung CancerS370
patients and their caregivers. CHESS, an advanced ICCS, has previ-
ously demonstrated improved QOL in early breast cancer patients 
through the provision of support, information, and skill building to its 
users. The CHESS Lung Cancer module includes a Clinician Report 
(CR) that provided the physician with the patient and caregiver’s self 
report of symptom burden and areas of distress. Our primary hypoth-
esis was that CHESS, provided to NSCLC patients and caregivers, 
will improve caregiver QOL and bereavement. A secondary endpoint 
was overall survival.
Methods: Advanced (stage III or IV) NSCLC patients and their 
caregivers, recruited at any point in the course of their illness at 4 
major cancer centers in the US, were randomized to receive internet 
or CHESS. All dyads were provided with computers and internet 
access for home use if not already available. Symptom burden, QOL 
measures, and usage records for internet or CHESS were collected at 
regular intervals from both patients and caregivers. Patient survival 
was calculated as the date from the time of randomization. 
Results: 285 patients were randomized, with equivalent distribu-
tion for age, stage, sex, and performance status in the two groups. 
Exploratory cox regression analysis examined the difference between 
three groups: (1) internet, (2) those randomized to CHESS who never 
logged on to the program (CHESS-No-Use), and (3) those random-
ized to CHESS who used the program at least once (CHESS-Use). 
The CHESS-Use group demonstrates a significant, early, and persis-
tent survival advantage over the internet and CHESS non-users (χ2 = 
5.104, p = 0.024).
Conclusion: The survival advantage in our randomized study is un-
expected and is viewed with caution given it falls outside the primary 
hypotheses for improved QOL and bereavement. Users who accessed 
the CHESS program at least once appear to derive a survival benefit 
from the time of randomization and the curves remain separated and 
clinically meaningful out to one year. The results and its mechan-
ism will be further evaluated in a replicate study with the primary 
endpoint of survival. The survival advantage may be due to reduced 
symptom burden as a result of CHESS or because of enhanced phys-
ician-patient communication leading to improved performance status 
and QOL resulting in increased benefit from anti-tumor therapies. 
C5.7 Supportive Care, Mon Aug 3, 10:30 - 12:00
Meeting needs of people with inoperable lung cancer 
through an innovative supportive care intervention: a RCT
Schofield, Penelope E.1; Ugalde, Anna1; Sharkey, Kerith1; 
Krishnasamy, Meinir1; Reece, John2; Ball, David1; Aranda, Sanchia 
K.1
1 Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; 2 
RMIT, Bundoora, VIC, Australia
Background: Lung cancer is associated with a high level of morbid-
ity, particularly fatigue, pain, breathlessness and coughing, which 
can substantially reduce quality of life. Given the poor prognosis for 
people with advanced lung cancer, there is a critical need to develop 
and rigorously test clinically feasible and sustainable interventions 
targeting distress and quality of life. This study investigated the 
impact of a multidisciplinary, supportive care intervention for people 
with advanced lung cancer. It was hypothesised that this innovative 
intervention would reduce unmet perceived needs (primary endpoint); 
reduce anxiety and improve quality of life (secondary endpoints).
Method: A randomised controlled trial design adhering to CON-
SORT criteria was used. A consecutive sample was drawn from 
patients at Peter Mac. Inclusion criteria were 1) a histologically or 
cytologically confirmed diagnosis of inoperable lung, mesothelioma 
or pleural cancer; 2) commencing external beam radiotherapy (with 
or without chemotherapy), or chemotherapy with palliative intent; 3) 
sufficient English. Exclusion criteria were 1) a psychiatric disorder or 
serious cognitive impairment; 2) ECOG of 3 or above; 3) 2 months 
or less since last treatment. Patients were recruited prior to or at treat-
ment commencement, and randomised to receive the intervention or 
usual care post-baseline. All measures were reliable and valid and in-
cluded Needs Assessment for Advanced Cancer Patients (NA-ACP), 
Hospital Anxiety and Depression Scale, Distress Thermometer, and 
EORTC Quality of Life C30. Data was collected at baseline, and at 8 
and 12 week follow-up.
The intervention consisted of two sessions of less than an hour with a 
health professional at treatment commencement and completion. The 
sessions involved a self-completed assessment of unmet needs, active 
listening, self-care education and multidisciplinary management of 
unmet needs. The program was tailored to each person’s needs by a) 
giving the multidisciplinary team information about their patients’ 
psychosocial and symptom needs for management and referral; and 
b) focusing the individual sessions on participants’ reported needs. 
Significant others were encouraged to attend the sessions.
Results: 108 patients consented and were randomised (consent 
rate=59%); 75 completed follow-up 1 and 79 follow up 2 (response 
rates of 69% and 73% respectively). Most drop out was due to illness 
and death. After controlling for baseline levels, significant differences 
were detected in the NA-ACP Symptom subscale (p < 0.05) and 
the EORTC QLQC30 Appetite Loss sub-scale (p < 0.05) at 8 week 
follow-up in the expected direction. No other significant results were 
found but a detailed analysis of effect size statistics revealed several 
more trends in the expected direction.
Conclusions: The strengths of this study are: 1) it is one of the 
largest studies of its type; 2) the homogeneous sample of people with 
advance lung cancer all commencing a new treatment; 3) rigorous ad-
herence to the CONSORT criteria; and 4) the use of reliable and valid 
measures as endpoints. The intervention was effective in reducing 
unmet symptom needs and improving appetite loss at 8 weeks post 
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baseline. These findings demonstrate the importance of systematic 
needs assessment and communicating patient unmet needs to the 
multidisciplinary team for action. 
Session C6: Combined Modality for NSCLC 
Monday, August 3
C6.1 Combined Modality for NSCLC, Mon Aug 3, 10:30 - 12:00
Efficacy of maintenance erlotinib versus placebo in 
patients with unresectable stage III non-small cell lung 
cancer (NSCLC) following concurrent chemoradiation 
(D0410, NCT00153803)
Rigas, James R.1; Carey, Mark A.1; Rubin, Mark S.2; Dragnev, 
Konstantin H.1; Aitken, Candice L.1; Ghazal, Hassan3; Waples, John 
M.4; Rathman, Jeorg5; Droder, Robert6; Manges, Robert7; Green, 
Nathan B.8; Evans, Amy9
1 Dartmouth Medical School, Lebanon, New Hampshire, USA; 
2 Florida Cancer Specialists, Fort Myers, FL, USA; 3 Kentucky 
Cancer Clinic, Hazard, KY, USA; 4 Clearview Cancer Institute, 
Huntsville, AL, USA; 5 St. Francis Care Regional Cancer Center, 
Hartford, CT, USA; 6 Tyler Hematology/Oncology PA, Tyler, TX, 
USA; 7 Investigative Clinical Research of Indiana, Indianapolis, IN, 
USA; 8 Southeast Nebraska Cancer Center, Lincoln, NE, USA; 9 PPD 
Development, Wilmington, NC, USA
Background: Concurrent chemoradiotherapy (cCRT) is the recom-
mended treatment for stage III NSCLC. The role of maintenance ther-
apy following cCRT remains undefined and concern has been noted 
with maintenance gefitinib in this stage of disease (S0023). This 
upfront randomized placebo-controlled phase III trial was designed to 
evaluate the effectiveness of maintenance erlotinib following cCRT in 
unresectable stage III NSCLC. 
Methods: Patients with unresectable pathologically confirmed stage 
III NSCLC were randomized, prior to any therapy (upfront), to 
receive either erlotinib or placebo 150 mg orally daily for 2 years 
beginning 3 to 7 wks following completion of cCRT (docetaxel 20 
mg/m2, carboplatin AUC=2 wkly for 6 wks with 61 Gy of RT). The 
primary endpoint was progression-free survival (PFS). Secondary 
endpoints were time to progression (TTP), overall survival (OS), and 
safety. Subjects were stratified by stage (IIIA vs. IIIB), weight loss 
(< 10% versus ≥ 10%) and functional status (ECOG 0-1 versus 2). 
Sample size of 200 patients per group was sufficient to detect a 40% 
increase in PFS with 80% power at 0.05 two-sided alpha. This was 
the second planned (150 events) and final efficacy analysis due to 
slow accrual. This trial is monitored by an independent committee. 
Results: The 2 groups were balanced. Patient characteristics for 243 
randomized patients; 59% males, median age 67 yrs (range 38-89 
yrs), 31% adenocarcinoma, 44% squamous cell, 56% stage IIIA, 
15% weight loss ≥ 10%, and 4% PS2. For all randomized patients, 
the median PFS and OS were not significantly different. Erlotinib/
placebo was not dispensed to 87 of 243 randomized patients (36%) 
following cCRT due to: 11% disease progression, 6% investigators 
decision, 5% withdrew consent, and 1.6% cCRT toxicity. Erlotinib/
placebo was dispensed to 156 subjects. Median PFS for subjects 
given erlotinib was 13.5 months vs. 10.4 months for placebo (p=0.12. 
HR 0.75, 95% CI 0.53-1.08). Median OS was 30.4 months for 
erlotinib vs. 25.1 months for placebo (p=0.20) and median TTP for 
erlotinib has not been reached vs. 13.1 months for placebo (p=0.005). 
Of the patients randomized to receive erlotinib, the discontinuation 
rate due to adverse events, primarily rash was 6.2% occurring in 5 of 
80 patients all dispensed erlotinib. 
Conclusions: Maintenance erlotinib following cCRT for unresect-
able stage III NSCLC significantly prolongs the time time to disease 
progression. For all subjects, PFS and OS were not significantly 
different and may not have reached statistical significance due to the 
smaller than planned sample size. The rate of treatment discontinua-
tion for erlotinib is greater than that reported in advanced disease. 
These results are in-line with the reports of maintenance erlotinib in 
advanced NSCLC. A larger study to confirm these observations is 
recommended. Funded by Sanofi-Aventis and Genentech. Erlotinib/
placebo supplied by OSI Pharmaceuticals. 
C6.2 Combined Modality for NSCLC, Mon Aug 3, 10:30 - 12:00
A phase II study of pemetrexed, carboplatin and thoracic 
radiation with or without cetuximab in patients with 
locally advanced unresectable non-small cell lung cancer: 
CALGB 30407
Govindan, Ramaswamy1; Bogart, Jeff2; Wang, Xiaofei .3; Hodgson, 
Lydia3, 3; Kratzke, Robert A.4; Vokes, Everett E.5, 6
1 Washington University School of Medicine, St Louis, MO, USA; 2 
State University Of New York, Syracuse, NY, USA; 3 Duke University, 
Durham, NC, USA; 4 University of Minnesota, Minneapolis, MN, 
USA; 5 University of Chicago, Chicago, IL, USA; 6 Cancer and 
Leukemia Group B, Durham, NC, USA
Background: Cisplatin, etoposide and concurrent thoracic radiation 
is the current standard treatment for locally advanced unresectable 
non small cell lung cancer (NSCLC) in the United States. The Cancer 
and Leukemia Group B (CALGB) conducted a randomized phase II 
study using a novel chemotherapy regimen administered in systemic-
ally active doses with thoracic radiation (CALGB 30407). 
Methods: Patients with previously untreated stage III NSCLC were 
randomized to receive thoracic radiation (70 Gy) along with carbo-
platin (AUC 5) and pemetrexed 500 mg/m2 on day 1 administered 
intravenously every 21 days for 4 cycles (arm A) or the same chemor-
adiation regimen with weekly cetuximab for 6 weeks concurrent 
with radiation (arm B). In addition, patients in each group received 
four additional cycles of pemetrexed (500 mg/m2 every 21 days) as 
consolidation therapy. The primary endpoint was the percentage of 
patients who lived longer than 18 months after starting initial treat-
ment. We planned to study the regimen (s) further if the 18 month 
survival rates equaled or exceeded 55%.
Results: Characteristics of the 99 eligible pts (48 in arm A and 51 
arm B) enrolled from 09/05 to 1/08: female 37%, 22% were 70 yrs or 
older. The most common histological type was adenocarcinoma (46% 
in Arm A and 41% in Arm B). Highest grade toxicity any time during 
treatment (grade 3 or greater, %) by arms (arm A/arm B): neutropenia 
40/47; febrile neutropenia 8/6, thrombocytopenia 36/34, nausea/
vomiting 8/10, esophagitis 32/24, skin rash 2/21 and fatigue 22/17. 
The median follow up time is 19.5 months. Preliminary efficacy data 
by arms (arm A/arm B) for 99 pts: complete or partial response 73% 
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(95% CI 59-83)/71% (95% CI 57-81%), median failure free survival 
(months) 13.5 (95% CI 11.0-NA)/11.8 (95% CI 8.7-18.9); 18 month 
survival 56% (95% CI 42-76)/48% (95% CI 34-66) and median 
survival (months) 22.3/18.7. 
Conclusions: The combination of pemetrexed, carboplatin and thor-
acic radiation has met the protocol-specified criteria for further study. 
Addition of cetuximab does not appear to confer additional benefit in 
this setting, though further follow-up is necessary.
C6.3 Combined Modality for NSCLC, Mon Aug 3, 10:30 - 12:00
Phase II trial of induction and adjuvant bevacizumab with 
cisplatin and docetaxel in patients with locally advanced 
NSCLC
Kris, Mark G.; Price, Katharine A.; Rusch, Valerie W.; Zhao, 
Binsheng; Schwartz, Lawrence H.; Guo, Pingzhen; Tan, Yongqiang; 
Subzwari, Sara; Finley, David; Rizvi, Naiyer A.
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Background: The induction setting provides a unique opportunity to 
measure benefit of anticancer therapies. This information can deter-
mine the success of preoperative treatment, help justify the adjuvant 
use of the agent in a particular patient, and permit pathologic correla-
tions in the resected specimens. After adding bevacizumab (BEV) 
improved response and survival in patients with stage IV non-small 
cell lung cancer (NSCLC) given chemotherapy, we designed this 
phase II trial to give BEV before and after surgery in patients receiv-
ing induction chemotherapy. Our aim was to improve upon the 20% 
downstaging rate seen in prior induction chemotherapy trials without 
BEV.
Methods: Patients with stages IB-IIIA NSCLC that were deemed 
operable and resectable received 4 cycles of induction docetaxel and 
cisplatin (DOCE/CIS, both 75 mg/m2) every 3 weeks. Patients with 
squamous tumors or hemoptysis received only induction chemother-
apy. All others additionally received 3 preoperative doses of BEV 
(15mg/kg), the first given as a single agent 2 weeks before the start 
of DOCE/CIS. All patients with induction response and resection 
received BEV 15 mg/kg every 3 weeks postoperatively for 1 year.
Results: 49 patients have enrolled: cStage I in 18%, II in 16% and 
IIIA in 65%. 48 were current or former smokers. 37 patients received 
BEV alone for 2 weeks. To date, 31 given BEV alone were evalu-
ated for response. Their median tumor size change (WHO) after BEV 
alone was a 15% shrinkage (range 41% shrinkage to 14% growth). 
Indicator lesion volume was reduced in all 25 patients where volume 
was determined. The median decrease in volume was 24% (range 
17 to 58%). WHO partial response to induction: 40% with DOCE/
CIS (n=12; 10 evaluable) and 58% with BEV+DOCE/CIS (n=37; 
31 evaluable). At surgery in 43 patients, R0 resections were seen in 
82% with DOCE/CIS and 91% with BEV+DOCE/CIS. Downstaging 
occurred in 27% with DOCE/CIS and 47% with BEV+DOCE/CIS. 
There was 1 pathological complete response after BEV+DOCE/
CIS. For the stage IIIA patients, 87% are alive at 1 year and 45% at 
3 yrs. 83% of pts received the planned 3 induction doses of BEV. 18 
patients received adjuvant BEV (median 12 doses, 5 all 18 planned). 
7 stopped adjuvant BEV due to toxicity (2 hypertension). There were 
no treatment-related deaths. Grade 3/4 perioperative morbidity was 
seen in 20%.
Conclusions: 1) Bevacizumab alone induces tumor regressions in pa-
tients with NSCLC. 2) The response rate to induction BEV+DOCE/
CIS was 58% and for CIS/DOCE was 40%. 3) The overall R0 
resection rate was 88%. 4) Pathologic downstaging was seen in 27% 
with DOCE/CIS and 47% with BEV+DOCE/CIS, both results better 
than our earlier induction therapy experience. 5) Response observed 
following a short course of an agent as part of an induction treatment 
can be used to select that same agent for adjuvant use in a particular 
patient. Supported in part by Genentech. 
C6.4 Combined Modality for NSCLC, Mon Aug 3, 10:30 - 12:00
Incorporation of bevacizumab (B) and erlotinib (Er) 
with induction (I) and concurrent (C) carboplatin (Cb)/
paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage 
III non-small cell lung cancer (NSCLC)
Socinski, Mark A.1; Stinchcombe, Thomas E.1; Halle, Jan S.1; Moore, 
Dominic T.1; Petty, William J.2; Blackstock, A W.2; Gettinger, Scott 
N.3; Decker, Roy H.3; Khandani, Amir H.1; Morris, David E.1
1 University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; 
2 Wake Forest University, Winston Salem, NC, USA; 3 Yale University 
School of Medicine, New Haven, CT, USA
Background: Therapies directed at both the epidermal growth factor 
receptor (EGFR) and the vascular endothelial growth factor (VEGF) 
pathways have been shown to improve survival in NSCLC and also 
have radiosensitizing properties.
Methods: Pts receive Ind Cb (AUC 6), P (225 mg/m2) and B (15 
mg/kg) on d1 and 22. PET scans are done pre- and post-I. On day 
43, pts receive weekly Cb (AUC 2 x 7) and P (45 mg/m2 x 7) with 
74 Gy (2 Gy/d) of thoracic conformal radiotherapy (TCRT). Cohort 
I (n=5) received B at 10 mg/kg q2wks during C therapy. Cohorts II 
and III (both n=5) received the same dose of B as in cohort I but also 
received Er at 100 mg and 150 mg po Tuesday - Friday of each week 
of C therapy, respectively. The primary endpoint is PFS at 1 year. All 
histologies are allowed including squamous (SQ) (an early stopping 
rule is in place for pulmonary hemorrhagic (PH) complications in the 
SQ pts).
Results: Thus far, 31 eligible PS 0-1 pts have been accrued (med age 
62 yrs, range 41-74, 19 non-squamous, 12 SQ, 63% IIIA, 37% IIIB). 
Ind CbP + B has been well tolerated (1 gr 3 hypertension). No PH 
during Ind has been seen (including the 12 SQ cell pts). Response 
after Ind, 37% PR, 59% SD, 4% PD. Tumor volumes and PET SUVs 
have significantly decreased comparing pre- and post-Ind studies 
(p=0.0001 and p=0.0002, respectively). Cohort II has been expanded 
as the phase II regimen. To date, 25 of 26 (96%) pts have achieved 
the dose of 74 Gy (1 pt stopped at 60 Gy due to ILD). During Conc 
therapy, the principal toxicity has been esophagitis (53.8% gr 2, 
19.2% gr 3). One grade 3 PH occurred in 1 SQ pt. One gr 5 late (> 2 
mos after treatment) PH occurred in a SQ pt. Overall response rate 
following treatment – 68.2% (95% CI, 45-86%). The PFS at 1 year is 
58% (95% CI, 34-76%) with an estimated 1-year overall survival rate 
of 79% (95% CI, 53-92%) which compares favorably to our historical 
experience.
Conclusions: Preliminarily, we conclude that 1) Incorporation of B 
and E into this treatment paradigm appears feasible, 2) Esophagitis 
remains the primary toxicity, 3) Phase II accrual continues but early 
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analysis of survival appears promising. Further details regarding the 
TCRT parameters and toxicity will be presented.
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Concurrent cetuximab and radiotherapy after docetaxel–
cisplatin induction chemotherapy in stage III NSCLC: 
a phase II study from the Swedish Lung Cancer Study 
Group
Nyman, Jan1; Hallqvist, Andreas1; Brodin, Ola2; Nilsson, Kristina 
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Background: Recent attempts to improve locoregional control in 
locally advanced lung cancer have included accelerated fractiona-
tion, dose escalation, and concurrent treatment with radiosensitizers. 
As the EGFR-targeted monoclonal antibody cetuximab has shown 
activity when given concurrently with radiotherapy in squamous cell 
carcinoma of the head and neck, and in stage IV NSCLC in combina-
tion with chemotherapy, we decided to investigate radiotherapy with 
concurrent cetuximab in stage III NSCLC, which also often expresses 
EGFR.
Methods: Between Feb 2006 and Aug 2007, 75 patients (pts) from 
eight institutions were enrolled in this phase II study. Eligible pts had 
stage III NSCLC, good performance status (PS 0/1), and adequate 
lung function (FEV1 >1.0). Treatment consisted of 2 cycles of induc-
tion chemotherapy (docetaxel 75 mg/m2 and cisplatin 75 mg/m2) 
with a 3-week interval between cycles. An initial dose of cetuximab 
400 mg/m2 was given 2 weeks later and the following week patients 
started 3D-CRT to 68 Gy (2 Gy per fraction over 7 weeks) with 
concurrent weekly cetuximab 250 mg/m2. Toxicity according to 
NCIC CTC, version 3.0 was scored weekly during radiotherapy. After 
completion of treatment, pts were assessed every 3 months with CT 
scans, toxicity scoring, and QLQ.
Results: Seventy-two pts were eligible for analysis (3 stage IV pts 
who were incorrectly enrolled were excluded). Baseline character-
istics were: adenocarcinoma 49%; squamous cell carcinoma 39%; 
non-squamous cell carcinoma 12%; stage IIIB 62%, PS 0 62.5%, 50 
% had > 5% pre-treatment weight-loss, median age 62.2 years (range 
42–81), female 50%, median FEV1 2.2 L (range 1.1–3.7). Ninety 
four percent of pts received two chemotherapy cycles, 77% of pts 
received all eight cetuximab infusions, and 87.5% of pts completed 
radiotherapy and received 68 Gy. Median follow-up was 25 months. 
While 54% of pts had grade 1 esophagitis and 18% had grade 2, only 
1 pt had grade 3 esophagitis. Six percent of pts had grade 3/4 hyper-
sensitivity reactions, 10% of pts had grade 3/4 febrile neutropenia, 
11% had grade 3/4 diarrhea. Seventy four percent of pts had grade 
1/2 skin reactions and 4% had grade 3 skin reactions. One grade 5 
pneumonitis reaction was observed (6% had grade 3; 26% of pts had 
grade 1/2). The median overall survival (OS) was 17 months; 1-, 
2-, and 3-year OS rates were 67%, 36%, and 33%, respectively. To 
date 28% of patients have experienced local or regional failure and 
39% have developed distant metastases (6 in combination with local 
relapse). Age, PS, stage, and gender were predictive for survival in 
univariate as well as in multivariate analyses. Analyses of potential 
biological markers, such as KRAS and EGFR mutations and amplifi-
cation from tumour biopsies and quality of life are ongoing.
Conclusions: Induction chemotherapy followed by concurrent 
cetuximab and radiotherapy to 68 Gy is feasible, with promising 
survival. Care is required to minimize pulmonary toxicity. Further re-
search is needed to clarify how best to integrate biological treatment 
and chemoradiation and to identify biological markers for response to 
therapy.
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A phase III comparison of prophylactic cranial irradiation 
(PCI) versus observation in patients with locally advanced 
non-small cell lung cancer (LA-NSCLC): initial analysis of 
primary and secondary endpoints. RTOG 0214
Sun, Alex1; Bae, Kyounghwa2; Gore, Elizabeth 2; Wong, Stuart3; 
Meyers, Christina 4; Movsas, Benjamin 5; Bonner, James 6; Schild, 
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Cooperative Oncology Group (ECOG), Philadelphia, USA; 7 
NCCTG, Philadelphia, USA; 8 South West Oncology Group (SWOG), 
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Background: The brain has become one of the most frequent sites 
of initial failure as loco-regional and extra-cranial systemic treat-
ment has improved for LA-NSCLC. The primary objective of this 
study was to determine whether PCI improves survival after effective 
loco-regional/systemic therapy for patients with stage III NSCLC. 
The secondary objectives were to determine the impact of PCI on 
the incidence of brain metastases, neuropsychological function, and 
quality of life (QOL).
Methods: Patients with Stage IIIA/B NSCLC without disease pro-
gression after loco-regional treatment with surgery and/or radiation 
therapy with or without chemotherapy were eligible for this trial. 
Participants were randomized to PCI or observation and stratified by 
stage (IIIA or B), histology (non-squamous or squamous) and therapy 
(surgery or no surgery). PCI was delivered to a total dose of 30Gy at 
2Gy/fraction, once daily. The primary endpoint was overall survival 
(OS). Secondary endpoints included disease free survival (DFS), in-
cidence of brain metastases, neuropsychological and QOL impact of 
PCI. Mini-Mental Status Examination (MMSE), Activities of Daily 
Living Scale (ADLS), and Hopkins Verbal Learning Test (HVLT) 
were used to assess neuropsychological function. EORTC QLQ-C30 
and QLQ-BN20 were used to assess QOL. Kaplan-Meier estimation 
with log-rank test was used for OS and DFS, and logistic regres-
sion was used for incidence of brain metastasis. P-values from T-test 
adjusted by Hommel’s stagewise rejective procedure were reported 
for neuropsychological and QOL tools.
Results: The total accrual was 356 patients of the planned 1058. 
This study opened on September 19, 2002 and closed due to slow 
accrual on August 30, 2007. 340 patients were evaluable. One year 
OS (75.6 % and 76.9% for PCI and observation, p=0.86) and one 
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year DFS (56.4% and 51.2% for PCI and observation, p=0.11) were 
not statistically significantly different. However, the incidence of 
brain metastases at 1 year was statistically significantly different with 
brain relapse of 7.7% for PCI vs. 18% for observation (p=0.004). 
Patients in the observation arm were 2.52 times more likely to 
develop brain metastases than those in the PCI arm (odds ratio=2.52, 
(95% CI=1.32-4.80)). There were no significant differences at 1 year 
between the two arms amongst any QOL components included in 
the EORTC QLQ-C30 or QLQ-BN20 (all adjusted p-values>0.05). 
Nor were there any differences found in MMSE (p=0.60) or ADLS 
(p=0.88). However, for HVLT, there was a statistically significantly 
greater deterioration in immediate recall (p=0.03) and delayed recall 
(p=0.008), but not in recognition (p=0.62) in the PCI arm at 1 year.
Conclusion: PCI in patients without progressive disease after 
definitive therapy for IIIA/B NSCLC significantly decreases the risk 
of brain metastases. There is not a statistically significant difference 
in OS or DFS at this point. There were no significant differences in 
neurocognitive function or QOL following PCI except for immediate 
and delayed recall. Longer follow-up is needed to determine the sig-
nificance of these changes. However, this prospective study provides 
data that can facilitate discussion with patients regarding the benefits 
and risks of PCI in this setting.
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Randomized, phase III study of mitomycin/vindesine/
cisplatin (MVP) versus weekly irinotecan/carboplatin (IC) 
or weekly paclitaxel/carboplatin (PC) with concurrent 
thoracic radiotherapy (TRT) for unresectable stage III 
non-small-cell lung cancer (NSCLC): final results of West 
Japan Thoracic Oncology Group trial (WJTOG0105)
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Masahiro12
1 Osaka City General Hospital, Osaka, Japan; 2 Shizuoka Cancer 
Center, Nagaizumi, Japan; 3 Hyogo Cancer Center, Akashi, Japan; 4 
Kinki University School of Medicine, Osaka-Sayama, Japan; 5 Osaka 
City Unuversity Medicak School, Osaka, Japan; 6 Aichi Cancer 
Center, Nagoya, Japan; 7 National Hospital Organization Kinki-chuo 
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Background: Weekly chemotherapy with concurrent TRT displays 
acceptable toxicities and dependable efficacy. We conducted a 
randomized phase III trial to assess the efficacy and toxicity of each 
weekly chemotherapy regimen with concurrent TRT against MVP 
with concurrent TRT via a non-inferiority design.
Methods: MVP: mitomycin (8 mg/m2 on days 1, 29), vindesine (3 
mg/m2 on days 1, 8, 29, 36), and cisplatin (80 mg/m2 on days 1, 29) 
with concurrent TRT (60 Gy). Patients (pts) subsequently received 
2 courses of consolidation chemotherapy with MVP; IC: weekly 
irinotecan (20 mg/m2)/carboplatin (AUC 2) for 6 weeks and TRT 
(60 Gy) followed by 2 courses of irinotecan (50 mg/m2)/carboplatin 
(AUC 5); PC: weekly paclitaxel (40 mg/m2)/carboplatin (AUC 2) 
for 6 weeks and TRT (60 Gy) followed by 2 courses of paclitaxel 
(200 mg/m2)/carboplatin (AUC 5). The primary endpoint was overall 
survival (OS), with secondary endpoints of progression free survival 
(PFS), response, and toxicity. 
Results: From September 2001 to September 2005, 456 pts were 
randomized. Pretreatment characteristics were well-balanced 
among 3 arms. Major toxicity incidences were as follows: grade 3-4 
neutropenia in MVP, IC, and PC arms were 95.9, 72.1, and 46.9 % 
(p<0.001),respectively, grade 3-4 non-hematologic toxicity inci-
dences in terms of fatigue, febrile neutropenia, and gastrointestinal 
disorder were 13.0, 6.1, and 4.8 % (p<0.001), 37.0, 8.8, and 10.2 % 
(p<0.001), and 24.0, 8.2, and 9.5% (p<0.001) in the respective arms. 
The overall response rates were 66.4, 56.5, and 63.3 %, in the MVP, 
IC and PC arms, respectively. The median survival times were 20.5, 
19.8 and 22.0 months and the median PFS (MPFS), 8.2, 8.0 and 9.5 
months in MVP, IC and PC, respectively. Non-inferiority of the 2 
experimental arms compared with MVP was not achieved, though no 
significant differences in OS and PFS were apparent among treat-
ments. The PC arm displayed the most favorable MST, MPFS, and 
hematologic/non-hematologic toxicities.
Conclusions: Weekly PC with TRT displays similar efficacy, more 
favorable toxicity profiles compared to MVP with TRT. Weekly PC 
with TRT warrants use as the reference regimen in forthcoming studies. 
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Prognostic value of primary tumor FDG uptake for occult 
mediastinal lymph node involvement in N2 node negative 
non small cell lung cancer as staged by positron emission 
tomography
Trister, Andrew Daniel1; Gillespie, Colin2; Haas, Andrew R.2; 
Sterman, Daniel2; Kucharczuk, John C.3; Cooper, Joel D.3; Friedberg, 
Joseph S.3; Wobb, Jessica L.4; Lukas, Thomas1; Pryma, Daniel A.5; 
Divgi, Chaitanya R.5; Lin, Lillie L.6; Rengan, Ramesh6
1 University of Pennsylvania, Philadelphia, PA, USA; 2 The Penn 
Lung Center, University of Pennsylvania, Philadelphia, PA, USA; 
3 Division of Thoracic Surgery, University of Pennsylvania, 
Philadelphia, PA, USA; 4 Temple University, Philadelphia, PA, USA; 
5 Department of Radiology, University of Pennsylvania, Philadelphia, 
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Background: Accurate staging of non-small cell lung cancer plays 
a large role in the management of the disease and in determining 
prognosis for the patient. Invasive staging of the mediastinum either 
through mediastinoscopy or endobronchial ultrasound is the gold 
standard for accurate staging of the mediastinum in NSCLC. PET/CT 
has come into increased use for non-invasive staging of the medias-
tinum; however, this modality can have a false negative rate of up to 
25%. The goal of this study was to identify predictive factors on sta-
ging PET for identification of occult mediastinal nodal involvement.
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Materials/Methods: We performed a retrospective review of 1889 
patients with suspected NSCLC who underwent a staging 18FDG 
PET from 1 January, 2000 through 31 August, 2008 in the University 
of Pennsylvania Health System. 593 of these patients were found to 
have no radiographic evidence of mediastinal FDG-avid lymphaden-
opathy. 174 of these clinical stage I (151 patients) or II (23 Patients) 
patients had biopsy proven NSCLC and underwent further invasive 
staging of the mediastinum. 163 of the scans were available for 
review and calculation of the primary tumor SUV. 
Results: 51 patients were found to have occult N2 disease by either 
mediastinal lymph node dissection, mediastinoscopy or endobronchi-
al biopsy and a primary tumor with pathologic FDG uptake (SUV > 
2.5). The mean SUV for these 51 patients with occult N2 metastases 
was significantly higher than the node negative patients (SUV of 9.33 
versus 7.25 p<0.05). We found that patients with hilar node metas-
tases at time of PET scan (N1) were more likely to have mediastinal 
metastases (48% increase in relative risk; p<0.0001). Although there 
was a greater incidence of right lung tumors (65%), tumors found 
in the left lung were more likely to have occult N2 metastases (50% 
increase in relative risk compared to overall population, p<0.005). 
Histology was not predictive for occult N2 disease, although all 4 
patients with large cell histology were found to have occult nodes 
upon invasive staging. 
Conclusions: Our data suggest that known hilar node involvement, 
tumors located in the left lung and higher SUV of the primary tumor 
site on staging PET scan are predictive of mediastinal node involve-
ment. These data suggest that invasive staging of the mediastinum 
may be of value in patients with a PET negative mediastinum with a 
high SUV primary tumor. 
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The value of 18F-FDG PET/CT in the management of 
patients with non-small cell cancer after potentially 
curative surgery: experience with 291 patients
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Background: Early diagnosis of recurrent lung cancer is important 
for selection of the optimal therapy. This study evaluated the value of 
PET/CT in the management of patients with NSCLC after potentially 
curative surgery.
Methods: Three hundred and forty-one PET/CT of 291 patients (178 
males and 113 females; age range38-87 years:, mean, 67.4years) 
between May 2006 and February 2008 were retrospectively evalu-
ated. All the 291 patients had undergone potentially curative surgery 
for NSCLC more than 6 month before PET/CT. The time interval 
between initial surgery and PET/CT ranges 6 to 215 month (median 
23 month). The histologic types were Adenocarcinoma and Bron-
choalveolar carcinoma in 209 patients; Squamous cell carcinoma in 
61 patients; Other histologic types in 21 patients. The stage at initial 
diagnosis according to the 1997 update of TNM classification were 
Stage IA in 122 patients, IB in 61 patients, IIA in 17 patients, IIB in 
41 patients, IIIA in 35 patients, and IIIB in 15 patients. One hundred 
patients were suspected of recurrence due to elevated tumor markers, 
or symptoms, or abnormal findings by conventional imaging modal-
ities. In 191 patients, PET/CT were performed as a routine medical 
check up. A final diagnosis of recurrence was confirmed by histologic 
or cytologic examination of the disease or by clinical and radiologic 
follow-up image analysis. Confirmation of recurrence free status was 
based on a clinical and radiologic image analysis follow up period of 
at least 12 month with no evidence of active malignancy. Incidental 
detection of other diseases was also analysed.
Results: The time interval between initial surgery and latest follow-
up ranges 8 to 228 month (median 43 month). Recurrences were 
confirmed in 53 (18%) patients, and 238 patients (82%) had no 
evidence of recurrence. PET/CT correctly diagnosed recurrence 
in 49 of 53 patients and gave true negative findings in 222 of 238 
patients who had no evidence of recurrence (sensitivity, specificity, 
and accuracy of 92%, 93%, 93%, respectively). Four patients who 
had false-negative PET/CT studies were finally diagnosed as pleuritis 
carcinomatosa in 2 patients, brain metastasis in 1 patient and local 
recurrence in 1 patient. Sixteen patients who had false positive PET/
CT studies were finally diagnosed as inflammatory mediastinal lymph 
nodes in 4 patients, inflammatory lung nodules in 3 patients, other 
diseases in 2 patients, non-specific FDG uptakes in distant organs 
in 4 patients, postoperative changes in 2 patients and a non-specific 
low density area in the brain in 1 patient. According to the site of 
recurrence, PET/CT correctly diagnosed 34 patients with mediastinal 
lymph node metastasis of 38 patients with mediastinal lymphaden-
opathy (accuracy 89%), and 31 patients with lung metastasis of 34 
patients with lung nodules (accuracy 91%). Malignancies other than 
recurrence were detected in 10 of all 291 patients (3%) including 6 
second primary lung cancers. 
Conclusions: PET/CT accurately detects recurrence of NSCLC after 
potentially curative surgery. PET/CT accurately diagnose mediastinal 
lymphadenopathies and lung nodules. PET/CT is useful for not only 
diagnosis of recurrence but also detection of other diseases.
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Usefulness of 18FDG-positron emission tomography for 
early prediction of response in non-small cell lung cancer 
(NSCLC) patients treated with erlotinib: results of a pilot 
study
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Background: 18-Fluorodeoxyglucose (FDG) positron emission 
tomography (PET) could be useful for early evaluation of tumor 
response to tyrosine kinase inhibitors (TKI) in cancer therapy. Glu-
cose metabolic activity seems closely reflect response to epidermal 
growth factor receptor (EGFR) TKI in vivo and in vitro (Su H et al, 
Clin Cancer Res 2006;12:5659-67). Thus, we attempted to assess the 
clinical value of FDG-PET for early prediction of tumor response to 
erlotinib (Eb), an EGFR-TKI used in the second- or third-line treat-
ment of NSCLC.
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
Copyright © 2009 by the International Association for the Study of Lung CancerS376
Methods: Patients with stage IV NSCLC in progression after at 
least one line of chemotherapy and PS 0-1 were treated with Eb (150 
mg orally once daily). FDG-PET was performed on days 0 and 2, 
after administration of 3 doses of Eb. FDG uptake was evaluated 
as the maximum standardized uptake value (SUVmax). FDG-PET 
responses were evaluated by quantitative changes on SUVmax/SUV 
liver ratio and classified according to the EORTC PET study group 
criteria. FDG-PET response were compared with radiographic tumor 
response (RECIST criteria) assessment based on CT scan at baseline 
and on day 45. The determination of EGFR status (protein expres-
sion, gene copy number and gene mutations) and K-ras gene muta-
tions were performed when tumor specimens were available.
Results: From May 2007, 27 pts were enrolled and 23 were evaluable 
(4 not-evaluable: 2 BAC PET negative and 2 protocol violations). 
FDG-PET revealed a metabolic partial response (PR) in 8 patients; 
subsequent CT scan assessment evidenced 4 PR and 4 stable disease 
(SD), respectively. Seven patients had metabolic progressive disease 
(PD) at PET scan and 8 had SD, all of them presented PD at CT scan. 
Metabolic-PR was associated with a longer median progression-free 
survival (152 vs 45 days, p < 0.0001) and longer overall survival 
(323 vs 122 days, p = 0.09); for PD pts who presented metabolic SD 
or PD, survival time was 220 and 101 days, respectively (p = 0.005). 
About the preliminary biological data, determined on 10 patients, 
EGFR FISH + and EGFR gene mutations were observed in 1 out of 
3 metabolic PR, while EGFR FISH + was presented in 1 out of 7 non 
metabolic responders, without gene mutations. Biological determina-
tions on other tumor specimens are ongoing. 
Conclusions: FDG-PET using changes on SUVmax/SUV liver 
ratio can predict disease control (SD or PR) and PD early (already 2 
days after initiation of Eb treatment). Thus, evaluation of the early 
metabolic response holds promise for assessment of patient selection 
for Eb treatment. The two different behavior of FDG-PET after Eb 
early observed on refractory pts deserve bio-molecular analysis for 
understanding mechanism of resistance.
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Detection of bone metastases in patients with lung cancer: 
99mTc-MDP planar bone scintigraphy, 18F-Fluoride PET 
or 18F-FDG PET-CT 
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Background: FDG PET-CT is increasingly been used as a “one stop 
shop” staging method for non small cell lung cancer (NSCLC). Aim 
of the study was to compare the diagnostic accuracy of FDG PET-CT 
versus standard planar bone scintigraphy (BS) and 18F-PET for the 
detection of bone metastases (BM) in NSCLC.
Methods: FDG PET-CT was performed in 126 patients with NSCLC. 
Within 7 days BS (n=58) or 18F-PET (n=68) were performed. FDG 
PET-CT, BS and 18F-PET were evaluated by two experienced 
readers. Lesions were graded on a scale from 1 (definite BM) to 5 
(degenerative lesion), equivocal lesions were determined as indiffer-
ent (grade 3). 
Results: 92 patients showed degenerative lesions (grade 4/5) at PET-
CT, BS or 18F-PET. In 34 patients (27%) BM lesions were diagnosed 
(grade 1 and 2). In 13/18 patients BM were concordantly diagnosed 
with PET-CT and 18F-PET. PET-CT showed more BM compared 
to 18F-PET (53 vs. 40). In one patient one osteolytic BM was false 
negative on 18F-PET. However, 18F-PET identified 4 patients with 
BM compared to negative findings on PET-CT. 11/16 patients had 
concordant findings of BM on PET-CT and BS. In 3 patients BS was 
false negative and in 2 patients BM were diagnosed as indifferent.
Conclusions: Integrated FDG PET-CT is superior to BS in the detec-
tion of osteolytic BM in NSCLC. Thus, PET-CT may obviate the 
need to perform additional BS or 18F-PET in the staging of NSCLC, 
which significantly reduces costs. However, in a minority of cases 
osteoblastic BM may lead to false negative results on PET-CT. 
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Accuracy of 18F-FDG PET-CT scanning for hilar and 
mediastinal lymph nodes in potentially operable non-small 
cell lung cancer in a tuberculous endemic country
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Background: Accurate staging of ‘early’, potentially operable non-
small cell lung cancer (NSCLC) is important not only for prognos-
tication and comparability across studies, but also for guiding treat-
ment decisions. The status of mediastinal lymph nodal involvement 
changes treatment decisions from primary surgery (if uninvolved) to 
neoadjuvant chemotherapy (if ipsilateral lymph nodes are involved) 
and palliative chemotherapy (if contralateral lymph nodes are in-
volved). Accuracy of staging by conventional modalities ranges from 
50-70%. PET-CT scanning is a promising investigation which has 
been incorporated into the staging protocol of NSCLC in developed 
countries. Most of the data on PET-CT scanning in NSCLC originates 
from developed countries where the incidence of infectious disease is 
low. Infectious and granulomatous diseases like tuberculosis are more 
common in developing countries and this could compromise the ac-
curacy of PET-CT scans in countries like India where these diseases 
are endemic.
Methods: We performed a retrospective study to evaluate the utility 
of PET-CT scans in the diagnostic workup of patients with potentially 
operable NSCLC. We retrieved medical records of all patients who 
underwent a PET-CT scan prior to surgery for suspected NSCLC 
and later underwent lung resection for lung cancer between January 
2005 and December 2008. Hilar and mediastinal lymph nodes were 
considered metastatic when the standardized uptake value (SUV) 
was more than 2.5 gm/ml. PET-CT findings were correlated with 
final histopathology of the resected specimen. Systematic mediastinal 
nodal sampling was performed on cases with proven malignancy 
with each lymph node station being labeled separately and sent for 
reporting. Histopathological reporting was done by pathologists 
experienced in lung cancer reporting using standard techniques. The 
data was entered into a database and analysis was performed using 
the SPSS for Windows, version 14 software package. Sensitivity, 
specificity, positive predictive value and negative predictive value 
were calculated using the binomial approximation test.
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Results: Two hundred and eighty patients underwent PET-CT scan 
and 149 (53.3%) were found suitable for surgery while 131 (46.7%) 
were treated with non-surgical options either because they were up-
staged or because they were unfit for major lung resection. Complete 
data was available on 131 patients who underwent systematic medi-
astinal lymph node dissection. The FDG uptake in the primary had 
a range of max SUV 5-32 and a mean SUV of 12. Using a SUV cut 
off of 2.5, the sensitivity, specificity, positive and negative predictive 
values and accuracy of hilar lymph nodal (N1) staging was 87, 80, 
74, 91 and 83% while that for mediastinal lymph nodal staging was 
83, 81, 71, 89 and 82% respectively. Out of the 16 false positives 
(12.2%), five were because of tuberculosis (3.8%) while 11 (8.4%) 
had reactive inflammatory, non-granulomatous nodes with increased 
uptake. 
Conclusion: PET-CT scanning gives acceptable sensitivity, negative 
predictive value and accuracy of staging mediastinal lymph nodes in 
NSCLC even in a tuberculous-endemic country like India. Prospect-
ive studies should evaluate the exact impact of PET-CT scanning on 
treatment decisions in early NSCLC.
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Intraoperative sentinel lymph node identification 
using novel receptor binding agent (Technetium-99m 
Neomannosyl Human Serum Albumin, 99mTc-MSA) in 
stage I non-small cell lung cancer 
Kim, Hyun Koo; Kim, SeungEun; Kang, Du-Young; Jeong, Jae Min; 
Choi, Young Ho
Department of Thoracic and Cardiovascular Surgery, College of 
Medicine, Korea Universtiy Guro Hospital, Seoul, Korea
Background: In order to simplify synthesis and labelling procedures 
and to improve the biological properties, we developed a novel man-
nose receptor-binding agent, Technetium-99m neomannosyl human 
serum albumin (99mTc-MSA). This study was designed to test the 
reliability and feasibility of sentinel nodes identification using this 
new radioactive agent in stage I non-small cell lung cancer.
Methods: A total dose of 1mCi of 99mTc- MSA in 0.2ml was admin-
istered in one shot at the peri-tumoral region under the chest CT or 
bronchoscope guidance 3 hours before surgery in the CT room. Dy-
namic whole-body SPECT lymphoscintigraphic image was obtained 
at 30 min after injection and static thoracic SPECT lymphoscintig-
raphy images were acquired at 1 and 2 hour after injection.
During operation, the radioactivity of the lymph nodes was counted 
with a handheld gamma probe before (in vivo) and after (ex vivo) 
dissection. Lymph nodes with an ex vivo radioactive count more than 
5 times the radioactivity count of the resected lung tissue were identi-
fied as sentinel nodes. The correlation between the in vivo and ex 
vivo results was examined. All harvested lymph nodes were exam-
ined histologically.
Results: Fourty-two patients (30 men, 12 women; mean age, 
63.3±8.91 years) who were candidates for lobectomy with mediastin-
al lymph node dissection for stage I non-small cell lung cancer were 
enrolled consecutively. Sentinel nodes could be detected from 30 
minutes to 5 hours after the injection of 99mTc-MSA on lymphoscin-
tigraphy (Figure 1). The mean number of dissected lymph nodes per 
patients was 22.1±11.55 (4~57). Among 42 patients, sentinel lymph 
nodes could be identified in 40 patients (95.2%). The mean number 
of sentinel lymph nodes identified was 2.3±1.07 stations (range, 1~5) 
per patient. Ten of the 40 patients (25.0%) had metastases in 11 sen-
tinel lymph nodes. Three of these 11 sentinel lymph nodes (27.3%) 
had skip metastases. No false-negative sentinel lymph nodes were 
detected in any of the 10 patients with N1 or N2 disease (0%). The 
relationship between in vivo and ex vivo results for mediastinal senti-
nel lymph nodes showed concurrence in 29 of 40 patients (72.5%).
Conclusions: The results of this clinical trial showed that 99mTc-
MSA had promising properties for sentinel nodes identification in 
non-small cell lung cancer. 
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D1.1 Early Detection and Chemoprevention, Tue Aug 4, 12:30 - 14:00
The pan-Canadian early detection of lung cancer study
Lam, Stephen1; Tsao, Ming-Sound2; Tammemagi, Martin3; Mayo, 
John4; Roberts, Heidi2; McWilliams, Annette 1; Tremblay, Alain5; 
Puksa, Serge6; Martel, Simon7; Johnston, Michael8; Nicholas, Garth9; 
Peacock, Stuart1; Sin, Don10; Liu, Geoffrey2; Goffin, John6; Evans, 
Bill 6; Burrowes, Paul5; Stewart, Lori6; Yasufuku, Kazuhiro2; Seely, 
Jean9; Soghrati, Kam2; Manos, Daria8; Gingras, Michael7; Amjadi, 
Kayvan9; Leighl, Natasha2; Gazdar, Adi11; Shepherd, Frances2
1 British Columbia Cancer Agency, Vancouver, BC, Canada; 
2 Princess Margaret Hospital, Toronto, ON, Canada; 3 Brock 
University, St. Catherines, ON, Canada; 4 Vancouver General 
Hospital, Vancouver, BC, Canada; 5 Foothills Hospital, U of Calgary, 
Calgary, AB, Canada; 6 Juravinski Cancer Center, McMaster 
University, Hamilton, ON, Canada; 7 Hôpital Laval & U de Laval, 
Quebec City, QC, Canada; 8 QEII HSC, Dalhousie U, Halifax, NS, 
Canada; 9 Ottawa Hospital Regional Cancer Centre, U of Ottawa, 
Ottawa, ON, Canada; 10 iCapture Center, Sr. Paul’s Hospital, 
Vancouver, BC, Canada; 11 UT Southwestern Medical Center, Dallas, 
TX, USA
Background: Sophisticated but relatively expensive technologies 
such as low dose helical computed tomography (CT) and autofluor-
escence bronchoscopy (AFB) exist for detection of early lung cancer. 
Our hypothesis is that the inclusion of low cost risk modeling and 
biomarkers to select population cohorts with the highest risk of lung 
cancer development will improve cost effectiveness of relatively 
expensive yet sensitive detection methods. This could render early 
detection of lung cancer an affordable program within the Canadian 
and other health care systems. The overall objective of our study is 
to develop a new multi-modal early detection strategy that integrates 
risk modeling, spirometry, AFB and blood biomarkers with CT for 
early detection of lung cancer. 
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Study Design: The study will recruit over 20 months 2,500 smokers 
age 50 to 75 from 7 Canadian centers. Subjects will have an esti-
mated 3-year lung cancer risk ≥ 2% based on a novel lung cancer risk 
assessment model incorporating demographic, socio-economic and 
clinical factors derived from the NCI Prostate Lung Colon Ovarian 
study. The model was validated using 2542 high risk smokers partici-
pating in several NCI sponsored chemoprevention trials. Following a 
detailed questionnaire, spirometry, collection of blood specimens for 
biomarker measurement and low dose non-contrast enhanced thoracic 
spiral CT are obtained on all participants at baseline and month 12. 
Baseline AFB is performed in the first 50% of participants. All par-
ticipants will be followed for a minimum of 3 years. The prevalence 
of CT & AFB abnormalities across the country, number of prevalent 
and incident lung cancers, resource utilization, actual cost of inves-
tigations and treatment (e.g. procedure costs, length of hospital stay, 
type of hospital ward, chemotherapy, radiotherapy, physician visits 
related to screening procedure) and the impact of early detection tests 
on the quality of life will be determined prospectively. The incremen-
tal value of spirometry and novel blood biomarkers such as CTAP III 
(J Clinical Oncology, in press) for lung cancer risk assessment will 
be evaluated. Results. Enrollment began in October 1, 2008. To-date, 
over 20% of the participants have been enrolled. It is anticipated the 
enrollment will be completed by June 2010. 
Significance of Study: If the two large randomized trials currently 
underway in the United States and Europe comparing helical CT with 
chest x-ray or no screening show a mortality reduction benefit, our 
study will provide the framework for a practical, low cost approach 
that can be adopted in a public health care setting. 
The study is sponsored by the Terry Fox Research Institute and the 
Canadian Partnership Against Cancer. The contribution of Dr. Chris-
tine Berg (US NCI) in the study methodology is also acknowledged.
D1.2 Early Detection and Chemoprevention, Tue Aug 4, 12:30 - 14:00
Stage-size relationship in long-term repeated CT screening 
for lung cancer: Anti-Lung Cancer Association projects
Seki, Nobuhiko1; Eguchi, Kenji 1; Kaneko, Masahiro 2; Ohmatsu, 
Hironobu 3; Kakinuma, Ryutaro 2; Matsui, Eisuke 4; Kusumoto, 
Masahiko 2; Tsuchida, Takaaki 2; Nishiyama, Hiroyuki 5; Moriyama, 
Noriyuki 2
1 Teikyo University School of Medicine, Tokyo, Japan; 2 National 
Cancer Center Hospital (NCCH), Tokyo, Japan; 3 NCCH East, 
Chiba, Japan; 4 Anti-Lung Cancer Association, Tokyo, Japan; 5 
Social Health Insurance Medical Center, Tokyo, Japan
Background: We have investigated the individualized benefit of CT 
screening as Anti-Lung Cancer Association projects (presented at 
ASCO 2006-2008). However, there has not been enough information 
about the relationship of lung cancer stage to tumor size in repeated 
CT screening. Therefore, we evaluated the stage-size relationship 
of these asymptomatic lung cancer cases diagnosed by long-term 
repeated screening with low-dose helical CT.
Methods: Among 2,120 participants (mean age 63 years, 87% male, 
and 83% smoker) at baseline screening, 1,877 underwent semian-
nually repeated screening from 1993 to 2004. Nineteen (0.90%) 
prevalence cancers and 57 (0.32%) incidence cancers were detected. 
Within categories of tumor size, the distribution of pathological stage, 
histology, lymph node status, and distant metastases was determined.
Results: Pathological stage has a strong relationship to tumor size at 
baseline screening (spearman r=0.63, p=0.013) and repeated screen-
ing (r=0.65, p<0.001). In the analysis of all 76 cases, lymph node 
status (r=0.59, p<0.001) and distant metastases (r=0.55, p=0.005) 
have also a strong relationship to tumor size. The percentages of 
cases with no metastases (N0M0) were 100% (0/21), 89% (17/19), 
62% (8/13), 83% (10/12), 50% (4/8), and 33% (1/3) for the categor-
ies 10 mm or less, 11 to 15 mm, 16 to 20 mm, 21 to 30 mm, 31 to 40 
mm, and 41 mm or greater, respectively. Histology for the categor-
ies 15 mm or less was localized bronchioloalveolar carcinoma in 
13 cases, adenocarcinoma with mixed subtype in 11 cases, invasive 
adenocarcinoma in 5 cases, other non-small cell carcinoma in 10 
cases, and small cell carcinoma in 1 case. Accumulated 10-year haz-
ard ratio of above histology was 2.4, 2.5, 2.6, 4.1, and 0.7, respect-
ively. In multivariate analyses, pathological stage was related to only 
tumor size (standardized regression coefficient beta=0.59, p<0.001) 
whereas histology was related to tumor size (beta=0.43, p<0.001) and 
smoking index (beta=0.28, p=0.016). 
Conclusions: These results provide direct evidence of a stage-size 
relationship in long-term repeated CT screening for lung cancer. 
Furthermore, early detection of lung cancer of 15 mm or less in 
diameter leads to the detection of early-stage (N0M0) lung cancer in 
repeated CT screening.
D1.3 Early Detection and Chemoprevention, Tue Aug 4, 12:30 - 14:00
The lung cell evaluation device (LuCED): early detection 
of lung cancer in sputum based on 3D morphology
Meyer, Michael G.; Patten, Florence W.; Neumann, Thomas; 
Hayenga, Jon W.; Steinhauer, David E.; Rahn, John R.; Nelson, Alan 
C.
VisionGate, Gig Harbor, WA, USA
Background: The Cell-CT produces 3D volumetric cell represen-
tations in isometric, sub-micron resolution based on computed 
tomography. VisionGate, Inc., in collaboration with the University of 
Washington, is developing the LuCED test to score sputum samples 
processed by the Cell-CT for evidence of cell dysplasia or cancer. 
LuCED scores may be used clinically to assist in patient triage. 
Methods: The LuCED test comprises a series of steps starting 
with cell preparation including fixation and staining with hema-
toxylin. Cells of each type found in sputum from normal patients 
were volumetrically sampled, as were cancer cells from culture and 
isolated from resected lung tissue. The 3D volumes were processed 
to extract features that correlate with the abnormal condition of the 
cell. LuCED scores were trained using cytological diagnosis as the 
reference. Training was done in a rigorous, cross-validated mode, 
using a genetic algorithm for feature selection and adaptively-boosted 
logistic regression to produce classifiers. LuCED score performance 
was assessed using receiver operator characteristic (ROC) analysis. 
Variance in ROC results were assessed using bootstrap techniques. 
Prevalence counts of abnormal cells in sputa from patients with con-
firmed cancer were used to estimate patient detection rates based on 
cell-classification performance. 
Results: Movies of rotating volumes were produced for a variety 
of cells and show the distinctive 3D morphology of each cell type. 
Figure 1 shows 2D maximum-intensity projections in different orien-
tations, created from a 3D reconstruction of a squamous-cancer cell 
(a-c). Figure 1 also shows the same cell from the perspective in (c), 
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whole and cropped, where coloring and opacity have been adjusted to 
enhance cell features. In (d) and (e), cytoplasm is in translucent gray, 
the nuclear wall is in opaque blue and the nucleoplasm is rendered in 
a green to red gradient, with nucleoli in opaque red. 
Normal cell versus cancer training on 3D data sets produced an ROC 
curve showing near-perfect discrimination. Analysis of sputa from 
patients with cancer shows that 75% have abnormal cells. Specimen-
based detection rates depend on the number of abnormal cells in 
the specimen. Based on cellular prevalence counts, we estimate that 
LuCED sensitivity exceeds 90% as specificity approaches 100% for 
patients with cancer cells in sputum. 
Conclusion: Cell analysis in 3D provides an unobstructed and 
unambiguous representation of normal and cancer cell morphology 
making the LuCED score an exceptionally accurate means for auto-
mated assessment of lung cancer risk based on patient sputum. 
D1.4 Early Detection and Chemoprevention, Tue Aug 4, 12:30 - 14:00
Improved accuracy for bronchial pre-neoplasia detection 
with videobronchoscopy
Lee, Pyng1; Eberhardt, Ralf2; Herth, Felix2
1 Department of Respiratory and Critical Care Medicine, Singapore 
General Hospital, Singapore, Singapore; 2 Thoraxklinik, Heidelberg, 
Germany; 3 Department of Clinical Research, Singapore General 
Hospital, Singapore, Singapore
Background: The incorporation of autofluorescence (AF) to white 
light bronchoscopy has improved the sensitivity for bronchial pre-
neoplasia detection. Past studies have demonstrated low sensitivity 
and high specificity using the fiberoptic bronchoscope. With the 
advent of videobronchoscope that allows for greater image enhance-
ment, sensitivity has correspondingly improved.
Aim: To evaluate efficacy of videobronchoscopy compared with AFI 
in detecting moderate and high-grade dysplasia and in discriminating 
dysplasia from bronchitis. 
Methods: 570 patients suspected of lung cancer underwent video 
and AFI bronchoscopy (Olympus, Japan). Each site was classified 
as normal, abnormal or suspicious by video and autofluorescence 
bronchoscopy. Biopsy was performed for all areas graded abnormal 
and suspicious. In patients with normal video and AFI bronchoscopy, 
specimens were obtained from second-generation carina. The biopsy 
specimens were graded in accordance with International Histological 
Classification of Tumours. 
Statistics: For the purpose of analysis, physician’s visual classifica-
tion was converted to 2-point scale where normal and abnormal 
became “negative” and suspicious became “positive”. Final patho-
logical diagnosis was also converted to 2-point scale where mild 
dysplasia and lower was labelled as “negative,” moderate dysplasia 
and worse as “positive”.
Results: 674 airway sites and biopsies were evaluated. Sensitivity 
and specificity values for videobronchoscopy and AFI in the detec-
tion of moderate dysplasia and worse were 90%, 99%, and 97%, 94% 
respectively. Kappa agreements between grading using videobron-
choscopy and AFI with histology were 0.91 (p <0.0001) and 0.86 (p 
<0.0001) respectively. In 46 sites where histology showed inflam-
mation, videobronchoscopy was better than AFI in discriminating 
bronchitis. These were graded abnormal but not suspicious with 
videobronchoscopy while 48% (n=22) were considered suspicious by 
AFI. 
Conclusion: Improvements in videobronchoscopy represent contin-
ual advances in image quality that allow detection of pre-neoplastic 
lesions, which are comparable to AFI.
D1.5 Early Detection and Chemoprevention, Tue Aug 4, 12:30 - 14:00
Methylation analysis in spontaneous sputum is suitable for 
lung cancer diagnosis 
Thunnissen, Erik1; van der Drift, Miep2; Prinsen, Clemens4; Wang, 
Yinghui5; Shivapurkar, Narayan6; Bolijn, Anne4; Feng, Ziding5; de 
Boo, Theo7; Dekhuijzen, Richard3; Gazdar, Adi6
1 PAthology, VUmc, Amsterdam, Netherlands; 2 Department of 
Pulmonology, University Medical Center Nijmegen, Nijmegen, 
Netherlands; 3 Dept. Pulmonology, UMCN, Nijmegen, Netherlands; 
4 Dept. Pathology, CWZ, Nijmegen, Netherlands; 5 Fred Hutchinson 
Cancer Research Center, Seattle, USA; 6 Hamon Center for 
Therapeutic Oncology Research, UT Southwestern Medical Center, 
Dallas, Netherlands; 7 Department of Statistics, UMCN, Nijmegen, 
Netherlands
Background: Lung cancer is the most common fatal cancer in the 
world due to presence of metastases at time of diagnosis. In a recent 
small study using quantitative mehylation specific PCR on prospect-
ively collected samples a difference between sputum samples of 
patients with lung cancer and controls was reported. The aim of the 
present study was to perform a larger validation study to hyperm-
ethylation as a diagnostic marker in sputum of lung cancer patients.
Materials and Methods: From the prospectively collected sputum 
bank two independent randomly selected study sets were prepared: 
a learning set of 204 cases equally distributed between controls 
(n=102) and lung cancers (n=102) collected within 6 months before 
diagnosis. The following methylation markers were determined with 
Q-MSP: 3-ost 2, APC, Cytoglobin, O6-methyl-guanine-DNA methyl-
transferase, p16, RASSF1A and TCF21 on the learning set. The test 
set consited of n= 61 lung cancer and n= 305 controls. Based on the 
learning set 3 markers were used on the test set.
Results: A total of 570 sputum samples were examined. Three 
markers (RASSF1A, cytoglobin and APC) were selected from the 
learning set data and evaluated on the test set. Consistent results were 
obtained: sensitivity 61% and specificity 90%. 
For the cytological diagnosis “suspicious for carcinoma” or “malig-
nant” combined the sensitivity for cytology was 29.5%. If we make 
prediction using RASSF1A only, the sensitivity was 41.0%. However, 
for prediction using either “suspicious for carcinoma/malignant” or 
RASSF1A as lung cancer cases, the sensitivity increased to 54.1% 
with similar specificity for these three analysis (98-99%).
Conclusion: This study shows that the outome of hypermethylation 
in the learning set is confirmed in the validation set and supports 
the use of methylation analysis in sputum as means for lung cancer 
diagnosis. 
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D1.6 Early Detection and Chemoprevention, Tue Aug 4, 12:30 - 14:00
Oral iloprost improves endobronchial dysplasia in former 
smokers
Keith, Robert L.1, 3; Kittelson, John K.2; Blatchford, Patrick J.2; 
Jackson, Mary3; Franklin, Wilbur A.3, 4; Hirsch, Fred R.3; Minna, 
John5; Bunn, Paul A.3; Miller, York E.1, 3
1 Denver VAMC/UC Denver, Denver, CO, USA; 2 University of 
Colorado School of Public Health, Aurora, CO, USA; 3 University 
of Colorado Comprehensive Cancer Center, Aurora, CO, USA; 4 
Department of Pathology, University of Colorado Denver, Denver, 
CO, USA; 5 Hamon Center for Therapeutic Oncology, University of 
Texas Southwestern, Dallas, TX, USA
Background: Tissue microarray studies have shown that the major-
ity of NSCLC have decreased expression of prostacyclin synthase 
(PGIS). Prostacyclin supplementation (genetic overexpression and 
the oral prostacyclin analogue iloprost) prevents development of 
lung cancer in a variety of murine models, including cigarette smoke 
exposure. Based on these promising results, a multi-center, double-
blind, placebo controlled, phase II trial of iloprost in subjects at 
increased risk for lung cancer was designed and recently completed.
Methods: Subjects were selected for the trial if they met the fol-
lowing criteria: current or former smoker (≥ 20 pack years tobacco 
exposure); at least mild cytologic atypia on sputum cytology or a 
history of endobronchial dysplasia; and no previous history of cancer. 
Fluorescent and white light bronchoscopy was performed with 6 stan-
dard endobronchial sites biopsied, along with all other abnormally 
appearing areas. Subjects were then randomized to oral iloprost (in 
escalating doses) or placebo for 6 months and then a second bron-
choscopy with repeat biopsy of all the central airway areas sampled 
during the first bronchoscopy. The primary endpoints for the study 
are bronchial histology and Ki-67 labeling index. 
Results: The enrollment goal of 152 subjects was met, of which 125 
completed both bronchoscopies. Baseline characteristics showed the 
subjects to be matched in terms of age and tobacco exposure. The 
endobronchial biopsies were scored on a 1-8 scale based on WHO 
criteria. Endobronchial histology was summarized within subjects 
using three separate measures: worst biopsy score (Max), dysplasia 
index (DI - defined as the percentage of biopsies with a score of 4 
(mild dysplasia) or worse), and average of all biopsy scores (Avg). 
The averages of these measures for all trial subjects at baseline were: 
Max = 4.0 (SD = 1.6), DI = 32.9% (SD = 30.1), and Avg = 2.6 (SD = 
1.1). The average number of baseline biopsies was 7.0 (SD = 1.7). At 
the baseline bronchoscopy, current smokers had a significantly higher 
Avg score than former smokers (3.0 vs. 2.1, p<0.001). There were no 
other statistically significant differences between treatment groups 
in any of the baseline histologic measures. Follow-up bronchoscopy 
was performed on 60 subjects in the iloprost group and 65 subjects in 
the placebo group. Former smokers randomized to iloprost treatment 
showed significantly greater improvement in all histology measures: 
Max (Iloprost vs. placebo: -0.59 vs. 0.50, p = 0.004), DI (-8.84 vs. 
0.10, p = 0.019) and Avg (-0.33 vs. -0.02, p = 0.046). Iloprost did 
not have any significant effects on histology among participants who 
continued to smoke during the trial. Biopsies are also currently being 
evaluated for Ki-67 labeling index and further data analyses are in 
progress.
Conclusions: The iloprost chemoprevention trial has been com-
pleted, and our recruitment model was able to identify subjects with 
endobronchial dysplasia. The treatment has been well tolerated. For-
mer smokers who received iloprost showed a statistically significant 
improvement in histologic measurements after 6 months of treatment. 
Current smokers did not exhibit any improvement.
D1.7 Early Detection and Chemoprevention, Tue Aug 4, 12:30 - 14:00
Preliminary validation of a lung cancer diagnostic 
biomarker panel identified through mass spectrometry-
based discovery in cancer tissues and cell lines 
Rom, William N.4; Pass, Harvey I.4; FitzHugh, William 3; Dhariwal, 
Gulshan2; Heidbrink, Jenny1; Ruben, Steve M.1; Birse, Charles E.1
1 Celera, Rockville, MD, USA; 2 Celera, New York, MD, USA; 3 
5AM Solutions, Reston, VA, USA; 4 New York University School of 
Medicine, New York, NY, USA
Background: Biomarkers may have considerable value at various 
stages in detection/diagnosis of lung cancer: in screening high risk 
individuals, in combination with imaging technologies to improve 
resolution of malignant nodules, as a means of enhancing manage-
ment of pulmonary nodules identified through CT-scanning, or in 
monitoring of treatment efficacy or tumor recurrence. The populariza-
tion of computed tomography (CT) in clinical practice has increased 
the frequency of resolving subtle nodules and nodular ground-glass 
opacity (GGO). It is possible that biomarkers may be able to ac-
curately distinguish GGO lesions with malignant potential from those 
that are more benign. However, the search for biomarkers for early 
detection and diagnosis of lung cancer has met with limited success; 
with markers resolved to date having inadequate sensitivity or specifi-
city to be clinically useful. We have employed a novel mass spec-
trometry (MS)-based approach to identify a collection of biomarkers 
which have been subsequently shown to be differentially expressed in 
the circulation of non-small cell lung cancer patients. 
Methods: Discovery of candidate biomarkers was achieved through 
Liquid Chromatography (LC)/MS analyses of resected lung tumor 
specimens and a panel of lung cancer cell lines. Candidate bio-
markers identified by MS were screened using ELISA analysis, in a 
pilot set of sera derived from 103 individuals with NSCLC and 104 
healthy smoker controls. Markers that showed elevated disease ex-
pression were further validated in an independent collection of serum 
samples that included: 39 subjects with NSCLC, 38 non-cancer 
smoking controls, 20 subjects with nodular GGO. 
Results: Of the ~500 cell surface/secreted proteins expressed at 
elevated levels in lung carcinoma, cell lines and conditioned media, 
13 were selected for subsequent screening in serum from subjects 
with NSCLCs and appropriate controls. Several of the selected mark-
ers have not previously been reported to show elevated expression 
in the circulation of lung cancer patients. A panel of 9 biomarkers 
was assembled that detected lung cancer with 82% sensitivity and 
92% specificity using split point analysis. Cross-validation of results, 
using logistic regression and Naïve Bayes analyses, confirmed high 
assay performance. The test to distinguish malignant GGOs will be 
discussed. A blinded study, aimed at confirming biomarker panel 
performance is planned. 
Conclusions: Proteomic analyses of lung tumors and cell lines en-
abled the identification of biomarker candidates subsequently shown 
to be expressed at elevated levels in sera from lung cancer patients, 
but not in the sera of healthy controls or individuals with benign 
lung diseases. Test panels were configured that detect lung cancer 
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with higher sensitivity and specificity than those panels previously 
reported. These markers provide the flexibility to design tests with 
performance specifications suitable for a variety of diagnostic ap-
plications.
Session D2: Advanced NSCLC - Novel Therapeutics II 
Tuesday, August 4
D2.1 Advanced NSCLC - Novel Therapeutics II, Tue Aug 4, 12:30 - 12:00
UFUR prolong disease-free survival of Taiwanese 
adenocarcinoma patients who receive gefitinib treatment – 
preliminary report of a phase II randomized trial
Chen, Yuh-Min1; Fan, Wen-Chien1; Shih, Jen-Fu1; Tsai, Chun-Ming1; 
Lee, Yu-Chin1; Perng, Reury-Perng1; Whang-Peng, Jacqueline2
1 Chest Department, Taipei Veterans General Hospital, Taipei, 
Taiwan; 2 School of Medicine, Taipei Medical University, Taipei, 
Taiwan
Background: UFUR (tegafur/uracil) is suitable for metronomic 
chemotherapy with its underlying anti-angiogenesis mechanism. 
Present study is to assess the feasibility and the efficacy of adding 
daily low dose of oral UFUR into gefitinib treatment in lung cancer 
patients with adenocarcinoma who failed previous chemotherapy.
Methods: Taiwanese patients who had adenocarcinoma and failed 
previous chemotherapy, were enrolled and randomized into two arms: 
Oral gefitinib 250 mg daily alone (G) or plus oral UFUR (tegafur 
100mg, uracil 224mg) twice daily (GU). From November 2005 to 
December 2008, 107 patients were enrolled.
Results: These 107 patients were evaluable for treatment response 
and toxicity at the end of February 2009, including 54 patients in G 
and 53 patients in GU. Objective response rates were 27.8% in G 
and 18.9% in GU. Disease control rate (partial response plus stable 
disease) was 57.4% in G and 71.7% in GU. No grade 3 or higher 
toxicity occurred in present study. There was no statistical significant 
difference regarding toxicity profiles between two treatment arms. 
Median time to disease progression was higher in GU (n=53, censor 
17) than G (n=54, censor 11) (4.97 months vs 2.83 months, p=0.099). 
Three-month progression-free survival was 49.9% in G and 62.7% in 
GU, respectively. 
Conclusions: Gefitinib are effective in Taiwanese patients with 
adenocarcinoma of lung and failed previous chemotherapy. Addition 
of daily UFUR treatment produced a better progression free survival, 
although statistically insignificant. 
D2.2 Advanced NSCLC - Novel Therapeutics II, Tue Aug 4, 12:30 - 12:00
A randomized, parallel-group, phase II study to evaluate 
the efficacy and safety of three doses of the integrin 
inhibitor cilengitide compared with docetaxel in patients 
with stage IV non-small cell lung cancer (NSCLC) after 
failure of first-line chemotherapy
Manegold, Christian1; Vansteenkiste, Johan2; Cardenal, Felipe3; 
Schütte, Wolfgang4; Woll, Penella5; Ulsperger, Ernst6; Rüter, Björn7; 
Picard, Martin7; Eckmayr, Josef8; von Pawel, Joachim 9
1 Universitätsmedizin, Medizinische Fakultät Mannheim der 
Universität Heidelberg, Chirurgische Klinik - Interdisziplinäre 
Thorakale Onkologie, Mannheim, Germany; 2 Respiratory Oncology 
Unit – Univ. Hosp. Gasthuisberg, Leuven, Belgium; 3 Institut 
Català d’Oncologia, L’Hospitalet, Spain; 4 Krankenhaus Martha-
Maria Halle-Dölau, Halle, Germany; 5 University of Sheffield, 
Sheffield, UK; 6 5th Medical Department, Oncology, KHR Hietzing, 
Vienna, Austria; 7 Merck KGaA, Darmstadt, Germany; 8 Klinikum 
Wels, Grieskirchen, General Hospital, Wels, Austria; 9 Asklepios 
Fachkliniken München-Gauting, Gauting, Germany
Background: Integrins are heterodimeric transmembrane recep-
tors that play key roles in cell–matrix and cell–cell interactions and 
trigger intracellular signaling to regulate multiple cellular processes. 
Integrin inhibitors are a new class of anti-cancer agents and cilen-
gitide (EMD 121974) is the most advanced compound in clinical 
development. Cilengitide selectively inhibits the cell-surface integrins 
αVβ3 and αVβ5 on tumor cells during growth and invasion and on 
activated endothelial cells during angiogenesis. 
Methods: This was a multicenter, randomized, open-label, parallel-
group, phase II study in patients with relapsed stage IV NSCLC who 
had failed first-line chemotherapy. Patients were randomized to one 
of three cilengitide doses, 240, 400, or 600 mg/m2 twice weekly, or 
docetaxel 75 mg/m2 once every 3-week cycle for 6 months. Patients 
who responded to cilengitide could continue treatment for up to 1 
year. The primary endpoint was progression-free survival (PFS). Sec-
ondary endpoints included overall survival (OS) and response. 
Results: A total of 140 patients were included: 34 received docetaxel 
75 mg/m2, 35 received cilengitide 240 mg/m2, 35 received cilengitide 
400 mg/m2, and 36 received cilengitide 600 mg/m2. Patient demo-
graphics were: median age 60 years (range 33–80); 94 patients (67%) 
were male; and 83% of patients had a KPS of ≥80%. Median PFS 
(95% CI) was 54 (43–64), 63 (53–66), 63 (42–67), and 67 (61–123) 
days for cilengitide 240, 400, 600, and docetaxel 75 mg/m2, respect-
ively. Median OS (95% CI) was 173 (81–197), 117 (92–209), 181 
(90–326), and 194 (135–298) days, respectively. The 1-year survival 
rate (95% CI) was 13% (1–24%), 13% (0–26%), 29% (12–37%), 
and 27% (10–43%), respectively. Survival rates were similar for 
cilengitide 600 mg/m2 and docetaxel 75 mg/m2 with median OS of 
181 versus 194 days and a 1-year survival rate (95% CI) of 29% 
(12–37%) versus 27% (10–43%). Five docetaxel patients (15%) had 
a partial response. Almost all patients (98%) experienced at least 
one adverse event. The most frequent adverse events were dyspnea 
(33%), nausea (30%), tumor progression (29%), and cough (23%). 
Dyspnea and tumor progression were more frequent with cilengitide 
than with docetaxel. Grade 3/4 treatment-related adverse events were 
more frequent with docetaxel (n=13, 41%) than with cilengitide 240 
(n=2, 6%), 400 (n=4, 11%), or 600 (n=4, 11%) mg/m2. Grade 3/4 
treatment-related adverse events for cilengitide were nausea, chest 
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pain, dyspnea, and fatigue, and for docetaxel were nausea, dyspnea, 
fatigue, leukopenia, and neutropenia. The only grade 3/4 treatment-
related adverse event for cilengitide 600 mg/m2 was fatigue. Overall, 
serious adverse events were more frequent with docetaxel 75 mg/
m2 (47%) than with cilengitide 240 (35%), 400 (46%), or 600 mg/
m2 (28%). There were generally no clinically significant differences 
between the cilengitide dose groups and docetaxel with respect to 
vital signs, ECG findings, and laboratory variables. 
Conclusion: PFS with cilengitide at all three doses was less than that 
of docetaxel. The cilengitide 600 mg/m2 dose showed similar OS to 
docetaxel and improved tolerability. Studies to investigate cilengitide 
in combination with standard chemotherapy are warranted.
D2.3 Advanced NSCLC - Novel Therapeutics II, Tue Aug 4, 12:30 - 12:00
Celecoxib in docetaxel/carboplatin treated patients (pts) 
with advanced non-small cell lung cancer (NSCLC): 
interaction of treatment with histology; a randomized 
placebo-controlled phase III study of the NVALT Group
Groen, Harry J.1; van Putten, John W.2; Hochstenbag, Monique M.3; 
Vincent, Andrew4; Dalesio, Otilia4; Smit, Hans J.5; Termeer, Rene6; 
van den Borne, Ben E.7; Biesma, Bonne8; Schramel, Franz M.9
1 Unversity Medical Center Groningen, Groningen, Netherlands; 
2 Martini Hospital, Groningen, Netherlands; 3 University Medical 
Center Maastricht, Maastricht, Netherlands; 4 Netherlands Cancer 
Institute Amsterdam, Amsterdam, Netherlands; 5 Alysis Zorggroep 
location Rijnstate Hospital Arnhem, Arnhem, Netherlands; 6 Canisius 
Wilhelmina Hospital Nijmegen, Nijmegen, Netherlands; 7 Catharina 
Hospital Eindhoven, Eindhoven, Netherlands; 8 Jeroen Bosch 
Hospital’s Hertogenbosch, s’-Hertogenbosch, Netherlands; 9 St. 
Antonius hospital Nieuwegein, Nieuwegein, Netherlands
Background: Cox-2 is overexpressed in NSCLC tumors and has 
a negative impact on survival. It is involved in proliferation and 
angiogenesis. The hypothesis is that there is an interaction between 
celecoxib and histology or between chemotherapy and histology 
prolonging survival.
Methods: We performed a phase III study in advanced NSCLC pts. 
Planned sample size was 540 pts. Included were pts with pathologic-
ally proven NSCLC, no prior chemotherapy, PS=0-2, measurable dis-
ease, adequate organ functions. Excluded were pts with CHF NYHA 
class II-IV, ischaemic heart, cerebrovascular and/or peripheral arterial 
disease, gastrointestinal bleeding, symptomatic brain metastases and 
chronic use of NSAIDs (defined as 1 wk for >3 wks per yr or more 
than 21 days throughout the year). Acetylsalicylic acid < 150 mg/d 
was allowed.
Pts were treated with docetaxel 75 mg/m², carboplatin (AUC = 6 mg/
ml.min) every 3 wks for 5 cycles and randomized for celecoxib 400 
mg bd, starting on day 1 for 3 years or placebo 400 mg bd. Stratifica-
tion was by WHO PS (0-1 vs. 2), stage (IIIB vs. IV), use of acetyl-
salicylic acid (yes vs. no) and hospital site. Primary endpoint was 
overall survival.
Results: From July 2003 until Dec 2007 561 pts were random-
ized. Median follow-up was 36 months (mo). Median (range) age 
61 yrs(33-84), M/F 63/37%, PS 0/1/2 45/48/6%, adeno/large cell/
squamous/other 48/27/18/7%, stage IIIB/IV 17/83%, 11% of pts used 
acetylsalicylic acid < 150 mg/day. Reason to end treatment (cele-
coxib/placebo arm) was therapy completed (51/45%), PD (17/22%), 
adverse events (8/10%), death (8/8%), or others (16/15%). Toxicity 
was mild and no increase in cardiovascular events were observed in 
the celecoxib arm. HR stratified by use of acetylsalicylic acid and PS 
for PFS and OS was 0,94 (0.79-1.13) and 0.95 (0.79-1.15), respect-
ively. There was no interaction between celecoxib and histology 
(squamous vs non-squamous) or between chemotherapy and histol-
ogy with respect to PFS or OS.
Conclusion: Neither celecoxib nor docetaxel containing chemother-
apy interacts with histology with respect to PFS or overall survival.
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Randomized, double-blind, phase II study of carboplatin 
and paclitaxel with either vorinostat, a histone deacetylase 
inhibitor (HDAC), or placebo for first line therapy of 
advanced non-small cell lung cancer (NCI 7863)
Ramalingam, Suresh S.8; Maitland, Michael2; Frankel, Paul3; Argiris, 
Athanassios1; Thomas, Sachdev2; Gitlitz, Barbara4; Koczywas, 
Marianna3; Espinoza-Delgado, Igor5; Vokes, Everett E.2; Gandara, 
David R.6; Belani, Chandra P.7
1 University of Pittsburgh, Pittsburgh, PA, USA; 2 Illinois Oncology 
Research Association, Peoria, IL, USA; 3 City of Hope Cancer 
Center, Duarte, CA, USA; 4 University of Southern California, Los 
Angeles, CA, USA; 5 National Cancer Institute, Bethesda, MD, USA; 
6 University of California Davis Cancer Center, Sacramento, CA, 
USA; 7 Penn State University, Hershey, PA, USA; 8 Emory University, 
Atlanta, GA, USA
Background: Vorinostat, a HDAC inhibitor, enhances paclitaxel 
and platinum-mediated anti-cancer activity in preclinical studies by 
enhanced tubulin acetylation and DNA fragmentation respectively. 
The promising anti-cancer activity in the phase I study of carbo-
platin, paclitaxel and vorinostat in patients with advanced NSCLC 
(Ramalingam et al, Clin Cancer Res, 2007), prompted this placebo-
controlled, randomized phase II study. 
Methods: Patients with stage IIIB (malignant pleural/pericardial 
effusion) or IV NSCLC, performance status (PS) 0/1, no prior sys-
temic therapy and adequate bone marrow, renal and hepatic function 
were randomized for therapy with carboplatin and paclitaxel with 
either vorinostat or placebo (2:1 randomization). Treatment regimen 
consisted of: carboplatin AUC=6 mg/ml.min; and paclitaxel 200 mg/
m2 both given on day 3 along with either vorinostat (400 mg PO QD) 
or placebo on days 1-14 of each 3 week cycle to a maximum of 6 
cycles. Cross-over from one arm to the other was not permitted. The 
estimated sample size to demonstrate a 50% improvement in response 
rate for vorinostat over placebo was 93 patients (one-sided P, type I 
error 10%).
Results: Ninety-four patients were enrolled. Baseline patient char-
acteristics were similar between the two arms (median age 64, male 
60%, PS 0 40%, brain mets 16%). Median number of cycles was 3.5 
for vorinostat arm and 4 for the placebo arm. The confirmed response 
rate was superior with vorinostat over placebo (34% vs. 12.5%, P = 
0.02). The preliminary median PFS for vorinostat and placebo were 
5.8 and 4.1 m respectively (intent-to-treat population). Follow up for 
survival is ongoing. Common grade 3/4 toxicities were (vorinostat 
vs. placebo): neutropenia (44% vs. 47%); thrombocytopenia (33% vs. 
16%); fatigue (13% vs. 3%); hyponatremia (21% vs. 6%); and diar-
rhea (5% vs. 0). Treatment discontinuation after cycle 1 was higher 
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with vorinostat (27% vs. 16%). Biomarker studies on baseline tumor 
tissues and peripheral blood cells are ongoing.
Conclusions: The combination of vorinostat with carboplatin and 
paclitaxel resulted in a significantly superior response rate for patients 
with advanced NSCLC. HDAC inhibition is a novel and promising 
therapeutic strategy for the treatment of NSCLC. 
Supported by NCI NO1-CM-62209 (California Cancer Consor-
tium), NO1-CM-62201 (University of Chicago Consortium), 
NO1-CM-62208 (South East Phase II Consortium). ASCO Career 
Development Award to Suresh S. Ramalingam.
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A randomized, controlled phase 2 trial of CDP791 plus 
carboplatin/paclitaxel in patients with stage IIIb/IV 
chemotherapy-naïve non-squamous NSCLC
Rolfe, Lindsey; Soranson, Julie; Hatty, Sarah; Currie, Alex; 
Zinkewich-Peotti, Karen
UCB, Slough, UK
Introduction: CDP791 is a PEGylated di-FAb´ that binds to and 
inhibits signalling through VEGF receptor 2. In a phase 1 monother-
apy study CDP791 was safe and well tolerated up to 30mg/kg and 
the maximum tolerated dose was not reached1. We have performed a 
study in patients with advanced non small cell lung cancer (NSCLC) 
to investigate the effects of CDP791 combined with carboplatin and 
paclitaxel (C/P).
Design: Participants had stage IIIb/IV chemotherapy-naïve non-
squamous NSCLC. This was a 2-part study. Part 1 assessed safety 
and tolerability of escalating doses of CDP791 (10mg/kg and 20mg/
kg) combined with standard dose C/P. In part 2, subjects were ran-
domized to receive either C/P alone or C/P plus CDP791 10mg/kg or 
20mg/kg given in 21-day cycles for up to 6 cycles then were eligible 
to receive CDP791 as monotherapy. Tumor response was assessed 
after cycles 3 and 6, and every other cycle thereafter. The primary 
objective of the study was to compare overall tumor response rate 
(ORR) of patients receiving C/P alone with that of C/P plus CDP791 
(both dose arms combined) when all subjects would have been on 
study for at least 24 weeks. Secondary objectives included assess-
ment of safety/tolerability of CDP791 combined with C/P, progres-
sion free survival (PFS) and overall survival (OS). Results presented 
are based on the second database lock when 80% of Part 2 subjects 
had died or experienced disease progression as defined by independ-
ent radiological review.
Results: Part 1. There were no dose limiting toxicities when CDP791 
was combined with C/P at doses of 10 (n=3) or 20 (n=6) mg/kg. 
CDP791 did not appear to affect the pharmacokinetics of carboplatin 
or paclitaxel.
Part 2. 156 patients (86 male, median age 59.13y, range 35.1-83.2y) 
were enrolled. ORR results based on independent radiological review 
are shown in the table.
Although the increase in ORR between the pooled CDP791 arms and 
control did not reach statistical significance, ORR in the 20mg/kg 
arm was significantly higher (p=0.048) than that in the control arm. 
A treatment effect was not observed for PFS however analysis of 
OS showed a positive trend albeit based on still immature data. The 
combination of CDP791 and C/P was well tolerated. The AE profile 
was as expected given the underlying disease of the population and 
the concomitant therapies (VEGF inhibitor ± C/P) received.
Outcome C/P 
(n=50) [n, 
(%)]
C/P + 
CDP791 
10mg/kg 
(n=53) [n, 
(%)]
C/P + 
CDP791 
20mg/kg 
(n=53) [n, 
(%)]
C/P + CDP791 
pooled data 
(n=106) [n, 
(%)]
pa (C/P vs 
pooled 
CDP791 
arms)
Overall Response 
Rate
10 (20.0) 9 (17.0) 20 (37.7) 29 (27.4) 0.322
Complete 
Response
0 0 0 0
Partial Response 10 (20.0) 9 (17.0) 20 (37.7) 29 (27.4)
Stable Disease 28 (56.0) 34 (64.2) 25 (47.2) 59 (55.7)
Progressive 
Disease
3 (6.0) 6 (11.3) 2 (3.8) 8 (7.5)
a 2-sided 
chi-square 
test
Conclusion: CDP791 combined with C/P was well tolerated, with 
encouraging signals of activity. Additional studies are warranted to 
confirm these findings.
Reference: 
1) Clin Cancer Res 2007;13:7113-8
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Final results of a randomized phase II trial of pemetrexed 
(P) + carboplatin (Cb) ± enzastaurin (E) versus docetaxel 
(D) + Cb as first-line treatment of patients (pts) with stage 
IIIB/IV non-small cell lung cancer (NSCLC) 
Stinchcombe, Tom 1; Raju, Robert N.2; Couch, Linda S.2; Kocs, 
Darren M.2; Jotte, Robert2; Wang, Yunfei2; Bromund, Jane3; 
Marciniak, Martin D.3; Treat, Joseph3; Obasaju, Coleman K.3; 
Socinski, Mark1
1 University of North Carolina, Chapel Hill, NC, USA; 2 US 
Oncology, Houston, TX, USA; 3 Lilly USA, Indianapolis, IN, USA
Background: E is a selective, oral serine/threonine kinase inhib-
itor that targets protein kinase C. The combination of PCb has 
shown clinical activity in two phase II trials of advanced NSCLC. 
A phase III trial among pts with Stage IIIB/IV NSCLC showed that 
P + cisplatin provides similar efficacy with better tolerability than 
gemcitabine + cisplatin (Scagliotti, JCO, 2008). The toxicity profile 
observed with this P + platinum doublets makes the regimen an at-
tractive backbone for the integration of novel agents with different 
mechanisms of action. In the TAX 326 trial, DCb was associated with 
a median survival of 9.4 months (Fossella JCO 2003). The current 
open-label three-arm trial was designed to assess PCb ± E versus a 
control arm of DCb. 
Methods: Between 3/06 and 5/08, pts with Stage IIIB (with pleural 
effusion) or IV NSCLC, ECOG performance status (PS) of 0 or 1, 
and no prior systemic therapy were enrolled. Pts were equally ran-
domized to one of three arms: (A) P 500 mg/m2 and Cb AUC 6 every 
3 wks X 6 cycles with E given orally as a loading dose of 1200 mg or 
1125 mg followed by 500 mg of E daily until disease progression; (B) 
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
Copyright © 2009 by the International Association for the Study of Lung CancerS384
The same regimen of PCb alone; or (C) D 75 mg/m2 and Cb AUC 6 
every 3 wks X 6 cycles. Pts receiving P were administered folic acid, 
vitamin B12 and steroid prophylaxis. Pts on D also received steroid 
prophylaxis.
Results:
 Characteristics/Results PCbE (Arm A)  PCb (Arm B)  DCb (Arm C)  
  N=72 N=74 N=72
 Median age, yrs 67 66 65
 Male gender, % 57 55 58
 Brain metastasis, % 7 10 6
 ECOG PS 0:1, % 47:53 47:53 44:56
 Squamous: nonsquamous, % 13:87 30:70 19:81
 Complete response, % 0 3 0
 Partial response, % 14 19 26
 Stable disease, % 53 57 33
 Progressive disease, % 15 13 13
 Not evaluable, % 18 8 26
 Disease control (RR+SD), % 67 79 59
 Chi square P value 0.33 0.008 Ref
 Median survival, mos (95% CI) 7.2 (5.6, 10.6) 11.8 (8.1, 21.6) 9.4 (5.9, 10.6)
 1-year survival, % 37.3 48.0 26.5
 2-year survival, % 10.1 31.6 0.0
 Censorship, % 37.5 48.6 38.9
 Log-rank P value 0.46 0.03 Ref
 Median PFS, mos (95% CI) 3.5 (2.6, 6.0) 6.0 (4.2, 6.5) 4.1 (2.6, 6.3)
 Censorship, % 18.1 14.9 23.6
 Log-rank P value 0.78 0.33 Ref
 Neutropenia, Grade 3/4, % 8/6 15/3 13/7
 Anemia, Grade 3/4, % 16/2 21/1 3/0
 Thrombocytopenia, Grade 3/4, % 25/12 25/7 4/1
 Febrile neutropenia Grade 3/4, % 2/0 1/0 6/3
 Fatigue, Grade 3/4, % 6/0 1/0 6/0
 Diarrhea, Grade 3/4, % 6/0 1/0 6/0
 Alopecia, Grade 2, % 2 6 17
 FACT-L Score at Baseline (n) 94.8 (70) 94.3 (68) 93.5 (68)
 Improved >0.5 SDs, n (%) 8 (14.8) 17 (27.4) 14 (25.9)
 Stable, n (%) 25 (46.3) 28 (45.2) 23 (42.6)
 Worsened >0.5 SDs, n (%) 21 (38.9) 17 (27.4) 17 (31.5)
Conclusions: First-line treatment with PCb was associated with a 
significantly longer overall survival and a significantly greater disease 
control rate compared with DCb in advanced or metastatic NSCLC. 
The 2-year survival rate of 31.6% is one of the highest reported to 
date of a platinum doublet. E did not add to the activity of the PCb 
doublet. PCbE, PCb, and DCb appeared to be well tolerated. Com-
plete results for all patients in the study will be available at the time 
of the meeting. 
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A phase II, double-blind, randomized study of enzastaurin 
versus placebo concurrently with pemetrexed as second-
line therapy in patients with advanced or metastatic non-
small cell lung cancer
von Pawel, Joachim1; Barlesi, Fabrice2; Soria, Jean-Charles3; Bearz, 
Alessandra4; Barata, Fernando5; Park, Keunchil6; Zhao, Yan D.7; 
Chouaki, Nadia8; Iscoe, Neill9; Bepler, Gerold10; Chiappori, Alberto10
1 Asklepios-Fachkliniken Munich-Gauting, Gauting, Germany; 2 
Universite de la Mediterranee-Assistance Publique Hopitaux de 
Marseille, Marseille Cedex, France; 3 Institut Gustave Roussy, 
Villejuif, France; 4 CRO-IRCCS, Aviano, Italy; 5 Centro Hospitalar 
Coimbra, Coimbra, Portugal; 6 Samsung Medical Center, 
Sungkyunkwan Univ School of Medicine, Seoul, Korea; 7 Eli Lilly and 
Company, Indianapolis, IN, USA; 8 Eli Lilly and Company, Paris, 
France; 9 Eli Lilly Canada Inc., Toronto, ON, Canada; 10 H. Lee 
Moffitt Cancer Center, Tampa, FL, USA
Background: The combination of pemetrexed and enzastaurin has 
exhibited additive and possibly synergistic antitumor activity in a pre-
clinical study and has been well tolerated in cancer patients. To deter-
mine the efficacy of the combination regimen as second-line therapy, 
a phase II, double-blind, randomized study was initiated in patients 
with locally advanced or metastatic (stage IIIA/B or IV) NSCLC. 
Methods: Patients received either 500 mg enzastaurin (250 mg BID: 
arm A, with an 1125-mg loading dose on day 1 of a 28-day cycle 1) 
or placebo (arm B) in combination with 500 mg/m2 pemetrexed (iv) 
on day 1 of 21-day cycles (day 8 in cycle 1). All patients received 
supplemental folic acid and vitamin B12. The primary objective was 
to compare progression-free survival (PFS) in the two arms. Second-
ary objectives included overall survival (OS), disease control, and 
safety. An interim analysis was conducted to assess efficacy after 72 
PFS events.
Results: The study was stopped prematurely because the interim an-
alysis showed no evidence of improved PFS with enzastaurin. Eighty 
patients (54 males, 26 females) were enrolled in each arm (total=160 
patients). Major baseline characteristics of age, gender, race, perform-
ance status, and smoking status were well balanced (median age 61.4 
years, 32.5% females, 89% Caucasians, 92.5% ECOG PS 0-1, and 
86% ever smokers). In arm A and B, respectively, 66.3% and 77.5% 
of patients had non-squamous histology and 33.7% and 22.5% had 
squamous histology. At the final analysis, there was no significant 
difference in PFS between arm A (median 2.96 months) and arm 
B (median 3.02 months, HR=1.13, p=0.544). The disease control 
rate was 49.4% in arm A and 48.7% in arm B. The median OS was 
9.63 months in arm A (66.25% censored) and 7.39 months (56.25% 
censored) in arm B (HR=0.7, p=0.171). There was no significant 
difference between arms in the use of systemic post-discontinuation 
therapy. Seven patients in arm A and 5 patients in arm B discontinued 
due to drug-related adverse events (AEs) including serious AEs of 
cerebrovascular accident, palpitations, and renal failure in arm A 
(n=1, each) and neutropenic sepsis, thrombocytopenia, and pan-
niculitis in arm B (n=1, each). Non-hematological drug-related grade 
3/4 toxicities were similar in both arms, with fatigue being the most 
common (11.4% in arm A, 7.5% in arm B). The incidence of grade 
3/4 hematological toxicities was higher in arm A, specifically leuko-
penia (5.6% vs 0%, p=0.028), neutropenia (15.2% vs 5%, p=0.038), 
and thrombocytopenia (8.9% vs 1.3%, p=0.034). Of the 26 deaths 
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reported on-study or within 30 days of discontinuation (10 in arm A, 
16 in arm B), none were drug-related.
Conclusions: The combination regimen of enzastaurin and pe-
metrexed was well tolerated. The study was stopped prematurely 
because the combination of enzastaurin plus pemetrexed did not 
show improved efficacy over pemetrexed for second-line treatment of 
patients with advanced NSCLC.
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TH-302: bench to bedside with a tumor-selective hypoxia-
activated prodrug for lung cancer 
Weiss, Glen J.2; Borad, Mitesh J.3; Chiorean, Elena G.4; Mita, Alain 
C.5; Langmuir, Virginia K.1; Kroll, Stewart1; Hart, Charles P.1; Sun, 
Jessica D.1; Meng, Fanying1; Infante, Jeffrey R.6
1 Threshold Pharmaceuticals, Redwood City, CA, USA; 2 Scottsdale 
Clinical Research Institute/TGen, Scottsdale, AZ, USA; 3 Mayo 
Clinic-Scottsdale, Scottsdale, AZ, USA; 4 Indiana University Simon 
Cancer Center, Indianapolis, IN, USA; 5 CTRC at University of Texas 
Health Sciences Center, San Antonio, TX, USA; 6 Sarah Cannon 
Research Institute, Nashville, TN, USA
Background: TH-302 is a nitroimidazole-linked prodrug of bromo-
isophosphoramide mustard activated by reductases under hypoxia. 
Preclinical in vitro and xenograft studies were used to help direct the 
clinical development of TH-302. The outcome of this translational 
work in lung cancer is summarized.
Methods: The hypoxia selectivity of TH-302 was assessed in hu-
man lung cancer cell lines in vitro. In vivo efficacy was assessed in 
ectopic, orthotopic and metastatic models in nude mice. In Phase 1, 
TH-302 was administered intravenously weekly alone (7.5 to 670 
mg/m2) or in combination (starting dose 240 mg/m2) with standard 
dose gemcitabine (G), docetaxel (D) or pemetrexed (P). Tumor as-
sessments were performed every 2 cycles. The primary objectives of 
the studies were to determine dose-limiting toxicity and maximum 
tolerated dose (MTD) of TH-302 alone and in combination. 
Results: Under hypoxia, cytotoxicity was enhanced up to 550-fold 
vs air in H460, Calu6 and H69. In H460 and Calu6 ectopic mod-
els, TH-302 in combination with chemotherapy was more active 
than either treatment alone and efficacy was optimal if chemother-
apy was given 2 to 4 hours after TH-302. In the intrapleural H460 
model, survival with combined therapy was increased over TH-302 
or docetaxel alone (p=0.047 and 0.014, respectively). In humans, 
the MTD of weekly TH-302 was 575 mg/m2. Mucosal toxicity was 
dose-limiting. The MTD has not been reached in the combination 
studies at TH-302 doses of 340, 240 and 340 mg/m2 for G, D and P, 
respectively. Hematologic toxicity of TH-302 alone has been minimal 
and at the doses studied does not appear to worsen the bone mar-
row suppression of G, D or P. Reversible skin and mucosal toxicity 
are common at the higher doses. Fourteen patients with lung cancer 
have enrolled and TH-302 demonstrates activity in both NSCLC and 
SCLC. One partial response (PR) with TH-302 monotherapy was 
seen in third-line SCLC treated at 480 mg/m2. In the combination 
study, the patients with PRs were treated at 240 mg/m2, had received 
2 and 3 prior systemic therapies and are continuing on study after 9 
and 8 cycles (Table). 
Conclusions: Preclinical evaluation of TH-302 alone and in com-
bination with chemotherapy in lung cancer models led to optimal 
clinical trial design with rapid escalation to active doses in targeted 
patient populations. In the clinic, TH-302 administered either alone 
or in combination with chemotherapy has resulted in significant anti-
tumor activity without dose-limiting hematologic toxicity. Skin and 
mucosal toxicity are common but reversible. 
 Study N Partial Stable Progressive Not Yet 
  (NSCLC/ SCLC) Response Diease Disease Evaluated
 Monotherapy 7 (2/5) 1 (SCLC) 3 (1 NSCLC/ 2 SCLC) 1 (adeno) 2
 Gemcitabine + TH-302 1 (1/0) 0 1 (SCC) 0 0
 Docetaxel + TH-302 2 (2/0) 0 1 (adeno) 0 1
 Pemetrexed + TH-302 4 (4/0) 2 (adeno) 1 (adeno) 0 1
SCLC= small cell lung cancer; NSCLC= non-SCLC; SCC=squamous cell carcinoma; 
adeno=adenocarcinoma
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The FGF receptor (FGFR) inhibitor PD0173074 blocks 
SCLC growth in vitro and in vivo
Seckl, Michael J.1; Pardo, Olivier E.1; Aboagye, Eric O.1; Latigo, 
John1; Stamp, Gordon1; Lemoine, Nick2; Spencer-Dean, Bradley1
1 Imperial College London, London, UK; 2 Barts and the London 
Medical School, London, UK
Lung cancer is the commonest cancer killer. Small cell lung can-
cer (SCLC) is initially chemo-sensitive, but, rapidly relapses in a 
chemoresistant form with an overall survival < 5%. Consequently, 
novel therapies are urgently required and will likely arise from an 
improved understanding of the disease biology. Our previous work 
demonstrated that fibroblast growth factor-2 (FGF-2) induces pro-
liferation and chemoresistance in SCLC cells. Here, we demonstrate 
that the selective FGFR inhibitor PD0173074 blocks H-510 and 
H-69 SCLC proliferation and clonogenic growth in a dose dependent 
fashion and prevents FGF-2-induced chemoresistance. These effects 
correlate with the inhibition of both FGFR1 and 2 transphosphoryla-
tion. We then determined the efficacy of daily oral administration of 
PD0173074 for 28 days in two human SCLC models. In the H-510 
xenograft, tumour growth was impaired similar to that seen with 
single-agent cisplatin administration, increasing median survival 
compared to control sham-treated animals. Crucially, the effect 
of cisplatin was significantly potentiated by co-administration of 
PD0173074. More dramatically, in H-69 xenografts, PD0173074 
induced complete responses lasting greater than 6 months in 50% 
of mice. These effects were not a consequence of disrupted tumour 
vasculature but instead correlated with increased apoptosis (caspase 
3 and cytokeratin 18 cleavage) in excised tumours. Moreover, in 
vivo imaging with [18F]FLT-PET showed decreased intra-tumoral 
proliferation in live animals treated with the compound at 7-14 days. 
Our results suggest that clinical trials of FGFR inhibitors should be 
undertaken in patients with SCLC and that [18F]FLT-PET imaging 
could provide early in vivo evidence of response.
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Alveolar hypoxia acts as a tumor promoter for murine 
lung cancer
Karoor, Vijaya1; Le, Mysan2; Miller, York E.1
1 University of Colorado Denver, Denver, CO, USA; 2 Denver VAMC, 
Denver, CO, USA
Background: Emphysema and chronic obstructive pulmonary 
disease (COPD) have been repeatedly demonstrated to be associ-
ated with increased risk for lung cancer, even after adjustment for 
smoking. The mechanism is unknown, but chronic inflammation 
or oxygen radical formation have been postulated to play roles. We 
hypothesized that the alveolar hypoxia which occurs in poorly venti-
lated regions of lung (which are perfused by mixed venous, rather 
than arterial, blood) may provide an environment that promotes lung 
carcinogenesis.
Methods: FVB/N mice were either exposed to chronic hypobaric 
hypoxia (equivalent to 18,000 ft elevation) or to Denver altitude 
(5280 ft) for two weeks. Gene expression analysis and cytokine 
protein expression was determined on lungs exposed to hypoxia 
and normoxia. For carcinogenesis experiments, mice were exposed 
to hypoxia or normoxia for varying periods starting one week after 
treatment with either single dose urethane or single dose 3-methyl-
cholanthrene (MCA) followed by weekly injections of butlyated 
hydroxytoluene (BHT). Mice were sacrificed and tumors enumerated 
and measured at varying times after carcinogen treatment. Lungs and 
tumors were analyzed for protein expression by immunoblotting and 
immunohistochemistry. 
Results: Gene expression analysis revealed that hypoxia upregulated 
mRNAs for a number of growth factors and oncogenes also upregu-
lated in lung tumors. Cytokine blot analysis revealed upregulation of 
a number of angiogenic peptides. Mice exposed to hypoxia did not 
have an increase in tumor multiplicity, but tumor volume showed 
a time dependent increase in hypoxic mice at 15, 21 and 30 weeks 
of exposure (p< 0.001), with tumor volumes in the hypoxic mice 
increased from 3-5 fold. Continuous, rather than intermittent, hypoxia 
was required for this tumor promoting effect. Immunoblotting dem-
onstrated that HIF-2, but not HIF-1, is upregulated in tumors of hy-
poxic mice. VEGFA and C, VEGR2, PDGFR, FGF2, myc, phospho-
ERK, phospho-AKT, c-IAP1, survivin and Bcl-2 are all upregulated 
in tumors from hypoxic animals.
Conclusions: Alveolar hypoxia promotes tumor growth in two mur-
ine lung carcinogenesis models. HIF-2, but not HIF-1, is increased 
in these tumors, concomitant with changes in signaling molecules 
and angiogenic factors. Hypoxia may be responsible for some of the 
increased incidence of lung cancer in patients with emphysema and 
COPD. Increased expression of specific angiogenic factors suggests 
targeted therapeutics that might be more effective in lung cancer 
patients with COPD than those without COPD.
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Diverging prognostic impacts of hypoxic markers in 
histologic non-small cell lung cancer (NSCLC) subtypes
Andersen, Sigve1, 2; Eilertsen, Marte1; Donnem, Tom1, 2; Al-Saad, 
Samer1, 3; Al-Shibli, Khalid1, 4; Busund, Lill-Tove5, 3; Bremnes, Roy1, 2
1 Institute of Clinical Medicine, University of Tromso, Norway, 
Tromso, Norway; 2 Department of Oncology, University Hospital 
of Tromso, Tromso, Norway; 3 Department of Pathology, University 
Hospital of Tromso, Tromso, Norway; 4 Department of Pathology, 
Nordland Central Hospital, Bodo, Norway; 5 Institute of Medical 
Biology, University of Tromso, Tromso, Norway
Background: Tumor hypoxia is considered an independent predictor 
of poor prognosis in several types of cancer. The hypoxia inducible 
factors (HIFs), and especially HIF1α, are considered the main regula-
tors of the hypoxic response pathway as promiscuous transcription 
factors with multiple downstream effects. Our study investigated the 
prognostic impact of HIFαs (HIF1α, HIF2α and HIF3α) in tumor 
cells and stroma from resected NSCLC tumors, as well as the down-
stream proteins Glucose Transporter Protein Type 1(GLUT1), Lactate 
Dehydrogenase 5 (LDH5) and Carbonic Anhydrase IX (CAIX). 
Methods: Tumor tissue samples from 335 unselected, resected pa-
tients with NSCLC stage I to IIIA were obtained. Tissue microarrays 
were constructed from duplicate cores of tumor cells and tumor-relat-
ed stroma from each specimen. Immunohistochemistry was used to 
evaluate the expression of HIFαs, GLUT1, LDH5 and CAIX. Tissue 
sections were scored semiquantitatively by two experienced patholo-
gists.
Results: Median follow-up was 99 months. 191 tumors were squa-
mous cell carcinomas (SCC), 113 were adenocarcinomas (AC) and 
31 were large cell carcinomas (LCC). 
In univariate analyses, high expression of HIF1α (p<.001) and 
GLUT-1 (p=.013) in tumor cells were negative prognostic indicators 
for disease-specific survival (DSS). Whereas, in tumor stroma, high 
expression of LDH5 (p=.011), HIF1α (p=.028) and HIF2α (p=.001) 
were positive prognostic indicators. In the multivariate analysis, high 
tumor expression of HIF1α (HR 2.3, p=.003) and GLUT-1 (HR 2.0, 
p=.018) were poor prognostic indicators for DSS, while high stromal 
expression of HIF1α (HR 0.55, p=.003) and HIF2α (HR 0.55, 
p=.006) were positive prognostic indicators.
When investigating subgroups according to histology, univariate 
analyses showed that high HIF1α expression in tumor and stroma 
had a significant, but inverse prognostic value in SCC only (p=.001 
and p=.009, respectively). For high stromal HIF2α expression, the 
positive prognostic significance was strongest for LCC (p=.001), 
but with significance also for SCC (p=.005). High tumor GLUT1 
expression was a negative prognostic indicator in AC (p=.012) and 
LCC (p=.027), while high stromal LDH5 expression was a positive 
prognosticator in AC (p=.032) only. In the multivariate analysis, 
tumor HIF1α expression (HR 3.3, p=.001) was independently associ-
ated with DSS in SCC while high tumor GLUT1 expression was an 
independent negative prognostic indicator for DSS in AC (HR=1.9, 
p=.047). In tumor stroma, HIF1α (HR 0.47, p=.008) and HIF2α 
(HR=0.44, p=.005) were independently associated with a better prog-
nosis for SCC, whereas LDH5 expression was independently associ-
ated with improved survival in patients with AC (HR=0.45, p=.033).† 
Conclusion: In NSCLC, tumor cell HIF1α and GLUT-1 mediate 
an inverse prognostic impact when compared to HIF1α and HIF2α 
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in stroma. However, the prognostic impact varied greatly between 
the NSCLC subgroups, suggesting that the prognostic role of these 
target molecules is highly dependent on histologic type. Further, the 
contrasting prognostic effect of HIF1α in tumor versus stroma dem-
onstrates the importance of interpreting the crosstalk between stromal 
and tumor cells, in order to define new treatment strategies.
†Due to the small number of events in the LCC subgroup and the 
large number of variables, the multivariate analysis could not do 
calculations for the LCC subgroup.
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Gene expression profile of lung carcinoma-associated 
fibroblasts
Navab, Roya1; Bandarchi, Bizhan 1; Strumpf, Dan 1; Pintilie, Melania 
1; Ibrahimov, Emin 1; Yun, James J.1; Gullberg, Donald 1; Jurisica, 
Igor 2; Tsao, Ming-Sound 2
1 University of Bergen, Bergen, Norway; 2 Princess Margaret 
Hospital, University of Toronto, Toronto, ON, Canada
Background: A hallmark of cancer cell invasion is the activation of 
stromal cancer-associated fibroblasts (CAF). Many reports have sug-
gested that CAF may promote tumor progression, but the molecular 
and biological mechanisms remain undefined. In lung cancer, the 
roles of CAF and cancer stroma have not been studied extensively. 
This investigation aims to define the stromal gene expression changes 
that may promote tumor formation of non-small cell lung cancer 
(NSCLC) cells, and that correlate with poor clinical outcome. 
Methods: Primary cultures of CAF were established from fifteen 
independent resected NSCLC. Non-cancer fibroblasts (NF) were also 
cultured concurrently from the corresponding normal appearing lung 
parenchyma harvested at least 5 cm from the primary tumor. In addi-
tion, we have microdissected tumor stroma from 15 of these tumors 
and corresponding non-neoplastic lung tissue. The mRNA from these 
samples was profiled using oligonucleotide microarrays, and expres-
sion changes of selected signature genes were verified by quantitative 
RT-PCR. To evaluate the biological role of CAF, we co-implanted 
CAF or NF with several NSCLC cell lines into the subcutaneous 
tissue of severe combined immune deficient (SCID) mice, and evalu-
ated the effect on tumorigenicity. The in vitro phenotype of CAF and 
NF were also compared using Matrigel invasion assay and gelatin 
zymography. 
Results: Comparing the gene expression profiles of CAF and NF 
identified 37 up-regulated and 41 down-regulated genes (>2-fold 
change, false discovery rate < 0.1). These 78 genes were significantly 
enriched (p< 0.01) for Extracellular region (GO cellular component 
term) and ECM-receptor interaction (KEGG pathway), and the high-
est-ranking genes were involved in actin cytoskeleton organization, 
G-protein signaling, and ECM-receptor interaction. Co-implantation 
studies with the NSCLC cell lines A549 and H460 showed significant 
differential enhancement of tumor growth by CAF compared to NF 
(p< 0.01). Co-culture of CAF with these NSCLC cell lines resulted 
in increased invasiveness in Matrigel assay (p< 0.01) and increased 
MMP-2 activation. Integrin Alpha-11 (α11) was overexpressed ≥ 
2-fold in 14 of 15 CAF. The growth of A549 and H460 cell lines were 
retarded significantly when implanted into α11-deficient SCID mice 
compared to wild type mice (p< 0.01). 
Conclusion: We have identified lung cancer stroma and CAF as-
sociated genes that may promote malignant progression in NSCLC 
and could represent early detection biomarkers or novel therapeutic 
targets. (Supported by grant from the Canadian Cancer Society)
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IGF-1 induced gene signature in stromal fibroblasts is 
prognostic in adenocarcinomas of the lung 
Rajski, Michal; Vogel, Brigitte; Herrmann, Richard; Rochlitz, 
Christoph; Buess, Martin
Basel University, Basel, Switzerland
Background: Insulin-like Growth Factor I (IGF – I) signaling has a 
key influence on cancer initiation and progression and high levels of 
circulating IGF – I are a risk factor for lung cancer. Its influence on 
global gene expression in lung cancer and its stroma is not yet well 
characterized. Focusing on the stromal cells, we hypothesized that 
specific gene expression signatures in stromal cells induced by IGF – 
I might be of clinical relevance. 
Methods: To characterize the specific IGF-1 induced gene expression 
changes we set up an ex vivo cell-culture model with primary human 
lung fibroblasts (CCL – 171), and determined associated gene expres-
sion changes with DNA microarrays. The obtained gene expression 
signatures were evaluated with data from publicly available lung 
cancer datasets (Garber and Bhatacharjee).
Results: Upon stimulation with IGF – I CCL-171 cells changed their 
gene expression profile inducing a gene expression signature, which 
was significantly enriched with cell cycle and proliferation associated 
genes, which was phenotypically paralleled by induction of prolifera-
tion. In vivo, in both datasets, the expression of the IGF – I induced 
genes was remarkably coherent, providing a basis for segregation of 
the tumors into two groups. In a univariate analysis, patients carry-
ing a lung cancer with a high expression level of “Lung fibroblast 
derived IGF – I signature” had shorter overall survival than patients 
with low expression levels (41% vs. 70% after 5 years, p = 0.007 for 
Bhatacharjee (Figure 1)and 66 % vs. 33 % after 2 years, p = 0.008 
for Garber dataset). The same gene signature proved to be a power-
ful prognosticator in breast cancer (p = 0.0294 and p = 7.96e-09 for 
the Norway/Stanford and the NKI dataset, respectively), suggesting 
that IGF- I induced deregulation of gene expression in the stromal – 
compartment is a general feature in solid tumors.
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Conclusion: Genes induced by IGF – I in stromal fibroblasts, in 
vitro, are strongly prognostic in human lung cancer. The influence of 
IGF-1 on the cancer stroma, which is serving as a nourishing cancer 
cell environment, might have implications for the currently developed 
anti-IGF therapies. 
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The individuality of tumor-stroma interaction in non-small 
cell lung cancer: insights from functional and molecular 
analyses
Gottschling, Sandra1; Kuner, Ruprecht2; Granzow, Martin3; Jauch, 
Anna3; Chang Xu, Elizabeth1; Muley, Thomas1; Hoffmann, Hans1; 
Dienemann, Hendrik1; Eckstein, Volker4; Ho, Anthony D.4; Herth, 
Felix F.1; Thomas, Michael1; Meister, Michael1
1 Clinic for Thoracic Diseases at University Hospital Heidelberg, 
Heidelberg, Germany; 2 German Cancer Research Center, Division 
of Molecular Genome Analysis, Heidelberg, Germany; 3 Institute 
for Human Genetics, University Heidelberg, Heidelberg, Germany; 
4 Internal Medicine V, University Hospital Heidelberg, Heidelberg, 
Germany
Tumor-stroma interaction plays a significant role for malignant 
growth. Results from prostate and breast cancer rodent models show 
cancerogenic properties of tumor-associated and genetically altered 
stromal cells (SC) when combined with initiated or normal epithel-
ium (Olumi et al., Cancer Res. 1999, Kuperwasser et al., PNAS 
2004). However, data on the mechanisms and sequels of tumor-stro-
ma interaction in lung cancer are scanty.
Here, we analyzed the functional and molecular sequels of cross-
talk between the non-small cell lung cancer (NSCLC) cell lines 
A549, H23, and H1703 and primary stromal cells (SC) derived 
from matched normal lung tissue and tumors of newly diagnosed 
NSCLC patients. Tumor cells were kept in a non-contact co-culture 
system with SC and analyzed for alterations in proliferation, colony 
formation, migration, adhesion, invasion, chemosensitivity and gene 
expression by Affymetrix HG U133 Plus 2.0 arrays.
Exposure to SC altered cellular functions and gene expression 
profiles related to tumor growth, metastasis and response to therapy. 
Each cell line showed individual alterations that were hierarchic-
ally governed by (1) the type of tumor cell, (2) the SC donor and his 
histology and (3) the local origin of the SC (normal lung tissue vs. 
tumomr-associated). This in vitro model demonstrates an individual 
pattern of tumor-stroma interaction in NSCLC that is determined 
by both, the properties of the tumor cells and those of the stromal 
environment. Thus, biomarker programs in NSCLC should also con-
sider the stromal compartment.
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Prediction of response to gefitinib after 3 days of therapy 
using F-18 Fluorothymidine PET in patients with 
adenocarcinoma of the lung
Baek, Sora1; Ryu, Jin-Sook2; Im, Ki Chun2; Oh, Seung Jun 2; Moon, 
Dae Hyuk2; Lee, Dae Ho3; Sohn, Hee-Jung3; Suh, Cheolwon3; Lee, 
Jung-Shin3; Kim, Sang-We3
1 Department of Nuclear Medicine, University College of Medicine, 
Asan Medical Center, Seoul, Korea; 2 Department of Nuclear 
Medicine, University of Ulsan College of Medicine, Asan Medical 
Center, Seoul, Korea; 3 Division of Oncology, University of Ulsan 
College of Medicine, Asan Medical Center, Seoul, Korea
Background: F-18 Fluorothymidine PET(FLT-PET) has been 
considered as promising imaging method for the early evaluation of 
treatment response. We evaluated the FLT-PET in predicting response 
after 3 days of gefitinib treatment in patients with non-small cell lung 
cancer (NSCLC). 
Methods: Nonsmokers with advanced adenocarcinoma(stage 
IIIB,IV) of the lung were eligible for this study. FLT-PET was per-
formed before and 3 days after gefitinib treatment (250 mg p.o.daily). 
The maximum standardized uptake value (SUVmax) of primary 
tumor was measured. Then, percent change in SUVmax after therapy 
was also calculated. Clinical treatment response was assessed by 
follow-up chest computed tomography(CT) at 6 weeks after therapy 
according to RECIST criteria. The cutoff value predicting subsequent 
CT response was obtained by receiver operating characteristic (ROC) 
curve analysis. We compared progression free survival of FLT-PET 
responder and nonresponder. 
Results: Thirty-eight patients were enrolled, and 36 patients who 
had complete data were analyzed. Chest CT reveled partial response 
(PR) in 18 (50%), stable disease(SD) in 3 (8.3%) and progressive 
disease(PD) in 15 (41.7%). Initial SUVmax of tumors did not differ 
between respontder and nonresponder. In responder(PR), SUVmax 
of tumor decreased significantly after 3 days of therapy(3.8 ± 1.3 
vs. 2.5 ± 1.1; p=0.027). In nonresponder(SD+PR), however, there 
was no significant change in SUVmax of tumor before and during 
therapy (2.5 ± 1.5 vs.3.1 ± 1.6; p=0.70). The percent changes in 
SUVmax of tumor were significantly different between responder 
and nonresponder (-31.0± 21.5% vs. 7.4 ± 21.5%; p< 0.001). Area 
under the ROC curve of percent change of SUVmax for predicting 
response was 0.904. When more than 10.4% of decrease considered 
as cut off value, the sensitivity and the specificity were 88.9% and 
77.8%, respectively. The time to progression was significantly longer 
in FLT-PET responder than nonresponder (median, 16.5 months vs. 
2.8 months; p=0.035)
Conclusions: FLT-PET can predict the response to gefitinib only 3 
days after treatment in nonsmoker with adenocarcinoma of the lung. 
The change in tumor SUVmax obtained by FLT-PET is a promising 
predictive variable.
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 CT respondse N SUVmax of Day 0)  SUVmax of Day 3  Percent change  P 
   (mean ± SD (mean ± SD) of SUVmax(%)
 Responder 18 3.8 ± 1.3 2.5 ± 1.1 -31.0 ± 21.5 .0027
 Nonresponder 18 2.9 ± 1.5 3.1 ± 1.6 7.4 ± 21.5 .701
 P  .083 .24 .0001 
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Early experience with [18F] fluorothymidine positron 
emission tomography (FLT PET) for response assessment 
in malignant pleural mesothelioma (MPM)
Nowak, Anna K.1; Francis, Roslyn2, 1; Segard, Tatiana2; Morandeau, 
Laurence2; Boucek, Jan2; Millward, Michael J.1, 2; Musk, Arthur W.2; 
Phillips, Michael3; Byrne, Michael J.2; van der Schaaf, Agatha2
1 University of Western Australia, Nedlands, WA, Australia; 2 Sir 
Charles Gairdner Hospital, Perth, WA, Australia; 3 WA Institute for 
Medical Research, Perth, WA, Australia
Background: [18F] Fluorothymidine positron emission tomography 
(FLT PET) is a novel approach to non-invasively measure cel-
lular proliferation that has not been evaluated in malignant pleural 
mesothelioma (MPM). We hypothesise that baseline tumor cellular 
proliferation characteristics may predict response to chemotherapy, 
and that change in tumor cellular proliferation after 1 treatment cycle 
may predict response and patient outcomes in MPM. Here we report 
pilot results using this imaging technique.
Methods: Consenting patients with confirmed MPM commencing 
first line chemotherapy with pemtrexed and cisplatin underwent both 
fluorodeoxyglucose (FDG) and FLT PET imaging prior to and after 
1 cycle of chemotherapy. FDG PET scans were analysed using total 
glycolytic volume (TGV) obtained with semi-quantitative volume-
based region growing software; decrease in TGV has been shown to 
correlate with survival in MPM (Francis et al, J Nucl Med(48)1449-
58;2007). FLT scans were analysed using representative volumes of 
interest (VOI) at the sites of maximal tumour intensity. Computed 
tomography (CT) imaging was obtained at the same time points.
Results: 13 of 15 patients completed both pre and post chemother-
apy FDG and FLT PET studies. Two withdrew after pre-treatment 
studies due to clinical deterioration. 12 of 13 patients had FLT uptake 
corresponding to sites of MPM on FDG PET or CT imaging. One 
patient with minimal uptake at disease sites on FDG PET had no cor-
responding FLT uptake. Semi-automated analysis of FLT scans could 
not be undertaken due to high background physiological FLT activity 
in bone marrow and liver adjacent to sites of tumour. Representa-
tive VOI at the site of maximal FLT tumour uptake was therefore 
used to determine maximum standardised uptake value (SUVmax). 
6 patients had a decrease in FLT SUVmax after chemotherapy (‘FLT 
responders’; mean reduction 19%, range 0.1 – 55% reduction). 6 
patients had an increase in FLT SUVmax after chemotherapy (‘FLT 
non-responders’; mean increase 24%, range 1.3 – 45% increase). FLT 
responders had a correspondingly greater reduction in TGV on FDG 
PET (TGV mean reduction 69%, range 43-88% reduction) than FLT 
non-responders (TGV mean reduction 16%, range: 60% reduction to 
24% increase). The baseline FLT SUVmax values in FLT responders 
(mean 6.1; range 2.1-10.7) appear slightly higher than FLT non-
responders (mean 3.9; range 3.2-5.4) but this was not statistically 
significant (p=0.17).
Conclusion: MPM demonstrates proliferative activity as assessed by 
FLT PET. Early results suggest there may be a relationship between 
change in FLT activity following chemotherapy and response to 
chemotherapy as measured by FDG PET. Correlation with radiologic-
al response and patient survival will be presented. Further patient 
recruitment is ongoing in order to validate these results.
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FDG-PET glucose metabolism of NSCLC is consistent with 
persistent stem cell metabolism
Downey, Robert J.; Moreira, Andre L.; Gonen, Mithat
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Background: If cancers arise as a failure of the differentiation pro-
cess of stem cells into somatic tissues, the properties of a cancer will 
reflect the degree to which it retains the properties of a stem cell. For 
example, differentiated cells utilize oxidative phosphorylation; poorly 
differentiated cancers and stem cells utilize aerobic glycolysis (‘the 
Warburg effect’). Cancer metastases may recapitulate stem cell traf-
ficking. The relationship of lung cancer differentiation, metabolism 
(by FDG PET), and risk of metastatic disease was explored. 
Methods: Patients (n = 443) with untreated NSCLC who had 
PET imaging and thoracic nodal biopsies at one institution during 
2/99-9/07 were reviewed. Tumor differentiation was obtained from 
pathologic review. Glycolytic activity by PET SUV was correlated 
with tumor differentiation and risk of metastases. Non-parametric 
regression was used to examine the relationship between SUV and 
nodal metastases; the first derivative of the estimated regression curve 
used to identify change points in the relationship.
Results: Med age 68 yrs; 53% F; 33% nodal metastases; med tumor 
size 2.5 cm; med SUV 6.7. Tumor differentiation was significantly 
associated with tumor glycolytic activity: 42% and 2% of poorly 
and well differentiated tumors had a SUV > 10 (p < .001) (Fig 1). 
Metastases to nodes was associated with glycolytic activity (Fig 2). 
The relationship of risk of metastases to glycolytic activity suggested 
a transition from one metabolic state to another (Fig 2). 
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Conclusions: Cinical data is consistent with the hypothesis that the 
metabolism of poorly differentiated human cancers reflects stem cell 
metabolism and that a sharp transition from glycolysis to oxidative 
phosphorylation occurs during the differentiation process. This data 
also supports the hypothesis that changes in metabolism during the 
differentiation process may be coupled to changes in the ability of the 
differentiating cell to traffic/metastasize.
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Radiosynthesis of [11C]SU11274 as MET-imaging agent in 
micro-PET in vivo imaging of human lung cancer xenografts
Ma, Patrick C.1, 2, 4; Wu, Chunying3; Tang, Zhe1; Zhu, Wenxia3; 
Fan, Weiwan C.1; Wang, Changning3; Somoza, Edurado 3; Wang, 
Yanming3, 4
1 Case Western Reserve University, Division of Hematology/
Oncology, Department of Medicine, Cleveland, OH, USA; 2 
University Hospitals Case Medical Center, Cleveland, OH, USA; 
3 Department of Chemistry and Radiology, Case Western Reserve 
University, Cleveland, OH, USA; 4 Case Comprehensive Cancer 
Center, Cleveland, OH, USA
Background: Lung cancer is a lethal disease which has a dispro-
portionately high cancer-related mortality. Targeted therapy against 
molecular targets such as epidermal growth factor receptor (EGFR) 
and vascular endothelial growth factor receptor (VEGFR), in recent 
years has begun to bring forth improvement in survival of patients 
with advanced stage non-small cell lung cancer (NSCLC). MET re-
ceptor tyrosine kinase is another therapeutic target that, together with 
its natural ligand HGF, plays key role in lung cancer biology. MET/
HGF signaling dysregulation promotes tumor cell proliferation, sur-
vival, motility and migration, invasion and metastasis. We and others 
have previously identified various missense mutations and alternative 
spliced variants of MET in human cancers including lung cancer. 
MET genomic amplification and protein overexpression, reported in 
gastric cancer and lung cancer, may predict for sensitivity to MET-
targeting small molecular kinase inhibitors. MET amplification may 
also play a role in gefitinib/erlotinib acquired resistance in NSCLC. 
We have previously characterized the preclinical selective MET 
inhibitors SU11274 and PHA665752. Recently, a number of MET 
inhibitors have entered early phase clinical trial investigations. How-
ever, molecular probe to assay and quantify MET receptors in vivo 
is still lacking. Development of such MET-imaging molecular probe 
will greatly facilitate the development of preclinical model to assess 
determinants of response and resistance towards MET inhibitors. 
Methods: We adopted a radiosynthetic approach to radiolabel the 
MET inhibitor SU11274 with C-11 through radiomethylation of its 
key precursor. The [11C]SU11274 was then tested in our pilot in vivo 
quantitative micro-PET studies in NSCLC lung cancer xenograft 
model. We used the NCI-H1975 cell line with medium to high MET 
expression and NCI-H520 cell line with negligible level of MET ex-
pression to establish our in vivo murine xenograft model. Nude mice 
with the corresponding lung cancer xenografts were injected with 
18.5 MBq of [11C]SU11274 via tail-vein and imaged with dynamic 
PET scanning performed for 90 minutes. PET images were then 
analyzed digitally through in-house softwares. Immunohistochemical 
staining of the xenograft tumors using anti-human MET antibody was 
performed to verify the levels of MET expression in the tumors and 
to correlate with the PET radiotracer uptake. 
Results: We have successfully synthesized [11C]SU11274 by radio-
synthesis. The structure of SU11274 was not altered after radiolabel-
ing, which was verified by HLPC through co-injection with cold 
standard of SU11274. The levels of MET expression in the xeno-
grafts were confirmed by MET immunohistochemical staining after 
imaging, to be similar to their expression patterns of the correspond-
ing cell lines in cell culture. In this pilot study, we demonstrated that 
in vivo quantitative micro-PET study is feasible in our preclinical 
model. The radiotracer uptake, in terms of standard uptake value 
(SUV, μCi/cc/μCi/g) of the MET-imaging probe [11C]SU11274 in 
NCI-H1975 xenograft was substantially higher than NCI-H520. We 
are extending the study to include further cancer cell lines such as 
NCI-H1993 which carries MET genomic amplification. 
Conclusion: We have successfully developed a novel in vivo MET-
imaging probe, [11C]SU11274, through radiosynthesis as a valuable 
means to quantify MET receptor in vivo. Further validation of this 
molecular imaging approach will facilitate in vivo studies to monitor 
the response of MET-expressing tumor cells against MET inhibition. 
It has potential applications in both preclinical and eventually clinical 
studies of MET targeted antagonists in personalized cancer therapy
D4.5 Imaging II, Tue Aug 4, 12:30 - 14:00
The use of PET-CT scan in the assessment of response to 
Tarceva (erlotinib) in non small cell lung (NSCLC) cancer 
patients
O’Brien, Mary E.; Myerson, James S.; Popat, Sanjay; Puglisi, 
Martina; Starling, Naureen; Trani, Leonardo; Sue, Chua; Bhupinder, 
Sharma; Gary, Cook; Sue, Ashley
Royal Marsden Hospital, Sutton, UK
Background: Tarceva (erlotinib) is an active tyrosine kinase inhibitor 
in all lines of therapy for NSCLC. However the objective response 
rate is low and the early progression is high. Selection for clinical 
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characteristics and phenotype can enrich the responding population. 
An early sensitive assessment tool is needed to minimise the time 
non-responding patients are exposed to futile treatment.
Methods: Patients were selected with at least 2 factors that would 
predict response to Tarceva (female, never smoker, adenocarcinoma 
and EGFR expression on immunohistochemistry). Patients had 
baseline PET-CT and CT scans and then a repeat PET-CT at 6 weeks 
and a repeat CT at 12 weeks. The study was powered on the basis that 
PET-CT would be considered a worthwhile tool if 12 or more patients 
stopped treatment at 6 weeks. The planned number of assessable 
patients was 40.
Patients: 47 patients were entered with a median age of 63 yrs (range 
42-82). There were more females than males (29;18), adenocarcin-
oma in 31/47 and bronchoalveolar in another 7/47. EGFR expression 
was present in 34 patients and negative in 13. 20/47 patients were 
never smokers and 22/47 ex-smokers. Most patients received Tarceva 
as first line therapy 34/47, 10/47 as secondline and 3/47 as third line. 
The overall median survival was 15 months and 40% were alive at 
1 year. There were 40 assessable at 6 weeks and 35 assessable at 12 
weeks. Most of the drop outs were for progressive disease(PD) but 
there was some intolerance due to toxicity. Progressive disease was 
reported using PET-CT in 16/40 patients and with CT at 12 weeks in 
14/34 patients. SUV results were in general unhelpful for assessing 
response as most of these patients had multiple lesions and differen-
tial responses did occur. No patients with stable disease (SD) (10/40) 
or PD on PET-CT went on to have a later response. Overall survival 
based on CT at 12 weeks was similar in the group with SD and PR 
and significantly better than in those with PD (10.5 versus 16 mths 
p=0.008). Symptom response at 6 weeks correlated closely with 
PET-CT response. However at 12 weeks although 14 patients had 
objective radiological progression only 4 patients described worsen-
ing of their symptoms. 14/35 patients could have had their treatment 
stopped early on the basis of the PET-CT alone at 6 weeks. 
Conclusions: PET-CT as used in this group of patients proved useful 
in minimising duration of exposure to futile treatment.
This was an investigator lead study with an educational grant from 
Roche and support from the RMH.
D4.6 Imaging II, Tue Aug 4, 12:30 - 14:00
Colour Doppler sonography - A simple and accurate 
technique for evaluating chest wall invasion by lung 
tumour
Sripathi, Smiti; Mahajan, Abhishek; Rao, Vrk
Kasturba Medical College, Manipal, India
Introduction: Lung cancer is one of the leading causes of cancer-re-
lated deaths worldwide. Imaging plays an important role in pre-oper-
ative staging and is important for patient management and surgical 
planning. Imaging modalities for assessing chest wall involvement 
pre-operatively include CT, MRI, ultrasound (US) and colour Dop-
pler sonography (CDS) but out of these CDS is a dynamic, highly 
accurate, widely available, cost effective and reliable method. 
Patients To evaluate sensitivity and specificity of CDS in determin-
ing chest wall invasion by lung tumour.
Method: Between March and September 2007, 55 patients with 
roentgenologically confirmed pleuro-pulmonary lesions were 
prospectively evaluated by B mode ultrasound and CDS. 4 patients 
were excluded from the study due to inadequate breath hold. All 
ultrasound and CDS examinations were done on Logiq 700. The 
following parameters were investigated: 1) Gray scale evaluation 
of the lesion, 2) Qualitative (low impedance monophasic flow in 
Bronchial Artery BA, high impedance predominantly triphasic flow 
in Pulmonary artery PA, low impedance monophasic/variable flow in 
Intercostal Artery IA and 3) Quantitative ( PSV, EDV, RI and PI) an-
alysis. Diagnosis was histopathologically confirmed in all malignant 
lesions (n=32) and benign lesions (n=19) were diagnosed on basis 
of microbiology/ clinical course/ response to management/ imaging 
follow up. In 19 out of 32 malignant lesions CT scan was done which 
was evaluated for signs of invasion of chest wall which included an 
obtuse angle between the mass and chest wall, obliteration of extra 
pleural fat, evidence of tumor growth in to the chest wall, or invasion 
of the ribs by tumor.
Results: 19 out of 51 lesions were benign which included collapse, 
consolidation with pleural effusion or empyema and abscesses. Out 
of 32 malignant lesions, vascularity was seen in 28 lesions. Qualita-
tive analysis showed 52 different arterial flow signals in 28 vascular 
lesions On quantitative CDS, RI and PI of Bronchial artery was 0.5± 
0.19 and 0.68 ± .02 respectively, RI and PI of intercostal artery was 
0.77± 0.01and 1.2± 0.00 while RI and PI values of Pulmonary artery 
were 1.28 ± 0.06 1.28 ± 0.06 respectively. There was a significant 
difference between all types of flow signals for RI and PI values (p < 
0.05) with benign lesions showing either pulmonary or intercostal ar-
terial waveforms. All malignant lesions showing vascularity (n = 28) 
had either Bronchial artery waveform or arteriovenous shunting and 
in tumor invading chest wall intercostal arterial waveform was seen. 
This is important in staging of tumor with invasion of parietal pleura 
and chest wall constituting stage T3 lesion. CT only shows abutment 
or indentation of parietal pleura and cannot definitely comment about 
chest wall invasion. Dual arterial supply of lesion on CDS showing 
intercostal arterial waveform was suggestive of chest wall invasion 
of mass which increased sensitivity and specificity of CDS over CT. 
The qualitative and quantitative CDS parameters were statistically 
significant showing high sensitivity, specificity and accuracy (> 90 
%) in showing chest wall invasion by malignant lesions.
Conclusion: Though CT is used for pre-operative work-up for lung 
cancers, qualitative and quantitative CDS has a better sensitivity and 
specificity as compared to CT for assessing chest wall invasion by 
lung cancer. This helps in differentiating stage T2 from T3 lesions 
which has an impact on patient management. 
D4.7 Imaging II, Tue Aug 4, 12:30 - 14:00
A pilot study comparing computerized volume 
measurement with diameter measurement as an early 
biomarker of the biologic activity of EGFR targeted 
therapy
Zhao, Binsheng; Oxnard, Geoffrey R.; Guo, Pingzhen; Rizvi, Naiyer 
A.; Kris, Mark G.; Schwartz, Lawrence H.
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Background: Unidimensional tumor measurement has been used as 
the standard method for assessing tumor response to systemic therapy 
in clinical trials and clinical practice since the establishment of the 
RECIST criteria in 2000. With the remarkable advances of multi-de-
tector CT and powerful computer software, volumetric measurement 
has the potential to detect tumor changes earlier and more accurately 
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than conventional unidimensional measurement. As a part of a phase 
II clinical trial, we incorporated an analysis of volumetric CT scans 
to determine the value of early radiographic changes in predicting the 
biologic activity of gefitinib therapy in NSCLC, using EGFR muta-
tion status as a reference.
Methods: Eligible patients had resectable stage I/II NSCLC and had 
at least one of the following: smoking history of less than 10 pack 
years and/or bronchioloalveolar histologic features. Patients under-
went CT at baseline and after 21 days of gefitinib therapy, and then 
underwent resection. Tumor DNA was analyzed for known EGFR 
and KRAS mutations. Tumor contour on baseline and follow-up 
high-resolution CT images was semi-automatically delineated using 
home-grown computer software, based on which tumor volume, 
diameter, and density distribution were derived automatically and 
their changes were calculated. 
Results: 48 patients enrolled to the trial were qualified for the data 
analysis. 21 patients (44%) had EGFR activating mutations while 
27 patients (56%) were EGFR wildtype (wt); 5 of these patients 
(10% of total) were found to have KRAS mutations and 22 (46%) 
were wt/wt for EGFR and KRAS. Using KRAS mutants as reference 
non-responders to EGFR targeted therapy, cut-offs for early diameter 
response (11% decrease) and early volume response (27% decrease) 
were selected (Figure). Of 21 patients with EGFR mutations, 11 had 
early diameter response (sensitivity 52%) and 18 had early volume 
response (sensitivity 86%). Of 27 patients who were EGFR wt, 4 had 
early diameter response (specificity 85%) and 3 had early volume 
response (specificity 89%). The positive predictive value of early 
volume response for EGFR mutation status in this clinically enriched 
patient population was 86%. Density analysis is pending at time of 
submission.
Conclusion: In this pilot study, early change in tumor volume was 
found to be more sensitive and equally specific when compared to 
early diameter change at predicting EGFR mutation following gefit-
inib therapy. Early volume change has promise as an investigational 
method for detecting the biologic activity of a systemic therapy in 
NSCLC. Prospective study of this novel biomarker is planned.
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D5.1 SCLC - Novel Agents, Biomarkers and Toxicities, Tue Aug 4, 12:30 - 14:00
Normal tissue toxicities in a phase II study of accelerated 
high dose thoracic radiation therapy (TRT) with 
concurrent chemotherapy for limited small cell lung 
cancer (LSCLC): radiation therapy oncology group 
(RTOG) 0239
Komaki, Ritsuko1; Paulus, Rebecca2; Ettinger, David S.3; Videtic, 
Gregory M.4; Bradley, Jeffery 5; Glisson, Bonnie S.1; Choy, Hak6
1 The University of Texas M. D. Anderson Cancer Center, Houston, 
TX, USA; 2 RTOG, Philadelphia, PA, USA; 3 John Hopkins Cancer 
Center, Baltimore, MD, USA; 4 Cleveland Clinic Foundation, 
Cleveland, OH, USA; 5 Washington University School of Medicine, 
St. Louis, MO, USA; 6 UT Southwestern Medical Center, Dallas, TX, 
USA
Background: Accelerated fractionation proved beneficial to improve 
a 5-year-survival compared to daily fractionation in INT0096. 
However the total dose was low and local recurrence was high with 
higher acute grade (Gr) 3+ esophagitis. There has not been any docu-
mentation of late normal toxicity. RTOG 0239 was a phase II trial 
to improve local control and survival with LSCLC with acceptable 
acute Gr. 3+ esophagitis using accelerated high dose TRT and concur-
rent cisplatin/etoposide. This is a report of normal tissue toxicity from 
RTOG 0239.
Methods: Patients (pts) with LSCLC without pleural effusion, 
contralateral hilar or contralateral supraclavicular nodes and PS 0-1 
were enrolled. TRT was given to large fields to 28.8 Gy @1.8 Gy per 
fraction, 5 days per week for 16 fractions followed by BID with large 
field in AM, boost in PM, then off-cord boost BID for last 5 days, all 
at 1.8 Gy per fx for a total dose of 61.2 Gy in 34 fx in 5 weeks. Con-
current chemotherapy was started with TRT with cisplatin, 60-mg/
m2 i.v. Day 1; etoposide, 120-mg/m2 i.v. day 1; etoposide, 240-mg/
m2 p.o. per day or 120 mg/m2 i.v. per day on days 2 or 3. Cycles were 
repeated q.3 wks during and for 2 cycles after TRT. Pts who have 
achieved complete response one month after completion of 4 cycles 
of chemotherapy were asked to participate in a prophylactic cranial 
irradiation (PCI) study. Common toxicity criteria (CTC) 2.0 were 
used for acute toxicity and the RTOG/EORTC Late Toxicity Criteria 
for late toxicity. The definition of late toxicity was toxicity occurring 
90 days after the start of RT.
Results: The study opened in June 2003, and closed in May 2006, 
after the study met the goal of accruing 72 pts.
Acute and late toxicity information is available on 71 and 69 pts, 
respectively. There were 2(3%) Gr5 chemotherapy/acute radiother-
apy toxicities reported [infection due to neutropenia; pulmonary 
(pneumonia)]. Acute toxicities included 12 pts (17%) with acute Gr3 
esophagitis/dysphagia and 1 pt (1%) with acute Gr4-esophagitis/dys-
phagia . 64 patients (90%) developed Gr3-4 blood/bone marrow tox-
icity in addition to 24 pts (34%) who developed Gr3-5 infection in-
cluding one death. Regarding late toxicity, there were 11(16%) Gr3-4 
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late radiotherapy toxicities reported including 1(2%) Gr3 esophageal 
toxicity (insertion of a feeding tube), 4(6%) Gr3 pneumonitis,1(2%) 
Gr3 dyspnea, 1(2%) Gr3 pneumonia, 1(2%) Gr3 pulmonary fibro-
sis, 1(1%) other Gr3 pulmonary toxicity (lower DLCO), 1(2%) Gr3 
weight loss, and 1(2%) Gr4 cardiac toxicity (myocardial infarction). 
Conclusions: This accelerated high dose TRT with concurrent 
chemotherapy for LSCLC resulted in 18% acute Gr.3+ esophagitis 
and 6% Gr3+ pneumonitis. There were 3% Gr5 toxicities including 
infection and pulmonary toxicities. There were 13% Gr3 and 3% Gr4 
late toxicities. Bone marrow toxicity is very high resulting in infec-
tion which requires better systemic treatment as well as appropriate 
bone marrow support and antibiotics. RTOG 0239 has demonstrated 
tolerable toxicity. Therefore, this trial has been included in one of 
arms of inter-group prospective randomized trial.
D5.2 SCLC - Novel Agents, Biomarkers and Toxicities, Tue Aug 4, 12:30 - 14:00
Neuro-cognitive follow-up among patients with limited 
small cell cancer (SCLC) treated with two different doses 
of prophylactic cranial irradiation (PCI) according to the 
intergroup phase III trial (PCI99-01, IFCT 99-01, EORTC 
22003-08004, RTOG 0212)
Le Pechoux, Cecile1; Laplanche, Agnes 1; Faivre Finn, Corinne 
2; Ciuleanu, Tudor 3; Wanders, Rinus 4; Kramer, GWP5; Lerouge, 
Delphine6; Hatton, Michael7; Videtic, G8; Dunant, Ariane 1; Senan, 
Suresh9; Wolfson, Aaron10
1 Institut Gustave Roussy, Villejuif, France; 2 The Christie Hospital, 
Manchester, UK; 3 Institutul Oncologic I. Chiricuta, Cluj-Napoca, 
Romania; 4 Maastro Clinic, Maastricht, Netherlands; 5 Arnhem’s 
Radiotherapeutisch Instituut, Arnhem, Netherlands; 6 Centre 
François Baclesse, Caen, France; 7 Weston Park Hospital, Sheffield, 
UK; 8 Cleveland Clinic Foundation, Cleveland, OH, USA; 9 VU 
University Medical Centre, Amsterdam, Netherlands; 10 University of 
Miami School of Medicine, Miami, FL, USA
Background: The rationale for this trial was based on the results of 
a meta analysis on PCI in SCLC complete responders, suggesting 
a reduction of the brain metastasis (BM) rate among patients who 
received higher PCI doses. Our goal was to search for the optimal 
PCI dose, not only in terms of efficacy but also possible neurological 
sequelae. 
Methods: From September 1999 to December 2005, 720 patients 
with limited SCLC in complete remission were randomised: 360 
patients to a standard PCI dose (25 Gy/10 fractions), 360 patients to a 
higher PCI dose (36 Gy) with conventional administration (36 Gy/18 
fractions) or accelerated hyperfractionated administration (36 Gy/24 
twice-daily fractions). Early PCI toxicity and primary end-point 
results have been presented. However it seemed important to evaluate 
possible clinical and radiological late sequelae (using the EORTC-
RTOG Lentsoma scale) assessed yearly as secondary end-points. 
For each item (headache, somnolence, intellectual deficit, functional 
competence, memory, neurologic deficit, cognitive functions, mood 
and personality changes, seizures and CT scan or MRI radiological 
abnormalities), repeated measurements at 1,2 and 3 years were ana-
lyzed with an ordinal logistic model of the grade on initial age, grade 
at baseline, time and PCI dose. A differential effect of the dose was 
considered significant with an alpha level of 1%.
Results: Median age was 60 years. Only patients with a baseline 
brain imaging and Lentsoma (LS) evaluation (94% of patients) were 
considered for the purpose of this analysis; patients were censored in 
case of death or if they developed BM. At 1 year (9-15 months), the 
percentage of available LS forms was 72% in the 25 Gy group and 
70% in the 36 Gy group, at 2 years (21-27 mo) and 3 years (33-39 
mo): this rate decreased with respectively 64% and 57% of available 
forms in the 25 Gy group and 57% and 49% in the 36 Gy group. In 
comparing the 2 PCI groups, we could not observe any differential ef-
fect on any of the items except a trend for an intellectual deficit more 
frequent in the higher dose group (p=0.04, with 7% more deficit). 
Considering the different items, we could observe a mild deteriora-
tion of intellectual deficit, memory and cognitive functions across 
time. Few grade 3 and 4 neurological deficits were observed (1% at 
3 years). As expected, some items worsen according to age category 
(neurologic deficit and radiological changes). We could also observe 
a significant variability according to age groups of both memory and 
cognitive functions in the baseline evaluation.
Conclusion: In this large scale phase III trial, with a yearly evalua-
tion, very few patients had severe deterioration of neuro-psycho-
logical and cognitive functions over 3 years. We could observe a mild 
deterioration of certain items such as memory, intellectual deficit and 
cognitive functions over time, more frequent in older patients (over 
65). This underlines the importance of baseline evaluations.
Supported by ARC (Association pour la Recherche sur le Cancer) and 
PHRC (Programme Hospitalier de Recherche Clinique) 2007
D5.3 SCLC - Novel Agents, Biomarkers and Toxicities, Tue Aug 4, 12:30 - 14:00
Phase 1b trial of two schedules of the BCL-2 inhibitor 
obatoclax in combination with carboplatin and etoposide 
for patients with extensive stage small cell lung cancer (ES-
SCLC) 
Chiappori, Alberto A.1; Schreeder, Marshall T.2; Moetzi, Mehdi M.3; 
Stephenson, Joe4; Blakely, Johnetta L.5; Salgia, Ravi6; Chu, Quincy 
S.7; Hermann, Robert8; Subramaniam, Deepa9; Modiano, Manuel 
M.10; Richards, Donald11; Ross, Helen J.12; Berger, Mark S.13
1 Moffitt Cancer Center, Tampa, FL, USA; 2 Clearview Cancer 
Institute, Huntsville, AL, USA; 3 Florida Oncology Associates, 
Jacksonville, FL, USA; 4 US Oncology, Greenville, SC, USA; 5 
The West Clinic, Memphis, TN, USA; 6 University of Chicago, 
Chicago, IL, USA; 7 Cross Cancer Institute, Edmonton, AB, Canada; 
8 Northwest Georgia Oncology Centers, Marietta, GA, USA; 9 
Georgetown University, Washington, DC, USA; 10 ACRC/Arizona 
Clinical Research Center, Tucson, AZ, USA; 11 US Oncology, Tyler, 
TX, USA; 12 Mayo Clinic Arizona, Scottsdale, AZ, USA; 13 Gemin X 
Pharmaceuticals, Malvern, PA, USA
Background: Bcl-2 family proteins, including MCL-1, are frequently 
expressed in SCLC, and SCLC cell lines are sensitive to obatoclax 
(Ob), a small-molecule antagonist of all the BCL-2 prosurvival 
proteins, at clinically achievable concentrations. In addition, Ob 
enhances the effects of the drugs cisplatin and etoposide in vitro. 
Methods: The objective of this study was to find the maximal toler-
ated doses (MTD) of Ob given on a 21 day (D) cycle together with 
carboplatin (AUC 5 D1) and etoposide (100 mg/m2 D1-3), in separate 
fixed dose escalations using Ob as a 3-hr infusion D1-3 (15 mg, 30 
mg and 45 mg) and as a 24-hr infusion D1-3 (30 mg, 45 mg and 60 
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mg). Eligible patients had ES-SCLC, measurable disease, f1 prior 
therapy, ECOG PS ≤1, & adequate hematological, renal and hepatic 
function. 3- 6 patients were enrolled into ascending dose cohorts with 
standard DLT rules evaluating safety in Cycle (C) 1 to determine 
MTD. 
Results: 25 patients were enrolled into 6 dosing cohorts (14 males; 
median age 66). ECOG PS was 0 for 9 patients, and 1 for 16 patients. 
7 patients had prior SCLC therapy, and 18 were previously untreated. 
There were no DLTs in the initial Ob 15 mg over 3 hr cohort (n=3). 
Two DLTs occurred in the Ob 30 mg over 3 hr cohort - both due to 
myelosuppression in previously treated patients. As a result, the trial 
was amended to exclude previously treated patients. 5 previously 
untreated patients receiving Ob 30 over 3 hr had no DLTs. There 
were 2 DLTs (somnolence, euphoria, & disorientation) in the Ob 45 
mg over 3 hr cohort (n=6) establishing MTD of Ob 30 mg over 3 hr 
daily x 3. There were no DLTs in the Ob 30, 45, or 60 mg over 24 hr 
cohorts (n=4,4,&1) but 2 patients in these cohorts had infusion pump 
malfunctions while at home. Preliminary safety data are available for 
23 of the 25 patients who have received 66 cycles to date. The most 
common (≥25%) AEs were neutropenia (78%), somnolence (52%), 
nausea (44%), anemia (38%), thrombocytopenia (38%), fatigue 
(35%), anorexia (30%), euphoric mood (30%), peripheral edema 
(26%), and dizziness (26%). After C2 the 6 previously untreated 
patients on Ob 24-hr infusion cohorts had 3 PRs, 1 SD, 1 PD, and 1 
too early to know; the 3 previously treated patients had 2 PRs and 1 
SD. After C2 11/12 previously-untreated patients in the 3-hr infusion 
cohorts had PR; the 4 previously treated patients had 1 PR and 3 SDs. 
Conclusions: The MTD for Ob combined with carboplatin and 
etoposide using a 3-hr infusion on D1-3 is 30 mg. Both 3-hr and 
24-hr infusion regimens are associated with high early response 
rates, perhaps due to inhibition of MCL-1. Due to practical issues 
with the 24-hr infusion arm, and based on the safety profile and high 
early response rate, the 3-hr 30 mg MTD dose will be utilized in the 
ongoing randomized Phase 2 portion of the trial versus carboplatin 
and etoposide alone.
D5.4 SCLC - Novel Agents, Biomarkers and Toxicities, Tue Aug 4, 12:30 - 14:00
A phase 1 study of ABT-263 in patients with relapsed small 
cell lung cancer (SCLC) and other solid tumors 
Gandhi, Leena 1; Camidge, David R.2; de Oliveira, Moacyr R.3; 
Bonomi, Philip D.4; Gandara, David 5; Chiu, Yi-Lin6; Xiong, Hao6; 
Enschede, Sari H.6; Krivoshik, Andrew P.6; Rudin, Charles M.7
1 Dana-Farber Cancer Institute, Boston, MA, USA; 2 University of 
Colorado, Denver, CO, USA; 3 Northwest Medical Specialties, PLLC, 
Tacoma, WA, USA; 4 Rush University Medical Center, Chicago, IL, 
USA; 5 UC Davis Cancer Center, Sacramento, CA, USA; 6 Abbott 
Laboratories, Abbott Park, IL, USA; 7 Johns Hopkins University, 
Baltimore, MD, USA
Background: ABT-263, a novel BH3 mimetic, binds with high af-
finity (Ki ≤ 1 nM) and inhibits multiple antiapoptotic Bcl-2 proteins. 
ABT-263 displays potent mechanism-based activity (EC50 ≤1 mM) 
against human lymphoid and SCLC tumor cell lines and in human 
SCLC xenograft models. Preclinical toxicities include reductions in 
spermatogenesis, circulating lymphocytes and circulating platelet 
survival, mediated by Bcl-w, Bcl-2 and Bcl-XL, respectively. ABT-
263 also enhances effects of both chemotherapy and radiation in cells 
derived from multiple tumor types.
Methods: This is an ongoing phase 1 study evaluating the pharma-
cokinetics (PK), safety and efficacy of ABT-263 in patients (pts) 
with SCLC or other solid tumors. A continuous reassessment method 
(CRM) based on toxicity data guided dose escalation (range: 10 to 
475 mg). ABT-263 was dosed at 10-475 mg on Day 1 for 14 consecu-
tive days followed by 7 d off (14d on/7d off, 21d cycle). A continuous 
once daily dosing following a fixed one week lead in dose of 150 mg 
is now being explored to evaluate effects on mitigating thrombocyto-
penia. 
Results: 45 pts have been dosed thus far in this ongoing study. The 
PK profile of ABT-263 is linear from 10-475 mg with a Tmax of 
approximately 7 h and a terminal half-life of 13 to18 h (n=28). PK 
properties were time-invariant during the first 14 d and body weight 
or surface area did not appear to affect the AUC of ABT-263. Among 
all 45 pts, 5 experienced dose-limiting toxicities; 3 with drug-related 
Grade 4 thrombocytopenia (1 each at 325, 425 and 475-mg doses), 1 
with fatal respiratory failure (10 mg) and 1 with decreased ejection 
fraction (475 mg). Observed mechanism-based, dose-related throm-
bocytopenia was consistent with preclinical models. 16 pts reported 
serious adverse events; 3 possibly related to study drug. One pt at 425 
mg (14/21d dosing) with SCLC has been on study for close to one 
year (14 cycles) with 22% regression in tumor by RECIST and no 
evidence of FDG avid disease by CT/PET. Stable disease was noted 
in 7 pts: 1 at 10 mg (SCLC), 2 at 130 mg (1 carcinoid & 1 SCLC), 3 
at 325 mg (1 NSCLC & 2 carcinoid) and 1 at 425 mg (SCLC).
Conclusions: Preliminary results show that ABT-263 is well toler-
ated and has activity as a single agent in previously treated pts with 
neuroendocrine carcinoma, including SCLC. Following confirmation 
of the recommended phase 2 dose, combinations of ABT-263 with 
etoposide/cisplatin (M10-234) will be explored in SCLC pts within 
subsequent trials. 
D5.5 SCLC - Novel Agents, Biomarkers and Toxicities, Tue Aug 4, 12:30 - 14:00
ERCC1 and KI67 in neuroendocrine tumors of the lung - 
carcinoids, large cell neuroendocrine carcinoma and small 
cell carcinoma - distribution and impact on survival
Guldhammer Skov, Birgit1; Erreboe, Anders2; Mellemgaard, Anders 
2; Krasnik, Mark3; Ramstedt, Julie 1; Holm, Bente2
1 KAS Herlev, Dept. of Pathology, Division Gentofte, Copenhagen, 
Denmark; 2 Dept. of Oncology, Herlev Hospital, Herlev, Denmark; 3 
Dept. of thoracic surgery, Rigshospitalet, Copenhagen, Denmark
Background: The clinical behaviour, treatment and survival of 
patients with neuroendocrine lung tumors (NE), i.e. Typical (TC) 
and Atypical (AC) Carcinoid, Large Cell Neuroendocrine Carcin-
oma (LCNEC) and Small Cell Lung Carcinoma (SCLC)) are quite 
different. The tumors show different response to platinum based 
chemotherapy, SCLC having high initial response whereas TC is 
non-responding. Excision repair cross-complementation group 1 
(ERCC1) is a key component of the platinum-DNA repair mechanism 
responsible for nucleotide excision repair. High expression has been 
associated with shorter survival when platinum-based chemotherapy 
was used in NSCLC and increased survival in patients with NSCLC 
not treated with such drugs. The distribution and significance in NE is 
less known. KI-67 is a cellular marker for proliferation and is correl-
ated with the clinical course of NE tumors. The correlation between 
KI67 and ERCC1 in NE are unknown.
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Materials: A total of 282 patients were included (TC (48), AC (16), 
Carcinoid NOS (3), LCNEC (28), SCLC (187)). ERCC1 and KI 67 
were measured by immunohistochemistry using antibodies against 
ERCC1 (clone 8F1), and KI-67 (clone Mib1). For ERCC1, the 
percentage of positive tumor cells was semiquiantitatively scored (4 
groups) and multiplied by the staining intensity (4 groups) to give the 
H-score. For KI67 the percentage of positive stained nuclei regardless 
of the intensity was measured. All included SCLC patients received 
platinum based-doublet chemotherapy. Other patients were treated by 
surgery only. 
Results: ERCC1: The distribution of ERCC1 was significantly dif-
ferent among the different tumor types (mean H-score TC 0.90/ AC 
0.71/ LCNEC 0.15/ SCLC 0.02 ( p< 0.001)). 79% TC and 8% SCLC 
had detectable levels of ERCC1. For TC and AC (none of them 
treated by platinum based chemotherapy) ERCC1 positive patients 
had better survival than ERCC1 negative patients. However, the 
number of deaths was too small for statistical analyses. This was also 
the case for LCNEC. For patient with SCLC no prognostic impact on 
survival according to ERCC1 level was noted (p=0.58). This was the 
case for all stages. 
KI67: The number of KI 67 positive cells among diagnoses was 
significantly different (mean TC 1.81/ AC 4.00/ LCNEC 25.56/ 
SCLC 41.91) (p< 0.001). Furthermore, the difference between TC 
and AC was statistically significant (p=0.02), as was the difference 
between LCNEC and SCLC (p=<0.001) and between low grade NE 
(TC+AC) and high grade NE (LCNEC+SCLC) (p<0.001). For all in-
cluded patients, an association between KI67 and stage was observed 
(p<0.001). However, within each tumor category, this was not the 
case. In univariate analysis, KI 67 was a predictor for survival for all 
included patients ((p<0.0001), whereas multivariate analyses revealed 
TNM stage (p<0.001) and diagnosis (p<0.001) as the only independ-
ent markers for overall survival.
Correlation: No correlation between KI67 and ERCC1 was observed 
for any diagnoses (RSquare = 0.19).
Conclusion: In contrast to NSCLC, ERCC1 in patients with SCLC 
treated with platinum based chemotherapy seems to have no impact 
on survival. The demonstrated high expression of ERCC1 in TC 
might be an explanation for the failure of platinum based therapy for 
these patients. Whether ERCC1 has prognostic impact in TC remains 
to be solved. KI 67 might be considered as a supplementum to the 
histopatologic classification of NE tumors.
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Feasibility of genome-wide characterization using 
Affymetrix Exon and Agilent miRNA arrays in small 
cell lung cancer with formalin-fixed, paraffin-embedded 
(FFPE) samples in a phase III clinical trial (GALES) 
Myrand, Scott1; Sandanaraj, Edwin2; Socinski, Mark3; Lorigan, Paul4; 
Ganji, Gopi2; Aggarwal, Amit2; Guba, Susan1; Thatcher, Nicholas5; 
Mullaney, Brian1; Smit, Egbert6
1 Eli Lilly and Company, Indianapolis, IN, USA; 2 Lilly Singapore 
Centre for Drug Discovery Pte Ltd., Singapore, Singapore; 3 
University of North Carolina School of Medicine, Chapel Hill, NC, 
USA; 4 University of Manchester c/o The Christie NHS Foundation 
Trust, Manchester, UK; 5 Christie Hospital, Manchester, UK; 6 Vrije 
Universiteit Medical Centre, Amsterdam, Netherlands
Background: Improvement in outcomes in extensive disease small 
cell lung cancer (ED-SCLC) patients over the past two decades 
has been restricted to improvements in radiation therapy, but not 
chemotherapy. Etoposide plus a platinum remains the standard of 
care, despite chemotherapeutic advances in NSCLC. A secondary 
objective of a phase III clinical trial, Global Analysis of pemetrexed 
in small cell Lung cancer Extensive Stage (GALES), employed 
a two-stage adaptive design to identify tumor markers that might 
classify patients into a “sensitive” population with which to compare 
treatment efficacy. GALES closed for futility following the interim 
analysis; therefore our study focused more generally on increasing 
the understanding of the SCLC disease process. The candidate genes 
were expanded to a genome-wide survey. We present the feasibility 
of applying several profiling technologies on formalin-fixed, paraffin-
embedded (FFPE) SCLC tumor tissues from patient samples. 
Methods: Of the 908 patients enrolled, 417 FFPE samples were 
evaluated for percentage tumor. Immunohistochemistry (IHC) for 
TYMS, ERCC1, GARFT and FPGS were evaluated. After IHC, 
samples with <70% tumor were enriched by macro dissection, and 
RNA extracted from 139 FFPE samples was hybridized on Affy-
metrix human Exon array 1.0 ST. Sixteen samples were run on 
Agilent miRNA arrays Rel 12.0. Standard quality assessment (QA) 
for both array types, as described by the manufacturer, was adapted 
to FFPE samples. Gene level expression for exon arrays was sum-
marized using robust multichip average method based on a median 
polish algorithm, implemented in the Affymetrix expression console 
software and Partek genomics suite 6.4. Background subtracted 
miRNA signals were normalized using a variance stabilization (VSN) 
algorithm.
Results: QA of exon array profiles were tested for area under curve 
metric (AUC>0.65) and percentage present call rate (>20%). In total, 
98/139 (~70%) samples passed QA criteria. A batch-effect removal 
algorithm was applied to remove noise from gene summary data. 
For matched samples, mRNA expression was compared with IHC 
H-scores. For TYMS, a high correlation exists between IHC and exon 
data (p=0.02), consistent with literature in lung cancer (Ceppi, et al). 
We found several genes of relevance to SCLC that were upregulated 
(>4.38 log2-based median expression units in >60% of patients): 
TYMS, MYCN, BCL2, IGF2, IGFBP, IGF1R along with folate path-
way members. A subset of these genes was found to be commonly 
up regulated in published expression profiling datasets. In the pilot 
miRNA experiment, 13/16 (81%) arrays were of sufficient quality 
for further investigations. QC cutoffs were standardized to screen for 
miRNA profiles having criteria of co-efficient of variation of non-
control probe signals <10, detection calls >50, presence of positive 
controls/absence of negative controls across samples. 
Conclusions: Genome-wide approaches using Affymetrix Exon and 
Agilent miRNA arrays are feasible with FFPE clinical trial samples. 
Integrating data from distinct assay types such as mRNA expression, 
miRNA and IHC will likely identify improved genetic determinants 
of disease/drug response. miRNA analysis of 200+ additional samples 
from GALES is ongoing. We are hopeful these multiple datasets will 
greatly enhance our understanding of SCLC. 
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DNA copy number alterations predict small cell lung 
cancer tumor behavior
Ocak, Sebahat; Miller, Alison; Chen, Heidi; Zou, Yong; Shyr, Yu; 
Massion, Pierre P.
Vanderbilt University, Nashville, TN, USA
Background: Small cell lung cancer (SCLC) represents approxi-
mately 15% of all lung cancers and is characterized by a tendency 
for early dissemination, a good initial response to therapy but a short 
survival. Despite years of research in the field and innovative treat-
ments, the five-year-survival remains as low as 5% and the molecular 
steps leading to SCLC are still poorly understood. We hypothesized 
that tumor DNA copy number alterations may predict response to 
therapy, as well as allow us to identify critical determinants of SCLC 
tumor development and progression.
Methods: Array comparative genomic hybridization (CGH) was 
performed on DNA extracted from paraffin embedded formalin 
fixed tissue specimens of 46 SCLC. Tumor and sex-matched control 
DNA were hybridized onto a 2,464 BAC clone array. In a first step, 
we used a weighted flexible compound covariate analysis to select 
genomic regions associated with response to therapy. In a second 
step, we focused on common (prevalence >50%) and significant (log2 
copy number ratio >0.3 or <-0.3) regions of copy number alterations. 
From these regions of interest, we outputted the Reference Sequence 
genes located within a 300 kb genomic distance fixed on the centroid 
of the BAC clone. Then, we determined whether our candidate genes 
were enriched for biological processes or molecular pathways using 
WebGestalt. 
Results: Array CGH profiles allowed the identification of recurrent 
genomic regions of amplification and deletion in 46 SCLC tumors. 
Complete follow-up records were obtained in 36/46 patients; 11 with 
complete response to therapy (chemotherapy and radiation) and 25 
with partial response, stable or progressive disease. We identified 
28 genomic regions predicting complete response to therapy in 63% 
patients and non-complete response in 76% patients for an overall ac-
curacy of 72% (leave-one-out cross- validation). Applying the above 
criteria of common and significant regions of copy number altera-
tions, we selected 70 amplified regions (including 342 genes) and 55 
deleted regions (including 102 genes). Using WebGestalt, we found a 
strong node of enrichment in our SCLC tumors for 10 genes associ-
ated with the focal adhesion pathway, as well as 8 genes associated 
with the neuroactive ligand-receptor interaction pathway.
Conclusions: Using array CGH, we found enrichment for genes as-
sociated with the focal adhesion and the neuroactive ligand-receptor 
interaction pathways in SCLC tumors. Moreover, we identified a 
signature consisting of 28 genomic regions that predicts complete re-
sponse to therapy. Investigation of these candidates at the functional 
level may lead to a better understanding of progression of SCLC.
This work was supported by an IASLC Lung Cancer Fellowship 
Award.
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Final pooled comparative outcomes analysis of JCOG 9511 
and SWOG 0124, phase III trials of cisplatin + irinotecan 
vs. cisplatin + etoposide in extensive stage small cell lung 
cancer
Lara, Primo N.1; Chansky, Kari2; Shibata, Taro3; Fukuda, H3; Tamura, 
T3; Saijo, Nagahiro3; Lenz, Heinz J.4; Natale, Ronald5; Crowley, John 
2; Redman, Mary2; Gandara, David R.1
1 University of California Davis Cancer Center, Sacramento, 
California, USA; 2 Southwest Oncology Group, Seattle, WA, USA; 
3 Japan Clinical Oncology Group, Tokyo, Japan; 4 University of 
Southern California, Los Angeles, CA, USA; 5 Cedars Sinai, Los 
Angeles, CA, USA
Introduction: S0124 was a large North American phase III trial 
(n=651) that failed to confirm a survival benefit for cisplatin/iri-
notecan over cisplatin/etoposide in patients with E-SCLC. These 
results were contrary to J9511, a phase III trial exclusively in 
Japanese patients (n=154). Accrual to J9511 was terminated early 
after a survival benefit was seen at interim analysis favoring the 
irinotecan arm. Since S0124 and J9511 protocols used identical treat-
ment regimens and similar eligibility criteria, we pooled patient-level 
data from both trials, compared demographics, toxicity, and outcomes 
using a “common arm” analysis to explore potential reasons for the 
divergent results.
Methods: Patients with documented E-SCLC and adequate end-
organ function were randomized in both trials to receive either 
Cisplatin 60 mg/m2 day 1 + Irinotecan 60 mg/m2 days 1, 8, & 15 Q 4 
weeks or Cisplatin 80 mg/m2 day 1 + Etoposide 100 mg/m2 days 1-3 
Q 3 weeks. Demographics and outcomes data were compared among 
805 patients enrolled in J9511 and S0124 receiving identical treat-
ment using a logistic model adjusted for age, sex, and performance 
status. Tumor response in J9511 and S0124 was assessed by WHO 
and RECIST criteria, respectively.
Results: Of 671 patients in S0124, 651 were eligible and included 
in this analysis as were all 154 patients from J9511. Patient charac-
teristics (J9511 & S0124, respectively): Mean age - 61 & 62 years; 
Male sex - 132 (86%) & 370 (57%), p<0.001; Performance status 
0 - 19 (12%) & 211 (32%), p<0.001. Results of the “Common Arm” 
comparative analysis are summarized in the table below.
Conclusions: Significant differences in patient demograph-
ics, toxicity, and efficacy were identified in the J9511 and S0124 
populations. These results, relevant in the current era of clinical 
trials globalization, warrant: 1) consideration of differential patient 
characteristics and outcomes amongst populations receiving identical 
therapy; 2) utilization of the “common arm” model in prospective 
trials; and 3) inclusion of pharmacogenomic correlates in cancer trials 
where ethnic/racial differences in drug disposition are expected
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Cisplatin/Etoposide Cisplatin/Irinotecan
J9511 S0124 p-value J9511 S0124 p-value
Response Rate 68% 57% 0.01 87% 60% <0.001
Progression free 
survival, median 
(months)
4.7 5.2 0.83 6.8 5.8 0.6
Overall 
survival, median 
(months)
9.4 9.1 0.5 12.8 9.9 <0.001
One year survival 38% 34% 0.5 58% 41% <0.001
Infection  
(Grade 3+)
3(4%) 52 (16%) <0.001 4 (5%) 36 (11%) 0.23
Neutrpenia  
(Grade 3+)
71 (92%) 220 (68%) <0.001 49 (65%) 107 (34%) <0.001
Leukopenia 
(Grade 3+)
41 (53%) 109 (34%) <0.001 20 (27%) 57 (18%) <0.04
Anemia  
(Grade 3 +)
25 (32%) 39 (12%) <0.001 21 (28%) 18 (6%) <0.001
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A multicenter international randomized phase III study 
comparing cisplatin in combination with irinotecan or 
etoposide in previously untreated small cell lung cancer
Zatloukal, Petr1; Szczesna, Aleksandra2; Gorbunova, Vera3; Cardenal, 
Felipe4; Moiseyenko, Vladimir5; Zhang, Xiaoxi6; Cisar, Laura6; Soria, 
Jean-Charles7; Thomas, Michael9; Domine, Manuel8
1 Charles University, Prague, Prague, Czech Republic; 2 Regional 
Lung Diseases Hospital, Otwock, Poland; 3 Cancer Research Centre, 
Moscow, Russia; 4 Institut Català d’Oncologia, Barcelona, Spain; 
5 N.N. Petrov Research Institute of Oncology under the Federal 
Agency for High-Tech Medical Treatment, St Petersburgh, Russia; 6 
Pfizer Inc, New York, USA; 7 Institut Gustave Roussy, Paris, France; 
8 Fundacion Jimenez Diaz Servico Oncologia, Madrid, Spain; 9 
Internistische Onkologie der Thoraxtumoren, Heidelberg, Germany
Background: This multicenter study compared the efficacy and 
safety of irinotecan plus cisplatin (IP) with etoposide plus cisplatin 
(EP), in an international cohort of previously untreated small cell 
lung cancer patients with extensive disease (SCLC-ED).
Methods: Patients were randomized to receive every three weeks: 
cisplatin, 80 mg/m2 day (d) 1 and either irinotecan, 65 mg/m2 d 1 and 
8, or etoposide, 100 mg/m2 d 1 - 3. The planned dose of irinotecan 
was initially 80 mg/m2 but was reduced to 65 mg/m2 in a protocol 
amendment based on the recommendation of the Independent Data 
Monitoring Committee. Data presented here are from the cohort of 
patients enrolled after the amendment and all received 65 mg/m2 
irinotecan in the IP arm. The primary endpoint was overall survival. 
In the event that the IP arm was not superior to the EP arm, a non-
inferiority test was planned with a pre-specified margin of a hazard 
ratio (HR) of 1.25 (IP/EP). Secondary endpoints included overall 
response rate (ORR), duration of response, time to tumor progression 
(TTP) and safety. 
Results: Patients randomized to receive IP (n=202) or EP (n=203) 
were well balanced for baseline characteristics including male 
gender; 76.2% vs. 76.4%, median age; 59.3 years vs. 60.0 years, 
median number of organs involved 3.0 [range 1.0-7.0] vs. 3.0 [range 
1.0-8.0] and with a WHO performance status of 0, 1 and 2 of 23%, 
76%, and 1% vs. 23%, 77% and 0% respectively. Median overall 
survival in the IP arm was 10.2 months and 9.7 months in the EP arm 
(HR 0.81, 95%CI 0.65-1.01 p=0.06). Although the overall survival of 
patients receiving IP was not significantly different from those receiv-
ing EP, non-inferiority of IP compared to EP is established since the 
lower bound of the 95% CI of the HR does not cross the pre-specified 
non-inferiority margin. Differences (IP vs. EP) in ORR (39.1% vs. 
46.3%), duration of response (5.5 months vs. 4.9 months) and TTP 
(5.4 months vs. 6.2 months) were not statistically significant. More 
patients receiving IP (27.7%) lost ≥5% of their body weight on treat-
ment than patients receiving EP (16.3%). Grade 3/4 vomiting (10.9% 
vs. 4.4%) and diarrhea (15.4% vs. 0.5%) were more common in the 
IP arm vs. EP arm. Grade 3/4 neutropenia was more frequent in the 
EP (59.6%) than the IP arm (38.1%).
Conclusions: In this cohort of SCLC-ED patients recruited from dif-
ferent countries the IP treatment regimen was found to be non-infer-
ior to EP in overall survival. Toxicity profiles were different between 
the regimens. 
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Cisplatin versus carboplatin-based regimens in the 
treatment of small cell lung cancer (SCLC): meta-analysis 
of published randomized clinical trials (RCTs)
Rossi, Antonio1; Di Maio, Massimo1; Martelli, Olga2; Garassino, 
Marina C.2; Maione, Paolo3; Gridelli, Cesare3
1 Unità Sperimentazioni Cliniche, Istituto Nazionale per lo Studio e la 
cura dei Tumori, Fondazione “G. Pascale”, Naples, Italy; 2 Division 
of Medical Oncology, “San Giovanni-Addolorata” Hospital, Rome, 
Italy; 3 Division of Medical Oncology, “S.G. Moscati” Hospital, 
Avellino, Italy
Background: Platinum-based chemotherapy is the standard of care 
for first-line therapy of SCLC. Whether cisplatin or carboplatin are 
equally effective in the treatment of SCLC is still controversial. A 
meta-analysis based on abstracted data was performed to compare 
cisplatin-based regimens with carboplatin-based regimens as first-line 
treatment of patients with SCLC. 
Methods: PubMed, Medline, and Cochrane databases were searched 
for RCTs addressing this issue. Also abstracts presented at meetings 
of the American Society of Clinical Oncology, the European Society 
for Medical Oncology, the European Cancer Conference, and the 
International Association for the Study of Lung Cancer websites 
search before February 2009 were analyzed. The following key-
words were used in all the possible combinations: “small cell lung 
cancer”, “SCLC”, “randomized trial”, “platinum therapy”, “lung 
cancer”, “oat-cell carcinoma”. Each identified trial was evaluated for 
eligibility and quality, and then the data were abstracted and analyzed 
(RevMan 5). End-points were overall survival (OS), progression-
free survival (PFS), response rate (RR) and toxicity. Time-to-event 
outcomes were analyzed using hazard ratios (HR), calculated with 
the information presented in each trial report according to published 
methods (Tierney JF, Trials 2007, 8:16). RR and toxicity were ana-
lyzed using odds ratio (OR).
Results: Three RCTs which included 608 patients (303 assigned to 
cisplatin-based chemotherapy and 305 to carboplatin-based treat-
ment) were considered eligible. All the studies were published 
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as full-text articles. Two trials compared cisplatin-etoposide with 
carboplatin-etoposide, the third compared cisplatin-etoposide 
with carboplatin-gemcitabine. HR of OS and PFS for carboplatin-
containing chemotherapy versus cisplatin-containing chemotherapy 
were 1.00 (95% confidence interval [CI] 0.84-1.20; p = 0.98) and 
0.95 (95% CI 0.78-1.15; p = 0.58), respectively. Proportion of RR 
was similar: 69.6% with carboplatin-based regimens and 67.8% for 
cisplatin-based regimens (OR 1.09, 95% CI 0.77-1.54; p = 0.62). No 
significant heterogeneity was present for the three efficacy outcomes. 
Hematological toxicity was significantly higher with carboplatin-
based chemotherapy while several non-hematological side effects 
resulted higher with cisplatin-based regimens.
Conclusions: Although the number of studies and patients available 
was limited, meta-analysis shows similar efficacy between cisplatin- 
and carboplatin-based regimens which resulted different for safety 
profile. In clinical practice, the choice of the platinum compound for 
first-line treatment of SCLC should take into account the expected 
toxicity profile, patient organ function and co-morbidities.
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SALUTE: a placebo-controlled, double-blind, multicenter, 
randomized, phase II study of bevacizumab in previously 
untreated extensive-stage small cell lung cancer (SCLC)
Spigel, David R.1; Townley, Peter M.2; Waterhouse, David M.3; Fang, 
Liang4; Adiguzel, Ibrahim4; Huang, Jane E.4; Scappaticci, Frank A.4; 
Socinski, Mark A.5
1 Sarah Cannon Research Institute, Nashville, TN, USA; 2 Nebraska 
Methodist Estabrook Cancer Center, Omaha, NE, USA; 3 Oncology/
Hematology Care, Inc., Cincinnati, OH, USA; 4 Genentech, Inc., 
South San Francisco, CA, USA; 5 Lineberger Comprehensive Cancer 
Center, University of North Carolina, Chapel Hill, NC, USA
Background: Bevacizumab (BV), a monoclonal antibody against 
vascular endothelial growth factor (VEGF), is approved for treatment 
of metastatic colorectal cancer, metastatic breast cancer, and meta-
static non-small cell lung cancer (NSCLC), and has shown activity 
against other tumor types. Patients with SCLC (15% of all lung can-
cers) have not previously been eligible for clinical trials that included 
BV. The SALUTE study was initiated to assess the activity of BV in 
patients with previously untreated extensive-stage SCLC. 
Methods: This was a placebo-controlled, double-blind, multicenter, 
randomized study for preliminary evaluation of the efficacy and 
safety of combining BV with cisplatin (or carboplatin) and etoposide 
in patients with previously untreated extensive-stage SCLC. Patients 
with previously untreated extensive-stage SCLC who were clinically 
stable, had an ECOG performance status of 0-2, and had not relapsed 
from limited-stage disease were eligible for the study. Patients were 
randomized 1:1 to either the BV chemotherapy arm or the placebo 
chemotherapy arm. Patients received cisplatin/carboplatin etopo-
side + BV/placebo for 4 cycles, followed by single-agent therapy 
with BV/placebo during subsequent cycles. Patients received BV or 
placebo until disease progression or toxicity, for up to 12 months. The 
primary objective of this study was to estimate duration of progres-
sion-free survival (PFS). Secondary objectives were to estimate 
duration of overall survival, objective response rate, and duration of 
objective response, and to evaluate safety.
Results: Enrollment in the study is complete. A total of 102 patients 
with extensive SCLC were randomized, 50 in the BV arm and 52 in 
the placebo arm. Median age was 62, 55% of patients were male, and 
88% were white. The study will be unblinded in April 2009. 
Conclusions: Efficacy and safety results will be presented at the 
meeting.
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Amrubicin monotherapy in patients with extensive disease 
small cell lung cancer (ED-SCLC) refractory to first-line 
platinum-based chemotherapy: updated results of a phase 
2 trial
Ettinger, David S.1; Jotte, Robert M.2; Lorigan, Paul 3; Gupta, 
Vicram4; Garbo, Lawrence5; Alemany, Carlos6; Spigel, David R.7; 
Dudek, Arkadiusz Z.8; Salgia, Ravi9; McNally, Richard10; Renschler, 
Markus10; Oliver, Jennifer W.10
1 The Sidney Kimmel Comprehensive Cancer Center at Johns 
Hopkins, Baltimore, MD, USA; 2 Rocky Mountain Cancer Center, 
Denver, CO, USA; 3 Christie Hospital NHS Foundation Trust, 
Manchester, UK; 4 St Joseph Oncology, St Joseph, MO, USA; 5 New 
York Oncology Hematology, P.C., Albany, NY, USA; 6 Cancer Centers 
of Florida, P.A, Ocoee, FL, USA; 7 Sarah Cannon Research Institute, 
Nashville, TN, USA; 8 University of Minnesota, Minneapolis, 
MN, USA; 9 University of Chicago, Chicago, IL, USA; 10 Celgene 
Corporation, Summit, NJ, USA
Background: Amrubicin (AMR), a 3rd-generation synthetic anthra-
cycline and potent topoisomerase II inhibitor, is approved in Japan 
for the treatment of small cell lung cancer (SCLC) and non-small cell 
lung cancer (NSCLC). Patients with SCLC, who are refractory to 1st-
line chemotherapy or progress within 3 months (mos) of treatment 
completion, are less likely to respond to additional chemotherapy and 
have an expected median survival of 3-5 mos. We investigated the 
efficacy and safety of AMR monotherapy for treatment of Western 
patients with refractory ED-SCLC.
Methods: In this phase 2 trial, patients with ED-SCLC refractory to 
prior 1st-line platinum-based chemotherapy (defined as progression 
(PD) while on therapy or relapse within 90 days of treatment cessa-
tion) and ECOG performance status (PS) ≤2 were eligible. Patients 
were treated with intravenous AMR 40 mg/m²/day x 3 days every 21 
days until PD or intolerable toxicity. The primary endpoint was over-
all response rate (ORR, by RECIST), with a goal of demonstrating 
an ORR ≥18% (point estimate). Secondary endpoints included time 
to progression (TTP) duration of response (DR), progression-free 
survival (PFS) and overall survival (OS).
Results: A total of 75 patients were enrolled; median age was 63 
years (range 43-88), 52% were female, and 17% were PS 2. Median 
time from completion of 1st-line therapy to PD was 1.3 mos. Sixty-
nine patients (92%) received AMR for a median of 4 cycles (range 
1–12); 6 patients died or discontinued before receiving AMR. The 
primary endpoint was met with an ORR of 21% (16/75, 95% confi-
dence interval [CI] 13.6%–31.9%), including CR in 1 pt (1%) and PR 
in 15 patients (20%). Stable disease (SD) was achieved by 30 (40%) 
patients. Seven patients with SD or PD as best response to 1st-line 
chemotherapy achieved a PR. Median duration of response was 4.3 
months (95%CI 3.1–5.8 mos) and time to progression was 3.8 mos 
(95%CI 2.7–4.2 mos). Median PFS was 3.3 mos (95% CI 2.5–4.0 
mos). Median OS was 6.1 mos (95%CI 4.9–7.2 mos) (Figure). The 
most common grade 3 or 4 adverse events were neutropenia (67%), 
Copyright © 2009 by the International Association for the Study of Lung Cancer S399
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
thrombocytopenia (41%), and leukopenia (35%). Eight patients 
(12%) experienced febrile neutropenia. Twenty-six patients (38%) 
required dose reductions. Final data will be presented at the meeting.
Conclusions: AMR shows promising activity in patients with 
refractory ED-SCLC, with an ORR of 21% and an acceptable safety 
profile. Further study is warranted in this difficult-to-treat patient 
population. 
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Second-line amrubicin (AMR) vs topotecan in extensive-
disease small cell lung cancer (ED-SCLC) sensitive to 
first-line platinum based chemotherapy: updated results of 
a randomized phase 2 trial
Jotte, Robert M.1; Conkling, Paul2; Reynolds, Craig3; Shah, Chirag4; 
Galsky, Matthew D.5; Klein, Leonard6; Fitzgibbons, James F.7; 
McNally, Richard8; Renschler, Markus8; Oliver, Jennifer W.8
1 Rocky Mountain Cancer Center, Denver, CO, USA; 2 Virginia 
Oncology Associates, Norfolk, VA, USA; 3 Ocala Oncology, Ocala, 
FL, USA; 4 SUNY Upstate Medical University, Syracuse, NY, USA; 
5 Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA; 
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Background: SCLC presents as ED-SCLC in 60% to 70% of patients 
(pts). AMR is a 3rd-generation synthetic anthracycline and potent 
topoisomerase II inhibitor approved for treatment of lung cancer in 
Japan. We compare the efficacy and safety of 2nd-line treatment with 
single-agent AMR vs topotecan in non-Japanese pts with ED-SCLC 
sensitive to 1st-line platinum-based chemotherapy. 
Methods: This phase 2, open-label, multicenter study enrolled pts 
with ED-SCLC sensitive to 1st-line platinum-based chemotherapy 
(recurrence or progression ≥90 days from completion of 1st-line 
treatment). Pts aged ≥18 years with ECOG performance status (PS) 
≤2 and only 1 prior therapy were eligible. Pts were randomized (2:1) 
to receive IV AMR 40 mg/m²/d (days 1-3) or IV topotecan 1.5 mg/
m²/d (days 1-5) and treated every 21 days until progression, unaccept-
able toxicity, or withdrawal. The primary endpoint, overall response 
rate (ORR, complete + partial response), used RECIST criteria. 
Secondary endpoints were progression-free survival (PFS), overall 
survival (OS), and safety. 
Results: In all, 76 pts were randomized to AMR (n=50) or topotecan 
(n=26). There was a higher proportion of ECOG PS 2 pts in the AMR 
group (n=6) than in the topotecan group (n=2) at baseline. AMR 
was given for a median of 6 cycles (range 1–16) and topotecan for a 
median of 4.7 cycles (1–16). AMR significantly improved ORR rates 
vs topotecan (p<0.03, Table). Older (≥65 years) pts showed similar 
improvement: ORR was 36% with AMR vs 7% with topotecan. Of 
pts with stable disease (SD) or progressive (PD) as best response 
to 1st-line treatment, 40% (4/10) of AMR pts and 0% (0/2) of 
topotecan pts achieved CR or PR. Median time to progression was 
5.6 mos (95%CI 2.8, 7.0 mos) with AMR vs 3.3 mos (95%CI 2.1, 
11.9 mos) with topotecan. Median PFS/OS was 4.6 months (95% CI 
2.1, 6.2)/9.4 months (95% CI 5.8, 12.2) with AMR vs 3.3 months 
(95% CI 2.1, 6.4)/9.0 months (95% CI 4.9, 14.0) with topotecan. The 
most common grade ≥3 adverse events with AMR vs topotecan were 
neutropenia (53% vs 74%), thrombocytopenia (37% vs 57%) and 
leukopenia (33% vs 30%). Three AMR pts (6%) died of neutropenic 
infection. Proportions of pts who had dose reductions were 43% and 
44% in the AMR and topotecan groups, respectively.
Conclusion: AMR significantly improves ORR and has acceptable 
tolerability as 2nd-line treatment in pts with sensitive ED-SCLC. 
Final results of this study will be presented at the IASLC meeting.
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Amrubicin (AMR) does not reduce LVEF with cumulative 
doses >1000 mg/m² in 2nd-line treatment of small cell lung 
cancer (SCLC): a pooled analysis of two phase II trials
Spigel, David R.1; Shah, Chirag2; Lorigan, Paul3; McNally, Richard4; 
Renschler, Markus4; Oliver, Jennifer W.4
1 Sarah Cannon Research Institute, Nashville, TN, USA; 2 SUNY 
Upstate Medical University, Syracuse, NY, USA; 3 Christie Hospital 
NHS Foundation Trust, Manchester, UK; 4 Celgene Corporation, 
Summit, NJ, USA
Background: Amrubicin (AMR) is a 3rd generation synthetic anthra-
cycline and a potent topoisomerase II inhibitor approved in Japan for 
the treatment of lung cancer. In Japanese pre- and post-marking stud-
ies, AMR treatment is associated with a better cardiotoxicity profile 
than traditional anthracyclines. The purpose of this analysis was to 
determine if AMR treatment of Western patients (pts) is associated 
with anthracycline-induced cardiomyopathy. 
Methods: To evaluate risk of cardiomyopathy, LVEF was measured 
by echocardiogram or by multiple gated acquisition (MUGA) scan. 
Data were pooled from pts enrolled in 2 trials of AMR in 2nd-line 
SCLC (sensitive or refractory). AMR was given IV 40 mg/m²/day x 
3 days q 21 days. Pts with measurable disease, ECOG PS 0-2, LVEF 
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≥50%, and prior platinum-based treatment were assessed at baseline, 
cycles 3, 6, then every 2 cycles, and end of treatment. Pts were to 
be assessed by the same method (ECHO or MUGA) throughout the 
study. Pts with a persistent ≥20% decrease in LVEF during treatment 
were to be removed from the study.
Results: 112 pts had at least 1 LVEF assessment (sensitive n=43, 
median 6 cycles; refractory, n=69, median 5 cycles). Of the 112 pts, 5 
did not have baseline LVEF assessments and were not included in the 
LVEF analysis. Median age was 63 years and median baseline LVEF 
was 60%. Changes in LVEF from baseline were minimal (Table) 
and similar across cumulative dosing groups including 15 pts who 
received a cumulative dose of >1000 mg/m² AMR. Two refractory pts 
(1.8%) experienced drops in LVEF >20%. One had baseline LVEF of 
85%, then 60% at cycle 3, and 70% subsequently with ongoing ther-
apy. The second, with a history of cardiomegaly, had LVEF of 55% at 
baseline, cycle 3, and 5 by ECHO, and 29% at the time of progres-
sion after cycle 9 (cumulative AMR dose 840 mg/m²) by MUGA. The 
patient died due to progressive disease.
Conclusions: In this pooled analysis of SCLC pts, LVEF remained 
stable even in pts with cumulative AMR dosing >1000 mg/m². AMR 
treatment for 2nd-line SCLC showed an improved cardiomyopathy 
profile compared with typical anthracyclines, but long-term effects 
are unknown.
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Thymidylate synthase (TS) RNA expression in non-small 
cell lung cancer (NSCLC): implications for personalizing 
pemetrexed therapy 
Gandara, David R.1; Mack, Philip C.1; Omori, Akiko3; Grimminger, 
Peter2; Lara, Primo N.1; Joshi, Mary-Beth M.4; Harpole, David H.4; 
Danenberg, Kathleen D.2
1 UC Davis Cancer Center, Sacramento, CA, USA; 2 Response 
Genetics Incorporated, Los Angeles, CA, USA; 3 University of 
Southern California, Los Angeles, CA, USA; 4 Duke University, 
Durham, NC, USA
Background: TS gene expression has predictive value for fluoroura-
cil (5-FU)-based therapy in colorectal cancer (CRC). TS is one of 
several molecular targets of pemetrexed, an agent reported to have 
histology-specific activity in NSCLC, with more benefit observed 
in non-squamous histology. Preliminary reports suggest that low 
levels of TS are also a predictive biomarker for pemetrexed activ-
ity in NSCLC. At present, data are limited regarding the distribu-
tion of TS expression in various histologic subtypes of NSCLC. We 
hypothesized considerable overlap between TS expression levels in 
different histologic subtypes of NSCLC. Here we describe TS analy-
sis in NSCLC from the RGI database, and potential implications for 
pemetrexed therapy. Secondarily, we report TS distribution in CRC in 
comparison to NSCLC.
Methods: RNA from microdissected formalin fixed paraffin embed-
ded (FFPE) tumor samples was analyzed as previously described, 
reported as the ratio of TS gene expression to B-actin. For reference, 
RGI TS levels in CRC <4.0 are considered low, for 5-FU-based treat-
ment planning purposes.
Results: 587 individual patient specimens are included in this an-
alysis; 324 NSCLC (141 adenoca, 183 squamous [SCCA]) and 263 
CRC. Median TS RNA expression for NSCLC-adenoca: 2.50 (0.39-
30.33) compared with NSCLC-SCCA: 4.10 (0.14-27.06), p<0.001. 
For NSCLC histologic subtypes combined, the median TS RNA level 
was 3.11 (0.14-30.33). In CRC, median TS level was 2.63 (0.46-
89.88) There was a significant difference between NSCLC (all sub-
types) compared with CRC (p<0.01). No significant difference was 
observed between NSCLC-adenoca compared with CRC (p=0.328). 
Conclusions: This analysis demonstrates considerable heterogeneity 
in individual patient TS expression levels within NSCLC histologic 
subtypes (adenoca range 0.39-30.33; SCCA range 0.14-27.06), 
although overall there is a statistically significant difference between 
grouped adenoca versus SCCA TS levels (p<0.001). These findings 
suggest that in the future, molecular biomarkers (including others 
now in development) may supplant histology in decision-making for 
personalizing pemetrexed therapy in patients with NSCLC. Updated 
analysis will include association of TS expression with clinical par-
ameters and other purported pemetrexed biomarkers.
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Thymidylate synthase expression in large cell carcinoma of 
the lung 
Scagliotti, Giorgio V.; Monica, Valentina; Ceppi, Paolo; Righi, 
Luisella; Cambieri, Alberto; Lo Iacono, Marco; Volante, Marco; 
Novello, Silvia; Papotti, Mauro
University of Turin_Department of Clinical and Biological Sciences, 
Orbassano, Italy
Background: High levels of Thymidylate Synthase (TS) expression 
have been correlated with lower activity of TS-inhibiting drugs in 
different cancer types. In non-small cell lung cancer (NSCLC), higher 
TS levels have recently been reported in squamous cell compared to 
adenocarcinoma, and three randomized clinical trials assessing the 
efficacy of the new antifolate pemetrexed recently showed a selective 
benefit in patients with non-squamous NSCLC. TS mRNA or protein 
expression in Large Cell Carcinoma (LCC) of the lung has not been 
investigated.
Patients and Methods: TS mRNA and protein expression levels 
were analysed in a series of LCC of the lung (n=42, including 8 large 
cell neuroendocrine carcinoma variants, LCNEC), and compared 
with control series represented by adenocarcinoma (ADC, n=41), 
squamous cell carcinoma (SCC, n=30), and small cell lung cancer 
(SCLC, n=33) specimens, respectively. TS expression was also 
correlated with Ki-67 proliferation index and with the transcription 
factor E2F1. Moreover, since in unresectable locally advanced or 
metastatic NSCLC only a generic diagnosis of NSCLC-not other-
wise specified (NOS) is often obtained on bronchial cytology or fine 
needle aspiration specimens, TS expression assessed in 22 cytological 
specimens were compared with TS expression in corresponding 
surgical specimens.
Results: By quantitative Real-Time PCR, significantly higher TS 
levels were found in both LCC and SCC compared to ADC histotype 
(p<0.001 and p=0.002, respectively); a strong association between 
TS mRNA and protein levels was also observed (p<0.001), but not 
in LCC. In the LCC group, LCNECs had the highest TS expression 
(p=0.001 compared to non-NE LCC) and in the non-NE LCC tumors, 
significantly (p=0.018) higher TS protein levels were detected in 
cases positive for p63 and Desmocollin3 (both markers of squamous 
differentiation) immunostaining, rather than for TTF-1 (a marker 
usually positive in adenocarcinoma). TS and Ki-67 immunostainings 
were significantly correlated in ADC and SCC (p=0.003), but not 
in LCC. Significantly higher TS mRNA expression was detected in 
SCLC compared to respectively LCNEC (p=0.001), non-NE LCC( 
p<0.0001), SCC and ADC (p<0.0001), with a comparably higher 
E2F1 mRNA expression. A high concordance for TS immunohisto-
chemistry scores was detected between matched cytological and the 
corresponding surgical specimens.
Conclusion: LCCs express higher TS levels than ADC histotype 
and comparable with SCC. LCNEC are characterized by even higher 
levels than LCC without neuroendocrine features, but lower than 
those detected in SCLC. TS levels can be reliably assessed in cyto-
logical specimens and could represent a diagnostic tool in selecting of 
patients for TS-directed therapies.
D7.3 Pharmacogenomic Markers, Tue Aug 4, 12:30 - 14:00
Prognostic value of Thyroid transcription factor 1 (TTF1) 
in non-small cell lung cancer by AQUA® analysis and its 
relationship with histology and folate pathway marker 
thymidylate synthase (TS)
Dolled-Filhart, Marisa1; Gustavson, Mark1; Christiansen, Jason1; 
Tonkinson, John1; Chen, Victor2; Myrand, Scott2; Mullaney, Brian2
1 HistoRx, Inc, New Haven, CT, USA; 2 Eli Lilly and Company, 
Indianapolis, IN, USA
Background: Thyroid transcription factor 1 (TTF1) is a putative 
lung oncogene and thymidylate synthase (TS) is a major target of 
anti-folate drugs. Therefore, objective quantitative assays for in situ 
measurement were developed to utilize AQUA® analysis to evaluate 
lung cancer histology and association with clinical outcome.
Methods: Antibodies against TS (Labvision TS106 and Zymed 
4H4B1) and TTF1 (DAKO clone 8G7G3/1) were utilized for assay 
development with cell line controls, lung and thyroid cancer samples. 
Epithelial nuclear and cytoplasmic compartments and ratios were 
measured by AQUA analysis and matched Western results. Commer-
cially available lung cancer tissue microarray (TMA) cohorts from 
Cybrdi were utilized for histology comparisons (adenocarcinoma, 
squamous and large cell carcinoma, n=63) as well as a non-small 
cell lung cancer TMA cohort from the Yale University tumor bank 
(n=165) with associated disease-specific survival.
Results: High levels of TTF1 expression were significantly associ-
ated with better 3 year disease specific survival (p=0.006, 86.8% vs 
61.0%). TTF1 expression was significantly higher in adenocarcinoma 
than squamous cell carcinoma in both the Cybrdi (p=0.017) and Yale 
TMA (p<0.001). For TS, a trend was observed for higher expression 
in squamous cell carcinoma as compared to adenocarcinoma. TTF1 
and TS overall show significant inverse correlation (TS 4H4B1 rho = 
-0.206, p=0.02). Interestingly, some squamous tumors show measur-
able but low levels of TTF1. High concordance between TS AQUA 
scores and chromagen IHC was observed.
Conclusions: TS and TTF1 can be measured effectively by AQUA 
analysis and are consistent with classic IHC. TTF1 is a prognostic 
marker for improved outcome in this lung cancer cohort. An inverse 
relationship between TS and TTF1 occurs and may define unique 
subpopulations of lung cancer.
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Ribonucleotide reductase (RRM1) expression in non-small 
cell lung cancer (NSCLC): implications for personalizing 
gemcitabine-based therapy 
Gandara, David R.1; Mack, Philip C.2; Omori, Akiko4; Grimminger, 
Peter3; Joshi, Mary-Beth M.5; Harpole, David H.5; Danenberg, 
Kathleen D.3
1 UC Davis Cancer Center, Napa, CA, USA; 2 UC Davis Cancer 
Center, Sacramento, CA, USA; 3 Response Genetics Incorporated, 
Los Angeles, CA, USA; 4 University of Southern California, Los 
Angeles, CA, USA; 5 Duke University, Durham, NC, USA
Background: Low gene expression levels of RRM1 have been re-
ported to have predictive value for platinum- and gemcitabine-based 
therapy in NSCLC. Most recently, gemcitabine-cisplatin has been 
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reported to have histology-specific activity in advanced NSCLC, with 
improved outcomes over pemetrexed-cisplatin in squamous (SCCA) 
versus non-SCCA (Scagliotti, JCO, 2008). At present, data are limited 
regarding the distribution of RRM1 expression in various histologic 
subtypes of NSCLC. Here we describe RRM1 analysis in NSCLC 
from the RGI database, and potential implications for gemcitabine-
based therapy. 
Methods: RNA from microdissected formalin fixed paraffin embed-
ded (FFPE) tumor samples was analyzed as previously described, 
reported as the ratio of RRM1 RNA gene expression to B-actin. For 
reference, RGI RRM1 RNA levels <0.97 are considered low, and 
have been associated with improved response and survival from 
gemcitabine-platinum therapy in NSCLC.
Results: 183 individual NSCLC patient specimens are included in 
this analysis: 92 adenoca and 79 squamous [SCCA]. Median RRM1 
RNA expression: all NSCLC: 1.43 (0.25-33.19); adenoca: 1.01 (0.25-
6.01) compared with SCCA: 2.8 (0.70-33.19), p<0.001. Regarding 
the reference value, 29% of all NSCLC, 45.7% of adenoca, and 8.8% 
of SCCA were below 0.97, previously associated with improved 
outcome from gemcitabine-platinum therapy. 
Conclusions: Contrary to clinical assumptions, this analysis demon-
strates significantly higher RRM1 RNA expression levels in NSCLC-
SCCA versus NSCLC-adenoca (p<0.001). However, considerable 
heterogeneity exists in individual patient RRM1 expression levels 
within the NSCLC histologic subtypes (adenoca range 0.25-6.01, 
SCCA range 0.70-33.19). These findings suggest that recommenda-
tions for histology-based decision-making for gemcitabine-containing 
chemotherapy in SCCA may be premature, and that personalized 
biomarker assessment in individual patients may optimize therapy 
of NSCLC. Updated analysis will include associations with clinical 
parameters and other purported predictive biomarkers.
D7.5 Pharmacogenomic Markers, Tue Aug 4, 12:30 - 14:00
ERCC 1/BRCA1 protein expressions and ERCC1/XPD/
XRCC1-3 gene polymorphisms as predictor factors of 
outcome in stage IIIB-IV non-small cell lung cancer 
(NSCLC) patients treated in first-line chemotherapy with 
or without cisplatin
Tiseo, Marcello1; Bordi, Paola1; Bortesi, Beatrice1; Boni, Luca2; 
Boni, Corrado3; Baldini, Editta5; Grossi, Francesco6; Recchia, 
Francesco7; Zanelli, Francesca3; Fontanini, Gabriella8; Naldi, Nadia1; 
Bordi, Cesare9; Ardizzoni, Andrea1
1 Medical Oncology Unit, University Hospital of Parma, Parma, 
Italy; 2 Clinical Trials Coordinating Center, Istituto Toscano 
Tumori, University Hospital Careggi, Firenze, Italy; 3 Oncology 
Unit, S. Maria Nuova Hospital, Reggio Emilia, Italy; 4 Oncology 
Unit, University Hospital, Pisa, Italy; 5 Oncology Unit, University 
Hospital, Pisa, Italy; 6 Oncology Unit A, National Institute for 
Cancer Research, Genova, Italy; 7 Oncology Unit, Civil Hospital, 
Avezzano, Italy; 8 Department of Pathology, University Hospital, 
Pisa, Italy; 9 Department of Pathology, University Hospital, Parma, 
Italy
Background: The FAST study is a 2x2 factorial trial aimed at an-
swering two unresolved questions in first-line treatment of advanced 
NSCLC: (1) the role of replacing cisplatin (P) with vinorelbine (N) 
and (2) the role of adding a third agent, ifosfamide (I), in a chemo-
therapy doublet with gemcitabine (G) plus P. Over-expression of 
ERCC1/BRCA1 and specific DNA repair gene polymorphisms have 
been associated with cisplatin-sensitivity. We have examined the ef-
fect of ERCC1/BRCA1 expression and ERCC1/XPD/XRCC1-3 gene 
polymorphisms on outcome of patients enrolled in the FAST trial.
Methods: Stage IIIB-IV NSCLC patients were randomized to one 
of four arms: GP, GN, GIP or GIN. For this retrospective biological 
study, we have considered only the first comparison of the 2x2 FAST 
design (N-containing vs P-containing regimens, GN + GIN vs GP + 
GIP). We used immunohistochemistry (IHC) to determine ERCC1 
(clone 8F1) and BRCA1 (clone MS110) expression in histological 
specimens. We used a TaqMan allelic discrimination assay to evalu-
ate genetic polymorphism of the ERCC1 (C8092A), XPD (Lys-
751Gln), XRCC1 (Arg399Gln) and XRCC3 (Thr241Met) genes on 
tumor DNA. 
Results: Tumor samples were collected from 93 patients out of 433 
randomized in the FAST trial (48 and 45, respectively, treated with 
and without P). ERCC1 and BRCA1 expressions were positive in 
48 and 52 patients, respectively. Overall ERCC1-negative patients 
showed better response rate, progression-free and overall survival 
compared to ERCC1-positive regardless of chemotherapy regimen 
used. No statistically significant differences were observed according 
to BRCA1 expression. Preliminary analysis about DNA repair gene 
polymorphisms showed a potential role only of ERCC1 (C8092A) 
gene polymorphism. 
Conclusions: This biological sub-study of multicenter randomized 
trial validates ERCC1 gene as reliable candidate for customized 
chemotherapy and shows a high impact for this gene on the outcome 
of NSCLC patients treated with or without platinum-based chemo-
therapy. Definitive results will be presented at the meeting. 
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Personalized chemotherapy may favorably alter intrinsic 
disease biology to produce a higher proportion of long 
term survivors in patients with advanced NSCLC
Simon, George R.1; Kim, Johgphil2; Schell, Michael2; Bepler, Gerold2
1 Fox Chase Cancer Center, Philadelphia, PA, USA; 2 H Lee Moffitt 
Cancer Center, Tampa, FL, USA
Background: Approximately 40% of NSCLC patients present with 
metastatic disease where treatment is considered palliative. However, 
long term survival is seen in a small proportion of patients and this 
is thought to be secondary to an indolent disease biology which is 
considered to be an intrinsic property of the tumor. High ERCC1 
and high RRM1 expression levels, in curatively resected early stage 
disease, predicts for a better prognosis and lower relapse rate. Pa-
tients with advanced stage disease with low ERCC1 and low RRM1 
respond better to platinum and gemcitabine based chemotherapy, 
respectively. We postulate that the tumors low in ERCC1/RRM1 will 
up regulate their ERCC1/RRM1 after they are exposed to platinum/
gemcitabine, thereby altering the intrinsic disease biology to a more 
indolent form, the benefit of which persists well after the chemo-
therapy has been discontinued. Here we show data that suggests that 
personalized chemotherapy approaches based on ERCC1/RRM1 in-
creases the proportion of patients with good PS and stage IV disease 
who will enjoy prolonged survival, essentially plateauing the tail end 
of the overall survival curve at a higher level. 
Methods: NSCLC pts with stage IV disease and an ECOG PS of 0/1 
were prospectively accrued to four phase II clinical trials, at the H. 
Lee Moffitt Cancer Center and treated with the following regimens; 
Trial A) carboplatin/gemcitabine first-line followed by docetaxel 
second-line, Trial B) docetaxel and gefitinib combination therapy in 
patients aged 70 years or older, Trial C) combination therapy with 
carboplatin/paclitaxel/atrasentan, Trial D) personalized therapy 
(PT) based on ERCC1 and RRM1. Pts with low RRM1/low ERCC1 
received gemcitabine/carboplatin; low RRM1/high ERCC1, gem-
citabine/docetaxel; high RRM1/low ERCC, docetaxel/carboplatin; 
high RRM1/high ERCC1, vinorelbine/docetaxel. Individual patient 
data were updated as of 10/23/08. Overall survival was estimated 
using the piecewise exponential survival function. 
Results: A total number of 181 patients were prospectively accrued 
to these four trials. The piecewise exponential survival function 
showed a dramatic shift at 29 months. The median survival rate for 
the entire cohort was 10.5 months improving dramatically to 85.3 
months, if alive at 29 months (adjusted P = 0.005). In the entire 
cohort, 16.7% of pts survived to 29 months compared to 25% of pts 
in the PT group. For patients who were alive at 29 months, the prob-
abilities of surviving to 48, 60, 72 and 84 months were 79%, 68%, 
59% and 51%, respectively. Detailed overall and progression free sur-
vival data and survival estimates based on the piecewise exponential 
survival function will be presented at the meeting. 
Conclusions: Long term survival is possible in a sizeable proportion 
of stage IV NSCLC with good PS. Treatment, with specific chemo-
therapy in patients with specific intratumoral genetic profiles, may 
favorably alter the intrinsic disease biology of the tumor the benefits 
of which will last well after the chemotherapy is discontinued. Early 
evidence suggests that ERCC1 and RRM1 based PT increases the 
proportion of patients so benefitted and thereby increases the propor-
tion of long term survivors. 
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A systems genetics approach to individualized lung cancer 
diagnosis and therapy
Kim, Il-Jin1; Quigley, David 1; To, Minh1, 2; Raz, Dan2; Kang, Hio 
Chung1; Mao, Jian-Hua3; Kim, Jae 2; Jablons, David 2; Balmain, Allan1
1 UCSF Cancer Center, San Francisco, CA, USA; 2 Thoracic Oncology 
Program, Department of Surgery, UCSF, San Francisco, CA, USA; 3 
Lawrence Berkeley National Laboratory, Berkley, CA, USA
Background: Lung cancer is the leading cause of death from cancer 
in the United States and is well known to have strong environmental 
causes including smoking and exposures to second-hand smoke, 
asbestos and radon. However, only 15-20% of smokers develop 
lung cancer, suggesting that genetics also have an important role in 
determining the risk of lung cancer development and progression. 
The goals of this project are to develop an approach to “Personalized 
Medicine” for lung cancer patients, with the ultimate aim of identify-
ing genetic and gene expression networks in both normal lung tissue 
and matched tumors from the same patients. 
Methods: Ninety-one lung adenocarcinomas and matched normal 
lung tissues were analyzed for gene expression by using Illumina 
expression arrays. Eighty-four matched tumor and normal DNAs 
were analyzed by Affymetrix/Parallele non-synonymous c-SNP ar-
rays. Sequencing was also carried out of selected genes known to be 
involved in lung cancer. Analysis involves determining association 
between molecular data and clinical parameters (tumor type/grade, 
patient response to treatment or survival time). In addition, network 
and eQTL (expression Quantitative Trait Loci) analyses are ongoing 
with the goal of visualizing the genetic architectures of normal lung 
tissues and lung adenocarcinomas to identify pathway components 
relevant to normal lung development and tumorigenesis. 
Results: Smoking status has a borderline significance for patients 
survival (p=0.06), and ever-smokers are more likely to have K-ras 
mutation in their lung tumors (p=0.03). Patients with K-ras mutation 
were associated with a poorer survival (p=0.06), and the presence of 
a K-ras mutation was positively correlated with tumor size (p=0.01). 
Patients with high EGFR mRNA levels in their tumors showed a 
better survival (p=0.02), but there was no correlation between EGFR 
copy number and survival (p=0.29). TP53 mutational status was 
also not predictive of survival (p=0.76). EGFR amplification was 
positively associated with TP53 mutation (p=0.0006), which was 
validated by real-time Taqman analysis (r2=0.91). In a gene expres-
sion analysis, we identified 78 genes in normal lungs and 35 in lung 
adenocarcinomas that showed evidence for significant eQTLs. Ten 
genes were overlapped in the two sets of data, and the expression of 
a number of these genes appeared to be under the regulation of the 
same eQTL locus, suggesting that it may contain a master regulator 
of gene expression in the lung. 
Conclusions: A unique feature of this study is the possibility to carry 
out eQTL analysis using the combination of SNPs and gene expres-
sion in lung adenocarcinomas and matched normal lung from the 
same patients. This eQTL data will be used to identify SNPs that are 
associated with candidate tumor susceptibility genes for lung cancer 
and the identified genes/SNPs or gene architectures from either lung 
normal or tumors will be also used to develop better predictors of 
prognosis or response to therapy.
This work was supported by a grant from The Bonnie J. Addario 
Lung Cancer Foundation. 
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RASSF1A silencing by exon 1 specific promoter 
methylation as a prognostic and predictive marker in early 
stage I & II non small cell lung cancer (NSCLC) patients: 
final results of bio-IFCT 0002, the French Intergroup 
phase III trial of perioperative chemotherapy (CT).
Zalcman, Gerard1; De Fraipont, Florence2; Creveuil, Christian1; 
Levallet, Guenaëlle1; Beau-Faller, Michèle3; Bergot, Emmanuel1; 
Antoine, Martine4; Mounawar, Mounia5; Braun, Denis6; Breton, Jean-
Luc7; Debieuvre, Didier8; Mazieres, Julien9; Favrot, Marie-Christine2; 
Brambilla, Elisabeth2; Morin, Franck10; Hainaut, Pierre8; Quoix, 
Elisabeth5; Depierre, Alain11; Milleron, Bernard7
1 Caen University Hospital, Caen, France; 2 Grenoble University 
Hospital, Grenoble, France; 3 Strasbourg University Hospital, 
Strasbourg, France; 4 Tenon University Hospital, Paris, France; 
5 International Agency for Research on Cancer (IARC), Lyon, 
France; 6 Briey General Hospital, Briey, France; 7 Belfort General 
Hospital, Belfort, France; 8 Vesoul General Hospital, Vesoul, France; 
9 Toulouse University Hospital, Toulouse, France; 10 Intergroupe 
Francophone de Cancérologie Thoracique (IFCT), Paris, France; 11 
Besançon University Hospital, Besançon, France
Background: IFCT-0002 phase 3 trial compared two timings of CT 
in early stage I & II NSCLC lung cancer, all before surgery (PRE) 
versus PERIoperative, and two CT regimens, CDDP-Gemcitabine 
vs. CBDCA-Paclitaxel. Final results showed no significant difference 
between the two CT regimens for response rate, survival or tolerance, 
but a better compliance in PRE vs. PERI arm. We hypothesized that 
molecular markers could help to define the subgroups that did not 
beneficiate from neoadjuvant CT. 
Methods: 528 patients were randomized. 208 Snap-frozen specimens 
were collected out of the 490 non complete responder patients (42%). 
20 Molecular alterations in key pathways regulating G1/S transition 
or apoptosis were screened with appropriate techniques. Median 
follow-up was 59 months at time of final analysis. Survival rates 
were estimated with the use of the Kaplan-Meier method. Prognos-
tic values of molecular alterations were studied with a Cox model 
adjusted for clinical variables showing a p value of less than 0.2 in 
univariate analysis. Two-sided p values were corrected according to 
the Bonferroni-Holm method for multiple-hypothesis testing.
Results: RASSF1A promoter gene methylation found in 21.8% of 
patients was not mutually exclusive with K-Ras or EGFR muta-
tions. Although not associated with tumor response, RASSF1A gene 
methylation was associated to a worse PFS in univariate analysis (HR 
= 2.02 95%CI [1.35-3.103], p=0.00068) and in multivariate analysis 
adjusted for histology, treatment arm, T, and Stage (HR=1.98, [1.30-
2.92], p=0.0027 with respectively 16.7 vs. 61.2 months of median 
PFS for RASSF1A methylated and wild-type patients. RASSF1A pro-
moter methylation was also associated to a worse median OS of 32.9 
months vs. more than 80 months for wild-type RASSF1A patients 
(HR=2.13 [1.34-3.37], p=0.0013). This adverse prognostic value 
remained significant in the multivariate model adjusted for histology, 
T and stage (adjusted HR=2.10, [1.32-3.33], p=0.01). In RASSF1A 
wild-type patients, there was no difference of PFS between the 
treatment arms (p=0.076). Conversely, in RASSF1A-methylated 
patients, le sub-group of patients treated with paclitaxel-carboplatin 
had a significantly longer median PFS as compared with patients 
treated with gemcitabine-cisplatin (HR=0.60 [0.29-1.22], p=0.042). 
The interaction test, adjusted for histology, T and stage, remained 
significant (p=0.032) showing a predictive value for RASSF1A 
gene methylation. Another gene, DAPK, regulating apoptosis, was 
shown to be silenced by promoter methylation in 50% of patients. 
DAPK-methylated patients were shown to have a better survival in 
univariate (HR=0.55 [0.34-0.89], p=0.016), but not in multivariate 
analysis (p=0.10). However, a stepwise Cox regression analysis using 
RASSF1A and DAPK methylation status led to define three groups of 
patients having significantly different PFS ranging from 9.7 months 
(wt DAPK and met RASSF1A), to 24.7 (wt or met DAK, and wt 
RASS1A) and 74.9 months (met DAPK and wt RASSF1A), with 
respective adjusted HRs=1.58, 2.88 and 1, p=0.0026). For overall 
survival analysis, the separation in three prognostic groups was also 
shown to be relevant since median OS significantly differed from 
29 months to more than 80 months (p= 0.0011, and p=0.00063 in 
adjusted multivariate analysis).
Conclusions: This study showed a dramatic negative prognostic 
impact for RASSF1A promoter gene methylation in resectable early 
lung cancer. A subset of RASSF1A-methylated patients with poor 
prognosis did not take any advantage from perioperative chemother-
apy. Methylation of RASSF1A and DAPK apoptosis genes could 
stratify three subsets of early lung cancer patients with drastically 
different prognosis and should be prospectively validated.
D8.2 Novel Approaches to Biomaker Development, Tue Aug 4, 12:30 - 14:00
A microRNA profile for predicting recurrence after 
surgical resection of stage I non-small cell lung cancer
Yendamuri, Sai2; Kannisto, Eric2; Dahlgaard, Jesper1, 3; Knudsen, 
Steen1; Patnaik, Santosh K.2
1 Medical Prognosis Institute, Hoersholm, Denmark; 2 Department of 
Thoracic Surgery, Roswell Park Cancer Institute, Buffalo, NY, USA; 
3 Institute of Pathology, Aarhus University Hospital NBG, Aarhus, 
Denmark
Background: We studied microRNA (miRNA) expression for 
prediction of recurrence after surgical resection of patients with 
pathologic stage I non-small cell lung cancer (NSCLC).
Methods: FFPE specimens were obtained from 77 surgically resected 
stage I NSCLC. MiRNAs were profiled using an LNA-based miR-
NAarray. Leave one out and Monte Carlo cross-validation methods 
were used to assess the ability to differentiate between patients with 
and without recurrence. From the same clinical dataset, 40 patients 
were used to develop a 3-miRNA-signature that was tested in a set 
of 18 patients. For technical validation of accuracy of expression, 
miRNA expression was examined in eight samples using QPCR. The 
DAVID, TargetScan & miRanda algorithms were used to examine 
the functional annotations of predicted targets for the three-miRNA-
signature.
Results: One hundred miRNAs were differentially expressed 
(FDR=0.01) between patients with recurrence and those without. 
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Leave one out cross-validation demonstrated the ability of the 
miRNA profile to predict disease recurrence (p<0.05). Accuracy in 
prediction of recurrence ranged from 43.3% to 90% (Monte Carlo 
cross-validation; mean 68.5%, 95% CI 56.7% - 83.3%). A miRNA 
signature consisting of three miRNAs identified in the training set 
accurately predicted disease recurrence in the test set (p<0.05). In the 
small cohort of 8 patients used for technical confirmation of miRNA 
expression of the three-miRNA-signature, PCA showed a separation 
of samples with and without recurrence (fig 1). Functional annota-
tions of predicted targets for the three-miRNA-signature revealed 
significant enrichment (FDR<0.05) of functional annotations for 
“mirA” targets (downregulated in relapse patients) for genes involved 
in (a) anatomical structure development and developmental processes 
(~30% of targets); (b) embryonic morphogenesis (~4%); (c) cell 
proliferation (~10%); (d) post-translational protein modification, e.g. 
protein kinase (~17%); (e) TGF-beta signaling pathway (~3%); (f) or-
gan morphogenesis and blood vessel/vasculature development (~6%). 
For “mirB” targets (downregulated in relapse patients), significant 
enrichment was observed for genes involved in (a) response to DNA 
damage stimulus; DNA repair; response to stress (~7%). For “mirC” 
targets (upregulated in relapse patients), significant enrichment 
was observed for genes involved in (a) EGF and EGF-like region 
(~3.5%); (b) cell differentiation (~11%); (c) negative regulation of 
smooth muscle cell proliferation (~0.44%); (d) immune effector 
processes and complement activation (~1.6%).
Conclusions: The miRNAprofile generated in this study is capable of 
predicting recurrence after surgery in stage I NSCLC. This promising 
profile targets mRNA species that are significantly enriched in cancer 
associated functional annotations and deserves to be validated in 
additional independent datasets.
D8.3 Novel Approaches to Biomaker Development, Tue Aug 4, 12:30 - 14:00
Levels of genetically abnormal circulating cells in patients 
with non-small cell lung cancer correlate with stage and 
genetic phenotype of tumor, recurrence and survival: a 
FISH based case and control study
Katz, Ruth L.1; He, Weigong 1; Khanna, Abha 1; Fernandez, Ricardo 
L.1; Caraway, Nancy P.1; Zhang, Hua-Zhong1; Spitz, Margaret R.1; 
Blowers, David2; Mehran, Reza J.1; Jimenez, Carlos A.1; Swisher, 
Stephen G.1; Roth, Jack1; Etzel, Carol1; El-Zein, Randa 1
1 MD Anderson Cancer Center, Houston, TX, USA; 2 Astra Zeneca, 
Alderly Edge, UK
Background: Quantification of circulating tumor cells (CTCs) for 
non-small cell lung cancer (NSCLC) has been performed using 
cytokeratin-based assays and magnetic beads or pins coated with 
EPCAM. However, these methods are difficult to perform and cannot 
be used to examine cell morphology. We developed a fluorescence in 
situ hybridization (FISH)-based assay on isolated peripheral blood 
mononuclear cells (PBMC) using probes targeting specific sites on 
chromosomes that are known to be abnormal in lung cancer to detect 
putative CTCs.
Methods: Our study population consisted of 59 cases with NSCLC 
(22 presented with stage IA or IB, 9 with stage II, 10 with stage III 
and 18 with stage IV) and 24 non cancer controls.
PBMCs isolated prior to surgery were hybridized with different DNA 
probes: 2-color in-house (3p, 3 and 10q, 10), and 4-color (3, 7, 17, 
9p21.3) and(EGFR, c-MYC, 6p11-q11, and 5p15.2) commercial 
FISH probes. Resected tumor specimens from a subset of the same 
patients (n=21) were hybridized with the same probe sets. Percent-
ages of chromosomal abnormalities (CAs) from blood and tumors 
were quantified via an automated scanner with specialized filters and 
were scored based on loss or gain of genetic regions in 250 intact 
cells/sample. For the 4-color FISH probes PBMCs with ≥2 genetic 
abnormalities per nucleus were presumed to be circulating tumor 
cells (CTCs). For the 2-color sets PBMCs with ≥1 genetic abnor-
mality of 3p/3 and 10q/10 per nucleus were considered to be CTCs. 
CTC/µl were calculated based on percentage of cells with CAs X 
number of mononuclear cells isolated from blood/amount of blood in 
mls/1000. 
Results: Cancer patients showed significantly higher levels of CTCs 
compared to controls for all probes tested with a trend to increase 
across stage of disease with the highest levels seen in stage IV 
patients. As an example, mean levels of CTCs/μl with abnormalities 
of any two chromosomes for the 3,7,17 or 9p21.3 set, ranged from 
6.3 ± 1.2 for controls, 13.1± 3.3 for stage IA and 25.4 ± 8.6 for stage 
IV cancer (p=0.006) Molecular staging, based on levels of CTCs, 
was highly correlative with pathological stage. Genetic abnormal-
ities in CTCs correlated with corresponding abnormalities in tumor 
tissue. Moreover, different markers could be used to differentiate 
cancer cases from controls at different stages of disease. Monosomy 
3/3p and gain of 6p11-q11 were specific to high stage disease, while 
abnormalities of 3p and 10q, and single gain of chromosomes 3, 7, 17 
or 9p21.3 correlated with relapse and overall survival (p=0.0002). In 
high stage patients an exact correlation between EGFR gain in CTCs 
and the primary tumor was noted.
Conclusions: We have developed a sensitive and novel FISH based 
test for detecting CTCs in lung cancer patients that correlated well 
with tumor stage, genetic phenotype and clinical outcome. Levels of 
CTCs detected were three fold higher than previously reported with 
standard methods. This may allow for expanded types of molecular 
profiling eventually leading to the use of CTCs as a surrogate for tar-
geted therapy. Further work is in progress to validate these findings.
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Expression of stem cell markers in non-small cell lung 
carcinoma (NSCLC) and correlation with clinico-
pathologic features
Yuan, Ping1; Behrens, Carmen1; Huang, Jiaoti 2; Spinola, Monica3; 
Prudkin, Ludmila1; Dong, Wenli1; Yin, Guosheng1; Moran, Cesar 
A.1; Kim, Edward S.1; Zhou, Bin-Bing4; Minna, Jonh D.3; Wistuba, 
Ignacio I.1
1 UT. MD.Andedon Cancer Center, Houston, TX, USA; 2 David 
Geffen School of Medicine at UCLA, Los Angeles, LA, USA; 3 
University of Texas Southwestern Medical Center, Dallas, TX, USA; 4 
Wyeth Pharmaceuticals, Pearl River, New York, NY, USA
Background: Cancer stem cells (CSCs) or cancer-initiating cells 
represent a minor population of self-renewing tumor cells which are 
believed to play an important role in tumor development, metastasis 
and resistance to therapy. Although some CSC markers have been 
described in NSCLC, there is no comprehensive characterization of 
multiple CSC markers in this disease. Our aim was to investigate the 
patterns of protein expression of a panel of CSC-related markers in 
a large series of NSCLCs, and correlate those findings with patients’ 
clinico-pathologic characteristics. 
Methods: We examined protein expression by immunohisto-
chemistry (IHC) of 287 NSCLCs (178 adenocarcinomas, and 109 
squamous cell carcinomas (SCC)) of a panel of seven CSC markers: 
EZH2, SOX2, CD24, CD44, C-kit, BMI-1 and Oct3/4. The patterns 
of expression of these markers were correlated with patients and 
tumors’ clinico-pathologic characteristics, including disease outcome. 
In the adenocarcinomas, CSC markers expression was correlated with 
the EGFR and KRAS mutation status of the tumors. 
Results: Expression of EZH2, SOX2, CD44, CD24 and C-kit was 
detected in a subset of NSCLC tumors. No expression of BMI-1 and 
Oct3/4 was detected in any of the tumors. The patterns of expression 
for these markers correlated with certain clinico-pathologic charac-
teristics, including tumor histology, pathological stage, and patients’ 
smoking history. EZH2 and SOX2 nuclear protein expressions 
were significantly higher in SCC than adenocarcinoma (P<0.001). 
CD44 membrane (P<0.001) was significantly higher in SCC than 
adenocarcinoma, and CD24 cytoplasmic (P<0.05) expressions was 
significantly higher in adenocarcinoma than in SCC. We identified a 
subset of NSCLCs having membrane CD44 high/CD24 low or nega-
tive expression. In adenocarcinomas, EZH2 and CD24 expression 
levels were significantly (P <0.001) higher in current smokers than 
never or former smokers, and CD44 expression level was signifi-
cantly (P <0.001; P<0.05) in never smokers. The presence of EGFR 
mutation in lung adenocarcinomas correlated significantly with low 
EZH2 (P=0.03) and high CD44 (P=0.032) expression. Interestingly, 
in multivariate analysis using the expression scores as a continuous 
variable, high nuclear expression of EZH2 correlated significantly 
with worse recurrence free survival (HR=1.007; P=0.0126) and 
overall survival (HR=1.006; P=0.0035) in patients with stage I/II 
adenocarcinomas. 
Conclusions: We provide a characterization of multiple CSC markers 
in a large series of NSCLCs. Our findings indicate that a different 
pattern of CSC markers expression is detected in adenocarcinomas 
and squamous cell carcinomas of the lung, and their expression cor-
relates with patients’ clinico-pathologic features, including survival. 
The understanding of the role of CSCs in NSCLC tumor development 
and progression may provide opportunities to design novel strategies 
to prevent and treat this disease. 
Supported by grants DoD W81XWH-04-1-0142, W81X-
WH-07-1-0306, and UT-Lung SPORE P50CA70907.
D8.5 Novel Approaches to Biomaker Development, Tue Aug 4, 12:30 - 14:00
A prospective study of serial measurements of cell-free 
DNA in plasma, radiographic response, and overall 
survival in patients with metastatic non-small cell lung 
cancer (NSCLC)
Azzoli, Christopher G.1; Johnson, Melissa1; Morita, Shinji2; 
Motoyama, K2; Subzwari, Sara1; Hsu, Meier1; Shen, Ronglai1; 
Danenberg, Kathy2; Danenberg, Peter2; Kris, Mark G.1
1 Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 2 
Department of Biochemistry, Keck School of Medicine, University of 
Southern California, Los Angeles, CA, USA
Background: Radiologic response by RECIST category (PR, SD, 
PD) and progression-free survival are surrogates for overall survival 
in phase II, and some phase III trials of chemotherapy for patients 
with metastatic NSCLC. Levels of cell-free DNA in plasma are 
higher in patients with metastatic NSCLC compared to early-stage 
patients, and healthy controls. Published data suggest that high levels 
of cell-free DNA in plasma predict worse survival, and that changes 
in DNA over time may be used to predict the efficacy of therapy. 
Methods: We conducted a prospective study to measure cell-free 
DNA in the plasma of patients with metastatic NSCLC before, and 
coincident with up to 3 radiologic response assessments during 
chemotherapy (until PD). Blood was collected in citrated tubes con-
taining Ficoll Hypaque density fluid and a polyester gel barrier, kept 
on ice, and processed within 1 hour of collection. Tubes were spun at 
1800 RCF for 20 minutes at room temperature. Plasma was removed 
without disturbing the mononuclear cell layer, and frozen at -80°C. 
DNA was extracted from a fixed volume of plasma, and measured 
using quantitative PCR of the β-Actin gene. Radiologic response was 
recorded by RECIST, including sum longest diameter of measurable 
lesions. Overall survival was analyzed by Cox regression. 
Results: Enrollment is complete, with 264 patients on study. To 
date, plasma DNA and radiologic response data are available on 70 
patients. Of these, 56 had at least one follow-up blood collection and 
CT scan. Cox regression analysis relating baseline DNA to overall 
survival: HR 1.10 (95% CI 0.96-1.25, p=0.164); DNA level at time 
of the first response assessment: HR 1.18 (0.98-1.42, p=0.08); rise in 
DNA at first scan: HR 0.99 (0.86-1.14, p=0.88). For patients scored 
as having radiologically stable disease at first scan (n=38), rise in 
DNA at first scan: HR 0.99 (0.79-1.23, p=0.89). 
Conclusions: In data from the first 70 of 264 patients, there is a 
trend towards worse survival with a high baseline, or high follow-up 
cell-free DNA in plasma. However, a rise or fall in cell-free DNA 
in plasma is not prognostic, and rise or fall in DNA level does not 
appear to add discriminatory value to patients categorized as having 
stable disease by RECIST at their first response assessment. Com-
plete data will be presented, making this the largest prospective 
study of changes in cell-free DNA in plasma as a surrogate efficacy 
endpoint. Association of DNA levels and progression free survival, 
and sub-group analyses based on age, gender, smoking history, histol-
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ogy, location of metastases, and type of chemotherapy are planned. 
Supported by R01-CA092315.
D8.6 Novel Approaches to Biomaker Development, Tue Aug 4, 12:30 - 14:00
Serum mass spectrometry profiling of cancer patients 
treated with epidermal growth factor receptor inhibitors 
Chung, Christine1; Seeley, Erin H.1; Maitland, Michael L.1; Roder, 
Heinrich2; Grigorieva, Julia2; Roder, Joanna 2; Argiris, Athanassios3; 
Vokes, Everett1; Carbone, David 4; Caprioli, Richard4; Cohen, Ezra E.1
1 University of Chicago, Chicago, IL, USA; 2 Biodesix, Inc., 
Steamboat Springs, CO, USA; 3 University of Pittsburgh, Pittsburgh, 
PA, USA; 4 Vanderbilt University, Nashville, TN, USA
Background: A previous study has shown that a proteomic profile 
in serum or plasma can predict survival in non-small cell lung cancer 
(NSCLC) patients treated with the epidermal growth factor receptor 
tyrosine kinase inhibitors (EGFR-TKIs). Here we examined whether 
this profile also predicts survival in NSCLC treated with cetuximab 
(anti-EGFR antibody), and other cancer types including head and 
neck squamous cell carcinoma (HNSCC) and colorectal cancer 
(CRC) treated with EGFR-TKIs or cetuximab. 
Methods: Pretreatment serum or plasma samples from 352 patients 
were analyzed by mass spectrometry (MS). The NSCLC cohort was 
treated with cetuximab and pemetrexed sequentially or in a combina-
tion. The HNSCC cohorts were treated with gefitinib, a combination 
of erlotinib/bevacizumab, cetuximab, surgery, or palliative chemo-
therapy. The CRC cohort was treated with cetuximab. Each sample 
was classified into “good” or “poor” groups using the previously de-
fined algorithm, and survival analyses of each cohort were performed 
based on this classification. For the CRC cohort, this classification 
was correlated with the tumor EGFR ligand levels and KRAS muta-
tion status. 
Results: In all EGFR inhibitor-treated cohorts, the classification 
predicted survival while the control cohorts showed no survival dif-
ference: 1) NSCLC cetuximab/pemetrexed overall survival (OS) log-
rank p=0.05, HR 0.40, 95% CI 0.16-1.00; 2) HNSCC gefitinib OS 
log-rank p=0.007, HR 0.41, 95% CI 0.22-0.79; 3) HNSCC erlotinib/
bevacizumab OS log-rank p=0.02, HR 0.20, 95% CI 0.05-0.78; 4) 
HNSCC cetuximab OS log-rank p=0.06, HR 0.26, 95% CI 0.06-1.06; 
5) CRC cetuximab progression-free survival log-rank p=0.007, HR 
0.51, 95% CI 0.31-0.83 (OS not available); and 6) HNSCC chemo-
therapy OS log-rank p=0.8, HR 0.88, 95% CI 0.40-1.94. Tumor 
EGFR ligand RNA levels were significantly associated with the 
classification, but KRAS status was not, while combined analyses 
of the two biomarkers provided additional information. Conclu-
sions: Serum proteomic profiling is predictive of survival in HNSCC, 
NSCLC and CRC patients treated with EGFR-TKIs or cetuximab. 
In addition, this classification is independent of KRAS status and 
provides an additional way to identify patients most likely to benefit 
from EGFR inhibitors.
D8.7 Novel Approaches to Biomaker Development, Tue Aug 4, 12:30 - 14:00
Analysis of serum proteomic profile, EGFR gene 
amplification, and polymorphisms in non small cell lung 
cancer (NSCLC) patients treated with EGFR TKIs
Spreafico, Anna1; Grigorieva, Julia2; Lazzari, Chiara1; Belli, 
Carmen1; Cattaneo, Angela3; Viganò, Maria Grazia1; Bachi, Angela3; 
Villa, Eugenio1; Roder, Heinrich2; Gregorc, Vanesa1
1 Dept. of Oncology, Scientific Institute San Raffaele University 
Hospital, Milano, Italy; 2 Biodesix Inc., Steamboat Springs, CO, 
USA; 3 Proteomic Laboratory, Scientific Institure San Raffalele 
Hospital, Milano, Italy
Background: Despite the existence of several clinical and biological 
markers for EGFR TKI therapy in NSCLC patient populations, none 
of them is used routinely in clinical practice. In our previous study 
(JNCI, 2007) we applied serum MALDI ToF MS analysis to build 
and validate a proteomic classifier (VeriStratTM, Biodesix, Inc) 
predictive for clinical benefit in NSCLC patients treated with EGFR 
TKIs, distinguishing two subgroups: those with good or poor prote-
omic profile. We have also demonstrated that the proteomic profile is 
stable during treatment and its changes, when the occur, are correl-
ated with disease progression (Chicago Symposium 2008). However, 
VeristratTM association with clinical and biological characteristics 
has not been explored yet. The aim of our study was to correlate 
VeristratTM test labels with patients’ clinical characteristics, genomic 
polymorphisms and tissue biomarkers.
Methods: Sera from advanced NSCLC pts treated with gefitinib were 
analyzed by MALDI ToF MS. Mass spectra were acquired in linear 
mode using a Voyager DE-STR mass spectrometer. Serum samples 
were prepared and spectral analysis was performed according to a 
standard protocol. The VeristratTM test was used to analyze the col-
lected spectra. 
Results: A total of 123 patients’ samples were analyzed. Data from 
111 patients were available for longitudinal analysis, and 121 samples 
had information on genetic polymorphism. Serum was collected at 
before treatment (baseline), at every CT-scan evaluation, and at treat-
ment withdrawal. Pt characteristics (%) were: male/female: 77/23; 
median age: 65; never/ever-smokers: 16/85; adeno/non-adeno: 72/28; 
ECOG PS 0/1/2: 34/44/22. At baseline 82 pts had a good proteomic 
profile, and 41 poor. The longitudinal analysis showed that changes 
from good to poor at treatment withdrawal occurred mainly in male 
and smoker patients who presented a clear progression of disease 
(P=.0007; P=0008 respectively). Of the clinical features, in univari-
ate analysis adenocarcinoma and ECOG PS 0-1 were statistically 
significantly correlated, to VeristratTM classification (P=.05; P<.0001 
respectively). With regards to biological biomarkers, no correlation 
between VeristratTM label, EGFR gene amplification or EGFR poly-
morphisms was found. 
Conclusions: The modification of proteomic profile at progression 
and the lack of association with EGFR genomic polymorphisms sug-
gested that VeristratTM label is not an inherited patient characteristic, 
and it also seems unrelated to EGFR gene amplification. These results 
strengthen the value of the proteomic profile in terms of OS and PFS 
in NSCLC patients treated with EGFR TKIs. 
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The functional MDM2 SNP309 polymorphism is associated 
with an earlier age of diagnosis in women with lung cancer
Axelson, Michael D.1; Sun, Sophie2; Xie, Xian-Jin1; Schiller, Joan1; 
Minna, John1; Tomlinson, Gail1
1 UT Southwestern, Dallas, TX, USA; 2 British Columbia Cancer 
Agency, Vancouver, BC, Canada
Background: MDM2 protein is a key negative regulator of p53 
protein by targeting its destruction through the ubiquitin pathway. A 
single nucleotide polymorphism (SNP309 T→G) has been identified 
in the promoter of the MDM2 gene which results in higher levels 
of MDM2 protein, attenuation of the p53 pathway, and enhanced 
tumorigenesis. Estrogen signaling has also been shown to upregu-
late MDM2 expression. Recent studies have suggested that the 
MDM2 SNP309 polymorphism is associated with earlier age of 
onset of certain cancers, particularly in women. These results have 
been controversial with regards to the impact of the SNP309 T→G 
polymorphism on lung cancer risk. The purpose of this study was to 
further explore whether the MDM2 SNP309 polymorphism is associ-
ated with lung cancer risk in a gender specific manner.
Methods: MDM2 genotype analysis was performed on a cohort of 
324 consecutive patients with histologically confirmed lung cancer 
using a PCR-based nucleotide polymorphism discrimination test. 
Allele status was described as homozygous wild-type (TT), homo-
zygous variant (GG) and heterozygous variant/wild-type (TG).
Results: In total, 138 female and 186 male lung cancer patients were 
screened for the MDM2 SNP309 polymorphism (Table 1). Females 
with the GG genotype were diagnosed at a significantly earlier age 
as compared to females with TT genotype (p=0.011), while a similar 
comparison for males showed no significant difference. With TT 
genotype, females were diagnosed at a significantly later age as 
compared to males (p=0.042). Smoking history was not available on 
all samples, but in women with the GG genotype fewer were smokers 
compared to women with the TT genotype. All the p-values were 
from two sided tests.
 MDM2 Genotype  n Age of Onset: Mean (SEM)
 TT  
 Male 95 59.2 (1.2)
 Female 75 62.7 (1.3)
   
 TG  
 Male 74 62.4 (1.4)
 Female 48 59.6 (1.6)
   
 GG  
 Male 17 62.5 (4.5)
 Female 15 54.0 (3.9)
Conclusions: In this study, we found that women, but not men, with 
the MDM2 SNP309 GG genotype were particularly susceptible to the 
development of lung cancer at an earlier age, supporting the hy-
pothesis that the expression of this polymorphism is gender-specific 
and possibly regulated by estrogen. Women with the MDM2 GG 
polymorphism represent a potential high-risk group for the focus of 
lung cancer screening and chemoprevention efforts with anti-estrogen 
therapy. Future clinical trials could consider anti-estrogen therapy for 
women with the SNP 309 GG genotype.
D9.2 Lung Cancer Epidemiology and Health Services, Tue Aug 4, 12:30 - 14:00
The predictive ability of LLP lung cancer risk model with 
and without seizure 6-Like (SEZ6L) gene
Raji, Olaide Y.1; Agbaje, Olorunsola F.2; Duffy, Stephen W.3; Field, 
John K.1
1 School of Cancer Studies, University of Liverpool, Liverpool, UK; 
2 Division of Cancer Studies, Cancer Epidemiology Unit, King’s 
College London, London, UK; 3 Cancer Research UK Centre for 
EMS, Wolfson Institute of Preventive Medicine, Barts and the London 
School of Medicine and Dentistry, London, UK
Background: Risk prediction models are essential tools for identify-
ing individuals at high risks of developing a disease. The Liverpool 
Lung Project (LLP) has previously developed and validated a risk 
model for prediction of 5-year absolute risk of developing lung 
cancer based on five epidemiological risk factors namely smoking 
duration, prior diagnosis of pneumonia, family history of lung cancer 
including age at onset, occupational exposure to asbestos and prior 
diagnosis of other cancer. SEZ6L, a Met430IIe polymorphic variant 
found on 22q12.2 region, has been linked with an increased risk of 
lung cancer in a case-control population and validated in other two 
studies. In this current work, we assess and quantify the improvement 
in risk prediction attributed to addition of SEZ6L in the LLP risk 
model.
Methods: Data from high-throughput DNA allele frequency genotyp-
ing using a dense genome-wide single nucleotide polymorphism 
(SNP) marker available on a subset of case-control patients partici-
pating in the Liverpool Lung Project (LLP) were combined with 
the previously identified epidemiological risk factors. There were 
427 cases and 848 controls with complete epidemiological data, of 
which 200 cases and 188 controls were genotyped for SEZ6L SNP. 
After exploring the bivariate association between the SNP and each 
of the epidemiological risk factors using the Pearson’s chi-squared 
test, multivariable conditional logistic regression was employed to 
predict 5-year absolute risk of lung cancer with and without the SNP. 
The improvements in the model associated with the SNP was assess 
through a pairwise comparison of the area under the receiver operat-
ing characteristic curve (ROC-AUC) and the Net Reclassification 
Improvements (NRI).
Results: The homozygote wild type SEZ6L genotype (GG) consti-
tutes the majority of the subjects (55%), and only approximately 7% 
had homozygote mutant genotype (TT). The case-control comparison 
revealed a statistically significant high proportion of homozygote 
mutant genotype among cases (10%) compared to controls (3%). We 
found no statistically significant relationship between any of the five 
epidemiological risk factors and the SEZ6L genotype either for the 
combined or separate analysis of the case and control subjects.
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The extended model showed better calibration compared to the 
baseline model. There was a statistically significant modest increase 
in ROC-AUC from 0.72 (0.66-0.77) for the baseline model to 0.75 
(0.71-0.80) for the extended model. The NRI also revealed a statistic-
ally significant improvement of around 12% for the extended model; 
this improvement was even better for subjects classified into the two 
intermediate risk categories by the baseline model (NRI=27%). 
Conclusions: Our results suggest that the addition of SEZ6L 
improved the performance of the LLP risk model particularly for 
subjects whose initial absolute risks were unable to discriminate 
them into ‘low’ or ‘high’ risk group. The limited number of subjects 
included in this analysis warrants a cautious interpretation of the ob-
served improvement. It is expected that this single SNP would have 
a modest impact on the overall predictive power of the model. How-
ever, this work demonstrates in principle an approach to incorporate 
genetic biomarkers in risk models for predicting lung cancer risk at 
an individual level.
D9.3 Lung Cancer Epidemiology and Health Services, Tue Aug 4, 12:30 - 14:00
An international comparison of barriers in opening clinical 
trials and trial enrollment
Wang-Gillam, Andrea1; Novello, Silvia 2; Williams, Kristina1; 
Baggstrom, Maria1; Gao, Feng1; Scagliotti, Giorgio2; Govindan, 
Ramaswamy1
1 Washington University in St. Louis, St. Louis, MO, USA; 2 
University of Turin, Orbassano, Italy
Background: Well-designed clinical trials are the only way to 
improve the outcomes of cancer patients. However, less than 3 % of 
patients with lung cancer participate in clinical studies. It is critical 
to understand the barriers to accrual for clinical trials. There are sig-
nificant administrative processes to “open” oncology clinical trials in 
the United States. This retrospective study examines the procedures 
and time required to open thoracic oncology trials at a United States 
academic center compared to a similar center in Europe. Additionally, 
the study analyzes enrollment profiles from the two institutions.
Methods: A retrospective review was performed of all thoracic 
oncology therapeutic trials submitted for regulatory review between 
2001-2008 at Washington University at St. Louis School of Medicine 
(WUSM) and the University of Turin, Italy (UT). A process map was 
drafted by both institutions to establish the order of required events. 
The timing data for each step was collected for comparison. Accrual 
data was also analyzed and compared.
Results: A total of 137 therapeutic thoracic oncology trials were 
reviewed, 83 from WUSM and 54 from UT. The majority of the 
studies are phase II studies (WUSM 72.3% vs. UT 81%). The median 
times to open a trial were 163 days (inter-quartile range [IQR] 91 to 
257 days) for WUSM and 122 days for UT (IQR 96 to 159 days) (p = 
0.048). The median times for regulatory approval were 75 days (IQR 
26 to 131 days) for WUSM and 31 days (IQR 10 to 67 days) for UT 
(p<0.0001). This difference in the timeline for regulatory approval 
was attributed to the additional requirement of Scientific Review 
Committee approval at WUSM prior to consideration by the Institu-
tional Review Board (IRB), while regulatory approval is a single step 
process at UT. However, the median time for the contract approval 
process was identified as the limiting step in the overall timeline to 
opening a study, with a median of 115.1 (WUSM, IQR 78 to 187) and 
84 (UT, IQR 44 to 124) days (p = 0.011). 
Enrollment information was compared for a subset of protocols that 
had permanently closed to enrollment at both institutions. WUSM 
(N=71) reported a median accrual of 2 patients per study while UT 
(N=40) reported 10 patients per study (p<0.0001). WUSM reported 
that 21.1% of trials had accrued no patients, while UT reported no 
accrual in 5%. Trials that accrued greater than 20 patients comprised 
2.8% of trials at WUSM and 30% of trials at UT. 
Conclusions: It takes additional steps and significantly longer time 
to open a therapeutic thoracic clinical trial at a representative U.S. 
site (WUSM) compared to an European site (UT). As global trial col-
laboration increases, uniform strategies must be developed to shorten 
the administrative process, encouraging the creation of streamlined 
systems that enable centers to increase the number of agents available 
to patients and to further therapeutic investigation. Further investiga-
tion of barriers in trials with low accrual is warranted. 
D9.4 Lung Cancer Epidemiology and Health Services, Tue Aug 4, 12:30 - 14:00
An economical, randomized, multicenter phase III trial 
of second line treatment for non small cell lung cancer 
(NSCLC) comparing docetaxel versus pemetrexed: GFPC 
(Groupe Français de Pneumo-Cancérologie) 05-06 study
Vergnenegre, Alain1; Corre, Romain2; Berard, Henri3; Paillotin, 
Dominique4; Dujon, Cecile5; Robinet, Gilles6; Crequit, Jacky7; Bota, 
Suzanna8; Thomas, Pascal9; Chouaid, Christos10
1 Service de Pneumologie, CHU, Limoges, France; 2 Service de 
Pneumologie, CHU, Rennes, France; 3 Service de Pathologie 
Respiratoire, HIA, Toulon Naval, France; 4 Service de Pneumologie, 
CHU, Rouen, France; 5 Service de Pneumologie, CH, Le Chesnay, 
France; 6 Institut de Cancérologie et d’hématologie, CHU, Brest, 
France; 7 Service de Pneumologie, CH, Beauvais, France; 8 Clinique 
Pneumologique, CHU, Rouen, France; 9 Service de Pneumologie, 
CHI, Gap, France; 10 Service de Pneumologie, CHU, Paris, France
Background: The costs of second line treatment for non small cell 
lung cancer (NSCLC) has dramatically increased during the last 
decade. The objective of this phase III, randomized, multicenter study 
was to compare from the payer’s perspective the economical impact 
of two widely used treatments: pemetrexed versus docetaxel.
Methods: This study included progressive NSCLC patients after a 
first line platin based chemotherapy: docetaxel 75 mg/m² (arm A) ver-
sus pemetrexed 500 mg/m² (arm B) every three weeks. The number 
of subjects was determined to find a second line direct cost differ-
ence of 10% between the two arms (α=0.05, β=0.20). The analysis 
recorded: transportation, drug, administration (outpatient or inpatient) 
and adverse events costs. The volumes were prospectively recorded 
and the cost calculation was based on national hospital and ambula-
tory care tariffs. Comparison between adverse events were performed 
by t-test or chi2 test. Overall survival (OS) and time to progression 
(TTP) were given by Kaplan Meier method. Average and 95% con-
fidence intervals, cost-differences were calculated by non parametric 
methods (bootstrap, SAS software). 
Results: 150 patients were enrolled between February 2006 and 
June 2008, by 27 centers. They were 126 males, 24 females with 
mean age: 58 years (36-75). There were no differences between the 
two arms in terms of sex, age, performans status, weight loss, body 
surface, history. 9 patients were still alive at the censor date, 2008 
december 31th. There were no differences in terms of objective 
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response: 8/75 (13.6%) arm A versus 5/75 (9.1%) arm B (p=0.59). 
TTP was 2.8 m [2.26-4.23] for arm A, 2.53 m [2.16-4.00] for arm B 
(p=0.85). The mean number of cycles was 3.7 ( ± 1.9) for arm A and 
3.6 ( ± 1.75) for arm B. There were no differences for overall toxici-
ties (p=0.55), and for grade 1-2 toxicities. In the opposite, there was a 
significantly difference in term of grade 3-4 haematological toxici-
ties 29/75 (38.7%) in arm A, 14/75 (18.7%) in arm B, p=0.007 and 
for overall grade 3-4 toxicities: 39/75 for arm A (52%) versus 25/75 
(33%) for arm B (p=0.02).
The table 1 depicts the global cost analysis (average cost per patient, 
95% CI) euros 2007
  Arm A (docetaxel) Arm B (pemetrexed)  
  n=75, cycles = 274 n = 75, cycles = 271 
 Chemotherapy costs 6,855 10,358 -3,503 
 (drugs, administration, transportation)
  [6,038-7,673] [9,292-11,426] 
 Follow up costs 743 743 0
  [636-849] [636-849] 
 Adverse event costs 1,570 1,460 +110
  [720-2,742] [744-2,335] 
 Global costs 9,136 12,560 -3,424
  [7,843-10,671] [11,127-14,085] 
In terms of chemotherapy costs, arm B was more costly: € 
777,082.76 versus € 513,700.42 (+ 51 %). In terms of global costs, 
the difference was decreased at +37 %. 
Conclusion: Chemotherapy with pemetrexed was more expansive 
for 2d line NSCLC treatment. The difference decreased according 
to adverse events and administration costs. Cost-effectiveness and 
sensitivity analyses will be presented at the meeting.
* supported by an educational grant from Sanofi-Aventis and Amgen 
companies
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Lung cancer survivor satisfaction with use of internet-
based survivorship care plans 
Hill-Kayser, Christine E.; Vachani, Carolyn; Hampshire, Margaret K.; 
Metz, James M.
University of Pennsylvania, Philadelphia, PA, USA
Background: Although lung cancer remains a prominent cause 
of death in the US and worldwide, survival rates have consistently 
improved over the past 3 decades. Approximately 340,000 persons 
are estimated to reside in the US after lung cancer diagnosis, all of 
whom are classified as survivors. In 2007, we launched the world’s 
first Internet-based tool for creation of survivorship care plans (SCP). 
Here, we report an update of patterns of use of this tool by lung can-
cer survivors, as well as user satisfaction with this tool.
Methods: OncoLife, a program for creation of was made publicly ac-
cessible in 5/2007 through OncoLink (www.oncolink.org), a website 
serving over 3.9 million pages/ month to 385,000 unique IP addresses 
and based at the University of Pennsylvania. Users responding to 
queries regarding demographics, diagnosis, and treatment receive 
comprehensive, individualized guidelines for future care; queries and 
guidelines have evolved over 4 iterations. In 7/2008, an optional user 
satisfaction survey was added. Data has been maintained anonym-
ously and securely, and collection and analysis processes reviewed by 
the institutional IRB. 
Results: From 5/07-3/09, 4796 individuals completed OncoLife sur-
veys, and 205 of these were lung cancer survivors (4%). Lung cancer 
survivors had a median age of 59 years at diagnosis, compared to 49 
years in the general user population (p < 0.0001). The average time 
since diagnosis was 1.7 years for lung cancer survivors vs 3.5 years 
for other cancers. Lung cancer survivors reported having been treated 
with surgery (46%), chemotherapy (80%), and radiotherapy (55%). 
Half of lung cancer survivors reported receiving follow-up care only 
from an oncologist, and only 5% reported having received survivor-
ship information previously. Of 516 users completing satisfaction 
surveys, 97% reported their experience using this tool to be “good,” 
“very good,” or excellent.” Most users (91%) reported having the ne-
cessary information to complete the OncoLife queries, 97% reported 
that the guidelines provided were helpful, and 81% reported planning 
to share SCPs with their healthcare providers. Creation of SCP using 
OncoLife required on average 6.2 minutes. Responses to these quer-
ies did not differ significantly for lung cancer survivors from the 
general user population.
Conclusions: OncoLife represents the first web-based program for 
creation of SCP, and utilization patterns demonstrate that survivors 
are willing to use this type of tool. Most lung cancer survivors have 
received multimodality care, placing them at risk for treatment-
related late effects. Half report receiving follow-up care only from 
an oncologist, and very few have received survivorship information 
previously, demonstrating a need for individualized guidelines for 
survivor care. Based on survey responses, users appear very satisfied 
with their experiences using this tool, with information access and 
time requirements being feasible, and information provided evaluated 
as helpful.
D9.6 Lung Cancer Epidemiology and Health Services, Tue Aug 4, 12:30 - 14:00
Identifying the issues of greatest importance for patients 
with lung cancer: a web-based survey of 660 patients to 
enhance content validity of quality of life measures
Gralla, Richard J.1; Hollen, Patricia J.2; Davis, Beverly J.3; Petersen, 
Judith A.3; Montgomery, Robert3
1 North Shore - LIJ Health System, Lake Success, NY, USA; 2 
University of Virginia, Charlottesville, VA, USA; 3 Nexcura, Seattle, 
WA, USA
Background: Identifying issues of importance for patients with 
cancer is central to assessing quality of life and patient reported 
outcomes (PROs). Such data are necessary to evaluate the effective-
ness of treatment programs and to ascertain that appropriate goals 
are being met. The first aim of this study was to enhance the content 
validity for quality of life and PRO instruments. Recently, guidance 
from such agencies as the FDA has recommended enhancing content 
validity in quality of life instruments by enlarging the patient input. 
Specifically, this evaluation helps in enhancing the background of the 
validated lung cancer instrument, the LCSS, by enlarging the patient 
panel (originally 121) with these additional 660 patients. These data 
can serve many other patient-oriented purposes as well. 
Methods: We utilized the established patient base NexCura (a web-
based patient information resource) to survey registered patients with 
lung cancer who elected to participate. Patient characteristics includ-
ed: stage of disease (metastatic 25%, locally advanced 35%, NED 
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34%); current treatment; gender (55% women); KPS (>80 = 44%, 
60-70 = 44%; <60 = 12%); median age 62; NSCLC = 77%, SCLC = 
18%. 660 patients completed the anonymous web-conducted survey. 
Patients ranked 20 issues on a 5-point scale assessing the importance 
of each item. Issues included general, lung-specific, psychosocial, 
spiritual and summative items. 
Results: The 10 highest (and 2 lowest) ranked items are seen in the 
table below; results are described by the percent of patients choosing 
the top category (very important) and the top 2 rating categories of 
importance (very important + important).
 ISSUES: VERY IMPORTANT VERY IMPORTANT+IMPORTANT
 Good Quality of Life 80% 98%
 Maintain Independence 71% 97%
 Being a burden to others 65% 89%
 Perform normal activities 64% 96%
 Able to sleep 63% 94%
 Having pain 59% 86%
 Being fatigued 58% 93%
 Having shortness of breath 58% 89%
 Having blood in the sputum 58% 78%
 Being Depressed 47% 82%
 Difficulty with urination 27% 65%
 Difficulty with sexuality 20% 48%
Conclusions: Results by disease subsets were generally similar to 
ratings reported for the whole group, with certain exceptions. Not 
surprisingly, pain was more highly ranked in those with metastatic 
disease compared with patients who were NED, while hemoptysis 
was seen as a greater concern for those who were NED. Only minor 
differences were seen by gender, with both men and women ranking 
overall quality of life and maintaining independence as their top two 
issues. These findings represent the largest survey of patient concerns 
in lung cancer to date and support using computer-assisted survey 
technology to assess such information in all malignancies to obtain 
patient input rapidly from large patient samples. In addition to adding 
content validity to quality of life and PRO instruments, these find-
ings can aid in assuring that a patient-focused approach concentrates 
on issues that are expressed as important by patients. These results 
provide additional strong support for content validity for the LCSS 
and suggest the need to expand the items. These ranked issues can 
be helpful in a variety of assessments and programs for patients with 
lung cancer.
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Cost implications in developing a video assisted 
thorascopic (VATS) lobectomy program: length of stay is 
the key
Hunt, Ian; Gazala, Sayf; Razzak, Rene; Chuck, Anderson; Valji, 
Azim; Stewart, Kenneth; Tsuyuki, Ross; Bédard, Eric L.
University of Alberta, Edmonton, AB, Canada
Background: Lobectomy continues to be the mainstay of treatment 
for early stage Non-Small Cell Lung Cancer (NSCLC). Increasingly, 
this is performed by Video Assisted Thorascopic Surgery (VATS). 
It offers equivalence in terms of survival and recurrence rates, and 
likely advantages in terms of recovery time over a thoracotomy. 
Recovery time and Length of Stay (LOS) as a clinical outcome is 
often but inconsistently described as being shorter in VATS lobec-
tomy patients. The cost implication of adopting a minimally invasive 
approach over an open procedure are poorly reported, though the 
perception is that a VATS lobectomy is a more expensive procedure 
but offers cost savings in terms of recovery. In a recently established 
VATS lobectomy program in a single center the cost implications 
of the pre-operative investigations, intra-operative management and 
post-operative outcomes were extensively analyzed against a cohort 
of patients undergoing a thoracotomy lobectomy. The average LOS 
for a VATS procedure to achieve at least cost neutrality against an 
open procedure was calculated. In a thoracic surgery center currently 
or in the future planning a VATS lobectomy program this has import-
ant implications in regard health source allocation, service provision, 
clinical audit and ultimately fiscal support for such a program. 
Methods: In a single center over 3 years (2006-2008) clinical demo-
graphics and costs incurred of 283VATS lobectomies performed by 
3 surgeons was analyzed retrospectively. Cost of 24hr surgical bed 
occupancy was obtained, and patients requiring ICU post surgery 
excluded. In total 252 VATS procedures were included as were 45 of 
50 thoracotomy lobectomy patients performed in 2006 prior to full 
implementation of the VATS lobectomy program. Capital costs of 
VATS equipment were not included in the analysis as no additional 
instruments or equipment were required to perform VATS lobectomy 
over and above other VATS operations.
Results: The clinical demographics of 252 VATS lobectomies and 45 
open lobectomies performed over a similar time period were matched 
with little difference between patient groups in terms of age, health 
status and TNM classification or significant post-operative complica-
tions. 
VATS lobectomy on average was twice as expensive as an open 
lobectomy ($2810CD vs. $1425CD) based on intra-operative costs 
alone, and with greater cost variability for a VATS procedure. The 
average mean overall LOS for VATS lobectomy was 4.9 days over 
the 3-year period (2006 5.0days, 2007 4.9days, 2008 4.8days) and 6.2 
days for an open case in 2006. Overall LOS was 1.3 days shorter than 
open cases. Based on a comparative analysis of overall costs a VATS 
lobectomy is at least equal or slightly less than an open lobectomy 
($8573CD vs. $8673CD).
Conclusions: Despite the number of minimally invasive VATS 
lobectomies continuing to increase worldwide its cost impact remains 
poorly studied. Based on this analysis, provided a true advantage in 
recovery time and shorter LOS is demonstrated VATS lobectomy is 
at least equal to an open resection in terms of cost. This will have 
important health resource implications for thoracic surgery centers 
supporting or preparing to adopt a VATS lobectomy program.
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Stromal HGF and VEGFR-1 are associated with acquired 
resistance to VEGFR tyrosine kinase inhibitors in non-
small cell lung cancer (NSCLC)
Cascone, Tina; Herynk, Matthew; Du, Danny; Kadara, Humam; 
Hanrahan, Emer; Nilsson, Monique; Lin, Heather Y.; Lee, J. Jack; 
Park, Yun-Yong; Lee, Ju-Seog; Heymach, John V.
MD Anderson Cancer Center, Houston, TX, USA
Background: Tyrosine kinase inhbitors (TKIs) targeting vascular 
endothelial growth factor/receptor (VEGF/VEGFR) pathway, such as 
cediranib (AZD2171) and the dual VEGFR-2/EGFR inhibitor van-
detanib (ZD6474) have demonstrated clinical benefit in NSCLC and 
other solid tumors. Unfortunately, while a subset of patients initially 
responds to these agents, therapeutic resistance inevitably emerges. 
The mechanisms underlying resistance are not well understood, but 
may include incomplete inhibition of VEGFR or EGFR activation, 
bypass of these pathways through redundant expression of proangio-
genic molecules, a switch in stromal cell dependency from VEGFR 
activation to alternative signaling pathways or other mechanisms. 
Therefore, there is a critical need for tumoral and stromal molecular 
markers able to predict resistance to TKIs such as vandetanib and 
cediranib in NSCLC.
Methods: To generate NSCLC xenograft models with acquired 
resistance to cediranib and vandetanib, A549 and H1975 human 
NSCLC cells were injected in athymic nude mice. Tumors were con-
sidered resistant to treatments when their volumes tripled compared 
to the starting volume and were then sacrificed. A murine specific ex-
pression array (mouseWG-6 v2 Expression BeadChip, ILLUMINA) 
was used to evaluate changes in the stromal microenvironment to 
develop gene signatures indicative of therapeutic resistance in van-
detanib and cediranib-resistant H1975 tumors compared to sensitive 
tumors (2 weeks of treatment) and vehicle treated controls. Differen-
tially expressed genes between the different treatment groups were 
selected based on a p<0.005 of the univariate t-test and at least a 1.5 
fold-change in expression.
Results: H1975 NSCLC xenografts initially responded to treatment 
with vandetanib and 33% of treated tumors developed resistance 
after a median time to progression of 210 days in the vandetanib-
treated group compared to 7 days in the control group (p<0.001). In 
cediranib-treated tumors, 60% of xenografts exhibited resistance after 
a median time to progression of 250 days following treatment. In 
A549 xenograft model, treatment with vandetanib induced resistance 
in only one tumor after 102 days. Cediranib-induced resistance was 
observed in two xenograft animals after 201 days of treatment. An 
up-regulation of stromal Hepatocyte growth factor (Hgf) (p=0.001) 
and Vegfr-1 (p<0.001) mRNA was observed in cediranib-resistant 
tumors, as compared to sensitive tumors. In addition, an increase 
in stromal Hgf mRNA was observed in vandetanib-resistant H1975 
tumors (p<0.001) relative to sensitive tumors. These interesting data 
are in accordance with our previous analysis of clinical specimens 
from patients with stage IIIB/IV NSCLC who participated in a 
randomized Phase 2 trial that showed HGF as a predictive marker for 
resistance to vandetanib treatment alone when compared to chemo-
therapy alone or the combination of both (p=0.004).
Conclusions: Our preliminary results identify HGF and VEGFR-1 
as potential markers associated with acquired resistance to VEGFR 
TKIs in NSCLC, pointing to the HGF/MET axis and/or VEGFR-1 
pathway as crucial therapeutic targets to overcome resistance to anti-
angiogenic therapy in NSCLC.
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A phase II study of erlotinib and sorafenib in 
chemotherapy-naïve patients with locally advanced/
metastatic non-small cell lung cancer (NSCLC)
Lind, Joline S.1; Dingemans, Anne-Marie C.2; Groen, Harry J.3; Smit, 
Egbert F.1
1 VU Univeristy Medical Center, Amsterdam, Netherlands; 2 
Maastricht University Medical Center, Maastricht, Netherlands; 3 
University Medical Center Groningen, Groningen, Netherlands
Background: This multicentre, phase 2 study evaluates efficacy and 
safety of erlotinib, an EGFR inhibitor, and sorafenib, a multi-kinase 
inhibitor, in advanced NSCLC. In addition tumor metabolic activity 
(18FDG-PET), and tumor blood flow (H215O-PET) were measured.
Methods: Chemotherapy-naïve patients (≥ 18 years; performance 
status 0-1) with pathologically proven irresectable stage IIIB or IV 
NSCLC were eligible. Pts received oral erlotinib (150 mg/od) and 
sorafenib (400 mg/bd) until disease progression or unacceptable 
toxicity. The planned sample size was 48. The primary endpoint was 
the rate of non-progression (NPR) at 6 weeks. Secondary endpoints: 
objective response rate (ORR; assessed by RECIST), time to progres-
sion (TTP), overall survival (OS) and adverse events (AEs). 18FDG-
PET and H215O-PET were performed on days 0 and 21. 
Results: 50 pts were enrolled in 3 centres: 22 females; median age 
60 yrs (range 41-78); 30 PS 0; 37 stage IV; 34 adenocarcinoma; 11 
never smokers; 10/28 EGFR mutations (exons 19 (n=5), 20 (n=1), 
21 (n=4)); 3/28 K-Ras mutations. Median FU is 4.4 mo (range 
0.6-13.8) with 14 pts on therapy. The NPR at 6 weeks was 76%: 12 
PR, 26 SD, 8 PD, 4 NE. 5/10 EGFR mutation positive pts had PR 
versus 4/18 EGFR mutation negative pts. Median TTP is 5.6 mo 
(95% CI 3.6-7.9). With 20 deaths the median OS is 12.0 mo (95% CI 
3.6-20.4). 14 pts received 2nd line chemotherapy. TTP and OS were 
longer in adenocarcinoma versus non-adenocarcinoma histology (6.0 
mo vs 2.7, p=0.01 and 12 mo vs 4.5, p<0.05 respectively).Treatment 
related grade ≥ 3 AE: anorexia (n=1), acneiform rash (n=3), diarrhoea 
(n=6), fatigue (n=5), hand-foot skin reaction (n=7), nausea (n=1), 
oral mucositis (n=2), rash (n=4), vomiting (n=1), fatal hemoptysis 
(n=1), hypophosphatemia (n=20), hypokalemia (n=4) and hypon-
atremia (n=4). AE related treatment interruption occurred in 6 pts 
and dose reduction in 14 pts. Metabolic response at day 21: 21 PR, 
11 SD, 2 PD. 18FDG SUV decreased by median 33% (p=0,000). A 
decrease larger than the median 18FDG SUV value was associated 
with a longer TTP (p<0.05). Tumor blood flow (n=14) measured 
with H215O-PET decreased by median 11% (n.s). Correlations with 
survival will be presented.
Conclusions: The combination of sorafenib and erlotinib is safe and 
has clinically significant anti-tumor activity in chemotherapy-naïve 
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patients with stage IIIB/IV NSCLC. Further testing of this combina-
tion is warranted.
D10.3 Anti-Angiogenesis and Anti-Coagulants, Tue Aug 4, 12:30 - 14:00
Phase Ib study of pemetrexed administered in combination 
with pazopanib (GW786034)
Infante, Jeffrey1; Bendell, Joanna1; Dy, Grace K.2; Ma, Wen W.2; 
Novello, Silvia4; Huff, Anne C.3; Graham, Alison3; Burris, Howard1; 
Ottesen, Lone H.3; Adjei, Alex A.2
1 Sarah Cannon Research Institute, Nashville, TN, USA; 2 Roswell 
Park Cancer Center, Buffalo, NY, USA; 3 GlaxoSmithKline, London, 
UK; 4 University of Torino School of Medicine, Torino, Italy
Background: Pazopanib is an oral angiogenesis inhibitor targeting 
VEGFR, PDGFR, and c-kit with clinical activity in several tumor 
types including non-small cell lung (NSCLC) cancer, renal cell 
cancer, sarcoma, and ovarian carcinoma. Prior studies have demon-
strated improved clinical outcomes in response to the combination of 
bevacizumab with chemotherapy. Pemetrexed is approved for treat-
ment of metastatic NSCLC and mesothelioma. These findings support 
combining pazopanib with the chemotherapeutic agent pemetrexed.
Methods: Patients (ECOG PS 0-1) with advanced cancer were 
eligible. Escalating doses of pemetrexed (400-500 mg/m2 IV on 
cycle day 1 every 3 weeks) plus pazopanib (400-800 mg daily) were 
evaluated for safety, pharmacokinetics, and preliminary evidence of 
clinical activity in cohorts of 3-6 patients. The maximum tolerated 
dose (MTD) was the dose at which no more than 1 out of 6 patients 
experienced a DLT. Six additional patients were to be enrolled to con-
firm the MTD and complete the pharmacokinetic analyses. Adverse 
events (AEs) were evaluated according to NCI CTCAE v3.0. 
Results: A total of 17 patients (median age 62 yrs) have received 
pemetrexed/pazopanib at doses of 400 mg/m2/400 mg (n=3), 500 
mg/m2/400 mg (n=5), and 500 mg/m2/800 mg (n=9). Tumor types 
were NSCLC (n=10), SCLC (n=2), unknown primary (n=2), and 
breast, bladder and esophagus (each n=1). The primary hematological 
toxicity reported was neutropenia (n=7): 1 patient with Gr 3 and 5 
patients with Gr 4. One patient experienced Gr 3 febrile neutropenia. 
Neutropenia did not result in any pemetrexed dose delays. The most 
frequent non-hematological AEs were nausea and vomiting (n=14), 
fatigue (n=11), diarrhea (n=9), constipation (n=7), and anorexia 
(n=7). Of these, the maximum toxicity was Gr 3 fatigue in 3 patients 
and Gr 3 diarrhea in 2 patients. Hypertension (Gr 1/2) was reported 
in 3 patients. A fatal event of pulmonary hemorrhage associated with 
tumor shrinkage was reported in 1 patient with metastatic poorly 
differentiated carcinoma of the lung. The MTD was determined to be 
500 mg/m2 pemetrexed IV on cycle day 1 every 3 weeks and 800 mg 
pazopanib daily. Three patients (2 NSCLC, 1 breast cancer) achieved 
a partial response, and an additional 3 patients had stable disease for 
at least 12 weeks. 
Conclusion: Concomitant administration of pazopanib 800 mg and 
pemetrexed 500 mg/m2 is feasible with a manageable toxicity profile 
and evidence of clinical activity. 
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Interim safety data on the FRAGMATIC trial: a 
randomised phase III clinical trial investigating the effect 
of FRAGMin® added to standard therapy in patients with 
lung cancer
Macbeth, Fergus R.1; Griffiths, Gareth O.2; Noble, Simon I.3; Burns, 
Sarah2; Maughan, Timothy S.2
1 National Institute for Health and Clinical Excellence, London, UK; 
2 Wales Cancer Trials Unit, Cardiff, UK; 3 Cardiff University, Cardiff, 
UK
Background: Venous thromboembolism (VTE) is common in lung 
cancer patients and the incidence is increased by treatments. Lung 
cancer patients often have advanced disease at presentation, as well 
as co-morbidities, such as heart failure and chronic lung disease all 
of which increase the risk of VTE. Low molecular weight heparin 
(LMWH) has been used in the prophylaxis of VTE but there are 
limited data on the use of LMWH as primary thromboprophylaxis 
in cancer patients. Because of this and interesting animal data sug-
gesting that LMWH may be anti-metastatic, the effect of long term 
LMWH on overall survival should be investigated. 
Methods: The Cancer Research UK funded and Pfizer Inc. supported 
FRAGMATIC trial, coordinated by the Wales Cancer Trials Unit, is 
an open label multi-centre Phase III randomised controlled trial in 
patients with lung cancer comparing a research arm of anticancer 
treatment according to local practice plus dalteparin (Fragmin®), 
against the control arm of anticancer treatment according to lo-
cal practice alone. Eligible patients must have histopathological or 
cytological diagnosis of primary bronchial carcinoma (small cell or 
non-small cell) within the last 6 weeks, performance status 0, 1, 2 or 
3 and willing and able to receive daily subcutaneous injection. The 
dalteparin is a daily 5000 IU subcutaneous injection administered by 
themselves or carer for 24 weeks. The primary outcome measure is 
overall survival and the secondary outcome measures include; tox-
icity, venous thrombotic event free survival, metastasis-free survival, 
quality of life, cost effectiveness and cost utility. Serious adverse 
events (SAE) are collected in real time and are assessed by both the 
treating clinician and the Chief Investigator for expectedness and 
causality to the dalteparin – i.e. whether a Serious Adverse Reaction 
(SAR) or Suspected Unexpected Serious Adverse Reaction (SUSAR). 
To detect an advantage of 5% in overall survival at 1 year (to 30%) a 
total of 2200 patients are required (1100 in each arm). 
Results: The trial opened to recruitment in August 2007. As of the 
1st March 2009 a total of 467 patients have been recruited from 93 
centres in the UK. We expect to have approximately 120 centres open 
to recruitment by summer 2009. 193 patients have now completed 6 
months of dalteparin or observation. So far 9 SARs and 2 SUSARs 
have been reported and the Independent Data Monitoring Committee 
(IDMC) is happy that there is no significant increased risk to those on 
dalteparin and the trial is continuing. 
Conclusions: Although this may be one of the biggest lung cancer 
trials ever conducted we are confident that the 2200 patients required 
will be recruited within the UK within the funding period. The IDMC 
has reviewed all the safety data including the SAE data and has rec-
ommended that there are currently no safety concerns with the use of 
dalteparin and recruitment into the trial should continue. 
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Safety and pharmacokinetics of the vascular disrupting 
agent (VDA) NPI-2358 combined with docetaxel for the 
treatment of non-small cell lung cancer (NSCLC)
Millward, Michael 2; Mainwaring, Paul3; Spear, Matthew A.1; Mita, 
Monica4; Federico, Kristine C.1; Lloyd, G K.1; Cropp, Gillian1; Mita, 
Alain4
1 Nereus Pharmaceuticals, Inc, San Diego, CA, USA; 2 Sir Charles 
Gairdner Hospital and University of Western Australia, Perth, 
Australia; 3 Mater Hospital, Brisbane, Australia; 4 Institute for Drug 
Development, San Antonio, TX, USA
Background: NPI-2358 is a vascular disrupting agent (VDA) with a 
novel structure. It destabilizes tumor vascular endothelial cell archi-
tecture leading to selective collapse of established tumor vasculature. 
Particular interest has focused on VDAs recently given indications 
of significant activity in NSCLC, as well as potential differentiation 
from other agents in terms of utility in certain patient subsets such 
as those with squamous cell carcinoma (SCC) or at risk for bleed-
ing events. NPI-2358 was seen to produce tumor regression alone 
and synergistically with chemotherapy agents including docetaxel in 
murine models, often with an apparent decrease in the toxicity from 
the cytotoxic agent.
Methods: Patients with advanced NSCLC or other appropriate ma-
lignancies were enrolled in this initial study to assess the pharmaco-
kinetics (PK) and safety of NPI-2358 combined with docetaxel. Do-
cetaxel (75 mg/m2) was given on Day 1 and NPI-2358 on Days 1 & 8 
in 21-day cycles. The dose of NPI-2358 was escalated from the single 
agent biologic effect dose (BED) of 13.5 mg/m2 (at which point ef-
fects such as increases in blood pressure, tumor pain and decreases 
in tumor blood flow are observed) to the single agent Recommended 
Phase 2 Dose (RP2D) of 30 mg/m2. Pharmacokinetics (PK) of both 
NPI-2358 and docetaxel were assessed using liquid chromatography 
mass spectometry. Plasma samples were collected for PK on Cycle 1 
Day 1 and Day 8 (with and without docetaxel), pre, post, 0.25, 0.5, 1, 
2, 3, 4, 6 and 24 h after infusion. 
Results: Ten of 13 patients enrolled had NSCLC (7 adenocarcinoma; 
2 large cell; 1 SCC). Adverse events commonly associated with 
NPI-2358 included nausea, vomiting, fatigue, fever, tumor pain and 
transient elevations in blood pressure. One DLT of nausea, vomiting, 
dehydration and neutropenia occurred. Increased toxicity with the 
combination was not seen. PK results for the 30 mg/m2 Cohort were 
for Day 1/Day 8: AUCtot 3296 ±1827 / 3482± 2333 ng/mL*h; Cmax 
822 ±201 / 781 ±270 ng/mL; CL 22.7±27.7 / 21.1±22.8 L/h; t1/2 
7.4±4.0 / 8.2±5.4 h and Vz 134±33 / 131±37L. NPI-2358 displayed 
stationery, linear, non-dose dependent kinetics. Docetaxel does not 
influence the kinetics of NPI-2358. The PK of docetaxel were T½ 
12±2.6h; CL 152±82L/h; Vz 2579±1453L, thus within published 
limits. Of the patients with NSCLC, 8 had measureable disease of 
which as a best response 2 demonstrated a partial response (PR), 
with 4 others having decreases in tumor measurements less than a 
PR. These responses occurred from the BED up to RP2D. Based on 
these outcomes 30 mg/m2 of NPI-2358 with 75 mg/m2 docetaxel was 
selected as the RP2D.
Conclusions: PK and safety data did not indicate an adverse drug-
drug interaction and activity appears favorable relative to the 5-10% 
response rate reported with docetaxel alone in this population, 
leading to continued development of the combination. Efficacy is 
now being assessed in Phase 2 (the ADVANCE study), a random-
ized comparison of docetaxel (75 mg/m2) ± of NPI-2358 (30 mg/m2) 
in NSCLC after 1-2 prior treatments. Patients with all histologies of 
NSCLC, including SCC are being enrolled.
D10.6 Anti-Angiogenesis and Anti-Coagulants, Tue Aug 4, 12:30 - 14:00
Sorafenib in pretreated patients with advanced non-small 
lung cancer harbouring a K-ras mutation
Dingemans, Anne-Marie C.1; van Wijk, Atie2; Hochstenbag, 
Monique1; Thunnissen, Erik2; Meulemans, Els1; Smit, Egbert F.2
1 Maastricht University Medical Center, Maastricht, Netherlands; 2 
VUMC, Amsterdam, Netherlands
Background: K-Ras is the most frequently mutated oncogene in non-
small cell lung cancer (NSCLC), occuring in 30% of patients. K-ras 
mutations are correlated with smoking and non-responsiveness to 
EGFR inhibitors and chemotherapy. Sorafenib is an orally available 
multitargeted tyrosine kinase potent inhibitor of c-Raf, b-Raf, VEG-
FR-1/2/3 and PDGFR-β. Sorafenib has activity in hepatocellular and 
renal cell carcinoma. Phase III studies in NSCLC are ongoing. Due to 
the fact that K-ras mutations upregulate the Raf/MEK/ERK pathway 
treatment with sorafenib seems a rational approach in patients with a 
K-ras mutation. In this proof of concept study the effect of sorafenib 
in patients with K-ras mutated NSCLC was evaluated. 
Methods: K-ras mutation analyses was performed on DNA extracted 
from paraffin-embedded tumor tissues. Patients with advanced 
NSCLC, progressive after at least one line of chemotherapy and 
harbouring a K-ras mutation were offered treatment with sorafenib. 
Sorafenib 200 mg or 400 mg bid was given untill progression or 
unacceptabel toxicity. Response was evaluated every 4-6 weeks by 
CT-scan.
sex age PS stage histol-
ogy
pretreatment K-ras sorafenib cavi-
tation
re-
sponse
M 70 1 IV BAC Lobectomy; Erlotin-
ib: SD; Velcade: 
MR; Erlotinib: PR; 
Gem-carbo: PD
G12V 06/06/08-
20/09/08
+ MR
F 48 2 IV SQ Gem-cis:PD G12V 28/08/08-
08/10/08
- PD
M 70 1 IV BAC pem-cis:PD; 
Erlotinib PD
G12V 15/10/08 
-ongoing
+ PR
F 44 1 IV adeno Gem-cis: PD G12C 02/11/08-
02/12/08
- PD
F 77 1 IV adeno Pneumonectomie; 
RT + gem-cis: PD; 
Pem-Cis:SD
G12C 02/12/08 
-ongoing
- PR
M 45 1 IV LC Gem-cis: PR; 
Cis-pem: PR; 
Erlotinib: PD
G13S 02/01/09 
-ongoing
- PR
F 62 0 IV LC Carbo-doc ± 
celecoxib: PR; 
Erlotinib: PD; 
Pemetrexed: PD; 
Gem-carbo: NE
G12V 13/01/09 
-ongoing
- MR
F 54 1 IV adeno Doc-carbo ± cele-
coxib: SD; WBRT; 
pemetrexed: SD
G12A 29/01/09-
03/03/09
+ MR
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Results: Eight patients with a k-ras mutation, 4 G12V, 2 G12C, 1 
G12A, 1 G13S, were treated. Mean age 56 years (range 44 –70), 1 
PS 0, 6 PS 1, 1 PS 2. All patients were current or ex-smokers. All 
patients were pretreated with at least one chemotherapy regimen. 
Toxicity consisted mainly of hand-foot syndrome. Three PR and 3 
MR responses were observed. In 3/8 patients tumor cavitation was 
observed after 4-6 weeks of treatment. A summary is depicted in 
Table 1.
Conclusions: Encouraging results were observed in patients with 
treatment resistant K-Ras mutated NSCLC. In part of the patients 
central cavitation of the tumor was observed. These results warrant 
further phase II investigation. 
D10.7 Anti-Angiogenesis and Anti-Coagulants, Tue Aug 4, 12:30 - 14:00
Axitinib (AG-013736) combined with paclitaxel/
carboplatin (Pac/Car), gemcitabine/cisplatin (Gem/Cis), or 
pemetrexed (Pem)/Cis in patients with advanced non-small 
cell lung cancer (NSCLC) and other solid tumors
Kozloff, Mark F.1, 2; Martin, Lainie P.3; Krzakowski, Maciej4; Samuel, 
Thomas A.5; Rado, Thomas A.6; Arriola, Edurne7; de Castro Carpeño, 
Javier8; Tarazi, Jamal9; Rosbrook, Brad9; Tortorici, Michael9; 
Olszanski, Anthony J.10; Cohen, Roger B.3
1 Ingalls Hospital, Harvey, IL, USA; 2 University of Chicago, 
Chicago, IL, USA; 3 Fox Chase Cancer Center, Department of 
Medical Oncology, Philadelphia, PA, USA; 4 Institute of Oncology, 
Warsaw, Poland; 5 MCG Cancer Center, Medical College of Georgia, 
Augusta, GA, USA; 6 Columbia Basin Hematology & Oncology, 
Kennewick, WA, USA; 7 Hospital del Mar, Barcelona, Spain; 8 
University Hospital La Paz, Madrid, Spain; 9 Pfizer Oncology, San 
Diego, CA, USA; 10 Pfizer Oncology, New London, CT, USA
Background: Axitinib is an oral, potent, selective inhibitor of VEGF 
receptors 1, 2, 3. Anti-VEGF therapies combined with chemotherapy 
improve survival over chemotherapy alone in advanced solid tumors, 
including NSCLC. The safety and tolerability of axitinib in combina-
tion with common NSCLC chemotherapy agents was evaluated in 
patients with squamous cell NSCLC and other solid tumors.
Methods: Patients without prior platinum or taxane treatment 
received Pac (200 mg/m2)/Car (AUC 6 mg*min/mL) every 3 weeks 
(q3w) + axitinib at lead-in doses of 1, 3, or 5 mg BID. After 3–5 
days, the axitinib dose was increased to 5 mg BID. Two additional 
patient cohorts, with any prior chemotherapy, received axitinib 5 mg 
BID + either Gem (1,250 mg/m2 on days 1 and 8)/Cis (80 mg/m2 on 
day 1) or Pem (500 mg/m2 on day 1)/Cis (75 mg/m2 on day 1) q3w. 
Patients receiving Pem/Cis were given 1,000 μg/9 weeks vitamin 
B12 and 350−1,000 μg folic acid daily. Following determination of 
dose-limiting toxicities (DLTs) with axitinib + Pac/Car, patients with 
squamous cell NSCLC were enrolled into an expansion cohort (prior 
anti-VEGF therapy not permitted) and received axitinib 5 mg BID + 
Pac/Car. DLTs, adverse events (AEs), objective response rate (ORR), 
and pharmacokinetics (PK) were evaluated. 
Results: A total of 55 patients were enrolled; 26 were evaluable in 
the Pac/Car group (n=12 with squamous cell NSCLC) and 21 in the 
Gem/Cis group. Five patients in the Pem/Cis cohort had evaluable 
safety data. The combination of axitinib 5 mg BID with Pac/Car, 
Gem/Cis or Pem/Cis was associated with acceptable tolerability. 
DLTs in the initial six patients of each cohort comprised fatigue (n=2) 
and proteinuria (n=1). Treatment-related AEs included hyperten-
sion (42%), diarrhea (35%), and fatigue (35%) in the Pac/Car group; 
headache (29%), hypertension (29%), and fatigue (24%) in the Gem/
Cis group; and anorexia (80%) and dyspnea, transaminase elevation, 
and abdominal pain (40% each) in the Pem/Cis group. No grade ≥3 
hemoptysis occurred among 12 patients with squamous cell NSCLC. 
The ORR was 29% and 26% for axitinib + Pac/Car (n=24) and Gem/
Cis (n=19), respectively. Data are pending for axitinib + Pem/Cis. 
Plasma PK and profiles for axitinib and chemotherapy were similar 
when given alone and in combination. Mean [%CV] exposure (area 
under the plasma–concentration time curve to infinity [AUCinf]; 
µg•h/mL) was similar in the absence and presence of axitinib for Pac 
(20.8 [21] vs. 20.6 [21]; n=11)/Car (45.7 [26] vs. 40.5 [30]; n=12), 
Gem (12.4 [32] vs. 12.7 [32]; n=17)/Cis (3.6 [24] vs. 3.5 [27]; n=13), 
and Pem (159 [16] vs. 138 [27], n=4)/Cis (2.9 [26] vs. 2.7 [32]; n=4), 
respectively.
Conclusion: Axitinib 5 mg BID can be combined with standard Pac/
Car, Gem/Cis, or Pem/Cis regimens with no apparent overlapping 
toxicities. In patients with squamous cell NSCLC, axitinib + Pac/Car 
was well tolerated with no evidence of grade ≥3 hemoptysis. Axitinib 
+ Pac/Car or Gem/Cis has antitumor activity. PK for each combina-
tion was similar to axitinib and chemotherapy alone. Additional phase 
II studies of axitinib in patients with NSCLC are ongoing.
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Survival by tumor histology and stage in non-small cell 
lung cancer (NSCLC) patients from the United States 
(U.S.) SEER Cancer Registry
Wang, Lisa1; Chu, Laura1; Scappaticci, Frank2
1 Epidemiology, Genentech, Inc., South San Francisco, CA, USA; 2 
Clinical Science, Genentech, Inc., South San Francisco, CA, USA
Background: Results from recent trials investigating the efficacy of 
new investigational drugs in NSCLC patients have shown differences 
in clinical outcomes based on tumor histology; however the reason 
for these differences in response is unclear. 
Methods: Patients diagnosed with NSCLC between 2000 to 2005 
were identified in Surveillance, Epidemiology and End Results 
(SEER). Five histology subgroups were identified based on the 
1999 WHO classification of malignant lung tumors and ICD-03 
codes: adenocarcinoma (AC), squamous cell carcinoma (SCC), 
bronchoalveolar carcinoma (BAC), large cell carcinoma (LCC) and 
Not Otherwise Specified (NOS) or ‘other’. Frequency distributions 
and median survival for demographic (age, gender, race) and tumor 
characteristics (stage, grade) were examined by histology. 
Results: From 2000 to 2005, over 225,400 NSCLC cases were 
diagnosed (34% AC, 22% SCC, 4.5% LCC and 4% BAC). Thirty-six 
percent of cases were classified as “NOS/Other” histology. 
Median age at diagnosis (~70 yrs) was similar across all histology 
subtypes and the majority (>80%) of patients were white. Patients 
diagnosed with BAC histology tended to be women (60%), while 
patients with SCC were more likely to be men (65%). Genders were 
equally distributed in LCC, AC and NOS/Other histology (51%-57% 
men). Prognosis for BAC histology was better in women than in men 
(OS: 56 months in women vs 32 months in men) as was the case for 
AC histology (OS: 13 months in women vs 9 months in men). 
For tumor grade, the majority of BAC cases had well- (32%) or 
moderately- (24%) differentiated cell types, while AC and SCC were 
moderately- (21% and 27% respectively) or poorly- (29% and 36% 
respectively) differentiated. LCC tended to be poorly- or un-differen-
tiated (27% and 32%, respectively). 
Patients with BAC histology presented predominantly with early 
stage cancer (59% stage I/II), while ~60% of patients with AC, 
LCC, and NOS/other histology presented with advanced/metastatic 
disease (Stage IIIb/IV). For early stage disease longer survival was 
observed for AC and BAC, compared with other histologies, whereas 
for advanced disease median survival was consistently poor (4-5 
months) across all histology subtypes, except for patients with BAC 
(12 months) (Table 1). These differences in survival by histology and 
stage did not vary by sex. 
Conclusions: From the most recent SEER data, prognosis for ad-
vanced/metastatic disease is generally poor for all histology subtypes, 
except BAC. However, survival among patients with early stage 
disease (stage I/II) appears to be increased for patients with AC com-
pared with SCC, LCC or NOS/Other histology. 
Table 1. Distribution of NSCLC cases and Median Survival by Histology 
and Stage, in SEER data, 2000-2005 
Histology Type Stage I/II Stage IIIa Stage 
IIIb/V
Unstaged
Adenocarcinoma  
(N =77,263)
%a 26.7 8.6 58.9 5.8
Median OS,b 
(95% CI)
51.0 (49.0, 
52.0)
17.0 (17.0, 
18.0)
5.0 (5.0, 
6.0)
10.0 (9.0, 
10.0)
Squamous  
(N = 49,364)
%a 32.3 14.0 46.3 7.4
Median OS,b 
(95% CI)
30.0 (29.0, 
31.0)
12.0 (NE, 
NE)
6.0 (5.0, 
6.0)
9.0 (8.0, 9.0)
BAC (N = 8,670) %a 58.7 5.4 30.1 5.6
Median OS,b 
(95% CI)
NE (71.0, 
NE)
27.0 (23.0, 
32.0)
12.0 (11.0, 
13.0)
14.0 (11.0, 
17.0)
Large Cell  
(N = 10,139)
%a 22.7 11.1 59.9 6.4
Median OS,b 
(95% CI)
28.0 (26.0, 
31.0)
12.0 (11.0, 
13.0)
4.0 (4.0, 
5.0)
9.0 (7.0, 9.0)
NOS/Other ( 
N = 82,645)
%a 15.0 8.3 59.2 17.5
Median OS,b 
(95% CI)
24.0 (23.0, 
25.0)
10.0 (10.0, 
11.0)
4.0 (3.0, 
4.0)
6.0 (NE, NE)
aRow percentages are presented; bKaplan Meier Overall Survival (OS) in months; NE = Not Evaluable 
PD1.1.2 Tobacco and Cancer Control and Health Services, Sat, 14:30 - 16:00
Changes of plasma cytokine levels during radiotherapy 
may be correlated with overall survival in patients with 
inoperable or unresectable non-small cell lung cancer
Cai, Xu-Wei1, 3; Xu, Luying1; Hayman, James A.1; Wang, Li1; Cease, 
Kemp B.2; Yuan, Shuanghu1; Kalemkerian, Gregory P.1; Kong, Feng-
Ming1, 2
1 University of Michigan, Ann Arbor, MI, USA; 2 Veterans Affairs Ann 
Arbor Healthcare System, Ann Arbor, MI, USA; 3 Shanghai Cancer 
Hospital, Fudan Univeristy, Shanghai, China
Background: There have been extensive studies searching for 
biomarkers for early diagnosis and prognosis in patients with non-
small cell lung cancer (NSCLC). The results have been variable, with 
reports showing some correlations between prognosis and baseline 
levels of numerous plasma cytokines, such as EGF, VEGF, GM-
CSF, IL-1β, IL-1Rα, IL-2, IL-5, IL-7,MIP-1α, TGF-β1, G-CSF, and 
TNF-α. In this study, we hypothesized that changes in cytokines 
during the course of treatment reflect tumor sensitivity and are thus 
correlated with long-term overall survival (OS). 
Materials/Methods: Patients with unresectable or inoperable stage I 
to III NSCLC were eligible. All patients received definitive radia-
tion therapy (RT) with or without concurrent weekly carboplatin and 
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paclitaxel. Plasma was obtained prior to and at 2 and 4 weeks during 
RT. The human cytokine LINCOplex Kit (96 well plate assay) was 
used to measure the concentrations of 29 cytokines, including above 
mentioned ones except for TGF-β1, which was measured using a 
molecular specific ELISA assay. Changes were defined as either a 
greater than two-fold increase or 50% reduction from pre-RT levels.
Results: A total of 51 patients enrolled between March 2004 and 
November 2008, 44 of whom with follow-up of > 6 months were 
included in this interim analysis. Male:female ratio was 7.8:1. 
Median age was 68 (44-85) years. The median total RT dose was 
65.4 Gy (45.0-81.4 Gy). There were no significant correlations 
between OS and the absolute level of any cytokine at any timepoint 
except for Fractalkine at baseline (prior to RT): patients with lower 
level of Fractalkine prior to RT had better survival than patients with 
higher level of Fractalkine (P=0.035). Log-rank analysis showed 
that patients with an increase in Fractalkine or IL-7 at 2 weeks of RT 
had better OS than patients without such an increase (P=0.046 and 
0.011, respectively). The changes in other cytokines at 2 weeks of RT 
did not have any significant associations with OS. Patients with an 
increase in EGF, Fractalkine, IL-10, IL-1β, IL-2, IL-7 or TGF-α at 4 
weeks of RT had better OS than patients without such an increase (P 
=0.013, 0.023, 0.016, 0.032, 0.014, 0.016 and 0.017, respectively). 
Using Cox Regression analysis, multivariate models including age, 
gender, stage, chemotherapy, RT dose and each of the cytokines or 
the changes during RT showed: 1) RT dose is a significant prognostic 
factor in all of the models at 2 weeks during RT (all P <0.05), 2) ele-
vations of IL-7 or IL-2 at 2 and 4 weeks during RT were significantly 
associated with improved survival (P=0.004, 0.008 and P=0.032, 
0.049, respectively), 3) elevations of EGF, Fractalkine, IL-10 and 
TGF-α at 4 weeks during RT were significantly correlated with im-
proved survival (P=0.031, 0.015, 0.018 and 0.009, respectively).
Conclusions: This study showed independent significant correlations 
between changes in IL-2 or IL-7 at 2 weeks and several other cyto-
kines at 4 weeks during RT with overall survival in patients with un-
resectable or inoperable stage I-III NSCLC. The biologic mechanisms 
for such correlations are unclear, but some may be due to the effects 
of specific cytokines, such as IL-2 and IL-7, may be partially due to 
the effects on the immunologic functions by attracting lymphocytes 
to the tumor site. 
PD1.1.3 Tobacco and Cancer Control and Health Services, Sat, 14:30 - 16:00
Use of phospo-SRC expression as a predictive and 
prognostic biomarker in non-small cell lung cancer
Kim, Lori C.1; Rawal, Bhupendra2; Schell, Michael J.2; Haura, Eric 
B.1
1 H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 
USA; 2 H. Lee Moffitt Cancer Center, Tampa, FL, USA
Background: Elevated levels of phospho-SRC (pSRC) expression 
have been correlated with malignant potential. We hypothesized 
that high levels of pSRC expression would lead to more aggressive 
tumors that would correlate with poor survival. We sought to examine 
pSRC as a prognostic biomarker for early stage non-small cell lung 
cancer and a predictive biomarker for response to SRC/multi-target 
tyrosine kinase inhibitor dasatinib. There is a need to identify pre-
dictive biomarkers for the subset of patients who may benefit from 
dasatinib.
Methods: To investigate Src Family Kinase (SFK) activation in early 
stage NSCLC, we analyzed expression of pSRC and correlated it 
with the following clinical variables: pathological stage, gender, and 
histological features. We quantitatively examined phosphorylation of 
tyrosine 416 on SRC, a surrogate of SRC kinase activity. All samples 
were obtained from patients who had undergone lung resection at H. 
Lee Moffitt Cancer Center and Research Institute for removal of early 
stage (IA, IB) non-small cell lung cancer. Tissue microarrays were 
prepared from formalin-fixed, paraffin-embedded blocks of resected 
samples from 184 patients. Immunohistochemistry (IHC) based on 
immunofluorescence combined with automated quantitative analysis 
(AQUA) was used to assess in situ expression of the target molecules. 
pSRC expression level from one to three tumor microarray scores 
were square rooted to approximately normalize the data and then 
were standardized across the tissue microarrays. In order to predict 
the pSRC expression using gender, histology, and pathological stage, 
we performed multiple linear regression using backward elimination 
with a significance-level-to-stay of 0.15. Human lung cancer cell 
lines were used to predict if pSRC would be a useful biomarker for 
response to dasatinib. We quantitatively examined phosphorylation of 
tyrosine 416 on SRC, a surrogate for SRC kinase activity in ten hu-
man lung cancer cell lines and plotted these values against the IC50 
for dasatinib in the same cell lines.
Results: pSRC expression was not significantly correlated with 
gender (p= 0.20) and histology (p=0.86), but was weakly correlated 
with pathological stage (p= 0.13). Patients were followed for 11.5 
years, median overall survival was 78 months, 95% CI (61.4-100.5). 
Overall survival was not associated with pSRC level (p =0.28). In-
hibition of tumor cell proliferation by dasatinib did not correlate with 
inhibition of SRC kinase activity in the human lung cancer cell lines. 
These results demonstrated no clear relationship between the levels 
of pSRC and sensitivity to dasatinib. 
Conclusions: pSRC is not a useful prognostic biomarker in regards 
to survival and not a useful predictive biomarker for response of cell 
lines to the SRC inhibitor dasatinib in the context of our study. 
This abstract is to be considered for the Young Investigator Award
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Survival from lung cancer in NSW, Australia 1980–2004
Tracey, Elizabeth A.; Bishop, Jim F.
Cancer Institute NSW, Eveleigh, NSW, Australia
Background: Lung cancer is the most common cause of cancer 
death in NSW and Australia and was responsible for 9 per cent of 
new cases and 19 per cent of cancer deaths in 2006. Five year relative 
survival in NSW was similar to the five year relative survival rates 
for the United States of 15 per cent. NSW survival was significantly 
higher by 8 per cent when compared to five year relative survival 
rates for the United Kingdom with 6 per cent. 
Method: All lung cancer cases in persons notified to the New South 
Wales Cancer Registry between 1980 and 2003. Death records from 
the ABS and NDI were matched for all patients to the end of 2004. 
Patients were classified by: age at diagnosis - under 40, 40-49, 50-
59, 60-69, 70-79, or 80+ years; socio-economic status - five ordinal 
categories using the residential Local government area (LGA) based 
Socio-economic Index for Areas (SEIFA); Accessibility/Remoteness 
Index (ARIA); and (4) country of birth - Australia, other English-
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speaking country, or non-English speaking country. Years of diagno-
sis were grouped into five successive periods of diagnosis from 1980 
to 2003 for statistical analysis. IARC histological categories – small 
cell and non small cell were used. The percentages of cases (+ 95 per 
cent CI) surviving lung cancer within five years of diagnosis were 
calculated using Kaplan Meier product-limit estimates. Cox pro-
portional hazards regression analysis was undertaken to confirm the 
importance of predictors of survival. All socio-demographic variables 
were entered stepwise into the model, retaining those variables that 
increased model fit (p<0.05). 
Results: There were 47,418 histologically confirmed cases of lung 
cancer diagnosed between 1980 and 2003 in NSW. The likelihood 
of dying of lung cancer was lower in females compared to males; in-
creased with age at diagnosis compared to the youngest age category; 
increases with the extent of cancer at diagnosis compared to localised 
lung cancer; was lower in those born in NESB countries compared to 
Australian born; lower in high SES areas compared to low SES areas; 
was lower for non small cell lung cancer compared to small cell lung 
cancer and was lower for later diagnostic periods compared to earliest 
period. In order of contribution, the spread of cancer at diagnosis, age 
at diagnosis and histological type of lung cancer contributed most to 
the likelihood of dying of lung cancer in NSW. 
Conclusion: At the current time no organisation recommends testing 
for the detection of early lung cancer in asymptomatic individuals. 
The results of prospective trials in the US and Europe to evaluate 
the efficacy of lung cancer screening are not currently available. 
Improvement in lung cancer survival will most likely be achieved by 
focusing on early detection and therefore increasing the proportion 
of patients presenting with localised disease. In addition, this study 
shows that more work is required to investigate ways of improving 
survival in people of low SES. 
PD1.1.5 Tobacco and Cancer Control and Health Services, Sat, 14:30 - 16:00
Lung cancer outcomes vary with referral patterns – results 
from the National Lung Cancer Audit 2005-2007
Beckett, Paul1; Woolhouse, Ian1; Stanley, Roz2; Peake, Mick1
1 Royal College Of Physicians, London, UK; 2 The Information 
Centre for Health and Social Care, Leeds, UK
Introduction: The National Lung Cancer Audit is run jointly by the 
Royal College of Physicians and The Information Centre for health 
and social care. Its development was driven by the realisation that 
lung cancer outcomes vary widely across the UK and are poor com-
pared to other western countries.
The aim of the audit is to record outcomes in lung cancer on a large 
scale and through case-mix adjustment, start to explain the wide 
variations noted. Although recently Wales and Scotland have been 
submitting data to the audit, this abstract presents results for England 
for the first three years of the audit, focusing on how outcomes vary 
with referral patterns.
Results: There are 52,799 patients suitable for analysis for the three 
years from 2005-2007. The source of referral to specialist care is 
shown below: 
 Referral Source Proportion of Cases
 Referral from a primary care physician 48%
 Referral from a consultant in a different specialty 17.6%
 Following an emergency admission to hospital 13.6%
 Referral source unknown/not recorded 8.7%
 Other referral source 7.0%
 Following a visit to emergency room/A&E 4.8%
 Referral following a domiciliary visit 0.2%
 Self-referral 0.1%
 Referral from a dental practitioner 0.1%
Further analysis was undertaken on the three most common routes 
of referral. Comparison of the following parameters is given in the 
graph below:
• Proportion of patients with performance status 0-1 (where PS 
recorded)
• Proportion of patients with disease stage of IIIA or below (where 
stage recorded)
• Proportion of patients with histological/cytological confirmation 
of the diagnosis
• Proportion of patients having anti-cancer treatment (surgery, 
chemotherapy, radiotherapy, brachytherapy)
• Proportion of patients having surgical treatment
• 1 year survival
Conclusion: Not surprisingly, patients diagnosed with lung cancer 
following an emergency admission have poorer performance status 
and more advanced stage of disease – their outcomes are con-
sequently worse with lower rates of treatment and poorer survival. It 
remains to be seen whether strategies to improve symptom awareness 
and encourage earlier diagnosis in primary care will influence these 
outcomes.
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The impact of new staging system for non-small cell lung 
cancer
Chien, Chun-Ru 1; Hsia, Te-Chun2; Chen, Chih-Yi3; Yang, Su-Tso4; 
Wu, Hui-Hua 5
1 Department of Radiation Oncology, China Medical University 
Hospital, Taichung, Taiwan; 2 Division of Pulmonary and Critical 
Care Medicine, Department of Internal Medicine, China Medical 
University Hospital, Taichung, Taiwan; 3 Division of Chest Surgery, 
China Medical University Hospital, Taichung, Taiwan; 4 Department 
of Radiology, China Medical University Hospital, Taichung, Taiwan; 
5 Cancer Center, China Medical University Hospital, Taichung, 
Taiwan
Background: To examine the feasibility of the new staging system 
for non-small cell lung cancer (NSCLC) as proposed by the Inter-
national Association for the Study of Lung Cancer (IASLC).
Methods: We evaluated the feasibility of this new staging system in 
our routine bi-weekly multidiisciplinary lung cancer staging confer-
ence in addition to the current (sixth) TNM classification of malig-
nant tumours in a prospective manner from Apr 2008 to Feb 2009. 
The work-up for clinical staging was categorized into conventional, 
positron emission tomography (PET) included, or cyto-pathological 
examination included as work-up A, B, C respectively, which were 
mainly decided by the treating physician. The impact of IASLC sta-
ging in addition to the 6th TNM staging was observed in three levels: 
change in sub-staging (such as from IIA to IIB), change in staging 
(such as from III to IV), or change in clinical management (which 
was based on the discussion within this conference). 
Results: Among those patients discussed during these conferences 
(n=278), 186 newly diagnosed NSCLC patients within the study per-
iod were reviewed and clinically staged in this conference. The other 
patients (n=92) were excluded due to no tissue diagnosis yet (n=50), 
histology other than NSCLC (n=22), recurrence (n=9), further work-
up needed (n=6), and double cancer (n=5). The staging work-up were 
113(61%), 39(21%), and 34(18%) for work-up A, B, and C respect-
ively. There were 98 male and 88 female patients, with a median age 
of 67 (range: 33 ~ 87). Ninteen (10%) patients had different staging 
in IASLC staging when compared with the 6th TNM staging. Most 
(9/19, 47%) of these differences were due to coding of malignant ef-
fusion as M1 instead of T4. The Impact on clinical management was 
seen in four (2%) of them, all were due to coding ipsilateral different 
lung lobe metastasis as T4 instead of M1. The association between 
work-up method and differences in staging were (7/113, 6/39, and 
6/34 for different work-up method A, B, and C respectively, p=0.08). 
Conclusions: Adaptation of the newly proposed IASLC staging for 
NSCLC is feasible in this routine multidisciplinary lung cancer sta-
ging conference. Although the newly proposed staging leads to some 
(10%) differences in staging, most of the changes were due to coding 
of malignant effusion as M1 instead of T4 and the impact on clinical 
decision making is not often seen (only 2%).
PD1.2.1 Tobacco and Cancer Control and Health Services, Sat, 14:30 - 16:00
Prevalence of early brain metastasis and associated 
risk factors in patients with non-small cell lung cancer 
(NSCLC): a SEER Registry study
Morgensztern, Daniel1; Goodgame, Boone1; Subramanian, 
Janakiraman1; Trinkaus, Kathryn1; Govindan, Ramaswamy1, 2
1 Division of Oncology, Washington University School of Medicine, 
660 S.Euclid Ave, Campus box 8056, St. Louis, MO, USA; 2 Alvin J 
Siteman Cancer Center, St. Louis, MO, USA
Background: Despite its common occurrence, there are only limited 
data on the prevalence of brain metastasis in patients with non-small 
cell lung cancer (NSCLC). The prevalence of early brain metastasis 
in NSCLC has not been estimated in a population based data set. 
Between 1988 and 1997, the Surveillance, Epidemiology, and End 
Results (SEER) documented the use of whole brain radiotherapy 
(WBRT) as part of the initial therapy for NSCLC. Since WBRT is 
the treatment of choice for brain metastases, and there is no role for 
prophylactic cranial irradiation in NSCLC, we used WBRT as a sur-
rogate measure for the presence of early brain metastasis. 
Methods: We searched the SEER database for patients with NSCLC 
diagnosed between 1988 and 1997, and with active follow-up. 
Clinical and pathologic factors included age, gender, race, histology, 
tumor grade, stage, tumor location, and use of WBRT. Patients with 
known radiation status were subdivided into no WBRT or WBRT 
indicated (given, refused, or unknown if used). For this study, early 
brain metastasis was defined to be present in those patients who had 
an indication for WBRT. 
Results: Early brain metastasis was identified in 10,963 (8.3%) of 
the 131,456 eligible patients. Of stage IV patients, 28% had early 
brain metastasis. In this group, female gender, younger age, and non-
squamous histology were independently associated with the increased 
odds for early brain metastasis. (Table) 
Conclusions: Brain metastasis is diagnosed in at least 8.3% of pa-
tients with NSCLC early in the course of the disease. 
 Variable Odds Ratio 95% confidence interval
 Histology - Squamous 1.00 
 Adenocarcinoma 1.36 1.16 to 1.59
 Large Cell 1.24 0.98 to 1.58
 Other 1.27 1.05 to 1.53
 Tumor Grade - Grade I  1.00 
 Grade II  1.01 0.69 to 1.48
 Grade III 1.38 0.97 to 1.97
 Grade IV  1.38 0.92 to 2.06
 Tumor Size - 0.0-3.0 cms 1.00 
 3.1-5.0 cms 1.01 0.88 to 1.16
 5.1-7.0 cms  0.997 0.84 to 1.18
 > 7 cms  0.88 0.73 to 1.06
 Race of patient - Black 1.00 
 White/Other  1.04 0.87 to 1.24
 Gender - Female 1.00 
 Male 0.85 0.76 to 0.96
 Age at Diagnosis - 0-40 years 1.00 
 41-60 years  0.88 0.58 to 1.33
 61-80 years  0.47 0.31 to 0.70
 > 80 years  0.21 0.13 to 0.35
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Polymorphisms in the AKAP9, SEZ6L, and CAMKK1 
genes are not significantly associated with lung cancer risk 
in a population of Caucasians
Su, Li1; Zhai, Rihong1; Lynch, Thomas2; Wain, John2; Asomaning, 
Kofi1; Lin, Xihong1; Christiani, David C.1; Chen, Feng1; Sheu, Chau-
Chyun1; Tejera, Paula1
1 Harvard School of Public Health, Boston, MA, USA; 2 
Massachusetts General Hospital, Boston, MA, USA
Background: The A-kinase anchor protein 9 (AKAP9), Seizure 
6-like (SEZ6L), and the calcium/calmodulin-dependent protein 
kinase kinase 1, alpha (CAMKK1) are proteins involved in multiple 
signal transduction pathways. Previous studies by others suggested 
that polymorphisms in the AKAP9, SEZ6L, and CAMKK1 genes 
may confer susceptibility to cancers. We evaluated the associations 
between the genetic variants in the AKAP9, SEZ6L, CAMKK1 genes 
and lung cancer risk. 
Methods: Polymorphisms of AKAP9 (M463I, rs6964587), CAM-
KK1 (E357G, rs7214723), SEZ6L (M430I, rs663048) were deter-
mined in 2392 Caucasian patients with histologically confirmed lung 
cancers and 1458 healthy controls. The data were analyzed using 
multiple logistic regression models, adjusting for relevant covariates, 
including age, gender, smoking status, pack-years, years since smok-
ing cessation for ex-smokers. 
Results: We found no statistically significant associations between 
genotypes of the AKAP9, SEZ6L, and CAMKK1 genes and lung 
cancer risk. The adjusted ORs for AKAP9 M463I, CAMKK1 E375G, 
and SEZ6L M430I polymorphisms were 1.04 (95%CI, 0.93-1.15), 
1.02 (95%CI, 0.92-1.13), and 0.96 (0.85-1.08), respectively. Results 
were unchanged using stratified analysis by age, gender, histological 
subtypes (adenocarcinoma, squamous cell carcinoma), smoking 
status, clinical disease stage (stages I/II, III/IV), and when the joint 
effects between the variant genotypes were examined. 
Conclusion: Results suggest that the variants of AKAP9, SEZ6L, 
and CAMKK1 do not statistically significantly influence lung cancer 
risk in Caucasians.
PD1.2.3 Tobacco and Cancer Control and Health Services, Sat, 14:30 - 16:00
Polymorphisms in telomere maintenance genes and risk of 
lung cancer
Choi, Jin Eun2; Kang, Hyo Gyoung1; Choi, Yi Young2; Yoo, Seung 
Soo3; Lee, Shin Yup3; Cha, Sung Ick4; Hyun, Dae Sung5; Kim, Chang 
Ho4; Jung, Tae Hoon4; Park, Jae Yong4
1 Deagu and Kyungpook Cancer Center, Kyungpook National 
University Hospital, Daegu, Korea; 2 Department of Biochemistry, 
School of Medicine, Kyungpook National University, Daegu, Korea; 
3 Departement of Internal Medicine, Kyungpook National University 
Hospital, Daegu, Korea; 4 Department of Internal Medicine, School 
of Medicine, Kyungpook National University, Daegu, Korea; 5 
Department of Internal Medicine, Catholic Medical University of 
Daegu, Daegu, Korea
This study was conducted to comprehensively evaluate the associa-
tions between polymorphisms in telomere maintenance genes (TERT, 
TRF1, TNKS1, TIN2, TRF2, RAP1 and POT1) and lung cancer risk. 
We captured 35 polymorphisms in the genes and determined their 
frequencies in 27 healthy Koreans. Ten haplotype-tagging poly-
morphisms were examined in a case-control study that consisted of 
720 lung cancer patients and 720 healthy controls.
The TERT rs2735940 g.C>T and rs2736098 g.G>A, and TNKS1 
rs6985140 g.A>G were significantly associated with the risk of lung 
cancer. In the haplotype analysis, the TERT rs2735940T/rs2736098A 
haplotype (ht4) was associated with a significantly increased risk 
of lung cancer compared to the rs2735940C/rs2736098G haplotype 
(adjusted OR = 1.26, 95% CI = 1.07-1.50, P = 0.008). When the 
TERT ht4 and TNKS1 rs6985140G as risk alleles, the risk of lung 
cancer increased in a dose-dependent manner as the number of risk 
alleles increased (Ptrend < 0.001). Subjects with from 2-4 risk alleles 
were at a significantly increased risk of lung cancer (adjusted OR = 
1.67, 95% CI = 1.23-2.27, P = 0.001) compared with subjects with 
zero risk allele. 
These findings suggest that genetic variants in the TERT and TNKS1 
genes contribute to genetic susceptibility to lung cancer.
PD1.2.5 Tobacco and Cancer Control and Health Services, Sat, 14:30 - 16:00
Derivation of utility values from EORTC QLQ-C30 values 
in lung cancer
Jang, Raymond1; Isogai, Pierre K.2; Mittmann, Nicole2; Bradbury, 
Penelope A.3; Shepherd, Frances3; Feld, Ronald3; Leighl, Natasha B.3
1 University of Toronto, Toronto, ON, Canada; 2 Sunnybrook Health 
Sciences Centre, Toronto, ON, Canada; 3 University Health Network, 
Toronto, Canada
Objective: Cancer clinical trials frequently incorporate quality of 
life (QoL) measures, but rarely patient utility and resource utiliza-
tion. Utility information is required for cost utility evaluations of 
novel cancer therapies in the decision making process. We assessed 
the feasibility of converting QoL data into utility scores using two 
commonly used instruments EORTC QLQ-C30 and the EQ-5D, in 
patients with non-small cell lung cancer (NSCLC).
Methods: Outpatients with non-small cell lung cancer (NSCLC) 
attending a major Canadian cancer centre completed the QLQ-C30 
and EQ5D on a single visit. Patients in all different disease states 
were included. Results of the QLQ-C30 were mapped to predict EQ-
5D utility scores using two different Methods: a) a linear regression 
model and b) a response mapping model (Figure 1). Response map-
ping maps the 15 QLQ-C30 scores to each of the EQ-5D descriptive 
system first, which are then converted into utility scores. To test the 
predictive power of the two methods, 10-fold cross validation was 
used.
Results: 172 patients participated. Median age of the sample was 
66 years (range 32-85 years); 46.5% were male. Utility values were 
not significantly different between disease state groups, including by 
disease status (relapse-free versus in relapse), and current treatment 
(chemotherapy, erlotinib or observation). Mean utility score for the 
validation set was 0.76 and 0.74 for the linear model and response 
mapping respectively, which are comparable to the actual mean util-
ity score of 0.76. The mean squared error for the 10-fold cross valida-
tion was 0.02 and 0.03 for the linear and response mapping models 
respectively. Scatter plots of actual versus predicted utility scores are 
shown in Figure 2. 
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Conclusions: Our study demonstrates the feasibility of deriving 
utility scores from prospective QoL data. This may further the ability 
to estimate cost utility of therapies for economic evaluations when 
utility values are not collected during the clinical trial. 
PD1.2.6 Tobacco and Cancer Control and Health Services, Sat, 14:30 - 16:00
Social trust and the development of lung cancer
Pfaff, Holger1, 2, 3; Ommen, Oliver1; Ernstmann, Nicole1; Staratschek-
Jox, Andrea4; Wolf, Juergen5, 3; Neumann, Melanie K.1
1 Center for Health Services Research Cologne (ZVFK), Medical 
Department of the University of Cologne, Cologne, Germany; 2 
Division of Medical Sociology of the Institute and Policlinic for 
Occupational and Social Medicine, University of Cologne, Cologne, 
Germany; 3 Centre for Integrated Oncology (CIO), University 
Hospital Cologne, Cologne, Germany; 4 University of Bonn, 
Germany, LIMES (Life and Medical Sciences Bonn), Program Unit 
Molecular Immune & Cell Biology, Functional Genomics, Bonn, 
Germany; 5 First Department of Internal Medicine, Molecular 
Tumour Biology and Tumour Immunology, University Hospital 
Cologne, Cologne, Germany
Background: Social trust can be defined, as the “default” belief 
in the benign nature of humans, presuming that they can be trusted 
(Yamagishi & Yamagishi, 1994). The mechanisms linking social trust 
to health outcomes are as follows: (1) Trust is an aspect of social net-
works that enable people to access information and use it efficiently 
(e.g. knowledge about health and healthcare, information about pro-
viders, treatment, preventive care); (2) An increase in trust increases 
cooperative behavior. More cooperation between e.g. healthcare 
providers (HCP) and patients can help accomplish tasks needed to 
diagnose and treat the patient more effective; (3) Trust motivates the 
parties involved to behave in trustworthy ways. This mechanism may 
motivate HCP who treat high-trust patients to provide better services. 
Moreover, a high trust patient is more likely to disclose sensitive 
health-related information and more compliant to medical advices. 
Nonetheless, according to Luhman (2000), trust and distrust depend 
on milieu and personal experience.
Based on this theoretical background, we assume that social trust has 
an impact on the development of lung cancer. We also hypothesize 
that the level of school education, as an indicator of milieu affiliation, 
plays a moderating role in this relationship.
Method: The subjects of the present study were patients who partici-
pated in the Cologne Smoking Study, a case-control study examin-
ing which genetic and/or psychosocial factors lead to a higher risk 
for smokers to suffer from lung cancer and/or become addicted to 
nicotine. In face-to-face interviews, we asked patients (lung can-
cer N=164, controls N=146) a question from the European Social 
Survey: “Generally speaking, would you say that most people can be 
trusted, or that you can’t be too careful in dealing with people? Please 
tell me on a score of 0 to 10, where 0 means you can’t be too careful 
and 10 means that most people can be trusted.” 
First, we conducted logistic regression analysis to examine the influ-
ence of social trust on the risk suffering from lung cancer, control-
ling for pack years, gender and age. In a second step, we conduct the 
same model in two regressions to compare patients with lower school 
education and those with a higher one.
Results: There is a significant association between social trust and 
the risk in lung cancer (OR=1.76, p=.033, CI=1.045-2.958). That is, 
by controlling for the aforementioned confounders, we can show that 
people who exhibit lower levels of social trust have a 76% higher odd 
to suffer from lung cancer. Conversely, comparing the two regres-
sions we can see that only patients with a higher school education ex-
hibit a 2.7 times higher odds suffering not from lung cancer, because 
of their higher level of social trust (OR=2.7, p=.023, CI=1.144-6.179; 
lower school education: OR=1.087, p=0.812, CI=0.545-2.163)
Conclusion: This study indicates that social trust is a protective fac-
tor for the development of lung cancer in patients with higher level of 
school education. It seems that these patients have more social net-
works that enable them to access information, behave more coopera-
tive and/or receive better services from their HCP.
PD1.3.1 Tobacco and Cancer Control and Health Services, Sat, 14:30 - 16:00
Demographic and geographic patterns of lung cancer by 
cell type differ greatly despite common smoking etiology
Mack, Thomas M.; Shoar, Zohreh
Keck School of Medicine, Los Angeles, CA, USA
Background: Lung cancer, responsible for the most cancer deaths in 
developed countries, has been known for 50 years ago to be a result 
of cigarette smoking. Pulmonary histology is varied, with cells of di-
verse embryology and biology, and pulmonary neoplasms have long 
been known to consist of a heterogeneous mixture of cell-specific 
neoplasms. This knowledge only came to be of practical importance 
when the effectiveness of therapeutic modalities was observed to vary 
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by cell type. However, the overwhelming and long-evident causal 
importance of smoking has retarded the progress of cell-specific etio-
logic research. Smoking has been clearly linked to each of the three 
major cell types: squamous carcinoma (SQC), small cell carcinoma 
(SCC) and pulmonary adenocarcinoma (PAC). Relative to the known 
causes of other malignant neoplasms (and to smoking as a cause 
of other malignancies), the magnitude of the association between 
smoking and each of the lung cancers is very large. Heavy long-term 
smoking increases the risk of PAC by a factor as high as five-fold, of 
SQC by at least four times that much and of SCC by a factor as high 
as 15 times the increase in PAC1. While other products of incomplete 
combustion have been linked to lung cancer generally, and other 
factors, including the type of cigarette and the mode of smoking have 
been tentatively linked to PAC2, the strength of all three associations 
would strongly lead to the expectation that the descriptive pattern of 
occurrence of each of the three, being based on the descriptive pattern 
of heavy smokers, would be similar.
Methods: In order to provide detailed epidemiological information 
for investigators and to reassure local residents about the patterns of 
cancer occurrence, the incidence of each of 75 malignancies, includ-
ing those comprising the 106,795 cases of cell-type specific lung 
cancer, that occurred among residents of Los Angeles County from 
1972-1997 and were reported to the County-wide population-based 
cancer registry, was examined by site and cell type, age, sex, race/
ethnicity, social class, and time trend. The sex-specific geographic 
distribution of occurrence of each neoplasm was described by identi-
fying those census tracts among the 1640 in the County with at least 
a 50% increase in incidence and a sufficiently large sample to exceed 
the upper confidence limit around an expectation based on the county 
mean incidence3. 
Results: Each of three major cell types of lung cancer showed a 
unique pattern of occurrence according to sex, race/ethnicity, social 
class and time trend. Most notably, the three geographic patterns of 
occurrence were distinctly different.
Conclusions: Despite the known importance of cigarette smoking in 
the etiology of each major type of lung cancer, this evidence strongly 
suggests that other causes co-determine the risk to individuals. 
These may consist of the particular habits of smokers and genetic 
co-determinants, but probably also include other local environmental 
determinants.
1 Kenfield SA, Wei EK, Stampfer MJ, Rosner BA, Colditz GA. Tobacco Control 
2008;17:198-204
2 Franceschi S, Bidoli E. Ann Oncol 1999;10 Supp 5:53-6
3 Mack TM. Cancers in the Urban Environment, Academic Press, 2004
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Comparison of demographics, diagnosis and treatment of 
American Asians with non-small cell lung cancer to the 
general U.S. population
Zhu, Nan1; Meguid, Robert1; Hooker, Craig3; Brock, Malcolm2; 
Yang, Stephen2
1 Johns Hopkins Medical Institutions, Baltimore, MD, USA; 2 Johns 
Hopkins Medical Institutions, The Division of Thoracic Surgery, 
Baltimore, MD, USA; 3 Johns Hopkins School of Public Health, 
Baltimore, MD, USA
Background: Lung cancer has become a growing problem in the 
Asian population around the world and in the United States. Previous 
research has shown some differences in presentation in this popula-
tion compared to the general U.S. population. The aim of this study is 
to improve the understanding of lung cancer demographics, treatment 
patterns, and outcomes in patients of Asian descent with non-small 
cell lung cancer (NSCLC). 
Methods: This is a retrospective study analyzing patients with 
NSCLC in our institution’s lung cancer database between 1975 and 
2003. Of the 6,423 patients, 114 were Asian. Data analyzed included 
patient age, smoking status, co-morbidities, lesion location, stage, 
histology, treatment, and survival. We compared findings in our Asian 
patients to previously reported results on the general U.S. population 
of NSCLC patients. [Reference population: Little et. al. National Sur-
vey of non-small cell lung cancer in the United States: Epidemiology, 
pathology and patterns of care. Lung Cancer (2007) 57, 253-260.] 
Results: In our study, both Asian males and females were younger 
at diagnosis, with more in the <60 age group (43% vs. 21% in the 
reference population, p<0.01), and fewer in the >=70 age group (25% 
vs. 51% in the reference population, p<0.01). Unlike Asian men and 
the general U.S. lung cancer population, there were more nonsmoker 
Asian women with NSCLC (49%) than smokers (41%). Asians had 
fewer overall comorbidities (cardiovascular, lung, and previous 
cancer) than lung cancer patients in the general population (55.3% 
vs. 71.8%, p<0.01), and a lower prevalence of COPD (5% vs. 27%, 
p<0.01). Asian females have more upper lobe disease (28% vs. 51% 
in the reference population, p=0.02) and bronchioalveolar carcinoma 
was seen more in Asian females (10% vs. 5% in the reference popula-
tion, p<0.01). No significant differences between Asians and the 
general U.S. NSCLC patient population existed in terms of surgical, 
radiation, and chemotherapy treatment received. Asians tended to 
present with more Stage IV disease (46% vs. 38% in the reference 
population, p=0.09), although median survival with stage 4 NSCLC 
was longer among Asians in our study compared to the general popu-
lation (22 months vs. less than 12 months).
Conclusion: There are many differences in lung cancer disease pres-
entation and overall health status of Asians compared to the general 
U.S. population, although the treatment courses pursued are similar. 
Overall, Asian NSCLC patients are diagnosed at an earlier age, 
and survive longer despite presenting with advanced stage disease. 
Further investigation is warranted to elucidate possible differences in 
tumor biology, as well as why survival is longer despite no differ-
ences in therapy while presenting with more advanced disease than 
the general U.S. population.
PD1.3.3 Tobacco and Cancer Control and Health Services, Sat, 14:30 - 16:00
Why do some lung cancer patients receive no anti-cancer 
treatment?
Vinod, Shalini K.1, 2; Sidhom, Mark1; Gabriel, Gabriel S.2; Lee, 
Mark3; Delaney, Geoff P.1, 2
1 Collaboration for Cancer Outcomes, Research & Evaluation 
(CCORE), Sydney, NSW, Australia; 2 University of New South Wales, 
Sydney, NSW, Australia; 3 Princess Margaret Hospital, Toronto, 
Canada
Background: A significant proportion of lung cancer patients receive 
no anti-cancer treatment. This ranges from 19% in USA, to 33% in 
Australia, 37% in Scotland and 50% in Ireland. The reasons behind 
this lack of treatment have been poorly studied. Potential reasons 
include patient factors such as age, performance status and comorbid-
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ities and health service factors such as access to treatment facilities 
and lack of specialist referral. Patient and clinician nihilism is also 
an influencing factor. The aim of this study was to identify reasons 
behind lack of anti-cancer treatment for lung cancer. 
Methods: The Lung Cancer Multidisciplinary Meeting (MDM) 
at Liverpool and Macarthur Cancer Therapy Centres in Sydney 
prospectively collects data on all patients discussed including patient 
demographics, comorbidities, performance status, histology, diagnos-
tic investigations, stage, prior therapy and records MDM recommen-
dations. An assessment is completed six months following the MDM 
discussion to determine the treatment actually received. All new lung 
cancer diagnoses presented to the MDM between 1/12/2005 and 
31/12/2007 were reviewed. Based on pathology, stage and perform-
ance status each patient was assigned optimal treatment based on 
evidence-based guidelines. Those patients in whom no anti-cancer 
therapy was recommended by guidelines were compared to those 
patients in whom the MDM recommended no treatment and to those 
patients who actually received no treatment. Analysis was performed 
using SPSS V 15.
Results: There were 335 newly diagnosed lung cancer patients 
presented with a median age of 69 years. The pathology and stage 
distribution were: 5% limited stage small cell lung cancer (SCLC), 
8% extensive stage SCLC, 17% Stage I & II non-small cell lung 
cancer (NSCLC), 34% Stage III NSCLC, 36% Stage IV NSCLC and 
5% no pathological diagnosis. Guidelines recommended no treatment 
in 3% (n=10) of patients, the MDM recommended no treatment in 
9% (n=31) and19% (n=65) actually received no treatment. Of these 
65 patients, 51% had metastatic lung cancer and 65% were aged 
70 years or above. In those who received no treatment, guideline 
recommended treatment was radiotherapy in 68% and chemotherapy 
in 62%. The main reasons for the difference between guideline and 
MDM recommendations were patient comorbidities (29%), poor 
performance status (29%) and clinician decision (23%). The main 
reasons for actually receiving no treatment were poor or declining 
performance status (37%) and patient preference (28%). 
Conclusions: The proportion of patients with lung cancer receiving 
no treatment is greater than that predicted by evidence based guide-
lines or recommended by the MDM. There is an over-representation 
of older patients with metastatic lung cancer in this group. Declining 
performance status, patient preference and comorbidities were the 
main factors responsible for lack of treatment. The proportion receiv-
ing no treatment in this MDM cohort however is still lower than that 
described in population-based studies suggesting that MDMs can 
improve treatment utilisation in lung cancer.
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Disparities in the management of N2 NSCLC: update from 
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Background: African American (AA) patients with N2-positive 
non-small cell lung cancer (NSCLC) have worse overall survival than 
Caucasian (C) patients. The physician-patient encounter has been 
implicated as a potential source of race/ethnicity-related outcome dis-
parities. Our specific aim was to isolate the effect of decision making. 
We used radiotherapy (RT) utilization as a proxy for different care 
plans patients (pts) maybe offered, and examined treatment employed 
by race/ethnicity. 
Methods: Using data from the Surveillance, Epidemiology, and End 
Results (SEER) Program, we identified 41263 pts with pathologically 
confirmed NSCLC diagnosed between 1998-2005, coded as having 
N2 involvement. Categorical variables investigated included age 
(<60, 60-69, and ≥70 yrs.), gender, histology (large-cell carcinoma, 
squamous cell carcinoma, or adenocarcinoma) tumor location, lateral-
ity, and race/ethnicity (C, AA, and other). As a measure of access to 
healthcare delivery, we obtained information from the 2000 census on 
income including the median 1999 household income averaged per 
county and stratified by the median (MEDINC).
Results: Our cohort included 34925 C, 4243 AA, and 2095 others. 
19,830 pts underwent a segmentectomy, lobectomy or pneumonec-
tomy; of these 3563 were additionally treated with RT. In multivariate 
analysis of all pts, variables associated with surgery being performed 
included younger age, female gender, adenocarcinoma histology, 
lower lobe location, and lower MEDINC (OR= 0.91; [CI] 0.87-0.94). 
AA race/ethnicity (odds ratio [OR] = 1.6; 95% confidence interval 
[CI] 1.5-1.7) predicted decreased probability of undergoing surgery. 
We then performed a subset analysis including only the pts that 
underwent surgery; AA race/ethnicity (OR = 1.0; [CI] 0.88-1.15) and 
lower MEDINC (OR= 0.97; [CI] 0.90-1.04) did not predict the use of 
radiotherapy in the treatment.
Conclusions: The optimal combination of surgery and RT is contro-
versial, but the treatment pts receive appears to be impacted by both 
race/ethnicity and access to care. Additional research should focus on 
the physician-patient encounter, how it pertains to the different oncol-
ogy specialties, as well as the team approach used to deliver care.
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Background: We performed a combined analysis of a Korean Cancer 
Center Registry and a regional California Cancer Registry database to 
analyze whether Asian ethnicity is an independent favorable prognos-
tic factor for overall survival (OS) in NSCLC.
Methods: Retrospective population-based analysis of Korean 
NSCLC patients from Samsung Cancer Center, Seoul, Republic 
of Korea (ROK) and Caucasian NSCLC patients from the Cancer 
Surveillance Program of Orange County and San Diego Imperial 
Organization for Cancer Control, California, USA. The study period 
(1998-2005) was evenly divided into two time periods (prior to the 
approval of gefitinib in ROK: 1998-2001 and after gefitinib approval 
in ROK: 2002-2005). Ten variables (age, gender, smoking status 
[ever-smoker versus never-smoker], period of diagnosis, histology, 
AJCC stage, surgery, radiation, and chemotherapy) common to both 
databases were analyzed.
Results: A total of 13,411 patients (4,846 Korean and 8,565 US 
Caucasian) were analyzed. Median age was 63 years versus 71 years 
for Korean and Caucasian patients (P < 0.0001). 21.1% of Korean 
compared to 8.1% Caucasian patients were never-smokers. For pa-
tients with known AJCC stage, the proportion of patients with stage 
I, II and III NSCLC were higher in Koreans than US Caucasians. 
Conversely, the proportion of patients with stage IV NSCLC was 
higher in US Caucasians than Koreans. The proportion of patients 
who underwent surgery was higher in Koreans than US Caucasians. 
There was no major difference in the proportion in the use of chemo-
therapy or radiation between Koreans and US Caucasians. There was 
significant improvement in OS among Korean patients from 2002-
2005 compared to 1998-2001 (P < .0001) but not among Caucasian 
patients (P = 0.7387). There was no significant OS difference be-
tween never-smokers and ever-smokers among Caucasian or Koreans 
patients across individual study period. Stage for stage, univariate 
analysis revealed Korean had improved OS compared to Caucasian 
patients (P < 0.0001 for stages I, III, and IV respectively and P = 
0.0341 for stage II). Cox proportional hazards regression analysis 
preformed on all patients revealed Korean ethnicity (vs. Caucasian; 
hazard ratio [HR] = 0.839; 95%CI: 0.800-0.880; P < 0.0001) was an 
independent favorable factor for OS. Other independent favorable 
prognostic factors were younger age, female gender (vs. male: HR 
= 0.822, 95%CI; 0.789-0.857; P < 0.0001), early AJCC stage, more 
recent period of diagnosis (2002-2005), and treatment delivered 
(surgery, radiation or chemotherapy). Bronchioloalveolar carcinoma 
[BAC] (vs. adenocarcinoma; HR = 0.598; 95%CI: 0.522-0.684; P < 
0.0001) was another independent prognostic factor but other histolo-
gies (squamous cell, large cell, NOS/mixed/other) were not. Smoking 
status was not an independent prognostic factor in this analysis. HR 
for Korean ethnicity when compared to Caucasian ethnicity improved 
during 2002-2005 (HR = 0.795; 95%CI: 0.744-0.851; P < 0.0001) 
compared to 1998-2001 (HR = 0.889; 95%CI: 0.828-0.955; P = 
0.0013).
Conclusions: Compared to US Caucasian ethnicity, Korean ethnicity 
was an independent favorable prognostic factor for OS independent 
of smoking status in NSCLC before (year 2002) and after the oral 
EGFR TKI era.
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database WORLD 07
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Background: Lung cancer is the leading cause of cancer mortal-
ity among women in many countries. Gender differences have been 
reported, most of them based on retrospective analysis. 
Methods: WORLD07 is a prospective, multicenter, epidemiologic 
female-specific lung cancer database developed by the Spanish Lung 
Cancer Group. Data on demographics, previous cancer history, repro-
ductive and hormonal status, diet, alcohol, tobacco, and occupational 
information are being collected just as histology, stage, treatment and 
survival. 
Results: From October 2007 to Feb 2009, 409 female newly diag-
nosed of lung cancer were collected in an e-database in 22 Spanish 
centers. Characteristics based on 342 patients (p) are: median age 
61.7 years (y) (range: 36 – 87); Caucasian: 98.2%; Marital status (%): 
married 67.7, unmarried 11.2, divorced 7.1, widow 14. Educational 
level (%): basic 57.4, secondary 29.1, university 13.5. Median age of 
menarche 12.7 y. Children: 79.4% (median: 2); Median age of first 
child 27 y. Oral contraceptive: 30.6%. Pre-menopausal 15.4%,post-
menopausal 84.6%. Median age of menopause 46.7 y. HRT: 5.3%. 
Median duration of HRT: 4.4 y. Obesity: 11.3%. Smoking habit (%): 
never (passive smoker/no exposition)/former/current smokers: 42 
(42.8/57.2) /19 /39; Median packs/year 72.4. Former smokers: 1-5/5-
10/10-15/>15 y (%): 51/11.8/7.8/29.4. Work exposure 3.5%. Alcohol 
consumption 3.2%. Familiar history of cancer: 45.5% (lung cancer 
29.7%). Previous history of cancer 13.8% (breast 33.3%). Cur-
rent lung cancer histology (%): adenocarcinoma / BAC/ squamous/ 
large cell/ NOS: 70.4/5.7/10.4/7.9/5.7. SCLC 11.8%. TNM I/II/III/
IV (%): 16/3.9/28.7/51.4. Surgical treatment 24.7 % (lobectomy/
pneumonectomy/exploratory: 85.5/9.2/5.3%). Available data of 122 
stage IV NSCLC p: 74.6% receive chemotherapy, 92.3% of them two 
drugs and 68.9 % platinum-based (59% cisplatin). EGFR mutations 
analysis 7.9% 
Conclusions: According this series, 42% Spanish lung cancer 
women are never smokers and 70.4% have adenocarcinoma. Updated 
collected information, choice of treatment and survival outcomes will 
be presented. 
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Japanese ethnicity as compared to Caucasian ethnicity and 
never-smoking status are independent favorable prognostic 
factors for overall survival in non-small-cell lung cancer: a 
collaborative epidemiologic study of the National Hospital 
Organization (NHO) study group for lung cancer in Japan 
and a southern California regional cancer registry
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Background: We previously reported that Asian ethnicity was a 
favorable prognostic factor for overall survival (OS) in NSCLC 
among US patients. Here we performed a combined analysis of a 
Japanese Hospitals Cancer Registry and a regional California Cancer 
Registry to further validate this observation.
Methods: Retrospective population-based analysis of Japanese 
NSCLC patients from the Japanese National Hospital Study Group 
for Lung Cancer and Caucasian NSCLC patients from the Cancer 
Surveillance Program of Orange County and San Diego Imperial 
Organization for Cancer Control, California, USA. The study period 
was between 1991 and 2001 prior to the approval of gefitinib in 
Japan. Ten variables (age, gender, smoking status [ever-smoker vs 
never-smoker], period of diagnosis, histology, AJCC stage, surgery, 
radiation, and chemotherapy) common to both databases were ana-
lyzed.
Results: A total of 27,942 (15,185 Japanese and 12,737 US Cauca-
sian) patients were analyzed. Median age of Japanese patients was 68 
years compared to 70 years for US Caucasian (P < 0.0001). 29.3% of 
Japanese compared to 7.2% Caucasian patients were never-smokers. 
For patients with known AJCC stage, the proportion of patients with 
stage I and III NSCLC were higher in Japanese than US Caucasians. 
Conversely, the proportion of patients with stage IV NSCLC was 
higher in US Caucasians than Japanese. There was no difference in 
the proportion of stage II NSCLC patients between Japanese and 
US Caucasian patients. The proportion of patients who received 
surgery and chemotherapy was higher in Japanese than US Cauca-
sians. Never-smoking status conferred numerically improved OS for 
Japanese (P < 0.0001) and Caucasian (P = 0.1939) patients. Stage for 
stage, univariate analysis revealed stage III (P < 0.0001) and IV (P = 
0.0149) Japanese patients had improved OS compared to Caucasian 
patients. Cox proportional hazards regression analysis performed on 
all patients identified Japanese ethnicity (vs. Caucasian; HR = 0.955, 
95%CI: 0.917 – 0.995; P = 0.0268) and never-smoker (vs. ever-smok-
er; HR = 0.945, 95%CI: 0.906 – 0.985; P = 0.0076) were independent 
favorable factors for OS. Other independent favorable prognostic 
factors were younger age, female gender (vs. male; HR = 0.829; 
95%CI: 0.804-0.856; P < 0.0001) early AJCC stage, squamous cell 
histology (vs. adenocarcinoma; HR = 0.943; 95%CI: 0.912-0.974; P 
= 0.0004), more recent period of diagnosis, and treatment received 
(surgery, radiation, and chemotherapy). Large cell carcinoma (vs. 
adenocarcinoma; HR = 1.173; 95%CI: 1.110-1.238; P < 0.0001) was 
an independent unfavorable prognostic factor.
Conclusions: Compared to US Caucasian ethnicity, Japanese ethni-
city is an independent favorable prognostic factor for OS in NSCLC. 
Never-smoking status is another favorable prognostic factor for OS in 
NSCLC in this study independent of other clinically relevant factors.
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Patient out-of-pocket payments for non-small cell lung 
cancer oncologic therapies: results from a U.S. claims data 
analysis
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Background: Currently, second-line (2L) treatment options for 
patients diagnosed with non-small-cell lung cancer (NSCLC) include 
docetaxel, pemetrexed, and erlotinib. Limited data are available dem-
onstrating the out-of-pocket (OOP) cost burden of chemotherapies 
to patients. The objective of this study is to evaluate patient OOP 
payments for three oncologic therapies approved for 2L advanced 
NSCLC in U.S. managed care plans. 
Methods: Patients aged 18+ years with 1 of 3 oncologic therapies 
and with a lung cancer diagnosis were identified in calendar year 
2007 from a nationally-representative database of medical and phar-
macy claims from over 90 U.S. health plans. The 3 therapies included 
erlotinib, an oral therapy, and docetaxel and pemetrexed disodium, 
intravenous therapies; lung cancer was identified using ICD-9-CM 
codes 162.9, 163.9, 196.x, 197.x (except 197.5, 197.8), 198.x. OOP 
payments were calculated as the allowed amount (dollar amount a 
health plan allows for a therapy, including any member liability) 
minus the paid amount (dollar amount paid by a health plan for a 
therapy). 
Results: 3,632 lung cancer patients with evidence of at least 1 of 
the 3 NSCLC oncologic therapies in 2007 were identified. The mean 
age was 63 years, 53% were male, and 84% had a commercial payer. 
Mean OOP per claim payments for year 2007 for the 3 oncologic 
therapies are provided in the table below. The average OOP payment 
for pemetrexed disodium ($1,060) was over 2.5 times higher than 
that for erlotinib ($339) or docetaxel ($375); however there is wide 
degree of variability. The proportion of the total allowed amount 
relegated to the patient was lowest for erlotinib (11.2%), followed 
by pemetrexed disodium (21.5%) and docetaxel (23.0%). Medicaid 
and commercial payers had higher mean OOP payments compared 
to Medicare Advantage and self-insurance for docetaxel and pe-
metrexed, while Medicare Advantage and Medicaid indicated higher 
average OOP payments for erlotinib.
2007 Average OOP Payments Per Claim
 Oncologic Therapy Total Mean OOP Payment OOP Payment as 
 for NSCLC Claims (Std Dev)  % of Allowed Amount
 Erlotinib 3,746 $339 (859) 11.2%
 Docetaxel 12,010 $375 (757) 23.0%
 Pemetrexed Disodium 3,977 $1,060 (2,130) 21.5%
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Conclusions: This study evaluated OOP payments for 3 oncologic 
therapies for NSCLC using current claims data. Results showed that 
the average OOP costs ranged from $339 to over $1,000 and were 
highest for pemetrexed disodium. As costs for therapy used to treat 
NSCLC become a greater part of the decision-making process, an 
understanding of the OOP cost burden to the patient will be critical in 
informing choices.
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Background: Lung cancer is the leading cause of cancer mortality 
in Australia accounting for 18.5% of cancer deaths and 5.5% of all 
deaths. There is limited literature on the estimated costs of managing 
lung cancer. An older Australian study showed that the major costs in 
small cell lung cancer were due to hospitalization and chemotherapy, 
with the former confirmed in studies from Canada, US, Ireland and 
Switzerland. With the high burden of care and escalating health care 
costs, the aim of this study was to evaluate the current pattern of re-
source use and costs required to diagnose, stage, treat and follow-up 
lung cancer in Sydney, Australia. 
Methods: The Lung Cancer Multidisciplinary Meeting (MDM) at 
Liverpool and Macarthur Cancer Therapy Centres in south-west Syd-
ney prospectively collects data on all patients discussed at the MDM 
including patient demographics, histology, investigations, stage and 
records MDM recommendations and treatment. All new cases of 
primary bronchogenic carcinoma presented at the MDM or seen at 
the Cancer Therapy Centre between 1/12/2005 – 31/12/2006 were 
included in the study. Cases presenting with recurrent disease were 
excluded. Data on timing and nature of investigations, hospitalisation 
at any time-point along disease trajectory, surgery, chemotherapy, 
radiotherapy and follow-up investigations were collected for the 
period beginning with the first consultation and ending with the last 
follow-up appointment, hospitalisation, death or up to 31/12/2008. 
Costing was based on the Australian Medicare Benefits Schedule and 
reported in Australian dollars (AUD). Infrastructure, staff and ancil-
lary costs were not included. 
Results: There were 210 patients (61% male) in the cohort with a 
median age of 68.2 years (range 39-90 years). The pathology and 
stage distribution were: 3.3% limited stage small cell lung cancer 
(SCLC), 10.0% extensive stage SCLC, 7.1% stage I non small 
cell lung cancer (NSCLC), 6.7% stage II NSCLC, 28.6% Stage III 
NSCLC and 44.3% stage IV NSCLC. Median follow up was 30 
months. The estimated total cost for managing this cohort of patients 
was AUD 2.91 million. The cost breakdown was 4.4% for diagno-
sis, 5.7% for staging, 41.2% for treatment (2.8% surgery, 15.8% 
radiotherapy and 22.6% chemotherapy), 43.7% for hospitalisation 
and 5.0% for follow-up investigations. The median costs for NSCLC 
and SCLC were AUD 10,675 (range AUD 669-612,789) and AUD 
14,799 (range AUD 908-31,057) respectively. The overall median 
survival was 9.4 months and the 2 year overall survival rate was 
27.6%. The median cost per month of survival for the entire cohort 
was AUD1,475 (range AUD 41-28,650).
Conclusion: Hospitalisation and cancer treatment account for the 
major components of lung cancer management related costs. In this 
MDM cohort the greatest treatment related costs were due to chemo-
therapy. However, this cohort of patients was predominantly managed 
non-surgically due to the stage of disease or histological subtype. 
This study is among the few contemporary studies addressing current 
direct costs in modern lung cancer management.
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lung cancer: why are patients not treated according to 
guidelines?
Sidhom, Mark A.1; Vinod, Shalini K.1, 2; Gabriel, Gabriel S.2; Lee, 
Mark3; Delaney, Geoff P.1, 2
1 Collaboration for Cancer Outcomes, Research & Evaluation, 
Liverpool, NSW, Australia; 2 University of New South Wales, Sydney, 
NSW, Australia; 3 Princess Margaret Hospital, Toronto, ON, Canada
Background: Published population-based estimates of the pro-
portion of lung cancer patients receiving stage-specific guideline 
recommended therapy (GRT) ranges from 32% to 64% . Factors 
associated with not receiving GRT include advanced stage, increas-
ing age, decreasing performance status, comorbidities and marital 
status. Reasons for this under-utilization of anti-cancer therapy may 
include physician or patient nihilism, ageism and barriers to health-
care access. However, there are also many legitimate reasons why 
patients are not recommended, or do not ultimately receive, stage and 
performance-status specific GRT. This study aimed to identify the 
reasons underlying the discrepancy between the actual and guideline-
recommended anti-cancer therapy of lung cancer patients referred to 
a tertiary hospital multidisciplinary meeting (MDM).
Method and Materials: The Lung Cancer MDM at Liverpool and 
Macarthur Cancer Therapy Centres in Sydney prospectively collects 
data on all patients presented to the MDM, including presenting 
symptoms, comorbidities, performance status, investigations per-
formed, histology, stage, prior therapy and MDM recommendations. 
An assessment is completed six months following the MDM discus-
sion to determine the treatment actually received. All new lung cancer 
diagnoses presented to the MDM between 1/12/2005 and 31/12/2007 
were reviewed. The MDM recommendations and treatment received 
were evaluated for consistency with stage and performance-status 
based GRT. The reasons for discordance between guideline-recom-
mended and actual treatment were recorded.
Results: There were 335 new patients discussed in the MDM dur-
ing the study period. Patient characteristics included median age 
68 years (range, 39–89), 86% non-small cell lung cancer (NSCLC) 
histology and 14% small cell lung cancer (SCLC), stage I-II NSCLC 
17%, stage III NSCLC 34% and stage IV NSCLC 36%, limited stage 
SCLC 5% and extensive stage SCLC 8%. Performance status was 
ECOG 0-1 in 64%, 2 in 23% and 3-4 in 13%. 84% of patients were 
recommended by the MDM to have guideline recommended radio-
therapy, but only 69% actually received this. 74% of patients were 
recommended by the MDM to have guideline-recommended chemo-
therapy, but this was only delivered in 54%. Overall, considering 
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both radiotherapy and chemotherapy indications, 71% were recom-
mended and 51% received stage and performance-status based GRT. 
Of the patients who did not receive GRT, 17% were due to technical 
factors precluding safe delivery of radiotherapy, 16% because of 
specific comorbidities contra-indicating GRT, 16% electively refused 
GRT, and 28% were recommended GRT, but their performance status 
declined or disease progressed such that commencing or completing 
GRT was no longer appropriate. In 22%, no reason could be identi-
fied for the failure to receive GRT.
Conclusion: In this tertiary referral patient population, legitimate 
clinical reasons underlie the majority of cases in which lung cancer 
patients do not receive GRT. Improving timely referral and treatment 
may decrease the proportion of patients that progress or decline in 
performance status before GRT can be instituted.
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Systematic review of the cost-effectiveness of PET in 
staging of non-small cell lung cancer and management of 
solitary pulmonary nodules
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Background: The clinical effectiveness of positron emission tom-
ography (PET) imaging in the assessment and management of lung 
cancer patients has been documented. However, due to its significant 
costs, some hospitals and cancer centres have been reluctant to imple-
ment PET as a standard of care. There are questions as to whether the 
decrease in morbidity and mortality are sufficient to justify the costs. 
Our objective was to perform a systematic review of the international 
literature describing the cost-effectiveness of PET imaging in the 
staging (ST) of non-small cell lung cancer and the management of 
solitary pulmonary nodules (SPN). 
Methods: The systematic literature searches were conducted in 
MEDLINE including PreMEDLINE (1950 to 2009), EMBASE (1980 
to 2009), NHS Economic Evaluation Database (1st Quarter, 2009) 
and were restricted to studies published in English language. Separate 
search strategies were developed for each particular database using 
specified terms and search fields to identify studies that assessed the 
cost-effectiveness of PET imaging in staging of NSCLC or manage-
ment of SPN. Our inclusion criteria also included a measurement 
of study quality as assessed by the previously validated Quality of 
Health Economic Studies (QHES) instrument. Studies which did 
not receive a QHES score greater than 75 were excluded. Various 
characteristics including study methodology/assumptions as well as 
cost-effectiveness metrics such as incremental cost-effectiveness ratio 
(ICER) based on life years saved (LYS) and average cost savings per 
patient (ACSP) were abstracted from the literature. Descriptive sta-
tistics were generated with all cost amounts converted to a common 
inflation-adjusted 2007 USD currency.
Results: We screened a total of 629 citations, retrieved full texts of 
57 potentially eligible articles and included 20 studies that met our 
inclusion criteria. All 20 studies received QHES scores greater than 
75 independently by two reviewers (average score 87.8). The studies 
were primarily based on the national health car system perspectives 
of 8 different countries: Australia (n=3), Canada (n=2), France (n=2), 
Germany (n=2), Italy (n=2), Japan (n=4), the Netherlands (n=1), and 
the United States (n=4). Investigations assessed the SPN scenario 
(n=8), the S scenario (n=11) and both the SPN and ST scenarios 
(n=1). In these studies, cost-effectiveness was characterized primarily 
using decision tree modeling and sensitivity analysis to determine the 
effects of changing variables on expected cost and life expectancy. 
Mean assumed cost of PET scanning was $1267 (range $769-$2580) 
in these studies. Median ICER for SPN and ST was $2039 ($181-
$3927) and $4037 ($527-$32618), respectively. Median ACSP for 
SPN and ST was $518 ($66-$1480) and $1390 ($143-1633), respect-
ively.
Conclusions: The cost-effectiveness metrics reported in these studies 
are highly variable and can depend on input variables/assumptions 
including: cost and disease prevalence, diagnostic operating charac-
teristics, the diagnostic strategies assessed, and statistical methodolo-
gies utilized. Despite this observed variation within this systematic 
review, these studies consistently have concluded that PET imaging 
in the context of SPN and ST has favorable cost effectiveness charac-
teristics compared to non-PET strategies. 
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Cost effectiveness of the addition of bevacizumab to 
carboplatin and paclitaxel for medicare beneficiaries with 
advanced non-small cell lung cancer
Fanucchi, Michael1; Clinton, Chelsea2; Mathur-Wagh, Usha3, 2; 
Twyne, Ellen 2; Reisch, Karen2; Muinde, Ruth2
1 New york Medical College-St. Vincent’s Comprehensive Cancer 
Center, New York, NY, USA; 2 Executive MPH Program, Mailman 
School of Public Health, Columbia University, New York, USA; 3 
Albert Einstein College of Medicine-Beth Israel Medical Center, New 
York, USA
The addition of bevacizumab (bev) to carboplatin (car) and paclitaxel 
(pac) improved the median survival of patients (pts) with advanced 
non-small cell lung cancer (NSCLC) and good performance status 
to 12.3 months from 10.3 months, and improved the response rate to 
35% from 15% (Sandler A, NEJM 2006; 355:2545). We estimated the 
cost effectiveness of the addition of bev for retired Medicare benefici-
aries, including physician, supportive care, imaging, laboratory and 
transportation costs. The utility estimate for both treatments was .63 
for the first year (Berthelot J-M, JNCI 2000;92:1321), reduced to .57 
for the 2nd year and .53 for the 3rd and 4th years. Pts were assumed 
alive or dead at the end of the calender year, with all pts dead at the 
end of the fourth year. Pts died from NSCLC, treatment toxicity 
(neutropenia with sepsis or bleeding) or comorbid condition (myo-
cardial infarction) at rates reported in the study. Pts received 7 cycles 
of carb/pac/bev and 5 cycles of carb/pac as reported and 4 months of 
erlotinib in the 2nd year as second line therapy. End of life costs with 
inpatient hospice care were estimated. Costs were discounted by 3%/
year. Results: QALY for carb/pac/bev was .98 and for carb/pac was 
.92. The incremental cost per QALY gained is $68,567. If the higher 
response rate with bev improves utility by 5%, the incremental cost 
per QALY gained is $37,897. Conclusion: carb/pac/bev is cost ef-
fective for Medicare beneficiaries with advanced NSCLC.
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Adverse effects and associated costs with 2nd- and 3rd-line 
therapies for non-small cell lung cancer
Lash, Stephen2; Ye, Xin1; Reyes, Carolina 2; Hille, Jeff2; Benn, 
Lucinda 2
1 i3 Innovus, Eden Prairie, MN, USA; 2 Genentech, Inc, South San 
Francisco, CA, USA
Background: Chemotherapies for non-small cell lung cancer 
(NSCLC) are associated with a number of adverse effects (AEs), 
which may increase health care use and costs for managing these 
AEs.
Objective: To compare occurrence of common AEs and associated 
costs among patients receiving docetaxel, erlotinib, or pemetrexed 
monotherapy as 2nd- or 3rd-line treatment of NSCLC.
Methods: This was a retrospective claims analysis. Commercial 
enrollees with lung cancer were identified using ICD-9-CM diagnosis 
codes between July 2004 and December 2006. Pharmacy and medical 
claims were used to identify docetaxel, erlotinib, or pemetrexed 
monotherapy as 2nd- or 3rd-line treatment. AEs were identified based 
on diagnosis codes, as well as procedure codes and prescription fills 
associated with treatments for these conditions. Due to the variable 
lengths of 2nd- and 3rd-line treatment, costs were compared between 
cohorts on a per month basis.
Results: Of 679 patients receiving 2nd-line treatment, 110 had do-
cetaxel, 145 had erlotinib, and 116 had pemetrexed. At least one AE 
was experienced by all patients in docetaxel and pemetrexed cohorts, 
while 128 (88%) erlotinib patients had at least one AE (p <0.001 vs. 
docetaxel; p <0.001 vs. pemetrexed). The most frequent AE was nau-
sea/vomiting (N/V) occurring in 90% of study subjects. Compared to 
docetaxel, erlotinib had significantly lower rates of neutropenia (3% 
vs. 46%; p < 0.001), N/V (60% vs. 100%; p < 0.001), and dehydra-
tion (10% vs. 20%; p = 0.030). Pemetrexed also had higher rates of 
neutropenia and N/V than erlotinib (22% and 97%, respectively; p < 
0.001), as well as a higher occurrence of anemia (74% vs. 49%; p < 
0.001). Costs to manage AEs were $1494 for erlotinib, which were 
significantly lower than $4386 for docetaxel (p = 0.004) and $6317 
for pemetrexed (p < 0.001). Of 335 patients with 3rd-line treatment, 
33 had docetaxel, 79 had erlotinib, and 80 had pemetrexed. At least 
one AE was experienced by all patients in docetaxel and pemetrexed 
cohorts, while 73 (92%) erlotinib patients had at least one AE (p = 
0.104 vs. docetaxel; p = 0.012 vs. pemetrexed). Costs to manage AEs 
in the 3rd-line setting were lower for erlotinib ($2765) than pe-
metrexed ($4718; p = 0.016), while costs for erlotinib and docetaxel 
($3680) were not significantly different (p = 0.276). 
Conclusion: Overall, occurrence of AEs commonly associated 
with 2nd- and 3rd-line agents for NSCLC was less frequent among 
erlotinib users than docetaxel or pemetrexed users. Costs associated 
with management of AEs were also lower with erlotinib.
PD1.5.1 Tobacco and Cancer Control and Health Services, Sat, 14:30 - 16:00
COPD is associated with a shift of histological distribution 
and stage of lung cancer favouring squamous histology and 
earlier diagnosis
Podmaniczky, Eszter; Bartusek, Dora; Sari, Istvan S.; Moldvay, Judit; 
Losonczy, Gyorgy; Barta, Peter
Dept. of Pulmonary Medicine, Semmelweis University, Budapest, 
Hungary
Background: Epidemiologic studies suggest a strong, independ-
ent association between COPD and Lung Cancer (LC) (Spitz M et 
al, JNCI 2007;99(9):715-6). COPD has been suggested to play a 
direct, causative role in lung carcinogenesis. Chronic inflammation, a 
hallmark of CODP, enhances LC development in mice (Moghaddam 
SJ et al, AJRCMB, 2008 Oct16), while antiinflammatory approaches 
reduce cancer risk in humans. 
Hypothesis: We hypothesized that histological types and stage of 
lung cancer change with presence of concomittant COPD. 
Methods: We analyzed digital and paper-based medical documenta-
tion of LC patients (n=460) of Semmelweis University from 2006 
for the concomitant diagnosis of COPD, LC histology, stage with a 
telephone-based follow-up survey in randomly selected patients of 
squamous and small cell histology for accurate smoking history. 
Results: LC patients with COPD were diagnosed at earlier stages 
(n=215, Stage I & II: 30% in COPD vs. 18% in non-COPD). A 
significant increase of squamous cell carcinomas (SQC) has been ob-
served among both men (n=279, 40% vs. 25%) and women (n=181, 
28% vs. 14%) with COPD compared to patients without COPD. The 
observed difference of average cigarette consumption (expressed 
in pack-year, PY) between COPD (n=21, 40.45PY) vs. non-COPD 
(n=38, 32.92PY) patients with SQC carcinomas seems to be insuffi-
cient to explain the increase of SQC among COPD patients. Further-
more, incidence of anaplastic carcinomas were significantly reduced 
in both sexes with COPD (1% vs. 6%) vs. patients without COPD. 
The relative reduction of adenocarcinomas (AC, 26% vs. 36%) and 
small cell (SC, 7% vs. 13%) carcinomas in COPD-associated lung 
cancer cases vs. non-COPD cases was gender-specific, observed 
exclusively in women and men, respectively. 
Conclusion: We conclude that COPD causes a shift in histological 
subtypes favoring squamous cell carcinomas. The pulmonologic 
attendance and annual chest X-ray screening of most COPD patients 
may explain the higher incidence of early lung cancer stages in these 
patients. The effect of concomitant COPD on lung cancer may not 
be explained by differential smoking habits of COPD patients sug-
gesting a role for chronic airway inflammation and genetic suscept-
ibility of COPD in lung carcinogenesis.
PD1.5.2 Tobacco and Cancer Control and Health Services, Sat, 14:30 - 16:00
Impact of race on survival outcomes in metastatic non 
small cell lung cancer
Telivala, Bijoy 1, 2; George, Gibson 1; Gupta, Sameer 1, 2; Gaughan, 
John 2; Ali, S.Asim1, 2
1 Temple University Hospital, Philadelphia, PA, USA; 2 Temple 
University Medical School, Philadelphia, PA, USA
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Introduction: Lung cancer is the leading cause of cancer related 
mortality in the United States. African Americans (AA) have been 
found to have a higher incidence of lung cancer and a higher age-
adjusted mortality rate from lung cancer compared with Non-AA. 
These differences in survival are thought to be associated with dif-
ferences in socioeconomic status, cultural beliefs, access to special-
ized medical care and level of education. The treatment of stage IV 
non small cell lung cancer (NSCLC) consists of palliative systemic 
chemotherapy, and patients who present with metastatic disease have 
a median survival of less than one year. We present the results of a 
single institution, retrospective, matched case control study look-
ing for differences in survival outcomes between AA and Caucasian 
patients with stage IV NSCLC. 
Methods: We performed a retrospective review of the tumor registry 
at Temple University Hospital and collected data on all AA patients 
with stage IV NSCLC diagnosed and treated at our institution be-
tween 1995 and 2005. Patients were matched for age and stage with 
Caucasian controls. The histological diagnosis was confirmed via 
pathology reports. Groups were compared using Fisher’s exact test 
and t-test. Survival was calculated using Kaplan-Meier analysis. 
Results: Ninety AA patients with stage IV NSCLC were identified 
and matched for age and stage with 90 Caucasian controls. Forty nine 
of the AA patients were males and 41 were females compared with 47 
males and 43 females in the Caucasian group (p=0.88). The median 
age of both groups was 65 (p=0.89).Thirty two of the AA patients 
had squamous cell histology compared with 30 in the Caucasian 
cohort, while the number of patients with adenocarcinoma in the two 
groups was 58 and 60 respectively (p=0.88). The most common site 
of metastasis was bone in both groups (25% in AA versus 29% in the 
Caucasian group; p=0.74). The number of patients with a history of 
tobacco use was 84 (93%) in the AA group verses 73 (81%) in the 
Caucasian group (p=0.02). The median survival for AA patients with 
adenocarcinoma was 196 days (95%CI 156, 161) compared to 131 
days (95%CI 87,161) for the caucasian group (p=0.20). The median 
survival in AA patients with squamous cell histology was 101 days 
(95%CI 73, 164) compared to 175 days (95%CI 128 to 360) for the 
caucasian group (p=0.015). The overall median survival was 161 
days (95%CI 115, 207) for the AA patients compared to 143 days 
(95%CI 112, 178) for the caucasian group (p=0.94). 
Conclusions: Our study showed no differences in overall survival 
based on race in matched patients with stage IV NSCLC treated at 
our institution. A subgroup analysis revealed that AA patients with 
squamous cell histology had significantly worse outcomes when 
compared to their Caucasian counterparts. Although based on a small 
number of patients with squamous histology, this is the first time this 
has been observed and needs to be studied further.
PD1.5.3 Tobacco and Cancer Control and Health Services, Sat, 14:30 - 16:00
Effect of diabetes mellitus on the epidemiology of lung 
cancer
Hack, Keely M.; Meza, Jane L.; Kessinger, Margaret A.; Ganti, Apar 
K.
University of Nebraska Medical Center, Omaha, NE, USA
Background: Diabetes mellitus (DM) seems to protect against the 
development of metastases in patients with non-small cell lung can-
cer. However the effect of diabetes on survival from lung cancer is 
unknown. This study was conducted to evaluate the effect of DM on 
the epidemiology of lung cancer.
Methods: A retrospective chart review of consecutive patients with 
lung cancer seen in the Medical Oncology clinic at the University of 
Nebraska Medical Center between 1996 and 2007 was conducted. 
Patient data was analyzed for differences in survival outcomes in 
lung cancer patients based on diabetes status after adjusting for age, 
gender, stage, and treatment received. Patient characteristics of the 
two groups were compared using Chi square test for categorical vari-
ables and t-test for continuous variables. Cox proportional hazards 
regression model was used to examine survival.
Results: Of the 617 patients included in this analysis, 80 (13%) had 
DM at lung cancer diagnosis. A higher percentage of DM patients 
with lung cancer were male (66% vs. 50%, p=0.006). Patients with 
DM were older at the time of diagnosis of lung cancer (65.0 vs. 
62.3 years, p=0.03). There was no effect of DM on the stage of lung 
cancer at diagnosis (p=0.36). The majority of patients were smokers 
(92% of non-DM and 100% of DM). The mean duration of smoking 
was higher in patients with DM, although not statistically significant 
(56.3 pack years vs. 51.20 pack years; p = 0.14). Estimated 3 year 
survival was similar in the two groups (48% for DM vs. 55% for non-
DM; p = 0.48). There was no effect of the degree of glucose control 
[hemoglobin A1c (HgbA1c) level within 6 months of diagnosis of 
lung cancer] on lung cancer outcomes. Patients with well controlled 
DM (HgbA1c ≤ 7) had similar overall survival compared to those 
with poorly controlled DM (HgbA1c > 7) (p = 0.67). 
Conclusions: Patients with DM developed lung cancer at an older 
age than those without DM. There was no effect of DM on either the 
stage at diagnosis of lung cancer or the overall survival from lung 
cancer. DM may protect against the development of lung cancer, 
since patients with DM developed lung cancer at a later age and at a 
higher level of tobacco exposure. The molecular basis of this needs 
to be explored further. Also, the differences in gender distribution of 
DM patients with lung cancer need further investigation.
PD1.5.4 Tobacco and Cancer Control and Health Services, Sat, 14:30 - 16:00
Primary lung cancer in patient with idiopathic pulmonary 
fibrosis
Kang, Hyeon Hui; Kim, Jin Woo; Lee, Sang Haak; Moon, Hwa Sik; 
Ahn, Joong Hyun; Park, Chan Kwon; Kim, Myung Sook; Kim, Ju 
Sang; Kim, Young Kyoon; Ko, Yoon Ho 
The Catholic University of Korea, College of Medicine, Seoul, Korea
Background: The aim of this study is to evaluate the clinical charac-
teristics of lung cancer in patients with idiopathic pulmonary fibrosis 
(IPF). 
Methods: We retrospectively reviewed medical records and radio-
graphs of 32 patients with combined lung cancer and IPF diagnosed 
during the period from 2003 to 2008 at St. Paul’s hospital and Holy 
Family Hospital, the Catholic University of Korea. 
Results: Twenty-nine patients were male and 3 were female with 
mean age of 72.2 years. All but one patient were past or current 
smokers, with mean exposure of 53.5 pack-years. In 18 patients 
(56%), the diagnosis of IPF preceded the detection of lung cancer by 
an average of 2.67 years. Thirteen patients (41%) had IPF and lung 
cancer diagnosed at the same period. Chief complaints at the time of 
diagnosis of lung cancer were respiratory symptoms such as cough, 
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sputum and dyspnea in 24 patients (75%). On pulmonary function 
test, an average of diffusion capacity was 67.5%. The most common 
CT pattern of lung cancer was a well-defined nodular lesion (68%), 
followed by ill-defined consolidation (25%). Lung cancer involved 
mainly the lower lobes in 21 (65.6%). The histologic types consisted 
of 12 small cell carcinoma (37.5%), 11 squamous cell carcinoma 
(34.4%), 9 adenocarcinoma (28%). In 26 patients (81%), lung cancer 
was developed within fibrotic area. Among those, small cell carcin-
oma (34.6%) and adenocarcinoma (34.6%) were most common. 
Conclusion: Lung cancer associated with IPF predominantly oc-
curred in older male smokers and was usually located in fibrotic 
area. Small and squamous cell carcinoma were the most common 
pathologic types. These findings suggest that smoking may have an 
important implication for lung carcinogenesis in IPF patients. 
PD1.5.5 Tobacco and Cancer Control and Health Services, Sat, 14:30 - 16:00
Second primary lung cancers (SPLC) in non small cell 
lung cancer (NSCLC) survivors: a report on treatment, 
outcomes, and impact on lung cancer specific mortality
Li, Linna; Egleston, Brian; Lally, Brian; Simon, George; Turaka, 
Aruna; Mehra, Ranee; Borghaei, Hossein; Lebenthal, Abraham; 
Walter, Scott; Kuritzky, Nicolas; Feigenberg, Steven J.
Fox Chase Cancer Center, Philadelphia, PA, USA
Background: Patients previously treated for lung cancer patients 
remains at risk for SPLC. Though the incidence of SPLC has been 
well characterized, its impact on treatment and lung cancer specific 
mortality is unknown. We report the treatment and outcomes of 2 
year NSCLC survivors with SPLC utilizing the Surveillance, Epi-
demiology, and End Results (SEER) database. 
Methods: Between 1992 and 2005, 2 year survivors of histologically 
confirmed NSCLC, with age greater 18 with active follow-up were 
identified. The incidence, tumor characteristics, treatment, and cause 
of death in patients with one primary lung cancer (OPLC) and SPLC 
were analyzed using SEER*Stat 6.4.4. 
Results: With a median follow up of 7 years, 49,577 patient with 
OPLC and 2914 (5.5%) patients with SPLC were identified. Median 
time to SPLC was 51 months (range: 0-156). Histological subtypes 
of SPLC include 1% small cell carcinoma, 32% squamous cell 
carcinoma, and 51% adenocarcinoma, 16% other/unknown. Time to 
diagnosis of SPLC was 26% within the first year, 45% from years 1 
to 5, and 28% after 5 years of initial lung cancer diagnosis. Median 
size of SPLC tumor was 2.6 cm (range: <1-15 cm). At diagnosis of 
OPLC versus SPLC, localized disease was 45% versus 60%, loco-
regional disease 35% versus 32%, and metastatic disease 14% versus 
5%, respectively. Treatment of OPLC versus SPLC was 68% versus 
87% with surgery, 31% versus 20% with radiation therapy, and 12% 
versus 12% with both surgery and radiation therapy. At time last 
follow up, 56% of OPLC and 67% of SPLC were deceased. Leading 
causes of death in patients with OPLC versus SPLC were 64% versus 
76% from lung cancer, 9% versus 6% from heart diseases, 6% versus 
5% from COPD, and 9% versus 6% from other cancers. 
Conclusions: When compared to OPLC, patients with SPLC were 
more likely to have localized disease at diagnosis, more likely to 
receive surgical treatment, and less likely to receive radiation treat-
ment. However, patients with SPLC have a 12% higher absolute lung 
cancer specific mortality. These differences in treatment and outcome 
should be studied in a prospective manner to improve the care of 
patients with SPLC.
PD1.5.6 Tobacco and Cancer Control and Health Services, Sat, 14:30 - 16:00
Prognostic role of tumor extent (T) and lymph node 
(N) involvement in stage IV non small cell lung cancer 
(NSCLC): a surveillance epidemiology end results (SEER) 
study
Subramanian, Janakiraman; Waqar, Saiama; Trinkaus, Kathryn; 
Govindan, Ramaswamy; Morgensztern, Daniel
Washington University School of Medicine, St. Louis, MO, USA
Background: Approximately 40% of all patients diagnosed with 
NSCLC present with advanced stage disease. The commonly known 
prognostic variables in this group include age, gender, performance 
status and co-morbidities. Traditionally T and N stage have not been 
considered a prognostic factor in patients with stage IV disease. 
In this study we evaluated the prognostic role of TNM staging for 
patients with stage IV NSCLC. 
Methods: We searched the SEER database for patients who were age 
21 years or older with stage IV disease diagnosed between the years 
2004 and 2005. Only those patients with known full TNM stage and 
active follow-up were included. 
Results: We identified 19,202 patients who met the inclusion criteria. 
As previously described age and gender were independent prognos-
tic factors. Overall survival decreased with higher T stages and T 
stage was an independent prognostic factor for patients with stage 
IV NSCLC. (Table) The 1 year survival for patients with T1/2 tumor 
was significantly greater than patients with T3/4 tumors; 23.3% vs. 
14.4% (Hazard Ratio 1.24, 95% confidence interval 1.2 to 1.3, p < 
0.0001). Actual tumor size was not associated with poor prognosis 
and N stage by itself was not a reliable prognostic factor in patients 
with stage IV disease. 
Copyright © 2009 by the International Association for the Study of Lung Cancer S431
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
Conclusion: The limitations in this study include the lack of infor-
mation on metastatic sites in the SEER database or disease burden, 
performance status, and chemotherapy use. Nevertheless in this large 
cohort study we report that T stage in addition to age, gender and his-
tology is an independent prognostic factor for patients with stage IV 
NSCLC. T stage may need to be considered for stratification in future 
prospective studies on patients with stage IV NSCLC.
 Variable Hazard Ratio 95% Confidence Limits
 T Stage = 0/1 1.00 
 = 2 0.98 0.94 to 1.03
 = 3 1.16 1.08 to 1.24
 = 4 1.26 1.22 to 1.30
 N Stage = 0 1.00 
 = 1 0.96 0.91 to 1.02
 = 2 1.06 1.03 to 1.10
 = 3 1.02 0.97 to 1.07
 Histology = Adenocarcinoma 1.00 
 = Squamous 1.05 1.00 to 1.09
 = Large Cell 1.22 1.13 to 1.32
 = Other Histology 1.23 1.19 to 1.27
 Tumor size = 0.0 - 3.0 cms 1.00 
 = 3.1 - 5.0 0.88 0.84 to 0.91
 > 5.0 1.01 0.97 to 1.04
 Age at Diagnosis < 40 years 1.00 
 41 - 60 years 1.17 0.99 to 1.38
 61 - 80 years 1.45 1.24 to 1.71
 > 80 years 1.99 1.69 to 2.35
 Gender = Female 1.00 
 = Male 1.13 1.09 to 1.16
 Race = White 1.00 
 = Black 1.00 0.96 to 1.05
 = Other 0.77 0.73 to 0.82
Session PD2: Oncology Nursing, Supportive 
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Design and rationale of a double-blind, randomized, 
placebo-controlled study to evaluate the long-term safety 
and efficacy of darbepoetin alfa administered 500mcg 
once every three weeks (Q3W) in anemic patients with 
advanced non-small cell lung cancer (NSCLC) receiving 
multi-cycle chemotherapy
Markus, Richard3; Henry, David1; Gascon, Pere2; Fleishman, Alex3; 
Borenstein, Jeff3
1 Department of Medicine, Pennsylvania Hospital, Philadelphia, 
PA, USA; 2 Department of Medical Oncology, Hospital Clínic de 
Barcelona, Barcelona, Spain; 3 Amgen Inc., Thousand Oaks, CA, 
USA
Background: Erythropoiesis-stimulating agents (ESAs) (such as 
darbepoetin alfa) include glycoproteins that stimulate red-blood-cell 
(RBC) production. Based on controlled studies showing ESAs can 
reduce RBC transfusion requirements in cancer patients receiving 
chemotherapy, ESAs have been approved for treating chemotherapy-
induced anemia (CIA). A significant proportion of patients with 
advanced lung cancer receiving first-line chemotherapy will develop 
CIA. The safety of ESAs in patients with lung cancer and CIA has 
been examined in several studies, including one in small cell lung 
cancer (SCLC) (Pirker et al. J Clin Oncol. 2008;26:2342-2349) and 
another in patients with SCLC or NSCLC (Vansteenkiste et al. J Natl 
Cancer Inst. 2002;94:1211-1220). Treatment with ESAs in these stud-
ies was not associated with increased mortality or disease progres-
sion outcomes. However, the use of ESAs to treat CIA in patients 
with other tumor types has been associated with adverse mortality 
or disease progression outcomes in some studies that employed 
hemoglobin targets exceeding current label recommendations. Safety 
signals have also been observed in one study of NSCLC patients not 
receiving chemotherapy or radiotherapy (Wright et al. J Clin Oncol. 
2007;25:1027-1032). Given the absence of data regarding (1) the 
general safety of ESAs for treating CIA using lower hemoglobin tar-
gets and (2) long-term outcomes with ESA treatment in patients with 
NSCLC and CIA, further investigation is warranted. We describe 
here a large, multinational, phase 3, randomized, placebo-controlled, 
non-inferiority trial that will comprehensively examine survival, 
disease progression, and reduced transfusion requirements in patients 
with NSCLC and CIA who are treated with darbepoetin alfa.
Methods: Approximately 3000 patients (≥18 years) from up to 500 
world-wide sites in North America, Europe, Latin America, Australia, 
Asia, and Africa will be randomized 2:1 to darbepoetin alfa (500mcg) 
or placebo Q3W until completion of chemotherapy or disease 
progression, whichever occurs first. Use of placebo is required as 
no therapeutic alternative to ESAs exists; however, transfusions will 
be allowed in both treatment groups when medically indicated. Key 
eligibility criteria include metastatic or advanced stage NSCLC, 
first-line chemotherapy for NSCLC, Eastern Cooperative Oncology 
Group performance status ≤1, and a screening hemoglobin ≤11g/dL. 
If hemoglobin reaches >12g/dL, study drug administration will be 
withheld until hemoglobin is ≤12g/dL. Overall survival will be as-
sessed in long-term follow-up. Throughout the study, an independent 
data monitoring committee will assess safety. Safety will be assessed 
by examining the non-inferiority of ESA-treated patients to placebo-
treated patients for overall survival (primary endpoint) and progres-
sion-free survival (secondary endpoint). Other safety endpoints will 
include objective tumor response, incidence of thromboembolic 
events, and incidence of transfusion-associated adverse events. The 
need for transfusions will be a secondary efficacy endpoint. 
Results: This study is anticipated to provide comprehensive data in 
NSCLC patients with CIA on how ESA use may affect survival and 
disease progression and impact transfusion requirements.
Conclusions: This study will provide a robust assessment of the risks 
and benefits of ESA use in CIA. Though ESAs are utilized with slight 
differences in various countries, a full understanding of the ESA 
risk:benefit profile in CIA will provide guidance for medical practice 
globally.
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Dutch observational study on anaemia management with 
epoetin alfa in daily oncology practice – interim analysis 
results on lung cancer patients
Lunde, Ragnar2; Strankinga, Wim3; van den Berg, Paul4; Bunnik, 
René5; Schlösser, Noël6; van Rens, Marcel7; Aerts, Joachim8; Brok, 
Ronald1
1 Janssen-Cilag B.V., Tilburg, Netherlands; 2 Sint Jans Gasthuis, 
Weert, Netherlands; 3 BovenIJ hospital, Amsterdam, Netherlands; 4 
Albert Schweitzer hospital, Dordrecht, Netherlands; 5 Maas hospital 
Pantein, Boxmeer, Netherlands; 6 University Medical Centre Utrecht, 
Utrecht, Netherlands; 7 Diakonessenhuis, Utrecht, Netherlands; 8 
Amphia Hospital, Breda, Netherlands
Background: ASCO/ASH and EORTC have published guidelines on 
epoetin use in anaemic cancer patients (pts) who undergo chemother-
apy (CT). This study is addressing the real-life situation of epoetin 
alfa (Eprex®) treatment (ET) in anaemic cancer patients receiving 
CT.
Material and Methods: Eligible pts were 18 years or older, received 
CT or where about to receive CT within a week as treatment for a 
solid tumour, Multiple Myeloma, Hodgkin’s Disease or non-Hodgkin 
disease and received ET. Data on haemoglobin level (Hb), blood 
transfusions (BTx), CT, ET and treatment-emergent adverse events 
(TEAE) were collected. Data were analyzed for the 468 pts with 
lung cancer out of the first 1000 pts enrolled. Continuous data are 
presented as mean±standard deviation.
Results: 60% male and 40% female. Average age is 63.4 ± 9.4 years. 
Pts had NSCLC (69%), SCLC (27%) and mesothelioma (4%). Major-
ity of pts had metastases (53%). CT was platinum-based for 91% 
of pts and majority of pts had 3-weekly CT cycles (98%). The last 
available Hb before start CT was 12.4 ± 1.6 g/dl. Time between start 
CT and start ET was 27.6 ± 28.7 days. All pts started with 40.000 IU 
ET once-weekly. Dose was increased for 35 pts (8%) of whom three 
pts had a subsequent dose decrease. ET started at an Hb of 10.8 ± 1.2 
g/dl.
Fiftyone percent of NSCLC pts and 49% of SCLC pts had a trans-
fusion-independent response to ET, defined as either a ≥1 g/dl Hb 
rise within first 4 weeks of ET or a ≥2 g/dl Hb rise after baseline 
or a maintenance of Hb within range 11–13 g/dl after 4 weeks ET 
onwards until end of study. During ET, 28% of NSCLC pts received 
BTx, with 60% of this group receiving a BTx within the first 4 weeks 
ET. For SCLC pts this is 34% and 44%, respectively.
NSCLC pts: ET lasted 9.6 ± 5.0 weeks resulting in a transfusion-
independent Hb-rise of 0.1 ± 1.5 g/dl after 28 days (28–35 days) 
(n.s.) and 0.7 ± 2.2 g/dl after 56 days (56–63 days) (p=0.0048), 
respectively. SCLC pts: ET lasted 10.5 ± 4.2 weeks resulting in a 
transfusion-independent Hb-decrease of -0.3 ± 1.6 g/dl after 28 days 
(28–35 days) (p=0.0524) and -0.1 ± 2.1 g/dl after 56 days (56–63 
days) (n.s.), respectively.
In both NSCLC and SCLC pts, 1% of all TEAE were assumed related 
to ET by investigators. Twentyfive NSCLC pts (8%) and three SCLC 
pts (2%) experienced thrombovascular TEAE, of which related to ET 
in three NSCLC pts and one SCLC patient. Four NSCLC pts died due 
to a thrombovascular TEAE, i.e., cerebrovascular accident (3 pts) and 
pulmonary embolism (1 pt), all not related to ET.
Conclusion: ET start in lung cancer pts is according to published 
guidelines and is an effective treatment option for CT-related anaemia 
in ±50% of pts. Important to notice is the difference seen between 
NSCLC and SCLC pts, especially regarding the ET effect on Hb and 
BTx. No unexpected AE occurred.
PD2.1.3 Oncology Nursing, Supportive Care and Patient Advocacy, Sat, 14:30 - 16:00
Persistence on monthly zoledronic acid impacts risk and 
frequency of skeletal complications and follow-up duration 
in lung cancer patients
Hatoum, Hind T.1, 2; Lin, Swu-Jane1, 2; Lipton, Allan3; Guo, Amy4; 
Smith, Matthew R.5
1 Hind T. Hatoum & Company, Chicago, IL, USA; 2 University of 
Illinois at Chicago, Chicago, IL, USA; 3 Hershey Medical Center, 
Hershey, PA, USA; 4 Novartis Pharmaceutical Corporation, Florham 
Park, NJ, USA; 5 Massachusetts General Hospital, Boston, MA, USA
Background: Zoledronic acid (ZA) treatment in lung cancer patients 
(pts) with bone metastasis (BM) has been demonstrated to significant-
ly reduce the risk for skeletal complications (SCs) when compared to 
no treatment. Yet, less is known about when to start patients on ZA or 
whether maintaining patients on dosing frequency of every 3-4 weeks 
(persistence) makes a difference in outcomes. 
Methods: Lung cancer patients who had first BM diagnosed from 
Jan. 02 to Oct. 06 were extracted from PharMetrics database, an inte-
grated claims database of 80 health plans across the U.S. Outcomes 
evaluated included follow-up duration (from first BM diagnosis to 
last claim, F/U), risk of developing SC, and rate of SCs . ZA users 
were defined as early (or late) users if ZA treatment was started 
before (or after) developing any SC. Persistence was defined as 
duration from initiating ZA treatment to date of first treatment gap of 
>45 days. 
Results: 3982 lung cancer pts were selected with 839 (21%) treated 
with ZA. Mean age was 58.9±10.1 years, and 58.8% of the patients 
were males. Logistic regression found that younger patients, those 
with 2 ≥ BM claims, those having extra skeletal metastases, and 
those diagnosed with BM in more recent years, were more likely to 
receive ZA. Patients in east and mid-west regions were more likely 
than those in the west region to receive early ZA treatment (p<0.05). 
Among the ZA treated, 365 (43.5%) were early users.There were 
no significant differences between early and late ZA users in age, 
gender, and other severity indicators. Poisson regression model 
controlling for age, gender, Charlson’s Comorbidity Index (CCI) and 
F/U duration, found early users experienced 25% fewer SCs than 
late users (p<0.05). Early ZA users were then grouped by treatment 
persistence into low (≤90 days, 178 pts), medium (91-180 days, 105 
pts) and high (>180 days, 82 pts). Calculated F/U durations were 
141.6±130 (median 96.5), 229.8±137.2 (194), 387.7±200.7 (332.5) 
days, and days to first SC were 112.1±125.1 (70), 181.9±125.9 (163), 
and 253.1±168.5 (233) days for the low, medium and high persistence 
groups, respectively. Multiple regression results indicated that low 
and medium persistence groups experienced significantly shorter F/U 
duration (27.6% and 59.9% of the high persistence group, respect-
ively). Low persistence group also had significantly higher risk to de-
velop SC than the high persistence group (HR=1.89, p<0.05). In the 
135 early ZA treated patients who developed at least 1 SC, low and 
medium persistence groups experienced more SCs (82.7% and 45.7% 
more, respectively) than high persistence group (p<0.05). Frequency 
of ZA administration decreased rapidly from 0.59 and 0.71 to 0.33 
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and 0.66 treatments per person per month by the end of first year for 
low and medium persistence groups, respectively. 
Conclusion: Time of initiating zoledronic acid in patients with bone 
metastasis involvement prior to skeletal complication development 
makes a significant difference in patients’ outcomes with the earlier 
treated patients experiencing risk reduction in skeletal complica-
tions. Persistence on zoledronic acid labeling dose of one injection 
every 3-4 weeks significantly contributed to the achievement of better 
outcomes.
PD2.1.4 Oncology Nursing, Supportive Care and Patient Advocacy, Sat, 14:30 - 16:00
Hormonal changes in women on erlotinib
Patel, Jyoti D.; LaCouture, Mario; Dunaif, Andrea; Rademaker, 
Alfred
Northwestern University, Chicago, IL, USA
The EGFR tyrosine kinase inhibitor, erlotinib, has single agent 
activity against advanced NSCLC. A subset of patients who derive 
substantial benefit from this drug has been partially defined, by clin-
ical characteristics such as never smoking history and adenocarcin-
oma histology and by molecular characteristics such are somatic 
activating EGFR mutations and increased gene copy number. In this 
group of patients with sensitivity to erlotinib, tumor regression can 
be dramatic and durable. As a result, some patients will remain on 
erlotinib for many months and occasionally even years. Common 
toxicities secondary to erlotinib include acneiform rash, xerosis, and 
diarrhea. We have noted a novel constellation of toxicities in some 
women with prolonged disease stabilization on erlotinib. Patients 
may complain of hirsutism, acne, androgenic alopecia and truncal 
weight gain; findings that are similar to those found in syndromes 
of androgen excess. We sought to evaluate a cohort of women with 
these symptoms for increased androgen levels and markers of insulin 
resistance to test the hypothesis that erlotinib may increase androgen 
production and/or induce insulin resistance in this pilot study. Inclu-
sion criteria included: advanced NSCLC, daily erlotinib for greater 
than 3 months, and female sex who had experienced hirsutism, acne, 
androgenic alopecia, amenorrhea, truncal weight gain or other clinic 
phenotype associated with syndrome of androgen excess. Patients 
were identified in Oncology or Dermatology Clinics and then under-
went 1. evaluation by Dermatology for hirsutism, rash, and alopecia, 
2. Polycystic Ovarian Syndrome Questionnaire, and 3. fasting blood 
sample for sex hormones, insulin and glucose. 
Results: 10 patients were enrolled between 12/07 and 4/08 with 
median age 56.5 years (range 37-68), median BMI was 24.2, (range 
19.5-29.9), median duration of erlotinib therapy 13 months (range 
3-29 months). All patients had experienced alopecia, and 4 patients 
had severe androgenic alopecia. All patients had experienced signifi-
cant hirsutism, and 7 patients had severe hirsutism on chest, chin and 
upper lip. No patient had a diagnosis of diabetes prior to initiation of 
erlotinib, but 4 patients developed fasting glucose >100 (median 98, 
range 110-125), 2 patients had elevated levels of insulin >20 (median 
13.5, range 4.6 – 34.4). No patient had increased levels of biologic-
ally active testosterone (median 3.84, range 2.03 to 9.33). Insulin 
resistance may be associated with EGFR tyrosine kinase inhibitor 
therapy and could lead to other metabolic derangements. Efforts to 
minimize these toxicities should be studied as some patients experi-
ence durable responses to this class of drugs. We plan to prospect-
ively study another cohort of women and include waist circumference 
measurements, blood pressure assessments and serum levels of lipids 
to further define the metabolic effects of erlotinib. 
PD2.1.5 Oncology Nursing, Supportive Care and Patient Advocacy, Sat, 14:30 - 16:00
The utilization of pain medications and the attitudes of 
lung cancer patients towards pain intervention
Simone, Charles B.1, 2; Vapiwala, Neha2; Hampshire, Margaret K.2; 
Metz, James M.2
1 National Cancer Institute, National Institutes of Health, Bethesda, 
MD, USA; 2 Hospital of the University of Pennsylvania, Philadelphia, 
PA, USA
Background: Pain is a common symptom among lung cancer 
patients. Patients can suffer from pain directly from their disease 
or from standard cancer treatment modalities, including surgery, 
chemotherapy, and radiation. Despite this, studies have shown that 
many patients receive inadequate medical management for their pain. 
Currently, there are little data quantifying pain medication utilization 
among lung cancer patients or reasons that lung cancer patients fail 
to receive optimal analgesic treatment. This study evaluated those 
reasons and investigated the perceived causes of pain in lung cancer 
patients. 
Methods: An IRB-approved Internet-based questionnaire assessing 
patient demographics and pain symptoms was piloted with patients 
and healthcare providers and posted on the OncoLink website (http://
www.oncolink.org). OncoLink is the oldest and one of the largest can-
cer information resources on the Internet and is based at the University 
of Pennsylvania. OncoLink serves 3.9 million web pages per month 
to over 385,000 unique IP addresses. The questionnaire was held on a 
secure server and included 22 queries evaluating medication utiliza-
tion, pain control, and attitudes regarding pain medications. 
Results: Between 11/2005-7/2008, 1172 patients responded to the 
survey. This analysis specifically evaluates the 90 patients (8%) 
with lung cancer who completed the survey. Patients were pre-
dominantly Caucasian (89%) and male (54%). Histologic diagnoses 
included non-small cell lung cancer [NSCLC] (64%), lung cancer 
not otherwise specified (14%), small cell lung cancer (12%), and 
mesothelioma (9%). Respondents received surgery (48%), chemo-
therapy (58%), and radiation (44%). One-fifth of the patients (21%) 
were enrolled in a clinical trial. Over half of the respondents (52%) 
reported experiencing pain directly from their cancer. Addition-
ally, 38% of patients reported pain from their cancer treatment, and 
67% suffered pain but were unsure of the primary cause. Patients 
described their pain as chronic (52%), intermittent (28%), or acute 
(14%). Their pain was primarily thoracic (63%), in the back/spine 
(53%), or diffuse (22%). Among patients experiencing pain, 38% did 
not use medication specifically to help manage their pain. Anal-
gesic utilization was significantly less in men than women (53% vs. 
73%, p=0.05) and trended less in minorities (40% vs. 65%, p=0.13). 
Patients with mesothelioma tended to use analgesics less (38%) 
than patients with NSCLC (64%) and small cell lung cancer (64%) 
[p=0.13]. Reasons most commonly cited for not taking analgesics 
included fear of becoming addicted or dependent (76%), the health-
care provider not recommending medications (71%), and an inability 
to pay for medication (56%). Participants experiencing pain, but not 
taking analgesics, pursued physical therapy (79%) or other alternative 
measure (21%) for pain control.
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Conclusions: Many lung cancer patients perceive pain from both 
their disease and their cancer treatment. However, many patients 
in this study did not seek analgesic intervention due to concerns 
of addiction, cost, or their healthcare provider not discussing pain 
medications. Some patients utilized complementary therapies to 
control pain. Healthcare providers should make pain management a 
priority and regularly have open discussions with patients regarding 
pain symptoms and treatment. Further study is needed to evaluate 
pain symptoms and analgesic utilization based on lung cancer type, 
treatment received, and stage of disease.
PD2.1.6 Oncology Nursing, Supportive Care and Patient Advocacy, Sat, 14:30 - 16:00
Association of comorbidity score with survival of lung 
cancer
Marr, Alissa; Siedlik, Emily; Loberiza, Fausto; Kessinger, Margaret; 
Ganti, Apar
UNMC, Omaha, NE, USA
Background: The Charlson Cormorbidity Index (CCI)1 was de-
veloped to help predict mortality from chronic medical conditions. 
Factors affecting survival of patients with lung cancer include stage 
of disease and presence of other co-morbid conditions. Treatment 
decision-making for individual patients based on co-morbid condi-
tions, although vital, is difficult. Whether CCI predicts for outcomes 
in lung cancer is unknown. The objective of this study was to evalu-
ate whether CCI is correlated with overall survival in lung cancer. 
Methods: A retrospective chart review was conducted on 617 
patients with lung cancer diagnosed between 1994 and 2007 at the 
University of Nebraska Medical Center. CCI was estimated for each 
patient. In order to evaluate the effect of co-morbid conditions other 
than an advanced age, CCI after excluding age as a parameter was 
calculated. Multivariate Cox proportional hazards regression analysis 
was used for the analysis. Co-morbidity score with or without age 
forced into the model building. Results were adjusted for relevant co-
variates (gender, smoking history/pack years, family history of lung 
cancer, histopathologic classification, stage at diagnosis, and type of 
initial treatment).
Results: Initial data was collected on 617 patients; 6 patients were 
excluded from the final analysis secondary to missing outcome or 
comorbidity data. Multivariate Cox proportional hazards regression 
analysis was conducted on 611 patients. The median age at diagnosis 
was 64 years (range: 16-89). The majority of patients (89%) had a 
personal history of smoking. Five hundred fourteen patients (84%) 
had non-small cell lung cancer (40% adenocarcinoma, 18% squa-
mous cell carcinoma) and ninety-seven patients (16%) had small cell 
lung cancer. At initial diagnosis, 47% of patients (n=287) with non-
small cell lung cancer had stage IV disease. When age was excluded 
from the comorbidity score, the majority of patients (50%) had a 
score of zero, and 48 patients (8%) had a score of ≥3. On multivariate 
analysis, CCI was not associated with an increased risk of death.
Conclusion: CCI did not demonstrate predictive validity in determin-
ing prognosis for persons with lung cancer patients. Further studies 
are needed to develop an accurate and predictive prognostic model 
for lung cancer patients to help estimate an individual patient’s 
prognosis.
1 Charlson ME, et al. A new method of classifying prognostic comorbidity in longitu-
dinal studies: development and validation. J Chronic Dis 1987;40:373-383.
 Variable Relative Risk of Death*  p-value 
  (95% Confidence Interval)
 Total Charlson Comorbidity Score with Age  
 0 (n=51) 1.00 
 1-2 (n=241) 1.29 (0.57 - 2.89) 0.54
 3 (n=139) 1.38 (0.60 - 3.19) 0.45
 4 (n=104) 1.11 (0.46 - 2.69) 0.82
 ≥5 (n=76) 1.37 (0.52 - 3.62) 0.53
 Total Charlson Comorbidity Score without Age  
 0 (n=305) 1.00 
 1 (n=151) 1.14 (0.75 - 1.72) 0.54
 2 (n=107) 0.86 (0.52 - 1.43 0.57
 ≥3 (n=48) 0.61 (0.24 - 1.56) 0.30
 * Models adjusted for histopathology type, stage at diagnosis, and smoking/pack yr history
PD2.1.7 Oncology Nursing, Supportive Care and Patient Advocacy, Sat, 14:30 - 16:00
What should a support program for people with lung 
cancer look like? Differing attitudes of patients and 
support group facilitators
Mileshkin, Linda R.1, 2; Devitt, Bianca1; Hatton, Allison1; Baravelli, 
Carl 1; Schofield, Penelope1, 2; Jefford, Michael1, 2, 3
1 Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; 
2 Faculty of Medicine, Dentistry and Health Sciences. The University 
of Melbourne, Melbourne, Australia; 3 The Cancer Council Victoria, 
Melbourne, Australia
Introduction: Compared with other cancer types, people with lung 
cancer have higher levels of unmet needs and greater psychological 
distress. However, uptake of available community-based support ser-
vices by those with lung cancer is low. We aimed to explore this issue 
by seeking the views of both patients with lung cancer and existing 
cancer support group facilitators.
Methods: Two purpose-built questionnaires were developed and ad-
ministered to a convenience sample of patients with lung cancer and 
facilitators of all cancer support groups registered with the Cancer 
Council Victoria, Australia (n = 145). Patients were required to have 
a current or previous diagnosis of lung cancer and sufficient English 
to complete the survey. Respondents were asked about preferred con-
tent, location, running and potential barriers to attendance of a lung 
cancer support program.
Results: The response rate was 58% (n = 101) for the patient ques-
tionnaires and 51% (n = 74) for the facilitator questionnaires, with 
35% of the facilitators recalling a patient with lung cancer attend 
their group (median total number = 3 patients, range 1-8). Facilitators 
were health professionals (42%), cancer survivors (35%) and volun-
teers (23%), with 51% having prior facilitator training. Fifty-three 
percent of patients reported willingness to attend a support program 
that suited their needs, although only 12% had previously attended 
an existing support group. Both patients and facilitators agreed that 
any group should be small and content include information about 
treatments, side-effects and self-care strategies. Facilitators preferred 
a program to be run in a community hall, led by a cancer survivor and 
predominantly focus on social and emotional support. In contrast, pa-
tients preferred a program to be run in a hospital and led by a health 
professional, with sessions primarily focussed on cancer informa-
tion and self-care strategies rather than emotional support. Overall 
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patients perceived fewer barriers to attendance than facilitators. Both 
agreed that a group environment, feeling unwell, having to talk about 
their lung cancer, parking and travel were barriers to attendance.
Conclusions: Significant discrepancies exist between the views of 
patients and facilitators about what is needed in a support program for 
patients with lung cancer. These results may in part explain the poor 
uptake of existing support programs by patients with lung cancer, and 
should be considered in the design of future programs. 
PD2.1.8 Oncology Nursing, Supportive Care and Patient Advocacy, Sat, 14:30 - 16:00
Evaluation of Edmonton symptoms assessment scale 
(ESAS) as symptoms improvement (SI) assessment in 
advanced lung cancer patients (pts): an observational 
prospective study
Gamucci, Teresa1; Narducci, Filomena1; Sperduti, Isabella2; 
Mentuccia, Lucia1; Giampaolo, Maria anna1; Trapasso, Tiziana1; 
Cianci, Giovanni1
1 SS Trinità Hospital, Sora (FR), Italy; 2 Regina Elena National 
Cancer Institute, Rome, Italy
Background: ESAS is a validated tool for physical symptoms assess-
ment in palliative care (PC) clinical practice which evaluates main 
symptoms through a numeric scale ranging from 0 to 10. The magni-
tude of SI is still under investigation and the use of SI as a prognostic 
factor is controversial. To this purpose, an observational prospective 
study in advanced lung cancer pts treated with chemotherapy (CT) 
plus PC or only PC was conducted.
Methods: Pts with lung cancer admitted to our department from 
January 2007 to January 2008 to receive chemotherapy and sup-
portive care or to receive only supportive care were considered for 
the study .Pts who received only supportive therapy and no longer 
susceptible to chemotherapy were evaluated for the multivariate 
analysis. 
Pts were scheduled to undergo ESAS assessment: 1) at the hospi-
talization time-point (TH); 2) at the hospital discharge time-point 
(TD). Symptoms’ scores were divided into 3 severity-classes (SC): 
mild (0-3, MI), moderate (4-6, MO) and severe (≥7, S). Differences 
across symptoms’ classes between TH and TD were analyzed with 
the paired-data McNemar-test. Kaplan-Meier method was used for 
overall/median survival calculation, according to ESAS score classes, 
and logrank test for curves comparison. Uni/multi-variate survival 
analysis including age, sex, symptoms number, symptoms’ score 
class, PaP score (Palliative Prognostic score), KPS, were carried out 
using the Cox regression model. 
Results: ESAS was administered to 101 lung cancer pts: median 
age 68 yrs (range 39-81), KPS ≤50/>50: 28 (27.8 %)/ 73 (72.3%), 
PaP-score A/B+C: 51 (52.5%)/50 (47.5%). 75 pts were susceptible 
to receive CT + PC and 26 were no longer able to receive any active 
anticancer treatment. A statistically significant reduction of S-SC 
rates was observed in the total of the pts as well as in the 26 pts no 
more suitable of chemotherapy treatment, as shown in the table:
In the multivariate analysis SI correlates with survival improvement: 
asthenia is the only significant variable (HR 5.11 CI 95% 1.86-14.03, 
p=.0.002) for NSCLC pts.
 pts Symptons TH TD p
 NSCLC (total) Pain 31.7% 5.0% <0.0001
  Asthenia 50.5% 37.6% 0.05
  Dyspnoea 43.6% 21.8% <0.0001
 NSCLC (Only PC) Pain 37.9% 3.4% <0.0001
  Asthenia 72.4% 62.1% 0.39
  Dyspnoea 58.6% 27.6% 0.001
Conclusions: The supportive care results in a significant improve-
ment of symptoms in patients with lung cancer and in particular 
SI, according to ESAS, after PC treatment represents an important 
prognostic factor for survival in pts no longer suitable to receive any 
anticancer active therapies
PD2.2.1 Oncology Nursing, Supportive Care and Patient Advocacy, Sat, 14:30 - 16:00
Nutritional risk screening predicts tumor response in lung 
cancer patients
Tomiskova, Marcela1; Tomiska, Miroslav2; Illa, Petr1; Skrickova, 
Jana1; Buresova, Lucie 3
1 Department of TB and Respiratory Diseases, Brno, Czech 
Republic; 2 Dept. of Internal Medicine, Masaryk University, Brno, 
Czech Republic; 3 Institute of Biostatistic and Analysis Institute 
of Biostatistic and Analysis, Faculty of Natural Science, Masaryk 
University, Brno, Czech Republic
Background: Malnutrition in cancer patients may be associated 
with poor tolerance of chemotherapy and lower response rate after 
oncological treatment.
Methods: Nutritional Risk Screening 2002 (NRS) adapted for 
oncological patients was used to assess the risk of undernutrition in 
the group of 187 lung cancer patients. The risk was evaluated on the 
6-point scale according to common signs of nutritional status (weight 
loss, BMI and dietary intake) and tumor and its treatment risk factors. 
The score 3 and more means significant risk of poor outcome.
Results: There were 132 men and 55 women, mean age of 64.9 years. 
Tumor stages from I to IV were classified in 10.6 %, 4.3 %, 33.7 % 
and 48.7 % patients, respectively. Non small cell lung cancer was 
diagnosed in 65.3 % and small cell lung cancer in 27.8 % of patients. 
Deterioration of nutritional status was only mild in most patients with 
median BMI 25.4 Kg/m2 and median weight loss before treatment 5.4 
%. Acceptable NRS score of 0-2 points was found in 50.5 %, while in 
44.6 % the 3-5 score suggested the risk of malnutrion. 
The rate of treatment response evaluated by imaging techniques was 
significantly higher in patients with acceptable compared to high risk, 
65.2 % versus 27.5 %, respectively (p=0.005). In patients with the 
highest NRS (4-5 points) response rate was only 11.3 % (p<0.001).
Unexpectedly, the toxicity of anticancer treatment was not signifi-
cantly different between the subgroups with median toxicity on the 
0-4 point scale 1.5 in patients with higher compared to 1.2 in lower 
NRS score group (p=0.237).
Overall survival rate evaluated by 75th percentile was significantly 
higher in lower risk patients, 7.7 compared to 3.1 months in high 
nutritional risk patients, p=0.002.
Conclusion: Nutritional risk screening is a significant predictor of 
tumor response in lung cancer patients. Worse response in patients 
with higher risk of undernutrition is probably not caused by higher 
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toxicity of anticancer therapy with subsequent dose reduction or de-
lay of treatment. The question remains whether concurrent nutrition 
support has the potential to improve tumor response in patients with 
high risk of undernutrition.
PD2.2.2 Oncology Nursing, Supportive Care and Patient Advocacy, Sat, 14:30 - 16:00
Impact of hypertension and ischemic heart disease (HD) 
without or with diabetes mellitus (DM) on cisplatin (CP) 
nephrotoxocity
Mathe, Csaba1; Bohacs, Aniko1; Duffek, Laszlo 2; Magyar, Pal 1; 
Losonczy, Gyorgy 1
1 Semmelweis University Dept. of Pulmonology, Budapest, Hungary; 
2 Semmelweis University Dept. of Oncotherapy and Radiology, 
Budapest, Hungary
Nephrotoxicity of CP is well known and powerful isosmotic hydra-
tion of the extracellular space is the only routinly available method 
of renal protection. Pre-CP hydration must be large enough for the 
induction of a saline diuresis >100 mL/hour (>2.4 L/day) by the time 
CP infusion is started. CP nephrotoxicity has remained unaccept-
ably high and although urine volume has not been controlled, serum 
creatinine (Cr) and blood urea nitrogen (BUN) within reference 
ranges are always fulfilled as enrollment criteria. We have compared 
the course of Cr and BUN among CP treated lung cancer patients 
suffering from neither DM nor HD (group I, n=80) with those who 
suffered from DM (group II, n=52) or HD (group III, n=110). Patient 
groups were sex- and age-matched and CP dose (per body surface 
area) was also similar in the three groups. In group I the highest 
post-treatment Cr concentration was 93.4±5.3 mmol/L vs 121.3±4.7 
in group II and 117.0±7.7 in group III (p<0.05 between group I vs 
both groups II and III). CP had to be omitted from later courses of 
chemotherapy in groups II and III, but never in group I. Since normal 
Cr and BUN did not predict nephrotoxicity of CP, in an other group 
of 11 untreated lung cancer patients with normal Cr and BUN, glom-
erular filtration rate (GFR) was estimaled with the measurement of 
99mTc-DTPA (dietlyenetriamine pentaacetate) clearance. In patients 
developing no post-CP azotaemia (highest Cr=80±18 mmol/L) 
pretreatment GFR was 61.3±10.1 mL/min/m2 vs 50.7±6.2 in those, 
whose Cr increased to 169±53 (p<0.05). These results indicate that 
frequent comorbidities as DM and HD are not rarely associated with 
increased nephrotoxicity of CP, which may be predicted by reduced 
GFR but not Cr or BUN. 
PD2.2.3 Oncology Nursing, Supportive Care and Patient Advocacy, Sat, 14:30 - 16:00
A nationwide survey on hydration regimens in 
cisplatinum-based chemotherapy in Dutch hospitals: large 
variations in a small country
van den Hurk, D.G.M.; Timmer-Bonte, J.N.H.; Schonenberg-van 
Tits, H.W.A.; Dernison, J.H.M.; van der Drift, M.A.
Radboud University Nijmegen Medical Centre, Nijmegen, 
Netherlands
Introduction: Cisplatinum is still the cornerstone of systemic 
treatment in thoracic oncology. Cisplatinum-induced nephrotox-
icity is an important side effect which can be reduced by applying 
hyperhydration. The optimal hydration schedule is not known and 
various schedules are being used. Prior research demonstrated that 
monitoring hyperhydration by means of weight can safely replace 
monitoring urinary output and body fluid balance [Mank et al. 2003]. 
We performed a nationwide survey to explore how hyperhydration is 
carried out and monitored in all Dutch hospitals (n=101).
Method: A questionnaire was sent to nurses with a minimum of two 
years of working experience at a lung- and/or oncology ward where 
chemotherapy is administered. Therefore, one hospital could receive 
two questionnaires. Questions aimed at the type and quantity of 
infusion fluids, infusion time, concomitant medications and patient 
monitoring during hyperhydration. Analysis was performed by using 
descriptive statistics.
Results: The response rate was 72% (91 of 127 questionnaires) cov-
ering 75% of all hospitals (75 of 101). Cisplatinum is administered in 
normal saline in 62% (21% used NaCl 3%) over 3 hours (hrs) (range 
1 – 4 hrs). In a vast majority (81%) the hydration schedule includes 
an overnight stay. Prehydration and posthydration consisted usually 
of 1 L (range 0-4 L) in 2-4 hours (range 1-24 hrs) and 3 L (range 1-6 
L) in 12-16 hrs (range 2-24 hrs), respectively. In 69% normal saline 
was used, whereas 34% used Gluc 2,5%/NaCl 0,9%. Fluid retention 
was monitored by weight (before, during and after hyperhydration) 
in almost all hospitals (97% of respondents). However, 23% measure 
urinary output and 39% monitors both in- and output. Almost all 
(92,3%) used furosemide in case of fluid retention. A wide range of 
electrolyte supplementation is being used: i.e magnesium in a range 
of 1000 - 10.000 mg and potassium in a range of 20 – 120 mmol.
Conclusion: Due to the high response rate to this survey, a repre-
sentative overview was obtained of cisplatinum-hydration regimens 
used in the Netherlands. Still, after several decades of cisplatinum-
treatment an evidence based optimal hydration schedule is lacking, 
leading to large variations. Further research is necessary in order to 
develop shorter and more convenient hydration schedules, making 
cisplatinum-based chemotherapy available as out-patient treatment.
Finally, this survey demonstrated that, despite earlier reports about 
safely monitoring hyperhydration by means of weight, still 39% of 
the nurses are exposed to chemotherapy-contaminated urine unneces-
sary. 
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Priority health needs for patients receiving concurrent 
chemotherapy and radiation for stage III non-small 
cell lung cancer and impact of the role of the advanced 
practice nurse (APN)
Martelli-Reid, Lorraine1, 2; Bryant-Lukosius, Denise1, 2; Arnold, 
Andrew1, 2; Ellis, Peter1, 2; Goffin, John1, 2; Okawara, Gordon1, 2; 
Hapke, Sally1; Akhtar-Danesh, Noori2
1 Juravinski Cancer Centre, Hamilton, ON, Canada; 2 McMaster 
University, Hamilton, ON, Canada
Background: Non-small cell lung cancer (NSCLC) accounts for 
75% of all lung cancers and is frequently diagnosed at an advanced 
stage. The use of combination chemotherapy and radiation has led 
to significant treatment advances in unresectable, locally advanced 
NSCLC. Cancer Care Ontario’s provincial practice guidelines for 
unresected stage III NSCLC recommend combined modality treat-
ment with cisplatin-based chemotherapy and 60 Gy in 30 fractions 
of radiation for patients with a good performance status (ECOG 0 or 
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1) and minimal weight loss (<5% in preceding 3 months). Multiple 
studies involving a variety of high risk patient populations have dem-
onstrated that improved patient health, improved coordination and 
continuity of care, appropriate use of health services, and decreased 
health care costs occur when Advanced Practice Nursing (APN) roles 
are designed to address unmet patient health needs and gaps in how 
health care services are organized and delivered. 
Methods: A descriptive prospective study design was used to 
complete the comprehensive needs assessment by surveying patient 
health needs and use of health resources prior to, during, and follow-
ing concurrent therapy. Supportive care health needs were assessed 
at various time points utilizing the Memorial Symptom Assessment 
Scale (MSAS), The Supportive Care Cancer Needs Scale Short Form-
34 (SCNS-SF34), The Functional Assessment of Cancer Therapy-
Lung Cancer (FACT-L), and a patient perception single question of 
priority needs. Use of health services was assessed using the Health 
Service Utilization Inventory (HSUI).
Results: This poster will report the results of patient health needs 
and use of health resources prior to, during, and following concurrent 
therapy and how the introduction of the APN to the model of care 
delivery has impacted deliverability and tolerability of concurrent 
treatment.
Conclusions: The results will aid the development and evaluation of 
an advanced practice nursing (APN) role and interdisciplinary model 
of care delivery designed to address unmet health needs and service 
priorities for this vulnerable patient population
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Clinical outcome of pericardial drainage alone group 
in non-small cell lung cancer (NSCLC) patients with 
malignant pericardial effusion in the modern era of 
chemotherapy 
Rhee, Jiyoung1; Kim, Yu Jung 2; Lee, Keun-Wook 2; Kim, Jee Hyun 
2; Lee, Se-Hoon 1; Kim, Dong-Wan 1; Heo, Dae Seog 1; Lee, Jong 
Seok 2
1 Seoul National University Hospital, Seoul, Korea; 2 Seoul National 
University Bundang Hospital, Seongnam Si, Korea
Background: Symptomatic malignant pericardial effusion is a life 
threatening complication that warrants immediate intervention for 
drainage of pericardial effusion such as pericardiocentesis. However, 
in NSCLC patients, the standard management for the prevention of 
fluid re-accumulation after pericardial drainage is not established 
yet. We investigated clinical outcome of NSCLC patients who had 
symptomatic malignant pericardial effusion and received pericardial 
drainage alone.
Methods: Medical records were reviewed from NSCLC patients 
underwent echo-guided percutaneous pericardiocentesis and tube 
drainage for treatment of initial symptomatic malignant pericardial 
effusion in Seoul National University Hospital or Seoul National Uni-
versity Bundang Hospital between March 2002 and May 2008. 
Result: A total 44 patients were included in the study. The median 
age was 58 years (range, 31-75 yrs) and 16 patients (36.4%) were 
female. Thirty patients (68.2%) received palliative systemic chemo-
therapy prior to having symptomatic pericardial effusion. The 
median duration of follow-up was 35.6 months (range, 1-79 months). 
Twenty-seven patients (61.4%) received systemic chemotherapy after 
pericardial drainage. Only six patients (13.6%) had relapse of symp-
tomatic malignant pericardial effusion. The median time to relapse of 
pericardial effusion was 98 days (time to relapse of each patient, 3, 
31, 98, 222, 263 and 900 days). Among 6 patients, 5 patients received 
surgical treatment (pericardial window) and 1 patient received peri-
cardial sclerotherapy. The median overall survival (calculated from 
the date of diagnosis of NSCLC to the date of death) was significant-
ly longer among patients with relapse of symptomatic pericardial ef-
fusion compared with patients without it (60.9months vs. 16months, 
respectively; p=0.006). The patients with relapse of pericardial 
effusion were related female and younger age (<65 years), favorable 
prognostic factors of NSCLC (p= 0.018 and 0.067, respectively). 
Conclusion: Among NSCLC patients underwent pericardial drain-
age alone for treatment of initial symptomatic malignant pericardial 
effusion, only a small number of the patients had relapse of it. Thus, 
necessity of pericardial sclerosis or surgical treatment for preventing 
recurrent pericardial effusion needs to be reevaluated.
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Photodynamic therapy in patients with malignant pleural 
effusion
Sokolov, Victor V.; Pikin, Oleg V.; Filonenko, Elena V.; Vursol, 
Dmitriy A.; Sukhin, Dmitriy G.; Mironenko, Dmitriy E.
Moscow Gertsen Cancer Research Institute, Moscow, Russia
Background: Malignant pleural effusion is a very common clinical 
manifestation of different neoplasms. Treatment of patients with pri-
mary (mesothelioma) and metastatic pleural spread is mostly pallia-
tive. The study was aimed to evaluate the effectiveness of intrapleural 
photodynamic therapy (PDT) as a method of pleurodesis in patients 
with malignant pleural effusion.
Methods: 120 patients with malignant pleural effusion were enrolled 
in controlled non-randomized study. 60 patients (control group) 
were treated by intrapleural administration of bleomycin (60 units 
diluted in 100 ml of 0.9% saline solution) through a chest tube and 60 
patients (PDT group) were treated by prolonged intrapleural photo-
dynamic therapy through 4-6 diffusers introduced into pleural cavity 
under local anesthesia or via thoracoscopy. “Photosense” (20 mg 
diluted in 100 ml of 0.9% saline solution) was administered through a 
chest tube 2 – 3 hours before PDT. Five courses of prolonged photo-
dynamic therapy were performed to each patient postoperatively in 
24 hours interval. Active suction systems were used in both groups 
to evacuate effusion. Chest tube drainage was removed when daily 
output was less than 100 ml.
Results: Complications or adverse effects of pleurodesis were regis-
tered in 38,6% of patients in control group and in 21,7% of patients in 
PDT group. Pleurodesis was effective in 80,0% of cases in bleomycin 
group versus 93,3% in FDT group (p<0,05). We did not register the 
recurrence of pleural effusion in PDT group during 12 months follow 
up, while there was 20,0% recurrence rate in control group.
Conclusions: Photodynamic therapy of malignant pleural effusion is 
an effective method of pleurodesis, permits to achieve good short-
term results and improve quality of life in that complex group of 
patients.
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Perspective study analysis of quality of life and efficacy 
of pleurodesis by uniportal access video-assisted-
thoracoscopy for malignant pleural effusions
Giudice, Gabriella; Lequaglie, Cosimo; Marasco, Rita Daniela; 
Garramone, Margherita
National Cancer Institute Rionero in Vulture, Rionero in Vulture, Italy
Purpose of this study was to determine the safety and long and 
medium term efficacy of pleurodesis by video-assisted-thoracoscopic 
(VATS) talc poudrage, as well as its impact on the respiratory func-
tion and therefore on the quality of life of the patients with the patient 
grade of benefit.
The clinical data collected in this perspective study originate from the 
record-charts of the Department of Thoracic Surgical Oncology of the 
National Cancer Institute of Rionero in Vulture, Italy.
From March 2006 to December 2008 100 evaluable cases were in-
cluded (58 males and 42 females; age range 29-85 years old) on 116 
consecutive cancer patients affected from malignant pleural effusion. 
We excluded 7 cases because entrapped lung after thoracentesis, 5 for 
poor performance status and the remainders 4 had a slurry talcage by 
chest drainage.
Lung cancer was the most frequent primary tumor (54 patients) 
followed by breast cancer recurrences (28 patients); moreover, there 
were 5 from malignant pleural mesothelioma (MPM), 4 from ovarian 
cancer, 2 from colic adenocarcinoma, 1 from parotidean carcinoma, 1 
from pharyngeal cancer, 3 from no-Hodgkin lymphoma, 2 from pan-
creatic adenocarcinoma. Twenty-six patients (26%) had previously 
treated for recurrent pleural effusion.
The disease diagnosis interval and the talc poudrage has been an 
average of 4.8 weeks with a range between 1 and 24 weeks.
In 14 cases, for the clinical conditions, we performed the VATS by 
mask anesthesia.
Uniportal access was employed in 84 VATS procedures (84%), 2 
accesses in the remaining 16 cases (16%). Ten pericardial windows 
were performed for cardiac tamponade. Steril talc was used for chem-
ical pleurodesis in 8 g dosage.
All the patients underwent pre and post-operatively chest X-ray, pul-
monary functional tests, blood gas analyses, and requested the grade 
of benefit after pleurodesis procedure.
The effusion was evacuated (media 1580 cc) with a range between 
200-5.000 cc in all 100 patients. There were no-surgical neither aller-
gic VATS related complications. In 2 MPM patients occurred locally 
cutaneous metastases after 30-45 days from procedure. 
The mean hospital stay was 4.5 days (range: 2-12 days).
The blood gas analysis pre-talc poudrage had shown a mean con-
centration of O2 of 72.1 mmHg (range: 42-90 mmHg) while the CO2 
mean was of 42.8 mmHg (range: 31.1-58 mmHg). After the treatment 
the O2 has been climbed little: 74.2 mmHg (range: 51-90.1 mmHg) 
while the CO2 has gone down to 39.2 mmHg (range: 31.4-48.1) more 
acceptable. 
The pre-operative FEV1 mean was 0.862 L/min but post-operative 
mean of 1.187 L/min.
Ninety patients (90%) referred grave dyspnoea before the VATS 
procedure; after, 84 patients (93,3%) referred important improving 
of symptoms but for 6 ones. In the 10 patients with moderate pre-
operative dyspnoea, it disappeared in 4 cases, it became mild in 4, 
no benefit in 1 and it was reported worsening in the last one (table1; 
Grade of benefit of the patient after VATS talc poudrage)
The patient’s percentage of free pleural effusion was after 1 month 
92.4 %, after 6 months it was 91.1 % and after 1 year it was 75,1%. 
The pleurodesis with talc in VATS gives sure positive results in 
malignant pleural effusions; it is few traumatic and executable even 
by local anesthesia and it improves above all the respiratory function 
and, therefore, the quality of life.
 Initial Symptom N° of patients Mild Moderate Important No benefit Worsening
 Grave dyspnoea  90  3 3 84 - -
 Moderate dyspnoea 10 4 - 4 1 1
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Injection laryngoplasty in oncology patients
Kupferman, Michael E.; Acevedo, Jason L.; Hutcheson, Kate A.; 
Lewin, Jan S.
UT M D Anderson Cancer Center, Houston, TX, USA
Objective: To examine the outcomes of office-based management of 
laryngeal dysfunction in oncology patients
Methods: A retrospective chart review was performed at a tertiary 
care cancer center, consisting of oncology patients referred to the 
Head and Neck Surgery clinic. Patients that underwent office-based, 
fiberoptic guided trans-cervical injection laryngoplasty were selected. 
All injections were performed by a single surgeon. Subjective out-
come measures, objective voice analysis parameters (fundamental 
frequency, noise to signal ratio, and mean phonation time) and swal-
lowing studies.
Results: 43 patients underwent injection laryngoplasty, with 31 hav-
ing at least one follow up visit. Adenocarcinoma of the lung was the 
most common cancer diagnosis (19.4%), and 50% of patients were 
patients with thoracic malignancies. Five patients (16.2%) required a 
secondary injection, and only two (6.5%) went on to medializiation 
thyroplasty. In patients with pre- and post-operative voice analysis 
(n=9), mean phonation time (MPT) increased from 5.94 seconds 
to 14.5 seconds, an increase of 243%. 85.7% of patients reported 
subjective improvement after injection. Of patients with pre-injection 
aspiration symptoms, 71.4%, no longer required a modified diet.
Conclusions: Interventions to improve the quality of life in oncol-
ogy patients is an evolving field. We report significant improvements 
in both subjective and objective measures of function. The majority 
of patients experienced immediate and sustained increases in vocal 
function. MPT more than doubled in patients in whom it data was 
available. We conclude that injection laryngoplasty is a safe and effi-
cacious procedure for the treatment of unilateral vocal cord dysfunc-
tion in oncology patients, resulting in palliation and improved quality 
of life. 
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A retrospective review of healthcare disparities among 
patients with lung cancer
Snell, Michael; Choi, Cecilia; Gula, Teresa; Subbiah, Shanmuga; 
Janakiram, Murali; Birdi, Shefali
MetroHealth Medical Center, Cleveland, OH, USA
Background: Inadequate access to health care is a rapidly growing 
problem in the United States. Those with low income are especially 
vulnerable, due to poor health care benefits and inability to afford pri-
vate insurance. In addition, due to financial concerns, these patients 
often delay seeking medical advice, thereby presenting at a higher 
cancer stage, and are non-adherent with treatment. 
The mission of MetroHealth Medical Center, the Cuyahoga county 
hospital, is to provide excellent health care to all individuals, regard-
less of their ability to pay. Along with financial and social staff to 
assist the large number of uninsured and under-insured patients in 
obtaining access to Medicare and Medicaid benefits, MetroHealth 
employs a unique rating system to assess patients’ financial needs in a 
timely manner and provide appropriate assistance. 
Our primary objective was to evaluate whether a lack of adequate 
health insurance significantly delayed the time to diagnosis and treat-
ment of patients with lung cancer. 
Methods: Patients with lung cancer, diagnosed between 1999 and 
2008, were identified using the computerized Tumor Registry Board 
at our institution. We retrospectively compared the diagnostic interval 
(time from presentation to a medical provider, with a symptom or 
finding clearly related to malignancy, until diagnosis) and the treat-
ment interval (time from diagnosis to treatment) in patients with and 
without insurance. We also considered covariates of age, sex, race 
and patient adherence (as measured by the number of “no show” ap-
pointments in the diagnostic and treatment intervals).
Results: Of nearly 1000 patients screened, 635 were identified for 
whom the relevant time intervals and covariates could be determined. 
Approximately 80 percent of the patients had advanced disease (stage 
III or IV) at presentation. Kaplan-Meier curves were constructed 
to compare subgroups based on insurance status, age, race, sex and 
patient adherence. 
In evaluating the diagnostic interval, we found no significant dif-
ference between insured and uninsured patient (median time to 
diagnosis: 14 vs 16 days, p = 0.09). This was also true when patients 
were evaluated by type of insurance (none vs private vs Medicare vs 
Medicaid; p=0.95) and by private insurance vs all others (p=0.30).
Using Cox proportional hazards models, a significant correlation was 
found between patient non-adherence and diagnostic interval (p < 
0.0001, HR = 0.70), but the other covariates did not significantly af-
fect the time to diagnosis (age: p=0.64, race: p=0.37, sex: p=0.61). 
Similar multivariate analysis was done for the treatment interval. 
It was found that only age (p=0.01, HR=0.988) and non-adherence 
(p<0.0001, HR=0.682) were significant predictors of time to treat-
ment. Sex (p=0.09), race (p=0.48) and insurance status (p=0.28) did 
not affect the treatment interval. 
Conclusion: The financial evaluation and assistance system em-
ployed at MetroHealth Medical Center allows patients to receive 
rapid access to needed health care. No delays in time to diagnosis or 
treatment, related to insurance status, were observed in patients with 
lung cancer seen at this institution over a 10 year period. At a time 
when national health care reform is being contemplated, this system 
may serve as a useful model for providing health care access to indi-
viduals with varying financial means. 
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Long-term lung cancer survivors (LTLCS): analysis of 106 
patients from a medical oncology department
Palmero, Ramon1; Esteller, Laura1; Nadal, Ernest1; Brao, Isabel1; 
Saldaña, Juana1; Romeo, Margarita1; Montes, Ana1; Mesia, Ricard1; 
Arnaiz, Maria Dolores1; Moya, Juan Antonio2; Germa, Jose Ramon1; 
Cardenal, Felipe1
1 Institut Català d’Oncologia, L’Hospitalet, Spain; 2 Hospital 
Universitari de Bellvitge, L’Hospitalet, Spain
Background: Survivorship care planning is one of the ten common 
goals of the “2008 ASCO-ESMO Consensus Statement on Quality 
cancer care”. Following the latest advances in non-small cell lung 
cancer (NSCLC) (adjuvant chemotherapy [CT], concomitant chemor-
adiotherapy [CTRT]…) and small cell lung cancer treatment (SCLC) 
(hiperfractionated radiotherapy [RT], profilactic craneal irradiation) 
there is a potentially increasing number of LTLCS. But there is lim-
ited information on LTLCS care. The objective of this presentation is 
to report the clinical characteristics, cancer treatment and outcome of 
a cohort of LTLCS seen in our medical oncology department.
Methods: Since 2003, we have prospectively identified all patients 
with lung cancer who were alive at 3 years from the diagnosis. 
Demographic data, clinical characteristics, cancer treatment received 
and outcomes were collected from medical records. Comorbidities 
at diagnosis were measured with the simplified comorbidity index 
(SCS).
Results: One-hundred and six patients (p) were identified as LTLCS. 
Date of diagnosis ranged from 1992 to 2006. Baseline clinical 
characteristics were: median age was 57 years (range 33-78); gender 
(male/female) 97/9p; Karnofsky index (100-90/80-70/≤60/NA) 
56/35/0/15p; smoking status (active/former/never) 47/57/2; median 
packs/year 50 (range 6-180). Baseline comorbidities: cardiovascular 
30 (28,3%), respiratory 25 (23,5%), neoplasic 6 (5,6%), diabetes 
mellitus 11 (10,3%), renal insufficiency 2 (1,8%), alcoholism 24 
(22,6%). SCS index was (0-7/8-9/10-11/≥12/NA) in 40/49/4/11/2p. 
Baseline tumor characteristics were: histology (adenocarcinoma/
squamous/large cell/non otherwise specified/SCLC) 28/31/7/20/18p; 
NSCLC stage (I/II/IIIA/IIIB/IV) 30/8/18/28/4. SCLC stage (lim-
ited/extensive disease) 18/0. First treatment received was: surgery 
55p (51,8%), neoadjuvant CT or CTRT 11p (10,4%), adjuvant CT 
13p (12,2%), postoperative RT 10p (9,4%), thoracic RT 4p (3,7%), 
sequential CTRT 11p (10,4%), concomitant CTRT 35p (33%), or 
paliative CT 1p. Platinum-based CT was administered in 62p and 
non-platinum CT in 8p. Median follow-up was 6,3 years. At the time 
of this analysis, 20p had relapsed/progressed, 11 locoregionally and 
9 at distance sites, with a median time to event of 20 months (range 
3 - 63) from diagnosis. Only 7p have died, 4 due to lung cancer and 3 
due to second cancer. Twelve p (11,3%) developed second cancers (5 
lung cancers), after a median time of 5,6 years (range 2,3 - 8,6) from 
lung cancer diagnosis.
Conclusions: In our cohort, LTLCS were young, almost all of them 
have been smokers, had good performance status and a low rate of 
comorbidity at baseline. All stages of the disease are represented, 
with the exception of ED-SCLC. Almost half of the patients had not 
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undergone surgical treatment. LTLCS are at high risk of second can-
cers. Further research about QoL, second malignancies and optimal 
follow-up is warranted in this increasing population.
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Do moral judgments, blame, and anger affect the empathic 
understanding by family caregivers on symptoms 
experienced by loved ones who have lung cancer?
Lobchuk, Michelle M.1; McClement, Susan E.1; McPherson, 
Christine2; Cheang, Mary1
1 University of Manitoba Faculty of Nursing, Winnipeg, MB, Canada; 
2 University of Ottawa School of Nursing, Ottawa, ON, Canada
Background: In our risk-oriented society in Canada, lung cancer is 
viewed as a stigmatized disease where the patient is often blamed in 
relation to cigarette smoking. Although these judgments are likely not 
openly talked about, it is possible that these reactions are experi-
enced by family caregivers that impact their empathic behaviors, and 
ultimately their understanding of patient’s symptom experiences. This 
study examined whether family caregivers’ blame and anger impacted 
their empathic understanding of patient’s symptoms in lung cancer. 
Mismanagement of patient symptoms by family caregivers can lead 
to unscheduled emergency room visits, inpatient hospital stays, and 
increased cost to the health care system. 
Methods: Weiner’s (1995, 2006) theory of social motivation guided 
our testing of associations among smoking cessation, judgments of 
responsibility, anger, pride, caregiver empathic helping, and percep-
tual understanding of patients’ symptoms. Latent-variable structural 
equation modeling was employed. Three hundred dyads of patients 
with lung cancer and their family caregivers were recruited from 
5 oncology settings in the City of Winnipeg, Canada. Participants 
completed, on a one-time basis, socio-demographic questionnaires 
that included items on smoking history and caregiving relationship, 
nine 5-point Likert-type response items on perceived responsibility, 
anger, and pride of caregivers, Long’s (1990), 20-item Other-Dyadic 
Perspective-Taking Scale to capture caregiver empathic behavior, and 
pain, fatigue, and shortness of breath as captured on the Memorial 
Symptom Assessment Scale. 
Results: There is a linkage among family caregiver judgments of 
responsibility toward the patient in controlling aspects of the disease, 
caregiver anger, and decreased empathic behavior and perceptual 
understanding by caregivers, especially if the patient continued to 
smoke. The results of this analysis provide preliminary support for 
Weiner’s theory on the linkage between attributional reactions, help-
ing behavior, and perceptual understanding by caregivers. 
Conclusions: The study results are intended to lay groundwork in 
developing a profile of family caregivers at risk for limited em-
pathic helping behavior and perceptual understanding of symptoms 
experienced by lung cancer patients. Study findings suggested that 
the impact of smoking cessation by patients on helping behaviors of 
caregivers is mediated by the cognition-affect linkage as postulated 
in Weiner’s theory. Put simply, caregivers who blame or fault patients 
for having smoked or continuing to smoke, and are angry with these 
patients are at risk for providing sub-optimal empathy and accurate 
understanding of patient symptom experiences. 
When caring for a patient with lung cancer, clinicians should assess 
the primary caregiver’s feelings toward the patient, particularly when 
the patient is still smoking. Part of the assessment should involve 
soliciting the caregiver’s beliefs about cigarette use with particular 
attention placed on whether they believe that cigarette smoking is a 
volitional act. Clinicians can intervene by educating caregivers about 
the addictive nature of cigarette use and help caregivers to avoid 
making attributions of blame that can pose a hazard to their empathic 
understanding that is essential to effective symptom management by 
caregivers.
Acknowledgment of Funding: This study was funded by the Nation-
al Cancer Institute of Canada (July 2005–July 2009) and a Manitoba 
Health Research Council Establishment grant to support research 
dissemination.
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How do lung cancer patients and their relatives 
rate educational intervention on chemotherapy? An 
exploratory study
Oyen, Christel; Vandenberghen, Martine; Peys, Maria; Coolbrandt, 
Annemarie; Nackaerts, Kris; Vansteenkiste, Johan
University Hospitals Leuven, Leuven, Belgium
Background: Lung cancer patients receiving chemotherapy often 
have many questions regarding the impact of their therapy and its 
side-effects on their physical and emotional functioning. An educa-
tional intervention providing specific information about chemother-
apy may support caregivers’ advice and help patients to cope better 
with their treatment.
Objectives: Survey and analysis of our intervention in order to de-
termine whether the information was satisfactory, for the patients, as 
well as for their families.
Methods: Since November 2006, all patients having chemotherapy 
in our unit receive an educational intervention by means of an oral 
education by a dedicated oncology nurse, supported by a brochure, 
developed as a resource for patients to have the information given 
by their doctor and nurse when needed, and to share this information 
with others. The brochure also includes a section to note items in a 
diary format. In this study, an independent observer (CO) surveyed 
the intervention by a questionnaire to both patients and family 
members. Questions were on 1/ use and content of the tool; 2/ use by 
relatives; 3/ quality of the tool; and 4/ usefulness of the diary section.
Results: In a 30 day interval (starting Feb 02, 2009), a total of 57 
lung cancer patients (male/female: 40/17) received a questionnaire 
about the educational intervention. Patients’ age ranged between 41 
and 79 years. Their treatment consisted of platinum-based doublet 
chemotherapy (67%) or single agent chemotherapy (33%).
All patients had the oral education and 38 (67%) read the informa-
tion brochure (42% read the brochure in parts to better assimilate the 
information, and 55% read the brochure afterwards at home). The 
majority of the patients felt that the information in the brochure was 
sufficient, especially about the side-effects of the chemotherapy. In 38 
cases (67%), a relative also read the information (mostly the partner, 
sometimes the children, a few instances the GP). For the 38 patients 
that used the brochure, the information was in general rated as good, 
suitable to be read again, and full of useful tips. Only 4 patients rated 
the information as too overwhelming. A total of 32 patients (56%) 
never used the diary. Those who did use it rated it as useful and good 
for the communication with their caregivers. Five patients rated the 
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diary as useless. Eighteen family members were surveyed as well. 
Their reason for reading the brochure was their need for informa-
tion on treatment and especially on the side-effects, in order to 
know when these would occur. They rated the information as good, 
recognizable, easy to read and full of useful tips. All of them found it 
important to have access to this information.
Conclusion: These data demonstrate the usefulness of an educational 
intervention by a dedicated oncology nurse in patients receiving 
chemotherapy for lung cancer. Support by an information brochure is 
important for two thirds of the patients. Of the surveyed relatives, all 
rated this information tool as satisfactory and of practical importance. 
This research will be continued in larger groups of patients.
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The development of an electronic directory to share nurse-
led practice
Docherty, Kirsty1; Byres, Jacqueline2; Brisbane, Iona3; Beattie, 
Pamela 4; Dawson, Fiona5; O’Hare, Gerry6; Preston, Heather7
1 Inverclyde Royal Hospital, Greenock, UK; 2 Victoria Infirmary, 
Glasgow, UK; 3 Beatson Oncology Centre, Glasgow, UK; 4 
Crosshouse Hospital, Ayr, UK; 5 NHS Lothian, Edinburgh, UK; 6 Vale 
of Levan Hospital, Alexandria, UK; 7 NHS Fife, Kirkcaldy, UK
Background: At a Strategy Development Day of the Scottish Lung 
Cancer Nurses Forum, it was agreed to benchmark nurse-led lung 
cancer initiatives in Scotland. Nurse-led care and cancer follow up 
can lead to greater patient satisfaction, lower anxiety and reduced 
costs (Corner 2003, Moore et. al. 2002), and is appropriate and effect-
ive when combined with telephone support (Cox et. al. 2006). 
It was felt that sharing examples of nurse-led initiatives for lung 
cancer patients would facilitate the development of and increase the 
establishment of nurse led services.
The audit performed by the group led to the development of The 
Scottish Lung Cancer Nurses Forum, Electronic Directory for Shar-
ing Practice. The purpose of this directory is to facilitate the develop-
ment of nurse led initiatives for lung cancer patients.
Lung cancer nurse specialists (LCNS’s) exploring the development 
of a nurse-led service within their local area can utilise this directory 
to access the contact details, information and protocols of established 
nurse-led initiatives for this group of patients.
Sharing this information should increase the establishment of nurse-
led services, which have been shown to improve the support, man-
agement and follow-up of lung cancer patients and their carers.
Brief information and contact details on lung cancer nurse-led initia-
tives can be found within this directory.
Method: The group used a questionnaire to identify:
· Examples of nurse-led initiatives.
· Any assistance given to set up the service.
· Any difficulties encountered.
· Use of guidelines / protocols and willingness to share.
Results: 28 questionnaires were sent out to LCNS’s in Scotland. 21 
were returned (75%). The remaining 7 LCNS’s worked within a team 
of LCNS’s. 
13 themes of nurse-led initiatives were identified:
1. Pre Assessment Clinic
2. Results Clinic (Breaking Bad News)
3. Chemotherapy
4. Radiotherapy
5. Breathlessness Clinic
6. Support Groups
7. Interagency Partnerships
8. Nurse-Led Follow-Up Clinic
9. Nurse-Led Telephone Follow-Up
10. Education Programmes for Staff
11. Education for Patients / Patients & Carers
12. Self Care Programmes
13. IT / Databases 
6 out of 21 had no help. 15 out of 21 received support from vari-
ous sources such as: MDT, Drug Company, Outpatient department, 
Management, Local Hospice, Social work, Citizens Advice Bureau, 
Practice Development, McMillan Funding, Roy Castle Foundation.
9 out of 21 encountered no difficulties, 9 out of 21 encountered dif-
ficulties of some sort. 3 out of 21 made no comment. Examples of 
difficulty were, physical, practical, financial and administrative.
12 out of 21 had guidelines/protocols and were willing to share with 
others, 8 out of 21 had no guidelines/protocols. 1 out of 21 made no 
comment.
Conclusions of Audit:
· There were a wide variety of nurse-led initiatives being carried 
out. 
· Support for the setting up of new initiatives is problematic.
· Centres with more than one LCNS tend to have more nurse-led 
initiatives.
· Protocols/guidelines can and should be shared to facilitate the 
development and implementation of nurse-led services.
· Development and distribution of an electronic directory sharing 
practice could provide LCNS’s with a tool to develop and imple-
ment nurse-led initiatives. 
References:
Corner J (2003). The role of nurse-led care in cancer management. The Lancet Oncology 
4 641-636
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Audit of telephone follow-up for patients receiving high 
dose radiotherapy for lung cancer
Dawson, Fiona; Borthwick, Diana C.; Mencnarowski, Julie; Whitson, 
Gillian
NHS Lothian, Edinburgh, UK
In the Edinburgh Cancer Centre patients with lung cancer who 
undergo high dose radiotherapy (HDRT) with or without chemother-
apy are reviewed weekly during treatment and followed up in clinic 
4-6 weeks after treatment. Patients often feel isolated following an in-
tense period of contact with health care professionals at a time when 
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they are dealing with significant toxicites from complex treatment. 
It is widely recognised that toxicity assocaited with treatment can 
adversely affect quality of life (Bulsara 2006), and that by supporting 
patients to anticipate and pre-empt problems you may empower them 
to take a more active role in the management of their care (Hibbard 
et al 2006). The lung cancer nursing team identified a gap in service 
provision for patients following high dose radiotherapy and felt that 
telephone follow up would help improve patient management and 
support.
Methods: Patients were contacted weekly by telephone follow-
ing completion of radiotherapy until first formal clinic visit. All 
patients in Lothian receiving HDRT (55Gy/20#and 60Gy/30#) for 
Non Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer 
(SCLC) (45/50Gy/20#) and Mesothelioma 54Gy/30#) were in-
cluded. Patients receiving Continuous Hyperfractionated Acceler-
ated Radiotherapy(CHART) (54Gy/36#) were excluded for first six 
months of follow-up due to practicalities of data collection. Toxicity 
of treatment was measured using the Common Toxicity Criteria Ver-
sion 3.0 (National Cancer Institute 2003).
Results: 177 patients received HDRT during the audit at the Edin-
burgh Cancer Centre. 91 patients were referred for follow-up in this 
period, of which 64 were contacted. Top six toxicities were fatigue, 
dyspnoea, cough, dysphagia, oesophagitis and anorexia. Interventions 
included GP contact, medication advice, hospital admission, facilitat-
ing earlier clinic appointments and referral to other agencies.
Conclusions: The overall aim of this project was to provide support 
for patients in the follow-up phase following HDRT. Audit has shown 
that the lung cancer nursing team has provided an effective service 
for this group of patients.
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Phase I studies of the novel oral EGFR inhibitor, icotinib, 
in health male subjects 
Liu, Dongyang2; Zhang, Li3; Jiang, Ji2; Tan, Fenlai1; Wang, 
Yinxiang1; Zhang, Don 4; Hu, Pei2
1 Zhejiang Beta Pharma Inc, Hangzhou, China; 2 Clinical 
Pharmacology Research Center, Peking Union Medical College 
Hospital & Chinese Academy of Medical Sciences, Beijing, China; 
3 Peking Union Medical College Hospital & Chinese Academy of 
Medical Sciences, Beijing, China; 4 Beta Pharma Inc, New Heaven, 
CT, USA
Background: Epidermal Growth Factor Receptor (EGFR) is now a 
well established target for the treatment of non-small cell lung cancer 
(NSCLC). Icotinib, a novel oral EGFR-Tyrosine Kinase Inhibitor has 
already demonstrated active and selective antitumor activities in both 
in vitro and in vivo preclinical studies. 
Methods: To evaluate its safety, tolerance and pharmacokinetic 
(PK) characteristics in men, we performed 3 phase I studies in health 
male subjects: 1, A dose escalation study was preceded in a total of 
76 healthy subjects administrated a single dose of Icotinib between 
25 mg and 1025 mg. 2, A randomized, 3-period crossover study for 
100mg, 350mg and 600mg groups was carried out for PK profiling of 
Icotinib in 12 health volunteers; 3. A randomized, 2-period crossover 
study was performed for characterization of influence of food intake 
on the PK characteristics of Icotinib in10 health subjects.
Results: Icotinib showed excellent tolerance in healthy subjects over 
a dosage range between 25 and1025 mg. No obvious drug related 
side effects were observed even in the 1025 mg group, thus the dose 
limited toxicity (DLT) of Icotinib was not defined in this study. The 
PK profiling study showed that Icotinib was rapidly absorbed and 
eliminated in the healthy subjects. A linear relationship for each 
PK parameter including Cmax and AUC was observed for dosages 
between 100mg and 350mg, suggesting a single dose administra-
tion up to 350mg could be employed in future patient usage. When 
administrated with a single dose of 600mg, a saturated characteris-
tics for each PK parameter was evidenced in these health subjects. 
Further PK analysis revealed Icotinib with a t1/2 of around 6 hours 
(6.02±4.00, 6.47±3.66, 7.83±4.50) and a Tmax of around 2 hours 
in all three different dose groups. When administrated with high-fat 
and high-calorie food, Icotinib demonstrated an increased absorp-
tion of 59%, as reflected by the Cmax of 3.05±0.775 ug/ml(fed) vs 
1.92±0.672 ug/ml (fasted). The overall exposure to Icotinib and its 
metabolites, as shown by the AUC under the plasma concentration-
time curve from zero to infinite, was increased by 79%, 21.6±10.1 
(hr*ug/mL, fed) vs 12.1±5.07 (hr*ug/mL, fasted). However, its 
clearance was significantly decreased as evidenced by the CL/F of 
21.8±8.85 (L/hr, fed) vs 46.1±41.0(L/hr, fasted). 
Conclusions: Icotinib represents a potential novel anti-cancer drug 
which is well-tolerated in man. A single dose administration between 
100mg and 350mg is an appropriate dose for future patient usage. 
Food intake can significantly increase the absorption and exposure of 
Icotinib in the health subjects.
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Icotinib, a potent and selective oral EGFR inhibitor, is well 
tolerated and active in patients with NSCLC: results from 
a phase I/II trial
Zhang, Li1; Jiang, Ji4; Liu, Dongyang4; Xia, Ying5; Tan, Fenlai3; 
Wang, Yinxiang3; Zhang, Don 2; Hu, Pei4; Hu, Shaojin 2
1 Peking Union Medical College Hospital & Chinese Academy of 
Medical Science, Beijing, China; 2 Beta Pharma Inc, New Heaven, 
CT, USA; 3 Zhejiang Beta Pharma Inc, Hangzhou, China; 4 Clinical 
Pharmacology Research Center,Peking Union Medical College 
Hospital & Chinese Academy of Medical Sciences, Beijing, China; 5 
Department of Pulmonary Medicine, Peking Union Medical College 
Hospital & Chinese Academy of Medical Sciences, Beijing, China
Background: Pre-clinical studies demonstrate that Icotinib (Coman-
aTM) is a powerful and selective EGFR TKIs. In 85 kinases profiled, 
Icotinib can powerfully inhibits EGFR and its 3 mutants, but no 
meaningful inhibition to the rest kinases tested. 
Methods: To investigate the safety, pharmacokinetics(PK), and 
preliminary anti tumor activity of Icotinib in patients with non 
small cell lung cancer (NSCLC), a total of 32 patients with locally 
advanced or metastatic NSCLC after failure of prior platinum-based 
chemotherapy,18yrs <age<75yrs,ECOG PS 0-2, and adequate organ 
function, were recruited for treatment of escalating doses of Icotinib 
given twice daily. PK profiling was performed in first 10 patients in 
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the cohort of 150mg Bid and 9 patients in the cohort of 200mg Bid. 
Toxicity and response to Icotinib according to RECIST were also 
evaluated in these patients. 
Results: Among 32 patients enrolled, 9 were allocated to the 200mg 
Bid cohort and 23 to the 150mg Bid cohort. The mean age for 32 pa-
tients is 55 yrs (39-74), with 5 subjects classified as stage IIIB and 27 
as stage IV. DLT didn’t occur up to 200mg Bid dose level and MTD 
was not reached, although 1 pt was reported had grade 3 rash. The 
most frequent drug-related adverse events (AEs) were rash (28.1%, 
9/32), diarrhea (3.13%, 1/32), nausea (3.13%,1/32) and abdominal 
pain (6.3%,2/32), All AEs were generally mild (grade 1/2), only 1 
grade 3 rash was observed in the 200mg cohort. Of 32 patients regis-
tered, 28 patients completed at least one cycle (28 days) treatment. 
Among them 6(21.4%,6/28) pts had PR, 1 pt had CR, 14 pts had SD, 
and 7 pts had PD, corresponding to a ORR of 25.0% (7/28) and DCR 
of 75.0%% (21/28). The medium PFS was 36 weeks. Pharmacokin-
etic analysis showed steady-state exposure to Icotinib occurred by 
day 7 with a t1/2 around 6 hours and Tmax around 2 hours. 
Conclusion: Icotinib is safe and well tolerated in later stage NSCLC 
patients, which seems to have a drastic difference comparing to the 
other 2 EGFR TKIs, Gefitinib and Erlotinib. No MTD was defined 
yet in this study. Pharmacokintic analysis indicated that Icotinib is 
suitable for administration as a 2 or 3 times daily oral tablet formula-
tion. A phase I/II study of Icotinib Tid with a starting dose of 225mg 
per day (75 mg Tid) escalated to 600mg per day (200mg Tid) has 
been recently finished. Icotinib at either 300mg(150 mg Bid) or 
400mg daily (200 mg Bid) appeared to be safe and effective dose 
and showed encouraging clinically significant anti tumor activities in 
NSCLC patients.
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Analyses of Japanese patients recruited in IPASS, a phase 
III, randomized, open-label, first-line study of gefitinib vs 
carboplatin/paclitaxel in selected pts with advanced non-
small-cell lung cancer
Ichinose, Yukito1; Nishiwaki, Yutaka 2; Ohe, Yuichiro3; Yamamoto, 
Nobuyuki4; Negoro, Shunichi5; Duffield, Emma6; Jiang, Haiyi7; 
Saijo, Nagahiro2; Mok, Tony8; Fukuoka, Masahiro9
1 National Kyusyu Cancer Center, Fukuoka, Japan; 2 National 
Cancer Center Hospital East, Chiba, Japan; 3 National Cancer 
Center Hospital, Tokyo, Japan; 4 Shizuoka Cancer Center, Shizuoka, 
Japan; 5 Hyogo Cancer Center, Hyogo, Japan; 6 AstraZeneca, 
Macclesfield, UK; 7 AstraZeneca, Osaka, Japan; 8 The Chinese 
University of Hong Kong, Shatin, Hong Kong; 9 Kinki University 
School of Medicine, Osaka, Japan
Background: IPASS (IRESSA Pan ASia Study) demonstrated superi-
ority of gefitinib (G) vs carboplatin/paclitaxel (C/P) for progression-
free survival (PFS) in 1217 clinically selected patients (pts) in Asia 
with advanced non-small-cell lung cancer (NSCLC). PFS favored 
C/P initially then G, likely driven by different outcomes according 
to EGFR mutation (M) status. Planned analyses of data from 233 pts 
recruited in Japan (19% of overall population) are reported.
Methods: Chemonaïve, never/light ex-smokers with, adenocarcin-
oma histology, and stage IIIB/IV NSCLC were randomized to G 250 
mg/day (n=114) or C (AUC 5 or 6)/P (200 mg/m2) (n=119) from 
Mar 06 to Oct 07. Primary endpoint was PFS in ITT population; a 
treatment by country interaction test (Japan vs other) was performed. 
Secondary endpoints were overall survival (OS), objective response 
rate (ORR, RECIST), QoL (FACT-L, TOI), symptom improvement 
(LCS), and tolerability.
Results: PFS results in pts in Japan did not significantly differ from 
other pts (interaction test p=0.4736). G demonstrated superior PFS 
compared with C/P; effect was not constant over time, favoring 
C/P initially then G. Preliminary OS (25% maturity) was similar 
for G and C/P. ORR was higher for G than C/P (41% vs 35%). QoL 
improvement rate (TOI) was higher with G than C/P (43% vs 28%). 
QoL (FACT-L) and symptom improvement (LCS) rates were similar 
for G and C/P (FACT-L 41% vs 43% and LCS 42% vs 46%). G had a 
more favorable tolerability profile than C/P. There were no deaths due 
to ILD-type events (frequency 1.8% [G] vs 0% [C/P]).
  HR/OR 95% CI p
 PFS HR: 0.69 0.51-0.94 0.0191
 OS HR: 0.89 0.53-1.48 -
 ORR OR: 1.34 0.78-2.30 0.2967
 FACT-L OR: 0.94 0.56-1.60 0.8263
 TOI OR: 1.92 1.11-3.34 0.0200
 LCS OR: 0.85 0.50-1.43 0.5340
Conclusions: For pts in Japan, efficacy and tolerability data were 
generally consistent with overall population. G demonstrated 
improved PFS and ORR, similar OS, higher QoL (TOI) and similar 
symptom improvement rates, and more favorable tolerability profile 
compared with C/P in chemonaïve, never/light ex-smokers with 
advanced NSCLC of adenocarcinoma histology. In IPASS, EGFR 
mutation status was a strong predictive biomarker for PFS and ORR 
benefit of gefitinib compared with C/P.
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Concurrent chemotherapy immediately following erlotinib 
(E) or gefitinib (G) induced apoptosis in previously 
untreated patients with advanced or metastatic non small 
cell lung cancer (NSCLC)
Natale, Ronald B.; Natale, Ryan B.
Cedars-Sinai Cancer Center, Los Angeles, CA, USA
Background: The EGFR-TKIs, E and G, block EGFR-mediated 
proliferative and anti-apoptotic signaling. The predominance of anti-
proliferative effects over the latter mechanism is postulated as the 
reason that no additional benefit was observed when either agent was 
given concurrently with 1st line chemotherapy in unselected NSCLC 
pts (INTACT 1 & 2, TALENT & TRIBUTE trials). However, a subset 
analysis of TRIBUTE pts with a never smoking history suggested 
that improved survival may occur when the pt population is partially 
enriched to increase the proportion with an EGFR-TKI induced 
apoptotic effect (Miller VA. Proc ASCO, 2004). IPASS demonstrated 
a median survival of 18 mos by the sequential use of an EGFR-TKI 
followed by chemotherapy in pts with EGFR-mutated lung cancer in 
which the EGFR-TKI induced apoptotic rate was about 70% (Mok 
et al. IASLC, Chicago, 2008). We hypothesized that pts demonstrat-
ing rapid tumor regression within a 3-4 week exposure to E or G 
represented a population maximally enriched for the apoptotic effect 
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and that immediate concurrent administration of chemotherapy would 
produce prolonged survival.
Methods: . Forty-one stage IIIB/IV pts, including 27 women and 14 
men, median age 67 (range 41 to 88) with limited smoking history 
(21 never smokers, 20 former light smokers) were treated with E 
100-150 mg/day (39 pts) or G 250 mg/day (2 pts) for an average of 
26 days (range, 21-34) before response assessment. Twenty-two pts 
achieved objective tumor responses (2 CRs, 20 PRs) and immediately 
received 4-6 cycles of platinum-based chemotherapy concurrently 
with continued E or G (group A). E or G was discontinued in 19 pts 
not achieving objective response and platinum-based chemotherapy 
alone was given after a 10-14 day washout (group B).
Results: With a median follow-up of 24 mos, the median TTPs are 
21+ mos and 7 mos and the median survivals are 31+ and 12 mos in 
groups A and B, respectively. Thus far, only 5 deaths have occurred 
in 22 group A pts. Results of EGFR mutation and other analyses in 
tumor tissue from 27 pts will be presented.
Conclusions: These data suggest that EGFR-TKI induced apoptosis 
may act synergistically with concurrent 1st line chemotherapy in 
selected pts with advanced or metastatic NSCLC and may be superior 
to sequential administration as demonstrated in IPASS. If confirmed, 
this would represent a new paradigm for incorporation of biologically 
targeted agents into chemotherapy regimens. 
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Activity of BIBW 2992, an oral irreversible EGFR/
HER2 dual kinase inhibitor, in combination with weekly 
paclitaxel in non-small cell lung cancer
Stavridi, Flora1; Kristeleit, Rebecca1, 3; Forster, Martin2, 3; Ang, Joo-
Ern2; Rudman, Sarah1; Uttenreuther-Fischer, Martina4; Pemberton, 
Karine5; Shahidi, Mehdi5; De Bono, Johann2, 3; Spicer, James1, 6
1 Guy’s and St Thomas’ NHS foundation Trust, London, UK; 2 Royal 
Marsden NHS Foundation Trust, Sutton, UK; 3 Institute of Cancer 
Research, Sutton, UK; 4 Boehringer Ingelheim, Biberach, Germany; 
5 Boehringer Ingelheim, Bracknell, UK; 6 King’s College London, 
London, UK
Background: BIBW 2992 (Tovok*) is a potent and irreversible oral 
inhibitor of both EGFR and HER2 receptor tyrosine kinases with 
activity in non-small cell lung cancer (NSCLC). The recommended 
dose for single agent Phase II study is 50 mg. The results for NSCLC 
patients treated in a Phase I open-label dose-escalation trial of BIBW 
2992 in combination with weekly paclitaxel are reported here. 
Methods: This study evaluated safety and efficacy of daily oral 
BIBW 2992 combined with paclitaxel administered on Days 1, 8 and 
15 of a 4-weekly cycle. The dose of paclitaxel was 80 mg/m2, and the 
BIBW 2992 starting dose was 20 mg, escalated in successive cohorts 
to 40 then 50 mg. After 6–8 cycles of combination therapy, patients 
benefiting and tolerating treatment were eligible to continue single 
agent BIBW 2992. Tumor EGFR and K-RAS mutation status is being 
evaluated.
Results: Nine patients with advanced NSCLC were enrolled into 
the study (three males / six females); median age 59 [range 42–72]; 
ECOG PS 0/1: 4/5. 100% of patients were white. 77% had adeno-
carcinoma (including bronchoalveolar cell) histology. The ratio of 
ever- to never-smokers was 6:3. Durable partial responses (PRs) were 
achieved in three patients and disease control (PR and stable disease) 
was seen in a total of seven of nine patients. Two female patients with 
adenocarcinoma remain on treatment beyond 12 months. The most 
frequent adverse events were fatigue, rash and diarrhea. Two patients 
needed dose reduction of BIBW 2992 because of persistent low grade 
adverse events. 
Conclusions: Marked anti-tumor activity was seen with the combina-
tion of BIBW 2992 and weekly paclitaxel in patients with NSCLC, 
with 33% of patients achieving PR. The combination treatment was 
well tolerated without evidence of additive adverse reactions. BIBW 
2992 40 mg daily in combination with weekly paclitaxel 80 mg/m2 
is the likely recommended dose for Phase II study. The addition of 
bevacizumab to BIBW 2992 with 80 mg/m2 weekly paclitaxel is cur-
rently being evaluated.
An international Phase III trial program investigating BIBW 2992 in 
NSCLC, LUX-Lung, is now recruiting patients.
*Trade name not FDA approved.
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Volociximab (V) in combination with carboplatin (C) and 
paclitaxel (P) in patients (pts) with advanced non small cell 
lung cancer (NSCLC)
Belani, Chandra P.1; Tsao, Claire2; Almokadem, Salah1; Ding, Han2; 
Chico, Isagani M.2; Soria, Jean-Charles3; Besse, Benjamin3
1 Penn State Hershey Cancer Institute, Hershey, PA, USA; 2 Facet 
Biotech, Redwood City, CA, USA; 3 Gustav Roussy, Villejuif, France
Background: Volociximab is a chimeric monoclonal antibody that 
blocks the binding of α5β1 to fibronectin and induces apoptosis 
in proliferating endothelial cells. Its anti-angiogenic actions are 
independent of the VEGF pathway. 
Methods: This phase 1b multi-center open-label, dose-escalation 
study was designed to determine the maximum tolerated dose of V 
in combination with full doses of C (AUC=6mg/ml.min) P (200mg/
m2) with cycles repeated every 3 wks for a maximum of 6 cycles 
followed by a maintenance treatment with V alone. Eligible pts had 
histologically confirmed untreated stage IIIb or IV NSCLC. In co-
horts 1 and 2, pts received V at 10 mg/kg and 20mg/kg IV, respect-
ively, on days 1 and 8, of the first 21 day cycle then every 21 days. In 
cohort 3, pts received V 30 mg/kg every 21 days from day 1. 
Results: A total of 33 pts were enrolled, screening ECOG 
PS0=19(58%), PS1=13(39%), missing =1(3%), predominant histol-
ogy: adenocarcinoma 23 (70%), large cell 4 (12%), squamous cell 
5 (15%), and missing 1 (3%). 29 pts (9, 6 and 14 in cohorts 1, 2 and 
3 respectively) who received at least one dose of treatment were 
included in the safety evaluable population. No pts experienced hem-
optysis including 5 (15%) pts with squamous cell carcinoma. The ma-
jority of adverse events were mild to moderate and the most common 
AEs of any grade were constipation (62%), asthenia (59%), nausea 
(59%), arthralgia (52%), diarrhea (48%), paresthesia (48%), vomiting 
(41%), myalgia (41%), abdominal pain (38%), peripheral neuropathy 
(38%), anorexia (38%) and cough (38%). Serious AEs in 8 (28%) 
pts include back pain (1), bronchitis (1), deep vein thrombosis (1), 
dehydration (1), peripheral arterial occlusion (1), pleural effusion (1), 
pneumonitis (1), proteinuria grade 3 (1), orthostatic hypotension (1), 
and small intestinal obstruction (1) which was a DLT in the 20 mg/
kg dose cohort. No DLT was observed at the highest dose of 30 mg/
kg. Preliminary PK analysis demonstrated that the average steady 
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state trough levels of V across all dose groups were above 150 mcg/
mL, the efficacious serum concentration based on preclinical models, 
and are proportional to doses. Preliminary efficacy assessment in 
evaluable pts who had at least one post-baseline RECIST assessment 
showed 8/21 (38%) with a partial response and 13/21 (62%) had 
stable disease. 14/21 (67%) with SD or PR continued on maintenance 
V beyond 6 cycles of chemotherapy with CP. 
Conclusions: V up to 30 mg/kg q3w in combination with CP and 
as maintenance after six cycles appears to be well tolerated and has 
promising clinical activity in pts with both squamous and non-squa-
mous histologies of NSCLC. 
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A single arm phase 2 study of enzastaurin in combination 
with erlotinib, both administered orally daily, to patients 
with advanced non-small cell lung cancer (NSCLC)
Wakelee, Heather A.1; Dubey, Sarita2; Krupitskaya, Yelena1; 
Osarogiagbon, Raymond U.3; Sanborn, Rachel E.4; Bernstein, Eric 
D.4; Dudek, Arkadiusz Z.5; Latz, Jane E.6; Yuan, Zheng6; Natale, 
Ronald B.7
1 Stanford University, Stanford, CA, USA; 2 University of California, 
San Francisco, San Francisco, CA, USA; 3 University of Tennessee, 
Memphis, TN, USA; 4 Providence Cancer Center, Portland, OR, USA; 
5 University of Minnesota, Minneapolis, MN, USA; 6 Eli Lilly and 
Company, Indianapolis, IN, USA; 7 Cedars-Sinai Cancer Center, Los 
Angeles, CA, USA
Background: Enzastaurin (ENZ), a serine/threonine kinase inhibitor, 
targets the PKC and PI3K/AKT pathways to inhibit angiogenesis and 
tumor cell proliferation and induce apoptosis. This study is evaluat-
ing the combination regimen of erlotinib (ERL) plus ENZ in patients 
with advanced NSCLC.
Methods: Patients with advanced NSCLC (Stage IIIB with pleural 
effusion or IV) who received 1-2 prior systemic treatment regimen(s) 
were enrolled. Patients received ERL 150 mg po qd on an empty 
stomach and ENZ 500 mg po qd with food (Day 1 ENZ loading dose 
of 1125 mg [375 mg tid]). A treatment cycle was 28 days. Primary 
endpoint was progression-free survival (PFS). Secondary endpoints 
included response rate, duration of response, overall survival (OS), 
and safety.
Results: From February through October 2008, 48 patients were en-
rolled. Median age was 66.5 years, range 42-83. Sex: male 28 (58%), 
female 20 (42%). Ethnicity: Caucasian 38 (79%), East Asian 6 (13%), 
African descent 3 (6%), Hispanic 1 (2%). Smoking status: smokers 
16 (33%), never smokers 29 (60%), smoking status was unknown for 
3 patients. Stage: IIIB 6 (12.5%), IV 42 (87.5%). ECOG performance 
status 0/1/2 was 18 (38%) /28 (58%) /2 (4%) respectively. Approxi-
mately 2/3 of the patients received 1 prior regimen and 1/3 received 
2 prior regimens. At interim analysis, 34 patients had discontinued 
protocol treatment and 14 patients were ongoing; approximately 31 
of 40 PFS events required for the final analysis had occurred. Most 
discontinuations (n=24) were due to progressive disease. Three pa-
tients died while on study, 2 due to lung cancer progression and 1 due 
to respiratory distress, not considered related to study drug. Two pa-
tients discontinued due to adverse events (AEs) (1 back pain, 1 rash) 
and 5 due to patient/physician decision. The median number of cycles 
delivered was 2 (range: 1-9+); 10 patients received 4 or more cycles. 
Best responses included 3 partial responses (PR) and 10 stable dis-
ease (SD) (response rate =6.3%, disease control rate =27.1%). All of 
these patients remained on treatment at the time of interim analysis. 
PR durations were 2.5-6.7 months (censored) and SD durations were 
1.8-5.6 months (censored). Six patients had SD >4.5 months. The 
most common possibly drug-related AEs included G1/2 rash (≥70%), 
diarrhea (≥55%), fatigue (≥25%), and nausea (≥25%). The overall in-
cidence of possibly drug-related G3 AEs was approximately 10-15% 
and consistent with the established AE profiles for the two drugs. 
There were no G4 AEs. Possibly drug-related serious AEs included (1 
patient each): G2 gastric ulcer and G3 radiation pneumonitis. Results 
for PFS, duration of response, and OS are pending data maturation. 
Although a formal analysis of PFS is pending, it does not appear that 
PFS for ERL+ENZ will be greater than the benchmark of 2.2 months 
previously established for ERL alone.
Conclusion: The addition of enzastaurin to erlotinib did not improve 
response rate nor disease control rate relative to those established for 
erlotinib alone in the BR.21 trial. There were no unexpected toxicities 
beyond those seen with either drug as a single agent.
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An open label, randomized phase I/IIA trial evaluating 
MK-0646, an anti-IGF-1R monoclonal antibody (MoAB), 
in combination with erlotinib for patients with recurrent 
non-small cell lung cancer (NSCLC)
Carcereny, Enric1; Moran, Teresa1; Felip, Enriqueta2; Borghaei, 
Hossein4; Fitzgerald, Timothy 5; Clark, Jason5; Guan, Shanhong5; 
Hsu, Karl5; Beckman, Robert5; Yan, Li5; Rosell, Rafael1; Johnson, 
David H.6
1 Institut Catala d’Oncologia- Hospital Germans Trias i Pujol, 
Badalona, Ctra Canyet s/n, Spain; 2 Hospital Vall d’Hebron, 
Barcelona, Spain; 3 Hospital 12 de Octubre, Madrid, Spain; 4 
University of Pennsylvania, Philadelphia, PA, USA; 5 Merck & Co, 
Inc, North Wales, PA, USA; 6 Vanderbilt Ingram Cancer Center, 
Nashville, TN, USA
Background: IGF-1R is a tyrosine kinase receptor that promotes pro-
liferation of cancer cells and is overexpressed in NSCLC. MK-0646 
is a humanized IgG1 MoAb that binds to IGF-1R. MK-0646 inhibits 
NSCLC tumor growth and enhances the anti-tumor activity of EGFR 
MAb in NSCLC mouse xenografts. The Phase I part of this trial has 
been completed. Phase I was designed to study the safety of this com-
bination and to identify a dose of each drug to be used in Phase II. 
Methods: Patients with Stage IIIB/IV NSCLC who previously failed 
at least 1, but no more than 2, prior chemotherapy regimens were 
allocated to the following panels of MK-0646 IV weekly using a 3 
+ 6 dose escalation scheme: 5 mg/kg and 10 mg/kg, in combination 
with erlotinib 150 mg p.o. daily. The recommended Phase II dose was 
considered well tolerated if DLTs were observed in ≤ 2 of 9 patients. 
Results: Two dose levels of MK-0646 were assessed in Phase I: 5 
mg/kg and 10 mg/kg. Four male patients, 3 of whom were evalu-
able, were allocated into the 5 mg/kg cohort (median age 53.5 years, 
ECOG PS 0/1: 3/1) and 13 patients, 8 of whom were evaluable, were 
allocated in the 10 mg/kg cohort (12 male, 1 female, median age 62 
years, ECOG PS 0/1: 5/8). No DLTs were observed in the 5 mg/kg 
cohort. One DLT was observed in the 10 mg/kg cohort (Grade 3 diar-
rhea). Most of the adverse events were considered unrelated to MK-
0646 and/or erlotinib and had an NCI CTCAE of Grade 1 or 2. The 
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most common adverse events were gastrointestinal disorders (94%), 
general disorders (82%), skin and subcutaneous tissue disorders 
(76%), and metabolism and nutritional disorders (58%). PK analysis 
is currently ongoing. No objective responses were observed. Median 
length of study medication treatment is 4 weeks (range: 2-26 weeks), 
and 5 weeks (range: 2-15 weeks) for patients in the 5 mg/kg and 10 
mg/kg cohorts, respectively. 
Conclusions: MK-0646 10 mg/kg weekly + erlotinib 150 mg daily 
is well-tolerated in patients with advanced NSCLC and therefore has 
been identified as the recommended Phase II dose. 
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Phase I study of daily or weekly RAD001 (R, everolimus) 
in combination with pemetrexed (P) in patients with 
advanced non-small cell lung cancer (NSCLC) previously 
treated with chemotherapy
Vansteenkiste, Johan2; Solomon, Ben3; Boyer, Michael4; Wolf, 
Jürgen5; Miller, Neil1; Di Scala, Lilla1; Petrovic, Katarina1; 
Dimitrijevic, Sasa1; Anrys, Beatrijs2; Laack, Eckart6
1 Novartis Pharma AG, Basel, Switzerland; 2 University Hospital 
Gasthuisberg, Leuven, Belgium; 3 Peter MacCallum Cancer Centre, 
Melbourne, Australia; 4 Sydney Cancer Centre, Sydney, Australia; 
5 University Hospital Cologne, Cologne, Germany; 6 University 
Hospital Eppendorf, Hamburg, Germany
Background: R, an oral inhibitor of the mammalian target of rapa-
mycin (mTOR), is in clinical development as an anticancer agent. 
As a single agent and in combination with other anticancer agents, 
R showed efficacy in in vitro and in vivo NSCLC models. Clinical 
benefit including objective tumor responses were observed in patients 
with NSCLC receiving R.
Methods: This open-label, multi-center, dose-escalation Phase 
1 study investigated both daily and weekly dosing schedules of 
RAD001 in combination with pemetrexed 500mg/m2 every 21 days 
in the second-line treatment of NSCLC. The planned dose levels were 
2.5, 5 and 10mg daily and 20, 30 and 50mg weekly RAD001.
The primary objective was to establish the feasible doses/regimens 
of R in combination with standard dose of P. Dose-escalation was 
based on a Time-to-DLT (Dose Limiting Toxicity) Bayesian model 
estimating the risk that patients experience a DLT at any timepoint 
and, specifically, on the probability of a DLT within Cycle 1 of treat-
ment (primary endpoint). Drug-drug-interaction was investigated by 
pharmacokinetic sampling and analysis.
Eligible patients had stage IIIb/IV NSCLC, maximum 1 prior regi-
men of chemotherapy for advanced disease, WHO Performance 
Status ≤ 1 and adequate bone marrow, renal and liver function.
Results: In the daily dosing schedule (qd) 24 patients were treated in 
4 different dose levels: 2.5mg qd (n=5), 5 mg qd (n=12), 10 mg qd 
(n=3) and, additionally, 7.5mg qd (n=4). Male/Female 14/10; median 
age (range) 59.5 (37-74); never smokers 13%; adenocarcinoma 75%, 
large cell 16%, invasive lobular 4% squamous 4%. Cycle 1 DLTs 
were rash and thrombocytopenia (n=2, 5mg qd), febrile neutro-
penia, pruritus, rash and thrombocytopenia (n=2, 7.5mg qd), and 
febrile neutropenia and neutropenia (n=2, 10mg qd). Most common 
CTC grade 3/4 events across dose levels were neutropenia (n=15), 
thrombocytopenia (n=5), febrile neutropenia (n=2), anemia (n=2), 
rash (n=3), pruritus (n=3), dyspnea (n=3) and fatigue (n=2). Median 
number of chemotherapy cycles administered was 3/3/2/4 for the 
2.5/5/7.5/10mg qd dose levels, respectively. Three partial responses 
according to RECIST were observed in the 5mg qd dose level.
In the weekly dosing schedule (qw) 19 patients were treated in 2 
different dose levels: 30mg qw (n=6) and 50mg qw (n=13). Male/
Female 11/8; median age (range) 60 (36-74); never smokers 16%; 
adenocarcinoma 79%, large cell 5%, squamous 16%. Cycle 1 DLTs 
were neutropenia and stomatitis (n=2, 50mg qw). Most common CTC 
grade 3/4 events across dose levels were neutropenia (n=11), throm-
bocytopenia (n=3), anemia (n=3), rash (n=1), dyspnea (n=4) and 
fatigue (n=2). Median number of chemotherapy cycles administered 
was 4 in both 30 and 50mg qw dose levels. Two partial responses ac-
cording to RECIST were observed in the 50mg qw dose level.
Conclusions: In stage IIIB/IV NSCLC patients, the combination of 
RAD001 5mg/daily or 50mg/weekly with the standard regimen of pe-
metrexed were established as safe, feasible doses for further evalua-
tion. A higher rate of G3/4 neutropenia was noted in both schedules 
when compared to the expected rate for pemetrexed alone.
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Everolimus (RAD001C) in combination with carboplatin 
(C) and paclitaxel (P) as first line treatment for patients 
(pts) with advanced NSCLC: a phase I trial
Papadimitrakopoulou, Vassiliki A.9; Malik, Shakun5; Brown, Michael 
P.3; Mitchell, Paul4; Thomas, Michael8; Mills, Glenn2; Pylävanäinen, 
Ilona7; Lilla, Di Scala7; Kunz, Tiffany1; Dimitrijevic, Sasa7; DeLeo, 
Jeffrey J.1; Korfee, Soenke6
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Center / LSU School of Medicine, Shreveport, LA, USA; 3 Royal 
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University / Lombardi Cancer Center, Washington, DC, USA; 6 Dept. 
of Medicine Universitaetsklinikum Essen, Essen, Germany; 7 Novartis 
AG, Basel, Switzerland; 8 Onkologie/Innere Med Thoraxklinik 
Heidelberg, Heidelberg, Germany; 9 University of Texas / MD 
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Background: Everolimus (E) is an oral inhibitor of mammalian 
target of rapamycin (mTOR). As a single-agent and in combination 
with other anticancer agents, E showed efficacy in vitro and in vivo 
in NSCLC models and clinical benefit including objective responses 
were observed in pts with NSCLC.
Methods: Eligible pts had stage IIIb/IV NSCLC and no prior sys-
temic treatment, WHO PS ≤ 1 and adequate bone marrow, liver, and 
renal function. Pts received C at AUC6 q3w + P at 200mg/m2 in 21 
day cycles combined with E daily (5mg) or E weekly (30mg). Dose-
escalation was based on a time-to-DLT (Dose Limiting Toxicity) 
Bayesian model design estimating the risk that pts experience a DLT 
at any time point and specifically on the probability of a DLT within 
Cycle 1 of treatment. Drug-drug-interaction was also investigated by 
pharmacokinetic sampling and analysis. 
Results: Thirteen chemotherapy-naive pts were treated in the E daily 
arm: median age: 58; gender: male/female (5/8); PS 0/1 (4/9): cancer 
stage IIIB/IV (2/11); histology (9 adenocarcinoma, 1 squamous cell, 
2 large cell, 1 other). Thirteen chemotherapy-naive pts were treated in 
the E weekly arm: median age: 62; gender: male/female (6/7); PS 0/1 
(3/10); cancer stage IIIB/IV (3/10); histology (7 adenocarcinoma, 1 
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large-cell, 5 other). The most common CTC grade 3/4 AE regardless 
of causality are presented below as well as the DLTs observed during 
the first cycle.
The median number of cycles administered was 4 and 3 in the E daily 
and weekly arms, respectively. Best overall response according to 
RECIST; 1 PR and 6 SD in the E daily arm. 1 PR and 8 SD in the E 
weekly arm. 
Conclusion: A higher rate of G3/4 neutropenia was noted in both 
schedules when compared to the expected rate using C and P alone. 
The combination of E daily (5mg) or E weekly (30mg) with the 
standard regimen of C and P is feasible. This regimen will be further 
evaluated in combination with bevacizumab (study step2). 
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A phase I multiple-peptides vaccine trial for treatment of 
patients with advanced or recurrent non-small cell lung 
cancer
Suzuki, Hiroyuki1; Mutoh, Satoshi1; Okabe, Naoya1; Yaginuma, 
Hiroshi1; Hasegawa, Takeo1; Yonechi, Atsushi1; Ohsugi, Jun1; 
Hoshino, Mika1; Higuchi, Mitsunori1; Shio, Yutaka1; Yoshida, Koji2; 
Tsunoda, Takuya2; Nakamura, Yusuke2; Gotoh, Mitsukazu1
1 Fukushima Medical University, Department of Surgery I, 
Fukushima, Japan; 2 Human Genome Center, Institute of Medical 
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Background: Several studies showing the clinical benefits of cancer 
vaccine as an adjuvant treatment after surgery or a maintenance 
therapy after standard cytotoxic chemotherapy for patients with non-
small cell lung cancer (NSCLC) have been reported lately. However, 
the efficacy of vaccine therapy for patients with advanced and/or re-
current NSCLC is still controversial. A phase I study for patients with 
advanced or recurrent NSCLC was conducted to evaluate the safety, 
immunogenicity and clinical response of multiple-peptides vac-
cines including 2 types of novel cancer testis antigens discovered by 
microarray based technology and also including 2 types of peptides 
targeting to tumor angiogenesis. 
Methods: HLA-A2402 restricted peptides originated from Up-
regulated Lung Cancer 10 (URLC10) and TTK protein kinase 
(TTK), both peptides were characterized as cancer testis antigen, and 
peptides originated from Vascular Endothelial growth factor recep-
tor 1 (VEGFR1) and Vascular Endothelial growth factor receptor 2 
(VEGFR2) were applied for 3 levels of dose escalation (0.5mg, 1mg 
and 3mg /body/vaccine) vaccine trial. Nine HLA-A2402 positive pa-
tients with advanced or recurrent NSCLC were enrolled sequentially 
into 3 levels of escalating doses (3 patients/ 1 level). Vaccines were 
administered with Montanide ISA-51 incomplete freund adjuvant 
weekly and subcutaneously into patients’ axillary region. Four times 
of vaccinations were set as 1 coarse vaccination and vaccinations 
were continued until progressive disease. Toxicity assessments were 
conducted at baseline and prior to each vaccination according to 
CTCAE v3.0 criteria. Immunological responses were evaluated with 
INF-γ ELiSPOT assay. Furthermore, the subset of CD8+ T cells and 
the frequency of Foxp3+/CD4+ regulatory T cells in peripheral blood 
were analyzed before and after vaccinations as an immunological 
parameter. Clinical responses were evaluated by RECIST criteria. 
Results: No severe adverse events were observed in all patients. 
Using INF-γ ELiSPOT assay, specific T cell responses against only 
1 kind of vaccinated antigen were observed in all patients receiving 
0.5mg, while specific T cell responses against 2 or more kinds of vac-
cinated antigen were observed in all patients receiving 1mg and 3mg. 
In terms of clinical response, 4/9 patients were categorized as SD 
by RECIST criteria. Moreover, 2/4 SD patients showed evident lack 
of progression with the decreasing of both tumor markers and FDG 
uptake by PET imaging. 
Conclusions: Multiple-peptides vaccination using URLC10, TTK, 
VEGFR1 and VEGFR2 peptides was safe. Every patient developed 
antigen specific T cell responses against 1 or more antigen. These 
encouraging immunological and clinical responses could recommend 
further stage of clinical trial. 
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A multicenter randomized phase II study of paclitaxel 
(P) and carboplatin (C) versus oral vinorelbine (oV) and 
carboplatin (C) as second-line treatment in patients (pts) 
with non-small cell lung cancer (NSCLC) pretreated with 
non-platinum based chemotherapy
Agelaki, S.; Syrigos, K.; Polyzos, A.; Agelidou, A.; Handrinos, V.; 
Kotsakis, A.; Christophyllakis, Ch.; Vardakis, N.; Georgoulias, V.
Hellenic Oncology Research Group (HORG), Athens, Greece
Background: Limited data is available on the activity of platinum-
containing doublets as second-line treatment of NSCLC pts who 
received non-patinum based first-line therapy. We performed a multi-
center randomized phase II trial to compare PC and oVC in pts with 
NSCLC pretreated with first-line docetaxel (D)/gemcitabine (G). 
Methods: Pts with stage IIIB/IV NSCLC and adequate performance 
status (PS), haematological, hepatic, cardiac and renal function pre-
treated with DG were eligible. Pts received P 140 mg/m2 combined 
with C AUC3 or oV 45 mg/m2 combined with C AUC3 on days 1 
and 15 of a 30-day cycle. Stratification was done for PS and response 
to prior treatment. Primary endpoint was response rate (RR) and 
secondary endpoints were time to progression (TTP), survival and 
toxicity. 
Results: 153 pts were randomized to PC (n= 75) or oVG (n= 78). 
Median age was 62 and 65 yrs (range, 39-74 and 38-85 yrs, re-
spectively) and PS was 0-1 in 91% and 85%, for PC and oVC arms, 
respectively. In an intension-to-treat analysis, a trend for a higher 
response rate was recorded for the PC arm (18.6% vs 7.7%, p=0.056). 
Median TTP was 3.50 (range, 0.03-23.7) vs 3.06 (range, 0.36-18.50) 
mo for PC and oVC, respectively (p=0.287). Median overall survival 
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was 7.83 (range, 0.03–45.03) vs 7.60 (range, 0.50–30.26) mo and 
1-yr survival was 34.4% vs 34.6% for PC and oVC, respectively 
(p=0.633). The two arms exhibited similar and acceptable rates of 
grade 3 and 4 toxicity. 
Conclusions: No significant difference in response rate, TTP or sur-
vival was observed between PC or oVC arms. Both treatments were 
well tolerated. 
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A phase II trial of low-dose metronomic oral vinorelbine as 
salvage treatment in advanced non-small cell lung cancer 
(NSCLC)
Agelaki, S.; Kontopodis, E. D.; Kentepozidis, N.; Giassas, S.; 
Vamvakas, L.; Androulakis, N.; Kotsakis, K.; Sfakiotaki, G.; 
Mavroudis, D.; Georgoulias, V.
Department of Medical Oncology, University General Hospital of 
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Background: Frequent administration of low doses of cytotoxic 
drugs (metronomic chemotherapy) has been suggested to suppress 
tumor growth possibly by inhibiting tumor angiogenesis. We con-
ducted a phase II trial to evaluate the antitumor activity and toxicity 
of metronomic oral vinorelbine in pretreated patients with advanced 
or metastatic NSCLC. 
Methods: Patients (pts) with confirmed NSCLC and measurable 
disease, pretreated with at least one chemotherapy regimen, were 
eligible. Oral vinorelbine was administered at a fixed dose of 50 mgr 
three times a week until disease progression or unacceptable toxicity. 
Results: Thirty-three pts were enrolled. Median age was 62 years 
(range, 46-82), 88% were male, 91% had disease stage IV, and 79% 
had an ECOG performance status of 0-1. Histology was adenocarcin-
oma in 61%, squamous cell carcinoma in 24%, and undifferenti-
ated in 6% of the pts. Metronomic vinorelbine was administered as 
second-line treatment in 7 (21%) pts and as ≥ third line in 26 (79%). 
All pts were evaluable for toxicity and 31 (94%) for response. Grade 
3/4 neutropenia was observed in 8 pts (24,3%), grade 3/4 anemia 
in 2 (6,1%) and grade 4 thrombocytopenia in 1 (3%). Four (12,1%) 
pts suffered grade 3/4 febrile neutropenia. Severe non-hematologic 
toxicity included grade 3/4 nausea/vomiting in 3 (9,1%), diarrhea 
in 1 (3%) and fatigue in 4 (12,1%) pts. No treatment related deaths 
were observed. In an ITT analysis 2 (6,1%) partial responses (PR) 
were recorded, 4 (12,2%) pts had stable disease (SD) and 25 (75,8%) 
progressed. Tumor growth control rate (PR + SD) was 18,3%. 
Median time to tumor progression (TTP) was 2,33 months (range, 
1,0 - 20,53) and median overall survival (OS) 8,37 months (range, 1,4 
- 20,53). Median TTP and OS was 2,13 and 7,53 months, respectively 
in pts who received metronomic vinorelbine as ≥ third line treatment 
compared to 2,57 (p=0,107) and 10,7 (p=0,057) months, for those 
treated with metronomic vinorelbine in the second line. 
Conclusion: Metronomic oral vinorelbine is safe and demonstrates 
antitumor activity in a population consisting mostly of heavily pre-
treated pts with advanced NSCLC. 
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Intravenous vinorelbine (NVBiv) on D1 and oral 
vinorelbine (NVBo) on D8 in combination with carboplatin 
(CBDCA) as first line treatment in advanced non-small 
lung cancer (NSCLC) patients: preliminary results of a 
prospective study 
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Background: Lung cancer is the leading cause of cancer mortality 
in the Czech Republic. Approximately 80% of cases are NSCLC and 
65% of patients have advanced disease at the time of diagnosis. For 
patients with advanced NSCLC and preserved functional status, the 
standard therapy is a double agent platinum-based chemotherapy. 
Most patients who receive first-line chemotherapy experience disease 
progression within 3 to 6 months of initiating therapy and the median 
survival time observed is 8 to 10 months. In this situation, there is a 
need to find a therapeutic regimen with an administration as simple as 
possible and the most favorable toxicity profile.
The purpose of this trial was to evaluate the activity and feasibility of 
CBDCA together with NVBiv and NVBo.
Patients and Methods: Patients with advanced NSCLC received 
NVBiv 25 mg/m² on D1 and NVBo 60 mg/m² on D8 combined with 
CBDCA AUC5 on D1 every three weeks. In stage III, chemotherapy 
was followed by external radiotherapy. Outcomes included: Overall 
response, median survival and PFS. Response was assessed by im-
aging techniques after 4-6 weeks of treatment and was confirmed one 
month later by chest X-ray and/or CT scanning.
Results: 153 patients were treated: 121 men (79%) and 32 women 
(21%), median age 65 years. ECOG performance status at inclusion 
was 0 in 34 patients, 1 in 107 and 2 in 12 patients. Most patients had 
stage IIIB 66 (43%) and stage IV NSCLC 82 (54%). Adenocarcinoma 
was confirmed in 33 patients (22%), squamous-cell carcinoma in 94 
(61%) and other in 26 (17%). Complete response was confirmed in 1 
patient, partial response in 74 (49%), stable disease in 50 (33%), 27 
(18%) patients progressed and 1 was not evaluated. Major toxici-
ties (Grade 3-4) were neutropenia in 33 (21.6%), leucopenia in 13 
(10.6%), anemia in 4 (2.3%), and thrombocytopenia in 1 (0.7%) 
patients. Febrile neutropenia was observed in 2 (1.4%) patients. With 
a median follow-up period of 0.87 year, the median survival is 14.8 
months and the progression-free survival 10.6 months. Final results 
will be assessed further reported.
Conclusions: In this group of 153 non-selected patients with ad-
vanced NSCLC treated with NVB-CBDCA in first line, switching 
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from NVBiv to NVBo allows a more convenient and well tolerated 
treatment with evidence of high antitumour activity.
PD3.3.4 NSCLC - Advanced Disease I, Sat, 14:30 - 16:00
Retrospective analysis of a phase II study of nab-paclitaxel 
plus carboplatin in advanced NSCLC: response based on 
histology
Socinski, Mark A.1; Stroyakovsky, Daniil L.2; Manikhas, Georgiy 
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Background: Previously we reported the efficacy and safety results 
of various doses and schedule of nab-paclitaxel combined with every-
3-week (q3w) carboplatin AUC=6 as first-line therapy in patients 
with advanced non-small cell lung cancer (NSCLC). The present 
retrospective analysis was to elucidate if efficacy outcomes were 
modified by histologic subtypes in NSCLC. 
Methods: Patients with advanced NSCLC were entered sequentially 
into escalating dose cohorts (C) of nab-paclitaxel (q3w [C1-C4]: 225, 
260, 300, and 340 mg/m2; weekly for 2 weeks, followed by a week of 
rest [C5]: 140 mg/m2; weekly for 3 weeks, with no rest [C6-7]: 100 
and 125 mg/m2). Carboplatin (AUC=6) was administered on day 1 
q3w for all cohorts. Patients were evaluated for overall response rate, 
stable disease (SD) ≥16 weeks, progression-free survival (PFS), and 
overall survival (OS). 
Results: 166 patients were treated and analyzed for histology. Pa-
tient baseline characteristics were similar among the arms. Patients 
with histologic conformation of adenocarcinoma receiving weekly 
nab-paclitaxel achieved better efficacy compared with q3w sched-
ule (overall response rate [ORR]: 59.4% vs 23.5%, respectively, 
P = 0.003). Although not statistically significant, progression-free 
survival (PFS) and overall survival (OS) were higher in patients with 
adenocarcinoma receiving weekly nab-paclitaxel versus q3w. On 
the other hand, PFS was significantly higher (P = 0.014) and OS was 
increased, with no difference in ORR in patients with squamous cell 
carcinoma receiving q3w versus weekly nab-paclitaxel.
 Squamous Cell Carcinoma   P-values
  Weekly Every-3-week 
  n =41 n = 59 
 Overall Response Rate, n (%) 16 (39) 21 (36) 0.727
 Progression-free Survival, mo 4.8 7.7 0.014
 Overall Survival, mo 12.0 14.6 0.339
 Adenocarcinoma   P-values
  Weekly Every-3-week 
  n = 32 n = 34 
 Overall Response Rate, n (%) 19 (59) 8 (24) 0.003
 Progression-free Survival, mo 7.7 5.3 0.070
 Overall Survival, mo 13.2 10.7 0.341
Conclusion: nab-Paclitaxel in combination with carboplatin was 
effective in both squamous and nonsquamous NSCLC. Patients with 
adenocarcinoma histology receiving weekly nab-paclitaxel achieved 
significantly higher ORR (P = 0.003), and >2 months longer PFS 
compared with q3w schedule.
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Phase II study of amrubicin (AMR) in patients (pts) 
with non-small cell lung cancer (NSCLC) previously 
treated with platinum-based chemotherapy: preliminary 
results of West Japan Thoracic Oncology Group study 
(WJTOG0401)
Mitsuoka, Shigeki1; Kaneda, Hiroyasu2; Hayashi, Hidetoshi3; Sawa, 
Toshiyuki4; Goto, Isao5; Akita, Kenji6; Saito, Hiroshi7; Shibata, 
Kazuhiko8; Okamoto, Isamu2; Nakagawa, Kazuhiko2
1 Department of Respiratory Medicine, Graduate School of 
Medicine, Osaka City University, Osaka, Japan; 2 Kinki University, 
Osakasayama, Japan; 3 Kurashiki Central Hospital, Kurashiki, 
Japan; 4 Gifu Munisipal Hospitak, Gifu, Japan; 5 Osaka Medical 
College, Takatsuki, Japan; 6 Nagoya Central Hospital, Nagoya, 
Japan; 7 Aichi Cancer Center Aichi Hospital, Okazaki, Japan; 8 
Koseiren Takaoka Hospital, Takaoka, Japan
Background: AMR, a totally synthetic 9-aminoanthracycline, is a 
unique agent capable of inhibiting topoisomerase II. AMR has shown 
promising clinical activity for advanced NSCLC as well as SCLC. 
This trial was conducted to evaluate the efficacy and safety of AMR 
for pts with NSCLC previously treated with platinum-based chemo-
therapy. 
Methods: Eligible pts had a performance status 0 to 1, previous 
treatment with one platinum-based chemotherapy for advanced 
NSCLC, and adequate organ function. Pts received AMR 40 mg/m2 
intravenously on days 1-3 every 3 weeks. The primary endpoint was 
the objective response rate, which determined the sample size based 
on an optimal two-stage design. With the target activity level of 18% 
and the lowest response rate of interest set at 5%, 60 eligible patients 
were required with a 90% power to accept the hypothesis and a 5% 
significance level to reject the hypothesis.
Results: Sixty-one pts (median age, 63 years; range 51-74 years) 
were enrolled. The median treatment cycles were 2 (range, 1-15). 
No complete responses and 7 partial responses were observed, giv-
ing an overall response rate of 11.5% (95% CI, 4.7-22.2%). Twenty 
patients (32.8%) had stable disease and 34 patients (55.7%) had 
progressive disease as the best response. The overall disease control 
rate (complete response + partial response + stable disease) was thus 
44.3% (95% CI, 31.5-57.6%). The median overall survival and 1-year 
survival rate were 8.5 months (95% CI, 7.7-10.4 months) and 32.0% 
(95% CI, 20.7-44%), respectively. Grade 3/4 hematological toxici-
ties were neutropenia (82%), anemia (27.9%) and thrombocytopenia 
(24.6%). Grade 3/4 non-hematological toxicities were anorexia 
(9.8%), febrile neutropenia (29.5%) and pneumonitis (1.6%). One 
treatment-related death owing to infection was observed. No cardiac 
toxicity was observed. 
Conclusions: AMR exhibits significant activity with manageable 
toxicities as second-line therapy for advanced NSCLC. 
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Notable progression free survival (PFS) and disease 
control rate (DCR) with the halichondrin B analogue 
eribulin mesylate in advanced non-small cell lung cancer 
(NSCLC) patients (pts) previously treated with a taxane: a 
California Consortium/University of Pittsburgh/University 
of Chicago NCI/CTEP sponsored phase II trial
Gitlitz, Barbara J.1; Davies, Angela M.2; Belani, Chandra P.3; 
Athanassios, Argiris4; Ramalingam, Suresh S.5; Hoffman, Philip C.6; 
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Background: Eribulin Mesylate is a structurally simplified synthetic 
macrocyclic ketone analog of halichondrin B and has a unique mech-
anism of microtubule dynamic inhibition, distinct from other agents 
in this class. Thus, it was our hypothesis that pts with prior taxane 
based therapy would respond to this agent. We conducted a phase II 
trial of Eribulin Mesylate in prior taxane-treated NSCLC pts. 
Methods: Eligible pts included: histologically confirmed advanced 
NSCLC, previous treatment with platinum-based therapy and a 
taxane, no more than 2 prior regimens, measurable disease, Zubrod 
performance status ≤ 2. Pts were classified by taxane-sensitivity 
status: taxane sensitive (TS) (progression >90 days after taxane) or 
taxane resistant (TR) (progression during or <90 days after taxane). 
Treatment: Eribulin Mesylate 1.4 mg/m2 intravenously over 1-2 
minutes on day 1 and 8 of a 21 day schedule until disease progression 
or unacceptable toxicity. 
Results: 41 pts were entered. There were 3 (15%) objective re-
sponses (7.2+, 8.5+, 10.6 mo) of 20 TS pts; and no response of 21 
TR pts. Stable disease rate was 60% and 24% in TS and TR pts. 
respectively. Median progression free survival (PFS) is 6.3 mos TS 
pts. 95%CI (2.5-8.6 mos) and 1.2 mos TR pts. 95%CI (1.1-4.1 mos). 
Median number of cycles (range): TS 4 (1-14); TR 2 (1-7). Major 
toxicity included: 19 pts (46%) with grade 3 or 4 hematologic toxicity 
including only 1 episode of febrile neutropenia and 8 pts (20%) with 
grade 3 or 4 non-hematologic toxicity attributable to drug including: 
fatigue (1), dehydration (2), nausea (2), constipation (2). Only 1 pt 
developed grade 3 neuropathy (course 9). 
Conclusions: Eribulin Mesylate was well tolerated with encouraging 
objective response, PFS and DCR in the TS cohort. This cohort is 
currently enrolling using a 2-stage design, to accrue up to another 25 
pts.
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Weekly and every-3-week nab-paclitaxel followed by 
carboplatin as first-line therapy is effective in patients with 
advanced non-small cell lung cancer: final results of a phase II 
study
Stroyakovsky, Daniil L.2; Manikhas, Georgiy M.3; Makhson, Anatoly 
N.4; Cheporov, Sergey V.5; Orlov, Sergei V.6; Yablonski, Petr K.7; 
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Background: Solvent-based paclitaxel 175–225 mg/m2 every-3week 
(q3w) combined with carboplatin AUC=6 demonstrated a 17% to 
32% overall response rate (ORR) in patients with advanced non-
small cell lung cancer (NSCLC) (Kelly et al., 2001; Lilenbaum et 
al., 2005; Scagliotti et al., 2002; Schiller et al, 2002). In a phase I/
II study with similar patient population, weekly nab-paclitaxel alone 
as monotherapy demonstrated a 30% ORR and overall survival (OS) 
was 11 months (Rizvi et al, 2008). This study presents the final ef-
ficacy and safety results of weekly or q3w nab-paclitaxel combined 
with carboplatin AUC=6 q3w as first-line therapy for patients with 
advanced NSCLC.
Methods: Patients (≥18 years old with untreated stage IIIB/IV 
NSCLC) in this nonrandomized open-label phase II trial were en-
rolled sequentially into escalating dose cohorts (C) of nab-paclitaxel 
(q3w [C1-C4]: 225, 260, 300, and 340 mg/m2; weekly for 2 weeks, 
followed by a week of rest [C5]: 140 mg/m2; weekly for 3 weeks, 
with no rest [C6-7]: 100 and 125 mg/m2). Carboplatin (AUC=6) was 
administered on day 1 q3w for all cohorts.
Results: A total of 175 patients received treatments and were 
evaluable for efficacy (n = 25 / cohort). Patient baseline character-
istics were similar among the arms. Patients who received weekly 
nab-paclitaxel (C5-7) had higher ORR (47%) compared with nab-
paclitaxel q3w (30%, C1-4). In the weekly nab-paclitaxel groups 
(C5-7), the median progression-free survival (PFS) was 5.6, 6.2, and 
6.4 months, respectively, with an overall median PFS of 6.1 months. 
Median OS was 12.3 months in these weekly groups (range 11.3 to 
15). In the q3w nab-paclitaxel groups (C1-4), the median PFS was 
5.9 months (range 4.8 to 6.9). Median OS was 12.2 months in these 
groups (range 8.3 to 14.6). Disease control rate (≥16weeks of stable 
disease or confirmed ORR) was 56% and 46% in the weekly and q3w 
groups, respectively. Overall, the most common treatment-related 
nonhematologic severe (grade 3/4) toxicities in all cohorts were per-
ipheral neuropathy (19%) and fatigue (9%). The most common grade 
3/4 adverse event was neutropenia (60%). For toxicities reported 
≥10% in either group, less peripheral neuropathy, myalgia, arthralgia, 
and alopecia occurred with weekly dosing compared to q3w dosing. 
In particular, the incidence of peripheral neuropathy was lowest in 
the 100 mg/m2 and 140 mg/m2 weekly arms. Although patients who 
received the 100 mg/m2 weekly dose were among patients with the 
highest median dose delivered (1,420 mg/m2) among the weekly 
cohorts C5-7, incidences of grade 3/4 neutropenia and thrombocyto-
penia were lowest in patients in this cohort. 
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Conclusions: nab-Paclitaxel and carboplatin therapy is an effective 
therapy for advanced NSCLC. Based on the favorable efficacy and 
toxicity profile of the weekly schedule of nab-paclitaxel, a phase 
III, randomized, multicenter study comparing 100 mg/m2 weekly 
nab-paclitaxel and carboplatin (AUC=6 q3w) to q3w solvent-based 
paclitaxel and carboplatin (AUC=6 q3w) has been initiated.
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Second-line chemotherapy with S-1 and gemcitabine for 
NSCLC: phase II study of Thoracic Oncology Research 
Group (TORG) 0705
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Background: S-1 is a recently developed oral fluorinated pyrimi-
dine combined with other 2 components to increase 5-FU uptake in 
cancer cells, and to decrease intestine- and neurotoxicity by means 
of biochemical modulation. A previous phase I/II study of combina-
tion chemotherapy consisting of S-1 and gemcitabine determined its 
recommended dose and suggested its clinical relevance for elderly 
patients with untreated NSCLC (2008 ASCO, abst. # 19050). Based 
on this previous study, the same combination was tested in the 
second-line setting for NSCLC. 
Methods: Patients meeting all following criteria were eligible: 
proven NSCLC refractory or recurrent after previous single- or 
2-regimen chemotherapy including at least 1 platinum regimen, PS 
(0-1), adequate organ functions, measurable lesions by RECIST, 
life expectancy exceeding 3 months, and written informed consent. 
Patients with any of the following conditions were ineligible: primary 
site resected, requirement of thoracic irradiation, interstitial lung 
disease, pleural, pericardial effusion or ascites requiring treatment, 
symptomatic brain metastasis, concomitant malignancy or other 
inadequate condition. S-1 (60 mg/m2 bid, p.o. days 1 to 14) and 
gemcitabin (1,000 mg/m2, days 8 and 15) were administered every 
3-week until reaching PD unless encountering defined skip and stop 
criteria. Calculated minimum sample size was 29 based on Simon 
two-stage optimal design with a target and threshold response rate 
of 20 and 5%, respectively, α error=0.05 and β error=0.10; planned 
sample size was 32. The primary endpoint was response rate, and the 
secondary ones were toxicity and survival time. 
Results: From Nov. 2007 to Sep. 2008, 34 patients (consisting of 29 
with adeno-, 3 with squamous, 1 with large cell carcinoma and 1 with 
NSCLC not further specified) with a median age of 61.5-years were 
enrolled. Chemotherapy was administered for a median 4 courses 
(range, 1 - more than 9). Compliance of S-1 was excellent and more 
than 90% in the first 3 courses in all cases. Response rate was 23.5% 
(8/34, 95% CI: 9.1-38.0%) consisting of 8 PR, 14 SD, 9 PD and 3 
NE. Prevailing toxicity of grade 3 or 4 in entire courses consisted of 
neutropenia (44%), thrombocytopenia (9%) and anemia (18%), with-
out other serious one. At the median follow up time of 8.9 months, 
MST has not been reached yet. 
Conclusions: This 2nd-line chemotherapy for NSCLC showed prom-
ising efficacy with tolerable toxicity.
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Randomized phase II study of two different schedules of 
gemcitabine and oral S-1 in chemo-naïve patients with 
advanced non-small cell lung cancer
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Background: TS-1, a novel oral fluorouracil derivative, has been 
shown to have anti-tumor activity with relatively mild adverse ef-
fects, and it is used in the treatment of NSCLC in Japan. The combin-
ation of gemcitabine (GEM) and 5-FU displays a marked synergistic 
cytotoxic effect in a sequence-dependent manner in in vitro assay. 
This study was conducted in order to evaluate the efficacy and safety 
and to compare dosing schedules of gemcitabine combined with TS-1 
in chemo-naïve NSCLC patients (pts). 
Methods: Pts with chemo-naive stage IIIB/IV NSCLC, an ECOG-PS 
of 0 or 1, and normal renal, liver, and bone marrow functions were 
randomized into 1 of 2 treatment arms. Oral TS-1 was administered 
daily from day 1 to 14, and GEM was given on days 1 and 8 (Arm A) 
or days 8 and 15 (Arm B). This cycle was repeated every 21 days. 
Results: A total of 80 pts were entered and 79 pts, treated in this 
trial. Randomization was well balanced across patient characteristics 
except for cell type (adenocarcinoma/squamous cell carcinoma = 
37/4 (Arm A), 27/10 (Arm B)). Grade 3/4 hematological toxicities 
were neutropenia (54%), febrile pneutropenia (9%), thrombocyto-
penia (11%) and anemia (4%). The hematological toxicity profiles did 
not differ very much between the two arms. Grade 3 pneumonitis was 
observed in 2 pts (3%). The response rate was 23.1% (95% confi-
dence interval [CI]=11.1-39.3%) in Arm A and 30.6% (95% CI=16.3-
46.1%), Arm B. Median time-to-progression (TTP) in Arm A was 4.1 
months (95% CI=2.8-5.6) and Arm B, 5.5 months (95% CI=3.8-6.3) 
(p=0.75). Median survival time in Arm A was 15.5 months (95% 
CI=8.0-23.1) and Arm B, 18.8 months (95% CI=11.7-24.5) (p=0.27).
The 1-year survival rate was 53.8% (95% CI= 38.4-68.9) in Arm A 
versus 65.8% (95% CI=50.7-80.9) in Arm B and 2-year survival rate 
was 34.2% (95% CI=19.6-48.7) in Arm A as opposed to 31.6% (95% 
CI=16.8-46.4) in Arm B. 
Conclusion: The combination of GEM and TS-1 was determined to 
be feasible and effective for advanced NSCLC, and these results, par-
ticularly the favorable MST of Arm B, warrant further investigation 
of the Arm B dosing schedule for this combination for NSCLC.
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EC-FV-03: a phase II study of EC145 (folate-receptor 
targeted therapy) in patients with advanced lung cancer
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Background: EC145 consists of a highly potent vinca alkaloid 
(desacetylvinblastine hydrazide / DAVLBH) conjugated to the 
vitamin folate. The EC145 molecule uses folate to target the folate 
receptor (FR), found at high levels on the surface of epithelial tumors, 
including NSCLC, ovarian, endometrial and renal cancers, etc. By 
binding directly to tumors that express FR, EC145 delivers the vinca 
moiety directly to cancer cells while avoiding normal tissue. Upon 
binding, EC145 is internalized into the cancer cell via endocytosis, 
releasing DAVLBH and causing cell death by inhibiting formation of 
the mitotic assembly required for cell division. 
We also report on the use of an FR-directed technetium-based 
imaging agent (EC20) used to identify patients that over-expressed 
FR. EC20 is a chemical conjugate of folate coupled to a technetium-
chelating moiety. EC20 imaging is being developed as a non-invasive 
method for identifying patients whose tumors express FR, and are 
thus candidates for therapy with EC145. 
Methods: EC-FV-03 is a single arm phase II study of the EC20 im-
aging agent (used to identify patients whose tumors express FR) and 
the FR-directed therapeutic agent EC145 in patients with advanced 
adenocarcinoma of the lung. Eligibility includes PS of ≤ 2, adequate 
organ function, prior exposure to ≥ 2 cytotoxic chemotherapeutic 
regimens, RECIST-defined measurable disease and a 99mTc-EC20 
positive scan. CT scans are performed every 8 weeks and adverse 
events are assessed using NCI CTCAE v. 3.0 criteria. Intravenous 
EC145 is administered as a bolus injection weeks 1-3 q 4-week cycle 
(x 2 cycles; induction phase), followed by injections M, W, F weeks 
1 and 3 of a 4-week cycle (maintenance phase). Patients remained on 
study until PD or intolerable toxicity. 
Results: Thirty-six (of 41 projected total) patients have been enrolled 
and 69% (36/52) of scanned patients were FR+ by EC20 scan. 
Twenty-four male and twelve female patients have been treated with 
EC145; median of three prior chemotherapeutic regimens (range 2 to 
8), median patient age is 66 years. Disease control rate (CR+PR+SD 
at 8 weeks) is 40% (12/30 evaluable patients). 58% (7/12) of patients 
with SD at 8 weeks also had a duration of response 6 months or 
greater. The most frequent drug related adverse events (all grades/
grade ≥ 3) in the 22 patients for which full toxicity data are available 
include fatigue (8/1), constipation (6/0), anorexia (5/1), weight loss 
(3/0), and dyspepsia (2/0).
Conclusions: Accrual into EC-FV-03 is nearing completion and 
final results will be available in Spring 2009. This report of EC145 in 
patients with advanced and heavily pretreated adenocarcinoma of the 
lung provides preliminary data indicating that EC20 can be used as 
a non-invasive method to identify patients whose tumors express FR 
and that subsequent treatment with EC145 results in disease stabiliza-
tion in a significant percentage of patients in the setting of low tox-
icity. These encouraging data indicate that further (i.e., randomized) 
clinical testing of EC20 / EC145 in patients with advanced NSCLC is 
warranted. 
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Phase II study of nedaplatin, a cisplatin analogue, and 
docetaxel in patients with advanced squamous cell lung 
carcinoma
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Background: New strategy including EGFR- and VEGF-targeting 
therapy emerges and the survival of adenocarcinoma has been 
improving. However the treatment of squamous cell lung cancer is 
still halted. Nedaplatin is a second generation platinum compound 
which is active against squamous cell lung cancer as single agent, 
with response rate of approximately 40%. To evaluate the efficacy 
and tolerability of combination chemotherapy consisting of neda-
platin and docetaxel, we conducted a phase II study.
Methods: Eligibility criteria were as follows; histologically or cyto-
logically proven squamous cell lung carcinoma; aged 20 to 75 years; 
ECOG performance status (PS) of 0 to 1; clinical stage III (unfit for 
definitive radiotherapy), IV or recurrence after surgery; chemother-
apy naive; and adequate organ function.. Patients were treated with 
docetaxel 60 mg/m2 day 1 given intravenously and nedaplatin 100 
mg/m2 day 1 given intravenously, which was determined by a prior 
phase I study. The treatment cycles were repeated every 3 weeks 
from 2 to 4 cycles. The primary endpoint was response rate, and the 
secondary endpoint was overall survival, progression-free survival, 
and tolerability.
Results: 21 patients were enrolled. 18 were male. Median age was 
67 years. Stage III/IV/recurrent disease were 11/8/2, respectively. 5 
patients were ECOG PS of 0. The objective response rate was 62%, 
with no complete response and 13 partial response out of 21. Median 
progression-free survival was 7.4 months (95% CI 3.5-11.4 months), 
and median overall survival did not reached. The adverse events were 
relatively mild and manageable except for one patient died of sepsis. 
The autopsy revealed that the patient was affected by liver cirrhosis, 
which was not apparent before treatment.
Conclusions: This histology-specific phase II trial showed that com-
bination chemotherapy of nedaplatin and docetaxel produced promis-
ing response rate and progression-free survival. We are planning the 
multicenter, confirmatory phase III trial in patients with advanced 
squamous cell lung cancer. UMIN000001227.
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Triplet chemotherapy more active than doublet in 
squamous cell carcinoma
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Purpose: Paclitaxel + Gemcitabine + Cisplatin showed promising re-
sults in a phase II trial with 59% response rate and 48 weeks median 
survival. Hence, it was compared to a standard doublet regimen to 
examine for superiority.
Methods: Histologically verified inoperable NSCLC patients (pts) 
aged 18-75 years, performance status 0-2 and normal organ function 
were randomized to regimen A (Paclitaxel 180 mg/m2 and Cisplatin 
100 mg/m2 day 1 with Gemcitabine 1000 mg/m2 day 1 and 8 every 
3 weeks) or regimen B (Cisplatin 100 mg/m2 day 1 and weekly i.v. 
vinorelbine every 4 weeks) for maximum 6 cycles. Totally 428 pts 
were needed to detect a 30% median survival increase with 80% 
power and two-sided type 1-error of 5%. 
Results: 221 pts.received reg. A and 222 reg. B. Overall, median age 
was 62 years (range 38-75 yrs), 58% were males, 11% had perform-
ance status 2, 62% stage IV disease, 46% adenocarcinoma, and 28% 
squamous cell carcinoma (SCC), equally distributed between the 
regimens. Median no. of treatment courses were 4 in both regimens. 
Frequencies of CTC grade 4 leucocytopenia, thrombocytopenia, 
or grade 3+4 nausea, neurotoxicity, or nephrotoxicity were 15%, 
17%, 19%, 8%, and 8% in reg. A, and 18%, 5% (p=0.001), 17%, 
11%(p=0.014), and 7% in reg. B, respectively. Febrile leucopenia epi-
sodes were 14% and 10% in reg. A and B, while thrombocytopenic 
bleedings occurred in 12% and 4% of pts (p=0.008), respectively, 
with two toxic deaths due to bleeding in reg. A and none in reg. B. 
Response rates were 52% and 49% in reg. A and reg. B, median 
response durations were 263 and 217 days (not significant), median 
times to progressions (TTP) 6.7 and 5.8 months (p=0.453), and 
median survival times 11.4 and 10.8 months (p=0.415), respectively. 
In SCC subtype, TTP was higher in reg. A than reg. B (medians 7.0 
mths vs. 4.1 mths, p=0.001) and survival was increased (medians 
13.5 mths vs 9.7 mths, p=0.020).
Conclusions: The triplet regimen A had significantly higher activ-
ity in SCC, both with respect to TTP and to survival with median 
survival in excess of one year and may be preferred in this histologic 
subtype.. 
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First-line treatment of over 1000 Italian patients affected 
by stage IIIB-IV NSCLC: results from the observational 
“Sun” (Survey on the Lung Cancer Management) study
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Background: Treatment options of locally advanced or metastatic 
non-small cell lung cancer (NSCLC) have substantially evolved dur-
ing the last decade. The positive impact of chemotherapy on survival, 
compared with supportive care alone, has been demonstrated by sev-
eral meta-analyses. The development of third-generation agents with 
better efficacy/toxicity ratios, such as vinorelbine or gemcitabine, has 
led to an improved therapeutic management of NSCLC, especially 
when tailored to patients’ comorbidities and performance status. 
Little is known about the actual approach in clinical practice in Italy.
Objective: To describe first-line pharmachological treatment (FLPT) 
choices and clinical outcomes from the SUN (Survey on the Lung 
Cancer Management) study.
Methods: SUN is a 12-month longitudinal observational study aimed 
at enrolling patients aged ≥18 years and newly diagnosed stage IIIB-
IV NSCLC in 74 oncology/pneumological centers throughout Italy. 
Performance Status (PS) was evaluated by means of ECOG Scale.
Results: A cohort of 1003 stage IIIB-IV NSCLC Italian patients was 
enrolled from January 2007 to January 2008 and followed-up for one 
year.
Eleven percent of patients did not receive any pharmacological treat-
ment at baseline, 11% started FLPT in clinical trial. The remaining 
patients (N=789) started FLPT according to site clinical practice. 
Patients who started FLPT had PS<2 in 79% of cases vs 47% of 
patients who did not begin any pharmacological treatment (p<0.001). 
Moreover the former were <70y old in 65% of cases vs 47% of 
patients who did not start pharmacological treatment (p<0.001). 
NSCLC stage did not play a key role in pharmacological treatment 
start (p=0.1266).
Baseline features of the 789 NSCLC patients with FLPT according to 
site clinical practice were: mean age 65 (DS=10, with 37% ≥ 70) yrs, 
75% males, 82% current or previous smokers, 78% with PS<2, 77% 
stage IV, 44% adenocarcinoma. FLPT was chemotherapy (CT) alone 
(86%), CT+ target therapy (2.5%), CT+ radiotherapy (11%). Combin-
ation chemotherapy was given in 79% of patients; the most frequent 
combinations were gemcitabine with cisplatin or carboplatin (42% 
and 27% respectively). Gemcitabine and vinorelbine were given as 
monochemotherapy in 56% and 33% of patients, respectively.
First-line CT lasted 75±46 days, and 4±2 cycles were performed on 
average.
Thirty percent of patients receiving FLPT switched to a second-line 
pharmachological treatment, 7% of patients finished FLPT not fol-
lowed by any further pharmacological treatment, 54% died before the 
end of FLPT, 9% dropped out.
Conclusions: SUN results report almost all patients undergoing 
cancer treatment: combination chemotherapy represents the main 
therapeutic approach for locally advanced or metastatic NSCLC 
patients. Good PS and younger age are the main criteria for providing 
treatment.
Support: Study fully sponsored by Roche, Italy.
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PD3.5.3 NSCLC - Advanced Disease I, Sat, 14:30 - 16:00
Phase II study of bevacizumab in combination with 
cisplatin and docetaxel as first line treatment of patients 
(p) with metastatic non squamous non-small-cell lung 
cancer (NSCLC) 
Paredes, Alfredo1; Cobo, Manuel2; Ferrer, Neus3; Méndez, Miguel4; 
Muñoz-Langa, José5; Rueda, Antonio6; Álvarez de Mon, Melchor7; 
Sánchez-Hernández, Alfredo8; Sánchez-Tauler, Rocío9; Torrego, Juan 
Carlos10
1 Hospital Donostia, San Sebastián, Spain; 2 Hospital Regional 
Universitario Carlos Haya, Málaga, Spain; 3 Hospital Son Llàtzer, 
Palma de Mallorca, Spain; 4 Hospital Universitario de Móstoles, 
Móstoles, Spain; 5 Hospital Universitario Dr. Peset, Valencia, 
Spain; 6 Hospital Universitario Puerta del Mar, Cádiz, Spain; 7 
Hospital Universitario Príncipe de Asturias, Alcalá de Henares, 
Spain; 8 Hospital Provincial de Castellón, Castellón, Spain; 9 Roche 
Farma, S.A., Madrid, Spain; 10 Hospital Universitario Río Hortega, 
Valladolid, Spain
Background: Bevacizumab (B), in addition to platinum-based 
chemotherapy, is indicated for 1st line treatment of p with advanced 
NSCLC other than predominantly squamous cell histology. B has 
been shown to improve progression free survival (PFS) and over-
all survival (OS) when combined with cisplatin/gemcitabine and 
carboplatin/paclitaxel, respectively. However, there are limited data 
on the safety and efficacy of B in combination with other widely 
used chemotherapy doublets for NSCLC. This is a single-arm, open-
labeled, single-stage phase II trial of cisplatin (C), docetaxel (D) and 
B for NSCLC.
Methods: Eligibility criteria: chemo-naïve, stage IIIB wet or IV, 
non-squamous NSCLC, PS 0-1, no brain metastases and no history 
of gross hemoptysis. P received D (75 mg/m2), C (75 mg/m2), and B 
(15 mg/kg iv) on day 1 every 3 weeks for up to 6 cycles, followed by 
B 15 mg/kg alone every 3 weeks until disease progression or toxicity. 
Primary endpoint: PFS. 
Results: 50 p were enrolled (enrollment completed): 24% female, 
median age 60 (36-74), PS 1: 64%, adenocarcinoma: 72%; stage IV: 
92%. Two p did not start treatment. Median follow-up is 5.3 months 
(range 0-13.6). Median number of cycles of B was 7 (range 0-18). 
56% completed 6 cycles of treatment; 24% received ≥ 12 cycles of B. 
Most frequent grade ≥ 3 toxicities: diarrhea (14.6%), fatigue (14.6%), 
dyspnea (9.8%), anorexia (4.9%), alopecia (4.9%), esophagitis 
(4.9%), constipation (4.9%), mucositis (12.2%), proteinuria (4.9%); 
hematological toxicities: neutropenia (22%), febrile neutropenia 
(9.8%), leucopenia (14.6%), lymphopenia (4.9%). Of interest, 41.5% 
developed grade <3 epistaxis and 17% hypertension (1 p grade 3). 
One p died due to hemoptysis. 46 p were evaluable for response: 29 
PRs (ORR: 63%). 18 of 48 p have experienced progression or death 
with a median SLP of 7.8 months (95% CI: 6.6-NR). Median OS is 
13.5 months (95% CI: 12.7-13.6; 81.2% p censored); 1-year survival 
is 83.9% (95% CI: 67.4%-92.5%).
Conclusions: Treatment with C, D and B, followed by maintenance 
B in 1st line of advanced nonsquamous NSCLC shows an acceptable 
toxicity profile and promising efficacy. Final results will be presented.
PD3.5.4 NSCLC - Advanced Disease I, Sat, 14:30 - 16:00
A phase II trial of pemetrexed (P), gemcitabine (G), 
and bevacizumab (BV) in untreated patients (pts) with 
advanced non-small cell lung cancer (NSCLC) 
Wozniak, Antoinette J.1; Kalemkerian, Gregory P.2; Gadgeel, 
Shirish M.1; Schneider, Bryan J.3; Valdivieso, Manuel1; Smith, 
Daryn1; Hackstock, Deborah M.1; Chen, Wei1; Heilbrun, Lance K.1; 
Ruckdeschel, John D.1
1 Karmanos Cancer Institute, Detroit, MI, USA; 2 University of 
Michigan Medical Center, Ann Arbor, Mi, USA; 3 Weill Cornell 
Medical College, New York, NY, USA
Background: P and G are active agents with acceptable toxicity 
profiles in the treatment of NSCLC. The addition of BV to chemo-
therapy has resulted in a significant improvement in survival for pts 
with non-squamous NSCLC. We are currently conducting a phase II 
trial of P, G and BV on a novel every two week schedule in untreated 
pts with advanced NSCLC.
Methods: Advanced, non-squamous NSCLC pts with measurable/
evaluable disease, no prior treatment for advanced disease, PS 0-1, 
adequate hepatic, renal and bone marrow function, treated brain 
metastases were eligible. No unstable hypertension/cardiac disease/
vascular disease, hemoptysis, anti-coagulation, recent major surgery, 
no cavitation or close proximity of primary cancer to a major vessel 
were allowed. Pts received P 500 mg/m2, G 1500 mg/m2, and BV 10 
mg/kg every 2 weeks for 12 cycles. Doses were reduced to P 400 mg/
m2 and G 1200 mg/m2 when grade 4 neutropenia occurred in the first 
2 patients. BV was continued until disease progression or toxicity. 
Planned accrual is 42 patients. Primary endpoint is progression-free 
survival. Secondary endpoints are response rate (RR), toxicity, time 
to progression and overall survival.
Results: 23 pts have been accrued. Median age 58 yrs, males-57%, 
stage IV 87%, adenocarcinoma 78%. 21 pts are response evaluable 
(2 pts were non-evaluable). 12/21 (57%) pts had a response (1 CR, 
9 PR, 2 unconfirmed PR) (90% CI for RR is 0.35 - 0.76), and 4 had 
SD (19%) for a disease control rate of 76%. 3 of the 21 were too 
early to assess. Currently the median treatment cycles for all pts are 
8 (range 1-12). All pts are evaluable for toxicity. Grade 3-4 toxicities: 
neutropenia 5, anemia 1, thrombocytopenia 2, lymphopenia 1, febrile 
neutropenia 2, fatigue 5, hypertension 1, GI 4, ALT/AST 3, pneumon-
itis 1, muscular weakness 1, metabolic 3, otitis media 1, leukocytes 
(total WBC) 3, PE 1, and DVT 1.
Conclusion: The combination of P, G, and BV is a very active and 
tolerable treatment for NSCLC despite the preliminary nature of these 
results. Updated information will be presented at the meeting.
This research is supported by Lilly Oncology and Genentech. 
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S0536: Carboplatin, paclitaxel, cetuximab and 
bevacizumab followed by cetuximab and bevacizumab 
maintenance in advanced non-small cell lung cancer 
(NSCLC), a SWOG phase II study
Kim, Edward S.1; Herbst, Roy S.1; Moon, James2; Redman, Mary 
W.2; Dakhil, Shaker R.3; Hirsch, Fred R.4; Mack, Phil5; Franklin, 
Wilbur4; Kelly, Karen6; Gandara, David 5
1 University of Texas M. D. Anderson Cancer Center, Houston, TX, 
USA; 2 Fred Hutchinson Cancer Research Center, Seattle, WA, 
USA; 3 Cancer Center of Kansas, Witchita, KS, USA; 4 University 
of Colorado Cancer Center, Aurora, CO, USA; 5 UC Davis Cancer 
Center, Sacramento, CA, USA; 6 University of Kansas, Topeka, KS, 
USA
Background: Both Cetuximab (CX) and Bevacizumab (B) in 
combination with platinum-based chemotherapy have demonstrated 
improved overall survival (OS) in advanced NSCLC (FLEX, E4599). 
Given the biologic rationale for combining EGFR and VEGFR 
targeted agents in lung cancer, S0536 investigated the safety and ef-
ficacy of Carboplatin (CB), Paclitaxel (P) and CX plus B. 
Methods: Eligibility: treatment-naïve advanced stage non-squamous 
cell NSCLC, no requirement for EGFR positivity, PS 0-1, no brain 
metastases or hemoptysis. Treatment: CB AUC 6, P 200 mg/m2, B 
15 mg/kg IV on day 1 every 3 weeks, and CX 400 mg/m2 on day 1 
then 250 mg/m2 weekly for up to 6 cycles, followed by B 15 mg/
kg every 3 weeks and CX 250 mg/m2 weekly until progression. The 
primary endpoint was feasibility defined by the frequency and sever-
ity of ≥grade 4 hemorrhagic toxicities. Secondary endpoints included 
response rate, progression-free survival (PFS), OS and toxicity. 
Results: 110 pts enrolled from August 2006 to September 2007; 104 
assessable. Pt characteristics: median age 64 years (range 42-78), 
Male/Female 52/52, PS 0/1 43/61, stage IIIB/IV 9/95, adenocarcin-
oma: 81, current/former smoker: 82. Overall toxicities were accept-
able and comparable to S0342 and E4599. Primary endpoint was met 
with grade ≥4 hemorrhage of 2% (95% CI: 0-7%). There were 4 treat-
ment-related deaths: lung hemorrhage (2), infection (1), unknown (1). 
Partial response (PR) was 51/95 assessable (54%; 43%-64%); Stable 
disease (SD) was 22/95 (23%). Disease control rate (PR+SD): 77%. 
With median follow up of 15 months (mos), PFS is 7 mos (18 pts 
remain progression-free) and OS is 14 mos. 1 year survival is 57% 
(47-67%). EGFR IHC by H score (>0 vs 0) showed a nonsignificant 
trend toward improved survival: 15 vs 11 mos (p=0.14). 
Conclusions: Combination CB/P, CX plus B demonstrates safety, 
tolerability and efficacy in advanced NSCLC and is the most active 
regimen studied to date in SWOG. Additional S0536 biomarker 
studies including tissue (EGFR FISH and k-ras) and blood (cytokine/
angiogenic profiling) are being performed. S0819, a Phase III trial of 
CB/P ± CX (plus B in eligible pts) is designed to validate the com-
bination therapy and EGFR FISH as a predictive biomarker. 
PD3.5.6 NSCLC - Advanced Disease I, Sat, 14:30 - 16:00
Multicenter phase II trial of motexafin gadolinium (MGd) 
and pemetrexed (PEM) for second-line treatment in 
patients with non-small cell lung cancer (NSCLC)
Edelman, Martin J.1; Otterson, Gregory A.6; Leach, Joseph 4; 
Malpass, Thomas5; Salgia, Ravi3; Jones, Dennie7; Szakacs, Nancy8; 
Govindan, Ramaswamy2
1 University of Maryland Greenebaum Cancer Center, Baltimore, 
Maryland, USA; 2 Washington University, St. Louis, MO, USA; 3 
University of Chicago, Chicago, IL, USA; 4 Park Nicollet Institute, 
St Louis Park, MN, USA; 5 Virginia Mason Medical Center, Seattle, 
WA, USA; 6 Ohio State University, Columbus, OH, USA; 7 University 
of New Mexico Health Science Center, Albuquerque, NM, USA; 8 
Pharmacyclics, Sunnyvale, CA, USA
Background: Motexafin gadolinium (MGd), disrupts redox-depend-
ent pathways by inhibiting oxidative stress-related proteins leading 
to apoptosis. MGd selectively targets tumor cells, disrupting energy 
metabolism and repair mechanisms, rendering cells more prone 
to apoptosis. Preclinical studies with MGd and pemetrexed show 
significant tumor growth delay in lung cancer cell lines. Prior studies 
demonstrated that full doses of both agents in combination are well 
tolerated. 
Methods: Pts with NSCLC, PS 0-1, one prior platinum containing 
regimen and normal organ function were treated with MGd 15 mg/
kg and pemetrexed 500 mg/m2 q21days. Pts were allowed to receive 
more than one regimen if the initial treatment was in the adjuvant 
or curative setting and administered >12 mo earlier. The primary 
endpoint was to demonstrate a 40% rate of 6 month progression free 
survival (PFS). 
Results: 72pts (30F,42M), PS 0/1 (30/42), median age 63 y were 
enrolled. Histology: squamous/adeno/other: 28%, 42%, 38%. Current 
or former smokers= 96%. Number of prior regimens: 1: 69%; 2:26%, 
>2:4%. Response to first line chemotherapy: nonresponder 18%, re-
sponse with TTP <3 mo, 36%, response with TTP > 3mo, 46%. Medi-
an number of cycles administered (range) 2 (1-12). Toxicity: grade 
3/4 ANC- 8.3%, febrile neutropenia - 1.4%, plts - 8.3%, fatigue 9.7%, 
pneumonia - 11.1% Response: 0 CR/7.8 % PR/56.3% SD/34.4% PD. 
6 mo PFS = 16%, Median PFS = 2.3 mo, OS = 6.6 mo. 
Conclusions: 1. The combination of MGd and PEM was well toler-
ated. Toxicity was similar to that of PEM alone. 2. The study did not 
achieve its endpoint of 40% 6 mo PFS. 3. RR, PFS and OS did not 
appear markedly different than prior phase II studies of PEM alone. 
4. There are no plans for further development of this combination.
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PD4.1.1 Mesothelioma and Small Cell Lung Cancer, Sun, 14:30 - 16:00
Phase I trial of cisplatin, pemetrexed, and imatinib 
mesylate in chemo-naive patients with unresectable 
malignant pleural mesothelioma
Tsao, Anne S.; Liu, Diane; Lee, Jack J.; Heymach, John; Pisters, 
Katherine; Brewer, Hannah; Hong, Waun K.; Blumenschein, George
University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Background: Malignant pleural mesothelioma (MPM) tumor cells 
express both platelet-derived growth factor (PDGF) and its receptor 
(PDGFR). Preclinical studies suggest that an autocrine growth loop 
mechanism exists. Additional studies hypothesize that targeting PDG-
FR in the stroma can lead to increased chemotherapy uptake into tumor 
cells. We conducted a phase I trial of cisplatin-pemetrexed and imatinib 
mesylate, a PDGFR inhibitor, in chemo-naïve patients with MPM. 
Methods: A standard 3+3 dose escalating trial schema was utilized. 
The inclusion criteria consisted of no prior therapy, PS 0-2, measur-
able disease, and adequate organ function. Imatinib mesylate was 
taken orally every day followed by cisplatin-pemetrexed adminis-
tered every 4 weeks. Table illustrates the dosing schema. The primary 
endpoint was to establish the MTD and secondary endpoints included 
response rate, progression-free and overall survival, safety/toxicity, 
serum and tumor PDGF/PDGFR levels, and perfusion CT results. 
Results: 13 patients were registered on the trial; eleven are evaluable 
for safety and toxicity. The study is currently enrolling patients at 
dose level 3. Median age was 64; 3F:10M; histology: 6 sarcomatoid, 
4 epitheliod, 3 biphasic. The MTD was established at dose level 3 
with the DLT of nausea and vomiting. The main side effects associ-
ated with this regimen have been grades 1-2 fatigue, edema (lower 
extremity, periorbital), hypomagnesemia, anorexia, nausea, and 
vomiting. One patient each had grade 3 neutropenia and anemia. One 
patient had grade 3 nausea/vomiting. There are no other grade 3 or 
4 toxicities. Ten patients are evaluable for best response: 1 partial 
response, 2 mixed response, 4 stable disease, and 3 progression of 
disease. 3 patients were inevaluable for response – one was non-
compliant and only received 5 days of imatinib before withdrawing, 
the second withdrew after receiving one cycle of therapy due to social 
issues, and the last patient developed grade 3 nausea/vomiting during 
cycle 1 and had to come off of the trial. 
Conclusions: Cisplatin-pemetrexed and imatinib mesylate is reason-
ably tolerated and may have activity in certain MPM patients. Trans-
lational studies with serum/tissue are underway. Targeting PDGFR 
with platinum-pemetrexed should be studied further in MPM. 
 Dose Level Cisplatin Dose Pemetrexed Dose Imatinib mesylate Dose
 0 60 500 300
 1 75 500 300
 2 75 500 400
 3 75 500 600
Sponsored by: NIH K12 Clinician Scientist Award
PD4.1.2 Mesothelioma and Small Cell Lung Cancer, Sun, 14:30 - 16:00
A phase II study of the VEGFR inhibitor pazopanib (P) 
in patients with newly diagnosed or relapsed malignant 
pleural mesothelioma (MPM): an NCCTG study 
Molina, Julian R.1; Mandrekar, Sumithra J.1; Allen Ziegler, Katie L.1; 
Soori, Gamini S.2; Rowland, Kendrith M.3; Schild, Steven E.4;  
Ivy, Percy5; Adjei, Alex A.6
1 Mayo Clinic, Rochester, MN, USA; 2 Missouri Valley Cancer 
Consortium CCOP, Omaha, NE, USA; 3 Carle Cancer Center, 
Urbana, IL, USA; 4 Mayo Clinic, Scottsdale, AZ, USA; 5 Cancer 
Therapy Evaluation Program National Cancer Institute, Rockville, 
MD, USA; 6 Roswell Park Cancer Institute, Buffalo, NY, USA
Background: MPM is a lethal tumor with a median survival of 7–11 
months. MPM is characterized by distinct angiogenesis with cells 
often expressing the vascular endothelial growth factor (VEGF). 
Pazopanib (P) is an orally active multiple kinase inhibitor of VEG-
FR-1, VEGFR-2, VEGFR-3, PDGFR-alpha and –beta, and c-kit. An 
antitumor effect with VEGF pathway inhibition is well established.
Methods: This CTEP sponsored phase II study was designed to 
assess the efficacy of P (800 mg QD every 3 weeks) in patients with 
newly diagnosed or relapsed MPM. A single stage three outcome 
phase II design with an interim analysis (IA) after the first 28 evalu-
able patients was used to test the hypothesis that the true success of 
PFS6: progression free at 6 months (m) and on treatment is at least 
65%. The trial would be terminated at the IA if only at most 14 suc-
cesses are observed. 
Results: The trial was permanently closed to accrual as of Decem-
ber 26, 2008 after not passing the IA. Thirty four pts (28 males, 6 
females) with a median age of 73 years were enrolled. 44% (15) 
had prior pemetrexed based therapy for MPM (47% PS=1or2), and 
56% (19) had no prior treatment for MPM (63% PS=1or2). Grade 3 
or higher adverse events (AEs) were seen in 65% of pts, and grade 
4 or higher AEs were seen in 12% of pts. Two pts had grade 4 AEs 
deemed at least possibly related to treatment: fatigue and ARDS. 
The median follow-up was 8.1 m on alive pts. The clinical benefit 
rate (confirmed response and stable disease >=6 weeks) was 56% 
(untreated: 63% (12/19); previously treated: 47% (7/15)). The median 
overall survival (OS) was 11.1 m (untreated: 14.4 m; previously 
treated: 5.0 m); and the median PFS was 4.4 m (untreated: 5.4 m; 
previously treated: 2.0 m). Only 10 of the first 28 (36%; 6 untreated; 
4 previously treated) pts met the PFS6 success criteria, thus not pass-
ing the protocol-defined IA criteria. 
Conclusions: Pazopanib at a dose of 800 mg daily x 21 days is very 
well tolerated for this group of pts. 63% of pts who received singe 
agent Pazopanib as first line treatment had PS of 1 or 2, and a median 
OS of 14.4 months, which represents an improvement of 2.2 m over 
more toxic regimens such as cisplatin plus pemetrexed (OS: 12.2 m). 
Based on these preliminary findings, we believe that Pazopanib war-
rants further study in the first line setting for MPM.
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Phase I trial of neoadjuvant dasatinib in patients with 
resectable malignant pleural mesothelioma
Tsao, Anne S.; Gil, James; Rice, David; Swisher, Stephen; Lee, Jack 
J.; Lippman, Scott; Pisters, Katherine; Blumenschein, George; Hong, 
Waun K.; Mehran, Reza
University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Background: The optimal multi-modality treatment for resectable 
malignant pleural mesothelioma (MPM) remains unknown. No prior 
neoadjuvant trials with targeted agents have been published due to 
limited funding and eligible patients. We designed a biomarker-based 
neoadjuvant trial from our preclinical studies showing that dasatinib, 
a multi-targeted Src kinase inhibitor, has activity against MPM and 
target specificity to Src Tyr419. 
Methods: Untreated MPM patients undergo extended surgical sta-
ging (ESS) with multiple biopsies along the future surgical incision 
line to account for tumor heterogeneity and evaluate for sarcomatoid 
features. If deemed a surgical candidate for either pleurectomy/decor-
tication (P/D) or extrapleural pneumonectomy (EPP), patients receive 
4 weeks of oral dasatinib (70 mg BID) followed by P/D or EPP. If 
either a radiographic or molecular response (de-phosphorylation 
of Src Tyr419 in tumor) is seen, an additional 2 years of dasatinib 
maintenance after adjuvant radiotherapy and systemic chemotherapy 
is given. Serum/blood/platelets and pleural effusion are collected for 
exploratory analysis of peripheral surrogate biomarkers. Primary end-
point of this trial is biomarker modulation of Src Tyr419. Secondary 
endpoints include response, survival, safety/toxicity, and biomarker 
modulation in tumor/serum/platelets/pleural effusion. 
Results: Thirteen patients have registered on the trial (4/08 – 2/09); 
nine have successfully completed the ESS, neoadjuvant dasatinib, 
and P/D (n=5) or EPP (n=4). Two patients are still receiving neo-
adjuvant dasatinib; and 2 patients were deemed to not be surgical 
candidates due to a rapid decline in PS and one was found to have 
bilateral mesothelioma. The main side effects to dasatinib were grade 
1-2: anemia, nausea, vomiting, anorexia, electrolyte abnormalities, 
fatigue, and anxiety. Grade 3 toxicities included hyperkalemia (1), 
infection - pneumonia (1), and hypoxia (1). There were no grade 4-5 
toxicities. Post-surgical grade 3 toxicity included anemia, electrolyte 
abnormalities, arrhythmia, HTN, and pleural effusion; one grade 4 
episode of hyperglycemia was seen. 
Conclusions: Conducting biomarker-based clinical trials with novel 
agents in MPM is feasible and necessary to further our understanding 
of this deadly disease. Updated clinical and translational correlative 
results will be presented.
Sponsored by: Department of Defense (PROSPECT grant), ASCO 
Career Development Award, Bristol-Myers-Squibb (dasatinib)
PD4.1.4 Mesothelioma and Small Cell Lung Cancer, Sun, 14:30 - 16:00
A pilot phase II clinical trial of the 20S proteasome 
inhibitor bortezomib in patients with relapsed malignant 
pleural mesothelioma
Fennell, Dean A.1; Van Meerbeeck, Jan2; O’Byrne, Kenneth J.8; 
Donnellan, Paul5; O’Reilly, Seamus4; McDermott, Ray11; Mutti, 
Luciano10; Gaudino, Giovanni9; Webb, Glenn6; Jackson, Shane7; 
Parker, Michael7; Baas, Paul3
1 Queen’s university Belfast, Belfast, UK; 2 Thoracic Oncology, 
University Hospital, Ghent, Belgium; 3 Netherlands Cancer Institute, 
Amsterdam, Netherlands; 4 Cork University Hospital, Cork, Ireland; 
5 University College Hospital Galway, Galway, Ireland; 6 All ireland 
cooperative oncology research group, Dublin, Ireland; 7 Clinical 
Research Support Centre, The Royal Hospitals, Belfast, UK; 8 St 
James’ Hospital, Dublin, Ireland; 9 DISCAFF University of Piemonte 
orientale “A.Avogadro”, Novara, Italy; 10 Lab. di Oncologia Clinica, 
Borgosesia, Italy; 11 Adelaide & Meath Inc the National Children’s 
Hospital, Dublin, UK
Background: There is currently no standard therapy for patients with 
mesothelioma that has been been refractory to, or relapsed following 
front line chemotherapy. New effective treatments in this setting are 
therefore urgently required given the rising incidence of this cancer. 
Targeting the 20S proteosome in mesothelioma with bortezomib (bz), 
has been reported to demonstrate promising preclinical efficacy, war-
ranting its clinical evaluation. ICORG 05-10, an international multi-
centre single arm phase II trial of bz monotherapy employed a Simon 
2 stage design, with bz administered at 1.6mg/m2 weekly x4 every 5 
weeks for 4 cycles or until progressive disease. Primary endpoint was 
response, and secondary endpoints, progression free survival (PFS), 
overall survival (OS), and toxicity. Biopsies were collected pre and 
post treatment, to support translational research. 
Patient characteristics: A total of 23 patients (pts) were treated 
with bz in the second line setting. Median age was 65.5 (49.6-78.6), 
gender ratio (M/F) was 20:3, with ECOG performance status distribu-
tion 0 (5), 1 (17), 2 (0), 3(1). IMIG stage: I (2), II (7), III (5), IV (9). 
Prior therapy: cisplatin (11), carboplatin (3), pemetrexed (7), pe-
metrexed/cisplatin (2). Of 23 evaluable patients receiving second-line 
bz their responses to their previous regimens were: 3 pts, minimal 
response (MR 13%), 11 pts no change (NC 48%), 3 pts partial remis-
sion (PR 13%), none with SD, and 6 pts with progressive disease (PD 
26%). 
Results: Pts received a median of 2 treatment cycles (range 0-4). Of 
the 23 evaluable pts in the intention to treat (ITT) population 1/23 pt 
had a confirmed radiological response (PR 4%), 19 pts had progres-
sive disease (PD 83%), and 3 withdrew (WD 13%). Median PFS was 
2.1 months (95% CI: 1.9 – 2.2), and the median OS was 6.2 months 
(95% CI: 2.5 - 9.9). Toxicity: G3, 13 pts (57%); G4, 6 pts (26%). 
G3/G4 events were probably unrelated to bz in 10/13pts and 4/6 pts 
respectively. Primary endpoint was not achieved in the ITT group, 
and enrollment was discontinued at the end of stage 1.
Summary: Bz monotherapy exhibits minimal clinical activity in 
relapsed mesothelioma. The mechanisms underlying bz resistance 
and strategies to overcome this in mesothelioma, are currently under 
investigation. Failure to upregulate NOXA is being explored. A phase 
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II trial investigating front-line bz monotherapy in PS2/platinum ineli-
gible pts is ongoing. 
PD4.1.5 Mesothelioma and Small Cell Lung Cancer, Sun, 14:30 - 16:00
Soluble mesothelin as a tool for early detection of 
malignant mesothelioma in asbestos-exposed workers
Hollevoet, Kevin1; Van Cleemput, Joris2; Thimpont, Joël 3; 
Vandeweerdt, Marc 3; De Vuyst, Paul 4; Nackaerts, Kristiaan 5; 
Delanghe, Joris 6; Legrand, Catherine 7; van Meerbeeck, Jan P.1
1 Dept of Respiratory Medicine, Ghent University Hospital, Ghent, 
Belgium; 2 Occupational Health Service, Eternit NV, Kapelle-op-den-
Bos, Belgium; 3 Fund for Occupational diseases, Brussels, Belgium; 
4 Respiratory Medicine, Erasme Hospital ULB, Brussels, Belgium; 
5 Dept of Respiratory Medicine, University Hospital Gasthuisberg, 
Leuven, Belgium; 6 Dept of Clinical Chemistry, Ghent University 
Hospital, Ghent, Belgium; 7 Institut de statistique, Université 
catholique de Louvain, Louvain-la-Neuve, Belgium
Background: Soluble mesothelin (SM), a malignant mesothelioma 
(MM) biomarker, is a promising tool for the early detection of MM 
in asbestos-exposed individuals, but needs further validation in pro-
spective studies.
Aim: Evaluation of the screening performance of SM in healthy 
asbestos-exposed and benign asbestos-related diseased individuals, 
enrolled in a Belgian prospective observational study.
Methods: A total of 100 healthy asbestos-exposed and 100 asbestos-
related diseased individuals are intended for enrolment with yearly 
blood sampling and medical follow-up for 2 years. Asbestos exposure 
(fiber years) is estimated with detailed questionnaires. Serum SM 
(nM) is measured with FDA approved ELISA kits (MESOMARKTM, 
Cis bio International).
Results: A first and second SM sample was already obtained in 92 
and 55 healthy and 72 and 21 diseased individuals, respectively. 
Among the diseased, 57 had pleural plaques, 5 asbestosis and 10 dif-
fuse pleural thickening. At follow-up none developed a malignancy. 
Mean baseline values differed significantly between healthy (0.81 
nM) and asbestos diseased individuals (1.15 nM) (p < 0.001, student 
t-test). 
A significant increase in SM, exceeding the assay variance (15%), 
was observed in both groups between baseline and follow-up (p < 
0.001, paired t-test). Using a cutoff of 2.5 nM, 1 case at baseline 
(3.65 nM) with pleural plaques and renal dysfunction and 1 case at 
follow-up (3.62 nM), without asbestos-related disease but with a pos-
sible inflammatory bowel disease, had increased SM levels. 
Conclusion: Although preliminary results showed SM was a marker 
for benign asbestos-related disease in asbestos-exposed individuals, 
SM was not validated as a screening tool for MM, likely due to the 
short follow-up period. Mean SM significantly increased between 
baseline and follow-up, suggesting an effect of age on SM levels. 
Updated results will be presented at the meeting.
--This study was made possible by a grant of the Belgian Foundation 
against Cancer--
PD4.1.6 Mesothelioma and Small Cell Lung Cancer, Sun, 14:30 - 16:00
Fluorescence in situ hybridization in the definitive 
diagnosis of malignant mesothelioma in effusion cytology
Savic, Spasenija1, 2, 6; Franco, Noteli2; Grilli, Bruno1; de Vito 
Barascud, Audrey 1; Herzog, Michelle 1; Bode, Beata3; Loosli, 
Heinz4; Spieler, Peter5; Schönegg, René 5; Clark, Douglas P.6; 
Herman, James G.2; Bubendorf, Lukas1
1 Institute for Pathology, University Hospital Basel, Basel, 
Switzerland; 2 Division of Tumor Biology, The Sidney Kimmel 
Comprehensive Cancer Center at the Johns Hopkins Medical 
Institutions, Baltimore, MD, USA; 3 Department of Pathology, 
Institute for Surgical Pathology, University Hospital Zurich, Zurich, 
Switzerland; 4 Institute for Pathology, University Bern, Bern, 
Switzerland; 5 Institute for Pathology, Cantonal Hospital St.Gallen, 
St. Gallen, Switzerland; 6 Department of Pathology, The Johns 
Hopkins Medical Institutions, Baltimore, MD, USA
Background: Distinction of malignant mesothelioma (MM) from 
reactive mesothelial cells (RM) in effusions is notoriously difficult. 
The aim of our study was to test chromosomal aberrations detected 
by fluorescence in situ hybridization (FISH) in the diagnosis of MM 
in effusion cytology and to explore the potential role of p16, p14 and 
p15 gene methylation as an alternative mechanism of tumour sup-
pressor gene inactivation.
Methods: 52 effusions of histologically confirmed MM and 28 
benign effusions were retrospectively analyzed by multi-target FISH 
assay for aberrations of chromosomes 3, 7, 17 and 9p21. In case of a 
negative result the corresponding MM biopsy was analyzed. Methyla-
tion specific polymerase chain reaction (MSP) for p16, p14 and p15 
was performed on FISH negative MM biopsies. 
Results: 79% of effusions with biopsy proven MM had chromosomal 
aberrations with loss of 9p21 as the most common finding. All benign 
effusions were FISH negative. Sensitivity, specificity, positive and 
negative predictive values for detection of MM by FISH were 79%, 
100%, 100%, and 72%, respectively. Six of nine FISH negative 
effusions with biopsy proven MM were also FISH negative in the 
MM biopsies. Four of five FISH negative biopsies showed promoter 
methylation in p16 and p14 as compared to one of 12 benign controls.
Conclusions: FISH is a sensitive and highly specific method for the 
definitive diagnosis of MM in effusion cytology. In the subset of 
FISH negative MM, tumour suppressor genes on the chromosomal 
region 9p21 are often inactivated by promoter methylation.
PD4.1.7 Mesothelioma and Small Cell Lung Cancer, Sun, 14:30 - 16:00
Cap-dependent translational control of oncolytic measles 
virus in malignant mesothelioma
Sadiq, Ahad A.1; Jacobson, Blake A.1; Jay-Dixon, Joe 1; Patel, Manish 
R.1; Russell, Stephen J.2; Kratzke, Robert A.1
1 University of Minnesota, Minneapolis, MN, USA; 2 Mayo Clinic, 
Rochester, MN, USA
Background: Malignant mesothelioma (MM) is a highly aggressive 
neoplasm that arises from the uncontrolled proliferation of meso-
thelial cells lining serosal cavities, most commonly the pleura. MM 
cells have enhanced cap-dependent translation compared to meso-
thelial cells resulting in a disproportionate increase in the translation 
of select mRNAs involved in malignancy. Live attenuated measles 
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virus (MV-Edm) and derivatives MV-CEA and MV-GFP, expressing 
soluble carcinoembryonic antigen and expressing green fluorescence 
protein, respectively, have shown to have potent oncolytic activity 
against multiple cancers. This virus targets cells that express high 
levels of CD46 receptors. In this investigation MM cells and benign 
mesothelial cells were treated with MV-Edm and cell survival, cap-
mediated translation strength and infection efficiency was measured. 
CD46 levels were assessed in MM cells and compared to mesothelial 
cells. Translational control of MV-induced cytopathic effects (CPE) 
in MM cells with enhanced or suppressed cap-mediated translation 
was analyzed.
Methods: CPE of MV-Edm was determined by seeding plates with 
MM or benign mesothelial cells followed by infection at different 
multiplicity of infection (MOI). MM viability was measured by either 
trypan blue exclusion or employing flow cytometry. Determination 
of CD46 density was measured by flow cytometry. CEA production 
in culture supernatant as the virus replicates can serve as a marker 
of viral gene expression and was measured using CEA-ELISA. 
Cap-mediated translation was suppressed with an antisense oligo-
nucleotide (ASO) targeting eIF4E mRNA. Elevation of translation 
was generated by IGF-I stimulation. Conditions to elevate or suppress 
translation were combined with MV-Edm treatment. The strength of 
cap-mediated translation was measured using a 7mGTP cap-affinity 
assay of eIF4E in cell lysates followed by immunoblot analysis. The 
level of eIF4E, eIF4GI, 4E-BPI and β-actin were measured following 
treatment.
Results: Prominent syncytia formation and cytopathic effects were 
evident after infection of MM cell lines with MV-Edm. MV-Edm 
led to pronounced inhibition of MM proliferation at every MOI 
compared to the benign mesothelial cells. Flow cytometry analysis 
confirmed that MM cell lines express CD46 abundantly. Enhanced 
cytopathic effects correlated with increased CEA levels in culture 
supernatants confirming that MV-Edm efficiently replicated in MM 
cells. Elevated cap-mediated translation by IGF-I stimulation of MM 
cells resulted in amplified CPE by MV-Edm treatment compared to 
unstimulated cells. In contrast, translation suppression mediated by 
eIF4E-ASO treatment engendered reduced CPE during MV-Edm 
MM infection. In MM the host cellular protein synthesis was reduced 
by MV-Edm infection. The mechanism is neither 4E-BP1 dephos-
phorylation nor decreased function of eIF4E but reduction of bound 
eIF4GI.
Conclusions: MV-Edm has potent therapeutic efficacy against 
MM in vitro. The host cell CPEs are dependent on the strength of 
cap-mediated translation. This discrimination based upon translation 
activation provides evidence that MV will target cancer cells prefer-
entially over normal tissues. MV-Edm infection of MM induces host 
shut-off of host protein synthesis. Currently a phase I clinical trial to 
treat MM patients with MV-Edm is being developed.
PD4.2.1 Mesothelioma and Small Cell Lung Cancer, Sun, 14:30 - 16:00
Prospective teritary centre study of combined modality 
treatment for malignant pleural mesothelioma (MPM): 
analysis of first 50 patients
Nafteux, Philippe1; Nackaerts, Kristiaan3; Lievens, Yolande2; Moons, 
Johnny1; Van Straelen, Bianca2; Vansteenkiste, Johan3; Decramer, 
Marc3; Van den Bogaert, Walter2; Lerut and Leuven Lung Cancer 
Group, Antoon1
1 University Hospital Gasthuisberg Dpt of Thoracic Surgery, Leuven, 
Belgium; 2 University Hospital Gasthuisberg Dpt of Radiotherapy, 
Leuven, Belgium; 3 University Hospital Gasthuisberg Dpt of 
Pulmonology, Leuven, Belgium
Purpose: Combined modality treatment (CMT) for MPM patients 
(pts) remains a matter of debate. We report our single centre prospect-
ive experience.
Patients and Methods: This prospective protocol on combined mo-
dality treatment (CMT) with induction chemotherapy (IC), followed 
by extended pleuropneumonectomy (EPP) and thoracic radiotherapy 
(RT) was started in our tertiary referral hospital in 2003. Eligibility 
of candidates (inclusion criteria: age ≤ 65 years, WHO ≤ 1, medically 
fit for pneumonectomy, MPM staging cT2N2M0 or less for epithelial 
subtypes and cT2N1M0 or less for other histologic subtypes) was 
discussed at the weekly multidisciplinary round. Treatment consisted 
of 3 cycles IC with cisplatin (75mg/m² D1 q3wks) and pemetrexed 
(500mg/m² D1), followed by EPP and hemithoracic RT (mostly by 
intensity-modulated radiotherapy, IMRT; dose 54Gy/1.8Gy ± boost). 
Survival was calculated from the initiation of CMT and analysed by 
Kaplan-Meier.
Results: In the interval between March 2003 and August 2008, 
in total 109 pts were discussed and fifty pts were finally included. 
Histologic subtypes were epithelial (n=37), non-epithelial or mixed 
(n=13). TNM classification was cT1aN0M0 (n=6), cT1bN0M0 (n=2), 
cT2N0M0 (n=36), cT2N2M0 (n=6). After IC, 6 pts were progres-
sive or deemed irresectable. Thirty-two pts underwent EPP, while 10 
pts had an exploratory thoracotomy (irresectable due to chest wall 
or oesophageal invasion) and 2 pts refused surgery. Postoperative 
mortality was 7.1% (3/42 pts). After EPP, 2 pts were not referred for 
RT (one patient with a homolateral unique kidney, one patient who 
developed bone metastases), and a third patient did not complete RT 
(due to intercurrent pneumonia/respiratory failure). More pts with 
epithelial MPM (22/37, 59.5%) did complete CMT compared to 
non-epithelial MPM pts (4/13, 31%). Intent-to-treat median sur-
vival (n=50) and median survival of those who completed the entire 
CMT (n=26) was 21.7 months and 29.5 months, respectively. Of the 
MPM pts who completed CMT (n=26), 11 pts are still alive (2 with 
recurrence), while 15 pts died (5 of non-tumor causes) resulting in 
a 3-year survival rate of 39.7%. Cox proportional hazards model 
showed a significant higher recurrence rate in non-epithelial MPM pts 
(HR=4.74, 95% CI=1.04-21.6; p=0.045); none of the other examined 
covariates (pT, pN nor R-status) reached significance. Subsequently, 
median recurrence-free survival of epithelial MPM pts is better 
than for non-epithelial MPM pts, 24.3 and 12.3 months respectively 
(p=0.01).
Conclusions: This study demonstrated that CMT for MPM pts is 
feasible and safe in a tertiary centre setting, but also that careful 
patient selection remains of highest priority, given that only half of 
eligible pts finish CMT. Recurrence of MPM is mostly observed in 
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pts with non-epithelial MPM. Median recurrence-free survival for 
epithelial MPM pts who completed CMT looks promising, but needs 
to be validated in larger experiences. 
PD4.2.2 Mesothelioma and Small Cell Lung Cancer, Sun, 14:30 - 16:00
Confirmation of the reliability and validity of lung cancer 
symptom scale for patients with malignant pleural 
mesothelioma: comparison of chemotherapy-pretreated 
versus chemotherapy-naïve patient populations
Arduino, Jean Marie1; Kindler, Hedy L.3; Hollen, Patricia J.5; Sun, 
Xing1; Baas, Paul4; Bucci, Maureen E.1; Lubiniecki, Gregory M.1; 
Hershock, Diane M.1; Krug, Lee M.2
1 Merck & Co., Inc., North Wales, PA, USA; 2 Memorial Sloan-
Kettering Cancer Center, New York, USA; 3 University of Chicago, 
Chicago, IL, USA; 4 The Netherlands Cancer Institute, Amsterdam, 
Netherlands; 5 University of Virgina, Charlottesville, VA, USA
Background: The LCSS-Meso patient scale has been shown to be a 
reliable and valid instrument to measure symptom burden and health-
related quality of life (HRQOL) in chemotherapy-naïve patients 
(Hollen et al. Support Care Cancer 2006; Hollen et al. Cancer 2004). 
It is of interest to confirm and compare the reliability and validity of 
the LCSS-Meso in patients who are pretreated with systemic chemo-
therapy and enrolled in a Phase III second line study (ClinicalTrials.
gov Identifier: NCT00128102) with a chemotherapy-naïve patient 
population. It is expected that chemotherapy-pretreated patients will 
be more symptomatic which may affect group equivalence.
Methods: Patients enrolled in an ongoing, Phase III, randomized, 
double-blind, placebo-controlled trial of vorinostat complete the 
LCSS-Meso at 2 visits prior to start of therapy and follow-up visits. 
The LCSS-Meso measures 5 symptoms (appetite loss, fatigue, cough, 
shortness of breath, and pain) and 3 summation items (symptom 
distress, normal activity level, and global quality of life). A total 
score and an average symptom burden index (ABSI) are estimated 
for each patient as an average of all 8 items and all 5 symptom items, 
respectively. Reliability is evaluated by test-retest reliability, using 
Pearson’s correlation coefficient (r) between 2 baseline assessments, 
and internal consistency, using Cronbach’s Alpha. Validity is assessed 
by whether baseline LCSS-Meso is responsive to Karnofsky perform-
ance status (KPS) and predicts overall survival, using Cox propor-
tional hazard models.
Results: Of the 660 target patients, 267 patients have enrolled. Base-
line characteristics are: median age=64, 82% men, 96% Caucasian, 
89% Stage III or IV, and 84% KPS ≥ 80. At least 88% of the patients 
reported experiencing each symptom, with 97% experiencing ≥ 3 
symptoms at baseline. The baseline median scores (based on 0-100 
mm visual analogue scale with 100 as worst possible outcome) are 
the following: appetite loss=27, fatigue=44, cough=12, shortness of 
breath=43, pain=27, interference with normal activities= 47, overall 
symptom distress=43, global quality of life=44, ASBI=34, and total 
score= 37. 
Acceptable reliability is demonstrated (Pearson=0.84, Alpha=0.88). 
Validity is supported by 1) increasing total score associated with 
worsening performance status; and 2) poor baseline scores for normal 
activity level, symptom distress, global quality of life, and total score 
inversely associated with survival (each p < 0.0002).
Conclusions: A larger percentage of chemotherapy-pretreated 
patients reported symptoms at baseline than chemotherapy-naïve pa-
tients. We confirm the psychometric properties of the LCSS-Meso to 
measure symptom burden and HRQOL in a chemotherapy-pretreated 
population.
 Chemotherapy Chemotherapy 
 -Naive -Pretreated 
 Population (N=495) Population (N=267)
 Patients with Baseline Symptoms Appetite loss 86.5% 94.4%
  (> 0mm) Fatigue 93.7% 98.1%
  Cough 74.9% 87.6%
  Shortness of Breath 89.1% 96.3%
  Pain 85.3% 94.4%
 Internal Consistency Total Score 0.86 0.88
 (Cronbach’s Alpha) Average Symptom Burden Index 0.72 0.75
 Test-Retest Reliability (r) Total Score  0.87 0.84 (N=220)
 Construct Validity KPS Categories  Median Total Median Total
   Score (n) Score (n)
  100 15 (57) 26 (33)
  90 21 (213) 26 (103)
  80 36 (151) 47 (72)
  70 48  53 (40)
  Missing - 34 (19)
PD4.2.3 Mesothelioma and Small Cell Lung Cancer, Sun, 14:30 - 16:00
18F-FDG PET scanning, modified RECIST criteria and 
correlation with survival and response to platinum/
pemetrexed chemotherapy in malignant pleural 
mesothelioma (MPM)
O’Flaherty, John D.1; Knox, Mark1; Farrelly, Cormac1; Lucey, Julie3; 
Cuffe, Sinead1; Power, Derek2; O’Byrne, Kenneth1
1 St. James’s Hospital, Dublin, Ireland; 2 Memorial Sloan Kettering 
Cancer Center, New York, NY, USA; 3 Blackrock Clinic, Dublin, 
Ireland
Background: Recent evidence has suggested that early metabolic 
response measured by sequential PET scans may predict for response 
to chemotherapy and survival. Also certain baseline SUV parameters 
have been implicated as poor prognostic indicators.
Methods: Patients with MPM suitable for platinum/pemetrexed 
chemotherapy were eligible for the study. Baseline pre-treatment PET 
and CT scans were performed with a further PET scan before cycle 
2. CT scans were repeated at least once during treatment and at the 
end of all 6 cycles. CT scans were reported using Modified RECIST 
criteria and CT response was compared to overall survival (OS). The 
following PET parameters were measured; maximum and mean SUV, 
PET Vol (volume of tumor above SUV threshold of 3.5) and Total 
Lesion Glycolysis (TLG). Metabolic response (MR), as measured by 
a 25% drop in SUV Max, SUV Mean, PET Vol and TLG were com-
pared to overall survival (OS) and to CT evaluated response. 
Results: 21 patients were included in the study. Median OS for this 
cohort was 10.9 months. All patients had baseline PET scans, 17 of 
whom had a further PET before cycle 2. 19 patients had CTs evalu-
able by Modified RECIST criteria. CT evaluated response using 
Modified RECIST criteria correlated well with OS. Patients with a 
PR, SD and PD had median OS of 25.6 months, 8.6 months and 4.6 
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months respectively (p=0.0072). Baseline SUV Max and SUV Mean 
predicted for OS . Median OS was 17.2 months for patients with 
SUV Max <15 vs 6 months for those with SUV Max >15 (p=0.0193). 
Median OS was 14.1 months for patients with SUV Mean <5 vs 6.5 
months for those with SUV Max >5 (p=0.0681). MR defined by SUV 
Max, SUV Mean, PET Vol or TLG did not predict for OS. MR on 
PET correlated poorly with CT response with Kappa values of 0.01, 
0.05, 0.15 and 0.31 for MR defined by SUV Max, PET Vol, SUV 
Mean and TLG respectively.
Conclusions: CT response as measured by Modified RECIST criteria 
correlated significantly with OS. Baseline SUV Max >15 and SUV 
Mean>5 were indicators of poor prognosis. MR measured by SUV 
Max, SUV Mean, PET Volume and TLG on early sequential PET 
scans did not predict CT assessed response to therapy or OS. 
PD4.2.4 Mesothelioma and Small Cell Lung Cancer, Sun, 14:30 - 16:00
The value of volumetric measurement of malignant pleural 
mesothelioma (MPM) to assess the therapy response
Tutic, Michaela1; Frauenfelder, Thomas2; Goetti, Robert2; Schramm, 
Alexandra1; Weder, Walter1; Marincek, Borut2; Stahel, Rolf3; Opitz, 
Isabelle1
1 Thoracic surgery, Zurich, Switzerland; 2 Institute of Diagnostic 
Radiology, Zurich, Switzerland; 3 Division of Oncology, Zurich, 
Switzerland
Purpose: The purpose of this study was to assess robustness of 
volumetric measurement of malignant pleural mesothelioma (MPM) 
compared to modified RECIST.
Method: 30 patients (mean age 60) with known MPM where 
included in the study. All patients underwent CT before and after 3 
cycles of platinol-based induction chemotherapy to evaluate therapy 
response. Modified RECIST criteria and tumor volumetric approach 
were applied on each CT exam as was the tumor volume using dedi-
cated software (Myrian, Intrasense, France). Modified RECIST-criter-
ia were independently assessed by three readers having both exams of 
each patient simultaneously available. Progressive disease (PD) was 
defined as >30% increase in the sum of unidimensional tumor meas-
urements, >20% decrease as partial response (PR), -20% - +30% as 
stable disease (SD). The tumor volume was independently measured 
by three readers. Interobserver agreement for tumor response and 
interclass correlation were assessed for both methods. 
Results: The determination of unidimensional tumor measurement 
with modified RECIST criteria showed a large variability between the 
three different readers: The mean difference of the measured tumor 
response ranged from 25-43% (reader 1 v. 2: mean 25%, SD ± 38%, 
range: 0.1-207%; reader 2 vs. 3 mean 43%: SD ± 65%, range: 0.4-
297%). Tumor volumetry showed a higher interobserver agreement 
compared to modified RECIST criteria (range of kappa=0.75-0.9 vs. 
0.29-0.42). Correlation between the different observers is illustrated 
in Figure 1 and 2: 
Conclusion: Volumetric measurement of the MPM is accurate and 
highly reproducible to evaluate therapy response. The interobserver 
agreement is very high in comparison to modified RECIST criteria. 
PD4.2.5 Mesothelioma and Small Cell Lung Cancer, Sun, 14:30 - 16:00
High impact of staging 18F-FDG-PET on prognostic 
stratification of newly diagnosed small cell lung cancer 
(SCLC)
Azad, Arun1; Chionh, Fiona1; Scott, Andrew M.2, 3, 4; Lee, Sze-Ting2, 
3, 4; Berlangieri, Sam U.3, 4; White, Shane1, 1; Mitchell, Paul L.1, 4
1 Ludwig Institute Oncology Unit, Austin Hospital, Melbourne, VIC, 
Australia; 2 Ludwig Institute for Cancer Research Ltd., Melbourne, 
VIC, Australia; 3 Centre for Positron Emission Tomography, Austin 
Hospital, Melbourne, VIC, Australia; 4 Department of Medicine, 
Austin Hospital, Melbourne, VIC, Australia
Background: The impact of 18F-FDG-PET on prognostic stratifica-
tion of newly diagnosed small cell lung cancer (SCLC) has not previ-
ously been assessed. We aimed to evaluate whether PET altered stage 
classification, management and prognostic stratification when used to 
stage newly diagnosed SCLC. 
Methods: We identified 46 consecutive patients undergoing PET 
during initial staging of SCLC from 1993 to 2008 inclusive. Data 
collected included stage classification before and after PET, treat-
ment history and date of death or last follow-up. Statistical analysis 
included estimation of overall survival (OS) by the Kaplan-Meier 
method using the log-rank test. 
Results: PET altered stage classification in 12 of 46 (26%) patients; 
four patients were upstaged from limited disease (LD) to extensive 
disease (ED) and eight were downstaged from ED to LD. Treatment 
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modality (chemotherapy ± radiotherapy) was altered in 9 of these 12 
patients; co-morbid illness or patient choice of no treatment impacted 
on management in the other three patients. PET altered the target 
mediastinal radiation field in another three patients with LD. There-
fore, PET altered management in 12 of 46 (26%) patients. In patients 
with LD on pre-PET staging, those with LD on PET (LD/LD) had 
significantly longer OS than those upstaged to ED (LD/ED) by PET 
(median 557 days versus 172 days; log-rank p<0.0001) (Figure 1). In 
patients with ED on pre-PET staging, those downstaged to LD (ED/
LD) by PET had significantly longer OS than those with ED (ED/
ED) on PET (median 328 days versus 177 days; log-rank p=0.037) 
(Figure 2). For the 18 patients with available data there was no clear 
relationship between SUVmax (standardised uptake value maximum) 
and survival.
Conclusion: Staging PET had a major impact on stage classifica-
tion, management and prognostic stratification of newly diagnosed 
SCLC. This is the first study to demonstrate that PET alters prognos-
tic stratification when used to stage newly diagnosed SCLC. Further 
evaluation of PET in the initial staging of SCLC is warranted. 
PD4.2.6 Mesothelioma and Small Cell Lung Cancer, Sun, 14:30 - 16:00
Positron emission tomography in small cell lung cancer: 
a systematic review and practice guideline in Ontario, 
Canada
Ung, Yee C.1; Ellis, Peter2; Leighl, Natasha3; Sun, Alex4; Walker-
Dilks, Cindy2; Evans, William K.2
1 Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; 2 
Juravinski Cancer Centre, Hamilton, ON, Canada; 3 Universtiy 
Health Network, Toronto, ON, Canada; 4 Princess Margaret 
Hospital, Toronto, ON, Canada
Background: The role of positron emission tomography (PET) in 
small cell lung cancer (SCLC) is not as well defined as for non-small 
cell lung cancer. A systematic review of the literature was done to 
evaluate the role for PET in SCLC specifically addressing its role in 
the diagnosis and staging, assessment of treatment response, detec-
tion of recurrence and restaging.
Methods: A systematic review of the literature was undertaken for 
relevant health technology assessments, randomized trials, prospect-
ive studies, retrospective studies and meta-analyses. Only 6 prospect-
ive studies and 4 retrospective reviews were identified. The relevant 
data was collated by clinical experts in the treatment of SCLC and 
then presented at a consensus meeting that included non-lung cancer 
oncologists, health policy advisors, nuclear medicine physicians, 
radiologists and research methodologists from Cancer Care Ontario’s 
Program in Evidence Based Care. Recommendations based on the 
available evidence were presented and voted upon to refine and 
develop consensus given the lack of available high quality evidence 
in the literature.
Results: The evidence based literature was reviewed and presented 
by the clinical experts for consensus. Four consensus statements were 
derived: (1) PET is recommended for staging in patients with SCLC 
who are potential candidates for the addition of thoracic radiother-
apy to chemotherapy. (2) A recommendation cannot be made for or 
against the use of PET for the assessment of treatment response in 
SCLC due to insufficient evidence. (3) A recommendation cannot be 
made for or against the use of PET for evaluation of recurrence or re-
staging due to insufficient evidence. (4) A recommendation cannot be 
made for or against the use of PET when metastectomy or stereotactic 
body radiation therapy is being contemplated for solitary metastases 
due to insufficient evidence. The degree of agreement with the rec-
ommendations between the clinical experts and non-clinical experts 
was high with some differences in the strength of the agreement.
Conclusions: This process of reviewing best available evidence 
and developing consensus among clinical experts and non-experts 
is novel and led to consensus on guideline recommendations where 
high quality evidence was not available.
PD4.2.7 Mesothelioma and Small Cell Lung Cancer, Sun, 14:30 - 16:00
Measurement of tumor volumes in patients with malignant 
pleural mesothelioma (MPM) correlates with prognosis
Zhao, Binsheng; Krug, Lee M.; Liu, Fan; Guo, Pingzhen; Ishill, 
Nicole M.; Moskowitz, Chaya S.; Rusch, Valerie W.; Flores, Raja M.; 
Schwartz, Lawrence H.
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
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Background: Conventional imaging techniques and measurements 
are not reliable or reproducible for assessing clinical stage, prognosis, 
and response to therapy in patients with MPM. We have developed a 
computerized modeling technique that extracts pleural disease from 
chest wall, mediastinal structures, and abdominal organs allowing 
calculations of tumor volume associated with MPM. 
Methods: We compiled the clinical characteristics and outcome 
from 30 patients enrolled on two clinical trials at our cancer center 
in which the patients were treated with induction chemotherapy fol-
lowed by surgery and radiation. CT scans with 5 to 7.5 mm cuts were 
obtained at baseline (30 patients) and after 2 cycles (27 patients) and 
additional 2 cycles (total 4 cycles) (21 patients) of chemotherapy. 
Tumor volumes were calculated in a semi-automated fashion using 
the computer algorithm. Overall survival was measured using a 
landmark time at three months post treatment start date such that all 
patients had already received 2 cycles of chemotherapy and a follow-
up scan. Association of volume changes with overall survival were 
determined by a Cox Proportional Hazards Model or log rank test. 
The relationship between pre- and post-operative stage with baseline 
tumor volume was analyzed using the rank sum test.
Results: Percent change of tumor volume from baseline to first 
follow-up CT after 2 cycles of chemotherapy was significantly as-
sociated with overall survival (Hazard Ratio: 1.90 (95% CI: 1.02 
– 3.55), p=0.04). By classifying changes of tumor volumes between 
2 scans into two groups, i.e., “increase” and “decrease”, a significant 
difference in survival was found between those who increased and 
decreased after 2 cycles of chemotherapy (p<0.05).(Figure) Patients 
with high pre-operative clinical stage (stages 3 and 4) had larger 
baseline tumor volume than patients with low pre-operative clinical 
stage (stages 1 and 2) do (p=0.05). 
Conclusions: Preliminary results indicated that change in tumor vol-
ume after 2 cycles of chemotherapy may predict overall survival and 
tumor volume measured at baseline may be associated to pre-oper-
ative clinical stage. We have incorporated this assessment in several 
ongoing prospective clinical trials to further validate the method.
PD4.3.1 Mesothelioma and Small Cell Lung Cancer, Sun, 14:30 - 16:00
Phase I dose-escalation study investigating RAD001 (R) 
in combination with cisplatin (C) and etoposide (E) in 
previously untreated patients with extensive-stage disease 
small-cell lung cancer (ED-SCLC)
Besse, Benjamin1; Suk Heist, Rebecca2; Papadimitrakopoulou, 
Vasiliki A.3; Camidge, D. Ross4; Beck, J. Thaddeus5; Schmid, 
Peter6; Mulatero, Clive7; Pylvaenaeinen, Ilona8; Petrovic, Katarina8; 
Johnson, Bruce E.9
1 Insitut Gustave Roussy, Villejuif, France; 2 Massachusetts General 
Hospital, Boston, MA, USA; 3 MD Anderson Cancer Center, Houston, 
TX, USA; 4 University of Colorado Health Sciences Center, Aurora, 
CO, USA; 5 Highlands Oncology Group, Fayetteville, AR, USA; 6 
Hammersmith Hospital, London, UK; 7 Leicester Royal Infirmary, 
Leicester, UK; 8 Novartis Pharma AG, Basel, Switzerland; 9 Dana-
Farber Cancer Institute, Boston, MA, USA
Background: Novel therapeutic agents are urgently needed to 
improve the treatment of ED-SCLC as the current prognosis remains 
poor despite the high sensitivity to chemotherapy. R (everolimus), 
an oral inhibitor of the mammalian target of rapamycin (mTOR), is 
currently in clinical development as an anticancer agent in patients 
with advanced lung cancer. As a single agent and in combination with 
other anticancer agents, R showed efficacy in in vitro SCLC models. 
Clinical benefit including objective tumor responses were observed in 
patients with NSCLC receiving R. 
Methods: This open-label, multi-center dose-escalation study inves-
tigated both daily and weekly dosing schedules of R in combination 
with C and E in the first-line treatment of patients with ED-SCLC. 
The primary objective was to establish the feasible doses/regimens 
of R in combination with C and E. Dose-escalation was based on a 
Time-to-DLT (Dose Limiting Toxicity) Bayesian model estimating 
the risk that patients experience a DLT at any timepoint and, specific-
ally, on the probability of a DLT within Cycle 1 of treatment (primary 
endpoint). Drug-drug interaction was also investigated by pharmaco-
kinetic sampling and analysis.
Eligible patients had ED-SCLC, no prior systemic treatment, WHO 
Performance Status ≤ 1 and adequate bone marrow, renal and liver 
function. Patients received 75mg/m2 C on day 1 and 100mg/m2 E on 
days 1-3 in a standard 21-day cycle combined with the assigned treat-
ment schedule of R. Investigated R doses were: 2.5 and 5mg in the 
daily and 20 and 30mg in weekly arm. 
Results: Twenty-eight chemotherapy-naive patients were treated in 
different R dose levels. Median age (range) 58 (36-74); male/female 
(21/8); PS 0/1 (14/14); smokers/previous smokers/never smokers 
(15/10/3). Grade 3/4 neutropenia was the most frequent DLT during 
the first cycle of study treatment (see table).
Median number of administered cycles of chemotherapy at 
2.5/5/20/30mg of R were 5/3/5/4, respectively. Best overall response 
according to RECIST was PR in 13 patients (1/2/3/7) and SD in 6 
patients (1/2/2/1). 
Conclusion: Dose escalation of both daily and weekly dosing regi-
mens of R combined with a standard regimen of C and E in patients 
with ED-SCLC was hindered by a high rate of CTC grade 3/4 neu-
tropenia. The study is ongoing allowing treatment with granulocyte-
colony stimulating factors (G-CSF) from the first cycle of study 
treatment.
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Table. Cycle 1 DLTs and most frequent CTC grade 3/4 toxicities reported (n). 
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Phase II study of RAD001 (everolimus) in previously 
treated small cell lung cancer (SCLC)
Kotsakis, Athanasios1; Tarhini, Ahmad1; Petro, Daniel1; Flaugh, 
Rick1; Vallabhaneni, Geetha1; Belani, Chandra2; Friedland, David1; 
Argiris, Athanassios1
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Background: Everolimus (E) is an oral inhibitor of mammalian 
target of rapamycin (mTOR), a novel target for anti-cancer therapy 
that plays a central role in the PI3K/Akt signaling pathway and other 
pathways that mediate tumor growth, proliferation, and angiogenesis. 
E has shown preclinical activity in SCLC cell lines and xenograft 
models.
Methods: Eligibility included SCLC with disease progression after 
up to 2 prior chemotherapy regimens, ECOG performance status (PS) 
0-2, and adequate bone marrow, liver, and kidney function. Patients 
(pts) were treated with E 10 mg, orally, once daily. Primary endpoint 
was the disease control rate (DCR), i.e. complete response (CR), 
partial response (PR) and stable disease (SD), after 2 cycles of E (6 
weeks) in pts who received at least 1 cycle. A 2-stage design was 
followed. PI3K/AKT signaling pathway molecular biomarkers (AKT, 
pAKT, PTEN, P-S6, p-4E- BP1) will be evaluated on baseline tumor 
tissue. 
Results: 40 pts were enrolled; 14 males/26 females; median age 64 
years (44-80); PS 0: 17, PS 1: 23; prior chemotherapy status: 1 prior 
regimen/sensitive relapse (i.e. relapse >60 days from completion of 
first-line chemotherapy): 23 pts; 1 prior regimen/refractory: 4 pts; 
2 prior regimens: 13 pts. 28 pts (70%) received ≥ 2 cycles of E, 7 
(18%) 1 cycle and 5 (12%) did not complete the first cycle of E due 
to adverse events or early progression. Best response in 35 evaluable 
patients: 1 (3%) PR, 8 (23%) SD and 26 (74%) progression; DCR at 6 
weeks was 26% with a duration of disease control of 2.7-6.3 months; 
median progression-free survival was 1.4 months and median overall 
survival 5.5 months, 95% CI (3.43, 7.63 months). No grade 4 toxicity 
was seen. Grade 3 toxicities included thrombocytopenia (2) neutro-
penia (2), infection (1), pneumonitis (1), fatigue (1), elevated trans-
aminases (1), hyperglycemia (1), diarrhea (1), and acute renal failure 
due to dehydration from diarrhea and poor oral intake (1). 
Conclusion: E is well tolerated but has limited single-agent antitu-
mor activity in unselected patients with pretreated SCLC. 
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Clinical responses to MP-470, an oral RAD51 inhibitor, in 
combination with standard of care doublet chemotherapy, 
in patients with SCLC and NE malignancies: a phase 1 
case series
Tolcher, Anthony W.1; Mita, Monica2; Rosen, Lee 3; Gordon, Michael 
4; Fine, Gil D.5; Taverna, Pietro5; Choy, Gavin S.5; Berk, Gregory I.5
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Background: MP-470 (MP) is an orally bioavailable multi-targeted 
tyrosine kinase inhibitor which hits a number of validated tumor tar-
gets including c-kit, flt3, and PDGFα. In 6 of 7 SCLC cell lines, MP 
inhibited proliferation with an average IC50 of 10µM (range, 4.8–18.9 
µM). LB12-SCLC/OC2 demonstrated the highest sensitivity to MP 
(IC50, 4.8 µM) while VP-16 and carboplatin reported IC50 were 53.4 
µM and 84.8 µM, respectively. Results presented herein are from a 
phase-1b 5-arm trial of MP combined with standard of care (SOC) 
anti-cancer therapies enrolled in the carboplatin/etoposide (CE) and 
carboplatin/paclitaxel (PC) arms with a diagnosis of SCLC and NE 
tumors. 
Methods: MP is administered in combination with SOC regimens in 
a 21-day cycle. Adults with ECOG PS of 0–2 and malignant disease 
appropriate for SOC regimens consisting of PC, CE, topotecan (T), 
docetaxel (D), and erlotinib (E) were enrolled. Each arm follows a 
3+3 design where MP is escalated based on the modified Fibonacci 
sequence until the MTD of MP in combination with SOC agents is 
reached. RECIST and CTCAE are utilized to assess response and 
safety, respectively. The objectives of the study are to determine 
the MTD, DLTs, and quantify the effects of MP on the PK of SOC 
agents. 
Results: Between December 2007 and August 2008, 42 subjects 
were enrolled across 5 arms; M/F 18/24; median age 55 years (range, 
24-84); ECOG PS 0/1/2: 9/32/1. Number of prior regimens (median 
= 3, range 0-19). Median follow-up was 2 cycles (max 7). Total 
enrollment included 3 SCLC and 6 NE subjects, with 2 and 5 of these 
9 enrolled in CE and CP, respectively. No CRs were observed. 3/7 
subjects (43%; 95% CI 10%-82%) achieved a confirmed PR in the 
PC and CE arms. Results of responses are tabled below.
The MTD have not been reached and DLTs have not been identified 
in the CE or CP arms. Grade 3/4 adverse events occurring ≥ 10% in 
the CE and CP were neutropenia, thrombocytopenia and leukopenia. 
There were no treatment related deaths. MP did not alter the PK of 
CE and CP (TAT 2009; abstract 48). 
Conclusion: CE and CP regimens in combination with MP in SCLC 
and NE tumors should be further explored in phase 2 clinical trials 
once the MTD is determined.
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Age Gender ECOG 
PS
On Study 
Treatment 
Regimen 
(Diagnosis)
Daily MP 
Starting 
Dose
Prior Treat-
ment Lines
# of 
Cycles 
Re-
ceived
Percent 
Tumor 
Reduc-
tion
Re-
sponse 
Per 
RECIST
Case 1 
(202)
65 M 1 CE (SCLC) 100 mg CDDP/VP-16 
Carbo/VP-16 
CDDP/CPT-11 
Carbo/Paclitaxel 
Genasense
5 61 PR
Case 2 
(204)
70 F 1 CE (SCLC) 100 mg None 2 46 PR
Case 3 
(102)
24 M 1 PC (NE) 100 mg VP-16/Cisplatin 
Topotecan
7 86 PR
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Phase II trial (N0621) of the c-Src inhibitor AZD-0530 
after 4 cycles of chemotherapy for patients with extensive 
stage small cell lung cancer (ED-SCLC)
Molina, Julian R.1; Foster, Nathan R.1; Nelson, Garth D.1; Grain ger, 
Andrew V.2; Steen, Preston D.3; Nikcevich, Daniel A.4; Schild, Steven 
E.5; Wright, John6; Adjei, Alex A.7
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Clinic, Scottsdale, AZ, USA; 6 National Cancer Institute, Bethesda, 
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Background: c-Src regulates a large number of important mechan-
isms in normal and cancer cells and thus represents a potential target 
for cancer therapy. The current understanding of the c-Src pathway 
suggests that c-Src dysregulation facilitates cell invasion and metasta-
sis in small cell lung cancer cell lines. AZD-0530 is a novel anilin-
oquinazoline that inhibits many cellular processes in which c-Src is 
involved.
Methods: Patients (pts) ≥18 years of age with ED-SCLC were 
eligible for participation. After 4 cycles of standard chemotherapy, 
AZD-0530 at a dose of 175 mg/day by mouth was given until disease 
progression, unacceptable toxicity, or patient refusal. The primary 
endpoint is the 12-week progression-free survival (PFS) rate from 
initiation of AZD-0530 treatment. Planned interim analysis in first 
20 pts, where 13 or more pts alive and progression-free at 12-weeks 
would allow continued enrollment to 40 total pts
Results: Data on first 20 pts shown. All 20 pts received platinum 
based standard chemotherapy (50% cis, 50% carbo). Median age was 
60 (range: 48 - 82). 95% of pts had a PS of 0/1. Median of 2 cycles 
given (range: 1 - 9). 19 (95%) pts have ended treatment, most for 
disease progression (16/19). The 12-week PFS rate was 30% (6/20; 
95% CI: 12 - 54%). From start of standard chemotherapy, median 
PFS and TTP were both 4.8 months (95% CI: 4.4 – 6.7). 7 (35%) and 
3 (15%) patients experienced at least one grade 3+ or grade 4 AE, 
respectively. No grade 5 events occurred. Commonly occurring grade 
3/4 AEs were fatigue (10%) and thrombocytopenia (10%).
Conclusions: AZD-0530 at a dose of 175 mg/day by mouth is 
safe. However, the progression-free survival rate observed at the 
pre-planned interim analysis did not meet the criteria for additional 
enrollment. Survival data will be presented at the time of the meeting.
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Clinical experience of IMGN901 (BB-10901) in patients 
with small cell lung carcinoma (SCLC)
Fossella, Frank V.2; Woll, Penella J.3; Lorigan, Paul 4; Tolcher, 
Anthony5; O’Brien, Mary6; O’Keeffe, Jessica1; Zildjian, Sybil1; Qin, 
Albert1; O’Leary, James1; Villalona-Calero, Miguel8
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Background: IMGN901 is a novel immunoconjugate comprising 
DM1, a maytansinoid cytotoxic agent, and huN901, a monoclonal 
antibody. IMGN901 binds with high affinity to CD56, an antigen 
expressed on virtually all SCLC cells. IMGN901 has demonstrated 
marked anti-tumor effect in human xenograft SCLC models in mice. 
Two early trials have been conducted in patients with CD56-positive 
solid tumors. 
Methods: IMGN901 is administered via intravenous infusion. In 
Study 001, a Phase I/II trial, IMGN901 was administered weekly for 
4 consecutive weeks every 6-10 weeks. In the ongoing Study 002, a 
Phase I trial, IMGN901 is administered daily for 3 consecutive days 
every 3 weeks. The majority of patients enrolled in these studies to 
date have been SCLC patients. Clinical efficacy and safety data will 
be presented based on the combined SCLC experience from both 
studies.
Results: Across both studies, 66 patients with relapsed or refractory 
SCLC received IMGN901. Of these patients, 62 were response-
evaluable. Patients received IMGN901 at doses ranging from 5 to 75 
mg/m2/week (20 – 300 mg/m2 per 6 week cycle) in Study 001 and 
at 4 to 75 mg/m2/day (12 – 225 mg/m2 per 3 week cycle) in Study 
002. Dose limiting toxicities (DLTs) reported in both studies included 
hyperaesthesia, fatigue, peripheral neuropathy, noninfective menin-
gitis and severe headache (meningitis-like symptoms). These DLTs 
were generally reversible and manageable. The Maximum Tolerated 
Dose (MTD) for Study 001 was defined as 60 mg/m2/week. Routine 
prophylaxis with steroids and a slower infusion rate has allowed 
dosing beyond 60 mg/m2/day in Study 002. The MTD for Study 002 
has not been defined and currently the study is enrolling patients at 
75 mg/m2/day. In Study 001, a partial response (PR) was noted after 
the first cycle of treatment in a SCLC patient dosed at 60 mg/m2/day. 
This patient had received 2 previous lines of chemotherapy consisting 
of etoposide/cisplatin and topotecan. This response persisted for 18 
weeks. In Study 002, a patient who had received two prior chemo-
therapy regimens of etoposide/carboplatin and doxorubicin/vincris-
tine/cyclophosphamide for SCLC demonstrated an unconfirmed PR 
after the first cycle of treatment of IMGN901 at a dose of 75 mg/m2/
day. Although the response was not confirmed, the patient appeared 
clinically stable for approximately 9 weeks. Of the 62 patients, 19 
patients had stable disease (SD) lasting for approximately 6 to 19 
weeks. Among them, 11 patients had SD for more than 8 weeks 
(>2 months) and 2 patients had SD for approximately 19 weeks (>4 
months). 
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Conclusions: IMGN901 has shown preliminary clinical activity 
and safety in patients with relapsed or refractory SCLC. Additional 
investigation is warranted
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VEGF-A and FLT-1 tumour gene expressions are of 
prognostic value in small cell lung cancer (SCLC) patients 
treated with first-line ACE chemotherapy
Brueckl, Wolfgang M.1; Wirtz, Ralph M.2; Dimmler, Arno3; Brunner, 
Thomas4; Klein, Peter5; Hahn, Eckhart G.6; Ficker, Joachim H.1; 
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Background: Small cell lung cancer (SCLC) is an aggressive tumour 
with poor outcome. Angiogenesis plays an important role in this can-
cer, however molecular and clinical data regarding molecular growth 
factors are rare. 
Patients and Methods: We examined the prognostic value of the 
expression of all members of the vascular endothelial growth factor 
(VEGF) family including all their receptors in SCLC. Formalin fixed 
paraffin embedded tumours of 47 patients with progredient SCLC 
who were treated with a palliative first line chemotherapy including 
adriamcyine, cyclophosphamid and etoposide (ACE) were analysed 
for gene expression of VEGF-A, -B, -C –D and their ligands Flt-1,kdr 
and Flt-4. The relationships between clinicopathological data, follow-
up and gene expressions were investigated. 
Results: All VEGFs and their ligands were expressed in SCLC, how-
ever to varying extents. Flt-1 expression was highly significantly as-
sociated with complete response (P<.001) and patients with tumours 
expressing high levels of VEGF-A and Flt-1 had a significant longer 
survival. In addition, Flt-1 expression was an independent predictor 
for improved survival in multivariate analysis (P=.002). 
Conclusions: Our results suggest that expression of VEGF-A and 
especially Flt-1 are associated with a prolonged survival in patients 
undergoing palliative first-line ACE chemotherapy. As this regimen 
has some antiangiogenic value, one might speculate, that during 
ACE chemotherapy, VEGF-A might reduce tumour hypoxia via Flt-1 
receptors on the tumour. As VEGFs and their ligands are expressed 
in SCLC, treatment with specific antiangiogenic substances might be 
effective and should be further investigated. 
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A subset of small cell lung cancer with low expression of 
neuroendocrine markers links to a good prognosis: a so far 
unrecognized subtype
Hamanaka, Wakako1; Motoi, Noriko1; Okumura, Sakae2; Nakagawa, 
Ken2; Nishio, Makoto3; Horai, Takeshi3; Ishikawa, Yuichi1
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Background: Small-cell lung carcinoma (SCLC) is characterized 
by unfavorable prognosis and sensitivity to chemo- or radiotherapy. 
However, there are reports that some SCLC patients are alive for a 
long time after therapy and that 10-20% of SCLC have poor response 
to such therapies. We hypothesized that basaloid nature and degree of 
neuroendocrine phenotype may relate to the above unusual characters 
of SCLC. 
Purpose: To evaluate the correlation expression of basal cell and 
neuroendocrine markers with clinical outcome.
Methods: 91 SCLC resected surgically at the Cancer Institute 
Hospital, Tokyo, during1964 - 2007 were employed for this study. 
To make tissue arrays two representative spots within a tumor, 2 mm 
in diameter, were chosen. We evaluated expression of two basal cell 
specific protein (p63, 34βE12) and three neuroendocrine markers 
(synaptophysin, SYP; chromogranin A, CGA; N-CAM) by immunos-
taining. We defined the case stained 10 % of all tumor cells or more 
as positive for each antibody. B+ group includes cases with any of 
p63 or 34βE12 being positive, and N+ group includes cases with any 
one of SYP, CGA, or N-CAM being positive. Accordingly all cases 
were divided into 4 groups: N+B-, N+B+, N-B+, and N-B-. Cause-
specific survival was analyzed for 44 patients who were treated with 
CDDP. Additionally, we assessed expression of TTF-1 for alveo-
lar type II cell differentiation, NSE, mASH-1 and PAX5 for other 
neuroendocrine nature, p53 for tumor suppressor protein and MIB-1 
for cellular proliferation.
Results: Among 91 patients, 14% were positive for p63, 11% for 
34βE12, 65% for SYP, 48% for CGA, and 74% for N-CAM. For the 
44 patients, correlation between immunoreactivity and prognosis was 
analyzed. The clinical background and histology of the 44 patients 
were largely similar to the entire group. 28 (64%) cases belong to 
N+B-, 6 (14%) as N+B+, 3 (7%) as N-B+, 7 (16%) as N-B-. The 
prognosis didn’t differ between Group B+ (n=9) and B- (n=35) (log-
rank test, p=0.7938). Meanwhile, patients of Group N- (n=10) had 
significantly better survival (p=0.0321) than Group N+ (n=34). The 
positive ratios (%) for additionally examined markers in Group N+ / 
N- were as follows. TTF-1: 67/0, NSE: 88/40, mASH-1: 76/0, PAX5: 
68/10, p53: 71/40. MIB-1 index was quite high such as 20-80% even 
in the Group N-, showing good prognosis.
Conclusions: Our study showed that about 20% of SCLC patients 
were positive for basal cell markers, but expression of them didn’t 
correlate to prognosis. Instead, 16% of SCLC were negative for three 
neuroendocrine markers and they had significantly better survival. 
These tumors were histologically indistinguishable from each other. 
These N-B- cases may be a so far unrecognized subset of SCLC with 
good prognosis.
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Phase I study of sagopilone (ZK-EPO) in combination with 
cisplatin in patients with chemotherapy-naïve extensive-
disease small-cell lung cancer (ED-SCLC)
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Rationale: Although improvements have been made in the treat-
ment of ED-SCLC, overall results remain disappointing, and there is 
a clear need to evaluate innovative chemotherapeutic agents in this 
tumor type. Sagopilone, a novel epothilone, has been found to be 
active and well tolerated in a Phase I single-agent trial, with periph-
eral neuropathy being the major dose-limiting toxicity (DLT). 
Methods: We have evaluated the maximum tolerated dose (MTD) 
and/or recommended Phase II dose of sagopilone combined with 
cisplatin (P) as 1st-line treatment in patients (pts) with ED-SCLC. 
Pts with measurable chemotherapy-naïve ED-SCLC were to receive 
a 3-h infusion of sagopilone followed by a fixed dose of P (75 mg/
m² 1-h infusion) d1 q3w. Dose escalation/de-escalation of sagopilone 
included 12 mg/m² (1st cohort), 16 mg/m² (2nd cohort), 22 mg/m² 
(3rd cohort) and 19 mg/m² (4th cohort). A total of 6 pts were planned 
to be treated at each dose level (DL), with dose escalation halted in 
the event of >1 DLT per cohort. 
Results: As of February 2009, 26 pts (17 male, 9 female) have been 
treated, with a median age of 60 years (range 43-74). Preliminary 
safety data are currently available for a total of 6 pts in the 1st cohort, 
7 pts in the 2nd, 6 pts in the 3rd and 5 pts in the 4th: no DLTs have 
been observed at dose levels 1, 2 and 4, a single DLT of grade (gr) 
3 bone pain was reported in the 3rd cohort. The MTD has not been 
reached. Dose de-escalation to 19 mg/m² was initiated in an attempt 
to maintain the encouraging level of activity observed at 22 mg/m² 
while reducing the incidence of peripheral neuropathy. Peripheral 
sensory neuropathy was the most commonly observed drug-related 
toxicity occurring in 14/24 pts, with gr 1 in 12.5%, gr 2 in 33%, gr 
3 in 12.5% of pts, and no gr 4 reported. Other drug-related toxicities 
(gr 3/4 >5%) were: leukopenia (12%), fatigue (12%), nausea (8%), 
anemia (8%). Objective responses have been observed at all dose 
levels for an overall RR of 71% (1 CR, 16 PR). 
Conclusions: A combination of 75 mg/m² P and sagopilone up to 
a dose of 22 mg/m² was safely administered to pts with ED-SCLC, 
and showed promising clinical activity. Further results of the 19 mg/
m² cohort will be available at the meeting, but the 19mg/m² dose of 
sagopilone seems to be the recommended phase II dose of this com-
bination in ED-SCLC. Phase II evaluation appears to be warranted.
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A triplet of carboplatin, irinotecan and etoposide as a first 
line regimen in the treatment of extensive small-cell lung 
cancer: a phase II study
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Background: Small cell lung cancer (SCLC) is an aggressive ma-
lignancy. The prognosis for the patients is very poor with metastases 
often present at the time of diagnosis. The aim of this study is to 
evaluate the efficacy and the tolerability of the triplet: carboplatin 
irinotecan and etoposide as frond line treatment in extensive small-
cell lung cancer.
Methods: Chemo-naïve patients (pts) with documented diagnosis 
of extensive small-cell lung cancer, performance status (PS) 0-2 and 
adequate organ function were eligible. Patients received Carboplatin 
AUC5 on day 1, Irinotecan 150mg/m2 on day 2 and Etoposide 75mg/
m2 on days 1,2,3 every 21 days for up to 6 cycles. Overall survival 
(OS) and time to progression (TTP) was estimated using Kaplan-
Meier method and log-rank (Mantel-Cox) test was used for the com-
parison of the survival distribution according to clinical (sites and 
number of metastases) and laboratory (LDH values) differences. 
Results: Fifty-four patients were enrolled. Forty-seven pts had PS 
0-1 and 7 pts had PS 2. Response rate (SD, PR and CR) was 75% and 
10 pts (18%) have achieved CR. The median TTP was 8 months (CI 
95% 6.6-8.9) and median OS was 12 months (CI 95% 10.25-13.85). 
Patients with 1 site of metastases, compared with more than 1, had 
better survival (p=0.043). Normalizing LDH values after treatment 
was not correlated with survival (p=0.085).Grade 3-4 neutropenia 
occurred in 9 pts (16%), fetal thrombocytopenia grade 3 in 1 pt and 
gastrointestinal abnormalities grade 3 in 5 (9.26%) pts. Two toxic 
deaths were reported. 
Conclusions: The carboplatin, irinotecan and etoposide triplet is very 
effective and well tolerated treatment combination for the dismal 
prognosis group of extensive stage small cell lung cancer patients. 
The replacement of cisplatin with carboplatin makes this regimen an 
attractive solution to administer in a day clinic settings.
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A combination of gemcitabine and paclitaxel in patients 
with relapsed small-cell lung cancer: a phase II pilot study
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Background: Although SCLC is a quite chemosensitive malignancy, 
with overall response rates of 80–95% and 60–80% in patients with 
limited and extensive stage disease, respectively, most patients 
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relapse within a year and almost more than 95% of them eventually 
die from disease progression. Results of second-line treatment for 
patients with relapsing or progressing disease are generally poor, with 
a median survival from the time to progression of 4–5 months. The 
response to second-line therapy depends on the response to first-line 
therapy and the time between the completion of first-line treatment 
and recurrence. In an effort to improve survival rates in this disease, 
the newer agents that became available during the last 20 years, such 
Topotecan, Docetaxel, Paclitaxel, Irinotecan and Gemcitabine were 
introduced in first and second-line treatment of SCLC. Based on the 
need to discover better systemic therapies, we conducted a phase II 
study to evaluate the activity and toxicity of a combination of Gem-
citabine and Paclitaxel as second line chemotherapy in patients with 
relapsed small-cell lung cancer.
Methods: Eligible patients had refractory or relapsed SCLC, ECOG 
performance status of 0 to 2 and measurable disease. Patients with 
CNS metastases as the only site of relapse were considered not 
eligible. Paclitaxel was administered at 135 mg/sqm days 1 and 8 
immediately followed by 
Gemcitabine at 1000 mg/sqm, every 3 weeks for up to 6 courses. 
Restaging of disease was scheduled every 2 courses of treatment. 
Results: Forty-one patients were enrolled into the study and treated. 
Median age was 65 years (range 36-75). Nineteen patients were 
considered refractory (progressive disease during or within 90 days 
from completion of first line treatment) whereas 22 patients were 
chemotherapy-sensitive. A total of 135 courses were administered 
(range 1-6, median 3). Nine patients achieved a partial remission (PR 
22%) and 10 patients had a stable disease (SD 24%), with a clinical 
benefit rate (PR + SD) of 46%. The clinical benefit was achieved in 
12/22 (55%) sensitive patients and in 7/19 (37%) refractory patients. 
All partial responses but one were observed in the sensitive group. 
The median duration of response was 5 months. The most frequent 
severe toxicities were neutropenia grade 3-4 and neurological grade 
3, respectively in 24% and 7% of delivered courses.
Conclusions: The combination of Gemcitabine and Paclitaxel 
investigated in our study achieved a high rate of clinical benefit in 
this setting of SCLC patients and merits to be further investigated in 
larger trials.
PD4.4.4 Mesothelioma and Small Cell Lung Cancer, Sun, 14:30 - 16:00
Phase II study of sequential topoisomerase (Topo) 
targeting regimens (Reg) with irinotecan/oxaliplatin (I/O) 
followed by etoposide/carboplatin (E/Crb) in chemonaïve 
patients with extensive small cell lung cancer (SCLC)
Rossman, Joanne F.; Reddy, Vishnu; Oster, Robert; Prescott, Betty; 
Messer, Anna; Robert, Francisco
University of Alabama at Birmingham, Birmingham, AL, USA
Background: Topo inhibitors are active agents in SCLC, and pre-
clinical models indicate that sequential administration of Topo I and 
Topo II targeting drugs can result in additive or synergistic antitumor 
activity. 
Methods: The primary objective of this study was to determine the 
objective response (OR) rate of sequential I/O (Reg A) followed 
by E/Crb (Reg B). Secondary endpoints included toxicities, time to 
progression (TTP), overall survival (OS), and immunohistochemical 
(IHC) evaluation of Topo II and excision repair cross complementa-
tion I (ERCC-I) expression in tumor specimens. Patients received 5 
cycles of sequential therapy of Reg A→B. Each cycle consisted of I 
(150-200 mg/m2) and O (85mg/m2) on day 1 followed by Crb (AUC 
= 6) on day 15 and E (100mg /m2) on days 15, 16, and 17. Pegfil-
gastrim was given on days 2 and 18 of each 28 day cycle. Response 
assessment was performed after every 2 cycles. 
Results: The 26 evaluable patients demographics were: median age 
62, gender ratio 13/13 (male/female). Two of the 26 had CNS disease 
upon presentation. One (4%) patient achieved a complete response. 
There were 21 (84%) partial responses, and 3 (12%) patients had 
stable disease. One patient was not evaluable for response. The medi-
an TTP was 9(range of 2.2 – 11.9) months. Grade 3 and 4 toxicities in 
the 1st cycle of Reg A were neutropenia (n=3) and fatigue (n=13) and 
in Reg B they were anemia (n=5), neutropenia (n=5), thrombocyto-
penia (n=16), and fatigue (n=4). The most common overall toxicities 
in Reg A were mild to moderate nausea and vomiting, diarrhea, and 
anemia. The main dose limiting toxicity was grade 4 thrombocyto-
penia in Reg B. Only 3 patients had febrile neutropenia on therapy, 
and one died of associated sepsis.
Conclusions: Early data indicates that this sequential approach may 
enhance the efficacy of chemotherapy in newly diagnosed SCLC 
patients. When compared to the historical TTP of approximately 3-4 
months, our TTP was 2 times longer. The median OS is being evalu-
ated and will be presented. The IHC studies for ERCC-1 and Topo 
II are ongoing at the time of abstract submission. To date, the effect 
of ERCC-1 and Topo II expression on SCLC patients treated with 
platinum and topo targeting agents is unknown. We will present these 
data in the context of patient outcomes. 
PD4.4.5 Mesothelioma and Small Cell Lung Cancer, Sun, 14:30 - 16:00
A phase I study of amrubicin and carboplatin for 
previously untreated patients with extensive-disease small-
cell lung cancer
Takemoto, Shinnosuke1, 2; Nagashima, Seiji2; Soda, Hiroshi2; Fukuda, 
Minoru3; Nakamura, Yoichi4; Iida, Tetsuya5; Nakatomi, Katsumi4; 
Kasai, Takashi6; Takatani, Hiroshi6; Fukuda, Masaaki6; Kinoshita, 
Akitoshi7; Soejima, Yoshifumi5; Oka, Mikio8; Kohno, Shigeru4
1 Department of Internal Medicine, Goto Central Hospital, Goto, 
Japan; 2 Department of Internal Medicine, Sasebo City General 
Hospital, Sasebo, Japan; 3 Department of Internal Medicine, 
Nagasaki Municipal Hospital, Nagasaki, Japan; 4 Second 
Department of Internal Medicine, Nagasaki University School of 
Medicine, Nagasaki, Japan; 5 Department of Internal Medicine, 
National Ureshino Hospital, Ureshino, Japan; 6 Department of 
Internal Medicine, Japanese Red-Cross Nagasaki Atomic Bomb 
Hospital, Nagasaki, Japan; 7 Department of Internal Medicine, 
National Nagasaki Medical Center, Ohmura, Japan; 8 Division of 
Respiratory Disease, Department of Medicine, Kawasaki Medical 
School, Kurashiki, Japan
Background: Amrubicin and cisplatin are active in the treatment 
of small-cell lung cancer (SCLC), and carboplatin is an analogue of 
cisplatin with less non-hematological toxicity. However, the appropri-
ate dose of amrubicin and carboplatin combination chemotherapy 
for previously untreated patients with extensive-disease (ED) SCLC 
has not been established. This study was designed to determine the 
maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of 
amrubicin and carboplatin in ED-SCLC. 
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Methods: Eligibility criteria were chemotherapy-naïve ED-SCLC 
patients, performance status 0−1, age ≤ 75, and adequate hema-
tological, hepatic, and renal function. Patients received escalating 
amrubicin doses under a fixed target AUC 5 of carboplatin (Chatelut 
formula). Amrubicin and carboplatin were administered by intra-
venous infusion on days 1 - 3 and day 1, respectively. The initial dose 
of amrubicin was 30 mg/m2, and the dose was escalated to 35 and 40 
mg/m2. 
Results: Sixteen patients were enrolled and 15 eligible patients 
were evaluated. One of 6 patients in level 1, 1 of 6 in level 2, and 3 
of 3 in level 3 experienced DLT. The presentation of DLTs included 
neutropenia, leukopenia, thrombocytopenia, febrile neutropenia, and 
liver dysfunction. The MTD doses of amrubicin and carboplatin were 
determined as 40 mg/m2 and AUC 5. Evaluation of responses was 2 
CR, 9 PR, 3 SD, and 1 PD (response rate, 73.3%; 95% confidence 
interval, 44.9 - 92.2%), and the median survival time was 13.6 
months. 
Conclusions: A dose of 35 mg/m2 amrubicin and carboplatin AUC 
5 were recommended. This regimen is associated with an acceptable 
tolerability profile, and warrants evaluation in the phase II setting.
PD4.5.1 Mesothelioma and Small Cell Lung Cancer, Sun, 14:30 - 16:00
Phase 1 dose escalation trial of limited field 
hypofractionated thoracic radiotherapy for limited stage 
small cell lung cancer
Yee, Don1; Chu, Quincy1; Butts, Charles1; Joy, Anil1; Fenton, David1; 
Smylie, Michael1; Reiman, Anthony2; Roa, Wilson1
1 Cross Cancer Institute, Edmonton, AB, Canada; 2 St. John Regional 
Hospital, St. John, NB, Canada
Background: When added to chemotherapy, thoracic radiotherapy 
improves local control and survival for limited stage small cell lung 
cancer (LS-SCLC). The optimal thoracic radiotherapy dose/ frac-
tionation regimen for LS-SCLC remains undefined. Published data 
indicate intensifying thoracic radiotherapy dose and minimizing over-
all treatment time improve local control and survival for LS-SCLC. 
Hypofractionation (increased daily radiotherapy doses) facilitates 
radiotherapy dose escalation without prolonging overall treatment 
time. The purpose of this study is to define the maximal tolerated 
dose of hypofractionated chest radiotherapy given with chemotherapy 
for LS-SCLC.
Methods: Accrued patients had biopsy-proven LS-SCLC, adequate 
pulmonary function and signed study-specific consent. Patients re-
ceived 1 of 4 thoracic radiotherapy doses: 54, 58, 62 or 65 Gy. Radio-
therapy was given in 25 daily fractions over five weeks and started 
with cycle 2 of chemotherapy at the latest. Six patients were accrued 
to each dose level and accrual to each dose level was done sequen-
tially based on observed acute radiotherapy toxicity rates in each 
dose level. Radiotherapy was planned with conformal techniques and 
targeted gross disease plus margin. Four cycles of platinum-based 
chemotherapy were prescribed. Patients were assessed before, during 
and after radiotherapy completion for treatment toxicities and disease 
status. Toxicity was graded with NCI Common Toxicity Criteria 
scales. Disease response was assessed 4-6 weeks after chemoradio-
therapy completion and complete/ near-complete responders were 
offered prophylactic cranial irradiation as per departmental treatment 
policy. The maximal tolerated radiotherapy dose was based on the 
dose which caused unacceptable acute radiotherapy toxicity rates ac-
cording to pre-defined trial stopping rules. 
Results: Accrual to each of the first 3 (54, 58 and 62 Gy) dose levels 
has completed (6 patients to each dose level, total 18 patients). There 
have been no radiotherapy-related deaths. There have been no grade 
3 toxicities in the 54 Gy and 58 Gy groups. The first patient receiv-
ing 62 Gy experienced grade 3 radiation pneumonitis which resolved 
with prednisone. The final patient receiving 62 Gy experienced acute 
grade 3 radiation esophagitis. Five patients were hospitalized during 
treatment, all for management of febrile neutropenia. Twelve of 
fifteen re-staged patients have attained complete responses. Eleven 
patients have received PCI. The median survival has not been reached 
yet. One patient died of neutropenic sepsis after receiving 20 radio-
therapy fractions and another of pneumonia 38 days after complet-
ing chest radiotherapy. Six others have died of recurrent metastatic 
disease. There has been one local in-field failure, two out-of-field 
mediastinal failures and five distant metastatic failures. As 2 of 6 pa-
tients given 62 Gy experienced an acute grade 3 radiotherapy-related 
toxicity, trial accrual has stopped according to trial stopping rules.
Conclusions: The maximal tolerated hypofractionated thoracic radio-
therapy dose in this trial is 58 Gy delivered in 25 daily fractions.
PD4.5.2 Mesothelioma and Small Cell Lung Cancer, Sun, 14:30 - 16:00
Omitting elective nodal irradiation (ENI) during thoracic 
irradiation in limited-stage small cell lung cancer (LS-
SCLC) – patterns of failure from a phase II trial
Colaco, Rovel J.1; Sheikh, Hamid Y.1; Lorigan, Paul C.2; Blackhall, 
Fiona H.2; Thatcher, Nicholas2; Taylor, Paul3; Faivre-Finn, Corinne1
1 The Christie NHS Hospitals Foundation Trust, Manchester, UK; 
2 Department of Medical Oncology, The Christie, Manchester, UK; 
3 Department of Medical Oncology,South Manchester University 
Hospital Trust, Manchester, UK
Background: The use of large radiotherapy (RT) fields in the context 
of concurrent chemo-radiotherapy for LS-SCLC can lead to rates of 
acute radiation-induced grade 3+ oesophagitis of 20-30% and pneu-
monitis of 5-10%. In the modern era of 3-D conformal RT, defining 
smaller treatment volumes by omitting ENI can reduce toxicity and 
allow dose-escalated regimes. We report our experience, omitting 
ENI in patients treated with concurrent CRT for LS-SCLC in a phase 
II trial. 
Methods: Patients with LS-SCLC, PS 0-1 and suitable for radical 
RT received cisplatin, 60 mg/m2 IV d1 with etoposide 120 mg/m2 IV 
d1-3, q3 weeks x 4 cycles with concurrent RT (3D conformal) from 
cycle 2. Prophylactic cranial irradiation was offered to all responders. 
The gross tumour volume was defined as identifiable primary tumour 
and involved lymph nodes on CT scan. Nodal involvement on CT 
scan was defined as nodes ≥ 1 cm in short axis. The clinical target 
volume comprised the GTV with a 0.5 cm margin of normal tissue in 
all directions. ENI was not used. 38 patients were enrolled in a phase 
II randomized trial with 2:1 allocation to once-daily (66 Gy in 33 
fractions) or twice daily RT (45 Gy in 30 fractions).
Patients identified with thoracic recurrence on CT scan had their RT 
plans reviewed by 2 radiation oncologists. Six patterns of recurrence 
were identified: recurrence within the Planning Target Volume (PTV) 
only, recurrence within the PTV + regional nodal recurrence and/or 
distant recurrence, isolated nodal recurrence (NR) outside the PTV, 
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NR outside PTV + distant recurrence, distant metastases only and no 
recurrence.
Results: At a median follow-up period of 14.5 months, 14 patients/31 
assessable patients relapsed. There were no isolated nodal recur-
rences. Six patients progressed with extra-thoracic distant metastases 
only . Of the eight patients who relapsed with intra-thoracic disease 
2 patients relapsed within the PTV only, 4 patients relapsed within 
the PTV and distantly. The remaining 2 patients had nodal recurrence 
outside the PTV plus distant metastases.. In these 2 patients (both 
with left upper lobe primaries) the sites of intrathoracic recurrence 
were: patient 1- aorto-pulmonary window (station 5) and subcarinal 
area (station 7) and patient 2- anterior mediastinum (station 6)..
The rates of grade 3+ acute oesophagitis and pneumonitis were 23 
and 3% respectively.
Discussion: Our series suggests that omitting ENI, based on CT 
imaging, is not associated with a high risk of isolated nodal recur-
rence in LS-SCLC. The routine omission of ENI will be further 
evaluated prospectively in the ongoing phase III CONVERT trial 
(NCT00433563) comparing once-daily RT without ENI against 
twice-daily RT in LS-SCLC patients. 
PD4.5.3 Mesothelioma and Small Cell Lung Cancer, Sun, 14:30 - 16:00
Higher doses of thoracic radiation (TRT) are associated 
with improved overall survival in limited stage small cell 
lung cancer (LS-SCLC): an analysis of practice patterns at 
a Canadian regional cancer centre
MacRae, Robert M.; Giffin, Megan; Laurie, Scott A.; Nicholas, Garth
The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
Background: The addition of TRT is known to improve outcome 
in patients with LS-SCLC, but the actual optimal radiation dose and 
schedule remain controversial. Improvements in technology have 
made it possible to safely deliver higher dose of TRT, leading to a 
change in practice over time at our institution. This analysis serves to 
see if there is an associated improvement in outcome.
Methods: The Ottawa Hospital Cancer Centre (TOHCC) is a region-
al cancer treatment unit that is the sole provider of oncologic care for 
a population of 1.2 million people. A retrospective analysis of all pa-
tients with LS-SCLC receiving chemoradiation with curative intent at 
TOHCC between January 1997 and December 2007 was undertaken. 
Statistical analysis was completed using SAS version 8.0.
Results: 247 patients were identified: 54.3% female, 85% ECOG 0/1 
median age 65.1 years, 67.5% current smokers, 10.9% with pleural 
effusions, 6.1% had involved supraclavicular nodes and 6.5% had 
documented at SVCO at presentation. Staging and systemic ther-
apy did not change during the study period. The majority received 
etoposide with either cisplatin (70%) or carboplatin (26%) chemo-
therapy for 4 – 6 cycles (4/5/6 cycles: 13.4%/14.5%/63.8%). TRT 
was commenced with cycle 1 in 5.7%, cycle 2 in 26.3%, cycle 3 in 
26.3%, cycle 4 in 15%, cycle 5 in 6.5% while 22.3% received TRT 
after completion of chemotherapy. The median dose of thoracic radia-
tion delivered was 50 Gy (range 40-66 Gy), with 74 patients being 
treated with >50 Gy (after 2003). 65.7% received prophylactic cranial 
radiation (PCI). 
With a minimum follow-up of 15 months, 201 patients have failed, 
died or been lost to follow-up. Median survival was 19.4 months 
(95% CI 17.5-22.6). Overall survival at 2 years is 42% and 20% at 5 
years. The five year survival for those who received TRT doses of 60 
Gy or more is 30% (HR=0.48, p=0.0006) compared to the 40-49 Gy 
group. There are 78 confirmed brain relapses and 87 other cases of 
systemic failure as well as 48 confirmed local-regional relapses. 
Statistical analyses for predictors of survival were undertaken using 
known prognostic and treatment factors. On univariate analysis: 
age, weight loss, pleural effusion, baseline white blood cell count 
(WBC) and platelet count, performance status, the numbers of cycles 
of chemotherapy, TRT dose, and the use of PCI were all predictive 
of outcome. By multivariate analysis, performance status, baseline 
WBC remained predictive of outcome, in addition to TRT dose: Haz-
ard ratio for survival associated with a dose of TRT > 60 Gy was 0.54 
(0.33-0.89; p<0.015) compared to < 60 Gy. 
Conclusions: Our data would suggest that pursuit of increased TRT 
dose is a reasonable strategy to improve outcome in LS-SCLC. The 
results of two large ongoing trials asking questions about radiation 
dose will serve to clarify the result of this retrospective analysis. 
PD4.5.4 Mesothelioma and Small Cell Lung Cancer, Sun, 14:30 - 16:00
Evaluating the safety of using G-CSF prophylaxis during 
concurrent chemotherapy and thoracic irradiation in 
patients with limited-stage small-cell lung cancer (LS-
SCLC): evidence from a phase II trial
Colaco, Rovel J.1; Sheikh, Hamid Y.1; Ashcroft, Linda2; Blackhall, 
Fiona H.2; Lorigan, Paul C.2; Taylor, Paul3; Thatcher, Nicholas2; 
Faivre-Finn, Corinne1
1 The Christie NHS Hospitals Foundation Trust, Manchester, UK; 
2 Department of Medical Oncology, The Christie NHS Foundation 
Trust, Manchester, UK; 3 Department of Medical Oncology, 
Wythenshawe Hospital, Manchester, UK
Background: The use of colony-stimulating factors (CSFs) during 
concurrent chemo-radiotherapy (CRT) is controversial. A random-
ised study evaluating GM-CSF in this context showed a significant 
increase in life-threatening thrombocytopaenia and grade 5 pulmon-
ary toxicity. The ASCO 2006 recommendations advised that CSFs 
should be avoided in patients receiving concomitant CRT, particularly 
involving the mediastinum. We report our experience of using CSFs 
in patients treated with concurrent CRT for LS-SCLC. 
Methods: Patients with LS-SCLC, PS 0-1 and suitable for radical 
radiotherapy received cisplatin (P), 60 mg/m2 IV d1 with etoposide 
(E) 120 mg/m2 IV d1-3, q3 weeks x 4 cycles with concurrent RT (3D 
conformal without elective nodal irradiation) from cycle 2. 38 pa-
tients were enrolled in a phase II randomized trial with 2:1 allocation 
to once-daily (66 Gy in 33 fractions) or twice daily RT (45 Gy in 30 
fractions) The use of CSFs was left to the discretion of each investi-
gator (primary prophylaxis in patients at high-risk of febrile neutro-
paenia or secondary prophylaxis to maintain chemotherapy dose 
intensity). Common toxicity criteria v3.0 was used to record toxicity.
Results: Of 38 patients (25 male, 13 female, median age 61 years), 
26 were allocated to receive once-daily RT and 12 patients to receive 
twice daily RT. Median follow up is 14.5 months. Twenty patients 
received G-CSF with at least 1 of the 4 chemotherapy cycles of 
which 13 received GCSF concomitantly during the thoracic irradia-
tion phase(G-RT), whereas 18 received no G-CSF support. The com-
monest G-CSF used was filgrastim 300mg daily for 7 days duration 
commenced on day 4 or 5 of the chemotherapy cycle.
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There was a significant difference in grade 3/4 platelet toxicity with 
7/13 patients (54%) in the G-RT group compared to 2/18 (11%) in 
the non-GCSF group (p=0.03) but there was no difference in the rate 
of platelet transfusion. There was no statistical difference in rates of 
grade 3+ anemia or leucopenia.
The rate of acute oesophagitis was not significantly different in the 
2 groups; there were 2/18 cases (11%) of grade 3+ toxicity in the 
non-GCSF group compared to 5/13 cases (39%) in the G-RT group 
(p=0.17). Similarly, there was 1/13 cases of grade 3 acute pneu-
monitis in the G-RT group compared to 0/18 cases in the non-GCSF 
group. There was 1 case of grade 3 late radiation-induced pneumon-
itis in the non-GCSF group and two in the G-RT group (p=0.70) . 
There were no treatment related deaths in either group.
Conclusions: Our data suggests that in the modern era of 3-D con-
formal RT, G-CSF is safe to administer with thoracic CRT. Therefore 
in the ongoing phase III CONVERT trial (NCT00433563) comparing 
once-daily RT against twice-daily RT in LS-SCLC patients G-CSF is 
permitted and its use will be prospectively evaluated to inform future 
guidelines. 
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Clinical features of acute exacerbation of interstitial 
pneumonia during chemotherapy in lung cancer patients
Kaji, Reiko1; Nanjyo, Shigeki1; Otsuka, Kyoko1; Kida, Yoko1; Hata, 
Akito1; Fujita, Shiro1; Katakami, Nobuyuki1; Nishimura, Takashi2; 
Tomii, Keisuke2
1 Department of Clinical Oncology, Institute of Biomedical Research 
and Innovation Hospital, Kobe, Japan; 2 Respiratory Center, Kobe 
City General Hospital, Kobe, Japan
Background: Acute exacerbation of interstitial pneumonia (IP) 
caused by anti-cancer therapy including chemotherapy and radiother-
apy has been considered to be one of the reasons for poor prognosis 
in lung cancer patients associated with IP. We investigated clinical 
features of acute exacerbation of IP during chemotherapy in lung 
cancer pts with IP.
Methods: The medical records and pertinent radiographs of the lung 
cancer patients with IP who received chemotherapy at our hospitals 
from November 2005 to December 2008 were reviewed. Data in-
cluded patient demographics, pathologic findings, stages, treatments, 
and occurrences of acute exacerbation of IP.
Results: A total of 65 lung cancer pts associated with IP received 
chemotherapy. The median age was 70 (53-82) years old; 83% were 
male; 83% were PS 0 or 1; 96% were current or ex-smoker. Seven 
(11%) pts received oral steroids or immunosuppressive drugs for the 
treatment of IP and home oxygen therapy was already introduced to 
5 (8%) pts for chronic respiratory failure caused by IP. There were 
15 (23%) pts with adenocarcinoma, 21 (32%) pts with squamous 
cell carcinoma and 27 (42%) pts with small cell carcinoma. Seven 
(10.5%) pts had stage 1B, 2A or 2B, 14 (21.5%) had stage 3A, 20 
(31%) pts had stage 3B and 24 (37%) pts had stage 4. The median 
number of chemotherapy regimen was 2 (1-6); 39 pts received com-
bination therapy of cisplatin-etoposide and 22 pts received carbo-
platin-paclitaxel. Nine (14%) pts received both chemotherapy and 
radiotherapy. At a median follow-up time of 9.2 months (mo), 40 pts 
(62%) died. Median survival time (MST) was 13.1 mo in all pts, 13.1 
mo in non-small cell lung cancer pts, 10.9 mo in small cell lung can-
cer pts. Besides, MST was 10.9 mo in 56 pts treated with chemother-
apy alone and 17.6 mo in 9 pts treated with both chemotherapy and 
radiotherapy. Acute exacerbation of IP after chemotherapy occurred 
in 9 pts (14%) and 4 pts (44%) died from respiratory failure. Pts with 
acute exacerbation of IP had worse prognosis than pts without acute 
exacerbation (MST: 7.2 mo vs 13.9 mo, p<0.05). Pts who received 
both chemotherapy and radiotherapy were more likely to experience 
acute exacerbation (33% vs 11%) than those who received chemo-
therapy alone. 
Conclusion: Acute exacerbation of IP deteriorate prognosis of 
lung cancer pts associated with IP. Radiotherapy had a tendency to 
increase the risk of acute exacerbation of IP. Although further studies 
with large numbers are needed to draw therapeutic strategy, it might 
be better to avoid radiotherapy in treating lung cancer pts associated 
with IP. 
PD5.1.2 Imaging, Pulmonary Medicine and Endoscopy, Sun, 14:30 - 16:00
Bronchoscopic microsampling is a useful complementary 
diagnostic tool for lung cancer patients
Soejima, Kenzo1; Nakayama, Sohei1; Yasuda, Hiroyuki1; Watanabe, 
Hideo2; Kawada, Ichiro3; Nakachi, Ichiro4; Yoda, Satoshi1; Satomi, 
Ryosuke1; Ikemura, Shinnosuke1; Terai, Hideki1; Naoki, Katsuhiko1; 
Ishizaka, Akitoshi1
1 School of Medicine, Keio University, Shinjuku-ku, Tokyo, Japan; 
2 Department of Medical Oncology, Dana-Farber Cancer Institute, 
Boston, MA, USA; 3 Hino Municipal Hospital, Tokyo, Japan; 4 
Saiseikai Utsunomiya Hospital, Utsunomiya, Japan
Background: Diagnosis of lung cancer is often difficult because ac-
cessibility to tumors is limited. Bronchoscopic microsampling (BMS) 
is a novel and direct method to obtain epithelial lining fluid (ELF) in 
the lung. We have reported measurement of tumor markers, such as 
CYFRA21-1 and CEA in ELF was a useful diagnostic adjunct in pa-
tients with small peripheral lung nodules. Analysis of DNA hyperm-
ethylation of tumor suppressor genes (TSGs) has been expected to be 
a sensitive tool for early detection of lung cancer. On the other hand, 
it has been reported that existence of certain EGFR mutations and 
EML4-ALK gene rearrangements are closely related to the sensitiv-
ity of EGFR- and ALK-tyrosine kinase inhibitors, respectively. The 
aim of this study is to evaluate the suitability of ELF as a sample 
for analyzing several molecular changes specific for lung cancer, 
such as DNA hypermethylation, EGFR mutations and EML4-ALK 
gene arrangements as well as to evaluate the usefulness of BMS as a 
complementary diagnostic tool for lung cancer. 
Methods: We performed BMS to 63 lung cancer patients with writ-
ten informed consent. The ELF was collected from tissue close to 
peripheral lung nodule and DNA and RNA were purified in each pa-
tient. We performed methylation specific PCR (MSP) for each ELF as 
well as matched serum and tumor tissue for 4 known TSGs, namely 
APC, ESR1, p16 and RARb. We examined known EGFR mutations 
in exons 18, 19, 20 and 21 by PNA-LNA PCR clamp method with 
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DNA in ELF, serum and tumor tissues and also performed multiplex 
RT-PCR for EML4-ALK rearrangement using RNA obtained from 
ELF samples.
Results: The sensitivity for detection of aberrant DNA hypermethyla-
tion by ELF vs serum was 83.3% vs 0% for APC, 75.0% vs 37.5% 
for ESR1, 87.5% vs 37.5% for p16 and 33.3% vs 0% for RARb. The 
specificity was almost more than 90% for all genes either by ELF or 
serum. The overall sensitivity was much higher with ELF (71.4%) 
compared to serum (21.4%). Finally, we found that 34 out of 63 
patients had at least one aberrant hypermethylation in ELF (54.0%), 
while only 12 had hypermethylation in serum (19.0%). Interestingly, 
DNA hypermethylation was detected even in stage I patients (62.0%) 
and the detection rate of aberrant hypermethylation in ELF was 
almost the same level in each clinical stage. We also found that the 
sensitivity for detecting EGFR mutation in ELF was 61.5%, while it 
was only 8.3% in serum. We could also detect gene rearrangement of 
EML4-ALK fusion gene using ELF in one patient. 
Conclusion: We conclude that BMS is an alternative method to 
detect cancer specific genetic and epigenetic changes and will be a 
useful complementary diagnostic tool for lung cancer.
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Diagnosing endoscopically nonvisible NSCLC: the value of 
RASSF1A hypermethylation in negative bronchoscopy
van der Drift, M.A.1; Knuiman, G.Jimmy2; Prinsen, Clemens F.M.2; 
Dekhuijzen, P.N.Richard1; Janssen, Julius P.2; Thunnissen, Frederik 
B.J.M.2, 3
1 Radboud University Nijmegen Medical Centre, Nijmegen, 
Netherlands; 2 Canisius-Wilhelmina Hospital, Nijmegen, 
Netherlands; 3 VUmc, Amsterdam, Netherlands
Background: The diagnostic yield of endoscopically nonvisible lung 
tumours is about 50% for washings, brushings and forceps biopsies 
combined. To improve the diagnostic yield molecular analysis is 
increasingly applied. 
Hypermethylation of tumor related genes is a mechanism for silen-
cing tumor suppressor genes. RASSF1A (Ras-association domain 
family 1A gene) hypermethylation has been found in about 40% of 
non-small cell lung cancer patients (NCSLC). In bronchial aspir-
ates RASSF1A hypermethylation was present in 28% of the NSCLC 
patients compared to 0% of non cancer patients1. RASSF1A hyper-
methylation was correlated with the amount of tumour cells in bron-
chial aspirates. Conversely, its presence when no tumour cells are 
found in bronchial washings of patients with NSCLC is not clear. The 
aim of this study was to analyse the additional diagnostic value of 
RASSF1A hypermethylation in washings in negative bronchoscopy 
in the analysis of patients with a endoscopically nonvisible tumour 
suspected of lung cancer.
Methods: A prospective study in 59 patients with a peripheral endo-
bronchial nonvisible tumour was performed. Patients were included 
in whom no cytological or histological diagnosis of lung cancer was 
made by bronchoscopy (n=21). Diagnosis of NSCLC was established 
by other diagnostic techniques. In bronchial washings the methylation 
status in the promoter region of the RASSF1A gene was determined 
by quantitative methylation-specific PCR (qMSP).
Results: 21 NSCLC patients were included, 14 males and 7 females, 
with a median age of 65 years. The pathologic diagnoses consisted 
of 8 adenocarcinomas, 5 squamous cell carcinomas and 8 large cell 
carcinomas. RASSF1A hypermethylation was detected in 5 patients 
(24%) (i.e. in 2 patients with adenocarcinoma, 2 patients with squa-
mous cell carcinoma and 1 patient with a large cell carcinoma). 
Conclusion: Our data suggest that detection of RASSF1A hyperm-
ethylation in bronchial washings may increase the diagnostic yield of 
negative bronchoscopy in patients suspected of NSCLC. Quantitative 
analysis of RASSF1A methylation in bronchial washing specimens 
is a promising biomarker assay for diagnosing lung cancer non-
invasively.
 Clinical characteristics % (no.) DNA ng/ml p-value 
   (interquartile range)
 Overall (46) 52 (64) 
 COPD   0.83
  absent 35 (16) 53 (67) 
  GOLD 1 13 (6) 60 (57) 
  GOLD 2 41 (19) 49 (64) 
  GOLD 3 11 (5) 27 (83) 
 Smoking   0.85
  current 65 (30) 52 (72) 
  former 33 (15) 49 (29) 
  never 2 (1) 777 (-) 
1 Grote HJ et al. Cancer 2006;108:129-134
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Breast cancer resistant protein (BCRP) is a molecular 
determinant of the outcome of photodynamic therapy 
(PDT) for centrally located early lung cancer
Usuda, Jitsuo; Ichinose, Shuji; Ishizumi, Taichirou; Ohtani, Keishi; 
Maehara, Sachio; Kajiwara, Naohiro; Saji, Osamu; Ohira, Tatsuo; 
Ikeda, Norihiko
Dept. of Thoracic Surgery, Tokyo Medical University, Shinjuku, 
Japan
The ATP-binding cassette (ABC) transporter protein, BCRP (breast 
cancer resistance protein)/ABCG2 pumps out some types of photo-
sensitizers used in photodynamic therapy (PDT) and causes resist-
ance to the antitumor effect of PDT. The purpose of this study was to 
investigate the association between the expression of BCRP and the 
efficacy of PDT using Photofrin, or the second-generation photo-
sensitizer, NPe6, for centrally located early lung cancers.
Using human epidermoid carcinoma cells, A431 cells and the BCRP-
overexpressing A431/BCRP cells, we examined the effects of BCRP 
expression on the effect of PDT by cell viability assay in vitro, and 
investigated the expression of BCRP by immunohistochemical analy-
sis in 81 tumor samples obtained from patients with centrally located 
early lung cancers.
The A431/BCRP cells were more resistant to Photofrin-PDT than 
A431 cells in vitro, and Fumitremorgin C, a specific inhibitor of 
BCRP, reversed the resistance.
However, there was no significant difference in the antitumor effect 
of NPe6-PDT between these cells. All of the 81 centrally located 
early lung cancer lesions were BCRP-positive (2+, 45 lesions; 1+, 
30 lesions) and all the patients were male and heavy smokers (> 30 
pack-years). The expression of BCRP significantly affected the ef-
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ficacy of Photofrin-PDT in cancer lesions ≥10 mm in diameter (P= 
0.04). On the other hand, NPe6-PDT exhibited a strong antitumor 
effect, regardless of the expression status of BCRP.
Photofrin may be a substrate of BCRP and be pumped out from the 
cells, therefore, BCRP may be a molecular determinant of the out-
come of Photofrin-PDT. 
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The usefulness of thin bronchoscopy and endobronchial 
ultrasonogram (EBUS) for peripheral lung lesion
Oak, Chul-Ho1; Lee, Song-Ju1; Jung, Min-Jeong2; Jang, Tae-Won1; 
Jung, Maan-Hong1
1 Kosin University, Busan, Korea; 2 Department of Pathology, Kosin 
University Gospel Hospital, Busan, Korea
Background: Thin bronchoscopy makes it possible to examine the 
peripheral lung lesions, not accessible by the routine bronchoscopy. 
In combination with the radial type of endobronchial ultrasonogram 
(EBUS), the diagnosis yield would be increasing.
Methods: Thirty patients with peripheral solitary pulmonary nodule 
of less than 3 cm in diameter and the accompanying bronchi were 
visible on the chest CT were enrolled. After verifying the lesions 
were not detected on the routine bronchoscopy, radial type EBUS 
probe with the external diameter of 2.5 mm (UM-3R, Olympus) 
inserted. When the lesions were found on the EBUS, specimens were 
obtained by biopsy and brushing cytology. Thereafter, with the thin 
bronchoscope of 3.2 mm in diameter (LF-10, Olympus), bronchial 
brushing cytology and biopsy were repeated. 
Results: There were 14 male and 16 female patients and their mean 
age was 63.1 years old. The diameter of the tumor was less than 1 
cm in five, less than 2 cm in eight, and less than 3 cm in 17 pa-
tients respectively. Access rate to the lesion was higher in the thin 
scope group than the EBUS group, 80% (24/30) vs. 66.6% (20/30) 
(p=0.04), but relevant sampling rate was higher in the EBUS group, 
85% vs. 54.1% (p=0.03). The diagnostic yield was 66.6% in the 
EBUS group and 60% in the thin scope group respectively, and 
increased to 73.3 % when combined. Diagnostic rate was highest in 
the lesions of 2 to 3 cm in diameter, 88.2% (15/17). There were no 
serious complications during the procedures.
Conclusions: In the diagnosis of the small peripheral pulmonary 
nodule, the thin bronchoscope was a useful and safe method and the 
radial type peripheral EBUS was complementary. 
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Narrow band imaging (NBI) videobronchoscopy improves 
assessment of lung cancer extension and influences 
therapeutic strategy
Zaric, Bojan1; Perin, Branislav 1; Stojanovic, Goran 1; Canak, 
Vukasin 1; Jovelic, Aleksandra 2; Secen, Nevena 1; Antonic, Milan 1
1 Institute for Pulmonary Diseases of Vojvodina, Clinic for 
Pulmonary Oncology, Faculty of Medicine, University of Novi Sad, 
Sremska Kamenica, Serbia; 2 Institute for Cardiovascular Diseases 
of Vojvodina, Faculty of Medicine, University of Novi Sad, Sremska 
Kamenica, Serbia
Introduction: Narrow band imaging videobronchoscopy (NBI) is a 
new technique aimed at lung cancer detection. This study investigat-
ed its sensitivity and specificity for evaluation of lung cancer exten-
sion and its possible influence on therapeutic decision, compared to 
white light videobronchoscopy. The major aim of our study was not 
detection of premailgnat lesions, but evaluation of NBI in everyday 
practice in respiratory endoscopy. Our aim was to investigate can 
NBI reveal greater extension of centrally located lung cancers than 
WLB alone, and can it in that case influence therapeutic planning 
before patient reaches surgery department. In that case the planning 
of surgical treatment, if needed, can be more accurate and faster. We 
wanted to determine specificity, sensitivity, positive predictive value 
(PPV) and negative predictive value (NPV) of NBI vs. WLB in the 
assessment of cancer extension. We have evaluated tissue surround-
ing the visible tumor, not using NBI for direct biopsy of visible 
tumor. We hypothesized that NBI will, in certain number of patients, 
reveal greater extension of visible tumor and that this technology will 
be able to influence therapeutic planning for lung cancer treatment. 
Our hypothesis was also that NBI will show better specificity and 
sensitivity than WLB alone.
Patients and Methods: In this prospective study we evaluated 106 
patients with suspected lung cancer. All patients were examined using 
EVIS LUCERA videoendoscopy system. In every patient at least 3 
biopsies were taken from places visualized as pathologic, surround-
ing primary tumor, and 3 biopsies from places that appeared normal. 
Overall number of biopsies performed in 106 patients was 636.
Results: Specificity and sensitivity of NBI in revealing greater lung 
cancer extension was 85.6% and 95% respectively; PPV and NPV 
were 84%, 95.6%. Specificity and sensitivity were significantly better 
when compared to WLB alone (p<0.01). NBI led to the change in 
therapeutic decision in 14 patients. There was statistically significant 
correlation between NBI assessment of tumor extension and change 
in therapeutic decision (p<0.000).
Conclusion: NBI showed significantly better specificity and sensitiv-
ity in assessment of lung cancer extension. NBI proved that it might 
have potential influence on therapeutic decision, making it more 
accurate. The procedure is safe and easily deployed in everyday 
practice.
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Use of Multi-projection Reconstruction (MPR) views of 
High Resolution CT reveals positive Air Bronchus Sign 
(ABS) and improves the Bronchoscopic diagnostic yield of 
peripheral lung tumors
Xu, Di2; Abdelrehim, Ola3; Yung, Rex C.1; McVeigh, Elliot2
1 Johns Hopkins University, Baltimore, MD, USA; 2 Johns Hopkins 
University Department of Biomedical Engineering, Baltimore, MD, 
USA; 3 Johns Hopkins School of Medicine Pulmonary & Critical 
Care Medicine, Baltimore, MD, USA
Background: Presence of Air Bronchus Sign (ABS) is associated 
with higher bronchoscopic yield of peripheral lung targets. Usually, 
only axial cuts of CT scans are viewed. On bedside computer work-
stations, Multi-Projection Reconstruction (MPR) viewing software 
of CT data allows manual plane tilting that can reveal ABS pathways 
towards peripheral lesions. We reviewed whether routine use of MPR 
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+ tilt plane views and higher resolution images can increase ABS 
findings and subsequent tissue diagnosis.
Methods and Patients: Retrospective review of 21 cases with 
suspected peripheral malignancies bronchoscoped between 9-08 
and 2-09. 13 males 8 females; age 34 to 83 years old; 42.86% 
T1a<2cm, 28.57% T1b2-3 cm, 23.81% T2a>3-5cm, 4.76% T2b>5-
7cm. Lesions’ locations: upper (63.16%), middle/lingular(10.53%) 
lower(26.32%) lobes.
Positive ABS is defined as a clear airway segment leading to a le-
sion. Uncertain ABS is when there isn’t an easily followed pathway. 
Firstly, we noted the frequency of ABS present on axial, coronal, 
sagittal and tilted plane views seen on standard 3mm slice thickness 
and subsequently 15/21with High Resolution thin slice 0.5-1.0mm 
slices. 
Results: The raw data for ABS frequency by MPR plane, CT slice 
thickness is presented in Table 1. 
Axial 
(A)
Coronal 
(C)
Sagittal 
(S)
Tilted 
Plane 
(TP)
Axial 
(A)
Coronal 
(C)
Sagittal 
(S)
Tilted 
Plane 
(TP)
ABS 
present
3mm 
thick-
ness
3mm 
thickness
3mm 
thick-
ness
3mm 
thick-
ness
0.5 
~1mm 
thickness
0.5 
~1mm 
thickness
0.5 ~1mm 
thickness
0.5 ~1mm 
thickness
Positive 19.05% 4.76% 9.52% 66.67% 26.67% 40.00% 26.67% 100.00%
Uncertain 23.81% 61.90% 42.86% 19.05% 26.67% 53.33% 40.00% 0.00%
Negative 57.14% 33.33% 47.62% 9.52% 46.67% 6.67% 33.33% 0.00%
P-value 0.012* 0.0008** 0.0008* 0.00002# 0.0004## 0.00002###
Fisher’s 
exact 
test 
LRCT TP 
Vs A*
LRCT TP 
Vs C**
LRCT TP 
Vs S***
HRCT TP 
Vs A#
HRCT TP 
Vs C##
HRCT TP Vs 
S###
By using MPR with plane-tilting for ABS detection to guide bron-
choscopic steering, the overall tissue diagnostic yield is 90.48%, 
66.67%(14/21) with cancer, 23.81%(5/21) granulomatous inflamma-
tion and 9.52%(2/21) with non diagnostic biopsies. 
Representative improvement for ABS present on HRCT images in a 
case is illustrated in image. 1.
Discussion: Although proprietary software and devices are now 
available for “Navigation bronchoscopy”, routine use of MPR views 
plus plane-tilting manipulation can reveal positive ABS in the major-
ity of cases. Our study suggests that using tilt-planes of HRCT is es-
pecially useful. We recommend acquiring CT scan in high resolution 
thin slices suitable for volumetric reconstruction and pre-procedural 
planning and selection of ABS pathways for enhanced diagnostic 
yield in peripheral lung lesions.
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Application of cryotechnology gives high efficiency and 
quality of bronchial biopsying in diagnosing of lung cancer
Marran, Sirje1, 2; Vanakesa, Tonu2; Sepper, Ruth1
1 Institute of Clinical Medicine, Tallinn, Estonia; 2 North-Estonian 
Medical Centre, Tallinn, Estonia
Background: In this study the efficiency and quality novel cryotech-
nology was investigated in applied flexible bronchoscopies to the 
patients with expected bronchial malignancies. 
Method: The cryo system which operates according to the principle 
of the Joule-Thomson effect was used for (CB) during fiberoptic 
bronchoscopy (FB) under local anaestesia (Erbokryo CA, ERBE 
Elektromedizin GmbH, Germany). 
Results: In one hundred and thirty seven patients with complaints re-
ferring to endobronchial cancer with mean age 64,5 yr were obtained 
cryobiopsies (CB) during FB in the Estonian Cancer Centre from Feb 
2007 to Dec 2008. To date, 127 CBs with median sample size of 10,1 
mm were obtained from central and 10 CBs with median sample size 
of 9,8 mm from periphery of airways. Expected cancer diagnosis was 
verified in 117 cases (in 91,4%) of central CBs, whereas one cryo-
bioptate was obtained in 107 and two in 10 cases investigated. For 2 
cases of 10 peripheral CBs were re-applied and the cancer diagnose 
verification was obtained. No CB-associated complications which 
could request special intervention were reported. In fourteen cases 
palliative re-canalization of bronchi obstructed by endobronchial 
tumor was followed to CB. 
Conclusion: CB is superior human bronchial tissue biopsying 
method; firstly, the biopsying efficiency is high, secondly, the high 
morphological quality of the cryo-bioptates was demonstrated with 
the sufficient size, representativeness of all bronchial epithelial 
structures and, importantly, with no artifacts within, thirdly, no 
post-procedural complications were detected, and fourthly, palliative 
re-canalization of obstructed bronchi could be reached as an added 
value of CB.
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Pilot study of single fiber reflectance spectroscopy during 
EUS procedure, difference in spectra between of benign 
and malignant lymph nodes
van der Leest, Kornelis H.1; Amelink, Arjen2; Sterenborg, Dick2; 
Aerts, Joachim G.1, 2; Hoogsteden, Henk2
1 Amphia Hospital, Breda, Netherlands; 2 ErasmusMC, Rotterdam, 
Netherlands
Introduction: Trans oesophageal endoscopic ultrasound guided fine 
needle aspiration (EUS-FNA) is used to analyse mediastinal lymphe 
Copyright © 2009 by the International Association for the Study of Lung Cancer S475
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
nodes. Purely based on the echographic imaging diagnostic value is 
limited, consequently FNA is obligatory.
In reflectance spectroscopy light that reflects or scatters from tissue 
is studied as a function of wavelight. Light enters solid tissue will be 
absorbed, reflected or pass through. Reflectance spectroscopy can be 
used to identify endobronchial tumors from normal tissue.
We constructed a novel optical device to obtain reflectance spectra 
in lymph nodes during EUS FNA procedure. In this pilot study we 
tested the feasibility of reflectance spectroscopy in detection of ma-
lignant mediastinal lymph nodes.
Methods: Reflectance spectra are obtained via an optical probe, 
small enough to led through a 460 µm EUS needle. After introducing 
the endoscope and placement in the correct position, a lymph node 
is punctured. The guide wire is removed and the optical probe is 
introduced. A tungsten-halogen lamp is used to light up the lymph 
node through the optical probe, and the remitting light is collected by 
the same probe and analyzed in a spectrometer. After measurement 
the probe is removed and cytological biopsies are performed. For the 
present pilot study 5 malignant and 5 benign nodes were analysed.
Results: We were able to differentiate benign from malignant nodes 
based on the spectroscopic determinations. The pattern of absorption 
dips and scattering differs in the 2 groups, probably related to cell 
metabolism and cell contents. 
Conclusion: From this preliminary report it can be concluded that 
reflectance spectroscopy in vivo during an EUS FNA procedure is 
feasible and may help to improve diagnostic yields of EUS.
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Narrow band imaging in medical thoracoscopy: a new 
technology for the detection of early-stage malignant 
pleural mesothelioma
Fukuoka, Kazuya; Yasumitsu, Akihiro; Terada, Takayuki; Hirayama, 
Noriko; Tamura, Kunihiro; Nakano, Takashi
Department of Respiratory Medicine, Hyogo College of Medicine, 
Mukogawa-cho, Nishinomiya, Hyogo, Japan
Background: NBI (Narrow Band Imaging) is an optical im-
age enhancement technology used for highlighting blood vessels 
on mucosal surface and/or fine mucosal patterns by changing the 
spectral features of light used for endoscopic observation. The NBI 
has two basic effects: one is enhanced display of capillary vessels on 
superficial layers of the mucous membrane, and the other is enhanced 
display of mucosal surface microstructure. In this study, we evalu-
ate the value of medical thoracoscopy using NBI system in detecting 
early-stage of mesothelioma.
Methods: Between 2006 and 2008, a diagnostic thoracoscopy under 
local anesthesia was carried out in a series of 52 patients with pleural 
effusion. Twenty-six patients were made a diagnosis of malignant 
pleural mesothelioma (MPM) by medical thoracoscopy using NBI 
system. There were 20 male and 6 female patients with MPM aged 
a mean of 67.0 years. Twenty-two patients had epithelioid histology, 
3 sarcomatoid histology, and 1 biphasic histology. Two patients had 
a stage I (T1a and b), 8 stage II, 5 stage III, and 11 stage IV disease. 
Pleural cavity was first screened with conventional white light (WL), 
and then was examined by NBI (Olympus LTF-240) for detection of 
additional lesions. All suspicious areas detected by NBI were biop-
sied and compared with pathological findings.
Results: NBI clearly visualized vascular architecture in the pleura 
comparing with conventional WL, which could distinguish superficial 
blood vessels from deeper ones, i.e., blood vessels near the pleural 
surface were displayed in brownish tones, and thick vessels in the 
deeper layer were shown in cyan tones. NBI revealed that intact 
mesothelium of the pleura appeared to be green in color, while the 
neoplastic lesions brownish in color. In the neoplastic lesions, the 
irregularity of mucosal surface was enhanced by NBI. The architec-
ture of capillary vessels in the neoplastic lesions detected by NBI was 
classified into two categories; scattered brown spots, and hypervas-
cularization of tortous and irregularly dilated vessels. Small nodule 
of T1a mesothelioma appeared brownish in color on NBI, with hyper-
vascularization of tortous and irregularly dilated vessels on mucosal 
surface. 
Conclusions: Advanced imaging modalities of NBI may allow 
the detection of early lesions of MPM. NBI system is feasible for 
detecting submesothelial vascularization in early-stage of mesotheli-
oma.
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Use of a pleural implantable access system for the 
management of malignant pleural effusion: the Institut 
Curie experience
Kriegel, Irene; Daniel, Catherine; Marcou, Aurore; Livartowski, 
Alain; Esteve, Marc
Institut Curie, Paris, France
Background: Malignant pleural effusion has a very poor prognosis, 
raises problems of medical management, and impairs quality of life. 
The authors report the first experience of a pleural implantable access 
system for the treatment of recurrent symptomatic malignant pleural 
effusion. 
Methods: Prospective follow-up of 95 patients between August 20, 
2005 and March 1, 2009 in a single center. 117 pleural implantable 
access systems were placed in 95 patients (71 patients with breast 
cancers, 14 patients with lung cancer, 18 patients with bilateral place-
ments, 2 patients with a replacement and 2 patients with a double 
ipsi-lateral placement) under sedation after the decision of a multi-
disciplinary meeting. 
Results: 92 patients (96,8 %) obtained partial or complete relief of 
their dyspnea. No placement failures were observed in this series. 
16 patients were lost to follow-up. 25 patients (31,6 %) underwent 
pleurodesis after a maximum of 2 months. In fact, 6 patients of this 
group had loculation of the pleural cavity making further thoracen-
tesis ineffective. Median survival in this group was 160 days (range, 
25-485 days). 6 catheters were removed without any difficulties. 18 
patients survived only less than one month. 8 patients died in our in-
stitution or in a palliative care unit without returning home. 3 patients 
had only one thoracentesis. The other 36 patients presented iteratives 
thoracentesis (4 to 63). Median survival in this group was 180 days 
(range, 90-760 days). 43 patients were receiving chemotherapy at the 
time of placement or after the time of placement (improvement in 
the functional status and the quality of life). Two infectious compli-
cations (infectious pneumonia and skin infection over the puncture 
site) and two mechanical complications (expulsion of the port and 
disconnection between the port and the catheter) were observed and 
easily treated. 
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Conclusions: The pleural implantable access system is an interesting 
alternative in terms of efficacy and safety for the outpatient manage-
ment of malignant pleural effusion. It presents a number of advan-
tages in terms of comfort and infectious risk compared with tunnelled 
pleural catheters. It avoids morbidity and the patient’s anxiety related 
to repeated puncture-aspiration. It provides a significantly less inva-
sive outpatient approach compared with thoracoscopy with drainage 
and talc poudrage.
Regardless of wether pleurodesis is achieved, the pleural implantable 
access system provide effective long term outpatient palliation of ma-
lignant pleural effusion and our patients reported good symptomatic 
relief following catheter placement with few major complications.
PD5.3.2 Imaging, Pulmonary Medicine and Endoscopy, Sun, 14:30 - 16:00
Safety and efficacy of spray cryotherapy in the treatment 
and management of malignant airway obstruction
Sarkar, Saiyad A.1, 2; deKeratry, Dominic R.3; Krimsky, William S.1, 2; 
Fields, Esther L.3; Malayaman, Navara1
1 Fanklin Square Hospital, Baltimore, MD, USA; 2 Pulmonary and 
Critical Care Associates of Baltimore, Baltimore, MD, USA; 3 Scott 
& White Healthcare, Temple, TX, USA
Background: Spray cryotherapy (SCT) is a non-contact method 
of destroying unwanted tissue using low-pressure liquid nitrogen. 
In addition to immediate tissue destruction, the rapid freezing and 
thawing of SCT evokes acute and chronic hemostatic effects and 
intracellular damage, leading to regeneration of healthy tissue. Prior 
studies of SCT in human and animal airways demonstrated safety and 
suggested feasibility in the treatment of thoracic disease. We review 
the first 43 patients treated with this modality for malignant airway 
obstruction.
Methods: SCT was administered to 43 patients suffering from ma-
lignant airway obstruction. These patients either had diffuse mucosal 
infiltration of tumor, required high degrees of supplemental oxygen 
concentration, or had had suboptimal results with other methods of 
tumor ablation. Patients received between 4 to 6 cycles of a 5 second 
spray dosimetry to the affected area with a complete thaw between 
each cycle. Throughout the procedure, patients received supplemental 
oxygen and were monitored as per institutional guidelines.
Results: Patients with less than 50% luminal obstruction (n=18) 
achieved luminal patency of their airway after SCT. Average pro-
cedure time was 20 minutes. Aside from balloon bronchoplasty, no 
additional treatments were required. For patients with greater than 
50% luminal obstruction (n=25), SCT was, on occasion, deployed 
in conjunction with rigid bronchoscopy and balloon bronchoplasty. 
Restoration of luminal patency was achieved in all patients by the end 
of the procedure. Procedure times averaged 35-40 minutes. Notably, 
rapid hemostasis was observed with the use of SCT. In one patient, 
there was a pneumothorax that required placement of a chest tube. No 
other adverse events were reported 
Conclusions: SCT is an alternative therapeutic option in patients 
with malignant airway obstruction. Luminal patency was reestab-
lished in all patients by the end of the procedure and rapid hemostasis 
with SCT was noted as well. Unlike the heat-related ablative mo-
dalities, SCT allows for the maintenance of high levels of supple-
mental oxygen during the procedure. These results also suggest that 
procedural efficiency is maintained in conjunction with the ability to 
treat broad areas of mucosal infiltration. Further studies are needed to 
optimize dosimetry of SCT on the human airway as well as to explore 
other potential application of SCT in other areas of thoracic disease. 
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Clinical utility of bronchoscopy-guided radiofrequency 
ablation for lung cancer
Koizumi, Tomonobu; Tanabe, Tsuyoshi; Tsushima, Kenji; Yokoyama, 
Toshiki; Agatsuma, Toshihiko; Suzuki, Toshirou; Kitaguchi, Yoshiaki; 
kanda, Shintarou; Itou, Michiko; Yoshikawa, Sumiko; Kobayashi, 
Takeshi; Yasuo, Masanori; Urushihata, Kazuhisa; Yamamoto, 
Hiroshi; Hanaoka, Masayuki; Kubo, Keishi
First Department of Internal Medicine, Matsumoto, Japan
Background: For patients with stage I non-small cell lung cancer 
(NSCLC), surgical resection is the standard treatment. However, the 
thoracic surgery is often not feasible for a high risk patient. We have 
developed a new internal cooled electrode (Japan Application No. 
2006-88228) suitable for forceps channel bronchoscopy. The aim 
was to assess the safety and clinical utility of bronchoscopy-guided 
radiofrequency ablation (RFA) for patients with stage I non-small cell 
lung cancer (NSCLC). 
Methods: This study was undertaken with the approval of our 
institutional human studies committee, and written informed consent 
was obtained from the patients. Eleven patients (mean age 75.4 years, 
ranging 64- 84), who were pathologically diagnosed with NSCLC 
and stage I (T1 or T2N0M0), but not indication for surgery because 
of other complications, such as synchronous multiple nodules, ad-
vanced age, cardiovascular diseases, poor pulmonary function test et 
al, were enrolled in the present study. 7 were women and 4 were man. 
The histological types of adeno and squamous cell carcinoma were 8 
and 3. respectively. RFA output power in the generator was fixed to 
be 20 W and a peristaltic pump was used to infuse cold water (4˚C) 
into the internal lumen of the catheter electrode at 50ml/minute.Three 
kinds of procedure for RFA were performed using an internal cooled-
electrode with 5 mm cylindrical active tip, for 30sec of ablation 
time, 8 mm for 40sec, and 10 mm for 50sec, respectively. CT guided 
bronchoscopy-guided cooled RFA were performed in these patients 
and followed CT. 
Results: Bronchoscopy-guided cooled RFA was repeated in a patient 
and total twelve RFA were performed in 3 years. All lesions ablated 
by RFA were changed to be scarred or decreased after bronchoscopy-
guided cooled RFA. During follow up (median 15 months, 5-27 
months) after bronchoscopy-guided cooled RFA, although local 
progression occurred in one patient, the other maintained stable after 
RFA. All patients were still alive. There were no adverse events and 
complications in the present study. 
Conclusion: Bronchoscopy-guided internal cooled-RFA was safe and 
feasible procedure that could become a potential therapeutic tool in 
local control. Bronchoscopy-guided internal cooled-RFA may be an 
alternative strategy, especially for local control in medically inoper-
able patients with stage I NSCLC. 
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Bronchoscopy-guided radiofrequency ablation as a novel 
intervention therapy for lung cancer
Tanabe, Tsuyoshi1; Koizumi, Tomonobu1; Tsushima, Kenji1; 
Agatsuma, Toshihiko1; Ushiki, Atsushi1; Yokoyama, Toshiki1; Suzuki, 
Toshirou1; Itou, Michiko1; kanda, Shintarou 1; Kobayashi, Takeshi 1; 
Yasuo, Masanori1; yamazaki, Yoshitaka 1; Yoshida, Kazuo 2; Uehara, 
Takeshi 3; Honda, Takayuki3; Kubo, Keishi1
1 First Department of Internal Medicine, Matsumoto, Japan; 2 
2nd Department of Surgery, Matsumoto, Japan; 3 Department of 
Laboratory Medicine, Matsumoto, Japan
Rationale: Surgery is recognized as the standard treatment for pa-
tients with localized primary lung cancer. We previously reported that 
internal bronchoscopy-guided cooled radiofrequency ablation (RFA) 
in normal sheep lung was a safe, effective and feasible procedure 
without major complications.
Objectives: The aim of this study was to evaluate the safe, effective 
and feasible condition of bronchoscopy-guided cooled RFA as a 
clinical application.
Methods: This study was undertaken with the approval of our insti-
tutional human studies committee, and written informed consent was 
obtained from 9 patients. These 9 patients who were pathologically 
diagnosed with non-small cell lung cancer (NSCLC), whose primary 
tumor size were smaller than 30 mm in diameter, who had absence 
of lymph node involvement and distant metastases (T1N0M0), were 
enrolled. RFA output power in the generator was fixed to be 20 W 
and a peristaltic pump was used to infuse cold water (4˚C) into the in-
ternal lumen of the catheter electrode at 50ml/minute.Three kinds of 
procedure for RFA were performed using an internal cooled-electrode 
with 5 mm cylindrical active tip, for 30sec of ablation time, 8 mm 
for 40sec, and 10 mm for 50sec, respectively. CT guided bronchos-
copy-guided cooled RFA were performed in these patients and then 
underwent the standard lung resection surgery. The resected lung tis-
sue was histopathologically examined to assess the ablated areas and 
compare the areas with different conditions of active tips. 
Results: The area of RFA lesion with the 10mm tip for 50sec ablation 
time significantly increased from that with the 5mm tip for 30sec ab-
lation time. Thus, the areas of RFA were increased with the improve-
ment of RFA catheter tips and prolongation of ablation time.
Conclusions: Internal bronchoscopy-guided cooled RFA in human 
used with CT imaging guidance was a safe and feasible procedure 
without major complications, such as bronchial bleeding or pneumo-
thorax. 
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Pathologic validation of the prognostic significance 
of fluorine-18-fluorodeoxyglucose uptake on positron 
emission tomography in patients with surgically resected 
lung adenocarcinoma 
Domen, Hiromitsu1, 2; Hida, Yasuhiro2; Okamoto, Syozo3; Kubota, 
Kanako1; Haga, Hironori1; Kaga, Kichizo2; Tamaki, Nagara3; Kondo, 
Satoshi2; Matsuno, Yoshihiro1
1 Department of Surgical Pathology, Hokkaido University Hospital, 
Sapporo, Japan; 2 Department of Surgical Oncology, Division of 
Cancer Medicine, Hokkaido University Graduate School of Medicine, 
Sapporo, Japan; 3 Department of Nuclear Medicine, Hokkaido 
University Graduate School of Medicine, Sapporo, Japan
Background: Fluorine-18-fluorodeoxyglucose (FDG) uptake on 
positron emission tomography (PET) is reported to have prognostic 
significance in patients with resected lung adenocarcinoma. However, 
its pathological background remains unknown.
Purpose: To clarify the correlation between FDG uptake and histo-
pathological characteristics of adenocarcinoma, which may explain 
the prognostic significance of FDG-PET. 
Materials and Methods: A retrospective analysis was conducted of 
patients with surgically resected lung adenocarcinoma who under-
went preoperative FDG-PET, between January 1999 and December 
2008 at Hokkaido University Hospital. Patients with tumors 1.0 
cm or less in diameter were excluded. A final total of 208 patients 
(median age 67 yr [range 31-92 yr], M:F=94:114, pT1 136, pT2-T4 
72, pN0 169, pN1-N3 39, pStageIA 120, pStageIB-IV 4, median 
tumor size 2.5 [1.1-7.7] cm) were included in the study. FDG uptake 
was measured as the maximal standardized uptake value (SUVmax, 
median 2.0 [0-14.4]). Histopathologic review was performed by two 
of the authors independently, in accordance with the World Health 
Organization classification for histologic subtypes. We paid attention 
to bronchioloalveolar carcinoma (BAC) component, and divided the 
cases into three categories: pure-BAC (BAC subtype only), complex-
BAC (BAC plus other subtypes), and non-BAC (subtypes other than 
BAC). Furthermore, fibroblastic tumor stroma (graded 0 to 3), necro-
sis (0 to 3), pleural involvement (p, 0 to 3), lymphatic invasion (ly, 0 
to 3), vascular invasion (v, 0 to 3), intracellular mucin (im, 0 to 3) and 
extracellular mucin (em, 0 to 3) were evaluated semiquantitatively. 
Then, statistical analyses were performed. The median SUVmax was 
used as cut-off threshold. The association between clinicopathologic 
parameters and SUVmax was analyzed using the Wilcoxon rank-sum 
test and Fisher’s exact test. Multivariate analysis (multiple logistic 
model) was then performed.
Results: Univariate analysis demonstrated that an elevated CEA level 
(>3.0ng/ml, p<0.01), larger tumor size (>2.0cm, p<0.01), upgraded 
pT (pT2-4, p<0.01), pN (pN1-3, p<0.01), pStage (pStageII-IV, 
p<0.01), non-BAC histology (p<0.01), abundant fibroblastic or hyal-
inized stroma (p<0.01), abundant necrosis (>10%, p<0.01), presence 
of p (p<0.01), ly (p<0.01), v (p<0.01), more im (>10%, p=0.03), and 
em (>10%, p=0.04) were significantly correlated with a SUVmax 
higher than the median. Multivariate analysis demonstrated that a 
tumor size of over 2.0 cm (odds ratio 3.0; 95%CI 1.2-8.2; p=0.03), 
non-BAC histology (3.8; 1.5-10.2; <0.01) and abundant fibroblastic 
or hyalinized stroma (3.3; 1.3-8.6; 0.01) were significantly correlated 
with a SUVmax higher than the median. 
Conclusion: This study revealed that there are more histopathologic 
factors reported to indicate a poor prognosis in lung adenocarcinomas 
showing a high SUVmax than in those showing a low SUVmax. 
Thus, prognostication of patients with resected lung adenocarcinoma 
on the basis of preoperative FDG uptake is considered to be patho-
logically valid.
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Staging of mediastinal and hilar lymph node metastases 
from non-small cell lung cancer: comparison of diagnostic 
accuracy of MRI and FDG-PET
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Junko 1; Iwamoto, Ryouji 1; Fujimoto, Naoko 1; Kurata, Shuji 1; 
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1 Department of Radiology, Kurume University School of Medicine, 
Kurume, Japan; 2 Department of Radiology, University of British 
Columbia, Vancouver, BC, Canada; 3 Department of Surgery, 
Kurume University School of Medicine, Kurume, Japan; 4 Center for 
Diagnostic Imaging, Kurume University Hospital, Kurume, Japan
Background: Several studies have demonstrated that 18F-fluoro-
deoxyglucose (FDG)-PET is superior to CT for diagnosing the N 
stage in nonsmall cell lung cancer (NSCLC). Recently, it has been 
shown that short-tau inversion-recovery (STIR)-magnetic resonance 
imaging (MRI) and diffusion-weighted (DW)-MRI may be helpful in 
the staging of nodal involvement in thoracic malignancy. 
Purpose: The aim of the study was to compare the diagnostic ac-
curacy of MRI using STIR and DW techniques and FDG-PET for 
the detection of metastases in mediastinal and hilar lymph nodes in 
patients with NSCLC. 
Methods: Sixty-five consecutive patients with NSCLC, who under-
went CT, MRI, and FDG-PET before surgery, were enrolled. MR 
techniques included the STIR method (STIR-MRI) and DW imaging 
using a non-breath-hold STIR-echo planar imaging sequence with 
a high b value of 1000 s/mm2 (DW-MRI). Two independent experi-
enced chest radiologists prospectively evaluated each study for medi-
astinal and hilar lymph node metastases on a per-patient basis. The 
results of all STIR-MRI were evaluated using a 5-point visual scoring 
system for qualitative analysis and metastasis-positive was defined as 
point 4 and 5. On DW-MRI, mediastinal lymph node metastasis was 
defined as a focus of low signal intensity at the site of a visible lymph 
node on corresponding T2-weighted image. On FDG-PET, lymph 
nodes with the standard uptake values (SUV) of greater than cutoff 
value (SUV > 2.7) were defined as positive metastases. These results 
were correlated with histopathologic findings obtained by resected 
lymph nodes (pathologic N stage).
The sensitivity, specificity, and accuracy of each coupled combina-
tion (STIR-MRI versus DW-MRI or STIR-MRI versus FDG-PET or 
DW-MRI versus FDG-PET) for N staging were compared by using a 
McNemar test.
Results: The agreement with pathologic N stage was 0.74 (95% 
confidential interval, 0.55 to 0.92) for STIR-MRI, 0.65 (0.45 to 0.85) 
for DW-MRI, or 0.69 (0.49 to 0.90) for FDG-PET.
The sensitivity, specificity, and accuracy of N staging in the 65 
patients were 0.76, 0.94, and 0.89 for STIR-MRI, 0.59, 0.96, and 0.86 
for DW-MRI and 0.71, 0.94, and 0.88 for FDG-PET, respectively. 
There was no statistically significant difference in diagnosing N stage 
between each coupled modality (McNemar test, all, P > 0.05). 
Conclusions: The results of this study suggest that STIR-MRI or 
DW-MRI are comparable to FDG-PET for the staging of nodal me-
tastases and has the potential to be a reliable alternative non-invasive 
imaging method for the preoperative staging of mediastinal and hilar 
lymph nodes in patients with NSCLC.
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Repeated 18F-FDG PET during cycle one as a predictor of 
early response to chemotherapy in advanced non-small cell 
lung cancer (NSCLC) patients (pts): preliminary results of 
a pilot study
Novello, Silvia1; Pelosi, Ettore2; Giaj Levra, Matteo1; Selvaggi, 
Giovanni1; Longo, Marina1; Capelletto, Enrica1; Scagliotti, Giorgio 
V.1
1 University of Turin, Orbassano (Turin), Italy; 2 IRMET Nuclear 
Medecine Service, Turin, Italy
Background: Despite its valuble contribution in the diagnosis and 
staging of neoplastic disease morphological imaging suffers from 
many shortcomings such as the delay between microscopic and 
macroscopic changes and incapability to provide information about 
biological processes. 18F-FDG PET has also a role in diagnosis 
and follow-up evaluation of lung cancer. Early prediction of tumour 
response is of particular interest in pts with advanced NSCLC giving 
the opportunity to avoid the administration of toxic therapy without 
benefit and 18F-FDG PET already showed to be a sensitive assess-
ment of activity in different solid tumours after the first cycle of 
therapy. 
Patients and Methods: From December 2007 to October 2008, 
34 chemonaïve pts with stage IIIB and IV (n=32; 94,1%) NSCLC 
treated in the Thoracic Oncology Unit of San Luigi Hospital in two 
clinical trials in which they were randomized to receive carboplatin/
paclitaxel plus placebo or two different oral multiple tyrosine kinase 
inhibitors, were prospectively and consecutively enrolled in this pilot 
study. Male/female ratio was 26/8, adenocarcinoma were 16 (47,1%), 
squamous 8 (23,5%), large cells carcinoma 2 (5,9%), NSCLC-NOS 
8 (23,5%). All pts underwent 18F-FDG PET scan at baseline (within 
one week before starting chemotherapy: PET1) and on day 15 of 
cycle one (PET2). PET/CT images derive from a PET/CT combined 
tomography: whole-body emission scans were acquired starting 
60 minutes after intravenous injection of FDG and PET data of the 
whole-body distribution of the tracer were acquired in 3D mode from 
the pelvis to the neck. For each patient we evaluate the change of 
standardized uptake volume (ΔSUV) from PET1 and PET2 in the 
primary tumour and the overall PET response of all visible lesions 
was evaluate according to EORTC criteria (Young, EJC 1999). 
Assessment of response, as per protocol procedures, was done with 
chest and abdominal CT scan according to RECIST criteria every 
two cycles (32 evaluable pts: in 2 cases pts dead before the first CT 
evaluation).
Results: Patients were dichotomized in PET responders and non-
responders: among PET responders, CT scan after 2 cycles showed 
an objective response (OR) of 66.6% (12/18) and only 2 OR (14,3%) 
in PET non-responders were observed (Fisher exact test, p=0.0045). 
Mean ΔSUV in the primary tumour was -42,3% ± 20.6 and -11,4% ± 
21.5 in PET responders and in non-responders, respectively. Overall, 
PET response overestimate CT response in 6/32 cases while under-
estimate it in 2/32 cases. Best response with CT scan achieved after 2 
cycles in 31 out of 32 cases. 
Adopting different cut-off values for baseline SUV or ΔSUV of 
the primary lesion no correlation was found with progression-free 
(PFS) or overall survival. We found a significant correlation between 
PFS and PET responders (38,2 vs 25 weeks; p= 0.04), while only a 
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trend for improved OS was found in overall responders versus non-
responders (52,4 vs 47,8 weeks; p= 0.12).
Conclusion: This pilot study indicates that in advanced NSCLC early 
PET restaging during cycle one of chemotherapy may predicts sub-
sequent objective response to CT scan after two cycles. This findings 
are worth of a prospective validation in a larger study. 
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Compliance with PET acquisition protocols for therapeutic 
monitoring of molecular targeted therapies in lung cancer: 
are multi-center international trials in this setting feasible?
Hicks, Rodney J.1; Mileshkin, Linda1; Binns, David S.1; Callahan, 
Jason1; Macfarlane, David J.2; Yu, Wei3; Pirzkall, Andrea3; Fine, 
Bernard3; on behalf of the OSI3926g study team4
1 The Peter MacCallum Cancer Centre, East Melbourne, VIC, 
Australia; 2 Queensland PET Service, Royal Brisbane and Women’s 
Hospital, Brisbane, Australia; 3 Genentech, Inc., South San 
Francisco, CA, USA; 4, USA
Background: The Response Criteria for Evaluation of Solid Tumors 
(RECIST) are widely used for therapeutic monitoring but have a 
number of critical limitations, including underestimating the activ-
ity of cytostatic agents that induce prolonged stable disease rather 
than objective response. Use of RECIST in lung cancer is further 
confounded by frequent structural abnormalities, before and after 
treatment, which may not contain tumor. Molecular correlates of drug 
activity, including changes in glucose metabolism using 18F-de-
oxyglucose (FDG) or reduced proliferation using 18F-deoxythymidine 
(FLT) positron emission tomography (PET), offer the potential to 
provide earlier and more robust assessment of treatment efficacy. 
However, there is concern regarding the lack of standardization of 
PET methodology. Accordingly, PET response is not yet a validated 
biomarker. The National Cancer Institute (NCI) has made recom-
mendations for the use of FDG PET (Shankar LK et al. J Nucl Med 
2006;47:1059-66) in therapeutic trials. 
Methods: We performed an audit of compliance with an imaging 
charter that was drafted to incorporate recommendations of the NCI 
within a prospective international trial (eight clinical sites in Australia 
and U.S.) evaluating the responses of patients with non-small cell 
lung cancer to erlotinib, a small tyrosine kinase inhibitor of epithelial 
growth factor receptor (EGFR). For baseline measurements, the char-
ter-specified time between tracer administration and scan commence-
ment (‘uptake time’) was 75 minutes ±10 minutes (FDG) and 60 ±10 
minutes (FLT). For follow-up FDG and FLT, the charter specified 
uptake times were within ±5 minutes of baseline uptake time.
Results: Data were reviewed from the first 30 consecutive patients 
enrolled who underwent baseline and early treatment follow-up (day 
14 and day 56) FDG (n= 60 studies) and FLT (n=58 studies) PET. 
Blood glucose was within the target range (<200 mg/dL) in 100% 
(60/60) of subjects undergoing FDG PET. Charter-specified uptake 
times were achieved in 93% (28/30) and 97% (28/29) of the baseline 
FDG and FLT scans respectively. In follow-up FDG and FLT stud-
ies, uptake times were not as consistent, with 68% (41/60) and 71% 
(41/58), respectively, achieving the charter-specified target of ±5 
minutes of baseline uptake time. If a time window of baseline uptake 
time ±15 minutes was applied, 97% (58/60) and 97% (56/58) of FDG 
and FLT PET studies, respectively, were within range. All other scan-
ning parameters were followed.
Conclusions: It is possible to achieve a high degree of reproducibil-
ity of scan acquisition methodology, provided that strict compliance 
guidelines are mandated as part of the protocol. For follow-up scans, 
there was some difficulty in attaining tracer uptake periods within 
the charter-specified ±5 minutes of baseline uptake period. However, 
when tight time windows were specified, the majority of scans were 
done within 15 minutes of the ideal time, which is probably adequate 
for reproducibility of semi-quantitative measures.
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PET-CT and lymphovascular invasion predict recurrence 
in stage I lung cancers
Shiono, Satoshi; Abiko, Masami; Sato, Toru
Department of Thoracic Surgery, Yamagata Prefectural Central 
Hospital, Yamagata, Japan
Background: Positron emission tomography (PET) can be used 
to predict survival after surgery for lung cancer. Lymphovascular 
invasion has also been suggested to be a prognostic factor. Although 
pathological stage I lung cancers generally have a favorable progno-
sis, 30% of patients experience recurrence after surgery. Therefore, a 
method of selecting patients who need adjuvant therapy is necessary. 
This study was conducted to evaluate the significance of PET-CT 
results after lung cancer surgery, and to identify the predictive fac-
tors of recurrence in cases of pathological stage I lung cancer using 
multivariate analysis. 
Methods: From January 2004 through December 2008, 356 lung 
cancer patients underwent surgery at our institution. Of these, 282 pa-
tients received F-18 fluorodeoxyglucose PET-CT, and the maximum 
standardized uptake value (max SUV) was measured. Patients with 
induction chemotherapy or incomplete resection were excluded from 
the study, leaving 212 patients with pathological stage IA and IB who 
were analyzed. There were 147 patients with pathological stage IA 
and 65 with stage IB cancer. The patients ranged in age from 32 to 86 
years old (average 68 years). Tumor size ranged from 0.6 to 7.8cm 
(average 2.6cm). There were 131 men and 81 women. The surgical 
procedures performed were lobectomy in 167 cases (78.8%), seg-
mentectomy in 15 cases (7.1%), wedge resection in 27 cases (12.7%), 
bilobectomy in 2 cases (0.9%), and bronchial resection in 1 case 
(0.5%). We analyzed the association between disease-free survival 
and the following clinicopathological factors: age, gender, smoking 
history (+ or -), CEA level (≤ 5.0 or > 5.0 ng/ml), tumor size (≤ 3.0 or 
> 3.0cm), max SUV values (≤ 7.5 or > 7.5), histology (adenocarcin-
oma or non-adenocarcinoma), lymphovascular invasion (+ or -), and 
pleural invasion (+ or -). 
Results: The median follow-up time was 24 months. The overall 
4-year survival rate after surgery was 82.7%. One perioperative 
death that occurred due to sepsis (0.5%). There were 16 patients 
(7.5%) with recurrence after surgery. The 4-year disease-free survival 
rate was 86.6%. Univariate analysis showed that CEA > 5.0ng/ml 
(P=0.01), max SUV > 7.5 (P=0.01), and lymphovascular invasion 
(P<0.01) were all independent predictive factors for recurrence. 
Multivariate analysis showed lymphovascular invasion (P=0.02) 
and max SUV > 7.5 (P<0.01) to be independent predictive factors. 
Patients with a max SUV value greater than 7.5 had a significantly 
high risk of recurrence. When patients were divided into those with 
a max SUV > 7.5 and lymphovascular invasion (n=15) and all others 
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(n=197), the disease-free survival of patients with a high max SUV 
and lymphovascular invasion was significantly reduced (P< 0.01).
Conclusions: Since SUV is affected by various parameters, using 
SUV as a predictive factor for recurrence might be controversial. 
Although the present data were taken after a short follow-up period, 
we found that the PET-CT results significantly correlated with recur-
rence in pathological stage I lung cancers. In addition, we determined 
that patients with a high max SUV and lymphovascular invasion 
were more likely to have recurrence. In the postoperative assessment, 
patients with a high max SUV and lymphovascular invasion, even 
those at pathological stage I, may be considered good candidates for 
adjuvant chemotherapy.
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Prognostic significance of maximum standardized 
uptake value on FDG-PET in surgically treated lung 
adenocarcinoma
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Background: Many patients with surgically resected lung adeno-
carcinoma often develop recurrent disease. We have conducted this 
retrospective study to determine whether the preoperative maximum 
tumor standardized uptake value (SUVmax) on F-18 fluorodeoxyglu-
cose positron emission tomography (18F) FDG-PET) was associ-
ated with recurrent disease in patients with surgically resected lung 
adenocarcinoma.
Methods: We analyzed consecutive 121 patients who underwent 
curative surgical resection for lung adenocarcinoma between 2004 
and 2008 who also have examined preoperative FDG-PET imaging. 
Disease free survival was calculated by means of Kaplan-Meier 
analysis and statistical significance between the groups was analyzed 
by using log-rank tests. Cox proportional hazard regression was used 
to ascertain independent predictors of recurrence. 
Results: Using the median SUVmax of 5.8, the patient population 
was subdivided. In a univariate analysis, tumor diameter greater 
than 3cm (p=0.04), nodal status (p=0.0105), venous involvement 
(p=0.0343), and SUVmax greater than 5.8 (p=0.0194) were correl-
ated with disease free survival. A multivariate Cox analysis had iden-
tified SUVmax (p=0.0482) as an independent predictor of recurrence. 
The 2-year disease free survival for patients with both tumor diameter 
less than 3cm and SUVmax less than 5.8 was 93.0%,; for those with 
tumor diameter less than 3cm and SUVmax more than 5.8, it was 
89.0%; for those with tumor diameter more than 3cm and SUVmax 
less than 5.8, it was 100%; and for those with tumor diameter more 
than 3cm and SUVmax more than 5.8, it was 35.5% (p<0.0001).
Conclusions: In patients with surgically managed lung adenocarcin-
oma, SUVmax could be a predictor of recurrence after resection. 
Furthermore, the addition of SUVmax to pathologic tumor diam-
eter could identify a subgroup of patients who had the highest risk 
for recurrence after surgery. The SUVmax combined with other 
well-known clinicopathological factors could be a useful marker for 
patient selection who needs to have an adjuvant treatment.
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Usefulness of FDG-PET for post operative lung cancer 
patients with elevation of tumor marker regardless of 
negative CT findings
Murakami, Koji; Kitajima, Kazuhiro; Yamazaki, Erena
Dokkyo Medical University PET Center, Tochigi, Japan
Purpose: There are some reports to describe the effectiveness of 
FDG-PET for detecting recurrence of colorectal cancer with elevation 
of CEA, but little reports for recurrent lung cancer. This study is to 
evaluate the usefulness of FDG-PET for lung cancer patients after 
surgery with elevation of tumor marker regardless of negative CT 
findings.
Materials and Methods: Whole body FDG-PET (or PET/CT) was 
performed in 16 patients with lung cancer after surgery because of 
continuous elevation of tumor marker, 14 of whom showed eleva-
tion of CEA, 2 showed elevation of SCC. Though all patients were 
underwent curative surgery, tumor recurrence was suspected in all of 
the cases due to increasing the tumor marker at least continuous two 
times. Chest CT, abdominal CT, and brain MRI that performed before 
PET study revealed no evidence of recurrence. 
Results: Nine of 16 patients showed abnormal activity; 7 of 9 posi-
tive patients were diagnosed as recurrence by histology or clinical 
follow-up (true positive), and 2 of 9 cases were considered to have 
no recurrence by follow-up study (false positive). Seven cases who 
validated as recurrence received radiation therapy and/or chemother-
apy. Six of 16 patients who demonstrating no abnormal FDG deposit 
revealed disease free at least 6-months follow up (true negative), 
and one case was missed by PET. The location of recurrent tumors 
included supraclavicular, mediastinum lymph nodes, pleura and bone. 
Sensitivity, specificity and accuracy were 87.5%, 75.0%, and 81.3%, 
respectively.
Conclusions: Whole body FDG-PET (PET/CT) is an accurate tools 
in diagnosis of recurrent lung cancer with rising tumor marker levels 
and with negative conventional imaging modality. It also can make it 
possible to change the therapeutic approach in some cases.
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CT diagnosis for thymic epithelial tumors: correlation of 
CT findings with pathologic findings and prognosis
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Sadohara, Junko 1; Kono, Rei1; Müller, Nestor L.2; Nishi, Tatsuya3; 
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Background: In patients with thymic epithelial tumor, recent reports 
suggested that CT findings are helpful in differentiating low-risk 
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(type A, AB, and B1) thymomas and high-risk (B2 and B3) thymo-
mas from thymic carcinomas and in evaluating tumor invasiveness 
of the circumference organs (Masaoka stage). Therefore we hypoth-
esized that some CT findings could be helpful in predicting patient 
outcome.
Purpose: The aim of this study was to compare the CT features with 
histological assessment of thymic epithelial tumors based on the 
current World Health Organization (WHO) histological classification 
and to determine CT features helpful in differentiating invasive from 
non-invasive tumors and in predicting patient outcome.
Methods: Seventy-five patients with thymic epithelial tumor who 
underwent CT within 2 weeks before surgery were retrospectively 
reviewed. The patients ranged in age from 24 to 79 years (median, 
58 years); 39 were women and 36 were men. There were 36 non-
invasive tumors (Masaoka stage I thymoma) and 39 invasive tumors 
(25 stage II to IV thymomas and 14 thymic carcinomas). Subtype of 
the thymic epithelial tumor was determined according to the WHO 
classification. Seventy-five tumors were regrouped into three categor-
ies: 38 low-risk thymomas (5 type A, 15 type AB, and 18 type B1), 
23 high-risk thymomas (15 type B2 and 8 type B3), and 14 thymic 
carcinomas. CT features were classified into 15 categories and were 
assessed by two independent chest radiologists without knowledge 
of histologic findings. Multivariate analysis was performed using the 
Cox proportional hazards model. 
Results: There was good to almost perfect agreement between the 
observers for presence and/or classification of each finding (kappa 
value = 0.67 to 1.0). 
Low-risk thymomas were more likely to have smooth contour than 
high-risk thymomas and carcinomas (P < .001). Inner characteristics 
of thymic carcinoma were more heterogenous than low-risk and high-
risk thymomas (P < .001). 
CT findings helpful in predicting invasive tumor included irregu-
lar margins, heterogeneity of inner characteristics, and presence of 
lymphadenopathy. These findings were seen more frequently in thym-
ic carcinomas than in other types (P < .001). Multivariable analysis 
revealed that the simplified groups according to the WHO histologic 
classification (P < .005; risk ratio, 3.008; 95% CI: 1.579, 5.729) and 
inner characteristics and invasiveness of tumor on CT (P < .05; risk 
ratio, 5.968; 95% CI: 1.256, 28.365) were related to prognosis. 
Conclusions: CT characteristics of thymic epithelial tumors and 
simplified groups according to the WHO histologic classification are 
correlated with tumor invasiveness and might be helpful in predicting 
patient outcome. 
PD5.5.3 Imaging, Pulmonary Medicine and Endoscopy, Sun, 14:30 - 16:00
Radiological evaluation using “Image J” software and its 
correlation to lung adenocarcinoma pathological findings
Yoshida, Yukihiro 1; Sugiura, Miki1; Fukami, Takeshi1; Murakawa, 
Tomohiro1; Maeda, Eriko2; Ohtsu, Hiroshi3; Ota, Satoshi4; Nakajima, 
Jun1
1 Department of Thoracic Surgery, Graduate School of Medicine, 
The University of Tokyo, Tokyo, Japan; 2 Department of Radiology, 
Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; 
3 Department of Clinical Trial Data Management, Graduate School 
of Medicine, The University of Tokyo, Tokyo, Japan; 4 Department of 
Pathology, Graduate School of Medicine, The University of Tokyo, 
Tokyo, Japan
Background: Lung adenocarcinomas 2cm or smaller in size with 
ground-glass opacity (GGO) are considered good candidates for 
limited resection. Several radiological predictions for pathological 
invasiveness have been proposed, but results have been neither 
objective nor reproducible among observers. Definitions of early 
lung adenocarcinoma using computer software have recently been 
reported and this method seems to be quite promising. In this study, 
we examined predictive performance for radiological evaluation of 
bronchioloalveolar carcinoma (BAC) defined as lung adenocarcin-
oma without invasion using “Image J” software provided by the 
National Institutes of Health.
Methods: A total of 157 cases of primary lung adenocarcinoma 2cm 
or smaller diagnosed as clinical stage IA and resected at The Univer-
sity of Tokyo Hospital from January 2001 to December 2008 were 
included in our study. Staging and pathological findings were based 
on the 1997 TNM staging and 2004 WHO classification. Two in-
dependent observers (YY and MS) traced tumor edges using “Image 
J” software. Consolidation was defined as pixels whose CT numbers 
were >-160 Hounsfield units (HUs) with both the proportion and 
area of consolidation calculated for each tumor. Predictive perform-
ance for the proportion and area of consolidation were evaluated by 
receiver operating characteristic (ROC) analysis and areas under the 
respective curves were represented by Az values.
Results: Adenocarcinoma with mixed subtypes (AwMS) was diag-
nosed in 123 cases and BAC in the other 34 cases. Seventy patients 
were females and 45% of all patients had never smoked previously. 
The average area of consolidation was 9.1mm2 (range, 0-89) for BAC 
and 90.5mm2 (range, 0-386.2) for AwMS while the average propor-
tion of consolidation was 7.4% (range, 0-65.9) for BAC and 44.3% 
(range, 0-95.7) for AwMS. Both the area and proportion of consolida-
tion were significantly smaller in BAC than in AwMS (p<0.001; t-
test). The Az value was 0.898 for the area of consolidation and 0.884 
for the proportion of consolidation. Inter-observer variability for the 
area of consolidation was less than for the proportion of consolidation 
(Figure 1).
Conclusions: The area of consolidation measured using high 
resolution CT (HRCT) images and “Image J” software was a more 
favorable value for predicting BAC with its limited inter-observer 
variability and higher predictive performance.
Figure 1. Area of Consolidation & Proportion of Consolidation Scattered 
Plots
Scattered plots of area of consolidation (left) and proportion of consolidation (right) measured by two 
independent observers. X-axis and Y-axis show values measured by observer YY and observer MS, 
respectively.
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PD5.5.4 Imaging, Pulmonary Medicine and Endoscopy, Sun, 14:30 - 16:00
Preoperative CT findings of small-size lung cancer with 
recurrence during 1 year after surgical lung resection
Kondo, Tetsuro; Murakami, Shuuji; Saito, Haruhiro; Oshita, 
Hirofumi; Suga, Yasuhiro; Ito, Hiroyuki; Tsuboi, Masahiro; 
Nakayama, Haruhiko; Yokose, Tomoyuki; Kameda, Youichi; Noda, 
Kazumasa; Yamada, Kouzo
Kanagawa Cancer Center, Yokohama, Japan
Background: In generally, tumor recurrence is often observed even 
if small-size lung cancer case of 2 cm or less in diameter. In this 
paper, small-size lung cancers with recurrence during 1 year after 
surgical lung resection were reviewed to clarify factors related to 
their outcome.
Methods: From July 1992 to August 2008, 598 patients with small-
size lung cancer of 2 cm or less in diameter were underwent surgical 
lung resection in our institution. Of them, 70 patients (11.7%) were 
occurred recurrent tumor after surgical lung resection. Of them, 
moreover, 20 patients (28.2%) were occurred recurrent tumor during 
1 year after surgical lung resection. In 70 patients occurred recur-
rence after surgical lung resection, clinicopathologcal factors and 
preoperative thin-section CT (TS-CT) findings were reviewed to 
clarify factors related to their outcome. TS-CT images of each case 
were evaluated in point of conjunction with several pulmonary ves-
sels, ground-glass opacity (GGO), spiculation, notch, lobulation and 
air-bronchogram.
Results: In a total of 598 patients with surgical resected small-size 
lung cancer of 2 cm or less in diameter, median age was 65 years 
(26-86), 281 male and 317 female, median tumor diameter 15 mm 
(5-20), 518 adenocarcinoma and 80 others, and pathological stage I, 
II, III and IV was 547, 20, 29 and 2, respectively. In clinicopatholog-
cal factors no correlation was statistically observed between patients 
relapsed within 1 year and over 1 year regarding with age, gender, 
tumor diameter, histology, smoking status, smoking index, relapse 
site and operative procedure, however, pathological stage was sig-
nificantly observed in patients relapsed within 1 year. In preoperative 
TS-CT image analysis, conjunction with several pulmonary vessels 
and notch findings were significantly observed in patients relapsed 
within 1 year. In multivariate analysis pathological stage, conjunction 
with several pulmonary vessels and notch findings were significantly 
related to early recurrence.
Conclusions: In preoperative TS-CT image analysis of small-size 
lung cancer cases of 2 cm or less in diameter, conjunction with sev-
eral pulmonary vessels and notch findings were significantly related 
to early recurrence during 1 year after surgical lung resection.
PD5.5.5 Imaging, Pulmonary Medicine and Endoscopy, Sun, 14:30 - 16:00
Imaging changes as non-mucinous lung adenocarcinoma 
progressed from noninvasive BAC to invasive 
adenocarcinoma
Eto, Takashi; Nakajima, Nbuyuki
Shizuoka General Hospital, Shizuoka, Japan
Background: The 2004 WHO classification recognized that the 
findings of bronchioloalveolar carcinomas (BAC) include septal wid-
ening with sclerosis. We analyzed imaging changes as noninvasive 
BAC progressed to invasive adenocarcinomas in comparison to the 
2004 WHO histologic criteria.
Methods: Sixty-one patients with surgically resected non-mucinous 
lung adenocarcinomas were divided into three groups. Group A (10 
patients) demonstrated noninvasive BAC, in which the uniformly 
thickened alveolar septa demonstrated preservation of elastotic 
framework. Findings in group B (25 patients) suggested semi-inva-
sive adenocarcinomas, in which there were fibroblastic foci within 
the almost preserved elastotic framework but these cases were still 
negative for pleural, vascular, lymphatic and nodal invasion. Group 
C demonstrated invasive adenocarcinomas (26 patients), in which 
fibroblastic foci showed disruption of the elastotic framework with 
either pleural, vascular, lymphatic or nodal invasion. Veins, arteries 
and bronchi were evaluated both inside and outside of the nodule. 
Retrospective imaging history was analyzed in 5 Group A, 2 Group B 
and 3 Group C patients. All patients were compared with the standard 
uptake value max (SUV max) on positron emission tomography 
(PET). 
Results: On imaging studies of the 10 group A patients, the pure 
nonsolid component/nonsolid component dominant ratio was 6/4, 
respectively. Veins were the major component in the nodule. Many 
short venous branches and vascular reticula were visualized in the 
nonsolid components. The dense vascular reticulum appeared to be 
a solid component. Arteries, in contrast, were more peripheral and 
inconspicuous. Bronchial dilatations were seen in 3 cases. SUV 
max ranged from 0 to 1.2. On imaging studies of the 11 group B 
patients with SUV max 0-1.5, the ratio of pure nonsolid component/
nonsolid component dominant/solid component dominant as 2/5/4, 
respectively. Many short venous branches or vascular reticulum in the 
nonsolid components were seen in all 11 cases. On imaging studies 
of the remaining 14 group B patients with SUV max 1.7-5.4, the ratio 
of the pure nonsolid component/nonsolid component dominant/solid 
component dominant/pure solid component was 1/2/10/1, respective-
ly. Vascular reticulum in the nonsolid component was seen in 4 cases. 
Draining veins from the solid components were seen in 13 cases and 
the veins tended to be larger in 9 cases. On imaging studies of the 26 
group C patients, the ratio of the nonsolid component dominant/solid 
component dominant/pure solid component was 1/7/18, respectively. 
Draining veins were more evident in group C. The size and num-
bers of draining veins were increased in proportion to the SUV max 
values. 
Conclusions: In non-invasive lung adenocarcinoma imaging, many 
short venous branches and abundant vascular reticula comprised the 
nonsolid component, and then the dense vascular reticulum subse-
quently transformed to the solid component. As an early route of 
invasion, draining veins progressed with transformation of the vas-
cular reticulum from a nonsolid to solid component. As the invasion 
progress, the growing solid components showed increases in the size 
and number of draining veins.
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The correlation of high-resolution CT, histopathological 
and clinical findings of bubble-like appearance type 
adenocacinomas
Kojima, Yoko; Saito, Haruhiro; Sakuma, Yuji; Kondo, Tetsuro; 
Oshita, Fumihiro; Ito, Hiroyuki; Tsuboi, Masahiro; Nakayama, 
Haruhiko; Yokose, Tomoyuki; Kameda, Yoichi; Noda, Kazumasa; 
Yamada, Kouzo
Kanagawa Cancer Center, Yokohama, Japan
Background: Some lung cancer tumors resemble focal organized 
pneumonia. These tumors grow slowly and are often diagnosed as 
old inflammatory lesions. Previously, we reported that bubble-like 
appearance (BLA) adenocarcinomas are the type of lung cancer 
which are very similar (in appearance) to old inflammation (JCAT 
33(1):42-48, 2009). High-resolution CT (HR-CT) images of these 
tumors appear as polygonal shapes. These tumors include slight GGO 
in periphery areas and dilated airbronchograms (resembling col-
lections of bubbles), and prominent pleural indentations. Presently, 
histopathological, clinical, and biological characteristics of BLA type 
adenocarcinoma have not been fully investigated.
Methods: We retrospectively reviewed records and HR-CT images 
of 26 patients (7 males, 19 females), who had undergone surgical 
resection between 1993 and 2008. The HR-CT images all revealed 
identical BLA type characteristic findings. All HR-CT images 
were acquired by model X-Vigor/Real or by Aquillion CT scan-
ner (Toshiba Medical System). All HR-CT images of tumors were 
obtained at 135kVp at 250mAs with 0.5-2mm section thicknesses. 
All images were photographed using lung (level, -600HU; width, 
1600HU) window settings. We analyzed correlations between HR-CT 
findings, histopathological findings, and clinical findings. Addition-
ally, we analyzed mutations of the epidermal growth factor receptor 
(EGFR) and K-ras genes. 
Results: All 26 cases show common characteristic HR-CT and 
histopathological findings. The HR-CT findings include: (1) solid 
polygonal shapes with straight margins (2) slight GGO regions in 
peripheral areas of tumors (3) dilated airbronchograms in tumors, 
which look like bubbles and (4) prominent pleural indentations. The 
histopatholical findings were identical with the HR-CT findings: (1) 
the solid part on HR-CT images is collapsed (about 80% of the tumor 
area). There were only a very few slightly invasive lesions. (2) The 
GGO part on the HR-CT is bronchioloalveolar cell carcinoma (BAC) 
less than 20% of tumor areas. (3) The dilated airbronchograms on 
HR-CT images reveal several ectatic small bronchi. Tumor diameters 
averaged 35.4mm. The pathological stages were classified from IA to 
IIIA. 9 of our 26 cases were initially diagnosed as old inflammatory 
lesions, which were observed over a period of time, ranging from 
three months to eight years. Tumor doubling time (using the Schwartz 
method) was calculated at 1165 days on average. We determined 
that these BLA types of adenocarcinomas grow in size slowly and 
the pathologically ectatic bronchi areas increase with simultaneous 
collapse. Polygonal shapes and slow growth characteristics make dif-
ferentiation from non-malignant tumors difficult.
The EGFR mutations were observed in 17 cases (65.4%). The L858R 
mutations were observed in 12 of 17 cases (70%). There were no 
EGFR mutations in the other 9 cases, nor were there any K-ras muta-
tions. After resection, the disease free survival rate is 96% and the 
5-year survival rate is 100%.
Conclusion: BLA type adenocarcinomas have unique HR-CT im-
ages, histopathological findings, and clinical characteristics, including 
almost total collapse, very slow doubling time, and a good prognosis 
after resection. These types of lesions require careful attention, be-
cause they are often diagnosed as old inflammatory scarring. 
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EML4-ALK fusion gene in resected non-small-cell lung 
cancer
Takahashi, Tsuyoshi; Sonobe, Makoto; Menju, Toshi; Nakayama, 
Ei; Mino, Nobuya; Iwakiri, Shotaro; Sato, Kiyoshi; Miyahara, Ryo; 
Okubo, Kenichi; Date, Hiroshi
Kyoto University, Kyoto, Japan
Background: A fusion gene between the echinoderm microtubule 
associated protein like 4 (EML4) and anaplastic lymphoma kinase 
(ALK) has recently been identified in non-small cell lung cancer 
(NSCLC) tissues. In this study, we investigated the frequency, gen-
etic, and clinico-pathologic profiles of lung cancer harboring EML4-
ALK fusion gene. 
Methods: This study included clinical samples from 313 NSCLCs 
(211 lung adenocarcinomas, 75 squamous cell carcinomas and 27 
other NSCLCs). Under approval of local Ethics Committee regarding 
genetic analysis of lung cancer tissue and obtaining informed con-
sent from each patient, all specimens were collected from patients 
who underwent pulmonary resection at Kyoto University Hospital 
between May 2001 and July 2005. For detection of EML4-ALK fu-
sion cDNAs, RT-PCR assay was performed according to the method 
reported by Soda et al. We used the GAPDH as an internal control of 
gene expression. Detected fusion genes were confirmed with direct 
sequence. Polymerase chain reaction-single strand conformational 
polymorphism (PCR-SSCP) analysis was used to detect mutations in 
the EGFR gene within exons 18-21 using the GenePhor System. We 
used a modified mutagenic PCR-RFLP method for screening muta-
tions in codon 12 of the K-ras gene. 
Results: Out of 313 NSCLCs, 6 (1.9%) had EML4-ALK fusion 
genes. Two out of 202 male and four out of 107 female patients had 
fusion-positive tumors (p=0.232). Five of 211 adenocarcinomas 
(2.4%) and one (squamous cell carcinoma) out 103 other carcinomas 
(0.97%) featured EML4-ALK fusion gene (p=0.67). Other types of 
NSCLCs (17 large cell carcinomas, seven pleomorphic carcinomas 
and three adenosquamous cell carcinomas) were all negative for 
EML4-ALK fusion gene. Two fusion-positive adenocarcinomas 
carried variant 1, two variant 3 and one variant 2. A fusion-positive 
squamous cell carcinoma had variant 2. Two fusion-positive adeno-
carcinomas were detected from pathological stage 1A tumors and 
three from 3A tumors. A fusion-positive squamous cell carcinoma 
was found in p-stage 1B tumor. Four out of five patients with fusion-
positive adenocarcinoma were nonsmokers and one with only 0.25 
pack year smoking history. 
Out of 313 samples, mutations of the EGFR gene were detected in 
105 adenocarcinomas and one in squamous cell carcinoma. K-ras 
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mutations were detected in 29 adenocarcinomas, three large cell 
carcinomas, two squamous cell carcinomas and one pleomorphic 
carcinoma. All the six EML4-ALK fusion-positive NSCLCs had no 
mutations within the EGFR or K-ras genes. 
Conclusions: EML4-ALK fusion genes were observed mainly 
in adenocarcinomas, tumors of female population, and tumors of 
patients with relatively fewer smoking habits. EML4-ALK fusion- 
genes were mutually exclusive with the EGFR gene mutations and 
the K-ras gene mutations. 
PD6.1.2 Pathology, Sun, 14:30 - 16:00
Genetic and immunohistochemical profile of pulmonary 
neuroendocrine tumor
Motoi, Noriko; Hamanaka, Wakako; Nagano, Hiroko; Nomura, 
Kimie; Oba, Takehiko; Inamura, Kentaro; Ishikawa, Yuichi
Japanese Foundation for Cancer Research, Tokyo, Japan
Background: The underlying oncogenic molecular alterations can in-
fluence the clinical features and phenotypes of lung cancer. Pulmon-
ary neuroendocrine tumors include various histological categories; 
high grade neuroendocrine tumor (NET) (e.g. small cell carcinoma 
(SCLC) and large cell neuroendocrine carcinoma (LCNEC)), low 
grade NET (e.g. typical and atypical carcinoid (TC and AC)). It is 
still controversial whether non-small cell lung carcinoma (NSCLC) 
with neuroendocrine (NE) morphology or with NE phenotype should 
be included to NET or not. 
The goal of this study is to clarify the genetic and immunohistochem-
ical profiling of pulmonary neuroendocrine tumors and to evaluate 
the clinicopathologic relevance of each tumor category, including 
NSCLC with NE morphology and with NE phenotypes. 
Methods: Surgically resected lung cancers, including 27 SCLC 
(including 2 combined SCLC and NSCLC), 26 LCNEC, 2 TC, 5 
NSCLC with NE-morphology (NS-NEm), 13 NSCLC with NE-
phenotype (NS-NEp), and 16 NSCLC (11 adenocarcinoma (AD) and 
5 squamous cell carcinoma (SQ)) were examined. Out of significantly 
differentially expressed genes between AD and HGNET examined by 
Affymetrix HG-U133A, which have been previously reported, seven 
selected genes (ASCL1, CDH2, NeuroD1, DLL3, KI67, Survivin and 
MCM10) were examined by quantitative realtime-PCR (qRTPCR) 
and by QuantiGene Assay (QG) using fresh frozen tumor samples. 
Protein expressions of neuroendocrine-differentiation and cell-pro-
liferation markers were examined by immunohistochemistry (IHC) 
using tissue microarray (TMA) of formalin-fixed paraffin-embedded 
materials. 
Results: SCLC and LCNEC showed similar mRNA expression sig-
nature of examined neuronal differentiation (ASCL1, CDH2, DLL3 
and NeuroD1), cell proliferation (KI67) and apoptosis (Survivin) 
related genes. Compared to NSCLC (both AD and SQ), HGNET 
showed high level of ASCL1, DLL3, NeuroD1, Survivin and KI67, 
moderate level of CDH2 and MCM10 mRNA expressions. TC 
showed high level of CDH2, moderate level of ASCL1 and low level 
of other examined genes expressions. NS-NEm and NS-NEp showed 
very low level of ASCL1, CDH2, DLL3, NeuroD1 and MCM10, and 
high level of KI67 and Survivin expressions. A few NSCLC showed 
moderate level of CDH2 and DLL3 expressions. NSCLC also 
showed high level of KI67 and Survivin. 
IHC expression levels of ASCL1 and KI67 (MIB1) were correlated 
well with mRNA expression levels of each gene, respectively. 
Conclusions: SCLC and LCNEC showed similar gene expression 
signature. They might be categorized as a high grade neuroendocrine 
tumor (HGNET) from a molecular stand point. LGNET showed a dis-
tinct gene expression profile which could be distinguishable from that 
of HGNET and of NSCLC. The gene expression profiles of NS-NEm 
and NS-NEp seemed to be different from that of NET. 
This study suggested that gene expression and IHC profiles can pro-
vide useful information to evaluate biological characteristics of NET. 
Although further validation will be needed, ASCL1, CDH2, DLL3 
and NeuroD1 can be used as neuronal differentiation markers for dif-
ferential diagnosis of NET from NSCLC.
PD6.1.3 Pathology, Sun, 14:30 - 16:00
EGFR and K-ras mutation analysis in pulmonary 
carcinomas: a Dutch experience
Thunnissen, Erik1; de Jong, Daphne3; Heideman, Danielle1; Smit, 
Egbert4; Postmus, Piet4; Burgers, Sjaak5; Grunberg, Katrien 1; 
Snijders, Peter1; Berkhof, Hans6; Meijer, Chris1; Nederlof, Petra3
1 Department of Pathology, VUmc, Amsterdam, Netherlands; 2 
Aberdeen University School of Medicine, Aberdeen Royal Infirmary, 
Aberdeen, UK; 3 Dept. of Pathology, NKI, Amsterdam, Netherlands; 
4 Department of Pulmonology, VUmc, Amsterdam, Netherlands; 5 
Department of Thoracic Oncology, NKI, Amsterdam, Netherlands; 
6 Department Epidemiology and Biostatistics, VUMC, Amsterdam, 
Netherlands
Background: Recently, an empirical treatment approach with EGFR 
antagonists showed in a subset of patients with advanced lung cancer 
dramatic responses. Subsequently in these patients EGFR mutations 
and DNA amplifications were detected. Histopathological subtyping 
revealed initially an association with bronchioloalveolar carcinomas 
and later also with papillary carcinomas. The aim of this study was to 
determine the relation between histopathological subtypes and EGFR 
and K-ras. 
Materals and Methods: In 350 patients mutation analysis for K-ras / 
EGFR was performed. Inclusion criteria were request of pulmonolo-
gist, i.e. either due cancer in non-smoking patient or due recurrence 
after first line treatment. Paraffin embedded archive material was 
used for EGFR and K-ras mutation analysis. Amplification was per-
formed With chromogenic in situ hybridisation (CISH). Classification 
and subtyping was performed according to the WHO with an addi-
tional distinction between micropapillary and papillary carcinoma. 
Odds ratio [OR] and p-value of Chi2 test are provided.
Results: In 20 cases material was insufficient for mutational analysis, 
19 cases were cytology specimen. The remaining 311 cases consisted 
of 167 biopsies and 144 resections. Adenocarcinomas were the larged 
group (n=244). Mixed histological subtypes occurred frequently. The 
acinar, bronchioloaveolar and micropapillary pattern were correl-
ated (P<0.01). These patterns were inversely correlated with solid 
type adenocarcinoma and large cel carcinoma (p.<0.01). A dominant 
papillary pattern was present in 8 cases (2.6%). Any or a dominant 
micropapillary pattern was seen in 138 and 40 times, respectively.
EGFR and K-ras mutations were mutually exclusive and detected 
in 82 (26%) and 57 (18%) adenocarcinoma cases, respectively. The 
fraction of EGFR mutations is relatively high when compared to 
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other western countries, most likely due to the inclusion criteria. 
EGFR exon 18, 19, 20 and 21 mutations were found in 3%, 58%, 
12% and 25%, respectively.
The presence of acinar subtype (dominant pattern or occasionally 
present) was related to EGFR mutations (OR 2, p<0.01), whereas a 
solid pattern was inversely related (OR 0.35, p<0.05). Any micropap-
illary pattern was associated with K-ras mutations (OR 1.9, p =0.02). 
CISH amplification was present in 31/ 169 (18%). No associations 
were found between amplification was and histological subtypes of 
adenocarcinoma. 
Conclusion: The acinar, bronchioloaveolar and micropapillary occur 
frequently in a combined fashion. The distinct histological patterns 
can not be used as surrogate marker to predict the presence or ab-
sence of mutations in the individual patient. 
PD6.1.4 Pathology, Sun, 14:30 - 16:00
Diagnostic test based on hsa-miR-205 expression 
differentiates squamous from non-squamous non small cell 
lung carcinoma
Lebanony, Danit2; Benjamin, Hila2; Gilad, Shlomit 2; Ashkenazi, 
Karin2; Nonaka, Daisuke 3; Feinmesser, Meora 4; Rosenfeld, Nitzan1; 
Chajut, Ayelet2; Cohen, Dalia2; Aharonov, Ranit2
1 Bioinformatics, Rehovot, Israel; 2 Rosetta Genomics, Rehovot, 
Israel; 3 Department of Pathology, NYU School of Medicine, New 
York, NY, USA; 4 Rabin Medical Center, Beilinson Campus, Petah 
Tikva, Israel
Background: Recent advances in biologically directed therapies 
for non-small cell lung carcinoma (NSCLC) emphasize the need for 
more accurate sub-classification of NSCLC, as treatment may be 
dictated by histologic subtype. In particular, squamous histology can 
be a counter-indication for treatment by VEGF inhibitors. Micro-
RNAs are highly tissue-specific biomarkers with potential clinical 
applicability for defining cancer type and origin. MicroRNAs are well 
preserved in formalin fixed tissue, making them ideal candidates for 
molecular markers for use in routinely processed material. Here we 
report on the development and performance of a microRNA-based 
assay for the differential diagnosis of squamous from non-squamous 
NSCLC.
Methods: We developed protocols for extraction of high-quality 
RNA that retain the microRNA fraction from FFPE archival tissue 
samples. MicroRNA microarrays were used to profile more than a 
hundred NSCLC samples. Specific microRNA qRT-PCR was used to 
validate results, and to develop a diagnostic assay.
Results: We identified that microRNA hsa-miR-205 is strongly over-
expressed in squamous cell NSCLC. A diagnostic test was developed, 
that utilizes qRT-PCR measurement of this microRNA, normalized 
by an additional microRNA and a small nuclear RNA. This assay was 
validated on a blinded test set of 64 tumor samples, and had sensitiv-
ity of 97% and specificity of 91%. More than ¾ of the samples were 
classified with high confidence, and these classifications were accur-
ate in 96% of the cases. 
Conclusions: Hsa-miR-205 was found to be an excellent biomarker 
for the identification of squamous histology in NSCLC. A diagnostic 
assay based on the specificity of this single microRNA was de-
veloped which provides an important new tool for the classification 
of NSCLC
PD6.1.5 Pathology, Sun, 14:30 - 16:00
The combination of phospho-AKT, phospho-MTOR, 
phospho-MAPK and EGFR predicts survival in non-small 
cell lung cancer
Kitano, Haruhisa1; Chung, Joon-Yong2; Ylaya, Kris2; Takikita, 
Mikiko2; Fukuoka, Junya3; Tezuka, Noriaki1; Hewitt, Stephen M.4
1 Department of Thoracic Surgery, Shiga University of Medical 
Science, Otsu, Shiga, Japan; 2 Tissue Array Research Program, 
Laboratory of Pathology, Center for Cancer Research, National 
Cancer Institute, NIH, Bethesda, MD, USA; 3 Laboratory of 
Pathology, Toyama University Hospital, Toyama, Japan; 4 Tissue 
Array Research Program, Laboratory of Pathology, Center for 
Cancer Research, National Cancer Institute, NIH, Bethesda, MD, 
USA
Activation of numerous pathways has been documented in non-small 
cell lung cancer (NSCLC). Significant cross-talk between these 
pathways has been observed, however these pathways may have 
prognostic significance as well as function as targets of therapeutic 
intervention. Epidermal growth factor receptor (EGFR) pathway has 
been identified as active in NSCLC. Two downstream elements of the 
EGFR pathway are mitogen-activated protein kinase (MAPK) and 
AKT signaling pathways. These pathways are deregulated via genetic 
and epigenetic mechanisms in many human cancers including lung. 
We investigated relation between the upstream and downstream of 
the MAPK and AKT/mTOR pathways in non-small-cell lung cancer. 
Two hundred thirty-one cases of non-small cell lung cancer patients 
were arrayed into tissue microarray. Phosphorylated AKT (p-AKT), 
phosphorylated MAPK (p-MAPK) and phosphorylated mTOR 
(p-mTOR), and EGFR were detected by immunohistochemistry 
and quantified by image analysis. Survival analysis by individual 
markers was not signifiant, but correlations were found for the ratio 
of p-mTOR to p-AKT (p-mTOR/p-AKT, p=0.043) and the ratio of 
p-MAPK to EGFR (p-MAPK/EGFR, p=0.031). The sum of these 
two ratios demonstrates a more significant correlation with survival 
(p=0.007). In multivariate analysis, this algebraic combination of four 
individual biomarkers remained statistically significant after adjust-
ment with gender, age, cancer type and stage (p=0.038). In conclu-
sion, the sum of p-mTOR/p-AKT and p-MAPK/EGFR is a predictive 
marker of survival in patients with NSCLC. Quantitative image an-
alysis of immunohistochemistry with algebraic-like equations offers 
novel biomarkers of survival and may provides clues in identification 
of patients for targeted therapy.
PD6.1.7 Pathology, Sun, 14:30 - 16:00
Cytokeratin expression profiling is useful for the 
distinction between squamous cell carcinoma of lung 
primary and lung metastasis from tongue
Ohba, Takehiko1; Kimura, Yukinori 2; Nakamura, Yu1; Hamanaka, 
Wakako1; Inamura, Kentaro 1; Motoi, Noriko1; Mun, Ming-yon 3; 
Sakao, Yukinori 3; Okumura, Sakae 3; Nakagawa, Ken 3; Kawabata, 
Kazuyoshi 2; Ishikawa, Yuichi 1
1 Division of Pathology, The Cancer Institute of Japanese Foundation 
for Cancer Research, Tokyo, Japan; 2 Department of Head and Neck 
Oncology, The Cancer Institute Hospital of Japanese Foundation for 
Cancer Research, Tokyo, Japan; 3 Department of Thoracic Surgical 
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Cancer Research, Tokyo, Japan
Background: When squamous cell carcinoma (SCC) occurred in the 
lung of a patient with history of tongue SCC, it is sometimes difficult 
to make distinction between primary and metastasis. Cytokeratin 
(CK) expression profile is different between proper squamous epi-
thelium and columnar epithelium. Tongue SCC arises from proper 
squamous epithelium, while primary lung SCC arises from colum-
nar epithelium in relation to squamous metaplasia. We elucidated 
whether CK expression profile was useful for the distinction between 
primary lung SCC and metastatic lung SCC from tongue.
Materials and Methods: Three groups constituted tumor materials: 
primary tongue SCC (Group A, n=25), lung SCC arising in Group 
A after surgery for tongue SCC (Group B, n=17), primary lung SCC 
without history of any other cancer (Group C, n=15). According 
to our clinicopathological criteria, shown below, diagnosis for the 
Group B was determined to be metastasis or primary. Then all the 
tumors were immunostained with CAM5.2, CK19, CK7, CK5/6 and 
p63.
Results: Based on the clinicopathological criteria, 11 and 4 lung 
tumors of Group B were determined as metastasis and primary, 
respectively. Two were undetermined. Expression ratio of CAM5.2 
in primary lung SCC (12/15=80%) was significantly higher than 
primary tongue SCC (5/25=20%, p<0.001), and metastatic lung SCC 
from tongue (1/11=9%, p<0.001). Also, expression of CK19 in the 
primary lung SCC (9/15=60%) was significantly higher than primary 
tongue SCC (3/25=12%, p=0.001) and metastatic lung SCC from 
tongue (2/11=18%, p=0.033). Expression ratios of CK7, CK5/6 and 
p63 were not significantly different among Groups A, B and C. In 
terms of differential diagnosis of lung tumors after tongue surgery, 
metastatic lung SCC (n=11) had characteristic features as compared 
with Group C (primary lung SCC), i.e. younger onset, lower cumula-
tive smoking and higher proportion of well-differentiated SCC.
Conclusion: CAM5.2 and CK19 were expressed more frequently 
in primary lung SCC than in primary tongue SCC and metastatic 
lung SCC from tongue. They were useful for the distinction be-
tween primary lung SCC and metastatic lung SCC from tongue. 
Criteria pro Metastasis: 1) Multiple lung lesions of similar size 
were present. 2) Survival time after removal of a lung tumor was 
less than 6 months. 3) Histological findings favored a metastasis (i.e. 
similar cellular appearance in both lung and tongue SCC or exceed-
ing central necrosis in the lung tumor). 
Criteria pro Primary: 4) Pathological N0 of tongue SCC was 
proved. 5) Carcinoma in situ was seen in a lung tumor. 6) Tongue 
SCC had been controlled for more than 2 years before emergence of 
lung tumor. 7) Survival time after removal of a lung tumor was more 
than 3 years. 8) The site of lung lesion was central (i.e. in the main, 
lobular or segmental bronchus).
PD6.1.8 Pathology, Sun, 14:30 - 16:00
Multiple EGFR family members, EGFR ligands expression 
and EGFR family gene status study
Sun, Menghong; Li, Xiaoling; Liu, Diane D.; Behren, Carmen; Tang, 
Ximing; Corvalan, Alejandro; Wistuba, Ignacio I.
MD Anderson Cancer Center, Houston, TX, USA
Background: It is well known that EGFR family members includ-
ing EGFR, Her2/Neu are involved in non-small cell lung cancer 
(NSCLC) tumorogenesis and tumor progression. A network might 
exist in clinical parameters and underlying protein and gene level 
alteration of these key. A comprehensive understanding about tumor 
behavior linked EGFR family member and their ligands, EGFR 
family gene status in same lung cancer patient group is needed to 
learn more about this network.
Methods: We designed this study to explore the expression of 
EGFR family members including EGFR, Her2/Neu, Her3 and their 
phosphorelated forms; all known EGFR ligands binding to above re-
ceptors including amphiregulin, EGF, TGF-α, NRG1, BTC, HB-EGF, 
NRG2 and epiregulin in a TMA set with 275 patient samples using 
immunohistochemical staining. Gene copy number analysis of EGFR 
and Her2 were also performed in the study using FISH analysis. K-
ras and EGFR gene mutation using DNA sequencing were accom-
plished in same patient group as well.
Results: A comprehensive connection was found in patients of non-
small cell lung cancer comparing these biological parameters. Cyto-
plasmic expression of amphiregulin correlated with nuclear pEGFR 
(P= 0.0039). EGF cytoplasmic expression was correlated to nuclear 
pEGFR expression (P=0.0313) and EGFR gene copy number increas-
ing (P=0.0026), whereas pEGFR and EGFR copy number increasing 
was connected each other (P=0.0024), too. Her2/Neu membrane 
expression correlated to pEGFR nuclear expression (P=0.0002) and 
Her2/Neu gene amplification. Her3 expression in cytoplasm showed 
a close correlation to pHer2 membrane expression (P <0.0001) 
and Her2 gene amplification (P=0.0160). Both Her2 and pHer2 
membrane expression were related to pEGFR nuclear expression 
(P=0.0002 and P=0.0005). Interestingly, we found correlation of Her2 
gene/Chromosome 17 centromere ratio was related to pEGFR nuclear 
expression (P=0.0315) and EGFR gene copy number increasing. 
Table 1. Significance of markers.
Marker pEGFR p_HER2 HER2 EGFR Her2 Her2 Her2 
  _Nuclear _mem _mem _FISH -AMP -AmpHP -AMP-HP
 Amphiregulin_Cyto  0.0105 ns ns ns ns ns ns
 TGFalpha_Cyto ns ns ns ns ns ns ns
 EGF_Cyto 0.0313 ns ns 0.0026 ns ns ns
 EGFR_Mem ns 0.0384 ns ns 0.0456 ns ns
 pEGFR_Mem <0.0001 ns ns 0.0424 ns ns ns
 pEGFR_Cyto ns <0.0001 ns ns ns ns ns
 pEGFR_Nuclear NA 0.006 0.035 ns ns ns ns
 HER2_mem 0.022 <0.001 NA 0.007 0.0008 0.0017 0.0127
 HER2_cyto ns <0.001 ns ns ns ns 0.0305
 p_HER2_mem 0.0012 NA ns ns ns ns ns
 pHER2_cyto 0.0225 <0.0001 ns ns ns ns ns
 pHER3_Cyto ns <0.0001 ns ns 0.016 ns 0.0307
 EGFR_FISH ns ns ns NA ns 0.0021 0.0055
 EGFR_AMP ns ns ns ns ns 0.0387 NA
 Her2-AMP ns ns ns ns NA NA NA
 RG 0.0315 ns ns 0.034 <0.0001 <0.0001 <0.0001
ns:not significant; NA: not applied.
Conclussion: a complex interation of EGFR family members under-
goes in NSCLC. Adenocarcinoma appeared related significantly to 
higher expression of EGFR receptors and EGFR ligands . Adjusted 
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for pathological stage, pHer3 nuclear expression was found to be 
a significant predictor in worse recurrence-free survival in adeno-
carcinoma, while adjusted for age and pathological stage, Her2 gene/
chromosome ratio was found to be a significant predictor in worse 
overall survival in squamous cell carcinoma. EGFR family and their 
ligands are involved in non small cell lung cancer. Targeted therapy 
could be set to individual with different combination of high expres-
sion.
PD6.2.1 Pathology, Sun, 14:30 - 16:00
A technique to improve diagnostic information from fine 
needle aspirations
Guldhammer Skov, Birgit; Kiss, Katalin; Ramstedt, Julie; 
Linnemann, Dorte
KAS Herlev, Dept. of Pathology, Division Gentofte, Copenhagen 
(Hellerup), Denmark
Background: Cytologic examination of fine needle aspirations 
(FNA) is being increasingly used for the diagnosis of pulmonary 
lesions. Accurate distinction between non small cell lung cancer 
(NSCLC), including subgroups, and small cell lung cancer (SCLC) 
and between primary lung cancer and metastases has therapeutic 
impact. New treatment modalities for subgroups of NSCLC have 
increased the demand for adequate separation of adenocarcinomas of 
the lung (ACL) from squamous cell carcinoma (SQC). For example 
bevazizumab should not be given to patients with SQC, and pe-
metrexed has better efficacy in patients with ACL than SQC. Further-
more the increasing frequency of potential metastatic lesions to the 
lung poses challenges with regard to differential diagnosis. However, 
the distinction between these groups may be difficult on smears. We 
describe a simple method, called cytoscrape (CS), to produce material 
useful for ancillary methods, including immunohistochemistry. 
Methods: Aspirations from 47 patients with a possibly malignant 
infiltrate on CT scan of the chest were included. Smears were stained 
by May-Grunwald- Giemsa (MGG) and Diff Quick (DQ) for diag-
nostic purposes. CS were made by gently scraping cells off the slides. 
Clots were made and sections stained for TTF1 and mucin. The 
utility of the CS technique was evaluated by assessing the sensitivity 
and specificity of the method and by quantifying the extra diagnostic 
information obtained by the method relative to smear alone. 
Results: Malignant tumor cells in the CS were found in 43 aspir-
ates (91%). The sensitivity and specificity for TTF1 was 100%. The 
sensitivity for mucin was 60% and the specificity was 100%. The 
diagnoses made on smears were improved by CS in 31 cases (72%) 
in that more precise separation of subgroups of NSCLC was possible 
or information on primary tumors was obtained. 
Conclusion: The CS technique improved the diagnostic information 
from FNA in a clinically relevant way. The method is simple, quick 
and inexpensive. 
PD6.2.2 Pathology, Sun, 14:30 - 16:00
Cytology-based treatment decision in primary lung cancer: 
is it accurate enough? A study of 467 cases
Sakr, Lama; Robaglia-Schlupp, Andrée; Payan, Marie-José; Liprandi, 
Agnès; Dutau, Hervé; Astoul, Philippe; Barlési, Fabrice
Université de la Méditerrannée - APHM, Marseilles, France
Background: Accurate distinction of lung cancer types has become 
increasingly important since recent trials have shown differential 
response to chemotherapy among NSCLC subtypes. Cytological 
procedures are frequently used but their diagnostic accuracy has been 
questioned in the past. However, new endoscopic and cytological 
techniques might have improved cytological accuracy in comparison 
to previous findings. 
Objectives: Reassess cytological accuracy with regard to histological 
analysis. 
Methods: We conducted a retrospective chart review of subjects 
who underwent flexible bronchoscopy for suspicion of primary lung 
cancer during 2007-2008. Cytology results were compared to those 
of bronchoscopic biopsies, while taking into account endoscopic find-
ings and type of investigational procedures.
Results: 467 flexible bronchoscopic procedures with their corres-
ponding cytological and histological results were reviewed. Patients 
consisted of 362 men and 105 women (median age, 65 yrs). Two 
hundred and fourty nine patients had positive histology, consisting of 
suspicious or clearly malignant cells. Among those 249 subjects, cy-
tology specimens did not show suspicious or cancer cells in 56 (22%) 
of them. Malignancy was diagnosed at cytology in 147 out of these 
249 cases. Malignant diagnosis on cytological specimens included 
squamous cell cancer (SCC) in 42, adenocarcinoma (ADK) in 6, 
undifferentiated large cell carcinoma (ULGC) in 56, small cell lung 
carcinoma (SCLC) in 10, poorly differentiated carcinoma in 14, and a 
highly suspicious profile in 19. Cytology material was of poor quality 
and therefore non interpretable in 46 specimens. Globally, a statis-
tically significant correlation between cytological and histological 
results was found (p<.0001). Interestingly, 59% of ULGC cases 
diagnosed on cytology were later classified as ADK by histology. 
SCC and non squamous (NSQ) carcinoma were correctly diagnosed 
in 56 and 62% of cases, respectively, while SCLC was accurately 
identified in 80% of cases. Accurate SCC diagnosis improved in case 
of an endobronchial lesion (59 vs 25%), while no such association 
was found for NSQ carcinoma. More details will be presented at the 
meeting, including cytological findings in specimens with negative 
histology.
Conclusion: In the era of histology-guided chemotherapy, cytologic-
al accuracy remains fair with regard to diagnosis of SQ and NSQ 
lung cancer subtypes. Improvement of cytological yield and accuracy 
is expected with novel diagnostic techniques, such as endobronchial 
ultrasound-guided needle aspiration, which would highly contribute 
to the current multimodality diagnostic strategy.
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PD6.2.3 Pathology, Sun, 14:30 - 16:00
Routine acquisition of histology material for predictive 
& prognostic biomarkers from 22 ga cytology sampling 
during trans-bronchial needle aspiration (TBNA)
Yung, Rex C.; Illei, Peter; Li, Kay Q.; Otell, Susan; Kirby, John; 
Adams, Christina; Clark, Douglas
Johns Hopkins University, Baltimore, MD, USA
Introduction: With advent of targeted therapies (EGFR-TKI, anti-
VEGF, etc.) and need to distinguish squamous from non-squamous 
NSCLC in choosing cytotoxic therapy (premetrexed), there is need 
for sufficient material to measure prognostic and predictive mark-
ers for Lung Cancer (LC) management. The majority of LC patients 
present with stages III/ IV diseases, usually diagnosed by minimally 
invasive cytologic and not surgical biopsies. We present methodolgy 
for obtaining histology material from a Transbronchial needle-aspira-
tion (TBNA) 22 gauge “cytology” needle that’s suitable for immuno-
staining and PCR studies of EGFR and KRAS.
Method: 21 patients (11M, 9F, ages 48-93) with suspected locally 
advanced or metastatic LCs undergo bronchoscopies using Endobron-
chial-Ultrasound (EBUS fig 1a) with real-time image-guided TBNA. 
Initial sample is evaluated by Rapid-On-Site Evaluation (ROSE) 
provided by pathology staff. With cytology confirmation of cancer 
or lymphocytes, additional passes collect specimen that is pooled 
and built into a “cone” of blood-clot/tissue coagulum on filter paper 
(figure 1b-d) that is then prepared for histology exam and ancillary 
studies. 
Results: The patients include 10 patients with prior other cancers (4 
H&N, 2 Renal cell, 2 colorectal, 1 each breast/pancreas). 33 lymph 
nodes targeted for sampling, 4R/precarina:12, 4L/left-paratrachea:2, 
station 7/subcarina:5, 11R/right-hilar:10, 11L/left-hilar:2, 12R/lower 
right-bronchial:1, 12L/lower left-bronchial:1.
Final Diagnosis: 13 LC (9 NSCLC including two poorly differenti-
ated;3 squamous;1adeno) Metastatic carcinoma: 1 each pancreas/
breast/RCC/H&N and a neuroendocrine tumor lung Vs pancreas. 6 
patients with benign lymphocytes, 1 awaiting confirmatory surgery. 2 
patients non-diagnostic EBUS with insufficient lymphocytes.
Immunostains applied to cell block include pancytokeratin AE1/3, 
CAM5.2, CK5/6, CK7; TTF1, CK20, p63, Synaptophysin, chromo-
granin, S100, PSA, mucicarmine, ER, PR, GCDFP, and DPC4 (loss 
shown in pancreatic met).
6 of the LC patients had EGFR/KRAS studies after review of H&E 
slides for sections with concentrated tumor cells, unstained slides sent 
for PCR analysis. 2 positive KRAS mutations in codon12/13; 1 posi-
tive EGFR exon 21 in an Asian non-smoking female.
Discussion & Conclusion: In era of expanding targeted therapies, 
to realize “individualized therapies” for LC, diagnostic procedures 
need to answer more than the question of SCLC Vs NSCLC. Current 
modalities of Image-guided minimally-invasive “cytologic” bron-
choscopic procedures (EBUS-TBNA) can provide sufficient material 
for immunostaining to distinguish between primary and metastatic 
cancers to chest, types of NSCLC cancer, and application of genetic 
studies such as EGFR/KRAS. This approach is potentially also useful 
for translational research in that it can provide material from non-
surgical patients for biomarker discovery and validation, and repeated 
samplings to determine response to novel therapies.
PD6.2.4 Pathology, Sun, 14:30 - 16:00
CT-guided fine needle aspiration cytology of lung lesions: a 
retrospective study of 1166 cases
Almeida, Margarida M.; Campos, Paula; Teixeira, Encarnação;  
Sotto-mayor, Renato
Hospital Santa Maria, Lisboa, Portugal
Background: CT- guided Fine Needle Aspiration Cytology (FNAC) 
of lung is routinelly used in our hospital. The aim of this study was 
to evaluate the accuracy of image-guided FNAC in the diagnosis of 
pulmonary lesions.
Materials and Methods: A total of 1166 FNAC were carried out 
and diagnosed in our departments between 1990 and 2006. All FNA 
were done by a radiologist under CT-guiding, using 22-25 G needles. 
There were 820 males and 346 females ranging in age from 21 to 90 
years. Cytological diagnosis were correlated with either the histo-
logical (26%) or clinical follow-up(74%).
Results: Diagnosis was possible in 1103 cases (94.6%). In 63 cases 
(5.4%) the material was insufficient for diagnosis. FNAC diagnosis 
were reported as: primary lung neoplasms ( n= 633, 58 %), metastatic 
tumors ( n= 52, 4.6%), suspicious for malignancy ( n=42, 3.6%), 
inflammatory processes (n=112, 10.1%), necrosis (n=35, 3.1%) 
and negative for malignancy ( n=223, 20.2%). All but one of 685 
malignant diagnosis were confirmed malignant either clinically or 
on subsequent histology. Forty of the 42 suspicious diagnosis had a 
malignant outcome, one patient had tuberculosis on excision biopsy 
and one was lost for follow-up. Three hundred thirty six out of 341 
benign diagnosis were confirmed benign. The remaining 5 cases 
were proven to be malignant. Four of the 35 necrosis diagnosis were 
confirmed on histology as malignant. Four of the 63 insufficient 
for diagnosis group, were later on, shown to be malignant, and six 
cases had a subsequent FNAC that were diagnosed as malignant. 
There were complications in 40 patients (3.1%) (36 pneumothorax, 3 
hemophtysis and one hemothorax). 
Conclusion: This study shows: 1- One false positive and 13 false 
negative cases, with a sensitivity of 98% and a specificity of 99,7%. 
2- False negative cases were due to sampling and necrosis. 3- Very 
low complications (3.1%). 4- Most suspicious lesions were malignant 
(40/42). In summary, FNAC is an accurate technique for the diagnosis 
of lung masses and can, therefore, be used with confidence for selec-
tion of various treatment modalities, avoiding unnecessary surgery. 
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PD6.2.5 Pathology, Sun, 14:30 - 16:00
Correlation between high-resolution CT findings of 
mixed ground-glass opacity (part-solid GGO) and 
histopathological invasive areas of small pulmonary 
adenocarcinomas
Saito, Haruhiro; Murakami, Shuji; Kondo, Testuro; Oshita, Fumihiro; 
Ito, Hiroyuki; Tsuboi, Masahiro; Nakayama, Haruhiko; Yokose, 
Tomoyuki; Kameda, Youichi; Noda, Kazumasa; Yamada, Kouzo
Department of Thoracic Oncology Kanagawa Cancer Center, 
Yokohama, Japan
Background: High-resolution CT (HR-CT) provides us with a more 
precise image of small pulmonary carcinomas. Thin-slice sections 
with thicknesses of 0.5 mm-1mm reflect with some accuracy, the 
histopathological findings. Mixed Ground-glass Opacity (part-solid 
GGO) is one characteristic finding of pulmonary adenocarciomas. 
These findings are various in appearence, for example; some contain 
mainly GGO components, and some contain mainly solid portions. 
CT findings of mixed GGO, pathological findings and prognoses 
have been reported. Presently, we do not fully understand the correla-
tion between HR-CT findings of mixed GGO and histopathological 
invasive areas.
Method: We retrospectively reviewed records and HR-CT scans 
of 24 patients with mixed GGO tumors. All patients had undergone 
surgical resection in 2003. Tumor diameters measured 20mm or less 
in size. All HR-CT images were acquired by Aquillion CT scanner 
(Toshiba Medical System). HR-CT images of tumors were obtained 
at 135kVp at 250mAs with 0.5-1mm section thickness. All images 
were photographed using mediastinal (level, 40HU; width, 400HU) 
and lung (level, -600HU); width, 1600HU) window settings. All 
HR-CT images on lung window setting were classified as: (1) GGO 
with solid type (GwS; solid portion areas less than 50% of tumor), 
(2) Heterogeneous type (heterogenous increased density), (3) Solid 
with GGO type (SwG; Solid portion areas more than 50% of tumor). 
HR-CT images were classified by evaluating lung and mediastinal 
window settings; (A) air-containing type (maximum diameter of 
tumor opacity on mediastinal window images was less than or equal 
to half of that seen on lung window images), (B) Solid-density type 
(maximum diameter of tumor opacity on mediastinal window images 
was more than half of that seen on lung window images) (Chest 
133; 441, 2008). Histopathological findings (HE and EVG stained) 
were evaluated by measuring percentages of pathological component 
areas using NIH image software. Component areas consisted of (1) 
Bronchioalveolarcell carcinomas (BAC), (2) Collapse and/or Col-
lapse with BAC (CwB), (3) Invasive area. We analyzed correlations 
between HR-CT findings and histopathological components.
Result: All 24 tumors were well-differentiated adenocarcinomas. 
GwS type; 4 cases (Air-type; 2 cases, Solid-type; 2 cases), Heteogen-
ous type; 6 cases (Air-type; 1 case, Solid-type; 5 cases) and SwG type 
14 cases (Air-type; 3 cases, Solid-type; 11 cases). Average percent-
ages of pathological component areas were GwS type; BAC; 86%, C/
CwB; 14%, invasive area; 0.4% (0~1.6%) and Heterogeneous type; 
BAC; 52%, CwB;46%, invasive 0.6% (0~3.3%) and SwG type; BAC 
39%, CwB; 41%, invasive area 7.8% (0~25.6). The average percent-
age of invasive areas of SwG/Solid type was larger than the SwG/Air 
type (7.8%(0~25.6) vs 2.5%(0~7.6)). Invasive areas were recognized 
in every type of mixed GGO tumor. Invasive areas of more than 5mm 
or percentages greater than 10%, were recognized in overlapping type 
tumors of SwG and Solid types.
Conclusion: Our results indicate that evaluating HR-CT findings of 
mixed GGO by way of lung and mediastinal window setting images 
may be helpful in speculating on the size of histopathological inva-
sive areas. 
PD6.2.6 Pathology, Sun, 14:30 - 16:00
A proposal of the diagnosis of high grade non-small cell 
neuroendocrine lung carcinoma by biopsy specimens
Watanabe, Reiko; Ito, Ichiro; Nakajima, Takashi; Endo, Masahiro; 
Kondo, Haruhiko; Yamamoto, Nobuyuki; Kameya, Toru
Shizuoka Cancer Center, Shizuoka, Japan
Background: We often see lung carcinomas with undifferntiated 
phenotype in biopsy specimens and diagnose as non-small cell 
carcinoma, undifferentiated large cell carcinoma or poorly differenti-
ated carcinoma. In advanced inoperable cases, we rarely have chance 
to get final diagnosis due to the lack of operated surgical specimens. 
On the other hand, it is an urgent task to know accurate diagnosis 
of surgically unresectable cases by biopsy specimens, because it is 
increasingly recognized that chemotherapeutic responses are signifi-
cantly different between neuroendocrine and non-neuroendocrine 
carcinomas, and that the response to the former carcinoma is similar 
to that of small cell carcinoma. We aimed to pick up high grade non-
small cell neuroendocrine carcinomas from lung biopsy specimens 
using histological and immunohistochemical analysis. 
Methods: During 5 years we diagnosed 788 lung biopsies. We tenta-
tively selected 30 cases of non-small cell carcinoma with neuroendo-
crine phenotype (positive immunostains for one or more antibodies 
against chromogranin A, synaptophysin and neural cell adhesion 
molecule) without any squamous cell carcinoma or adenocarcinoma. 
In these cases we analyzed their morphology and proliferation activ-
ity using MIB-1/Ki-67 immunostain. Their clinical aspects have also 
been reviewed. 
Results: Morphologically there were some similarities among 30 
cases described below; 1. solid tumor nesting without either acinar 
or squamous differentiation (29/30); 2. moderate or marked cellular 
atypia (29/30); 3. large nuclear size larger than 3 times the diameter 
of a small resting lymphocyte (30/30); 4. large cell size with low 
nuclear to cytoplasmic ratio or abundant cytoplasm (28/30); 5. ves-
icular or fine nuclear chromatin (29/30); 6. frequent mitoses (17/30); 
7. frequent massive necrosis (18/30); 8. intercellular space or cleft 
with loose intercellular adhesion (16/30) and 9. more than 40% of 
MIB-1/Ki-67 labeling index (26/30). The age of these patients ranged 
from 53 to 89 (mean 70.3). Male to female ratio was 26:4. Twenty-
eight out of 30 were smokers. The tumor diameter in computerized 
tomogram (CT) ranged from 1.5 cm to 8.0 cm (mean 4.4 cm). The 
tumors showed well defined lobulated contoured nodules and periph-
erally located in 26 cases. Eighty-three percent of our cases were at 
TNM stage III (3 cases) or IV (22 cases) because of their lymph node 
and/or distant metastases. Five cases were at stage I. Among the 30 
cases, 5 tumors were surgically resected and diagnosed as large cell 
neuroendocrine carcinoma (LCNEC). 
Conclusions: By using neuroendocrine immunostain it was possible 
to pick up high grade non-small cell neuroendocrine carcinomas in 
biopsy specimens which had been diagnosed as histologically non-
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
Copyright © 2009 by the International Association for the Study of Lung CancerS490
small cell carcinoma, undifferentiated large cell carcinoma or poorly 
differentiated carcinoma. The results of histological phenotypes eluci-
dated in this study imply that our selected cases are most likely to be 
LCNECs including their combined subtypes. Clinical characteristics 
of our 30 patients with old age, high smoking rate, male preponder-
ance, CT findings and those of all may belong to the characteristics of 
LCNEC.
PD6.3.1 Pathology, Sun, 14:30 - 16:00
Characteristics affecting inter-observer reproducibility 
in morphologic diagnoses of non-small cell lung cancer 
(NSCLC) subtypes
Grilley-Olson, Juneko E.1; Hayes, D. Neil1; Socinski, Mark A.1; 
Moore, Dominic T.1; Qaqish, Bahjat F.1; Leslie, Kevin O.2; Travis, 
William D.3; Funkhouser, William K.1; VOILA Group, 4
1 University of North Carolina, Chapel Hill, NC, USA; 2 Mayo Clinic, 
Scottsdale, AZ, USA; 3 Memorial Sloan Kettering Cancer Center, 
New York, NY, USA; 4 USA
Background: Histology remains the best biomarker for NSCLC 
chemotherapy selection. Both bevacizumab and pemetrexed (in 1st 
line) are FDA approved for non-squamous NSCLC only, demanding 
precise classification of morphologic subtypes. With no gold standard 
for histology “truth,” consensus by qualified pathologists based on 
the WHO diagnostic classification system (WHOC), Ed. 4 impacts 
both clinical trials and patient care. Recently, we have shown the IOR 
of squamous cell (SC) versus non-SC to be only moderately precise 
by H&E stains alone. Here, we describe characteristics affecting IOR 
of NSCLC specimens. 
Methods: Pathologists assigned WHOC diagnoses to virtual H&E 
slides from an incident surgical cohort of 96 primary lung tumors. 
At a power of 80% we estimated 24 pathologists reviewing 48 slides 
each would allow for an overall IOR measure in the clinically useful 
range kappa (K)=0.7, standard error=0.09. We considered the full 
44 diagnostic classification system (DC), a simplified 10 DC and a 
chemotherapy-directed 2 class system. Characteristics of pathologists 
include self-identification as “lung expert” or “community,” experi-
ence and confidence in a given slide diagnosis. Characteristics of 
the slide include technical quality, individual requests for additional 
stains and grade (based on the original clinical diagnosis).
Results: Twelve expert and 12 community pathologists scored slides 
based on the 44 possible WHOC DC totaling 222 pathologist-pairs 
and 7130 slides-pairs. Pathologists had a median 17 years experience 
(range 1-36). Distribution of DC included SC 31%, AD 36% and 
large cell (LC) 17%. Overall, pathologists rated confidence as: high 
53%, moderate 38% and not confident 8% (the latter was not further 
analyzed due to small sample size.) Virtual slides were scored as 
technically adequate 91% and inadequate 9%. Pathologists requested 
confirmatory stains in 10%. 
Conclusion: Overall confidence is higher for the simplified 10 DC 
than the full 44 DC system, reflecting the complexity of the WHOC. 
SQ and AD demonstrate good IOR when pathologists express high 
confidence in the assigned classification, although LC remained poor. 
IOR is highest with experts expressing high confidence and trends 
with, but surpasses grade as an indication of IOR. However, moder-
ate confidence results in a sharp decline in K. Although this model 
does not reflect the clinical diagnosis of lung cancer, in an era where 
“NSCLC not otherwise specified” is no longer adequate, this suggests 
the need for further studies assessing standardized stains as well as 
good pathologist-medical oncologist communication.
 Diagnostic Reviewing Overall High Moderate  Not Poorly Poorly 
 Categories (DC) Pathologists Confidence Confidence Confidence Differentiated Differentiated 
   (kappa) (kappa) (kappa) (kappa) (kappa)
 44 DC All 0.25 0.38 0.15 0.27 0.22
 44 DC Expert (E) 0.30 0.41 0.15 0.31 0.28
 44 DC Community (C) 0.19 0.37 0.19 0.24 0.13
 10 DC All 0.48 0.69 0.31 0.52 0.41
 10 DC E 0.55 0.77 0.32 0.59 0.48
 10 DC C 0.36 0.51 0.28 0.41 0.28
 SC / Non-SC All 0.55 0.78 0.28 0.60 0.46
 SC / Non-SC E 0.64 0.84 0.25 0.68 0.53
 SC / Non-SC C 0.41 0.63 0.37 0.46 0.32
 AD/Non-AD All 0.59 0.74 0.40 0.64 0.48
 AD/Non-AD E 0.69 0.83 0.45 0.70 0.60
 AD/Non-AD C 0.46 0.49 0.22 0.55 0.30
 LC/Non-LC All 0.27 0.23 0.24 0.20 0.25
 LC/Non-LC E 0.32 0.24 0.27 0.20 0.31
 LC/Non-LC C 0.15 0.10 0.12 0.14 0.12
PD6.3.2 Pathology, Sun, 14:30 - 16:00
Analysis of bronchial histology and incident lung cancer - 
a prospective approach
Feser, William J.2; Baron, Anna E.2; Wolf, Holly J.2; Jayaprakash, 
Vijay3; Reid, Mary3; Keith, Robert L.4, 5; Kennedy, Timothy C.5; 
Hirsch, Fred R.5, 6; Franklin, Wilbur A.6; Miller, York E.4, 5; Byers, 
Tim2
1 University of Colorado Cancer Center, Aurora, CO, USA; 2 School 
of Public Health, University of Colorado Denver, Anschutz Medical 
Campus, Aurora, CO, USA; 3 Division of Cancer Prevention and 
Population Sciences, Roswell Park Cancer Institute, Buffalo, NY, 
USA; 4 Denver Veterans Affairs Medical Center, Denver, CO, USA; 
5 School of Medicine, University of Colorado Denver, Anschutz 
Medical Campus, Aurora, CO, USA; 6 Department of Pathology, 
University of Colorado Denver, Anschutz Medical Campus, Aurora, 
CO, USA
Background: Bronchial histology is often used as an intermedi-
ate endpoint in chemoprevention trials with the assumption that 
bronchial histology is associated with lung cancer. There have been 
no previous analyses of the strength of the relationship between bron-
chial histology and incident lung cancer risk.
Methods: 748 subjects were enrolled in one or more of 22 Colorado 
SPORE in Lung Cancer studies involving a bronchoscopy between 
1993 and 2008. Histology readings were scored on a scale of 1-8 ac-
cording to the World Health Organization scale (1 being normal and 8 
being invasive cancer). Follow-up was done annually on all patients 
to determine cancer and vital status using data matches with Colorado 
state registries. The patient population studied included those who 
had a readable bronchial histology at the initial bronchoscopy, did 
not develop cancer over the course of follow-up or developed cancer 
1 year or more after the initial bronchoscopy, and were current or 
former smokers. A Cox Proportional Hazard time-to-event model was 
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employed to analyze the relationship between bronchial histology and 
the outcome of incident lung cancer risk, adjusting for age, gender, 
race, and year of first bronchoscopy. For purposes of the Cox model, 
time began at the age of initial bronchoscopy and ended at the age 
of diagnosis of lung cancer, the age the patient died or the age of last 
follow-up. 
Results: Among the 748 subjects, a total of 23 incident lung cancers 
were observed between 1993 and 2008. These included 8 squamous 
cell, 4 adenocarcinoma, 5 other types and 6 undetermined. Three 
groups of histologic risk were defined: normal to mild dysplasia, 
moderate dysplasia and severe dysplasia. Results presented use all 
available subject bronchoscopies. These results are slightly stronger 
than using baseline bronchoscopy results. Using the histologic three 
group predictor linearly yielded an adjusted hazard ratio of 1.36 
(0.76, 2.44). Using the histologic three group predictor categorically 
(with normal to mild dysplasia as a reference group) yielded adjusted 
hazard ratios of: moderate dysplasia, 1.18 (0.43, 3.20) and severe 
dysplasia, 1.99 (0.59, 6.67). As mentioned, 8 of the 23 incident lung 
cancers were squamous cell carcinoma. A histologic subtype analysis 
showed that the adjusted hazard ratio for the 8 squamous cell carcin-
oma incident cases was 2.62 (1.06, 6.45).
Conclusions: We did not observe an association between bronchial 
histology and the overall incidence of lung cancer, although an as-
sociation with squamous cell histology is suggested. However, this 
analysis was low in power with only 23 incident cases available so 
far. Additional cases from other institutions should provide increased 
power to determine any relationship between endobronchial histology 
and incident lung cancer risk. 
PD6.3.3 Pathology, Sun, 14:30 - 16:00
“Micro-invasive” peripheral lung squamous cell carcinoma 
based on alveolar space filling predominancy
Watanabe, Yukihiro1; Yokose, Tomoyuki 1; Sakuma, Yuuji2; 
Hasegawa, Chikako1; Saito, Haruhiro1; Yamada, Kouzou1; Ito, 
Hiroyuki1; Tsuboi, Masahiro1; Nakayama, Haruhiko1; Kameda, 
Youichi1
1 Kanagawa Cancer Center, Yokohama, Japan; 2 Kanagawa Cancer 
Center Research institute, Yokohama, Japan
Background: Squamous cell carcinomas(SqCCs) of the lung can 
be divided into two types: in central or peripheral type. Although 
many morphological finding on the dysplasia-carcinoma sequence 
in the central type have been reported, the carcinogenic pathway and 
prognostic factors have not been fully established in the peripheral 
SqCCs of the lung. Funai et al. indicated that peripheral SqCCs can 
be divided into distinctive structural patterns, based on the tumor 
growth pattern and the condition of the elastic framework: the 
alveolar space filling (ASF) type, the expanding type and the mixed 
type. Pure ASF type tumors which showed no destruction of elastic 
fiber framework thought to be classfied as incipent peripheral SqCCs 
and have a favorable prognosis. On the other part, Maeshima et al. 
proposed the division of peripheral SqCCs into three types, based on 
the minimal tumor nest pattern(TNP): large nest consisting of more 
than 6 tumor cells, small nest consisting of 2-5 tumor cells, or single 
cell. They considered large or small nest component appear to have 
a low potential for malignancy and reccurence. The aim of this study 
was to identify favorable and unfavorable clinicopathological factors 
for small peripheral SqCCs of the lung measuring 30mm or less in 
diameter.
Materials and Methods: The subjects of the study were cosecutive 
81 patients with small peripheral SqCC of the lung(defined as tumors 
located in or more peripheral from the third branching bronchus), 
who underwent surgical resection between January1993 and Septem-
ber 2008.We reviewed the clinical parameters; age, gender, smok-
ing habit, exposure to asbestos, limited or standard resection, and 
pathological parameters; histological differentiation, stage, vessel and 
lymphatic invasion, pleural involvement, presence of usual interstitial 
pneumonia, inflammatory cell infiltration, percentage of necrosis, 
maximum dimeter of invasion area, percentage of alveolar space 
filling(ASF) by tumor cells, tumor nest pattern(TNP). 
Result: Univariate analysis showed that disease free suvival(DFS) 
rate was better in patients with ASF area of 70% or more, and/or 
maximum diameter of invasion area of 10mm or less. Multivariate 
analysis showed that propotion of ASF area was a only significant 
prognostic factor, in fact patients with ASF area of 70% or more had 
no reccurence. Other parameters including TNP, maximum diameter 
of invasion area, and vessel and lymphatic invasion did not affected 
the outcome of the patients.
Conclusion: The propotion of ASF area is a useful prognostic factor 
for small peripheral SqCCs. Although a previous report indicated 
pure alveolar space-filling tumors which propotion of ASF was 100% 
had a good prognosis, we showed mixed alveolar space-filling tumors 
which propotion of ASF was 70% or more had a favorable progno-
sis as well as pure. Therefore the result of this study indicated that 
this type of small invasive peripheral SqCCs could be classified as 
“micro-invasive” cancers,and that they may be curable by partial lung 
resection and without adjuvant chemotherapies.
PD6.3.4 Pathology, Sun, 14:30 - 16:00
Carcinoma NOS (not otherwise specified) is a common 
histologic diagnosis and is increasing in proportion among 
non-small-cell lung cancer (NSCLC) histologies
Ou, Sai-Hong I.; Zell, Jason A.
Chao Family Compehensive Cancer Center, University of Irvine 
Medical Center, Orange, CA, USA
Background: Recent clinical trials have demonstrated differential 
survival benefits from chemotherapy regimens according to NSCLC 
histology. We investigated whether the proportion of carcinoma NOS 
(not otherwise specified) among NSCLC cases has been increasing or 
decreasing.
Methods: Retrospective population-based study of 175,298 NSCLC 
patients diagnosed histologically or cytologically from the statewide 
California Cancer Registry from 1989 to 2006. The study period 
was evenly divided into 3 periods of diagnosis (period 1:1989-1994; 
period 2: 1995-2000; period 3: 2001-2006).
Results: The number of NSCLC patients diagnosed was evenly 
distributed among the 3 calendar periods of diagnosis. The propor-
tion of NSCLC patients diagnosed histologically as compared to the 
proportion of NSCLC patients diagnosed cytologically was also rela-
tively constant among the 3 periods. Carcinoma NOS accounted for 
22.1% of all NSCLC patients. Carcinoma NOS was most commonly 
diagnosed cytologically (37.0%) and had the highest proportion of 
unknown tumor differentiation (59.2%) among the six histologies 
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studied. Patients with carcinoma NOS presented with highest propor-
tion of stage 4 disease (44.7%) and had the poorest 5-year survival 
estimates (5.8%) and median overall survival (OS) (5 months). 
The proportion of carcinoma NOS among all NSCLC increased 
significantly from 15.8% (period 1) to 22.0% (period 2) to 29.0% 
(period 3) while conversely squamous cell carcinoma and large cell 
carcinoma decreased significantly. Specifically, the proportion of 
carcinoma NOS has increased significantly from 1989 to 2006 among 
both males and females, among both histologically and cytologic-
ally diagnosed NSCLC, among all 4 major ethnicities (Caucasian, 
African-American, Hispanic, and Asian), among all age-categories, 
and among all AJCC stages. The percentage of the very elderly (80+) 
increased from 10.8% to 17.1% among all NSCLC patients, and 
this age group of patients had the highest proportion of carcinoma 
NOS and cytologically diagnosed NSCLC among all age categories. 
Stage 4 carcinoma NOS patients derived less survival benefit from 
chemotherapy than adenocarcinoma patients during the most recent 
period of diagnosis. Cox proportional hazards regression analysis 
applied to stage 4 NSCLC patients indicated that carcinoma NOS 
(vs. adenocarcinoma; HR = 1.061, 95% CI: 1.039-1.083; P < 0.0001) 
was an independent unfavorable prognostic factor. Tumors with other 
than well-differentiated histology, cytologically-diagnosed NSCLC 
(vs. histologically-diagnosed NSCLC, HR = 1.043, 95% CI: 1.024-
1.062; P < 0.0001) and large cell carcinoma (vs. adenocarcinoma; 
HR = 1.085, 95%CI: 1.048-1.123; P < 0.0001) were also independent 
unfavorable prognostic factors for OS. 
Conclusions: Carcinoma NOS is a common histologic diagnosis and 
the proportion of carcinoma NOS among NSCLC has been increasing 
with time. Among the six NSCLC histologies in this study, carcin-
oma NOS is most likely to be diagnosed cytologically. Patients with 
carcinoma NOS has the poorest survival outcome. Carcinoma NOS 
and cytologically-diagnosed NSCLC are independent unfavorable 
prognostic factors for OS among stage 4 patients. 
PD6.3.5 Pathology, Sun, 14:30 - 16:00
EU-USA pathology panel for uniform diagnosis in 
randomised controlled trials for HRCT screening in 
lung cancer: Dutch-Belgium lung cancer screening trial 
(NELSON study) 
Thunnissen, Erik1; Kerr, Keith2; Brambilla, Elisabeth3; Comin, 
Camilla 4; Guldhammer Skov, Birgit5; Franklin, Wilbur6; Westra, 
Bill7; Verbeken, Erik8; Timens, Wim9; Vink, Aryan10; van Klaveren, 
Rob11; Flieder, Douglas12
1 Pathology, VUmc, Amsterdam, Netherlands; 2 Aberdeen University 
School of Medicine, Aberdeen Royal Infirmary, Aberdeen, UK; 
3 INSERM U823, Grenoble, France; 4 University of Florence, 
Florence, Italy; 5 Dept of Pathology, KAS Herlev, div. Gentofte, 
Hellerup, Denmark; 6 Dept of Pathology, University of Colorado, 
Denver, USA; 7 The Johns Hopkins Medical Institutions, Baltimore, 
USA; 8 Dept. Pathology KU Leuven, Leuven, Belgium; 9 Dept. 
Pathology, UMCG, Groningen, Netherlands; 10 Dept. Pathology, 
UMCU, Utrecht, Netherlands; 11 Dept. Pulmonology, Erasmus MC, 
Rotterdam, Netherlands; 12 Dept. Pathology, Fox Chase Cancer 
Centre, Philadelphia, USA
Introduction: The assumption behind computed tomography lung 
cancer screening is that diagnosing carcinomas earlier will lead to 
improved disease-specific survival. While this assumption has yet 
to be proven or refuted, resection specimens may be challenging for 
surgical pathologists. Recent lung cancer screening studies have high-
lighted differences in pathology diagnoses. The optimal diagnosis 
of these lesions requires additional pathologic training (Am J Surg 
Pathol 2006;30:606-13; Eur Respir J 2006;28:1186-9; Lung Cancer. 
2007;56:193-9). The aim of this study is to report the pathology diag-
nosis of panel and local diagnosis in the NELSON study. 
Materials and Methods: Cases were retrieved from four centers 
(Haarlem, Groningen, Leuven and Utrecht). For panel reading cases 
were scanned and digital images made available on the web. After 
web reading, panel members also reviewed the cases by microscopy 
during a central meeting in Amsterdam.
Results: A total of 130 cases were reviewed of which 33 were be-
nign. The distribution of the 96 malignant tumours (panel diagnosis) 
was: adenocarcinomas n=57 (59%), bronchioloalveolar carcinoma 
(BAC =in situ) n=1, 1 doubt between atypical adenomatous hyper-
plasia (AAH) and BAC, squamous cell carcinoma n=15, large cell 
carcinoma n=14, adenosquamous carcinoma n=1, small cell carcin-
oma n=3, typical carcinoid n=3, mucoepidermoid carcinoma n=1, 
thymoma n=1. Regarding the discrepant case, four panel members 
showed preference for AAH and four for BAC. 
The 33 benign lesions were intrapulmonary lymph nodes n=8, 
granulomatous inflammation with (n=8) and without necrosis (n=1), 
hamartoma (n=5), infarct (n=2), organising pneumonia (n=2), abscess 
(n=1), anthracosilicotic nodule (n=1), reactive not otherwise specified 
(n=4).
Most local and panel diagnoses were concordant. In the adeno-
carcinomas a local diagnosis was BAC, and another reactive (false 
negative). Other discordant cases were: a low grade mucoepidermoid 
carcinoma was called: papillary adenosquamous carcinoma; in the 
poorly differentiated carcinomas more variation between panel and 
local diagnosis was present.
The panel diagnoses in the NELSON study shows less variation with 
the local diagnosis than reported for the ELCAP study. This is ex-
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plained to some extend by the training which was performed for the 
Dutch pathologists before the start of the NELSON study (Eur Respir 
J. 2006 Dec;28(6):1186-9).
The web-based reading led to concordant diagnosis in >80% of the 
cases. For the remaining 20% discussion on the microscope was felt 
necessary to reach consensus diagnosis.
Conclusion: Quality control for pathology diagnosis in screening 
studies is useful. For comparison of international studies and for 
combining randomized control study data, pathology panel diagno-
sis is obligatory. A Web based approach facilitates histopathologic 
diagnosis.
PD6.3.6 Pathology, Sun, 14:30 - 16:00
Pulmonary adenocarcinomas: a single-centre validation 
study of the clinical and prognostic utility of the WHO/
IASLC subtype classification
Ruffini, Enrico1; Asioli, Sofia2; Macrì, Luigia2; Filosso, Pier Luigi1; 
Buffoni, Lucio3; Schena, Marina3; Novello, Silvia4; Bruna, Maria 
Cristina1; Solidoro, Paolo5; Mossetti, Claudio1; Oliaro, Alberto1
1 Thoracic Surgery, University of Torino, Torino, Italy; 2 Pathology, 
University of Torino, Torino, Italy; 3 Medical Oncology, AOU S. 
Giovanni Battista, Torino, Italy; 4 Medical Oncology, AOU S. Luigi, 
Orbassano, Orbassano, Italy; 5 Pneumology, AOU S. Giovanni 
Battista, Torino, Italy
Objective: Adenocarcinoma is the most frequently reported histo-
logical subtype of lung carcinoma in many series as well as the most 
histologically variable and heterogeneous form. A WHO/IASLC clas-
sification of pulmonary adenocarcinomas was proposed in 2004 sug-
gesting clinical and prognostic implications for the different subtypes. 
The aim of the present study was to analyze our patient population of 
resected patients with adenocarcinoma according to the WHO/IASLC 
classification to evaluate its clinical and prognostic utility 
Methods: From January 2004 to October 2008 a total of 277 patients 
received curative resection of primary lung adenocarcinoma at our 
Institution. There were 191 men (69%) and 86 women (31%) with 
a mean age of 65 years (range 42-82 years). The tumours were clas-
sified according to the 2004 WHO/IASLC classification into: acinar 
adenocarcinomas (AC), papillary/micropapillary adenocarcinomas 
(PAP), bronchiolo-alveolar carcinomas (BAC), and solid adeno-
carcinomas with mucin production (SOL). Adenocarcinomas with 
mixed subtypes were reclassified according to the most prevalent 
histotype. Prevalence, correlations and survival analysis both univari-
ate and multivariate using some clinico-pathological variables (age, 
microscopic vascular invasion, grading, perineural invasion, tumour-
infiltrating lymphocytes, T, N status and pathologic Stage) were 
performed among the different subgroups. 
Results: There were 41 AC, 82 PAP ( 45 pure papillary and 37 mixed 
papillary/micropapillary when a >5% micropapillary component was 
present), 30 BAC, 15 SOL. 10 adenocarcinomas were variant sub-
types, including clear cell (4), signet ring (4) and pseudosarcomatous 
(2) adenocarcinomas. In 99 patients the histological subtype could 
not be defined. BAC were significantly associated with a less micro-
scopic vascular invasion (p=0.01), a lower grading (G1) (p=0.0001) 
and a lower N status (p=0.02). Acinar and solid adenocarcinomas 
showed no significant correlation with any clinico-pathological vari-
able. Papillary/micropapillary adenocarcinomas were associated with 
a higher grading (G3) (p=0.05). 3-year survival rates for the differ-
ent subtypes were: BAC, 78%; AC, 75%; SOL, 67% and PAP 62% 
(pure papillary 68%, mixed papillary/micropapillary 53%). The 99 
undefined adenocarcinomas had a 3 year survival rate of 75%. The 
differences among the groups were not significant (p=0.6). In multi-
variate analysis, the subgroup classification was not an independent 
prognostic indicator (HR 1.02, 95%CI 0.84-1.23). 
Conclusions: In our experience, about one-third of resected pulmon-
ary adenocarcinomas cannot be classified into subtypes using stan-
dard histopathologic techniques. The papillary/micropapillary pattern 
is associated with a higher dedifferentiation, and the micropapillary 
component confers a survival disadvantage which however was not 
significant in the present series. Classification of pulmonary adeno-
carcinomas into subtypes was not an independent prognostic factor 
in multivariate survival analysis. Although promising, the prognostic 
utility of the WHO/IASLC adenocarcinoma classification needs to be 
verified on a larger number of patients.
PD6.4.1 Pathology, Sun, 14:30 - 16:00
Does histology predict survival of advanced non-small cell 
lung cancer (NSCLC) treated with standard platin-based 
chemotherapy? Retrospective analysis of E1594
Hoang, Tien1; Dahlberg, Suzanne2; Schiller, Joan H.3; Johnson, David 
H.4
1 University of Wisconsin, Madison, WI, USA; 2 Dana Farber Cancer 
Institute, Boston, USA; 3 University of Texas Southwestern Medical 
Center, Dallas, USA; 4 Vanderbilt University, Nashville, USA
Background: We conducted this analysis to determine whether there 
was a difference in survival of advanced NSCLC patients treated with 
standard platin-based doublets based upon histology.
Methods: We analyzed data of the randomized phase III study 
E1594 in which advanced NSCLC patients were randomized into 4 
chemotherapy arms: cisplatin/paclitaxel (CP), cisplatin/gemcitabine 
(CG), cisplatin/docetaxel (CD) and carboplatin/paclitaxel (CbP). The 
logrank test was performed to compare the overall survival (OS) and 
progression free survival (PFS) distributions among the 4 histology 
groups: squamous cell (SCC), adeno- (AC), large cell (LCC) and 
other (including not otherwise specified NSCLC). In each histology 
group, we also analyzed survival among chemotherapy regimens.
Results: Of 1139 eligible patients, AC was the most common 
histologic type (n=647; 56.8%), followed by SCC (n=224; 19.7%), 
other (n=194; 17%) and LCC (n=74; 6.5%). Compared to men, 
women more likely had AC (62.6% vs. 53.4%) and less likely had 
SCC (14.4% vs. 22.8%). Compared to those with stage IV or recur-
rent disease, stage IIIB (wet) patients were more likely to have AC 
(66.9% vs. 55.3%). There were no imbalances between histology 
and other baseline variables. No differences in OS and PFS were 
observed between the 4 histology groups, regardless of treatment 
arm (Table). There were also no survival differences between the 
4 chemotherapy regimens in each histology group. For example, 
although patients with AC in the CP arm appeared to have a longer 
median OS compared to other histologies, the difference was not 
statistically significant (p=0.09). Similarly, although median PFS was 
slightly better with CG in the SCC and AC groups, the difference was 
also non-significant (p=0.20 and 0.19, respectively).
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
Copyright © 2009 by the International Association for the Study of Lung CancerS494
Conclusions: Regardless of histology types, OS and PFS were 
similar in chemo-naive NSCLC patients treated with standard platin-
based doublets involving paclitaxel, docetaxel or gemcitabine. 
PD6.4.2 Pathology, Sun, 14:30 - 16:00
Postoperative recurrence and the prognosis in patients 
with pulmonary large cell neuroendocrine carcinoma
Iyoda, Akira1; Jiang, Shi-Xu2; Ijima, Daisuke1; Nezu, Kenji1; Ogawa, 
Fumihiro1; Matsui, Yoshio1; Amano, Hideki1; Hara, Hidenori1; 
Okayasu, Isao2; Masuda, Noriyuki 3; Hayakawa, Kazushige4; 
Yoshimura, Hirokuni1; Satoh, Yukitoshi1
1 Department of Thoracic Surgery, Kitasato University, School 
of Medicine, Sagamihara, Japan; 2 Department of Pathology, 
Kitasato University,School of Medicine, Sagamihara, Japan; 3 
Department of Respiratory Medicine, Kitasato University,School of 
Medicine, Sagamihara, Japan; 4 Department of Radiology, Kitasato 
University,School of Medicine, Sagamihara, Japan
Objective: The prognosis for patients with large cell neuroendocrine 
carcinoma (LCNEC) of the lung is very poor. Some reports referred 
that the biological behavior of LCNEC resembles that of small cell 
lung carcinomas, those show features of high-grade neuroendocrine 
tumors, and those are aggressive tumors. However, the optimal treat-
ment for patients with LCNEC is not decided. In order to improve 
the prognosis of patients with LCNEC, it is important for us to 
understand the prognosis and recurrent tumors of LCNEC tumors. 
In this study, we describe the clinical features of recurrent tumors of 
LCNEC, and the prognosis in patients with LCNEC.
Patients and Methods: We retrospectively analyzed clinical data 
from 39 patients with primary lung carcinoma diagnosed as LCNEC 
according to the classification of World Health Organization in 1999, 
which underwent treatment at Kitasato University Hospital. We 
evaluated recurrence patterns in patients who experienced relapse and 
the prognosis in patients with LCNEC.
Results: Of 39 patients with LCNEC, there are 35 male and 4 female 
with a mean age of 64 years old (range 50 to 85). Thirty-five patients 
had complete resection, and 4 did incomplete resection. There are 
five patients in stage IA, 11 in stage IB, 2 in stage IIA, 5 in stage IIB, 
9 in stage IIIA, 6 in stage IIIB, and 1 in stage Ⅳ. Eighteen patients 
did not have detectable recurrent tumors following surgical resec-
tion, and the other 21 had confirmed recurrent tumors upon follow-up 
examinations including 9 with local recurrences and 18 with distant 
metastases. Sites of distant metastases included the bone in 8 cases, 
the liver in 7 cases, the brain in 7 cases, and the lungs in 4 cases. Of 
16 patients with stage I, 6 patients had distant metastases without 
local recurrences. Of those with recurrent tumors, 20 cases (95.2%) 
had their first recurrent tumors within 3 years. The 5-year overall 
survival rate of all cases was 31.5%, and that of patients with stage 
I was 54.5%. Especially, the 5-year overall survival rate of patients 
with stage IA was 33.3%.
Conclusions: Patients with LCNEC had frequent recurrence follow-
ing resection of the primary tumor. Because patients with LCNEC 
have poor prognosis, surgery alone may be not enough to cure tumors 
of LCNEC even if pathological stage is ⅠA. 
PD6.4.3 Pathology, Sun, 14:30 - 16:00
Prognostic impact of visceral pleural involvement in 
patients with lung cancer
Sakurada, Akira
Tohoku University Hospital, Sendai City, Japan
Background: Proposals for the revision were published on Journal 
of Thoracic Oncology (JTO) as a series of papers. In the current 
revision, major change is going to be made on T descriptor and M 
descriptor intending to predict accurate prognosis. Visceral pleural 
involvement has been reported to be a prognostic factor, however, the 
latest proposal for revision published on JTO pointed that the impact 
of visceral pleural involvement is still not conclusive. Therefore, 
confirmation of the significance of pleural involvement on prognosis 
is an important issue.
Patients and Methods: Medical records of lung cancer patients 
underwent pulmonary resection from 1990 to 2002 in our hospital 
were reviewed. A total of 1308 patients who have pathological T1 
or T2 disease were retrospectively analyzed. Pleural invasion was 
screened by elastic stain in addition to usual hematoxylin and eosin 
staining. Pleural invasion was evaluated as positive when tumor 
cells invaded beyond elastic layer but remain within pleural surface 
(p1) or when beyond the pleural surface (p2) according to the rule of 
Japanese Lung Cancer Society. Overall survival was calculated ac-
cording to Kaplan-Meier method and statistical difference was tested 
by log-rank test. Statistical result was regarded as significant when p 
value was less than 0.05.
Results: By including all T1 and T2 cases in this study, 5-year 
survival (5ys) in patients with p0, p1, and p2 was 70.2%, 56.6% 
and 44.4%, respectively. There were statistical significance between 
p0 and p1 (p=0.0001), p1 and p2 (p=0.034). In the patients with n0 
disease, 5ys in patients with p0, p1 or p2 was 77.9 % and 70.9%, 
respectively. By dividing patients with n0 disease in T1a to T2b 
subgroups, there was no significant difference in 5ys regardless the 
status of pleural involvement, probably due to insufficient number of 
cases. By multivariate analysis by Cox regression proportional hazard 
model, pleural involvement (p1 or p2) was independent prognostic 
factor with significance (hazard ratio, 1.38; 95 percent confidence 
interval, 1.16-1.64; p<0.001).
Conclusion: Visceral pleural involvement is a prognostic factor 
for poor prognosis. To conclude the impact in each subgroup of T 
descriptors, larger number of cases is required.
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Nuclear grading of primary pulmonary adenocarcinomas - 
correlation between nuclear size and prognosis
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Satomi, Kaishi2; Anami, Youichi2; Tsuta, Kouji4; Goya, Tomoyuki3; 
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Medical Sciences, Kyorin University, Tokyo, Japan; 4 Pathology 
Division, National Cancer Center Hospital, Tokyo, Japan
Background: According to the World Health Organization Clas-
sification of Tumors, morphometric cytologic atypia is not assessed 
in pulmonary adenocarcinoma diagnosis. Nuclear morphometry is a 
method for quantitative measurement of histopathologic changes in 
the appearance of stained cell nuclei. It is used to estimate the malig-
nancy of lung adenocarcinoma. 
Methods: . Primary tumors of 133 pulmonary adenocarcinomas that 
were 2 cm or less in diameter were analyzed using image processing 
to quantify the following nuclear size features: area, major axis diam-
eter and form features. The results were evaluated by receiver operat-
ing characteristic (ROC) analysis, and survival curves were drawn by 
the Kaplan-Meier method. In addition, we compared our results to 
lymphocyte data and evaluated precision (interobserver variability) 
and accuracy with kappa statistics to try to determine whether the 
technique could be applied to clinical practice.
Results: Using the nuclear area (NA) and nuclear major axis diam-
eter (ND), lung adenocarcinomas were divided into two groups: 
extremely favorable prognosis and fairly favorable prognosis. The 
ROC curve analysis showed that a cut-off NA level of 67 μm2 could 
separate the two groups with a sensitivity of 75% and a specificity 
of 70%. An ND level of 10.7 μm could separate the groups with a 
sensitivity of 75% and a specificity of 65%. An NA level of less than 
67 μm2 correlated with longer survival (p<0.0001), and the five-year 
survival rate was 90.4%. Similarly, an ND level of less than 10.7 μm 
correlated with longer survival (p=0.0002), and the five-year survival 
rate was 88.6%. The critical NA level of 67 μm2 was about seven 
times larger than that of lymphocytes. The critical ND level of 10.7 
μm was about four times larger than that of lymphocytes. The mean 
kappa statistic of four pathologists was 0.58±0.10 (0.47-0.76), and 
the mean of the accuracy metric was 0.66±0.10 (0.56-0.080).
Conclusions: Nuclear area and nuclear major diameter are two useful 
markers to evaluate the prognosis of lung adenocarcinomas. Since the 
two markers can be applied similarly to all histologic subtypes, they 
may be good metrics for defining minimally invasive adenocarcinoma.
PD6.4.5 Pathology, Sun, 14:30 - 16:00
Survival in bronchioloalveolar carcinoma: the role of 
inflammation
Roseman, Michelle; Witkowski, Leora; Kasymjanova, Goulnar; 
Gagnon, Bruno; MacDonald, Neil; Agulnik, Jason; Cohen, Victor; 
Pepe, Carmela; Kreisman, Harvey; Small, David
Sir Mortimer B. Davis Jewish General Hospital, Division of 
Pulmonary Diseases of Department of Medicine, Montreal, QC, 
Canada
Background: Of patients with non-small cell lung cancer (NSCLC), 
those with bronchioalveolar carcinoma (BAC) tend to have a better 
prognosis than those with adenocarcinoma, even after adjusting 
for stage. Past studies have focused on the clinical profile of BAC 
patients, who are more likely to be female, non-smokers, and earlier 
stage. However, the possible role of markers of inflammation in this 
population has not been investigated. We have previously shown that 
baseline CRP and WBC, combined into a prognostic index (PI), pre-
dict survival in advanced NSCLC (N. MacDonald, ASCO 2006). The 
aim of this study is to explore the possible role of PI in explaining the 
improved survival in BAC, compared with adenocarcinoma. 
Methods: This is a population-based cohort study using the database 
of the pulmonary oncology clinic of the Jewish General Hospital 
in Montreal. Patients were considered to have BAC if the tumor 
contained any BAC patterns. Survival analysis was performed using 
a Kaplan Meier analysis and Cox regression. Patients were assigned 
a PI score of 0 if CRP ≤10mg/L and WBC ≤ 11x109/L, 1 if one of the 
markers was elevated, or 2 if both were elevated. We investigated the 
association between PI and survival in patients with BAC and adeno-
carcinoma. The factors included in the model were age, gender, stage, 
performance status (PS) histology, CRP, PI and smoking status. 
Results: 215 patients with either adenocarcinoma or BAC subtype 
(M: F=100:115) having a mean age of 64 (39-87) were included. 38 
(18%) were stage IA-IIB, 48 (22%) were stage IIIA-IIIB, and 128 
(60%) were stage IIIB pleural effusion-IV. 184 (86%) had a PS of 
0-1, and 170 (79%) were smokers or ex-smokers. 178 (83%) of those 
were diagnosed with adenocarcinoma, and 37 (17%) were diagnosed 
with BAC. Patients with BAC were more likely to be never-smokers 
(p=0.06), stage IA-IIB (p<0.005), and to have lower CRP (<0.001) 
and WBC (p=0.003). There was significantly higher prevalence of PI 
0 – 1 among pts with BAC (p<0.001). Overall median survival was 
significantly higher in BAC (p<0.001) and remained significant even 
in the subset of 19 BAC pts with stages IIIA-IV (see table). None of 
the 19 pts with BAC had PI 2 whereas 82/158 (52%) of adenocarcin-
oma were PI 2. 
PI BAC Stages 
IIIB-IV (N)
BAC Stages 
IIIB-IV (Median 
survival in 
months (CI 
95%))
Adeno 
Stages IIIB-
IV (N)
Adeno 
Stages IIIB-IV 
(Median 
survival in 
months (CI 
95%))
P Value
0  
(n = 64)
16 (84%) 25.5 (14.5-36.4) 48 (30%) 19.6  
(13.8-25.9)
0.29
1  
(n= 85)
3 (16%) 13.6 (8.6-18.5) 28 (18%) 9.8 (7.8-11.8) 0.66
2  
(n= 28)
0 (0%) 82 (52%) 6.6 (2.5-10.7)
Total 
(n=177)
19 (100%) 20.6 (14.0-27.2) 158 (100%) 10.8 (8.9-12.7) <0.012
The Cox regression analysis demonstrated that stage, PI, BAC histol-
ogy and ECOG PS were independent significant prognostic factors 
for survival. 
Conclusions: Patients with BAC have lower inflammatory response 
when compared to adenocarcinoma, as evidenced by significantly 
lower PI. This may provide an additional explanation for the survival 
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advantage in this population, in addition to well known factors, such 
as stage, PS and smoking status. 
PD6.4.6 Pathology, Sun, 14:30 - 16:00
The impact of tumor infiltrating lymphocytes on the 
survival of patients with primary lung cancer
Matsumoto, Isao1; Oda, Makoto1; Tamura, Masaya1; Fujimori, 
Hideki1; Shimizu, Yosuke1; Zen, Yoh2; Watanabe, Go1
1 Department of General and Cardiothoracic Surgery, Kanazawa 
University, Kanazawa, Japan; 2 Department of Pathology, Kanazawa 
University, Kanazawa, Japan
Background: Tumor infiltrating lymphocytes (TIL) are sometimes 
identified in malignant tumors of several organs. Although the mech-
anism of TIL has not been elucidated it is reported that TIL has an 
impact on the survival of the patients with malignant tumor. There are 
few reports concerning TIL in lung tumors. We examined the impact 
of TIL in patients with primary lung cancer and atypical adenomatous 
hyperplasia (AAH). 
Patients and Methods: This retrospective study included 440 
patients with primary lung cancer and AAH treated between Janu-
ary 1998 and March 2003. More than 5 years have passed since the 
pulmonary surgery of all patients. The degree of TIL was evaluated 
as follows in the lung tumors by H.E. stain; grade 1: less than 25% 
of the tumor area, grade 2: 25-50%, grade 3:51-75%, grade 4: >75%. 
None of the patients were infected with EB virus, thus pulmonary 
lymphoepithelioma-like carcinoma was ruled out. Lymphocytes were 
also evaluated by immunostaining.
Results: The patients comprised of 294 males and 146 females with 
an average age of 66 (25-86) years. Pathology was as follows: AAH 
8, adeno Ca (AC) 283 (Noguchi classification; A24, B18, C72, D17, 
E3, F14), squamous Ca (SqC) 98, adenosquamous Ca (ASC) 16, 
small cell Ca (SCC) 13, large cell Ca (LCC) 13 including 4 large cell 
neuroendocrine Ca, carcinoid 5, others 9. Number of patients with 
Grade 1/2/3/4 of TIL was 354/68/0/18. There was no patient with 
grade 3. Grade 4 TIL was seen only in AC 11 and SqC 7. Almost all 
patients with AAH, non-invasive AC and neuroendocrine tumors 
revealed grade 1 TIL, thus they were excluded. Clinicopathological 
data and survival was compared between Grade 1+2 group (350 
pts) and Grade 4 group (18 pts). There were no significant differ-
ences concerning gender, age, maximum tumor diameter, lymphatic 
invasion, venous invasion, and pathological stage between the two 
groups. Regarding the degree of tumor differentiation, Poorly/Mod-
erately/Well were 69/128/153 in Grade 1+2 and 7/9/2 in Grade 4. 
Degree of tumor differentiation was significantly poorer in Grade 
4 group (p=.017). Three and 5 -year survival rate of Grade 1+2 and 
Grade 4 groups were 74.4/66.7% and 86.7/86.7% respectively. There 
was a trend towards a better survival in the presence of high grade 
TIL though there was no significant difference (p=.08). This result 
was noted in ACs and SqCs and all patients with Grade 4 have sur-
vived. Infiltrating lymphocytes were T cell lymphocytes by immunos-
taining.
Conclusion: Concerning primary lung cancer, TIL is a specific 
biological reaction to invasive non small cell carcinoma without 
neuroendocrine tumors. High grade TIL may have a major impact on 
the good survival for the patients with primary lung cancer. Eluci-
dation of the mechanism of TIL could lead to the development of 
immunotherapy for primary lung cancer. 
PD6.5.1 Pathology, Sun, 14:30 - 16:00
Histologic assessment of residual carcinoma after 
neoadjuvant chemotherapy for resectable NSCLC predicts 
survival 
Gounant, Valérie1, 3, 2; Colombat, Magali4, 2; Baudrin, Laurence5; 
Lavole, Armelle1, 2; Herman, Dominique6; Bazelly, Bernard3, 2; 
Milleron, Bernard1, 2
1 Service de Pneumologie, Hôpital Tenon, AP-HP, Paris, France; 
2 Université Pierre et Marie Curie, Paris, France; 3 Service de 
Chirurgie Thoracique, Hôpital Tenon, AP-HP, Paris, France; 4 
Service d’Anatomie Pathologique, Hôpital Tenon, AP-HP, Paris, 
France; 5 Intergroupe Francophone Cancérologie Thoracique 
(IFCT), Paris, France; 6 Service de Pneumologie, Hôpital de Nevers, 
Nevers, France
Background: Tumor response is considered a surrogate marker of 
survival. We investigated whether the pathologic residual carcinoma 
after neoadjuvant chemotherapy for resectable non-small-cell lung 
cancer (NSCLC) is independently prognostic of survival.
Methods: Between 1999 and 2005, 109 consecutive patients received 
neoadjuvant chemotherapy followed by surgical resection to treat 
a resectable NSCLC stage IA to IIIB (T4 with two lesions in one 
lobe). Patients underwent CT scan before and after completion of 
neoadjuvant chemotherapy. CT-scan response was based on OMS 
criteria. All pathological samples were retrospectively analyzed on 
H&E sections to evaluate histological type, pTNM, mitotic index 
and to quantify the percentage of residual carcinoma. First, a logistic 
regression was performed to identify factors associated with residual 
carcinoma ≤ 30%. Cancer-specific survival was estimated using the 
Kaplan-Meier method, measured from the date of surgery to the date 
of death, whose cause was cancer. To further examine association 
between survival and pathologic residual carcinoma, a Cox model 
was performed. 
Results: Patients’ characteristics and results are presented in the table 
below.
No. of 
patients
Residual 
carcin-
oma ≤ 
30% (%)
p Cox 
univariate 
analysis 
HR, 95%CI
p Cox multi-
variate 
analysis 
HR, 95%CI
p
Sex
female 11 8.1 0.7454 1
male 98 91.9 0.64 
[0.20 - 
2.08]
0.4591
Age
≤ 60 yrs 50 40.5 0.3865 1
> 60 yrs 59 59.5 0.79 
[0.43 - 
1.45]
0.4426
Histological type
Adenocarcin-
oma
40 19.4 0.0155 1
Squamous cell 
carcinoma
53 58.3 0.55 [0.29 - 
1.07]
0.0792
Other 15 22.2 0.75 [0.28 - 
2.00]
0.5713
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Disease stage
III 50 35.1 0.2058 1 1
II 28 35.1 0.13 [0.04 - 
0.37]
0.0001 0.13 [0.04 - 
0.36]
0.0001
I 31 29.7 0.21 [0.09 - 
0.47]
0.0002 0.17 [0.07 - 
0.40]
< 
0.0001
No. of neoadjuvant chemotherapy cycles
2 61 40.5 0.0149 1
3 38 40.5 0.94 [0.49 - 
1.81]
0.8649
4 10 18.9 0.17 [0.02 - 
1.22]
0.0779
Chemotherapy
CDDP-Gem-
citabine
74 75.7 0.5924 1
Carboplatine-
Docetaxel
30 21.6 0.49 [0.22 - 
1.11]
0.0894
Other 5 2.7 0.27 [0.04 - 
1.98]
0.1981
Surgery
Pneumonec-
tomy
40 16.2 0.0012 1
Lobectomy-
Bilobectomy
69 83.8 0.44 [0.24 - 
0.82]
0.0102
CT-scan response
NC-P 37 13.5 0.001 1
RC-RP 72 86.5 0.70 [0.37 - 
1.32]
0.274
Residual carcinoma
≤ 30% 37 100 1
> 30% 71 0 0.44 [0.22 - 
0.91]
0.0266 0.42 [0.20 - 
0.89]
0.0225
Missing value1
 
Pathologic residual carcinoma ≤ 30% was significantly associ-
ated with the number of neoadjuvant chemotherapy cycles, surgery 
(lobectomy and bilobectomy vs pneumonectomy), histological type, 
pTNM and CT-scan response. Using a backward selection procedure, 
after adjustment for surgery and histologic type, CT-scan response 
was significantly associated with residual carcinoma ≤ 30%, OR 
(CR+PR)=4.2, 95%CI: [1.32; 13.13], p=0.0151. Median survival was 
73.8 months. The 2-year and 4-year cancer-specific survival rates for 
all patients were respectively 87.2% and 58.2%. Factors associated to 
cancer-specific survival were surgery type, cTNM, pTNM, pathologic 
residual carcinoma and vascular limit. Using backward selection 
procedure and after adjustment for cTNM, Cox model showed that 
patients with ≤ 30 % of residual carcinoma have significantly bet-
ter survival than patients with residue > 30 % HR=0.44, 95%CI: 
[0.22;0.91], p=0.027. Mitotic index and CT-scan response were not 
predictive.
Conclusion: Among patients with resectable NSCLC treated with 
neoadjuvant chemotherapy, we found that the pathologic residual 
carcinoma predicts independently specific survival contrary to CT-
scan response. 
PD6.5.2 Pathology, Sun, 14:30 - 16:00
Clinical implications and determinants of inaccurate 
pathologic staging of lung cancer in a large US 
metropolitan area
Farooq, Aamer1; Allen, Jeffrey W.1; O’Brien, Thomas2; Ratliff, 
Thomas1; Ninan, Mathew1; Osarogiagbon, Raymond U.1
1 University of Tennessee, Memphis, TN, USA; 2 Duckworth 
Pathology Group, Memphis, TN, USA
Background: Pathologic staging, obtained during attempted 
resection is the most accurate predictor of survival in patients with 
lung cancer. Patients who have had a potentially curative resection 
continue to be at significantly high risk for cancer-related mortality, 
which can be partially mitigated in those with stage II-III disease by 
administration of adjuvant therapies. Moreover, numerous clinical 
trials designed to further improve post-resection survival are on-
going. However, correct prognostication, selection of post-operative 
management, and enrollment into clinical trials require accurate path-
ology evaluation of resection specimens. The role of surgeons in de-
termining proper staging is well recognized. The role of pathologists 
is less well so. We sought to evaluate the extent to which pathologists 
might contribute to incorrect staging after lung cancer resection.
Methods: We reviewed the final pathology reports of all patients 
who underwent potentially curative resection for lung cancer in the 
Memphis Metropolitan Area from January 1, 2004 to December 31, 
2007 in order to compare the final TNM stage attributed to actual 
TNM stage as determined by careful interpretation of the descrip-
tors provided in each report compared to the AJCC staging manual 
(7th Edition). We excluded patients who had pre-operative therapy 
(chemotherapy, radiation therapy, or both) from this analysis.
Results: 806 patients had surgery for lung cancer during this period, 
60 were excluded because of pre-operative therapy. Of the 746 re-
maining patients, 240 (32.2%) had no declared T-stage, 252 (33.8%) 
no N-stage, and 240 (32.2%) no M-stage. Overall, 253/675 37.5%) of 
patients had at least one missing piece of staging. 
Inaccuracies in T staging were found in 35/471 (7.4%) cases for 
which T staging was declared, 30 of which would have upstaged the 
patient. 15/461 (3.3%) had inaccuracies in N staging, 13 of which 
would have upstaged the patient to N1 from N0 (1 patient) or to N2 
from N1 (12 patients).
Conclusions: There is a high percentage of non-reportage of patho-
logic TNM staging by pathologists examining lung cancer resection 
specimens (37.5%) in our cohort. Although the information necessary 
to attribute TNM stage can be abstracted by reading the detailed path-
ology report, it is possible that this information might be incomplete. 
This practice falls short of the College of American Pathologists’ 
mandate to report TNM stage.
Furthermore, when available, the reported TNM stage is erroneous 
to a variable degree, with errors in T-stage discovered in 7.4% and 
N-staging in 3.3% of patients. The most common error in T-stage is 
the under-staging of satellite tumor nodules in the ipsilateral primary 
tumor lobe (currently T4, stage IIIB; soon to change to T3 (stage IIB 
with proposed IASLC/AJCC 8th Edition). There are very few over-
staged patients in this cohort. 
Patients re-assigned to a corrected stage have a survival rate is that is 
identical to that of others accurately attributed to the same pathologic 
stage, therefore validating the stage correction. 
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Use of a standardized tool for data interpretation should be mandated 
in pathology departments to avoid these clinically meaningful errors 
in stage attribution.
PD6.5.3 Pathology, Sun, 14:30 - 16:00
The evaluation of liquid-based ‘ThinPrep’ cytology of 
intrapulmonary specimens against conventional specimens
Kakihana, Masatoshi; Kato, Yasuhumi; Uchida, Osamu; Kajiwara, 
Naohiro; Ohira, Tatsuo; Ikeda, Norihiko
Tokyo Medical University Faculty of Medicene, Tokyo, Japan
Background and Objective: Recent advances in cytopathological 
techniques have included the development of liquid-based cytology 
test. The liquid-based cytological test (LCT) is widely used to assess 
gynecological cytology. 
One of the advances in liquid-based cytology have led to a revolution 
in cytological specimen preparation. ThinPrep (Cytyc Corporation, 
Boxborough, MA, USA) system (TP) is an automated liquid-based 
cytology system. This study aimed to determine the feasibility of 
using a TP processor for the processing and compare the cytological 
findings, morphological appearance and diagnostic sensitivity of 
LCT with those of the pick-and-smear (PS) method for diagnosing 
intrapulmonary lesions. Furthermore, we determined the effect of TP 
fixation on RNA integrity to assess the suitability of clinical samples 
collected in this medium for RNA-based molecular assays.
Methods: Total 59 samples were studied. 32 of fine needle aspiration 
specimens, obtained from resected lung tumor, were diagnosed with 
lung cancer or benign lung tumor. A total of 27 samples from patients 
with radiographically detectable lesions underwent TV-brushing 
or BAL procedures at Tokyo Medical University hospital over a 
4-month period. RNA isolation was performed on selected fine needle 
aspiration samples fixed in TP. The RNA integrity was evaluated by 
analysis of ribosomal RNA as an indicator of quality. The effect of TP 
preservation on PCR amplification was evaluated by real-time reverse 
transcriptase (RT)-PCR. [Results] LCT slides showed decreased areas 
of cell monolayers, a clearer background and distinct, stereoscopic 
cytological features. The LCT had a higher diagnostic sensitivity for 
lung cancer than the PS method. 
Conclusions: The results show that LCT technique identified more 
malignancies than the PS preparation in both brushing specimen and 
fine needle aspiration specimen. LCT is a useful and easily performed 
technique that can be widely applied, and is suitable for screening for 
the diagnosis of intrapulmonary lesions. Furthermore, the potential 
for ancillary tests including immunocytochemical staining and DNA 
(or RNA) analysis makes this technique a promising candidate for 
more widespread usage.
PD6.5.4 Pathology, Sun, 14:30 - 16:00
A grading system of lung adenocarcinomas (AD) is 
predictive of earlier disease recurrence in stage 1 
adenocarcinoma
Sica, Gabriel; Downey, Robert; Rusch, Valerie; Travis, William D.; 
Moreira, Andre L.
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Background: AD mixed subtype, the most common histologic type 
of lung cancer, is a heterogeneous group composed of a mixture of 
different patterns and pattern combinations. The prognostic signifi-
cance of each individual type of AD within the mixed subtype is not 
clearly understood. In this study, the role of the predominant pattern 
of AD is compared with the pattern seen in the metastatic site in an 
attempt to correlate with higher stage of disease and devise an object-
ive and prognostically significant pattern based grading system..
Methods: This is a retrospective study of 74 patients with mixed 
subtype ADs that presented with regional lymph node and/or brain 
metastasis. Histologic subtyping was evaluated by comprehensive 
semiquantitation and classified by major subtype and compared in the 
primary and metastatic site. A three tiered, pattern based grading and 
scoring system was derived from this data and applied to a separ-
ate set of 375 patients with stage I lung AD with known disease free 
interval.
Results: In the advanced stage lung AD group, acinar was the pre-
dominant pattern in 61% of the tumors, followed by papillary (24%), 
solid (25%), micropapillary (15%). 
In contrast, the predominant metastatic pattern was solid (37%), 
acinar (33%), micropapillary (41%), and papillary (14%). The overall 
correlation coefficient between predominant pattern in the primary 
site and metastasis was of 0.489. 
In the cases that micropapillary (n=9) or solid (n=15) types were the 
predominant patterns in the primary tumor, the there was 89% and 
80% concordance in the metastasis. The presence of a minimal of 
5 to 10% of micropapillary or solid types in the primary tumor was 
enough for an overrepresentation of these patterns in the metastatic 
site.
A three tiered pattern based grading system, derived from the obser-
vation that the micropapillary and solid patterns are more often seen 
in the metastatic sites and by corollary demonstrate a more aggressive 
phenotype, was developed and applied to a separate group of stage I 
lung AD. Scoring schemes based on this grading system was able to 
stratify patients into low, intermediate and high risk for disease recur-
rence. Patients with the highest scores had a 30% recurrence rate at 
2.7 years which contrasted with a 5% recurrence rate at 2.7 years for 
the lowest scoring patients (p<0.005).
Conclusions: AD classification, using the most prominent subtyp-
ing reveals the presence of solid and micropapillary components are 
overrepresented in metastatic sites, a finding that correlates with the 
known high grade nature of these subtypes. A predominant acinar 
or papillary pattern in mixed subtype does not appear to correlate 
with the pattern in the metastatic site. Therefore, the high grade solid 
and micropapillary subtypes of AD are more likely to metastasize to 
lymph nodes even if they are not the most prominent subtype in the 
primary tumor. A three tiered grading and scoring system based on 
this observation is able to identify stage I patients at highest risk for 
earlier disease recurrence.
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Quantitative analysis of tumour in bronchial biopsy 
specimens
Coghlin, Caroline L.1; Smith, Louise J.1; Bakar, Salmah1; Stewart, 
Keith N.1; Devereux, Graham S.1; Nicolson, Marianne C.2; Kerr, 
Keith M.1
1 Aberdeen University Medical School, Aberdeen, UK; 2 Aberdeen 
Royal Infirmary, Aberdeen, UK
Background: Diagnostic bronchial biopsy is routinely carried out in 
lung cancer patients. Gene mutations and amplifications, and quan-
titative mRNA assessment in tumours will be used to select therapy 
and provide prognostic information. The validity of using bronchial 
biopsy fragments for such molecular studies, bypassing histological 
examination, has been questioned. We analysed bronchial biopsy 
specimens from lung cancer patients to assess the frequency and 
quantity of tumour present in biopsy samples.
Methods: The proportion of tumour in 100 consecutive malignant 
bronchial biopsy specimens was assessed by measuring tumour area 
in histological sections of biopsy samples using digital morphometry. 
A “Color View-II” digital camera (Soft imaging systems GmbH, 
Munster, Germany) attached to an Olympus BX41 light microscope 
was used. Digital images of the biopsies captured at x20 magnifi-
cation were analysed using “AnalySIS®” software (Soft Imaging 
Systems). Total tissue area and tumour area were calculated and the 
tumour area was expressed as a percentage of the total tissue area. 
Fragment number (total and those containing tumour) was recorded 
for each sample.
Statistical analysis of data was undertaken using the PRISM software 
statistical package using ANOVA or Mann-Whitney test where ap-
propriate
Results: In only 48% cases did all of the fragments obtained from a 
bronchial biopsy procedure contain tumour. Two cases of rigid bron-
choscopic biopsy samples were excluded from further analysis.
  All Small  All Squam Adeno NSCLC, 
  Cases Cell NSCLC -ous -carcinoma NOS
No. of Cases 98 28 70 37 11 20
Total No. of Fragments      
Mean (Range) 3.9 (1-14) 3.4 (1-5) 4.2 (1-14) 4.1 (1-14) 4.6 (3-8) 3.8 (1-7)
Median Number 4 4 4 4 4 4
Sum 386 96 290 152 51 79
Fragments with Tumour      
Mean (Range) 2.8 (1-8) 2.9 (1-5) 2.7 (1-8) 2.8 (1-8) 3.3 (1-6) 2.0 (1-5)
Median Number 3 3 2 2 3 2
Sum 272 83 189 105 36 40
Area of Tumour (%)      
Mean (Range) 33.4% (0.1-94) 46.5% (0.1-90) 28.2% (0.1-94) 31.1% (1-89) 32.1% (3-94) 19.6% (0.1-74)
Median 28% 49% 22% 27% 23% 10%
The mean and median total surface areas of tumour in bronchial 
biopsy samples are generally low. Biopsy samples with small cell 
carcinoma show significantly more tumour than those with non-small 
cell carcinomas (NSCLC) (P<0.005). Samples with NSCLC, not 
otherwise specifiable (NOS) contained less tumour than samples with 
specific tumour types (P=0.002). For all samples and those with small 
cell or adenocarcinoma a median of 3 out of 4 tissue fragments con-
tained tumour while for samples with squamous carcinoma, NSCLC, 
NOS and for all NSCLC cases the median value was only 2.
Conclusion: The amount of tumour tissue in bronchial biopsies 
containing primary carcinoma is frequently limited. In general, one or 
more of the biopsy fragments will not contain tumour and overall, the 
proportion of the sample comprising tumour is usually substantially 
less than 50%. This has important implications for the storage and 
use of bronchial biopsy samples for genetic analysis. Histopatho-
logical examination is required to confirm the presence of tumour and 
microdissection may be needed to increase the tumour content of any 
material used for genetic analysis.
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Genomic profiling associated with survival in stage IIIA-B 
non-small cell lung cancer (NSCLC) patients treated with 
radiotherapy 
Bi, Nan1; Wang, Luhua1; Zhang, Li 2; Yang, Ming2; Chen, Xiabing2; 
Lin, Dongxin2
1 Department of Radiation Oncology,Cancer Institute and Hospital, 
Chinese Academy of Medical Sciences and Peking Union Medical 
College, Beijing, China; 2 Cancer Hospital (Institute), Chinese 
Academy of Medical Sciences, Peking Union Medical College, 
Beijing, China
Background: Polymorphisms in critical pathways of cancer pro-
gression (i.e. DNA repair, apoptosis, and tumor microenvironment) 
may influence clinical outcomes to radiotherapy. To establish the 
prognostic genomic profiling on stage IIIA-B non-small-cell lung 
cancer (NSCLC) patients treated with radiotherapy, we genotyped 27 
polymorphisms in 14 genes, including ATM, NBN, PARP1, XRCC1, 
XRCC3, XPC, ERCC2, ERCC5, FAS, FASL, CASP8, COX2, TP53, 
and TGF-β1.
Methods: From January 2004 to December 2007, a total of 136 Chi-
nese patients with Stage IIIA-B NSCLC were included. All of them 
were inoperable and underwent thoracic radiotherapy with or without 
chemotherapy. DNA was extracted from baseline peripheral lympho-
cytes and was genotyped using polymerase chain reaction (PCR)-
based restricted fragment length polymorphism (RFLP) techniques.
Results: Patients were 115 men (84.6%) and 21 (15.4%) women, 
with a median age of 60 years (range, 26 to 83 years). Thirty-three 
(24.3%) patients were Stage IIIA and 103 (75.7%) were Stage IIIB. 
The median follow-up was 22.3 months and the median survival was 
18.05 months (range, 2.7-60.3).The COX2 -1195G/A SNP and ATM 
-111 G/A SNP emerged as significant predictors of survival (P =0.006 
and 0.013, respectively). The COX2 -1195G/A SNP also had a 
marginally significant association with progression (P=0.071). When 
variant alleles of COX2 -1195G/A and ATM -111 G/A were examined 
in combination, a greater number of variant alleles was associated 
with longer time to survival (P <0.001) (table1). In the multivariate 
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analysis of survival, the combination of COX2 -1195G/A and ATM 
-111 G/A was the most important prognostic factor (HR 0.63, 95% 
CI: 0.48-0.84; P =0.002), and also was radiation technique (HR 0.51, 
95% CI: 0.31-0.86; P =0.012).
Conclusion: Genetic polymorphisms in COX2 and ATM were 
prognostic factors in stage IIIA-B NSCLC patients treated with 
radiotherapy. These findings support the notion that genomic profil-
ing may help to identify those who are more likely to benefit from 
radiotherapy.
 Genotype No(%) PFS  OS 
   HR(95%CI) P HR(95%CI) P
 COX2 -1195G/A     
 AA 56(41.2) 1  1 
 GA+GG 73(53.7) 0.69(0.47-1.04) 0.07 0.58(0.39-0.86) 0.006
 ATM -111G/A     
 GG 49(36.0) 1  1 
 GA+AA 87(64.0) 0.85(0.57-1.26) 0.41 0.62(0.42-0.91) 0.01
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Stromal signatures in microarray analyses of NSCLC: 
a challenge in data interpretation of gene expression 
profiling
Botling, Johan 1; Edlund, Karolina1; Göransson, Hanna2; Ekman, 
Simon3; Bergqvist, Michael3; Lamberg, Kristina4; Berglund, Anders 
5; Lambe, Mats 5; Ståhle, Elisabeth 6; Nyberg, Fredrik7; Thomas, 
Andrew8; Holmberg, Lars9, 5; Isaksson, Anders2; Micke, Patrick1
1 Uppsala University Hospital, Pathology, Uppsala, Sweden; 2 
Uppsala University Hospital, Medical Science, Uppsala, Sweden; 3 
Uppsala University Hospital, Oncology, Uppsala, Sweden; 4 Uppsala 
University Hospital, Pulmonary Division, Uppsala, Sweden; 5 
Uppsala University Hospital, Regional Oncology Centre, Uppsala, 
Sweden; 6 Uppsala University Hospital, Thoracic and Cardiovascular 
Surgery, Uppsala, Sweden; 7 Astra Zeneca R&D, Mölndal, Sweden; 
8 Astra Zeneca, Alderley Park, Macclesfield, UK; 9 King’s College 
London, Medical School, Division of Cancer Studies, London, UK
Background: Microarray-based gene expression analysis has become 
a powerful tool in cancer research. Resulting expression profiles have 
been used to explain cancer biology, define new tumour subtypes, 
and to predict clinical outcome or response to therapy. When human 
lung cancer tissue is utilised the variable admixture of non-malignant 
stromal cells, such as fibroblasts and inflammatory cells, influence 
subsequent results. The aim of our study was to evaluate the impact 
of stroma-derived gene expression signatures on microarray experi-
ments using tissue from a well-defined NSCLC-patient cohort.
Methods: Fresh frozen tumour tissues from 60 NSCLC patients 
(stage I-IIIb) with good or bad prognosis (overall survival (OS) <20 
months, n=30; OS >58 months, n=30) were histologically charac-
terised and RNA was extracted from 2-5 consecutive whole tissue 
sections. Additionally, from five of these samples, 5000-10000 tu-
mour cells were isolated by laser microdissection. All RNA prepara-
tions - whole tissue and laser microdissected samples - revealed good 
RNA quality and were subjected to microarray analysis (Affymetrix, 
Human Genome U133 Plus 2.0 Array). 
Results: Unsupervised hierarchical clustering showed that the five 
microdissected samples clustered together and were distinguished 
from the corresponding whole “parental“ tumour cases. A comparison 
of the expression profiles of the microdissected “tumour only“ sam-
ples with the matched whole tissue samples (stroma and tumour cells) 
revealed a list of differentially expressed genes, including typical 
stromal and inflammatory genes, that were significantly upregulated 
in the whole tissue sample, i.e. likely to reflect a “stromal profile”. 
When these “stromal genes” were excluded from the cluster analysis 
of all 60 whole tissue specimens the correlation with histopathologic-
al subtype increased. In addition new molecular subgroups (clusters) 
were created, and using modified calculations improved associations 
with survival data were obtained.
Conclusions: Stroma and inflammatory cells have a significant im-
pact on global gene expression experiments of NSCLC tissue. Since 
biological or clinical associations may be obscured, the stromal sig-
nature must be considered during data interpretation. The definition 
of stromal gene expression signatures may permit “microdissection 
in-silico” of heterogenous clinical tumour samples. Additionally, the 
stroma signature per se can include important biological information 
about the cancer environment.
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Use of biomarker response to celecoxib to predict radiation 
induced lung and esophageal toxicity: a strategy to 
individualize thoracic radiation therapy
Csiki, Ildiko1; Morrow, Jason 1; Choy, Hak 2; Carbone, David P.1; 
Johnson, David H.1; Lu, Bo1
1 Vanderbilt University Medical Center, Nashville, USA; 2 UT 
Southwestern Medical Center, Dallas, USA
Objectives: Preclinical research shows that treatment with selective 
cyclooxygenase-2 (COX-2) inhibitors strongly enhances radio-
response of both rodent tumors and human tumor xenografts in nude 
mice without significant modification of radiation damage of normal 
tissues. The hypothesis that inhibition of COX-2 activity enhances 
tumor response to radiation therapy without increasing the risk of 
treatment related toxicities has been recently examined in a phase II 
trial including 17 patients at Vanderbilt University using celecoxib 
in combination with paclitaxel, carboplatin, and radiotherapy for 
patients with inoperable stage IIIA/B non-small cell lung cancer 
(NSCLC). We found that the urinary prostaglandin E2 metabolite 
(PGE-M) is a promising biomarker for predicting response to COX-2 
inhibition in NSCLC as significant association between objective 
response (CR/PR vs. SD/PD) and the initial PGE-M levels and rates 
of decline was demonstrated (p = 0.005). A significant concern during 
lung radiation treatment is development of pulmonary and/or esopha-
geal toxicity. Our goal was to correleate clinical response with tox-
icity development during therapy and to identify biomarkers that may 
be able to predict radiation-induced lung and esophageal toxicity.
Methods: We correlated the pulmonary and esophageal toxicity of 
NSCLC patients receiving celecoxib while undergoing concurrent 
chemo-radiation with their clinical response and urinary PGE-M 
levels as measured by mass spectrometry. Serum celecoxib levels 
were also assessed. 
Results: We find that the incidence of esophageal and/or pulmon-
ary toxicity correlated with clinical response, such that patients with 
stable (SD) or progressive disease (SD) after therapy were more 
likely to experience Common Toxicity Criteria (CTC) grade 2 or 
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higher esophageal and/or pulmonary toxicity compared to patients 
with a partial response (PR). Pulmonary toxicity was noted in 5 out 
of 9 (55.5%) patients with PD/SD whereas none of the patients (0 out 
of 6)with PR experienced pulmonary toxicity. Esophageal toxicity 
was seen in 4 out of 9 (44.4%) patients with PD/SD and 1 out of 
6 (16.6%) patients with PR. In addition, patients with high pre-
treatment urinary PGE-M levels or an increase/insignificant change 
noted in PGE-M levels post-celecoxib were more likely to experience 
esophageal and pulmonary toxicity. Average pre-treatment PGE-
M levels in patients with pulmonary and esophageal toxicity were 
52.8ng/ml and 52.7 ng/ml, compared to patients who did not experi-
ence these toxicities (12.5ng/ml). 
Conclusions: We find that a short course of celecoxib prior to con-
current chemo-radiation for NSCLC may aid in identifying patients 
that are more likely to experience significant and potentially therapy-
limiting toxicity. Furthermore, identification of biomarkers or models 
that can accurately predict radiation-induced lung or esophageal dam-
age at an early stage, before completion of chemo-radiation, would 
allow physicians to tailor therapy to alter the toxicity profile.
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CD133+ hematopoietic progenitor cells in non-small cell 
lung cancer patients as indicator of an anti-angiogenic 
therapeutic response
Vroling, Laura; Lind, Joline S.; Smit, Egbert F.; Verheul, Henk M.; de 
Haas, Richard R.; Broxterman, Henk J.
VU Univeristy Medical Center, Amsterdam, Netherlands
Background: Currently, various phase II/III trials are investigating 
the multi-targeted tyrosine kinase (TK)-inhibitor sorafenib (Nexa-
var®) in non-small cell lung cancer (NSCLC) patients. Biomarkers 
for patient selection, validated dose-schedules and prediction of treat-
ment response for sorafenib in these patients are lacking. We assessed 
the changes in plasma vascular endothelial growth factor (VEGF), 
circulating endothelial cell (CEC) and (CD133+) hematopoietic pro-
genitor cell (HPC) numbers in NSCLC patients treated with sorafenib 
plus the epidermal growth factor receptor (EGFR) inhibitor erlotinib 
or erlotinib alone. The changes were correlated with clinical outcome 
parameters.
Methods: CECs, characterized by CD45neg/CD34bright/CD133neg/
VEGFR2pos, HPCs characterized by CD45dim/CD34bright and 
CD133+ subfraction of HPCs were measured in the peripheral blood 
of 35 NSCLC patients; 25 treated with sorafenib (400 mg twice 
daily) plus erlotinib (150 mg/day) and 10 treated with monotherapy 
erlotinib. Plasma VEGF was measured with ELISA. Blood was 
drawn before treatment (D0), on D7 and D21. Blood parameters were 
compared with responses assessed by RECIST, responses incorporat-
ing cavitation of the primary tumor1 and time to progression (TTP). 
Results: After 7 days of therapy sorafenib treated patients showed 
a 191% increase in CECs (median from 44 cells/mL D0 to 129 D7, 
p<0.0001). CECs during monotherapy erlotinib did not change after 
7 days of treatment (median, from 48 cells/mL D0 to 51 D7, p=0.8). 
CD133+/HPCs showed a marked decrease after 7 days of sorafenib 
treatment (median, from 1086 cells/mL D0 to 361 D7, p< 0.0001) 
and even lower numbers were demonstrated after 21 days (median, 
from 1086 cells/mL D0 to 264 D21, and from 361 cells/mL D7 to 
264 D21, p< 0.0001 and p< 0.05 respectively). HPC numbers did not 
change significantly with erlotinib treatment. In sorafenib treated pa-
tients pre-treatment and changes in CEC and CD133+ HPC numbers 
did not correlate with RECIST responses. When incorporating tumor 
cavitations pre-treatment levels of CD133+/HPCs were significantly 
lower in responding (defined as partial response) patients (p=0.01) 
and the changes in CD133+ HPCs after 7 and 21 days of treatment 
were significantly higher in non-responding (defined as stable disease 
plus progressive disease) patients (p=0.035). Baseline CECs or chan-
ges in CECs after 7 or 21 days still did not correlated with response. 
Pretreatment CD133+ HPC numbers less than the median of 1086 
cells/mL and a decrease less than the median decrease of 710 cells/
mL after 7 days of treatment correlated with a longer TTP (p<0.05 
and p<0.01 respectively). Plasma VEGF did not correlate with re-
sponse or TTP. Correlations with survival will be provided.
Conclusions: CECs increased in NSCLC patients treated with 
sorafenib in combination with erlotinib, but not with erlotinib mono-
therapy. This suggests their specificity for this anti-angiogenic agent. 
CD133+ HPCs decreased significantly in all patients and pretreat-
ment CD133+HPC as well as changes in CD133+HPC levels after 
7 days correlated with the TTP. These may therefore give an early 
indication of therapeutic outcome.
References:
(1)  Crabb SJ, Patsios D, Sauerbrei E et al. Tumor Cavitation: Impact on Objective 
Response Evaluation in Trials of Angiogenesis Inhibitors in Non-Small-Cell Lung 
Cancer. J Clin Oncol 2008.
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A transcriptomic approach to identifying a genomic 
biomarker of AT-101 sensitivity in non-small cell lung 
carcinoma (NSCLC)
Ready, Neal2; Leopold, Lance1; Yang, Dajun1; Wood, Brian A.1; Potti, 
Anil2
1 Ascenta Therapeutics, Malvern, PA, USA; 2 Duke University, 
Durham, NC, USA
Background: AT-101 is a direct and indirect pan Bcl-2 family protein 
inhibitor. AT-101 direct effects include binding to the Bcl-2 family 
proteins (Bcl-2, Bcl-xL, Mcl-1, and Bcl-w); indirect effects include 
transcriptional upregulation of Noxa and Puma, the natural inhibit-
ors of the Bcl-2 proteins. AT-101 displays broad preclinical activity 
including synergy with chemotherapeutic drugs such as docetaxel.
Methods: Using Affymetrix gene expression data with correspond-
ing in vitro drug sensitivity data (MTT assay) in NSCLC cell lines, a 
biomarker of AT-101 activity was developed. This signature was then 
validated in an independent cohort of cell lines treated with AT-101, 
demonstrating a paradigm for drug-biomarker development strategies 
that will likely enrich for appropriate patient populations. 
Results: Analysis of gene expression data from cell lines that consti-
tuted the extremes of sensitivity, from amongst a panel of 55 NSCLC 
cell lines, using Bayesian regression methodology, revealed a robust 
500 gene predictor of sensitivity to AT-101 that was cross validated 
in a leave-one-out analysis and more importantly in an independent 
cohort of 32 NSCLC cell lines treated with AT-101. The 500 gene 
predictor of AT-101 sensitivity is constituted by several genes that are 
involved in the regulation of apoptosis and bcl-2 function. Validation 
of the predictor in patient samples from a randomized phase II trial of 
AT-101 in NSCLC is ongoing.
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Conclusions: An internally validated, robust genomic biomarker for 
AT-101 sensitivity was developed using an in vitro drug sensitivity 
model and gene expression data. External validation of this bio-
marker, using overall survival data from the just completed random-
ized, blinded phase 2 trial, of AT-101 or placebo in combination with 
docetaxel in 2L NSCLC is ongoing. A genomic predictor of AT-101 
sensitivity is likely to enrich for responders and identify novel thera-
peutic combinations for future studies.
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Measurement of gene expression biomarkers by qNPATM 
from archived NSCLC FFPE: prognosis of 5-year survival
Joshi, Mary-Beth M.1; Seligmann, Bruce2; Harpole, David H.1
1 Duke University Medical Center, Durham, NC, USA; 2 High 
Througput Genomics, Inc., Tucson, AZ, USA
Background: There are vast archives of formalin-fixed, paraffin- em-
bedded (FFPE) tissue samples that are clinically annotated offering 
great research potential. However, the technology currently available 
to assess gene expression is limited to fresh, frozen, tissue. Recently, a 
method for measuring gene expression from FFPE using the quantita-
tive Nuclease Protection Assay (qNPA) has been published in a model 
of diffuse large B-cell lymphoma. It was demonstrated that identical 
results were obtained from small amounts of FFPE as from matched 
frozen tissue, or from freshly fixed versus 18 year archived FFPE.
Methods: This study used the qNPA assay to measure gene expres-
sion in archived FFPE primary tumor samples of patients with stage 
1 NSCLC for whom the survival outcomes are known (n=86). HTG 
lysis buffer is added to the sample; nuclease protection probes that 
are complementary to the mRNA of interest are then added to the 
solution. The probes hybridize to all RNA, soluble and cross-linked. 
After hybridization, S1 nuclease was added to destroy all nonspecific, 
single strand nucleic acid, producing a stoichiometric amount of 
large-mRNA to probe duplexes. Base hydrolysis releases the probe 
from these duplexes. Probes were transferred to a programmed 
ArrayPlate, detection linker added, and both probes and detection 
linkers were captured on to the array. The ArrayPlate was washed, 
HRP-labeled detection probe added, incubated, washed, and chemi-
luminescent substrate was added. Finally, the ArrayPlate was imaged, 
to measure the expression of each gene in all the wells.
Results: Mantel-Cox analysis indicates that the detection increased 
expression of G-CSF(p=0.07; H.R. = 1.0904; 95% CI=0.9003-4.028) 
and Leptin (p=0.09;H.R.=1.910; 95% CI=0.9299-3.924) individually 
suggest an improved survival. Age, gender and T-size were found to 
not to be significant in this data set. 
Conclusions: These results suggest an improved survival advantage 
in patients with an elevated native GCSF level in stage 1 NSCLC that 
is consistent with the survival benefits associated with the prophyl-
actic treatment with GCSF for chemosensitivity in stage III or IV 
NSCLC patients. These results are currently being assessed in a 
larger cohort.
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Impact of clinical and biological markers on progression-
free survival (PFS) and overall survival (OS) in patients 
(pts) with advanced non-small-cell cancer (NSCLC) 
treated by erlotinib: results of the ERMETIC cohort 
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Degeorges, Armelle9; Madelaine, Jeannick10; Chouaid, Christos11; 
Morin, Franck1; Pignon, Jean-Pierre6
1 IFCT, Paris, France; 2 AP-HP Hôpital Tenon, Paris, France; 
3 CRLCC - CHU, Dijon, France; 4 HUS - Nouvel Hopital Civil, 
Strasbourg, France; 5 Hôpital Foch, Suresnes, France; 6 Institut 
Gustave Roussy, Villejuif, France; 7 CRLCC - CHU, Lille, France; 
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Background: Although it has been suggested that results of EGFR-
IHC, EGFR-FISH, EGFR and KRAS mutations are predictive of 
EGFR-TKIs efficacy, they are not used in clinical practice. ERMET-
IC is a French NCI granted prospective study aiming to facilitate 
implementation of these biomarkers in France.
Methods: After a preliminary phase of validation in 16 French 
centers, these biomarkers were studied in available tumor specimens 
collected from consecutive NSCLC pts newly treated by erlotinib. 
Patients were followed until progression or death. Biomarkers i.e., 
EGFR-IHC and FISH, KRAS (exon 2) and EGFR (exons 18-21) 
mutations by direct sequencing, as well as demographic, clinical and 
pathological characteristics were studied by Cox model as predictors 
of PFS and OS.
Results: 520 of the 530 pts enrolled between 02/07 and 03/08 are 
included in this analysis. Median age was 62 (33-93); 87% were of 
European origin and 32% females; 18% were never smoker, 67% 
former and 15% active. 18% were PS0, 51% PS1 and 31% PS2-
3. 91% pts were metastatic and 63% had adenocarcinoma (ADC). 
Erlotinib (150 mg in 98% of pts) was given as 1st-, 2nd- and 3rd-or-
more-line in 11, 46 and 41% of pts, respectively. 86 and 51% of pts 
had received previous platin-based and taxan-based chemotherapy, 
respectively. 423 (81%) tumor specimens were collected among 
which 370 (71%), 130 (25%), 317 (61%) and 324 (62%) were ana-
lyzed by EGFR-IHC, EGFR-FISH, EGFR and KRAS sequencing, 
respectively. With a 15.2 months (mo.) median of follow-up, median 
of PFS was 2.4 mo. and of OS 5.6 mo., with a 30% 1-year OS. Clin-
ical factors independently associated with shorter PFS were: patients 
of European origin (Hazard ratio (HR)=1.4, p=.05); former and 
active smoking (HR=1.8 and 2.0, p<.0001); PS1 and PS2-3 (HR=1.5 
and 2.3, p<.0001); histology other than ADC and squamous cell 
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(HR=1.6, p=.0006); 2 metastasis sites and 3 or more (HR=1.4 and 
1.7, p<.0001), and pts that had received a taxan-based CT (HR=1.3, 
p=.01). Clinical factors independently associated with shorter OS 
were: patients of European origin (HR=1.4, p=.04); former and active 
smoking (HR=1.6 and 2.2, p=.0002); PS1 and PS2-3 (HR=1.8 and 
4.0, p<.0001) and 2 metastasis sites and 3 or more (HR=1.5 and 1.9, 
p<.0001). In multivariate analysis, line of treatment was not prognos-
tic, both for PFS and OS. Prognostic values of EGFR-IHC, EGFR-
FISH, and EGFR & KRAS mutations will be reported at the meeting.
Conclusions: The study confirmed the independent prognostic 
value of several factors on PFS and OS in erlotinib-treated advanced 
NSCLC pts. This large study will allow to identify erlotinib-treated 
pts with good prognostic based on clinical and biological factors.
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Comparative analysis and prognostic association of EGFR 
protein expression with survival using a novel antibody 
specific for the intracellular domain of EGFR
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1 University of Colorado, Division of Medical Oncology, Aurora, 
CO, USA; 2 Medical University of Gdansk, Dept. of Oncology and 
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Background: Lung cancer is the leading cause of death among all 
cancers. The EGFR signaling pathway is thought to play a funda-
mental role in carcinogenesis and progression of many malignancies 
including NSCLC, however, the prognostic power of EGFR expres-
sion is controversial. Consequently, we measured EGFR protein ex-
pression and determined prognostic association with progression-free 
survival (PFS) and overall survival (OS) using antibodies specific for 
either the intracellular domain or the extracellular domain of EGFR.
Methods: EGFR immunohistochemistry, using a novel intracellular 
domain specific 5B7 (Ventana Medical Systems, Inc., Tucson, AZ) or 
extracellular domain specific 3C6 (VMSI), was performed on a tis-
sue microarray containing triplicate samples from 189 pts surgically 
treated for NSCLC (median follow-up 4 years and 5-year survival 
probability of 40%). There were 76% males, 54% squamous cell car-
cinomas, 29% adenocarcinomas, 3% large cell carcinomas and 14% 
not otherwise specified/other histologies. The pathological stages 
were I: 40%, II: 22%, III: 32%, IV: 4% and unknown; 2%, while the 
grades were well-differentiated: 11%, moderately- differentiated: 
43%, poorly-differentiated: 33% and unknown: 13%. The staining 
index, from two readers (MP and XLY), was determined by multiply-
ing the percent of stained tumor cells by the staining intensity graded 
from 0 to 3, resulting in an index value between 0 and 300. The 
maximum score per triplicate was chosen for analysis. 
Results: We found a highly significant correlation both between the 
readers and between the antibodies; 3C6 MP vs. 3C6 XLY (r=0.768, 
p<0.001, n=179), 5B7 MP vs 5B7 XLY (r=0.811, p<0.001, n=179), 
3C6 MP vs. 5B7 MP (r=0.578, p<0.001, n=180) and 3C6 XLY and 
5B7 XLY (r=0.701, p<0.001, n=178). The corresponding scores 
from each reader were averaged for each antibody and compared 
to stage, grade, histology, OS and PFS. Neither antibody showed 
a statistical difference between pathological stages, in contrast to 
grade and histological pattern. Both antibodies revealed significantly 
less EGFR staining in poorly- vs. moderately-differentiated tumors 
(3C6: p=0.018, 5B7: p=0.008) and poorly- vs. well-differentiated 
(3C6: p=0.002, 5B7: p=0.028). Additionally, both antibodies showed 
statistically higher staining in squamous cell carcinoma vs. others 
(3C6: p=0.010, 5B7: p<0.001), whereas only the 5B7 antibody 
showed statistically less staining in adenocarcinomas vs. others (3C6: 
p=0.238, 5B7: p<0.001). Both the median index scores 250 (for 3C6) 
and 215 (for 5B7) as well as 100 were used as cut points for high 
vs. low expression. 49% vs 52% of pts (3C6 vs 5B7) were high for 
EGFR using the median cut point whereas 87% vs 78% of pts were 
high using 100. Kaplan Meier analysis of OS and PFS revealed no 
statistical difference between EGFR high vs. low expression using 
either antibody or either cut point. 
Conclusions: Neither an antibody directed against the extracellular or 
the intracellular domain of EGFR demonstrated prognostic association 
in the cohort we examined. However, both antibodies did reveal less 
EGFR expression in poorly-differentiated tumors and adenocarcin-
omas as well as higher expression in squamous cell carcinoma.
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Mutations of EGFR (mEGFR) in tumor tissue and serum 
DNA from stage IV non-small-cell lung cancer (NSCLC) 
patients (p) prospectively treated with erlotinib
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Universitario Dexeus, Barcelona, Spain; 3 Pangaea Biotech, USP 
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Background: We evaluated mEGFR in tumor and matched serum 
at baseline and assessed their role in a multicenter trial of first- and 
second-line erlotinib in stage IV NSCLC p with mEGFR in tumor.
Methods: mEGFR were detected in 350 of 2105 p (16.6%) screened. 
217 p with mEGFR received erlotinib; 79 did not due to patient or 
physician decision. mEGFR were assessed in paired serum samples 
from 164 p with mEGFR in tumor for whom baseline blood samples 
were available. mEGFR testing in both tumor and serum was per-
formed centrally. EGFR exon 19 deletions (del 19) were studied by 
length analysis of fluorescently labeled PCR products and the exon 
21 L858R by a PCR Taqman assay. 
Results: Overall response rate was 70%, time to progression (TTP) 
was 14 months (m), and median survival (MS) was 27 m. mEGFR 
status in the serum matched that in the tumor tissue in 97/164 p 
(59.1%), in 44.1% of p with PS 0, in 57.4% of p with PS 1, and in 
78% of p with PS 2 (P=0.01). There were no differences in the meta-
static patterns either according to the presence of mEGFR in serum 
or according to the type of mEGFR. Response rate was 69.8% in 67 p 
without mEGFR in serum and 71.7% in 97 p with mEGFR in serum. 
TTP was 19 m for p with mEGFR only in tumor and 12 m for p with 
mEGFR in tumor and serum (P=0.14). TTP for p with del 19 only in 
tumor was 22 m vs 13 m for p with del 19 in both tumor and serum 
(P=0.36). TTP for p with L858R only in tumor was 16 m vs 11 m for 
p with L858R in both tumor and serum (P=0.13). In the multivariate 
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analysis, male gender, L858R and the presence of mEGFR in serum 
were independent factors for poor prognosis (Table). MS was 31 m 
for p with mEGFR only in tumor and 28 m for p with mEGFR in 
tumor and serum (P=0.21). When only the 97 p with mEGFR in both 
tumor and serum were analyzed, p with L858R were older than those 
with del 19 (73 vs 63 years, respectively; P=0.01). Response rate 
was higher in p with del 19 (78.3%) than in p with L858R (59.4%) 
(P=0.05). TTP for p with del 19 was 13 m vs 11 m for p with L858R 
(P=0.07). MS for p with del 19 was 31 m vs 18 m for p with L8585R 
(P=0.01). 
Conclusion: mEGFR in serum could be an ancillary non-invasive 
method for genotyping when there is insufficient tumor tissue. The 
presence of mEGFR in serum is a prognostic marker for shorter TTP. 
   Hazard Ratio 95% CI P
 Gender Female 1 (ref)  
  Male  2.39 0.39-0.93 0.001
 mEGFR del 19 0.55 0.36-0.85 0.008
  L858R 1 (ref)  
 EGFR in serum wild-type 1 (ref)  
  mEGFR 1.63 1.05-2.55 0.03
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Comparison of nationwide performance of EGFR and 
K-ras mutation analysis, EGFR amplification and 
immunohistochemistry: a Dutch quality control ring 
study*
Thunnissen, Erik1; Nederlof, Petra2; Heideman, Danielle1; Schuuring, 
Ed3
1 PAthology, VUmc, Amsterdam, Netherlands; 2 Dept. of Pathology, 
NKI, Amsterdam, Netherlands; 3 Dept. Pathology, UMCG, 
Groningen, Netherlands
Background: In lung cancer EGFR tyrosine kinase inhibitor (TKI) 
treatment is indicated in a subset of patients with non-small cell lung 
cancer. EGFR and K-ras mutation, EGFR amplification and pos-
sibly immunhistochemistry may play a role in predicting response 
to EGFR TKI. Before this mutation analysis will be widely imple-
mented adequate performance in different laboratories needs to be 
warranted. The aim of this study was to perform a nationwide ring 
study in 2008.
Materials and Methods: Laboratories could apply for participation 
of one or more of the three analysis: 1) mutation, 2) amplification 
with fluorescent (FISH) or chromogenic in situ hybridisation (CISH) 
or 3) immunohistochemistry. From formalin fixed and paraffin em-
bedded resections of lung adenocarcinomas were selected based on 
the presence or absence of K-ras and EGFR mutations. 17 cores of 6 
mm diameter were used for construction of tissue microarray (TMA). 
Coded material was sent to laboratories consisting of A) 3 samples 
with cell line DNA with either EGFGR or K-ras mutations and B) 4 
histologic sections of TMA. Cell line DNA should be used for EGFR 
and K-ras mutation analysis and TMA for EGFR immunohistochem-
istry and amplification with FISH or CISH. Amplification analysis 
should be scored as no amplification, low or high amplification/
polysomie.
Results: In EGFR and K-ras mutation the number of participating 
laboratories was 9 and 10, respectively. One cell line DNA contained 
a K-ras mutation. This was found by 9/10 labs. For K-ras mutation 
analysis one laboratory had discordant results. The second cell line 
contained an EGFR exon 19 deletion, detected by 9/9 labs: 100% 
concordancy. The third cell line contained an EGFR exon 21 muta-
tion as well as T790M exon 20 mutation. The exon 21 mutation was 
shown in 9/9 labs and the exon 20 mutation in 5/9. This was partly 
due to limited cell line DNA distributed.
With EGFR amplification analysis 8 laboratories participated. In 3/17 
cases 7, 6 and 6 times FISH/CISH showed high polysomy or ampli-
fication. One lab showed mild low amplification in these 3 cases and 
another lab had no adequate (NA) CISH in 2 of the 3 cases. In 12/17 
cases no amplification was shown by 6-7/8 labs. The other scores 
were low amplification or NA. In 2/17 cases low amplification/ 
polysomy was present in 4-5/8 labs. The other scores varied from no 
amplification, NA, to amplification.
In EGFR immunohistochemistry 8 participated. 7 different antibodies 
were used, 6 with extracellular and one with intracellular epitope. 
The outcome showed a wide variation between the labs.
Conclusion: Due to high variation in EGFR immunohistochemistry 
this method cannot be used for prediction of EGFR TKI without fur-
ther drastic standardization. EGFR mutation analysis and amplifica-
tion was performed with high concordancy in most laboratories
* Presentation on behalf of the Dutch Quality Control Committee, 
Molecular Working Group, Dutch Pathological Society.
PD7.2.5 Early Detection, Chemoprevention, Progn. & Pred.  Markers, Sun, 10:30 - 12:00
Comparison of e-cadherin IHC status with clinical 
outcomes from erlotinib in the non-small cell lung cancer 
(NSCLC) clinical trial NCIC CTG BR.21
Richardson, Frank; Young, David; Wolf, Julie; Sennello, Gina; 
Wacker, Bret; Davies, Angela
OSI Pharmaceuticals, Boulder, CO, USA
Background: Preclinical data demonstrate that e-cadherin (Ecad) 
expression corresponds to sensitivity to erlotinib (E). In TRIBUTE, 
(E plus chemo trial vs. E) Ecad positive patients (pts) had better 
outcomes than Ecad negative pts. BR.21 was designed to compare E 
to no-treatment placebo (P) and demonstrated E improved survival in 
advanced NSCLC pts. Pt tumor samples from this study provide the 
opportunity to evaluate the relationships between Ecad and clinical 
outcome in a placebo-controlled study.
Methods: 163 residual pt tumor slides were stained for Ecad (Cell 
Signaling Technologies) using immuno-histochemistry (IHC). Nine-
ty-five tissues were deemed evaluable based on unbiased pathologic/
histologic evaluation. The % tumor cells staining at a 0, +1, +2, and 
+3 staining intensity were determined. Cut-point analyses compared 
overall survival (OS) and progression-free survival (PFS) to IHC 
scores using three different IHC scoring systems: % tumor cells 
with any staining, % tumor cells with +2, +3 staining intensity, and a 
modified H-score that summed the % cells in each intensity category 
with a scoring range of 0 to 300. 
Results: The 95 samples evaluated were from pts that demographic-
ally represented the treatment groups for the overall BR.21 popula-
tion of (N=731). The univariate Cox proportional hazard ratio (HR) 
for comparison of E to P in the Ecad population was 0.69 compared 
to the univariate Cox proportional HR of 0.76 in the overall BR.21 
population and a multivariate Cox proportional HR of 0.73. Based on 
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cut-point sensitivity analyses, the Ecad positive (+) cut-point was de-
fined as tumors having ≥ 40% of tumor cells with +2 or +3 intensity. 
Univariate OS HR (with 95% CI) for E vs P was 0.47 (0.26-0.88) in 
Ecad + pts compared to an OS HR for E vs P of 1.12 (0.52-2.44) in 
Ecad - pts. The univariate OS HR for Ecad + vs Ecad - in the E pts 
was 0.68 (0.35-1.33) compared to an OS HR of 1.48 (0.69-3.15) in 
the P pts. 
Conclusions: Based on a representative subset of samples from this 
placebo-controlled trial, preliminary analyses indicate that Ecad may 
be a predictive marker for outcome from E treatment in advanced 
NSCLC. These results agree with preclinical and clinical results sup-
porting Ecad as a marker for enhanced benefit from E. 
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Dual role of T lymphocytes in non-small cell lung cancer 
development
Yagui-Beltran, Adam3, 2; Johansson, Magnus 1, 2; He, Biao2, 3; 
Coussens, Lisa M.1, 2; Jablons, David M.3, 2
1 Department of Pathology. University of California San Francisco, 
San Francisco, CA, USA; 2 The University of California San 
Francisco Helen Diller Family Comprehensive Cancer Center, San 
Francisco, CA, USA; 3 Department of Surgery. Division of Thoracic 
Surgery, San Francisco, CA, USA
Lung cancer is the leading cause of cancer mortality in the U.S., ac-
counting for more deaths than breast, prostate, colon, liver and kidney 
cancer combined. Five-year survival is 15% and clinical benefit from 
conventional chemoradiotherapy is disappointing, thus highlighting 
the need for novel therapeutic strategies. Most human solid tumors 
bear antigens that are specifically recognized by cytotoxic T lympho-
cytes (CTLs). Tumor-specific CTLs have been reported in neoplasia, 
including non-small cell lung carcinoma (NSCLC). However, despite 
the presence of tumor-specific CTLs, tumors still progress indicat-
ing that tumors utilize various mechanisms to evade CTL-mediated 
rejection and/or subversion of host anti-tumor immune responses. 
One plausible explanation for how this occurs is that accumulation 
of regulatory T cells (Tregs) and/or subsets of innate immune cells, 
e.g. immature myeloid cells (iMCs), indirectly contribute to cancer 
development via suppression of anti-tumor adaptive immunity and 
activation of pro-tumor bioactivities of iMCs. We have found that 
human NSCLC is associated with significant accumulation of CD45+ 
leukocytes when compared to adjacent normal lung tissue. Interest-
ingly, these infiltrates are composed of CD4+FoxP3+ Tregs, but not of 
iMCs (CD45+CD34+; CD11b+CD14-CD15+ or CD14+HLA-DR-/low), 
indicating that local immunosuppression in NSCLC is likely imparted 
by Treg cells as opposed to iMCs. Moreover, in a mouse model of de 
novo NSCLC development, i.e. CC10-TAg mice, we also revealed 
accumulations of Tregs, but not of CD11b+Gr1+ iMCs. To reveal the 
functional significance of lymphocyte accumulation, we evaluated the 
dynamics and characteristics of NSCLC development by genetic-
ally manipulating CC10-TAg mice and rendered them deficient for 
all B and T lymphocytes (RAG1-/-), T-helper and Tregs (CD4-/-), 
CTLs (CD8-/-) and B cells (JH-/-). Our data indicate that complete 
absence of both B and T lymphocytes in CC10-TAg mice results in 
a significant acceleration of tumor development that is dependent on 
CD8+ CTLs, i.e. suggesting that tumor cell rejection is CD8+CTL 
dependent. In order to test the hypothesis that tumor-associated Tregs 
facilitate tumor progression through CTL suppression, we depleted 
Tregs in CC10-TAg mice. We found that Treg depletion significantly 
attenuated tumor growth, thus suggesting that NSCLC progression is 
regulated by a balance of CTL-mediated rejection and Treg mediated 
immunosuppression. 
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Secreted cytokine and angiogenic factor (CAF) profiles 
associated with age and sex in NSCLC
Herynk, Matthew H.; Hanrahan, Emer; Lin, Heather; Cascone,Tina; 
Yan, Shaoyu; Byers, Lauren; Yordy, John S.; Lee, J. Jack; Tran, Hai 
T.; Heymach, John V.
M.D. Anderson Cancer Center, Houston, TX, USA
Background: Subgroup analyses from recent clinical trials in non-
small cell lung cancer (NSCLC) suggest therapeutic efficacy in a 
sex-specific manner from drugs such as bevacizumab and vandetanib. 
These differences suggest that factors inherent in the basic male/
female biology may impact growth and survival mechanisms in 
NSCLC tumors. We sought to identify if there are sex-specific differ-
ences in secreted cytokine and angiogenic factors (CAFs) in NSCLC 
cell lines and patient samples.
Methods: Thirty-five CAFs were measured by multiplex bead 
suspension arrays (MBSA) and ELISAs from pre-treatment plasma 
(N=123) and serum (N=151) collected from patients with stage IIIB/
IV NSCLC participating in a randomized phase 2 trials of vandetanib 
alone or in combination with chemotherapy. MBSA were used to 
measure the levels of 48 secreted CAFs in conditioned media from 
36 NSCLC cell lines (female N=17, male N=19). Subconfluent cells 
were serum-starved overnight and the media was changed, 24 hours 
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later, conditioned media was collected and the cells were lysed. 
Measured CAF levels were normalized to total protein from whole 
cell lysates. 
Results: Univariate analysis of serum and plasma samples revealed 
statistically significant differences in the concentrations of 18 CAFs 
between male and female patients with most being higher in females 
including; plasma IL-15 (mean 1193 vs. 291 pg/ml; P =0.0009), sIL-
2R (mean 1413 vs. 577 pg/ml; P =0.004), MIG (CXCL-9) (mean 184 
vs. 67 pg/ml; P =0.0007), and macrophage inflammatory protein-1 
(MIP-1alpha, CCL3) (mean 319 vs. 108 pg/ml; P =0.0067). Condi-
tioned media from 36 NSCLC cell lines was analyzed for levels of 
secreted CAFs. Nine CAFs determined to be statistically significant 
in patient samples were also present in the cell line analyses and two 
factors, MIP-1alpha and intracellular adhesion molecule-1 (ICAM-1) 
also demonstrated increased levels in female versus male cell lines, 
but these differences did not reach statistical significance. While 18 
CAFs were statistically significant in patient samples, no individual 
factors were statistically significant in conditioned media from cell 
lines. Subgroup analysis of female cell lines revealed an age associa-
tion with 26 secreted CAFs in NSCLC cell lines. The majority were 
upregulated in cell lines originally derived from patients >50 y/o 
(N=10) vs <50 (N=5) including IL-15 (2.05 vs.1.27 pg/ml, P=0.011), 
MIG (0.12 vs. 0.095 pg/ml, P=0.033), EGF (14.21 vs. 11.25 pg/ml, 
P=0.034), and ICAM-1 (11.08 vs. 7.66 pg/ml P=0.057). 
Conclusions: Significant CAF differences were observed when male 
and female patient samples and conditioned media from cell lines 
were analyzed, thus suggesting an important role for age and sex in 
the secreted CAF profiles of NSCLC. Because EGFR inhibitors have 
shown preferential efficacy for females, and hormone signaling varies 
between male vs. female populations as well as between younger vs. 
older women, the contributions of EGFR and hormone signaling on 
the sex-different secreted factors is being further investigated. These 
secreted factors are involved in a number of signaling networks and 
thus may contribute to a broad range of effects on tumor growth, 
metastases, and therapeutic efficacy of angiogenesis inhibitors and 
other targeted agents. 
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Cross-validation analysis of the prognostic significance 
of mucin expression in patients with resected non-
small cell lung cancer (NSCLC) treated with adjuvant 
chemotherapy: results from IALT, JBR.10 and ANITA
Graziano, Stephen L.1; Azougagh, Said2; Vollmer, Robin3; Kratzke, 
Robert4; Popper, Helmut5; Filipits, Martin6; Tsao, Ming7; Seymour, 
Lesley8; Rosell, Rafael9; Taron, Miquel9; Pignon, Jean-Pierre2
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Background: CALGB 9633 was a randomized trial of observation 
versus adjuvant chemotherapy (CT) with carboplatin and paclitaxel 
for patients (pts) with stage IB NSCLC. In CALGB 9633, the pres-
ence of mucin in the primary tumor was associated with shorter 
disease-free survival (DFS; hazard ratio (HR) =1.9 [95% CI 1.3-2.8], 
p=0.002) and overall survival (OS; HR=1.9 [1.2-2.9], p=0.004). 
Methods: To validate these results, mucin staining was performed on 
primary tumor specimens from 780 pts treated on the IALT trial, 353 
on JBR.10 and 158 on ANITA; 19 were not assessable, so a total of 
1272 patients were analyzed. Immunohistochemical (IHC) staining 
for mucicarmine was performed with a positive result being the pres-
ence of mucin in the tumor cytosol. The prognostic value of mucin 
for DFS and OS was tested in a Cox model stratified by trial and 
adjusted for clinical and pathological factors. A pooled analysis of all 
4 trials (CALGB, IALT, JBR.10 and ANITA) was performed for the 
predictive value of mucin for benefit from adjuvant CT. 
Results: Mucin staining was positive in IALT 24%, JBR.10 30%, 
ANITA 23% compared with 45% in the CALGB trial. The valida-
tion group had 47% squamous cell, 40% adenocarcinoma and 13% 
other NSCLC compared with 34%, 52%, and 14% respectively in 
CALGB. Histology was the only covariate significantly (p<0.0001) 
related to mucin staining in multivariate analysis. Mucin was more 
common in adenocarcinoma. Mucin was a negative prognostic fac-
tor for DFS (HR 1.22 [1.0-1.5], p=0.04) but not for OS (HR 1.14 
[0.94-1.4], p=0.19). There was no variation of the prognostic impact 
according to trial (heterogeneity test: DFS p=0.64, OS p=0.49). 
Prognostic value did not vary according to histology: HR 1.11 [0.86-
1.4] in adenocarcinoma vs. 1.34 [0.95-1.9] in other histology for OS 
(interaction p=0.87); HR 1.23 [0.8-1.9] vs. 1.5 [1.1-2.1] for DFS 
(interaction p=0.84). Mucin status was not predictive for benefit from 
adjuvant chemotherapy (test of interaction: DFS p=0.36; OS p=0.55).
Conclusion: Mucin staining was less frequent in the validation group 
due to its higher percentage of squamous cell carcinomas. The nega-
tive impact of mucin was confirmed on DFS but not on OS. There 
was no predictive value for mucin on benefit from adjuvant CT.
Supported by Ligue Nationale Contre le Cancer (LNCC).
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AP2β nucleolar localization predicts poor survival after 
lung cancer resection in stage I patients
Kim, Min P.; Chen, Ying; Khanna, Abha; Chen, Jie Q.; Bekele, B N.; 
Spitz, Margaret R.; Ji, Lin; Roth, Jack A.; Katz, Ruth L.
MD Anderson Cancer Center, Houston, TX, USA
Background: Activating enhancer-binding protein-2β (AP2β) is a 
nuclear transcription factor that regulates human telomerase reverse 
transcriptase (hTERT) expression. AP2β is found in normal lung 
tissue and in non-small cell carcinoma (NSCLC). It was recently 
shown that up regulation of AP2β leads to up regulation of telomer-
ase expression through interaction with the hTERT promoter while 
down regulation of AP2β inhibits both telomerase activity and tumor 
cell growth. 
Methods: Immunohistochemistry staining (IHC) for AP2β was 
performed on tissue microarrays prepared from resected NSCLC 
from 192 patients with either squamous cell carcinoma (n=63) or 
adenocarcinoma (n=129). There were two distinct patterns of stain-
ing: diffuse nuclear staining characterized by diffuse staining of the 
nucleus with absent nucleoli, and nucleolar staining characterized by 
staining of several small nucleoli or a single large macronucleolus, 
with or without diffuse nuclear staining. IHC scoring was based on 
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percentage of stained nuclei and/or nucleoli multiplied by intensity of 
stain (from 1 to 4). The array patterns, IHC score and histology were 
correlated with prospectively collected clinical data. 
Results: The average age of the group was 66 years-old with 49% 
males and 51% females. Most of the patients had stage I (n=126) 
disease. By histology, the majority of tumors were moderately (n=85) 
or poorly (n=82) differentiated. Among the patients with adenocarcin-
oma, there were 16 patients (12%) with bronchioalveolar features. 
There were 22 patients who never smoked. The IHC score did not 
correlate with the stage, tumor differentiation or histology. There 
were more patients with nucleolar staining (n=143) compared to 
diffuse nuclear staining (n=49). There was no significant difference 
in age, gender, histology or stage between the two groups. How-
ever, diffuse nuclear staining was correlated with well differentiated 
carcinoma while nucleolar staining was correlated with poorly dif-
ferentiated carcinoma (p=0.038). The size of the tumor was signifi-
cantly smaller in the diffuse nuclear staining group compared to the 
nucleolar staining group (p=0.008). In addition, in the patients with 
adenocarcinoma, there were significantly more patients with bron-
chioalveolar features with the diffuse nuclear pattern compared to the 
nucleolar pattern (p=0.023). Moreover, patients who never smoked 
were more likely to have diffuse pattern compared to the nucleolar 
pattern (p=0.008). The histologically normal lung tissue adjacent 
to the tumor showed a diffuse pattern of AP2β staining irrespective 
of the AP2β staining pattern of the tumor. In stage I, patients with a 
nucleolar pattern (n=90) had a significantly worse five-year survival 
(67%) compared to patients with the diffuse nuclear pattern (n=36, 
86%) (p=0.027).
Conclusion: Activating enhancer-binding protein β is found in both 
adjacent histologically normal lung tissue and lung cancer. In the 
adjacent lung tissues, AP2β is in the nucleus and not located in the 
nucleoli. In the cancer cells, AP2β may be in the nucleus or in the 
nucleoli. The presence of the protein in the nucleoli correlated with 
factors that are typically thought of as predictors of poor outcome, 
such as being a smoker, lack of bronchioalveolar features, poorly 
differentiated tumor and larger size of the tumor. Furthermore, the 
patients with AP2β in the nucleoli had significantly worse survival. 
This information may be useful in determining the group of stage I 
patients who have more aggressive tumors.
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Expression of thymidylate synthase (TYMS) and Insulin 
growth factor 1 (IGF1) in completely-resected NSCLC 
patients: associations with histological subtype and 
prognosis
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The search for biological markers associated with prognosis and 
response to therapy has become an important research subject in thor-
acic oncology. We have investigated the relation between expression 
of thymidylate synthase (TYMS) and Insulin Growth Factor 1 (IGF1) 
and histological subtype and survival in a series of patients with Non-
Small-Cell Lung Cancer (NSCLC) Stage I and II, who underwent 
complete surgical resection. 
Previously determined microarray-based full-genome gene expres-
sion data of NSCLC tumor samples (1) was analyzed for expression 
levels of TYMS and IGF1. The sample cohort included 92 squamous 
cell carcinomas (SCC) and 56 adenocarcinomas (AC).
Expression levels of TYMS were significantly different between SCC 
and AC (p=0.03) with higher levels in SCC samples. For IGF1, the 
pattern was reversed with significantly (p=0.05) higher expression 
levels in adenocarcinomas. Classification of the NSCLC samples by 
high and low expression (i.e. above or below median levels) indicated 
a significantly better survival of patients with high IGF1 levels with a 
HR of 2.02 (p=0.025). Classification by TYMS showed no differ-
ences in survival (HR 0.98).
While confirming the observation by others that TYMS expression is 
significantly lower in AC than in SCC, we did not find TYMS expres-
sion to be related to prognosis of patients with completely resected 
NSCLC. IGF1 expression is the highest in AC and high expression 
levels are associated with longer survival. Expression of TYMS and 
IGF1 will be a guide to tailored treatment choices.
1. Roepman P. et al, Clin Cancer Res 2009;15(1);284-290 
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Insulin-like growth factor binding proteins and response 
in advanced non-small cell lung cancer (NSCLC) patients 
treated with erlotinib
Fidler, Mary J.; Gimelfarb, Alla; Dehghan-Paz, Irene; Basu, Sanjib; 
Fhied, Christina; Kaiser-Walters, Kelly A.; Farlow, Erin C.; Rouhi, 
Omid; Batus, Marta; Coon, John S.; Bonomi, Philip; Borgia, Jeffrey A.
Rush University Medical Center, Chicago, IL, USA
Background: Expression of the insulin-like growth factor recep-
tor (IGFR) pathway in NSCLC has recently been associated with 
advanced disease and the IGFR pathway has been proposed as one of 
the possible mechanisms for epidermal growth factor receptor tyro-
sine kinase inhibitor (EGFR-TKI) resistance. Recent retrospective 
tissue analyses show counterintuitive results with prolonged progres-
sion free survival (PFS) on gefitinib in advanced NSCLC patients 
with insulin-like growth factor (IGF) receptor expression (Cappuzzo 
et al 2006, Fidler et al 2008). This study examines levels of IGF and 
IGF binding proteins (BP) in prospectively collected serum samples 
of advanced NSCLC patients prior to initiation of erlotinib therapy.
Methods: Luminex-based immunoassays were used to measure 
circulating levels of IGF and IGFBPs 1-7 in serum prospectively 
collected from advanced NSCLC patients before the initiation of 
erlotinib therapy. Patients were classified as erlotinib non-responders 
(progression free survival (PFS) <2 months), and erlotinib responders 
(PFS > 6 months). Data was analyzed using log rank and Mann-Whit-
ney two sided rank sum test in SPSS v15.0.
Results: 75 patients were enrolled. 16 patients were not included 
in analyses due to concurrent anti-angiogenic therapy, incomplete 
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follow-up, and discontinuation of erlotinib for reasons unrelated 
to disease progression. Of the remaining, 34 were erlotinib non-
responders, 13 erlotinib responders, and 12 patients on erlotinib from 
2 to 4 months. 8 patients died within 30 days of beginning erlotinib 
therapy. 34 patients had adenocarcinoma, 35 were women, and there 
were 7 never smokers though smoking history was not available on 
all patients. Low levels of all seven IGFBPs were significantly as-
sociated with prolonged progression free survival (PFS) with p values 
<0.05. Shortened overall survival (OS) and death within 30 days of 
starting erlotinib were strongly associated with high IGFBP-1, 2, 4, 5 
(OS log-rank p<0.0093, p<0.0018, p<0.0021, p<0.0145 and Mann-
Whitney p=0.006, p=0.017, p=0.007, p=0.023 respectively). 
Conclusions: These preliminary results support the role of the IGFR 
pathway as a mechanism for resistance to erlotinib therapy through 
IGFBPs. Low levels of IGFBPs are associated with improved surviv-
al in this prospective analysis of erlotinib treated advanced NSCLC 
patients. Further studies of IGFBPs in NSCLC patients receiving 
erlotinib are warranted and validation studies are planned.
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Prognostic role of insulin-like growth factor receptor-1 
(IGFR-1) and insulin-like growth factor binding protein-3 
(IGFBP-3) expression in small cell lung cancer 
Chang, Myung Hee; Kim, Kyoung Ha; Jun, Hyun Jung; Kim, Hyo 
Song; Lee, Jeeyun; Park, Yeon Hee; Ahn, Jin Seok; Ahn, Myung-ju; 
Park, Keunchil
Division of Hematology/Oncology, Department of Medicine, 
Samsung Medical Center, Seoul, Korea
Background: Insulin-like growth factor receptor-1 (IGFR-1) is a 
cellular membrane receptor overexpressed in many tumor cell lines 
and in some human tumors that seems to play a critical role in anti-
apoptosis by enhancing cell survival. Also, insulin-like growth factor 
binding protein-3 (IGFBP-3) was reported to be a growth suppressor 
in variable pathways. Purpose of this study was to evaluate the state 
IGFR-1 and IGFBP-3 expression in patients with small cell lung 
cancer (SCLC) and its prognostic value.
Methods: We analyzed IGFR-1 and IGFBP-3 expression in 194 
SCLC tissues specimens by immunohistochemical stain. The rela-
tionship between IGFR-1 and IGFBP-3 expression and cliniopatho-
logical factors was evaluated. Univariate and multivariate analyses 
were performed to define its prognostic significance.
Results: Median age was 63 years (range 38-85), 84% were men. 
One hundred-seventeen patients had extensive disease (60.3%), and 
77 had limited disease (39.7%). With the median follow- up duration 
of 49.5 months (24-82), the median progression free survival (PFS) 
and overall survival (OS) were 8 months (95% CI: 7.3-8.7 months), 
and 14.4 months (95% CI: 12.7-16 months), respectively, The IGFR-
1 expression was observed in 154 of 190 tumor tissues (79.4%), 
whereas there was no tissue stained by IGFBP-3. Multivariate an-
alysis showed that stage (p<0.001), response to treatment (p<0.001), 
LDH level (p<0.001) were the independent prognostic factors for 
PFS, and age (p=0.014), LDH level (p<0.001), and stage (p<0.001) 
for OS. The IGFR-1 positivity was not associated with PFS or OS in 
the whole cohort. However, 84% of 115 extensive disease patients 
showed IGFR-1 positivity. The subgroup analysis revealed that OS 
was significantly longer for patients with IGFR-1 positive compared 
to those with IGFR-1 negative in extensive disease (11.3% vs 0% at 
2year, p=0.034).
Conclusion: These results suggest that IGFR-1 expression may be 
useful as a prognostic marker in patients with extensive disease of 
SCLC. 
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Polymorphisms in the caspase genes and survival of early 
stage non-small cell lung cancer
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Purpose: This study was conducted to investigate the impact of 
potentially functional polymorphisms in the CASPASE (CASP) genes 
on the survival of early stage non-small cell lung cancer (NSCLC) 
patients.
Experimental Design: We conducted a two-stage study to evalu-
ate the association of polymorphisms in the CASP-3, -7, -8, -9, -10 
genes with survival outcomes of patients. In stage 1, nine polymorph-
isms were genotyped in 205 cases. Promising polymorphisms were 
selected for stage 2 evaluation and genotyped in an additional set of 
206 cases. The genotype associations with overall survival (OS) and 
disease-free survival (DFS) were analyzed using Cox proportional 
hazards model, Kaplan-Meier method and the log-rank test. 
Results: Two polymorphisms (CASP7 rs2227310 and CASP9 
rs4645981) had consistent results between two stages of the study. 
In combined analysis, the rs2227310C>G exhibited a worse OS 
(adjusted Hazard ratio [aHR] = 1.62, 95% CI = 1.15-2.27, P = 0.006) 
and DFS (aHR = 1.57, 95% CI = 1.15-2.14, P = 0.005) under a 
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recessive model. The rs4645981C>T had also significant effect on 
OS and DFS under a recessive model (aHR for OS = 1.87, 95% CI = 
1.02-3.65, P = 0.04; and aHR for DFS = 2.59, 95% CI = 1.49-4.51, 
P = 0.0008). When the rs2227310 and rs4645981 genotypes were 
combined, patients with one or two bad genotypes had a worse OS 
and DFS compared with those with zero bad genotype (aHR for OS 
= 1.75, 95% CI = 1.26-2.44, P = 0.0009; and aHR for DFS = 1.70, 
95% CI = 1.26-2.30, P = 0.0006). CASP9 mRNA expression in lung 
tissues was significantly correlated with the rs4645981 genotypes.
Conclusion: The CASP7 rs2227310 and CASP9 rs4645981 poly-
morphisms may affect survival in early-stage NSCLC. The analysis 
of these two polymorphisms can help identify patients at high risk of 
a poor disease outcome.
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Prediction platin-based chemotherapy severe toxicity 
in non-small cell lung cancer patients from XPD 
polymorphisms detection
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Shen, Jie 1; Zhong, Yu 2; Qiao, Rong 1
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Background: chemotherapeutic treatment is widely associated with 
dose-limiting toxicity which may reduce quality of life for patients. 
Toxicity has presented a challenge in the care of cancer patients. 
Better predictive methods are needed for the selection of patients who 
tend to experience severe toxicity during the therapy course. Assess-
ing germ-line genetic polymorphisms as either prognostic or predict-
ive markers has much appeal especially in the setting of advanced 
NSCLC where tumor tissues are rarely available XPD play key roles 
in the repair of DNA cross linking and adducts, especially in patents 
who had platin-based chemotherapy. 
Objective: Genetic polymorphisms of XPD may lead to different 
capacity to remove the deleterious DNA lesions in normal tissue and 
platin-based chemotheapy-related toxicity. In this study three single 
nucleotide polymorphisms (SNP) of XPD gene (in codons 156, 312, 
and 711) were investigated 
Methods: We evaluated the association between three polymorph-
isms of XPD at codons 156,312, and 711 and the occurrence of grade 
3 or 4 toxicity in 209 stage IIIB and IV non-small cell lung cancer 
patients treated with platinum-based chemotherapy. 
Blood samples were collected from all study subjects at the time 
of recruitment. Then the genomic DNA was prepared from periph-
eral leukocytes using QIAamp DNA Maxi Kit. SNPs were typed 
using iPLEX™ chemistry on a MALDI-TOF Mass Spectrometer. 
PCR reactions were carried out in standard 384-well plates, The 
samples were then manually desalted by using 6 mg of clean resin 
and a dimple plate and subsequently transferred to a 384-well 
SpectroCHIP(Sequenom Inc.) using a nanodispenser. Mass spectra 
was acquired by Compact Mass Spectrometer and analysed by Mas-
sARRAY® Typer 3.4 Software.
Results: The variant homozygotes of XPD C156A polymorphism are 
associated with a significantly increased risk of grade 3 or 4 hema-
tologic toxicity [adjusted odds ratios (OR) = 3.24, 95% confidence 
interval (CI) = 1.35-7.78, P=0.009], and overall toxicity (adjusted 
OR = 2.31, 95% CI = 1.05-5.11, P=0.038). No statistically significant 
association was found for the three polymorphisms and grade 3 or 
4 gastrointestinal toxicity. Haplotype CG (in the order of C156A- 
G312A) reduced the risk of grade 3 or 4 hematologic toxicity 
(P=0.026).
Conclusions: We conclude that XPD C156A polymorphism might 
be an important marker in the prediction of severe toxicity among 
platinum-treated non-small cell lung cancer patients.
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Polymorphisms of genes involved in platinum/gemcitabine 
(P/G)-based metabolism correlate with clinical response 
and toxicity in patients (pts) with advanced non-small cell 
lung cancer (NSCLC)
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Background: Selecting patients according to key genetic character-
istics may help to tailor chemotherapy and optimize the treatment 
in NSCLC. Genetic variations in drugs metabolism may affect the 
clinical response, toxicity and prognosis of NSCLC pts treated with 
P/G-based therapy.
Methods: We evaluated 8 single nucleotide polymorphisms (SNPs) 
of 6 genes (P53 Arg72Pro (G/C); XRCC3 Thr241Met (C/T); XPD 
Lys751Gln (A/C); ERCC1 Asn118Asn (C/T); CDA Lys27Gln (A/C), 
Ala70Thr (G/A), Thr145Thr (C/T) and RRM1 C524T) involved in 
P/G-based metabolism in a homogeneous population of pts with 
advanced NSCLC treated with this regimen. Genomic DNA was 
extracted from whole blood samples of pts using the QIAamp DNA 
estraction kit and automatically purified by Biorobot EZ1 (Qiagen). 
Polymorphisms were detected with TaqMan-probe based assays using 
the ABI PRISM 7300 instrument equipped with the Sequence Detec-
tion System version 2.0 software (Applied Biosystems, Foster City, 
CA). Association between SNPs and response, toxicity, progression 
free survival and overall survival was estimated using logistic regres-
sion model, the Kaplan-Meier method, the long-rank test and the Cox 
proportional hazard model.  
Results: We performed a retrospective analysis in 192 chemotherapy-
naїve pts (median age 63 years), including M/F:74/26%; stage IIIb/
IV:24/76%; Adeno/Squa/other Ca:42/27/31%; ECOG PS:0-1/2-
3:94/6%. Overall response rate was 32.3%, stable disease 25% and 
disease progression 42.7%. The CDA Thr145Thr T/T genotype sig-
nificantly correlated with poorer response (partial response in 23.1% 
of pts versus 42.3% and 34.6% in C/T and C/C genotypes, respective-
ly; p=0.03). The ERCC1 T/T genotype was significantly associated 
with hematological toxicity (G1-4) (p=0.05) compared to ERCC1 
C/C and C/T allele. The CDA Thr145Thr C/T genotype was signifi-
cantly associated with non-hematological toxicity (G3-4) (p=0.02) 
compared to CDA Thr145Thr C/C and T/T allele. The median overall 
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survival (OS) time and progression free survival (PFS) were 12.7 and 
4.7 months, respectively. None of the analyzed polymorphisms was 
related to PFS or OS.
Conclusions: These data suggest that genetic polymorphisms in the 
ERCC1 and CDA genes may modulate the toxicity and response to 
P/G-based therapy in pts with advanced NSCLC.
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Association of polymorphisms in AKT1 and EGFR with 
clinical outcome and toxicity in non-small cell lung cancer 
patients treated with gefitinib
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Background: EGFR mutations are strongly predictive of EGFR-
TKIs activity in non-small cell lung cancer (NSCLC), but resistance 
mechanisms are not completely understood. The interindividual vari-
ability in toxicity also points out to the need of novel pharmacogen-
etic markers to select patients before therapy. Therefore, we evaluated 
associations between EGFR and AKT1 polymorphisms and outcome/
toxicity in gefitinib-treated NSCLC patients. 
Methods: EGFR -191C/A and R497K, and AKT1-SNP3 and SNP4 
polymorphisms and EGFR and K-Ras mutations were assessed in 
DNA isolated from blood samples and/or paraffin-embedded tumor 
from 96 gefitinib-treated NSCLC patients. Univariate and multivari-
ate analyses compared genetic variants with clinical efficacy and 
toxicity using Fisher’s, log-rank test and Cox’s proportional hazards 
model. AKT1-SNP4 association with survival was also evaluated in 
127 chemotherapy-treated/gefitinib-naive NSCLC patients, while its 
relationship with AKT1 expression and gefitinib cytotoxicity was 
studied in 15 NSCLC cell lines.
Results: AKT1-SNP4 A/A genotype was associated with shorter 
time-to-progression (P=0.04) and survival (P=0.01). Multivariate an-
alyses and comparison with the gefitinib-untreated population under-
lined its predictive significance, while the in vitro studies showed its 
association with lower AKT1 mRNA levels and gefitinib resistance. 
In contrast, EGFR activating mutations were significantly correl-
ated with response, and longer TTP and OS, while both the EGFR 
-191C/A (P<0.001) and the EGFR R497K (P=0.01) polymorphisms 
were strongly associated with grade>1 diarrhea.
Conclusions: AKT1-SNP4 A/A genotype appears to be a marker of 
primary resistance, while EGFR -191 and EGFR-R497K polymorph-
isms are associated with gastrointestinal toxicity when using gefitinib 
in NSCLC patients, thus offering potential new tools for treatment 
optimization.
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Early detection of lung cancer in induced sputum using a 
new technique combining morphology and fluorescence in 
situ hybridization (FISH) 
Gottfried, Maya1; Zissin, Rivka1; Guber, Alexander1; Rona, Ronni1; 
Greif, Joel2; Pal, Boaz3; Kaplan, Tal3; Daniely, Michal3
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Background: Most patients with lung cancer (LC) are diagnosed at 
advanced stage. If detected early, about 60% of LC patients can be 
cured following surgical resection. Conventional diagnostic tech-
niques are usually unable to detect LC at early stage. Lung cancer 
has been proposed to reflect a field cancerization process. High-risk 
individuals for developing LC (e.g., heavy smokers) often exhibit 
lesions in their lungs such as bronchial metaplasia or dysplasia. Mo-
lecular and cellular examinations of lung tissue from smokers with 
or without LC demonstrate various types of genetic and epigenetic 
changes. These changes can be detected throughout the exposed lung. 
Recently, two biomarkers located at 3p22.1 and 10q22.3, were found 
to be altered by Fluorescence in situ hybridization (FISH) in early 
stage LC. We postulate that the combination of cytology and genetic 
analysis of these loci in bronchial cells isolated from induced sputum 
(IS) samples will enable early diagnosis of LC. 
Methods: We used an automated scanning station (Duet, BioView 
Ltd, Rehovot, Israel), allowing the analysis of the same slide under 
two different staining Methods: morphology and FISH. A total of 
55 IS samples were tested: 25 samples from patients with advanced 
LC, 19 samples from patients with stage I LC and 11 samples from 
high risk patient (i.e. heavy smokers). All high risk patients were 
screened by low-dose CT. Induction and processing of IS were done 
by conventional methods. Cells were stained in Papnicolaou (Sigma, 
St Louis, MO), scanned and analyzed for their morphology. Cells 
originated at the lower airways or the lungs were defined as “target 
cells”. Subsequently, slides were hybridized to a 3-color FISH mix-
ture containing home-brew probes for chromosomes 3p22.1, 10q22.3 
and a centromeric 10 probe. Then, target cells were relocated and 
analyzed by their FISH pattern. The cutoff for malignancy was 7% of 
cells showing abnormality at the tested chromosomal loci.
Results: Bronchial cells exfoliated from advancers and stage I LC 
patients showed genetic aberrations at significantly higher levels 
than high risk patients (14.15%, 10.72% and 6.83%, respectively). 
The level of genetic abnormalities was not correlated with smoking 
history (correlation = 0.1). 43/44 patients with LC were identified 
correctly by the combined analysis technique. 3/11 heavy smokers 
had a positive result while no suspicious lesions were found by CT in 
this population. 2/3 suspicious patients had borderline values (8.09% 
and 8.4%) and one was highly positive (20%). These patients will be 
evaluated again in 6 months. 
Conclusions: The combined analysis of morphology and FISH for 
chromosomes 3p22.1 and 10q22.3 in IS was found to be a highly 
sensitive. All patients with stage I disease were diagnosed success-
fully. The level of genetic abnormalities was not correlated with 
smoking history, suggesting they are directly related to the presence 
of cancer. Therefore, high risk patients with high with positive com-
bined analysis results should be followed up closely. The potential of 
this assay as a non-invasive test for early detection of LC in high-
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risk population will be further validated by enlarging the number of 
screened heavy smokers.
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Highly multiplexed SLaptamer-based proteomics 
technology discovers biomarkers in plasma for the 
detection of lung cancer
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Background: Lung cancer is the leading cause of cancer death in the 
United States and the world. There are no validated screening tests. 
CT scans are promising in this respect, but detect a large number 
of indeterminate nodules for which the decision between repeat CT 
scan and immediate biopsy can often be difficult. A blood test would 
potentially be useful for screening at risk populations or informing 
decisions on nodules detected on CT scan.
Methods: SLaptamers are DNA molecules that are selected for high 
affinity and very specific binding with extremely slow dissociation 
rates to target proteins through an iterative in vitro selection pro-
cedure termed SELEX. The long off-rates (>30min) of SLaptamers 
allow for highly selective multiplexed assays where several hundred 
plasma proteins can be detected simultaneously. Detection limits in 
the array-based assay reach sub-pM concentrations. A set of plasma 
samples from a group of individuals diagnosed with lung cancer and 
matching control groups of current and ex-smokers or never-smokers 
were evaluated using the aptamer array technology. Over 600 plasma 
proteins were measured in duplicate for each sample. Each measured 
analyte was tested for differential expression between the groups in 
order to identify potential lung cancer biomarkers.
Results: A significant number of differentially expressed analytes 
were observed between the lung cancer group and the smoker control 
group. The magnitude of differential expression for these potential 
biomarkers is significant using the AUC as a metric for differential 
expression. A Bayesian Classifier was constructed using a small set of 
these proteins, with an estimated sensitivity and specificity of 80% on 
the training set.
Conclusions: These results present the potential for early detection 
of lung cancer using the biomarkers and classifier discovered with the 
SLaptamer assay. Refinement and validation of these biomarkers are 
essential steps for advancing these discoveries to the clinic.
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Raman spectroscopy as an adjunct to autofluorescence 
bronchoscopy
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Background: Newton Laboratories Inc. and the Lahey Clinic 
Department of Pulmonary and Critical Care Medicine are currently 
conducting an NIH-sponsored clinical program to test the ability 
of an in vivo Raman spectroscopy probe to improve the specificity 
of Autofluorescence Bronchoscopy for the detection of CIS and 
premalignant bronchial lesions. Bronchial tissue autofluorescence, 
excited by 408 nm laser illumination and directly imaged, is typically 
reduced in areas of dysplasia. This detection method is highly sensi-
tive but specificity has been found to be lacking. Near-infrared light 
is only weakly absorbed by hemoglobin and can probe more deeply 
into the tissue. Measurements of near-IR fluorescence and Raman 
scattering may improve both sensitivity and specificity by providing 
an independent indicator of premalignant and early malignant chan-
ges in bronchial tissue.
Methods: The Raman probe is deployed through the biopsy chan-
nel of a PENTAX SAFE-3000 autofluorescence endoscope system 
(HOYA PENTAX HD, Tokyo, Japan) and is directed to suspect tissue 
sites by using the bronchoscope’s 408 nm illumination which remains 
on during the measurements. A footswitch initiates a 3-second, 830 
nm laser exposure and the storage of the resulting time-integrated 
near-IR fluorescence and Raman scattering spectra. Measurements 
are taken from three separate sites on the suspect lesion. Three separ-
ate measurements are then taken from sites on bronchial tissue that 
are visually judged to be normal. One or more biopsies are taken 
from the suspect lesion and are subsequently classified by pathology. 
Patients with known or suspected primary lung cancer who were to 
undergo flexible bronchoscopy were recruited for the study. Informed 
consent was obtained. The Lahey Clinic IRB approved the study.
Results: A preliminary data set of 22 normal and cancerous tis-
sue spectra from 4 patients has been characterized with Principal 
Component Analysis which identifies orthogonal functions which 
best describe the complete set. Each spectrum was characterized by 3 
parameters from fits with the first 3 principal components. A decision 
plane was visually identified within this 3-D parameter space which 
best separates the normal and cancerous data points as classified by 
pathology. The tissue fluorescence is larger than the Raman scattering 
in these spectra and the data set was analyzed both with and without 
subtracting individual estimates of the fluorescence from each spec-
trum. When the fluorescence estimates were removed to emphasize 
the Raman scattering the decision plane was able to separate all of 
the sites with verified cancers (7) both from the assumed normal sites 
(10) and from tissue sites which were near the cancers but which had 
no local biopsy results to verify their true state (5). When the total 
signal was analyzed, including fluorescence, a new decision plane 
gave similar results except for one false negative in which a cancer 
was classified as normal. This false negative was found to be due to 
high near-IR fluorescence from adjacent scar tissue.
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Conclusions: Raman spectroscopy can distinguish cancerous bron-
chial tissue from normal bronchial tissue with high sensitivity and 
specificity. To date, no false positive identifications of dysplasia have 
been made by the SAFE-3000 autofluorescence system.
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Cost effectiveness of automated 3D sputum cytology
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Background: The Lung Cell Evaluation Device (LuCED) employs 
a high-resolution 3D cell-by-cell analysis of sputum cells, making it 
possible to achieve test performance superior to 2D sputum cytol-
ogy. We estimated the cost-effectiveness ratio (CER) of a lung cancer 
screening protocol that uses LuCED as the primary test, combined 
with x-ray computed tomography (CT) as the secondary test. 
Methods: We developed a Monte-Carlo natural-history model, EL-
CID, to compute the costs and life-years saved over the course of 
15 years from initiation of the screening protocol. The hypothetical 
screening population consisted of high-risk current and former smok-
ers. We compared results for this population with (1) no screening, 
(2) x-ray CT screening, and (3) LuCED screening as the primary test, 
with x-ray CT as the secondary test. We applied multiple scenarios 
and a range of LuCED test accuracies. These scenarios were:
(A) The default scenario with lung cancer incidence of 0.6% annu-
ally;
(B) Faster disease progression;
(C) Slower disease progression;
(D) Higher background death rate, in which there is a greater chance 
of death from causes other than lung cancer;
(E) Lower lung cancer incidence (0.45% annually);
(F) Lowest lung cancer incidence (0.3% annually);
(G) Lower early-stage cure rate;
(H) Lowest early-stage cure rate. 
The model was validated by comparing the results with known 
benchmarks in the unscreened case, including five-year survival 
by stage at diagnosis, distribution by stage of detected cancers, and 
treatment cost by stage. We used a triage model in which detection of 
dysplasia led to increased testing frequency. We varied the sensitivity 
and specificity of the LuCED test for each scenario. 
Results: The CER depended on the performance of the LuCED test 
as well as on the parameters of each scenario. The highest CER’s 
were found for the scenarios characterized by a poor rate of early-
stage treatment success (G and H), lowest lung cancer incidence (F), 
or slower rates of disease progression (C). The CER remained close 
to the default value (A) for scenarios with fast disease progression 
(B), annual incidence of 0.45% or higher (E), or an elevated back-
ground death rate (D). The cumulative CER was evaluated for each 
year; for scenario A, the CER fell below $40,000 per life-year saved 
by year 10. After an initial spike in detected cancers, steady-state 
cost and life savings were reached within four years of screening 
implementation.
Conclusion: A screening protocol for high-risk patients that com-
bines LuCED sputum analysis with x-ray CT can be comparable in 
cost-effectiveness to biennial mammography screening.
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Low-dose spiral CT screen for lung cancer in patients with 
high family risk
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Background: Lung cancer is the leading cancer death all over the 
world. The incidence of nonsmoking related lung cancer is increasing 
rapidly in the past ten years. The family history of lung cancer was an 
important risk factor in the research, “Genetic epidemiological study 
of lung cancer in Taiwan and clinical application- Focusing on female 
lung adenocarcinoma (GEFLAC). So, we initiate the study to evalu-
ate the feasibility of lung cancer screening using low-dose spiral CT 
(LDCT) in lung cancer family.
Methods: The nonrandomized screen program enrolled asymptom-
atic volunteers from GEFLAC program and new family members of 
lung cancer. The enrolled criteria limited to family members having 
first-degree relatives of lung cancer patients or multiplex family 
members. The age should be 55 years or older, or greater than the 
lung cancer family patients if younger than 55 years. All subjects 
accepted into the screening program will be offered annual LDCT 
and chest X ray for successive three years and structured question-
naire for risk identification of lung cancer. The modified Early Lung 
Cancer Action Project (ELCAP) protocol was used as guidelines for 
diagnostic and follow-up investigation. Participants were recruited 
from six medical centers: Chang Gung Memorial Hospital, National 
Taiwan University Hospital, Taipei Veterans General Hospital, Tai-
chung Veterans General Hospital, National Cheng Kung University 
Hospital and Kaohsiung Medical University Memorial Hospital.
Results: 527 participants from 266 families of lung cancer were 
recruited in this project between August 2007 and December 2008. 
323 patients were from 175 simplex families and the other 204 came 
from 91 multiplex families. The mean age of participants was 60.21 
(±9.81 SD). 228 (43.2%) patients were male. Non-calcified nodules 
were detected in 210 (39.8%) participants by low-dose CT in the 
baseline screening. The diameters of the largest relevant nodules 
were 2-5 mm for 76 (36%) patients, 5-10 mm for 98 (47%) patients, 
10-15 mm for 17 (8%) patients and greater than 15 mm for 19 (9%) 
patients. Biopsies were performed on 19 patients. Ten had malignant 
nodules (nine adenocarcinomas and one atypical carcinoid tumor) 
and nine showed benign lesions. The mean size of cancer was 20.1 
mm, ranged from 16 to 34 mm. Four of ten malignant tumors were 
only detected in LDCT not seen in chest X ray. The CT morphologies 
in nine adenocarcinoma nodules were three solid, three part-solid and 
three non-solid patterns respectively. The seven of nine adenocarcin-
oma patients were female (78%). Four patients were stage I, one 
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was stage III and the other four belonged to stage IV. Among the ten 
cancer patients, nine (9/204; 4.4%) were from multiplex family and 
the other one (1/323; 0.3%) occurred in simplex family.
Conclusions: LDCT revealed high proportion of lung cancer amoung 
multiplex families in the baseline screen. High prevalence of non-
calcified nodules detected in this baseline screen needed closely 
monitoring in annual repeat examination.
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What have we learned from recent high profile reports 
of observational trials on computed tomography (CT) 
screening for lung cancer? Mortality, survival, curability, 
and measuring effectiveness in nonrandomized trials
Strauss, Gary M.1; Dominioni, Lorenzo2
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In October 2006, the International Early Lung Cancer Action 
Program (IELCAP) generated excitement by reporting that “an-
nual spiral CT screening can detect lung cancer that is curable” 
(NEJM,355;1763,2006). However, shortly thereafter Bach and 
colleagues reported that “screening…with low-dose CT…may not 
meaningfully reduce the risk of…death from lung cancer” (JAMA, 
297:953,2007). The question is which report provides more useful 
insights regarding the effectiveness of CT-screening. In IELCAP, 
31,567 current or former smokers underwent a prevalence CT, while 
27,456 had an incidence CT 7-18 months thereafter. With median 
follow-up of 3.3-years, CT-screening detected 484 lung cancers, 
including 405 (84%) prevalence, 74 (15%) incidence, and 5 (1%) 
interval cancers. Overall, 412/484 (85%) had stage I disease, and 
10-year survival was 80% (88% among stage I cases). Bach and col-
leagues reported a pooled analysis of 3,246 current/former smokers, 
participating in observational studies at Mayo Clinic, Moffit Cancer 
Center, or Milan, Italy (median follow-up=3.9 years). Comparisons 
of observed versus projected lung cancer event rates were estimated 
from logistic regression models derived from the Carotene and 
Retinol Efficacy Trial (CARET) and Alpha-Tocopherol, Beta-
Carotene (ATBC) Cancer Prevention Study. Bach reported that lung 
cancer incidence was >3-fold higher than expected (144-observed 
vs. 44.5-expected; RR=3.2; 95%-confidence interval=CI=2.7-3.6), 
while resection rate was 10-fold higher (95%-CI=8.2-11.9). Number 
of advanced cancers was similar (42-observed vs. 33.4-expected; 
RR=1.2), and lung cancer mortality was identical (38-observed vs. 
38.8 expected; RR=1.0; 95%-CI=0.7-1.3). Unquestionably, contra-
dictory and apparently irreconcilable conclusions relate to different 
endpoints. IELCAP reports survival, while Bach reports mortality 
utilizing a simulated control group. Since it is assumed that mortal-
ity provides an unbiased measure of screening effectiveness, while 
survival can be confounded by lead-time, length, and overdiagnosis 
biases, many have inferred that the Bach study provides the more 
valid assessment of the value of CT-screening. However, the ability 
of the mortality endpoint to provide an unbiased measure of screen-
ing effectiveness in randomized population trials (RPTs) has never 
been validated (Chest,127:1146,2005). Our conclusion is that neither 
of these observational studies provides an accurate measure of 
screening efficacy. The problem with IELCAP is that 84% of cases 
were previously unscreened prevalence cases. In the context of a 
prevalence screen, many more advanced cancers would be expected, 
limiting the generalizability of IELCAP results. While randomiza-
tion provides an opportunity to eliminate lead-time and length-biases 
(JCO:20:1973,2002), this is untrue in observational trials, where 
length-bias (and conceivably overdiagnosis) are particular concerns. 
In nonrandomized trials, such as I-ELCAP, survival cannot provide 
an unbiased measure of effectiveness. In the Bach analysis, the high 
rate of advanced cancer is not problematic, since it is expected in a 
prevalence-screen population. The detection of numerous advanced 
cancers predictably translates into relatively high lung cancer mortal-
ity. The problem is the assumption that 3-fold higher detection rates 
and 10-fold higher resectability predominantly reflects overdiagnosis. 
In reality, these observations likely reflect lead-time producing earlier 
diagnosis and treatment, precisely what must be accomplished if 
screening were to enhance curability. Reporting lung cancer mortality 
in an uncontrolled prevalence screen employing a simulated control 
group provides absolutely no useful insight on the true effectiveness 
of CT-screening. Indeed, an accurate measure of the effectiveness of 
CT-screening must await the results of ongoing RPTs. However, the 
question of how to best measure efficacy should remain the focus of 
study rather than supposition. Whether CT-screening will be appro-
priate for population-based screening remains to be determined. 
PD7.6.2 EEarly Detection, Chemoprevention, Prognostic and Predictive Markers, 
 Sun, 10:30 - 12:00
Quantitative analysis and mutation screening of plasma 
DNA in lung cancer patients and matched controls
Xue, Xiaoyan Y.; Teare, M D.; Woll, Penella J.
University of Sheffield, Sheffield, UK
Background: Plasma DNA concentrations are higher in cancer 
patients than controls and also demonstrate genetic alterations typical 
of the tumour. The analysis of plasma DNA is therefore of interest for 
diagnosis, prognosis and disease monitoring. Here, we assessed the 
association between plasma DNA concentration and oncogenic muta-
tions in lung cancer.
Methods: Lung cancer patients aged ≤60 or with a strong family his-
tory of lung cancer were recruited in the ReSoLuCENT study. Their 
partners and first-degree relatives were controls. They completed a 
detailed lifestyle questionnaire and gave a single blood sample. Plas-
ma DNA was purified using an efficient phenol extraction protocol 
and lymphocyte DNA was isolated using a QIAamp kit. Plasma DNA 
concentration was estimated using SYBR-Green fluorescence real-
time PCR for hGAPDH gene. Whole genome amplification of plasma 
DNA was performed before mutation screening. p53 (exon 4-9) and 
k-ras (exon 2&3) gene mutation screening was done by compar-
ing PCR-SSCP in plasma DNA and lymphocyte DNA. Suspicious 
samples were then cloned and sequenced. Mutations were confirmed 
by forward and reverse sequencing. 
Results: 45 lung cancer patients and 45 matched controls were 
included. Evaluable plasma DNA was obtained from 89/90 samples. 
The mean plasma DNA concentrations were 20.2 ng/ml for cases and 
7.2 ng/ml for the controls (p < 0.0001). There were no significant 
associations between plasma DNA concentration and gender, age, 
disease stage, histological subtype or survival. Smoking exposure 
(pack years) was higher in cases than controls (p=0.0003). There was 
a weak but significant correlation between smoking exposure and 
plasma DNA concentration in cases (p = 0.019, Pearson r = 0.35) but 
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not in controls. Interestingly, a significantly higher plasma DNA con-
centration was found in ex-smokers who quitted within 1 year before 
enrolment compared to current smokers (p = 0.012) and ex-smokers 
who quitted more than 1 year before enrolment (p = 0.018). P53 gene 
mutations were found in plasma DNA from 3 cases and 1 control 
(table). No k-ras mutations were detected in exons 2 & 3.
 ID Case/control Age Sex Pathology p53 exon Base Change Consequence
 R026 Lung cancer 60 2 Large cell 7 225 GGT > GCT Val > Ala
      7 252 CTC > CAC Leu > His
 R029 Control 34 2 Control 6 207 GAT > GGT Asp > Gly
 R030 Lung cancer 60 2 SCLC 5 131 AAC > AGC Asn > Ser
      7 261 AGT > GGT Ser > Gly
 R148 Lung cancer 38 1 SCLC 7 247 AAC > AGC Asn > Ser
Conclusions: We have confirmed that plasma DNA concentrations 
are higher in lung cancer patients than matched controls, but the 
size of difference is unlikely to be useful in diagnosis. Plasma DNA 
concentration is higher in patients developing lung cancer within 1 
year of quitting smoking. Whole gene amplification and SSCP offer 
a useful method for screening plasma DNA for oncogenic mutations. 
Specific genetic changes in plasma DNA may be useful in the diagno-
sis and monitoring of lung cancer patients. 
PD7.6.3 Early Detection, Chemoprevention, Prognostic and Predictive Markers, 
 Sun, 10:30 - 12:00
Correlation of baseline Ki67 expression with degree of 
atypia on rebiopsy in normal and dysplastic bronchial 
mucosa
Merrick, Daniel T.1; Lewis, Marina T.2; Franklin, Wilbur A.2; Miller, 
York E.1; Keith, Robert L.1; Kennedy, Tim C.2; Blatchford, Patrick2; 
Baron, Anna E.2; Chesnut, Partrick2; Hirsch, Fred R.2
1 Denver VAMC/University of Colorado Health Sciences Center, 
Denver, Colorado, USA; 2 University of Colorado Cancer Center, 
Denver, CO, USA
Background: Ki67 is a marker of cellular proliferation and its level 
of expression has been directly correlated with degree of atypia and 
level of EGFR expression in bronchial dysplasia. We hypothesized 
that bronchial sites for which follow-up biopsies had been collected 
would demonstrate an association between Ki67 expression levels 
and degree of histologic atypia in post-baseline biopsies.
Methods: 433 sites from 76 different subjects were analyzed. Percent 
of Ki67 positive cells in the baseline biopsy from each site were 
counted (200-400 cells total) on immunohistochemical stains of 
formalin fixed paraffin embedded tissue. Each site was assigned a 
histologic change score (HC) between -5 and +5, generated by sub-
tracting the histologic designation for the baseline biopsy from that at 
follow-up (numeric histologic designations were assigned as 1 - 6 for 
normal, basal cell hyperplasia, squamous metaplasia, mild, moderate 
and severe dysplasia respectively). Time interval for follow-up bi-
opsy ranged from 6 months to 5 years (85.9% had follow-up between 
0.5 – 2 years from baseline biopsy). Correlation between Ki67 levels 
and follow-up histology was calculated by least squares method for 
linear regression analysis of HC versus Ki67 percent positivity plots 
for each of the six baseline histology groups. All biopsies from sub-
jects with documented exposure to agents with suspected or known 
chemopreventive activity were excluded.
Results: Although there was great variability of Ki67 expression at 
each HC score within baseline groups, a direct correlation of Ki67 
expression levels with HC was demonstrated for sites with baseline 
non-dysplastic and mild dysplasia diagnoses (p-value, baseline group 
1-normal, p=0.047; 4-mild dysplasia, p=0.053). There was a positive 
relationship between HC and the amount of Ki67 positive cells at 
baseline biopsy for all groups except severe dysplasia. Mild dysplasia 
demonstrated the greatest rate of change (slope 3.25, Ki67% /unit 
HC). No relationship was found between baseline Ki67 expression or 
HC and tobacco status (current, former or never), pack year smoking 
history, age or gender.
Conclusions: A relationship between Ki67 expression level and risk 
for subsequent atypia is present for non- and mildly dysplastic bron-
chial epithelium but predictive capacity diminishes significantly with 
increasing baseline atypia. Given the variability of Ki67 levels within 
HC groups, utilization of Ki67 scores may be more informative in 
conjunction with other biomarkers for evaluation of chemoprevention 
efficacy and clinical risk assessment.
PD7.6.4 Early Detection, Chemoprevention, Prognostic and Predictive Markers, 
 Sun, 10:30 - 12:00
The use of aberrant gene methylation as a molecular 
marker for sputum cytology examination
Kondo, Kazuya1; Urakawa, Yuka 1; Idogawa, Asami 1; Ito, Kayoko 
1; Tsuji, Sai 1; Tominaga, Mana 1; Hirose, Yukiko 2; Toba, Hiroaki1; 
Nakagawa, Yasushi1; Takizawa, Hiromitsu1; Kenzaki, Koichiro1; 
Sakiyama, Shoji1; Tangoku, Akira1
1 University of Tokushima Graduate School, Tokushima, Japan; 2 
Shizuoka Cancer Center, Shizuoka, Japan
Background: Recently therapeutic and diagnostic tools, such as 
photodynamic therapy (PDT) and fluorescent bronchoscopy) for 
early lung cancer of the central bronchi have developed. However, 
screening test for detecting central type early lung cancers is only 
sputum cytology examination. Although the specificity of the sputum 
cytology examination is high, the sensitivity is low. The develop-
ment of the recent molecular biology demonstrated that the promoter 
hypermethylation of cancer-related genes is recognized as a major 
epigenetic event during lung cancer initiation and progression. This 
study evaluated whether detection of methylation of cancer-related 
genes in materials of sputum cytology examination has the potential 
to become more sensitive screening approach for the early detection 
of lung cancer or not
Material and Methods: Sputum samples from 67 patients were iden-
tified from the files of the Tokushima University Hospital between 
1987 and 2006. There are sputa from 54 patients with squamous cell 
lung carcinoma (22 sputa with class VI or V: group A, 32 sputa with 
classI or II: groupB) before surgery and 13 patients without lung 
carcinoma (group C). There was no significant difference of mean 
age and mean Brinkman Index among 3 groups. DNA was prepared 
from Papanicolaou’s atain materials. Genomic DNA was modified 
by treatment with sodium bisulfite using an EpiTect Bisulfite Kit. 
PCR amplification was performed with bisulfite-treated DNA, using 
specific primers for methylated and unmethylated forms of the DAP-
K, p-16 and MGMT genes. We performed a nested, two-stage PCR 
approach, which improved the sensitivity to detect methylated alleles.
Results: In DAP-K gene, methylation was detected in 36 % for group 
A, 16 % for group B and 18 % for group C. In MGMT gene, methyla-
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tion was detected in 32 % for group A, 19 % for group B and 8 % for 
group C. In p16 gene, methylation was detected in 0 % for group A, 
4 % for group B and 0 % for group C. In 3 genes, methylation was 
detected in 10 of 22 (46 %) for group A, 10 of 32 (31 %) for group 
B and 2 of 13 (15 %) for group C. The methylation specific PCR for 
sputum cytology can detect methylation in 31% of class I or II sputa 
from the patients with lung cancer, although it detects methylation in 
15% of sputa from the patients without lung cancer. In a nested PCR 
of the DAP-K gene, methylation was detected in 20 of 22 (91 %) for 
group A, 22 of 32 (69 %) for group B and 4 of 11 (36 %) for group 
C. The nested-PCR method can detect methylation in 69% of class 
I or II sputa from the patients with lung cancer, although it detects 
methylation in 36% of sputa from the patients without lung cancer.
Conclusions: The use of aberrant gene methylation as a molecular 
marker for sputum cytology examination seems to offer a potentially 
powerful approach to population-based screening for the detection of 
squamous cell lung cancer.
PD7.6.5 Early Detection, Chemoprevention, Prognostic and Predictive Markers, 
 Sun, 10:30 - 12:00
Genomic profiling for risk assessment of preneoplastic 
endobronchial lesions
Heideman, Danielle1; Reinen, Emilie1; Lee, Pyng2; Wilting, Saskia1; 
Thunnissen, Erik1; Kooi, Clarissa1; Ylstra, Bauke1; Meijer, Chris1; 
Sutedja, Thomas2; Postmus, Pieter2; Smit, Egbert2; Snijders, Peter1
1 VU University Medical Center; Department of Pathology, 
Amsterdam, Netherlands; 2 VU University Medical Center, 
Department of Pulmonary Diseases, Amsterdam, Netherlands
Background: Clinical tools have been invented that are sensitive 
for the detection of precancerous endobronchial lesions, including 
autofluorescence bronchoscopy (AFB). However, only a relative min-
ority of AFB-visualized lesions will progress towards more severe 
histological grades, thereby making AFB findings rather low specific. 
Histological assessment cannot reliably predict the clinical course of 
AFB-visualized lesions at presentation. Therefore, efforts should be 
made to identify novel biomarkers that allow distinguishing lesions 
that are potentially malignant and therefore need early intervention.
Aim: To determine the outcome of AFB-visualized precancerous le-
sions according to their chromosomal profile. 
Methods: Baseline endobronchial biopsies from AFB-suspicious 
locations of 31 patients at risk of lung cancer were subjected to 
maCGH (4x44K oligo array, Agilent). Patients underwent repeated 
AFB (medium follow-up of 13 months (range 3-46)), and were classi-
fied according to the clinical course of the AFB-visualized lesion into 
‘progressors’ (i.e., having progressive disease defined as an increase 
in histopathological severity by at least 2 grades at follow-up, n=12) 
and ‘non-progressors’ (i.e., having non-progressive disease defined 
as histologically stable or regression at follow-up, n=19). Of the 
progressors, 11 presented at baseline with an AFB-visualized lesion 
histologically classified as squamous metaplasia (SqM) and 1 with 
normal histology. Eighteen non-progressors had SqM at baseline and 
one moderate dysplasia. In addition, 43 non-small cell lung cancer 
(NSCLC) cases were subjected to maCGH analysis.
Results: Five out of 12 (45%) AFB-visualized baseline lesions of 
progressors had multiple chromosomal alterations (average percent-
age of altered features of 47.5%, range 25.9-58.1%), including gains 
at chromosome 1, 3, and 7, and losses at chromosome 3, 4, 6, and 9. 
These altered profiles clustered together with those obtained from 43 
lung carcinoma cases. Conversely, the remaining progressors as well 
as all non-progressors demonstrated rather ‘flat’ profiles (average of 
0.11% altered features, range 0-1.32%). A chosen cut-off of >1.51% 
altered features revealed a sensitivity of 45% and a specificity of 100% 
for progressive disease. Of note, the sensitivity increased to 71.5%, at 
the same specificity, when persistent progressive disease (defined as an 
increase in histological severity of at least two grades that persists at 
two consecutive bronchoscopies) was used as outcome measure.
Conclusions: This study identified an aberrant chromosomal profile 
associated with disease progression of AFB-suspicious lesions. Our 
results suggest that molecular analysis of endobronchial biopsies 
obtained by AFB may be a very useful means to discriminate patients 
with AFB-visualized lesions at highest risk of progressive disease 
who may benefit from immediate endobronchial treatment. 
PD7.6.6 Early Detection, Chemoprevention, Progn. & Pred.  Markers, Sun, 10:30 - 12:00
Diagnosis of non-small cell lung cancer from peripheral 
blood gene expression
Vachani, Anil1; Kossenkov, Andrew2; Rom, William N.3; Albelda, 
Steven M.1; Showe, Michael K.2; Showe, Louise C.2
1 University of Pennsylvania, Philadelphia, PA, USA; 2 Wistar 
Institute, Philadelphia, PA, USA; 3 New York University School of 
Medicine, New York, NY, USA
Background: CT screening results in the detection of lung nodules 
in 20-60% of subjects. This high false positive rate requires patients 
to undergo extensive follow-up investigations (e.g. serial CT, PET, 
biopsy). Thus, there is interest in the development of peripheral blood 
biomarkers that could be used with CT to improve diagnostic ac-
curacy. We evaluated whether PBMC (peripheral blood mononuclear 
cell) gene expression would differ between lung cancer cases and 
appropriately matched controls.
Methods: We conducted a cross-sectional study of 137 NSCLC cases 
and 91 controls. Subjects were similar in age, smoking status, race, 
and gender. 84% of the control group and 93% of the NSCLC group 
were either current or former smokers. PBMC RNA was amplified, 
labeled and hybridized to Illumina gene expression arrays. The data 
was analyzed using SVM (support vector machine) with recursive 
feature elimination and10-fold cross-validation. This yields a dis-
criminant score for each subject which is used for classification.
Results: We identified a 29-gene expression signature with yielded 
an overall classification accuracy of 86% (sensitivity of 91%, speci-
ficity of 79%). A ROC curve was generated by varying the cutoff of 
the discriminant score, resulting in an AUC of 0.92.
The signature was 100% accurate for patients with either Stage III or 
IV disease. The classifier was validated in two independent datasets. 
In the first, an independent group of 18 early stage NSCLC cases 
from Penn yielded a sensitivity of 78%. In the second, 17 subjects 
recruited at NYU were evaluated and included 12 Stage I NSCLC 
and 15 controls. The overall accuracy was 74% (sensitivity 67%, 
specificity 80%). 
Conclusions: PBMC gene expression can accurately distinguish lung 
cancer cases from controls. This may be useful for the evaluation of 
patients with lung nodules or for screening of high-risk populations.
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PD7.6.7 Early Detection, Chemoprevention, Progn. & Pred.  Markers, Sun, 10:30 - 12:00
MicroRNAs as biomarkers of NSCLC as measured by 
qRT-PCR in patients plasma
Shin, Kyeong-Cheol3, 2; Franklin, Wilbur A.3; Chesnut, Patrick3; 
Sugita, Michio3; Haney, Jerry3; Helfrich, Barbara3; Robinson, William 
A.3; Feser, William3; Wolf, Holly3; Miller, York3; Bemis, Lynne3
1 University of Colorado Denver School of Medicine, Aurora, CO, 
USA; 2 Department of Internal Medicine, College of Medicine, 
Yeungnam University, Daegu, Korea; 3 University of Colorado 
Cancer Center, University of Colorado Denver School of Medicine, 
Aurora, CO, USA
Background: Presentation at late stage is a determinant of high mor-
tality in lung cancer but to date no molecular markers have been iden-
tified that might permit earlier detection. A major problem in early 
detection biomarker development is that many molecular markers 
expressed by lung cancer patients are also highly expressed in heavy 
smokers (greater than 25 pack years). To address the problem of 
identifying lung cancer patients with early stage disease and to avoid 
a biomarker that identifies smoking history but is not specific for lung 
cancer we have interrogated MicroRNA microarray data from lung 
cancer cell lines to identify microRNAs that are highly expressed in 
lung cancer cells but are silent in normal bronchial cells. 
Methods: Candidate microRNAs were cloned into the TOPO TA 
plasmid vector (Invitrogen) to serve as standards in a qRT-PCR assay 
in which copy numbers for the candidate biomarker is normalized to 
the starting amount of total RNA in the cDNA reaction. Total RNA 
was isolated from 175 ul of frozen archival patient plasma and pro-
vided enough RNA to examine multiple microRNAs. We examined 3 
microRNAs in the plasma of 20 lung cancer patients and 20 smokers 
without lung cancer by qRT-PCR. 
Results: The qRT-PCR test for a single microRNA biomarker was 
highly sensitive and significant with 84% sensitivity and a specificity 
of 100%. The AUC at 95% C.I. is .961 for miR-221 and .972 for miR-
24. This pair of microRNAs are highly promising markers for distin-
guishing between lung cancer patients and smokers with dysplasia. 
Conclusions: From this initial set of patients we conclude that micro-
RNAs may provide robust biomarkers of lung cancer and are detect-
able in accessible fluids, including peripheral blood with minimal 
specimen preprocessing before testing. 
Session PD8: Combined Modality and Radiotherapy 
Monday, August 3
PD8.1.1 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
A randomised phase II study of two regimens of high dose 
palliative chemoradiation therapy in the management of 
locally advanced non-small cell lung cancer (TROG 03.07)
Michael, Michael 1; Burmeister, Bryan2; Burmeister, Elizabeth 2; 
Cox, Sharon2; Horwood, Keith 2; Wirth, Andrew1; Sasso, Guiseppe3; 
Forouzesh, Bahram3; Lehman, Margot2; Ball, David1
1 Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; 2 
Princess Alexandra Hospital, Brisbane, QLD, Australia; 3 Townsville 
Hospital, Townsville, QLD, Australia
Background: Patients (pts) with unresectable locally advanced 
NSCLC, not suitable for radical chemoradiotherapy (CRT), are usu-
ally treated with chemotherapy or low dose palliative radiotherapy 
alone. Two regimens of high dose palliative chemoradiotherapy 
(HDPCRT) had been developed in parallel for the treatment of 
such patients to improve local control and increase survival. Both 
regimens demonstrated promising efficacy and tolerance. The aim of 
this study was thus to directly compare in a randomised phase II trial, 
within the cooperative clinical trial group setting, the relative activity 
of these 2 regimens. 
Methods: Eligible pts included those who had locally advanced 
NSCLC requiring local control, not suitable for curative radical CRT 
on the basis of intra-thoracic disease extent, weigh loss > 10% or 
medical co-morbidities. Pts with solitary distant metastases detected 
only on FDG-PET were also eligible. Pts were required to have 
ECOG PS 0-1, adequate organ function and no prior therapy. Arm A: 
40Gy/20#s/5 per wk + Vinorelbine 25mg/m2 days 1, 8, 22 and Cis-
platin 20mg/m2 weekly. Arm B: 30Gy/15#s/5 per wk + Gemcitabine 
200mg weekly. Endpoints of the study included efficacy, feasibility, 
toxicity, survival and quality of life. 
Results: Eighty four patients were recruited and data from 79 pts 
was analysed. Arm A:Arm B = 40:39. Median age: 62 years (range 
40–85), Male:Female = 51:28. Adnocarcinoma:Squamous cell cancer 
= 33:18, Stage 3A/B = 42, Stage 4 = 25. Reason not suitable for rad-
ical CRT: Local disease extent = 27, Regional Nodal + Distant me-
tastasis = 31, Weight Loss + Concurrent illness = 15. Completion of 
planned HDPCRT Arm A versus Arm B; Radiotherapy 100%:100%, 
Chemotherapy 88%:94% (NS). Grade 3 toxicity 32%:7% (P = 0.006), 
mainly respiratory toxicities. Overall median survival 13.1 versus 8.1 
months (NS). No significant difference in progression-free survival 
(6.0 versus 5.2 mos.), response rates, distribution of sites of relapse or 
quality of life between the 2 arms. 
Conclusions: The combination of 40Gy and Vinorelbine and Cis-
platin produces superior median survival to a combination of 30Gy 
+ Gemcitabine in the HDPRT setting. This regimen will form the 
experimental arm of a phase III trial compared to palliative radiation 
alone in patients with locally advanced NSCLC who are unsuitable 
for radical chemoradiotherapy. 
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PD8.1.2 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
A phase III study of radiation therapy with concurrent 
docetaxel versus radiation therapy alone in patients with 
non-small cell lung cancer stage IIIA/B
Brunsvig, Paal F.1; Sundstrom, Stein .2; Aasebo, Ulf3; Bremnes, 
Roy4; Hansen, Olfred5; Helle, Svein I.6; Gronberg, Bjorn H.7; Ryberg, 
Marianne8; Soerensen, Bente T.9; Rytter, Carsten10, 9; Heikkila, 
Reino11; Aamdal, Steinar12
1 Norwegian Radium Hospital, Oslo, Norway; 2 Department of 
Oncology, St Olavs Hospital, Trondheim, Norway; 3 Department 
of Pulmonology, University Hospital of Northern Norway, Tromso, 
Norway; 4 Department of Oncology, University Hospital of Northern 
Norway, Tromso, Norway; 5 Department of Oncology, Odense 
University Hospital, Odense, Denmark; 6 Department of Oncology, 
Haukeland University Hospital, Bergen, Norway; 7 Department of 
Cancer Research and Molecular Medicine,Norwegian University 
of Science and Technology, Trondheim, Norway; 8 Department of 
Oncology, Herlev Hospital, University of Copenhagen, Copenhagen, 
Denmark; 9 Department of Oncology, Vejle Hospital, Vejle, Denmark; 
10 Department of Oncology, University Hospital of Aarhus, Aarhus, 
Denmark; 11 Department of Oncology, Stavanger University Hospital, 
Stavanger, Norway; 12 Department of Clinical Cancer Research, The 
Norwegian Radiumhospital, Oslo University Hospital, Oslo, Norway
Background: After completion of a phase I/II study with concurrent 
docetaxel and radiotherapy, we performed an international phase III 
study in patients with stage III NSCLC.
Methods: Eligible patients were those with locally advanced NSCLC 
stage IIIA/B not candidates for surgical resection, with ECOG PS 
0-2, weight loss < 10% last 6 months and tumor size less than 8 cm. 
Induction chemotherapy prior to radiation was optional according to 
institution policy. When induction chemotherapy was administered, 2 
courses of docetaxel 75mg/m2 and carboplatin AUC 6 at a 3-weekly 
interval was given. Patients were randomized to receive radiother-
apy (2 Gy x 30) with concurrent weekly docetaxel 20 mg/m2 (arm 
A) or radiotherapy alone (arm B). The study, planned to include 600 
patients in 5 years, was closed after including 249 patients due to 
slow accrual.
Results: Between April 2000 and July 2006, 249 patients (157 males 
and 92 females) were included. 157 patients (63%) received induc-
tion chemotherapy. 15 patients did not complete the scheduled treat-
ment, 13 patients (11%) in Arm A and two patients in arm B (2%). 
Survival was calculated from start of radiotherapy and was similar 
for the two arms, 14.1 months in arm A vs 14,9 months in arm B 
(p=0.47). Treatment with induction chemotherapy, female gender and 
favourable ECOG PS status were significantly positive prognostic 
factors in multivariate analysis. Dysphagia was the most prominent 
side effect with grade 3- 4 reported in 12% in arm A vs none in arm 
B (p<0.0001). There was no difference in local control at time of first 
relapse (p=.38). Brain metastases as first site of relapse were equal in 
the two treatment arms (17% in arm A vs 16% in arm B). 
Conclusion: Concurrent chemotherapy with weekly docetaxel 20 
mg/m2 and radiotherapy to 60 Gy was not superior to radiotherapy 
alone in patients with NSCLC stage IIIA/B. Dysphagia was signifi-
cantly more pronounced in the radio-chemotherapy arm.
This study was supported by an unrestricted grant from RPR (Sanofi–
Aventis)
PD8.1.3 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
Ongoing phase II study of pemetrexed plus carboplatin 
or cisplatin with concurrent radiation therapy followed 
by pemetrexed consolidation in patients with favorable-
prognosis inoperable stage IIIA/B non-small-cell lung 
cancer: interim safety update
Choy, Hak1; Schwartzberg, Lee2; Dakhil, Shaker R.3; Garon, 
Edward4; Choksi, Janak K.5; Govindan, Ramaswamy6; Sahoo, Tarini 
P.7; Peng, Guangbin8; Koustenis, Andrew8; Treat, Joseph8; Obasaju, 
Coleman8
1 University of Texas Southwestern, Dallas, TX, USA; 2 ACORN 
and West Clinic, Memphis, TN, USA; 3 Cancer Center of Kansas, 
Wellington, KS, USA; 4 UCLA/Translational Oncology Research 
International Network, Santa Monica, CA, USA; 5 Alamance 
Regional Medical Center, Burlington, NC, USA; 6 Washington 
University, Saint Louis, MO, USA; 7 Jawaharlal Nehru Cancer 
Hospital and Research Center, Bhopal, India; 8 Lilly USA, LLC, 
Indianapolis, IN, USA
Background: Concomitant chemoradiotherapy is current standard 
treatment for inoperable Stage IIIA/B non-small-cell lung cancer 
(NSCLC), but there is not consensus on a single accepted chemother-
apy regimen. Pemetrexed (P) is a multi-targeted antifolate that inhib-
its thymidylate synthase and interferes with the synthesis of pyrimi-
dines and purines. P is synergistic with carboplatin (Cb) and cisplatin 
(C) in clinical models, and these doublets have shown efficacy with a 
favorable toxicity profile in multiple Phase II/III trials. All three drugs 
have shown activity as radiosensitizers. The Phase I portion of this 
trial examined the combination of P with either Cb or C and concur-
rent radiation therapy (CRT), followed by consolidation with P. Based 
on the Phase I results of this trial and those of CALGB 30407, P 500 
mg/m2 every 21 days in combination with Cb AUC=5 or C 75 mg/m2 
with CRT is well tolerated, so these doses were chosen for evaluation 
in the Phase II portion of this trial.
Methods: Since June 2007, patients with inoperable Stage IIIA or 
IIIB NSCLC have been enrolled and randomized to receive either 
P 500 mg/m2 IV plus Cb AUC 5 IV every 21 days for three cycles 
(PCb) or P 500 mg/m2 IV plus C 75 mg/m2 IV every 21 days for three 
cycles (PC). Patients in both arms receive CRT 64–68 Gy (2 Gy/day, 
5 days/week, Days 1–45). Consolidation P 500 mg/m2 IV every 21 
days for 3 cycles is begun 3 weeks after completion of chemoradia-
tion. The primary endpoint of this ongoing trial is 2-year overall 
survival; secondary endpoints include toxicity, response rate, time to 
progression, and median survival.
Results: To date, 38 patients have been evaluated: 22 received PCb 
and 16 received PC. Average dose compliance (actual number of 
doses/expected number) for 32 of the subjects was 90.7% (P) and 
82.4% (Cb) in the PCb arm, 90.5% (P) and 83.3% (C) in the PC arm. 
Summary records for 16 patients indicate all received the planned 
CRT dose. Among 174 available CRT records from 21 patients, 
there were 15 dose interruptions in 8 patients due to patient decision, 
equipment failure, adverse events, or other reasons.
The most common hematological toxicities in both cohorts were 
anemia (22.7% and 18.8% in PCb and PC, respectively) and 
neutropenia (22.7% and 12.5%, respectively). The most common 
non-hematological toxicities in both cohorts were fatigue (36.4% and 
25.0%, respectively), constipation (27.3% and 31.3%, respectively), 
and nausea (22.7% and 25.0%, respectively). The most common 
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Grade 3/4 hematological toxicities were neutropenia (9.1% and 0% in 
PCb and PC, respectively), anemia (9.1% and 0%, respectively), and 
thrombocytopenia (9.1% and 0%, respectively). The most common 
Grade 3/4 non-hematological toxicities were hypokalemia (4.5% and 
12.5% in PCb and PC, respectively) and esophagitis (9.1% and 6.3%, 
respectively).
Conclusions: Overall, there was a low level of Grade 3 and 4 
esophagitis and other adverse events. Based on these results, it ap-
pears that P plus either Cb or C in combination with CRT is well 
tolerated as a treatment for locally advanced NSCLC. 
PD8.1.4 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
A prospective randomized study of adjuvant 
chemotherapy in completely resected stage III-N2 non-
small cell lung cancer
Zheng, Shi Ying; Jiang, Dong; Li, Hong
The First Affiliated Hospital of Suzhou University, Suzhou, China
Background: Since NSCLC cooperation group reported Meta-an-
alysis result that adiuvant chemotherapy could increase survival rate 
by 5%.To evaluate the effect of postoperative adjuvant chemotherapy 
on survival after complete resection of stage III-N2 non-small-cell 
lung cancer. From Jan. 2003 to Dec. 2007, a RCT were performed in 
150 patients with stage IIIA NSCLC postoperatively to investigate 
efficacy of adjuvant chemotherapy.
Methods: From Jan. 2003 to Dec. 2007, one-hundred and fifty pa-
tients, who were diagnosed as stage III-N2 non-small cell lung cancer 
after operation, were randomly divided into chemotherapy group and 
control group. The former received four cycles of chemotherapy with 
NVB (25 mg/m, D1, D5)/paclitaxel(175 mg/m, D1) and Carboplatin 
(AUC=5, D1).
Results: In chemotherapy group, 75.8% (68/79) of patients had 
finished the 4 cycles of chemotherapy and no one died of toxic effects 
of chemotherapy. Twenty-five percent of the Patients had grade 3-4 
neutropenia and 2% had febrle neutropenia. The median survival for 
the entire l50 patients was 879 d, with 1-year survival rate of 8 1%. 
2-year survival rate of 59% and 3-year survival rate of 43%. There 
was no significant difference in median survival between chemother-
apy and control group (897 d vs 821 d, P=0.0527), but there was sig-
nificant difference in the 1-year and 2-year overall survival (94.71%, 
76.28% vs 512 d, P=0.122), but there was significant difference in 
the 2-year survival rate between two groups with brain metastases 
(66.7% vs 37.6% P<0.05). The median survival after brain metastasis 
appeared was 190 days.
Conclusions: Postoperative adiuvant chemotherapy does not sig-
nificantlY improve median survival among patients with completely 
resected stage II-N2 non-small-cell lung cancer, but significantly im-
proves the 1-year and 2-year overall surviva1, It neither decreases the 
incidence of brain metastasis but put off the time of brain metastasis.
PD8.1.5 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
Phase II trial of cisplatin (C), etoposide (E), and radiation 
(RT) followed by gemcitabine (G) vs G and docetaxel (D) 
in stage III A/B unresectable non-small cell lung cancer 
(NSCLC)
Langer, Corey J.1; Movsas, Benjamin2; Ross, Helen J.3; Wang, 
Luhua4; Jotte, Robert6; Feigenberg, Steve7; Xu, Feng8; Huang, Chao9; 
Monberg, Matthew J.10; Obasaju, Coleman K.10
1 University of Pennsylvania, Philadelphia, PA, USA; 2 Henry Ford 
Health System, Detroit, MI, USA; 3 Mayo Clinic Arizona, Scottsdale, 
AZ, USA; 4 Cancer Hospital & Institute of CAMS and PUMC, 
Beijing, China; 5 US Oncology, Houston, TX, USA; 6 Rocky Mountain 
Cancer Center, Denver, CO, USA; 7 Fox Chase Cancer Center, 
Philadelphia, PA, USA; 8 West China Hospital, Sichuan University, 
Chengdu, China; 9 Kansas City VA Medical Center, Kansas City, MO, 
USA; 10 Lilly USA, Indianapolis, IN, USA
Background: Southwest Oncology Group (SWOG) 9504 demon-
strated the feasibility and potential benefit of D consolidation after C, 
E, and RT in patients with locally advanced NSCLC. This study as-
sessed consolidation with gemcitabine, either alone or in combination 
with D after identical chemoradiation as used in SWOG 9504.
Methods: The treatment schema included concurrent C 50 mg/m² 
Day 1, 8 + E 50 mg/m² Day 1-5 for two 28-day cycles + RT 61-62 
Gy once daily over 7 weeks. Thereafter, pts were randomized to 
consolidation with either G 1000 mg/m² Day 1, 8 (Arm A) or G 1000 
mg/m² Day 1, 8 + D 75 mg/m² Day 1 (Arm B) every 21 days for 3 
cycles. Eighty-three pts were registered and 64 were randomized to 
consolidation.
Results: 
 Characteristics/Results Induction Arm A Arm B
 No. of available pts 83 32 32
 Median age, yrs 59.0 59.5 59.5
 Male, n 66 27 26
 Female, n 17 5 6
 ECOG PS 0, n 32 11 13
 ECOG PS 1, n 51 21 19
 No. assessed for safety, Consolidation  32 32
 Neutropenia, Grade 3/4  22%/6% 28%/28%
 Febrile Neutropenia, Grade 3/4  0%/0% 0%/6%
 Thrombocytopenia, Grade 3/4  6%/0% 19%/0%
 Anemia, Grade 3/4  3%/0% 13%/6%
 Dyspnea, Grade 3/4  3%/0% 6%/6%
 Fatigue, Grade, 3/4   6%/0% 16%/0%
 Alopecia, Grade 2   3% 3%
 Esophagitis, Grade 3/4  0%/0% 0%/0%
 Pneumonitis, Grade 5  0% 3%
 Number of cycles of consolidation   
 One  6% 6%
 Two  3% 25%
 Three  91% 69%
 Response to Chemoradiation   
 No. assessed 83 32 32
 Complete response 1% 3% 0%
 Partial response 58% 56% 75%
 Stable disease 23% 41% 16%
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 Progressive disease 8% 0% 0%
 Unknown 10% 0% 9%
 No. progressed for PFS  27 24
 Median PFS, months  8.3 mo. 16.2 mo.
 (95% CI)  (5.4, 9.2) (7.6, 25.8)
 No. for survival  32 32
 Median follow-up for survival, months  34.8 mo. 35.4 mo.
 No. deaths for survival  20 18
 Median survival, months  19.1 mo. 32.8 mo.
 (95% CI)  (12.7, NR) (19.3, NR)
 1-year survival, % (95% CI)  75.0 (56.2, 86.6) 71.9 (52.9, 84.3)
 2-year survival, % (95% CI)  43.5 (26.2, 59.7) 58.9 (39.9, 73.7)
Conclusions: The median PFS of 16.2 months and median survival 
of 32.8 months associated with the doublet consolidation exceeds his-
toric results from SWOG 9504. G or G+D following chemoradiation 
in Stage IIIA/B NSCLC is reasonably well tolerated. The doublet, 
as expected, resulted in more toxicity, particularly myelosuppression 
and fatigue. Final results of this study will be available at the time of 
the meeting.
PD8.1.6 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
Early results of a phase I trial of the HIV protease 
inhibitor nelfinavir with concurrent chemoradiotherapy 
(CT-RT) for stage IIIA/IIIB NSCLC
Rengan, Ramesh1; Mick, Rosemarie1; Lin, Lilie L.1; Maity, Amit1; 
Gupta, Anjali K.2; Evans, Tracey L.1; Stevenson, James1; Langer, 
Corey J.1; Kucharczuk, John1; Friedberg, Joseph1; Prendergast, 
Susan1; Driesbaugh, Jason1; Hahn, Stephen M.1
1 University of Pennsylvania, Philadelphia, PA, USA; 2 University of 
Iowa, Iowa City, IA, USA
Background: Preclinical studies have shown that HIV protease 
inhibitors can radiosensitize cells in vitro and in vivo. (Gupta Cancer 
Res 2005). The objective of this Phase I trial was to determine 
dose-limiting nelfinavir related toxicities (DLTs) and the maximally 
tolerated dose of nelfinavir in combination with concurrent CT-RT in 
locally advanced non-small cell lung cancer (NSCLC).
Methods: Nelfinavir (doses 625mg PO BID, 1250mg PO BID) was 
administered for 7 to 14 days prior to and concurrently with con-
current CT-RT to patients (pts) with biopsy confirmed IIIA or IIIB 
inoperable NSCLC. Five pts were treated at 625mg PO BID; 7 pts 
were treated at 1250mg PO BID. Pts were treated with concurrent 
cisplatin 50 mg/m2 days 1 and 8, 29 and 36, etoposide 50 mg/m2 days 
1-5 and 29-33 with thoracic radiotherapy to a definitive dose of 6000-
6660 cGy in 180 cGy fractions. DLTs were defined as any treatment 
related Grade 4 hematologic toxicity requiring a break in therapy or 
non-hematologic Grade 3 or higher toxicity except esophagitis and 
pneumonitis. Patients were followed with CT or PET/CT scans at 
three month intervals after completion of treatment to monitor for 
recurrence. 
Results: 16 pts were enrolled and 12 pts were treated with nelfinavir 
and concurrent chemoradiotherapy. Two pts were excluded due to 
identification of metastatic disease during eligibility screening. One 
patient provided consent and then withdrew prior to initiation of 
Nelfinavir. One pt withdrew after 2 days of Nelfinavir prior to initiat-
ing CT-RT due to anxiety but was followed for DLT and is included 
in the toxicity analysis. No DLTs have been observed at either dose 
level. Two pts experienced grade 4 neutropenia at weeks 3 and 8. One 
pt experienced grade 4 thrombocytopenia at week 8. No other grade 4 
toxicities were observed. No dose limiting esophagitis or pneumonitis 
was observed. Median follow-up for survivors is 7.5 months (range 
3-17 months). Of the 12 patients who received treatment, 3 have 
died; 2 with distant progression, one without disease progression of a 
probable pulmonary embolus. One pt experienced local and regional 
progression at 9 months. The remaining 11 patients were locoregion-
ally controlled at the time of last follow-up or death. Three pts experi-
enced distant progression at 2, 4, and 8 months.
Conclusion: Nelfinavir administered with concurrent CT-RT at a 
dose of 1250mg PO BID is associated with acceptable toxicity in 
stage IIIA/IIIB NSCLC. With limited follow-up, these data suggest 
that Nelfinavir has promising activity in pts with locally advanced 
NSCLC without a dose-dependent increase in chemoradiotherapy-
associated toxicities.
PD8.2.1 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
Phase III study of concurrent chemotherapy and 
radiotherapy (CR) followed by surgery (S) vs. 
chemotherapy (C) followed by S for stage IIIA (pN2) non-
small cell lung cancer (NSCLC): results of prematurely 
terminated trial, WJTOG9903
Mitsudomi, Tetsuya1; Tada, Hirohito5; Katakami, Nobuyuki3; 
Nishimura, Yasumasa4; Kurata, Takayasu2; Tanaka, Masahiro5; 
Semba, Hiroshi6; Matsui, Kaoru7; Nakagawa, Kazuhiko4
1 Aichi Cancer Center Hospital, Nagoya, Japan; 2 Osaka Medical 
College, Takatsuki, Japan; 3 Kobe City Medical Center General 
Hospital, Kobe, Japan; 4 Kinki University School of Medicine, 
Osakasayama, Japan; 5 Osaka City General Hospital, Osaka, Japan; 
6 Kumamoto Regional Medical Center, Kumamoto, Japan; 7 Osaka 
Prefectural Medical Center for Respiratory and Allergic Diseases, 
Habikino, Japan
Background: To see whether addition of concurrent preoperative 
radiotherapy to induction chemotherapy followed by surgery would 
improve survival outcome for patients with stage IIIA NSCLC with 
mediastinal lymph node metastases (N2).
Methods: NSCLC patients with pathologically proven N2 disease 
were randomized either to receive induction chemotherapy (docetaxel 
60 mg/sqm and carboplatin AUC 5 x 2 cycles) plus concurrent 
radiotherapy (up to 40 Gy) (CRS) or only induction chemotherapy 
(CS). The patients subsequently underwent pulmonary resection if the 
tumor was judged resectable. Original sample size was 180 to detect 
a 20% survival difference (alpha=0.05) with a power of 0.8. The 
primary endpoint was overall survival.
Results: From Jan. 2001 through Dec. 2005, 60 patients were entered 
into the trial. However, because accrual of the patients was slow, the 
study was prematurely terminated in Jan. 2006. Two patients assigned 
to CRS were ineligible due to staging misconducts. Age ranged 
from 34 to 70 (median 57), and 66% of the patients were male. Two 
groups were well balanced in terms of age, sex, smoking status, T 
stage and operative procedures. However, distribution of squamous 
cell carcinoma /adenocarcinoma differed slightly between two groups 
(28%/55% for CS, 17%/72% for CRS). Induction therapy was well 
tolerated and there was no treatment-related death in both groups. 
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Neutropenia (grade 3≤) occurred in 75% and 89% and thrombo-
cytopenia (grade 3≤) in 0% and 7% for CS and CRS, respectively. 
Objective response rate was 25% for the both groups (CR/PR/SD/PD 
was 0%/25%/68%/7% for both groups). Surgical resection was per-
formed in 86% and 89%of the patients for CS and CRS, respectively. 
Progression-free and overall survival curves are shown below. Hazard 
ratios for PFS and OS were 0.68 (95% CI: 0.38-1.21) and 0.77 (95% 
CI: 0.42-1.41), respectively. Down staging was achieved in 21% for 
CS and 40% for CRS. Recurrent diseases at either hilar or medias-
tinal lymph nodes were observed in 58% for CS and 20% for CRS.
Conclusions: Both CS and CRS were well tolerated and safe. Addi-
tion of induction radiotherapy appeared to confer better local control 
without adding significant adverse events. However this good local 
control was not projected to statistically significant survival differ-
ence probably due to small number of patients.
PD8.2.2 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
Combined induction chemo/immunotherapy in the 
treatment of N2 non-small cell lung cancer
Ratto, Giovanni B.1; Costa, Roberta3; Maineri, Paola2; Alloisio, 
Antonella1; Piras, MariaTeresa1; Verna, Anna1; Lupi, Paolo2; Dozin, 
Beatrice4; Bruzzi, Paolo4; Melioli, Giovanni5
1 Unit Thoracic Surgery, Dept Surgical Oncology, Nat Cancer 
Research Inst, Genoa, Italy; 2 Unit Thoracic Surgery, Santa Corona 
Hospital, Pietra Ligure, Italy; 3 Dept Cardiothoracic Surgery, SS 
Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy; 4 
Unit Clinical Epidemiology, Dept Epidemiology and Prevention, Nat 
Cancer Research Inst, Genoa, Italy; 5 G. Gaslini Institute, Genoa, 
Italy
Background: The outcome of N2-NSCLC patients remaining poor, 
a number of new therapeutic approaches, including immunother-
apy, are presently under evaluation. Immunotherapy has been first 
investigated in the adjuvant setting. A randomized study from our 
group showed that adoptive immunotherapy with tumor-infiltrating 
lymphocytes (TIL) and interleukin-2 (rIL-2) significantly improves 
survival in resected patients with N2-NSCLC. Since then, the routine 
use of neo-adjuvant chemotherapy made “in vitro” expansion of 
TILs impossible. Thus, we planned a pilot study aimed to assess the 
feasibility, safety and potential usefulness of combined neo-adjuvant 
chemotherapy and immunotherapy with peripheral blood mono-
nuclear cells (PBMC) and rIL-2 in resectable N2-NSCLC patients.
Methods: During the study period (2002-2005), 82 consecutive 
patients with mediastinoscopically demonstrated N2-NSCLC under-
went 3 cycles of induction chemotherapy with cisplatin and gem-
citabine. Out of them, 23 patients accepted the combined treatment 
(Group A: chemo-immunotherapy), while the remaining 59 patients 
refused the experimental therapy (Group B: chemotherapy only) and 
their records were merely used for comparative purposes. In group 
A, patients underwent leukapheresis, before induction chemother-
apy. PBMC were in vitro cultured with rIL-2, stored frozen, and 
infused intravenously, after completion of induction chemotherapy 
(5 days before surgery). After the infusion, rIL-2 was administered 
subcutaneously (3 millions/sqm daily). Only patients with a partial or 
complete response to neo-adjuvant chemotherapy underwent surgery: 
13 patients in group A and 32 in group B, respectively. The mean 
follow-up was 3.7 years.
Results: The two groups were homogeneous for all major prognostic 
factors, except for “grading”, G3 being more frequent in group A (p= 
0.012). A complete mediastinal node response to induction therapy 
was seen in 6 patients of group A, and in 15 of group B. Leukapher-
esis had a good yield (median: 10 billion PBMC). After thawing, 2 
billion PBMC were infused. The phenotypic analysis showed that 
a variable proportion of CD4 and CD8 cells was present. A similar 
proportion was also observed in T lymphocytes isolated from the 
surgical specimen. No adverse reactions were observed following 
the infusions, and symptoms related to rIL-2 administration were 
easily managed. Post-operative complications were similar in the 
two groups. During the study period, 26 deaths had been recorded, 
6 (23.1%) in group A and 20 (76.9%) in group B. No significant dif-
ference in OS was seen between the two groups (p=0.184), although 
a trend to a better survival was seen in group A patients (cumulative 
OS at 5 years: 59%, 95% CI 56-62, in the study group; 32%, 95% CI 
29-35, in the control group). Cumulative EFS was similar for both 
groups, being 35% (95% CI 32-38) in group A and 25% (95% CI 23-
28) in group B, at 5 years. 
In multivariate analyses, after adjustment for major prognostic fac-
tors, a statistically significant 66% reduction in the hazard of death 
was associated with the combined treatment (HR = 0.34, 95% CI 
0.12-1.0; p=0.034). 
Conclusion: In patients with resectable N2-NSCLC, combined 
induction chemo-immunotherapy with PBMC and rIL-2 is feasible 
and safe. The combined neo-adjuvant treatment seems to reduce the 
hazard of death with respect to induction chemotherapy only. 
PD8.2.3 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
Pneumonectomy is not a risk factor in trimodality therapy 
for stage III NSCLC
Steger, Volker1; Walles, Thorsten1; Kosan, Bora1; Veit, Stefanie1; 
Walker, Tobias 2; Kyriss, Thomas1; Friedel, Godehard1
1 Department of Thoracic Surgery Schillerhoehe Hospital, Gerlingen, 
Germany; 2 Department of Cardiac, Thoracic and Vascular Surgery, 
Tuebingen University, Tuebingen, Germany
Objective: In stage III NSCLC there is still ongoing controversy 
about optimal therapy. Especially in neoadjuvant trimodal therapy 
some authors precludes patients in case of necessitating pneumonc-
tomy because mortality rates up to 30%. We analysed our experience 
with pneumonectomy after neoadjuvant chemoradiotherapy.
Method: Between 1989 and 5/2006 we did neoadjuvant therapy for 
stage III NSCLC in 152 patients.
From 1989 until 1998 protocol consisted of 2 cycles of platin based 
chemotherapy with sequential radiotherapy of 36 Gy, standard 
fractionation, in 47 patients. Since 1999 we did 6 cycles polychemo-
therapy and 45 Gy hyperfractionated accelerated radiotherapy in 96 
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patients. 7 patients had radiotherapy alone and 2 patients received 
only inductionchemotherapy without radiotherapy. Survival is 
calculated with Kaplan-Meier-Method and risk-factors for survival 
were analysed using univariate log-rank test. Factors analysed were 
pretherapeutic T-stage, N-stage, ypUICC0 stage, ypT-Stage, ypN-
Stage, and Pneumonectomy respectively.
Results: We had 82 T4, 33 T3, 32 T2, and 5 T1 Tu mors respect-
ively with N-stage of 95 mediastinoscopy positive pN2 or pN3, 18 
mediastinoscopy negative pN1/N0, 25 cN2/N3 and 24 cN0/1 and 5 
M1 patients with isolated brain metastases, curative treated before 
neoadjuvant therapy, resulting in 7 IIb, 47 IIIa, 93 IIIb and 5 IV 
UICC stage NSCLC.
There were 88 squamous cell carcinoma, 48 adenocarcinoma, 4 giant 
cell carcinoma, 2 small cell carcinoma, and 8 adenosquamous carcin-
oma respectively.
We did 66 lobectomy, 7 bilobectomy, 76 peumonectomy and 2 
explorative thoracotomy for 140 R0 and 12 R1 resections. After 
resection we saw 41 ypT0, 45 ypT1, 34 ypT2, 17 ypT3, and 13 ypT4 
respectively. ypN-Stage was 77 N0, 24 N1, 42 N2 and 7N3. We also 
had 10 patients with a seperat tumor in another lobe on the same site, 
presenting ypM1-stage UICC IV.
Hospitalmortality was 2.6% (4/152) and 120 day mortality was 6.6% 
(10/152). Comorbidity was 53.3%.
Overall mean and median survival was 60 and 31 months respect-
ively with 5-year survival rate of 37%. In case of ypT0, ypN0 and 
UICC0 mean and median survival rate were 85/136, 84/136 and 
100/136 months respectively.
 Variable p-value log-rank-test 5-year-survival-rate
 T-stage 0.771 
 N-stage 0.909 
 ypT0 0.004 55%
 ypT-stage <0.001 
 ypN0 < 0.001 56%
 ypN-stage 0.001 
 ypUICC0 < 0.001 71%
 pneumonectomy 0.984 
Conclusion: Trimodal therapy for stage III NSCLC offers remark-
able improvement of survival in selected patients. Pneumonectomy 
is not a risk factor for survival; therefore patients necessitating pneu-
monectomy should not be precluded surgery for R0 resection after 
neoadjuvant chemoradiotherapy.
PD8.2.4 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
Therapeutic efficacy of sub-lobar resection with 
absorbable mesh I-125 brachytherapy for early stage non-
small cell lung cancer (NSCLC)
Bryant, Curtis M.; Manning, Matthew; Burney, Patrick 
Moses Cone Health System, Greensboro, NC, USA
Background: For patients with early stage NSCLC and pulmonary 
dysfunction, there are a variety of emerging treatment options. Non-
invasive approaches such as stereotactic radiotherapy fail to provide 
pathologic staging and surgical tumor clearance. This study describes 
results from sub-lobar resection with brachytherapy (SLR-B) in a 
clinical series characterizing the overall survival, the progression 
free survival, and local control rates associated with this lung-sparing 
surgical approach. It also describes the acute and late complications 
of SLR-B.
Methods: Between 7/2006 and 2/2009, 74 consecutive patients with 
peripherally located clinical stage IA NSCLC based on PET-CT, 
underwent SLR-B. Intraoperatively, histology/margins were verified 
and lymph nodes were sampled. Then, I-125 seeds embedded in a 
vicryl mesh were applied to the site of resection to deliver a dose of 
100-120 Gy at a depth of 5 mm. Patients were restaged pathologically 
post surgery. The survival analysis was perfomed using Kaplan-Meier 
curves. 
Results: At surgery, 47/74 (64%) patients were confirmed to have 
stage IA disease and underwent SLR-B. The average FEV1 was 1.49. 
One and two year progression free survival for stage IA patients was 
92.6% and 84.5% respectively. Local control rates were 96.8% at two 
years. The most common sites of failure were regional and distant 
which accounted for 71% of recurrences with a median follow up of 
24 months. The relatively low overall survival at one (85.2%) and 
two (60.3%) years was governed by patient co-morbidities. Stage IB 
disease was discovered in 13/74 (17%). One year progression free 
survival for these patients was 87.5%. Acute complications occurred 
in 23.3% of those with stage IA and IB disease and the most common 
were post-operative pneumonia, atrial fibrillation and air leak which 
occurred in 4, 4, and 6 patients respectively. Late complications 
occurred in 4.1% with one patient each experiencing bronchopleural 
fistula, an air cavity and/or prolonged supplemental oxygen require-
ment.
Conclusions: For patients with Stage IA NSCLC and significant 
pulmonary dysfunction, SLR-B offers excellent local control rates 
and progression free survival. Acute complications occurred at 
comparable rates to lobectomy and late complications were rare even 
for patients with significant pulmonary dysfunction. Additionally, 
SLR-B led to the recognition of more advanced subclinical disease 
that would have been overlooked by non-invasive ablative techniques 
such as SRT. In a significant proportion of patients, this may alter 
subsequent treatment recommendations leading to superior survivals 
over non-invasive therapy.
PD8.2.5 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
Non-small cell lung carcinoma of the superior sulcus: 
the evolution of treatment outcomes with multimodality 
treatment at a single institution
Kometani, Takuro1; Tagawa, Tetsuzo1; Osoegawa, Atsushi1; 
Fukuyama, Sei-ichi1; Ondo, Kaoru1; Hirai, Fumihiko 1; Nosaki, 
Kaname1; Shinotoh, Makoto2; Seto, Takashi1; Sasaki, Tomonari2; 
Ichinose, Yukito1
1 Department of Thoracic Oncology, National Kyushu Cancer Center, 
Fukuoka, Japan; 2 Department of Radiation Oncology, National 
Kyushu Cancer Center, Fukuoka, Japan
Background: The management of non-small cell lung carcinoma of 
the superior sulcus has been developed over time with evolution of 
treatment strategy, and the concurrent chemoradiotherapy followed 
by surgery is currently regarded as optimal treatment for SS NSCLC. 
We introduced the multimodality treatment for SS NSCLC from late 
1980s. The aim of this study is to evaluate the role of multimodality 
approach for superior sulcus non-small cell lung carcinoma.
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Methods: We retrospectively analyzed the records of 57 patients 
with superior sulcus non-small cell lung carcinoma who were treated 
initially at our institution between 1982 and 2007. The median age 
was 61. There were 49 men and 8 women. To analyze time trends in 
outcomes for SS NSCLC, we reviewed our data by year from 1982 
to 2007 and divided the study period into a former half (1982-1994) 
and a latter half (1995-2007) era to evaluate the changes in outcomes 
over time.
Results: During the study period, 3- and 5-year survival increased 
significantly from 42.6% and 42.6% in the former half era (1982-
1994) to 72.7% and 65.4% in the latter half era (1995-2007), respect-
ively. Between two time periods, clinical staging unchanged, the 
ratio of adenocarcinoma was increased, and multimodality treatment, 
especially concurrent chemoradiotherapy followed by surgical resec-
tion was used more frequently. The 5-year survival of the patients 
who received preoperative chemoradiotherapy followed by surgery 
(n=27) was better than that of the patients who received other treat-
ments (64.6% vs 46.2%, p=0.025). Twenty four patients (89%) had 
complete resection after chemoradiotherapy. The 5- year survival in 
patients with complete resection after chemoradiotherapy was 70.4%. 
There were 13 patients who received a pathologic complete response 
or a minimal microscopic disease. 
Conclusions: Multimodality treatment with concurrent chemoradia-
tion followed by surgery seems to contribute to improved outcomes 
over time in patients with superior sulcus non-small cell lung carcin-
oma.
PD8.2.6 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
Docetaxel is not feasible as consolidation therapy after 
cisplatin/etoposide/ concurrent radiotherapy followed by 
surgical resection for pancoast tumors: preliminary results 
of SWOG 0220
Kraut, Michael J.1; Moon, James2; Thomas Jr, Charles R.3; Sonett, 
Joshua R.4; Jett, James R.5, 6; Rusch, Valerie W.7; Gillenwater, H8; 
Lyss, Alan9; Laurie, S10; Gandara, David R.11, 12
1 Providence Cancer Institute, Southfield, Mi, USA; 2 Southwest 
Oncology Group Statistical Office, Seattle, WA, USA; 3 OHSU Knight 
Cancer Institute, Portland, OR, USA; 4 Columbia University Medical 
Center, New York, NY, USA; 5 Mayo Clinic, Rochester, MN, USA; 6 
NCCTG, Rochester, MN, USA; 7 Memorial Sloan-Kettering Cancer 
Center, New York, NY, USA; 8 ECOG, Philadelphia, PA, USA; 9 
CALGB, Chicago, IL, USA; 10 NCIC, Toronto, ON, Canada; 11 UC 
Davis Cancer Center, Sacramento, CA, USA; 12 Southwest Oncology 
Group, Ann Arbor, MI, USA
Background: Our previous trial, SWOG 9416 (INT 0160) estab-
lished cisplatin/etoposide with concurrent thoracic RT followed by 
surgical resection as the standard of care for pancoast tumors (T3-4, 
N1-0 superior sulcus tumors). In that trial, of 111 enrolled patients 
(pts), of which 81 were resected, only 47 pts received 2 cycles of 
consolidation cisplatin/etoposide post-operatively as prescribed by 
the protocol (42% of all pts, 57% of resected). In the current trial, we 
tested the feasibility of giving 3 cycles of docetaxel as post-operative 
consolidation chemotherapy, based on the encouraging results of 
SWOG 9504.
Methods: Pts were required to have histologically-proven T3 or 
T4, N1 or N0, M0 non-small cell lung cancer of the superior sulcus 
(defined as an apical lung tumor with a) pancoast syndrome, or b) 
invasion of the chest wall, spine or subclavian vessels demonstrated 
by CT or MRI). Pts with malignant effusion were excluded. Medias-
tinoscopy was required if nodes were present in the mediastinum by 
CT, to rule out N2 disease. If the mediastinum was negative by CT, 
a negative 18FDG-PET in the mediastinum was sufficient. Induction 
therapy consisted of cisplatin 50 mg/m2 IV days 1, 8, 29,and 36, and 
etoposide 50mg/m2 IV days 1-5 and 29-33, given concurrently with 
thoracic RT, 45 Gy in 1.8 Gy fractions, beginning on day1. Patients 
that had stable disease, or complete or partial response, went on to 
surgical resection within 8 weeks after completion of induction. After 
recovery from surgery, all pts were to receive docetaxel 75 mg/m2 IV 
every 3 weeks for 3 doses.
Results: Forty-six pts were enrolled; one subsequently refused treat-
ment and is inevaluable. Of the 45 pts who underwent induction, 33 
pts had measurable disease by RECIST criteria. Of these, 10 achieved 
PR (response rate 30% [CI:16-49%]). One patient died during induc-
tion due to toxicity. Thirty pts underwent surgical resection; 2 of 
these died of ARDS post-operatively, and 2 additional pts experi-
enced grade 4 toxicity. Of the 45 evaluable pts, 21 completed 3 cycles 
of post-operative docetaxel (47% of all pts [CI:32-62%], 70% of 
resected pts). Though this represents an improvement over the previ-
ous trial, it failed to achieve the protocol-specified target of 67% (30 
of 45). No serious pulmonary toxicity has been reported secondary to 
consolidation docetaxel therapy. The survival data is not fully mature; 
1-yr PFS is 77%, 1-yr OS is 81%; 3-yr PFS and OS is 60% .
Conclusion: Docetaxel consolidation is not feasible in this group 
of patients. It is likely that no postoperative chemotherapy regimen 
will be tolerable in a high percentage of patients after such rigorous 
therapy. Early survival data support the efficacy of the core treatment 
regimen of induction chemoradiotherapy with cisplatin/etoposide fol-
lowed by surgical resection.
PD8.3.1 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
Identification of prognostic groups in patients (pts) with 
unresectable stage III non-small cell lung cancer (NSCLC) 
treated with chemoradiotherapy on Cancer and Leukemia 
and Group B trial (CALGB) 39801
Stinchcombe, Thomas E.1; Hodgson, Lydia2; Herndon II, James E.2; 
Kelley, Michael J.3; Cicchetti, M. Giulia 4; Ramnath, Nithya 5; Niell, 
Harvey 6; Atkins, James N.7; Akerley, Wallace 8; Green, Mark R.9; 
Vokes, Everett E.10
1 University of North Carolina at Chapel Hill, Chapel Hill, NC, 
USA; 2 CALGB Statistical Center, Duke University Medical Center, 
Durham, NC, USA; 3 Duke University Medical Center, Durham, NC, 
USA; 4 University of Massachusetts Medical School, Worcester, MA, 
USA; 5 Roswell Park Cancer Institute, Buffalo, NY, USA; 6 University 
of Tennessee, Memphis, TN, USA; 7 Wake Forest University School 
of Medicine, Winston-Salem, NC, USA; 8 Rhode Island Hospital, 
Providence, RI, USA; 9 Medical University of South Carolina, 
Charleston, SC, USA; 10 University of Chicago, Chicago, IL, USA
Background: CALGB 39801 was designed to test whether treatment 
with induction chemotherapy and concurrent chemoradiotherapy 
(arm B) would improve OS in comparison to identical chemoradio-
therapy alone (arm A), and demonstrated no significant benefit in OS 
for induction therapy. The objective of this analysis was to dichotom-
ize pts into prognostic groups using factors predictive of survival, 
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and to investigate if induction chemotherapy was beneficial in either 
prognostic group. 
Patients and Methods: Between July 1998 and May 2002, 331 pts 
were studied. A Cox proportional hazards model was used to assess 
the impact on survival of the following factors previously reported 
to be prognostic among patients who received combined modality 
therapy with stage III disease: age (≥ 70 vs. < 70 years), gender, race/
ethnicity, hemoglobin (hgb) (< 13 vs. ≥13), stage (IIIB vs. IIIIA), 
performance status (PS) (1 vs.0), pretreatment weight loss (wt loss) 
(≥5% vs. <5%), treatment arm, and weight loss and hgb interaction.
Results: Cox regression analysis identified weight loss ≥ 5%, age ≥ 
70, PS of 1, and hgb < 13 as predictive of worse survival (p<0.05). 
Treatment assignment was not significant (p=0.60). An interaction 
between weight loss and hgb was detected. The median survival for 
pts with 0 (n=66), 1 (n=100), 2 (n=100), or ≥ 3 (n=65) risk factors 
were 24, 18, 10, and 8 months, respectively (p=0.0001). The pts 
were dichotomized into “poor prognosis” (PP) defined as ≥2 factors 
(n=165) and “good prognosis” (GP) defined as ≤ 1 factor (n=166). 
The hazard ratio (HR) for overall survival for the PP in comparison 
GP was 1.88 (95% CI, 1.49 to 2.37; p-value < 0.0001); the median 
survival times (MST) observed were 9 and 18 months, respectively 
(p<0.0001). The 5-year OS rate observed of all patients was 11.8% 
(95% CI, 8.7 to 15.8%), and the 5-year OS rate observed of the PP 
and GP groups was 4.7% (95% CI, 2.3 to 9.4%) and 18.8% (95% CI, 
13.7 to 25.9%), respectively. 
The reasons for discontinuing treatment, and the rates of hematologic, 
non-hematologic adverse events and maximum toxicity were similar 
between the two groups. In the PP group the OS was similar between 
arms chemoradiotherapy (n=82) and induction chemotherapy and 
chemoradiotherapy (n=83) (HR=0.97, 95% CI, 0.70 to 1.4; p=0.34); 
MST of 8.7 and 9.5 months, respectively. In the GP the OS was 
similar between chemoradiotherapy (n=79) and induction chemother-
apy and chemoradiotherapy (n=87) (HR=0.86, 95% CI, 0.63 to 1.1; 
p=0.87); MST of 19.3 and 17.6 months, respectively. 
Conclusions: Factors predictive of OS can be used to dichotom-
ize pts into prognostic groups. There is no evidence that induction 
chemotherapy is beneficial in either prognostic group.
PD8.3.2 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
Impact of age on outcome and toxicity in patients treated 
aggressively with curative intent trimodality treatment for 
locally advanced non-small cell lung cancer (NSCLC)
Coate, Linda E.1; Ma, Clement1; Hope, Andrew J.1; Pierre, Andrew 
F.1; Bezjak, Andrea1; Brade, Anthony1; Darling, Gail1; Feld, Ronald1; 
Leighl, Natasha1; Sun, Alex1; Keshavjee, Shaf2; Shepherd, Frances 
A.1
1 Department of Medical Oncology, Princess Margaret Hospital, 
University Health Network, Toronto, ON, Canada; 2 Department of 
Thoracic Surgery, Princess Margaret Hospital and Toronto General 
Hospital, University Health Network, Toronto, ON, Canada
Introduction: Non-small cell lung cancer (NSCLC) is the leading 
cause of cancer death in the Western World. Trimodality therapy with 
surgery may be curative in stage III disease. There are few reports 
describing outcomes for elderly patients. In this retrospective review, 
we assess the effect of age on toxicity and outcome in patients treated 
with tri-modality therapy including surgery for Stage III NSCLC.
Methods: Following REB approval, charts of all patients in the UHN 
Cancer Registry with a diagnosis of Stage III NSCLC were exam-
ined. Patients treated with induction chemo-radiation followed by 
surgery with curative intent were identified. 
Results: Complete data were available for 104 patients (n= 78 <65y, 
26 >65y) treated from 1997-2006. There were 45 females and 59 
males, median age 60.4 years (range 16-80). Patients received a 
median of 45 Gy (18-70 Gy) delivered concurrently with cisplatin/
etoposide. All patients were planned for trimodality therapy although 
7 did not undergo surgery following induction chemo-radiation 
(n=5 <65, n=2 >65, p=NS). Of 97 patients undergoing operation, 
63 patients had lobectomy, 18 pneumonectomy and 16 extended 
lobectomy. Adjuvant chemotherapy was administered to only 59 
patients (n=47 <65, n=12 >65, p=NS). Median follow-up time is 2.97 
years (0.17-9.73). Overall five-year survival (OS) for all patients 
was 40%. When the cohort was dichotomized according to age (<65 
v. >65) there was no significant difference in OS between the two 
groups (HR 1.12 p=0.7); however there was a difference in dis-
ease free survival (DFS) with shorter DFS seen in younger patients 
(HR=0.46, p=0.06). Female sex predicted for better OS (HR 0.59, 
p=0.05), whereas weight loss >5% predicted for worse OS (HR 2.92, 
p=0.0004). There were no other significant baseline characteristics 
that were predictive of survival. There were no significant differences 
in rates of grade 3 or 4 toxicity between the age groups, with only 36 
patients experiencing Grade 3 or 4 toxicity during induction chemo-
radiation. However, there was a trend for patients >65 to experience 
more hematological toxicity (30.8 v. 21.8%, p=0.36), whereas the 
older age group experienced less non-hematological toxicity (11.5 v. 
20.5%, p=0.31). With respect to surgery, the median inpatient stay 
was 7.5 days (range 4-150); the median stay for patients <65 was 
7 days compared to 8 days for patients >65 (p=0.47). Patients who 
underwent lobectomy were less likely to experience toxicity than 
those undergoing pneumonectomy (OR 0.35, p=0.04). No patient 
within this cohort died within 30 days of operation. 
Conclusion: Trimodality therapy including surgery may be safely 
offered to carefully selected fit older patients with Stage III NSCLC.
Figure 1. Disease Free Survival (DFS) and Overall Survival (OS).
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PD8.3.3 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
The impact of extent and location of mediastinal lymph 
node (LN) involvement on survival of stage III non-small 
cell lung cancer (NSCLC) patients treated with definitive 
radiotherapy
Fernandes, Annemarie T.; Faerber, Jennifer; Lin, Lilie; Evans, 
Tracey; Stevenson, James; Langer, Corey; Eaby, Beth; Kucharczuk, 
John; Glatstein, Eli; Hahn, Stephen; Rengan, Ramesh
University of Pennsylvania, Philadelphia, PA, USA
Background: Surgical series have demonstrated that the extent and 
location of mediastinal LN involvement in NSCLC patients at the 
time of surgery impacts survival. These series show poorer survival 
outcomes in patients with subcarinal, contralateral and multi-level 
nodal involvement, presumably due to the difficulty in achieving 
complete surgical clearance of all mediastinal disease. The purpose 
of this study is to evaluate the impact of mediastinal LN involvement 
on survival in patients with stage III NSCLC treated with definitive 
radiotherapy.
Methods: For the purpose of this analysis, the mediastinal LN sta-
tions were divided into 5 regions: ipsilateral superior mediastinum 
(ISM), contralateral superior mediastinum (CSM), ipsilateral inferior 
mediastinum (IIM), contralateral inferior mediastinum (CIM) and 
subcarina. The inferior limit of the aortic arch separated the superior 
mediastinum from the inferior mediastinum. Mediastinal LN involve-
ment was defined as enlargement (>1cm on short axis) on CT scan, 
pathologic FDG avidity on PET scan or biopsy proven disease.
Results: A total of 98 consecutive pts with stage III NSCLC treated 
with definitive radiotherapy (RT) from January 2003 to August 2008 
were analyzed. Eighty-five percent of patients received chemother-
apy either sequentially or concurrently with RT using a platinum 
based regimen. The median follow-up time for all patients was 11.4 
months. The median RT dose was 6660cGy (5400cGy-8400cGy). 
Sixty percent of patients had multiple LN station involvement and 
26% of patients had only single station involvement. Lymph node 
involvement at the time of diagnosis was as follows: 59% ISM, 18% 
CSM, 50% IIM, 6% CIM and 35% subcarina. A multivariate analysis 
including each individual nodal region and multi-station disease vs. 
single station disease as co-variates was performed using survival 
as an endpoint. The hazard ratio (HR) for death for each lymph 
node station was as follows: ISM involvement (HR= 0.63; 95% CI: 
0.28-1.42), IIM involvement (HR=0.81; 95% CI: 0.35-1.89), CSM 
involvement (HR=0.44; 95% CI: 0.18-1.08), CIM involvement (HR= 
0.36; 95% CI: 0.098-1.30), subcarinal involvement (HR= 1.78; 95% 
CI:0.87-3.64), multiple node involvement compared to single node 
involvement (HR=0.96; 95% CI: 0.35- 2.64). 
Conclusions: In this series of patients treated with definitive radia-
tion, the extent and location of mediastinal LN involvement does not 
appear to have a significant impact on survival. These results differ 
from outcomes reported in surgical series. This suggests that survival 
after definitive RT is not as sensitive to location or extent of lymph 
node involvement as is observed in patients undergoing surgical 
resection. 
PD8.3.4 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
Gender differences in survival among lung cancer patients 
treated in radiation therapy oncology group (RTOG) trials
Siddiqui, Farzan1; Langer, Corey J.2; Bae, Kyounghwa3; Coyne, 
James2; Gamerman, Victoria 2; Bryan, Charlene2; Komaki, Ritsuko4; 
Choy, Hak5; Curran, Walter J.6; Watkins-Bruner, Deborah2; Movsas, 
Benjamin1
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USA; 3 Department of Statistics, RTOG, Philadelphia, PA, USA; 
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of Texas Southwestern Medical Center, Dallas, TX, USA; 6 Emory 
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Objective: This meta-analysis determined the influence of gender, 
race and marital status on overall survival (OS) in Radiation Therapy 
Oncology Group (RTOG) non-operative non-small cell lung cancer 
(NSCLC) trials. 
Material and Methods: Data from 1365 patients treated on 9 pro-
spective RTOG non-operative NSCLC studies activated during the 
1990’s were analyzed. The combination of the use of chemotherapy 
and accrual year was used to stratify the data. A heterogeneity test 
was performed by Chi-square test statistics and the pooled hazard 
ratio (HR) with weight of the inverse of variance of estimator was 
used. The impact of gender, marital status (married/partnered vs. 
single/divorced/widowed), and race (White vs. non-White) were the 
evaluated in the Cox proportional hazards models. Age, Karnofsky 
Performance Status (KPS), weight loss, stage, histology, location of 
primary tumor, biological equivalent dose, deviation from protocol 
dose, and education level were adjusted in the model. A two-sided 
p-value <0.05 was considered statistically significant.
Results: The metadata from 9 studies were homogeneous with re-
spect to the HRs of OS. Males had significantly higher mortality than 
females adjusted for other covariates (HR=1.23, 95% CI=1.1-1.4). 
However, race and marital status were not independently predictive 
for OS. White males (HR=1.25) and non-white males (HR=1.28) 
had significantly higher mortality than white females. Single males 
(HR=1.35) and married males (HR=1.23) had significantly lower 
OS than married females. Married white males (HR=1.23), single 
white males (HR=1.46), and married non-white males (HR=1.33) had 
significantly lower OS than married white females. 
Conclusion: These results suggest that while certain sub-groups (the 
combinations of gender, race and/or marital status) have better out-
comes regarding OS, gender appears to be the most significant factor 
driving OS results among non-operative NSCLC patients.
PD8.3.5 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
Patterns of failure comparison of two clinical studies 
using radiosensitizing taxanes with and without induction-
chemotherapy for stage III non-small cell lung cancer 
Chen, Yuhchyau1; Pandya, Kishan J.2; Anderson, Joy1; Smudzin, 
Therese1; Qazi, Raman2; Smith, Brian D.2; Watson, Thomas3; 
Johnstone, David W.4; Feins, Richard H.5
1 James P. Wilmot Cancer Center, University of Rochester Medical 
Center, Rochester, USA; 2 James P Wilmot Cancer Center, University 
of Rochester Medical Center, Medical Oncology, Rochester, NY, USA; 
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Medical Center, Div. of Cardiothoracic Surgery, Lebanon, NH, USA; 
5 University of North Carolina at Chapel Hill, Div. of Cardiothoracic 
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Background: Aggressive combination chemoradiation (CRT) treat-
ment is the current standard therapy for stage III non-small cell lung 
cancer (NSCLC), but both local and distant failure rates remain high. 
The 5-year survival rates are less than 25% in average. While distant 
failure results in poor survival, the local failure rates are as high as 
50% -85%. Uncontrolled local tumors can seed distant metastases. 
Taxanes remain favored chemotherapeutic agents for the treatment 
of NSCLC due to both the cytotoxic effect and the radiosenstitizing 
effect. We have applied pre-clinical studies of lung cancer cell lines 
in the response to paclitaxel and docetaxel and in the interaction with 
radiation to the design of two clinical studies for stage III NSCLC. 
The first study applied sensitizing paclitaxel CRT for stage III 
NSCLC, and a second phase II study was designed to target distant 
micrometastasis up-front by one-cycle induction chemotherapy of do-
cetaxel and cisplatin w/o the further delay of local therapy. Three to 6 
weeks after induction chemotherapy, low-dose sensitizing docetaxel 
(Doc) was applied to concurrent radiation treatment. We report the 
patterns of failure comparison of the two studies. 
Methods: The first study delivers low-dose paclitaxel 15 - 20 mg/m2 
three times per week (M,W,F), while daily RT was given 4 hrs later 
for cycle delay, using 1.8 Gy daily fractions to 64.5 Gy. The second 
study was conducted with one-cycle induction chemotherapy with 
docetaxel 75mg/m2 & cisplatin 75mg/m2, and rhG-CSF (150 mg/m2 
days 2-10), followed by twice-weekly docetaxel at 12 mg/m2 (M,Th) 
and daily delayed RT using same radiation dose and fractions. 
Results: With more than 3 years of follow-up, the pulsed paclitaxel 
CRT study without induction chemotherapy vs. the induction 
docetaxel/cisplatin followed by pulsed docetaxel study revealed the 
following: overall response rate of 100 % (22% CR and 78% PR) 
vs. 69% (19% CR and 50% PR), median survival of 12 mo vs. 24 
mo, radiation In-field failure of 7% vs. 55%, chest failure (including 
RT in-field failure and out of field nodules, pericardial effusion, and 
lymph nodes) 43% vs. 77%, distant failure (excluding brain) 25 % vs. 
32%, and brain failure of 32% vs. 23%, respectively. 
Conclusions: Our analyses showed clear differences in the response 
rates, median survival rates, radiation in-field failure rates, distant 
failure rates and brain failure rates of the two clinical studies. Pulsed 
low-dose paclitaxel without the induction chemotherapy is remark-
ably effective in gross tumor control in the radiation portal, while 
associated with higher failure rates in the brain and intrathoracic 
out-of- field failures from hematogenous cancer spread. Data showed 
that one-cycle induction docetaxel/cisplatin followed by pulsed 
docetaxel is much more effective in improving median survival, in 
reducing micrometastasis either in the chest or in the brain, while not 
so effective as pulsed paclitaxel in controlling gross chest tumors in 
the radiation portals. An ideal study can be considered by combining 
the strengths of two studies to maximize the local tumor control and 
to minimize distant cancer metastases.
PD8.3.6 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
Toxicity and patterns of failure of dose-escalated proton 
therapy in early-stage medically inoperable non-small cell 
lung cancer
Chang, Joe Y.; Komaki, Ritsuko; Wen, Hong; Gracia, Beth; Gillin, 
Michael; Mohan, Radhe; Cox, James D.
MD Anderson Cancer Center, Houston, USA
Background: The ability to deliver ablative radiation doses to medic-
ally inoperable T2, T3 or centrally located lung lesions with conven-
tional or stereotactic body radiation therapy is limited by normal-tis-
sue toxicity. We analyzed the toxicity and patterns of failure of proton 
therapy given in ablative doses for medically inoperable early-stage 
non-small cell lung cancer (NSCLC).
Methods: Fifteen patients with medical inoperable T1N0M0 (central 
location) or T2-3N0M0 (any location) NSCLC were treated with 
our phase I/II study using dose-escalated proton therapy to 87.5 
cobalt-Gray equivalents (CGE) at 2.5 CGE/fraction without adjuvant 
chemotherapy. Central location was defined as being within 2 cm of 
the bronchial tree, major vessels, esophagus, heart, trachea, peri-
cardium, brachial plexus or vertebral body. All patients underwent 
4-dimensional (4D) CT simulation; the internal gross tumor volume 
(IGTV) was delineated using the maximal intensity projection (MIP) 
and modified by visual verification of the target volume throughout 
10 breathing phases. IGTV with MIP density was used to design 
compensators and apertures to account for tumor motion. Therapy 
consisted of passively scattered protons in a 3-field arrangement. 
All patients underwent 4D CT resimulations during treatment to 
determine whether adapted replanning was needed. Follow-up care 
comprised CT imaging and clinical examination every 3 months after 
treatment for 2 years plus PET imaging at 3-5 months and annually 
thereafter. Recurrence was defined as evidence of persistent or pro-
gressive disease on avid PET or biopsy. 
Results: At a median follow-up time of 16.5 months (range, 5-24.1 
months), no patient had experienced grade 4 or 5 toxicity. The most 
common adverse effect was dermatitis (grade 2, 11 patients [73%], 
grade 3, 2 patients [13%]), followed by grade 2 fatigue (5 patients 
[33%]), grade 2 pneumonitis (1 patient [7%]}, grade 2 esophagitis (1 
patient), and grade 2 chest wall pain (1 patient). Rates of local control 
were 93% (14/15), regional lymph node failure 7% (1/15), and distant 
metastasis 20% (3/15). Twelve patients (80%) were still alive at 
last follow-up; 2 had died of metastatic disease and 1 of preexisting 
cardiac disease.
Conclusions: Proton therapy escalated to ablative doses is well 
tolerated and produces promising local control rates for medically 
inoperable early-stage NSCLC. Distant metastasis remains the most 
common pattern of failure.
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PD8.4.1 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
PET response and long term survival after resection of 
non-small cell lung cancer (NSCLC) following induction 
therapy (IT)
Barnett, Stephen A.; Park, Bernard J.; Plourde, Gabriel; Zheng, 
Junting; Bains, Manjit S.; Downey, Robert J.; Flores, Raja M.; Rizk, 
Nabil P.; Shen, Ronglai; Kris, Mark G.; Akhurst, Timothy J.; Rusch, 
Valerie W.
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Objective: It is difficult to predict which patients will have long-
term survival following multimodality therapy for locally advanced 
NSCLC. We reviewed our recent experience to assess whether 
change in PET avidity after IT could predict long term survival after 
surgical resection.
Methods: An IRB-approved retrospective review of a prospectively 
maintained, single institution database identified patients who under-
went IT and attempted curative resection of NSCLC. Overall survival 
was defined from the date of surgery to the date of death or the last 
follow up. PET scan SUV values were categorized as pre induction 
SUV (PreSUV) or post induction SUV (PostSUV), and difference 
in SUV (D) values was calculated. Log-rank test and Kaplan-Meier 
method were used to examine the univariate association between pre 
operative variables and survival. Multivariable Cox regression was 
used to evaluate the effect of change in SUV on overall survival, 
controlling for the PreSUV, age and initial clinical stage.
Results: From Jan 2000 to Dec 2006, 629 patients were identified. 
Eighty-four were excluded (superior sulcus tumor, bilateral synchron-
ous primary disease, tyrosine kinase inhibitor only) leaving 545 for 
analysis. The majority of patients received chemotherapy (542/545). 
Median overall survival for the entire group was 30.5 months (95% CI: 
28.2-35.9 months). Both PreSUV and PostSUV PET scan data were 
available in 229 patients. On univariate analysis age (p<0.001), initial 
clinical stage (p=0.006), pathological stage (p<0.001), PostSUV pri-
mary > 4.8 (group median) (p=0.015) and a decrease in SUV (p=0.009) 
were associated with survival. Controlling for age (p=0.017), initial 
clinical stage (p=0.05), and PreSUV primary (p=0.15), increase in 
PostSUV was associated with worse survival (HR 1.93, 95%CI: 1.24 
– 3.00, p=0.004). Further, patients with a PreSUV≤9.8 (group median) 
and a decrease in SUV after induction (D≤0) had a 2-year survival rate 
of 72% (95%CI: 61% - 80%) (figure 1).
Conclusions: Independent of traditional predictors of outcome, in-
crease in SUV of the primary tumor following IT in locally advanced 
NSCLC is associated with reduced long-term survival after resection. 
This reduction is even more pronounced when the pretreatment SUV 
is high. PET scan for initial evaluation and restaging following induc-
tion therapy may provide useful information for further treatment 
stratification.
PD8.4.2 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
Cost-effectiveness of 18FDG-PET-CT in the follow-up of 
non-small cell lung cancer patients treated with (chemo-)
radiotherapy
van Loon, Judith1; Grutters, Janneke2; Wanders, Rinus1; Dingemans, 
Anne-Marie 2; Bootsma, Gerben3; Geraedts, Wiel4; Pitz, Cordula5; 
Simons, Jean6; Brans, Boudewijn2; Snoep, Gabriel2; Lambin, 
Philippe1; DeRuysscher, Dirk1
1 Maastro Clinic, Maastricht, Netherlands; 2 Maastricht University 
Medical Centre, Maastricht, Netherlands; 3 Atrium Medical Centre, 
Heerlen, Netherlands; 4 Orbis Medical Centre, Sittard, Netherlands; 
5 Laurentius Hospital, Roermond, Netherlands; 6 Sint Jans Hospital, 
Weert, Netherlands
Background: The optimal follow-up strategy of NSCLC patients 
after curative intent therapy is still not established. In a recent 
prospective study, including 86% stage III patients, we showed that 
FDG-PET-CT 3 months after radiotherapy (RT) or chemo-radiation 
could identify patients with progression amenable for radical treat-
ment. Of all 100 patients, 55 were asymptomatic. Of that group, 
3 patients (5%, 95% CI: 2-15%) had potentially curable tumour 
progression. In none of the symptomatic patients, potentially curable 
progression was detected (van Loon et al, Eur J Cancer 2009). 
Here, we report on the economic evaluation of this prospective trial. 
Methods: A decision-analytic Markov model was developed with 
health states based on the presence of progression. We modeled the 
long-term cost-effectiveness of three follow-up strategies: a PET-CT 
scan 3 months after therapy; only a CT scan 3 months after therapy; 
and conventional follow-up with repeated chest X-rays. A hypothet-
ical cohort of 1000 patients entered the model after the follow-up 
visit 3 months after radical treatment. Patients were divided over 
the health states on basis of the results of our prospective study. 
Progression, survival and quality of life data were obtained from 
literature. Costs were estimated using standardized unit prices. The 
cost-effectiveness of the different follow-up strategies was compared 
using incremental cost-effectiveness ratios (ICERs), calculating costs 
per quality adjusted life year (QALY) ratios. A probabilistic sensitiv-
ity analysis was performed to account for uncertainty. Because the 
results of our prospective study implied that the advantage of the 
PET-CT seems to be confined to the asymptomatic patient group, we 
additionally examined a strategy where a PET-CT was applied only in 
the asymptomatic subgroup. 
Results: The total costs per patient over 5 years were €12.175 for 
PET-CT based, €11.175 for CT based and €10.829 for conven-
tional follow-up. Median predicted survival from the time of the 
first follow-up visit was 24 months for conventional and CT based 
follow-up and 25 months for PET-CT based follow-up. The conven-
tional and CT strategy yielded 1.28 QALYs, the PET-CT strategy 
1.30 QALYs. Concerning PET-CT based follow-up, the additional 
costs per extra radically treated patient were € 64.120 compared to 
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conventional follow-up. The ICER for PET-CT based follow-up was 
€ 69.115 per QALY gained compared to conventional follow-up. CT 
based follow-up was less costly, but also less effective than PET-
CT based follow-up, resulting in an ICER of € 261.740 per QALY 
gained. The strategy in which a PET-CT was only performed in the 
asymptomatic subgroup resulted in an ICER of € 42.294 per QALY 
gained. With this strategy, given a ceiling ratio of € 80.000 (informal 
ceiling ratio of the Dutch Health Council), PET-CT based follow-up 
had the highest probability of being cost-effective (74%) compared to 
conventional follow-up (26%). 
Conclusions: Based on the results of our prospective study, per-
forming a PET-CT scan three months after radical (chemo-)RT is a 
potentially cost-effective follow-up method, and is more cost-effect-
ive than CT alone. Applying a PET-CT scan only in the subgroup 
of asymptomatic patients is probably as effective and more cost-
effective. 
PD8.4.3 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
Transfer factor spared from receiving 5 Gray - an 
improved metric for predicting risk of developing 
radiation pneumonitis (RP) following radical radiotherapy
Jenkins, Peter
Gloucestershire Oncology Centre, Cheltenham, UK
Background: Currently used dose volume metrics are of only limited 
value for the prediction of RP. Multiparametric models which incor-
porate patient factors may have improved accuracy. Previous studies 
addressing such non-dosimetric factors have been of small size and 
confounded by the heterogeneity of the treatment doses/techniques 
employed. 
Methods: The cases of 156 patients treated for Stage I-III NSCLC 
were studied. All patients were treated with a single radiotherapy 
dose (CHART, 56Gy in 36 fractions over 12 days) and technique (3 
dimensional conformal radiation therapy employing 2-3 coplanar 
fields). The incidence of RP ≥ grade 2 (requiring steroids) was 
recorded prospectively. Multiple dose volume metrics, lung function 
parameters and tumour variables were analysed for their ability to 
predict for the development of RP.
Results: 26 (16%) patients developed RP. On univariate analysis the 
following factors were found to be associated with RP: fractional 
volumes of lung receiving 5-20Gy (V5-20), absolute volumes of lung 
spared from 5-15Gy, mean lung dose (MLD), cranio-caudal position 
of the field, and corrected transfer coefficient for carbon monoxide 
(KCOc). By calculating the product of the absolute volume spared 
from receiving 5Gy and KCOc, we defined a new metric which we 
termed Transfer Function Spared from 5Gy (TFS5). The correlation 
of TFS5 with RP was striking (see figure). The area under the ROC 
curves for TFS5 and V20 and MLD were 0.78, 0.67 and 0.68. Using 
a cut-point for TFS5 of 2.17 the sensitivity, specificity, PPV and NPV 
of this new metric for predicting RP were 84%, 66%, 36% and 94% 
respectively.
Conclusions: The predictive accuracy of dose volume metrics can be 
improved by the inclusion of measures of pulmonary function. TFS5 
should be considered when assessing the risk of RP.
PD8.4.4 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
Association of single nucleotide polymorphisms with 
radiation-induced esophagitis
Zhang, Li1; Yang, Ming2; Lin, Dong xin2; Wang, Luhua3
1 Department of Oncology, Tongji Hospital, Tongji Medical College, 
Huazhong University of Science and Technology, Wuhan, China; 2 
Department of Etiology and Carcinogenesis, and Key Laboratory 
for Carcinogenesis and Cancer Prevention, Cancer Institute and 
Hospital, Chinese Academy of Medical Sciences and Peking Union 
Medical College, Beijing, China; 3 Department of Radiation 
Oncology, Cancer Institute and Hospital, Chinese Academy of 
Medical Sciences and Peking Union Medical College, Beijing, China
Background: The objective is to examine the relationship between 
genetic polymorphisms in DNA repair and inflammatory cytokine 
genes with radiation-induced esophagitis (RIET) in patients with lung 
cancer.
Materials and Methods: Between January 2004 and August 2007, 
one hundred and eighty-seven non-small cell lung cancer patients and 
sixty-six small cell lung cancer inoperable patients underwent thor-
acic radiotherapy were enrolled in this study. The total target doses 
were between 45 Gy and 70 Gy (median 60Gy). Two hundred and 
six patients (81.4%) were treated with three-dimensional conformal 
radiotherapy (3D CRT) and 47 patients (18.6%) with two-dimension-
al radiotherapy (2D RT). Two hundred and three patients (80.2%) 
received chemotherapy and 77 (37.9%) of them received concurrent 
chemoradiotherapy. All of them consented for blood sampling, SNP 
analysis and follow up more than three months. The primary endpoint 
was ≥ grade 2 RIET according to NCI CTC3.0 criteria. We analyzed 
35 genetic variations in 18 DNA repair and inflammatory cytokine 
genes including ATM, P53, XRCC3, NBS1, XRCC1, ADPRT, 
ERCC1, XPD, XPC, XPG, ZNF350, FAS, FASL, CASP8, COX-2, 
TGF-β1, CD14, and ACE by PCR-based restricted fragment length 
polymorphism (RFLP) method. Student’s t-test or χ2-test was used 
to compare clinical characteristics and the differences in luciferase 
reporter gene expression, and the non parametric Mann-Whitney ex-
act test for quantitative variables. Binary logistic regression analysis 
including those factors having univariate significance (p<0.05), were 
performed using a backward regression procedure with a P value ≤ 
0.05 being considered significant.
Results: Sixty-one (24.1%) of the 253 patients developed radiation-
induced esophagitis of Grade ≥2, with 55 patients (21.7%) in grade 
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2 and 6 patients in grade 3 (2.4%). Univariate analysis revealed that 
radiation technique and concurrent chemoradiation were statistical 
significant relative to the incident of esophagitis (P = 0.032, 0.049), 
and both of them had the trend to associate with the esophagitis (P 
= 0.072, 0.094) in multivariate analysis. An increased incidence of 
esophagitis was observed associating with the TGF-β1 –509T allele 
(rs1800469) and XPD 751Lys/Lys (rs13181) genotypes (χ2 = 5.651 P 
= 0.017; χ2 = 3.837 P = 0.048) in logistic regression analysis. 
Conclusion: Genetic polymorphisms in TGF-β1 gene and XPD gene 
have a significant association with radiation-induced esophagitis.
PD8.5.1 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
The growth kinetics of therapy naïve lung tumours 
according to 18F-FDG PET/CT 
Everitt, Sarah J.1, 2; Hicks, Rodney J.1; Plumridge, Nikki1; Herschtal, 
Alan1; Ball, David1; Callahan, Jason1; Kron, Tomas1; Schneider-
Kolsky, Michal2; Binns, David1; Mac Manus, Michael1
1 Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; 2 
Monash University, Clayton, VIC, Australia
Background: Evidence to date has demonstrated that timely initia-
tion of cancer therapy can minimize the likelihood of disease progres-
sion in patients diagnosed with lung cancer. This is vital to ensure the 
appropriate administration of treatment and to minimize treatment 
toxicity resulting from extensive localized treatments. The litera-
ture also suggests that tumor growth can adversely impact patients 
in terms of local recurrence and overall survival. Nevertheless, the 
kinetics of tumor growth are multi-factorial and doubling times vary 
widely. Gaining further evidence to establish tumor growth observed 
with the most accurate available technology is of great importance 
when determining treatment strategies for this patient population. 
This study was initiated to analyze tumor progression in patients with 
therapy naïve non-small cell lung cancer (NSCLC) using serial 18F-
FDG PET/CT scans. 
Methods: Eligibility for this study included patients with therapy 
naïve NSCLC who underwent two pre-treatment 18F-FDG PET/
CT scans. All patients were considered eligible for radical treatment 
based on their initial scan. Inter-scan comparisons included disease 
stage, according to TNM and overall stage criteria, and treatment in-
tent. The metabolic characteristics of tumours were compared includ-
ing maximum and average standardised uptake values (SUVmax and 
SUVave), and percentage of injected dose (%ID). The doubling time 
of metabolic tumour volumes were compared using SUV settings 
individualised for each case and using a standardised SUV of 3.0. 
Results: Of the 83 patients enrolled in the prospective study between 
October 2004 and February 2007, 28 (34%) patients underwent two 
pre-treatment 18F-FDG PET/CT scans. The median inter-scan period 
was 24 days (range 8-176 days). Disease progression according to 
TNM disease stage was reported in 11 (39%) patients. Treatment 
intent changed from radical to palliative in 8 (29%) cases, including 
5 (18%) patients who developed distant metastatic disease. Ac-
cording to a change in TNM staging, the estimated probabilities of 
disease progression at 7, 14 and 28 days were 9.7% (95% CI: 4.96, 
16.7), 18.4% (95% CI: 9.6, 30.6) and 33.5% (95% CI: 18.2, 51.8), 
respectively. Of the 18 (22%) patients who underwent both scans at 
our centre, there was a mean relative inter-scan increase of 19% in 
SUVmax (p=0.022), 16% in SUVave (p=0.004) and 116% in %ID 
(p=0.002) in the primary gross tumor. Based on individualised SUV 
criteria, the expected TVDT of primary lesions was 66 days and there 
was a 2.5% and 97.5% probability of tumour doubling in 51 days and 
95 days, respectively. 
Conclusions: We have demonstrated significant rates of therapy 
naïve tumour progression in this patient cohort scanned with 18F-
FDG PET/CT. The observation of local progression in a significant 
proportion of patients highlights the importance of initiating treat-
ment in a timely manner. 
PD8.5.2 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
Pathologic correlation of PET-CT based auto contouring 
for radiation treatment planning in lung cancer
Fogh, Shannon E.1; Kannarkatt, Joseph1; Farach, Andrew1; McCue, 
Peter1; Axelrod, Rita1; Nelson, Aaron2; Werner-Wasik, Maria1
1 Thomas Jefferson University Hospital, Philadelphia, PA, USA; 2 
MIMvista Corp, Cleveland, OH, USA
Background: Radiation therapy is used to treat lung cancer and relies 
on CT and functional imaging (FDG-PET) to delineate gross tumor 
volume (GTV). Various methods have been used to delineate FDG-
positive signal including visual interpretation which may be prone to 
inter-observer bias and intrinsic differences in imaging equipment. 
Semi-automatic contouring tools have been developed to improve 
contouring. A common method involves using a threshold method 
using a given percentage of the maximal activity, which may be less 
accurate with smaller tumors and tumors with low source to back-
ground ratio. In an attempt to overcome this, a gradient algorithm, 
which detects changes in image counts at the border of the tumor, 
has been developed. Few studies have correlated these methods to 
pathological specimens. We conducted a retrospective study in order 
to determine which contouring technique method was most strongly 
correlated with gross pathology. 
Methods: Sixty-eight patients with Stage I and II non-small cell lung 
cancer underwent lobectomy at Thomas Jefferson University between 
2006 and 2007, 18 of which had PET or PET/CT imaging prior to 
resection available for our review. We retrospectively contoured lung 
tumors using 1) a constant threshold algorithm which delineated the 
structure by including all voxels within a defined region that have 
counts greater than a fixed percent of the maximum count level 
(34%) in that region. and 2) a commercially-available gradient-based 
“PET edge” tool (Mimvista Inc, Cleveland, OH). Largest resected 
tumor diameters were recorded from gross pathology reports and 
were compared to the largest tumor diameter measured by either PET 
contouring method. Pearson’s correlation coefficient (CC) was used 
to compare the diameters.
Results: Eighteen patients were analyzed (12 with T1; 5 with T2 and 
one patient with a T3 tumor). The median largest tumor diameters 
were as follows: from pathology reports, 2.5 cm (range 1.5-7.0 cm); 
from 34% threshold method, 3.4 cm (range 2.3-5.5cm); from gradient 
tool, 2.9 cm (range 1.6-6.3 cm). CC between maximal diameter con-
toured with the gradient tool or 34% percent threshold and the actual 
tumor maximal diameter was .72 and .08, respectively. Of note, the 
threshold method grossly overestimated the tumor volume in three 
patients with low SUV levels (2.5-3.0). When these patients were 
removed from the analysis, the CC for the 34% threshold improved 
to .45.
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Conclusions: Based on our results, maximal diameter obtained with 
the gradient method was more closely correlated with maximal patho-
logic diameter compared to the constant threshold method. To our 
knowledge this is the only study to compare lung pathology to both 
threshold and gradient semi-automatic contour methods. 
PD8.5.3 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
AT-101, a pan-Bcl-2 inhibitor, leads to radiosensitization of 
non-small lung cancer
Moretti, Luigi; Li, Bo; Niermann, Kenneth; Lu, Bo
Vanderbilt University, Nashville, TN, USA
Purpose: Radiotherapy has a central role in the treatment of locally 
advanced non-small cell lung cancer. The effectiveness of this modal-
ity, however, is often limited, in part, due to the presence of defects in 
key apoptosis regulators, such as Bcl-2 and related proteins. Over-
expression of anti-apoptotic members of the Bcl-2 family shifts the 
balance between cell survival and death, contributing to the ability of 
cancer cells to evade apoptosis.
Understanding how radiation affects Bcl-2-dependent lung cancer 
cell death may enable the development of strategies to restore apop-
totic sensitivity in lung tumors and ultimately to enhance therapy. 
In this study, we tested the potential of AT-101, a novel pan-Bcl-2 
inhibitor (targeting anti-apoptotic proteins Bcl-2, Bcl-XL and Mcl-1), 
as a radiosensitizer in lung cancer. 
Methods/Results: Clonogenic assays were used to determine 
radiosensitivity of multiple lung cancer cell lines. Apoptosis was 
measured in each cell type by detecting and quantifying caspase-3 
cleavage. Based on their response to radiotherapy, lung cancer cells 
were tested and then stratified into two groups: 1) highly radiation 
resistant, and 2) highly radiation sensitive. In each group, we selected 
a representative lung cancer cell line for more in depth study: A549 
for the highly resistant group and HCC2429 for the highly sensitive 
group. Expression levels of anti-apoptotic Bcl-2 proteins (Bcl-2, 
Bcl-XL, mcl-1) and pro-apoptotic (Bax, Bak, and Bid) proteins were 
determined for each lung cancer groups. Although levels of Bcl-2 and 
mcl-1 were low and similar for both groups, Bcl-XL expression was 
dramatically higher in the A549 group, while almost not detected in 
the HCC2429 group. Notably, levels of Bax and Bak proteins were 
40% higher in the HCC2429 group as compared to the A549 group. 
We then tested the effects of AT-101 alone or in combination with 
radiotherapy in both groups. AT-101 resulted in increased apoptosis 
in concentration- and time-dependent manner against both lung can-
cer groups, with a particularly enhanced activity on HCC2429 cells 
even at low concentration (1µM/ml). The administration of AT-101 
markedly enhanced sensitivity of both A549 (DER=1.19, p<0.005) 
and HCC2429 (DER=1.22, p<0.005) lung cancer cells to radiation in 
clonogenic assays. This enhanced radiosensitization was associated 
with an increase in apoptosis in both lung cancer groups. Interesting-
ly, A549 cells required increased AT-101 dose and/or longer treatment 
duration to achieve a similar radiocytoxicity to HCC2429 cells. These 
results were confirmed by MTT assays, which showed a synergistic 
effect of AT-101 with radiotherapy against HCC2429 and an additive 
effect against A549 cells. Again, these effects were dramatically en-
hanced by increasing the dose of AT-101 and/or extending treatment 
time. 
Conclusions: These investigations suggest that the anti-apoptotic 
proteins of the Bcl-2 family may serve as effective therapeutic targets 
in the treatment of lung cancer due to the relative elevation of these 
proteins in a majority of human lung cancer cancers and due to the 
association of these proteins with radiation resistance. Further studies 
are warranted to study the clinical potential of AT-101 as an agent 
that may effectively raise the therapeutic ratio of radiotherapy in lung 
cancer.
PD8.6.1 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
Comparison of tumor coverage in radical lung 
radiotherapy: impact of cone-beam CT image guidance 
using spine or carina matching
Lavoie, Caroline1; Higgins, Jane1; Bissonnette, Jean-Pierre1; 
Alexander, Sun1; Brade, Anthony1; Hope, Andrew1; Cho, John1; Le, 
Lisa W.2; Bezjak, Andrea1
1 Radiation Medicine Program, Princess Margaret Hospital, 
University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada; 2 
Department of Biostatistics, Princess Margaret Hospital, University 
of Toronto, OB, Canada, Toronto, ON, Canada
Background: Traditional radiation (RT) treatment uses tattoos for 
patients setup on a daily basis to reproduce the planning CT pos-
itioning. The accuracy of this setup is verified with megavoltage 
radiographic films done at strategic time points throughout the course 
of RT. Cone-beam CT (CBCT) scans produce 3-dimensional images 
and allow clearer visualization of bony landmarks, but also soft-tissue 
structures to guide patient alignment. The purpose of this study is to 
assess the tumor coverage between (i) the patient setup based on tat-
toos and (ii) the positioning after correction of setup errors obtained 
from registration between CBCT and planning CT. 
Methods: A retrospective analysis was conducted for 98 consecu-
tive locally advanced lung cancer patients treated with radical RT. 
A total of 5194 daily CBCT scans were registered to planning CT 
scans throughout all treatment fractions. The image data sets were 
registered automatically using first, the spine and then the carina 
as target surrogates. The setup errors were measured and recorded. 
Systematic and random errors were calculated for the setup errors for 
each patient. Adequacy of tumor coverage [both primary and nodal 
disease within the gross tumor volume (GTV), internal treatment 
volume (ITV), planning treatment volume (PTV) or outside the PTV] 
was assessed before and after the two registration methods for the 
first fraction of RT.
Results: Spine registration identified setup errors ≥5mm in 35% of 
fractions and rotational errors ≥3° in 23% of fractions throughout the 
course of RT. Using carina matching, these setup errors were found in 
46% and 26% of fractions respectively. Systematic and random errors 
using spine registration were 25mm (18mm) in left-right direction, 
33mm (24mm) in supero-inferior direction and 22mm (16mm) in 
antero-posterior direction; for carina registration they were 26mm 
(18mm), 38mm (26mm) and 29mm (16mm) respectively. At first 
fraction of RT, the percentage of both primary and nodal tumor inside 
the GTV were 6% for tattoos positioning, 36% for spine matching 
and 45% for carina matching; the percentage of tumor inside the 
ITV were 71%, 94% and 95% respectively. The paired difference in 
primary and nodal tumors coverage improved significantly (p≤0.001) 
in favor of both CBCT registration methods compare to tattoos 
positioning. For the spine matching, the improvement of target cover-
age were 51% for the primary and 50% for the nodal tumors; for the 
carina matching, the improvement were 52% and 59% respectively. 
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Conclusion: Results reveals frequent systematic and random 
positional errors throughout the course of RT. These errors can be 
corrected by using either spine or carina as target surrogate. Both 
landmarks improved significantly the tumor coverage, but carina 
appeared to be more accurate. Additional analysis studying the 
dosimetric impact are still needed to validate the utility of these new 
image guidance practices in RT. 
PD8.6.2 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
A novel approach for independent verification of lung 
radiotherapy
Muirhead, Rebecca1; van Sornsen de Koste, John2; Munro, Peter3; 
Senan, Suresh2
1 The Beatson, West of Scotland Cancer Centre, Glasgow, UK; 
2 VUMC, Amsterdam, Netherlands; 3 Varian Medical Systems, 
Chollerstr, USA
Background: The increasing use of sophisticated delivery techniques 
for radiation of lung cancer has increased the risk of errors, and has 
led to calls for the development of methods of independent verifica-
tion of treatment delivery. MV cine-images can be generated using 
doses exiting the patient during treatment delivery, with no increase 
in treatment time or radiation dose. We hypothesized that MV 
cine-images could provide a novel, independent verification tool for 
internal anatomy. 
Methods: In 6 patients with stage III lung cancer, MV cine-images of 
all fields were analyzed. 
AIM 1: Two observers, reviewed one MV cine-image from each field 
during one fraction of radiation belonging to each patient. Observers 
were asked if they could identify the carina, the hilus and the tumor 
mass respectively in each field. The Beams Eye View (BEV) of the 
treatment plan with the different structures highlighted was available 
for assistance in identifying structures. 
AIM 2: If the structures mentioned above could not be identified, the 
observers were asked to document the reasons for this. MV cine-im-
ages were also assessed to see whether a complete respiration cycle 
had occurred and compared this to the number of MU’s used in the 
field, as without an entire breathing cycle, internal structure move-
ment would be underestimated.
AIM 3 : The two-dimensional (2D) motion path for several thoracic 
structures on MV-cine images, were measured offline using experi-
mental research software (RPM-Fluoro tool kit version 0.7.5, Varian 
Medical Systems, Palo Alto, CA). 
Results: The carina was identifiable in 83% of images, the primary 
tumor mass in 68%, and the hilus in 73%. Factors which limited 
the ability to visualize internal structures were a dense mediastinal 
shadow of similar density, 60inch dynamic wedge obliterating the 
field and fields where <30 monitor units were delivered. The presence 
of a treatment bed bar over the internal structure prevented motion 
assessement. Median 2D movement of the carina during radiation 
was 2.8mm (range, 0.6 – 10.1mm) in comparison to during the 4DCT 
scan 6.95mm (range, 3.7- 10mm). Similarly, median 2D motion of 
the primary tumor during radiation was 4.7mm (range, 1 – 14.8mm) 
in comparison to 7.4cm (range, 2.0 – 10.5cm) on 4DCT. 
Conclusions: 4DCT remains a snap-shot of respiratory movement 
however the use of MV cine-images allows the assessment of tumour 
motion throughout a course of thoracic radiation. With significant 
software development, MV cine-images could be used as a routine 
verification tool to ensure internal structure movement during radia-
tion treatment, does not exceed that encompassed in the planning 
4DCT scan. 
PD8.6.3 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
Towards adaptive radiotherapy – role of image guidance 
on the radiotherapy treatment unit in assessing tumor 
change during a course of radical chemo-radiotherapy in 
non-small cell lung cancer (NSCLC)
Lim, Gerald2; Bezjak, Andrea1; Higgins, Jane1; Moseley, Doug1; 
Hope, Andrew J.1; Sun, Alex1; Cho, John1; Brade, Anthony M.1; Ma, 
Clement1; Bissonnette, Jean-Pierre1
1 Princess Margaret Hospital, Toronto, ON, Canada; 2 Tom Baker 
Cancer Centre, Calgary, AB, Canada
Background: Image Guidance on the radiotherapy (RT) treatment 
unit, such as using cone beam CT (CBCT), a volumetric kV imaging 
device that is mounted on a linear accelerator, allows for accurate 
and precise positioning of the patient to ensure that the planned RT 
fields cover the target. It may also reveal changes in the tumor size or 
position during RT that may have implications for the delivery of RT. 
The frequency and magnitude of such changes is unknown. We used 
respiratory-correlated cone beam CT (rcCBCT) imaging to study 
volumetric and positional changes throughout the course of radical 
radiotherapy in a group of non-small cell lung cancer (NSCLC) 
patients treated with conventionally fractionated RT with concurrent 
chemotherapy.
Methods: We retrospectively studied 60 consecutive NSCLC patients 
treated with concurrent platinum-based chemotherapy and either 
preoperative (45Gy/25 fr, n=33) or definitive radiotherapy (60-66 
Gy/30-33 fr, n=27). Primary tumor volumes were contoured on 
weekly rcCBCT images, or assessed visually as no shrinkage, 10-
30% shrinkage or >30%; comparisons were made with planning CT 
in the exhale phase. Nodal disease was not assessed due to limitations 
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of CBCT imaging soft tissue structures within the mediastinum. Pos-
itional changes of the primary tumor were assessed by comparing the 
centres of mass of the tumor volumes contoured on CBCTs.
Results: CBCT images in 31/60 patients were of sufficient quality 
for contouring of the primary tumor. The remaining 29 were assessed 
visually. In the 31 pts with quantitative data, tumor volume decreased 
on average by 36.5% of original volume by fraction 15, and by 
51.7% by RT completion. CBCTs of 11/29 visually assessed patients 
revealed clinically relevant findings (atelectasis formation (7 pts, 2 
of which could not be assessed for tumor change due to it), atelecta-
sis improvement (2); new pleural effusion (2)). At fraction 15, 8/27 
visually assessed patients had >30% tumour regression by volume, 
this increased to 14/27 at RT completion. There were no patients 
who had evidence of tumour progression. Overall, 47% patients had 
at least 30% volume reduction by fraction 15 and 67% by end of 
RT. Between the first fraction and the end of treatment, statistically 
significant 3D tumour migration was demonstrated in 6/27 patients 
studied.
Conclusion: Current rcCBCT image quality allows assessment of 
tumors located more peripherally within the lung, but not nodal dis-
ease or central tumors. Tumor regression by volume of at least 30% 
is seen in almost half of the patients at midpoint of RT, and in 2/3 by 
end of RT. In addition, clinically relevant changes that may require 
further assessment or potential replanning were identified in 18% of 
patients. This has important implications for image guidance in lung 
RT, as the information provided by CBCTs may require clinical ac-
tion, to ensure appropriate coverage of the target. Whether the clinical 
target volumes should be revised as the tumor shrinks in response to 
therapy is not known, and requires further study.
PD8.6.4 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
Locating and targeting moving tumors with radiation 
beams: 2mm system accuracy for lung tumors
Keall, Paul J.1; Cho, Byungchul1; Poulsen, Per1, 2; Ruan, Dan1; 
Sawant, Amit1; Suh, Yelin1, 3
1 Stanford University, Stanford, CA, USA; 2 Aarhus University 
Hospital, Aarhus, Denmark; 3 Virginia Commonwealth University, 
Richmond, VA, USA
Background: To accurately hit moving lung tumors with radia-
tion beams there are two required tasks: locate the tumor in real 
time using measurements and/or estimation methods and align the 
radiation beam to the tumor based on the location information. Most 
modern linear accelerators have three imaging streams available to 
acquire tumor location information during treatment: kilovoltage 
(kV) imagers, megavoltage (MV) imagers and optical monitoring. 
Most linear accelerators also have dynamic multileaf collimators 
(DMLCs). The purpose of this work was to use these tools to develop 
and quantify the accuracy of a system to locate and target moving 
lung tumors with radiotherapy beams. 
Methods: We developed three distinct algorithms for real-time tumor 
localization using (1) only the kV imager, (2) the kV and MV imagers 
and (3) the kV and MV imagers and an optical respiratory signal. 
A method to adjust the DMLC leaf positions to align the radiation 
beam based on a real-time position stream was also developed. The 
algorithms to locate and target moving tumors were integrated and 
experimentally tested on a linear accelerator (Varian Trilogy). Tumor 
motion was simulated by a programmable motion stage containing 
an embedded implanted marker with tumor motion and periodic 
motion as input, with a range of motion up to 2cm. Measured tumor 
motion (3D motion) and the respiratory signal (1D motion) were 
programmed into the motion stage. No prior knowledge of the target 
motion was assumed for any of the methods. A modified linear 
adaptive motion prediction algorithm was implemented to reduce 
the deleterious effects of system latency (the time between tumor 
position change and the response of the treatment beam). 
Results: All three real-time localization methods, though they use 
quite different algorithms, result in average targeting errors less than 
2mm in end-to-end tests. The errors tend to be predominantly random 
with a small systematic component, indicating a negligible contribu-
tion to the required PTV margin. Further accuracy improvements can 
be expected with reductions in the system latency time, which is 570, 
450 and 160ms for the kV, KV/MV and kV/MV/optical methods re-
spectively. Significant system latency time reductions are potentially 
feasible given that the linac used was not specifically designed for 
real-time tumor tracking. 
Conclusions: Real-time lung tumor targeting using tools available 
on modern linear accelerators have been developed and reduced to 
practice in phantom experiments and therefore have a clear path to 
clinical implementation. For a range of guidance methods, the system 
accuracy has average targeting errors below 2mm. This substantially 
improved targeting accuracy may impact local control and toxicity for 
stereotactic and conventionally fractionated lung cancer radiotherapy. 
PD8.6.5 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
Target delineation uncertainty in stereotactic body 
radiotherapy for peripheral early lung cancer
Sonke, Jan-jakob1; Duppen, Joop1; Belderbos, Jose1; Guckenberger, 
Matthias2; Hope, Andrew3; Grills, Inga4
1 The Netherlands Cancer Institute / Antoni van Leeuwenhoek 
Hospital, Amsterdam, Netherlands; 2 Julius-Maximilians University, 
Wuerzburg, Germany; 3 Princess Margaret Hospital, Toronto, ON, 
Canada; 4 William Beaumont Hospital, Royal Oak, MI, USA
Background: Target definition uncertainty of up to 10mm (1SD) has 
been observed in conventional non-small cell lung cancer (NSCLC) 
external-beam radiotherapy. Delineation errors cannot be managed 
by image guided radiotherapy and, therefore, are persistent over the 
course of treatment, with a potentially significant impact on the dose 
delivered to the tumor. Target delineation uncertainty for peripheral 
early stage lung cancer, however, is unknown. These tumors are 
often treated with stereotactic-body-radiotherapy (SBRT). GTV-PTV 
margins in SBRT are generally quite small, often ignoring target 
delineation uncertainties. The purpose of this study was to character-
ize the target delineation uncertainty for small peripheral NSCLCs 
commonly treated with SBRT.
Methods: Sixteen patients with clinical Stage-I (T1-T2;N0) NSCLC 
were included in this study in consecutive order from our SBRT data-
base. Ten experienced radiation oncologists from four institutions de-
lineated the GTV on the planning CT. In house developed delineation 
software was used containing the delineation tools usually provided 
by most commercial treatment–planning systems. Preset Level (-450 
Hounsfield Units (HU)) / Window (750 HU) settings were included in 
the software, but were allowed to be adjusted.
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A median surface of the delineated GTVs of all observers was com-
puted in 3D, i.e., each voxel inside the median surface is designated 
by 50% of the radiation oncologists as a part of the GTV. Subsequent-
ly, for each point describing the median surface, the perpendicular 
distance was measured to each individual delineated GTV. The varia-
tion in distance to a single point was expressed in a local standard 
deviation. The variation (root-mean-square) in distance to all points 
describing the median surface was expressed in an overall SD, which 
is a measure of overall observer variation. 
Results: An example of an axial CT slice with all delineations from 
the ten radiation oncologists is shown in Figure 1a.The relative 
histogram of the local SD over all patients and observers is shown in 
Figure 1b. The histogram peaks at 2.0mm, but has a tail to the right 
of this peak. The target definition variability over all observers and 
patients collectively was 2.5mm (1SD). Considerable inter-institu-
tional variation was observed, where some consistently defined larger 
volumes than others. Analyzing these two groups separately, yielded 
observer variations of 1.7mm and 2.6mm for the smaller and larger 
delineating group respectively. 
Conclusion and Discussion: Relatively small target definition un-
certainty of 1.6mm–2.6mm (1SD) was observed for these peripheral 
T1-T2 N0 NSCLCs, which is substantially smaller than for more ad-
vanced NSCLC cases. Nevertheless, GTV-to-PTV margins to account 
for this uncertainty alone would equal 4.3mm-6.5mm given that these 
constitute systematic errors (M=2.5Σ). Due to the excellent local 
control achieved with high biological dose SBRT, the significance of 
potential geometric miss is unclear and requires further study.
PD8.6.6 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
Strategies for deriving mediastinal nodal target volumes 
for lung cancer 
Pantarotto, Jason R.1; Senan, Suresh2
1 The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; 2 VU 
University Medical Center, Amsterdam, Netherlands
Background: Involved-field mediastinal radiotherapy is considered 
the standard approach for stage III lung cancer by the EORTC and 
RTOG. 4-dimensional (4D) CT analysis revealed that motion of 
mediastinal lymph nodes can rival that of primary tumor motion 
[Pantarotto 2009]. Up to 10% of nodes moved > 10mm, and 77% 
> 5mm, with greatest motion observed in the lower mediastinum. 
A failure to properly account for nodal motion risks local failure 
when involved-field or gated radiotherapy is performed without 4D 
information. As 4DCT scans are not widely available, we evaluated 
contouring strategies that could help clinicians derive accurate nodal 
target volumes.
Methods: A database of treatment planning 4DCT scans was retro-
spectively evaluated to identify lung cancer patients with clearly 
visible pathological mediastinal lymph nodes. Nodes were individ-
ually contoured manually in each of 10 respiratory phase bins by 
one physician. The union of these 10 volumes was used to derive an 
“ITV-10”, 95% coverage of which was defined as the gold standard 
for comparison with less time consuming methods, namely: A) single 
volume from a mid-ventilatory phase (analogous to 3DCT image) 
with margin, B) union of 2 volumes from 4D phases corresponding to 
extremes in the respiratory cycle, and C) single volume from an aver-
age intensity projection (Av-IP) of all 10 phases of the 4DCT.
Results: A total of 50 nodes from 8 nodal stations in 16 patients 
were contoured, and the mean nodal motion was 7.4mm (range 
2.2-14.2mm). Method A: Contoured volumes from a 3D static im-
age covered only 55.7% (range 23.6-78.7%) of the ITV-10. A 7mm 
isotropic margin achieved >95% coverage of ITV-10, with 2 of 50 
nodes requiring an 8mm margin. Analysis based on node location 
revealed that a 3mm isotropic margin ensured ITV-10 coverage for 
upper mediastinal nodes, 5mm for middle mediastinal nodes and 
7mm for infra-carinal nodes. Method B: The union of volumes from 
extreme 4D phases did not provide ITV-10 coverage for any node 
(mean coverage = 73.8%, range 51.7- 91.5%) due to hysteresis and 
phase offsets between tumor and nodal trajectories. However, addi-
tion of a 2mm margin provided ITV-10 coverage for 48 of 50 nodes. 
Method B resulted in smaller contours that conformed tighter around 
ITV-10 than method A (mean excess tissue covered 9.1cc vs 15.0cc, 
p < 0.001, t-test). Method C: Contouring nodes on Av-IP images was 
hindered by poor contrast of mediastinal structures, despite varying 
the settings on the Advantage imaging workstation [GE Healthcare]. 
When identified, an 8mm margin was required to achieve coverage of 
the ITV-10.
Conclusions: The amplitude and direction of nodal motion varied 
from patient to patient, and 4DCT-based target volumes derived from 
multiple phases of respiration provided the most conformal target 
coverage. When only conventional 3DCT scans are available, nodal 
coverage can be improved by applying population-based margins of 
3mm, 5mm and 7mm for the upper, middle and lower mediastinum, 
respectively. Additional margins for microscopic tumor extension and 
daily set-up are required.
PD8.6.7 Combined Modality and Radiotherapy, Mon, 10:30 - 12:00
Inter-observer and intra-observer reliability for lung 
cancer target volume delineation in the 4D-CT era
Rodrigues, George1; Louie, Alexander1; Olsthoorn, Jason1; Palma, 
David2; Yu, Edward1; Yaremko, Brian1; Ahmad, Belal1; Aivas, Inge1; 
Gaede, Stewart1
1 University of Western Ontario, London, ON, Canada; 2 University 
of British Columbia, Vancouver, BC, Canada
Purpose: The purpose of this study is to investigate inter and intra-
observer target volume delineation (TVD) error in the setting of 
4D-CT image data acquisition in thoracic tumours.
Methods and Materials: Six radiation oncologists contoured the 
primary and nodal gross tumour volumes (GTV) of 10 lung tumours 
on the 10 respiratory phases of a 4D-CT scan. The coefficient of 
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variation (COV) and the percentage shared internal target volume 
(sITV) of the 6 physicians for each patient was used to assess inter 
and intra-observer variability. ANOVA analysis was performed to 
assess differences in inter and intra-physician variability based on 
case difficulty, respiratory phase, physician seniority, and physician 
observer.
Results: Inter-physician percentage sITV for primary tumour ranged 
from 31.1% to 83.3% (SD 4.4% - 15.8%) and 16.4% to 66.8% (SD 
5.8% - 21.1%) for nodes. Intra-physician sITV for primary tumour 
ranged from 59.6% to 72.7% (SD 13.0% - 23.9%), and 28.3% to 
57.0% (SD 18.6% - 34.2%) for nodes. Inter-physician mean COV 
between respiratory phases ranged from 0.061 to 0.602 for primary 
tumour (SD 0.010 - 0.123) and 0.186 to 0.590 for nodes (SD 0.026 - 
0.117). Intra-physician mean COV between respiratory phases ranged 
from 0.031 to 0.151 (SD 0.012 - 0.070) for primary tumour and 0.102 
to 0.254 (SD 0.023 - 0.091) for nodes. ANOVA analysis for COVs 
found case difficulty to be significant for inter-physician primary 
tumour and intra-physician nodal disease delineation (Table 1). Phys-
ician seniority, respiratory phase, and individual physician were not 
found to be significant for TVD error. 
Conclusion: High observer variability in TVD continues to be a 
major source of error in the 4DCT era for lung cancer. Inter-physician 
variability appears to be more significant source of this error than 
intra-physician variability. Development of measures to reduce inter-
observer and intra-observer TVD variability are necessary in order to 
deliver high quality radiotherapy.
Table 1: Inter-physician and Intra-physician Covariance ANOVA analysis
 ANOVA  Cases* Physician Seniority Case Respiratory  
      Difficulty Phase
 Inter-physician Primary 39/45 p < 0.001 - - p < 0.001 p = 1.000
  Nodes 26/28 p < 0.001 - - p = 0.589 p = 1.000
 Intra-physician Primary 21/45 p < 0.001 p = 0.150 p = 0.596 p = 0.463 -
  Nodes 7/28 p = 0.004 p = 0.467 p = 0.727 p < 0.001 -
* = ratio of case combinations differing significantly from each other.
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PD9.1.1 NSCLC - Advanced Disease II, Mon, 10:30 - 12:00
Histological analysis in pemetrexed treated patients 
with stage IIIB/IV NSCLC: results from an open label 
randomized phase II study
Niho, Seiji2; Kubota, Kaoru2; Enatsu, Sotaro1; Nambu, Yoshihiro1; 
Nishiwaki, Yutaka2; Saijo, Nagahiro2; Fukuoka, Masahiro3
1 Lilly Research Laboratoties Japan, Kobe, Japan; 2 National Cancer 
Center Hospital East, Kashiwa, Japan; 3 Kinki University School of 
Medicine Sakai Hospital, Sakai, Japan
Background: Recent pivotal phase III studies in patients with 
advanced non-small cell lung cancer (NSCLC) consistently showed 
a greater survival benefit of pemetrexed for non-squamous cell 
carcinoma (Non-Sq) than squamous cell carcinoma (Sq) (Scagliotti, 
et al: J Clin Oncol 2008). To evaluate overall and dose-specific ef-
ficacy of pemetrexed by histology, we conducted a subgroup analysis 
of data from a Japanese randomized phase II study NS01 compar-
ing pemetrexed 500 mg/m2(P500) with 1000 mg/m2 (P1000) arm in 
advanced NSCLC patients previously treated with chemotherapy.
Methods: Response rate, overall survival (OS) and progression free 
survival (PFS), and toxicity were analyzed by histology in both arms.
Results: There were significant improvements in RR [20.8% (n=168) 
versus 2.1% (n=48), p<0.001], MST [16.0 months versus 8.5 months, 
p<0.001], and PFS [3.1 months versus 1.6 months, p<0.001] with 
Non-Sq versus Sq, respectively. 
In the P500 arm (n=108), RR were 23.5% (20/85) and 0% (0/23) 
(p = 0.0062), MST were 19.4 months (Incidence of death: 49.97%) 
and 7.9 months (p<0.001), and PFS were 3.1 months and 1.4 months 
(p<0.001) in patients with Non-Sq and Sq NSCLC, respectively. 
Likewise in the P1000 arm (n=108), RR were 18.1% (15/83) and 
4.0% (1/25) (p=0.1113), MST were 13.5 months and 8.6 months 
(p=0.0971), and PFS were 3.1 months and 1.7 months (p=0.0024), 
respectively. The incidence of adverse events in patients with Non-Sq 
NSCLC was similar to that in patients with Sq NSCLC in both P500 
and P1000 arms.
Conclusions: This result shows the differences in RR, MST, and PFS 
based on histological type in the Japanese randomized phase II study 
of pemetrexed in patients with advanced or metastatic NSCLC. Pa-
tients with Non-Sq NSCLC are provided similar tolerability and bet-
ter efficacy than those with Sq NSCLC in both P500 and P1000 arms. 
This evidence supports the treatment-by-histology effect observed in 
the past pivotal Phase III studies. The consistent results across these 
clinical studies demonstrate the advanced efficacy of pemetrexed in 
patients with non-squamous NSCLC.
 Variable Non-squamous Squamous P-value
 P500 and P1000 arms pooled n = 168 n = 48 
 Response rate, % 20.8 2.1 <0.001
 Median survival time (MST), months 16.0 8.5 <0.001
 Median progression-free survival (PFS), months 3.1 1.6 <0.001
 P500 arm n =85 n =23 
 Response rate, % 23.5 0 0.0062
 Median survival time (MST), months 19.4* 7.9 <0.001
 Median progression-free survival (PFS), months 3.1 1.4 <0.001
 P1000 arm n =83 n =25 
 Response rate, % 18.1 4.0 0.1113
 Median survival time (MST), months 13.5 8.6 0.0971
 Median progression-free survival (PFS), months 3.1 1.7 0.0024
 * Incidence of death: 49.97%   
PD9.1.2 NSCLC - Advanced Disease II, Mon, 10:30 - 12:00
Increasing role of tumor histology as a prognostic factor in 
patients with stage IV non small cell lung cancer
Morgensztern, Daniel2; Subramanian, Janakiraman1; Gao, Feng3; 
Govindan, Ramaswamy2
1 Washington University School of Medicine, St. Louis, Missouri, 
USA; 2 Division of Oncology, Washington University School of 
Medicine, St. Louis, MO, USA; 3 Division of Biostatistics, Washington 
University School of Medicine, St. Louis, MO, USA
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
Copyright © 2009 by the International Association for the Study of Lung CancerS534
Background: Until recently, there were minimal reported differences 
in outcomes for patients with stage IV non-small cell lung cancer 
(NSCLC) according to histology. Recent studies however, have 
shown improved response rates and survival for adenocarcinoma, 
particularly with the development of epidermal growth factor recep-
tor (EGFR) tyrosine kinase inhibitors. We searched Surveillance, 
Epidemiology, and End Results (SEER) database to evaluate if these 
differences were observed in a large cohort of unselected patients. 
Methods: The SEER database was queried for patients with NSCLC 
stage IV, aged 21 or older, and diagnosed between 1990 and 2005. 
The diagnostic years were equally divided into four time periods 
(1990-1993 or period 1, 1994-1997 or period 2, 1998-2001 or period 
3, 2002-2005 or period 4). Overall survival (OS) was estimated by 
the Kaplan-Meier method. 
Results: There were 130,664 patients meeting the inclusion cri-
teria, including 53,300 (41%) adenocarcinomas (Ad), 22,944 (17%) 
squamous cell carcinomas (Sq), 8,842 (8%) large cell carcinomas 
(LC), and 45,558 (34%) tumors of other or non-specified histolo-
gies. OS was significantly improved for Ad and Sq compared to LC 
and other histologies in multivariate analysis. Despite numerically 
superior survival rates for Ad compared to Sq, the difference was 
not significant in multivariate analysis for all periods combined (p = 
0.07). The difference became evident only in period 4 (HR 1.03, 95% 
CI 1.00-1.06; p = 0.02). 
Conclusions: Our large cohort study showed an increasing role 
of tumor histology in the prognosis of stage IV NSCLC. The most 
likely explanation is the recent introduction of targeted therapies with 
improved benefit in adenocarcinomas. 
PD9.1.3 NSCLC - Advanced Disease II, Mon, 10:30 - 12:00
Skin rash as a surrogate marker of cetuximab efficacy in 
advanced NSCLC: a retrospective analysis of BMS099
Neal, Joel W.1; Woytowitz, Donald2; Patel, Taral3; Dreisbach, Luke4; 
McCleod, Mitchell2; Heim, William J.5; Weber, Martin R.6; Siegel, 
Jonathan6; Gustafson, Nancy6; Lynch, Thomas J.1
1 Massachusetts General Hospital Cancer Center, Boston, MA, 
USA; 2 Florida Cancer Specialists, Fort Myers, FL, USA; 3 Mid 
Ohio Oncology/Hematology, Inc., Columbus, OH, USA; 4 Desert 
Hematology Oncology Medical Group, Rancho Mirage, CA, USA; 5 
Hematology & Oncology Associates of Northeastern Pennsylvania, 
Dunmore, PA, USA; 6 Bristol-Myers Squibb, Wallingford, CT, USA
Background: The phase III BMS099 trial investigated the addi-
tion of cetuximab to taxane/carboplatin for first-line treatment of 
advanced NSCLC. Progression-free survival (PFS) was not signifi-
cantly longer with cetuximab (HR=0.90), but response rate (RR) was 
significantly better, and median overall survival (OS) was longer but 
not statistically significant, similar in magnitude to the significant OS 
improvement from the FLEX trial (cisplatin/vinorelbine±cetuximab). 
A subset analysis of the FLEX trial revealed that the benefit of ce-
tuximab therapy was more pronounced in the 56% of patients treated 
with cetuximab that experienced early skin rash (onset <21 days, any 
grade), with a median OS (computed from randomization) of 15.0 
months versus 8.8 months in those without rash.
Methods: Chemonaïve patients with stage IIIB/IV NSCLC (any 
histology or EGFR expression status) were randomized to taxane/
carboplatin±cetuximab. Acneiform rash was evaluated following the 
NCI-CTC scale. Early onset rash was defined as acneiform rash of 
any grade appearing during day 1-21 of the study. A landmark analy-
sis, based on patients alive at day 21, compared OS between those 
with and without early onset rash (computed from day 21 until death, 
or last-known-alive date). 
Results: A total of 676 patients were randomized, 338 to cetuximab/
taxane/carboplatin and 338 to taxane/carboplatin. After 21 days on 
study, 315 patients treated with cetuximab/taxane/carboplatin were 
alive, and 185 (58.7%) had experienced acneiform rash of any grade. 
Using day 21 of the study as starting point, median survival for 
patients with acneiform rash was 10.4 months (95% CI, 7.7-12.0), as 
compared with 8.9 months (95% CI, 6.8-10.9) for the 130 patients 
who did not have early onset rash (HR=0.76; 95% CI, 0.59-0.98). 
Additional analyses are underway to explore the relationship between 
early onset rash and efficacy outcomes after cetuximab/taxane/carbo-
platin treatment.
Conclusions: Early onset acneiform rash may be related to ef-
ficacy in patients treated with cetuximab in advanced NSCLC. In 
the BMS099 trial, the group of patients with early onset rash had 
longer OS than those without. Additional analyses of the relation-
ship between early onset rash and the activity of cetuximab/taxane/
carboplatin in first-line advanced NSCLC in the BMS099 study are 
ongoing, and results will be presented.
PD9.1.4 NSCLC - Advanced Disease II, Mon, 10:30 - 12:00
Correlation between rash, hyperlipidemia, other 
characteristics and clinical outcome in patients with 
advanced non-small cell lung cancer (NSCLC) treated with 
erlotinib and bexarotene
Cyrus, Jobin2; Dragnev, Konstantin H.1; DiSalvo, Wendye M.1; 
Rigas, James R.1; Dmitrovsky, Ethan2
1 Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA; 2 
Dartmouth Medical School, Hanover, NH, USA
Background: Studies of the EGFR tyrosine kinase inhibitor er-
lotinib (E) have shown improved survival for NSCLC patients who 
developed skin rash. The nonclassical retinoid bexarotene (B) used 
alone or in combination with chemotherapy improved survival for 
the subset of NSCLC patients with hypertrigyceridemia. We have 
completed a phase II trial of E and B in patients (pts) with advanced 
NSCLC showing minimal toxicities and evidence of clinical activity. 
We now perform subset analyses to assess the correrlation between 
various clinical characteristics and outcomes. 
Methods: E 150 mg, B 400 mg/m2 were administered daily orally to 
pts with stage IV NSCLC, mostly as third line or higher. The appear-
ance of skin rash at any time during therapy was documented. Lipid 
levels and other clinical features were assessed in the first 6 weeks.
Results: Forty out of 42 enrolled pts were treated, and are included 
in the analyses, including 52% women and 74% with subtypes of 
adenocarcinoma. Median age was 64 years, median number of prior 
therapies was 2 (range 0-5), 20% were current smokers, 17 % were 
never smokers, 22% had prior anti-EGFR therapy. Median overall 
survival was 151 days (intent-to-treat). Survival was longer for pa-
tients who developed a rash (101 vs 174 days), Spearman coefficent 
was r=0.35, p=0.04. Patients with hypertryglyceridemia had better 
survival (115 vs 166 days) r=0.44, p=0.01. Patients with adenocarcin-
oma subtypes had longer survival than patients with other histologies 
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(157 vs 49 days), r=0.33, p=0.03. Patients with low albumin had 
shorter survival, as did patients with anemia. There was no associa-
tion between survival and cholesterol levels, presence of diarrhea, 
LDH levels, gender, lines of prior treatment, smoking status and prior 
anti-EGFR therapy. 
Conclusions: The regimen of E and B is well tolerated and shows 
evidence of activity in heavily pretreated pts with NSCLC. Develop-
ment of rash and hypertriglyceridemia in the first 6 weeks is associ-
ated with improved survival. The exploratory analyses for correlation 
of outcome and other clinical features suggest that the combination 
of E and B that target both EGFR and cyclin D1 may benefit a wider 
group of pts than therapy with the individual agents. Identification of 
the molecular basis for these associations is needed to allow selection 
of pts more likely to benefit from the combined therapy.
PD9.1.5 NSCLC - Advanced Disease II, Mon, 10:30 - 12:00
Homocysteine levels in newly diagnosed patients with non-
small cell lung cancer
Kelly, Veronica; Maguire, Joseph; Ledson, Martin; Smyth, Colin; 
Walshaw, Martin
Liverpool Heart and Chest Hospital, Liverpool, UK
Background: Plasma homocysteine level is the most sensitive 
marker of sub-clinical folate deficiency. Elevated levels of homo-
cysteine have been associated with several pathologies, particularly 
vascular and cardiac disease. Patients with lung cancer are frequently 
elderly and may have insufficient intake of folate. Sub-clinical folate 
deficiency may lead to increased morbidity during chemotherapy and 
radiotherapy, and possibly reduced response rates to both treatment 
modalities.
Methods: We have measured plasma homocysteine levels in 280 
patients with a diagnosis of non-small cell lung cancer who were 
referred to the Liverpool Heart and Chest Hospital between 2005 and 
2008. One hundred and fifty seven patients were male, one hundred 
and twenty three were female. The median age was 71. 23% of pa-
tients were PS 0-1, 30% PS2 and 47% PS3. 
Results: The local laboratory reference range for homocysteine is 
≤15 micromoles per litre. 124 patients (44%) had elevated plasma 
levels of homocysteine. In 98 (35%) the level was between 15.1 and 
25 micromoles per litre, and in 26 cases (9%) the homocysteine level 
was greater than 25 micromoles per litre. 
Patients with elevated plasma homocysteine levels had inferior 
median and one year survival rates, both for stage III disease (464 vs 
356 days ms, 1 year 65% vs 47%) and stage IV disease (212 vs 190 
days ms, 1 year 30% vs 21%).
Conclusion: The finding of elevated homcysteine levels in 44% of 
newly diagnosed patients with non-small cell lung cancer is of pot-
entially profound significance. There could be a possible therapeutic 
benefit from folate and B12 supplementation before and during treat-
ment for this group of patients with non- small cell lung cancer.
PD9.1.6 NSCLC - Advanced Disease II, Mon, 10:30 - 12:00
Mechanism of vascular endothelial growth factor blockade 
induced myelosupression in lung cancer patients treated 
with anti-VEGF therapy
Csiki, Ildiko; Novitsky, Sergei; Dikov, Mikhail; Sandler, Alan; 
Johnson, David H.; Carbone, David P.
Vanderbilt University Medical Center, Nashville, USA
Background: Lung cancer remains the number one cause of cancer 
death worldwide. Recently, a phase III study demonstrated that 
addition of bevacizumab, a monoclonal antibody against vascular 
endothelial growth factor (VEGF), to a standard, platin-based, two-
agent chemotherapy regimen conferred a significant improvement in 
overall survival, rate in patients with non–squamous-cell carcinoma 
of the lung, leading to subsequent FDA approval of the bevacizumab, 
carboplatin and paclitaxel (BCP) regimen in these patients. Along 
with these findings it was noted in several studies that increased toxic 
effects, particularly febrile neutropenia and pulmonary hemorrhage, 
were associated with the addition of bevacizumab. The purpose of the 
present study is to elucidate the mechanism of combination chemo-
therapy and bevacizumab induced myelosupression and to examine 
the role of VEGF and its receptors in the proliferation of hematopoi-
etic progenitor cells (HPCs). As VEGF receptors play important role 
in hematopoietic recovery after myelosuppression, we hypothesized 
that the combination of chemotherapy and anti-VEGF receptor 
treatment causes delayed hematopoietic recovery and neutropenia in 
patients. 
Methods: We retrieved laboratory data of patients with various 
cancers enrolled on different trials receiving bevacizumab and these 
data were retrospectively examined. We then examined the effect of 
myeloablative agents and VEGF receptor tyrosine kinase inhibitors 
(VEGFR TKI) on HPCc proliferation in-vivo. We also examined the 
pattern of HPC proliferation and WBC repopulation in knock-out 
mice for VEGF receptor treated with chemotherapy. 
Results: Through a retrospective analysis of patients receiving 
bevacizumab in combination with different chemotherapeutic agents 
for various cancers compared to matched patients receiving chemo-
therapy alone, we observed that bevacizumab in combination with 
chemotherapy significantly delays repopulation of white blood cells 
(WBC) that is patients treated with chemotherapy alone had an 
average decrease of 186WBC/µl/day during their therapy whereas 
patients treated with bevacizumab in addition to chemotherapy had a 
decrease of 335WBC/µl/day (p<0.005). Furthermore, we examined 
the combination effect of myeloablative agent and VEGFR TKI on 
the proliferation of HPCs in-vivo and found that wild-type mice 
treated with chemotherapy and VEGFR TKI as well as knock-out 
mice for VEGF receptor treated with chemotherapy had significantly 
delayed repopulation of WBC and impaired proliferation of HPCs 
(p<0.005). 
Discussion: Addition of bevacizumab to chemotherapeutic regimen 
in patients leads to delayed repopulation of WBCs leading to neutro-
penias. When present, VEGF increases the cell cycling of bone mar-
row cells and the proportion of HPCs in the bone marrow. However, 
interference with VEGF signaling at multiple levels delays WBC 
recovery and repopulation of bone marrow in mice. Furthermore, 
inhibition of VEGFR TKI and blockade of VEGF receptor signaling 
by anti-VEGF or anti-receptor reagents decreases proliferation of 
HPCs. These results aid in our understanding of the mechanism of 
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increased bone marrow toxicity observed clinically when using the 
BCP regimen in lung cancer patients as well as further our under-
standing of the role of VEGF and its receptors in angiogenesis and 
hematopoiesis. 
PD9.1.7 NSCLC - Advanced Disease II, Mon, 10:30 - 12:00
Erlotinib improves the symptoms and quality of life (Q&L) 
of patients (p) with non small cell lung cancer (NSCLC) 
independently of their smoking status 
Oramas, Juana1; Garrido, Pilar 2; Jimenez, Ulpiano6; Isla, Dolores 
3; García, Ramón7; Viñolas, Nuria4; Lianes, Pilar 5; Maestu, 
Inmaculada8; Regueiro, Pilar9; Massutí, Bartomeu10
1 Santa Cruz de Tenerife, Spain; 2 Hospital Ramón y Cajal, Madrid, 
Spain; 3 Hospital Lozano Blesa, Zaragoza, Spain; 4 Hospital Clinic, 
Barcelona, Spain; 5 Hospital de Mataró, Barcelona, Spain; 6 Hospital 
La Princesa, Madrid, Spain; 7 Hospital Gregorio Marañón, Madrid, 
Spain; 8 Hospital Dr. Peset, Valencia, Spain; 9 Roche Farma, Madrid, 
Spain; 10 Hospital General de Alicante, Alicante, Spain
Background: Erlotinib is a selective EGFR inhibitor approved for 
the treatments of p with NSCLC after failure of at least one prior 
chemotherapy. The pivotal BR.21 trial demonstrated that erlotinib 
improves significantly the symptoms related to the tumor, and aspects 
of the Q&L of the p, like pain, cough and dyspnea. 
Methods: The TargeT trial was an open-label, multicenter, non-ran-
domized phase II clinical trial carried out in 103 Spanish institutions. 
Patients with histological confirmed stage IIIB or IV NSCLC, 18 
years old, ECOG 0–2, adequate bone marrow, hepatic and renal func-
tion, written informed consent that had received previous treatment 
with chemotherapy as well as chemotherapy-naïve patients non suit-
able for first line chemotherapy were eligible. The p received 150mg/
day oral erlotinib. In July 2005, the protocol was amended to asses 
the Q&L and symptoms of the p, through the FACT-L (Functional 
Assessment of Cancer Therapy - Lung) questionnaire and its specific 
index TOI (Trial Outcome Index) which is the sum of the physical, 
functional and lung cancer subscales (LCS) of the FACT-L. 
We describe the results of Q&L and symptoms of the current/former 
and non smokers p wich at least completed the baseline and the first 
three cycles questionnaire. 
Results: From April 2004 to March 2006, 1,796 patients were 
included in the TargeT trial and 134 were evaluable for this analysis. 
Main baseline characteristics: non smokers (ns) 53 p and current/
former smokers (c/fs) 81 p; median age 67 years for ns (range 40-82) 
and 61 years for c/fs (range 30-85); males were 17% of the ns and 
80% of the c/fs; histology: adenocarcinoma (including BAC) 77% of 
the ns and 52% of the c/fs, squamous 2% of the ns and 27% of the c/
fs, large cell carcinoma 17% of the ns and 15% of the c/fs. Percentage 
of p receiving erlotinib in 1st/2nd/3rd lines was 40/41/19 for the ns 
population and 25/40/35 for the c/fs. Percentage of p ECOG 0/1/2 of 
the ns group was 26/57/17 and 32/63/5 in the c/fs group.
Rate of clinical benefit (CR+PR+SD) of the ns p was 91.8% 
(6%CR/51%PR/35%SD), and of the c/fs p was 72.6% 
(1%CR/18%PR/53%SD).
Related to the ns p, 51% improved their Q&L assessed by the 
FACT-L, 47% improved their TOI index and 56% improved all the 
symptoms measured by the LCS reaching statistical significance in 
shortness of breath (p<0.0001), cough (p<0.0001) and tightness of 
the chest (p<0.001). 
In the c/fs p, 46.5% and 31.5% improved their Q&L assessed respect-
ively by the FACT-L and TOI index. 52% of the p improved all the 
symptoms of the LCS, reaching statistical significance in shortness of 
breath (p<0.001), clear thinking (p<0.05), cough (p<0.05), tightness 
of the chest (p<0.001) and easy breathing (p<0.01).
The rate of clinical benefit (CR+PR+SD) of the ns p is associated 
with and improvement in the FACT-L and TOI index (p<0.05), but it 
is not in the case of the c/fs p (p=0.48). 
Conclusions: Q&L and symptoms improvement are the main ob-
jectives when we treat NSCLC p in second or third line. We should 
have always in mind novel targeted agents like erlotinib, which is 
as effective as the more toxic chemotherapies options in this setting. 
Moreover, erlotinib improves the specific symptoms associated to 
lung cancer in more than half of the p, even in those with worst 
prognosis, the c/fs.
PD9.2.1 NSCLC - Advanced Disease II, Mon, 10:30 - 12:00
Blood-based CHRNA3 single nucleotide polymorphisms 
(SNPs) and outcome in advanced non-small-cell lung 
cancer (NSCLC) patients 
Isla, Dolores2; Cobo, Manuel 3; Ramirez, Jose Luis1; Sanchez-Ronco, 
Maria4; de Aguirre, Itziar1; Provencio, Mariano5; Lopez-Vivanco, 
Guillermo6; Camps, Carlos7; Domine, Manuel8; Alberola, Vicente9; 
Taron, Miquel1; Rosell, Rafael1
1 Institut Catala d’Oncologia- Hospital Germans Trias i Pujol, 
Badalona, Ctra Canyet s/n, Spain; 2 Hospital Lozano Blesa, 
Zaragoza, Spain; 3 Hospital Carlos Haya, Malaga, Spain; 4 
University of Alcala de Henares, Alcala de Henares, Spain; 5 
Hospital Puerta de Hierro, Madrid, Spain; 6 Hospital de Cruces, 
Cruces-Baracaldo, Spain; 7 Hospital General de Valencia, Valencia, 
Spain; 8 Fundacion Jimenez Diaz, Madrid, Spain; 9 Hospital Arnau 
de Vilanova, Valencia, Spain
Background: Nicotine acetylcholine receptors (nAChRs) are as-
sociated with resistance to gemcitabine, cisplatin and paclitaxel in 
NSCLC cell lines. SNPs of CHRNA3, CHRNA5 and LOC123688 
increase lung cancer risk. We hypothesized that these SNPs may have 
influenced outcome in patients treated in our phase III trial of custom-
ized chemotherapy based on ERCC1 mRNA expression. 
Methods: 305 stage IV NSCLC patients were treated with custom-
ized chemotherapy. Patients in the control arm received docetaxel/
cisplatin; patients in the genotypic arm with low levels of ERCC1 
received docetaxel/cisplatin; patients in the genotypic arm with 
high levels of ERCC1 received docetaxel/gemcitabine. DNA was 
extracted from lymphocytes, and CHRNA3 (rs1051730), CHRNA5 
(rs16969968) and LOC123688 (rs8034191) SNPs were genotyped 
with the Taqman allele discrimination assay.
Results: A significant interaction was found for CHRNA3 genotype 
and PS (P = 0.02). In patients with PS 0, those with the heterozygous 
CT genotype had a better overall response rate (ORR) than both 
those with the homozygous wild-type CC (P = 0.01) and those with 
the variant TT (P = 0.02). Patients in the low genotypic group also 
had a better response (P = 0.01). When the CHRNA3 genotype was 
added in the multivariate analysis for progression-free survival (PFS), 
an improvement was observed in the low genotypic group in PS 0 
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patients (P = 0.02). PS 0 patients in the low genotypic group with the 
CT genotype attained an 84% ORR, 12.1-month (m) PFS, and 19-m 
median survival (MS). The table shows outcomes for PS 0 patients in 
each treatment group according to CHRNA3 genotype. 
Conclusions: CHRNA3 (rs1051730) genotyping can improve cus-
tomized chemotherapy based on tumor assessment of ERCC1 mRNA 
in stage IV NSCLC with PS 0. 
Con-
trol
Con-
trol
Con-
trol
Low 
ERCC1
Low 
ERCC1
Low 
ERCC1
High 
ERCC1
High 
ERCC1
High 
ERCC1
CC CT TT P CC CT TT P CC CT TT P
ORR 30.8% 56.5% 16.7% 0.12 50% 84% 50% 0.05 50% 62.5% 50% 0.85
PFS 
(m)
4.9 6.8 1.4 0.006 6.7 12.1 7.8 0.05 2.5 8.3 13.3 0.37
MS 
(m)
11.7 27.5 8.7 0.16 12.6 18.9 10.7 0.41 10.8 21.4 13.4 0.87
PD9.2.2 NSCLC - Advanced Disease II, Mon, 10:30 - 12:00
Revisiting the role of DNA repair polymorphisms 
in general prediction of patients responsiveness to 
chemotherapy in non-small cell lung cancer (NSCLC)
Pesek, Milos1; Benesova, Lucie2; Belsanova, Barbora2; Bittenglova, 
Radka1; Krakorova, Gabriela1; Minarik, Marek2
1 Dept. of Pulmonary Diseases, Pilsen, Czech Republic; 2 Laboratory 
for molecular genetics and oncology, Genomac International, Ltd., 
Prague, Czech Republic
Background: Over the past several years, importance of Single-
nucleotide polymorphisms (SNPs) of DNA repair genes has been 
numerously scrutinized in lung cancer susceptibility as well as in 
connection of the treatment outcome prediction for specific chemo-
therapy regimes. The results have often shown a borderline statis-
tical significance with low level of reproducibility among different 
research groups. It was the purpose of this work to evaluate the 
importance in a panel of DNA repair SNPs. Rather than aiming to-
wards a tool to select among the various chemotherapy combinations, 
we focused on a potential association with a general responsiveness 
towards chemotherapy.
Methods: A prospective study included patients with confirmed 
NSCLC treated at our clinic between 2006 and 2008. The final group 
consisted of 111 individuals with gemcitabine/taxanes cisplatine/
carboplatine combinations. A set of 5 SNPs (ERCC1 Asn118Asn, 
ERCC2 Lys751Gln, ERCC2 Asp312Asn, XRCC1 Arg399Gln and 
XRCC3 Thr241Met was genotyped from peripheral blood using a 
combination of denaturant capillary electrophoresis and standard 
PCR sequencing. Contribution of individual genotypes towards the 
objective response (CR, PR, SD or PD) was evaluated by a chi-square 
test. For each statistically significant result either the risk-allele or the 
protective-allele was subsequently identified.
Results: We have uncovered ERCC1 Asn118Asn and XRCC3 
Thr241Met as statistically significant predictors of therapy response 
across the various chemotherapies. T allele of the ERCC1 Asn118Asn 
marker bears a protective role (p=0,0288, chi-square test), while T 
allele of the XRCC3 Thr241Met bears a risk for poor response to any 
given chemotherapy (p = 0,0039, chi-square test). From the clinical 
data a plot was constructed for a cumulative trend in probability of 
positive response using the ERCC1 Asn118Asn and XRCC3 Thr-
241Met genotypic combinations. In addition, a previously suggested 
association between two polymorphisms in ERCC2 gene (Lys751Gln 
and Asp312As) was also confirmed (p < 0,001, chi-square test).
Conclusion: Probability of chemotherapy response may be estimated 
from a combination of ERCC1 Asn118Asn and XRCC3 Thr241Met 
genotypes. Typing of these two markers may therefore assist in deci-
sion for or against particular anticancer therapy types.
PD9.2.4 NSCLC - Advanced Disease II, Mon, 10:30 - 12:00
Baseline TGF-α and amphiregulin levels in non small cell 
lung cancer (NSCLC) patients treated with erlotinib or 
placebo in the NCIC Clinical Trials Group (NCIC CTG) 
BR.21 clinical trial
Bradbury, Penelope A.1; Addison, Christina L.2; Goss, Glenwood3; 
Shepherd, Frances A.4; Seymour, Lesley1; Le Maitre, Aurelie1; Ding, 
Keyue1
1 NCIC Clinical Trials Group, Kingston, ON, Canada; 2 Centre for 
Cancer Therapeutics/ Ottawa Health Research Institute, Ottawa, 
ON, Canada; 3 The Ottawa Hospital/ University of Ottawa, Ottawa, 
ON, Canada; 4 Princess Margaret Hospital/ University of Toronto, 
Toronto, ON, Canada
Background: BR.21 demonstrated that erlotinib, an epidermal 
growth factor receptor tyrosine kinase inhibitor (EGFR TKI), 
prolonged overall survival of previously treated NSCLC patients. 
We evaluated the predictive and or prognostic effects of the EGFR 
ligands, TGFa and amphiregulin. 
Methods: Plasma samples were collected prior to erlotinib/placebo 
in consenting patients. TGFa and amphiregulin were analyzed by 
ELISA (R&D Systems). Samples were blinded, measured in dupli-
cate and ligand concentrations determined following interpolation 
of a standard curve generated from known quantities of recombin-
ant proteins. The sensitivity of both assays was ~3pg/ml. If feasible, 
assays were performed on previously-thawed samples in addition to 
non-thawed, and average values were used. Cutoff points for both 
TGFa and amphiregulin were <10 (low) and ≥10 (high) pg/ml. Stan-
dard statistical methods, including Kaplan-Meier and Cox regression 
models were used to correlate biomarker data with baseline char-
acteristics and outcomes such as overall (OS) and progression free 
survival (PFS). 
Results: Among 731 randomized patients, 539 were evaluable for 
both markers; there was a significant interaction (p=0.03) between the 
evaluable cohort and the inevaluable cohort (erlotinib benefit favor-
ing the evaluable cohort). At baseline, high TGFa was associated with 
poorer ECOG PS (p=0.03) while high amphiregulin was associated 
with worse ECOG PS (p<0.0001), anemia (p<0.0001), increased 
LDH (0.02), no response to prior therapies (p=0.01) and no prior plat-
inum therapy (p=0.007). Although TGFa was not prognostic for OS 
(HR=1.0, p=0.99), high amphiregulin was (HR=2.05, 95% C.I. 1.45-
2.91, p<0.0001). High TGFa was a poor prognostic factor for PFS 
(HR 1.40, 95% C.I. 0.96–2.08, p=0.07) as was elevated amphiregulin 
(HR 1.67, 95% C.I. 1.19-2.33, p=0.002). In multivariate analyses 
including both ligands, high amphiregulin remained prognostic, but 
neither ligand was predictive. 
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Conclusions: High levels of baseline amphiregulin appears to be a 
poor prognostic factor, while low levels of TGFa showed a trend to 
predict benefit from erlotinib
Overall Survival 
Erlotinib Arm 
(months)
Overall Survival 
Placebo Arm 
(months)
HR (95% CI) Interaction
TGFa Low 7.8 4.5 0.64 (0.52-
0.80)
P=0.09
TGFa High 3.7 3.6 1.06 (0.64-
1.74)
Amphiregulin 
low
8.4 5.8 0.66 (0.52-
0.83)
P=0.88
Amphiregulin 
high
4.3 2.6 0.71 (0.49-
1.02)
Progression Free 
Survival Erlotinib 
Arm (months)
Progression Free 
Survival Placebo 
Arm (months)
HR (95% CI) Interaction
TGFa Low 2.1 1.8 0.62 (0.51-
0.76)
P=0.89
TGFa High 2.0 1.8 0.53 (0.32-
0.89)
Amphiregulin 
low
2.7 1.9 0.55 (0.44-
0.69)
P=0.50
Amphiregulin 
high
1.8 1.6 0.70 (0.49-
1.01)
PD9.2.5 NSCLC - Advanced Disease II, Mon, 10:30 - 12:00
The nicotinic acetylcholine receptor (nAChR) subunit 
alpha3 (CHRNA3) polymorphism in advanced non-
small-cell lung cancer (NSCLC) patients (p) with EGFR 
mutations treated with erlotinib
Rosell, Rafael1; Ramirez, Jose Luis1; de Aguirre, Itziar1; Benlloch, 
Susana2; Cuello, Mauricio2; Cardona, Andres Felipe1; Moran, 
Teresa1; Carcereny, Enric1; Massuti, Bartomeu3; Taron, Miquel1; 
Gonzalez, Nuria1; Porta, Ruth4
1 Institut Catala d’Oncologia- Hospital Germans Trias i Pujol, 
Badalona, Ctra Canyet s/n, Spain; 2 Pangaea Biotech, USP Instituto 
Universitario Dexeus, Barcelona, Spain; 3 Hospital General de 
Alicante, Alicante, Spain; 4 Hospital Trueta, Girona, Spain; 5 
Hospital de Bellvitge, Institut Català d’Oncologia, Bellvitge, Spain; 6 
Hospital de Sevilla, Sevilla, Spain
Background: Polymorphisms in the 15q region, containing the 
genes for alpha3 and alpha5 subunits of heteromeric nAChRs, are 
associated with a predisposition to lung cancer even in a smoking-
independent manner. Activation of the nAChR pathway leads to 
upregulation of the CREB (CMP response element-binding) protein, 
which transactivates the EGFR and induces the release of EGF and 
VEGF. CREB overexpression decreases survival in never-smokers 
with NSCLC. We hypothesized that CHRNA3 would influence out-
come in NSCLC p with EGFR mutations treated with erlotinib. 
Methods: Stage IV NSCLC p with EGFR mutations were prospect-
ively treated with erlotinib. Genomic DNA was derived from tumor 
tissue obtained by laser capture microdissection. Deletions in exon 19 
(del 19) were determined by length analysis after PCR amplification 
with a FAM-labelled primer in an ABI Prism 3130 DNA Analyzer. 
Exon 21 point mutations L858R were detected with a TaqMan assay. 
DNA was extracted from lymphocytes and CHRNA3 (rs1051730) 
polymorphism was genotyped with the TaqMan allele discrimination 
assay. 
Results: 185 NSCLC p with EGFR mutations were treated with er-
lotinib. Median age, 68; 136 females; 182 Caucasians, 3 Asians; 123 
never-smokers, 44 ex-smokers, 10 current smokers; 145 adenocarcin-
omas, 21 BAC, 19 LCC; 179 stage IV, 6 stage IIIB with malignant 
pleural effusion; 99 first-line erlotinib, 86 second-line; 110 del 19, 75 
L858R. 62 p had the homozygous (CC) CHRNA3 genotype; 94 were 
heterozygous (CT); 29 were homozygous for the variant (TT). No 
differences in p characteristics were found according to the CHRNA3 
genotype. Overall response: CR, 19 p (11.6%); PR, 97 p (59.1%); 
ORR, 116 p (70.7%); SD, 33 p (20.1%); PD, 15 p (9.1%); 21 p had 
no measurable disease according to RECIST criteria. No differences 
in response were observed according to the CHRNA3 genotype. 
Median follow-up, 14 months (m) (range, 1-42 m). Median time to 
progression (TTP), 14 m (95%CI, 10.9-17.1). Median survival (MS), 
28 m (95%CI, 24.9-31.1). Hazard ratios for shorter TTP were 3.7 for 
male gender (P=0.05), 4.65 for PS 2 (P=0.19), 0.18 for CT geno-
type (P=0.03), 0.21 for CC genotype (P=0.07), and 2.31 for L858R 
(P=0.23). 
Conclusion: p with EGFR mutations have an impressive response 
rate and TTP when treated with erlotinib. However, a subgroup of 
p with the variant CHRNA3 TT genotype have a significant risk of 
relapse, perhaps due to overexpression of EGF and VEGF through 
hyperactivation of the nAChR pathway. Assessment of the CHRNA3 
polymorphism can help identify these patients and provide a useful 
guide for additional therapeutic decisions. 
PD9.3.1 NSCLC - Advanced Disease II, Mon, 10:30 - 12:00
Approved therapies for advanced non-small cell lung 
cancer, food and drug administration overview
Malik, Shakun1; Justice, Robert1; farrell, Ann T.2; Sridhara, 
Rajeshwari1; Pazdur, Richard1
1 FDA, Silver Spring, MD, USA; 2 FDA/CEDR, Silver Spring, MD, 
USA
Background: FDA considers improved overall survival (OS) in a 
randomized controlled trial to be the standard for establishing clinical 
benefit for drug approval in patients with advanced non-small cell 
lung cancer (NSCLC). Response rate (RR) and progression-free 
survival (PFS) may support accelerated approval (AA) if they are 
reasonably likely to predict clinical benefit. 
Methods: The AA regulations (21 CFR 314, subpart H and 21 CFR 
601, subpart E) allow use of surrogate endpoints to support approval 
of drugs to treat serious or life-threatening diseases if the drug either 
demonstrates an improvement over available therapy or provides 
therapy where none exists. These endpoints must be reasonably likely 
to predict clinical benefit and the sponsor must conduct additional 
studies to establish clinical benefit.
Results: The basis for approval of the majority of drugs approved 
for advanced NSCLC was OS (table). Gefitinib and pemetrexed are 
the only drugs granted AA. Gefitinib’s approval was based on two 
phase II randomized trials, IDEAL-I trial conducted in 43 non-US 
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centers (Fukuoka, JCO 2003) and IDEAL-II trial conducted in 30 
centers within the U.S. (Kris, JAMA 2003). The post-marketing study 
to establish clinical benefit failed to show a statistically significant 
improvement in OS (Thatcher, Lancet 2005). These findings led 
to labeling revisions for gefitinib restricting use to patients already 
receiving and benefiting from the drug. Concurrently, erlotinib dem-
onstrated a survival advantage over BSC. However, debate remains 
regarding possible benefit from EGFR tyrosine kinase inhibitors in 
patients with tumors harboring high EGFR expression by IHC, with 
high gene copy number by FISH, or with KRAS and EGFR muta-
tions. 
Pemetrexed received AA as monotherapy based on a randomized 
Phase III Trial which compared pemetrexed to docetaxel in second-
line therapy (Hanna, JCO 2004). The study objective of noninferior-
ity for OS could not be demonstrated because of significant patient 
crossover and inability to characterize docetaxel effect size. However, 
comparable RR and a more favorable safety profile supported the 
accelerated approval of pemetrexed. A randomized trial compared 
OS following first-line treatment with pemetrexed/cisplatin versus 
gemcitabine/cisplatin. Although patients with non-squamous histol-
ogy appeared to benefit from pemetrexed, the drug had a detrimental 
survival effect in patients with squamous cell histology. (Scagliotti, 
JCO 2008). 
Conclusion: FDA recognizes that NSCLC is a heterogeneous disease 
and recommends that clinical trials be prospectively designed to 
evaluate the new treatments in subpopulations. These trials should 
not only be based on histology alone, but on biomarkers as well. 
Regulatory Experience with New Drug approvals for the Treatment of 
Non-Small Cell Lung Cancer (NSCLC)
Drugs Trial Design Approval Endpoints
First-line inoperable/metastatic 
NSCLC
Vinorelbine monotherapy Open-label, randomized, active-
control trial vs. 5FU/leucovorin
OS, ORR
Vinorelbine in combination with 
cisplatin
Open- label, randomized, active-
control trial vs. cisplatin
OS, ORR
Open- label, randomized, active-
control trial, paclitaxel/cisplatin 
vs. vinorelbine/cisplatin
OS, TTP, ORR 
Gemcitabine in combination with 
cisplatin
Open-label, randomized, active-
control trial vs. gemcitabine 
OS
Open-label, randomized, active-
control trial, gemcitabine + 
cisplatin vs. etoposide + cisplatin
TTP, ORR
Bevacizumab1 in combination 
with paclitaxel/carboplatin
Open-label, randomized, 
active-control trial vs. paclitaxel/ 
carboplatin 
OS 
Paclitaxel in combination with 
cisplatin
Open-label, active-controlled, 
dose-ranging, randomized, 
3-arm trial, paclitaxel (135 mg/
m2) /cisplatin vs. paclitaxel (250 
mg/m2)/cisplatin vs. etoposide/
cisplatin
TTP, ORR, OS
Pemetrexed in combination with 
cisplatin1,2
Open-label, active controlled, 
randomized trial; pemetrexed/cis-
platin vs. gemcitabine/cisplatin
OS
Second-line NSCLC
Docetaxel Randomized, placebo-controlled 
study, docetaxel vs. best sup-
portive care
OS, TTP, ORR
Erlotinib Randomized, placebo-controlled 
study, 
OS, TTP, ORR
Pemetrexed1,2 Randomized, placebo-controlled 
study, 
Durable ORR, 
Decreased toxicity
Third-line NSCLC
Erlotinib Randomized, placebo-controlled 
study 
OS, TTP, ORR
 Gefitinib Single-arm trial Durable ORR
Partially or completelyObstructing 
Endobronchial tumor NSCLC and 
Microinvasive Endobronchial 
NSCLC in non-surgical candidates
Porfimer sodium and photo-
dynamic therapy (PDT)
Randomized, open-label active-
controlled trial vs. YAG laser
Improvement in 
disease-related 
symptoms
1 limited to non-squamous, non-small cell lung cancer; 2 accelerated approval
PD9.3.2 NSCLC - Advanced Disease II, Mon, 10:30 - 12:00
Evaluation and rating of anti-cancer drugs in non-small-
cell lung cancer
Guirgis, Helmy M.
University of CA, Irvine, Dana Point, CA, USA
Background: We analyzed the survival (S), adverse effects (AEs) 
and Cost (C) of the recent 150 anti-cancer drugs and combinations 
and reported methodology to evaluate drugs in gastrointestinal malig-
nancies.
Objectives: Further develop scoring quantitative methodology to 
evaluate and grade anti-cancer drugs in NSCLC..
Methodology: Previously reported OS and AEs were used. Scales 
were constructed in point (P) system and 0.5 P-increments to grade A 
and AEs. Administration was graded from 3P (oral) to zero P ( daily 
injections) depending on convenience, route, frequency of injections 
and duration of infusion.
CTCAE v 3.0 was utilized. However, highest P (4) assigned to 
placebo and zero P to fatalities. Tyrosine kinase Inhibitors (TKIs) 
or Cetuximab (Cet) 2P; Chemotherapy combined with TKIs, Cet or 
Bevacizumab (BV) 1.5P.
Cost in US $ to treat one patient weighing 70 kg or 1.7 m2 was div-
ided by S gain in days over control (C/S). C-scores were calculated 
by dividing C/S by (A plus AEs). C/S > 960 or C-scores > 480 were 
rated D while C/S < 30 or C-scores < 15 were rated A+. 
Results: After resection, adjuvant Cisplatin (Cis) + Vinorbine (Vin) 
in stage II and III scored the highest S and and lowest C/S and C-
scores (A+). In metastatic or advanced disease, BV at 15mg/kg q 3w 
in combination with Paclitaxel (Pac) + Carboplatin improved OS at 
C+ and B rating. However, BV added to Cis and Gemcitabine (Gem) 
demonstrated the lowest S and ratings at high C/S.
Discussion: The proposed methodology was based the association 
between C/S and arbitrary but relative weights of AEs and A. C-score 
approach rewards drugs for convenience and safety and penalizes 
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
Copyright © 2009 by the International Association for the Study of Lung CancerS540
them for cumbersome A and more AEs. Each drug was evaluated on 
S as well C/S. Higher C/S, increased AEs and cumbersome A resulted 
in higher C-scores and lower ratings. 
Conclusion: C-scores might provide quantitative and practical basis 
for preliminary drug evaluation
Drug & Combination 0S Gain Cost US $ C/D/S & 
Rating
Cost 
Ratio
Cost 
Ratio
C score (CR/
A+AEs) 
x 100 & 
Rating
Cistplatin (Cis)+ 
Vinorlbine (Vin) 
after resection 
Stage II 
369
$880 2.39 A+ 0.16 2 + 2 3.97 A+
vs. no adjuvant 
(IALT)
Stage III 
434
$880 2.03 A+ 0.14 2 + 2 3.38 A+
Cis + Vin x 6 Cy + 
Cetuximab x 12 Cy, 
mNSCLC (FLEX), IV 
and IIIB, 1st-line, 
36 S17,010 472.5 B 31.5 2 + 1.5 900 C
Erlotinib (Er) 150mg 
daily x 6m, 2nd or 
3rd line
60 $9,540 159 B+ 10.6 3 + 2  212 B+
EGFR screening: 
Exon 19 or 22 
mutations
330 $9,540 28.9 A+ 1.93 3 + 2 38.5 A+
Exon 19 deletion 
Women vs men 
Rosell et al, 2008.
150 $9,540 63.6 A+ 4.24 3 + 2 85 B
Pulse Er 1500mg 
d1+2,Pac + Pac d 
3 x 6y
150 $6,360 42.4 A 2.83 2+ 1.5 81 A
PD9.3.3 NSCLC - Advanced Disease II, Mon, 10:30 - 12:00
Challenges in regulatory marketing approval of drugs 
for the treatment of advanced non-small cell lung cancer 
based on non-inferiority trials
Sridhara, Rajeshwari; Malik, Shakuntala
Center for Drug Evaluation and Research, USFDA, Sliver Spring, 
MD, USA
Background: Efficacy of an experimental drug can be demonstrated 
either using a randomized superiority trial or a randomized non-infer-
iority trial. In a superiority trial the efficacy is established by showing 
a superior benefit with the experimental drug (T) over placebo or 
standard treatment (C). In a non-inferiority trial, efficacy is estab-
lished indirectly and assumes that the standard or control treatment 
(C) has known established efficacy. A non-inferior efficacy implies 
that the experimental treatment (T) has no clinically meaningful loss 
of effectiveness compared to the control treatment (C). Generally a 
non-inferior efficacy is considered if the new drug is believed to be 
less toxic. In this paper the assumptions, requirements and the chal-
lenges in establishing a non-inferior efficacy will be presented.
Methods: There are different methods that are used in the design and 
analysis of non-inferiority trials. There is no one method that is suit-
able under all circumstances. Two commonly used methods include 
(1) a fixed margin approach where a margin based on informative 
judgment (clinical margin) is pre-specified, and (2) a margin is 
pre-specified based on the standard errors in the historical and the 
non-inferiority trials. In both methods the evidence of efficacy of the 
control treatment (C) is assumed. A non-inferiority trial is designed 
to establish the effectiveness of the experimental drug by demonstrat-
ing that it is not worse than the effectiveness of the control treatment 
(C) by more than the pre-specified margin. Examples of advanced 
non-small cell lung cancer trials that were designed as non-inferiority 
trials reported in the literature will be presented.
Discussion: Superiority trials provide direct evidence of effectiveness 
and understanding of the benefit-risk of an experimental treatment. 
Design and interpretation of non-inferiority trials are challenging. For 
a non-inferiority design consideration the efficacy of the control treat-
ment over placebo or best supportive care has to be well established 
and quantifiable using more than one randomized historical study. 
Also the patient population, other treatment conditions, and methods 
of outcome measures in the non-inferiority trial should be the same 
as in the historical studies of the control treatment. These assump-
tions are difficult to verify and it is common to observe change of 
clinical practice over time. The advanced non-small cell lung cancer 
trials that have been reported in the literature pose some of these 
challenges. Non-inferiority trials are difficult to interpret and provide 
indirect evidence of effectiveness compared to placebo. The Agency’s 
current thoughts on these issues will be discussed.
PD9.3.4 NSCLC - Advanced Disease II, Mon, 10:30 - 12:00
Do the time to chemotherapy response and the dose 
intensity have an impact on patient outcome in advanced 
non-small cell lung cancer?
Radosavljevic, Davorin Z.; Golubicic, Ivana; Gavrilovic, Dusica; 
Kezic, Iva; Jelic, Svetislav
Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
Background: To better define the importance of early response rate 
(RR) as well as dose intensity (DI) in advanced non small cell lung 
cancer (NSCLC) patients treated with platinum-based combination 
chemotherapy.
Methods: Analysed were stage IIIB and IV NSCLC patients included 
in 4 prospective clinical trials. All of them were treated with cisplatin 
120 mg/m2 (the majority of patients) or carboplatin 500 mg/m2, and 
since 2000. AUC 5 (the minority of patients) with second-generation 
platinum-based regimens. Responding patients (complete response/
CR and partial response/PR) were divided into 4 different categor-
ies, depending on the time when response was first registered. DI 
and total dose (TD) of cisplatin was calculated for 93 patients with 
response or stable disease (SD).
Results: Among 362 patients analysed, 117 (32%) were responders. 
Although “early” responders (54 patients after the 2nd cycle, median 
survival 10 months; 42 patients after the 3rd cycle, median survival 
11 months) lived shorter than “late” responders (11 patients after the 
4th cycle, median survival 12months; 10 patients after the 5th cycle, 
median survival 19 months), these differences were not statistic-
ally significant, neither in terms of overall survival (OS) nor in time 
to progression (TTP). DI in patients with CR+PR+SD was 30 mg/
m2/week (median). TD of cisplatin in CR+PR patients was 577 mg, 
whereas it was 475 mg in patients with SD (p=0.004). These differ-
ences followed significant differences in the number of the cycles 
received and median survival between CR+PR vs. SD patients. 
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Conclusion: Early response was not associated with better survival, 
DI in SD patients did not differ from responding patients, but re-
sponding patients received more cisplatin and lived longer.
PD9.3.5 NSCLC - Advanced Disease II, Mon, 10:30 - 12:00
Cost effectiveness of erlotinib treatment given by a 
clinically based approach and an EGFR/KRAS testing-
guided approach in advanced non small-cell lung cancer: a 
prospective multicentric French study (ERMETIC)
Borget, Isabelle1; Cadranel, Jacques2; Pignon, Jean-Pierre4; Danton, 
Guillaume4; Coudert, Bruno5; Dansin, Eric6; Friard, Sylvie7; Daniel, 
Catherine8; Quoix, Elisabeth9; Madelaine, Jeannick10; Madroszyk, 
Anne11; Morin, Franck12; Chouaid, Christos 13
1 Health Economics Department, Institut Gustave Roussy, Villejuif, 
France; 2 Hopital Tenon, Paris, France; 3 Biostatistics and 
epidemiology, Villejuif, France; 4 Biostatistics and epidemiology, 
Institut Gustave Roussy, Villejuif, France; 5 CLCC Dijon, Dijon, 
France; 6 CHU-CLCC Lille, Lille, France; 7 Hopital Foch, Suresnes, 
France; 8 Institut Curie, Paris, France; 9 CHU Strasbourg, 
Strasbourg, France; 10 CHU-CLCC Caen, Caen, France; 11 CLCC 
Marseille, Marseille, France; 12 IFCT, Paris, France; 13 Hopital 
Saint-Antoine, Paris, France
Rational: Few studies have evaluated the economic impact of erlotin-
ib in the treatment of advanced non small-cell lung cancer (NSCLC) 
in regard to its efficacy. Although several clinical (histology, gender, 
smoking status and ethnicity) and biological (EGFR-IHC, EGFR-
FISH and EGFR/KRAS sequencing) parameters are known prognostic 
factors, their medico-economic impact in the prescription of erlotinib 
in such setting has never been evaluated. In attempt to address this 
question French NCI granted the ERMETIC prospective study. The 
objectives of this study were to determine the global cost of manage-
ment of advanced NSCLC patients treated by erlotinib and to evaluate 
if the cost-effectiveness ratio is decreased in populations selected on 
clinical-guided or biomarkers-guided arguments. 
Methods: Biomarkers were studied in all available tumor specimens 
collected from consecutive advanced NSCLC pts newly treated by 
erlotinib. Patients were followed until progression or death. Cost-
effectiveness evaluation was performed using clinical and economic 
data extracted from the prospective cohort. Direct medical costs (in-
cluding erlotinib and hospitalization costs) were computed from the 
perspective of the health system with a time horizon of 2 years. Hos-
pitalisation costs were computed using the cost accounting system. 
Cost-effectiveness ratios (CER) were calculated as the global cost of 
management of patients treated by erlotinib divided by the number 
of days of life remaining when the treatment by erlotinib is initiated 
(censured delay between erlotinib initiation treatment and death). 
CER were calculated in all patients, in clinical-selected patients (non/
ex-smoking women with non-squamous cell carcinoma (SCC) histol-
ogy) and in biomarker-selected patients.
Results: 520 of the 530 pts enrolled between 02/07 and 03/08 
were included in this analysis. Median age was 62 (33-93); 32% 
were female; 18% were never and 67% former smokers; 63% had 
adenocarcinoma. Erlotinib was given as 2nd-or-more-line in 87% of 
pts. With a 15.2 months (mo.) median of follow-up, median of PFS 
was 2.4 mo. and of OS 5.6 mo., with a 30% 1-year OS. The mean 
global cost of management was 10 284±8562 € per NSCLC patients 
treated by erlotinib, with a median of 168 days remaining to live 
from the initiation of erlotinib treatment to death (i.e. 61 €/day of life 
remaining). Direct erlotinib cost was 78% of the global management 
cost per patient. Non-smoking women with non-SCC histology lived 
127 days longer than other patients (277 and 150 days, respectively), 
resulting in an extra-cost management of 2637 € (12 258 € and 
9620 €, respectively), mainly due to a longer erlotinib treatment. 
However, CER was lower (44 €/day of life remaining to live) in 
non-smoking women with non SCC histology than in other patients 
(64€/day). CER of biomarkers-selected patients will be available for 
the congress. 
Conclusion: Clinical-guided arguments allowed to identify patients 
associated with lower management costs per day of life remaining to 
live. Planned analyses would evaluate if the impact of the selection of 
patients according the biomarkers results in term of cost of manage-
ment per day of life remaining. 
PD9.3.6 NSCLC - Advanced Disease II, Mon, 10:30 - 12:00
To what degree do patients with advanced lung cancer 
want to be informed and involved in medical decision-
making? A multicentre study in 13 hospitals in Belgium
Pardon, Koen1; Van Meerbeeck, Jan2; Schallier, Denis3; Germonpré, 
Paul4; Galdermans, Danny5; Van Kerckhoven, Willem6; Bernheim, 
Jan1; Deschepper, Reginald1; Mortier, Freddy7; Vander Stichele, 
Robert8; Deliens, Luc1, 9
1 End-of-Life Care Research group, Vrije Universiteit Brussel, 
Brussels, Belgium; 2 University Hospital Ghent, Ghent, Belgium; 
3 University Hospital Brussels, Brussels, Belgium; 4 Antwerp 
University Hospital, Antwerp, Belgium; 5 ZNA Middellheim Hospital, 
Antwerp, Belgium; 6 Sint Augustinus Hospital, Wilrijk, Belgium; 
7 Bioethics Institute Ghent, Ghent University, Ghent, Belgium; 8 
Heymans Institute for Pharmacology, Ghent University, Ghent, 
Belgium; 9 Department of Public and Occupational Health, EMGO 
Institute for Health and Care Research, VU University Medical 
Centre, Amsterdam, Netherlands
Background: Patients with advanced lung cancer are understudied 
with regard to their preferences for information and participation in 
decision-making in treatment options, healthcare-setting transfers and 
end-of-life decision-making. This study aimed to identify the infor-
mation and participation preferences and the socio-demographic and 
clinical patient characteristics associated with these preferences. 
Methods: Over the course of 1 year, pulmonologists and oncologists 
in 13 hospitals in Flanders, Belgium, invited patients with an initial 
diagnosis of stage IIIB/IV non-small-cell lung cancer for an interview 
with a structured questionnaire. 
Results: 128 patients with a median estimated survival time of 10 
months were eligible and participated. Ninety nine point two percent 
of patients wanted information on diagnosis, 97.7% on treatment 
options and 96.9% on chances of cure. There was more variation be-
tween patients on specific topics: 88% of patients wanted information 
on life expectancy, 63 % on palliative care and 57% on end-of-life 
care. With regard to participation in treatment, transfer and end-of- 
life decisions, respectively 63%, 48% and 16% of patients preferred 
the doctor to make the decisions. Patients with comorbidity were 
less likely to prefer active involvement in end-of-life decisions than 
patients with no comorbidity.
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Conclusions: This study shows that preferences might differ 
depending on the type of decision and on situational factors in the 
evolving process of care and palliation. A patient-centered approach 
to participation in decision-making in patients with advanced lung 
cancer implies full information for most, as well as participation 
in end-of-life decision-making. A minority prefer to be involved in 
treatment decision-making. In order to understand the complex end-
of-life preferences of their patients, pulmonologists or oncologists 
treating patients with advanced lung cancer should establish good and 
continuous communication.
PD9.4.1 NSCLC - Advanced Disease II, Mon, 10:30 - 12:00
Baseline characteristics of patients enrolled in a study 
investigating the effects of ethnicity on treatment for non-
small cell lung cancer (NSCLC) in the second-line setting 
with pemetrexed
Peltz, Gerson1; Girvan, Allicia C.1; Schwartzberg, Lee S.2; Pennella, 
Eduardo1; Pohl, Gerhardt1; Bendaly, Edmond A.1; Walker, Mark S.2; 
Faries, Douglas E.1; Obasaju, Coleman K.1; Stepanski, Edward 2; 
Marciniak, Martin D.1; Adjei, Alex A.3
1 Eli Lilly & Co., Indianapolis, IN, USA; 2 ACORN, Memphis, TN, 
USA; 3 Roswell Park Cancer Institute, Buffalo, NY, USA
Background: A paucity of information is available concerning the 
impact of race and ethnic origin on clinical outcomes and resource 
utilization during cancer treatment. More specifically, very few stud-
ies have examined such impact in NSCLC. Furthermore, barriers 
associated with enrollment of minority patients in clinical trials may 
help to explain some of these gaps. We present a preliminary analysis 
of baseline characteristics from an ongoing prospective observa-
tional study designed to evaluate the effects of ethnicity on clinical 
outcomes and resource utilization of patients with advanced NSCLC 
treated with pemetrexed used as second-line chemotherapy in routine 
clinical practice. 
Methods: Eligibility criteria included stage IIIB or IV NSCLC 
patients receiving pemetrexed for second-line therapy with no 
restrictions on performance status. It is expected an accrual of 400 
Caucasians, 200 African-Americans, 200 Asian-Americans, and 
200 Hispanics. Baseline data from an initial cohort of 304 patients 
(251 Caucasians, 34 African-Americans, 12 Asian-Americans, and 7 
Hispanics) were analyzed to identify differences in the distribution of 
social and clinical characteristics, as well as responses from activities 
of daily living (OARS-IADL) and symptom burden (MDASI-LC) 
questionnaires. The comparisons were carried out using Fisher’s 
exact test.
Results: Compared to Caucasians, African-Americans had a lower 
education level (at least some college: 36.6% and 14.7%, respective-
ly; p = 0.012), less private insurance (43.7% and 23.1%, respectively; 
p = 0.02), and lower income (less than $25,000.00: 36.0% and 63.0%, 
respectively; p = 0.01). Among current and former smokers, African-
Americans smoked on average fewer cigarettes daily compared to 
Caucasians (17.7 and 25.2, respectively; p = 0.01), whereas there 
were no current smokers among Asian-Americans. There was no 
significant difference in the medical history, but African-Americans 
were likely to have less depression (8.8% and 23.7%, respectively; 
p = 0.05) and fewer fractures (6.1% and 20.4%, respectively; p = 
0.06) than Caucasians. There were no differences in disease stage 
and histology subtype, although 9 out of 12 Asian-Americans (75%) 
had adenocarcinoma. The various ethnic groups were not signifi-
cantly different in terms of prior therapy received (surgery, radiation, 
number of prior chemotherapy cycles) and response to front-line 
treatment; however, more surgeries were performed in Caucasians 
compared to African-Americans (31.2% and 14.7 %, respectively; p = 
0.07). Performance status prior to initiation of second-line treatment 
was comparable across ethnic groups. Hispanics showed IADL scores 
associated with less impairment compared to Caucasians (IADL total 
score: 13.7 and 11.8, respectively; p = 0.001).
Conclusions: Race/ethnicity was associated with differences in co-
variates that may influence clinical outcomes and resource utilization 
in the second-line treatment of advanced NSCLC with pemetrexed. 
Continued enrollment to a final sample size of 1,000 patients is 
planned at which point the direct effects of race/ethnicity may be 
clarified. In addition, the current enrollment count demonstrates that 
the barriers of enrolling minority patients are also seen in an observa-
tional study setting. 
PD9.4.2 NSCLC - Advanced Disease II, Mon, 10:30 - 12:00
Assessment of the cost-effectiveness of zoledronic acid 
in the management of skeletal metastases in lung cancer 
patients in France, Germany, and the United Kingdom
Botteman, Marc F.1; Kaura, Satyin2
1 Pharmerit North America LLC, Bethesda, MD, USA; 2 Novartis 
Pharmaceuticals Corporation, East Hanover, NJ, USA
Background: Zoledronic acid (ZOL) reduces the risk of skeletal-re-
lated events (SREs) in lung cancer (LC) patients with bone metasta-
ses. The present retrospective analysis compares the economic impact 
of ZOL in LC patients in France, Germany, and the United Kingdom 
(UK).
Methods: Estimated direct costs and quality-adjusted life years 
(QALYs) experienced by LC patients with bone metastases receiving 
placebo (PBO) or ZOL were modeled and compared. Overall survival 
(OS), SRE incidence, and number of infusions administered were 
obtained from a 21-month randomized clinical trial comparing the 
proportion of patients who experienced an on-study SRE with 4 mg 
ZOL or PBO every 3 weeks (Rosen et al. J Clin Oncol. 2003). Costs 
of treatments and SREs were estimated using national reimburse-
ment listings (eg, diagnosis-related groups), private databases, and 
published literature. The mean number of SREs was calculated by 
multiplying the mean SRE rate by the mean OS for LC patients in 
the study. For QALYs, OS was multiplied by a utility factor of 0.53. 
Consistent with similar economic analyses, it was assumed that qual-
ity of life (QOL) decreased 20% to 80% (depending on the SRE type) 
for 1 month after each SRE experienced. Sensitivity analyses were 
performed to test the effects of alternate scenarios, with less than 
€30,000 per QALY considered cost-effective.
Results: During the median OS of 179 days, PBO patients (n = 120) 
experienced a mean of 2.07 SREs versus 1.32 SREs among ZOL 
patients (n = 124). QALYs were estimated at 0.352 per patient (ZOL 
patients) and 0.335 per patient (PBO patients). Use of ZOL resulted 
in a net increase of 0.017 QALY per patient versus PBO. ZOL 
drug-related costs were €1,610, €1,510, and €1,597 per patient in 
France, Germany, and the UK, respectively. Use of ZOL resulted in 
reductions in SRE costs of €2,221, €2,031, and €2,014 per patient, 
respectively. Overall, ZOL saved €598 per patient in France, €521 
in Germany, and €417 in the UK. In sensitivity analyses, ZOL was 
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cost-effective under a variety of scenarios (total range, –€98,356 to 
+€34,052 per QALY).
Conclusions: ZOL leads to fewer SREs, better estimated QOL, and 
lower estimated costs relative to PBO in German, French, and UK 
LC patients with bone metastases. Use of ZOL in these populations is 
therefore cost-saving and highly cost-effective.
PD9.4.3 NSCLC - Advanced Disease II, Mon, 10:30 - 12:00
Bone disease progression (BDP) is associated with 
significantly increased risk of skeletal-related events 
(SREs) in patients with advanced solid tumors including 
non-small cell lung cancer (NSCLC) 
Tchekmedyian, Simon N.1; Chen, Yin-Miao2; Hirsh, Vera3
1 Pacific Shores Medical Group, Long Beach, CA, USA; 2 Novartis 
Pharmaceuticals Corporation, East Hanover, NJ, USA; 3 McGill 
University Health Centre (MUHC), Royal Victoria Hospital, 
Montreal, QC, Canada
Background: Approximately 35% of patients with metastatic 
NSCLC develop bone lesions. Patients with bone metastases are at 
risk for potentially debilitating SREs, defined as pathologic fractures, 
the need for palliative radiotherapy or surgery to bone, spinal cord 
compression, and hypercalcemia of malignancy. The resulting bone 
pain and SREs can contribute substantially to the overall morbidity 
in these patients. Intravenous zoledronic acid (ZOL; 4 mg monthly) 
is the only bone-directed therapy with established efficacy for re-
ducing the risk of SREs in the NSCLC setting. However, it is unclear 
whether progression of the underlying bone lesions directly correlates 
with the risk of SREs or treatment benefits. 
Methods: Data from the 21-month, randomized, placebo-controlled 
phase III trial of ZOL (every 3 weeks) in patients with bone metasta-
ses from lung cancer or other solid tumors excluding breast or pros-
tate cancer (N = 773; Rosen et al. J Clin Oncol. 2003) were analyzed 
to determine rates of bone lesion progression, potential correlations 
between bone disease progression and risk of SREs, and treatment 
benefits. Radiographic assessments of bone lesions were performed 
every 3 months or as clinically indicated. BDP, defined as progres-
sion of an existing lesion or appearance of a new lesion, was assessed 
by a central radiographer blinded to treatment allocation and disease 
history. All analyses were stratified by cancer type. Risk ratios for 
first SRE and all on-study SREs were assessed in Cox regression 
and Andersen-Gill multiple event analyses, respectively. Multivari-
ate models incorporated baseline variables previously identified as 
being risk factors for SREs (SRE history, pain, performance status, 
number of bone lesions), treatment groups (ZOL 4 mg, ZOL 8/4 mg, 
or placebo), and BDP as a time-dependent variable. 
Results: Approximately 50% (n = 383) of the enrolled patients had 
advanced NSCLC. In the overall trial population (N = 773), median 
time to BDP was 109 days for placebo versus 145 days for ZOL 4 mg 
and 238 days for ZOL 8/4 mg. Median time to first SRE (most com-
monly palliative radiotherapy or pathologic fracture) was 155 days 
for placebo and 236 days for the approved dose of ZOL (4 mg; P = 
.009). In multivariate Cox regression analyses, BDP was associated 
with a greater than 4-fold increased risk of first SRE (P < .001) and 
an approximately 1.5-fold increased ongoing risk of any SREs (P 
= .003) versus no BDP. The benefits of ZOL 4 mg for reducing the 
risk of SREs were maintained in both multivariate models (approxi-
mately 35% risk reduction for first or any SRE; P ≤ .001 for both), 
suggesting that treatment was beneficial even in patients whose bone 
lesions progressed on-study. 
Conclusions: BDP significantly increases the risk of SREs in patients 
with bone lesions from solid tumors. Ongoing treatment with ZOL 
significantly reduces the risk of SREs compared with placebo in 
multivariate models, even after adjusting for the effects of significant 
covariates including BDP.
PD9.4.4 NSCLC - Advanced Disease II, Mon, 10:30 - 12:00
Survival of patients with non small cell lung cancer 
(NSCLC) following diagnosis of brain metastases
Ellis, Peter M.; Ali, Asma; Goffin, John R.; Arnold, Andrew
Juravinski Cancer Centre, Hamilton, ON, Canada
Background: The prognosis of patients with brain metastases from 
NSCLC is generally considered poor. However, some reports suggest 
that the outlook of patients presenting with brain metastases at the 
time of diagnosis may be similar to that of patients with advanced 
NSCLC without brain metastases. We undertook a retrospective 
review of NSCLC patients with brain metastases to examine whether 
the outcomes of care for patients presenting with brain metastases is 
different from that of patients developing brain metastases at a later 
date.
Methods: All new lung cancer patients seen in our institution be-
tween July 2005 and June 2007 were identified from a database. The 
subset of patients from this cohort who developed brain metastases, 
were selected for inclusion in this retrospective review. Baseline 
characteristics, treatment and outcome data were extracted from the 
chart. The primary outcome of interest was a comparison of survival 
of patients with brain metastases at diagnosis compared with patients 
who developed brain metastases later. 
Results: Ninety one of 878 (10.4%) new patients seen during the 2 
year time period developed brain metastases at some point in their 
illness. There were 43 men and 48 women. The median age was 64 
yrs (sd 10.6yrs). Histology was adenocarcinoma (52%), squamous 
(12%), large cell (3%), NOS (33%). 45 patients had brain metastases 
at presentation while 46 developed brain metastases later in their 
illness. The majority of patients (87%) were symptomatic from their 
brain metastases. 34 (37%) had a solitary brain metastasis and 18 
(20%) underwent surgical resection. The radiation dose was 20Gy 
in 5 fractions (67%), or 30Gy in 10 fractions (33%). Only 17% of 
patients received systemic therapy following a diagnosis of brain 
metastases. The median overall survival for all patients was 7.8m. 
Patients with brain metastases at diagnosis had a significantly shorter 
overall survival than patients who developed brain metastases later 
(9.8m v 4.3m, p=0.001). Survival following diagnosis of brain me-
tastases was similar for both groups (3.7m v 4.8m, p=0.53). Patients 
presenting with brain metastases were less likely to be referred to a 
medical oncologist (51% v 74%, p=0.02) and less likely to receive 
chemotherapy (18% v 41%, p=0.01). 
Conclusion: These data suggest that NSCLC patients with brain me-
tastases at diagnosis have a significantly worse survival than patients 
who develop brain metastases at a subsequent time point in their ill-
ness. Few patients received systemic therapy following diagnosis of 
brain metastases. It is unclear whether greater use of systemic therapy 
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would have impacted on survival and further research is needed to 
determine the utility of chemotherapy in this patient group.
PD9.4.5 NSCLC - Advanced Disease II, Mon, 10:30 - 12:00
Can upfront systemic chemotherapy replace stereotactic 
radiosurgery or whole brain radiotherapy in the treatment 
of non-small cell lung cancer patients with asymptomatic 
brain metastases?
Kim, Kyoung Ha1; Lee, Jeeyun 2; Park, Yeon Hee 2; Ahn, Jin Seok 2; 
Park, Keunchil2; Ahn, Myoung-Ju 2
1 Soonchunhayng University Hospital, Seoul, Korea; 2 Samsung 
Medical Center, Seoul, Korea
Background: The optimal treatment for non-small cell lung cancer 
(NSCLC) patients with asymptomatic brain metastasis is still contro-
versial. This study aimed to analyze the outcome for various treat-
ment modalities including chemotherapy only, upfront whole brain 
radiotherapy (WBRT) or stereotactic radiosurgery (SRS) in NSCLC 
patients with asymptomatic brain metastases.
Methods: We retrospectively reviewed the medical records of 
patients with histopathologically proven NSCLC and synchronous 
asymptomatic brain metastasis between January 2003 and December 
2007. 
Results: From the database, 741 NSCLC patients were identified 
to have been diagnosed of brain metastases during initial staging 
or follow-up between January 2003 and December 2007. Of 741 
NSCLC patients, 135 (18%) NSCLC patients were identified to have 
synchronous brain metastasis without associated symptoms. Of the 
129 patients included in the analysis, 78 (57.8%) patients received 
systemic chemotherapy only, 27 (20.0%) upfront WBRT followed 
by chemotherapy and 24 (17.8%) patients received upfront SRS 
and chemotherapy. There was no significant difference in overall 
survival among three groups (systemic chemotherapy alone, 13.9 
versus upfront SRS followed by chemothemotherapy, 22.4 versus 
upfront WBRT followed by chemotherapy, 17.7 months, respectively; 
P=.086). Subset analysis of 110 adenocarcinoma patients showed that 
the median OS for patients treated with upfront SRS was longer than 
those of upfront WRBT (29.3 months versus 17.7 months; P=0.01) or 
chemotherapy alone (29.3months versus 14.6 months; P=0.04). 
Conclusion: This study suggested a potential role of systemic 
chemotherapy alone or upfront SRS followed by chemotherapy 
instead of WBRT as an initial treatment of NSCLC patients with 
synchronous, asymptomatic brain metastases. The optimal treatment 
modality, however, needs to be defined in prospective trials for this 
subset of patients.
PD9.4.6 NSCLC - Advanced Disease II, Mon, 10:30 - 12:00
Whole brain radiation therapy plus concomitant 
temozolomide for the treatment of brain metastases from 
non-small cell lung cancer: a randomized, open-label, 
phase II study
Chua, Daniel1; Krzakowski, Maciej2; Chouaid, Christos3; Pallotta, 
Maria G.4; Martinez, Jose I.5; Gottfried, Maya6; Curran, Walter7; 
Throuvalas, Nikolaos8
1 Queen Mary Hospital, Pokfulam, Hong Kong; 2 Maria Sklodowska-
Curie Memorial Hospital, Warsaw, Poland; 3 Hopital Saint Antoine, 
Paris, France; 4 Hospital Italiano, Buenos Aires, Argentina; 5 
Instituto Nacional de Cancerologia, Bogota, Colombia; 6 Meir 
Medical Center Oncology Institute, Kfar-Saba, Israel; 7 Thomas 
Jefferson University Hospital, Philadelphia, USA; 8 Athens Medical 
Center, Athens, Greece
Purpose: A previous phase III study suggested that temozolomide 
concurrent with whole brain radiotherapy (WBRT) significantly 
increased median survival and time to central nervous system (CNS) 
progression versus WBRT alone in patients with brain metastases 
primarily from lung cancer. This study sought to confirm those results 
in patients with non-small cell lung cancer (NSCLC). 
Methods and Materials: This planned phase III study (target = 
380 events) was converted to a phase II study (target = 70 events), 
because of poor enrollment. Patients with NSCLC and ≥1 newly 
diagnosed brain lesion were randomized to WBRT (30 Gy in 10 
fractions) alone or combined with temozolomide (75 mg/m2/day) for 
21 to 28 days. Study endpoints included overall survival and time to 
CNS progression. 
Results: Median overall survival was 4.4 months in the WBRT + 
temozolomide arm (n = 47) versus 5.7 months in the WBRT arm (n 
= 48). Median time to CNS progression was 3.1 months for WBRT 
+ temozolomide versus 3.8 months for WBRT alone. The differ-
ence was not statistically significant. The addition of temozolomide 
to WBRT increased the frequency of nausea, vomiting, alopecia, 
fatigue, anorexia, and constipation; most adverse events were mild to 
moderate. 
Conclusions: The benefit of adding temozolomide to WBRT was not 
confirmed; however, the original accrual goal for the planned phase 
III trial was not reached and the treatment regimen used in the cur-
rent trial differed from the regimens used in earlier studies. There-
fore, the role of temozolomide in treating brain metastases remains 
unresolved. 
PD9.5.1 NSCLC - Advanced Disease II, Mon, 10:30 - 12:00
Prospective evaluation of quality of life and patient 
reported outcomes as primary endpoints using the 
computer-assisted LCSS in a large multi-national 
docetaxel-based trial in non-small cell lung cancer 
(NSCLC): the Asia-Pacific QL Trial
Park, K2; Gralla, Richard J.1; Hollen, Patricia J.3; Thongprassert, 
Sumitra4; Hsia, Te-Chun5; Yuankai, Shi6; Kim, H7; Kejing, Y8; 
Namkanisorn, T9; Kim, AM10
1 North Shore - LIJ Health System, Lake Success, NY, USA; 2 
Samsung Medical Center, Seoul, Korea; 3 University of Virginia, 
Charlottesville, VA, USA; 4 Maharaj Nakorn Chiang Mai Hospital, 
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Chiang Mai, Thailand; 5 China Medical University Hospital, 
Taichung, Taiwan; 6 Chinese Academy of Medical Sciences, Beijing, 
China; 7 The Catholic University of Korea, Gyeonggi-do, Korea; 
8 Sir Run Run Shaw, Hangzhou, China; 9 Prapokklao Hospital, 
Chanthaburi, Thailand; 10 National Cancer Centre, Singapore, 
Singapore
Background: Few large trials in advanced NSCLC have focused 
on health-related quality of life (QL) and patient reported outcomes 
(PROs) as primary endpoints. Improvement in survival in this highly 
symptomatic malignancy is a desired but somewhat elusive end-
point for all patients in repeated randomized trials. Achieving both 
QL/PRO and survival advantages remain key goals for lung cancer 
therapy. QL and PRO evaluation have been hampered by several per-
ceived barriers. The Asia Pacific-QL Trial was designed to: 1) evalu-
ate the impact of chemotherapy on QL and symptoms for all patients; 
2) evaluate QL by response category (CR+PR = major response; 
stable disease; and progression); and 3) test whether barriers in QL 
evaluation are overcome by using a computer-assisted validated 
instrument (LCSS-QL) in a trial conducted at 43 cancer centers.
Methods: All patients were previously untreated with chemotherapy 
and received docetaxel-based treatment (83% with cisplatin or with 
carboplatin) based on known response and survival results (Fossella 
JCO 2003). Patients were assessed every 3 weeks with the LCSS-QL. 
Results: To date, 300 patients have been entered and 243 evaluated. 
Repeated QL and PRO measures are available in 91% of patients 
through 3 cycles of chemotherapy. Demographics: 77% Stage IV 
and 33% Stage III; 72% men; 67% adenocarcinoma; median age 58; 
KPS 90-100 = 66%, 70-80 = 34%. A 37% major response rate was 
achieved. QL feasibility: high patient and staff acceptability was 
found (at 43 sites, in 8 countries). For the whole group (using 5% as 
a minimally important difference), after 3 chemotherapy cycles, all 9 
LCSS parameters were stable or improved. Improvements were noted 
in overall QL and in cough (> 5% and 7%, respectively). By chemo-
therapy response, rapid differences in PRO effects were observed. 
Within as few as 6 weeks of chemotherapy initiation, patients with 
major response had better symptom control than patients with pro-
gression (p<0.05 in 4 of the 6 major symptoms after cycle 3). Total 
LCSS-QL score was better for patients with major response (p=.007) 
or stable disease (p=.03) compared with progressive NSCLC.
Conclusions: 1) The 91% compliance rate with QL assessment in 43 
centers demonstrates that the computer-assisted LCSS-QL approach 
overcomes barriers to QL assessment; 2) these results support the 
feasibility of evaluating QL during chemotherapy trials with this 
methodology; 3) at least with docetaxel-based chemotherapy, major 
response is associated with better symptom control and total QL 
improvement than stable disease or progression; 4) for the whole 
group of patients there was no detriment in QL and PRO status even 
though only a minority (37%) had a major response; and 5) assess-
ment of QL and PRO parameters could be accomplished early into 
treatment (by the key decision points of 2 and 3 chemo cycles). This 
trial demonstrates that QL and PRO evaluation can be practical, can 
be incorporated into clinical trials and into standard patient care when 
aided by computer-assistance, and can help guide chemotherapy 
treatment decisions.
PD9.5.2 NSCLC - Advanced Disease II, Mon, 10:30 - 12:00
Overcoming barriers in evaluating health-related quality 
of life in lung cancer – assessing the attitudes of patients, 
physicians and nurses using a computer-assisted quality of 
life instrument (LCSS-QL) in non-small cell lung cancer: 
results from the Asia-Pacific QL Trial
Hollen, Patricia J.2; Gralla, Richard J.1; Thongprassert, Sumitra3; 
Kim, Hoon-Kyo4; Hsia, Te-Chun5; Yuankai, Shi6; Lee, Seung-Se 7; 
Wang, Jui-Long 8; Tantimongkolsuk, Chaturong9; Zaatar, Adel10
1 North Shore - LIJ Health System, Lake Success, NY, USA; 2 
University of Virginia, Charlottesville, VA, USA; 3 Maharaj Nakorn 
Chiang Mai Hospital, Chiang Mai, Thailand; 4 St. Vincent’s Hospital, 
Suwon, Korea; 5 China Medical University Hospital, Taichung, 
Taiwan; 6 Chinese Academy of Medical Sciences, Beijing, China; 7 
Kangbuk Samsung Hospital, Seoul, Korea; 8 Chang-Gung Memorial 
Hospital, Taipei, Taiwan; 9 Somdej-Phra Pinklao Hospital, Bangkok, 
Thailand; 10 Mount Miriam Cancer Hospital, Penang, Malaysia
Objectives: Barriers to the assessment of health-related quality of life 
(QL) in practice and in clinical trials have been identified in several 
surveys. Reported barriers include insufficient clinic time available, 
a lack of resources for performing QL evaluation, and a perceived 
lack of validated QL instruments. If QL and symptom evaluation is 
to become part of standard patient and trial assessment, these barriers 
must be addressed and overcome. A major goal of the Asia-Pacific 
QL Trial is to determine if conversion of a well-validated QL instru-
ment (LCSS) into a computer-assisted format using an inexpensive 
pocket-pc enhances feasibility, provides immediate results, and helps 
overcome these and other barriers. This analysis determines the 
acceptability and value of the electronic LCSS-QL as assessed by 
patients, physicians and nurses.
Methods: All patients entered into this large multi-center trial were 
receiving their initial chemotherapy and utilized the LCSS-QL at 
baseline and then every three weeks. Additionally, patients completed 
a form evaluating their experiences with the electronic QL measure 
and handheld pc. All received docetaxel-based chemotherapy (83% 
with cisplatin or with carboplatin). Treating physicians and nurses 
administered the LCSS-QL and also completed an evaluation form 
assessing their views. The form evaluated: time required, satisfaction 
with the process, value of assessment, impact on communication, 
resource utilization.
Results: To date, 242 patients have been treated and assessed by 
31 physicians and 41 nurses in 8 Asian countries at 43 sites. Patient 
characteristics include: Stage IV (77%) and Stage III (23%); median 
KPS 90%; 72% male; median age 58 years. Patients reported little 
prior computer experience. The table below gives the results from the 
categorical scales of the questionnaires concerning the LCSS-QL (not 
all individuals answered all questions). 
Patients generally needed less than 3 minutes to complete the LCSS-
QL. Using the LCSS-QL added no time to the physician visit, and 
the nurses and physicians felt that overall having this available could 
save time. Healthcare professionals had high computer skills and 
found the LCSS-QL easy to learn and use. 
Conclusions: Patients and professionals found that using a validated 
QL instrument in a computerized format was easy, added value and 
satisfaction, while enhancing communication and QL awareness. 
Ongoing analyses are comparing results by country and with a similar 
evaluation in Canada for cross-cultural assessment. These results 
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indicate that this computer-assisted method can overcome barriers to 
QL assessment and can make QL and symptom evaluation a practical 
part of standard patient care. 
 ISSUES: PATIENTS AGREEING MDs / RNs AGREEING
 The LCSS-QL was easy to use 93% 92%
 Acceptable to complete the LCSS-QL at each visit 88% ---
 QL evaluation aided communication 84% 92%
 QL evaluation made the visit more difficult 2% ---
 The effect of chemotherapy could be identified earlier --- 72%
 QL evaluation could result in ordering fewer tests --- 75%
 It helped in addressing QL and symptom issues --- 70%
 The LCSS-QL could save time with patient visits --- 83%
 QL evaluation increased satisfaction with the visit --- 88%
PD9.5.3 NSCLC - Advanced Disease II, Mon, 10:30 - 12:00
Docetaxel plus carboplatin versus docetaxel for the 
patients with old age or poor performance in advanced 
non-small cell lung cancer: randomized phase III study
Kang, Byung Woog; Lee, Dae Ho; Suh, Cheolwon; Lee, Jung Shin; 
Choi, Chang Min; Shim, Tae-Sun; Kim, Woo-Sung; Hong, Jeong 
Sook; Kim, Sang-We
University of Ulsan College of Medicine, Asan Medical Center, 
Seoul, Korea
Background: Docetaxel has shown clinical activity in elderly pa-
tients with advanced non-small cell lung cancer (NSCLC). Although 
the platinum agent is important for usual chemotherapy for advanced 
NSCLC, the role of platinum based chemotherapy is unclear in 
patients with old age or poor performance status. This randomized 
phase III study evaluated the efficacy and safety of docetaxel plus 
carboplatin (DC) versus docetaxel (D) for the patients with old age or 
poor performance in advanced NSCLC.
Methods: Chemotherapy-naïve patients with stage IIIB or IV docu-
mented NSCLC who were older than 70 years or ECOG performance 
status 2 were eligible. The primary objective was to compare overall 
survival between DC and D at the 1-sided 10% significance level. 
One hundred and sixty patients were planned to be assigned to treat-
ment arm DC (docetaxel 35mg/m2 on Days 1 and 8 plus carboplatin 
at area under the curve 2.5 on days 1 and 8, every 3 weeks) or arm D 
(docetaxel 75mg/m2 on day 1, every 3 weeks). 
Results: From July 2004 to October 2008, 83 patients were enrolled. 
Fourty-one patients were assigned to receive DC arm and 42 patients 
to D arm. Median age was 72 years (range 49-87). The objective 
response rate was 19.5% (DC arm) and 26.2% (D arm), respectively. 
No differences were noted in median overall survival (7.3 months for 
DC arm; 7.5 months for D arm; P=0.668) and median time to pro-
gression (5.4 months for DC arm; 5.9 months for D arm; P=0.995). 
Toxicities were mild and similar in both treatment arms. The most 
common grade 3 to 4 toxicity was neutropenia (34.1% for DC arm; 
23.8% for D arm). The result of QoL will be presented.
Conclusions: Although DC was well-tolerated and showed modest 
activity for the patients with old age or poor performance in advanced 
NSCLC, it failed to show superiority in survival compared with D.
PD9.5.4 NSCLC - Advanced Disease II, Mon, 10:30 - 12:00
Treatment and outcomes of elderly vs younger patients 
with advanced NSCLC at Mayo Clinic Arizona (MCA) 
Paripati, Harshita; Tong, Wilson; Karlin, Nina J.; Dueck, Amylou C.; 
Ross, Helen J.
Mayo Clinic, Scottsdale, AZ, USA
Background: Non-small cell lung cancer (NSCLC) is predominantly 
a disease of the elderly. Most patients present with incurable ad-
vanced disease, but chemotherapy for good performance status (PS) 
patients improves quality and quantity of life. Despite good PS, many 
elderly patients with metastatic NSCLC do not receive chemotherapy. 
This study compared treatment, outcomes, and survival in elderly vs 
younger patients with stage IV NSCLC.
Methods: All analytic MCA Cancer Registry patients with stage IV 
NSCLC from 1998-2007 were retrospectively reviewed for type of 
therapy and outcome. Patients were analyzed by age: <75 vs ≥75 
years old. Categorical variables were compared using chi-squared 
tests and survival was compared by Cox regression.
Results: 344 patients with stage IV NSCLC were identified. 234 
(68%) patients were <75 years old, and 110 patients (32%) were ≥75 
years old. Median survival for all patients was 7 months. Among 
302 patients with treatment data available, 60.8% of patients <75 
years old received some form of systemic therapy (chemotherapy/
targeted therapy) compared to only 32% of patients ≥ 75 years old 
(p <0.0001). Among patients with PS 0-1, patients <75 years old 
more frequently received systemic therapy than elderly patients 
(88.5% vs 32.1%, p<0.0001); whereas a difference was not evident 
in patients with PS 2-4 (34.1% vs 41.7%, p=0.49). Median survival 
in the <75 age group was 7 months vs. 3.4 months in the ≥75 age 
group (p=0.048). In the <75 age group, median survival was 12 
months in patients who received chemotherapy vs. 2 months in the 
other or no treatment group (p<0.0001). In the elderly group, median 
survival was 10 months in the chemotherapy group vs. 2 months in 
the patients who received other or no treatment (p=0.0003).Thus, the 
median survival was significantly improved among the patients who 
received systemic therapy independent of age. Statistical significance 
persisted when stratifying by performance status.
Conclusions: Patients with stage IV NSCLC have improved survival 
with systemic therapy independent of age. Our results confirm that 
despite an improvement in survival similar to younger patients, 
elderly patients with metastatic NSCLC are often undertreated. 
Prospective trials should be designed to include metastatic NSCLC 
patients without age discrimination.
PD9.5.5 NSCLC - Advanced Disease II, Mon, 10:30 - 12:00
Salvage therapy for elderly patients with advanced non-
small cell lung cancer who failed previous chemotherapy
Wu, Chieh-Hung; Fan, Wen-Chien; Chen, Yuh-Min; Tsai, Chun-
Ming; Perng, Reury-Perng; Lee, Yu-Chin
Chest Medicine Department, Taipei Veteran General Hospital, Taipei, 
Taiwan, Taipei, Taiwan
Background: Lung cancer is the leading cause of cancer death in 
the world, and the non-small cell lung cancer (NSCLC) accounts for 
more than 80% of the lung cancer. There were several clinical trials 
that showed several chemotherapeutic agents and EGFR-TKI can be 
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effective second-line salvage therapeutic agents for advanced NSCLC 
patients. However, whether elderly patients (>=70 year-old) fit the 
salvage therapy as non-elderly patients (<70 year-old) and whether 
EGFR-TKI is more favorable than chemotherapeutic agents as sal-
vage therapy agents in elderly NSCLC patients are unknown. 
Methods: We retrospectively reviewed and updated the data of our 
NSCLC patients who received second-line salvage therapies, classi-
fied them into elderly and non-elderly group, and compared the ef-
ficacy, toxicities and survival of the patients for the salvage therapies.
Results: 461 cases were reviewed. The non-elderly group had 
statistical insignificant better response rate, disease control rate and 
median survival time than the elderly group (23.5% vs 18.5%, p=0.2, 
68.2% vs 67.9%, p=0.93, 9.3 months vs 8.3 months, p=0.47, respect-
ively). The non-elderly group had statistical insignificant less hemato-
logic toxicities than the elderly group, but more nausea and fatigue 
than the elderly group. Besides, in the elderly group, when comparing 
with salvage chemotherapies, the EGFR-TKI salvage therapy resulted 
in similar disease control rate and median survival time (66.2% vs 
70%, p=0.805, 7.6 months vs 6.5 months, p=0.836, respectively), and 
with more favorable toxicity profiles.
Conclusions: The elderly patients had similar responses with the 
non-elderly patients, both in salvage chemotherapies and EGFR-TKI 
therapy, with acceptable toxicities. Among the elderly patients, the 
EGFR-TKI salvage therapy resulted in similar responses and more 
favorable toxicities compared with salvage chemotherapies. Thus, 
age itself should not preclude NSCLC patients from second line 
salvage therapy.
PD9.5.6 NSCLC - Advanced Disease II, Mon, 10:30 - 12:00
Evaluation of the efficacy of chemotherapy for advanced 
non-small-cell lung cancer patients aged over 80 years old
Tamiya, Akihiro; Tsuya, Asuka; Nakamura, Madoka; Kaira, Rieko; 
Ono, Akira; Ayabe, Eriko; Shukuya, Takehito; Igawa, Satoshi; 
Nakamura, Yukiko; Naitou, Tateaki; Kaira, Kyouichi; Murakami, 
Haruyasu; Takahashi, Toshiaki; Endo, Masahiro; Yamamoto, 
Nobuyuki
Shizuoka Cancer Center, Suntou-gun, Japan
Background: In elderly patients with advanced non-small lung 
cancer (NSCLC), Mono-chemotherapy, such as Vinorelbine and Do-
cetaxel, is the standard chemotherapy. But little information is avail-
able regarding the management of advanced NSCLC patient aged 
over 80 years old (octogenarians), a rapidly expanding, potentially 
vulnerable population cohort. The purpose of our present study is to 
evaluate the safety and efficacy of chemotherapy in octogenarians 
with advanced NSCLC. 
Methods: In this study, we retrospectively evaluated the octgenarians 
with advanced NSCLC who received chemotherapy between January 
2005 and August 2008, and compared with the octgenarians with 
advanced NSCLC who received best supportive care (BSC) and with 
the 75-79 years patients with advanced NSCLC who received chemo-
therapy. We evaluated the toxicity using with the common terminol-
ogy criteria for advanced events (CTCAE), and calculated the overall 
survival (OS) and the progression free survival (PFS) using with the 
Kaplan-Meier estimate.
Results: Between January, 2005 and August, 2008, there were110 
patients aged over 75 years old. In this group, there were 63 patients 
aged 75-79 years old, 55 patients were received chemotherapy, and 
8 patients received BSC because of bad PS. And 47 patients were 
octogenarians, 21 octogenarians received mono-chemotherapy, and 
26 octogenarians received BSC. The median overall survival (MST) 
was 205 days in octogenarians who received chemotherapy and was 
148 days in octogenarians who received BSC (P=0.03). The median 
PFS was 86 days in octogenarians who received chemotherapy and 
was 124 days in 75-79 years patients who received chemotherapy 
(P=0.157). And, the MST was 205 days in octogenarians who re-
ceived chemotherapy and was 270 days in 75-79 years patients who 
received chemotherapy (P=0.477). 
The toxicity of the 21 octogenarians with advanced NSCLC in the 
chemotherapy was acceptable toxicity; over grade 3 of leucopenia 
was occurred 33.3%; over grade 3 of neutropenia was occurred 
52.3%; but no febrile neutropenia was occurred; and over grade 3 
of non-hemotological toxicity was occurred 14.3%, including AST 
(4.8%) and fatigue (9.5%).
Conclusion: It seems that there is no distinguished necessity between 
75-79 years old patients with advanced NSCLC and octogenarians 
with advanced NSCLC in elderly patient’s chemotherapy. And, in 
octogenarians with advanced NSCLC, there is some benefit to receive 
chemotherapy compared with to receive BSC. We must positively 
consider the chemotherapy to octogenarians with advanced NSCLC 
who have good PS.
Session PD10: Basic Science and  
Translational Research 
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PD10.1.1 Basic Science and Translational Research, Mon, 10:30 - 12:00
Morphine induced EGFR activation via mu opioid 
receptor
Fujioka, Naomi; Nguyen, Julia; Li, Yunfang; Patel, Manish R.; 
Kratzke, Robert A.; Gupta, Kalpna
University of Minnesota, Minneapolis, MN, USA
Background: EGFR (epidermal growth factor receptor) is over-
expressed in the majority of non small cell lung cancers (NSCLC); 
despite major advances in EGFR targeted therapies, NSCLC remains 
the leading cause of cancer deaths in the United States, indicating a 
need to further elucidate the mechanisms of resistance against tar-
geted therapies such as erlotinib, and describe alternate pathways of 
EGFR activation in search of more effective targeted therapies. 
Mu opioid receptor (MOR) is upregulated in some NSCLC cell lines, 
and NSCLC tumors in humans have been shown to uptake tagged 
MOR agonists as detected by PET scanning. The MOR agonist 
morphine has been shown to transactivate EGFR, leading to phos-
phorylation of its downstream effectors MAPK/ERK and Akt, hence 
identifying a potential mechanism of resistance to EGFR inhibitors. 
Moreover, MOR agonist induced transactivation of EGFR may lead 
to disease progression in NSCLC.
We hypothesize that MOR antagonism at least partially ameliorates 
EGF induced phosphorylation of EGFR and therefore MOR antagon-
ists may have a role in cancer therapy.
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Methods: Human 2009 (H2009) NSCLC (adenocarcinoma) cells, 
which have been shown to overexpress MOR, were stimulated with 
morphine (0.1 μM) and EGF (100 ng/ml) for 10 and 30 minutes 
after serum starvation overnight. The EGFR tyrosine kinase inhibitor 
erlotinib (1 μM) (Tarceva®, Genentech) or naloxone was added 10 
minutes prior to morphine or EGF stimulation. Lysates were prepared 
and 100 μg of protein were resolved on an 8-13% gradient SDS gel, 
transferred to a PVDF membrane, and immunoblotted with phospho/
total EGFR, phospho/total MAPK/ERK, phospho/total Akt, and 
beta-actin. Anti-mouse ECF was used as the secondary antibody for 
phosphoEGFR; anti-rabbit ECF was used as the secondary antibody 
for the remainder.
For immunofluorescent staining, H2009 cells were serum starved, 
and erlotinib or naloxone (MOR antagonist) or both were added 10 
minutes prior to stimulation with morphine or EGF for 10 and 30 
minutes, respectively. Cells were fixed with 4% paraformaldehyde, 
permeabilized with 0.1% Triton, washed, blocked with 3% BSA, in-
cubated with phosphoEGFR, and incubated with anti-mouse TRITC. 
DAPI was added to co-stain the nucleus. Immunofluorescent images 
were obtained using an Olympus 1X70 microscope fitted with an 
Olympus DP70 digital camera.
MOR siRNA was transfected into H2009 cells using Lipofectamine 
(Invitrogen), and knock down was analyzed by reverse transcription 
PCR.
Results: Morphine coactivated EGFR in a time dependent fash-
ion, and naloxone partially inhibited morphine induced EGFR and 
MAPK/ERK phosphorylation as well as EGFR translocation to the 
nucleus. Erlotinib partially inhibited morphine induced EGFR phos-
phorylation, and subsequently MAPK/ERK and Akt activation. More-
over, the combination of erlotinib and naloxone completely inhibited 
morphine induced EGFR phosphorylation. Likewise, the combination 
of erlotinib and naloxone completely inhibited EGF induced EGFR 
phosphorylation. 
Conclusions: These data suggest that simultaneous inhibition of 
MOR and EGFR can inhibit the activation of the downstream MAPK/
ERK pathway and hence may be a useful strategy to overcome anti 
EGFR therapy resistance in lung adenocarcinoma. Further studies are 
needed to characterize the mechanism of this dual inhibition.
PD10.1.2 Basic Science and Translational Research, Mon, 10:30 - 12:00
Effect of HGF and AKT on erlotinib resistance in NSCLC
Farneth, Nichole C.; Holland, William; Snyder, Leslie; Gandara, 
David; Mack, Philip
University California, Davis, Sacramento, CA, USA
Introduction: EGFR tyrosine kinase inhibitors, such as erlotinib, 
have demonstrated clinical benefit in select NSCLC patients. Patients 
with tumor EGFR gene copy number abnormalities or kinase domain 
mutations tend to respond favorably to treatment. Potential mechan-
isms of acquired resistance to erlotinib include aberrant activation of 
other receptor tyrosine kinases and/or downstream signaling path-
ways such as AKT. Here, we investigated the effects of hepatocyte 
growth factor (HGF) treatment and AKT inhibition in combination 
with erlotinib in NSCLC cell lines. We hypothesized that addition of 
HGF to erlotinib-treated cells would promote resistance in NSCLC 
cell lines sensitive to erlotinib and that subsequent inhibition of the 
AKT pathway would abrogate this resistance. 
Methods: The NSCLC cell lines HCC827 (EGFR mt/KRAS wt/
erlotinib-sensitive) and A549, H727, A427, Calu-1 and H1355 
(EGFR wt/KRAS mt/erlotinib-resistant) were used. Cells were 
treated with erlotinib (E) at a high (10 microM) or low (0.1 microM) 
dose, HGF at 25 ng/ul, and perifosine (P), an alkyl-lysophospholipid 
that inhibits activation of AKT, at 10 microM (a clinically achievable 
concentration). MTT, a short-term growth assay, and Western blotting 
were used to assay for drug effects on cell proliferation, apoptosis 
and signal transduction. Plasma specimens from a phase I/II trial of 
NSCLC using intermittent docetaxel and erlotinib were analyzed by 
ELISA for baseline levels of HGF.
Results: In the erlotinib-sensitive line HCC827, treatment with 
HGF protected cells from E-induced cytotoxicity (E alone: 65% 
inhibition; E+HGF: 11% inhibition, p<0.0001). Additionally, HGF 
reversed PARP cleavage and dephosphorylation of Met, EGFR and 
AKT caused by erlotinib. The combination of E+P was additive (82% 
growth inhibition) and was accompanied by enhanced PARP cleav-
age. The addition of HGF to the combination of E+P was protective, 
significantly reducing growth inhibition and blocking PARP cleavage 
while restoring Met phosphorylation. In the erlotinib-resistant cell 
line A549, E showed minimal activity, with no effect on signaling 
or PARP cleavage. All KRAS mt cell lines showed marginal activity 
from E or P treatment individually, with additive growth inhibition 
between the two agents. For example, A549 cells demonstrated a 33% 
growth inhibition following 10 microM E, and10% growth inhibition 
following P, with 54% combined growth inhibition. HGF stimulation 
in the A549 cell line had little apparent effect on cell growth in any 
combination; however, in E+P-treated cells, HGF resulted in reduced 
PARP cleavage. In plasma specimens from EGFR-wt patients treated 
on an erlotinib-containing regimen, baseline levels of HGF were as-
sociated with improved response rates. Patients with a partial clinical 
response or stable disease had lower median HGF concentrations 
compared to patients with progressive disease (n= 26, p=0.012). 
Conclusions: The combination of erlotinib and perifosine was addi-
tive in both EGFR- and KRAS-mt NSCLC cell lines. Stimulation 
with HGF, the ligand for c-MET, can reverse PARP cleavage and 
growth arrest resulting treatment from erlotinib alone or in combina-
tion with perifosine. HGF levels may be a contributing factor in 
erlotinib resistance.
PD10.1.3 Basic Science and Translational Research, Mon, 10:30 - 12:00
CYP1A1*2A polymorphism is a new predictor of the 
clinical outcome in patients with advanced lung cancer 
treated with EGFR-TKI and has combined effects with 
EGFR intron1(CA)n polymorphism
Nie, Qiang; An, She j.; Li, Rong; Yang, Xue n.; Zhong, Wen z.; Liao, 
Ri q.; Wu, Yi l.; Guo, Ailin
Guangdong General Hospital, Lung Cancer Rearch Institute 
and Cancer Center, Guangdong Academy of Medical Sciences, 
Guangzhou, China
Purpose: The study aimed to investigate whether polymorphisms 
of EGFR and CYP1A1 gene are associated with clinical outcome of 
NSCLC patients treated with EGFR-TKI.
Methods: We evaluated the genotypes for R497K, intron 1 (CA) n 
repeat genetic polymorphisms in EGFR gene and *2A(3801T>C), 
*2C(2455A>G) single nucleotide polymorphisms (SNPs) in CYP1A1 
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gene by PCR-RFLP, DNA sequence and genescan methods in 115 
Chinese patients with advanced NSCLC. Genetic polymorphisms 
were correlated to clinical outcomes of EGFR-TKI. As to subgroup 
patients whose tumor tissues were available, the associations between 
the somatic EGFR mutations, the EGFR expression and genomic 
polymorphisms were analyzed.
Results: The EGFR intron 1 (CA) n and CYP1A1*2A polymorph-
isms were independent predictive factors (P=0.028, P=0.007, 
respectively) and the latter was also prognostic factors (P=0.0029) 
for patients treated with EGFR-TKI. Moreover, we observed a strong 
synergistic joint effect of the two genotypes. Patients with both m1/
m1 allele of CYP1A1 gene and shorter Intron 1 CA repeats(any al-
lele≤16 CA) of EGFR gene showed better response (P=0.002) and 
longer survival time (P=0.0022) than patients with any m2 allele and 
longer Intron 1 CA repeats(both alleles> 16 CA). In contrast, the 
other two polymorphisms, EGFR R497K and CYP1A1*2C, had no 
relationship with clinical outcome of the patients treated with EGFR-
TKI (P=0.953; P=0.370, respectively). Moreover, there were no asso-
ciations between EGFR mutations and the genomic polymorphisms.
Conclusions: The findings of this study suggest that the CYP1A1*2A 
polymorphism is a new predictor for clinical outcome of NSCLC 
patients with EGFR-TKI therapy, combining analysis of both 
CYP1A1*2A and EGFR intron1(CA)n polymorphism may be use-
ful molecular markers for predicting treatment outcome of NSCLC 
patients treated with EGFR-TKI.
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PD10.1.4 Basic Science and Translational Research, Mon, 10:30 - 12:00
Multiple EML4-ALK fusion transcripts and concurrent 
EGFR kinase mutation in Chinese non-small cell lung 
cancer
Zhang, Xuchao; Zhang, Shirley; Yang, Xuening; Yang, Jinji; Guo, 
Ailin; Zhou, Qing; An, Shejuan; Lin, Jiaying; Zhu, Mike; Wu, Yilong
Guangdong Lung Cancer Institute, GGH-ICC Joint Lab, Guangdong 
general Hospital, Guangdong Academy of Medical Sciences, 
Guangzhou, China
Background: Anaplastic lymphoma kinase (ALK) gene could 
translocate in the genome and fuse with other genes in a variety of 
human malignancies including leukemia, neuroblastoma as well as 
lung cancer. The fused partners of ALK can be NPM, EML4, TPM3, 
ATIC, TFG, CARS, and CLTC, etc. To elucidate ALK fusion patterns 
and its clinicopathological profiles will be helpful to understand lung 
cancer biology. 
Methods: RACE (rapid amplification of cDNA ends)-coupled 
PCR-based sequencing method was used to detect all possible ALK 
fusion patterns in 109 Chinese patients with NSCLC, including 64 
adenocarcinoma, 33 squamous cell carcinoma, 9 large cell carcinoma, 
1 smooth musle sarcoma and 2 lymphoepithelioma-like carcinoma. 
Sequenced results were then confirmed by RT-PCR assays. PCR 
based sequencing was used to detect potential ALK mutation. 
Results: Twelve tumors (11.01%) had 5 fusion transcript variants of 
EML4-ALK with variable segments from 5’ EML4 fused to 3’ ALK 
kinase domain. The most common variant consisted of 4 tumors 
with variant 1 that involved EML4 exon 13. The others included 3 
tumors with variant 3 (exon 6), 1 tumor with variant 2 (exon 20), 
and 1 tumor with variant 5 (exon 2). There are also 3 tumors with 
fusion transcripts newly-detected as ALK fused with EML4 exon 
18 in 3 cases of histological adenocarcinoma. Here we did not find 
previously reported EML4-ALK variant 4 (exon 14). There are 10 
adenocarcinoma (1 of which with mixed squamous component) and 2 
squamous cell carcinoma. In these patients ALK fusion was mutually 
exclusive to KRAS mutation. Whereas notably, to our knowledge 
here we first time identify concurrent EGFR exon 19 del and EML4-
ALK fusion mutations in one patient who was a female nonsmoker 
with histological adenocarcinoma. Though EML4-ALK was not 
detected as associated with nonsmokers (P =0.23), patients with ALK 
fusion had less smoking package-years than others (6.9 vs. 19.1, 
P=0.01). Patients with EML4-ALK fusion also had a younger age (53 
vs. 61, P = 0.03) compared with patients without the fusion gene. No 
mutation of ALK was detected by sequencing samples of 50 NSCLC 
cases. 
Conclusions: Comprehensive study on the ALK fusion partners 
showed that more than 5 types of EML4-ALK fusion transcripts 
exist in Chinese NSCLC and no other fused partners of ALK were 
detected. One case of concurrent EML4-ALK fusion with del745-749 
in exon 19 of EGFR suggested that ALK alteration might cooperate 
with EGFR activation in NSCLC, which imply dual targets inhibition 
might be one useful therapeutic option in clinical practice. 
PD10.1.5 Basic Science and Translational Research, Mon, 10:30 - 12:00
VEGFR inhibitor AV-951 exhibits potent anti-angiogenic 
and antitumor activity in engineered Kras G12V and in 
EGFRL858R/T790M TKI resistant lung adenocarcinomas 
Lin, Jie; Yang, Hongmei; Sun, Xiaojian; Zhou, Yinghui; Heyer, Joerg; 
Rideout III, William M.; Bressel, Angela; Robinson, Murray .
AVEO, Cambridge, MA, USA
Background: AV-951, a small molecule VEGFR inhibitor that has 
been shown to be active and well tolerated in RCC in a phase 2 study, 
is currently being evaluated as a monotherapy in a phase 1b/2a study 
in NSCLC. NSCLC is a highly heterogeneous disease, with both 
histologically and genetically defined subclasses. To obtain data on 
AV-951 efficacy in specific genetic subclasses of lung cancer, we 
sought to create and treat genetically engineered lung adenocarcin-
oma models driven by either EGFRL858R/T790M or KRAS G12V.
Methods: We have developed a unique approach to make complex 
inducible tumor models generated by creating chimeric mice incor-
porating genetically modified ES cells. In this series of models, the 
expression of the indicated tetracycline promoter-linked oncogene 
is activated post natally in lung precursor cells using a tetracycline 
dependent transactivator expressed in lung precursor cells using the 
CCSP promoter. The ES cells in these models also are deleted for the 
INK4A tumor suppressor and harbor a luciferase reporter to facilitate 
imaging. In this work, we examined tumors driven by difficult to treat 
tumor specific alleles EGFRL858R/T790M or KRAS G12V. Tumors 
from these models have been propagated in vivo and tumor inhibit-
ory activity of AV-951 in both subcutaneous and orthotopic settings 
examined. 
Results: Treatment of subcutaneous lung KRAS tumors with AV-951 
2mg/kg and 5mg/kg daily PO for 2 weeks resulted in complete tumor 
growth inhibition and 44% tumor regression respectively. Histologic 
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analysis of tumors revealed alteration in microvessel morphology 
and significant central necrosis with proliferating (Ki67+) tumor cells 
present only at the tumor periphery, typical of an anti-angiogenesis 
mechanism. Lung EGFRL858R+T790M tumors were tested in an 
orthotopic setting by intravenous seeding. AV-951 treatment was initi-
ated after tumor establishment was detected by in vivo imaging of the 
luciferase reporter. Five mg/kg daily dosing for 10 days significantly 
decreased the luciferase signal and continued treatment resulted in 
prolonged survival. Upon termination of treatment on day 42, gross 
pathologic examination (lesions number, size and weight) showed no 
difference between AV-951 and vehicle treated mice. However, histo-
logic analysis showed the same dramatic anti-angiogenic changes as 
in the subcutaneous KRAS tumors, indicating AV-951 is effective in 
killing these orthotopic lung tumors that are resistant to EGFR TKIs. 
The finding that necrotic lung lesions showed no sign of resorption 
or elimination after 6 weeks of treatment raised the question whether 
early prolonged treatment would prevent tumors from progressing. 
We subsequently tested effect of AV-951 in orthotopic lung KRAS 
tumors when only small tumor lesions (<1mm) are detected. AV-951 
2mg/kg was given daily for 11 weeks and the mice were sacrificed to 
compare with untreated group. Gross pathologic analysis showed that 
while lesions in the untreated group had progressed (1-3mm: 3.25/
mouse; >3mm: 2/mouse), those in treated animals remained small 
(<1mm: 2.75/mouse; 1-3mm: 0.875/mouse; >3mm: 0.2/mouse). 
Conclusions: These results provide direct evidence in genetically en-
gineered tumor models that AV-951 has potent anti-angiogenesis and 
antitumor activity in lung tumors driven by either KRAS or EGFR 
TKI resistant mutations. These data support a hypothesis that human 
tumors exhibiting either KRAS or EGFR L858R/T790M mutations 
may be sensitive to single agent AV-951 treatment. 
PD10.1.6 Basic Science and Translational Research, Mon, 10:30 - 12:00
The antitumor effect of orally active heat shock protein 90 
Inhibitor, 17-DMAG, on the growth of gefitinib-resistant 
non-small cell lung cancer
Kubo, Takafumi; Toyooka, Shinichi; Jida, Masaru; Hayashi, Tatsuro; 
Otani, Hiroki; Yamamoto, Hiromasa; Kobayashi, Naruyuki; Soh, 
Junichi; Sano, Yoshifumi
Department of Cancer and Thoracic Surgery, Okayama University 
Graduate School of Medicine, Dentistry and Pharmaceutical 
Sciences, Okayama, Japan
Background: It has been reported that non-small cell lung cancer 
(NSCLC) cell lines with activating mutations of epidermal growth 
factor receptor (EGFR) gene were significantly sensitive to Heat 
Shock Protein 90 (Hsp90) inhibitors regardless of the secondary 
T790M mutation. 
Methods: We examined the antitumor effect of 17 dimethylamino-
ethylamino–17-demethoxygeldanamycin (17-DMAG), the orally 
active Hsp90 inhibitor, on the growth of NSCLC cell lines in vitro 
and in vivo. 
Results: In MTS assay, the IC50 values for 3 cell lines with EGFR 
mutation (PC-9, RPC-9, and NCI-H1975) ranged from 0.15 to 0.28 
μM. RPC-9 is a gefitinib-resistant lung cancer cell line with the 
secondary T790M mutation established from PC-9. By contrast, 
those of 7 EGFR-wild type cell lines ranged from 1.63 to 28.5 μM. 
Western blot analysis revealed that mutant EGFRs were more readily 
depleted than wild-type EGFRs after the treatment of 17-DMAG. 
Furthermore, expression of phospho-Akt, phospho-MAPK, cdk4, and 
cyclin D1 was depleted after exposure to lower concentrations of 17-
DMAG in EGFR-mutant cells. Cleaved PARP expression confirmed 
apoptosis in response to 17-DMAG in EGFR-mutant cells. In animal 
models, 17-DMAG significantly reduced the growth of EGFR mutant 
cell lines PC-9 and RPC-9 compared with controls and induced deg-
radation of mutant EGFR. In contrast, 17-DMAG did not inhibit the 
growth of EGFR wild type cell lines compared with controls. 
Conclusion: These results suggested that 17-DMAG could become 
a novel therapeutic agent for patients with lung tumors expressing 
mutant EGFR and having developed clinical resistance to gefitinib. 
PD10.2.1 Basic Science and Translational Research, Mon, 10:30 - 12:00
Aberrant promoter methylation of RASSF1A in serum 
correlates with disease stage in small-cell lung cancer 
patients
Nadal, Ernest1; Gallegos, Marc1; Palmero, Ramon1; Brao, Isabel1; 
Saldaña, Juana1; Navarro, Valentí1; Rigo, Raul2; Llatjós, Roger2; 
Esteller, Laura1; Romeo, Marga1; Capellà, Gabriel1; Cardenal, Felipe1
1 Institut Català d’Oncologia, Barcelona, Spain; 2 Hospital 
Universitari Bellvitge, Barcelona, Spain
Background: Epigenetic inactivation of certain tumor suppressor 
genes by aberrant promoter methylation may play an important role 
in the pathogenesis of small-cell lung carcinoma (SCLC). RASSF1A 
(3p21.3) and TMS1/ASC (16p11.2-12.1) are frequently inactivated 
by promoter hypermethylation in SCLC cell lines and tumor tissues. 
The clinical and prognostic significance of serum DNA methyla-
tion of these promoters has not been studied in SCLC patients. We 
assessed the methylation status of RASSF1A and TMS1/ASC in 
serum DNA of SCLC patients and studied the association of these 
epigenetic alterations with clinical and biochemical parameters and 
outcome.
Materials and Methods: From June 2005 to June 2008, we collected 
plasma and serum from 50 histologically proven SCLC at baseline. 
Patient characteristics were: median age 61.5 (range 47-83), M/F: 
44/6, Performance Status (PS) 0-1/2-3: 34/16 and limited disease 
(LD)/extensive disease (ED): 12/38. All patients were treated with 
chemotherapy: 27 with cisplatin plus etoposide, 17 with carboplatin 
plus etoposide and 6 with other schedules. 18 patients received thor-
acic radiotherapy and prophylactic cranial irradiation. Median follow-
up time was 19 months. The overall response rate was 78% and 
median survival time was 8.1 months (95% confidence interval (CI): 
5.9-10.3) and median progression free survival was 6.4 months (95% 
IC: 5.3-7.5). Methylation status of RASSF1A and TMS1 in serum 
DNA was assessed by methylation-specific PCR (MSP). Bisulphite- 
sequencing was used to confirm results. Plama lactate dehydrogenase 
(LDH), neuron-specific enolase (NSE) and vascular endothelial 
growth factor (VEGF) levels were also measured in plasma using 
spectrophotometry and immunoanalysis. 
Results: Hypermethylation of RASSF1A and TMS1 were detected 
in 15/49 patients (31%) and 12/47 (25,5%), respectively by MSP 
and bisulphite-sequencing. All patients with RASSF1A hyperm-
ethylation had extensive-disease and there was strong correlation 
between RASSF1A methylation status and disease stage (p=0.001). 
No correlation was observed with age, gender or PS. The follow-
ing variables had a significant impact on survival in the univariate 
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analysis: PS (p=0,005), disease stage (p<0,0001), high levels of LDH 
(p<0,0001), high levels of NSE (p=0,036) and RASSF1A hyperm-
ethylation (p=0,001). In the multivariate analysis PS [p 0.009, rela-
tive risk (RR): 2.58; 95%% CI 1.3-5.3] and disease stage [p 0.012, 
RR: 6.67; 95%% CI 1.5-29.3] remained as independent prognostic 
factors, while RASSF1A hypermethylation showed a statistically non 
significant trend toward worst prognosis [p 0.066, RR: 1.97; 95% CI 
0.96-4.1]. LDH and NSE didn’t stand as independent prognostic fac-
tors in this multivariate model. 
Conclusion: Serum RASSF1A hypermethylation status might be a 
stronger prognostic marker than other currently used serum markers 
in SCLC. Larger studies are warranted to further explore its prognos-
tic value.
PD10.2.2 Basic Science and Translational Research, Mon, 10:30 - 12:00
TITF-1 protein expression associates with gene 
methylation and gene copy gain in non-small cell lung 
carcinoma
Tang, Ximing; Yang, Fei; Huang, Jiannan; Woods, Denise M.; 
Alejandro, Corvalan; Hong, Waun K.; Wistuba, Ignacio I.
UT MD Anderson Cancer Center, Houston, TX, USA
Background: The thyroid transcription factor-1 (TITF-1, NKX2-
1) is a lineage-specific transcription factor normally expressed in 
peripheral pulmonary epithelial cells. TITF-1 protein is frequently 
expressed in adenocarcinoma, and absent in squamous cell carcinoma 
of the lung. TITF-1 gene copy number gain (CNG) has been reported 
in a relatively small subset of adenocarcinoma of the lung, and we 
have also recently detected this abnormality in lung squamous cell 
carcinomas (Tang et al, unpublished data). To better characterize 
the mechanisms responsible to the different pattern of expression of 
TITF-1 protein in these two types of non-small cell lung carcinomas 
(NSCLC), we investigated the correlation between protein expression 
with CNG and methylation abnormalities in a large series of NSCLC 
specimens. 
Methods: DNA extracted from NSCLC cell lines (n=21) and tumor 
tissue (n=173) samples was analyzed for TITF-1 gene methylation by 
bisulfite DNA sequencing, CNG by quantitative-PCR (qPCR), and 
protein expression by immunohistochemistry (IHC).
Results: 14 out of 21 NSCLC cell lines demonstrated TITF-1 gene 
methylation in exons 1 and 2, but not in the promoter region. In the 
14 methylated cell lines, the percentage of average methylation of 
CpG sites in exon 2 (43.9%) was much higher than in exon 1 (6.7%). 
Methylation was more frequently detected in squamous cell carcin-
oma (48/72, 72%) compared with adenocarcinoma (46/106, 43%, 
P=0.002). TITF-1 CNG was detected in 35% of adenocarcinoma and 
25% of squamous cell carcinoma, respectively. In adenocarcinomas, 
TITF-1 protein overexpression was associated with CNG; while in 
both tumor histologies reduced expression of the protein was correl-
ated with gene methylation (R=-0.4, P=0.002). Of interest, nearly half 
of NSCLC tumors with CNG also showed gene methylation. No gene 
methylation and CNG were detected in non-malignant lung tumor 
tissues adjacent to lung tumors having those abnormalities. 
Conclusion: Our findings indicate that, in NSCLC, TITF-1 increase 
and lack/reduction of protein expression correlates with gene copy 
number gain and methylation of the gene, respectively, suggesting 
that these two mechanisms are important for TITF-1 protein expres-
sion modulation in lung tumors. 
(Supported by Grant DoD-W81XWH-04-1-0142 and W81X-
WH-05-2-0027).
PD10.2.3 Basic Science and Translational Research, Mon, 10:30 - 12:00
Targeting histone deacetylases in non-small cell lung 
cancer
Datta, Pran K.
Departments of Surgery and Cancer Biology, Nashville, TN, USA
Background: Histone deacetylation is a crucial step in the loss of 
specific homeostatic molecular signals in the transition from normal 
lung epithelium to in situ carcinoma, and finally to invasive and 
metastatic cancers. The loss of TGF-ß-induced tumor suppressor 
function in tumors plays a pivotal role in this process, and resistance 
to TGF-ß in lung cancer occurs mostly through the loss of type II 
receptor (TßRII) expression. 
Methods and Results: We have observed that the expression of 
TßRII is lost or reduced in 77% lung tumors. As a proof of prin-
ciple, we have determined that stable expression of TßRII in lung 
adenocarcinoma cell lines, lacking TßRII expression, restored TGF-ß 
mediated biological effects including Smad2/3 and Smad4 complex 
formation, TGF-ß responsive reporter gene activation, inhibition of 
cell proliferation, increase in apoptosis and decrease in tumorigen-
icity. Our initial experiments have resulted in an important observa-
tion that activation of MAPK/ERK pathway by either activated Ras 
or activated EGF signaling causes downregulation of TßRII through 
histone deacetylation. In order to understand the mechanism, we have 
identified a region of the TßRII promoter required for its activation 
by HDAC inhibitors (HDI) and proteins that are involved in the 
regulation of TßRII expression using proteomics and biochemical 
methods. TGF-ß-induced tumor suppressor function is restored in 
TGF-ß resistant lung cancer cell lines by the treatment of HDIs. In 
addition, the expression of other tumor suppressor genes including 
PGDH, E-cadherin and p21Cip1 is reduced in lung cancer cell lines 
due to histone deacetylation. 
Conclusions: These results suggest that restoration of TGF-ß signa-
ling and the expression of tumor suppressor genes by HDIs, anti-
cancer drugs currently in clinical trials, may be a potential alternative 
for therapeutic intervention of lung cancers, preferably for patients 
with loss of TßRII expression. 
PD10.2.4 Basic Science and Translational Research, Mon, 10:30 - 12:00
VEGF and the epigenetic regulation of its receptors in non-
small cell lung cancer
Barr, Martin1; Gray, Steven 1; Gately, Kathy1; Pidgeon, Graham2; 
O’Byrne, Kenneth3
1 St. James’s Hospital, Dublin, Ireland; 2 Trinity College Dublin/St. 
James’s Hospital, Dublin, Ireland; 3 St. James’s Hospital, Dublin, 
Ireland
Background: VEGF is a potent angiogenic cytokine that is over-
expressed in non-small cell lung cancer (NSCLC). In this study, we 
examined the role of VEGF in non-small cell lung cancer cells and 
the epigenetic mechanisms regulating expression of its receptors.
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Methods: A549 (adenocarcinoma) and SKMES1 (squamous cell) 
NSCLC cells were screened for the VEGF receptors VEGFR1 (Flt-1), 
VEGFR2 (KDR), Neuropilin-1 (NP1) and Neuropilin-2 (NP2). The 
effect of VEGF on proliferation and apoptosis was examined using 
the BrdU assay and FACS analysis, respectively. The effect of VEGF 
blockade on the cell cycle was assessed by propidium iodide staining. 
Phosphorylation of the downstream signalling proteins, Akt/PKB 
(PI3K) and Erk1/2 (MAPK) was examined by confocal microscopy. 
The cell survival effects of VEGF on A549 and SKMES1 cells fol-
lowing NP1 and NP2 gene silencing were examined using the MTT 
assay. VEGF receptor expression in response to the histone deacetyl-
ase inhibitor, TSA (Trichostatin A), was assessed, in addition to its 
effect on proliferation and apoptosis of NSCLC cells. Cells were 
treated with TSA and VEGF levels were measured in conditioned 
media by ELISA. The ChIP assay was used to study the associa-
tion between histone proteins and DNA while the effect of TSA on 
acetylation of histones H3 and H4 was examined by Western blotting. 
Results: VEGF increased proliferation and decreased apoptosis of 
NSCLC cells while VEGF blockade induced growth arrest in the 
G0/G1 phase of the cell cycle. VEGF induced phosphorylation of 
the cell signal proteins Akt and Erk1/2. Silencing of NP1 and NP2 
receptors reduced survival of A549 and SKMES1 cells. VEGF was 
unable to rescue siNP1- and siNP2-treated NSCLC cells. TSA, which 
itself induced cell death, upregulated the expression of VEGFR1 and 
VEGFR2 and downregulated NP1 and NP2. De novo protein syn-
thesis was required for downregulation of the Neuropilin receptors 
by TSA but not for VEGFR1 and VEGFR2. Increased acetylation of 
histones H3 and H4 by TSA was observed in both cell lines. VEGF 
secretion by NSCLC cells was decreased in response to TSA. Addi-
tion of VEGF however, was unable to rescue cells from TSA-induced 
cell death.
Conclusions: This study confirms that VEGF is a growth factor for 
NSCLC acting, at least in part, through NP1 and NP2. While TSA up-
regulated VEGFR1 and VEGFR2 and downregulated the Neuropilin 
receptors, in particular NP1, VEGF was unable to rescue cells from 
TSA-induced cell death and in siNP1- and siNP2-treated NSCLC 
cells. These findings implicate the NP receptors as critical survival 
factors for NSCLC cells. 
PD10.2.5 Basic Science and Translational Research, Mon, 10:30 - 12:00
Sequential DNA methylation of genes during lung 
adenocarcinoma development
Selamat, Suhaida A.1; Galler, Janice S.1; Joshi, Amit2; Fyfe, M. N.3; 
Siegmund, Kimberly D.2; Kerr, Keith M.3; Laird-Offringa, Ite A.1
1 University of Southern California/Norris Cancer Center, Los 
Angeles, CA, USA; 2 University of Southern California, Dept. 
Preventive Medicine, Los Angeles, USA; 3 Aberdeen University 
Medical School, Aberdeen, UK
Background: Lung adenocarcinoma is the most commonly diag-
nosed form of lung cancer and is also the most prevalent subtype 
among women and never smokers. Understanding the etiology of 
lung adenocarcinoma is important to improve diagnostic as well as 
therapeutic approaches to this lethal disease. The presence of aberrant 
promoter DNA hypermethylation in lung adenocarcinoma has long 
been established, but its role during the stepwise development of this 
cancer has not been clarified. It is becoming generally accepted that 
least a fraction of lung adenocarcinoma begins as a small hyperplastic 
lesion (atypical adenomatous hyperplasia or AAH), progresses to 
bronchioalveolar carcinoma (BAC, a noninvasive tumor or “adeno-
carcinoma in situ”), and subsequently becomes invasive cancer, or 
adenocarcinoma (AD). We had previously identified 15 genes that are 
highly significantly hypermethylated in adenocarcinoma compared 
to adjacent non-tumor lung from the same patients. Here we aimed to 
determine at which stage of adenocarcinoma development methyla-
tion of these loci might occur. 
Methods: We examined the DNA methylation levels of the 15 genes 
and of two repeat sequences (the latter as markers for global DNA 
hypomethylation) in 41 AAH lesions, 16 BACs and 50 AD. For 
comparison, we studied 63 specimens of adjacent non-tumor lung 
(AdjNTL) and 30 non-tumor lung specimens from patients resected 
for a single pulmonary metastasis from a non-lung primary cancer 
(MetNTL). Using the sensitive MethyLight technology, we obtained 
quantitative DNA methylation information for the 17 DNA methyla-
tion loci in the five different types of tissues. We used analyses for 
trend and for deviation from linearity to determine whether there was 
progressive DNA methylation in the different types of samples, and 
if so, in which type of tissue the alteration in DNA methylation first 
becomes apparent. 
Results: We find that some genes become significantly hypermethyl-
ated in AAH (“early genes”), while others become methylated in 
BAC (“intermediate genes”). Some genes show no significant hyper-
methylation in AAH or BAC and become hypermethylated only in 
AD (“late genes”). Hypomethylation only becomes significant in AD, 
suggesting it is a late event in adenocarcinoma development. 
Conclusion: Our analysis of 17 methylation loci in AAH, BAC and 
AD is to our knowledge the largest study of its kind, and pro-
vides an initial roadmap of DNA methylation changes during lung 
adenocarcinoma development. Our data support a model in which 
AAH progresses to BAC and then to invasive adenocarcinoma. We 
postulate that sequential DNA hypermethylation events contribute 
to the step-wise development of lung adenocarcinoma by providing 
epigenetic hits that accumulate as preneoplastic lesions progress to 
local and then invasive cancer. 
PD10.2.6 Basic Science and Translational Research, Mon, 10:30 - 12:00
Integrative genetic, epigenetic, and gene expression 
analysis of lung adenocarcinoma
Chari, Raj; Lockwood, William W.; Malloff, Chad A.; Coe, Bradley 
P.; Buys, Timon P.; MacAulay, Calum; Lam, Stephen; Lam, Wan L.
BC Cancer Agency Research Centre, Vancouver, BC, Canada
Background: High throughput strategies to profile aberrations in 
gene dosage (DNA copy number) and gene expression have proven 
useful in the identification of oncogenes and tumor suppressor genes 
as well as signatures associated with patient outcome. Epigenetic 
changes including aberrant DNA methylation have also been shown 
to be important in the deregulation of gene expression in lung cancer. 
Aberrations by one mechanism tend not to occur in all individuals. In 
order to determine what alterations are causal to cancer development 
versus reactive changes, it is important to integrate genetic, epigen-
etic and gene expression changes from the same tumors. 
Objectives: To employ a multi-dimensional and integrative approach 
examining genetic, epigenetic, and gene expression aberrations in 
lung adenocarcinoma for 1) identification of key genes and pathways 
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involved in tumorigenesis altered by multiple mechanisms and 2) 
identification of key pathway systems commonly altered among 
tumors.. 
Methods: Ten lung adenocarcinoma tumor and matched normals 
were assayed for gene dosage (DNA copy number) using tiling path 
array CGH, allelic status using Affymetrix SNP 6.0, DNA methyla-
tion using Illumina Infinium platform, and gene expression using 
Affymetrix exon arrays. SNP array data were processed and analyzed 
using Partek Genomics Suite; Infinium data were processed using 
Bead Studio; and exon array data were processed using the aroma.
affymetrix package in R. All ‘omics data were merged and visualized 
using SIGMA2 software.
Results: When merging data between the different platforms, 11,992 
genes had data represented in all four assays. Examining for multiple 
concerted disruption (MCD) in at least one sample, where there is 
alteration in all dimensions (i.e. copy number gain, allelic imbalance, 
hypomethylation and overexpression), 192 genes were identified. We 
then examined the impact of multi-dimensional analysis on the iden-
tification of frequently altered genes. Employing a frequency cut-off 
of 40%, examining any single DNA dimension alone (copy number, 
allelic status, or DNA methylation), we maximally identify 567 genes 
that meet this criteria. However, when we utilize all three dimensions 
and examine for alterations in copy number or DNA methylation or 
allele status, at the same frequency threshold, we identify 1234 genes. 
Subsequent Ingenuity Pathway Analysis of the two gene sets identi-
fied six canonical pathways of statistical significance using the list 
of 567 genes while thirteen pathways were identified with the larger, 
integrated gene list. As an example, the Ephrin receptor signaling 
pathway would have been missed if single DNA dimensional analysis 
were performed alone. Analyzing tumors on an individual basis 
identified common significant pathways between tumors, but also 
demonstrated differences at the pathway level.
Conclusions: By utilizing a multi-dimensional approach, we identify 
more genes and pathways that are altered at both the DNA and RNA 
level than using any single DNA dimension such as gene dosage 
or DNA methylation. In addition, identification of genes exhibiting 
MCD associated with potential oncogenic processes highlights the 
utility of this approach. Variation in aberrant pathways in different 
tumors suggests the need to move beyond standard group-based 
analysis to tailor therapy according to pathways deregulated in indi-
vidual tumors.
PD10.3.1 Basic Science and Translational Research, Mon, 10:30 - 12:00
Correlation between cytidine deaminase (CDA) genotype 
and clinical outcome/toxicity in advanced non-small cell 
lung cancer (NSCLC) patients treated with gemcitabine/
platinum-based chemotherapy
Tibaldi, Carmelo1; Giovannetti, Elisa2, 3; Tiseo, Marcello4; Danesi, 
Romano2; Leon, Leticia G.3, 5; Bartolotti, Marco4; D’Incecco, 
Armida1; Erozenci, Ayse L.3; Falcone, Alfredo1; Peters, Godefridus 
J.3; Ardizzoni, Andrea4
1 Department of Medical Oncology, Azienda USL-6 of Livorno, 
Livorno, Italy; 2 Department of Internal Medicine, University of Pisa, 
Pisa, Italy; 3 VU University Medical Cente, Amsterdam, Netherlands; 
4 Department of Medical Oncology, Azienda Ospedaliero-
Universitaria of Parma, Parma, Italy; 5 Universidad de La Laguna, 
Tenerife, Spain
Background: Detection of genomic differences predictive of drug 
response/toxicity may allow oncologists to tailor chemotherapy in 
individual patients. Gemcitabine is a deoxycytidine analogue used 
against several tumours, and in combination with platinum is one 
of the most common regimens for advanced NSCLC. CDA is the 
main enzyme involved in gemcitabine catabolism, and the common 
nonsynonymous A→C single nucleotide polymorphism (SNP) in 
exon 79, resulting in lysine to glutamine substitution at position 27 
(Lys27Gln), alters its activity. 
Our previous study in 65 advanced NSCLC patients treated with 
gemcitabine-cisplatin showed that the CDA Lys27Lys genotype sig-
nificantly correlated with better clinical benefit (i.e. response+stable-
disease, P=0.04) and grade >3 neutropenia and thrombocytopenia, 
as well as with longer time to progression (TTP) and overall survival 
(OS) (Tibaldi et al., Clin Cancer Res 2008). Therefore, the aim of 
this study was to evaluate whether this SNP influenced gemcitabine 
deamination and clinical outcome in a larger cohort of NSCLC 
patients treated with gemcitabine/platinum-based chemotherapy, 
enrolling 132 patients from 2 Italian institutions. 
Methods: The CDA Lys27Gln polymorphism was studied in genom-
ic DNA with Taqman®-probes-based PCR, while CDA enzymatic 
activity was evaluated by HPLC analysis in 20µl whole blood, using 
250µM gemcitabine as substrate with 30-min incubation time. As-
sociation between genotype and response, clinical benefit, toxicity, 
TTP and OS was estimated using Pearson χ2, Kaplan-Meier method, 
Log-rank test and Cox’s proportional hazard model. 
Results: Up to now a total of 117 patients were evaluable for CDA 
genotype. The frequencies of CDA27 Lys/Lys, Lys/Gln and Gln/Gln 
genotypes were 38.5, 49.6 and 11.9%, respectively. All the patients 
with data on CDA genotype were evaluable for response, while OS 
and TTP data were available in 102 and 104 patients, respectively. 
No significant correlations were detected with response, clinical 
benefit and TTP, while the CDA Gln27Gln polymorphic variant was 
associated with shorter OS (P=0.017), and the CDA Lys27Lys and 
Lys27Gln genotypes with grade≥2 neutropenia/anemia/thrombocyto-
penia (P=0.018). Finally, the enzymatic activity assay, performed in 
50 patients, showed a significant lower mean in subjects harbouring 
the CDA Lys27Lys and Lys27Gln genotypes, associated with clinical 
benefit (P=0.048).
Conclusions: Our data suggested a significant relationship between 
the CDA Lys27Gln polymorphism, gemcitabine deamination, 
haematological toxicity and survival. This SNP is likely a predictive 
biomarker of the activity and toxicity of gemcitabine/platinum-
based chemotherapy, and should be used for treatment optimization. 
However, clinical response may also be influenced by functional 
polymorphisms affecting the gemcitabine-activating enzyme deoxy-
cytidine kinase (Lamba et al., J Pharmacol Exp Ther 2007) and the 
final results of all these genotypic analyses will be presented at the 
meeting.
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Response to gemcitabine-platinum chemotherapy by single 
nucleotide polymorphisms (SNPS) of RRM1 and ERCC1 
genes in patients with non-small cell lung cancer (NSCLC)
Kim, Young-Chul1; Kim, Kyu-Sik1; Oh, In-Jae1; Na, Kook-Joo1; 
Kim, Yun-Hyeon1; Ahn, Sung-Ja1; Choi, Song1; Lee, Kwan-Ho2; 
Jeon, Young-June3; Cho, Hyun-Ju1; Back, Sun-Mi1; Gong, Kang-
Eun1; Park, Song-Ran1
1 Chonnam National University Medical School Hwasun Hospital, 
Hwasungun, Korea; 2 Yeungnam University, Daegu, Korea; 3 
Keimyung university, Daegu, Korea
Background: RRM1, the regulatory subunit of ribonucleotide reduct-
ase, is involved in carcinogenesis, and the response to gemcitabine. 
Two SNPs (RR37 and RR524) in the promoter region of RRM1 gene 
impacted promoter activity, and were associated with prognosis. 
Previously we reported these two promoter polymorphisms as a sig-
nificant prognostic marker for gemcitabine treated NSCLC1. ERCC1, 
the excision repair cross-complementation group 1, is associated with 
platinum resistance. A SNP in codon 118 (exon 4) of ERCC1 gene 
was reported as a prognostic marker in platinum treated NSCLC.
Methods: The patients (male 161, female 51, mean age 62.9 years) 
had advanced stage NSCLC treated with gemcitabine and platinum 
(GP) as a first line chemotherapy. Adenocarcinoma was the most fre-
quent histologic type (n=109), followed by squamous cell carcinoma 
(n=84), unclassified non-small cell lung carcinoma (n=15) and large 
cell carcinoma (n=4). SNPs were analyzed with real time-PCR using 
genomic DNA extracted from peripheral blood of patients.
Results: Responses to GP were classified as responders (n=92, CR 
3, PR 89) and non-responders (n=120, SD 53, PD 67). Patients were 
classified into 4 groups with RRM1 and ERCC1 allelotypes; group 1 
(RRM1-AC-CT and ERCC-CC, 15.1%, n=32) group 2 (RRM1-AC-
CT and ERCC-CT/TT, 15.1%, n=31), group 3 (RRM1-CC-TT and 
ERCC1-CC, 42.0%, n=89), and group 4 (RRM1-CC-TT and ERCC-
CT/TT, 27.8%, n=59). Response rate to GP was not significantly 
different between the 4 groups in total population. However, when we 
consider non-squamous histology only (n=128), there was a signifi-
cant difference in response rate; group 1 (63.2%), group 2 (61.9%), 
group 3 (36.5%), and group 4 (22.2%) (p=0.004, Figure 1.)
Conclusion: We observed significantly different responses to GP 
regimen according to SNPs of RRM1 and ERCC1 gene in NSCLC 
with non-squamous histology. The allelotype with the lowest pre-
dicted expression of both genes was associated with the best patient 
outcome. Further functional and prospective clinical trials should be 
followed.
PD10.3.3 Basic Science and Translational Research, Mon, 10:30 - 12:00
Preclinical studies for a phase 0 microdosing trial to 
identify chemoresistance in non-small cell lung cancer
Pan, Chong-xian1; Li, Tao1; He, Miaoling1; de Vere White, Ralph1; 
Gandara, David1; Mack, Philip C.1; Lara, Primo N.1; Turteltaub, 
Kenneth2; Henderson, Paul1
1 University of California at Davis, Sacramento, CA, USA; 2 
Lawrence Livermore National Laboratory, Livermore, USA
Background: DNA damage is the critical step in cancer cell response 
to platinum (Pt) chemotherapy. We hypothesize that low levels of 
Pt-induced DNA damage are predictive of chemoresistance. Ac-
celerator mass spectrometry (AMS) is an ultrasensitive method for 
measuring radiocarbon. By measuring 14C on DNA, AMS can detect 
carboplatin-induced DNA damage when carboplatin is labeled with 
14C. This technology will enable the detection of Pt-induced DNA 
damage when cells and patients are exposed to subtoxic microdoses 
of 14C-carboplatin. 
Methods: Cancer cells and mice bearing tumor xenografts were 
treated with one microdose (1/100th of the therapeutic dose) or one 
therapeutic dose of [14C]carboplatin. Relevant parameters such as 
drug influx/efflux, intracellular drug inactivation, DNA damage and 
repair, were measured and correlated with response to chemotherapy. 
Results: AMS can detect Pt-DNA damage when cancer cells and 
mice with tumor xenografts are exposed to one microdose of 14C-
carboplatin. The levels of microdose-induced DNA damage are dir-
ectly proportional to the DNA damage caused by a therapeutic drug 
dose (p<0.001); and these levels of DNA damage correlated with 
chemoresistance as measured by MTT assay. Measuring drug uptake/
efflux and intracellular inactivation allows insights into resistance 
mechanisms. Pt-resistant cells have low DNA damage and decreased 
cell uptake of carboplatin. Intracellular glutathione (GSH) is involved 
in intracellular inactivation of Pt. Depletion of GSH with buthionine 
sulphoximine enhanced cellular sensitivity to carboplatin. A Phase 0 
microdosing trial has been designed to study patients with non-small 
cell lung cancer who are planning to receive Pt-based chemotherapy. 
One microdose of 14C-carboplatin is administered to these patients 
4 hours before biopsy. Pt-induced DNA damage and repair in tumor 
biopsy specimens and other relevant parameters will be measured and 
correlated with the response and toxicity of chemotherapy.
Conclusion: These data support the conclusion that the levels 
of DNA damage induced by microdosing can potentially predict 
chemoresistance in patients. We have designed a phase 0 microdos-
ing trial employing AMS to identify chemoresistance and determine 
the underlying chemoresistant mechanisms for personalized therapy 
before patients receive Pt chemotherapy.
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Restoration of absent mitochondrial death signals by an 
MCL-1 antagonist bypasses cisplatin resistance in non-
small cell lung cancer 
Crawford, Nyree1; Chacko, Alex D.1; Busacca, Sara2; Paul, Ian1; 
Liberante, Fabio1; Gaudino, Giovanni2; Savage, Kienan1; McCoy, 
Francis1; Hurwitz, Jane1; Holt, Robert3; Wilson, Claire L.3; Kennedy, 
Richard D.3; Johnston, Patrick1; Fennell, Dean A.1
1 Queen’s university Belfast, Belfast, UK; 2 DISCAFF University 
of Piemonte orientale “A.Avogadro”, Novara, Italy; 3 Almac 
diagnostics, Craigavon, UK
Background: Resistance to cisplatin chemotherapy remains a major 
hurdle preventing effective treatment of non-small cell lung cancer 
(NSCLC), where tumour response rates to conventional therapy at 
relapse remain unacceptably low. BAX and BAK are pivotal regula-
tors of the mitochondrial apoptosis pathway, however little is known 
regarding their regulation in the cisplatin-resistant setting.
Results: Cells were selected for resistance to cisplatin (CisRH460). 
They exhibited a complete block in death signalling via the mito-
chondrial apoptosis pathway following cisplatin, as evidenced by lack 
of caspase 9 activation or PARP cleavage, compared with parental 
cells (parH460). However, CisRH460 did initiate H2AX phosphoryl-
ation, cell cycle arrest and p53 stabilization consistent with cisplatin 
induced DNA damage. BAK activation and mitochondrial SMAC 
release occurred post-cisplatin in parH460 but not CisRH460, con-
sistent with a block in death signalling via the mitochondrial pathway. 
However, CisRH460 conserved susceptibility to exogenous BH3 
domain (BID, BIM) induced apoptosis both at the whole cell and 
mitochondrial levels. These BH3 domains required BAX and BAK to 
mediate apoptosis and lost activity when mutated in a critical leucine 
residue, confirming specificity. Cross resistance was not observed 
with either recombinant full length BID or TRAIL. We identified 
downregulation of the endogenous MCL-1 inhibitor and BH3-only 
proapoptotic protein NOXA in CisRH460, suggesting selection for 
loss of this tumour suppressor. Restoration by cell permeable NOXA 
BH3 domain reactivated the mitochondrial apoptosis pathway. Ac-
cordingly, the MCL-1 inhibitor obatoclax (obx) was sufficient to 
activate caspase 9 and mediate loss of viability in not only parH460, 
but CisRH460 cells. Equieffective proapoptotic activity of obx was 
confirmed in a panel of cisplatin resistant versus parental cell line 
pairs. The genes which suppress pre-mitochondrial death signals 
remain unknown. Accordingly, we conducted lung cancer specific 
transcriptome profiling of cisRH460 and parH460 pre and post 
cisplatin, followed by selectively targeted siRNA screening, leading 
to identification of genes required for suppression of critical death 
signals in the cisplatin resistant phenotype, which will be presented. 
Summary: Cisplatin resistance in NSCLC is associated with a com-
plete block of mitochondrial apoptosis due to suppression of critical 
pre-mitochondrial death signals. However, mitochondrial susceptibil-
ity to BH3 domain induced apoptosis is conserved in platinum resist-
ance, potentially enabling therapeutic bypass of “apoptosis block”. 
This hypothesis is being tested in a phase II clinical trial. 
PD10.3.5 Basic Science and Translational Research, Mon, 10:30 - 12:00
The synergistic effects between gefitinib and anti-
microtubule agents in non-small cell lung cancer cells and 
patients
Tsai, Chun-Ming; Chang, Kuo-Ting; Chiu, Chao-hua; Chen, Tina; 
Hsiao, Shih-Yin 
Section of Thoracic Oncology, Chest Dept. Taipei Veterans Gen. 
Hospital, Taipei, Taiwan
Background: While randomized trials failed to show benefit in 
combining epidermal growth factor receptor tyrosine kinase inhibitor 
(EGFR-TKI) with standard platinum-based chemotherapy in ad-
vanced non-small cell lung cancer (NSCLC) patients, it might not be 
true for combination of EGFR-TKI with individual agents which are 
substrates of the ATP-binding cassette transporters (ABCTs) because 
EGFR-TKI can act as an inhibitor of the efflux system. 
Methods: Testing a panel of 15 cell lines established from untreated 
NSCLC patients and two cell lines with acquired P-glycoprotein 
(Pgp) overexpression, we evaluated the combination effects of 
gefitinib with four anticancer drugs, namely gemcitabine, paclitaxel, 
docetaxel and vinorelbine by the MTT assay with application of clas-
sical isobole method. We determined and correlated the levels of Pgp, 
breast cancer resistance protein (BCRP), multidrug resistance-asso-
ciated protein 1 (MRP1) and MRP2 expression with the combination 
effects. A proof-of-concept phase II trial was conducted to evaluate 
the oral gefitinib (250 mg daily) plus intravenous paclitaxel (60 mg/
m2 d1, 8 and 15, every 4 weeks) regimen (G+P) in patients who 
had failed both gefitinib monotherapy and anti-microtubule agent 
(AMTA) treatment. 
Results: There was a synergistic effect in combination of gefitinib, 
in clinically relevant concentrations, with AMTA at the cellular level. 
This effect was correlated with AMTA, but not gefitinib, sensitivity, 
and more robust in cells with Pgp overexpression or wild type EGFR. 
In contrast, the combination effect between gefitinib and gemcitabine 
was addictive at best. In 34 patients having drug resistance already, 
G+P still provided a response rate of 29.4% (95% C.I., 14.1-44.7%), 
disease control rate of 38.2% (95% C.I., 21.9-54.5%), median 
progression-free survival of 3.2 months (95% C.I., 1.7-4.7 months) 
and median overall survival of 7.8 months (95% C.I., 4.1-11.5 
months). The treatment outcome was significantly correlated with 
prior response to AMTA treatment but not gefitinib. 
Conclusions: Gefitinib is a clinically useful Pgp inhibitor which can 
overcome the resistance of AMTAs in NSCLC cells and patients.
PD10.3.6 Basic Science and Translational Research, Mon, 10:30 - 12:00
Effects of inhibition of c-Src kinase by dasatinib (BMS-
354825) in the sensitivity to cisplatin of non-small cell lung 
cancer cell lines
Ceppi, Paolo; Monica, Valentina; Lo Iacono, Marco; Saviozzi, Silvia; 
Pautasso, Marisa; Novello, Silvia; Mussino, Stefano; Bracco, Enrico; 
Volante, Marco; Papotti, Mauro; Scagliotti, Giorgio V.
Department of Clinical and Biological Sciences, University of Turin, 
Orbassano, Italy
Background: c-Src is a tyrosine kinase involved in many aspects of 
tumorigenesis, including proliferation, migration and angiogenesis 
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and has been shown to modulate the cytotoxicity of cancer cells fol-
lowing cisplatin-induced DNA damages. Src is frequently activated 
in NSCLC, but no data are available on the effect of its inhibition on 
the sensitivity to cisplatin. We tested the effect of a novel Src kinase 
inhibitor, dasatinib (BMS-354825) in combination with cisplatin in a 
panel of NSCLC cell lines. 
Materials and Methods: Seven human NSCLC cell lines (Calu-1, 
H520, SK-MES-1, H596, H522, H1395 and H1299) were used. Cell 
viability and apoptosis following drugs administration were evaluated 
with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) and Annexin V/Propidium Iodide assays. The activity of Src 
kinase was estimated by Western Blot (WB) with phospho-specific 
antibodies. In addition, the level of expression of Src mRNA was 
quantified by means of Real-Time PCR (qPCR) in 44 consecutive 
fresh-frozen surgically resected NSCLC and in the corresponding 
normal lung tissues, including 28 adeno, 15 squamous and 1 large 
cell carcinomas. All patients and cell lines carried wild-type EGFR 
gene. 
Results: Treatment with dasatinib for 24 hours at a dose of 100nM 
completely abrogated c-Src phosphorylation in all the cell lines 
tested, except in the adenocarcinoma H522, with modest effects on 
growth and survival and no alterations of Src gene transcription. By 
contrast, dasatinib increased the sensitivity to cisplatin in 5 out of 7 
cell lines, as evaluated by MTT assay, and the effect was not related 
to the endogenous Src expression or phosphorylation level. Simi-
larly, all the cell lines had an increased number of apoptotic/dead 
cells when treated with dasatinib/cisplatin combination as compared 
to cisplatin alone, with the exception of H522. The strongest effect 
was observed in the squamous carcinoma NCI-H520 cell line and 
the effective block of cisplatin-induced Src phosphorylation was 
demonstrated by WB analysis. Furthermore, treatment with dasatinib 
significantly blocked cisplatin-induced transcription of a panel of 
genes belonging to DNA repair and synthesis pathways, including 
ERCC1, TS, Pol η, BRCA1, TopoII-α, RRM1 and E2F1, as assessed 
by qPCR experiments. This effect was evident at different levels 
of intensity in the cell lines tested, being more intense in the H520, 
while no changes were observed in H522. The results of transcript 
quantification in surgical samples indicated that Src is significantly 
up-regulated in 23% of tumors compared to the normal lung tissues, 
without any associations with patients’ clinico-pathological factors or 
survival. 
Conclusions: The present study shows that dasatinib can enhance 
cisplatin cytotoxicity, likely impairing the cisplatin-induced modula-
tion of DNA repair and synthesis genes, and that a subset of NSCLC 
patients have an increased Src kinase mRNA expression in tumors. 
Taken together, these data support the hypothesis of an integration of 
cytotoxic chemotherapy with inhibitors of specific molecular path-
ways, in the attempt to ameliorate the outcomes of NSCLC patients. 
Future studies evaluating the efficacy of Src-inhibiting agents in 
combination with cisplatin are clearly warranted. 
PD10.4.1 Basic Science and Translational Research, Mon, 10:30 - 12:00
Aldehyde dehydrogenase activity selects for cancer stem 
cell population dependent on the notch signaling pathway 
in non small cell lung cancer 
Sullivan, James P.; Spinola, Monica; Dodge, Michael; Gao, Boning; 
Minna, John D.
UT Southwestern Medical Center, Dallas, TX, USA
Background: Lung carcinoma is the most frequent cause of cancer 
related death for both men and women. A considerable amount of 
evidence has indicated that cancer growth, metastasis and recur-
rence after therapy are caused by a rare population of cancer stem 
cells (CSCs). These findings make CSCs an appealing target for 
new targeted therapeutics. Although CSCs have been identified and 
characterized in leukemia, brain, breast and colon cancer, little is 
known about lung CSCs. For this reason we set out to enrich for and 
characterize lung CSCs by utilizing techniques that have selected for 
CSCs in other tissues. 
Methods: We tested over 30 non-small cell and small cell lung 
cancer lines and several fresh NSCLC tumor specimens for ALDH 
activity using the Aldefluor assay kit and FACS sorting. The ALDH 
inhibitor DEAB was used to determine true ALDH+ tumor cells. The 
ALDH+ and ALDH- cells were resorted and found to have ~75% and 
>99% purity for ALDH activity respectively. Clonigenic assays were 
performed in soft agar, and xenograft testing was done in ~5 NOD/
SCID mice each with small numbers of cells (1,000 to 10,000). A 
panel of 40 stem cell pathway related genes had their mRNA expres-
sion quantitated by qRT-PCR. 
Results: We found that lung cancer cells with increased aldehyde 
dehydrogenase activity (ALDH) have stem/progenitor properties. 
ALDH+ cells represented a small fraction [0.2-20%] of the bulk 
population of most non small cell lung cancer tumor samples and 
cell lines tested. When isolated by FACS, ALDH+ lung cancer cells 
produced larger and more frequent tumors in immunodeficient mice 
than ALDH- cells. Furthermore ALDH+ cells were observed to be 
more clonigenic and proliferative in vitro than bulk ALDH- cells and 
produced more ALDH+ cells after two weeks in culture whereas this 
ability was diminished in ALDH- cells. Analysis of a panel of 40 
stem cell self-renewal genes by qRT-PCR revealed an elevated level 
of Notch pathway transcripts in ALDH+ cells compared to ALDH- 
cells, suggesting increased pathway activity in the ALDH+ fraction. 
To determine what role this molecular pathway plays in the mainten-
ance of ALDH+ lung cancer cells, Notch pathway activity was sup-
pressed by treatment with a gamma-secretase inhibitor, resulting in a 
significant decrease in the percent of ALDH+ cells. 
Conclusions: Taken together these findings suggest that ALDH+ lung 
cancer cells represent a population of lung cancer stem cells. Further 
molecular characterization of these ALDH+ lung cancer cells may 
eventually lead to the discovery of lung CSC specific drug targets.
Research supported by NCI SPORE P50CA70907, NASA NNJ05H-
D36GD DOE DE-AI02-05ER64068
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Stromal cells derived from non-small cell lung cancer 
and normal lung tissue display mesenchymal stem cell 
characteristics and differ in their gene expression profiles 
and functional behaviour
Gottschling, Sandra1; Jauch, Anna2; Granzow, Martin2; Kuner, 
Ruprecht3; Muley, Thomas1; Chang Xu, Elizabeth1; Hoffmann, 
Hans1; Dienemann, Hendrik1; Eckstein, Volker4; Ho, Anthony D.1; 
Herth, Felix F.1; Thomas, Michael1; Meister, Michael1
1 Clinic for Thoracic Diseases at University Hospital, Heidelberg, 
Germany; 2 Institute for Human Genetics, University Heidelberg, 
Heidelberg, Germany; 3 German Cancer Research Center, Division 
of Molecular Genome Analysis, Heidelberg, Germany; 4 Internal 
Medicine V, University Hospital Heidelberg, Heidelberg, Germany
Stromal microenvironment plays a vital role for the induction and 
maintenance of solid tumours. However, detailed knowledge on the 
microenvironment in non-small cell lung cancer (NSCLC) is scanty. 
Here, we provide a systematic and comparative analysis of genetic 
and functional properties of autologous stromal cells (SC) derived 
from NSCLC and microscopically normal lung tissue (NLT) of five 
newly diagnosed lung cancer patients. SC were derived from 2 large 
cell, 2 squamous cell, and 1 adenocarcinoma. For all analyses, SC of 
passage 5 were used. Screening by comparative genetic hybridization 
revealed no genetic alterations of the SC.
Both, NSCLC-SC and NLT-SC displayed mesenchymal stem cell 
(MSC) characteristics according to their immunonphenotype and 
multilineage differentiation potential. However, analysis of growth 
behaviour and sensitivity to cisplatin revealed significant differences 
between NSCLC-SC and NLT-SC. NSCLC-SC contained about twice 
as much colony forming units fibroblast (CFU-f) than NLT-SC and 
displayed stable colony efficiencies over several passages. This re-
sulted in faster growth kinetics and 27- vs. 12-fold expansion after 10 
passages. Moreover, exposure to the cytostatic agent cisplatin demon-
strated significantly reduced sensitivity of NSCLC-SC with delayed 
onset of apoptosis and increased survival of CFU-f. In line with these 
results, Affymetrix HG U133 Plus 2.0-based arrays and real time 
PCR showed different expression levels of genes such as ENDOD1, 
MTP18, QSOX1, or SEMA3C involved in DNA repair, apoptosis, 
proliferation, and ageing of MSC. Epithelial-to-mesenchymal transi-
tion or contamination by tumour cells was excluded by broad surface 
marker analysis and the absence of epithelium-specific transcripts.
These data strongly suggest the presence of distinct stromal cells in 
the vicinity of NSCLC that might modulate the cancerogenic process 
and response to therapy.
PD10.4.4 Basic Science and Translational Research, Mon, 10:30 - 12:00
Notch inhibition induces apoptosis in lung cancer cell lines 
and prevents reimplantation of xenografts
Hassan, Khaled A.; Kalemkerian, Greg P.; Wicha, Max
University of Michigan, Ann Arbor, MI, USA
Background: Notch is a highly conserved signaling pathway that 
regulates cell fate during development and tissue homeostasis. Notch 
also regulates the self-renewal potential of stem/progenitor cell popu-
lations in multiple contexts and appears to mediate the self-renewal 
capacity of cancer stem cells. 
Results: Non-small cell (NSCLC; NCI-H1299, NCI-H460, NCI-
H358) and small cell (SCLC; NCI-H82) lung cancer cell lines 
were screened for expression of the four Notch receptors and other 
pathway components (Hey1, Hes1, Jag1) using semi-quantitative 
RT-PCR. Expression of at least one Notch receptor was detected in 
all cell lines with variable expression of other pathway mediators. 
Treatment of cell lines with a Notch inhibitor, gamma-secretase 
inhibitor MRK003, followed by MTT assay established an IC50 
range of 10-30 μM in these cell lines. MRK003 induced cell cycle 
arrest within 24 hrs of treatment. Interestingly, G2/M arrest was noted 
in NCI-H82 SCLC cells, while G1/S arrest was noted in NCI-H1299 
NSCLC cells. By Western blot, MRK003 also induced an increase in 
inactive phospho-cdc2 protein levels within 12 hrs of exposure, thus 
preventing cyclinB1-cdc2 nuclear translocation and resulting in mi-
totic inhibition. Prolonged exposure to MRK003 for 6 days induced 
significant apoptosis (~40%) in both NCI-H82 and NCI-H1299 cells. 
Xenograft models utilizing NOD/SCID mice and subcutaneously in-
jected NCI-H82 or NCI-H1299 cells were used to evaluate the in vivo 
effects of MRK003 in both SCLC and NSCLC, respectively. Mice 
were divided into four groups that were treated with either MRK003 
alone (100 mg/kg po days 1-3 every 14 days), docetaxel alone (10 
mg/kg IV every 14 days), MRK003 plus docetaxel (MRK003 100 
mg/kg po days 1-3 and docetaxel 10 mg/kg IV on day 8 every 14 
days), or no treatment. Treatment was initiated when tumor volume 
reached 5 mm3. Single-agent MRK003 did not induce significant 
growth inhibition when compared to control, while docetaxel alone 
caused significant inhibition of tumor growth. The growth inhibitory 
effect of MRK003 plus docetaxel was similar to that of docetaxel 
alone. However, tumors that were removed from MRK003-treated 
NCI-H1299 xenograft mice and reimplanted in naive NOD/SCID 
mice failed to regenerate tumors, while those from mice treated with 
docetaxel alone did generate new tumors upon reimplantation.
Conclusion: Notch pathway components are commonly expressed 
in lung cancer cells and Notch inhibition with MRK003 induces cell 
cycle arrest and apoptosis in both SCLC and NSCLC cell lines. The 
lack of tumor regeneration from MRK003-treated xenografts suggests 
that the Notch pathway may play an important role in the self-renew-
al capacity of lung cancer stem/progenitor cells. 
PD10.4.5 Basic Science and Translational Research, Mon, 10:30 - 12:00
Sulf-2, a heparan sulfate endosulfatase, promotes human 
lung carcinogenesis 
Lemjabbar Alaoui, Hassan; van Zante, Annemieke; Singer1, Mark S.; 
Xue, Qing; He, Biao; Jablons, David M.; Rosen, Steven D.
UCSF, University of California at San Francisco, San Francisco, CA, 
USA
Heparan sulfate proteoglycans (HSPGs) bind multiple growth factors/
morphogens and regulate their signaling. 6-O-sulfation (6S) of glu-
cosamine within HS-chains is critical for many ligand interactions. 
Sulf-1 and Sulf-2, extracellular neutral-pH sulfatases, provide a 
novel mechanism for regulation of HSPG function by removing 
6S from intact HS-chains. The Sulfs can thereby modulate several 
signaling pathways, including Wnt signaling. We found induction of 
SULF2 transcripts and Sulf-2 protein in human lung adenocarcinoma 
and squamous cell carcinoma, two major classes of non-small cell 
lung cancers (NSCLC). We studied five Sulf-2+ NSCLC cell lines, 
including two derived from cigarette-smoke transformed bronchial 
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epithelial cells. Sulf-2 knockdown in these lines reversed their trans-
formed phenotype in vitro, eliminated autocrine Wnt signaling, and 
blunted xenograft tumor formation in mice. Conversely, forced Sulf-2 
expression in non-malignant bronchial epithelial cells produced a 
transformed phenotype. Our findings support a pro-oncogenic role for 
Sulf-2 in lung cancer, the leading cancer killer.
PD10.4.6 Basic Science and Translational Research, Mon, 10:30 - 12:00
Inflammation-induced and snail-mediated EMT during 
early lung cancer development
Walser, Tonya C.1; Yanagawa, Jane1; Goodglick, Lee1; Hong, Long-
Sheng1; Fishbein, Michael C.1; Spinola, Monica2; Minna, John D.2; 
Shay, Jerry W.2; Dubinett, Steven M.1
1 David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; 
2 University of Texas Southwestern Medical Center, Dallas, TX, USA
Background: The pulmonary environment at risk for carcinogenesis 
contains inflammatory mediators that potently promote epithelial-
mesenchymal transition (EMT) through the induction of E-Cadherin 
transcriptional repressors, including Snail. EMT is often activated 
during cancer invasion and metastasis, but the role of inflammation-
induced and Snail-mediated EMT during early lung cancer develop-
ment has not been defined. 
Methods and Results: By Western analysis, immortalized human 
bronchial epithelial cells (HBECs) stably transduced to express Snail 
(HBEC-S) have up-regulated Snail and down-regulated E-Cadherin 
compared to HBEC vector control cells (HBEC-V). Snail expression 
by HBECs results in EMT, as lung epithelial markers are down-regu-
lated in HBEC-S compared to HBEC-V, while mesenchymal markers 
are up-regulated. We utilized Affymetrix Gene Chip Human Genome 
U133 Plus 2.0 gene arrays to profile HBEC-S and HBEC-V. Numer-
ous inflammation-related genes are up-regulated by Snail expression, 
including prostaglandin synthases, IL-1β, TGF-β, and IL-17, sug-
gestive of the existence of an inflammation/Snail autocrine feedback 
loop. Also by microarray analysis, the putative stem cell markers 
CD44, ABCG, ALDH, Sox, Notch, Jag, Hes, Wnt, KLF, and Myc are 
up-regulated in HBEC-S compared to HBEC-V. PCR and Western 
analysis confirmed Snail-mediated up-regulation of numerous stem 
cell markers, including CD44, Oct4, Nanog, Sox2, Notch1, Jag1, and 
Myc. Additionally, there is a 2-fold expansion of the ALDH+ stem 
cell population in HBEC-S compared to HBEC-V by flow cytom-
etry analysis, and the CD44+CD24- cancer stem cell phenotype is 
expanded by nearly 10-fold. A role for Snail in EMT and stem cell 
population expansion during early lung cancer development was con-
firmed by studies conducted in a 3D organotypic model of squamous 
metaplasia. In the 3D model, HBEC-V form well-organized epi-
thelial cell layers atop a modified basement membrane. In contrast, 
HBEC-S epithelial cell layers are disorganized and discohesive. 
Immunohistochemical staining of E-Cadherin is intense in HBEC-V 
but nearly absent in HBEC-S, where loss of E-Cadherin is indica-
tive of cells that have undergone EMT. Snail over-expression also 
appears to drive expansion of the basal cell population, as marked 
by p63, Ck14, CD44, and ALDH staining. Finally, Bmi1 and EZH2, 
markers associated with stem cell self-renewal and differentiation, 
stain more intensely in HBEC-S compared to HBEC-V. As measured 
by Annexin-V staining and flow cytometry analysis, HBEC-S are 
also 12-fold more resistant to apoptosis, a characteristic ascribed to 
cells with enhanced “stemness”. In situ, precursor lesions of human 
squamous cell carcinoma and adenocarcinoma over-express Snail 
compared to normal lung tissues. A “field defect” of a histologically 
normal airway and areas of hyperplasia are also intensely positive for 
Snail. Importantly, where normal tissues are positive for Snail expres-
sion, there is an association with inflammation. 
Conclusion: These findings indicate that Snail over-expression 
can induce normal non-mutated cells of the bronchial epithelium to 
undergo EMT and to initiate programs of inflammation and stem cell 
population expansion both in vitro and in a 3D organotypic model 
of squamous metaplasia. This is the first report of Snail staining of 
human premalignant lung lesions, and the staining pattern suggests 
that Snail is a possible biomarker of the “field defect” and early lung 
cancer development. 
PD10.5.1 Basic Science and Translational Research, Mon, 10:30 - 12:00
Clinical and therapeutic relevance of primary tumor 
xenograft models of NSCLC 
John, Thomas1; Ishizawa, Kota2; Karisch, Robert3; Li, Ming1; Zhu, 
Chang-Qi1; Neel, Benjamin G.3; Waddell, Thomas2; Shepherd, 
Frances A.1; Tsao, Ming-Sound1, 3
1 University Health Network, Princess Margaret Hospital, Toronto, 
ON, Canada; 2 Toronto General Research Institute, Toronto, ON, 
Canada; 3 Ontario Cancer Institute, Toronto, ON, Canada
Background: Compared to cell lines, primary tumor xenografts dem-
onstrate closer fidelity to the original cancer. Response to treatment 
in NSCLC xenografts also closely parallels that observed in the clinic 
with response rates to individual chemotherapeutic agents of ~30%. 
In different tumor types and using in vitro models, others have shown 
that chemotherapy may enrich for tumor initiating cell frequency 
(TIF). Such tumor initiating cells may represent cancer stem cells. 
Primary tumor xenografts may be better models to study molecular 
predictors of response and the cellular effects of chemotherapy in 
NSCLC. However, only a fraction of tumors engraft successfully and 
can be passaged serially in SCID mice. Furthermore, despite exten-
sive use of the model, few studies have correlated patient clinico-
pathological features with the ability of a tumor to engraft. 
Methods: Fresh primary NSCLC tumors were harvested from 
patients who underwent curative resection. Tumor fragments were 
implanted into the subcutaneous and/or subrenal capsule of non-
obese diabetic (NOD)-SCID mice within 24 hrs of harvesting. Patient 
characteristics for tumors that engrafted (XG) and did not engraft 
(No-XG) were compared. Only tumors from patients with >1-yr 
follow-up were evaluated for time to progression (TTP) and correla-
tion of clinico-pathological features with engraftment. For response 
to chemotherapy, 30 mice per tumor XG were treated with a single 
intraperitoneal dose of 6mg/kg cisplatin, 10mg/kg vinorelbine or 
with saline, and tumor size was measured serially for 30 days. At 
sacrifice, dissociation using collagenase and epithelial cell isolation 
was performed prior to secondary SC implantation into NOD/SCID 
mice at limiting dilutions ranging from 10 cells to 100,000 cells with 
4 replicates per dilution. Mice were monitored thrice weekly for the 
development of tumor.
Results: From March 2005 to October 2008, 110 tumors were 
implanted and 45 (41%) engrafted to form NSCLC xenografts. Squa-
mous cell carcinomas engrafted significantly more than adenocarcin-
omas (57% versus 26%, p=0.03). There were no significant differ-
ences in histological grade and clinical stage between the XG and 
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No-XG groups. XG patients had significantly shorter TTP than the 
No-XG group (10.19 versus 22.8 months, p=0.003). In multivariate 
analysis the ability to form a xenograft was an independent predictor 
of relapse (Odds Ratio 3.48 95% CI 1.09-11.13, p=0.03). Nine XGs 
have been treated with cisplatin and vinorelbine; 3 (30%) responded 
to one or both agents. TIF was evaluated in two tumors treated with 
cisplatin. TIF was significantly increased from 1/467 cells in untreat-
ed controls to 1/14 cells treated with cisplatin (p<0.05) in one tumor 
but did not change in the second model. Interestingly the first tumor 
briefly responded to cisplatin whereas the second continued to grow.
Conclusions: The ability of a primary NSCLC to engraft and form a 
xenograft may be predictive of a more aggressive biology and poorer 
clinical outcome. In a preliminary experiment chemotherapy appears 
to increase tumor initiating cell frequency in a responding xenograft. 
Primary tumor xenografts may be a more clinically relevant model to 
investigate tumor-initiating cells. 
PD10.5.2 Basic Science and Translational Research, Mon, 10:30 - 12:00
Bronchoscopy acquired lung cancer tissue is a convenient 
and effective tumor source for the generation of primary 
small and non-small cell lung cancer xenografts
Yung, Rex C.1; Brock, Malcolm1; Peacock, Craig1, 2; Watkins, David 
N.3; Rudin, Charles2
1 Johns Hopkins University, Baltimore, MD, USA; 2 Johns Hopkins 
School of Medicine Oncology Center, Baltimore, MD, USA; 3 Monash 
Medical Center, Clayton, VIC, Australia
Introduction: Lung Cancer (LC) xenografts have potential ad-
vantages over cell-lines for studies of lung cancer biology, gene 
expressions and responses to antineoplastic therapies. Xenografts are 
typically generated using surgical specimens, however small cell lung 
cancers (SCLC) and advanced stages NSCLC are seldom resected. 
Bronchoscopy, are routine for diagnostic and therapeutic purposes. 
Lesions from peripheral nodules to central masses, regional lymph 
nodes can be sampled by a variety of techniques and tools. These 
minimally-invasive sampling may yield tissue suitable for generating 
primary xenografts useful for translational research.
Patients and Methods: LC tissue collection for xenografting is 
approved by institutional IRB. In a 62 months period (Dec 2003 to 
Feb 2009), LC xenografts are made using portions from surgical re-
section(26), malignant effusions (17), endobronchial/ transbronchial 
biopsies (26) and transbronchial needle aspiration (TBNA) of medi-
astinal mass/adenopathy (3). Non-thermal methods are used to collect 
endobronchial tumor, including forceps, cryoprobe and mechanical 
microdebrider. TBNA uses 19 and 21 gauge needles with aspiration.
After Rapid On-site cytology or Fresh Frozen pathology confirmed 
LC, residual cells from needle rinses and debrided tumor were passed 
onto technicians who homogenized the tissues, and injected the tumor 
resuspended in Matrigel into NOD-SCID mice. Xenografts that suc-
cessfully graft were harvested for serial passage, establishment of 
conventional cell lines, prepared for paraffin sections and frozen for 
future studies.
Results: Of 32 successfully propagated LC xenografts, 11 came 
from endobronchial biopsies and 3 from TBNA of tumor mass/nodes. 
7/9 SCLC & 6/23 NSCLC xenografts came from bronchoscopic 
sampling.
Cell Type Small Cell Lung Ca SCLC Non-Small-
Cell LC
NSCLC
Harvest Technique Successful Xenograft 
(rate)
Failed Xenograft Successful 
Xenograft
Failed 
Xenograft
Endobronchial Bx 6* (40%) 9 (60%) 5 (50%) 5 (50%)
TBNA 2* (100%) 0 1 (100%) 0
Malignant Effusion 1 (100%) 0 3 (23%) 10 (77%)
Surgical Resection 1 (100%) 0 15 (65.2%) 8 (34.8%)
summarizes # and (%)yield of xenografts from different techniques.
* 1 SCLC xenograft grew from endobronchial and TBNA specimens from same bronch
Discussion & Recommendations: We demonstrate effective genera-
tion of both SC and NSCLC xenografts, from bronchoscopy samples 
that would otherwise be discarded as waste. Familiarity with non tis-
sue-destructive debridement techniques and practice of sterile transfer 
are required, but these are easily learned. Follow-up translational 
studies have documented value of xenografts as irreversible changes 
in gene expression are seen in in-vitro cell lines (ref Daniel: Can Res 
2009). We suggest that attention to bronchoscopy-xenografting may 
expand opportunities for LC translational research. 
PD10.5.3 Basic Science and Translational Research, Mon, 10:30 - 12:00
RNAi library screen reveals RSK1 as a key regulator of 
lung cancer metastasis
Seckl, Michael J.1; Pardo, Olivier E.1; Lara, Romain1; Mauri, 
Francesco1; Bates, Paul2; Zicha, Daniel2; Downward, Julian2
1 Imperial College London, London, UK; 2 London Research 
Institute, London, UK
Lung cancer is the commonest cancer killer with a 5-year survival 
rate <5%. Non-small cell lung cancer (NSCLC) accounts for more 
than 80% of cases of which adenocarcinoma represents the majority. 
Surgical resection of localised disease provides the best chance of 
cure in what is usually a relatively chemo and radiotherapy resistant 
disease. Unfortunately, most patients present with metastatic lesions 
and so are incurable. Consequently, a better understanding of the bio-
logical processes underlying lung cancer cell motility, invasion and 
metastasis is urgently needed to improve the poor clinical outcome.
A relatively limited number of proteins have been implicated in driv-
ing cell motility/invasion including some small GTPases and several 
kinases such as Src, FAK, MAP4K4, AKT2, EphB6. However, there 
are more than 600 kinases in the human kinome that could potentially 
play a role in driving this process. The identification of additional 
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kinases should yield novel biomarkers and/or therapeutic targets for 
patients with cancer.
To identify regulators of lung cancer cell motility, we performed 
a kinome-wide RNA interference screen in A549 non-small cell 
lung cancer cells. 59 novel kinases were identified that increased or 
decreased cell migration including several members of the ribosomal 
S6 kinase (RSK) family. In particular, RSK1 silencing increased, 
while RSK2 and 4 downregulation inhibited, cell motility. Bio-
informatic analyses revealed a highly interactive subgroup amongst 
our candidates. This included a previously unrecognsied link between 
RSK2 and VASP, validated by co-immunoprecipitation. Moreover, 
we experimentally identified Mena, another actin regulator, as a new 
interactor for RSK1 and 2. VASP and Mena targeting counteracted 
RSK1-mediated migration changes. A secondary 3-dimensional 
invasion screen for our candidates revealed that RSK1 downregula-
tion increased the invasiveness of A549 cells. Our results could be 
reproduced in several other non-small cell lung cancer cell lines. 
Crucially, our in vitro data for RSK1 was confirmed in isogenically 
matched primary and metastatic material from human lung cancer 
patients. RSK1 protein expression decreased in metastatic lesions 
compared to matched primary lung tumours. Moreover, patients 
with RSK1-negative lung tumours showed an increased number of 
metastases. These data demonstrate the role of RSK family members 
in lung cancer cell metastasis and suggests that loss of RSK1 might 
predict poor outcome.
PD10.5.4 Basic Science and Translational Research, Mon, 10:30 - 12:00
Molecular characterisation of circulating tumour cells 
using CellSearch and ISET technologies to enhance early 
phase development of pro-apoptotic agents in lung cancer
Krebs, Matthew1, 2; Hou, Jianmei1; Priest, Lynsey1; Sloane, Robert1; 
Hughes, Andrew3; Dive, Caroline1; Blackhall, Fiona2, 1
1 Paterson Institute for Cancer Research, Manchester, UK; 2 The 
Christie NHS Foundation Trust, Manchester, UK; 3 AstraZeneca, 
Manchester, UK
Background: Circulating Tumour Cells (CTCs) have potential as 
pharmacodynamic and predictive biomarkers in clinical trials of pro-
apoptotic agents. We have investigated CellSearch™ (Veridex, New 
Jersey) and ISET™ (Isolation by Size of Epithelial Tumour Cells, 
Metagenex, Paris) to detect clinical diagnostic molecular markers 
TTF-1, CD56; and pro-apoptotic drug targets Mcl-1/Bcl-2 in CTCs. 
Methods: CellSearch enriches CTCs using EpCam coated immuno-
magnetic beads then fluorescently labels with DAPI, CD45 and 
cytokeratins 8, 18 and 19. ISET isolates cells by size exclusion onto 
a polycarbonate membrane. H146 (SCLC) and H441 (NSCLC) cells 
were spiked into healthy volunteer donor blood at a concentration 
of 1000 cells/ 7.5ml blood. Clinical samples were collected from 
chemo-naïve SCLC and NSCLC patients with metastatic disease 
using ethically approved protocols and processed to GCLP standards. 
CTCs were enumerated using CellSearch alone. Standard immuno-
histochemistry, immunofluorescence were compared on CellSearch 
and ISET enriched CTCs for selected markers. 
Results: CD56 was detectable using ISET and CellSearch (image 
a and b). Similarly, in both systems Bcl-2 and Mcl-1 were detect-
able in SCLC patient samples using immunohistochemistry (ISET) 
or immunofluorescence (CellSearch). TTF-1 is nuclear and not 
detectable by CellSearch but cellular morphology could be clearly 
defined by ISET (image c). In general CTCs were detected in a higher 
proportion of SCLC cases and were more abundant compared with 
NSCLC. Using a cut-off value of 2 CTC/7.5ml blood for positivity, 
29/30 (97%) pts with extensive stage SCLC were positive compared 
with 11/48 (23%) pts with advanced stage NSCLC. Mean CTC 
numbers were significantly higher in patients with SCLC (mean ± 
sd, 7172±11821, median 237) vs patients with NSCLC (mean 5±21, 
median 1). 
Conclusion: CellSearch and ISET can be used for molecular charac-
terisation of CTCs but there are demonstrable differences. CellSearch 
enriches CTC on the basis of EpCAM expression and yields robust 
quantification whereas ISET relies on cell size irrespective of surface 
marker. Since EpCAM loss is associated with the metastatic pheno-
type, CellSearch and ISET may provide complementary data in clin-
ical studies. The choice of technique for CTC characterisation should 
be guided by tumour type and molecular marker of interest. These 
technologies will now be applied to inform Bcl-2 and Mcl-1 protein 
expression in patients recruited to trials of pro-apoptotic agents. 
PD10.5.5 Basic Science and Translational Research, Mon, 10:30 - 12:00
Spectral biopsy of lung cancer by auto fluorescence of 
cellular components of blood
Salhi, Mohamad Al2; Elangovan, Masilamani3; Trinka, Vijmasi4; 
Masilamani, Vadivel1; Diab, Abdulrahman Al2; Hajjar, Waseem 2; 
Ainia, Mohamad2; Mustapha, Abdullah Al2
1 University, Riyadh, Saudi Arabia; 2 King Saud University, Riyadh, 
Saudi Arabia; 3 Thendrel Inc, Fairfax, VA, USA; 4 Masila’s Cancer 
Diagnostics, Chennai, India
There are very limited methods for detection of lung cancer, based 
on serum biomarker evaluations. In this paper, we present results of a 
study done on auto fluorescence of blood components to detect lung 
cancers with a sensitivity of 90%.
Methods: For this study normal controls (N=2100) in the age group 
of 30-60 and lung cancer patients (N=40) were recruited. Exactly 5 
ml of intravenous fasting blood from each of them was drawn into 
EDTA vial, then centrifuged at 4000 rpm for 15 minutes. The super-
natant plasma and the cellular components left as sediments were 
separated and analyzed independently. We identified the unique lung 
cancer biomarker in the plasma (please see the accompanying paper) 
and generic cancer biomarkers in the acetone extract of the cellular 
component. 
For each of these samples Fluorescence Emission Spectra (FES) was 
obtained with excitation at 400nm.
Results: Fig.1 (a) gives the average of FES of 40 normal (a) and 
Fig. 1(b) that of 15 early lung cancer patients and Fig. 1(c) that of 25 
advanced lung cancer patients.
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It can be seen that there are four bands: one at 490nm (due to back-
ground and 585 nm (due to a basic form of porphyrin) and another 
at 630 nm (due to neutral porphyrin) and yet another at 685nm (due 
to acidic porphyrin). The bands at 630nm and 685nm are grossly 
elevated for the lung cancer patients. 
We define R1 as the ratio between fluorescence intensity at 630nm 
against 585nm (i.e. R1=I630/ I 585); this is about 1.7 for normal, but 
is 2.6 for early localized lung cancer and 4.6 or more for advanced 
stage tumor. Similarly, 
R2= I685/ I585 is about 0.8 for normal and goes to 1.2 for early and 
1.7 for advanced stages. A multi varriate statistics incorporating all 
these three parameters could distinguish the advanced lung cancer 
with 100% sensitivity and early lung cancer with 90% sensitivity, all 
in comparison with the tissue histopathology. 
Conclusion: Based on our study involving blood components of 
a few thousand normals and 40 lung cancer patients, diagnosis is 
possible for lung cancer with a sensitivity of 90%. All these because 
bio fluorophores porphyrin, is elevated two to four times in the body 
fluids of the diseased due to abnormal cell proliferation of cancer.
Based on the above work a patent has been submitted to Indian and 
US patent office. 
PD10.5.6 Basic Science and Translational Research, Mon, 10:30 - 12:00
Novel characteristic proteins of large cell neuroendocrine 
carcinoma, large cell carcinoma and small cell lung 
carcinoma detected from formalin fixed paraffin embedded 
tissues
Nomura, Masaharu1; Nishimura, Toshihide1; Bando, Yasuhiko4; 
Fukuda, Tetsuya4; Fujii, Kiyonaga2; Nishiyama, Ryutaro3; Hamasaki, 
Hiroko5; Hike, Hiroshi6; Tsuboi, Masahiro1; Ohira, Tatsuo1; Kato, 
Harubumi7; Ikeda, Norihiko1
1 Tokyo Medical University, Tokyo, Japan; 2 Hokkaido University, 
Sapporo, Japan; 3 Leica Microsystems, Tokyo, Japan; 4 Biosys 
Technologies Inc., Tokyo, Japan; 5 The University of Tokyo, Tokyo, 
Japan; 6 AMR Inc., Tokyo, Japan; 7 International University of 
Health and Welfare Graduate School, Tokyo, Japan
Among non-small cell lung cancer (NSCLC), the prognosis of 
three types of lung cancer, Large cell carcinoma (LCC), Large cell 
neuroendocrine carcinoma (LCNEC) and small cell lung cancer 
(SCLC) is poorer than others. Morphologically, both LCC and 
LCNEC have similar distinct nucleoli. Characteristically, both 
LCNEC and SCLC have neuroendocrine differentiation. Generally, 
chemotherapy is more effective to SCLC than others. However, there 
are some cases of SCLC resistance against chemotherapy, while there 
are some cases of LCNEC response to chemotherapy. We may need 
new regulation to distinguish these three types of lung cancers. We 
performed Multiple-reaction monitoring (MRM) assays to quantify 
proteins from formalin fixed paraffin embedded (FFPE) samples. 
Tumor cells were microdissected by laser microdissection (Leica 
LMD7000) and treated with Liquid Tissue (Experimental pathol-
ogy) for LC-MS/MS experiments. A exploratory semi-quantitative 
comparison among tissue samples LCNEC (4 cases), LCC (5 cases), 
and SCLC (5 cases) were performed by the nanoLC-high resolution 
MS and MS/MS with triplicate runs for each sample, and resulted in 
more than 1,000 proteins identified for individual groups. We have 
applied the spectral counting method along label-free semi-quanti-
tative analyses and proteins specific to individual groups have been 
determined by their statistical evaluations (U- and G-tests). Then 
various numbers of significant proteins have been listed as protein 
candidates which include known markers recommended for can-
cers of neuroendocrine (NE) such as secretagogin (SEGN), neuron 
specific enolase (NSE), neural cell adhesion molecule (NCAM), and 
chromogranin A (CgA). This MRM system was applied to biomarker 
verification on lung cancer tissues. We have performed MRM assays 
for more than 40 protein candidates comprised of their 182 MRM 
transitions designed, and have verified more than 20 new proteins 
which would be promising as marker candidates. SEGN as one of the 
known markers were found to be consistently specific to both SCLC 
and LCNEC as expected. We are going to verify these candidates 
of biomarker in serum of peripheral blood. Our data may lead new 
categories of these three types of NSCLC according to proteomic 
pattern. 
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PD11.1.1 Surgery for NSCLC, Tue, 12:30 - 14:00
The proposed IASLC seventh revision for non-small cell 
lung cancer staging: prognostic validation using a surgical 
series
Cheng, Andrew1, 3; Wainer, Zoe1; Eapen, Renu1; Alam, Naveed1; Yap, 
Cheng-Hon3; Wright, Gavin M.1, 2
1 St. Vincent’s Hospital Melbourne, Fitzroy, VIC, Australia; 2 Peter 
MacCallum Cancer Centre, East Melbourne, VIC, Australia; 3 
Barwon Health, Geelong, VIC, Australia
Background: Accurate staging is essential for treatment planning, 
prognostication and patient selection for research trials in Non-small 
cell lung cancer (NSCLC). The proposed 7th revision (REV7) has 
made several alterations to T and M descriptors to better distinguish 
5-year survival rates for each disease stage. We aim to assess these 
TNM predictors of survival in REV7 compared with those in the cur-
rent (sixth) TNM Classification of Malignant Tumours (REV6).
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Methods: All NSCLC resections from February 1999 to March 
2009 were identified. Patients with M1 disease as defined by REV6 
were excluded. Histopathological review confirmed the pathological 
staging for each patient using both REV6 and REV7 descriptors, and 
stratified them according to disease stage under each system. The 
Kaplan-Meier method was used to predict survival. Survival curves 
were then plotted and compared between REV6 and REV7.
Results: Four hundred and twenty four patients met the inclusion 
criteria. Fifty-two cases were down-staged and 44 cases upstaged 
with the implementation of REV7. In comparison with REV6, better 
survival curve segregation was achieved. Furthermore, REV7 distrib-
uted more patients into stage IIA, however IIA and IIB had similar 5 
year survival rates. REV7 IASLC staging parameters clearly separ-
ated stages IA, IB, II, III, and provided more accurate 5-year survival 
curves. In the interest of clarity, we did not graph stage IIIB in REV7, 
as there were only 5 patients and none of these were followed up 
beyond 32 months.
Conclusion: The overall stratification of 5 year survival is greatly 
superior using REV7 staging compared to the current REV6. On the 
basis of our surgical series we conclude that the proposed IASLC 
seventh revision for NSCLC staging is a valid predictor of survival.
PD11.1.2 Surgery for NSCLC, Tue, 12:30 - 14:00
The feasibility of the revised IASLC staging system to 
operable non-small cell lung cancers
Suzuki, Makoto; Yoshida, Shigetoshi; Tamura, Hajime; Wada, 
Hironobu; Moriya, Yasumitsu; Hoshino, Hidehisa; Shibuya, Kiyoshi; 
Yoshino, Ichiro 
Thoracic Surgery, Chiba, Japan
Background: New staging system for lung cancer (2009 system) 
is proposed by The International Association for the Study of Lung 
Cancer Staging Committee. We assessed its feasibility for surgical 
patients.
Methods: We reviewed surgical outcome of 1623 consecutive 
patients with non–small cell lung cancers (NSCLCs) who underwent 
pulmonary resection in our institution with regard to subpopulations 
categorized by the 2009 system and current system for postoperative 
pathologic staging. 
Results: Proportion of patients with stages IIA, IIB, IIIA, and IV 
increased while those of stages IB and IIIB decreased. Then stage 
IIIA or earlier diseases had significantly increased in results (current 
system N = 1281; 78.9% vs. new system N = 1457; 89.8%). The 
5-year survival rates of the patients with new stage IB and IIA disease 
were clearly dissociated with 72.5% and 51.3%, respectively (P < 
0.0001). The 5-year survival rates of the newly classified T1 patients 
were 90.3% for T1aN0M0 and 81.5% for T1bN0M0 (P = 0.009). Re-
classification of T2bN0M0 as stage IIA and T3 (same lobe nodules) 
N0M0 as stage IIB emphasize prognostic difference appropriately, 
while T4 (ipsilateral different lobe nodules) N2-3M0 (stage IIIB) and 
M1a (pleural effusion, stage IV) do not. 
Conclusions: Our study demonstrated that the new 2009 system is 
superior to the current system in terms of proportion of each stage 
and prediction of prognosis of each stage although it contains minor 
contradictions. Revision of the staging system will contribute for 
the decision for limited operation and adjuvant therapy of resected 
NSCLC.
PD11.1.3 Surgery for NSCLC, Tue, 12:30 - 14:00
Sentinel lymph nodes detection using indocyanine green in 
patients with lung cancer
Matsuoka, Hisashi1; Kondo, Kazuya2; Takizawa, Hiromitsu1; Uyama, 
Koh1; Hiroaki, Toba1; Koichiro, Kenzaki1; Sakiyama, Shozi1; 
Tangoku, Akira1
1 Dept.of thoracic,endocrine Surg.& Oncology,Grad.Sch. of 
Tokushima Univ., Tokushima, Japan; 2 Dept.of Oncological Medical 
Services,Grad.Sch.of Tokushima Univ., Tokushima, Japan
Background: The sentinel node (SN) technique has been used in the 
management of a variety of cancers to avoid unnecessary lymphaden-
ectomy. Legal considerations and costs limit the use of radioactive 
substances in general hospitals; thus, the dye-guided method is safe, 
convenient, and cost-effective compared with the radioactive probe- 
guided method. However, the technique has certain limitations, 
such as loss of visibility in dense fat and rapid transit of the dye and 
especially mediastinal lymph nodes are black because of their anthra-
cosis. Our study was a clinical exploration/feasibility study of a novel 
detection technique for SN biopsy using ICG fluorescence imaging in 
lung cancer surgery. 
Patients and Methods: SN biopsy using ICG was performed in 12 
patients who had cT1 or T2N0M0 lung cancer (mean age;68.8, male/
female;10/2, adenocarcinoma/squamous cell carcinoma;10/2 ). Fluor-
escence images were obtained using the ICG fluorescence imaging 
system. The light source was a xenon lamp equipped excited filter 
that permeated light at a wavelength of 690-790 nm, and the detector 
was a charge-coupled device (CCD) camera equipped to filter out 
light with a wavelength below 800 nm. The xenon lamp and excited 
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filter were aligned on a light source equipment, and the CCD camera 
was set at camera head of the thoracoscopy. The fluorescence signals 
were sent to a digital video processor. ICG in a volume of 0.25ml was 
injected just around the primary tumor and the injected situ was mas-
saged to spread ICG for about 5 minutes. 
Results: Immediately after intraoperative ICG injection, the fluor-
escence imaging system allowed easy visualization of the lymphatic 
vessels draining from the primary tumor toward the lymph nodes and 
tracing of the moving injected dye. All lymph nodes in the area which 
belonged to fluorescently labeled nodes were dissected out. We con-
firmed SNs from the removed lymph nodes using ICG fluorescence 
imaging system ex vivo. 
Sentinel nodes were successfully identified in 8 of 12 cases (detection 
rate: 66.7%). In 6 of 8 cases, either SNs and non-SNs had not metas-
tasis. In 2 cases, only SNs had metastatic tumor, and non-SNs had 
not metastasis (table1).The 4 cases which could not detected tended 
to large tumor size, high age, high smoking rate, and high Brinkman 
index. 
Conclusions: The detection technique for SN biopsy using ICG 
fluorescence imaging in lung cancer surgery is a potentially safer, 
more convenient, and more cost-effective replacement of the radio-
guided one.
No age sex location Max-
imum 
diam-
eter
operation 
method
SLN Lymphatic  
route
Patho-
logical  
findings 
of LN
B.I
1 70s M Lt.S10 31mm lobectomy #10 T→#10→#7 N0 0
2 70s M Rt.S9+10 48mm lobectomy not de-
tected
N0 4000
3 60s M Rt.S2/1 28mm lobectomy not de-
tected
N0 800
4 80s F Rt.S8 15mm lobectomy not de-
tected
N0 0
5 60s M Rt.S2 22mm lobectomy #4 T→#4→#3 N0 0
6 70s M Lt.S3 20mm segment-
ectomy
#12u T→#12u→#5 #5[0/6], 
#12u[1/1], 
#13[3/10]
0
7 50s M Lt.S1+2 31mm lobectomy #10 T→#11→#10 N0 740
8 70s M Lt.S9 19mm segment-
ectomy
#12l T→#121 N0 1280
9 60s F Rt.S8 17mm segment-
ectomy
#7 T→interlobar→#7 N0 0
10 70s M Lt.S8 47mm lobectomy not de-
tected
N0 1620
11 70s M Rt.S6 15mm segment-
ectomy
#7 T→#7→upper 
mediastinum
N0 660
12 50s M Rt.S4 33mm lobectomy #11s T→hilum→upper 
mediastinum
#3[0/11], 
#7[0/10], 
#11[1/6]
0
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Sentinel node navigation surgery (SNNS) using 
indocyanine green (ICG) and near infrared spectroscopy 
in lung cancer
Ichinose, Shuji; Usuda, Jitsuo; Maehara, Sachio; Ohtani, Keishi; 
Ishizumi, Taichirou; Ohira, Tatsuo; Kato, Harubumi; Ikeda, Norihiko
Tokyo Medical University Hospital, Tokyo, Japan
Background: The method of sentinel node navigation surgery 
(SNNS) has now applied in many cancers, especially in breast cancer. 
Sentinel nodes are usually detected by blue dye, contrast medium of 
CT, contrast medium of MRI or radioactive colloid commonly. Sev-
eral reports were published with SNNS in lung cancer however the 
accuracy rate were not sufficient. In this investigation, we detected 
sentinel nodes by indocyanine green (ICG) and near infrared spec-
troscopy as a fluorescence image. 
Methods: After thoracotomy, we injected 2-5ml ICG nearby a tumor. 
Then we observe the sentinel node by using near infrared spectros-
copy as a fluorescence image. Fluorescence images were obtained 
using a charge coupled device camera with a cut filter as the detector, 
and light emitting diodes at 760 nm as the light source. After com-
plete lymph node dissection, all resected lymph nodes were examined 
one by one. 
Results: We performed twenty cases (male/17, female/3), primary 
lobe were RUL/11, RLL/2, LUL/5, LLL/2 respectively. The tumor 
size ranged from 15 to 120 (mean 41.85) mm. We could identified 
at least one sentinel node using ICG and near infrared spectroscopy. 
pN0 were 12 cases, pN1 were 3 cases, and pN2 were 5 cases. Two 
cases of pN1, sentinel lymph nodes and metastatic lymph nodes were 
same. But in one case, sentinel lymph node (lobar, interlobar) and 
metastatic lymph node (hilar, subsegmental ) were different. It is sug-
gested that the lymph pathway had been changed due to lymph node 
metastasis to subsegmental and hilar. Otherwise the lymph pathway 
from subsegmental to hilar was filled with tumor cells, so ICG could 
not arrive at hilar. All cases of pN2, there were N1 metastsis and 
these were all sentinel lymph nodes.
Conclusion: The novel technique indicates efficient lymph node 
identification in lung cancer. To establish the strategy of sentinel 
lymph node navigation surgery in lung cancer, we need further stud-
ies and analysis. 
PD11.1.5 Surgery for NSCLC, Tue, 12:30 - 14:00
Systematic lymph node dissection (SLND) - the mainstay 
of surgical management of stage II and IIIA lung cancer
Davydov, Mikhail; Allakhverdiyev, Arif; Polotsky, Boris; Laktionov, 
Konstantin; Davydov, Mikhail M.; Nikulichev, Lev; Bagirov, 
Rahmat; Gotsadze, Ilya
N.N.Blokhin Cancer Research Center, Moscow, Russia
Objective: The role of systematic lymph node dissection in the sta-
ging and treatment of NSCLC remains controversial. We performed a 
prospective nonrandomized study to address this guestion.
Methods: We analyzed immediate and long-term results of 925 
patients with stage II and IIIA NSCLC who underwent curative-intent 
surgery between 1980 and 2005. Of total number of operative proced-
ures, 560 (60,5%) were extended resections, and 365 (39,5%) patients 
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underwent typical pulmonary resections. Comparison of results was 
accomplished in groups stratified according to tumor stage based on 
TNM descriptors. In the group of extended surgical procedures, stage 
II NSCLC was diagnosed in 370 (66,1%), stage IIIA – in 190 (33,9%) 
patients. Among patients with typical resections, stage II NSCLC was 
established in 210 (57,5%), stage IIIA – in 155 (42,5%) patients.
Results: Statistical evaluation of life times of patients operated on for 
stage II NSCLC according to extent of surgery revealed the following 
Results: 3 and 5-year survival rates were 60% and 49,4%, respect-
ively for patients who underwent extended surgery (i.e., with SLND) 
and 38,7% and 31% for patients of typical surgery group (p<0,01). 
Similar results, i.e., improved survival rates after extended surgery, 
were obtained for stage IIIA disease. Among patients of this group, 3 
and 5 year survived 44% and 31,3% of patients who underwent ex-
tended surgery vs. 28,5% and 18% of patients after typical operations 
(p<0,05). After typical surgical procedures, the bronchial stump 
recurrences occurred in 6,2% of patients, metastases to intrathoracic 
and supraclaviular lymph nodes were revealed in 8,7% and 1,7%, 
respectively. As to extended surgery, bronchial stump relapse and 
recurrences in intrathoracic and supraclaviular lymph nodes arose in 
1,9%, 3,6% and 0,9% of patients, respectively. Obtained data suggest 
that extended surgery with SLND significantly diminishes the rate of 
locoregional failure (p<0,05). 
Conclusions: Basing on our findings, we postulate that SLND allows 
not only accurate staging of lung cancer, but also improves long-term 
results of surgery in patients with stage II and IIIA NSCLC by dimin-
ishing local failure rate without increasing the postoperative morbid-
ity and mortality rates. Extended resections should be the standard for 
surgical treatment of patients with NSCLC, regardless of tumor size, 
its histological type, clinical-anatomic form and localization. 
PD11.1.6 Surgery for NSCLC, Tue, 12:30 - 14:00
Visceral pleura invasion impact on non-small cell 
lung cancer patient survival: its implications for the 
forthcoming TNM staging based on a large-scale nation-
wide database
Yoshida, Junji1; Nagai, Kanji1; Asamura, Hisao2; Goya, Tomoyuki3; 
Koshiishi, Yoshihiko3; Sohara, Yasunori4; Eguchi, Kenji5; Mori, 
Masaki6; Nakanishi, Yohichi7; Tsuchiya, Ryosuke2; Miyaoka, Etsuo8
1 Division of Thoracic Surgery, National Cancer Center Hospital 
East, Kashiwa, Japan; 2 Division of Thoracic Surgery, National 
Cancer Center Hospital, Tokyo, Japan; 3 Department of Surgery, 
Kyorin University School of Medicine, Mitaka, Japan; 4 Department 
of Surgery, Jichi Medical School, Shimotsuke, Japan; 5 Department 
of Internal Medicine, Teikyo University School of Medicine, Tokyo, 
Japan; 6 Department of Pulmonary Medicine, Sapporo-Kosei 
General Hospital, Sapporo, Japan; 7 Department of Clinical 
Medicine, Research Institute for Diseases of the Chest, Faculty of 
Medical Sciences, Kyushu University, Fukuoka, Japan; 8 Department 
of Mathematics, Science University of Tokyo, Tokyo, Japan
Background: No analyses have been reported on the impact of 
visceral pleura invasion (VPI) on staging, in relation with the IASLC 
proposals for the 7th edition of the TNM classification of the Inter-
national Union Against Cancer (UICC) staging system. The purpose 
of this study was to evaluate the VPI impact on survival and to pro-
pose how to incorporate VPI status into the TNM classification. 
Methods: We reviewed 9,758 non-small cell lung cancer patients, 
who underwent anatomic surgical resection in 1999, accumulated 
by the Japanese Joint Committee for Lung Cancer Registration, to 
gain insight into their clinicopathologic characteristics and outcomes. 
VPI was defined as tumor extension beyond the elastic layer of the 
visceral pleura. Patients were divided into 9 groups according to VPI 
status and tumor diameter in accordance with the IASLC proposals. 
Results: Based on survival, the 9 groups were divided into the fol-
lowing 5 levels: tumors ≤2 cm without VPI (group A); tumors ≤2 cm 
with VPI (group B) and tumors 2.1 to 3 cm without VPI (group C); 
tumors 2.1 to 3 cm with VPI (group D) and tumors 3.1 to 5 cm with-
out VPI (group E); tumors 3.1 to 5 cm with VPI (group F) and tumors 
5.1 to 7 cm without VPI (group G); tumors 5.1 to 7 cm with VPI and 
tumors >7 cm without VPI (group H) or T3 tumors. 
Conclusions: The T status of tumors 7 cm or less with VPI should 
be upgraded to the next T level in the future edition of the TNM clas-
sification of UICC staging system. 
 Groups Tumor diameter VPI IASLC proposals Our 
    for TNM classification proposal
 A ≤ 2 cm - T1a T1a
 ≤ 2 cm + T2 T1b
 C 2.1 - 3 cm - T1b T1b
 D 2.1 - 3 cm + T2 T2a
 E 3.1- 5 cm - T2a T2a
 F 3.1- 5 cm + T2a T2b
 G 5.1 - 7 cm - T2b T2b
 H 5.1 - 7 cm + T2(b) T3
PD11.2.1 Surgery for NSCLC, Tue, 12:30 - 14:00
Broncho-angioplastic procedures for the treatment of non-
small cell lung cancer after induction chemotherapy
Galetta, Domenico; Solli, Piergiorgio; Borri, Alessandro; Petrella, 
Francesco; Gasparri, Roberto; Casiraghi, Monica; Veronesi, Giulia; 
Spaggiari, Lorenzo
Division of Thoracic Surgery, European Institute of Oncology, Milan, 
Italy
Background: Bronchial sleeve resection combined with angioplastic 
procedure for non-small cell lung cancer is considered a challenging 
lung-sparing procedure associated with a high risk of postoperative 
morbidity and mortality. Few data are available for patients per-
forming broncho-angioplastic surgery who receive induction chemo-
therapy (IC). We reviewed our experience analyzing surgical results 
and long-term outcome.
Methods: Patients who underwent a bronchial sleeve resection as-
sociated with pulmonary arterioplasty between September 1998 and 
December 2008, and for whom pneumonectomy was contraindicated, 
were retrospectively reviewed using a prospective clinic and opera-
tive database. 
Results: The study population consisted of 42 patients (35 men, 
mean age 66 years). Of these, 22 (52.3%) had IC. We performed 31 
pulmonary artery (PA) sleeve resection (28 partial and 3 circum-
ferential), 9 PA reconstruction by a pericardial patch (8 autologous, 
and one heterologous), and 2 PA reconstruction by an heterologous 
conduit (PTFE). Angioplasty was associated with a right upper lobec-
tomy in 11 patients, left upper lobectomy in 23, and superior bilobec-
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tomy in 8. A negative bronchial and vascular margin was achieved in 
all cases. Operative death was nil. Major complications occurred in 4 
patients (9.5%): fatal broncho-vascular fistulas in 2 patients (4.7%); 
cardiac dislocation in one case, and ARDS in one patient. Eleven 
patients (26.2%) had early minor complications: 5 (45.4%) cardiac 
(3 atrial fibrillations and 2 ischemic events); 5 (45.4%) pulmonary 
(2 atelectasis and 3 prolonged air leaks); 1 (9.2%) stroke. IC did not 
influence complications rate. Pathologic staging was: 9 stage I, 12 
stage II, and 21 stage III (13 IIIA, and 8 IIIB). After a mean follow-
up of 44 months (range, 1 to 118 months), and a median survival of 
30 months, 16 patients (38%) were alive (3 with disease). Overall 
5-year survival rate and disease free was 39.3% and 37.9%, respect-
ively. Survival according to pathological stage was 75% for stage I, 
50% for stage II, and 19% for stage III (log-rank, p = .006). Five-year 
survival according to pathologic nodal status was 73.3% for N0, 
40.3% for N1, and 7.7% for N2 (log-rank, p = .003). Patients receiv-
ing induction chemotherapy had a best prognosis (63.6% vs 11.1%, p 
= .0005). At multivariate analysis, IC influenced long-term survival 
(p=.005).
Conclusions: Although technically demanding, combined broncho-
plastic and angioplastic intervention remains a feasible and effect-
ive surgical procedure in experienced hands providing acceptable 
morbidity. Pathologic staging and nodal status are the main factors 
affecting survival . In our experience, patients receiving IC had good 
results at long-term follow-up.
PD11.2.2 Surgery for NSCLC, Tue, 12:30 - 14:00
Is right upper sleeve lobectomy in non-small cell lung 
cancer (NSCLC) a feasible and effective alternative option 
to right pneumonectomy? 
Zuin, Andrea; Schiavon, Marco; Marulli, Giuseppe; Breda, Cristiano; 
Rebusso, Alessandro; Di Chiara, Francesco; Sartori, Francesco; Rea, 
Federico
Thoracic Surgery - Department of Cardio-Thoracic and Vascular 
Sciences, University of Padua, Padua, Italy
Background: Right pneumonectomy is known to be associated with 
high rate of postoperative morbidity and mortality, particularly after 
neoadjuvant therapy; therefore, every effort to avoid this procedure 
should be carefully considered.
Bronchial sleeve resections, with or without angioplastic proced-
ures, are well accepted and valid alternatives to pneumonectomy 
in NSCLC and right upper sleeve lobectomy is, by far, the most 
frequent bronchoplastic procedure.
Aim of this study is to review and to compare the impact of these 
procedures in terms of short- and long-term results, focusing on 
locally advanced right upper lobe neoplasms.
Methods: A retrospective study was carried out by reviewing the 
records of 93 consecutive patients submitted to right upper sleeve 
lobectomy for NSCLC at our Institution from January 1990 to De-
cember 2005. This group was compared with 95 consecutive patients 
who underwent right pneumonectomy in the same period.
Results: In sleeve group males were 83 and females 10, with a 
median age of 66 years (range: 45-79); in 11 cases an angioplastic 
procedure was associated. Pathologic staging revealed 3 stage IIa, 56 
stage IIb, 30 IIIa and 3 IIIb; in one case, after neoadjuvant chemo-
therapy, there was no evidence of residual disease. Inductive therapy 
was administrated in 25 patients.
In pneumonectomy group males were 83 and females 12, with a 
median age of 64 years (range: 39-79); pathologic staging revealed 
26 stage Ib, 3 IIa, 27 IIb, 20 IIIa, 15 IIIb and 4 IV; neoadjuvant ther-
apy was administrated in 14.
In sleeve and pneumonectomy group perioperative mortality rate was 
2.1 % and 11.6%, respectively (p=0.01); overall morbidity rate was 
22.6% and 29.5%, respectively (p=0.28); no complication was associ-
ated with angioplastic procedure. Overall 5-year survival rate was 
41% and 30%, respectively (p=0.07).
Regarding long-term survival, in both groups multivariate analysis 
identified pathologic stage as the only significant predictive factor 
(p=0.009); sleeve procedures, even without reaching a statistical 
significance (p=0.07), were associated with a more favourable trend 
compared to pneumonectomy.
Conclusion: Compared with sleeve lobectomy, right pneumonectomy 
is associated with an higher morbidity and mortality rate and worse 
long-term survival for comparable stages of right upper lobe cancer.
Therefore, whenever feasible, parenchyma sparing lung surgery, even 
if associated with vascular procedures, should always be attempted, 
particularly after neoadjuvant therapy or when adjuvant chemother-
apy is scheduled.
PD11.2.3 Surgery for NSCLC, Tue, 12:30 - 14:00
Isolated tumor cells in pulmonary vein blood of resected 
lung with non-small cell lung cancer: a pilot study of 
morphological qualification
Sawabata, Noriyoshi; Nakagiri, Tomoyuki; Funaki, So-ichiro; 
Inoue, Masayoshi; Utsumi, Tomoki; Kadota, Noriyoshi; Shigemura, 
Norihisa; Minami, Masato; Okumura, Meinoshin 
Osaka University Graduate School of Medicine, Suita, Japan
Background: During surgery for non-small cell lung cancer 
(NSCLC), manipulating the lung is thought to cause tumor cell 
implantation into the blood through pulmonary vein (PV), which 
may become a metastasis. While detection of singuler tumor cells or 
biomarker expression in the pulmonary vein blood has been re-
ported, morphological characteristics of tumor cells in the PV blood 
remainds unclear. 
Methods: From the blood harvested via pulmonary vein of the re-
sected lung, isolated tumor cells (ITC) were enriched using a negative 
selection method followed by Papa- nicolaou method and immuno-
histochemical stain for cytokeratin 7, 8, 18 and 19. Only 1 ml of the 
pulmonary vein blood was needed for each examination.
Results: From 25 NSCLC patients (15 male and 10 female, median 
age of 59 years), PV blood was harvested with a median amount of 
4ml (1ml to 6ml), of which ITC was revealed in 12 (48 %). The ITC 
could be classified morphologically into 3 types as follows: bulky 
cluster (>200μm in size) cells, non-bulky cluster (<200μm in size) 
cells, singular cells and no tumor cells. Bulky cluster was observed in 
one case (4%), non-bulky cluster in 6 (24%) and only singular cells 
in 5 (20%), and no malignant cell in 13 (52%). Cytokeratin examina-
tion was negative in 2 ITC positive cases of singular cell pattern; 
mucinous bronchioloalveolar carcinoma and carcinosarcoma. Within 
a median follow up period of 3 months (1 month - 6 months), cancer 
recurrence occurred as distant metastases (brain and liver)in one case 
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of huge (12cm in size) pathological stage IB adenocarcinoma at 5 
months after the latest operation. The ITC pattern of this case was 
bulky cluster (Fig 1).
Conclusions: This method examined is possible to detect ITC using 
only 1 ml blood, providing morphological characteristics of them, 
which may be a prognostic indicator of resected non-small cell lung 
cancer cases.
PD11.2.4 Surgery for NSCLC, Tue, 12:30 - 14:00
Activated carbon nanoparticles and methylene blue 
increase the detected number of lymph nodes during 
video-assisted thoracic surgery for lung cancer
He, Jianxing1; Li, Shuben1; Chen, Manyin 2; Chen, Hanzhang 1; Liu, 
Jun 1; Shao, Wenlong 1; Tucker, Steven 3; Zhong, Baoliang 1; Wang, 
Daoyuan1
1 First Affiliated Hospital of Guangzhou Medical College, 
Guangzhou, China; 2 Toronto General Hospital Institute, University 
Health Network, University of Toronto, Toronto, Canada; 3 Pacific 
Cancer Centre, Singapore, Singapore
Background: Although the optimal number of lymph nodes (LNs) 
that should be evaluated is contentious, it is well-established that 
removing a sufficient number of LNs is necessary to accurately stage 
non-small cell lung cancer (NSCLC) patients.
Methods: Three groups of 20 patients each were obtained from 
randomization of 60 patients with NSCLC requiring Video-Assisted 
Thoracic Surgery (VATS) with systematic nodal dissection (SND) 
from February 2007 and December 2008, there were 17, 16 and 17 
patients analysed in group A (injection 1 ml of activated carbon nano-
particles in four 0.25 ml doses in a 4-quadrant region around mass), 
group B (methylene blue) and group C (controls), respectively. 
Results: There was difference of the total number of dissected lymph 
nodes per patient among three groups (P<0.001). The total number 
of dissected LNs and mediastinal nodes per patient in group A and 
group B was more than in group C (P<0.001). There were 20, 18, and 
14 metastatic LNs dissected in 6 patients of group A, 6 patients of 
group B, and 7 patients of group C, respectively. There was differ-
ence of total number of dissected metastatic LNs per patient among 
three groups (P=0.002), in group A and group B was more than group 
C (P<0.05). However, there was no difference between group A and 
group B. 
Conclusions: Methylene blue can be as effective as activated carbon 
nanoparticles being tracer to increase the detected number of LNs in 
the systematic nodal dissected tissue during VATS for NSCLC.
PD11.2.5 Surgery for NSCLC, Tue, 12:30 - 14:00
Improved staging using intraoperative ultrasound for 
mediastinal lymphadenectomy in non-small cell lung 
cancer surgery
Ilic, Nenad1; Juricic, Josko1; Banovic, Josip1; Tripkovic, Andro1; 
Lojpur, Misa1; Frleta Ilic, Nives2; Tripkovic, Ingrid 3
1 University Surgical Hospital, Split, Croatia; 2 Policlinic Cito, 
Oncology Department, Split, Croatia; 3 Public Health Department, 
Split, Croatia
Objectives: The extend of lymph node involvement in patients with 
non-small cell lung cancer (NSCLC) is the cornerstone of staging and 
influences both multimodality treatment and final outcome. We stud-
ied safety, accuracy and characteristics of intraoperative ultrasound 
(US) guided systematic mediastinal nodal dissection in patients with 
resected NSCLC.
Methods: Intraoperative hand held ultrasound probe was used in 
systematic mediastinal nodal dissection in 84 patients after radical 
surgery for NSCLC. Mapping of the lymph nodes by their number 
and station followed by histopathologic evaluation was performed. 
Data were compared with 86 patients who underwent lung resections 
and standard systematic mediastinal nodal dissection for NSCLC 
within the same time period at our institution. Statistical analysis was 
carried out.
Results: The surgical procedure used depended on the extent of the 
disease, as well as the cardiopulmonary reserve of the patients and 
was comparable in both groups of patients. Operating time was pro-
longed for 12 (6 – 20) minutes in patients with US guided mediastinal 
nodal dissection, but number and stations of evaluated lymph nodes 
was significantly higher (p>0.001) at the same group of patients. 
Skip nodal metastases were found in 24% of patients without N1 
nodal involvement. We found 12 (10%) of downstaged patients using 
US guided mediastinal lymphadenectomy. Standard staging system 
seemed to be improved in US guided mediastinal lymphadenectomy 
patients. Complications rate showed no difference between analyzed 
groups of patients.
Conclusion: Higher number and location of analyzed mediastinal 
nodal stations in patients with resected NSCLC using hand held 
ultrasound probe suggested to be of great oncology significance. 
Procedure showed absolute safety and high accuracy. Our results 
indicate that intraoperative US may have important staging implica-
tion. Further clinical studies should be carried out in order to improve 
intraoperative staging in NSCLC patients.
PD11.2.6 Surgery for NSCLC, Tue, 12:30 - 14:00
Usefulness of the preoperative CT-guided marking by 
lipiodol for small peripheral lesions of the lung
Mogi, Akira; Yamaki, Ei; Kosaka, Takayuki; Yajima, Toshiki; Tanaka, 
Shigebumi; Kuwano, Hiroyuki
Department of General Surgical Science, Gunma University, 
Graduate School of Medicine, Maebashi Gunma, Japan
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Background: Recently, small peripheral lesions including ground-
glass opacity (GGO) are increasingly discovered, because of progres-
sive imaging diagnostic technologies. Despite such small lesions are 
detected, sometimes it is quite difficult to make a definitive diagnosis 
by ordinary methods. 
Methods: Twenty patients with undiagnosed small peripheral 
lesion(s) of the lung were involved. By using 64-slice helical CT 
scanning, approximately 0.2cc lipiodol were percutaneously injected 
by 21-guage needle adjacent to targeted lesion within 4 days of 
surgery. Video-assisted thoracoscopic surgery was performed using 
C-arm type X-ray fluoroscopic apparatus. 
Results: Pneumothorax needed no chest tube drainage occurred on 
two patients (10%) after CT-guided marking, but any other serious 
complications were not occurred. During an operation, all lesions 
except one case were visualized radiologicaly, and were successfully 
resected with a sufficient surgical margin. The resected specimens 
were promptly presented to an intraoperative pathological examina-
tion. There were no inadequate specimens for pathological examina-
tion cause of injected lipiodol. 
Discussions: It is probably safe to conclude that the preoperative 
CT-guided marking by lipiodol demonstrate several advantages over 
other marking methods, such as metallic coil, dye and barium. First, 
it is possible to determine the proper central surgical cut lines because 
of injected lipiodol adjacent targeted lesions. Second, unlike barium 
and colored dye, colorless lipiodol is favorable for pathological 
examination. Third, because injected lipiodol remain confined to that 
area for a few days in almost cases, it is not necessary to perform a 
surgery on the same day of marking. Fourth, it remains possible that 
the materials used for marking, such as metallic coil or hook wire, 
are missed in thoracic space during the operation, but not in case of 
marking by lipiodol. 
Conclusions: The preoperative CT-guided marking by lipiodol for 
small peripheral lesions of the lung is very useful for a subsequent 
surgery.
PD11.3.1 Surgery for NSCLC, Tue, 12:30 - 14:00
Predictors of hospital mortality in lung cancer surgery
Kupis, Wlodzimierz R.; Rudzinski, Piotr M.; Orlowski, Tadeusz M.; 
Langfort, Renata
National Institute of Tuberculosis & Lung Diseases, Warsaw, Poland
Objective: This study was undertaken to determine factors associ-
ated with hospital mortality among patients after surgical treatment of 
lung cancer.
Material and Method: We analyze retrospectively clinical notes 
of 3223 patients, who underwent the resection of lung cancer at our 
institution between 1998 and 2008 (10 years). We prepared the list of 
risk factors that included: post-op hemorrhage, pleural haematoma, 
blood transfusion, fibroptic bronchoscopy (to clean bronchial tree 
of secretion), intubation, early bronchial fistula, pneumonia, ARDS, 
pleural space, wound infection, pleural empyema, air leak, late bron-
chial fistula, mechanical ventilation, myocardial infarction, pulmon-
ary embolism, renal failure, chylothorax, psychological disturbances, 
cerebral stroke, FEV1<50%, FVC < 50%, myocardial infarction in 
the past, COPD.
Results: We estimated odds ratio when possible and we found the 
strongest coincidence of the mortality with ARDS (OR 208), cerebral 
stroke (OR 47,6), bronchial fistula (OR 45,7), mechanical ventilation 
(OR 42,5) and pneumonia (OR 41,2). In all this circumstances the 
differences were statistically significant (Fisher’s exact test, p-value 
< 0,05). 
We also found the statistically significant difference between in-
hospital mortality among men (2,0%) and women (0,4%). OR (M vs 
F) = 4.62, p<0,0001. The kind of resection performed had an influ-
ence on mortality, too, being the highest in inferior bilobectomy (RLL 
+ ML) – 3,1% and the lowest in culmenectomy (resection of segment 
1+2+3 of the left upper lobe) – 0,0%. Another well known risk factor 
of high mortality is an age of patient. In our group we noticed the 
highest rate of post-op deaths in the oldest group of patient – septua-
genarians (3,5%).
Conclusions: The strongest predictors of high rate mortality in lung 
cancer surgery are age of patient exceeding 70 years, gender (male) 
and post-op complications such as ARDS (75%), cerebral stroke 
(40%), early bronchial fistula (38,5%), necessity of mechanical venti-
lation (34,6%) and pneumonia (35%).
PD11.3.2 Surgery for NSCLC, Tue, 12:30 - 14:00
Risk factors of 1-st year death following radical resection 
of lung cancer
Orlowski, Tadeusz; Rudzinski, Piotr; Kupis, Wlodzimierz; Langfort, 
Renata
Institute of Chest Dieases, Dprt. of Thoracic Surgery, Warsaw, 
Poland
Objective: Inspite of very precise diagnostics and pre-op staging as 
well as radical surgical treatment at least part of our patients die with-
in the first year following the operation due to progression of disease. 
Therefore the study was undertaken to determine factors associated 
with 1-st year death following radical resection of lung cancer
Material and Method: The group of 281 (13,6%) patients who die 
within first year following the surgery was extracted from the whole 
number of 2069 patient operated on between 1998 and 2003 for 
NCSLC. Those who died for post-op complications were excluded 
from this analysis.
We analyzed 20 different clinical and histological factors as well as 
TNM staging data. 
The log-rank test was used for analyzing the significance, and Cox 
proportional hazards regression models were used to investigate the 
factors affecting survival. The results were presented as hazard ratio 
with confidence interval 95%.
Results: We have found out the strongest risk factors of 1-st year 
deaths following lung surgery are as follows: stage of disease at the 
time of operation – p=0,01 in stage IIB, p<0,01 in stage IIIA and 
p<0,01 in stage IIIB. The pleural involvement (feature P) was also 
very significant prognostic factor (p<0,01) as well as tumor size ex-
ceeding 5cm (p<0,01) and neoplastic emboli in lymphatics. Histology 
of tumor and the extent of resection were of no significance.
Conclusions: Quite large number of deaths within first year fol-
lowing surgery (ranging from 17% in IIB to 31% in IIIB) indicates 
that potential risk of neoplastic spread exists at the time of surgical 
treatment of patients in this stages of disease. Therefore the combined 
therapy in this stages should be concider very usefull. 
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PD11.3.3 Surgery for NSCLC, Tue, 12:30 - 14:00
Risk analysis of major pulmonary resection in lung cancer 
with symptomatic idiopathic pulmonary fibrosis
Kim, Hyeong Ryul; Kim, Dong Kwan; Cho, Hyun-Jin; Kim, Yong 
Hee; Park, Seung-Il; Lee, Hyun Joo
Asan Medical Center, Seoul, Korea
Background: Idiopathic pulmonary fibrosis (IPF) is associated with 
lung cancer. Furthermore, lung cancer is the cause of death in up to 
10% of patients with IPF. But the operative risk and the survival fol-
lowing resection are unknown in lung cancer with IPF.
Methods: We retrospectively reviewed the medical records of 30 
patients with lung cancer and symptomatic IPF who were surgically 
treated between 1995 and June 2008, and analyzed the risk factor for 
acute lung injury/acute respiratory distress syndrome (ALI/ARDS) 
and survival rates.
Results: Early mortality was occurred in 6 patients (20%) and the 
major causes of death were hospital acquired pneumonia and acute 
progression of IPF. Two patients who underwent a pneumonectomy 
died early. Late mortality was occurred in 17 patients (57%) and the 
major causes of death were community acquired pneumonia and 
the progression of IPF. Follow-up duration was 14.2 ±18.0 months 
(0.3-76.6 months). Immediate postoperative ALI/ARDS was occurred 
in 7 patients and 6 patients of them died. 1-year and 3-year survival 
rates were 42.0 ±9.3%, 23.6 ±8.7%. Risk factors for mortality were 
preoperative dyspnea on exertion (p=0.033) and lower forced vital 
capacity (% predicted FVC, p=0.002) in multivariate analysis. In pos-
toperative ALI/ARDS group, % predicted forced expiratory volume 
in 1 second (85.2 ±17.6% vs 98.7 ±11.5%, p=0.024) and % predicted 
FVC (76.7 ±20.9% vs 90.1 ±9.4%, p=0.022) were significantly lower 
than control group (without ALI/ARDS group).
Conclusion: Major pulmonary resection in lung cancer with IPF is 
associated with increased postoperative morbidity and mortality. For 
better postoperative results, careful selection of patients considering 
preoperative dyspnea and pulmonary function, and appropriate perio-
perative management are important. Larger prospective studies are 
needed to confirm these results.
PD11.3.4 Surgery for NSCLC, Tue, 12:30 - 14:00
Audit of surgically resected non small cell lung cancer, 
survivals and prognostic factors
Al-Alao, Bassel1, 2; O’Callaghan, Dermot S.2; Gately, Kathy1; Coate, 
Linda2; Cuffe, Sinead2; Nicholson, Siobhan2; O’Connell, Finbarr2; 
McGovern, Eilis2; O’Byrne, Kenneth J.1, 2; Young, Vincent K.2
1 Institute of Molecular Medicine, Dublin, Ireland; 2 St. James’s 
Hospital, Dublin, Ireland
Background: Few patients diagnosed with lung cancer are alive 
five years after diagnosis. However, following surgical resection for 
non-small cell lung cancer (NSCLC) overall 5-year survival rates 
of 30-50% can be expected. The aim of the current study was to 
conduct a 10-year review of a consecutive series of patients under-
going curative-intent surgical resection at the largest tertiary referral 
centre in the Republic of Ireland. The data series was examined for 
prognostic factors. 
Methods: The case records of all patients operated on for lung cancer 
between 1998 and 2008 were reviewed. The clinical features and 
outcomes of those with surgicopathological-confirmed (p)-stages I to 
IIIA NSCLC were recorded. 
Results: There were 648 patients who underwent surgical resec-
tion with curative intent during the study period. Of these, 566 with 
confirmed pathological stage I to IIIA disease (stage IA: 19.2%; stage 
IB: 34.8%; stage IIA: 4.4%; stage IIB: 20.8%; stage IIIA: 20.8%). 
The overall median age at time of surgery was 66.2 yrs (range 27 to 
86), with males accounting for 62.5% of the total. Lobectomies were 
performed in 81.7% of cases, while pneumonectomy was necessary 
in 18.3% of patients. Sleeve resections were undertaken in 7% of 
cases, showing an increase in the latter half of the study. Distribution 
of histological subtypes was: squamous cell, 51.9%; adenocarcin-
oma, 40.9%; mixed cellularity carcinomas, 4.2%; and the large cell 
neuroendocrine variant, 3.0%. Median overall survival for the entire 
cohort was 37 months. Cox regression analysis identified female sex, 
younger age, history of smoking, tumour (T) stage and overall (p)-
stage as independent favourable prognostic factors.
Conclusions: We identified several factors that predict improved 
outcome for NSCLC patients undergoing curative-intent surgical re-
section. Survival rates in our series are comparable to those reported 
from other European thoracic oncology centres. 
PD11.3.5 Surgery for NSCLC, Tue, 12:30 - 14:00
Outcomes of surgical treatment for unsuspected N2 
(pathologic stage IIIA) non-small cell lung cancer
Kim, Hong Kwan; Park, Joon Suk; Choi, Yong Soo; Kim, 
Kwhanmien; Kim, Jhingook; Shim, Young Mog
Samsung Medical Center, Seoul, Korea
Background: Non-small cell lung cancer (NSCLC) patients with 
microscopic N2 disease incidentally detected at surgery have more 
favorable survival than those with bulky N2 disease visible on 
computed tomography (CT) scans. The objective of this study was 
to evaluate the outcomes after curative-intent surgical resection in 
NSCLC patients who were staged N2 negative on preoperative im-
aging tests but had unsuspected N2 disease at surgery.
Methods: This was a retrospective, single-institution review of 
patients with NSCLC who were staged N2 negative by CT scans 
or integrated positron emission tomography (PET)/CT. All patients 
underwent curative-intent surgical resection with complete medias-
tinal lymph node dissection and then had unsuspected, pathologic N2 
disease.
Results: Between March 1995 and December 2007, there were 225 
patients (164 men). Mediastinoscopy was also performed in 139 pa-
tients (62%). Seventy-seven patients had no adjuvant therapy whereas 
149 patients received adjuvant therapy (radiotherapy, n = 82; chemo-
therapy, n = 23; chemoradiation, n = 44). The overall and disease-free 
survivals at 5 years were 34% and 27%, respectively. The 5-year sur-
vival for the 168 patients with single N2 disease was 40%, compared 
with 20% for the 57 patients with multiple N2 disease (p = 0.0012). 
Age, pathologic T stage, and multiplicity of nodal involvement were 
independent predictors of survival on multivariate analysis.
Conclusions: Outcomes of surgical treatment for NSCLC patients 
with pathologic N2 disease were favorable when unsuspected on 
preoperative imaging tests. Our findings suggest that patients with 
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unsuspected, single-station N2 disease can benefit from primary 
surgical treatment.
PD11.3.6 Surgery for NSCLC, Tue, 12:30 - 14:00
Completion pneumonectomy for lung cancer treatment: 
early and long term outcomes 
Zhang, Peng; Jiang, Gening 
The General Thoracic Department of the Pulmonary Disease Hosptal 
of Tongji University, Shanghai, China
Background: Completion Pneumonectomy is a more chanllenging 
technical procedure associated with reported increased operative 
mortality and morbidity. In this article,we analyzed the experience of 
completion pneumonectomy for lung cancer at a single institution in 
China . 
Methods: From January 1988 to December 2007, 92 patients under-
went completion pneumonectomy for the treatment of lung cancer. 
The indications were second primary lung cancer(n=51), Local 
recurrence (n=37) and Lung metastasis(n=4) . The median interval 
between the primary operation and completion pneumonectomy was 
24.4 months ( 1.5—145m). 
Results: For the completion pneumonectomy, there was no intrao-
perative deaths . The procedure lasted 4.3h(1.5h—8h). Blood loss in 
this performance was 1854.5ml (200—9100ml). 9 (9.78%) patients 
died in the postoperative period: pulmonary embolism(n=2), dis-
seminated intravascular coagulation after the multisystem failure 
(n=1), respiratory failure after contralateral pneumonia(n=5), bron-
chopleural fistula with acute respiratory distress syndrome( ARDS) 
(n=1) . 31(33.7%) patients had at least one major nonfatal compli-
cation. The 1,3 and 5 year survival rates were 81%, 26% and 14% 
respectively. 
Conclusions: Completion pneumonectomy for lung cancer is a safe 
surgical procedure for the skilled surgeon though it has a relatively 
high complications and the long-term survival is acceptable.
PD11.3.7 Surgery for NSCLC, Tue, 12:30 - 14:00
Long-term results of prospective study of limited resection 
for bronchioloalveolar adenocarcinoma of the lung
Tsuchida, Masanori; Hashimoto, Takehisa; Shinohara, Hirohiko; 
Hayashi, Jun-ichi
Niigata University, Niigata, Japan
Background: We previously demonstrated mid-term results of 
prospective study of limited resection for bronchioloalveolar adeno-
carcinoma (BAC) of the lung (1, 2). This study was closed in 2004 
and all patients have been followed more than 5 years and long-term 
results are now opened.
Purpose: The purpose of this study is to demonstrate our long-term 
result of intentional limited resection for BAC.
Patients: From October 1996 to April 2004, 72 patients who had 
small lung nodules of 2cm or less and were suspected of BAC based 
on CT or CT-guided lung biopsy were enrolled in a single center trail. 
The patient population consisted of 34 males and 38 females with 
a mean age of 61.6 years old. The mean diameter of these lesions 
was 13.2mm on CT. 59 out of 72 had GGO component more than 
50% on high resolution CT. Limited resection was completed when 
intra-operative diagnosis revealed that the tumor was a BAC without 
obvious fibroblastic proliferation or invasive sign to the stroma. 
Otherwise, patients underwent lobectomy with systemic lymph nodes 
dissection. 
Result: Intra-operative diagnosis was BAC without obvious fibro-
blastic proliferation or invasive sign to the stroma in 62, adenocarcin-
oma with mixed subtype in 4, atypical adenomatous hyperplasia in 4. 
Surgical procedures were wedge resection in 57, segmental resection 
in 4, and lobectomy in 11. In 11 patients, procedure was converted 
to lobectomy because of microscopic invasive sign in 4, active 
fibroblastic proliferation in 5, multiple lesions in 1 and non-palpable 
lesion in 1. Postoperative follow-up of the patients ranged from 60 to 
149 (median, 121) months. The 5-year-survival rate was 98% with a 
mean follow-up period of 116 months. The final pathologic diagno-
sis was changed in two patients who had undergone limited resec-
tion and one of these patients recurred 4 and half years later. Thus, 
accuracy of intra-operative diagnosis was 97% and 2 lesions were 
underestimated. 
Conclusion: Long-term follow-up results demonstrated that limited 
resection for BAC of 2cm or less is accepted procedure. Wedge resec-
tion was a choice of procedure for a peripheral BAC.
References
1) Tsuchida M, Yamato Y, et al. Mid-term results of ongoing prospective study of 
limited resection for bronchioloalveolar adenocarcinoma of the lung. Lung Cancer 
2000; 29: 145
2)  Yamato Y, Tsuchida M, et al. Early result of a prospective study of limited resection for 
bronchioloalveolar adenocarcinoma of the lung. Ann Thorac Surg 2001; 71: 971-4.
PD11.4.2 Surgery for NSCLC, Tue, 12:30 - 14:00
TTP: a good choice for malignant pleural effusions
Yu, Lei; Li, Jianye; Ma, Shan; Zhang, Yunfeng; Zang, Nan N.
Department of Thoracic Surgery,Beijing Tongren Hospital, Capital 
Medical University, Beijing, China
Background: Patients with malignant pleural effusions have 
limited life expectancy. Dyspnea and reduction of physical capabil-
ity severely affect the quality of life for them. Simple drainage of 
the pleural cavity has not proven to be sufficient for treatment of 
malignant pleural effusions, as 90% of patients will relapse within 
one month. Our objective was to evaluate the feasibility and efficacy 
of thoracoscopic talc pleurodesis (TTP) in the treatment of malignant 
pleural effusions.
Methods: 316 patients suffering from malignant pleural effusions 
underwent thoracoscopic talc pleurodesis from 1998 to 2007. TTP 
was performed in the operating room using video-assisted thora-
coscopy under general double-lumen endotracheal anesthesia in all 
patients in the lateral decubitus position.
Results: 94.3% (298/316) of TTP were successful, and 2.8% (9/316) 
failed. 9 patients died within 30 days postoperatively. In most cases, 
pain lasted for less than 2 days. 11 patients had soft tissue emphy-
sema after surgery. There were 46 patients with temperature greater 
than 38.0˚C and 12 having pulmonary infection. The mean drainage 
time was 4.5±0.6 days. Mean survival after TTP was 6.9 months. 
Nine cases showed recurrence in 3 months after talc pleurodesis. And 
12 cases had dyspnea and severe cough without evidence of recur-
rence within 5 months after talc pleurodesis.35 patients were still 
alive 12 to 18 months after the operation of TTP. 
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Conclusions: TTP is a good choice in the management of malignant 
pleural effusions. It can result in successful palliation. But there is 
no use performing TTP in patients who appear moribund or do not 
become ambulatory after thoracentesis.
PD11.4.3 Surgery for NSCLC, Tue, 12:30 - 14:00
Surgical therapeutic strategy for non-small cell lung 
cancer with mediastinal lymph node metastasis
Ma, Qian li
Department of Thoracic Surgery, Chinese-Japan Friendship 
Hospital, East Yinghua road, Chaoyang District, Beijing, China, 
100029, Beijing, China
Background: Approximately 30% of patients who are newly diag-
nosed with non-small-cell lung cancers (NSCLCs) will be classified 
as N2 on the basis of metastasis to the mediastinal lymph nodes. A 
certain population of N2 patients apparently benefits from surgery, 
but the role of surgery remains controversial. So it is necessary to 
identify the surgical indication and evaluate the prognostic factors.
Methods: 173 patients with N2 NSCLC were treated in our depart-
ment between January 1999 and May 2003, 165 received surgery. 
The database included the patients’ medical history, age, sex, the 
location and size of the tumor, operation date, methods, histologic 
diagnosis, clinical stage, post-operative TNM stage, neoadjuvant 
treatment and chemoradiotherapy. The methods of clinical stage 
include chest X-ray, chest CT, PET, mediastinoscopy, bronchoscope, 
brain CT, abdominal B ultrasound, and bone ECT. The pathological 
classification was given according to the international standard for 
lung cancer (UICC 1997). Survival time was analyzed from the oper-
ation date to 2008.5. Kaplan-Meier survival analysis was used, the 
differences were compared using the Log-rank test, and Cox multipli-
city for prognosis was also used. Statistical analyses were performed 
using the SPSS (Statistical Package for the Social Sciences) program.
Results: The median survival was 22 months, 3-, and 5-year sur-
vival rate was 28.1% and 19.0%, There was no survival difference 
observed in the categories of age, sex or different histological clas-
sification, chemoradiotherapy. The 5-year survival of unexpected N2 
discovered at thoractomy and proven N2 discovered during preopera-
tive work-up who have a mediastinal down-staging after induction 
therapy were 30.4% and 27.3%, higher than other N2 subtypes 
(P<0.01). Induction therapy could downstage 73.3% proven N2, so 
the opportunity of surgery could be obtained. The 5-year survival 
were 23.6% and 13.0% for completely resection and Uncompletely 
resection (P<0.001). Survival was higher in patients who underwent 
lobectomy (23.2%), less mortality and mobility rate, as compared to 
pneumoectomy (14.8%) (P<0.01). 5-year survival of T4 was 11.1%, 
less than T1 (31.5%) and T2 (24.3%) P=0.01. Whether completely 
resection or not, and primary T status have significant correlativity 
with the 5-year survival rate after Cox analysis. 
Conclusion: It is suggested that surgery (lobectomy preferentially) is 
the best choice for N2 NSCLC patients with T1 or T2, unexpected N2 
discovered at thoractomy when a complete resection can be obtained, 
and proven N2 discovered during preoperative work-up who have a 
mediastinal down-staging after induction therapy. Bulky N2 and T4 
is a risk factor for a poor prognosis. Neoadjuvant chemotherapy in-
crease survival, postoperative radiotherapy decrease local recurrence 
rate but not survival.
PD11.4.4 Surgery for NSCLC, Tue, 12:30 - 14:00
Mediastinoscopy remains indicated in patients with 
non-small cell lung cancer with mediastinal lymph nodes 
having maximum standardized uptake value more than 2.8 
in regions where the incidence of inflamatory lung disease 
is high
Iskender, Ilker; Kir, Altan; Sevim, Tulin E.; Kosar, Altug; Atasalihi, 
Ali
Sureyyapasa Chest Diseases and Thoracic Surgery Training and 
Reserch Hospital, istanbul, Turkey
Background: Mediastinal lymph nodes fluorodeoxyglucose (FDG) 
uptake in positron emission tomography/computed tomography 
imaging (PET/CT), which is used in staging of non-small cell lung 
cancer (NSCLC) is expected to be high in regions where high inci-
dence of inflamatory lung disease. Maximum standardized uptake 
value (SUVmax) higher than 2.5 (or higher than 5.3 according to 
other several studies) is defined as lymph node positivity. The aim 
of this study was to define the most appropriate SUVmax value in 
mediastinal lymph node staging of NSCLC with PET/CT.
Methods: PET/CT and mediastinoscopy or thoracotomy is performed 
on consecutive 299 NSCLC patients between September 2005 – Oc-
tober 2008. Forty-five patients with receiving neoadjuvant chemo-
therapy (n:16), time interval longer than 6 weeks between PET-CT 
and mediastinoscopy (n:12), exploratory thoracotomy (n:10), and 
synchronous or metachronous lung cancer (n:7) were excluded from 
the study. Patients with negative mediastinoscopy results underwent 
surgical resection. The pathological results were correlated with PET-
CT findings. 
Results: Histopathological examination was performed on 1010 
N2 lymph nodes. A duration of 2 to 41 days of PET/CT has been 
performed prior to mediastinoscopy, over 254 patients (235 male and 
19 female; mean age:58.4 years) with NSCLC. The mean SUVmax 
value for all N2 lymph nodes was 1.6 ± 3.65 (range 0 - 22.3) and for 
primary tumour was 15.22 ± 6.8 (0 - 40.2). There was pathologic 
evidence of metastasis in 129 (12.8%) of 1010 lymph nodes in 73 
(28.7%) of 254 patients. The optimal SUVmax cutoff for mediastinal 
lymph nodes was 2.8 by means of receiver operator characteristic 
analysis (Figure 1). The sensitivity, spesifity, positive and negative 
predictive values and accuracy for cutoff values of 2.5, 2.8 and 5.3 
are presented in Table 1.
Conclusions: SUVmax value higher than 2.8 is more accurate cutoff 
value for mediastinal lymph node staging by PET/CT.
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 Table 1: Results of PET/CT by using a SUVmax cutoff values of 2.5, 2.8 and 5.3
 SUVmax cutoff for malignancy 2.5 2.8 5.3
 Sensitivity(%) 81.4 81.4 65.9
 Specificity(%) 86.9 87.7 94.6
 Positive predictive value 47.7 49.3 63.9
 Negative predictive value 96.96 96.98 94.9
 Accuracy 86.2 86.9 90.9
PD11.4.5 Surgery for NSCLC, Tue, 12:30 - 14:00
Influence of the mediastinal lymphadenectomy in non 
small cell lung cancer prognosis
Romero Vielva, Laura5; Rosell Costa, Rafael2; Maestre Alcácer, 
Jose Antonio 5; Felip Font, Enriqueta6; Sole Montserrat, Joan5; 
Deu Martin, Maria5; Sanchez Hernandez, Jose Javier3; Armengol 
Carrasco, Manel7; Rochera Villach, Maribel4; Montero Fernandez, 
Angeles1; Ojanguren Arranz, Amaia5; Teixidor Sureda, Joan5
1 Servicio de Anatomía Patológica, Hospital Universitario Vall 
d’Hebron, Barcelona, Spain; 2 Servicio de Oncologia Medica, 
Hospital Universitari Germans Trias i Pujol, Badalona, Spain; 3 
Facultad de Medicina Universidad Autonoma de Madrid, Madrid, 
Spain; 4 Servicio de Anestesiología y Reanimación, Hospital 
Universitario Vall d’Hebron, Barcelona, Spain; 5 Servicio de 
Cirugía Torácica, Hospital Universitario Vall d’Hebron, Barcelona, 
Spain; 6 Servicio de Oncologia Medica, Hospital Universitario Vall 
d’Hebron, Barcelona, Spain; 7 Servicio de Cirugía General, Hospital 
Universitario Vall d’Hebron, Barcelona, Spain
Background: Mediastinal lymph node (MLN) involvement is the 
main prognostic factor in NSCLC. An accurate staging allows provid-
ing the patient the most suitable postoperative treatment.
We evaluated the role of the extension of the lymphadenectomy to 
make a more correct staging, and to determine if an extensive lymph-
adenectomy, based on the number of obtained MLNs, improved 
survival and disease-free survival. 
Methods: Retrospective study of 485 consecutive NSCLC patients 
operated between 1995 and 2001. MLNs resected were analyzed. 
Factor T-based groups were divided in two subgroups according to 
the number of MLNs resected (<10 and ³ 10). Contingency tables 
were used to analyze the differences between the joint distribution of 
the qualitative variables. Kaplan-Meier’s method, log-rank, Breslow 
and Tarone-Ware hypothesis tests were used to analyze survival and 
disease-free survival. Cox proportional hazards regression was used 
to identify possible associations between the different prognostic fac-
tors and disease-free survival or survival.
Results: The average of MLN resected was of 11.16 (0-48). A greater 
percentage of positive MLNs were obtained when a greater number 
of MLNs were resected (statistically significant differences, 38.85% 
of patients with positive MLNs in the group of <10 MLNs resected 
and 61.14% in the one of ³10 MLNs resected). 5-year survival rate of 
all patients was 40%, and diminished until 21% in those with positive 
MLNs. Survival univariate analysis showed that the resection of a 
great number of MLNs is a protecting factor. In a multivariate analy-
sis it is observed that the number of resected MLNs also behaves like 
protecting factor as much in survival (HR 0.97, I.C. 95%:0,95-0.99, 
p=0,001) as in disease-free survival (HR 0.97, I.C. 95%:0,96-0.99, 
p=0,004). Both median survival and disease-free survival of patients 
with negative MLNs were better in the group with more than 10 
MLNs resected, as well as in the group with positive MLNs (statistic-
ally significant differences). 
Conclusions: The probability of finding some positive MLN in-
creases with a more extensive lymphadenectomy. Median survival 
and disease-free survival of all patients with more than 10 MLNs re-
sected are better. A complete mediastinal lymphadenectomy provides 
a better staging and improves survival and disease-free survival, so it 
must be recommended as a fundamental step in the surgical treatment 
of NSCLC. 
PD11.4.6 Surgery for NSCLC, Tue, 12:30 - 14:00
Results of initial surgery for clinical single station N2 non-
small cell lung cancer
Nakagawa, Kazuo; Ohde, Yasuhisa; Okumura, Takehiro; Kondo, 
Haruhiko
Division of Thoracic Surgery, Shizuoka Cancer Center, Shizuoka, 
Japan
Background: The optimal treatment for stage IIIA (N2) non-small 
cell lung cancer (NSCLC) remains controversial. Several studies 
demonstrated that patients with single station N2 disease had a favor-
able prognosis compared with those with multiple station N2 disease 
after surgery. However, most of those studies present the prognosis 
of patients with pathological single station N2 disease, the prognosis 
of patients with clinical single station N2 disease after surgery is not 
fully examined. In our division, clinical single station N2 NSCLC 
has been a candidate for initial surgery since our hospital was opened 
in 2002. The aim of this study was to investigate the results of initial 
surgery in NSCLC patients with clinical single station N2 disease.
Methods: Among the 936 primary NSCLC patients who underwent 
resection at Shizuoka Cancer Center between September 2002 and 
March 2009, 17 patients with clinical single station N2 disease (both 
CT- and PET- N2 disease: n=9, PET-N2 disease: n=8) did initial re-
section. During the same period, 45 patients who underwent resection 
had unsuspected N2 (clinical N0 or N1) disease. To assess the valid-
ity of our treatment strategy for clinical single station N2 disease, we 
evaluated the differences in clinicopathologic findings and prognosis 
between clinical single station N2 disease and unsuspected N2 (clin-
ical N0 or N1) disease.
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Results: There were 62 patients (36 men and 26 women) with a 
median age of 63 years (range, 41 to 79 years). Forty-five of 62 
(73%) patients had adenocarcinoma, 13 of 62 (21%) patients had 
pathological multiple station N2 disease, and 26 of 62 (42%) patients 
received adjuvant chemotherapy. Clinicopthological findings between 
two groups were similar (age, sex, smoking status, location of 
primary tumor, type of adjuvant chemotherapy, histology, status of 
pathological N2). The 3-year disease-free survival rates were 60% 
for patients with clinical single station N2 disease and 42.5% with a 
median survival of 30.4 months for 45 patients with unsuspected N2 
(clinical N0 or N1) disease. The difference in survival between two 
groups was not statistically significant (p = 0.272). (Figure 1)
Conclusions: Although this study had a small number of patients 
with a short follow-up period, our findings suggested that patients 
with clinical single station N2 NSCLC was expected to have a favor-
able prognosis after surgery. Initial surgery should be considered to 
be a treatment option for these patients. 
PD11.5.1 Surgery for NSCLC, Tue, 12:30 - 14:00
Video-assisted thoracic surgery (VATS) for primary lung 
cancer: assessments for post-operative morbidity and 
mortality, and long-term prognosis
Tajiri, Michihiko1; Omori, Takahiro1; Takahashi, Ko1; Seike, Ayako1; 
Watanabe, Katsuya2
1 Kanagawa Cardiovascular and Respiratory Center, Yokohama, 
Japan; 2 Kanto Rosai Hospital, Kawasaki, Japan
Background: Video-assisted thoracic surgery (VATS) lobectomy is 
considered minimally invasive for treating early-stage lung cancer. 
However, large-scale studies, which have shown supporting data in 
long-term as well as short-term outcomes, have been few. Here, we 
report the post-operative morbidity and mortality and the long-term 
prognosis in a VATS lobectomy.
Methods: Five hundred and thirteen patients consecutively under-
went a VATS lobectomy at our institute. We retrospectively reviewed 
these cases and divided these patients into two groups in terms of 
two different VATS procedures, the complete video-thoracoscopic 
method (CV, n=353) in which we manipulates through an extra-small 
thoracotomy and access ports and use camera visualization only, and 
the mini thoracotomy with video-assistance (MV, n=160) in which 
we spread mini thoracotomy with a small metallic retractor and use 
occasional direct vision. As a control group, we examined 311 cases 
of primary lung cancer in which we performed lobectomy via poster-
olateral thoracotomy (PL). From these data we analyzed the post-
operative morbidity and mortality and the long-term prognosis.
Results: Blood loss was lower in the CV (20.9±31.3 ml) and MV 
(88.9±87.1ml) groups than in the PL group (227.6±138.2ml). Lengths 
of hospital stays were shorter in the CV (10.5±3.9days) and MV 
(11.8±4.6days) groups than in the PL group (25.5±9.4days). The rates 
of post-operative complications were less in the CV (7.7%) and MV 
(11.8%) groups than in the PL group (14.0%). The 5-year recurrence-
free rate for p-Stage I A was 94.1% for CV (n=198), 91.8% for MV 
(n=56) and 91.4% for PL (n=86). The 5-year survival rate for p-Stage 
I A was 93.1% for CV, 83.7% for MV and 82.7% for PL. There was 
a significant difference between three groups (p=0.0225). The 5-year 
recurrence-free rate for p-Stage I B was 90.6% for CV (n=76), 77.3% 
for MV (n=40), 74.6% for PL (n=75). The 5-year survival rate for p-
Stage I B was 93.3% for CV, 64.7% for MV, 64.8% for PL. We found 
a significant difference between three groups (p=0.0014). The 5-year 
recurrence-free rate for p-stage II A+II B excluding the cases which 
we needed rib resection was 57.5% for VATS (MV and CV, n=44) 
and 45.0% for PL (n=61). The 5-year survival rate for p-stage II A+II 
B excluding the cases which we needed rib resection was 51.8% for 
VATS and 36.7% for PL. There was a significant difference between 
them (p=0.0248). 
Conclusion: The VATS procedure is superior to the PL in the 
post-operative morbidity and mortality. Despite the insufficiency of 
statistical analysis, our results suggest that the prognosis after CV 
may be superior to PL for stage I A, stage I B and most cases in stage 
II. At least the prognosis after VATS does not seem to be inferior to 
the PL group.
PD11.5.2 Surgery for NSCLC, Tue, 12:30 - 14:00
3 dimension-conformal radiation therapy vs. limited video-
assisted thoracic surgery for clinical stage I non-small cell 
lung cancer
Sakaguchi, Koji2; Horio, Hirotoshi1; Harada, Masahiko1; Kamisawa, 
Osamu2; Karasawa, Katsuyuki1
1 Tokyo Metropolitan Komagome Hospital, Tokyo, Japan; 2 Nagano 
Prefectural Suzaka Hospital, Suzaka, Japan
Background: Lobectomy is the standard of care for patients with re-
sectable non-small cell lung cancer (NSCLC). 3 dimension-conform-
al radiation therapy (3D-CRT) may be one of options for high risk 
patients who are not lobectomy candidates. Our technique of 3D-CRT 
is 25 fractions of 3Gy in 5 weeks (total dose 75Gy) with 10-fixed-
field 6MV non-coplanar photon beams. This technique is mainly used 
for those tumors located near certain critical structures such as heart, 
large vessels, esophagus, which are sensitive to large fraction radia-
tion dose. As another option for high risk patients, segmentectomy 
or partial resection of the lung by video-assisted thoracic surgery 
(Limited VATS) are performed for patients with low pulmonary func-
tion. We compared 3D-CRT with Limited VATS to estimate the local 
control rate and the survival in clinical stage I NSCLC patients.
Methods: Patients who were medically inoperable for lobectomy were 
offered 3D-CRT (24 cases) or performed limited VATS (2 segmentec-
tomies, 15 partial resections) non-randomly during the period of Janu-
ary 2001 to December 2005 in Tokyo Metropolitan Komagome Hos-
pital. Thoracic surgeons evaluated all patients’ conditions and planned 
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treatment in collaboration with radiation oncologists. The background 
of patients, local control rate, and overall survival were investigated.
Results: The median age of patients were 76.3±7.9years (range, 
53-90) in 3D-CRT, 75.7±5.6years (range, 72-86) in limited VATS 
(p=0.79), respectively. In clinical TNM classification, 18 cases were 
stage IA and 6 cases were stage IB in 3D-CRT, 12 cases were stage 
IA and 5 cases were stage IB in limited VATS, respectively. Local 
control rate during 2 years were 95.5% in 3D-CRT, 93.3% in limited 
VATS (P=0.74), respectively. Overall survival rate during 2 years 
were 83.3% in 3D-CRT, 88.2% in limited VATS (p=0.75), respect-
ively. No group had significant adverse events. 
Conclusions: Lobectomy is the best treatment for resectable stage 
I NSCLC patients. However, 3D-CRT and limited VATS may offer 
curative treatment chance to high risk patients in clinical stage I 
NSCLC.
PD11.5.3 Surgery for NSCLC, Tue, 12:30 - 14:00
Comparison of complete VATS lobectomy and hybrid 
VATS lobectomy for non-small cell lung cancer
Tsunezuka, Yoshio; Yachi, Tsuyoshi; Waseda, Ryuichi
Department of General Thoracic Surgery, Ishikawa Prefectural 
Central Hospital, Kanazawa, Japan
Background: “Video-assisted thoracic surgery(VATS) lobectomy” 
is accepted approach for non small cell lung cancer(NSCLC). The 
term“ VATS lobectomy” had been streched the meaning of “video-
assisted minithoracotomy( Hybrid VATS)” in Japan, but Dr. Ginsberg 
emphasized that VATS lobectomy is a totally closed procedure with 
no rib spreading of the access thoracotomy which is only used for 
insertion of thoracoscopic instruments and extraction of the specimen 
by his definition (World J. surg.24,30-31,2000). Therefore, VATS lob-
ectomy means a lobectomy under a monitor –vision, called complete 
VATS (c-VATS) as a byname. We conducted retrospective study of 
NSCLC patients who underwent lobectomy to compare Hybrid VATS 
and c-VATS. The merit of the procedure is the magnifying vision of 
a monitor. 
Methods: All patients undergoing systematic nodal dissection. The 
outcome of 99 consecutive patients with NSCLC who received c-
VATS or Hybrid VATS were reviewed. We have used 1088HD High-
definition 3CCD camera system and a 26-inch highvision monitor 
by c-VATS. We defined that Hybrid VATS means a minithoracotomy 
procedure with 4-7cm with no rib spreading using both a monitor and 
direct visualization. We have performed VATS using S or XS typed 
Wound Retraction System (WR:Alexis Wound Retractor,Applied 
Medical,CA,USA).Outcome variables analyzed included chest 
tube duration, length of hospitalization, hemorrhage, postoperative 
complications and pain score. The student t-test and X2 were used to 
compare continuous and categoric variables, respectively.
Results: Lobectomy was performed by Hybrid VATS in 56 patients 
and c-VATS in 43 patients, with complete resection in all patients. 
The length of major skin incision was 6.3±0.7cm by Hybrid VATS 
and 3.5±0.5cm by c-VATS. No significant differences were observed 
in the amount of blood loss, operating time, chest tube duration and 
length of hospitalization. Almost all cases displayed intraoperative 
uneventful course.In Hybrid VATS group, 3 patients required initial 
pleurectomy for pleuro-pulmonary adhesions before using WR. There 
were no patients with severe postoperative complication and wound 
infection. In Hybrid VATS group, 3 patients suffered from chronic 
pain but none in c-VATS group. 
Conclusions: C-VATS is more cosmetic and less invasive technique 
than Hybrid VATS but outcomes are similar to Hybrid VATS or 
c-VATS. Both Hybrid VATS and c-VATS are feasible approach for 
NSCLC patients. Long term follow-up of survival and surgions’skill 
will determine the role of each procedure. 
PD11.5.4 Surgery for NSCLC, Tue, 12:30 - 14:00
Pulmonary function after lung resection with complete 
video-assisted thoracoscopic surgery (C-VATS)
Mostard, R.L.M.1; Belgers, H.J.2; Siebenga, J.2; Custers, F.L.J. 1; van 
Noord, J.A.1
1 Department of Respiratory Diseases, Atrium medisch centrum 
Heerlen, Netherlands; 2 Department of Surgery, Atrium medisch 
centrum Heerlen, Netherlands
Background: Open thoracotomy leads to loss of pulmonary function 
depending on the extend of the resection and the time point of the 
measurement during the first 6 months after resection. Detailed data 
on lung function in the first 3–6 months after c-VATS are lacking. 
Objective: To investigate short-term effects of c-VATS resection on 
lung function. 
Methods: In a prospective study we measured in 35 patients, who 
underwent lung resection with c-VATS, lung function before and 2, 
6 and 12 weeks after resection. Predicted postoperative (PPO) values 
of FEV1, VC, TLC, RV, FRC, TLCO and KCO were calculated from 
quantitative lung perfusion scans and counting open segments to be 
removed. 
Results: In 35 patients 28 lobectomies, 1 bilobectomy, 4 sublobair re-
sections and 2 anterior mediastinal tumor resections were performed. 
13 patients were excluded from analysis because of confounding fac-
tors i.e., adjuvant therapy, pleural effusion or pneumothorax. 
  Preoperative PPO 2 weeks 6 weeks 12 weeks
     postoperatively (p.o.) 
 FEV1 91 ± 21 73 ± 23 77 ± 19 79 ± 18* 80 ± 18*
 VC 107 ± 17 85 ± 19 91 ± 22* 95 ± 19* 99 ± 19*
 TLC 107 ± 14 86 ± 16 91 ± 15* 92 ± 14* 93 ± 16*
 RV 118 ± 29 96 ± 26 100 ± 25 96 ± 27 93 ± 28
 FRC 112 ± 26 90 ± 25 99 ± 24* 98 ± 23 96 ± 22
 TLCO 79 ± 16 64 ± 15 65 ± 14 69 ± 14* 70 ± 14*
 KCO 93 ± 18 75 ± 16 85 ± 16* 88 ± 17* 89 ± 18*
N=22. All values are presented as mean ± SD in %pred. 
All differences between mean VC 2 and 6, 6 and 12 weeks p.o. were significant (p<0.05). Mean differ-
ences between TLCO, KCO 2 and 6 weeks p.o. and between RV 2 and 12 weeks p.o. were also significant. 
*p<0.05 compared to PPO values.  
Conclusions: 
1. Lung resection with c-VATS causes permanent functional loss 
depending on the extent of resection. There is a small additional 
loss, recovering completely within 6 weeks p.o., except for VC 
that continues to improve till 12 weeks p.o.
2. The method of calculating postoperative pulmonary function 
overestimates functional loss beyond 6 weeks p.o.
3. VC is the most sensitive parameter to assess recovery of chest 
wall function
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PD11.5.5 Surgery for NSCLC, Tue, 12:30 - 14:00
Introduction of the complete VATS lobectomy in a low 
volume hospital in the Netherlands: a single center 
feasibility study
Belgers, Eric; Siebenga, Jan; Bosch, Anne Marie; van Haren, Eric; 
Bollen, Ewald
Atrium Medisch Center Parkstad, Heerlen, Netherlands
Background: Data regarding the benefits for the complete video-as-
sisted thoracic surgery (c-VATS) lobectomy over the open lobectomy 
is numerous. Despite the positive data, the technique is still not 
accepted worldwide. This presentation describes the experience of 
introducing this technique in a training hospital, the first reported co-
hort in The Netherlands. The study presents the reproducibility of the 
benefits for patients with early lungcancer in a relative low volume 
hospital.
Methods: From March 2006 to November 2008, all patients operated 
on for proven or suspected lung cancer were analyzed. Prospective 
data from these patients was evaluated on procedure, operation time, 
blood loss, hospital stay, conversion rates and complications. A sub-
group analysis for the c-VATS lobectomy is presented.
Results: A total of 184 operations were performed on 172 patients. 
In 122 (66.3 %) of the operations the resection ended in a lobectomy 
of which 70 were done by complete thoracoscopic procedure. For the 
c-VATS lobectomy the mean operating time was 150 minutes, with 
a mean blood loss of 400 milliliters. The median hospital stay was 4 
days. Complications were present in 10 % of c-VATS lobectomies. 
The main intra-operative complication was tumor spill in 3 patients. 
Postoperative complications included long term pleural drainage in 
4 patients, once cardiac dysfunction needing inotropic support, in 
one patient supraventricular tachycardia was treated by the cardiolo-
gist and in one patient a costal artery bleeding ended spontaneously 
but transfusion was necessary. No mortality was seen in the c-VATS 
group. The median hospital stay for open lobectomies was 8 days. 
During the learning curve the mean operating time and mean blood 
loss are gradually reduced. With the intention to treat principle even 
more patients could be treated by c-VATS lobectomy as was not 
expected based on preoperative information.
Conclusion: After thorough evaluation and training, c-VATS 
lobectomy is a safe procedure that can be performed in a relatively 
low volume hospital. It has exceptional short term benefits for the 
patient due to the reduced surgical trauma without compromise to the 
oncological aspects. For training purposes, gathering extra informa-
tion about the tumor and patients being unexpectedly suitable for c-
VATS, all operations must start thoracoscopically. In contrast with the 
published data to date from high volume hospitals we show that the 
introduction of the technique with its learning curve and maintaining 
the skills for c-VATS lobectomy is feasible and safe in relative low 
volume hospitals. Still concentrating patients with early lungcancer in 
dedicated centers is advisable.
PD11.5.6 Surgery for NSCLC, Tue, 12:30 - 14:00
Role of sublobar resection in the surgical treatment for 
non-small cell lung cancer
Shimamoto, Akira; Takao, Motoshi; Suzuki, Hitoshi; Shimpo, Hideto
Mie University Graduate School of Medicine, Tsu, Japan
Objective: Sublobar resection is performed to high-risk patients as 
a palliative operation. Recently, selected patients with small-sized 
non-small cell lung cancer (NSCLC) undergo sublobar resection as a 
radical operation, but it is still controversy. In this study, we analyzed 
the outcomes of sublobar resection.
Methods: We retrospectively reviewed clinical records of all patients 
operated on for NSCLC from 1997 to 2008 (n=632). Lobectomy 
was the standard of care for selected patients with adequate cardio-
pulmonary reserve. Sublobar resection was reserved for patients 
with a peripheral cT1N0M0 NSCLC who were able to tolerate a 
lobectomy (radical sublobar resection), or stage IA or more ad-
vanced staged patients with cardiopulmonary impairment prohibiting 
lobectomy (palliative sublobar resection). Endpoints were periopera-
tive morbidity, incidence of recurrence, and disease-free and overall 
survival.
Results: Sublobar resection was underwent for 124 patients (19.6%), 
who were including 77 cases of radical sublobar resection for small-
sized NSCLC and 47 cases of palliative sublobar resection. In the 
radical sublobar resection group, tumor size was 1.1±0.5 (0.4-2.5) 
cm, and adenocarcinoma constituted the most common pathologic 
subtype of NSCLC (n=64, 83.1%), which were subclassified into 
localized bronchioloalveolar carcinoma (LBAC, n=18), LBAC with 
collapse of alveolar structure (n=20), LBAC with foci of active 
fibroblastic proliferation (n=22), tubular adenocarcinoma (n=2), 
and papillary adenocarcinoma with compressive and destructive 
growth (n=3). Overall survival at 5 years was 91.0% and disease-free 
survival was 100% (median follow-up was 52 months). In the pallia-
tive sublobar resection group, overall survival at 5 years was 41.9% 
(median follow-up was 35 months), however, incidence of postopera-
tive complications was reduced (overall complications: 32.4%, major 
complications: 5.9%, 30 days mortality: 0%). In p-IA staged patients 
underwent sublobar resections (n=88), overall survival at 5 years was 
82.3%, disease-free survival was 90.7% (median follow-up was 52 
months), and mortality due to recurrence was only 3 cases (3.4%). 
These survivals depended on tumor size (≤20mm vs. >20mm, overall 
survival: 85.0% vs. 50.0%, overall survival: 94.9% vs. 50.0%).
Conclusions: Radical sublobar resection was equivalent of lobec-
tomy in patients with pathological stage IA NSCLC, and resulted in 
similar perioperative outcomes and disease-free and overall survivals. 
Palliative sublobar resection could reduce an incident of postopera-
tive complication. Survivals in patients with p-stage IA depended on 
tumor size. 
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PD12.1.1 NSCLC - Early Stage, Tue, 12:30 - 14:00
Very early stage lung malignancies: when is 
lymphadenectomy nonessential?
Veronesi, Giulia1; Casiraghi, Monica1; Pardolesi, Alessandro1; 
Petrella, Francesco1; Maisonneuve, Patrick2; Bellomi, Massimo3; 
Travaini, Laura4; Brambilla, Daniela1; Spaggiari, Lorenzo1
1 Division of Thoracic Surgery European Institute of Oncology, 
Milano, Italy; 2 Division of Epidemiology and Biostatistics European 
Institute of Oncology, Milan, Italy; 3 Division of Radiology European 
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Background: with the advancement of diagnostic technique and 
screening programs, a high number of lung tumors are diagnosed at a 
very initial stage of disease. Lobectomy with lymph node dissection, 
that still represents the standard treatment of lung cancer independ-
ently of size and biological features of nodules, may be an overtreat-
ment in some of these cases. We analysed a consecutive series of 
clinical N0 screening detected lung malignancy to identify predictive 
criteria of nodal involvement. 
Methods: a single centre prospective study on chest computed 
tomography screening (the Cosmos study) was carried on since 2004 
in our Institute. All subjects with suspected lung nodules underwent 
preoperative PET scan. We included in this analysis patients with 
clinical stage T1-2N0M0 lung malignancy who underwent curative 
anatomical resection with radical mediastinal lymph node dissection 
with no prior treatment for lung cancer or history of lung malignan-
cies. Nodules characteristics were reviewed to identify predictors of 
lymph node involvement. 
Results: 78 patients enrolled in the COSMOS study encountered the 
including criteria. Seventy two patients (92%) were N0 at pathologic-
al exams while 6 were N1 or N2 (7.7%). All patients with max SUV 
(standardised uptake value) of nodule < 2.5 (p=0.03) or a nodule size 
< 10 mm (p=0.08) were N0 at pathological exam (47 cases); 7 had 
both variables (p=0.003). All the cases of nodal metastasis occurred 
among the group of patients with size larger than 1 cm in diameter 
and/or max SUV higher than 2.5 (despite negative PET scan at nodal 
site) with a rate of nodal involvement of 19%.
The predictive role of these two variables was validated on a retro-
spective series of 154 consecutive patients with non- screening de-
tected clinical stage I lung cancer treated in our Division in the same 
period. All patients (35 cases) that satisfied at least one of the two 
criteria were pN0 while among the other 120 cases, 26 cases (21%) 
had pathological nodal involvement.
Conclusions: according with this limited experience, in very small 
(less than 1 cm) or PET negative tumors, hilar and mediastinal lymph 
node dissection is nonessential with no risk of nodal involvement. 
These results should be validated in a larger series. The role of lim-
ited resection should be investigated in such initial lung cancers.
PD12.1.2 NSCLC - Early Stage, Tue, 12:30 - 14:00
Number of lymph nodes examined and likelihood of lymph 
node positivity after resection of lung cancer
Osarogiagbon, Raymond U.1; Allen, Jeffrey W.1; Farooq, Aamer1; 
O’Brien, Thomas2; Spencer, David3; Ratliff, Thomas1; Ninan, 
Mathew1
1 University of Tennessee, Memphis, TN, USA; 2 Duckworth 
Pathology Group, Memphis, TN, USA; 3 Trumbull Laboratories, 
Memphis, TN, USA
Background: The presence and extent of lymph node involvement is 
the most important prognostic factor after resection of NSCLC, but 
there is great variation in surgical and/or pathologic practice of lymph 
node examination which could impact on the accuracy of staging, 
post-resection clinical management, and perceived prognosis. We 
examined the relationship between pathologic nodal stage and num-
ber of lymph nodes examined after resection for NSCLC to determine 
if patients with more lymph nodes examined were more likely to have 
node-positive disease.
Methods: Retrospective review of all surgical resections for NSCLC 
in the Memphis Metropolitan Area from January 1, 2004 to De-
cember 31, 2007. Resections were identified by search of pathology 
databases at all hospitals. Patients who had pre-operative chemother-
apy, radiation therapy, or both were excluded. Categorical variables 
were compared by chi-square test, medians by the Wilcoxon-Mann-
Whitney test and survival estimates by log-rank test.
Results: Of 806 resections in the cohort, 60 (7%) patients had pre-
operative therapy and 90 (11%) had no lymph nodes examined and 
were excluded from this analysis. The characteristics of the remaining 
656 patients are presented in Table 1. The median number of lymph 
nodes examined in the whole cohort was 5 (range 1 – 46). Patients 
with N0 disease had significantly fewer lymph nodes examined than 
those with N1 disease, who in turn had fewer lymph nodes examined 
than those with N2 disease. Also, the number of mediastinal lymph 
nodes examined in those with N0 and N1 disease was significantly 
less than those with N2. 
  N0 (506 patients) N1 (94 patients) N2 (56 patients) P-value
 Age, yrs. Median (range) 68 (42, 89 66 (37, 84) 65 (39, 85) 0.15
 Gender, n(%): Female/Male 240 (47)/ 266 (53) 40 (43)/ 54 (58) 29 (51)/ 27 (48) 0.52
 Race: Black/White 106 (20)/ 397 (79) 25 (27)/ 67 (71) 18 (32)/ 38 (68) 0.11
 Adenocarcinoma 218 (43) 37 (39) 37 (66) 0.0023
 Squamous cell 192 (37.9) 39 (42) 7 (13) 
 Other 96 (19) 18 (19) 12 (21) 
 T1 250 (49) 38 (40) 23 (41) 0.053
 T2 194 (38) 43 (46) 24 (43) 
 T3 18 (4) 5 (5) 4 (7) 
 T4 40 (8) 8 (9) 5 (9) 
 Number of LN*    
 All stations 5 (1-45) 6 (1-28) 7 (1-35) 0.0016
 Stations 10-14 1 (0-38) 4 (1-22) 3 (0-24) 0.0002
 Stations 1-9 (mediastinal) 1 (0-45) 1 (0-10) 3 (1-12) <0.0001
 % with fewer than 10 LN examined 15 21.3 28.6 
 No LN from 10-14, n(%) 46 (9) 0 6 (10.7) 
 No LN from 1-9, n (%) 179 (35) 54 (47.9) 0 
 Extent of resection    
 Pneumonectomy 40 (8) 27 (29) 14 (25) <0.0001
 Lobe/bilobectomy 438 (87) 66 (70) 35 (63) 
 Segmental/wedge 28 (6) 1 (1) 7 (13) 
 *LN = lymph node    
Conclusions: 
1.  A large population of patients who underwent surgical resec-
tion for NSCLC did not have sufficient lymph nodes examined, 
irrespective of N-stage. 
2.  The total number of lymph nodes examined was directly propor-
tional to the N-stage, those with N0 having the fewest and N2 the 
most. This probably led to understaging of pathologic N-status 
in patients with N0 and N1. For example, 35% of N0 and 48% of 
N1 patients had no mediastinal lymph nodes examined. 
3.  There was correlation between the extent of resection, likelihood 
of lymph node examination and advanced N-stage, despite the 
similarity of T-stage between the 3 groups. 
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4.  About 10% of patients with N0 and N2 disease did not have any 
lymph nodes examined from levels 10-14, which suggests that 
pathologists bear some responsibility for sub-optimal lymph node 
staging since these nodes would be expected to be present in 
the resection specimen irrespective of the surgeon’s mediastinal 
lymph node biopsy technique. 
5.  We are currently testing interventions in the operating room and 
the pathology laboratory to improve the harvesting and exam-
ination of nodes after lung cancer resection, to more accurately 
reflect pathologic staging and provide for post-operative manage-
ment.
PD12.1.3 NSCLC - Early Stage, Tue, 12:30 - 14:00
The impact of occult micrometastases on survival 
following resection of stage I non-small cell lung cancer: 
final analysis of CALGB 9761
D’Cunha, Jonathan1; Wang, Xiaofei2; Groth, Shawn S.1; Vollmer, 
Robin T.2; Abraham, Naif Z.3; Herzan, Debra L.1; Gu, Lin2; Patterson, 
G A.6; Kohman, Leslie J.7; Green, Mark R.5; Kratzke, Robert A.1; 
Maddaus, Michael A.1; Group B, Cancer and Leukemia8
1 University of Minnesota, Minneapolis, MN, USA; 2 Duke University 
School of Medicine, Durham, NC, USA; 3 Syracuse VA Medical 
Center, Syracuse, NY, USA; 4 Care Alliance Roper Hospital, 
Charleston, SC, USA; 5 University of South Carolina, Charleston, 
SC, USA; 6 Washington University School of Medicine, St Louis, MO, 
USA; 7 SUNY Upstate Medical Center, Syracuse, NY, USA; 8 Cancer 
and Leukemia Group B, Chicago, IL, USA
Background: Survival after resection of stage I non-small cell 
lung cancer (NSCLC) is poor, potentially due to undetected occult 
micrometastases (OMs). The clinical significance of OMs have not 
been clearly defined in a prospective, multi-institutional clinical 
study. Cancer and Leukemia Group B (CALGB) 9761 was a pro-
spectively designed translational research study aimed at definitively 
determining the prognostic significance of OMs. 
Methods: From 1997-2002, 502 patients with suspected or biopsy-
proven clinical stage I (T1-2N0M0) NSCLC were prospectively 
enrolled at 12 institutions. Primary tumor and mediastinal lymph 
nodes (MLNs) were collected and sent to a single tumor bank for mo-
lecular analysis. 302 patients who underwent resection of pathologic 
stage I disease were included in the final analysis. Tumor and MLN 
specimens were assayed for OMs using immunohistochemistry (IHC) 
for cytokeratin (AE1/3) (reviewed by two independent pathologists) 
and quantitative real-time reverse transcriptase polymerase chain 
reaction (QRT-PCR) for carcinoembryonic antigen (CEA) (positivity 
defined by threshold cycle value < 42). Between group comparisons 
(based on OM-positivity) were made using a t-test for continuous 
variables and chi-square test for categorical variables. We analyzed 
the association between OM-positivity and unadjusted overall (OS) 
and disease-free survival (DFS) using the Kaplan-Meier method; we 
adjusted for potential confounding variables using a Cox proportional 
hazards regression model. A two-sided significance level of 0.05 was 
used for all statistical testing.
Results: Of the 502 patients who were enrolled, 489 underwent 
complete surgical staging. Of these, 302 (62%) had pathologic stage 
I NSCLC (T1, 58%; T2, 42%); 298 (59%) of these patients were 
included in the final analysis. 56% had adenocarcinomas, 34% had 
squamous cell carcinomas, and 10% had other histologies. MLNs 
from all 298 patients were analyzed by IHC; 41 (14%) were IHC+. 
Of the IHC-positive patients, 63% had T1 disease and 37% had T2 
disease; 42% had N1 disease and 59% had N2 disease. There was no 
significant correlation between IHC-positivity and histology. Patients 
that had IHC+ MLNs did not have a worse OS or DFS as compared 
with IHC- patients; however, patients that had IHC+ N2 MLNs had 
a trend towards a worse survival rate (Figure 1A). MLNs from 256 
patients were analyzed by QRT-PCR; 176 (69%) were PCR+. Of the 
PCR+ patients, 59% had T1 disease and 41% had T2 disease; 52% 
had N1 disease and 48% had N2 disease. Adenocarcinomas were 
more frequently PCR+ (p < 0.005). Neither OS nor DFS were as-
sociated with PCR-positivity (Figure 1B). Importantly, there was no 
relationship between the quantitative estimation of micrometastatic 
tumor cell burden in MLNs and survival.
Conclusions: Though NSCLC tumor markers can be detected in 
histologically negative MLNs by AE1/3 IHC and CEA QRT-PCR, 
OMs appear to have minimal prognostic significance as defined by 
this landmark study. These results strongly suggest that other factors, 
such as primary tumor biology, likely account for the poor prognosis 
seen in early stage NSCLC. 
PD12.1.4 NSCLC - Early Stage, Tue, 12:30 - 14:00
Intratumoral lymphatic vessel involvement is an invasive 
indicator of completely resected pathologic stage I non–
small cell lung cancer
Harada, Masahiko; Hato, Tai; Horio, Hirotoshi
Tokyo Metropolitan Cancer and Infectious Diseases Center 
Komagome Hospital, Tokyo, Japan
Background: Non-small cell lung cancer (NSCLC) patients with 
pathologic stage I disease have the best chance of cure by surgery 
alone. Within the stage I designation, however, there may be patient 
characteristics that influence worse long-term survival. Furthermore, 
therapeutic strategy still remains controversial in the group having 
poor prognostic factors. In the present study, we attempted to clarify 
the prognostic factors based on the survival
Methods: Between January 1990 and December 2005, 610 patients 
were eventually given a diagnosis of pathorogic stage I NSCLC. 
Ten clinicopathologic factors, namely age, gender, primary location, 
histopathology, differentiation, tumor size (T-factor), pleural involve-
ment (p), blood vessel involvement (v), lymphatic vessel involvement 
(ly) and extent of surgical resection, were investigated by univariate 
and multivariate analyses to identify significant prognostic factors 
among resected pathologic stage I disease. For the univariate analy-
sis, we constructed survival curves using the Kaplan-Meier method 
and compared survival between groups using log-rank tests. Multi-
variate analysis was performed by constructing a Cox proportional 
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hazards model using the significant factors from the univariate analy-
sis. The analyses were performed with the Stat view v5.0 statistical 
software program.
Results: The overall 5-year survival rate was 75.1%. Univariate 
analysis among overall patients revealed eight significant prognostic 
factors (P <.05): age, gender, histopathology, differentiation, tumor 
size (T-factor), pleural involvement, blood vessel involvement, and 
lymphatic vessel involvement. Based on the result, 5-year survival 
rate in each factor were compared statistically by Kaplan–Meier’s 
method; <70 vs. >70 = 81.9% vs. 65.2% (p<0.001), female vs. male 
= 80.9% vs. 71.4% (p=0.001), Ad. vs. non-Ad. = 81.2% vs. 64.4% 
(p<0.0001), well vs. non-well. = 80.7% vs. 70.3% (p<0.001), T1 vs. 
T2 = 83.4% vs. 64.9% (p<0.001), p(+) vs. p(-) = 65.2% vs. 80.1% 
(p=0.007), ly(+) vs. ly(-) = 61.5% vs. 83.1% (p<0.001), v(+) vs. 
v(-)= 67.3% vs.82.6% (p<0.001). Multivariate analysis revealed age, 
tumor size (T-factor), and lymphatic vessel involvement remained 
statistically significant. The hazard ratio for death for being under 
70 years was 0.563 [95%CI 0.409-0.774] (p=0.0004), for having T1 
tumor was 0.629 [95% CI 0.437-0.905] (p=0.0126), and for having 
no lymphatic vessel involvement was 0.514 [95%CI 0.364-0.726] 
(p=0.0002). Five-year survival rate in patients with T1 & ly(-), T1 & 
ly(+), T2 & ly(-) and T2 & ly(+) were 88.7, 69.8, 73.5 and 56.1%, 
respectively. Overlapping prognoses were seen between T1 with 
ly(+) group classed as stage IA and T2 with ly(-) classed as stage IB 
disease. Furthermore, overall survival of T2 with ly(+) group showed 
worse than the prognosis of 61.0% for pathologic stage IIA based on 
a Japanese lung cancer registry study in 2005.
Conclusions: Our analyses indicated that lymphatic vessel involve-
ment was an independent indicator of cancer invasiveness surpassed 
in the size-dependent TNM staging system in pathologic stage I 
NSCLC. The patient who would take survival benefit from adjuvant 
chemotherapy might be found stratifying by prognostic factors.
PD12.1.6 NSCLC - Early Stage, Tue, 12:30 - 14:00
Risk factors for distant recurrence and brain metastases 
observed on American College of Surgical Oncology 
Group trial Z0030: randomized trial of mediastinal lymph 
node sampling versus complete lymphadenectomy during 
pulmonary resection in the patient with N0 or N1 (less 
than hilar) non- small cell lung cancer (NSCLC)
Stinchcombe, Thomas E.1; Decker, Paul A.2; Darling, Gail E.5; Allen, 
Mark S.3; Putnam Jr, Joe B.4
1 University of North Carolina at Chapel Hill, Chapel Hill, NC, 
USA; 2 Division of Biomedical Statistics and Informatics, Mayo 
Clinic, Rochester, MN, USA; 3 Mayo Clinic, Rochester, MN, USA; 4 
Vanderbilt University, Nashville, TN, USA; 5 University of Toronto, 
Toronto, ON, Canada
Background: American College of Surgical Oncology Group trial 
Z0030 investigated the impact of mediastinal lymph node dissec-
tion in comparison to lymph node sampling on overall survival in 
patients clinically resectable T1 or 2, N0 or non-hilar N1 lymph node 
(LN) involvement in patients with resectable NSCLC. The primary 
objectives of this analysis were estimating the rate, location, and risk 
factors of distant recurrence, and the rate and risk factors of brain 
metastases.
Methods: Patients underwent lymph node sampling and were then 
intra-operatively randomized to complete mediastinal dissection or 
no further lymph node surgery. Patients did not receive post-operative 
chemotherapy, and were followed on regular intervals for disease 
recurrence. At the time of distant disease recurrence the date and 
location of recurrence was recorded. A Cox regression analysis was 
performed including histology, pathological stage, nodal stage, tumor 
stage, gender, race, performance status, tumor location, extent of re-
section (R0 vs. R1) to identify risk factors for distant recurrence and 
the development of brain metastases.
Results: Between May 6, 1999 and February 27, 2004 1023 eligible 
patients received treatment on the trial; 525 in the LN dissection 
arm and 498 in the LN sampling arm which form the basis of this 
report. Median follow-up for survivors was 5.7 years (range 0 to 9.1 
years). Patient characteristics were median age 69 years (range 24 
to 90 years), male/female 52%/48%, and stage IA (42%), IB (41%), 
IIA (3%), IIB (11%), IIIA (1%), and IIIB (2%). The most common 
histologies were adenocarcinoma (39%), squamous (27%), and 
NSCLC-not otherwise specified (21%); 98% of patients underwent a 
complete resection. Data is available for distant disease recurrence on 
464 of the sampling patients and has occurred in 107 patients (23%) 
The 2-year recurrence free rate observed was: IA: 91% (95% CI: 
87-95), IB: 84% (95% CI: 78-89), IIA: 75% (95% CI: 54-100), IIB: 
65% (95% CI: 52-80) and IIIA/IIIB: 42% (95% CI: 18-96). The most 
commonly identified sites of relapse were: brain (n=26), bone (n=26), 
contra-lateral hilum or lung (n=24), liver (n=14), separate ipsilateral 
lobe of the lung (n=13), and adrenal (n=9). Statistically significant 
risk factors for distant recurrence were tumor stage (p=0.004) and 
overall stage (p<0.001), and for brain metastases were nodal stage 
(p=0.007) and overall stage (p=0.013). Of note histology was not 
identified as a risk factor for distant or brain metastases. 
Conclusions: Advanced tumor and overall stage is a risk factor of 
distant recurrence, and nodal stage and overall stage are risk factors 
for the development of brain metastases in early stage NSCLC. 
Histology does not appear to be a risk factor for distant recurrence or 
brain metastases.
PD12.1.7 NSCLC - Early Stage, Tue, 12:30 - 14:00
Standardized uptake value at positron emission 
tomography (PET-SUV) predicts long-term survival of CT 
screening-detected lung cancer in heavy smokers
Pastorino, Ugo1; Claudio, Landoni2; Sozzi, Gabriella1; Marchianò, 
Alfonso1; Calabrò, Elisa1; Miceli, Rosalba1; Picchio, Maria2; Mariani, 
Luigi1; Fazio, Ferruccio2
1 National Cancer Institute, Milan, Italy; 2 San Raffaele Hospital, 
Milan, Italy
Background: PET has proven its value in the diagnosis of undeter-
mined pulmonary lesions, lung cancer staging, and assessment of 
prognosis by SUV value.
Methods: We tested the predictive value of PET-SUV on long-term 
survival of 34 lung cancers, detected from 1,035 heavy smokers ≥50 
yrs monitored by annual low-dose CT for 5 years, with a median 
follow-up of 75 months from diagnosis.
Findings: PET scan was performed in 34 (89%) of 38 lung cancers 
diagnosed during the 5 years of screening, and was positive in 32 
(94%). Complete resection was achieved in 30 cases (88%), 20 
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(59%) were pathological stage I, and 23 (68%) were adenocarcinoma. 
Median SUV was 5.0 overall, being significantly lower in stage I (2.5 
vs. 10.1, p=0.001) and in adenocarcinoma (2.5 vs. 13.0, p=0.001). 
The 5-year survival of lung cancer patients was 100% for SUV 
levels ≤2,5, 60% for SUV >2,5 and <8 and only 20% for SUV ≥8 
(p=0.001).
Interpretation: PET-SUV can predict long-term survival of screen-
ing detected lung cancer, in a non-invasive manner. Metabolic assess-
ment of biologic behaviour might improve the clinical management 
of CT-detected lung cancer, and reduce the risk of unnecessary treat-
ments for indolent disease.
PD12.2.1 NSCLC - Early Stage, Tue, 12:30 - 14:00
Prognostic role of cytoskeletal protein human mena 
(hMena), estrogen receptor-beta (ER-beta), and epidermal 
growth factor receptor (EGFR) in resected node-negative 
non-small cell lung cancer (NSCLC)
Bria, Emilio; Mottolese, Marcella; Sperduti, Isabella; Visca, Paolo; 
Antoniani, Barbara; Facciolo, Francesco; Di Modugno, Francesca; 
Cognetti, Francesco; Nisticò, Paola; Milella, Michele
Regina Elena National Cancer Institute, Rome, Italy
Background: Recent evidences have been released speculating 
upon the possible role of estrogen receptor expression, in the biology 
and clinical behavior of NSCLC, suggesting to investigate EGFR 
pathway alterations, isoform-specific expression of the cytoskelatal 
proteins, and hormone receptor expression. Moreover, ER-beta 
nuclear expression appear strictly related to EGFR mutations and 
its favorable prognostic significance in NSCLC is influenced by 
the EGFR mutations. hMena is a cytoskeleton regulatory protein 
involved in adhesion and cell motility, particularly in response to 
EGFR activation. In addition, a possible correlation between ER-beta 
and EGFR expression has been recently suggested in NSCLC. We 
therefore investigated the potential relationship and prognostic value 
of hMena, ER-beta and EGFR expression in node-negative NSCLC 
patients (pts) who underwent surgery at our institution. 
Methods: A Cox multivariate model was accomplished, by explor-
ing the independent impact of hMena, ER-beta (isoforms 1, 2), and 
EGFR expression (analyzed on Tissue Micro Array), on disease-free, 
cancer-specific, and overall survival (DFS/CSS/OS), including sex, 
stage, age, grading, histology, and number of resected nodes (RN) as 
clinico-pathological factors. In order to evaluate predictors, the sig-
nificant Cox-model variables were analyzed according to both logis-
tic and generalized linear models. The functions of different variables 
were studied using Martingale residuals, C&RT, maximally selected 
log-rank statistic, and Receiver Operative Curve (ROC) analyses to 
find optimal cut-offs for dichotomized variables. Internal cross-valid-
ation (100 simulations with 80% of the dataset) was accomplished. 
Results: 248 pts were gathered (median follow-up 26 months, range 
1-75; male/female 71/29%; adeno/other 43/57%; grading G1-2/G3 
45/55%; Stage I/II 82/8%; RN ≤10/>10 34/66%). Independent out-
come predictors at the multivariate analysis, are shown in the table.
When hMena was removed from the multivariate model, both factors 
became independent predictors of DFS/CSS; ER-beta2 and EGFR 
strongly predicted hMena overexpression (p=0.009, p=0.01). Cross-
validation analysis confirmed the prognostic role of hMena with a 
replication rate of 43/66% for DFS/CSS. 
  DFS CSS OS
  HR (95% CI); p-value HR (95% CI); p-value HR (95% CI); p-value
 Grading 1.71 (0.97, 3.01); 0.006 n.s. 1.80 (1.00, 3.25); 0.05
 RN 1.97 (1.14, 3.41); 0.01 n.s. 2.77 (1.27, 4.88); 0.0001
 Stage 2.03 (1.07, 3.87); 0.03 3.21 (1.57, 6.59); 0.0001 2.93 (1.59, 5.40); 0.001
 hMena 1.82 (1.05, 3.15); 0.03 2.25 (1.14, 4.44); 0.02 n.s.
Conclusions: hMena expression seems to have a prognostic role 
in NSCLC pts undergoing curative surgery. The expression of both 
ERbeta2 and EGFR strongly correlates with hMena status, suggesting 
a further deep investigation into a larger series.
PD12.2.2 NSCLC - Early Stage, Tue, 12:30 - 14:00
New biomarkers for non small cell lung cancer by 
microarray gene expression with cell lines and xenograft 
tumor cells
Sugita, Michio; Bemis, Lynne; Haney, Jerry; Zhang, Zhiyong; Chan, 
Daniel; Franklin, Wilbur
University of Colorado Denver, School of Medicine, Aurora, CO, 
USA
Background: Gene expression may be context dependent with cell 
lines in culture exhibiting gene expression profiles that differ from 
those of tumor cells in situ. For this reason we have evaluated expres-
sion profiles of a tumor cell line passaged in xenografts to identify 
lung tumor specific biomarkers. 
Materials and Methods: 1) Human adenocarcinoma (AD) cell line 
H2122 cells were tagged with GFP and implanted subcutaneously or 
orthotopically in athymic rats. In vivo fluorescent imaging was used 
to follow patterns of tumor growth and metastasis formation. When 
animals developed advanced metastases, tumor tissues from a sub-
cutaneous tumor, a primary lung tumor, and metastatic tumors from 
various other sites were isolated, propagated briefly in vitro culture. 
2) RNAs were extracted with RNeasy (Qiagen) and hybridized to 
Affymetrix HG U133 plus 2.0 gene expression arrays (U133 plus 
2.0). Results of gene expression were compared with results from 22 
non small cell lung cancer cell lines (nine squamous cell carcinomas 
(SQ) and 13 AD, U133 plus 2.0) using GeneSpring software (Agilent 
Technologies). 3) In addition, some genes discovered through the 
microarray analysis were further tested by the quantitative RT-PCR 
with Taqman probe (Applied Biosystems) or regular RT-PCR on 
cell lines and normal bronchial epithelial cells to confirm if the 
microarray data is consistent with the RT-PCR data. 4) To compare 
histological specificity, 18 SCLC (SM) cell line chip data with U133 
plus 2.0 were also evaluated. 
Results: 3062 genes were significantly up-regulated (p< 0.05) in 
H2122 xenografts regardless of anatomic site. Forty six genes were 
up-regulated in 22 NSCLC cell lines (over 30 Fold Change at least 
12 of 22 cell lines). Seventeen candidate biomarker genes including 
MAGE A2, A3, A6 and EEF1A2 were common to both xenografts 
and cell lines. RT-PCR data was compatible with microarray data. 
ZIC2 showed the excellent correlation (r=0.985) between copy num-
bers by qRT-PCR and microarray fluorescence results in cell lines. 
TMC5 was overexpressed in adenocarcinoma predominantly (AD vs. 
SQ: p=0.0066, AD vs. SM: p=0.00042, AD vs. normal: p= 0.00017).
Conclusions: Combining cell lines and xenograft models provides 
a unique biomarker mining methodology and has identified 17 
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up-regulated candidate genes. In particular, ZIC2 is a wide-range bio-
marker and TMC5 is an AD specific biomarker. Data obtained from 
xenografts and cell lines identify unique candidate tumor-associated 
markers that may be useful for early detection. 
PD12.2.3 NSCLC - Early Stage, Tue, 12:30 - 14:00
Genomic and mutational profiling to assess clonal 
relationships between multiple non-small cell lung cancers
Girard, Nicolas; Ostrovnaya, Irina; Lau, Christopher; Park, Bernard; 
Ladanyi, Marc; Finley, David; Deshpande, Charuhas; Rusch, Valerie 
W.; Orlow, Irene; Travis, William D.; Pao, William; Begg, Colin B.
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Background: The incidence of synchronous and metachronous 
multiple non-small cell lung cancer (NSCLC) is increasing. When pa-
tients have multiple lesions, clinicians must decide, based on clinico-
pathological grounds, whether patients have independent tumors or 
metastases and tailor treatment accordingly. Comprehensive genomic 
profiling of tumors could improve the ability to assess clonality in 
these instances. 
Methods: Fresh frozen tissue from patients that underwent resection 
for presumptively independent NSCLCs were used to perform array 
comparative genomic hybridization (aCGH) and mutational profil-
ing of select genes. Detailed clinico-pathological review was done to 
characterize each case as multiple primaries or metastases. 
Results: A total of 42 tumors from 20 patients (6 patients with 
synchronous tumors; 14 patients with metachronous tumors; 24 po-
tential tumor pair comparisons) were evaluated. 22 tumor pairs were 
evaluable by aCGH. Classification based upon genomic profiling 
contradicted the clinico-pathologic diagnosis in 4 (18%) of the com-
parisons, identifying independent primaries in one case diagnosed 
as metastasis and metastases in 3 cases diagnosed as independent 
primaries. Matching somatic point mutations were observed in these 
latter 3 cases. Another 4 tumor pairings were assigned an “equivocal” 
result based on aCGH; however, matching somatic point mutations 
were also found in these tumor pairs. None of the tumor pairs deemed 
independent primaries by aCGH harbored matching mutations. 
Conclusion: Both genomic characterization and comprehensive 
mutational profiling show promise as ways to assess clonality of 
multiple primary lung carcinomas. The development of rapid, 
inexpensive and reliable molecular tools to distinguish multiple lung 
primaries from intrapulmonary metastases may allow for refinement 
of clinico-pathologic criteria currently used in this setting.
PD12.2.4 NSCLC - Early Stage, Tue, 12:30 - 14:00
Surfactant protein A expression and gene deletion as 
prognostic markers in non-small cell lung cancer
Savic, Spasenija1; Zlobec, Inti1; Schneider, Sandra1; Tamm, Michael2; 
Lardinois, Didier3; Katz, Ruth L.4; Bubendorf, Lukas1
1 Institute for Pathology, University Hospital Basel, Basel, 
Switzerland; 2 Clinic of Pneumology, University Hospital Basel, 
Basel, Switzerland; 3 Clinic of Thoracic Surgery, University Hospital 
Basel, Basel, Switzerland; 4 Department of Pathology, The University 
of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Background: Molecular markers are becoming increasingly import-
ant in non-small cell lung cancer (NSCLC) patients for personalized 
therapy decisions. Recent data suggest that Surfactant Protein A (SP-
A) deletion is common in NSCLC. The aim of the present study was 
to investigate the prognostic value of SP-A protein expression and 
SP-A gene deletion in a large series of NSCLC patients.
Methods: Tissue micro arrays with a total of 1413 NSCLC were 
analyzed. SP-A expression was detected by immunohistochemistry 
(IHC) and SP-A gene copy number aberrations by fluorescence in 
situ hybridization (FISH). IHC and FISH data were correlated with 
clinicopathological features and overall survival.
Results: In multivariable analysis both SP-A expression (HR= 0.48, 
95% CI: 0.3-0.8; p=0.001) and SP-A deletion (HR= 1.54, 95% CI: 
1.1-2.1; p=0.006) were independent prognostic factors in NSCLC 
patients. The combined IHC/ FISH results stratify patients into four 
prognostic groups with SP-A IHC+/ FISH- NSCLC having the best 
(5-year survival rate: 69.3%, 95% CI: 54-80%) and SP-A IHC-/ 
FISH+ NSCLC having the worst prognosis (5-year survival rate: 
32.3%, 95% CI: 21-44%) (p<0.001). These prognostic groups differ 
in histological cancer types. SP-A expression is prognostic in both 
adeno- and large cell carcinomas (p=0.007 and p= 0.018, respect-
ively), but SP-A deletion only in large cell carcinomas (p= 0.018). 
Neither SP-A expression nor SP-A deletion have a prognostic value 
in squamous cell carcinomas. SP-A expression remains prognostic-
ally significant in early stage IA and SP-A deletions in IB NSCLC 
patients (p= 0.017 and p= 0.045, respectively).
Conclusions: SP-A expression and SP-A deletion are prognostic in 
NSCLC and could become especially valuable in stage I NSCLC to 
stratify patients who might benefit from adjuvant treatment. Assess-
ing the histological cancer type is important to select the appropriate 
molecular test.
PD12.2.5 NSCLC - Early Stage, Tue, 12:30 - 14:00
Prognostic value of microRNAs profiling in early stage 
squamous cell lung cancer (SqCLC) 
Skrzypski, Marcin T.1; Szymanowska, Amelia1; Jassem, Ewa1; 
Rzyman, Witold1; Rzepko, Robert1; Pawłowski, Ryszard 1; Wyrwicz, 
Lucjan2; Goryca, Krzysztof 2; Jassem, Jacek1
1 Medical University of Gdansk, Gdansk, Poland; 2 Maria 
Sklodowska-Curie Memorial Cancer Center and Institute of 
Oncology, Warsaw, Poland
Background: About 50% of NSCLC patients develop distant 
metastases following surgery. Currently, apart from clinical stage 
at diagnosis, there are no reliable clinical factors to select high risk 
patients for adjuvant chemotherapy. MicroRNAs (MiRs) expression 
profiling is expected to indicate patients with particularly aggressive 
disease course who are at high risk of distant metastasis after com-
plete resection. There is growing evidence to suggest that NSCLC 
pathology may influence gene expression levels and confound the 
gene expression quantitative analysis interpretation. Thus, it is justi-
fied to search for prognostic miRNAs separately in lung SqCLC and 
adenocarcinoma. 
Materials and Methods: Fresh frozen tumor tissue was obtained 
from 51 SqCLC stage I-II patients during curative pulmonary resec-
tion. None of the patients received adjuvant chemotherapy. Twenty 
patients developed distant metastases after surgery and 31 were 
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free of relapse after a median follow-up of 5.4 years (range, 3.1-6.9 
years). RNA was isolated from tumor sections containing >60% of 
tumor cells per section. Expression of 677 miRNAs was analyzed 
by RT-PCR in TLDA arrays (Appliedbiosystems). Raw data were 
normalized vs. the expression of U6 RNA and calibrated by ΔΔCt 
method. The differences in expression levels between metastasis and 
no metastasis groups were tested with t-Student test. Top of the list 
microRNAs were included in the multivariate analysis of progression 
free survival together with stage and grade. A risk score (RS) based 
on the expression of the top 7 microRNAs was calculated by adding 
z-score normalized gene expression values multiplied by correspond-
ing beta factors. RS values higher than 60th percentile for the entire 
group qualified patients as high risk. Survival analysis (PFS and OS) 
was carried out according to the risk score status. 
Results: The expression of 457 (67%) of the analyzed miRNAs could 
be reliably assessed in all tumor tissues. Expression of seven miRNA 
differed between groups with and without metastases (t-Student 
test, p<0.02). MicroRNA 10b was significantly related to high risk 
of relapse after correction for multiple comparisons. Cox analysis 
performed for the top 7 miRNA identified with t-Student test showed 
significant correlation for 2 microRNAs: 10b and 192* (p=0.0086 
and p=0.018, respectively). Patients qualified as high or low risk 
after according to risk score had significantly different progression 
free and overall survival (log-rank test, p=0.00002 and p=0.00003, 
respectively). The test accuracy was estimated at 82%. 
Conclusions: Risk score based on the expression of 7 microRNAs 
was shown to carry high prognostic information in early stage 
SqCLC patients. These results need to be validated in an independent 
population of patients. 
PD12.2.6 NSCLC - Early Stage, Tue, 12:30 - 14:00
High resolution genomic analysis of NSCLC reveals 
regions of DNA copy number gain that may be predictive 
of benefit from adjuvant chemotherapy
Craddock, Kenneth J.1; Buys, Timon P.2; Zhu, Chang Q.3; Strumpf, 
Dan3; Pintilie, Melania3; Ding, Keyue4; Seymour, Lesley4; Jurisica, 
Igor3; Shepherd, Frances A.3; Lam, Wan L.2; Tsao, Ming-Sound1
1 Laboratory Medicine & Pathobiology, University Health Network, 
University of Toronto, Toronto, ON, Canada; 2 Cancer Genetics and 
Developmental Biology, British Columbia Cancer Research Centre, 
Vancouver, BC, Canada; 3 Ontario Cancer Institute, University 
Health Network, Toronto, ON, Canada; 4 NCIC, Clinical Trials 
Group, Queens University, Kingston, ON, Canada
Background: Non-small cell carcinomas (NSCLC) typically have 
complex karyotypes with multiple chromosomal aberrations that result 
in net gains and losses of genetic material. Although recurring areas 
of amplification have been described involving genes thought to be 
important in carcinogenesis, studies correlating these genomic events 
with patient outcome and response to chemotherapy are lacking. 
Methods: All tumor samples were from patients enrolled in the 
BR.10 Phase 3 placebo controlled trial that compared adjuvant 
vinorelbine plus cisplatin to observation alone in completely resected 
stage IB or II NSCLC patients. Array comparative genomic hybrid-
ization (CGH) analysis was performed on genomic DNA isolated 
from tumors of 113 patients (57 In observation arm, 56 in chemo-
therapy arm) using the whole genome tiling path bacterial artificial 
chromosome (BAC) array with 26,363 overlapping clones. Circular 
binary segmentation (DNAcopy) was used to define the segmental 
DNA copy number gains and losses in each tumor genome. Minimal 
common regions (MCRs) of gain and loss were then identified for 
the entire tumor panel using STAC algorithm. The association of 
copy number changes at MCRs with patient outcome and response to 
chemotherapy was determined using univariate and multivariate Cox 
proportional hazards statistical models.
Results: Observed segmental alterations were in concordance with 
previous studies, including frequent gains at chromosome 1q, 3q, 
5p, and 8q, and frequent losses at 3p, 5q, 6q, 8p, 9p, 13q, and 17p, 
with MCRs encompassing genes previously shown to be amplified 
in NSCLC (e.g. MYC, TERT, CCND1). After correcting for multiple 
testing, MCRs of gain within a 6Mb region of 12q were found to be 
significantly associated with poor survival in the absence of chemo-
therapy (p < 0.001, q < 0.05). When this region was examined for 
benefit of chemotherapy, a significant improvement of survival was 
identified at one of the MCRs (interaction p < 0.01). These as-
sociations remained significant (p < 0.05) in a multivariate model 
incorporating known prognostic clinical factors (i.e., age, sex, stage, 
grade). Other potential predictive associations included an improved 
survival with chemotherapy for patients with gains at MCRs on 8q 
(interaction p = 0.02) and 11q (interaction p = 0.08).
Conclusions: High-resolution array-CGH analyses on a subset of the 
BR.10 patients have identified regions of recurrent DNA copy num-
ber gain that may be predictive of benefit from adjuvant chemother-
apy. (Supported by grants from the Canadian Cancer Society, Ontario 
Institute of Cancer Research and Genome Canada)
PD12.3.1 NSCLC - Early Stage, Tue, 12:30 - 14:00
Comparative uptakes of peri-operative chemotherapy 
(CT) in non-small cell lung cancer (NSCLC) between 2004 
and 2007
Le Naour, Béatrice1; Mauguen, Audrey 1; Fabre, Dominique2; Pignon, 
Jean P.1; Soria, Jean C.1; Dartevelle, Philippe2; Besse, Benjamin1
1 Insitut Gustave Roussy, Villejuif, France; 2 Centre Chirurgical 
Marie Lannelongue, Plessis Robinson, France
Background: Adjuvant (ADJ) platinum-based CT has become a 
new standard of care for patients (pts) with resected stage II and III 
NSCLC, and is discussed in selected stage IB pts. Impact of posi-
tive randomized trials which showed significant survival improve-
ment (first published in 2004) on the use of ADJ CT has been poorly 
studied to date.
Methods: A retrospective study of consecutive pts with NSCLC who 
underwent curative surgery during the first half of year 2004 and 2007 
in the surgical center Marie Lannelongue (France) was conducted. 
Logistic regression models were employed to identify cofactors asso-
ciated with the use of ADJ CT (excluding stage IV). Odds ratio (OR) 
> 1 corresponds to a more frequent use than in reference group.
Results: A total of 240 pts (116 in 2004, 124 in 2007) underwent 
curative surgery for NSCLC (11% IA; 30% IB; 27% II; 27% III; 5% 
IV). Among all pts, 12 % received neoADJ CT (less in 2007, 8% vs 
16% p=.04), 35% ADJ (4% both). Reasons for not receiving ADJ CT 
included stage I (34%), death (11%), comorbidities (10%), poor per-
formance status (10%), advanced age (8%), post-operative complica-
tions (7%), patient refusal (3%). More ADJ CT was prescribed in 
2007 (41% vs 30% in 2004, p=.009). Overall, 45% of pts with stage 
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II-III received ADJ CT in 2004 versus 69% did so in 2007. In multi-
variate analysis, ADJ CT was associated with the year of inclusion 
(OR=2.67 p=.009), stage (stage II, OR=6.77, stage III, OR=16.85; 
p<.0001), serious medical history (OR=.41 p=.01) and salvage sur-
gery (OR=.26 p=.03). Cisplatin was the preferred platinium com-
pound in 76% of neoADJ regimens (mostly cisplatin-docetaxel), and 
70% of ADJ CT (mostly cisplatin-vinorelbine).
Conclusions: The presentation and publication of “positive” ADJ CT 
trials had significantly increased daily prescription of ADJ CT in pts 
with stage II-III NSCLC. Nevertheless 31% of the stage II-III did not 
received CT mostly because of comorbidities, highlighting the need 
of a personalized CT.
PD12.3.2 NSCLC - Early Stage, Tue, 12:30 - 14:00
Clinicians’ preferences for adjuvant chemotherapy (ACT) 
in non-small-cell lung cancer (NSCLC): what makes it 
worthwhile? 
Blinman, Prunella1; McLachlan, Sue-Anne2; Nowak, Anna3; Duric, 
Vlatka1; Wright, Gavin2; Millward, Michael3; Brown, Chris1; 
Coskinas, Xanthi1; Fong, Kwun4; Stockler, Martin1
1 NHMRC Clinical Trials Centre, Sydney, Australia; 2 St Vincent’s 
Hospital, Melbourne, Australia; 3 University of Western Australia, 
Perth, Australia; 4 The Prince Charles Hospital, Brisbane, Australia
Background: ACT for NSCLC improves survival at the cost of side 
effects and inconveniences that can impair quality of life. Decisions 
about ACT involve a trade-off between these disparate benefits and 
harms. We sought (i) lung cancer clinicians’ judgements about the 
smallest benefits in survival that would make the harms of ACT 
worthwhile after surgery for NSCLC, (ii) factors associated with 
their judgements, and (iii) comparisons with breast and colon cancer 
clinicians surveyed similarly in 2002-3.
Methods: Delegates at the 2008 Australian Lung Cancer Conference 
were invited to complete a validated, self-administered questionnaire. 
The questionnaire uses the time trade-off technique to determine the 
smallest improvements in survival that would make ACT worthwhile 
in 4 hypothetical scenarios. The baseline prognosis of each scenario is 
consistent with survival data from modern ACT trials: survival times 
of 3 years and 5 years; and baseline survival rates of 50% and 65% 
at 5 years. ACT was 4 cycles of cisplatin and vinorelbine as per the 
JBR.10 trial. All statistical tests are two-sided and non-parametric.
Results: Characteristics of the 156 respondents were: median age 
41 yrs (range 23 to 62), female (55%), married (83%), with depend-
ent children (62%), respiratory physician (28%), medical oncologist 
(14%), radiation oncologist (12%), thoracic surgeon (4%), nurse 
(24%), and trial nurse/coordinator (12%). Most clinicians judged an 
extra 9 months in survival time sufficient whether the baseline was 3 
years or 5 years (55% v 60%, p = 0.8). More clinicians judged an ex-
tra 5% sufficient when the baseline survival rate was 65%, than when 
it was 50% (60% v 39%, p < .001). Smaller benefits were judged 
sufficient by clinicians who were married (p = .01) or had dependants 
(p = .04) than by their counterparts. Age, gender, type of clinician 
and smoking history were not associated with the benefits judged suf-
ficient (p > 0.1). The benefits judged sufficient by these lung cancer 
clinicians were significantly smaller than those judged sufficient by 
breast cancer (n=89) and colon cancer (n=72) clinicians (eg 9 months 
sufficient for 60% of lung cancer clinicians v 42% of colon and breast 
cancer clinicians, p = .002).
Conclusions: Most lung cancer clinicians judged moderate improve-
ments in survival sufficient to make ACT worthwhile. Smaller 
improvements in 5 yr survival rates were judged sufficient for the 
better prognosis scenario. Smaller benefits were judged sufficient 
by lung cancer clinicians in 2008 than by breast and colon cancer 
clinicians 5-6 years earlier. Research is needed to determine patients’ 
judgements about the benefits needed to make ACT worthwhile after 
surgery for NSCLC.
PD12.3.3 NSCLC - Early Stage, Tue, 12:30 - 14:00
Quantification of the difficulty of accruing patients into 
quality-restrictive post-resection clinical trials for non-
small cell lung cancer (NSCLC)
Allen, Jeffrey W.; Farooq, Aamer; Ramirez, Robert; Ninan, Mathew; 
Osarogiagbon, Raymond U.
University of Tennessee, Memphis, TN, USA
Background: The wide variation in pattern of surgical resection 
for lung cancer complicates efforts to clarify the best operative and 
post-operative interventions for patients with resectable lung cancer. 
Clinical trials specify inclusion and exclusion criteria to control for 
factors such as histology, stage, extent of resection, and extent of 
lymph node sampling. Stringent criteria have the advantage of clearly 
defining test populations, but potentially slow accrual, impairing the 
ability to complete trials in a timely manner. These criteria further 
limit the generalizability of study findings to routine practice. For 
example, three large clinical trials, each asking an important question 
in patients with resectable NSCLC (RADIANT, ECOG 1505, and 
CALGB 140503) are currently suffering from slower than expected 
patient accrual. We sought to demonstrate in a semi-quantitative man-
ner, the degree to which various entry criteria would have affected 
the eligibility of patients into five recently completed or on-going 
landmark lung cancer clinical trials.
Methods: The records of all patients who underwent surgery for lung 
cancer in the Memphis Metropolitan Area from January 1, 2004 to 
December 31, 2007 were reviewed for disease and resection charac-
teristics which were compared to the entry criteria of five landmark 
clinical trials JBR.10, RADIANT, ECOG 1505, ACOSOG Z0030, 
and CALGB 140503 (table 1) in order to determine the impact of 
each criteria on patient selection.
Trial Eligible 
stage
Extent of 
resection
Preopera-
tive 
therapy?
Margin 
require-
ment
Excluded 
histology
Minimum lymph 
node examina-
tion
JBR.10
T2N0M0, 
T1N1M0, 
T2N1M0
Lobectomy or 
greater
No R0
SCLC, mixed 
SCLC/NSCLC
10 negative
RADI-
ANT
IB - IIIA
Lobectomy or 
greater
No R0
SCLC, 
carcinoid, 
LCNEC
Two mediastinal 
stations
E1505
Bulky IB 
(>4cm) - IIIA
Lobectomy or 
greater
No R0 SCLC
Right side: 4R+7; 
Left side: 5/6+7
ACOSOG 
Z0030
T1-2
Segment-
ectomy or 
greater
No R0 None
Right side: 
2R+4R+7+10R; 
Left side: 
5+6+7+10L
CALGB 
140503
Tumor & 
<2cm
Not specified No R0 None
Right side: 
4R+7+10R; Left 
side: 5+6+7+10L
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Results: 
See Table 2
Trial Percent-
age of
Stage
patients 
rendered 
Extent of 
resection
ineligible 
by specific
Pre-
operative 
therapy
criteria
Margin
Histol-
ogy
Minimum 
lymph 
node 
examina-
tion
Total 
disquali-
fied
JBR.10 64 11 7 9 2 27 79
RADIANT 54 11 7 9 3 73 88
E1505 67 11 7 9 1 83 (no 4R); 
84 (no 7)
97
ACOSOG 
Z0030
14 9 7 9 0 58 (no 10); 
84 (no 7)
100
CALGB 
140503
62 0 7 9 0 85 (no 10); 
84 (no 7)
99
Conclusions: ery few patients who underwent potentially curative 
surgical resection for lung cancer in our cohort would have been 
eligible for enrollment into each of five very important recent or on-
going clinical trials involving lung cancer resection. The vast major-
ity of patients are disqualified because of failure to meet lymph node 
examination criteria. Failure to examine level 10 lymph nodes would 
have eliminated 58.4% of patients while failure to examine level 7 
nodes would have eliminated 84.1% of patients (90% of patients 
with left sided tumors and 79% of patients with right sided tumors). 
Mandating examination of level 5 nodes for left-sided lung resections 
similarly would have eliminated 72.3% of patients.
Either the American College of Surgeons/AATS and the College 
of Amerian Pathologists have to embark on an intensive campaign 
to educate surgeons and pathologists on the need for more specific 
operative dissection and specimen labeling and handling of lymph 
nodes by the ATS map or clinical trials need to be designed with less 
station-specific stringency. Along these lines, the IASLC proposal for 
6 lymph node zones might help simplify selection criteria, if proved 
valid. However, this will not eliminate the high percentage of patients 
with no mediastinal lymph nodes examined (41% in our cohort).
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Pemetrexed in combination with cisplatin or carboplatin 
as adjuvant chemotherapy in early stage NSCLC
Manegold, Christian1; Chemaissani, Assaad2; Fischer, Jürgen R.3; 
Schütte, Wolfgang4; Mazières, Julien5; Viñolas, Nuria6; Wolf, 
Martin7; Thareau-Vaury, Alexandra8; Leschinger, Monika9; Reck, 
Martin10
1 Dept. of Surgery, University Medical Center Mannheim, 
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Cologne-Merheim, Cologne, Germany; 3 Department of Oncology, 
Klinikum Loewenstein gGmbH, Loewenstein, Germany; 4 Hospital 
Martha-Maria, Halle-Doelau, Department of Internal Medicine II, 
Halle, Germany; 5 Department of Pneumologie, Larrey Hospital, 
Toulouse Cedex, France; 6 Hospital Clinic i Provincial, Oncology 
Service, Villarroel, Barcelona, Spain; 7 Department of Hematology 
and Oncology, Klinikum Kassel, Medizinische Klinik IV, Kassel, 
Germany; 8 Lilly France - Statistiques Projet Regional Onco France, 
Suresnes Cedex, France; 9 Lilly Deutschland GmbH, Bad Homburg, 
Germany; 10 Department of Pneumology and Thoracic Surgery, 
Hospital Großhansdorf, Großhansdorf, Germany
Background: After complete resection of stage I-IIIa Non-Small 
Cell Lung Cancer (NSCLC), platinum based adjuvant chemotherapy 
has improved 5-yr survival by 4-15%. In 1st line treatment (Tx) of 
advanced NSCLC, Pemetrexed (Pem) in combination with Cisplatin 
(Cis) or Carboplatin (Carbo) has shown to be effective and safe, thus 
being a promising option in the adjuvant setting.
Methods: Open-label, multicenter, phase 2 study in patients (pts) 
with completely resected stage Ib or II NSCLC. A total of 106 pts 
was planned to evaluate feasibility of either regimen independently 
for each Tx-arm. Pts were randomized to Pem (500 mg/m2)+Cis (75 
mg/m2) or Pem (500 mg/m2)+Carbo (AUC5) d1 q3 wks, for 4 cycles; 
adequate organ function and ECOG PS 0-1 were required. Feasibility 
of the regimen, defined as compliance to 4 Tx cycles with ≥ 95% of 
the planned dose administered and without remaining ≥ Grade 3 tox-
icities (tox) at 30 days after last infusion, was the primary endpoint of 
this trial. If the rate (feasible pts/total pts) was >60%, a regimen was 
deemed feasible. 
Results: 
Conclusions: According to the strict definitions in this protocol 
neither regimen was feasible. The reason was poor compliance 
with at least one of the components that defined feasibility. In the 
Pem+Cis Tx-arm, this was most frequently early discontinuation, but 
with a low rate of adverse event related Tx-discontinuations. In the 
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Pem+Carbo Tx-arm, the most frequent reason was dosing <95% of 
planned dose, however, dose intensity and % pts completing all 4 Tx 
cycles was notably high in both Tx-arms, especially when com-
pared to other adjuvant trials in this setting. Pem+Cis was the more 
favourable regimen concerning feasibility and relevant hematoxicity. 
In terms of tolerability, Pemetrexed could be combined with either 
platinum compound. Apart from hematology, the non-hematologic 
toxicity-profile was also notably mild in both regimens. 
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Randomized trial of adjuvant chemotherapy (Cx) with 
gemcitabine plus cisplatine (GC) versus docetaxel plus 
cisplatine (DC) in patients (pts) with completely resected 
non small cell lung cancer (NSCLC) with quality of life 
(QoL) as the primary objective
Barlesi, Fabrice1; Chouaid, Christos2; Crequit, Jacky3; Lecaer, 
Hervé4; Pujol, Jean-Louis5; Bérard, Henri6; Vergnenegre, Alain7; 
Letreut, Jacques8; Fabre-Guillevin, Elizabeth2; Loundou, Anderson1
1 Université de la Méditerranée - Assistance Publique Höpitaux 
de Marseille, Marseille Cedex 09, France; 2 Assistance Publique 
Hôpitaux de Paris, Paris, France; 3 CHG Beauvais, Beauvais, 
France; 4 CHG Draguignan, Draguignan, France; 5 CHU 
Montpellier, Montpellier, France; 6 HIA Sainte-Anne, Toulon, France; 
7 CHU Limoges, Limoges, France; 8 CHG Aix en Provence, Aix en 
Provence, France
Background: Adjuvant Cx with vinorelbine plus cisplatin (VC) 
improves survival of resected NSCLC but has an immediate negative 
impact on QoL (Bezjak, JCO 2008). In advanced stages NSCLC, GC 
and DC have comparable efficacy and might be superior to VC in 
QoL outcomes. This trial was designed to provide with data on the 
optimal adjuvant Cx regimen.
Methods: Pts with stage IB to III resected (R0) NSCLC, without 
major postoperative complication, were eligible. Surgery has to be 
standardized. Cx consisted of cisplatin (75mg/m², D1) plus gem-
citabine 1250mg/m² (D1,8) or docetaxel (75mg/m² D1) for 3 cycles. 
The primary endpoint was QoL (EORTC QLQC30) and the trial was 
designed to detect a 10 points difference in QoL scores (α=0.05; 
power 80%). Relapse-free survival, overall survival (OS), safety 
profile and costs were the secondary endpoints.
Results: 136 pts (median age: 57 yrs, 74% males, pTNM: 32% IB, 
34% II, 34% III; histology: 55% ADC, 23% SCC) were included. 67 
and 69 pts were randomized in the GC and DC arms, respectively. 
Surgery was a lobectomy or a pneumonectomy in 77 and 15% of 
cases. No imbalance was found between arms regarding major pts 
characteristics. Overall, a Gr3/4 hematological toxicity occurs for 
33.8% and 21.7% of pts (p=0.11) and a Gr3/4 non-hematological tox-
icity occurs for 33.8% and 26.1% of pts (p=0.33), in the GC and DC 
arms. Compliance to QoL assessment was good (93%). At inclusion, 
global health status (GHS) scores (/100) were comparable between 
arms (mean score, 63.5 and 62.7, in the GC and DC arms, p=0.8). At 
the end of treatment (3rd month), GHS scores have slightly improve 
(mean score, 64.5 and 65.4, in the GC and DC arms, p=0.8). At the 
time of analysis, 15 pts (7 GC, 8 DC) have died. At 1 year, 100 and 
96.8% of the pts were alive in the GC and DC arms; At 2 years, 92.9 
and 89.8% of the pts were alive in the GC and DC arms (log-rank, 
p=0.88).
Conclusions: Adjuvant GC and DC have comparable effect on 
post-operative QoL and equivalent efficacy among pts with resected 
NSCLC. The GC and DC efficacy, safety profiles and QoL outcomes 
favorably compare with the results reported for the VC regimen. 
Detailed analyses will be presented at the meeting.
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Adjuvant docetaxel plus carboplatin compared with 
surgery only in patients with completely resected stage IB-
IIIA non-small cell lung cancer: final results of CSLC201/
TAX210 with Chinese Society of Lung Cancer
Wu, Yi-Long1, 3, 4; Yang, Xue-ning1; Chen, Gang1; Zhong, Wen-zhao1; 
Ben, Xiao-Song1; Gu, Li-Jia2; Liao, Ri-Qiang1; Yang, Jin-Ji1
1 Guangdong General Hospital, Guangzhou, China; 2 The 3rd 
Hospital, Sun Yat-sen University, Guangzhou, China; 3 Guangdong 
Lung Cancer Institute, Guangzhou, China; 4 Guangdong Academy of 
Medical Sciences, Guangzhou, China
Background: Adjuvant chemotherapy for resected non-small cell 
lung cancer (NSCLC) have shown significant OS advantages. Unless 
vinorelbine plus cisplatin whether other third generation doublet 
chemotherapy regimen improves survival of patients with non-
small-cell lung cancer is unclear. We aimed to compare the effect of 
adjuvant docetaxel plus carboplatin versus observation on survival in 
patients with completely resected NSCLC. 
Methods: 82 patients with stage IB-IIIA NSCLC from 3 centres in 
China were randomly assigned to 75mg/m(2) docetaxel plus AUC=5 
carboplatin (n=43) or to observation (n=39). The primary endpoint 
was disease free survival (DFS). The second endpoint was overall 
survival, response rate in the chemo group and safety. Analysis was 
by intention to treat. This trial was closed early by the EC as adjuvant 
chemotherapy became a standard therapy for resected NSCLC in 
2005. 
Results: 43 patients in the chemotherapy group and 39 in the obser-
vation group received their assigned treatment. 45 (54.9%) patients 
had stage IB disease, 20 (24.4%) had stage II disease, and 17 (20.7%) 
had stage IIIA disease. Adenocarcinoma accounted for 62.2% (51 
cases, Tab.1). The median chemotherapy cycles were 3. After a 
median follow-up of 51.5 months (range 3-69.1), DFS is in favor of 
adjuvant chemotherapy. The hazard ratio [HR] is 2.23; CI, 1.10 to 
4.54 (p=0.015). Median overall survival in both groups is not reached 
(Fig.1).  
  Adjuvant (%) Observation (%) Total
 Gender   
  male 28(54.9) 23(45.1) 51
  femal 15(48.3) 16(51.6) 31
 Age   
  median 59 63 61
 Histology   
  adenocarcinoma 27(52.9) 24(47.1) 51
  non-adeno. 16(51.6) 15(48.3) 31
 Stage   
  I  25(55.6) 20(44.4) 45
  II  8(40.0) 12(60.0) 20
  III 10(58.8) 7(41.1) 17
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Conclusion: Adjuvant docetaxel plus carboplatin extends disease 
free survival in patients with completely resected NSCLC.
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Indications and accuracy of repeat mediastinoscopy in a 
series of 100 cases
Call, Sergi1; Obiols, Carme1; Rami-Porta, Ramon1; Serra-Mitjans, 
Mireia1; Martinez, Elisabeth1; Iglesias, Manuela1; Saumench, Roser1; 
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1 Thoracic Surgery Service. Hospital Universitario Mutua de 
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Background: Remediastinoscopy remains a controversial procedure 
and some authors do not believe that this technique is a valuable tool 
for restaging the mediastinum because of adhesions and fibrosis.
The objective of this study is to evaluate the technical feasibility and 
the sensitivity, specificity and accuracy of repeat mediastinoscopy 
(reMS) in all its indications, specially in restaging non-small cell lung 
cancer (NSCLC) after induction therapy. 
Methods: From July 1992 to February 2009, 97 patients (88 men, 9 
women; median age: 61.3 years), underwent 100 reMS (three patients 
required a repeat reMS) for the following indications: restaging after 
induction therapy for cyto-histologically proven N2 disease (83 
cases), inadequate first mediastinoscopy (5: in 4 the indication was 
for suspected lymphoma), metachronous second primary (6) and 
recurrent lung cancer (6). Patients with positive reMS underwent de-
finitive chemotherapy or chemoradiotherapy. Patients in whom reMS 
was negative underwent thoracotomy for lung resection and system-
atic nodal dissection. Systematic nodal dissection was considered the 
gold standard to compare the negative results of reMS. Pathologic 
findings were reviewed and staging values (sensitivity, specificity, 
positive predictive value, negative predictive value, and diagnostic 
accuracy) were calculated using the standard formulas. 
Results: In the group of reMS for restaging after induction ther-
apy, the staging values were: sensitivity 0.74, specificity 1, positive 
predictive value 1, negative predictive value 0.79 and accuracy 0.87. 
In the group of other indications, sensitivity, specificity, positive 
predictive value, negative predictive value and accuracy were 1. Two 
patients with negative reMS were considered true negative by the 
follow-up: suspected lymphoma (20 months) and benign paratracheal 
cyst (36 months). There were the following complications: superficial 
wound infection, unintended lung biopsy, bleeding from superior 
vena cava and one intraoperative death due to injury to the innomin-
ate artery and heart arrest. 
Conclusion: Repeat mediastinoscopy is feasible in all the indica-
tions described. After induction therapy it is a useful procedure to 
select patients for lung resection with high accuracy. It is a reliable 
restaging procedure if other less invasive methods are negative or 
unavaliable.
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Does pneumonectomy compromise adjuvant chemotherapy 
delivery?
Planchard, David3; Girard, Philippe 4; Boudaya, Mohamed Sadok4; 
Gossot, Dominique4; Debrosse, Denis4; Besse, Benjamin3; Tredaniel, 
Jean1; Monnet, Isabelle2; Caliandro, Raffaele4; Soria, Jean-Charles3; 
Magdeleinat, Pierre4; Validire, Pierre4
1 Hopital saint louis, Paris, France; 2 Centre Hospitalier 
Intercommunal Créteil, Creteil, France; 3 Institut Gustave Roussy, 
Villejuif, France; 4 Institut Mutualiste Montsouris, Paris, France
Background: Since 2004, adjuvant chemotherapy (AC) has become 
a standard of care in Non-small Cell Lung Cancer (NSCLC) in patho-
logical stages II and III after complete resection. However, because of 
its specific morbidity, pneumonectomy might compromise subsequent 
delivery of AC.
Methods: In a retrospective monocenter study, the morbidity of 
pneumonectomy over a period of 4 years (January 2004 to De-
cember 2007) was estimated. For this study, we arbitrarily defined 
AC-eligible patients as having pathological stages II or III NSCLC, 
age<76 years, and no neo-adjuvant treatment. The proportion of AC-
eligible patients who actually received AC after pneumonectomy was 
compared with that observed in a sample of patients who underwent a 
lobectomy for NSCLC during the same period by the same surgeons.
Results: From January 2004 to December 2007, three surgeons 
performed 105 pneumonectomies with mediastinal lymphadenectomy 
for NSCLC. The median age was 60 years (range: 43 to 88 years), 87 
were male and 14 patients had received a neo-adjuvant treatment. The 
pathological stages (pTNM or ypTNM) were I (n=9), II (n=30), IIIA 
(n=44), IIIB (n=22). The median number of resected lymph nodes 
was 14, pneumonectomy was right-sided in 40 % of cases. Histology 
was squamous cell carcinoma in 58.7% of cases. Postoperative com-
plications occured in 27 patients, including infectious complications 
in 21 cases. The mortality rate at 30 days was 4.7% (5/105). Among 
70 AC-eligible patients who were alive at day 30 (mean age 60.0 
years, male 81.4%, squamous cell 60%, stages IIA 2.9%, IIB 32.8%, 
IIIA 40.0%, IIIB 24.3%), only 44 (63%) received at least one cycle 
of AC. In a sample of 117 AC-eligible patients who underwent a 
lobectomy for NSCLC during the same period (mean age 60.0 years, 
male 53.0%, squamous cell 24.7%, stages IIA 10.2%, IIB 32.5%, IIIA 
43.6%, IIIB 13.6%), 92 patients (79%) received at least one cycle of 
AC (44/70 vs 92/117: p = 0.019).
Conclusion: Despite morbidity and mortality rates similar to those 
reported in the literature, pneumonectomy per se seemed to com-
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promise the delivery of AC in this series, which may affect the long-
term prognosis of these patients. These results need to be confirmed 
in larger studies and other centers. If pneumonectomy proves to be 
an independent factor that compromises AC delivery, pre-operative 
chemotherapy might be considered as an option when a pneumonec-
tomy appears necessary. 
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Limited resection trial for pulmonary ground-glass opacity 
nodules: case selection based on high resolution computed 
tomography
Yoshida, Junji1; Ishii, Genichiro2; Nagai, Kanji1; Nishimura, 
Mitsuyo1; Hishida, Tomoyuki1; Ito, Hiroyuki3; Yokose, Tomoyuki4; 
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Background: Japanese researchers have reported good correlation 
between radiologic and pathologic findings in early lung adenocarcin-
omas. For negative margin confirmation, we found a technique using 
lavage and cytological examination.
Objectives: Confirm limited resection efficacy as radical surgery in 
patients with high resolution CT indicated minimally invasive lung 
cancer. Confirm intraoperative cytology as a negative margin indica-
tor and reliable margin non-recurrence predictor. 
Methods: Enrollment requires patients with a tumor ≤2 cm in diam-
eter, diagnosed or suspected as a clinical T1N0M0 carcinoma in the 
lung periphery based on a CT scan. They had to have a high-resolu-
tion CT scan indicating a sub-solid nodule with tumor disappearance 
ratio; TDR ≥0.5. (TDR = 1- DM/DL; DM: maximum tumor diameter 
on mediastinal settings, DL: maximum tumor diameter on lung set-
tings). Patients with a malignancy history within the past 5 years or 
those unfit for lobectomy and systematic lymph node dissection are 
excluded. 
We perform a wedge or segmental resection. The used stapling car-
tridges are washed with 50 ml saline. Washing saline is centrifuged 
and sediment stained using Papanicolaou’s method and examined 
for cancer cells. If cytology is cancer positive, additional margin is 
resected, and cytologic examination repeated. If the second exam is 
positive, a routine lobectomy and systematic lymph node dissection 
is performed. 
Patients are followed up every 6 months by chest CT for the first 3 
years, and annually thereafter for at least 5 years. The endpoint is 5 
year local recurrence free survival rate.
Results: This prospective study started in November 2003, and 81 
patients have been enrolled as of December 2008. This is 4.5% of all 
resected lung cancer patients during this period. There were 32 men 
and 49 women, aged 30-75, with an average 61 years. Tumor sizes 
ranged from 7 to 20 mm on high-resolution CT, averaging 15 mm. 
There were 9 Noguchi type A tumors, 44 type B tumors, 21 type C 
tumors, 3 inflammatory fibroses, one malignant lymphoma, one atyp-
ical adenomatous hyperplasia, one atypical cuboidal cell hyperplasia, 
and one alveolar hyperplasia. All cancers showed no vessel invasion. 
Although no positive cytology results were obtained, pathologically 
positive margin was reported after surgery in one type C patient. He 
later underwent a routine lobectomy and systematic lymph node dis-
section. There was no clear correlation between tumor size, TDR, and 
Noguchi subtype. No mortality or recurrence has occurred, but one 
patient developed postoperative pneumothorax and pneumonia, and 
another hemorrhagic gastric ulcer.
Summary: We are on a limited resection trial, selecting patients 
based solely on high resolution CT findings. So far, no recurrence 
has occurred, and high resolution CT scans appear to predict non- or 
minimally invasive GGO lung cancers with high reliability.
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The efficacy of computed tomography-guided 
bronchoscopic metalic coil marking for small peripheral 
pulmonary lesion
Toba, Hiroaki; Kondo, Kazuya; Miyoshi, Takanori; Nagao, Taeko; 
Takizawa, Hiromitsu; Kenzaki, Koichiro; Sakiyama, Shoji; Tangoku, 
Akira
Department of Thoracic, Endocrine Surgery and Oncology, 
Tokushima, Japan
Background: Small peripheral pulmonary lesions have frequently 
discovered with the advance of Computed Tomography (CT). But we 
can’t often detect these lesions during thoracoscopic surgery. There-
fore several marking techniques have been introduced in many insti-
tutes. The hook-wire method used to be introduced in our institute. 
But it carries the risk of pneumothorax, air embolism, dislocation of 
wire and so on. Since we have experienced a case of fatal air embol-
ism, we have performed fluoroscopy-assisted thoracoscopic resection 
after CT-guided bronchoscopic metallic coil marking (FATS-CM) to 
detect lesions certainly. We evaluated the efficacy of this method.
Materials and Methods: Forty eight patients (11 men and 37 
women, mean age 62.7 years) with 53 small peripheral pulmonary 
lesions were performed FATS-CM. The average maximal diameter 
of the lesion on CT was 11.9 mm, with a range from 6 to 25 mm. 
Preoperatively all lesions were not histologically diagnosed. Metallic 
coil was instilled into the nearest bronchus to lesion under CT fluoro-
scopic guidance with ultrathin bronchoscopy. At that time, we used 
the virtual bronchoscopic navigation (VBN) system to select the best 
root to the lesion. Afterwards we performed thoracoscopic resection 
using a C-arm-shaped roentgenographic fluoroscope. In principle, 
wide wedge resection (WWR) was performed by 3 trocars at first and 
the final procedure was determined by intraoperative histodiagnosis 
of lesions using frozen sections.
Results: We could instill coils into the objective bronchi in all cases 
(100%). The average distance from lesion to coil was 6.5 mm, with 
a range from 0 to 15 mm. Pneumothorax was recognized in one case 
(0.02%) as complication but fatal complication such as air embolism 
and tension pneumothorax didn’t occur. We also could instill coil for 
each lesion in 4 patients (9 lesions) who had multiple lesions. And 
the VBN system was used in 4 cases, which examination time tended 
to be shorter than that of other 44 cases (34 minutes vs. 44 minutes, 
p=0.10) even if there is no significant difference. WWRs were cer-
tainly performed for 52 (98%) of 53 lesions by 3 trocars during thora-
coscopic surgery. Lobectomy was initially performed in only one case 
by reason of the migration of coil. Finally, 36 lesions were diagnosed 
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as bronchioloalveolar adenocarcinoma (BAC), which consisted of 25 
type A/B, 9 type C and 2 type F according to Noguchi’s classification 
and 4 as adenocarcinoma, 4 as AAH, 2 as metastatic tumor and 6 as 
benign lesion. Regarding BAC, WWRs were only performed in 25 of 
30 lesions diagnosed as AAH and type A/B and in 7 lesions showing 
>50% ground-grass opacity (GGO) area of 9 lesions diagnosed as 
type C. But there were no local-regional recurrences in all cases. The 
median follow-up times were 31.8 months. 
Conclusion: Using our marking method, we can perform WWR cer-
tainly with a sufficient surgical margin for small peripheral pulmon-
ary lesions by 3 torcars during thoracoscopic surgery. Our procedure 
also was found to be: (1) safe in terms of no fatal complication, (2) 
feasible in terms of the possibility of correspondence to multiple 
lesions and (3) favorable in terms of the possibility to prevent the 
excessive resection of normal lung tissue and preserve respiratory 
function.
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Percutaneous computed tomography-guided lung 
biopsy and pleural dissemination: an assessment by 
intraoperative pleural lavage cytology
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Background: Percutaneous computed tomography (CT)-guided 
needle biopsy remains one of the most important diagnostic tools in 
the management of lung nodules. The purpose of the present study 
was to use intraoperative pleural lavage cytology (IPLC) to evalu-
ate whether percutaneous CT-guided transthoracic needle biopsy 
is associated with an increased risk of pleural dissemination. We 
compared the results of IPLC between a group of patients with sur-
gically resected lung cancer who underwent percutaneous CT-guided 
transthoracic needle biopsy and a concurrent cohort of patients who 
did not undergo this procedure.
Methods: The study was approved by our Institutional Review 
Board, and written informed consent was obtained from all patients 
before the procedure. Patients who had macroscopic pleural effusion, 
dissemination, or severe adhesion were excluded from the analysis. 
CT-guided lung biopsy was performed before surgery in 171 (34.8%) 
of 491 patients. A coaxial biopsy system was used that consisted of 
a 19-gauge introducer needle and a 20-gauge core biopsy needle. 
A total of 412 (83.9%) of the 491 patients underwent intraoperative 
pleural lavage cytology (IPLC) just after thoracotomy. IPLC was 
performed immediately after opening the thorax, after the pleural 
cavity was gently washed with 50 mL of saline. Cytologists classified 
the specimen into three categories: Papanicolaou classes I, II, and III 
as negative and classes IV and V as positive.
Results: The sensitivity of the CT-guided needle biopsy was found 
to be 95.9%, and its positive predictive value was 100%. No patients 
had implantation of cancer cells in the chest wall after a median 
follow-up of 20.2 months. IPLC results were positive for 5 (2.9%) 
of 171 patients who underwent CT-guided biopsy before surgery, in 
contrast to 13 (5.4%) of 241 patients who did not undergo biopsy 
before surgery. The difference between the biopsy and non-biopsy 
groups was not statistically significant (Fisher’s exact test: p = 0.217). 
When the analysis was limited to patients with Stage IA disease, 
IPLC results compared to positive for 1 (0.8%) of 128 patients who 
underwent CT-guided biopsy and 3 (2.7%) of 110 patients who did 
not undergo biopsy. This difference was also not statistically signifi-
cant (Fisher’s exact test; p = 0.338).
Conclusions: When invasive diagnostic or therapeutic procedures are 
provided, it is necessary to consider both the benefits and the risks of 
these options. We found no significant association between per-
cutaneous CT-guided lung biopsy and intraoperative pleural lavage 
cytology results, even in patients with Stage IA disease. Percutaneous 
CT-guided lung biopsy with a co-axial needle does not seem to cause 
pleural dissemination.
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Stage I non-small cell lung cancer in non-surgical patients: 
the radiofrequency ablation option
Ambrogi, Marcello C.1; Dini, Paolo1; Fanucchi, Olivia1; Cioni, 
Roberto2; Deliperi, Annalisa3; Davini, Federico1; Picchi, Alessandro1; 
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Introduction: Although surgical resection remain the mainstay of 
treatment for patients with early stage non-small cell lung cancer 
(NSCLC), about on fifth of these one’s are unsuitable to this treat-
ment. Radiofrequency ablation (RFA) has recently gained increas-
ing attention as an alternative minimally-invasive option. We report 
herein one of the largest series from a single referral centre in Europe, 
with a long-term follow-up.
Methods: From October 2001 to March 2008 we performed 76 RFAs 
of 55 stage I NSCLC in 53 patients. Two patients were treated for 
2 separate lesions. Nine lesions were re-treated up to 5 times. They 
were 43 males and 10 females with a mean age of 74 years (range 
of 40 – 86). All patients had clinical or pathological evidence of 
NSCLC, which was in stage IA in 43 cases and in stage IB in the 
other 12 cases. The mean size of the lesions was 2.57 cm (range of 
1.1 – 7 cm). The procedure was always performed under local anaes-
thesia and conscious sedation. A generator of RF with max power 
output of 200-250 W was utilized together with a needle with nine 
deployable electrodes (AngioDynamics, Queensbury, NY). The target 
temperature of operation was 90°C, which was maintained for 15-27 
minutes according to the size of the lesions. The most of the proced-
ures were performed under CT guidance. Six peripheral lesions were 
ablated under ultrasonography guidance. 
Results: RFA was technically successful in all cases. No mortality 
was recorded and morbidity consisted in 9 cases of partial pneumo-
thorax, 4 requiring pleural drainage. At a mean follow-up of 40.7 
months (range of 6 – 82) we recorded a 64.8% of complete responses, 
with a higher rate in the stage IA lesions (73.8%) (Image 1). Median 
overall survival was 30.9 months and that cancer related (CR) 34 
months, also in this case with significant better results in stage IA 
disease. Kaplan-Meier analysis yielded an actuarial survival of 83% 
at 1 year (CR 86%), 63% at 2 years (CR 77%), 34% at 3 years (CR 
49%), 23% at 3 years (CR 33%).
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Conclusions: RFA ablation of early stage NSCLC seems to be a safe 
and efficacious minimally-invasive therapy also in the long-term per-
iod, above all in stage IA disease. Notwithstanding these encouraging 
results, RFA remains an alternative local therapy only when surgery 
can’t be performed. 
PD12.4.7 NSCLC - Early Stage, Tue, 12:30 - 14:00
CT guided percutaneous radio frequency ablation in 
treatment of nonoperable lung cancer: clinical analysis of 
72 cases
Hu, Mu; Zhi, Xiuyi; Liu, Baodong; Liu, Lei; Zhang, Yi; Wang, 
Ruotian; Chen, Donghong; Xu, Qingsheng; Su, Lei; Qian, Kun
Lung Cancer Center Xuanwu Hospital Capital Medical University, 
Beijing, China
Objective: To investigate the efficacy and safety of radiofrequency 
ablation (RFA) in treatment of advanced lung cancer. 
Methods: Seventy-two patients with advanced local lung cancer 
were treated with RFA at the average temperature of 90 degrees C 
under local anesthesia under CT scan guide. 102 times of RFA were 
done in 72 patients, 21 of them being treated with 2 ablation sites and 
9 treated with tree ablation sites. Followed up was conducted for3 - 
24 months. The outcomes were evaluated by plain and contrast spiral 
CT scan and SPECT scan. 
Results: During and after RFA 35 patients experienced cough and 
hemoptysis. After RFA pneumothorax was seen in 47 of the patients, 
1 need closed drainage . No sever complications and mortality. Con-
trast spiral CT scanning showed devascularization and/or reduction 
of tumor size in 51 lesions. The T/N Value of SPECT decreased in 69 
lesions. 
Conclusion: Removing tumor load rapidly and with excellent short-
term outcome, percutaneous RAF is safe to treat advanced local lung 
cancer.
PD12.4.8 NSCLC - Early Stage, Tue, 12:30 - 14:00
A randomised trial of radical radiotherapy with or without 
low dose gemcitabine in medically inoperable patients with 
T1-2 N0-1 M0 non-small cell lung cancer (NSCLC)
Price, Allan1; Yellowlees, Ann2; Faivre-Finn, Corinne3; Gilligan, 
David4; Snee, Michael5; Erridge, Sara1; Mohammed, Nazia6; Russell, 
Susan7
1 Edinburgh Cancer Centre, Edinburgh, UK; 2 QUANTICS, Melrose, 
UK; 3 Christie Hospital, Manchester, UK; 4 Addenbrooke’s Hospital, 
Cambridge, UK; 5 Yorkshire Cancer Centre, Leeds, UK; 6 Beatson 
Oncology Centre, Glasgow, UK; 7 CACTUS, Edinburgh, UK
Background: Preclinical and phase I data suggest gemcitabine to 
be a potent radiosensitiser. This multicentre phase III study was set 
up to assess whether the addition of low dose gemcitabine to radical 
radiotherapy improved event-free survival in patients with stage I-II 
NSCLC who were medically inoperable, but closed early because of 
poor accrual.
Aim: To determine whether low dose gemcitabine increases event–
free survival in patients with T1-2 N0-1 M0 NSCLC deemed unfit for 
surgery. 
Methods: Patients with T1-2 N0-1 M0 NSCLC deemed unfit for 
surgery were randomised to 3D conformal radiotherapy delivering 55 
Gy in 20 fractions over 4 weeks to known sites of cancer with (Arm 
B) or without (Arm A) 100 mg/m2 weekly gemcitabine. Elective 
nodal irradiation was not given. CT assessment of response was 
carried out at 3 and 24 months and lung volumes and gas transfer 
measured at baseline, 3 and 12 months.
Results: 111 patients were randomised between March 2003 and De-
cember 2005, of whom 4 withdrew consent and 2 were lost to follow-
up. Median age was 75 (range 49-88) years and 67 (63%) were male. 
86 (81%) were PS0-1 and 31 (30%) Charlson index 2 or greater. 
Event-free survival in arm A and B respectively was 46% and 46% at 
2 years and 31% and 39% at 3 years (p = 0.38), while overall survival 
was 57% and 52% at 2 years and 37% and 45% at 3 years (p = 0.53). 
Two deaths from accelerated interstitial lung disease were seen in 
arm B, but toxicity was otherwise mild. Of those who relapsed from 
their cancer, over half did so at distant sites.
Conclusion: No evidence of an improvement in event-free survival 
was seen with the addition of weekly gemcitabine at this dose for pa-
tients with early stage NSCLC unfit for surgery, although the power 
of the study was low. Despite significant co-morbidities, mortality in 
this population was largely due to cancer. While newer radiotherapy 
techniques such as stereotactic treatment might improve local control, 
effective systemic therapy will also be important in this group. 
PD12.5.1 NSCLC - Early Stage, Tue, 12:30 - 14:00
The risk of relapse in resected small non small cell lung 
cancer is not small
Sezhiyan, Ananth; Gopalan, Priya; Goodgame, Boone; Gao, Feng; 
Govindan, Ramaswamy
Washington University School of Medicine, St Louis, MO, USA
Background: The proposed IASLC staging system for non-small cell 
lung cancer (NSCLC) defines T1a tumors as less than 2 cm. Five year 
survival in pathologic T1a tumors was 84% in this international data 
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set. The rates of tumor recurrence from this data set have not been 
published. We describe here the rates of recurrence and risk factors 
associated with relapse in patients with resected tumors 2 cm or less 
in size from a large institutional database.
Methods: Patients who had curative resection for stage I NSCLC at 
our institution from 1990-2005 with tumor sizes less than or equal to 
2 cm were included in this retrospective analysis. Recurrence rates 
were estimated by the Kaplan-Meier method. Death without evidence 
of recurrence was considered to be a censoring event in this analy-
sis. Clinical and pathologic variables, including gender, age, type 
of resection, T status, histology, tumor grade, and tumor size were 
examined for association with recurrence. 
Results: We identified 386 patients who met inclusion criteria. 
Median age was 67 and 55% of patients were male. Lobectomy was 
performed in 78% of patients, wedge or segmental resection in 21%, 
and pneumonectomy in 1%. Pathologic findings showed T1 and T2 
tumors in 83% and 17% respectively; adenocarcinoma, squamous 
cell carcinoma, and other NSCLC histologies in 56%, 24%, and 20% 
respectively; high grade in 33%; and a median tumor size of 1.5 cm. 
Median duration of follow-up was 4.9 years and 5-year survival was 
68%. A total of 58 patients (15%) developed recurrent disease at a 
median time to recurrence of 24 months. The 5-year Kaplan-Meier 
estimate of recurrence was 17%. An additional 42 patients (11%) 
developed second primary lung cancers, as defined by standard 
clinical criteria. Independent risk factors for recurrence were surgery 
other than lobectomy (p=0.001) and high tumor grade (p=0.004). T2 
classification (including pleural invasion or major bronchus inva-
sion) was not associated with increased recurrence rates. Independent 
risk factors for increased mortality were age (p<0.0001) and type of 
resection (p=0.003) 
Conclusions: The risk of relapse following resection of “small” 
NSCLC is not insignificant. 
PD12.5.2 NSCLC - Early Stage, Tue, 12:30 - 14:00
NSCLC stage I revisited: current 6th TNM edition 
compared with the proposed 7th edition in a cohort of 
stage I NSCLC population of Argentina 
Poleri, Claudia; Morero, José L.; Rayá, Mercedes; Martín, Claudio
Hospital María Ferrer, Buenos Aires, Argentina
The clinical observation that patients carrying stage I NSCLC present 
different clinical courses and may respond differently to similar treat-
ments is not completely understood.
Together with advances in molecular biology, the accurate staging of 
lung cancer is essential in planning treatment, and has fundamental 
prognostic significance.
Our purpose was to apply the IASLC revision of TNM staging pro-
posed on the 7th edition on NSCLC to previously stage I patients in 
order to identify subgroups of higher risk of recurrence which could 
help to guide new treatment strategies.
We analyzed 77 patients at “María Ferrer” Hospital, Argentina, with 
NSCLC and complete surgical resection, without any posterior clin-
ical treatment pT1-T2 pN0M0. According 6th edition system there 
were 23 (30 %) patients in stage IA and 54 (70 %) in IB. Among 
them, 13 (17%) were women and 64 (83%) were men; median age: 
62 (42-81) years, median follow-up time 59 months. The median 
overall survival was 108 months, 68 % at 5 years. 
We regrouped T factor in: 14% T1a (≤2 cm), 14% T1b (>2 but ≤3 
cm), 35% T2a (>3 cm but ≤5 cm), 25% T2b (>5 cm but ≤7 cm) and 
12% T3 (>7 cm). Tumours with visceral pleura invasion beyond the 
elastic layer (PL 1) or surface (PL2) were considered T2a if ≤ 5cm. 
Cases staged IA (30%) kept in this category and those staged in IB 
(70%) changed to IB (35%), IIA (25 %) and IIB (12 %). Univari-
ate analyses did not demonstrate significant differences between 
groups neither 6th nor 7th edition staging, may be because of small 
subgroups. We observed that stage IB 6th edition had 88 months of 
median time to progression (TTP), and that new proposed stage IB 
had 108 months of median TTP. Patients now included in IIA and IIB 
proposed stages (previously included in IB stage) had 87 months and 
53 months median TTP respectively.
This study showed that proposed system better describes the early 
stages cases, improving distinction between IB and IIA. The IIB 
group appears with distinctive poor prognosis.
We found that proposed changes better differentiate patients with di-
verse prognosis. In early 6th edition the IB stage was a heterogeneous 
group including patients with dismal prognostic factors, like large 
tumors. The 7th edition move these patients to IIA and IIB, and our 
study showed up that proposed changes better differentiate patients 
with different prognosis, which is one of the objectives of the TNM 
classification.
PD12.5.3 NSCLC - Early Stage, Tue, 12:30 - 14:00
Comparison of survival difference according to primary 
tumor size between the current (6th) and the proposed 
(7th) TNM staging system in non-small cell lung cancer (a 
single center experience)
Sohn, Byeong Seok2; Sohn, Hee-Jeong1; Choi, Chang-Min2; Shim, 
Tae Sun2; Kim, Woo Sung2; Kim, Young-Hee2; Kim, Dong-Kwan2; 
Park, Seung-Il 2; Lee, Dae Ho2; Suh, Cheolwon2; Lee, Jung-Shin2; 
Kim, Sang-We2
1 Bundang Jesaen General Hospital, Sungnam, Korea; 2 Asan 
Medical Center, Seoul, Korea
Background: Recently, the seventh version of the TMN staging sys-
tem was proposed, however, the current (6th) version of TMN staging 
system still on wide usage. We investigated the differences between 
the current and the proposed staging system by the primary tumor 
characteristics (T), one of the descriptor of TMN staging system and 
compared overall survival (OS) rate among both the staging system.
Methods: We found 390 patients with a diagnosis of NSCLC with 
stage of pTxN0M0 from December 1997 to December 2002. We ana-
lyzed the patient’s OS rates according to T stage of both the staging 
system.
Results: Both the current T staging system and the proposed T 
staging system showed a statistical significance in discriminat-
ing the patient’s overall survival according to the grade of T stage 
(both, P<0.05). In 95 patients who had T1N0M0 in the current (6th) 
staging system, 39 patients classified to T1a in the proposed (7th) 
staging system, and 56 patients to T1b. There was no statistically 
significant difference in OS rates of between the patients with T1a 
and T1b (P=0.867). In 239 patients who had T2N0M0 in the current 
(6th) staging system, 186 patients classified to T2a in the proposed 
(7th) staging system, 32 patients to T2b and 21 patients to T3. In 
this current T2 stage, there was a significant difference in patient’s 
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OS rate according to the sub-divided T stage of the proposed (7th) 
staging system (P<0.001). The median OS did not reach in the pa-
tients who classified to T2a in the proposed (7th) staging system until 
120-month follow-up; however, the median survival was 56.4 months 
in the patients who classified to T2b and 56.6 months in the patients 
who classified to T3. 
All forty-four patients, who had T3N0M0 stage in the current (6th) 
staging system, still showed T3 in the proposed (7th) staging system. 
The median OS was 42.2 months. In 12 patients who had T4N0M0 
in the current (6th) staging system, there were seven patients who 
showed down-staged T3 according to the proposed (7th) staging sys-
tem, and only five patients still had T4 in the proposed (7th) staging 
system
Conclusions: The proposed (7th) staging system has some changes 
from the current (6th) staging system. In T staging system, the T2 
stage was subdivided according to the primary tumor size, and there 
was a statistical significance in discriminating the patients’ prognosis. 
Nevertheless, in T1 stage, we did not find the significant difference in 
survival rate between T1a and T1b.
PD12.5.4 NSCLC - Early Stage, Tue, 12:30 - 14:00
Role of new IASLC revised staging system in radically 
resected stage IIIa-b NSCLC with adjuvant therapy 
Lequaglie, Cosimo; Giudice, Gabriella; Garramone, Margherita; 
Marasco, Rita Daniela
National Cancer Institute Rionero in Vulture, Rionero in Vulture, Italy
In the Thoracic Surgery Department of the National Cancer Institute 
of Rionero in Vulture, Italy, a retrospective study was performed on 
lung cancer patients with advanced stage of disease with the aim of 
evaluate the role of new IASLC Revised Staging System in radically 
resection with adjuvant therapy and to analyse long-term results. 
From May 2004 to August 2008, 51 patients underwent surgery for 
advanced stage lung cancer. Forty-five were males and 6 females. All 
the subjects were completely staged preoperatively also by PET/CT 
scan. In order to establish operability criteria, we considered some 
selection parameters. Patients general conditions were evaluated 
using Karnofsky score accepting only the ones with 70% or more 
for surgery, all the cases performed cardio-respiratory functional 
evaluation. Patients with: a) FEV1 <60% of predicted value or FEV1 
<1 l; b) PaO2 <60 mmHg e PaCO2 >40 mmHg were excluded from 
surgery. 
Neo-adjuvant chemotherapy (CDDP-based 3 cycles) were given to 4 
T2N2 tumor patients.
We performed surgery procedure according to cStage: 25 bi- or 
simple lobectomies (7 associated thoracectomies), 5 wedge resections 
(2 associated thoracectomies), 2 pneumonectomies, 6 VATS pleurec-
tomies, 3 VATS talc poudrages, 5 pericardial windows, 4 VATS 
mediastinal dissections, 1 thoracectomy.
Histological examination showed 23 adenocarcinomas (3 associ-
ated BAC), 15 squamous carcinomas, 5 adenosquamous carcinomas, 
1 mucoepidermal carcinoma, 1 carcinosarcoma and 6 no-defined 
carcinomas (all T4). 
Twelve tumors were classified T3N0, 3 T1N2, 5 T2N2, 2 T3N1, 9 
T3N2, 7 T4N0 and 13 T4N2.
We considered the previous CF Mountain 1997 Staging System and 
the new IASLC 2009 revision. According 1997 Staging System there 
were 12 IIb, 19 IIIa and 20 IIIb; according the new IASLC revision 
there were 12 IIb, 26 IIIa and 13 IIIb.
Adjuvant chemotherapy (CDDP-based 4 cycles) were given to all 
patients but 10. Only 7 patients received adjuvant sequential medias-
tinal radiation. 
According to the 2 different classifications (1997 versus 2009) the ac-
tuarial 3-years overall survivals predicted with Kaplan-Meier method 
were similar: 24%; there was no difference also for the Stage IIb: 
26%. According to the 1997 CF Mountain Staging the Stage IIIa ac-
tuarial 3-years overall survival was 34% and 11% for the Stage IIIb.
According to the new IASLC 2009 revision the Stage IIIa actuarial 
3-years overall survival was 49% and 0% for the Stage IIIb.
To reinforce the new 2009 IASLC Revised Staging System we 
reported a different survival rate according to the different T4N0 
location in Stage IIIb.
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A pilot trial of erlotinib in combination with stereotactic 
body radiation therapy (SBRT) for patients with recurrent 
non-small cell lung cancer (NSCLC)
Kavanagh, Brian D.1; Abdulrahman, Ramzi2; Camidge, D R.1; 
Gerber, David E.2; Bunn, Paul A.1; Schiller, Joan2; Choy, Hak2; 
Gaspar, Laurie E.1; Wu, Jean2; King, Tracy3; Timmerman, Robert D.2
1 Department of Radiation Oncology, University of Colorado 
Denver School of Medicine, Aurora, CO, USA; 2 University of Texas 
Southwestern, Dallas, TX, USA; 3 University of Colorado Cancer 
Center, Aurora, USA
Background: Erlotinib is an orally administered molecular-targeted 
EGFR tyrosine kinase inhibitor that improves overall survival in 
recurrent NSCLC. Stereotactic body radiation therapy (SBRT) 
is a potent spatially targeted therapy that provides a high rate of 
local control for discrete metastatic lesions. We have previously 
established the safety of combining EGFR inhibition and cranial 
stereotactic radiosurgery for recurrent brain tumors [1]. The present 
IRB-approved prospective study explored the safety and efficacy of 
combining erlotinib and SBRT for recurrent NSCLC.
Methods: Eligible patients had ≤6 discrete, measurable, active extra-
cranial lesions on PET scan after receiving at least one prior chemo-
therapy regimen for NSCLC. The treatment plan involved erlotinib 
(starting dose, 150 mg po/day) followed by SBRT to all sites 1-4 
weeks after the initiation of erlotinib. SBRT was given in 1-5 fractions 
according to guidelines established in prior studies of SBRT for meta-
static disease; conservative tumor and normal tissue dose constraints 
were applied. Maintenance erlotinib continued until disease progres-
sion or intolerable toxicity. Endpoints included in-field local control, 
out-of-field distant metastasis (DM), and overall survival (OS).
Results: Twelve patients have been enrolled to date: 6 female, 6 
male; median age, 66 yrs (range, 56-86); 2 or more prior regimens, 
n=5; median number of sites irradiated, 2 (range 1-5). A total of 24 
lesions were treated with SBRT to a median dose of 31.5 Gy in 3 
fractions (range, 16-40 in 1-5 fractions). Two patients discontinued 
erlotinib because of intolerable rash. Four patients had grade 3 or 
higher toxicity probably or definitely attributable to therapy: rash 
(1 grade 3), diarrhea (1 grade 3, 1 grade 4), and fatigue (1 grade 4). 
Eight patients remain alive after a median follow-up of 8.6 months, 
and median OS has not been reached. Among 24 lesions irradiated, 
only 1 in-field failure has been observed, occurring 10 months after 
SBRT. The 6 month actuarial DM-free survival estimate was 50%.
Conclusions: The combination of erlotinib and SBRT was well toler-
ated and rendered in-field progression to be minimal while providing 
encouraging rates of DM-free and OS that compare favorably with 
reports of erlotinib alone. Further investigations of the paradigm of 
combining molecular-targeted and spatially-targeted agents are war-
ranted for specific cancer types.
References: 
1. Schwer AL, Damek DM, Kavanagh BD, et al. A phase I dose-escalation study of 
fractionated stereotactic radiosurgery in combination with gefitinib in patients with 
recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 70(4):993-1001, 2008.
PD13.1.2 Novel Therapeutics, Tue, 12:30 - 14:00
Induction erlotinib therapy in stage IIIA-N2 non-small cell 
lung cancer 
Zhong, Wen-Zhao; Yang, Xue-Ning; Guo, Ai-Lin; Chen, Hua-Jun; 
Su, Jian; Liao, Ri-Qiang; Zhou, Qing; Nie, Qiang; Xu, Chong-Rui; 
Yang, Jin-Ji; Wu, Yi-Long 
Guangdong Lung Cancer Institute, Guangzhou, China
Background: Stage IIIA NSCLC represents a relatively heterogen-
eous group of patients with ipsilateral mediastinal (N2) lymph nodes 
involvement. The relative roles of treatment modalities are not clearly 
defined. The epidermal growth factor receptor (EGFR) tyrosine kin-
ase inhibitor (TKI) may provide dramatic responses in patients with 
pulmonary adenocarcinoma carrying EGFR activating mutations. The 
purpose of this study is to evaluate the value of induction erlotinib 
therapy in IIIA-N2 (confirmed by mediastinoscopy) non-small cell 
lung cancer (NSCLC) selected by EGFR gene analysis and to explore 
a new treatment strategy for this subset. 
Methods: A Phase II trial conferring induction EGFR-TKI therapy 
is currently recruiting participants (ClinicalTrials.gov Identifier: 
NCT00600587). Patients with resectable NSCLC of stage IIIA-N2 
confirmed by mediastinoscopy were assigned to induction erlotinib 
therapy arm or induction gemcitabine/carboplatin(GC) arm based on 
the EGFR mutations analysis (Figure 1 Flow chart). 
Study type: Interventional. 
Study Design: Active Control, Factorial Assignment, Non-Random-
ized, Open Label, Safety/Efficacy Study, Treatment; Primary out-
come measures: Response to induction therapy, disease free survival; 
Estimated enrollment: 46 cases.
Results: From Jan 2008 till now, six patients with IIIA-N2 pulmon-
ary adenocarcinoma confirmed by mediastinoscopy were enrolled in 
the trial. The two cases with EGFR activating mutation were assigned 
to the erlotinib arm. After 30 days of erlotinib induction therapy, 
both of them got a stable disease. In the other group, the four cases 
harboring wild-type EGFR received 3 cycles chemotherapy of GC 
regimen and got a 50% response rate (2 PR, 1 SD and 1 PD). (Table 1 
Patient profile)
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Gender Arms Age Smoke N2 
sta-
tion
Medi-
astinos-
copy
EGFR 
muta-
tion 
(T)
EGFR  
muta-
tion 
(N)
Re-
sponse 
(T)
Re-
sponse 
(N)
Thor-
ac-
tomy
Pro-
gres-
sion
Death The last 
follow 
up
Female erlotinib 77 Never 2,4 2008 
8.8
- 19 -25% 19% - 2009 
2.9
2009 
2.9
2009 2.9
Male erlotinib 64 Heavy 2,4 2008 
12.2
21 21 -9% 7% - - - 2009 3.8
Male GP 45 Heavy 2,4 2008 
1.2
WT WT -56% 100% 
(PCR)
2008 
3.20
- - 2009 3.8
Male GP 70 Heavy 2 2008 
1.14
- WT 35% PD - 2008 
7.10
2009 
2.18
2009 2.18
Female GP 54 Never 2,4 2008 
4.17
WT WT -23% 100% 
(PCR)
2008 
7.11
- - 2009 3.8
Male GP 75 Heavy 5 2008 
9.9
WT WT -21% 0% - - - 2009 3.8
Conclusions: The EGFR mutation status of the primary carcinomas 
was consistence with the N2 disease. Induction erlotinib therapy in 
IIIA-N2 NSCLC based on the EGFR gene analysis is a promising 
strategy. Further studies and larger sample sizes are warranted to 
establish the role of induction EGFR-TKI therapy in patients with 
IIIA-N2 NSCLC.
PD13.1.3 Novel Therapeutics, Tue, 12:30 - 14:00
A phase I study of sorafenib and pallative radiation in 
patients with intrathoracic malignancy: preliminary 
results
Brade, Anthony M.1; Wan, Jonathan F.2; Chung, Caroline1; 
Southwood, Bernadette3; Jarvi, Andrea3; Wang, Lisa4; Milosevic, 
Michael1; Oza, Amit3
1 Dept. of Radiation Oncology, University Health Network, University 
of Toronto, Toronto, ON, Canada; 2 Dept. of Radiation Oncology, 
Montreal General Hospital, McGill University, Montreal, QC, 
Canada; 3 Drug Development Program, Dept of Medical Oncology, 
University Health Network, Princess Margaret Hospital, Toronto, 
ON, Canada; 4 Dept of Biostatistics, University Health Network, 
Toronto, ON, Canada
Background: Significant preclinical evidence suggests that agents 
targeting VEGF axis signaling may improve outcome with radiother-
apy. Little clinical or preclinical data is available however regarding 
potential toxicities of these combinations. Some case reports have 
suggested potentially severe iterations. Therefore we initiated a phase 
I study to evaluate the combination of sorafenib (tyrosine and serine/
threonine kinase inhibitor of VEGFR-2/3, PDGFR-b, raf, c-kit, FLT-
3) with palliative radiotherapy in patients with intrathoracic primary 
or metastatic malignancy.
Methods: Eligible patients had advanced cancer ineligible for cura-
tive treatment with symptomatic or progressive measureable disease 
within the chest cavity, ECOG performance status <2 and normal 
bone marrow, liver and renal function. Target (irradiated) tumour 
nodule(s) were required to be within visceral soft tissue (subcuta-
neous and bony metastases excluded). Cohorts of 3-6 patients 
received escalating doses of sorafenib (starting at 200 mg od) for 4 
weeks with radiotherapy (30 Gy in 10 daily fractions) delivered in 
weeks 2 and 3. Predefined lung and cardiac radiation dose-volume 
constraints had to be met. Toxicities were evaluated according to the 
NCI common toxicity criteria v3.0. The primary endpoint was acute 
toxicity (on treatment and up to 8 weeks post-radiation) and dose 
limiting toxicities (DLT) were defined as > Gr 3 and attributable to 
radiotherapy (or Gr 2 or worse infield hemorrhage). 
Results: From May 2007 to Dec 2009, 9 patients were registered on 
the study. Three patients received treatment on dose level 1 (sorafenib 
200 mg od x 4 weeks) and 6 patients on dose level 2 (200 mg od x 4 
weeks). Three patients were deemed inevaluable due to early discon-
tinuation of sorafenib for systemic, non-radiation related toxicities 
(e.g. generalized rash Gr 2 or 3 (2), Gr 1 dizziness (1)). No infield 
RT-related toxicities >grade 1 were observed in the 3 dose level one 
patients. In all 3 patients who completed 4 weeks of sorafenib on 
dose level 2, grade 2 radiation dermatitis was observed and in the sole 
patient with the esophagus within the full dose radiation treatment 
portals, Gr 3 esophagitis (requiring continuous IV hydration > 24 
hours) was noted. This was deemed a DLT and no other Gr3+ event 
attributable to radiation were noted. An additional 3 patients will be 
accrued at the current dose level. 
Conclusions: A consistent observation of Gr 2 radiation dermatitis 
was noted in patients receiving 4 weeks of sorafenib 200 mg bid with 
radiation (30 Gy in 10 fractions) which appears unusually severe and 
prevalent for this radiotherapy dose. In addition, a similar process 
may have contributed to the development of Gr 3 esophagitis seen 
in one patient who received esophageal irradiation. Combining 
sorafenib with higher dose irradiation may require dose reduction of 
the drug to mitigate acute cutaneous or esophageal reactions. Addi-
tional toxicity and response data will be presented.
PD13.2.2 Novel Therapeutics, Tue, 12:30 - 14:00
Duplex RNAs targeted to the TP53 promoter (agRNAs) are 
potent inhibitors of cancer cell growth and survival
Shames, David S.; Greer, Rachel M.; Schwartz, Jacob C.; Dineen, 
Sean; Sullivan, James P.; Frink, Robin E.; Gao, Boning; Peyton, 
Michael; Janowski, Bethany; Corey, David R.; Brekken, Rolf A.; 
Minna, John D.
UT Southwestern, Dallas, TX, USA
Background: More than 50% of human cancers including lung 
cancers have mutations in the p53 tumor suppressor gene. Approxi-
mately 80% of these mutations are missense point mutations in the 
DNA binding domain (DBD). DBD mutants of p53 frequently exhibit 
gain-of-function activities in tumor cells. Tumor cells with mutant 
p53 may be “addicted” to these gain-of-function activities, which 
suggests that targeted modulation of mutant p53 function may be a 
useful therapeutic strategy. Recently we showed that antigene RNAs 
(agRNAs) are potent modulators of gene transcription and require 
complementary sense and antisense transcripts within the target 
region for activity. In addition, the p53 gene locus has an antisense 
transcript (Wrap53) with identity to the 5’-UTR and promoter of p53, 
which appears to regulate the expression and function of p53. 
Methods: >20 different synthetic agRNAs (complementary 21mers 
targeting the p53 promoter) with scrambled and mismatched controls 
were transfected into multiple immortalized human bronchial epithel-
ial cells (HBECs) and lung cancer cell lines (N=20) including both 
NSCLC and SCLC and tested for their effect on cell viability, cell 
cycle, and gene expression. Gene expression changes were evaluated 
by QPCR and western blotting; changes in cell viability were tested 
by microtiter assay, colony formation, and flow cytometry. In vivo 
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studies used intra-tumoral injection of agRNAs complexed in cationic 
lipids. 
Results: We first identified 4/20 agRNAs which selectively killed 
lung cancers with p53 missense mutations but not tumors with wild-
type p53, homozygous deletions of p53, or truncating p53 muta-
tions. Similarly, all HBECs with wild type p53 showed no agRNA 
toxicity. The death occurred by apoptosis and was not dependent on 
cell cycle stage, and was blocked through concurrent expression of 
mutant exogenous p53 cDNA from a viral promoter. We compared 
agRNA treatment to siRNA knockdown of p53 in the same cells and 
surprisingly the siRNA knockdown of mutant p53 had no effect on 
the tumor cells. agRNA treatment led to both increases and decreases 
in p53 and Wrap53 mRNAs depending on the tumor line, but the 
p53/Wrap53 changes were always coordinated. Finally, intra-tumoral 
treatment of tumor xenograft with agRNAs in cationic lipid led to 
dramatic induction of tumor necrosis. 
Conclusions: Taken together our results demonstrate: 1. 21-mer 
agRNAs targeted to very specific regions of the p53 promoter select-
ively induce apoptosis in lung cancers with missense p53 mutations 
but have no effect on tumors and normal HBECs with wild-type 
p53; 2. siRNA knockdown of mutant p53 has no effect on tumor cell 
viability; 3. the effect was exquisitely specific for the presence of 
p53 mutations and could be “rescued” by a mutant p53; 4. agRNA 
treatment led to changes in Wrap53 and p53 mRNA. We conclude 
that targeting the promoter of oncogenic p53 in tumor cells has a 
highly potent and specific cytotoxic effect in p53 mutant lung cancer 
cells. In addition, our data are proof of principle that agRNAs have 
potential applications in cancer therapy. 
Research supported by IASLC Research Fellowship and NCI SPORE 
P50CA70907
PD13.2.3 Novel Therapeutics, Tue, 12:30 - 14:00
Resistance to the BH3 peptidomimetic obatoclax in non-
small cell lung cancer associated with a block in BCL-2 
family post-translational regulation 
McCoy, Francis1; Hurwitz, Jane1; Chacko, Alex D.1; Paul, Ian1; 
Liberante, Fabio1; O’Hagan, Barry2; McKerr, George2; Johnston, 
Patrick1; Fennell, Dean A.1
1 Queen’s university Belfast, Belfast, UK; 2 FEI Advanced Imaging 
Centre, University of Ulster, Coleraine, UK
Background: Failure to induce apoptosis is a critical factor limiting 
chemotherapeutic efficacy. Apoptosis is regulated by the functional 
balance of pro- versus antiapoptotic BCL-2 family proteins. Obato-
clax (obx) is a novel pan-inhibitor of the prosurvival BCL-2 family 
under clinical evaluation in lung cancer. It interacts with BCL-2, 
BCL-XL, MCL-1, BCL-W, and A1, allowing activation of of pro-
apoptotic BCL-2 family members which include the critical regula-
tors BAX and BAK. Understanding the molecular mechanisms that 
underpin resistance to this agent will be essential for tailoring patient 
therapy. 
Results: We identified non-small cell lung cancer (NSCLC) cells 
with log-fold resistance to obx (H727s) compared with more sensitive 
H1975 and H460s, as measured by ATP assay, caspase 3, and long 
term clonogenic survival. Obx activated the intrinsic pathway as evi-
denced by caspase 9, caspase 3 and PARP activation but not caspase, 
8 or 2 cleavage. Obx dissociated BAK from BCL-XL consistent with 
on-target pharmacodynamics, but caused miitochondrial SMAC and 
cytochrome c release in obx sensitive H1975 only. However, obx did 
initiate the activation of BAK, with conformation change evidenced 
by limited N terminal BAK proteolysis in isolated mitochondria, in 
both sensitive and resistant cell lines. Obx caused upregulation of 
BIM and loss of MCL-1 in sensitive but not resistant cells. Further-
more, NOXA was constitutively expressed only in sensitive cells, 
with no significant differences in the expression of other prosurvival 
or proapoptotic BCL-2 family members. Dissociation of BCL-2 and 
BCL-XL from beclin-1 initiates ‘self-eating’ or autophagy which can 
proceed in the absence of BAX and BAK. Accordingly, obx caused 
cleavage of LC-3 to LC3b with extensive ultrastructural changes 
characterised by vacuolation, consistent with initiation of autophagy. 
This phenomenon was observed in SCLC as well as NSCLC cells. 
Loss of viability in obx sensitive H460s was not protected by shRNA 
stable, double knockdown of BAX and BAK. This was more pro-
nounced in obx sensitive cells, which expressed higher levels of the 
autophagy regulator and putative tumour suppressor, beclin-1. 
Summary: Although obx activates the initial step of BAK activa-
tion in sensitive and resistant cells, full activation resulting in SMAC 
release from mitochondria is blocked in resistant cells. Post transla-
tional regulation of MCL-1 may account for inhibition of full BAK 
activation, and resistance to obx induced cell killing. Autophagic 
(type II) cell death could play a role in obx mediated apoptosis. 
H1975 cells stably expressing beclin 1 knockdown have been se-
lected, and data will be presented describing the role of autophagic 
death in obx pharmacodynamics, which may be relevant to clinical 
drug sensitivity. 
PD13.2.4 Novel Therapeutics, Tue, 12:30 - 14:00
Identification of tumour-suppressor-gene candidates 
in small cell lung cancer, which combined with a p53 
reactivating molecule, can be used for cancer gene therapy
Zandi, Roza1; Selivanova, Galina3; Willumsen, Berthe M.4; Poulsen, 
Hans S.2
1 Department of Radiation Biology, Copenhagen University Hospital, 
Copenhagen, Denmark; 2 Department of Radiation Biology, 
Copenhagen, Denmark; 3 Department of Microbiology, Tumor and 
Cell Biology, Karolinska Institute, Stockholm, Sweden; 4 Department 
of Molecular Biology, University of Copenhagen, Copenhagen, 
Denmark
Small cell lung cancer (SCLC) is a deadly disease with no satisfac-
tory treatments. This necessitates the need to develop more efficient 
treatment modalities for patients with this cancer type. One intriguing 
modality is tumour-suppressor-restoration-therapy, involving reintro-
duction of a wild-type tumour suppressor gene (TSG) into cancer 
cells, in which the gene is inactivated. This generally induces apop-
tosis and/or cell cycle arrest. However, as different types of cancers 
have different tumour suppressor deficiencies, the strategy must be 
customized to each cancer type, either by using tumour specific TSG 
or by combining different TSG. 
p53 is mutated in up to 90% of SCLC tumours, and as mutant p53 
tend to accumulate in tumour cells, an effective approach would be 
to reactivate mutant p53 in cancer cells combined with reintroduction 
of another TSG, frequently inactivated in SCLC. PRIMA-1met (p53-
dependent reactivation and induction of massive apoptosis) is a small 
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molecule reported to have the capability of restoring tumour-suppres-
sor function to mutant p53 and hence induce cancer cell death. 
We investigated the cytotoxic effects of PRIMA-1met on several 
SCLC cell lines with various p53 mutation types using MTT assay 
and Flow-cytometry. PRIMA-1met inhibited the growth of the SCLC 
cell lines with p53 mutation markedly and induced a substantial in-
crease in the proportion of sub-G1 cells compared to the two control 
cell lines CCD32Lu (wt-p53) and H1299 (p53 null). PRIMA-1met 
treatment of SCLC cell lines induced the expression of the two p53 
target genes p21 and MDM2 and resulted in caspase-3 activation, 
PARP cleavage and decrease in total levels of mutant p53. These 
results suggest that PRIMA-1met reactivates mutant p53, resulting 
in the transactivation of target genes, which subsequently leads to 
apoptosis and p53 downregulation.
Furthermore, the growth suppression effect of the three genes Cyr61, 
FUS1, and FHIT - previously reported to posses tumour suppressor 
activity in human lung cancer – were evaluated in SCLC cell lines 
by transient transfection. Neither of the genes had a cytotoxic effect, 
indicating that the genes are not effective alone in SCLC. We are 
currently testing the effect of the above mentioned genes on SCLC 
cells in the presence of PRIMA-1met in order to see, if substantial 
SCLC cell death can be achieved when combining different TSG. 
The combination of several TSG in cancer gene therapy might help to 
open novel avenues for the treatment of SCLC patients. 
An update will be presented.
PD13.3.1 Novel Therapeutics, Tue, 12:30 - 14:00
MEK1/2 blockade by AZD6244 (ARRY-142886) inhibits 
tumor growth and progression in an orthotopic human 
lung adenocarcinoma model with enhanced efficacy when 
combined with cediranib 
Takahashi, Osamu1; Komaki, Ritsuko1; Smith, Paul D.2; Ryan, 
Anderson2; Jurgensmeier, Juliane M.2; Welsh, James W.1; Jacoby, 
Joerg J.1; Hosho, Keiko1; Korshunova, Maria V.1; Erez, Baruch1; 
Herbst, Roy S.1; O’Reilly, Michael S.1
1 Department of Radiation Oncology and Thoracic/Head and 
Neck Medical Oncology, The University of Texas MD Anderson 
Cancer Center, Houston, TX, USA; 2 Astra Zeneca, Alderly Park, 
Macclesfield, UK; 3 Department of Troracic/Head and Neck Medical 
Oncology, The University of Texas MD anderson Cancer Center, 
Houston, TX, USA
Background: Lung cancer is a leading cause of cancer death and 
conventional treatments have reached a therapeutic plateau. The 
mitogen-activated protein kinase/extracellular signal-regulated kinase 
1/2 kinase (MEK) pathway plays a critical role in regulating tumor 
cell proliferation and survival. AZD6244 is a potent, selective, and 
orally available MEK 1/2 inhibitor that has shown preclinical activ-
ity in tumor xenograft models and is currently in phase II clinical 
trials. In the current study, we evaluated the therapeutic efficacy of 
AZD6244 alone and in combination with cediranib (RECENTINTM), 
an orally available and highly potent inhibitor of all three VEGFR 
tyrosine kinases, in an orthotopic model of human adenocarcinoma 
which mimics clinical patterns of lung cancer progression.
Methods: NCI-H441 (KRAS mutant) human lung adenocarcinoma 
cells (1x106) were injected into the left lungs of nude mice. Five mice 
were sacrificed after 14 days and lung tumors were observed in all 
of them. The remaining mice were randomized (n=10–15/group) to 
treatment with AZD6244 (12.5 or 25 mg/kg/BID orally), cediranib (3 
mg/kg/day orally), paclitaxel (200 µg/week ip), AZD6244 (25 mg/kg) 
plus cediranib, or vehicle control. After 55 days of treatment, when 
control mice showed signs of the onset of morbidity, all animals 
were sacrificed and assessed for lung tumor burden and locoregional 
metastasis. Lung tumors and adjacent normal tissues were frozen or 
formalin-fixed for immunohistochemical analyses. 
Results: AZD6244 at 12.5 and 25 mg/kg reduced the median primary 
lung tumor volume by 71% (p=0.0011) and 82% (p=0.0008) com-
pared with control, respectively. AZD6244, particularly at the higher 
dose, significantly reduced the incidence of mediastinal lymph node 
metastasis (p=0.037). Paclitaxel treatment reduced the median tumor 
volume by 74% (p=0.023) compared with control but had only mod-
est effect on mediastinal lymph node metastasis. Cediranib monother-
apy was also efficacious and reduced median tumor volume by 67.5% 
(p=0.0019) and metastasis. The antitumor and antimetastatic effects 
of AZD6244 and cediranib were markedly enhanced when they 
were combined. After combined therapy, the median primary tumor 
volume was reduced by 90% (p<0.0001) and median left lung weight 
by 73% (p<0.0001) compared with control, and there were no gross 
mediastinal lymph node metastases (p=0.0002). All treatments were 
well tolerated with no significant differences in body weight in any 
group. Preliminary analyses of tumor cell apoptosis reveal increased 
apoptosis in the cediranib and 25 mg/kg AZD6244 treatment groups 
with the highest levels of apoptosis observed after combined treat-
ment with AZD6244 and cediranib, compared with control. Analyses 
of tumor and endothelial cell apoptosis and proliferation, microvessel 
density, VEGF, VEGFR-2, and ERK are underway. 
Conclusions: Targeted therapy against MEK1/2 with AZD6244 or 
against VEGF signaling with cediranib significantly inhibits tumor 
growth and progression in an orthotopic model of human lung 
adenocarcinoma. Combining AZD6244 with cediranib enhanced the 
antitumor effects with a near complete suppression of lung tumor 
growth and metastasis to the mediastinal nodes. These data show that 
AZD6244 combined with cediranib is a promising strategy for lung 
cancer treatment and provide a strong basis for the design of clinical 
trials combining AZD6244 and cediranib in lung cancer patients.
PD13.3.2 Novel Therapeutics, Tue, 12:30 - 14:00
The inhibition of c-Met and its downstream mTOR 
induces anti-tumor effect in NSCLC cell line resistant to 
EGFR tyrosine kinase inhibitor
Nakachi, Ichiro2; Naoki, Katsuhiko1; Soejima, Kenzo1; Kawada, 
Ichiro3; Watanabe, Hideo1; Yasuda, Hiroyuki1; Nakayama, Sohei1; 
Yoda, Satoshi1; Satomi, Ryosuke1; Ikemura, Shinnosuke1; Terai, 
Hideki1; Ishizaka, Akitoshi1
1 School of Medicine, Pulmonary Department, Keio University, 
Shinjuku, Japan; 2 Saiseikai Utsunomiya Hospital, Utsunomiya, 
Japan; 3 Hino Municipal Hospital, Hino, Tokyo, Japan
Background: Epidermal growth factor receptor tyrosine kinase 
inhibitors (EGFR-TKIs), gefitinib and erlotinib show anti-tumor 
activity in a subset of non-small cell lung cancer (NSCLC) patients 
having mutations of EGFR gene. However, the initial tumor response 
is typically followed by recurrence. Several studies suggested the 
importance of other receptor tyrosine kinases (RTKs) and their 
downstream kinases as potential molecular targets in the treatment 
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of NSCLC. The aim of our study is to find out the essential target to 
induce the anti-tumor effect in the NSCLC cell lines including resist-
ance to EGFR-TKIs. 
Methods: We used three human NSCLC cell lines, namely, A549, 
H1650 and H1975. A549 has wild type EGFR, H1650 harbors a 
deletion mutation in exon 19 which accounts for a sensitive mutation 
to erlotinib, while H1975 possesses double mutations at L858R and 
T790M, which account for sensitiveness and resistance to erlotinib, 
respectively. We treated these cells with erlotinib, AEE788 and 
RAD001 in variable concentrations. AEE788 has abundant target 
RTKs such as vascular endothelial growth factor receptor (VEGFR) 
and HER2 in addition to EGFR. RAD001 is an inhibitor of mammal-
ian target of rapamycin (mTOR). mTOR is a downstream kinase of 
RTKs, located in phosphatidylinositol-3 kinase (PI3K)/Akt pathway. 
We evaluated the effect on cell growth as well as the phosphorylation 
of receptors and downstream kinases.
Results: In these cell lines, AEE788 inhibited the cell growth more 
effectively than erlotinib. However, in H1975, cell growth inhibition 
by AEE788 was moderate, and the phosphorylations of its lead-
ing targets such as VEGFR2 and HER2 as well as EGFR were not 
inhibited. Interestingly, AEE788 induced the additional cell growth 
inhibition when combined with RAD001, rather than single use in 
H1975. In the phospho-RTK array, we detected that c-Met was highly 
phosphorylated in H1975, as well as EGFR and HER2, and was 
inhibited effectively by AEE788. 
Conclusions: The combination of RAD001 and AEE788 resulted in 
more striking anti-tumor effect in H1975. Inhibiting other upstream 
RTKs such as c-Met than EGFR would lead to overcoming the 
acquired resistance to erlotinib, when combined with an inhibitor of 
downstream kinases. 
PD13.3.3 Novel Therapeutics, Tue, 12:30 - 14:00
A phase I/II study of the specific retinoid X receptor (RXR) 
agonist, NRX 194204, in relapsed/refractory solid tumors 
and non-small cell lung cancer (NSCLC)
Gitlitz, Barbara J.1; Gill, Parkash1; Chandraratna, Roshantha2; Ashai, 
Zeno2; Hughlett, Claire1; Quinn, David1
1 University of Southern California Keck School of Medicine, Los 
Angeles, CA, USA; 2 NuRx Pharmaceuticals, Inc, Irvine, CA, USA
Background: NRX 194204, a second generation rexinoid, is a highly 
potent and specific activator of the Retinoid X Receptor (RXR). 
Rexinoids play a variety of roles in regulating tumor cell survival, 
and in pharmacological doses exhibit both anti-cancer and anti-
cachectic effects. NRX 194204 is significantly more selective for the 
RXRs relative to the Retinoic Acid Receptors (RARs) and thus could 
be associated with fewer adverse events. Moreover, the lung cancer 
promoting effects that may be associated with RAR activity can be 
avoided with an RXR specific activator.
Methods: Patients with histologically confirmed solid tumors refrac-
tory to conventional therapy, are eligible for our phase I dose escala-
tion study of NRX 194204. Pts are enrolled sequentially into cohorts 
using a “3+3” design. NRX 194204 is given at a single, daily oral 
dose of 3, 6, 12 or 24 mg/m2. Phase I objectives include determina-
tion of safety, pharmacokinetics, and biological surrogate activity 
for RXR activation as measured by the thyroid stimulating hormone 
(TSH) levels. Eligibility for the phase II NSCLC trial include >2 
prior lines of therapy for metastatic disease. Subjects receive a fixed 
daily dose of 10 mg daily. Phase II objectives include response, safety 
and survival outcomes.
Results: Fourteen patients with advanced relapsed/refractory tumors 
are presently accrued to the first three dose levels of the phase I 
trial. NRX 194204 was generally well tolerated. Notable side effects 
included grade 3 and 4 increases in serum triglycerides and decreases 
in TSH levels. These toxicities were asymptomatic and thus did not 
meet definition for dose limiting toxicity. Both effects are expected 
outcomes of RXR activation. After one week of treatment, TSH 
levels declined from baseline by an average of 70%, 98%, and 99% 
at the first, second, and third dose levels, respectively. Preliminary 
pharmacokinetic analyses indicate a dose related increase in blood 
levels of NRX 194204: on day 1, average Cmax (nM) values were 
25, 50, and 74 and average AUC0-24h (ng.hr/ml) values were 13, 28, 
and 65 at the first, second, and third dose levels, respectively. Blood 
levels of NRX 194204 appear to decrease ~30% after 1 week of dos-
ing, but remain constant subsequently. Clinical observations include 
prolonged progression-free survival of 8 months (at 6mg/m2) and 5 
months (at 12 mg/m2) in two heavily pretreated patients with adeno-
carcinoma of the lung enrolled in the phase I portion. Interestingly, 4 
pts with symptomatic, metastatic adenoid cystic carcinoma who had 
progressed on preceding chemotherapy had PFS of 8 and 10+ months 
at 6mg/m2; and 1 and 8+ months at 12mg/m2. 
Conclusions: NRX 194204 is a highly specific RXR agonist which 
is well tolerated at daily doses of 3, 6, and 12 mg/m2. Dose limiting 
toxicity has not been reached. Plasma drug levels and suppression 
of TSH levels (a well-characterized marker of RXR agonist activ-
ity) indicate that a dose of 6mg/m2/day is sufficient to provide robust 
RXR agonist activity. A Phase II study of NRX 194204 (10mg/day) is 
currently enrolling using a 2-stage design to accrue to a maximum of 
48 patients. Updated results to be presented at the meeting.
PD13.3.4 Novel Therapeutics, Tue, 12:30 - 14:00
A phase I study of everolimus, an mTOR inhibitor, in 
combination with docetaxel for recurrent/refractory non-
small cell lung cancer
Owonikoko, Taofeek K.; Ramalingam, Suresh S.; Harvey, Donald; 
Saba, Nabil F.; Kauh, John; Shin, Dong M.; Sun, Shi-Yong; 
Browning, Karen; Tighiouart, Mourad; Khuri, Fadlo R.
Emory University, Atlanta, GA, USA
Background: Aberrant signaling through the mammalian target of 
rapamycin (mTOR) pathway has been demonstrated in non-small cell 
lung cancer (NSCLC). Everolimus, an mTOR inhibitor, is active as 
monotherapy for advanced NSCLC. Based on the preclinical synergy 
between everolimus and docetaxel, we conducted a phase I and feas-
ibility study of this combination in patients with advanced NSCLC.
Methods: Patients with stage IIIB (wet) or IV NSCLC, who have 
progressed on platinum-based chemotherapy and have adequate 
ECOG performance status (PS) of 0-2 were eligible. Sequential 
patient cohorts were treated with increasing doses of docetaxel (day 
1) and everolimus (PO QD, days 1-19) in a 21-day treatment cycle 
(C). Dose limiting toxicity (DLT) was assessed at the end of the first 
cycle. A standard ‘up and down’ dose escalation scheme was utilized. 
The primary endpoint was determination of optimal doses of the two 
agents that can be administered in combination. 
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Results: Twenty three patients were enrolled. Median age - 62 (42-
74); Gender: M/F – 12/ 11; ECOG PS: 0-6; 1 -16, 2 -1; # of prior 
regimens: 1-12, 2-6, >3 -5. At dose level 1 (Docetaxel- 60 mg/m2, 
Everolimus- 5mg), none of 6 patients had DLT. Four of 12 patients 
had DLT of fever with neutropenia at dose level 2 (Docetaxel-75 
mg/m2, Everolimus-5 mg). At dose level 3 (Docetaxel- 75 mg/m2, 
Everolimus- 7.5 mg), 2 of 3 pts had DLT (fever with neutropenia & 
grade 3 mucositis). Pharmacokinetic (PK) sampling for everolimus 
was performed on days 1 (n=14), 8 (n=9), and 15 (n=10) of cycle 1. 
Mean half-life (hr) on days 1, 8, and 15 were 9.66 (2-14), 12.6 (2.2-
21.1), and 14.8 (2-21.2), respectively. Everolimus accumulation was 
greater than expected. In contrast to the mean predicted accumula-
tion factor (R) based on AUC of 1.22 (1-1.44), actual R on day 8 and 
15 were 1.78 (0.72-3.17) and 1.88 (0.37-3.3) respectively. Twenty 
patients were evaluable for response - 1 had a partial response and 10 
had disease stabilization. Six patients completed 6 cycles of combina-
tion therapy and continued on everolimus as maintenance therapy.
Conclusions: The recommended doses of docetaxel and everolimus 
when administered in combination for the treatment of advanced 
NSCLC are 60 mg/m2 and 5 mg PO QD respectively on a 21-day 
cycle schedule. The PK characteristics of everolimus appear un-
affected by co-administration with docetaxel. Promising anti-cancer 
activity was noted with clinical benefit in 55% of the pts. A phase II 
study has been initiated in refractory NSCLC. Supported by: NCI 5 
P01 CA116676-03
PD13.4.1 Novel Therapeutics, Tue, 12:30 - 14:00
Pharmacokinetics (PK) of motesanib in a randomized, 
open-label, phase 2 study of motesanib or bevacizumab 
in combination with paclitaxel and carboplatin (P/C) 
for advanced nonsquamous non-small cell lung cancer 
(NSCLC): analysis of population PK model predictions
Melara, Rebeca1; Sutjandra, Liviawati1; Bruenner, Bernd1; Wake, 
Cindy 1; Blumenschein, Jr, George2; Schwartzberg, Lee3; Sikorski, 
Robert4; Hei, Yong-jiang4; Lu, Jian-Feng1; Sun, Yu-Nien1
1 Pharmacokinetics & Drug Metabolism, Amgen Inc., Thousand 
Oaks, CA, USA; 2 M.D. Anderson Cancer Center, Houston, TX, USA; 
3 The West Clinic, Memphis, TN, USA; 4 Oncology Development, 
Amgen Inc., Thousand Oaks, CA, USA
Background: Motesanib is a highly selective inhibitor of angiogen-
esis with direct antitumor activity, targeting VEGF receptors 1, 2, and 
3; PDGFR, and Kit. Previous studies have shown that motesanib is 
rapidly absorbed after oral administration, and its PK profile and par-
ameter values are approximately dose proportional after monotherapy 
or combination therapy with once daily (QD) dosing. Population PK 
simulations suggest that twice daily (BID) dosing with an interrupted 
dosing schedule may provide effective target coverage (continuous 
receptor inhibition) while managing toxicity as observed with BID 
dosing in other motesanib studies. 
Methods: Patients with advanced NSCLC were randomized (1:1:1) 
to receive P/C (paclitaxel, 200 mg/m2; carboplatin, AUC of 6 mg/
mL x min) every three weeks plus motesanib 125 mg QD (Arm A) 
or 75 mg BID for 5 days followed by a 2-day treatment-free period 
(BID-5/2) (Arm B); or bevacizumab (Arm C). PK samples were col-
lected from patients in Arms A and B at 1 hour (Cmax) and 24 hours 
(Cmin) postdose on day 1 of cycle 1 (C1D1) and prior to dosing (Cmin) 
on day 1 of every third cycle thereafter. Motesanib plasma con-
centrations were determined by a validated liquid chromatography 
coupled with tandem mass spectrometry method. PK results from this 
study were compared to the predicted profiles based on the 2-com-
partmental population PK model developed using concentration 
data from a previous monotherapy study (Rosen et al, J Clin Oncol 
2007;25:2369).
Results: 181 patients received ≥1 dose of treatment (Arms A/B/C, 
n=59/62/60), of which 94 patients (Arms A/B, n=46/48) were 
included in these preliminary PK analyses. Median motesanib Cmax 
and Cmin values following co-administration with P/C on C1D1 
were similar to the values observed in previous monotherapy (Rosen 
et al, J Clin Oncol 2007;25:2369) and combination therapy (Blu-
menschein et al. J Thoracic Oncol 2007;2(suppl4):S469; Price et al. 
Br J Cancer 2008;99:1387) studies. Consistent with population PK 
model predictions, median Cmin values at 24 hours after dosing on 
C1D1 were above the in vitro human umbilical vein endothelial cell 
(HUVEC) proliferation assay IC90 value for the 75 mg BID-5/2 dose 
group, and between the IC50 and IC90 values for the 125 mg QD dose 
group. Median Cmin values at subsequent cycles for 75 mg BID-5/2 
were below 1 ng/mL, suggesting that a 2-day wash-out is sufficient 
to attain motesanib plasma concentrations below the IC50 value. This 
observation is consistent with model predictions, in which motesanib 
plasma concentrations were expected to be below the IC50 value of 
in vitro HUVEC proliferation for approximately 1 day during the 
7-day cycle. With minimal accumulation after daily dosing, median 
motesanib trough (Cmin) concentrations at subsequent cycles for 125 
mg QD were similar to the values on C1D1. PK/pharmacodynamic 
modeling is ongoing.
Conclusions: In this study, motesanib PK following 125 mg QD or 
75 mg BID-5/2 dosing plus P/C in patients with advanced NSCLC 
were consistent with population PK model-predicted values. These 
two dosing regimens provide alternative approaches to inhibiting the 
target receptors.
PD13.4.2 Novel Therapeutics, Tue, 12:30 - 14:00
Synergistic proapoptotic effects of the two tyrosine kinase 
inhibitors pazopanib and lapatinib on NSCLC carcinoma 
cell lines
Commo, Frédéric1; Olaussen, Ken A.1, 2, 3; Tailler, Maximilien2, 
3; Lacroix, Ludovic1; Vitale, Ilio2, 1, 3; Raza, Syed Q.2, 1, 3; Richon, 
Catherine1; Dessen, Philippe1; Lazar, Vladimir1; Kroemer, Guido2, 1, 3; 
Soria, Jean-Charles1, 3
1 Institut Gustave Roussy, Villejuif Cedex, France; 2 INSERM U848, 
Villejuif, France; 3 Université Paris-Sud XI, Kremlin-Bicêtre, France
Background: Pazopanib and lapatinib are two tyrosine kinase 
inhibitors designed to inhibit tyrosine kinase receptors: respectively 
VEGFR-1, -2, -3, and both HER1 and HER2 receptors. Pazopanib 
has also been reported to mediate inhibitory effect on a selected panel 
of additional tyrosine kinases such as PDGFR and c-kit. The aim of 
the study was to assess the benefits of a combination of such inhibit-
ors on cell death induction, compared to each drug alone or combined 
with standard drugs (cisplatin, pemetrexed).
Methods: Different combinations of drugs were defined following 
a rotatable matrix construction and applied on the A549 cell line. 
Effects on cell proliferation were then quantified, after 72h of treat-
ment, by a colorimetric assay (WST-1), and analyzed with a response 
surface method to estimate the influence of the combination on the 
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
Copyright © 2009 by the International Association for the Study of Lung CancerS596
proliferation. The fitted responses were next compared for validation 
with an independent set of experiments under different concentrations 
of the combination. Cell viability was also explored by a clonogenic 
assay as well as a cytofluorometric analysis of apoptosis and cell 
cycle distribution.
The CelluSpot™ kinase-arrays technology was used to compare 
kinase activities on the A549 cell line between different conditions of 
treatment: cytotoxic concentration of pazopanib/lapatinib combina-
tion, single drug treatment or DMSO-control. The detection of phos-
phorylated substrates was carried out by fluorometric measurement 
with a GenePix microarray scanner.
The same cytotoxic combination was used on the A549 cells and 
a panel of 4 additional cell lines (H1975, H1299, HCT116 and 
AGS) for Gene Expression analysis. This transcriptomic study was 
performed by dual color competitive hybridization on Agilent 4x44K 
gene expression microarrays, for which each untreated cell line was 
used as its own reference. The kinase-inhibitors combination was 
also compared to single drugs and to 4 other combinations of drugs: 
pazopanib (or lapatinib) with CDDP, pazopanib (or lapatinib) with 
pemetrexed.
Results: Cell death was highly induced by the pazopanib/lapatinib 
combination. The fitted model showed a significant effect of the 
combination, while pazopanib or lapatinib alone had poor effects. 
This was confirmed by the independent experiments. Systematic as-
sessment of the kinome revealed that both pazopanib and lapatinib in-
hibited dozens of different tyrosine kinases and that their combination 
could suppress the activity of tyrosine kinases (such as c-Met) that 
were not or only partially affected by either of the two agents alone. 
We also found that pazopanib and lapatinib induced selective changes 
in the transcriptome of the A549 cells, some of which were specific 
for the combination of both agents. Analysis of a panel of different 
human carcinoma cell lines revealed a signature of 52 genes whose 
up- or downregulation reflected the combined action of pazopanib 
and lapatinib. Indeed, pazopanib and lapatinib exerted synergistic 
cytotoxic effects on several distinct non-small cell lung cancer cells 
as well as on unrelated carcinomas.
Conclusions: Altogether, these results support the contention that 
combinations of tyrosine kinase inhibitors should be evaluated for 
synergistic antitumor effects. Such combinations may lead to a 
“collapse” of pro-survival signal transduction pathways that leads to 
apoptotic cell death.
PD13.4.3 Novel Therapeutics, Tue, 12:30 - 14:00
Inhibition of the platelet-derived growth factor receptor 
alpha (PDGFRα) signaling pathway with the human 
monoclonal antibody MEDI-575 in preclinical mouse 
models of NSCLC
Steiner, Philipp1 Schifferli, Kevin1 Camara, Margarita1 Funelas, 
Cherryl2 Narwal, Rajesh 1 Chen, Cui1 Wetzel, Leslie1 Czapiga, 
Meggan1 Liang, Meina2 Tabrizi, Mohammad2 Baffa, Raffaele1 Coats, 
Steve1 Robbie, Gabriel1 Roskos, Lorin1 Jallal, Bahija1 LaVallee, 
Theresa1 Chang, Yong1
1 MedImmune, Gaithersburg, MD, USA; 2 MedImmune, Hayward, 
CA, USA
The PDGFRα pathway plays an important role in the regulation of 
cellular proliferation, survival and migration. Activation of PDGFRα 
or its ligands is involved in the pathogenesis of human cancers 
which leads to stimulation of the signaling pathway in tumor cells 
but also acts as a mediator of stromal support for cancer cell growth. 
The clinical benefits of small molecule drugs which target multiple 
receptor tyrosine kinases have validated PDGFRα as a target for 
therapeutic intervention in cancer patients. MEDI-575 is a novel 
human IgG2 monoclonal antibody that selectively targets human 
PDGFRα. Treatment of tumor cells with MEDI-575 significantly 
inhibited PDGFRα kinase activity induced by PDGF ligands but had 
no measurable activity against PDGFRbeta. MEDI-575 is currently in 
a phase I clinical trial for cancer patients with solid tumors including 
NSCLC. While reports on the frequency of tumoral expression of 
PDGFRα in NSCLC are variable, activated PDGFRα is frequently 
detected on the surrounding tumor stroma. To test the consequences 
of inhibition of PDGFRα by MEDI-575 in tumor or stromal cells 
in vivo, two NSCLC xenograft mouse models were evaluated that 
depend on PDGFRα signaling: i) PDGFRα-positive H1703 cells 
grown in athymic nu/nu mice and ii) PDGFRα-negative Calu-6 cells 
grown in human PDGFRα Knock-In/Knock-Out (KIKO) SCID mice. 
The KIKO mouse model was required to evaluate whether inhibition 
of PDGFRα on the tumor stroma alone would result in antitumor 
activity because MEDI-575 did not cross-react with mouse PDGFRα. 
In the H1703 nu/nu system, MEDI-575 caused tumor stasis at 10 mg/
kg and tumor regressions at 20 mg/kg when dosed twice per week 
which correlated with a decrease in PDGFRα kinase activity. In the 
Calu-6 KIKO model, 10 mg/kg and 30 mg/kg of MEDI-575 both 
caused ~50% tumor growth inhibition which was accompanied by 
a decrease in stromal phosphorylated PDGFRα. To determine the 
PK/PD relationship of MEDI-575, the concentration of circulating 
drug was determined in mouse serum. Approximately 300 ug/ml 
of MEDI-575 was required for inhibition of pPDGFRα resulting in 
tumor stasis in the H1703 model and ~200 ug/ml of MEDI-575 in the 
Calu-6 KIKO model. Furthermore, MEDI-575 was equally active at 
20 mg/kg total dose whether dosed on a once weekly schedule or a 
two times per week schedule in the H1703 model. Both dosing regi-
mens produced similar steady-state drug levels over seven days. In 
summary, our analysis of anti-tumor activity and PK/PD relationship 
of the anti-PDGFRα antibody MEDI-575 indicated that blockade of 
autocrine and paracrine PDGFRα signaling in two mouse models 
of lung cancer supports further clinical evaluation of MEDI-575 in 
patients with NSCLC. 
PD13.4.4 Novel Therapeutics, Tue, 12:30 - 14:00
The impact of tumor cavitations on objective and 
metabolic response assessment in a phase II study of 
erlotinib and sorafenib in patients with advanced non-
small cell lung cancer (NSCLC)
Lind, Joline S.1; Smit, Egbert F.1; Groen, Harry J.2; Dingemans, 
Anne-Marie C.3; Hoekstra, Otto S.1; Frings, Virginie 1
1 VU Univeristy Medical Center, Amsterdam, Netherlands; 2 
University Medical Center Groningen, Groningen, Netherlands; 3 
Maastricht University Medical Center, Maastricht, Netherlands
Background: Tumor cavitation is frequently observed in clinical 
trials of angiogenesis inhibitors in patients with NSCLC. RECIST 
(Response Evaluation Criteria in Solid Tumors), the standard re-
sponse assessment, does not take such cavitations into account and 
may underestimate response .We assessed the impact of cavitation 
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on response evaluation in patients receiving sorafenib, a multi-kinase 
angiogenesis inhibitor, combined with erlotinib, an EGFR inhibitor, 
for advanced NSCLC and the correlation with tumor metabolic 
response (18FDG-PET).
Methods: We performed a radiological review of patients with stage 
IIIB or IV NSCLC enrolled in an ongoing phase II trial of sorafenib 
(400 mg/bd) and erlotinib (150 mg/od). Response was assessed by 
RECIST and a novel alternate method introduced by Crabb et al in 
which the longest diameter of any cavitation is subtracted from the 
overall longest diameter of that lesion to measure target lesions. 
Objective response at 6 weeks, time to response (TTR) and time to 
progression (TTP) were evaluated with both methods. Metabolic 
response was measured by change in maximal standardized uptake 
value (SUVmax) between baseline and week 3 18FDG-PET scans. 
Results: Cavitation of the primary tumor occurred in 36% (18/50) 
of patients, and this was >10% of the longest diameter in 11/18. The 
overall response rate at 6 weeks assessed by RECIST was 24%: 12 
PR, 26 SD, 8 PD and 4 NE, vs. 32% using the alternate response 
measurements (changing from SD to PR in 4 pts). Out of the 11 pts 
with marked cavitations, TTR was shorter in 2 (3 vs 6 weeks (n=2)) 
and TTP was shorter in 2 other pts (12.7 vs 30.7 weeks and 10.4 vs 
24.3 weeks) with the alternate method compared to RECIST, with 3 
patients remaining progression free with both methods. The response 
rate at 6 weeks of the primary tumor alone assessed by RECIST was 
24%:12 PR, 24 SD, 1 PD, 13 NE. With the alternate method primary 
tumor response changed in 6 pts from SD to PR to give a 36% 
response rate. 34 (68%) pts, 8 with primary tumor cavitation, had a 
18FDG-PET scan at baseline and week 3. Primary tumor metabolic 
response at 3 weeks was 42%: 21 PR, 11 SD and 2 PD. In the patients 
with cavitations 6 had metabolic PR, 1 SD and 1 PD. Pts with cavita-
tions had a significantly higher decrease in SUVmax compared to 
patients without cavitations (mean -44% vs -23%, p=0.02). Metabolic 
response was the same as primary tumor response assessed by both 
RECIST and alternate method in only 64% of pts.
Conclusions: Primary tumor cavitations were observed in more 
than a third of NSCLC patients treated with sorafenib and erlotinib. 
Incorporating cavitations influenced response assessment in a number 
of patients but did not appear to reflect early metabolic response more 
closely, which has shown to correlate with longer TTP and survival in 
NSCLC patients. The alternate method and early metabolic response 
evaluation may improve response assessment in clinical trials with 
cavitating tumors. 
PD13.5.1 Novel Therapeutics, Tue, 12:30 - 14:00
Combination of SAHA and adenovirus-TRAIL showed 
synergistic antitumor effect by increasing TRAIL 
expression in lung cancer cell lines
Lee, Choon-Taek1; Kim, Dal Rae1; Park, Mi-Young1; Yoon, Ho-Il1; 
Lee, Jae Ho1; Kim, Yeon-Soo2
1 Department of Medicine, Seoul National University Bundnag 
Hospital, Seongnam, Korea; 2 Institute of Molecular Biology and 
Department of Medical Laboratory Science, Inje University, Seoul, 
Korea
Background: Soluble TRAIL and adenovirus (ad)-TRAIL showed 
the strong antitumor effect by inducing apoptosis. However, the 
resistance of cancer cells to TRAIL and low TRAIL expression 
from adenovirus-TRAIL transduced cells limits the clinical applica-
tion. SAHA is the HDAC inhibitor that regulates the expression of 
silenced genes. We proposed the new strategy that SAHA will induce 
high expression of ad-TRAIL and investigated its mechanism.
Methods: The changes of CAR, main cellular receptor for adenoviral 
entry, after SAHA treatment in lung cancer cell lines were measured 
by Western blot assay. SAHA treatment was performed before and/or 
after transduction of ad-luciferase (luc) and ad-TRAIL and expres-
sions of luciferase and TRAIL was measured. In human lung cancer 
cell lines, antitumor effects were measured by MTT assay after com-
bined treatment of SAHA and ad-TRAIL and the drug interactions 
were investigated by Calcusyn software.
Results: SAHA increased the expression of CAR in lung cancer cell 
lines. SAHA also increased the expression of luciferase from ad-luc 
transduced cells and TRAIL from ad-TRAIL transduced cells (figure 
1). Selective SAHA treatment revealed that SAHA may enhance 
TRAIL expression from ad-TRAIL by increasing transduction via 
enhanced CAR expression and increasing adenoviral transgene 
transcription. Combined SAHA and ad-TRAIL treatment showed the 
synergistic antitumor effect in human lung cancer cell lines regardless 
of resistance of cancer cells to TRAIL. 
Conclusion: Combination of SAHA and ad-TRAIL showed the syn-
ergistic antitumor effect on lung cancer cell lines. Increased expres-
sion of TRAIL via enhanced adenoviral transduction and increased 
transcription of TRAIL will be the mechanisms of this synergistic 
interaction.
PD13.5.2 Novel Therapeutics, Tue, 12:30 - 14:00
Cetuximab activity in non-small cell lung cancer is 
enhanced in vivo by the HDAC inhibitor entinostat
Witta, Samir E.1; Girard, Luc2; Zheng, Di1; Zhang, Zhiyong1; Minna, 
John 2; Bunn, Jr., Paul A.1; Chan, Daniel C.1; Hirsch, Fred R.1
1 University of Colorado Cancer Center, Aurora, CO, USA; 2 
University of Texas Southwestern Medical Center at Dallas, Dallas, 
TX, USA
Background: We previously demonstrated the synergistic effect 
of the class I histone deacetylase inhibitor (HDACi) entinostat 
(SNDX-275) and gefitinib in non-small cell lung cancer (NSCLC) 
cell lines with wild type EGFR and lacking E-cadherin expression. 
In this study we examined the correlation of cetuximab activity with 
E-cadherin, caveolin, β-catenin and ZEB-1 expression in a panel of 
46 NSCLC cell lines. We then evaluated the effects of entinostat and 
cetuximab alone or in combination in vivo in a Ras mutant, EGFR 
FISH negative NSCLC cell line, A549.
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Methods: The growth inhibitory effect of cetuximab was determined 
using a 5-day 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide assay. E-cadherin, caveolin, β-catenin and ZEB-1 expres-
sion was evaluated in microarray affymetix analysis. In vivo efficacy 
of entinostat alone was tested first in athymic nude mice bearing 
NSCLC xenografts, A549, H157 or H460. Combined treatment of 
entinostat with cetuximab was then studied in A549 xenografts. 
Results: Among the 46 NSCLC only 5 were sensitive to cetuximab, 
H2073, H3255, HCC827, H1666 and H820. All the other 41 cell 
lines were resistant in vitro (log IC50 <2microM). There was no 
correlation between the activity of cetuximab and expression of 
EGFR, E-cadherin, caveolin, β-catenin and ZEB-1. Ongoing studies 
are evaluating the effect of entinostat on e-cadherin expression in 
xenografts. The in vitro data were expanded on by demonstrating 
that entinostat or cetuximab as a single agent suppressed the tumor 
growth of H460, A549 or H157 xenografts in a dose-dependent man-
ner. When entinostat (E; 5mg/kg) was combined with cetuximab (C; 
25mg/kg), an enhanced tumor growth inhibition was detected over 
each drug alone in nude mice bearing the A549 xenografts (Growth 
Inhibition: E: 70%; C: 65%; E+C: 88%). Testing of the combination 
in additional tumor models is ongoing. 
Conclusions: Cetuximab is effective in a Ras mutant, EGFR FISH 
negative NSCLC when combined with entinostat. The enhanced ac-
tivity of the combination may be due to entinostat’s ability to down-
regulate activated growth factor pathways, which mediate EGFR re-
sistance. This combination of entinostat and cetuximab could provide 
the rational for developing clinical trials in patients with NSCLC. 
Supported by Syndax Pharmaceuticals and NCI SPORE 
P50CA058187, P50CA70907
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Differences in in vitro azacitidine and decitabine activities 
in non-small cell lung cancer
Nguyen, Aaron N.1; Hollenbach, Paul W.1; Luna-Moran, Antonio1; 
Brady, Helen1; Heise, Carla2; MacBeth, Kyle J.2
1 Celgene Corporation, San Diego, CA, USA; 2 Celgene Corporation, 
San Francisco, CA, USA
The azanucleosides 5-azacytidine (azacitidine; Vidaza; AZA) and 
2’-deoxy-5-azacytidine (decitabine; Dacogen; DAC) are DNA 
methyltransferase (DNMT) inhibitors that have shown clinical benefit 
in the treatment of myelodysplastic syndromes (MDS) and are ap-
proved by the Food and Drug Administration for the treatment of 
MDS. While AZA has demonstrated the ability to significantly extend 
overall survival in MDS patients, DAC failed to show a survival 
benefit over conventional therapy in a similar trial. The different 
outcomes of these late-stage clinical studies suggest that AZA and 
DAC may have different modes of action. To better understand the 
mechanism of action of these two drugs, we examined the effects of 
AZA and DAC in a panel of cancer cell lines. We found that AZA and 
DAC differentially affected the viability of many cell lines, with the 
greatest difference exhibited in non-small cell lung cancer (NSCLC) 
cells. Of the six NSCLC lines tested, all were sensitive to AZA (EC50 
of 1-6 µM) while only one was sensitive to DAC (EC50 of 5 µM). 
Both inhibitors caused DNMT1 depletion and DNA demethylation in 
these cells; however, only AZA induced histone-H2AX phosphoryla-
tion (a marker of DNA damage) and PARP cleavage (a marker of 
cell death), suggesting that mechanisms in addition to, or other than 
DNA hypomethylation, are important for AZA-mediated reduction of 
NSCLC cell viability. Consistent with these results, AZA-treated, but 
not DAC-treated, cells were positive for AnnexinV staining, indica-
tive of cells undergoing apoptosis. Cell cycle analysis indicated that 
AZA induced an accumulation of cells in the sub-G1 phase whereas 
DAC mainly caused an increase of cells in G2/M. Gene expression 
analysis of AZA- and DAC-treated cells revealed strikingly different 
profiles, with many genes distinctly regulated by each drug. Col-
lectively, these results in NSCLC cell lines suggest that besides the 
common activities of AZA and DAC on DNMT depletion and DNA 
hypomethylation, these drugs differ in other aspects, including regu-
lation of gene expression and induction of apoptosis. 
PD13.5.4 Novel Therapeutics, Tue, 12:30 - 14:00
A phase I combination study of olaparib (AZD2281; KU-
0059436) and cisplatin plus gemcitabine in adults with 
solid tumors
Rajan, Arun; Carter, Corey A.; Gutierrez, Martin; Kummar, Shivaani; 
Yancey, Mary Ann; Ji, Jiuping; Zhang, Yiping; Simmons, Dwight; 
Parchment, Ralph; Tomaszewski, Joseph; Doroshow, James H.; 
Giaccone, Giuseppe
National Cancer Institute, National Institutes of Health, Bethesda, 
MD, USA
Background: Poly (ADP-ribose) polymerase (PARP) group of 
NAD+-dependent enzymes bind to DNA single- and double-strand 
breaks and participate in multiple DNA-related functions. Increased 
PARP activity can help tumor cells avoid apoptosis caused by DNA 
damaging agents and cause drug resistance. Olaparib, an orally 
administered potent inhibitor of PARP-1 and PARP-2 may partially 
overcome resistance to cisplatin and gemcitabine when used in 
combination. 
Methods: Eligibility: histologically confirmed metastatic or unresect-
able solid tumors, PS 0–2, normal organ functions. Treatment at dose 
level 1 (DL1): olaparib 100 mg orally every 12 hours (h) on days 
1–4, gemcitabine 500 mg/m2/h intravenously (IV) over 1h on day 
(D) 3 and 10, cisplatin 60 mg/m2 over 1h on D3 after gemcitabine; 
treatment was repeated every 21 days x6. Respective doses (with 
the same schedule) at dose level –1 (DL –1): olaparib 100 mg orally 
once daily, gemcitabine 400 mg/m2/h, cisplatin 50 mg/m2. Periph-
eral blood mononuclear cells (PBMCs) were collected in 4-mL CPT 
citrate tubes and processed within 2 hours of collection. 
Results: From 5/2008 to 3/2009, 12 patients enrolled; 8 males, medi-
an age 59 years (43 to 83). Tumor types: 3 NSCLC; 3 ovarian; 2 pan-
creatic; 1 mesothelioma, 1 esophageal, 1 adrenocortical, 1 head and 
neck cancer. 3 patients were treated at DL1; 2 dose limiting toxicities 
(DLTs) were noted: 1 grade (G) 4 thrombocytopenia; 1 G4 febrile 
neutropenia. Therefore the protocol was amended to (i) treat at DL –1 
(ii) enroll patients treated with < 2 prior, severely myelosuppressive 
chemotherapy regimens. No DLTs were noted at DL –1. However, 2 
patients developed G3 neutropenia; 1 patient received daily G-CSF 
(Neupogen®) x3 from D4. After amendment 3 patients have been 
treated at DL1, with 1 DLT: G4 thrombocytopenia in C1W3. 1 patient 
had G1 thrombocytopenia and G3 neutropenia before C2; treatment 
was delayed 1 week. 1 patient had G4 non-febrile neutropenia lasting 
1 day; C2 was delayed 1 week. Responses: 1 PR at DL –1 (patient 
progressed after study completion), 3 SD (at DL –1), and 3 PD (1 at 
DL1; 2 at DL –1). 2 patients withdrew (1 due to clinical progression, 
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1 tolerated treatment poorly). 3 patients treated at DL1 after amend-
ment haven’t undergone restaging scans at the time of reporting. 
Pharmacodynamically, post-treatment the drug inhibited its primary 
target in surrogate (PBMCs) and tumor tissue. Data for the first two 
patients on study (i.e. DL 1) are shown in Table 1. 
 Relative PAR Level in Post-dose sample/Pre-dose (%)
  Pt. 1 Pt. 2
 PBMC 19.5 3.2
 Tumor 10.4 7
Conclusions: Combination of olaparib with cisplatin and gem-
citabine was associated with significant myelosuppression in patients 
who had received >2 prior severely myelosuppressive chemotherapy 
regimens. Recruitment has been completed at DL –1; patients toler-
ated treatment better with no further hematological DLTs. Recruit-
ment is ongoing in patients with good bone marrow function at DL1. 
PD13.5.5 Novel Therapeutics, Tue, 12:30 - 14:00
Identification of predictors of response to NVP-AUY922, 
an HSP90 inhibitor, in an in vitro panel of human non-small-
cell lung cancer (NSCLC) cell lines
Garon, Edward B.2; Finn, Richard S.2; Dering, Judy2; Ginther, 
Charles2; Adhami, Shariar2; Pitts, Sharon2; Kamranpour, Naeimeh2; 
Hosmer, Wylie2; Rugaard Jensen, Michael1; Quadt, Cornelia1; 
Slamon, Dennis J.2
1 Novartis Institutes for Biomedical Research, Basel, Switzerland; 
2 Division of Hematology and Oncology; David Geffen School of 
Medicine at University of California, Los Angeles, Los Angeles, CA, 
USA
Background: Heat shock protein 90 (HSP90) is involved in protein 
folding and functions as a chaperone for client proteins. Many of the 
client proteins are felt to play a role in lung cancer pathogenesis, such 
as vascular endothelial growth factor receptors and mutant epidermal 
growth factor receptor. The exact mechanism of action of HSP90 
inhibitors is not completely understood. NVP-AUY922 is a highly 
potent inhibitor of HSP90 that is currently undergoing clinical study. 
We hypothesized that a subgroup of NSCLC would have greater 
susceptibility to HSP90 inhibitors, and evaluated that hypothesis in a 
panel of human NSCLC cell lines. 
Methods: To explore the potential of NVP-AUY922 as a therapeutic 
agent in NSCLC, we evaluated the biologic effects of NVP-AUY922 
in 34 human NSCLC cell lines growing in vitro. Using cell count 
assays, a growth-adjusted IC50, based on individual growth rates for 
each line, was generated. Cell death/lethality (LD50) was also as-
sessed for each cell line. Baseline gene expression data was generated 
for each cell line using the Agilent Human 1A V1 platform. These 
data were analyzed to identify potential predictors of sensitivity and/
or resistance. 
Results: All 34 cell lines were sensitive to the anti-proliferative 
effects of NVP-AUY922, with IC50’s ranging from 0.56 nM to 111 
nM. In contrast, a large difference was seen with regard to lethality 
among the cell lines. 18 cell lines had an LD50 less than 100 nM, 
and the remaining 16 cell lines had an LD50 greater than 250 nM. 
ANOVA of baseline gene expression profiles identified 284 dif-
ferentially expressed genes between low LD50 (sensitive) and high 
LD50 (resistant) cell lines. Interestingly, nine ribosomal proteins (L9, 
L12, L17, L31, L35a, L37a, S2, S3a, S4 X-linked) were elevated in 
sensitive cell lines as compared to the resistant lines. No ribosomal 
proteins were elevated in resistant cell lines. 
Conclusion: NSCLC cell lines are almost uniformly inhibited at low 
doses of NVP-AUY922, however, there is a separation of sensitive 
and resistant cell lines in regards to lethality. Differences in baseline 
gene expression were seen between sensitive and resistant cell lines. 
Cell lines with an LD50 less than 100 nM had high baseline gene ex-
pression of several ribosomal proteins. Ribosomal proteins have been 
demonstrated to be client proteins of HSP90, and increased degrada-
tion of ribosomal proteins could be a potential mechanism of action 
of NVP-AUY922. Ongoing studies are evaluating the molecular 
effect of treatment with NVP-AUY922 in both sensitive and resistant 
cell lines. 
PD13.5.6 Novel Therapeutics, Tue, 12:30 - 14:00
In vitro histoculture drug response assay (HDRA)-based 
adjuvant chemotherapy improves survival of locally 
invasive non-small cell lung cancer (NSCLC) patients
Niwa, Hiroshi; Tanahashi, Masayuki; Moriyama, Satoru; Suzuki, 
Eriko; Haneda, Hiroshi; Yoshii, Naoko
Division of Thoracic Surgery, Respiratory Disease Center, Seirei 
MIkatahara General Hospital, Hamamatsu, Japan
Background: This study investigated the value of the in vitro histo-
culture drug response assay (HDRA) for predicting the efficacy of 
chemotherapy in patients with non-small cell lung cancer (NSCLC). 
An ability to predict the response would facilitate tailored chemother-
apy for individual patients.
Method: Chemosensitivity testing by HDRA was performed with 
fresh specimens of primary tumors at surgery. Chemosensitivity to 
CDDP, CBDCA, paclitaxel (PTX), CPT-11, gemcitabine (GEM), 
and docetaxel (DOC) were examined by HDRA. Positive cutoffs 
of the inhibition index were 50% for CDDP, 40% for CBDCA, 
70% for PTX, 50% for CPT-11, 30% for GEM, and 40% for DOC. 
Patients were classified in two groups according to the number of 
administered HDRA-positive drugs. The prediction-sensitive group 
(n=28) comprised patients treated with 2 HDRA-positive drugs. The 
prediction-non-sensitive group (n=30) comprised patients treated 
with a combination of 1 HDRA-positive drug and 1 HDRA-negative 
drug or 2 HDRA-negative drugs. The clinical outcomes of these 2 
groups were analyzed.
Results: Fifty-eight patients received HDRA-based adjuvant chemo-
therapy using two drugs between January 2001 and December 2007. 
The median age was 61 years, with a 76% male (n=44) population. 
There were 35 adenocarcinomas, 17 squamous cell carcinomas, and 
6 others. The pathological stage was determined after surgery, and 
there were 5 stage IIA patients, 12 stage IIB patients, 17 stage IIIA 
patients, and 24 stage IIIB patients. The lymph node status was N0 in 
12 patients, N1 in 20 patients, and N2 in 26 patients. Seventy-eight 
percent of patients underwent complete resection. There was no 
significant difference in age, sex, histological type, stage, N status, or 
complete resection rate between prediction-sensitive and prediction-
non-sensitive groups. Multimodality chemotherapy based on in vitro 
HDRA was performed. Nineteen patients received a combination of 
CDDP and PTX, 15 patients a combination of CBDCA and PTX, 
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15 a combination of CPT-11 and PTX, 7 a combination of CDDP 
and DOC, 1a combination of CBDCA and GEM, and another 1 a 
combination of CBDCA and DOC. The overall 5-year survival rate 
was 96.4% in the prediction-sensitive group (n=28) and 18.7% in 
prediction-non-sensitive group (n=30) (p=0.003). The 5-year disease-
free survival rate was 38.3 % in the prediction-sensitive group and 
28.9% in prediction-non-sensitive group (p=0.002). The difference 
was apparent in stage III disease. The overall 5-year survival rate 
was 95.5% in the prediction-sensitive group (n=22) and 0% in the 
prediction-non-sensitive group (n=19) (p=0.003). The 5-year disease 
free survival rate was 66.7 % in the prediction-sensitive group and 
15.1% in the prediction-non-sensitive group (p=0.002). Multivariable 
analysis showed that the chemotherapy based on in vitro HDRA was 
an only significant prognostic factor (p=0.02).
Conclusion: Adjuvant chemotherapy based on in vitro HDRA im-
proves survival in patients with locally invasive NSCLC.
PD13.6.1 Novel Therapeutics, Tue, 12:30 - 14:00
Response to spray cryotherapy in a patient with 
malignancy of the parietal pleura
Downie, Gordon1; Harley, Daniel P.2; DeKeratry, Dominic3; Fields, 
Ester3; Faucet, Rick1; Young, Jay1; Krimsky, William2
1 Titus Regional Medical Center, Mt Pleasant, TX, USA; 2 Franklin 
Square Hospital Center, Baltimore, MD, USA; 3 Scott & White 
Memorial Hospital, Temple, TX, USA
Background: Malignancy of the parietal pleura is a therapeutic 
challenge; barriers to local regional pleural treatments include cost, 
complex dosimetry, and efficacy. Spray cryotherapy, a non-contact 
application of liquid nitrogen through a cryocatheter has been suc-
cessfully used in patients to ablate neoplastic tissue in the airway 
and on the parietal pleura. We report the initial safety and feasibility 
results for 20 patients who received treatment in the pleural space.
Methods: The outcomes of 20 patients treated with spray cryother-
apy for biopsy-proven neoplastic disease in the parietal pleura are 
reported. The parietal pleura was accessed in the OR or procedure 
room; all patients had lesion biopsies for diagnostic confirmation. 
Once confirmed, tumors were treated and duration of spray cryother-
apy treatment, as well as attendant thaw time, was recorded. Pleura 
were re-examined for clinical response 1-3 days after initial treat-
ment, and were biopsied and re-treated as necessary. Quality of life 
and dyspnea questionnaires were given at baseline and 30 days after 
final treatment.
Results: Primary clinical observations were the safety and feasibility 
of delivering spray cryotherapy to visible parietal-based lesions. The 
pleural lesions were easily accessed, and full dose of spray cryother-
apy to all visible tumors was accomplished. Treatment was applied 
exactly without any noticeable bystander side effect. Pleuroscopic 
reexamination revealed a greater than 50% reduction in the size of all 
treated tumors. No patient experienced adverse events and all patients 
showed symptomatic improvement over 30 days. 
Conclusions: Pleural neoplasm is a marker of systemic disease; 
often patients receive palliative rather than therapeutic modalities. 
As targeted therapies for cancer expand, exactly defining the burden 
of pleural disease becomes more relevant. Spray cryotherapy offers 
a low-complexity, relatively low-cost therapeutic option for pleural-
based malignancies. The first 20 patients’ results suggest that this 
technique is safe and feasible with encouraging tumor ablation. Our 
initial findings suggest a multi-center prospective trial is warranted.
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Aerosoltherapy for lung tumors using the monoclonal 
antibody cetuximab
Maillet, Agnès1; Guilleminault, Laurent1; Azzopardi, Nicolas2; 
Montharu, Jerome3; Vecellio, Laurent4; Sobilo, Julien5; Legrain, 
Brigitte6; Douvin, Dominique H.6; De Monte, Michèle1; Diot, 
Patrice1; Lerondel, Stéphanie5; Paintaud, Gilles2; Lemarié, Etienne1; 
Heuzé-Vourc’h, Nathalie1
1 INSERM U618, Tours, France; 2 UMR CNRS 6239, Tours, France; 
3 PPF Animaleries, Tours, France; 4 Aerodrug, Tours, France; 
5 CNRS UPS 44 –CIPA, Orléans, France; 6 Novaxia, St Laurent 
Nouan, France
Airways are an attractive alternative route to systemic administra-
tion that are routinely used in pulmonary diseases such as asthma or 
COPD for local delivery of drugs. However, they are not yet con-
sidered for lung cancer treatment in clinical practice. We previously 
showed that cetuximab, a chimeric anticancer monoclonal antibody 
binding to EGFR, resists to the physical constraints of nebulization. 
Herein, we studied the antitumor efficiency, biodistribution and phar-
macokinetics of cetuximab after aerosol delivery. 
After checking in normal mice that administration of cetuximab 
through airways did not result in any additional toxic effects com-
pared to its systemic injection, we analyzed the antitumor response to 
the antibody following aerosolization. Three weeks after the implant-
ation of A431 cells (reference line for this antibody) within the lungs 
of nude mice, the animals received either cetuximab aerosolized with 
a Microsprayer™ during three weeks or no treatment. Mice receiving 
cetuximab through airways had less lung tumors than control ani-
mals. To analyze biodistribution and pharmacokinetics of cetuximab 
administered through different routes, nude mice bearing human lung 
tumors received cetuximab labelled with a fluorescent dye through 
either airways or i.v. Cetuximab biodistribution was analyzed using 
optical imaging. Serum samples were collected and used to estimate 
cetuximab pharmacokinetics. Proteins extracted from lungs were 
subjected to western blot to evaluate the integrity of the antibody. 
Because FcRn, that regulates IgG half-life, is expressed in the alveoli 
in mouse, the influence of FcRn distribution in the lung tissues on the 
pharmacokinetics of the antibody was studied in non human primate. 
Our results showed that cetuximab was rapidly captured by the liver 
after i.v. injection and that only a small amount reached lung tumor. 
In contrast, after aerosol delivery, cetuximab accumulated durably 
in lungs and tumor. Non compartmental pharmacokinetic analysis 
indicated that cetuximab passage into the circulation was slow and 
limited after pulmonary delivery. In addition, cetuximab immuno-
detection in mice lung extracts suggested that cetuximab was still in 
its native form in the pulmonary tract. 
Our results demonstrate that aerosol delivery of cetuximab results 
in increasing its concentration within the target organ, limiting its 
passage into the bloodstream and reducing lung tumor formation. 
Altogether, our findings highlight the potential interest of pulmonary 
delivery of recombinant antibody for lung cancer treatment. 
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PD13.6.3 Novel Therapeutics, Tue, 12:30 - 14:00
The Src-PI3K-Akt and apoptosis signaling pathway-
targeted therapy with novel pro-apoptotic FUS1-
nanoparticles and Src kinase inhibitors for lung cancer
Ji, Lin; Wu, Guanglin; Sakai, Ryo; Roth, Jack A.
UT MD anderson Cancer Center, Houston, TX, USA
Background: the Src family kinases are key mediators for multiple 
signaling pathways and often aberrantly activated in human lung 
cancer, and, thus are attractive therapeutic targets. We have previ-
ously shown that the novel tumor suppressor FUS1 functions as a 
key mediator in the intrinsic apoptosis signaling pathway by directly 
interacting with Apaf-1 protein for facilitating induction of apoptosis 
and could also directly or indirectly interact with multiple protein 
tyrosine kinases such as EGFR, PDGFR, RAR-α, Src, and c-Abl and 
down-regulate their oncogenic kinase activities in lung cancer cells.
Methods: we evaluated a rationalized therapeutic strategy using 
a combined systemic treatment with the multifunctional FUS1-
nanoparticles and the Src kinase inhibitor Dasatinib or KX2-391 to 
simultaneously target the dysregulated Src-PI3K-Akt and apoptosis 
signaling pathways found in human lung cancer cells. We have com-
pared the effectiveness of the orally-available Src inhibitor dasatinib 
(a ATP competitive inhibitor) or KX2-391 (a novel non-competitive 
inhibitor that interrupts binding of the Src kinase to its substrates) 
as an single agent or in combination with FUS1-nanopaticles for 
potentiating their anticancer efficacy in NSCL and SCLC cells with 
a defined status of Src and EGFR and sensitivity to EGFR inhibitors 
in vitro. We also evaluated therapeutic efficacy of systemic treatment 
with FUS1-nanoparticles by i.v. injection and src inhibitors by oral 
administration on tumor development and growth in human A549 
lung experimental metastases tumor xenograft mouse models using a 
quantitative bioluminescence imaging (BLI) analysis. 
Results: we found that the dasatinib treatment alone showed a 
moderate level of tumor cell growth arrest and cell viability reduction 
but a low degree of apoptosis induction in the wt-EGFR-containing 
and gefitinib-resistant NSCLC cells and exhibited a very low degree 
of tumor cell killing in SCLC cells. In comparison, the KX2-391 
demonstrated a 10-100 fold higher tumor cell killing and apoptosis 
induction than Dasatinib in more than 20 NSCLC and SCLC cells 
tested and is independent of the status of the endogenous EGFR 
expression and the sensitivity to EGFR inhibitors. Furthermore, the 
ecotopic expression by FUS1- nanoparticle-mediated gene transfer in 
these lung cancer cells markedly enhanced the dasatinib- or KX2-
391-mediated tumor cell killing and their IC50s in NSCLC cells were 
dramatically decreased when combined with FUS1-nanoparticles. We 
also found that the combination treatment suppresses NSCLC cells 
growth by a significant induction of apoptosis and G1 arrest through 
a mechanism of action by the down-regulation of activated EGFR, 
PI3K, Akt, and Src kinases. A significant inhibition on the develop-
ment and growth of A549 lung tumor xenografts was detected in 
mice treated with KX2-391 by oral administration at a dose of 5 mg/
kg every 12 hr for one week and a combination systemic treatment 
with FUS1-nanoparticles and KX2-391 significantly enhanced Src 
inhibitor-mediated tumor growth inhibition. 
Conclusions: our findings suggest that a combination of the pro-
apoptotic FUS1-nanoparticle with novel Src inhibitors targeting the 
Src-PI3K-Akt signaling pathway that is predominantly activated 
in lung cancer cells could sensitize their response to Src inhibitors 
by more efficiently inhibiting tumor cell proliferation and sur-
vival, facilitating apoptosis, and overcoming drug resistance. (This 
abstract is supported by NIH/NCI Grants SPORE P50CA70907 and 
RO1CA116322).
PD13.6.5 Novel Therapeutics, Tue, 12:30 - 14:00
Trans-mediastinal delivery of lymphatic targeted 
chemotherapy for control of lymphatic metastasis in an 
H460 orthotopic lung cancer model
Liu, Jiang 1; Johnston, Michael R.2
1 Princess Margaret Hospital, Toronto, ON, Canada; 2 Dept. of 
Surgery, Queen Elizabeth II Health Sciences Centre, Dalhousie 
University, Halifax, NS, Canada
Background: An implantable lymphatic drug delivery device 
composed of gelatin sponge impregnated with biodegradable poly-
(lactide-co-glycolide) (PLGA) paclitaxel (PTX) colloid particles has 
previously developed. This study investigates the effect of the device 
in controlling lymphatic metastasis following mediastinal placement 
in an H460 orthotopic lung cancer model. 
Methods: A well characterized gelatine sponge device containing 
PLGA-PTX microspheres was synthesized in the laboratory. Each 
sponge contains 6.7 mg PLGA-PTX microparticles with a drug 
loading of 18% (1.2 mg PTX/sponge). A placebo control sponge 
containing an equivalent amount of blank PLGA microspheres was 
fabricated in the same fashion. Our previously described ortho-
topic human lung cancer model was established by endobronchial 
implantation via a tracheotomy of 1×106 H460 lung cancer cells into 
the left lung of nude rats. Using the same surgical incision, dissection 
was carried out along the pretracheal space to the carina, thus creat-
ing a tunnel for access to the mediastinum. The sponges were inserted 
into the mediastinum of tumor bearing rats in a PLGA-PTX treatment 
group (n=6) and a PLGA placebo control group (n=6). Animals were 
sacrificed 4 weeks following sponge insertion for both macro and 
microscopic assessment of lymph node metastasis. The incidence of 
lymph node metastasis, the ratio of lymph node involvement with 
tumor metastases and lymph node weight (as a measure of tumor 
involvement) were compared. The primary lung tumor weight and the 
animal body weight were also recorded. 
Results: All animals tolerated the procedures without complications. 
All the animals from the control group (6/6) developed mediastinal 
lymph node metastasis, while 66.7% (4/6) of the animals from the 
treatment group developed lymph node metastasis. The ratios of 
tumor involved lymph nodes to total lymph nodes recovered were 
22/27 (81.48%) and 8/25 (32%) for control and treatment groups, 
respectively. The mean lymph node weight (mean ± SD) was 0.395 
± 0.059 g for the control group vs 0.099 ± 0.018 g for the treatment 
group (p < 0.01). PLGA-PTX and PLGA blank particles were seen 
microscopically in both cancerous and noncancerous lymph nodes. 
There was no significant difference in primary lung tumor weight and 
animal body weight between the two groups. 
Conclusions: Direct trans-mediastinal lymphatic delivery of chemo-
therapy significantly inhibits growth of regional lymph node metas-
tasis in the H460 orthotopic lung cancer model. However, the system 
does not inhibit primary lung tumor growth. This novel therapeutic 
modality is well tolerated by the experimental animals and can be 
potentially applied to control lymph node metastasis via mediastinos-
copy in lung cancer patients. 
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P1.001 Basic Science and Translational Research, Sat Aug 1 
The application of plasma proteomic patterns for 
discrimination of patients with adenocarcinoma of lung 
from healthy controls
Akhmedov, Bakhrom B.; Shevchenko, Valeriy E.; Arnotskaya, 
Natalia; Zborovskaya, Irina B.; Polotskiy, Boris; Gotsadze, Ilya
N.N. Blokhin Russian Cancer Center, Moscow, Russia
No satisfactory plasma biomarkers were discovered till now for 
the early detecting and monitoring of lung cancer, one of the most 
frequently encountered cancers. In the present research the new meth-
odology for the search of tumor markers of lung cancer, involving 
profiling the low-molecular plasma proteomes (1-20 кDa) of blood, is 
developed, unified and approved. The given approach included three 
basic components: robotics pre-preparation of samples, matrix-assist-
ed laser desorption/ionization time-of-flight mass spectrometry and 
bioinformatics software for mass spectral data processing. Oppor-
tunities and prospects of the developed approach for the detection of 
potential lung cancer markers were shown.The plasma samples have 
been prefractionated using magnetic beads kits functionalized with 
weak cation exchange coatings. We compiled MS protein profiles for 
74 patients with adenocarcinoma of lung (AL) (stages III-IV) and 
compared them with profiles from 189 healthy controls. The control 
group was subdi¬vided into a preliminary set (125 controls) for mod-
el generation and a second validation set (64 controls). The AL group 
was also subdivided into a training cohort with 48 patients and test 
cohort with 26 patients for validation. Peptide profiles were acquired 
with an Ultraflex II mass spectrometer in linear positive mode. The 
MALDI-TOF spectra were analyzed statistically using ClinProTool-
sTM bioinformatic software. We detected about 385 peaks/spectrum 
in a mass range of 1000 – 20000 Da. 184 of these proteins had statis-
tically differential expression levels between AL and control plasma 
(P < 10-5). Compared to controls, 6 peaks (p<10-5) are increased in 
AL and 178 peaks are decreased. The series of the peaks were auto-
matically chosen as potential biomarker patterns in the training set. 
They allowed to discriminate plasma samples from healthy control 
and samples from AL patients (sensitivity – 89%, specificity – 95% 
for support vector machine) in external validation test. These results 
suggest that plasma MALDI-TOF MS protein profiling can distin-
guish AL patients from normal subjects with relatively high sensitiv-
ity and specificity, and the MALDI-TOF MS is a potential tool for the 
screening of lung cancer.
P1.002 Basic Science and Translational Research, Sat Aug 1 
Mechanisms of cancer vaccine induced tumor immunity in 
an experimental murine pulmonary metastasis preclinical 
model
Alalawi, Raed; Lowe, Devin B.; Aldrich, Joel F.; Shearer, Michael 
H.; Jumper, Cynthia A.; Kennedy, Ronald C.
Texas Tech University HSC, Lubbock, TX, USA
Our laboratory has developed an in vivo murine experimental pul-
monary metastasis model to evaluate the capacity of various cancer 
vaccination strategies to induce tumor immunity. This preclinical 
animal model provides insight into the mechanisms of cancer vaccine 
induced tumor immunity at both local and systemic sites. In this 
study, we utilized a viral encoded tumor specific antigen and a re-
combinant protein vaccination approach to study tumor immunity in 
the murine experimental pulmonary metastasis model. Simian virus 
40 (SV40) is an oncogenic DNA virus that has been associated with 
various human malignancies including malignant pleural mesotheli-
oma (MPM) - a tumor originating in the pleura of the lung. The SV40 
viral protein, large tumor antigen (Tag), represents a target for an 
immunologic based non-invasive modality for cancer treatment. Fol-
lowing immunization and immunologic depletion schemes employing 
recombinant SV40 Tag and rat monoclonal antibodies to CD4 and 
CD8 T cells, respectively, mice where challenged with a tumorogenic 
cell line expressing the SV40 T-ag protein. Tumor immunity was 
examined based on survival and tumor burden that is associated with 
the formation of lung tumor foci. Within our system, we determined 
the critical need for CD4+ and CD8+ T lymphocytes in the induction 
and effector phases of the systemic anti-tumor immune responses, 
respectively.
P1.003 Basic Science and Translational Research, Sat Aug 1 
TGF-beta1 stiffens lung carcinoma cells in culture
Acerbi, Irene; Pereda, Javier; Mollina-Molina, Maria; Reguart, 
Noemi; Navajas, Daniel; Alcaraz, Jordi
Universitat de Barcelona, Barcelona, Spain
Background: each tissue and organ is characterized by a unique stiff-
ness which is intimately associated with its specific function. While 
tissue stiffness is maintained in normal physiological conditions, it 
becomes abnormally high in many solid tumors. Studies in culture 
have revealed that epithelial cells grown on substrata that are stiffer 
than their tissue of origin exhibit a loss of differentiation markers, 
a raise in proliferation and, in some occasions, the acquisition of a 
migratory phenotype suggestive of epithelial-to-mesenchymal trans-
formation (EMT). The lung is a moderately soft organ with unique 
elastic properties that are necessary for breathing. However, how the 
mechanical properties of the lung become altered during tumorigen-
esis at the cellular level remains largely unexplored. 
Methods: we used the Atomic Force Microscopy (AFM) nanotech-
nique to measure the Young’s modulus (E) – a common indicator of 
cell stiffness – of cultured human lung carcinoma cell lines. We chose 
cell lines known to either undergo EMT (A549) or to not undergo 
EMT (H441) in response to transforming growth factor beta1 (TGF-
b1). Cells were cultured for 3 days in serum-free media without or 
with TGF-b1 (5 ng/ml). 
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Results: untreated A549 and H441 cells exhibited low E (450 ± 30 
and 1600 ± 500 Pa, respectively). In contrast, TGF-b1 treatment 
induced an eight- and three-fold increase in E in A549 and H441, 
respectively. Because fibrillar collagens such as collagen type I and 
type III are well known regulators of tissue stiffness in the lung and 
in other organs, we examined the expression of these collagens by 
quantitative RT-PCR. We found that TGF-b1 treatment induced a 
fold-increase of collagen I expression comparable to that of E data in 
both cell lines. In contrast, TGF-b1 had a weak induction of collagen 
III. 
Conclusions: our findings strongly support that TGF-b1 may com-
promise the normal mechanical properties of the lung microenviron-
ment by stiffening carcinoma cells and promoting expression of 
collagen I. Moreover, our data suggest that EMT is not necessary for 
TGF-b1 dependent mechanical alterations in lung carcinoma cells, 
although EMT enhances these TGF-b1 effects. These findings reveal 
a novel function of TGF-b1, i.e. stiffening of lung carcinoma cells, 
which may contribute to lung tumorigenesis by altering the normal 
balance of forces in the lung microenvironment and ultimately com-
promising lung function.
P1.004 Basic Science and Translational Research, Sat Aug 1 
Lung metastasis and growth of the tumors are enhanced 
with Thromboxane A2-TP receptor through platelet 
activity and production 
Amano, Hideki1; Matsui, Yoshio1; Ito, Yoshiya1; Nezu, Kenji1; Hara, 
Hidenori1; Ogawa, Fumihiro1; Yoshimura, Hirokuni1; Narumiya, 
Shuu2; Majima, Masataka3; Satoh, Yukitoshi1
1 Departmane of Thoracic Surgery, Kitasato University School of 
Medicine, Sagamihara, Japan; 2 Department of Pharmacology, Kyoto 
University, Kyoto, Japan; 3 Department of Pharmacology, Kitasato 
University Scool of Medicine, Sagamihara, Japan
Background: Platelet activity is known to correlates with poor prog-
nosis of cancers. However, the precise mechanism of this phenom-
enon remains unknown. Thromboxane A2 (TXA2) is a prostanoid 
formed by thromboxane synthase using the cyclooxygenase product 
prostaglandin H2 as the substrate and known as a potent stimulator of 
platelet aggregation and smooth muscle constriction. It has been al-
ready reported that TXA2 regulates endothelial migration, angiogen-
esis and tumor metastasis (BBRC 2000). We here studied whether TP 
receptor has a critical role with tumor growth and lung metastasis. 
Methods: 3.0X105 Lewis lung carcinoma cells (LLC) and Melan-
oma cells (B16) were injected into subcutaneous tissue of C57Bl/6 
(wild type mice, WT) and TP receptor knock out mice (TP-/-). 
3.0X104 LLC and B16 were injected into tail vein to WT and TP-/-. 
Tumor volume were assessed every 3days (calculated as (length X 
width2)/2)). Plasma level of Vascular Endothelial Growth Factor 
(VEGF), Stromal cell derived factor-1 (SDF-1) and Stem Cell Factor 
(SCF) were measured by ELISA. The number of metastatic colonies 
was counted under a light microscope on 28 days following after 
injection.
Results: LLC and B16 growth after subcutaneous injection and for-
mation of metastatic colonies in the lung after intravenous injection 
to TP-/-were significantly reduced compared to WT (P<0.05). Plasma 
level of VEGF and SDF-1 were significantly reduced in TP-/- com-
pared to WT (P<0.05). Interestingly, the plasma level SCF was down 
regulated in TP-/- (P<0.05). Furthermore the number of platelets were 
significantly reduced in TP-/- following after 21 and 28 days after 
tumor injection (P<0.05). By 28 days, almost 80% of WT injected 
LLC and B16 were died, but TP-/- were not. 
Conclusions: These results suggested that TXA2-TP receptor 
signaling enhances platelet activity, and production, release VEGF 
and SDF-1, resulting in enhancement of stem cell remobilizing that 
stimulate tumor growth and lung metastasis. Therefore, TP antagonist 
may be useful to protect tumor metastasis or recurrence.
P1.005 Basic Science and Translational Research, Sat Aug 1 
Association of vascular endothelial growth factor 
receptor-2 -271 G>A polymorphism with outcome of 
patients treated with bevacizumab plus chemotherapy in 
Advanced non-small cell lung cancer
An, She-Juan; Wu, Yi-Long; Yang, Yan; Zhou, Hai-Yu; Tang, Hong-
Yan; Wu, Hong-Sui
Guangdong Lung Cancer Institute, Guangdong General Hospital, 
Guangdong Academy of Medical Sciences, Guangzhou, China
Background: No biomarkers have been identified to predict outcome 
with the use of an antiangiogenesis agent for lung cancer. Our previ-
ous study indicated that the vascular endothelial growth factor recep-
tor-2 (VEGFR2, also known as KDR) -271 G>A polymorphism has 
been associated with altered gene’s transcriptional activity. Therefore, 
we evaluated the association of this genotype with efficacy and tox-
icity in 44 patients from SAiL, a single-arm, multicenter international 
trial evaluating the safety and efficacy of first-line bevacizumab with 
standard chemotherapy in over 2,000 patients (pts).
Patients and Methods: DNA was extracted from the lymphocytes of 
whole blood samples of patients from SAIL. The -271 G>A poly-
morphisms of KDR gene were tested by PCR and DNA sequencing 
methods in 45 patients. 1 patient was excluded from the study be-
cause of the non-cancer death. 44 samples were available to evaluate 
associations between genotype and outcome. 
Results: Of these 44 patients, 1 was large cell carcinoma, 43 were 
adenocarcinoma; 11 were IIIB stage, 33 were IV stage; 29 were male, 
15 were female; 18 died of lung cancer, 26 survive now. The mean 
age of these patients was 56.27 years, range from 34-76 years. The 
observation endpoints were progress free survival (PFS) and overall 
survival (OS). The main treatment-associated adverse events (AE) 
were thrombocytopenia, neutropenia, hypertension, proteinuria, and 
haemoptysis. All AEs were assessed using the National Cancer Insti-
tute Common Terminology Criteria for AEs (NCI CTC-AE) criteria 
(v3.0). The KDR -271 AA genotype was associated with significantly 
less thrombocytopenia when compared with the AG/GG genotypes 
combined (Chi-Square=4.314, P (2-sided)=0.046, Fisher’s Exact 
Test). AA genotype had a worse PFS and OS than AG/GG genotype, 
but no statistic significance was found(P=0.2429 and 0.4384, respect-
ively, log-rank test).
Conclusion: The present study suggests that patients with KDR -271 
AA genotype treated with bevacizumab plus chemotherapy have 
lower toxicity. The results need further confirmation study in a large 
sample size.
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P1.006 Basic Science and Translational Research, Sat Aug 1 
Lung repair after epithelial injury accelerates tumor 
growth via MIF dependent anti-apoptotic function
Arenberg, Douglas; Carskadon, Shannon L.; Zhao, Liujian; 
McMillan, Tracy
University of Michigan, Ann Arbor, MI, USA
Tissue injury, inflammation and repair involve highly conserved 
processes governed by molecular mechanisms which can be co-opted 
in tumors. We hypothesized that the lung’s stereotypical response 
to epithelial injury promotes orthotopic tumor growth. We initiated 
lung injury in C57Bl6 mice using different stimuli, injected Lewis 
Lung carcinoma cells via tail vein, and assessed tumor growth in the 
lung 14 days later. Tumor cells were injected after the acute phase of 
injury in response to bleomycin, or naphthalene, or one week after 
cessation of tobacco smoke exposure. Regardless of the mechanism, 
injured lungs contained more numerous, and larger tumors than sham 
injured lungs. Tumor growth was increased whether tumor cells were 
delivered via tail vein, or via intratracheal injection, suggesting that 
the increase in tumor growth was not due to increased lung micro-
vascular permeability. Tumors from injured lungs were not more 
vascular, but had higher levels of angiogenic CXC chemokines than 
tumors from non-injured lungs. Apoptotic indices in tumors from 
mice with injured lungs was reduced. The cytokine macrophage 
migration inhibitor factor (MIF) is highly expressed in tumors and in 
models of tissue injury, and promotes the expression of angiogenic 
CXC chemokines, and is anti-apoptotoc. We hypothesized that the ac-
celeration in growth seen in the injured lung microenvironment was 
due to MIF expressed in response to lung injury. MIF was expressed 
at higher levels in the lungs of injured mice. Consistent with this, we 
observed no increase in tumor growth, and no increase in tumor asso-
ciated angiogenic CXC chemokines after lung injury in MIF knock-
out mice, and the rate of apoptotsis was restored to control levels in 
MIF-/- mice. We induced lung specific over-expression of MIF in a 
double transgenic mouse, and determined that MIF over-expression 
by itself was sufficient to accelerate the growth and reduce the level 
of apoptosis of orthotopic LLC tumors. 
P1.007 Basic Science and Translational Research, Sat Aug 1 
MicroRNA expression profiling in lung adenocarcinoma 
from never-smokers with respect to EGFR mutation status
Au, Joseph Siu-kie; Cho, William C.S.; Chow, Andrew S.C.; Law, 
Stephen C.K.
Department of Clinical Oncology, Queen Elizabeth Hospital, Hong 
Kong, Hong Kong
Background: The most consistent and important genetic change in 
lung adenocarcinoma of never-smokers is the high incidence (about 
50%) of epidermal growth factor receptor (EGFR) mutations. The 
genomic and proteomic profiles with respect to smoking history and 
EGFR mutation status have already been extensively studied. Our 
present study focussed on the expression profiles at the microRNAs 
(miRNAs) level. MiRNAs are non-coding RNAs that regulate gene 
expression by targeting mRNAs for degradation or translational 
inhibition and have been shown to be important in major cellular pro-
cesses like development, differentiation, metabolism and neoplasia. 
Methods: The primary lung adenocarcinoma tissue and normal lung 
parenchyma from the same lobectomy/ neumonectomy specimen 
were collected from 10 never-smokers undergoing curative lung 
cancer resection surgery at Queen Elizabeth Hospital, Hong Kong. 
EGFR mutations were detected by DNA sequencing of exons 18 
through 21. Those cases with deletions at exon 19 were excluded 
from the present study. MicroRNA microarray profiling were 
performed using Eight-Multiplex Human MicroRNA Array v1.0 
containing 534 miRNA probes (470 unique human miRNAs and 64 
human-related viral miRNAs). Significant up- or down-regulated 
expression levels were validated by qRT-PCR. Implicated miRNAs 
were further studied by transfection on cell lines. 
Results: Seven out of 10 tumor specimens harboured EGFR muta-
tions (3 with L858R mutation alone, 1 with T790M mutation alone, 3 
with both L858R and T790M mutations). Fifty-five miRNAs showed 
significantly differential expression between adenocarcinoma and 
normal lung parenchyma (p<0.05 and >2-fold change). Significantly 
decreased expression of hsa-miR-145 (P=5.83E-4) was observed in 
those cancer tissues with EGFR mutation but not for those without 
EGFR mutations. On further study of the functions of the candidate 
miRNAs on cell viability of normal lung fibroblasts and various lung 
cancer cell lines, the transfection of hsa-pre-miR-145 significantly 
inhibited 45% of cancer cell growth in EGFR mutant lung adeno-
carcinoma. Quantitative RT-PCR assays showed that the relative 
expressions of hsa-pre-miR-145 were effectively increased in all the 
lung tissue cell lines following transfection with hsa-pre-miR-145 . 
Cell morphology in human lung adenocarcinomas with or without 
EGFR mutation revealed hsa-pre-miR-145 obviously induced apopto-
sis of cancer cells in lung adenocarcinoma with EGFR mutation. We 
are currently examining the downstream targets that play significant 
roles in EGFR mutation of non-smoking patients with lung adeno-
carcinoma. 
Conclusions: This study suggested that there were distinct miRNA 
expression profiles for adenocarcinoma in never-smokers. Down-
regulation of hsa-pre-miR-145 appeared to be important for the sur-
vival of adenocarinoma cells with EGFR mutations. Further elucida-
tion of the subsequent miRNA gene regulatory pathways would give 
insights into the pathogenesis and the potentially useful biomarkers 
for diagnosis, prognosis or therapy for this increasingly prevalent 
sub-type of lung cancer.
P1.008 Basic Science and Translational Research, Sat Aug 1 
SMO mRNA expression in Chinese patients with lung 
adenocarcinoma by real-time quantitative PCR
Bai, Xiaoyan; Lin, Jiaying; Wu, Yilong
Guangdong General Hospital of China, Guangzhou, China
Background: The Hedgehog (Hh) signaling pathway is crucial to 
the growth and patterning during embryonic development. Constitu-
tive activation of the Hh pathway has been found in several types 
of tumors. SMO is a crucial component of HH signaling pathway, 
many HH antagonists directly target SMO, and have shown promis-
ing effects inhibiting the proliferation of tumor cells. Although SMO 
has been shown to be overexpressed in pancreas, gastric, and prostate 
cancers, its role in the development and progression of lung adeno-
carcinoma has not been examined.
Methods: We used real-time quantitative PCR to assess SMO mRNA 
expression levels in tumor and matched normal tissue from 20 lung 
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adenocarcinoma patients and correlated the results with patient 
clinicopathological characteristics. Relative expression of SMO was 
measured by 2-ΔΔCT method. B2M was used as reference gene. Gene 
expression over two fold was regard as overexpression.
Results: SMO overexpression is found in 45% (9/20) patients, in 
which 4 are female and 5 are male. SMO is also high expressed in 
50% none smoker (7/14) and 40% smoker (2/3). In addition, 50% 
(5/10) lung adenocacinoma in early stage (I/II) and 40% (4/6) in ad-
vanced stage (III/IV) are detected SMO overexpressions. We can not 
find the significant correlation between SMO expression and gender, 
smoking history and stage.
Conclusions: SMO overexpression is found in Chinese patients with 
lung adenocacinoma. 
P1.009 Basic Science and Translational Research, Sat Aug 1 
Cancer cells suppress p53 in adjacent fibroblasts
Bar, Jair1; Feniger-Barish, Rotem2; Moskovits, Neta 4; Lukashchuk, 
Natalia3; Goldfinger, Naomi4; Rotter, Varda4; Goss, Glenwood1; Oren, 
Moshe4
1 The Ottawa Hospital Cancer Center, Ottawa, ON, Canada; 2 Chaim 
Sheba Medical Center, Tel-Hashomer, Israel; 3 The Beatson Institute 
for Cancer Research, Glasgow, UK; 4 Weizmann Institute of Science, 
Rehovot, Israel
Background: The p53 tumor suppressor serves as a crucial barrier 
against cancer development. In tumor cells and their progenitors, 
p53 suppresses cancer in a cell-autonomous manner. However, p53 
also possesses non-cell-autonomous activities. For example, p53 of 
stromal fibroblasts can modulate the spectrum of proteins secreted by 
these cells, rendering their microenvironment less supportive of the 
survival and spread of adjacent tumor cells. We speculated that suc-
cessful cancer cells have evolved a method to overcome the suppres-
sive effect of stromal p53, by inhibiting p53 activity in neighboring 
stromal cells.
Methods: p53 protein levels was evaluated at basal conditions and 
after a DNA damaging treatment, as a measure of the p53 activa-
tion pathway. Protein and mRNA levels of p53 target genes was also 
evaluated. Cancer cells were co-cultured with fibroblasts, or condi-
tioned medium was transferred among the cultures. Fibroblasts were 
produced from tumor or normal tissues of cancer patients. In vitro 
immortalized and transformed epithelial cells were used as a model 
of cancer progression. 
Results: Epithelial tumor cells can suppress p53 induction in neigh-
boring fibroblasts, an effect reproducible by tumor cell conditioned 
medium. The ability to suppress fibroblast p53 activation is acquired 
by epithelial cells in the course of neoplastic transformation. Specific-
ally, stable transduction of immortalized epithelial cells by mutant 
H-Ras and p53-specific short inhibitory RNA endows them with the 
ability to quench fibroblast p53 induction. Importantly, cancer associ-
ated fibroblasts are more susceptible to this suppression than normal 
fibroblasts. 
Conclusions: Tumor cells can suppress p53 induction in neighboring 
fibroblasts. This finding underscores a mechanism whereby epithelial 
cancer cells may overcome the non-cell-autonomous tumor suppres-
sor function of p53 in stromal fibroblasts. Unveiling the mechanisms 
by which cancer cells inhibit p53 of stromal cells might reveal a 
novel cancer therapeutic target. 
Reference: 
Bar et al, Oncogene (2009) 28, 933–936.
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invasion 
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Objective: Osteopontin (OPN) is a multifunctional glyco-phospho-
protein with a well established, but poorly understood role in the 
pathogenesis of non-small cell lung cancer (NSCLC). Moreover, 
the role of the three human isoforms (OPNa, OPNb, and OPNc) on 
the specific molecular pathways for OPN tumorigenicity is incom-
pletely understood. Tumor invasion is an essential component of the 
metastatic pathway. We hypothesize that expression of the individual 
OPN isoforms and their associated secreted proteins have differential 
effects on invasive properties of NSCLC.
Methods: Four NSCLC cell lines, H153, H358 (low native OPN 
expression) and H460 and A549 (high native OPN expression) were 
transfected with plasmids specific to each of the OPN isoforms (Ori-
gene, Rockville,MD) and empty vector control. Conditioned media 
was harvested at 48H in serum free conditions. Expression of plasmid 
was verified by PCR and OPN secretion was measured by ELISA 
(IBL, Japan). Comparisons were made between isoforms transfected 
and control cell lines in a MatrigelTM invasion assay. The impact of 
conditioned media from each transfected cell line was evaluated with 
the corresponding wild type (wt) cells on the same invasion platform. 
Results: Overexpression of OPNa resulted in a significant increase in 
invasion, while overexpression of OPNc resulted in a significant de-
crease in invasion in all four cell lines (Table, Column 1). OPN secre-
tion into media was significantly increased compared to controls with 
overexpression of OPNc, while OPNa and OPNb resulted in only 
moderate increases in secretion compared to controls. This effect was 
seen in all cell lines regardless of the level of native OPN secretion. 
(Table, Column 2) Conditioned media from OPNa transfected cells 
caused a significant increase of invasive capacity of the correspond-
ing wt cells compared to media from empty vector controls, while 
OPNc media resulted in a significant decrease in invasion in all four 
cell lines. OPNc media was then diluted to equivalent protein levels 
as media from OPNa (OPNc.dil) and the significant inhibitory effect 
persisted compared to control in all four cell lines (Table, Column 3). 
Conclusion: We have demonstrated that overexpression of OPNa 
increased invasion, while overexpression of OPNc reduced invasion. 
Conditioned media from the OPNa and OPNc transfected cell lines 
conferred a similar divergent effect on invasion of their correspond-
ing wt cells. This data indicates opposing impact of individual OPN 
isoforms on the invasive properties of NSCLC, and could lead to 
therapeutic strategies which selectively target these properties in an 
isoform specific manner. 
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Expression and epigenetic regulation of prostacyclin 
synthase in non-small cell lung cancer 
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Background: Prostacyclin synthase (PTGIS) inhibits platelet ag-
gregation and promotes vasodilation. Overexpression of this gene has 
been shown to inhibit lung cancer growth in a mouse model. Hyper-
methylation of the PTGIS promoter resulting in downregulation of 
PTGIS expression has been implicated in colorectal cancer. In this 
study we have examined both the expression patterns and epigenetic 
regulation of PTGIS in NSCLC. 
Methods: DNA/RNA and protein was extracted from matched tu-
mour/normal samples (Thoracic Oncology Research Group BioBank, 
St James Hospital). PTGIS in these samples and a panel of retrospect-
ive resected lung samples was examined by immunohistochemistry 
and western blotting. A panel of NSCLC cell lines were treated with 
inhibitors to histone deacetylases (HDi) and DNA methyltransferases 
(DNMTi) and PTGIS expression examined by RT-PCR. Chromatin 
immunoprecipitation (ChIP) was used to examine changes to the 
PTGIS promoter in response to HDi. 
Results: PTGIS was found to have variable expression in both tu-
mour samples and a panel of lung cancer cell lines. PTGIS expression 
was demonstrated in the vascular endothelial and bronchial epithel-
ial cells of normal sand cancerous sections. A striking variation in 
intratumoural PTGIS expression was observed. Methylation analysis 
of cell lines demonstrated hypermethylation of the PTGIS promoter. 
Treating cells with epigenetic inhibitors resulted in significant up-
regulation of PTGIS expression. Direct chromatin remodelling of the 
PTGIS promoter was confirmed. 
Conclusions: PTGIS is epigenetically regulated. The discrepancy 
between PTGIS mRNA and protein levels in tumor samples indicates 
that post-transcriptional and post-translational regulation of PTGIS 
is central to both its expression and regulation, and requires further 
elucidation. Strategies to increase PTGIS expression may provide a 
potential therapeutic opportunity for tumour prevention. 
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Background: Prostacyclin Synthase (PGIS) and Thromboxane synth-
ase (TXS) metabolize the cyclooxygenase product, prostaglandin H 
(2), into prostacyclin (PGI2) and thromboxane (TXA2) respectively. 
PGI2 and TXA2 have opposing actions, and changes in their ratio 
underlie many pathological conditions. PGIS over-expression inhibits 
cancer growth in a murine model, while over-expression of TXS 
has the opposite effects. TXS over-expression has been reported in 
a number of cancers and is associated with a poor prognosis and 
increased metastasis. The aim of this study was to determine the indi-
vidual contributions of these enzymes to the pathogenesis of NSCLC. 
Methods: Stable cell lines over-expressing PGIS and TXS were 
generated, and their effect on tumor cell survival was examined by 
BrdU, FACS, and cell invasion assay. PGIS and TXS expression was 
examined in human lung tumors (adenocarcinoma and squamous cell 
carcinoma) and matched normal controls by western analysis and 
IHC. In a separate IHC study, a 200-patient NSCLC TMA was gener-
ated in our unit and stained for TXS expression. TXS staining inten-
sity was correlated with clinical parameters (tumour subtype, gender, 
stage, nodal status). Kaplan-Meiers survival curves were constructed, 
correlating TXS staining intensity with survival following initial 
diagnosis. Cell proliferation/survival was examined in A-549 and 
SKMES-1 cell lines, following 24 h selective TXS inhibition with 
ozagrel (50 nM, 500 nM 5 µM). Following TXS inhibition, apoptosis 
was assessed by High Content Screening (HCS) and validated by 
DNA laddering and Cell Death ELISA. 
Results: To examine the individual contributions of PGIS and TXS 
to tumor cell survival pathways in NSCLC, cell lines over-expressing 
these enzymes were generated. Tumor cells over-expressing PGIS 
proliferated at a significantly slower rate than controls, were less 
invasive, and were also more sensitive to apoptosis following 
serum-starvation. In contrast, over-expression of TXS resulted in the 
opposite effects. Subsequent examination of the expression profiles 
of these enzymes in NSCLC revealed PGIS to be down-regulated or 
absent in human tumor protein samples relative to normal, while TXS 
was up-regulated in tumors. TMA analysis revealed TXS expression 
to be significantly higher in adenocarcinoma patients, relative to 
squamous (p<0.0001) and in males, relative to females (p<0.05). No 
significant correlation between TXS expression and patient survival 
was observed, suggesting that TXS may not be a prognostic factor in 
the disease. Targeting this enzyme with a selecive inhibitor (ozagrel) 
significantly reduced tumour cell proliferation/survival (p<0.05) and 
increased apoptosis in both cell lines. HCS for multi-parameter apop-
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tosis showed enlarged nuclei, decreased f-actin staining and a loss in 
mitochondrial mass potential following TXS inhibition. 
Conclusion: Overexpression of TXS increased proliferation and 
invasiveness of lung cancer cells, while PGIS overexpression had 
contrasting effects. Furthermore, expression patterns of these en-
zymes are altered in NSCLC, relative to normal. The expression ratio 
of these enzymes may underlie the pathogenesis of NSCLC. While 
TXS does not appear to be a prognostic factor, our data suggests that 
it may be a potential therapeutic target in NSCLC. In contrast, PGIS 
over-expression may be a novel strategy for future chemoprevention 
studies.
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apoptosis of Lewis lung cancer 
Chen, Zhiwei
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Lung cancer is one of the most lethal cancers known to human-
kind because of the high incidence and the high mortality. Cancer 
immunotherapy will not only restrain the growth of primary tumors 
but will generate systemic antitumor immunity capable of destroy-
ing distant metastases. The T-cell costimulator B7-1 (CD80), which 
costimulates T-cell proliferation via the CD28 pathway, will be use to 
stimulate antitumor immunity. 
Objective: To investigate the effect of B7-1 expression on growth 
and apoptosis of Lewis lung cancer.
Materials and Methods: Tumor was established by s.c. injection of 
2 x 106 Lewis lung cancer (LLC) cells into the right flank of mice, 
and growth was determined by measuring two perpendicular diam-
eters. LLC tumors reached 0.6 cm in diameter after approximately 14 
days. All experimental groups included six mice (Female C57BL/6 
mice, 6 weeks of age).
In B7-1 group, tumor was injected at multiple sites with 100 
µl(1×107pfu) of retrovirus carrier contains B7-1 gene every week 
for twice time. In control group, tumor was injected with 100 µl of 
saline. Tumors were excised on the 14 day after administration of 
therapeutic agents and controls, sections of 5-µm thickness were 
prepared. The expression rates of B7-1 and CD8+ were determined 
by immunohistochemisty, apoptotic index(AI) were calculated with 
TUNNEL methods.
Results: The B7-1 molecules expression rate of B7-1 group was 
46.6±5.7%, Apoptotic index (AI) of B7-1 group was 5.3±1.0%. They 
were higher than control groups (B7-1 expression rate 8.8±0.9%, AI 
0.2±0.4%, P<0.05). The percent of CD8+ cells in blood and spleen 
of B7-1 group was 15.4±3.2% and 41.8±21.8% respectively, which 
were higher than control groups (10.1±3.6% and 11.7±2.2%,P<0.05). 
Compared with the control group, growth of the implanted tumor was 
significantly reduced. The tumor suppress rate of B7-1 group was 
34.6% and 87.0% in day 8 and day 14 respectively (P<0.05).
Conclusion: To increase the B7-1 expression of tumor can suppress 
tumor growth and induce apoptosis. 
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Background: The clinical features of non-smoking, women, of east-
asian ethnicity, and adenocarcinoma with broncho-alveolar features 
predict for a good response to reversible Epidermal Growth Factor 
Receptor (EGFR) tyrosine kinase inhibitors (TKI). It is thought that 
these characteristics predict for the presence of sensitizing EGFR 
mutations, which are predictive of a good response to EGFR TKIs. 
The selection of patients for EGFR TKIs is thus often based on the 
above phenotypic selection, although the incidence of sensitizing 
EGFR mutations in this highly selected population is not well de-
scribed. This may become increasingly important given the increas-
ing use of EGFR TKIs as first line treatment in the “appropriate” 
patient. We sought to determine the incidence of EGFR mutations in 
this highly selected patient population, and to explore if these clinical 
characteristics would substitute for testing for the presence of the 
mutation. 
Methods: We examined the mutation status of EGFR in sixteen 
patients with newly diagnosed non-small cell lung cancer (NSCLC) 
with adenocarcinoma histology. These were all non-smoking women 
of east-asian origin, and were all chemotherapy and radiotherapy 
naïve. The paraffin embedded tissue samples were obtained from 
either fine needle aspirates performed for diagnosis or from surgical 
samples. These were sequenced to look for mutations in exons 18-21 
of EGFR. Tests were done in triplicates. 
Results: We found sensitizing EGFR mutations in only 58% of 
those sequenced, thus suggesting only a fair correlation between the 
phenotypic features and the presence of sensitizing EGFR mutations. 
There were 5 mutations in exon 19, and these were the classical 15 
bp deletion mutant most commonly described. 2 point mutations 
were present in exon 21 at L858R. 3 patients had wild type EGFR. 
Surprisingly, despite being chemo and radiotherapy naïve, there were 
2 patients with T790M mutation, without a concomitant sensitizing 
EGFR mutation. One of these patients had a trial of Gefitinib (before 
the results of sequencing were known), and had progressive disease. 
We were unable to obtain sufficient DNA for sequencing analysis for 
four patients, three of which had only fine needle aspirate samples. 
This is a common problem with small sample size of fine needle 
aspirate samples, although unfortunately, this is commonly the route 
used for diagnosis, especially in patients with advanced disease. 
This presents a problem especially when TKI use is considered, and 
biopsies, rather than fine needle aspirate samples should routinely be 
done when possible.
Conclusion: This is a small series of patients, but nonetheless allude 
to the possible need for testing for EGFR mutation, especially if 
EGFR TKI is considered for first line therapy for reasons as follow. 
The traditional clinical features of non-smoking, east-asian women 
with adenocarcinomas is associated only with a 58% correlation for 
the presence of sensitizing EGFR mutations in our cohort of patients. 
We find also the resistance conferring mutation T790M in 2 treatment 
naïve patients, and these patients should not be treated with reversible 
EGFR TKIs. 
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Background: Breathing difficulties associated with chronic obstruct-
ive pulmonary disease (COPD) as well as byproducts of cigarette 
smoke reduce the amount of oxygen available in blood, leading to 
instances of acute and/or chronic hypoxia. Hypoxia is recognized as 
a major therapeutic concern due to its ability to reduce the efficacy 
of both radiotherapy and chemotherapy. Moreover, hypoxia has been 
suggested to promote genetic instability as exposure of cultured cells 
to low oxygen levels can result in an elevated mutation frequency. 
This contribution to genetic instability may provide an explanation 
for clinical data, which associates hypoxia with more aggressive 
disease and poor outcome. The hypoxia responsive transcrip-
tion factor HIF1α is regarded as the primary molecular switch to 
alter gene expression in response to reduced oxygen tension. The 
nuclear translocation and consequent activation of HIF1 requires the 
heterodimerization with the dually named cofactor HIF1β or aryl 
hydrocarbon receptor nuclear translocator (ARNT). Interestingly, the 
ARNT/HIF1β protein is also a required cofactor for the aryl hydro-
carbon receptor (AhR). AhR is a receptor for a number of potent 
environmental chemical carcinogens including polycyclic aromatic 
hydrocarbons (PAHs). Upon ligand activation, AhR heterodimerizes 
with ARNT leading to the induction of xenobiotic metabolizing 
enzymes including the cytochrome P450 family members, CYP1A1 
and CYP1B1. These enzymes are critically involved in the metabolic 
activation/detoxification of carcinogenic PAHs. 
Methods: It is our hypothesis that HIF1 activation attenuates the 
AhR mediated protective gene expression, which may lead to 
increased genetic instability and malignant progression associated 
with exposure to PAHs. We first assessed if hypoxia influences AhR 
signalling by dually stimulating A549 human lung cancer cells with 
the hypoxic mimetic CoCl2, and the prototypical carcinogenic PAH 
benzo[a]pyrene (B[a]P). Cells were preincubated with CoCl2 for 1 h 
followed by cotreatment with B[a]P and CoCl2 for 18 h prior to an-
alysis by quantitative PCR (QPCR) and Western blotting to determine 
alterations in the gene and protein expression. The cellular conse-
quences of DNA adduct formation and genetic stability were deter-
mined by 32P-postlabelling and HPRT mutation analysis, respectively.
Results and Conclusions: QPCR and immunoblotting analysis indi-
cated that induction of the hypoxic response pathway upregulates the 
expected HIF1 target, carbonic anhydrase IX (CAIX) while partially 
reducing the transcription of AhR downstream targets CYP1A1 and 
CYP1B1. Although CoCl2 only marginally increased B[a]P-DNA ad-
duct formation, the B[a]P induced mutation frequency was markedly 
amplified by CoCl2. These data suggest a novel mechanism by which 
hypoxia can induce genetic instability by altering AhR downstream 
processes.
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Chronic inflammation is considered to be a risk factor for cancer 
development. However, the underlying processes have not yet been 
fully defined. In the lung, neutrophils are thought to affect carcino-
genesis by accelerating the metabolism of inhaled chemical car-
cinogens, thereby enhancing the formation of pro-mutagenic DNA 
adducts. Moreover, we showed recently that activated neutrophils, via 
the release of myeloperoxidase (MPO), interfere with the removal of 
such DNA adducts by inhibiting nucleotide excision repair (NER) in 
co-cultured lung epithelial cells1. 
The aim of the present study was to elucidate the effect of neutro-
philic inflammation on NER in vivo, using a mouse model of chronic 
lung inflammation (COPD). Therefore, mice were intratracheally 
instilled with 20 µg lipopolysaccharide (LPS), a contaminant present 
in cigarette smoke, provoking neutrophil infiltration into the airways, 
followed by the assessment of phenotypical NER capacity in pulmon-
ary tissues at 72 hours post exposure, using a modified comet assay.
Our data demonstrate that local LPS exposure caused a significant 
reduction of NER in the WT mouse lung. To be able to clarify these 
NER inhibiting effects, we analyzed the expression of relevant NER 
genes and found that LPS exposure significantly down regulates the 
expression of several NER related genes (XPA, XPC, XPF, XPG and 
ERCC-1), which was further confirmed for XPA on protein level by 
immunoblotting. 
In order to characterize the role of MPO, deficient mice without this 
enzyme were subjected to LPS and similar analyses were performed. 
Inhibition of NER was present but less pronounced in the Mpo-/- 
mice, because MPO deficiency attenuated the neutrophil influx in 
the airways. Furthermore, to provide direct evidence for the relation 
between neutrophils and NER inhibition, neutrophils were systemic 
depleted by treating the LPS exposed mice with specific antibodies. 
However, NER inhibiting effects were not abrogated in this mouse 
model. So, in contrast to our in vitro study, inhibition of NER activity 
as well as the expression of NER related genes appeared not fully 
dependent on the release of MPO and the influx of neutrophils. Resi-
dent alveolar macrophages may play a possible role regarding this 
discrepancy between our in vivo and in vitro study concerning MPO 
and neutrophil dependency of the observed NER inhibition.
In conclusion, in this study we demonstrated that in an LPS induced 
acute lung inflammation model, pulmonary nucleotide excision 
repair is inhibited which is only partly mediated by the infiltration of 
neutrophils and the consequent release of the enzyme myeloperoxi-
dase. Taken together, our data suggest a novel mechanism clarifying 
the link between chronic pulmonary inflammatory diseases, such as 
COPD, and lung cancer development. 
1. Nejla Güngör, Roger W.L. Godschalk, Daniëlle M. Pachen, Frederik J. Van Schoo-
ten, Ad M. Knaapen, 2007, Activated neutrophils inhibit nucleotide excision repair in 
human pulmonary epithelial cells: role of myeloperoxidase, Faseb J., 21., 2359-2367. 
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Plasminogen activator inhibitor type 1 (PAI-1) via complexing with 
urokinase and its receptor inhibits plasmin driven proteolysis and 
therefore regulates tumor-related an-giogenesis, invasion and metas-
tasis. It was however suggested that PAIs biological effect depends on 
its active concentration in the cellular milieu, with lower concentra-
tions inducing cancer cells bioactivity but supraphysiological exerting 
opposite effect. In or-der to assess the impact of PAI-1 anti-proteinase 
activity on the process of lung cancer cells proliferation we analyzed 
the effect of PAI-1 cysteine mutant (VLHL PAI-1) char-acterized by 
the prolonged half-life time (T1/2>700 h) and therefore enzymatic-
ally much more stable than wild type PAI-1 (T1/2~2 h). Two func-
tionally different lung cancer cell systems A 549 and H1299 charac-
terized respectively by normal and high urokinase production were 
evaluated. In H1299 cultures significant inhibitory effect was exerted 
by high PAI-1 concentrations (p<0,001). Its time-dependence was 
also observed as the inhibition was considerably more pronounced 
after 72 hrs of culture than 48 or 24 hrs (respectively (p<0,001, 
p<0,05). In A 549 proliferation was suppressed only by the high PAI-
1 concentration following 72 hrs of culture (p<0,01). Accordingly, the 
dosage- and time-dependent down-regulation of VEGF production 
was demonstrated, though inhibition rate was significantly higher for 
the H1299 cells. No changes in the bFGF production by cultured lung 
cancer cells were noticed. PAI-1 could be a negative regulator of lung 
cancer cells due to its anti-proteinase activity. Its biological effective-
ness is time and dosage-dependent.
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Background: Lung cancer remains a major worldwide health 
problem, representing 17.8% of the total number of deaths caused by 
cancer. VEGF is a central player in tumor mediated angiogenesis in 
NSCLC. Polymorphisms VEGF +936 C>T, -460 T>C and +405 G>C 
are believed to have functional activity. The aim of this study was 
to evaluate the genetic influence of such polymorphisms in survival 
outcomes of early and advanced stages of NSCLC patients. 
Methods: Caucasian patients admitted to the Portuguese Institute 
of Oncology of Porto (IPO-Porto), Portugal, with cytological or 
histological confirmed NSCLC, have been prospectively recruited to 
the study (1997-2009) (Table1). Patients were divided in: stage I/II 
patients with surgical resection and stages III/IV patients treated with 
chemotherapy (CT). The first line CT protocol consisted of platin in 
combination with paclitaxel, gemcitabine or docetaxel. DNA was 
extracted from peripheral-blood samples. The VEGF polymorphisms 
+936C>T, –460T>C, and +405G>C were genotyped by allelic dis-
crimination. Overall survival (OS) was the endpoint of this analysis 
and was calculated from the date of diagnosis to the patient’s date of 
death. Survival data were analyzed according to VEGF polymorph-
isms’ genotypes. 
Results: The VEGF +405G>C polymorphism was significantly asso-
ciated with survival in stages III/IV subgroup. Patients with geno-
types carrying C allele (CC/CG) had significantly diminished survival 
when compared with patients with GG genotype (18.2 months and 
23.5, respectively; P=0.018). 
VEGF+936 polymorphism was not associated with overall survival 
in patients with stages III/IV, but there was a statistically significant 
correlation between this polymorphism and survival in I/II stages 
(27.5 months for genotypes carrying the T allele and 49.0 months for 
genotype CC; P=0.017). 
After adjusting for age, gender, smoking status and histologic type, 
both polymorphisms (VEGF +405G>C and VEGF+936C>T) remain 
significantly associated with survival (P=0.037, P=0.006, respect-
ively).
VEGF-460 polymorphism was not associated with overall survival.
  Patients 
  No of Patients %
 Gender  
 Female  49 21.0
 Male 184 79.0
 Age  
 Mean+-S.D. 62.5+10.3 
 Histology  
 Squamous 92 39.5
 Adenocarcinoma 105 45.1
 Large Cells 9 3.9
 Other NSCLC 27 11.5
 Staging  
 I 20 8.6
 II 15 6.4
 III 97 41.6
 IV 101 43.4
 Smoking  
 Never 62 26.6
 Current 117 50.2
 Former 54 23.2
 VEGF+936 Genotypes  
 CC 163 70.0
 CT 53 22.7
 TT 5 2.10
 ND 12 5.20
 VEGF-460 Genotypes  
 TT 58 24.9
 CT 115 49.4
 TT 48 20.6
 ND 12 5.1
 VEGF+405 Genotypes  
 GG 95 40.8
 GC 104 44.6
 CC 25 10.8
 ND 9 3.8
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Conclusions: High VEGF expression and/or high angiogenic activity 
is noted in only about 30–40% of NSCLC. The reason for such a di-
vergence of VEGF expression remains obscure. The results obtained 
in this study suggest an association between VEGF polymorphisms 
and overall survival in patients with NSCLC. However, the VEGF 
status was assessed in blood samples, so further studies should be 
conducted in tumour tissue samples, to confirm these results. More-
over, controversial results have been published in literature regarding 
the influence of the studied variants in VEGF expression in tissue and 
its serum levels, future functional studies are urgent to clarify these 
issues.
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Background: HuD gene belong to n-ELAV (neuronal-Embryonic 
Lethal, Abnormal Vision)-like genes family that codify for onconeur-
al RNA-binding proteins. In the last few years the human members 
of ELAV are becoming of particular interest since they are tumour 
antigens predominantly associated with Small Cell Lung Cancer 
(SCLC). It has been observed that, during the course of their disease, 
a specific group of SCLC affected patients expresses a tissue-specific 
Hu antigen and develops antibodies against these proteins, normally 
expressed in the Central Nervous System. To date, few studies have 
been published focused on the genetic causes of the ectopic nELAV 
genes expression in Neuro-Endocrine Lung Tumours (NELT) and on 
the identifications of somatic mutations in patients affected by SCLC 
and Lung Carcinoid.
Methods: DNA from paraffin embedded blocks of tumour and 
normal lung tissues was extracted from 20 subjects with NELTs (1 
large cell neuroendocrine carcinoma, 4 SCLC, 11 typical carcinoids 
and 4 atypical lung carcinoids) and from 5 tumor cell lines. Screening 
by direct sequencing and cloning of the whole HuD coding sequence 
was performed and Loss Of Heterozygosity (LOH) was determined 
by fluorescence-based analysis of three microsatellite markers 
(D1S2748, D1S197 and D1S247) flanking the HuD locus.
Results: 20 primary NELTs were analyzed. A total of 13 DNA 
sequence variations (8 previously unreported) were found both in the 
regulative and in the coding HuD gene region in 7 different samples 
of NELTs. Microsatellite analysis showed LOH for at least one in-
formative marker in about 40% (7/19) of tumors. Interestingly, 4 out 
of the 7 tumors harbouring HuD mutations also had LOH for at least 
one marker.
Conclusions: Our preliminary data on NELTs tissues support the 
hypothesis that not only promoter but also coding regions alterations 
of HuD gene could contribute to the onset and/or NELT progres-
sion. It remains to be clarified how some of these variations could be 
involved in these events.
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4EGI-1 represses cap-dependent translation in malignant 
pleural mesothelioma and translationally regulates the 
expression of a cohort of potential cancer-related genes
De, Arpita1; Larsson, Ola2; Jacobson, Blake A.3; Peterson, Mark S.3; 
Kratzke, Marian G.3; Bitterman, Peter B.3; Kratzke, Robert A.3
1 Department of Pharmacology, University of Minnesota, 
Minneapolis, MN, USA; 2 Department of Biochemistry, McGill 
Cancer Center, McGill University, Montreal, Quebec, Canada; 3 
Department of Medicine, University of Minnesota, Minneapolis, MN, 
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Background: Malignant pleural mesothelioma (MPM) is a devas-
tating disease with a poor prognosis and a median survival time of 
only 1 year. Many of the newer targeted therapies that have gained 
use for the treatment of other tumors are relatively ineffective in the 
treatment of mesothelioma. Thus it is essential to identify new drug 
targets and validate their efficacy in the treatment of mesothelioma. 
Deregulated cap-dependent translation is a widely documented es-
sential feature of malignant cells. 4EGI-1 is a novel small-molecule 
inhibitor of cap-dependent translation and inhibits the interaction 
between translation initiation factors eIF4E and eIF4G. Here, we 
studied the effects of inhibited cap-dependent translation (by 4EGI-
1), in mesothelioma. 
Methods: Cell proliferation and chemosensitivity were measured 
by the Cell counting Kit 8. Cap-binding assay was carried out to 
study the inhibition of the formation of the cap-dependent initiation 
complex. The effect on PARP cleavage and the alteration in the phos-
phorylation of the translational repressor, 4EBP-1 were measured by 
western blot analysis. Polyribosome assay followed by microarray 
analysis were performed to identify genes that were translationally 
regulated upon 4EGI-1 treatment. Monte Carlo simulations were 
used to evaluate the significance of the correlation of this translation 
profile to another earlier established translationally regulated gene 
set. Finally, western blotting and quantitative real time PCR analysis 
are done to validate the translational regulation.
Results: 4EGI-1 inhibited eIF4E binding to the cap structure in both 
cell lysates and in growing cells. Interestingly, 4EGI-1 preferentially 
inhibited proliferation of the cancer cells compared to nontrans-
formed LP9 cells and inhibition of cap-binding was more profound 
in growing cancer cells compared to growing LP9 cells. Treatment 
with 4EGI-1 was associated with increase in the hypophosphorylated 
form (active form) of the translational repressor 4EBP-1 in the cancer 
cells and appeared to induce apoptosis in the cancer cells by cleaving 
PARP .The protein expression of certain well known translation-
ally regulated transcripts like c-myc, osteopontin and survivin were 
decreased after 4EGI-1 treatment. All these effects were however 
not apparent in the LP9 cells. Also, 4EGI-1 seemed to act additively 
in combination with Alimta (the approved chemotherapy drug for 
mesothelioma) or gemcitabine in cancer cells. Polyribosome analysis 
revealed a large cohort of genes that were altered on treatment of can-
cer cells with 4EGI-1.This gene set was found to have a very signifi-
cant negative correlation (p-value=0) with a previously published set 
of genes altered by the overexpression of eIF4E in human mammary 
epithelial cells. Lastly, western blot analysis validated the altered 
expression of some of these proteins on 4EGI-1 treatment. Validation 
by real time PCR should be completed soon.
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Conclusions: In conclusion, 4EGI-1 treatment reveals a possible new 
strategy for treating mesothelioma. Additionally, treatment with this 
drug might help us to identify new targets preferentially translated by 
cap-dependent translation in mesothelioma and establish their poten-
tial significance in the actual treatment of the disease.
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Department of Medicine, University of Minnesota, Minneapolis, MN, 
USA
Background: Non-small cell lung cancer (NSCLC) is a leading 
cause of cancer in the United States. Current treatment options are 
not significantly effective in reducing the mortality rate. Hence, 
identification of new treatment options is important. Since enhanced 
cap-dependent translation is a well-established cause of malignant 
transformation, we attempted to study the effect of a small molecule 
inhibitor, 4EGI-1 on NSCLC cells. 4EGI-1 inhibits the interaction 
between translation initiation factors eIF4E and eIF4G and thus 
represses cap-dependent translation. 
Methods: Cell proliferation and chemosensitivity were measured 
by the CCK-8 cell counting kit. The inhibition of the cap-binding 
translation initiation complex was analyzed by a cap-binding assay. 
Western blot analysis was used to study the effect on PARP cleavage 
and on the phosphorylation of the translational repressor, 4EBP-1. 
Polyribosome assay and subsequent microarray analysis were per-
formed to identify the global profile of genes that were translationally 
altered on treatment with this drug. Finally, western blot analysis and 
quantitative real time PCR will be done to validate that the altered ex-
pression of these genes is due to translational repression by 4EGI-1.
Results: 4EGI-1 inhibited proliferation of the NSCLC cells. It also 
inhibited cap-binding in the cell lysates as well as in the growing 
cells. 4EGI-1 treatment appeared to increase the hypophosphoryl-
ated form (active form) of the translational repressor, 4EBP-1 in the 
cancer cells. 4EGI-1 treatment also induced apoptosis in the cancer 
cells by cleaving PARP. Additionally, this drug repressed the protein 
expression of some common translationally regulated genes like c-
myc, survivin and cyclin D1 in the cancer cells. Also, 4EGI-1 exerted 
an additive effect in combination with gemcitabine in the cancer 
cells. Results of the microarray analysis will be available shortly.
Conclusions: Our results showed that this drug, 4EGI-1 introduces 
a new methodology for targeting this cancer. Furthermore, the global 
gene expression profile of translationally regulated genes can aid in 
the discovery of candidate cancer-related proteins. Hence, a valid 
future approach would be to analyze the significance of these proteins 
in the development of cancer and evaluate their importance in treat-
ing this disease.
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A proteomic profile from plasma samples to identify 
basal biomarkers of radiological response to cisplatin in 
combination with docetaxel for advanced non-small cell 
lung cancer patients
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Background: Non- small cell lung cancer has no predictive bio-
markers different to histological analysis. Several groups have 
evaluated several approaches to identify a few genes, transcripts or 
proteins that predict response to chemotherapy. However, a whole 
proteome analysis has been never tested to identify a basal profile 
associated with radiological response to a cisplatin doublet for ad-
vanced non- small cell lung cancer.
Methods: We have evaluated in a multicenter prospective study the 
value of a proteomic profile in plasma from 100 patients diagnosed 
with advanced/ disseminated non small cell lung cancer that received 
a chemotherapy schedule based on a cisplatin (50mg/m2) and 
docetaxel (50 mg/m2) combination every 2 weeks for six cycles. If 
a RECIST response were evidenced then patients continued to a max-
imum of nine cycles. After the first chemotherapy dose we obtained 
by peripheral venopuncture 5 ml of whole blood and plasma was 
extracted by double- centrifugation. Similarly, a new plasma sample 
was obtained in all patients after the sixth cycle. A SELDI-TOF ap-
proach was used to identify a common proteomic profile from plasma 
of patients that achieved a partial/ complete response. First, an initial 
cohort of patients (n=40) was used to identify the common profile. 
Then, a confirmative cohort of 60 patients was used to corroborate 
findings from the initial cohort in a discovery- screening approach, 
critical for this type of high- throughput technology.
Results: We report response data from the discovery cohort of 40 pa-
tients. Surprisingly, we obtain a high- degree of radiological response 
with 10.34% of complete responses (95% CI 2.78 to 27.19) and 
31.04% of partial responses (95% CI 25.49 to 59.29). Stable and pro-
gressive disease were reported for 41.38% (95% CI 25.49 to 59.29) 
and 17.24% (7.13 to 35.02) of patients respectively. Toxicity was 
mild without grade 3-4 effects. Median progression free survival was 
8 months. We have no enough events to report overall survival data.
Conclusions: This bi- weekly schedule has a high- degree of radio-
logical response and a favourable toxicity profile. Additional data of 
response and preliminary findings from the proteomic profile identi-
fied in the first cohort of patients will be presented at the meeting.
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lung carcinoids by ArrayCGH 
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Lung carcinoids can be classified in typical (TC) and atypical (AC) 
carcinoids. This classification is unreliable to predict biological be-
havior. Previous studies have mainly shown 11q deletions and MEN1 
gene mutations in tumorigenesis. To identify new gene loci and 
critical genetic events, we investigated 34 lung carcinoids by array 
comparative genomic hybridization (arrayCGH).
The lung carcinoids were classified according to the WHO in 19 
TC and 14 AC (1 case could not be reliably classified). The Ki67 
proliferative index was determined using MIB1 immunostaining. 
Genomic tumor DNA was used in ArrayCGH analysis, performed on 
3.7k genomic BAC arrays (resolution ≤1 Mb). Fluorescence in situ 
hybridization for chromosome centromeres 1, 3, 7 and 11was used to 
validate chromosome copy number.
The Ki67 proliferative index ranged from 0-7% in all lung carcin-
oids but was not significantly different between TC (1.1 ± 1.3) and 
AC (1.8 ± 1.5). In the total group of tumors the average number of 
chromosomal alterations (≥ 10Mb) was 6.2 ± 6.2 (range 0-28), and 
9q34.11 gains as well as 1p31.1 and 11q22.3 losses (≥ 1Mb, ≥ 3 
clones involved, ≥ 25% of tumors) were most frequently detected. 
When comparing TC with AC our data revealed: 1) a strong differ-
ence in the average number of chromosomal alterations (≥10 Mb), 
i.e. 4.1 ± 3.4 versus 9.2 ± 8.9, respectively; p=0.028); 2) particularly 
in AC deletion (≥10Mb) of chromosome 11q (7/14 vs. 1/19) with a 
critical region of loss at 11q21-q25; and 3) multiple gains at chromo-
some 8pq, 9q, and 17pq, and multiple losses at 1p, 2q, and 11q in 
≥25% of ACs.
In conclusion, lung carcinoids are characterized by a low Ki67 prolif-
erative index and heterogeneous chromosome profiles. Nevertheless, 
ACs harbor significantly more copy number changes than TCs at 
confined chromosomal regions, indicating the presence of putative 
carcinoid-promoting genes. For example, the 11q21-q25 deletion may 
point to a tumor suppressor gene telomeric of MEN1 at 11q13.
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Tumor-specific auto-antibodies as an early detection 
screening tool for non-small cell lung cancer
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Background: Non-small cell lung cancer (NSCLC) has an overall 
survival of less than 15%; however the 5-year survival for stage I 
disease is 57-67%. Unfortunately, 75% of NSCLC is diagnosed at an 
advanced stage. A screening test capable of early detection of NSCLC 
should, therefore, decrease mortality. Research is ongoing for low-
dose CT as a screening modality; however, CT trials currently lack 
proof of survival benefit. Through novel immunoproteomic methods, 
our group recently identified multiple tumor-specific autoantibodies 
in serum of patients with adenocarcinoma including alpha-enolase, 
fumarate hydratase (FH), glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), inositol-5-monophosphate dehydrogenase (IMPDH), and 
methylthioadenosine physophorylase (MTAP). We hope to broaden 
this work by evaluating serum of patients with multiple NSCLC 
histologies and control patients for these auto-antibodies using the 
Luminex platform. 
Methods: Luminex microspheres were conjugated to recombinant 
proteins of interest using standardized protocols. Each conjugated-
microsphere was validated using specific PE-conjugated antibodies; 
both individually to verify protein loading and multiplexed to evalu-
ate interassay cross-reactivity. Once validated, these microspheres 
were run as fluorescence-emitting antibody-capture assays against 
serum from 207 patients - 40 with COPD, 16 with benign resected 
lung nodules, 31 healthy controls, and 120 with NSCLC (84-T1-
2N0M0 and 36-T1-2N1-2M0). Median fluorescence intensity values 
(MFI), which correspond to the concentration of the auto-antibodies 
in the serum, were recorded for each sample. Statistical analyses 
were performed with SPSS-v15.0 using ROC area-under-the-curve 
(ROC-AUC) to describe the degree of correlation to the MFI and a 
given group. 
Results: Initially, all 3 benign populations together were compared 
to the NSCLC group. (See table, group1.) The ROC-AUC were 
significant for alpha-enolase, FH and IMPDH. Upon data review, 
control patients with surgically resected benign nodules (primarily 
caseating granulomas) appeared to have higher MFI for all analytes 
than other controls. When these patients were excluded from the an-
alysis (group2), the AUC and p-value was even stronger. Finally, no 
significant difference in autoantibodies to these 5 analytes was seen 
between node-postive and node-negative disease (group3). 
   Analyte ROC-AUC Mann-Whitney p-value
 Group1: NSCLC vs all controls   
  Alpha-enolase 0.630 0.001
  Fumarate-hydratase 0.679 0.000
  GAPDH 0.548 0.272
  IMPDH 0.743 0.000
  MTAP 0.593 0.013
 Group2: NSCLC vs healthy controls and COPD   
  Alpha-enolase 0.709 <0.001
  Fumarate-hydratase 0.765 <0.001
  GAPDH 0.597 0.034
  IMPDH 0.851 <0.001
  MTAP 0.658 <0.001
 Group3: Lymph node ±   
  Alpha-enolase 0.547 0.431
  Fumarate-hydratase 0.496 0.939
  GAPDH 0.512 0.868
  IMPDH 0.511 0.850
  MTAP 0.553 0.363
Conclusions: Increased auto-antibodies to FH, IMPDH, alpha-
enolase, and MTAP are seen in NSCLC, in both early and late stage 
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disease. Given the improved correlation after infectious lung diseases 
are removed from the control cohort, discriminating infectious/
inflammatory lung nodules from NSCLC is a much more difficult 
task. Further exploratory research is needed to define more specific 
auto-antibodies to assist in differentiating NSCLC from benign dis-
ease, with hopes to integrate these analytes into a multivariate, serum 
screening test. 
P1.025 Basic Science and Translational Research, Sat Aug 1 
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Background: Apoptosis resistance remains a major problem related 
to failure of drug therapy in cancer. New strategies for overcoming 
and reversing this problem are urgently requried. Activation of the 
extrinsic apoptosis pathway is one such strategy. TRAIL receptor 
activation is currently under investigation in clinical trials, however 
the molecular basis for the relatively sensitivity of cancer versus 
normal cells, remains unclear. 
Results: We found that procaspase 8 was overexpressed in non-small 
cell lung cancers (NSCLCs) compared to matched normal tissues. 
The caspase 8 inhibitor FLIP was also overexpressed in the major-
ity of NSCLCs. Silencing FLIP induced caspase 8 activation and 
apoptosis in NSCLC cell lines, but not in normal lung cell lines. 
Apoptosis induced by FLIP silencing was dependent on both TRAIL 
death receptors DR4 and DR5, but was not dependent on ligation of 
the receptors by TRAIL. Interestingly, FLIP silencing induced co-
localization of DR5 and ceramide in NSCLC cells, but not in normal 
cells. This cell surface DR5/ceramide clustering was necessary for 
induction of apoptosis and was abrogated by procaspase 8 down-
regulation. FLIP silencing supra-additively increased TRAIL-induced 
apoptosis of NSCLC cells, however, normal lung cells were resistant 
to TRAIL, even when FLIP was silenced. Importantly, FLIP silencing 
sensitized NSCLC cells but not normal cells to chemotherapy in 
vitro, and silencing FLIP in vivo retarded NSCLC xenograft growth 
and enhanced the anti-tumour effects of cisplatin. Moreover, NSCLC 
cells with acquired cisplatin resistance were re-sensitized to cisplatin 
following FLIP silencing. 
Summary: Collectively, our results suggest that due to frequent 
procaspase 8 overexpression, NSCLCs may be particularly sensitive 
to FLIP-targeted therapies.
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Identification of VDAC1 as a putative inhibitor of TRAIL 
induced apoptosis in non-small cell lung cancer
Chacko, Alex D.; Liberante, Fabio; Paul, Ian; Fennell, Dean A.
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Background: Resistance to apoptosis is both a hallmark of cancer 
and a critical problem limiting the efficacy of chemotherapy, particu-
larly in non-small cell lung cancer. Activation of death receptors by 
TRAIL receptor agonists is a strategy currently under investigation in 
non-small cell lung cancer such as the upcoming EORTC 08071 clin-
ical trial. Identification of resistance biomarkers will be important for 
optimal tailoring of TRAIL receptor agonist therapy. We have utilized 
short hairpin based RNAi screening as a tool to dissect components 
of the core apoptosis signalling machinery in order to identify poten-
tial resistance biomarkers. 
Results: A library of H460 non-small cell lung cancer cells were 
selected with stable knockdown of BAX, BAK, BAX and BAK, BID, 
BIM and VDAC1. Cells were then exposed to TRAIL ligand, which 
activates the DR4 and DR5 surface receptors. Two shBID clones 
(shBID1H460 and shBID2H460) partially blocked TRAIL induced 
caspase 3 activation consistent with a requirement for mitochon-
dria for full TRAIL induced death signalling. Unexpectedly, stable 
knockdown of mitochondrial VDAC1 to virtually undetectable levels 
protected cell against TRAIL induced apoptosis using ATP assay (2 
independent stable clones versus non-targeting vector expressing 
cells). Caspase 3 activation was markedly reduced by VDAC1 knock-
down, and caspase 8 activation was also attenuated. TRAIL induced 
PARP activation was blocked by VDAC1 knockdown. Using a prote-
omics strategy, we mapped the binding of haemagluttinin tagged BID 
BH3 to VDAC1, and mapped an outer membrane binding domain 
using peptide array. VDAC1 binds to inner membrane prohibitin 1 
and 2 forming a putative transmembrane spanning complex. VDAC 
is expressed at the mitochondrial surface. Recently, full caspase 8 
activation involving mitochondrial translocation has been reported, 
requiring mitochondrial tafazzin. Our findings suggest that this pro-
cess may be regulated at the mitochondrial surface by VDAC1. 
Summary: VDAC1 expression is required for activation of type II 
apoptosis by TRAIL ligand. Loss of VDAC1 expression in primary 
tumours could therefore be clinically associated with resistance to 
TRAIL receptor agonists. 
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Molecular characterization of NSCLC: prelude to 
treatment decisions with anti-EGFR based regimens
Murray, Samuel; Kosmidis, Paris; Kostopoulos, Ioannis; Bobos, 
Mattheos; Skarlos, Dimosthenis; Pectasides, Dimitrios; Fountzilas, 
George
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Background: Patient stratification based on molecular profiling holds 
promise for improvements in both response and overall survival. The 
search for candidate predictive and prognostic biomarkers has identi-
fied several related to anti-EGFR tyrosine kinase inhibitor (TKI) 
mono-therapy in advanced NSCLC. Following the identification 
of somatic mutations in EGFR correlating with responses to TKIs; 
KRAS, HER2, and BRAF have also been implicated in determin-
ing response and potentially survival in this setting. In addition, the 
expression (immunohistochemical; IHC) and/ or gene gain or loss 
of select genes has been added to a growing biomarker candidate 
list. We have assessed a series of TKI treated patients with advanced 
NSCLC for a panel of such candidate biomarkers in order to add to 
our understanding of their potential for patient stratification.
Methods: We retrospectively reviewed the files of patients who 
received Gefitinib (Iressa) as part of an expanded access program, 
and prospectively accrued patients who were treated with Erlotinib 
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(Tarceva). Patient demographics, stage, histology and smoking histor-
ies were recorded. Paraffin embedded tissue blocks were retrieved 
and histologically re-examined. Immunohistochemistry (IHC) was 
performed to assess expression of EGFR, pEGFR and MET. Gene 
copy number for EGFR, MET and candidate tumor-suppressor locus 
D7S486 (7q31) status was assessed by FISH. DNA was isolated from 
paraffin blocks (>75% tumor cell content) and exons 18-21 of the 
EGFR and exon 2 of the KRAS genes were amplified by PCR and 
bi-directionally sequenced. Mutant allele specific amplification for 
exon 19 deletions and L858R; and RFLP was used for L858R and 
KRAS codons 12/13. Incidence and correlation of response to these 
biomarkers were analyzed.
Results: A total of 43/47 patients were included in the analysis, 34 
Gefitinib and 9 Erlotinib treated. There were 26 (60%) males and 
17 (40%) females, all of Greek descent. Median age was 65 years 
(range, 37-80), 13 (30%) received a TKI in the 1st line setting. There 
were 25 smokers and former smokers (58%), 12 never-smokers 
(28%), and 26 adenocarcinomas (60%). We detected 12 classical 
somatic EGFR mutations (delEx19, L858R), and 4 KRAS codon 
12/13 mutations, these were mutually exclusive. Protein (IHC) ex-
pression of EGFR (63%), pEGFR (57%), MET (67%) was common. 
Gene gains of EGFR (7%) and MET (14%); and gene loss of D7S486 
(28%) were non-mutually exclusive. The presence of somatic EGFR 
mutations (p=0.008) and EGFR gene gain (p=0.011) correlated with 
disease control. No patient with a KRAS mutation achieved disease 
control, and no other biomarker correlated with response.
Conclusions: As indicated in many previous studies, somatic EGFR 
mutational status, EGFR gene amplification status and KRAS muta-
tional status appear to the more important biomarkers for predicting 
response to anti-EGFR TKIs in NSCLC. The search for additional 
effective biomarkers relative to patient stratification of NSCLC for 
any given therapy will potentially require the integration of data from 
multiple studies. This may allow for treatment algorithms, utiliz-
ing such biomarkers, leading to improvements in the likelihood of 
response and ultimately survival for this disease. Further molecular 
analysis is ongoing; survival data based on molecular biomarkers will 
also be presented.
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Background: Patients with malignant pleural mesothelioma (MPM) 
usually develop pleural fluid as an initial presentation. However, 
diagnosis of MPM with cytological evaluation of pleural fluid is 
usually difficult and has limited utility. Useful molecular marker 
especially for the differential diagnosis with lung cancer (LC) or 
other pulmonary diseases is urgently needed. The aim of this study 
is to investigate the diagnostic value of DNA methylation profiles in 
pleural fluid for the differential diagnosis of MPM.
Method: Pleural fluid was collected and DNA was extracted from 39 
patients with MPM and 46 with LC. Pleural fluid was also collected 
with 26 patients with benign asbestos pleurisy (BAP) and 18 with 
tuberculous pleurisy (TB), as control. The methylation status of 5 
tumor-suppressor genes, O6-methylguanine-DNA methyltransferase 
(MGMT), p16INK4a, ras association domain family 1A (RASSF1A), 
death-associated protein kinase (DAPK), and retinoic acid recep-
tor ß (RARß) was examined with methylation-specific polymerase 
chain reaction. The relative level of methylated genes in each sample 
was quantified and methylation ration was determined as the ratio 
of MSP-amplified genes to ß-actin (ACTB), a reference gene and 
described on a log scale and analyzed by using non-parametric two-
sided statistical tests.
Results: DNA methylation of RASSF1A, p16INK4a and RARß was 
detected in 12 patients (30.8%), 3(7.7%) and 11(28.2%) in MPM, 
and 22(47.8%), 14(30.4%) and 24(52.1%) in LC, respectively. The 
odds ratio of having LC compared with MPM was 2.86 (P=0.030) for 
patients with abberant methylation in at least one of these 3 genes. 
Methylation of MGMT and DAPK were detected in few samples. 
The mean methylation ratios of RASSF1A in MPM, LC, BAP, and 
TB were 0.37 (range, 0 - 2.84), 0.87 (0 - 3.14), 0.37 (0 - 2.79), and 
0.00 (0 - 0), respectively. The mean ratios of p16INK4a in MPM, LC, 
BAP, and TB were 0.10 (0 - 2.67), 1.16 (0 – 5.35), 0.16 (0 - 3.94), 
and 0.00 (0 - 0), respectively. The mean ratios of RARβ in MPM, AC, 
BAP, and TB were 0.44 (0 – 3.32), 1.68 (0 – 6.49), 0.27 (0 – 3.44), 
and 0.04 (0 – 0.66), respectively. Methylation ratio of these 3 genes 
were significantly higher in LC than in MPM (RASSF1A; P=0.039, 
p16INK4a; P=0.005, and RARβ; P=0.004). 
Conclusion: Our results suggest that identification of aberrant pro-
moter methylation of these tumor suppressor genes in pleural fluid 
DNA may be a potential useful maker to aid in differential diagnosis 
between MPM and LC.
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Localization of carboxypeptidase M in BHP-induced rat 
lung adenocarcinomas
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Background: Carboxypeptidase M (CPM), an extracellular 
glycosylphosphatidylinositol(GPI)-anchored membrane glycopro-
tein, cleaves the C-terminal arginine or lysine residues of proteins 
and peptides. CPM may participate in a variety of process, such as 
control of peptide hormone activity at the cell surface, degradation 
of extracellular proteins and peptides, and switching the peptide 
hormone receptor specificity. Although it was previously reported in 
1993 that CPM expressed on the plasma membrane of alveolar type 
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I epithelial cells, the localization of CPM still remains contraversial. 
We obtained monoclonal antibodies after immunization of mice 
with a membrane fraction isolated from embryo rat lung. One of the 
antibodies, 7F9, reacted with a 65-kDa protein that is expressed most 
prominently around birth. The antigen of 7F9 antibody was purified 
by serial column chromatography and immunoprecipitation, and 
identified by mass spectrometry. The epitope for 7F9 antibody was 
determined using a series of truncated proteins as the amino acid resi-
dues TSYGKDAEMTRLIDS of rat CPM on the protein databases. 
As this antibody was very sharp and specific, we applied it to the 
BHP-induced rat lung cancer . 
Methods: Five-week-old male Wistar rats were given 2000 ppm 
N-nitrosobis (2-hydroxypropyl)amine (BHP) in their drinking water 
for 12 weeks and then maintained for 12 weeks with normal water. 
All rats were exsanguinated from the abdominal aorta under light 
ether anesthesia 25 weeks after the start of the experiment. Lung with 
adenocarcinomas was isolated and homogenized for assessment of 
CPM expression by Western blotting analysis. The tissue was fixed 
and sectioned for HE staining and immunohistochemistry. 
Results: High yields of adenomatous lesions, including adenocarcin-
omas, were obtained from all BHP-received rats. HE staining showed 
that adenocarcinomas were histologically well differentiated. In the 
immunohistochemistry, the 7F9 antibody recognized signals on the 
plasma membrane of alveolar type II epithelial cells in normal lung.
In adenocarcinomas lesions, the signal of the 7F9 antibody was more 
strongly detected on the plasma membrane of tumor cells.
Western blotting analysis of the whole lung adenocarcinomas lysate 
showed stronger signal than of normal lung lysate. 
Conclusions: Localization of CPM is not on the surface of alveolar 
type I epithelial cells but type II epithelial cells in normal lung. In the 
well differentiated lung adenocarcinomas, CPM is localized in the 
type II like tumor cells with a sharp signal. CPM should be treated 
as a marker protein of alveolar type II epithelial cells. This model is 
useful for investigation of the molecular mechanisms involved in the 
development of lung adenocarcinomas.
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Analysis of OGG1 genetic variants among non-small cell 
lung cancer Brazilian patients
Garcia Carneiro, Juliana1; Bianchi Leidenz, Franciele Antonieta1; 
Melilo Carolino, Rachel1; Bastos Rodrigues, Luciana1; Camargos 
Bicalho, Maria Aparecida1, 2; Vilhena, Alyne2; Cunha De Marco, Luiz 
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1 Department of Molecular and Biochemical Pharmacology, 
Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; 
2 Thoracic Surgery Department, Hospital Julia Kubitschek, Belo 
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Background: DNA repair defects are trusted to be one of the causes 
of cancer development. The 8-oxoguanine DNA glycosylase 1 
(OGG1) gene is mapped on human chromosome 3. It participates on 
the base-excision repair pathway by encoding a DNA repair enzyme 
that removes 8-hydroxyguanine (8-OHG), an oxidatively damage 
product from double-stranded DNA. A Ser326Cys variant is found 
on OGG1 gene, and its prevalence is higher in Asian compared to 
Caucasian population. It has been demonstrated that OGG1-326Cys 
protein has a lower ability to prevent DNA damage repair than 
OGG1-326Ser protein. Previous studies have shown an association 
between OGG1-Ser326Cys polymorphism and an increased risk of 
Non-Small Cell Lung Cancer (NSCLC), especially among smokers. 
The present work aims to establish a relationship among the presence 
of Ser326Cys polymorphism, smoking status and incidence of lung 
cancer in patients of a Brazilian population.
Methods: Forty-seven non-small cell lung cancer patients [33 men 
and 14 women, average 61.1± 9.5 years (mean ± SD, range 35-77)] 
were selected for this study. These patients were classified according 
tumor histological type and smoking status. DNA extraction from 
tumor tissue samples and PCR reactions covering the whole gene 
were done. Sequencing analyses of OGG1 exons were performed to 
verify any alterations at the gene level, including Ser326Cys poly-
morphism. 
Results: Sequencing analyses showed that 25.5% of our patients 
carry the polymorphic allele encoding a cysteine at position 326 of 
Ogg1 protein. From this, 33.3% are in homozygosity state. All pa-
tients whom the polymorphism was found were heavy-smokers, with 
the exception of one. According to cancer histological type, 50.0% 
were classified as squamous cell carcinoma, 41.7% as adenocarcin-
oma and one case of big cell carcinoma. Interestingly, an intronic 
polymorphism IVS4-15C>G was found only in patients with the 
OGG1-Ser326Cys polymorphism. 
Conclusions: The present study has shown a prevalence of the 
polymorphic OGG1-326Cys allele in 25.5% of NSCLC patients. 
This percentage is higher than the prevalence of this variant among 
Caucasians showed in previous studies. The high percentage found in 
our study could be explained by the great heterogeneity characteristic 
of Brazilian population. However, there is still a need to increase the 
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number of cases in our work to confirm our data. It is also of great 
interest to perform more studies on this DNA repair pathway.
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IGF1R expression & mutational status in non-small cell 
lung cancer (NSCLC)
Forde, Lydia; Gately, Kathy; Gray, Stephen; Cuffe, Sinead; O’Byrne, 
Ken
St James Hospital, Dublin, Ireland
Background: Lung cancer is the commonest cause of cancer related 
death worldwide and has a very poor prognosis. An increased under-
standing of the molecular biology of lung cancer may result in the 
development of effective novel targeted therapies. IGF1R overexpres-
sion has been identified in several tumour types and protects cancer 
cells from apoptosis. IGF1R suppresses apoptosis primarily through 
the phosphoinositide 3-kinase (PI3K) pathway. Currently, several 
different approaches are being investigated for targeting the IGF1R, 
including small-molecule kinase inhibitors, IGF1R monoclonal 
antibodies, antisense oligonucleotides and RNA interference. Somatic 
mutations and single nucleotide polymorphisms (SNPs) in the kinase 
domain of a receptor may alter its kinase activity and impact the 
ability of a therapeutic agent to act efficiently. To date there is limited 
knowledge of mutations in the IGF1R. 
Aims of study: To examine a cohort of 197 patients with NSCLC for 
IGF1R expression, to screen for mutations in the tyrosine kinase do-
main of the IGF1R and to correlate the results to the patient clinico-
pathological data and prognosis. 
Methods: The expression of IGF1R was examined in a panel of cell 
lines (SKMES1, A549, HCC827, H1819, H1299) and patient samples 
(10 squamous and 10 adenocarcinomas) using Western Blot analysis. 
IGF1R expression was evaluated in 197 NSCLC patients (92 - squa-
mous, 87 - adenocarcinoma, 18 - others) using immunohistochem-
istry analysis and the results were scored by a pathologist as follows: 
0 (negative), 1+ (weak), 2+ (moderate) and 3+ (strong). The DNA 
from the same cohort of patients is being examined for SNPs and 
mutations in the tyrosine kinase domain of the IGF1R using sequen-
cing analysis.
Results: The panel of 6 NSCLC cell lines examined showed vari-
ability in IGF1R expression. In the fresh frozen resected NSCLC 
tumours IGF1R was overexpressed relative to matched normal 
tissues. Furthermore squamous cell carcinomas had higher levels of 
expression than adenocarcinomas. Immunohistochemistry analysis 
demonstrated that squamous cell tumours have higher IGF1R expres-
sion levels than adenocarcinomas (3+/2+ Squamous [70/197] versus 
3+/2+ Adenocarcinoma 27/197)] p<0.0001). To date 70 patients have 
been screened for mutations and we have detected a polymorphism 
(3129A >G) in exon 16 of IGF1R in 54.8% of NSCLC patients and 
34% in an age/race/gender-matched disease-free control population. 
Conclusions: Our findings indicate that IGF1R is overexpressed in 
NSCLC, particularly squamous cell cancer and is a potential target 
for therapeutic intervention. The role of polymorphisms and muta-
tions in the receptor remains to be determined. 
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non-small cell lung cancer 
Rothschild, Sacha1; Kappeler, Andreas2; Ratschiller, Daniel3; 
Betticher, Daniel C.4; Tschan, Mario P.1; Gugger, Mathias2; Gautschi, 
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Background: Inhibitor of differentiation 1 (Id1) plays a potential role 
in cancer stem cells, tumor invasion, and angiogenesis. We previously 
demonstrated that Id1 is regulated by Src kinase in non-small cell 
lung cancer (NSCLC) cell lines (Gautschi, Cancer Res. 2008). In this 
study, we examined the expression of Id1, Src and MMP9 in primary 
NSCLC. 
Methods: From our previously established tumor bank, 56 samples 
were selected for the production of a tissue microarray (TMA), based 
on the availability of histopathological and clinical data. Two samples 
lacking visible tumor were excluded from the analysis. A new, highly 
specific antibody (BioCheck Inc, California) was used to detect Id1. 
Optimal protocols for Id1, Src and MMP9 immunohistochemistry 
were developed. Staining intensities and fractions of positive cells 
were visually scored by an experienced pathologist (MG). H-scores 
were determined using the formula “staining intensity” x “fraction of 
positive cells”.
Results: The TMA contained 54 tumors, each from a different patient 
(pt). Clinical disease stage was I in 23 pts, II in 10 pts, III in 17 pts, 
and IV in 4 pts. Histology subtypes included 25 adenocarcinomas, 25 
squamous cell carcinomas, 2 large cell carcinomas, 1 LCNEC, and 
1 unclassified NSCLC. Histology grading was 1 in 9 pts, 2 in 22 pts, 
and 3 in 23 pts. Id1 nuclear expression was detected in 33/54 (61%) 
of the tumors. Id1 nuclear staining intensity was + in 19 pts, ++ in 12 
pts, and +++ in 2 pts. The percentage of Id1-positive tumor cells was 
<5% in 5 pts, 5-50% in 18 pts, and >50% in 10 pts. Expression of Id1 
in vascular endothelial cells was used as an internal control. Src was 
expressed in 54/54 (100%) of the tumors, located in the cytoplasm 
and at the cell membrane. In non-squamous tumors (n=29), H-scores 
for Id1 and Src correlated significantly (Z-test, p=0.019). MMP9 was 
expressed in 50/54 (93%) of the tumors. MMP9 H-score correlated 
significantly with histology grade (p=0.042). Staining intensities for 
MMP9 and Src correlated significantly (p=0.043).
Conclusions: Frequent co-expression of Id1 and Src supports 
our previous finding on the cooperation of these two molecules in 
NSCLC. Further studies to examine the role of Id1 as a potential drug 
target in NSCLC are ongoing. 
Notes: MG and OG contributed equally. Grant support to MG and 
OG from the Swiss Cancer League KLS 02164-02-2008, and the 
Bernese Cancer League. 
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An internet-based protocol to collect clinical 
information and blood from patients with lung 
cancer who never smoked cigarettes: www.mskcc.org/
neversmokerswithlungcancer
Girard, Nicolas; Klein, Robert; Riely, Gregory J.; Reddy, Rekha; 
Kris, Mark G.; Pao, William
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Background: Around 10% of patients develop non-small cell lung 
cancer despite smoking less than 100 cigarettes in a lifetime. These 
“never smokers” with lung cancer have a unique clinical course and 
likely represent a genetically susceptible subgroup distinct from lung 
cancer patients with a history of cigarette smoking. In the recent 
genome-wide association studies (GWAS) conducted in lung cancer, 
the role of smoking was inconsistent, and no risk variants have yet 
been definitively established specifically in never smokers. To iden-
tify such risk alleles, we plan to perform GWAS in a large group of 
patients with lung cancer who never smoked cigarettes. We hypoth-
esized that we could use the internet to collect clinical information 
and blood from these patients across the U.S.
Methods: We established an IRB-approved protocol to collect pro-
spectively clinical information and blood samples from patients re-
cruited via the internet. Interested patients enroll via a website hosted 
by Memorial Sloan-Kettering Cancer Center, New York (www.
mskcc.org/neversmokerswithlungcancer), by email (neversmok-
erswithlungcancer@mskcc.org), or by phone at 1-866-854-4652 (toll 
free number). Eligibility criteria are age>18yo, pathologic diagnosis 
of non-small cell lung cancer, smoking history <100 cigarettes in a 
lifetime, no previous invasive cancer, and resident of the U.S. Study 
materials are directly shipped to patients. Information packets include 
a cover letter detailing study goals and requirements, a consent form, 
a release of medical records form, and a self-administered question-
naire. The questionnaire assesses the eligibility criteria and collects 
information regarding other risk factors, diagnosis and treatment of 
the tumor. Once the eligibility is established, bloods are drawn at 
routine local doctor visits and returned to study investigators by free 
overnight shipping. Patients could also provide saliva samples in 
place of blood. DNA is extracted and processed for GWAS.
Results: The website went online on 09/14/08. As of 02/27/09, 86 
patients contacted us via the internet. Patients were from 26/50 states 
in the U.S.; 47 (55%) patients signed the consent form, and 39 (45%) 
were eligible, including 27 women and 12 men. Median age was 
50 years-old. 37 patients were Caucasian, 2 were Asian, and 1 was 
Black. Tumor histology was adenocarcinoma in 38 patients and squa-
mous cell carcinoma in 1 patient. EGFR mutational status was known 
for 17 patients: 2 had a L858R mutation, 6 an exon 19 deletion, and 
9 had no mutation. Overall, 29 of the 39 (74%) eligible patients sent 
back blood or saliva samples. The median time between first email 
contact and receipt of blood was 31 days. The study is active and 
currently recruiting.
Conclusion: Collection of clinical information and blood samples 
from cancer patients is feasible over the internet. We strongly encour-
age thoracic oncologists across the U.S. to inform potentially eligible 
patients about this unique program, which will be the largest of its kind 
for never-smokers with lung cancer. The identification of risk variants 
associated with this disease could facilitate the development of novel 
strategies for lung cancer prevention, diagnosis, and treatment. 
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Background: Approximately 10% -30% patients with lung cancer 
around the world report no history of tobacco smoking. Apart from 
the higher prevalence of mutations in the epidermal growth factor 
receptor tyrosine kinase domain, very little is known about molecular 
changes associated with lung cancer in never smokers. EphA2 is a 
receptor tyrosine kinase which has been associated with metastasis 
and poor prognosis in lung cancer (Clin Ca Res, 9:613-618, 2003). 
E-cadherin is a normal epithelial cell adhesion molecule which is 
down-regulated in the metastatic process of epithelial mesenchymal 
transition. We compared the expression of E-cadherin and EphA2 in 
never-smokers and smokers with resected non small cell lung cancer 
(NSCLC). 
Methods: From the Washington University/Barnes-Jewish Hospital 
tumor registry, we identified patients with NSCLC who reported no 
history of smoking tobacco. Smoking history was verified by individ-
ual chart review. These cases were compared to patients with resected 
NSCLC who had a smoking history. A tissue microarray (TMA) was 
constructed using two 0.8 mm cores per case from the original paraf-
fin tumor blocks. Expression levels of E-cadherin and EphA2 were 
evaluated by immunohistochemistry based on the staining intensity 
and the percentage of tumor cells which stained. E-Cadherin was 
graded on a continuous scale from 0 to 300. EphA2 expression was 
evaluated on a binary scale of low (includes no expression) or high. 
Fisher’s exact and X2 tests were used to compare the two cohorts. 
The Wilcoxon rank sum and t-tests were used to compare E-cadherin 
expression levels.
Results: A total of 53 never smokers and 61 smokers with NSCLC 
were included in this analysis. The never smoker cohort included 
more women (79% vs. 41%, p<0.001), and a greater proportion of 
adenocarcinoma (66% vs. 46%, p=0.023) compared to the smokers. 
Average E-cadherin levels were higher in never-smokers compared to 
smokers (271 vs. 229, p<0.001) and in adenocarcinoma compared to 
non-adenocarcinoma. (p < 0.001) When the analysis was restricted to 
patients with adenocarcinoma, never-smokers still had higher expres-
sion of E-cadherin compared to smokers (277 vs. 249, p=0.05). Low 
expression of EphA2 was seen more often in never smokers than in 
smokers (35% vs. 17%, p=0.03). No other clinical variables were 
associated with EphA2 expression.
Conclusion: Never smokers are less likely to have gene expression 
changes associated with metastasis, as evidenced by higher levels of 
E-cadherin and lower levels of EphA2.
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Background: PGE2 exerts its effects through binding to specific 
receptors. Four PGE2 receptors exist, designated as EP1, EP2, EP3, 
and EP4, according to their pharmacological profiles and signal 
transduction pathways. Evidence suggests these receptors may have 
predictive, prognostic and therapeutic value in non-small cell lung 
cancer (NSCLC), and currently, emerging data point to a role for 
epigenetics in the aberrant regulation of EP receptors in cancer.
Methods: A panel of normal and lung cancer cell lines were screened 
for EP1-4, by RT-PCR under conditions of normoxia and hypoxia 
(0.5%). Their expression in matched tumor/normal NSCLC patient 
samples was also examined. Epigenetic mechanisms regulating their 
expression were studied using HDAC inhibitors and DNA methyl-
transferase inhibitors. 
Results: Expression of all four EP receptors could be readily detected 
in all cell lines with the following exceptions; Beas-2B and A549 
did not express EP3, and H1299 did not express any EP2. In primary 
NSCLC lung tumour samples (n=20) with matched normal tissue, 
altered expression for EP receptors was observed in all tumour speci-
mens. EP receptor expression in NSCLC cell lines were demonstrated 
to be directly regulated via epigenetic mechanisms including DNA 
CpG methylation and via histone post-translational modifications 
(histone acetylation). Chromatin immunoprecipitation (ChIP) studies 
confirmed the direct remodelling of the EP promoters in response to 
histone deacetylase inhibitors. EP1 expression was induced follow-
ing 24 hour exposure to hypoxia, and we are currently evaluating the 
effect of hypoxia on the other EP receptors in these samples. 
Conclusions: Aberrant expression of EP receptors is common in 
NSCLC. Epigenetic mechanisms underpin their transcriptional regu-
lation. In addition, their expression is also affected by hypoxia. Fur-
ther investigations are required to delineate the role of these receptors 
in NSCLC, and targeting the epigenetic mechanisms underpinning 
this pathway may be of therapeutic value in the treatment of NSCLC. 
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IL-20 and its receptors are expressed and epigenetically 
regulated in non-small cell lung cancer
Baird, Anne-Marie1; Al-Sarraf, Nael1; Gray, Steven G.1; O’Byrne, 
Kenneth J.2
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Background: IL-20 is a pleiotrophic member of the IL-10 family and 
plays a role in skin biology and the development of haematopoietic 
cells. It has potent angiogenic, inflammatory and chemo-attractive 
characteristics with an involvement in rheumatoid arthritis and 
atherosclerosis. It activates STAT3 through two receptor complexes, 
IL-20RA/IL-20RB or IL-22R1/IL-20RB, which in turn promotes 
proliferation, apoptosis resistance and immune tolerance. STAT3 
activation is recognised as an important link between inflammation 
and cancer. 
Methods: Three normal bronchial epithelial (HBEC3, 4 & 5) and 
two lung cancer (A549-adenocarcinoma & SK-MES-1-squamous cell 
carcinoma) lines were examined. The effect of Trichostatin A (TSA-
250ng/ml) and 5-aza-2-deoxycytidine (DAC-1μM) on the mRNA 
expression of the IL-20 family was also studied. Chromatin immuno-
precipitation (CHiP) was used to investigate the effect of TSA on the 
IL-20 promoter. Matched tumour/normal pairs isolate from chemo- 
naïve patients at surgery, were examined at both the mRNA and 
protein level for expression of IL-20 and its receptors. 
Results: IL-20 was induced by TSA treatment in all cell lines. 
The effect on receptor expression varied between normal and lung 
cells. Results from a CHiP assay performed on A549 confirm that 
the induction of IL-20 by TSA is an immediate-early and response. 
DAC treatment slightly increased the expression of IL-20 in all cell 
lines with no significant effect on receptor expression apart from the 
reactivation of IL-20RA in the A549 and a decrease of IL-22R1 in 
SK-MES-1. In chemo naïve tumour normal matched pairs the follow-
ing was observed at the mRNA level: IL-20 and its receptors were 
increased in both squamous and adenocarcinoma tumour samples bar 
IL-22R1 (squamous) and IL-20RA (adenocarcinoma). IL-20 protein 
was not detected in normal or tumour for either sub-type. In contrast 
IL-20RB and IL-22R1 were increased in the tumours for both cancer 
types, while IL-20RA was decreased in 5/8 tumours (adenocarcin-
oma) and there was no clear pattern in the squamous samples with as 
many increased as decreased. 
Conclusions: IL-20 is an attractive treatment option in cancer owing 
to its roles in angiogenesis and inflammation. It has previously been 
demonstrated to have anti angiogenic properties in lung cancer 
cells, but this is contentious and remains to be clarified. If this is 
true, epigenetically targeting the upregulation of IL-20 via histone 
deacetylase inhibitors may be an attractive therapeutic target. This 
study demonstrates that this family are epigenetically regulated by 
histone post-translational modifications and DNA CpG methylation 
in these cell lines. Our results for IL-20RA at the protein/mRNA in 
adenocarcinoma confirm data previously published which found that 
IL-20RA was silenced by DNA CpG methylation in approximately 
60% of samples studied. HDAC inhibition or use of DNA methyl 
transferase inhibitors may therefore be a potential means of thera-
peutically targeting this pathway in lung cancer.
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Expression & epigenetic regulation of the CXC (ELR+) 
chemokines in NSCLC
Baird, Anne-Marie1; Al-Sarraf, Nael1; Gray, Steven G.1; O’Byrne, 
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Background: Chemokines are a group of small, mostly basic, 
structurally related molecules that regulate cell trafficking of vari-
ous types of leukocytes. The CXC (ELR+) chemokines have been 
demonstrated to play a variety of significant roles in oncogenesis. 
They have effects on endothelial cells involved in angiogenesis, and 
have been implicated in breast cancer metastasis to the lung. Histone 
deacetylase inhibitors have been shown to inhibit angiogenesis and 
are currently undergoing clinical trials for the treatment of cancer. We 
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are interested in examining the expression of the CXC (ELR+) family 
in normal and lung cancer cells and their epigenetic regulation.
Methods: A panel of normal and lung cancer cell lines were screened 
for the presence of CXC (ELR+) chemokines; CXCL1, 2, 3, 8 and 
their receptors CXCR2 and CXCR1 at the mRNA level by RT-PCR. 
The chemokine expression in matched tumor/normal samples from 
patients with NSCLC was also examined. Epigenetic mechanisms 
regulating their expression were examined using a) two HDAC inhib-
itors, 10mM Phenylbutyrate (PB) and 250ng/ml Trichostatin A (TSA) 
and b) a DNA methyltransferase inhibitor, 1μM 5-aza-2-deoxycyti-
dine (DAC), and chromatin remodelling at the promoter level was 
studied using Chromatin immunoprecipitation (ChIP). 
Results: All the chemokines tested were detected in the cell lines. 
However, an extremely low level of their receptors was observed 
in the lung cancer lines. TSA treatment decreased the expression 
of CXCL-1-3; and increased the levels of CXCL8 and CXCR1 and 
CXCR2 receptors. This trend was evident for all cell lines. PB (a drug 
with pleiotropic activities including the ability to inhibit HDACs) 
revealed a different trend in the lung cancer lines as it increased all 
chemokines and receptors. Chromatin immunoprecipitation (ChIP) 
confirmed that the upregulation of CXCL8 and receptors by TSA was 
a direct response to HDAC inhibition. Treatment with DAC signifi-
cantly increased the expression of CXCR2 in A549 and CXCR1 in 
SK-MES-1 indicating that this receptor is regulated at the level of 
DNA CpG methylation. A normal bronchial epithelial cell line treated 
with DAC had a significant increase in CXCL8 and receptors CXCR1 
and CXCR2. This would indictate that the regulation of these genes is 
different between normal and cancer cells. Finally, in NSCLC chemo- 
naïve tumour samples the expression of chemokines and receptors 
were reduced in both adenocarcinoma and squamous cell carcinoma 
samples when compared with their matched normal counterparts. 
Conclusions: This study indicates that members of the CXC (ELR+) 
family are epigenetically regulated by both histone post-translational 
modifications and DNA CpG methylation. It remains to be deter-
mined whether epigenetic targeting of this family represents a viable 
therapeutic target in NSCLC. Further investigations are required to 
delineate the vital balance of these chemokines in NSCLC, and to de-
termine if aberrant epigenetic regulation of these genes plays a role in 
NSCLC pathogenesis. Additional studies are warranted to investigate 
whether targeting this pathway may be of potential therapeutic value 
in the treatment of NSCLC. 
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Background: Hypoxia and chronic inflammation are key triggers 
in the transformation process with at least 20% of all malignancies 
initiated or exacerbated by inflammation. The aim of this project 
is to examine inflammation in the process of lung carcinogenesis 
with a particular emphasis on TNF-α, IL-1β and hypoxia. This will 
provide a cell line model in which to examine their effects on normal 
bronchial epithelial cells with the ultimate aim to modify the cells’ 
phenotype from normal to malignant.
Methods: A normal bronchial epithelial cell line (HBEC4) was modi-
fied to functionally over-express TNF-α and IL-1β. The cells were 
grown for three months under normoxia or hypoxia (0.5% oxygen) 
after which time a range of experimental assays were carried out to 
assess for cellular changes. These included: assays to examine cel-
lular proliferation, invasion, transformation, migration, and angiogen-
esis; sequencing for mutations and examination of gene expression 
changes using a Cancer PathwayFinder PCR Array. 
Results: Although cellular transformation was not detected as 
assayed by soft agar, the expression levels of c-Myc and p53 were 
found to have changed over time. There were no mutations detected 
in K-ras (Exon 2), However the invasion and adhesion potential has 
amplified and the growth rate has increased over time. Differences 
were also detected in the gene expression profile involved in other 
pathways involved in the hallmarks of cancer - invasion, adhesion, 
cell signalling, apoptosis, angiogenesis and cell cycle regulation. 
Conclusions: While malignancy is not yet evident in these cells, 
there are distinct indications that change is occurring. As pro-longed 
chronic exposure to inflammation is a pre-requisite for many disease 
states, these results warrant extended growth studies to further delin-
eate the complex roles of TNF-α, IL-1β and hypoxia in the process 
of carcinogenesis. This will assist in the development of novel cancer 
therapeutics and chemo-preventive agents in lung cancer.
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Combination of cytology and novel fluorescence in situ 
hybridization (FISH) biomarkers for diagnosis of lung 
cancer in induced sputum samples
Greif, Joel2; Guber, Alexander3; Gottfried, Maya3; Schwartz, 
Yehuda2; Rona, Ronni3; Yemini, Zipi2; Kaplan, Tal1; Pal, Boaz1; 
Daniely, Michal1
1 BioView Ltd, Rehovot, Israel; 2 Soraski Medical Center, Tel Aviv, 
Israel; 3 Meir Medical Center, Kfar Saba, Israel
Background: Examination of sputum is the least invasive method 
for obtaining a cytological diagnosis in subjects suspected of lung 
cancer (LC). However, sputum cytology is considered to be a test 
with high specificity (98%) but with low sensitivity (65%) in central 
tumors. The yield of sputum cytology is much lower in peripherally 
located tumors; in these cases fine needle aspiration (FNA) or surgery 
are usually required for diagnosis. Lung cancer has been proposed to 
reflect a field cancerization process. Genetic and epigenetic changes 
can be detected in lung tissue and cells from the airways of patients 
with LC. Recently, two biomarkers located at 3p22.1 and 10q22.3, 
were found to be altered in early stage LC by FISH. We assume that a 
pattern of genetic abnormalities in these regions in cells isolated from 
induced sputum (IS) might serve as an indicator of LC. We postulate 
that the combination of cytological staining and biomarkers in spu-
tum samples will enable an effective diagnosis of lung cancer. 
Methods: We blindly tested 86 IS samples from advanced and 
early stage LC patients and from healthy smokers and non-smoking 
controls (22, 19, 34 and 11 samples, respectively). Samples were 
evaluated using the Duet system (BioView Ltd, Rehovot, Israel), al-
lowing two consecutive scans of the same slide in two different stain-
ings: morphology and FISH. Cells were isolated from IS samples, 
stained in Papanicolaou and scanned automatically. Following the 
scan, “target cells” defined as normal and atypical cells derived from 
the lower airways and the lungs, were selected. Subsequently, cells 
were hybridized to a 3-color probe mixture containing locus-specific 
home-brew probes for chromosomes 3p22.1 & 10q22.3 and a centro-
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meric 10 probe. Then, the slides were scanned again and target cells 
were relocated and analyzed by their FISH pattern. The cutoff for 
malignancy was 7% of target cells showing genetic abnormalities by 
FISH.
Results: A pathological diagnosis was made by bronchoscopy in 12 
patients and in 29 by FNA. 14/41 cancer patients had adenocarcin-
oma, 1/41 has bronchoalveolar carcinoma, 11/41 had squamous 
cell carcinoma and 16/41 were defined as NSCLC. The majority of 
patients had a peripheral tumor (36/41). 40/41 LC patients were de-
tected by IS/FISH (97.56% sensitivity), with a specificity of 82.22%. 
The mean percentage of genetic abnormalities detected in LC patients 
was significantly higher than in controls (13.09±10.58 and 5.56±2.66, 
respectively, p=0.0035).
Conclusions: The current study presents for the first time that com-
bined analysis of cytology and FISH biomarkers at chromosomes 
3p22.1 and 10q22.3 in IS can be used as a reliable non-invasive 
diagnostic test for lung cancer. This technique was capable of de-
tecting central as well as peripheral tumors in both adenocarcinoma 
and squamous cell carcinoma. The high sensitivity and specificity 
(97.56% and 82.22%, respectively) imply on the potential of using 
this technique as first line evaluation prior to using a more invasive 
procedures. Also, this approach might be potentially used for mass 
screening of high-risk populations. 
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Establishment and characterization of a novel lung 
adenocarcinoma cell line derived from malignant pleural 
effusion in gefitinib resistance Chinese patient
Guo, Ailin
Guangdong General Hospital, Guangzhou, China
Background/Aims: Clinical intrinsic resistance to the EGFR tyrosine 
kinase inhibitor Gefitinib exists, but studies of the intrinsic resistance 
mechanisms are hampered by the lack of suitable experimental model 
systems. In the present study we describe the establishment and char-
acterization of a new human lung adenocarcinoma cell line DJR from 
gefitinib primary resistance Chinese patients. 
Method: The in vitro studies included karyotype analysis, tumor 
markers immunohistochemistry, Growth Rate Assay, analyzed of 
the cell cycle by FACS. Direct sequencing of exons 18 to 21 of 
EGFR and exons 2 of KRAS and NRAS was performed using DNA 
extracted from tumor cells. FISH were performed to analyze the copy 
number of EGFR. Subcutaneous inoculations into nude mice were 
carried out to study the tumorigenicity of this cell line. Cell sensitiv-
ity to drugs were analysized in vitro and in vivo.
Results: It was established from malignant pleural effusion of one 
Chinese lung adenocarcinoma patient who received gefitinib treat-
ment. This cell line has grown well for 22 months and has been 
cultured more than 80 times.The cell line growes as an adherent 
monolayer and shows typical morphological characteristics of 
pulmonary tumor cells. The cells exhibit a human karyotype, cells 
are hyperdiploid with a modal number of 77. The doubling time was 
18 h. Subcutaneous inoculation of the cells into nude mice yielded 
100% tumorigenicity and produced tumors resembling the original 
tumor. The cell line had not EGFR and KRAS mutations, EGFR copy 
numbers were 3/cell. EGFR,Vimentin, cytokeratin 7, ki67, ERCC1, 
were identified positive in the heterotransplanted tumor, HER-2, 
HER-3, HER-4, E-cad, cytokeratin 20, CEA, TTF1, FAK, SRC were 
negative by immunohistochemical staining. It showed an epithelial 
to mesenchymal transition (EMT). The cells were resistance to the 
growth inhibitory effects of gefitinib in vitro and in xenograft tumors, 
consistent with clinic treatment . 
Conclusions: The DJR cell line can be used as a new model for 
studying various aspects of the biology of human lung adenocarcin-
oma and gefinib resistance approaches for the disease. The data 
suggest that EMT may be as a biomarker predicting clinical activity 
of the EGFR inhibitor gefitinib in NSCLC patients.
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Real-time PCR analysis of microRNA expression profile in 
Chinese patients with lung adenocarcinoma
Zhang, Xin 2; Feng, Shipeng 3; Du, Bowen 3; Li, Huiping 3; Wen, 
Danping 2; Deng, Qiuhua 2; nan sheng, Zhong 2; He, Jianxing1, 2, 4; 
Zhang, Biliang 4, 3
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Purpose: MicroRNAs (miRNAs) are small noncoding RNAs with 
20-24 nucleotides, which negatively regulate the translation of tar-
geted mRNAs through incomplete base-pairing with their 3’-untrans-
lated regions (UTR). Many observations indicate that miRNAs play 
an important role in the development of human cancers including 
lung cancer. Our goal is to obtain microRNA profile and detect the 
different expression of microRNA in Chinese patients with lung 
adenocarcinoma. 
Patients and Methods: We collected the tumor tissues and normal 
adjacent tumor tissues (NATs) of 21 patients with stage I-IIIA lung 
adenocarcinoma during the surgery. Real-time PCR was applied to 
analyze 270 cancer-related microRNAs.
Results: We have investigated the different expression of 270 tumor-
related microRNAs in patients with Stage I-IIIA lung adenocarcin-
oma between tumor tissues and NATs, and its potential relationship 
to clinicopathological characteristics. We identified 49 miRNAs with 
different expression in the lung adenocarcinoma tissues compared 
with their normal tissue counterparts, 34 miRNAs of them were 
up-regulated and 15 miRNAs down-regulated. 21 patients were 
characterized by a dramatic down-regulation of some miRNAs (about 
10-fold; P <0.001) and up-regulation of several other miRNAs (about 
4 fold, P<0 .001).
Conclusions: Several miRNAs may serve as the molecular bio-
markers for lung adenocarcinoma and disease progression.
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A critical role of RhoE in tumor progression of non-small 
cell lung cancer cells
He, Jie1; Yu, Zhen2; Chen, Zhaoli2
1 AACR member, Beijing, China; 2 Beijing, China
Background: RhoE/Rnd3 is a member of the family of Rho GTPases 
that regulates many intracellular signaling pathways involved in 
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tumorigenesis, invasion, and metastasis. Increasing evidence has sug-
gested that RhoE plays an important role in carcinogenesis and tumor 
progression. Although it is reported that the expression of RhoE is 
significantly reduced in prostate cancer compared to correspond-
ing normal tissue, its expression is elevated in pancreatic tumors, 
colon cancer, and melanomas. These reports suggest that RhoE 
has multifunction in different cancer by mediating different signal 
pathway as a small G protein. Many potential function of RhoE and 
its mechanism still need to be further identified. Our former research 
demonstrated that overexpression of RhoE has a prognostic value 
in Non–Small Cell Lung Cancer. In current study, we investigated 
the expression of RhoE in Non-small cell lung cancer cell lines 
and characterizing the association of RhoE with NSCLC malignant 
progression.
Method: To validate the oncogenic potential of RhoE in lung cancer 
progression, we investigated the biological effects of either increased 
or suppressed RhoE expression in human lung adenocarcinoma cell 
line NCI-H1299, NCI-A549 and Anip973 cells. Then we investigated 
the effect of RhoE on the actin cytoskeleton organization of tumor 
cells. Furthermore, we elucidated the effect and mechanism of RhoE 
in lung cancer by estimating the role of RhoE in cell proliferation, 
cell cycle regulation, cell migration and invasion .
Result: Our study showed that overexpression of RhoE promoted 
cell cycle progression by increasing cyclin D1 and β-catenin expres-
sion in NSCLC cell line. In control Anip973 cells (pEGFP-C1), 
F-actin were arranged mainly as actin filaments bundles, which 
traversed through the cell body. By contrast, in RhoE up-regulated 
cells (pEGFP-C1-RhoE), F-actin formed a few thin stress fibers 
located around periphery of the cells. Moreover, overexpression of 
RhoE greatly enhanced the cell ability of proliferation, motility, and 
invasiveness of H1299 and Anip973 cells. Downregulated RhoE ex-
pression by RhoE-specific siRNA1# and siRNA2# could significantly 
inhibit cell migration and invasion of H1299 cells. In athymic nude 
mice, overexpression of RhoE efficiently enhanced tumor formation 
and metastasis of Anip973 cells compared to control.
Conclusion: The findings presented in this report suggest that over-
expression of RhoE may contribute to proliferation and metastasis of 
NSCLC cell by regulating the cell cycle progression and cytoskeleton 
remodeling. Interference with RhoE function may provide an import-
ant tool to block the malignant phenotype of lung adenocarcinoma 
cells.
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Significance of vascular endothelial growth factor 
polymorphisms on the angiogenesis in non-small cell lung 
cancer 
Hirami, Yuji; Maeda, Ai; Yukawa, Takuro; Shimizu, Katsuhiko; 
Nakata, Masao
Division of Thoracic and Cardiovascular Surgery, Kawasaki Medical 
School, Kurashiki, Japan
Background: The vascular endothelial growth factor (VEGF) is 
an important mediator of angiogenesis involving tumor growth and 
metastasis, and the VEGF protein expression was reported to be asso-
ciated with worse prognosis in non-small-cell lung cancer (NSCLC). 
We investigated the influence of the VEGF polymorphisms, which 
may regulate VEGF function and/or production, on the angiogenesis 
of NSCLC. 
Methods: Paraffin-embedded samples of fourteen patients (9 male, 5 
female; median age 71 years) undergoing complete surgical resec-
tion for pathological IA-IIIA NSCLC were studied retrospectively. 
VEGF genotyping of the polymorphisms (-460T/C and +405G/C) 
was performed using polymerase chain reaction/multiplex SNaPshot 
genotyping method. We also evaluated VEGF protein expression, 
microvessel density (MVD) by CD34, and Ki-67 labeling index by 
MIB-1 by immunohistochemistory. 
Results: The -460T/T, -460T/C, and -460C/C genotypes of VEGF 
polymorphisms were identified in 42.8%, 50.0% and 7.2%, re-
spectively. The +405C/C and +405G/C genotypes of VEGF poly-
morphisms were identified in 50.0% and 50.0%, respectively. The 
individual VEGF polymorphisms was not significantly correlated 
with VEGF protein expression, MVD, Ki-67 labeling index, or any 
clinicopathological factors, including age, sex, stage, histology, and 
smoking history. VEGF protein expression showed a significant cor-
relation with high MVD (p=0.02). 
Conclusions: Our results indicated that the polymorphisms (-460T/C 
and +405G/C) might not influence the VEGF production or function, 
although the role of other polymorphisms cannot be excluded.
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Therapeutic efficacy of a plasmid based vaccine 
encoding IGFBP-2 peptides is augmented by concurrent 
administration of plasmids encoding immunostimulatory 
cytokines
Holt, Greg Earl; Gad, Ekram; Disis, Mary L.
University of Washington, Seattle, WA, USA
Plasmid DNA is a potential vehicle for immunizing against tumor 
associated antigens. A DNA based vaccine strategy offers the advan-
tages of stability, easy modification and low cost over other vaccina-
tion methods. Our lab has previously demonstrated the ability of three 
MHC class II peptides derived from the non small cell lung cancer 
antigen insulin like growth factor binding protein-2 (IGFBP2) to both 
stimulate mouse T cells and produce anti tumor effects in mice chal-
lenged with an IGFBP2 expressing tumor cell line. We constructed a 
plasmid encoding these peptides and questioned whether the addition 
of genetic adjuvants encoding GM-CSF and IL-12, which would 
activate dendritic cells (DC), could enhance the therapeutic effi-
cacy. Cohorts of mice were vaccinated with either an IGFBP2 class 
II peptide based vaccine or a DNA plasmid encoding the IGFBP2 
peptides and challenged with IGFBP2 expressing tumor cells. Both 
the peptide and DNA based vaccines produced superior levels of anti 
tumor protection compared to controls, p = 0.01 and p = 0.0006, re-
spectively and equivalent levels of protection when compared to each 
other, p = 0.44. Immunization with plasmids encoding the IGFBP2 
peptides along with plasmids encoding GM-CSF and IL-12 was more 
efficacious in terms of tumor protection that the IGFBP2 DNA based 
vaccine alone, p = 0.034. Thus, the inclusion of the plasmid DNA 
encoding immunostimulatory cytokines improved the potency of a 
tumor antigen based plasmid DNA vaccine and allows future experi-
mentation to elucidate the underlying mechanism of the enhanced 
anti tumor effect.
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study of intratumor heterogeneity using FFPE tissue
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There is considerable interest in the use of gene expression data to 
generate prognostic and predictive biomarkers from non-small cell 
lung cancer (NSCLC) tissue. Since individual NSCLC tumors exhibit 
histological diversity, it is possible that different areas of individual 
tumors will exhibit distinct molecular profiles. This represents a po-
tential problem for the development of expression-based biomarkers.
To date, intratumoral gene expression has primarily been studied to 
determine the feasibility of using small biopsies in expression studies, 
e.g. in ovarian cancer. NSCLC studies describing EGFR mutations 
suggest that these tumors demonstrate tissue heterogeneity, however 
gene expression data is limited.
We are currently developing an early NSCLC prognostic gene 
signature using approximately 1500 FFPE tumor samples. The study 
of intratumoral gene expression in these samples will play a crucial 
role in facilitating the development of a robust gene signature. Ten 
samples were selected, representing five adenocarcinoma and five 
squamous carcinoma tumors. Five tissue blocks representing dif-
ferent parts of each tumor were analysed. RNA was extracted from 
both macrodissected and whole FFPE sections and processed onto 
the Lung Cancer DSA™, a lung cancer specific DNA microarray 
platform.
Bias and variations in gene expression were assessed at the intra- and 
inter patient (FFPE block) level and between adenocarcinoma and 
squamous samples. Unsupervised clustering and visualisation of gene 
expression data indicated that variations in gene expression were 
present between FFPE blocks taken from a single patient. However, 
the variations in gene expression observed between individual pa-
tients and disease states were greater. Gene expression data was also 
fitted to a repeated measures ANOVA model to assess the statistical 
significance of observed variations within and between samples and 
disease states. The implications for the development of expression-
based biomarkers are discussed.
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Background: Metastasis is the most common cause of cancer deaths. 
There is a high correlation between tumor invasion and patient sur-
vival in cancers and this pathway involves complex gene regulation. 
Invasion-associated DNA copy number aberrations may be useful for 
outcome prediction of cancer patients.
Methods: The invasion abilities and copy number aberrations of 11 
non-small-cell lung cancer cell lines were collected. Based on the 
invasion data, these cell lines were divided into two groups, the high 
invasion group and the low invasion group. The aCGH probes with 
significant copy number difference between these two groups were 
first listed (p<0.01) and the false discovery rate (FDR) was calculated 
for each chromosome separately. The cutoff value, 10%, for FDR was 
used to determine the invasion-associated probes. To further associate 
with the clinical outcome, we applied the univariate Cox regression 
to each of invasion-associated probes on an 80 Taiwanese NSCLC 
patients dataset. We further inspected the direction of correlation 
with survival to identify genes consistent with their invasion abilities. 
Finally, we validated the usefulness of these invasion-associated 
genetic markers for clinical prediction by Kaplan-Meier survival 
analysis.
Results: After comparative analysis (t-test) and FDR analysis, four 
chromosomes, chr6 (310 out of 2292 probes), chr12 (257 out of 1780 
probes), chr15 (723 out of 1061 probes), and chr17 (100 out of 992 
probes), were found significantly associated with invasion abilities. 
Among these probes, there are 33 probes which are significantly 
associated with patients’ survival. Furthermore, after checking the 
direction consistency, we found 28 invasion-associated genetic mark-
ers (27 protective probes, 1 risk probe) and these genetic markers had 
significant prediction power on our 80 Taiwanese NSCLC patients 
(log rank test, p=0.000556).
Conclusions: Genomic aberrations in NSCLC were powerful mark-
ers for survival prediction. We conclude that aCGH and invasion 
analysis were useful to identify chromosome regions associated with 
NSCLC patients’ survival.
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The Influence of benzo[a]pyrene on the expression of 
Aurora-A protein in XWLC-05 cells
Huang, Yunchao; Gao, Jia; Yang, Kaiyun; Zhao, Guangqiang; Li, 
Xiaoming; Ma, Qianli; Lei, Yujie; Wang, Kun; Ye, Lianhua
Yunnan Tomor Hospital, Kunming, China
Objective: To investigate the influence of benzo[a]pyrene on the 
expression of Aurora-A in Xuanwei Femalelung adenocarcinoma 
(XWLC-05), and further elucidate the underlying molecular mechan-
ism of the occurrence of this kind of carcinoma. 
Method: Incubation the cells in culture with different concentrations 
of benzo[a]pyrene,and analyze the expression of Aurora-A by FCM. 
Result: Expression of Aurora-A protein in Lung adenocarcinoma 
cells from Xuanwei Females (XWLC-05) was enhanced when the 
concentration of benzo[a]pyrene in cell culture increasing (P<0.05), 
and was reduced when the concentration of benzo[a]pyrene decreas-
ing (P<0.05). 
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Conclusion: Certain amount of Benzo[a]pyrene can promoter the 
expression of Aurora-A protein in XWLC-05 cells.
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Lipid nanocapsules: an original drug nanocarrier for lung 
cancer therapy
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Lipid nanocapsules (LNCs) are an original, solvent-free technol-
ogy allowing the production of new drugs nanocarriers able to make 
soluble lipophilic drugs as paclitaxel (1). The LNCs structure is 
composed of a lipid core in which the solubilised lipophilic drug is 
limited by a membrane of lecithin and pegylated poly-ethyleneglycol 
hydroxystearate chains with a size ranging from 25 to 100nm. The 
intrinsic properties of LNCs are the increasing of the amount of 
paclitaxel in the tumour due to enhanced permeability and retention 
(EPR) effect, the sustained release of paclitaxel, and the inhibition of 
P-glycoprotein (P-gp). The authors describe the first paclitaxel-loaded 
LNCs preclinical studies in lung cancer therapy.
First, the in vitro cytotoxic activity levels of paclitaxel-loaded LNCs 
versus Taxol® for NCI-H460 human lung cancer cells were deter-
mined using a growth-inhibition assay. Secondly, the pulmonary 
drug delivery of paclitaxel entrapped in LNCs by nebulisation was 
assessed. Finally, the antitumour efficacy of paclitaxel-loaded LNCs 
(L) versus Taxol® (T) and saline serum (S) in NCI-H460 xenograft 
model in nude mice was performed. The paclitaxel-loaded LNCs 
formulation was given i.v. at the dose of 12 mg/kg per day for 5 
consecutive days when tumours reached a volume of 100mm3 (Day 
1). A toxicological study was performed with the same schedule in 
Swiss mice (histological examination of lungs, liver, spleen and kid-
neys, complete blood counts and biochemical quantification of total 
bilirubin, creatinine).
The overall studies were made on 50-nm-diameter LNCs prepared 
according to the original process (1). The 50% growth inhibition 
(IC50) of Taxol® and paclitaxel-loaded LNCs were 4.4 and 3.8nM, 
respectively. The LNCs allowed a suitable form of paclitaxel aerosol 
to be produced. This aerosol, composed of water droplets in which 
the LNCs are dispersed, was compatible with a therapeutic study in 
humans. For nebulised paclitaxel-loaded LNC, the growth inhibition 
curves and the IC 50 parameters were similar to fresh paclitaxel-load-
ed LNC dispersion. The antitumour efficacy study revealed at Day 
8 that the mean tumoral volume was equal to 423 ± 42mm3, 277 ± 
19mm3* et 167 ± 34mm3*,** in the groups S, T and L, respectively 
(*P < 0.04 vs group S; **P <0,04 vs T, U tests with Bonferroni ‘s 
correction). No histological toxicity was observed in interest’s organs 
of Swiss mice. No difference in complete blood count, total bilirubin, 
creatinine were observed.
Our studies demonstrate the potential interests of LNCs in lung can-
cer therapy. Although IC50 of Taxol® and paclitaxel-loaded LNCs 
are similar, a significant improvement of the antitumour effect in ob-
served in a NCI-H460 xenograft model after a five-day i.v. injection 
schedule. This schedule does not induce any histological or biochem-
ical significant abnormality in Swiss mice. mice. In addition, LNCs 
could be nebulised and could permit the research of new therapeutic 
effects of paclitaxel in pulmonary delivery strategies for both primary 
and secondary lung malignancies.
References:
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Background: C4.4A is a structural homologue of the urokinase-type 
plasminogen activator receptor1, which is a well-established prognos-
tic marker in human cancer, and its expression is tightly regulated in 
normal squamous epithelium. C4.4A has been implicated in cancer 
invasion and metastasis, possibly playing a role in cell/cell inter-
actions. We recently showed a very interesting correlation between 
high levels of C4.4A and the survival of patients with non-small cell 
lung cancer (NSCLC)2. The prognostic impact could predominantly 
be attributed to patients with adenocarcinoma (AC), who had a par-
ticularly poor survival when the expression of C4.4A was high, while 
the subgroup of squamous cell carcinoma (SCC) showed no differ-
ence in the survival of patients with high and low levels of C4.4A. 
Methods: In the present study, we examine the pattern of C4.4A in 
the progression from normal epithelium to SCC and AC by immuno-
histochemical staining. We have focused on early reactive and 
premalignant changes of the lung epithelium: bronchial hyperplasia, 
metaplasia, dysplasia and carcinoma in situ (CIS) in the pathogen-
esis of SCC, and atypical alveolar hyperplasia (AAH) and bronchi-
oloalveolar carcinoma (BAC) in the pathogenesis of peripheral AC.
Results: C4.4A expression was absent in normal and hyperplastic 
bronchial epithelium, but was prominent in squamous metaplasia 
(see Figure 1) and remained high in dysplasia. CIS and invasive SCC 
showed a more heterogeneous pattern of expression. The reactivity of 
C4.4A in AAH was variable, but the majority of foci were positive, in 
contrast to the negative normal and reactive alveolar epithelium from 
patients with benign lung diseases. BAC and invasive AC compon-
ents exhibited a low, heterogeneous expression with some patients 
being devoid of C4.4A.  
Figure 1: C4.4A expression in bronchial squamous metaplasia
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Conclusions: The distinct patterns of C4.4A in the two histological 
subtypes of NSCLC reflect its regulated expression in normal squa-
mous epithelium. The presence of C4.4A already at the non-trans-
formed stage of squamous metaplasia offers an explanation for the 
lack of prognostic relevance in SCC patients and suggests that C4.4A 
rather is a new, early marker of squamous differentiation. The more 
variable expression of C4.4A in AAH precludes its use as a general 
marker for this AC precursor lesion, but combined with the striking 
impact of C4.4A on the prognosis of AC patients, its expression level 
may, interestingly, identify a further subtype of this disease. 
1 Jacobsen B and Ploug M. Curr. Med. Chem (2008) 15, 2559-2573.
2 Hansen LV et al. Lung Cancer (2007) 58, 260-266.
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Expression of sex hormones in tumor and normal lung 
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Background: Non-smokers constitute around 15% of NSCLC cases 
in the Western countries. Molecular characterization of NSCLC 
of non-smokers might give valuable insight into pathogenesis and 
etiology of this disease. As women constitute the majority of NSCLC 
patients who never smoked, we investigated the expression of sex 
hormone receptors in NSCLC samples from smokers vs. non-smokers 
and in tumors vs. in normal lung tissue. 
Methods: 46 pts (42 women and 4 men) underwent pulmonary 
resection with curative intent. Tumor samples from 27 non-smoking 
and 19 smoking NSCLC pts (with corresponding normal lung tissues 
from 15 and 10 pts, respectively) were analyzed. Gene expression of 
4 sex hormone receptors (estrogen receptor alfa, estrogen receptor 
beta, progesterone receptor and androgen receptor) was assessed by 
RT-PCR in snap frozen tissue. The raw gene expression data were 
normalized vs. the normalization factor based on the expression of 
18S, POLR2A and ESD. Gene expression was obtained by ΔΔCT 
method.
Results: Expression of androgen and progesterone receptors was 
significantly higher in tumors of non-smokers vs. smokers (p=0.0005 
and p=0.001, respectively). Of note, expression of progesterone 
receptor (p<0.0004) and androgen receptor (p<0.0002) in tumor sam-
ples was 2-fold and 4-fold higher, respectively, in non-smoking vs. 
in smoking female patients. Expression of progesterone and andro-
gen receptors in the normal lung tissue was not related to smoking 
status. Tumors expressed lower levels of progesterone and androgen 
receptors in comparison to normal lung tissue. Expression of estrogen 
alfa and beta receptors was not related to smoking status and did not 
differ between tumors and normal lung tissue both in smokers and 
non-smokers. 
Conclusions: Overexpression of progesterone and androgen recep-
tors in NSCLC samples from patients who never smoked suggests 
possible hormonal dependence of this type of NSCLC. This finding 
may be suggestive of new therapeutic possibilities of NSCLC in 
never smokers.
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Adenovirus mediated ING4 to induce the apoptosis
Jiang, Dong; Li, Fang
Medical College of Suzhou University, suzhou, China
Background: In present, in some developed countries of West 
Europe and North America the incidence of lung cancer has ranked 
the first among all the other type of malignant tumors. While in our 
country, more and more young people have been affected by lung 
cancer, which has an upward trend in the incidence these years, 
and could only been diagnosed at an advanced stage and has a poor 
prognosis. The conventional treatments for lung cancer are resection, 
radiotherapy and chemotherapy, immunotherapy, even the hyperther-
mia, but no one could be regarded as the effective and specific for 
lung cancer in an advanced stage, with lymph node metastasis. But 
the treatment and prevention of lung cancer are major unmet needs 
that can probably be improved by a better understanding of the tumor 
related genes and the associated mechanisms also. The candidate 
tumor suppressor protein inhibitor of growth family member 4 
(ING4) has recently been implicated as a repressor of angiogenesis 
and tumor growth through association with NF- B. Here we demon-
strate that suppression of ING4 on human lung cancer cell A549 and 
the possible related mechanism of action, through the new set-up and 
effective Recombinant Adenovirus. 
Methods: After amplifying and recombining Ad-ING4 virus (experi-
mental team) and Ad (control team), we infected human cancer A549 
cells by this Ad virus after its value was qualified. The method of 
RT-PCR was adopted to detect the transcription of aimed gene ING4, 
and Western-blotting to detect the expression of aimed proteins. To 
observed the effect of Ad-ING4 on human lung cancer cells, we used 
MTT method to detect the influence of AD virus on the growth of 
lung cancer cells through drawing the growth curve and calculating 
the inhibition cancer rate, the apoptosis and cell cycle of cells were 
analyzed by flow cytometry. Transmission electron microscope to 
observe the cell morphology of lung cancer cells after Ad virus infec-
tion, RT-PCR method to detect the transcription of Fas, FasL, and 
immunocytochemical method to detect the expression of apoptosis-
related proteins such as p53, Bcl-2 and Bax.
Results: The value of amplified Ad and Ad-ING4 is as high as 
108pfu/ml. After infecting lung cancer cells, the results of RT-PCR 
and Western-blotting indicated that the transcription and translation 
of aimed gene were observed in the experimental team. MTT results 
indicated that ING4 inhibited the growth of human lung cancer A549 
cells obviously, especially after 48 hours (P<0.05). The apoptosis rep-
resentations as cell nucleus shrinkage and disappearance of caryoth-
eca were observed in the early period through transmission electron 
microscope 48h~60h later after been infected by the Ad virus. flow 
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cytometry to show the expression of ING4 led the cell cycle of A549 
to arrest at G2/M phrase to inhibit the proliferation of the cells. RT-
PCR presented up-regulated expression of Fas, FasL after Ad-ING4 
virus infected the lung cancer cells. The results of immunocyto-
chemistry indicated that the number of P53 and Bax expressed cells 
increased while the number of Bcl-2 expressed cells decreased after 
Ad-ING4 infected lung cancer cells. 
Conclusion: Humanize improved Ad-ING4 virus can significantly 
inhibit the growth of lung cancer cells, while this mechanism of the 
apoptosis of lung cancer cells is probably induced by the p53 depend-
ent pathway .
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Combined inhibition of IGF1R enhances growth-inhibitory 
effect of gefitinib in H1650, a lung cancer cell line with 
EGFR mutation and primary resistance to EGFR-TK 
inhibitors
Kim, Hye-Ryoun; Na, Im Il; Choi, Yun Jung; Rho, Jin Kyung; Kim, 
Cheol Hyeon; Lee, Jae Cheol 
Department of Internal Medicine, Korea Cancer Center Hospital, 
Korea Institute of Radiological & Medical Science, Seoul, Korea
Background: H1650 non-small cell lung cancer cells show the pri-
mary resistance to epidermal growth factor receptor-tyrosine kinase 
inhibitors (EGFR-TKIs) although they have an activating deletion 
mutation on exon 19 of EGFR gene. We investigated the effect of 
combined inhibition of both insulin-like growth factor 1 recep-
tor (IGF1R) and EGFR signaling on these resistant cells as IGF1R 
activation has been suggested to interfere with the anti-tumor effect 
of EGFR-TKIs. 
Methods: The combined effects of α-IR3, a monoclonal anti-
body blocking IGF1R, and gefitinib were determined by MTT and 
3-dimensional culture assay. Western blot analysis was used to evalu-
ate the alteration of EGFR/IGFR downstreatm signaling pathways by 
simultaneous inhibition of IGFR and EGFR.
Results: H1650 cells exhibited resistance to gefitinib and erlotinib 
more than 1000 times than HCC827 and PC-9 cells which have the 
same EGFR mutation. PTEN loss and sustained p-Akt signal despite 
treatment with gefitinib were found only in H1650. Interestingly, 
the expression of p-IGF1R and p-mTOR was decreased by gefitinib 
in HCC827 and PC-9 while it was maintained in H1650. Combined 
treatment of α-IR3 enhanced the growth-inhibitory effect of gefitinib 
on MTT assay. The number and size of colony were also reduced 
in 3-dimensional culture. The expression of p-Akt in addition to 
p-EGFR and p-IGF1R was down-regulated by the combination treat-
ment. 
Conclusions: In summary, combined inhibition of IGF1R signaling 
enhanced the effect of gefitinib suggesting it could be one of useful 
measures to overcome the primary resistance to EGFR-TKIs in lung 
cancer. 
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Induction of ER stress-mediated apoptosis by α-Lipoic 
acid in A549 lung cancer cell lines 
Cho, Sung Rae; Kim, Jong In
The Korean Society for Thoracic and Cardiovascular Surgery, Seoul, 
Korea
Background: α-Lipoic acid (α-LA) has been studied as anticancer 
agent as well as therapeutic agents for diabetes and obesity. This 
study was performed to evaluate anticancer effects and mechanism of 
α-LA in lung cancer cell line, A549. 
Materials and Methods: Apoptosis of A549 induced by α-LA was 
detected by FACS analysis and DNA fragmentation assay. Expres-
sion of apoptosis-related genes was analyzed by Western blot and 
RT-PCR. 
Results: α-LA induced apoptosis and DNA fragmentation of A549 in 
dose- and time-dependent manner. α-LA increased caspase activity 
and degradation of PARP. It induced expression of ER stress-related 
genes, such as GRP78, CHOP and short form XBP-1, and decreased 
anti-apoptotic protein XIAP. ROS was induced by α-LA, and anti-
oxidant, NAC, decreased the expression of apoptosis and ER stress-
related proteins induced by α-LA.
Conclusion: α-LA induces ER stress-mediated apoptosis in A549 by 
using ROS as intermediate. These results shows α-LA may be clinic-
ally useful for the treatment of lung cancer. 
P1.054 Basic Science and Translational Research, Sat Aug 1 
Formation of multicomponent multicellular tumor 
spheroids (MMCTS) is the new model of cancer research 
Kim, Ki-Up; Kim, Yang Ki; Lee, Young Mok; Uh, Soo-taek
Soonchunhyang University, School of Medicine, Seoul, Korea
Introduction: Cancer resarches, in vitro, are promising to control of 
cell invasion or respond to therapeutic trals. However, using their re-
sults to in vivo had disappoointed. That may be caused by tumor cells 
and matrix because tumors have 3 dimensional structure, not pure cell 
components, and cell to cell/matrix interactions. Multicellular tumor 
spheroids (MCTS), which are composed tumor cell lines, remarkably 
ameliorate these 2 dimensional limitations but they also had some 
because of lack of stromal cells and tumor associated macrophages. 
We tried a multicomponent multicellular tumor spheroids (MMCTS) 
from 3 kinds of cells of cancer cell line, human fibroblasts and 
peripheral blood mononuclear cells (PBMC) as a model to cancer 
research.
Method: A549 cell line from lung cancer, fibroblasts cultured from 
lung cancer patients, and PBMC were cultured at agar coated plate 
apart or combined in DME media with 10% fetal calf serum. Their 
formation of spheroids were observed daily by inverted microscope 
and got samples serially for 4 weeks. Cell components from com-
bined spheroids were stained immunohistochemically by antibody to 
cytokeratin, fibroblast and CD68. 
Result: Cells were gathered and made clusters except PBMC only 
within a few days and formed spheroids between 4 to 7 days. Fibro-
blast were formed earlier and A549, later than others. The mixed 
cluster with A549, fibroblast and PBMC were formed round shape. 
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Cell components from spheroids had been confirmed by immuno-
histochemical stain. 
Conclusion: MMCTS will be a new model for tumor research, resist-
ance to apoptosis, tumor-stromal cell interaction, therapeutic trials 
and 3 dimensional structures.
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Antiproliferative effect of zoledronic acid and sequence 
dependant cytotoxic effect when combined with cytotoxic 
agent in A549 lung cancer cell lines
Kim, Kyu-Sik; Kim, Young-Chul; Oh, In-Jae; Na, Kook-Joo; Kim, 
Yun-Hyeon; Ahn, Sung-Ja; Choi, Song; Cho, Hyun-Ju; Back, Sun-
Mi; Gong, Kang-Eun; Park, Song-Ran
Chonnam National University Hwasun Hospital, Jeollanamdo, Korea
Introduction: Bone metastases in patients with lung cancer de-
teriorate the patients’ quality of life with pain, pathologic fracture, 
hypercalcemia. It has been reported that nitrogen containing bisphos-
phonates could decrease skeletal related events in patients with lung 
cancer as well as other solid tumors. These osteoclast inhibitors also 
have antiproliferative effects in tumor cells by inducing apoptosis, 
anti-angiogenesis, and inhibition of cancer cell adhesion to bone 
matrix. In this study, we studied interactive effects between zoled-
ronic acid and cytotoxic drugs in A549 lung cancer cell line, and we 
investigated the best combination sequence. 
Method: Using various combinations of cytotoxic agents 
(gemcitabine(G), Paclitaxel(P) and Docetaxel(D)) and zoledronic 
acid (Z) in different sequences, we studied anti-proliferative effect 
and cell cycle distributions. The cell viability assay and cell cycle 
analysis were conducted via an MTT assay and flow cytometry. Zole-
dronic acid and cytotoxic drugs were applied in different sequences 
to observe sequence-dependent effects. The results of the sequential 
treatment with cytotoxic drugs and zoledronic acid were assessed 
using the combination index (CI). 
Result: Zoledronic acid showed cytotoxic effect in dose dependent 
manner. Regardless of dosing sequence (concurrent or sequential 
treatment), zoledronic acid and cytotoxic drugs showed synergis-
tic interaction in cytotoxic effect. The best synergistic effect was 
observed when zoledronic acid and cytoxic agents were treated 
concurrently. 
Conclusion: In A549 lung cancer cell line, combination of zoledronic 
acid and cytotoxic agents showed synergistic anti-proliferative effect. 
Our results suggest that concurrent administration of zoledronic acid 
may enhance the anti-tumor effect of cytotoxic agents in patients with 
non-small cell lung carcinoma.
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Is anemia more common in patients with COPD-associated 
lung cancer in the course of chemotherapy?
Kaczmarczyk, Grzegorz; Kozielski, Jerzy
Department of Lung Diseases and Tuberculosis, Silesian Medical 
University in Zabrze, Zabrze, Zabrze, Poland
Background: Anemia often accompanies many chronic diseases, 
including COPD. This is the result of inflammation and resistance to 
higher concentrations of erythropoietin.
Aim of the study: To determine whether in lung cancer patients with 
COPD (group I) anemia occurs more frequently as compared to pa-
tients without COPD (group II) in the course of chemotherapy.
Material and Methods: 111 patients examined at the age of 41 to 
79yrs (mean age 59yrs), 72 men and 39 women, hospitalized in the 
Department of Lungs Diseases and Tuberculosis in Zabrze in the 
years 2003 - 2006. All patients had confirmed lung cancer by histo-
pathological examination. Small cell lung cancer was diagnosed in 39 
cases and non-small cell lung cancer in 72. The diagnosis of COPD 
was established according to GOLD criteria. Patients had normal 
concentration of hemoglobin before treatment (>13g/dl). There were 
55 patients (49.5%, mean age 60yrs) in I group and 56 (50.5%, mean 
age 59yrs) in II group. All patients received 4 cycles of chemotherapy 
based on cisplatin.
Results: Anemia was observed in 104 patients (93.7%), including 50 
patients (91%) in group I and 54 (96%) in group II. 
In group I, after cycle I anemia occurred in 28 patients (51%), after 
cycle II in 8 (15%), after cycle III in 7 (13%) and after the IV in 7 
patients (13%). 
In group II, similar results were observed: after cycle I in 27 patients 
(48%), after cycle II in 12 (21%), after cycle III in 11 (20%) and after 
cycle IV in 4 patients (7%).
Conclusions: On the basis of obtained data one may conclude that 
anemia is not more frequent in patients with treated lung cancer and 
concomitant COPD.
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Tobacco-specific carcinogens and epithelial-mesenchymal 
transition in pulmonary carcinogenesis
Lee, Gina; Hazra, Saswati; Walser, Tonya; Yanagawa, Jane; Krysan, 
Kostyantyn; Dubinett, Steven
David Geffen School of Medicine UCLA, Los Angeles, CA, USA
Background: Tobacco-specific carcinogen 4-(N-methyl-N-
nitrosamino)-1-(3-pyridyl)-1-butanone (NNK) induces lung cancer. 
The exact mechanisms of carcinogenesis have not yet been fully elu-
cidated. We have shown that chronic exposure to NNK in non-small 
cell lung cancer (NSCLC) cells in vitro induces epithelial mesen-
chymal transition (EMT) with loss of E-cadherin and upregulation of 
zinc finger transcriptional repressors Zeb1 and slug. In order to better 
understand the mechanisms of EMT and the contribution of NNK 
to early carcinogenic events, we have extended our chronic NNK 
exposure model to human bronchial epithelial cell (HBEC) lines 
immortalized by overexpression of cyclin-dependent kinase (Cdk) 
4 and human telomerase reverse transcriptase (hTERT) (provided in 
collaboration with J. Minna and J. Shay, UT Southwestern).
Methods: Non-small cell lung cancer and immortalized HBEC lines 
were cultured and continuously exposed to either NNK or DMSO 
vehicle control. For immunoblot and microarray studies, samples 
were collected at least 2 weeks following treatments. Apoptosis was 
evaluated by immunoblots after samples were treated with either 
staurosporine or rosiglitazone.
Results: Exposure to NNK revealed progression of EMT in HBEC3 
and HBEC4 including upregulation of the transcriptional repressor 
snail. NNK exposure also leads to decreased PARP cleavage and 
increased survivin, an inhibitor of apoptosis protein. Gene expression 
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profiling studies in NSCLC lines revealed significant fold changes in 
several EMT associated genes including E-cadherin. 
Conclusions: HBEC3 and A549 NSCLC cells demonstrate EMT 
when chronically exposed to NNK and this is accompanied by resist-
ance to drug-induced apoptosis. Current investigations are assessing 
the NNK-induced coordinated expression of gene, microRNA and 
proteins implicated in pulmonary carcinogenesis.
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Potential increase in the prognostic value of P53 mutation 
by Pro72 allele in stage I non-small cell lung cancer
Lee, Huei1; Wu, Tsu-Chin 2, 1; Chien, Wen-Pin 1; Wong, Ruey-Hong 1; 
Cheng, Ya-Wen 1; Chen, Chih-Yi 3
1 Chung Shan Medical University, Taichung, Taiwan; 2 Chung Shan 
Medical University Hospital, Taichung, Taiwan; 3 China Medical 
University, Taichung, Taiwan
Purpose: Accumulated evidence suggests that p53 function altered 
by its gene mutation or genetic polymorphism contributes to tumor 
malignancy. Association of p53 mutation and its codon 72 poly-
morphism with lung cancer prognosis has been extensively studied. 
However, the joint effect of p53 mutation and p53 codon 72 poly-
morphism on lung cancer prognosis remains uncertain. 
Methods: In the present study, 266 primary lung cancer patients 
were included and overall survival was calculated. Genomic DNA 
prepared from adjacent normal lung and lung tumor tissues was used 
to determine p53 codon 72 genotype and p53 mutation by PCR-RFLP 
and direct sequencing, respectively. 
Results: Our results showed that for all stages neither p53 codon 72 
genotype nor p53 mutation is associated with lung cancer prognosis. 
However, stage I patients with p53 mutation had a 1.79 fold hazard 
ratio (95% CI, 1.04-3.10) for overall survival when compared with 
p53 wild-type patients. Notably, stage I patients with p53 mutation 
and p53 codon 72 Pro/Pro genotype experienced a 2.31-fold hazard 
ratio (95% CI, 1.08-4.95) for overall survival when compared with 
those with p53 wild-type and Arg/Arg genotype. An increased prog-
nostic value was not observed in stage I patients with p53 wild-type 
and p53 Pro72 allele or in those with p53 mutation and p53 codon 72 
Arg/Arg genotype. 
Conclusions: We therefore suggest that p53 codon 72 Pro allele 
potentially increases the prognostic value of p53 mutation in stage I 
non-small cell lung cancer. 
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The antitumor effects of COX-2 inhibitors are mediated by 
the inhibition of Th17 cells in lung cancer mouse model
Lee, Sung Yong1; Choi, Hye Kyoung1; Moon, Jae Young1; Kim, 
Je Hyeong 2; Shin, Chol2; Shim, Jae Jeong 1; Lee, Sang Yeub 3; In, 
Kwang Ho 3; Kang, Kyung Ho 1; Kim, Jun Suk 1; Yoo, Se Hwa 3
1 Department of Internal Medcine, Guro Hospital, Korea University, 
Seoul, Korea; 2 Department of Internal Medicine, Ansan Hospital, 
Korea University, Ansan, Korea; 3 Department of Internal Medicine, 
Anam Hospital, Korea University, Seoul, Korea
Background: Th17 cells represent a unique subset of CD4 T cells 
that produce the proinflammatory cytokine IL-17. Th17 cells play 
an active role in inflammation and autoimmune diseases. The nature 
and regulation of Th17 in the context of tumor immunity remain 
unknown. However, according to recent studies, Th17 cells have 
immune tolerogenic properties in tumor microenvironment. Cyc-
looxygenase-2 (COX-2) and its metabolite, PGE2 affect tumorigen-
esis, including angiogenesis, invasion and tumor-induced immune 
suppression. Their overexpression is association with inflammation 
and impaired immune cell function in many tumors. Therefore, we 
investigated the effects of COX-2 inhibitors on Th17 cells activation 
in tumor cells. 
Methods: Lewis lung cancer cells (3LL) were inoculated into 
C57Bl/6 mice. Twenty mice were randomized into normal controls, 
3LL inoculated controls, and celecoxib 10 or 100mg/kg/day treated 
3LL inoculated mice. The mice were sacrificed on day 28. The tumor 
mass of 3LL inoculated control mice was removed for isolation of 
tumor infiltrating lymphocytes (TIL). The isolated TIL were treated 
with PGE2 and various concentrations of COX-2 inhibitor (PTPBS; 
5, 15 and 30μΜ) for IL-17 ELISA assay. In addition, we assessed 
Western blotting for transcription factor retinoic acid-related orphan 
receptor (ROR)-γand p-STAT3 that were recently described to be 
essential for differentiation of Th17 cells. For the FACS analysis, 
splenocytes that were isolated from the mice of each group were 
stained with CD4 FITC and IL-17 PE monoclonal antibodies. 
Results: We assessed the effects of PTPBS on IL-17 production and 
found that the IL-17 production of TIL was increased with PGE2 
and decreased with PTPBS treatment, dose dependent manner. The 
expression of ROR-γand p-STAT3 were increased in PGE2 treated 
TIL; however, they decreased with PTPBS treatment. The FACS 
analysis demonstrated a decline in the percentage of CD4+IL-17+ in 
the celecoxib treated groups. A significant inhibition of tumor growth 
was observed in the groups of mice treated with celecoxib compared 
to the untreated 3LL inoculated control group.
Conclusion: These results of this study show that COX-2 inhibitor 
reduced IL-17 production, as well as ROR-γ and p-STAT3 expres-
sion in TIL. The percentage of Th17 was attenuated and ultimately 
decreased the tumor burden with celecoxib treatment. These findings 
suggest that the COX-2 inhibitor promotes antitumor reactivity 
through the inhibition of Th17 cells.
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Investigation of ion channel mechanism for the regulatory 
volume decrease 
Li, Hui1; He, Wei1; Liu, Jie 2; Shi, Lu-Ping 2; Xu, Meng 2; Zhang, 
Zhi-fei 2; Wang, Jun 2
1 Department of Thoracic Surgery, Beijing Chaoyang Hospital, 
Capital Medical University, Beijing, China; 2 Department of 
Physiology, Capital Medical University, Beijing, China
Background: Apoptosis is an essential process in organ develop-
ment, tissue homeostasis, somatic cell turnover, and the pathogenesis 
of degenerative diseases. Apoptotic cell death occurs in response to 
a variety of stimuli in physiological and pathological circumstances. 
This study was designed to observe the regulatory volume decrease 
(RVD) process in human lung adenocarcinoma cell line A549 and the 
role of chloride channels in cell proliferation and cell cycles. 
Methods: Electric measurement system of cell volume was used to 
detect the volume changes following exposure to hypotonic solution. 
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Whole-cell patch clamp recordings were applied to investigate the 
characteristics of the volume-sensitive Cl- channel in human lung 
adenocarcinoma cell line A549. 
Results: Extracelluar hypotonicity induced cell swelling followed by 
a typical RVD process, which can be inhibited by Cl- channel blocker 
(NPPB 100µmol/L) and K+ channel blocker (CsCl 5mmol/L). Mean-
while, hypotonicity induced chloride currents recorded in human 
lung adenocarcinoma cell line A549 by using the whole cell patch 
clamp recording showed outwardly rectifying behavior and could be 
blocked by NPPB. 
Conclusions: The human lung adenocarcinoma cell line A549 
has RVD process which is dependent on the parallel activation of 
Cl- channel and K+ channel. The volume-sensitive Cl- channel is 
involved in volume regulation of lung adenocarcinoma cells.
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Adenovirus-mediated transfer of shRNA against survivin 
enhances the radiosensitivity of human non-small cell lung 
cancer cells
Lin, Yu-Ching; Yang, Cheng-Ta
Chang Gung Memorial Hospital at Chiayi, Chiayi Hsien, Taiwan
Purpose: Survivin is a member of the inhibitor of apoptosis family 
(IAP). Overexpression of survivin has been found in lung cancer 
and reported to be correlated with shorter survival for patients with 
non-small cell lung cancer (NSCLC). Recent evidences indicated 
overexpression of survivin correlated with radioresistance in various 
human cancers. We studied whether knockdown of surviving by 
siRNA could increase the radiosensitivity of NSCLC cells.
Materials and methods: NSCLC cell lines, H460, A549, H1650 and 
H1975, were used for study. The short hairpin RNA (shRNA) against 
survivin was transferred to lung cancer cells by an adenoviral vector 
(AdsiSurvivin). The effects of AsdiSurvivin infection on growth and 
radiosensitivity of lung cancer cells were examined.
Results: AdsiSurvivin infection could knowdown surviving expres-
sion efficiently. AdsiSurvivin infection inhibited lung cancer cells 
growth at various doses (m.o.i.). Knowdown of survivin by AdsiSur-
vivin infection in lung cancer cells resulted in increased sub-G1 
population in flow cytometry and degradation of poly-(ADP-ribose) 
polymerase (PARP) in Western blots. Combined AdsiSurvivin infec-
tion and radiotherapy showed that shRNA against survivin could 
enhance the radiosensitivity of NSCLC cells.
Conclusions: Survivin inhibition by an adenovirus-mediated shRNA 
suppressed cells growth, induced apoptosis, and enhanced the 
radiosensitivity in NSCLC cells. In addition to growth inhibition and 
apoptosis induction, anti-survivin treatment, as by an adenvirus-medi-
ated transfer of shRNA in this study, may be applicable to improve 
the response to radiotherapy for lung cancer cells.
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Analysis of signaling network in non-small cell lung cancer
Liu, Wei; Ye, Fei; Li, Guanghu; Wu, Yong; Wang, Libo; Glaser, 
Laurel; Yin, Guanghao; Xue, Menghua; Zhu, Dongshan; Zhang, 
David Y.
Changchun, China
Background: Lung cancer is the leading cause of cancer deaths 
worldwide. Several small molecular inhibitors have been developed 
successfully in clinical practice, but the understanding of multi-
factorial processes of lung carcinogenesis is still unclear. Because 
different signal pathways interact with one another to finally form the 
signaling network, thorough understanding of the signaling network 
will contribute to detect key hubs which may play an important role 
in pathogeneses of lung cancer. We developed the powerful Pathway 
Array system and used Bayesian Network (BN) to identify dysregu-
lated signaling network in NSCLC. 
Methods: 43 pairs of proteins were extracted from the NSCLC 
tumor tissues and the surrounding non-tumor tissues. Data collected 
included age, gender, histopathologic diagnosis, smoking history and 
Pathological TNM stage. 
The proteins were separated using SDS-PAGE and transferred 
to a nitrocellulose membrane and blotted using a Western blot-
ting manifold. The multiplex immunoblot was performed using 72 
protein-specific or phosphorylation site-specific antibodies. Chemi-
luminescence signals were captured using ChemiDoc XRS System. 
Differences in protein level are estimated by densitometric scanning 
and normalized using internal standards. The data was imported into 
computer programs and statistical methods for further analysis. P-
value <0.05 is considered significant. 
BN was used to represent the probabilistic relationships between the 
proteins and to determine which one is upstream or downstream in 
the signaling network using statistical correlations. 
Results: 23 significant dysregulated proteins/ phosphorylations were 
detected in tumor tissues compared with the surrounding non-tumor 
tissues with p<0.05, including EGFR, AKT, p-ERK, p-cdc2 p34, 
p-CREB, CDK4, CDK2, Cyclin B1, XIAP, Beta-catenin, HSP90, etc. 
We further placed the significant proteins into the signaling pathways 
using BN and found a few master regulators (such as XIAP, AKT, 
ERK and Beta-catenin) in the signaling network of NSCLC, which 
play important roles of controlling NSCLC behavior including cell 
survival, proliferation and apoptosis.
Conclusions: We unlocked the complex signaling networks and 
found a few master regulators of NSCLC. In the future, we will 
further investigate the roles of the master regulators in NSCLC and 
correlate them with clinical parameters, and further determine key 
hubs existed in NSCLC.
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Multidrug resistant protein-three (MRP3) gene regulation 
by Nrf2 and p53 in human bronchial epithelial and non-
small cell lung carcinoma: clinical implications
Mahaffey, Christopher M.1, 2; Zhang, Hongqiao1; Holland, William 
2; Farneth, Nichole2; Rinna, Alessandra1; Mack, Philip C.2; Forman, 
Henry J.1
1 UC Merced, Merced, CA, USA; 2 UC Davis Cancer Center, 
Sacramento, CA, USA
Background: Multidrug Resistant Proteins (MRPs) are members of 
the ATP-binding cassette superfamily that facilitate detoxification by 
transporting toxic compounds, including chemotherapeutic drugs, 
out of cells. Chemotherapy, radiation, and other xenobiotic stresses 
can increase levels of select MRPs, although the underlying mechan-
ism remains largely unknown. MRP3 is expressed in non-small cell 
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lung carcinoma (NSCLC), and is suspected of playing a role in drug 
resistance. Analysis of the MRP3 promoter revealed the presence of a 
p53 binding sequence and multiple electrophile responsive elements 
(EpRE). EpREs are putative sequences that suggest possible regula-
tion by Nrf2, the key transcription factor that binds to this sequence. 
Keap1, a key regulator of Nrf2, sequesters Nrf2 in the cytoplasm, 
preventing entry into the nucleus. The α,β-unsaturated aldehyde 
4-hydroxynonenal (HNE) is a major lipid peroxidation product 
formed by reactive oxygen or nitrogen species and has been previ-
ously established to cause the activation of the Nrf2-EpRE signaling. 
HNE was used as a surrogate for oxidative stress and has been shown 
to stimulate release of Nrf2 from Keap1. The goal of this investiga-
tion was to determine 1) whether MRP3 induction was dependent 
upon the transcription factor Nrf2, and 2) whether p53 acts to repress 
this induction as it does in MRP1. 
Methods: We used the human bronchial epithelial cell line HBE1 
(Keap1 wt/p53 E6 viral disruption) and the NSCLC cell lines H358 
(Keap1 wt/p53 null), H460 (Keap1 mt/p53 wt), and A549 (Keap1 mt/
p53 wt). Relative MRP3 RNA levels were determined by RT-PCR. 
Protein levels for p53, Nrf2, and MRP3 were evaluated by Western 
Blot and immunofluorescence approaches. 
Results: We found that treatment with HNE up-regulated MRP3 
mRNA and protein levels in cell lines with wild type Keap1, but not 
in Keap1-mutant NSCLC cell lines. Cell lines with mutant Keap1 had 
constitutively higher MRP3 that was not increased by HNE treat-
ment. Silencing of Nrf2 with siRNA inhibited induction of MRP3 by 
HNE in HBE1 cells. Transient transfection of H358 with a p53-ex-
pressing plasmid completely inhibited the induction of MRP3 mRNA 
by HNE. In H358 cells, cisplatin (5μM for 24h) resulted in induction 
of MRP3. Additionally, Nrf2 silencing resulted in an approximate 
40% increase in cytotoxicity following cisplatin treatment (2.5μM for 
72h) compared to a non-specific siRNA control. 
Conclusions: These results therefore support the hypothesis that 
MRP3 induction is positively regulated by Nrf2 activation and 
subsequent nuclear localization, and negatively regulated by p53. 
Chemoresistance is thought to be derived by two principle mechan-
isms: the first involves an improved capacity for DNA repair, the 
second involves up-regulation of the cellular detoxification pathways 
such as the MRP family of proteins. Therefore, the mutational status 
of Keap1 and p53 may play a key role in MRP3 regulation. An 
understanding of the interplay between these factors could lead to 
improved therapeutic decision-making for NSCLC.
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Reduced expression of DNA mismatch repair gene hMLH 
protein in early stage of carcinogenesis of chromate lung 
cancer
Nagao, Taeko; Kondo, Kazuya; Toba, Hiroaki; Takizawa, Hiromitsu; 
Kenzaki, Koichiro; Sakiyama, Shoji; Tangoku, Akira
The University of Tokushima, Tokushima, Japan
It is known that chromium is an inhaled carcinogen and an import-
ant risk factor in the development of lung carcinoma. In our previ-
ous study, we measured the accumulation of chromium in 90 biopsy 
specimens (dysplasia, squamous metaplasia, goblet cell hyperplasia, 
basal cell hyperplasia and normal bronchial epithelia) from chromate 
workers, and demonstrated that the amount of chromium accumula-
tion significantly increased according to the progression of malig-
nant change of the bronchial epithelium. On the other hand, it have 
revealed that the frequency of replication error in chromate lung 
cancer is very high and that the inactivation of DNA mismatch repair 
gene hMLH1 expression strongly correlated with the microsatellite 
high instability phenotype. We speculate the carcinogenesis process 
of chromate lung cancer:the repression of hMLH1 proteinthe genetic 
instabilitythe abnormality of cancer related genes. In this study, we 
examined the expression of hMLH protein in pre-malignant lesions 
of the bronchial biopsy specimens from chromate workers, and the 
relationship between the expression of hMLH protein and the amount 
of chromium accumulation. To detect lung carcinoma at an early 
stage, we performed biopsies of the bronchus using fiberoptic bron-
choscopy for 83 chromate industry workers. Dysplasia was recorded 
in 3 specimens, squamous metaplasia in 14, goblet cell hyperplasia in 
12, basal cell hyperplasia in 13, hypertrophy of basement membrane 
in 14, and normal epithelia in 27. We examined the expression of 
hMLH1 protein in the bronchi of 2 dysplasia, 7 squamous metaplasia, 
2 goblet cell hyperplasia and 4 basal cell hyperplasia specimens. We 
quantified the amount of chromium accumulation in the biopsy tissue 
specimens. As Control, we performed biopsies of the bronchus using 
fluorescence bronchoscopy against the patients of lung cancer and 
heavy smokers. We examined 3 cases of carcinoma in situ, 5 cases 
of squamous metaplasia, 4 cases of hyperplasia. Immunohistochem-
ical staining for hMLH1 was performed. The frequency of nuclear 
staining was scored as none (0%), scant (<30%), moderate (30%, 
80%), and diffuse (>80%).The hMLH1 protein was expressed scantly 
in 5 (42%) of 12 chromate lung cancers, and moderately in seven 
(58%). On the other hand, scantly in 2 (29%) of 7 non-chromate 
lung cancers, and moderately in one (14%). The repression rate of 
hMLH1 protein in chromate lung cancer (100%) was significantly 
more than that in non-chromate lung cancer (43%). Reduction of 
DNA mismatch repair hMLH1 expression in pre-malignant lesions 
of workers with chromate exposure was more than those of non 
chromate exposure (100% vs 45%). There was reduction of DNA 
mismatch repair hMLH1 expression not only in advanced lung cancer 
but also early lung cancer and pre-malignant lesions of workers with 
chromate exposure. We speculate that dysfunction of hMLH involves 
the carcinogenesis of chromate lung cancer. 
P1.065 Basic Science and Translational Research, Sat Aug 1 
Prognostic significance of carbonic anhydrase IX 
expression by cancer-associated fibroblasts in pulmonary 
adenocarcinoma
Nakao, Masayuki; Ishii, Genichiro; Nagai, Kanji; Kawase, Akikazu; 
Kenmotsu, Hirotsugu; Kon-no, Hidehiro; Hishida, Tomoyuki; 
Nishimura, Mitsuyo; Yoshida, Junji; Ochiai, Atsushi
National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
Background: Cancer tissue consists of cancer cells and several 
types of stromal cells, including cancer-associated fibroblasts (CAF). 
Recent studies have shown that CAF plays important roles in cancer 
progression, communicating with cancer cells and other stromal cells 
through growth factor. Carbonic anhydrase (CA) IX is used as an 
endogenous hypoxia marker in many studies on cancer microenviron-
ment. Although its expression by cancer cells has been reported to 
be associated with a poor outcome in a board range of tumors, the 
biological significance of its expression by CAF remains unclear. 
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Methods: We investigated CA IX expression by CAF and cancer 
cells immunohistochemically in consecutive 158 pulmonary adeno-
carcinomas resected from January 1994 through December 1996 at 
the National Cancer Center Hospital East.
Results: CA IX expression was observed in CAF in 39 (24.7%) of 
the 158 tumors and in cancer cells in 40 (25.3%). CA IX expression 
by CAF was significantly associated with conventional prognostic 
factors, including pathological T classification (p < 0.01), nodal 
involvement (p < 0.01), vascular invasion (p < 0.01), lymphatic 
permeation (p < 0.01), and pleural invasion (p = 0.02). A univariate 
analysis and the log-rank test showed CA IX expression by CAF (p < 
0.01 and p < 0.01, respectively) and by cancer cells (p = 0.02 and p = 
0.02, respectively) had a significant unfavorable impact on survival. 
When CA IX expression was analyzed together with these conven-
tional prognostic factors by multivariate analyses, neither expression 
by CAF nor that by cancer cells proved to be a significant independ-
ent prognostic factor. However, when only CA IX expression by CAF 
and that by cancer cells were compared by multivariate analysis, 
CA IX expression by CAF proved to have a statistically significant 
impact on survival (HR = 1.797, 95% CI: 1.053-3.066, p = 0.03), 
while that by cancer cells did not (HR = 1.561, 95% CI: 0.915-2.661, 
p = 0.10). 
Conclusion: CA IX expression by CAF was significantly associated 
with advanced, aggressive tumor status. CA IX expression by CAF 
had a significant impact on survival, but that by cancer cells did not. 
These findings provide new insights into the biological significance 
of CAF in the hypoxic microenvironment of pulmonary adenocarcin-
omas and showed the importance of assessing biological behavior of 
both cancer cells and CAF to better understand cancer microenviron-
ment.
P1.066 Basic Science and Translational Research, Sat Aug 1 
The impact of metastasis tumour supressor-1 (MTSS1) on 
the metastatic characteristics of non small cell lung cancer 
and its association with smoking history 
Noble, Simon I.1; Parr, Christian2; Ye, Lin2; Zhang, Li3; Jiang, Wen 
G.2
1 Cardiff University, Newport, UK; 2 Cardiff University, Cardiff, UK; 
3 Peking University School of Oncology, Peking, China
Background: MTSS1, also known as Missing In Metastasis (MIM) 
gene encodes an intracellular protein that is implicated in actin 
cytoskeleton reorganisation and often down-regulated in certain types 
of tumour cells. Its absence has been implicated in the metastatic 
spread of bladder and breast cancer with a survival benefit in those 
expressing the gene. This study aimed to provide new insights into 
the impact of MTSS-1 in non small cell lung cancer and to correlate 
these results with clinical parameters. 
Methods: MTSS-1 expression levels were evaluated in a cohort of 
paired NSCLC resection samples (n=83) in association with patient 
clinical variables using quantitative and qualitative analysis of the 
MTSS-1 transcript. MTSS-1 was also experimentally over-expressed 
in human NSCLC lines (SKMES-1, which is negative in MTSS1 
expression) and an anti-MTSS1 transgene construct generated to 
force MTSS-1 down regulation (A549, which is positive in MTSS1). 
The effects of MTSS-1 over-expression and down-regulation were 
examined through a series of in vitro studies.
Results: Here we show that MTSS-1 is weakly expressed in patients 
who smoke compared to non smokers (p=0.046) although the sample 
size was too small to identify any survival difference. Furthermore 
we demonstrate MTSS-1 knock down significantly increases the 
migratory properties of the lung cancer cell line tested (p<0.05) and 
MTSS-1 over expression significantly decreased the invasive and 
migratory properties (p<0.05). 
Conclusions: Missing in metastasis or MTSS-1 is a putative 
metastasis suppressor protein that is expressed in many malignan-
cies as well as normal tissues. Our study suggests MTSS-1 may act 
as a suppressor gene on the metastatic spread of lung cancer by a 
similar mechanism to that previously suggested in bladder and breast 
cancer. Interestingly it is more weakly expressed in smokers than non 
smokers although the clinical significance of this data is unclear. It is 
possible that smoking as well as being an associated risk factor for 
lung cancer may confer a more aggressive phenotype with respect to 
metastatic progression. Further studies are warranted.
P1.067 Basic Science and Translational Research, Sat Aug 1 
Biomarker analysis by micro RNA profiles of lung cancer 
patients in Folmalin-fixed tissue
Ohira, Tatsuo; Oikawa, Takeshi; Kuwajima, Yuka; Maehara, Sachio; 
Ichinose, Shuji; Kakihana, Masatoshi; Usuda, Jitsuo; Nomura, 
Masaharu; Kajiwara, Naohiro; Uchida, Osamu; Hirano, Takashi; 
Ikeda, Norihiko
Tokyo Medical University, Tokyo, Japan
Background: The incidence of lung cancer has been increasing 
in the world. Lung cancer has been the most frequent malignancy. 
The prognosis of lung cancer is poor. It should be important to find 
biomarker for detection of early stage lung cancer cases and selec-
tion of therapies in order to improve outcome. We are interesting in 
the micro RNA. Micro RNAs are a distinct class of small encoding 
RNAs that post-transcriptionally repress expression of target genes. 
MicroRNA expression profiles were investigated for the involvement 
in carcinogenesis. If we could detect micro RNA with Formalin-fixed, 
Paraffin-embedded tissue, it should give us much more information. 
So, we investigated possibility to use Formalin-fixed, Paraffin-em-
bedded tissue for detection of microRNAs.
Methods and Materials: We performed micro RNA expression 
profiles using fresh frozen tissue specimens collected at surgery and 
Formalin-fixed, Paraffin-embedded tissue. We compared micro RNA 
profiles among these samples. These lung cancer patients are received 
operation in our department.
Results: We could take high quality samples from Formalin-fixed, 
Paraffin-embedded tissue. We could get similar micro RNA profiles 
between Formalin-fixed, Paraffin-embedded tissue and fresh frozen 
tissue specimen. Specific microRNA profiles for lung cancer were 
detected from both of these samples. Has-let 7f and has-miR-16, 21, 
26a are detected in both samples. High expression of Has -miR-205 
was detected. We could also show some data of microarray data. 
Conclusion: We got good RNA samples from Formalin-fixed, 
Paraffin-embedded tissue for investigation of microRNA profiles. 
Microarray was also tried to be analyzed. RNA samples from Forma-
lin-fixed, Paraffin-embedded tissue could be available for Microarray. 
It should give us much information and possibility of discovery of 
biomarkers that are useful for early stage lung cancer cases and/or 
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selection of therapies. We will some differences between groups in 
micro RNA profiles, such as poor prognosis lung cancer cases and 
good prognosis cases.
P1.068 Basic Science and Translational Research, Sat Aug 1 
FK866, an inhibitor of NAD+ biosynthesis, suppresses 
growth of T790M EGF receptor gene mutant lung cancer 
cells
Okumura, Shunsuke1; Minami, Yoshinori1; Endo, Satoshi1; Sasaki, 
Takaaki1; Hasebe, Naoyuki2; Kitada, Masahiro1; Ohsaki, Yoshinobu1
1 Respiratory Center, Asahikawa Medical College, Asahikawa-
shi, Japan; 2 Department of Cardiovascular Medicine, Asahikawa 
Medical College, Asahikawa-shi, Japan
Background: T790M epidermal growth factor receptor (EGFR) gene 
mutant cells have high affinity of ATP toward ATP-binding site of 
EGFR, and results in acquiring resistance to EGFR tyrosine kinase 
inhibitor (TKI). FK866 is an inhibitor of the biosynthesis of Nico-
tinamide adenine dinucleotide (NAD+), and decreases intracellular 
ATP level. In the present study, we evaluated the effect of FK866 on 
NSCLC cells with EGFR gene mutation. Further, we examined the 
effect of FK866 on the growth of xenograft tumors using a nude mice 
model.
Methods: H358 (wild type EGFR), PC9 (del E746-A750), LC2 
(L858R) and H1975 (L858R, T790M) cells were treated with FK866 
or gefitinib. Proliferation and apoptosis were evaluated by BrdU cell 
proliferation assay and flow cytometric assay. Western blotting was 
performed to evaluate activation of EGFR including its downstream 
mediator proteins with and without FK866 or gefitinib. Intracellular 
ATP levels were measured by ATP assay kit. Mutant NSCLC cells 
were subcutaneously injected into the lateral flank of CD1Foxn1nu/
nu nude mice. Tumor bearing mice were treated with FK866 or gefit-
inib by i.p. injection every day. 14 days after the first injection, mice 
were sacrificed and immunohistochemistry was performed to study 
status of the EGFR downstream mediator proteins in the xenografts.
Results: Cell proliferation assay revealed FK866 had an antipro-
liferative activity against H1975 cells (P<0.05, Figure.1). FK866 
increased the apoptotic population in the flow cytometric analysis. 
Intracellular ATP levels were lower in the treated cells. Western blot 
analysis showed FK866 decreased expression level of phosphorylated 
p44/42 MAPK protein (Figure.2). FK866 also inhibited the growth 
of H1975 xenografts (P<0.05), and decreased expression levels of 
phosphorylated EGFR downstream mediator proteins in the immuno-
histochemistry. 
Conclusion: FK866 has an anti-tumor activity against EGFR gene 
T790M mutant NSCLC cells. FK866 has a potential to overcome 
the EGFR gene T790M mutation associated resistance of NSCLC to 
EGFR TKI.
P1.069 Basic Science and Translational Research, Sat Aug 1 
Adiponectin inhibits the growth of non-small cell lung 
cancer cells and suppresses recruitment of bone-marrow-
derived cells to the tumors in vivo
Okumura, Shunsuke1; Minami, Yoshinori2; Endo, Satoshi1; Sasaki, 
Takaaki1; Hasebe, Naoyuki3; Kitada, Masahiro1; Ohsaki, Yoshinobu1
1 Respiratory Center, Asahikawa Medical College, Asahikawa-
shi, Japan; 2 Asahikawa Medical College, Asahikawa-shi, Japan; 
3 Department of Cardiovascular Medicine, Asahikawa Medical 
College, Asahikawa-shi, Japan
Background: Adiponectin is a protein deriving from adipose tis-
sue. Adiponectin has anti-diabetic and anti-arteriosclerosis effects. 
Recently, it was reported that adiponectin has an anti-tumor activity 
against malignant tumors, for example, fibrosarcoma and breast can-
cer. In order to evaluate whether adiponectin has an anti-tumor effect 
on non-small cell lung cancer (NSCLC) proliferation, we examined 
the effects of human adiponectin on human NSCLC cell growth using 
a GFP transgenic (Tg) mice bone-marrow-transplantation (BMT) 
model.
Methods: Human NSCLC cells, A549 cells, were treated with vari-
ous concentrations of human full-length adiponectin, then prolifera-
tion assay was performed using MTS assay. Reverse transcriptase 
polymerase chain reaction (RT-PCR) was used to detect adiponectin 
receptors, AdipoR1 and AdipoR2, on the A549 cells. In vivo study, 
CD1Foxn1nu/nu nude mice were transplanted bone marrow mono-
nuclear cells from GFP Tg mice, C57/BL6JGFP/WT, after near fetal 
bone marrow irradiation. 14 days after BMT, NSCLC cells were sub-
cutaneously injected into the lateral flank of recipient mice. Xengraft 
mice were divided into two subgroups, treated group with adiponec-
tin via tail vein injection every day, and non-treated group. 10 days 
after starting the treatment, mice were sacrificed and bone marrow 
derived cells in xenograft tumors were evaluated using fluorescent 
microscope. Tumor volume was measured on the day of sacrifice.
Results: A549 cells expressed AdipoR1 and AdipoR2 protein. Cell 
proliferation assay showed a trend toward inhibition of A549 cell pro-
liferation by adiponectin treatment. In vivo study, adiponectin sup-
pressed the growth of the xenograft tumors. Fluorescent microscopic 
analysis revealed that significantly less bone marrow derived cells 
were exist in xenograft tumors treated with adiponectin in compari-
son with non-treated xenografts (P<0.05, figure). 
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
Copyright © 2009 by the International Association for the Study of Lung CancerS632
Conclusion: Adiponectin has a potential to suppress growth of 
NSCLC inhibiting recruitment of bone marrow derived cells to the 
tumor.
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Epithelial progenitor cells in non-small cell lung cancer
Ooi, Aik T.1; Nickerson, Derek W.2; Elashoff, David4; Wallace, W. 
Dean3; Goodglick, Lee3; Dubinett, Steven M.3; Gomperts, Brigitte 
N.2
1 UCLA Mattel Children’s Hospital, Los Angeles, CA, USA; 2 
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Biostatistics, Los Angeles, CA, USA
Lung cancer is the most deadly malignancy worldwide and kills more 
people than breast, prostate, and colon cancer combined. Lung cancer 
develops in a continuum from squamous metaplasia, to dysplasia to 
carcinoma in situ to invasive carcinoma. The initial events that lead 
to uncontrolled self-renewal of cells in the airway epithelium are not 
well understood. Progenitor cells of the proximal airway epithelium 
have been identified in the submucosal glands, submucosal gland 
ducts and basal cells. These cells express an immature cytokeratin 
(CK) 5 and are capable of self-renewal and differentiation to all 
mature airway epithelial cell types.
We previously identified circulating epithelial progenitor cells 
(CEPC) that contribute to repair of the airway epithelium in a mouse 
model of airway injury. We found that resident and circulating 
epithelial progenitor cells are both essential for repair of the normal 
pseudostratified airway epithelium and preventing the traffick-
ing of CEPC into the airway resulted in the premalignant lesion of 
squamous metaplasia. We therefore hypothesized that a reduction in 
CEPC could be associated with the development of lung cancer. To 
test this, we used CK5 mRNA expression levels as a surrogate marker 
for CEPC. We developed a quantitative real time PCR assay to 
determine the amount of CK5 mRNA in the buffy coat of normal hu-
man subjects (n=38) and non-small cell lung cancer patients (n=60) 
with different pathologic subtypes and stages of disease. There was a 
statistically significant decrease in CK5 mRNA levels in lung cancer 
patients compared to healthy human subjects (p<0.001). We found a 
significant decrease in CK5 mRNA levels in circulation in patients 
with early stage lung cancer (stage I and II) compared to patients with 
late stage lung cancer (stage III and IV) (p=0.03). There was also a 
significant decrease in CK5 mRNA expression in the circulation of 
early stage lung cancer patients compared to normal human subjects 
(p=0.005). The amount of CEPC may therefore act as a diagnostic 
and prognostic biomarker of lung cancer and could potentially also be 
used as an early predictor of tumor recurrence or metastasis.
We also examined the resident CK5 expressing cells in the airway 
epithelium. In the proximal airway, we identified a subpopulation 
of resident CK5 progenitor cells in the airway epithelium that also 
express CK14 and are located in the deep submucosal glands. In syn-
geneic tracheal transplant mouse model of hypoxic-ischemic injury, 
these CK14-expressing cells proliferate and contribute to airway 
epithelial repair. After proper repair, normal basal cells lose CK14 
expression in the pseudostratified columnar epithelium. Uncontrolled 
or aberrant repair leads to reserve cell hyperplasia and squamous 
metaplastic lesions with retained CK14 expression. This expression 
pattern is also observed in majority of squamous cell carcinoma, 
implying that CK14-expressing cells are critical in the initial events 
leading to lung cancer. 
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Characterization of pre-malignant dysplasia and 
squamous cell carcinoma in the NTCU-induced murine 
model
Opincariu, Laura I.1; Hudish, Tyler M.1; Merrick, Daniel1; Malkoski, 
Stephen2; Cleaver, Tim2; Mozer, Anthony B.1; Keith, Robert L.1, 2
1 Denver Veteran’s Affairs Medical Center, Denver, CO, USA; 2 
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Background: Squamous cell carcinoma (SCC) is the second most 
common form of non-small cell lung cancer (NSCLC) commonly 
found in the central airways of former and current smokers. The main 
interest of our laboratory is to find pre-clinical models of airway 
dysplasia that allow for better evaluation of chemopreventive agents 
in clinical trials. There are multiple murine lung adenocarcinoma 
models but very few functional models for SCC have been reported. 
Topical application of N-nitroso-tris-chloroethylurea (NTCU) has 
been shown to induce pre-malignant lesions in the airways of treated 
mice and we evaluated the NTCU model regarding its ability to 
induce pre-malignant squamous lesions in FVB/N mice.
Methods: FVB/N mice 8-10 weeks old had their skin painted with 
25μl of NTCU (diluted in acetone) biweekly for 32 weeks at concen-
trations of 4mM, 8mM and 40mM. Control animals were treated with 
vehicle alone (acetone). Following sacrifice, lungs were preserved in 
paraffin blocks and serial lung sections were stained with hematoxy-
lin and eosin and analyzed by study personnel. 
Results: Serial lung sections of mice completing the trial revealed 
a variety of successive squamous pathologies: SCC, carcinoma in 
situ and dysplasias of squamous cell origin. We found that a dose of 
40mM NTCU as previously described, results in a significant amount 
of SCC and pre-malignant dysplastic lesions, but unfortunately, was 
associated with excess mortality. We next studied lower doses (4mM 
and 8mM) which produced dysplasias, albeit to a lower degree and 
lower frequency. The control group did not exhibit any notable le-
sions in the airways. 
To determine whether these lesions were of squamous origin, repre-
sentative lung sections from the 8mM and the 40mM groups were 
immunostained for cytokeratin 5 (CK5), p63 and thyroid transcrip-
tion factor 1 (TTF-1).
CK5 is an intermediate size basic keratin that is mainly expressed 
in squamous epithelium and stains dysplasias and carcinomas from 
stratified epithelia. p63 is a p53 homologue and is critical in epithelial 
development. TTF-1 is expressed in type II pneumocytes in the lung 
and it stains positive in adenocarcinomas and negative in squamous 
cell carcinomas. Our lesions consistently stained CK 5 positive, p63 
positive and TTF-1 negative, analogous to human endobronchial 
lesions. 
Conclusions: NTCU induces pre-malignant lesions in the airways 
of FVB/N mice. The 40mM dose is excessively toxic to the animals. 
The 8mM dose induced lesions and was better tolerated. Histol-
ogy and IHC staining prove these lesions to be squamous in origin. 
The NTCU model will allow for improved pre-clinical modeling of 
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endobronchial dysplasia which is a main target of current human 
chemoprevention trials. 
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Influence of CXCR4 receptor localization on the migration 
of non small cell lung cancer (NSCLC) cell lines
Otsuka, Shannon; Muzik, Huong; Morris, Don; Ding, Yu; Bebb, 
Gwyn
University of Calgary/Tom Baker Cancer Centre, Calgary, AB, 
Canada
Background: Metastatic spread is the primary source of morbidity 
and mortality in Non Small Cell Lung Cancer (NSCLC). Migration 
of cells is an important step in the metastatic process. CXCR4, a G 
protein coupled chemokine receptor, and its ligand, stromal cell de-
rived factor-1 (SDF-1), play a critical role not only in the homing of 
hematopoietic stem cells but also in organ specific tumor metastasis. 
Expression of CXCR4 has been shown to correlate with migration, 
invasion and adhesion in various tumor cell lines. However, it has 
been suggested that not only the presence but the specific localization 
of CXCR4 is important. The cellular localization of CXCR4 and its 
role in the migration of NSCLC cells has not been extensively ex-
plored. We investigated the effect of CXCR4/SDF-1 axis modulation 
on NSCLC cell migration and correlated the magnitude of this effect 
to the localization of the CXCR4 receptor.
Methodology: Three human NSCLC cell lines (H460, A549 and 
H1299) were used. CXCR4 localization was determined by cell 
fractionation followed by western blot, immunocytochemistry (ICC), 
immunoflorescence (IF), and flow cytometry. Membrane localiza-
tion was assessed in reference to positive (Hela) and negative control 
(786-O) cell lines. Migration patterns were investigated using a 
48-well Boyden chamber. Cells with or without inhibitors are added 
to the upper wells; SDF-1 to the lower wells. Migrating cells were 
stained with hematoxylin and counted microscopically at 20x magni-
fication.
Results: Flow cytometric analysis demonstrated that H460 and 
H1299 showed moderate expression and A549 showed weak mem-
brane expression of CXCR4. Cell fractionation followed by western 
blotting confirmed FACS results. Stimulation of CXCR4 by SDF-
1 increased migration of all NSCLC cell lines by at least 2 times 
compared to control, while inhibition of this axis by anti CXCR4 
antibodies, anti SDF-1 antibodies or small molecular inhibitors to 
CXCR4 reduced cell migration to varying degrees compared to con-
trols (Table 1). This inhibition was greater for the moderate express-
ing cell lines (H1299 and H460) compared to the weak expressing 
A549 cell line.
 Cell Line Membrane Receptor Inhibition  Inhibition by Anti- Inhibition by Anti- 
  Expression by FACS by SMI (%) CXCR4 MAb (%) SDF-1 MAb (%)
 H1299 Moderate 25.8 65.8 63.8
 H460 Moderate 26.9 32.3 59.6
 A549 Weak 10.2 12.3 12.8
Conclusions: Interruption of the CXCR4/SDF-1 axis appears to in-
hibit the migration of NSCLC cells in vitro. This inhibition correlates 
to membrane localization of the CXCR4 receptor. The CXCR4 axis 
may play a role in influencing the migrational behavior of NSCLC 
cells in vivo. Additional experiments to assess the role of combina-
tion therapies against CXCR4 and SDF-1 are currently underway. 
These results suggest that use of CXCR4 inhibition strategies may be 
a useful therapeutic tool to reduce lung cancer metastasis but will best 
be guided by analysis of CXCR4 localization within malignant cells. 
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Erlotinib-resistant NSCLC cells maintain enhanced cap-
dependent translation via altered receptor tyrosine kinase 
activity
Patel, Manish R.; Jay-Dixon, Joe; Sadiq, Ahad A.; Jacobson, Blake 
A.; Kratzke, Robert A.
University of Minnesota Medical School, Minneapolis, MN, USA
Background: The use of epidermal growth factor receptor (EGFR) 
inhibitors, erlotinib and gefitinib, has resulted in modest gains in 
survival in patients with non-small cell lung cancer (NSCLC). While 
EGFR mutation status predicts response to therapy, the mechan-
isms of resistance are not well-defined as yet and current evidence 
shows that multiple events may lead to acquired resistance including 
activating k-ras mutations, insulin-like growth factor receptor (IGFR) 
stimulation, and met amplification. Regulation of the initiation of 
cap-dependent protein translation has been shown to be a critical 
regulatory node in NSCLC and has been postulated to integrate sig-
nals from numerous oncogenic pathways. Therefore, we hypothesized 
that maintenance of active cap-dependent translation after EGFR-TKI 
treatment would result in resistance to such therapy.
Methods: We used H2009, H522, H460, H2030, A549, H520, H838, 
H2122a NSCLC cell lines for these experiments, all of which express 
wild-type EGFR. Cells were grown in RPMI + 10% calf serum + 1% 
antibiotic (R10). Erlotinib sensitivity was determined by prolifera-
tion assay in 96-well plates using the CCK-8 kit. Cells were treated 
at various doses of erlotinib for 72 hours and IC50s were determined. 
Serum-starved cells were treated with and without 1μM erlotinib 
overnight, followed by stimulation with 100ng/mL EGF for vari-
ous time points. For cells in regular growing conditions, cells were 
treated with DMSO control, 2, or 5μM erlotinib for 24 hours. At the 
appropriate time points, lysates were made, quantified by Bradford 
Assay and then subjected to SDS-PAGE and Western analysis for key 
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signaling molecules in the EGFR pathway. Translation initiation was 
assessed by using a cap-affinity assay using 7mGTP sepharose beads 
to pull-down eIF4E and binding partners. 
Results: Of the cell lines tested, only H838 and H2122a were sensi-
tive to erlotinib (IC50<2μM). The rest were resistant (IC50 >10μM). 
Upon treatment with erlotinib, near complete hypophosphorylation 
of 4E-BP1 was observed in sensitive cell lines. Cap-affinity data also 
showed that the erlotinib treatment repressed translation in the cap-
affinity assay in sensitive cells. In resistant cell lines, H2009, H2030, 
H460, A549, and H520, erlotinib treatment had minimal effect on 
hyperphosphorylation of 4E-BP1 when EGF-stimulated, however, 
4E-BP1 hyperphosphorylation was decreased in erlotinib-resistant 
H522 cells. Treatment of H2009 with erlotinib resulted in increased 
IGFR phosphorylation, sustained phosphorylation of 4E-BP1, and 
activation of translation. In H522 cells, decreased 4E-BP1 phos-
phorylation and translational repression were observed upon erlotinib 
treatment. In this cell line, no enhancement of IGFR was seen, 
however, c-Met activation was seen upon erlotinib treatment. In both 
H522 and H2009 cells, erlotinib resulted in increases in p-AKT, p-
MAPK, and p-JNK and decreased p-eIF4E. Combination of erlotinib 
and translational inhibitors were also assessed for synergistic action.
Conclusions: This work shows that erlotinib resistant cells maintain 
activity of cap-dependent translation. Our preliminary work suggests 
that IGFR-mediated erlotinib resistance involves the activation of 
cap-dependent translation while c-Met mediated erlotinib-resistance 
involves alternate pathways.
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Detection of plasma proteins in bronchoalveolar lavages 
from lung cancer patients
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Background: Cytologic examination of bronchoalveolar lavage is 
a common diagnostic procedure for lung cancer although yields are 
often low. Molecular biomarkers are useful in distinguishing between 
benign and malignant ascites, and may be helpful in the diagnosis of 
lung cancer. The aim of this study was to assess the diagnostic value 
of molecular markers present in bronchoalveolar lavage fluid. 
Methods: We initially analyzed 78 bronchoalveolar lavage samples 
from 22 patients with non-malignant respiratory disease and 56 pa-
tients with lung cancer (both NSCLC and SCLC). The concentrations 
of albumin, factor H, and total protein were analyzed in all samples. 
Albumin and factor H were quantified by ELISA. Total protein was 
determined using the BCA protein assay.
Results: There was a significantly higher concentration of all three 
markers in the lung cancer group, when compared to the control 
group. This increase was independent of tumor histology. A highly 
significant correlation between the three markers was also observed. 
Bleeding was excluded as the source of blood proteins in the samples 
since no correlation was found between any of the markers and hemo-
globin. The sensitivity for malignancy was 83, 82 and 82% respect-
ively for albumin, factor H and total protein content. The specificity 
was 71, 77 and 71%. Moreover, 70% of central tumors and 55% of 
peripheral tumors initially reported as cytologically negative were 
classified as positive using these molecular markers. The results were 
validated in an independent series of bronchoalveolar lavage samples 
from 26 patients with non-malignant respiratory disease and 25 
patients with lung cancer. Both total protein content and factor H were 
determined in this series. Sensitivity and specificity were 76 and 73%, 
respectively, for total protein content and 80 and 81% for factor H. 
Conclusions: The presence of plasma proteins in bronchoalveolar 
lavage samples is a common finding in lung cancer and may improve 
the diagnostic yield of this technique. Quantification of biomarkers 
such as factor H, albumin or total proteins may be used as a simple 
and inexpensive complement to cytologic examination.
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Signal transduction through EGFR is complicated by 
promiscous association with other receptor ligands and 
signal transducers
Plate, Janet M.; Bonomi, Philip; Sutton, Parnetta 
Rush University Medical Center, Chicago, IL, USA
To gain a better understanding of the mechanisms of activation 
through ErbB family members in lung cancer, we undertook a study 
of ErbB signaling in non-small cell lung cancer cell lines (NSCLC) 
where EGFR pathways were constitutively activated. We found con-
stitutively activated EGFR in the calu3 line to be physically associ-
ated with erbB3 and c-met in pulldown experiments with anti-erbB3 
and anti-phospho c-met. The co-immunoprecipitation experiments 
also revealed an association of EGFR and c-met with src-kinase. 
Thus, we identified complexes of EGFR with erbB3, c-met and src 
kinases within calu3 cells. Inhibitors of EGFR, AG1478 and erlotinib, 
inhibited the phosphorylation and co-immunoprecipitation of phos-
phorylated c-met, suggesting that EGFR kinase was responsible for 
phosphorylation of c-met. A c-met inhibitor, SU11274 on the other 
hand, had no affect on c-met or EGFR phosphorylation but did inhibit 
downstream phosphorylation of erk1,2. A src-kinase inhibitor, PP2, 
inhibited the phosphorylation of both EGFR and c-met. These data 
suggested a reversed signal flow, and that by including a src inhibitor 
in a combination therapy, greater inhibition of Calu3 cell growth 
would result. In fact, we found that combining the src inhibitor, PP2, 
with erlotinib led to decreased cell survival after 72 hours of culture. 
Our studies underscore the complexity of signaling pathways in lung 
cancer and emphasize a need for combining other kinase targeted 
agents with EGFR inhibitors to achieve tumor growth inhibition.
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Overcoming the chemotherapy resistance in non-small-cell 
lung cancer by tamoxifen
Bogush, Tatiana; Dudko, Evgeniy; Bogush, Elena; Tikchomirov, 
Mikchail; Beme, Anna; Laktionov, Konstantin; Vakhtadze, Levan; 
Polotsky, Boris; Davydov, Mikchail
Russian N.N. Blokhin Memorial Cancer Research Center Russian 
Academy of Medical Sciences, Moscow, Russia
Background: Tamoxifen is an effective drug in standard therapy of 
breast cancer as an antiestrogen. But there are a lot of other clinical 
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important activities of tamoxifen, one of them is overcoming the 
chemotherapy resistance by tamoxifen in various tumors including 
non-small-cell lung cancer (NSCLC). Analyzing the results we have 
taken notice that in all cases tamoxifen was used in chemotherapy 
included anticancer drug(s) associated with multidrug resistance 
mechanism (MDR) that is determined by extruding of MDR-drugs 
out of the cells. That is why thinking over the reasons of overcoming 
the chemotherapy resistance under tamoxifen action we have sup-
posed tamoxifen interaction with ABC-transporters, as well as with 
vault protein LRP that may prevent further MDR-drug(s)’ binding 
to these MDR-markers and thereby inhibit main MDR mechanism: 
anticancer drug transport out of the cells. 
Materials and methods: Tumor cells obtained from surgical 
biopsy specimens of NSCLC were studied. Fluorescence of specific 
monoclonal antibodies (mAb) bound to Pgp, MRP1 and LRP (4E3, 
MRPm5 and LMR5 respectively) as well as the isotypic antibodies 
(MG2a-53 for Pgp and MRP1, RTK4530 for LRP) was estimated by 
flowcytometry. Mean fluorescence of mAb-labelled cells as well as 
the number of mAb-labelled cells were calculated over fluorescence 
area of isotypic controls. 
Results: 1. Incubation of the cells with mAbs increased significantly 
their fluorescence intensity compared to the isotypic controls. In 
some tumors it was shown for MRP1 and LRP mAbs only, in the 
other one – for MRP1, LRP and Pgp. 2. It was not any influence of 
tamoxifen on isotypic antibodies binding to the cells. 3. Incubation of 
the cells with 50x10-6M tamoxifen changed interaction of mAbs with 
the MDR-markers investigated. In all cases the mean fluorescence 
intensity of the cells in the area of specific fluorescence of mAbs as 
well as the number of mAb-labeled cells was changed but with dif-
ferent manner for different MDR-markers. Under tamoxifen action 
the indexes for MRP1 and LRP antibodies decreased up to more than 
2 times. Tamoxifen effect on mAb interaction to Pgp was different 
in living cells and in the cells after 0.5% Tween 20 permeabilization. 
For the first one, tamoxifen increased the mean specific cell fluor-
escence intensity as well as the number of mAb-labeled cells up to 
more than 4 times. For the second one, the indexes decreased up to 
more than 2 times under tamoxifen action.
Conclusion: These data are direct evidence for the tamoxifen inter-
action with the Pgp, MRP1 and LRP in NSCLC cells. It should de-
crease further binding of anticancer drugs with the MDR-markers and 
thereby inhibits MDR-mechanism through decrease of the MDR-drug 
transport out of the cells. This can be regarded as confirmation of our 
assumption that tamoxifen interaction with Pgp, MRP1 and LRP may 
be one of the reasons for overcoming the MDR-drug chemotherapy 
resistance of NSCLC under tamoxifen action. The conclusion is true 
for the tumors only expressing MDR-phenotype and explains the 
tamoxifen insufficient in increase chemotherapy efficacy in some pa-
tients. Supported by Russian Foundation for Basic Research (Grants 
N07-04-00082 and N08-04-13647).
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Aberrant promoter methylation in sputum and bronchial 
washing in patients at risk for lung cancer
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Background: bronchial dysplasia is an obliged step in the progres-
sion to squamous cell carcinoma. One of the genetic disorders as-
sociated with histological progression is aberrant DNA methylation. 
The initial genetic damage assayed in sputum and bronchial washing 
(BW) would help to identify a subset of patients with dysplastic 
epithelial progression.
Aim: to correlate epigenetic changes analyzed in induced sputum and 
BW obtained in patients at risk for lung cancer.
Methods: baseline analysis of a prospective study aimed to detect 
bronchial dysplasia. Autofluorescence bronchoscopy was performed 
and BW routinely obtained in subjects having a smoking history 
of >30 pack-years (smokers and former smokers), 45-75 years old, 
without chronic respiratory failure or FEV1% < 35%, chemo or 
radiotherapy naïve and not using systemic corticosteroids. DNA was 
isolated from sputum and BW and the aberrant promoter methylation 
was assessed in p16, death associated protein kinase (DAPK) and ras 
effector homolog 1 (RASSF1) genes using the methylation-specific 
PCR assay.
Results: sputum and BW DNA were analyzed from 80 patients. 
Aberrant promoter methylation of DAPK was obtained in 26 BW 
(32.1%) and 24 sputum (29.6%); p16 in 13 BW (17.8%) and 6 
sputum (8.2%), and RASSF1 in 1 BW and 1 sputum (1.3%). No 
statistical differences were observed between BW and sputum in any 
of the 3 genes analyzed. 
Conclusion: induced sputum may be a suitable sample to detect 
aberrant methylation in patients with high risk of bronchial dysplasia 
because the detection level is similar to BW and it is easier to obtain. 
Funded by: FIS-051715, CIBERES, SOCAP, FUCAP
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Metabolic phenotyping of alternative fuels in non small 
cell lung cancer (NSCLC)
Sadiq, Ahad A.1; Okar, David A.2; Kratzke, Marian G.2; Kratzke, 
Robert A.1
1 University of Minnesota, Minneapolis, MN, USA; 2 Veterans Affair 
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Background: According to Warburg phenomenon high glycolytic 
rate and proportioning of pyruvate to lactate (fermentation), even in 
the absence of hypoxia, are characteristic of transformed cells. This 
Glycolytic Phenotype (GP) is most beneficial at the leading edge of 
a developing tumor, while in the trailing edge, cancer cells compete 
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among themselves and the GP offers no clear advantage. We hypoth-
esize that these interior cells will benefit from an ability to mobilize 
alternative fuels, especially in response to glucose deprivation.
Methods: Lung cancer cell lines (h441, h522, h2009) and immortal-
ized Human Bronchoepithelial Cell line (HBEC) were utilized for our 
experiments. Biolog® Phenotype MicroArraysTM Panels (96 wells) 
were used for scanning and measuring the energy metabolism path-
ways in the above mentioned cell lines. Cells were initially grown in 
RPMI+PSF (5% FBS). After washing with PBS Biolog IF-M1 and 
IF-M2 media were used for PM1 and PM-2/3a/4a plates respectively. 
5000 cells/well were plated. Cells were incubated for 40-44 hrs. 
Using Biolog Redox Dye-A cellular metabolism was recorded with 
the help of visual charting scale.
Results: The non-malignant cells appear to be less discriminating 
than the lung cancer cells in terms of fuel preference. H441 cells ap-
pear to be relatively non-responsive to the putative glucose depletion, 
yet this may be because these mobilize alternative fuels constitu-
tively, as opposed to the other cell lines that mobilize them as needed. 
The results clearly establish differences in alternative fuel use among 
lung cancer cell lines, as well as in comparison to the HBEC cultures, 
suggesting distinct alternative fuel phenotypes (AFPs). Parallel stud-
ies indicate that differential changes lactate metabolism in response to 
glucose depletion are a critical aspect of the observed AFPs.
Conclusion: Our results compellingly support the existence of 
distinct AFPs in human lung cancer cell lines which encourages our 
continued effort to identify cancer-specific regulatory mechanisms 
that work to provide the neoplasm the ability to readjust fuel metabol-
ism in response to signals from the microenvironment.
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Epidermal growth factor receptor gene amplification in 
surgical resected Japanese lung cancer 
Sasaki, Hidefumi1; Okuda, Katsuhiro1; Hikosaka, Yu1; Kawano, 
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To evaluate the epidermal growth factor receptor (EGFR) protein 
expression and gene amplification as predictors of clinical outcome 
in patients with non-small-cell lung cancer (NSCLC), we have 
performed fluorescence in situ hybridization (FISH) and immuno-
histochemistry (IHC) using Clone2-18C9(Dako NorthAmerica Co.). 
We investigated the EGFR amplification and EGFR protein expres-
sion statuses in 109 surgically treated non-small cell lung cancer 
(NSCLC) cases. The presence or absence of EGFR mutations of 
kinase domains was analyzed by genotyping analysis and sequences, 
and already reported. EGFR amplification was defined as Cap-
puzzo et al. criteria. FISH-positive was found from 36/109 (33.0%) 
lung cancer patients, including 30 high polysomy cases and 6 gene 
amplification cases. FISH positive cases were significantly correlated 
with worse prognosis (log-rank test p=0.0237). Multi-variate analyses 
showed p-stage (p=0.0001, HR=1.959, 1.393-2.756) and FISH results 
(p=0.0421, HR=1.938, 1.024-3.676) were prognostic factors. Within 
55 EGFR mutant patients, FISH-positive was also prognostic factor 
(p=0.05). FISH-negative tumors were found to be more frequently 
well-differentiated histology. Smoking status (never smoker vs. 
smoker, p=0.1510), and gender (p=0.5248) did not correlated with 
FISH positive. However, FISH positive cases tend to have higher 
pathological stages (p=0.1188). EGFR IHC results were correl-
ated with FISH results (p=0.004), but not correlated with prognosis 
(p=0.2815). Although EGFR FISH-positive rate did not correlated 
with EGFR mutation (p=0.1973), EGFR polysomy or amplification 
cases were correlated with EGFR mutations (p=0.0023). 53 gefitinib 
treated patients (28 were overlapped) were also evaluated with EGFR 
mutation and FISH statuses. EGFR mutation (p=0.0142) but not 
FISH status (p=0.9224) was prognostic factor for gefitinib treatment. 
In conclusion, the EGFR FISH-positive rate in Japanese patients with 
NSCLC was similar to rates in Western populations, unlike the higher 
frequencies of EGFR mutation in East Asians. A high EGFR gene 
copy number itself might predict worse survival in NSCLC.
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In search of secreted protein biomarkers for 
chemoresistance in non-small cell lung cancer by 2D-DIGE
Sun, Qiangling; Sha, Huifang; Yang, Xiaohua
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University, Shanghai, China
Background and Objective: Lung cancer is a major cause of cancer-
related deaths world-wide with non-small cell lung cancers (NSCLC) 
representing the majority of these cancers. Paclitaxol is used in the 
first line treatment of lung cancer, but acquired resistance represents 
the most important clinical problem and a major obstacle to a suc-
cessful therapy. To date, there is no known clinically useful blood-
based biomarker related to chemoresistance for lung cancers. How-
ever chemotherapy treatments can cause tumor lysis and release of 
intracellular proteins that can be detected in the blood with a highly 
sensitive approach and the level of such proteins can provide immedi-
ate response information for clinical decision. To better understand 
molecular resistance mechanisms and to provide new candidates of 
serum biomarkers for chemotherapy reponse evaluation, a compara-
tive proteomic approach was undertaken on the secreted protein of 
chemosensitive A549 lung adenocarcinoma cell and cells resistant to 
paclitaxel.
Methods: Total secreted proteins in the conditioned serum-free 
media of A549 and paclitaxol resistant cell line A549-Taxol were 
separated by fluorscent differential gel electrophoresis(DIGE). Image 
analysis was carried out with the DeCyder 2D 6.5 software. Proteins 
associated with chemoresistance process were identified by matrix-
assisted laser desorption/ionization time-of-flight tandem mass spec-
trometry (MALDI-TOF-MS/MS). Some key molecules were valuated 
by Western blot.
Results: Among 1659 matched protein spots, 35 were signficantly 
up-regulated in the chemoresistant cells (ratio (chemoresistance/
chemosensitive) ≥2, p≤0.01; ), whereas 41 spots were down-regulated 
(ratio (chemoresistance/chemosensitive) ≤2, p≤0.01; ). 19 proteins 
were identified, including ezrin, cathepsin D, lactotransferrin, matrix 
metalloproteinase-7(MMP7), GST Class-pi(GSTP1-1), nidogen-2, 
nuclebindin-1, phosphoglycerate kinase 1(PGK1), keratin 8(CK8), 
fructose bisphosphate aldolase A(ALDOA) and so on. All these pro-
teins can be detected in blood. Among them, GSTP1-1, CK8, MMP7, 
ALDOA, PGK1 were reported to be related with paclitaxol resistance 
in other cancer. Ezrin and NID-2 were further confirmed by Western 
blot analysis. Most of these proteins were related to the category of 
metabolism, immune response, proteolysis, calcium homeostasis, cell 
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cycle and apoptosis, cell adhesion, suggesting that alterations of those 
processes might be involved in paclitaxel resistance mechanisms. 
Conclusions:  To our knowledge, this is the first direct secretomic 
comparison of paclitaxel sensitive and resistant lung cancer cells. The 
utilization of DIGE is effective in identifying the secreted protein 
expression profiles. Mutiple secreted proteins related to chemoresist-
ance of A549-Taxol cells were identified in this study for the first 
time and may be useful for further studies of resistance mechanisms 
and screening of serologic resistance biomarkers for clinical use. 
Future directions will focus on valuation the key molecules in the 
clinical chemoresistant sera samles in order to identify a diagnostic 
circulating protein signature for NSCLC chemoresistance.
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Cancer stem cell marker expression in pulmonary 
squamous cell carcinoma
Shimada, Yoshihisa; Ishii, Genichiro; Yoshida, Jyunji; Hishida, 
Tomoyuki; Nishimura, Mitsuyo; Nagai, Kanji; Ochiai, Atsushi
Pathology Division, Research Center for Innovative Oncology, 
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Background: Cancer stem cells (CSC), a very small population of 
specialized cells, have self-renewal and extensively proliferative 
characteristics to sustain tumor formation. The notion that cancers 
formation and growth may depend on CSC has changed our perspec-
tive in pursuit of new cancer treatment modalities. The purpose of 
this study was to examine CSC marker expression in pulmonary 
squamous cell carcinomas (SqCC) and its relationship with survival 
outcome. 
Method: We examined histologically the expression of three CSC 
markers, podoplanin, CD44, and p63 in 162 consecutive SqCC by 
immunohistochemical staining and analyzed CSC marker expression 
impact on outcome.
Result: Of the 162 tumors, podoplanin expression was observed in 
107 (66.0%) tumors, CD44 in 145 (89.5%) and p63 in 151 (93.2%), 
respectively. In 102 (95.3%) of the 107 podoplanin positive tumors, 
tumor cells showing strong expression were localized in the periph-
ery of the tumor nests. However, this peripheral localization pattern 
was observed in only 55.9 % (81/145) of the CD44 positive tumors 
and 43.0% (65/151) of p63 positive tumors. In 95 (88.8%) of the 107 
podoplanin positive tumors, positive cells were localized more per-
ipherally in the tumor nests than CD44 or p63 positive tumors. When 
CD44 and p63 expressions were compared in these 95 podoplanin 
positive tumors, p63 positive cell layers in tumor nest periphery were 
broader compared to CD44 positive cell layers. These findings sug-
gest, in most podoplanin positive tumors, tumor cells are aligned in 
a “-hierarchical distribution pattern-” according to the expression of 
the three markers. Patients who had podoplanin positive tumors with 
the “-hierarchical pattern-” resulted in significantly better overall sur-
vival than those who had podoplanin negative tumors (log-rank test; 
p=0.043), suggesting that the CSC hierarchical pattern may indicate 
lower biological aggressiveness. 
Conclusion: Hierarchical expression of the CSC markers, podo-
planin, CD44, and p63 in pulmonary SqCC appeared to suggest 
podoplanin expression reflects the most immature CSC status in its 
differentiation process. The CSC markers hierarchical expression 
suggests lower biological aggressiveness. These findings may change 
perspectives in pulmonary SqCC biology. 
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Purpose: KRAS is an oncogene that can be activated by mutations. 
Non-small cell lung cancer patients that have mutations in KRAS do 
not respond to tyrosine kinase inhibitors, therefore accurate detec-
tion of KRAS mutations is very important for making therapeutic 
strategies. Sequencing related techniques has been frequently used, 
but they are usually too complex, have low sensitivity, and are time 
consuming for routine screening in clinical situations. 
Method: We adopted PNA-clamp Smart amplification process ver-
sion2 (SmartAmp2) to KRAS codon12 mutation detection method 
in clinical samples and compared to traditional PCR based methods. 
We examined 172 DNA samples, which were extracted from lung 
adenocarcinoma surgical specimens, for KRAS mutations using 
PNA-clamp SMAP2, direct sequencing, enzyme-enriched sequencing 
and PNA-enriched sequencing. We then examined for KRAS muta-
tions in 8 formalin-fixed paraffin-embedded (FFPE) tissues of lung 
adenocarcinoma that harboured KRAS mutations previously identi-
fied, using PNA-clamp SMAP2. 
Results: Among 172 lung adenocarcinoma samples, direct sequen-
cing, enzyme-enriched sequencing and PNA-enriched sequencing 
showed that 16 (9.3%), 26 (15.1%), and 28 (16.3%) tumors con-
taining KRAS mutation allele in codon12 respectively. Whereas, 
using PNA-clamp SmartAmp2, we could identify 31 (18.0%) tumors 
to have KRAS mutations in codon12 with in 60 min and 3 tumors of 
them were identified to have no mutation by PCR-based methods.
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 case SmartAmp2 Direct Enzyme- PNA- AA 
   sequencing enriched enriched change
 1 Mut Wt Wt G35T G12V
 2 Mut Wt G34T G34T G12C
 3 Mut Wt G35A G35A G12D
 4 Mut G35T G35T G35T G12V
 5 Mut Wt G35A G35A G12D
 6 Mut Wt G35C G35C G12A
 7 Mut G35T G35T G35T G12V
 8 Mut Wt Wt Wt G12D
 9 Mut G34T G34T G34T G12C
 10 Mut Wt Wt Wt G12C
 11 Mut G34T, G35T Wt G34T, G35T G12F
 12 Mut G35T G35T G35T G12V
 13 Mut G35T G35T G35T G12V
 14 Mut G35C G35C G35C G12A
 15 Mut G35C G35C G35C G12A
 16 Mut G35A G35A G35A G12D
 17 Mut G35A G35A G35A G12D
 18 Mut Wt G35A G35A G12D
 19 Mut G35A G35A G35A G12D
 20 Mut G35T G35T G35T G12V
 21 Mut Wt G34T G34T G12C
 22 Mut Wt G34T G34T G12C
 23 Mut Wt G35A G35A G12D
 24 Mut G35A G35A G35A G12D
 25 Mut G35A G35A G35A G12D
 26 Mut Wt Wt Wt G12C
 27 Mut Wt G35A G35A G12D
 28 Mut G35A G35A G35A G12D
 29 Mut G35A G35A G35A G12D
 30 Mut Wt G35A G35A G12D
 31 Mut Wt G34T G34T G12C
 Mutation rate (%) 18.0 9.3 15.1 16.3 
On the other hand, we examined 30 peripheral lung tissue speci-
mens as nonmalignant samples and found no mutations in any of the 
samples using SmartAmp2. Eight FFEP tissues had KRAS mutations 
detected by PNA-clamp SMAP2.
Conclusions: We confirmed that PNA-clamp SmartAmp2 has high-
sensitivity, high-accuracy and reproducibility and is suitable for clin-
ical diagnosis of KRAS codon12 mutations. PNA-clamp SmartAmp2 
will contribute to make effective and safety therapeutic strategy of 
lung cancer.
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Angiogenic marker expression in tumor cells versus 
stromal cells in non-small cell lung cancer
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Background: In tumor angiogenesis there is a complex interplay 
between endothelial, stromal, and tumor cells. One of the major 
pathways involved in angiogenesis is the vascular endothelial growth 
factor family of proteins and receptors (VEGF and VEGFR). This 
family comprises six secreted glycoproteins of which VEGF-A, -B, 
-C, -D are of great significance. These VEGF ligands mediate their 
angiogenic effect via the receptor tyrosine kinases VEGFR-1 (flt-1), 
VEGFR-2 (KDR or Flk-1), and VEGFR-3. This study investigates 
the correlations between the expression of ligands and receptors of 
VEGF in tumor cells and tumor stroma of resected non-small cell 
lung cancer (NSCLC) tumors.
Methods: Primary tumor tissues (n=22) from anonymized patients 
(stage I to IIIA NSCLC) were used in this retrospective study. The 
most representative areas of tumor cells and tumor stroma were 
carefully selected and marked on the H&E slide and sampled for the 
tissue microarray blocks (TMA). RNA was extracted from 2 cores 
pieces of the TMA using a standard protocol and real-time PCR was 
performed using TaqMan® probes. Relative quantification was cal-
culated by Pfaffl formulae, using Actin-beta as endogenous control. 
Results were normalized against a calibrator sample (NCI-H23 cell 
line). We correlate the expression of ligands and receptors of VEGF 
family in stroma and tumor samples. All statistical analysis were 
done using the SPSS 13.0 software.
Results: Significant difference were found in the expression of 
VEGF-A between tumor cells and tumor stroma (p=0.024, Wilcox-
on’s test). In tumor there were significant correlations between the 
mRNA expression of VEGF-A and VEGFR-1 and between VEGF-B 
and VEGFR-3 (p=0.001 and p=0.009, Spearman’s test). Interestingly, 
when we correlate the expression of VEGF ligands in tumor samples 
with the expression of their receptors in tumor stroma, there were 
significant correlations between VEGF-A and VEGFR-1, -2 and -3 
(p=0.017, 0.050 and 0.032, respectively).
Conclusion: This is the first report showing the mRNA expression 
of angiogenic genes in tissue microarray samples from tumor and 
stroma cells in resectable NSCLC. A correlation between the expres-
sion of VEGF ligands in tumor cells and VEGFR in tumor stroma 
was found. This may allude the importance of the tumor-stroma inter-
action when trying to understand the angiogenic process in NSCLC.
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High expression epidermal growth factor receptor (EGFR) 
and telomerase protein in “smoker” non-small cell lung 
cancer patients
Syahruddin, Elisna; Agustin, Heidy; Hidayat, Heriawati; Suzanna, 
Evelyn; Wibawanto, Agung; Hudoyo, Ahmad 
Faculty of Medicine, University of Indonesia, Jakarta, Indonesia
Background: Epidermal growth factor receptor (EGFR) and telo-
merase are involve in lung carcinogenesis and would be target of 
treatment. Over expression of EGFR is one of the earliest and most 
consistent abnormalities in bronchial epithelium of smokers. On other 
hand, telomerase activity was found to be closely associated with 
the subset which expressed predominantly EGFR. We analyzed the 
expression of EGFR and telomerase in surgical specimen’s patients 
with non-small cell lung cancer (NSCLC). We explored the correla-
tion between expression of EGFR and telomerase protein level, their 
relationship with clinicopathological parameters and their impact on 
outcome in resected NSCLC patients. 
Copyright © 2009 by the International Association for the Study of Lung Cancer S639
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
Samples and Methods: Using immunohistochemical techniques, we 
retrospectively analyzed formalin-fixed, paraffin-embedded samples 
from 36 patients with pStage I-III NSCLC. A semi quantitative grad-
ing on average of 500 cells/section was used. Patients characteristic 
were 26 of 36 (72.2%) male, 10 of 36 (27.8%) female, average age 
was 56.3 years old with range 39 to 72 years old. According to smok-
ing habit were obtained from a total of 36 patients, 26 of 36 (72.7%) 
patients had a smoking history and mostly used “kretek” or mixed 
with white cigarette. Kretek is difference with white cigarette. Kretek 
is containing tobacco leaf with clove with stronger smell and more 
heavy smoke. Divided in histolpathological type was adenocarcinoma 
21 of 36 (58.3%) squamous cell carcinoma 15 of 36 (41.7%) 
Results: We have found that epidermal growth factor receptor 
(EGFR) and telomerase protein expression in all specimens. High 
expression EGFR have found in 28 of 33 (84.8%) and telomerase 30 
of 33 (90.9%) specimens Based on histological types, high expres-
sion of EGFR have found in 15 of 21 ( 71.4%) adenocarcinoma and 
12 of 12 squamous cell carcinoma, high expression of telomerase 
have found in 20 of 20 (100%) adenocarcinoma and also in 13 of 13 
(100%) of squamous cell carcinoma.. Synchronous over expression 
of EGFR and telomerase was found in 21 of 28 (75%) speciments. 
High expression EGFR and telomerase had not correlation with sex, 
type of histopatology and ciggarete type retrospectively. The log 
Rank test and Kaplan Meyer there were nor significant difference (p= 
0.821 ) in 1-year survival rate or median survival rate. 
Conclusion: High expression of EGFR and telomerase in smoker 
NSCLC patients but regarding with prognosis there was no cor-
relation between expressions of EGFR and telomerase protein with 
smoking.
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Real-time PCR measurement of free-circulating DNA 
concentration in plasma of NSCLC patients during 
treatment and follow-up
Szpechcinski, Adam1; Struniawski, Radoslaw1; Chabowski, 
Mariusz2; Zaleska, Jolanta3; Dancewicz, Maciej 4; Kopinski, Piotr5; 
Kowalewski, Janusz4; Roszkowski, Kazimierz3; Orlowski, Tadeusz2; 
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Background: minute amounts of free-circulating DNA are present in 
plasma of healthy individuals, whereas increased levels are found in 
a number of benign and malignant pathologies including lung cancer. 
It is believed that quantitative real-time PCR analysis of plasma DNA 
in treated lung cancer patients, though cancer unspecific, might sup-
port the imaging modalities in therapy efficiency monitoring by indi-
cation of the early physiological response. In the presented research 
we preliminarily evaluated the plasma DNA levels in non-small cell 
lung cancer (NSCLC) patients prior and after the surgery with respect 
to healthy controls. 
Methods: plasma samples were collected prospectively from 30 
NSCLC patients (I-IIIA) before and after surgery and from 16 healthy 
volunteers in order to free-circulating DNA extraction and quantita-
tive real-time PCR analysis. 
Results: the values of plasma DNA concentration ranged from 0.9 
up to 7 ng/ml in healthy individuals, and from 1.5 up to 50 ng/ml in 
NSCLC patients before treatment. Cancer group showed several-fold 
higher mean free-circulating DNA concentration with respect to the 
controls (mean 12.10 vs. 2.65 ng/ml). The drastic increase in plasma 
DNA level up to mean 68.74 ng/ml was observed one week after the 
primary tumor resection. Statistical analysis showed the differences 
between the values to be significant (p<0.02). A greater variability of 
plasma DNA concentrations was observed in patients than in controls 
(SD 13.72 vs. 2.02 respectively). The area under the ROC curve built 
preliminarily was 0.87 (95% CI, 0.744 to 0.954, p<0.0001). 
Conclusions: resectable NSCLC patients show significantly higher 
plasma DNA concentration than healthy individuals. Postsurgical 
trauma causes the drastic increase in the plasma DNA level and 
real-time PCR method can effectively measure that phenomenon. 
The study is to be extended for non-operable (IIIB) and follow-up 
NSCLC patients.
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Tissue engineered tumor cultured on chick embryo 
chorioallantoic membrane (CAM): a new model of 
spontaneous metastasis
Tan, Qiang1; Steiner, Rudolf2; Hilbe, Monika3; Hillinger, Sven4; 
Weder, Walter4; Lu, Shun1
1 Shanghai Lung Tumor Clinic Center, Shanghai Chest Hospital, 
Shanghai, China; 2 Department of Oncology, University Hospital 
Zurich, Zurich, Switzerland; 3 ECVP Institute of Veterinary 
Pathology, FVH (Pathology), Zurich, Swaziland; 4 Department of 
Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland
Background: In this study we applied tissue engineering 3D culture 
and medium perfusion techniques to develope spontaneous metastasis 
model in chick embryo chorioallantoic membrane (CAM). 
Methods: Tissue engineered tumor were created by seeding 107 
Lewis lung cancer cells onto tubular Degrapol scaffold (5mm in 
length, 2mm in diameter and 0.5mm in thickness) with a inserted 
catheter connected to a peritalic pump system which created a con-
tinuous DMEM medium flow at 5ml/hour
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The tissue engineered tumor were place on CAM for one day before 
harvest of bone and skin tissue from the embryo for HE and Keratin 
staining to identify metastasis tumor cells. Pure scaffold without can-
cer cells were used as control group with five CAMs in each group. 
Results: All the CAMs from the study group died within one day 
with Keratin positive cell demonstrated in bone and skin tissue, while 
the corresponding tissues from the control group showed normal 
structure and Keratin negative. 
Conclusions: Tissue engineered tumor better represents in-vivo 
tumor characteristics and, together with CAM, develops an efficient 
spontaneous metastasis model with potential for anti-metastasis drug 
screening.
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CD22, CD26, CD52, EG5 and IGF-1R immunostaining in 
thymic epithelial tumors classified according to the WHO
Taranchon, Estelle1; Abedallaa, Nader2; Soria, Jean Charles2; Besse, 
Benjamin2; De Montpréville, Vincent T.3
1 IGR, Villejuif, France; 2 Gustave Roussy Institute, Villejuif, France; 
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Background: Thymic epithelial tumors (TETs) have shown modest 
responses to standard chemotherapy. The aim of this study was to 
identify the presence of biomarkers/ therapeutic targets with potential 
predictive value in these rare thoracic cancers. Five candidate mark-
ers (CD22, CD26 CD52, EG5, IGF-1R) were selected for evaluation 
in patients with advanced TET. 
Methods: 92 TETs (4 of type A, 15 of AB, 6 B1, 26 B2, 18 B3, 12 C, 
5 micronodular TETs, 1 sarcomatoïd thymoma and 5 carcinoid TETs) 
including 3 paired primary/secondary tumors (of type B2, B3, C re-
spectively) were reviewed according to the WHO classification. Each 
tumor was assessed by immunohistochemistry with a binary score (0 
if negative, 1 if positive). The staining was considered positive when 
more than 10% of tumor cells were stained.
Results: A CD22 nuclear staining, verified with 2 different CD22 
antibodies was observed in all histo-pathological types of TET: in 
type AB: 67% were positive, in B3: 40%, C: 40%, and in A, B1, and 
B2 types: 25%, 17%, and 23% respectively. The only sarcomatoïd 
thymoma, 20% (1/5) of micronodular, and 40% (2/5) of carcinoid 
TETs also were CD22 positive.
There was a CD52 cytoplasmic staining of unknown significance in 
8% of B2, 22% of B3, and 20% of micronodular TETs while all other 
cases were negative. 
EG5 analysis revealed nuclear and cytoplasmic staining. The staining 
was present in all the TET types except the sarcomatoïd thymoma, 
which was negative. We found 75% of EG5 positivity in C type, 64% 
in AB, 60% in micronodular types, 50% in B1, 46% in B2, 41% in 
B3, 25% in A, and 25% in carcinoid TETs
Conclusion: CD22 positive staining was observed in all types of 
TET. CD52 positive tumors were restricted to B2 and B3 types. EG5 
positivity was most frequently observed in the C types (TET patients 
with the highest risk of recurrence and metastases). CD26 and IGR-
1R data will also be presented. This exploratory study demonstrates 
the presence of molecular targets in a rare thoracic cancer that might 
be useful in future treatment options.
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carcinogens in human lung cells 
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Background: It has been hypothesized that a higher lung cancer risk 
among females could be related to sex differences in ability to bio-
activate tobacco-smoke carcinogens. Polycyclic aromatic hydrocar-
bons (PAH) are considered important carcinogens in tobacco-smoke. 
The majority of these compounds need to be bioactivated by enzymes 
of the CYP1-family to reach their carcinogenic potential. Previously 
published results from our group have shown that female smokers 
exhibit a higher expression of CYP1A1 along with higher levels of 
PAH-related DNA-adducts in their lungs compared to male smok-
ers. Sex differences in CYP1A1 gene expression may be related to 
estrogen receptors and their interaction with the main modulator of 
CYP1A1 transcription, the aryl hydrocarbon receptor (AHR). The 
aim of this study was to elucidate whether sex differences in capacity 
to bioactivate PAH is an intrinsic characteristic of human lung cells 
and to determine the role of estrogen receptors in regulation of 
CYP1A1. Furthermore, we wanted to establish the relative contri-
bution of CYP1A1 in bioactivation of the model PAH compound 
benzo[a]pyrene (B[a]P) in human lung cells. 
Methods: Eleven lung adenocarcinoma cell lines, five of female and 
six of male origin, were exposed to B[a]P, cigarette smoke conden-
sate (CSC) or vehicle control. Subsequent expression analysis of 
genes in the PAH bioactivation pathway was conducted by Real-Time 
RT-PCR. DNA adducts were measured by 32P-postlabelling analysis. 
RNAi was used to down regulate estrogen receptor expression in lung 
cell lines and the effects on CYP1A1 and CYP1B1 gene expression 
were measured by Real-Time RT-PCR. Similarly, RNAi directed 
against CYP1A1 and CYP1B1 was used to elucidate their relative 
importance in the bioactivation of B[a]P. Formation of B[a]P-metab-
olites in cell culture media was measured by fluorescence-HPLC. 
Results: The results revealed significantly higher levels of both basal 
(P = 0.03) and induced expression of CYP1A1 by B[a]P (P = 0.017) 
or by CSC (P = 0.0043) in lung cell lines from women, compared to 
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cell lines from men. Analysis of DNA adducts also displayed close 
to significant sex differences in levels of B[a]P-DNA-adducts (P = 
0.052). Down regulation of the estrogen receptors affected both basal 
and B[a]P- or CSC-induced expression of CYP1A1 and CYP1B1. 
RNAi experiments with subsequent fluorescence-HPLC analysis 
revealed, however, that formation of the ultimate B[a]P-carcinogen 
primarily was dependent on the presence of CYP1A1.
Conclusions: The present in vitro findings confirm earlier in vivo ob-
servations regarding sex differences in CYP1A1 gene expression and 
formation of DNA adducts. Our results also indicate a major role of 
CYP1A1 in bioactivation of B[a]P to the ultimate carcinogenic form 
in human lung cells. Together, these data provide evidence towards a 
higher susceptibility to PAH in female lung. One possible underlying 
mechanism could be related to expression of estrogen receptors. This 
could be due to direct interaction between estrogen receptors and the 
AH receptor, or it could be the result of a shared pool of necessary 
transcriptional co-activators. 
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Association of TGFb1 polymorphisms involved in 
radiation toxicity with TGFb1 secretion in vitro
De Ruyck, Kim2; Beels, L2; van Meerbeeck, Jan P.1; Deneve, 
Wilfried2; Thierens, Hubert2
1 Ghent University Hospital, Gent, Belgium; 2 Ghent University, 
Gent, Belgium
Background: Radiation induced lung toxicity, in particular radiation 
pneumonitis and pulmonary fibrosis, is the most common complica-
tion in radiotherapy for lung cancer. The profibrotic cytokine TGFβ1 
plays a crucial role in the development of these sometimes fatal 
toxicities. Several research groups showed that the risk for radiation 
toxicity is modulated by a number of polymorphisms in the TGFβ1 
gene. These polymorphisms, in particular c.-509 and c.29 (Leu-
10Pro), are located in the promoter region or start sequence of the 
gene and are effective in TGFβ1 secretion. Most studies investigating 
the association between TGFβ1 genotype and TGFβ1 secretion, de-
termined the level of circulating TGFβ1 in blood serum which turned 
out to unreliable. Moreover, as these studies considered the influence 
of one polymorphism on TGFβ1 secretion, the observed effect can 
be influenced by other functional polymorphisms. The relationship 
between TGFβ1 genotypes and TGFβ1 secretion was unequivocally 
shown by a number of cloning studies which, however, used animal 
or tumor cells. Accordingly, the aim of this study was to investigate 
the association between the TGFβ1 genotype, considering a panel of 
polymorphisms, and in vitro TGFβ1 secretion in human non-tumor 
cells. Apart from four polymorphisms in TGFβ1 (c.-800, c.-509, c.29, 
c.74 (Arg25Pro)) which have an impact on TGFβ1 secretion, a de-
letion (c.69_77del9) in TGFβR1 which is involved in TGFβ1 signal 
transduction was also considered.
Methods: The study material consisted of 296 frozen lymphocyte 
samples of cancer free individuals. All samples were genotyped for 
the four polymorphisms in TGFβ1 and for the deletion in TGFβR1. 
Lymphocytes of individuals with the wild type (WT) genotype for 
the five polymorphisms served as reference genotype. Opposite 
the reference, the following combined genotypes were tested (1) 
c.-800 heterozygous and WT for the four other polymorphisms, (2) 
c.-509/c.29 heterozygous and WT for the three other polymorph-
isms, (3) c.-509/c.29 homozygous variant and WT for the three other 
polymorphisms, (4) c.69_77del9 heterozygous and WT for the four 
other polymorphisms and (5) c.69_77del9 homozygous variant and 
WT for the four other polymorphisms. Depending on the genotype, 
three to ten cultures were started and reproducibility was tested by 
setting up three subcultures for every individual. The lymphocytes 
were stimulated with PHA and IL-2. After one week the supernatant 
was collected and the TGFβ1 level was determined with ELISA.
Results: Lymphocyte cultures with a minimal cell growth of 25% 
and with a minimal cell viability of 60% were considered. Stimu-
lated lymphocytes with the WT, (1), (2), (3), (4) and (5) genotype 
produced, respectively, 1041 pg, 765 pg, 622 pg, 892 pg, 726 pg and 
2.844 pg per 106cells. Due to relatively high standard deviations 
none of these results were statistically significant. Percentages of 
CD4/CD8/CD56 did not influence TGFβ1 secretion.
Conclusions: This study could not clarify the effect of a number of 
genetic polymorphisms in TGFβ1/ TGFβR1 on secreted and circulat-
ing levels of TGFβ1 in vitro. It seems that differences in TGFβ1 
levels associated with genotypes causing enhanced radiotoxicity are 
too small to be measured via in vitro secretion.
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Expression of FAK and PTEN in bronchioloalveolar 
carcinoma (BAC) and lung adenocarcinoma
Wang, Changli; Zhang, Zhenfa
Cancer Institute and Hopital, Tianjin Medical University, Tianjin, 
China
Background: bronchioloalveolar carcinoma(BAC) is classified as a 
subset of lung adenocarcinoma but has a distinct clinical presentation, 
tumor biology, response to therapy, and prognosis compared with 
other subtypes of lung adenocarcinoma. The aim of this study was to 
investigate; (1) the clinicopathologic differences between BAC and 
adenocarcinoma; (2) expression of FAK and PTEN and their clinical 
significance in BAC and adenocarcinoma. 
Methods: A retrospective analysis was carried out on 77 patients 
with BAC and 172 patients with pure adenocarcinoma seen during 
the period from January 1998 to December 2000. All patients under-
went lobectomy or pneumonectoomy and systematic lymph node 
dissection. Paraffin-embedded tissue blocks from these patients were 
obtained and expressions of PTEN and FAK were evaluated using 
immunohistochemical staining. Clinicalpathologic characteristics and 
survival outcome were reviewed and compared between patients with 
BAC and adenocarcinoma. 
Results: Lymph node status, clinical symptoms, CT appearence and 
expression of FAK were different between BAC and adenocarcinoma 
.The overall survival of BAC was better than that of adenocarcin-
oma. In patients with FAK(-), the overall survival was not different 
between BAC and adenocarcinoma. In patients with adenocarcinoma, 
the overall survival was better for FAK(-) compared to FAK(+). Ex-
pression of PTEN had a prognostic significance in patients with BAC 
and adenocarcinoma.
Conclusions: BAC and adenocarcinoma have different clinicopatho-
logic presentations. Expression of FAK has some effect on such 
differences and affects survival of lung adenocarcinoma. Expression 
of PTEN can predict outcome of resected lung adenocarcinoma and 
BAC.
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primary cultures established with non-small cell lung 
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Background: Detection of lung cancer at early stage is critical for 
successful clinical therapy and increased survival rate. Having moved 
from one-gene-at-a time analyses to more synthetic approaches, 
genomic researchers are profiling thousands of gene transcripts to 
generate entire patterns of information. This study is to develop a pro-
file of proteins associated with non-small cell lung cancers (NSCLCs) 
and to search for the biomarkers in the circulating plasma. 
Method: Based on the novel method established in this laboratory 
previously, which could be used to detect cancer-related free proteins 
released into the blood, primary organ cultures were generated from 
the tumor tissues and matched adjacent normal bronchial epithelia de-
rived from 9 cases of NSCLC. The conditioned media were collected 
from the primary cultures, and subsequently analyzed by LC-MS/
MS (liquid chromatography-mass spectrometry/MS). Bioinform-
atic analysis with a label-free quantitative proteomic technique was 
adopted to explore the spectrum of proteins dysregulated in the lung 
cancer. The resulting proteins were then validated in human samples 
of peripheral plasma and tumor tissue. 
Results: In total, about 1,000 unique proteins were identified with 
high confidence. Quantitative protein differences between the pair 
samples were determined by comparing the spectral counts (label-
free). Gene Ontology term enrichment analysis revealed that the 
predominant functional classes of the proteins were related to the 
oxidoreductase activity, glycolysis and the subcellular location 
was mainly membrane-bound. According to the statistical analy-
sis together with the gene annotation information, alpha-enolase, 
ALCAM (activated leukocyte-cell adhesion molecule), clusterin, 
decorine, MMP1 (matrix metalloproteinase 1) were validated in 
human specimens. The elevated alpha-enolase expression, and 
repression of clusterin and decorine were confirmed by Western blot 
analysis in 87.5%, 66.7%, and 62.5% of the tumor tissues of NSCLC, 
respectively. Examining by ELISA, the plasma level of alpha-enolase 
was significantly higher in lung cancer patients than that in patients 
with nonmalignant diseases in lung and healthy individuals, while 
the ALCAM plasma level was significantly lower compared to the 
control subjects. Moreover, the result showed that the high levels of 
MMP-1 in both tumor tissue and peripheral plasma were correlated 
with lung cancer progression and poor prognosis. 
Conclusions: Label-free quantification method could be a feas-
ible and effective strategy to search potential protein biomarkers of 
cancer in the simplified conditional media system. The differentially 
expressed proteins reported in this study would make promise for a 
group of protein markers for non-small cell lung cancers. 
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Background: MET amplification is reported to occur in non-small-
cell lung cancer (NSCLC) with acquired resistance to gefitinib. To 
investigate MET gene status in lung cancer not treated with EGFR 
tyrosine kinase inhibitors (TKIs), we previously analyzed MET copy 
number in 28 NSCLC cell lines and 100 serial untreated primary 
lung tumors using real-time quantitative-PCR. In untreated primary 
tumors, we only found 2 tumors with MET amplification. However, 
one of them had MET copy number of 15.5, which was the highest 
among cell lines and primary tumors we analyzed. 
Methods: To investigate the features of the tumor with high-level 
MET amplification, we analyzed whole genomic status by array CGH 
and studied EGFR and KRAS mutational status using this tumor 
sample. Besides, we followed the clinical course of the patient having 
this tumor. 
Results: CGH revealed EGFR amplification in addition to MET 
amplification in this tumor. Any other genes which were well known 
to be frequently amplified or deleted in NSCLC were not altered. 
This tumor did not have any activating mutations or T790M muta-
tion in EGFR or mutations in KRAS. As for the clinical course, this 
tumor invaded the chest wall at the time of diagnosis and left upper 
lobectomy and systemic lymph node dissection combined with chest 
wall resection were performed (p-T3N0M0 stage IIB). The patient 
received adjuvant chemotherapy consisting of carboplatin and pa-
clitaxel after surgery. PET/CT scan revealed bilateral metastases of 
adrenal glands 7 months after surgery. 
Conclusions: The results of CGH suggested that the pivotal gene 
alterations of this tumor were in MET and EGFR. The clinical course 
of this patient suggested that the lung cancer with MET amplification 
was very aggressive, which is concordant with the recent report de-
scribing that lung cancer with MET amplification had poor prognosis. 
Considering the recent development of the new drugs targeting MET, 
evaluation of MET copy number in NSCLC may provide significant 
information as to novel therapeutic options.
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Analysis of copy number gain of VEGF and VEGFR2/
KDR in non-small cell carcinoma (NSCLC) cancer cell 
lines and primary tumors
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Background: The VEGF family plays an important role in lung 
cancer angiogenesis. The VEGF receptor 2 (VEGFR2) is the pre-
dominant mediator of VEGF-stimulated endothelial cell migration, 
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proliferation, survival and enhanced vascular permeability. Recently, 
VEGF copy number gain, and VEGFR2/KDFR copy number gain 
and mutation, have been described in lung adenocarcinoma tissue 
specimens. To better characterize the molecular changes of these two 
genes in NSCLC, we investigated their frequency of abnormalities in 
NSCLC cell lines and tumor tissue specimens. 
Methods: We studied DNA extracted from 37 NSCLC cell lines and 
101 tumor tissues obtained from surgically resected tumors, including 
61 adenocarcinomas and 40 squamous cell carcinomas. VEGF and 
VEGFR2/KDR copy number were examined by quantitative (q)-
PCR, and VEGFR2/KDR mutations of exons 11, 21, 26, 27 and 30, 
by PCR-based sequencing. 
Results: VEGF and VEGFR2/KDR copy number gains were 
detected at low frequencies in NSCLC cell lines and tumor tissue 
specimens. In cell lines, the frequency of copy number gains was 
1/37 (copy number=4.6) for VEGF, and 1/37 (copy number=5.0) for 
VEGFR2/KDR. In primary tumors, copy number gains were detected 
in 3/101 (3%; 1 adenocarcinoma, and 2 squamous cell carcinomas) 
for VEGF, and 5/101 (5%; 3 adenocarcinomas, and 2 squamous cell 
carcinomas) for VEGFR2/KDR. These copy number changes were 
not detected non-malignant lung tissues adjacent to the tumors in the 
8 lung cancers with copy number increase. VEGFR2 protein expres-
sion was detected by immunohistochemistry in all 5 lung tumors with 
VEGFR2/KDR copy number changes. In the VEGFR2/KDR muta-
tion analysis, one single nucleotide polymorphism (SNP1416A/T) in 
exon 11 was frequently detected in NSCLC cell line and tumor tissue 
specimens. In tumors, the genotype frequency of the SNP1416A/T 
was as follows: AA=61(60%), AT=37(37%), and TT=3 (3%), with 
a trend toward higher frequency of AT genotype in squamous cell car-
cinomas (18; 45%) than adenocarcinomas (19; 31%). 
Conclusion: Our findings indicate that copy number gain of VEGF 
and VEGFR2/KDR are identified at low frequencies in NSCLC, af-
fecting to both major histology types, adenocarcinoma and squamous 
cell carcinoma. A better characterization of the clinicopathologic 
features of the tumors having such genetic abnormalities will help to 
identify their role in lung cancer pathogenesis and progression, and 
eventually in the response to VEGFR targeted therapy. Supported by 
grant US DoD W81XWH-07-1-0306. 
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Autophagy is known for its role in cellular homeostasis, develop-
ment, cell survival, aging, immunity, and cancer. Autophagy has 
emerged as another major`programmed’ mechanism to control life 
and death much like “programmed cell death” is for apoptosis in 
several types of cancer. To be elusive that autophgic cell death on 
nutrient starvation in combination with cytotoxic drugs, we investi-
gated whether its increase synergistically in two mixed conditions. 
When cancer cells were subjected to extreme nutrient starvation 
by culturing in a medium without serum and amino acids or with 
2-deoxyl-D-glucose, a chemical inhibitor of glucose metabolism, 
cells death occurred within early time. At nutrient deprived media 
with cisplatin or gemcitabine treatment, Cell survival revealed a 
markedly decrease in percentage of living cells undergoing nutrient 
starved medium with each of two cytotoxic drugs compared with 
those drugs respectively. The staining of cells in normal media with 
acridine orange displayed green fluorescence with cytoplasmic and 
nuclear components in normal media but showed considerable red 
fluorescence in combined medium or cytotoxic drugs in each treated 
cells, suggesting formation of numerous acidic autophagolysosomal 
vacuoles. LC3 modification, as autophagy marker, was analyzed by 
western blotting. LC3 proteins have two forms: type I is cytosolic 
and type II is membrane-bound. During autophagy is advanced, LC3 
type II increased by conversion from LC3 type I. We figured out that 
the autophagosome-incorporated LC3 II protein expression more 
increased in cell contained nutrient-deprived medium with cytotoxic 
drugs compare with cisplatin or gemcitabine alone. These results 
demonstrated that the autophagic cell death potentially increased in 
nutrient-deprived conditions combined with cytotoxic drugs in hu-
man lung cancer cell lines.
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Bcl-2 family proteins contribute to multicellular resistance 
in lung cancer
Yang, Tsung-Ming1, 2, 4; Barbone, Dario2, 4; Fennell, Dean A.3; 
Broaddus, Courtney 2, 4
1 Chia-yi Chang Gung Memoral Hospital, Taiwan, Chiayi County, 
Taiwan; 2 Lung Biology Center, University of California San 
Francisco, San Francisco, CA, USA; 3 Queen’s University Belfast, 
Centre for Cancer Research and Cell Biology & Northern Ireland 
Cancer Centre, Belfast, UK; 4 Comprehensive Cancer Center, 
University of California San Francisco, San Francisco, CA, USA
Background: The proteasome inhibitor bortezomib has been shown 
to induce apoptosis in non-small cell lung cancer (NSCLC) cell lines 
grown as monolayers, either by itself or when combined with other 
agents. However, the response to bortezomib in NSCLC clinical trials 
has been disappointing. One possible explanation for this discrepancy 
is that the 2D monolayer culture model used in preclinical studies 
may not represent the apoptotic resistance of the actual tumor in 
patients. Previous studies showed that 3D spheroid culture may be 
a better model than traditional 2D monolayer culture for the study 
of drug resistance in solid tumors. In this study, we have confirmed 
the effectiveness of bortezomib plus TNF-related apoptosis inducing 
ligand (TRAIL) to induce apoptosis in NSCLC cell lines that are 
grown as monolayers, and have shown that a high level resistance 
is acquired when the cells formed 3D spheroids. The cause of this 
acquired resistance was then investigated. 
Methods: Multicellular spheroids were generated by culturing cells 
in non-adherent round bottomed 96-well plates. The monolayers and 
spheroids were treated with bortezomib plus TRAIL for 24 h, and 
the apoptotic rate was measured by Hoechst 33342 nuclear staining. 
The proteasome activity of monolayer and spheroids was measured 
before and after bortezomib treatment. NFκB activity in monolayers 
and spheroids was measured in an A549 stable reporter line in which 
the cells express the luciferase gene under a NFκB promoter, using 
a commercial luciferase assay kit. The location of apoptotic cells in 
spheroids were detected by staining cleaved caspase 3 in spheroids 
after bortezomib plus TRAIL treatment. The expression level of anti-
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apoptotic and pro-apoptotic proteins were evaluated by immunoblot-
ting. Chemical inhibitors and siRNA were used to evaluate whether 
cell survival pathways or anti-apoptotic Bcl-2 family proteins con-
tribute to multicellular resistance of lung cancer spheroids. 
Results: Both A549 and H1299 cells acquired apoptotic resistance to 
bortezomib plus TRAIL after the cells formed multicellular spher-
oids. This acquired resistance of spheroids was not due to limited 
diffusion of reagents into spheroids, or to activation of survival 
pathways such as NFκB or PI3K/Akt/mTOR. When cells formed 
spheroids, the balance of Bcl-2 family proteins was altered, with an 
increased expression of anti-apoptotic Bcl-2 and a decreased expres-
sion of anti-apoptotic Mcl-1. In A549 spheroids, a small molecule 
that inhibits Bcl-2 but not Mcl-1 (ABT-737) abolished the multi-
cellular resistance to bortezomib plus TRAIL. In H1299 spheroids, 
which had a higher expression of Mcl-1, ABT-737 did not block the 
multicellular resistance until Mcl-1 was knocked down.
Conclusions: Our study shows that an altered balance of Bcl-2 
family proteins contributes to the acquired multicellular resistance 
of lung cancer spheroids and suggests a possible target to bypass 
multicellular resistance.
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A549 lung cancer cells overexpressing microRNA 210 but 
not 30a or 191 are more proliferative and tumorigenic
Patnaik, Santosh K.; Kannisto, Eric; Yendamuri, Sai
Roswell Park Cancer Institute, Buffalo, NY, USA
Background: Previous studies of microRNA (miR) expression in hu-
man lung cancer have identified miRs 30a, and 191 and 210 as being 
among the miRs whose levels are the most down- or up-regulated, 
respectively, in the disease. Similar observations on the levels of 
these miRs have also been noted in cancers of other organs such as 
the colon and prostate. This study focused on the functional effects 
of overexpressing these miRs in cell-lines derived from human lung 
cancer (A549) or normal bronchial epithelium (BEAS-2B) .
Methods: Human pre-miR sequences for miRs 30a, 191 or 210 were 
inserted into the 3’UTR of a CMV promoter-driven gene encoding 
a red fluorescent protein (RFP). Lentiviruses carrying the RFP gene 
and a gene conferring puromycin resistance were used to generate 
stable populations of A549 and BEAS-2B cell-lines expressing the 
various recombinant genes. Control cell-lines did not have a pre-miR 
sequence in the 3’UTR of the RFP gene. Levels of mature miRs in 
the various cell-lines were assessed by semi-quantitative RT-PCR-
based TaqMan assays. Cell proliferation, cell cycle kinetics, colony 
formation, and tumorigenicity of the cells were studied.
Results: A549 and BEAS-2B cell-lines overexpressing one or none 
of human miRs 30a, 191 or 210 were generated. TaqMan assays for 
mature miRs showed that compared to controls, the various cell-lines 
overexpressed mature miRs 30a-5p, 191 and 210 to various degrees: 
approximately 2-, 4-, and 30-fold, respectively, in case of the A549 
cell-lines, and 2-, 12- and 30-fold, respectively, in case of the BEAS-
2B cell-lines. However, no differences in cell proliferation, cell cycle 
kinetics, or colony formation were observed among the various test 
and control BEAS-2B lines. Furthermore, none of the BEAS-2B 
cell-lines was successful in generating tumors in SCID mice injected 
subcutaneously with 0.75 million cells and observed for nine weeks. 
Similar assays using the A549 cell-lines showed that cells over-
expressing miRs 30a or 191 behaved alike, and like the control cells, 
formed tumors of similar size in SCID mice. However, A549 cells 
overexpressing miR 210 proliferated faster, formed larger colonies 
on plates, and generated larger tumors in SCID mice. Cell cycle 
analysis showed that these cells had a higher proportion of cells in the 
S phase. A549 cells overexpressing miR 210 also had morphological 
alterations suggestive of epithelial to mesenchymal cell transition 
(EMT).
Conclusions: Overexpression of human miR 210 but not 30a or 
191 in the A549 human lung cancer cells increased cell proliferation 
and tumorigenicity, and produced morphological changes indicating 
EMT. However, overexpression of none of the three miRs had any ef-
fect on the BEAS-2B normal human lung epithelial cells. Functional 
effects of miR level alterations in a cell are clearly affected by other 
factors such as the state of the rest of its transcriptome.
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Molecular discrimination of primary versus recurrent 
pulmonary adenocarcinomas of metachronous lung cancer
Yoshida, Tsutomu1; Nakazato, Yoshimasa2; Tanaka, Ryota1; 
Yoshizumi, Masakazu3; Seki, Erina1; Iijima, Misa2; Kojima, Masaru2; 
Goya, Tomoyuki4
1 Division of Thoracic Surgery, Gunma Prefectural Cancer Center, 
Gunma, Japan; 2 Division of Diagnostic Pathology, Gunma 
Prefectural Cancer Center, Gunma, Japan; 3 Gunma Prefectural 
Institute of Public Health and Environmental Sciences, Gunma, 
Japan; 4 Department of Surgery, School of Medicine, Kyorin 
University, Tokyo, Japan
Background: The differential diagnosis of metachronous multiple 
pulmonary adenocarcinomas can often be difficult, especially if 
the lesions show similar pathologic types. However, the prognostic 
significance between second primary lung cancer and recurrence 
cannot be ignored due to its impact on the tumor stage. It has been 
reported that the analysis of various genomic mutation can be used to 
discriminate a primary tumor from metastasis or recurrence in vari-
ous cancers. To discriminate between second primary lung cancer and 
recurrence, we performed molecular discrimination.
Methods: We examined 179 cases of resected primary pulmon-
ary carcinoma during the period from January 2005 to December 
2008 at the Gunma Prefectural Cancer Center, Japan. Three of these 
patients (1.7%) had metachronous multiple lung tumors. One of these 
3 patients was analyzed for gene mutations. Genomic DNAs were 
extracted from a formalin-fixed block of the tumor and non-tumor 
samples. Exon 5, 6, 7 and 8 of the p53 gene, exon 18, 19, 20 and 21 
of the EGFR gene, and the K-ras gene were analyzed using direct 
sequencing.
Results: Two cases of metachronous multiple lung tumors could 
be diagnosed pathologically and immunohistochemically; however, 
one case could not be discriminated between second primary lung 
cancer and recurrence. Thus, we tried gene mutation analysis for this 
case of a 70-year-old Japanese female who underwent a right upper 
lung lobectomy for right lung cancer (pT2N0M0, stage IB), with the 
lesion showing papillary adenocarcinoma pathologically. Nine years 
after the previous surgery, the patient had a medical examination with 
a complaint of chest pain. Chest computed tomography revealed a 
solid-density tumor with an irregular margin in the right lower lobe 
(S6). No other critical disease or metastatic lesion was proven by 
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other clinical studies including positron emission tomography. The 
patient underwent residual right pneumonectomy for the metachron-
ous lung lesion, and the lesion showed acinar and papillary adeno-
carcinoma. A mutation of the p53 gene was detected in exon 8 (codon 
320, TGC-AGC) of the current tumor; however, a mutation of the p53 
gene was not detected in the previous tumor. EGFR and K-ras gene 
mutations were not detected in any of the tumor samples. Therefore, 
we considered the current tumor to be second primary lung cancer 
(pT2N0M0 stage IB). The other two cases will be confirmed by diag-
nosis with this method.
Conclusions: For the diagnoses of metachronous multiple lung can-
cers, mutation analysis of p53, EGFR and K-ras genes can be used to 
discriminate between second primary and recurrent carcinomas of the 
lung. In this particular case, a 9-year-old formalin-fixed tumor sample 
could be analyzed with this method. 
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Discovery and development of small-molecule dishevelled 
antagonists that down-regulates Wnt canonical pathway
You, Liang1; Xu, Zhidong1; Hung, Ming-Szu1; Punchihewa, 
Chandanamali2; Fujii, Naoaki2; Jablons, David M.1
1 UCSF, San Francisco, CA, USA; 2 St. Jude Chireden’s Reseach 
Hospital, Memphis, TN, USA
Background: Activation of Wnt signaling seems to play an important 
role in carcinogenesis. Overexpression of downstream components 
of the Wnt receptor complex can act synergistically with upstream 
Wnt autocrine up-regulation in tumorigenesis. Dishevelled, PDZ 
domain-containing mediators of Wnt signaling, have been reported 
to be up-regulated in tumors with β-catenin activation. Overexpres-
sion of Dvl is a dominant event in malignant pleural mesothelioma 
and non–small cell lung cancer. The Fz family of human proteins 
comprises Wnt receptors that maintain a conserved KTXXXW motif 
in the cytoplasmic domains that is essential in mediating Wnt signals. 
This motif of Fz7 has been shown to interact directly with the PDZ 
domain of Dvl. To date, Dvl is the only direct downstream signaling 
partner of Fz that has been identified. 
We have made progress in the discovery and development of nonpep-
tide small-molecule antagonists of PDZ domain interactions that per-
meate cells and exert effects attributable to their targeted biochemical 
antagonism. As proof of principle, we developed a small-molecule 
compound (FJ9) that inhibits intracellular interactions of the Dvl 
PDZ domain, down-regulates T-cell factor-mediated transcription, 
and suppresses tumor growth in a mouse xenograft model. These 
findings suggest that a nonpeptide antagonist of the Dvl PDZ domain 
can provide novel antitumor therapy by reducing Tcf transcriptional 
activity. Here, we report an evaluation of chemical library to ration-
ally generate small-molecule agents that suppress tumor cell growth 
by down-regulating canonical Wnt signaling. 
Methods: All commercial chemicals were purchased from Aldrich 
or Fisher Scientific. Human cell lines (HEK293T, MDA-MB231, 
HepG2, BJ, and NCI-H460) were obtained from the American 
Type Culture Collection. The chemical library was synthesized at 
UCSF. The potency with which each compound inhibited interaction 
between the Dvl PDZ domain and the Fz7 PDZ-binding region was 
measured by using the AlphaScreen Glutathione S-Transferase Detec-
tion kit (Perkin-Elmer). Annexin V-FITC (Apoptosis Detection kit, 
Oncogene) was used for apoptosis analysis.
Results: We have identified several compounds that both biochem-
ically antagonized Dvl PDZ domain and actively down-regulated 
Tcf-mediated transcription. Our results suggest that the down-regu-
lation of Tcf-mediated transcription by these compounds is specific. 
These compounds also showed cancer cell–selective apoptotic effect. 
We tested the in vivo efficacy of two compounds that most potently 
induced apoptosis of the NSCLC cell line NCI-H460. NCI-H460 
cells were transplanted into nude mice and allowed to grow for 7 
days. Compounds were then administered daily for 14 days. The mice 
showed no significant weight loss. One compound exerted a statistic-
ally significant growth-suppressive effect (P = 0.002) that was greater 
than the effect of the original compound FJ9 (P = 0.02).
Conclusions: The compounds that have parallel effects in the bio-
chemical and Tcf reporter assays also showed cancer cell–selective 
apoptotic effect. A new compound that met the criteria for high 
biochemical antagonism, Tcf–mediated transcription, and induction 
of tumor-selective apoptosis was found to significantly suppress the 
growth of NCI-H460 xenografts. 
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Studies on anti-proliferation and inducing apoptosis effects 
of curcumin on cisplatin resistance A549/DDP human lung 
adenocarcinoma cells
Zhang, Jian; Wu, Changgui; Li, Zhikui; Shi, Jieran
Xijing Hospital of Fourth Military Medical University, Xi’an, China
Objective: To investigate the inhibitory effect of curcumin on the 
human lung adenocarcinoma cell line A549/DDP and its effect on 
apoptosis. 
Methods: The inhibitory effects of cisplatin and curcumin on cell 
proliferation were tested by MTT assay. The morphologic changes of 
tumor tissue were observed under inverted phase contrast microscope 
and fluorescence microscope. The apoptosis of A549/DDP induced by 
curcumin were measured by TUNEL and flow cytometry. Western-
blot was used to determine modification of certain protein related to 
apoptosis. 
Results: The A549/DDP cells resisted the cytotoxic effect of cisplatin 
and the resistance index was 10.82. The inhibition of curcumin on 
A549 cells and A549/DDP cells was shown in the dose-dependent 
and ime-dependent manner(P<0.05) following 48h treatment with 
curcumin. IC50 value of curcumin to A549 cells was approximated 
that of A549/DDP cells. Under fluorescence microscope, cells treated 
with curcumin showed shrunk or distorted nucleus with fluorescence 
conglomerated like grain in them. The apoptosis indexes of A549/
DDP cells induced by curcumin were significantly different from the 
control. And the level of caspase8 p10 protein of A549/DDP cells 
induced by curcumin increased as the concentration of curcumin 
increased. 
Conclusions: A549/DDP is sensitive to curcumin. Curcumin can 
inhibit A549/DDP cells from proliferating and induce cell apoptosis. 
The activation of caspase-8 is one of the mechanisms.
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Preclinical and clinical estimates of a cancer’s basal 
apoptotic rate (BAR) predict for TRAIL-sensitivity in 
non-small cell lung cancer (NSCLC) cell lines and tumor 
radiation-sensitivity in patients undergoing stereotactic 
body radiation therapy (SBRT)
Zhang, Lian; Li, Yalin; Kavanagh, Brain D.; Thorburn, Andrew; 
Camidge, D. Ross
University of Colorado Cancer Center, Aurora, CO, USA
Background: Apoptosis is the major route of cell death in malig-
nant cells induced by traditional chemo- and radiotherapy. Most 
biomarkers for predicting response focus on factors influencing 
the amount of caspase induction resulting from specific insults. We 
hypothesize that a cancer cell’s BAR, which reflects it’s overall prox-
imity to the apoptotic threshold, may independently predict outcome 
given the same level of extrinsic or intrinsic apoptotic pathway-relat-
ed caspase induction. Most in vitro apoptosis assays reflect a snapshot 
and may underestimate the BAR. In addition, biopsy-based clinical 
methods are subject to sampling error and impractical for repeated 
assessment. We have developed practical preclinical and clinical 
methods for assessing the BAR using specific normalizations of the 
M30 Apoptosense ELISA, which detects soluble caspase cleaved 
cytokeratin 18 in culture media and serum. The validation and poten-
tial predictive significance of our novel BAR assay in NSCLC cell 
lines and in patients undergoing SBRT is reported. 
Methods: In vitro BAR assay: The same starting number of HCC44, 
A549 or SW173 NSCLC cells were seeded and grown in the presence 
of 10%, 2%, or 0.5% FBS without changing media until confluence. 
Replicate plates were sacrificed daily to assess cumulative cell death 
in the media using M30 ELISAs, and the corresponding cell number 
was counted. The M30 values of time points at approximately equiva-
lent viable cell numbers were compared, normalized to exact cell 
number. 
Predictive significance in vitro: Stable shRNA XIAP knockdowns in 
NSCLC cell lines A549 (adenocarcinoma) and SW1573 (squamous 
carcinoma) were generated. Dose responses to TRAIL or lexatu-
mumab were determined by MTS assay. Baseline and on treatment 
cumulative M30 BAR estimates were compared to caspase 3/7 
activity in the cells/media and TUNEL assays performed on the fixed 
plates.
Predictive significance in patients: Serum samples of cancer patients 
(n=14) undergoing 1-5 fractions of SBRT to all known sites of 
disease were collected for M30 assay before SBRT and on the last 
day of treatment. Baseline tumor volumes were calculated from the 
planning CT scans. 
Results and Conclusions: HCC44, A549 and SW173 cells produced 
highly comparable results. Serum deprivation and XIAP knockdown 
each resulted in an increased BAR assessed by the cumulative M30 
assay, consistent with the idea that reduced growth factor or reduced 
anti-apoptotic stimuli push cells closer to the apoptotic threshold. The 
BAR rank ordering of WT and different XIAP knockdown cell lines 
using the cumulative M30 assay recapitulated TUNEL and caspase 
3/7-based rankings but with a greater dynamic range. Cumulative 
M30 BAR ranking paralleled the TRAIL or lexatumumab sensitiv-
ity of the different cell lines. SBRT significantly increased mean 
serum M30 values (P=0.006) consistent with apoptosis induction on 
treatment. Baseline M30 normalized to tumor volume (‘clinically 
determined BAR’) strongly correlated with the proportional change 
in individual patients’ M30 from SBRT (correlation coefficient=0.89). 
In summary, utilizing appropriate normalizations of the M30 ELISA, 
the BAR of cancers can be assessed both in vitro and in patients, 
and may be an independent variable predictive of extrinsic (TRAIL-
receptor agonist) and intrinsic (radiation) apoptotic pathway-related 
treatment sensitivity. 
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Relationship between genetic susceptibility of non-small 
cell lung cancer and TGF-βRI gene*
Zheng, Shi Ying; Zhao, Jun; Jiang, Dong
The First Affiliated Hospital of Suzhou University, Suzhou, China
Background: Transforming growth factor-beta receptor type I(TGF-
βRI) gene is a tumor-suppressing gene. The loss of its biological 
activity due to the mutation of this gene has been found in a variety 
of human tumors. It has been shown that, during the occurrence 
of cancers in human, the cells show the insensitivity to the growth 
inhibition mediated by the TGF-β signal transduction. Despite that 
numerous evidences demonstrated the TGF-βRI acted as a tumor-
suppressing gene, the relation between the TGF-βRI and the non-
small cell lung cancer (NSCLC) is yet understood poorly. In present 
study, the TGF-βRI gene mutation and its relation to the occurrence 
of non-small cell cancer was investigated. 
Methods: The non-small cell tumor tissues and the corresponding 
cancerous tissues were sample from a total of 53 patients (including 
44 males and 9 females) who had just received the lung resection 
operation (the patient group). The tissues were frozen immediately 
after the surgery, and then stored in the liquid nitrogen. These patients 
had not received the radiation therapy or the chemotherapy before 
the surgery. Beside the tumor samples, the blood samples from 89 
of adults without the patient history of cancer were included as the 
negative controls (the control group). Those in control group came 
from the same geographic region, and their age range was similar 
to that of the above cancer patients. The questionnaire showed that 
58% and 70% of the subjects in the patient and control groups were 
non-smokers, respectively. The entire coding region of TGF-βRI and 
flanking intron sequences from 53 NSCLC tissues were examined for 
alterations using Single strand conformation polymorphism (SSCP) 
and direct sequencing. 
Results: Two experimental evidences were obtamed in the present 
genetic study. Firstly, The PCR-SSCP assay showed that the genomic 
DNA-based RFLP profile of the NSCLC patients had the two varia-
tions compared to the control group: one was at the No. 6 exon, while 
another at the No. 7 exon. The above genomic DNA samples were 
then sequenced, and it was found that the 344th codon changed from 
AAT into AAC, while the 406th from TTA into CTA. Secondly, we 
also found that a SNP polymorphic site (G/A) located at the 24th bp 
in the No.7 intron. Accordingly, the 53 patients in the patient group 
could be assigned into three genotypes: A/A, G/G and G/A; among 
them were 18 cases (34%) of the G/G genotype, 24 (45%) of G/A, 
and 11(21%) of A/A To clarify the relation between this polymorph-
ism and the incidence of NSCLC, the PCR-SSCP-based genotyp-
ing assay was performed on the blood samples of the 89 patients in 
the control group. Accordingly, the G/G, G/A and A/A genotypes 
accounted for 34.8% 58.4% and 6.7% of the patients, respectively. 
According to the case-control analysis, we found that the risk rate of 
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falling ill of the A/A genotype of patients was three times higher than 
that of the G/G genotype of ones (OR = 3.16 95%, and CI =1.00 to 
9.99). 
Conclusions: As the first report, this study showed that TGF-βRI 
gene is not a frequent site of spontaneous mutational inactivation 
while the detected polymorphism could be a susceptibility allele that 
predisposes to carcinogenesis of NSCLC.
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Methylated mechanism underlying downregulation of 
E-cadherin gene and its linical meaning
Zheng, Shi Ying; Jiang, Dong; Ge, Jin Feng
The First Affiliated Hospital of Suzhou University, Suzhou, China
Background: To investigate the promoter methylation status of E-
cadherin gene in non-samll cell lung cancer and its correlation with 
clinicopathological parameters, and explore the relationship between 
downregulation of E-cadherin expression and methylation status of 
its promoter region. 
Methods: The nested methylation specific PCR (MSP) was per-
formed to examine CpG methylation within the 5’ CpG island of 
E-cadherin in 37 tumor and paired normal tissue specimens from 
patients with primary NSCLC. Then, real-time quantitative PCR 
analysis was applied to measured the level of E-cadherin mRNA 
(excluding 2 samples with unavailable mRNA). 
Results: Of thirty-seven cases, 12 (32.4%) samples showed aberrant 
CpG methylation in tumor tissues compared with the corresponding 
normal tissues. In addition, reduction of E-cadherin mRNA level was 
observed in 11 of 12 (91.7%) tumor tissues carrying methylation. 
However, only 10 (43.5%) cases displayed reduced mRNA levels in 
the rest of tumor tissues from other 23 cases (excluding 2 samples 
with unavailable mRNA) without methylation event. Downregula-
tion of E-cadherin expression was found to correlate significantly to 
promoter methylation of this gene.
Conclusions: These results provide strong evidence for supporting 
the idea that the methylation status of E-cadherin gene contribute 
clearly to the reduced expression of E-cadherin mRNA and may play 
a role in the development and progression of NSCLC. 
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Formation of immune escape in lung cancer was induced 
by expression of Fas Ligand and Caspase-3
Zheng, Shi Ying; Jiang, Dong; Ge, Jin f.; Li, Hong
The First Affiliated Hospital of Suzhou University, Suzhou, China
Background: To study the role of Fas ligand (FasL) and Caspase-3 
expression in carcinogenesis and progression of Lung cancer and 
molecular mechanisms of relevant immune escape.
Methods: FasL and Caspase-3 expression was studied in adjacent 
epithelial cells, cancer cells and lymphocytes of primary foci, and 
cancer cells of metastatic foci from 113 cases of Lung cancer by 
streptavidin-biotin-peroxidase (S-P) immunohistochemistry. Expres-
sion of both proteins in cancer cells of primary foci was compared 
with clinicopathological features of Lung cancer. The relationship 
between FasL expression in cancer cells and Caspase-3 expression in 
cancer cells or infiltrating lymphocytes of primary foci was investi-
gated.
Results: Cancer cells of primary foci expressed FasL in 53.98 % 
(61/113) of Lung cancers, more than their adjacent epithelial cells 
(34.51 %, 39/113) (P=0.003, χ2=8.681), while the expression of 
Caspase-3 in cancer cells of primary foci was detected in 32.74 % 
(37/113) of Lung cancers, less than in the adjacent epithelial cells 
(50.44 %, 57/113) (P=0.007, χ2=7.286). Infiltrating lympho- cytes of 
the primary foci showed positive immuno- reactivity to Caspase-3 
in 70.80 % (80/113) of Lung cancers, more than their correspond-
ing adjacent epithelial cells (P=0.001, χ2=10.635) or cancer cells of 
primary foci (P=0.000, χ2=32.767). FasL was less expressed in cancer 
cells of metastases (51.16 %, 22/43) than in those of the correspond-
ing primary foci (81.58 %, 31/38) (P=0.003, χ2=9.907). Conversely, 
Caspase-3 was more expressed in cancer cells of metastases (58.14 
%, 25/43) than in those of the corresponding primary foci (34.21 %, 
13/38) (P=0.031, χ2=4.638). FasL expression was significantly correl-
ated with tumor size (P=0.035, rs=0.276), invasive depth (P=0.039, 
rs=0.195), metastasis (P=0.039, rs=0.195), differentiation (P=0.015, 
rs=0.228) and Lauren’s classification (P=0.038, rs=0.196), but not 
with age or gender of patients, growth pattern or TNM staging of 
Lung cancer (P>0.05). In contrast, Caspase-3 expression showed 
no correlation with any clinicopathological parameters described 
above in cancer cells of the primary foci (P>0.05). Interestingly, 
FasL expression in primary Lung cancer cells paralleled to Caspase-3 
expression in infiltrating lymphocytes of the primary foci (P=0.016, 
χ2=5.825).
Conclusions: Up-regulated expression of FasL and downregulated 
expression of Caspase-3 in cancer cells of primary foci play an 
important role in Lung carcinogenesis. As an effective marker to 
reveal the biological behaviors, FasL is implicated in differentiation, 
growth, invasion and metastasis of Lung cancer by inducing apopto-
sis of infiltrating lymphocytes. Chemical substances derived from the 
primaryfoci and metastatic microenvironment can inhibit the growth 
of metastatic cells by enhancing Caspase-3 expression and diminish-
ing FasL expression.
P1.104 Basic Science and Translational Research, Sat Aug 1 
The experimental study of lung carcinoma vaccine 
modified by human B7-1 and IFN-γ genes
Zheng, Shi Ying; Jiang, Dong; Ge, Jin Feng; Li, Hong
The First Affiliated Hospital of Suzhou University, Suzhou, China
Background: CD80 (B7-1) and Interferon-gamma (IFN-γ) play 
important roles in antitumor immunity induced by T lymphocyte. To 
study the antitumor immune effects of lung carcinoma vaccine modi-
fied with human B7-1 and IFN-γ genes, we examined the character-
istics of a clonally derived A-549 cell line modified with B7-1 and 
IFN-γ genes, and detected decreased tumorigenicity following their 
implantation intrader- mally into human immune reconstituted SCID 
mice (hu-PBL-SCID).
Methods: Recombinant retrovirus vectors pLXSN/B7-1,pLXSN/
IFN-g, and pLXSN/B7-1+ IFN-γ were constructed. In vitro, the pri-
mary lung carcinoma cells A-549 were transduced with the retroviral 
vector and prepared as a vaccine. Clonal derivates of A-549 cells 
were isolated by G418 selection, expanded to cell lines, and named as 
A-549/pLXSN, A-549/B7-1, A-549/IFN-γ, and A-549/B7-1+ IFN-γ. 
The phenotype changes of transduced A-549 cells were detected 
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by the following Methods: immunoflow cytometry; reverse tran-
scription-polymerase chain reaction (RT-PCR) and dot blot for the 
expression and coexpression of B7-1 and IFN-γ gene; flow cytometry 
for the individual phases of cell cycles; and cell counts for growth 
curves.Then autologous lymphocytes were irritated with the lung 
carcinoma cells for competition inhibitory cytotoxic testing. 
Results: A-549 cells were transduced with four kinds of vectors. 
expanded to cells and named as A-549/pLXSN, A-549/B7-1, A-549/ 
IFN-γ, and A-549/B7-1+ IFN-γ.The results of immunoflow cytom-
etry showed that the expression rate of the CD80 molecule in A-549/ 
B7-1 was 94% and that of IFN-γ in A-549/ IFN-γ was 32%, while 
the coexpression rate of the CD80 and IFN-γ molecules in A-549/
B7-1 + IFN-γ was 32.2%. There was no expression of the CD80 
and/or IFN-γ molecule in A-549/pLXSN and parental A-549. Three 
to five days after transduction with B7-1 and IFN-γ, the expression 
rate of the CD80 molecule in the primary lung carcinoma vaccines 
was 30%, and that of the IFN-γ molecule was 10–15%. Competition 
inhibitory testing by the MTT method was used to detect the presence 
of autologous lymphocytemediated specific immunity toward primary 
lung carcinoma cells. The results showed that the cytotoxic activities 
induced by B7-1–and IFN-γ– modified vaccines were much higher 
than those induced by single gene–modified vaccines, which were 
also significantly higher than those induced by vaccines transduced 
with the control pLXSN vector. Our findings indicated that lung car-
cinoma vaccines modified with B7-1 and IFN-γ were able to induce a 
stronger specific antitumor immune response in vitro. mice with un-
modified or single gene–modified A-549 cells developed discernible 
tumors at the second week after inoculation. However, those injected 
with A-549/B7-1 + IFN-γ developed discernible tumors at the third 
week. After 5 weeks, the mice were all killed. Tumors. Spleens were 
taken from SCID mice that had been inoculated intraperitoneally with 
human leukocytes. Immunoflow cytometry results indicated that the 
number of human CD3+ lymphocytes in mice spleen cell suspen-
sions ranged from 10% to 60%. By direct ELISA, the concentration 
of human IgG in the reconstituted mice sera ranged from 1.5 mg/ml 
to 5 mg/ml. 
Conclusions: the B7-1– and IFN-γ–modified vaccine was able to 
enhance the systemic immune response, resulting in reduced tumor 
growth, which demonstrated that the coexpression of B7-1 and IFN-γ 
was sufficient to promote an antitumor immune response.
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Apoptosis-inducing effect of Caspase-3 over-expressed on 
lung cancer cell line A-549
Zheng, Shi Ying; Jiang, Dong; Ge, Jin Feng
The First Affiliated Hospital of Suzhou University, Suzhou, China
Background: Lung carcinoma is one of the most common causes 
of malignancy-related death in China.Apoptosis is closely related 
to tumor. Although there are many factors involved in apoptotic 
program, Caspases are shown to play a major role in the transduction 
of the apoptotic signal and the execution of apoptosis in mammal-
ian.In this study, the eukaryotic expression vector of recombinant 
Caspases-3 was constructed and the apoptosis-inducing effect of its 
expression on A-549 cell line was observed.
Methods: To investigate the apoptosis-inducing effect of Caspases-3 
expressed by constructed eukaryotic vector on lung cancer cell line 
A-549.Plasmid pcDNA/ Caspases-3 contains all the cDNA sequences 
of Caspases-3 gene. It was used as template to amplify the sequences 
of small and large subunits of Caspases-3 by PCR.Its products were 
separately cloned into the Sma I site of pBluescript KS+ togenerate 
both plasmids pBS/SS and pBS/LS. The small subunit fragment was 
excised from plasmid pBS/SS with BamH I and then inserted into the 
BamH I site of plasmid pBS/LS preceding that of the large subunit 
to yield plasmid pBS/Rev-Caspase-3. Rev-Caspase-3 cDNA was ex-
cised with Kpn I+Xba I and then subcloned into plasmid pcDNA3.1 
(+) to construct Rev-Caspase-3 eukaryotic expression vector pcDNA/
Rev- Caspase-3, which was used to transiently transfect A-549 cell 
line. Cell count, MTT assay and electron microscopy were used 
to confirm the antiproliferation and apoptosis-inducing effect of 
Rev-Caspase-3 expression on lung cancer cells.Plasmid pBS/Rev- 
Caspase-3 and eukaryotic expression vector pcDNA/Rev-Caspase-3 
were successfully constructed. A-549 cells were transiently trans-
fected by either pcDNA/Rev- Caspase-3 or pcDNA3.1 (+) for 24, 48, 
72, and 96 h respectively. Cell growth was measured by cell count 
and MTT assay. 
Results: In cell count assay, the cell numbers were 1.8×106, 
1.55×106, 2.0×106, and 3.1×106 in the experimental group and 
2.5×106, 3.1×106, 4.0×106, and 5.7×106 in the control group at 24, 
48, 72 and 96 h respectively. The growth of A-549 cells was sup-
pressed by Rev-Caspase-3 in a time-dependent manner (P<0.05). The 
results of MTT assay were similar to that of cell count (P<0.05). The 
characteristics of apoptosis such as chromatin condensation, crescent 
formation and margination were seen and more obvious with time in 
the given-experimental period in the experimental group, but not eas-
ily observed in the control group.The expression of Rev-Caspase-3 
by the apoptosis of lung cancer cell line A-549, which may exhibit a 
potential way in lung cancer gene therapy.
Conclusions: In the present study, to test the effect of recombinant 
Caspases-3 on lung cancer cell, we constructed a eukaryotic expres-
sion vector of constitutively active recombinant Caspases-3 and used 
it to transiently transfect lung cancer cell A-549. The results showed 
that the expressed recombinant Caspases-3 could inhibit the growth 
of A-549 in a time dependent manner. In addition, the apoptosis-in-
ducing effect of recombinant Caspases-3 on A-549 was also evident. 
This study demonstrates the possible use of recombinant Caspases-3 
in lung cancer gene therapy. But the effects of growth inhibition and 
apoptosis induction conducted by recombinant Caspases-3 on other 
cell lines of lung cancer or on lung cancer cell in vivo need to be 
further investigated.
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Adenovirus-mediated FasL gene transfer into human lung 
carcinoma
Zheng, Shi Ying; Jiang, Dong; Ge, Jin Feng
The First Affiliated Hospital of Suzhou University, Suzhou, China
Background: Lung cancer is one of the most common cancers in 
China. Although an increasing number of lung cancer patients have 
benefited from the development of modern tumor therapies, the prog-
nosis of this disease is still relatively poor. Lung cancer often resists 
various treatments, including immunotherapy, wherein deficient 
tumor-specific T-cell responses result in poor immune response. we 
used adenoviral gene transfer to trigger high-level FasL expression 
in A-549 (human lung cancer) cells to investigate the possible use of 
FasL in lung cancer gene therapy.
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Methods: An adenoviral vector encoding the full-length human FasL 
cDNA was constructed and used to infect a human gastric cancer 
(SGC-7901) cell line. FasL expression was confirmed by X-gal stain-
ing, flow cytometric analysis and RT-PCR. The effect of FasL on cell 
proliferation was determined by clonogenic assay, cytotoxicity was 
detected by MTT assay, and cell viability was measured by trypan 
blue exclusion. The therapeutic efficiency of Ad-FasL in vivo was 
investi- gated with a xenograft tumor model in nude mice.
Results: A-549 cells infected with Ad-FasL showed increased 
expression of FasL, Total RNA was extracted from the test and 
control cells, and FasL-specific primers were used for amplifica-
tion by RT-PCR. The expected 231-bp fragment was amplified from 
A-549-FasL cells, but not from A-549-vect cells. A-549-FasL cells 
were smaller and became more round in shape. Over the next 4 d, the 
plasma membranes of these cells blebbed, the cytoplasm and nuclei 
condensed, and the cells ultimately lysed into membrane-bound apop-
totic bodies. Cytotoxicity was determined by MTT 4 d after infec-
tion. Ad-FasL cultures showed 84% fewer viable cells than Ad-LacZ 
infected cultures, suggesting that Ad-FasL was cytotoxic to lung 
cancer cells. Clonogenic assay showed that A-549 cells infected with 
Ad-FasL (100 MOI) did not form colonies, whereas Ad-LacZ cultures 
formed numerous colonies, demonstrating that expression of FasL 
significantly decreased colony formation.Ad-FasL-infected cultures 
showed fewer cells in S or G2M phase, and more cells in G1 phase, 
indicating that FasL could inhibit amplification of gastric tumor cells. 
A sub-G1 peak (apoptosis peak) appeared 4 d after infection of Ad-
FasL, indicating that the FasL gene not only induced G1 phase arrest, 
but also induced apoptosis of A-549 cells.
A-549 cells were infected with Ad-FasL or treated with anti-Fas anti-
body, and the resulting cytotoxicity was compared with that of ActD, 
a RNA synthesis inhibitor known as cytotoxin. The cytotoxicity of 
the anti-Fas antibody (CH-11) to lung cancer cells was stronger than 
that of ActD, and the cytotoxicity of Ad-FasL was stronger than that 
of CH-11. Nude mice were sub- cutaneously injected with A-549 
cells, then intratumoral injections of Ad-FasL were administered. The 
growth of tumor infected with Ad-FasL was inhibited by 54%, sug-
gesting that Ad-FasL was a viable gene therapy candidate. 
Conclusions: Infection of human lung carcinoma cells with Ad-FasL 
induces apoptosis, indicating that this target gene might be of poten-
tial value in gene therapy for lung cancer.
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The research on the effect of hyperthermia on growth of 
A549 and H1299 lung cancer cells
Zheng, Shi Ying; Jiang, Dong; Ge, Jin f.; Li, Hong
The First Affiliated Hospital of Suzhou University, Suzhou, China
Background: The hyperthermia was become one of the useful meth-
ods in tumor curing recently. The morbidity and mortality of lung 
cancer both have a high ratio in male, for about 65% patients were 
already in advanced stage losing the opportunity for operation before 
their disease could get conformed, so the comprehensive treatment 
including hyperthermia plays an important role in the treatment of 
the Advanced Lung Cancer. The effects of hyperthermia on antitumor 
has already been conformed, concerning an complicated mechanism 
including killing the tumor cell directly, apoptosis of the tumor cells, 
and other aspects as immune reactions. In this research humane lung 
cancer cell A549 and the H1299 expressing different state p53 gene 
were both selected as the objects to be observed their conditions as 
the growth, the cell cycle, and the apoptosis of these cells when be-
ing treated under different heating temperature of hyperthermia. To 
observe the influence of hyperther- mia under different temperature 
on the growth, apoptosis of Human Lung Cancer cell of A549, H1299 
to investigate the possible mechanism of apoptosis in lung cancer cell 
caused by p53 with different activity.
Methods: Human Lung Cancer cell of A549, H1299 was heated 
under 40℃, 42℃, 44℃ separately for 2 hours each in the water bath 
case. After the hyperthermia under different temperature, the inhib-
ition ability of A549 cells and H1299 cells were determined by MTT, 
the apoptosis and cell cycle of A549 cells and H1299 cells were 
analyzed by FACS, and RT-PCR was adopted to detect the expression 
of the apoptosis related gene of p53 and caspase-3.
Results: When the Human Lung Cancer cell of A549 was heated 
under 40℃, 42℃, 44℃, and the inhibitory rate of cell growth of 
29.0%, 47.6%, 78.4% could be observed separately; while when the 
Human Lung Cancer cell of H1299 was heated under 40℃, 42℃, 
44℃, the inhibitory rate of cell growth were 17.1%, 32.2%, 69.3% 
separately, which showed that the thermotherapy did have inhibit-
ory effect on the growth in A549 cells and H1299 cells both., and 
the inhibitory rate of cell growth increased with the incretion of the 
heating temperature. when A549 cells were heated under different 
temperature as 37℃, 40℃, 42℃, 44℃, for 2 hours, the cellular 
proportion in G0/G1 phase were 67.842±1.463%, 62.173±1.324%, 
52.871±0.539%, 54.983±1.217%; and the apoptosis rate were 
0.505±0.109%, 5.812±1.356%, 14.249±0.499%, 10.315±1.162%.
When H1299 cells were treated the same as the A549 cells, the cellu-
lar proportion in G0/G1 phase were 64.196±1.324%, 64.743±0.979%, 
62.985±2.364%, 63.623± 1.657%; and the apoptosis rate were 
0.593±0.247%, 4.918±1.326%, 10.454±0.473%, 9.285±0.321%. after 
thermotherapy under 40℃, 42℃, 44℃, the expression of P53 in 
A549 cells increased dramatically, especially the expression of P53 
heated under 42℃,but heating could not induce the expression of P53 
in H1299 cell. However, thermo- therapy under 40℃, 42℃, 44℃ 
can induce the expression of caspase-3 in both A549 and H1299 cells. 
The ex- pression of caspase-3 in A549 cells was higher than in H1299 
cells after different temperature heating, and especially in A549 cells 
in 42℃-heating-group.
Conclusions: Thermotherapy can suppress the growth of the tumor 
cell effectively; regulate the cell cycle to arrest at the G0/G1 phase 
by p53 pathway, and activate the Caspase cascade pathway to induce 
the apoptosis of the tumor cell to ultimately achieve the goal of anti 
tumor effect, besides, our research also showed that different heating 
temperature thermotherapy made differences, and the ideal heating 
temperature is 42℃.
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Microvessel damage may play an important role in 
tumoricidal effect for Murine A549 lung cancer cells with 
lung cancer
Zheng, Shi Ying; Li, Hong; Jiang, Dong
The First Affiliated Hospital of Suzhou University, Suzhou, China
Background: Lung cancer is the application of heat to attain elevated 
tumor temperatures of 42°C-47°C with the aim of receiving thera-
peutic benefits. It has been used most frequently in cancer therapy as 
an adjuvant to radiotherapy and chemotherapy or as a monotherapy.
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In the present study, murine A549 Lung cancer cells were provided 
Lung cancer with different thermal dose in vitro and in vivo, there-
after we investigated the apoptosis, necrosis rates, and intratumoral 
microvessel density (MVD) to determine that microvessel damage 
plays an important role in the tumoricidal effect of Lung cancer.
Methods: Kunming mice weighing 19-21 g were obtained from 
Animal Center of Soochow University, housed in a controlled 
environment at 22°C for 12 h of artificial light per day. The medium 
was preheated in a water bath at 43°C, and immediately thereafter 
the medium was added to the flask, the flask was incubated at 43°C 
for 15, 30, and 45 min, respectively, in an incubator that had been 
preset at 43°C. At the end of treatment, with the addition of Annexin 
V-FITC and PI.A549 Lung cancer cells were inoculated in the right 
hind legs of mice with immunosuppression. Local Lung cancer was 
administered to these mice for 15, 30, and 45 min, respectively. 
After Lung cancer, some mice with heat treatment of 30 min were 
killed at 3, 6, 12, 24, 48, 72, and 96 h after operation and others were 
immediately sacrificed. All tumor tissues were removed. They were 
analyzed for the death rate of tumor cells by flow cytometer (FCM) 
and observed MVD by immunohistochemistry. 
Results: A strong positive linear correlation (r=0.879) was observed 
between the death rate of tumor cells and MVD. The difference of the 
death rate between in vivo and in vitro was significant for Lung can-
cer for 15 min, 30 min, and 45 min (P<0.05). The death rate further 
increased at 3 h, and was highest at 48 h after heating. the changes in 
MVD of the tumors with Lung cancer for different time at 43°C. With 
the time of Lung cancer prolonged, the micro- vessels were dam-
aged further. Regression analysis showed a strong linear correlation 
between the MVD and death rate of tumor cells in vivo (r= -0.879). 
The changes in MVD of the tumors from 0 to 96 h after heating for 
30 min at 43°C. The MVD of unheated control tumors was 50.4± 
1.14. The MVD decreased to 25.0±1.58 immedia- tely after heating. 
Correlative histological sections revealed dilation, congestion, and 
rupture of the tumor microvessel. The MVD further decreased at 3 h, 
and was lowest at 48 h after heating. Then the MVD had increased 
at 72 h after operation. The MVD differed significantly in every time 
point (P< 0.01, respectively). The MVD was also significantly nega-
tive linear correlation with death rate of tumor cells (r= -0.853).
Conclusions: This study has shown microvessel damage may play 
the important role in tumoricidal effect of Lung cancer. Intratumoral 
MVD changes induced by heat may contribute very much to the 
cytotoxic effect. First, Lung cancer lesions the tumor microvessel, 
subsequently tumor cells are killed because of microvessel damage. 
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Anti-lung cancer active immunity induced by FasL/B7-1 
genes modified tumor cells 
Zheng, Shi Ying; Jiang, Dong; Ge, Jin Feng; Li, Hong
The First Affiliated Hospital of Suzhou University, Suzhou, China
Background: Research has revealed that one major reason for the 
low response- veness of cytotoxic T lymphocytes (CTLs) to cancer-
ous cells lies in the loss of inter- acttion between costimu- latory 
factors CD28 and CD152 and B-7 molecules on tumor cell surface 
which results from the low expression of the costimulatory factors of 
B-7 family on the surface of tumor cells . This precludes CTLs par-
tially activated after recognition of antigens from being fully activated, 
making it impossible to generate cytokines with immunological at-
tacking activity against tumor cells and membrane lysis signals (from 
the Fas-FasL system) as well. In the present study, we constructed the 
recombinant adenovirus vector (AdV) containing the human FasL and 
B7-1 genes (termed FB-11), which was used to transfect human lung 
cancer cells. In vitro inducing tumor-specific CTLs from peripheral 
blood T lymphocytes (PBT) and tumorigenicity in mice of the FasL/
B7-1 modified lung cancer cells were obser- ved.
Methods: C57BL/6 (H-2b) inbred mice at the age of 6-8 weeks were 
bought from the Shanghai Laboratory Animal Research Center of 
Chinese Academy of Sciences. SV40 promoter (PSV40) driven hu-
man B7-1 cDNA was presented by Professor Daru Lu at the Institute 
of Molecular Genetics, Fudan University, Shanghai. Human lung 
cancer cell lines A-549 were provided by the Institute of Cell Biology 
of Chinese Academy of Sciences, Shanghai. FasL and B7-1 genes 
were transfected into human A-549 cancer cells with adenovirus vec-
tors. The positive clones were selected by G418. FasL and B7-1 were 
detected by Flow cytometry and RT-PCR . The abdominal infiltrating 
lymphocytes and sensitized spleen cells were obtained from the mice 
who were immunized with A-549/FB-11 or wild type A-549 cells 
intraperitoneally, and the cytotoxicity of these CTLs against tumor 
cells was determined by MTT assay.
Results: Flow cytometry and RT-PCR showed that FasL and B7-1 
were highly expressed. FasL+/B7-1+ A-549 cells (A-549/FB-11) 
were inoculated subcutaneously in the dorsal skin of C57BL/6 mice 
and then they decreased their tumorigenicity greatly (z=2.15-46.10, 
p<0.01). The A-549/FB-11 cell-sensitized mice obtained the protect-
ive immune activity against the rechallenge of wild type A-549 cells 
(z=2.06-44.30, p<0.05). It was showed that the cytotoxicity of CTLs 
induced by A-549 /FB-11 cells against A-549 was significantly higher 
than that of CTLs activated by wild-type A-549 cells (84.1±2.4% vs 
30.5±2.3%, p<0.05). The results suggest that the FasL and B7-1 can 
effectively promote the activity of CTLs against esophageal cancer 
cells.
Conclusions: 0verexpression of FasL can still increase the immuno-
genicity of the lung cancer cell lines in the presence of overexpressed 
B7-1 gene, which promotes the development of antitumor immunity 
in mice. Overexpression of both tumor immunity-associated gene 
B7-1 and apoptosis-inducing gene FasL in one lung cancer cell line 
can generate synergistic anti-tumor activity.
Acknowledgments: This work was supported by the Medical Scien-
tific Foundation of Jiangsu Province, No.H200147
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Study on immuno escape of tumor cell transfected with 
CD44 antisense oligonucleotide
Zheng, Shi Ying; Jiang, Dong; Ge, Jin Feng
The First Affiliated Hospital of Suzhou University, Suzhou, China
Background: TheF as-FasL pathway ist he best-known mechan-
ism that induces apoptosis of tumor cells.However the induction 
of apoptosis by ligation of Fas is often markedly reduced in tumor 
cells and in many cases the level of Fas on tumor cells appears to be 
reduced in vivo. In this s tudy,we first designed and synthesized the 
antisense phosphorothioate oligodeoxyribonucleotides(ASODN) of 
CD44,which targeted to 5’-UTR of CD44mRNA.OligofectamineTM 
reagent was used to transfect oligonucleotides into A-549 lung cancer 
cells with high eficiency and high functional activity. We here,in dif-
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ferent level of gene-protein-cell, investigated CD44ASODN’s ability 
to down-regulate CD44 protein and CD44 mRNA,improve tumor 
cells’ lysis suscepbility to CD3AK and it’s influence on Fas and 
apoptosis-associated gene such as bcl-2.
Methods: FACS assay was used to detect the expression of CD44 
and Fas on A-549 lung cancer cells treated with CD44ASODN,FasL 
on CD3AK and apoptosis of A-549 cells induced by Fas mAb.RT-
PCR assay was used to examine CD expression at the mRNA level 
and apoptosis- associated gene bcl-2 of A-549 cells.MT assay was 
used to explore the efects of CD44 ASODN on A-549 cells prolifera-
tion and sensitivity to lysis by CD3AK effector cells.
Results: Expression of CD44 was obviously depressed on A-549 
cells when treated with 0.8 al mol/ml, 1.2 am ol/ml,1 .6u m ol/
ml CD44ASODN.The positive expression rate decreased from 
86.80% to 53.45%, 38.97%, 34.39% respectively. The depression 
of CD44 expression by CD44ASODN could improve Fas expres-
sion rate on A-549 cells in the presence of fragmented HA (0.1m 
g /ml),which was the most important ligand of CD44,from6 .69% 
to1 6.81%. CD44ASODN could improve apoptosis rate of A-549 
cells which was induced to apoptosis by Fas mAb,after treated with 
CD44ASODN and fragmented HA for 48h.Apoptosis rate was en-
hanced from 0 to 26.55%. CD44ASODN could enhance the suscept-
ibility of A-549 to lysis by CD3AK.It was enhanced from 29.42%, 
26.65%, 24.81% to 52.39%. 47.05%, 35.35%,when the ratio of efect-
or to target wa 25:1,12.5:1,6.25:1. Enhancement of susceptibility of 
of A-549 to lysis by CD3AK was time-dependent.It were7 7.22%,57 
.05%,38 .35% in4 8h,obviously higher than that of 24h,which were 
52.39%, 47.05%, 35.35%. CD44ASODN could obviously decrease 
expression of apoptosis- associated gene bcl-2 on A-549 cells inter-
acted with CD3AK cells.Bcl-2 mRNA relative expression level was 
reduced from 1.06 to 0.32.
Conclusions: In this study, we explained the mechanism of CD44 
in tumor Immuno- escape,explored the molecular mechanism of 
CD44ASODN in reverse immunoescape and provided theoretical and 
experimental support to tumor biotherapy.
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Rapid identification of downstream metastatic-related 
genes associated with nm23-H1 in lung cancer 
Zhou, Qinghua
Tianjin Lung Cancer Institute, Tianjin, China
Background: Nm23-H1 is one of several genes that have been iden-
tified to suppress cancer metastasis in different cancer types including 
lung cancer. However, the mechanisms underlying the suppressive 
function of nm23-H1 remain unclear.
Methods: We have screened and identified the potential metastasis-
related genes affected by nm23-H1 gene using suppression subtract-
ive hybridization (SSH) and cDNA microarray. The cDNA libraries 
was constructed using SSH from cell lines with differential expres-
sion of nm23-H1 and metastatic potential.Real-time PCR and West-
ern blot were used to validate the the results of cDNA microarray. 
Results: A total of 508 cDNAs clones were detected in the two 
subtracted libraries that represented either up- or down-regulated 
genes associated with nm23-H1 expression levels. Subsequently, 
these cDNA clones were used to make specific cDNA microarray 
chips. Probes prepared from the cell lines were hybridized to the 
microarray chips. Nineteen genes were selected, 10 genes out of 19 
were up-regulated in cells with nm23-H1 gene overexpression. In 
contrast, 9 out of 19 were down-regulated in the cells with nm23-H1 
gene deregulation. Real-time RT-PCR analysis revealed that 10 genes 
(PSMA7, SBDS, ODC1, YARS, CSDA, PTP4A1, SHPRH, TOMM7, 
PKM2 and GMNN) showed differential expression consistent with 
the results obtained from the cDNA microarray analysis. Further-
more, Western blot confirmed that the expression of SHPRH, CSDA, 
SBDS and YARS were significantly increased while that of PKM2 
was dramatically decreased in L9981-nm23-H1 cell compared with 
L9981 cell.
Conclusion: To our knowledge, this is first report that these genes are 
reported to be associated with nm23-H1 in lung cancer. Our results 
has shed more light in understanding the molecular mechanisms of 
nm23-H1 gene and help us in developing these gene products as 
potential therapeutic targets. 
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The molecular mechanisms of Nm23-H1 gene transfection 
on reversing invasion and metastasis phenotype in human 
high-metastataic large cell lung cancer cell line L9981
Zhou, Qinghua
Tianjin Lung Cancer Institute, Tianjin, China
Background: Our previous studies have proved that nm23-H1 gene 
was a tumor metastatic suppressive gene, tumor metastasis phenotype 
of human lung cancer could be reversed by transfection of nm23-
H1 cDNA, but the molecular mechanism of nm23-H1 for inhibiting 
tumor invasion and metastasis is unclear. The aim of this study is to 
explore the molecular mechanism of nm23-H1 reversing the invasion 
and metastasis phenotype in human high-metastatic large cell lung 
cancer line L9981. 
Methods: The cell growth and the invasive ability were detected in 
L9981 (the primary lung cancer cell line), L9981-pLXSN (the lung 
cancer cell line transfected with vector) and L9981-nm23-H1 (the 
lung cancer cell line transfected with nm23-H1) by MTT assay and 
modified Boyden chamber, respectively. The mRNA and protein 
expression of β–catenin, E-Cadherin, CD44S, CD44V6, MMP-2, 
TIMP-1, VEGF were detected in the same three lung cancer cell lines 
by RT-PCR and Western blot. The change of gene expression and 
signal transduction were determined before and after transfection of 
nm23-H1 gene by microassay. 
Results: Cell proliferation, clone formation and invasive ability in 
the L9981-nm23-H1 lung cancer cell line transfected with nm23-
H1 gene were significantly lower than those in L9981 and L9981-
pLXSN lung cancer cell lines(P<0.001).No Significant difference of 
cell proliferation, clone formation and invasive ability was observed 
between in L9981 and L9981- pLXSN lung cancer cell line(P<0.05). 
The mRNA and protein expression of β–catenin, E-Cadherin, 
TIMP-1 were significantly up-regulated in L9981- nm23-H1 lung 
cancer cell line transfected with nm23-H1 cDNA than those in 
L9981 and L9981-pLXSN lung cancer cell lines (P<0.001), but no 
significant difference of mRNA and protein expression of β–Catenin, 
E-Cadherin and TIMP-1 existed between L9981 and L9981-pLXSN 
lung cancer cell line (P>0.05). The mRNA and protein expression of 
MMP-2, CD446V and VEGF were significantly down-regulated in 
the L9981-nm23-H1 lung cancer cell line than those in L9981 and 
L9981-pLXSN lung cancer cell lines (P<0.001), but no significant 
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difference of mRNA and protein expression of MMP-2, CD446V and 
VEGF existed between L9981 and L9981-pLXSN lung cancer cell 
line(P>0.05). 24 gene related to metastasis were upregulated and 34 
gene related to metastasis were down-regulated after transfection of 
nm23-H1 gene. 36 genes related to signal pathway were up-regulated 
and 29 genes related to signal pathway were down-regulated after 
transfection of nm23-H1 gene. 
Conclusions: (1) nm23-H1 might be a key regulatory gene of metast-
sis related genes and it may play an important role in the Lung Can-
cer Metastatic Suppressive Cascde. (2) nm23-H1 gene can reverse 
the invasive and metastasis phenotype of human high-metastatic large 
cell pulmonary carcinoma cell line L9981 through regulation of the 
expression of metastatic genes and signal transduction pathway.
* This work was partly supported by the grants from the Key Project 
of National Natural Science Foundation of China (No.30430300, to 
Qinghua Zhou) and Key Projects of Tianjin Sci-Tech Support Pro-
gram (No. 07SYSYSF05000 and No. 06YFSZSF05300, to Qinghua 
Zhou).
P1.113 Basic Science and Translational Research, Sat Aug 1 
Genetic variation in nicotinic acetylcholine receptor 
subunit CHRNA3-CHRNA5-CHRNB4 gene cluster on 
15q25 is associated with lung cancer in the Chinese Han 
population
Niu, Xiaomin; Liu, Yun; Chen, Zhiwei; Luo, Qingquan; Zhou, 
Daizhan; Yu, Yongfeng; Zhang, Jie; Li, Ziming; Zhang, Di; He, Lin; 
Lu, Shun; Zhen, Zhou
Lung Cancer Center, Shanghai Chest Hospital, Jiaotong University, 
Shanghai, China
Background: Lung cancer is the leading cause of cancer-related 
death in the world. Genome-wide association studies have recently 
described novel lung cancer susceptibility loci located in nicotinic 
acetylcholine receptor subunit CHRNA3-CHRNA5-CHRNB4 gene 
cluster on 15q25. This study was to investigate the potential asso-
ciation of polymorphisms of CHRNA3-CHRNA5-CHRNB4 gene 
cluster with the risk of lung cancer in Chinese Han population. 
Methods: Population-based case-control study was carried out. 
Three representative SNPs (rs3743073, rs3743076 and rs3743078 in 
CHRNA3-CHRNA5-CHRNB4 gene cluster) in 1114 Chinese Han 
population, including 547 lung cancer patients and 567 cancer-free 
healthy control individuals, were genotyped using TaqMan® technol-
ogy on an ABI7900 system. The odds ratio (OR) and 95% confidence 
intervals (CI) were calculated using unconditional logistic regres-
sion. The difference of genotype and allele frequency was compared 
between lung cancer patients and healthy control individuals. 
Results: We identified one SNP, rs3743073 (G>T), was associated 
with lung cancer in the Chinese Han population after adjustment of 
age, gender, and smoking status (adjusted OR=1.352, 95% CI=1.116-
1.640, P=0.002). The adjusted OR and 95% CI for heterozygous car-
riers TG of rs3743073 was 1.602 (1.150-2.232) and for homozygous 
carriers GG was 1.824 (1.239-2.686). The OR in dominant genetic 
model was further significantly increased in lung cancer patients 
(adjusted OR=1.671, 95% CI=1.221-2.286, P=0.001). Interestingly, 
The polymorphisms of rs3743073 were also indicated to be associ-
ated with lung cancer in the Chinese Han non-smokers (adjusted 
OR=1.325, 95% CI=1.048-1.674, P=0.019). 
Conclusions: Our results suggest that genetic variation in CHRNA3-
CHRNA5-CHRNB4 gene cluster of 15q25 contributes to lung cancer 
in the Chinese Han population.
P1.114 Basic Science and Translational Research, Sat Aug 1 
Intratracheal administration of 5-azacytidine avoids 
systemic toxicity and enhances antitumor efficacy in 
orthotopic human non-small cell lung cancer xenograft 
models
Zou, Yiyu; Perez-Soler, Roman
Albert Einstein College of Medicine, Bronx, NY, USA
Purpose: To evaluate the efficacy and toxicity of the demethylating 
agent 5-azacytidine administered intratracheally (by locoregional 
injection or aerosol) for the treatment of early lung cancer.
Experimental design: To treat early lung cancer and prevent its local 
recurrence, we developed an aerosol formulation of 5-azacytidine. 
The demethylation function of the formulation was tested in human 
non-small cell lung cancer cell lines. Toxicity and antitumor efficacy 
of the aerosolized and intratracheally-administered formulation was 
determined in normal mice and orthotopic human non-small lung 
cancer xenografts, respectively.
Results: The aerosol formulation of 5-azacytidine did not reduce the 
potency of 5-azacytidine. Its growth inhibition effect in several hu-
man non-small cell lung cancer cell lines tested was dose dependent. 
Treatment of these cell lines with aerosolized 5-azacytidine caused 
reexpression or up-regulation of tumor-suppressor genes including, 
p16, E-cadherin, and hMLH etc. In animal studies, intratracheal 
injection of aerosolized 5-azacytidine had negligible pulmonary 
toxicity and significantly less myelosuppression than intravenously 
administered 5-azacytidine. Intratracheal administered 5-azacytidine 
also significantly prolonged survival of mice with orthotopic human 
non-small cell lung cancer xenografts, endobronchial A549, H358, 
and H460 tumors, by >2-fold compared to intravenous 5-azacytidine 
and untreated controls.
Conclusion: Aerosolized 5-azacytidine should be considered for the 
treatment of early lung cancer or advanced bronchial premalignancy 
in humans.
Cancer Control and Epidemiology
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May diabetes mellitus affect the development of lung 
cancer?
Turan, Onur; Akkoclu, Atila
Dokuz Eylul University Faculty of Medicine, Izmir, Turkey
Background: The incidence of lung cancer in diabetic patients is 
thought to be lower because of reduced life expectancy in diabetes 
mellitus (DM) with complications that increases morbidity and mor-
tality, as lung cancer is generally seen in later part of life.
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DM is a multisystemic disease which impairs immune system. It is 
thought that chronic hyperglycaemia may lead to increase oxida-
tive stress and cause mutations and neoplastic transformations by 
damaging DNA repair mechanism. Hyperinsulinemia may affect the 
development of lung cancer directly or through insulin-like growth 
factor (IGF) or stimulation of IGF receptors. 
Smoking is the major known risk factor for lung cancer. As insulin 
resistance and type 2 diabetes have been reported to be increased in 
smokers, it was thought that the prevalence of DM may be different 
in lung cancer patients compared with the general population. 
Methods: 222 smoking and 10 non-smoking, 232 lung cancer pa-
tients (197 men and 35 women), followed in our clinic in 2007, were 
evaluated about DM presence. 
Results: 34 patients (14.7 %) had been known to have type II DM 
diagnosis in the group of lung cancer patients, which seemed to be 
greater than the prevalence of DM in Turkish population found by 
results of the Turkish Diabetes Epidemiology Study (7.2 %) . 
As chronic hyperglycaemia may be a risk factor for cancer, the DM 
patients were investigated about duration of DM diagnosis. 40 % of 
patients had DM diagnosis for the last 5 years, 20 % for 5-10 years, 
28 % for more than 10 years, and there were 3 new diagnosis of DM. 
There was not any significant difference between the histological 
types of lung cancer about the presence of DM. It was found that 
only 3 patients (3.4 %) had normal glucose level (between 0-110) at 
the time of lung cancer diagnosis. The serum glucose level had been 
found over 200 mg /dL in 14 (41.2 %), 126-200 mg /dL in 15 (44.1 
%) cases, when 2 patients (5.9 %) had impaired glucose tolerance 
(111-125 mg /dL). It was remarkable that that all lung cancer patients 
with DM had smoking history. 
Conclusion: Finally, in contrast to general knowledge, the presence 
of diabetes mellitus may play a role in the formation of lung cancer, 
especially in smokers. We are planning to compare smoker and non-
smoker groups of DM patients in regard of having lung cancer and 
to investigate that if unregulated serum glucose level may be a risk 
factor of lung cancer for DM. 
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Clinico-pathological characteristics of Iranian patients 
with lung cancer referred to thoracic oncology 
department: a single institute study from National 
Research Institute of Tuberculosis and Lung Disease of 
Iran
Khodadad, Kian1; Esfahani-Monfared, Zahra1; Khosravi, Adnan1; 
Azadi, Amir2; Radmand, Golnar 3
1 Thoracic Oncology Department, National Research Institute of TB 
& Lung Disease, Tehran, Iran; 2 National Research Institute of TB 
& Lung Disease, Tehran, Iran; 3 Biostatistics Department, National 
Research Institute of TB & Lung Disease, Tehran, Iran
Background: There could be some differences between lung cancer 
patients from different geographical regions and ethnicities in terms 
of etiology, genders ratio, stage of disease at the time of presenta-
tion and probably their response to treatment. We retrospectively 
determined some of characteristics of our Iranian patients, referred 
to our thoracic oncology clinic for further treatment. Our institute is 
a unique tertiary referral center for whole of country taking care of 
patients with all pulmonary diseases. 
Methods: Retrospectively, the demographic and clinico-pathological 
data of 632 patients were retrieved from their files. All these patients 
were referred to our clinic from different parts of Iran between 2000-
2006. 
Results: In 632 cases male to female ratio was 3.48 (491/141) with 
mean age of 59.95±11.90 years (range 20-99 yrs), although the 
women were younger than men at the time of diagnosis (56.87±12.6 
vs 60.84±11.5 yrs, respectively; P=0.001). The majority of patients 
had regionally advanced or metastatic disease at diagnosis (stage 
I+II: 4.9%, IIIA: 6%, IIIB: 19.3%, IIIB-wet: 19.7%, IV: 36.4%, not 
accessible: 13.8%). In our review only 58.7% (n=371) has history 
of smoking. Men were much more likely to be smoker than women 
(71.8% vs 21.9%, respectively; P=0.0001). The most common histol-
ogy subtypes were: Adenocarcinoma 38.65%, squamous cell car-
cinoma 24.45%, undifferentiated non-small cell carcinoma 17.21%, 
small cell carcinoma 15.2%, large cell carcinoma 0.56%, and mixed 
3.93%. In both genders adenocarcinoma was the predominant pathol-
ogy (females 63.1%, males 35.2%). The most prevalent pathology in 
male smokers was squamous cell carcinoma vs small cell carcinoma 
in female smokers (37.6% and 42.8%, respectively).
Conclusions: Some results of our study seem to be different from 
western countries’ data. For instance the incidence of smoking in 
Iranian patients with lung cancer is lower than western population 
suffering lung cancer. This may translate that male smokers may die 
due to other smoking–induced diseases as COPD and cardiovascular 
diseases before developing lung cancer. Otherwise, genetic back-
ground and other etiologies (e.g. indoor and outdoor pollutions and 
undetermined environmental exposure to different carcinogens) may 
predispose more nonsmokers and females to lung cancer. Evidently 
more patients in our country are diagnosed in advanced diseases and 
make the prognosis more dismal. More joint team working from 
different part of the world is needed to elucidate these differences 
between western and eastern populations.
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Female lung cancer – treatment results of patients in 
Lithuania (10 years single institution experience) 
Cicenas, Saulius3, 2; Kurtinaitis, Juozas1
1 Scientific Research Center, Institute of Oncology, Vilnius University, 
Vilnius, Lithuania; 2 Institute of Rehabilitation, Sport Medicine and 
Nursing, Faculty of Medicine, Vilnius University, Vilnius, Lithuania; 3 
Department of Thoracic Surgery and Oncology, Institute of Oncology, 
Vilnius University, Vilnius, Lithuania
Background: This study attempts to asses the survival rate of female 
lung cancer treated at the Institute of Oncology of the Vilnius Univer-
sity, Lithuania during the period 1996-2005. 
Methods: During the period 1996-2005, 471 women diagnosed with 
lung cancer were treated at the Department of Thoracic Surgery of 
Institute of Oncology, Vilnius University. Data on their morphol-
ogy, stage and treatment was collected from their medical records. 
Non-small cell lung cancer was diagnosed in 395 (83.5%) cases, 
small lung cancer in 63 (13.3%) cases and the pathology type was not 
assessed in 15 (3.2%) cases. Cases diagnosed as being at stage I were 
10.8%, stage II – 15.9%, stage III – 40.6%, stage IV – 32.7%. 62% 
of the patients were 50-74 years of age, and the median age was 63 
(95% CI 61-64) years. Their vital status was assessed as of Decem-
ber 31, 2007, by passive follow-up, using data from the population 
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registry. It was found that 411 (87.3%) of the patients had died. The 
median follow-up time was estimated to be 8.7 (95% CI 7.4-10.8) 
months. Lung cancer patient smoking status was assessed among 
95% of the patients. The data shows that 25% of the women were 
current smokers. The median age of SCLC patients was 61 (55.2 
– 65.6) years, of NSCLC patients, 63 (61-64.5) years. Surgery treat-
ment was applied to 42.7% of the patients, chemotherapy – 25.5%, 
radiotherapy – 21.9%. Best supportive care was applied for 16.1% of 
the patients. 
Results: The median survival rates of NSCLC and SCLC patients 
were found to be very close – 8.4 months compared to 9.3 months. 
Median survival of operated patients was more than 13 months. Best 
results were achieved for stage I of NSCLC – 36.1 months. Patients 
at stage IV had poor prognosis – the median survival time was 3.5 
months. Median survival of SCLC was more than 9 months. Only 
marginal differences have been found between limited and extended 
disease – 9.5 compared to 9.2 months. One and five year overall sur-
vival rates of the patients by type of tumor (SCLC and NSCLC) were 
estimated to have close values. One and two year survival rates for 
non-small cell lung cancer patients were 80.4% and 71.4%, respect-
ively. One year survival rate at stage IV was 21.5%. 
Conclusions: 1. The single center study covering 23.1% of female 
lung cancer from general population diagnosed during 1996-2005 in 
Lithuania show the median survival to be 8.7 month - 8.4 month with 
NSCLC and 9.3 month with SCLC. Majority of the patient (more 
than 70%) were never smokers. 2. A significantly better chance of 
survival was noted in resectable NSCLC. This was more than 20 
month (stages I, II, IIIA). NSCLC survival in advanced stages was 
less than 7 month. SCLC survival differences at limited and extended 
stages of the disease were only modest - 9.5 compared to 9.2 months. 
3. NSCLC patients most frequently were treated by surgery (27.0%), 
surgery and other (19.6%), chemotherapy (16.3%), radiotherapy 
(12.2%), chemo- and radiotherapy (6.9%) and BSC (18.1%). SCLC 
patient treatment included chemo- and radiotherapy (27.0%), chemo-
therapy (19.1%), radiotherapy (17.5%), surgery and other (15.9%), 
surgery (11.1%) and BSC (16.9%). 
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Prevalence of brain metastasis at presentation in patients 
with non small cell lung cancer
Goodgame, Boone; Morgensztern, Daniel; McDuffie, Jeremy; Gao, 
Feng; Govindan, Ramaswamy
Washington University School of Medicine, St Louis, MO, USA
Background: Despite its common occurrence, there are very limited 
data on the prevalence of brain metastasis at presentation in patients 
with non-small cell lung cancer (NSCLC). We performed a large, 
retrospective, single-institution study in order to better characterize 
this common problem.
Methods: We identified all patients who were diagnosed with 
NSCLC at our institution from 1990-2005. Our institutional tumor 
registry captures relevant baseline demographic, clinical, and patho-
logic characteristics, including sites of disease at diagnosis. We tested 
age, gender, race, T status, N status, histology, and tumor grade for 
correlation with brain metastasis in patients with stage IV disease.
Results: A total of 6112 patients met inclusion criteria. Stage distri-
bution at presentation was: stage I, 28%; stage II, 8%; stage III, 29%; 
and stage IV 33%. Of stage IV patients, the median age was 65 years, 
58% were male, 71% were white, and 28% were black. T status was: 
T1, 18%; T2, 37%; T3, 12%; and T4, 31%. N status was: N0, 33%; 
N1, 8%; N2, 45%; and N3, 13%. Histologic subtypes were: adeno-
carcinoma, 42%; squamous cell carcinoma, 18%; and other or un-
specified subtypes of NSCLC, 40%. Grade was classified as “high” 
in 73%. Brain metastasis was present at diagnosis in 623 patients 
(10.2%). Of stage IV patients, 31% had brain metastasis at diagnosis. 
Independent risk factors for brain metastasis in stage IV patients were 
younger age, higher T status, higher N status, and non-squamous 
histology (all p < 0.05). 
Conclusion: Approximately 10% of all patients with NSCLC, and 
31% of patients with stage IV disease present with brain metastasis. 
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The expression of PAH-DNA adducts in lung tissues 
Huang, Yunchao; Yang, Kaiyun; Zhao, Guangqiang; Li, Xiaoming; 
Ye, Lianhua; Gao, Jia; Lei, Yujie; Wang, Kun; Ma, Qianli
Yunnan Tumor Hospital, Kunming, China
Objective: To study the expression of PAH-DNA adducts in lung 
tissues of Xuanwei female lung cancer patients. To explore the 
relationship between the large number of coal-fired pollution PAHs 
materials and the high incidence of Xuanwei female lung cancer. 
Methods: Use immunofluorescence to detect the expression of PAH-
DNA adducts in Xuanwei female lung cancer patients, Xuanwei male 
lung cancer patients, Non-Xuanwei lung cancer patients, and benign 
lung lesion patients group. SPSS13.0 statistical software was used to 
analyze the data. 
Results: The positive expression of PAH-DNA adducts in lung can-
cer tissues, adjacent cancer tissues and normal lung tissues of Xuan-
wei female lung cancer patients were 90%,80% and 65%. They were 
higher than the positive expression of PAH-DNA adducts in Xuanwei 
male lung cancer patients (35%,30%,30%) and Non-Xuanwei female 
lung cancer patients (20%,15%,10%)(p<0.01). The expressions of 
PAH-DNA adducts in lung tissues of Xuanwei female lung cancer 
patients and Xuanwei female benign lung lesion patients(positive 
expression is 70%) were higher than it in Xuanwei male lung cancer 
patients, Non-Xuanwei female lung cancr patients and Non-Xuanwei 
female benign lung lesion patients(positive expression is 10%). With 
the direction changing from cancer tissues, adjacent cancer tissues 
to normal lung tissues, the expressions of PAH-DNA adducts were 
decreased but had no statistical difference (p>0.05). 
Conclusions: The expressions of PAH-DNA adducts in lung tissues 
of Xuanwei female lung cancer patients and Xuanwei female benign 
lung lesion patients were higher than which in Xuanwei male lung 
cancer patients, Non-Xuanwei female lung cancr patients and Non-
Xuanwei female benign lung lesion patients.
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Risk factors for oral and lungs cancer in developing 
country
Joshi, Shambhu D.1; Pandit, N2
1 DPHO, Dhangadhi, Nepal; 2 NMC Teaching Hospital, Kathmandu, 
Nepal
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Background: Cancer of the oral and lungs are common in Nepal. 
The risk factors predisposing to cancer in Nepalese patients are not 
known.
Objectives: To determine the role of smoking, alcohol and their com-
bination, and diet factors in the etiology of cancer of the lungs.
Methods: Risk factors like alcohol consumption, smoking, tobacco 
chewing,use of bio-mass at kitchen and pre-illness diet details in 90 
patients with cancer of the lungs were compared with those in age- 
and sex-matched control subjects. 
Results: The risk for oral and lungs cancer were 3.5 times higher 
with alcohol consumption with smoked food, 2.5 times higher for 
tobacco users, and 2.8 times higher each for betel nut chewers and 
smokers. The calculated odds ratio for the social habits and diet 
factors(smoked foods) was significant amongst cases of oral & 
esophagus cancer. 
Conclusion: Alcoholism, smoked food, smoking, and chewing of 
tobacco are factors predisposing to oral and lungs cancer in Nepal. 
Inspite of poverty, illiteracy and work load most of the people takes 
local made alcohol, unfiltered cigarette smoking, chewing of tobacco 
with slaked lime and burning coal in kitchen which is also a trig-
gering factor.
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Satellite nodules in lung cancer: is current TNM staging 
system valid?
Kim, Hyeong Ryul; Kim, Dong Kwan; Lee, Hyun Joo; Kim, Yong 
Hee; Park, Seung-Il
Asan Medical Center, Seoul, Korea
Background: The current international TNM staging system of lung 
cancer designates satellite nodules in the same lobe with primary 
tumor as T4, and different lobe as M1. In this study, we retrospect-
ively review the medical records of patients who underwent resection 
of satellite nodules with primary tumor in the same lobe or different 
lobe to evaluate for prognostic implications according to the sub-
groups of T4 or M1 category.
Methods: 83 patients with satellite nodules were received pulmonary 
resection from October, 1990 to December, 2007. We divided these 
patients with two groups which have 45 T4 (satellite nodule(s) in the 
same lobe) patients (T4s group) and 38 M1 (satellite nodule(s) in the 
different lobe(s)) patients (M1s group). Median follow-up duration 
was 65.8 months in T4s group, and 55.1 months in M1s group. 
There were no differences between the two groups with the age, sex, 
adjuvant chemoradiation therapy, but the number of patients with 
adenocarcinoma were significantly higher in the M1 group (p<0.01).
Results: Among T4s group, lobectomy was performed in 31, bilobec-
tomy in 3, pneumonectomy in 10, and wedge resection in 1 patient 
for resection of non-small cell lung cancer with satellite nodules. In 
M1s group, 40 operations were performed including 2 staged-oper-
ation patients. Lobecotomy and wedge resection was performed in 14 
patients, bilobectomy in 4, pneumonectomy in 9, and wedge resection 
in 13. 19 patients (42.2%) were recurred in T4s group and 14 patients 
(36.8%) in M1s group. All recurrences except one patient in each 
group were distant. Overall 1-year, 2-year, and 3-year survival rates 
were 79.8%, 65.7% and 42.2% in T4s group, respectively, and 78.3%, 
70.6% and 23.8% in M1s group, which have no statistical differences 
(p=0.943). 1-, 2- and 3-year disease-free survival rates were 58.5%, 
52.6% and 48.8% in T4s group, and 83.0%, 74.2% and 48.4% in 
M1s group, which also have no differences (p=0.843). These survival 
rates and disease-free survival rates were higher than those of other 
categorical T4 or M1 patients. 
Conclusion: There were no significant differences in survival and 
disease-free survival rates between T4s and M1s groups, and showed 
better outcomes than might be predicted by their stage T4 or M1 
designation. So, T4 and M1 patients with satellite nodules in cur-
rent TNM staging system should be re-classified. Surgical resection 
should be considered with chemo- or radiation therapy as one of the 
treatment modalities of patients with satellite nodules.
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Lung carcinoma in patients aged below 40 years
Kaczmarczyk, Grzegorz1; Porębska, Irena2; Szmygin-Milanowska, 
Katarzyna 3; Gołecki, Marcin 2; Korzeniewska, Anna 2; Zalewa, 
Elżbieta 3; Jankowska, Renata 2; Milanowski, Janusz 3; Kozielski, 
Jerzy1
1 Department of Lung Diseases and Tuberculosis, Silesian Medical 
University in Zabrze, Zabrze, Zabrze, Poland; 2 Department 
of Pulmonology and Lung Cancer, Silesian Piasts University 
of Medicine in Wrocław, Wrocław, Poland; 3 Department of 
Pneumonology, Oncology and Allergology, Medical University of 
Lublin, Lublin, Poland
A group of 42 patients (23 men and 19 women) aged under 40 years 
suffer from lung carcinoma hospitalized in the years 2003 - 2008 in 
the Departments of Lung Disease in Zabrze, Wrocław and Lublin was 
analyzed. Primary bronchial carcinoma was found in 98% cases. 71% 
patients were aged from 35 to 39yrs. The most frequent histological 
type of carcinoma was adenocarcinoma (33%). Small cell lung cancer 
was detected in 10 patients (24%). In 78% of cases the degree of 
tumor progression was considerable (ED in small cell lung cancer 
and III - IV according to TNM in non-small cell lung cancer). Carcin-
oma most often was diagnosed on the basis of cytological examina-
tion of sputum or bronchial lavage (38%) and histological examina-
tion of bronchial biopsy specimen (36%). Hypertrophic changes 
were dominated in bronchoscopy (48%). The most frequently disease 
symptoms reported by patients were progressive weakness (38%), 
chest pain (38%) and dyspnoea (33%). The diagnosis of carcinoma 
was delayed up to 6 weeks due to erroneous initial diagnosis which 
included non-specific pneumonia and bronchitis. 
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Epidemiology and diagnosis of lung cancer in the Czech 
Republic
Marel, Miloslav; Krejbich, Frantisek; Spasova, Irena; Skacel, 
Zdenek; Zemanova, Milada
1st Pulmonary Department of the 1st Medical Faculty of the Charles 
University, Prague, Czech Republic
Purpose: To describe the incidence, mortality and results of diagno-
sis of lung cancer (LC) in the Czech Republic (CR). 
Methods: The source of epidemiological and diagnostic data are of-
ficial statistics of the Czech National Oncological Society 
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Results: The standardized incidence and mortality of LC in the CR 
to world standard in men and in women are shown in graph 1 and in 
graph 2.
The LC was diagnosed in the CR in 2005 in 4632 men and in 1617 
women and 4170 men and 1373 women died from this disease in the 
same year. 
The results of the LC diagnosis and treatment of all pts in the Czech 
Republic in the 2005 are summarized in table 1.
 Diagnosis Men % Women %
 Morfologic verification 76 74
 Diagnosis up to 3 weeks 67 62
 Diagnosis over 6 weeks 8 10
 Stage TNM I 12 13
 Stage TNM II 8 6
 Stage TNM III 28 27
 Stage TNM IV 52 54
 Therapy  
 Surgical resection 12 13
 Radiotherapy 24 22
 Chemotherapy 35 32
 Best supportive care 41 45
Conclusions: Epidemiological data shows that LC morbidity and 
mortality reached it´s peak in men in the CR in the past years and are 
still raising in women. The diagnosis of LC continues to be late and 
the early stages are diagnosed only in 19%. There is strong need for 
introducing the early diagnosis programme in the CR.
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Epidemiological evaluation of patients with non-small cell 
lung cancer diagnosed from 1997 to 2008, comparing the 
last 6 years to the others 6 years previous to them, in the 
institution Nucleo de Oncologia da Bahia, Salvador-Bahia, 
Brazil
Mascarenhas, Eldsamira Mascrenhas; Santos, Tâmara Ribeiro de 
Azevedo; Portocarrero, Mariana Lima; Pereira, Maria Clara Sampaio 
Barreto; Azevedo, Luciana Carvalho; Silva, Larissa Karine Leite; 
Matutino, Adriana Reis Brandão; Silva, Jamile Almeida; Alban, 
Gabriela Machado; Oliveira, Carla Coutinho de Sá; Seoane, Marcela 
Sales; Mathias, Clarissa Maria de Cerqueira 
Nucleo de Oncologia da Bahia, Salvador, Brazil
Lung cancer is the neoplastic disease most frequently diagnosed 
in the entire world since 1985, being one of the main causes of 
avoidable death. It is the most widespread carcinoma with very poor 
prognosis, and is the leading cause of cancer death in both developed 
and developing countries. In 2002, the last world-wide statistics, 
there were related 1,35 millions of new cases or 12.4% of all the 
cancer cases with 1,18 million deaths or 17,6% of deaths by cancer 
all over the world. In the United States, in the year of 2007, 213,380 
new cases, being 114,760 in men and 98,620 in women, occurred. In 
Brazil, the incidence of that disease resembles the global behaviour, 
with increased incidence in the south and southeastern regions. For 
2008, 17.810 new cases in men and 9,460 in women are expected. 
This study intends to make an epidemiological survey on lung cancer 
analyzing some variables such as sex, race, smoking, histological 
types, age, stage at diagnosis, kind of treatment, comparing the last 
six years with the other six years previous to these years, in the city 
of Salvador-Bahia, in the north-east of Brazil. For this purpose, 
the charts of patients diagnosed with lung cancer of the Nucleo de 
Oncologia da Bahia (NOB) will be revised. The collected data will be 
stored in a database and later, analyzed by the EpiInfo program.
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High frequency rate of lung cancer in oil refinery counties 
Masri, Fares A.1; Sheikh Yusuf, Amer 2
1 University of Kalamoon, Faculty of Pharmacy, Deratiha, Syria; 2 
Nuclear Medical Center at Alburoni hospital, Damascus, Syria
Background: Cancer is a major public health problem all over the 
world. Cancer-causing pollution threatens every family and every 
community. New research shows a significant link between lung 
cancer and cancer-causing chemical pollution, especially from large 
industrial facilities such as oil refinery. Worldwide, lung cancer is the 
most commonly diagnosed cancer and causes more deaths than any 
other cancer. Monitoring the frequency of lung cancer among Syrian 
counties is of great value but has never been explored in comprehen-
sive manner. The aim of the study was to determine the pattern of 
lung cancer occurrence in oil refinery counties, during one year, and 
make comparisons with non oil refinery counties in Syria. 
Methods: All our data were collected from the Nuclear Medical 
Center at Alburoni hospital in Damascus, which has the only Cancer 
disease registry in Syria. All patients (n=2790) who were diagnosed 
in 2006 with any type of cancer from oil refinery counties (HOMS, 
TARTOS) and non oil refinery counties ( DAMASCUS, LATAKIA, 
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DAIR AL-ZOUR) in Syria were included in this study according to 
their residency place and cancer type. The diagnostic classification of 
definite cancer cases was made according to the International Clas-
sification of Disease. 
Results: The frequency rates (FR) of lung cancer in oil refinery coun-
ties [HOMS: ( total cancer n= 615, lung cancer n=58, FR=9.43%); 
TARTOS: ( total cancer n= 308, lung cancer n=31, FR=10.06%) were 
higher than free-oil refinery counties [DAMASCUS: ( total cancer n= 
1043, lung cancer n=76, FR=7.28%); DAIR Al-ZOUR: ( total cancer 
n= 407, lung cancer n=30, FR=7.3%) LATAKIA: (total cancer n= 
417, lung cancer n=28, FR=6.7%). Statistically, the frequency rates 
(FR) of lung cancer in oil refinery counties was significantly higher 
than non oil refineries counties [refineries counties (n=2): 9.75 ± 
0.45; non refineries counties (n=3):7.1 ± 0.34; P=0.005]. Unexpected-
ly, only 47.3% of lung cancer patients in oil refineries counties were 
smoker and 5.2% were ex-smoker while the rest were non smoker. 
We also observed an excess risk of lung cancer in aged group 0–29 in 
oil refinery counties. 
Conclusions: To our knowledge, this is the first study of its kind that 
compared frequency rates of lung cancer among five major counties 
in Syria which two of them have oil refinery. Our data showed that 
the lung cancer rates were highest in oil refinery counties. Although 
the study is not conclusive, it provides new information suggesting 
that oil refinery products may play an important role in lung carcino-
genesis. it will be important for future studies to determine whether 
individuals with lung cancer have actually had previous high expos-
ures to oil refinery products.
P1.126 Cancer Control and Epidemiology, Sat Aug 1 
Pulmonary metastasectomy for orthopedic malignancies: 
analysis of surgical resection for longer survivals
Mizuno, Tetsuya; Usami, Noriyasu; Taniguchi, Tetsuo; Ohata, 
Norihisa; Sakakura, Noriaki; Yokoi, Kohei
Department of Thoracic Surgery, Nagoya University Graduate 
School of Medicine, Nagoya, Aichi, Japan
Background: Lung is one of the most common metastatic sites from 
orthopedic malignances. Though efficacy of pulmonary metastasec-
tomy (PM) has been reported recently, the prevalence has not been 
enough, especially among thoracic surgeons. Moreover, beneficial 
effects of repeated PMs for longer survivals have been poorly evalu-
ated. The aims of this study are to examine our outcome of PMs for 
orthopedic malignancies and efficacy of repeated PMs for re-reccured 
diseases.
Methods: We reviewed 45 patients who underwent PMs for ortho-
pedic malignancies from April 1996 thorough February 2009. These 
factors below were evaluated; age, gender, histology of primary 
tumors, disease free survival (DFS) to the first PM, pulmonary sur-
gical procedure, number of resected tumors, frequency of PMs, DFS 
after the first PM, re-recurrent sites, survival time after the first and 
last PM and prognosis. 
Results: Among 45 patients, 30 were male, and 15 were female. The 
median age was 43 (range: 7-74) years old. Histology of primary 
tumors was following; 20 osteosarcomas, 6 undifferentiated pleo-
morphic sarcomas (MFHs), 6 liposarcomas, 3 synovial sarcomas 
and 10 others. Mean number of resected nodules at the first PM was 
1.9, the maximum was 5. Wedge resections were performed in 36 
patients, segmentectomies in 5, and others in 4. Frequency of PMs 
was following; once in 30 patients, twice in 13, and three times in 
2. Median DFS to the first PM was 11 (1.2-123) months. Among 
40 patients with complete resection at the first PM, their median 
survival time (MST) and median DFS after the first PM were 26.0 
and 9.1 months, respectively, and 28 (70%) experienced pulmonary 
recurrences. MST of 15 patients who underwent repeated PMs was 
35 months, which was more favorable than that of single PM (19 
months) patients. Furthermore, MST of the repeated PM pateints after 
the last resection was good as long as 17.4 months. It is also better 
than that of single PM patients survival after re-recurrence who did 
not underwent repeated PM (7.9 months).
Conclusions: Though majority of patients with PMs for orthopedic 
malignancies experiences pulmonary reccurences, the prognosis 
was not so poor after receiving repeated PMs and other treatment 
modalities. Especially, patients who underwent repeated PMs showed 
comparably better survival. According to these results, we suggest 
potential efficacy and aggressive indication of repeated PMs may be 
acceptable for selected patients with orthopedic malignancies.
P1.127 Cancer Control and Epidemiology, Sat Aug 1 
Lung cancer in Pahang Malaysia
Ng, Teck Han; How, Soon Hin; Kuan, Yeh Chuun; Abdul Rani, Mohd 
Fauzi
International Islamic University Malaysia, Kuantan, Pahang, 
Malaysia
Background: Lung cancer remains one of the most common cause 
of cancer death. An estimated 213380 new cases of lung cancer will 
be diagnosed in 2007 in United States. Adenocarcinoma is the most 
common lung cancer nowadays. This article reveals the epidemiology 
of lung cancer in Pahang Malaysia. 
Method: All patients confirmed to have lung cancer by histology 
from November 2007 were recruited. Each patient detail demo-
graphic data, full medical history, all investigations findings and 
histopathological results were recorded.
Results: From November 2007 till December 2008, 68 patients were 
confirmed lung cancer. 78% were males and 22% were females. 66% 
of them were Malay, 27% were Chinese, 3% were Indian and 4% 
were arbogine. The mean age was 60 + 10 years. 55% of the patients 
had ECOG 0/1. 93% of the confirmed lung cancer patients presented 
at advanced stage ( Stage 3b or 4) and the remaining were stage 3A. 
No patient presented with stage 1 and 2. The commonest site for 
lung cancer metastasis was the lung (17%) followed by brain (10%), 
liver (9%), and the remaining were adrenal, bone and celiac lymph 
node. 80% of our lung cancer was smoker. About 10% had under-
lying chronic lung disease ( 2% lung fibrosis, 8% COPD). 84% were 
NSCLC, 5% were SCLC, 1% was carcinoid and the remaining was 
undifferentiated carcinoma. Commonest NSCLC was adenocarcin-
oma(43%) followed by squamous cell (20%), large cell cancer (2%) 
and the remaining were labeled as NSCLC. 
Conclusion: Adenocarcinoma is the commonest lung cancer in our 
region.
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Lung cancer in the elderly; how are we managing our 
increasingly aging population in a deprived inner city 
population?
O’Dowd, Caroline A.1; Davidson, Scott1; Dunn, Grainne2
1 Southern General Hospital, Glasgow, UK; 2 Beatson Oncolgy 
Centre, Glasgow, UK
Introduction: Lung cancer is the leading cause of cancer death 
worldwide. 85% of lung cancers occur in patients over 60 years old, 
with incidence peaking between age 75-84 years.1
Despite chronological age not being an independent prognostic factor 
(2,3,4) in patients with lung cancer it is recognised that treatment 
decisions are often negatively influenced by the age of the patient. 
We therefore assessed our approach to investigation and manage-
ment, and overall survival of elderly patients (≥75 years old) with 
lung cancer in our Clinic. 
Methods: All patients aged 75-years or older discussed at our lung 
cancer multi-disciplinary team meeting (MDTM), January to Decem-
ber 2007 were included. A retrospective case note review provided 
details on deprivation category, investigations, staging, histology, 
co-morbidities, treatment, and complications. Surviving patients were 
followed up for a median of 20 months. 
Results: 45 patients’ were included, accounting for 29% of all new 
lung cancers in this period. 51% female and median age was 80-years 
old (range 75-91). 
89% were current or ex-smokers and the median DEPCAT score was 
5. 89% had co-morbid disease. 
Histology was obtained in 71% (32/45). 58% had Non-small cell 
lung cancer (NSCLC), 13% small-cell lung cancer (SCLC) with 29% 
unspecified. 
53% had radically treatable disease on stage of disease alone, and 
31% underwent treatment with curative intent. Two thirds of pa-
tients had active treatment of their disease with the remaining third 
receiving Best Supportive Care. 13% of those treated had significant 
adverse effects.
Overall median survival was 45 weeks. Median survival was best in 
those treated with curative intent compared with those treated with 
palliative intent and best supportive care, 64.5, 35.5 and 18 weeks 
respectively.
Conclusion: We have demonstrated that chronological age should not 
be the reason for under treatment of lung cancer. Our study highlights 
that investigating elderly patients with suspected lung cancer within 
the context of a multidisciplinary Lung Oncology team can impact on 
survival and treatment decisions should be based on proven prog-
nostic markers and the presence of co-morbid disease rather than age 
alone. 
P1.129 Cancer Control and Epidemiology, Sat Aug 1 
Epidemiology and clinical characteristics of patients with 
lung cancer in Jalisco Mexico
Rubio, Jaime Ernesto; Ronquillo, Ramírez C.
UMAE Centro Médico Nacional de Occidente, Guadalajara, México
Introduction: There are only a few references about the characteris-
tics of patients with lung cancer (LC) in our country.
Purpose: To analyze in a prospective/descriptive study the charac-
teristics of the population of patients with lung cancer in the state of 
Jalisco in México. 
Methods: We captured in a prospective way the characteristics of pa-
tients with LC who were treated with chemotherapy in both hospitals.
Results: Since January 2007 was included 92 patients, the medium 
age was 65 years, range of 40 to 86 years. 69 was male (75%) and 23 
(25%) female. The habit of smoke was present in 71 (81.5%). About 
the symptoms, in order of frequency was: Weight loss more of 10% 
in 71.7 %, cough or changes in cough 54.3%, Pain in 48 %, anorexia 
in 34.7%, dyspnea in 33.6 %, hemoptoicos in 27.1 %, asthenia in 7.6 
%, others in 6.5 %. The diagnostic procedure was bronchoscopy in 
35.8 %, Fine needle aspiration in 23.9 %, biopsy in 22.8 % cytology 
in 13 % and trucut biopsy in 4.3 %. The histology type was: Adeno-
carcinoma in 51 %, squamous 32.6 %, undifferentiated 8.6 %, giant 
cell 4.3 %. The hepatic ultrasound was positive in 18.9 % and the 
bone scan in 16.3% the majority of the metastasis was in homolateral 
or contralateral lung. The clinical stage was IIIA in 14.1 %, IIIB in 25 
% and stage IV in 60.86 %.
Conclusions: There is not infrequent early age as 40 years, the inci-
dence in women is increasing, the most frequent type is adenocarcin-
oma and the most frequent symptom is not specific.
P1.130 Cancer Control and Epidemiology, Sat Aug 1 
Epidemiological study to describe non-small cell lung 
cancer (NSCLC) clinical management patterns in Europe, 
EPICLIN-Lung
Carrato, Alfredo2; Vergnenègre, Alain3; Thomas, Michael5; Cruciani, 
Giorgio4; Bischoff, Helge G.5; Medina, Esteban1; Tafalla, Mónica1
1 AstraZeneca Farmaceutica Spain, Madrid, Spain; 2 Ramon y Cajal 
University Hospital, Madrid, Spain; 3 Höpital du Cluzeau, Limoges, 
France; 4 Hospitale di Ravenna, Ravenna, Italy; 5 Thoraxklinik 
Heidelberg University, Heidelberg, Germany
Background: The lack of good, updated, organized and accessible 
local epidemiological data, clinical management data and knowledge 
of how to use healthcare resources in view of the many different 
treatment regimens available, leads to an underestimation of the 
actual burden of lung cancer and associated unmet medical needs. 
This influences in Health Authorities decisions, at the national and 
European level, as well as in physicians, patients and society. Cur-
rently, most lung cancer investigation, specially NSCLC, is focused 
on the clinical outcomes of some treatment strategies and/or novel 
drugs as well as assessing the likely risk factors associated with the 
disease. As National Cancer Institute (NCI) stated, only 3% of the 
US and 2% of the European adult cancer patients are recruited in 
clinical trials and there are only a few local current studies on how 
patients are managed in real life practice. We have started a study to 
be informed of treatment strategies used across Europe and its impact 
on overall costs and patient outcomes, in order to identify objectives 
for improving and to determine the best management pattern for each 
type of patient.
Methods: The EPICLIN-Lung study is an epidemiological prospect-
ive cohort study being conducted across Europe, which plans to re-
cruit more than 4,000 patients from January 1st to March 31st, 2009, 
Copyright © 2009 by the International Association for the Study of Lung Cancer S659
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
in the participating counties (Belgium France, Germany, Greece, Italy 
Portugal, Spain and Turkey). Patients are going to be followed up 
during at least one year, but no longer than 15 months. The over-
all aim of the study is to provide accurate and reliable information 
regarding NSCLC clinical management across European countries in 
order to detect unmet medical needs of this disease in terms of: pa-
tient and hospital characteristics, diagnostic and treatment approaches 
(initial and subsequent), follow-up patterns in clinical management, 
and clinical and patient related outcomes (symptoms, functionality, 
quality of life, death). It will also be focused on the use of resources 
on patients and health care systems.
Results: Descriptive statistics of patients and sites included will be 
available for July 2009. Preliminary results will be obtained on last 
quarter of 2009.
Conclusions: This prospective study will allow medical society to 
know more precisely the NSCLC clinical management patterns used 
across Europe on a day-to-day basis. It will be informative on, the 
impact that different ways of treating patients have in their clinical 
and patient reported outcomes.
P1.131 Cancer Control and Epidemiology, Sat Aug 1 
Descriptive epidemiological characteristics of lung cancer 
in a public hospital
Vigo, Silvina; Antonelli, Martina; Mainella, Andrea; Sansano, 
Mariana; Price, Paola; Mohamed, Fernanda; Marmissolle, Fabiana; 
Giacomi, Nora
Breast Clinic de la Mama, La Plata, Argentina
Background: Lung cancer ranks among the most common and most 
lethal malignancies worldwide, and appears more frequently among 
women in many countries. Although case fatality rates have not 
changed significantly, there have been advances in diagnosis, staging 
and management.
The aim of this study is to characterize lung cancer patients by 
histological type, age, sex, initial stage, smoking status and treatment; 
over a period of 6 years, and compare them with bibliography.
Methods: a retrospective review of patients diagnosed with lung 
cancer from January 2002 through January 2008, who were studied in 
a public hospital, and compared with published data.
Results: a total of 189 patients were studied. The most common 
histological type was Squamous Cell Carcinoma (SCC)(48.67%; age 
52.1 years), Adenocarcinoma (AC)(43.38%; age 48.1 years), and 
small cell carcinoma (7.93%; age 62.1 years). AC and SCC were both 
more common in men (77.24%). Initial stage: SCC: stage I (5.43%), 
stage II (11.95%), stage IIIA (8.7%), stage IIIB (53.26%) and stage 
IV (20.65%); AC: stage I (9.75%), II (9.75%), IIIA (12.19%), IIIB 
(48.78%), IV (19.51%); Small Cell Carcinoma: localized stage 
(60%), extensive stage (40%). Smoking status: SCC 93.47% smok-
ers; AC 75.60% smokers; Small Cell Carcinoma 92% smokers. 
At stage I 100% underwent surgery, at stage II 89.47% underwent 
surgery plus adjuvant chemotherapy, and 10.52% underwent neoadju-
vant chemoradiotherapy plus surgery; at stage IIIA 66% underwent 
definitive chemoradiotherapy and 11.11% underwent chemotherapy 
and 22 % underwent surgery plus adjuvant chemotherapy; at stage 
IIIB 67.41% underwent chemoradiotherapy, 32.58% chemotherapy; 
at stage IV 100% underwent chemotherapy; Small Cell Carcinoma, 
localized stage underwent 100% chemoradiotherapy, and extensive 
stage 100% chemotherapy.
Conclusion: according to our results, the age of disease onset was 
similar compared with bibliography; the proportion of smokers was 
higher in SCC. Unlike published data, the most common histological 
type was SCC, and the initial stage in most cases was IIIB. In this 
population, both SCC and AC were more frequent in men. The 
elected treatment according to stage was similar to the published 
data. It is to be highlighted that we found differences with analyzed 
bibliography, most cases were SCC, and most AC occurred in men.
P1.132 Cancer Control and Epidemiology, Sat Aug 1 
Stage change under the new IASLC lung cancer system: 
what are the most common alterations?
Witkowski, Leora; Roseman, Michelle; Kasymjanova, Goulnar; 
Agulnik, Jason; Pepe, Carmela; Cohen, Victor; Kreisman, Harvey; 
Small, David
Sir Mortimer B. Davis Jewish General Hospital, Division of 
Pulmonary Diseases of Department of Medicine, Montreal, QC, 
Canada
Background and Objectives: The 7th edition of the International 
Association for the Study of Lung Cancer (IASLC) has revised the 
T and M descriptors and disease stages of non-small cell lung cancer 
(NSCLC). We re-evaluated the staging in our lung cancer database to 
determine the proportion with a resultant stage shift and attempted to 
categorize the most frequent alterations in the staging system. 
Methodology: Pathologic and/or clinical stages in 833 patients be-
tween January 2000 and December 2008 undergoing treatment from a 
prospectively collected pulmonary oncology database at the SMBD-
Jewish General Hospital were analyzed. Each patient had been as-
signed a stage based on the 6th edition. The stage was reassigned ac-
cording to the 7th edition of staging based on the previously recorded 
tumor size/location and the location of metastases. 
Results: 833 cases of NSCLC were recorded. Of these, 120 (14.4%) 
patients were reassigned to different T or M descriptors and as a 
result their stage was changed. The stage changes were classified into 
four categories:
Group 1. Tumor size (T1a/b, T2a/b). Stage change due to additional 
cutoffs in tumour size: 28 pts were either upstaged (18pts) or down-
staged (10pts).
Group 2. Pleural effusion (M1a).Stage change due to pleural effusion: 
55 patients were upstaged from stage IIIB to stage IV.
Group 3. Multiple nodules in the same lobe (T3). 20 pts were down-
staged from stage IIIB to stage IIB (8pts) or IIIA (12pts).
Group 4. Multiple nodules in the same lung, different lobe (T4): 
17 pts were downstaged from stage IV to stage IIIA (7pts) or IIIB 
(10pts).
Conclusion: The new staging system resulted in a change in stage 
for 14% of patients. The predominant changes were an upstaging for 
73 (61%) and a downstaging for 47 (39%) pts. Further prospective 
studies are required to determine whether these changes will affect 
therapeutic clinical decisions.
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How many adenocarcinoma lung cancers (ALC) come 
from bronchioloalveolar carcinoma (BAC)?
Wong, Alvin S.1; Seto, Kar-Yin2; Ang, Bertrand2; Wong, Eunice3; 
Chin, Tan-Min1; Soo, Ross1
1 Department of Haematology Oncology, National University 
Hospital, Singapore, Singapore; 2 Department of Diagnostic Imaging, 
National University Health System, National University of Singapore, 
Singapore, Singapore; 3 Cancer Science Institute of Singapore, 
National University of Singapore, Singapore, Singapore
Background: BAC has traditionally been thought to be a separate 
histologic and clinical entity in lung cancer. In recent years, there is 
emerging evidence that BAC and ALC form one clinico-pathologic 
spectrum. The incidence of BAC is strikingly high in screening stud-
ies in Japan, and tends to occur in women, non-smokers and Asians. 
These clinical features also characterize the group with ALC that 
tends to respond to Epidermal Growth Factor Receptor (EGFR) tyro-
sine kinase inhibitors (TKIs). Since advanced ALC is often diagnosed 
on cytology alone, we hypothesize that the incidence of BAC is 
under-reported, and that a large proportion of ALC in our population 
are part of the BAC-adenocarcinoma sequence. 
Methods: We identified patients with ALC from our institutional 
lung cancer database. Patients with ALC diagnosed in 2008 were in-
cluded, regardless of stage and whether pathologic diagnosis was by 
surgical specimen, core biopsy or cytology. As BAC is well known to 
have distinct radiologic features on computer tomographic (CT) scan, 
we reviewed the pre-treatment CT features of these patients, looking 
in particular for characteristic features of BAC as described in current 
literature. 
Results: 69 ALC patients diagnosed in 2008 were included for analy-
sis. Patient characteristics: Median age 63 (35-82), Chinese/Malay/
Indian/others 52/8/6/3, male/female 39/30, smokers/non-smokers/
unknown 25/18/26. Best pathologic specimen: surgical resections 19, 
core biopsies 17, cytology 33. The presence of BAC components was 
reported in the pathology of 16 patients (23%), including 14 surgical 
specimens and 7 core biopsies. CT features classically associated 
with BAC were found in 35 patients (51%). Ground glass opacities 
18 (26%), air bronchograms or bubble-like lucencies or pseudocavita-
tion 17 (25%), consolidation or pneumonic picture 11 (16%), diffuse 
small or miliary nodules 8 (12%), CT angiogram sign 4 (6%). 37 
patients (54%) had BAC features on either pathologic specimen or 
CT scan (or both). 14 patients (20%) had BAC features on CT scan, 
with only cytologic diagnosis. 
Conclusion: We found provocative albeit circumstantial evidence 
that a large proportion of our ALC cases arise from BAC. Confirma-
tory research is warranted, with a view to directing resources at 
screening for BAC in our population.
Health Services Resources
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Elderly patients with non-small cell lung cancer (NSCLC): 
A community cancer center experience
Adonizio, Christian S.1, 2; Pope, Jane1; Frantz, Andrea3
1 Hematology and Oncology Associates of Northeastern 
Pennsylvania, Dunmore, PA, USA; 2 The Commonwealth Medical 
College, Scranton, PA, USA; 3 The University of Pennsylvania, 
Philadelphia, PA, USA
According to recent reviews of SEER data, “most elderly patients 
with advanced NSCLC do not receive chemotherapy”1 and “little is 
known about patterns of treatment for elderly patients with NSCLC”2. 
We performed a retrospective review of new patients referred 
(inpatient and outpatient consultations) to our center (our center 
serves the six counties-- Lackawanna, Luzerne, Pike, Susquehanna, 
Wyoming, and Wayne) of Northeastern Pennsylvania (USA) during 
the six month period of 1/1/07 to 6/30/07. We identified patients by 
the use of the Varian ARIA EMR system (Varian, Palo Alto, CA) and 
the Centricity Billing System (GE, St. Giles, UK). We identified 94 
patients with an ICD-9 code for lung cancer (162.0-162.9) who were 
Medicare subscribers. We excluded 19 patients who had earlier stage 
NSCLC or who were Medicare subscribers younger than age 65, we 
also excluded 22 patients with SCLC, 1 patient with mesothelioma, 
and 8 patients because of incomplete data. We then performed a 
manual chart review in the EMR of 44 patients over the age of 65 
with inoperable NSCLC. The median age of patients was 74 with 29 
male pts (66%) and 15 female pts (34%). Median survival was 275 
days (39 weeks), which is similar to previously reported studies.
 Treatment Modality  # of patients  % of patients 
 No treatment 8 18%
 Radiation Alone (1st line) 4 9%
 Platinum Doublet (1st line) 18 41%
 Bevacizumab w Platinum Doublet (1st line) 12 27%
 Combined Modality Therapy 9 20% 
 (concurrent platinum regimen w concurrent XRT)
 Treated on Protocol 2 5%
 Treated w second line therapy 12 27%
 Treated w third line therapy 3 7%
Results: 1.) In our center 82% of elderly patients with inoperable 
NSCLC received therapy for advanced NSCLC (vs. 60% in the 
SEER data set) 2.) 61% of elderly patients received platinum-based 
chemotherapy either as a doublet, in combination with Bevacizumab, 
or as part of combined-modality therapy 3.) Only 5% of patients were 
treated on protocol 4.) We were unable to analyze 8 (15%) patients 
(even in the setting of an EMR system). 
Conclusions: In our experience, it is common practice to treat elderly 
patients with platinum-based regimens in the community setting and 
this is associated with an expected overall survival as compared to 
historical controls. The volume of these patients treated in the com-
munity setting is adequate to design and perform studies of elderly 
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patients with NSCLC in cooperative group or industry sponsored 
trials. 
1.  M Tang, AJ Davidoff, CD Mullins et al. “Chemotherapy (C) and survival among 
21,441 elderly (E) patients (pts) with advanced (adv) NSCLC: Analysis of SEER-
Medicare claim data 1997-2002. J Clin Oncolo 26:2008 (May 20 suppl; abstr 8090)
2.  MJ Edelman, M Tang, JF Gardner et al. “Therapy (Tx) of locally advanced (LA) 
NSCLC in the elderly: Analysis of 6,325 patients from Surveillance, Epidemiology, 
and End Results (SEER)-Medicare. J Clin Oncol 26:2008 (May 20 suppl; abstr 7549
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Who’s role is it anyway?
Guerin, Maria; Beattie, Vanessa
NLCFN, Liverpool, UK
In 2006 National Institute Clinical Excellence (NICE) Department 
of Health (DoH) guidelines for the diagnosis and treatment of lung 
cancer recommended that all patients should be discussed at a locally 
based MDT (multi disciplinary team meeting) 
Increased MDT working has meant that most patients are now seen 
by a specialist and discussed at local MDT (National Lung Cancer 
Audit)
Despite universal implementation of the recommendation anecdotal 
evidence suggests that there are significant diversities in the roles 
performed by core members of the MDT.
The audit aims to review the current status and roles carried out 
within the MDT.
Questionnaires were sent to all 230 members of the National Lung 
Cancer Forum for Nurses (NLCFN) across the UK. It is known that 
in some areas there is more than one Lung Clinical Nurse Specialist 
(CNS) the reviewers therefore requested one response per MDT. A 
total of 67 responses were received.
The audit highlighted the complexity of, and variation of the roles 
within the MDT. In particular those of the Lung CNS / Cancer 
Tracker / Data Clerk / MDT coordinator. These include compilation 
of MDT list; collation of documentation; organisation of investiga-
tions; appropriate follow up appointments; verbal input into the meet-
ing. Alarmingly there were many inconsistencies in the collection and 
recording of data, which in turn leads to incomplete data nationally.
If MDT meeting’s are to continue to achieve the positive impact on 
patient care including: improved waiting times; speedy diagnostic 
pathway; effective tracking and coordination of care, then clarity and 
resource of membership are imperative to secure roles and improve 
quality MDT working leading to better outcomes. These considera-
tions must be taken into account in areas where MDT meetings are in 
the developmental stage both nationally and internationally.
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Enrollment of lung cancer patients on clinical trials at an 
NCI comprehensive cancer center
Horn, Leora1; Keedy, Vicki1; Campbell, Norma1; Garcia, Gabe1; 
Hayes, Amy1; Spencer, Brady1; Sandler, Alan2; Carbone, David1; 
Johnson, David H.1
1 Vanderbilt Ingram Cancer Center, Nashville, TN, USA; 2 Oregon 
Health & Science University, Portland, OR, USA
Background: Enrollment of cancer patients (pt) in clinical trials is 
considered essential in order to improve cancer care. However, can-
cer clinical trials participation remains low. Understanding barriers to 
pt enrollment is necessary to overcome this problem. Previous reports 
have identified pt age, race & ethnicity, disease stage, performance 
status (PS) & relationship with their health care provider as factors 
that can influence the enrollment of pts in clinical trials. 
Methods: We conducted a retrospective review of the charts of all 
lung cancer pts seen in the Thoracic Oncology Clinic at Vanderbilt 
Ingram Cancer Center between 11/05 & 11/08. 
Results: 1056 patient charts were audited. Pt demographics: median 
age was 64 yrs. 53.9% of patients were male. 95.1% were Cauca-
sian, 3.5% were African American and 1.2% were Asian. 13% of 
patients were never smokers. 80.2% of patients had NSCLC of which 
59.2% had stage IV disease. 16.8% of patients had SCLC of which 
70.9% had extensive stage disease. Median distance of patients from 
Vanderbilt hospital was 79 miles. A study protocol was available for 
59.7% of pts; 56% of pts proved eligible; 35.8% were entered into 
a study (12% total population). There was a significant difference in 
trial availability by stage, patients with advanced disease were more 
likely to have a study available in which they could enroll (P<0.001). 
Male pts were more likely than females to be eligible for a study 
(P=0.056), of eligible patients there was no difference in enrollment 
by gender. There was no difference in eligibility or enrollment be-
tween ethnic groups. Significantly more protocols were available for 
NSCLC pts compared to pts with SCLC (64% versus 49% P< 0.001). 
There was no difference in eligibility between NSCLC and SCLC 
patients, however, there was a non-significant trend towards higher 
enrollment of eligible NSCLC pts (37% versus 32%). The most 
common reasons for not enrolling in a study included a preference 
for treatment closer to home (25%), patient refusal (21%), PS (18%) 
& co-morbidities (20%). Patients living > 79 miles from the hospital 
were significantly less likely to enroll in a study (P=0.004)
Conclusions: A total of 12% of lung cancer pt evaluated in our Thor-
acic Oncology Clinic were enrolled in clinical trials. Our data suggest 
additional strategies are needed to attract minority groups to larger 
institutions as they are likely to enroll in clinical studies, increase 
enrollment of women & pts with co-morbidities & poor PS. Travel 
distances influence pt willingness to participate in clinical trials. 
Strategies are also needed to overcome this factor.
P1.137 Health Services Resources, Sat Aug 1 
An examination of the exceptional case funding process for 
Erlotinib within a large UK based cancer network
Irshad, Sheeba; Shah, Riyaz
Maidstone & Tunbridge Wells NHS trust, Kent, UK
Background: Comparisons of Britain’s reliance on general taxa-
tion to finance its healthcare with the American model of private 
insurance and the French and German systems of compulsory social 
insurance have been the subject of debate in various medical and non 
medical forums. The conflict between excellence and affordability is 
a topic of current discussion in the field of lung cancer management.
The availability of high cost ‘new’ anticancer drugs in England and 
Wales usually depends on a positive appraisal by ‘The National 
Institute for Health and Clinical Excellence’ (NICE). This process 
is lengthy and subject to appeal. Where NICE guidance is lacking, a 
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clinician may apply to the patient’s local commissioner-the Primary 
Care Trust (PCT). Each PCT has an “exceptional case panel” (ECP) 
which may approve the funding of a treatment. Oncologists are usu-
ally not part of such panels.
Erlotinib was licensed for 2nd/3rd line use in light of data presented 
at ASCO 2004 and published in 2005. FDA and EMEA approval 
were obtained in Nov 2004 and Sept 2005 respectfully. A positive 
appraisal by NICE was obtained in November 2008.
During the 4-year hiatus between data presentation and NICE ap-
praisal, the drug was only available via an exceptional case applica-
tion.
We examined all ECP applications for Erlotinib in large regional 
cancer network covering a total population of 1.8 million people. 
This population was served by 9 different PCTs (later merged into 3 
during the course of this study).
Methods: All applications for erlotinib between July 2005 and 
November 2008 were identified. From case note review we identified 
demographic factors, reasons for exceptionality, length and outcome 
of appeals.
Results: 18 ECP applications were made between July 2005 and Nov 
2008. Baseline demographics: 10 female; 8 male; median age 62 (33-
80y); 7/18 non-smokers (6 lifelong); 17/18 adenocarcinoma, 1 squa-
mous. EGFR mutation analysis was not performed in any patients.
Reasons for exceptionality stated by the physician fell into two 
broad groups: 1) Contraindication to standard regimens (e.g. poor 
PS, co-morbidities and previous allergic reaction), and 2) favorable 
predictive features for response to erlotinib (female, adenocarcinoma, 
non-smokers).
The median PCT-response time to an application was 60 days (range: 
18-105 days). On initial application, 6/18 (33%) were successful, 8 
(44%) were refused and 4 (22%) died whilst awaiting decision (mean 
time from application to death=60 days). 
Four of the 8 initial refusals were appealed, of which 3 were success-
ful (mean days to successful outcome = 177 days and requiring upto 
4 appeals). The overall success rate for application was 50% (9/18).
No predictive markers for a positive outcome were identified with no 
trends seen in the baseline characteristics in either the accepted or the 
refused groups. Four of the 8 initial refusals had a reason given for 
refusal by the PCT which included disagreement with exceptionality 
status (n=2) and failure to recognize exceptionality (n=2). The latter 
included reasons such as “Drug is not NICE approved”, showing a 
failure of understanding of NICE guidance and the appeals process. 
Conclusions: Our analysis shows that the local-level application 
process for erlotinib at this cancer network was not transparent, 
standardized and unnecessarily lengthy for patients. There are almost 
150 PCT’s in England and Wales suggesting a significant lottery in 
decision making if these data are replicated Nationwide. Other health 
economies will need to develop robust strategies to address these 
inequities before adopting similar systems.
P1.138 Health Services Resources, Sat Aug 1 
Underutilisation of radiotherapy for lung cancer in NSW, 
Australia
Vinod, Shalini K.2, 3; Goldsbury, David1; Simonella, Leonardo1; 
O’Connell, Dianne L.1; Delaney, Geoff P.2, 3
1 The Cancer Council NSW, Sydney, NSW, Australia; 2 Collaboration 
for Cancer Outcomes, Research & Evaluation (CCORE), Sydney, 
NSW, Australia; 3 University of New South Wales, Sydney, NSW, 
Australia
Background: Lung cancer is the leading cause of cancer deaths in 
NSW, Australia. Radiotherapy is important in the treatment of this 
disease with an optimal utilisation rate estimated to be between 45 
and 68 percent at initial diagnosis. The aim of this study was to de-
scribe radiotherapy practice for lung cancer in NSW. 
Methods: Lung cancer patients were prospectively identified from 
the NSW Central Cancer Registry (CCR) from 1 November 2001 to 
31 December 2002. Questionnaires were mailed to diagnosing and 
treating clinicians to obtain detailed information on diagnosis, sta-
ging, referrals and treatment. We report the management of patients 
for whom a completed radiotherapy questionnaire was obtained. 
Results: Of the 1812 lung cancer patients identified, 943 (52%) were 
referred for radiotherapy, 846 (47%) had a radiotherapy questionnaire 
and 727 (40%) patients received radiotherapy. Compared to optimal, 
there was less curative radiotherapy to the primary site (20% actual 
vs 50% optimal) and more palliative radiotherapy to metastatic sites 
(36% actual vs 11% optimal). The greatest shortfall in radiotherapy 
utilisation was seen in limited stage small cell lung cancer (46% 
actual vs 94% optimal). The use of combined modality treatment for 
Stage III non-small cell lung cancer and limited stage small cell lung 
cancer was uncommon. 
Conclusions: There is underutilisation of radiotherapy for lung can-
cer in NSW, especially in small cell lung cancer. The use of combined 
modality treatment for potentially curable lung cancers is suboptimal. 
These issues have to be addressed in order to improve survival and 
quality of life for lung cancer patients. 
P1.139 NSCLC Advanced Disease, Sat Aug 1 
A prospective phase II trial of erlotinib as first-line 
treatment in Caucasian non- and ex-smokers with 
advanced lung adenocarcinomas
Agelaki, S.1; Kentepozidis, N.1; Giassas, S.1; Kotsakis, A.2; Kalbakis, 
K.1; Androulakis, N.1; Kalykaki, A.1; Saloustros, E.1; Milaki, G.1; 
Rovithi, M.1; Mavroudis, D.1; Georgoulias, V.2
1 Department of Medical Oncology, University General Hospital of 
Heraklion, Heraklion, Greece; 2 Hellenic Oncology Research Group 
(HORG), Athens, Greece
Background: Erlotinib is a standard treatment associated with favor-
able toxicity profile in pretreated advanced NSCLC. Clinical predict-
ors of response include smoking history, histology, race and gender. 
This phase II trial evaluated the efficacy and safety of erlotinib in 
previously untreated Caucasian patients (pts) with NSCLC. 
Methods: Chemo-naive pts, non- or ex-smokers with stage IIIB-
IV NSCLC and adenocarcinoma histology, PS 0-2, age ≥ 18 years, 
adequate organ functions, measurable disease and written informed 
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consent were included. Erlotinib was given orally at 150 mg per day 
until disease progression or unacceptable toxicity. Samples were ana-
lysed for potential molecular markers of response and survival. 
Results: Forty-five pts [median age: 68 years (range, 36-81), stage 
IIIB/IV: 8/37, male/female ratio: 18/27, PS 0/1/2: 12/31/2, adeno-
carcinoma/BAC: 42/3, non-smokers/ex-smokers: 35/10] were 
included. One pt has not been evaluated for response yet. In an ITT 
analysis tumor response rate was 24.4% with 1 complete response, 
10 partial and 17 (37.8%) cases of disease stabilization for an overall 
tumor growth control rate of 62.2%. Response rate was not correl-
ated with gender, PS, stage, age, or rash grading. After a median f-up 
of 12.5 months, the median duration of response was 15.03 months, 
median TTP was 7.33 months and median overall survival was 13 
months with a 1-yr survival rate of 56.2%. Toxicity was manageable 
as expected (rash, diarrhea, and emesis). Molecular analyses were 
performed in 33 biologic samples available. Classic EGFR tyrosine 
kinase mutations (TK) were identified in 9 (25%) out of 33 pts, Kras 
mutations in 4 (12%), EGFR expression by IHC in 23 (67.6%), and 
high polysomy in 1 pt. Response was significantly correlated with the 
presence of classic EGFR TK mutations (p=0.032) but not with pro-
tein expression. Among patients with Kras mutations none responded. 
The patient with high polysomy progressed on erlotinib. Median 
overall survival has not been reached for pts with classic EGFR 
mutations. Only the severity of rash (0+1 vs 2+3) was significantly 
correlated with survival (p=0.026). 
Conclusions: Single agent erlotinib shows significant antitumor 
activity, which may be comparable to chemotherapy, in the first-line 
treatment of advanced NSCLC selected by clinical characteristics and 
lacks severe side effects. 
Non-Small-Cell Lung Cancer - Advanced Disease
P1.140 NSCLC Advanced Disease, Sat Aug 1 
Alimta as salvage therapy in patients with heavily 
pretreated non-small cell lung cancer and clinical 
correlation with thymidylate synthase (TS) expression
Chang, Myung Hee; Kim, Kyoung Ha; Jun, Hyun Jung; Kim, Hyo 
Song; Lee, Jeeyun; Park, Yeon Hee; Ahn, Jin Seok; Ahn, Myung-Ju; 
Park, Keunchil
Division of Hematology/Oncology, Department of Medicine, 
Samsung Medical Center, Seoul, Korea
Background: At present, there is no standard treatment as third- or 
further-line therapy in patients with advanced non-small cell lung 
cancer (NSCLC). Pemetrexed with role role of second-line treatment 
has been also used as third-line treatment. 
We evaluated the efficacy and safety of pemetrexed as a salvage 
regimen in heavily pretreated NSCLC patients. We also analyzed TS 
expression in tumor tissues to determine whether TS expression is 
correlated with clinical efficacy of pemetrexed.
Methods: One hundred ten NSCLC patients who received pe-
metrexed as third- or fouth- line treatment at the Samsung Medical 
Center between June 2006 and June 2008, were analyzed. And, 
TS expression was analyzed by immunohistochemical stain in 55 
NSCLC tissues specimens. The relationship between TS expression 
and cliniopathological factors was evaluated. Univariate and multi-
variate analyses were performed to define its predictive factor and 
prognostic significance.
Results: Median age was 59 years (range 24-84), 50.9% were men. 
The ever smokers were 27 (24.6%), 65 patients (59%) received 
pemetrexed as third- line treatment. Ninety-five (86.4%) had non-
squamous cell carcinoma (adenocarcinoma: N=90, mucoepidermoid 
carcinoma: N=1, undifferentiated carcinoma: N=3, sarcomatoid 
carcinoma: N=1), and 15 patients had squamous cell carcinoma. Plat-
inum based chemotherapy (84.6%) was the most common regimen 
as first-line therapy and, EGFR TKIs [erlotinib (17.3%) or gefitinib 
(43.6%)] were as second-line therapy. The median time from the 
date of diagnosis to the date of first pemetrexed treatment was 12.8 
months (range: 1.80-62.23 months). The median cycle of pemetrexed 
treatment was four cycles (range, 1-22), Eighteen patients achieved 
PR (18/110, 16.3%), SD in 41 patients (41/110, 37.3%) and PD in 
43 patients (43/110, 39.1%), with disease control rate of 53.6%. 
With 16.1 months of median follow-up, the median progression free 
survival (PFS) was 3.22 months (95% CI: 1.94-4.50 months), and the 
median overall survival (OS) was 11.57 months (95% CI: 9.04-14.10 
months). Male (p=0.017) and squamous cell type (p=0.050) were 
associated with significantly worse PFS in univariate analysis. Poor 
performance status (p=0.001) and history of smoking (p=0.018) were 
statistically significant factors associated with poor OS. In multi-
variate analysis, male was only Independent predictive variable for 
poor PFS (p=0.031, HR=1.585, 1.043-2.410), and poor performance 
status (p=0.002, HR=2.432, 95% C, 1.390-4.254), history of smok-
ing (p=0.006, HR=2.201, 1.256-3.858), third-line therapy (p=0.026, 
HR=1.838, 1.076-3.318) were independent factors affecting poor OS. 
Thirteen of 55 tumor tissues (23.6%) showed TS expression. How-
ever, there was no significant correlation between TS expression and 
clinicopathological factor.
Conclusion: In this study, pemetrexed showed favorable efficacy and 
well tolerated as salvage therapy. Given the frequent use of EGFR 
TKIs as second-line therapy in Korean NSCLC patients, further 
studies will be warranted to define the sequence of salvage treatment 
especially, in patients with adenocarcinoma of lung caner.
P1.141 NSCLC Advanced Disease, Sat Aug 1 
Useful estimates of survival for patients starting first line 
chemotherapy for advanced non-small-cell lung cancer 
based on a systematic review of recent randomized trials
Alam, Mahmood1; Blinman, Prunella2; Stockler, Martin R.2
1 Medical Oncology, Liverpool, NSW, Australia; 2 CTC, NHMRC, 
University of Sydney, Sydney, NSW, Australia
Background: We sought estimates of best case, typical range and 
worst case scenarios to help doctors discuss prognosis with patients 
starting first line chemotherapy for advanced non-small-cell lung 
cancer. 
Methods: 10 major journals were searched from Jan 2000 to Apr 
2008 for pertinent randomized trials with ≥100 patients per treatment 
group. The median survival and 4 other percentiles were recorded 
from each survival curve to reflect worst case (90th), lower typical 
(75th), upper typical (25th) and best case (10th) scenarios. For each 
curve, we calculated the ratios of the 90th, 75th, 25th and 10th per-
centiles to the median survival. Estimates of these 4 percentiles for 
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each curve were calculated as simple multiples of its median survival 
(quarter, half, double and triple), and were deemed accurate if within 
0.75 to 1.33 times the actual value. Age, gender, performance status, 
stage, histology and year of publication were tested as predictors of 
survival using generalized estimating equation regression models. 
Results: We analyzed 134 survival curves including 29,657 patients 
from 60 trials. The median (range) times in months for the various 
scenarios were: worst case 2.2 (1 to 5), lower typical 4.8 (3 to 9), 
median survival 9.2 (6 to 14) upper typical 16.5 (10 to 24), and best 
case 25 (13 to 40). The median (ranges) of the ratios of the 4 per-
centiles to the median survival were: worst case 0.26 (0.11 to 0.48), 
lower typical 0.53 (0.37 to 0.70), upper typical 1.79 (1.3 to 2.3), and 
best case 2.9 (1.8 to 4.3). Simple multiples of the median survival 
provided accurate estimates of the 4 scenarios in 77%, 97%, 97% 
and 87% of curves. A statistically significant survival difference was 
reported in 12 of 74 (16%) treatment comparisons (mean hazard ratio 
0.8, range 0.75 to 0.92). Performance status and histology were the 
only independent predictors of survival (p<0.001). 
Conclusions: Simple multiples of the median survival from recent 
randomized trials provided good estimates of scenarios that are useful 
for discussing prognosis.
P1.142 NSCLC Advanced Disease, Sat Aug 1 
Role and impact of “non- conventional / alternative 
medicines” on quality of life as well as disease free and 
overall survival in patients with locally advanced and 
metastatic lung cancer 
Attili, Suresh V.; Sinha, Sudha; C, sairam
Dept of Medical Oncology, Hyderabad, India
Background: In India, the use of alternative medicines is very wide 
spread and often it is used in adjunct to conventional treatment (like 
radio/chemotherapy) or alone. One of the recent surveys suggested a 
staggering 25% of patients with terminal illness use them as a single 
modality and as high as 45% in all forms. 
Aim: Therefore we conducted this study to evaluate the role and 
impact of “non- conventional / alternative medicines” on quality 
of life as well as disease free and overall survival in patients with 
locally advanced and metastatic lung cancer who achieved partial or 
complete response to chemotherapy.
Methods: All the patients with locally advanced or metastatic non 
small cell lung cancer presenting to the dept of medical oncology 
were treated with standard NCCN guidelines (we have chosen pa-
clitaxel 175 mg/m2 with carboplatin (AUC-6) as standard treatment). 
Those patients who achieved partial or complete responses to therapy 
were enquired whether they were taking any alternative medica-
tions or not. They were given an indigenously developed quality of 
life questionnaire to fill and patients were followed up at 2 monthly 
intervals till disease free progression. Intention to treat analysis was 
used to calculate the outcome. Kaplan Maier curves were drawn for 
the disease free as well as overall survival periods.
Results: out of the 90 patients treated, 42 achieved either partial (31) 
or complete (11) response. Of them 65% (27) patients were using al-
ternative medicines. The commonest ones are ayurveda [n=22](in 17 
patients the basic content is gold [swarna bhasma] in 12 patients it is 
a plant derivative from Tinosporium caudifola and 8 patients the ex-
tract - Pippali (Piper longum) and Hirak Rasayan and majority using 
a combination]. The reminder [n=14] used a homeopathic medication 
Canova method {homeopathic dilutions of Aconitum napellus, Arsen-
icum album (arsenic trioxide), Bryonia alba, Lachesis muta venom 
and Thuya occidentalis}. At the end of the study we found that there 
is statistically significant improvement in the global quality of life in 
patients using alternative medicines compared to those who are not 
using any medications [increment of 4 points p=0.03]. The disease 
free survival remains the same [4.8 months in patients not using 
alternative medicines vs. 5.6 months in patients using the medica-
tions], the overall survival [8.9 months vs. 12.2 months favoring use 
of alternative medications] was better in patients using alternative 
medicines, though the difference was not statistically significant.
Conclusion: The use of alternative medications especially canova 
method and use of tinosporium in adjunct to chemotherapy leads 
to improvement in quality of life. It warrants further studies, as the 
present sample size is inadequate to measure differences among 
various alternative medicines and an overall survival advantage of 3 
months. 
P1.143 NSCLC Advanced Disease, Sat Aug 1 
Pemetrexed on brain metastasis from Non Small Cell Lung 
Cancer
Bearz, Alessandra1; Garassino, Isabella2; Tiseo, Marcello3; Caffo, 
Orazio4; Soto-Parra, Hector5; Boccalon, Massimo6; Talamini, 
Renato1; Santoro, Armando2; Marco, Bartolotti3; Berretta, 
Massimiliano1; Tirelli, Umberto1
1 CRO-IRCCS, Aviano, Aviano, Italy; 2 Istituto Clinico Humanitas-
IRCCS, Rozzano (MI), Milano, Italy; 3 General Hospital Parma, 
Parma, Italy; 4 General Hospital Trento, Trento, Italy; 5 Azienda 
Ospedaliera Garibaldi, Catania, Italy; 6 General Hospital 
Pordenone, Pordenone, Italy
Background: The reported incidence of brain metastases in patients 
affected by Non Small Cell Lung Cancer (NSCLC) ranges between 
20-40%, depending on whether autopsy, surgical or radiologic data is 
reviewed Optimal treatment for brain metastases is controversial, and 
the use of chemotherapy has been limited because of a presumed lack 
of effectiveness due to the blood-brain barrier. However a number of 
phase II study reported response rate ranging between 35 to 50% for 
the brain with cisplatin-containing combinations, while temozolamide 
remained ineffective. In particular we were interested to understand 
the role of Pemetrexed, upon brain metastases from NSCLC. To our 
knowledge, there are no data about any activity of Pemetrexed on 
cerebral metastases from NSCLC in the literature.
Patients and Methods: We analyzed data from patients affected by 
advanced NSCLC in stage IV, with radiological evidence of metasta-
sis at the central nervous system (CNS), and treated with Pemetrexed 
in second or further line of therapy. The diagnosis of CNS metastasis 
was done before the beginning of treatment with Pemetrexed for 
all of them; all the patients received Pemetrexed as second line of 
chemotherapy.
Results: From May 2005 and July 2008 we analysed 22 patients with 
advanced NSCLC and brain metastases from several Italian Institu-
tions. 11 patients never received cerebral radiotherapy and 11 patients 
received it before Pemetrexed and showed cerebral progression 
before starting therapy with Pemetrexed. Median age was 63 years 
(range 34-77), ECOG Performance Status was 0-1 for all of them, 
14 (64%) were male and 8 (36%) female. Three only patients (14%) 
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were affected by squamous-cell carcinoma, they mostly had adeno-
carcinoma (15, 68%), 4 patients had poorly differentiated carcinoma. 
Four patients had only cerebral metastases, mostly of them, 18 out of 
22 (82%) had both visceral and cerebral localizations. 
Treatment with Pemetrexed was well tolerated in all the patients. 
Median number of Pemetrexed cycles was 5 cycles per patient ( range 
2-10).
Overall response was as follows: 8 (36%) patients showed progres-
sive disease, 6 (27%) stable disease, 8 (36%) partial response; about 
cerebral response, we observed 7 patients (32%) with progressive 
disease, 10 (45%) and 5 patients (23%) with stable disease and partial 
response, respectively.
In particular all the patients, experiencing a clinical overall bene-
fit (SD or PR) from Pemetrexed, reported a benefit over cerebral 
metastases as well. Cerebral progressive disease was observed only in 
some of the patients not responders to Pemetrexed. 
Median overall survival was 10 months. The survival was calculated 
from the beginning of treatment with Pemetrexed to death or last 
follow-up visit.
Conclusion: We observed an interesting good response even on 
cerebral metastasis from NSCLC, suggesting that Pemetrexed may be 
an active and effective option on this metastatic 
localization.
P1.144 NSCLC Advanced Disease, Sat Aug 1 
Irinotecan and Cisplatin in advanced lung cancer - 
chemotherapy of the poor?
Behera, Digambar1; Jaiswal, Anand1; Singh, Navneet2; Saini, J K.1; 
Aggarwal, Ashutosh N.2; Aggarwal, Ritesh2; Gupta, Dheeraj2; Jindal, 
Surender K.2; Kapoor, Rakesh2; Sharma, S C.2; Mohanty, B K.3
1 LRS Institute of Tuberculosis and Respiratory Diseases, New Delhi, 
India; 2 Postgraduate Institute of MedicalEducation and Research, 
Chandigarh, India; 3 All India Institute of Medical Sciences, New 
Delhi, India
Although overall survival of lung cancer has not improved signifi-
cantly over the years, chemotherapy is one option in most cases. 
Cisplatin-based chemotherapy provides survival advantage & im-
prove symptoms and quality of life (BMJ 1995, Rinaldi M et al 2006) 
even in developing countries (Shajeem & Behera 2003). A number of 
new active drugs have been used, but cost factor is an important and 
perhaps the only constraint in resource limited countries. We have 
used a relatively cheaper drug combination of irinotecan and cisplatin 
in patients of advanced lung cancer (NSCLC and SCLC) and this is 
our further experience of this regimen. 
Irinotecan 70mg/m2, and cisplatin (60 mg/m2) were administered 
with proper hydration and anti-emetics every 28 days. There were 
320 histologically proven patients. 104 had small cell and 205 had 
non small lung cancer. 11 had positive malignant cells. Those who 
completed three or more cycles of chemotherapy were included for 
the data analysis (72 small cell and 147 non-small types). There were 
47 extensive and 25 limited stage small cell lung cancers. There were 
180 males (35 to 70 years; 39 females (age 44-66). Performance 
status ranged from 70 to 100 (Kornofsky). 86 patients received local 
radiotherapy of 20 to 50Gy. 26 completed 6 cycles, 142 completed 5 
cycles, 51 completed 4 cycles. The remaining received three cycles at 
the time of data analysis. Complete response was in 24 (10.9%) and 
partial in 52(23.7%). Lesions remained stable from 8 to 354 weeks 
(median - 29.5 weeks; for small cell- 34.5 weeks; non-small cell - 29 
weeks). At time of analysis; the median survival was 39+ weeks for 
those who completed five cycles. For others it was 27+ weeks and 
are still under follow up. 136 patients (62.1%) are surviving beyond 
6 months and 41 patients (18.7%) are alive beyond one year and 19 
patients (8.7%) are still alive after 2 years. 
103 patients gained weight during therapy with the mean increase of 
3.6 kg and 63 lost weight with a mean of 2.7 kg. Performance status 
improved in 108 and deteriorated in 53; in the remaining it was static. 
Side effects were minimal (alopecia, nausea, vomiting, diarrhea, skin 
changes and neuropathy) and not serious.
Irinotecan and cisplatin regimen is effective and well tolerated in pa-
tients with new, relapsed or refractory SCLC and NSCLC (Hong et al 
2006; Jeong et al 2006; Hino et al 2006, Kim et al 2008). A four-arm 
co-operative study reported that this combination has similar efficacy 
compared to other commonly used regimens (Ohe et al 2006). 
One of the important constraints of chemotherapy of lung cancer in 
developing countries is affordability of newer drugs. The cost of the 
drugs used in the present regimen is less than US$ 100. Thus, those 
who wish to take the advantage of chemotherapy, but could not afford 
high cost with taxanes/gemcitabine, irinotecan and cisplatin should 
be offered to them for improved survival. It seems to be the chemo-
therapy of the poor.
P1.145 NSCLC Advanced Disease, Sat Aug 1 
Assessing response to chemotherapy in advanced non small 
cell lung cancer (NSCLC): morphological or metabolic 
criteria?
Van Ruychevelt, Valérie; Garcia, Camilo; Paesmans, Marianne; 
Berghmans, Thierry; Meert, Anne-Pascale; Leclercq, Nathalie; 
Flamen, Patrick; Sculier, Jean-Paul
Institut Jules Bordet, Brussels, Belgium
Background: Fluorodeoxyglucose positron emission tomography 
coupled to computed tomography (FDG-PET-CT) is an effective im-
aging technique for assessing cTNM in NSCLC. However, little data 
are available about the predictive value of response assessment with 
FDG-PET-CT on further survival. Study objective was to explore 
different response assessments in relationship with patients survival 
(OS). Morphological response was assessed using WHO/RECIST 
criteria. Metabolic response was defined on the primary tumor using 
EORTC criteria (>25% reduction of the SUVmax in the absence of 
any new lesion) and on a whole-body basis (response requiring the 
same relative reduction for each lesion).
Methods: We retrospectively selected patients with advanced 
NSCLC who underwent both FDG-PET-CT and CT alone, before 
any treatment and after 3 chemotherapy cycles. The physicians who 
assessed response were blinded for patients outcome. The relation 
between response and further OS was analyzed through Cox regres-
sion models.
Results: Fifty-nine patients, diagnosed between 2004 and 2008, 
were included in the study (38M/21F, median age: 63 years, stage 
IIIA/IIIB/IV:3/15/41, adenocarcinoma:31). High concordance was 
found between WHO and RECIST criteria (kappa=0.97) while poor 
concordance between metabolic and morphological response was 
observed: kappa=0.25 and 0.15, respectively for T and whole-body 
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based criteria. Negative and positive predictive values of metabolic 
response for morphological response were 0.90 and 0.39 (T criteria), 
0.88 and 0.47 (whole-body criteria). Median further OS was 40 
weeks (44 deaths observed). The table below reports the distribution 
of response and the hazard ratios for OS:
Assessment 
 method
R/NR/PD HR for NR 
versus R
HR for NR/PD 
versus R
HR for PD versus 
R/NR
RECIST 17/37/5 0.79 (0.41-1.52) 0.89 (0.47-1.69) 3.01 (1.17-7.74)
Metabolic EORTC on T 38/10/10 0.99 (0.45-2.21) 1.00 (0.51-1.96) 2.85 (1.33-6.07)
Metabolic whole-
body criteria
30/19/10 1.40 (0.67-2.92) 1.41 (0.78-2.58) 2.85 (1.33-6.07)
Combined EORTC on T 
and RECIST
15/33/11 0.83 (0.41-1.69) 1.06 (0.54-2.06) 2.91 (1.40-6.09)
Combined whole 
body criteria and 
RECIST
10/38/11 0.80 (0.36-1.77) 0.99 (0.46-2.13 2.91 (1.40-6.09)
R=response, NR=non response excluding PD, PD=progressive disease
Conclusion: all methods allow to identify a subgroup of patients 
with PD and worse OS; however, we failed to identify a subgroup of 
responding patients with better prognosis. Due to patients selection 
and limited sample size, further research has to be conducted looking 
at identifying such a subgroup.
P1.146 NSCLC Advanced Disease, Sat Aug 1 
Gefitinib and erlotinib in advanced Non-small –Cell Lung 
Cancer (NSCLC) patients: a retrospective review from the 
Hospital Universitario Central de Asturias
Berros, Jose Pablo; Esteban, Emilio; Corral, Norberto; Crespo, 
Gillermo; Muriel, Carolina; Fernández.Sanmamed, Miguel; Pardo, 
Pablo; Izquierdo, Marta; Sierra, Marta; Losa, Raquel; Jimenez, Paula; 
Villanueva, Noemi
Hospital Universitario Central de Asturias, Oviedo, Spain
Background: Gefitinib (G) and erlotinib (E), both specific tyrosin 
kinase Inhibitors (TKIs) have demonstrated efficacy in second and 
third line treatment of patients with NSCLC. The aim of this study 
has been to report the experience of a single centre with the utiliza-
tion of these agents in an unselected population.
Methods: A retrospective analysis was carried out from August 2002 
to March 2008 of patients with advanced NSCLC treated with G or E. 
Criteria of response and toxicity were those recommended by OMS 
and Kaplan and Meier method for determination of median progres-
sion free (PFS) and overall survival (OS).
Results: 132 patients were treated with TKI (17 with Gefinitib and 
88 with Erlotinib). Patients treated with Gefitinib (G) received all 250 
mg/day and 150 mgs of median with Erlotinib(E) (50-150). Epidemi-
ological characteristics were as follow (G/E); median of age (55(38-
74)/60(37-80)), Karnosfky (70(50-100)/70(50-90)),lines of previous 
chemotherapy (2(1-3)/2(0-6)). Percentage of males (76/69), stage IV 
(88/89), never smokers (65/31) and non-squamous histology (88/78). 
Among 128 patients considered evaluable for activity, there were 
5,9% objective responses rate (ORR) in the G and 16,5% in E group 
with an additional 47% of disease stabilization with G and 36,5% 
with E group. The median PFS and overall survival with G were 71 
and 282 days, with E 90 and 206, respectively. Adnocarcinoma histol-
ogy and never smokers and development of rash were independent 
variables related longer PFS and OS but not with objective response.
The most important toxicities grade 1-2 were (G/E; %): rash (59/63), 
diarrhoea (18/21), pneumonitis (0/4) and grade 3-4 toxicities (0/20).
Dose reduction and/or delay of treatment were required in any pa-
tients with G and 18% with E. 
Conclusion: In this retrospective analysis the efficacy of G and E in 
terms of ORR survival have been confirmed in an unselected group 
of patients with advanced NSCLC. The TKI gefitinib seems to have 
similar efficacy but with a better profile of toxicity than erlotinib
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A cost effectiveness analysis of bevacizumab plus cisplatin 
and gemcitabine (BCG) compared with induction 
pemetrexed plus cisplatin (iPC) for the treatment of 
advanced or recurrent non-small cell cancer (NSCLC) in 
Germany
Bischoff, Helge1; Heigner, David2; Wiesner, Christof3; Walzer, 
Stefan4
1 Thoraxklinik Heidelberg GmbH, Heidelberg, Germany; 2 
Krankenhaus Grosshansdorf, Grosshansdorf, Germany; 3 Roche 
Pharma AG, Grenzach-Wyhlen, Germany; 4 F. Hoffmann-La Roche 
Pharmaceuticals AG, Basel, Switzerland
Background: Although new treatment options for advanced NSCLC 
offer improved survival over standard treatment with chemotherapy 
they must also offer value for money. Bevacizumab, a humanized 
monoclonal antibody directed against vascular endothelial growth 
factor has been shown to increase overall survival and time to 
progression in patients with advanced NSCLC when combined with 
chemotherapy compared with chemotherapy alone. Pemetrexed, an 
inhibitor of thymidylate synthase has shown non-inferiority over 
cisplatin plus gemcitabine. The aim of this study was to evaluate the 
cost-effectiveness of BCG compared with iPC in Germany. 
Methods: A Markov model was used to evaluate the average costs 
and benefits of treating patients with advanced or recurrent NSCLC 
with either BCG or IPC. The patient characteristics of an average 
German hospital patient were applied. The model assumes patients 
move from pre-progressive to progressed disease to death, according 
to a set of transition probabilities derived from the respective pivotal 
trials and appropriate indirect comparison methodology. Drug costs 
assume underlying chemotherapy (CG and PC) is given for up to 6 
cycles, but that bevacizumab is administered until progression or un-
acceptable toxicity. The model estimates average survival, PFS, drug, 
administration and progression costs per patient treated with either 
BCG or iPC and the incremental cost-effectiveness ratio (ICER). 
Results: BCG treatment resulted in a mean survival of 1.51 vs. 1.31 
years with iPC with a mean PFS of 0.75 vs. 0.54 years, respectively. 
The mean total costs per month of treatment for the base case analy-
sis were €6,476 compared with €6,637 respectively, a difference of 
€161 per patient. Reduction in the cost of gemcitabine by 30% and 
50% increased the monthly mean cost difference between BCG and 
iPC to €986 and €1,537 per patient respectively. 
Conclusions: BCG triplet therapy offers greater clinical benefits than 
doublet iPC therapy at a lower overall cost. This suggests that the 
addition of bevacizumab to cisplatin and gemcitabine is dominating 
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iPC in the treatment of patients with advanced NSCLC in Germany. 
Furthermore, the overall cost of BCG is likely to reduce even further 
following the patent expiry of gemcitabine in 2009, providing poten-
tial further cost savings for the German health care system. 
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Health-related quality of life (HRQOL) with sunitinib (SU) 
as maintenance therapy for locally advanced or metastatic 
non-small cell lung cancer (NSCLC) 
Blais, Normand1; Torigoe, Yasuhiro2; Luo, Yingchun2; Wei, Greg 
C.3; Cappelleri, Joseph C.4; Kim, Sindy T.3; Chao, Richard3; Goss, 
Glenwood5
1 Höpital Notre-Dame du CHUM, Montreal, QC, Canada; 2 Pfizer 
Global Outcomes Research, New London, CT, USA; 3 Pfizer 
Oncology, La Jolla, CA, USA; 4 Pfizer Oncology, Groton, CT, USA; 5 
The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
Background: SU is an oral, multitargeted tyrosine kinase inhibitor 
of VEGFRs, PDGFRs, KIT, RET, CSF-1R, and FLT3. An open-label, 
multicenter, phase II study was conducted in patients (pts) with stage 
IIIB/IV NSCLC investigating SU as maintenance therapy follow-
ing first-line treatment with carboplatin (C)/paclitaxel (P). We report 
HRQOL data during the SU maintenance period from this trial.
Methods: HRQOL was assessed with the EORTC QLQ-C30 and 
QLQ-LC13 in this study. Pts were treated with P (175-225 mg/m2) 
plus C (AUC=6 mg•min/mL) for 4 cycles followed by SU mainten-
ance monotherapy (50 mg/d in 6-wk cycles: 4 wks on treatment, 2 
wks off). Questionnaires were completed on days 1 and 28 of each 
6-wk SU cycle. Long-term SU effect on global quality of life (GQL), 
functioning, and symptom scales were examined with mean change 
from baseline compared with day 1 of each 6-wk SU cycle. Short-
term effect of SU was examined with mean change during “on” treat-
ment period compared with “off” treatment period using paired t-tests 
with cycle 1 data.
Results: A total of 84 pts received C/P, and 66 pts received SU 
maintenance therapy. The data were available for 66 pts for assess-
ment of long-term effect and 29 pts for short-term effect. Long-term 
improvements were observed in GQL at cycle 4 (+7.5 points), fatigue 
at cycles 4 (-11) and 7 (-18.5), and insomnia at cycle 4 (-20). Worsen-
ing symptoms included diarrhea at cycles 2 (+15.2) and 3 (+24.4) 
and sore mouth at cycle 2 (+12.4). Statistically significant improve-
ments were observed with peripheral neuropathy and alopecia due to 
cessation of C/P in nearly all visits. Short-term worsening HRQOL 
included GQL (-2.4), diarrhea (+2.2) and sore mouth (+3.2) and 
improvements included cognitive functioning (+2.4), constipation 
(-2.1) and arm and shoulder pain (-2.3). All results reported are 
significant (p<0.05).
Conclusions: While this study reported increases in some treatment-
related symptoms, switching to SU after C/P chemotherapy leads to 
a long-term improvement in overall quality of life and functioning. 
In addition, patient-reported pain improved during SU treatment. SU 
maintenance therapy may offer an important treatment option for pts 
with advanced NSCLC. 
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Potential benefit with erlotinib (E) in patients with 
advanced non-small cell lung cancer (NSCLC) after first-
line treatment with a cetuximab containing regimen (C)
Borghaei, Hossein1; Ruth, Karen J.1; Tuttle, holly1; Cohen, Roger1; 
Langer, Corey2; Simon, George1
1 Fox Chase Cancer Center, Philadelphia, PA, USA; 2 University of 
Pennsylvania, Philadelphia, PA, USA
Introduction: We have previously reported the result of a phase II 
clinical trial utilizing carboplatin, paclitaxel and cetuximab as first-
line treatment of 53 patients with advanced NSCLC (Borghaei, et. al. 
JTO, 2008). We now report follow up of a subgroup of this cohort of 
patients who received E after progression.
Methods: Fifteen patients (9 female) received E post study at a dose 
of 150mg/d until progression. Patients were followed with CT Scans 
every 2 to 3 months. Treatment dates were estimated when the actual 
dates were unavailable. Kaplan-Meier methods were used to estimate 
median time on treatment and survival. 
Results: Nine, five and one patient(s) received E as second, third 
and fifth line treatment, respectively. Eleven of these 15 patients 
subsequently died of their disease. Four are still alive with dates of 
last follow-up between July 2008 and January 2009; of these, one is 
still receiving erlotinib. For the 14 patients who are no longer on E, 
the median length of treatment was 2.6 months (range: 1.0 to 18.6 
months). The one patient who remains on this agent has been on it 
for 10.8 months. Overall, for all 15 patients, the median time from 
the start of E to end of E was 2.7 months. E was started for PD on the 
C trial for two patients, as a second line treatment for seven patients, 
and beyond second line for six patients; median time on treatment 
was 2.8, 3.5 and 1.7 months respectively (logrank p=0.24). Female 
patients remained on E longer, with a median duration of 3.5 months 
compared to men with a median duration of 2.0 months (log rank p= 
0.02). Median survival (MS) for the entire group was 12.9 months 
from the start of E. Survival trended better for patients who had 
initially responded (CR or PR) to C (9 patients; MS of 14.6 months), 
compared to patients who had stable disease (3 patients; MS of 8.0 
months, p=0.06) Survival also trended better for women vs men: 12.9 
vs 5.4 months (log rank p= 0.13). 
Conclusion: E has potential activity in patients treated with a C 
containing regimen first-line. Female patients and patients who previ-
ously responded to a C containing regimen are more likely to benefit 
from subsequent treatment with E with respect to PFS and MS. 
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Phase II study of Bevacizumab and Erlotinib in treatment-
naïve elderly patients (> 70 years of age) with advanced 
Non-Small Cell Lung Cancer (NSCLC)
Borghaei, Hossein1; Mehra, Ranee1; Millenson, Michael1; Tuttle, 
Holly1; Ruth, Karen J.1; Magdelinski, Anthony2; Mintzer, David3; 
Simon, George1; Langer, Corey4
1 Fox Chase Cancer Center, Philadelphia, PA, USA; 2 Grand 
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Background: The median age of NSCLC in the United Stages is 71 
and hence more than 50% of the patients will be 70 years of age or 
older. The elderly are under represented in clinical trials and typically 
constitute only about 20% of patients accrued. As compared to their 
younger counterparts, the ‘fit elderly’ (PS 0-1) derive the same level 
of benefit from systemic therapy but tend to have a lower tolerance 
for drug toxicities. Innovative treatment strategies with favourable 
toxicity profiles are, therefore, needed. This study explores the ef-
ficacy and tolerance of an ‘all-biologic’ therapy in treatment-naïve 
elderly patients with advanced NSCLC. 
Methods: Fit elderly patients (>70 years of age) with treatment-
naïve stage IV or IIIB (with malignant pleural effusion (MPE)) 
disease were treated with standard dose erlotinib (150 mg/day) and 
bevacizumab (15 mg/kg Q 3 weeks) in 21 day cycles. Progression 
Free Survival was the primary endpoint. Secondary endpoints were 
overall survival (OS) and response rate. Quality of Life was also 
assessed using the FACT-L scale and data were collected at baseline 
and at the end of every other cycle of therapy (e.g., cycle 3 day 1, 
cycle 5 day 1, etc.). CT imaging was obtained after every two cycles. 
EGFR status was not required for enrollment but, when possible, was 
determined. Observed drug related grade 3 and 4 adverse events were 
documented. 
Results: To date 14 evaluable patients (9 female) have been enrolled. 
Median age is 78 (range: 71-84). Eight patients have ECOG per-
formance status of 1. Four patients have stage MPE+ IIIB disease. 
Kaplan-Meier estimate of median time from starting therapy to going 
off protocol is four months (95% confidence interval = 1.5-6.7). Of 
the 12 patients now off protocol, the median number of cycles is 4.5 
(range: 1-20). Two patients are currently on protocol, at 19 and 24 
cycles (57 and 72 wks). Drug-related grade 3(G3) and 4(G4) toxici-
ties include hypertension (G3: 3 patients), fatigue (G3: 1 patient), 
rash (G3: 1 patient), diarrhea (1 G3 and 1 G4) and 1 G3 anorexia. 
Four patients had a partial response as their best response with three 
of them being confirmed. Three additional patients had stable disease 
and four patients had progressive disease. The response status of 
three additional patients is still pending. The Kaplan Meier estimate 
of the median time to progression for the entire population is 4.8 
months (95% confidence interval is 1.5 to 14.9 months). Updated 
response and PFS data will be presented at the meeting. 
Conclusion: On preliminary analyses, treatment with erlotinib and 
bevacizumab appears efficacious in the first line management of 
elderly patients with advanced NSCLC and is well tolerated. 
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Preliminary results of a phase II trial of Docetaxel (D) and 
Gemcitabine (G) in advanced Non-Small Cell Lung Cancer 
(NSCLC) in elderly and/or unfit patients (PTS)
Buffoni, Lucio; Grillo, Raffaella; Barone, Carla; Dongiovanni, 
Diego; Gaspari, Fabio; Giacobino, Alice; Consito, Lorena; Ciuffreda, 
Libero; Schena, Marina
Medical Oncology S. Giovanni Battista Hospital, Turin, Italy
Background: Recent trials have demonstrated efficacy of chemother-
apy (CT) in elderly pts (defined as age > 70) affected by NSCLC. The 
risks and benefits of CT in pts with poor PS (=2) have been poorly 
defined as the better schedule in pts affected by severe cardiopathy. 
We conducted a phase II study of D/G administered in a every two-
weeks schedule. 
Methods: Eligibility included: chemonaive pts with stage IIIA/IIIB 
(pleural effusion or N3)/IV, age ≥ 70 yrs and/or controindication to 
cisplatin due to cardiopathy and/or PS 2. Pts received D 40 mg/m2 
plus G 1500 mg/m2 on day 1 every 15 days. Responders and stable 
pts continued up to 10 administrations. Intermediate radiological 
evaluation was executed after first 5 administrations.
IADL/ADL evaluation was conducted at the bseline and at the end of 
the study while QoL was tested every two cycles.
Results: From april 2008 and February 2009 we enrolled 29 pts. 
  N(%)
 Males/females 7/20 (26%-74%)
 Median age 74 (52-76)
 Stage IIIA/IIIB/IV 3/9/15 (11%-32%-54%)
 PS 0-1/2 22/5 (80%-20%)
 Cardio 16 (60%)
28 pts were evaluable for efficacy. CR+PR in 13 pts (46%), SD in 
7 pts (25%) and PD in 5 pts (18%). 2 pts discontinued CT due to 
woresening of PS. Whitin the responders 1 pt underwent surgery after 
5 cycles and 3 pts received radiotherapy sequentially to CT.
No dose adjustment were required and no CT interruptions occurred 
due to haematological toxicity. No grade 3/4 ANC and PLTS were 
observed, while only 3 pts experienced grade 3 anemia. Considering 
non-hematological toxicity the main 3/4 toxicities were alopecia 
(37%); fatigue (22%); oncolisis (11%).
Conclusions: Preliminary data suggest that the combination of D 
and G administered every 15 days is a very safe schedule with very 
low toxicity profile both in elderly pts ± cardiopathy and poor PS. 
The efficacy was also very interesting considering the 46% of overall 
response rate which is absolutely comparable to cisplatin-based 
schedules.
QoL improvement was demonstrated on the majority of pts who 
underwent CT and ADL/IADL evaluation proved real impact on pts 
selection. Further data on QoL improvement and correlation between 
ERCC1 expression-histology and CT efficacy will be presented.
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Survival of advanced lung adenocarcinoma patients 
and report of the first epidermal growth factor receptor 
mutations recognized in Colombia (ONCOLGroup study)
Cardona, Andrés F.1; Otero, Jorge M.2; Reveiz, Ludovic3; Campo, 
Felipe4; Carranza, Hernán 2; Vargas, Carlos A.2; Reguart, Noemí5; 
Cuello, Muricio 6; Sánchez, Oswaldo7; Castro, Carlos2
1 Catalan Institute of Oncology, Barcelona, Spain; 2 Clinical 
Oncology Group, Fundación Santa Fe de Bogotá, Bogotá, Colombia; 
3 Clinical Research Institute, Sanitas University Foundation, Bogotá, 
Colombia; 4 Thoracic Medicine Department, Hospital Clínico 
Lozano Blesa, Zaragoza, Spain; 5 Medical Oncology Department, 
Hospital Clinic, Barcelona, Spain; 6 Medical Oncology Department, 
Hospital Dexeus, Barcelona, Spain; 7 Clinical Oncology Group, 
Centro Javeriano de Oncología, Hospital Universitario San Ignacio, 
Bogotá, Colombia
Introduction: The incidence of lung adenocarcinoma increased by 
100% since 1950.
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Methods: This study included 147 advanced lung adenocarcinoma 
(ALA) patients treated in Bogotá between 2000 and 2007. Overall re-
sponse rates (ORR), clinical benefit (CB), time to progression (TTP) 
and overall survival (OS) were estimated. EGFR mutations were 
studied in a subgroup of patients.
Results: Mean age was 66±12.8 years. Seventy-eight patients were 
women, 40% had never been exposed to tobacco smoke and perform-
ance status (PS) was ≥ 70% in 119 patients. The brain was the domin-
ant site for metastasis followed by the lungs. Sixty-nine percent of the 
patients received a platinum doublet as first-line intervention and 32 
patients (22%) had received erlotinib as part of their treatment. Re-
sponse to first-line treatment was available in 110 patients; ORR was 
28%, CB 39% and TTP 3.7 months (0.6-18.2). Second-line therapy 
was administered to 46 patients; ORR was 8%, CB 25% and TTP 3.7 
months (2.1-17). Median OS was 9.8 months (6.3-19) and the PS, ab-
sence of tobacco exposure, and administration of erlotinib, positively 
influenced this outcome. EGFR mutational profile was assessed in 
10 highly-selected patients; four presented mutations in exon (E) 19 
(two patients had a 3 serine-rich nucleotide insertion (L747_S750) 
which has not been previously reported) and two presented the E21 
mutation (L858R). For this subgroup, ORR to erlotinib was 85% and 
in 5 cases the survival was greater than 16-months.
Conclusions: Outcomes for patients suffering from ALA in Colom-
bia are similar to those described in other Latin American countries. 
Six patients with EGFR alterations were identified in this cohort.
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Assessment of pharmacokinetic (PK) interactions between 
Carboplatin (C), Paclitaxel (P) and ABT-869 in patients 
with advanced or metastatic non-small cell lung cancer 
(NSCLC)
Gupta, Neeraj; Palaparthy, Rameshraja; Awni, Walid; Carlson, Dawn; 
Pradhan, Rajendra 
Abbott Laboratories, Abbott Park, IL, USA
Background: ABT-869 is a novel orally active, potent and selective 
inhibitor of vascular endothelial growth factor and platelet derived 
growth factor receptor tyrosine kinases. Preclinically, ABT-869 
potentiates the action of C and P in a number of tumor models (eg 
breast carcinoma and NSCLC tumors) and may enhance the clinical 
activity of C and P in NSCLC patients. This study was conducted to 
determine the clinical efficacy and toxicity of ABT-869 in combina-
tion with C and P in the treatment of patients with NSCLC.
Methods: This is a phase 2 randomized, placebo-controlled, double-
blinded study of C and P in combination with ABT-869 versus C and 
P alone in patients with advanced or metastatic NSCLC. We are con-
ducting an open-label, lead-in cohort of 6-12 patients to assess the PK 
interaction of the combination of 0.2 mg/kg ABT-869 administered 
orally once daily on Day 3 of Cycle 1, with C (6 mg/mL/min) and 
P (200 mg/m2) administered on Day 1 of every 21-day cycle. Blood 
samples were collected after administration of C, P and ABT-869 as a 
single agent and after concomitant administration of ABT-869, C and 
P. For C, the samples were analyzed for total platinum. Maximum 
observed plasma concentration (Cmax) and area under the concen-
tration-time curve from 0-24 h (AUC24) were determined by the 
standard non-compartmental analysis using WinnonLin software ver-
sion 5.2. Dose normalization (DN) of PK parameters were performed 
by dividing Cmax and AUC2¬4 values by actual administered dose 
of ABT-869, C and P. DN ratio of 1.0 for ABT-869 signifies no effect 
of C and P on ABT-869 exposure.
Results: PK data are available from 4 patients. Baseline character-
istics were: M (N=3)/F (N=1); mean age 72 years (range 69-74); 
mean weight 74 kg (57-93). The following table provides the ratio of 
DN Cmax and AUC when the drugs were administered alone or in 
combination. 
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Wood-smoke exposure (WSE) as a predictor of response 
and survival in erlotinib-treated advanced lung 
adenocarcinoma (ALA) patients (pts) (ONCOLGroup 
study)
Otero, Jorge M.2; Cardona, Andrés F.1; Carranza, Hernán 2; Vargas, 
Carlos A.2; Sánchez, Oswaldo3; Reveiz, Ludovic4; Campo, Felipe5; 
Cuello, Muricio 6; Reguart, Noemí7; Castro, Carlos2
1 Catalan Institute of Oncology, Barcelona, Spain; 2 Clinical 
Oncology Group, Fundación Santa Fe de Bogotá, Bogotá, Colombia; 
3 Clinical Oncology Group, Centro Javeriano de Oncología, Hospital 
Universitario San Ignacio, Bogotá, Colombia; 4 Clinical Research 
Institute, Sanitas University Foundation, Bogotá, Colombia; 5 
Thoracic Medicine Department, Hospital Clínico Lozano Blesa, 
Zaragoza, Spain; 6 Medical Oncology Department, Hospital Dexeus, 
Barcelona, Spain; 7 Medical Oncology Department, Hospital Clinic, 
Barcelona, Spain
Background: There is consistent information suggesting that 
long-term WSE constitutes a risk factor for lung cancer. More than 
50 years of WSE was associated with non-small cell lung cancer 
(NSCLC). In Colombia the prevalence of WSE in areas having less 
economic development is approximately 24%. The aim of the study 
was to evaluate WSE as a predictor of response and survival in ALA 
pts. 
Methods: This study included 168 pts with ALA treated between 
2002 and 2007 in four referring hospitals of Bogotá. Retrospectively, 
we estimated overall response rates (ORR), time to progression 
(TTP) and overall survival (OS) in a subgroup of pts with signifi-
cant WSE (exposure >5 years for at least 4 hours/day) treated with 
erlotinib, and compared them with the non-WSE population treated 
with the same compound. 
Results: Median age was 66 years (range, 29-96), 53% were female, 
39% had never been smokers, 24% of all cohort pts had been con-
siderably exposed to WS and 45 pts had received erlotinib during 
disease treatment (as 2nd or 3rd line). Sixteen of these pts (F11/M5, 
PS ≥70% 9 pts) had been exposed to WS and 29 not so (F17/M12, 
PS ≥70% 22 pts); 10 pts having WSE had been smoking for a mean 
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of 14pk/yr history. ORR to erlotinib was 7% and 32% in pts with and 
without WSE respectively (p = 0.02). TTP was significantly higher 
in pts treated with erlotinib with no history of WSE (4.9 mo. vs 1.7 
mo., p = 0.034). and in those who had received this compound as 
second-line (vs erlotinib used as third line, p = 0.044). Among pts 
with WSE history, OS was 6.6 mo. (range, 5.8-7.3) for those treated 
with Erlotinib and 12.7 mo. (range, 10.2-17) for those not treated 
with this compound (p = 0.04). Multivariate analysis was carried out 
for determining the factors influencing mortality between pts with 
WSE; only PS (HR: 4.6, 95%CI: 1.2-29, p = 0.050) and gender (HR: 
3.6, 95%CI: 2.7-18, p = 0.036) were significant.
Conclusions: WSE was associated with a poorer response and sur-
vival in ALA pts treated with Erlotinib in Colombia.
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A cost effectiveness analysis of bevacizumab plus cisplatin 
and gemcitabine (BCG) versus cetuximab plus vinorelbine 
and cisplatin (CVC) in patients with advanced or recurrent 
non-small cell cancer (NSCLC) in Spain
Castro Carpeno, Javier d.3; Castro Gomez, Antonio J.1; Walzer, 
Stefan2
1 Roche Farma S.A., Madrid, Spain; 2 F. Hoffmann-La Roche 
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Background: New treatment options for advanced NSCLC can offer 
improved survival over standard treatment with chemotherapy (CT). 
However, they should also offer value for money. Bevacizumab 
(BEV), a humanized monoclonal antibody (MAb) directed against 
vascular endothelial growth factor has been shown to increase overall 
survival and time to progression in patients with advanced NSCLC 
when combined with CT compared with CT alone. Cetuximab 
(CTX), an IgG1 MAb which targets the epidermal growth factor re-
ceptor has also improved outcomes in these patients when combined 
with CT and marketing authorization is expected in 2009. The aim 
of this study was to compare the costs and outcomes associated with 
treating patients with BCG or CVC in Spain. 
Methods: A Markov model was used to compare costs and outcomes 
associated with treating patients with advanced or recurrent NSCLC 
with either BCG or CVC. The model assumes patients move from 
pre-progressive to progressed disease then to death, according to a set 
of transition probabilities derived from an indirect comparison of the 
efficacy of BCG and CVC in terms of progression-free survival (PFS) 
using data from the respective pivotal trials and appropriate indirect 
comparison methodology. Cost data were derived from local sources. 
Drug costs assumed CT was given for up to 6 cycles, that CTX was 
administered at an initial dose of 400 mg/m² followed by 250 mg/m² 
weekly until progression and that BEV was administered at 7.5 mg/
kg until progression. The model estimated average survival, PFS, 
drug and administration costs and total costs per patient treated with 
either BCG or CVC. 
Results: BCG treatment results in a mean survival of 1.51 years 
versus 1.38 years with CVC. Both drug and administration costs 
were lower with BCG than CVC and the mean total cost per patient 
treated with BCG was less costly than CVC, (€33,153 vs. €40,700 
respectively).
Conclusions: BCG, when compared with CVC, gives a greater clin-
ical benefit and is less costly. Therefore, BCG is dominant over CVC 
and should be considered to be the target therapy of choice for the 
treatment of patients with advanced NSCLC. 
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Survival outcome of gefitinib antitumor activity in Asian 
chemonaive patients with advanced nonsmall cell lung 
cancer. A study from India
Chandra, Anita; Martin, Jovitha P.
SRI Ramachandra Medical College and Research Institute, Chennai, 
India
Recently, gefitinib was documented to be more effective in an Asian 
population, as well. Chemonaive patients had higher response rates 
than chemotherapy-treated patients in previous analyses of Asian 
patients with advanced nonsmall cell lung cancer. The survival out-
come and the predictors for antitumor activity in chemonaive patients 
who received gefitinib as first-line treatment are unclear. Thus, we 
performed pilot study of gefitinib trial in Indian patients to assess the 
efficacy of of this regimen as there is paucity data in this population. 
Methods: Clinicopathologic predictive factors, objective tumour 
responses, and the survival of consecutive patients with advanced, 
chemonaive nonsmall cell lung cancer who received gefitinib as first-
line treatment were collected and analyzed. Treatment consisted of 
gefitinib 250 mg one tablet daily until disease progression with plat-
inum based combination chemotherapy and concurrent radiotherapy. 
Results: 10 patients were enrolled from July 2008 to December 2004. 
Gefitinib was first-line treatment in all. All patients were evaluable 
for toxicity profile and response rate. After 6 months of treatment, 3 
patients had a complete response (CR) and six had a partial response 
(PR), and one with progressive disease. All treatment-related toxici-
ties were few and mild in severity. All patients suffered from skin 
toxicity like acne form rashes. The median time to disease progres-
sion was > 10 months, and the median survival was > 12 months. 
The one-year survival rate was 90%. Survival was also better in 
those who demonstrated disease control using gefitinib (CR, PR, and 
stable disease) than in those who did not. 9 males and 1 females were 
analyzed. 
Conclusions: The daily gefitinib with combined modality treatment 
has high activity, is well tolerated, and provides very good survival in 
India NSCLC patients who have newly diagnosed disease, especially 
in those who responded to gefitinib treatment. A further phase III 
prospective study comparing gefitinib to standard chemotherapy to 
define the efficacy of gefitinib is appropriate in advanced NSCLC 
patients is needed.
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Number of Chemotherapy cycles in Non Small Cell Lung 
Cancer; are four sufficient or are six better?
Chandra, Subhash1; Singh, Vikas1; Agarwal, Dipti2; Mohan, Anant1; 
Guleria, Randeep1
1 Departemtn of Medicine, All India Institute of Medical Sciences, 
New Delhi, India; 2 Mayo Clinic, Rochester, MN, USA
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Background: Chemotherapy (CT) is an important therapeutic 
modality for lung cancer but has high toxicity profile and financial 
implications. There is no universal consensus regarding the optimum 
number of chemotherapy cycles to be administered in non small cell 
lung cancer (NSCLC). 
Objective: A retrospective comparison of clinical and radiological re-
sponse in NSCLC using treatment with 4 or 6 cycles of chemotherapy.
Methods: Treatment-naive patients who underwent chemotherapy for 
NSCLC during 2002 to 2008 were studied. They were administered 
4-6 cycles of CT with carboplatin - paclitaxel combination. Patients 
were evaluated at the end of 4 or 6 cycles using computed tomog-
raphy and clinical symptoms. Response was classified as complete 
remission (CR), partial remission (PR), stable disease (SD) and 
progressive disease (PD). Response could not assess in 9 patients.
Settings: Tertiary health care and academic center.
Results: Out of 68 patients [Male-56 (82.35%), mean (SD) age, 
56.95 (9.34) years], 37 (54.41%) received 4 cycles and 31 (45.59%) 
received 6 cycles of chemotherapy. 51 patients (75%) were smokers 
with median (range) smoking-pack-years of 26 (0.5 to 87.5). The 
effect of 4 and 6 cycles of chemotherapy on tumor size and symp-
toms is shown in Table-1 and 2 respectively. There was no signifi-
cant difference in tumor response to 6 cycles or 4 cycles (p = 0.37). 
Symptomatic response was higher after 6 cycles compared to 4 cycles 
of CT; however, this difference did not reach statistical significance. 
(p= 0.22).
Conclusion: This study demonstrates that six cycles of chemother-
apy does not improve symptoms or tumor regression significantly 
greater than that achieved by four cycles. Hence, it may be prudent to 
continue chemotherapy beyond four cycles only after considering risk 
of toxicity and cost-effectiveness for the patient.
 Response 4 Cycles 6 cycles
 Progression of Disease 12(34.29%) 8(33.33%)
 Stable Disease 11(31.43%) 9(37.50%)
 Partial remission 8(22.86%) 7(29.17)
 Complete remission 4(11.43%) 0(0%)
 Not assessed 2 7
 Total Assessed 35 24
 Symptomatic Improvement 4 Cycles 6 Cycles
 No Improvement 14 (37.84%) 5(19.23%) 
 <50% Improvement 13 (35.14%) 14(53.85%)
 >50% improvement 10(27.03%) 7(26.92%)
 Not assessed 0 5
 Total Assessed 37 26
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Cisplatin with attenuated dose of docetaxel in Thai 
patients with advanced or recurrent non-small cell lung 
cancer
Charoentum, Chaiyut; Tharavijitkul, Ekapong; Buranochokepaisarn, 
Manote; Chewasakulyong, Busayamas; Thongprasert, Sumitra 
Chiang Mai University, Chiang Mai, Thailand
Background: Doublet platinum with taxanes regiemens are among 
the most active regimen in patients with advanced non-small cell lung 
cancer (NSCLC). Previous reports showed that Asian population ex-
perienced more hematologic toxicities but achieved higher response 
to this doublet. We therefore tested this doublet regimen with attenu-
ated dose of docetaxel in Thai patients with NSCLC.
Patients and Methods: Chemo-naïve stage IIIB with malignant 
effusion and stage IV NSCLC patients with measurable disease were 
included. These patients received cisplatin at 75 mg/m2 and attenu-
ated dose of docetaxel at 60 mg/m2 on day 1, in 3-week cycle for a 
maximum of 6 cycles. 
Results: From December 2006 - December 2008, 26 patients were 
included. There were 18 males and 8 females with a median age of 
55 years (range 32-74) and the median performance status was 1. The 
majority of patients had adenocarcinoma histology (77%). Eighty 
five percents had stage IV disease. 104 cycles of chemotherapy were 
given. Nine patients obtained a partial response (35%) while 11 
(42%) patients and 6 (23%) patients had SD and PD respectively. 
Grade 3 diarrhea occurred in 3 patients (12%). Febrile neutropenia 
occurred in 1 patient (4%). There was no treatment-related death. 
Other toxicities were generally mild including gr 2 anemia (15%), gr 
2 edema (8%), gr 2 hypersensitivity reaction (4%) and mild mu-
cositis. The median time to tumor progression was 9 months (range 
1 – 13+).
Conclusion: Doublet cisplatin with attenuated dose of docetaxel is an 
active regimen in Thai patients with advanced NSCLC. The overall 
toxicities are manageable.
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Comparison of single agent docetaxel and pemetrexed plus 
oxaliplatin combination agent as second-line treatment in 
advanced non-small cell lung cancer
Chen, Zhiwei; Chen, Yurong; Lu, Shun
Chest Hospital Affiliated to Shanghai Jiaotong University, Shanghai, 
China
Purpose: To determine efficacy and toxicity of docetaxel or 
pemetrexed plus oxaliplatin regimens as second-line treatment in pa-
tients with locally advanced or metastatic non–small cell lung cancer. 
Experimental Design: Patients had histologic or cytologic confirma-
tion of locally advanced or metastatic NSCLC (stage IIIB or IV) were 
enrolled this study. Patients were assigned to receive pemetrexed 
500 mg/m2 plus oxaliplatin 120 mg/m2 (PemOx) or docetaxel 120 
mg/m2. All drugs were given on day 1 of a 21-day cycle for up to 4 
cycles. Folic acid and vitamin B12 were given to PemOx patients. 
The exact binomial method was used to determine the 95% CI for 
tumor response rate estimates. Time-to-event efficacy variables were 
estimated using the Kaplan-Meier Method.
Results: Twenty patients received PemOx and twenty received 
docetaxel. Objective tumor response rates were 10% for both groups. 
Disease control rates (DCR) were 75% for PemOx patients and 60% 
for docetaxel patients (P>0.05). Median progression-free survival 
time (PFS) was 4.9 (95% CI 3.8 to 6.5) and 3.0 months (95% CI 2.5 
to 4.8), respectively, for PemOx and docetaxel (P=0.03) . Common 
toxicity criteria grade 3 or 4 toxicities among PemOx patients were 
grade 3 fatigue (30%), grade 3 rash (10%)and grade 3 neurosensory 
toxicity(5%). Docetaxel patients experienced grade 3 or 4 neutro-
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penia (35%), grade 3 thrombocytopenia (10%) and grade 3 fatigues 
(20%). 
Conclusions: The pemetrexed plus oxaliplatin doublet maybe a safe 
and active combination. Comparing to standard second-line therapies 
in a large randomized trial is warranted
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Randomized phase II trial of pemetrexed versus gefitinib 
in previously treated non-small cell lung cancer: 
preliminary results
Cho, Eun Kyung; Kyung, Sun Young; Sym, Sun Jin; Kim, Yujin; Lee, 
Sang Pyo; Park, Jeong Woong; Jung, Sung Hwan; Park, Jinny; Shin, 
Dong Bok; Lee, Jae Hoon 
Gachon University Gil Hospital, Inchon, Korea
Background Interest: established non-inferior survival of gefitinib 
compared with docetaxel for pretreated patients with advanced non-
small cell lung cancer. This randomized phase II trial is to compare 
the efficacy and safty of pemetrexed versus gefitinib in patients with 
previously treated locally advanced or metastatic non-small cell lung 
cancer. 
Methods: Eligible patents had a performance status 0 to 2, previous 
treatment with one prior chemotherapy regimen for advanced non-
small cell lung cancer, and adequate organ function. Patients received 
pemetrexed 500mg/m2 intravenously day 1 with vitamin B12, folic 
acid and dexamethasone every 3 weeks or gefitinib 250mg per day 
orally. The primary end point was progression free survival. 
Results: Tweenty-seven patients were randomly assigned. Four of 
14 patients in pemetrexed group and 2 of 13 in gefitinib had stable 
disease, One patient have partial response in gefitinib group. Median 
progression free survival was 1.9 versus 3.5 months (P=.751) and 
median survival time was 8.1 versus 7.9 months (P=.574) for pe-
metrexed and gefitinib, respectively. Toxicity was mild and tolerable 
in both. The most common adverse events were anorexia (75% vs 
58%) and fatigue (58% vs 50%) for pemetrexed versus gefitinib, 
respectively. Rash or acne (58% vs 16%) was more in gefitinib. 
Conclusions: This preliminary results showed that treatment with 
gefitinib could have clinically equivalaent efficacy compared with 
pemetrexed in the pretreated patients with advanced non-small cell 
lung cancer. Each regimen had a mild manageable toxicity. The ac-
crual is ongoing. 
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Sunitinib combined with pemetrexed and carboplatin 
in patients with NSCLC and other advanced solid 
malignancies: maximum tolerated dose and safety results
Chow, Laura QM1; Blais, Normand2; Jonker, Derek J.1; Soulières, 
Denis3; Laurie, Scott A.1; Diab, Sami G.4; Ruiz-Garcia, Ana5; Thall, 
Aron5; Chao, Richard5; Eckhardt, S. Gail6; Camidge, D. Ross6
1 The Ottawa Hospital Cancer Center, Ottawa, ON, Canada; 2 
Höpital Notre-Dame du CHUM, Montreal, QC, Canada; 3 Höpital 
Notre-Dame du CHUM, Montreal, QC, Canada; 4 Rocky Mountain 
Cancer Centers, Aurora, CO, USA; 5 Pfizer Oncology, La Jolla, CA, 
USA; 6 University of Colorado Cancer Center, Aurora, CO, USA
Background: Sunitinib malate (SU) is an oral multitargeted tyrosine 
kinase inhibitor of VEGFRs, PDGFRs, KIT, FLT3, CSF-1R and RET, 
approved multinationally for the treatment of advanced RCC and 
imatinib-resistant/intolerant GIST. Nonclinical data from NSCLC 
xenograft models suggest that antitumor activity is enhanced by the 
addition of SU to pemetrexed (Pem). The maximum tolerated dose 
(MTD) of SU with Pem was established to be SU 37.5 mg/day plus 
Pem 500 mg/m2 q21d. Additional patients are being studied on a SU 
with Pem and carboplatin (Carbo) dosing regimen. The MTD and 
safety of the triple combination in patients with NSCLC and other 
advanced solid malignancies are reported here.
Methods: Patients in successive dose-escalation cohorts received 
oral SU (37.5 to 50 mg) either daily on the continuous daily dose 
(CDD) schedule or for 2 wks of a 3 wk cycle on Schedule 2/1, with 
Pem at 400–500 mg/m2 IV q21d and Carbo at AUC=5 mg•min/mL 
IV q21d. The MTD was defined as the highest dose at which 0/3 or 
≤1/6 patients had dose-limiting toxicity (DLT) during the first 22 days 
of treatment. Safety, pharmacokinetic (PK) profiles, and objective 
response were also evaluated. 
Results: As of October 2008, 16 patients with advanced solid malig-
nancies (NSCLC n=4) received SU plus Pem/Carbo (n=3 on CDD 
schedule; n=13 on Schedule 2/1). The MTD on the CDD schedule 
was not determined as 2 of 3 patients developed DLTs in the first 
CDD cohort (SU 37.5 mg plus Pem 400 mg/m2 plus Carbo AUC=5 
mg•min/mL). One subject had grade (G) 3 hand–foot syndrome and 
another subject had G4 neutropenia and G3 anorexia. On Schedule 
2/1, the MTD was determined to be SU 37.5 mg plus Pem 500 mg/
m2 plus Carbo with 1/6 subjects developing a DLT (G4 neutropenia). 
Two patients developed DLTs (G4 neutropenia [2/6]) at the next high-
er dose of SU 50 mg plus Pem 500 mg/m2 plus Carbo. The most fre-
quent non-hematologic AEs for patients on all schedules of the triple 
combination were fatigue, nausea, constipation, diarrhea, dysgeusia 
and anorexia. G3/4 hematological AEs in all SU/Pem/Carbo cohorts, 
were neutropenia (50%), thrombocytopenia (31%) and anemia (19%). 
2/16 (13%) patients had G3 febrile neutropenia. No significant drug–
drug interactions were identified on the SU/Pem arm; PK data for 
the SU plus Pem/Carbo arm are being investigated. On Schedule 2/1 
partial responses (PR; 8 weeks duration) were observed in 1 pt with 
NSCLC at the MTD of the triple combination and in 2 pts at the next 
higher dose escalation (gastric carcinoma and NSCLC). Stable dis-
ease (≥12 weeks) occurred in 4 patients: malignant thymoma, gastric 
carcinoma, prostate cancer and NSCLC (each n=1).
Conclusions: On Schedule 2/1, the triple combination of SU/Pem/
Carbo was well tolerated and the MTD was determined as SU 37.5 
mg/day plus Pem 500 mg/m2 q21d plus Carbo AUC=5 mg•min/mL 
q21d. One PR was observed in a patient on Schedule 2/1 at the MTD; 
the triple combination is undergoing further study in NSCLC and 
mesothelioma patients and updated information on tolerability and 
efficacy will be presented.
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Phase II study of Docetaxel (D) and Carboplatin (C) 
combination in advanced Non-Small Cell Lung Cancer 
(NSCLC)
Chowdhury, Qamruzzaman1; Begum, Ferdous A.1; Nahar, Ferdous2; 
Fairuz, Saima2; Faruqui, Mesba3
1 National Institue Of Cancer Research & Hospital, Dhaka, 
Bangladesh; 2 Square Hospital, 18/F West Panthapath, Dhaka, 
Bangladesh; 3 sanofi-aventis 6/2/a segun bagicha, Dhaka, 
Bangladesh
Purpose: To evaluate the efficacy and safety profile of the combina-
tion of D with C as front-line treatment of chemotherapy- naive 
patients with advanced NSCLC. 
Methods & Patients: Twenty-three pts (21 males) fulfilling the 
following inclusion criteria were enrolled: chemotherapy-naive with 
bidimentionally measurable disease, good performance status (PS: 
0-2), stage IIIb/IV, without brain metastases, and adequate hemato-
logical, hepatic and renal function. 
Results: The median age was 65 years, stage IIIb (n=1), IV (n=22); 
squamous cell carcinoma (n=8), adenocarcinoma (n=9), large cell 
carcinoma (n=1), undifferentiated (n=5). D (100 mg/m2) was given 
on day 1 followed by C (AUC-6). The cycles were repeated every 
3 weeks for six cycles. So far, 23 pts are evaluable for toxicity and 
20 for response. One CR (5%), 7 PR (35%), 6 SD (30%) and 6 PD 
(30%). The overall response rate was 40% (95% C.I 8.53%-61.47%). 
The median duration of response was 4months and the median TTP 
was 8 months. The median survival was 11.5 months. A total of 115 
cycles of chemotherapy were delivered. The toxicity was as follows: 
neutropenia grade III in 4pts (17%) and grade IV in 8pts (34%), no 
grade III or IV thrombocytopenia, 4 episodes of febrile neutropenia 
but without treatment-related death. Grade 2 diarrhea occurred in 
3 pts (13%), grade 2 neurotoxicity in 2 (8%), grade 2 asthenia in 4 
(17%) and moderate fluid retention syndrome in 3 (13%). 
Conclusions: These preliminary results suggest that the D&C 
combination is a well tolerated and active front-line regimen for the 
treatment of advanced NSCLC. 
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Clinical experience of gemcitabine and carboplatinum or 
gemcitabine and cisplatinum in advanced Non-Small Cell 
Lung Cancer (StageIIIB)
Chowdhury, Qamruzzaman1; Naher, Ferdousi2; Fairuz, Saima2; 
Begum, Ferdous A.1; Nazim Uddin, Mirza2
1 NICRH,Mohakhali, Dhaka, Bangladesh; 2 Square hospital Ltd, 
Dhaka, Bangladesh
Purpose: To evaluate the clinical benefit and safety profile of 
combination therapy using gemcitabine and carboplatinum or Gem-
citabine and cisplatinum in stage IIIb Non-Small Cell Lung Cancer 
cases in our institution.
Methods: Between 2007 and 2008 forty three patients clinic-
ally diagnosed as stage IIIB non-small cell lung cancer with good 
performance status( ECOG:PS 0-2) having adequate hematological, 
renal and hepatic functions has been randomized into arm A compris-
ing gemcitabine(1000mg/m2 D1, D8) and Carboplatinum (AUC-5 on 
D1) and Arm B comprising gemcitabine (1000mg/m2 D1, D8) and 
Cisplatinum (75mg/m2 on D1).The treatment cycles were repeated 
every three weeks.
Results: Twenty two cases in Arm A and twenty one cases in Arm 
B with a median age of 50 years were treated with combination 
therapy with adequate hydration and premedication. A total of 198 
cycles of chemotherapy distributed between the two arms during the 
whole treatment period. A maximum of 6courses were given. All the 
patients were included for evaluation regarding clinical response and 
toxicity.
Analysis of result showed one complete response (4.5%), 11 partial 
response (50%), 4 stable disease (18.18%) in armA. Arm B showed 
two complete response ( 9.5 %),12 partial response (57.1%) and 5 
stable disease (23.80%).Median duration of response was 4.5months 
and time to tumour progression(TTP) was 6.5 months in Arm-A and 
5 months and 6.5 months in Arm-B respectively. GradeIII neutopenia 
in 3(13.6%)cases and 2(9.52%)cases was noted in Arm-A and Arm-B 
respectively. There was no treatment related death.
Conclusion: This preliminary study with limited number of cases 
clearly proved that gemcitabine and cisplatinum combination is the 
platinum of choice to treat advanced nonsmall cell lung cancer with 
effective tumour control having least toxicity.
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Divided administration low dose of docetaxel is safe and 
efficient as standard dose of pemetrexed in advanced 
NSCLC (Stage IIIb/IV) fails previous treatment
Chung, Fu-Tsai; Lee, Kang-Yuan; Fang, Yueh-Fu; Hsieh, Meng-
Heng; Chen, Hao-Cheng; Yu, Chih-Teng; Kuo, Han-Pin
Chang Gung Memorial Hospital, Chang Gung University, College of 
Medicine, Taipei, Taiwan
Objective: The aim was to determine and compare the divided 
administration low dose of docetaxel use to standard pemetrexed use 
in advanced non-small cell lung cancer (NSCLC) patients who failed 
previous chemotherapy.
Methods: We retrospectively analyzed data from our institute and ad-
dressed the efficacy and toxicity of divided administration low dose 
of docetaxel (30mg/m2, on day 1 and 8 every 3 weeks) to standard 
dose of pemetrexed (500mg/m2, tri-weekly) in these subjects.
Results: From 2005 to 2008, 179 patients were included (docetaxel, 
79, and pemetrexed, 100). Overall disease control rates significantly 
favored docetaxel over pemetrexed (50.6 % vs. 36.0%; p= 0.03). The 
median progression-free survival time with docetaxel was significant-
ly longer than with pemetrexed (4.0 months vs. 2.4 months; hazard 
ratio, 0.64; 95% CI, 0.47 to 0.87; p= 0.005). The median overall 
survival time with docetaxel was also significantly longer than with 
pemetrexed (15 months vs. 8.5 months; hazard ratio, 0.54; 95% 
CI, 0.38 to 0.77; p= 0.0006). One-year survival rates were 51.9% 
and 31% for docetaxel and pemetrexed, respectively. There was 
no significant difference of both hematologic and non-hematologic 
toxicities in each group.
Conclusions: Our data supported efficacy and safety of divided ad-
ministration low dose docetaxel in advanced NSCLC failed previous 
treatment and was non-inferior to standard dose of pemetrexed.
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A phase II first line study of gemcitabine, carboplatin and 
bevacizumab in advanced stage non-squamous non-small 
cell lung cancer
Clement-Duchene, Christelle1; Krupitskaya, Yelena1; Ganjoo, 
Kristen2; Lavori, Philip1; Kumar, Atul1; Zhao, Gary3; Padda, 
Sukhami1; San Pedro-Salcedo, Melanie1; Wakelee, Heather1
1 Stanford University, Stanford, CA, USA; 2 Veterans Administration, 
Palo Alto, CA, USA; 3 Santa Clara Valley Medical Center, San Jose, 
CA, USA
Background: Bevacizumab improves response rate and progres-
sion free survival when added to first line paclitaxel/carboplatin or 
cisplatin/gemcitabine for patients with advanced non squamous non 
small cell lung cancer (NSq-NSCLC). Gemcitabine/carboplatin has 
equivalent efficacy to paclitaxel/carboplatin with a different toxicity 
profile, including decreased risk of hypersensitivity reaction, de-
creased neuropathy and decreased alopecia, but increased myelosup-
pression. This study was designed to evaluate toxicities and adverse 
events of gemcitabine/carboplatin/bevacizumab and to estimate event 
free and overall survival with the regimen.
Methods: Patients with untreated advanced NSq-NSCLC, with good 
performance status, not on anticoagulation and with no evidence of 
cerebral metastases were eligible. Patients received gemcitabine 1000 
mg/m2 on days 1, 8; carboplatin AUC 5 day 1; and bevacizumab 15 
mg/kg day 1 every 3 weeks for up to 6 cycles. Bevacizumab was then 
continued every 3 weeks until disease progression or unacceptable 
toxicity. Chemotherapy dose reductions were mandated for signifi-
cant cytopenias. Imaging was every 2 cycles with measurements per 
RECIST criteria.
Results: From July 2006 to December 2008, accrual was completed 
with 48 patients enrolled: 23 (48%) men, 19 (40%) never smokers, 
median age 59 years (35-81). One patient died prior to receiving 
therapy and is not included in the analysis. Median cycle number 
is 6 (0-39). To date, 37 patients (78.7%) completed > 4 cycles of 3 
drugs. Dose reductions occurred in 31 (66%) of patients. Grade 3/4 
adverse events included: neutropenia (47%/17%), thrombocytopenia 
(11%/15%), and anemia (6%/0%). No patients were hospitalized 
for neutropenic fever. Grade 3/4 non-hematologic adverse events 
included dyspnea (6%/2%), bacterial pneumonia (4%/0) hyperten-
sion (4%/2%), 1 grade 3 wound dehiscence, 1 grade 4 myocardial 
infarction, 1 grade 3 transaminitis and hyperbilirubinemia, 1 grade 3 
proteinuria and 1 grade 3 leucocyturia. One patient died from hemop-
tysis with untreated aspergillosis found post-mortem. Other bleeding 
included one case each with grade 3 epistaxis, hemorrhoidal bleeding 
and ecchymosis. Common grade 1/2 adverse events included fatigue, 
hypertension, anemia, constipation, nausea, headaches, transaminitis 
and epistaxis. In 45 evaluable patients: we saw 7 (17%) partial re-
sponses, and 34 (74%) stable disease at first follow-up. 44/47 patients 
were followed for a median of 10.5 months. Median time to first 
event (progression/death/toxicity requiring discontinuation) was 6.4 
months [95%CI 4.6-8.6 months]. 21/47 (44.7%) patients have died 
with median overall survival not reached but preliminarily estimated 
at 16.7 months [95%CI 13.4 months-inf]. Estimated overall survival 
is 73% at 1 year and 32% at 2 years.
Conclusions: Treatment with gemcitabine/carboplatin/bevacizumab 
has an acceptable toxicity profile with promising median overall 
survival despite a low response rate and frequent dose reductions in a 
population with a high proportion of non-smokers and women. 
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Erlotinib as maintenance therapy after platinun-based 
chemotherapy in advanced non-small-cell lung cancer 
(NSCLC): a phase II trial
Cobo, Manuel1; Barneto, Isidoro2; Bernabé, Reyes3; Valdivia, Javier4; 
Fernández, Inmaculada5; Villatoro, Rosa6; Belón, Joaquín7; Rueda, 
Antonio8; de la Cruz, Luis9
1 Hospital Carlos Haya, Málaga, Spain; 2 Hospital Reina Sofía, 
Cordoba, Spain; 3 Hospital N S Valme, Sevilla, Spain; 4 Hospital 
Virgen de las Nieves, Granada, Spain; 5 Hospital de Jerez, Jerez de la 
Frontera, Spain; 6 Hospital Costa del Sol, Marbella, Málaga, Spain; 
7 H.D. Oncogranada, Granada, Spain; 8 Hospital Puerta del Mar, 
Cádiz, Spain; 9 H. V. Macarena, Sevilla, Spain
Background: We conducted this prospective phase II trial to evalu-
ate the efficacy and toxicity of the sequential therapy of erlotinib in 
advanced NSCLC patients (pts) without progression after platinum-
based chemotherapy (CT) .
Methods: Eligibility criteria: advanced NSCLC, Performance status 
(PS) 0 or 1, adequate renal, hepatic and bone marrow function, no 
progressive disease after ending chemotherapy. Treatment consisted 
on: erlotinib 150 mg/day starting 3-4 weeks after last day of CT until 
progression or unacceptable toxicity. Safety was evaluated monthly 
and tumor evaluation was performed bimonthly.
Results: 47 pts were enrolled, 42 (89%) stage IV and 5 (11%) wet 
stage IIIB, all valid for response and toxicity. The median age was 62 
years (range:39 -77) with 39 (83%) males and 8 (17%) females. His-
tology subtypes: adenocarcinoma 28 pts (61.7%), bronquioloalveo-
lar 3 pts (6.4%), large cell 3 pts (6.4%) and squamous cell 12 pts 
(25.5%). PS 0 was found in 23 pts (49%) and PS 1 in 24 pts (51%). 
38 pts (81.9%) completed at least six cycles of chemotherapy. The 
response to CT was: CR: 1 pt (2.1%), PR: 24 pts (51.1%), ED: 22 pts 
(46%). Sequential erlotinib improved response in 6 pts (12.8%), in 23 
pts (48.9) prolonged stabilization, and 18 pts (38.3%) had progres-
sion. The median time to progression (TTP) and survival (OS) were 
9.4 months (m) (95% CI, 4.96-13-84), and 19.23 m (95% CI, 8.82-
29.64) respectively. No significant differences in TTP were found 
according to age, sex, PS, histology or previous response to chemo-
therapy, but yes depending on response to erlotinib: PR: 31.5 m (95% 
CI 15.37-47.63), EE: 12.8 m (95% CI, 10.58-15.03), Progression: 6.3 
m (95% CI, 5.36-7.3), p < 0.001; and moreover depending on smok-
ing status: Never: 21.67 m(95% CI, 5.39-37.94), previous smoker > 5 
years: 14.03 m(95% CI, 10.77-17.30), previous smoker 1 year: 7.77 
m(95% CI, 7.62-7.91), current smoker: 5.9 m(95% CI, 5.12-6.34), p 
<0.001. In Cox-regression model, again smoking status ( p< 0.001), 
and response to erlotinib (p=0.002) were associated with a significant 
difference in TTP. Very similar results respect OS, although in Cox-
regression model only never smoker or more than 5 years previous 
smoker patients had a significant better survival. Toxicity: The most 
frequent side effect was skin rash, grade (g) 1 in 11 pts (23.4%), g 2 
in 16 pts (34%) and g 3 in 3 pts (6.4%). Only 1 pt had diarrea g 3, and 
no other significant side effects were observed. We found a significant 
benefit in pts with g 2-3 skin toxicity respect those with g 0-1, in both 
TTP( p= 0.0003) and OS (p= 0.0014).
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Conclusion: Erlotinib administered as maintenance therapy after 
platinum-based CT had promising results. Pts with the best benefit 
were those with response to erlotinib, in never or past (more than 
5 years) smokers and with g 2-3 skin toxicity. Results of SATURN 
randomized study will show us definitive data. 
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Heterogeneity of response to tyrosine kinase inhibitors 
between primary tumors and matched metastases in Non-
Small-Cell Lung Cancers
Cortot, Alexis B.2, 4; Duruisseaux, Michael2; Arpin, Dominique3; 
Perrot, Emilie2; Gérinière, Laurence2; Perol, Maurice3; Souquet, 
Pierre-Jean2
1 Lowe Center for Thoracic Oncology - Dana Farber Camcer 
Institute, Boston, MA, USA; 2 Department of Pulmonary Diseases 
- Centre Hospitalier Lyon Sud, Lyon, France; 3 Department of 
Pulmonary Diseases - Hôpital de la Croix-Rousse, Lyon, France; 4 
International Agency for Research on Cancer, Lyon, France
Background: EGFR activating mutations and gene amplification 
are associated with sensitivity of Non-Small-Cell Lung Cancers 
(NSCLC) to the EGFR tyrosine kinase inhibitors (TKI) erlotinib and 
gefitinib, whereas KRAS mutations are associated with resistance to 
these drugs. However, recent data show that EGFR and KRAS status 
may differ between primary NSCLC and matched metastases. These 
results raise the question of homogeneity in the response to TKI 
among the different tumor sites within a single patient.
Methods: We performed a multi-center retrospective analysis of 
metastatic NSCLC patients treated with TKI, with at least two 
measurable target lesions in two different involved organs, evaluated 
either by CT scan or by Magnetic Resonance Imaging. Response to 
TKI was reported separately for primary tumors and main measurable 
metastatic lesions, before TKI treatment, at the time of best response 
(according to RECIST criteria), and at the time of relapse, and ana-
lyzed with respect to the tumor sites.
Results: Among 238 patients treated with TKI between December 
2003 and November 2007, 172 were excluded of the study because 
of non-measurable disease (n=52), early death (before first evalua-
tion, n=45), local or systemic treatment associated to TKI (n=19), or 
unavailable data (n=56). Among the remaining 66 patients included 
in the study, median age was 58.2 years (range 33-86), 57% were 
male, 30% were never-smokers, 68% had adenocarcinoma, and 92% 
had received erlotinib (8% had received gefitinib). TKI was given 
as a first- or second-line treatment in 51% of patients. Best response 
was observed within an average of 5.3 weeks (range 1.8-18.9) after 
introducing TKI. Objective Response (OR), Stable Disease (SD) 
and Progressive Disease (PD) were observed in primary tumors and 
matched biggest metastases in 15%, 59%, 26% and 20%, 46%, 34% 
respectively. Response was different between primary tumors and 
matched metastases in 38% of patients. A truly dissociated response 
was observed in only one patient in whom primary tumor resulted in 
OR whereas liver metastase resulted in PD. Median time to progres-
sion was 8.3 weeks (95%CI: 7.3-11.1) and median overall survival 
time was 24.7 weeks (95%CI: 16.6-31.5). Among patients whose re-
lapse was due to the appearance of one or more new lesions, 60% of 
the primary tumors and initial metastatic lesions were still controlled 
(OR or SD) at the time of relapse.
Conclusion: Sensitivity to TKI may differ among tumor sites in a 
single patient. If these results are confirmed in further studies, we 
believe that decision to withhold or withdraw TKI should take into 
account this heterogeneity.
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NSCLC in never smokers: treatment outcome: a single 
institution experience
Crinò, Lucio; Minotti, Vincenzo; Meacci, Marialuisa; Betti, Maura; 
Molica, Carmen; Ludovini, Vienna; Pistola, Lorenza; Tofanetti, 
Francesca R.; Flacco, Antonella; Chiari, Rita
Department of Medical Oncology, S Maria della Misericordia 
Hospital, Perugia, Italy
Background: Although most lung cancers are a result of smoking, 
approximately 25% of lung cancer cases worldwide are not attribut-
able to tobacco use, accounting for over 300,000 deaths each year. 
Striking differences in the epidemiological, clinical and molecular 
characteristics of lung cancers arising in never smokers versus smok-
ers have been identified, suggesting that they are separate entities. 
Methods: We report the data of never smokers NSCLC patients (pts) 
of a single institution experience enrolled from July 2005 to Decem-
ber 2008. Genomic DNA was isolated from paraffin-embedded tumor 
specimens, amplified for EGFR (exons 18, 19, 20 and 21), KRAS 
(exon 2) by nested polymerase chain reaction and sequenced in both 
sense and antisense directions. RECIST criteria were used to assess 
response to treatment .
Results: 51 of 250 (20,4%) pts with stage IIIB (12 pts) and IV (39 
pts) NSCLC treated at our centre were never smokers. Median age 
was 61.7 years (range 31-84), F/M: 33/18, ECOG PS 0-1/2: 49/2, 
adeno/squamous/not otherwise specified NSCLC: 40/2/9. Nine of 34 
pts (26.5%) were mutated at the EGFR gene: 5 in exon 19 (delE746-
A750), 1 in exon 20 (dupl770 insASV) and 3 in exon 21(missense 
L858R). None of the EGFR mutated pts carried a KRAS mutation. 
Only one pt had KRAS mutation (G12V) and he did not respond 
to tyrosine kinase inhibitor (TKI) treatment. Brain metastases were 
diagnosed in 9 of 39 pts (23.1%) having stage IV disease with 6 of 
them being positive at diagnosis. All patients received first line treat-
ment which has been a platinum-based doublet chemotherapy in 42 
pts (82.4%), gemcitabine monochemotherapy in 6 pts (11.7%) and 
first-line (TKI) in 3 pts (5.9%). Response to first line chemotherapy 
was as follows: 18 (37.5%) stable disease (SD), 19 (39.5%) partial 
response (RP) and 11 (22.9%) progressive disease (PD). 39 of 51 
pts (76.4%) received a small molecule TKI either as second or third 
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line of treatment and 34 of them were evaluable for response. We ob-
served complete response (RC) in 2 pts (5.8%), RP in 15 (44.1%), SD 
in 12 (35.2%), and PD in 5 (14.7%) with a disease control exceeding 
80 %. Among the 3 pts receiving fist-line TKI treatment, 1 progressed 
very quickly while the other 2 obtained SD. 27 of 51 pts (52.9%) 
received a second line of chemotherapy with a carboplatin doublet 
including pemetrexed in 16 pts and a monochemotherapy with either 
pemetrexed (8) or taxotere (3) in the remaining 11. Response to 
second line chemotherapy was evaluable in 24 of 27 pts and was as 
follows: 8 RP, 6 SD, 10 PD. 
At a median follow-up of 18.5 months, 33.3 % (17/51 pts) of the 
population died. Median estimated PFS was of 7.7 months (95% CI 
4.1 - 11.3 months).
Conclusions: Our data appear to be in line with those that have pre-
viously been reported. Never-smokers in whom NSCLC develops are 
more likely to be young, female, and almost exclusively of adeno-
carcinoma histology. Never-smokers might have a better prognosis 
both in terms of PFS and OS respective to smokers NSCLC pts.
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EGFR, KRAS, PIK3CA mutations and response to 
tyrosine kinase inhibitors (TKIs) in advanced NSCLC 
patients
Ludovini, Vienna1; Bianconi, Fortunato2; Pistola, Lorenza 1; Chiari, 
Rita1; Minotti, Vincenzo1; Colella, Renato3; Mameli, Maria G.3; 
Giuffrida, Dario4; Tofanetti, Francesca R.1; Flacco, Antonella1; 
Cavaliere, Antonio3; Crinò, Lucio1
1 Department of Medical Oncology, S Maria della Misericordia 
Hospital, Perugia, Italy; 2 Department of Electronic and Information 
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Pathological Anatomy and Histology, Division of Cancer Research, 
Perugia University, Perugia, Italy; 4 Medical Oncology, Istituto 
Oncologico del Mediterraneo, Catania, Italy
Background: Molecular alterations of the EGFR pathway are 
considered the major determinant of clinical outcome in response to 
EGFR TKIs in non small cell lung cancer (NSCLC) patients (pts).The 
aim of this study was to determine the clinical implication of EGFR, 
KRAS, PIK3CA gene mutations in pts with advanced NSCLC who 
had been treated with gefitinib or erlotinib after failure of 1st or 2nd-
line platinum-based chemotherapy. 
Methods: Genomic DNA was isolated from paraffin-embedded 
tumor specimens, amplified for EGFR (exons 18, 19, 20 and 21), 
PIK3CA (exons 9 and 20) KRAS (exon 2) by nested polymerase 
chain reaction and sequenced in both sense and antisense directions. 
RECIST criteria were used to assess response to TKIs. 
Results: One hundred twenty-eight pts have been treated with TKIs. 
Median age was 60 yrs (range 25-81.5), M/F: 71/57, ECOG-PS 
0/1/2/3: 82/39/6/1; stage IIIB/IV: 36/92; adeno/bac/squamous/large-
cells/other: 82/10/25/3/8; never/former/current smokers:43/28/46. 
EGFR mutations were detected in 32 of 122 pts (25%); 20 (16.4%) 
had deletional mutations in exon 19, 6 (4.7%) had point mutations 
in exon 20 and 6 (4.7%) in exon 21. One pt had two mutations (exon 
19:delE746-A750, exon 20:missense mutation T790M). KRAS 
and PIK3CA mutations were detected in 5.7% and in 2.7% of pts, 
respectively. Overall, pts with EGFR mutations had a response rate 
(RR) of 58.4% vs 19.7% (p=0.001), disease control rate of 74.2% vs 
49.4% (p=0.02) median time to progression of 8 months vs 3 months 
(p=0.06), with respect to EGFR non mutated pts. No difference in 
overall median survival was observed. However when we considered 
25 pts with TKI-sensitive EGFR mutations (deletion in exon 19, 
missense L858R) we observed a significant longer TTP (p=0.008, 
median 8 vs 3 months in non mutants) and a better OS (p=0.07, 
median not reached vs 11 months in non mutants). In this setting the 
RR was 88% (22 of 25) and TTP was significantly better also in the 
multivariate analysis (p=0.03). All pts with KRAS mutations did not 
responded to TKIs treatment as the pts with PIK3CA mutations. 
Conclusions: In this experience we confirmed that EGFR muta-
tions (deletion in exon 19, missense L858R) are the most important 
predictor of TKI sensitivity. In addition the evaluation of KRAS and 
PIK3CA mutations could contribute to identify lung cancer patients 
who are most suitable for TKIs treatment.
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An incremental cost–consequence analysis of bevacizumab 
plus cisplatin and gemcitabine (BCG) compared with 
induction pemetrexed plus cisplatin (PC) in patients with 
advanced or recurrent non-small cell cancer (NSCLC) in 
Italy
de Marinis, Filippo1; Grossi, Francesco1; Giuliani, Giovanni2; 
Aultman, Rick3
1 S. C. Oncologia Medica A, Genova, Italy; 2 Roche S. p. A., Monza, 
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Background: Although new treatment options for advanced NSCLC 
offer improved survival over standard treatment with chemotherapy 
(CT) they should also offer value for money. Bevacizumab (BEV), a 
humanized monoclonal antibody directed against vascular endothelial 
growth factor has been shown to increase time to progression in ad-
vanced NSCLC when combined with cisplatin plus gemcitabine (CG) 
compared with CG alone (AVAiL study). In the same population, 
pemetrexed (PMX), an inhibitor of thymidylate synthase, has shown 
non-inferiority over CG when combined with cisplatin. The aim of 
this study was to run a cost-consequence analysis of BCG compared 
with PC in Italy. 
Methods: A Markov model was used to evaluate the average costs 
and benefits of treating patients with advanced or recurrent NSCLC 
with either BCG or PC. The model assumed patients moved from 
pre-progressive to progressed disease to death, according to a set of 
transition probabilities derived from an indirect comparison of the 
efficacy of BCG and PC in terms of progression-free survival (PFS) 
using data from the respective pivotal trials and appropriate indirect 
comparison methodology. A common post progression survival risk 
was assumed. Drug costs assumed underlying chemotherapy (CG or 
PC) was given for up to 6 cycles and that BEV was administered at 
7.5 mg/kg until progression. The model determined average survival, 
PFS, drug and administration costs per patient treated with either 
BCG or PC. 
Results: BCG treatment results in average survival of 1.51 years 
compared with 1.31 years with PC. Mean PFS was 0.75 vs. 0.54 
years, respectively. The mean total costs per month of treatment per 
patient were €2,837 for BCG and €2,886 for PC; monthly drug costs 
were €2,686 for BCG and €2,819 for PC, while administration costs 
were €151 and € 66, respectively. 
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Conclusions: The analysis suggests that BCG could offer greater 
clinical benefits than PC with a comparable cost. This indicates that 
the addition of BEV to cisplatin and gemcitabine offers good value 
for money for the treatment of patients with advanced NSCLC in 
Italy. 
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Cisplatin (CDDP) plus oral vinorelbine (NVBO) as first-
line treatment for advanced non-small-cell lung cancer 
(NSCLC): prospective analysis to improve the patient’s 
convenience on day 8 NVBO administration
Domine, Manuel2; Sanchez, Alfredo3; Artal, Angel5; Constenla, 
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Provencio, Mariano10
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Background: Severe neutropenia observed during chemotherapy is 
a clinical finding leading to treatment modification and, sometimes, 
life-threatening events. The results of a previous study with 180 
patients (p) treated with IV vinorelbine plus CDDP as first-line treat-
ment for advanced NSCLC could lead to consider not performing 
a blood count prior to day 8 vinorelbine administration for patients 
aged 70 years (y) or less who presented a good haematological toler-
ability profile during previous cycles (cy) in order to improve treat-
ment convenience. The aim of this study is to prospectively validate 
these results with the combination of NVBO plus CDDP.
Methods: Between October 2007 and September 2008, 31 chemo-
naïve p with histologically confirmed stage IIIB/IV NSCLC were 
included. Treatment consisted of CDDP 75 mg/m2 day 1 plus NVBO 
80 mg/m2 days 1 and 8, with a prior test of myelosensitivity at 60 mg/
m2 for the first cycle, every 21 days. Patient’s characteristics were: 
Median age, 62 years (range 32-73); males, 93.5%; smokers, 38.7%; 
all PS 0-1; adenocarcinoma, 33.3% / squamous, 36.7%; stage IIIB, 
14.8% / IV, 85.2%.
Results: We analyzed 129 cy. NVBO administration on day 8 was 
cancelled in 3 cycles due to haematological events (2.3% [95% CI: 
0.4%-6.6%]. The reported events were: 1 grade-2 neutropenia, 1 
grade-4 neutropenia and 1 grade-2 thrombocytopenia. One case of 
febrile neutropenia was reported, but this event was observed prior 
to a NVBO day 8 administration. Toxicity was mild with neutropenia 
WHO grade 3-4 observed in 2.1% cy (9.7% p), leukopenia grade 
3 in 1.4% cy (6.5% p). Grade-3 fatigue was observed in 6 cy (6 p), 
grade-3 nausea in 2 cy (2 p) and grade-3 vomiting in 2 cy (2 p). 
Among 22 p evaluable for response, 10 p achieved partial response 
(overall response rate, 45.5% [95% CI: 24.4-67.8]). 
Conclusions: The findings of this study could lead to consider not 
performing a blood count prior to day 8 NVBO administration for 
patients aged 70 y or less who presented a good haematological 
tolerability profile during previous cycles in first-line treatment for 
advanced NSCLC. 
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Feasibility of administration of dose-dense pemetrexed 
given every two weeks in patients with advanced non-small 
cell lung cancer
Emmanouilides, Christos; Serpanou, Anastasia; Sapountzi, Evdoxia; 
Mantziari, Polyxeni; Philipou, Dimitrios
Interblalkan Hospital, Pylaia, Greece
Pemetrexed is a multitargeted folate pathway inhibitor with docu-
mented activity in non-small cell lung cancer (NSCLC). It has been 
approved at the presumed maximum tolerated dose of 500 mg/m2 
given every 3 weeks. However, the hematologic toxicity is greatly 
ameliorated when folate and B12 supplementation is provided and 
therefore higher dose intensity may be tolerated. The current explora-
tory study assesses the feasibility of administration of pemetrexed 
at a fixed dose of 1000 mg every 2 weeks in patients with relapsed 
or refractory NSCLC. The first cohort of 12 patients received pe-
metrexed meonotherapy; as no dose-limiting grade 4 toxicity was 
noted during the first phase, the subsequent cohort of 12 patients 
received additional anticancer agents (bevacizumab, erlotinib, 
carboplatin, docetaxel, vinorelbine) given along with dose-dense 
pemetrexed. Toxicity overall was reversible and manageable. Grade 
3-4 hematologic toxicity was noted in 10 out of 24 patients (45%; 
95% CI:26-64%) after a median of 4 cycles (range 1-12 cycles); for 
patients who received pemetrexed either alone or with non-myelo-
suppressive targeted agents, the incidence of grade 3-4 hematologic 
toxicity was 41% (95% CI: 21-61%), with only 2 instances of grade 
4 neutropenia in long-term treated patients. There was no signifi-
cant additional toxicity nor any treatment-related deaths. Thus, our 
preliminary observations indicate that dose-dense pemetrexed every 
2 weeks is feasible and this regimen may be a useful scaffold for 
combination studies. 
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Intravenous Topotecan in patients with advanced non-
small cell lung cancer pre-treatred with platinum and 
taxanes: Results of a phase II study
Esteban, Emilio; Berros, Jose Pablo; Crespo, Guillermo; Muriel, 
Carolina; Sanmamed, Miguel; Pardo, Pablo; Corral, Norberto; Sierra, 
Marta; Losa, Raquel; Fernández, Yolanda; Fra, Joaquin; Estrada, 
Enrique
Hospital Universitario Central de Asturias, Oviedo, Spain
Background: Topotecan, a semi-synthetic camptothecin analogue 
with topoisomerase I interaction has shown to be an active agent in 
the treatment of advanced refractory lung cancer and ovarian cancer. 
In this report, experience with this drug is described when used as a 
single agent in patients with advanced NSCLC refractory to chemo-
therapy regimens containing at least platinum and taxanes.
Methods: Patients with NSCLC refractory to previous chemotherapy 
including planitum and taxanes in first and/or subsequent lines of 
treatment and KI ≥ 60% were eligible for the study. Topotecan was 
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given at a dose of 1.25 mg/m2 I.V. daily for five days, repeated every 
21 days until progression disease or intolerable toxicity occurred. 
Efficacy and toxicity were assessed following OMS criteria. The 
Simon two-stage design and the Kaplan-Meier method ware applied 
to estimate activity and progression free survival (PFS) respectively. 
Results: Thirty four patients were included showing the following 
features: median age of 52 years (range 43-69) and karnofsky PS of 
70 (50-80), 26 were male and 8 female. Twenty-one (63 %) pts had 
adenocarcinoma, ten (25%) squamous cell and three (12%) undiffer-
entiated carcinoma. The median number of disease sites and prior 
regimens received were two in both cases. After 64 cycles adminis-
tered, patients received a median of 2 cycles of treatment (1-9). All 
patients except one were considered evaluable for toxicity, with the 
recording of five episodes of (15%) nausea/vomiting grade 1-2 and 
two (6%) of asthenia grade 1. Four (12%) patients developed anaemia 
grade 2-3 and neutropenia grade1. Three additional patients (9%) 
had neutropenia grade 2 and one (3%) grade V. Among 32 evaluable 
patients for activity, one (3%) showed partial response, nine (27%) 
stable disease and 23 (70%) progression disease. Median PFS was 52 
days (12-210).
Conclusion: Intravenous topotecan at that dose and schedule of 
administration has little activity in terms of response rate in third 
line of advanced NSCLC. The role and utility of chemotherapy in 
this setting warrants further investigation and confirmation through 
comparatives studies.
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A tolerance and pharmacodynamics/ pharmacokinetics 
study with modified 3 weeks regimen of Gemcitabine 
Plus Cisplatin in advanced Non-Small Cell Lung Cancer 
patients
Fan, Yun; Lin, Ming n.
Zhejiang Cancer Hospital, Hangzhou, China
Aim: To investigate the tolerance and pharmacodynamics/ pharma-
cokinetics of gemcitabine(dFdC) administered on days 1 and 5, plus 
cisplatin administered on day 1 in chemotherapy-naive patients with 
stage IIIB or IV non-small cell lung cancer (NSCLC). 
Methods: In each combination cycle, Gemcitabine was adminis-
tered at a dose of 1250mg/m2 as a 30 min intravenous(i.v.) infusion 
on day 1 and 5 followed by cisplatin at a dose of 75mg/m2 as a 3 
h i.v. infusion on day 1 every 3 weeks. An interval of 1 h between 
the two infusions was applied. Clinical response and toxicity of the 
regimen were monitored. In addition, the plasma concentration of 
gemcitabine and its metabolite(dFdU) were evaluated at different 
time intervals during the first cycle of treatment. PKS software was 
used to estimate the pharmacokinetic parameters of gemcitabine and 
its metabolite(dFdU). 
Results: A total of 28 patients were included in the study. Median 
age of the patients was 54 years (range 27–75) and most of the pa-
tients were in good clinical condition. 27 patients received 2 or more 
treatment cycles. The overall clinical response rate was 33.3%. The 
median overall survival time was 13 months, the estimated median 
time to tumor progression(TTP) was 6.2 months and the one-year 
survival rate was 55.6%. The main regimen toxicity noticed was 
myelosuppression, 35.7% of the patients had grade 3/4 hematologic 
toxicities. 28.6% had grade 3/4 non-hematologic toxicities, which 
were in general GI related .The pharmacokinetic parameters of dFdC 
and dFdU showed no difference in statistics after gemcitabine was 
administered on days 1 and 5. Minimal residue of dFdU was seen 
(0.729 ± 0.637ug/ml) before gemcitabine was infused on day 5, 
whereas gemcitabine didn’t have any detectable residue. 
Conclusion: This modified 3 weeks regimen is effective and well-
tolerated in chemotherapy-naive patients with stage IIIB or IV non-
small cell lung cancer (NSCLC). After gemcitabine was administered 
on days 1 and 5, the pharmacokinetic parameters of dFdC and dFdU 
showed no difference in statistics. Minimal residue of dFdU was 
noted before gemcitabine was administered on day 5.
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A resrospective analysis of efficacy of cytotoxic agents in 
patients with EGFR mutation positive Non-small cell lung 
cancer
Fujii, Tomoki; Naoki, Katsuhiko; Tsujimura, Shuko; Hida, Naoya; 
Kunikane, Hiroshi; Okamoto, Hiroaki; Watanabe, Koshirou
Department of Thoracic Oncology,Yokohama Municipal Citizen’s 
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Background: There were some evidences of subgroup analysis in 
randomized phase Ⅲ trials in East Asia that both response rate and 
survival in patients receiving cytotoxic agents with EGFR mutation 
positive (M+) non-small cell lung cancer (NSCLC) were superior 
than that in mutation negative (M-) patients. However these were not 
confirmed completely until now. 
Methods: From March 2007 to February 2009, patients with ad-
vanced NSCLC were analyzed about EGFR mutation, who agreed 
with the test. The timing of the test was heterogeneous among the 
patients. We have analyzed the characteristics and the relationship 
between the EGFR status and response or survival. EGFR muta-
tions were screened with PCR invader assay which was previously 
reported by us at 2008 ESMO conference. 
Results: Fifty-one patients with stage IIIB/IV NSCLC were analyzed 
in this study and the patient characteristics and main results were as 
follows; 
Conclusions: Although excellent efficacy of EGFR-TKI in M+ 
patients was found in this retrospective analysis, we failed to show 
the statistical superiority of the response and survival of M+ patients 
over M- patients when administered with cytotoxic agents. Large 
scale prospective studies are warranted to search for the relationship 
between upfront EGFR mutation status and efficacy with cytotoxic 
agents. 
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patients with postoperative recurrent Non-small Cell Lung 
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Background: At the present time, there is no standard treatment or 
defined guideline for the patients with postoperative recurrence. In 
general clinical practice, gefitinib (Gef) treatment in similar fashion 
of certain chemotherapy regimens for NSCLC has already became 
a treatment option in recurrent patients after surgery as well as in 
inoperable advanced patients in Japan. We believe that this new 
treatment modality should also be evaluated by population-based 
studies. In this study, we review the patient characteristics, response 
to therapy, toxicity and survival of recurrent NSCLC patients treated 
with Gef who received surgical resection previously.
Methods: This retrospective population-based study included 
patients with NSCLC who had received Gef at 14 institutions in the 
province Ibaraki Prefecture (population of 3 million) between Jul. 
2002 and Sep. 2007. Eligible patients were identified in the clinical 
database in each hospital and the following information extracted 
from their data: patient demographics at the Gef therapy (age, gender, 
smoking history, histology, stage, EGFR mutation) and objective 
tumor response. 
Results: The data were obtained from 141 pts with NSCLC. Forty 
eight pts had recurrence at local site (34.0%) and 93 pts had distant 
metastasis (66.0%). Median follow-up period after Gef treatment was 
9 mo. (1-60 mo.). Median age was 65 years (range 33-86) and 54.6% 
of pts were female, 68.1% had PS 0-1, 85.8% had AD, and 48.9% 
were non-smoker. The ORR to Gef therapy was 46.5% (53CR+PR, 
36 SD, 25 PD, 27 NE). Higher responses were documented in fe-
males compared with males with AD of either non-smoker or smoker 
(43.6% vs. 40.0% in non-smoker, 43.8% vs. 31.6% in smoker). The 
MST was 12.0 mo. and one- and two-year survival was 48.9% and 
28.9%, respectively. The MST was 19.0 mo. for female, and 9.0 mo. 
for male (P=0.002). Not only female gender but also AD, PS0-1 and 
no smoking history were favorable prognostic factors in univari-
ate analysis. The MST was 10.0, 16.0, and 9.0 mo. for the patients 
who received Gef as first, second, and third- or later line therapy, 
respectively (P=0.891). Female with AD demonstrated higher MST 
both in non-smoker (22.0 mo.) and smoker (24.0 mo.) compared 
to male with AD. In the multivariate analysis, female gender (HR: 
0.575) and PS0-1 (HR: 0.543) were shown as independent statistical 
significant prognostic factors. ILD more than grade 1 were reported 
in 5 pts (3.5%), however, there was no death due to ILD. Non-smoker 
demonstrates less ILD occurrence (0-1.8%) compared to smoker 
(5.3- 6.3%).The mutation was observed 60.0 % in female, 52.6% 
in non-smoker, 37.0% in AD, which were similar results to those 
previously reported. There were significance difference of mutation 
rate in gender (p=0.006) and smoking status (p=0.013). In the EGFR 
mutation positive group, higher tumor response rate was obtained 
compared to the mutation negative group (50% vs. 26.1%).
Conclusions: Gef treatment for NSCLC with recurrence after sur-
gical resection is feasible, and should be considered for female AD, 
PS0-1 and non-smoker. Further investigations of prospective study 
and EGFR mutation will demonstrate the evidence.
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First-Line Cisplatin (P) With Docetaxel (D) Or Vinorelbine 
(V) in patients with advanced NSCLC: A Quality of Life 
(QoL) directed randomized phase II trial of Goim
Gebbia, Vittorio1; Galetta, Domenico2; Lorusso, Vito3; Caruso, 
Michele4; Maiello, Evaristo5; Borsellino, Nicolò6; Riccardi, 
Fernando7; Ferraù, Francesco8; Colucci, Giuseppe2
1 La Maddalena Clinic for Cancer, University of Palermo, Palermo, 
Italy; 2 Istituto Oncologico, Bari, Italy; 3 Ospedale Fazzi, Lecce, 
Italy; 4 CCO/Humanitas, Catania, Italy; 5 IRCCS Sollievo della 
Sofferenza, San Giovanni Rotondo, Italy; 6 Ospedale B. La Ferla, 
Palermo, Italy; 7 Ospedale Cardarelli, Napoli, Italy; 8 Ospedale San 
Vincenzo, Taormina, Italy
Background: QoL has gained greater importance in the management 
of metastatic NSCLC due to the palliative nature of treatment. DP 
has been reported to be associated to a better QoL than the weekly 
VP. Recently a newer more tolerated schedule of the VP regimen has 
been published and is widely employed in medical practice. The im-
pact of these regimens on patients’ QoL as well as symptoms control 
and type and grading chemo-related side-effects has been compared 
prospectically. 
Methods: Pts received P 75mg/m2 plus D 75 mg/m2 d1 q3 wks 
(arm A) or P 80 mg/m2 d1 plus V 30mg/m2 day 1+8 q3 wks (arm 
B). G-CSF/EPO were employed as needed. Health related QoL was 
assessed at entry and after every cycle by the EORTC-QLQ-C30 and 
LC13 questionnaires, toxicity by the NCI-NCCN CTC vs 2, and ITT 
objective response by the Recist criteria. 
Results: The QoL questionnaires were completed by 37 pts (88%) 
in the DP arm and 39 pts (87%) in the VP arm. Baseline mean scores 
and rates at which pts failed to complete QoL assessment were 
similar in the two arms. Global health status of the EORTC QLQ-C30 
scale and specific symptoms control (LC13 module) improved during 
treatment without any statistically significant difference between 
the two arms. Emotional functioning remained stable in both groups 
during treatment, whereas physical and role improved slightly. In the 
DP arm 14 pts (33%; 95%CL 24-40%) had PR, and 10 (24%) SD for 
a 57% TGCR. In the VP arm 12 pts (27%) achieved PR, 18 (41%) SD 
a 68% TGCR. Differences were not statistically significant. Median 
TTP was 4.2 ms in the DP arm and 4.5 ms in the VP one, and median 
OS was 12.1 (r1-26+ ms) and 12.5 ms (r 1-28+ ms) for DP and VP 
arms respectively. Febrile neutropenia rate was higher in the VP arm 
(p=0.02) as well as G3-4 anemia (p=0.005) and G-CSF/EPO use 
(p=0.019) (table 1).
Conclusions: Global and specific health related QoL data similar in 
both treatment groups with no statistically significant difference. Ef-
ficacy measures, ORR, TTP and OS are equal in both arms. However, 
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severe anemia and febrile neutropenia are statistically more frequent 
in the VP arm than in the DP one. These data should be considered in 
treatment decision making for pts with advanced NSCLC and for the 
design of future trials with chemotherapy plus biologics. 
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Third-line chemotherapy in advanced non-small cell lung 
cancer: identifying the candidates in routine practice
Girard, Nicolas1; Jacoulet, Pascale2; Gainet, Marie2; Elleuch, Rami2; 
Pernet, Didier2; Depierre, Alain2; Dalphin, Jean-Charles2; Westeel, 
Virginie2
1 Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 2 
Service de pneumologie, CHU de Besançon, Besançon, France
Background: The interest of first- and second-line treatments in non-
small cell lung cancer (NSCLC) has been demonstrated by random-
ized trials. Improvements in lung cancer care have allowed a signifi-
cant proportion of patients to be considered for third-line treatment in 
routine practice. Although erlotinib is the only approved agent in this 
setting, many patients are already routinely given third-line chemo-
therapy. In this study, our objective was to determine which patients 
benefit from third-line treatment, using symptom relief and overall 
survival as primary endpoints. 
Methods: A retrospective analysis was performed, including all con-
secutive patients with advanced NSCLC, who received at least three 
lines of systemic anti-neoplastic treatment from 2000 to 2006 at our 
institution. Patients who underwent surgery and/or radiotherapy on 
the lung tumor were excluded.
Results: A total of 173 patients (128 men, 45 women) received 
third-line treatment for advanced NSCLC. At initiation of third-line 
treatment, median age was 62 years and 72 (42%) patients had no 
extra-thoracic metastases. Of these 173 patients, 131 (76%) had 
cancer-related symptoms, and 85 (49%) had a PS≥2. Third-line 
treatment was cytotoxic chemotherapy for 131 (76%) patients (single 
agent in 125 patients) and EGFR tyrosine kinase inhibitor for 42 
(26%) patients. 
Third-line treatment was highly feasible as 160 (92%) patients 
received at least 75% of the theoretical dose-intensity. Treatment 
was discontinued following severe toxicity in only 15 (9%) patients. 
Disease control rate was 36%, significantly lower than after first- and 
second-line treatments (77% and 44%, respectively; p<0.001). 
Symptom relief and performance status improvement were observed 
in 121 (92% of the 131 patients with symptoms) and 90 (52%) 
patients, respectively. Median, 6- and 12-month survival after third-
line treatment were 5.8 months, 47% and 25%, respectively. Using 
multivariate analysis, disease control after both first- and second-line 
treatments was the strongest predictor of prolonged survival after 
third-line treatment (HR=2.12, 95% CI:1.49-3.02, p=0.001). Other 
favorable prognostic factors included: age <70 years, smoking history 
<10 pack-years, no cancer-related symptoms, weight-loss <5kg since 
the beginning of the second line, PS 0-1, and no extra-thoracic tumor 
at initiation of third-line treatment. 
Conclusions: Third-line treatment is a reasonable option in selected 
patients with advanced NSCLC. Although disease control is obtained 
in approximately one third of patients, most of patients amenable 
to third-line treatment experienced a clinical benefit. To identify the 
best candidates for third-line treatment, well-recognized favorable 
prognostic factors in the first-line setting should still be taken into 
account. Disease control obtained with both first and second-line 
treatments should encourage to give third-line treatment. 
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Long survivors in advanced non small cell lung cancer: 
impact of clinical factors, tumoral response and 
maintenance chemotherapy
Giroux Leprieur, Etienne; Lavole, Armelle; Gounant, Valérie; 
Cadranel, Jacques; Milleron, Bernard
Service de Pneumologie Höpital Tenon, Paris, France
Background: The prognosis of non small cell lung cancer (NSCLC) 
remains very bad, and only a small proportion of patients with ad-
vanced stage has a life expectancy more than two years.
Objective: We have reviewed retrospectively the patients treated by 
chemotherapy for a stage wet-IIIb or IV NSCLC in our department. 
The group of long survivors (more than two years) was compared 
to the other patients, according to forty-three clinical, biological and 
radiological criteria, relative to the tumor, the patient, the treatment 
and the evolution. 
Results: Two hundred and forty five consecutive patients, collected 
from a prospective file, were treated by chemotherapy between Janu-
ary 2003 and December 2006. The median of overall survival was 
11,2 months. Thirty nine patients (15,9%) had a survival more than 
two years.Three-years and 5-years survival rates were respectively at 
4,1% and 0,4%. The median age was 61 years (25-91), a sex ratio of 
2,1, and 14% of stage wet-IIIb and 86% of stage IV. Forty percents 
received in first line an association of platine and gemcitabine, 33% 
platine and taxane, <1% platine and navelbine, and 25% another 
chemotherapy. The initial performans status (PS) was 0-1 (78%), 
2 (12%) and 3-4 (10%). The study of long survivors (> 2 years) in 
comparison to the other patients showed significantly: a lactico-de-
hydrogenase (LDH) rate at the diagnosis less than 500 UI/l (p=0,05), 
a fewer number of metastatic sites (p=0,02), less bone metastases 
(p=0,01), a greater tumoral response to the first line of chemother-
apy (p=0,0003), a more frequent use of maintenance chemotherapy 
(p=0,04) and of curative surgery (p<0,0001), a longer delay to the 
first tumoral progression (p<0,0001), a best PS and an haemoglobin 
rate greater than 10g/dl at the first tumoral progression (p=0,02 and 
0,002), and a greater initial and final tumoral response to second line 
of chemotherapy (p<0,0001 and 0,002). All these criteria were pertin-
ent in term of survival in univariate analysis. We note that tobacco 
use was not a significative criteria. In multivariate analysis, only a 
normal LDH rate (OR=0,6; CI 0,41-0,88), an absence of curative 
surgery (OR=4,32; CI 1,58-11,85), the delay to the first tumoral pro-
gression (OR=0,57; CI 0,47-0,69), the PS and an anaemia less than 
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10g/dl at the first progression (OR=1,27; CI 1,1-1,46 and OR=7,52; 
CI 1,4-40,49, respectively), the number of treatment lines (OR=0,69; 
CI 0,56-0,84) and the response to the second line (OR=0,89; CI 0,79-
0,99) were statistically significative. The survival median of long 
survivors was 2,9 years versus 9,5 months for the other patients.
Conclusion: Identification of these criteria at the beginning of the 
disease and during the initial evolution could allow to identify a 
population of patients subject to have a prolonged life expectancy, 
and so to benefit from a more active therapeutic. 
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BLP25 liposome vaccine (L-BLP25): long-term safety 
results from a phase IIb study of patients with stage IIIB 
and IV non-small-cell lung cancer (NSCLC) treated for 2 
years or more
Goss, Glenwood1; Anderson, Helen2; Maksymiuk, Andrew3; Vergidis, 
Dimitrios4; Soulières, Denis5; Cormier, Yvon6; Davis, Mary7; 
Marshall, Ernie8; Falk, Martin9; Butts, Charles10
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Background: BLP25 liposome vaccine (L-BLP25, Stimuvax), an 
innovative, investigational, therapeutic cancer vaccine that incorpor-
ates immunoadjuvant monophosphoryl lipid A and synthetic MUC1 
lipopeptide in a liposomal delivery system, is designed to induce an 
immune response that may result in rejection of tumor cells express-
ing the MUC1 antigen. A total of 171 patients with stage IIIB/IV 
NSCLC who had responded to or had stable disease after first-line 
chemotherapy were included in an open-label, phase IIb study 
conducted in the UK and Canada. Patients were randomized to best 
supportive care (BSC) + L-BLP25 (1000 μg lipopeptide) (n=88) or 
BSC alone (n=83). Patients randomized to L-BLP25 received weekly 
vaccinations for 8 weeks and could continue maintenance vaccina-
tions every 6 weeks from week 13. The results of this phase IIb study 
were encouraging (Butts et al., JCO 2005) and a remarkable number 
of patients received prolonged treatment with L-BLP25. Based on 
these results, a global phase III study (‘START’) has been started. 
Methods: Sixteen patients from the phase IIb study received L-
BLP25 therapy for ≥2 years and the safety results for these patients 
are reported. 
Results: Demographics in these 16 patients were: median age 57.5 
years (range 48.0–73.0); ECOG performance status was 0 in five 
(31%) patients and 1 in 11 (69%) patients; 11 (69%) patients had a 
family history of cancer, and all patients had a history of tobacco 
use. Compared with the overall phase IIb study population, there 
were more patients with locoregional stage IIIb disease at study entry 
(13/16 [81%] versus 65/171 [38%]) and more females (9/16 [56%] 
versus 76/171 [44%]) among the long-term survivors. Treatment 
duration with L-BLP25 ranged from 2.0 to 7.7 years and 10 patients 
received L-BLP25 for >5 years. Treatment compliance was good, 
with almost all (96%) maintenance vaccinations administered every 
6 weeks as per the treatment schedule. The most frequent treatment-
emergent adverse events (TEAEs) with L-BLP25 were cough (n=12, 
75%), fatigue (n=12, 75%), and dyspnea (n=11, 69%). There was no 
significant change in the pattern of TEAEs over time and the inci-
dence of TEAEs did not increase with increasing time on treatment. 
Among the most frequent TEAEs in years 1, 2, and >2 were nausea 
(44, 19, and 38%), fatigue (56, 18, and 38%), chest pain (38, 31, and 
31%), and cough (38, 25, and 31%). Possibly or probably treatment-
related TEAEs were experienced by 12 patients (75%), which were 
grade 1 in seven (44%) patients, grade 2 in four (25%) patients, and 
grade 3 in one (6%) patient. The most common treatment-related 
TEAEs were injection-site reactions: erythema (n=6, 38%), nodules 
(n=5, 31%), and pain (n=4, 25%). The incidence of treatment-related 
TEAEs decreased with increasing time on treatment. There was no 
evidence of any TEAEs related to autoimmunity. The results of lab-
oratory values showed that there was no long-term hematologic, liver, 
or renal toxicity. 
Conclusion: There were no identifiable safety issues with long-term 
use of L-BLP25. In addition, prolonged use of L-BLP25 was not as-
sociated with any evidence of autoimmune reactions.
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Phase I dose-escalation study of CP-751,871 combined with 
carboplatin and paclitaxel in treatment-naïve Japanese 
patients with advanced non-small cell lung cancer 
(NSCLC)
Goto, Yasushi1; Misawa, Shuji1; Tanioka, Maki1; Shibata, Takeshi1; 
Tanai, Chiharu1; Asahina, Hajime1; Nokihara, Hiroshi1; Yamamoto, 
Noboru1; Sekine, Ikuo1; Kunitoh, Hideo1; Ohe, Yuichiro1; Ohki, 
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Research Oncology, Pfizer, Tokyo, Japan
Background: CP-751,871 is a fully humanized IgG2 monoclonal 
antibody specific to insulin-like growth factor type 1 receptor (IGF-
IR). Binding of CP-751,871 to IGF-IR inhibits ligand binding and 
receptor signaling, and causes receptor down-regulation in cells. The 
objectives of this study were to evaluate the safety, tolerability, phar-
macokinetics (PK), and pharmacodynamics (PD) in chemotherapy-
naïve Japanese patients with advanced NSCLC.
Methods: In this ongoing phase I dose-escalation trial, CP-751,871 
was administered with carboplatin (AUC=6 mg•min/mL) and 
paclitaxel (200 mg/m2) on day 1 of 21-day cycles. The dose of CP-
751, 871 was escalated from 6 to 20 mg/kg. The standard ‘3+3’ dose 
escalation scheme was used, and 3 patients were added for safety 
analysis in the 20 mg/kg cohort.
Results: A total of 19 patients (six at 6 mg/kg; seven at 10 mg/kg; six 
at 20 mg/kg) aged 21–74 (median 57) years were enrolled. Fourteen 
(74%) patients presented with adenocarcinoma, and four (21%) with 
squamous cell carcinoma. As of March 2009, 18 patients completed 
the first cycle. One patient in the 10 mg/kg cohort discontinued 
study due to a serious paclitaxel-related adverse event (AE) and did 
not receive CP-751,871. Three patient (each in 6, 10, and 20 mg/kg 
cohorts) completed 4 cycles of treatment, and two patients (each in 6 
and 10 mg/kg cohorts) completed 6 cycles. Three patients on 6 mg/kg 
discontinued due to disease progression (PD) and three patients on 10 
mg/kg discontinued due to AEs (one with hyperuricemia, hyperma-
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gnesemia, hyponatremia and hyperkalemia, one with increase in AST, 
and the other with neutropenia). AE of Grade (Gr) 3/4 with incidence 
of >10% are listed in the table. In the 6 mg/kg cohort one patient 
had DLT (Gr 4 thrombocytopenia). Two patients receiving 10 mg/
kg experienced DLTs (one with Gr 4 hyperuricemia, Gr 3 hyperma-
gnesemia, hyponatremia, and hyperkalemia, and another with Gr 4 
thrombocytopenia). No DLTs were observed in the 20 mg/kg cohort. 
There was no Gr 3/4 hypoglycemia or hyperglycemia related to with 
CP-751,871. Fifteen patients were evaluated for response. Five (one 
in 6mg/kg cohort, three in 10 mg/kg, and one in 20 mg/kg cohort) 
had partial response (PR) and six patients had stable disease (SD). PK 
and PD data will be presented.
Conclusions: CP-751,871 was well tolerated in combination with 
carboplatin and paclitaxel at doses up to 20 mg/kg in Japanese pa-
tients with advanced NSCLC. Further investigation of the safety and 
efficacy of this combination is ongoing. 
 Grade 3/4 AEs with incidence of >10% Cycle 1(N=18) All cycles (N=18)
  Gr3 No. Gr4 No. G3/4 No. G3/4 (%) Gr3 No. Gr4 No. G3/4 No. G3/4 %
 neutropenia 5 5 10 52.6 6 8 14 73.7
 thrombocytopenia 1 2 3 15.8 1 3 4 21.1
 leucopenia 1 0 1 5.3 3 0 3 15.8
 hyperuricemia 0 2 2 10.5 0 2 2 10.5
 hyponatremia 3 0 3 15.8 3 0 3 15.8
 anorexia 1 0 1 5.3 2 0 2 10.5
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Receptor tyrosine kinases and resistance to Erlotinib in 
NSCLC 
Easty, David 1; Gray, Steven G.2; Kennedy, John 1; O’Byrne, Kenneth 
J.1; O’Donnell, Dearbhaile M.1
1 St James’s Hospital, Dublin, Ireland; 2 Institute of Molecular 
Medicine, Dublin, Ireland
Background: Non-small cell lung cancer (NSCLC) is the leading 
cause of cancer death. Response to chemotherapy remains limited 
and targeted therapy including EGFR inhibitors such as erlotinib are 
used in relapse, although, response to erlotinib is often temporary as 
resistance commonly emerges. 
Methods: In ongoing studies we used phospho-RTK arrays to 
identify relative levels of phosphorylation of 42 RTKs in NSCLC 
cell lines and NSCLC surgical specimens. Here we extend this study 
to include samples of normal lung from six NSCLC patients. In 
addition, we have used adenoviral vectors to express RTK and RTK 
ligands in NSCLC cells sensitive to erlotinib. NSCLC cells, sensi-
tive to erlotinib were infected with adenoviral vectors and cultured 
in the presence of erlotinib. After 5 days cell number was counted by 
automatic miroscopy.
Results: On kinase arrays, normal lung samples contained only 8/42 
activated kinases, compared to 24/42 in NSCLC. Adenoviral medi-
ated expression of IGF2 partially rescued HCC827 but not HCC3255 
cells from the affects of erlotinib. 
Conclusions: NSCLC contains multiple activated RTKs, that are not 
detected within normal lung, and these include possible targets for 
tyrosine kinase inhibitors. Absence of HCC3255 response to IGF2 
may reflect absence of IGF1R expression. Up-regulation of IGF2 
is one possible mechanism for resistance to erlotinib in NSCLC 
patients. A better understanding of RTK function in NSCLC may 
translate into novel therapeutic approaches. 
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Histology and Rash driven therapeutic outcomes of 
erlotinib in advanced NSCLC 
Grohe, Christian; Lueders, Heike; Kurzeja, Annette; Schoenball, 
Frank; Leschber, Gunda; Dederke, Bettina; Wormanns, Dag
ELK Thorax Center, Berlin, DE, Germany
Response to erlotinib in NSCLC has been associated with the develop-
ment of rash and outcome according to the underlying histology. 
These two items become increasingly more important how to plan 
therapeutic options in advanced disease. We therefore evaluated our 
single center experience of the most recent 163 patients who have 
been treated with erlotinib and who were monitored between 1-05 
and 9-08. Out of 163 patients 32 were still alive and 131 patients had 
passed away. Of these, 134 pts had received treatment longer than 
60 days. 48 % of the patients had a squamous NSCLC, 52 % were 
classified as non squamous NSLC. Overall survival was superior in 
pts with non/squamous - adeno carcinomas. Never smokers with non 
squamous histology in particular adeno carcinoma pts had a signifi-
cant survival benefit compared to squamous cell carcinoma patients. 
Nonsquamous lung cancer patients were to higher percentage never 
smokers with a better survival. Interestingly, ex smokers faired poor 
compared to current smokers. Development of rash showed no bias 
towards histology. Low grade rash was associated with better overall 
survival, however development of high grade rash (2/2 to 3/3) was 
associated with a poorer overall survival in both histology groups. 
In particular, in squamous cell carcinoma patients treatment with 
erlotinib and development of low grade rash significantly improved 
survival while high rash in these patients resolved in a poor outcome.
In summary, we found that both, patients with squamous and non 
squamous histology had a benificial outcome if low grade rash de-
velopment under erlotinib treatment. 
P1.184 NSCLC Advanced Disease, Sat Aug 1 
Optimal duration of chemotherapy (CT) for advanced 
non-small cell lung cancer (NSCLC) in the 1st and 2nd line 
settings 
Grossi, Francesco1; Belvedere, Ornella 2; Defferrari, Carlotta1; 
Brianti, Annalisa1; Massoni, Carola1; Follador, Alessandro3; Rijavec, 
Erica3; Ceschia, Tino3; Pronzato, Paolo1; Fasola, Gianpiero3; Aita, 
Marianna3
1 National Institute for Cancer Research, Genova, Italy; 2 Institute 
of Molecular Medicine, Leeds, UK; 3 University Hospital of Udine, 
Udine, Italy
Background: No difference in efficacy has been observed between 
3 or 4 vs 6 cycles of 1st line CT in patients (pts) with advanced 
NSCLC. Although longer treatment may improve progression-
free survival, this must be weighed against increased toxicity and 
potential for worse quality of life. There are no prospective, random-
ized data on the optimal duration of 2nd line CT. The aims of this 
retrospective study were to (i) confirm the lack of impact of treatment 
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duration on response rate in 1st line NSCLC and (ii) investigate the 
impact of treatment duration in the 2nd line setting.
Methods: Eligible pts had received at least 4 cycles of 1st line (n=95) 
or 2nd line (n=55) CT for stage IIIB/IV NSCLC in clinical trials 
of the ATOM group, Udine, Italy, or the National Cancer Institute, 
Genoa, Italy and achieved stable disease or responded to treatment; 
trials included one in the elderly, and the addition of biological agents 
to CT. Response was assessed according to RECIST after alternate 
CT cycles and tumor dimensions recorded. The proportion of pts 
achieving a complete or partial response, as well as its timing and any 
subsequent tumor shrinkage, were analyzed by treatment line.
Results: In the 1st line setting, 48 of 95 pts responded; they did so 
after 2 (29 pts, 61%), 4 (15 pts, 31%) and 6 cycles (4 pts, 8%). In 
these pts, 16 (55%) and 9 (41%) pts who had responded by the 2nd 
and 4th cycle respectively and continued on treatment showed further 
tumor shrinkage; the median further reduction in tumor size was 
16% (range 1-52%) and 6% (range 1-11%), respectively. In the 2nd 
line setting, 12 of 55 pts responded; they did so after 2 (3 pts, 25%), 
4 (7 pts, 58%), and 6 cycles (2 pts, 17%). One and two pts who had 
responded by the 2nd and 4th cycle respectively and continued on 
treatment showed further tumor shrinkage of 25%, 5% and 24%, 
respectively.
Conclusions: Approximately 90% of CT-naive pts who responded 
did so by the 4th cycle; most such pts achieved only minor tumor re-
duction with further CT and did so at the likely expense of increased 
toxicity. In the 2nd line setting the achievement of response appeared 
slower. These results support the discontinuation of 1st CT after 4 
cycles and suggest the same is true for 2nd line CT. 
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Clinical impact of regulatory T cells in peripheral blood of 
patients with non small cell lung cancer
Hasegawa, Takeo; Suzuki, Hiroyuki; Shio, Yutaka; Higuchi, 
Mitsunori; Hoshino, Mika; Ohsugi, Jun; Yonechi, Atsushi; Yaginuma, 
Hiroshi; Okabe, Naoyuki; Gotoh, Mitsukazu
Chest Surgery, Fukushima Medical University, Fukushima-shi, Japan
Background: Regulatory T cells (Treg) has became a rock-star status 
in immunology in the past decade. They have immunosuppressive 
function, therefore once called suppressor T cells, but their definitive 
maker had not been identified for a long time. It has been reported 
that Treg express CD4 and CD25 on their cell surface, and also have 
master control molecule Foxp3 in nuclear, which is responsible for 
maintaining tolerance to self antigen to avoid autoimmune disease. To 
date, Treg are worthy of attention in various fields containing auto-
immune disease, allergy, organ transplantation, and cancer therapy. 
Recently, Treg are thought to be a major role of hampering antitumor 
immune response by producing immunosuppressive cytokines such 
as TGF-beta or IL-10. In the present study, we analyzed Treg in per-
ipheral blood of patients with non-small cell lung cancer (NSCLC), 
and investigated the correlation between Treg and clinic-pathological 
parameters.
Methods: We analyzed peripheral blood mononuclear cells (PBMC) 
obtained from 67 patients with NSCLC(45 adenocarcinoma, 15 squa-
mous cell carcinoma, and 7 other carcinoma) who were underwent 
complete resection.
PBMC were obtained before surgery and separated using Ficoll-
Paque procedure. Treg were detected as CD4+ and Foxp3+ cells 
by using Flow cytometry. PerCP labeled anti-human CD4 antibody 
(BD Pharmingen™), and Phycoerythrin labeled anti-human Foxp3 
antibody (eBioscience) were applied for our study. The correlations 
between the frequency of Treg and the clinic-pathological parameters 
of patients were analyzed statistically.
Results: There were significant correlation between the frequency 
of Treg and pleural invasion (p=0.0054), blood vessel invasion 
(p=0.0004), lymphatic vessel invasion (p=0.0014), and recurrent 
disease (p=0.0169), whereas no significant difference was found 
as compared to age (p=0.09462) and sex (p=0.3936). Histological 
canvas did not differ although adenocarcinoma containing BAC had a 
trend to have lower frequency of Treg than squamous cell carcinoma 
(p=0.2813). Furthermore, the frequency of Treg were significantly 
elevated in patients with advanced disease (stageI-IIB vs IIIA-IIIB: 
10.3% vs 15.2%, p=0.019).
Conclusion: The frequency of Treg were significantly correlated with 
several important clinic-pathological parameters including recurrent 
disease of patients with NSCLC. Since peripheral Treg in patients 
with NSCLC could be a useful prognostic marker, larger scaled fur-
ther study would be needed to confirm our results.
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Correlations between disease progression and risk of 
Skeletal-Related Events (SREs) in patients with Bone 
Metastases (BM) from Non-Small Cell Lung Cancer 
(NSCLC) and other solid tumors
Tchekmedyian, Simon N.1; Chen, Yin-Miao2; Hirsh, Vera3
1 Pacific Shores Medical Group, Long Beach, CA, USA; 2 Novartis 
Pharmaceuticals Corporation, East Hanover, NJ, USA; 3 McGill 
University Health Centre (MUHC), Royal Victoria Hospital, 
Montreal, QC, Canada
Background: Treatment decisions in patients with aggressive tumors 
involve an important balance between the potential benefits of a ther-
apy versus adverse events (AEs) during the patient’s lifetime. Bone 
metastases develop in approximately 35% of patients with stage IV 
NSCLC and place patients at risk for potentially debilitating SREs, 
defined as pathologic fractures, the need for palliative radiotherapy or 
surgery to bone, spinal cord compression, and hypercalcemia of ma-
lignancy. Zoledronic acid (ZOL; 4 mg via intravenous infusion every 
3 weeks) has been shown to significantly reduce the risk of SREs 
in patients with BM from a broad range of aggressive solid tumors. 
However, the ongoing benefit:risk profile of ZOL therapy in patients 
with overall disease progression (ODP) during treatment, who may 
have limited survival, is unknown. This retrospective analysis evalu-
ates the effect of ODP on SRE risk and ZOL treatment benefits, and 
the long-term AE profile of ZOL.
Methods: Correlations between ODP and SRE risk were analyzed 
using data from the 21-month, placebo-controlled, phase III trial of 
ZOL in patients with BM from lung cancer and other solid tumors (N 
= 773; Rosen et al. J Clin Oncol. 2003), of whom 383 (49.5%) had 
NSCLC. All analyses were stratified by cancer type. Models included 
baseline covariates that have been previously associated with SRE 
risks (SRE history, pain, performance status, number of bone lesions), 
treatment group (ZOL 4 mg, ZOL 8/4 mg, or placebo), and ODP as a 
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time-dependent variable. Risk ratios (RR) were estimated using Cox 
regression analyses for first SRE and Anderson-Gill multiple event 
analyses for all on-study SREs. Models comparing the approved dose 
of ZOL (4 mg) versus placebo are presented herein.
Results: Consistent with aggressive tumors, median time to ODP was 
≤ 3 months for each treatment group. Overall disease progression was 
associated with a greater than 4-fold increase in the risk of first SRE 
(RR = 4.08; P < .001) versus no ODP. In multiple event analyses, 
ODP correlated with a 45% increase in the ongoing risk of SREs (RR 
= 1.446; P = .016). Treatment with ZOL (4 mg) decreased the risk of 
SREs by approximately 34% in both multivariate analyses (P ≤ .004 
for both). During the 21-month trial, the incidence and severity of 
all AEs and frequencies of most grade 3/4 AEs were similar between 
treatment groups; rates of renal AEs were similar for placebo and 
ZOL 4 mg via 15-minute infusion. However, the incidence of severe 
bone pain, the most common AE, was lower in patients treated with 
ZOL 4 mg versus placebo (grade 3, 17.3% for ZOL versus 26.7% for 
placebo; grade 4, 3.1% for ZOL versus 5.7% for placebo).
Conclusions: Although ODP has been associated with reduced sur-
vival, it is also associated with greatly increased SRE risk. Ongoing 
treatment with ZOL reduces the risk of SREs even after adjusting for 
the effects of ODP in multivariate models, and may palliate bone pain 
without introducing substantial treatment-related AEs. These analyses 
support ongoing treatment with ZOL despite ODP in patients with 
BM from solid tumors.
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Brain metastases in advanced non-small cell lung cancer 
post bevacizumab
Huang, Yujuan; Yang, Jinji; Wang, Zhen; Huang, Yisheng; Wu, 
Yilong
Guangdong Lung Cancer Institute & Cancer Center, Guangdong 
General Hospital, Gaungzhou, China
Background: Bevacizumab can act directly at endothelium of 
vessel in brain without the restriction of blood brain barrier (BBB). 
The antiangiogenic compounds also have been shown to synergize 
with chemotherapeutic compounds in non-small cell lung cancer 
(NSCLC), based on vessel normalization that cause the restoration of 
the BBB. All of these would result in the change of the microenviron-
ment which affects the brain metastases.
Purpose: To evaluate magnetic resonance imaging (MRI) features 
and the prognosis of brain metastases in advanced NSCLC post 
bevacizumab.
Method: 45 patients of non-squamous NSCLC were enrolled, 
received 6 cycles bevacizumab combined with chemotherapy of 
paclitaxel plus carboplatin followed by bevacizumab single agent 
maintenance till disease progress (PD). MRI was performed for every 
patient once the symptom of the brain metastases present.
Result: The mid-follow up duration was 16 month, 38 patients 
experienced diseased progress.7 brain metastasis of 8 patients who 
developed neurology symptoms were confirmed by MRI. No revers-
ible posterior leukoencephalopathy syndrome (RPLS) and intracer-
ebral bleeding was observed.6 of the lesions in the brain were diffuse, 
small, no edema around the lesion and the leptomeninges metastases 
were frequent (3 of 7, 43%). The mid-overall survival is 48 days. 
Treatment could improve only 1 patient’s symptom. 4 patients 
received tyrosine kinase inhibitor (TKI), 2 were PD and 2 were SD. 1 
patient was stable disease after whole brain radiation (WBRT). Only 
1 patient’s symptom could be improved by dehydration and WBRT.
Conclusion: Brain metastases in advanced NSCLC post 
bevacizumab presumably had some particular features. The leptome-
ninges metastases (Type1) and diffuse, small and no edema surround 
lesions (Type2) were frequent. The further treatment to improve 
symptoms of these two types is less effective compared with that of 
type 3. Our findings will need to be confirmed in a larger sample trial 
to determine the optimal option of treatment. 
Figure 1: Type 1, widespread leptomeninges metastases (3 of 7) 
Figure2: Type 2, multiple diffuse small nodules (6 of 7)
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Phase I dose-finding study to investigate tolerability of 
daily oral vinorelbine (Navelbine® oral) in patients with 
stage IIIB/IV non-small cell lung cancer (NSCLC)
Huber, Rudolf M.1; Gütz, Sylvia2; Borgmeier, Astrid1; Rittmeyer, 
Achim 3; Monnoyer-Favrel, Stéphanie4; Rosé, Christian5
1 University of Munich, Munich, Germany; 2 Robert-Koch-Klinik, 
Leipzig, Germany; 3 Lungenfachklinik, Immenhausen, Germany; 4 
Pierre Fabre Medicament, Boulogne, France; 5 Pierre Fabre Pharma 
GmbH, Freiburg, Germany
Background: Results of conventional chemotherapy in advanced 
NSCLC are not satisfactory. Therefore new substances, applications 
and schedules have to be tested. Vinorelbine is one of the standard 
treatments for stage IV NSCLC. Oral vinorelbine has similar activ-
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ity as intravenous vinorelbine, but is easier to administer. Taking 
advantage of the oral form, more frequent, even daily administrations 
differing from conventional schedules can be used. Here we report 
about the primary objective, the determination of maximum tolerated 
dose (MTD) of daily oral vinorelbine during cycle one. Furthermore 
first PK-data are provided.
Methods: Treatment with oral vinorelbine was started in cohorts 
of up to 6 patients with ascending doses per cohort. 3 dose levels 
were planned for this dose-finding study according to the following 
schedule (one cycle = 28 days; day 29 = day 1 of next cycle): Level 
I: 20 mg oral vinorelbine daily on D1 to D21; Level II: 30 mg oral 
vinorelbine daily on D1 to D21; Level III: 40 mg oral vinorelbine 
daily on D1 to D21. Doses were not adjusted for body surface area or 
weight. In each patient treatment continued until progressive disease, 
non tolerable toxicity, patient’s wish to discontinue treatment or until 
other circumstances where continuation is not in the patient’s best 
interest. Antiemetic prophylaxis with 5-HT3 antagonists was recom-
mended. Dose limiting toxicity (DLT) in the first cycle was defined 
as follows: (1) Fever (± clinical infection) - defined as 3 elevations 
of oral temperature to >38°C during 24 hours or a single elevation to 
>38.5°C - concomitant with grade 4 neutropenia (CTCAE, version 
3.0) and requiring intravenous antibiotics and/or hospitalisation; (2) 
grade 4 neutropenia and/or grade 2 thrombocytopenia lasting for 
>= 7 days; (3) grade 4 or symptomatic grade 3 thrombocytopenia 
(CTCAE); (4) any non-haematological toxicity higher than grade 
2 (CTCAE; excluding nausea/vomiting and any toxicity related to 
other causes than treatment, e.g. caused by tumour and/or concomi-
tant diseases). Pharmacokinetics of vinorelbine were studied during 
the first treatment-cycle at D1 and D21 (PK-profiles for first and last 
administration) with trough levels at D8 and D15.
Results: All 3 dose levels were without DLTs. Grade 2 (CTCAE) was 
the maximum intensity of adverse events observed during cycle 1 at 
dose level III (N=3). The pharmacokinetic interim analysis containing 
data from twelve patients included in the study demonstrated no 
evidence for a clear relationship between PK-data and toxicities dur-
ing cycle one at any of the three dose levels. The actual accumulation 
ratios calculated between D1 and D21 were low and in line with the 
theoretical ratio in all three dose levels; the steady state was already 
reached on D8.
Conclusions: Based on the results of the three dose levels, a daily 
oral dose of 40 mg vinorelbine appears to be well-tolerated and safe. 
None of the patients experienced a DLT during cycle one. Therefore 
this phase I study will now continue with a further dose level of 50 
mg vinorelbine daily. The recommended dose level determined in this 
study will be used in subsequent Phase II studies.
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Phase I study of high dose gefitinib in patients with 
leptomeningeal metastases from EGFR-mutant non-small 
cell lung cancer
Jackman, David M.1; Kesari, Santosh1; Cioffredi, Leigh-Anne1; 
Sequist, Lecia V.2; Rabin, Michael S.1; Lynch, Thomas J.2; Marcoux, 
J. P.1; Johnson, Bruce E.1
1 Dana-Farber Cancer Institute, Boston, MA, USA; 2 Massachusetts 
General Hospital, Boston, MA, USA
Background: Leptomeningeal metastases (LM) from lung cancer 
is an ominous development, partly due to the absence of effective 
treatment options. In a prior series of lung cancer patients with LM, 
median survival was only 1.8 months. For patients with sensitiz-
ing EGFR mutations, however, an EGFR-tyrosine kinase inhibitor 
(TKI) might represent an effective treatment option if adequate drug 
concentrations in the cerebrospinal fluid (CSF) can be achieved. We 
explored use of high-dose gefitinib for non-small cell lung cancer 
(NSCLC) patients with known sensitizing EGFR mutations and LM.
Patients and Methods: Eligible patients had stage IV NSCLC with 
cytologically-documented LM; known EGFR mutation or prior 
response to EGFR-TKI; and baseline performance status 0-3. Patients 
were enrolled in successive cohorts of escalating gefitinib doses. 
Each 28-day cycle consisted of 14 days of daily high-dose gefitinib 
(planned dose levels: 750mg, 1000mg, 1250mg), followed by 14 days 
of maintenance therapy of 500mg daily. At baseline and at comple-
tion of each high-dose portion of the cycle, patients underwent MRI 
of brain and spine and had blood and CSF fluid obtained for steady-
state gefitinib concentrations. Treatment continued until evidence of 
central nervous system progression or intolerable toxicity.
Results: Between 5/06 and 8/08, 7 patients were enrolled. Demo-
graphics: Median age 51 (range 46-72). Sex: 5F/2M. 6 Caucasian, 1 
Asian. EGFR status: 5 exon 19 deletions, 1 L858R mutation, 1 not 
tested. Prior EGFR-TKI: 2 erlotinib, 2 gefitinib, 1 vandetanib, 1 gefit-
inib/erlotinib, 1 erlotinib/HKI-272. Efficacy: 4 patients had dramatic 
clinical improvements in CNS symptoms. No cases of radiologic 
resolution of LM. One patient achieved negative CSF cytology, while 
2 others had CSF that was negative in 1 of 2 independently-analyzed 
samples. Survival: median 3.5 months, range 1.6–5.1 months. 
Steady-state gefitinib concentrations on day 14 (completion of 2 
weeks of high-dose therapy): 750 mg/day - median 41.5nM (range 
14.7-48.8nM); 1000 mg/day - median 57.6nM (range 21.7-93.6nM). 
Safety/toxicity: No drug-attributed DLTs in the 750mg cohort (n=3). 
In the 1000mg cohort (n=4), there was one DLT (toxic epidermal 
necrolysis) in a patient with known history of Sjogren’s syndrome. 
Other notable toxicities included 5 diarrhea (1 grade 3); 1 nausea/
vomiting (grade 3); 2 fatigue (grade 1); 1 elevated hepatic transamin-
ases (grade 1); 2 elevated alkaline phosphatase (grade 1). All grade 
3 toxicities occurred at the 1000 mg dose level. There were three 
patients who developed pulmonary emboli, though these were felt to 
be disease-related. 
Conclusions: While penetration of EGFR-into the CNS has been 
suspected, this study confirms a consistent ability to achieve CSF 
concentrations of gefitinib approximating or exceeding the known 
IC50 for this drug in sensitive cell lines. Moreover, it shows that this 
strategy is reasonably tolerated at the 750mg dose level; a formal 
MTD could not be defined because the study was stopped due to poor 
accrual. There was significant clinical improvement in 4 of 7 patients, 
and overall survival compares favorably to those seen in prior series. 
For patients with LM from EGFR-mutant NSCLC, further study of 
this or other strategies of high dose EGFR-TKI’s could be explored.
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Inter-hospital heterogeneity in cisplatin delivery in the 
British Isles: A survey of current practice, changing 
practice via the BTOG2 trial and the potential health 
economic implications of change
Jarrett, Hugh W.1; Billingham, Lucinda1; O’Byrne, Kenneth2; Ferry, 
David3
1 Cancer Research UK Clinical Trials Unit, Birmingham, UK; 
2 St James’ Hospital, Dublin, Ireland; 3 New Cross Hospital, 
Wolverhampton, UK
Background: Current guidelines provided by the National Institute 
for Clinical Excellence in the United Kingdom on the use of chemo-
therapy for the treatment of advanced NSCLC advocate that patients 
should be treated with either cisplatin or carboplatin in combination 
with a single third-generation drug. The British Thoracic Oncology 
Group’s second trial (BTOG2) is investigating the optimal dose of 
cisplatin and whether carboplatin can substitute for cisplatin. Results 
from the trial will be available in 2010. Parallel to the issue of which 
platinum agent to employ, is the issue of optimal cisplatin delivery. 
There is currently no national strategy concerning the precise tim-
ing and volumes of hydration required to simultaneously deliver 
therapeutic doses, whilst keeping the associated nephrotoxicity low. 
This paper reports the results of a survey of hydration regimens that 
were in practice across the British Isles prior to the BTOG2 trial and 
discusses the impact of the BTOG2 trial on this practice.
Methods: As part of the initiation process for hospitals requesting 
participation in the BTOG2 trial, prescription proformas were re-
quested for their proposed method of delivering cisplatin, which were 
then assessed for compliance with the BTOG2 recommended regi-
men by the Chief Investigator. Directions were given, as necessary, to 
ensure greater standardisation across the participating hospitals.
Results: The pre-trial survey included 67 participating hospitals 
from across the British Isles. Assessment of the hydration schedules 
showed great heterogeneity in current practice. Duration ranged 
from 150 to 1110 minutes with mean of 508 compared to the BTOG2 
protocol of 360 minutes. Total fluid volume ranged from 2250 to 
7250 ml with mean of 4010 compared the BTOG2 protocol of 3950 
ml. For 32 hospitals (48%), routine practice for cisplatin administra-
tion involved admitting patients overnight whilst 35 (52%) adminis-
tered it as day-case treatment. Following enrolment into the BTOG2 
trial, 65 of these 67 hospitals were subsequently able to deliver cis-
platin, via a standardised short infusion regimen, in a day-case setting 
which has potential for major impact on health care resources.
Conclusions: Implementation of the BTOG2 trial protocol has 
reduced the heterogeneity of practice for cisplatin delivery and shown 
that a short hydration schedule represents a feasible way of delivering 
cisplatin in the out-patient setting. National guidelines to this effect 
would have clear, positive, implications for both the National Health 
Service and local policy in terms of finance and resource.
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Long Term Survivors (LTS) in Advanced NSCLC treated 
non-surgically: treatment patterns and Paradigms for 
success
Johnson, Ewan D.; Hanneken, Jan M.; Taylor, Sarah; Erasmus, 
Jeremy; Karp, Daniel D.
MD Anderson Cancer Center, Houston, TX, USA
Background: The prognostic spectrum for NSCLC ranges from 
weeks to years and depends on stage, age, sex, and performance 
status. We have undertaken to identify treatment patterns in advanced 
stage lung cancer that may be associated with long term survival 
(LTS) in patients treated non-surgically.
Methods: We analyzed the records of 14,764 NSCLC patients from 
the MDACC tumor registry who were evaluated between 1991-2001 
to find LTS treated with chemotherapy (C), and or radiation (R) 
only. We excluded all patients who had pneumonectomy, lobectomy, 
segmental or wedge resection. LTS was defined as survival of 36 
months or greater. LTS were analyzed by tumor location, histological 
subtypes, smoking status, stage and the presence of pleural effusions.
Results: Only 5,114 / 14,764 (34.6%) received initial treatment at 
MDACC; 1,925 / 5,114 (37.6%) had surgery. The remaining 3,189 
(62.4%) had Chemotherapy(C) alone, Radiation (R) alone, concur-
rent Chemotherapy/Radiation (CR) in varied sequences. LTS patients 
totaled 294 / 3,189 (9.2%). Median survival for LTS was 5.2 years. 
91% were either current or former smokers, 9% never smoked). The 
advanced LTS clinical stages were, IIIA/IIIB, 52%, IV 30%. In Stage 
IIIA/B adenocarcinoma represented 38% and squamous represented 
30%, while in Stage IV 59% was adenocarcinoma and 8% was 
squamous.
  Stage IIIa/IIIb  Stage IV 
 Adenocarcinoma 58 38.0% 51 58.6%
 Squamous 46 30.0% 7 8.0%
 NSC/NOS 33 21.6% 11 12.6%
 Other 16 10.5% 18 20.7%
In the treatment of stage IIIA/B lung cancer, 18.3% received chemo-
therapy then radiation in contrast to stage IV where 3.4% received 
chemotherapy then radiation. In Stage IV 66.7% received chemother-
apy alone while only 8.49% received chemotherapy alone in stage 
IIIA/B. Concurrent chemotherapy/radiation was applied in 47.1% of 
Stage IIIA/B while only 9.19% in stage IV.
  Stage IIIa/IIIb Stage IV
 Chemo(C) only 13 58
 Radiation(R) only 27 14
 CR--C 1 0
 CR 72 8
 CAM--C 0 1
 C--R--T 1 0
 CT 0 1
 C--R 28 3
 C--CR 9 0
 R--C 1 1
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Conclusions: Adenocarcinoma histology predominated in Stage 
IV NSCLC while squamous predominated in the Stage IIIA/B. The 
biology of the advanced NSCLC is not all the same. We assert that 
stage IV is a heterogeneous group with some being oligometastatic 
while others are metastatic to multiple organ systems. Some biologies 
progress slowly, while others show distinct PET scan profiles .We as-
sert that these tissue types have distinct genetic profiles and patterns. 
We pledge to elucidate the genetic profiles and radiographic profiles 
of these histologies in NSCLC.
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Phase II trial of dasatinib for patients demonstrating 
acquired resistance to treatment with the epidermal 
growth factor receptor (EGFR) tyrosine kinase inhibitors 
(TKIs) erlotinib (E) or gefitinib (G).
Johnson, Melissa L.1; Riely, Gregory J.1; Rizvi, Naiyer A.1; Azzoli, 
Christopher G.1; Kris, Mark G.1; Ginsberg, Michelle S.1; Pao, 
William1, 2; Miller, Vincent A.1
1 Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 2 
Vanderbilt University, Nashville, TN, USA
Background: Worldwide, tumors from approximately one third of 
patients with lung adenocarcinomas harbor activating mutations in 
the tyrosine kinase domain of the EGFR. When treated with EGFR-
TKIs, 70% will have major tumor regression and a median progres-
sion free survival of one year (Mok, ESMO, 2008). However, all such 
patients will eventually progress despite TKI therapy; these tumors 
are said to have “acquired resistance” to these agents. EGFR T790M 
and MET amplification have been identified in 50% and 20% of these 
cases, respectively, but are not mutually exclusive. Src and down-
stream family members are frequently phosphorylated in many cell 
lines and tumor samples in which EGFR is also activated (Rikova. 
Cell. 2007), and when some EGFR mutant cell lines are treated with 
dasatinib, an oral Src inhibitor, they undergo apoptosis (Song. Cancer 
Res. 2006). Dasatinib is currently approved for use in patients with 
chronic myelogenous leukemia (CML) who develop acquired resist-
ance after imatinib. We aimed to study dasatinib in a clinical trial for 
patients with acquired resistance to EGFR-TKIs.
Methods: Eligibility: 1) previous treatment with a TKI for at least 
6 months AND radiographic partial or complete response as defined 
by RECIST or WHO criteria OR a documented mutation in EGFR 
from tumor DNA; 2) acquired resistance by radiographic progres-
sion during treatment with E or G; 3) consent to biopsy at a site of 
progressive disease in an attempt to identify molecular determinants 
of acquired resistance. Baseline CT was required within one month 
of study entry. Enrolled patients were instructed to discontinue their 
TKI, and one week later they began treatment with dasatinib 70 mg 
bid. Response assessment with CT scan was planned at 4 and 8 weeks 
and every 8 weeks thereafter. The primary end-point was response 
rate (RR). A two-stage clinical trial design (stage I-n=12, stage II, 
n=25, Ho=5%, H1=25%, 90% power) was planned; an early stopping 
rule stipulated that the trial would be stopped if 4 of the initial 12 
patients entered developed pleural effusions. 
Results: Ten patients were consented, 9 were treated with dasatinib. 
EGFR mutations: exon 19 deletions (4), exon 21 L858R mutations 
(4), none detected (1). One patient had a T790M acquired resistance 
mutation. All patients exhibited rapidly progressive disease and were 
removed from the study after a median of 2.4 weeks of treatment. The 
trial was stopped after four patients developed clinically significant 
pleural effusions. No responses were seen. 
Conclusions: Single-agent dasatinib is not an effective treatment 
for patients with acquired resistance to EGFR-TKI therapy, and in 
this study was associated with development of pleural effusions. 
However, additional data has emerged that dramatic disease progres-
sion commonly occurs in patients with acquired resistance when their 
TKI is discontinued (Riely, GJ. Clin. Cancer Res. 2007). It is now our 
standard practice to continue treatment with a TKI in addition to any 
subsequent therapy in patients who demonstrate acquired resistance. 
Further, attenuations in the dose and schedule of dasatinib in the 
CML experience have improved its side effect profile (Shah. JCO. 
2008). Given this collective data, our protocol has been amended so 
that patients will continue E or G in addition to treatment with dasat-
inib 100 mg once daily. To date, 2 patients have been entered in this 
study. Supported, in part, by NIH R21 CA (30343-01).
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Cisplatin-vinorelbine chemotherapy in non-small cell lung 
cancer is safe and well-tolerated. Results of a retrospective 
Hungarian clinical data analysis
Juhasz, Erzsebet; Tamási, Lilla
Koranyi National Institute for Pulmonology, Budapest, Hungary
The efficacy of cisplatin-vinorelbine chemotherapy (CT) in non-small 
cell lung cancer (NSCLC) is well established. In this retrospective 
data analysis, hematological safety and tolerability, furthermore the 
effects of cisplatin-vinorelbine combination on patients’ quality of 
life (QoL) were examined, by reviewing the clinical data of NSCLC 
patients (N=25) in a retrospective manner. All patients received the 
following regimen: cisplatin (80 mg/m2; day 1; intravenous infusion) 
- vinorelbine (30 mg/m2; day 1 and 8; intravenous infusion; 21 day 
cycles; patients received four cycles of CT). Hematological labora-
tory and QoL data of the day 1 of all cycles were collected. QoL 
was assessed by reviewing the data of patients’ charts considering 
physical limitation, fatigue, nausea, vomiting, diarrhea, constipa-
tion, social activities, fever, appetite and weight loss. The absence 
of problems was scored 0 points; moderate complains 1, and serious 
deterioration 2 points (data are presented in mean ± SD).
The QoL data showed no significant deterioration in the analyzed 
symptoms of patients during the four cycles of cisplatin-vinorelbine 
CT (total QoL score was 3.0 ± 1.4 points before treatment vs. 3.6 ± 
0.5 on the day 1 of the last cycle, p>0.05). Hemoglobin values were 
118.4 ± 12.3 g/L before CT and 109.0 ± 11.3 g/L on the day 1 of last 
cycle of CT (p>0.05). The mean number of platelets in the begin-
ning and in the end were 256 ± 123*1012/L and 217 ± 119*1012/L, 
respectively (p<0.05). White blood cell count was 8.36 ± 3.21*109/L, 
absolute granulocyte count 5.95 ± 5.81*109/L before the treatment, 
and these data were 4.50 ± 1.96*109/L and 2.15 ± 1.21*109/L, re-
spectively, on the day 1 of last cycle of chemotherapy (both p<0.005). 
According to these observations, cisplatin-vinorelbine CT is a safe 
and well tolerated chemotherapeutic option of NSCLC.
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Erlotinib response of brain and/or leptomeningeal 
metastases in patients with lung adenocarcinoma who 
showed initial good response to gefitinib
Katayama, Tatsuya; Shimizu, Junichi; Fukui, Tkayuki; Ito, Simon; 
Hatooka, Shunzo; Hida, Toyoaki; Yatabe, Yasushi; Mitsudomi, 
Tetsuya
Aich Cancer Center Hospital, Aichi, Japan
Background: Metastases involving the central nervous system 
(CNS) such as brain or leptomeningeal metastases are relatively 
common in clinical course of non-small cell lung cancer (NSCLC) 
even in patients with EGFR mutation whose diseases outside of 
CNS are initially controlled by gefitinib (G) successfully. Efficacy 
of high-dose G (1250mg) for leptomeningeal metastasis in a patient 
with lung cancer harboring EGFR mutation was reported (Jackman 
et al., JCO, 24, 4517-4520, 2006). In this study, serum concentration 
of G was 3.7uM while that in CSF was 39 nM due to blood brain 
barrier (BBB). On the other hand, trough serum concentration with 
G (250mg/day) and E (150mg/day) were reported to be 0.4uM and 
3.5uM, respectively. Based on these observations, we speculated 
that E instead of high-dose G might be effective for CNS lesions in 
patients with EGFR mutation.
Methods: Patients with lung cancer in whom CNS lesions developed 
after initial good response of their extra CNS lesions to G were 
enrolled. G was switched to E without interposition of other drugs. 
Tumor response, time to progression, change in performance status 
(PS), and change in serum carcinoembryonic antigen (CEA) level 
were evaluated. 
Results: Patient characteristics and clinical courses are summarized 
in the table. There were seven such patients. All patients had EGFR 
mutations in their primary tumors except one patient for whom tumor 
specimen was not available. Interval between G and E ranged from 
1-47 days (median 5 days) Three patients showed PR, three SD 
and one PD. Performance status and metastasis-related neurogenic 
symptoms were improved in five patients. Overall survival from the 
initiation of E ranged from 15 to 530 days (median 88 days). Tumor 
cells in CSF of Patient 7 had T790M resistant mutation in addition to 
exon 19 deletion. Her disease progressed rapidly and she died 23 days 
after switching to E.
Conclusions: E elicited tumor response and improvement of PS in 
most patients who developed CNS lesions after initial good response 
of extra CNS tumors to G. Tumor cells in CNS in general had not 
been exposed to such concentration of G that induced apoptosis 
because of BBB. Therefore these cells did not need to develop resist-
ant mechanism such as T790M. We conclude that treatment with E is 
one useful option for gefitinib-resistant CNS diseases, except in rare 
examples as Patient 7 for whom T790M already developed in CNS 
lesions while being treated with G. 
Case Age(y) 
/Sex
EGFR 
Muta-
tion
TTP 
for G 
(days)
Inter-
val 
Be-
tween 
G & E 
(days)
Time 
E to 
Death 
(days)
Re-
sponse 
to E 
in the 
CNS 
site
PS Metastasis-
Related 
Neurogenic 
Symptoms
Post-E 
Neuro-
genic 
Symp-
toms
CEA 
(ng/
ml)
1 81/M X19 
del.
275 35 178 PR 4 » 4 Dysmnesia, 
Gait Disorder
im-
proved
43.6 » 
11.5
2 63/F X19 
del.
516 2 247 SD 3 » 1 Consciousness 
Disorder
im-
proved
451.0 » 
7.1
3 58/F L858R 113 47 60 SD 4 » 3 Headache,  
Postural-
Disorder
im-
proved
67.0 » 
47.6
4 60/F X19 
del.
1211 5 530 PR 1 » 1 Syncope attack, 
Polyopia
im-
proved
3249.5 
» 1294.5
5 64/M N.A. 192 2 88 PR 3 » 2 Consciousness 
Disorder, Gait 
disorder
im-
proved
N.A.
6 60/F L858R 242 8 15 SD 4 » 4 Dysmnesia, 
Gait Disorder
Pro-
gres-
sion
17.4 » 
9.5
7 61/F X19 
del.
382 1 23 N.A. 3 » 4 Headache, 
Nausea,  
Vomiting
Pro-
gres-
sion
136.7 » 
110.8
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Phase II study of pemetrexed and carboplatin as a salvage 
therapy in patients with advanced NSCLC
Kim, Jung Han1; Kim, Hyeong Su 1; Lee, Gyeong-Won 2; Kim, Ho 
Young1; Kim, Hyo Jung 1; Kwon, Jung Hye 1; Jang, Hyun Joo1; Jung, 
Joo Young 1; Zang, Dae Young1
1 Hallym University Medical Center, Seoul, Korea; 2 Gyeongsang 
National University College of Medicine, Jin Ju, Korea
Background: Pemetrexed and carboplatin have been demonstrated to 
be synergistic in preclinical model. In this study, we evaluate the ef-
ficacy of the combination with pemetrexed and carboplatin as salvage 
therapy in patients with advanced NSCLC.
Patients and Methods: Patients with advanced non-small cell lung 
cancer (NSCLC) who received one or more prior chemotherapy were 
eligible. Treatment was consisted of pemetrexed (500mg/m2 over 10 
minutes intravenous infusion) and carboplatin (AUC 5 mg/mL/min 
over 30 minutes intravenous infusion) on day 1 of 21-day cycle. All 
patients were supplemented with folic acid and vitamin B12 to reduce 
hematological toxicity of pemetrexed. 
Results: From March 2007 to August 2008, 30 patients were en-
rolled. The majority of patients were male (90%), and median age 
was 62.5 years (range, 36-75). One patient (3.3%) achieved complete 
response and five (16.7%) showed partial response. Eight patients 
had stable disease. On intent-to-treat basis, the overall response rate 
was 20.0% (95% CI: 9.1% - 37.7%). With a median follow up of 
5.3 months, median time to progression was 2.3 months and median 
overall survival was 8.7 months (range, 0.3-17.2 months). Five 
patients (16.7%) experienced grade 3 or 4 hematologic toxicities, 
and two patients (6.7%) experienced grade 3 or 4 non-hematologic 
toxicities. 
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Conclusion: The combination of pemetrexed and carboplatin as a 
salvage chemotherapy for patients with advanced NSCLC is active 
and well-tolerated. 
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Optimal therapeutic sequence for EGFR TKI and 
pemetrexed
Lee, Jeong Eun; Park, Hee Sun; Jung, Sung Soo; Lim, Seung Pyung; 
Kim, Ju Ock; Park, Ji Won; Shin, Ji Young; Kim, Sun Young
Chungnam National University & Cancer Research Institute, 
Daejeon, Korea
Background: The epidermal growth factor receptor (EGFR) tyrosine 
kinase inhibitor and the multitargeted antifolate pemetrexed are 
effective for the treatment of relapsed non-small cell lung cancer 
(NSCLC). Preclinical studies reported differences in the tumor re-
sponse according to the therapeutic sequence of the two drugs.1,2 We 
compared the disease control rate between sequential treatment with 
an EGFR-TKI (erlotinib or gefitinib) and pemetrexed and the reverse 
order in patients with relapsing NSCLC.
Methods: We collected data on 176 patients with previously treated 
NSCLC. The patients were treated sequentially with pemetrexed 
followed by an EGFR-TKI (pemetrexed/EGFR-TKI) or in the reverse 
order (EGFR-TKI/pemetrexed). The tumor response was evalu-
ated according to the Response Evaluation Criteria in Solid Tumors 
(RECIST).
Results: Baseline characteristics were collected for 69 patients in the 
pemetrexed/EGFR-TKI group and 107 patients in the EGFR-TKI/pe-
metrexed group. The median age of the two groups was 63.0 and 59.0 
years, respectively (p=0.694). Ten (14.5%) and 51 (47.7%) patients 
were female in the respective groups (p=0.000). The diagnosis was 
adenocarcinoma in 25 (36.2%) and 72 (67.3%) patients, respect-
ively (p=0.004). The Eastern Cooperative Oncology Group (ECOG) 
performance status was ≥2 in 67 (97.1%) and 94 (87.9%) patients, 
respectively (p=0.032). The disease control rates were 47.7% (31/65) 
and 44.4% (44/99), respectively (p=0.683). Although the EGFR-TKI/
pemetrexed group had advantages in terms of more adenocarcinoma 
and more female patients, the difference in the disease control rate 
between the two groups was not significant.
Conclusion: This study showed that the preclinical result in which 
EGFR-TKI before pemetrexed decreases the tumor response is clinic-
ally meaningful.
References:
1. Li T, Ling YH, Goldman D, et al. Schedule-dependent cytotoxic synergism of 
pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res 
2007;13:3413–3422
2. Giovannetti E, Lemos C, Tekle C, et al. Molecular mechanisms underlying the syn-
ergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase 
inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer 
cells. Mol Pharmacol 2008;73:1290–1300
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Phase II study of combination chemotherapy with 
docetaxel and carboplatin for elderly patients with 
advanced non-small cell lung cancer
Kim, Hye Jin; Kim, Tae Gyoon; Park, Won Hyoung; Song, Dae 
Geun; Min, Bo Young; Park, Hyoun Kyoung; Lee, Hyun Jung; Nam, 
Seung-Hyun; Kim, Bong-Seog 
Seoul Veterans Hospital, Seoul, Korea
Background: More than 50% of advanced non-small cell lung cancer 
(NSCLC) are diagnosed in patients older than age 65 years. Cisplatin-
based chemotherapy has been used in patients with advanced NSCLC 
as standard treatment, and we investigated the efficacy and safety of 
combination chemotherapy with docetaxel and carboplatin for elderly 
patients with advanced non-small cell lung cancer.
Methods: Chemotherapy-naïve patients (age ≥ 65 years) with stage 
IIIB or IV NSCLC were enrolled. Patients received docetaxel (75 
mg/m2 on D1) and carboplatin (AUC of 5 mg/ml/min on D1) every 
3 weeks. End points included response, time to progression, overall 
survival, and toxicity.
Results: Total 37 patients were enrolled between March 2005 and 
August 2008. Median age was 75 years old (range, 65 to 84 years), 
and 33 patients (89.2%) had ECOG PS 0 or 1. Twenty two patients 
(59.5%) had increased Charlson comorbidity index score (CCI ≥1). 
The median number of treatment cycles was five (range, 1-8), and 
relative dose intensity was 95.6% in docetaxel and 95.8% in carbo-
platin. Overall response rate was 51.3% (95% CI 34.9-67.1) with 
one complete response, and 18 partial responses. The median time 
to progression was 6.7 months and median overall survival was 12.3 
months. In 164 cycles, grade 3 or 4 hematologic toxicities included 
neutropenia (10.4%), anemia (1.8%), and thrombocytopenia (1.2%). 
Non-hematologic toxicities were tolerable.
Conclusions: The combination chemotherapy with docetaxel and 
carboplatin was effective with tolerable toxicities in elderly patients 
with advanced non-small cell lung cancer.
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Diagnostic Value of CEA and CYFRA 21-1 for the 
differential diagnosis of 
Kim, Yong Hoon; Choi, Jae Sung; Seo, Ki Hyun; Na, Joo Ok; Lee, 
Ho Sung 
The Korean academy of Tuberculosis and Respiratory Diseases, 
Cheonan-si, Chungcheongnam-do, Korea
Introduction: The purpose of this study was to assess the clinical 
usefulness of carcinoembryonic antigen (CEA) and CYFRA 21-1 
tumor markers as diagnostic tools that are complementary to cytology 
or pleural biopsy in the diagnosis of malignant pleural effusions.
Methods: The levels of CEA and CYFRA 21-1 in pleural fluid and 
serum were prospectively assayed in 260 patients with pleural effu-
sions (205 benign effusions, 55 malignant effusions). 
Results: The cut-off levels of CEA and CYFRA 21-1 in malignant 
pleural effusions, depending on the basis of the best diagnostic acur-
racy (CEA 92.2%, CYFRA 21-1 74.1%), were 5.1 ng/mL and 52 ng/
mL, respectively. In malignant pleural effusions, the sensitivity of 
CEA and CYFRA 21-1 were 74% and 26.3%, respectively, with the 
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specificity of 97.8% and 81.9%, respectively. Using a combination of 
two marker, the sensitivity increased to 81.2%. But combination of 
two marker was not significant difference(ρ>0.05).
Conclusions: The study suggests that pleural CEA could provide a 
useful parameter for the differential diagnosis between benign and 
malignant pleural effusion. CYFRA 21-1 might serve as alternatives 
when CEA assay is normal value. But, when compared with CEA, 
CYFRA 21-1 has no advantage.
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Beneficial effect of selected vegetables in treatment of 
patients with advanced Non-small Cell Lung Cancer
Ko, How-Wen1; Chen, Chih-Hung 1; Tsai, Ying-Huang1; Liu, Hui-Ping 
2
1 Department of Chest Medicine, Chang Gung Memorial Hospital, 
Taoyuan, Taiwan; 2 Division of Thoracic Surgery, Chang Gung 
Memorial Hospital, Keelung, Taiwan
Background: Systemic treatments with chemotherapy for advanced 
non-small cell lung cancer (NSCLC) have low efficacy. The median 
survival for patients with advanced disease treated with platinum-
based chemotherapy is in the range of 8-10 months. Therapies that 
target the epidermal growth factor receptor (EGFR) are effective in 
NSCLC patients; however, only a subset of these patients has re-
sponse. Selected vegetables (SV) contain a mixture of vegetables and 
herbs having anti-tumor components. The objective of this study was 
to evaluate the effect of SV on the survival of stage IIIB/IV NSCLC 
patients.
Methods: Between September 2003 and July 2006, 49 stage IIIB/IV 
NSCLC patients who took SV in our hospital were included as study 
group. Patients with stage IIIB/IV NSCLC who were diagnosed in 
our hospital in 2005 without SV supplement were included as control 
group. Medical records were reviewed to determine patient gender, 
age, pathology, stage, performance, smoking status and treatment 
type, including chemotherapy, radiotherapy and targeted therapy. The 
starting date and duration of taking SV were also reviewed. These 
patients were followed until death or Dec 31, 2007. In the retrospect-
ive analysis, we compare patients with matched age and demographic 
distribution in both SV and control groups. Categorical data and 
continuous variables were compared using chi-square and Student’s t 
test. The survival time was calculated from the starting date of SV in 
study group or the first line treatment in control group to the date of 
death or to the cutoff date. Overall survival was estimated by using 
the Kaplan and Meier method. 
Results: In study group, 38 patients (mean age of 59.5±11.6 yr; 
42.1% female) received systemic treatment with chemotherapy and/
or EGFR tyrosine kinase inhibitor (EGFR-TKI), such as gefitinib 
or erlotinib, when they took SV as supplement. Among them, 23 
(60.5%) patients was stage IV NSCLC; 36 (94.7%) had a perform-
ance status of 0, 1, or 2. Nineteen (50%) patients were non-smoker, 
and 22 (57.9%) had adenocarcinoma. The median survival of the 
38 patients in SV group was significantly longer than age-matched 
control group (20.10 months vs. 13.08 months, p = 0.0078). The re-
mainder, 11 ones (mean age of 59.0±11.4 yr; 36.4% female), received 
regional radiotherapy or best supportive care only. Of the 11 patients, 
10 (90.9%) were stage IV disease; 8 (72.7%) had a performance 
status of 3 or 4. Six (54.5%) patients were non-smoker and 5 (45.5%) 
had adenocarcinoma. The median survival in these 11 patients was 
significantly longer than age-matched control group (5.67 months vs. 
2.46 months, p = 0.0031). 
Conclusion: Our retrospective study results suggest that taking SV 
as a supplement in patients with advanced NSCLC who received sys-
temic treatment with chemotherapy and/or EGFR-TKI or supportive 
care with or without local radiotherapy was associated with better 
survival time, compared with age-matched control group. Whether 
the outcome of SV supplement is more effective and has more favor-
able toxicity profile than systemic therapies alone in all lung cancer 
patients requires confirmation from further prospective randomized 
trial.
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The efficacy of erlotinib for patients with non-small cell 
lung cancer with wild type of EGFR mutations
Kobayashi, Takashi1; Koizumi, Tomonobu1; Tanabe, Tsuyoshi1; 
Tsushima, Kenji1; Urushihata, Kazuhisa1; Yamamoto, Hiroshi1; 
Hanaoka, Masayuki1; Kubo, Keishi1; Koyama, Shigeru2; Ooura, 
Nariaki3
1 First Department of Internal Medicine, Shinshu University School 
of Medicine, Matsumoto, Japan; 2 Nagano Red Cross Hospital, 
Nagano, Japan; 3 Saku Central Hospital, Saku, Japan
Background: Epidermal growth factor receptor (EGFR) muta-
tion status is associated with efficacy of non-small cell lung cancer 
(NSCLC) to EGFR tyrosine kinase inhibitors (EGFR-TKIs). It is 
well known that a high response rate to EGFR-TKIs is observed in 
patients harboring with EGFR mutations and less than 10% response 
rate in wild-type EGFR. However, little information about the ef-
ficacy in NSCLC patients with wild-type EGFR existed, especially 
about erlotinib in Japan. We conducted this study to evaluate the 
efficacy of erlotinib in patients with advanced NSCLC without EGFR 
mutations.
Methods: Patients with stage IIIB/IV NSCLC whose tumor have 
wild-type EGFR and never underwent any EGFR-TKIs were eligible. 
They received erlotinib (150mg/day), and the response and toxicity 
were evaluated.
Results: Thirteen patients, median age of 72 yr (range 48 to 81), 
ten male and three female were enrolled. Eight had adenocarcinoma 
and five had squamous cell carcinoma. Ten were smoker and three 
were non-smoker. Stage IIIB and IV was five and eight, respectively. 
Performance status 0/1/2/3/ was 3/5/2/3, respectively. Erlotinib was 
administered as 2nd (7 cases), 3rd (4 cases) and 4rh (2 cases) line 
chemotherapy. One patient achieved complete response and four were 
stable disease, resulted in 8 % of response rate and 39% of disease 
control rate, respectively. Interstitial lung disease (ILD) occurred in 
two patients (15%); however they all recovered ILD by steroid ther-
apy. Skin eruption was observed ten (77%). Progression free survival 
and overall survival is now analyzing.
Conclusions: The response rate of erlotinib for Japanese patients 
with wild type of EGFR mutation is low and the clinical efficacy 
remains obscure in patients with NSCLC without EGFR mutations.
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Prognostic value of synaptophysine and chromogranine 
A serum levels in advanced non-small cell lung cancer – 
retrospective analysis.
Kowalski, Dariusz M.1; Jaskiewicz, Piotr1; Olszewski, Wlodzimierz 
T.2; Krzakowski, Maciej1
1 M. Sklodowska-Curie Memorial Cancer Centre and Institute, 
Department of Lung Cancer and Chest Tumours, Warsaw, Poland; 
2 M. Sklodowska-Curie Memorial Cancer Centre and Institute, 
Department of Pathology, Warsaw, Poland
Background: Performance status, weight loss, age, clinical stage, 
extent of metastases, increased LDH activity, and pretreatment 
hemoglobin value are prognostic in advanced non-small cell lung 
cancer (NSCLC). Numerous molecular factors (eg, EGFR protein 
expression, BCL2, K-RAS, C-MYC, TP53 gene status, mitotic index, 
ploidy and neuroendocrine markers) are potentially prognostic.
Materials and Methods: Between 2002 and 2004, 139 stage III or 
IV NSCLC patients (pts) received palliative chemotherapy. Synapto-
physine and chromogranine A levels were retrospectively analysed 
for prognostic value. There were 116 male and 23 female pts. Median 
age was 57.3 (range 31-75). Karnofsky performance status 100-80 
and 70-60 was found in 79.9% and 21.1% of pts, respectively. Clin-
ical stage IIIA, IIIB and IV was diagnosed in 28 (20.9%), 63 (45.3%) 
and 48 (33.8%) pts. Pathology revealed squamous-cell carcinoma 
in 92 pts (66.2%), adenocarcinoma in 26 pts (18.7%), and large-cell 
carcinoma in 3 pts (2.2%); unspecified type in 18 pts (12.9%). Weight 
loss >10% and <10% were observed in 51 (36.7%) and 88 (66.3%) 
pts, respectively. Pretreatment hemoglobin concentration in a range 
of 14-12 g/dl, 12-10 g/dl, and <10 g/dl was observed in 47 (33.8%), 
62 (44.6%), 28 (20.1%), 2 (1.4%) pts, respectively. All treated pts 
received cisplatin-based chemotherapy.
Results: No expression of synaptophysine was observed in 127 
(91,4%) pts, whereas expression was confirmed in 12 (8,6%) pts. 
Lack of chromogranine A expression was found in 134 (96,4%) pts, 
and 3 (3,6%) pts were positive (Table).
Table. Synaptophysine and Chromogranine A expression
 score pts N %
  Synaptophysine 
 0 127 91.4
 1 12 8.6
  Chromogranine A 
 0 134 96.4
 1 5 3.6
No statistically significant correlation between synaptophysine and 
chromogranine A expression and clinical factors (histologic type, 
sex, TNM and stage) were found. Median survival time for all pts 
was 11.7 months (range: 1.01-43.47 months). Probability of 12- and 
24-month survival rates were 0,48 (95%CI 0,38-0,58) and 0,22 
(95%CI 0,13-0,31). Probability of 12- and 24- month survival with 
respect to synaptophysine expression status (positive vs negative) 
was 64% (95%CI 0,35-0,93) vs 46% (95%CI 0,35-0,93) and 64% 
(95%CI 0,36-0,56) vs 16% (95%CI 0,07- 0,25), difference significant 
respectively(p=0.008). Probability of 12- and 24-month survival in 
patients with respect to chromogranine A status (positive vs negative) 
was 80% (95%CI 0,44-1,00) vs 47% (95% CI 0,44-0,1,00) and 80% 
(95% CI 0,37-0,57) vs 19% (95% CI 0,10-0,28); difference signifi-
cant (p=0.014).
Conclusions: Synaptophysine and Chromogranine A expression may 
potentially represent positive prognostic factor in advanced NSCLC 
patients exposed to cisplatin-based palliative chemotherapy.
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Erlotinib in the treatment of patients with multiple 
metastases from non-small cell lung cancer – could clinical 
parameters be a surrogate predictor of response?
Fenton, Paul; Bayne, Mike; Cherrett, Lynn; Laurence, Virginia
Dorset Cancer Centre, Poole, UK
Background: Both erlotinib and gefitinib are epidermal growth 
factor receptor (EGFR) tyrosine kinase inhibitors shown to have 
activity in non-small cell lung cancer patients. Asian ethnic origin, 
non-smoking status and adenocarcinomas have been reported as 
independent predictors of survival and there is much ongoing work 
investigating molecular predictors of response. Following experience 
with expanded access programmes for both of these drugs it was 
noted that clinically useful responses occurred in patients with small 
volume metastatic disease especially within the brain. This report 
covers our experience to date with erlotinib and demonstrates an 
excellent response rate and enhanced survival in responding patients 
compared to published literature.
Methods: We conducted a retrospective review of consecutive pa-
tients who received erlotinib therapy for non-small cell lung cancer at 
the Dorset Cancer Centre. A policy of selecting patients for erlotinib 
therapy who had small volume metastatic disease (including brain 
metastases) was employed. All patients received 150mg erlotinib 
daily and underwent monthly clinical assessment. Treatment was 
discontinued if there was no clinical or radiological response at two 
months or, in responding patients, at the time of clinical or radio-
logical progression.
Results: 35 patients commenced erlotinib therapy during the study 
period: 20 (57%) male and 15 (43%) female. 85% had previously 
received chemotherapy. The overall response rate was 40% and the 
mean duration of treatment was 4.9 months. In the 14 patients with 
brain metastases the response rate was 50% and the mean duration 
of treatment was 11 months. In those who had previously received 
chemotherapy the response rate was 43%. For responding patients the 
mean duration of treatment was 8.9 months.
Conclusions: We submit that patients with small volume metastatic 
non-small cell lung cancer, including those with brain metastases, 
have an excellent response rate with erlotinib therapy and may be a 
clinical group who should be considered for early treatment with er-
lotinib. Randomised trials of tyrosine kinase inhibitors would need to 
confirm that clinical parameters may predict for biological response.
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Routine administration of single dosis cisplatin ≥75 mg/
m2 after short hydratation in an outpatient clinic for lung 
cancer
Lavole, Armelle1; Danel, Sophie1; Baudrin, Laurence2; Epaud, 
Christelle1; Gounant, Valerie1; Rosencher, Lise1; Milleron, Bernard1
1 service pneumologie et réanimation respiratoire, paris, France; 
2 Unité de Biostatistiques, Intergroupe Francophone d’Oncologie 
Thoracique, Paris, France
Background: Cisplatin is a pivotal drug in combination chemo-
therapy for non-small cell and small-cell lung cancers (NSCLC and 
SCLC), but its renal toxicity is limiting. Current guidelines recom-
mend, 24 h hydration and, consequently, hospitalization is required. 
The aim of their retrospective study was to confirm the safety of 
a short hydratation of intermediate to high dose of cisplatin in an 
outpatient clinic. 
Patients and Methods: Patients eligible for the retrospective study 
(between January 2001 and May 2007) had NSCLC or SCLC and 
were treated at the outpatient clinic with a chemotherapy regimen that 
included cisplatin ≥75 mg/m2 with the same short hydration protocol 
for one day. Nephrotoxicity was defined as ≥ grade 1 according to 
NCIC Common Toxicity Criteria. Predictive factors for nephrotox-
icity were analyzed. Creatinine clearance variation (∆CC) (difference 
between the initial calculated CC and the minimal CC recorded up to 
completion of the last course with cisplatin) was calculated too. 
Results: 357 consecutive patients (median 58 years, range 25-81) 
were reviewed. 
Twenty one patients (6%) had nephrotoxicity of ≥grade 1. Among 
these 21 patients, all except one had toxicity of grade=1. Predict-
ive factors independently associated with nephrotoxicity included 
frequently associated co-morbid conditions (hypertension, diabetes, 
heart disease) (OR=4.97 CI 95% [1.8-13.7] p=0.002), initial serum 
creatinine ≥100 µmol/L (OR=8.3 CI 95% [2.55-27.4] p=0.0005) 
and dose cycle cisplatin ≥ 100 mg/m2 (OR=10.8 CI 95% [3.6-32.5] 
p<0.0001). 
Conclusion: Rapid outpatient administration of single dosis cisplatin 
at ≥75 mg/m2 is feasible without high risk of nephrotoxicity. 
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Comparison of gefitinib and erlotinib for Korean patients 
with advanced non-small cell lung cancer
Lee, Jin Hwa; Jo, You Ri; Park, Hye Sung; Ryu, Yon Ju; Chun, Eun 
Mi; Chang, Jung Hyun
Ewha Womans University School of Medicine, Seoul, Korea
Background: The epidermal growth factor receptor tyrosine kinase 
inhibitors (EGFR-TKIs) became an attractive therapeutic option for 
advanced non-small cell lung cancer (NSCLC). Several studies sug-
gested that there might be some different response predictors between 
gefitinib and erlotinib. We compared the efficacy and toxicity of 
gefitinib and erlotinib in Korean patients with advanced NSCLC 
and evaluated whether each of gefitinib and erlotinib has different 
predictors of response. 
Methods: We collected the clinical information of advanced NSCLC 
patients treated with gefitinib or erlotinib for more than two weeks at 
Ewha Womans University Hospital between July 2003 and Febru-
ary 2009. Median survivals were calculated using the Kaplan-Meier 
method. 
Results: Eighty-six patients (52 gefitinib vs. 34 erlotinib) were 
enrolled. Their median age was 64 years and 53 (62%) were male. 
Thirty-eight patients (44%) were non-smokers and 44 (51%) had 
adenocarcinoma. There were 38% at stage IIIb and 62% at stage 
IV. Out of the 86 patients treated, 35 achieved a partial remission 
(PR) and 12 experienced stable disease (SD) while 31 experienced 
progressive disease (PD), resulting in a response rate of 41% and a 
disease control rate of 55%. After a median follow-up of 502 days, 
the median progression-free and overall survival (OS) time was 129 
and 259 days, respectively. There were no significant differences in 
the overall response rate (gefitinib 42% vs. erlotinib 38%, p=0.786), 
median survival time (gefitinib 301 days vs. erlotinib 202 days, 
p=0.151), and time to progression (gefitinib 136 days vs. erlotinib 92 
days, p=0.672). Although a 71-year-old woman with adenocarcin-
oma, showing dramatic response to erlotinib, died of interstitial lung 
disease associated with erlotinib, both EGFR-TKIs showed similar 
toxicity. As many previous studies, in a multivariate analysis using 
Cox regression model, adenocarcinoma was an independent predictor 
of survival (p=0.004; relative risk [RR], 0.478; 95% confidence 
interval [CI], 0.288-0.791). Under subgroup analysis, female patients 
showed longer time to progression in the gefitinib group compared to 
erlotinib group (230 days vs. 129 days, p=0.034 by Breslow [Gener-
alized Wilcoxon] test). 
Conclusions: Between gefitinib and erlotinib, there were no differ-
ences in the response rate, overall survival, and time to progression. 
Although the number of subjects was very small in this study, there 
might be gender difference between responses to these drugs. 
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A Phase IV, multicenter, non-randomized, open-labeled 
study to evaluate the efficacy of Gefitinib (IRESSA®) as a 
second-line therapy in Korean patients with non-small cell 
lung cancer (NSCLC)
Lee, Kwan-Ho1; Lee, Kye-Young2; Jeon, Young-June3; Jung, Maan-
Hong4; Son, Choon-Hee5; Lee, Min-Ki6; Ryu, Jeong-Seon7; Yang, 
Sei-Hoon8; Lee, Jae-Cheol9; Kim, Young-Chul10; Kim, Sun-Young11
1 Department of Pumonology Yongnam Univ. Medical Center, 
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Department of Pumonology Konkuk Univ. Hospital, Seoul, Korea; 
3 Department of Pumonology Kyemyung Univ. Dongsan Medical 
Center, Daegu, Korea; 4 Department of Pumonology Kosin University 
Gospel Hospital, Busan, Korea; 5 Department of Pumonology 
Dong-A University Medical Center, Busan, Korea; 6 Department of 
Pumonology Pusan National University Hospital, Busan, Korea; 
7 Department of Pulmonology, Inha University Hospital, Incheon, 
Korea; 8 Department of Pumonology Wongwang University hospital, 
Iksan, Korea; 9 Department of Pulmonology,Korea Cancer Center 
Hospital, Seoul, Korea; 10 Department of Pumonology Chonnam 
National Univ. Medical School, Hwasun, Korea; 11 Department of 
Pumonology Chungnam Univ. Hospital, Daejeon, Korea
Background: This Phase IV, multicenter, non-randomized, open-
labeled study (SELINE [SEcond-Line IRESSA Phase IV study in 
NSCLC patiEnt]) was conducted to evaluate the efficacy of gefitinib 
as a second-line therapy in Korean patients with advanced NSCLC.
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Methods: Between January 2007 and December 2008, 156 patients 
(86% female, 86% adenocarcinoma, 84% never smoker, 42% EGFR 
mutation-positive) were enrolled. The primary objectives were to 
evaluate the objective response rate (ORR), and to determine the 
relationship between clinical outcome and the following clinical and 
biological characteristics: EGFR mutation status, sex, smoking status, 
tumor histology. Secondary endpoints were progression-free survival 
(PFS), overall survival (OS), quality of life (QoL; Functional Assess-
ment of Cancer Therapy Lung [FACT-L]), and symptom improve-
ment (FACT-L lung cancer subscale [LCS]) with gefitinib treatment. 
Safety was assessed with reference to NCI CTCAE (version 3.0).
Results: The ORR was 29.8 % (0.7 % [n = 1] complete response, 
29.1 % [n=41] partial response), and 54 (38.3 %) patients demon-
strated stable disease as best response to treatment. The ORR among 
patients who were EGFR mutation-positive was 40.68 % and the 
ORR among patients who were EGFR mutation-negative was 16.33 
% (p=0.0058). There were no statistically significant differences in 
ORR between female vs. male (29.8% vs. 30.0%, p=0.9821) and 
between non-smoker vs. ever-smoker (30.3% vs. 27.3%, p=0.7789) 
and among adenocarcinoma vs. squamous carcinoma vs. other sub-
types (32.0% vs. 14.3% vs. 20.0%, p=0.4756). Median PFS was 5.67 
months (95% C.I., 3.77 ~ 7.13) for the overall population; a positive 
EGFR mutation status was associated with longer PFS (p=0.0038) 
than those with who were EGFR mutation-negative. OS was signifi-
cantly longer in women than in men (p=0.0087). There were no sta-
tistically significant differences in mean QoL and LCS scores during 
the treatment compared to change from baseline. In total 29 serious 
adverse events (AEs) were reported by 20 patients (13.2 %).
Conclusions: Gefitinib demonstrated significant antitumor activ-
ity with a favorable tolerability profile as a second-line therapy in 
Korean patients with advanced NSCLC. A positive EGFR mutation 
status was strongly associated with greater response to gefitinib and a 
prolonged PFS.
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Comparison if pleurodesis agents for malignant pleural 
effusion: talc causes selective apoptosis lf cancer cells
Lee, Pyng1; Li, Sun 2; Aw, Swee Eng2; Colt, Henri G.3
1 Department of Respiratory and Critical Care Medicine, Singapore 
General Hospital, Singapore, Singapore; 2 Department of Clinical 
Research, Singapore General Hospital, Singapore, Singapore; 3 
Pulmonary and Critical Care, University of California, Irvine, 
Orange, CA, USA
Background: Majority of patients with lung cancer present at 
advanced stage, and treatment is largely palliative. For patients with 
malignant effusions, pleurodesis with talc is one method to prevent 
recurrence. Although talc is widely used in clinical practice and is 
the preferred agent, mechanisms for its efficacy as well as apoptotic 
effects on cancer cells have not been studied.
Methods: Talc, bleomycin and doxycycline were applied at in-
creasing concentrations of 25, 50 and 75 μg/ml to commercial lung 
adenocarcinoma cell line and normal mesothelial cells isolated from 
transudative pleural effusions. Silicone beads were used as control. 
Apoptosis of lung cancer cells and pleural mesothelial cells was 
measured with propidium iodide staining and flow cytometric analy-
sis at 24, 48, and 72 hours. 
Results: Talc induced apoptosis of lung adenocarcinoma cells in a 
dose and time dependent fashion (table), which was superior to bleo-
mycin and inferior to doxycycline (figure). No apoptosis of normal 
mesothelial cells was documented with talc but was observed with 
doxycycline, and to a lesser degree with bleomycin.
Conclusion: Talc causes selective apoptosis of cancer cells and 
spares the normal mesothelium essential for pleurodesis. These find-
ings may explain its superior efficacy over other agents for malignant 
effusion due to lung cancer. 
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Lung cancer patients treated with chemotherapy: 30-day 
death rates in SE Wales
Howe, Theresa; Brewster, Alison E.; Hanna, Carol L.; Keni, 
Manjusha; Lester, Jason F.
Velindre Hospital, Cardiff, UK
Introduction: In England, Wales and Northern Ireland, the National 
Confidential Enquiry into Patient Outcome and Death (NCEPOD) 
studied the deaths of those patients who died within 30 days of 
systemic anti cancer treatment (SACT), looking at whether death was 
due to treatment-related toxicity, progressive disease or an unrelated 
cause. All patients with solid or haematological malignancies were 
included. Overall, 2.2% of patients died within 30 days per SACT 
cycle. Velindre Cancer Centre has a catchment population of 1.4 
million people in South East Wales, and treats lung cancer patients 
via six multidisciplinary teams based in peripheral district general 
hospitals. A retrospective audit was carried out to compare 30-day 
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death rates in lung cancer patients receiving chemotherapy in South 
East Wales with the NCEPOD report.
Methods: All Velindre Hospital lung cancer patients who started 
chemotherapy between 1st April 2003 and 31st March 2004 were 
identified. Using electronic records and paper case notes, data were 
collected on patient demographics, cancer details, treatment received 
and caused of death, Information was also obtained from laboratories, 
post mortem reports and GP surgeries. 
Results: In total, 130 lung cancer patients received chemotherapy. 
Treatment was given with palliative intent in 90% of cases. In total, 
53/130 (41%) patients were performance status (PS) 2/3. Overall, 
27/130 (21%) patients died within 30 days of receiving chemotherapy. 
Patients received a median of 3 cycles, giving an estimated 7% aver-
age death rate within 30 days per chemotherapy cycle. In total, 8/130 
(6%) patients died due to treatment-related toxicity (~2% average 
death rate within 30 days per chemotherapy cycle). This suggests 
that up to 5% of patients may have died of progressive disease per 
chemotherapy cycle. 30-day mortality was higher with poorer PS: 
patients: PS 3=33%, PS 2=29%, PS 1= 17%, PS 0 = 5%.
Conclusions: The estimated 7% average death rate within 30 days 
per chemotherapy cycle is much higher than the 2% NCEPOD rate, 
which included all tumour types and adjuvant treatments. Advanced 
lung cancer has a poor prognosis and patients often have signifi-
cant comorbid disease. In addition, it is clear that poor PS patients 
have higher 30-day mortality and 41% of our patients were PS 2 or 
worse. Death rates might therefore be expected to be higher than the 
NCEPOD average. However, it is probable many patients are dying 
of progressive disease when on chemotherapy. Health professionals 
require clear guidelines to ensure prompt recognition and appropri-
ate treatment of chemotherapy-related toxicity. Selecting patients for 
chemotherapy needs careful consideration. The majority of chemo-
therapy is given with palliative intent and decisions about chemo-
therapy require honest communication with patients about potential 
toxicities as well as possible benefits. In addition, it is important 
that patients are carefully assessed during chemotherapy to ensure 
ineffective treatment is not continued longer than necessary.
We are planning to review our management of chemotherapy com-
plications and look for common themes which may identify patients 
likely to have a very poor prognosis.
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Influence of comorbidity on the choice of treatment and 
survival of elderly patient non-small cell lung cancer
Li, Hong; Zheng, shi y.; Jiang, Dong; Ge, Jin f.
Department of Thoracocardiac Surgery, The First Affiliated Hospital 
of Suzhou University, Suzhou, China
Background: To identify the influence of comorbidity on the choice 
of treatment and survival of elderly patients ( 70 years)with advanced 
non-small cell lung cancer (NSCLC).
Methods: The clinical characteristics and the choices of treatment 
of 177 elderly patients, who had a good performance status(PS≤1)
were retrospectively analyzed in Department of Geriatrics, The First 
Affiliated Hospital of Suzhou University between January 2005 to 
December 2005. Survival data were only analyzed in those whose 
had received chemotherapy. All patients were stratified by number of 
comorbidity as none(0), mild (1-2) and severe(3)groups.
Results: The proportion of patients who received chemotherapy, with 
none, mild and severe comorbidity was significantly different (79.3%, 
76.2% and 57.4%, P=0.038), and there was also significantly differ-
ent about palliative radiotherapy rate among the three groups (21.7%, 
11.7% and 37.0%, P=0. 014). The median survival and 1-year sur-
vival rate in none. mild and severe comorbidity groups were 1 3.6 vs. 
10.2 vs. 7.6 months and 5.5% vs. 41.3% vs. 20.8% respectively (Log-
rank, P=0.071). In univariate and multivariate Cox models analysis, 
only severe comorbidity was a independent hazard factor of survival 
of elderly patients with NSCLC. Relative ratio (RR, 95% CI): (209, 
1.06-4.1 5), P=0.034.
Conclusions: Comorbidity may affect the choice of treatment of 
elderly patients with advanced NSCLC slightly, but only severe com-
orbidity is a independent prognostic factor of survival.
P1.209 NSCLC Advanced Disease, Sat Aug 1 
An open-label single-arm phase IV study of pemetrexed in 
Taiwanese patients with advanced Non-Small Cell Lung 
Cancer who have had prior chemotherapy
Chang, Gee-Chen2; Tsai, Chun-Ming3; Hsia, Te-Chun4; Yang, Chih-
Hsin5; Scheuer, Nicolas1; Blair, Julie1; Linn, Carlos6
1 Eli Lilly Australia Pty Ltd, Macquarie Park, NSW, Australia; 2 
Taichung Veterans General Hospital, Taichung, Taiwan; 3 Taipei 
Veterans General Hospital, Taipei, Taiwan; 4 China Medical 
University Hospital, Taichung, Taiwan; 5 National Taiwan University 
Hospital, Taipei, Taiwan; 6 Eli Lilly and Company (Taiwan) Inc, 
Taipei, Taiwan
Background: The primary objective of this open-label single-arm 
study determined objective response rate to single-agent pemetrexed 
used at escalated or reduced dosing by tolerability after Cycle 1 
in Taiwanese patients with advanced non-small cell lung cancer 
(NSCLC) who had had prior chemotherapy.
Methods: Eligibility criteria included histologic/cytologic NSCLC 
diagnosis, stage IIIB/IV, one prior chemotherapy regimen for pallia-
tion with/without subsequent targeted biologic therapy, and Eastern 
Cooperative Oncology Group performance status 0 or 1. Pemetrexed 
was given on Day 1 of each 21-day cycle. A 500 mg/m² dose was 
given in Cycle 1: this increased to 1000 mg/m² from Cycle 2 if the 
patient had no toxicity exceeding predefined levels in Cycle 1; other-
wise, it was reduced to 375 mg/m². All patients received folic acid, 
vitamin B12 and dexamethasone. Data were analyzed when the last 
enrolled patient had received 6 cycles of pemetrexed.
Results: Between November 2006 and April 2008, 33 patients were 
enrolled (20 males, 13 females) of mean age 58.0 years (range, 39-85 
years), 25 with non-squamous and 8 with squamous histology. At 
Cycle 2, pemetrexed dose was escalated for 25/33 patients (75.8%) 
and reduced for 5/33 patients (15.2%); 3 patients discontinued before 
Cycle 2. Scheduling conflicts or toxicity delayed 21/191 cycles 
(11.0%); toxicity reduced dose for 6 cycles (3.1%). Patients com-
pleted 1-17 cycles (median, 4 cycles), receiving a median 99.3% of 
the planned mean dose. Patients had a median relative dose intensity 
of 251.5 mg/m²/week (range, 125-323).
For best overall response, there were no complete responders and 6 
partial responders for an objective response rate of 18.2% (Exact 95% 
CI: 7.0%, 35.5%), and 12 patients with stable disease for a disease 
control rate of 54.5% (Exact 95% CI: 36.4%, 71.9%). Ten patients 
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(30.3%) had progressive disease. Five patients (15.2%) were non-
evaluable for best overall response. 
Kaplan-Meier median time-to-event secondary objective param-
eters were 6.9 months for progression-free survival, 6.6 months for 
duration of response for responding patients, 2.9 months for time-
to-treatment failure, and 6.9 months for time-to-documented tumor 
progression. Median overall survival was not estimable with current 
data but 6-month survival rate was 76.5% (95% CI: 56.8%, 88.1%).
There were 2 possibly study drug-related serious adverse events 
(SAEs) (neutropenia and leukopenia), and 2 study drug-related dis-
continuations due to non-SAEs. Seventeen patients (51.5%) reported 
Grade 3/4 toxicity; of these, 12 (70.6%) experienced study drug-relat-
ed toxicity, including 7 patients with neutropenia and 2 with fatigue.
There were no patient deaths on study therapy or within 30 days of 
receiving last study drug dose. There were 10 deaths after the 30-day 
post-therapy follow-up phase, none of which was thought to be study 
drug-related.
Conclusions: Though this is a single-arm study, the objective re-
sponse and disease control rates in this Taiwanese patient population 
are comparable with other similar East Asian studies. This, coupled to 
the favorable toxicity profile, supports the use of pemetrexed as a 2nd 
line treatment for NSCLC in this population.
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Percutaneous CT-guided radiofrequency ablation of 
advanced Non–Small Cell Lung Cancer: preliminary 
report
Liu, Bao Dong; Zhi, Xiu yi
Xuanwu Hospital, Beijing Lung Cancer Center, Capital Medical 
University, Beijing, China
Objective: To assess technical feasibility,efficacy,and complications 
of percutaneous computed tomography (CT)-guided transthoracic 
radiofrequency ablation (RFA) for treating advanced non–small cell 
lung cancer (NSCLC). 
Methods: Sixty-six patients with advanced non–small cell lung 
cancer underwent RFA with RITA electrodes with percutaneous CT 
guidance. Patients were not candidates for surgery because of either 
advanced-stage disease (n=48) and/or comorbid processes (n=15) or 
refusal to undergo surgery (n=3). Contrast –enhanced CT was per-
formed immediately, 1 month, and then every 3 months after RFA to 
evaluate the response to therapy. Time to death for each patient was 
calculated with Kaplan-Meier analysis. 
Results: No lesions showed complete necrosis, 49 lesions (74.2%) 
showed partial response, contrast CT revealed cavity formation 
or scar formation.7 lesions with stable disease, 5 lesions showed 
progressive disease. Tumor recurrence of 5 patients received second 
session of RFA. Remainder 5 cases died at 2 months after the 
procedure due to metastasis. The density of 62 lesions was lowered 
(93.93%) and 4 lesion is increased (6.06%). Post-procedure PET or 
SPECT showed loss of virtually all FDG activity in the previously 
positive areas in 54 of 66 patients (81.8%). Mean survival of patients 
with partial necrosis (15.6 months) was significantly better than that 
of patients with stable disease and progressive disease (6.9 months) 
(P<0.01). No procedural mortality occurred. Minor complications 
included small pneumothorax in 6, none requiring drainage, intrapul-
monary hemorrhage in 2, chest pain in 2, cough in 4.Side effects 
(moderate-grade fever <38.5℃, and/or chest pain) were commonest 
complications, however, most of them were cured within a couple of 
days. 
Conclusion: This pilot clinical study demonstrates that CT-guided 
RFA is a relatively safe, effective and promising procedure for the 
treatment of inoperable NSCLC and metastases. Follow-up CT 
is helpful in assessing the effect of RFA, accurate localization of 
the electrode needle and searching possible complications. PET or 
SPECT is also a good and sensitive procedure for follow-up, provid-
ing good discrimination between residual granulation tissue and 
recurrent tumor.
P1.211 NSCLC Advanced Disease, Sat Aug 1 
Safe and long-lasting tumor control with erlotinib in 
advanced non-small cell lung cancer
De Sanctis, Rita; Longo, Flavia; Sollami, Rossella; Frantellizzi, 
Viviana; Stumbo, Luciano; Gori, Bruno; Del Signore, Ester; Grassi, 
Paolo; Quadrini, Silvia; Di Seri, Marisa
Department of Clinical Oncology A, “Sapienza” University of Rome, 
Rome, Italy
Background: Erlotinib, an EGFR tyrosine kinase inhibitor, demon-
strated significantly prolonged survival, with low toxicity profile, in 
patients (pts) with advanced non small cell lung cancer (NSCLC), 
who had progressed after standard chemotherapy. Erlotinib ap-
proval was supported by the results of a large multicentre random-
ized placebo-controlled phase III trial (National Cancer Institute of 
Canada-NCIC BR.21 study). In the BR.21 study, 73 pts showed a 
significant progression-free (PFS) and overall survival (OS) benefit 
(2.2 months and 6.7 months respectively); overall response rate to 
Erlotinib was 9%, with a median response duration of 7.9 months; the 
disease-control rate, DCR (complete response CR, partial response 
PR or stable disease SD), was 45%. 
The aim of this study was to estimate the efficacy and tolerability of 
erlotinib monotherapy in patients with locally advanced or metastatic 
NSCLC, who had failed prior taxane and/or platinum-based chemo-
therapy.
Patients and Methods: Since EMEA approval through February 
2009, thirty-one NSCLC pts received the standard dose of erlotinib 
(150 mg orally once daily) until disease progression or unacceptable 
toxicity. 
Safety profile was assessed according to NCI-CTCAE, version 3.0. 
Antitumour activity was evaluated by CT-scan every 3 months and 
response graded according to RECIST criteria. Kaplan-Meier method 
was used to estimate PFS and OS.
Results: The men-to-women ratio was 2/1. Median age was 66 years 
(range 39-77). ECOG PS was 0-1 in 18 pts (58%) and 2 in 13 pts (42 
%). 27 pts had data available for response evaluation. Erlotinib was 
administered as second-line treatment in 20 patients (65%) and III 
or superior line in 11 pts (35%). Median treatment duration was 9.9 
months (range 1-37). Five pts (16%) had PR, lasting a median of 22 
months (range 12-29), and seventeen patients (55%) had SD, lasting a 
median of 9 months (range 5-29), giving a disease control rate (DCR) 
of 71%. Nine patients (29%) had progressive disease after a median 
of 3 months (range 1-5). At the time of analysis, 11 pts are still on 
treatment (1 PR and 10 SD). Median overall survival (OS) was 8 
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months (95% CI, 4-18 months), with a 1-year survival rate of 42%. 
Median PFS was 5 months (95% CI, 3-15 months). 
Erlotinib was generally well tolerated. The most common adverse 
events (AEs) were rash (54%; maximum grade: G3, 12%) and diar-
rhea (22%; G3, 3%). AEs had been treated with topical treatment 
alone or associated with a systematic treatment with tetracyclines and 
steroids for G1-2 rash. For G2 AEs affecting quality of life (QoL) 
we considered dose interruptions (3-5 days) or, if necessary, a dose 
reduction to 100mg/day (29%); for G3 toxicity we reduced erlotinib 
dose at 100mg/day (22%). 
Conclusion: The safety profile appears favorable and manageable. 
Although modest response rate to erlotinib was observed, DCR was 
not restricted to any subgroup of pts who may achieve a long-term 
survival. 
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Docetaxel in combination with gemcitabine as second line 
treatment in patients with platinum resistant advanced 
NSCLC
Gori, Bruno2; Longo, Flavia1; Zivi, Andrea2; Sperduti, Isabella3; 
Stumbo, Luciano2; Del Signore, Ester2; De Sanctis, Rita2; Quadrini, 
Silvia2; De Filippis, Lucilla2; Di Seri, Marisa2
1 "Sapienza" University of Rome, Rome, Italy; 2 Department of 
Clinical Oncology A, “Sapienza”University of Rome, Rome, Italy; 
3 Department of Medical Statistics, Regina Elena Institut Hospital, 
Rome, Italy
Background: Docetaxel and Gemcitabine are active in advanced 
NSCLC: our purpose is to verify the efficacy of this combination as 
second-line treatment in patients with platinum-resistant advanced 
NSCLC. 
Methods: From June 2006 to December 2008, 42 chemotherapy-
naive pts with NSCLC, stage IIIB or IV, ECOG PS 0-1. They all 
received two cycles of Cisplatin 75 mg/mq plus Docetaxel 75 mg/
mq (CD) every three weeks and then were evaluated with a CT scan. 
Patients with partial response (PR) or stable disease (SD) continued 
the same regimen until severe adverse event or progression. Patients 
with progressive disease (PD) received a second-line chemotherapy 
with Docetaxel 75 mg/mq d1 and Gemcitabine 1000 mg/mq d1-8 
every three weeks (DG) until progression. Primary endpoint was to 
evaluate the 6-months overall survival (OS) in the DG-pts; secondary 
endpoints were progression free survival (PFS), tolerability and qual-
ity of life (QoL) with EORTC QLQ-C30 questionnaire. 
Results: After two cycles of CD, 14 pts (33,3%) had PR, 16 pts 
(38,1%) were stable and 12 pts (28,6%) had PD. These 12 pts were 
in early progression after two CD-cycles and performed DG as a 
second-line therapy. At the CT scan evaluation, after two cycles of 
DG, 1 pt achieved RP, 5 SD and 6 PD. The non-PD pts continued 
performing DG. The median PFS, since the DG regimen switch, was 
13 weeks (CI95% 12-14) and the 6-months-OS was 16,7%. Patients 
who continued with DC (n= 30) obtained a 1-year-OS of 54,9 %, a 
1-yr PFS of 27.1% and a median PFS of 9 months (CI95% 6-11). 
Five patients of the CD-arm received a surgical resection after three 
or six cycles of CD and downstaging to IB (UICC 2002) occurred in 
one patient. In the DG-arm we observe one patient who received a 
surgical resection with a OS of 18 months. In the same group we ob-
serve three patients had an OS longer than 1 year, respectively 19 and 
25 months, and they are still in follow up. The most common adverse 
events (AE) were alopecia (80%), nausea/vomiting (75%), neutro-
penia (45%), anaemia (10%), and diarrhoea (10%). No significant 
differences in AEs were observed, except for alopecia and nausea/
vomiting, which occurred more frequently with CDDP-Docetaxel, 
but the DG group had an improvement in the emotional functioning. 
Conclusions: The combination of gemcitabine and docetaxel is well 
tolerated in patients with advanced NSCLC who have failed prior 
taxane platinum chemotherapy and improves pts palliative outcomes 
without compromising quality of life. 
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Second-line treatment for non-small cell lung cancer: data 
from single institution experience
Lu, Shun; Zhang, Yifei; Cheng, Baijun; Chen, Zhiwei; Li, Ziming; 
Yu, Yongfeng
Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai 
Jiao Tong University, Shanghai, China
Objective: To compare the efficacy and toxicity in second-line treat-
ment for non-small cell lung cancer (NSCLC) in different regimens. 
Methods: 239 NSCLC patients treated with docetaxel,pemetrexed, 
gefitinib or erlotinib as second-line therapy in Shanghai Chest 
Hospital from 2002 to 2008 were retrospectively analyzed. Survival 
analysis was evaluated by Kaplan-Meier and Life-Table. 
Results: DCR of these patients were 66.47%, 73.08%, 81.25% and 
84.21% respectively. MST of these patients were 18.30m, 16.03m, 
21.23m and 21.77m respectively (image 1). PFS of these patients 
were 5.00m, 5.20m, 6.77m and 4.67m respectively (image 2). And 
1-year survival rate of these patients were 72.03%, 55.49%,62.50% 
and 78.95% respectively. There was no statistically significance in 
DCR χ2=5.04, P=0.17, PFS (χ2=2.09, P=0.55), OS (χ2=3.97, P=0.26) 
or 1-year survival rate: χ2=4.07, P=0.25, among these four regimens. 
Meanwhile, the hematologic toxicity of docetaxel agent was signifi-
cantly higher than the other regimens(P=0.00).The gastro-intestinal 
toxicity of docetaxel and pemetrexed were much more severe than 
the other two regimens(P=0.00). Rash and diarrhea were more fre-
quently happened with gefitinib and erlotinib(P=0.00). 
Conclusion: These four regimens share similar efficacy in the 
secone-line treatment for NSCLC. All the toxicities were tolerable.
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Hard Choices: a qualitative study of influences on the 
treatment decisions made by patients with advanced non 
small cell lung cancer (NSCLC) 
Macbeth, Fergus R.1; Mead, Donna2; Thornton, Matthew 2; Gill, 
Paul2; Parry, Maria2
1 National Institute for Health and CLinical Excellence, London, UK; 
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Background: The majority of patients with NSLC present with 
incurable, advanced disease and treatment decisions may be hard. 
Radiotherapy can be used to palliate local symptoms but has little 
effect on survival for most, while chemotherapy is only modestly 
effective with a significant risk of side effects. For many patients with 
NSLC there is a difficult decision, with risks and benefits needing 
to be openly discussed. No study has yet explored the factors that 
influence a patient’s choice of treatment during the oncologist-patient 
consultation.
Methods: Five participants were recruited into the study from a 
regional oncology unit in Cardiff, UK. Audio taping and subsequent 
analysis of the oncologist-patient consultation allowed an interview 
schedule to be devised which was then used for a semi-structured 
interview with the participant to elicit factors that influenced their 
choice of treatment during the consultation. Interviews were tran-
scribed verbatim and analysed using a process of thematic content 
analysis. 
Results: Participants opting for chemotherapy, presented with fewer 
symptoms, had been more active in their information seeking before 
the consultation and were more willing to accept the risk of side 
effects. Some participants opting for chemotherapy had made the 
decision to accept chemotherapy before seeing the oncologist. Par-
ticipants opting for radiotherapy were less willing to accept the risk 
of side effects from chemotherapy for the possible small survival gain 
and focussed on symptom relief. Three participants said that they 
had reached a decision on their own, while one felt the oncologist 
had influenced their decision. One had asked the oncologist to make 
a decision on their behalf. Analysis of the doctor-patient tapes in 
conjunction with the participants recollections indicated a consulta-
tion style which varied between an “informed” and “shared” decision 
making model. The effect of “framing” was also noted and could be 
a possible source of bias with detailed quantitative information about 
the possible benefits of chemotherapy being discussed whereas risks 
were explained using terms such as “significant,” which could be 
open to interpretation. All the participants expressed shock at the poor 
prognosis but felt well supported in reaching a decision for treatment. 
Conclusion: Some patients actively seek information before the 
consultation with the oncologist from a variety of formal (health pro-
fessionals) and informal (family and friends) sources. This may ad-
versely affect the oncologist - patient consultation as this information 
may be incomplete or inaccurate. Patients vary in their willingness to 
accept potential risks for small potential gains, with treatment plans 
needing to be explored on an individual basis. Information about 
prognosis and the aims and side effects of treatment was provided in 
a clear and balanced manner but the likelihood of adverse events was 
less explicitly described. Some patients require more support than 
others in reaching a decision. Further research should explore the 
ways of describing risks and the use of decision aids in this clnical 
context.
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A phase II study of a combination of carboplatin plus 
gemcitabine following a pretreatment of dexamethazone
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Graduate School of Medicine and School of Medicine, Sendai, Japan; 
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Background: Several studies have demonstrated that the combina-
tion of CBDCA plus GEM appears as effective as cisplatin (CP) 
containing regimens. CBDCA plus GEM regimens are associated 
with more haematological toxicity but with lower non-hematological 
toxicity as compared to CP-based regimens. Some reports dem-
onstrated a pretreatment of dexamethazone(DEX) did not only 
decreased hematologic toxicity but also increase anti-tumor effect. 
We conducted multicenter phase II study of pretreatment of DEX 
before administration of CBDCA/GEM to evaluate both rate of G3/4 
thrombocytopenia and tumor response rate. 
Method: A primary objective of this trial is the rate of G3/4 
thrombocytopenia during 1st course and secondary objective are 
response rate, safety, and rate of transfusion of platelet. The eligible 
pts had previously untreated aNSCLC with PS0/1. Pts received the 
GEM1000 mg/m2 day 1,8, CBDCA AUC=5 day1, DEX 8 mg/day 
day-1,0,1, DEX 4 mg/day day8. 
Result: The previously untreated NSCLC 34 pts were registered. Pt 
characteristics were male/female 21/13, median age 66 (range:39-77 
years), histologic subtype Ad/Sq/La/others: 25/5/3/1, clinical stage 
IIIB/IV/recurrence after surgery: 2/28/4, median course is 4 courses 
and the response rate was 23.5% (PR/SD/PD/NE: 8/20/5/1). G3/4 
thrombocytopenia of the 1st course was seen to 13 cases (38%) and 3 
cases among them needed platelet transfusion. 
Conclusion: This study suggested that pretreatment of DEX before 
CBDCA/GEM treatment relieves hematological toxicity.
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Gefitinib in chemo-naive, poor performance status, 
Non Small Cell Lung Cancer (NSCLC) patients – A 
randomized, single institution pilot study
Malhotra, Hemant1; Sharma, Rajesh2; Khandelwal, PD3
1 Head, Division of Medical Oncology, Jaipur, India; 2 Medical 
Officer, Birla Cancer Center, SMS Medical Colelge Hospital, Jaipur, 
India; 3 Professsor & Head, Dept of Medicine, SMS Medical College 
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Background: The oral epidermal growth factor receptor (EGFR) 
inhibitor, Gefitinib, has been found to be effective in the treatment 
of NSCLC especially in certain subsets of patients (non-smokers, 
women, adeno or bronchio-alveolar carcinomas, Asian ethnicity). 
The majority of patients of lung cancer in India present in advanced 
stages and in poor Performance Status (PS), where chemotherapy is 
too toxic to be recommended. Other than best supportive care (BSC), 
treatment options for this group of patients are limited. The present 
study reports the results of a randomized, pilot study from the SMS 
Medical College Hospital, Jaipur, India of the use of generic Gefitinib 
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compared with BSC in patients of advanced stage, poor performance 
status NSCLC patients.
Methods: Between January 2005 to December 2006, 40 patients 
of advanced (stage IIIB or IV), chemo-naïve, cytological/histo-
pathologically confirmed NSCLC with poor ‘PS’ (ECOG PS 2 or 
3) were randomly assigned to receive BSC + oral Gefitinib 250 mg/
day (G arm) versus BSC only (BSC arm). None of the patients were 
given chemotherapy. Patients were clinically and radiologically (X-
ray Chest PA & lateral views) followed up monthly while CT scans 
were done three monthly. Primary end point of the study was overall 
survival. EGFR mutation studies were not performed.
Results: There were 29 males and 11 females with mean age of 56 
years (range 44 to 73 years). Squamous cell carcinoma was the com-
monest histology (18/40) followed by adenocarcinoma (14/40), un-
classified NSCLC (07/40) and bronchio-alveolar carcinoma (01/40). 
Thirty six of the 40 patients (90%) were smokers. Twenty one and 19 
patients were randomized to the G arm and BSC arm, respectively. 
There were no complete responses. Partial responses (PR) were seen 
in 05/21 (23.8%) in the G arm and none in BSC arm, stable disease 
(SD) 03/21 (14.3%) in G arm and 01/19 (5.3%) in BSC arm, giving a 
disease control rate of 37.9% versus 5.3% between G and BSC arms. 
The median overall survival (OS) in the G arm was 7.7 months versus 
3.9 months in the BSC arm. Main toxicities observed in the G arm 
were acneform rash [grade3 to 4 in 1/21 (4.8%), grade 1 to 2 in 07/21 
(33.3%)], diarrhea [grade 1 to 2 in 05/21 (23.8%)] and increase in 
hepatic enzymes [grade 1 to 2 in 03/21 (14.3%)]. No patient required 
stoppage of Gefitinib because of toxicity or intolerance.
Conclusions: In this small trial, Gefitinib treatment, in addition to 
BSC, in patients with advanced stage, poor ‘PS’ NSCLC patients, 
produced disease control in significantly more patients (37.9% versus 
5.3%) and improved overall survival by 3.8 months (from 3.9 to 7.7 
months) as compared to BSC with minimal toxicities. It is suggested 
that a therapeutic trial of this simple, minimally toxic and affordable 
oral treatment be offered to all patients who are not candidates for 
systemic chemotherapy. With evaluation of EGFR mutation status of 
these patients, it should be possible to further select patient who are 
likely to respond. A similar, larger trial is underway at our institution.
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Phase II Trial of Carboplatin, Pemetrexed, Bevacizumab 
in Advanced non-Small Cell (non-Squamous) Lung Cancer
Guarino, Michael J.; Masters, Gregory A.; Biggs, David D.
Helen F. Graham Cancer Center, Newark, DE, USA
This trial, designed to examine PFS, OS and toxicities of a novel 
three drug combination in NSC lung cancer began enrollment on 
3/17/08. Entry criteria included patients with non-squamous stage 
IIIB (non-RT candidates) or IV, measurable disease, ECOG 0-1; for 
first line therapy. Patients with significant hemoptysis, cavitary le-
sions, lesions in proximity to major blood vessels, or with prior chest 
RT were excluded.
Treatment consisted of Carboplatin AUC5, Pemetrxad 500mg/m2, 
Bevcizumab 15mg/kg q21d x 6 cycles; then Bevacizumab mainten-
ance q3wk for up to one year. This is a preliminary report on the first 
15 patients entered.
Nine women and six men, age range 40-80 years; median age 67; 
two with stage IIIB, the rest with metastatic disease; are reported 
on through 64 cycles of treatment. Nine tumors were categorized as 
adeno- or predominantly adenoca. The rest were recorded as NSC. 
In general,treatment has been well tolerated. 12 of the patients have 
completed chemotherapy: 5 completed all six cycles; 2 five cycles. 
Three patients have completed cycle #5 and are still under treatment. 
Only one treatment related hospitalization has occured to date: for 
grade 4 fatigue. Three other grade 4 toxicities have been encountered: 
a platelet count of 4K and another of 18K (each in a patient on the 
last cycle of treatment); and a PE which was treated with out-patient 
therapy. No grade 4 Leucopenia or Neutropenia has been encoun-
tered, and there have been no episodes of Febrile Neutropenia. Only 
one “dose reduction” has been required- the patient with the PE had 
Bevacizumab discontinued. Three patients have received a total of 
10 units RBC transfusion. Two patients each received a single donor 
platelet pheresis pack.
With 3 patients still on chemotherapy at 14+ weeks, and data for 
them censored, PFS in the rest ramnges fron 2-35+ weeks; median 20 
weeks. Survival ranges fron 11-39+ weeks, with only 4 deaths thus 
far; not enough time has transpired to make this statistic meaningful. 
All 15 patients are evaluable for RECIST response to treatmentr (not 
yet confirmed by independent review): 1CR, 6PR, 6SD, 2PD.
In summary, a novel three drug combination for advanced NCS (non-
squamous) lung cancer shows promising efficacy with modest tox-
icity. The study is on-going, with a maximum of 50 patients planned.
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[11C] labeled erlotinib as a new radiotracer for 
identification of patients responding to erlotinib treatment: 
A preliminary study on lung cancer patients
Memon, Ashfaque A.1; Weber, Britta 1; Jakobsen, Steen2; Winterdahl, 
Michael2; Dagnaes-Hansen, Frederik3; Madsen, Henrik T.4; 
Meldgaard, Peter5; Sørensen, Boe S.6; Keiding, Susanne2; Nexo, 
Ebba6
1 Aarhus University Hospital, Aarhus, Denmark; 2 PET Center, 
Aarhus University Hospital, Aarhus, Denmark; 3 Department of 
Medical Microbiology and Immunology, Aarhus University, Aarhus, 
Denmark; 4 Department of Radiology, Aarhus University hospital, 
Aarhus, Denmark; 5 Department of Oncology, Aarhus University 
Hospital, Aarhus, Denmark; 6 Department of Clinical Biochemistry, 
Aarhus University Hospital, Aarhus, Denmark
Erlotinib (Tarceva®) is a tailored drug targeting the Epidermal 
Growth Factor Receptor (EGFR), which is commonly overexpressed 
in various human cancers including lung cancer. The purpose of 
this study was to develop a method for identification of lung cancer 
patients that respond to erlotinib treatment by PET scanning. We 
demonstrate that erlotinib can be labeled with [11C] by reacting the 
normethyl precursor with [11C] methyl iodide followed by HPLC 
purification. 
First we tested [11C] erlotinib on nude mice xenografted with lung 
cancer cell lines with either a high (A549, NCI358) or low (HCC827) 
degree of sensitivity to erlotinib treatment. Dynamic micro-PET stud-
ies showed that the sensitive tumors had the highest [11C] erlotinib 
uptake among all tumor models examined. These results were also 
confirmed on biodistribution studies with [11C] erlotinib. In mice 
carrying the sensitive cancer cells the accumulation of [11C] erlotinib 
was higher in the tumor than in all other organs except the liver 
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which is the main organ of erlotinib metabolism (Cancer Research, 
2009 69: 873-878).
We have now extended this study to patients with the aim to identify 
the subset of patients that will respond to Erlotinib treatment (10-15 
%). Tumors were identified by routine CT scan and [18F]-2-fluoro-
2-deoxyglucose (FDG) PET/CT and compared with [11C] erlotinib 
PET/CT. As expected, all patients examined so far (n=4) showed 
[18F] FDG uptake. Our results with [11C] erlotinib show that tumors 
can be identified by [11C] erlotinib. However we do not know yet 
if this accumulation can be used to identify the subgroup of patients 
responding to erlotinib.
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A multi-centre randomized, open-label phase ii trial of 
erlotinib plus gemcitabine or gemcitabine monotherapy as 
first-line therapy in ECOG PS2 patients with chemo-naive 
advanced NSCLC
Michael, Michael1; Pavlakis, Nick2; Clingan, Philip3; De Boer, 
Richard4; Johnston, Michael5; Clarke, Stephen6
1 Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; 2 
Royal North Shore Hospital, St Leonards, NSW, Australia; 3 Southern 
Medical Day Care, Wollongong, NSW, Australia; 4 Royal Melbourne 
Hospital, Parkville, VIC, Australia; 5 Roche Products Pty Limited, 
Dee Why, NSW, Australia; 6 Concord Repatriation General Hospital, 
Concord, NSW, Australia
Background: The majority of research effort in advanced NSCLC 
has focused on patients with good performance status (ECOG PS 
0-1). Treatment of patients with ECOG PS 2 is poorly defined. 
Erlotinib, a selective inhibitor of EGFR tyrosine kinase, is cur-
rently approved for the use in the treatment of NSCLC after failure 
of platinum containing therapy. Gemcitabine has been successfully 
combined with erlotinib in patients with advanced pancreatic cancer 
with improved efficacy. The aim of this study was to assess the activ-
ity and tolerance of the combination of gemcitabine + erlotinib in 
patients with chemonaive NSCLC who are ECOG PS2.
Methods: Eligible patients had chemotherapy-naive NSCLC either 
stage IIIB (with plural effusion) or stage IV with measurable disease 
and ECOG PS 2, and adequate organ function. Patients were random-
ized to receive either erlotinib (150 mg/day p.o.) plus gemcitabine 
(1000 mg/m2 Day 1,8 +15 q28 days), (EG), or gemcitabine mono-
therapy (1000 mg/m2 Day 1,8 +15 q28 days), (G). Recruitment over 
a 12 month period was slow due to a lower than expected number 
of suitable ECOG PS 2 patients. Consequently the study was closed 
early.
Results: A total of 17 patients (pts) were randomized (12 male, 
16 current or former smokers, 4 squamous cell, 4 large cell and 9 
adenocarcinoma). Sixteen pts received treatment (each arm n = 8). 
Incidence of treatment-related adverse events (AEs) was n = 8/8 in 
the EG arm and 6/8 in the G arm (n=number of pts). Most AEs were 
grade 1-2. No difference in the number of treatment-related hema-
tological toxicities was seen (each arm, n = 3/8). The most common 
treatment-related non-hematological AEs in the EG arm were rash 
(n = 7/8) and diarrhea (n = 7/8), most of which were grade 1-2. No 
treatment-related rash or diarrhea was reported in the G arm. No pts 
withdrew due to treatment-related AEs. Efficacy was evaluable in 15 
pts (1 patient received no treatment in G arm, 1 patient in EG arm 
had no follow-up tumor assessment). The best overall response was 
partial response (PR) in 2 pts in the EG arm (duration of response 
was 16 and 47+ weeks, respectively), with no responses seen in the 
G arm. Both responders were former smokers, one male and one 
female, with squamous cell and large cell carcinoma respectively. At 
8 and 16 weeks, 6/7 and 3/7 pts in the EG arm and 6/8 and 2/8 pts in 
the G arm, respectively, had not progressed.
Conclusion: The investigated regimen of erlotinib in combination 
with gemcitabine for the treatment of advanced stage, chemotherapy-
naive NSCLC ECOG PS 2 patients seems to be feasible with ac-
ceptable toxicity. No new safety signals were identified for erlotinib. 
Although the observed PR in the combination arm of this difficult 
to treat patient population is encouraging, the efficacy of adding er-
lotinib to gemcitabine therapy needs to be further evaluated. Further 
investigations which allow for the inclusion of a wider patient-popu-
lation (ECOG PS 2 and elderly) and which combines intercalated 
administration of erlotinib and gemcitabine are ongoing.
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A randomized phase II study comparing a 21-day schedule 
of Pemetrexed (P) and Gemcitabine (G) versus biweekly 
P and G in patients with advanced Non-Small Cell Lung 
Cancer (NSCLC)
Qi, Yingwei1; Molina, Julian R.1; Adjei, Alex A.3; Nelson, Garth1; 
Nikcevich, Daniel A.4; Rowland, Kendrith M.5; Geeraerts, Louis H.6; 
Dakhil, Shaker R.7; Obasaju, Coleman K.2
1 Mayo Clinic, Rochester, MN, USA; 2 Lilly USA, Indianapolis, IN, 
USA; 3 Roswell Park Cancer Institute, Buffalo, NY, USA; 4 Duluth 
Clinic, Duluth, MN, USA; 5 Carle Clinic Association, Urbana, IL, 
USA; 6 MeritCare Medical Group, Fargo, ND, USA; 7 Cancer Center 
of Kansas, Wichita, KS, USA
Background: Pemetrexed (P), a multi-targeted antifolate, is syner-
gisitic with gemcitabine (G) in preclinical models. Among patients 
with advanced NSCLC, the combination has been shown to have 
activity in several Phase II trials employing 21-day treatment cycles 
(West et al. Ann Oncol 2009, Treat et al. Lung Cancer 2006, Ma et al. 
JCO 2005, Monnerat et al. CCR 2004) and in one trial employing a 
14-day treatment cycle (Dudek et al. JTO 2008). The current random-
ized trial was initiated to investigate the optimal scheduling of P plus 
G in advanced NSCLC.
Methods: Patients with Stage IIIB (with pleural effusion) or IV 
NSCLC, ECOG performance status (PS) of 0 or 1, no prior systemic 
chemotherapy, immunotherapy, or biological therapy were enrolled. 
Treatment consisted of P 500 mg/m2 followed by G 1250 mg/m2 on 
Days 1 and 8 repeated every 21 days, up to 6 cycles (Arm A) or P 
500 mg/m2 followed by G 1500 mg/m2 on Day 1 every 14 days, up to 
9 cycles (Arm B). All patients received folic acid, vitamin B12, and 
steroid prophylaxis. The primary endpoint was response rate. Planned 
sample size was 80 patients.
Results: Between 2/07 and 1/08, 19 patients were enrolled (10 in 
Arm A and 9 in Arm B). This trial was subsequently discontinued 
prior to achieving the full planned sample size. One patient (Arm B) 
was not included in efficacy analysis due to a protocol violation.
Conclusion: Every 21-day or biweekly schedules of G and P appear 
to be well tolerated in advanced NSCLC. Early termination of this 
trial precludes definitive conclusions.
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Characteristics/Results Pemetrexed-
Gemcitabine 21-Day 
Schedule (Arm A) N=10
Pemetrexed-Gemcitabine 
Biweekly Schedule (Arm 
B) N=9
Median age, yrs 70.5 63.0
Male gender, % 50 67
Squamous: nonsquamous. % 10:90 22:78
Disease stage IIIB:IV, % 20:80 22:78
Number evaluated for efficacy 10 8
Mean number of cycles 3.3 4.6
% receiving protocol-specified 
limit of cycles
40 25
Complete response, % 0 0
Partial response, % 20 0
95% CI for response rate 2.5, 55.6 --
Fisher’s exact P value 0.48
Median survival, mos (95% CI) 5.1 (2.4, 14.2) 8.1 (5.5, 10.1)
1 year survival, % 26.7 0
Censorship, % 20 0
Log-rank P value 0.56
Median PFS, mos (95% CI) 1.7 (0.7, 4.3) 5.0 (1.7, 6.0)
Censorship, % 0 0
Log-rank P value 0.015
Neutropenia, Grade 3/4, % 60/20 22/22
Anemia, Grade 3/4, % 30/10 11/0
Thrombocytopenia, Grade 3/4, % 10/10 0/0
Febrile neutropenia Grade 3/4, % 10/0 0/0
Fatigue, Grade 3/4, % 0/0 33/22
Dyspnea, Grade 3/4, % 20/0 22/0
Pneumonia, Grade 3/4, % 0/0 22/0
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α-Galactosylceramide-pulsed antigen presenting cell 
treatment in patients with advanced NSCLC
Motohashi, Shinichiro1; Nagato, Kaoru1; Taniguchi, Masaru3; 
Nakayama, Toshinori1; Yoshino, Ichiro2
1 Department of Medical Immunology, Graduate School of Medicine, 
Chiba University, Chiba, Japan; 2 Department of Thoracic Surgery, 
Graduate School of Medicine, Chiba University, Chiba, Japan; 3 
RIKEN Research Center for Allergy and Immunology, Chiba, Japan
Purpose: Human invariant NKT cells are a novel, unique lympho-
cyte population, characterized by an invariant T-cell receptor Vα24 
chain paired with Vβ11. Vα24 iNKT cells recognize glicolipid 
antigens, such as α-Galactosylceramide (αGalCer; KRN7000), in a 
CD1d-dependent manner. Previous findings showed that αGalCer-
pulsed antigen presenting cells (APCs) exerted a strong anti-tumor 
activity in the mouse tumor metastatic models. With these results, 
we performed phase I-II study of αGalCer-pulsed APCs in patients 
with advanced or recurrent non-small cell lung cancer (NSCLC) to 
obtain more findings about safety, immune responses and anti-tumor 
responses.
Methods: Patients with advanced or recurrent non-small cell lung 
cancer refractory to the standard therapy were eligible. αGalCer-
pulsed APCs (1x109/m2) were intravenously administered four times. 
Immune responses were monitored weekly by a flow cytometry an-
alysis and an enzyme-linked immunospot assay of IFN-γ. Additional 
follow-up was performed to clarify the prognosis and cause of death.
Results: Seventeen patients were enrolled and completed. No severe 
adverse event related to the treatment was observed. After the injec-
tion of αGalCer-pulsed APCs, increased numbers of IFN-γ producing 
cells in the peripheral blood were detected in 10 patients (58.8%). 
Five cases remained as stable disease (SD), and the remaining twelve 
cases were evaluated as progressive disease (PD). The estimated 
median survival time (MST) of the 17 cases was 18.6 months and 
2-year survival rate was 41.2% (range, 3.8 to 44.6 months). Ten 
patients who displayed increased IFN-γ producing cells (>2 fold) 
showed prolonged MST (29.3 months, range, 14.5 to 44.6 months) as 
compared to poor-responder patients (n=7, 9.7 months, range, 3.8 to 
25.0 months) (Log-rank test p=0.0011).
Conclusion: The administration of αGalCer-pulsed APCs, which 
induces the activation of endogenous iNKT cells and iNKT cell-de-
pendent responses, was well tolerated. The increased IFN-γ produ-
cing cells that results from αGalCer stimulation in PBMCs might be 
associated with prolonged survival. These results are encouraging and 
warrant further evaluation for survival benefit of this immunotherapy.
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Phase II study of biweekly Gemcitabine and Docetaxel as 
first line treatment for advanced disease in elderly Non 
Small Cell Lung Cancer (NSCLC) patients
Muñoz-Langa, José1; Sánchez-Hernández, Alfredo2; Gómez-Codina, 
José3; Esquerdo, Gaspar4; Catot, Silvia5; Maciá, Sonia6; Juan, Oscar7; 
Giner, Vicente8
1 Hospital Doctor Peset, Servicio de Oncología, Valencia, Spain; 2 
Hospital Provincial de Castellón, Castellón, Spain; 3 Hospital La 
Fe, Valencia, Spain; 4 Hospital Clínica de Benidorm, Benidorm, 
Spain; 5 Hospital Althaia Xarxa Asitencial de Manresa, Manresa, 
Spain; 6 Hospital de Elda, Elda, Spain; 7 Hospital Arnau de Vilanova, 
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Background: Lung cancer is one of the most common malignancies 
worldwide and the leading cause of cancer-related deaths in Western 
countries. Standard treatment for patients with good PS stage IIIB/
IV NSCLC currently includes a two-drug platinum-based chemother-
apy regimen, but optimum treatment for elderly patients is less well 
defined due to platinum related toxicities. Several drugs with novel 
mechanisms of action and significant activity in NSCLC have been 
developed; including docetaxel and gemcitabine that are also active 
in patients previously treated with cisplatin-based regimens and 
have a more favourable toxicity profile. The more favorable toxicity 
profile of docetaxel and gemcitabine supports its use as first-line 
chemotherapy, especially in patients with severe comorbidities as 
elderly patients. To improve the therapeutic index of this combina-
tion, we performed a study with biweekly gemcitabine and docetaxel 
in elderly patients.
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Material and Methods: Patients ≥ 70 years old with cytological or 
histological confirmation of advanced NSCLC, PS ≤ 1, measurable 
lesion according RECIST criteria, adequate bone marrow, renal and 
hepatic function were included. Prior systemic therapy for NSCLC 
was not allowed. Patients with symptomatic brain metastases were 
not included. Patients received biweekly docetaxel 50 mg/m2 iv, 
Gemcitabine 2000 mg/m2 iv days 1 and 14. This scheme was re-
peated up to 24 weeks. Toxicity was evaluated on each treatment day 
according to CTCAE 3.0. Lung Cancer Symptom Scale was fulfilled 
by patients every 14 days as a self assessment questionnaire and 
LCSS observer scale was fulfilled by the physician.
Results: Twenty six patients were included in this interim analysis, 
with a median age of 76 years (71-83), 23% had ECOG PS 0 and 
77% ECOG PS 1. Principal disease diagnoses were adenocarcinoma 
(35%) and squamous cell carcinoma (31%). Most common sites of 
metastases were lymph nodes (30%), adrenal gland (22%), pleura 
(13%), liver (13%) and bones (13%). Median number of lesions was 
3. Prior radiotherapy treatment was administered to 8% of patients. 
Nine patients were current smokers. Chronic obstructive pulmon-
ary disease (63%) and cardiovascular disease (33%) were the main 
comorbidities. Most of patients (88%) perform the activities of daily 
living without assistance. A total of 71 cycles (median 2, range 1-6) 
were administered. Median relative dose intensity was 86% for 
docetaxel and 85% for gemcitabine. Over 15 patients assessable for 
response, 7 patients achieve partial response; overall response rate 
was 46.7% (95% CI: 21.5%-71.9%). Median follow up time was 
2.2 months. Only one patient had grade IV toxicity: Leucopenia 
(4%). Main grade III non haematological toxicities per patient were 
asthenia (15%), anorexia (4%), diarrhea (4%), and mucositis (4%). 
Main grade III haematological toxicities were leucopenia (8%) and 
neutropenia (4%).
Conclusions: docetaxel and gemcitabine administered every 14 
days as first line treatment for advanced disease in elderly NSCLC 
patients seems to be a safe and active regimen, with a low incidence 
of severe hematologic and nonhematologic toxicity. Updated results 
and information of new patients included will be presented during the 
Conference.
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Phase I study of sunitinib (SU) in combination with 
pemetrexed (Pem) in patients (pts) with advanced solid 
tumors (ST)
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Miyazaki, Masaki2; Tsurutani, Junji2; Ichikawa, Yasuko2; Terashima, 
Masaaki2; Takeda, Masayuki2; Fumita, Soichi2; Kiriyama, Tsukasa1
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Background: SU is an oral, multitargeted tyrosine kinase inhibitor 
of VEGFRs, PDGFRs, KIT, RET, FLT3, and CSR-1, and shows 
antitumor activities in several types of solid malignancies. Non-
small-cell lung cancer (NSCLC) xenograft data indicate SU enhanced 
the antitumor activity of Pem. This phase I study was designed to 
evaluate the safety, tolerability, and pharmacokinetics (PK) of com-
bination therapy with the oral SU and Pem for Japanese patients with 
advanced ST.
Methods: Pts with ST refractory to standard therapy were randomly 
assigned to receive either oral SU 50 mg/day for 2 weeks followed 
by 1 week rest (Schedule 2/1, S-2/1) or SU 37.5 mg continuous daily 
dose (CDD). Fixed-dose Pem (500mg/m2 IV) was administered on 
day1 every 21 days. A standard “3+3” design was employed in both 
treatment schedules and treatment continued until tumor progression 
or dose-limiting toxicity (DLT) was observed.
Results: A total of 12 pts (med. age 63 years, range 49-69; 10 Male/ 
2 Female) have been enrolled (6 pts in the S-2/1 arm and 6 pts in the 
CDD arm). The most common cancer is NSCLC (9 pts, 75%). All 
patients completed their first cycle for DLT evaluation, and no DLTs 
were observed in either treatment arm. The most common toxicities 
were fatigue (n=8), anorexia (n=6), and thrombocytopenia (n=12). 
Treatment-related ≥ grade 3 adverse events (AEs) included fatigue 
(n=1), hypertension (n=1), neutropenia (n=4), leucopenia (n=3), 
thrombocytopenia (n=2), lymphopenia (n=2), and increased ALT 
(n=1). Three pts (S-2/1: 2, CDD: 1) required dose reduction of SU 
due to G3 toxicities. All toxicities were clinically manageable and 
reversible. One pt with NSCLC had a documented PR with cavity 
formation inside the tumor.
Conclusions: SU 37.5 mg/day (CDD schedule) plus Pem 500mg/m2 
every 21 days, and SU 50 mg/day (S-2/1 schedule) plus Pem 500mg/
m2 every 21 days were well tolerated and associated with encour-
aging antitumor activity.
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Phase I/II trial on TS-1 monotherapy for aged patients 
with advanced non-small cell carcinoma
Nanki, Nobuki1; Yamaji, Yasufumi1; Bandoh, Syuji2; Miyawaki, 
Hiroshi3; Ueda, Yutaka3
1 Mitoyo General Hospital, Kanonji, Japan; 2 Kagawa University, 
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Background: Because lung cancer is a neoplasm representative of 
those affecting older individuals, a surgical treatment is not possible 
even for those stages in which such a modality is indicated. Among 
the cases with advanced cancers, there are a number of patients for 
whom potent chemotherapy cannot be applied and best supportive 
care (BSC) is the only means of treatment. The guideline on therapy 
for lung cancer recommends chemotherapy only for aged patients 
who exhibit a satisfactory performance status (PS). The efficacy of 
TS-1 monotherapy applied against advanced non-small cell lung 
carcinoma (NSCLC) was 22.0% in the latter part of phase II clinical 
trial, exhibiting a high effectiveness in comparison with conventional 
5-FU oral agents. Thus it has been concluded that TS-1 monotherapy 
is one of the promising therapeutic modalities that can be applied to 
NSCLC (Br J Cancer, 2001). The purpose of the present study was 
to evaluate the safety of TS-1 monotherapy applied as the initial treat-
ment for advanced NSCLC in the oldest old, determine its recom-
mended dosage (RD), and investigate the efficacy and safety of this 
RD. 
Method: The subjects were those patients aged 75 years or older 
suffering from advanced (stage IIIB or IV) NSCLC with PS 0-1 but 
without a severe organ dysfunction. Phase I: For the initial treatment, 
TS-1 monotherapy was conducted to estimate its RD. Phase II: The 
efficacy and safety of this TS-1 monotherapy were evaluated at the 
dosage determined above. TS-1 was administered via the oral route 
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continually for 14 days, followed by withdrawal for 7 days. This regi-
men constituted one course. Drug administration was continued in 
this manner until PD was occurred or the standard for adverse effects 
forced drug withdrawal or the condition warranted it. There were no 
specifications for post-medication therapy. 
Results: Consequent to Phase I trial, RD was determined to be 
80 mg/m2. The trial was followed by Phase II trial. There were 23 
patients who were composed of the following: males (14), females 
(8) and unknown (1); age, 77 to 88 years (mean, 81.2); adenocarcin-
oma (19) and squamous cell carcinoma (4); neoplasm stages of IIIA 
(2), IIIB (6) and IV (15); PR, 10.5% (2 of 19 patients); DCR, 89.5% 
(16 of 19 patients); MST, 210 days. No serious adverse effects were 
noted in any of the 23 patients. 
Conclusion: This therapeutic modality may be safe and effective 
when applied to aged patients with advanced NSCLC.
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Chemotherapy and chemoradiotherapy for patients with 
brain metastases from advanced non-small cell lung cancer
Gorbounova, Vera A.; Bychkov, Mark B.; Naskhletashvili, David R.; 
Rzaev, Dzarahmad S.; Chmutin, Gennadiy E.; Karakhan, Vladislav 
B.; Michina, Zoya P.; Alieva, Sevil B.
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Background: Brain metastases is a serious complication of neoplas-
tic disease, seen in 12—20% of all cancer patients. The most frequent 
cause of brain metastases is lung cancer, comprising up to 50% of 
cases. The poor results of anticancer treatment in this population 
stimulated researchers around the world to conduct clinical studies 
of new chemotherapy and chemoradiation regimens in patients with 
brain metastases from non-small cell lung cancer (NSCLC).
Methods: 79 NSCLC patients with brain metastases were enrolled in 
phase II non-randomized trial starting June 2004 till May 2009. 
49 patients received chemotherapy in the following regimen: Gemzar 
1000 mg/m2 IV days 1, 8 with Cisplatin 50 mg/m2 IV days 1, 8 every 
3 week (till 6 cycles).
20 patients received chemoradiotherapy with Temodar 75 mg/m2 per 
os daily for 14 days + whole brain irradiation total dose 30Gy, single 
dose 3Gy
10 patients previously treated for brain metastases with progression 
disease received 2-3 lines of chemotherapy: Temodar 150 mg/m2 
per os daily on days 1-5 with Campto 250 mg/m2 IV on day 6 (till 6 
cycles). 
Tumor assessment was done with brain CT/MRI with IV bolus con-
trast enhancement.
Conclusions: Chemotherapy with Gemzar + Cisplatin and chemor-
adiotherapy Temodar + WBI showed significant efficacy and 
favorable results of overall survival in NSCLC patients with brain 
metastases. Prolonged brain disease stabilization may be achieved 
with Temodar + Campto in NSCLC patients with brain metastases of 
poor prognosis. 
The results of treatment of NSCLC patients with brain metastases 
Group of 
patients
CR PR SD MS 
(months)
Sur-
vival (12 
months)
Sur-
vival (24 
months)
Gemzar+Cisplatin 
(49 pts)
18,4%  
(9 pts)
26,5% 
(13 pts)
40,8% 
(20 pts)
9,0 30,6%  
(15 pts)
6,1% 
(3 pts)
Temodar+WBI 
(20 pts)
15%  
(3 pts)
40%  
(8 pts)
35%  
(7 pts)
7,5 20%  
(4 pts)
5%  
(1 patient)
Temodar+Campto 
(10 pts) II-III lines 
chemotherapy 
0 0 70%  
(7 pts)
8,0 30%  
(3 pts)
 --
CR – complete response
PR – partial response
SD - stable disease
MS – median survival
Pts - patients
WBI – whole brain irradiation
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Palliative chemoradiotherapy is superior to palliative 
radiotherapy in stage IIIA-IIIB non-small cell lung cancer 
patients not eligible for radical treatment – final results of 
randomized phase II study
Nawrocki, Sergiusz1; Rucińska, Monika1; Krzakowski, Maciej2
1 Univeristy of Warmia and Mazury, Olsztyn, Poland; 2 M. Curie-
Sklodowska Memorial, Warsaw, Poland
Usually only two categories of patients with non-small cell lung 
cancer (NSCLC) are recognized (1) eligible for definitive treatment 
and (2) eligible for palliative treatment. In subpopulation of stage 
IIIA-IIIB patients not amenable for definitive chemoradiotherapy due 
to large tumor and/or poor pulmonary reserve, palliative radiotherapy 
alone seems to be suboptimal treatment. The aim of the study was to 
compare palliative radiotherapy and novel “palliative chemoradio-
therapy” in stage IIIA-IIIB NSCLC patients not eligible for radical 
treatment.
99 patients with inoperable IIIA (27/99) or IIIB (72/99) NSCLC, 
median age 66 years, PS 0-1 (73/99), PS 2 (26/99), FEV1<40% or/
and tumor ≤8cm were enrolled into the phase II, randomized study. 
Patients were randomized for arm A-radiotherapy (30Gy/10fractions 
with 3D-conformal planning) or arm B-chemoradiotherapy (two 
cycles of Cisplatin 80mg/m2 on Day 1 and Navelbine 25mg/m2 on 
Day 1 and 8 plus radiotherapy as above; given together with 3rd 
chemotherapy cycle in case of no progression after 2 chemotherapy 
cycles). Primary end-point was response rate (RR), secondary end-
points were overall survival (OS), progression free survival (PFS), 
toxicity, symptoms control. 
There were 13/48 (27%) responses in arm A and 27/51 (53%) in arm 
B; (p=0.08). OS and PFS were significantly longer in arm B. Median 
OS 12.9 vs 9.0 months (p=0.034), 2-years OS 24% vs 6% in arm B 
and A respectively. Median PFS 7.3 vs 4.7 months (p=0.046), 2-year 
PFS 14% vs 4% in arm B and A respectively. Toxicity: early deaths: 
arm A-0, arm B-6 (4 related to progression, 2 to toxicity); hemato-
logical G3-4: arm A-0, arm B-14, other G3-4: arm A-4, arm B-10. 
Symptom control (dyspnoea, pain, cough, haemoptysis) was satisfac-
tory and similar in both arms. 
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For subpopulation of IIIA-IIIB NSCLC patients not amenable for 
definitive chemoradiotherapy “palliative chemoradiotherapy” is 
superior to palliative radiotherapy at the expense of increased but 
acceptable toxicity. 
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Erlotinib for relapsed or refractory Non-Small-Cell Lung 
Cancer after failure of gefitinib
Nishihira, Ryuichi; Ogura, Takashi; Tajiri, Michihiko; Kato, 
Terufumi; Sekine, Akimasa; Shinohara, Takeshi; Baba, Tomohisa; 
Takahashi, Hiroshi
Kanagawa Cardiovasucular and Respiratory Centor, Yokohama, 
Japan
Background: Erlotinb and gefitinib,two kinds of epidermal growth 
factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), are used 
in clinically under Japanese public medical insurance system. Since 
erlotinb was approved in Japan 2007 after approval of gefitinib, we 
have an opportunity to use erlotinib for relapsed or refractory non-
small-cell-lung cancer (NSCLC) after treatment with gefitinib. 
Methods: In relapsed or refractory NSCLC patients treated with 
erlotinib after failure of gefitinib in our institution from 2002 to 2008, 
we investigated clinical feature of these patients retrospectively. 
Results: 18 patients was treated with both erlotinib and gefitinib 
(6 male,12 female) . In the treatment with gefitinib, one patient had 
complete response (CR), 10 patients had partial response (PR), 4 
patients had stable disease (SD), 3 patients had progressive disease 
(PD). Response and disease control rate of gefitinib were 61.1% (11 
of 18) and 83.3%(15 of 18).Median period between the final use of 
gefitinib and start of erlotinib was 65 days (range,1-619days).EGFR 
mutations were detected in 10 patients,9 patients were mutation-
positive. Mutations in exon 19 and 21 were found in 5 and 3 patients, 
double mutation in exon 19 plus exon21 was found in one patient. 
Median duration of treatment with erlotinib was 98 days (range, 
15-365days).In the treatment with erlotinib, no patient had CR, one 
patient had PR, 5 patients had SD, 9 patients had PD, and 3 patients 
were not evaluated. Response and disease control rate of erlotinib 
were 5.6 %( 1 of 18) and 33.3 %( 6 of 18).Response to erlotinib was 
not always consistent with response to gefitinib. Ten patients died, 
other patients are alive. Three patients continue to use erlotinib. 
EGFR mutation status did not always influence response to erlotinib. 
Conclusions: Response to erlotinib for NSCLC after failure of 
gefitinib does not always depend on response to gefitinib, and is not 
always related to EGFR mutations. Use of second EGFR-TKI needs 
further investigation.
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A phase I dose escalation study of gemcitabine and 
cisplatin with the anti-IGF-IR antibody figitumumab (CP-
751,871) as first-line treatment of patients with advanced 
Non-Small Cell Lung Cancer (NSCLC)
Paz-Ares, Luis1; O’Byrne, Ken2; Corral, Jesus1; Iglesias, Lara3; 
Ferguson, Andrea2; Garcia-Carbonero, Rocio1; Carpentieri, Marina4; 
Gallo, Jorge4; Gualberto, Antonio5; Sanchez Torres, José Miguel3
1 Hospitales Universitarios Virgen del Rocio, Seville, Spain; 2 St 
James Hospital, Dublin, Ireland; 3 Hospital Universitario 12 de 
Octubre, Madrid, Spain; 4 Pfizer Oncology, Milan, Italy; 5 Pfizer 
Oncology, New London, USA
Background: Figitumumab (F, CP-751,871) is a potent and select-
ive fully human IgG2 monoclonal antibody against the Insulin-like 
Growth Factor I Receptor (IGF-IR) that is often expressed in human 
tumors, including lung cancer. Preclinical data indicate that F increas-
es the anti-tumor activity of chemotherapy agents in cancer xenograft 
models, including those of non-small cell lung cancer (NSCLC). We 
evaluated the safety, tolerability, pharmacokinetics (PK) and phar-
macodynamics (PD) of F in combination with gemcitabine (G) and 
cisplatin (C) in patients with treatment-naïve advanced NSCLC.
Methods: This study is an open-label, dose-escalation study of F at 
doses of 6–20 mg/Kg given in 2.5 hour IV infusions on day 1 of q3 
weeks cycles in combination with G (1250 mg/m2, days 1 & 8) and C 
(80 mg/m2, day 1) for a maximum of 6 cycles. Patients were eligible 
to receive additional cycles of single-agent F upon chemotherapy 
discontinuation. The primary objective was the identification of the 
Maximum Tolerated Dose (MTD) and the recommended phase II 
dose of F in combination with GC. The tolerability of 1.0-hour F 
infusion time was also investigated in an expansion cohort.
Results: A total of 32 treatment-naïve NSCLC patients of all histo-
logical types have been enrolled. Median age was 59.8 years. Histol-
ogy was: squamous cell carcinoma (n=6), adenocarcinoma (n=16), 
large cell carcinoma (n=5) and others (n=5). 25% patients were 
Stage IIIB and 75% were Stage IV. Fifteen patients were enrolled 
in 3 escalation cohorts (6 patients at 6 mg/Kg, 3 at 10 mg/Kg and 6 
at 20 mg/Kg). Seventeen additional patients were enrolled in the 20 
mg/Kg trial expansion cohort. No Dose Limiting Toxicities (DLTs) 
were reported. A MTD was not identified. No patients required dose 
reduction. Patients received a mean of 4.7 treatment cycles (range 
1–14). Grade 3/4 treatment-related adverse events (CTCAE v3.0) 
included hyperglycemia (12.5%), asthenia (9.4%), neutropenia 
(28.1%), thrombocytopenia (12.5%) and anemia (9.4%). Twelve 
objective responses (1 complete response [CR, 3.1%] and 11 partial 
responses [PRs, 34.4%]) in 32 evaluable patients were reported so far. 
In addition, 4 patients achieved stable disease ≥12 weeks (12.5%). 
Clinical Benefit Response (CBR) is 50% (95% CI:32%–68%). Two 
responding patients underwent surgery, and no residual tumor was 
found (pathologic CR). Median time-to-progression was 6.2 months. 
Analyses of PK and PD endpoints are underway.
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Conclusions: F was well tolerated in combination with G and C for 
the first-line treatment of NSCLC patients. Based on the favorable 
safety profile, the 1.0-hour IV infusion 20 mg/Kg/q3 weeks regimen 
of figitumumab was selected as the recommended phase II dose for 
further investigation. Preliminary efficacy results are encouraging. 
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Erlotinib therapy in non small cell lung cancer patients- 
survival of “poor prognosis patients”
Pesek, Milos1; Krejci, Jana1; Skrickova, Jana2; Zatloukal, Petr3; 
Kolek, Vitezslav4; Salajka, Frantisek5; Koubkova, Leona6; Sixtova, 
Dimka7; Petruzelka, Lubos8; Roubec, Jaromir9; Vyzula, Rostislav10; 
Pavlik, Tomas11
1 Dept. of Pulmonary Diseases, Pilsen, Czech Republic; 2 Faculty 
Hospital, Dept. of Pulm. Dis., Brno, Czech Republic; 3 Uni Hosp., 
Dept. of Pneumology, Praha - Bulovka, Czech Republic; 4 Uni Hosp, 
Dept. of Pneumol., Olomouc, Czech Republic; 5 Uni Hosp., Dept. of 
Pneumology, Hradec Králové, Czech Republic; 6 Uni Hosp., Dept. of 
Pneumology, Praha-Motol, Czech Republic; 7 Thomayer Uni Hosp., 
Dept. of Pneumology, Praha - Krč, Czech Republic; 8 Charles uni 
Hosp., Dept. of Oncology, Praha, Czech Republic; 9 Uni Hosp., Dept. 
of Pneumology, Ostrava, Czech Republic; 10 Masaryk Memorial 
Cancer Institute, Brno, Czech Republic; 11 Institute of Biostatistics 
and Analyses Masaryk University, Brno, Czech Republic
Background: Erlotinib is a standard treatment of recurrent/metastatic 
non-small cell lung cancer (NSCLC) in second and subsequent lines. 
It is important do define predictive criteria that could help to select 
patients suitable for erlotinib treatment. We assumed that progression 
during or early after first line chemotherapy could be such a predict-
ive factor. 
Methods: All patients with NSCLC treated in nice pulmooncology 
centers by erlotinib are followed in the Czech Tarceva Registry. We 
compare patients with “poor prognosis”, e.g. patients who did not re-
ceive at least 4 cycles of first line chemotherapy and/or relapsed early 
after first line chemotherapy versus “non-poor prognosis” patients.
Results: 394 patients with full data set needed for the analysis were 
identified in the registry. Two separated analyses were performed: 1. 
patients who received less than for cycles chemotherapy either due 
to progression (group 1a, n=24) or due to other reason – mostly due 
to toxicity (group 1b, n=30) versus patients who received at least 4 
cycles (n=340; and 2. patients with “early” progression within 14 
weeks after chemotherapy started (group 2, n=65) versus patients 
with later progression (n=329). Due to different criteria groups 1 
and 2 overlap. 302 patients had neither early discontinuation of 
chemotherapy nor early progression. We did not find differences ion 
baseline characteristic of the given groups of patients. The overall 
response rate (ORR) was not different in the “poor” and “non-poor 
prognosis” groups (9,2 versus 10,6 %), but in both the “poor progno-
sis” groups progressive disease (PD) as the best response was seen 
more often – 44,4% in group 1 and 41,5 % in group 2 versus 30% 
in “non-poor prognosis” patients. The higher rate of PD reflected in 
shorter progression free survival (PFS) 1,8 versus 2,7 moths, p=0,022 
in the “poor prognosis” and “non-poor prognosis” patients, respect-
ively. PFS was 1,8 months in group 1 and 1,4 months in group 2 ) 
The overall survival (OS), however, was 5,7 month in both the “poor 
prognosis” and non-poor prognosis” patients, p=0,684- OS was 4,4 
months in group 1 and 6,0 months in group 2. 
Conclusion: In our group the patient who relapsed during first line 
chemotherapy or soon after its completion (or who did not finish 
chemotherapy for other reasons) also progressed more often on the 
subsequent erlotinib treatment, but the overall survival was not af-
fected by this fact. Thus progression during or early after first line 
chemotherapy should not be a negative selection criterion for subse-
quent erlotinib treatment. 
P1.230 NSCLC Advanced Disease, Sat Aug 1 
Erlotinib therapy in non small cell lung cancer: 186 
patients and 4 years of experience at the pilsen faculty 
hospital
Pesek, Milos1; Krejci, Jana2; Benesova, Lucie3; Belsanova, Barbora3; 
Bruha, Frantisek1; Mukensnabl, Petr4; Pavlik, Tomas5; Minarik, 
Marek3
1 Dept. of Pulmonary Diseases, Pilsen, Czech Republic; 2 Dept. 
of Pulmonary Diseases, Brno, Czech Republic; 3 Laboratory 
for Molecular Genetics and Oncology, Genomac International, 
Ltd., Prague, Czech Republic; 4 Faculty Hosp., Pathology, Plzen, 
Czech Republic; 5 Institute of Biostatistics and Analyses Masaryk 
University, Brno, Czech Republic
Background: Erlotinib is a standard treatment of recurrent/metastatic 
non-small cell lung cancer (NSCLC) in the second and subsequent 
lines. Mutations of the EGFR and K-ras genes are candidates to be-
come factors prognostic and/or predictive factors directing selection 
of patients most profiting for the therapy. We have analyzed past and 
current clinical and genetic data of patients treated at our institution 
by erlotinib. 
Methods: 186 NSCLC patients with median age 63 (40-84) years 
were treated with erlotinib since 2005 till January 2009 in our depart-
ment. Of them, 171 patients (91,9%) have already finished treatment 
with a median therapy duration of 1,5 (0,1-24,2) months. All patients 
with were followed in the Czech Tarceva Registry. Clinical data along 
with the information on the EGFR and K-ras mutation status from 
the registry were evaluated. Evaluations were aimed at the objective 
therapy response and survival with respect to the genetic factors.
Results: Complete response (CR) was reached in 2,2%, partial re-
sponse (PR) in 10,8% and disease stabilization (SD) in 37,6%, which 
gives the clinical benefit rate (CBR) of 50,6%. Median progression 
free (PFS) and overall survival (OS) were 1,9 and 9,2 months respect-
ively. Status of the K-ras gene was available for 91 patients, 77 pa-
tients exhibited wild type and 14 patients mutated gene (15,4%). The 
response rates for wild-type/mutated K-ras status were: CR 2,6%/0%, 
PR 13,0%/35,7%,SD 31,2% 7,1% and CBR 46,8%/42,8% (no 
statistical significance detected). Median PFS was 1,3 vs. 1,6 months 
(p=0,497) and OS 7,7 vs. 5,4 months (p=0,849) for wild-type vs. mu-
tated K-ras. EGFR mutation status was known for 103 patients, 91 of 
them wild-type and 12 mutated (11,7%). Responses for wilt-type/mu-
tated forms were CR 0%/16,7 %, PR 14,3%/33,3%, SD 27,9%/50,0% 
and CBR 44%/100% with a statistical significance (p<0,001). Also 
PFS and OS were significantly superior in patients with mutated 
EGFR gene. Median PFS reached were 1,3 vs. 6,6 months for wild-
type vs. mutated EGFR, OS for mutated EGFR patients was not 
reached vs. 7,6 months for wild-type patients. We confirm favorable 
safety profile, 52,7% of the patients experienced rash (all grades) and 
21,5% diarrhea. There were no differences in the incidence of toxicity 
with respect to the K-ras gene status, but, interestingly, patients with 
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wild type EGFR experienced less toxicity – any toxicity 62,6 and 
100% (p=0,01), rash 49,5 and 83,3% (p=0,027), the difference in soft 
tissue infections 5,5% and 16,7% was not significant.
Conclusion: In general, our efficacy and safety data are in agreement 
with the results of the BR.21 study. Also the superior response, PFS 
and OS in patients with EGFR gene mutation are consistent with 
the published data, but until data of a prospective randomized study 
are available, we cannot distinguish the prognostic and predictive 
significance of the EGFR molecular marker. Observed toxicity in pa-
tients with mutated EGFR gene needs further evaluation. We did not 
confirm previously published data, that patients with K-ras mutation 
do not respond to the EGFR tyrosine-kinase inhibitors, there were 
no differences in PFS and OS in patients with wild type and mutated 
K-ras gene. Thus, at this time, we do not suggest that patients with 
mutated K-ras gene to be excluded from erlotinib treatment. Sup-
ported by Czech Ministry of Health project 9087.
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Major pulmonary resections in patients with locally-
advanced NSCLC
Trakhtenberg, Alexander K.; Pikin, Oleg V.; Kolbanov, Konstantin I.; 
Glushko, Vladimir A.; Amiraliev, Ali M.; Bagrov, Vladimir A.
Moscow Gertsen Cancer Research Institute, Moscow, Russia
Background: The problem of major pulmonary resections in patients 
with NSCLC is a matter of discussion for decades. Prognosis of 
surgically treated IIIA stage NSCLC patients is generally poor with 
5-year survival rate from 13,3 to 30,0%. The study was aimed to de-
fine indications, prognostic factors and outcomes of major pulmonary 
resections in patients with locally-advanced NSCLC.
Methods: 4407 patients with NSCLC were operated on in our clinic. 
Among them, major pulmonary resections with systematic medi-
astinal lymphadenectomy were performed in 644 patients (14,6%). 
Pneumonectomy with carinal resection was done in 92, partial 
esophagus resection – in 42 patients. Vascular-atrial type of resection 
was performed in 379 (pericardial resection – in 262, resection of the 
left atrium – in 60, superior vena cava – in 31, aorta wall resection – 
in 14 and conus pulmonalis – in 12) patients; parieto-diaphragmatic 
type of resection was performed in 131 patients. Metastases to 
intrathoracic lymph nodes were found in 65,0 % of patients. Among 
them N2 disease was established in 39% of patients. The lymph node 
metastases rate strongly correlates with T category: in Т1 cases posi-
tive mediastinal lymph nodes were found only in 13%, Т2-3 – in 43% 
and Т4 – in 59% of patients. 
Results: 5-year survival after pneumonectomy with carinal resec-
tion (T3-4N0-2M0) is 28,6% and strongly depends on regional 
lymph node status (from 12% in N2 group of patients to 42% in N0 
patients). The important prognostic factors in patients with NSCLC 
and chest wall involvement (T3N0-2M0) are: status of intrathoracic 
lymph nodes and complete resection with negative resection margins. 
Overall survival in this cohort of patients is 29%: in N0 patients – 
41%, N1 – 18% and N2 – 8%. Only 12,5% of patients underwent 
pneumonectomy with left atrium resection survived more then 3 
years. The five-year survival of patients with upper-lobe lung cancer 
and upper mediastinal lymph node metastases was 45,0% versus 
7,2% in case of upper and lower mediastinal lymph nodes station 
involvement. Similar results were obtained in the group of patients 
with lower-lobe lung cancer and only lower mediastinal lymph nodes 
metastases. 
Conclusions: Surgery is indicated in cases of locally-advanced (T3-
T4) NSCLC to the great number of patients, especially with minimal 
mediastinal lymph node involvement. Extended operations with 
resection of adjacent organs and structures are justified, resulting in 
significant increasing of survival and resectability rate. New thera-
peutic approaches are needed to improve five-year survival in that 
complex group of patients.
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Surgery in patients with advanced NSCLC following 
Induction polychemotherapy 
Porhanov, Vladimir A.; Selvaschuk, Andrew P.; Poliakov, Igor S.; 
Sitnik, Sergey D.; Kononenko, Valery B.; Bodnia, Vadim N.
Regional Clinical Hospital # 1 – Cardiothoracic Surgery Center, 
Krasnodar, Russia
About 80% patients with primarily diagnosed NSCLC have non-
surgical stages and they are administered polychemotherapy. Such 
therapy may improve tumor respectability. From January 2003 to 
January 2008, 31 patients have been referred to cardiothoracic sur-
gery center for neoadjuvant (induction) therapy, of those, 14 patients 
had advanced unresectable tumor - Т4 ( 5 carinal invasions, 3 SVC 
invasions, 4 apical lung cancers, 2 tumors growth lobar bronchus, 
but pneumonectomy was contraindicated), other 17 patients had 
multiple mediastinal LN invasion (N2-3). Morphological diagnosis 
was established before treatment by means of transthoracic biopsy, 
fiber-optic bronchoscopy, VATS, videomediastinoscopy. Functional 
status corresponds to ECOG 0-3. Re-staging was performed follow-
ing induction therapy. Six patients (42%) in the group T4 showed 
benefitial treatment and they were transferred to the operable stage. 
We performed 2 pneumonectomy with carinal resection, in 1 case – 
carinal resection and SVC plasty, 3 pneumonectomies, 1 resection of 
upper lobe with bronchoplasty. Of 17 patients with N2-3, 5 patients 
(29%) had favorable effect, they underwent various volume oper-
ations. Postoperative complication rate was 9%, there was no mortal-
ity cases. Survival in operated and non-operated patients was 23 and 
7 months, respectively. Practical application of induction therapy 
with treatment results assessment has allowed to expand possibilities 
of combined treatment for NSCLC and to re-stage non-resectable 
tumors, to down-stage and to improve the outcomes.
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Multi-targeted therapy in recurred and advanced Non-
Small Cell Lung Cancer (NSCLC) in Thailand
Prempree, Thongbliew; Wongpaksa, Charlorboon
Piyavate Hospital, Bangkok, Thailand
Objective: To determine 1) The effectiveness of combinations of tar-
geted agents such as Anti-VEGF and EGFR-TKI to control recurred 
and advanced NSCLC. 2) The tolerability of patients undergoing the 
two-targeted treatment.
Materials and Methods: 17 cases of NSCLC were included in our 
study. 13 cases were initially presented with stage IV disease and 4 
cases recurrence after chemotherapy. Three genes VEGF, EGFR and 
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KRAS were studied from cancer tissues. For protien study, we used 
Immunohistochemical (IHC)technique and for DNA study, we used 
standard method of DNA extraction, PCR with proper primers and 
automated DNA Sequencing. 
Inclusion Criteria: VEGF protein Overexpression and EGFR protein 
Overexpression.
Results: 1) Of 17 cases of NSCLC Genes studied, EGFR Muta-
tions were found in 16 cases(94%), VEGF Mutation was found in 1 
case(6%) and KRAS Mutation were found in 2 cases(12%)
2) Objective Response Rate 15/17 = 88%
3) Failure Rate 2/17 = 12%
Discussion and Conclusion: Since all 17 cases of NSCLC were 
highly selective to be included in this study, we anticipated and 
received an excellent response rate of 88% versus only 12% failure 
rate. Obviously, the EGFR Mutations appeared to play a major role 
in having objective tumor response of 88%. VEGF Gene Mutation 
did not appear to have any effect on the objective response. KRAS 
Mutation on the other hand appeared to play a significant role in hav-
ing negative objective response(12%) in spite of one KRAS mutant 
also had EGFR classic mutation (exon 19 deletion). All 17 patients 
have been tolerating the treatment well with manageable side effects 
of skin and skin appendages. In our study, the objective response ap-
peared to be quick and sustainable.
Conclusion: The combination of two targeted agents, anti-VEGF and 
EGFR-TKI appeared to offer quick and excellent response in recurred 
and advanced NSCLC with minimal manageable side effects. We 
hope that the combination of treatment of anti-VEGF and EGFR-TKI 
will be expanded further to include a larger group of NSCLC patients 
to confirm our findings.
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Phase 2 study of ABT-869 in combination with 
Carboplatin/Paclitaxel (CP) in patients with advanced or 
metastatic Non-Small Cell Lung Cancer (NSCLC): lead-in 
cohort results
Ramalingam, Suresh1; Owonikoko, Taofeek 1; Khuri, Fadlo 1; Saba, 
Nabil 1; Wallace, James 2; Qian, Jiang 3; Gupta, Neeraj 3; Ricker, 
Justin3; Carlson, Dawn3
1 Emory University School of Medicine, Atlanta, GA, USA; 2 
University of Chicago, Chicago, IL, USA; 3 Abbott Laboratories, 
Abbott Park, IL, USA
Background: ABT-869 is a novel orally active, potent and selective 
inhibitor of vascular endothelial growth factor and platelet derived 
growth factor receptor tyrosine kinases. ABT-869 potentiates the 
action of CP in a number of preclinical tumor models including 
NSCLC. The lead-in cohort portion of this study was conducted to 
assess pharmacokinetic (PK) interaction and safety of the combina-
tion of ABT-869 with carboplatin and paclitaxel, and to provide guid-
ance for ABT-869 dose in the randomized portion of this study. 
Methods: In this open-label lead-in cohort, patients received car-
boplatin (AUC6 mg/mL/min) and paclitaxel (200 mg/m2) on Day 
1 of every 21-day cycle and ABT-869 0.2 mg/kg orally once daily 
(QD) via continuous dosing starting on Day 3 of Cycle 1. CT scans 
were performed every 2 cycles. Patients received this regimen until 
progressive disease (PD), or unacceptable toxicity was observed. 
Adverse events (AE) were graded by NCI CTCAE V3.0; Efficacy 
was evaluated using RECIST criteria. In addition, PK interactions 
between these agents were evaluated.
Results: 6 patients have been enrolled in the lead-in portion of this 
study as of February 2009. Preliminary AE and response data for 5 of 
these patients are shown in the table below. Three of 5 patients had 
confirmed partial responses (PRs). There were no dose reductions or 
discontinuations due to AE; 3 patients experienced CP-related dose 
delays (Grade 2 thrombocytopenia [2], Grade 3 fatigue [1]) while 2 
patients had interruptions of ABT-869 (Grade 2 thrombocytopenia, 
Grade 3 fatigue). One patient had serious adverse events (SAEs) of 
fever, dehydration, and febrile neutropenia possibly related to CP. No 
SAEs were attributed to ABT-869. Based on preliminary assessment, 
PK interaction between CP and ABT-869 appears less likely.
Conclusion: These preliminary findings suggest that the regimen (CP 
Day 1 q21 days with ABT-869 QD) is tolerable. Confirmed PRs have 
been observed. There does not appear to be a PK interaction between 
ABT-869 and CP in this study. Updated results of this ongoing study 
will be presented at the meeting. A randomized phase II study will be 
initiated for patients with advanced NSCLC.
Patient # Initial ABT-
869 Dose 
(mg)
Current 
ABT-869 
Dose (mg)
Cycle 2 CP 
Delays
End Cycle 2 
Assessment
End Cycle 4 
Assessment
301 15 15 G2 TCP (Day 
42)
SD PR
302 17.5 17.5 G2 TCP (Day 
36)
PR PR
303 15 15 G3 Fatigue 
(Day 29)
PD Off Study
304 10 10 - SD PD
305 12.5 12.5 - PR PR
307 15 15 - - -
G= grade    
SD= stable disease    
TCP= thrombocytopenia
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Gefitinib as first line therapy in newly diagnosed advanced 
adenocarcinoma lung - A prospective study
Menon, Hari; Raut, Nirmal v.; Ghadyalpatil, Nikhil; Prabhash, 
Kumar; Shanmugan, Pramesh
ESMO, Mumbai, AL, India
Introduction: Standard therapy for advanced non small cell lung 
cancer remains a platinum based doublet. Old age, co-morbidities 
and other patient characteristics are of major concern in these patients 
usually interfering with the completion of treatment. Geftinib, an 
EGFR tyrosine kinase inhibitor, has demonstrated significant efficacy 
in the Asian non smokers with adenocarcinoma as 2nd line therapy. 
This study explored the feasibility, efficacy and utility of Geftinib 
as 1st line therapy in this subset of newly diagnosed advanced stage 
adenocarcinoma lung.
Methods and Materials: Forty six patients with advanced stage lung 
cancer were enrolled into this study. None of the patient received any 
prior treatment.Geftinib (250 mg/day) was administered orally. The 
primary end points was response at the end of 6 months of treatment 
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while secondary end points were safety and tolerability. The toxicity 
was graded as per CTC v3. The response was graded on the basis of 
subjective clinical improvement, CT scans and chest skiagrams. 
Results: Forty six patients were enrolled and followed up for 
response and toxicity. Median age was 61 years. 60 % were females 
.87% were stage IV disease while others stage IIIb. Histology was 
Adenocarcinoma in all these patients. There were no interruptions in 
therapy. At median follow up of 6.4 months, overall response rates 
were 63.1 % out of which 43.5% (n=20) had a partial response while 
19.6% (n=9) had stable disease. 6.5% (n=3) had disease progression 
while 30.4 % (n=14) had died at the end of 3 months. The median 
survival was 6.1 months. Four patients developed grade 2 diarrhea. 
Dry skin was the commonest toxicity seen in around 18% while 
acneiform rash was reported in only 3 patients. No statistical correla-
tion between the skin toxicity and the clinical response was observed. 
There was no single episode of hematological toxicity. None of the 
patients required inpatient admission 
Conclusion: Geftinib as initial therapy yield comparable results to 
standard chemotherapy with a excellent toxicity profile. Data from 
this study suggests a comparable frontline therapy as an alternate to 
chemotherapy in carefully selected patients. However longer follow 
up is needed to demonstrate improved survival as compared to stan-
dard chemotherapy.
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A Phase II double-blind study to investigate efficacy and 
safety of the triple angiokinase inhibitor BIBF 1120 in 
patients with relapsed advanced non-small cell lung cancer
Reck, Martin1; Kaiser, Rolf2; Eschbach, Corinna3; Stefanic, Martin2; 
Love, James2; Staab, Alexander2; Freiwald, Matthias2; Bruno, Rene4; 
Stopfer, Peter2; Gatzemeier, Ulrich1; von Pawel, Joachim5
1 Hospital Grosshansdorf, Hamburg, Germany; 2 Boehringer 
Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; 3 
Asklepios Hospitals Harburg, Hamburg, Germany; 4 Pharsight 
Corporation, Mountain View, Cary, NC, USA; 5 Asklepios Hospitals, 
München-Gauting, Germany
Background: BIBF 1120 (Vargatef*) is an oral potent angiokin-
ase inhibitor, targeting vascular endothelial, platelet-derived and 
fibroblast growth factor receptor tyrosine kinases. The objective of 
the population pharmacokinetic (PK) analysis was to describe the PK 
of BIBF 1120 in patients with advanced/metastatic non-small cell 
lung cancer (NSCLC) and to explore the impact of patient factors 
on the PK parameters of BIBF 1120 using data from a double-blind, 
randomized Phase II study.
Methods: In this double-blind multicenter trial, 73 patients with an 
Eastern Cooperative Oncology Group (ECOG) score of 0–2 with 
locally advanced or metastatic (stage IIIB/IV) relapsed NSCLC after 
failure of first- or second-line chemotherapy were randomly assigned 
to continuous twice-daily treatment with 150 mg or 250 mg of BIBF 
1120 until disease progression or limiting toxicity. Trough samples 
for PK analysis were taken at various visits. Sparse absorption 
profiles were determined at two visits. PK data from 71 patients (736 
plasma samples) were available. Demographics, laboratory values 
and cancer-specific covariates including baseline ECOG score were 
tested for their effect on PK parameters. The analysis was performed 
using NONMEM®.
Results: A one-compartment model with first-order absorption (ka) 
and elimination rate described the PK data adequately. The slightly 
delayed absorption was accounted for by a lag time of 20 minutes. 
Clearance (CL/F), volume of distribution (V/F) and ka were 697 L/h, 
8170 L and 1.31h-1, respectively. Interindividual and interoccasion 
variability estimates for CL/F and V/F were moderate to high. None 
of the covariates tested showed a clinically relevant effect on the PK 
parameters of BIBF 1120 and thus none were included in the model. 
A trend towards lower CL/F values with increased liver enzymes was 
observed but its effect was small.
Conclusion: BIBF 1120 plasma concentrations in NSCLC patients 
were described by a one-compartment model. No clinically relevant 
covariates influencing the PK of BIBF 1120 were detected. An inter-
national Phase III trial program investigating BIBF 1120 in NSCLC, 
LUME-Lung, is now recruiting patients.
*Trade name not FDA approved
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Health-related quality of life and tolerability of 
pemetrexed with or without enzastaurin as second-line 
therapy for advanced non-small cell lung cancer
Reck, Martin 2; Chiappori, Alberto3; Liepa, Astra M.1; Zhao, Yan D.1; 
Mazieres, Julien4; Schwartzberg, Lee S.5; von Pawel, Joachim6
1 Eli Lilly and Company, Indianapolis, IN, USA; 2 Hospital 
Grosshansdorf, Grosshansdorf, Germany; 3 H. Lee Moffitt Cancer 
Center, Tampa, FL, USA; 4 Larrey Hospital, Toulouse, France; 5 
West Clinic, Memphis, TN, USA; 6 Asklepios-Fachkliniken Munich-
Gauting, Munich-Gauting, Germany
Background: Pemetrexed is a standard second-line therapy for the 
treatment of advanced non-small cell lung cancer (NSCLC). It has 
demonstrated efficacy and symptom palliation, along with a more 
favorable toxicity profile than docetaxel (Hanna et al. J Clin Oncol 
2004; de Marinis et al. J Thorac Oncol 2008). Here we report the 
health-related quality of life (HRQL) and tolerability results from a 
randomized, double-blind, phase II trial comparing pemetrexed with 
or without enzastaurin in the second-line setting.
Methods: Patients with Stage III or IV NSCLC and performance 
status (PS) 0-2 who had received one prior therapy for advanced dis-
ease were randomized to receive pemetrexed 500 mg/m2 once every 
3 weeks plus placebo or enzastaurin 500 mg orally daily. All patients 
received standard pemetrexed vitamin supplementation. Patients 
completed the Lung Cancer Symptom Scale (LCSS) prior to start 
of each cycle of therapy. Toxicity was assessed with the Common 
Terminology Criteria for Adverse Events (version 3) and supportive 
care (transfusions, concomitant medications, hospitalizations) was 
recorded at each cycle. Time to worsening (TWS) in LCSS items was 
defined as a 15-mm increase from baseline and was analyzed using a 
Cox proportional hazards model with stratification and other baseline 
factors as co-variates. Patients who completed the LCSS at baseline 
and at least one other assessment were included in the analysis. Tox-
icity and supportive care were compared with Fisher’s exact test.
Results: Eighty patients were randomized to each arm. Baseline 
characteristics were well balanced with 67.5% males, 92.5% PS 
0/1, and 71.9% stage IV. Addition of enzastaurin did not improve 
efficacy. In both arms, patients received a median of 3 cycles and 
20.3% in the enzastaurin arm and 21.3% in the placebo arm received 
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>6 cycles. Sixty-four patients from each arm were included in the 
TWS analyses. Global HRQL was the only LCSS item for which 
there was a statistical difference between arms with a longer TWS 
for the pemetrexed plus placebo arm (hazard ratio = 2.11; p=0.010; 
median 8.1 versus 3.1 months). For pemetrexed plus placebo, median 
TWS ranged from 2.4 to 3.8 months for anorexia, fatigue, dyspnea, 
symptom distress, and interference with activity level; median TWS 
was not estimable for cough or hemoptysis due to censoring. Select 
grade 3/4 drug-related toxicity and supportive care are summarized in 
the table. 
  Pemetrexed + enzastaurin  Pemetrexed + placebo  
p-value 
  (% patients) (% patients)
 Anemia 5.1% 5.0% >0.999
 Neutropenia 15.2% 5.0% 0.038
 Thrombocytopenia 8.9% 1.3% 0.034
 Febrile neutropenia 3.8% 2.5% 0.681
 Transfusions 17.7% 16.3% 0.836
 G-CSF 11.3% 6.3% 0.402
 Erythropoiesis-stimulating agents 12.5% 8.8% 0.609
 Toxicity-related hospitalizations 13.9% 15.0% >0.999
Conclusions: As second-line therapy for advanced NSCLC, the 
addition of enzastaurin to pemetrexed did not improve efficacy, but 
increased neutropenia and thrombocytopenia. HRQL, toxicity and 
resource use results for the control arm of single-agent pemetrexed 
are consistent with previous reports.
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Phase I trial of vorinostat in combination with erlotinib 
for advanced non-small cell lung cancer (NSCLC) patients 
(pts) with EGFR mutations after erlotinib progression
Reguart, Noemi1; Isla, Dolores2; Cardenal, Felipe4; Cardona, Andres3; 
Palmero, Ramon4; Moran, Teresa3; Rolfo, Christian Diego5; Nadal, 
Ernesto Samuel 4; Massuti, Tomeu6; Montañes, Ana3; Queralt, 
Cristina3; Taron, Miquel3; Rosell, Rafael3
1 Hospital Clinic Barcelona, Barcelona, Spain; 2 Hospital Lozano 
Blesa, Zaragoza, Spain; 3 Hospital Germans Trias i Pujol, Barcelona, 
Spain; 4 Hospital Duran i Reynals, Barcelona, Spain; 5 Clinica 
Rotger, Palma de Mallorca, Spain; 6 Hospital General Universitario 
de Alicante, Alicante, Spain
Background: Vorinostat (Suberoylanilide hydroxamic acid, SAHA) 
is a histone deacetylase (HDAC) inhibitor that induces differentia-
tion, growth arrest and apoptosis of malignant cells both in vivo and 
in vitro. In vitro, there is a synergistic antiproliferative interaction 
of vorinostat in combination with gefitinib in NSCLC cell lines. 
Moreover, inhibition of HDAC by vorinostat increases levels of 
E-cadherin, p21, and downregulates expression of phospho-AKT and 
phospho-ERK1/2. These molecular findings could reverse resistance 
to erlotinib in mutant patients.
Methods: A 3+3 rule dose escalation was used to determine the max-
imum tolerated dose (MTD) of oral erlotinib 150 mg QD in combina-
tion with oral vorinostat (dose level 1 [DL1], 300 mg QD on days 
1-7 every 21 days; DL2, 400 mg QD on days 1-7 every 21 days, and; 
DL3, 400 mg QD on days 1-7 and 15-21 in a 28-day cycle). Cycles 
were repeated for a maximum of 6 until progressive disease (PD) or 
intolerable toxicity. Pts with advanced NSCLC with EGFR mutations 
(Exon 19 and 21) after erlotinib progression and ECOG ≤2 were eli-
gible. The primary objective was to determine the maximum tolerated 
dose (MTD) and the dose limiting toxicity (DLT). Activity and safety 
of the combination regimen were also assessed. 
Results: The combination was administered to twelve pts (median 
age, 59 years; range 41-77) at 3 dose levels. One pt remains on treat-
ment. The MTD of the combination was reached at Erlotinib 150 mg 
QD plus vorinostat at 400 mg QD on days 1-7 and 15-21 in a 28-day 
cycle. There was a single DLT at third cohort (Grade 3 diarrhoea). 
The most common drug-related toxicities of any grade in the first 
cycle of treatment were anemia (77.8%), skin alterations (66.7%), 
diarrhoea (66.7%), xerostomy (55.6%), asymptomatic changes in 
liver function tests (55.6%), and asthenia (55.6%). There were no 
Grade ≥3 drug-related adverse events during first cycle of treatment 
and the global analysis of cycles showed asthenia (11.1%), somno-
lence (11.1%) and hyporexia (11.1%). No accumulate toxicity was 
observed in patients who were longer on treatment. Of 10 evaluable 
pts for efficacy, seven had stable disease as best response (median 
duration of treatment 6.0 cycles, range 3-12). 
Conclusions: The combination of vorinostat and erlotinib appears to 
be well tolerated in this group of advanced NSCLC pts with EGFR 
mutations after erlotinib progression; the combination demonstrated 
prolonged disease stabilization and a phase II trial is planned. 
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A phase II Study of administration of Docetaxel and 
Vinorelbine with Gemcitabine for inoperable Stage III or 
IV Non-Small Cell Lung Cancer (NSCLC)
Reza, Md S.2; Hai, Mohammad A.1; Chowdhury, Qamruzzaman2
1 Bangladesh Cancer Hospital & Welfare Home, Dhaka, Bangladesh; 
2 Ahsania Mission Cancer Hospital, Dhaka, Bangladesh
Introduction: Non-platinum combination of vinorelbine and gem-
citabine showed promising results in patients with inoperable locally 
advanced NSCLC, where response rate was 46%. However, median 
survival was relatively short; 8 months. Docetaxel has excellent 
single-agent activity in NSCLC; therefore, we have added docetaxel 
sequentially to the previous combination to improve the results and to 
be able to administer full doses of each drug. 
Methods: Previously untreated patients with stage III/IV NSCLC, 
no symptoms of brain metastases, and WHO PS of 0-2, receive do-
cetaxel 100mg/m2 on day 1 for 3 cycles (21days interval). Vinorel-
bine 35mg/m2 followed by gemcitabine 1200mg/m2 is given on days 
1 and 15 for 3 cycles (28 days interval). Premedication includes 
steroids for 2-5 days in the docetaxel cycles. Response Rates were 
evaluated. 
Results: Thirty-two (23 M/9 F) patients have entered so far. Median 
age is 61 years (48-76). 11 patients had stage IIIB and 21 patients 
stage IV disease. There were 17 cases of adenocarcinoma, 11 squa-
mous cell carcinoma and 4 large-cell carcinoma. Twenty-six patients 
are now evaluable for response: 16 PR, 10 PD and RR was 62%. Four 
patients discontinued treatment before evaluation as a result of early 
progression (1pt), anaphylactic reaction (1pt), grade 4 infection (1pt) 
and early death due to pulmonary embolism (1pt).The main toxicity 
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has been febrile neutropenia (7/32) and grade 3-4 neutropenia (6/32). 
Nausea grade 2-3 has been infrequent (3/32). 
Conclusion: This intensified non-platinum chemotherapy regime 
is feasible and has acceptable toxicity, and the addition of 3 cycles 
of docetaxel, appear to improve the response rate over vinorelbine-
gemcitabine alone. 
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Phase 1 trial of cetuximab and erlotinib in patients with 
lung adenocarcinoma and acquired resistance to erlotinib
Riely, Gregory J.; Janjigian, Yelena Y.; Pereira, L K.; Azzoli, 
Christopher G.; Pietanza, M. C.; Krug, Lee M.; Rizvi, Naiyer A.; 
Kris, Mark G.; Ginsberg, Michelle S.; Pao, William; Miller, Vincent 
A.
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Background: Patients with EGFR mutant lung adenocarcinoma 
have a 70% radiographic response rate after treatment with erlotinib 
or gefitinib. Despite this good initial response, patients invariably 
develop progressive disease after a median of one year of treatment 
with erlotinib or gefitinib. The most common mechanism of acquired 
resistance to erlotinib (i.e. initial radiographic response followed by 
progressive disease) in such patients is development of a secondary 
mutation in EGFR, suggesting that these tumors continue to depend 
upon EGFR signaling. We hypothesized that combined EGFR block-
ade with erlotinib and cetuximab would overcome acquired resistance 
to erlotinib in patients with lung adenocarcinoma. To determine the 
maximum tolerated dose of cetuximab in combination with erlotinib, 
we conducted this phase 1 trial of erlotinib and cetuximab in patients 
who were previously treated with erlotinib.
Methods: Eligible patients had lung adenocarcinoma with either 
radiographic response (RECIST partial or complete response) to 
treatment with erlotinib or a documented EGFR mutation. All pa-
tients had previous treatment with erlotinib for more than 3 months, 
radiographic progression by RECIST during treatment with erlotinib, 
and continuous treatment with erlotinib for 1 month prior to initiating 
treatment. Patients with grade 2 or greater skin toxicity on erlotinib 
monotherapy were not eligible. All patients received erlotinib 100 mg 
daily. Cetuximab was administered every two weeks without a load-
ing dose with 3 patients per cohort and inter-cohort dose escalation.
Results: Between August 2008 and February 2009, 14 patients were 
treated with erlotinib and cetuximab. Two patients treated at 375 
mg/m2 had hypersensitivity reactions during the first infusion of 
cetuximab and were removed from study. Twelve patients completed 
the first cycle of treatment with erlotinib and cetuximab (3 at 250 
mg/m2, 3 at 375 mg/m2, and 6 at 500 mg/m2). The median age was 
63 (range 50-78). The median time from beginning erlotinib was 17 
months (range 5-45 months). Baseline EGFR mutations: exon 19 de-
letions (6), L858R (2), none detected (1), unknown (3). Two patients 
had development of EGFR T790M prior to enrollment in this trial. 
The median number of cycles received was 2.5 (Range 1-3+), with 3 
patients currently continuing on study. There was one first-cycle dose 
limiting toxicity of Grade 3 elevation in AST and ALT in a patient 
treated with cetuximab 500 mg/m2. Additional toxicities observed 
after the first cycle include grade 3 skin (1 each at 250 mg/m2 and 
375 mg/m2), grade 3 hypomagnesemia (1 at 500 mg/m2), grade 4 
hypomagnesemia (1 at 375 mg/m2), and grade 3 fatigue (1 at 375 mg/
m2). One RECIST partial response was seen in a patient treated at 
500 mg/m2. 
Conclusions: The recommended phase 2 dose for combination 
EGFR inhibition in this patient population with this schedule is er-
lotinib 100 mg daily and cetuximab 500 mg/m2 every 2 weeks. With 
this evidence of clinical activity, we are currently exploring the ef-
ficacy of the combination of erlotinib and cetuximab in a phase 2 trial 
of patients with acquired resistance to erlotinib. Supported, in part, by 
Bristol-Myers Squibb and Imclone. 
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Dose-ranging study of the combination of paclitaxel 
poliglumex and pemetrexed in advanced non-small cell 
lung cancer (NSCLC)
Slagle, Brendan M.; Rigas, James R.; Dragnev, Konstantin H.; 
DiSalvo, Wendye; Williams, Ian; Simeone, Sara; Engman, Cocav; 
Lipe, Brea
Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
Background: Taxanes continue to play an important role in the 
treatment of advanced NSCLC. Paclitaxel poliglumex (OPAXIO™, 
formerly known as Xyotax™, CT-2103) is an ester α-poly-L-
glutamic acid conjugate of paclitaxel allowing for solubility in 
aqueous solution, not requiring Cremophor or ethanol for intravenous 
administration or premedications. This is a non-randomized single-
arm, single-institution open label dose-ranging study was designed to 
evaluate the combination of pemetrexed and paclitaxel poliglumex. 
Methods: The primary objective of this study was to evaluate the 
safety of this combination. Patients were enrolled in 2 different dos-
ing levels. The first 6 received 135 mg/m2 paclitaxel poliglumex and 
500 mg/m2 pemetrexed intravenously every 3 weeks. None of the 6 
patients experienced an initial dose limiting toxicity (IDLT) following 
2 cycles of therapy and the paclitaxel poliglumex was then escal-
ated to 175 mg/m2 with 500 mg/m2 pemetrexed. Eligibility included 
advanced NSCLC, one or more measurable lesions (RECIST), ECOG 
performance status of 0-2, prior chemotherapy and radiation allowed, 
no grade 2+ peripheral neuropathy, no untreated brain metastases, 
and no active cardiac disease. 
Results: Twelve patients were enrolled, 6 patients to each dose 
level. Four of the patients were female, the median age was 65 years 
(48-74), 11 had a performance status of 0-1, and only 1 patient had 
received prior chemotherapy. There were no IDLTs at the first dose 
level, and there was one IDLT of infection with neutropenia at the 
second dose level. The median number of cycles completed was 5 
(range 1-12 cycles). Aside from grade 3 fatigue in 2 patients there 
were no grade 3 or greater non-hematologic toxicities. Common 
non-hematologic toxicities included peripheral neuropathy, constipa-
tion, fatigue, and alopecia. Of the 12 patients, the best response was 
stable disease in 9 patients, 2 are without disease progression, and 6 
patients are alive to date. The median progression free survival was 
3.3 months (range 0.7-10.7 months). 
Conclusion: The combination of paclitaxel poliglumex and pe-
metrexed was well tolerated at the proposed phase II dose of 175 mg/
m2 paclitaxel poliglumex and 500 mg/m2 pemetrexed. The progres-
sion free survival is encouraging and future studies of this combina-
tion are recommended. 
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Cross presentation of tumor antigens from lung tumor 
dendritic cells is blocked
McDonnell, Alison M.; Prosser, Amy C.; van Bruggen, Ivonne; 
Currie, Andrew J.; Robinson, Bruce W.
The University of Western Australia, Perth, WA, Australia
In order to understand why clinical response rates to immunother-
apies in patients with lung malignancies such as lung cancer and 
mesothelioma are weak, we asked whether the dendritic cells [DCs] 
infiltrating tumors can cross-present antigens to tumor specific CD8+ 
T cell.
Methods: We examined the ability of DCs infiltrating tumors and 
draining lymph nodes to cross-present tumor antigens by following 
presentation of a nominal tumor antigen (influenza A hemagglu-
tinin, HA) expressed in the murine mesothelioma cell line, ABI-HA. 
Lyons-Parish CFSE dilution assays were used for analysis of tumor 
antigen cross-presentation in vivo and ex vivo. For antigen uptake 
and processing studies, DCs were cultured with DQ-ovalbumin or 
AB1HA cell preparations ex vivo and antigen acquisition assessed by 
flow cytometry.
Results: Whereas DCs isolated from the tumor-draining lymph nodes 
of mice cross-presented HA antigen to antigen-specific CD8+ T cells, 
those from within tumors (TiDC) failed to do so. TiDC were not 
deficient in surface MHC or co-stimulatory molecules, yet remained 
hyporesponsive to activation stimuli. Importantly, TiDC were highly 
proficient at processing soluble and tumor protein. Despite this, TiDC 
were unable to induce any significant proliferation of HA-specific 
CD8+ T cells. Interestingly, presentation of tumor antigen in the 
draining lymph nodes was not restricted to DCs, with macrophages 
and B cells having a role.
Conclusions: Together these results indicate that mesothelioma 
tumor infiltrating DCs are paralysed in their ability to cross-present 
tumor antigen and that the location of the tumor may affect utilization 
of different antigen presenting cells for antigen presentation, a fact 
which may be crucial for the development of effective immunother-
apies. 
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Immunohistochemistry of biomarkers associated with 
metastatic and cancer stem-cell like phenotypes in non-
small cell lung cancer
Rouhi, Omid; Kaiser-walters, Kelly A.; Escarzaga, Diana; Steker, 
Danielle; Basu, Sanjib; Kim, Anthony W.; Liptay, Michael J.; Faber, 
L P.; Bonomi, Philip; Coon, John; Borgia, Jeffrey A.
Rush University Medical Center, Chicago, IL, USA
Background: Tumor metastasis is the primary cause of mortality 
in non-small cell lung cancer. Many pathways and biomarkers have 
been studied to clarify the mechanism of the seeding of the tumor 
cells to remote areas; however, the exact mechanism of metastasis 
is poorly understood. In our study we examined the differential 
expression of CXCR4, given its involvement in cellular migration, 
sonic hedgehog (Shh) for its involvement in metastatic progression 
and embryonic development, and CD133 as a characteristic stem-cell 
marker. 
Methods: Immunohistochemical staining for CD133, CXCR4, 
Shh, and Patch-1 was performed on 34 primary non-small cell lung 
carcinomas and matching metastatic lymph nodes. All patients were 
treated by complete anatomic resections and were limited to T1-2N1-
2M0, with patients groups consisting of adenocarcinoma (n=19) and 
“non-adenocarcinoma” (n=15) histology. Scoring was accomplished 
by evaluating stain intensity and frequency for up to four cells per 
field, with 50 random fields surveyed per section. A score was then 
calculated based on these parameters for statistical comparisons. Par-
ameters that were compared include differential primary and lymph 
nodes staining, tumor histopathological subtype, and disease-free and 
overall survival. All statistical comparisons were performed in SPSS 
v15.0 and consisted of either Mann-Whitney rank sums test (two-
sided) or Kaplan-Meier curves.
Results: A strong trend in the pattern of CD133 staining in primary 
tumor versus local lymph node metastases was observed within the 
patient cohort, with tumor cells located in the local lymph nodes hav-
ing a higher portion of intensely staining cells. This relationship only 
approached statistical relevance, however (p=0.08). CXCR4, CD133, 
and Shh were expressed in adenocarcinoma at a significantly higher 
level and more frequently than compared to non adenocarcinoma 
samples (p-values: 0.037, 0.002, 0.008 respectively). No significant 
trend was observed in Patch-1, the receptor for Shh, in this analysis. 
After comparing the IHC data with clinical information, we realized 
that overall survival was better in CD133 positive tumor samples 
compared to negative group (p=0.02). 
Conclusion: Therefore, based on our results, there is a statistically 
relevant difference in expression of CXCR4, CD133, Shh in different 
subtypes of NSCLC. These markers all are representative of either 
metastatic or embryonic phenotypes, suggesting divergent mechan-
isms for metastatic progression in the histological subtypes.
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Erlotinib in lung cancer patients with EGFR mutations 
and amplification; a focus on toxicity
Ruder, Aimee D.; Blazer, Marlo; Poirier, Jessica; Zhao, Weiqiang; 
Villalona-Calero, Miguel A.
The Ohio State University, Columbus, OH, USA
Purpose: Erlotinib, an oral tyrosine kinase inhibitor directed against 
the Epidermal Growth Factor Receptor (EGFR), is approved for re-
fractory advanced or metastatic non-small cell lung cancer (NSCLC). 
Retrospective studies showed that somatic activating mutations (ex-
ons 19 and 21) in the tyrosine kinase domain of EGFR and amplifica-
tion of this gene are predictors of antitumor responses and survival in 
lung cancer patients receiving treatment with EGFR tyrosine kinase 
inhibitors. Toxicities commonly observed with these agents include 
skin rash and diarrhea. The intensity of these side effects varies 
among patients and it has been suggested that there is an association/
correlation between the rash and antitumor efficacy. In vivo/vitro 
studies suggest that the concentration required for EGFR inhibition in 
tumors with these mutations is considerably less. Thus, the possibil-
ity exists that recommended doses of erlotinib are larger than those 
required for EGFR inhibition in this patient population. The object-
ive of the study is to determine whether patients with known EGFR 
mutations and or EGFR amplification receiving erlotinib are more 
prone to require dose reductions due to toxicities.
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Methods: All eligible patients from January 2008 to April 2009 seen 
at OSUCCC hospitals with a diagnosis of NSCLC and amplification 
and/or mutations in either exon 19 or 21 of the EGFR in their tumors 
were evaluated for erlotinib tolerability in this IRB approved obser-
vational study. Mutation and amplification analysis was performed at 
the CLIA-certified molecular laboratory of OSUCCC. The primary 
endpoint was dose reductions secondary to moderate or severe tox-
icity. Secondary endpoints include rate and degree of dermatologic 
and gastrointestinal (GI) adverse events using the National Cancer 
Institute (NCI) toxicity grading scale. Baseline characteristics includ-
ing smoking history and mutation type was collected.
Results: 48 patients were tested for EGFR mutations ± amplifica-
tion, 15 (31%) had mutations and eight (17%) had amplification 
only. Mutations included exon 19 (60%), exon 21 (33%) and both 
(7%). 53% of EGFR mutant tumors also had amplification. Of the 
23 patients with known mutations and/or amplification, the average 
age was 65 years old, primarily Caucasian (87%), female (61%), and 
never smokers (61%), with all adenocarcinomas. Ten and four pa-
tients with mutations and amplifications, respectively, have received 
erlotinib to date. Five mutant and 2 amplified patients required dose 
reductions due to NCI grade 2 or higher toxicity. The adverse events 
included rash (60%), asthenia (30%), and diarrhea (10%). 
Conclusion: Erlotinib related toxicities and resulting dose reductions 
appear common among patients with EGFR mutations at the starting 
recommended dose of this agent. Since lower doses may be biologic-
ally active in this group of patients, larger studies assessing different 
starting dosing strategies may be applicable.
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The prognostic significance of 18FDG uptake by PET in 
advanced Non Small Cell Lung Cancer 
Ryoo, Hun Mo; Bae, Sung Hwa; Hyun, Dae Sung
Internal medicine, Daegu Catholic Univ Medical Center, Daegu, 
Korea
Background: Lung cancer is the leading cause of cancer-related 
death in Korea. Non small cell lung cancer(NSCLC) comprises 
80-85% of lung cancer. Positron emission tomography with [18F]
fluorodeoxyglucose(FDG- PET) shows various levels of FDG uptake 
for patients with NSCLC. The aims of this study were to determine 
whether the standardized uptake value (SUV) of FDG uptake by PET 
could be a prognostic factor for advanced NSCLC. 
Method: FDG-PET was performed for 59 patients with stage IIIb 
and IV non small cell lung cancer. The SUV was calculated for each 
patient. Overall survival(OS), progression free survival(PFS) were 
calculated by the Kaplan- Meier method and evaluated with the log-
rank test. The prognostic significance was assessed by univariate and 
multivatiate analysis. 
Results: A cutoff of 7 for the SUV showed the best criminative 
value. In a univariate analysis, performance status(p=0.02) and 
SUV(p=0.03) were the significant predictors of OS. The patients with 
low SUVs(≤7) showed significantly better PFS than those with high 
SUVs(>7, p=0.04). A multivariate Cox analysis identified perform-
ance status and the SUV as important for the prognosis. 
Conclusion: These results suggest that SUV was the significant 
prognostic factor among the patients with advanced non small cell 
lung cancer. 
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Association of pharmacokinetics and germline mutations 
in ABC transporters with erlotinib toxicity in patients with 
non-small cell lung cancer (NSCLC)
Sasaki, Jiichiro1; Hamada, Akinobu1; Saeki, Sho 1; Iwamoto, Norihiro 
2; Inaba, Megumi 3; Kishi, Hiroto 4; Ushijima, Jun 3; Fujii, Shinji 5; 
Semba, Hiroshi 5; Saito, Hideyuki 1; Kohrogi, Hirotsugu 1
1 Kumamoto University Hospital, Kumamoto, Japan; 2 Saiseikai 
Kumamoto Hospital, Kumamoto, Japan; 3 Kumamoto Chuo Hospital, 
Kumamoto, Japan; 4 Kumamoto Citizens Hospital, Kumamoto, 
Japan; 5 Kumamoto Regional Medical Center, Kumamoto, Japan
Background: Erlotinib demonstrates substantial inter-individual 
differences in response and the development of skin rash (grade≥2) 
was correlated with efficacy. Erlotinib interacts with its target EGFR 
and the efflux transporter ABCB1 and ABCG2. A 421C>A SNP 
in ABCG2 and 1236C>T, 2677 G>(T/A), and 3435C>T SNPs in 
ABCB1 are associated with reduced protein expression. The aim of 
this study was to evaluate the effects of these variants and pharma-
cokinetics of erlotinib on toxicity grade in Japanese patients treating 
single agent erlotinib.
Methods: Twenty-two patients with NSCLC received erlotinib orally 
at 150 mg/day and plasma levels of erlotinib were measured on days 
1(D1), 8(D8), and stable phase (>day 14) by high-performance liquid 
chromatography. DNA from plasma was screened for SNPs in the 
EGFR, ABCB1, and ABCG2 genes using direct nucleotide sequen-
cing or TaqMan assay. Eligibility criteria included: performance 
status (PS) < 3, stage IIIB-IV, and written informed consent.
Results: The mean Cmax of D1 and D8 were 1.8 and 3.1 µg/ml, 
respectively. Trough concentration (Cmin) at D1 and steady state 
were 0.9 and 1.7 µg/ml, respectively. Grade 1-2 skin rash or diarrhea 
occurred in 95% of patients. One patient (Cmax at D1, 3.0 µg/ml) 
developed interstitial lung disease after continuous treatment with 
erlotinib for 3 days. The area under curves and Cmax on D1 were 
correlated with the severity of skin rash (p=0.05 and 0.01), however, 
Cmin were not correlated. Patients with homozygous variant and 
heterozygous for ABCB1 1236C>T, 2677 G>(T/A), and 3435C>T 
genotype as compared to patients carrying the wild-type were associ-
ated with higher Cmin at steady state (2.4 vs 1.2 µg/ml, p=0.01). All 
Patients with homozygous variant for ABCB1 1236TT-2677TT/TA/
AA-3435TT developed grade 2 skin rash or diarrhea.
Conclusions: The present study suggests that ABCB1 gene poly-
morphism is associated with the variable toxicity and pharmacokinet-
ics to erlotinib treatment.
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Treatment of patients with advanced non-small-cell lung 
cancer (NSCLC) with erlotinib: results from clinical 
practice
Faehling, Martin1; Eckert, Robert2; Kuom, Sabine1; Kamp, Torsten2; 
Stoiber, Kathrin3; Kropf, C3; Rüdiger, S3; Schumann, Christian3
1 Klinikum Esslingen, Germany, Esslingen, Germany; 2 Onkologische 
Schwerpunktpraxis, Wendlingen, Germany; 3 Clinic of Internal 
Medicine II, University Ulm, Ulm, Germany
Background: The EGFR-TKI erlotinib has shown benefit in pre-
treated NSCLC. Post-hoc subgroup analyses of randomized studies 
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suggest that nonsmokers, women, and patients with adenocarcinoma 
histology may have a superior response to treatment. We performed 
a retrospective analysis to answer the question, whether these 3 
response criteria can be used in routine clinical practice for selection 
of patients.
Methods: We analyzed all consecutive patients with NSCLC starting 
treatment with erlotinib (150 mg/d) between May 2005 and January 
2009. Response was assessed radiologically using RECIST criteria 
after 4 – 8 weeks of treatment with erlotinib.
Results: Patient characteristics: 121 caucasian patients were 
analysed. Compared with the phase III study (BR.21) of erlotinib, 
our patients were older, but had a better performance status. Our 
population included a higher proportion of patients with adenocarcin-
oma, but similar percentage of women and smokers. Nine patients 
who were unfit to receive conventional chemotherapy including one 
patient on chronic haemodialysis were treated with erlotinib as 1st 
line therapy.
Response to erlotinib: 16.5% of patients demonstrated a partial remis-
sion, 33.9% experienced stable disease. The patient on haemodialysis 
tolerated erlotinib well and had stable disease for 11 months. Partial 
remissions were seen more frequently in never-smokers, in females, 
and in patients with adenocarcinoma histology. The disease control 
rate (PR + SD) was higher in non-smokers than in ex-smokers or 
smokers. However, diseases control rate was higher in male than in 
female patients, and there was no difference in between patients with 
adenocarcinoma and non-adenocarcinoma histology. In 12% (14 
patients), the response lasted for at least a year. 79% of these patients 
were never-smokers with adenocarcinoma. None of the longterm 
responders was a current smoker, and 93% had adenocarcinoma 
histology.
Survival: Never-smokers had a median progression free survival 
(PFS) and overall survival (OS) of 7.5 and 13 months, respectively. 
Ex-smokers had a PFS and OS of 3.5 and 7.5 months, and current 
smokers had a PFS and OS of 2 and 5.5 months, respectively. There 
was a trend towards better PFS and OS with longer duration of ex-
smoking. Gender or histology had no significant effect on PFS or OS 
in our caucasian population. Treatment line did not influence PFS or 
OS, in particular patients treated with erlotinib 1st line experienced a 
similar PFS and OS compared with chemotherapeutically pretreated 
patients.
Conclusions: The above clinical criteria may be valid for prediction 
of partial responses and of longterm response to erlotinib. However, 
except for smoking, the clinical selection criteria do not predict PFS 
and OS. This may be due to the significant survival advantage we 
found for patients with SD compared with patients progressing radio-
logically. Our retrospective data need to be confirmed with larger 
patient numbers (e. g. from registries) in order to define the clinically 
and economically appropriate method of patient selection.
Furthermore, our data indicate that erlotinib may be effective as a 
first-line monochemotherapy in selected patients. This needs to be 
confirmed in a prospectively randomized manner comparing TKI 
monotherapy and cytotoxic chemotherapy in the first line setting of 
NSCLC.
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Possible differences in efficacy of two carboplatin based 
regimen in the treatment of advanced NSCLC
Schytte, Tine; Hansen, Olfred; Hansen, Karin H.; Sørensen, Peter; 
Olsen, Karen E.
Odense University Hospital, Odense, Denmark
Background: Recent data suggest that various chemotherapy regi-
men may have different efficacy in subsets of patients (pts.) with 
advanced NSCLC. We have therefore studied if this was the case for 
two Carboplatin (C) regimens: C-Vinorelbine (V) or C-Gemcitabine 
(G) used as standard treatment in our centre for two periods.
Methods: From 1998-2007, 807 consecutive pts. were treated with a 
3-weekly schedule of C, AUC=5, plus either V (30 mg/m2 d.1+8), or 
G (1000 mg/m2 d.1+8) for 4–6 cycles. CV was used as the standard 
regimen 1998 – 2003, and CG, 2004 – 2007. The endpoint of this 
study was crude survival. The data was analysed according to per-
formance status (PS), gender, age, and histology 
Results: 316 pts. were treated with CV, 491 with CG. Median, 1 yr 
and 2 yr survival was for CV: 8.6 m, 34% and 12%, and for CG: 8.7 
m, 37% and 16%, p=0.24. Pts. with adenocarcinoma (AC) had better 
median survival, 9.6 m. than non-AC, 8.1 m, p= .003, females better 
than males 10.1 m. vs. 7.9 m., p=.01, and PS 0-1 better than PS=2, 
10.1 m. vs. 4.7 m. (p=.000). In females, PS 0-1 and CG regimen were 
statistically significantly good favourable prognostic factors while 
in males only PS 0-1 was of significance. In the 381 pts. with AC, 
PS and gender was of significance while the chemotherapy regimen 
was of borderline significance (p=.051). In non-AC, only PS was of 
significance. 
Conclusions: While CV and CG were overall equal effective in the 
treatment of NSCLC, CG may be the superior regimen in females, 
and in AC.
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Phase I study of erlotinib and hydroxychloroquine in non-
small cell lung cancer
Sequist, Lecia V.; Sharma, Sreenath V.; Supko, Jeffrey G.; Neal, Joel 
W.; Fidias, Panos; Temel, Jennifer; Suk Heist, Rebecca; Shaw, Alice 
T.; Engelman, Jeffrey A.; Settleman, Jeffrey E.; Lynch, Thomas J.
Massachusetts General Hospital, Boston, MA, USA
Background: Epidermal growth factor receptor (EGFR) mutations 
define a subset of non-small cell lung cancer (NSCLC) with distinct 
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biology. Though initially sensitive to EGFR tyrosine kinase inhib-
itors (TKIs) like erlotinib or geftinib, resistance ultimately arises. 
Preclinical data suggest hydroxychloroquine (HCQ) may delay or 
reverse TKI-resistance in EGFR mutant NSCLC, potentially via chro-
matin modulation. HCQ is well-tolerated; principal side effects are 
nausea and retinopathy. This study examined the safety and pharma-
cokinetics (PK) of dose-escalating HCQ, with or without erlotinib, in 
NSCLC patients likely to harbor EGFR mutations.
Methods: Patients had advanced NSCLC, adequate performance 
status and organ function, and ≥12 weeks of prior erlotinib or gefit-
inib. Brain metastases were definitively treated; screening eye exams 
were required. Initially, patients were randomized to HCQ alone or 
HCQ plus erlotinib 150 mg QD, with standard 3+3 dose escalation 
cohorts for HCQ of 400, 600, 800 and 1000 mg QD in each arm. 
After the 800 mg HCQ dose cohort, the HCQ alone arm was closed 
because it was determined that follow-up trials would include HCQ 
plus erlotinib. The combination arm was continued to 1000 mg HCQ.
Results: 20 patients have been treated (8 HCQ alone, 12 combina-
tion), ages 27-76, including 10 women and 14 EGFR mutants (10 
exon 19 del, 2 L858R, 2 other). Median of 2 prior therapies, 9 
patients transitioned consecutively from TKI to protocol therapy. No 
DLTs have been observed; the anticipated last patient in the 1000 mg 
HCQ dose cohort has begun treatment. Treatment related adverse 
events were typical for erlotinib with mild increase in nausea/diar-
rhea, see table. One patient had fatal pneumonitis during cycle 2; no 
significant ocular toxicities were observed (one each eye irritation, 
conjunctivitis, floaters). One patient with exon 19 del EGFR mutation 
had a partial response to HCQ 600 mg plus erlotinib and remains on 
therapy after 17+ cycles. Three additional patients have received ≥4 
cycles combination therapy. PK data will be available at the meeting.
HCQ + 
Erlotinib
HCQ + 
Erlotinib
HCQ Alone HCQ Alone
Toxicity Type Grade 1-2, 
n (%)
Grade 3+, 
n (%)
Grade 1-2, 
n (%)
Grade 3+, 
n (%)
Total, n (%)
Acneiform rash/
dry skin
7 (58%) 1 (8%) (G3) - - 8 (40%)
Nail changes 2 (17%) 1 (8%) (G3) - - 3 (15%)
Diarrhea/
bloating
8 (67%) - 1 (13%) - 9 (45%)
Nausea/vomit-
ing
6 (50%) 1 (8%) (G3) 3 (38%) - 10 (50%)
Fatigue/weak-
ness
4 (33%) - 1 (13%) - 5 (25%)
Anorexia 3 (25%) - - - 3 (15%)
Pneumonitis - 1 (8%) (G5) - - 1 (5%)
Occular 3 (25%) - - - 3 (15%)
Anemia 1 (8%) - 1 (13%) - 2 (10%)
Neutropenia - 1 (8%) (G3) - - 1 (5%)
Alk Phos - - 1 (13%) - 1 (5%)
Headache - - 2 (25%) - 2 (10%)
Cough 2 (17%) - - - 2 (10%)
Voice change 1 (8%) - - - 1 (5%)
Elevated 
creatinine
1 (8%) - - - 1 (5%)
Conclusion: HCQ may reverse or delay EGFR TKI-resistance in 
EGFR mutant NSCLC. HCQ is well tolerated in combination with 
erlotinib; toxicity is not significantly different than erlotinib alone. 
The highest dose tested was 1000 mg QD HCQ. Evidence of activity 
was observed in patients with acquired TKI-resistance. 12 additional 
patients will be treated with erlotinib plus HCQ in a phase IB expan-
sion and a randomized phase II study is planned for 1st-line therapy 
of EGFR mutant NSCLC. 
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Bi-weekly administration of gemcitabine and docetaxel in 
patients with non-small cell lung cancer
Shiina, Takayuki1; Kondo, Ryoichi1; Yoshida, Kazuo1; Amano, Jun1; 
Takasuna, Keiichiro2; Hayasaka, Muneharu3; Kobayashi, Takeshi4; 
Koizumi, Tomonobu4; Kubo, Keishi4; Hachiya, Tsutomu5; Eda, 
Seiichiro6
1 Department of Thoracic Surgery, Shinshu University Hospital, 
Matsumoto, Japan; 2 Department of thoracic surgery, Ina chuo 
Hospital, Ina, Japan; 3 Department of respiratory medicine, 
Chushinmatsumoto Hospital, Matsumoto, Japan; 4 Department of 
respiratory medicine, Shinshu University Hospital, Matsumoto, 
Japan; 5 Department of respiratory medicine, Suwa red-cross 
Hospital, Suwa, Japan; 6 Department of respiratory medicine, 
Matsumoto Kyouritsu Hospital, Matsumoto, Japan
Background: Combination of gemcitabine and docetaxel (GEM/
DOC) has shown a favorable activity with its response rate of 34-
37.5%, similar to that of cisplatin and docetaxel in chemotherapy-
naïve patients with stage IIIB or IV non-small cell lung cancer 
(NSCLC). However, neutropenia and pulmonary toxicities were re-
lated to the combination chemotherapy. Especially relatively high rate 
of pulmonary toxicities have been identified in monthly or weekly 
administration setting of both combination. 
Purpose: We evaluated the feasibility and efficacy of biweekly 
GEM/DOC chemotherapy in patients with NSCLC.
Patients and Methods: Seventy patients with post-operative recur-
rences and 60 patients with unresectable advanced NSCLC were 
enrolled in this study. Those patients received 1000mg/m2 of GEM 
and 30mg/m2 of DOC bi-weekly, q=2 weeks. Response rate, toxici-
ties, and completion rate are evaluated after 4 cycles. Those patients 
were basically treated on outpatient basis.
Results: A total of 130 patients were treated with combination of 
GEM/DOC. 
Patients characteristics were as follows; recurrent/unresectable: 
70/60; male/female: 90/40; median age: 67.7 (range 32-83); per-
formance status 0/1/2: 77/43/10; adenocarcinoma/squamous cell 
carcinoma/adenosquamous cell carcinoma/large cell carcinoma/
pleomorphic carcinoma: 86/34/1/8/1; chemotherapy naive/previously 
treated: 46/84. A response rate was22.3% (CR 4, PR 25, SD 63, PD 
32 and NE 6). Response rates by tumor pathological type were 25.6% 
(22/86) with adenocarcinoma, 14.7% (5/34) with squamous cell car-
cinoma, 12.5% (1/8) with large cell carcinoma and 12.5% (1/8) with 
pleomorphic carcinoma. Over grade 3 leucopenia was occurred in 
10.8% (14/130), neutropenia in 20.0% (26/130). Grade 2 anaphylaxis 
in 1.5% (2/130) and pulmonary toxicities in 5.4% (7/130). Chemo-
therapy related death was not observed in the present study. Treat-
ment completion rate was 76.9% (100/130). The reasons of treatment 
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discontinuation were progression disease, hematological toxicity, 
heart disease, pneumonia, and interstitial lung disease.
Conclusion: GEM/DOC regimen is a feasible and efficacious regi-
men against advanced and/or recurrent NSCLC. Biweekly adminis-
tration of GEM/DOC may decrease hematological toxicities and be 
well-tolerated regimen. In addition, the rate of pulmonary toxicities 
in biweekly GEM/DOC may be less compared with other scheduled 
combination.
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Erlotinib (Tarceva®) in patients with non-small-cell lung 
cancer (NSCLC): results on 394 patients from Tarceva 
Register of Czech Republic 
Skřičková, Jana1; Pešek, Miloš2; Zatloukal, Petr3; Kolek, Vítězslav4; 
Koubková, Leona5; Salajka, František6; Zemanová, Milada8; 
Tomíšková, Marcela1; Sixtová, Dimka9; Pavlík, Tomáš7
1 Department of Respiratory Diseases and TB, University Hospital 
Brno, Brno, Czech Republic; 2 Department od Respiratory Diseases 
and TB, Charles University Hospital Plzen, Plzen, Czech Republic; 
3 Department of Respiratory Medicine and TB Charles University 
Hospital Praha Bulovka, Praha, Czech Republic; 4 Department 
od Respiratory Diseases and TB, University Hospital Olomouc, 
Olomouc, Czech Republic; 5 Department of Respiratory Medicine 
and TB Charles University Hospital Praha, Motol, Praha, Czech 
Republic; 6 Department of Respiratory Medicine and TB, Charles 
University Hospital Hradec Králové, Hradec Králové, Czech 
Republic; 7 Institute of Biostatistics and Analyses, Masaryk 
University Brno, Brno, Czech Republic; 8 Deparment of Oncology, 
Charles University Hospital Praha, Praha, Czech Republic; 9 
Department of Respiratory Diseases and TB, Thomayer University 
Hospital, Praha, Czech Republic
Background: Erlotinib (Tarceva®) is the active and selective EGFR-
TKI (epidermal growth factor receptor tyrosine kinase inhibitor). This 
is the only one tyrosin kinase inhibitor of epidermal growth factor 
receptor (EGFR), which has been recommended in the Czech Re-
public for second and third line treatment of advanced NSCLC. The 
Czech Republic has had an opportunity to use erlotinib in patients 
with NSCLC from the year 2005. Our study evaluates the data from 
Czech Tarceva Register, which is the common project of the Czech 
Pneumological and Phtiseological Society, Czech Society for Oncol-
ogy and Institute of Biostatistics and Analyses of Masaryk University 
Brno. We evaluated the efficacy and toxicity of the first 394 patients 
with NSCLC treated with erlotinib between December 2005 and 
December 2008 in 10 institutions in the Czech Republic.
Patients and Methods: In 394 patients was erlotinib administered 
orally 150mg/day until disease progression. Female were 143 (36,3 
%) and male 251 (63,7%) patients. Non-smokers were 88 (22,3%), 
stop-smokers 163 (41,4%) and current smokers143 (36,3%) patients. 
Median age was 63 years.
We treated 45 patients who were unsuitable for chemotherapy and 
349 patients who had failed prior chemotherapy. The outcomes 
include following: response, survival and PFS (progression free sur-
vival). Response was evaluated after 2 weeks of treatment. Objective 
response was evaluated by imaging techniques after 4-6 weeks of 
erlotinib treatment and had to be confirmed one month later (chest 
X-ray, CT scanning).
Results: Erlotinib was used as 1st line therapy in 45, as 2nd line 
in 195 and as 3rd line in 154 patients. At the time of indication for 
erlotinib was ECOG PS 0 in 22 patients, PS 1 in 224, PS 2 in 139 
and PS 3 in 9 patients. The most patients were stage III (31%) and 
stage IV (58,6%). Adenocarcinoma was confirmed in 203 (51,5%), 
squamous-cell carcinoma in 121 (30,7%) and other in 60 (17,8%) 
patients. CR (complete response) was confirmed in 3, PR (partial 
response) was confirmed in 38 (30,7%), SD (stable disease) in 159 
patients, 126 patients progressed and 78 patients was not evealu-
ated. Major toxicities were skin toxicity in 206 (60,3%) patients 
and diarrhoea in 82 (24 %) patients, but the therapy was finished 
due to toxicity grade 3-4 only in 30 patients. Median survival (95% 
CI) was 5,7 month (4,5; 6,8). Probability of 3-month survival was 
68,3% (63,4;73,3), probability of 6-month survival was 47,0% (41,0; 
52,9) and probability of one-year survival was 31, % (24,8; 38,6). 
The differences between the lines of treatment were not statistically 
significant (p = 0,489). PFS (95% CI) was 2,2 months. The probabil-
ity of 3-months PFS was 41,5% (36,3; 46,6), probability of 6-month 
survival was 18,4% (14,1;22,7) and probability of one-year PFS 
was 6,7% (3,4; 9,9). The differences between the lines of treatment 
were not statistically significant (p = 0,675). The differences between 
groups of patients according to PS (0+1 vs. 2+3) were statistically 
significant (p < 0,001). Median survival(95% CI) 8,1 (4,5; 11,7) 
months was in th group of patients with PS 0+1 and only3,5 (2,9; 4,2) 
months in the group of patients with PS 2+3
Conclusions: Erlotinib (Tarceva®) was well tolerated with evidence 
of antitumor activity in 1st, 2nd and 3rd line of antitumor therapy in 
non-selected group of 394 patients with advanced NSCLC. Median 
survival was statistically significant longer in the group of patients 
with PS 0+1.
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Phase 1 study of safety of gefitinib and palliative thoracic 
radiotherapy in advanced non-small cell lung cancer
Snee, Michael1; Price, Allan2; Bond, Marylin1; Williamson, 
Deborah1; Ironside, Janet3; Erridge, Sara3
1 St James Institute of Oncology Leeds, Leeds, UK; 2 University of 
Edinburgh, Edinburgh, UK; 3 Deapartment of Radiotherapy Western 
General Hospital Edinburgh, Edinburgh, UK
Aims: To determine whether gefitinib when given with common pal-
liative thoracic radiotherapy regimes increases treatment toxicity in 
stage 3B/4 non-small cell lung cancer.
Methods: 2 centre phase 1 study, patients with stage 3B or 4 non-
small cell lung cancer who were due to receive palliative thoracic 
radiotherapy but not candidates for chemotherapy by virtue of 
performance status or co-morbidity were prescribed gefitinib 250 mg 
daily for 7-10 days prior to radiotherapy and continued until progres-
sion of disease or withdrawal from the study. Patients suitable for 
low dose radiotherapy received 20Gy in 5 fractions deliv-ered over 1 
week and those suitable for high dose palliative radiotherapy 39Gy in 
13 frac-tions over 2.5 weeks. 
The primary objective was to characterise the safety profile of this 
combination, in particu-lar whether it would increase acute radiother-
apy toxicity. Secondary objectives were to measure quality of life and 
change in disease related symptoms compared with baseline.
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Results: 19 patients were enrolled between May 2004 and April 
2006. The mean age was 74 (range 36-82), 10 males and 9 females, 4 
patients had previously received chemotherapy All were treated with 
gefitinib and allocated to a radiotherapy dose level (12 to 20Gy and 
7 to 39Gy). Radiotherapy was received by 18 patients. No patients 
completed 12 months of gefitinib and all patients had died by this 
time-point. Reasons for discontinuation were death (7 patients), dis-
ease progression (6 patients) and adverse events (6 patients 
No patient experienced a dose limiting toxicity event. However only 
2 patients remained in the study for 3 months or longer. Median 
exposures to gefitinib were 39 days (6-102) for the 20Gy treat-
ment group and 55 days (6-183) for the 39Gy treatment group. The 
majority of patients (18, 95%) experienced at least 1 adverse event, 
generally mild or moderate (CTC grade 1 or 2). Diarrhoea, lower 
respiratory infection, nausea, rash and vomiting were the most 
frequently reported adverse events. Only 1/7 patients, treated with 
39Gy experi-enced Grade 2 oesophagitis and 0/12 treated with 20Gy 
experienced oesophagitis. Only 1 patient had clinically significant 
improvement in quality of life and improvement in disease related 
symptoms was minimal.
Conclusions: The safety profile of gefitinib in combination with pal-
liative thoracic radiotherapy in stage 3B/4 NSCLC was acceptable, 
although results should be treated with caution due to small numbers 
and only 2 patients remained in the study for 3 months or longer. The 
incidence and severity of drug related side effects and events with 
the combination indicated no new safety concerns. No firm conclu-
sions can be made about effect on quality of life or disease related 
symptoms due to limited data.
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Highly active chemotherapy in very elderly NSCLC (>75 
years) versus younger patients
Sorensen, Jens B.; Wallerek, Sandra; Jensen, Soren A.
Dept. Oncology, Finsen Centre/National University Hospital, 
Copenhagen, Denmark
Purpose: To examine tolerability and activity of platinum-based 
doublet chemotherapy in very elderly inoperable NSCLC patients 
aged >75 years compared to younger patients. 
Patients and Methods: Chemotherapy naïve inoperable NSCLC 
patients aged > 18 years with no upper age limit received Carboplatin 
AUC 5 and Vinorelbine (VNB) 25 mg/m2 day 1 and VNB 80 mg/m2 
orally day 8 q 3 weeks for maximum 6 courses without g-csf. They 
were divided in group A being <70 years, group B 70-75 years, and 
group C > 75 years.
Results: A total of 135 patients received 530 treatment courses 
(group A 70 patients, group B 40 patients, and group C 25 patients). 
There were no differences in pre-treatment characteristics such as 
gender, histologic subtype, performance status, weight loss, or stage. 
The median age (with range), and frequencies of performance status 
2, stage IV, and subsequent 2nd line chemotherapy were in group A 
61 years (36-69), 19%, 69%, and 30%, in group B 72 years (70-75), 
25%, 60%, and 18%, and in group C 78 years (76-84), 20%, 60%, 
and 0%, respectively. Number of treatment courses and time spent on 
treatment were similar for all three groups, as were the case for all 
toxic effects except leucopenia. The frequency of grade 4 leucopenia 
was 16% in group C and 1% in group A (p<0.01), and the frequency 
of febrile leucopenia higher in C (48%) than in A (14%) (p<0.001) 
with group B being intermediate. There were no toxic deaths. Re-
sponse rates were for groups A, B, and C 33%, 35%, and 56% and 
median survivals (with range) were 35 weeks (1-115+), 38 weeks 
(2-104+), and 41+ weeks (8-108+), respectively (not significant). 
Median times to progression were 19, 29, and 16 weeks, respectively.
Conclusions: Very elderly patients aged > 75 years could receive 
similar number of courses as younger patients and with similar 
level of toxicity except for neutropenia and febrile episodes during 
neutropenia which were considerably more frequent. The activity of 
Carboplatin and Vinorelbine was statistically similar between age 
groups, though with a remarkable trend towards higher response rate 
and longer survival among the very elderly. Platinum-based doublet 
chemotherapy is feasible and highly active in very elderly NSCLC 
patients but require close hematologic monitoring. The use of bone 
marrow stimulating treatment may be considered to diminish toxicity 
in this population. 
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Background: Standard therapy for advanced non-small cell lung 
cancer (NSCLC) is platinum-based double agent chemotherapy. Ce-
tuximab as a single agent and in combination with chemotherapy has 
demonstrated activity in NSCLC.
Patients and Methods: This was a single arm, multi-center phase 
II trial investigating the activity of the combination of carboplatin 
and cetuximab. Patients received carboplatin area under the curve 
of 6 on day 1, and an initial cetuximab dose of 400 mg/m2, and all 
subsequent weekly doses were 250 mg/m2. One cycle was considered 
21 days. The primary objective was response rate which was assessed 
using a two-stage design; secondary objectives were progression-free 
and overall survival, toxicity, and symptom response.
Results: Between December 2004 and April 2007, 57 patients were 
consented and treated at seven centers. The patients characteristics 
were: median age 65 (range 41 to 90), the majority had stage IV dis-
ease (90%), a performance status of 0 (56%), and the most common 
histology was adenocarcinoma (44%). The overall response rate ob-
served was 9% (95% confidence interval (CI), 3 to 19), the progres-
sion-free survival was 2.9 months (95% CI, 1.9 to 3.6), the median 
overall survival was 8.2 months (95% CI, 4.9 to 10.5), and one-year 
survival rate was 33% (95% CI, 21 to 45). The most frequent grade ≥ 
3 toxicities observed were infusion-related reaction (12%), includ-
ing one grade 5 infusion-related reaction, and rash (7%). The rate of 
grade 3 or 4 hematologic toxicity was low; thrombocytopenia (2 %), 
anemia (2 %), and neutropenia (5 %). Of the patients evaluable for 
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symptom response (n=49) 20 patients (41%) experienced a symptom-
atic response.
Conclusion: The combination of carboplatin and cetuximab was well 
tolerated, but had modest activity. 
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Fitness of RECIST 1.1 for non-small cell lung cancer 
(NSCLC) treated with EGFR tyrosine kinase inhibitor 
(TKI)
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Background: RECIST has been revised in 2009 (RECIST 1.1) 
to clarify some controversial issues since initial RECIST 1.0 was 
published in 2000. Two key changes in RECIST 1.1 were the lymph 
node (LN) measurement and the definition of disease progression 
(PD). The correct LN measurement is important in NSCLC where 
many equivocally enlarged LNs are. The judicious decision of PD is 
also critical because most of NSCLC patients which have responded 
to EGFR TKI (gefitinib or erlotinib) eventually show slow progres-
sion. Therefore, we evaluated the fitness of RECIST 1.1 for NSCLC 
treated with EGFR TKI. 
Method: We re-analyzed the responses of 104 NSCLC patients en-
rolled in eight prospective phase II studies treated with EGFR TKI by 
the criteria of RECIST 1.1, and compared with those by RECIST 1.0.
Results: The overall response rates according to RECIST 1.0 and 
RECIST 1.1 were 41.3 % and 44.2%, respectively (κ=0.94, P<0.001). 
Six best responses were reclassified by RECIST 1.1. Two partial re-
sponses (PR) by RECIST 1.0 were categorized as complete response 
(CR) because the sum of short diameter of LNs was less than 1 cm. 
Three stable diseases (SD) were reclassified as PR due to excluding 
equivocally enlarged LNs from baseline target lesions. One patient, 
who suffered obstructive pneumonia due to definitely enlarged LN, 
was reclassified into PD from SD. In addition, the progression-free 
survivals of three patients who had achieved PR were extended 
because equivocal new lesion or less than 5 mm of absolute increase 
in sum was not met as PD. 
Conclusion: RECIST 1.1 showed slightly increased overall response 
rate compared with RECIST 1.0, and this revised version might 
reflect tumor burden more accurately than RECIST 1.0, in NSCLC 
patients treated with EGFR TKIs.
Table. comparison of best response between RECIST 1.0 and RECIST 1.1
   RECIST 1.0  
 RECIST 1.1 CR (n=1), n (%) PR (n=42), n (%) SD (n=25), n (%) PD (n=36), n (%)
 CR 1 (100) 2 (5) 0 0
 PR 0 40 (95) 3 (12) 0
 SD 0 0 21 (84) 0
 PD 0 0 1 (4) 36 (100)
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Objective: Adipose tissue secretes adipokines with proinflammatory 
and anti-inflammatory properties. Our aim was to assess the role of 
adipose tissue in generalized inflammatory state of advanced NSCLC 
patients and the possible use of leptin, adiponectin and resistin as 
diagnostic and prognostic markers. Correlation of adipose tissue with 
weight loss in advanced NSCLC patients was also studied. 
Methods: Fasting serum levels of leptin, adiponectin and resistin 
were determined in 101 inoperable NSCLC patients and 51 healthy 
volunteers. Adipokines levels were determined at diagnosis, at the 
end of chemotherapy and at the time of disease progression Epi-
demiological, anthropometrical and laboratory data were assessed for 
patients as well as for healthy volunteers.
Results: Serum leptin and adiponectin levels presented no differen-
ces between NSCLC patients and healthy volunteers. Serum resistin 
levels were significantly increased in patients than in healthy controls 
after adjustment for age, sex and BMI (5.0±4.0 vs.3.5±1.4 ng/ml 
P=0.007). Multivariate analysis showed that serum levels of leptin, 
adiponectin and resistin at diagnosis could not be used as predict-
ive factors for overall survival or time to progression. Of all three 
adipokines, only serum resistin levels were associated with weight 
loss in NSCLC patients (4.4±2.8vs.6.9±6.2 ng/ml, P=0.04 in patients 
without weight loss and patients with weight loss, respectively) 
Conclusions: There was a lack of direct involvement of leptin and 
adiponectin in the systemic inflammatory response of patients with 
NSCLC while the role of resistin as proinflammatory cytokine needs 
further evaluation. Moreover, resistin may play a role in the patho-
genesis of weight loss in these patients.
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Lung Cancer
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Objective: Ghrelin is an orexigenic peptide implicated in body 
weight regulation and cell proliferation. Cachexia is a multifactorial 
effect of NSCLC presented in the advanced disease. The aim of this 
study was to detect the role of ghrelin in cachexia of advanced Non 
Small Cell Lung Cancer (NSCLC) patients as well as its role as a 
diagnostic and prognostic tool. 
Methods: Serum ghrelin levels were measured in 101 inoperable 
NSCLC patients before receiving any therapy (75 patients with 
weight loss and 26 without weight loss) and 60 healthy control vol-
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unteers. Epidemiological, anthropometrical and laboratory data were 
assessed for patients as well as for healthy volunteers.
Results: Increased serum ghrelin levels were determined in patients 
with cancer cachexia (0.56±0.24 vs. 0.52±0.44 ng/ml, P=0.017, in 
patients with weight loss and without weight loss, respsectively). 
NSCLC patients presented significantly higher serum ghrelin levels 
than healthy subjects after adjustment for sex, age and BMI (0.5±0.4 
vs. 0.4±0.3 ng/ml, P<0.001). Multivariate analysis showed that gh-
relin serum levels at diagnosis could not be used as predictive factors 
for overall survival or time to progression.
Conclusions: Ghrelin may be actively involved in the development 
of NSCLC cachexia. It may also have a role in lung cancer pathogen-
esis. Its potential role as a diagnostic tool needs further evaluation. 
P1.258 NSCLC Advanced Disease, Sat Aug 1 
Survey of European lung cancer evaluating choice of 
treatment and tolerability in observed 2nd line NSCLC 
(SELECTTION): cluster analysis of baseline results
Moro-Sibilot, D2; Vergnenegre, A3; Smit, E F.4; Toy, E5; Parente, 
B6; Schmitz, S7; Taipale, Kaisa1; Soldatenkova, Victoria8; Leteneux, 
Claudia1; Kraaij, Kees9
1 Eli Lilly and Company Ltd, Surrey, UK; 2 University Hospital, 
Grenoble, France; 3 Cluzeau Hospital, Limoges, France; 4 University 
Medical Centre, Amsterdam, Netherlands; 5 Exeter Oncology Centre, 
Exeter, UK; 6 Hospital de Vila Nova de Gaia, Vila Nova de Gaia, 
Portugal; 7 Medical Oncology and Haematology Clinic, Köln, 
Germany; 8 Eli Lilly and Company, Bad Homburg, Germany; 9 Eli 
Lilly and Company, Houten, Netherlands
Background: This pan-European, observational, prospective cohort 
study investigated associations between chemotherapy, patient/
disease characteristics and outcomes in patients with advanced/meta-
static non-small cell lung cancer (NSCLC) in clinical practice. From 
October 2006 to January 2008, 1012 patients eligible for second-line 
treatment after failure of first-line therapy for NSCLC, were enrolled 
in 11 countries. Patients’ baseline data were analyzed.
Methods: ultivariate analysis was performed on patients’ baseline 
data. Hierarchical cluster analysis based on Ward’s minimum-vari-
ance method was used to define groups of patients based on their age, 
gender, smoking status, and histological tumour type. Other baseline 
data was not statistically relevant.
Results: Cluster analysis was performed on data of 897 patients 
at baseline. Four distinct clusters were identified. The table below 
illustrates the baseline characteristics by cluster. The proportion of 
variance accounted for by clusters was about 75%.
The first cluster comprised 268 patients (30%) who were mainly 
female (89%), diagnosed with adenocarcinoma (72%), with higher 
proportion of non-smokers (43%) than for the overall population. The 
second cluster comprised 308 patients (34%), all male, former smok-
ers, all with non-squamous histology. The third cluster comprised 179 
patients (20%), mainly male (93%), all with squamous cell carcin-
oma, who were older (median 66 years), had poorer performance 
status (12% of patients with ECOG grade 0 compared to 18% for the 
overall population), all smokers (33%) or former smokers (67%). 
The fourth cluster comprised 142 patients (16%), who were younger 
(median 58 years), all male smokers, mainly with adenocarcinoma 
(68%).
The planned second-line treatment was pemetrexed for 46% and 53% 
of patients in clusters 2 and 4 respectively. Moreover, almost half of 
the patients (43%) with erlotinib as second-line treatment fell into 
cluster 1. Twenty percent and 22% of patients who were planned to 
receive pemetrexed and docetaxel respectively fell into cluster 3.
Conclusions: Recent studies have shown a predictive effect of histol-
ogy on outcomes of treatment in NSCLC. This study showed that 
in daily practice female non-smokers with non-squamous histology 
(cluster 1) were more frequently prescribed erlotinib than in the 
other clusters. Furthermore, it was planned that patients with non-
squamous histology, current or former smokers (clusters 2/4) would 
mainly receive pemetrexed. The indications of pemetrexed have been 
more clearly defined during the study enrolment period. This explains 
why pemetrexed was prescribed to patients with squamous cell car-
cinoma (cluster 3). The validated clinical and histological predictive 
factors can influence the choice of second-line treatment.
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Introduction: Limited information is available concerning the treat-
ments of elderly patients with advanced non-small-cell lung cancer 
(NSCLC) since these populations are usually excluded from clinical 
trials. There are several reports that bi-weekly administration of the 
gemicitabine (GEM) combination with carboplatin (CBDCA) was 
shown to be safe and effective in NSCLC. The aim of this prospect-
ive, multicenter, phase II study is to evaluate the efficacy and safety 
of bi-weekly regimen in patients older than 70 year with advanced 
NSCLC. 
Methods: Chemotherapy-naive patients aged >70 years with 
advanced stagte (IIIB/IV) NSCLC were enrolled into a multicen-
ter phase II trial and treated with GEM (1000mg/m2) and CBDCA 
(AUC3) bi-weekly. Treatments were continued until disease progres-
sion or unacceptable toxicity. 
Results: Between Dec 2005 and May 2007, 48 patients were enrolled 
in this study, and all patients were eligible and analyzed. In the 
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clinical background, the median age was 76 (70-83) with 73% males, 
73% PS1, 58% Adenocarcinoma, 71% stage IV. The median number 
of cycles administered was seven cycles. The overall response rate 
was 29.2% (95% CI; 17.0-44.1%). The median progression free 
survival time and the median overall survival time were 178 days 
and 398 days respectively. Grade 3 or 4 hematological toxicities were 
neutropenia (35.4%), anemia (20.8%), thrombocytopenia (6.3%). 
Nonhematological toxicities of grade 3 or 4 included constipation 
(2.1%), thrombosis (2.1%) and elevation of ALT (2.1%). 
Conclusion: Bi-weekly GEM plus CBDCA regimen showed a prom-
ising efficacy and tolerable toxicities for elderly advanced NSCLC 
patients.
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Background: ASA404 (DMXAA; vadimezan) is a novel Tumor-
Vascular Disrupting Agent (Tumor-VDA) that induces rapid tumor 
endothelial cell apoptosis and a sustained, indirect anti-vascular effect 
resulting in increased tumor necrosis factor-α, nitric oxide and cyto-
kine production. Combined, these effects cause tumor vasculature 
disruption and extensive tumor necrosis. ASA404 has been shown 
to induce a profound necrotic effect on the poorly perfused tumor 
core, whereas chemotherapeutic agents are active against the highly 
oxygenated, proliferating cells at the tumor periphery. Synergistic 
interactions have been demonstrated between ASA404 and taxanes, 
and combination with paclitaxel and carboplatin increased the median 
overall survival of previously untreated NSCLC patients from 8.8 to 
14.0 months in Phase II clinical trials.
Methods: This was a Phase I trial to assess the safety profile and 
tolerability of ASA404 when administered in combination with fixed 
doses of paclitaxel (200 mg/m2) and carboplatin (AUC 6) in Japanese 
patients with NSCLC. Three dose levels for ASA404 were investi-
gated: 600 mg/m2, 1200 mg/m2, and 1800 mg/m2. ASA404, paclitaxel 
and carboplatin were administered every 3 weeks. The dose escala-
tion was evaluated by incidence of Dose Limiting Toxicity (DLT) 
during Cycle 1.
Results: A total of 15 patients with Stage IIIb/IV NSCLC were 
treated at the following doses: ASA404 600 mg/m2 (n=3), 1200 mg/
m2 (n=6), and 1800 mg/m2 (n=6). DLT was observed in 2 patients 
with Grade 3 febrile neutropenia at the 1200 mg/m2 dose. At 1800 
mg/m2, one patient experienced Grade 3 QT prolongation. Frequently 
occurring adverse events were injection site pain (n=13), anorexia 
(n=12), arthralgia (n=12), neutropenia (n=11), nausea (n=11), and 
peripheral sensory neuropathy (n=10). Serious Adverse Events, oc-
curring in 3 patients, were hemorrhagic colitis (1200 mg/m2), tumor 
hemorrhage (1200 mg/m2), and pneumonia (1800 mg/m2). The safety 
profile of ASA404 when administered in combination with paclitaxel 
and carboplatin appears to be comparable to that in non-Japanese 
patients. PK analysis is ongoing.
Conclusions: A dose of ASA404 1800 mg/m2 is tolerable in Japanese 
patients when administered every 3 weeks in combination with pa-
clitaxel (200 mg/m2) and carboplatin (AUC 6). Based on the observed 
safety profile, treatment of Japanese patients with ASA404 (1800 
mg/m2) in combination with paclitaxel (200 mg/m2) and carboplatin 
(AUC 6) is currently ongoing in a Phase III clinical trial.
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Background: Bevacizumab, an anti-VEGF monoclonal antibody, im-
proves response rates and prolongs survival in p with non squamous 
NSCLC when combined with carboplatin-paclitaxel or cisplatin-
gemcitabine. This single-arm, open-labeled phase II trial aims to 
evaluate the efficacy and safety profile of B in combination with 
another widely used chemotherapy doublet for NSCLC: cisplatin and 
vinorelbine.
Methods: Chemotherapy-naïve p diagnosed with stage IIIB or IV 
non squamous NSCLC received cisplatin (80 mg/m2), vinorelbine (25 
mg/m2 IV days 1 and 8) and B (15 mg/kg IV) on day 1 every 3 weeks 
for up to 6 cycles followed by B 15 mg/kg alone every 3 weeks until 
disease progression. Main eligibility criteria were: PS 0-1, no brain 
metastases, no history of hemoptysis, stable cardiac condition and 
no full dose anticoagulation Primary endpoint was progression-free 
survival and secondary endpoints were RR, duration of response, OS, 
1-year survival and safety profile of the combination.
Results: 47 p have been enrolled in the study and data of 27 p have 
been included in this analysis. P characteristics were: male 66.7%; 
median age 57 years (range 41-74); ECOG PS 0/1 (%) 33.3/66.7; 
adenocarcinoma/other (%) 74.1/25.9; stage IIIB/IV (%) 25.9/74.1. 
Median number of cycles for B/cisplatin/vinorelbine was 4.0 (range 
1-6) and median number of cycles for B maintenance was 2 (range 
1-4). 17 p were evaluable for response according to RECIST criteria: 
PR 29.4% and SD 41.2%. With a median follow-up of 3.9 months 
(range 0.7-11.1), median PFS was 4.6 months (95% CI: 2.6-6.6) and 
median OS has not been reached yet. Hematological toxicities were: 
1 p gr. 3 anemia; 2 p gr. 3 and 2 p gr. 4 leucopenia; 10 p gr. 3, 1 p 
gr. 4 neutropenia and 3 p febrile neutropenia. Most common grade 
3/4 non hematological toxicities were: vomiting (1p gr. 4), high 
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blood pressure, asthenia and hyperglycemia. 1 p experienced gr. 4 
abdominal pain, 1 p. gr. 4 constipation, 1 p. gr. 4 nausea and 1 p gr. 4 
respiratory infection. No grade 3/4 hemoptysis were reported. 
Conclusions: This interim analysis shows that B in combination with 
cisplatin and vinorelbine is safe and well tolerated and has a promis-
ing activity in chemo-naïve p with non squamous NSCLC. Survival 
data will be updated.
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Background: TTFields (Tumor Treating Fields) are low intensity, 
intermediate frequency, alternating electric fields which effectively 
slow the growth of solid tumors in-vivo, and have shown promise in 
pilot clinical trials in patients with advanced solid tumors. TTFields 
are a regional treatment modality which acts both by interfering with 
microtubules polymerization and by physical disruption of the cell 
structure during cytokinesis. It has been shown previously that TT-
Fields sensitize non-small cell lung cultures to Pemetrexed. In animal 
studies, TTFields did not increase pemetrexed related toxicity.
Methods: A prospective clinical trial was performed in 14, pre-
treated, stage IIIb-IV, NSCLC patients. Patients with brain metastases 
were excluded, as were patients with abnormal marrow, kidney, liver 
or cardiac functions. Patients with history of clinically significant ar-
rhythmias or those having pacemakers were excluded as well. 
Patients received Pemetrexed 500mg/m2 IV q3w together with daily 
TTFields (12 h/day) using a portable medical device (NovoTTF-
100L). The device generated 2 direction (AP and Lat), 150 kHz 
TTFields. Patients were followed every three weeks and had a lung 
CT every 9 weeks. 
The primary endpoint was the safety and tolerability of the Novo-
TTF-100L device in combination with pemetrexed. 
Results: The 14 patients received an average of 5 courses of pe-
metrexed (Range 1-11) and a cumulative TTFields treatment time of 
214 weeks. The device was well tolerated as indicated in the device 
log files which showed an average daily use of 12±3 hours. There 
were no device-related, nor pemetrexed-related SAEs. In addition, no 
unexpected abnormalities were evident in the lab tests or EKGs, done 
every 3 weeks for all patients. There were no reports of arrhythmias. 
The only device related AE seen in all patients was dermatitis under 
the electrodes. This improved with meticulous skin care, topical 
steroid use and in extreme cases oral steroids. 
One patient (7.5%) had a CR, 1 a PR (7.5%), 7 SD (50%) and 5 PD 
(35%). 57% of patients were progression free after a minimal follow 
up of 26 weeks and the 6 month survival was 86% (12 of 14 patients 
alive).
Conclusions: TTFields are well tolerated when given together with 
pemetrexed. The excellent safety profile and promising initial ef-
ficacy results reported here justify further clinical testing. 
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Background: Chemotherapy is the mainstay treatment for advanced 
non-small cell lung cancer (NSCLC). Gefitinib, an epidermal growth 
factor receptor - tyrosine kinase inhibitor (EGFR-TKI), has been re-
cently shown to be effective as a first-line treatment in Asian patients 
with advanced NSCLC, especially for those with favourable clinical 
features such as female, non-smoker and adenocarcinoma. However, 
resistance to gefitinib ensues invariably and there is little evidence as 
for the effectiveness of subsequent salvage treatment. 
Purpose: To evaluate the efficacy of erlotinib, another EGFR-TKI, 
after failed first-line use of gefitinib. 
Method: Retrospective review of NSCLC patients with favourable 
clinical features who received gefitinib as first-line treatment and 
subsequent salvage treatment with erlotinib. 
Results: A total of 21 patients with NSCLC were included in the 
study. Among them, 18 (85.7%) patients had disease control with 
gefitinib and 11 (52.4%) patients with erlotinib. There was an as-
sociation between the disease control with gefitinib and erlotinib 
(p=0.016). The disease control rate of erlotinib was independent of 
the chemotherapy use between the two EGFR-TKIs. 
Conclusion: For NSCLC patients with favourable clinical features, 
erlotinib was effective in those who had prior disease control with 
first-line gefitinib. 
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Background: BIBW 2992 (Tovok*), a dual irreversible inhibitor 
of epidermal growth factor receptor (EGFR) and human epidermal 
growth factor receptor (HER2) has shown preclinical activity against 
non-small cell lung cancer (NSCLC) tumors harboring the EGFR 
secondary resistance mutation. A Phase I/II study of BIBW 2992 
in patients with NSCLC progressing after chemotherapy and/or 
erlotinib/gefitinib has been conducted. Results of the Phase I study 
are being presented.
Methods: In this Phase I study, patients with NSCLC (stage IIIB/IV; 
Eastern Cooperative Oncology Group [ECOG] 0–1), who have failed 
the standard chemotherapy or for whom no other appropriate therapy 
is available, are eligible. Oral BIBW 2992 started at 20 mg od and 
doses were increased to 50 mg od until 33.3% or more toxicity Grade 
>2 occurred. Pharmacokinetic (PK) sampling was performed in 
all patients on Days 1–2 and at steady state of the initial treatment 
course. Trough PK samples were taken during the initial and repeated 
treatment courses. EGFR mutation analysis was performed where 
possible.
Results: Nine evaluable patients have been treated at doses of 20–50 
mg (four male, five female); median age 61 (range 46–67). One dose-
limiting toxicity was seen in Course 1; a patient developed Grade 
3 mucositis at 50 mg, which subsided upon dose reduction. Other 
adverse events were mild (Grade 1 or 2) and included stomatitis, 
diarrhea, rash, dry skin, mucosal dryness, paronychia, anorexia and 
fatigue. Six out of nine patients had tumor size reductions with two 
achieving prolonged stable disease. Updated clinical and PK data and 
the recommended dose for the Phase II study will be presented at the 
meeting.
Conclusion: The safety profile of BIBW 2992 in Japanese patients is 
similar to non-Japanese patients. Durable stable diseases were seen in 
two patients in this study, including one patient having mutations in 
EGFR exon 19 and T790M. 
An international Phase III trial program investigating BIBW 2992 in 
NSCLC, LUX-Lung, is now recruiting patients.
*Trademark not FDA approved.
P1.265 NSCLC Advanced Disease, Sat Aug 1 
The timing of the chemotherapy and whole brain 
radiotherapy for the newly diagnosed non-small cell lung 
cancer patients with asymptomatic brain metastasis
Li, Zhanxia; Zhou, Caicun; Zhang, Lin
Dept of Medical Oncology, Shanghai Pulmonary Hospital, Tongji 
University, Shanghai, China
Objectives: To evaluate the timing of whole brain radiation therapy 
(WBRT) and chemotherapy for non-small cell lung cancer (NSCLC) 
patients with asymptomatic brain metastasis.
Patients and Methods: We performed a retrospective analysis of 87 
NSCLC with asymptomatic brain metastasis diagnosed by magnetic 
resonance imaging(MRI) or computer tomography(CT). The patients 
was stratified into groups according to the timing of the chemo-
therapy and WBRT:WBRT followed by chemotherapy(group A); 
chemotherapy followed by WBRT(group B); concurrent WBRT plus 
chemotherapy(group C). 
Results: A total of 87 patients were enrolled between 1 April 2003 
and 31 September 2007. The PFS were 4.5, 4.1 and 5.7 months in 
Groups A, B and C, respectively (P=0.407).The overall survival were 
11.2, 10.0 and 11.7 months in Groups A, B and C(P=0.82) respect-
ively. Adverse events of grade 3 and 4 were not significantly different 
among three groups.
Conclusions: Concurrent chemotherapy and WBRT had a tendency 
to prolong PFS and OS although there was no significant difference. 
Our data suggests that concurrent chemoradiotherapy was well toler-
ated.
P1.266 NSCLC Advanced Disease, Sat Aug 1 
Induction of BIM Is essential for apoptosis triggered by 
EGFR kinase inhibitors in mutant EGFR-dependent lung 
adenocarcinomas
Li, Zhanxia; Zhou, Caicun
Dept of Medical Oncology, Shanghai Pulmonary Hospital, Tongji 
University, Shanghai, China
Background: Mutations in the epidermal growth factor receptor 
(EGFR) gene are associated with increased sensitivity of lung cancer 
to kinase inhibitors like gifitinib. Mechanisms of cell death that oc-
curs after kinase inhibition in these oncogene-dependent tumors have 
not been well delineated. We sought to improve understanding of 
this process in order to provide insight into mechanisms of sensitiv-
ity and/or resistance to tyrosine kinase inhibitors and to uncover new 
targets for therapy.
Methods: Using a panel of human lung cancer cell lines that harbor 
EGFR mutations, MTT Assay was applied to study the responses 
of these cell lines to gefitinib, cisplatin and paclitaxel. Then flow 
cytometry analysis and western blot were performed for the apoptosis 
and the expressions of Bim and other Bcl-2 family proteins before 
and after the treatment of the cell lines with gefitinib,cisplatin and pa-
clitaxel . The expressions of Bim protein and changes of apoptosis of 
the cell lines were also examined after knocking down the expression 
of bim using SiRNA technique. 
Results: EGFR kinase inhibition in drug sensitive cells provoked 
apoptosis via the intrinsic pathway of caspase activation. The process 
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required induction of the proapoptotic BH3-only BCL2 family 
member BIM (i.e., BCL2-like 11, or BCL2L11); gefitinib dramatic-
ally induced BIM levels in sensitive but not in resistant cell lines, and 
knockdown of BIM expression by RNA interference virtually elimin-
ated drug-induced cell killing in vitro. BIM status is regulated at both 
transcriptional and posttranscriptional levels and was influenced by 
the extracellular signal-regulated kinase (ERK) signaling cascade 
downstream of EGFR. All the cell lines including H129, A549, PC-9 
and PC-9/BB4 cells treated with paclitaxel, induced obvious apopto-
sis. But cisplatin or paclitaxel did not induced expression of BIM. 
Conclusions: BIM is involved in TKI-induced apoptosis in sensitive E
Tobacco Control
P1.267 Tobacco Control, Sat Aug 1 
Love to Quit: Relevance of universal human values 
education in smoking cessation 
Haranath, Sai Praveen2; Govindarajan, Geetha1; Bhat, Jyothsna S.3
1 North Shore University Health Systems, a University of Chicago 
Affiliate, Chicago, IL, USA; 2 Kaiser Permanente/The Permanente 
Medical Group, Walnut Creek, CA, USA; 3 Antoinette S. Cordell and 
Associates, Dayton, OH, USA
Background: Tobacco is responsible for 4.9 million deaths globally 
annually. If current trends persist, mortality from smoking will double 
by 2020 with 70% dying in developing countries. Lung cancer is a 
global epidemic with over 90% from smoking. Thirty percent of all 
cancer deaths are due to tobacco. Smoking cessation will clearly save 
lives. Current methods of tobacco cessation have had inadequate 
success in preventing relapse. While behavioral & pharmacological 
interventions have been critical, we propose an additional dimension 
to the smoking cessation process that has not received mainstream 
attention despite anecdotal of success. 
Methods: The use of universal human values education can highlight 
aspects of human behavior that are conducive to smoking cessation 
& move people from a pre-contemplation phase to the contempla-
tion phase. Anecdotal experience from former smokers indicates 
pivotal events that trigger cessation. Nicotine addiction may have a 
normal distribution with respect to intensity & ease of cessation but 
we propose a rapid low cost exercise to initiate cessation in most 
smokers. As humans, emotion dictates behavior and decision-making. 
Concepts of love of fellow individuals, family, pets & other expres-
sions of this phenomenon have motivated individuals to quit. This 
fits into the Relevance component of the 5R’s model. We hypothesize 
that all smoking cessation counseling sessions should incorporate a 
conversation on the impact of cessation on whatever the individual 
decides is worthy of expression of love. Writing in a journal about 
their care and compassion for this person/pet/object and a daily log 
may help and in fact inspire others to quit by becoming a role model. 
This seemingly abstract concept is easily testable by prospectively 
surveying sustained quitters who have been administered placebos in 
randomized controlled trials of smoking cessation. There is limited 
current evidence for this approach. It must be distinguished from 
other established modes of behavioral interaction like hypnosis & 
psychoanalysis. Avoiding introduction of feelings of guilt is import-
ant. It is critical that questions relating to interpersonal value systems 
are integrated with traditional & proven techniques of initiating inter-
est in tobacco cessation.
Tobacco cessation is vital for newly diagnosed lung cancer patients 
since continued smoking decreases treatment efficacy and increases 
surgical complications. Smoking is also associated with shorter 
survival & may interact with certain cancer treatments. This unique 
subset needs specialized advice given the complex emotions at play 
around diagnosis and subsequent therapy. There is lack of awareness 
among both patients & healthcare providers about the benefits of 
tobacco cessation even after a diagnosis of lung cancer. We believe 
our approach can be rapidly deployed and has minimal cost even in 
this group. 
Conclusions: Simple, cost effective interviews with smokers must 
incorporate individual value analysis of the benefits of cessation and 
one dimension that must be explored is identification of a person, pet 
or other object that will benefit from cessation of tobacco use by the 
individual from the perspective of the smoker. It is time for a new 
paradigm: ‘Love to Quit’.
P1.268 Tobacco Control, Sat Aug 1 
The Risk of lifelong DNA damage caused by lung cancer 
among rural male smokers who begin at teenage
Odiase, Emmanuel O.
SmokeFree Foundation, Abuja, Nigeria
Goals: To examine the effect of smoking on lung cancer risk and 
entire DNA damage in a relative large number of rural men, many of 
whom are poor and started smoking as teenagers.
Methods: We followed 50,232 men, ages 25 to 50 years, through a 
community-based tobacco control outreach programme with ques-
tionnaires both in English and the local language to the North western 
and North eastern Nigerian Cohort Study in 2002/2003, through 
December 2007. We estimated relative risk (RR) of lung cancer as-
sociated with different measures of smoking initiation, duration, and 
intensity adjusting for confounding variables. We conducted analyses 
on the entire study population, among men who had smoked for at 
least 15 years, among non drinkers, and separately for each geo-
political zone.
Results: Altogether, 10,240 men were diagnosed with lung cancer. 
Compared with never smokers, men who smoked for at least 15 years 
and who smoked 10 cigarettes or more daily had a higher RR. In 
contrast, men who had smoked for at least 15 years, but started after 
their 19th birthday, did not experience an increased lung cancer risk. 
The increased RR associated with smoking was observed among 
nondrinkers of alcohol, men with and without a family history of lung 
cancer in both geo-political zones in Nigeria.
Conclusion: Our results support the notion that men who start smok-
ing as teenagers and continue to smoke for at least 15 years may in-
crease their lung cancer risk with dramatic and lifelong DNA damage.
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P1.269 Tobacco Control, Sat Aug 1 
Smoking cessation project: findings of Indian Cancer NGO 
Sankpal, P D.1; Vaishali, P S.2
1 Health Alert Organization Of India [Ngo], Dhule, India; 2 Public 
Health BMC, Mumbai, India
Background: this was Phase II project in rural India from 2007. 
Cigarette smoking single biggest avoidable cause of death and 
disability in developing countries. Smoking cessation programs non-
existent in Indian healthcare system .Smoking behavior multifactor-
ial. Motivation is fundamental-aspect in smoking cessation. 
Objectives: 1] Assess effectiveness and factors associated with 
outcomes of smoking-cessation-program 2] Investigate time course 
of quit rate from beginning to one year after-quitting. 3] Analyze 
predictable factors of smoking cessation 
Methods: 417 filter-less tobacco-users from Rural-India enrolled. 
Retrospective study based on motivation, dependence, conviviality 
with smokers and tobacco abstinence after one year. n=153. QUIT-
Smoking-Project carried out by 5 counseling sessions/week. Subject-
evaluation done every Bi-monthly. 
Sex, age, smoking pattern, previous attempts to quit, education, mari-
tal status, psychological background, other addictions and nicotine 
dependence through Fagerstrom (FTND) were evaluated as predict-
ors of abstinence in an univariate analysis. individual counseling on 
behavioral modification, written information, advice about quit aids, 
support and group sessions by psychologist.
Results: Total 381 smokers willing to QUIT, but 364 completed 
study. age 40 5, 40% females, previous attempts to quit in 64%, 
cigarettes/day 3 1/per-day, FTND 5.99 2.11. 171 subjects had abstin-
ence of one year. Reduced abstinence associated >with females 95%, 
p=0.03). Mean age at the beginning of smoking habits-16.1 4.8 yrs. 
Pathologies: lung cancer 27%, COPD, 56%%; cardiovascular dis-
ease>19%; Depression>42%.
Reasons for cessation-efforts: Health-64%, family/society pres-
sure-23%, children-4% and economy-11 % were the main reasons 
for cessation. Dependence: high in 73%. QUIT-Success rate in 
smokers <35 yrs-22%, being 40% >65 yrs. About 30% with depend-
ence stopped smoking. 68% had quit smoking by end of this NGO 
counseling-project. Sustained quit rates after 12 months increased 
from 18% to approximately 52% during the third year of PHASE-II 
of this MGO project.
Conclusions: Our NGO-project STOP-QUIT tobacco & Save lung 
successfully motivated 74% subjects to QUIT tobacco by 17 months 
counselling & educational efforts. This proportinaltely reduces risk 
of Lung-cancer & early deaths from lung diseases due to smoking. 
Unavailability of nicotine replacement therapies reduced our success 
rate. Our Phase III stdy protocol with inclusion of Nicotinic drug-
delivery-systems will be distributed at IASLC-2009 venue.
P1.270 Tobacco Control, Sat Aug 1 
Tobacco control: A long awaited dream fulfilled by peer-
education models community NGO’s
Sankpal, P D.1; Vaishali, P S.2; Salgokar, R N.1
1 Health Alert Organization Of India [Ngo], Dhule, India; 2 Public 
Health BMC, Mumbai, India
Issues: In resource-poor-nations Tobacco-induced-cancer care-
services are non-existent. Primary-Health-Care backbone of rural/
tribal India. Tobacco-cessation programs inaccessible to rural/tribal 
communities. NGO’s cater to this vast gap, but have limited resour-
ces/training. Young people potentially vulnerable to tobacco-risk due 
to lack of literacy/knowledge. Our NGO devised model of peer-
education-pattern since November-2003. Especially for youths mak-
ing choices out of lack of parental-support and ignorance of crude 
tobacco consumption.
Methods: NGO-workers reduce burden of existing healthcare-sys-
tem. Youth oriented programs achieve more effective results. Lack of 
skill-building services for youth is reflected in number of youth who 
are addicted to tobacco . But despite their vulnerability, young people 
are also force for fighting tobacco-menace.
Results: this model increases awareness on Tobacco-control. 
Establishing care and counseling centers and handing over peer-
education-programs to local communities is best suited to resource-
poor-developing-nations. Our model graphically shown at 13th 
WCLC Congress. Our approach provide opportunities for sustainable 
Tobacco-induced-diseases awareness education program.
Lessons Learned: Challenge of distance/isolation/poor-infrastructure 
can be overcome through committed/trained NGO-Peer-Education-
Model. BUT we need to provide regular hands-on training at field 
level. IASLC needs to support/train such NGO-Initiatives in rural/
tribal India where crude locally-made-tobacco is consumed by ado-
lescents. skills and knowledge gained at WCLC 2009 congress will 
provide tools to make impact on tobacco-cancer control.
P1.271 Tobacco Control, Sat Aug 1 
Effect of continuation of tobacco consumption/ cessation 
on the global Quality of life (QOL) and disease outcome in 
patients with metastatic lung cancer
Vutukuru, Anuradha; Bogi, SAndhya; Gajula, Viswanath
Dept. of Pathology, Osmania Medical College, Hyderabad, India
Background: Tobacco consumption is one of the most common 
causes of lung cancer across the globe as well as in Indian sub contin-
ent as well. Once the patient is diagnosed with stage IV lung cancer 
and will be explained regarding the expected survival, mots of them 
are not willing to quit the habit. However previous studies showed 
that continuation of the habit has resulted in more adverse events 
while on chemotherapy as well as further reduction in life expect-
ancy. Till now the decreased in QOL due to abstinence/ withdrawal 
symptoms is not weighed against the decreased QOL due to increased 
complication of continuation of tobacco consumption. 
Aim: The present study was conducted to evaluate the effect of 
continuation of tobacco consumption/ cessation on the global Quality 
of life (QOL) and disease outcome in patients with metastatic lung 
cancer
Methods: all the patients of lung cancer with habit of tobacco con-
sumption on chemotherapy were evaluated. Global QOL is calculated 
using QTACT for (indigenously developed for lung cancer patients in 
Telugu language). Those who quit tobacco consumption are analyses 
as one group and those who continued as the second group. The QOL 
was compared between both groups
Results: There is no difference in the global QOL in both groups. 
However the psychological QOL is better in patients who continued 
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tobacco consumption vs. who stopped. The same is counter balanced 
by the worsening of physical and symptom QOL in tobacco consum-
ing group. There is no difference in the response rates, disease free or 
overall survival among either groups.
Conclusion: The continuation of tobacco consumption habit in 
advanced lung cancer patients did not affect the overall global Qual-
ity of life and therefore it might not be worth insisting the same if 
patients are not comfortable/willing to quit the habit.
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P2.001 Endoscopy and Intervention Bronchoscopy, Sun Aug 2 
Endobronchial brachytherapy (EBB) provides excellent 
long term control of recurrent granulation tissue following 
tracheal stenosis
Allen, Aaron M.1; Abdelrahman, Nader M.2; Silvern, David 1; Fenig, 
Eyal 1; Kramer, Mordechai R.2
1 Davidoff Center, Rabin Medical Center, Petah Tikvah, Israel; 2 
Department of Pulmonology Rabin Medical Center, Petah Tikvah, 
Israel
Background: Subglottic and tracheal stenosis is a difficult clinical 
problem. Metallic stenting is the standard of care. However, granula-
tion tissue formation (GTF) is serious complication stenting particu-
larly in benign conditions. We report the largest known series of EBB 
for granulation tissue. 
Methods: 
The medical records of patients who underwent brachytherapy after 
stent insertion at the Rabin Medical Center from 2001 to 2008 were 
reviewed. 29 patients were treated. 55% were male (16/29) with a 
median age of 70 (32-87).22 were treated for subglotic stenosis due 
to previous intubation and mechanical ventilation of whom 13 had 
tracheostomy, 4 had tracheal stenosis from other causes (Wegener’s, 
Diphteria, enlarged thyroid) and 3 cases had bronchial stenosis ( lung 
transplant, Silicosis and post tablet aspiration). In 13 cases decanula-
tion was performed after stent insertion. Patients were followed every 
three months post stent insertion with bronchoscopy and spirom-
etry with additional bronchoscopy when clinically indicated. EBB 
was performed at mean 69 days post stent insertion (range 1-322 
days) . EBB was planned with BrachyVison (Varian, CA) with dose 
prescribed to 1 cm circumference. Treatment was delivered with 
Varisource high dose rate brachytherapy
remote afterloader with an 192-Ir source. Median active length was 
7 cm (range 4-10 cm). Standard dose was 1000cGy in a single treat-
ment. Residual granulation tissue was scored as minimal, moderate or 
severe based on two separate pulmonologists review of all the follow-
up bronchoscopies.
Results: With a mean follow-up of 27 months (range 4-72), 19/29 
(66%) patients had non or minimal granulation tissue following EBB, 
3/29 (10%) had moderate granulation tissue following EBB which 
was successfully treated with repeat laser resections. 7/29 (24%) had 
severe granulation despite therapy, brachytherapy of whom 3 required 
stent replacement and 3 open tracheostomy. One patient developed 
bronchopleural fistula and died. As of the most recent follow-up 
14/29 (48%) patients have died. All but 1 death was due to underlying 
condition. No patient developed necrosis or in situ malignancy. 
Conclusions: Endobronchial brachytherapy is an effective treatment 
which can effectively prevent recurrent granulation tissue after metal 
stenting. Early application following stent insertion is recommended 
with periodically bronchoscopic and lung function follow up.
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P2.002 Endoscopy and Intervention Bronchoscopy, Sun Aug 2 
Comprehensive diagnosis by CT, FDG-PET, EBUS-TBNA 
and EUS-FNA for preoperative staging for lung cancer
Anayama, Takashi; Kume, Motohiko; Okada, Hironobu; Sasaguri, 
Shiro
Surgery Faculty of Medicine, Kochi University, Nankoku Kochi, 
Japan
Background: Endobronchial ultrasound-guided transbronchial 
needle aspiration (EBUS-TBNA) and Endoscopic ultrasound guided 
fine needle aspiration (EUS-FNA) are reported to be useful in 
diagnosis for mediastinal lymph node metastasis. However, under 
local anesthesia with routine technique, the limited number of the 
lymph nodes could be examined. So key lymph node which influ-
ences lymph node status in TNM classification should be extracted 
by radiological examination such as computed tomography (CT) and 
integrated positron emission tomography (PET) in advance of EBUS-
TBNA or EUS-FNA. 
Methods: We prospectively performed CT and PET for 89 poten-
tially operable NSCLC patients. Lymph nodes of larger than 10mm 
in short axis in CT, and/or lymph nodes of 2.5 or more SUVmax in 
PET were adopted as object lymph nodes for EBUS-TBNA or EUS-
FNA. EBUS-TBNA or EUS-FNA was performed 1 to 3 lymph nodes 
for each patients. Finally, preoperative comprehensive lymph node 
diagnosis was compared with pathological diagnosis. 
Result: The result of the CT diagnosis was sensitivity 34.5%, 
specificity 93.6%, positive predictive value(PPV) 45.5%, negative 
predictive value(NPV) 90.2%, and diagnostic accuracy 85.6%. The 
result of FDG-PET was sensitivity 53.3%, specificity 82.9%, PPV 
33.3%, NPV 91.7% and diagnostic accuracy 78.8%. comprehensive 
diagnosis of CT and FDG-PET indicated sensitivity 64.5%, specifi-
city 81.2%, positive PPV 36.4%, NPV 93.2% and diagnostic accur-
acty 78.8%. The combination of these two radiological examinations 
included 35 cases with false positive lymph nodes. The 32/35 false 
positive lymph nodes were accurately diagnosed as negative with 
EBUS-TBNA or EUS-FNA. 
Conclusion: The good diagnostic yield can be expected by per-
forming EBUS-TBNA or EUS-FNA to the CT/PET false-positive 
lymph nodes.
P2.003 Endoscopy and Intervention Bronchoscopy, Sun Aug 2 
The utility of EBUS-TBNA in the diagnosis or staging of 
lung cancer 
Kim, Sun Young; Kim, Yong Hee; Kim, Dong-Kwan; Park, Seung-
Il; Park, Young Soo; Jang, Se Jin; Shim, Tae Sun; Kim, Woo Sung; 
Choi, Chang-Min
University of Ulsan College of Medicine, Seoul, Korea
Background: Ultrasound-guided transbronchial needle aspiration of 
mediastinal lymph nodes(LNs) or central parenchymal lesion (EBUS-
TBNA) can be effective and preferable in patients with suspected 
or potentially operable lung cancer, especially when endobronchial 
lesion is not visible or operative biopsy is expected to be intolerable. 
We evaluated the diagnostic utility of Endobronchial ultrasound-
guided transbronchial needle aspiration (EBUS-TBNA). 
Methods: We analyzed 137 patients who were performed EBUS-
TBNA for diagnosis or staging of lung cancer retrospectively 
between July 2008 and February 2009. 
Results: Among total subject (Mean age: 63±11 years, Male: 111, 
81%), Lymph nodes were aspirated 134 times in the mediastinum (67 
times in station 7, 61 times in station 4), 36 times in station 10, and 
12 times in station 11. The location of central lung lesion was right 
lower lobe (7 times), right and left upper lobe (4 times for each), left 
lower lobe (3 times), and right middle lobe (2 times). The diagnosis 
was confirmed through EBUS-TBNA in 116 patients (85%), and 
this was non-small cell lung cancer in 63 (46%) and small cell lung 
cancer in 15 (11%). Also, it was proven that there was no malignant 
cell in potentially operable lung cancer in 22 patients (16%). In addi-
tion, there was no malignancy in possibly recurred lung cancer in 3 
patients (2%) who had not discovered the evidence of malignancy in 
3 to 6 months of follow-up CT. In the patients who were confirmed 
diagnosis, the sensitivity was 91% with a negative predictive value 
of 74%. There were a few complications associated with proced-
ures (transient hypoxia in two patients and reversible stress induced 
cardiomyopathy in one patient).
Conclusions: In our study, EBUS-TBNA was a sensitive and useful 
test for diagnosing central lung lesion or lymph nodes when malig-
nancy is suspected or staging is required. 
P2.004 Endoscopy and Intervention Bronchoscopy, Sun Aug 2 
Accuracy of endoscopic ultrasonography-guided fine-
needle aspiration (EUS-FNA) and repeat mediastinoscopy 
in mediastinal restaging in patients with non small cell 
lung cancer (NSCLC) after induction therapy
Martinez-Tellez, Elisabeth1; Maria Angels, Gines2; Rami Porta, 
Ramon1; Carme, Obiols1; Sergi, Call1; Mireia, Serra-Mitjans1; 
Manuela, Iglesias Sentis1; Cristina, Pellicer1; Roser, Saumench-
Perramon1; Lluis, Cirera3; Carlos, Bidegain Pavon1; Jose, Belda 
Sanchis1
1 Thoracic Surgery Service, Hospital Universitari Mútua de Terrassa, 
Terrassa, Spain; 2 Department of Gastroenterology, Hospital Clinic 
i Provincial de Barcelona, Barcelona, Spain; 3 Department of 
Oncology and Hematology, Hospital Universitari Mútua de Terrassa, 
Terrassa, Spain
Background: Multimodal therapy is the standard of care for NSCLC 
in patients with mediastinal disease (stage IIIA). Survival of patients 
with residual lymph node (LN) disease after induction therapy fol-
lowed by lung resection does not differ from that of patients treated 
with chemo-radiotherapy alone. It is crucial to identify the patients 
with complete LN response before surgery. The aim of this study is 
to investigate the accuracy of EUS-FNA and repeat mediastinoscopy 
in the mediastinal restaging of patients with NSCLC after induction 
therapy.
Methods: From May 2005 to February 2009, 22 patients (16 males 
and 6 females; median age: 60.3 years) with NSCLC in stage IIIA 
(cyto-histologycally proven N2) treated with cisplatinum-based 
induction therapy were prospectively studied. All tumors had been 
staged by mediastinoscopy (n=21) or transbronchial needle aspiration 
(n=1) before induction therapy. Invasive restaging of the mediastinum 
before surgery was indicated routinely regardless of computerized 
tomography and positron emission tomography findings. EUS-FNA 
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was performed with a lineal echoendoscope (Olympus®UCT-160) 
and a 22G needle (EchoTip EUSN-3 Cook Ireland Ltd). Metastatic 
LN in the pre-induction staging was/were sampled first and evaluated 
by an on-site cytopathologist. If negative, the other LN were then 
sampled in order to assess the global impact of EUS-FNA in this set-
ting. A repeat mediastinoscopy was performed in those patients with 
negative EUS-FNA. Patients without mediastinal spread of NSCLC 
underwent thoracotomy and systematic nodal dissection. Pathological 
findings obtained by repeat mediastinoscopy or lymphadenectomy 
were reviewed and staging values were calculated.
Results: All patients received induction therapy with chemotherapy 
(n=14) or concurrent chemoradiotherapy (n=8). Staging values of 
EUS-FNA in the 22 patients were: sensitivity 0.35,specificity 1, posi-
tive predictive value (PPV) 1, negative predictive value (NPV) 0.47 
and accuracy 0.59; staging values of repeat mediastinoscopy were: 
sensitivity 0.66, specificity 1, PPV 1, NPV 0.72 and accuracy 0.82.
Conclusions: EUS-FNA could be a useful technique for restaging 
mediastinal disease after induction treatment in the multidisciplinary 
management of NSCLC. However, if EUS-FNA is negative, repeat 
mediastinoscopy should be performed because its staging values are 
much higher.
P2.005 Endoscopy and Intervention Bronchoscopy, Sun Aug 2 
Delivery of Ablative therapy to pleural based neoplasm in 
an outpatient procedure room setting
Young, J.; Austin, P.; Krimsky, W.; Downie, G. H.; Faucett, R,
Titus Regional Medical Center, Mt Pleasant, TX, USA
Introduction: The Clinical barriers for the symptomatic relief 
of pleural malignancy rather than direct tumor ablation are: cost, 
time, complexity of treatment, and operating room scheduling. The 
preferred outpatient treatments are:pleurex catheter placement, 
chest tube talc pleuradesis or repetitive needle thoracentesis. Spray 
cryotherapy may offer a time and cost effective outpatient procedure 
room based tumor ablative treatment option for patients. We report 
10 patients with biopsy proven pleural malignancies that underwent 
outpatient procedure room based ablative therapy that safely and ef-
ficaciously overcame these limitations.
Methods: 10 patients seen at Titus Regional Medical Center from 
October 2008 through March 2009 with biopsy proven pleural 
neoplasm (one melanoma, one breast cancer and 8 primary lung 
cancers) received ablative therapy in the endoscopy procedure room 
via pleuroscopic delivery of spray cryotherapy. Parameters for admin-
istrative success of this approach included safety, efficacy, duration 
of procedure; ability to use conscious sedation only, FTE’s needed 
for the procedure, cost and reimbursement. Outpatient charts, billing 
flow sheets and direct patient questionnaires were reviewed.
Results: All ten patients were treated without discomfort or signifi-
cant side effects, 5/10 patients had chest tube removed in the proced-
ure room and were discharged as 23 hour admissions. The remaining 
5 patients required chest tubes for 2 days but were discharged post 
removal without complication. Initial treatment sites revealed at 
least greater than 50% tumor regression. The average duration in the 
procedure room was 120 minutes, 9/10 patients required conscious 
sedation only, one required diprivan boluses. 3 FTEs only were 
required for all procedures, the average hospital cost was X and aver-
age reimbursement was X.
Discussion: Pleural malignancy is a significant sequalae in the 
course of many oncologic patients, especially in lung cancer. Has the 
symptom relief based approach currently viewed as standard of care 
evolved because of best therapeutic option or easiest less costly op-
tion? Clinical efficacy of the spray cryoablation therapy is currently 
understudy, we report the impact of this procedure on the hospitals 
resources. Compared to OR based pleural procedures there is shorter 
duration in rooms, less FTE use, and less cost with excellent reim-
bursement. Patients were safely treated with little discomfort and no 
significant side effects.
P2.006 Endoscopy and Intervention Bronchoscopy, Sun Aug 2 
Release of metal particles from needles used for 
transbronchial needle aspiration
Gounant, Valérie1, 6, 5; Ninane, Vincent2; Janson, Xavier3; Colombat, 
Magali4, 5; Wislez, Marie1, 5; Assouad, Jalal6, 5; Milleron, Bernard7, 5; 
Fleury-Feith, Jocelyne8, 5
1 Service de Pneumologie, Höpital Tenon, AP-HP, Paris, France; 2 
Service de Pneumologie, Hôpital Saint Pierre, Bruxelles, Belgium; 3 
Laboratoire d’Etude des Particules Inhalées, Mairie de Paris, Paris, 
France; 4 Service d’Anatomie Pathologique, Höpital Tenon, AP-HP, 
Paris, France; 5 Université Pierre et Marie Curie, Paris, France; 
6 Service de Chirurgie Thoracique, Hôpital Tenon, AP-HP, Paris, 
France; 7 Service de Pneumologie, Höpital Tenon, AP-HP, Paris, 
France; 8 Service d’Histologie Biologie tumorale, Hôpital Tenon, 
AP-HP, Paris, France
Background: Minimally invasive procedures have been developed 
for the diagnosis of mediastinal adenopathy using trans-bronchial 
needle aspiration (TBNA) via flexible bronchoscope or via linear 
echo-endoscope (endobronchial ultrasound, EBUS) allowing real-
time guided puncture of lymph nodes. 
Aim: As we observed black foreign particles on some samples ob-
tained by TBNA, we designed this study to determin their nature and 
to identify the source.
Methods: From June 2007 to December 2008, 141 consecutive pa-
tients underwent blinded TBNA (n = 84) or EBUS-guided TBNA (n = 
57). All cytological samples were reexamined blindly. The contam-
ination was assessed by a semi-quantitative score. Mineral analysis of 
the liquid obtained after rinsing new unused needles was performed 
using an analytical transmission electron microscope equipped with 
an energy dispersive X-ray spectrometer. 
Results: Extra-cellular black particles different from dusts or an-
thracosis were identified only in the 57 samples from EBUS-TBNA 
aspiration (p<0.0001). No difference was observed between five 
batches of needles. The contamination score and the number of pass-
es during the procedure was correlated (p=0.035). Mineral analysis 
of the washing products showed no particle when using conventional 
needles while iron, titanium, nickel and chromium were found when 
using EBUS dedicated needle. 
Conclusion: The use of a dedicated EBUS-TBNA needle is associ-
ated with metallic particle deposition. Friction between stylet and 
needle may be responsible. 
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Diagnostic yield of TBNA for lung cancer in Iceland
Gudmundsdottir, Thorgerdur; Jonsson, Steinn; Bjornsson, Johannes; 
Ingibjorg, Ingibjorg; Hardardottir, Hronn
Reykjavík, Iceland
Background: Transbronchial needle aspiration (TBNA) is a simple 
and safe technique that can be performed without additional resour-
ces in centers with bronchoscopy services. This technique allows for 
assessment of the most important mediastinal lymph node locations 
when enlargement is detected on CT scan. With this procedure it is 
possible to provide important information on diagnosis and staging 
of lung cancer that may avoid risks, hospital admission and financial 
costs associated with surgical exploration of the mediastinum. The 
aim of this study is to determine the diagnostic yield of TBNA in the 
workup for patients suspected of lung cancer in Iceland and its utility 
in avoiding the need for mediastinoscopy. 
Methods: This is a retrospective study where data for all patients 
who underwent TBNA during diagnostic bronchoscopy in Iceland 
between January 2007 and April 2008 was collected. Clinical and 
bronchoscopic information were obtained from hospital records. 
TBNA was performed with 21-gauge needle for both cytological and 
histological examination. TBNA results were considered diagnos-
tic when the sampling contained malignant cells or nonmalignant 
lymphoid cells. 
Results: During the examination period 41 TBNA interventions were 
done in Iceland on 35 individuals. The majority (57%) of patients 
were male and most patients (80%) were either former or current 
smokers but only five individuals were non-smokers (14%). Lung 
cancer was diagnosed in 23 individuals and TBNA gave diagnostic 
or staging information in 52% of lung cancer cases using cytology 
specimens. A tissue biopsy was obtained in about one third of TBNA 
and 38% were diagnostic. TBNA in patients with lung cancer was 
diagnostic in 56% of interventions. Mediastinoscopy was needed in 
four patients (17%). TBNA results prevented mediastinoscopy in 15 
cases (65%). No complications resulted from TBNA interventions. 
Conclusions: Our data show that the diagnostic yield of TBNA 
in Iceland for patients with lung cancer is 56%. TBNA is a safe 
minimally invasive intervention that should be done during routine 
bronchoscopy of patients with enlarged mediastinal lymph nodes 
suspected of lung cancer. 
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Outcomes of airway stenting for advanced lung cancer
Hayashi, Hiroki; Saji, Hisashi; Furukawa, Kinya; Tsutsui, Hidemitu; 
Usuda, Jitsuo; Kajiwara, Naohiro; Kato, Harufumi; Ikeda, Norihiko
Tokyo Medical University, Tokyo, Japan
Background: Interventional therapeutic bronchoscopy can provide 
immediate and gratifying palliation,therefore it is essential to improve 
quality of life in those patients. Many patients with central airway 
obstruction caused malignant tumor are rare surgical candidates on 
the basis of either physiologic or oncologic criteria. 
Methods: We retrospectively examined all patients who underwent 
interventional therapeutic bronchoscopy in our institution and ana-
lyzed the effectiveness of airway stenting for patients with advanced 
lung cancer lesion. 
Result: From June 1994 through May 2008, 361 patients underwent 
interventional therapeutic bronchoscopies becaused of central airway 
obstruction caused by malignant disease (n=256) and benign disease 
(n=105). Ninety-three of those patients underwent because of ad-
vanced lung cancer with central airway obstruction. The histological 
classification was 24 adenocarcinoma, 29 squamous cell carcinoma, 
4 large cell carcinoma, 4 small cell carcinoma, 3 adenoid cystic 
carcinoma, 2 mucoepidermoid carcinoma, 1 carcinoid tumor and 26 
unclassified carcinoma. 
Conclusion: Airway stenting itself could not contribute toward 
survival benefit, Interventional therapeutic bronchosocopy with 
airway stenting were performed in 59 advanced lung cancer patients 
with central airway obstruction with no intraoperative death, however 
percutaneous cardiopulmonary support (PCPS) was initially prepared 
or intraoperatively required in 5 (8.5%) cases. Stenting for central 
airway obstruction is very dangerous method. We must select appro-
priate patient and only after thoroughly exploring all other treatment 
options. May contribute to patients quality of life and it can be neces-
sary for palliative therapy.
P2.009 Endoscopy and Intervention Bronchoscopy, Sun Aug 2 
Pleuroscopy in Czech Republic-the first experience with 
semirigid thoracoscope
Kosatova, Katerina; Votruba, Jiri; Simovic, Juraj
Na Homolce Hospital, Prague, Czech Republic
Background: Medical thoracoscopy or pleuroscopy is a renewed 
method of the investigation and management of pleural involvement 
by interventional pneumologist under local anestesia and sedation. 
Semirigid thoracoscope is a relatively new tool for this purpose.. Its 
main advantage is the inspection of whole pleural surface and real 
time pleural biopses. Reported diagnostic outcome metastatic pleural 
involment is 90-95% by medical thoracoscopy, 40-70% by blind 
biopsy, 30-60% by pleural cytology .
In the context of Proposal for the 7th Edition of the TNM Classifica-
tion of Lung Cancer the differentiation between M1a due to pleural 
nodules or malignant pleural effusion and M0 is really importan. Its 
impact on oncological therapy is clear.
Methods: We evaluate Czech experience with semirigid thoraco-
scope from November 2007 till February 2009.The procedure was 
conducted in the endoscopy suite under local anesthesia. There were 
35 eligible patients with undiagnosed unilateral pleural fluid or pari-
etal pleural nodules/thickening, 18 male and 17 female, median age 
67 years, 36 procedure were performed.The most common indica-
tion were biopsy and pleurodesis, 25pt, 71%, resp. 16 pt, 46%.,then 
both procedure 9pt, 25%. Poudrage pleurodesis in 13pt, 37%, talc 
slurry pleurodesis in only 3pt, 9%. 4pt, 11% managed for empyema 
/ fibrinolyses, drenage, redrenage, second puncture entry to check 
drenage/. We have performed four time second minithoracotomy with 
2,3mm mini thoracoscope, in 3 pt. just to check drenage position or 
evacuate encapsulated fluids. In l pt. through with the first entry to 
obtain histological diagnosis after previous failure method.
Results: The evaluation includes: duration of chest tube drainage, 
duration of hospitalisation, diagnostic accuracy, complications.
Mean duration of chest tube drainage/ except empyema/ was 3,8 
days and hospitalization 8,1 days. Prolonged chest tube drenage resp. 
hospitalisation was for delayed lung reexpansion in advanced lung 
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cancer, in postiradiation fribrosis of lung, in pleural fibrosis with 
metastatic process of visceral and parietal pleura. 
Semirigid thoracoscopy was 92% accurate and yielded a diagnosis in 
23 from 25 pts. We had 2 histological failure in patients suspected of 
pleural malignancy . The high grade of suspicion was expressed by 
macroscopic wiew of the pleuroscopist and by CT pleural thickening 
and nodularities.
We have observed nonsevere complications as subcutaneous emphy-
sema, algic reaction and culture-negative fever after talc pleurodesis. 
Death as a complication is extremely rare, we had no death and no 
ARDS after talc using, no surgical intervention in our set of patients.
Conclusions: Our experience confirms a good clinical value of 
semirigid thoracoscopy as diagnostic as therapeutic method with no 
severe complications.
The semirigid thoracoscopy technic is challenge for future, especially 
in the management of lung cancer patiens. The semirigid thoracos-
copy has some advantages over the rigid instruments and mainly in 
comparison with surgery technic. Combination of semirigid thoraco-
scope with second minithoracoscopical technic and use rigid forceps 
in primary entry can improve in some cases diagnostic accuracy.
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Endobronchial metastasis from extrapulmoanry 
malignancies in Korea
Lee, Byoung Jun1; Jeong, Iin1; Park, Moo Suk2; Kim, Se Kyu2; 
Jang, Tae Won3; Jung, Mann Hong3; Nam, Hae Sung4; Ryu, Jung 
Seon4; Lee, Sung Young5; Kim, Hee Joung6; Lee, Kye Young6; Son, 
Choonhee7; Yoon, Ho-Il8; Lee, Choontaek8; Kim, Young Whan1; 
Yang, Seok-Chul1
1 Seoul National University Hospital, Seoul, Korea; 2 Yonsei 
University Hospital, Seoul, Korea; 3 Kosin University Hospital, 
Busan, Korea; 4 INHA University Hospital, Incheon, Korea; 5 Korea 
University Hospital, Seoul, Korea; 6 Konkuk University Hospital, 
Seoul, Korea; 7 Dong-A University Hospital, Busan, Korea; 8 Seoul 
National University Bundang Hospital, Bundang, Korea
Objective: Endobronchial metastases (EPM) from extrapulmonary 
malignant tumors are rare. The most common extrapulmonary malig-
nancies associated with EBM are breast, renal and colorectal carcin-
omas. This study was performed to evaluate the clinical, radiographic 
and bronchoscopic findings of patients with EBM.
Methods: A total of 129 patients with biopsy proven EPM who were 
diagnosed bronchoscopically between 2000 and 2008 in eight tertiary 
referral hospitals in South Korea were retrospectively evaluated. 
Clinical features such as patients’ presenting symptoms, broncho-
scopic and radiographic findings, treatment modalities, mean recur-
rence interval and median survival times were noted.
Results: Median age of the 129 patients at time of diagnosis of EBM 
was 61.0 years (18-91 years) and 64 patients were female (49.6%). 
The mean interval from initial diagnosis of primary cancer to diag-
nosis of EBM was 49.4 months (0-314). The most common primary 
tumors associated EBM were colorectal cancers (38, 29.5%), breast 
cancers (26, 20.2%), uterine cervix cancers (13, 10.1%) and stom-
ach cancers (12, 9.3%). Most common symptoms were cough (61, 
47.3%) and dyspnea (44, 34.1%). Twenty eight patients had abnormal 
chest X-ray without clinical symptoms. Mediastinal or hilar lymph-
adenopathy (42, 32.6%) and multiple pulmonary nodules (39, 30.2%) 
were the most common radiographic findings. Mass or nodules 
(85, 65.9%) was the most common bronchoscopic finding. Eighty 
patients (62.0%) showed right sided endobronchial lesions. Most of 
EBM were located at the same side with radiographic findings (114, 
91.5%). Most of patients with EBM were treated by chemotherapy 
(71, 59.2%). Recently bronchoscopic interventions were performed in 
8 patients (6.2%). The median survival time was 9.9 months. 
Conclusions: The most common primary cancers associated with 
EBM in Korea were colorectal cancer and breast cancer. Since the 
interval between primary cancers and EMB is usually long and 
symptoms and bronchoscopic and radiographic findings are not dif-
ferent from those in lung cancer, EBM should be discriminated from 
primary lung cancer histopathologically. 
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A pilot study of auto-fluorescence imaging bronchoscopy 
for a diagnosis of the early lung carcinoma and narrow-
band imaging bronchoscopy for a diagnosis of the 
carcinomatous lymphangitis
Miyoshi, Takanori; Yoshida, Mitsuteru; Hino, Naoki; Tsuyuguchi, 
Masaru
Department of Surgery, Tokushima Municipal Hospital, Tokushima, 
Japan
Introduction: Early diagnosis and early treatment can improve the 
prognosis of lung cancers. Despite expanding knowledge about endo-
scopic features, the early detection of superficial neoplasms during 
routine examination of bronchus remains difficult, because there are 
few morphologic changes. Recently, the trial of the diagnosis of the 
early cancer by an auto-fluorescence imaging bronchoscope (AFI) 
and a narrow band imaging bronchoscope (NBI) has been performed. 
In addition, a photodynamic therapy (PDT) has been performed for 
early lung cancer, early esophageal cancer and early uterine cervix 
cancer. The AFI system can specify lesions, including malignancies 
by differences in tissue fluorescence properties, and can reveal early 
stage cancers not detectable by conventional white light broncho-
scope (WL). [Case 1] A 67-year-old man had a superficial squamous 
cell carcinoma in the right B10 bronchus. Patients underwent AFI and 
WL, and diagnosis was established by biopsy. We decided to perform 
the PDT because of a low pulmonary function. We carried out the 
PDT, and the lesion was treated with an irradiation with quantity of 
100J. The lesion became the necrosis after the PDT and an enough 
curative effect was provided. [Case 2] A 64-year-old man had a ad-
vanced adenocarcinoma in the left S1+2. Patients underwent NBI and 
WL, and diagnosis was established by biopsy. There were carcinoma-
tous lymphangitis findings from the left upper bronchus to the trachea 
by NBI, but WL could not detect these findings. 
Discussion: AFI identified dysplasia or early lung cancer that was 
difficult for detection by WL. NBI identified carcinomatous lymph-
angitis that was not detected by WL. Further studies are needed to 
determine the efficacy of AFI and NBI in detection of early carcin-
omatous lesions or carcinomatous lymphangitis lesions in an at-risk 
population.
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Comparison of cell block (CB) preparation and direct 
conventional smear in citological samples obtained 
by endobronchial ultrasound guide real-time needle 
aspiration (EBUS-rTNA)
Monsó Molas, Eduard1, 2; Sanz Santos, Jose 1; Serra, Pere1; Andreo, 
Felipe1; Llatjòs, Maria1; Mesa, Miguel1
1 SEPAR (Spanish Pulmonary Association), Barcelona, Spain; 2 ERS 
(European Respiratory Society), Laussane, Switzerland
Aim: To compare the accuracy of cell block preparations versus 
direct conventional smears in citological samples obtained by EBUS 
-rTNA in the diagnosis/staging of mediastinal and hiliar nodes in 
patients with lung cancer.
Material and Methods: We studied 206 patients (185 (89%) men, 
21 (11%) women, mean age 63 years (SD±10 yrs) who underwent 
an EBUS-rTNA for diagnosing/staging lung cancer. Final diagnoses 
were: 80 (39%) adenocarcinoma, 51 (25%) squamous cell carcinoma, 
7 (3%) large cell carcinoma, 45 (22%) non-differentiated non-small 
cell carcinoma, 22 (10.7%) small cell carcinoma and 1 (0.3%) atyp-
ical carcinoid. Cell block preparations were obtained in adition to 
the standard smears whenever was feasible. CB were processed from 
the aspirates rinsed in phormaldehyde solution. Inmunocytochemical 
stains were performed on CB. In case of adenocarcinoma, detection 
of epitelial growth factor receptor (EGFR) mutation was carryied out.
Results: 410 nodes (n:410) were sampled (median short-axis 
diameter 10mm (IQR:7-14 mm)) from hiliar and mediastinal nodal 
stations (7 (1.8%) upper paratracheal, 127 (31%) lower paratracheal, 
208 (50.8%) subcarinal, and 68 (16.4%) hilar). In 137 cases (33.5%) 
CB could be obtained. In 28 cases (6.8%) CB provided the diagnosis 
while direct conventional smear was non-diagnostic. In one case 
(5.3%) of non-differentiated non-small cell carcinoma diagnosed 
by direct conventional smear, CB achieved the histological type. In 
39 cases (9.5%) of adenocarcinoma CB allowed to detect the EGFR 
mutation, being positive in 2 cases. 
Conclusions: Whenever feasible, samples for CB preparation from 
EBUS-rTNA should be obtained because CB provides aditional rel-
evant information to standard smears in the diagnosis of lung cancer, 
in our study, in a 7% of cases.
Funded by grants from CIBERES (CIBER de enfermedades respira-
torias), FUCAP and Acción Transversal del Cáncer.
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How many nodes per nodal station should be sampled 
during real time endobronchial ultraosund-guided 
transbronchial needle aspiration?
Monsó Molas, Eduard; Sanz Santos, Jose; Serra, Pere; Llatjòs, Maria; 
Andreo, Felipe; Mesa, Miguel
SEPAR (Spanish Pulmonary Association), Barcelona, Spain
Aim: To determine the benefit of sampling more than one node per 
nodal station in patients who undergo an endobronchial ultrasound-
guided real-time needle aspiration (EBUS rtNA).
Material and Methods: We study patients to whom more than one 
node per station was sampled during EBUS for diagnosing/staging 
lung cancer. Then we compared the accordance of cytologic diagno-
ses of nodes from the same station.
Results: We included 50 patients (43 males (86%) and 7 females 
(14%), mean age 62 years (SD 8)) with 127 nodes (short axis diam-
eter median 11 mm (IQR 8-14 mm) sampled from 55 nodal stations 
where 2 o more nodes were sampled. Nodal stations sampled were 
subcarinal (45, 82%), paratracheal (9,16%) and interlobar (1, 2%). 
Final diagnoses of all stations sampled were: 15 (27%) adeno-
carcinoma, 4 (7%) oat-cell, 7 (13%) non-small cell lung cancer, 6 
(11%) squamous and 23 (42%) normal nodes. Citologic diagnoses 
were in accordance in every node of the same station in 48 cases 
(87%). Of the other 7 stations (13%) with discordant samplings, in 6 
cases (11%) the malignant node was the one with higher short-axis 
diameter and in one station (2%) the malignant node had the smallest 
short-axis diameter. 
Conclusions: In lung cancer, nodal involvement in most cases affects 
all nodes from the same station. Sampling the node with a higher 
short-axis diameter, guarantees the identification of nodal malignancy 
in 98% of the cases.
Funded by grants from CIBERES (CIBER de enfermedades respira-
torias), FUCAP and Acción Transversal del Cáncer.
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Airway stents: an important adjunct in the palliative 
management of malignant airway obstruction
Rueth, Natasha M.; D’Cunha, Jonathan; Groth, Shawn S.; Maddaus, 
Michael A.; Andrade, Rafael
University of Minnesota, Minneapolis, MN, USA
Background: Airway stents are an accepted modality in the manage-
ment of malignant airway pathology. In this study we reviewed our 
experience with the use of airway stents for symptomatic, malignant 
obstruction. Our aim was to demonstrate symptomatic improvement 
in this challenging patient population.
Methods: We performed an institutional review board-approved, 
retrospective review of our prospectively maintained airway stent 
database. Data was collected on patients who underwent airway 
stent placement for symptomatic, non-operable, malignant airway 
disease between October of 2005 and December of 2008. Information 
regarding patient demographics, diagnosis, clinical history, respira-
tory symptoms, operative indications, and post-stent outcomes was 
collected and analyzed utilizing descriptive statistical methods. The 
frequencies of pre-stent and post-stent respiratory symptoms were 
compared using chi-square analysis (α=0.05).
Results: Twenty-four airway stents were placed (11 left or right 
mainstem, 8 tracheal, and 5 bronchus intermedius) into 24 patients. 
The most common indications for placement were: primary air-
way malignancy (58.3%), malignant extrinsic airway compression 
(27.5%), and malignant tracheoesophageal fistula (8.3%). Other indi-
cations included hemorrhage, bronchopleural fistula, and dysphagia. 
Presenting symptoms included dyspnea (87.5%), cough (41.9%), 
hemoptysis (25%), dysphagia (16.7%), and stridor (4.1%). Nine 
patients (37.5%) presented with post-obstructive pneumonia.
Five of our procedures (20.8%) were performed on an outpatient 
basis. The median hospital stay for inpatients was 3 days (range 0-72 
days). Complications related to placement were minor and included 
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stenosis or kink requiring replacement (12.5%), migration (8.3%), 
and atelectasis (4.2%).
Patients experienced notable improvements in respiratory symptoms 
following stent placement (p<0.001) and had a decreased incidence 
of obstructive pneumonia (p=0.02) (Table 1). Respiratory support 
was weaned in 40% of patients after stent placement. Importantly, 
20% were able to tolerate post-stenting palliative therapy, including 
laser debridement, airway dilation, or radiation therapy (n=5). As 
expected, one-year survival was 12.5%. 
Table 1: Clinical findings related to airway obstruction pre and post-stent 
placement
 FINDING PRE-STENT [n (%)] POST-STENT [n (%)] p-value
 Dyspnea 21 (87.5) 6 (25.0) <0.001*
 Cough 10 (41.2) 7 (29.1) 0.54
 Obstructive Pneumonia 9 (37.5) 2 (8.3) 0.02*
 Hemoptysis 6 (25.0) 3 (12.5) 0.45
 Respiratory Support (BiPAP or Ventillator) 5 (20.8) 3 (12.5) 0.41
Conclusions: Airway stents are a useful and safe adjunct for the 
treatment of patients with non-operative, symptomatic, malignant 
airway obstruction. Stents markedly improved dyspnea, reduced the 
incidence of obstructive pneumonia, and may allow reduction of res-
piratory support. Notably, in selected cases, airway stents permit pa-
tients to undergo additional therapy that they may not have otherwise 
been able to tolerate. Our findings demonstrate that the use of airway 
stenting is an important palliative adjunct; this modality should be 
reserved for patients with malignant disease who are not candidates 
for definitive therapy.
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Awake epidural anesthesia for limited thoracoscopic 
procedures
Steppert, Claus; Holl, Torsten; Sommer, Christoph; Habich, Gernot
Bezirksklinikum Obermain, Ebensfeld, Germany
While diagnostic thoracoscopy is mainly performed under local 
anesthesia, thoracic surgeons prefer general anesthesia with single 
lung ventilation even for limited thoracoscopic procedures. While 
mapping biopsies or talc powder pleurodesis can be painful in local 
anesthesia general anesthesia is very resource consuming.
To overcome both limitations we invented thoracic epidural anesthe-
sia for diagnostic thoracoscopy and limited thoracoscopic procedures 
like talc powder pleurdesis or partial pleurectomy.
Since september 2006 98 patients (60m, 38f, aged 29 to 87, mean 66, 
median 68.5 years) with pleural effusions underwent thoracoscopy 
in thoracic epidural anaesthesia. Epidural anesthesia was performed 
at level TH5/6 with 5ml ropivacaine 0.75% and 5µg sufentanil. In 
90 pts. an epidural block between TH2 and TH10 could be achieved. 
Only in 5 patients epidural anesthesia couldn’t be performed, in 
another 3 patients epidural anesthesia was not sufficient and had to be 
augmented by systemic analgesia.
Collapse of the lung was sufficient in most cases. Additional to map-
ping biopsies talc powder pleurodesis with 4-8g talc powder was 
performed in 58pts, partial pleurectomy in 3 pts. Intervention time 
was 5 to 35, mean 17.3, median 16.5 min. According to the ASA 
risk stratification only 13 pts were in the favorable classes I and II, 
34 were in class III and 39 in the high risk class IV. Beside a small 
drop in arterial pressure that had been treated with theodrenaline no 
significant side effects occurred. Oxygen saturation remained stable 
during the procedure. All pts. could be immediately transferred to the 
ward after the intervention.
Conclusion: awake thoracic epidural anesthesia is a safe alternative 
for diagnostic and limited thoraacoscopic interventions. It combines 
perfect intraoperative and postoperative analgesia with comfort for 
the patient and the surgeon with resource savings compared to gen-
eral anesthesia and can be highly recommended for either interven-
tional or diagnostic thoracoscopies.
Imaging
P2.016 Imaging, Sun Aug 2 
Evaluation of tumor response: Comparison of RECIST 
version 1.0 and RECIST version 1.1
Chang, Myung Hee; Ahn, Hee Kyung; Kim, Kyoung Ha; Jun, Hyun 
Jung; Kim, Hyo Song; Lee, Jeeyun; Park, Yeon Hee; Ahn, Jin Seok; 
Ahn, Myung-ju; Park, Keunchil
Division of Hematology/Oncology, Department of Medicine, 
Samsung Medical Center, Seoul, Korea
Background: Both objective response and time to progression are 
common endpoints which are anatomically based in cancer clinical 
trial. Although RECIST (Response Evaluation Criteria in Solid 
Tumors) has been widely used in clinical oncology practice since 
2000, several issues including the number of lesions, rule of lymph 
node measurement, and needed for confirmation of response remain 
controversial. Recently, revised RECIST guideline (version 1.1) was 
proposed on the base of these questions. We conducted this study 
to validate RECIST version 1.1 in solid cancer patients who were 
enrolled in clinical trials and treated with systemic chemotherapy.
Methods: We acquired data of 83 patients from thirteen prospective 
phase II studies at Samsung Medical Center, retrospectively. The two 
guidelines were applied separately for evaluation of tumor response. 
Results: Using the RECIST version 1.1, four cases were reclassified 
for response evaluation (1:PR→SD; 1:SD→PR; 2:SD→PD). And 
two patients were classified as not-evaluable due to absence of meas-
urable lymph node by RECIST version 1.1. The overall response rate 
was 39.8% by RECIST version 1.0, and 38.5% by RECIST version 
1.1, respectively. The κ statistics for concordance for overall response 
was 0.948.
    RECIST 1.0  
 RECIST 1.1 CR (N=0) PR (N=33) SD (N=37) PD (N=13)
 CR 0 0 0 0
 PR 0 31 (94%) 1 (2.7%) 0
 SD 0 1 (3%) 33 (89.2%) 0
 PD 0 0 2 (5.4%) 13 (100%)
 Not evaluable 0 1 (3%) 1 (2.7%) 0
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Conclusions: This study showed that the response rates using the 
revised RECIST guidelines are comparable to those of the RECIST. 
Given simple and reproducible, the new guidelines can be applied to 
oncology practice in the measurement of response.
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An updated meta-analysis (MA) of the literature assessing 
the prognostic role of primary tumour standardized 
uptake value (SUV) measured on fluorodeoxyglucose 
positron emission tomography (FDG-PET) in non-small 
cell lung cancer (NSCLC). A study by the European Lung 
Cancer Working Party for the IASLC Staging Project
Berghmans, Thierry1; Paesmans, Marianne1; Dusart, Michelle2; 
Garcia, Camilo1; Hossein-Foucher, Claude3; Lafitte, Jean-Jacques3; 
Mascaux, Céline1; Meert, Anne-Pascale1; Roelandts, Martine1; 
Scherpereel, Arnaud3; Terrones Munoz, Vanessa4; Sculier, Jean-Paul1
1 Institut Jules Bordet, Brussels, Belgium; 2 Centre Hospitalier de 
la Citadelle, Liège, Belgium; 3 CHRU Lille, Lille, France; 4 CHU 
Brugmann, Brussels, Belgium
Background: FDG-PET is an effective imaging technique for as-
sessing cTNM in NSCLC. In a previous MA including 13 studies, we 
found that SUV measured on primary tumour has a prognostic value 
for survival in NSCLC (J Thorac Oncol 2008; 3: 6-12). Since, the 
number of publications on the topic has doubled. We aimed to update 
the results of our first MA. 
Methods: We searched for all studies published in the French and 
English languages literature assessing the prognostic role of SUV 
on survival in lung cancer. For each publication, we extracted an 
estimate of the hazard ratio (HR) for comparing patients with a low 
or high SUV and aggregated the individual HRs into a combined HR, 
using a random-effects model.
Results: Twenty-six studies including NSCLC only, published 
between 1998 and 2008, were eligible for the systematic review. 
Data allowing a quantitative aggregation (MA) were available in 20 
studies, contacts with investigators are ongoing. In two publications, 
patients without definite diagnosis of cancer were reported leading us 
to perform two separate MA, including or not those studies. Among 
the 20 meta-analysable studies, 15 included patients with stages I 
to III/IV and fourteen used a SUV assessment corrected for body 
weight. Numbers of patients ranged from 36 to 487 (total: 2591); 17 
studies identified a high SUV as a poor prognostic factor for survival 
and 3 concluded to a non significant effect. SUV measurement and 
threshold for defining high SUV were study dependent; nine stud-
ies used the median value, eight studies looked for a “best” cut-off 
(maximizing the logrank test statistic) but without adjusting the p 
value for multiplicity. The threshold was arbitrarily chosen in two or 
the authors used a threshold provided in another publication in one.
Conclusion: We confirmed the results of our previous MA showing 
that SUV measured on the primary tumour is of prognostic value for 
survival in NSCLC when assessed in univariate analysis. Further sub-
group analyses will be performed to better delineate the prognostic 
role of SUV according to neoplastic stage.
Number of 
patients
HR 95% CI
All studies (n = 20) 2591 2.04 1.65-2.52
Meta-analysis including only 
pathologically proven lung cancer 
(n = 18)
2225 2.04 1.65-2.52
“Best cut-off” excluded (n = 13)* 1573 1.88 1.47-2.42
Studies without patients with 
metastatic cancer (n=12)
1561 2.22 1.71-2.89
Study dedicated to advanced cancer 
(n=1)
214 1.29 0.94-1.76
*for two studies, it was possible to use median value of SUV instead of the author’s best cut-off 
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Evaluation of 18F-FDG PET-CT for rapid lung cancer 
diagnosis in an approach of out-patient fast track 
assessment
Aukema, Tjeerd S.; Klomp, Houke M.; Valdés Olmos, Renato A.; 
Teertstra, Hendrik J.; Belderbos, José S.A.; Vogel, Wouter V.; Baas, 
Paul; Burgers, Sjaak A.; Van den Heuvel, Michel M.
Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, 
Amsterdam, Netherlands
Background: In the management of malignancies a shift to a multi-
disciplinary model of care has been shown to improve quality of 
care. 18F-fluorodeoxyglucose positron emission tomography (FDG 
PET) plays an important role in staging patients with NSCLC and has 
become important for therapeutic management. The aim of our study 
was to evaluate the clinical performance/implementation of FDG 
PET/CT in diagnosing lung cancer in an approach of out-patient fast 
track assessment. 
Methods: A prospective study was performed in 114 consecutive 
patients with pulmonary symptoms and/or abnormal chest X-ray, 
referred for fast track assessment to the Netherlands Cancer Institute 
from March 2005 to September 2007. The presence of malignancy 
was evaluated in a multidisciplinary setting, including FDG-PET/CT, 
diagnostic CT, and bronchoscopy (including biopsy), with histopatho-
logical evaluation as the reference standard.
Results: In 105 patients (92%) a final diagnosis was achieved. A ma-
lignancy was diagnosed in 84% of the patients; non-small cell lung 
cancer in 67%, small cell lung cancer in 7%, and metastases or other 
malignancies in 10%. Non–malignant lesions were found in 16% of 
the patients. The PET/CT was positive in 93 out of the 96 patients 
with a malignancy. A malignancy was confirmed in 92% of the PET/
CT positive patients. In patients (n=18) with a benign lesion 8 out of 
the 18 PET/CT scans were positive. Sensitivity, specificity, accuracy, 
positive predictive value and negative predictive value of positive 
PET/CT for the presence of malignancy were respectively 97%, 56%, 
90%, 92% and 77%. PET/CT showed unexpected M1 disease (not 
detected on CT) in 10% of the patients. Almost half of the patients 
with a malignancy were scheduled for curatively treatment, 29 pa-
tients for surgery and 14 patients for chemoradiotherapy. 
Conclusion: In this out-patient fast track setting, PET/CT provides 
valuable information for diagnosing lung cancer, with a high positive 
predictive value, and is useful for clinical decision making.
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Recurrence and survival patterns in Stage 3 non-small 
cell lung cancer (NSCLC) with the addition of positron 
emission tomography (PET) imaging to standard CT 
Chan, Elisa3, 1, 4; Kiss, Alex2; Balogh, Judith3, 1, 4; Barbera, Lisa3, 1, 
4; Cheung, Patrick3, 1, 4; Poon, Ian3, 1, 4; Spayne, Jacqueline3, 1, 4; Ung, 
Yee C.3, 1, 4
1 Sunnybrook Health Sciences Centre, Toronto, ON, Canada; 2 
Institute for Clinical Evaluative Sciences, Toronto, ON, Canada; 3 
Odette Cancer Centre, Toronto, ON, Canada; 4 University of Toronto, 
Toronto, ON, Canada
Background: PET imaging is increasingly being used to stage and 
plan radiotherapy treatment in NSCLC patients. Its impact on radio-
therapy treatment volumes is not yet fully known, but it is hoped to 
improve the precise delineation of the tumour and lymph nodes. This 
study evaluated differences in recurrence patterns and overall sur-
vival in Stage 3 NSCLC patients staged with PET and CT compared 
to CT alone.
Methods: 83 patients were enrolled at out institution for a prospect-
ive study investigating the role of PET in staging Stage 3 NSCLC 
patients. These patients were planned for radical radiotherapy treat-
ment ± chemotherapy ± surgery. 36 patients were randomly assigned 
to undergo PET and CT imaging as part of their workup while the 
remaining 47 patients underwent CT alone. 
Patients were then followed for a period of 2 years to completion of 
the study and first recurrence sites were documented as being local, 
locoregional, locoregional and distant or distant alone. Survival time 
was calculated as the period between the beginning of radiation treat-
ment to date of death (determined study follow up or clinical notes).
Results: In terms of survival, fewer patients died in the PET and 
CT group (10/36 patients, 28%) compared to 17/47 (36%) in the CT 
alone group. As for overall survival, there was a trend towards higher 
survival probability in the PET and CT group as compared to the CT 
along group. However these differences were not statistically signifi-
cant (log rank test p-value = 0.48).
In terms of recurrence, 41/83 patients recurred within the 2 year fol-
low up study period. During this time, fewer patients staged with PET 
and CT recurred compared to patients staged with CT alone (26/47, 
or 55% in PET and CT group versus 15/36, or 42% in CT alone 
group). These results were not statistically significant. 
In terms of patterns of local failure, the incidence was 1/15 in the 
PET and CT group versus 3/26 for the CT alone group. The incidence 
of locoregional and both locoregional and distant failures were 7/15 
in the PET and CT group and 6/26 in the CT group alone. Distant 
failures alone occurred less often in patients staged with PET and CT 
(7/15) compared to patients staged with CT alone (17/26).
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PET imaging of hypoxia with the new tracer 18F-HX4: A 
phase 1 trial
van Loon, Judith1; De Ruysscher, Dirk1; Janssen, Marco1; Oellers, 
Michel1; Dingemans, Anne-Marie 2; Hochstenbag, Monique2; 
Lalisang, Roy2; Brans, Boudewijn2; Windhorst, Bert3; van Dongen, 
Guus3; Zhang, James4; Lambin, Philippe1
1 Maastro Clinic, Maastricht, Netherlands; 2 Maastricht University 
Medical Centre, Maastricht, Netherlands; 3 Free University Medical 
Centre, Amsterdam, Netherlands; 4 Siemens Molecular Imaging, 
North Wales, USA
Background: Non-invasive imaging of tumour hypoxia with the aid 
of PET-scans could help to select patients who could benefit from 
chemotherapy or radiation with specific anti-hypoxic treatments 
such as bioreductive drugs or hypoxic radio-sensitizers. 3-[18F]
fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-
yl)propan-1-ol ([18F]HX4), member of the 2-nitroimidazole family, 
has in preclinical models been shown to be a hypoxia-marker with a 
relative short half life and a favourable tumour to background ratio. 
In this phase 1 trial, we aimed to determine the toxicity of [18F]HX4 
at different dose levels, with as a secondary aim to analyze image 
quality at different time points and doses. 
Methods: Patients with a histology proven solid tumour with no 
curative treatment options were eligible for the study. A two dose-
step study design was used. In step 1, a single dose of maximum 222 
MBq was injected. Step 2 consisted of a single dose up to 444 MBq. 
Haematological, kidney and liver toxicity was scored twice a week 
from the day of injection up to 7 days after injection, according to 
the CTCAE 3.0 scoring system. Six patients were included, 3 in each 
dose step. If in any patient grade 2 or higher toxicity was observed, 
three more patients were included in this dose step. 
PET-CT images of the largest tumour site were acquired 60, 90, 
150 and 210 minutes after injection. Images were analyzed using 
dedicated software (TrueD, Siemens Medical, Erlangen, Germany). 
Tumour to skeletal muscle ratios (TMR) for [18F]HX4 uptake were 
calculated. 
Results: ix patients, with an age of 54-68 years, were included. Four 
patients had stage IV NSCLC (3 adenocarcinoma, 1 squamous cell 
carcinoma), 1 patient had stage IV thymus carcinoma and 1 patient 
had stage IV colon carcinoma. No toxicity according to the CTCAE 
3.0 criteria was observed in any of the patients. 
The most optimal TMR was obtained120 minutes after injection, 
with a median TMR of 1.26. TMRs of the 6 patients were: 1.15, 1.42, 
1.10, 1.32, 1.77 and 1.20, respectively. Of the 3 patients with detect-
able tumour hypoxia, 1 was in the low dose level, 2 received the high 
dose. A representative image of a patient is depicted in the figure. 
Conclusions: The current data show that [18F]HX4 imaging with 
PET for the detection of hypoxia is encouraging, and is not associ-
ated with any toxicity. On basis of these data, a phase II trial with 444 
MBq [18F]HX4 in lung and head and neck cancer patients will be 
started. 
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High-resolution pulmonary ventilation imaging using local 
volume change in four-dimensional CT data
Zhang, Geoffrey G.1; Huang, Tzung-Chi2; Stevens, Craig1; Dilling, 
Thomas1; Forster, Ken1
1 Radiation Oncology, Moffitt Cancer Center, Tampa, FL, USA; 2 
Department of Medical Radiological Technology, China Medical 
University, Taichung, Taiwan
Background: Nuclear medicine techniques are commonly employed, 
but demonstrate poor spatial resolution. Because thoracic cancer 
patients typically undergo four-dimensional (4D) CT scans for radio-
therapy planning, deriving quantitative ventilation information from 
these data sets would decrease cost and inconvenience to the patient. 
Ventilation information can be used to minimize treatment dose to 
better-functioning lung and assess changes to regional ventilation 
after radiotherapy.
Ventilation imaging using 4D CT and Hounsfield unit (HU) change 
has been reported(1). This technique is problematic in that fluctuation 
of HU in a CT generates significant noise within the ventilation im-
ages. Consequently, they must be smoothed by averaging HU change 
over a number of voxels, which degrades the high spatial resolu-
tion inherent within the original CT images. Furthermore, a slight 
misregistration between blood vessels or other high-density objects 
may yield erroneous results (edge artifact), as falsely large changes in 
density (and hence, ventilation) would be reported. 
In contrast, the ventilation calculation technique reported here em-
ploys deformable image registration to assess local volume change of 
the lung voxels directly, rather than to assess the HU/density changes 
within them to determine regional changes in ventilation across the 
respiratory cycle.
Methods: In a CT image volume, each voxel can be represented by 
a cuboid. The 8 vertices that compose the cuboid in one phase are 
deformed to create a polyhedron in another phase, which still derives 
from the 8 corresponding vertices. Deformable image registration 
using an optical flow algorithm establishes the correspondence of the 
vertices without human intervention. This deformed polyhedron is 
comprised, in turn, of 6 deformed tetrahedrons.
Thus the volume change is the sum of the 6 tetrahedron volumes 
minus the volume of the orginal cuboid. Calculating the local volume 
change ∆V/V for every voxel generates a 3-D high-resolution pul-
monary ventilation image.
Results: We generated sample pulmonary ventilation images from a 
number of 4D CT image sets. The local displacement of each voxel 
can be fractional. Consequently, the technique was shown to be ac-
curate: calculated tidal volumes varied within 5% of results derived 
using 4D CT lung segmentation. Tidal volume differences between 
left and right lungs (noticeable on 4D CT) were also confirmed and 
quantified with this technique. Additionally, in some cases, aerated 
segments of lung distal to small tumors were observed to have de-
creased ventilation in the derived ventilation images.
Graphical examples and corresponding quantitative data will be 
provided.
Conclusions: Deformable image registration and local volume 
change calculation provide a practical and robust algorithm for 
high-resolution ventilation imaging using 4D CT data. The technique 
described here is less artifactual than the previously published one. 
It holds promise for use in selective avoidance of better-functioning 
lung in radiotherapy treatment planning. Similarly, it could be 
employed in follow-up to assess changes in regional ventilation due 
to prior radiotherapy where lung toxicity is one of the overriding 
concerns. 
1. Guerrero T, Sanders K, Noyola-Martinez J, et al. Quantification of regional ventila-
tion from treatment planning CT. int J Radiat Oncol Biol Phys 2005; 62:630-634.
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Evaluation of Siemens syngo LungCARE CT and Lung 
CAD volumetric lung nodule measurements
Ashraf, H.1; de Hoop, B.2; Dirksen, Asger3; Shaker, S.B.3; Bach, 
K.S.1; H. Hansen, H.1; Prokop, M.2; Pedersen, J.H.4
1 Department of Radiology, Gentofte Hospital,University, 
Copenhagen, Denmark; 2 Department of Radiology, University 
Medical Centre, Utrecht, Netherlands; 3 Department of Respiratory 
Medicine, Gentofte Hospital, University of Copenhagen, 
Copenhagen, Denmark; 4 Department of Thoracic Surgery, Gentofte 
University Hospital, Copenhagen, Denmark
Aim: To evaluate the reproducibility of semi-automated lung nodule 
evaluation using software that offers multiple algorithms for deter-
mining the volume of screen detected lung nodules.
Material: As part of the Danish Lung Cancer Screening Trial, 2,052 
current or former smokers aged 50-70 years were screened with low 
dose CT. At baseline 188 nodules >5 mm were identified in 161 par-
ticipants. For each nodule, both baseline and annual follow-up scans 
were included.
Methods: Nodules were independently double read by two readers 
using Siemens syngo LungCARE version VE25A. The software of-
fers readers 3 different analysing algorithms: Small Size or All Size 
for solid nodules and Subsolid for ground glass opacities. Bland-
Altman plots were used to evaluate the reproducibility obtained when 
the readers used the same or different algorithms. 
Results: The software correctly segmented nodules in 72 %. For 
these 391 readings, the readers chose the same algorithm in 80 %, 
and measured exactly the same volume in 50 % of these readings. 
When the readers used the same algorithm, 4 % of the measurements 
showed a difference of >25%. When the readers used a different 
algorithm, 83 % of the measurements showed a difference in volume 
of more than 25%. 
Conclusion: Modern volumetric software failed to correctly segment 
in a high number of manually detected screen nodules. If the same 
software algorithm is used, 96% of the volumetric measurements will 
show a variability of less than 25%. Use of same analysing algorithm 
is essential for correct longitudinal assessment of lung nodules.
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Quantification of pre-treatment metabolic tumor growth 
rate in lung cancer
Eastham, David V.1; Chapman, Christopher H.1; Rao, Aarti K.1; 
Balasubramanian, Narasimhan2; Quon, Andrew3; Vasanawala, Minal 
S.3; Wakelee, Heather4; Le, Quynh-Thu1; Colevas, Dimitrios A.4; 
Maxim, Peter A.1; Graves, Edward 1; Loo, Billy W.1
1 Stanford Department of Radiation Oncology, Stanford, CA, USA; 
2 Stanford Deprtment of Health and Research Policy, Stanford, CA, 
USA; 3 Stanford Department of Nuclear Medicine, Stanford, CA, 
USA; 4 Stanford Department of Medical Oncology, Stanford, CA, 
USA
Background: We previously reported that pretreatment metabolic 
tumor volume (MTV) measured by FDG-PET is a strong prognos-
tic factor in patients with lung cancer treated by radiation therapy 
(most with concurrent chemotherapy). Metabolic tumor growth rate 
(MTGR) measured by serial PET imaging is a dynamic assessment 
that may be a more sensitive indicator of biological tumor aggressive-
ness. We conducted an exploratory study to quantify pre-treatment 
MTGR in patients with lung cancer treated with radiation therapy.
Methods: We retrospectively identified patients with lung cancer 
who had both a treatment planning PET-CT and a prior diagnostic 
PET-CT. We then limited inclusion for analysis to patients with newly 
diagnosed lung cancer who were treated with curative intent with 
radiotherapy (with or without chemotherapy), and who received no 
treatment between the two pre-treatment scans. MTV (primary tumor 
only as well as total body tumor burden) was segmented on each 
scan using semi-automated software employing an intensity gradient-
based algorithm to define the edges of the metabolically active 
regions. MTGR was defined as percent change in MTV between two 
measurements divided by time between them.
Results: Of 187 patients with two pretreatment scans, 39 met the 
inclusion criteria for analysis. The median time interval between the 
two scans was 4.9 weeks (range 1 to 15.3). The median total body 
MTV increase between scans was 23.6%; 6 of 39 had over 100% in-
creases. Median total body MTGR was 6.0% per week (range -5.7% 
to 38.5% per week). 11 of 39 patients (28.2%) had a MTGR greater 
than 10% per week (Figure 1).
Conclusions: MTGR may reflect tumor biology more accurately than 
static measures of tumor size. While an observed MTV change within 
±10% might be due to measurement error, approximately a third of 
the patients in this cohort had MTGR greater than 10% per week, 
indicating that clinically significant growth was occurring during the 
pretreatment interval and suggesting that expeditious initiation of 
treatment will improve outcomes. The next step will be to analyze the 
impact of MTGR on progression-free and overall survival in a larger 
cohort of patients.
Figure 1: Metabolic Tumor Growth Rate. X-axis shows groups 
of metabolic tumor growth rates as percent changes from original 
volumes per week. Y-axis shows number of patients in each group. N 
= 39.
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Optimal PET response following stereotactic body 
radiotherapy (SBRT) for non-small cell lung cancer 
(NSCLC) is closely related to the pre-SBRT maximum 
standard uptake value
Feigenberg, Steven Joel1; Sharma, Navesh1; Yu, Jian Q.1; Lally, 
Brian1; Borghaei, Hossein1; Mehra, Ranee1; Simon, George1; Scott, 
Walter1; Buyyounouski, Mark1; Unger, Michael1; Movsas, Benjamin2
1 Fox Chase Cancer Center, Philadelphia, PA, USA; 2 Henry Ford 
University Hospital, Detroit, MI, USA
Purpose: Given the success of stereotactic body radiotherapy 
(SBRT) for non-small cell lung cancer (NSCLC) and the interest 
in comparing this approach with surgery, early surrogates of SBRT 
failures are imperative to allow timely surgical salvage. Previously, 
we have reported that a drop in the maximum standardized uptake 
value (SUV max)of > 55% at 3 months following SBRT predicted 
an improved local control. This study tries to determine predictors of 
this optimal PET response (i.e. > 55%).
Material and Methods: Between April 2004 and December 2008, 
71 patients underwent SBRT for 76 NSCLC at Fox Chase Cancer 
Center. For patients treated with curative intent, PET/CT scans were 
obtained 1 month prior to and 3 months post-SBRT based on the 
work by MacManus et. al. in 47 patients (53 tumors) which make up 
the cohort of interest. 15 patients were treated on a prospective phase 
I dose escalation protocol and received 40 Gy, 48 Gy or 56 Gy in 4 
equal fractions typically over 8 days. The majority of patients treated 
off study received 48 Gy in 4 fractions. Treatment volumes were in-
dividualized for each patient using 4 D CT simulation or a combina-
tion of 2 breath hold scans at maximum end inspiration or expira-
tion which was fused to a free breathing CT (ITV). Five millimeter 
margins were added to the ITV to make a planning target volume. 
The endpoint for this study was based on SUV max from the PET/CT 
as reviewed by the same author (JQY).
Results: The median age was 72 years (range 43 to 87), of which 
50% were male with a mean tumor size of 2.2 cm (range 7 mm to 6.2 
cm). The median SUV max pre-SBRT was 4.8 (range 1.7 to 18) and 
2.1 (range 0.5 to 7.9) post-SBRT. 18 patients had a post-SBRT SUV 
max > 2.5. The post-SBRT PET/CT was obtained at 94 days on aver-
age (range 33 to 240). The average PET response was a drop of 40% 
in the max SUV (range 91% to – 82%) with 50% of patients having 
an optimal PET response. Nine had an increase in the SUV max that 
was usually related to surrounding treatment effect (i.e. pneumonitis). 
Interestingly 8 of these patients had a low initial SUV max < 3 (one 
with 4.4). If the patients with an initial SUV max of < 3 are removed, 
the average PET response was a drop of 59% in the SUV max. Early 
post SBRT PET scans (<60 days) and pathology did not seem to have 
an impact on PET response.
Conclusion: Optimal PET response is closely tied to the pre SBRT 
SUV max. When the initial SUV max is < 3, a post SBRT PET is 
not a good predictor of response due to a higher risk of radiographic 
pneumonitis.
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Interstitial shadow on CT is associated with the prognosis 
in patients with NSCLC
Fujita, Yuka; Nishigaki, Yutaka; Fujiuchi, Satoru; Hiramatsu, Mie; 
Yamamoto, Yasushi; Takeda, Akinori; Yamazaki, Yasuhiro; Fujikane, 
Toshiaki
Dohoku National Hospital, Asahikawa, Japan
Background: Interstitial lung disease (ILD) is known to be an 
adverse event in cancer chemotherapy and radiotherapy. In addition, 
tyrosine kinase inhibitor (TKI) as gefitinib and erlotinib causes. This 
study aimed at determining the prognostic significance of interstitial 
shadow on pretreatment computerized tomography (CT) of the chest 
as a prognostic factor in non-small cell lung cancer (NSCLC).
Methods: Thirty hundred ninety-seven histologically or cytologically 
proven and previously untreated NSCLC patients have been studied. 
They were diagnosed between January 2004 and December 2006. 
These included 213 adenocarcinomas, 143 squamous cell carcinomas, 
32 large cell carcinomas. We reviewed retrospectively pretreatment 
spiral CT of the chest. Ground-glass opacity, consolidation, reticular 
shadow or honey-combing shadow without segmental distribution 
was defined as interstitial shadow. Interstitial shadow was graded 
as follows. Mild: area of interstitial shadow <10% in bilateral lower 
lob; moderate: 10–30% in bilateral lower lobes; and severe: >30% in 
bilateral lower lobe. Preexisting interstitial shadow was compared in 
relation to clinicopathologic findings. The data were analyzed using 
Chi-square test, Mann-Whitney U test, Kaplan-Meier method and a 
Cox multivariate regression model for survival.
Results: Fifty-nine patients (14.9%) had interstitial shadow on 
pretreatment CT. Mild, moderate and severe interstitial shadow was 
identified in 24(6.0%), 20(5.0%) and 15(3.8%) of patients, respect-
ively. Interstitial shadow showed significant correlation with age, 
gender, smoking status, and first-line treatment (p=0.0386, p<0.0001, 
p=0.0001, p=0.0193, respectively). Median overall survival (OS) 
for patients without interstitial shadow (44.8 months) was signifi-
cantly greater than for those with interstitial shadow (11.6 months) 
(p<0.0001, log-rank test). Median OS for mild group, moderate 
group, and severe group were 22.9 months, 9.3 months, 5.6 months, 
respectively (p<0.0001, log-rank test). Median overall survival (OS) 
for patients without interstitial shadow (44.8 months) was similar to 
those with mild interstitial shadow (22.9 months) (p=0.4282, log-
rank test). Univariate analyses showed that age ≥75, male gender, 
clinical stage IV, Performance status (PS) 2-4, best supportive care as 
first-line treatment, and interstitial shadow on CT were significantly 
associated with poor prognosis (p=0.0219, p=0.0032, p<0.0001, 
p<0.0001, p<0.0001, p=0.0097, respectively). Multivariate analyses 
showed stage IV, PS 2-4, best supportive care as first-line treatment, 
and interstitial shadow on CT of the chest were significantly associ-
ated with poor prognosis (p=0.0079, p<0.0001, p=0.0033, p=0.0380, 
respectively)
Conclusions: Interstitial shadow on the spiral CT of the chest is a 
significant factor to predict worse prognosis in patients with non-
small cell lung cancer.
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FDG-PET/CT differ lung carcinoids from hamartomas
Grundberg, Oscar1; Jacobsson, Hans2; Kölbeck, Karl Gustav3
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Background: Lung carcinoids account for approximately 1% of all 
lung cancers and usually require surgical removal. Hamartoma is a 
benign tumor not necessary to treat. The two conditions may have 
a very similar radiological appearance when studied by chest x-ray 
or CT, especially when the carcinoid has a peripheral location. The 
objective was to assess if integrated FDG PET-CT examination could 
contribute to the decision-making process.
Methods: Between October 2006 – September 2008, out of 331 
thoracotomies, 27 resected carcinoids and 29 hamartomas were iden-
tified in retrospect. Of these, 21 hamartomas and 15 carcinoids had 
in addition to CT also been examined by FDG PET/CT. All exam-
inations were reviewed by one single radiologist/nuclear medicine 
physician. SUV-values were measured as well as morphological 
characteristics were assessed.
Results: Of the 15 carcinoids, 7 were peripheral and 8 central ac-
cording to radiological appearance. Of the central carcinoids, 4 were 
visible by bronchoscopy (one patient did not undergo such examina-
tion). No hamartoma was detected endoscopically.
Mean SUVmax of the carcinoids was 3.0 (median 2.4, range 0–7.4). 
3 carcinoids did not show any FDG-uptake, 6 showed a weak up-
take, 4 an intermediate uptake and 2 showed a strong uptake. The 3 
carcinoids that did not show any FDG-uptake were central lesions, 
two of them associated with large atelectasis, which were difficult 
to separate from the lesions. All peripheral carcinoids showed some 
FDG-uptake (mean SUVmax 3.2, range 0.9–7.4), whereas 6 of the 21 
hamartomas showed an FDG-uptake (p<0.05, Fisher exact test). 
Mean SUVmax of the hamartomas was 0.5 (median 0.0) and a 
SUVmax 0.0–3.7. Fifteen of the 21 hamartomas (71%) showed no 
FDG-uptake, 5 (24 %) showed a weak uptake (SUVmax 1.3–1.9) and 
1 (5%) showed an intermediate uptake (SUVmax 3.7).
 Gender Age Tumor Size SUV SUV Localization Type 
 (m/f) (y)  (CT) in mm max mean
 f 78 26 7.4 7.0 Peripheral Atypical
 f 73 18 5.0 4.6 Peripheral Atypical
 f 68 16 0.9 0 Peripheral Atypical
 f 62 13 1.5 0 Peripheral Typical
 f 61 12 1.5 1.6 Peripheral Typical
 f 58 18 2.7 2.4 Peripheral Typical
 f 58 9 3.5 0 Peripheral Typical
 f 74 20 6.7 6.5 Central Atypical
 f 72 32 2.0 1.4 Central Atypical
 m 71 * 0 0 Central Typical
 f 62 27 0 0 Central Atypical
 m 60 17 6.6 6.2 Central Typical
 m 57 49 1.5 1.3 Central Typical
 m 52 21 2.8 1.9 Central Typical
 m 44 * 0 0 Central Typical
 Mean 63,3 20,7 3.0   
Conclusion: Although peripheral carcinoids may be indistinguishable 
to hamartoma at CT, the two conditions differ in FDG-PET appear-
ance. Thus, it may be possible to avoid unnecessary thoracotomy 
when a peripheral solid lesion shows absence of FDG-uptake.
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Ground glass opacity should not be included for 
measurement to determine T descriptors of primary lung 
cancers
Hida, Yasuhiro; Kaga, Kichizo; Kuroda, Aki; Miura, Hidehiko; 
Takahashi, Yasuhiro; Hirano, Satoshi; Kondo, Satoshi
Surgical Oncology, Hokkaido University, Sapporo, Japan
Background: TNM classification for primary lung cancers has been 
revised this year. It aimed to achieve a better separation of survival 
curves in each stage. T1 is divided into T1a and T1b at 2 cm, ac-
cording to historical survival data. Most of primary lung cancers 
with ground glass opacity (GGO) are bronchioloalveolar carcinomas 
(BAC) which are least invasive and are associated with an excellent 
prognosis. It has been reported that adenocarcinomas accompan-
ied with GGO are less invasive compared to those without GGO. 
There is no special rule to measure GGO. If GGO is measured as 
same as solid portion, cancers with GGO may be over-diagnosed 
for T descriptors. It might be resulted in misleading to inappropriate 
resections or adjuvant therapies. We hypothesized that T descriptors 
predict patients’ prognosis better when only solid part is measured 
and GGO part is omitted.
Methods: Primary lung cancers resected from 2000 to 2005 at Hok-
kaido University Hospital, Japan were retrospectively measured by 
either including or excluding GGO portion using CT scan. Of 248 
tumors, 140 classified as T1 were used for further analyses. 
Results: Of 140 T1 tumors, 81 were T1a and 59 were T1b. When 
only solid portion was measured, 17 T1b tumors were migrated to 
T1a due to exclusion of GGO portion for measurement. All of these 
17 cancers were adenocarcinomas. None of them had lymph node 
metastasis or recurrence. When T descriptors are determined by 
measuring only solid portion, survival curves of T1a and T1b were 
separated better than by measuring GGO with solid portion.
Conclusions: GGO should not be measured to determine T descrip-
tors.
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The correlation of thin-section CT findings with 
clinicopathological features and survival in small-sized 
lung adenocarcinoma: novel two methods using lung 
window level setting images
Ishikawa, Yoshihiro; Kondo, Tetsuro; Saito, Haruhiro; Oshita, 
Fumihiro; Ito, Hiroyuki; Tsuboi, Masahiro; Yokose, Tomoyuki; 
Kameda, Youichi; Noda, Masakazu; Yamada, Kouzo; Nakayama, 
Haruhiko
Kanagawa Cancer Center, Yokohama, Japan
Background: Distinction of non-invasive adenocarcinoma of the 
lung using the computed tomography (CT) provides valuable infor-
mation on selecting treatment procedures such as a radical sublobar 
resection. The pathological proportion of size of invasive compon-
ent to its surrounding lepedic growth component in peripheral small 
adenocarcinoma is known to be relevant to prognosis. Recently, 
assessment of clinicopathological features of such lesion by thin-
section CT (TS-CT) scan has been examined well in a various ways. 
We expected using a mediastinal window level setting (MWLS) in 
addition to a lung window level setting (LWLS) on TS-CT would 
predict its clinicopathological features more accurately.
Methods: We reviewed TS-CT scan findings and pathologic speci-
mens from 441 consecutive patients who underwent surgical resec-
tion for peripheral lung adenocarcinomas 20 mm or less in diameter 
during the period from July 1997 to May 2008. Maximal diameters of 
tumor in MWLS and LWLS were measured in all cases in increments 
of 1 mm, and two methods of assessment based on measurement were 
set; Tumor Disappearance Rate (TDR) method and MWLS method. 
TDR was calculated as following: subtraction of maximal diameter of 
MWLS from its LWLS was divided by its LWLS. Tumors with TDR 
50% or larger were classified as air-containing types (n=187) and 
those with TDR less than 50% were as solid-density types (n=254). 
MWLS method was classification by a maximal diameter of MWLS 
alone. Based on clinicopathological findings, all tumors were divided 
into two categories; invasive tumors (n=113) and non-invasive 
tumors (n=328). Invasive tumors presented pleural invasion, vascular 
invasion, lymph node involvement, and postoperative relapse, and 
whereas, non-invasive tumors did none of them. We compared TS-CT 
findings with pathological findings.
Results: By TDR method, all tumors of air-containing type were 
included in non-invasive tumors. 141 tumors of solid-density type 
were non-invasive, and 113 of solid-density type were invasive 
tumors. Sensitivity of distinction of non-invasive tumors was 57.0%, 
and specificity was 100%. By MWLS method, all tumors less than 
and equal to 6mm (n=145) were non-invasive. Tumors larger than 
6mm contained invasive tumors and its proportion was climbing up 
as diameter was getting larger. Setting a cut-off value as 6mm or 
larger, sensitivity of distinction of non-invasive tumors was 44.2% 
and specificity was 100%. Specificity was clearly equivalent between 
two methods (not significant, χ2 test), but sensitivity was statistic-
ally higher in TDR method (p<0.0001, χ2 test). The area under the 
receiver operating characteristic (ROC) curve of TDR method was 
higher than MWLS method (0.867 and 0.833, respectively).
Conclusions: Both methods were useful in detecting clinocopatho-
logically non-invasive adenocarcinomas, but TDR method was 
thought to be superior in its sensitivity.
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Expression of periostin in small peripheral lung 
adenocarcinoma: correlation with high-resolution CT 
findings, pathologic findings, and likelihood of tumor 
recurrence
Iwamoto, Ryouji 1; Fujimoto, Kiminori1; Müller, Nestor L.2; 
Fujimoto, Naoko 1; Sadohara, Junko 1; Hayabuchi, Naofumi 1; 
Takamori, Shinzo 3; Ohshima, Koichi 4; Izuhara, Kenji5
1 Department of Radiology, Kurume University School of Medicine, 
Kurume, Japan; 2 Department of Radiology, University of British 
Columbia, Vancouver, BC, Canada; 3 Department of Surgery, Kurume 
University School of Medicine, Kurume, Japan; 4 Department of 
Pathology, Kurume University School of Medicine, Kurume, Japan; 
5 Department of Molecular Sciences, Saga University School of 
Medicine, Saga, Japan
Background: Periostin is a disulfide-linked 90-kilodalton secre-
tory protein originally identified in osteoblasts which predominantly 
expressed in collagen-rich fibrous connective tissue. It has been 
considered that periostin functions as a cell adhesion molecule, but 
also promotes tumor growth and there may be helpful in determining 
tumor invasiveness and likelihood of metastases and tumor recur-
rence in small peripheral lung adenocarcinoma.
Purpose: The aim of this study was to compare the high-resolution 
CT (HRCT) features with histological assessment of small peripheral 
lung adenocarcinoma based on the immunohistochemistry stain using 
periostin for determining the CT features helpful in differentiating 
invasive tumors from non-invasive tumors and in predicting patient 
outcome.
Methods: Fifty-seven consecutive patients with a peripheral lung 
adenocarcinoma (smaller than 3-cm in diameter) who underwent 
HRCT within 2 weeks before surgery were examined. The patients 
ranged in age from 46 to 85 years (median 66 years); 30 were men 
and 27 were women. HRCT features were classified into 5 categor-
ies and were assessed by two independent expert chest radiologists 
without knowledge of histologic findings. 
For immunohistochemical detection of periostin in lung adenocarcin-
oma, resected lung tissues were fixed with formaldehyde and pro-
cessed by standard methods and they were incubated with antiperi-
ostin serum overnight at 4˚C. The expression of periostin was graded 
4-points scale as 0, 1, 2 and 3 and was assessed by two independent 
expert pathologists. Finally, immunochemistry positive for periostin 
(periostin-positive) was defined as points 2 and 3. 
Multivariate analysis was performed using the Cox proportional 
hazards model. 
Results: There were good to almost perfect agreement between the 
observers for presence and/or classification of each HRCT finding 
(kappa value = 0.73 to 1.0) and excellent agreement for the expres-
sion of periostin (kappa value = 0.81).
Periostin-positive tumors were more likely to have irregular contour 
with spicula and pleural indentation on HRCT than periostin-negative 
tumors (P < 0.001). The mean ratio of solid part area against the 
ground-glass opacity area in the periostin-positive tumors was higher 
than that of periostin-negative tumors (P < 0.01). Periostin-positive 
tumors were more likely to have lymph node metastases and post 
operative local recurrence than periostin-negative tumors (both, P < 
0.001).
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Multivariable analysis revealed that the periostin expression was 
related to likelihood of post operative local recurrence (P < 0.04; risk 
ratio 10.810; 95% CI: 1.232, 94.876) but was not related to prognosis. 
Conclusions: The results of this study support the hypothesis that the 
expression of periostin may be a significant predictor of presence of 
lymph node metastases and postoperative recurrence in patients with 
small peripheral lung adenocarcinoma. 
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Localization of pulmonary nodules with lipiodol before 
thoracoscopic surgery
Jeong, Yeon-Joo; Kim, Do-Kyung; Kim, Yeong-Dae; Kim, 
Changwon
Pusan National University Hospital, Pusan, Korea
Purpose: To evaluate the effectiveness of localization of pulmonary 
nodules with lipiodol before video-assisted thoracoscopic surgery.
Materials and Methods: After institutional review board approval 
and informed consent were obtained, lipiodol marking was performed 
under CT guidance in 35 patients (17 men and 18 women, mean 
age; 57 years) with 36 nodules. All nodules were marked with 0.5 to 
0.7 mL lipiodol under CT guidance on the day of surgery. The size 
of the targeted nodule and its distance to the closet pleural surface 
were measured. The composition of nodules (pure GGO, partly solid, 
solid) was also evaluated. Lipiodol accumulation of the targeted 
nodule was scored by using a four-point scale (0; none, 1: within 1 
cm around the nodule, 2: partly accumulation within nodule, 3; total 
accumulation within nodule). Note was made of any complications 
after localization of nodules.
Results: The average nodule size was 11.5 mm (range, 3-24 mm) 
and the average distance to the pleural surface was 10.9 mm (range, 
0-39.2 mm). Of 36 nodules, 26 (72%) were solid nodules, 9 (25%) 
were partly solid nodules, and the remaining one (3%) was pure 
GGO nodule. The scores of lipiodol accumulation of nodules were 
as follows: score 3 (n=7), score 2 (n=23), score 1 (n=4), and score 0 
(n=2). Small pneumothoraces after localization occurred in 13 (36%) 
patients. Spillage of lipiodol into pleural space occurred in two (5%) 
patients.
Conclusions: Lipiodol marking under CT guidance is a useful and 
safe procedure for the intraoperative localization of pulmonary 
nodules.
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Prognostic value of integrated FDG-PET/CT in Non-Small 
Cell Lung Cancer 
Krueger, Stefan1; Glatting, Gerhard2; Pauls, Sandra3; Reske, Sven 2; 
Buck, Andreas K.2
1 Medical Clinic I, University Clinic RWTH, Aachen, Germany; 2 
Department of Nuclear Medicine, University Clinic, Ulm, Germany; 
3 Department of Diagnostic and Interventional Radiology, University 
Clinic Ulm, Ulm, Germany
Background: The aim of this prospective clinical trial was to evalu-
ate the accuracy of combined anatomical and functional imaging with 
FDG-PET/CT for staging lung cancer and for prediction of long-term 
survival. 
Methods: 205 pts with histologically proven non-small cell lung 
cancer were included. All pts underwent whole body FDG-PET/CT 
imaging using a GE Discovery LS hybrid scanner. CT, FDG-PET and 
fused PET/CT images were used for evaluation of tumour stage ac-
cording to the TNM and UICC classification system. Histopathology 
served as reference in 87 pts undergoing resective surgery. 118 pts 
received palliative treatment. Median follow-up was 950 days (range, 
6 - 1710 days). 
Results: On a patient basis, the sensitivity of PET/CT for detecting 
N1 lymph nodes was 38% (specificity 96%, accuracy 88%), and for 
N2 lymph nodes 67% (89%, 86%). For differentiation between nodal 
positive (N1, N2, N3) and negative (N0) pts, the sensitivity of PET/
CT was 74%, the specificity 92% and the accuracy 86%. For differen-
tiation of operable (UICC stage I-IIIa, <N2) vs. inoperable pts (UICC 
stage IIIa, =N2; UICC stage IIIb-IV) the accuracy of PET/CT was 
96%. After a median follow-up of 950 days, pts with operable tumour 
stage at PET/CT subsequently undergoing resective surgery had a 
favourable outcome and did not show significantly reduced survival. 
However, in pts staged as having UICC stage IIIb-IV undergoing 
palliative treatment, median overall survival was as low as 334 days 
(p<0.0001, hazard ratio 0.32). 
Conclusion: Combined FDG-PET/CT imaging offers high accuracy 
for tumour staging, differentiation of operable vs. inoperable pts and 
is a strong predictor of survival in pts with non-small cell lung cancer.
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Detection of hypoxia and blood flow using PET and CT 
scans in patients with advanced non-small cell lung cancer 
receiving chemotherapy with and without bevacizumab: 
Preliminary findings
Laskin, Janessa J.1; Wilson, Don1; Murray, Nevin1; Sun, Sophie1; 
Bally, Marcel2; Skov, Kirsten2; Ruth, Thomas3; Adam, Michael3; 
O’Dwyer, Helena1; Benard, Francois1; Yapp, Donald2
1 British Columbia Cancer Agency, Vancouver, BC, Canada; 2 British 
Columbia Cancer Research Centre, Vancouver, BC, Canada; 3 
University of British Columbia TRIUMF-PET Program, Vancouver, 
BC, Canada
Background: Hypoxia is associated with genetic instability and 
increased resistance to radiation and chemotherapy. Animal models 
suggest hypoxia may be an important prognostic and predictive factor 
in NSCLC. Antiangiogenic drugs and standard chemotherapy may 
alter tumour blood flow and oxygenation but this has never been 
demonstrated in living patients (pts) on active treatment. This study 
uses PET/CT scanning with the radiotracer 18F-EF5 (a nitroimi-
dazole) that is preferentially taken up by hypoxic tissues to measure 
oxygenation, and perfusion CT scanning (GE Advantage workstation) 
to noninvasively quantify tumour blood flow and oxygenation before, 
during, and after chemotherapy (with and without bevacizumab) in 
patients with advanced NSCLC.
Methods: Eligibility includes pts with incurable stage III/IV NSCLC 
who are to receive first-line platinum-based doublet chemotherapy 
alone or in combination with bevacizumab (as part of other clinical 
trials). No prior radiation is permitted. 20 pts will be enrolled: 10 
treated with chemo alone and 10 with chemo plus bevacizumab. At-
tempts will be made to match patients for age, stage and chemother-
apy regimens; there is no randomization. Each pt will have 4 sets of 
scans (18F-EF5 PET and perfusion-CT): baseline, at day 15 of cycle 
1, after 4 cycles of therapy, and at the time of disease progression.
Results: Since Oct 2008, 3 pts have been enrolled; 2 on chemo alone 
and 1 on chemo plus bevacizumab. 2 pts have undergone 3 sets of 
scans – before, day 15 and after 4 cycles. All pts had quantifiable 
hypoxia in their primary tumours at baseline and notable changes 
in oxygenation and tumour perfusion on the day 15 and cycle 4 
scans. Differences in hypoxia levels have been detected between the 
primary tumour and local lymph nodes. In this limited data set, in 
the 2 pts who have had day 15 CTs there has been a near doubling of 
blood flow to the central tumour mass and corresponding decreases in 
hypoxia on the corresponding 18F-EF5 PET scans compared to their 
baseline scans. 
Conclusions: Antiangiogenic strategies and chemotherapy alone 
may significantly impact tumour oxygenation and blood flow. In the 
limited studies done so far there have been clear changes in tumour 
blood flow and hypoxia, many more scans are underway. This study 
represents the first non-invasive documentation of lung cancer oxy-
genation and changes with therapy suggesting that hypoxia may be an 
important predictive and prognostic factor for NSCLC.
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Changes on the chest CT with lung cancer patients during 
and after treatment; Clinicoradiological correlation is 
essential for diagnosis
Lee, Choong Wook; Jang, Yu Mi; Do, Kyung-Hyun
Department of Radiology, Asan medical center, University of Ulsan 
College of Medicine, SongpaGu, Korea
Purpose: 
1.  To classify various abnormalities that could be encountered in 
lung cancer patients during treatment 
2.  To understand abnormal radiological finding on chest CT with 
clinical viewpoint and pathologic correlation. 
3.  To give a clinical and radiological clue for narrowing the differ-
ential diagnosis.
Contents:
1. Opportunistic infection: viral, bacterial, tuberculosis, pneumocys-
tis jiroveci etc.
2. Drug related lung disease 
A. Chemotherapeutic agents: Cisplatin, Gemcitabine, Vinorel-
bine, Paclitaxel, Irinotecan, Etoposide(VP-16), Rituximab, 
Gefitnib (iressa) etc. 
B.  Disease pattern: Interstitial lung disease, pulmonary edema, 
pulmonary hemorrhage, airway disease, pleural change, vas-
cular change. 
3.  Radiation related change 
4.  Change of lung cancer itself
Conclusion: 
1. Changes of radiological findings on chest CT during treatment for 
lung cancer are variable. Causes of the change include opportun-
istic infection, drug and radiation related lung disease and change 
of lung cancer itself. 
2.  Recognition of the clinical and radiological features of the vari-
ous complications that may occur during and after treatment is 
critical for the prompt diagnosis and tailored therapy.
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Prognostic value of FDG uptake in early stage NSCLC 
Lee, Shih-Chun; Chen, Jen-Chih; Chang, Hung; Cheng, Yeung-
Leung; Ching, Tzao; Huang, Wen-Shen
Tri-Service General Hospital, Taipei, Taiwan
Aim: To assess whether the standard uptake value of primary lung 
tumor differs between stage I and non-stage I non-small cell lung 
cancer.
Methods: We retrospectively reviewed the 163 patients with non-
small cell lung caner who underwent surgical resection from 2003 
and 2006 June. Patients of clinical stage I with pre-operative FDG-
PET-CT scan underwent R0 resected non-small cell lung cancers 
were included. Suspicious nodal stations were tissue proved before 
operation. Patients were proved with N2 diseases were excluded. 
These entire patients underwent complete lymph nodes dissection 
after anatomic resection. We reviewed the clinical features of 55 
patients with an average follow-up of 24 months. 
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Results: The clinical features between 36 patients of stage I non-
small lung cancer and 19 patients of non-stage I non-small cell lung 
cancer analyzed. In non-stage I group, stage II: 8 patients; stage III: 
7 patients; stage IV: 4 patients. There were no statistical differences 
in sex, age, tumor size, histological type, location, and differentia-
tion of tumor between stage I and non-stage I groups. In the stage I 
group, patients had lower SUVmax (4.9± 2.7 vs 8.1 ± 3.8, P=0.001). 
In multiple logistic regression, the Patients with higher SUVmax 
and higher serum CEA level in pre-operative work-up are predicted 
with advanced pathological stage after operation (SUVmax ≥4.7, 
Odd ratio: 7.65; CEA ≥3.5ng/ml, Odd ratio: 8.39 respectively). The 
median SUVmax in this study was 4.7. The High FDG uptake was 
significantly associated with reduced median survival (62.69 months 
for SUVmax<4.7 and 40.89months for SUVmax ≥4.7) 
Conclusions: High FDG uptake was significantly associated with 
reduced overall survival of patients with completed resected clinical 
stage I patients. SUVmax and serum CEA level might help preopera-
tively considering patients for induction therapy or surgical interven-
tion. Despite without correlation with pathology type, PET SUVmax 
of tumor demonstrates biological aggressive and in vivo virulence
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Monitoring neo-adjuvant chemotherapy (antiangiogenic 
therapy) in lung cancer: Predictive value of perfusion CT 
in evaluating response
Mahajan, Abhishek; Sripath, Smiti; Rao, Vrk; Vidyasagar, M S.
Indian Medical Council, Manipal, India
Perfusion CT tool is helpful in oncology, providing a higher degree 
of diagnosis security and can predict in vivo pre and post treatment 
tumor response. We correlated changes in CT Perfusion (CTp) param-
eters following neo-adjuvant chemotherapy (NAC, bevacizumab and 
ipilimumab) with changes of tumor perfusion and evaluated whether 
baseline CTp can predict tumor volume changes following ther-
apy. 102 patients with lung malignancies undergoing neo-adjuvant 
chemotherapy (bevacizumab and ipilimumab) ± radiotherapy were 
prospectively enrolled in the study. From our results we concluded 
that, consensual change of tumor volume and CTp parameters fol-
lowing NAC shows the potential of CTp for monitoring such therapy. 
Criterions such as high BF and BV and low MTT may predict high 
tumor volume reduction following therapy.
  BLOOD BLOOD MEAN TRANSIT TIME PEAK ENHANCED 
  FLOW VOLUME TIME TO PEAK INDEX
 RESPONDER HIGH HIGH LOW LOW HIGH
 NONRESPONDER LOW LOW HIGH HIGH LOW
 P VALUE < 0.05 < 0.05 < 0.05 > 0.05 > 0.05
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A pilot study of Percutaneous perfusion CT-guided biopsy 
of lung nodules: Does it really make a difference?
Mahajan, Abhishek; Sripath, Smiti; Rao, Vrk
Indian Medical Council, Manipal, India
The study aimed at: To explore the value of 64-detector CT perfu-
sion imaging in guiding biopsy of pulmonary lumps. To assess the 
achievement ratio of biopsy, the accuracy in grouping and grading of 
lung cancer. To compare the incidence of complications in patients 
undergoing perfusion guided biopsy vs routine CT guided biopsy. 
CT guided biopsy was performed on 279 patients with pulmonary 
lumps between May 2006 and Dec 2008. The patients were divided 
into 3 groups: 73 cases guided by CT perfusion imaging as group I, 
87 cases guided by contrast-enhanced CT as group II, and 119 cases 
guided by plain CT as group III. The achievement ratio of biopsy, the 
accuracy in grouping and grading of lung cancer and the incidence of 
complication were compared. From the results we concluded that CT 
perfusion imaging guided biopsy of pulmonary lumps using 64-detec-
tor CT has a potential to improve the accuracy of histopathological 
diagnosis with lower risk and higher achievement ratio, but more 
research and technical improvements are needed before it is widely 
used.
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Lung perfusion CT: its predictive value in characterizing 
and differentiating Benign vs. Malignant cavitary mass
Mahajan, Abhishek; Sripath, Smiti; Rao, Vrk
Indian Medical Council, Manipal, India
We evaluated lung perfusion maps based on region of interest 
(ROI)-studies in the differentiation of cavitary mass and assessed 
the predictive value of perfusion map parameters in differentiating 
cavities. 63 histopathologically proven lung cavitary masses were 
examined with 64-detector row CT. Except for MTT (mean transit 
time), which was statistically lower in malignant cavities (p <0.05), 
all CTP (CT perfusion) parameters values were significantly higher 
in malignant cavities when compared with the benign cavities (P <0 
.05). The ratios of BF (blood flow), BV (blood volume), MTT, PEI 
(peak enhanced index) and TTP (time to peak) parameters between 
malignant and benign cavities were statistically significant (p <0.05). 
In conclusion, lung perfusion CT is a promising and feasible method 
for distinguishing benign from malignant cavity. Thus, it could be 
very beneficial in allowing for noninvasive diagnoses of cavitary 
mass and in planning the proper therapeutic planning.
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Interval Computerised Tomography (CT) scanning to 
evaluate and monitor Solitary Pulmonary Nodules (SPNs) 
- the patient experience
Milroy, Robert1; Downer, Penny2; Davidson, Scott1; Sarvesvaran, 
Joseph1; O’Neill, A3
1 Department of Respiratory Medicine, Stobhill Hospital, Glasgow, 
UK; 2 NHS Greater Glasgow and Clyde Healthcare, Glasgow, UK; 3 
University of Glasgow, Glasgow, UK
Introduction: CT scans of thorax are performed for a variety of 
reasons including the investigation of suspected pulmonary embolism 
or cancer. Such scans can reveal unexpected findings, including the 
Solitary Pulmonary Nodule (SPN).
Radiologically it is difficult to determine if an SPN has a benign or 
malignant cause. Patients may require up to 2 years of repeat scans at 
intervals to monitor a nodule.
At any one time, 20-30 patients are undergoing interval CT scanning 
at this institution (Stobhill Hospital).
The authors’ wished to assess what effect prolonged investigation had 
on individuals facing a potentially serious diagnosis.
The aims of this research were:
• To describe patients’ experiences of prolonged investigations, 
• To identify patients’ concerns and stressors during this period 
• To determine information and support needs during this period.
Methods: A descriptive qualitative approach was utilised. Five 
participants (62 – 78 years) were interviewed. Each was interviewed 
once using a semi-structured format. The interview transcripts were 
analysed using content analysis to identify common themes.
Findings: The main themes identified were scan experience, uncer-
tainty and concern, coping strategies and communication. These find-
ings suggest that patients were not unduly concerned by the CT scans 
but that the prolonged period of investigation results in considerable 
stress and uncertainty not just for the patient but also for their carers.
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Correlation of maximum FDG uptake on PET with TS-CT 
findings, pathological invasive area, and Ki-67 index in 
lung adenocarcinomas 30 mm or less in size
Murakami, Shuji; Saito, Haruhiro; Sakuma, Yuji; Kondou, Tetsuro; 
Oshita, Fumihiro; Yokose, Tomoyuki; Kameda, Youichi; Suga, 
Yasuhiro; Ito, Hiroyuki; Tsuboi, Masahiro; Nakayama, Haruhiko; 
Noda, Kazumasa; Yamada, Kouzo
Kanagawa Cancer Center, Yokohama, Japan
Background: 18F-fluorodeoxyglucose positron emission tomography 
(FDG-PET) is commonly used to distinguish benign from malignant 
lesions. The validity of FDG-PET as a diagnostic procedure for 
small-size lung cancer (≤ 30 mm in diameter) remains controversial. 
The purpose of this study is to evaluate the correlation of maximum 
pixel standard uptake value (maxSUV) with maximum diameter 
on mediastinal window CT images, Ki-67 index, and pathological 
invasive area. Ki-67 index and pathological invasive area greater than 
5 mm are known as molecular markers of tumor proliferation.
Patients and Methods: Thin-section CT (TS-CT) and FDG-PET 
were performed on 140 patients with resectable lung adenocarcin-
omas ≤ 30 mm in diameter between March 2006 and May 2008. 
Tumors were classified as air-containing type or solid-density type 
based on whether the ratio of the maximum tumor diameter on 
mediastinal windows to the maximum diameter on lung windows was 
more or less than 0.5, respectively. In all cases, resected specimens 
were used to assess the diameter of the pathological invasive area 
of each tumor and the Ki-67 index, and to diagnose the presence of 
intratumoral lymphatic or vascular invasion and pleural involvement 
as markers of proliferative activity. 
Results: Air-containing type tumors were found to have lower 
maxSUV than did solid-density tumors (0.97 vs. 3.96, respectively). 
In solid-density type tumors, maxSUV positively correlated with 
the maximum tumor diameter on mediastinal window CT images, 
Ki-67 index, and diameter of the pathological invasive area. Among 
these relationships, maxSUV correlated most significantly with the 
diameter of invasive area (r=0.672, p<0.0001). The cut-off value of 
maxSUV for predicting an invasive area over 5 mm in diameter was 
determined as 2.15 by ROC analysis, with sensitivity of 88.3% and 
specificity of 84.6%. Lymphatic invasion, vascular invasion, and 
pleural involvement were more frequently found in adenocarcinoma 
with maxSUV greater than 2.15 than in adenocarcinoma with max-
SUV less than 2.15 (66 vs. 15%, respectively).
Conclusion: Small solid-density adenocarcinoma ≤ 30 mm in 
diameter was detectable by FDG-PET. The amount of FDG-uptake 
on PET, as measured by maxSUV, was strongly correlated with the 
expression of Ki-67 and the histopathological maximum diameter 
of the invasive area, both of which are known as markers of tumor 
proliferation. Tumors with invasive size less than 5 mm in diameter 
are reported to have good prognosis; a small component of invasive 
area in the absence of lymphatic metastasis does not adversely af-
fect prognosis in comparison with true bronchioalveolar type. The 
results of the present study suggest the potential role of FDG-PET in 
predicting adenocarcinomas with invasive area greater than 5 mm for 
solid-density type tumors.
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Exploratory trial evaluating the role of Magnetic 
Resonance Imaging and Perfusion Weighted Imaging in 
assessing the effect of sunitinib on brain metastases in 
patients (pts) with Non Small Cell Lung Cancer
Novello, Silvia1; Capelletto, Enrica1; Sardo, Diego2; Rapetti, 
Simonetta Grazia1; Crida, Benedetta1; Giaj Levra, Matteo1; Longo, 
Marina1; Fava, Cesare2
1 University of Turin, Orbassano (Turin), Italy; 2 University of Turin, 
Radiologic Dept AUO San Luigi Orbassano, Turin, Italy
Background: Metastatic disease to the brain is the commonest 
intracranial neoplasm in adults and in lung cancer brain metastases 
(mts) are frequently reported at diagnosis or at relapse, ranging from 
35 to 60% of all cases. Therapeutic approaches for brain mts include 
surgery, whole brain radiotherapy (WBRT), stereotactic radiosurgery 
and chemotherapy. Targeted therapies such as epidermal and vascular 
endothelial growth factor inhibitors (Soffietti R. et al. Curr Opin 
Oncol 2008) are currently investigated in non-small cell lung cancer 
(NSCLC) pts with brain mts and have showed activity in this setting. 
Traditional morphologic measures of efficacy may not be appropri-
ate to evaluate the activity of targeted agents. This exploratory trial 
aimed to evaluate the role of magnetic resonance imaging (MRI) 
and perfusion weighted imaging (PWI) in predicting response and 
survival in pts with NSCLC and brain mts treated with sunitinib, an 
oral multitargeted tyrosine kinase inhibitor with promising activity in 
previously treated NSCLC (Socinski M. et al. J.Clin. Oncol. 2008).
Materials and methods: From April 2007 to August 2008 we 
enrolled 12 NSCLC pts with asymptomatic brain mts (9 males, 
42% adenocarcinoma, median age 58 years) consecutively treated 
in a clinical trial testing sunitinib in different lines of treatment. Pts 
started single agent sunitinib 37.5 mg/daily continuous dosing after 
WBRT and were evaluated using overall (RECIST) and intracranial 
tumor assessment with CT scan and MRI (1.5 T Philips Achieva, 
dynamic susceptibility contrast imaging technique), respectively. 
Nine pts were evaluated with PWI: for every pts the longest diameter 
and the perfusional status of each brain lesion was assessed. We ana-
lysed the correlation between the average value of the sum of longest 
diameter of all intracranial lesions and median perfusional varia-
tions (Δdiam/ΔrrCBV-relative regional Cerebral Blood Volume) of 
brain mts at baseline and after 4 wks of treatment and the correlation 
between progression free survival (PFS) and the median perfusional 
variations in the same period of time (PFS/ΔrCBV). Statistical analy-
sis were performed using the Pearson test (1-tailed test).
Results: 
 pt Number of Diameter Diameter rrCBV rrCBV Δdiameter ΔrrCBV PFS 
  brain mts Baseline after 4 wks Baseline after 4wks   (wks)
 1 2 6,60 6,00 2,46 2,42 -0,60 -0,04 7,7
 2 3 15,70 14,30 1,56 2,09 -1,40 0,53 7,9
 3 3 7,10 7,30 5,38 2,19 0,20 -3,19 15,6
 4 21 7,40 6,10 3,50 3,12 -1,30 -0,38 11,9
 5 6 20,10 17,30 7,53 4,53 -2,80 -3,00 17,3
 6 2 7,90 10,30 2,80 7,15 2,40 4,35 8,0
 7 3 10,60 11,10 2,76 2,87 0,50 0,11 23,4
 8 5 6,80 5,80 3,82 3,08 -1,00 -0,74 15,6
 9 3 20,20 18,40 12,35 4,37 -1,80 -7,98 34,9
Δdiam/ΔrrCBV showed a Pearson’s coefficient of 0.647 (p-value 0.03) with a R-square of 0.419. PFS/
ΔrrCBV showed a Pearson’s coefficient of -0.801 (p-value 0.005) with a R-square of 0.641. 
Conclusions: These very preliminary results suggest a role of PWI 
as a surrogate end-point of antiangiogenic drug activity and its role 
as a predictive test. Considering the increasing interest in functional 
bio-imaging in NSCLC, this technique should be evaluated in larger 
prospective trials.
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Cancer targets: The Impact of PET-CT on the lung cancer 
patients journey
O’Dowd, Caroline A.; Davidson, Scott
Southern General Hospital, Glasgow, UK
Introduction: The accurate staging of disease is vital in the man-
agement of patients with non small cell lung cancer (NSCLC). The 
introduction of functional imaging with integrated positron emission 
tomography - computed tomography (PET-CT) has improved the 
staging of NSCLC and may result in changes in clinical manage-
ment1,2. National guidelines state that all patients with potentially 
radically treatable disease should undergo PET-CT, to exclude medi-
astinal or distant disease, prior to definitive treatment 3, 4. 
The introduction of the urgent 62 day ‘referral to treatment’ target in 
Scotland has been a positive step forward for patients with suspected 
Lung cancer,5. Introducing this new, multiregional, investigation to 
the investigative pathway has been an obvious challenge to these 
targets. Our audit examines the impact of PET-CT scanning on our 
patient population with respect to TNM staging and overall manage-
ment when compared to traditional staging techniques as well as its 
effect on the waiting times targets.
Methods: ll patients from our unit who had undergone PET-CT scan 
were included, May ‘07 -Nov ‘08. Results of CT scan, PET-CT scan 
and overall outcome were obtained. TNM stage, changes to stage, 
time lag between CT and PET-CT and details of incidental findings 
were recorded.
Results: 77 PET-CTs were included. 73% were done to confirm stage 
of disease prior to treatment.
46% (35/77) of patients had a change in TNM stage following PET-
CT. Stage was unchanged in 42% (32/77) and cancer excluded in 
12%(10/77). Of those with changes to staging 74% (26/35) had their 
disease upstaged, precluding radical treatment in 65% (17/26). In 
those downstaged, 75% (6/8) changed from incurable to potentially 
curable disease. 
Median time interval between CT thorax and PET-CT was 30 days 
(range 12-112), although this improved over time. 38%(29/77) 
breeched the 62-day target, with most lengthy delays due to patient 
specific problems.
34% (26/77) had incidental findings on PET-CT, of which 65% 
recommended further investigation. Further investigation confirmed 
abnormality in only 27%(7/26).
Conclusion: This audit demonstrates the importance of the PET-
CT in the investigation of lung cancer. It highlights the challenge of 
introducing an essential investigation within Government waiting 
time targets and the impact it has on treatment planning. Multidisci-
plinary teams must be aware of these factors and build PET-CT into 
their Lung Cancer protocols accordingly.
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Will PET-CT imaging reduce our surgical resection rate 
for NSCLC?
Featherstone, Carolyn1; Paterson, Claire1; Han, Sai2; Gunaseelan, 
Vidhya3; Jones, Richard1
1 Beatson, West of Scotland Cancer Centre, Glasgow, UK; 2 PET/CT 
Department, Beatson West of Scotland Cancer Centre, Glasgow, UK; 
3 West of Scotland Managed Clinical Networks for Cancer, Glasgow, 
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Background: Accurate staging for non small cell lung cancer 
(NSCLC) is vital to ensure that patients undergo appropriate interven-
tion for the stage of their disease, both to try to improve poor survival 
rates and to prevent futile therapy in patients who have already 
developed metastatic disease. 18FDG PET-CT allows more accur-
ate staging of nodal and metastatic disease. In the West of Scotland, 
where surgical rates and overall survival are already low, there was 
concern that this new modality may further reduce the number of 
patients treated with radical intent.
United Kingdom guidelines suggest that all patients who are candi-
dates for surgery or radical radiotherapy should undergo an 18FDG 
PET-CT prior to treatment. We look at the initial experience of a new 
PET-CT centre in the West of Scotland. 
Methods: From April to July 2008, all patients referred to the 
Beatson West of Scotland Cancer Centre PET-CT department with 
NSCLC for assessment prior to radical treatment were identified. 
If surgery was subsequently performed, pathological staging was 
recorded. Where thoracic radiotherapy was administered, treatment 
intent was noted. The proportion receiving other palliative treatments 
was also noted.
Comparison was made between CT, PET-CT and pathological sta-
ging. 
The number of patients with NSCLC who underwent radical treat-
ment in 2006, prior to routine PET-CT scanning, was obtained.
Results: 144 patients with a diagnosis, or suspected diagnosis, of 
NSCLC underwent an 18FDG PET-CT scan prior to radical treat-
ment.
18FDG PET-CT stage was consistent with CT for 73(50%) patients, 
with 50 (35%) and 21 (15%) being upstaged and down staged 
respectively. Upstaging was more frequent for unsuspected nodal 
disease (n=29) than distant metastases (n= 14). T stage was increased 
in 7 patients after PET-CT.
94 (65%) patients went on to receive radical treatment. 59 (41%) 
patients underwent surgical resection. 35 (24%) patients underwent 
radical radiotherapy. A further 20 (14%) patients underwent pallia-
tive chest radiotherapy. The remaining 30 patients may have received 
other palliative treatments including chemotherapy, whole brain 
radiotherapy and palliative radiotherapy to bone metastases.
In the 59 patients who underwent surgical resection PET-CT and 
pathological staging were identical in 27 (46%) patients. The patho-
logical staging was more advanced than PET-CT in 15 (26%) and 
less advanced in 10 (17%). Wedge resections only were carried out in 
3 patients so lymph node status was not assessed pathologically. No 
malignancy was found in 4 patients who underwent surgical resection 
of a suspected NSCLC.
59 patients underwent surgical resection over the examined 3 month 
period. This is comparable to the 226 patients with NSCLC who had 
surgery in 2006 prior to introduction of PET-CT.
Conclusion: In a region where radical treatment rates are already 
low, there was concern that PET-CT staging may further reduce 
our proportion of NSCLC patients undergoing surgical resection or 
radical radiotherapy. This audit would suggest that it has not changed 
our surgical resection rates.
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Incidental head and neck FGD-PET findings during 
NSCLC Staging: Are further investigations necessary? 
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Background: PET/PET-CT is routinely performed as a non-invasive 
staging investigation for patients with suspected Non-Small Cell 
Lung cancer (NSCLC). However, unexpected extra-thoracic FDG 
uptake is a common occurrence, and may present a dilemma to the 
thoracic surgeon. Head and neck FDG uptake is of particular concern 
since lung cancer, and cancers of the upper aerodigestive tract share 
many of the same risk factors. The goal of this study is to review the 
management of incidental non-thyroidal head and neck findings at 
our institution, and how those findings impact healthcare, and course 
of treatment in patients with NSCLC.
Methods: All initial PET scans for lung cancer staging performed 
from October 2002 to May 2008 were reviewed. Those with un-
expected non-thyroidal head and neck findings were identified. In 
those with biopsy proven NSCLC, clinical and pathological courses 
were followed. Data collected included demographics, location of 
PET findings, clinical presentation, investigations, and time to defin-
itive treatment for NSCLC.
Results: 1520 PET/PET-CT scans were reviewed. From those, 31 
(2%) scans demonstrated head and neck abnormalities. In this group 
of 31, 22 patients had proven NSCLC. 16 (72%) of the NSCLC pa-
tients were investigated for their incidental head and neck PET find-
ing. 6 (27%) went on to have a biopsy. 2 (9%) patients were shown to 
have a squamous cell carcinoma of the head and neck, one of which 
was a recurrence of a previously treated SCC. The other patient with 
SCC had frank clinical evidence of a head and neck tumor. Of the 
remaining biopsies, 3 (14%) demonstrated hyperplasia of lymphatic 
tissue and 1 (4.5%) biopsy yielded normal tissue. Those patients with 
incidental findings that had no investigations were unaffected by 
any head and neck pathology through their period of follow up for 
NSCLC. There was a significant increase (p < 0.01) in time to treat-
ment for NSCLC in those patients with incidental head and neck PET 
findings compared to patients with no incidental findings. Mean time 
to treatment after PET in these two groups was 99.6 and 52.1 days 
respectively.
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Conclusions: Incidental non-thyroidal head and neck findings on 
PET/PET-CT are uncommon, and rarely represent significant pathol-
ogy. In this subset of patients, PET has high false positive and low 
negative predictive values. We conclude that NSCLC patients with 
incidental head and neck findings should be followed up with focused 
history and physical exam; however, investigations for these findings 
should not take precedence over treatment for a known NSCLC. 
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18FDG-PET in lung cancer: relationship between 
histology, stage and EGFR with metabolic activity 
Rolfo, Christian Diego; Valero, Marta; Fuertes, Silvia; Arrivi, 
Antonio
Clinica Rotger - Oncology Unit, Palma de Mallorca, Spain
Background: 18FDG-PET is a diagnostic and monitoring tool wide-
ly used in patients with lung cancer. The uptake value (SUVmax) has 
been identified as a prognostic factor in these patients. We analyzed 
the relationship among histology type, stage and tumor metabolic 
activity in patients with lung carcinoma.
Materials and methods: We retrospective analyzed 115 patients 
diagnosed at our institution with lung carcinoma. All patients had a 
18 FDG-PET during his illness. Patients were classified
according to histology as SCLC and NSCLC (adenocarcinoma, 
squamous, large cell and unclassified NSCLC) and stage (according 
to the AJCC staging group). The analysis of the 18 FDG-PET images 
was performed both qualitatively and quantitatively (calculating the 
SUVmax in the different sites of disease). In a subgroup of NSCLC 
patients EGFR determination was preformed.
Results: 115 patients were analyzed: 10 (8.7%) had SCLC and 105 
(91.3%) NSCLC of which: 55.24% had BAC and adenocarcinoma, 
squamous 12.38%, 13.33% large cell undifferentiated and 19.5% 
unclassified NSCLC. Staging was: 5.24% IA, 8.33% IB, 7.40% IIA, 
11.11% IIB, 9.25% IIIA, 14.81% IIIB and 43.52% Stage IV. The 
median SUVmax in lung was 8.52 (2 -25) in adenocarcinoma, 12.53 
(6.9 -19.5) in squamous, 8.17 (3-19,4) in large-cell / undifferentiated, 
9.68 (1,60-24,5) NSCLC unclassified and 5.9 (0.8-11.9) in SCLC. 
ANOVA analysis between histology and metabolic activity in the 
lung showed statistically significant differences(p <0.05) for every 
histological subgroup and also between NSCLC and SCLC. No 
statistically significant relationship was found between the 18FDG 
uptake in other locations than lung and histology. The the average 
level of uptake in the lung for all stages was statistically significant 
(p< 0,005).In 44 patients with NSCLC EGFR was determined and 
20.45% had the mutation. We found no statistically significant differ-
ences in SUVmax between mutated and non mutated patients.
Conclusions: Our study points a relationship between tumor histol-
ogy and staging and metabolic activity in the lung. EGFR expression 
does not seem to have a direct relationship with the degree of 18FDG 
lung uptake. Further studies are necessary to corroborate our findings.
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Objective: Recent advances in computed tomography (CT) have 
increased the incidences of detecting minute lesions in peripheral 
lung fields. Nodule and ground-glass opacity (GGO) findings are 
generally recognized as initial CT findings of lung cancer. In clinical 
situations, we sometimes run across scar-like lesions on CT images. 
Some of these lesions grow in size and are pathologically diagnosed 
as invasive cancer (JCAT 33:42,2009). The purpose of our study was 
to evaluate lung cancer, which has been diagnosed as scar-like lesions 
on initial CT images.
Method: We retrospectively reviewed 39 cases (dating back from 
1998 to 2008) of lung cancer, which had been diagnosed as scar like 
lesions on initial CT images. We studied follow-up CT images and 
noted changes and developments. The pathological diagnosis was 
confirmed by surgical resections in every case. We evaluated the 
initial CT findings, and the clinicopathological characteristics. Cases 
involving 16 nodules and 36 GGO-like lesions were investigated and 
compared with scar-like lesions. The shortest interval between initial 
and follow-up CT scans was determined to be three months. 
Result: In the scar-like group, 26 patients had findings of emphy-
sema, fibrosis, or old inflammatory damage in background lung fields 
on initial CT images. The other 13 patients had no significant find-
ings. The scar-like group had a higher rate of background lung field 
findings than the other two groups (p<0.05). The mean Brinkman 
index of the scar-like group (696) was higher than the GGO (281) 
and nodule (349) groups (p<0.05). The mean tumor doubling time 
(TDT) of scar-like group (322 days) was higher than the GGO group 
(1313 days) (p<0.05). Of 39 cases, 29 cases of adenocarcinoma were 
diagnosed, including 3 bronchioloalveolar carcinomas (BAC) and 
26 other adenocarcinomas. The remaining 10 cases were non-adeno-
carcinomas. The rate of BAC, which is non-invasive carcinoma, ac-
cording to the WHO classifications was lower in the scar-like and the 
nodule groups than in the GGO group (p<0.05). The rate of positive 
findings of pleural, vascular, or lymphatic invasion, in the scar-like 
group (56%) was higher than the GGO group (0%) (p<0.05). The 
5-year survival rates for the scar-like, nodule, and GGO groups were 
57%, 76% and 100%, respectively. In comparison with the GGO 
group, the 5-year survival rate for the scar-like group was statistically 
lower (p<0.05). 
Conclusion: Lung cancer diagnosed as scar-like lesions on initial CT 
images tend to occur more often in patients whose background lung 
field have findings. In these cases, a tendency of short tumor doubling 
time was noted. Some cases of invasive carcinomas have a poor 
prognosis. Although it is difficult to diagnose these lesions on initial 
CT images, a careful follow-up examinations can result in a better 
prognosis.
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Analysis of false-positive mediastinal lymph nodes on 
FDG-PET findings in squamous cell lung carcinoma
Shigematsu, Hisayuki; Andou, Akio; Mastuo, Kiyoshi; Higashi, 
Ryohei
NHO Okayama Medical Center, Okayama, Japan
Background: Preoperative accurate staging of mediastinal lymph 
nodes is an important factor for considering the indication for sur-
gical resection in patients with non-small cell lung cancer (NSCLC). 
Although positron emission tomography (PET) with 18F-fluoro-
deoxyglucose (FDG) has been widely applied for the evaluation of 
preoperative staging, the discrepancies between clinical stage based 
on FDG-PET and pathological stage after surgery still remain in some 
patients with NSCLC. We focused on the factors related to false-
positive mediastinal lymph nodes in patients with squamous cell lung 
carcinoma.
Methods: We reviewed 20 patients with squamous cell lung carcin-
oma who underwent FDG-PET preoperatively between November 
2006 and March 2009. All patients underwent complete lung resec-
tions and systematic lymph nodes dissection and resected lymph 
nodes were histologically examined.
Results: This study comprised 19 males and one female aged 54-86 
years. In 15 (75%) of 20 patients, the mediastinal staging was cor-
rectly diagnosed. Four cases were shown to be false positive (Table 
1) and one case was shown to be false negative. All false positive 
cases were male gender and smoker. All tumors were categorized as 
clinical-T2 or T3 and tumor localization was central part (proximal to 
segmental bronchus). Two of four false positive patients underwent 
mediastinoscopy before surgical resection and no mediastinal metas-
tases were identified. One patient proceeded directly to thoracotomy 
because of single N2 node and the other because of obstructive pneu-
monia with atelectasis. All false positive patients received adjuvant 
chemotherapy and are alive without recurrence at 9 to 21 (mean 12) 
months after surgical resection.
Conclusions: To avoid the unnecessary chemo-radiotherapy and the 
potential denial for a curative surgical resection, mediastinoscopy is 
mandatory in patients with T2 or T3 tumor located in the central part 
(proximal to segmental bronchus) in squamous cell lung carcinoma.
Table 1. False positive FDG-PET findings in squamous cell lung carcinoma
 No. Age/Gender c-TNM c-Stage p-TNM p-Stage Surgical Procedure Outcome
 1 57/M 320 IIIA 200 IB RUL Alive at 21 months
 2 68/M 220 IIIA 200 IB RUL Alive at 10 months
 3 54/M 320 IIIA 210 IIB Mediastinoscopy--->RML Alive at 9 months
 4 57/M 220 IIIA 200 IB Mediastinoscopy--->LLL Alive at 9 months
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Variation of CT perfusion (CTP) parameters in different 
histological types, sizes and tumors with necrosis in 
patients with lung carcinoma in a tertiary referral hospital 
in southern India – our initial experience 
Sripathi, Smiti; Mahajan, Abhishek; Rao, Vrk
Kasturba Medical College, Manipal, India
Introduction: Perfusion CT is a new technology that allows 
measurement of tumor vascular physiology. An increasing number 
of vascular-modulating drugs are used in the treatment of cancers, 
which in turn increase demand for noninvasive methods of assessing 
tumor vascularity in vivo. Apart from being noninvasive and fast, it 
can be repeated at regular intervals to assess tumor response to anti-
angiogenic therapy
Purpose: To analyze the variation of CT perfusion (CTP) parameters 
in different histological types, sizes and tumors with necrosis in 
patients with lung carcinoma.
Material and Methods: It’s an ongoing study in which 69 cases with 
histopathologically proven lung malignancies were prospectively 
evaluated between January 2008 to January 2009 with 64-detec-
tor row CT. First-pass CTP study comprised of 30 repeated spiral 
acquisitions over 60 s following 50-ml intravenous bolus of contrast 
medium at 5 ml/sec. Perfusion (BF), Peak Enhancement Intensity 
(PEI), Time To Peak (TTP), Blood Volume (BV) and Mean Transit 
Time (MTT) were calculated and statistically compared among dif-
ferent histological types, size and necrotic and non-necrotic compon-
ent. Interobserver agreement was tested by another radiologist who 
was blinded to the histopathology and the previous perfusion results. 
After interclass correlation agreement between the 2 observers, aver-
age values of the two sets were chosen .
Results: Perfusion (BF) in malignant lesions was 30.1± 13.4, BV 
was 19.4± 11.8, MTT was 5.9± 2.0, TTP was 23.9± 8.5 and PEI was 
26.6± 8.9.
No statistical differences were found between the histological types 
regarding the CTP parameters (p > 0.05). BF, PEI, MTT and BV 
of stage T2 tumors were significantly lower than those of stage T1 
tumors (all p < 0.05), however no statistically significant differ-
ences was seen between rest of the stages of tumors (p > 0.05). 
Considerable differences with higher BF, PEI and BV were noted 
in tumor ≤3.0 cm than in tumor > 3.0 cm (p < 0.05). The necrotic 
tumors showed significantly lower BF, PEI, MTT and BV compared 
with non-necrotic tumors (p < 0.05), but TTP longer than those of 
non-necrotic part of the necrotic tumors (p < 0.05). Perfusion, PEI, 
and BV were highest and TTP & MTT were lowest for small cell 
carcinoma, followed by adenocarcinoma, squamous cell carcinoma, 
and large cell carcinoma, but these differences were not statistically 
significant (all p > 0.05).
Conclusion: First-pass perfusion imaging using 64-detector row CT 
is a noninvasive method for assessment of tumour perfusion and can 
be used for evaluating tumor necrosis and angiogenesis. 
Clinical Relevance/ Future Application: To assess response to a par-
ticular chemotherapeutic agent by measuring pre and post chemother-
apy perfusion parameters. 
One of the important applications is the indication of a highly 
perfused area, which could be used to guide biopsy to the site of the 
most active tumour, reducing the chance of sampling error.
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18F-FDG PET/CT in the evaluation of adrenal tumors in 
the patients with lung cancer
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Background: When staging or restaging lung cancer in patients with 
adrenal nodules, problems are frequently encountered. Recently, 
positron emission tomography (PET)/computed tomography (CT) is 
being used for this problematic diagnosis of adrenal metastasis. The 
purpose of this retrospective study is to declare diagnostic accuracy 
for adrenal metastasis with PET/CT.
Methods: In the two years between January 2006 through December 
2007, 126 patients with lung cancer or suspected of lung cancer re-
ceived PET/CT. Of the total 126 cases, 10 cases were detected of ab-
normality of adrenal gland with either CT scan or PET scan. Diagnos-
tic accuracy in the 10 cases was retrospectively studied. PET scans 
were acquired after 60 min and 120 min after 18F-fluorodeoxyglu-
cose (FDG) injection. The visual interpretation of FDG uptake was 
correlated with the final histological diagnosis or clinico-radiological 
follow-up. Adrenal nodules were defined by size change as benign if 
stable for more than 6 months and as metastatic if size enlarged. 
Results: Ten patients with 11 adrenal abnormality were evaluated on 
follow-up. The final diagnosis was 7 adrenal metastases and 4 tumors 
classified as benign. The visual interpretation of PET had a sensitivity 
of 100%, a specificity of 25%, a positive predictive value (PPV) of 
70%, and a negative predictive value (NPV) of 100%. By combining 
PET with adrenal tumor diameter >10mm on CT scan had an excel-
lent accuracy of 100% sensitivity, specificity, PPV and NPV. 
Conclusions: With PET alone, a tendency to misdiagnose for adrenal 
nodules exists. By combining tumor diameter and PET observations a 
high diagnostic accuracy can be obtained.
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Background: Radiologically, the nodules with ground-glass opacity 
(GGO) include a pathological non-invasive cancer, such as a bronchi-
oloalveolar carcinoma (BAC). However, some nodules without GGO 
can also be a pathological non-invasive cancer or a non-malignant 
lesions, such as a mucinous BAC or an organizing pneumonia. It 
can be difficult clinically to distinguish whether a nodule represents 
invasive or non-invasive cancer. Recently, magnetic resonance im-
aging (MRI) with various technological advancements has generally 
been used to elevate the accuracy of diagnosis for several malignant 
tumors. This study retrospectively evaluated the efficacy of newer 
MRI techniques for differentiating among the different types of 
invasiveness in lung adenocarcinoma by comparing the MRI findings 
with the pathological findings. 
Methods: From May 2005 to April 2007, forty-six patients with lung 
adenocarcinoma measuring 3 cm or less across the greatest dimen-
sion underwent a surgical operation including preoperative MRI 
study in this hospital. MRI was performed on a 1.5T system (Mag-
netom Avanto; Siemens, Erlangen, Germany) with high-performance 
gradients and total imaging matrix (Tim). The MR imaging protocol 
included three pulse sequences: 1) respiratory-triggered T2-weighted 
short TI inversion recovery (STIR); 2) respiratory-triggered high 
b-value diffusion weighted imaging (DWI); 3) gadolinium-enhanced 
dynamic MRI studies. Both STIR and DW imaging were visually 
graded on a four-point score by signal intensity. On the dynamic MR 
images, time-intensity curves and morphological characteristics were 
accessed in this study. The time-intensity curves were made based 
on the dynamic MR images obtained from the scans of protocols 
and then their kinetic enhancement patterns were analyzed. Differ-
ences were considered to be statistically significant if the P value was 
<0.05.
Results: Of all the tumors, 13 were bronchioloalveolar carcinoma 
(BAC), 24 were adenocarcinomas with mixed subtypes (advanced 
BAC) and 9 were other histological subtypes (non-BAC). Both the 
moderate and strong signal intensity on DWI was significantly greater 
in the advanced BAC (79.2%) and the non-BAC (88.9%) than in the 
BAC (38.5%). In the dynamic study, a strong enhancement on the 
time-intensity curve was significantly greater in the advanced BAC 
(95.2%) and the non-BAC (87.5%) than in the BAC (25%). When 
the lesions demonstrated a strong enhancement in dynamic study or 
showed strong signal intensity on DWI or STIR, they were judged 
to be positive. The sensitivity, specificity and accuracy based on the 
results of a dynamic study and STIR were 96.7%, 69.2%, and 89.1%, 
respectively. The sensitivity, specificity and accuracy based on the 
results of a dynamic study and DWI were 97%, 76.9%, and 91.3%, 
respectively. All of the false positive cases had pathologically strong 
alveolar collapse, fibrosis and lymphocyte infiltration within the le-
sions in comparison to the other types of non-invasive cancer.
Conclusions: MRI with different sequences may be used to help 
characterize lung adenocarcinomas, and these findings may provide 
useful supplementary information before deciding to perform surgery 
for limited resections. However, the sensitivity of the MRI sequences 
for the detection of lesions might depend on the lesion size. There-
fore, the results of this study need to be confirmed in a larger study 
population, especially, in an evaluation of smaller-sized lesions. 
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of non-small cell lung cancer? A single institution 
experience of 1889 studies
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Background: 18FDG PET and PET/CT have been shown to have 
high diagnostic accuracy in characterizing pulmonary nodules as 
benign or malignant. Specificity has been limited by significant 
overlap in FDG uptake in malignant and benign inflammatory/infec-
tious lesions. Dual time point imaging has been suggested to improve 
the diagnostic specificity based on the hypothesis that cancers will 
uniformly increase intensity over time as measured by maximum 
standardized uptake value (SUV) and benign lesions will not. A 
cutoff of at least 10% increase in SUV between time points has been 
proposed as a diagnostic criterion for malignancy. We undertook a 
retrospective review to examine this hypothesis.
Materials/Methods: We performed a retrospective review of 1889 
patients with suspected NSCLC who underwent a staging 18FDG 
PET or PET/CT from 1 January 2000 through 31 August 2008 in the 
University of Pennsylvania Health System. Of these, 98 were biopsy 
proven to have NSCLC, clinical stage I or II and underwent dual-
point imaging as part of their pre-treatment work up. All images were 
interpreted by a single reader and SUV of the primary tumor was 
measured for both time points. Percent change in SUV between time 
points was calculated.
Results: In this cohort of patients with known malignant pulmonary 
nodules, the range of intensity change over time (% change in SUV 
on second time point) was -28% to +73%. 34/98 (35%) had < 10% 
increase in tumor SUV between time points, with 13 demonstrat-
ing an absolute decrease in SUV. 16 patients had a primary tumor 
SUV<2.5. Of these, 4 (25%) had < 10% increase in tumor SUV 
between time points with an absolute decrease in SUV in 2. 
Conclusions: Known primary clinically early stage lung cancers 
have tremendous variability in change of intensity over time on PET. 
Incorporation of dual time point imaging is of questionable value 
in the evaluation of pulmonary nodules in these potentially curable 
patients. Future studies will evaluate the utility of dual time point 
imaging in a matched cohort of biopsy proven benign lesions.
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Management change as a result of positron emission 
tomography (PET) in a prospective randomized clinical 
trial
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Background: Positron emission tomography (PET) is increasingly 
used for staging of non-small cell lung cancer (NSCLC) patients. 
Retrospective and cohort studies indicate potential stage migration 
rates of 20-30% with the use of PET in Stage III NSCLC patients 
who have undergone conventional imaging for staging. However, sig-
nificant management changes occur if patients are upstaged to Stage 
IV or if the radiation treatment volume is too large to safely deliver 
a radical dose of radiation (RT). The PET START trial is the first 
prospective randomized clinical trial in Stage III NSCLC patients to 
evaluate the impact of PET on this management change. 
Methods: Patients with Stage III NSCLC (based on histology/cytol-
ogy, brain CT/MRI, CT thorax, CT/US abdomen, and bone scan) 
who were considered candidates for combined modality therapy 
(CMT) were randomized to either PET-CT or CT-based RT treatment 
planning. The primary outcome was the proportion of patients who 
did not receive CMT because their tumor was upstaged to Stage IV 
or their intrathoracic tumor was too extensive for radical RT. Overall 
survival (OS) and alteration of RT treatment planning volume were 
secondary outcomes. Target sample size was 400 patients based on a 
relative risk reduction of 15.5% in OS at 2 years in favor of PET-CT 
with alpha = 0.05 and 80% power. We also postulated that 200 pa-
tients would be required to detect a 20% difference between arms for 
the primary endpoint. Five centers in Ontario participated.
Results: The trial commenced in August 2004. In March 2008, the 
first planned interim analysis was done after accrual of 200 patients. 
The Data Safety and Monitoring Board (DSMB) recommended con-
tinuing the trial as planned. In November 2008 after a second interim 
analysis for the primary outcome, the DSMB recommended stopping 
recruitment. Of 304 patients randomized, 289 had analyzable data. 
25 patients were unsuitable for CMT: 21 in the PET-CT arm (16 
upstaged to Stage 4 and 5 unsuitable for radical RT) and 4 in the CT 
arm (upstaged to Stage 4). Thus, 21 of 140 (15%) in the PET-CT arm 
achieved the primary outcome compared with 4 of 149 (2.7%) pa-
tients in the CT arm, P= 0.0002. The trial was stopped due to superior 
efficacy of the PET-CT arm.
Conclusions: The PET START trial has shown that PET-CT is 
superior to CT planning alone in selecting appropriate patients for 
CMT. The rate of management change from radical intent to pallia-
tive as a result of PET imaging is about 12%.
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Background: Determining the efficacy of antiangiogenic agents by 
RECIST criteria may underestimate their efficacy, since their effect is 
cytostatic rather than cytotoxic.
The aim of the current study was to compare 2 analytical models of 
DCE-MRI in assessing early response to treatment with bevacizumab 
and erlotinib in advanced NSCLC patients. 
Methods: In a multicenter phase II study chemonaive patients with 
advanced NSCLC were treated with bevacizumab and erlotinib until 
disease progression (Groen et al Proc ASCO 2007).
DCE-MRI (1.5 Tesla MRI scanner) was performed at week 0, 3,6. 
DCE-MRI included five pre-contrast T1-weighted measurements (3D 
fast spoiled gradient echo, TR 4.5 ms, echo time 2 ms, 5 transversal 
slices (slice thickness 10 mm), FOV 350 mm, matrix 144x256) with 
different flip angles (FA) to determine the T1 relaxation time in blood 
and tissue before contrast arrival. Thereafter a DCE series using the 
same sequence, but with a FA of 35˚, containing 30-35 scans of 2 
seconds each. We used a fast data acquisition period (2 sec) to freeze 
breathing motion. 
A pharmacokinetic two-compartment, bidirectional exchange model 
was used to determine the tumor endothelial transfer coefficient 
(Ktrans) by a region of interest (ROI) that covers the whole tumor 
cross-section. Data analysis was also performed on a pixel per 
pixel basis to determine intratumor heterogeneity. The analysis was 
performed by using a functional form of arterial input function. Due 
to considerable variability in the baseline enhancement of tumors, 
the relative rather than the absolute Ktrans was used. A response was 
defined as a reduction of Ktrans of 40% and a decrease of 15% in 
SDEV of histogram analysis.
Results: DCE-MRI data are available from 28/47 patients included. 
Whole tumor Ktrans decreased with 32% (IQR -60% to + 26%) 
after 3 weeks. No significant correlation was found with TTP or OS. 
(p=0.5, p=0.9).
Histogram analysis of tumor Ktrans on a pixel per pixel basis shows a 
shift towards a lower and less heterogeneous tumor. (figure1) 
A decrease of 15% in intratumor heterogeneity after 3 weeks of treat-
ment predicted TTP (p=0.015) and OS (p=0.099). 
Conclusion: DCE-MRI derived Ktrans shows reduction in microves-
sel bloodflow and permeability within the tumor after 3 weeks of 
treatment. Histogram analysis show a lower and less heterogenous 
tumor, which correlates with TTP and OS. 
Decrease in tumor heterogeneity as assessed by DCE-MRI seems a 
valuable biomarker in monitoring early response to antiangiogenic 
treatment in patients with advanced NSCLC.
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Background: Tumor hipoxia induces the up-regulation of several 
genes via the hipoxia-inducible transcription factors (HIF) 1 and 
2. HIF-2 alpha (HIF-2α) and HIF-1 alpha (HIF-2α) are associated 
with the prognosis of operable NSCLC patients. We studied the 
immunohistochemical expression of HIF1-alpha and HIF2 alpha in 
patients with NSCLC and the possible correlation with the maximum 
standardised uptake value (max SUV) of 18F-FDG as well as other 
biological parameters. 
Methods: We used a Tissue Arrayer device (Beecher Instruments. 
WI) to construct a TMA block, according to conventional protocols 
for the study of immunohistochemical expression of HIF1α, HIF2α, 
EGFR, bcl-2, MIB1, p16, p63 and cyclins A, B1, D1 and D3. Sec-
tions were scored as positive if >10% of cells stained positively. 
Staining patterns were correlated to clinical variables. 
Results: HIF1α expression was observed in 84/96 patients (34/39 
adenocarcinomas and 50/57 squamous cell carcinomas), however 
it did not correlate with clinical stage (I-II: 41/45 vs III-IV: 44/51). 
HIF1α correlated positively with HIF2a (p:0,001) and EGFR 
(p:<0,001) expressions. The maxSUV values of 18F-FDG-PET 
were higher (p:0,039) in HIF1α-positive (17,1±8,6) than in negative 
tumors (11,8±4,4). HIF2α expression was observed in 60/103 cases 
(27/42 adenocarcinomas and 33/61 squamous cell carcinomas);It did 
not correlate with clinical stage ((I-II: 28/45 vs III-IV: 32/57), It cor-
related positively with HIF1a (p:0,001), MIB1 (p:0,045) and EGFR 
(p:0,091) expressions. After multivariate analysis, only the clinical 
stage (RR: 2,2) was a prognostic factor. 
Conclusions: 1) HIF1α and HIF2α expressions are frequent in 
patients with NSCLCs and it did not correlate with clinical stage; 
2) maxSUVs FDG-PET values were higher in HIF1alpha positive 
than in HIF1alpha negative patients; 3) HIF1alpha was correlated 
with EGFR expression, while HIF2alpha was correlated with MIB1 
expression.
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Background: MicroRNAs (miRNAs) are small non-coding RNAs 
of approximately 22 nucleotides of which a subset has been impli-
cated in cancer. Dysregulation of miRNAs can lead to malignant 
progression. miRNA arrays can classify human cancers with fewer 
discriminators than gene expression arrays. In non-small cell lung 
cancer (NSCLC), brain metastasis is a very common and devastating 
complication that can occur in up to 2/3 of patients with this disease. 
The ability to identify those at risk for developing brain metastasis 
may guide therapeutic decision making. We sought to determine if 
there are miRNA and/or imaging characteristics by CT and 18F-FDG 
PET scan features associated with brain metastasis. 
Methods: In this IRB approved cohort study, NSCLC patients with 
brain metastasis (BM+) on MRI were matched by age, gender, histol-
ogy, and stage at presentation to NSCLC patients without brain me-
tastasis (BM-) on MRI. Diagnostic CT, MRI and 18F-FDG PET/CT 
studies performed within 30 days of one another were available and 
assessed. Multiple parameters were evaluated including SUVmax for 
primary tumor, brain, muscle, spleen, and chest nodal disease. Only 
patients with adequate tumor RNA yield (>100ng total RNA) were 
included in this analysis. miRNA expression profiling was performed 
(Sanger miRNA Registry v.12 Sept 2008). Significant miRNA were 
found using a mathematical model for in-silico conditioning that 
identifies statistically significant cellular contexts where one or more 
miRNA can be attributed to control the state of the class (BM+ or 
BM-). We set correlations that are ≥ 0.7 as the minimum threshold for 
statistically significant correlations. 
Results: Of the 13 patients identified meeting the clinical criteria, 
only 12 patients had tumor cells available for extraction. All 12 
patients had sufficient RNA yield (mean 2.2 ug ± 1.2 ug). Of these, 
there were 7 BM+ and 5 BM-. There were no differences in clinical 
characteristics. Amongst 18 CT imaging characteristics, BM+ are 
more likely to be centrally located (p=0.02). Amongst 12 PET/CT im-
aging characteristics, there were no features associated with BM+. By 
miRNA profiling, there were 5 significantly upregulated (p < 0.05) 
and 11 downregulated (p < 0.07) in BM+ compared with BM-. Only 
4 of these miRNAs were associated with 5 imaging characteristics. 
Only one miRNA, miR-601, was associated with the significant CT 
scan imaging characteristic seen in BM+ (p=0.02). QRT-PCR valida-
tion of these miRNAs is ongoing. 
Conclusions: In this retrospective study, only a few miRNAs appear 
to be associated with BM+. Only 1 CT imaging characteristic appears 
to associate with BM+, and we have identified 1 miRNA correlating 
with both BM+ and this imaging feature. PET/CT features do not ap-
pear to associate with BM+. Further validation studies are warranted. 
Acknowledgments: We thank the IBIS Foundation, TGen Foundation, 
and Scottsdale Healthcare Foundation for support of this project. 
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Background: With low-dose Computed Tomography (CT) screening 
for lung cancer, early-stage lung cancers are detected in a high pro-
portion. Drawback of current regimens is the high rate of false-posi-
tive test results, which lead to many additional diagnostic procedures 
and invasive for benign lesions in 24-37%.
Purpose: To determine the rate of false-positive test results in a 
randomised lung cancer CT screening trial (NELSON) in which for 
the first time the screening strategy was based on volume and volume 
doubling time (VDT) only. 
Methods: The NELSON screening strategy is unique in that the nod-
ule management algorithm is based on volume and volume doubling 
time only, without the use of additional diagnostic investigations. Al-
though in most screening test positives positron emission tomograph-
ies (PET) scans have been made for research purposes, the NELSON 
screen strategy did not allow for the use of the PET scan results. 
Therefore, the effect of the NELSON strategy on the prevalence of 
invasive procedures for benign lesions could be evaluated without 
the confounding effect of PET. Only test positives were referred to 
a chest physician for work-up and diagnosis. If no diagnosis could 
be by bronchoscopy, an invasive diagnostic procedure had to be 
performed (mediastinoscopy, video-assisted thoracoscopy (VATS), 
thoracotomy).
Results: At baseline in 13% (25/196) of the test positives and in 34 
% (31/92) of all invasive procedures a benign diagnosis was made 
by mediastinoscopy (n=1), VATS procedure (n=5) or thoracotomy 
(n=19). During thoracotomy a histological true-cut biopsy was taken 
in 2 subjects, 13 underwent a wedge resection and 4 a lobectomy. In 
3% (6/196) a malignancy other than lung cancer was diagnosed by 
thoracotomy (n=5) or VATS procedure (n=1). At 2nd round screening 
in 9% (12/128) of the test positives and in 22% (13/60) of all invasive 
procedures a benign diagnosis was made by mediastinoscopy (n=1), 
VATS procedure (n=1) or thoracotomy (n=10). During thoracotomy 
only a subcarinal lymph node was removed in one, 6 underwent 
a wedge resection, 1 a segmentectomy and 2 a lobectomy. In 1% 
(1/128) a malignancy other than lung cancer was diagnosed by means 
of a sternotomy. None of the surgical procedures was complicated by 
30-day post-operative morbidity or mortality. 
Fifty-two percent (23/44) of the invasive procedures for non-lung can-
cer lesions appeared to be not futile because of the detection of other 
clinical relevant disease including pre-invasive lesions (n=3), other 
cancers (n=7) and inflammatory or infectious lesions (n=13). In the 
remaining not clinical relevant 48% (21/44) normal or benign tissues 
have been removed. In 80% of the test-positives in total 233 PET-scans 
were made for research purposes. The sensitivity, specificity, positive 
and negative predictive value of PET for malignancy in screening test 
positive cases was 76%, 86%, 81% and 78% respectively. 
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Conclusions: Our novel screening strategy based on volume and 
VDT led to a very low rate of invasive procedures for benign lesions. 
The additional diagnostic value of PET was low.
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Background: We have a lot of opportunity to see non-palpable 
pulmonary GGA lesions with developing of radiological diagnostic 
procedure. On the other hand, there are some expectations of less 
invasive surgery via VATS methods. In this paper, we investigated the 
patients group of VATS operation for non-palpable pulmonary GGA 
lesions with hook wire marking under CT scan.
Patients and Methods: We experienced 240 patients of primary lung 
cancer for recent 4 years. In this cases, eleven patients were needed 
the hook wire marking under CT scan before VATS surgery due to 
non-palpable GGA lesions. Mean age is 68.8 years old (range 37-78 
years old), mean diameter of tumor is 13mm (6mm–30mm), mean 
length from the pulmonary surface is 9.6mm (5mm- 25mm). There 
included five patients with double primary lung cancer. 
Results: All patients had VATS surgery after hook wire marking 
under CT scan without severe complication. All patients had min-
imum pneumothorax without any drainage after marking and during 
the inducing of general anesthesia. All patients had Bronchioloalveo-
lar Carcinoma (BAC) by pathological examination. They are all 
survived without any recurrent of lung cancer. 
Conclusions: The VATS surgery after marking under CT scan is 
very useful for the patients with non-palpable lung cancer. However, 
some literature pointed out a warning of air emboli with pulmonary 
puncture method. So, We need careful informed consent before this 
procedure. 
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Background: The aim of this study was to establish a preopera-
tive clinical model for predictimg resected pure bronchioloalveolar 
carcinoma (BAC), and to analyze the effect of limited resection for 
BAC patients. 
Methods: An original cohort of 190 surgically resected BAC patients 
from Dec 1994 to Jun 2007 at Shanghai Chest Hospital affiliated to 
Shanghai Jiaotong University were reviewed to analyze the relation-
ship between imaging features and pathological characteristics. Two 
prospective validation cohorts comprised 54 patients with resected 
BAC from two independent hospitals respectively. A clinical predict-
ive model was set up as an approach in evaluating the likelihood of 
pure BAC using logistic regression analysis in the original cohort and 
confirmed in the two validation cohorts. 123 patients followed-up 
for at least two years in the original cohort were included to perform 
survival analysis by Cox regression multivariable method. 
Results: (1) The preoperative clinical predictive model for pure BAC 
was: logit (P)=8.181–2.068×GGO (ground glass opacity) – 1.240×PI 
(pleural invasion) – 1.273×LN (lobulated nodule) – 1.000×TS (tumor 
size). P≥0.220 was considered as a clinical predictive sign for pure 
BAC. (2) Lobectomy or limited resection (P=0.630) was not statistic-
ally significant for BAC, while histopathology (P=0.050) and TNM 
new staging recommended by the International Association for the 
Study of Lung Cancer (IASLC) (P=0.015) were independent prog-
nostic factors. 
Conclusions: P≥0.220 in our model was considered as a preoperative 
clinical predictive sign for pure BAC patients, who might be eligible 
for limited resection in clinical practice.
Mesothelioma, Thymoma and Others
P2.058 Mesothelioma, Thymoma and Others, Sun Aug 2 
Delayed bronchial stump fistula following trimodality 
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Background: Post pneumonectomy bronchopleural fistula repre-
sents the most serious complication in thoracic surgery. Studies have 
shown that diagnosis and therapeutic management remain major 
problems with a high mortality rates ranging from 20-70%.
Delayed bronchial stump fistula (more than 6months after surgery) 
following tri modality treatment for malignant pleural mesotheli-
oma is a more serious problem regarding diagnosis and treatment. 
Surgical repair of the bronchial stump through a lateral thoracotomy 
is a dangerous attempt due to mediastinal fibrothorax and the risk of 
pulmonary artery stump damage.
Material: Between 2002 and 2007, 85 extra pleural pneumonecto-
mies for malignant pleural mesothelioma were performed. Only 58 
patients completed the assigned tri modality treatment, five ( 8.6%)
of them developed delayed bronchial stump dehiscence. The interval 
between extra pleural pneumonectomy and stump dehiscence ranged 
from 6 months to 2 years. By bronchoscopy, no recurrence was 
observed, but all patients with stapled bronchus had longer remaining 
stump. Empyema was present in all patients.
Results: There were 4 right and one left sided fistulae. We had 4 
males and one female, the mean age was 41 years. Bronchial stump 
was stapled in 3 patients and hand sewn closure was used in the 
remaining 2. All patients complicated with disruption of the bronchial 
stump received 2 field post operative radiotherapy with mediastinal 
dose 40- 45 Gys. The initial treatment consisted of tube thoracostomy 
followed by exploration through the previous thoracotomy incision 
with thorough curettage and wash of the infected space and removal 
of any exposed infected mesh. Bronchial stump was identified and 
dissected posteriorly first to avoid injury of the pulmonary artery. 
Re enforcement of the bronchial stump was done by using serratus 
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anterior muscle flap in 3 patients and latissimus dorsi muscle in the 
remaining 2. All patients developed post operative pneumonia, 2 of 
them required mechanical ventilation and died 3 and 12 days post 
operatively.
Hospital stay range was 1-3 weeks, surgery was successful in the 
remaining 3 patients.
One patient developed peritoneal recurrence and died one year after 
fistula repair. The remaining two patients were alive and disease free.
Conclusion: Delayed bronchial stump dehiscence following tri 
modality treatment for malignant pleural mesothelioma is liable to 
develop especially on right sided lesions following 2 field mediastinal 
radiation and the use of bronchial stapler. Marking of the bronchial 
stump with clips, prophylactic augmentation of right sided stumps 
with well vascularised muscle flap, shielding of pathology proven 
negative stump during radiotherapy and the use of conformal radio-
therapy are all factors associated with reduced incidence of stump 
dehiscence. Early and rapid intervention is life saving as the infection 
spreads rapidly to the contra lateral side and soft tissue of the chest 
wall due to absence of pleural barrier. 
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Introduction: Malignant pleural mesothelioma is a malignancy 
very much influencing the immune system. Dendritic cells (DCs) are 
extremely potent antigen presenting cells specialized for inducing 
activation and proliferation of CD8+ cytotoxic T lymphocytes and 
other lymphocytes. Exploiting these immunostimulatory capacities 
of DCs holds great promise for cancer immunotherapy. DCs can be 
generated in large amounts in vitro, in the absence of the suppressing 
tumor microenvironment, and subsequently injected in a mature state 
to induce anti-tumor responses. In the present clinical trial we defined 
the safety, toxicity and efficacy of tumor lysate-pulsed DCs injected 
in patients with mesothelioma after chemotherapy. 
Methods: Patients with enough tumor cells (> 150x10e6 tumor cells) 
in their pleural effusion at time of diagnosis were included in the 
study. Tumor cell lysates were generated by repeated freeze-thaw 
cycles and irradiation. After chemotherapy, patients underwent leu-
kapheresis. Monocytes were isolated by elutriation and DCs could be 
cultured in sufficient amount using GM-CSF and IL-4. After 5 days 
in culture, DC were pulsed with autologous tumor lysate and keyhole 
limpet hemocyanin (KLH). A cytokine cocktail induced the final 
maturation step at day 8. The morphology and phenotype of cultured 
cells was consistent with dendritic cells. 
Results: Nine patients received the three planned DC vaccinations. 
It was shown that injection of DCs was overall well tolerated without 
systemic toxicity, with the exception of a low-grade flu-like symp-
toms: fever, rigors, and a temporarily local skin reaction after DC 
injection (mild grade 1 or 2). Local accumulation of T cells were 
found at the vaccination sites. Body temperature was increased in 5 
patients but did not exceed 39˚C mainly after the second and third 
vaccination. All participants thus far experienced no rash or lymph-
adenopathy or developed any clinical evidence of autoimmunity or 
rheumatoid disease. DTH and strong antibody immune responses 
(IgM and IgG) on KLH were seen in all patients indicating that im-
mune responses were generated. CT scans and X-rays from a few 
patients revealed small to substantial regressions of the tumor during 
the DC treatment. Cr51 release assays did sow the presence of a 
specific cytotoxic Tcell response due to the DC immunotherapy.
Discussion & Conclusion: First results from our clinical trial indi-
cate that DC-immunotherapy is safe and feasible for mesothelioma 
patients. In a subgroup of patients the therapy may have therapeutic 
benefit. Further studies are momentarily performed on decreasing 
the immunosuppressive environment of mesothelioma, in order to 
increase the therapeutic efficacy. Data on this will be shown during 
the meeting.
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Purpose: It has been reported that cisplatin-based chemotherapy 
shows beneficial effects in certain patients with advanced thymic 
carcinoma. However, the usefulness of salvage therapy has not been 
reported. We focused on a new anthracycline agent, amrubicin, com-
bined with platinum compounds as salvage chemotherapy in patients 
with thymic carcinoma. We evaluated the efficacy and toxicity of 
amrubicin plus platinum agent chemotherapy.
Methods: Six cases of unresectable and locally advanced thymic 
carcinoma relapsed from prior cisplatin-containing chemotherapy 
were treated with amrubicin (30-40 mg/m2 on day 1-3) plus platinum 
compounds (cisplatin 60 mg/m2 on day 1, or nedaplatin 70 mg/m2 
on day 1) chemotherapy as salvage chemotherapy. The median age 
of the treated patients was 59.3 years (range 40-76), consisting of 
four men and two women. The stage of the disease in all patients was 
metastatic thymic carcinoma (stage IVa or b).
Results: Each patient received 2-4 courses of the current chemother-
apy. Partial response and stable disease were observed in two and 
three cases, respectively. However, leukopenia or neutropenia over 
grade 3 were seen in all patients, and thrombocytopenia and anemia 
over grade 3 were observed in 2 cases each of 6 cases. No patients 
developed febrile neutropenia. Non-sustained ventricular tachycardia 
and Herpes Zoster infection were observed in one case each during 
the current chemotherapy. No treatment-related death was observed 
in this series.
Conclusion: We conclude that thymic carcinoma is sensitive to 
platinum-based chemotherapy and that amrubicin appears to have 
significant activity against thymic carcinoma. The major toxicity is 
hematological toxicities. This novel regimen merits further clinical 
investigation for treatment of patients with thymic carcinoma.
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Acase of malignant pleural mesothelioma: a clinical 
presentation with spontaneous pneumothorax and 
spontaneous remission following alternative therapy
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A 46 year-old male patient was admitted to our hospital with acute 
dispnea. He had no asbestosis exposure in his occupational and 
environmental history. After spontaneous pneumothorax had been 
found out and tube thoracostomy had been performed, the patient 
was called for controls for investigating the etiology of pneumo-
thorax. Control thorax computed tomography revealed diffuse pleural 
nodules and right pleural effusion, so he was hospitalized again for 
advanced examination. The pleural fluid was evaluated as an exudate, 
and malignant pleural cells were found in the cytological evaluation. 
A pleural biopsy was performed; and he was diagnosed as malignant 
pleural mesothelioma (epithelioid type) by histopathological analysis. 
The patient refused to take chemotherapy or radiotherapy, so he 
was discharged from hospital with palliative therapy. In the control 
thorax CT after 3 months, there were no initial radiological findings; 
it was evaluated as spontaneous and complete remisssion of malig-
nant mesothelioma. We learnt that he used stinging nettle extract as 
alternative therapy in this period. The histopathological confirma-
tions of the preparats had been done by pathology department, and 
there was no doubt about the diagnosis. Mesothelioma is an agressive 
tumour, in which spontaneous regression is rarely seen. On the other 
hand, the incidence of spontaneous pneumothorax is also reported to 
be low in mesothelioma. We would like to report our case of malign 
mesothelioma, who had a clinical presentation with spontaneous 
pneumothorax, and spontaneous regression of tumour after a usage of 
stinging nettle as alternative therapy.
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Objective: There are non-randomized data which suggest that radical 
surgery for malignant pleural mesothelioma (MPM) should be per-
formed as part of a multi-modality therapy program. We believed that 
this strategy was not universally supported . We wished to study the 
variability in treatment and any temporal changes in policy to identify 
future areas of research.
Patients and Methods: In a 10-year period referrals were received 
from 38 oncology centers, 203 patients underwent radical surgery 
for MPM: 126 underwent extrapleural pneumonectomy (EPP) 
and 77 radical pleurectomy/decortication (P/D) with an intention 
for trimodality therapy of pre or postoperative chemotherapy and 
postoperative radiotherapy (radical hemithorax post EPP or wound 
irradiation post P/D). 
We analyzed our prospective database to determine the use of 
chemotherapy or radiotherapy in this surgical group. The reasons for 
non-compliance were recorded. Temporal changes in treatment were 
analyzed by allocating the patients into 4 equal consecutive cohorts. 
Group 1,2,3 and 4 contained patients operated from 08/1999 to 
04/2003, 04/2003 to 02/2005, 02/2005 to 11/2005 and 11/05 to 07/08 
respectively (table1).
Results: Of the initial 203 patients, 20 died prior to assessment and 
a further 32 were considered too unwell for adjuvant therapy. 151 
(74%) patients were referred for multimodality treatment. 80 (39%) 
patients had trimodality treatment; 35 surgery + chemotherapy, 35 
surgery + radiotherapy and 1 patient surgery alone. Of the 36 patients 
who did not receive chemotherapy: 33% refused treatment and 67% 
were refused treatment by their oncologist because of their fitness; 
the postoperative time-interval or most commonly (57%) because 
there was not thought to be enough evidence . Of the 115 patients 
who received postoperative radiotherapy only 33 (29%) underwent 
radical hemithorax irradiation. Of the 35 patients who did not receive 
adjuvant radiotherapy 37% refused treatment and 63% were refused 
treatment by the oncologist most commonly due to a perceived lack 
of evidence (58%). 
Patients underwent significantly more EPP in groups 1 and 2 than 
groups 3 and 4. There was a higher use of chemotherapy (particularly 
pemetrexed) in group 3 (p<0.05). The use of radical hemithorax ir-
radiation was highest in groups 2 and 3 (p<0.05)
Conclusion: The initial surgical enthusiasm for radical mesothelioma 
treatment was not matched by oncological practice until the use of 
pemetrexed became accepted. The shift in surgical practice away 
from EPP to radical P/D has resulted in a reduction of multimodality 
therapy. The lack of high grade evidence in mesothelioma treatment 
has resulted in this inco-ordinated approach and highlights the need 
for future surgical trials. 
  Group 1 Group 2 Group 3 Group 4 
  08/99 - 04/03 04/03 - 02/05 02/05 - 11/05 11/05 - 07/08 
 SURGICAL PROCEDURE     
  EPP 43 44 28 11 
  radical P/D 8 7 23 39 p<0.05
 CHEMOTHERAPY     
  cisplatin/pemetrexed 2 14 11 10 p<0.05
  total chemotherapy 20 30 36 29 
  no chemotherapy 31 21 15 21 p<0.05
 RADIOTHERAPY     
  to wound /drain site 16 12 28 26 
  radical hemithorax 5 12 14 2 p<0.05
  total radiotherapy 21 24 42 28 
  no radiotherapy 30 27 9 22 p<0.05
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The study of the molecular mechanisms underlying resistance to 
apoptosis is key to improving existing therapy for cancer. While 
cancer cells attain a chemoresistant phenotype on a single cell (uni-
cellular) level, they acquire further resistance to apoptosis when they 
form three-dimensional (3D) structures (multicellular resistance). 
In vitro 3D cell cultures (multicellular spheroids) have emerged as 
a valuable platform to study the acquired multicellular resistance of 
cancer. Bortezomib, a proteasome inhibitor, has been effective as a 
single agent in multiple myeloma but has been generally ineffective 
in solid tumors such as mesothelioma. Bortezomib has been shown 
to modulate several pro-/anti-apoptotic members of the Bcl-2 family, 
including upregulation of pro-apoptotic Noxa, shifting the balance to-
wards apoptosis. We asked whether mesothelioma spheroids develop 
multicellular resistance to bortezomib and whether changes in the 
Bcl-2 repertoire could account for the acquired resistance. 
Using monolayers and spheroids grown from two human mesotheli-
oma cell lines, M28 and REN, we found that cell lines acquire a 
marked multicellular resistance when grown as spheroids. Nonethe-
less, bortezomib inhibits proteasomal activity equally in both mono-
layers and spheroids and caused the accumulation of a comparable 
amount of ubiquitinated proteins in both systems. However, the Bcl-2 
repertoire was different in spheroids compared to monolayers, both at 
baseline and after bortezomib. One major difference was that Noxa, 
although upregulated in monolayers by bortezomib as expected, was 
not upregulated in spheroids. A cell-permeable Noxa-BH3 peptide 
was able to bypass bortezomib resistance. In addition, ABT, an inhib-
itor of the anti-apoptotic proteins Bcl-2/XL/w, was also able to by-
pass the bortezomib resistance acquired by cells in 3D. In conclusion, 
we find that Bcl-2 proteins can account for bortezomib resistance in 
3D. Manipulation of the Bcl-2 repertoire may be a successful adjunct 
to bortezomib therapy of solid tumors. 
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Mesothelioma is a highly apoptosis resistant cancer, however the 
biological basis for this resistance is poorly defined. Apoptosis 
resistance is likely to underpin clinical drug resistance, consequently, 
an understanding of the mechanisms that regulate cell survival 
could identify novel targets for therapy. When mesothelioma cells 
are grown as three dimensional culture (spheroids), they acquire 
reversible apoptosis resistance associated with increased threshold 
for initiating therapy. Accordingly, 3D growth of mesothelioma cells 
may be more representative of the in vivo setting. To gain an insight 
into the genetic regulation underpinning this phenotypic transforma-
tion during transition from 2D to 3D growth, expression microarray 
analysis was conducted so as to compare differentially expressed 
genes, pathways and gene networks. Dual-color Microarray data from 
spheroid and monolayer REN cells generated using an operon plat-
form and scanned using genepix, were analysed to find the principal 
components that contributed to the maximum variance in the data 
(using Partek Genomic Software Suite). Genes which were found to 
be highly correlated with the first principal component (above 90%) 
were further analysed to study the associated biological pathways and 
networks (using GeneGo MetaCore). The pathways most signifi-
cantly associated with transition to 3D REN growth were involved 
in cell cycle regulation (overall p-value: 1.71x10-19) followed by 
DNA damage regulation (overall p-value 2.04x10-6), and apoptosis 
(p=0.002). Gene network analysis was conducted and the results 
will be presented. In brief, networks were built with sub-networks 
highly saturated with the selected genes. Sub-networks were ranked 
by a P-value and G-Score and interpreted in terms of Gene Ontology. 
Cell cycle ranked as a highly significant Go process. In summary, the 
phenotypic transformation that is associated with acquisition of apop-
tosis resistance when REN mesothelioma cells grow in 3D, involves 
widely differing expression of several genes involved in cell cycle, 
DNA damage and apoptosis regulation. Selective targeting of one or 
more of these pathways could enable reversion to 2D like apoptosis 
sensitivity.
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An angiosarcoma (AS) is an uncommon malignant neoplasm char-
acterized by rapidly proliferating anaplastic cells derived from blood 
vessels and lining irregular blood-filled spaces. Angiosarcomas may 
occur in any region of the body but mostly occurs in skin, soft tissue, 
liver, breast, spleen, bone, or heart.
Angiosarcoma are tumors of vascular origin, accounting for 2 – 3 % 
of all sarcomas. Primary pulmonary angiosarcoma are extremely rare 
and there have not been many cases reported in literature.
A 32-years old man presented with the history of sudden loss of con-
scious and fever was admitted to the A&E department. A chest X-ray 
showed left pleural effusion. Because of the past history of the chest 
trauma six months ago, a hematoma was suspected. The patient was 
operated to evacuate a hematoma. A fragment of resected lung was 
sent to the pathologist. Immunohistological result suggested inflam-
matory reaction. The patient was discharge (1/28/2009). After a few 
weeks (3/5/2008) he was again admitted to be hospital because of the 
pain of the operated area. He was anemic with leucocytosis. His ESR 
was elevated. A CT demonstrated a thicken pleura with many masses, 
left lung with a small pneumothorax, right lung without metastasis, 
enlarged nodes of the carina A radiologist suggested mesothelioma. 
An ultrasound of the abdomen showed two hyperechogenic struc-
ture described as angioma. There weren’t any pathological findings 
in bronchoscopy. A hematological consultation suggested anemia 
caused by hemorrhage and disorders of metabolism of iron caused 
by neoplastic disease. A histopatological sample was taken from the 
operated area. Immunohistological 
Result: CD31(++),CK(+),Ki67 in 50-60% of the cells, CD 34(-), 
Mesothelina(-), WT1(+), Kalretinina(-), CD15(-), CEA(-) suggested 
angiosarcoma epithelioides. He was sent to the Department of Oncol-
ogy (4/10/2008), where he received six cycles of chemotherapy based 
on ifosfamide and doxorubicin with partial remission. Progression 
was noted one month after the last course with metastasis in the right 
lung. The patient died 11/25/2008.
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Pleural angiosarcoma have been described in patients with the history 
of irradiation or chronic tuberculous pyothorax. None of these factors 
were presented in the patient. Primary chest wall angiosarcoma is 
asymptomatic or is presented with chest pain, dyspnoea, swelling, 
hemothorax, cough, hemoptysis, weight loss, fever.
There are variety of radiolographic appearance associated with pul-
monary angiosarcoma: linear infiltrates, pleural effusion, pneumo-
thorax, thin wall of the chest or cystic lesions.
Diagnosis of angiosarcoma can be difficult and should be confirmed 
by immunohistochemical staining: CD31, CD34, factor VIII related 
antigen. Cytokeratins, pankeratin are used to exclude epithelial 
origin.
Primary angiosarcoma is very malignant. Even if there are many 
therapeutic modalities (chemotherapy, radiation, surgery) most of 
the patient die within a few months after diagnosis. A 5-year survival 
rate is 5 – 10 % . Local recurrence usually appear within 2 years. The 
most common site of metastasis are lymph nodes and lungs. 
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Objectives: HAPLN1 is an extra-cellular matrix protein which plays 
a crucial role in cancer progression, mediating host-tumor inter-
actions. Previous work has demonstrated increased HAPLN1 mRNA 
and protein expression in malignant pleural mesothelioma (MPM) 
tumor specimens compared to matched normal tissue. MPM cell 
lines that express HAPLN1 have greater metastatic potential, but the 
molecular pathways for HAPLN1 tumorigenicity are incompletely 
understood. Increased angiogenesis is essential for tumor growth and 
metastasis. We hypothesize that HAPLN1 confers increased angio-
genic potential in MPM.
Methods: Mutated HAPLN1 constructs were created to assess the 
impact of select regions of the protein on angiogenesis. HAPLN2 is 
defined by deletion of the n-terminal signal peptide and HAPLN5 
by deletion of two c-terminus link domains with retention of the 
signal peptide. The angiogenic properties of HAPLN1 and the two 
mutated constructs was evaluated by transfecting cDNA plasmids 
unique to each subtype into MPM cell lines (Hmeso and H2595), and 
comparing conditioned media collected after 72 hours in serum free 
conditions to that from pCMV empty vector controls. Media was ana-
lyzed on a bovine capillary endothelial (BCE) angiogenesis platform 
measuring tubule formation, and VEGF (pg/ml) concentrations were 
measured by ELISA (IBL, Japan). 
Results: Overexpression of HAPLN1 resulted in a significant 
increase in BCE tubule length in both Hmeso (1220u, p<0.001) and 
H2595 (1273u, p<0.001) compared to controls (468u). VEGF secre-
tion was also significantly increased with HAPLN1 overexpression 
compared to controls.(Fig) Overexpression of the mutated construct 
HAPLN5 resulted in a similar significant increase in tubule length 
compared to controls in Hmeso (1056u, p<0.001) and H2595 (1293u, 
p<0.001).(Fig) HAPLN2 overexpression resulted in a significant in-
crease in tubule length (668u and 652u respectively, p<0.03), but the 
effect was less pronounced. VEGF secretion was also significantly 
increased by the mutated constructs over controls.(Fig) HAPLN5 was 
comparable to native HAPLN1 in all experiments. 
Conclusion: We have demonstrated that HAPLN1 overexpression 
markedly increases angiogenesis in an in vitro BCE platform. The 
native protein and mutated construct which retained the N terminal 
signal peptide (HAPLN5) showed the most significant increases. 
HAPLN2, which lacks the signal peptide, also increased tubule 
formation, with a reduced effect. All HAPLN proteins increase VEGF 
secretion. This observation may lead to therapeutic strategies which 
target the n-terminus of HAPLN1 to potentially alter the malignant 
properties of MPM.
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Background: natural course of Malignant Pleural Mesothelioma 
(MMP) expose to dyspnea and chest pain but sometimes medullary 
compression can occur.
Observations: we report a 8 cases study of MMP with medullary 
evolution. They are men 56 to 74 years old. Histologic findings are 
epithelioid (n=5), sarcomatoid (n=2) or mixte (n=1). Overall survival 
is 7 to 86 monthes. Medullary involvment is regional, distant or both. 
medullary compression occurs by foraminal infiltration (n=5) or 
vertebral involvment (n=3). It occurs 7 to 84 monthes after diagnosis. 
7 patients benefit from radiotherapy, 3 in addition to chemotherapy. 5 
die in early 60 days after medullary invasion but survival can reach 9 
to 15 monthes (n=3) in patients who previously responded to platine-
alimta schedule.
Comments: medullary compression is uncommon presentation 
of progression disease in MPM. It can occur because of regional 
extension or bone metastasis. Different mechanisms are responsible: 
hematogenic diffusion, foraminal infiltration or vertebral metastasis. 
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It is poor a prognostic factor but radiotherapy can be benefit, with no 
evidence of relationship beetween histological presentation, espe-
cially when associated with platine-pemetrexed chemotherapy if prior 
response in first-line treatment.
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Background: Response assessment with conventional criteria based 
on computed tomography (CT) is challenging in malignant pleural 
mesothelioma (MPM) due to its diffuse pattern of growth. Prelim-
inary reports have shown promising results with the use of fluoro-
deoxyglucose positron emission tomography (FDG-PET) imaging.
Methods: Two consecutive series of MPM patients treated with 
first-line pemetrexed-based chemotherapy were evaluated by FDG-
PET and CT at baseline and after two cycles of therapy. Metabolic 
response (MR) was defined by a decrease of ≥ 25% in maximum 
standardized uptake value (SUVmax), or by any decrease of Total 
Glycolytic Volume (TGV), a volume-based parameter defined using a 
previously validated semi-automated region-growing algorithm. Best 
overall response from CT scans was determined according to modi-
fied RECIST criteria. MR was correlated to patient outcome in terms 
of progression-free survival (PFS) and overall survival (OS). 
Results: Forty-five patients were included in the study. MR defined 
by variation of both SUVmax and TGV was significantly correlated 
to PFS, with an hazard ratio (HR) of 2.60 (95% CI 1.27-5.20, p< 
0.001) for SUVmax and of 2.80 (95% CI 1.46-5.36, p=0.001) for 
TGV. Similar results were obtained when OS was considered, with 
an HR of 2.61 (95% CI 1.19-5.73, p=0.024) for SUVmax and of 2.41 
(95% CI 1.20-4.85, p=0.009) for TGV.
Conclusions: This study confirms that MR evaluated by FDG-PET 
is effective in predicting patient outcome in MPM. Volume-based 
analysis of PET scans is feasible, but further studies are needed to 
define the optimal response criteria. 
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Pleuropulmonary blastoma PPB is an extremely rare, intrathoracic 
neoplasm of early childhood with unfavourable outcome. Pleuro-
pulmonary blastoma (PPB) is a dysontogenetic neoplasm of child-
hood that involves lung and/or pleura. Characterized histological by 
a variably mixed blastematous and sarcomatous patterns. We present 
a case of a 27-year-old young man with progressive dyspnea due 
to intrathoracic mass. After the CT scan showed large multilocular 
lesions containing air and solid areas involving the right lower lobe, 
and its related pleura. CT scan guided biopsy was carried out. On 
histological examination, the tumour consisted of cystic walls and 
associated solid lesions which showed undifferentiated blastemal 
tissues with focal fibrosarcomatous and rhabdoid features. Immuno-
histochemically the tumour cells only showed diffuse strong positiv-
ity for vimentin. The histologic findings corresponded to a type II 
PPB. Treatment for PPB consists primarily of surgery and chemother-
apy. The patient was started on chemotherapy Bleomycin, Etoposide, 
platinum based. The patient progressed on therapy and developed 
metastasis in bone and soft tissue and expired due to progressive 
disease. 
Conclusion: The classic pulmonary blastoma is described as a 
neoplasm with a mixture of primitive tubular profiles, immature 
blastema, and a spindle cell stroma. More recently, some have in-
cluded the well-differentiated adenocarcinoma of fetal type as a pure 
epithelial expression of pulmonary blastoma. By contrast, most cases 
of pulmonary blastoma in children have been described as having 
an exclusive mesenchymal composition, either embryonal rhabdo-
myosarcoma or a complex, mixed blastematous and sarcomatous 
neoplasm. There is no consensus for its management.
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Background: Malignant pleural mesothelioma is a disease with a 
poor prognosis. At present, it is unclear whether a second line chemo-
therapy might improve the outcome and what is the best schedule to 
be used. Moreover, it is also possible that only patients selected with 
histology and previous response to first line chemotherapy might 
benefit of this treatment. For this aim we reviewed the casistic of five 
Italian Institutions.
Matherials and Methods: We retrospectively reviewed all the charts 
of patients affected with mesothelioma in every institution and the 
outcome of those treated with a second line regimen. Data were 
evaluable for the outcome and for the main clinical and histopatho-
logical characteristics. Analysis was performed with Kaplan Meier 
curves and Log Rank was used for testing differences .
Results: We analyzed 216 patients affected with mesothelioma and 
we retrieved 84 patients underwent to a second line regimen. Patients 
were 60% male and 40% female; the median age of all sample was 62 
years (range: 40-78). Main regimens were: 1) pemetrexed rechallenge 
in 26 (31%) pts, 2) Platinum rechallenge in 35 (42%) pts, 3) Vinorel-
bine in 1 (1%) pt, 4) Gemcitabine in 1 (1%) pt and no rechallenge in 
the other 25% of patients.
Patients achieving a control disease with a second line regimens were 
38 (49%).
Median OS for all patients treated with a second line regimen was 25 
months (range: 20-33), median PFS was 15 months (range: 14-18). 
A statistical significant effect was seen for those patients obtaining a 
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response with the second line treatment in terms of PFS (p <0.0001) 
and in terms of OS (p=0.036). A significant effect was seen also for 
those patients rechallenged with platinum (p=0.0089) and for those 
having an epithelial histology (p=0.007).
Conclusions: A certain effect was seen in second line chemotherapy, 
this independently by the regimes used. This advantage seems more 
pronounced for patients with an epithelial histology than others, and 
in patients responders to a first line regimen. This advantage must be 
tested in prospectively properly planned studies.
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posterior mediastinum: case report
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Introduction: Mesothelial (coelomic) cysts are rare congenital be-
nign lesions. They can be seen in extrathoracic regions such as liver, 
vena portae, spleen, kidney, surrenal gland, pancreas, tuba uterina, 
ovary, paratesticular region and diaphragma and the pleura. We 
present a case of benign paravertebral coelomic (mesothelial) cyst in 
the posterior mediastinum which is a rare lesion. 
Case: In the PA/lateral thoracic graphy of a forty seven year old fe-
male patient, a uniformly bounded lesion in the paravertebral region 
of the left lung which was near the ascendant aorta was detected. 
In her thorax CT, a 9x12 cm uniformly bounded, septated cystic 
lesion in the left paravertebral region which was near the aorta and 
esophagus was detected (fig 1 ). Diagnostic and theurapeutic surgery 
was done because the cystic lesion in the posterior mediastinum was 
seen uniformly bounded in thorax MRI. Left video- assisted thoraco-
scopic surgical (VATS) exploration was applied but then left lateral 
mini-thoracotomy was applied because of the pleural adhesiveness. 
Paravertebral cyst in the posterior mediastinum which was behind the 
ascendant aorta was seen and the bright liquid was drained away by 
ponction. The wall of the cyst was completely resected. The pathol-
ogy of the lesion showed benign mesothelial (coelomic) cyst. The 
patient was discharged at the 4th day, postoperatively.
Conclusion: Neurogenic tumors, bronchogenic cysts and enteric 
cysts are the most common tumors in the posterior mediastinum. 
Congenital mesothelial (coelomic) cysts are rarely seen tumors which 
can be localised in the posterior mediastinum.
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Giant thymolipoma of the anterior mediastinum: case 
report
Dubus, Turkan1; Celik, Gurhan2; Pasaoglu, Esra3
1 Istanbul Training and Research Hospital Thoracic Surgery Clinic, 
Istanbul, Turkey; 2 Istanbul Training and Research Hospital General 
Surgery Clinic, Istanbul, Turkey; 3 Istanbul Training and Research 
Hospital Pathology Clinic, Istanbul, Turkey
Introduction: Thymolipomas are benign neoplasms of the thymus 
composed of mature adipose tissue and thymic tissue which dif-
ferenciate from endoderm and mesoderm. They are rare, slowly 
growing, benign mediastinal tumors accounting for 2% to 9% of all 
thymic tumors. No sexual predominance has been observed, and the 
tumor may appear at any age. Thymolipomas can be asymptomatic 
but dyspnea, chest pain and weight loss can occur if they attain a 
huge size because of the compressive characteristic of the tumor 
and also myasthenia gravis can be seen as it is seen in other thymic 
lesions. The association with other diseases, such as hyperthyroid-
ism, lymphangioma, aplastic anemia, chronic lymphocytic leukemia 
and the Hodgkin lymphoma has been well documented . The only 
curative therapy is resection of the tumor and no recurrence has been 
documented.
Case: We detected a mass localized at the right paracardiac region 
of a 25 year old male patients’ incidental posteroanterior chest 
radiograph. In contrasted CT, a 12x14x17 cm diametered mass was 
detected at the right paracardiac region of anterior mediastinum. The 
mass was seen as a uniformly bounded mass in thorax MRI. The 
gastroscopic examination results were normal. The patient underwent 
right anterior toracotomy with the indication of anterior mediastinum 
originating tumor. The mass was removed completely and his hysto-
pathological report revealed giant mediastinal thymolipoma (fig 1).
Conclusion: If thymolipomas are diagnosed lately they can show 
themselves with compressive-related symptoms. Because no recur-
rence has been documented after surgical therapy, it is the only cure.
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Assessing the efficacy of radiotherapy for local control 
of malignant pleural mesothelioma using total glycolytic 
voluming of serial 18F-FDG PET scans
Feigen, Malcolm1; Lee, Sze Ting2; Wada, Mori1; O’Keefe, Graeme 2; 
Lawford, Catherine3; Lawlor, Marita4; Scott, Andrew M.2
1 Senior Radiation Oncologist, Heidelberg West, VIC, Australia; 
2 Centre for PET, Austin Health, Heidelberg, VIC, Australia; 3 
Senior physicist, Heidelberg, VIC, Australia; 4 Radiation therapist, 
Heidelberg, VIC, Australia
Background: Despite major advances in anticancer therapies over 
the past two decades, few patients with malignant pleural mesotheli-
oma are cured. Surgical excision, either by extrapleural pneumonec-
tomy (EPP) or pleurectomy/decortication (PD) is followed by local 
recurrence in up to 90% of operable patients. The contributions of 
radiotherapy, chemotherapy and biologic targeted agents remain lim-
ited and appear unable to make any durable impact on this disease. 
Hemithoracic radiotherapy is now standard for preventing loco-
regional relapse after EPP and in recent series intensity-modulated 
radiotherapy (IMRT) has been found to minimize radiation toxicity to 
adjacent organs. 
The aim of our study was to assess the effect of radiotherapy on gross 
disease in mesothelioma patients. 
Methods: FDG-PET scans from patients who received high dose 
wide-field hemithoracic radiotherapy were compared before and 
after treatment. The radiotherapy planning target volume was defined 
on each PET scan as a volume of interest and a region-growing 
algorithm software program generated the high activity volume on 
each scan to calculate the total glycolytic volume (TGV). A software 
program that has been validated for chemotherapy response in meso-
thelioma was used. 
Results: From 2003 to 2008 we delivered radiation doses of 45 to 60 
Gy to the involved hemithorax of eleven mesothelioma patients who 
in most cases had gross residual disease after incomplete surgery. 
Nine patients underwent PD, one had an EPP and one had primary 
radiotherapy alone. Nine were treated with 3D-conformal RT and 2 
with IMRT. No neoadjuvant or postoperative chemotherapy was ad-
ministered, except in one patient who developed progressive disease 
on chemotherapy following EPP, and any other chemotherapy was 
only given as palliation once relapse had been documented.
All patients had PET scans prior to radiotherapy planning to assist 
in targeting metabolically active disease. A total of 17 followup PET 
scans were performed between three months and three years after 
irradiation. The TGVs of two patients were nonevaluable due to dif-
ficulty distinguishing normal cardiac activity and radiation pneu-
monitis from tumor uptake. Of the 9 remaining patients, TGVs were 
reduced to a mean of 38% by radiotherapy. There were no serious 
radiation toxicities, and four patients had grade 2 radiation pneumon-
itis, including one whose scans are featured in Figure 1. Typically, 
tumor progression occurred in this and most other patients in regions 
outside the treated volumes. Four patients remain alive, two disease-
free.
During the course of the study, improved hardware and software 
became available to improve precision in radiotherapy targeting 
(dedicated PET/CT scanners, PET/CT fusion software, immobil-
ization devices, IMRT) and it is likely that some regions of poor 
responses were due to geographic misses from suboptimal localisa-
tion. Assessment of additional patients using this program will allow 
dose-volume responses to be critically analysed. 
Conclusions: Our findings indicate that mesothelioma is a radio-
responsive tumor and that radiotherapy should be adopted as an im-
portant component of multimodality programs to delay or prevent the 
local manifestations of progressive disease in suitable patients after 
surgery. High radiation doses should be considered for long-term pal-
liation, with or without systemic therapies.
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Investigation report of 108 malignant mesothelioma cases 
in Japan diagnosed between 2005 and 2007
Fujimoto, Nobukazu1; Gemba, Kenichi1; Aoe, Keisuke2; Yamasaki, 
Koichi3; Kishimoto, Takumi1
1 Okayama Rosai Hospital, Okayama, Japan; 2 NHO Yamaguchi-Ube 
Medical Center, Ube, Japan; 3 Hokkaido University Medical School, 
Sapporo, Japan
Background: Malignant mesothelioma (MM) is an uncommon 
neoplasm arising from the mesothelial cells lining the pleura. MM is 
considered to be associated with history of asbestos exposure (AE); 
however, the relationship between occupational AE and develop-
ment of MM has not been fully investigated in Japan. This study is a 
nationwide survey to examine the clinical features of MM in Japan, 
including the association with occupational AE.
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Methods: We investigated the clinical features and working environ-
ment or residential history of malignant mesothelioma cases by send-
ing the survey sheets to Rosai Hospital Groups and related facilities 
in Japan. 
Results: We found 108 MM cases (median age: 61 years, range 
35-80, male/female: 89/19) with confirmed diagnosis from 31 
institutions, including 97 (89.8%) originated in pleura, 7 (6.5%) in 
peritoneum, 2(1.9%) in pericardium, 1(0.9%) in tunica vaginalis 
testis. Pathological subtypes of MM were 61(56.5%) epithelioid, 
19(17.6%) biphasic, 17(15.7%) sarcomatoid and 11 undetermined. 
Characteristic radiological findings indicating AE were as follows; 
Pleural effusion was documented in 75(69.4%), pleural plaque in 
44(40.7%) and asbestosis was found in 1 (0.9%). As a principal treat-
ment option, 57(52.8%) cases were undergone systemic chemother-
apy and surgery was performed in 39(36.1%) cases. As an initial 
chemotherapy regimen, cisplatin + pemetrexed was delivered in 24, 
vinorelbine + gemcitabine in 14, and cisplatin + gemcitabine in 7 
cases. Occupational history was obtained from all the patients and AE 
was indicated in 94 cases (87.0%), including 24 patients in shipbuild-
ing industry, 17 in construction industry, 9 in plumbing, 8 in electric 
work, 7 in manufacturing industry, 5 in asbestos products industry 
and automobile manufacture, and others. There were 2 patients in 
which AE was indicated in life environment, who was living in the 
neighborhood of asbestos products industry. Median time of AE was 
29 (1-60) years and median time between first AE and development 
of MM was 41 (4-65) years. 
Conclusion: The association between MM and AE were revealed by 
this nationwide survey. Medical information including occupational 
history or life environment should be obtained carefully in MM 
patients.
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Can soluble mesothelin-related peptide (SMRP) in pleural 
effusion be a useful biomarker for an early diagnosis of 
malignant pleural mesothelioma?
Fukuoka, Kazuya; Yamada, Syusai; Kuribayashi, Kozo; Nakano, 
Takashi
Department of Respiratory Medicine, Hyogo College of Medicine, 
Mukogawa-cho, Nishinomiya, Hyogo, Japan
Background: Early diagnosis for malignant pleural mesothelioma 
(MPM) is believed to play an important role in the improvement of 
its prognosis. We have demonstrated that soluble mesothelin-related 
peptide (SMRP) in serum is highly specific and moderately sensitive 
biomarker for MPM. In the present study, we investigate whether 
SMRP in pleural effusion can be a useful biomarker for an early 
diagnosis of MPM.
Methods: Pleural fluid was collected from 84 patients with MPM, 46 
with lung cancer (LC), 23 with benign pleural disease (BPD), and 8 
with benign asbestos-pleurisy (BAP). SMRP levels in effusion were 
determined by a double determinant ELISA and cut-off value was set 
at 20 nM. 
Results: SMRP in pleural effusion had a sensitivity of 65.5% for 
MPM and a specificity of 93.5% when compared with LC; 100% 
BPD; 100% BAP. Receiver operating characteristics (ROC) curve 
demonstrated that the area under the curve (AUC) for differentiating 
between MPM and the other diseases ranged from 0.782 to 0.878. 
According to each stage of MPM, the mean levels of SMRP and 
sensitivity showed as follows; 84.3 nM; 66.7% in stage I, 48.6nM; 
55.6% in stage II, 65.9 nM; 87.5% in stage III, and 76.8 nM; 60.0% 
in stage IV patients. SMRP levels in effusions were elevated not only 
in advanced stage, but also in early stage.
Conclusions: Measurement of SMRP levels in pleural effusion may 
contribute to make an early diagnosis of MPM.
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Molecular prognostic markers in Malignant Pleural 
Mesothelioma (MPM) 
Bahnassy, Abeer A.; Gaafar, Rabab M.; Zekri, Abdel-Rahman N.; 
Abdelrahman, Abdelrahman M.; Aboulkassem, Fatma A.; Elsherif, 
Ghada M.
National Cancer Institute, Cairo University, Cairo, Egypt
Background: Malignant pleural mesothelioma (MPM) is a highly 
aggressive disease with a generally poor prognosis. Recent data 
demonstrate that escape from G1 checkpoint control is a frequent 
event in several solid tumors. The INK4A/ARF locus and its encoded 
proteins, p16INK4A and p14ARF, plays an important role in this con-
trol mechanisms. The aim of this study is to evaluate the role of the 
following cell cycle regulatory genes p16INK4A, p14ARF, p21WAF, 
p27kip1, p53, mdm2 and Rb in the development and progression of 
MPM. 
Patients and Methods: In a prospective study performed in the 
National Cancer Institute, Cairo, we assessed 55 Egyptian cases of 
MPM for aberrant protein expression of p16INK4A, p14ARF, p53, 
mdm2, p21waf, p27KIP1 and Rb using immunohistochemistry, p53 
mutation via SSCP/sequencing, mdm-2 gene amplification and Rb 
loss by differential PCR and methylation of p16INK4A, p14ARF 
genes by methylation specific PCR. The results were correlated with 
the standard clinico-pathological prognostic factors for MPM as well 
as overall survival (OS). 
Results: The median age of he studied patients was 46 years (range 
20-70), 29 were males and 26 were females (ratio 1.1:1). Twenty 
two patients had Performance status (PS) grade 1, 29 had PS2 and 
4 had PS3. Thirteen patients were stage I and IV (each), 15 were 
stage II and 9 were stage III. The pathological type was epithelioid in 
28 patients, sarcomatoid in 21 and mixed in 6 cases. The history of 
asbestos exposure was given by 47 cases.
Altered expression of p14ARF, p16INK4A, p53, mdm2, p21waf, 
p27KIP1 and Rb was detected in 50%, 53%, 40%, 51.7|%, 53.3%, 
61.7% and 70% of the cases respectively. There was a significant cor-
relation between increased expression of mdm2 and reduced expres-
sion of p14ARF (p=0.001), p21waf (p=0.02) as well as between p53 
overexpression and p21waf loss and (p=0.02). Also, there was a sig-
nificant correlation between p27KIP1 loss and altered Rb expression 
(p= 0.011). However, multivariate analysis showed that only PS≥2, 
p27KIP1 loss and altered Rb expression were independent prognostic 
factors affecting the OS in Egyptian MPM patients.
Conclusions: MPM is a complex disease characterized by multiple 
genetic aberrations in the cell cycle regulatory genes. The p14ARF, 
mdm2, p53, p21waf pathway seems to play a pivotal role in the 
pathogenesis of MPM whereas the p16INK4A, p27KIP1, Rb pathway 
is involved in disease progression as it contributes to survival. 
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Treatment of malignant pleural mesothelioma with 
cisplatyl based chemotherapy
Gamaz, Bensaou M.; Kamel, Bouzid 
Medical Oncology Department, Algiers, Algeria
Background: Malignant pleural mesothelioma (MPM) is an ag-
gressive and rapidly lethal cancer, and before having a new drug as 
pemetrexed, there was no standard to treat this disease. The purpose 
of this study is retrospective analysis of three bitherapy containing 
cisplatin, in terms of toxicity, response and survival. We analyzed all 
consecutive patients treated with cisplatyl based chemotherapy as-
sociated with either etoposid, gemcitabin or pemetrexed. 
Patients and Methods: Between January 2000 and December 2008, 
a total of 24 patients were treated. Four (4) patients received CDDP 
+ etoposide (CE), 18 pts CDDP + GMZ (CG) and 2 pts CDDP + 
pemetrexed (CP). 
Chemotherapy regimen consisted: cisplatin (C) 70 mg/m² on D1 + 
etoposid (E) 150 mg/m² on D1 every 3 weeks in group A; + gem-
citabin (GMZ) 1250 mg/m² D1 & 8 every 3 weeks in group B; + 
pemetrexed (P) 500 mg/m² D1 every three weeks for group C.
Results: The median age was 59 years (range 38 to 77 years). The 
groups were comparable in terms of age, performance state and stage 
of disease. 
Grade III-IV toxicities include vomiting 20 %, leucopenia 9.4 %, 
neutropenia 1.2 %, thrombocytopenia 2 %, anemia 10 % .
Complete response was observed in one patient, partial response in 
two patients, and stable disease in 11 patients. 
The median survival was 11 months in group CE, 10.1 months in 
group CG and 15.5 months in group CP. The median progression free 
survival was 12 months.
Conclusion: The activity of chemotherapy is Malignant Pleural 
Mesothelioma is limited. Chemotherapy with platin is well tolerated 
and active; the association with pemetrexed seems good and better 
regarding to the median survival.
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Survival of malignant mesothelioma in a retrospective 
survey in the west part of Japan
Gemba, Kenichi1; Aoe, Keisuke2; Kato, Katsuya3; Nojiri, Shuko 
4; Sato, Tsugumichi4; Yamagichi, Takuhiro 5; Kubota, Kiyoshi 5; 
Kishimoto, Takumi 1
1 Okayama Rosai Hospital, Okayama, Japan; 2 Yamaguchi Ube 
Medical Center, Ube, Japan; 3 Okayaa University, Okayama, Japan; 
4 DSRU Japan, Tokyo, Japan; 5 Tokyo University, Tokyo, Japan
Background: There are very limited data regarding malignant meso-
thelioma (MM) in Japanese population and the recommendations for 
treatment have been rather empirical.
Objectives: To identify variables including therapies associated with 
prognosis of Japanese patients with MM.
Methods: A retrospective cohort study was conducted in patients 
with MM in the west part of Japan. The diagnosis of MM was evalu-
ated by 4 specialists using immunohistochemistry and other informa-
tion. Of a total of 402 patients registered, the diagnosis of MM was 
confirmed with 328 by the review committee. The main treatments 
included operation, radiation, pleurodesis, and chemotherapy 
(Gemcitabine, Vinorelbine, Platinum compounds, etc). The survival 
analysis was performed and association with survival was examined 
for variables by the univariate analysis and Cox proportional hazard 
regression model.
Results: A majority (87%) of patients were males and the median 
age was 66.5 years old. During the observation period, the median 
survival was 307.0 days. Factors associated with poor survival was 
old age, non-ephithelioid type, high PS, high TNM stage and high 
WBC, high and low platelet count, low Hb values. Regarding thera-
peutic measures, pleurodesis and any chemotherapy were neutral and 
operation and radiation showed positive and negative associations 
with survival, respectively. When the systemic chemotherapies were 
included in the model separately, some of them showed negative as-
sociation with survival.
Conclusions: The present study on Japanese patients with meso-
thelioma may provide baseline data for future research as it shows 
important prognostic factors such as age, PS, TNM classes and some 
of laboratory data.
P2.079 Mesothelioma, Thymoma and Others, Sun Aug 2 
Phase II study of the Histone Deacetylase (HDAC) 
Inhibitor Belinostat in thymic malignancies
Giaccone, Giuseppe1; Rajan, Arun1; Carter, Corey A.1; Kelly, Ronan 
J.1; Berman, Arlene1; Trepel, Jane 1; Lee, Min J.1; Espinoza-Delgado, 
Igor1; Spittler, John2; Loehrer, Patrick J.2
1 National Cancer Institute, National Institutes of Health, Bethesda, 
MD, USA; 2 Indiana University, Indianapolis, IN, USA
Background: Thymic malignancies are rare tumors of the anterior 
mediastinum. Platinum-based chemotherapy is used for first-line 
treatment of advanced disease. About 50% of patients with advanced 
disease may fail initial therapy. There is no established role of 
second-line therapy in patients with refractory or recurrent disease. 
Belinostat is an HDAC inhibitor which is being investigated in sev-
eral solid tumors. One prolonged minor response (31 m) was seen in 
a phase I study of this agent in a patient with thymoma.
Methods: Patients with recurrent thymoma or thymic carcinoma, 
progressing after platinum-based chemotherapy were eligible. They 
were required to have measurable disease, PS 0-2 and normal organ 
functions. Belinostat was given intravenously (IV) at 1.0 g/m2/d on 
days 1-5 of a 21-day cycle until disease progression or intolerable 
side effects. For patients who had received more than 12 cycles of 
therapy, belinostat was administered every 28 days. Correlative mark-
ers of activity in blood and tumor were performed.
Results: From December 2007 to March 2009, 28 patients with 
thymic malignancies have been enrolled at 2 institutions; 18 thymo-
mas and 10 thymic carcinomas. 15 patients are males and the median 
age is 50.5 years (23-72). Mean number of prior regimens was 3.2 (1-
10). 18 patients underwent prior tumor resection and 4 had myasthe-
nia gravis. A median of 4 cycles of belinostat has been administered 
(1-18+). Treatment was well tolerated, with nausea being the most 
common side effect and well controlled with prophylactic antiem-
etics. 24 patients are evaluable for response: 2 had a partial response 
(11+, 11+ m), 14 stable disease (2-12+ m) and 8 progression. No 
responses were seen in 8 evaluable patients with thymic carcinomas. 
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Peripheral blood mononuclear cells (PBMCs) were obtained and 
acetylated lysine, a measure of pan-protein acetylation, and acetyl-
ated tubulin were analyzed in lymphocytes and monocytes by multi-
parameter flow cytometry. Tubulin and lysine protein acetylation in 
PBMCs was generally observed one hour after belinostat infusion 
on day 3 of the first cycle. In 9/9 patients analyzed for acetylated 
lysine at baseline and 1 hour post-infusion on day 3 of the first cycle, 
a response of between 2.2-fold and 10.4-fold over baseline was ob-
served. In 5/5 patients analyzed at the same time points for acetylated 
tubulin, a response of between 2.1-fold and 8.9-fold over baseline 
was observed. Other correlative markers are being analyzed.
Conclusions: Belinostat has activity in patients with recurrent or 
refractory thymoma. The thymoma cohort has been expanded to the 
second stage of the study and enrollment is ongoing.
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Insulin-like Growth Factor-1 Receptor expression in 
thymic malignancies
Girard, Nicolas; Teruya-Feldstein, Julie; Riely, Gregory J.; Pao, 
William; Rusch, Valerie W.; Kris, Mark G.; Zakowski, Maureen F.
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Background: Thymic epithelial tumors are intrathoracic malignan-
cies that can be aggressive and difficult to treat. At the pathologic 
level, these tumors are classified as thymomas and thymic carcin-
omas. The former are further subdivided into types A, AB, B1, B2, 
B3, depending on the extent of the lymphocytic component, the 
degree of atypia, and the resemblance with normal thymus. Insulin-
like Growth Factor-1 Receptor (IGF-1R) is a tyrosine kinase impli-
cated in cell growth and survival. IGF-1R has recently emerged as a 
potential therapeutic target in various epithelial cancers. In a recent 
phase I trial with the IGF-1R inhibitor CP-751,871, one patient with 
thymoma experienced tumor shrinkage (Haluska P, et al. 2007 ASCO 
meeting. Abstract 3586). Here, we assessed expression levels of total 
IGF-1R, along with EGFR and KIT, in thymic malignancies.
Methods: We collected 52 thymic tumor tissue specimens from pa-
tients operated on at Memorial Sloan-Kettering Cancer Center. After 
a pathological review, cores from formalin-fixed, paraffin-embedded 
tissues were taken and assembled in triplicate into a tissue microarray 
(TMA). We performed IHC using antibodies against EGFR (clone 
31G7, Invitrogen, Camarillo, CA), KIT (clone A4502, Dako, Carpin-
teria, CA), and IGF1R (Clone G11, Ventana-Roche, Tuscon, AZ) by 
automated staining according to manufacturer’s instructions. Staining 
was evaluated semi-quantitatively from 0 (absence of staining) to 
1+ (low intensity staining), 2+ (moderate intensity staining), and 3+ 
(high intensity staining). We explored correlations between the in-
tensity of staining and clinico-pathological characteristics, including 
WHO type and Masaoka stage, using Fisher’s exact test. 
Results: Immunohistochemical stainings were interpretable for 48 
tumors. Tumor type was thymoma in 42 cases (type A n=3, type AB 
n=12, type B1 n=8, type B2 n=14, type B3 n=5), and thymic carcin-
oma in 6 cases. Tumors were stage I in 24 cases, stage II in 17 cases, 
stage III in 6 cases, and stage IV in 1 case. EGFR staining was 0 in 1 
(2%) case, 1+ in 14 (29%) cases, 2+ in 12 (25%) cases, and 3+ in 21 
(44%) cases. KIT staining was 0 in 46 (96%) cases, and 3+ in 2 (4%) 
cases. IGF-1R staining intensity was 0 in 12 (25%) cases, 1+ in 15 
(31%) cases, 2+ in 16 (33%) cases, and 3+ in 5 (10%) cases. Overall, 
moderate (2+) to high (3+) IGF-1R staining was observed in 5/6 
(83%) thymic carcinomas and in 16/42 (38%) thymomas (p=0.049, 
Fisher ‘s exact). Moderate (2+) to high (3+) IGF-1R staining was 
significantly associated with moderate (2+) to high (3+) EGFR stain-
ing (p=0.004, Fisher ‘s exact). IGF-1R staining did not correlate with 
Masaoka stage or KIT staining.
Conclusion: We observed positive IGF-1R immunohistochem-
ical staining in 83% of thymic carcinomas and 38% of thymomas. 
Coupled with the earlier observation of clinical activity with an IGF-
1R inhibitor in a patient with thymoma, this data supports further 
evaluation of IGF-1R inhibitors in thymic malignancies.
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RON kinase activation in mesothelioma
Easty, David; Gray, Steven G.; Kennedy, John; O’Donnell, 
Dearbhaile M.; O’Byrne, Kenneth J.
St James Hospital, Dublin, Ireland
Background: Expression of receptor tyrosine kinases (RTK) and 
their cognate ligands has been described in mesothelioma, leading to 
the hypothesis that autocrine growth pathways could be therapeutic 
targets of tyrosine kinase inhibitors (TKIs). 
Methods: Phospho-RTK arrays were used to evaluate phosphoryla-
tion of 42 RTKs in 4 mesothelioma cell lines and 11 mesothelioma 
surgical specimens. RON emerged as a frequently identifed kinase 
and an extended panel of sixteen mesothelioma tumour and five 
benign pleural tissue samples were characterised by western blot 
analysis. The presence of RON message was confirmed by RT-PCR 
with specific primers in mesothelioma cell lines. 
Results: Tumours contained 14 phospho-RTKs, including RON 
which has not been previously reported in mesothelioma. Western 
blot analysis detected RON in 16 tumours and 4 cell lines but not in 
the SV-40 transformed normal mesothelial MET-5A cells. Mesotheli-
oma expressed different isoforms of RON compared to benign pleural 
plaques: both benign pleural plaques and mesotheliomas expressed 
the shortform of RON (sf-RON), whereas, the larger RON variants, 
160 and 165 kDa, were seen only in mesothelioma samples. 
Conclusions: Mesothelioma contains multiple activated RTKs 
including RON. Previously, RON was shown to mediate epithelial 
mesenchymal transition (EMT). This may be significant given the 
epithelioid to sarcomatoid spectrum of mesothelioma. Expression 
of 160 and 165 kDa RON was previously reported in gastric and 
colorectal cancers and may be associated with oncogenesis. RON 
has been identified as a therapeutic target in pancreatic cancer and 
this may also apply in mesothelioma. Functional studies of RON 
silencing using siRNA in mesothelioma are ongoing and data will be 
presented at the meeting.
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A case of mesothelioma which had aggressive course with 
unusual distant organ metastases
Akpınar, Evrim E.2; Haliloğlu, Ahmet H.1; Ataoğlu, Ömür3; Gülhan, 
Meral2
1 Ufuk University,Department of Urology, Ankara, Turkey; 2 Ufuk 
University, Department of Chest Diseases, Ankara, Turkey; 3 Mikro-
pat Pathology Laboratory, Ankara, Turkey
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Aim: Malignant mesothelioma is the most common malignant tumor 
of plevra, however it is rarely seen. The disease usually has a ten-
dency of making local metastasis. Although, the rate of hematgenous 
metastases is more than 50% in autopsy series, distant organ metas-
tases that are clinically evident are rarely seen. The aim of the study 
is to present a mesothelioma case that cause conflict in the diagnosis 
due to unusual distant organ metastases. 
Case: A fifty nine years-old male patient who admitted to a clinic 
with the complaints of pleuretic chest pain was diagnosed as 
sarcomatous type of mesothelioma by the pleural biopsy and left 
pleuropneumonectomy was performed. The patient was admitted to 
our clinic for adjuvant chemotherapy with a delay of three months 
due to postoperative complications. He had right shoulder pain and a 
swelling on the right scrotum. Phsyical examination revealed a mass 
of 4x2 cm on scrotum with redness and ulceration on the overlying 
skin. There was multiple nodules in the right lung on chest X-ray. 
PET-CT revealed pathological activity in the nodules on the right 
lung, in the mass on the right shoulder and in the scrotal mass.The 
diagnosis of mesothelioma was in doubt because of distant organ 
metastases that were developed in a short period of time. So, the mass 
on the right scrotum was excised to confirm diagnosis histopatho-
logically. The pathologic diagnosis was sarcomatous type malignant 
mesothelioma like the first diagnosis. The patient had been lost due to 
massive pulmonary embolism when he had applied for second course 
of pemetrexed+cisplatin treatment.
Conclusion: This is the first case of mesothelioma which cause scro-
tal metastasis in the literature. We suggest that clinicians should kept 
in mind that mesothelioma, especially sarcomatous form, might cause 
rapidly developing distant organ metastases like our case. 
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Inhibition of Hsp90 leads to cell cycle arrest and apoptosis 
in human malignant pleural mesothelioma
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Dawn T.1; Clement, Genevieve1; Yagui-Beltran, Adam1; Ray, M R.1; 
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Heat shock protein 90 (Hsp90) is an abundant molecular chaperone 
that mediates the maturation and stability of a variety of proteins 
associated with promotion of cell growth and/or survival. Inhibition 
of the Hsp90 function leads to the proteasomal degradation of its 
misfolded client proteins. Recently, Hsp90 has emerged as being of 
prime importance to the growth and survival of cancer cells and its 
inhibitor has already been used in phase I and II clinical trials. We 
investigated whether the role of 17-allylamino-17-demethoxygel-
danamycin (17-AAG), a small molecule inhibitor of Hsp90, has 
important implications in human malignant pleural mesothelioma. We 
found that 17-AAG led to significant G1 or G2/M cell cycle arrest, 
inhibition of cell proliferation, and the decrease of AKT, AKT1 and 
Survivin expression in all human malignant pleural mesothelioma 
cell lines examined. We also observed significant apoptosis induction 
in all MM cell lines treated with 17-AAG. Furthermore, 17-AAG 
induced apoptosis in freshly cultured primary MM cells and caused 
identical signaling changes as that in 17-AAG treated MM cell lines. 
These results suggest that Hsp90 is strongly associated with the 
growth and survival of MM and that inhibition of Hsp90 may have 
therapeutic potential in the treatment of MM. 
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Arsenic trioxide induces apoptosis of human malignant 
mesothelioma cells through induction of reactive oxygen 
species
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Background: Malignant mesothelioma is a malignant tumor refrac-
tory to current treatments. Arsenic trioxide is used clinically to treat 
acute promyelocytic leukemia, and also inhibits the growth of cells 
from several solid tumors including hepatoma, esophageal and gastric 
cancer in vitro. As a novel anticancer agent for malignant meso-
thelioma, we here examined the effect of arsenic trioxide on human 
mesothelioma cell lines. 
Methods: Growth-inhibitory effects of arsenic trioxide on 4 human 
mesothelioma cell lines were examined by CCK-8 assay. Arsenic 
trioxide-induced apoptosis was evaluated by the expression of 
annexin-V using flow-cytometry. 
Results: Arsenic trioxide inhibited the proliferation of mesothelioma 
cell lines in a dose-dependent manner. Treatment of arsenic triox-
ide induced apoptotic cell death of mesothelioma cells. Apoptosis 
induced by arsenic trioxide accompanied by the increased activity of 
caspase-3 in a dose-dependent manner. Furthermore, N-acetyl-L-cyst-
eine, a thiol-containing anti-oxidant, completely blocked caspase-3 
activation and apoptosis, which indicated that reactive oxygen species 
(ROS) initiated apoptosis. 
Conclusions: These results suggest that arsenic trioxide induces 
apoptosis in mesothelioma cells via induction of ROS and may serve 
as alternative anticancer agent for currently uncurable malignant 
mesothelioma.
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Background: Malignant pleural mesothelioma (MPM) is usually 
diagnosed at an advanced stage, and is associated with a poor progno-
sis without therapy. Surgery alone for MPM is associated with a high 
recurrence rate even if complete resection is achieved. Longer surviv-
al is expected with multimodality regimens employing extrapleural 
pneumonectomy (EPP) in combination with adjuvant chemotherapy 
and radiotherapy. However, not all of the patients treated with EPP 
can live longer. We encountered seven cases in whom the survival 
after EPP was surprisingly prolonged. The aim of this study was to 
evaluate the histological features shared by these seven cases and de-
termine the prognostic significance of promoter methylation of genes 
in patients with MPMs.
Methods: We have analyzed 22 MPM cases. Sixteen were epi-
thelioid, four were sarcomatoid, and two were biphasic mesotheli-
omas. Ten cases were treated with EPP and 12 were treated with 
therapy other than surgery. Patients with MPM were divided into two 
groups: those who survived for < 5 years in EPP cases or < 2 years 
in non-EPP cases (short-time survivor, SS), and those who survived 
for > 5 years in EPP cases or > 2 years in non-EPP cases (long-time 
survivor, LS). DNA was extracted from paraffin-embedded sections 
mounted on glass slides by scraping with a needle under a stereo-
microscope. The dissected sections were digested by proteinase K 
over 2 nights at 37°C. Extracted DNA was modified by sodium bi-
sulfite with the EZ DNA Methylation Kit (Zymo Research). We have 
analyzed the methylation of p16INK4A, p14 ARF, p15INK4B, RASSF1A, 
and IGFBP-3 with methylation specific PCR. Forty cycles of ampli-
fication were used in the analysis of modified DNA samples. PCR 
products were loaded onto 3.0% agarose gels, stained with ethidium 
bromide, and visualized under ultraviolet illumination.
Results: There were 15 SSs and 7 LSs. Macroscopically, there was 
no visible tumor except one case in LS, and there was focal adhesion 
between parietal and visceral pleura. The thickness of the pleural 
tumor was < 5mm in LS. Histologicaly, they were well differenti-
ated, and showed papillary, tubular, or micorocystic patterns. Myxoid 
stroma was observed but desmoplastic change was not. Necrosis was 
not observed. Nuclear atypia was mild in two cases in LSs. Ki-67 la-
beling indices were 2-10% (mean 5%) in LS and 2-58% (mean 28%) 
in SS. The methylation frequency for individual genes was 20% for 
p16INK4A, 10% for p14ARF, 53% for p15INK4B, 10% for RASSFA1, and 
26% for IGFBP-3. Patients with p16 INK4A methylation had shorter 
survival than patients without p16INK4A methylation (p = 0.0243). 
Conclusions: Our study demonstrates that tumor volume of meso-
theliomas of LS is less than those of SS, and mesotheliomas of LS 
have common histological findings. The methylation of p16INK4A in 
MPM correlates with poor prognosis. These results suggest that there 
is a group of malignant mesothelioma with much less aggressive 
behavior than the usual MPM. These patients are diagnosed as meso-
thelioma at early stage. EPP with adjuvant therapy in these patients 
would prolong their survival.
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Background: The biomarker soluble mesothelin (SM) has recently 
been approved by the FDA as a monitoring tool for malignant meso-
thelioma (MM) patients (pts).
Aim: Validation of the clinical use of SM as a monitoring tool for 
MM pts, enrolled in a Belgian prospective observational study.
Methods: A total of 100 MM pts are planned for enrolment, with a 
blood sample taken at diagnosis (before treatment) and after every 
therapy session. Relative SM differences between baseline and the 
last follow-up are used to assess the kinetics during therapy, differ-
ences below 15% (ELISA kit variance) are considered stable. Serum 
SM (nM) was measured with FDA approved ELISA kits (MESO-
MARKTM, Cis bio International). Clinical response was determined 
with the RECIST guideline: partial response (PR), stable disease 
(SD) or progressive disease (PD). 
Results: From the 31 MM pts (28 epithelial histology) already 
included, 22 pts had a nearly complete follow-up. In 21 pts with a 
confirmed IMIG tumour stage, 6 presented stage I, 10 stage II, 3 stage 
III and 2 pts had stage IV. 
In 4 out of 8 pts with PR, a strong decrease of SM (56-80%) was 
present, while 3 pts had stable SM levels (Fig. 1). In 1 pt with 
PR, SM levels increased 86%. However, shortly afterwards the pt 
developed PD and deceased. In pts with SD, 2 out of 6 showed a de-
crease of SM levels (20-30%), 2 had increased SM levels (64-154%) 
and 2 presented stable SM levels. 4 out of 5 pts with PD showed 
increased SM levels (24-97%) and 1 had stable SM levels (Fig. 1). 
Finally, in 2 pts with tri-modality therapy, SM levels decreased 84-
95% after surgery.
Figure 1. SM correlated with the clinical response of MM pts: a 
decreasing trend in pts with partial response (left) and an increasing 
trend in pts with progressive disease (right) was present. c1-6: chemo 
cycle 1-6.
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Conclusion: Preliminary results demonstrated a strong relationship 
between the kinetics of SM and the clinical response of MM pts, 
illustrating the potential clinical value of SM as a monitoring tool. 
Updated results will be presented at the meeting.
--This study was made possible by a grant of the Belgian Foundation 
against Cancer--
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Background: Soluble mesothelin (SM), a 40-kDa biomarker for ma-
lignant mesothelioma (MM), is a low-molecular weight protein which 
can accumulate in serum due to a decrease in glomerular filtration 
rate (GFR). As GFR is age-dependent, declined GFR can be present 
in middle aged asbestos-exposed workers at risk of developing meso-
thelioma.
Aim: We investigated the impact of GFR on serum SM levels of 
individuals with different grades of renal failure.
Methods: 66 individuals (49 males, 17 females), without mesothelin 
overexpressing conditions, were included. All were referred for 
51Cr-EDTA clearance, the golden standard for GFR determination 
(ml/min/1.73 m²). Renal function was further assessed by creatinine, 
cystatin C and beta-trace levels (Siemens Diagnostics, Roche) in 
sera. Serum SM (nM) was measured with FDA approved ELISA kits 
(MESOMARKTM, Cis bio International). 
Results: Spearman rank analysis showed a significant correlation 
between the reciprocal values of serum SM and GFR (r = 0.494), the 
reciprocal values of creatinine (r = 0.462), cystatin C (r = 0.370) and 
beta-trace protein (r = 0.402). Using the regression line between re-
ciprocal SM values and GFR (1/SM = 0.268 + 0.01*GFR, r² = 0.255, 
P < 0.001), a theoretical correction of measured SM (SMcorr) can be 
derived (Fig. 1).
In 24 of 66 patients SM exceeded 1.5 nM, the manufacturer’s cutoff 
for differentiating healthy controls from MM pts, resulting in a false 
positive rate of 36%. These false positive results were uniquely 
present in cases with decreased GFR (< 90 ml/min/1.73 m²) (Fig. 
1). In addition, mean SM values differed significantly between cases 
with a normal GFR (0.85 nM, range 0.30-1.37 nM) and a decreased 
GFR (1.6 nM, range 0.50-5.82 nM) (p <0.001, student t-test). 
Conclusion: Serum SM correlated significantly with GFR, which 
makes GFR a confounder in application of the SM ELISA kit. There-
fore, caution is advised when interpreting test results in individuals 
with impaired renal function, e.g. in screening high risk populations, 
since reductions in GFR can result in falsely-increased SM concen-
trations. 
Figure 1. Scatterplot of 1/SM (nM) versus GFR (ml/min/1.73m²), with the regression line, 95% 
CI and the correction formula. Concentrations below the vertical dotted line (cutoff of 1/1.5 nM) are 
considered false positive results.
--This study was made possible by a grant of the Belgian Foundation 
against Cancer--
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Recent clinical experience with thymic neuroendocrine 
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Objective: Neuorendocrine tumors of the thymus, also known as 
thymic carcinoids, typically carry a poor prognosis and are quite rare. 
As such, their management has not been standardized. We reviewed 
our recent experience with neuroendocrine tumors of the thymus for 
outcomes.
Methods: Retrospective review of a single institution surgical and 
pathologic database. Data included patient demographics, staging, 
treatment, pathologic findings, and post-operative outcomes.
Results: During the 18 year period from 1990-2008, 26 patients 
with neuroendocrine tumors of the thymus were seen at our insti-
tution. Patient characteristics are listed in the table below. With a 
mean follow-up of 34.7 months (range 0.8-122.4, median 28.7), the 
actuarial 5-year overall survival was 64% and the 5-year progression-
free survival was 0%. The median overall survival was 68.6 months 
but the median time to progression or recurrence was 25.0 months. 
Of the 16 patients who have recurred so far, the majority ultimately 
developed distant failures (14/16 – 87.5%), with metastases most 
commonly to bone (9/14), lung (6/14) and liver (4/14).
Conclusion: Surgical resection remains the mainstay of treatment for 
neuroendocrine tumors of the thymus. Neoadjuvant therapy remains 
of unclear utility, and further investigation into better systemic 
therapies is needed. Given the high propensity for nodal spread, the 
Masaoka staging system may not be appropriate for determining 
prognosis in these patients. Despite a high propensity for recurrence, 
good long-term survival can be achieved. 
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 Age (Years) 
  Median 47.5
  Range 22-80
 Male Gender 19/26 (73%)
 Associated Syndromes (%) 
  Multiple Endocrine Neoplasia 3/26 (11%)
  Cushing’s Syndrome 2/26 (7%)
 Treatment Paradigm 
  Metastatic at Presentation / Non-Surgical Management 5/26 (19%)
  Preoperative Chemotherapy and Surgical Resection 5/26 (19%)
  [Response rate (Partial or Complete Response)] [1/5 (20%)]
  Surgical Resection Alone 16/26 (62%)
 Surgical Resection Status 
  Grossly Complete Resection 17/21 (81%)
  R0 Resection 10/21 (48%)
 Reasons for Incomplete Resection 
  Bilateral Phrenic Involvement 2 (50%)
  Myocardial Involvement 1 (25%)
  Unresectable Pleural Involvement 1 (25%)
 Additional Resected Structures 
  Superior Vena Cava / Innominate Vein 9 (43%)
  Pericardium 9 (43%)
  Lung Wedge / Lobectomy 7 (33%)
  Phrenic Nerve 4 (19%)
 Sites of Recurrence 
  Distant and Locoregional 9/16 (56%)
  Distant Only 5/16 (31%)
  Locoregional (Mediastinal and/or Pleural) Only 2/16 (12%)
 Masaoka Stage 
  I 4 (15%)
  II 1 (4%)
  III 1 (4%)
  IVa 3 (12%)
  IVb 17 (65%)
 Proportion of Patients with Lymph Node Metastases 14/16 (87%)
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Pneumonectomy and medical treatment in 60 patients.
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Background: The management of MPM continues to evolve, but no 
standard therapeutic strategy has been accepted worldwide. Trimodal-
ity therapy including neoadjuvant chemotherapy with pemetrexed-
based regimens, radical surgery and adjuvant radiotherapy (RT) has 
been recently proposed to improve survival in selected patients (pts).
Methods: Sixty consecutive pts submitted to extrapleural pneumon-
ectomy (EPP) in our Institute over a 9-year period were retrospective-
ly reviewed. Disease-free survival (DFS) and overall survival (OS) 
were analyzed, according to prognostic variables (stage, histology, 
nodal status) and to peri-operative treatments. The influence of med-
ical treatments on the pattern of relapse was also determined. 
Results: Forty-six pts were male (76.7%), with a median age of 61 
years (range 35-72). Twenty-one pts (35%) had EPP alone; 24 (40%) 
had induction chemotherapy (in 20 cases including pemetrexed), fol-
lowed by adjuvant RT in 13 cases; 10 pts had adjuvant RT only, and 6 
pts received post-operative chemotherapy. Median hospital stay was 
9 days (range 5-70). Thirty-day operative mortality was 1.7% (1 pt 
died of abdominal herniation); 27 patients (45%) had complications. 
Histology was epithelial in 49 cases (81.7%). Three patients were 
stage I (5%), 8 stage II (13.3%), 44 stage III (71.7%) and 6 stage IV 
(10%). In 35 patients nodes were negative (58.3%), 12 patients had 
pN1 (20%) and 13 patients had pN2 disease (21.7%). 
Median OS of the whole population was 21 months, with an overall 
1, 2 and 3-year survival rate of 67, 42 and 20%, respectively. Median 
OS was 31 months in stage I-II, 21 months in stage III, and 8 months 
in stage IV pts; however, these differences did not reach statistical 
significance (p=0.27). Pts with pN2 disease had a shorter survival 
than those with pN0-1 disease (median OS 16 vs 22 months, p=0.05). 
Median DFS of the whole group was 11 months. Median DFS was 
27, 11 and 5 months respectively for stage I-II, stage III and stage IV 
pts (p=0.008). One ypT3N0 pt is disease-free at 48 months from the 
start of induction chemotherapy.
OS and DFS were not statistically influenced by chemotherapy or RT, 
although median DFS for patients submitted to EPP only was shorter 
than for pts who had EPP and medical treatment (8 vs 12 months, 
p=0.5). A lower rate of both local (34.5% vs 61.3%, p=0.04) and dis-
tant (34.5% vs 54.8%, p=0.12) recurrence was observed in the group 
of patients who received chemotherapy.
Conclusions: EPP can be performed with the same mortality of other 
major thoracic procedures, but the rate of complications remains 
high. Presence of pN2 disease is confirmed as a negative prognostic 
factor. In selected patients with early stage prolonged survival can be 
obtained, but available treatments still have modest results. Ran-
domized trials are needed to determine the role of surgery and non 
surgical treatments in MPM.
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Expression profiling of glycosylation pathways in pleural 
mesothelioma 
Ivanov, Sergey; Pass, Harvey I.; Huflejt, Margaret
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Background: Malignant mesothelioma (MM) is a lethal cancer of the 
pleura associated with exposure to asbestos. Poor median survival, 
resistance to chemo- and radio-therapies, and a delayed onset of the 
disease (10-20 years after exposure) demand the development of 
more efficient diagnostic, prognostic, and therapeutic tools. Under-
standing the molecular mechanisms of cancer-specific glycosylation 
that facilitate evasion from immune surveillance and which stimu-
lates tumor growth and invasion is critical for development of novel 
clinical applications. Recent progress in characterization of human 
genes and proteins involved in glycosylation provided the opportun-
ity to correlate their activity with MM tumor growth and metastatses. 
Methods: We performed expression profiling of 301 glyco-genes 
using RNA isolated from fully annotated diagnostic and prognostic 
sets of tissue specimens derived from MM patients. Using Xenobase 
software we identified among these genes 91 diagnostic and 29 prog-
nostic discriminators (p<0.05) and validated a substantial portion of 
them by RT-PCR. In ensuing work, we performed unsupervised hier-
archical clustering of microarray data and searched KEGG database 
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
Copyright © 2009 by the International Association for the Study of Lung CancerS764
to analyze cellular pathways associated with differentially expressed 
gene groups. 
Results: We demonstrated that MM cells up-regulate the N- and 
O-glycosylation pathways as well as Golgi and ER functions through 
transcriptional stimulation of genes that encode glycosyltransferases, 
glucosidases, and other proteins involved in proteoglycan degrada-
tion, synthesis and secretion. The group of genes down-regulated in 
MM included immunoregulatory C- and L-type lectins and selectins. 
Representational Oligonucleotide Microarray Analysis (ROMA) of 
genomic copy number alterations in MM and expression profiling of 
clinical specimens of MM suggested that at least one of these genes, 
CLEC3B that encodes a C-type lectin (tetranectin) and is located in 
the critical 3p21.3 loss area, may serve as a tumor suppressor. 
Conclusions: Our study demonstrates that a large fraction of 
glycosylation-associated genes may have important therapeutic 
implications and may be used in future for diagnostic and prognostic 
purposes as well as to provide more detailed insight into the mechan-
isms of cancer-associated glycosylation.
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FUS1 is a novel tumor suppressor located in the critical 3p21.3 
chromosomal region frequently deleted in multiple cancers. We 
previously showed that Fus1-deficient mice display a complex 
immuno-inflammatory phenotype with a predisposition to cancer. The 
goal of this study was to analyze possible involvement of FUS1 in 
malignant mesothelioma (MM) – an aggressive inflammatory cancer 
associated with exposure to asbestos. Here, we demonstrated FUS1 
insufficiency in MM through different approaches. First, FUS1 down-
regulation in the majority of MM specimens (~84%) was established 
at the mRNA and protein levels. Second, we used Representational 
Oligonucleotide Microarray Analysis (ROMA) to report 3p21.3 loss 
in ~36% of MMs including stage 1 tumors. Third, pursuing a possible 
link between FUS1 and exposure to asbestos, we established involve-
ment of asbestos-generated reactive oxygen species (ROS) in FUS1 
down-regulation. Global profiling of FUS1 transcriptional effects in 
MM showed that FUS1 stimulated expression of multiple genes with 
tumor suppressor properties and down-regulated pro-tumorigenic 
genes supporting its role as a tumor suppressor. In agreement with 
our knockout model, FUS1 up-regulated IL-15 and also modulated 
more than 40 other genes (~20% of total FUS1-affected genes) 
associated with immune system. Finally, clinical significance of 
FUS1 transcriptional effects was validated on expression array data 
produced on 30 MM and 7 control specimens. In this analysis, 42 
FUS1 targets proved to be modulated in MM and served as disease 
discriminators. Thus, our data support therapeutic potential of FUS1, 
define its targets, and underscore its importance as a transcriptional 
regulator of anti-tumorigenic pathways. 
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Background: The number of deaths world-wide from malignant 
pleural mesothelioma (MPM) is expected to increase substantially in 
the next 20 years, particularly where large-scale use of asbestos has 
occurred. There is thus a growing need to develop new therapies for 
treating patients with this disease. Levels of IL-6 protein in pleural 
fluid of MPM patients have been reported to be markedly high and 
various studies indicate a pathogenic role for IL-6 in the progres-
sion of this disease. The IL-6/JAK/STAT3 signaling pathway may 
therefore represent a novel therapeutic target in patients with MPM. 
The suppressor of cytokine signaling 3 (SOCS3) protein is a negative 
regulator of this signaling pathway, however the therapeutic potential 
of SOCS3 delivery in MPM has not been previously explored. In this 
report we have evaluated the therapeutic potential of SOCS-3 gene 
delivery as a novel treatment for MPM. 
Methods: IL-6 protein levels in 24-hr culture supernatants of MPM 
cell lines were quantitated by ELISA. MPM cell lines were transi-
ently transfected with a replication-defective recombinant adenoviral 
vector expressing SOCS3 (AdSOCS3) or dominant-negative STAT3 
(AddnSTAT3). Levels of JAK1 and STAT3 protein in cell lines fol-
lowing transfection with AdSOCS3 or AddnSTAT3 or treatment with 
JAK inhibitor 1 (an inhibitor of JAK activation), were determined 
by Western blot analysis. To investigate a cancer inhibitory effect of 
SOCS3 gene delivery in vivo, AdSOCS3 was injected intrathoracical-
ly in nude mice 7, 14 and 21 days following implantation of MPM 
cells into the thoractic space. Twenty-eight days after cell inoculation, 
tumors in the thoracic spaces were removed and weighed.
Results: In MPM cell lines, the highest levels of IL-6 secretion were 
observed in cultured H226 and EHMES-1 cells. IL-6 activated JAK1 
and STAT3 in cultured H226 and EHMES-1 cells. AdSOCS3 inhib-
ited the growth of cultured H226 and EHMES1 cells. Jak inhibitor 1 
inhibited the growth of EHMES1 cells but not of H226 cells. In H226 
cells, AdSOCS3 and JAK inhibitor I inhibited STAT3 phosphoryla-
tion, but only AdSOCS3 inhibited JAK1 phosphorylation. These 
results indicate that STAT3 activation is activated by molecules other 
than JAK1 in H226 cells. AddnSTAT3 did not inhibit cell growth, 
but JAK1 siRNA inhibited cell growth in H226 cells. These results 
indicate that the growth of H226 cells is partially regulated by JAK1 
signaling pathways independent of STAT3. AdSOCS3 also induced 
apoptosis and G0/G1 arrest in cultured H226 cells. Injection of Ad-
SOCS3 into the thoracic cavity of a mesothelioma xenograft mouse 
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model significantly (p<0.01) inhibited tumor growth (mean tumor 
weight at 28 days± SD= 49±21 mg) compared with control AdLacZ-
injected mice (mean tumor weight at 28days± SD= 82±21 mg. Thus, 
AdSOCS3 exhibited potent anti-tumor activity in a mesothelioma 
xenograft mouse model.
Conclusions: We demonstrate that SOCS-3 gene delivery signifi-
cantly inhibits the growth of cultured MPM cell lines and strongly 
inhibits tumor growth in a mesothelioma xenograft mouse model. 
These cancer cell growth inhibitory effects of SOCS-3 are mediated 
via STAT3-dependent and STAT3-independent pathways. Import-
antly, SOCS-3 gene delivery may represent a novel and effective 
therapeutic strategy for the treatment of human MPM.
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Targeting eukaryotic translation with an eIF4E-specific 
antisense oligoncleotide in mesothelioma
Jacobson, Blake A.1; Thumma, Saritha C.1; Jay-Dixon, Joe 1; Patel, 
Manish2; Sadiq, Ahad A.1; Graff, Jeremy R.3; Kratrzke, Robert A.1
1 University of Minnesota, Department of Medicine, HOT, 
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Background: Malignant mesothelioma (MM) is an aggressive cancer 
arising from the serosal lining of the pleural cavity with a median 
survival of less than one year from diagnosis. Current therapeutic 
options are limited. Deranged cap-dependent protein translation 
is implicated in tumorigenesis in multiple tumor types including 
mesothelioma. The rate-limiting step in the initiation of translation 
is the binding of eukarotic initiation factor 4E (eIF4E) to the 5’-cap 
structure of mRNA. Mesothelioma cells have been shown to have 
enhanced cap-dependent translation compared to benign mesothelial 
cells and this results in a disproportionate increase in the translation 
of select mRNAs involved in malignancy. In this study, MM cells 
were treated with an antisense oligonucleotide (ASO) that specifically 
targets eIF4E mRNA for destruction. Disabling the eIF4F molecular 
complex by targeting eIF4E with eIF4E-specific ASO is assessed as a 
potential cancer therapy for MM. 
Methods: MM cells or untransformed mesothelial cells were trans-
fected with second-generation ASOs (Eli Lilly). eIF4E-ASO was 
designed to target the 3’-untranslated region of human eIF4E mRNA. 
Mismatch ASO-control contains the same base composition as 
eIF4E-ASO. Following treatment, the cells were either harvested or 
counted 72 hours later. The level of eIF4E, ODC, Bcl-2 and β-actin 
were assessed using Western analysis following treatment. Cell 
survival was measured in MM treated with eIF4E-ASO combined 
with either gemcitabine or pemetrexed. The strength of cap-mediated 
translation in treated cells was measured using a 7mGTP cap-affinity 
assay of eIF4E in cell lysates followed by immunoblot analysis. 
Results: eIF4E protein level decreased in response to treatment with 
eIF4E-ASO for MM cell lines, while non-transformed mesothelial 
cells (LP9) were affected substantially less. Additionally, treatment 
with eIF4E-ASO repressed cap-dependent translation as assessed in 
the cap-affinity assay. Specific suppression of eIF4E mRNA in MM 
cells that were treated with eIF4E-specific ASO led to pronounced 
inhibition of MM proliferation compared to the mismatch control. 
Following treatment, nearly 50% of H2373 cells were killed with 
100 nM eIF4E-ASO and 40% of H2596 with 200 nM. LP9 showed 
little affect at all concentrations. There is a direct correlation between 
suppression of eIF4E protein and MM cell growth inhibition upon 
eIF4E-ASO treatment. Translationally regulated proteins (ODC, 
Bcl-2) involved in malignancy were shown to extensively decrease 
along with reduced eIF4E expression. In contrast β-actin levels were 
unaffected. Combination therapy of eIF4E-ASO with pemetrexed or 
gemcitabine led to additional MM cell toxicity when compared to 
each drug alone. 
Conclusions: eIF4E-ASO is a novel drug that selectively reduces 
eIF4E levels, cap-dependent translation, and proliferation of 
mesothelioma cells. Knockdown of eIF4E results in decreased anti-
apoptotic protein and cell growth proteins and as a result leads to 
enhanced chemosensitivity. Further development of drugs that target 
cap-dependent translation are warranted for this disease.
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Functional significance of macrophages in the pathogenesis 
of malignant pleural mesothelioma and its therapeutic 
potential
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Broaddus, Courtney V.3; Coussens, Lisa M.1, 4
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CA, USA; 4 Helen Diller Family Comprehensive Cancer Center, 
University of California, San Francisco, San Francisco, CA, USA; 
5 Division of Thoracic Surgery, Brigham and Women’s Hospital, 
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Mesothelioma is a life-threatening cancer initiated as a result of 
inhaled asbestos fibers, commonly found in pleural spaces, which 
is largely resistant to most chemotherapeutic approaches. We have 
revealed that, within human mesotheliomas, there is a population 
of immune cells, i.e., macrophages, that regulate the sensitivity 
of mesothelioma cells to cytotoxic anticancer agents. Recent data 
indicate that macrophages can be targeted therapeutically to minimize 
some aspects of cancer development. Thus, the overall goal of our 
studies is to determine the functional significance of macrophages as 
regulators of chemosensitivity of human mesotheliomas, and to target 
macrophages pharmacologically to enhance chemosensitivity. In our 
preliminary studies, we have found that 1) mesothelioma has a larger 
population of macrophages (27% of all immune cells present) as 
compared to other thoracic cancers such as non-small cell lung cancer 
(<9%) or esophageal cancer (<4%), and 2) macrophage phenotype 
can be altered by cytokine exposure and thereby alter mesothelioma 
cell death responses to standard chemotherapy. These studies indicate 
that the chemo-resistance of mesotheliomas to pharmacologic agents 
that typically induce apoptosis, is largely regulated by the presence of 
macrophages within tumors. Interestingly, macrophages found within 
mesothelioma spheroids display a unique cell surface marker profile 
characteristic of TH2-activation, i.e., CD14+CD32+CD68+HLA-
DR+CD115lowCD23lowCD1a-. To determine the functional signifi-
cance of macrophage phenotype on mesothelioma cell survival, we 
have engineered an ex vivo 3-dimensional organoid model enabling 
heterotypic culture of mesothelioma cells with macrophages, where 
macrophage phenotype can be manipulated by TH1 versus TH2 cyto-
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kines. To be presented will be recent data evaluating the functional 
significance of macrophage phenotype on mesothelioma cell survival 
as well as data demonstrating the functional significance of macro-
phages as regulators of mesothelioma apoptosis ex vivo. 
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Prolonged pemetrexed(P)/platinum treatment for 
advanced malignant mesothelioma - renal safety aspects 
Karthaus, Meinolf1; Schuth, Irmgard2, 2; Schuth, Elisabeth3
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Background: Malignant mesothelioma (MPM) is a rare and aggres-
sive neoplasm with a short life expectancy. Standard care of MPM is 
P + cisplatinum (DDP). The optimal duration of chemotherapy(ctx) 
for MPM remains an open question. There are sparse data on the 
feasibility of maintenance with P/DDP. Maintenance treatment of 
MPM requires long term organ safety. A major obstacle to sustained 
P/DDP for MPM is renal safety beside neurotoxicity. At present, there 
are very few data regarding renal safety in pts receiving > 6 cycles of 
P/DDP in MPM.
Methods: We evaluated long term renal function of P(500 mg/m2)/
DDP(75 mg/m2) for MPM prospectively. Chemotherapy (ctx) on 
d1 was repeated on d22 until disease progression or toxicity. Pts 
with impairment of renal function (creatinine-clearance <60 ml/
min) switched to P/carboplatin (CP) AUC 5 for further ctx. P ctx was 
stopped if creatinine-clearance (CrCl) <45 ml/min. Routine folinic 
acid and vitamine B12 was administered to prevent AE. Study end-
point was long term renal function for sustained therapy of P/DDP 
followed by P/CP and/or P-mono. 
Results: Between 12/02 and 05/06 86 consecutive MM pts were 
treated. Staging revealed peritoneal MM in 19, and pleural MM in 67 
pts. Five pts did not receive ctx. First-line ctx was P/DDP in 66 pts 
(prior s-crea 0.85; SD 0.17) given a mean of 4.9 cyles (range 1-11) 
for a mean of 120 d (21-397 d) and a mean of 138 mg DDP/cycle. 
28 pts received CP/P sequentially for further maintenance up to 27 
cycles (mean 6.4). A change from P/DDP to P/CP was necessary due 
to a worsening renal function in all of those pts. Mean s-crea/CrCl 
prior to DDP ctx in those pts was 0.87 mg/dl (SD 0.17)/96.0 ml/min 
(SD 26) and 1.01 mg/dl (SD 0.29)/73.4 ml/min (SD 22) at the end 
of P/DDP. Mean given CP dose was 425 mg/cycle (range 175 - 725 
mg). Pts subsequently receiving P/CP had a s-crea of 1.16 mg/dl 
(CrCl 73.4 ml/min) prior to ctx that did not change during P/CP (1.13 
mg/dl/CrCl 73.2 ml/min). 13 pts received P-mono with a mean of 8 
cycles (1-26) subsequently. Renal function showed a s-crea(CrCl) of 
1.13 mg/dl (71.2 ml/min) prior and 1.11 mg/dl (70.8 ml/min) at the 
end of P ctx.
Conclusions: Long term maintenance P/DDP of MPM is limited by 
renal impairment due to DDP, while subsequent P/CP or P-mono was 
feasible and not associated with further deterioration of renal func-
tion. Further trials with sustained P/CP or P ctx for MPM are war-
ranted to evaluate the efficacy of maintenance for advanced MPM.
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Background: The differential diagnosis of benign reactive mesothel-
ium (RM) from malignant mesothelial proliferations by morphology 
can be a major challenge. A number of markers have been proposed, 
including epithelial membrane antigen (EMA), p53 protein, and 
P-glycoprotein, however, up to present, there exists no immunohisto-
chemical marker which confidently allows for the separation of RM 
and MPM. 
A family of glucose transporter isoforms (GLUT), of which GLUT-
1 is a member, facilitates the entry of glucose into cells. GLUT-1 is 
largely undetectable in normal epithelial tissues and benign epithelial 
tumors by immunohistochemistry, but the expression is recognizable 
in a variety of carcinomas. The expression of GLUT-1 appears to 
be a potential marker for malignant transformation. Recently, some 
studies have shown that GLUT-1 expression is useful in resolving the 
common diagnostic dilemma of distinguishing benign from malig-
nant lesions. There is the report that Glut-1 is availability in diacrisis 
of MPM and RM immunohistologically. The purpose of the present 
study was to evaluate the diagnostic utility of GLUT-1 expression in 
the differential cytological diagnosis between MPM and RM. 
Methods: A total of 50 pleural effusion smears of RM and 20 smears 
of MM were retrieved for this study. Diagnosis of MM was con-
firmed by surgery or biopsy samples with immunostaining studies 
and/or electron microscopy. Diagnosis of RM was confirmed by 
clinical history.
Immunohistochemical staining for GLUT-1 was performed in 50 
RM and 20 MPM cases. D2-40 immunohistochemistry were also 
performed for comparison. 
Results: Immunohistochemical GLUT-1 expression was seen in 20/ 
20 (100%) MPMs, and the expression was distributed in cytoplasmic 
and membranous part in all cases. On the other hand, only one RM 
cases were positive for GLUT-1. The sensitivity, specificity, and ac-
curacy for Glut-1 were 100%, 98%, and 98.6%, respectively.
Conclusions: GLUT-1 is a sensitive and specific immunohistochem-
ical marker enabling differential diagnosis of RM from MPM in 
pleural effusion.
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Establishment of orthotopic xenograft models of human 
malignant mesothelioma and the effect of combined 
inhibition of MET and EGFR in vivo
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Background: Malignant pleural mesothelioma (MPM) is a devastat-
ing disease with resistance to conventional therapies, and patients 
with MPM show poor prognoses. We previously presented the effect 
of combined inhibition of MET and EGFR on malignant mesotheli-
oma cell lines in vitro. To test the effect of this combination in vivo, 
we established orthotopic xenograft models of human MPM cell lines 
and performed a preliminary experiment to administer inhibitors of 
MET and EGFR. 
Materials and Methods: Twenty-two MPM cell lines including 16 
Japanese cell lines we established were used. We first examined the 
tumorigenicity of the cell lines by subcutaneous implantation of 5 x 
106 MPM cells into nude mice. Fourteen cell lines were also inocu-
lated into the right thoracic cavity of mice, monitored for 6 months or 
until death, and then dissected to evaluate tumor growth. To deter-
mine the effect of inhibition of MET and/or EGFR in vivo, NCI-
H290, which had been demonstrated to induce the earliest remarkable 
tumor formation in the thoracic cavity of mice, was implanted into 
thoracic cavities of 12 mice. After the 4th day from implantation, 
PBS (control), SU11274 (MET inhibitor) at 10 mg/kg, PD153035 
(EGFR inhibitor) at 10 mg/kg, or SU11274 at 10 mg/kg and 
PD153035 at 10 mg/kg, were administered orally to 3 mice of each 
group for 6 days, and their weights and survivals were measured.
Results: Of 22 MPM cell lines injected subcutaneously into mice, 
6 (27%) tumors grew successfully to more than 5 mm in diameter. 
Regarding orthotopic models among 14 MPM cell lines tested, mice 
injected with 9 cell lines including all the 6 cell lines succumbed to 
tumor progression, with a mean survival of 74 days (range; 21-185). 
Concerning the effect of inhibitors against the orthotopic model with 
NCI-H290 cells, while no significant differences in survival were ob-
served among each group in this preliminary experiment, the weight 
loss in the SU11274+PD153035 group was the least of all.
Conclusions: We previously found elevated expression and activa-
tion of MET and EGFR in most human MPM cell lines and showed 
that their combined inhibition exerted a stronger inhibitory effect on 
tumor cell proliferation. For more clinically relevant MPM models, 
we established orthotopic xenograft animal models of human MPM 
cells, which would be useful for the assessment of new molecularly 
targeted drugs. 
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WIF1 expression is down-regulated by its promoter 
methylation in mesothelioma
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Background: Mesothelioma is an aggressive tumor that derives from 
the pleura or other mesothelial surfaces. Its incidence is increasing 
and has been recognized as a worldwide problem including Japan. On 
the other hand, Wnt inhibitory proteins, WIF1 (Wnt inhibitory factor 
1) and SFRPs (secreted frizzled-related proteins) have been shown as 
important implications in tumorigenesis, and promoter hypermethyla-
tion of WIF1 and SFRPs has been frequently identified in various 
human cancers. Our previous microarray analysis of whole genome 
expression revealed down-regulation of WIF-1 gene in mesothelioma. 
This prompted us to analyze the promoter methylation of WIF1 and 
SFRPs.
Methods: Eight mesothelioma cell lines, 50 mesothelioma tissues 
and 22 peripheral lung tissues with mesothelial lining cells were 
analyzed for promoter methylation of WIF1 and SFRPs (SFRP1, 2, 
4) genes by methylation-specific polymerase chain reaction (MSP). 
Mesothelioma cell lines were cultured in RPMI1640 media with 10% 
fetal bovine serum, kanamycin, and fungizone. Cell lines adhering 
to the culture dish were treated with 0 or 30 µmol 5-aza-2’-deoxy-
cytidine for 6 days, with the media and demethylating agent changed 
every 48 hours. DNA, RNA, and protein were extracted from har-
vested cells. WIF1 promoter methylation and mRNA expression were 
analyzed using MSP and real-time RT-PCR, respectively. Protein 
expression was analyzed by Western blotting.
Results: WIF1 promoter methylation was observed in all mesotheli-
oma cell lines (100%), and more frequently in mesothelioma tissues 
(36/50, 72%) than in peripheral lung tissues (3/22, 13.6%; P<0.0001). 
Treatment with 5-aza-2’-deoxycytidine demethylated WIF1 gene and 
restored WIF1 expression in 4 mesothelioma cell lines. Promoter 
methylation of SFRP1,2,4 was also observed in 20/37 (54%), 27/45 
(60%), and 18/38 (47.4%) of mesothelioma tissues, respectively. 
WIF1 and/or SFRPs promoter methylation was observed in 92% of 
mesothelioma tissues.
Conclusion: Our data suggest that WIF1 promoter hypermethylation 
is a common event in mesothelioma, and might play an important 
role in regulation of WIF1 expression. The high percentage of WIF1 
and/or SFRP promoter methylation in mesothelioma suggests that 
WNT inhibitory proteins may be involved in mesothelioma tumori-
genesis. WIF1 promoter methylation analysis may help to distinguish 
mesothelioma from non-neoplastic pleural lesions.
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Malignant mesothelioma: cytological and 
immunocytochemical study of pleural effusion
Kumar, Perikala V.; Owji, Seyed Mohammad; Mokhtari, Maral 
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Background: Malignant mesothelioma of the pleura is a rare malig-
nant neoplasm. The tumor contains pleomorphic cells, glandular and 
papillary like structures. We present the cytological and immuno-
cytochemical findings of malignant pleural mesotheliomas and 
discuss the differential diagnosis with special emphasis on the role of 
immunocytochemistry[ICC].
Materials and Methods: Cytospin smears were prepared from 
pleural effusion of 27 patients. Two smears were air dried and six 
smears were fixed in 95% ethyl alcohol.
In the present study a detailed cytologic study was done in 27 cases 
along with ICC and the histopathologic study.
Results: A total of 27 FNAB cases that were confirmed by histo-
pathologic study were identified over the 30-year study period. The 
ages ranged between 58-66 years, 25 were male and two were female.
The smears revealed numerous isolated and groups of atypical meso-
thelial cells with intercellular windows. Many glandular and papillary 
structures, composed of malignant cells with anisocytosis were seen. 
Bi and multinucleated malignant cells were also noticed. Reed-
Sternberg like cells seen frequently. Mitoses were frequently noticed. 
Asbestos bodies were not identified in these cases.
Mucicarnine stain was negative. Based on cytologic features, these 
cases were diagnosed as malignant tumors. However ICC was 
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performed to differentiate malignant mesothelioma from metastatic 
adenocarcinoma and reactive mesothelial proliferation.
ICC studies showed negative reaction with CEA and MOC-31 and 
positive reaction with EMA, calretinin and CK5/6.
Conclusion: Cytodiagnosis of malignant pleural Mesothelioma is 
difficult by cytomorphology alone. Clinical history is very important 
and helps for the interpretation of cytology smears. Cytological find-
ings of reactive mesothelial proliferation and metastatic adenocarcin-
oma can be confused with malignant mesotheliomas.
ICC study is mandatory for the diagnosis of malignant mesothelioma.
Some cases also require electron microscopic study for definite 
diagnosis. 
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Specialist pathological review of cases referred to a 
Mesothelioma Multi-Disciplinary Team 
Lester, Jason F.1; Gibbs, Allen R.2; Duckers, Jamie2; Linnane, Seamus 
J.2
1 Velindre Hospital, Cardiff, UK; 2 Llandough Hospital, Cardiff, UK
Introduction: The South East Wales Lung Cancer Network serves 
1.4 million people via six Multi-Disciplinary Teams (MDTs). In an 
attempt to facilitate and improve patient care, a regional mesotheli-
oma MDT was set up in March 2006, which included a central expert 
pathological review service. Referrals of confirmed cases or those 
clinically/radiologically suspicious of malignant mesothelioma were 
accepted. A review of cases referred to the mesothelioma MDT was 
carried out to establish how often the histological/cytological submit-
ted diagnosis was changed as a result of specialist MDT pathological 
review.
Methods: All patients discussed at the mesothelioma MDT between 
March 2006 and June 2008 were retrospectively assessed. Cases 
where biopsy/cytology material was submitted were included. Cases 
where the submitted diagnosis was uncertain but felt most likely to 
be mesothelioma were classified as ‘probable mesothelioma’. In all 
other cases, the submitted pathological diagnosis was recorded as that 
deemed most likely by the referring pathologist
Cases where the MDT carried out further diagnostic procedures to 
obtain tissue were excluded. The submitted pathological diagnosis 
was then compared to the specialist MDT pathological diagnosis. 
Results: In total, 56 cases were identified. In 37/56 cases (66%) 
the MDT pathological diagnosis was the same as the submitted 
pathological diagnosis. In 19/56 (34%) cases there was a difference 
between the submitted and MDT diagnoses. In 9/56 (16%) cases a 
submitted diagnosis of probable mesothelioma was confirmed, and 
in 2/56 (4%) cases a submitted diagnosis of mesothelioma NOS 
was changed to a specific mesothelioma subtype. In 1 case (2%) the 
mesothelioma subtype was changed. In 7/56 (13%) cases* there was 
a significant difference between the submitted and MDT diagnosis.
Conclusions: Overall, in 12/19 (63%) cases it is unlikely that the 
change in diagnosis significantly altered patient management. In 
these cases, the MDT pathological review either confirmed a prob-
able diagnosis of mesothelioma or defined/changed mesothelioma 
subtype. However in 7/19 (37%) cases highlighted in the table there 
was a significant difference between submitted pathological diagnosis 
and MDT pathological diagnosis. In the most obvious examples, 2 
patients with a submitted pathological diagnosis of mesothelioma 
were found to have benign conditions. These patients may have been 
spared inappropriate investigation and treatment. Overall, in this 
series MDT pathological review significantly changed the diagno-
sis in 7/56 (13%) cases. Specialist pathology review is an essential 
component of a regional mesothelioma MDT and has a direct effect 
on patient management.
 Submitted pathological diagnosis MDT pathological diagnosis No. of cases (%)
 Probable mesothelioma NOS Mesothelioma NOS 6 (11)
 Probable mesothelioma NOS Mesothelioma subtype 3 (5)
 Mesothelioma NOS Mesothelioma subtype defined 2 (4)
 Mesothelioma subtype Different mesothelioma subtype 1 (2)
 Other malignancy Mesothelioma 3* (5)
 Mesothelioma Other malignancy 1* (2)
 Other malignancy Benign 1* (2)
 Mesothelioma Benign 2* (4)
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The study of the molecular changes induced by asbestos in 
mesothelial cells using system biology approach
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Background: Mesothelioma, an aggressive tumor arising from the 
mesothelium, is usually associated with previous exposure to asbes-
tos. Although the causative linkage between asbestos exposure and 
mesothelioma has been well established epidemiologically, the mo-
lecular mechanisms by which asbestos induces the deleterious effects 
are still poorly understood. The long latency period between asbestos 
exposure and tumor development implies that multiple and likely 
diverse processes occur in malignant transformation of mesothelial 
cells. We recently developed a powerful Pathway Array system that 
is specifically designed to unlock the complex cell signaling network 
and provide answers to how tumors develop. 
Methods: (1) Pathway array--Total proteins were extracted from 
three cell lines including SV40 transformed nonmalignant human 
pleural mesothelial cells (MeT-5A, ATCC# CRL-9444), biphasic 
MM cells (MSTO-211H, ATCC# CRL-2081) and epithelial MM 
cells (NCI-H28, ATCC# CRL-5820), which treated with 5ug/cm2 of 
crocidolite or chrysotile for 24 hours, respectively, and then separated 
using SDS PAGE gel. The protein was then transferred to a nitro-
cellulose membrane using an electrotransfer apparatus (BioRad). The 
immunoblot was performed using 81 protein-specific or phosphoryla-
tion site-specific antibodies. (2) siRNA silencing: We transfected 
CDK6 siRNA into mesothelial cells using TransMessenger Transfec-
tion reagent (Qiagen Sciences, MD, USA) according to the manufac-
turer’s instructions. (3) MTT assay. 
Results: A total of 57 proteins/phosphorylations were detected by 
Pathway Array, and we demonstrated many important signaling 
pathways, such as CDK6, STAT3, TRAP, Wee-1 and ETS1, are dys-
regulated in exposed mesothelial cells. In order to determine the role 
of the dysregulated proteins in controlling cell signaling networks, 
we employed small interfering RNA (siRNA) technique. Out of 81 
protein/ phosphorylation tested, 20 of them showed more than 2 fold 
changes (either increased or decreased) after silencing CDK6. For 
example, many cell cycle related proteins were decreased after CDK6 
silencing, including 14-3-3β (14.29 folds), cdc25C (12.5 folds), 
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cyclin B1 (9.09 folds), cyclin D1 (3.7 folds), CHK1 (3.45 folds), and 
PCNA (2.38 folds). These results indicate that CDK6 has a broad 
effect on the cell signaling network controlling cell proliferation. We 
further tested whether inhibition of cdks, critical regulators of cell 
cycle progression, can enhance the growth inhibition of cisplatin, 
the most effective first-line treatment for malignant mesothelial. Our 
results showed that olomoucine, which is a selective inhibitor for 
cdks (cdk1, cdk2, cdk4, cdk6 and cdk7), synergistically enhanced the 
cisplatin’s activity for MM cells (combination index, CI = 0.47 for 
MSTO and CI=0.56 for NCI-H28). However, MSTO-221H is more 
sensitive to olomoucine and cisplatin than NCI-H28. In contrast, 
olomoucine had little effect on non-malignant mesothelial cells 
(MeT-5A) and did not enhance cisplatin’s activity (CI=1.9). 
Conclusion: These results indicate that the biomarkers (such as 
CDK6) identified by Pathway Array have great potential to be used as 
targets for drug therapy.
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Treatment of thymic tumors with long-acting somatostatin
Longo, Flavia1; De Filippis, Lucilla1; Zivi, Andrea1; Del Signore, 
Ester1; Gori, Bruno1; De Giacomo, Tiziano 3; Anile, Marco3; Venuta, 
Federico3; Diso, Daniele3; Coloni, Giorgio Furio3; Vitolo, Domenico2
1 Department of Clinical Oncology, “Sapienza” University of Rome, 
Rome, Italy; 2 Department of Pathological Anatomy, “Sapienza” 
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Background: Thymic tumors (TT) are rare and slowly growing 
cancers, sometimes associated with paraneoplastic autoimmune syn-
dromes such as myasthenia gravis, PRCA (pure red cell aplasia) and 
hypogammaglobulinemia. The prognosis of TT is highly influenced 
by recurrences, occurring up to 35% of cases even 10 years after 
treatment. Pleura is the most frequent site of relapse, together with 
the previous surgery area. Recurrence rate is usually low (2%) for 
stage I encapsulated tumors, although it approximately reaches 28% 
for stage II and III. When thymectomy is followed by radiotherapy 
relapse rate drops to 5%.
Thymomas cells highly express on their surface somatostatin 
receptors; for this reason they can show an elevated Indium-labeled 
octreotide (111-In-DTPA-D-Phe-octreotide) uptake when Octreoscan 
is performed. In the last few years, long-acting somatostatin analogs 
have been used as experimental treatment for patients diagnosed 
with an invasive TT and/or with residual disease after conventional 
therapies and a positive Octreoscan result.
Methods: In this retrospective, monoinstitutional study we evaluated 
the efficacy of the treatment with long-acting somatostatin in terms of 
progression free survival (PFS) and the safety profile; as secondary 
end point we evaluated the overall survival. From 1994 to 2008, 44 
patients with thymic malignancies were evaluated. Octreoscan was 
performed in 27 patients (61%): 20 patients after S and/or RT and/or 
CHT to confirm the results of first-level exams (CT scan and/or PET 
scan), 5 patients during the follow-up period after a CT and/or PET 
scan suggestive for disease recurrence, 2 patients in the early diag-
nostic phase to confirm a CT scan suggestive for thymic neoplasia. 
According to octreotide uptake, after obtaining written informed 
consent, 12 patients (3 with relapsed and 9 with residual disease) 
were treated with long-acting octreotide (Sandostatin LAR 20 mg) 
every 2 weeks. 
We evaluated the efficacy of the treatment expressed in terms of 
Complete Response, Partial Response and Stable Disease and the 
safety expressed in terms of occurrence of side effects due to the 
treatment. Treatment response was evaluated according to the RE-
CIST criteria; toxicity was evaluated according to the CTCAE v3.0.
Results: Treatment with Sandostatin LAR® of 12 patients, with posi-
tive Octreoscan, yielded the following Results: partial response in 3 
pts (25%), stable disease in 5 pts (42%), and progressive disease in 4 
pts (33%). Treatment was always well tolerated and only minor side-
effects were recorded (excepting 1 case of gallbladder calcolosis). 
Conclusions: Treating TT recurrences or residual disease with 
octreotide seems to be feasible and safe, even considering the short 
follow-up and the limited number of evaluated patients. All pts 
showed good compliance. Somatostatin has an antiproliferative ef-
fect in neuroendocrine tumor probably mediated by the inhibition of 
hormone-releasing hormone, the modulation of the immunity activ-
ities and the inhibition of angiogenesis. Positive Octreoscan gives the 
oncologist the possibility to address a new target, the somatostatin’s 
receptor, through the octreotide.
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Correlation between serum mesothelin related proteins 
and quantitative exposure to asbestos in occupationally 
exposed to asbestos: an exploratory preliminary analysis
Mencoboni, Manlio 1; Bruzzone, Andrea 2; Figliomeni, Mirna 1; 
Racchi, Omar 1; Migliazzi, Luca 3; Cioe’, Alex 3; Mortara, Virginia 
4; Marroni, Paola 5; Serra, Maria 1; Bergaglio, Marina 1; Filiberti, 
Rosangela 5; Spigno, Fabio 3
1 “Villa Scassi” Hospital, Genoa, Italy; 2 University of Genoa-
Department of Internal Medicine, Genoa, Italy; 3 University of 
Genoa-Occupational Medicine Department, Genoa, Italy; 4 INAIL-
National Institute for safe work, Genoa, Italy; 5 National Cancer 
Institute, Genoa, Italy
Background and Aims: Serum mesothelin-related proteins (SMRP) 
proved promising as predictive biomarkers of malignant mesotheli-
oma in asbestos exposed populations. A relevant matter could be 
to find a link between quantitative exposure to asbestos and SMRP 
levels. A few studies exist on the correlation between asbestos expos-
ure intensity and mesothelin levels, even if higher levels of SMRPs 
were observed in subjects highly exposed to asbestos. The finding of 
a positive correlation between quantitative exposure to asbestos as-
sessed with retrospective method and SMRP levels, would represent 
a further and effective tool for a better quantification of the risk. 
This study is part of a larger prospective cohort study on the predict-
ive role of SMRP in subjects occupationally exposed to asbestos. 
The aim is to estimate the correlation between SMRP levels and dif-
ferent scoress of asbestos exposure. 
Methods: SMRP was evaluated in a group of 406 subjects aged 55-
70 years, previously exposed to asbestos in the shipbuilding, iron and 
steel industries.
Assessment of exposure has inferred with an interview on the lifetime 
history, using a questionnaire form administered by trained interview-
ers (occupational physicians), including items on individual habits, 
pathological data, lifetime job title, occupational task, type of activity, 
calendar period, duration and frequency of asbestos exposure. 
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Results: SMRP was positively correlated with age (p=0.002). Median 
serum SMRP levels in subjects with higher exposure (high, continous 
and long exposure: HE) were similar to those with lower expos-
ure (LE, median 0.52 vs 0.50 nmol/L). Assuming a cut-off of 1.00 
nmol/L, SMRP was higher in 20% of subjects with HE vs 11% of LE. 
When considering age of studied subjects, SMRP did not discriminate 
between HE and LE in people younger than 65 years (median 0.46 
vs 0.49 nmol/L). On the other side, SMRP concentration was slightly 
higher in HE than in LE among subjects older than 65 years (median 
0.71 vs 0.53 nmol/L, p=ns ). 
Conclusions: Overall, no differences exist in SMRP levels according 
to different exposure scores. Nevertheless, the differences in SMRP 
distribution according to subjects’ age suggest to deepen the cor-
relation between SMRP and the exposure calendar period in a larger 
series of subjects. 
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Clinical feature and outcome of malignant pleural 
mesothelioma: Analysis of 80 cases, multi-institutional 
clinicopathological study
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Chikabumi3; Shiba, Mitsutoshi7; Iwai, Naomichi10; Saitoh, Yukio8; 
Nomoto, Yasushi11; Hiroshima, Kenzo9; Fujisawa, Takehiko1; 
Yoshino, Ichiro1
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Background: Malignant mesothelioma is a highly aggressive 
primary neoplasm of the pleural, peritoneal and pericardial surface. 
It is a challenging disease in all aspects from diagnosis to staging 
and treatment. The relative rarity of malignant pleural mesotheli-
oma (MPM) in Japan makes it difficult to perform a large-scale 
clinicopathological study of this tumor at a single institute. Thus, we 
performed a multiinstitutional study to evaluate the current status of 
diagnosis and treatment in Japan. 
Methods: We analyzed the records of 80 patients with MPM, 
obtained from the 13 institutions comprising the Japanese Chiba 
Multicenter Study Group. 
Results: In 72 patients, the tumor was detected after a visit to a 
medical facility for subjective symptoms such as chest pain, short-
ness of breath, and cough. It took a median period of 47 days from 
the initial visit to establish the diagnosis. The overall survival rates 
of 43 patients with unresectable MPM 1, 2, and 3 years after the 
diagnosis were 35.1%, 13.4%, and 0%, respectively, whereas those 
of 37 patients who underwent surgery were 68.4%, 36.0% and 
16.0%, respectively (P = 0.002 ). According to multivariate analysis, 
histological type, International Mesothelioma Interest Group clinical 
stage, sex, and the presenting symptom of shortness of breath were 
significant prognostic factors. 
Conclusions: The definitive diagnosis of early MPM is difficult, but 
establishing the best diagnostic modality would improve survival 
rates, since radical surgery is likely to be effective for resectable 
disease. 
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Correlation of invasive micropapillary pattern in pleural 
malignant mesothelioma with pulmonary metastasis.
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and Pathology, National Hospital Organization Kyushu Medical 
Center, Fukuoka, Japan; 4 Department of Medicine (Division of 
Medical Oncology, Infectious Disease and Hematology), Fukuoka 
University Hospital and School of Medicine, Fukuoka, Japan; 
5 Department of Surgery (Division of Thoracic, Endocrine and 
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Background and Methods: The micropapillary pattern (characterized 
by papillary structure with tufts lacking a central fibrovascular core) 
is a predictor of aggressive carcinoma. In this study, we reviewed 34 
pleural malignant mesotheliomas (21 epithelioid, 5 sarcomatoid, 7 
biphasic and 1 lymphohistiocytoid subtypes), with special reference to 
the presence of invasive micropapillary component. 
Results: We identified two micropapillary pattern-positive cases. The 
micropapillary pattern showed focal distribution in 15-20% of the 
tumor tissues. The majority of the micropapillary clusters expressed 
MUC1 along the outer cell surface immunohistochemically. Analysis 
of pleural malignant mesotheliomas with epithelioid features and 
with or without invasive micropapillary component (21 epithelioid 
and 7 biphasic subtypes) showed pulmonary micrometastases in only 
the micropapillary-positive tumors (p<0.0128), and the spread was 
probably via the lymphatics. Lymphatic involvement (confirmed by 
immunohistochemistry with D2-40 antibody), including lymph node 
metastasis, was found in both micropapillary-positive tumor cases, 
whereas they were noted in only one of 16 (6.3%, p<0.0196) and 3 
(30%) cases of micropapillary-negative tumors. 
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Conclusions: To our knowledge, this is the first study to indicate the 
presence of invasive micropapillary component in pleural malignant 
mesothelioma, which can predict more aggressive lymphatic spread 
similar to carcinomas in other organs with micropapillary pattern.
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Irinotecan in combination with gemcitabine as second-
line chemotherapy in patients with malignant pleural 
mesothelioma previously treated with pemetrexed-cisplatin 
regimen: a phase 2 study
Fukuoka, Kazuya; Nakano, Takashi; Kuribayashi, Kozo; Iida, Shin-
ichiro; Tamura, Kunihiro; Tabata, Chiharu
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Background: Pemetrexed-Cisplatin(PEM/CDDP) is currently 
considered as the standard first-line treatment of malignant pleural 
mesothelioma (MPM). Post-study chemotherapy after the pivotal 
randomized PEM/CDDP trial has been demonstrated a statistically 
significant prolonged survival, usually with gemicitabine(GEM)-
based chemotherapy, vinorelbine, or doxorubicin monotherapy. Most 
trials for MPM chemotherapy have focused on chemo-naïve patients, 
however, many patients receiving first-line treatment still maintain a 
good PS when progression occurs. No chemotherapeutic regimen de-
fining the role of a second-line treatment for MPM patients has been 
demonstrated to date. Feasibility of second-line chemotherapy after 
the standard care with PEM/CDDP requires clinical investigation. 
The objective of this study was to evaluate the activity and toxicity of 
irinotecan (CPT-11) in combination with GEM as a second-line treat-
ment for MPM patients previously treated with PEM/CDDP. 
Methods: Patients 18 years old with histologically diagnosed ad-
vanced MPM, progression/refractory after the front-line PEM/CDDP 
treatment, ECOG performance status 0-2, presence of measurable 
disease, adequate major organ function, and no active CNS metastasis 
were eligible. CPT-11 60 mg/m2was administered intravenously, fol-
lowed by GEM 800 mg/m2 on days 1 and 8 every 3 weeks. Treatment 
was repeated until disease progression or occurrence of unacceptable 
toxicity. Tumor assessment was repeated every 6 weeks
Results: 17 patients ( median age: 64.0 years, 14 epithelioid and 
3 biphasic) were enrolled. No objective responses were noted 
and 15 patients had stable disease and 2 progressive disease (PD) 
after the treatment. A disease control rate was achieved in 88.2% 
(95%CI:59.5%-98.3%). The median time to progression was 4.0 
months. Hematologic toxicity was acceptable, with grade 3 or 4 
neutropenia occurring in 6% of patients; no case of febrile neutro-
penia was observed. Nonhematologic toxicity was mild and accept-
able. Subgroup analysis showed that 2 patients with PD had a poor 
response to the prior first-line chemotherapy..
Conclusions: The combination of CPT-11 and GEM had no sig-
nificant tumor response as second-line setting, but had an accept-
able toxicity profile and high disease control rate for the patients 
with MPM failing front-line PEM/CDDP chemotherapy. This study 
demonstrated that send-line treatment with CPT-11/GEM can delay 
disease progression for advanced MPM patients after the standard 
PEM/CDDP treatment.
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Clinicopathologic characteristics and prognostic factors 
for overall survival (OS) of malignant mesothelioma (MM) 
in California with comparison by primary site of disease 
(pleural versus peritoneal)
Ou, Sai-Hong I.; Zell, Jason A.
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Background: We compared the clinicopathologic characteristics and 
identified independent prognostic factors for overall survival (OS) of 
malignant mesothelioma (MM) patients according to primary site of 
disease (pleural versus peritoneal).
Methods: Retrospective population-based analysis of MM patients 
from the California Cancer Registry between 1989 to 2006. The study 
period was evenly divided into three periods of diagnosis (1989-
1994, 1995-2000, 2001-2006).
Results: 4089 MM patients were analyzed. 359 (8.8%) patients 
presented with malignant peritoneal mesothelioma (MPeM). MPeM 
patients were significantly younger than malignant pleural meso-
thelioma (MPM) patients (median age: 63 years vs. 71 years; P < 
0.0001). Additionally, the median age of MPM patients had increased 
significantly with time while the median age of MPeM patient had 
decreased with time although non-significantly. The proportion 
of female patients was greater among MPeM than among MPM 
patients (39.6% vs. 19.6%; P < 0.0001). The proportion of MPM who 
received “curative” surgery increased significantly with time although 
the actual numbers remained small. The proportion of MPM patients 
who received chemotherapy also increased significantly with time. 
Cox proportional hazards regression analysis performed on all MM 
patients revealed younger age, female gender, epithelioid histol-
ogy (non-epithelioid versus epithelioid, hazard ratio [HR] = 1.368; 
95%CI: 1.207-1.550; P < 0.0001), well- or moderately-differentiated 
histology, early AJCC stage, most recent period of diagnosis, and 
treatment with either surgery or chemotherapy were independently 
associated with improved survival. Among surgical techniques, “cur-
ative” surgery resulted in the lowest HR of death (vs. no surgery, HR 
= 0.653, 95%CI: 0.561-0.760; P < .0001). Primary tumor site (peri-
toneal vs. pleural, HR = 1.014; 95% CI: 0.893- 1.152; P = 0.8280) 
and the basis of pathologic diagnosis (cytologic vs. histologic, HR 
= 0.990; 95% CI: 0.893-1.098; P = 0.8527) were not independent 
prognostic factors. There was no prognostic difference between 
AJCC stage I and II by Cox proportional hazards regression analysis, 
and survival of stage II MPM was numerically better than stage I 
MPM patients by univariate analysis. Ethnicity, martial status, and 
socioeconomic status were not independent prognostic factors by uni-
variate or multivariate analyses. Trimodality combination treatment 
approach of curative surgery and chemotherapy and radiation resulted 
in the lowest HR (vs. no treatment, HR = 0.416; 95%CI: 0.288-
0.601; P < 0.0001) among MPM patients when surgery techniques 
and radiation and chemotherapy were analyzed together in Cox 
proportional hazards regression analysis. 4.3% of MPM and 13.1% of 
MPeM patients were long-term survivors (> 48 months) with median 
survival of 84 months and 99 months for MPM and MPeM patients 
respectively. Long-term survivors tended to be younger, female (es-
pecially among MPeM patients), with well-differentiated mesotheli-
oma, had disease diagnosed histologically rather than cytologically, 
and had undergone debulking or “curative” surgery.
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Conclusions: We identified independent prognostic factors for OS 
in MM. Primary site of the mesothelioma (pleural versus peritoneal) 
was not an independent prognostic factor. Among these independent 
prognostic factors, younger age, female gender, well-differentiated 
histology, and having undergone debulking or curative surgery were 
more commonly found in long-term survivors in both MPM and 
MPeM.
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Thymomas: prognostic factors and survival
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Introduction: Thymomas are neoplasias originating from epithelial 
cells of the thymus and represent the most common tumor of the 
anterior mediastinum and affect patients over 40 to 60 years old.
Aim(s): to present a serie of surgically treated thymomas at the 
Hospital de Rehabilitación Respiratoria María Ferrer and to deter-
mine which factors affected the survival of these patients during the 
follow-up time. 
Design: retrospective analytical cohort study from January 1972 to 
December 2006.
Materials and methods: all patients with diagnostic of thymoma 
treated surgically were included. A total of 120 cases were analized, 
9 of which were lost to follow-up (6%); of the remaining 111, 26 
were dead at the end of the study (23%). The average follow-up time 
was 9 ± 7 years. The following variables were analyzed: age, gender, 
symptoms of myasthenia gravis at the time of diagnosis, staging of 
Masaoka (1994) of the original tumor, the current WHO classifica-
tion, postoperative radiotherapy treatment and clinical course of 
myasthenia gravis defined by the modified Osserman classification. 
Results: Out of the 111 patients studied, 63 were men (57%) and 48 
female (43%), with an mean age of 47 years (range 13-78); 71/111 
had myasthenia gravis at the time of diagnosis (64%). Sixty-one 
percent of patients with myasthenia gravis presented early stage of 
Masaoka (I and II) vs 39% who presented more advanced stages, 
in contrast to 60% of non myasthenic ones, who belonged to stages 
III and IV, although difference between groups was not statistically 
significant (p = 0.40). In univariate analysis, symptoms of myasthe-
nia gravis at the time of diagnosis (HR 0.524, 95% CI 0.242-0.134, 
P = 0.10), clinical course of myasthenia according to the Osserman 
classification (HR 18.11, CI 95 % 3.914-83.811, p = 0.000) and 
staging of Masaoka (HR 1916, 95% CI 0.87-4.20, p = 0.10) showed 
a significant association with the frequency of death in patients with 
thymoma. 
In multivariate analysis, patients with Masaoka stages III and IV 
proved to have a frequency of death almost 7 times higher than in 
stages I and II (HR 6758, 95% CI 2.04-22.39, P = 0.002), whereas the 
postoperative adjuvant therapy decreased in a 79% the risk of death 
in our population (HR 0.215, 95% CI 0.0652-0.7095, P = 0.012). The 
diagnosis of myasthenia gravis at the time of diagnosis reduced the 
frequency of death by almost 50% (HR 0.493, 95% CI 0225-1.078, 
p = 0.077) and therefore was retained in the model because of its 
clinical relevance, although not presented a statistically significant 
association.
Conclusions: In the population analyzed, the early stages of Masao-
ka, the presence of myasthenia gravis at the time of diagnosis and the 
adjuvant treatment in advanced lessions are independent factors of 
good prognosis. Patients with Masaoka stage II, III and IV should be 
considered locally advanced and postoperative radiotherapy improves 
overall survival for them. 
Finally, it is important to consider myasthenia gravis a disease associ-
ated with thymoma and not simply a paraneoplastic syndrome, given 
the persistence of symptoms after tumor resection.
P2.109 Mesothelioma, Thymoma and Others, Sun Aug 2 
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Methods: The National Lung Cancer Audit is run jointly by the 
Royal College of Physicians and The Information Centre for health 
and social care. The aim of the audit is to facilitate service improve-
ment by recording outcomes in lung cancer on a large scale and 
through case-mix adjustment, start to explain the wide variations 
noted. This abstract presents results for England, for three years of 
the audit (2005-2007), focusing on mesothelioma.
Results: There were 2469 patients with mean age 70.9 yrs. Of these 
2043 (82.7%) were male and 426 (17.3%) were female. 41.6% have 
right-sided disease, 24.1% are left-sided, 0.6% are bilateral and 0.1% 
are midline with the location recorded as unknown in 33.7%.
46.4% are referred by their GP, 15.7% are emergency admissions, 
16.6% are referred by another consultant, 4.9% are referred following 
an A&E episode, 8.7% come through other routes and in 7.6% the 
referral route is recorded as unknown.
Survival was calculated from a census date of 13/01/09 to the date 
of diagnosis (or date first seen if not available). Overall the median 
survival is 249 days with a 1YS of 36.1%. Further analysis by histo-
logical subtype is shown below:
  % of subtype Median survival (days) 1 year survival (%)
 Unspecified 44.6 249 35
 Epithelioid 27.0 353 49
 Sarcomatoid 5.2 117 14
 Biphasic 0.5 177 23
 No histology 22.7 200 32
The figure below details the treatments recorded as being along with 
the average survival for patients having specific first treatments.
Conclusions: There is a striking tendency for mesothelioma to be 
right-sided. 23% of cases have no histological confirmation recorded, 
but where this is obtained, the epithelioid subtype has a much better 
prognosis. Patients receiving chemotherapy have the best survival but 
this result is subject to selection bias.
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Diffuse Pleural Malignant Mesothelioma: 
clinicopathological features in Argentina
Poleri, Claudia; Morero, José L.; Patané, Ana K.; Martín, Claudio; 
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Diffuse Pleural malignant Mesothelioma is a rare disease with 
unknown effective treatment. Surgical staging is not applicable in the 
majority of patients, and scoring systems have been proposed based 
in the clinicopathological features, like EORTC score.
Our purpose is to study the clinical and pathological features of pa-
tients from Argentina and to recognize prognostic factors.
We analyzed the clinical records of 31 patients, 9 (29%) were women 
and 22 (71%) were men; age mean was 60.68 (36-82), and 12 months 
was the median follow-up time. The median overall survival was 33 
months from initial symptoms and 18 months from diagnosis. We 
found that 32 % start with pleural effusion, 10 % with chest pain, 
and 58 % with both. The 41 % had Performance status (PS) 0, and 
59 % had PS 2-3. Only 6 patients had clear exposition to asbestos, 
and 60 % were never smokers. According EORTC prognostic score 
we cluster 57 % in a low risk group and 43 % in a high risk group. In 
all cases, diagnoses was based upon histological and immunohisto-
chemistry diagnosis. Histological types were: 25 (81 %) epithelial, 2 
(6 %) sarcomatoid and 4 (13 %) biphasic. We evaluated expression of 
Epidermal Growth Factor Receptor (EGFR) by immunohistochem-
istry (Zymed EGFr Kit, Clone 31G7), in 17 tumors: 4 were negative 
(score 0 and 1), and 13 were positive (score 2 and 3). We found no 
association between EGFR expression and histological type. Survival 
was calculated from the beginning symptoms date because of the 
large period until diagnosis. Univariate analyses showed no signifi-
cant differences between EORTC scoring risk groups. Sarcomatoid 
and biphasic type had shorter median survival time (5 and 19 months) 
than epithelial type (37 months), log rank test: p = 0. 0000; and 
EGFR positive expression was associated with better prognosis than 
EGFR negative (median survival time: 24 and 9 months), log rank 
test: p = 0.0139. 
This study could not confirm the EORTC scoring system value to 
selecting patients risk groups, and only sarcomatoid and biphasic 
types from the items of score were significant high risk factors. We 
also found that EGFR expression is a common feature in pleural 
mesothelioma, and that it was associated a favorable prognosis in 
agreement with other series.
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Pathologic staging of biphasic mesothelioma
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Background: The biphasic histologic variant of diffuse malignant 
pleural mesothelioma (MPM) is less common than the epithelial 
variant and is associated with significantly shorter survival duration. 
Patient cohorts used for prior validation of pathologic staging systems 
have included both variants, impeding assessment of stage correlation 
with patient outcome. 
Methods: With IRB approval, we retrospectively reviewed the 
medical records of 164 consecutive patients with biphasic MPM who 
underwent EPP at Brigham and Women’s Hospital (BWH) between 
1988 and 2006. Kaplan-Meier survival from surgery was calcu-
lated. Those who underwent EPP were staged using BWH (J Thorac 
Cardiov Surg 117:5463;1999) and AJCC (Cancer Staging Manual, 
6th ed., 2002) criteria. Operative deaths were included in the analysis 
and patients received varied adjuvant regimens. All cases underwent 
pathology review by the pathology reference panel.
Results: Of the 164 patients, 146 (89%) were male. Median age at 
diagnosis was 60 years (24-77). Eight patients died perioperatively 
(4.9%). Median, 1-, 2- and 3-yr survival was: 10.4 mo., 40%, 10%, 
and 3%, respectively. The table below presents median Kaplan-Meier 
survival for each stage. For BWH stage IV and AJCC stage I, insuffi-
cient events were observed for valid Kaplan-Meier analysis; instead, 
patient survival duration in months is presented in brackets.
 BWH BWH BWH  BWH AJCC AJCC AJCC AJCC 
 Stage I Stage II Stage III Stage IV Stage I Stage II Stage III Stage IV
 Count 11 47 105 1 3 16 105 40
 Median 21.3 11.9 8.1 [11.8] [11.8, 21.3, 52.9] 17.0 11.0 5.9
Conclusions: BWH and AJCC staging systems each stratified 
survival in this cohort, although each is limited by uneven stage dis-
tribution. A majority of patients are classified by each system to stage 
III. BWH criteria identify more stage I - II patients with favorable 
prognosis, 58 (36%) vs 19 (12%), whereas AJCC criteria identify 
more stage IV patients, 40 (24%) vs 1 (1%). Data-driven modeling 
using classification criteria from both systems may optimize stage 
distribution and survival stratification of biphasic MPM patients.
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Human and mouse mesotheliomas express TLR7: evidence 
for in-vivo sensitivity to local treatment with Imiquimod
Broomfield, Steve; van der Most, Robbert; Prosser, Amy C.; 
Mahendran, Sathish; Robinson, Bruce W.; Currie, Andrew J.
The University of Western Australia, Perth, WA, Australia
Mimicking viral infection by application of various toll-like recep-
tor ligands has shown clinical promise in the treatment of persistent 
viral infections and more recently with malignant tumors. Commer-
cially available toll-like receptor 7 ligands (TLR7L), such as those 
of the Imidazoquinoline family have been applied clinically for the 
treatment of a number of conditions including basal cell carcinoma 
and HPV-induced genital warts. These compounds are known to 
retard tumor growth indirectly by promoting activation and migration 
of DCs, leading to a strong Th1 cellular response, and directly via 
release of pro-inflammatory cytokines and promotion of tumor cell 
apoptosis. Malignant mesothelioma (MM), an aggressive tumor with 
a mean survival of 9 months, is highly resistant to chemotherapy, 
radiotherapy and surgery and is therefore an interesting candidate for 
immunotherapy in the form of TLR7 ligand treatment. Whilst TLR7 
is known to be selectively expressed in immune cells and its relative 
expression low amongst other cell and tissue types in mammals, its 
expression on tumor cells and the consequences of such expression 
on tumor growth are unknown. Here we describe the presence of 
TLR7 (mRNA and protein) directly in a range of different tumors, 
including several murine and human MM cell lines. In-vivo Im-
iquimod treatment of the murine MM tumor AB1-HA significantly 
retarded tumor growth in all treated mice. Nude mouse and depletion 
studies revealed a significant role for CD8 T cells and NK cells in the 
local anti-tumor immune response. A systemic response was observed 
from in-vivo CTL analysis and Ly6A/E staining of lymphocytes, 
suggesting the potential of a systemic vaccine response. Interestingly, 
TLR7L synergized with systemic anti-CD40 treatment to significantly 
enhance local tumor resolution. Inducing inflammation and apoptosis 
by targetting TLR7 in the tumor environment may be a useful thera-
peutic approach for the treatment of malignant mesothelioma. 
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Feasibility of pleural Intensity-Modulated Radiation 
Therapy (IMRT) for malignant pleural mesothelioma
Rosenzweig, Kenneth; Krug, Lee; Laser, Benjamin; Yorke, Ellen; 
Flores, Raja; Brown, Andrew; Rusch, Valerie W.
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Purpose: In patients with malignant pleural mesothelioma (MPM) 
who are unable to undergo a pneumonectomy, it is difficult to deliver 
tumoricidal doses to the pleura without significant toxicity. We have 
implemented a technique of using intensity-modulated radiotherapy 
(IMRT) to treat these patients. This report assesses the feasibility and 
toxicity of treating MPM using pleural IMRT in patients who have 
not had a pneumonectomy. 
Methods and Materials: Between 2005 and 2008, 26 patients with 
MPM were treated with pleural IMRT to the hemithorax without 
pneumonectomy (median dose: 47.4 Gy, range: 41.4-50.4 Gy) at 
Memorial Sloan-Kettering Cancer Center. 
Results: Patient characteristics were: right sided (58%), histology 
(epithelial – 77%, sarcomatoid – 8%, mixed – 15%), stage (I – 8%, 
II – 35%, III – 23%, IV – 35%). Twenty-two patients (85%) received 
induction chemotherapy (mostly cisplatin and pemetrexed). Surgery 
was: pleurectomy/decortication – 12 patients (46%), pleurectomy 
alone – 3 patients (12%), unresectable – 11 patients (42%). Of the 
26 patients, there were 6 patients (23%) with acute grade 3 or worse 
pulmonary complications (including one case of Grade 5) and 2 cases 
of acute grade 3 fatigue. Of the 13 patients with adequate follow-up 
to assess late toxicity, there were three cases of continuing grade 3 
pneumonitis. With a median follow-up of 15 months, the 1-year and 
2-year overall survival rates were 72% and 37% respectively with 
a median overall survival of 17.4 months. The median time to local 
failure from the end of radiation therapy was 14.3 months in surgical 
patients and 3.4 months in inoperable patients. 
Conclusions: Treating the intact lung with pleural IMRT in patients 
with MPM is a safe and feasible treatment option to a dose of 50.4 
Gy, with the major side effects of pneumonitis and fatigue. We have 
initiated a phase II trial of induction chemotherapy with pemetrexed 
and cisplatin followed by pleural IMRT in patients with unresectable 
disease.
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A phase I study of intrapleural perfusion hyperthermo-
chimotherapy with cisplatin in patients with malignant 
pleural effusion and dissemination
Sakaguchi, Hirozo; Kaneko, Koichi; Ishida, Hironori; Nitanda, 
Hiroyuki; Yamazaki, Nobuhiro
Saitama Medical University Nationai Medical Center, Hidaka-city, 
Japan
Background: The preferred treatment for patients with malignant 
pleural effusion and dissemination has not been determined. In order 
to get adequate control of malignant effusion for next treatment, we 
have introduced intrapleural perfusion hyperthermo-chemotherapy 
(IPHC) with cisplatin.
Methods: Twenty patients with pleural malignancy underwent IPHC. 
Mean age was 63 years old (range, 38-78). Perfusion was performed 
with a roller pump and heat exchanger. Cisplatin was added when the 
temperature stabilized to a mean of 42.5 ˚C. Dosages of cisplatin used 
were 80mg/ m2 . The circuit was filled with 2000ml saline. A IPHC 
was performed for 60 minutes with a pump flow rate of 1 L/min 
under double-lung ventilation. Morbidity, pharmacokinetics, control 
of pleural perfusion were studied. 
Results: IPHC was carried out in 20 patients. Causes of malignant 
pleuritis were lung cancer in 8 patients, malignant mesothelioma in 
7 patients, and other disease in 5 patients (renal cell cancer, ovarian 
cancer, thymic cancer, thymoma, unknown primary cancer). There 
were no serious clinical complications associated with this proced-
ure. The maximum temperature in the thoracic esophagus reached 
38.2±0.7˚C, and the temperature rise was 1.9±0.6˚C. Six had tempor-
ary mild rise of serum creatinin (Grage1) and 7 had mild nausea 
(Grage1). Duration of tube drainage were 6.9±0.8 day. The platinum 
concentration in serum after IPHC were 0.51±0.25μg/ml at 30 min, 
0.66±0.31μg/ml at 60 min., 0.28±0.12μg/ml at 24 hr, 0.21±0.11μg/
ml at 48 hr. The transitional rate of total platinum from pleural space 
to body was 33.8±17.0% (range, 5.9-56.9 %). This procedure had 
brought an ideal pleural adhesion. The pleural effusion was well 
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controlled in all patients. Adjuvant chemotherapy were performed in 
18 patients within 37 days.
Conclusions: IPHC with cisplatin is feasible and relatively safe. This 
method may offer excellent local control for patients with malignant 
pleural effusion and dissemination. 
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Megakaryocyte potentiating factor is a more effective 
marker for the differential diagnosis of malignant pleural 
mesothelioma compared with mesothelin.
Serada, Satoshi1; Iwahori, Kota1; Fujimoto, Minoru1; Kishi, Yoshiro2; 
Naka, Tetsuji1
1 National Institute of Biomedical Innovation Laboratory for Immune 
Signal, Ibaraki (Osaka), Japan; 2 Medical & Biological Laboratories 
Co. Ltd, Ina (Nagano), Japan
Background: An early and reliable blood test is one deficiency in the 
diagnosis of malignant pleural mesothelioma (MPM). Megakaryocyte 
potentiating factor (MPF) and mesothelin variants (MSLN) are mem-
bers of the mesothelin gene family and have been reported to repre-
sent candidate serum markers for the detection of MPM. However, it 
has not yet been established which of these proteins (MPF or MSLN) 
is the most effective marker for the differential diagnosis of MPM. 
Therefore we have designed novel enzyme-linked immunosorbent 
assay (ELISA) systems to compare the diagnostic efficacy of MPF 
and MSLN as serum markers for the specific detection of MPM.
Material and Methods: Serum samples were collected from 27 
consecutive patients with non-resectable MPM. The patient popula-
tion included 13 with epithelial type MPM, three with sarcomatoid 
type, five with mixed type and six with unclassified type (diagnosed 
by cytological analysis). For controls, we used 47 patients with lung 
cancer, 35 with other cancers (18 ovarian, eight stomach and nine 
colon cancers), nine asbestos-exposed asymptomatic subjects and 
38 healthy adults without a history of asbestos exposure. The serum 
concentrations of MPF and of the soluble form of mesothelin were 
measured by each specific sandwich ELISA.
Results: Elevated levels of serum MPF and MSLN protein were 
detected in MPM patients in comparison with every control group 
(MPF mean ± SD values: MPM patients 68.7 ± 101.1 ng/ml, lung 
cancer 16.6 ± 15.3 ng/ml, other cancers 15.1 ± 9.7 ng/ml, healthy 
asbestos-exposed subjects 9.7 ± 5.3 ng/ml, healthy adults 9.0 ± 2.9 
ng/ml; MSLN mean ± SD values: MPM patients 130.0 ± 112.9 ng/
ml, lung cancer 83.4 ± 50.4 ng/ml, other cancers 74.4 ± 45.3 ng/ml, 
healthy asbestos-exposed subjects 59.5 ± 25.6 ng/ml, healthy adults 
61.4 ± 21.4 ng/ml. The area under the receiver operating character-
istic curve (AUC) was calculated for differentiation of MPM, lung 
cancer, healthy asbestos-exposed subjects and healthy adults. While 
the AUC for serum MPF was 0.879, cutoff = 19.1 ng/ml (sensitivity 
= 74.1%, specificity = 90.4%), the AUC for serum MSLN was 0.713, 
cut-off = 93.5 ng/ml (sensitivity = 59.3%, specificity = 86.2%). A 
comparison between AUC for MPF and MSLN values showed that 
MPF is significantly superior to MSLN (p = 0.025). 
Conclusions: Levels of serum MPF and MSLN are elevated in MPM 
patients compared with control disease subjects and healthy individ-
uals. However, our analysis of the diagnostic efficacy of MPF and 
MSLN as serum markers for the detection of MPM, revealed that 
MPF has superior sensitivity and specificity for MPM compared with 
MSLN. Thus, this study supports the measurement of serum MPF 
levels by ELISA rather than MSLN, for the improved detection and 
diagnosis of MPM.
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Comparison and combination of the tumor markers for 
mesothelioma: N-ERC/mesothelin, Osteopontin, CA125, 
CYFRA21-1, Hyarulonic Acids
Shiomi, Kazu11, 12; Sakuraba, Motoki11; Hino, Okio1; Masuda, 
Kimihiko2; Kobayashi, Masashi13; Hirabayashi, Masataka3; Ishida, 
Atsuko4; Moroboshi, Takao5; Yoshiyama, Takashi6; Inoue, Akira7; 
Izumi, Hiroshi8; Segawa, Tatsuya9; Maeda, Masahiro9; Takahashi, 
Kazuhisa10; Suzuki, Kenji11; Miyashita, Kazuya9; Kohno, Tadasu12; 
Hagiwara, Yoshiaki9
1 Department of Pathology and Oncology,Juntendo University,School 
of Medicine, Tokyo, Japan; 2 Department of Respiratory 
Diseases,National Organization Tokyo Hospital, Tokyo, Japan; 3 
Department of Respiratory Medicine, Hyogo Prefectural Tsukaguchi 
Hospital, Hyogo, Japan; 4 Division of Respiratory and Infectious 
Diseases, Department of Internal Medicine,St. Marianna University 
School of Medicine, Kanagawa, Japan; 5 Division of General 
Thoracic Surgery,Yokosuka Kyosai Hospital, Kanagawa, Japan; 
6 Department of Respiratory Medicine,Fukujuji Hospital, Japan 
Antituberculosis Association, Tokyo, Japan; 7 Respiratory Medicine 
and Translational Research Clinic,Tohoku University Hospital, 
Miyagi, Japan; 8 Department of Human Pathology,Juntendo 
University,School of Medicine, Tokyo, Japan; 9 Immuno-Biological 
Laboratories Co., Ltd., Gunma, Japan; 10 Department of Respiratory 
Medicine,Juntendo University,School of Medicine, Tokyo, Japan; 11 
Department of General Thoracic Surgery, Juntendo University,School 
of Medicine, Tokyo, Japan; 12 Thoracic Surgery Respiratory 
Center,Toranomon Hospital, Tokyo, Japan; 13 Department of 
Respiratory Surgery, Hyogo Prefectural Tsukaguchi Hospital, Hyogo, 
Japan
Background: There is a limit to diagnose at an early stage and to 
effectively monitor of Malignant mesothelioma(MM) with current 
imaging technologies. Therefore we have studied the potential tumor 
marker, N-ERC/mesothelin. In this study, we examined the compari-
son and the combination with several markers reported previously as 
tumor marker of mesothelioma. 
Methods: Serum levels of N-ERC/mesothelin, CA125, CYFRA21-1, 
Hyaluronic acid(HA) and plasma Osteopontin(OPN) levels were 
measured in 66 patients who were diagnosed with mesothelioma, 43 
with lung cancer, 8 patients with diseases that is difficult to distin-
guish from mesothelioma and 106 subjects were diagnosed with 
asbestos-related nonmalignant diseases (including 51 pleural plaque, 
20 benign pleuritis, 7 asbestosis and 28 simple exposure). Receiver 
operator characteristic curve were generated to compare the diag-
nostic accuracy of these markers and logistic regression model was 
used to test the combination of markers. Furthermore, we reviewed 
the reported literatures of these markers to assess the validity of the 
combination. 
Results: N-ERC/mesothelin had better ability to diagnose meso-
thelioma, especially the epithelioid type of mesothelioma than all 
other markers. In the two setting (the marker for mesothelioma/the 
marker for epithelioid mesothelioma), the AUC of N-ERC/meso-
thelin, CA125, CYFRA21-1, HA and plasma OPN are 0.787/0.873, 
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0.756/0.709, 0.761/0.761, 0.789/0.789, 0.782/0.736 respectively. 
The Combination analysis using stepwise logistic regression model 
selected the N-ERC/mesothelin and Osteopontin as the markers for 
mesothelioma (AUC:0.863). Furthermore, N-ERC/mesothelin and 
CA125 were selected as the markers for epithelioid mesothelioma 
(AUC:0.882). 
Conclusions: N-ERC/mesothelin should be the mainstay of the blood 
markers of mesothelioma. Statistically, the combination of markers 
increases the sensitivity and specificity. However, at the present time, 
the combinations of these markers are not recommended positively, 
because the specificity of OPN is low and the effects of the adding 
CA125 is small
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A case of primary endobronchial leimyosarcoma noticed 
by massive hemoptysis
Park, Sun-Hyo; Song, Jun-Whi; Kang, Kyung-Woo
Samsung Medical Center Masan Samsung Hospital, Masan, Korea
A primary pulmonary leiomyosarcoma is a very rare pulmonary 
malignancy and arises from smooth muscle of either the bronchial or 
arterial walls. Common symptoms of the tumor are cough, dyspnea, 
chest pain and hemoptysis. The diagnosis of a primary pulmonary 
sarcoma can be established only after extensive clinical and radio-
logic examinations have failed to identify an alternative primary 
source. The only effective treatment for the tumor is a complete 
surgical resection when feasible. The type of resection is dictated by 
the local anatomic extent of the tumor. 
We report a case of a 21-year-old male with primary endobronchial 
leiomyosarcoma who presented with massive hemoptysis. A necrotic 
ulcerative endobronchial lesion was observed in the orifice of left 
lower lobe bronchus on a bronchoscopic examination. He was treated 
with a complete sleeve resection of the left lower lobe. Three months 
later, local recurrence of tumor was noticed on the follow up bron-
choscopy and a left pneumonectomy was then performed. Fifteen 
month later, the patient died from empyema with a bronchopleural 
fistula that associated with tumor recurrence at the stump of the 
pneumonectomy.
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A case of spontaneously regressed endobronchial sarcoma 
after obstructive pneumonia
Park, Sun-Hyo; Song, Jun-Whi
Samsung Medical Center Masan Samsung Hospital, Masan, Korea
The spontaneous regression (SR) of cancer is defined as the complete 
disappearance of a malignant disease without adequate treatment. SR 
is a very rare biological event, particularly in a pulmonary sarcoma.
We encountered a rare case of a 72-year-old woman with an undiag-
nosed intrapelvic cystic mass, who presented with a smooth surfaced 
endobronchial tumor obstructing the orifice of the right lower lobe 
bronchus on a bronchoscopic examination. She had a prior history 
cervical cancer and adenocarcinoma in the right middle lobe lateral 
segment of her lung for which she had undergone radiation therapy. 
The tumor was diagnosed as an endobronchial sarcoma by the histo-
pathology and immunohistochemistry. It was unclear if the tumor was 
a primary sarcoma of the lung or a metastatic lesion of an intrapelvic 
cystic mass because she refused a diagnostic exploratory laparotomy. 
Two months later, obstructive pneumonia of the right lower lobe 
with parapneumonic effusion developed with fever above 38.5˚C 
for 10 days. After recovering from pneumonia, she was followed up 
regularly in the outpatient clinic without any specific treatment. One 
year later after treating the obstructive pneumonia, the follow-up 
bronchoscopy revealed a complete SR of endobronchial sarcoma. It is 
believed that the obstructive pneumonia accompanied by fever above 
38.5˚C for 10 days might have played a role in this SR.
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Cisplatin-based neoadjuvant chemotherapy followed 
by extrapleural pneumonectomy for malignant pleural 
mesothelioma
Spaggiari, Lorenzo1; Galetta, Domenico1; Petrella, Francesco1; 
Solli, Piergiorgio1; Veronesi, Giulia1; Borri, Alessandro1; Gasparri, 
Roberto1; Casiraghi, Monica1; De Pas, Tommaso M.2
1 Division of Thoracic Surgery, European Institute of Oncology, 
Milan, Italy; 2 Department of Medicine, New Drugs; Development 
and Clinical Pharmacology Unit, European Institute of Oncology, 
Milan, Italy
Background: Malignant pleural mesothelioma (MPM) is a locally 
aggressive neoplasm with a poor prognosis. Trimodality approach 
seems to improve survival with good results in terms of local control 
and survival. The aim of this study is to analyze the results of our 
institutional experience in the treatment of MPM.
Methods: We conducted a retrospective review of all patients with 
MPM who received cisplatin-based induction chemotherapy followed 
by extrapleural pneumonectomy (EPP) ± adjuvant radiotherapy be-
tween February 2004 and February 2009 in our institution. 
Results: Over a 5-year period, 46 patients with MPM were con-
sidered for a trimodality approach. Histology was epithelioid in 40 
patients, biphasic in 4, and sarcomatoid in 2. Chemotherapy regimen 
included cisplatin/pemetrexed (n=32), cisplatin/gemcitabine (n=12), 
and cisplatin/vinorelbine (n=2). No major chemotherapy-related 
complications were recorded. All patients were suitable for surgery. 
EPP was performed in 36 patients (78.3%); 10 patients (21.7%) had 
explorative thoracotomy for locally advanced disease. There were 32 
males; median age was 62 years (range, 42-73 years). Postoperative 
hemithoracic radiation therapy was administered to 18 patients. MPM 
was located in the right side in 14/36 patients (38.9%). Thirty-day 
mortality was 13.8% (5/36); Thirty-day morbidity rate was 44.4% 
(16/36) and included hemothorax in 8 patients, chylothorax in 5, dia-
phragmatic hernia and bronchopleural fistula in 3 cases, respectively, 
ARDS in 2, and esophageal fistula in 1. Late major complications 
occurred in 2 patients: one bronchopleural fistula and one esophageal 
fistula. Pathologic nodal status was N0 in 22 patients, N1 in 7, and 
N2 in 7. Median survival and disease-free interval were 10 months 
(range, 0-60 months) and 8 months (range 0-37 months), respect-
ively. Three-year overall survival and disease free interval for the 36 
operated patients was 42.7% and 31.7%, respectively. Seventeen/36 
patients (47.2%) are alive, 5 with disease. Histology did not signifi-
cantly influence survival (46.2% for epithelioid vs 0% for biphasic + 
sarcomatoid). Three-year survival according to pathological N status 
was 36.8% for N0, 45.7% for N1, and 60% for N2 (p = not signifi-
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cant). Patients receiving adjuvant radiotherapy had a best prognosis 
(54.5% vs 26.3% at 3-year, p= 0.02).
Conclusions: This single center experience shows that one fifth of 
the patients with MPM had progression of the disease after neoadju-
vant treatment even if cisplatin-based regimen was feasible and with-
out major complications. Postoperative mortality is acceptable even 
if the rate of postoperative surgical complications remains high. In 
our experience nodal status and histology did not influence survival. 
Adjuvant hemithoracic radiotherapy improve survival in surgically 
treated patients. 
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Therapy-Oriented large scale gene expression analysis In 
lung carcinoids
Toffalorio, Francesca1; Belloni, Elena1, 2; Fumagalli, Caterina1; 
Micucci, Carla1, 2; Minardi, Simone P.2; Bucci, Gabriele2; Pelosi, 
Giuseppe1, 3; Solli, Piergiorgio1; Veronesi, Giulia1; Spaggiari, 
Lorenzo1; Pelicci, Pier Giuseppe1, 2; de Braud, Filippo1; De Pas, 
Tommaso1
1 European Institute of Oncology, Milan, Italy; 2 IFOM-IEO Campus, 
Milan, Italy; 3 University of Milan, Milan, Italy
Background: Lung carcinoids are rare tumors and surgical resec-
tion is to date the only curative option for their treatment. When 
surgery is not feasible, common strategies for their cure are missing, 
since chemotherapy efficacy is often not satisfactory. Due to the low 
incidence and prevalence of these tumors, drug efficacy and treat-
ment strategy cannot be demonstrated by large-scale clinical trials, 
as suggested by the criteria of “evidence based” medicine. Therefore, 
we used an alternative strategy in order to genetically characterize 
this tumor type. This will allow to select the best existing therapeutic 
treatment, on one side, and possibly identify new drugable targets, on 
the other.
Methods: We followed a genetic approach in order to identify genes 
that may play a role in lung carcinoid tumorigenesis and, more 
importantly, that can become effective “drugable” targets. Gene 
expression microarray analysis was conducted, using a 54.000 probe 
set (Affymetrix Human GeneChip U133 2.0). We compared atypical 
versus typical carcinoids, in order to identify specific gene signa-
tures, which are expected to greatly improve the knowledge of these 
tumors, mainly in terms of disease development and progression 
(aggressiveness).
Results: We have analyzed a first group of lung carcinoids, constitut-
ed of 8 typical, 11 atypical (5 lymph node negative and 6 lymph node 
positive cases), and 8 normal (matched to 4 typical and 4 atypical 
analyzed tumors) samples. Our preliminary results show that:
• the expression profile of normal lung tissue is homogenous and 
different from both typical and atypical carcinoids;
• the derived expression profiles are able to strikingly separate the 
typical versus atypical subtypes;
• it is possible to evidence a few markers, which specifically iden-
tify one of the two subtypes exclusively and could become new 
tools for diagnosis;
• by comparing atypical versus typical tumors, we observed an 
alteration of specific cellular pathways, which could be used as 
target for already available and/or new drugs.
Conclusions: Our data translate into two main conclusions, relevant 
for therapy and diagnosis: 
i) we identified specific gene expression profiles, suggesting resist-
ance/sensitivity to standard chemotherapy regimens. Moreover, it 
was possible to point out putative targets for already available or 
newly-designed drugs; 
ii)  ng carcinoids.
These preliminary results, although still requiring a complete valida-
tion, are intriguing and encourage to collect a higher number of 
samples, verifying on a larger scale the hypotheses we inferred. 
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Malignant pleural mesothelioma in the Veterans Affairs 
Health Care System
Torgerson, Sara R.1; Recely, Pat 2; Choong, Nicholas W.1
1 Medical College of Wisconsin Affiliated Hospitals, Milwaukee, WI, 
USA; 2 Clement J Zablocki VAMC, Milwaukee, WI, USA
Background: In the U.S. there is an estimated 3300 cases of malig-
nant pleural mesothelioma (MPM) annually. The Department of Vet-
erans Affairs (VA) provides a large, multiregional health care system 
for veterans. The VA cancer registry provides a national database to 
analyze epidemiology, treatment and survival for MPM. 
Methods: We performed a retrospective study of MPM diagnosed 
from 1999 – 2007. Demographic information, year of diagnosis, VA 
region, clinical stage, histology, treatment modality and survival were 
abstracted from the VA cancer registry and analyzed.
Results: Between 1999 and 2007, 554 cases of MPM were diagnosed 
in the VA system. 551 (99%) were male and only 3 (0.01%) were 
female. 88% of patients were Caucasian and 8% African American. 
Age at diagnosis: 40-49 (1%), 50-59 (13%), 60-69 (29%), 70-79 
(39%), and above 80 (18%). Year of diagnosis: 1999 (11%), 2000 
(9%), 2001 (13%), 2002 (15%), 2003 (14%), 2004 (11%), 2005 
(15%), 2006 (10%), and partial year 2007 (3%). The highest inci-
dence of MPM occurred in the non-coastal southwest region (9.7%), 
gulf coast region (9.4%) and Northern California (7.9%). The lowest 
incidence of MPM occurred in the Midwest (1.8%) and central Texas 
(1.8%). Histologic classification were malignant mesothelioma NOS 
(75%), epithelioid (15%), biphasic (5%) and sarcomatoid (4%).
Almost 60% (327 patients) did not receive any MPM directed treat-
ment. Only 69 patients (0.12%) underwent a surgical resection for 
curative intent. Chemotherapy was utilized in 140 (25%). Of those 
patients who received chemotherapy, 70 (50%) were treated between 
1999 and 2003 and 70 (50%) between 2004 and 2007. Pemetrexed 
was available in the VA system in 2004. Survival analysis of patients 
treated before and after 2004 showed an improvement in median 
survival from 6.6 months to 8.1 months (log-rank p = 0.028). 
Conclusion: Our study shows that MPM is an uncommon malig-
nancy even in VA patients. This is a disease that is prevalent in older 
patients and its prognosis remains poor. In 2003, Vogelzang et al. 
reported a phase III study showing significant survival benefit with 
cisplatin-pemetrexed compared to cisplatin. Our study showed that 
the median survival of MPM patients in the VA has also improved 
with the introduction of pemetrexed.
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An unusual pathology with an undefined etiology: solitary 
fibrous tumours of the pleura
Turhan, Kutsal; Ergun, Sinem; Cakan, Alpaslan; Cagirici, Ufuk
Ege University Faculty of Medicine, Izmir, Turkey
Objectives: The aim of this study is to evaluate the etiology, clinical 
and patholological behavior, the best appropriate surgical approach 
and long-term follow up of solitary fibrous tumours of the pleura.
Methods: Clinical records of 8 patients which were operated for 
solitary fibrous tumours of the pleura between 2001 and 2009, were 
reviewed retrospectively. Etiological factors, diagnostic procedures, 
clinical courses, and outcome of these patients were studied. Tumors 
were classified as malignant or benign according to England Criteria.
• Malignancy criteria described by England et al.
• More than four mitoses per 10 high-power fields
• Presence of necrosis
• High cellularity (nuclear crowding and overlapping)
• Nuclear atypia
Results: There were five male (%62.5) and three female (%37.5) 
patients with a median age of 54.4±8.5 (41-66 years). There was none 
marked common etiological factor. Only one patient had the correct 
diagnose preoperatively. Five patients (%62.5) were asymptomatic. 
Predominant symptoms for the other three patients were cough and 
chest pain. Surgical excision was performed by muscle sparing lateral 
thoracotomy in five patients (%62,5), posterolateral thoracotomy in 
one patient (%12.5) and by video-assisted thoracoscopy in one pa-
tient (%12.5). In one patient excision was started with video-assisted 
thoracoscopy, but for removing the large tumor completely, a small 
thoracotomy was added. At surgery, seven lesions (%87.5) arose from 
the visceral pleura, five of them were pedunculated (%62.5) and high 
vascularity was observed. Complete resection was achieved in all 
patients. There was no peroperative and postoperative mortality and 
no major complication occured. Except one patient, all patients were 
classified as benign solitary fibrous tumours. Median follow up was 
42.4±32.3 (1-88) months and no recurrence was detected in radio-
graphic controls.
Conclusion: These very rare seen tumors of the pleura are usually be-
nign, asymptomatic and the preoperative diagnosis is difficult. Clinical 
and pathological behavior is unpredictible and treatment consists of 
complete resection. Minimaly invasive techniques such as video-as-
sisted thoracoscopy could be selected for surgery if the tumour size is 
appropriate. Because of the risk of recurrence and malignant trans-
formation, long-term follow up is recommended in all patients.
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Trimodality treatment of early stage Malignant Pleural 
Mesothelioma (MPM): a single institutional experience
Vandenbroucke, Elke; Praet, Marleen; Vermaelen, Karim; Surmont, 
Veerle; De Ryck, Frederic; Tournoy, Kurt G.; Gosselin, Robert; De 
Neve, Wilfried; Vermassen, Frank; Van Meerbeeck, Jan P.
Long Oncologisch Netwerk UZ Gent, Ghent, Belgium
Background: The optimal treatment for early stage MPM remains 
controversial. We report a single institute’s experience with trimodal-
ity treatment of early stage MPM.
Methods: Patients (pts) with early stage MPM were enrolled between 
2003 and 2008 in an institutional trimodality treatment protocol, 
consisting of induction chemotherapy (IC) with cisplatin-pemetrexed, 
extrapleural pneumonectomy (EPP) and postoperative hemithoracic 
intensity modulated radiotherapy (IMRT). Preoperative staging 
according to the IMIG-system was done with CT-scan of the chest 
and upper abdomen, FDG-PET, thoracoscopy, and mediastinoscopy. 
Response evaluation with chest CT-scan was done after 3 cycles of 
chemotherapy. EPP was performed 3-5 weeks thereafter, IMRT (54 
Gy) followed 4-6 weeks after surgery.
Results: 18 consecutive pts (all male, median 56 years, range 45-68) 
with clinical stage I-II (T1-3N0M0) MPM entered the protocol. There 
were 11 right sided, 15 epithelial, 1 sarcomatous and 2 mixed MPMs. 
The tumor was thought resectable and patients were found operable 
by preoperative functional evaluation. One pt did not receive IC and 
15 completed IC of whom 4 had a clinical partial response (PR) and 
10 stable disease (SD). Clinical and haematological tolerance was 
good. IC was discontinued in 2 pts due to either progressive disease 
(PD) or peritoneal sepsis respectively. Of the 15 pts who underwent 
EPP (83%), 2 died of major postoperative complications (multiple 
organ failure) within 30 days and 1 of cardial luxation 90 days after 
surgery. Other postoperative complications were pneumonia (13%), 
cardiac arrhythmia (13%), heart failure (6%) and chylothorax (6%). 
The median hospital stay was 16 days of which 3 at the ICU. 9 pts 
completed IMRT (2 pending). Its complications were mainly gastro-
intestinal (anorexia, dysphagia and oesophagitis CTC-grade 1-3), 
asymptomatic liver dysfunction in 1 pt but no radiation pneumonitis 
CTC-grade ≥ 2 was reported. 7 pts (39%) included are still alive with 
2 having contralateral and mediastinal relapse. Site of recurrence was 
intrathoracic in 3 pts (17%) and distant in 4 pts (22%). With a median 
follow-up of 8 months, median and progression-free survival in all 
pts is 14 and 13 months vs. 18 and 15 months in the EPP pts.
Conclusion: Combined modality treatment for early stage MPM is 
feasible in selected patients with mortality and morbidity rates com-
parable to other series. In-treatment drop-out and recurrence rates are 
high, emphasizing the need for better systemic and local approaches.
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Large cell neuroendocrine carcinoma of the lung: a french 
retrospective study: 1987-2003 
Bonnichon, Augustin1; Vaylet, Fabien1; Duvillard, Pierre2; Margery, 
Jacques1, 2; Le Pechoux, Cecile2; Besse, Benjamin2; Baudin, Eric2; 
Guigay, Joel2
1 HIA Percy, Clamart, France; 2 Institut Gustave Roussy, Villejuif, 
France
Large cell neuroendocine carcinomas are rare, high-grade tumors, 
as small cell lung cancer, but still defined as a subgroup of large cell 
carcinomas of the lung and best treatment remains unclear.
Purpose: Description of the natural course of large cell neuroendo-
crine carcinomas and evaluation of therapeutics response.
Method: Retrospective study based on the data files of the Gustave 
Roussy Institute since 1987 to 2003, with diagnostic based on Tra-
vis’s criteria and reviewied by neuroendocrine histopathologic expert.
Results: 33 patients (25 males/8 females) with median age 57 years 
old [36-79], 91% smokers. Pathologically stages are I (18%), II 
(18%), III (24%) and IV (40%); with 60% central presentation and 
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70% nodal involvement (N1=21%; N2=19%; N3=30%). Initial 
diagnosis is wrong in 55% of cases without difference based on mo-
dalities of biopsy (p=0,70). 15 patients suffer surgery (45%) and 94% 
recieve chemotherapy, 27/31 platin-etoposide based schedule (88%). 
Objective response rate is 50%. Recurence is 23% local, 58% distant 
and 29% both and occurs early (39%<6 month), after one year (39%) 
ore within 6 to 12 month (22%). The most frequent metastatic site 
is encephalic (19%). Overall and disease-free survivals are respect-
ively 67%, 33%, 14% and 41%, 14%, 7% at 1, 2 and 5 years. Overall 
and disease-free survival for stages I, II versus III, IV are significa-
tively different (p<0,0001) and (p=0,0037). There are 31% but later 
recurence than entire group after first nodal radiotherapy (>12 month 
in 80% of cases).
Conclusion: Prognosis of large cell neuroendocrine carcinomas is 
severe but adjuvant therapy seems to be benefit even in early stage 
with platine-etoposide chemotherapy and radiotherapy may increase 
local control. 
P2.125 Mesothelioma, Thymoma and Others, Sun Aug 2 
Liposomal doxorubicin and cisplatin as first-line 
chemotherapy in unresectable malignant pleural 
mesothelioma: A phase II study
Arrieta, Oscar1; Medina, Luis A.1; Guzman, Enrique2; Rios-Trejo, 
Miguel A.1; Villanueva, Geraldine1; Mendoza, Daniel2; Astorga-
Ramos, Alma M.1; Martinez-Barrera, Luis2; Hernandez-Pedro, 
Norma1; Arechaga-Ocampo, Elena1; de la Garza, Jaime1
1 Instituto Nacional de Cancerologia, Mexico City, Mexico; 2 Instituto 
Nacional de Enfermedades Respiratorias, Mexico City, Mexico
Background: Malignant pleural mesothelioma (MPM) is a poor 
prognosis neoplasm. Its worldwide incidence is rising, until recently 
chemotherapy has not been shown to be effective in its treatment, the 
combination of cisplatin (Cis) and pemetrexed (PMX) is the approved 
“standard” treatment in unresectable MPM.
Liposomal doxorubicin (LD) consists of pegylated phospholipid-
vesicles that encapsulate doxorubicin confering minimal capture from 
the reticulo-endothelial system resulting in a greater serum half-life, 
an enhanced liposome deposition in the tumor and a lower degree of 
toxicity. We evaluated the combination of LD and Cis in chemonaive 
patients with unresectable MPM.
Methods: From September 2006 to October 2008, consecutive 
patients with stage III/IV MPM were included to receive LD (Dox-
opeg®) 40 mg/m2 and Cis (Tecnoplatin®) 60 mg/m2 every 21 days. 
CT-scans were performed prior and after 2 cycles to assess response. 
Gamma camera images (GCI) of Tc-99m-labeled LD were acquired 
to evaluate LD accumulation in measurable tumor tissue. Patients 
gave written informed consent.
Results: Twenty seven patients were included, 81.5% were stage III 
and 18.5% were IV. According to EORTC prognostic factors, 33.3% 
and 66.7% had poor and good prognosis, respectively. Median age 
was 59.2 years (33–80). Median follow-up was of 5.2 ± 0.8 months. 
Median survival has not been reached. The 2-year overall survival 
was 52.5% ± 14.2. Median time to progression was 5.0 ± 1.1 months 
(CI 95%, 2.7–7.3). Overall response was 45.5%, stable disease 36.4% 
and progression of 18.2%. GCI showed good accumulation and reten-
tion (60%) of the labeled LD in tumor tissue at 4 h after the initial 
injection. There were no toxic deaths. 
Conclusion: Cis+LD is a highly active regime in MPM with compar-
able results to those of Cis+PMX. A phase III trial is warranted to 
confirm these findings.
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Interim report of safety and effectiveness of pemetrexed 
in malignant pleural mesothelioma in Japan: all case drug 
registry study
Watanabe, Morihiro; Yamamoto, Takanori; Arakawa, Kimiko; 
Sekiguchi, Risa; Imai, Junya; Enatsu, Sotaro; Nambu, Yoshihiro
GPS, Kobe, Japan
Background: Approximately 1000 patients are newly diagnosed as 
malignant pleural mesothelioma (MPM) each year in Japan, how-
ever, MPM patient profile and their outcome are not well understood. 
Pemetrexed is the only approved chemotherapeutic agent for MPM in 
combination with cisplatin. Limited safety information was avail-
able at launch of pemetrexed in Japan where drug-induced interstitial 
pneumonitis is reported at higher rate than the rest of the world. 
Therefore, postmarketing drug registered study for pemetrexed was 
conducted to investigate patient characteristics, adverse events and 
survival of MPM patients based on a regulatory requirement for ap-
proval.
Methods: From February 2007 to May 2008, all of histologically 
proven MPM patients to be treated with pemetrexed were required to 
register to this study. The observation period was six-months. Supply 
of pemetrexed was restricted to institutes with experienced medical 
oncologists based on pre-determined criteria. 
Results: During the 15-months enrollment period, 951 MPM patients 
were registered. Among the information of enrolled patients collected 
until August 2008, data for 437 patients were analyzed. Three hun-
dred eighty nine patients were male, 48 female, median of age was 
65 years old (range: 35-86). 72.3% of patients had a known history 
of being exposed to asbestos. The distribution of performance status 
(PS) of patients was PS0 29.5%, PS1 56.8% and PS2 12.4%. The first 
cycle of pemetrexed treatment was given in combination with cis-
platin to 93.1% of patients. Folic acid and vitamin B12, both of which 
are essential supplements prior to pemetrexed, were administered in 
99.8% of patients before the first cycle. Median treatment cycle was 
3.0. Side effect was reported in 84.4% of patients in total. Side effects 
with more than 10% incidence were leukocytopenia (30.2%), neutro-
penia (27.2%), anemia (22.2%), thrombocytopenia (13.3%), lympho-
cyte decrease (11.4%), nausea (35.2%), vomiting (15.6%), anorexia 
(13.3%) and constipation (12.1%). Serious side effects occurred in 
more than 5% of patients were anemia (9.6%), neutropenia (9.6%) 
and leukocytepenia (8.7%). Pneumotoxicity was found in 1.4%. In 
total, 152 deaths (34.8%) were observed and six-month survival rate 
estimated by Kaplan-Meier method was 70.9%.
Conclusions: This large size post marketing all case registry study 
shows that the safety profile of pemetrexed appeared similar to that 
of previous clinical trials without additional safety signal. Because 
all patients treated with pemetrexed were registered, the study has 
minimum selection bias and provides useful information to health 
care professionals on safety and effectiveness of pemetrexed in real 
clinical setting in Japan.
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Clinical, hematological and pathological prognostic factors 
in Malignant Mesothelioma (MM): A review of 131 cases 
from 1990 to 2007 in Nova Scotia (NS), Canada.
Yeung, Gordon4; Husain, Saima4; Gao, Jun3; Dewar, Ron3; Xu, 
Zhaolin2; Morzycki, Wojtek1
1 Division of Medical Oncology, Department of Medicine, Queen 
Elizabeth II Health Sciences Centre, Halifax, NS, Canada; 2 
Department of Pathology, Queen Elizabeth II Health Sciences Centre, 
Halifax, NS, Canada; 3 Surveillance and Epidemiology Unit, Cancer 
Care Nova Scotia, Halifax, Canada; 4 Department of Medicine, 
Queen Elizabeth II Health Sciences Centre, Halifax, Canada
Background: The incidence of MM, a fatal malignancy related to as-
bestos exposure, continues to rise. Data exploring possible prognostic 
factors for overall survival (OS) remains limited and inconsistent. 
This study aims to examine potential prognostic factors in MM and 
their impact on patient survival.
Methods: One-hundred thirty-one MM cases diagnosed between 
1990 and 2007 in the province of NS were identified through the NS 
Cancer Registry. Clinical and hematological data (white blood cells 
(WBC), hemoglobin (HGB) and platelets (PLT)) were abstracted 
through a retrospective chart review. Tissue microarray with immuno-
histochemical staining for epidermal growth factor receptor (EGFR), 
phosphorylated EGFR (phos-EGFR), vascular endothelial growth 
factor (VEGF), and simian virus 40 (SV40) was performed. Survival 
was analyzed using Kaplan-Meier method, Log-Rank and Wilcoxon 
tests, and Cox multivariate models.
Results: Men comprised 81% of the study population. Median age 
at diagnosis was 69 years. The most common presenting symptoms 
were dyspnea (62%), chest pain (42%) and weight loss (42%). The 
majority of patients (74%) had an Eastern Cooperative Oncology 
Group (ECOG) performance status of 1 or 2. Histological cell type 
was epithelioid in 69 (53%), sarcomatoid in 15 (11%), biphasic in 21 
(16%) and unspecified in 26 (20%).
Median survival time was 201 days (95% CI, 148-262 days). Cumu-
lative survival was 53.4% (95% CI, 44.9-62.0%) at 6 months, 26.0% 
(95% CI, 18.5-33.5%) at 1 year and 7.6% (95% CI, 3.1-12.1%) at 2 
years. In univariate analysis: the absence of cough, ECOG <2, and 
normal WBC, HGB and PLT were each associated with improved 
OS (p <0.05). In multivariate analysis, controlling for age, gender 
and cell type: the absence of cough and ECOG <2 were statistically 
significantly associated with reduced risk of death (hazard ratio 0.47 
(95% CI, 0.25-0.86) and 0.21 (95% CI, 0.08-0.58) respectively). 
Hematological factors were not statistically significant in multivariate 
analysis.
Conclusion: The diagnosis of MM generally portends a poor out-
come and knowledge regarding prognostic factors impacting OS con-
tinues to evolve. Numerous studies have observed that age, gender, 
symptoms, performance status and histologic cell type are important.
In our cohort, clinical, hematological and pathological factors were 
studied. Favorable predictors in univariate analysis included absence 
of cough, good performance status and normal WBC, HGB and PLT. 
The absence of cough and good performance status were associated 
with a reduced risk of death in multivariate analysis. Despite being 
one of the largest cohorts reported to date, limited sample size may 
still have impacted power to detect clinically relevant prognostic 
factors. Expression of EGFR, phos-EGFR, VEGF and SV40 and their 
prognostic relevance will be presented.
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Management of malignant pleural mesothelioma in the era 
of trimodality therapy: solved and unsolved questions
Marulli, Giuseppe1; Zuin, Andrea1; Schiavon, Marco1; Nicotra, 
Samuele1; Favaretto, Adolfo G.2; Loreggian, Lucio3; Sartori, 
Francesco1; Rea, Federico1
1 Thoracic Surgery-University of Padova, Padova, Italy; 2 Oncology-
Veneto Oncologic Institute, Padova, Italy; 3 Radiotherapy-Veneto 
Oncologic Institute, Padova, Italy
Background: Malignant pleural mesothelioma (MPM) is an aggres-
sive tumor with poor response to chemo and radiotherapy.
Despite diversity of treatment modalities for MPM, the impact on sur-
vival is unsatisfactory and an ideal treatment protocol is still lacking.
Methods: Review of prospectively collected data of 34 patients with 
MPM, who received trimodality therapy between 2000 and 2007. Our 
protocol includes carboplatin-based induction chemotherapy (plus 
Gemcitabin or Pemetrexed), followed by extrapleural pneumonec-
tomy and postoperative radiotherapy. There were 22 (64.7%) males 
and 12 (35.3%) females, with a median age of 60 years (range 37-75 
years).
Results: Twenty patients (58.8%) received 4 cycles of chemother-
apy, 12 (35.3%) had 3 cycles and 2 (5.9%) had 2 cycles. Grade 3-4 
haematological toxicity occurred in 12 patients (35.3%). A partial 
response to chemotherapy was observed in 12 patients (35.3%). No 
perioperative mortality occurred, 15 patients (44.1%) experienced 
postoperative complications, 6 (17.6%) of them required redo-
operation. Overall 1, 3 and 5 years survival was 85%, 41% and 26%, 
respectively (median 26 months. Fig.1); disease free survival at 1 and 
3 years was 78% and 27%, respectively (median 17 months. Fig.2).
Patients with epithelial histology and N0 had a longer survival (3 and 
5-years survival 63% and 40%; median 37 months). At the last fol-
low up 23 patients (67.6%) developed recurrence, distant recurrence 
represented 87%.
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Conclusions: Trimodality therapy with carboplatin-based induction 
chemotherapy is feasible and provides a favourable survival rate 
with acceptable morbidity and mortality. A clear survival advantage 
is identifiable in patients with early stage, epithelial histology and no 
nodal involvement and it emphasizes the need for a strict selection of 
candidates.
Current treatment of MPM had modest impact on long term survival 
and distant recurrence represents the main pattern of failure. This 
requires a search for more effective treatment protocols.
Non-Small-Cell Lung Cancer - Early Disease
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Single-institution experience with stage IB Non-small cell 
carcinoma in adjuvant chemotherapy era
Paravati, Anthony J.2; Candice, Aitken L.1; Dragnev, Konstantin H.1; 
James, Rigas R.1; William, Nugent C.1; Johnstone, David W.1
1 Dartmouth Hitchcock Medical Center, Lebanon, NH, USA; 2 
Dartmouth Medical School, Hanover, NH, USA
Purpose: The role of adjuvant chemotherapy (CT) following 
resection of stage IB non-small cell lung cancer (NSCLC) remains 
controversial. We have offered CT to these patients routinely for over 
3 years.
Materials and Methods: A single-institution retrospective review 
was conducted of all patients undergoing surgical resection for stage 
IB (T2N0) NSCLC from January 2005 through September 2008. 
Chart and tumor registry review was conducted. Survival was calcu-
lated by Kaplan-Meier method.
Results: 81 patients had pathologic stage IB NSCLC completely re-
sected, with 70 lobectomies, 3 bilobectomies, and 8 wedge resections. 
Gender was balanced (40 male, 41 female). There were 35 left-sided 
and 46 right-sided carcinomas. Preoperative biopsy was performed in 
38 cases, of which 24 were diagnostic. Final pathology demonstrated 
adenocarcinoma (52%), squamous cell (41%), and other non-small 
cell histologies (7%). Tumor size varied considerably with little 
difference between histologies (adenocarcinoma 4.0 cm median, 
range1.0–13.0 cm; squamous cell 4.4 cm median, range 1.6-7.6 cm; 
other histology 5.0 cm, range 4.0–7.5 cm). Lymphadenectomy was 
routine, yielding median 12.5 nodes per case (adeno 12, squamous 
14, other 9), with range of 0–32 nodes per case. 
Median follow-up was 19.2 months (range 0.4–46 mos). There was 
one postoperative mortality from pneumonia. Overall mortality was 
14 of 81 patients. Of these, 9 died without recurrence, 3 recurred at 
distant sites, and two were unknown. 3-year overall survival is 85% 
(Kaplan-Meier method). 
Six patients were lost to follow-up regarding disease recurrence. 8 of 
75 patients developed recurrent disease (11%). 
Adjuvant CT was discussed with all patients postoperatively. Four 
patients lacked documentation of CT status. Seventeen of 77 patients 
received CT (22%); 11 completed at least 3 cycles (14%). Two addi-
tional patients received erlotinib. 
Of patients who developed recurrent disease, 38% (3 of 8) received 
adjuvant CT; of patients without recurrence, 19% received adjuvant 
CT. Comparison of tumors between these two groups shows a larger 
median tumor size among those with recurrence (5.2 cm vs. 4.0 cm), 
but no difference in histologic composition. Patients with smaller 
tumors staged T2 by virtue of pleural invasion tended to not get adju-
vant CT. There was no significant difference in extent of lympadenec-
tomy (median # nodes: 13.5 recurrent vs. 12.0 non-recurrent). There 
were no recurrences among patients undergoing a wedge resection 
only (median tumor size 3.0 cm vs. 4.4 cm in other patients).
Limitations of this study are a small patient population and moderate 
follow-up. This patient group includes some treated when data sup-
porting adjuvant CT was just emerging, along with patients treated 
recently when adjuvant therapy is common practice.
Conclusion: In our practice, a minority of stage IB patients receive 
adjuvant CT. Our outcomes suggest a higher recurrence risk among 
patients with larger tumors. This is consonant with results from CAL-
BG 9633. Further research is needed to define the role of adjuvant CT 
for resected stage IB NSCLC.
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A study of the survival of patients with resected stage II 
NSCLC followed by Post-Operative Radiotherapy (PORT)
Ashby, Samuel L.; Grannis, Frederic; Bogardus, Alicia; Tiep, Brian
City of Hope, Duarte, CA, USA
Background: The efficacy and safety of adjuvant postoperative 
radiation therapy in non-small cell lung cancer (NSCLC) has been 
questioned in recent studies, but data on patients in Stage II is very 
limited. Results of treatment in Stage II are sub-optimal, and effective 
adjuvant therapy would be desirable but the relatively small num-
ber of cases (5% of total lung cancer cases) makes it problematic to 
study in a prospective randomized manner. Postoperative adjuvant 
chemotherapy is recommended for Stage II NSCLC patients in some 
guidelines.
Method: A retrospective chart review was performed on stage II 
NSCLC patients (T1 N1, T2 N1, T3 N0, M0) resected by a single sur-
geon (FG) between 1986 to 2002 with or without adjuvant therapy at 
an NCI and NCCN Comprehensive Cancer Center. During the years 
of the study consultation with radiation oncologists was frequently 
requested in Stage II patients. 
Results: There were 56 patients reviewed; 37.5% (21) received only 
surgery, 58.9% (33) received surgery and adjuvant radiation therapy, 
and 3.6% (2) received surgery with adjuvant radiation therapy as well 
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as chemotherapy. All patients included in the study received primary 
treatment at The City of Hope National Medical Center (COH). 
A Kaplan-Meier actuarial survival curve was generated to analyze 
and graph the data collected on the subjects. There is no difference 
in 5-year survival in surgically resected patients without adjuvant 
therapy compared to patients who received adjuvant radiation therapy 
(HR 0.92, p=0.77,). An analysis of patients with no margins showed 
no difference in patient survival (HR 1.02, p=0.94). Patients with 
positive margins may see benefit from PORT (HR .76, P=0.58) based 
on a noted trend in the data.
Conclusion: Our study shows no evidence of benefit for routine 
post-operative adjuvant radiation therapy. The question of whether 
PORT is beneficial in Stage II patients with positive margins remains 
inconclusive due to a small sample size. The potential benefit of 
receiving both adjuvant radiation and chemotherapy cannot be ad-
dressed because of insufficient numbers of patients. 
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Cisplatinum plus docetaxel (CD) as induction 
chemotherapy prior to radical locoregional (LR) treatment 
for patients (pts) with stage III Non-Small-Cell Lung 
Cancer (NSCLC): Results of a prospective phase II study. 
Berros, JPablo; Esteban, Emilio; Crespo, Gillermo; Muriel, Carolina; 
Fernández Sanmamed, Miguel; Pardo, Pablo; Izquierdo, Marta; 
Jiménez, Paula; Luque, Maria; Villanueva, Noemi; Olay, Luis; J. 
Lacave, Angel
Hospital Universitario Central de Asturias, Oviedo, Spain
Introduction: Several Comparative studies have indicated that 
induction chemotherapy with cisplatinum regimens improves overall 
survival of patients with stage III NSCLC compared with surgery 
and/or radiotherapy alone. Nevertheless, the optimal third generation 
cisplatinum combination in this setting remains controversial. The 
aim of the present study has been to test the value of cisplatinum and 
docetaxel as induction chemotherapy prior to radical locoregional 
treatment in non-selected patients with stage III. 
Methods: Eligibility included histological or cytological proven che-
monaïve clinical stage III (A or B not wet), measurable disease, age 
< 75 years, Karnofsky performance status (KPS) ≥ 70, adequate renal 
and hepatic function. Patients were treated with 75 mg/m2 of cisplatin 
and docetaxel repeated every three weeks for three cycles. Tumor as-
sessments were performed after three cycles of treatment and before 
local radical treatment. 
Results: From September 2004 to December 2008 a total of 44 pts 
received at least one cycle of induction chemotherapy and were con-
sidered evaluable for activity and toxicity. Patient characteristics were 
as follows: median age: 60 years (range 36-74), seven female/ 37 
male, median KPS 80% (60-100), twenty three stage IIIA / 21 IIIB . 
The median cycles of treatment was 3 (1-4) and dose intensity of cis-
platin and docetaxel was 98%. The side effects registered were mild 
to moderate with 34 % of neutropenia (9 % febrile), 22.7% anaemia, 
and 2.3% nausea/ vomiting grade 3-4. In an attempt to treat basis 
(ITT) objective response rate among 39 eligible patients was 56% 
(5.1% complete response and 50.9% partial response). Most patients 
(72.7%) received radiotherapy as part of LR treatment. Pathological 
complete response was confirmed in 11.1% of 9 patients treated with 
surgery. Median time to progression and overall survival were 355 
days and 438 days respectively. Local and distant failure alone were 
22.7% and 4.5% respectively. Simultaneous local and distant failures 
were registered in 20.4 % of patients. 
Conclusions: Within the constraints of the number of patients of the 
present study, CD combination as induction chemotherapy is a toler-
able and active regimen in non-selected patients with clinical stage 
IIIA-B NSCLC.
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Genomic characterization of asymtpomatic CT-detected 
lung cancers
Belloni, Elena1, 2; Veronesi, Giulia1; Galetta, Domenico1; Solli, 
Piergiorgio1; Casiraghi, Monica1; Micucci, Carla1, 2; Javan, Soheil1, 
2; Minardi, Simone P.2; Venturini, Elisa2; Maisonneuve, Patrick1; 
Spaggiari, Lorenzo1; Bellomi, Massimo1; Taliento, Giulio1; Pelosi, 
Giuseppe1, 3; Pece, Salvatore1, 2; Pelicci, Pier Giuseppe1, 2
1 European Institute of Oncology, Milan, Italy; 2 IFOM-IEO Campus, 
Milan, Italy; 3 University of Milan, Milan, Italy
Background: CT screening of lung cancer allows the detection of 
very small tumors. The objective of our study was to verify whether 
initial asymptomatic lung cancers, identified by high-resolution low-
dose computed tomography (CT) on a high-risk population, show 
genetic abnormalities able to mark the early events of lung carcino-
genesis. 
Methods: 78 tumor samples were analyzed: 21 (pilot population) 
from heavy smokers with asymptomatic clinical early stage lung 
cancers, non-screening detected, and 57 as part of a low-dose CT 
screening study, enrolling 5203 asymptomatic heavy smokers volun-
teers. During surgical resection of the detected tumors, tissue samples 
were collected and short-term cultures were started for karyotype 
evaluation. Samples were classified according to the normal (NK) or 
aneuploid (AK) karyotype. NK samples were further analyzed by the 
Affymetrix SNPs technology. 
Results: Metaphase spreads were obtained in 73.0% of the selected 
samples: 80.7% showed an aneuploid karyotype. The majority of can-
cers, even if stage I and grade 1, showed aneuploidy. A statistically 
significant correlation was found between presence of vascular inva-
sion and an abnormal karyotype. 10 NK samples were suitable for 
SNPs analysis. Subtle genomic alterations were found in 8 tumors, 
the remaining 2 lacking to date of an evidence for chromosomal aber-
rations throughout the genome. Two common regions of amplifica-
tion were identified at 5p and 8p11. 
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Conclusions: We can conclude that: i) the majority of screening-
detected tumors shows aneuploidy; ii) less aggressive tumors tend to 
harbor a less abnormal karyotype; iii) 5p and 8p11 amplifications are 
common early events in lung carcinogenesis. 
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Computed tomography (CT) predicts accurately the 
pathologic tumor size in stage I non-small cell lung cancer 
(NSCLC)
Cedrés Pérez, Susana; Martínez, Pablo; Quispe, Isela; Serrano, César; 
Braña, Irene; Muñoz, Eva; Rodriguez, Vïctor; Deu, María; Felip, 
Enriqueta
Vall d'Hebron University Hospital, Barcelona, Spain
Background: In stage I NSCLC large tumor has been the most 
consistent determinant of survival. The choice of therapy option is 
based on accurate definition of the stage. The aim of our study is to 
correlate tumor size by CT scan with pathologic size and to determine 
possible prognostic factors in surgically resected pathologic stage IA 
and IB NSCLC patients.
Methods and Patients: Retrospective review of CT scans and 
medical history data from 89 patients with stage I NSCLC who 
underwent curative resection in our institution. Clinical prognostic 
factors analyzed were gender, smoking status, pulmonary function, 
performance status (PS), surgical procedure, histopathology, vessel 
invasion, pleural infiltration and tumor size. According the proposal 
for the revision of the T descriptors in the seventh edition of the TNM 
classification for lung cancer tumor size was divided in five groups 
(I: <2cm, II: 2-3 cm, III: 3-5 cm, IV: 5-7 cm and V: > 7 cm). Overall 
survival was calculated by the Kaplan-Meier method and the relation-
ship between clinical and pathologic staging by Pearson correlation. 
Results: Baseline characteristics of the patients were: median age 65 
years; males 95%; formal/current smokers 64%/29.2%; moderate ob-
structive lung disease 44%; PS 0: 91%, tumor size in CT scan: group 
I: 15%, II: 24%, III: 36%; IV 17% and V: 2%; partial atelechtasia: 
10%, obstructive pneumonitis: 4%; pneumonectomies 20.2%, squa-
mous, 49%, adenocarcinoma, 29%; grade 2: 41%, vascular invasion: 
19%; lymphatic invasion: 5%, pleural infiltration: 32%; pathologic 
tumor size: group I: 14%, II: 21%, III: 40%, IV: 21% and V: 2%. 
After a median surveillance of 55.2 months, 42 patients relapsed and 
55 had died. The 5-year progression free survival was 55.7% and 
5-year overall survival 49.9%, (median 58.97 months). Excluding 
patients death as a result of other causes, the 5-year overall survival 
was 60.5%. None of the clinical parameters analyzed were predictors 
of overall survival. Significant correlation was found between tumor 
size in CT scan and pathologic stage (Pearson 0.75). 
Conclusion: In our retrospective analysis with 89 surgically resected 
stage IA and IB NSCLC patients we found a good correlation be-
tween clinical and pathologic tumor size by CT scan. The prognoses 
factors analyzed had no significant impact on survival. 
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Carboplatin- Pemetrexed as adjuvant chemotherapy in 
resectable NSCLC: A phase II study
Charpidou, Andriani G.1; Boura, Paraskevi1; Karapanagiotou, Eleni1; 
Sepsas, Evangelos2; Papamichalis, George2; Konstantinou, Marios3; 
Syrigos, Kostas N.1
1 Oncology Unit, 3rd Dpt Of Medicine, Athens Med School, Athens, 
Greece; 2 1st Department of Thoracic Surgery Sotiria General 
Hospital, Athens, Greece; 3 2nd Department of Thoracic Surgery, 
Sotiria General Hospital, Athens, Greece
Background: As adjuvant chemotherapy has established its role in 
completely resected NSCLC, efforts are being made to identify the 
optimal regimen and dosing schedule that would provide the best 
outcome with the least possible toxicity. 
We conducted a preliminary phase II trial to evaluate the activity and 
tolerability of the Carboplatin plus Pemetrexed combination adminis-
tered as adjuvant treatment for completely resected NSCLC
Methods: Forty-three patients with mean age 61 years (40-76) and 
completely resected stage IB, II, IIIA NSCLC were included in the 
study. Adequate hematological profiles, renal and hepatic functions 
were met. Carboplatin AUC5 and Pemetrexed 500mg/m2 were ad-
ministered on days 1 in 21 days cycle for three consecutive cycles on 
an outpatient basis. Standard anti-emetic treatment, pre/post medi-
cation with oral dexamethasone, folic acid and vitamin B12 were 
received. Disease status follow-up was performed every 3 months 
for the 1st year and every 6 months afterwards. After progression, 
survival follow-up continued every 2 months.
Results: All patients were evaluated for relapse and toxicity. 6 
patients had progressive disease (6/43, 14%). The mean time to pro-
gression of patients was 20 months (95%CI: 18-21). No grade III and 
IV toxicities were observed. The reported side-effects were generally 
mild to moderate and entirely manageable.
Conclusions: The administration of Carboplatin – Pemetrexed is a 
safe, well tolerated and convenient chemotherapy regimen in the adju-
vant setting of completely resected NSCLC with efficacy which seems 
to be similar to that reported in other regimens and less toxicity. 
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Clinicopathological features of small-sized non-small cell 
lung cancer with mediastinal lymph node metastasis
Fukui, Takayuki; Katayama, Tatsuya; Ito, Simon; Mitsudomi, Tetsuya
Aichi Cancer Center Hospital, Nagoya, Japan
Introduction: The use of recently developed methods of radiograph-
ic investigation, particularly low-dose helical computed tomography 
(CT) for lung cancer, has increased the incidence of detection of 
small peripheral lung lesions. Among these small lesions, bronchi-
oloalveolar carcinoma, which is classified as a noninvasive carcin-
oma with no evidence of stromal, vascular, or pleural invasion in the 
revised histological classification of the World Health Organization, 
shows better outcomes when compared with invasive adenocarcin-
omas. In contrast, peripheral small-sized lung cancers with positive 
mediastinal lymph nodes are sometimes detected in clinical practice. 
To understand the characteristics of these aggressive tumors, we 
reviewed the clinicopathological data of small-sized (2 cm or less) 
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non-small cell lung cancer (NSCLC) patients with mediastinal lymph 
node metastasis treated in our institution.
Patients: During an 11-year period from 1997 through 2007, 1,513 
patients with primary lung cancers underwent pulmonary resection at 
the Aichi Cancer Center. In this study, we reviewed 360 of these pa-
tients presenting with a small-sized lesion with a maximum diameter 
of 2.0 cm or less. Data extracted from each patient's medical record 
included age, sex, smoking history, tumor histology and location, 
tumor size, surgical procedure, preoperative serum carcinoembry-
onic antigen (CEA) level, date of last follow-up, and death from any 
cause. The patients' cohort included 162 men (45%) and 198 women 
(55%) ranging in age from 26 to 83 years (median, 62 years). There 
were 326 (91%) adenocarcinomas, 21 (6%) squamous-cell carcin-
omas, nine (2%) large-cell carcinomas, and four (1%) other types of 
cancers. 
Results: The breakdown by pathological N category was 322 (89%) 
pN0, 17 (5%) pN1, and 21 (6%) pN2 patients. Among the pN2 
patients, 17 had lung lesions larger than 1.5 cm. No mediastinal nodal 
involvement was found in patients with squamous cell carcinomas. 
In contrast, mediastinal nodal involvement was significantly com-
mon in patients with poorly differentiated carcinoma (P = 0.004) and 
high serum CEA levels detected during preoperative evaluation (P = 
0.006). Metastasis was found at a single station in 12 patients, where-
as nine patients had multistation metastasis. The most frequent site 
of metastasis in the mediastinum differed according to the location 
of the primary tumor. None of the 14 patients with upper lobe tumor 
had a positive subcarinal lymph node. Lower lobe tumors frequently 
developed extensive multiple-level involvement, which included the 
upper mediastinum. Preoperative radiographic evaluation of pN2 
patients using CT showed a total absence GGO, or the presence of a 
small (25% or less) GGO area. 
Conclusions: Most small-sized NSCLC cases with mediastinal 
lymph node metastasis were invasive adenocarcinoma with poor 
differentiation, which usually showed a solid shadow without GGO 
on CT. 
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Surgery of expanded forms of lung cancer in patients with 
advanced physical status – alternative for incurability
Kuchava, Vladimer; Gagua, Rezo; Giorgadze, David
ESMO, Tbilisi, Georgia
Lung cancer holds the first place among malignant tumors in Georgia. 
Traditional radical methods of treatment, like radical surgery with 
additional chemo- or radiotherapy theoretically, may be applied in 
20-26% of primary revealed patients. Inoperable cancer is diagnosed 
in the rest cases. The practice showed that approximately 20-30% 
of patients out of this population are not undergone radical surgery. 
The main reasons are: the refusal of the patients themselves and the 
functional intolerance of surgery, when recommended volume of 
operation – pneumonectomy - especially at the T2-3N1-2 M0, causes 
fatality. 
The goal of the research was to find ways of treatment of such pa-
tients by means of application of lung partial resections at the stage 
T2-3N1-2 M0
Materials and Methods: During the last 10 years at the Thoracic 
Department of National Cancer Centre, out of 1029 lobotomies, 278 
were forced done i.e. they were performed with taking into account 
not only the degree of local and regional distribution of tumor but 
advanced physical status of patients as well. In all cases non-small 
cellular lung cancer was diagnosed at the stage T2-3N1-2 M0. In all 
cases systemic lymphadenectomy with skeletization of all mediastinal 
structures was performed. Metastatic lesion of mediastinal lymphatic 
nodes before operation was verified in 137 and after operation – in 
89 cases. Expanded lobectomy with resection of pericardium, auricle, 
superior vena cava, diaphragm or thorax was performed in 67 and 
circular resection of main bronchus and/or lung artery with formation 
of bronchial and/or vascular anastomosis – in 72 cases.
Results: 12 patients died after surgery at the hospital. Different post 
surgical complications occurred in 21 cases. Average stay at the 
hospital was 12 days. Three year survival rate was 21.1% and five – 
11.2%. These rates were 32.8% and 12.8% after pneumonectomies in 
patients with the same distribution degree and 2.1% and 0% in cases 
with chemo/radiotherapy, correspondingly.
Conclusion: In locally extended lung cancer patients with advanced 
physical status the only method of treatment, which provides rather 
satisfactory remote results, is the radical operation in the volume of 
lob/bilobectomy with expended removal of mediastinal lymphatic 
nodes as well as intrathoracic structures.
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Pilot phase II study of neoadjuvant docetaxel (T) and 
cisplatin (P) followed by adjuvant erlotinib (E) in patients 
with stage I-III non-small cell lung cancer (NSCLC)
Gold, Kathryn A.; Lee, J. Jack; Rice, David; Tse, Warner; Stewart, 
David; Wistuba, Ignacio I.; Herbst, Roy S.; Lippman, Scott M.; 
Hong, Waun K.; Kim, Edward S.
MD Anderson Cancer Center, Houston, TX, USA
Background: Pts with node positive, early stage NSCLC have a 
poor prognosis despite curative intent therapy. It is unclear which 
pts may derive the benefit of chemotherapy. The primary endpoint of 
the study was to assess the tolerability of the treatment regimen. In 
addition, the clinical response of the chemotherapy regimen as well 
as tumor biomarkers modulation was examined.
Methods: Pts had previously untreated, potentially surgically resect-
able, stage IB-III NSCLC with ECOG performance status (PS) 0-1 
and adequate laboratory parameters. After pretreatment tissue was 
obtained for baseline biomarker assessment, chemotherapy was 
administered (T 75 mg/m2 and P 80 mg/m2 every 3 wks) for 3 cycles. 
Subsequently, pts underwent restaging, and surgical resection. Pts 
were then offered treatment for 1 year with E 150 mg PO daily. 
Bronchoscopic biopsies were performed at 6 months and 1 year post-
surgery.
Results: 46 pts were enrolled between 2/07 and 3/09. 3 were not 
eligible and did not receive treatment. Of the 43 eligible pts: median 
age was 66 years (42-80); 26 (62%) were male; 28 (67%) were PS 
1. Clinical stage was IB 19% (8), IIB 35% (15), IIIA 42% (18), IIIB 
5% (2). 33 pts completed all 3 cycles (39 pts completed at least 2 
cycles). 34 pts underwent definitive surgical resection and 4 pts are 
pending surgery. 5 did not undergo surgery because of pneumonia 
(1), progressive disease (1), or definitive chemo-radiation (3). Grade 
3/4 toxicities included neutropenia (8 pts), hypokalemia (4 pts), and 
hyponatremia (3 pts). For pts completing at least 2 cycles of chemo-
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therapy, the radiographic response rate was 59% (23) by RECIST cri-
teria and 38% (15) had stable disease. 1 pt had a complete pathologic 
response. 20 pts have started adjuvant E and 4 have completed 1 yr 
of treatment. Blood and tissue specimens will be analyzed to assess 
biomarker modulation and sensitivity to chemotherapy. 
Conclusions: Neoadjuvant T and P is a tolerable and active regimen 
with an encouraging response rate in stage I-III resectable NSCLC. 
In addition to clinical characteristics, determining which patients will 
benefit from chemotherapy by analyzing their tumor biomarkers may 
help improve overall outcomes of curative lung cancer pts. (Sup-
ported by grant DoD# W81XWH-07-1-0306)
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Plasma free amino acid profiling as a novel screening 
marker for Non-Small Cell Lung Cancer (NSCLC)
Higashiyama, Masahiko 1; Maeda, Jun1; Nakayama, Tomio2; 
Imaizumi, Akira3; Yamamoto, Hiroshi4; Ando, Toshihiko3; Imamura, 
Fumio2
1 Department of Thoracic Surgery, Osaka Medical Center for Cancer 
and Cardiovascular Diseases, Osaka, Japan; 2 Dept. of Pulmonary 
Oncology, Osaka Medical Center for Cancer and Cardiovascular 
Diseases, Osaka, Japan; 3 Inst. of Life Sciences, Ajinomoto, CO., 
Inc., Tokyo, Japan; 4 HI Dept., Ajinomoto, CO., Inc., Tokyo, Japan
Aim: Amino acids balance is changed in patients of various diseases 
due to metabolic transition while it is maintained in healthy human. 
For example, Fisher ratio (ratio of branched amino acids to aromatic 
amino acids) is established as a primary index of hepatic failure. It 
is also known that the metabolism of cancer cells is totally altered. 
Recent post-genomic technologies permit one to derive multivariate 
function easily with the aid of a computer using metabolic profil-
ing data to define biological status for diagnostic purposes. Several 
reports demonstrate that multivariate analysis of plasma free amino-
acid profiles (Amino Index™) is a promising and versatile method 
for diagnosing various diseases. In this study, the possibility of 
plasma amino acid profiling as a novel screening marker of NSCLC 
was investigated. 
Subjects and Methods: Venous blood samples after overnight fast-
ing were drawn both of NSCLC patients (n=159) before medical 
treatment, who were hospitalized at Osaka Medical Center for Cancer 
and Cardiovascular Diseases and healthy volunteers as control sub-
jects (n=103). Amino acid concentrations were measured by LC-MS 
using deproteinized plasma samples. Seventy patients were randomly 
chosen and seventy gender-matched controls were chosen as training 
data. Then multiple logistic regression model composed of plasma 
amino acid concentrations as explanatory variables discriminating 
NSCLC patients from healthy controls was inferred using train-
ing data. The rest was used as test data to valid the performance of 
discriminant function. 
Results: Several plasma amino acid concentrations were different 
between patients and control subjects, suggesting that the onset of 
cancer caused the plasma amino acid profile. Obtained classifier 
showed high discrimination performance; more than 0.8 of area under 
ROC curve was observed for discrimination NSCLC patients from 
controls when test data was used. Furthermore, this classifier also 
could discriminate early stage cancer patients at high performance. 
Conclusion: It was suggested that classifier composed of plasma free 
amino acid concentration would be a promising marker for early de-
tection of NSCLC. The feature of this technology is its versatileness; 
it can generate multiple diagnostic indices from only one measure-
ment of plasma sample.
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Does the lobectomy plus lymph node dissection still remain 
a standard surgical procedure for patients with cT1N0M0 
adenocarcinoma of the lung?
Iwamaru, Arifumi
Tachikawa Hospital, Tokyo, Japan
Objective: Controversies still exists regarding treatment for 
cT1N0M0 adenocarcinoma of the lung. Topics as; 1) Should all 
patients undergo lobectomy plus lymph node dissection?, and 2) Are 
there poor-prognostic subgroup that may need adjuvant therapy?, still 
remain unanswered.
Methods: Between 1990 and 1999, 141 patients with cT1N0M0 
adenocarcinoma of the lung underwent lobectomy plus lymph node 
dissection. Fifteen clinicopathological characteristics of the entire 
population were investigated with regard to survival. Forty-seven 
samples, which were possible to re-examine among 68 patients with 
small adenocarcinoma 2 cm or less in greatest dimension, were as-
sessed according to Noguchi’s classification. 
Results: Nine of fifteen clinicopathological variables are significant 
for a poor prognostic factor in univariate analysis: gender, differentia-
tion, p-T status, p-N status, pm, lymphatic invasion, vascular invasion, 
pleural invasion, and serum carcinoembryonic antigen (CEA) level. 
p-N status and high serum CEA level were independent predictive 
variables in multivariate analysis. A five-year survival rate for patients 
with Noguchi’s type A and B was 100%. However, six patients (8.8%) 
of 68 patients with small adenocarcinoma had lymph node involve-
ment and four patients (5.9%) had pulmonary metastasis. 
Conclusions: It is not appropriate to omit lobectomy or lymph node 
dissection only on the basis of tumor size. Therefore, it seems reason-
able to conclude that lobectomy plus lymph node dissection still 
remains as a standard surgical procedure to treat cT1N0M0 adeno-
carcinoma of the lung. We must continue to search for new charac-
teristics in order to choose candidates for limited operation among 
patients with cT1N0M0 adenocarcinoma of the lung. 
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Oral vinorelbine in combination with cisplatin or 
carboplatin in adjuvant chemotherapy of non-small cell 
lung cancer: a prospective multicentre study of feasibility 
and tolerability
Kolek, Vitezslav 9; Grygarkova, Ivona9; Chaloupa, Jiri7; Koubkova, 
Leona3; Svecova, Jirina4; Skrickova, Jana 8; Ostrizkova, Lenka5; 
Sixtova, Dimka6
1 Department of Respiratory Medicine, Olomouc, Czech Republic; 
2 department of oncology, Liberec, Czech Republic; 3 University 
Hospital, Motol, Prague, Czech Republic; 4 Department of 
Oncology, Tabor, Czech Republic; 5 Department of Oncology, Batova 
nemocnice, Zlin, Czech Republic; 6 Department of Pneumology, 
Nemocnice Krc, Prague, Czech Republic; 7 Department of Oncology, 
Liberec, Czech Republic; 8 Department of Pneumology, FN Bohunice, 
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University Hospital, Olomouc, Czech Republic
Background: Adjuvant cisplatinum-based chemotherapy is recom-
mended for routine use in patients with stages IIA, IIB, and IIIA of 
non small-cell lung cancer (NSCLC) after radical resection. Results 
in stage IB were not conclusive. Vinorelbine is a preferable associat-
ed drug in this indication and a randomized study proved the compar-
able effectiveness and tolerability of vinorelbine given both orally or 
intravenously (i.v.) in advanced NSCLC, meanwhile oral vinorelbine 
gives better comfort to patients. 
Methods: This prospective multicentre study evaluates the feas-
ibility, toxicity and short time survival of adjuvant chemotherapy 
(ACT) based on cisplatin- CDDP (80mg/m2) or carboplatin- CBDCA 
(AUC 5) with vinorelbine (25 mg/m2 D1 i.v. and 60mg/m2 D8 given 
orally). After radical resection, ACT (4 cycles of 21 day regimen) was 
applied to patients with stage IB, II, and IIIA of NSCLC in 21 Czech 
and Slovak centres. Selection of CDDP or CBDCA was based on 
individual centre preference. 
Results: ACT was applied to 154 eligible patients (110 men, 44 
women, median of age 63 years). Out of them, 89 were smokers, 
49 ex-smokers and 16 non smokers. Surgically determined stages 
were IB in 46 pts, IIA in 18 pts, IIB in 38 pts and IIIA in 52 pts. 
CBDCA was given to 77 patients and CDDP to 77 patients, 4 of 
whom switched to CBDCA. All of them were treated as out-patients. 
Altogether 586 cycles (mean no 3.81, in CDDP 3.77, in CBDCA 
3.84) were administered, 84% of patients finished four cycles of 
planned ACT. The reasons for 25 patients ending ACT prematurely 
were hematological toxicity in 8 pts, non-hematological toxicity in 
9 pts and other reasons in 8 pts. The most frequent WHO grade 3/4 
of toxicity were neutropenia in 10.3%, leucopenia in 4%, anemia in 
4.5%, thrombocytopenia in 1.9%, alopecia in 2.9%, nausea in 5.8%, 
neurotoxicity, diarrhoea and mucositis in 0.7%. There was signifi-
cantly higher incidence of neutropenia (p 0.034) and slightly higher 
incidence of vomiting (p 0.055) in CDDP regimen, and non signifi-
cantly higher incidence of anemia (p 0.054) in CBDCA regimen. 
During the follow-up period, median 0.96 year, 22 (14,3 %) pts died, 
9 (5,8%) survived with appearance of recurrence and 123 (79,9%) pts 
lived without progression of the disease. 
Conclusions: ACT with vinorelbine given orally on day 8 appears 
to be a feasible and tolerable regimen in radically resected NSCLC. 
Present study is ongoing and the trends of overall survival, disease 
free interval and other survival parameters will be evaluated in the 
future.
This study was supported by Grant IGA NS-9959-3 of the Czech 
Ministry of Health 
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Multi-center phase II study of cetuximab in combination 
with thoracic radiotherapy followed by consolidation 
chemotherapy in patients with unresectable stage III non-
small cell lung cancer (NSCLC): A preliminary report 
Ramalingam, Suresh S.2; Kotsakis, Athanasios P.1; Heron, Dwight1; 
Tahini, Ahmad A.1; Burton, Steven A.1; Smith, Ryan1; Gooding, 
William1; Friedland, David1; Petro, Daniel1; Flaugh, Rick1; Raez, 
Luis3; Brahmer, Julie4; Greensberger, Joel1; Landreneau, Rodney J.1; 
Luketich, James1; Belani, Chandra P.5; Argiris, Athanassios6
1 University of Pittsburgh, Pittsburgh, PA, USA; 2 Emory University, 
Atlanta, GA, USA; 3 University of Miami, Miami, FL, USA; 4 Johns 
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Background: Concurrent chemoradiation with or without subsequent 
consolidation chemotherapy is the standard of care for unresect-
able stage III NSCLC. Cetuximab, an anti-epidermal growth factor 
receptor monoclonal antibody, enhances the efficacy of both radia-
tion and chemotherapy. To exploit both effects, we are evaluating a 
novel strategy of combining cetuximab with radiation followed by 
cetuximab combined with chemotherapy as consolidation therapy. 
Methods: Patients with unresectable stage IIIA or IIIB NSCLC 
without malignant pleural effusion, ECOG performance status (PS) 
0-1, no history of pulmonary fibrosis, and adequate end organ func-
tion are eligible. Treatment consists of chest radiotherapy (RT) to a 
total dose of 73.5 Gy in 35 fractions/7 weeks, one fraction/day, with 
lung and tissue heterogeneity corrections, and cetuximab 250 mg/
m2 intravenously weekly during RT (after an initial dose of 400 mg/
m2 the week prior to the start of RT). Cetuximab continues weekly 
without interruption after RT completion and during consolidation 
chemotherapy for a total of 26 weeks. Consolidation chemotherapy 
starts 4-6 weeks after RT completion, and consists of paclitaxel 200 
mg/m2 and carboplatin AUC of 6 administered intravenously every 3 
weeks for a total of 3 cycles. Primary endpoint is the overall survival. 
The target sample size is 40. 
Results: 27 patients have been enrolled; 19 males/ 8 females; 
median age 67 years (40-80); PS 0: 15, PS 1: 11; Histology: adeno-
carcinoma-11; squamous cell-8; NSCLC non-otherwise specified-7; 
other-1; Stage: IIIA-13, IIIB-14. Median RT dose delivered is 73.5 
Gy (56-73.5); median number of cetuximab dose 14.5 (1-26). 4 
patients received only 1 dose of cetuximab for the following reasons: 
change in treatment plan (1), ineligibility due to pleural effusion 
(1), insurance issues (1), and infusion reaction (1). 13 patients have 
received at least one cycle of consolidation carboplatin and paclitax-
el. Grade 4 toxicities during treatment with RT plus cetuximab are: 
infection (1), infusion reaction (1) and grade 3 toxicities: infection(2), 
fatigue(1), and rash(2). Grade 4 toxicities during treatment with 
consolidation carboplatin/paclitaxel plus cetuximab include neutro-
penia (6), neutropenic fever(1), and infection(1); grade 3 toxicities: 
neutropenia (2) and rash(2). One patient died from pneumonitis that 
developed after 56 Gy and was possibly related to cetuximab. Best 
response using RECIST criteria in 19 evaluable patients: 11 partial re-
sponses, 6 stable disease, 2 disease progression. With a median follow 
up of 8.5 months, 9 patients have died, 7 due to disease progression. 
Conclusions: Preliminary results suggest that the cetuximab-based 
regimen is feasible and the side effects are generally manageable. 
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Treatment was not associated with any grade 3-4 esophagitis. Antitu-
mor activity is encouraging. Follow-up and accrual are ongoing.
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Middle lobe syndrome caused by endobronchial malignant 
tumor
Kurowski, Krzysztof; Plech, Marcin; Matuszek, Jolanta I.
Hospital de Torrevieja, Torrevieja, Alicante, Spain
Review of the major literature dealing with the right middle lobe 
syndrome (RMLS) shows that benign inflammatory disease is the 
most common etiological factor (62%). However, 22% of patients re-
viewed had malignant tumors as a cause of the syndrome. Bronchial 
occlusion is the pathophysiological abnormality leading to develop-
ment of the RMLS has been rejected by more recent authors. 
We described a case of a 26-year-old man who presented massive 
hemoptysis. He was found to be bleeding from a endobronchial 
tumor on the right middle lobe orifice. The Surgical treatment was 
undertaken and superior bilobectomy was successfully performed. 
Postoperatively the patient was clinically and radiologically disease- 
free.
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Evaluation of the deliverability and tolerability of intensive 
weekly doublet adjuvant chemotherapy in Non Small Cell 
Lung Cancer
Kuruvilla, M. S.1; Martelli-Reid, Lorraine2; Goffin, John R.3; Arnold, 
Andrew3; Ellis, Peter M.3
1 Clinical Research Fellow - Thoracic Oncology and Clinical Trials, 
Hamilton, ON, Canada; 2 Advanced Practitioner Nurse, Hamilton, 
ON, Canada; 3 Medical oncologist, Hamilton, ON, Canada
Background: Recent data support the use of Cisplatin-Vinorelbine 
doublet as adjuvant chemotherapy in completely resected Non Small 
Cell Lung Cancer (NSCLC). These regimens, however, are more in-
tense than regimens typically used in advanced lung cancer and data 
has demonstrated the need for frequent dose reductions. Consequent-
ly, many centers in Canada have been reluctant to adopt this practice. 
The primary objective of this study was to assess the deliverability of 
Cisplatin doublet-based adjuvant chemotherapy in patients with stage 
IB, II and III NSCLC within our center. Secondary objectives were 
aimed at determining tolerability and toxicity for this regimen.
Methods: A retrospective review was undertaken of patients with 
completely resected NSCLC receiving adjuvant Cisplatin (50mg/
m2 D1, 8) and Vinorelbine (25mg/m2 D1, 8, 15 & 22) referred to the 
Juravinski Cancer Center between January 2005 and October 2007. 
Information was abstracted from the chart including data on patient 
demographics, chemotherapy start and stop dates, total chemother-
apy dose administered, treatment delays, reductions and omissions, 
treatment duration, and toxicity profiles. Dose intensity (DI) and 
relative dose intensity (RDI) were calculated as the total dose of drug 
received (mg/m2) divided by the duration of treatment (weeks) and 
total dose of drug received divided by total planned dose. 
Results: Forty one patients received adjuvant Cisplatin-Vinorelbine. 
The mean age of subjects reviewed was 62 yrs (SD=8). 52% of 
patients were female and about 81% had been ex-smokers. 93% 
had pre-existing co-morbidities. 37% had Stage 1B disease, 39% 
had Stage II disease and 24% had stage III disease. Approximately, 
68% underwent lobectomy or bilobectomy, 29% underwent pneu-
monectomy and 1 patient underwent wedge resection. At baseline, 
55% and 33% patients had an ECOG performance status of 0 and 
1 as compared to 7% and 62%, respectively, post-treatment. The 
median dose intensity was 23.5mg/m2/week (range: 13- 25mg/m2/
week) for Cisplatin and 18.8mg/m2/week (range: 8mg- 25 mg/m2/
week) for Vinorelbine. The median RDI for Cisplatin and Vinorelbine 
was 94% and 63% respectively. 68% of patients received four cycles 
of treatment. 61% and 12% received all treatments of Cisplatin and 
Vinorelbine, respectively. Toxicities ≥ Grade 3 included neutropenia 
(63%), fatigue (18%), anemia (12%), febrile neutropenia (7%), 
vomiting (5%), and constipation (2%). 24% and 18% received packed 
red blood cell transfusions and Erythropoiesis Stimulating Agents, 
respectively. Less severe toxicities included nausea (64%), flare of 
surgical site pain (54%), ototoxicity (48%), alopecia (34%) peripheral 
neuropathy (44%), mucositis (27%) and nephropathy (12%). 40% 
of patients used supportive care services, primarily related to social 
work and psychosocial supports. 2 patients needed a nutrition consult. 
5 patients required hospitalization for treatment related toxicities.
Conclusion: The deliverability of adjuvant chemotherapy with 
Cisplatin and Vinorelbine, administered weekly for sixteen weeks, 
appears as good or better when compared to published data. These 
data support the evidence based argument that adjuvant Cisplatin and 
Vinorelbine should be administered according to schedules evalu-
ated in randomized clinical trials. The success of this regimen at our 
center may, in part, be related to the services of an advanced practice 
nurse in this setting. 
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Validation of APE1/ref-1 as a biomarker for the prediction 
of Stage I, non-small cell lung cancer recurrence
Lim, Seung Pyung 1; Kang, Min-Woong2; Chang, Gang Won3; Kang, 
Shin Kwang 1; Lee, Choong-Sik4
1 Chungnam National University Hospital, Daejeon, Korea; 2 
Samsung Medical Center, Seoul, Korea; 3 Cancer Research Center, 
Samsung Bioresearch institute, Seoul, Korea; 4 Department of 
Pathology, Chungnam National University hospital, Daejeon, Korea
Introduction: Biomarkers play important roles in clinical application 
such as early diagnosis, prediction of prognosis and drug targeting. 
Lung cancer as the leading cause of cancer related deaths still lacks 
reliable biomarkers. Apurinic/apryrimidinic endonuclease1/ref-
1(APE1/ref-1) is a multi functional protein involved in the base exci-
sion repair of DNA damaged by oxidative stress or alkylating com-
pounds as well as in the regulation of multiple transcriptional factors 
such as AP-1, NF-kB, HIF-1, and P53. Previous study showed that 
APE1/ref-1 was related with non-small cell lung cancer (NSCLC) 
carcinogenesis and increase of the its expression was associated with 
up-staging of NSCLC. In this study, we validate the APE1/ref-1 as a 
biomarker for prediction of lung cancer recurrence. 
Methods: Study population was 42 patients who received curative 
resection and mediastinal lymph node dissection for stage I, NSCLC 
from 2000 through 2004 at in Chungnam National University Hospi-
tal. This study population was divided into two groups based on the 
recurrence, and these were compared by immunohistochemistry of 
the paraffin embeded tissues. Western blot analysis was performed 
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for APE1/ref-1 in nuclear or cytoplasmic proteins of the fresh frozen 
tissues from 8 non-recurrent patients who had surgery in 2004, and 8 
recurrence patients who had surgery between 2004 and 2006. Single 
pathologist scored the immunohistochemical staining. Statistical 
evaluation was performed using Student’s t-test, with p<0.05 con-
sidered significant. 
Results: Forty-two patients were classified as 17 non-recurrent group 
and 7 recurrent group for adenocarcinoma, and 11 non-recurrent and 
7 recurrent for squamous cell carcinoma, showing 33.3% recurrence 
rate in total. Mean follow-up duration was 48.7 months. Squamous 
cell carcinoma group showed significant discrepancy between 
non-recurrent and recurrent group in immunohistochemistry. Study 
patients for western blot analysis were 4 patients for each of the 
cancer cell type and recurrency. Mean follow up duration were 47.67 
months for non-recurrent group and 32.9 months for recurrent. Re-
current adenocarcinoma group showed increased level of expression 
of APE1/ref-1 in cytoplasm, nucleus and total (p=0.0435, p=0.0238, 
p=0.0082, respectively), whereas recurrent squamous cell carcinoma 
group showed decreased level of expression in nucleus (p=0.0441) 
in western blot analysis. Further analysis of immunohistochemical 
staining results that compare expression level between cytoplasm and 
nuclear fraction showed significant elevation in cytoplasmic fraction 
of the recurrent patients than the non- recurrent patients (p=0.002, 
p=0.0315, respectively) in adenocarcinoma, like a results of Western 
blot analysis.
Conclusions: This study suggests that the APE/ref-1 could be bio-
marker that predicts the recurrence of the stage I, adenocarcinoma. 
For the clinical application as a prognostic marker for adenocarcin-
oma, further investigation in the role of APE1/ref-1 in carcinogenesis 
and expanded prospective study should be needed.
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Analysis of 5-fluorouracil-related enzymes in non-
small-cell lung cancer: Specific biological properties of 
bronchioloalveolar carcinoma
Nagasaki, Toshiya
Division of Surgical Oncology, Department of Surgery, Nagasaki 
University Graduate School of Biomedical Sciences, Nagasaki, Japan
Background: The expression levels of 5-fluorouracil (5-FU)-related 
enzymes, dihydropyrimidine dehydrogenase (DPD), orotate phos-
phoribosyltransferase (OPRT), and thymidylate synthase (TS) are as-
sociated with sensitivity to 5-FU based chemotherapy. However, the 
significance of these enzymes has not been fully investigated in non-
small-cell lung cancer (NSCLC). This study examined the biological 
properties and differential sensitivities to 5-FU among NSCLC types, 
particularly between bronchioloalveolar carcinoma (BAC) and non-
BAC, by analyzing the expression of these enzymes. 
Materials and Methods: Tumor specimens were obtained from 
47 patients (34 men, 13 women) with primary NSCLC. The tumors 
were histopathologically classified as adenocarcinoma (ADC) in 34 
patients (20 BAC and 14 non-BAC) and squamous cell carcinoma 
(SCC) in 13 patients. The mRNA levels of 5-FU-related enzymes 
were analyzed by laser capture microdissection, compared with 
immunohistochemical findings and correlated with clinicopatho-
logical factors.
Results: Higher DPD and lower OPRT mRNA levels correlated 
with female gender, early tumor status, negative lymphatic and ves-
sel invasions, well differentiation, and ADC. For the two types of 
ADCs, the differences in DPD and OPRT mRNA levels were more 
remarkable between BAC and SCC (DPD; p=0.004, OPRT; p<0.001) 
than between non-BAC and SCC (DPD; p=0.253, OPRT; p<0.001). 
Immunohistochemical study revealed significant correlation between 
TS protein expression and SCC (p=0.002). 
Conclusion: The differential expression of 5-FU-related enzymes 
between NSCLC tumor types might explain, in part, the different 
biological properties and clinically observed sensitivities to 5-FU 
based chemotherapy between ADC and SCC, and between BAC and 
non-BAC.
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CNS recurrences are frequent in asymptomatic, early 
T-stage lung adenocarcinoma patients 
Nelson, Jennifer S.1; Allen, Lauren D.2; Parker, Leonard A.3; Hayes, 
David N.4; Hayward, Michele5
1 University of North Carolina Hospitals, Durham, NC, USA; 2 
University of North Carolina School of Medicine, Chapel Hill, NC, 
USA; 3 Department of Radiology, University of North Carolina 
Hospitals, Chapel Hill, NC, USA; 4 Lineberger Comprehensive 
Cancer Center, University of North Carolina, Chapel Hill, NC, USA; 
5 Lineberger Cancer Center, University of North Carolina, Chapel 
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Background: According to the 2.2009 version of the Non-small Cell 
Lung Cancer Guidelines, preoperative brain imaging is not recom-
mended for T1-T2 N0 disease in clinically asymptomatic patients. 
Many patients originally diagnosed with T1 or T2 disease unfortu-
nately present with central nervous system (CNS) metastasis within 
18 months of their pulmonary resection, especially in patients with 
adenocarcinoma. Detection of silent brain metastasis could therefore 
prevent unnecessary operations and provide earlier referral for treat-
ment. A systematic literature review does not definitively support 
the current guidelines regarding preoperative brain imaging for early 
T stage NSCLC patients. The purpose of this study was to evalu-
ate patients with early stage adenocarcinoma who received surgical 
intervention without preoperative brain imaging for CNS recurrence 
within 18 months. 
Methods: We completed a retrospective analysis of all patients who 
underwent pulmonary resection at our institution from 1990-2005 for 
primary, early T-stage adenocarcinoma. The patients were all oper-
ated on without preoperative brain imaging. Their medical records 
were reviewed and the patients with early postoperative development 
of brain metastasis were identified. Eighteen-month follow-up data 
was available for 94% of patients. CNS recurrence was determined 
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by documentation of new neurologic symptoms and new lesion(s) 
confirmed on head CT or brain MRI.
Results: Over the 15-year period, 247 patients underwent pulmonary 
resections for T1 or T2 adenocarcinoma of the lung without preopera-
tive brain imaging. All patients were neurologically asymptomatic 
at time of surgery. Of these, 14 (5.7%) developed brain metastasis 
within 18 months. Mean time to recurrence was 7 months (range: 
5 days – 16 months). Patients most frequently presented with gait 
disturbance (3 patients), dizziness (3 patients), and visual changes (2 
patients). Mean lesion size at time of detection was 2.2 cm (range: 
0.6cm – 5.0cm), and in four patients, lesions were multiple.
Conclusions: A significant fraction of patients with early stage 
adenocarcinoma developed CNS recurrences within one year, sug-
gesting that subclinical disease may have been present at the time of 
surgical intervention. This suggests that preoperative CNS imaging 
may need to be reconsidered in these patients.
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Prognostic factors in completely resected stage IB non-
small cell lung cancer with a diameter of 4cm or more
Okamoto, Junichi1; Hioki, Masafumi2; Kubokura, Hirotoshi1, 2; 
Mikami, Iwao1; Hirata, Tomomi1; Haraguchi, Shuji1; Koizumi, 
Kiyoshi1; Shimizu, Kazuo1
1 Nippon Medical School, Tokyo, Japan; 2 Nippon Medical School 
Musashi-kosugi hospital, Kawasaki, Japan
Background: Surgical resection is one of the best treatments for 
early stage patients in Non-Small Cell Lung Cancer (NSCLC). In 
Japan, the 5-year survival rates were about 80% for stage IA and 
about 60% for stage IB. Several studies reported that tumor size 
should be prognostic factor. Taken to together, even if patients, who 
had difference of tumor size among each other, were categorized in 
same stage, they seemed to have other prognosis. The purpose of this 
study was to evaluate the prognostic factors in patients with resected 
stage IB non-small cell lung cancer with a diameter of 4 cm or more.
Methods: We retrospectively analyzed 140 patients with NSCLC 
who underwent complete resection till 2008 and were diagnosed with 
stage IB disease. We examined overall survival and clinicopathologic 
differences of these patients.
Results: We divided into two groups based on tumor size: S-group 
(less than 4cm) and L-group (4cm and more). Five-year survival rate 
of patients in S-group or L-group was 79.9% and 62.1%. Overall 
survival of S-group was significantly better than L-group (HR, 0.33; 
CI, 0.14 to 0.78; p = 0.012), respectively. Median survival was not-
reached in S-group v.s. 90.6 months Ll-group, respectively. Visceral 
pleural invasion did not influence overall survival.
Conclusion: The current study suggested that tumor size was 
prognostic factor for overall survival in resected stage IB NSCLC 
with a diameter of 4cm or more. This results supported that stage 
IB patients, who had tumors 4cm or more, should receive adjuvant 
chemotherapy after complete surgical resection.
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Video-Assisted Thoracic Surgery (VATS) lobectomy 
for pathologic stage I Non-Small Cell Lung Cancer: A 
comparative study with thoracotomy lobectomy
Chang, Sung Wook; Park, Joon Suk; Kim, Hong Kwan; Choi, Yong 
Soo; Kim, Jhingook; Shim, Young Mog; Kim, Kwhanmien
Samsung Medical Center, Seoul, Korea
Background: The surgical treatment of stage I non-small cell lung 
cancer (NSCLC) can be performed by thoracotomy or video-assisted 
thoracic surgery (VATS) lobectomy. The aim of study was to evaluate 
the feasibility of VATS lobectomy for NSCLC patients with patho-
logic stage I lung cancer.
Methods: Between December 2003 and December 2007, 529 pa-
tients with pathologic stage I NSCLC underwent lobectomies (373 
thoracotomy, 156 VATS). Patients in both groups were matched by 
age, gender and pathologic stage to create two comparable groups: 
thoracotomy lobectomy and VATS lobectomy groups. We performed 
a retrospectively analysis in NSCLC patients with pathologic stage 
I to compare the overall survival, recurrence-free survival, com-
plication and length of hospitalization between patients underwent 
conventional thoracotomy lobectomy and VATS lobectomy.
Results: After patient matching by age, gender and stage, there were 
272 patients eligible for analysis, 136 in each group (mean age of 
59.5 years; 70 men, 66 women; 80 stage IA, 56 stage IB). There 
was no statistical difference in preoperative clinical characteristics 
between two groups. No hospital mortality was observed in both 
groups. The overall 3-year survival rate was 97.4% in thoracotomy 
and 96.6% in VATS groups (p=0.76). During the follow-up, 20 
patients (14.7%) experienced tumor recurrence in thoracotomy group, 
including loco-regional recurrence in 7 patients, distant metastasis in 
13. In VATS group, 13 patients (9.6%) experienced tumor recurrence, 
including loco-regional recurrence in 4 patients, distant metastasis in 
9. The 3-year recurrence-free survival rate was 81.8% in thoracotomy 
and 85.3% in VATS groups (p=0.43). There was no statistical differ-
ence in postoperative complications between thoracotomy and VATS 
groups (30 cases / 22 patients vs 19 cases / 17 patients, p=0.65, odds 
ratio=1.19). The mean length of hospital stay of the patients who 
underwent VATS was 2 days shorter than that of thoracotomy group 
(8.8 ± 6.5 days vs 6.3 ± 3.3 days, p<0.05).
Conclusions: VATS lobectomy for pathologic stage I lung cancer 
is feasible operation with shorter hospitalization and comparable 
survival rate.
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Systematic bilateral lymphnode dissection in patients with 
stage III A-B 
Porhanov, Vladimir A.; Poliakov, Igor S.; Bodnia, Vadim N.; 
Kononenko, Valery B.; Selvaschuk, Andrew P.
Regional Clinical Hospital # 1 – Cardiothoracic Surgery Center, 
Krasnodar, Russia
Stages III A-B are commonly defined as a contraindication to surgery, 
although this population with mediastinal involvement is not uniform. 
From September 1991 to December 2007, of 6629 patients operated 
on for lung cancer, we have randomized 158 patients with NSCLC 
and mediastinal lymph nodes invasion for the study. Mean age was 
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60,5 years. Neoadjuvant chemotherapy was administered in 34% 
patients preoperatively. All patients underwent systematic bilateral 
lymphodissection via thoracotomic (T) - 81 cases and sternotomic 
(S) accesses - 77 cases. Stage cTIIIb was found in 9 (5,6%) patients. 
Pneumonectomy was performed in 71% (112 cases), in others – lob-
ectomy and bilobectomy. Mean follow-up was 3 months. Postopera-
tively stage pTIIIb was found in 27 cases (17%) – with thoracotomy 
in 6 (7,4%), with sternotomy in 21 (27%). Postoperative complica-
tions were developed in 8,6% patients in group T and in group S in 
7,7% patients (n.s.). Mortality rate was 2,3% and 2,6% respectively 
(n.s.). Five-year survival rate for N2 –14% (T) vs. 28% (S). There 
was zero 5 – year survival for N3 (Т), and in a group with sternotomy 
survival rate was 10%. In N2 population with neoadjuvant chemo-
therapy survival rate showed the best results. Systematic bilateral 
lymphodissection does not worsen immediate postoperative results. 
This procedure enables to make proper staging and select accurate 
further treatment, which improves life-span in patients with NSCLC 
and mediastinal lymph node invasion. Neoadjuvant therapy improves 
survival in patients with mediastinal lymph node invasion.
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Surgery for locally advanced NSCLC with SVC invasion
Porhanov, Vladimir A.; Selvaschuk, Andrew P.; Poliakov, Igor S.; 
Sitnik, Sergey D.; Bodnia, Vadim N.
Regional Clinical Hospital # 1 – Cardiothoracic Surgery Center, 
Krasnodar, Russia
Surgery for SVC invasion is not indicated; other non-surgical 
modalities achieve minor palliative benefits. This study is aimed to 
demonstrate treatment results of patients with NSCLC. From 1989 to 
December 2007 we have performed 51 operations for SVC resection, 
of those, 49 patients (96%) had NSCLC as an indication to surgery. 
In 31 cases we observed less or more noticeable SVC syndrome, 
caused by direct tumorous invasion in SVC (69%), or mediastinal 
lymph nodes (31%). In 38 cases (79%) we performed standard pos-
terior lateral thoracotomy and in 11 cases (21%) it was sternotomy. 
In all cases we performed systematic mediastinal lymphodissection. 
We performed 3(6%) pneumonectomies with carinal resection, 20 
(40%) right pneumonectomies, 26 (53%) upper lobe \92; bilobecto-
mies. For SVC prosthesing we applied PTFE Y-form prosthesis in 
13 (26%), linears ones in 31 (63%), in 5 cases (10%) there was no 
prosthesis used. Mean time of SVC complete clamping was 42 min. 
Complications developed in 11 (21%) cases; intraoperative mortality 
rate was 0. Hospital mortality rate was 10%. Prosthesis and cerebral 
vessels thrombosis, myocardial infarction and single lung pneumonia 
resulted in death. Postoperative chemotherapy was indicated in 21 
cases. Total 5-year survival for this group was 16%. Despite the 
rather high rates of postoperative complications and mortality, this 
study shows that surgery for this population has a positive impact and 
improves survival and life quality in patients with locally advanced 
NSCLC and SVC invasion. 
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Pneumonectomy in non-small cell lung cancer patients – is 
it worth?
Rzyman, Witold2; Stangiewicz, Michal1; Gibas, Artur2; Chwirot, 
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Background: Pneumonectomy in non-small cell lung cancer 
(NSCLC) patients is associated with high morbidity and mortality 
and thus should be performed in limited patients population but due 
to late diagnosis still consists 10-30% of all operations. 
Material and Methods: Eight hundred fifty one (31%) pneumonec-
tomies were performed in 2745 NSCLC patients operated between 
1993 and 2000 in three thoracic departments. Median age was 60 
years (28-79 years). One hundred forty nine patients (16,7%) re-
ceived perioperative oncological treatment. 
Results: Median survival was 20 months, and 5-year survival was re-
corded in 255/851 (29,9%) patients. Probability of survival after 1,2,3 
and 5 years after pneumonectomy was 63,9%, 46,4; 38,8 and 29,8% 
respectively. Thirty-days or in-hospital death was recorded in 46/851 
(4%) patients. Complications occurred in 304/851 (35,7%) patients. 
Pathological stage was the strongest negative predictor of survival 
(p<0,0001). Median survival in months according to pathological 
stage was as follow: Ia – 81, Ib – 60, IIa – 48, IIb – 25, IIIa – 13, IIIb 
– 12. Median survival in patients with large cell carcinoma, adeno-
carcinoma and squamous cell carcinoma was 8, 13 and 26 months re-
spectively (p<0,001). Patients lived longer after left pneumonectomy 
(25 versus 15 months, p=0,005) as well as they were under 60 years 
of age (p<0,001). Neither co-morbid diseases (p=0,33) nor other risk 
factors (p=0,739) had negative impact on survival but had such an 
impact on the rate of postoperative complications (p<0,0001). 
Conclusions: A man older than 60 years, with right sided large cell 
carcinoma that has stage higher than IIa is the worst candidate for 
pneumonectomy concering complications and long term survival. 
Pneumonectomy is the procedure of high risk of death and complica-
tions with a poor long-term survival and thus should be limited to 
selected patients population.
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A clinicopathological study of resected peripheral non-
small cell lung cancer 2.0 cm or less in diameter
Shi, Chunlei; Han, Baohui
Shanghai Jiaotong University, Shanghai, China
Background: The diagnosis of small-sized (2 cm or less) non-small 
cell lung cancer(NSCLC) has increased with the development of 
computed tomography(CT). In order to establish the optimal surgical 
strategy, we analyzed the clinicopathologic features and survival 
status in the patients with different tumor sizes of peripheral small-
sized NSCLC.
Methods: A total of 185 peripheral non-small cell lung cancer 2.0 
cm or less in diameter were studied, surgical methods, lymph node 
involvement, CT scan findings and survival rates of those patients 
were retrospectively analyzed.
Copyright © 2009 by the International Association for the Study of Lung Cancer S791
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
Results: 102 patients were adenocarcinoma, 62 patients were squa-
mous cell carcinoma, and 21 patients were adeno-squanous carcin-
oma. Of these, 26 patients (14.05%) with mediastinal lymph node 
involvement. There was no statistically significant difference in the 
incidence of lymph node involvement between in tumors1.6~2.0 cm 
(15.84%) in diameter than in those 1.0~1.5 cm(14.93%)(P=0.121). 
There was no lymph node metastasis in tumors less than 1.0 cm 
in diameter. The 5-year survival rates cases with or without lymph 
node involvement were 88.05% and 57.69%, respectively, showing 
significant difference (P=0.000). The 5-year survival rate for patients 
with a tumor of 1.6~2.0 cm in diameter, 1.0~1.5 cm and ≤1.0cm was 
80.19%, 85.07% and 100%, respectively. The 5-year survival rate of 
12 patients showing ground-glass opacity (GGO) on chest CT was 
94.74%(18/19) and one patient died of heart disease. 
Conclusion: NSCLC tends to metastasize to the regional lymph 
nodes even with tumor diameter less than 2 cm. The results of the 
present study suggested that routine lymph node dissection is neces-
sary even for cases with tumor diameter less than 2 cm. However, 
if the tumor is within 1.0 cm in diameter with a high GGO ratio 
showing on chest CT, these are good candidates for partial resection 
without mediastinal lymph node dissection. A large multicenter study 
is necessary to confirm this postulate.
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Occult nodal metastasis in patients with non-small cell 
lung cancer at clinical stage T1N0M0 as determined by 
18F-FDG PET/CT 
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Background: The introduction of integrated 18F-FDG PET/CT scan-
ning has enhanced the diagnostic accuracy of nodal staging for non-
small cell lung cancer (NSCLC). We analyzed risk factors for occult 
nodal metastases in patients with clinical stage T1N0M0 (cT1N0M0) 
NSCLC as determined by 18F-FDG PET/CT. 
Methods: Data for 161 patients diagnosed as cT1N0M0 NSCLC 
from January 2005 to December 2007 were retrospectively reviewed. 
All study patients underwent 18F-FDG PET/CT scanning and cer-
vical mediastinoscopy or systemic lymph node dissection for lung 
cancer staging. 
Results: 104 patients (64.6%) were staged as pathologic stage 
T1N0M0. Cervical mediastinoscopy was fulfilled in 81 patients 
(50.3%) and N2 involvement was detected in 3.7% (3/81) of these 
patients. Five patients (3.2%, 5/158) were diagnosed with N2 disease 
after systematic lymph node dissection. Total N2 involvement was 
5% (8/161). As 8.7% (14/161) of study patients had N1 disease, 
13.7% (22/161) of patients in total suffered occult nodal (N1 or 
N2) metastasis. In univariate analyses, larger tumor size and higher 
primary tumor maximum standardized uptake value (SUVmax) were 
associated with occult nodal metastasis. Tumor histology including a 
bronchioloalveolar carcinoma (BAC) component as well as ground 
glass opacity (GGO) on CT scans were less likely to have nodal 
metastasis. Multivariate analyses demonstrated that a primary tumor 
SUVmax was an independent predictor of occult nodal metastasis. 
Conclusions: Preoperative PET/CT scan reduces the frequency of 
occult nodal metastasis compared with the results of the pre-PET/
CT era. Cervical mediastinoscopy is rarely necessary in patients with 
PET/CT-staged cT1N0M0 NSCLC involving a BAC component or 
GGO on CT scans.
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Pemetrexed (P) and Cisplatin (C) as either Induction (IC) 
or Adjuvant (AC) Chemotherapy in stage IB-II Non-Small 
Cell Lung Cancer (NSCLC): A randomized phase 2 study 
(EORTC 08051)
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Welch, John3; Van Schil, Paul E.2
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Background: Both IC and AC have resulted in moderately improved 
outcome in patients (pts) with resectable early stage NSCLC (Gilli-
gan 2007, Stewart 2007). Pemetrexed (P) is an antifolate with prom-
ising activity in advanced non-squamous NSCLC (Scagliotti, 2008).
Aim: To analyze the activity and toxicity of a PC regimen given 
either as IC or AC in patients (pts) with resectable early stage 
NSCLC.
Methods: Eligible pts had pathologically proven NSCLC in stage 
cIB-cII, a WHO PS ≤2, and were considered fit for resection and 3 
cycles of chemotherapy: P 500 mg/m² and C 75 mg/m² given 3 weekly 
on d1, either 4-6 weeks before (IC) or 4-8 after surgery, with vitamin 
supplementation. The main endpoint, success of treatment delivery, 
was defined as receiving 3 cycles of chemotherapy with a relative dose 
intensity (RDI) of ≥80% for each drug and having surgery. 
Results: This study was closed after accrual of 13 pts in 2 institutions 
in 2 years: 8 non-squamous cancer, median age 59 y, PS 1 in 10 pts, 
stage cIB in 8 and cII in 5, left-sided in 7. Five pts were allocated 
to the IC arm (PR in 1), 8 to AC, of whom 2 never received chemo-
therapy. Surgery was exploratory in 1 (unforeseen T4), lobectomy in 
9, left pneumonectomy in 2. In 11 pts actually receiving AC or IC, 
3 cycles were given with a RDI of P of 99% and of C of 94 % . No 
grade 3-4 toxicity was reported. Downstaging was noted in 2 pts (all 
AC), upstaging in 3 (2 IC, 1 AC). 1 AC pt died from PD. A formal an-
alysis of the primary endpoint is not possible due to low numbers. 
Conclusion: This randomized phase 2 trial failed to accrue due to 
competing studies and loss of interest in IC. Survival data will be pre-
sented at the meeting. 3 cycles of a peri-operative PC regimen seems 
feasible and well tolerated
This trial was supported by Eli Lilly
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The feasibility of adjuvant carboplatin and docetaxel in 
patients with curatively resected locally advanced non-
small cell lung cancer 
Wang, Si-yu; Sun, Haibo; Zhang, Bin-bin; Ou, Wei; Yang, Hua; Fang, 
Qin
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Background: It has been established that adjuvant cisplatin-based 
chemotherapy benefits selected patients with stage III non-small 
cell lung cancer (NSCLC). However, cisplatin-based chemotherapy 
compliance has been difficult. Carboplatin (C) is better tolerated than 
cisplatin, and carboplatin-based adjuvant therapy may have better 
chemotherapy compliance. The aim of this study is to investigate 
the feasibility and toxicity of adjuvant carboplatin and docetaxel in 
patients with curatively resected locally advanced non-small cell lung 
cancer,
Materials and Methods: From June 2006 to November 2008, 
eighty-two patients with curatively resected locally advanced 
non-small cell lung cancer were enrolled on the trial .Adjuvant 
chemotherapy was initiated between 2 and 4 weeks after surgery,and 
consisted of four cycles carboplatin (AUC=5),and docetaxel 
(Taxotere,75mg/m2) every 3 weeks. After chemotherapy patients 
received prophylactic G-CSF supportive therapy and the patients took 
blood test every week. 
Results: Patient demographics were: mean age 56 years (range 
34-73), gender male/female (56.1%/43.9%), stageIIIA(70.7%), 
stageIIIB(29.3%),and the two most common histologies were: adeno-
carcinoma (63.4%) and squamous cell carcinoma(17.1%). Sixty-six 
patients (80.5%) received four cycles therapy within 12 weeks and 
16(19.5) of patients did not complete four cycles therapy for the fol-
lowing reasons: patient refusal (n=12), severe adverse events(n=1), 
bone metastases during chenmotherapy(n=1). Two patients received 
2 cycles neoadjuvant chemotherapy and received 2 cycles adju-
vant chemotherapy after surgery. No treatment related deaths were 
observed and the primary adverse events were hematologic toxicity 
(grade 2 leucopenia 41.5% and grade 3 neutropenia 34.1% of patients 
), alopecia, fatigue, gastointestinal reaction(nausea, vomiting, diar-
rhea). 
Conclusion: Carboplatin and docetaxel (Taxotere) has an acceptable 
toxicity profile with the use of G-CSF supportive therapy and the ma-
jority of patients completed four cycles of therapy within 12 weeks.
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Adjuvant cisplatin and docetaxel (CDDP-Doc) for Non 
Small Cell Lung Cancer (NSCLC): the Hospital of the 
University of Pennsylvania (HUP) experience
Weiss, Jared1; Evans, Tracey1; Eaby, Beth1; Stevenson, James2; 
Kucharczuk, John5; Cooper, Joel1; Kaiser, Larry3; Shrager, Joseph4; 
Rengan, Ramesh1; Langer, Corey1
1 Hospital of the University of Pennsylvania, Philadelphia, PA, USA; 
2 Penn Presbyterian Medical Center, Philadelphia, PA, USA; 3 The 
University of Texas Health Science Center at Houston, Houston, TX, 
USA; 4 Stanford University School of Medicine, Stanford, CA, USA; 5 
Hospital of the University of Pennsylvania, Philadelphia, PA, USA
Background: The ANITA and JBR.10 studies demonstrated a surviv-
al advantage for adjuvant cisplatin and vinorelbine following surgical 
resection for NSCLC. The TAX326 study demonstrated improved 
response-rate, overall survival and quality of life for CDDP-Doc 
compared to cisplatin and vinorelbine in the metastatic setting. This 
trial has prompted many thoracic oncologists to hypothesize that the 
CDDP-Doc doublet might be superior in the adjuvant setting. Others 
have argued that extrapolation from the metastatic setting is a flawed 
assumption and that dose delivery of CDDP-Doc is not feasible 
because of toxicity in the post-operative period.
Methods: Using a tumor database augmented by chart reviews, 
we retrospectively evaluated the treatment outcomes of 56 patients 
without major co-morbidity who received postoperative CDDP-Doc 
between August 2003 and November 2007. Aggressive supportive 
care was provided including the use of pegylated filgrastim in all 
patients.
Results: Demographic data are shown in table 1. 85.7% of patients 
received all 4 planned cycles of CDDP-Doc; 7.1% received 3 cycles; 
and 3.6% received 1 or 2 cycles. Survival and progression-free-sur-
vival are shown in figure one.
 Median Age (Range) 59.5 (34-74)
 Sex- male 30 (53.6%)
 Sex- female 26 (46.4%)
 Race- white 43 (76.8%)
 Race- black 8 (14.3%)
 Race- other 5 (8.9%)
 ECOG PS 0 11 (19.6%)
 ECOG PS 1 43 (76.8%)
 ECOG PS 2 1 (1.8%)
 ECOG PS 3 1 (1.8%)
 Stage I 14 (25%)
 Stage II 20 (35.7%)
 Stage IIIa 14 (25%)
 Stage IV (isolated brain) 1 (1.8%)
 Histology- Adenocarcinoma 35 (62.5%)
 Squamous Cell Carcinoma 11 (19.6%)
 Large Cell Carcinoma 4 (7.1%)
 BAC or Adenocarcinoma with BAC features  3 (5.4%)
 Adenosquamous 1 (1.8%)
 NSCLC, NOS 2 (3.6%)
 Ever smoker 36 (80%)
 Never smoker 9 (20%)
 Surgery type-Lobectomy 43 (76.8%)
 Pneumonectomy 8 (14.3%)
 Other 5 (8.9%)
 Treated with adjuvant XRT 10 (17.9%)
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Conclusions: In a fit population with resected NSCLC, aggres-
sively supported with IVF, anti-emetics, and routine use of pegylated 
filgrastim, treatment with adjuvant CDDP-Doc proved a practical 
regimen, with a very high proportion of patients (85.7%) receiving 
all 4 planned cycles of therapy. Survival was comparable to results 
observed with CDDP and vinorelbine in JBR.10 and ANITA. The 
CDDP-Doc regimen allows favorable dose delivery and increased 
convenience compared to historic results with CDDP and vinorelbine.
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Surgical result for synchronous multiple primary lung 
cancers existing in two lobes or more
Yamashita, Motohiro; Tada, Ryuhei; Suehisa, Hiroshi; Ogino, Atsuko; 
Nogami, Naoyuki; Komori, Eisaku; Sawada, Shigeki; Segawa, 
Yoshihiko; Kurita, Akira; Shinkai, Tetsu
NHO Shikoku Cancer Center Hospital, Matsuyama, Japan
Background: Synchronous multiple primary lung cancer is uncom-
mon entity, but the standard treatment strategy for this entity is 
unknown. In order to identify the surgical prognosis of multiple lung 
cancer patients, we reported on a single institution experience focus-
ing on survival. 
Methods: Retrospectively our institutional medical records were 
reviewed since 1998. The lung tumors were found simultaneously in 
different lobes in 47 consecutive patients who underwent either sin-
gle-staged or second-staged lung resections. The case of lung tumors 
located only in the same lobe was excluded because of intra-pulmon-
ary metastasis possibility. Inclusion criteria for these kind resections 
were no evidence of mediastinal nodal involvement, adequate post 
operative pulmonary functions (presumed post operative forced ef-
fort volume exceeds more than 800ml/m2), good performance status 
(ECOG PS score is level 0 or 1), and no serious co-morbidity. 
Results: The mean age of the patients was 68, and men were 26. The 
tumors were located bilaterally in 24 patients or ipsilaterlly in 23 
patients. The operative procedures for multiple lung cancers were one 
pneumonectomy, bi-lobectomy in 3, lobectomy with segmentectomy 
in 18 or wedge resection in 14, segmentectomy with wedge resection 
in 9, and all wedge resections in 2 cases. Single-staged resections 
were performed in 38 cases and second-staged resections were done 
in 9 cases. Histology combination of the tumors were as follows; 
every adenocarcinomas (Ad) in 34 cases, every squamous cell car-
cinoma (Sq) in 6 cases, Ad-Sq in 5 cases, Ad-small cell carcinoma in 
one case, and Ad-large cell carcinoma in one case. The lung cancer 
recurrence or new nodules were founded in 15 cases and 4 cases 
underwent tumor resection again. Eight cases were lost due to recur-
rence of lung cancer. The 30-day mortality was found in one case 
(2%) because of cerebral infarction and subsequent pneumonia. All 
over The survival rate was 76% at three years and 67% at five years. 
Ad histology combination group showed significantly better survival 
curve than the other histology combinations (p< 0.001). 
Conclusion: Surgical resections for multiple primary lung cancers 
yielded feasible results in our selected patients. Synchronous multiple 
primary lung cancer is expected to benefit from surgery and the opti-
mal histological combination will be adenocarcinoma.
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Possible delayed cut-end recurrence after limited resection 
for ground-glass opacity adenocarcinoma, intraoperatively 
diagnosed as Noguchi Type B, in three patients
Yoshida, Junji1; Ishii, Genichiro2; Yokose, Tomoyuki3; Aokage, 
Keiju1; Hishida, Tomoyuki1; Nishimura, Mitsuyo1; Onuki, Takuya4; 
Noguchi, Masayuki4; Nagai, Kanji1
1 Division of Thoracic Surgery, National Cancer Center Hospital 
East, Kashiwa, Japan; 2 Pathology Division, Research Center 
for Innovative Oncology, National Cancer Center Hospital East, 
Kashiwa, Japan; 3 Pathology Division, Kanagawa Cancer Center, 
Yokohama, Japan; 4 Department of Pathology, Graduate School of 
Comprehensive Human Sciences, University of Tsukuba, Tsukuba, 
Japan
Background: In our limited resection trial of pulmonary peripheral 
ground-glass opacity (GGO) lesions from 1998 through 2002, limited 
resection of Noguchi Type A and B carcinomas appeared to have a 
positive outcome. However, recently 3 of the 24 patients, with mixed 
GGO lesions intraoperatively diagnosed as Type B, developed a solid 
lesion at the cut end scar.
Methods: Medical records and radiology and pathology findings of 
the 3 patients were reviewed. We also analyzed epidermal growth 
factor receptor (EGFR) gene mutations when possible. 
Case 1: A 67-year-old, non-smoking woman underwent right upper 
lobe wedge resection for a 1.2 cm lesion. Due to a positive cut-end 
in the first frozen section evaluation, she needed additional margin 
resection. The final pathologic diagnosis was adenocarcinoma, mixed 
subtype with predominant BAC component, Type B. The resection 
scar became thicker and was judged tumorous 8 years after surgery. 
She underwent right upper lobectomy and node dissection 8.7 years 
after the initial resection. Pathologically, there was an adenocarcin-
oma, mixed subtype with BAC, papillary, acinar and solid com-
ponents, T2N0M0 and an incidental BAC in atypical adenomatous 
hyperplasia (AAH), T1N0M0. In the T2N0M0 tumor, the atypia was 
fairly mild in the peripheral BAC areas, suggesting primary lung 
adenocarcinoma. No vessel invasion was identified. The initial GGO 
lesion had EGFR mutations L858R and S768I, but the second and 
third tumors had only L858R.
Case 2: A 63-year-old, non-smoking woman underwent right middle 
lobe wedge resection for a 1.1 cm lesion. The final pathologic 
diagnosis was BAC with pseudopapillary growth pattern, Type B. 
A solid tumor developed around the cut-end staples 5 years later. 
She underwent right middle lobectomy and lymph node dissection 
5.8 years after the initial resection. Pathologic diagnosis was an 
adenocarcinoma, mixed subtype with BAC, papillary, acinar and 
solid components, T4(pm1)N2M0 with visceral pleura invasion and 
lymphatic permeation. The initial GGO and recurring tumors had the 
same EGFR mutation: E746-A750 del type 2.
Case 3: A 70-year-old man underwent a percutaneous needle biopsy 
for a 2.0 cm lesion in the right upper lobe, which yielded atypical 
cells suspected of adenocarcinoma. He underwent wedge resection, 
and the final pathologic diagnosis was adenocarcinoma, mixed sub-
type with predominant BAC and minimal invasion, Type C, with 3 
AAH in the resected specimen. Despite the intraoperative underdiag-
nosis, he decided not to undergo additional treatment. After 8 years, 
the cut-end scar suddenly grew, accompanied by pleural effusion. 
Adenocarcinoma cells were confirmed in the effusion. Although he 
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had been a smoker and no EGFR mutations were identified in the 
initial GGO lesion or in the effusion adenocarcinoma cells, he de-
cided to try Gefitinb. The response was SD. He developed interstitial 
pneumonia 5 months later, which he survived. He died of lung cancer 
11 months after recurrence.
Conclusions: Radiologically, these 3 second tumors were clearly 
cut-end scar area recurrences. However, other findings suggest pos-
sible metachronous primary cancers in Case 1, cut-end recurrence 
in Case 2, and needle biopsy implantation in Case 3. It is difficult to 
definitively conclude whether the second tumors were recurrences or 
metachronous primaries.
However, these second tumors have convinced us that our initial 
caution in concluding GGO lesions can be cured by limited resection 
was a good one. Our experience definitely indicates that continu-
ing follow-up attention for more than 5 years is needed after limited 
resection even for GGO BAC lesions.
Novel Therapeutics and Modalities
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Molecular targeted therapy gefitinib in Non Small Cell 
Lung Cancer – a continuing experience from India
Behera, Digambar1; Jaiswal, Anand1; Aggarwal, Ashutosh N.2; Gupta, 
Dheeraj2; Saini, J K.1; Jindal, Surender K.2; Aggarwal, Ritesh2; 
Kapoor, Rakesh2; Sharma, S C.2; Mohanty, B K.3
1 LRS Institute of Tuberculosis and Respiratory Diseases, New Delhi, 
India; 2 Postgraduate Institute of MedicalEducation and Research, 
Chandigarh, India; 3 All India Institute of Medical Sciences, New 
Delhi, India
With the better understanding of the molecular basis of carcinogen-
esis, a number of growth-factor-receptor-targeted agents have been 
tried with encouraging results in patients with advanced NSCLC (1). 
Women, non-smokers, adenocarcinoma and Asians respond better. 
This communication is a further experience of our earlier presenta-
tions. 
Histologically proven advanced (stage IIIB or IV) non-small cell lung 
cancer patients earlier treated with chemotherapy received gefitinib 
250mg daily orally. We have been using Gefitinat since the beginning 
of our study, this drug being the only Indian brand available at that 
time and a very cheap, almost 10% of the cost of the internationally 
available brands. There were 39 females (37-59 yrs) and 95 males 
(44-67 yrs). 72 were non-smokers and the remaining were smokers. 
83 had adenocarcinoma and 51 had squamous cell carcinoma. The 
disease was of stage IIIB (n=72) and stage IV (n=62). The duration 
of gefitinib therapy varied from 20 weeks to 62 weeks with median of 
34 weeks. 
The disease remained static in 86 (64.1%) with stabilization or 
improvement in the Kornofsky performance scales in 88. The mean 
performance status improved from 70 to 90 in 62 cases, deterior-
ated in 29 and in the rest remained static. There was no radiological 
progression in 65 cases, while 39 cases showed radiological progres-
sion. The median survival (calculated after completion of chemother-
apy and start of gefitinib) was 32.5 weeks with 31 patients surviving 
beyond 1 year. The drug was well tolerated by all patients. 52 patients 
complained of mild skin rash (three fixed drug eruptions). 49 patients 
had grade 1-2 diarrhea.  
We found an Indian brand of gefitinib (Gefitinat) to be beneficial. The 
drug is well tolerated by Indian patients. This may be due to a differ-
ent pharmacogenomic property of gefitinib in this population. This 
being a cheaper brand and having beneficial effect, the drug can be 
safely used when indicated. 
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Amino Bisphosphonate as a modulator for angiogenesis in 
lung cancer: 
schedule dependant dosing
Bhattacharyya, Gouri Shankar; Malhotra, Hemant; Agarwalla, Dillip
Department of Medical Oncology, AMRI, Hospitals, Dhakuria, 
Kolkata, India
Angiogenesis is an important driver for tumor progression and me-
tastasis. Control of angiogenesis has an important impact on disease 
control, respiratory rate and survival. However, control of angiogen-
esis drugs that are not free of major side effects and they are also 
expensive. Metastasis is also dependant on angiogenesis circulating 
tumor cells and a recipient site which is favorable. This is best seen in 
breast cancer, prostate cancer and lung cancer. One of the commonest 
methods of management in bone metastasis, is use of third generation 
amino bisphosphonate like zoledronic acid. It has been shown that 
besides stabilizing the bone by inhibition of osteoclast, bisphosphon-
ate make the bone a hostile environment for seedlings of tumor cells. 
It also shows response to some extent by inhibiting VEGF. This is a 
single institution unblinded study of using zoledronic acid at 1 mg 
per day once in a week for 3 weeks followed by once in 3 week use 
of zoledronic acid. Chemotherapy was used 24 hours after the use of 
zoledronic acid. This was compared with once in 3 weeks use of 4 
mg of zoledronic acid with chemotherapy which was given 24 hours 
after zoledronic acid.
There were 12 patients in each arm. The decline of VEGF to max-
imum levels was seen in 1 mg per week schedule which dropped by a 
factor of 50% in 3 weeks in 9 out of 12 patients. This drop was seen 
upto 10 months in 5 patients. 2 patients are maintaining low VEGF 
levels even today. Pre median survival time was 16 months.
In the control group the VEGF levels dropped to 20% in the first 3 
weeks in 3 patients. The maximum drop was seen in 4 patients. The 
median time to progression was 9 months.
There was a co-relation between drop in VEGF levels, normalization 
of calcium creatinine ratio in urine, fibroblast growth factor and IL-6 
and IL-8. However very interesting results are seen when weekly 
angiogenic dosing is done with biphosphonate weekly.
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Anti-tumor activity of ADH-1 in vitro and in vivo in 
combination with erlotinib (Tarceva®) in lung cancer cell 
lines
Chan, Daniel C.1; Gupta, Mukur1; Zhang, Zhiyong2; Zheng, Di2; Sui, 
Xiaomei2; Peters, Williams P.1; Bunn, Jr, Paul A.2
1 Adherex Technologies Inc, Durham, NC, USA; 2 University of 
Colorado Denver, Aurora, CO, USA
Background: ADH-1 is a novel N-cadherin (Ncad) antagonist. Ncad 
is a novel protein target present on approximately 50% of cancer 
cells. N-cad expression on cancers generally increases as tumors 
become more aggressive, invasive and metastatic. Antigrowth effects 
of ADH-1 and derivatives have been studied in a panel of lung cancer 
cells. ADH-1 has been well tolerated with evidence of antitumor 
activity in phase I and phase II single agent and combination studies. 
Here we report the anti-tumor activity of ADH-1 in combination with 
erlotinib in lung cancer cell lines in vitro and in the H157 squamous 
cell carcinoma lung xenograft model in vivo. Erlotinib is a HER1/
EGFR inhibitor approved as a second line agent for the treatment of 
patients with locally advanced or metastatic NSCLC.
Methods: In vitro cytotoxicity of cells exposed to ADH-1 and new 
derivatives or erlotinib alone and in combinations was assessed 
by the MTT assay. Growth inhibition was analyzed for synergistic 
effects with Isobologram/Combination Index. In vivo anti-tumor 
activity of ADH-1, erlotinib, and the combination was evaluated 
in the H157xenograft model in athymic nude mice. ADH-1 was 
administered ip at 100 mg/kg/day and erlotinib at 50 mg/kg two times 
per week. Tumor volumes were measured once a week. Tumors were 
isolated, fixed in formalin and valuated by IHC for the expression of 
markers such as N-Cad, E-Cad, CD-31 and Ki67.
Results: Ecad and Ncad gene expressions were analyzed in a panel 
of lung cancer cell lines by Affymetrix analysis, and correlated with 
drug sensitivity to either erlotinib or ADH-1. Cells with high E-cad 
expression are more sensitive to erlotinib, while cells with high 
N-Cad are sensitive to ADH-1. Interestingly, strong synergistic ef-
fects (CI < 1) were detected when H157 cell line was treated with a 
combination of ADH-1 and erlotinib in vitro. In vivo studies showed 
that on day 43, erlotinib treatment reduced the tumor volume by 
36.6%, with a TGD of 5.5 days when compared to control; there were 
two TFS and no CRs. ADH-1 alone reduced tumor growth by 75.2% 
with 16.5 days TGD, and there was one TFS but no CRs. While the 
combination of ADH-1 and erlotinib reduced tumor volume by 49.6% 
and produced a TGD of 6 days, there were two TFS but no CRs. Data 
from IHC suggested that ADH-1 reduced the number of N-cad posi-
tive cells and inhibited angiogenesis by inhibiting host endothelial 
cells and gave impressive anti-proliferative effects as indicated by 
Ki67 marker. 
Conclusions: In vitro studies demonstrated a synergistic effect 
when ADH-1 was combined with erlotinib in a squamous cell lung 
carcinoma cell line H157. Our studies clearly demonstrate that ADH-
1 alone is effective and superior to erlotinib alone for the treatment 
of some NSCLC cells with high N-cad expression, which is also a 
strong biomarker for the resistance to EGFR inhibitors. However, in 
vivo combination studies demonstrated that combined ADH-1 and 
erlotinib was antagonistic, suggesting a drug interaction potentially 
related to mechanism or schedule. Further studies are underway to 
elucidate this effect and determine the optimal combination strategy. 
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Anti-cancer effect of the Chinese herb Fuzheng decoction 
in the NSCLC
Cui, Youbin; Chen, Yulong; Fu, Xianming; Zhou, Da; Liu, 
Guangming; Deslauriers, Jean; Liu, Guojin
First Hospital of Jilin University, Changchun, China
Background: Fuzheng decoction is an effective novel anti-cancer 
drug. Recent clinical studies shows that it can improve the quality of 
life and relive adverse reactions in patients with non-small cell lung 
cancer.
Objective: The aim of this study was to evaluate the anti-cancer ef-
fect of the Fuzheng Decoction in the patient with primary non-small 
cell lung cancer (NSCLC).
Methods: We choose 80 post- surgery patients who are diagnosed 
as primary non-small cell lung cancer (NSCLC) and divide them 
into two group randomly. The treatment group(40 patients) using 
Fuzhengfang injection from the third day of post-surgery to 21th 
day, while the control group do the same radio- and chemotherapy 
treatment except the Fuzhengfang injection. We determine the level 
of TSGF, C3, C4, IgG,IGA, IgM,CRP respectivly in the 3th day,14th 
day and 21st day post-surgry.
Result: The level of C3,C4, CRP and the TSGF (Tumor Specific 
Growth Factor )of the treatment group int the 14th day and 21st day 
is obviously lower than the control group(p<0.05), while the level of 
IgG, IgA,IgM is much higher than the control group(p<0.05). 
Conclusion: the Fuzhengfang can enhance the effect of radio- and 
chemotherapy by improving immune function and can reduce the 
side effects of the chemotherapeutics.
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Epidemiology and medical impact of bone metastases 
in lung cancer patients: a prospective French national, 
multicentric study (GFPC 06-01 study)
Decroisette, Chantal1; Monnet, Isabelle2; Berard, Henri3; Robinet, 
Gilles4; Le Caer, Herve5; Bota, Suzanna6; Audigier-Valette, Clarisse7; 
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Background: Lung cancer bone metastases related (LCBMR) are an 
important emerging problem and are leading to increasing consump-
tion of health care resources. 
Objectives: To assess the epidemiology, the management strategies 
and the costs of LCBMR. 
Methods: prospective, national, multicentric, observational, epi-
demiological study planned to include all patients with a diagnosis of 
LCBMR between may 2006 and may 2007 in GFPC centers (n= 40), 
with a one year follow up, a monthly report of skeletal-related events 
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(SRE), resources consumptions and an economic analysis (limited to 
direct costs, health care payer’s perspective).
Results: 554 patients included: men: 76,5%, mean age: 62,1±11 
years, PS 0-2/3-4: 92%/8%; small cell lung cancer: 10%; bone 
metastasis as first sign of LC: 27,3%. At inclusion: mean number of 
bone lesions: 3.6±3; hypercalcemia 11,6%; renal clearance < 50 ml/
mn: 12,5%; SRE: 17,6%; analgesic treatment: 74.6%, biphosphonates 
therapy: 26.7%; radiotherapy: 12.8%; bone-surgery: 3.6%. During the 
one year follow up: SRE 10,8%, hypercalcemia 1,1%, analgesic treat-
ment: 89,4%, biphosphonates therapy: 48,8%; radiotherapy:37,5%; 
bone-surgery: 5,1%. The median survival was 5,7 months. The 6 
months and one year survival were respectively: 47,6% and 22,5%.
Conclusion: complete demographic, clinical and economical datas 
will be presented at the WCLC meeting.
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HDAC inhibitors as a means to allow for metabolic 
targeting in non-small cell lung cancer?
Gray, Steven G.1; Davies, Anthon M.1; O’Byrne, Kenneth J.2, 1
1 Trinity College Dublin, Dublin, Ireland; 2 HOPE Directorate, St 
James’s Hospital, Dublin, Ireland
Background: Due to their inherently hypoxic ennvironment, cancer 
cells often resort to glycolysis, or the anaerobic breakdown of 
glucose to form ATP to provide for their energy needs, known as 
the Warburg effect. At the same time, overexpression of the insulin 
receptor in NSCLC is associated with an increased risk of metastasis 
and decreased survival. The uptake of glucose into cells is carried 
out via glucose transporters or GLUTs. Of these, GLUT4 is essential 
for insulin-stimulated glucose uptake. We suggest that epigenetic 
therapies which reactivate GLUT4 in non-small cell lung cancer 
(NSCLC) may be useful for a) NSCLC diagnosis and b) to metabol-
ically targeting strategies.
Methods: Normal and NSCLC cancer cell lines were screened 
for expression of GLUT4, and responses to inhibitors to histone 
deacetylases (HDi) and DNA methyltransferase (DNMT) were exam-
ined by RT-PCR. Chromatin immunoprecipitation (ChIP) was used to 
examine changes to the GLUT4 promoter in response to HDi. 
Results: GLUT4 expression can be strongly induced in NSCLC cell 
lines following treatment with agents which target HDACs or DN-
MTs, with minimal responses in transformed normal human bronchial 
epithelial cells (HBECs). Bioinformatic analysis of the promoter for 
GLUT4 indicates that it may also be regulated by several chromatin 
binding factors or complexes including CTCF, SP1 and SMYD3. 
Chromatin immunoprecipitation studies demonstrate that the promot-
er for GLUT4 is dynamically remodelled in response to HDi. Studies 
are currently ongoing to molecularly dissect the chromatin binding 
factors critical for GLUT4 regulation, to examine the functionality of 
the induced GLUT4, and to metabolically target NSCLC cells.
Conclusions: These results may have value within the clinical set-
ting. 1) It may be possible to use this to enhance FDG-PET imaging 
sensitivity. 2) Alternatively, it may be possible to to target NSCLC 
through the use of HDi and insulin mediated uptake of the metabolic 
targeting drug 2-deoxyglucose (2-DG). 3) Finally, both 2-DG and 
HDi have been shown to enhance or sensitize NSCLC to chemother-
apy. These represent novel avenues for further study, which we are 
currently pursuing. 
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Thymoquinone (TQ) enhances activity of Cisplatin 
(CDDP) in non-small cell lung cancer (NSCLC) cell line 
and inhibits invasion
Jafri, Syed H.; Boyd, Molly; Glass, Jonathan; Shi, Runhua; Kleiner, 
Heather
LSUHSC, Shreveport, LA, USA
Background: NSCLC is the most common cause of cancer death 
worldwide. The ability of TQ, a derivative of black caraway seed, to 
potentiate the action of Cisplatin (CDDP) was evaluated in vitro in a 
NSCLC cell line NCI-H460.
Methods: NCI-H460 cells were seeded at a density of 5,000 cells 
per well in 96 well plates. Cells were treated with TQ at doses of 80 
and100 µMolar (µM) alone, CDDP at 1.25, 2.5 and 5.0µM alone or 
in combination and cell proliferation determined compared to DMSO 
controls.
Cell proliferation was determined at 24, 48 and 72 hrs intervals using 
3-(4,5-dimethyltiazol 2-yl)-2,5-diphenyltetraolium bromide (MTT) 
assay.
The effect of TQ on invasion was assayed using a modified Boyden 
chamber assay. Transwell inserts (8 microns pores, 3 wells per condi-
tion) were coated with Matrigel (1:25 dilution), placed in a 24 well 
dish containing complete medium and seeded with NCI-H460 cells at 
a density of 25,000 cells per insert. After 2 hrs cells were treated with 
DMSO or TQ at 20, 40 or 80µM. After 24 hrs cells on the top layer 
were removed, and invasive cells were fixed with 10% neutral buf-
fered formalin and then stained with hematoxylin. Membranes were 
removed from inserts, mounted on slides, and cells undergoing inva-
sion were counted using a microscope with a 40X objective. Factorial 
analyses of variance (ANOVA) were used to determine the effect of 
TQ, CDDP and control with the time. Student-Newman-Keuls test 
was used to determine statistical significance with P value <0.05.
Results: TQ synergistically enhanced the effect of CDDP on inhib-
ition of cell proliferation. The combined effects of TQ and CDDP 
were synergistic at all three time points although the synergism was 
most noticeable at 48 hrs. The combination of TQ (100µM) and 
CDDP (5µM) at 72 hrs showed 89% inhibition of cell proliferation as 
compared to control.
Tumor cell invasion as assayed by growth into Matrigel assay showed 
that TQ at low 20 (µM), intermediate 40 (µM) and high 80 (µM) con-
centrations significantly inhibited invasion as compared to control. 
Inhibition of invasion was greatest at 40 µM where inhibition by TQ 
was 85% as compared to control.
Conclusion: TQ acts synergistically with CDDP to inhibit growth of 
the NSCLC cell line NCI-H460 and by itself inhibits invasion.
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Cap-dependent translation blockade and fixed dose-rate 
gemcitabine: Interaction in an in vitro bioreactor system
Kirstein, Mark N.1; Williams, Brent W.1; Chang, Jessica J.1; Chi, Ruth 
M.1; Marker, Paul H.2; Frethem, Chris D.3; Le, Chap T.4; Kratzke, 
Robert A.5
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Department of Biostatistics, Minneapolis, MN, USA; 5 Department of 
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Background: Translation initiation commences with the binding of 
eIF-4F to the mRNA 5’-end cap. eIF-4F binds the cap structure via 
its eIF-4E subunit, which is the rate-limiting step for the initiation 
of translation. This pathway can be inhibited by 4E-binding proteins 
(4E-BPs). The present study investigated prolonged gemcitabine in-
fusion in combination with reduced eIF-4E function on NSCLC cell 
viability in an in vitro bioreactor system. 
Methods: To assess attachment to the hollow fibers, H2009 and 
H522 cells with dominant active 4E-BP1 (TTAA) were first analyzed 
by scanning electron microscopy. Cells were treated with 0.5- or 2.5 
hr (fixed dose rate) infusion (same total dose), simulating human 
plasma gemcitabine concentration-time profiles. Cell cycle analysis 
was performed with flow cytometry. PARP cleavage, bcl-XL, and 
total 4E-BP1 expression were assessed with immunoblotting. Surviv-
al was measured with clonogenic assay and results between treatment 
groups were compared with three-way Analysis of Variance.
Results: Attached cells displayed shapes ranging from small and 
rounded to flattened and epithelial-like. No morphologic differences 
between control and translational deficient cells were observed. It 
appears that the cells utilize long thin filaments for attachment to the 
fiber surface and to each other. Following gemcitabine treatment, G1 
decreased by 50% for control H2009 cells (EV) and by 70% for cells 
with dominant active 4E-BP1 (TTAA). Further, subG1 was high-
est for the dominant active 4E-BP1 cells, and also for cells treated 
with the 2.5 hr infusion. PARP cleavage was highest for cells with 
dominant active 4E-BP1 and also for cells following 2.5 hr infusion. 
Regarding clonogenic survival, an interaction was observed between 
fixed dose rate infusion gemcitabine and presence of dominant active 
4E-BP1 (p=0.01). Treatment of control cells with gemcitabine is as-
sociated with a decrease in the top-most, highly phosphorylated band 
relative to the other isoform bands (p=0.04; t-test). 
Conclusions: We conclude that cap-dependent translation blockade 
and fixed dose rate infusion gemcitabine treatment results in a signifi-
cant interaction affecting cell viability in vitro . Further studies that 
enable investigators to establish the role of pharmacologic interven-
tion of cap-dependent translation are needed to advance our findings.
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In vitro activity of p16INK4a peptide mimetics in non-small cell 
lung cancer cells
Klein, Mark A.1; Jacobson, Blake2; Frizelle, Sandra3; Kratzke, 
Marian3; Mayo, Kevin2; Kratzke, Robert2
1 Veterans Affairs Medical Center, Minneapolis, MN, USA; 2 
University of Minnesota, Minneapolis, MN, USA; 3 Veterans Affairs; 
University of Minnesota, Minneapolis, MN, USA
Background: The transition from G1 to S phase in the cell cycle is 
highly regulated by Cdk4, which in turn is inhibited by the tumor 
suppressor p16INK4a. Replacement of lost p16INK4a activity in lung 
cancer may be beneficial in the treatment of lung cancers that express 
low levels of p16INK4a. Previously, we have discovered compounds 
that inhibit Cdk4 activity. These were identified via virtual screening 
and were based on the pharmacophore constructed from the combina-
tion of the NMR-derived structure of a peptide that mimics p16INK4a 
activity and the known functional data to mine the NCI Chemical 
Database. 
Methods: Two previously identified compounds, denoted NCI29997 
and NCI29992, were evaluated for their effects on lung cancer 
cell proliferation, Rb phosphorylation, and cell cycle progression. 
Non-small lung cancer cells (H661 and H2030) were treated with 
compound or control and proliferation was evaluated using Cell 
Counting Kit 8. Non-small cell lung cancer cells (H2030) were 
treated in a similar fashion, and Rb phosphorylation was measured 
via immunoblotting. Non-small cell lung cancer cells (H2030) were 
also treated with compound or control, and cell cycle progression was 
analyzed via flow cytometry.
Results: The two compounds were subsequently shown to inhibit Rb 
phosphorylation and lung cancer cell proliferation at low micromolar 
concentrations. One of the compounds was shown to inhibit cell cycle 
progression at the G1/S transition at a low micromolar concentration. 
Conclusions: These compounds form lead peptide mimetic com-
pounds upon which further cell cycle inhibitors can be developed as 
potential lung cancer therapeutics. 
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The suicide fusion gene YCD-YUPRT induces high and 
specific cytotoxicity in small cell lung cancer cell lines and 
tumor growth delay in xenografts when regulated from a 
cancer-specific promoter
Christensen, Camilla L.1; Gjetting, Torben1; Poulsen, Thomas T.1; 
Ramesh, Rajagopal2; Roth, Jack A.2; Poulsen, Hans S.1
1 Department of Radiation Biology, Copenhagen, Denmark; 2 
Department of Thoracic and Cardiovascular Surgery, M.D. Anderson 
Cancer Center, Houston, TX, USA
Suicide gene (SG) therapy is a novel treatment strategy for cancer in 
which the introduced therapeutic gene encodes an enzyme capable of 
transforming a non-toxic prodrug into a cell poison. Using a cancer-
specific promoter it is possible to control SG expression and resulting 
cytotoxicity exclusive to cancer cells.
The fusion SG consisting of the yeast cytosine deaminase and the 
yeast uracil phosphoribosyl transferase (YCD-YUPRT) was cloned 
for regulated expression from the small cell lung cancer (SCLC) 
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specific promoter Insulinoma-associated 1 (INSM1). YCD converts 
the prodrug 5-fluorocytosin (5-FC) into the known chemotherapeutic 
agent 5-fluorouracil (5-FU) while YUPRT augments the conversion 
of 5-FU into active cytotoxins. 
SCLC cell lines transiently transfected with INSM1-YCD-YUPRT 
vector were greatly sensitised to 5-FC exposure resulting in extensive 
cell death as compared to mock-transfected cells. In contrast cancer 
cell lines of other origins and non-immortalized cell lines were un-
affected to YCD-YUPRT/5-FC treatment, manifesting the high speci-
ficity of the strategy. Due to limited efficiency of gene delivery in 
vivo an important characteristic of SG therapy is the ability to induce 
cytotoxicity to bystander cells due to the spread of produced suicide 
toxins To investigate the bystander cytotoxicity, YCD-YUPRT-
transfected SCLC cells were mixed with untransfected SCLC cells 
in different ratios and it was established that significant cell death 
was achieved when 5 % SCLC cells expressed the YCD-YUPRT 
transgene. YCD-YUPRT/5-FC therapy was additionally compared to 
the effect of one of the most established SG system consisting of the 
Herpes simplex virus thymidine kinase (HSVTK) gene and prodrug 
ganciclovir (GCV) showing that the YCD-YUPRT/5-FC therapy was 
superior to HSVTK/GCV treatment in all tested cell lines. Combining 
the YCD-YUPRT/5-FC therapy with HSVTK/GCV rendered SCLC 
cell more sensitive to treatment, however, only at low 5-FC doses. 
At high 5-FC doses HSVTK/GCV therapy could not increase the 
cytotoxicity induced from YCD-YUPRT/5-FC therapy.
To study the YCD-YUPRT/5-FC strategy in vivo SCLC xenografts 
were established on nude mice. Mice were treated for 3 consecutive 
days with i.t. injections of INSM1-YCD-YUPRT vector encapsulated 
in a liposome delivery vehicle, DOTAP:Cholesterol in combination 
with daily i.p. administration of 500 mg/kg 5-FC for 10 days. Data 
demonstrate a significant tumor growth delay compared to mock 
treated mice. 
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Insertion of transcription factor nuclear factor kappa 
B binding sites into plasmid DNA facilitates increased 
nuclear uptake in small cell lung cancer cell lines 
Cramer, Frederik; Poulsen, Thomas T.; Gjetting, Torben; Poulsen, 
Hans S.
Department of Radiation Biology, Copenhagen, Denmark
Many cancer diseases cannot be cured by presently available treat-
ments. One such disease is small cell lung cancer (SCLC), which 
accounts for approximately 20 % of lung cancers. SCLC is a highly 
aggressive malignancy with widespread metastasis and a 5-year 
survival rate below 10 %. 
One way to overcome the complex problems that SCLC currently 
present is to use gene therapy.
Since SCLC is a highly metastatic disease, gene therapy must be 
administered systemically in order to target both primary and meta-
static tumor tissue. For that purpose we have identified SCLC specific 
promoters that enable efficient transcriptional targeting of SCLC 
tissue. We aim to design a non-viral delivery vehicle for the systemic 
transport of the therapeutic DNA to the SCLC tissue. However, 
the efficiency of non-viral delivery vehicles is currently low and 
especially the translocation of the therapeutic plasmids through the 
nuclear envelope (NE) has proven to be a substantial barrier for deliv-
ery. This is particularly a problem in non-dividing cancer cells, where 
the nuclear envelope is intact. Many strategies designed to improve 
nuclear transport in relation to gene therapy has been developed, but 
none have been tested in SCLC. The present study therefore aimed 
to investigate if a promising NE translocation strategy could improve 
gene therapeutic nuclear uptake in SCLC in vitro.
The strategy chosen takes advantage of the transcription factor 
nuclear factor kappa B (NFκB) system that due to nuclear localiza-
tion signals can gain access over the NE and recognize specific 
NFκB DNA sequences in the chromosomal DNA. To investigate 
this strategy, NFκB DNA sequences containing either 5 or 10 NFκB 
binding sites was cloned into an expression plasmid containing the 
SCLC specific promoter Insulinoma-associated 1 (INSM1) and the 
reporter gene luciferase. A gel-shift binding assay was used to verify 
specific binding of NFκB subunit p50 to the NFκB binding site. A 
non-dividing cell-model was established using a SCLC cell line and 
verified by flowcytometri. The cell cycle analyses data showed 80-90 
% of the cells were in the G0/G1. 
Nuclear translocation activity was measured by a luciferase assay 
and plasmids containing either 0, 5 or 10 NFκB binding sites was 
compared. The luciferase data show that a significant elevation (4-6 
fold) of nuclear translocation can be obtained by using the NFκB 
system. Furthermore, the results show a positive correlation between 
the numbers of NFκB-inserts and improved nuclear translocation 
in that increased luciferase expression was detected in the plasmid 
containing 10 NFκB binding sites compared to 5. By cloning a 
PNA-rhodamine target sequence into the above-mentioned plasmids, 
microscopy will be used to verify elevated uptake. We can at this 
time conclude, that utilizing the NFκB strategy in SCLC cell lines 
significantly improves the nuclear uptake of the therapeutic DNA 
in vitro. Since an upregulation of the NFκB-system activity have 
been showed to be both an early and a regularly phenomenon in lung 
cancer, this strategy could potentially improve the efficiency of gene 
therapy for this malignancy.
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Photodynamic therapy for treatment of endobronchial 
tumors
Ragulin, Yury A.; Kaplan, Michael A.; Medvedev, Victor N.; 
Kapinus, Victoria N.; Peters, Vitaly V.
Medical Radiological Research Center RAMS, Obninsk, Kaluga 
region, Russia
Background: Photodynamic therapy (PDT) is a novel method for 
treatment of malignancies. It is effective modality for palliation of 
lung cancer and non-pulmonary metastatic endobronchial tumors 
which can improve results of combined treatment. Therapeutical 
improvement in this field may result from using of new photosensitiz-
ers and combining PDT with radio- and chemotherapy. The aim of 
this study is to estimate direct effects of photodynamic therapy with 
chlorine photosensitizers on the endobronchial cancer. 
Methods: The photodynamic therapy with chlorine photosensitizers 
(Photolon, Photoditazin) was carried out on 47 patients with central 
lung cancer. 42 males, 5 females, aged 42-81 years (mean 60.3) with 
advanced inoperable cancer and endobronchial luminal obstruction 
were studied. The histology of the tumors was: non-small cell lung 
cancer in 36 patients, small cell lung cancer in 5 patients, squamous 
cell esophageal cancer spreading on trachea in 2 patients, thyroid 
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cancer spreading on trachea in 1 patient, endobronchial metastases of 
renal cancer, breast cancer and esophageal cancer in 1 patients. Most 
patients were at the stage IIIb-IV. The pre/post-treatment protocol 
consisted of: clinical, radiological and bronchoscopic examina-
tion, pulmonary function testing. Intravenous injection of chlorine 
photosensitizers (1.5-2.4 mg/kg body weight) was given, 2-3 h later 
the tumor was illuminated with 662 nm laser light. We use a flexible 
fiberoptic bronchoscope for visualization and placement of the optical 
fiber, which was passed through the biopsy channel of the instrument 
to the target tissue. For 3 days after the procedure the patients were 
under special light conditions. 
Results: In central lung cancer patients positive radiological dynam-
ics in the form of the atelectasis resolution and altered ventilation 
elimination was observed in 66.7 percent cases. In a month after the 
PDT bronchoscopy was done (37 patients) complete response was 
observed in 23 (62.2 %) cases, partial response in 12 (34.4%) and in 
2 patients reductions of tumor was not revealed. Vital capacity (VC) 
after PDT increased as many as from 3 % up to 33% (mean 20 %). 
Reduction of cough and haemophtisis was noted in 55 % patients. 
Dyspnoea was reduced in 47.4 percent patients. 
In patients with non-pulmonary metastatic endobronchial tumors 
complete response was observed in 3 (50.0 %) cases, partial response 
in 3 (50.0%) cases.
Complications: pneumonia - 4 patients, bronchitis - 5. Neither treat-
ment related mortality not complications caused by the photosensitiz-
ers were observed.
Conclusions: Photodynamic therapy with chlorine photosensitizers is 
effective in palliation of inoperable lung cancer and non-pulmonary 
metastatic endobronchial tumors and causing low rate of complica-
tions. After the treatment patients have been followed up, quality of 
their life and survival rate are estimated.
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Antiproliferative effects of novel acridine-based 
topoisomerase II inhibitors on NSCLC and mesothelioma
Sadiq, Ahad A.1; Kratzke, Marian G.2; Jacobson, Blake A.1; Patel, 
Manish R.1; Jay-Dixon, Joe 1; Hiasa, Hiroshi1; Kratzke, Robert A.1
1 University of Minnesota, Minneapolis, MN, USA; 2 Veterans Affair 
Hospital, Minneapolis, MN, USA
Background: Malignant Mesothelioma (MM) and Non-small cell 
lung cancer (NSCLC) are two diseases with grave prognosis. Most 
effective drugs used against them are topoisomerases II poisons 
which can lead to DNA mutations and secondary treatment related 
cancers. A small library of novel substituted 9-aminoacridine deriva-
tives have been identified that inhibit cell proliferation of pancreatic 
cancer cell lines by inducing apoptosis .To further investigate their 
anti-proliferative activities, we have assessed the anti-proliferative 
and apoptotic activity of these acridine-based compounds against 
several NSCLC and mesothelioma cell lines
Methods: Inhibition of topoisomerase II (TII) by these compounds 
and a known TII inhibitor, etoposide, were done by in vitro assay 
using varying concentrations of each drug and purified human TII. 
DNA unwinding assay was used to assess the ability of the acridine-
based compounds to intercalate into plasmid DNA. To accurately 
assess the effects of the acridine-based compounds on the catalytic 
activity of topoisomerase II, a DNA strand passage assay was used, 
instead of a standard relaxation assay using negatively super-coiled 
plasmid DNA as substrate. Mesothelioma cell lines (H2373, H2461 
and H2596) and NSCLC cell lines (H441) were used. Cell prolifera-
tion assays were performed in 96-well plates using the CCK-8 kit 
(Dojindo inc.). Treated cells were assayed by flow cytometer (An-
nexin V) for the induction of apoptosis.
Results: These acridine-based compounds can intercalate into DNA 
unlike etoposide which is a non-intercalative topoII poison. The 
acridine-based compounds inhibit the catalytic activity of human 
topoisomerase II but do not poison human topoisomerase II. We have 
shown good antiproliferative activity against NSCLC and meso-
thelioma cell lines (low µM conc.). Apoptosis has been shown using 
Annexin V assay on a flow cytometer.
Conclusions: These novel acradine base compounds have strong 
activity against the mesothelioma and NSCLC cell lines. Further 
work needs to be done to exactly know the mechanism of inhibition 
of topoII activity by these compounds.
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The influence of clinical predictors on the results of 
treatment with erlotinib in patients with advanced NSCLC
Salajka, Frantisek1; Pesek, Milos2; Krejci, Jana2; Skrickova, Jana3; 
Zatloukal, Petr4; Koubkova, Leona5; Grygarkova, Yvona6; Pavlik, 
Tomas7
1 Department of Pneumology, Hradec Kralove, Czech Republic; 2 
Department of Pneumology, Charles University Hospital, Plzen, 
Czech Republic; 3 Department of Pneumology, Masaryk University 
Hospital, Brno, Czech Republic; 4 Department of Pneumology, 
Charles Univesity Hospital Praha Bulovka, Praha, Czech Republic; 
5 Department of Pneumology, Charles University Hospital Praha 
Motol, Praha, Czech Republic; 6 Department of Pneumology, Palacky 
University Hospital Olomouc, Olomouc, Czech Republic; 7 Institute 
of Biostatistics and Analyses, Masaryk University Brno, Brno, Czech 
Republic
Background: Wide use of erlotinib in patients with NSCLC enables 
to collect data leading to enlightening of the factors influencing the 
treatment effect, and thus, subsequently, to precising the indication 
criteria. 
Methods: Analysis of complete data of all NSCLC patients treated 
with erlotinib registered in the Czech Tarceva Register was per-
formed. In this analysis, the influence of particular clinical factors on 
the treatment result and overall survival was evaluated.
Results: In total, data of 394 patients were available to the date of 
evaluation (January 31st, 2009). In majority of them, the NSCLC was 
primarily of advanced stage (st. III 31,0%, st. IV 58,6%). Evaluat-
ing the treatment response, the significant correlation with rush 
occurrence and smoking habit (both p<0.001) was detected. The 
correlations with gender, and histology didn’t reach the statistical 
significance. The overall survival was significantly influenced only 
by the histology (p = 0.044), however, the trend of influencing also 
by the best response to the previous therapy (p = 0,092) was possible 
to detect. Significant correlations between overall survival and gender 
or smoking habit were not found.
Conclusions: The first analysis of non-selected group of NSCLC pa-
tients treated with erlotinib showed most powerful factors influencing 
the treatment results and overall survival. In our group, the factors 
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influencing the treatment result were not significantly correlated with 
the overall survival and vice versa. With continuously increasing 
number of followed patients, more relevant data will be available in 
the future. 
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Chemical genomics of RAD001 in Non-Small Cell Lung 
Cancer
Seidel, Daniela3; Ansén, Sascha 1; Thomas, Roman3, 1, 2; Wolf, Jürgen1
1 Department I of Internal Medicine and Center of Integrated 
Oncology Köln – Bonn, University of Köln, Germany, Cologne, 
Germany; 2 Chemical Genomics Center of the Max Planck 
Society, Germany, Dortmund, Germany; 3 Max Planck Institute for 
Neurological Research with Klaus-Joachim-Zülch Laboratories of 
the Max Planck Society and the Medical Faculty of the University of 
Köln, Germany, Cologne, Germany
We have developed an approach to identify genetic aberrations as-
sociated with therapeutically relevant oncogene dependency. This 
approach integrates genomic data sets on oncogene mutation status, 
gene copy number and gene expression pertinent to a large collec-
tion of non-small cell lung cancer (NSCLC) cell lines. We show by 
comparing gene copy number alterations and somatic mutations that 
the genomes of these cell lines are highly representative of those 
of primary NSCLC tumors. Furthermore, by high-throughput cell 
line screening we recapitulate the unique clinical responsiveness of 
EGFR-mutant lung tumors to EGFR inhibition (p< 0.0001) thereby 
validating our approach phenotypically. By high-throughput cell line 
screening of a set of small molecules coupled to diverse computation-
al approaches integrating genomic and biochemical data we identify 
molecular predictors of response to clinically relevant compounds. In 
particular, we find that RAD001 inhibits the growth of a wide variety 
of tumors, with a special enrichment of cells with lesions affecting 
the Pi3-kinase pathway. Thus, patients with lesions associated with 
this pathway may benefit from treatment with RAD001. 
Pulmonary Medicine
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Lung cancer in HIV-positive patients in India
Dhir, Aruna A.; Sawant, Sheela; Agarwal, Jaiprakash; Jambhekar, 
Nirmala; Pramesh, CS
Tata Memorial Hospital, Mumbai, India
Objective: Lung cancer is known to occur in a higher incidence 
among HIV positive patients. Presently there is not much data from 
India in this setting. We studied the clinical profile of HIV positive 
patients with lung cancer at Tata Memorial Cancer Hospital, a tertiary 
referral cancer centre in Mumbai.
Materials and Methods: HIV positive patients with pathologically 
proven lung cancer between the years 2000-2005 were reviewed.
Observations: There were16 patients who were HIV positive and 
diagnosed with lung cancer during the study period. Median age was 
50yrs, 87.5% were males.81.3% consumed tobacco.81.3% patients 
presented with advanced stage.50% patients had adenocarcinoma, 
43.8% were non-small cell carcinoma, and 6.3% were small cell 
carcinoma.62.5% patients received cancer directed treatment. 37.5% 
patients received HAART.50% patients of the study group had a pre-
viously diagnosed seropositive status.75% patients had a CD4 count 
>200/cumm.8 patients were lost to follow up, 8 patients expired with 
median survival of 4.5 months, No opportunistic infections were 
detected in either of these patients.
Conclusions: Male predominance and median age of incidence [50 
yrs] for lung cancer are similar to those in non HIV patients.Adeno-
carcinoma is the commonest histopathology in these patients. Smok-
ing is related to the incidence of lung cancer as in non HIV patients. 
Lung cancer presents at an advanced stage in HIV positive patients. 
The prognosis and survival is poor. Significant immunosuppression 
was not seen. Smoking cessation must be strongly emphasized for 
prevention of lung cancer among HIV positive patients.
P2.175 Pulmonary Medicine, Sun Aug 2 
6-minute-walk in lung cancer - a new predictor for 
response and the performance status?
Dickgreber, Nicolas J.1; Schumann, Evelyn1; Fischer, Stefan2; Welte, 
Tobias1; Golpon, Heiko A.1
1 Dept. of Pulmonology, Hannover Medical School, Hannover, 
Germany; 2 Cardiac, Thoracic, Transplant, and Vascular Surgery, 
Hannover Medical School, Hannover, Germany
Aim: 6-minute-walk is a well established test in a variety of pulmon-
ary diseases, e.g. COPD, pulmonary hypertension. In this retrospect-
ive study we investigated the correlation between the 6-minute walk 
and the ECOG performance status as well as the change in the 6 
minute walk and the staging result regarding to the recist criteria.
Methods: From 12/06 to 12/08 we examined 59 lung cancer patients 
with stage IV disease at different timepoints. They underwent a ct-
scan (according to the recist guidelines), an evaluation of the ECOG 
performance status (PS) and a 6-minute-walk. These data were 
statistically correlated.
Results: The mean walking distance for patients with PS 0 was 
430,49m, with PS 1 389,32m and with PS 2 338,5 m. The mean 
change in the walking distance for patients with stable disease was 
2,84 m (n=57 measurements), for patients with progressive disease 
the mean change was -38,11 m (n=19 measurements). 
Conclusion: In lung cancer patients the 6-minute-walking distance 
correlates well with the ECOG performance status, it could become a 
more objective parameter for the performance status. Its change also 
correlats with the staging result, therefore it could become a simple 
parameter to detect patients without benefit from palliative chemo-
therapy early.
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Change in respiratory symptoms after smoking cessation
Etter, Jean-Francois
University of Geneva, Geneva, Switzerland
Background: Some reports suggest that respiratory symptoms may 
deteriorate immediately after smoking cessation (e.g. increased cough 
and phlegm).
Aim: To describe associations between smoking status and self-
reported respiratory symptoms 
Methods: Internet survey of current and former smokers, in 2005-
2008. Follow-up survey after 31 days
Results: There were 8625 participants at baseline and 1156 (13%) at 
follow-up. 
In cross-sectional data, in baseline former smokers, all the 4 symp-
toms were less frequent in longer-term quitters than in recent quitters 
(p<0.001 for all symptoms, Fig 2).
In the 124 baseline smokers who had quit smoking at 31-day follow 
up, there was a substantial improvement in all the 4 symptoms as-
sessed (p<.001 for all before-after comparisons, Fig 3).
Conclusions: Smoking cessation is followed by a rapid and sub-
stantial improvement in self-reported respiratory symptoms (cough, 
phlegm, short breath and wheezing respiration). This information can 
be used to motivate smokers to quit. 
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How to get to the diagnosis of lung and pleura cancers?
Gomes, Joana; Antunes, Ana; Barroso, Ana; Ferreira, Diva; Neves, 
Sofia; Conde, Sara; Parente, Barbara
Centro Hospitalar Gaia/Espinho, EPE, Vila Nova Gaia, Portugal
Introduction: Lung cancer is usually suspected in individuals who 
have an abnormal chest radiograph finding or have symptoms caused 
by either local or systemic effects of the tumor. The method of 
diagnosis of suspected lung cancer depends on the histology of lung 
cancer (ie, small cell lung cancer [SCLC] or non-SCLC [NSCLC]), 
the size and location of the primary tumor, the presence of metastasis, 
and the overall clinical status of the patient.
Aims: To determine which method of diagnosis led to a histological 
diagnosis of lung and pleura cancer.
Methods: Retrospective study of patients seen in the Oncology Unit 
of Pneumology, from 1st January to 31st December of 2008, con-
sisting in consultation of the computer records of all patients seen in 
this unit and complementary tests for diagnosis performed.
Results: 128 cases were diagnosed histologically, of which 24% 
women and 76% men, mean age of 65.6 years. In 18 cases we 
concluded by clinical and radiological diagnosis. Histological types 
identified: adenocarcinoma (33.5%), non-small cell lung carcin-
oma (19.5%), epidermoid (26%), small cell lung carcinoma (12%), 
mesothelioma (3%), large cell carcinoma (3%), neuroendocrine (3%). 
The method that allowed the histological diagnosis was in most cases 
(66%) bronchoscopy, followed by transthoracic aspiration biopsy 
(TTAB) (17%), thoracic surgery (4%), thoracentesis (4%), aspiration 
biopsy of lymph nodes (3%), medical thoracoscopy (2%), pleural bi-
opsy (1.5%), cytology of sputum (1.5%) and mediastinoscopy (1%). 
Althought bronchoscopy diagnosed the largest number of cases in all 
histological types, we found that the methods of diagnosis of more 
peripheral lesions (TTAB, thoracentesis, pleural biopsy and thoracos-
copy) were important in the diagnosis of adenocarcinoma, with 17% 
of those diagnosed with this technique. In more central tumors as epi-
dermoid, the bronchoscopic methods have been decisive for the diag-
nosis of 82% of cases. Although the pathology has not differentiated 
histologically the NSCLC, the high percentage of cases diagnosed by 
bronchoscopy (72%) leads us to believe that most are of more central 
location. In some cases the diagnosis was difficult, motivating the 
implementation of several complementary tests. (Table1)
Conclusion: Given the differentiation and technological advance-
ment in technology, bronchoscopy was the method that has enabled 
the majority of histological diagnoses, which reinforces its import-
ance and requirement in assessing the patient suspected of lung 
cancer regardless of their location. Other complementary tests may 
be needed to conclude on a diagnosis, particularly in more peripheral 
lesions.
SCLC Epiderm-
oid
Adeno-
carcinoma
NSCLC Large 
cell 
carcin-
oma
Neuroendo-
crine
Meso-
thelioma
Bronchos-
copy
13 
(86%)
27 
(82%)
21 (49%) 18 
(72%)
2 (50%) 3 (75%) 0
TTAB 1  
(7%)
4 (12%) 11 (25%) 4 (16%) 1 (25%) 0 1 (25%)
Thoracentesis/
pleural biopsy
0 0 4 (9%) 1 (4%) 0 0 2 (50%)
Medical 
thoracoscopy
0 0 2 (5%) 0 0 0 1 (25%)
Mediastinos-
copy
0 0 1 (2%) 0 0 0 0
Thoracic 
surgery
0 1 (3%) 2 (5%) 1 (4%) 0 1 (25%) 0
Others 1  
(7%)
1 (3%) 2 (5%) 1 (4%) 1 (25%) 0 0
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Comparison of clinical features and survival between 
adenocarcinoma and squamous cell carcinoma of lung
Hyun, Dae Sung; Kim, Kyung Chan; Lee, Sang Chae; Ryoo, Hyun 
Mo
Catholic University of Daegu, Daegu, Korea
Background: The incidence of adenocarcinoma of the lung has 
been increasing worldwide, especially in women or never-smoker. 
The clinical features and survival of adenocarcinoma compared with 
squamous cell carcinoma of lung were investigated.
Methods: The medical records of 558 patients diagnosed with adeno-
carcinoma (n=223) and squamous cell carcinoma (n=335) of lung 
at Daegu city, South Korea, from January to December 2005 were 
reviewed. We compared the clinical features and survival of these 
two histologic groups.
Results: The median age at diagnosis showed no difference between 
two groups (67 years vs 68 years; p>0.05). The proportion of female 
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and never smoker were higher in adenocarcinoma group compared 
with squamous cell carcinoma group (38.1% vs 11.9%; p=0.00 and 
38.1% vs 7.8%; p=0.00, respectively). Asymptomatic patients were 
more common in adenocarcinoma group and symptoms of cough and 
hemoptysis were more common in squamous cell carcinoma group. 
Distribution of the disease stage and median survival were similar 
in both groups. However, distant metastasis was more frequent in 
adenocarcinoma group. The frequent organs of distant metastasis 
were lung (26.0% vs 12.5%), bone (21.5% vs 7.5%), brain (8.5% vs 
3.3%) and adrenal gland (7.6% vs 1.5%).
Conclusions: The clinical features are different across the major 
types of lung cancer and adenocarcinoma group showed higher pro-
portion of female, never smoker, asymptomatic patients and distant 
metastasis.
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To study the tolerability of fiber-optic bronchoscopy in 
lung cancer patients at medium altitude (2250 meters) of 
Shimla city, North-Western Himalayan region of India
Kashyap, Surender; Sarkar, Malay; Negi, Rameshwar s.; Sidhu, 
Kiranjit
Indira Gandhi Medical College, Shimla, Shimla, India
Introduction: Fiberoptic bronchoscopy (FOB) is generally con-
sidered a safe procedure with low rates of morbidity and mortality. 
Arterial oxygen desaturation is a relatively common complication 
accompanying fiber-optic bronchoscopy. 
In the present study, patients had compromised lung functions due to 
presence of lung mass, associated COPD and relatively hypoxic en-
vironment of medium altitude of Shimla .At Shimla altitude there is 
a state of ambient hypoxia as study done by us in the past has shown 
a mean PaO2 level of 70mmHg in healthy subjects. The aim of the 
present study was to find out the impact of FOB on patients with lung 
cancer and coexisting COPD at the medium altitude of Shimla (PB 
580mmHg).
Material & Methods: 38 patients with a clinical diagnosis of Bron-
chogenic carcinoma were enrolled for the study over a period of three 
months in the department of Pulmonary Medicine, Indira Gandhi 
Medical College, Shimla. The population, mainly rural inhabitance 
has high frequency of smoking habit and exposure to indoor air pol-
lution. 
FOB was performed under local anesthesia and parameters were 
measured at different stages of the procedure.
Results: At baseline, all patients were in sinus rhythm with no evi-
dence of ischemia. Median duration of the procedure from insertion 
to removal of bronchoscope was 13.4 min (range 6.4 to 28.2min).
Of the 38 patients enrolled initially for the study, diagnosis of lung 
cancer was confirmed on histopathological/cytological examination 
in 30 patients. Therefore, 30 patients were considered for final analy-
sis. Of the 30 patients studied. 83.33 %( n=25) were males and 16.67 
%( n=5) were females. The age range for females was 57-81years 
with mean age of 65.80±9.25 years and for males the range was 
45-85 years with mean of 65.28±10.09 years. Out of the 30 patients, 
diagnosis of COPD was made in 18 patients (GOLD criteria). Out of 
30 patients, 25 patients developed oxygen desaturation during FOB.
Mean SpO2 at the baseline level was 94.59±2.56%.On comparing 
baseline SpO2 values between COPD and non-COPD lung cancer 
patients, SpO2 was 95.96±1.38 %in non-COPD and 93.67±2.77 % 
in COPD patients (p-value 0.013).There was significant fall in SpO2 
and rise in PR and BP during FOB in both the groups. Overall,post 
procedure SpO2 measured was 73.90±2.51 (p value 0.000) sug-
gesting significant fall in SpO2.Similarly, pulse rate (PR), systolic 
blood pressure (SBP) and diastolic blood pressure (DBP) showed 
significant increase during and after bronchoscopy (Table 1). None of 
our patients developed arrhythmia. No statistical significant differ-
ences were observed between two groups in respect to changes in 
various parameters. Majority of patients had moderate COPD (n=10) 
with 4 patients each of mild and severe COPD. We did not find any 
significant difference between the different COPD groups except rise 
in SBP which showed significant difference between moderate and 
severe COPD groups (p value 0.036).
Conclusion: This study showed a significant fall in SpO2 and signifi-
cant increase in PR and BP in patients with lung cancer undergoing 
bronchoscopy. No significant influence of COPD was observed when 
compared with non-COPD lung cancer patients. Despite significant 
changes in various parameters, it did not result in increase in morbid-
ity among lung cancer patients undergoing FOB at medium altitude 
of Shimla. It is concluded that FOB is a safe procedure at an altitude 
of 2250 meter even in patients with preexisting COPD in carefully 
selected patients.
Table-I Showing changes in different variables during fiber optic bron-
choscopy
Baseline 
spo2 value
Post 
Procedure-
SPO2 Value 
(Mean±SD)
95% CI 
of the 
difference 
(Lower) 
95% CI 
of the 
differ-
ence 
(Upper) 
t-value p-value
SPO2 94.59 ±2.56 73.90 ±2.511 15.62 25.75 8.36 0.000
Pulse 
Rate
82.13 ±9.89 107.70 ±17.89 31.99 19.14 8.14 0.000
Systolic 
Blood 
Pressure
122.33 
±24.05
152.6 0±28.57 41.78 18.75 5.37 0.000
Diastolic 
Blood 
Pressure
78.06 ±15.82 94.16 ±13.61 21.47 10.72 6.12 0.000
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Symptoms of 353 patients with lung cancer and correlation 
with diagnostic results and therapeutical decisions
Marel, Miloslav; Krejbich, Frantisek; Spasova, Irena; Stranska, 
Pavla; Skacel, Zdenek; Zemanova, Milada
1st Pulmonary Department of the 1st Medical Faculty of the Charles 
University, Prague, Czech Republic
Background: The incidence of lung cancer (LC) in the Czech Re-
public has been declining in men (94/100 000) since 90´, in women is 
still increasing (30/100 000). There is strong need for improvement of 
diagnostic process. 
Methods: A prospective study on 353 consecutive lung cancer 
patiens (pts) from the 1st Pulmonary Department of the 1st Medical 
Faculty in Prague, Czech Republic. 
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Results: The ratio men:women was 2:1, the average age in men was 
67 and in women 69 years. 
The symptoms in the time of diagnosis were as follows: cough in 
69%, dyspnoe in 54%, lost of weight in 49%, expectoration of spu-
tum in 39%, pain on the chest in 37%, hemoptysis in 18%, fever in 
16%. Smoking men and women suffer from lung cancer in younger 
age than nosmokers, 64 vs 71 years (p<0,0001). 
COPD was found in 40% of the studied set, more frequently have 
had epidermoid lung cancer which was in this subgroup diagnosed in 
earliest stages.
The TNM stages were as follows: Ia 6,5%, Ib 10,8%, IIa 0,8%, IIb 
3,4%, IIIa 13%, IIIb 24,6%, IV 40,8%. The most frequent histologic-
al types were epidermoid cancer in 22,1% followed by adenocarcin-
oma (21,2%). 17,4% of pts from the whole set and 25,5% of pts from 
the non small cell lung cancer subgroup underwent surgery.
We look consequently for correlations between symptoms and 
other pts data. The pts with overusing of alcohol beverage fell in to 
a disease in a younger age. The pts with central tumor suffer from 
stronger cough more frequently, they had more often direct tumor 
changes at bronchoscopy. The pts with stage IV TNM suffered more 
frequently from fever and pain. Significantly fewer pts with dyspnoe, 
loss of weight and lower FEV1 underwent surgical resection. FEV1 
was lower in pts with central than with peripheral type of tumor. In 
pts with direct bronchoscopical tumor changes were found more fre-
quently hemoptysis, broader spectrum of symptoms, lower FVC and 
FEV1. Dyspnoe correlated with PaO2 but not with PaCO2. CRP was 
lower in pts with peripheral type of LC, higher in pts with small cell 
LC (SCLC). Occurrence of hemoptysis did not correlate with number 
of smoked cigarettes. In our presentation we would like to show other 
interesting findings which may be helpfull in the diagnosis of lung 
cancer. 
Conclusions: We proofed that proper taking of medical history may 
accelerate and improve the diagnostic process as well as may predict 
therapeutical decisions. 
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The significance of co-morbidity in newly diagnosed 
patients with lung cancer
Milroy, Robert1; Grose, Derek2; Louden, Greg3; McIntosh, David2; 
Brown, Louise4; Docherty, Kirsty5; Downer, Penny6; Singh, 
Jasminder7; Selby, Colin8; Jones, Richard 9; Sharma, David10; 
Nicolson, Marianne11; Devereux, Graham12
1 Consultant Respiratory Physician, Glasgow, UK; 2 SpR in 
Oncology, Glasgow, UK; 3 SpR in Medicine, Glasgow, UK; 4 Lung 
Cancer Nuse Specialist, Aberdeen, UK; 5 Lung Cancer Nurse 
Specialist, Ayr, UK; 6 Lung Cancer Nurse Specialist, Glasgow, 
UK; 7 Respiratory Nurse, Glasgow, UK; 8 Consultant Respiratory 
Physician, Dunfermline, UK; 9 Consultant Oncologist, Glasgow, 
UK; 10 Respiratory Physician, Ayr, UK; 11 Consultant Oncologist, 
Aberdeen, UK; 12 Consultant Respiratory Physician, Aberdeen, UK
Introduction: Treatment and survival rates for patients with lung 
cancer in Scotland appear lower than many other European countries. 
Five year survival is quoted at 6-7% compared with 8-16% in other 
European countries and the USA. It has been suggested that such 
disparity in treatment and outcome may relate to co-morbidity and 
poor performance status at presentation although this has never been 
proven.
Methods: Following a pilot study we devised a quantative co-
morbidity tool to measure common co-morbidities including COPD, 
vascular disease, dementia, diabetes and significant others. We also 
measured lung function, MRC dyspnoea score, albumin and CRP at 
baseline. We also recorded performance status at time of diagnosis 
and estimated performance status 6 months previously.
Results: A total of 882 newly diagnosed lung cancer patients were 
prospectively assessed at time of diagnosis. Between-centre differen-
ces in practice were identified both in terms of pursuing histology and 
in terms of radical treatment rates (surgery and radical radiotherapy). 
Significant differences in deprivation, performance status at time of 
presentation and co-morbidity were identified.
Summary: Increase in deprivation and co-morbidity and declin-
ing performance status are associated with a reduced ability to offer 
radical/curative treatment rates. Future studies of lung cancer and 
future prospective audit should incorporate robust assessments of co-
morbidity in addition to deprivation and performance status.
* Louise Brown died suddenly in July 2008.
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Asbestos body quantification in the lung of male patients 
with primary lung cancer
Okabe, Kazunori1; Matsuda, Eisuke1; Tao, Hiroyuki1; Kobayashi, 
Seiki1; Sugi, Kazurou1; Aoe, Keisuke2; Ueoka, Hiroshi2
1 Yamaguchi Ube Medical Center, Ube, Japan; 2 Division of Medical 
Oncology, Yamaguchi Ube Medical Center, Ube, Japan
Background: Inhalation of asbestos fibers is widely known to cause 
primary lung cancer. Asbestos-related lung cancer is likely to have 
accounted for 2-3% of all lung cancer deaths among males in Great 
Britain over the last two decades of the 20th century (Darnton A.J., 
et al. Ann occup Hyg 2006; 50:29-38). The aim of this study is to 
identify the asbestos body numbers in the lung of male patients with 
primary lung cancer. 
Methods: Asbestos body quantification in this medical center started 
in August 2006. Regarding primary lung cancer, the asbestos body 
numbers in the lung of the selected cases with suspected occupa-
tional asbestos exposure and/or pleural plaque finding and/or request 
of patient are counted. The pathology reports of fifty male patients 
with primary lung cancer from August 2006 to January 2009 were 
reviewed. Most of them underwent lobectomy. Asbestos body quan-
tification involves digestion of 1-4 grams of lung tissue in bleach by 
modified Smith and Naylor method (Smith, M. J. and Naylor B. Am J 
Clin Pathol 1972; 58:250-254). 
Results: The median age of 50 male patients with primary lung 
cancer, 35 male patients with adenocarcinoma, and 15 male patients 
with non-adenocarcinoma is 68 (37-87), 67 (37-87), and 68 (44-87) 
years old respectively. The median asbestos body number in the lung 
of 50 male patients with primary lung cancer, 35 male patients with 
adenocarcinoma, and 15 male patients with non-adenocarcinoma is 
1,008 (lower than detection limit – 359,659), 945 (lower than detec-
tion limit – 359,659), and 1007 (lower than detection limit – 91,676) 
/g dry lung respectively. The proportion of the asbestos body number 
higher than 5,000/g dry lung, 1,000 – 5,000/g dry lung, and lower 
than 1,000/g dry lung of 50 male patients with primary lung cancer, 
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35 male patients with adenocarcinoma, and 15 male patients with 
non-adenocarcinoma are 28, 22, 50%, 26, 23, 51%, and 33, 20, 47% 
respectively. 
Conclusions: Asbestos body quantification in the selected patients 
with primary lung cancer who have suspected occupational asbestos 
exposure and/or pleural plaque finding and/or request for asbestos 
body count is performed. The median asbestos body number in the 
lung of male patients with primary lung cancer is 1,008 (lower than 
detection limit – 359,659) /g dry lung. Approximately 50% of male 
patients with primary lung cancer have the asbestos body number in 
the lung more than general population. Inhalation of asbestos fibers 
may be an important risk factor for lung cancer. 
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Bronchial carcinoids: clinical-pathology study on 57 
operated patients
Stanic, Jelena; Sarcev, Tatjana; Andjelkovic, Aleksandra; Eri, Zivka; 
Djukic, Nevena; Zaric, Bojan
Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, 
Serbia
Aim: The aim of the study was to determine the influence of gender, 
N status, T status and stage on median survival time (MST) in oper-
ated patients with bronchial carcinoid (BC).
Methods: The study retrospectively included 57 patients with early 
stage of bronchial carcinoid (BC), 52 with typical BC and 5 patients 
with atypical BC, who were surgically treated in period 2000-2008. 
The analysis included gender, age, stage, lymph node involvement, 
tumor size and survival in comparation to gender, N status, tumor 
size and carcinoid type. Data were pulled from hospital charts and 
outpatients files. 
Results: We have analyzed 32 females and 25 males. The young-
est patient was 21 year old and the oldest was 74, with median age 
66.2 years. In time of analysis, 51/57 patients were alive. Analyzing 
MST in comparation to gender, there were no significant differ-
ences in MST (p=0.128). MST in males was 46.64 months and in 
females 50.84 months. In 39 patients we discovered N0 status and in 
9 patients N1 and N2 metastasis were found. The analysis showed 
statistically significant differences in survival concerning N status 
(p=0.032). MST of patients with N0 status was 50.28 months and 
with N1 and N2 status 48.78 and 33.00 months, respectively. In 20 
patients the tumor diameter was ≤ 2 cm. In 14 patients tumor was 
>2-3 cm and in 14 patients the size of the tumor was ≤5 cm. Tumor 
larger than 5 cm was found in 4 patients. The tumor size had signifi-
cant influence on MST due to the fact that MTS was significantly 
shorter in patients with tumor size ≤5 cm and >5-7 cm. Patients with 
typical BC had longer MST comparing to patients with atypical BC 
(49.67 months vs 22.80 months, respectively; p=0.010).
Conclusion: Factors found to be significant for poor MST in patients 
with BC were N1 and N2 status, tumor size ≤5 cm and >5-7 cm and 
atypical BC.
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Muscle force and mass in patients with respiratory cancer: 
effects of radical treatment
Salhi, Bihiyga1; Holvoet, Tom1; Derom, Eric1; van Meerbeeck, Jan 
P.1, 2
1 Departement of Respiratory Medicine, Ghent, Belgium; 2 Lung 
Oncological Network Ghent (LONG), Gent, Belgium
Introduction: Cancer and its treatment are known to contribute to 
functional impairment, fatigue and muscle weakness. The latter is 
thought to result from loss of muscle mass and strength. 
Aim: To investigate the effect of lung cancer or mesothelioma and its 
radical treatment on exercise capacity, muscle force, muscle mass and 
quality of life. 
Methods: Pulmonary function testsd, exercise capacity, quality of 
life, peripheral muscle force and peripheral muscle mass (by CT) 
were assessed in patients scheduled for radical treatment for early 
stage lung cancer and mesothelioma.
Results: 16 patients were enrolled of whom 5 patients have already 
completed all assessments. 
Conclusion: Preliminary data show that exercise capacity, muscle 
force, muscle mass and quality of life decrease after radical treat-
ment. Mature data will be presented at the meeting.
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Quantitative Perfusion Scintigraphy (QPS) or the 
Anatomic Segment Method (ASM) for estimating 
Postoperative Pulmonary Function (PF) in patients treated 
for non-small cel lung cancer (NSCLC): a retrospective 
comparison
Holvoet, Tom1; Derom, Eric1; van Meerbeeck, Jan P.1, 2
1 Department of Respiratory Medicine, University Hospital Ghent, 
Ghent, Belgium; 2 Lung Oncological Network Ghent (LONG), Gent, 
Belgium
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Background: Radical surgery yields the highest survival rates in 
patients with NSCLC. Unfortunately resection of lung parenchyma 
has detrimental effects on the PF in a population whose respiratory 
reserve is often compromised by age and comorbidity. Although 
QPS is widely used for estimating the postoperative PF, its cost and 
disadvantages are considerable (the net cost of QPS being €130 in 
Belgium) and the ASM could be a valuable and cheap alternative.
Methods: Single institutional retrospective cohort study in pts with 
NSCLC, candidate for radical surgery in whom postoperative FEV1 
and DL,CO was estimated by a preoperative QPS as well as by ASM 
and compared to the actual PF measured at least 3 months after 
resection. Correlation between these values was determined using 
parametric Pearson’s coefficient r and non-parametric Spearman’s 
coefficient ρ. A Bland-Altman analysis was also performed.
Results: Between 2003 and 2009, 32 patients (median age: 69 
years,range 46-80 / median FEV1: 2.04 L, range: 1.09-5.13) were 
retrieved among whom 19 underwent a lobectomy, 10 a pneumonec-
tomy and 3 a lesser resection. 
Correlation between both methods in calculating predicted postopera-
tive (ppo) FEV1 (r = 0.96; ρ = 0.89) and ppoDL,CO (r = 0.93; ρ = 
0.89) was high. Results of other correlations are presented in the 
table.
 Correlation QPS ppo Values ASM ppo Values
 All Cases (N=32)  
 Postop. FEV1 r = 0.82; ρ = 0.77* r = 0.82; ρ = 0.79*
 Postop. DL,CO r = 0.61; ρ = 0.63* r = 0.60; ρ = 0.65*
 Lobectomy (N = 19)  
 Postop. FEV1 r = 0.84; ρ = 0.72* r = 0.84; ρ = 0.75*
 Postop. DL,CO r = 0.61; ρ = 0.63* r = 0.53; ρ = 0.56**
 Pneumonectomy (N = 10)  
 Postop. FEV1 r = 0.76; ρ = 0.83** r = 0.70; ρ = 0.79**
 Postop. DL,CO r = 0.24; ρ = 0.21 r = 0.30; ρ = 0.33
 * statistically significant with p < 0.001
 ** statistically significant with p < 0.05
In a subanalysis of cases with FEV1 ≤ 70 % predicted, QPS failed to 
maintain statistically significant good correlation with postoperative 
FEV1, in contrast to ASM (r = 0.72, ρ = 0.78)
The Bland-Altman analysis showed that ASM underestimated actual 
postoperative FEV1 and DL,CO more than QPS in all subgroups. 
These effects were even more pronounced in a subanalysis of cases 
with FEV1 ≤ 70 % predicted.
Conclusions: Both methods equally predict postoperative FEV1 and 
DL,CO, with QPS being more accurate after pneumonectomy. As 
ASM underestimates actual PF more than QPS, it can be regarded 
safe and a valuable alternative from a cost-benefit point of view. 
Based on these results, we can conclude QPS should only be done 
when ASM suggests functional inoperability.
Small Cell Lung Cancer
P2.186 Small Cell Lung Cancer, Sun Aug 2 
Topotecan for relapsed small cell lung cancer: 
retrospective study
Alegria, Ana M.1; Rodrigues, Cidália2; Teixeira, Encarnação1; Barata, 
Fernando2; Sotto-Mayor, Renato1; Figueiredo, Ana2; Rito, Emília1; 
Almeida, António B.1
1 Hospital de Santa Maria, Lisbon, Portugal; 2 Centro Hospitalar de 
Coimbra, Coimbra, Portugal
Introduction: After failure to first line treatment, prognosis of pa-
tients with SCLC is poor. Topotecan has shown significant antitumor 
activity in these cases.
Purpose: To analyse the results of Topotecan administered as a stan-
dard regimen (1,5mg/m2 days 1 to 5 of a 21 day cycle) after failure of 
first-line therapy with platinum/etoposide for patients with SCLC and 
correlate response rate and overall survival with time free progression 
after first-line therapy. 
Methods: We performed a retrospective study including 51 consecu-
tive patients who relapsed after first line treatment with platinum/
etoposide between February 2001 and December 2007. Patients were 
divided in three groups according the time of failure after first-line 
therapy. Group 1 – patients who progressed during first line therapy 
or in less than three months. Group 2 – progression in three to six 
months and Group 3 – progression in more than six months. Each one 
of the groups was correlated to Topotecan response by Chi-Square 
Test and with overall survival and Topotecan survival using Kaplan-
Meier curves and comparing them with the Logrank Test. 
Results: In this group of patients 80% were male. Median age was 
61 years old and median smoking habbits were 54 unit pack year. 
The median number of Topotecan cycles was 3. Correlation of data is 
outlined in the forward table. 
 Group 1 Group 2 Group 3 p 
  (N=21) ≤ 3m  (N=16) 3-6m  (N=11) ≥ 6m
 topotecan Response (%) 8 25 18 =0.782
 Topotecan Survival (m) 5.7Ã±3.2 6.2Ã±3.3 7.5Ã±5.3 =0.56
 Overall Survival (m) 12.7Ã±4.3 15.3Ã±3.6 25.3Ã±10.9 =0.0004
Progressive disease was seen in 67%, 44% and 46% in Group 1,2 and 
3 respectively and stable disease was very alike in the three groups 
(21%, 25% and 27%, respectively). Hematologic toxicity, Grade 3 
or 4, was reported in a considerable number of patients: neutropenia 
80%, anemia 41% and thrombocytopenia 39%. 
Conclusion: Although Topotecan is more effective in treatment of 
sensitive patients, it also has some benefit in the resistent patients. 
Toxicity was high but expectable and therefore manageable. 
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
Copyright © 2009 by the International Association for the Study of Lung CancerS806
P2.187 Small Cell Lung Cancer, Sun Aug 2 
Expression of insulin-like growth factor 1 receptor 
(IGF1R) in small cell lung cancer (SCLC) and correlation 
to clinicopathological features
Badzio, Andrzej1; Dziadziuszko, Rafal1; Wynes, Murry W.5; Merrick, 
Daniel T.3; Pardo, Marta 3; Kowalczyk, Anna1; Jassem, Jacek1; 
Hirsch, Fred R.4
1 Department of Onclogy and Radiotherapy, Medical University 
of Gdańsk, Gdańsk, Poland; 2 University of Colorado Cancer 
Center, Aurora, CO, USA; 3 Department of Pathology, University of 
Colorado Cancer Center, Aurora, CO, USA; 4 Division of Medical 
Oncology and Pathology, University of Colorado Cancer Center, 
Aurora, CO, USA; 5 Department of Immunology, University of 
Colorado Cancer Center, Aurora, CO, USA
Background: IGF1R is a transmembrane tyrosine kinase receptor 
that is overexpressed by a number of tumors. In addition to mediating 
cell proliferation and survival, IGF signalling also influences tumor 
cell motility and adhesion, thus affecting the propensity for inva-
sion and metastasis. Consequently, IGF1R is now an attractive target 
for anti-cancer treatment, however, there is a paucity of data on the 
expression and clinical relevance of this protein in SCLC. 
Methods: We analyzed expression of IGF1R in primary tumors from 
78 SCLC patients. All patients had limited disease and were treated 
with surgery followed by chemotherapy between 1982 and 2001 
(median follow-up 86 months). In all cases the diagnosis of SCLC 
was established only after the examination of surgical specimen. This 
series included 56 males and 22 females, 10 T1, 45 T2,14 T3 and 9 
T4 tumors, 40 N0, 15 N1, 22 N2 and 1 N3. IGF1R expression was 
evaluated by immunohistochemistry using Ventona CONFIRM anti-
body and scoring was done by three observers, who took into account 
percentage of positive cells (0-100%) and staining intensity (0-4). 
H-score was calculated as a proportion of positive cells times staining 
intensity. Continuous data as well as cut-offs of 10 and median H-
score were used to assess relationships with clinical data.
Results: Median H-scores for IGF1R was 81 (range 0-352). The 
positive immunostaining rates (cut-off H-score of 10) in the en-
tire group were 77%. IGF1R expression did not correlate with any 
clinicopathological parameters such as age, tumor size, lymph node 
involvement and stage of the disease. Survival was not influenced by 
expression of IGF1R (p=0.34). 
Conclusions: IGF1R protein is commonly overexpressed in SCLC 
but, in the SCLC cohort examined, did not affect patients overall 
survival. However, this does not preclude the potential for IGF1R 
expression to be a valid predictive factor for therapy targeting the 
IGF1 signalling pathway.
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Outcome of poor performance status small cell lung cancer 
patients treated with chemotherapy
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Surgery, Instituto Nacional do Cancer (INCA), Rio de Janeiro, 
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Nacional do Cancer (INCA), Rio de Janeiro, Brazil
Background: Small cell lung cancer (SCLC) is an aggressive malig-
nancy, but with a high response rate to chemotherapy (CT). Perform-
ance status (PS) has been recognized as one of the main prognostic 
factors in SCLC. Early deaths and poor survival after CT were found 
to correlate with poor PS. There are few data about risk-benefit ratio 
of CT in PS 3 and 4 patients, although it has been often used. This 
study was performed to assess the outcome of poor PS SCLC patients 
that received CT in our institution.
Materials and Methods: A retrospective review of patients medical 
records with SCLC showing PS 3-4, who received systemic CT, was 
performed between January 2001 and December 2006 at Instituto 
Nacional do Cancer, Rio de Janeiro, Brazil.
Results: A total of 140 patients who had cytological or histological 
diagnosis of SCLC were evaluated. Patients with pretreatment PS 
3 and 4 that received CT were selected for analysis. Forty patients 
(28.5%) were eligible. The median patient age was 65 years and 
67.5% were male. Extensive disease was observed in 85% of these 
patients and 25% had PS4. All PS4 patients had extensive disease. 
There were 30% of early deaths, 50% of them in patients with PS4. 
Twenty nine patients (72.5%) required hospitalization during the 
first CT cycle. Of note, the median overall survival was only 53 days 
(64 days for PS 3 and 7 days for PS 4). On univariate analysis, PS 
(p=0.001), high LDH pretreatment value (p=0.001), requirement for 
hospital admission (p=0.01) and exposure to radiotherapy (p=0.006) 
had impact on survival. PS 3 patients had better survival than PS 4 
patients, even when adjusted for stage (p=0.004). Pretreatment LDH 
value, age, PS and stage were selected for multivariate analysis. A 
new variable combining PS and stage (EPS) was created to reduce a 
possible interaction between these factors. There was a statistically 
significant correlation of EPS 4 (HR: 3.31; p=0.005) and high serum 
LDH (HR: 2.86; p<0.001) with survival.
Conclusion: Our results show a dismal survival for poor PS patients, 
in particular for those with PS4, treated with chemotherapy. These 
data suggest that further studies are required to support the decision-
making process on how to best treat this high-risk population. 
Thereby reducing the rate of early deaths, by identifying the subgroup 
who probably derive no benefit from chemotherapy.
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Characterization of Genomic Alterations in Small Cell 
Lung Cancer Using Pooled RNAi Library Screens and 
Single-Template DNA Sequencing
Banerji, Shantanu1, 2; Luo, Biao1; Barretina, Jordi1, 2; Root, David1; 
Meyerson, Matthew1, 2
1 Broad Institute, Cambridge, MA, USA; 2 Dana-Farber Cancer 
Institute, Boston, MA, USA
Background: Cancer arises from genomic alterations that cause 
defects in the regulation of normal cellular function. These altera-
tions include somatic mutations and chromosomal rearrangements, 
the latter including regional DNA amplifications and deletions. The 
identification of oncogenes in particular can guide the development 
of novel targeted anti-cancer drugs. Small cell lung cancer (SCLC) 
is an almost universally fatal diagnosis and treatment of this disease 
has remained relatively unchanged for the last 20 years. Due to 
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limited surgery for SCLC, there is a paucity of SCLC primary tumor 
samples. By contrast, there is an abundance of SCLC cell lines. 
Discovery of new candidate target genes using novel approaches will 
help advance the development of therapy for SCLC.
Methods: We propose to study the SCLC genome by combining 
systematic genome scale functional and structural analytic meth-
ods. Our functional approach involves performing a genome scale 
pooled short-hairpin RNA (shRNA) screen to identify genes essential 
for proliferation in SCLC cell lines. The pool consists of 55,000 
lentiviral vector based shRNAs targeting ~11,000 genes (median 5 
shRNAs per gene). Individual cell lines are infected with the pooled 
shRNA library and passaged for a total of 16 doublings (~8 passages; 
6-8 replicates). Cells from each passage are frozen and stored for 
DNA analysis. DNA will be isolated from cells, PCR amplified, and 
then hybridized to a custom microarray capable of interrogating all 
shRNAs in the pool. shRNAs will be scored and ranked according 
to their differential abundance between early and late passages after 
lentiviral infection. The genes that appear most significantly depleted 
are candidate oncogenes. We will then prioritize these genes for 
additional functional and structural characterization including the use 
of single template nucleotide sequencing.
Results: Our goal is to infect a total of 8-10 SCLC cell lines with the 
pooled lentiviral shRNA library to have sufficient statistical power to 
detect genes essential for SCLC proliferation. To date, two SCLC cell 
lines (H82 and H187) have been profiled and compared to cancers 
of other lineages (glioblastoma, leukemia, non-SCLC) infected and 
passaged according to the same protocol. Unsupervised hierarchical 
clustering of microarray data grouped SCLC cell lines separately 
from the other lineages and also distinctly from the non-SCLC cell 
lines. Further analysis reveals SCLC lineage specific essential genes. 
The complete analysis will be presented at the meeting.
Conclusions: A combined functional and structural analysis of the 
SCLC genome may help elucidate key genetic targets and lead the 
way to novel therapy for this disease.
P2.190 Small Cell Lung Cancer, Sun Aug 2 
ERCC1 expression of small cell lung cancer
Hennemann, Marluce; Sostruznik, Maria H.; Gaiger, Ana; Barrios, 
Carlos H.
Porto Alegre, Brazil
Background: The excision repair cross-complementation group 1 
(ERCC1) protein expression has been reported as possibly related to 
outcome associated to the administration of cisplatin-based chemo-
therapy in non-small cell lung cancer. We explore it’s expression in a 
group of small cell lung cancer (SCLC) patients (pts). 
Methods: We reviewed 44 pts previously diagnosed and treated for 
SCLC. Tumor tissue was explored with immunohistochemistry (ICH) 
for the ERCC1 protein in all cases. Criteria for IHC reporting were 
based on the percentage of cells with positive staining. Clinical find-
ings and response were correlated to the IHC expression. In all cases 
pts received standard cisplatin-based chemotherapy and radiotherapy 
when appropriate. 
Results: We had 26 men (59%) and a median age of 60,8 years 
(±10) in the group. Limited disease (LD) was present in 41% (n=18), 
extensive disease (ED) in 55% (n=24) and was not available from the 
clinical data in 3 pts. Median survival time (MST) was 15,84 (±9,73) 
months (m) for LD pts while it was 8,39 m (±8,53) in ED. 
Overall, 50% (n=22) of the pts showed positive ERCC1 staining: 12 
pts (54%) with > 50% of positive cells (median survival 10,8 m) and 
10 pts (45%) with <50% of positive cells (median survival 13 m). LD 
pts had 45% of ERCC1 expression and a median overall survival of 
17 m [≥50% staining (n=6): median survival 12,1 (±3,9) m; <50% 
staining (n=4): median survival 24,4 (±6,1) m]. In the ED group, 11 
patients had ERCC1 expression with an overall median survival of 
7.9 m [≥50% staining (n=6): median survival 9,4 (±12) m; <50% 
staining (n=5): median survival 6,1 (±1,5) m].
The group with no ERCC1 expression (n=22) had an overall survival 
of 9,7 (±10,1) mo. Of these, 7 pts had LD with a median survival of 
14,03 (±12,4) mo, while 13 pts of this group had ED and a median 
survival of 8,76 (±8,73) mo. 
Conclusion: ERCC1 expression by IHC does not seem to discrimin-
ate survival probabilities in this small group of patients.
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N-cadherin, E-cadherin, ERCC1, c-kit, and IGFR1 
expression in small cell lung cancer (SCLC) and potential 
for new therapeutic targets
Batus, Marta; Myint, Ronald; Coon, John; Basu, Sanjib; Kaiser, 
Kelly; Fidler, Mary J.; Bonomi, Philip D.
Rush University Medical Center, Chicago, IL, USA
Background: Minimal advances have been made in the treatment 
of SCLC. Molecular markers may allow us to better stratify patients 
for new treatment options and drug combinations. The objective of 
our study was to determine the frequency and potential prognostic 
significance of N-cadherin (N-cad), E-cadherin (E-cad), ERCC1, 
c-kit (CD117), and IGFR1 (insulin-like growth factor type 1 receptor) 
expression in SCLC and ccrrelate this data with clinical outcomes.
Methods: Tissue from 124 patients (pts) with SCLC were stained for 
N-cad, E-cad, ERCC1, c-kit, and IGFR1. Frequency and intensity of 
expression were measured on a scale of 1-4 (freq 0=no expression, 
freq 1=1-10%, freq 2=11-35%, freq 3=36-70%, freq 4=71-100%). 
Tumor marker frequency and intensity were assimilated as a product 
of the two on a scale of 0-16. Charts were retrospectively reviewed 
for stage, performance status, date of diagnosis/death, survival, and 
treatment (type, dates, response). 
Results: Of the 124 pts, 73% had tumors that expressed (frequency 
>1) N-cad, 51% E-cad, 72% ERCC1, 50% c-kit, and 9% IGFR1. For 
N-cad, a significant difference in survival was seen between tumors 
with product expression (prod) < 8 (median survival of 285 days) and 
prod > 8 (576 days, p=0.0245). For ERCC1, a difference in survival 
was seen between tumors with prod<1 (226 days) and prod>1 (452 
days, p=0.072). For c-kit, a difference in survival was seen between 
tumors with prod<6 (312 days) and prod>6 (496 days, p=0.0641). 
Comparing tumor marker expression with survival using either the 
Log-Rank Test or the Wilcoxon Test, there was no significant associa-
tion for E-cad or IGFR1. 
Conclusions: In our retrospective study of 124 SCLC pts, we found 
that all 4 markers (except IGFR1) were expressed in at least 50% 
of specimens, and that N-cad, ERCC1, and c-kit may have prog-
nostic significance as the higher product expression correlates with 
increased survival. Although N-cad was related to more aggressive 
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disease in breast cancer, we found that pts with increased N-cad in 
SCLC had a statistically significant longer survival, which may indi-
cate that tumors expressing N-cad are more responsive to chemother-
apy. These findings may allow us to target more effective treatments 
for SCLC pts. 
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Effect of chemotherapy in patients (pts) with resected 
small cell (SCLC) or large-cell neuro endocrine carcinoma 
(LCNEC) 
Abedallaa, Nader 1; Tremblay, Lise1; Baey, Charlotte1; Fabre, 
Dominique2; Planchard, David1; Pignon, Jean P.1; Guigay, Joel1; 
Soria, Jean C.1; Besse, Benjamin1
1 Insitut Gustave Roussy, Villejuif, France; 2 Centre Chirurgical 
Marie Lannelongue, Plessis Robinson, France
Background: Chemotherapy and concurrent radiotherapy is the cur-
rent standard of treatment for limited-stage (LS) SCLC. The role of 
surgery is limited and remains a matter of controversy. Surgical resec-
tion of undiagnosed lung lesion may lead to unintentional removal of 
SCLC. The benefit of peri-operative chemotherapy in resected SCLC 
or large cell neuroendocrine tumors is unknown. 
Material and Methods: This retrospective analysis included LS-
SCLC and LCNEC surgically removed between 1979 and 2007 at 
Surgical Centre Marie Lannelongue. Logrank test was used to com-
pare overall survival 
Results: Among 74 total pts identified, 29 pts (25 male, 4 female, 
median age of 64 years) underwent surgery (S) and 45 (38 male, 7 
female, median age of 58 years) underwent surgery plus chemother-
apy (S+C). Four and 21 pts had pre- and post-operative radiotherapy 
respectively. Pathological diagnosis was as follow: (1) group S: 25 
SCLC, 4 LCNEC, 15 pN0 and 10 pN+, and only 2 resections were in-
complete (2) group S+C: 34 SCLC, 11 LCNEC, 15 pN0, 27 pN+ and 
only 3 resections were incomplete. Chemotherapy was preoperative 
in 9 pts and postoperative in 37 pts; 62% of the pts received etopo-
side/platinum, 13% platinum/other agent, 25% other. The overall 
median follow-up of pts was 3.1 years (range [0.01 - 5.9] years) for 
the group S and 5.5 years (range [0.15 - 12.8] years) for the group 
S+C. Among the patients alive at 6 months or followed at least 6 
months (n=58), the median survival of the group S (n=19) and S+C 
(n=39) were 4.8 years and 6.1 years respectively. The hazard ratio of 
death was 0.59 (95% CI [0.25 - 1.36], p = 0.21) for the group S+C 
compared to the group S. The overall survival at 3 years was 57% in 
the group S compared to 63% in the group S+C.). 
Conclusion: These results suggest that peri-operative chemotherapy 
may be beneficial in pts with resected SCLC or LCNEC.
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Small-cell lung cancer (SCLC): is angiogenesis a relevant 
target?
Loriot, Yohann1; Abedallaa, Nader 1; Baey, Charlotte1; Tremblay, 
Lise1; Besse, Benjamin1; Planchard, David1; Guigay, Joel1; Soria, 
Jean C.1; De Montpreville, Vincent T.2; Brambilla, Elisabeth3
1 Insitut Gustave Roussy, Villejuif, France; 2 Centre Chirurgical 
Marie Lannelongue, Plessis-Robinsson, France; 3 CHU Albert 
Michallon, Grenoble, France
Background: Recent evidence suggests that angiogenesis in many 
solid tumors is key player of tumor progression and a relevant thera-
peutic target. Recent studies have failed to demonstrate the benefit 
of anti-angiogenic agents in SCLC, while their efficacy is clear in 
NSCLC. The aim of this study was to evaluate biomarkers of the 
angiogenic pathways in small cell lung cancer
Methods and Patients: We collected tumor blocks from all patients 
who were treated surgically at Centre Chirurgical Marie Lannelongue 
between 2000 and 2006 for localized SCLC. All the diagnosis of 
small cell lung cancer were centrally reviewed by a senior patholo-
gist. Different angiogenic markers were evaluated by means of 
immunochemistry: VEGF A, FLT1 R1, FLK1 R2, FLT4 R3, and 
VEGF C. A composite score taken into account percentage of positive 
cells and intensity was used (0-300), the threshold for positivity was 
100. Then we studied the correlation between the expression of these 
biomarkers and overall survival..
Results: Evaluation of angiogenic biomarkers was performed on 29 
patients. Two of them had preoperative chemotherapy of cisplatin-
based. Clear positivity of tumor cells was observed for VEGF A (83% 
[95%CI] 64%-94%), FLT1 R1 (100% [88%-100%]), FLK1 R2 (93% 
[77%-99%]), FLT4 R3 (62% [42%-79%]) and VEGF C (90% [72%-
98%]). 
There was no significant (p=0.32) association between VEGFA and 
FLK1: both negative: 1 pts, both positive 23 pts, negative/positive, 4 
pts, positive/negative, 1 pts. There was no significant (p= 1) associa-
tion between VEGFC and FLT4: both negative: 1 pts, both positive 
17 pts, negative/positive, 1 pts, positive/negative, 8 pts. 
Conclusion: Our data demonstrates a frequent overexpression of 
angiogenic factors in SCLC, but in this limited series. It seems that 
none of these markers have a prognostic value. 
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Surgical procedures and outcome of patients (pts) with 
resected small cell (SCLC) or large-cell neuro endocrine 
carcinoma (LCNEC)
Fabre, Dominique2; Abedallaa, Nader 1; Tremblay, Lise1; Baey, 
Charlotte1; Pignon, Jean P.1; Soria, Jean C.1; Besse, Benjamin1; 
Dartevelle, Philippe2
1 Insitut Gustave Roussy, Villejuif, France; 2 Centre Chirurgical 
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Background: SCLC accounts for approximately 15% of new 
cases of lung cancer diagnosed annually and approximately 30% of 
patients with SCLC have a limited-stage (LS). SCLC has always 
been considered a chemotherapy-sensitive and radiotherapy-sensitive 
disease. The surgery was abandoned after the publication of Fox et al. 
(Lancet 1969), which provided a 2% improvement in overall survival 
at 2 years. However, some centres continued to support surgery 
because experience suggested that in selected patients it was possible 
to achieve a long-term survival. The role of surgery is limited and 
remains a matter of controversy. 
Patients and Methods: This retrospective analysis included LS 
SCLC or large-cell neuro endocrine carcinoma (LCNEC) surgically 
removed between 1979 and 2007 at Centre Chirurgical Marie Lan-
nelongue. We report the surgical procedures and outcome of the 
patients. The prognosis value of several variables: type of surgery 
(complete vs. incomplete), nodular status of the patient (N- vs. N +) 
and type of cancer (SCLC vs. LCNEC) was studied, using a logrank 
test. 
Results: 74 patients were included, 63 male, 11 female, median age 
of 61 years. Preoperative diagnosis was made in thirty-two patients 
(including 18 SCLC, 8 LCNEC). The pathological diagnosis after 
surgery was established as the following: 60 SCLC, 14 LCNEC, 30 
pN0 and 37 pN+. Pre and post-operative pathological diagnosis was 
different in 9 pts (6 pts had a diagnosis pre operative non-small cell 
lung cancer (NSCLC) which were SCLC post operative, 2 pts had 
carcinoma of indeterminate nature which were LCNEC and 1 pt had 
a carcinoid which was LCNEC). The type of surgery was the follow-
ing: 21 pts (28%) required pneumonectomy, 45 (61%) lobectomy, 
6 (8%) bi-lobectomy and 2 (3%) segmentectomy. Sixty-nine pts 
had a complete excision and 5 an incomplete excision. 30% of pts 
received peri operative chemotherapy alone, 30% pts chemotherapy 
plus radiotherapy and 4% pts radiotherapy alone. Four patients died 
within one month after surgery. The overall median follow-up of pts 
was 5.1 years (range [0.01 - 12.8] years). The median overall survival 
was 6.1 years. Prognostic study was performed in the 58 patients who 
survived 6 months or followed at least 6 months. Among the three 
prognostic factors, complete resection was significantly associated 
with overall survival (HR 0.33, 95% CI [0.11 - 0.97], p = 0.04) 
Conclusion: These data show that surgery may have a positive im-
pact on selected patients with LS-SCLC or LCNEC.
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MG624, an alpha7-nicotininic receptor antagonist, inhibits 
cell proliferation and angiogenesis in human small cell 
lung cancer
Brown, Kathleen2; Witte, Ted3; Luo, H1; Chen, Yi C.1; Mangiarua, 
Elsa I.2; Grover, Larry2; Egleton, Richard2; Hardman, W. E.3; 
Dasgupta, Piyali3
1 Alderson Broaddus College, Phillipi, WV, USA; 2 Dept of 
Pharmacology, Marshall University, Huntington, WV, USA; 3 Dept. 
of Biochem and Microbiology, Marshall University, Huntington, WV, 
USA
Small cell lung cancer (SCLC) is characterized by rapid progression, 
early metastasis and a dismal survival rate. Chemotherapy remains 
the cornerstone of treatment for SCLC. However, the acquisition of 
chemotherapy resistance and subsequent relapse are responsible for 
the poor treatment outcomes in SCLC patients. Recent studies have 
shown that nicotine (the active and addictive component of cigarette 
smoke) can stimulate the growth and progression of human SCLCs. 
The proliferative effects of nicotine are mediated by the nicotinic 
acetylcholine receptors (nAChR) and nAChRs have been detected 
in a variety of non-neuronal cells, such as SCLC cells. The alpha7-
nAChR has been implicated in the proliferative and pro-angiogenic 
activity of nicotine in lung cancer cells. Therefore, we conjectured 
that treatment with alpha7-nAChR antagonist should inhibit the 
growth of human SCLC cells. Here we show that the alpha7-nAChR 
antagonist MG624 displays potent growth-inhibitory activity on 
multiple human SCLC cell lines. TUNEL and caspase-3 cleavage 
assays show that MG624 induced robust in apoptosis in human SCLC 
cells. In addition, MG624 also suppressed angiogenesis in “Matrigel 
Assays” as well as in “Ex vivo rat aortic ring angiogenesis assay”. 
The apoptotic activity of MG624 correlates with induction of the pro-
apoptotic protein p73alpha in human SCLC cells. Depletion of p73 
levels by siRNA techniques ablated the growth-inhibitory effects of 
MG624 in human SCLC cells. Taken together, our data suggest that 
MG624 may have potential applications for the treatment of human 
SCLCs.
P2.196 Small Cell Lung Cancer, Sun Aug 2 
Progress in the management of small cell lung cancer 
(SCLC) in the Instituto Nacional del Torax (INT). Chile 
Guachalla, Jaime U.; Campos, Monica M.; Rodriguez, Juan C.
Insituto Nacional del Torax, Santiago, Chile
Background: SCLC has dismal prognosis, poor treatment effective-
ness and short survival. SCLC patients from 1994 to 2001, were 
presented previously to the IASLC, now we compare them with those 
from 2002 to 2007. 
Material and Methods: From our database registry of lung cancer, 
the management of 70(28%) patients (period 1 (1994-.2001) are com-
pared with that of period 2 (2002-2007) patients. Then the differences 
in treatment, response, toxicity and survival of period 2 (2002-2007) 
patients are analized according to stages. 
Results: (Table 1) PS Karnofski less than 70% were more frequent 
in period 1. The global mortality of chemoradiotherapy of 61(87%) 
patients of period 2, was 94% and median survival 11 months while 
mortality of 32(42%) patients of period was 100% with median 
survival 6 months. 
The data of Period 2 patients (Table 2) shows that of 32 patients of 
LD with chemoradiotherapy, 24(74%) received 4 to 6 courses of Cis-
platin Etoposide, and of 28(96%) with ED 13 (45%) 4 to 6 courses. 
Radiotherapy of 22(67%) patients with LD (19(86%) in IRAM) 58% 
was with 60 Gy/30F plus PCI in 10 (59%) patients and of 8 (28%) 
patients with ED palliative radiotherapy (5(62%) in IRAM) 80% 1,8 
Gy to 30Gy/10F. Carboplatin etoposide received 4(12%) patients 
with LD and 3% with ED. 
Complete plus partial response had 24(80%) patients with LD and 
10(35%) with ED.
Toxicity: Hematologic 21(48%) patients and no heratologic 8(24%) 
patients with LD and with ED 11(39%) and 5(17%) respectively. 
Mortality in LD was 87% and median survival 14 months, with 
5(16%) over 2 años. Mortality with ED was 100% and median sur-
vival 7 months with 83% less than one year. 
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Table 1. SCLC patients of the I.N.T.:.Comparison in two periods
  Period 1 (1994-2001)* Period 2 (2002-2007)
   n = 76(8%) n = 76(8%) n= 70 (28%)
  Characteristics n (%) n(%) 
 Sex  
  Males  52 (68) 39(51) 
  Females 24 (32) 31(49)
 Age (years)  
  Mean 60.5 61
  Range 33â??85  35-84 
 Stages  
  Limited 63 (82) 33(47)
  Extended 13(18) 37(53)
 Weight Loss   
  No 12(17) 22(40)
  <10% 32(46) 8(33)
  >10%  25(36 5(27)
 PS Karnofski   
  less 70% 25(41) 3(9)
  more 70% 36(59) 31(91)
   
 Chemoradiotherapy 32(42) 61(87)
 Syntomatic Treatment 44(58) 9(13)
   
 Follow up  
  Global Mortality 76(100) 66(94)
  Survival (months)  
  Mean 10.83 12.26
  Median 6.00 11.00
   
 p=0.2867  
 * Presented in 2007  
Table 2.
   Limited Extended
 Characteristics  n =32(52%)  n= 29(47%)
 Gender M 20(62) 15(52)
  F 12(38) 14(48)
    
 Age (years) Mean 65 61
  Range 49-84 35-74
 Yteatment Chemoradiotherapy 22(67) 8(28)
  Chemotherapy 10(33) 21(72)
 CT drugs CDDP- VP16 28(87) 28(97)
  CBDCA VP16 4(12) 1(3)
 Courses 6 12(37) 4(14)
  5 9(28) 5(17)
  4 3(9) 4(14)
  les than 4 8(25) 16(55)
 Radiotherapy 22(67%) IRAM 19(86) (PCI 10(53%) 5(62)
  Dosis 60Gy/30F 11(58) 1(20)
  27Gy/10 8(42) 4(80)
 Response Complete 11(39) 2(7)
  Partial 13(41) 8(28)
  Stable 5(16) 11(38)
  Progress 3(9) 8(28)
 Hemotoxicity 21(66%) Leukopenia 18(56) 8(28)
  Anemia 2(6) 2(7)
  Thrombopenia 1(3) 1(3)
 Nonhemotox 7(22%)  Renal 3(9) 2(7)
  pneumonitis 2(6) 2(7)
  Oesophagitis 2(6) 
 Follow up Mortality 28(87) 29(100)
  Survival (months) Mean 17.30 7.03
  Median 14 7.00
  Survival (years) Les 1 12(37) 24(83)
  More 1 15(47) 5(17)
  More 2 5(16) 0
 *p<0.0572   
Conclusion: There were no clinical differences in both periods. 
In the period 2002-2007 more patients with extended disease were 
treated Treatment and control management improved in the INT but a 
prospective database and better follow up of patients is necessary.
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Retrospective analysis of Patterns of failure in patients 
with LD-SCLC treated with “involved fields” at Hospital 
Clínic of Barcelona (2005-2008)
Casas, Francesc1
1 Radiation Oncology Department, Barcelona, Spain; 2 
MedicalOncology Department, Barcelona, Spain
Background: There is a controversy about whether “involved fields” 
are safe to treat LD-SCLC without mediastinal node relapses outside 
these fields. We analyzed the patterns of failure of patients treated 
at Hospital Clínic and the possible impact on the image method of 
staging at chest level exclusively (CT or / and PET-CT) in this local 
failure.
Material: We analysed retrospectively all the LD-SCLC patients 
treated between 2005 and 2008. We used an adaptation of Turrisi’s 
method (CDDP and VP16 for 4 cycles and BID accelerated RT till 45 
Gy beginning with the second cycle of CT). Three-D planning was 
made between first and second cycle. GTV contain identifiable tu-
mour and CT nodes > 1cm at this moment. After the RT-CH regimen 
PCI were realized in all the “responders” (CR and PR). From 2005 
to final 2006 the patient chest staging was only made with CT. From 
2007 the PET-TAC was also authorized and introduced for staging in 
our centre.
Results: We analysed 17 patients. Nine were female and 8 men. The 
median age was 50 years (40-79). All patients had PS 0-1, except one 
who had PS2. In the TNM classification all the patients were stage 
IIIA or IIIB (two patients with supraclavicular involment). Nine pa-
tients were staged till final 2006 and 8 between 2007 from 2008 with 
CT and PET-CT.
In March 2009, 6 patients are free of relapse (one in the first period 
and five in the second period); 4 patients progressed exclusively into 
the radiotherapy field; 2 patients relapsed exclusively out of the chest 
(brain and liver); 2 patients presented local failure exclusively out 
the RT field (at supraclavicular level); and 3 relapsed at local and 
at distance. In one of these last patients the local relapse was only 
at supraclavicular level. All three patients who have nodal failure 
outside the RT field at supraclavicular level the chest staging was 
carried out only with CT. In any of 8 patients where PET-CT was 
available for staging had mediastinal nodal failure outside RT field. 
In 6 of 8 patients chest staged with CT and PET-CT, had a divergence 
on mediastinal node affectation between both image methods (at 
supraclavicular or contralateral mediastinal level).
Conclusion: PET-CT information to decide GTV volume seems 
mandatory to avoid local nodal failure if “involved fields” in LD-
SCLC are used.
Copyright © 2009 by the International Association for the Study of Lung Cancer S811
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
P2.198 Small Cell Lung Cancer, Sun Aug 2 
Topotecan plus Epirubicin as a second line chemotherapy 
in Small Cell Lung Cancer: A phase II study
Charpidou, Andriani G.1; Chondrou, Evangelia1; Tsimpoukis, 
Sotirios1; Kotteas, Elias1; Tourkantonis, Ioannis1; Demertzis, Panos2; 
Papaetis, George 1; Syrigos, Kostas N.1, 3
1 Oncology Unit, 3rd Dpt Of Medicine, Athens Med School, Athens, 
Greece; 2 1st Department of Chest Diseases, Sotiria” General 
Hospital, Athens, Greece; 3 Department of Clinical Oncology, Yale 
University School of Medicine, New Haven, CT, USA
Background: Small cell lung cancer (SCLC) accounts for 15-20% of 
lung cancers. It is initially sensitive to chemotherapy and radiother-
apy. However, the majority of patients relapse within the first year 
after the diagnosis.We conducted a phase II study to determine the 
efficacy and tolerability of Topotecan plus Epirubicin as second-line 
chemotherapy for Small Cell Lung Cancer (SCLC).
Patients and Methods: Patients with histologically or cytologically 
confirmed extensive SCLC disease who relapsed after platinum-based 
prior chemotherapy were eligible. Patients received 2,5 mg/m2 of 
Topotecan Hydrochloride and 40 mg/m2 of Epirubicin on days 1 and 
15 every 4 weeks for up to 6 cycles or until they had either progres-
sive disease or intolerable side effects. Both sensitive and resistant 
patients (defined as patients with relapse after or within 90 days from 
completion of first line therapy, respectively) were evaluated. 
The primary end point of the study was response rates (complete 
or partial response plus stable disease). Secondary end points were 
time to progression (measured from the date of the first administra-
tion of second-line chemotherapy till a new relapse or death), overall 
survival and toxicity.
Compute Tomography-based response evaluations were performed 
after the third and the sixth cycle and every 2 months therefore. 
Response assessed according to the RESIST criteria. Therapy related 
toxicity was assessed according to the National Cancer Institute Com-
mon Toxicity Criteria, version 3,0. 
Results: 35 patients, 30 men and 5 women, all smokers, with a mean 
age of 63 years (range 42 to 76), performance status of 0 to 2 accord-
ing to the Eastern Cooperative Oncology Group (ECOG) received 
a total number of 100 cycles (median 2,5). 22 of the patients had a 
sensitive relapse. Totally, 8 of the 35 patients (22,9%) responded; 7 
with sensitive and 1 with resistant relapse. 1 patient achieved com-
plete response, 2 patients achieved partial response and 5 had stable 
disease. 
The median time to progression was 17 weeks (95% of CI: 5,1-18,9) 
similar for both sensitive and resistant patients. The median overall 
survival was 19 weeks (95% of CI: 14,5-23,6) also similar for sensi-
tive and resistant patients. 
2 patients (5,7%) had grade III to IV neutropenia, of which one 
developed fever; 2 patients (5,7%) developed grade III to IV anaemia 
and 2 patients (5.7%) had grade III to IV thrombopenia. Non-hema-
tological toxicities were grade I to II constipation (28,6%), alopecia 
(25,7%), diarrhea (11,4%), peripheral neurotoxicity (11,4%) and 
nausea-vomiting (8,6%). No therapy-related deaths were reported.
Conclusions: The regimen Topotecan and Epirubicin is equally ef-
fective in patients with sensitive and resistant refractory SCLC. The 
doublet is also well tolerated achieving acceptable toxicity. 
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Elevated serum C-reactive protein as a prognostic marker 
in small cell lung cancer 
Hong, Soojung; Cho, Byoung Chul; Jung, Minkyu; Moon, Yong 
Wha; Kim, Hyo Song; Choi, Hye Jin; Kim, Joo Hang
Department of Internal Medicine, Yonsei Cancer Center, Yonsei 
University College of Medicine, Seoul, Korea
Background: An elevated C-reactive protein (CRP) level is associ-
ated with poor prognosis in several malignancies such as esophageal 
cancer, hepatocellular carcinoma, colorectal cancer, and renal cell 
cancer. The purpose of this study was to investigate CRP as a prog-
nostic serum marker in small cell lung cancer (SCLC).
Methods: We retrospectively reviewed 157 patients who were 
diagnosed as SCLC and received chemotherapy from August 2000 to 
December 2008 at Yonsei Cancer Center, Seoul, Republic of Korea. 
The CRP level was measured before initial treatment and normal 
serum level was defined as 0.8mg/dL. The correlation between 
serum CRP level and other clinical markers was analyzed by Pearson 
correlation coefficient. Univariate analyses were conducted using 
Kaplan-Meier survival curve and log-rank test. Multivariate analyses 
were performed to find prognostic markers using Cox’s proportional 
hazards model.
Results: Patients and disease characteristics included median age 
65 years (range 46-82); male sex (n=140, 89.2%); extensive disease 
(n=98, 62.4%); weight loss (n=29, 18.5%); Eastern Cooperative 
Oncology Group performance status 0-1 (n=124, 79%); responder 
to chemotherapy (n=104, 66.3%). The initial CRP concentration 
was within normal range in 72 (45.9%) patients and elevated in 85 
(54.1%) patients. The mean values of CRP were 0.3±0.2 (range 0.1-
0.8) in normal CRP group and 8.4±8.8 (range 0.9-40.5) in high CRP 
group, respectively. There was a significant correlation between CRP 
level and the extent of disease (p<0.001) or weight loss (p=0.026). 
Median overall survival in the normal CRP group was significantly 
longer compared with high CRP group (22.5 months vs. 11.2 months, 
p<0.001). Additionally, extent of disease (p<0.001), age (p=0.026), 
performance status (p<0.001), and chemo-responsiveness (p<0.001) 
were statistically significant factors in univariate analysis. In multi-
variate analysis, elevated CRP level was an independent prognostic 
factor for poor survival (HR=1.8, 95% CI, 1.1-3.0; p=0.017), regard-
less of extent of disease (HR=2.5; p=0.001), performance status 
(HR=2.1; p=0.002), and chemo-responsiveness (HR=3.5; p<0.001).
Conclusions: In this study, high level of CRP was an independent 
poor prognostic serum marker in small cell lung cancer. 
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An open-label Phase II trial of the Plk1 inhibitor BI 2536, 
in patients with sensitive relapse small cell lung cancer
Chu, Quincy1; Gandhi, Leena2; Stephenson, Joe3; Johnson, Bruce E.1; 
Govindan, Rawasmamy3; Bradford, Daniel5; Bonomi, Phil6; Ellison, 
David7; Eaton, Keith8; Fritsch, Holger9; Munzert, Gerd9; Socinski, 
Mark10
1 University of Alberta, Edmonton, AL, USA; 2 Dana-Farber Cancer 
Institute, Boston, MA, USA; 3 Cancer Center of the Carolinas, 
Greenville, SC, USA; 4 Washington School of Medicine, St. Louis, 
MO, USA; 5 Highlands Oncology Group, Fayetteville, AR, USA; 6 
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Rush University Medical Center, Chicago, IL, USA; 7 Charleston 
Hematology/Oncology, Charleston, SC, USA; 8 Fred Hutchinson 
Cancer Center, Seattle, WA, USA; 9 Boehringer Ingelheim Pharma 
GmbH & Co. KG, Biberach, Germany; 10 University of North 
Carolina, Chapel Hill, NC, USA
Background: BI 2536 is a potent, selective inhibitor of Polo-like 
kinase 1 (Plk1), a regulator of mitotic progression. BI 2536 demon-
strated favorable tolerability and antitumor activity in Phase I trials. 
We investigated the antitumor efficacy, safety and pharmacokinetics 
(PK) of BI 2536 in patients with sensitive relapse small cell lung 
cancer (SCLC).
Methods: This open-label, single arm, Phase II study followed a 
Gehan two-stage design. Primary objective was to determine the 
antitumor efficacy of BI 2536 in SCLC patients with disease progres-
sion ≥60 days after completion of first-line chemotherapy. 18 patients 
had to complete 2 courses to be evaluable for stage 1 analysis. In case 
of ≥2 partial or complete antitumor responses (Response Evaluation 
Criteria In Solid Tumors criteria), stage 2 accrual would continue 
until 40 patients were entered. Patients received 200 mg BI 2536 as 
a 1-hour i.v. infusion on Day 1 every 3 weeks. Dose escalation to 
250 mg (Cycle 3 onwards) was encouraged in patients with <Grade 2 
drug related non-hematologic and <Grade 3 hematologic toxicity.
Results: Of the 23 patients enrolled, 14 were women. The median 
age was 60 years (range: 35–77). A median of 2 courses were given 
(range: 1–12). Frequent adverse events (AEs) were neutropenia 
(48%), fatigue (39%), nausea (30%), anemia, vomiting, constipation 
(26% each) and thrombocytopenia (22%). Drug-related Grade 3/4 
AEs were neutropenia (13%/26%), Grade 3/4 thrombocytopenia (one 
patient each), Grade 3/4 anemia (one patient each), Grade 4 sepsis 
(one patient), Grade 4 acute respiratory distress syndrome (one pa-
tient) and Grade 3 fatigue (one patient). No objective responses were 
observed. Seven patients had stable disease as best response, 14 had 
progression and two were not evaluable. 6 patients were progression-
free at 3 months (25%), only one patient was progression-free after 
6 months of therapy. Due to the lack of antitumor responses, trial 
accrual was terminated after stage 1. PK analyses indicate that BI 
2536 has high clearance (>1,000 mL/min) and quickly distributes in 
multiple compartments in a large volume of distribution (>1,000 L). 
Estimated elimination half-life was >25 h. 
Conclusion: Though well tolerated, BI 2536 is not active in relapsed 
SCLC. BI 2536 will not be assessed further as a single agent in 
SCLC. 
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ProGRP: A marker for small cell lung cancer
Dowell, Barry L.1; Yoshsimura, Tohru2; Kinukawa, Hideki2; Stieber, 
Petra3
1 Abbott Laboratories, Abbott Park, IL, USA; 2 Abbott Laboratories, 
Matsudo, Japan; 3 Univerisity of Munich, Munich, Germany
Background: Pro-gastrin releasing peptide (ProGRP) is a precursor 
of gastrin releasing peptide (GRP) that is found in neuroendocrine 
tissues. ProGRP is secreted by neuroendocrine type tumors, such 
as, small cell lung cancer (SCLC), medullary thyroid carcinoma, 
and hormonal-resistant, neuroendocrine-type prostate cancer. Dr. 
Yamaguchi demonstrated that GRP was highly expressed in SCLC 
tissue, but serum GRP measurement was not clinically useful due 
to its very short half-life in serum. He found that proGRP was more 
stable in serum and demonstrated its increased expression in the 
serum of patients with lung cancer. ProGRP has been identified as an 
important tumor marker for SCLC in the recent draft NACB Tumor 
Marker Guidelines. In this study, we report recent studies of the use 
of proGRP as a tumor marker for SCLC.
Methods: In this retrospective study, we investigated the ProGRP 
levels in serum samples from healthy subjects, patients with benign 
diseases, and patients with SCLC, non-SCLC (NSCLC) and other 
cancers. Sequential samples from patients monitored following treat-
ment for SCLC were also evaluated. Serum was stored at -80 degrees 
C until used. ProGRP levels were determined with a ProGRP ELISA 
(ALSI, Japan) or the automated ARCHITECT® ProGRP assay (Ab-
bott Diagnostics, North Chicago, USA). Neuronal-specific enolase 
was determined using the Roche NSE assay (Roche Diagnostics, 
Mannheim, Germany). Specimen testing was performed at the Insti-
tute of Clinical Chemistry, University of Munich (Munich, Germany).
Results: Elevated ProGRP expression (>100 pg/mL) was found in 
many SCLC samples (n=123), but not in samples from benign lung 
disease (n=183), or NSCLC (n=343). High levels of ProGRP were 
found in SCLC of both limited and extensive disease stages. The 
AUC for ProGRP for SCLC vs. benign disease was 0.858. At a speci-
ficity of 95%, the sensitivity of ProGRP for SCLC was 70%. In this 
study, the addition of NSE to ProGRP increased the AUC to 0.947. 
ProGRP was not found in other types of cancers or other benign 
diseases, with the exception of prostate cancer with neuroendocrine 
features. The data are consistent with previous studies that suggest 
that ProGRP can be used to help in the differential diagnosis of SCLC 
from benign disease, NSCLC and other types of cancer. The AUC for 
SCLC vs. all other types of cancers tested was 0.875. The data are 
consistent with previous studies that suggest that ProGRP can be used 
to help in the differential diagnosis of SCLC from benign disease, 
NSCLC and other types of cancer. A rising level of ProGRP was 
found to be associated with disease relapse in SCLC patients being 
followed after therapy. Whether earlier detection of relapse with Pro-
GRP can lead to a survival benefit requires additional clinical studies.
Conclusions: In this study, ProGRP was a sensitive and specific 
marker for SCLC that could be useful for the differential diagnosis 
and management of patients with SCLC. 
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Paclitaxel and carboplatin combination chemotherapy for 
relapsed small cell lung carcinoma: a retrospective study
Dubey, Sidharth; Talbot, Tobby; Cloos, Birgit; Yiannakis, Dennis
Department of Clinical Oncology, Derriford Hospital, Plymouth, UK
Purpose: This was a retrospective study to assess the efficacy of 
carboplatin and paclitaxel chemotherapy regimen in relapsed small 
cell carcinoma of lung, which has been the second line regimen for 
this disease in our unit. 
Patients and Methods: Patients with relapsed small cell lung carcin-
oma and treated with carboplatin (AUC 5 over 1 hour infusion) and 
paclitaxel (175mg/m2 over 3 hour infusion) on day 1, every 3 weeks 
for a maximum of six cycles, between 2004-2008 were considered in 
this analysis. 
Results: Included in the study were fifteen patients (mean age - 60.9 
years, nine with initially extensive stage disease and six with initially 
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limited stage disease). All the patients have had prior platinum and 
etoposide combination as primary chemotherapy. Eleven of these 
patients also had thoracic radiotherapy and prophylactic cranial radio-
therapy. After first line chemotherapy with platinum and etoposide, 
the median disease free survival was 7.5 months and the median 
time to relapse after completion of chemotherapy was 4 months. The 
median number of carboplatin-paclitaxel cycles administered was 
three (range 1-6). Two patients (13.3%) achieved complete response, 
seven (46.7%) had partial response, one (6.6%) had stable disease 
and five (33.3%) had progressive disease. After carboplatin-paclitaxel 
chemotherapy, the median disease free survival was 4 months. The 
median disease free survival in responders versus nonresponders to 
carboplatin-paclitaxel chemotherapy was 4.5 months and 1.8 months. 
The median overall survival from carboplatin-paclitaxel chemother-
apy was 7 months. The corresponding median overall survival in 
responders versus non responders was 7 months and 1.8 months. The 
median overall survival of the whole group from diagnosis was 15 
months (range 8-64 months)and the acturial 2 year overall survival 
was 23.5%.
Conclusion: Salvage chemotherapy with carboplatin and paclitaxel 
yields high response rates in previously platinum – etoposide treated 
small cell lung carcinoma patients. 
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Result of chemotherapy in small cell lung cancer (SCLC)
Gamaz, Bensaou M.; Kamel, Bouzid 
Medical Oncology Department, Algiers, Algeria
Background: The purpose of this study is the evaluation of a single 
institution experience of treatment by chemotherapy in Small Cell 
Lung Cancer (SCLC). 
Patients and Methods: During the period of January 2000-septem-
ber 2008, 35 consecutive SCLC patients were treated with chemo-
therapy based on alterned protocol of chemotherapy with cisplatin 70 
mg/m² + etoposide 100 mg/m² on D1, cyclophosphamide 750 mg/m² 
+ doxorubicin 50 mg/m² + vincristine 1.4 mg/m² on D21, 
Thirty (30) male (85.7%) and 5 female (14.2 %) with median age of 
60 (range 36-71) years. 
Twenty (20) patients had locally disease and 15 patients had diffuse 
disease (VALG classification). 
Results: A total of 119 cycles were administered, with median of 3 
(range 1-6) cycles per patient. No WHO grade 3-4 non-hematological 
toxicities were observed. WHO grade 3-4 hematological toxicity rate 
were as follows: neutropenia 2 (5 %), anemia 2 (5 %).
Objective response was observed in 12 (34.2 %) patients, stable dis-
ease was achieved in 2 (5.7 %) patients, and disease progression was 
observed in 21 (60 %) patients.
Median time to progression was 12 months and median survival 11.9 
(3 – 52) months.
Conclusion: Alterned protocol of chemotherapy CAV/PE is well 
tolerated and effective in treatment of small cell lung cancer.
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Topotecan as salvage therapy of refractory small cell lung 
cancer
Hatabay, Nilgun1; Erdal, Nuray 1; Ece, Ferah2
1 Sureyyapasa Chest Diseases Hospital, Istanbul, Turkey; 2 Istanbul 
Bilim University Avrupa Florence Nightingale Hospital, Istanbul, 
Turkey
Purpose: Small cell lung cancer( SCLC) is an agressive cancer gen-
erally sensitive to first line chemotherapy( chT).However prognosis is 
poor when there is progression or relapse. The purpose of this study 
was to evaluate the efficacy of intravenous Topotecan in patients (pts) 
with refractory SCLC. 
Patients and Methods: From 2001 to 2007 fiftytwo pts with refrac-
tory SCLC were included to this study. Pts characteristics were:47 
males and 5 females,median age of 57 years (r:34-77), ECOG p 0/1/2 
was 4/20/28,second line/third line/fourth line chT was 18/30/4.All 
of the pts received first or second line chT with Cisplatin or Carbo-
platin, prior to Topotecan therapy. Treatment consisted of intravenous 
Topotecan 1-1,5 mgr/m2 daily for 5 consecutive days every 3 weeks. 
Results: All of the pts were evaluable for overall response rate 
(ORR), time to progression (TTP) and median survival (MS). A total 
of 155 cycles were administered. Median number of cycles was 3 
(r:1-8). ORR was %13, 4 with no CR,7 PR,23SD and 22 PD. Median 
TTP was 11 weeks (r:1-47) MS was 19 weeks and one year survival 
was %5.7. Grade 3/4 anemia was seen in 44 pts. 36 pts needed RBC 
transfusion. There was 13 netropenia, 4 febrile netropenia and 5 
pansitopenia. 
Conclusion: Although significant bone marrow toxicities were ob-
served, intravenous Topotecan can be effective in salvage therapy of 
pts with refractory SCLC.
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Role of pulmonary resection for limited-stage small cell 
lung cancer
Iwata, Takashi; Nishiyama, Noritoshi; Nagano, Koshi; Izumi, 
Nobuhiro; Tsukioka, Takuma; Tei, Keikou; Hanada, Shoji; Inoue, 
Kiyotoshi; Suehiro, Shigefumi
Department of Thoracic Surgery, Osaka City University Graduate 
School of Medicine, Osaka, Japan
Background: Small cell lung cancer (SCLC) is considered as a 
systemic disease, such as leukemia because of its rapid progression 
and frequent dissemination at the time of diagnosis. Thus, chemother-
apy plays a central role in the treatment and the role of surgery is still 
controversial, even for the limited-stage (LD) SCLC. We investigated 
long-term outcome and factors influencing survival after complete 
resection of LD-SCLC, to evaluate the role of surgery.
Methods: We retrospectively reviewed clinical records of patients 
who underwent surgery between 1991 and 2007 in our institute. Clin-
ical features, including clinical and pathologic stages due to TNM 
classifications, were investigated. Overall survivals were estimated by 
Kaplan-Meyer methods. Primary endpoint was overall death. Factors 
influencing survival were estimated by univariate and multivariate 
analyses.
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Results: We identified 36 patients who underwent complete resection 
for LD-SCLC. The mean age (min-max) was 70 (55-86) years old 
and 28 patients (78%) were men. Twenty-nine patients (80.5%) were 
graded as clinical stage 1, however; only twenty patients (50.5%) 
were confirmed as pathological stage 1, postoperatively. Thirty-three 
patients (91.6%) underwent lobectomy or more and 3 underwent 
wedge resection. Twenty-nine patients (80.5%) underwent medias-
tinal dissection and the rest 7 underwent mediastinal sampling. Perio-
perative chemotherapy was added in 21 patients (58.3%). Median 
follow-up time (min-max) was 41.2 (1.2-132.9) months. Overall 
5-year survival was 57.5%. Tumor size less than 3 cm (p=0.0050) 
and absence of nodal spread (p=0.0141) were significant factors 
for better survival by univariate analysis. Wider operative methods, 
such as lobectomy and/or additional mediastinal dissection did not 
improve the long-term survival. Perioperative chemotherapy also 
did not show the better survival. Tumor size (p=0.0168) and nodal 
stage (p=0.0364) were only significant factors influencing survival 
also by multivariate analysis. Five-year survival of clinical stage 1B 
or less (n=29) was 61.2% and those of stage 2A or more (n=7) was 
44.4%. The difference between the two groups was not significant 
(p=0.6386). However, 5-year survival of pathological stage 1B or less 
(n=20) was 73.9% and those of 2A or more (n=16) was 37.5%, show-
ing significant difference between the two (p=0.0313). Locoregional 
recurrence was developed only in one patient.
Conclusion: Surgical treatment was beneficial for patients with very 
early stage of SCLC. Especially T1-2 N0 diseases are good candi-
date. Mediastinal dissection does not improve the outcome, however, 
gives an important pathological information predicting survival 
that could be hardly obtainable from preoperative workup. Surgical 
treatment may also prevent the locoregional recurrence and may be 
beneficial even for patients with stage 2 and 3 diseases. Effective-
ness of perioperative chemotherapy could not been confirmed in this 
study. However, we believe perioperative chemotherapy is very im-
portant and strongly recommended. Because SCLC is very sensitive 
to the chemotherapy, and surgical treatment alone could not prevent 
rapid systemic dissemination of SCLC. Surgery may be beneficial for 
the early stage of the disease, but should be located as only a part of 
multimodal treatment for LD-SCLC.
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The utilization rate of prophylactic cranial irradiation 
(PCI) in small cell lung cancer (SCLC): A review of 
practice in British Columbia
Khaira, Mandip K.2; Lee, Christopher W.2; Schellenberg, Devin2; 
Joffres, Michel1
1 Simon Fraser University, Burnaby, BC, Canada; 2 BC Cancer 
Agency - Fraser Valley Centre, Surrey, BC, Canada
Background: A role for PCI in extensive SCLC was established fol-
lowing the report of EORTC 08993-22993 in 2007, which prompted 
a change in routine practice in the province of British Columbia 
(BC). Our primary objective was to compare the rates of PCI delivery 
before and after July 2007, when the policy change was made by the 
BC Cancer Agency (BCCA).
Methods: All patients diagnosed with small cell carcinoma between 
July 2006 and June 2008 were identified in the BC Cancer Registry. 
The clinical records of those referred to the BCCA were reviewed. 
Data were collected on patient demographics and treatment. Excluded 
from analysis were those with an extrathoracic primary, and individ-
uals with SCLC not considered typical candidates for PCI, that is: 
those treated with single-agent chemotherapy; with brain metastases 
at diagnosis; with progressive disease or who died whilst on chemo-
therapy. Otherwise those who completed combination chemotherapy 
were included for analysis of PCI utilization, and their Charlson 
Comorbidity Index (CCI) was determined.
Results: A total of 585 cases of small cell carcinoma were diagnosed 
in the time period specified. Clinical records were not available for 
99. A further 34 had an extrathoracic primary, while the diagnosis 
was revised for 15 on pathology review. There was no record of 
systemic therapy having been prescribed in 93 cases, and 1 patient 
was treated outside BC. Of the remaining 343, 36 had brain metasta-
ses at diagnosis, 43 developed progressive disease or died whilst on 
chemotherapy, 29 did not complete treatment due to toxicity or poor 
performance status, 26 had single agent oral chemotherapy and 1 is 
currently on treatment.
Of the 208 patients eligible for PCI, 110 (53%) were female and 98 
(47%) male whilst 110 had extensive disease (ED) and 98 limited dis-
ease (LD). The rates of PCI delivery in patients with ED diagnosed 
before and after July 2007 were 25 % (15/59) and 55 % (28/51), 
respectively (p=0.0007), and 68 % (32/47) and 80 % (41/51) for 
LD (p=0.16). When examining six-month intervals during the study 
period, there was a significant increase in rates of PCI over time (p = 
0.0005). The most common radiation schedule used was 25 Gy in 10 
fractions (68%) followed by 20 Gy in 5 fractions (16%). The median 
time between completing chemotherapy and starting radiotherapy 
was 3.3 weeks. Kaplan-Meier survival analysis showed a significant-
ly higher survival for patients with ED treated with PCI (p=0.0005). 
Individuals with high CCI scores were less likely to be offered PCI 
(P<0.0001). 
Conclusion: An increase in the utilization of PCI in ED SCLC has 
been seen since the change in BCCA policy in July 2007. There is a 
proportion of eligible patients who do not receive PCI, but our results 
suggest that comorbidity influences the decision making process. The 
majority of patients with LD receive PCI, and utilization rates appear 
relatively stable over the study period.
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A case of extensive stage small cell lung cancer presenting 
as an acute appendicitis with perforation
Kim, Dojin
Soonchunhyang University Bucheon Hospital, Bucheon, Korea
The incidence of appendiceal metastatic cancer is quite low. In 
particular, in small cell lung cancer, there is a very low incidence of 
a metastasis to the appendix. A 75-years old man with right lower 
quadrant pain, cough and sputum was transferred to pur hospital. 
Abdominal CT revealed acute appendicitis with a perforation. The 
patient underwent surgery. The frozen sections of the tissue obtained 
during surgery, indicated a malignancy, but a right hemicolectomy 
was not performed due to the patient’s poor general condition. The 
histology findings of the appendix were identified as a small cell 
carcinoma. The abdominal CT scan and chest x-ray at admission day 
showed a mass in the right lower lobe, and a further evaluation of the 
lesion was performed including positron emission tomography and 
flexible bronchoscopy with a biopsy. The pathology findings of the 
lung mass were also small cell lung cancer. The specimens from both 
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site stained positive for cytokeratin, cluster designation 56, synapto-
physin, chromogranin-A and thyroid transcription factor 1. It was 
concluded that the appendiceal small cell cancer originated from the 
lung. 
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Limited-stage small-cell lung cancer treated with two 
cycles etoposide-cisplatin chemotherapy followed by once-
daily concurrent chemoradiotherapy
Kim, Yeon-Sil; Kang, Jin-Hyoung; Kim, Young-Kyoun; Kim, Seung-
Jun; Ahn, Myeong-Im; Yoo, Ie-Ryung; Wang, Young-Pil; Park, Jae-
Kil; Lee, Kyu-Young
Kang-Nam St. Mary’s Hospital, Catholic University of Korea, Seoul, 
Korea
Background: To review the outcomes in patients with limited-stage 
small-cell lung cancer receiving etoposide-cisplatin based concurrent 
chemoradiotherapy.
Methods: The results of 31 patients treated with prospectively 
designed concurrent chemoradiotherapy for limited-stage small-cell 
lung cancer between October 2004 and May 2008 at Catholic Med-
ical Center were evaluated. 30 patients completed thoracic radiother-
apy (TRT) with median 54 Gy (range, 50.4-55.8) and concurrently 
etoposide-cisplatin chemotherapy. Prophylactic cranial irradiation 
was delivered to 21 patients. Age ranged from 43 to 76 (median: 62). 
Median ECOG performance status was 1 (range, 0-2). The median 
follow-up was 34.1 months (range, 5.8-63). 
Results: The 2-year actual failure rate, failure-free survival and over-
all survival were 44.4%, 36.7% and 47.3%. Thirty patients developed 
failures at any site and 7 of 13 patients developed local failures. One 
patient experienced acute grade 3 pneumonitis and 2 patients experi-
enced acute grade 3 esophagitis. No one experienced late grade 3/4 
esophageal/pulmonary toxicities. 
Conclusion: In our study, the clinical outcome was comparable to 
other reported results and showed lower complication rates. Recently, 
once-daily TRT with a higher dose has been tried to improve clinical 
outcome and reduce toxicities. However, long-term efficacy still re-
mains unclear. On-going RTOG 0538/CALGB 30610 trial might have 
answers to the question of the optimal radiation dose and fractiona-
tion scheme.
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A Phase I/II trial of topotecan in combination with 
cisplatin for extensive-disease small cell lung cancer
Kubota, Kaoru1; Nishiwaki, Yutaka1; Yokoyama, Akira 2; Sakai, 
Hiroshi3; Kiura, Katuyuki4; Segawa, Yoshihiko5; Ichinose, Yukito6; 
Ando, Masahiro7; Takeda, Koji8; Kudo, Shinzo9; Matsui, Kaoru11; 
Eguchi, Kenji10; Masuda, Noriyuki12; Shibuya, Masahiko13; 
Watanabe, Koshiro14
1 National Cancer Center Hospital, Kashiwa Chiba, Japan; 2 Nigata 
Cancer Center Hospital, Niitgata, Japan; 3 Saitama Cancer Center, 
Saitama, Japan; 4 Okayama University Hospital, Okayama, Japan; 
5 Shikoku Cancer Center, Matsuyama, Japan; 6 National Kyushu 
Cancer Center, Fukuoka, Japan; 7 Tsuboi Cancer Center Hospital, 
Fukushima, Japan; 8 Osaka City General Hospital, Osaka, Japan; 9 
Osaka City University Hospital, Osaka, Japan; 10 Tokai University 
Hospital, Isehara, Japan; 11 Osaka Prefectural Medical Center 
for Respiratory and Allergic Diseases, National Kyushu Cancer 
Center, Osaka, Japan; 12 Kitasato University Hospital, Sagamihara, 
Japan; 13 Tokyo Metropolitan Cancer and Infectious diseases Center 
Komagome Hospital, Tokyo, Japan; 14 Yokohama Municipal Citizen's 
Hospital, Kanagawa, Japan
Background: In-vitro studies have shown synergistic anti-tumor 
activity between topotecan (Tp) and cisplatin (CDDP) presumably 
due to inhibition of DNA repair mechanisms . In a phase III trial in 
patients with metastatic, recurrent, and persistent cervical cancer, 
patients in the Tp and CDDP arm demonstrated an improvement 
in response rate, progression-free survival, and overall survival. To 
investigate this combination in patients with extensive-disease small 
cell lung cancer (ED-SCLC) we conducted, a phase I/II trial to deter-
mine a safe and effective combination regimen of IV Tp and CDDP 
with granulocyte-colony stimulating factor (G-CSF) support. 
Methods: Patients with histologically or cytologically diagnosed 
ED-SCLC, performance status 0 or 1 and aged 20 – 74 were enrolled. 
Combination therapy was constituted at escalating doses of Tp for 5 
consecutive days at 6 dose levels from 0.50 to 1.40 mg/m2 and fixed 
dose of CDDP (60 mg/m2) either on day 1 or day 5 every 21 days. In 
the first stage of trial (phase I) previously treated patients received 
the combination of Tp and CDDP on day 1 to estimate maximum 
tolerable dose (MTD) and recommendable dose (RD) for therapy 
naïve patients enrolled later in the trial. In second stage of the trial 
(phase II), we conducted a randomized, open-label, comparative 
study to evaluate safety and antitumor effect of CDDP on day 1 or 
day 5 administration schedules. Each of 15 chemo naïve patients was 
randomized to one of the two arms (CDDP on day 1 or day 5 sched-
ule). The RD of Tp was administered to patients in each arm (step1). 
In selected CDDP arm, 15 patients from phase 1 and an additional 
15 therapy naïve patients from phase II were evaluated for safety and 
antitumor effect of Tp and CDDP combination (step 2). Preventive G-
CSF was administered on day 6 after Tp administration.
Results: In phase I, 34 patients were enrolled. Both the MTD and the 
RD of Tp in combination with CDDP on day 1 administration sched-
ule were estimated as 0.65 mg/m2. In CDDP on day 5 administration 
schedule, the MTD and the RD of Tp were estimated as 1.4 mg/m2 
and 1.0 mg/m2, respectively. In phase II, 30 and 14 patients were 
enrolled in step 1 and step 2, respectively. The response rates (80% 
for each) were similar for CDDP on day 1 and day 5 administration 
schedules. However, CDDP on day 5 schedule had a better hemato-
logical toxicity profile (Step1). In phase II, 29 patients with CDDP 
on day 5 administration schedule yielded a response rate of 83% 
(1 complete response, 23 partial response, 3 stable disease, 2 non 
evaluable, 95%CI, 64.2 - 94.2%). Hematological adverse events were 
grade 3/4 neutropenia (50%), grade 3/4 anemia (58.6%) and grade 
3/4 thrombocytopenia (44.4%). Non hematological adverse events 
were anorexia (89.7%), nausea (86.2%), vomiting (51.7%), constipa-
tion (69.0%), hiccoughs (37.9%), fatigue (72.4%), alopecia (72.4%), 
increased AST (48.3%), and increased ALT (58.6%). The MST in 29 
patients on CDDP day 5 administration schedule was 415 days.
Conclusion: The combination of topotecan on 5 consecutive days 
and cisplatin on day 5 schedule with G-CSF support was a safe and 
effective regimen for therapy naïve patients with ED-SCLC. 
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Clinical Study of CPT-11 with cisplatin in second line 
small-cell-lung- cancer (SCLC) patients
Lu, Shun1; Ye, Xiangyun1; Zhang, Yifei2
1 Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai 
Jiao Tong University, Shanghai, China; 2 CSCO, Shanghai, China
Objective: To evaluate therapeutic effect of CPT-11 with cisplatin on 
patients with retreated small cell lung cancer (SCLC) and to further 
explore potential therapy for those SCLC patients failing first-line 
treatment.
Methods: Retrospective study on all retreated SCLC patients who 
admitted to Shanghai Chest Hospital during Mar, 2007 to Mar, 2008. 
Kaplan-Meier curve and log-rank test were used for survival analysis.
Results: To tolly, 19 patients were enrolled in this study. The overall 
response rate was 21.1% (PR+CR), while the overall disease control 
rate was 79%. The progression-free survival (PFS) time of patients 
was 5.5 month, the mean survival time(MST) was 6.6month and 1 
year survival rate was 26.3%. When subgroups(chemosensitive or 
non-sensitive) were divided according to different effect of their first-
line therapy, the analysis showed that after receiving CPT-11 therapy, 
the chemosensitive patients(with first line PFS >3 month) had a better 
prognosis when compared to those PFS less than 3 month, whose 
PFS, MST and 1 year survival rate reached to 6.6month, 10.7month 
and 35.7% respectively, while the PFS, MST and 1 year survival 
of those non-chemosensitive were 2.6month, 2.9month and none 
respectively. However, the difference between two subgroups was 
not significant. Overall, toxicity was mild after CPT-11 treatment, the 
incidence of patients experienced grade III and grade IV leukopenia 
were 31.6% and 10.5% respectively and the incidence of grade III 
and grade IV thrombocytopenia were 10.5% and none. While only 1 
patient occurred diarrhea and 2 had gastrointestinal complaints. 
Conclusions: CPT-11 seems to be safe and feasible in second line 
SCLC patients. The chemosensitive patients could achieve longer 
PFS and MST when receiving CPT-11 therapy after first line chemo-
therapy and 1-year survival rate could also be improved. 
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Prognostic impact of patterns of nodal subcategories and 
pleural or pericardial effusions in Small Cell Lung Cancer 
(SCLC)
Lwin, Zarnie3; Patsios, Demetris1; Ma, Clement2; Leighl, Natasha3
1 Department of Medical Imaging, University Health Network, 
Toronto, ON, Canada; 2 Department of Biostatistics, Princess 
Margaret Hospital, Toronto, ON, Canada; 3 Department of Medical 
Oncology, Princess Margaret Hospital, Toronto, ON, Canada
Background: Limited Stage SCLC can be heterogeneous and the 
patterns of precise nodal involvement, presence of cytology-positive 
or –negative pleural effusions, and presence of pericardial effusions 
may be important in treatment modality decision, radiotherapy and 
prognosis. This study explores the prognostic impact of different pat-
terns of nodal involvement within N subcategories, cytology-negative 
or -positive pleural effusions, and presence of pericardial effusions on 
outcome in SCLC applying the seventh edition of the TNM classifi-
cation.
Methods: Imaging and medical records of patients with a pathologic 
diagnosis of SCLC, treated at Princess Margaret Hospital (PMH) 
are under review. Patients with mixed non-small cell histology and 
those not treated at PMH were excluded. Imaging is being independ-
ently reviewed by a thoracic radiologist, and cases staged using the 
seventh edition of the TNM staging classification. Location and 
number of nodal stations involved by radiologic criteria, nodal size, 
ipsilateral or contralateral nodes, presence of “skip” nodal metastasis 
(only contralateral nodal involvement) are assessed. The presence 
of pericardial effusions, and confirmed pleural effusion cytology if 
available is also documented. Prognostic variables including gender, 
performance status (PS), weight loss and pretreatment biochemistry 
will be included in multivariate analyses, and data on treatment and 
outcome are collected. Data collection is ongoing, and updated data 
for progression-free (PFS) and overall survival (OS) will be analyzed 
using multivariate Cox Proportional-Hazards regression.
Results: 100 patients treated from 2001-2003 are under review, with 
complete data on 29 patients at the time of abstract submission. Ten 
patients (34%) were female, median age was 70 years, (range 47 to 
80), with a median 49 pack-year smoking history (range 12 to 100 
pack-years). Nineteen patients (65%) were PS 0-1, 24% PS2 and 
the rest PS>2. Six patients were staged as Tx, 12 (52%) as T1, and 
11(48%) had T2 or higher stage tumours. Pathologic N status was not 
assessed routinely in this population. Seven patients (24%) had N0 
or N1 disease on imaging, while most, (76%), had N2 or N3 disease. 
Five patients(17%) had only ipsilateral nodes, and none had “skip” 
contralateral nodal metastases. While 9(31%) patients had unilateral 
pleural effusions, 4(13%) had bilateral effusions. Pleural fluid cytol-
ogy was available for only 2 patients, positive in 1. There were 2 
patients with radiologic evidence of pericardial effusions; none were 
investigated with pericardiocentesis. At a median follow-up of 11.8 
months from diagnosis to death or last follow-up, (range 0.7 months 
to 7.1 years), median PFS was 9.5 months, (95% CI: 7-50). Using 
univariate Cox Proportional-Hazards regression, patients with PS >1 
had shorter PFS than patients with PS 0 or 1, (HR= 4.19, p=0.009).
Conclusions: Patterns of nodal involvement, cytology-positive 
pleural effusions or pericardial effusions may have prognostic impact 
in addition to the new TNM staging system. Updated data will be 
presented at the meeting exploring the impact of these factors on PFS 
and OS. 
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A Phase II study of dasatinib in patients with chemo-
sensitive relapsed small cell lung cancer (SCLC): CALGB 
30602
Miller, Antonius A.1; Pang, Herbert2; Hodgson, Lydia2; Ramnath, 
Nithya3; Otterson, Gregory A.4; Vokes, Everett E.5
1 Wake Forest University, Winston-Salem, NC, USA; 2 Duke 
University, Durham, NC, USA; 3 Roswell Park Cancer Institute, 
Buffalo, NY, USA; 4 Ohio State University, Columbus, OH, USA; 5 
University of Chicago, Chicago, IL, USA
Background: SRC is an oncogene with an essential role in the in-
vasiveness and metastasis of solid tumors including SCLC. Dasatinib 
is a potent inhibitor of SRC as well as other tyrosine kinases. The pri-
mary objective of this study was to determine the efficacy of second-
line dasatinib in patients with chemo-sensitive (relapse or progression 
≥90 days after completing first-line therapy) SCLC. 
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Methods: Patients with measurable disease, performance status (PS) 
0-1, no more than 1 prior platinum-based chemotherapy regimen, 
and adequate hematologic, hepatic, and renal function were eligible. 
Dasatinib was administered orally at 70 mg twice daily continu-
ously (1 cycle = 21 days) until disease progression or unacceptable 
toxicity. Response was determined after every 2 cycles. Patients were 
followed until disease progression or death. The study was prospect-
ively designed to simultaneously discriminate between complete 
plus partial response rates of 5% versus 20% and progression-free 
survival (PFS) rates at 6 weeks of 50% versus 70.7% in 53 evaluable 
patients with at least 92% power. The study was to be terminated 
early and declared negative if 1 or less objective response and 14 or 
fewer instances of PFS ≥ 6 weeks were observed among the initial 
27 patients; however, patient accrual continued while the initial 27 
patients were evaluated. 
Results: Between 4/2007 and 12/2008, 45 patients were enrolled: 
male/female, 17/28; white/black/other, 42/2/1; median age, 69 
(range, 36-88) years; and PS 0/1, 12/33. No objective response was 
recorded among all 45 patients. Among the initial 27 patients, only 
13 instances of PFS ≥ 6 weeks were observed. With a median follow 
up time of 1.6 months, the median estimated overall survival and PFS 
times for all 45 patients were 22 and 6 weeks, respectively. Common 
reasons for removal of patients from protocol treatment were progres-
sive disease (51%) and adverse events (27%). Toxicity was generally 
mild to moderate: grade 3 events of approximately 10% frequency 
included fatigue, pleural and pericardial effusions, and dyspnea, but 
higher grade toxicity was infrequent. 
Conclusions: Dasatinib did not reach our specified efficacy criteria in 
this clinical setting, and the study was terminated.
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Retrospective analysis of the response and toxicity of 
amrubicin for relapsed small-cell lung cancer: one 
institute’s experience
Minato, Koichi; Sato, Koji; Suzuki, Kuniaki
Gunma Cancer Center, Gunma, Japan
Background: Amrubicin is thought to be an effective agent for 
small-cell lung cancer. The purpose is to determine retrospectively 
the response and toxicity of amrubicin used in practical setting for the 
patients with relapsed small-cell-lung cancer.
Methods: Twenty-three relapsed small-cell-lung cancer patients 
were received amrubicin alone in Gunma Cancer Center to October 
2008. Patient characteristics were as follows: median age 66 years 
(53-80 years), male/ female 20/3, Performance status 0-1/2-3 19/4, 
limited disease/ extensive disease 2/21, sensitive relapse(SR)/ refrac-
tory relapse(RR) 8/15. Patients were treated by 23-45 mg/m2/day of 
amrubicin day 1-3 repeated every 3-4 weeks. Mean cycles received 
were 3(1-7). One patient was excluded the toxicity analysis because 
of early death. 
Results: The overall response rate was 41%(9/22). The response 
rate of SR and RR was 50%(4/8), 36%(5/14), respectively. Grade 3 
and 4 leucopenia, neutropenia, thrombocytopenia were observed in 
64%(14/22), 86%(19/22), 45%(10/22), respectively. Grade 3 febrile 
neutropenia was observed in 23%(5/22). Grade 3 left ventricular sys-
tolic dysfunction was 5%(1/22). Median survival time from the start 
of amrubicin was 6.6months.
Conclusion: Amrubicin has the activity for the patients with relapsed 
small-cell-lung cancer. Severe hematologic toxicity was frequently 
observed. Therefore, the study will need to determine the optimal 
dose of amrubicin for relapsed small-cell lung cancer.
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Outcomes of second-line chemotherapy in Japanese 
patients with small cell lung cancer previously treated with 
platinum-based chemotherapy
Murakami, Haruyasu; Naito, Tateaki; Kaira, Kyoichi; Tsuya, Asuka; 
Nakamura, Yukiko; Takahashi, Toshiaki; Endo, Masahiro; Yamamoto, 
Nobuyuki
Shizuoka Cancer Center, Shizuoka, Japan
Background: Small-cell lung cancer (SCLC) is exquisitely respon-
sive to first-line chemotherapy, but the majority of patients with 
SCLC relapse quickly. Although most patients with a good functional 
status are candidate for second-line chemotherapy, evidence for the 
clinical benefit of those patients is limited. Recent data suggest that 
amrubicin (AMR), a synthetic anthracycline analogue and potent 
DNA topoisomerase II inhibitor, can be an active agent for refractory 
or relapsed SCLC patients. 
Methods: We reviewed the clinical record of 153 consecutive 
patients with SCLC treated with platinum-based chemotherapy at 
Shizuoka Cancer Center between October 2002 and December 2007. 
Of the 153 patients, 72 (47%) patients received second-line chemo-
therapy. We have retrospectively analyzed the efficacy of second-line 
chemotherapy in 72 patients (44 patients with refractory and 28 
patients with sensitive relapse) with SCLC. 
Results: The overall response rates were 16% in refractory relapse 
and 46% in sensitive relapse. Median progression-free survival (PFS) 
and overall survival (OS) were 2.1 months and 7.0 months in refrac-
tory relapse, and 6.0 months and 16.3 months in sensitive relapse. 
Refractory relapse patients had significantly shorter PFS (p<0.01) and 
OS (p<0.01). The most commonly administered second-line regimen 
was single-agent AMR. Thirty-three patients (22 patients with refrac-
tory and 11 patients with sensitive relapse) were treated with AMR, 
and the overall response rates were 23% in refractory relapse and 
36% in sensitive relapse. Median PFS and OS were 2.7 months and 
10.8 months in refractory relapse, and 5.5 months and 11.0 months in 
sensitive relapse. In refractory relapse, AMR provided significantly 
longer PFS (p = 0.02) and OS (p = 0.01) than other regimens. 
   With Amrubicin Without 
Amrubicin
 Refractry relapse SCLC patients  22 22
 Age Median 64 71
  Range 54-82 51-77
 Sex Male 19 17
  Female 3 5
 PS 0 2 1
  1 13 14
  2 7 7
 Response rate (%) 23 9
 Median prgression free survival  (months) 2.7 1.5
 Median overall survival  (months) 10.8 5.8
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Conclusions: AMR provides promising response rate and survival 
in Japanese patients with small cell lung cancer previously treated 
with platinum-based chemotherapy. AMR may improve survival in 
patients with refractory SCLC.
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The challenge of stable, poor survival in small cell lung 
cancer (SCLC)
Nicolson, Marianne C.; Urquhart, Gordon N.; Bissett, Donald; 
Christie, Gordon; Kerr, Keith M.
Aberdeen Royal Infirmary, Aberdeen, UK
Introduction: We diagnose and treat approximately 380 new patients 
(pts) with lung cancer annually in our Cancer Centre. Of these, 15% 
have SCLC. Most recent audit figures indicate that 63% receive 
chemotherapy (CT). We have looked at the numbers receiving second 
line therapy and measured survival at 1 and 2 years for pts treated in 
years 2000 and 2005.
Methods: A specialist oncology trainee (GNU) retrieved as many 
casenotes as were available and entered data directly on to an Excel 
spreadsheet for analysis of predetermined fields. All pts had been 
diagnosed in Aberdeen by respiratory physicians (GC) and patholo-
gist (KK) or cytopathologist. Fitness for treatment (CT and radiother-
apy) was decided by oncologists (MCN and DB).
Results: In 2000, 46% had limited disease (LD) and 54% exten-
sive disease (ED). CT was etoposide (E)+ carboplatin (40%) or 
E+cisplatin (10%), or cyclophosphamide (C), doxorubicin (A), 
vincristine(CAV; 40%) or ACE (10%). In 2005, 16% had LD and 
84% ED. 68% received ECarbo and 32% ECis. Median number of 
cycles was 4. Only 4 pts each year received second line CT. The 
1-year survival was 31% in 2000, 19% in 2005, with 2-year survivals 
26% and 9% respectively. This poor survival and low retreatment rate 
make new therapy approaches urgent but there are few clinical trials 
for this pt group.
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Cost-effectiveness of oral topotecan plus best supportive 
care versus best supportive care alone in patients with 
relapsed small–cell lung cancer (SCLC) in the UK
O’Brien, Mary E.1; Morris, Stephen2; Papo, Natalie L.3; Lykopoulos, 
Konstantinos3
1 Royal Marsden Hospital, Sutton, UK; 2 Brunel University, 
Uxbridge, UK; 3 GSK, Uxbridge, UK
Background: In a recent international randomised Phase III trial 
patients with relapsed SCLC not considered as candidates for stan-
dard IV therapy were randomly assigned to oral topotecan plus best 
supportive care (OT+BSC) (n=71) or BSC alone (n=70) and followed 
until death. OT+BSC was associated with significantly longer overall 
survival. The aim of this study was to assess the lifetime cost-
effectiveness of OT+BSC versus BSC alone in patients with relapsed 
SCLC in the UK. 
Patients and Methods: We developed a cost-effectiveness model 
based on patient level data from the trial. Outcomes were measured 
in quality adjusted life years (QALYs). Costs attributable to OT+BSC 
were included in an incremental analysis. 
Results: The baseline estimate of the incremental cost per QALY 
gained was £26,833. Results were most sensitive to the measure-
ment of health related quality of life, drug administration cost and the 
cost of treating adverse events. OT+BSC was more cost-effective in 
patients in whom the time to progression from prior therapy was ≤ 60 
days, in females, and in those with no liver metastasis
Conclusions: Given a most plausible estimate of the incremental cost 
per QALY gained <£30,000, the findings suggest that OT+BSC may 
be a cost effective therapy in this patient group
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Retrospective study of patients with large-cell 
neuroendocrine tumors of the lung
Vaslamatzis, Michael M.2; Papaxoinis, George2; Vamvouka, 
Chrisanthi1; Alevizopoulos, Nektarios2; Patila, Elissavet2; Tsiga, 
Alexia1; Ntelaki, Aikaterini2; Karra, Panagiota1; Zisis, Charalambos3; 
Karathanasi, Afroditi2; Exarchos, Dimitrios4; Stathopoulos, 
Charalambos2; Bellenis, Ion3
1 Department of Pathology, “Evaggelismos” Hospital, Athens, 
Greece; 2 Department of Medical Oncology, “Evaggelismos” 
Hospital, Athens, Greece; 3 Department of Thoracic Surgery, 
“Evaggelismos” Hospital, Athens, Greece; 4 Department of 
Radiology, “Evaggelismos” Hospital, Athens, Greece
Background: Large-cell neuroendocrine carcinoma (LCNC) of the 
lung is a recently documented clinicopathologic entity, with many 
similarities with small cell lung carcinomas according to the clinical 
characteristics and the choice of treatment. However, remarkable dif-
ferences, mainly in the outcome of the patients (pts), distinguish the 
two groups. 
Patients: Thirteen pts, all heavy smokers (>30 pack/years), first diag-
nosed with LCNC, among 234 (5%) with small cell lung carcinomas, 
were consecutively admitted in the Department of Medical Oncology, 
Evaggelismos Hospital, Athens, Hellas, between 1/1996–1/2009. 
Their main characteristics are shown in Table 1. The presenting 
symptoms, at diagnosis were: cough ± haemoptysis ± fever in 2 
(15%), palpable cervical lymph nodes in 2 (15%), bone pain in 3 
(23%), chest pain in 1 (8%), superior vena cava syndrome in 1 (8%), 
paraneoplastic tetraplegy in 1 (8%), and paraneoplastic myopathy 
in 1 (8%), pts. Two asymptomatic patients were diagnosed during 
routine check-up. Five (38%) pts underwent curative surgery (4 lob-
ectomy, 1 pneumonectomy), while the diagnosis was established by 
lymph node biopsy in 2 (15%), and during bronchoscopy in 2 (15%) 
patients. Diagnosis by FNA biopsy was established in 4 (31%) pa-
tients. All the neoplasms showed typical neuroendocrine morphology 
with extensive necrosis and atypical mitosis. Immunophenotipically 
stained positive for CD 56 and synaptophysin or/ and chromogranin. 
The metastatic sites were: lymph nodes in 8 (62%), liver in 4 (31%), 
CNS in 3 (23%), bones in 3 (23%), lung in 2 (15%) and adrenal in 1 
(8%), pts. 
Results: Three (23%) pts, two with stage I and one with stage 
IIIA were only followed-up, while 9 (69%) received etoposide 
based chemotherapy, 5 in combination with platinum and 4 with 
cyclophosphamide, vincristine, adriamycin, and the last (8%) patient 
was treated with cisplatin-pemetrexed combination. After a median 
follow-up of 9 (1 - 80) months, two patients with stages I and IIIA, 
respectively, were disease free after radical surgery, for 22+ and 80+ 
months, respectively, while the pts treated with adjuvant chemother-
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apy or for metastatic disease had median PFS of 2.5 (1-20) months 
and median survival of 6 (1-36) months. According to the extent 
of disease, the median PFS was 20 (16-80+) and 1.5 (1-4) months, 
(p=0.004) for stages ≤IIIA and IV respectively. The median survival 
was 24 (22+ - 80+) and 5 (1-12) months, (p=0.001) for stages ≤IIIA 
and IV respectively. 
Conclusions: According to our results, in patients with LCNC:
• The prognosis is very poor and the disease seems to be chemore-
fractory 
• Pts with operable disease have the best outcome after radical 
surgical procedure.
• Further studies for the identification of markers of chemosensitiv-
ity are needed. 
 Median age (range)  56 years (33-72) 
 Males: Females  12: 1 
 Performance status (ECOG)  
 0 3 (23%) 
 1 5 (38%) 
 2 0 (0) 
 3 4 (31%) 
 4 1 (8%) 
 Histology  
 Pure LCNC 8 (62%) 
 Mixed LCNC-SCLC  2 (15%) 
 Mixed LCNC-adenocarcinoma  3 (23%) 
 Clinical stage (AJCC)  
 I 3 (23%) 
 II 0 (0) 
 IIIA 2 (15%) 
 IIIB 0 (0) 
 IV 8 (62%) 
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Effects of hypoxia on small cell lung carcinoma cells
Munksgaard Persson, Matilda1; Johansson, Martin2; Pahlman, Sven1; 
Pettersson, Helen M.1
1 Lund University, Center for Molecular Pathology, Malmoe, Sweden; 
2 Lund University, Division of Pathology, Malmoe, Sweden
Background: Small cell lung carcinoma (SCLC) is an extremely ag-
gressive form of cancer and the 5-year survival rate for these patients 
is only approximately 9-15%. Regions of hypoxia (~1% oxygen) 
often appear in solid tumors and are associated with aggressive tumor 
behaviour and poor outcome in several tumor forms. In response to 
hypoxia, tumor cells adapt by changing the transcription of genes 
involved in a variety of processes, like angiogenesis, cell survival, 
and metabolism. This adaptive response is primarily regulated by the 
transcription factors hypoxia-inducible factor (HIF)-1α and HIF-2α, 
which become stable at low oxygen levels. Studies using among 
others neuroblastoma and breast carcinoma cells have demonstrated 
that HIF-1α primarily mediates acute hypoxic response, whereas 
HIF-2α mediates chronic responses to hypoxia. Here we study the 
adaptive capacity of SCLC cells to hypoxia and evaluate the import-
ance of activation of HIF transcription factors in SCLC cells.
Methods: We investigated cell survival in a panel of SCLC cell lines 
cultured at different oxygen pressures. In these cells we also studied 
expression levels of known hypoxia-driven genes using quantita-
tive real-time PCR. Quantitative real-time PCR, Western blot and 
immunohistochemistry were used to characterise the expression of 
HIF transcription factors in SCLC cells as well as in SCLC speci-
mens. In all experiments non-small cell lung carcinoma cells and 
neuroblastoma cells were included for comparison.
Results: Our results show that SCLC cells adapt well to low oxygen 
pressures and the proliferation is only to some extent reduced at 1 % 
oxygen. Based on investigated genes, a moderate response to hypoxia 
seems to occur in SCLC cells, though the cells have a high adaptive 
capacity. In addition, the expression patterns of HIF-1α and HIF-2α 
differ in SCLC as compared to other forms of lung carcinoma.
Conclusions: Since tumor hypoxia correlates with poor prognosis 
it is important to elucidate how tumor cells adapt in response to 
hypoxia. As cultured SCLC cells grow well at hypoxia and only a 
moderate up regulation was observed for the investigated known 
hypoxia-driven genes upon hypoxia, our data indicate that a “typical” 
adaptive response to hypoxia does not occur in SCLC cells. This may 
be explained by the fact that the HIFs are differently expressed in 
SCLC cells as compared to non-SCLC cells and studies are ongoing 
to further characterise the hypoxic adaptive response in SCLC cells.
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Phase II study of temozolomide for relapsed sensitive or 
refractory small cell lung cancer
Pietanza, Maria Catherine; Pereira, Leanne; Dunne, Meghan; Travis, 
William D.; Chan, Timothy A.; Ginsberg, Michelle S.; Holodny, 
Andrei; Kris, Mark G.; Krug, Lee M.
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Background: Temozolomide is an alkylating agent approved for 
use in patients with glioblastoma multiforme and refractory astro-
cytoma. We designed this phase II study of temozolomide in patients 
with SCLC based on the following rationale: alkylating agents have 
established efficacy in SCLC; temozolomide penetrates into the 
central nervous system with the potential to treat the brain metastases 
commonly seen in SCLC; SCLC has aberrantly methylated MGMT, 
which is correlated with improved outcomes to temozolomide in 
glioma; anecdotal responses to temozolomide in patients with SCLC 
have been observed.
Methods: Temozolomide is administered to patients with relapsed 
sensitive (relapse after 60 days) or refractory (no response to initial 
therapy, or progression within 60 days) SCLC. Patients who have 
disease progression after one or two prior chemotherapy regimens are 
eligible. Additional eligibility criteria include Karnofsky performance 
status ≥ 60% and normal organ and marrow function. The primary 
endpoint is objective response rate. Temozolomide is administered 
daily for 21 consecutive days of a 28-day cycle. The starting dose for 
the first cycle is 75mg/m2/day. For those patients without grade 3 or 
higher toxicities at that dose, in subsequent cycles a single dose es-
calation to 100mg/m2/day is given. Treatment is to be continued until 
documentation of disease progression, unacceptable toxicity or with-
drawal. The target accrual is 64 patients. MGMT promotor methyla-
tion status is assessed in available tissue and in peripheral blood.
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Results: Fifteen patients (8 men, 7 women) have been accrued to 
date, of which 9 patients have sensitive and 6 have refractory SCLC. 
Temozolomide was second- and third-line treatment for 6 and 9 
patients, respectively. Nine patients have brain metastases. The 
median age is 66 (range 49 to 79). Thirteen patients are assessable 
for response. One patient has achieved a partial response and two 
patients have stable disease (confirmed responses). The remainder of 
the patients have had progression of disease within one cycle of treat-
ment. One patient received two cycles and three patients have been 
treated beyond two cycles of temozolomide. The overall response 
rate is 8%. Regressions have been observed in three patients with 
progressive brain metastases, including one patient with recurrent 
disease after whole brain radiation therapy. Toxicities include: grade 
3 lymphopenia (15%; requiring initiation of pneumocystis prophyl-
axis); grade 1/2 fatigue (46%); grade 1/2 emesis (23%); and grade 3 
rash and pruritis (15%). 
Conclusions: 1) In this ongoing trial, one partial response has been 
seen in a patient with sensitive SCLC. 2) Temozolomide causes 
regression in SCLC brain metastases. 3) Temozolomide is well toler-
ated when given on this dose and schedule. 4) Correlation of response 
with MGMT methylation status is underway and will be available by 
the time of presentation. Supported by Schering-Plough.
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In silico design of novel synthetic regulatory promoters with 
superior activitity and specificity for regulation of SCLC gene 
therapy
Poulsen, Thomas T.1; Gjetting, Torben1; Sandelin, Albin2; 
Christensen, Camilla L.1; Poulsen, Hans S.1
1 Department of Radiation Biology, Copenhagen, Denmark; 2 
Center for Bioinformatics, University of Copenhagen, Copenhagen, 
Denmark
Small Cell Lung Cancer (SCLC) is an aggressive disease with no 
satisfactory treatment presently available. Due to its disseminated 
nature SCLC must be treated systemically in order to target both the 
primary tumor and metastases. Transcriptionally targeted suicide 
gene therapy, where a cancer specific promoter region is used to 
regulate expression of a cytotoxic therapeutic gene, constitutes such a 
systemic strategy with a therapeutic potential for SCLC.
To date we have identified, cloned and evaluated three gene regula-
tory regions from the ASCL1, EZH2 and INSM1 genes alone and in 
combination for SCLC gene therapy. Of these, the ASCL1 and EZH2-
promoters in combination (ASCL1:EZH2) and the INSM1-promoter 
activates a reporter gene in SCLC cells, while only demonstrating 
background activity in a panel of control cell lines of different origin. 
When fused to either of two suicide genes, both ASCL1:EZH2 and 
INSM1 induce SCLC specific cell death. 
Although the promoters identified to date exhibit SCLC specificity 
and activity, it is likely that incomplete gene delivery and transfection 
efficiency of gene therapy in vivo may require even higher activa-
tion of gene expression in the tumor cells, than what can be obtained 
from the INSM1 and ASCL1:EZH2 promoter candidates. Moreover, 
these promoters are derived from genes associated with an embryonic 
phenotype and it may be necessary to target the cancer cells via dif-
ferent parts of the transcriptional machinery to compensate for tumor 
heterogeneity and avoid treatment resistance.
We have developed an in silico approach based on novel bioinform-
atic tools and gene expression microarray analyses to identify and 
extract novel specific promoter regions for SCLC gene therapy from 
SCLC specific genes. We have applied the method to identify and ex-
tract regions from the upstream regulatory regions of the INSM1 and 
ASCL1 genes. Potential regions exhibiting high conservation between 
mammalian species (indicative of functionality) have been identi-
fied, isolated and combined in a synthetic promoter construct, which 
is currently being evaluated in a reporter gene assay for specificity 
and activity after transfection of SCLC and control cells. Thus far we 
have demonstrated expression levels comparable to the highly active 
but unspecific SV40-promoter in SCLC cells and - compared to the 
INSM1 promoter - even lower activity in control cells of other origin.
These results are promising for the extension of this in silico strategy 
to genomewide datasets in order to identify, extract and combine 
extremely active and specific regulators for gene therapy and other 
malignancies. An update will be presented.
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The use of 3D conformal planning in the treatment of 
limited small cell lung cancer
Ryberg, Marianne1; Larsen, Jeanette H.1; Soendergaard, Jimmi2; 
Jeppesen, Nina3; Nielsen, Henrik A.4; Kamby, Claus1
1 Department of Oncology, Herlev Hospital, University of 
Copenhagen, Herlev, Denmark; 2 Department of oncology, 
Aarhus University Hospital, Aarhus, Denmark; 3 Department of 
Oncology,Roskilde Hospital, Roskilde, Denmark; 4 Department of 
Oncology and Palliation, Hilleroed Hospital, Hilleroed, Denmark
Background: Adding thoracic radiotherapy (RT) during chemother-
apy has improved the survival of patients with limited small cell lung 
cancer (LD-SCLC). In nearly all studies the thoracic RT have been 
planned using a 2D planning system. The value of a modern planning 
system as 3D has yet to be evaluated. 
Methods: Data were collected from patients with LD-SCLC referred 
to Herlev Hospital, University of Copenhagen, Denmark for RT 
from January 2002 to January 2008. Systemic treatment consisted 
of six cycles of intravenously; carboplatin AUC 5 (CrEDTAclear-
ence)), etoposide 120 mg/m2 days 1, 2 and 3 and vincristin 1.3 mg/
m2 (vincristin until 2007) all given day 1 every three weeks. The total 
radiation dose was 45.10 Gy delivered in 22 single fractions. The 
target included the primary tumor and enlarged lymph-nodes. If pos-
sible, normal lymph-node in stations 3-7 (Mouitains) and the whole 
ipsilateral hilar region also were included. A 3-D conformal planning 
system was used. No screening for CNS metastasis was performed. 
RT started as soon as possible after the first cycle of chemotherapy. 
Prophylactic cranial irradiation (PCI) was delivered with a total dose 
of 25 Gy in 10 fractions about three weeks after the last chemother-
apy cycle. Resist criteria were used for response evaluation. Toxicity 
was scored according to WHO guidelines. Statistics. Survival was 
estimated by Kaplan-Meiers survival plot. 
Results: Forty-eight patients were included. Thirty patients (62 %) 
were female and 18 (38 %) were male. The median age was 63 years 
(range 44-80 years). Forty-four (92%) patients received six cycles of 
chemotherapy. All patients completed the thoracic RT. Twenty-nine 
(60 %) patients received PCI. The median follow-up time was 41 
months (range 3 – 85 months). The median survival time after start of 
chemotherapy was 43 months (range 3- 85 + months), with 26 (52 %) 
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patients were still alive. Twenty-seven (56%) patients had complete 
response, nine (19%) partial response, five (10%) stable disease, 
three (6 %) progressive disease and while in four (8 %) patients the 
response status was not applicably. Relapse has occurred in 25 (52%) 
patients for a median time of 20 weeks (range 1 - 90 weeks). Local 
failure occurred in 15 % of the patients and 6 % had nodal relapse in 
the irradiation area. Thirteen (27%) patients developed CNS metas-
tases and in six of those patients (13 %), there were no other sign of 
recurrence. The cause of deaths was; progressive disease, 12 patients, 
CNS metastasis, six patients, and treatment related toxicity one 
patient (as the patient developed severe dementia six weeks after the 
PCI). Furthermore, three patients died of other causes with no sign of 
relapse. Acute RT toxicity: five (10%) patients had oesophagitis grade 
III and one (2%) had grade IV. One patient developed stricture of the 
oesophagus. 
Conclusion: The use of 3D conformal planning system in patients 
with LD-SCLC seems to have a positive impact of the outcome of the 
treatment. Furthermore, the once daily RT schedule used in combina-
tion with six cycles of chemotherapy seems to be well tolerated.
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Therapy efficacy, clinical research regulation and the pace 
of progress
Stewart, David J.1; Whitney, Simon2; Markman, Maurie1; Kurzrock, 
Razelle1
1 M. D. Anderson Cancer Center, Houston, TX, USA; 2 Baylor 
College of Medicine, Houston, USA
At the current pace of progress in lung cancer (survival probabil-
ity 13% in 1974, 16% in 2003), it will take >800 years to cure all 
lung cancers. We feel that regulators have set inappropriately low 
efficacy bars and inappropriately high safety bars. Together, these 
slow progress (JCO 2009;27:328-33). With respect to the efficacy 
bar, several different mutations may give rise to common tumors 
and each mutation may require distinct treatments. Large random-
ized trials can detect outcome differences of a few weeks and use 
the statistical power of large numbers to overcome the fact that only 
small subpopulations benefit from a therapy. If studies yield p>0.05, 
agents that are highly useful, but only in a minority of patients may 
be abandoned (eg, gefitinib in NSCLC). With p<0.05, the therapy 
may be widely applied, including to subpopulations that will not 
benefit (eg, erlotinib in NSCLC). Using a data set of 334 lung cancer 
patients, we simulated a therapy that quintupled survival time in 10% 
of the population with poor prognosis, 10% with good prognosis, 
10% in the middle of the curve, and 10% scattered evenly through 
the curve, and compared each of these to the original population 
(668 patient “studies”). For the 10% in mid curve, p was <0.05, but 
for the others, p was >0.05. Hence, the extent to which a drug target 
itself also alters patient prognosis may influence whether the drug is 
inappropriately abandoned or inappropriately applied widely. When 
we selected out the subpopulation “benefiting”, p was <0.02 with just 
8 patients per arm, indicating potential marked gains in clinical trials 
efficiency by identifying subpopulations affected. We feel molecular 
profiles should be assessed prospectively in patients from earliest 
phase I trials on, to permit the possibility of differentiating those 
who will vs will not benefit and to rapidly narrow down populations 
tested. We should aim for small trials with large gains, not large trials 
with small gains.
Safety & financial regulations governing clinical trials should also be 
altered. Currently these regulations are assumed to protect individ-
uals from harm and exploitation. However, actual benefit from some 
of the regulations has not been demonstrated, and they substantially 
decrease the number of new therapies that can be tested and mark-
edly escalate costs. Hypothetically, if it takes 10,000 patients studied 
to make an advance, if regulations (optimistically) decrease toxic 
death rates on study by 3%, and if average life expectancy of study 
participants is 12 months, then the regulations save 300 life-years. If 
the advance is delayed 5 years by the cumulative effect of regula-
tions (a conservative estimate?), if the new therapy increases lung 
cancer cure rates by 1% and increases median survival of uncured 
patients by 3 months, and if median survival of the cured patients is 5 
years, then the regulations cost 288,000 life years in the US and >106 
worldwide, seriously challenging equipoise. Both low efficacy bars 
and high safety bars in clinical trials may be detrimental and ethically 
questionable. 
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Prognostic factors for radiological response, survival and 
survival time in Small Cell Lung Carcinoma
van de Wal-Visscher, E. R.1; Martens, E. J.2, 3; van den Borne, 
B.E.E.M1
1 Department of Respiratory Medicine, Catharina Hospital, 
Eindhoven, Netherlands; 2 Department of Research and Education, 
Catharina Hospital, Eindhoven, Netherlands; 3 Centre of Research on 
Psychology in Somatic Diseases, Department of Medical Psychology, 
Tilburg University, Tilburg, Netherlands
Background: In literature extensive disease (ED) is reported as the 
most important prognostic factor for survival in patients with small 
cell lung carcinoma (SCLC). Prognostic factors for radiological 
response and survival time (ST) after treatment are unknown. The 
purpose of this study was to identify prognostic factors for radio-
logical response, survival and ST in patients with SCLC. 
Methods: Charts and radiographs of patients (N=135) diagnosed 
with SCLC from the first of January 2000 to the first of December 
2008 in the Catharina Hospital Eindhoven, The Netherlands, were re-
viewed. Predictors of response, ST and survival were assessed using 
regression analyses.
Results: Of 135 patients, 118 (87%) died. The mean ST for the total 
group was 294 days; for patients with limited disease (LD) (n=45) 
485 days and for patients with ED (n=90) 199 days (p<0.001). 
Patients with LD received more often treatment than patients with 
ED (91% versus 78%, p=0.056). In first line treatment, complete 
and partial response was seen in 23% and 71% respectively, in LD 
patients and in 8% and 72% in ED patients (p=0.102 and p=0.015). 
In second and third line treatment, complete response was not 
observed in either LD or ED. The mean time-to-progression in first 
line treatment was 259 days for LD and 102 days for ED (p=0.002). 
LDH was found to be the only significant predictor for response in 
the total group (OR:1.002; 95%CI: 1.00-1.01; p=0.030). With regard 
to mortality, predictors in the total group were stage of disease (OR: 
2.487; 95%CI: 1.49-4.17; p=0.001), age (OR: 1.039; 95%CI: 1.01-
1.07; p=0.004), performance score (OR: 2.047; 95%CI: 1.36-3.09; 
p=0.001), and a trend was observed for pleural effusion (OR: 1.547; 
95%CI: 0.94-2.55; p=0.088). Stratifying by LD and ED, pleural effu-
sion (OR: 4.506, 95%CI: 1.64-7.49; p=0.001) was predictive of mor-
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tality in LD and age (OR: 1.057; 95%CI: 1.03-1.09; p≤0.001), per-
formance score (OR: 2.293; 95%CI: 1.61-3.26; p≤0.001) and number 
of metastatic locations (OR: 2.354, 95%CI: 1.43-3.89; p=0.001) were 
significant predictors in ED. With regard to ST in the total group, sig-
nificant predictors were stage of disease (β; -0.315; 95%CI: -596.5--
1422.7 p=0.001), age (β: -0.171; 95%CI: -12.1--0.48; p=0.034) and 
there was a tendency for pleural effusion (β: -0.147; 95%CI: -234.2-
8.6; p=0.068). In the LD group, the only significant predictor for 
ST was pleural effusion (β: -0.312; 95%CI -592.8--19.9, p=0.037). 
In the ED group, significant predictors for ST were age (β: -0.200; 
95%CI: -10.3--0.06; p=0.048), performance score (β: -0.328; 95%CI 
-180.3--44.2; p=0.002) and number of metastatic locations (β: -0.240; 
95%CI: -217.6--20.0; p=0.019).
Conclusions: We confirm that stage of disease is an important prog-
nostic factor for survival and ST in SCLC patients. Other prognostic 
factors are age, performance score, pleural effusion and the number 
of metastatic locations. The level of LDH is predictive for radio-
logical response. Radiological response itself is not observed as a 
predictive factor for survival and survival time.
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Concurrent chemoradiation (CRT) with conventional 
fractionation for limited disease small cell lung cancer 
(SCLC-LD): a retrospective analysis in a single institution
Vandenbroucke, Elke; Pelgrims, Ans; Lievens, Yolande N.; Moons, 
Johnny; Vansteenkiste, Johan; Nackaerts, Kristiaan
Leuven Lung Cancer Group UZ Gasthuisberg, Leuven, Belgium
Background: CRT followed by prophylactic cranial irradiation (PCI) 
is now the standard of care in patients (pts) with SCLC-LD. Recent 
meta-analysis put major emphasis on the importance of short overall 
treatment time and early incorporation of radiotherapy, favouring 
hyperfractionated schedules. This retrospective study reports on sur-
vival, response rate and treatment-related toxicity of SCLC-LD pts, 
treated with a concurrent CRT schedule with conventional fractiona-
tion.
Methods: All consecutive pts with confirmed diagnosis of SCLC-
LD and good PS, who were treated with concurrent CRT between 
February 2002 and October 2006, were retrospectively reviewed. LD 
was determined using CT-scan of the chest and upper abdomen, bone 
scan, brain imaging and FDG-PET-scan (in most cases). Treatment 
regimen consisted of 4 cycles of cisplatin (60 mg/m2 d1,Q3w) and 
etoposide (120 mg/m2 IV d1-3,Q3w) and 3D conformal thoracic 
radiotherapy (TRT) up to a total dose of 50 Gy/2 Gy starting on day 
1 of cycle 2. Clinical response after CRT was evaluated with CT-
(PET)-scan and pathologically confirmed where possible. In case of 
complete response (CR), PCI (30 Gy/2 Gy) was given within 6 weeks 
after completion of chemotherapy.
Results: In total 39 SCLC-LD pts were screened, but 5 were 
excluded due to mixed type SCLC/NSCLC (2 pts) or change to 
sequential CRT (3 pts). Finally, 34 pts were included for analysis (25 
male, 9 female), median age 59 years (range 39-72) and PS-WHO 
0-2. Clinical TNM-stage was cT1-4N0-3M0. Histology was obtained 
with broncho-scopy/TBNA (65%), mediastinoscopy (32%) or thora-
coscopy (3%). 
Median treatment time for CRT was 70 days of which 33 days for 
TRT. CRT was well tolerated except for fatigue (CTC-grade 1 in 
3%, grade 2 in 26%) and dysphagia/oesophagitis (CTC-grade 2 in 
56%, grade 3 in 3%). No radiation pneumonitis was reported. Severe 
neutropenia grade 3/4 was seen in 64% and thrombocytopenia grade 
3/4 in 12%. There were no treatment-related deaths.
CR was achieved in 23 pts (68%), pathologically confirmed in 41%. 
In 9 pts with PR (26%) no PCI was given, while 2 pts (6%) had pro-
gressive disease in the bone and brain respectively.
With a median follow-up of 23.4 months, the overall survival in the 
intention-to-treat population was 30.7 months, with 1-, 2- and 5-year 
survival rates of 76%, 50% and 36% respectively. In pts with CR, 
median recurrence-free survival was not met, whereas it was 6.6 
months in the non-CR pts (p=0.0011).
Of the CR-pts, one pt (4%) had an in-field local relapse only, while 
distant metastases occurred in 7 pts (30%). 3 pts (13%) had brain 
metastases which was the first site of recurrence in 1 pt. Local and 
distant relapse at the same time was noticed in 2 pts (9%). 
Conclusion: The favourable outcomes and acceptable toxicity 
for SCLC-LD pts treated with concurrent CRT with conventional 
fractionation followed by PCI, are comparable to other series. In our 
institution, CR was high and comparable to some CRT reports using 
hyperfractionated radiotherapy schedules.
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Phase II trial of consolidation chest radiotherapy for 
extensive stage small cell lung cancer
Yee, Don1; Butts, Charles1; Chu, Quincy1; Fenton, David1; Joy, Anil1; 
Reiman, Anthony2; Smylie, Michael1; Roa, Wilson1
1 Cross Cancer Institute, Edmonton, AB, Canada; 2 St. John Regional 
Hospital, St. John, NB, Canada
Background: The usual initial treatment for extensive stage small 
cell lung cancer patients is palliative chemotherapy. Despite good 
response rates to chemotherapy, local intrathoracic recurrence 
rates post-chemotherapy are in excess of 50% and usually result 
in distressing symptoms such as dyspnea, cough, hemoptysis, pain 
and dysphagia, negatively impacting patients’ quality of life and in 
some instances, hastening their death. A recent randomized clinical 
trial demonstrated the local control and overall survival benefits of 
radiotherapy (RT) given to another common recurrence region (brain) 
in extensive stage small cell lung cancer patients who respond to 
chemotherapy, raising the question of whether or not chest radio-
therapy given to the same patient population would confer similar 
benefits. The efficacy of post-chemotherapy chest RT is not well 
defined. The purpose of this trial is to define the effect of applica-
tion of consolidation chest RT after chemotherapy in extensive stage 
small cell lung cancer on rate of development of symptomatic local 
recurrences.
Methods: Eligible patients had biopsy-confirmed extensive stage 
small cell lung cancer and attained an objective radiologic response 
after completing at least one cycle of chemotherapy. Eligible patients 
were also offered prophylactic cranial irradiation (PCI) as per depart-
ment guidelines. Target accrual was 30 patients. PCI and chest RT 
were given simultaneously 4-6 weeks after completion of chemother-
apy. Thoracic RT planning target volume included post-chemotherapy 
residual intrathoracic disease plus margin. PCI dose was 25 Gy in 10 
daily fractions over 2 weeks. Chest RT was planned using 3D con-
formal techniques and patients were prescribed 40 Gy in 15 fractions 
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over 3 weeks. Patients were followed regularly during RT for toxicity 
and after RT completion for local control, toxicity, disease-free and 
overall survival.
Results: Eighteen patients have been accrued. One patient died of 
liver failure before commencing RT. One patient quit chest RT after 
completing 11 fractions. All other patients completed prescribed 
RT with no treatment delays. Patients were prescribed 4 cycles of 
platinum-based chemotherapy. All patients completed prescribed 
chemotherapy except one, who had 3 of 4 prescribed cycles. Maximal 
acute RT toxicity was grade 2 radiation esophagitis. There were no 
treatment-related deaths. With a median follow-up of 7.8 months, the 
median time to disease progression was 8.1 months. Median survival 
has not been reached yet. Of the 17 patients who have received chest 
RT, there have been 3 intrathoracic recurrences (one hilar, two medi-
astinal). Other sites of failure include: leptomeninges, liver, supracla-
vicular nodes, bone and pericardium.
Conclusions: Our preliminary data suggests post-chemotherapy con-
solidation chest RT for extensive stage small cell lung cancer patients 
who respond to chemotherapy is well-tolerated and decreases local 
intrathoracic recurrence rate compared to historical data. Accrual 
to the trial continues and further follow-up with more patients will 
further define the efficacy of consolidation chest RT in this patient 
group.
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Temporal lung tumor volume changes in small cell lung 
cancer patients undergoing chemoradiotherapy
Yee, Don; Rathee, Satyapal; Robinson, Don; Murray, Brad
Cross Cancer Institute, Edmonton, AB, Canada
Background: The standard radical treatment for limited stage small 
cell lung cancer is concurrent chemoradiotherapy. Small cell lung 
tumors are characteristically very sensitive to both chemotherapy and 
radiotherapy, with typical response rates to treatment of 80-90%. The 
tumor volume response dynamics of small cell tumors treated with 
concurrent chemoradiotherapy have not been systematically quanti-
fied. The purpose of this work is to quantify variations in lung tumor 
volumes in limited-stage small cell lung cancer patients undergoing 
chemoradiotherapy treatments.
Methods: Eligible patients had pathologically-confirmed limited 
stage small cell lung cancer undergoing concurrent chemoradio-
therapy and provided study-specific consent. Thoracic radiotherapy 
started with cycle 2 of chemotherapy at the latest. Patients were 
prescribed four cycles of platinum/ etoposide chemotherapy. Patients’ 
radiotherapy was planned using conformal techniques which required 
they undergo a planning CT scan of their thorax for radiotherapy 
planning purposes. In addition to their planning CT scans, patients 
underwent serial chest CT scans using a CT simulator coupled with 
the Varian Real Position Management (RPM) device which times 
image acquisition to occur at the same phase of a patient’s respiratory 
cycle. Serial RPM-aided CT scans were planned to be obtained at the 
time of planning CT scan and then three times a week during radio-
therapy. The serial RPM-aided CT scans were transferred to a Varian 
Eclipse treatment planning station and gross tumor volumes were 
contoured on each scan. Gross tumor volumes defined on each serial 
CT scan were analysed for their changes over the course of each 
patient’s radiotherapy treatments relative to pre-radiotherapy scans.
Results: Five accrued patients have undergone chemoradiotherapy 
treatments and study scans. A total of 54 RPM scans were obtained 
during treatment (mean 10.8 scans/ patient, median 12 scans/ patient, 
range 5 - 15 scans/ patient). Patients received a mean dose of 50.3 Gy 
to gross disease (median 50 Gy, range 30 - 62 Gy). Mean radiother-
apy treatment time was 22.8 days (median 25 days, range 15-25 
days). Median GTV volume at the time of planning CT scan was 83.9 
cm3 (mean 152.8 cm3, range 57.8 cm3 - 412.4 cm3). Median GTV 
volume at the final serial CT scan was 12.9 cm3 (mean 25.3 cm3, 
range 9.24 cm3 - 81.6 cm3). The median, mean and range of amount 
of tumor volume shrinkage relative to the pre-radiotherapy CT scan 
occurring in each week of radiotherapy was: week 1: 30.2%, 41.0%, 
range 13.2% - 83.6%, week 2: 4.6%, 10.3%, 2.5 - 28.8%, week 3: 
5.3%, 5.5%, -3.5% - 11.4%, week 4: 1.7%, 2.0%, -2.7% - 7.2%, and 
week 5: 4.1%, 6.8%, 1.6% - 14.8%.
Conclusions: Dramatic shrinkage of small cell lung tumor volumes 
occurred in patients undergoing chemoradiotherapy on this trial, 
occurring mostly during the first week of radiotherapy. The observed 
dramatic shrinkage response may facilitate an adaptive approach to 
radiotherapy delivery for small cell lung cancers and allow for safe 
radiotherapy dose escalation.
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Carboplatin plus etoposide with sequential thoracic 
radiotherapy in limited disease small cell lung carcinoma
Yilmaz, Ufuk1; Anar, Ceyda1; Korkmaz, Esra2; Yapicioglu, Sena1; 
Halilcolar, Huseyin1; Karadogan, Ilker2; Akcay, Cimen2; Ozkok, 
Serdar1
1 Dept. of Radiation Oncology, Faculty of Medicine, University of 
Ege., Izmir, Turkey; 2 Dept. of Radiation Oncology, Suat Seren Chest 
Disease and Surgery Traning and Research Hospital, İzmir, Turkey
Background: Combined modality treatment with chemotherapy and 
radiotherapy in limited-disease small-cell lung cancer (LD-SCLC) is 
considered as standard therapy. However, there remains controversy 
over the optimal sequence of chemotherapy and radiation (concurrent 
or sequential), choice of chemotherapy agents, schedule and timing 
of radiation. The aim of this trial was to determine the efficacy and 
tolerance of carboplatin (C) plus etoposide (E) regimen followed by 
thoracic radiotherapy (TRT) in patients with LD-SCLC. 
Methods: The eligibility criteria are as follows: Previously untreated 
patients (pts) with histologically or cytologically confirmed LD-
SCLC, age ≥ 16 years, adequate organ function, ECOG PS 0 – 2, no 
logistic problems of the patients. Patients received four-six courses of 
carboplatin AUC 6 IV, day 1 and etoposide 100 mg/m² IV, days 1-3, 
followed by TRT (total dose 45-60 Gy, daily fractions 2 Gy). Cycles 
were repeated every 21 days.
Results: Between 2001 Feb and 2007 March, 47 patients were en-
rolled. 43 patients were evaluable for the objectives. 4 were deemed 
inevaluable for the following reasons: no avaliable baseline data 
(n=2), treatment refusal after enrollment (n=2). Radiotherapy was not 
delivered to nine patients due to early distant progression (n=2), poor 
performance status (n=1), early death (n=2), lethal treatment-related 
toxicity (n=4). But, these patients included to all of the analysis. 
Median age 62 years (range: 40–78); 38 males; performance score; 
ECOG 0-1 of 91%. A total of 214 cycles were administered dur-
ing the study with a median of 6.0 cycles per patient. Radiotherapy 
was delivered to the patients in the range of 46-60 Gy. The overall 
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response rate was 76.7% and 69.8% after chemotherapy and chemor-
adiotherapy, respectively. The median overall survival was 13.5 mo 
(95% CI; 10.6-16.4 mo. Fig 1). 1, 2 and 4-year survival rate was 
53%, 22% and 6%, respectively. The progression free survival (PFS) 
was 9.1 mo (95% CI; 8.0-10.2 mo.Fig 2). 1, 2 and 4-year PFS was 
34%, 10% and 6%, respectively. Prophylactic cranial irradiation was 
given in 15 (35%) patients. Seven (16%) patients suffered from fe-
brile neutropenia and four of these patients died . The other hemato-
logical and non-hematological toxicity profile of this treatment were 
mild with a 23% and 23% incidence of grades 3/4 neutropenia. 
Conclusion: The induction chemotherapy with carboplatin plus eto-
poside followed by TRT used in this study appears moderately effect-
ive but the toxic deaths were seen during chemotherapy in patients 
with LD-SCLC. The chance of the long-term survival in our patients 
were not high. The reasons of the results will be presented.
Figure 1: Overall survival
Figure 2: Progression free survival
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VP16-Ifosphamide, a non-platinum-containing 
combination for extensive Small-Cell-Lung Cancer 
(SCLC): a phase II French, open single-arm multicentric 
trial
Zalcman, Gerard1; Monnet, Isabelle2; Vaylet, Fabien3; Daniel, 
Catherine4; Madelaine, Jeannick1; Margery, Jacques3; Jabot, 
Laurence2; Porret, Emilie1; Zengerling, Valérie1; Poupon, Marie-
France4; Nemati, Fariba4; Decaudin, Didier4; Livartowski, Alain4
1 Caen University Hospital, Caen, France; 2 University Hospital CHI 
Créteil, Creteil, France; 3 Military Hospital Percy, Clamart, France; 
4 Curie Cancer Center, Paris, France
Background: Extensive Small Cell Lung Cancer is an aggressive 
malignancy, with still an abyssal median overall survival not exceed-
ing 10 months with etoposide/platinum-based chemotherapy. In such 
an incurable disease with short survival, the balance between efficacy 
and toxicity is meaningful for patients. Non-platinum-containing 
combinations have been extensively studied in NSCLC, but have not 
been evaluated in SCLC yet. We previously reported, in a model of 
SCLC-xenografted nude mice, that the association of Vepeside and 
Ifosfamide was not only equivalent, but superior, in terms of response 
and survival, to the classical vepeside-cisplatin doublet (Nemati F. et 
al. Clin Cancer Res. 2000). Therefore, we aimed to test twhether this 
doublet without platinum salt could represent a rationale alternative 
to the cisplatin-etoposide base regimens, in first or second-line set-
ting, in extensive SCLC.
Methods: Pluricentric open single-arm phase II trial, in 3 French cen-
ters, cancer center, military or university Hospitals. Eligible patients 
had histologically proved extensive SCLC, PS 0-2, no symptomatic 
cerebral metastasis, age under 80, normal renal and hematological 
functions. Primary endpoint: Response Rate (RR). Secondary End-
point: overall survival. Stratification factors: PS (0-1/2), first-line 
or second-line setting, metastasis site (brain/liver/others), center. 
Patients received Vepeside 80 mg/m2 D1-D3, Ifosfamide 2000 mg/
m2 (VP-Ifo), at D1-D3, on a 21-days schedule, until progression or 
toxicity with a maximum of 8 courses. Response was assessed every 
2 courses of chemotherapy, and the best overall response registered..
Results: 42 patients have been enrolled and 210 cycles have been 
administered (mean number of 5 cycles per patient). Mean age: 60.2 
(range 44.4-73.4), 1st-line setting: 39/42 (93%); WHO PS 0:1:2 = 
6 (14.3%):27 (64.3%):9 (21.4%). 18 (43%) of patients completed 
at least four courses of chemotherapy. 12 (28,5%) patients received 
up to 8 cycles. Of 42 pts assessed for radiological response, 32/42 
(76.2%; 95% CI [60.5-90.2]) had PRs+CRs, 5 (12%) PDs, 1 (2.38%) 
SD and 2 (4.76%) were non evaluable. Median overall survival (OS) 
was 10 months (95% CI [7.7-13.9]). Radiological responses were ob-
served in all kind of metastatic sites, and patients with non-symptom-
atic brain metastases were also shown to have encephalic metastasis 
partial or complete response, showing a good encephalic diffusion of 
this chemotherapy doublet without platinum.
Conclusions: VP16-Ifo doublet chemotherapy for extensive SCLC 
patients was well tolerated and the 10 months median overall survival 
compared favorably with published data obtained with platinum-
based chemo regimens, especially in patients with poor PS or mul-
tiple metastatic sites. Therefore we feel that those data deserve further 
confirmation in a prospective randomized phase III trial comparing 
this non-platinum containing doublet, with the classical etoposide/
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platinum based regimens, with special emphasis on quality of life. 
Up-dated tolerance and efficacy data will be presented at the meeting. 
P2.229 Small Cell Lung Cancer, Sun Aug 2 
Long acting somatostatin analogues in combination to 
antineoplastic agents in the treatment of SCLC patients 
(preliminary findings)
Zarogoulidis, Kostantinos1; Eleftheriadou, Ellada1; Gerasimou, 
Georgios2; Zarogoulidis, Pavlos1; Gkioka, Chrisoula1; Balassoulis, 
Georgios1; Sapardanis, Iordanis1; Kontakiotis, Theodore3; 
Gotzamani-Psarrakou, Anna2; Karatzas, Nikolaos4; Sichletidis, 
Lazaros5
1 Lung Tumour Research Section, Aristotle University Pulmonary 
Clinic, ‘G. Papanikolaou” Hospital, Exohi, Thessaloniki, Greece; 
2 2nd lab of Nuclear Medicine, Aristotle University of Thessaloniki, 
AHEPA Hospital, Thessaloniki, Greece; 3 Bronchoscopic Unit, 
Aristotle University Pulmonary Clinic, ‘G. Papanikolaou” Hospital, 
Exohi, Thessaloniki, Greece; 4 3rd Laboratory of Nuclear Medicine, 
Aristotle University of Thessaloniki, Papageorgiou Hospital, 
Thessaloniki, Greece; 5 Respiratory Dept, Faculty of Medicine, 
Aristotle University of Thessaloniki, Thessaloniki, Greece
Background: Long acting somatostatin analogues combined with 
platinum analogues have demonstrated an antiproliferative effect on 
growth of human SCLC xenografs. 
Method: 49 previously untreated SCLC patients with positive som-
atostatin receptors were included in the study. All patients performed 
111In-Octreotide scanning before CHT every 3 months and up to 4 
times. All patients were treated with paclitaxel 190mg/m2 + Carbo-
platin AUC=5.5 for up to 8 cycles. 48 hours after each CHT 16/49 
patients (Group A) also received 30mg somatuline® (lanreotide) in 
order to block somatostatine receptors for 2 weeks. 20/49 patients 
(Group B) received 60mg somatuline® to block somatostatine recep-
tors for 4 weeks. 13/49 patients (Group C, control) received only 
CHT. No differences were observed between the 3 Groups regarding 
LD and ED patient ratios, age and PS. Patients in Groups A and B 
after the completion of the CHT continued maintenance therapy with 
somatuline. Both non and hematological toxicity had no statistical 
significant differences between the Groups and generally toxicity was 
well managed.
Results: Group A (median: 11.33months, 95%CI: 8.53- 14.13) had 
a survival benefit (p<0.001) in comparison to Group B (median: 
6.9months, 95%CI: 6.5- 7.4). In comparison to Group C (median: 
8.83months, 95%CI: 2.33-15.33), Group A had a survival benefit only 
in limited disease patients (p<0.014). 
Conclusion: Long acting somatostatin analogues could be used as an 
additive therapy in combination to antineoplastic agents. However, 
further investigation is needed to establish the timing of somatostatin 
addition in relation to the administration of CHT and the duration of 
the blockage of somatostatin receptors. 
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Evaluation of outcome in 508 cases with small cell lung 
cancer by different modality therapy
Zhang, Yi
IASLC, Beijing, China
Background: To summarize the experience of treatment for small 
cell lung cancer(SCLC) in 508 patients and evaluate the effect on 
survival rate for SCLC by different modality therapy. 
Methods: A retrospective study was undertaken in 294 patients with 
SCLC who had undergone pulmonary resection (lobectomy 128, 
pneumonectomy 122, sleeve lobectomy 16 and segmentectomy 6) 
and in 214 patients who had undergone chemo/radio (VPCO, COM, 
EP, CE) therapy according to the new international staging sys-
tem(1997 system). 
Results: The 1-,3-,5-year overall survival rate was 65.9%(335/508), 
21.6%(97/449), 11.8%(49/416) respectively. Overall resection rate of 
surgery was 92.5%(272/294). The way of operation had no effect of 
long-term survival rate. The combined modality therapy in patients 
who selected surgery or chemo/radio therapy as first treatment was 
better than single therapy, but no difference of survival rate between 
two group of combined modality therapy. No difference of distant 
metastasis rate between surgery and no surgical treatment. 
Conclusion: These results in SCLC suggest that the operation should 
be considered as an important choice of surgery can not increase the 
distant metastasis probability. The combined modality therapy is still 
the treatment tendency of SCLC.
Surgery
P2.231 Surgery, Sun Aug 2 
Endobronchial chondroid hamartoma with an increased 
18F-FDG uptake in PET-CT
Onen, Ahmet; Orcen, Cihan; Kargi, Aydanur; Arslan, Asli; Akkoclu, 
Atila; Sanli, Aydin; Ozdemir, Nezih; Turan, Onur
Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey
A 71-year-old male patient was admitted to our hospital with dysp-
nea. A chest X-ray and thorax computed tomography revealed a mass 
of 4.5 x 3 cm, located in the inferior lobe of right lung. Fiberoptic 
bronchoscopy showed an endobronchial tumor totally obstructing the 
right lower lobe bronchus, and pathological examination of broncho-
scopic biopsy revealed a neoplastic, atypical lesion concordant with 
lipomasarcoma. PET-CT images demonstrated increased 18-F FDG 
uptake in lateral and posterior basal segments of the right inferior 
lobe with 5.2 as maximum standart uptake value (SUV). The patient 
who underwent right lower bilobectomy, had the diagnosis of endo-
bronchial chondroid hamartoma by histopathological evaluation of 
operation material. Pulmonary hamartomas are the benign neoplasms 
of the lung commonly seen in parencyma and rarely in bronchi. 
We would like to present a case of an endobronchial chondroid 
hamartoma which occluded the bronchus of right lower lobe, with 
increased 18-F FDG uptake in PET-CT. We hope to see that PET-
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CT, a non-invazive method, may be used as a alternative to invazive 
diagnostic methods in benign lesions like hamartomas. 
P2.232 Surgery, Sun Aug 2 
Tracheal bifurcation lymphangitis in lung cancer: a 
negative prognostic factor for surgical resection
Akopov, Andrey; Molodcova, Valentina; Bazanov, Andrey; 
Dvorakovskaya, Ivetta
Research Institute of Pulmonology, Pavlov Medical University, St. 
Petersburg, Russia
Background: The retrospective study evaluates the role of neoadju-
vant chemotherapy followed by surgery in non-small cell lung cancer 
patients with carcinomatous lymphangitis of tracheal carina. 
Methods: From January 1996 to December 2006, 29 patients with 
centrally located lung cancer who underwent pneumonectomies 
(17-right including 9-carinal, 12-left), had lymphangitis of tracheal 
carina, diagnosed preoperatively during bronchoscopy. Histological 
diagnosis was squamous cell carcinoma in 20 patients, adenocarcin-
oma in nine. 21 patients prior operation received three cycles of 
platinum-based chemotherapy; eight were operated without neo-
adjuvant treatment. All patients except the six underwent adjuvant 
chemotherapy.
Results: Preoperative chemotherapy resulted the macroscopic regres-
sion of tracheal lymphangitis in all 21 patients. In postoperative 
histological examination the bronchial resection margin was positive 
(R1) in 16 cases after chemotherapy (0,76) and in six cases without 
neoadjuvant chemotherapy (0,75). At the conclusion of the study 24 
patients died: one with post-operative complication, 23 with main 
disease progression. 5-year survival was 4,5% (median 13 months) 
with no statistically significant difference between patients with and 
without neoadjuvant chemotherapy (p=0,13), with positive and nega-
tive bronchial resection margin (p=0,37), who received and did not 
receive adjuvant chemotherapy (p=0,41).
Conclusions: Lymphangitis of tracheal carina is a negative prognos-
tic factor for surgical treatment of patients with non-small cell lung 
cancer. Although preoperative chemotherapy reduces lymphangitis it 
does not influence the radicalism of the surgical procedure.
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Thoracoscopic lobectomy: a safe and effective strategy for 
patients with early stage lung cancer
Allakhverdiyev, Arif; Laktionov, Konstantin; Polotsky, Boris; 
Davydov, Mikhail
N.N.Blokhin Cancer Research Center, Moscow, Russia
Background: Thoracoscopic lobectomy is emerging as a potential 
alternative to thoracotomy for early stage lung cancer. However, 
controversies about the procedure remain regarding the safety and 
associated morbidity and mortality of that procedure. This series is 
reviewed to assess these issues.
Methods: Between 2008 and 2009, we performed 28 thoracoscopic 
lobectomies in 10women (35.7%) and 18 men (64.3%), with a mean 
age of 55.3 years. All operated patients had clinical stage I or II of 
lung cancer. Right upper lobectomy met 8(28.6%), midell – 5(17.9%) 
and lower – 9(32.1%) from the total number of operated patients. 
Left completed 5(17.9%) lower and 2(7.1%) upper lobectomy. Of the 
primary lung cancers, 20 (80%) were adenocarcinoma. All patients 
with primary lung cancer performed hilar and mediastinal lymph 
node dissection. 
Results: Thoracoscopic lobectomy and mediastinal lymph dissec-
tion was successfully performed in 26 patients (92.9%); 2 patients 
required conversion to thoracotomy to control bleeding in the setting 
of dense hilar adenopathy. There were no intraoperative and perio-
perative deaths. Сomplications included pneumonia - 3 patients and 
prolonged air leak - 2 patients.
Median time to chest tube removal was 3 days, and median length of 
stay was 6 days.
Conclusions: Thoracoscopic lobectomy is a safe and effective strat-
egy for patients with early stage lung cancer. The risk of intraopera-
tive bleeding or recurrence in an incision seems minimal.
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Clinical impact of pleural lavage cytology before and after 
lung resection in non-small cell lung cancer patients
Aokage, Keiju2; Yoshida, Junji1; Ishii, Genichiro3; Hishida, 
Tomoyuki1; Nishimura, Mitsuyo 1; Nishiwaki, Yutaka1; Nagai, Kanji1
1 Division of Thoracic Surgery, National Cancer Center Hospital 
East, Kashiwa, Japan; 2 Thoracic Surgery Division National Cancer 
Center Hospital East, Kashiwa, Japan; 3 Pathology Division, 
Research Center for Innovative Oncology, National Cancer Center 
Hospital East, Kashiwa, Japan
Background: Pleural lavage cytology (PLC) for non-small cell lung 
cancer (NSCLC) has been reported to be a possible prognostic factor 
in resected NSCLC patients. However, many of the reports dealt 
only with PLC immediately after thoracotomy, before lung resection 
(pre-PLC). Although PLC after radical NSCLC resection and before 
chest closure (post-PLC) has also been appreciated by some studies, 
the comparative significance of pre- and post-PLC remains controver-
sial. The aim of this study was to analyze intraoperative pre-PLC and 
post-PLC results in NSCLC patients and clarify these roles in clinical 
practice.
Methods: From August 1992 through November 2006, we performed 
intraoperative PLC in 2494 NSCLC patients before (pre-PLC) and in 
2204 patients after (post-PLC) lung resection. We assessed the pre-
PLC impact on survival, comparing with 9 factors available before 
lung resection by multivariate analyses; age, gender, smoking index, 
preoperative serum CEA level, pre-PLC, clinical T status, clinical N 
status, clinical stage (univariate analysis only) and surgical (gross) 
pleural involvement. We also compared the impact with that of pleur-
al dissemination or malignant pleural effusion (D+). For post-PLC, 
we analyzed its survival impact in relation with 14 clinicopathologic 
factors including those available after resection, by multivariate 
analyses; age, gender, smoking index, preoperative serum CEA level, 
resection type, histology, differentiation, pathologic T status, patho-
logic N status, pathologic stage (univariate analysis only), pathologic 
pleural involvement, lymphatic permeation, vascular invasion, pre-
PLC result, and post-PLC result.
Results: Pre-PLC proved to be a strong independent prognostic 
factor among 9 factors available before lung resection, but the 
3-year and 5-year survival rates were 52% and 41% in the D- and 
positive pre-PLC group, significantly higher than 32% and 12% in 
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the D+ group, respectively. When factors available after resection 
were combined, post-PLC showed a stronger survival impact than 
pre-PLC. The post-PLC prognostic hazard ratio for overall survival 
was higher at 1.782 than that of pre-PLC at 1.546. The 16% 3-year 
and 2% 5-year recurrence free survival rates for positive post-PLC 
patients were significantly worse than the 77% and 70% for negative 
post-PLC patients, respectively. The post-PLC hazard ratio for recur-
rence was the highest at 2.946 among the clinicopathologic factors 
analyzed. The positive post-PLC population had a marginally, but 
not significantly, better survival compared with the population with 
dissemination. Almost all positive post-PLC patients relapsed within 
5 years.
Conclusions: Although macroscopic pleural dissemination is an 
indicator to discontinue NSCLC resection, positive pre-PLC patients 
fared better than to contraindicate lung resection. Pre-PLC is of less 
use in clinical practice. Post-PLC results are obtained after lung 
resection and therefore have no impact on surgical indications. A 
positive post-PLC result had an extremely strong impact on overall 
and recurrence-free survival. Its hazard ratios were almost identical 
to those of pathologic N status. We propose that positive post-PLC 
status should be classified similarly to dissemination with appropriate 
management.
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Subcarinal lymph node in upper lobe non-small cell lung 
cancer patients: is selective lymph node dissection valid?
Aokage, Keiju1; Yoshida, Junji2; Ishii, Genichiro3; Hishida, 
Tomoyuki2; Nishimura, Mitsuyo 2; Nagai, Kanji2
1 Thoracic Surgery Division National Cancer Center Hospital East, 
Kashiwa, Japan; 2 Division of Thoracic Surgery, National Cancer 
Center Hospital East, Kashiwa, Japan; 3 Pathology Division, 
Research Center for Innovative Oncology, National Cancer Center 
Hospital East, Kashiwa, Japan
Background: For the past 5 decades, the standard intervention for 
resectable non-small cell lung cancer (NSCLC) has been lobec-
tomy and systematic lymph node dissection (LND). Little has been 
investigated on selective LND. Systematic LND provides accurate 
nodal staging, which is a strong outcome predictor and determinant 
for adjuvant therapy. However, its role in improving survival remains 
controversial. We reviewed subcarinal node involvement for its 
frequency and impact on outcome to determine whether it is valid to 
omit subcarinal LND in upper lobe NSCLC patients.
Methods: We analyzed 1095 consecutive patients who underwent 
complete resection from August 1992 through October 2005 for 
NSCLC originated in the upper lobe. We reviewed mediastinal node 
metastasis distribution according to node region, tumor location, and 
histology. We paid special attention to subcarinal metastases patients 
without superior mediastinal lymph node metastases, because their 
pathological stages would have been underdiagnosed if subcarinal 
lymph node dissection had been omitted. To identify subcarinal 
lymph node involvement predictors, we analyzed 8 clinical factors.
Results: Only a small fraction of patients had subcarinal node metas-
tases (1.9%; 21/1095). Only one among 179 squamous cell carcin-
oma patients had subcarinal metastases. This patient had multiple 
pN3 metastases and died of lung cancer 17 months after resection. 
The 5-year survival rate of the 21 subcarinal metastases patients was 
8.6%, which was significantly lower than 31.5% of 140 patients only 
with superior mediastinal node metastases (p = 0.012). Of the 21 
patients with subcarinal node metastases, 2 (0.2% of the entire cohort 
of 1095 patients) had no superior mediastinal metastases. These 2 pa-
tients died of the disease at 1 month and due to an unknown cause at 
18 months, respectively. Of the 21 subcarinal metastases patients, 18 
recurred within 37 months and all of them developed multi-site recur-
rence. Clinical diagnosis cN1-2 of node metastases was significantly 
predictive of subcarinal lymph node metastases. Of the 122 cN1-2 
patients, 8 (6.6%) had subcarinal metastases pathologically. Seven 
of the 8 patients died of disseminated disease, and the remaining one 
died of other causes within 11 months.
Conclusions: Upper lobe NSCLC rarely metastasized to subcarinal 
nodes. Only 0.2% of the upper lobe NSCLC patients and no squa-
mous cell carcinoma patient would have been pathologically under-
staged, if subcarinal lymph node dissection had been omitted. The 
prognosis of patients with subcarinal lymph node metastases was dis-
mal. Clinical diagnosis of N1-2 was predictive of subcarinal lymph 
node metastases. However, only 6.6% of cN1-2 patients actually 
had subcarinal metastases and they resulted in dismal outcomes. It 
appears valid to omit subcarinal LND in upper lobe NSCLC patients, 
especially in clinical N0, squamous cell carcinoma patients.
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(Im) possibilities of complete thoracoscopic surgery
Bosch, Anne M.; Siebenga, Jan J.; Belgers, Eric H.; Bollen, Ewald C.
Atrium Medical Center Heerlen, Heerlen, Netherlands
Objective: In March 2006 we performed in our general hospital our 
first complete thoracoscopic lobectomy. Since then nearly all thoracic 
operations are started thoracoscopically and proceeded as long as 
there is no reason for conversion to a thoracotomy. Not only the lob-
ectomy but a variety of other thoracic operations proved possible by a 
complete thoracoscopic procedure. 
Methods: We describe the effect of learning the thoracoscopic 
lobectomy on performing other thoracic procedures complete thora-
coscopically by showing the possible indications and restrictions of 
complete thoracoscopic operations in our hands.
Results: Between March 2006 and February 2009 290 patients 
underwent an intrathoracic operation. A total of 188 lungresections 
for parenchymal lesions (mainly (bi)lobectomies and wedgeresec-
tions) were performed. The remaining 102 operations included 
surgical treatment for empyema or haematothorax, biopsy of pleural 
or mediastinal laesions and pleurectomy with or without bullectomy. 
Hundred and ninety five of these operations could be performed 
complete thoracoscopically (67%). There is a considerable increase 
of this percentage over the last years as is shown in table 1.
Table 1: Percentage complete thoracoscopic operations in 2006 and 2008
  % scopic in 2006 % scopic in 2008
 (Bi)Lobectomy 16 74
 Wedgeresection (metastases or pro diagnosi) 42 69
 Bullectomy and pleurectomy 78 93
 Drainage of empyema or haematothorax 14 63
 Biopsies of pleural or mediastinal laesions pro diagnosi 100 100
 Mediastinal tumour resection 0 100
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Three times a complete thoracoscopic lobectomy was performed 
because of a benign laesion (one intrapulmonary sequestration and 
two persistent bronchiectasis of a whole lobe). Ten mediastinal 
tumours were resected, of which 7 could be resected complete thora-
coscopically. The histology of these tumours were leiomyosarcoma, 
haemangioma, thymic cyst, 3 schwannomas and 3 thymomas (once 
uncertain radical).
Reason for conversion was: no progression because of adhesion of 
the pleura (n =14), tumour to big (n=36), tumour to small to identify 
thoracoscopically (n=20), uncontrollable bleeding (n=5), marginal 
lungfunction to be ventilated on one lung (n=4) and logistics or 
unknown reasons (n=16).
Conclusions: Since we perform the complete thoracoscopic lobec-
tomy our experience in thoracoscopic lungresections in general as 
well as other thoracic surgical procedures has increased. Especially 
the mediastinal tumours are suitable for complete thoracoscopic 
resection. We think in the future the indications will extend and the 
ratios thoracoscopic vs thoracotomic approach will increase.
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A data base of lung cancer from the Instituto Nacional del 
Tórax (INT) (1994-19999): Its value for surgical treatment 
and follow-up
Guachalla, Jaime U.; Campos, Monica M.
Insituto Nacional del Torax, Santiago, Chile
Background: The first results of our retrospective database was 
presented to the IASLC 95% complete and coded. In 2003 from 
1025(4%) lung cancer patients admitted to the INT between 1994-
1999, 949(23%) had non-small Cell Lung Cancer (NSCLC) patients. 
The 222 patients with surgical treatment were reported. The purpose 
now is to determine the role of the database in the treatment of pa-
tients with NSCLC in the INT. 
Methods: From a similar method and of the Nacional Cancer Data 
Base, and the model from Hospital Sante Foi Canada and other 
Cancer Centres we analised the clinicopathological features, staging 
and survival. 
Results: There were 68% males, median age was 63 years, range 
34-83 years. Adenocarcinoma 37% and squamous 43%. In 60% the 
tumor was in the upper lobes and in 12% over 8 cm in diameter. 
From the known prognostic factors 35% lost more than 10% weight 
and 14% Karnofski was less than 70%. In 19% the stage was IIIB and 
IV, that means were selected for surgery patients with advanced and 
high tumour burden. 63(24%) had pneumonectomy and 55(25%) pa-
tients received adyuvant chemo and radiotherapy in other institutions. 
Survival in IA and IB stages was 50% at 1 year, 402% at 3 years and 
20% at 5 years. And in IIA and IIB stages 50% at 1 year, and 21% at 
3 years. Mean global survival was 43 months and median 20 months. 
This data was significant to learn more of lung cancer and to evaluate 
surgical treatment suggesting that this hospital population is idoneous 
for global evaluation of lung cancer in Chile. 
Conclusions: The known poor survival of lung cancer would im-
prove with new strategies. A prospective database from several Hos-
pitals is of prime importance to control cost- effectivity of diagnosis 
and treatment of cancer in Chile.
 Characteristics   n 
 Gender Females  72 (32)
  Males 150 (68)
 Age (years) Mean(range) 63 (34-83)  
 Ressidence Rural 70 (35)
  Santiago 130 (65)
  N/R 22 (9)
 Histology Squamous 93 (43)
  Adenocarcinoma 83 (37)
  Large Cell 39 (18)
  Bronchoalveolar 5 (2)
 Tumor site Upper lobes 133 (60)
  Middle lobes 15 (7)
  Lower Lobes 74 (33)
 Tumor size(cm) < 3 64 (33)
  >4_<8 108 (55)
  >8 24 (12)
  N/R 26 (12)
 Weifht Loss (in 6 months) No 71(64%)* (32)
  >10% 39(35%)* (18)
  N/R 112 (50)
 PS Karnofski >70% 113(86$(* (51)
  <70% 19(14%)* (9)
  N/R 90 (40)
 Clinical Stage  cIa 2 (1)
  cIb 42 (19)
  cIIa 6 (3)
  cIIb 39 (17)
  cIIIa 91 (41)
  cIIIb 30 (14)
  cIV 12 (5)
 *$ Unknown Prognostic factors   
  Treatment Characteristics of 222 pacients with NSCLC with surgical treatment 
 Characteristic n (%)
 Trearment  
  Surgical 167  (75)
  Adyuvant  
  Radiation 39(71%)* (18)
  CT/RT 13)24%)* (6)
  CT Surg 3(6%)* (1)
   
 Surgical Treatment  
  Lobectomy 156 (59)
  Pmeumonectomy 63 (24)
  Segment (RLL,ML, LLL)  3 (1
   
 Pathologic Stages  
  pIa 10 (4) 
  pIb 31 (14) 
  pIIa  8 (4)
  pIIb 41 (18)
  pIIIa 61 (27)
  pIIIb 49 (22)
  pIV 21 (9)
   
 *Percentage of Adjuvant Therapy  
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Surgical treatment for lung cancer in octogenarian 
patients
Chen, Donghong; Dong, Bing; Zhi, Xiuyi
Lung Cancer Centre, Capital Medical University, Beijing, China
Objective: To explore the clinical characteristics of bronchial carcin-
oma in elder patients and discuss the operative indication, surgical 
technique, and management in the perioperative period. 
Methods: From January 2001 to December 2005, 23 patients 
with bronchial carcinoma aged 80 and over received muscle-
sparing thoracotomy major pulmonary resection. The operative 
procedures were lobectomy(13 cases), pneumonectomy(3 cases), 
bilobectomy(3casea), sleeve lobectomy(2cases), and lobectomy plus 
wedge resection(2cases). Clinical data were analyzed retrospectively. 
Results: Of the 23 patients, 3 had stage I disease, 13 had stage II and 
7 had stage III disease. There were no perioperative death occurred. 
The most popular postoperative complications were cardiac arrhyth-
mia, pulmonary infection and hypoxemia. 
Conclusion: Elder age is not the major determining factor for sur-
gical treatment of bronchial carcinoma. Selecting potential patients 
suitable for surgical treatment Properly, sufficient preoperative prep-
arations, appropriate procedure of anesthesia and operation, intensive 
monitoring during the perioperative period and treating postoperative 
complications promptly are the key points to succeed.
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Analysis of prognostic factors of old surgical –treated non-
small cell lung cancer
Cui, Youbin; Fu, Xianming; Chen, Yulong; Lu, Tianming; 
Deslauriers, Jean; Liu, Guojin
Ffirst Hospital of Jilin University, Changchun, China
Background: The incidence of lung cancer in the elderly is increas-
ing in the world and this disease is an important cause of death. 
Surgical resection is the current mainstay of treatment for early 
non-small cell lung cancer (NSCLC).The aim of this study was to 
analyze the effectiveness of surgery in elderly patients with NSCLC 
and to evaluate the prognostic factors that influence survival in this 
population.
Methods: The clinical characteristic date were retrospectively ana-
lyzed from 150 patients of 70 years or older who underwent surgical 
resection for NSCLC between January 2000 and January 2004 at the 
first hospital of Jilin University. The relationship between prognosis 
and clinical characteristics, such as sex,smoking habits, pathological 
type,TNM stage, operation, were analyzed by Kaplan-Meier and the 
significance of prognostic factors was assessed by univariate and 
multivariate COX regression analyses.
Results: Overall 5-year survival rate was 44.7% in this series. There 
were significant difference of 5-year survival rate among different 
TNM stages(P=0.006) and histological types(P=0.005) . The patients 
who underwent wedge resection and lobectomy had a better progno-
sis than who underwent pneumonectomy(p=0.030). Age, sex,smoking 
habits and co-morbidity had no impact on survival rate. 
Conclusions: Elderly patients with NSCLC should not be denied 
surgical resection based on chronologic age. A good efficacy can 
be made in elderly patient with NSCLC by surgical treatment.TNM 
stage,histological type and Lobotomy are important prognostic fac-
tors in operated NSCLC in the elderly . Continued careful selection 
of elderly patients for surgical resection is important for acceptable 
operative results
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Comparison of the efficacy of two treatments in  locally 
advanced non-small cell lung cancer
Cui, Youbin; Liu, Guangming; Zhang, Jie; Zhou, Da
First Jospital of Jilin University, Changchun, China
Background: To investigate 133 patients with stage IIIB or IIIA 
NSCLC in our hospital to evaluate the different treatments of 
NSCLC.
Methods: From march,2000 to march 2005.there were 133 patients 
with  stage  IIIB or  IIIA NSCLC received surgical operation. They 
were divided into two groups according to treatment method: oper-
ation alone group(n=112)and preoperative neoadjuvant chemother-
apy group(n =21). The operative quality and curative outcome were 
compared between these groups.
Results: The gross complete resection rates and l-, 3-, 5-years 
survival rates are significantly higher in preoperative neoadjuvant 
chemotherapy group (45.8% and 41.4%, 33.2%, 23.1%) than those of 
in operation alone group (22.3% and 34.5%, 21.6%, 13.6%, P<0.05) 
respectively.
Conclusion: Compared with operation along, preoperative neoadju-
vant chemotherapy can obviously improve surgical curative effect in 
patients with operable locally advanced (stage IIIA or  IIIB) non—
small cell lung cancer.
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Effects of varying thoracotomies in treating elderly lung 
cancer patients
Dang, Wilfred1; Zhang, Xiaxin2; Khalifa, Abubaker2; Soeyonggo, 
Tony2; Miller, John2
1 St. Joseph’s Hospital, Division Thoracic Surgery, Department of 
Surgery, Mcmaster University, Toronto, ON, Canada; 2 St Joseph’s 
Hospital, Division Thoracic Surgery, Department of Surgery, 
Mcmaster University, Hamilton, ON, Canada
Background: Lung cancer is a leading cause of cancer-related 
deaths. Over half of all lung cancers are diagnosed in patients aged 
65 years or over. Because of the significantly higher surgical risks 
in this population group, some clinicians are reluctant to offer them 
surgical treatments. This has led to greater efforts in making surgeries 
safer for elderly patients. In this study, we compare postoperative 
outcomes in patients who have undergone Muscle Sparing Thoracot-
omy (MST) or Posterolateral Thoracotomy (PLT) to discern which 
approach provides optimal recovery times and minimal complications 
for elderly patients. 
Methods: Perioperative data from 1581 patient charts between years 
2002 - 2007 were retrospectively collected in a tertiary thoracic sur-
gical center. 282 individuals had confirmed diagnoses of lung cancer 
and underwent a MST (n=159) or PLT (n=123) by the same single 
surgeon. 100 and 69 of these patients were aged 65 years or older, re-
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spectively. Length of hospital stay (LOS), chest tube drainage (CTd), 
amount of intraoperative blood loss and number of postoperative 
complications were evaluated by thoracotomy types (MST or PLT) 
and age group (65 years and older, or 18-64 years old). Statistical 
analysis was completed using t-tests to compare average LOS and 
CTd. Fisher Exact Tests were used for analysis of blood loss and pos-
toperative complications between age groups and thoracotomy types.
Conclusions: Results of all patients have demonstrated that MST is 
consistently superior to PLT for LOS, CTd, postoperative complica-
tions, and blood loss (Results Table 1). However, due to small sample 
sizes, not every observation was found to be statistically significant. 
In addition, when looking within each age group, elderly patients 
experienced a significant difference in LOS with MST leading to 
shorter hospital stays (Results Table 2). While further analysis is 
still pending, we hypothesize that a similar trend will occur for other 
variables in the elderly population group. 
Results Table 1 – Comparison of Postoperative Variables between MST 
and PLT
 Variables Muscle Sparing Posterolateral Statistical 
  Thoractomy Thoracotomy Significance 
  (N=159) (N=123)
 Length of Hospital Stay (days) 8.74 (±7.28) 10.88 (±10.29) P=0.052
 Chest Tube Drainage Duration (days) 5.09 (±3.23) 7.77 (±6.99) P<0.05
 Post-Op Complications (Percentage of Total Patients) 23.39% 30.89%  P=0.2234
 Blood Loss (Percentage of Total Patients with >=500cc) 3.14% 4.88%  P=0.5415
Results Table 2 – Comparison of LOS between MST and PLT by Age
 Age Group Muscle Sparing Posterolateral Statistical 
  Thoractomy Thoractomy Significance 
  (N=159) (N=123)
 LOS for Patients 65 years of age or older (days) 9.14 (±6.35) 12.49 (±12.20) P=0.021
 LOS for Patients 18-64 years old (days) 8.07 (±8.63) 8.81 (±6.73) P=0.611
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Sclerosing hemangioma of the lung: a benign tumor with 
lymph node metastasis in mediastinum
Erdogan, Abdullah1; Baser, Hasan1; Ozbilim, Gulay2; Demircan, 
Abit1
1 General Thoracic Surgery, Akdeniz University, School of Medicine, 
Antalya, Turkey; 2 Pathology, Akdeniz University, School of Medicine, 
Antalya, Turkey
Sclerosing hemangiomas of the lung are very rare tumors and they 
are believed to be benign. However, the histopathologic findings and 
clinicopathological features of these tumors have not been elucidated. 
We report a case of sclerosing hemangiomas of the lung in a 32-year-
old-woman with a cough and left-sided thoracic pain. Computed 
tomography of the chest revealed a centrally located, irregular-
circumscribed and lobulated growth, measuring approximately 9 by 
10 by 10 cm in diameter in the left lung. Intraoperative findings were 
suggestive of a lung cancer. The tumor was completely removed by 
left pneumonectomy followed by systematic mediastinal lymphaden-
ectomy. The hystopathological investigation indicated a sclerosing 
hemangioma of the lung, a rare benign tumor. But there was a tumor 
metastasis in one station (aortic window, no: 5) lymph node. 
Sclerosing hemangiomas are true neoplasm derived from alveolar 
pneumocytes. Although, there has been some limited report concern-
ing this type of tumor; such as local recurrences, and pulmonary 
satellite nodule in the medical literature. There is very little data 
available on its potential malignant behavior; such as lymph node 
metastases. 
Conclusion: Generally, wedge resection is justified in the majority 
of cases, but in cases of uncertain intraoperative diagnosis, anatomic 
resection with systematic mediastinal lymphadenectomy is recom-
mended.
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Surgical margin recurrence in cases of sublobar resection 
for small sized peripheral lung cancer 
Funaki, Souichirou; Sawabata, Noriyoshi; Minami, Masato; Inoue, 
Masayoshi; Kadota, Yoshihisa; Utsumi, Tomoki; Shigemura, 
Norihisa; Tokunaga, Toshiteru; Nakagiri, Tomoyuki; Okumura, 
Meinoshin 
Osaka University Graduate School of Medicine, Suita-City, Japan
Backgroud: Small-sized (<2cm) peripheral lung cancer is considered 
as a suitable lesion for sublober resection, which is assessed by some 
clinical investigations. The lobectomy poses lower recurrence risk 
than sublober resection, but less postoperative respiratory function 
preservation. In contrast, limited resection has a merit on respira-
tory function, but the grade of curativity may be inferior to that of 
lobectomy. 
One of the crucial failures is surgical margin recurrence, which might 
be reduced by removal with a sufficient surgical margin distance from 
the tumor. We conducted a retrospective observation in this issue.
Methods: We retrospectively analyzed eight recurrent cases (5.9%) 
among 136 non small-size lung cancer cases performed limited resec-
tion in our institution from 1999 to 2008.
The recurrence pattern, gross findings, and pathological examination 
were assessed.
Results: There were 6 men and 2 female with a median age of 70 
years old (range from 39 to 77 years). The median tumor size was 
18mm (range from to mm). All CT images were solid lesions apptern 
and postoperative stage was IA in all cases. Wedge resection was 
performed in 5 cases, and segmentectomy in 3.
As for the recurrence pattern, surgical margin recurrence was 7, and 
lymph node recurrence was one. The postoperative histopathological 
diagnosis was squamous cell carcinoma in 2 and adenocarcinoma in 
6.In the 7 surgical margin recurrence, sufficient surgical margin (dis-
tance from the tomor to the margin > tumor size) was obseved only in 
2cases of wedge resection. 
Conclusions: Local recurrence rate was low in our sublober resection 
cases for small-sized peripheral lung cancer accompanied by high 
rate of surgical margin recurrence, which occurred mainly in cases of 
insufficient distance from the tumor to the surgical margin or wedge 
resection, thus segmentectomy with sufficient margin distance may 
be recommended for small sized peripheral lung cacner.
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Simultaneous mediastinal and pleural surgical staging 
procedure using N.O.T.E.S (Natural Orifice Transluminal 
Endoscopic Surgery) technology instrumentation
Assouad, Jalal; Steltzlen, Camille; Vignes, Stephane; Gounant, 
Valerie; Grunenwald, Dominique 
Department of Thoracic Surgery, University of Paris VI, Paris, 
France
Background: invasive mediastinal and pleural explorations remain 
the « gold standard » in lung cancer surgical staging. N.O.T.E.S. 
techniques are rapidly evolving and few applications in abdominal 
surgery have been reported yet. Recently, technical feasibility and 
safety of trans-oesophageal approach of the mediastinum and pleural 
cavity were achieved in animal models. Authors present the prelimin-
ary results of an experimental study using N.O.T.E.S instrumentation 
for the exploration of both mediastinum and thoracic cavity in human 
dead bodies.
Methods: an experimental work on refrigerated and non embalmed 
cadavers was initiated. The cadavers were free from chest and neck 
disease. Simultaneous exploration of the mediastinum and the right 
pleura through a unique cervical incision was achieved using as 
unique device a flexible endoscope. 
Results: mediastinal exploration was easy and allowed identification 
and adequate biopsies of mediastinal lymph nodes at levels 2R, 4R, 7 
and 4L [1]. A complete assessment of the pleural cavity and multiple 
pleural biopsies were performed through the same incision. A silicone 
chest tube 20 French was placed in the thoracic cavity at the end of 
the procedures. 
Conclusions: N.O.T.E.S techniques have already been evaluated in 
abdominal surgery. The potential advantages of their application to 
thoracic surgery are a diminution of chest pain and the ability of a 
simultaneous exploration of both the mediastinum and the pleural 
cavity and sheets. Actually, none of the reported procedures applied 
to the thorax through a natural orifice (trans-esophageal, or transdia-
phragmatic) can be considered as ethically acceptable due to a high 
level of major complications. Authors present a new minimal invasive 
approach for simultaneous mediastinal and pleural surgical staging 
avoiding these risks by the use of a small cervical skin incision. 
Reference:
1. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer stag-
ing. Chest 1997;111:1718-23
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Lung resection for bronchogenic carcinoma after 
pneumonectomy
Assouad, Jalal1; Mazzaschi, Olivia 1; Le Pimpec Barthes, Françoise 2; 
Gounant, Valerie 1; Riquet, Marc2; Grunenwald, Dominique 1
1 Department of Thoracic Surgery, University of Paris VI, Paris, 
France; 2 Department of Thoracic surgery, European Hospital 
Georges Pompidou, Paris, France
Background: after pneumonectomy for bronchogenic carcinoma, 
the residual lung may be the site of a new lung cancer or a metastatic 
spread. Surgery can be the therapeutic option only in a small propor-
tion of patients because of functional problems and surgical feas-
ibility. The aim of this study is to report the experience and outcomes 
of two surgical centres in pulmonary resection on the remaining lung 
after pneumonectomy for lung cancer. 
Materiel and Methods: between 1986 and 2007, we operated on 21 
patients for curative lung resection on the residual lung. There were 
19 males and 2 females. Median age was 60.46 years. Twelve wedge 
resections, 7 segmentectomies and two lobectomys were performed. 
Overall survival probabilities were calculated by the Kaplan-Meier 
method.
Results: no post operative mortality was observed. Four patients had 
postoperative complications. Pathologic diagnosis reveals a meta-
chronous cancer in 10 cases and metastases of the first cancer in the 
other 11 patients. The mean disease free interval was 57.84 months 
(ranged from 9 to 132). Mean preoperative Fev1 was 1467 (range 
from 920 to 2930) corresponding to 52% of predicted Fev1 (range 
from 39 to 96%). The overall median survival was 22.28 months, 
with a probability of survival at 3 and 5 years of 40% and 32% 
respectively.
Conclusion: limited resection for lung cancer on a single lung is 
a safe procedure with acceptable morbidity and mortality rates. In 
highly selected patients, surgical resection might prolong survival.
P2.246 Surgery, Sun Aug 2 
Prognosis and survival after surgery for lung cancer based 
on the proposed new TNM classification in the forthcoming 
edition of the TNM Classification of Malignant Tumours: 
Nippon Medical School Group’s experience
Haraguchi, Shuji; Koizumi, Kiyoshi; Mikami, Iwao; Nakajima, Yuki; 
Kinoshita, Hiroyasu
Nippon Medical School, Tokyo, Japan
Background: The seventh edition of the TNM Classification of Ma-
lignant Tumors is due to be published in the near future. 
Methods: We report prognosis after surgery for lung cancer based on 
proposals for the revision of the TNM stage groupings in the forth-
coming edition of the TNM Classification of Malignant Tumours by 
the IASLC Lung Cancer Staging Project. The survival rate was sta-
tistically analyzed using Kaplan-Meier estimated survival curves, and 
the significance of the difference was analyzed by the log-rank test. A 
statistical analysis was performed using SPSS 10.0 software package 
(SPSS, Inc, Chicago, IL, USA). P<0.05 was considered significant. 
Results: From January 1990 to March 2004, 1,659 patients under-
went lung resection with systemic lymph node dissection for non-
small cell lung cancer including squamous cell carcinoma, adeno-
carcinoma, large cell carcinoma, adenosquamous cell carcinoma 
at Nippon Medical School and Saitama Cancer Center. The overall 
5-year survival and median survival time by clinical and pathological 
stages using six and proposed seventh editions of the TNM was 
shown in Table 1 and 2, respectively. There were significant prog-
nostic differences between stage IA and stage IB, stage IIA and stage 
IIB, and stage IIIA and IIIB in the clinical stage due to the proposed 
seventh edition of the TNM, but there was no significant difference 
between stage IB and stage IIA, stage IIB and stage IIIA, and stage 
IIIB and stage IV. There were significant differences between each 
stage except for stage IB and stage IIA and stage IIIB and stage IV 
in the pathological stage due to the proposed seventh edition of the 
TNM. 
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Conclusions: The proposed new TNM staging system is useful in 
planning treatment, evaluating prognosis and survival, and exchan-
ging information than the previous staging system.
  Sixth edition    Seventh edition 
 Stage n 5-year MST p n 5-year MST p 
   survival    survival
 cIA 644 79 60  644 79 60 
 cIB 431 58 60 0.0000 370 57 55 0.0000
 cIIA 27 58 21 0.4153 148 61 59 0.8627
 cIIB 175 45 35 0.5534 123 44 27 0.0040
 cIIIA 275 45 25 0.5580 303 43 25 0.8184
 cIIIB 78 35 15 0.0608 46 30 11 0.0197
 cIV 25 28 18 0.9388 21 22 18 0.8356
 c0 2    2   
 cOccult 2  42  2  42 
 Total 1659    1659   
  Sixth edition    Seventh edition 
 Stage n 5-year MST p n 5-year MST p 
   survival    survival
 pIA 575 84 60  575 84 60 
 pIB 372 69 60 0.0000 303 69 60 0.0000
 pIIA 46 74 56 0.5618 165 66 58 0.4913
 pIIB 171 47 37 0.0040 147 45 31 0.0003
 pIIIA 270 36 22 0.0085 380 31 20 0.0012
 pIIIB 179 21 19 0.0087 48 18 13 0.0072
 pIV 42 22 14 0.1155 37 18 19 0.4714
 p0 4  60  4  60 
 Total 1659    1659   
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Evaluation of surgical treatment for lung cancer patients 
with the use of “Lung age”
Haruki, Tomohiro; Nakamura, Hiroshige; Taniguchi, Yuji; Miwa, 
Ken; Adachi, Yoshin; Fujioka, Shinji
Department of General Thoracic Surgery, Tottori University 
Hospital, Yonago-city, Japan
Background: The number of lung cancer patients with poor respira-
tory function due to conditions such as chronic obstructive pulmon-
ary disease (COPD) has been increasing yearly. Pulmonary function 
testing (PFT), which is preoperatively performed on lung cancer 
patients in general, is important for determining operative procedures, 
prediction and prevention of postoperative complications. However, 
the interpretation of the results is sometimes difficult not only for 
patients and their family, but also for medical workers. To explain the 
state of one’s respiratory function more easily, the Japanese Respira-
tory Society (JRS) recently proposed the concept of “Lung age” and 
is working to promote it widely. In the present study, we investigated 
whether Lung age could be a useful parameter for the selection of 
operative procedure and the prediction and prevention of postopera-
tive respiratory complications in lung cancer surgery patients.
Methods: The subjects were 308 patients who underwent surgery 
for primary non-small cell lung cancer. All patients routinely had 
PFT within a month before surgery. From the results of the examina-
tion, we calculated the Lung age in accordance with the calculation 
method advocated by JRS. The calculations were as follows:
Male: Lung age (years old) = (0.036 × body height (cm) – 1.178 – 
FEV1.0 (L)) / 0.028
Female: Lung age (years old) = (0.022 × body height (cm) – 0.005 – 
FEV1.0 (L)) / 0.022
According to the difference between the patients’ Real age and the 
calculated Lung age, the patients were classified into five groups: 
Real age–Lung age(R–L)>15:group A, 5<(R–L)≤15:group B, 
-5≤(R–L)≤5:group C, -15≤(R–L)<-5:group D, -15>(R–L):group 
E. Based on these classifications, we analyzed clinicopathological 
factors such as gender, smoking status, smoking index, pathological 
stage, histology, tumor differentiation, selected operative procedure, 
approaches, duration of postoperative chest drainage, and postopera-
tive respiratory complications and performed comparison among 
each group.
Results: The numbers of patients in each group were as follows: 
group A 37, group B 50, group C 73, group D 54, and group E 94. 
The mean Lung age of all the patients was 75.9±21.7 years old 
(mean±SD) (range:20-142). Clinicopathological factors associated 
with the group classification included gender (p<0.0001), smoking 
status (p<0.0001), pack×year of smoking index (p<0.0001), histol-
ogy (p=0.0002), and operative approach (p=0.0137). The respiratory 
morbidity rate was 11.4 % (35/308), and the mortality rate was 0.64 
% (2/308). The respiratory morbidity rate of each group were 2.7 % 
(1/37) in group A, 10.0 % (5/50) in group B, 8.2% (6/73) in group C, 
7.4 % (4/54) in group D, and 20.2 % (19/94) in group E, respectively. 
The incidence of these complication were significantly different 
among each group (p=0.0364).
Conclusions: The group classification by the difference between 
Real age and calculated Lung age is useful and convenient for the 
prediction and prevention of postoperative respiratory complications 
in lung cancer surgery patients.
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Novel method to repair huge tracheal defect by pectoralis 
major myocutaneous flap
He, Jianxing; Xu, Xin; Chen, Manyin; Li, Shuben; Yin, Weiqiang; 
Wang, Susheng; Gu, Yingying 
First Affiliated Hospital of Guangzhou Medical College, Guangzhou, 
China
Inflammatory myofibroblastic tumor is extremely uncommon in the 
trachea. Surgery is recommended when the air way is obstructive. 
The surgical technique and type of material used for repairing mas-
sive tracheal defeat is a big challenge for the thoracic surgeon. We 
present a case of repair and reconstruction of the thoracic trachea 
and right mainstem bronchus massive defect with a pectoralis major 
myocutaneous flap after an inflammatory myofibroblastic tumor 
resection. Through this case, we demonstrated the excellent sur-
gical technique used to manage the massive tracheal defect. Muscle 
myocutaneous flap provides a reliable material to repair and recon-
struct the huge central airway defect. This novel surgical procedure 
may open a new window for the treatment of extensive defect of the 
trachea.
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Respiratory fuction indications for pnemonectomy in lung 
cancer
Kajiwara, Naohiro1; Kato, Yasufumi1; Kakihana, Masatoshi1; Usuda, 
Jitsuo1; Uchida, Osamu1; Ohira, Tatsuo1; Kawate, Norihiko2; Ikeda, 
Norihiko1
1 Tokyo Medical University, Tokyo, Japan; 2 Waseda University 
School of Human Sciences, Saitama, Japan
Background: The operative method in lung cancer is generally deter-
mined by the resectable extent, which itself depends on the clinical 
stage, respiratory function and physical status.
The prognosis of pneumonectomy is poor compared with other opera-
tive methods, despite meticulous postoperative management. Thus 
the selection of pneumonectomy as a therapeutic strategy requires 
rigorous evaluation.
Methods: We retrospectively evaluated the outcome all 126 cases of 
pneumonectomy due to lung cancer in our hospital between 1990 and 
1998, based on their preoperative respiratory function. Furthermore, 
we reviewed the limiting criteria for the possibility of pneumonec-
tomy in terms of outcome and evaluated the appropriateness of the 
operative method.
The male: female ratio was 92:34, with an average age of 58.5 years 
(range, 17 to 77 years), with 7 under 40. The left: right ratio was 
59:67. They included 43 squamous cell carcinomas, 65 adenocarcin-
omas, 7 large cell carcinomas, one small cell carcinoma and 10 
others. The pathological stage was I in 11, II in 14, IIIA in 38, IIIB in 
34 and IV in 29.
Results: We examined factors affecting outcome in the first pos-
toperative decade. The 5-year survival rate and mean survival time 
(MST) were 44% and 49.2 months in stages I + II, 21% and 27.8 
months in stage IIIA, < 4% and < 20.5 months in stages IIIB and 
IV. Squamous cell carcinoma patients showed a significantly better 
outcome than those with adenocarcinoma (P < 0.01). The long-
term outcome was also significantly better for patients with normal 
pulmonary function compared with those whose %FEV1.0 and PaO2 
were less than 70% and 85 mmHg, respectively (P < 0.01).
Conclusions: The outcomes did not show any significant difference 
related to operation side, gender or age, but pathological type and 
postoperative stage were significant independent prognostic factors. 
In particular, among preoperative respiratory function tests, it was 
suggested that preoperative data of %FEV1.0 and PaO2 have marked 
influence on the long-term prognosis of lung cancer patients after 
pneumonectomy.
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Clinical features of primary lung cancer adjoining 
pulmonary bulla
Kaneda, Masanori2; Adachi, Katsutoshi2; Tarukawa, Tomohito1; 
Watanabe, Fumiaki1; Sakai, Takashi2; Nakabayashi, Hiroshi3
1 Mie University, Department of Thoracic and Cardiovascular 
Surgery, Tsu, Japan; 2 Mie Chuo Medical Center, Department 
of Thoracic Surgery, Tsu, Japan; 3 Mie Chuo Medical Center, 
Department of Clinical Pathology, Tsu, Japan
Purpose: A few investigators have suggested a possible association 
between lung cancer and pulmonary bulla. Its carcinogenic correla-
tion is not yet understood but some peculiar clinical features could be 
pointed out. The purpose of this study is to clarify some properties of 
the lung cancer that adjoined to the pulmonary bulla and to demon-
strate its problems.
Methods: 545 cases with primary lung cancer that underwent 
surgical operation from July 1998 to June 2008 were studied by 
re-evaluation of chest CT scan. The cancer adjoined the bulla in 19 
cases. In these instances, their clinical course, pathological findings 
and surgical results were investigated.
Results: Bulla/cancer incidence was 3.5% of surgical cases. All cases 
were men. Their average age was 60.8 years old (three under 50 years 
old). All were smoker. Average smoking history was 1.4 packs/37.3 
yrs. Initial symptoms were common respiratory symptoms in five cases 
(26.3%). Other symptoms were hemosputa and hoarseness in one case 
respectively. The other 12 cases (63.2%) were founded by surveillance 
chest CT scans or health check program. Growth pattern of the cancer 
was classified into three types. Cancer had grown up in the bulla in 
only one case (Type A, 5.3%). In 15 cases, cancer had grown up into 
the lung tissue adjoining the type II or type III bulla (Type B, 78.9%). 
In the other 3 cases, cancer was existed at the wall of small bulla (Type 
C, 15.8%). Histological type of the cancer was large cell carcinoma in 
Type A. In type B, the incidence of squamous cell carcinoma was high 
(1 ADC, 8 SCC, 3 adenosquamous, 2 large and 1 pleomorphic car-
cinoma) and differentiation of the cancer cells tend to be poor (1/G1, 
5/G2, 6/G3 and 3/G4). The same trend was also recognized in Type 
C (1 ADC, 1 SCC, and 1 large) (2/G2 and 1/G4). All cases received 
surgical resection successfully but one. Total pneumonectomy was 
necessary in two cases due to the invasion of metastatic lymph node 
to the right main bronchus. In one case after the induction chemother-
apy, resected mediastinal lymph nodes were fully metastatic, and he 
was decided to be incomplete resection. In four cases, pleural lavage 
cytology examined at the operation was positive, which means occult 
cancer dissemination into the pleural cavity. Preoperative staging was 
underestimated in 7 cases out of 19 (26.3%), especially due to the 
under estimation of N factor in 4 cases. The survival curve of the bulla-
cancer group was similar to that of Stage 3A.
Conclusion: Primary lung cancer adjoining pulmonary bulla tends 
to be poor in prognosis, even if it was small in size. Some reports 
also suggested a higher incidence of lung cancer among the patients 
with bullous lung disease in comparison with that among the general 
population. Low-density mass adjoining the bulla should be carefully 
examined and resected as soon as possible.
P2.251 Surgery, Sun Aug 2 
Barclay operation of the bronchial cancer invasion on the 
tracheobronchial angle (case report)
Ceylan, Kenan C.; Polat, Hakan; Akpinar, Deniz; Kaya, Seyda O.
Izmir, Turkey
Bronchogenic carcinoma involving the carina or tracheobronchial 
angle still presents a challenge to thoracic surgeons due to problems 
related to surgical technique and airway management.
A 43 year-old patient with hemoptysis was diagnosed non small cell 
lung cancer. After the examination he underwent to operation of right 
carinal sleeve, end-to-end anastmosis with left main bronchus and 
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trachea, end-to-site anastmosis with intermediate bronchus and left 
main bronchus (Barclay operation). There was no complication and 
mobidity. After the ten months follow up period he is healthy. 
Carcinoma involving the tracheobronchial angle is performed, with 
acceptable mortality and morbidity rate in selected patients. Because 
of the rare performed operation was occasionally seen presented with 
the review of the literature.
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Surgical resection for locally advanced lung cancer after 
induction therapy
Polat, Hakan; Ceylan, Kenan C.; Akpinar, Deniz; Kaya, Seyda O.
Izmir, Turkey
Background: Induction therapy in non small cell lung cancer 
increases resectability in especially locally advanced stage. In this 
study we analyzed our experience with resection after induction 
therapy in patients non small cell lung cancer.
Methods: Between 2004 and 2008, we reviewed the records of 64 
patients with non-small cell lung cancer after induction therapy. The 
patients were evaluated clinical findings, histology, surgical resec-
tion type, postoperative follow up and survival rate. All patients had 
potentially resectable disease.
Results: There were 61 male and 3 female patients in our study. The 
mean age was 55.1 years. Histology was reported squamous cell 
carcinoma in 41 patients, adenocarcinoma in 14 patients, large cell 
carcinoma in 2 patients and tumour necrosis in 7 patients. 39 patients 
had lobectomy while 23 had pneumonectomy and 2 had wedge 
resection. Complet resection rate was 94%. One patient had pos-
toperative mortality, 18 patients (28%) had morbidity. Most common 
morbidity was athelectasis. Survival analysis was performed using 
the Kaplan-Meier method. Bad prognostic factors were detected N2 
disease (p:0.027) and pulmonary artery invasion (p:0.039). The calcu-
lated 1-year, 3-year, and 4-year survival rates of all 64 patients were 
96.5%, 72.4% and 36.2% respectively.
Conclusion: Induction therapy in locally advanced lung cancer 
increases resectability and survival rate. We think that multicenter 
prospective investigations of induction therapy followed by surgey 
are necessary. 
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Lung cancer, tuberculosis and neoadjuvant therapy: the 
potential misleading triad
Ceylan, Kenan C.; Kaya, Seyda O.; Usluer, Ozan; Polat, Hakan
Izmir, Turkey
Background: The diagnosis and staging of coexistence of lung can-
cer and TB may cause certain problems for the clinician.The aim of 
this study is to elucidate the coexistence of lung cancer and tubercu-
losis. In addition, we want to draw attention to the development of 
TB after neoadjuvant chemotherapy in patients with lung cancer.
Methods: This retrospective study was inclusive of processing the 
preoperative and postoperative data obtained for 21 patients who 
underwent thoracic surgery for lung cancer with TB in our clinic at 
last five years. 
Results: Coexistence of cancer and TB was found in 2.8 % of the 
cases (21/749). History of TB was known before the surgery in 5 
(23.8%) patients while 16 (76.2%) patients were diagnosed with TB 
after surgery. Seven cancer patients, who developed TB afterwards, 
had a history of receiving induction chemotherapy. Eleven patients 
were diagnosed to have TB after the surgical intervention for medias-
tinal or hilar lymph nodes. Second primary lung cancer was suspected 
in two patients after the initial lung resections. 
Conclusions: Regarding the rare coexistence of these diseases, this 
problem should be taken into consideration as a misleading situation.
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Comparison of sleeve lobectomy and pneumonectomy for 
right side non-small cell carcinoma
Ceylan, Kenan C.; Akpinar, Deniz; Duman, Elif; Kaya, Seyda O.
Izmir, Turkey
Background: At the beginning, the sleeve lobectomy was performed 
the patients whom would not tolerated the pneumonectomy but 
recently sleeve lobectomy can be performed all of the appropriate pa-
tients with non small cell carcinoma. The aim this study is to compare 
the postoperative results of sleeve lobectomy and pneumonectomy in 
right upper lobe non-small cell carcinoma.
Methods: Between 2004 and 2008 retrospective analysis was done 
for 33 patients who had endobronchial lesion, main bronchus inva-
sion or central N0 or N1 tumors which were located at the right upper 
lobe of the lung. Right upper sleeve lobectomy was performed in 17 
patients and right pneumonectomy was performed in 16 patients. Pos-
toperative mortality, morbidity and survival was compared between 
the two homogeneous groups.
Results: The histologic type was predominantly squamous cell 
carcinoma, followed by adenocarcinoma in both group. In pneu-
monectomy group all of the patients had N0 disease, eight patients 
had N1 disease in sleeve resection group and adjuvant theraphy was 
performed these patients. Postoperative complication occured in 5 
(31%) patient after pneumonectomy and 6 (35%) patients after sleeve 
lobectomy. There were no operative mortality in two groups. Overall 
2-year after sleeve lobectomy was 92.8%, and after pneumonectomy 
32% (p=0.077). Statistical comparison of 2-years actuarial survival 
didn’t show a significant differance.
Conclusion: Sleeve lobectomy is achieved with similar morbidity 
and mortality with pneumonectomy. Especially in the right upper 
lobe tumors, sleeve lobectomy has much better long term results than 
right pneumonectomy.
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Local advanced lung cancer: optimal surgery strategies
Kshivets, Oleg
Thoracic Surgery Dep., Klaipeda University Hospital, Klaipeda, 
Lithuania
Objective: Survival of patients with local advanced non-small lung 
cancer (ALC) takes several months. Radical operations are com-
plex and remain the prerogative of world best surgeons. The search 
of optimal surgery strategies for AEC patients (ALCP) with stage 
T3-4N0-2M0 was realized. We examined factors associated with gen-
eralization of ALC after complete (R0) combined pneumonectomies 
and lobectomies (PL).
Methods: We analyzed data of 155 consecutive ALCP (age=58.5±8.2 
years; tumor diameter: D=6.7±2.6 cm) radically operated and 
monitored in 1985-2008 (m=143, f=12; pneumonectomy=88, bi/
lobectomy=67, mediastinal lymphadenectomy=155; combined pro-
cedures with resection of pericardium=48, atrium=6, aorta=4, v. cava 
superior=9, carina=19, trachea=11, diaphragm=16, ribs=41, liver=7, 
esophagus=6; only surgery: S=66, adjuvant chemoimmunoradio-
therapy-AT: CAV/gemzar+thymalin/taktivin+radiotherapy=52, 
postoperative radiotherapy=37; squamous=113, adenocarcinoma=30, 
large cell=12; T3=114, T4=41; N0=75, N1=35, N2=45; G1=35, 
G2=42, G3=78; stage IIB=60, IIIA=54, IIIB=41). Variables selected 
for 5-year survival (5YS) study were input levels of blood, biochemic 
and hemostatic factors, sex, age, TNMG, D. Survival curves were 
estimated by Kaplan-Meier method. Differences in curves between 
groups were evaluated using a log-rank test. Neural networks com-
puting, Cox regression, clustering, discriminant analysis, structural 
equation modeling, Monte Carlo and bootstrap simulation were used 
to determine any significant regularity.
Results: Cumulative 5YS was 58.3%, 10-years survival – 49.7%. 
91 ALCP were alive, 70 ALCP lived more than 5 years without any 
features of ALC progressing (life span: LS=2438.3±1004.2 days). 
60 LCP died because of generalization during the first 5 years after 
radical procedures (LS=462.0±367.8 days). AT significantly im-
proved 5YS compared with S (P=0.003 by log-rank test) and with 
RT (P=0.002). Cox modeling displayed that 5YS of ALCP after PL 
significantly depended on: N0-2, T3-4, sex, AT, prothrombin index, 
fibrinogen-B, heparin tolerance, thrombocytes, cell ratio factors 
(P=0.000-0.047). Neural networks computing, genetic algorithm se-
lection and bootstrap simulation revealed relationships between 5YS 
and N0-2 (rank=1), AT (2), histology (3), type of operations (4), G 
(5), RT (6), heparin tolerance (7), S (8), T (9), sex (10), recalcification 
time (11), fibrinogen-B (12), eosinophils (13), protein (14), Hb (15), 
lymphocytes (16), prothrombin index (17), ESS (18), thrombotest 
(19), monocytes (20), thrombocytes/Cancer Cells (21), segmented 
neutrophils (22), coagulation time (23), eosinophils/Cancer Cells 
(24), D (25). Correct prediction of 5YS after PL was 100% by neural 
networks computing (area under ROC curve=1.0; error=0.0021).
Conclusions: Optimal surgery strategies for ALCP are: 1) availability 
of experienced surgeons because of complexity of radical procedures; 
2) aggressive en block surgery and adequate mediastinal lymph-
adenectomy for completeness; 3) precise prediction; 4) adjuvant 
chemoimmunoradiotherapy for ALCP with unfavorable prognosis.
P2.256 Surgery, Sun Aug 2 
Management of a difficult tracheogastric fistula
Kurowski, Krzysztof; Navarro, Rafael David C.; Alcalde, Oscar L.
Hospital de Torrevieja, Torrevieja, Alicante, Spain
Granulomatous infection, foreign bodies, and trauma used to be the 
most common causes of benign acquired Tracheoesophageal fistulas. 
Added to these were fistulae from complications of surgical proced-
ures as Tracheogastric fistula after Akiyama procede due to esofageal 
cancer appears as a rare complication. Various treatment options have 
been described and the general consensus is to use stents to cover 
them and relieve patient symptoms, that in our case failed. We de-
scribe a case in which a surgical treatment - closure of tracheogasrtric 
fistula with pediculated muscle flap was successfully used.
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Isolation and characterization of tumor initiating cells 
from primary human lung large cell carcinomas - G1022 
and G1022A
Li, Huiling1; Xie, Siming2; He, Jianxing 1; Zhong, Nanshan 1
1 First Affiliated Hospital of Guangzhou Medical College, 
Guangzhou, China; 2 Postdoctoral station of Clinical Medicine, 
Jinan University, Guangzhou, China
Background: Lung cancer is the leading cause of cancer related mor-
tality in China with an estimation of 600,000 lung cancer deaths in 
2008. The majority of lung cancer patients are diagnosed in advanced 
late stages and are insensitive to conventional chemotherapies. 
Recent studies showed that the presence of cancer stem cells or tumor 
initiating cells may account for chemodrug resistance and tumor 
relapse in human cancers. In this study, we developed tumor initiating 
cell lines from primary human lung large cell carcinomas. 
Methods: A 69 year old male patient who lived in Southern China 
for over 50 years was referred to the First Affiliated Hospital of 
Guangzhou Medical College and State Key Laboratory of Respira-
tory. He was diagnosed with non-small cell lung cancer - undiffer-
entiated large cell carcinoma. Surgically resected tumor specimens 
from this patient was immediately processed aseptically and cultured 
in DMEM medium supplemented with 20% FBS, at 37 degrees C 
with 5% CO2. The original tumor cells were comprised of small 
spindle cells and large polygonal cells. These two types of cells were 
separated by flow cytometer and have been in continuous culture for 
6 months. 
Results: We have isolated and established two cell lines, G1022 and 
G1022A, from the primary lung tumors. G1022 was derived from 
the large polygonal cells and G1022A from the small spindle cells. 
G1022 grew half adherently to cell culture vessels with the popula-
tion doubling time of 23 hours. G1022A grew completely attached 
to cell culture vessels with the population doubling time of 19 hours. 
Results from soft-agar assays showed that both G1022 and G1022A 
cell lines were able to form colonies. The colony efficiencies were 
23.1% and 21.5% for G1022 and G1022A, respectively. In vivo 
tumorigenecity was carried out in athymic nude mice. Our results 
showed that both cell lines formed tumor xenografts by s.c. im-
planting one million cells for 2.5 months. Results from immunohisto-
chemical analyses revealed that G1022 cells showed vimentin (+), 
CK7 (-), epithelial membrane antigen EMA(+), EGFR (+) and P53 
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(+), while G1022A cells showed, with a weak tendency to differenti-
ate into glandular cells, vimentin (-), CK7 (+), EMA(+), EGFR (+) 
and P53 (+). 
Conclusion: In this study, we have isolated and established two cell 
lines from primary human lung large cell carcinomas that demonstrat-
ed tumorigenicity by colony formation assays in soft-agar and by in 
vivo xenogfrafts in nude mice. Further analyses with different cancer 
stem cell markers are underway. These two cell lines will be a valuable 
tool for further studies on the mechanisms for lung carcinogenesis. 
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Prognosis of lung cancer combined with idiopathic 
interstitial pneumonia
Matsunaga, Takeshi; Takamochi, Kazuya; Oh, Shiaki; Suzuki, Kenji
Department of General Thoracic Surgery, Juntendo University 
School of Medicine, Tokyo, Japan
Background: Idiopathic interstitial pneumonia (IIPs) is frequently 
consistent with primary lung cancer. Surgical indication is still con-
troversial because of a poor prognosis and high rates of postoperative 
complications. 
Patients and Methods: A retrospective study was conducted on 
35 lung cancer patients with concomitant IIPs, which were resected 
between January 2000 and December 2008. Among them, we in-
vestigated prognostic factors and predictors for postoperative lethal 
complications. Survival was estimated with Kaplan-Meyer method 
and the significance was evaluated with log-rank methods. 
Results: There were 30 men and five women and age ranged 53 
to 80 with a madian of 60. The actuarial 5-year survival of overall 
patients was 57.6%. The significant prognostic factors were as fol-
lows: gender (p< 0.05), age (p<0.05) and vital capacity (p<0.05) in 
the univariate analysis. Four patients developed postoperative lung 
injury (ARDS/ALI). In three of these patients, ARDS/ALI followed 
bronchopleural fistula (BPF) which was severe complication. BPF 
was related to right lower lobectomy (p<0.05) and Body mass index 
(BMI) (p<0.05).
Conclusion: Surgical outcome for lung cancer patients with idio-
pathic interstitial pneumonias was not so poor in this study. And we 
have experienced four severe complications of one postoperative 
acute ARDS/ALI and three BPF, and two patients of four had died.
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Video-assisted thoracoscopic surgery (VATS) 
segmentectomy for small lung cancer
Miyawaki, Michiyo; Tokuishi, Keita; Yamamoto, Satoshi; Yamashita, 
Shinichi; Kawahara, Katsunobu
Yufu-City, Japan
Objective: Segmentectomy for small or early stage non-small cell 
lung cancer(NSCLC) has been controversial. Further, video-assisted 
thoracic surgery (VATS) for lung cancer was accepted during the past 
decade. We show our procedure and outcome of VATS segmentec-
tomy.
Methods: In the retrospective study, between October 2003 and June 
2008, VATS segemntectomy was performed 44 patients. Of these 44 
patients, 35 underwent radical segmentectomy,and 9 patients without 
radical intent.
Results: Five of 38 VATS radical segmentectomy relapsed during 
the follow-up period. In the relapsed patients,3(7.9%)were local 
recurrence and 2(5.3%) were distant metastases.Five-year overall 
and disease-free survival of radical segmentectomy were 83.7 %and 
93.8%,respectively.
Conclusion: Although it remains controversial whether VATS seg-
mentectomy is an appropriate procedure for stage I NSCLC, VATS 
segmentectomy is the preferable procedure if adequate patient selev-
tion is possible. 
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Comparison of the surgical outcomes of VATS lobectomy, 
segmentectomy, and wedge resection for clinical stage I 
non-small cell lung cancer
Nakamura, Hiroshige; Taniguchi, Yuji; Miwa, Ken; Adachi, Yoshin; 
Fujioka, Shinji; Haruki, Tomohiro
Tottori University Hospital, Yonago, Japan
Background: Video-assisted thoracic surgery (VATS) for clinical 
stage I non-small cell lung cancer has been widely applied as a 
less-invasive surgical procedure, but the resection method is still 
controversial. We compared the surgical outcomes of lobectomy and 
sublobular resection (segmentectomy and wedge resection). 
Methods: Of 678 surgical cases for lung cancer between 1996 and 
2008, 375 patients with clinical stage I non-small cell lung cancer 
who underwent VATS (198 males and 177 females, aged 69.6 years, 
adenocarcinoma: 316, squamous cell carcinoma: 49, others: 10) were 
investigated. The surgical procedure was lobectomy in 269, segment-
ectomy in 31, and wedge resection in 75. The surgical outcome was 
compared among these 3 groups with regard to the over all survival 
and cause of death. 
Results: Regarding the demographic characteristics among three 
groups, the rate of elderly and male patients was high, and the tumor 
size was the smallest in the wedge resection group. The 5-year sur-
vival rate in all patients was 73.5%. Those by tumor size were 83.1, 
72.8, 53.4, and 47.6% in patients with a tumor size of 20 or smaller, 
21-30, 31-50, and greater than 50 mm, respectively, showing that the 
prognosis worsened as the tumor size increased. The 5-year survival 
rates of the lobectomy, segmentectomy, and wedge resection groups 
were 77.8, 86.4, and 47.6%, respectively, showing that the survival 
rate was significantly lower in the wedge resection group. In the 
wedge resection group, the 5-year survival rate was 87.5% in patients 
with positive intent surgery (16 cases), and 39.7% in those with 
negative conservative surgery (59 cases), and 7 of 18 patients with 
complications died of other diseases. On comparing postoperative 
pathological stage IA cases, the 5-year survival rates of those treated 
with lobectomy, segmentectomy, and wedge resection were 90.3, 100, 
and 57.2%, also showing a poor outcome in those treated with wedge 
resection. On the other hand, both lobectomy and segmentectomy 
showed the very expectable result. On Cox’s proportional multivari-
ate analysis including the sex difference and tumor size as co-influent 
factors, the surgical procedure was a significantly poor prognostic 
factor, and the hazard ratio of wedge resection relative to lobectomy 
was 4.66 (95% confidence interval: 2.52-8.64). 
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Conclusions: The outcomes of VATS applying lobectomy and 
segmentectomy for clinical stage I non-small cell lung cancer were 
equivalent, but that employing wedge resection was inferior, and the 
prognosis following limited wedge resection was particularly poor, 
with marked mortality due to other diseases. 
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Video-assisted thoracic surgery for clinical stage I lung 
cancer – Kanazawa experience
Oda, Makoto; Matsumoto, Isao; Tamura, Masaya; Shimizu, Yosuke; 
Fujimori, Hideki; Sawada, Koichiro; Ishikawa, Norihiko; Watanabe, 
Go
Department of General and Cardiothoracic Surgery, Kanazawa 
University, Kanazawa, Japan
Background: We evaluated our single institutional results of video-
assisted thoracic surgery (VATS) performed for lung cancer over 8 
years.
Patients and Methods: Between April 2000 and October 2008, a 
total of 409 (60.9%) underwent VATS among 602 resected lung can-
cer patients. Our indications of VATS for lung cancer were clinical 
stage IA lung cancer and clinical stage IB lung cancer less than 5cm 
in tumor diameter. VATS was performed via 5-7cm skin incision 
+ 1 port or via only 3-/4- ports. Operative procedures as a radical 
operation were partial resection in 58 patients, segmentectomy in 64 
patients, and lobectomy in 229 patients. 
Results: There was one patient with operative death including 
hospital death due to pulmonary thromboembolism. In a median 
follow up period of 22 months, the 5-year cause specific survival rate 
was 93.7%. According to operative procedures, the 5-year survival 
rates were 100% in patients underwent partial resection and seg-
mentectomy, and 91.1% in patients underwent lobectomy. According 
to pathological stages, the 5-year survival rates were 98.8% in 289 
patients with stage IA, 69.1% in 34 patients with stage IB, and 68.2% 
in 14 patients with stage IIIA.
Conclusions: VATS lobectomy and VATS intentional limited resec-
tion can be performed with low mortality and good prognosis for 
clinical stage I lung cancer patients.
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Recent results of postoperative morbidity and mortality 
for surgical resections in lung cancer
Oh, Shiaki; Takamochi, Kazuya; Sakuraba, Motoki; Anami, Yoichi; 
Suzuki, Kenji
Juntendo University School of Medicine, Tokyo, Japan
Background: Recent advancement in surgical resection of lung can-
cer changes the status of postoperative morbidity and mortality. The 
purpose of the present study was to identify the cause of mortality 
and preoperative risk factors.
Methods: Retrospective study was performed on 822 consecu-
tive patients who underwent pulmonary resection for primary lung 
cancer between October 1996 and December 2007 at our institute. 
Univariate and multivariate analysis using logistic regression models 
was performed for selecting predictors for postoperative 30-day or 
in-hospital mortality. The following factors were investigated; gender, 
age, preoperative pulmonary or cardiac complications, smoking 
status, operation time, blood loss at surgery, type of procedure, and 
postoperative complications. 
Results: Six postoperative deaths were found during the last 12 
years. Thirty-day and in-hospital mortality were 0.3% (2/822) and 
0.7% (6/822), respectively. The 6 deaths were caused by pneumonia 
(50%, n=3), unknown (17%, n=1), cancer death (33%, n=2). Based 
on multivariate analysis, operative time (min), postoperative pneu-
monia, and preoperative cardiac complication were selected to be sig-
nificant predictors for postoperative deaths following lung resection. 
Conclusions: Surgical mortality and morbidity was acceptable at our 
institute. Three clinico-surgical factors have significant relationship 
with postoperative deaths. Prevention of postoperative pneumonia is 
one of the most important factors for postoperative management in 
lung resection.
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Surgery and novel bronchoscopic technique in radical 
treatment of patients with bilateral NSCLC
Pikin, Oleg V.; Trakhtenberg, Alexander K.; Sokolov, Victor V.; 
Kolbanov, Konstantin I.; Telegina, Larisa V.; Amiraliev, Ali M.; 
Astakhov, Dmitriy N.
Moscow Gertsen Cancer Research Institute, Moscow, Russia
Background: Radical surgery in patients with bilateral NSCLC is a 
matter of discussion for decades due to poor functional condition in 
majority of cases. Prognosis of surgically treated bilateral NSCLC 
patients is generally poor with 5-year survival rate from 10,0 to 
25,0%. The study was aimed to define indications, prognostic factors 
and outcomes of surgery and novel bronchoscopic procedures in 
patients with synchronous and metachronous bilateral NSCLC.
Methods: 61 patients with bilateral (synchronous – 29, metachronous 
– 32) NSCLC were operated on in our clinic. Among them, bilateral 
pulmonary resections with systematic mediastinal lymphadenec-
tomy were performed in 38 (62,3%), radical surgery on one side 
with bronchoscopic procedures on contralateral lung in 23 (37,7%) 
patients. Pulmonary resections after left-side pneumonectomy were 
performed in 4 patients (lobectomy – in 2, sublobar resection – in 2). 
The majority of patients underwent consecutive surgical procedures 
in 6 – 8 weeks interval via thoracotomy. In cases of early central syn-
chronous or metachronous lung cancer confirmed by CT and EBUS 
we performed endobronchial photodynamic therapy (PDT) or argon 
coagulation as an alternative to standard surgical approach. 
Results: Postoperative morbidity and mortality was 19,7% and 
3,4%. Three and 5-year survival after bilateral pulmonary resections 
was 22,2% and 11,1% in patients with synchronous lung cancer 
versus 33,3% and 14,3% with metachronous disease. In the group of 
patients treated by combination of methods (surgery+endobronchial 
procedure) 3- and 5-year survival was 25,0% and 14,8 % in cases of 
synchronous versus 34,6% and 16,2% in cases of metachronous lung 
cancer. 5-year survival was significantly better in N0 patients (36,8%) 
versus 17,4% in N1 and 5,2% in N2 disease.
Conclusions: Surgery of bilateral NSCLC is indicated in patients 
with good functional status. Novel bronchoscopic technique in 
patients with early central synchronous or metachronous lung cancer 
is an alternative treatment for patients with poor respiratory function 
especially underwent pneumonectomy. 
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Metastasectomy and hyperthermic isolated lung perfusion 
with TNF and Melphalan
Ratto, Giovanni B.1; Alloisio, Antonella1; Piras, MariaTeresa1; Verna, 
Anna1; Maineri, Paola2; Lupi, Paolo2; Barraco, Alessandro1; Di 
Natale, Claudia1; Mazza, Federico1; Ferrari, Enrico1
1 Unit Thoracic Surgery, Dept Surgical Oncology, Nat Cancer 
Research Inst, Genoa, Italy; 2 Unit Thoracic Surgery, Santa Corona 
Hospital, Pietra Ligure, Italy
Background: Even in patients treated with complete resection of 
multiple lung metastases from sarcomas and systemic chemotherapy, 
pulmonary recurrence is frequent. This supports the need for a multi-
modality approach, in which surgery would remove all the detectable 
tumor burden, while regional chemotherapy would eradicate the 
microscopic foci. Sarcomas represent an ideal model for pulmonary 
perfusion, since metastases remain often restricted to the lung, at least 
during the initial distant spread phase. For the isolated lung perfusion, 
we adopted the same therapeutic schedule that already proved to be 
effective in the regional treatment of limb sarcomas: hyperthermia, 
TNF and Melphalan. The aim of the present study was to assess the 
feasibility and safety of the multimodality approach, as well as its 
pulmonary parenchyma toxicity. 
Methods: In a previous experience from our group using normo-
thermic lung perfusion with Platinum, a conspicuous interstitial 
and alveolar edema developed in the treated lung during the first 48 
hours from treatment. Accordingly, in this study single lung perfu-
sion was used. Six perfusions were performed in four patients. Staged 
thoracotomies were used in two patients with bilateral metastases. 
The administered doses of TNF (1 mg) and Melphalan (30 mg) were 
chosen according the literature data. Half doses (0,5 mg of TNF and 
15 mg of Melphalan) were preliminary tested in two patients without 
any toxic effect. Inclusion criteria were: 1) complete control of the 
primary sarcoma; 2) no extrapulmonary metastases; 3) multiple lung 
metastases judged completely resectable; 4) vital organ function 
consistent with the planned treatment; 5) signed informed consent. 
At surgery, all metastases were first identified and traced. Regional 
chemotherapy was given as the first treatment because blood supply 
was still not compromised. The pulmonary artery and a portion of the 
left atrium were occluded by vascular clamps and cannulated. The 
cannulas were connected to the perfusion circuit, basically consisting 
of an oxygenator, a roller pump, a reservoir, and a heat exchanger. 
Hyperthermic lung perfusion was done for 90 minutes. The circuit to 
systemic circulation leak was measured by 99m Tc (5 MBq) labeled 
eritrocytes. Lung damage was assessed at 1, 3, 6 and 12 months 
from perfusion by blood gas analysis, spirometry, and CO diffusing 
capacity; trans-bronchial biopsies were carried out in two patients at 
1 and 3 months from treatment. 
Results: The mean circuit to systemic circulation leak was 6.5%/
hr. Lung temperature range was 40.5-41.3 °C; lung perfusion flow 
rate was maintained between 370-510 ml/min, and mean pulmon-
ary artery pressure not exceeded 50 mm Hg. Lung perfusion was 
accomplished without any death, peri-operative complications or 
systemic toxicity. Patients were mechanically ventilated for 24 hours 
after surgery, and no interstitial or alveolar edema developed. The 
decrease of FVC and FEV1 values were compatible with the amount 
of the removed lung parenchyma. Trans-bronchial biopsies evidenced 
mild interstitial fibrosis. In two patients who completed the 12 month 
follow-up, CT scan showed no pulmonary relapse. 
Conclusions: Hyperthermic lung perfusion with TNF and Melphalan, 
coupled with metastasectomy, is feasible and safe. Systemic toxicity 
is nil, due to minimum leakage from the circuit. Its efficacy in pre-
venting pulmonary relapse remains to be demonstrated. 
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Direct cryosurgery for primary and secondary lung cancer 
– the Harefield experience
Roberts, Neil; Beeson, Julie; Maiwand, Omar; Anikin, Vladimir
Harefield Hospital, London, UK
Background: Many patients with thoracic malignancy are unsuitable 
for anatomic resection due to poor lung function, extensive disease 
stage or prohibitive comorbidity. 
Our institutaion has extensive experience in the use of cryosur-
gery for endobronchial palliation of both primary and secondary 
malignancy in the thorax. This paper reviews our series of patients 
receiving direct pulmonary cryotherapy for otherwise inoperable 
lung malignancy via thoracotomy or VATS. Our initial experience 
with direct cryosurgery took place in patients found inoperable for 
extensive pulmonary resection at thoracotomy. In such patients direct 
cryotherapy was applied to the tumour via the thoracotomy incision. 
Following encouraging results the procedure has been expanded as a 
planned intervention on patients unsuitable for pulmonary resection. 
Methods: Retrospective review of prospectively collected cryosur-
gery database from 2003 - 2008. Initial patients included were only 
those found inoperable at exploratory thoracotomy, however as the 
series progressed patients were included where direct cryosurgery 
was pre planned.
Histology was always confirmed with intraoperative frozen section 
prior to cryosurgery. 
Results: 34 patients are included in the series with mean age 66 
years ± 11.9. 27 patients were treated for primary lung cancer with 7 
treated for secondary lung malignancy. 4 patients received treatment 
via VATS and 30 via thoracotomy. Overall length of stay was 7 ± 3.0 
days with no pre discharge mortality.
At last follow up (ongoing) mean survival was 20.1 months ± 16.9. 
The most common post operative complications were prolonged air 
leak and chest infection requiring antibiotics. 
Conclusions: Direct cryosurgery is feasible via both VATS and thora-
cotomy. It is a useful adjunct to the surgeon when patients are found 
inoperable at the time of thoracotomy. 
As an elective procedure for patients unsuitable for standard lung re-
section, it should be compared with other forms of ablative procedure 
such as radiofrequency ablation, as such its role in the management 
of lung cancer is yet to be fully defined. It may be suitable for sub-
groups of patients not fit for lung resection who are also unsuitable 
for radiofrequency ablation.
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Prognostic evaluation based on a New TNM staging system 
proposed by the IASLC for resected non-small cell lung 
cancer
Rudzinski, Piotr; Kupis, Wlodzimierz; Orlowski, Tadeusz; Langfort, 
Renata
National Istitute of Tuberculosis & Lung Diseases, Warszawa, Poland
TNM classification is being widely used to establishe the stage of 
lung cancer and to make the right terapeutic decision possible. The 
IASLC introduced a new classicication that is supposed to work since 
2009.
Method: The data of 1672 patient operated in one institution between 
1998 and 2002 had been analyzed. Operating data, histology, follow-
up and survival detailes were collected in data base including every 
single patient operated on for primary lung cancer.
Results: Among 489 patients classified, according to old TNM sys-
tem, into IB group 9 (1,8%) were determined in new classification as 
IA, another 308 (63%) as IB, 103 (21,1%) as IIA, 69 (14,1%) as IIB. 
Among 381 patients classified in old TNM system into IIB group 169 
(44,4%) moved up to IIA group, 159 (41,7%) remained in stage IIB 
and 53 (13,9%) went down to IIIA. 5-year survival rates in subgroups 
created by new TNM system present quite remarkable differences in 
comparison to the old ones.
We have noticed that new classification brings statistically significant 
differences in survival rates in old stage IB. In groups IIB and IIIB 
this diversity was at border line of statistical significance. The divers-
ity in stage IV was not significant, however this group was relatively 
smallest.
It is also interesting that conciderable differences in 5-year survival 
rates appear in subgroups created by new staging even in lack of 
statistical significance.
Conclusions: Our analyze justified introducing a new staging when 
compared with the old one established in 1997.
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Induction Chemo-radiotherapy with TS-1 plus Cisplatin 
for patients with stage IIIA /IIIB non-small cell lung 
cancer
Seto, Takashi1; Ichinose, Yukito3; Sasaki, Tomonari2; Kometani, 
Takuro3; Osoegawa, Atushi3; Hirai, Humihiko3; Fukuyama, Seiichi3; 
Ondo, Kaoru3; Nosaki, Kaname3; Sugio, Kenji3; Oshima, Yumiko3
1 National Kyushu Cancer Center, Fukuoka, Japan; 2 Radiation 
Oncology National Kyushu Cancer Center, Fukuoka, Japan; 3 
Thoracic Oncology National Kyushu Cancer Center, Fukuoka, Japan
Background: Several small randomized trials showed the efficacy of 
induction chemotherapy before the resection than resection alone for 
stage III. Adding the thoracic irradiation for induction chemotherapy 
might course the high local disease control. Therefore active without 
increasing the sever toxicity regimen for induction therapy is war-
ranting. TS-1 plus cisplatin have a potential of at full dose concurrent 
use with thoracic irradiation without sever toxicities. We conducted 
the study to evaluate the feasibility of induction therapy of TS-1 plus 
cisplatin with thoracic irradiation. 
Methods: Patients with technically resectable IIIA/IIIB were treated. 
TS-1 40mg/m2 b.i.d were administered orally after the meal between 
day 1 to 14. Cisplatin 60mg/m2 was infused intravenously on day 1, 
this chemotherapy regimen was repeated 3 weeks. Thoracic irradia-
tion was performed at 2Gy par 1 fraction par day up to total 40Gy par 
4 weeks from day 1. Surgical resection was done within 4 weeks after 
the final thoracic irradiation.
Result: Eighteen patients with stage IIIA/IIIB NSCLC were enrolled 
to this study. Every 18 patients completed the 40Gy irradiation, 
Fifteen patients completed 2 cycle of TS-1 and cisplatin (1 patient 
did not recovered from G2 neutoropenia treated without TS-1, 1 
patient could not continue the TS-1 due to stomatitis and treated with 
vinorelbine and cisplatin at second cycle, 1 patient did not recovered 
from G2 creatinine treated without cisplatin). G3/4 toxicities were 
observed in neutropenia (11.1%), hemogrobine (11.10%) and one 
febrile neutropenia. One patient refused the operation. Seven patients 
were treated completely with pneumonectomy, 1 was bi-lobectomy 
and 9 were lobectomy. Five patients were treated median sternotomy 
and posterolateral thracotomy aprorch Pathological complete re-
sponse and down staging were observed in 3 and 9 patients respect-
ively. Post operable morbidities were observed in 9 patients but were 
controllable and no treatment related death was observed. Twelve 
patients received 2 cycle of cisplatin based adjuvant chemotherapy 
after the operation. 
Conclusion: TS-1 plus cisplatin with thoracic irradiation was one 
of feasible and active induction therapies. It is worth to evaluate this 
tri-modality in prospective multicenter trial.
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Effects of pulmonary veins ligation style for the patients’ 
stress and cardiac on lung cancer
Shen-tu, Yang
Shanghai Chest Hospital, Shanghai, China
Background: It is needed to explore the effects of operative on stress 
statue, myocardial damage and arrhythmia to lung cancer. This study 
would compare the effects of two styles of pulmonary veins surgical 
managements on lung cancer patients’ stress postoperative. 
Methods: 60 cases were divided into two groups randomly: the 
trunk-ligation group(trunk group, 30 cases) and the branch-ligation 
group(branch group, 30 cases). The blood concentrations of hydro-
cortisone (HC), blood glucose (BG) and cardial troponin-I (cTnI) 
were determined at diffident time point. The surgical data, the quan-
tum of pain and ECG also recorded. 
Results: 
1. The HC of the two groups’ ascend obviously on the end of oper-
ation and descend during postoperative.
2. The BG and HC show a direct positive correlation postoperative.
3. The cTnIs of the trunk group ascend immediately after operation, 
but there’s no statistically significance between two groups. 
4. The arrhythmia incidence is higher in the trunk group. 
Conclusion: 
1. The effects of two pulmonary veins operative-styles on pos-
toperative stress show no significance differences. 
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2. The operative-style of pulmonary vein trunk-ligation has a more 
obvious tendency to do harm to heart than that of pulmonary vein 
branch-ligation. 
3. The operative-style of pulmonary vein branch-ligation may 
reduce the arrhythmia incidence after operation.
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Prognostic Implication of Cytodiagnosis of Subclinical 
Pleural Effusion found at Thoracotomy in NSCLC Patients
Shiba, Mitsutoshi; Nagato, Kaoru; Iida, Tomohiko; Kakizawa, 
Kimitaka; Kunimatsu, Eiji; Matsuzaki, Osamu
Kimitsu General Hospital, Kisarazu, Chiba, Japan
Purpose: In order to clarify clinical implication and therapeutic strat-
egies managing subclinical malignant pleural effusion unexpectedly 
found at thoracotomy, we analyzed diagnostic results of cytodiag-
nosis of pleural effusion found at thoracotomy and prognosis of the 
patients treated in our institute retrospectively. 
Patients and Method: From 1999 to 2008, 444 non-small cell lung 
cancer patients were surgically treated in our institute. At the time of 
thoracotomy pleural effusion cytology (PEC) was performed in the 
cases that small amount of subclinical pleural effusion was found. In 
some cases pleural lavage cytology (PLC) was performed simultan-
eously. 
Result: In 168 patients (37.8%) out of 444, subclinical pleural effu-
sion was detected and PEC was performed. In 19 patients (11.3%) 
malignant pleural effusion was demonstrated. PLC was performed 
in 49 cases, and positive results were obtained in 5 cases (10.2%). In 
these five cases, PEC was also performed in four cases and positive 
results were also obtained in all cases. And in one case no pleural 
effusion was found. Post operative survival of malignant pleural effu-
sion group was 53.7% (4 years). And in seven p-N0 cases, 4 yrs post 
operative survival was 75% that was poorer than surgically treated 
stage one cases. 
Conclusion: Cytodiagnosis of subclinical pleural effusion found at 
thoracotomy was performed in 38% of surgical cases of NSCLC. 
Subclinical malignant pleural effusion found at thoracotomy may be a 
prognostic factor in clinical stage one case. PLC at the time of thora-
cotomy may become a complementary examination of PEC.
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Pulmonary resection for non-small cell lung cancer in the 
elderly
Shitara, Yoshinori1; Yajima, Toshiki1; Saitoh, Kana1; Osawa, 
Hidenobu1; Negishi, Takeshi1; Kamisaka, Koji1; Kuwano, Hiroyuki2
1 Isesaki Municipal Hospital, Isesaki, Japan; 2 General Surgical 
Science, Gunma University, Maebashi, Japan
Background: The purpose of this retrospective study was to inves-
tigate the morbidity, mortality, and survival of pulmonary resection 
for non-small cell lung cancer (NSCLC) in elderly patients in two 
subgroups:75 to 79 years old and 80 years or greater. 
Methods: From August 1991 to December 2008, 105 patients aged 
older than 75 years with NSCLC underwent pulmonary resection. We 
investigated patient characteristics, morbidity and mortality within 
30 days of operation, and long-term survival. These factors, hospital 
outcomes and survival were compared in two subgroups.
Results: There were 70 men and 35 women with a mean age of 78 
years: 83 patients were 75 to 79 years old, and 22 patients were 80 or 
older. The cancer was adenocarcinoma in 61 patients (58.1%), squa-
mous cell carcinoma in 39 patients (37.1%), large cell carcinoma in 3 
patients (2.9%) and others in two patients (1.9%). There were 73 pa-
tients with clinical stage I NSCLC. Co-morbidities were present in 37 
patients (35.2%). The surgical procedures comprised 91 lobectomies, 
3 bilobectomies, one pneumonectomy, and 10 sublober resections 
(one segmentectomy, 9 wedge resections). There were 35 patients 
(33.3%) underwent video-assisted thoracic surgery (VATS). Pos-
toperative complications occurred in 25 patients (23.8%). There were 
two operative deaths (1.9%). In octogenarian patients, postoperative 
complications occurred in 11 patients (50%) and operative mortality 
rate was 0%. Median hospital stay was 15.8 days. Median follow-
up was 31.4 months. The overall 5-year survival for the elderly was 
46.5% and 5-year survival for stage I NSCLC was 55.2% (75 to 79 
years old) and 55.7% (80 or older), respectively.
Conclusions: Elderly patient with NSCLC have increased morbidity. 
However, mortality and long-term survival of pulmonary resection in 
selected elderly patients are similar to younger patients.
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The impact of using the proposed IASLC definitions for 
T descriptors to non-small cell lung cancer (NSCLC): 
Experience at a community hospital in Buenos Aires, 
Argentina
Quadrelli, Silvia; Lyons, Gustavo; Chimondeguy, Domingo; Silva, 
Carlos; Jordán, Pablo
Thoracic Oncology Center, Hospital Británico, Buenos Aires, 
Argentina
Background: Controversy remains about using 3 cm as the cut-off 
value to define tumor size, as it may prove to be inadequate to predict 
differences in survival. The working group for the IASLC Inter-
national Staging Committee recommended changes in the seventh 
edition of the TNM classification. The purpose of this study was 
to evaluate the impact of the use of the new staging system on the 
categorization of patients and in their survival after resection of a 
NSCLC.
Methods: Between August 1985 and January 2007, 414 patients 
underwent pulmonary resection with a curative intention for NSCLC. 
Patients were included only if they were pathologically staged as N0-
M0. Patients we staged using the current T factor definition and also 
by using the new suggested T factor definition. 
Results: During the study period, 231 patients (173 men, 58 women, 
median age 62, range, 38 to 88 years) were identified as pN0. When 
the new T definition was applied 12,1 % changed their T factor clas-
sification and 17,7% changed their pathological staging: 6,1% were 
downstaged and 11,7% were upstaged. Among 103 patients in Stage 
IB 27 were upstaged and in the group of Stage IIIB (n = 14) all of 
them were downstaged. The current and new T definition were both 
efficient to differentiate survival between different stages but the new 
T definition showed a statistically significant difference between the 
two T 1 subgroups (93% versus 70% 5 years survival between T 1a 
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and T 1b, p =0,027) identifying a subgroup with a better prognosis (T 
1a). 
Conclusions: The results of this study show that the implementation 
of the new T classification in a group of surgically resected NSCLC 
patients may result in a significant number of patients changing their 
T factor. The clinical impact of the using the IASLC proposed staging 
system would be modest but relevant as the magnitude of change 
in survival may be in the range of the potential benefits of chemo-
therapy. Ideally it will allow an improvement of prediction of which 
patients harbor micrometastatic disease before undergoing surgical 
resection and the prediction of which patients would benefit from dif-
ferent systemic therapies. 
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The Results of surgical therapy for bilateral multiple 
primary lung cancers
Tsunezuka, Yoshio; Yachi, Tsuyoshi; Waseda, Ryuichi
Department of General Thoracic Surgery, Ishikawa Prefectural 
Central Hospital, Kanazawa, Japan
Background: With the development of diagnostic radiology 
containing computed tomography scanning and the spread of mass 
screening for lung cancer, and careful follow up of patients after lung 
cancer surgery, Synchronous or metachronous multiple primary lung 
cancer (MPLC) has increased in recent decades.This study reviews 
our experience in the clinical assessment and surgical management of 
bilateral multiple primary lung cancer (MPLC).
Methods: Between January 1998 and December 2008 a series of 
1004 patients with primary lung cancer underwent surgical resec-
tion in Ishikawa prefectural central Hospital. We could identify 20 
patients (2.0%) who had developed a MPLC using criteria set out by 
Martini and colleagues (J Thorac Cardiovasc Surg 70,606,1975).
Results: In these 13 patients had synchronous lesions, and the other 
7 patients had metachronous lesions. In 13 patients with synchron-
ous cancers, ten patients(77%) had N0 cancers in unilateral lung 
at least( BAC in 6). Patients with synchronous cancer had their 
unilateral cancer treated by lobectomy in 5 patients and one patient 
had bilateral cancer by lobectomy. One patient was treated by sleeve 
segmentectomy and four patients were done by bilateral limited re-
section (segmentectomy or wedge resection). While, the metachron-
ous cancers were treated by bilateral lobectomy in 3 patients. Among 
them, sleeve lobectomy was performed in 1 patients. The actuarial 
5-year survival for bilateral synchronous cancers was 65%. While the 
actuarial 5-year survival for second metachronous cancers was 48%. 
The 5-year survival difference for patients with bilateral synchronous 
cancers versus second metachronous cancers approached statistical 
significance (p<0.01).
Conclusion: A long term follow-up after the initial resection of the 
primary lung cancer is necessary, annual CT scanning is necessary 
for detection of early stage second lung cancer even after 5 years 
postoperatively. Limited operation such as extended segmentectomy 
or wedge resection must be considered to give a chance of second 
operation to patient with small-sized peripheral lung cancer. 
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Complication risk after lung resections for primary lung 
cancer: Younger patients with a comorbid disease versus 
older patients without a comorbid disease
Turhan, Kutsal; Ozdil, Ali; Cakan, Alpaslan; Cagirici, Ufuk
Ege University Faculty Of Medicine, Izmir, Turkey
Introduction: Pulmonary resection is the most effective method of 
controlling the local disease in patients with primary bronchial car-
cinomas, and is the only treatment consistently associated with cure. 
Although current operative and anesthetic techniques have resulted in 
significantly improved outcome, mortality and morbidity after lung 
resection for carcinoma are still high.
In this study, our aim was to compare the postoperative complication 
rates in young patients with a comorbid disease versus older patients 
without a comorbid disease with non-small cell lung cancer who were 
treated surgically and to investigate the effects of comorbid diseases 
and the age on postoperative complications.
Methods: Sixty-nine patients younger than 55 years (Group 1) and 
65 patients older than 65 years (Group 2) had been treated surgically 
for non-small cell lung cancer in our clinic between 2001-2007. All 
patients were reviewed retrospectively according to age, gender, com-
orbid diseases, histology, operation type and postoperative complica-
tions. 
Results: The mean ages of group 1 and group 2 were 47.9 ± 6.65 
years (range from 19 to 54 years), 69.3 ± 3.80 years (range from 65 to 
79 years), respectively. Twenty-seven (31.9%) patients had comorbid 
disease in Group 1 and fourty-eight (73.8%) patients had comorbid 
disease in Group 2. Postoperative complication rates in group 1 and 
group 2 were 24.6% (17 patients) and 32.3% (21 patients), respect-
ively. There was only one postoperative mortality in group 2.
There was no significant difference between two groups according 
to the effects of comorbid diseases on postoperative complication 
rates. We also did not find significant difference between the patients 
in each group according to comorbid diseases and postoperative 
complications.
Conclusion: This and previous studies have shown that properly 
selected elderly patients regardless of comorbid diseases, can tolerate 
lung cancer surgery as well as younger patients with a similar chance 
for cure. Older patients and patients with comorbid diseases may 
need to undergo a more rigorous pre-operative evaluation to ensure 
that surgery can be performed safely and with an acceptable risk. 
Furthermore no statistically significant difference between young pa-
tients with a comorbid disease and older patients without a comorbid 
disease was determined in our study. Therefore it can be concluded 
that advanced age and comorbid diseases cannot be accepted as any 
contrindication for lung cancer surgery.
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The importance of the type of resection in survival 
of patients with Stage I Non-small cell lung cancer: 
Comparision of sublobar resection and anatomic resection.
Turhan, Kutsal; Ozdil, Ali; Cagirici, Ufuk; Cakan, Alpaslan
Ege University Faculty Of Medicine, Izmir, Turkey
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Introduction: Surgical resection is the treatment of choice for stage I 
non-small cell lung cancer (NSCLC) and patients with stage I disease 
have the most favourable prognosis. Recurrence is the most common 
cause of mortality for NSCLC after resection. The most important 
factor that affects the rate of recurrence and survival is the type of 
resection (sublobar resection and complete (anatomic) resection).
The aim of this study is to evaluate the recurrence rates, disease free 
survival and overall survival rates of resected stage I NSCLC in 
groups of sublobar and complete resection.
Methods: Between January 1997 to December 2007, 107 patients 
(95 male, 12 female) underwent resections for pathological stage I 
NSCLC in our department. Recurrence rates, disease free survival 
and overall survival rates were analysed for the groups of sublobar 
(Group 1) and complete resections (Group 2). All patients were 
staged postsurgically according to the TNM classification of the 
American Joint Committee for Cancer Staging and Revised Inter-
national System for Staging Lung Cancer. No patients required 
neoadjuvant or adjuvant chemotherapy or radiation therapy.
Results: Twenty-one (19.6%) sublobar resections and 86 (80.4%) 
complete resections (7 pneumonectomies, 79 lobectomies) were 
performed. The mean age of the patients were 66.43 ± 6.47 years 
(range from 48 to 79 years) and 58.63 ± 10.05 years (range from 35 
to 86 years) in group 1 and 2, respectively. Recurrence after surgical 
resection was detected in 15 (71.4%) of 21 patients in group 1 and 
23 (26.7%) of 86 patients in group 2. There was significant differ-
ence between two groups according to the recurrence (p<0.005). The 
median follow up time was 30.0 months for overall survival and 24.0 
months for disease free survival. The means of the overall survival 
and disease free survival in group 1 were 51.08 ± 8.65 months and 
45.62 ± 9.63 months. In group 2 the means were 106.51 ± 5.53 
months and 106.24 ± 5.60 months for overall survival and disease 
free survival, respectively. We compared two groups acoording to 
overall survival and disease free survival with Kaplan Meier method. 
There was a significant difference between the groups for both overall 
survival and disease free survival (p<0.002). Cox regresion analy-
ses also showed that there was a significant difference between the 
groups. The patients in complete resection group lived longer (OR= 
3.137, 95% CI=1.485 to 6.625) (p=0.003)and the recurrence occured 
lately (OR=4.277, 95% CI=2.204 to 8.289)(p<0.00001).
Conclusion: The type of surgery (sublobar or complete anatomic re-
section) is a prognostic predictor for recurrence, overall survival and 
disease free survival in stage I NSCLC patients. Complete surgical 
resection should always be considered in appropriate candidates with 
resectable disease.
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Medical and economic aspects of minithoracotomy in 
diagnostics and treatment of peripheral lung neoplasms
Voitko, Oleksandr1; Zavertylenko, Sergii1; Batsey, Ivan1; Shvydak, 
Radeon1; Voitko, Volodymyr2
1 Kyiv City Oncology Hospital, Kyiv, Ukraine; 2 National 
O.O.Bogomolets Medical University, Kyiv, Ukraine
Background: High cost of equipment and consumables required 
for endoscopic surgery limit its use in diagnostics and treatment of 
peripheral lung neoplasms (PLN). One of the methods of lower-
ing traumatic impact and cost of surgery is minithoracotomy. Main 
minithoracotomy features are: decrease of intercostal muscles dissec-
tion’s length to 8-10 cm, absence of injuries of ligaments, sterno-
costal and vertebrocostal joints and regional neurovascular bundles. 
Therefore, minithoracotomy is roughly equal in traumatic impact to 
endoscopic surgery. Minithoracotomy can be done using traditional 
surgical tools. It does not interfere with direct palpation of pathologic 
focuses and thoracoscopy.
The aim of current work was to compare safety, efficacy and eco-
nomic impact of minithoracotomy versus traditional thoracotomy for 
diagnostics and treatment of PLN.
Materials and Methods: Following algorithm was used for diagnos-
ing and treating PLN:
• General clinical tests, chest X-ray and CT, transthoracal biopsy of 
the neoplasm for estimation of minithoracotomy site according to 
the neoplasm localization;
• Minithoracotomy, intraoperative revision of pleural cavity, resec-
tion of lung with neoplasm and intraoperative histopathological 
review of the resected material;
• Conclusion of the surgery or expansion of surgical access and 
extent of the surgery depending on pathohistology results and 
concomitant diseases.
Results: Investigational group included 62 patients who had surgery 
for PLN with minithoracotomy without conversion. Female – 29 
(46,8%), male – 33 (53,2%), aged 19-81 years.
Control group included 72 patients who had surgery for PLN using 
traditional thoracotomy and was similar to the investigational group 
in terms of pathological process nature, extent of surgery, age and 
gender structure.
Minithoracotomy was performed in the 3rd -6th intercostal space 
(based upon pre-surgery marks), length of incision was 4-10 cm, in 
2 cases transection of adjacent rib was performed. Patients in control 
group were operated using lateral thoracotomy in the 4th-5th inter-
costal space.
Removed neoplasms measured from 1 to 6 cm. All tumors had 
peripheral localization. In 57 cases (91,9%) airtightness of lung tissue 
was restored with manual sutures, in 5 cases (8,1%) – using stapler 
(in control group stapler was used in 65 cases (95,8%).
Final results of histopathological review were identical to intraopera-
tive ones (peripheral lung cancer – 3, solitary metastases – 6, benign 
neoplasms – 28, non-tumoral lesions – 22).
Average surgery duration in investigational group was 64 (25-110) 
minutes, in control – 118 (80-190) minutes. Average duration of post-
surgery inpatient treatment was 8 days in investigational group, and 
13 in control.
1 (1,6%) postoperative complication in investigational and 2 (2,7%) – 
in control group were observed. No fatal outcomes were observed.
3 patients with peripheral lung cancer after minithoracotomy and lung 
resection (typical thoracotomy and lobectomy were contraindicated 
due to severe concomitant diseases) were followed-up for 16-31 
months without disease prolongation.
Using of minithoracotomy decreased by half cost of treatment com-
pared to traditional thoracotomy in similar situations.
Conclusions: 
• Minithoracotomy substationally reduces surgical injuries and 
provides sufficient access for resection of lung with PLN;
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• Minithoracotomy allows to perform surgery in patients with 
severe concomitant diseases when traditional thoracothomy is 
impossible;
• Minithoracotomy reduces costs of surgical treatment of PLN.
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Transitory blocking of pulmonary artery and veins as a 
novel strategy in pulmonary surgery: an experimental 
study in a rabbit model
Xu, Lin; Yin, Rong; Jiang, Feng; Zhang, Zhi
Department of Thoracic Surgery, Cancer Hospital of Jiangsu 
Province, Nanjing, China
Background: Pulmonary vessels blocking, as a novel strategy in 
pulmonary surgery, recently has been being applied to treat the 
patients of local advanced non-small cell lung cancer. The aim of this 
study is to establish pulmonary vessels blocking model in rabbit and 
investigate the LIRI feature and safe time window of this manipula-
tion as well. 
Methods: New Zealand rabbits were randomly divided into 3 groups 
(n=42 for each group): group I, sham group, thoracotomy only; group 
II, blocking left pulmonary artery; group III, blocking left pulmon-
ary artery and veins. The physicologic data, as well as the blood and 
tissue samples were collected at the time of thoracotomy, at 1h after 
ischemia and at 1, 2, 4, 6, 24h after reperfusion respectively. Lung 
injury was assessed by determining the level of oxidative stress mark-
ers and wet/dry (W/D) ratio of left lung tissue and cytokine levels in 
serum. Histologic examination and electron microscopic observation 
was also preformed.
Results: Hemadynamics was stable in all three groups. MDA 
concentration and W/D ratio were both significantly decreased in 
group II and III when compared with group I at the time points of 1h 
after ischemia and 1, 2, 4, 6h after reperfusion. However, there was 
no significant difference observed among three groups at 24h after 
reperfusion. Similar time course of LIRI was observed under light 
and electron microscopes between group II and III at each time point. 
The extent of injury was peaked at 4h after reperfusion, gradually at-
tenuated at 6h and completely recovered at 24h after reperfusion.
Conclusions: The features of LIRI were similar when blocking pul-
monary artery and blocking pulmonary artery and veins. Moreover, it 
was definitely safe to block pulmonary vessels within 1 hour during 
pulmonary surgery. 
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Introducing a novel technique of specimen extraction 
facilitating video-assisted thoracic surgery
Yin, Rong; Jiang, Feng; Zhang, Zhi; Xu, Lin
Department of Thoracic Surgery, Cancer Hospital of Jiangsu 
Province, Nanjing, China
Background: Currently most surgeons extract specimen using a 
tough nylon sac when performing lung lobectomy by video-assisted 
thoracic surgery (VATS). However it is somewhat time-consuming 
and a little difficult to be learned by a new trainee. We here describe a 
novel technique to extract specimen from incisions facilitating VATS.
Methods: We invented a novel extraction sac, which looks like a 
lactoprene medical glove with only two fingers, which we called 
positioning finger sac. The thickness of sac, 0.3mm approximately, is 
much thicker than conventional gloves just in case it is broken. Once 
a large specimen is isolated and ready to be extracted, a surgeon first 
inserts an oval clamp into two finger sacs (see image1 panel A) and 
then passes them through a working port. With the aid of an assistant, 
the small end of the specimen is clamped by oval clamp which looks 
like pinching something by two fingers (panel B). Subsequently, 
the whole extraction sac is reversed from the cuff, just like drawing 
off a glove (panel C). By lifting the edge of cuff, the assistant helps 
surgeon fill sac with the specimen simultaneously (panel D). Once the 
whole specimen enters sac, surgeon looses oval clamp, lifts the cuff 
of sac and draws it from the working port with the help of assistant 
(panel E). Finally, the specimen is extracted from the incision by 
slowly shaking to adapt the thinner port (panel F). 
Results: We have already applied this technique to extract specimens 
of 39 patients underwent lobectomy with VATS. The average extrac-
tion time was 2.42±1.09 seconds. Although the extraction time is 
impacted by the size of tumor, skill of surgeon etc., our new tech-
nique is obviously time-saving and very easy to be grasped by even a 
new trainee.
Conclusions: The concept of our technique is grasping specimen 
first and then clothing it with sac instead of putting them into sac. By 
doing a “drawing off gloves” like action, it is very convenient to get 
the specimen into our sac and extract it out of incision. We therefore 
conclude that this strategy is an effective, prompt and safe technique.
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En bloc extended total thymectomy and extrapleural 
pneumonectomy in Masaoka stage IVA thymoma
Yang, Hee Chul1; Yoon, Yoo Sang1; Kim, Hong Kwan1; Choi, Yong 
Soo1; Kim, Kwhanmien1; Shim, Young Mog 1; Ahn, Myung-Ju2; 
Kim, Jhingook 1
1 Department of Thoracic and Cardiovascular Surgery, Samsung 
Medical Center, Sungkyunkwan University School of Medicine, Seoul, 
Korea; 2 Division of Hematology Oncology, Department of Medicine, 
Samsung Medical Center, Sungkyunkwan University School of 
Medicine, Seoul, Korea
Background: Surgical procedure is considered as the main treatment 
for thymoma. However treatment is controversial for extensively 
advanced thymoma within thoracic cavity or in recurred cases with 
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pleural dissemination (Masaoka stage IVA). The aim of this study 
is to evaluate retrospectively the safety of operation, recurrence, 
and survival of 7 patients, who underwent en bloc extended total 
thymectomy and extrapleural pneumonectomy in Masaoka stage IVA 
thymoma. 
Methods: From May 2004 to September 2008, 5 patients, initially 
diagnosed with pleural dissemination and 2 patients with recurrent 
tumors in ipsilateral pleura and lung after total thymectomy. Seven 
patients were performed extrapleural pneumonectomy. In initially 
presented cases (n=5), en bloc extended total thymectomy and 
extrapleural pneumonectomy was done. 
Results: Mean age was 48.9 years (range:34-65). Two recurrent cases 
were discovered on postoperative 55.2 and 12.3 months, respect-
ively. Two patients had WHO type B1-B2 tumors, 2 with B2, 2 with 
B2-B3, and 1 with B3. Mean postoperative hospital stay was 15.3 
days (range:7-29). There was no operative mortality. Four patients 
had neoadjuvant chemotherapy and 6 were treated with adjuvant 
chemotherapy. The median survival was 26.7 months and the Kaplan-
Meier 2-year survival was 100% (95% confidence interval: 23.5-30 
months). One patient, who did not receive neoadjuvant chemother-
apy, had distant metastasis in 8.8 months after the surgery. 
Conclusion: En bloc extended total thymectomy and extrapleural 
pneumonectomy can be safely conducted on selected patients with 
Masaoka stage IVA thymoma and is expected to improve survival. 
The treatment strategy has yet to be standardized, however complete 
resection with appropriate systemic treatment will be helpful in 
improving survival in otherwise fatal disease. 
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Clinical implementation of new cutpoints of tumor size in 
non-small cell lung cancer patients
Perin, Branislav; Zaric, Bojan; Jovanovic, Svetlana; Lalic, Nensi; 
Stojanovic, Goran; Sarcev, Tatjana; Antonic, Milan
Pulmonary Oncology Clinic, Institute for Pulmonary Diseases 
of Vojvodina, Medical Faculty University of Novi Sad, Sremska 
Kamenica, Serbia
Background: New revision of the T descriptors in the forthcoming 
edition of the TNM classification for lung cancer offers tumor size 
cutpoints of 2, 3, 5 and 7 cm, as well as grouping into stages accord-
ing to these cutpoints. The aim of this study is to evaluate the clinical 
implementation of proposed cutpoints of tumor size in lung cancer 
patients.
Methods: In this study 228 patients with measurable, cytologicaly/
histologicaly diagnosed non-small cell lung cancer were analyzed. 
They were diagnosed, treated and followed from 1990 to 1996. The 
Kaplan-Meier method was used to calculate survival and the survival 
curves were compared using the log-rank test.
Results: The survival curves of the all patients were analyzed ac-
cording to proposed cutpoints for tumor size. The univariate analysis 
of tumor size showed statistical significance (p=0.000). The overall 
survival analysis with pair comparison between neighboring groups, 
showed significant difference between survival curves of patients 
with tumor size >2 to ≤3cm and >3 to ≤5cm (p=0.045) as well as >5 
to ≤7cm and >7cm (p=0.007). Between the groups of patients with 
tumor size ≤2cm and >2 to ≤3cm as well as between >3 to ≤5cm and 
>5 to ≤7cm there was no significant difference (p=0.867 and p=0.183 
respectively). This survival analysis was made with no regards to N 
status and applied therapy.
Conclusions: The number of cases with smaller tumors in our study 
was to small (13 cases of tumor ≤ 2 cm and 17 cases of tumor > 2 to 
≤ 3 cm) to completely confirm the value of new cutpoints. However, 
our data support the conclusion that patients with tumors >2 to ≤3cm 
have better survival than patients with tumors >3 to ≤5cm, as well as 
that patients with tumors >7 cm have a significantly poorer prognosis 
than those with smaller tumors.
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Depression and quality of Life before diagnosis and after 
surgery of non-small cell lung cancer patients
Zhang, Peng; Jiang, Gening; Wang, Hao
The General Thoracic Department of the Pulmonary Disease Hosptal 
of Tongji University, Shanghai, China
Background: Although many previous studies focused on depression 
or quality of life (QoL) after sur gery for Non-small cell lung cancer 
(NSCLC) patients, few of them had detected the two variables before 
surgery or the diagnosis for a comparison. The aim of the present 
study was to assess, in NSCLC patients with surgical treatment, the 
frequency of depression and QoL both before diagnosis and after 
curative resection, and to investigate the potential related factors.
Methods: The subjects consisted of 115 consecutive adult patients 
newly diagnosed for NSCLC in department of thoracic surgery, 
Shanghai Pulmonary Hospital between April 2008 and October 2008. 
Depression and QoL were evaluated before the diagnosis for baseline, 
the same evaluation was repeated after surgery. The Median interval 
was 34.6 (ranged 28-44) days. Patients’ biomedical characteristics 
were noted from patients’ medical records, while the demographic 
factors were obtained during the interview. Univariate and multivari-
ate analysis were used to identify the significant predictors.
Results: The overall frequency of depression before diagnosis and 
after surgery was 22.6% and 17.4 %, respectively. No significant 
change in the prevalence of depression was found in our study. Edu-
cation (0.016), cost of hospitalization(0.018),Smoking Status(0.025) 
were associated with an increased risk of depression before diagnosis. 
Age (0.039), Having confidant (0.006),Performance Status (0.018), 
Type of surgery (0.048) were found related with postoperative 
depression. patients’ QoL had a decrease in every subscales After sur-
Copyright © 2009 by the International Association for the Study of Lung Cancer S845
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
gery. Changes in role(0.004),social (0.028) functionning scales and 
fatigue(0.014),pain(0.001) symptom scales were found significantly. 
In Qol subscales, Preoperative Dyspnea (0.036), postoperative Role 
functioning(0.014), fatigue (0.001), pain(0.001) were associated with 
changes of depression.
Conclusion: Depression may be present prior to diagnosis in NSCLC 
patients and it does not seem to decrease significantly after surgery, 
indicating the need for psychological screening and appropr iate 
intervention during the perioperative period. A poorer QoL was de-
tected after surgery, which partly contributed to the impaired mental 
health.
P2.281 Surgery, Sun Aug 2 
Video-assisted thoracic surgery (VATS) lobectomy for 
clinical early stage lung cancer—present experience
Zhao, Xiaojing; Qian, Liqiang; Lin, Hao; Tan, Qiang; Luo, Qingquan; 
Lu, Shun
Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai 
Jiaotong University, Shanghai, China
Objective: Video-assisted thoracic surgery (VATS) lobectomy pro-
vides a minimally invasive approach for the management of early-
stage lung cancer. It’s controversial on the safety of VATS lobectomy 
and its adequacy as a cancer operation compared with open thoracot-
omy. The purpose of this report is to review our experience of video-
assisted thoracic surgery (VATS) lobectomy and clarify the feasibility 
of VATS lobectomy.
Methods: 95 patients underwent VATS lobectomy between June, 
2007 and Feb, 2009 were enrolled in this study. The operative tech-
nique for lobectomy is sequential anatomic ligation. If lung cancer 
was identified by operative frozen section, we performed lobectomy 
with systematic node dissection (SND). We evaluated the number of 
procedures converted to open thoracotomy and the reasons for con-
version, the intraoperative blood loss, interval between surgery and 
chest tube removal, length of postoperative hospital stay, postopera-
tive complications, mortality rate and the number of dissected lymph 
nodes station.
Results: There were 37 men and 58 women with a mean age of 59.1 
years .We successfully performed VATS in 93 patients, whereas in 
another 2 patients (2%) conversion to open thoracotomy was required 
because of the injury of hilar vessel. The operative procedures were 
lobectomy in 11 patients(3 AAH, 4 adenoma, 2 tubercoloma and 
2 bulla), lobectomy with SND in 84 patients(4 BAC, 6 squamous 
carcinoma, 49 adenocarcinoma, 7 squamous-adenocarcinoma, 18 
adenocarcinoma mixed with BAC). The mean intraoperative blood 
loss is 139ml(range, 20 to 1000). Postoperative complications 
developed in 9 patients (1 required re-operation because of massive 
bleeding, 3 recurrent laryngeal nerve injury, 2 arrhythmia, 1 per-
sistant air leakage, 1 pneumonia, 1 died of pulmonary embolism).The 
mean chest tube drainage time was 4.4 days(range, 2 to 8 days). The 
mean postoperative hospital stay was 6.6 days (range, 3 to 15 days). 
The mean number of mediastinal nodal stations in right-side is 5.23, 
the mean number of mediastinal nodal stations in left-side is 4.9. The 
postoperative pathological stage is: Ia 29, Ib 53, IIb 5, IIIa 8. In a 
mean follow-up period of 9 months with patients having lung cancer, 
all patients survived without recurrence.
Conclusion: Lobectomy with SND by VATS is acceptable in view 
of its low perioperative mortality and morbidity. With regard to the 
number of dissected nodes, VATS seems to be a feasible cancer oper-
ation for clinical early lung cancer. Further follow-up is needed for 
long-term survival rate.
P2.282 Surgery, Sun Aug 2 
A study of the number and metastatic status of lymph 
nodes ressected during non-small cell lung cancer surgery
Zheng, Shi Ying; Jiang, Dong; Ge, Jin f.
First Affiliated Hospital of Suzhou University, Suzhou, China
Background: In China, Non-small cell lung cancer(NSCLC)is one 
of most common malignant tumors, with a poor prognosis and high 
mottality. For curative treatment, surgical resection remains the most 
effective therapy. Among the prognostic factors, regional lymphnode 
metastasis are an important factor for patients with operable NSCLC. 
To analyze the number and the metastatic status of lymph nodes 
resected during NSCLC surge and to determine the relationship of the 
lymph node status to the prognosis.
Methods: Clinical data from 1575 inpatient NSCLC cases were 
retrospectively reviewed, and the number and the differenl metastatic 
status of the LNs resected analyzed. All patients were postoperatively 
staged according to the 1 997–TNM classification of NSCLC. Lymph 
node levels were classified according to the American Thoracic Soci-
ety system. The Kaplan-Meier method was used for survival analysis.
Results: Stage NO patients with 7 to 1 2 LNs resected during surgery 
had a significant increase in survival (P=0.001, 0.021), compared to 
patients with less than 6 LNs or more than 12 LNs Stage N1 or N2 
patients with more than 1 2 LNs resected had a significanl increase 
in survival(P=0.000 - 0.003), compared with cases who had less than 
6 LNs or 7 to 12 LNs resected. The 5-year survival rate of Stage NO 
patients was superior to Stage N1 and N2 patients(P=0.000, 0.000), 
and the 5-year survival rates of Stage NO and skip N2 patients were 
superior to the continue N2 patients. Patients with a single station 
of LNs metastasis had a significant increase in survival (P=0.000), 
compared with lhose with multiple stations of LNs metastasis.
Patients with 1 lo 2 metastatic LNs had a significant increase in 
survival (P=0.000), compared with patients having more than 2 meta-
static LNs. The metastatic LN ratio(percentage of metastatic lymph 
nodes resected1 was divided into four subgroups: <25%, 25% ~ 50%, 
51 ~ 75, >75. The 5-year survival rate gradually decreased with an 
increase in the metastatic ratio.
Conclusions: For patients with NSCLC the number of LNs resected 
during surgery should be 7 to 12: the range and number of LN metas-
tasis and the metastatic LN ratio significantly affect the prognosis of 
patients with NSCLC.
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
Copyright © 2009 by the International Association for the Study of Lung CancerS846
Poster Abstracts 
Monday, August 3 – Tuesday, August 4 
Combined Modality Therapy
P3.001 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Primitive neuroectodermal tumor: nine years single 
institution experience
Abdelrahman, Abdelrahman Mohamed; Gaafar, Rabab Mohamed; 
Baki, Hoda Abdel; Elhosieny, Hesham Abdelkader; Bastawissy, 
Ahmed El; Farahat, Iman Gouda; Aziz, Hala Aziz
National Cancer Institute Cairo University, Cairo, Cairo, Egypt
Background: The first description of malignant small round-cell 
tumors of the thoracic region was by Askin in 1979.. Currently, Ew-
ing sarcoma (ES), primitive neuroectodermal tumors (PNETs), and 
malignant small round-cell tumors of the thoracopulmonary region 
are suggested to be different manifestations of a single tumor family. 
These tumors are rare, have a very high rate of local recurrence and 
a propensity to metastasize, often occur in childhood or adolescence 
and are difficult regarding diagnosis and therapy. 
Methods: We conducted a retrospective case series study between 
1999 and 2008, 24 patients with thoracic Ewing sarcoma family of 
tumors (ESFT) were investigated. All tumors were diagnosed by 
histological and immunohistochemical examinations . All patients 
underwent CT scan of the chest and abdomen; three patients also had 
MRI (due to suspected intra spinal extension). During treatment and 
follow-up, CT was performed in all patients. In 18 patients, the tumor 
was of chest wall origin, infiltrating adjacent ribs in all of them and 
parts of the lung in 6 of them. The remaining 6 patients presented 
with posterior mediastinal mass, intra spinal extension was found in 
3 of them.
Results: There were 15 males and 9 females,mean age was 10.5 
years (range 3-21y)Clinical features included chest wall mass (13), 
pain (20), dyspnea (4), and Para paresis in 2 patients. All patient 
received chemotherapy (National Cancer Institute protocol for ES) 
as a primary therapy with partial response in 19 (66.6%), pathologic 
complete response in 2 and no response was found in 3 patients . Pre 
operative radiotherapy was given to 3 patients due to large tumor 
size. Radical surgery was offered t o all patients, chest wall resec-
tion (1-4 ribs ) was done for 18 patients. Extended resections in this 
group included: wedge lung resection in 4, lobectomy in 2, pericar-
dial resection in 1 and diaphragmatic resection in another patient. In 
patients with mediastinal location combined tumor and chest wall 
resection was done in 4 patients ( including one with intra spinal ex-
tension), in the remaining 2 patient combined resection of the tumor 
with intra spinal part was done. The tumor size range was 4.5cmx 
3.5 cm – 18.5cm x 14cm, close margin was found in 6 patients and 
margin was inadequate in another 5 patients. We had one opera-
tive related mortality and morbidity was encountered in 4 patients . 
Radiotherapy was added post operatively at 35-50 Grays. Five pa-
tients developed local tumor recurrence, 2 of them had disseminated 
metastases, the other 3 were re operated.
Ten patient lost to follow up within 2years after therapy, we had only 
2 (8.3%) patients survived 5 or more years.
Conclusion: Askin tumor should be included in the differential diag-
nosis when a chest wall or thoracic paraspinal mass is identified in a 
young individual. Our data demonstrate that Askin tumors require an 
aggressive multimodality treatment consisting of pre- and postopera-
tive chemotherapy, radical surgical resection and postoperative 
irradiation, which may be given preoperatively in selected patients.
P3.002 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Radiation pneumonitis in patients with locally advanced 
non-small-cell lung cancer treated with concurrent 
radiotherapy and gemcitabine 
Michel, Rosa M.2; Gallardo-Rincon, Dolores2; Villarreal-Garza, 
Cynthia1; Astorga-Ramos, Alma2; Zamora, Jesus2; Martinez-Barrera, 
Luis3; de la Garza, Jaime2; Arrieta, Oscar2
1 Instituto Nacional de Nutricion y Ciencias Medicas, Mexico City, 
Mexico; 2 Instituto Nacional de Cancerologia, Mexico City, Mexico; 
3 Instituto Nacional de Enfermedades Respiratorias, Mexico City, 
Mexico
Background: The combination of chemotherapy (CT) and thoracic 
radiation (RT) is the standard treatment for locally advanced non-
small cell lung cancer (NSCLC). The most favorable CT regime, 
timing of full-dose CT and the best way to combine CT with RT to 
maximize systemic and radiosensitizing effects remain to be deter-
mined. The aim of this study was to assess the efficacy, safety and 
tolerability of gemcitabine concurrent with RT after induction CT 
(gemcitabine + carboplatin) in locally advanced NSCLC. 
Patients and Methods: Patients with histologically proven NSCLC 
IIIA and IIIB received carboplatin (AUC of 2.5) and gemcitabine 
(800 mg/m2) on day 1 and 8, every 21 days (two cycles)as induction 
chemotherapy. This was followed by conventional fractioned RT 
(up to 60 Gy) and concomitant weekly gemcitabine 200 mg/m2, and 
consolidation CT in a similar schedule to that of induction for up to 4 
cycles. Toxicity was graded according to CTCAE v2.0.
Results: Median follow-up was of 11.9 months, 11 patients (57.9%) 
had stage IIIB disease. Patient inclusion was discontinued due to high 
grade 3/4 radiation pneumonitis events (5/19 patients, 26.3%). Figure 
1 demonstrates the development of radiation pneumonitis in two pa-
tients, the upper line depicts their Chest tomography images prior to 
receiving radiochemotherapy and the lower line after it was received. 
One treatment-related death from radiation pneumonitis occurred. 
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The most common hematological side effects grade 3/4 were anemia 
and neutropenia 3/19 (15.8%) each and thrombocytopenia 4/19 
(21.1%) during induction CT. 
Partial response was observed in 10 patients (52.6%) following 
induction. After concurrent chemo-radiotherapy, overall response was 
68.4%.
 WHO criteria Induction chemotherapy Radiochemotherapy
 Progression 0/19 2/19
 Stable disease 9/19 4/19
 Partial response 10/19 7/19
 Complete response 0/19 6/19
 Overall response 10/19 (52.6%) 13/19 (68.4%)
Four patients underwent surgical resection. Median progression-free 
survival was 12 ± 1 months (95% CI, 9.8 -14.1). Overall survival was 
of 21 ± 3.5 months (95% CI, 14-27.9). 
Conclusion: Concurrent RT with gemcitabine after induction CT 
with gemcitabine and carboplatin showed a high response rate. How-
ever, it is associated with excessive pulmonary toxicity. Adjustments 
in gemcitabine dosage during RT or changes in RT planning could 
reduce toxicity. 
P3.003 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
The role of third generation agents as an induction 
treatment in concurrent chemoradiotherapy (CRT) for 
locally-advanced non-small cell lung cancer: a systematic 
review and meta-analysis of randomized clinical trials
Aydiner, Adnan; Can, Gulbeyaz
Istanbul University Institute of Oncology, Istanbul, Turkey
Objectives: We aimed to evaluate the efficacy and safety profile of 
concurrent chemoradiotherapy (CRT) with third-generation chemo-
therapeutic agents as an induction treatment for inoperable locally ad-
vanced stage non-small cell lung cancer (NSCLC) by meta-analysis 
of randomized trials. To our knowledge this is the first meta-analysis 
evaluating this subject.
Methods: A Systematic literature search was performed through 
MEDLINE, PubMed, Cochrane, ASCO, EORTC, Current Contents, 
and EMBASE and through the abstracts in the NSCLC sections 
of ASCO website to February 2009. The keywords for the third 
generation agent search were [taxane or docetaxel or paclitaxel or 
gemcitabine or irinotecan or vinorelbine]. The meta-analysis models 
for pair wise comparisons between different types of CRT regimens 
and types of chemotherapeutic agents were constructed for response 
rate, survival, and toxicity data; and results were given as pooled 
odds ratio (OR) or hazard ratio (HR) with 95% confidence interval 
(CI). [For survival data, hazard ratios (HR) and confidence intervals 
(CI) of individual studies were calculated based on survival curves-
published in the manuscript (Parmar MKB, 1998)]. Quality of trials 
were assessed based on the reporting of method of randomization and 
allocation concealment, comparability of baseline treatment groups, 
reasons for drop-outs, if there was any evidence of differential drop-
outs between treatment arms, and level of data reporting. 
Results: We identified five studies had sufficient data published 
for inclusion and 961 patients were included in these studies. The 
overall response and overall survival for concurrent CRT were same 
in comparison to “induction chemotherapy (CT) - concurrent CRT” 
(OR: 1.04, 95%CI 0.42–2.56, p=0.93; HR: 1.15, 95%CI 0.93–1.44, 
p=0.21) and overall survival was same in “induction CT - concur-
rent CRT” when compared with “concurrent CRT-consolidation CT” 
(HR: 0.85, 95%CI 0.62–1.17, p=0.32). Anemia and neutropenia were 
lower in concurrent CRT than “induction CT - concurrent CRT” (OR: 
0.35, 95%CI 0.15-0.79, p=0.01 and OR: 0.42, 95%CI 0.26-0.68, 
p=0.0001). Thrombocytopenia, febrile neutropenia, esophagitis/dys-
phagia, dyspnea were not significantly different between concurrent 
CRT and “induction CT - concurrent CRT”. However, the pulmon-
ary toxicity risk may be less in concurrent CRT when compared 
with “induction CT - concurrent CRT” (OR: 0.41, 95%CI 0.17-1.01, 
p=0.054). All the toxicities were same between “induction CT - con-
current CRT” when compared with “concurrent CRT - consolidation 
CT”. 
Conclusion: In locally advanced NSCLC “induction CT - concurrent 
CRT” has higher toxicity and has no response or survival advantage 
over concurrent CRT only, and we need more trials with concurrent 
CRT vs “concurrent CRT - consolidation CT”.
P3.004 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Cetuximab, in addition to concurrent chemo-radiotherapy 
(CRT) in locally advanced non-small cell lung carcinoma 
(NSCLC), a feasibility study
Belderbos, José2; Verheij, Marcel9; Dalesio, Otilia3; van de Pol, 
Marjan4; Uitterhoeve, Lon5; van de Vaart, Paul6; van Zandwijk, 
Nico7; Valdes Olmos, Renato8; Teertstra, Jelle 2; van den Heuvel, 
Michel 1
1 Medical Oncology Department, The Netherlands Cancer Institute 
/ Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands; 
2 Department of Radiology, The Netherlands Cancer Institute / 
Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands; 
3 Department of Biostatistics, The Netherlands Cancer Institute / 
Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands; 4 
Department of Radiation Oncology, Dr Bernard Verbeeten Instituut, 
Tilburg, Netherlands; 5 Department of Radiation Oncology, Academic 
Medical Centre, Amsterdam, Netherlands; 6 Department of Radiation 
Oncology, Medisch Centrum Haaglanden, The Hague, Netherlands; 7 
University of Sydney, ADRI, Bernie Banton Centre, Sydney, Australia; 
8 Department of Nuclear Medicine, The Netherlands Cancer Institute 
/ Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands; 9 
Department of Radiation Oncology, The Netherlands Cancer Institute 
/ Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands
The epidermal growth factor receptor monoclonal antibody (Ce-
tuximab) has been shown to be an active anti-cancer agent and en-
hance the radiation response in head and neck cancer. A phase II trial 
was initiated to assess the safety of combining Cetuximab with daily 
chemotherapy and concurrent high dose radiotherapy.
Methods: In patients presenting with non-operable locally advanced 
NSCLC Cetuximab (loading dose 400 mg/m2 on day 1, followed by 
a weekly dose of 250 mg/m2 from week 2 to 6) was administered in 
combination with daily low-dose Cisplatin (6 mg/ m2 from week 2 
to 6), and high dose radiotherapy (66Gy in 24 fractions from week 2 
to 6). Early response monitoring, using a repeat FDG-PET-CT scan, 
4 weeks after the last fraction of radiotherapy was done according 
to the EORTC criteria for standardized uptake value (SUV) meas-
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urement (with complete metabolic response defined as complete 
resolution of FDG-uptake within the tumor volume, partial metabolic 
response is a reduction > 25% SUV in tumor).
Results: Between April and July 2008, 12 consecutive patients 
entered the study protocol and received Cetuximab in addition to the 
standard concurrent chemo-radiotherapy. Dermatitis and radiation 
esophagitis were the most severe side effects (maximum score 3 
according to CTC-3 criteria). Evaluating the response with CT scans 
at 8 weeks after the last irradiation (according to RECIST criteria) 
revealed in 8 out of the 10 patients a partial response and in 2 patients 
progressive disease.
In 10 patients repeat FDG-PET revealed a metabolic response in 5 
patients (3 complete and 2 partial metabolic responses) 4 patients 
were non-responders and one patient showed progressive disease. 
Conclusion: The addition of Cetuximab to concurrent CRT was well 
tolerated with no unexpected toxicity. A multi-centre randomized 
phase II study comparing concurrent chemo-radiation with or without 
Cetuximab is ongoing in the Netherlands.
P3.005 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Low-dose carboplatin and thoracic radiotherapy (TRT) 
for stage III non-small cell lung cancer (NSCLC) in elderly 
patients: what is the optimal dose of carboplatin in this 
setting?
Berzinec, Peter1; Arpasova, Magdalena2; Baratova, Helena3; 
Galikova, Jana3; Kuzmova, Helena1; Strhan, Marian1; Cavarova, 
Zdenka1; Chowaniecova, Gabriela1
1 Department of Oncology, Specialised Hospital of St. Zoerardus 
Zobor, Nitra, Slovak Republic; 2 Specialised Hospital of St. Zoerardus 
Zobor, Nitra, Slovak Republic; 3 Department of Radiotherapy, 
Faculty Hospital, Nitra, Slovak Republic
Background: Japanese Phase II/III studies evaluating carboplatin 
with TRT in elderly patients used daily carboplatin at a dose of 
30 mg/m2 (Atagi et al, Jpn J Clin Oncol 35(4) 195-201). Another 
Japanese study recommended carboplatin at a daily dose of AUC 0.40 
mg/mlxmin to be used with standard TRT (Ieda et al, Acta Med Kinki 
Univ 26(2) 35-44). Purpose of this study was to evaluate impact of 
carboplatin AUC dose in combination with TRT on treatment results 
of stage III NSCLC in central European patients aged 65 years or 
over. 
Methods: Twenty-four elderly or frail patients were treated for 
inoperable stage III NSCLC with conventional TRT 60 Gy (2 Gy 
fractions, 5 days a week) concurrently with low-dose carboplatin (25 
mg/m2 as a 30 min infusion, 1 hour before TRT, daily over 4 weeks 
starting on day 1). In twenty patients aged 65 - 84 years (mean/
median: 74/75) was it possible to calculate retrospectively AUC of 
carboplatin by the start of therapy (AUC1) and then after 2 - 3 weeks 
(AUC2). AUC1, AUC2, and AUCm (mean) were calculated using the 
Calvert formula. The basic statistical characteristics, t-tests, correla-
tions and linear regressions were used for data evaluation. 
Results: Calculated AUC of carboplatin daily dose was: AUC1: 
mean/median: 0.49/0.46 (range: 0.29 - 0.71), AUC2: 0.51/0.49 (0.25 
- 0.85), AUCm: 0.50/0.46 (0.27 - 0.71) mg/mlxmin. Overall response 
rate to chemo-radiotherapy: 60% (95% CI: 39-78), CR: 0, PR: 60%, 
SD: 35%, PD: 5%. Survival time: mean/median: 21/19 months 
(range: 2 - 48, 95%CI for median: 10 - 26). There was a highly 
significant dependence of AUC1, AUC2 and AUCm on patients´ age 
(AUCm: coefficient of determination = 0.352). We did not find any 
effect of carboplatin dose on the response rate or on the patients’ sur-
vival, neither in the whole group of patients, nor in the different sub-
groups (according to the stage A or B, patients’ performance status, 
age, sex, histological/cytological type of NSCLC). Hematological 
and non-hematological toxicities grade 3 occurred in five patients 
treated with carboplatin daily dose of AUC 0.54 mg/mlxmin or over, 
grade 4 in one patient by AUC over 0.70 mg/mlxmin. 
Conclusion: Daily carboplatin dose of AUC 0.50 mg/mlxmin may 
be recommended as a less toxic and equally effective alternative to 
the higher or fixed doses in this chemo-radiotherapy protocol in the 
central European population.
Copyright © 2009 by the International Association for the Study of Lung Cancer S849
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
P3.006 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Gemcitabine (G) and cisplatin (C) induction chemotherapy 
followed by weekly G, concurrent with thoracic 
radiotherapy (TRT), for patients (pts) with inoperable 
stage III non-small cell lung cancer (NSCLC): preliminary 
results from a multicentric phase II study
Caffo, Orazio1; Murgia, Viviana1; Vanoni, Valentina2; Ceribelli, 
Anna 3; Masotti, Alessandro4; Meschiari, Emmanuela5; Mirri, Maria 
Alessandra6; Romano, Mario7; Schiavon, Stefania8; Seebacher, 
Christine 9; Caldara, Alessia1; Galligioni, Enzo1
1 Medical Oncology Department - Santa Chiara Hospital, Trento, 
Italy; 2 Radiation Therapy Department - Santa Chiara Hospital, 
Trento, Italy; 3 Regina Elena Institute, Rome, Italy; 4 Pneumology 
Department, Peschiera, Italy; 5 Pneumology Department, Modena, 
Italy; 6 San Filippo Neri Hospital, Rome, Italy; 7 Radiotherapy 
Department, Verona, Italy; 8 Medical Oncology Department, Vicenza, 
Italy; 9 Pneumology Department, Bolzano, Italy
Background: G has shown a synergistic activity when combined to 
C and the GC regimen represents one of the most widely used treat-
ments for advanced NSCLC. Furthermore G is a potent radiosensi-
tizer and, at the dose of 300 mg/sqm/week, G given concurrently with 
TRT has shown to be active and tolerable. Induction chemotherapy 
therefore, followed by concurrent chemoradiotherapy, is a reason-
able treatment strategy for patients with inoperable stage III NSCLC. 
Aim of this study was to evaluate the activity and toxicity profile of 
2 courses of induction CG chemotherapy, followed by concurrent 
weekly G and TRT. 
Methods: From April 2004 until today, 30 pts with inoperable locally 
advanced NSCLC, stage IIIAN2/IIIB (no pleural T4), entered a phase 
II study of 2 cycles of induction chemotherapy with G 1250 mg/sqm 
on days 1,8 and C 75 mg/sqm on day 8, every 3 weeks. Pts with no 
progressive disease and susceptible of limited TRT fields received G 
300 mg/sqm/week for 6 courses, during conformal TRT (64-66 Gys, 
200 cGy/day). 
Results: The pts characteristics were as follows: median age 65 years 
(51-75); M/F: 26/4; stage IIIAN2: 4 pts and stage IIIB: 26 pts. All but 
1 pt (who refused further chemotherapy after the first administration) 
were evaluable for response and toxicity. After induction therapy we 
observed a partial response (PR) in 13 pts (43%), a stable disease 
(SD) in 9 (30%), and a progressive disease (PD) in 7 pts (23%). 
Among the 22 pts with no PD, G + TRT was excluded in 4 pts, due 
to the large TRT fields required. Among the 18 pts who received 
concurrent G and TRT, we observed 7 PR (41%), 3 SD (18%) and 7 
PD (41%), while 1 pt is still ongoing. Major toxicities observed dur-
ing induction therapy were G 3 neutropenia in 3 cases, while during 
concurrent chemoradiotherapy were G 3 thrombocitopenia in 1 case 
and G 3 neutropenia in another one. After a median follow-up of 11.5 
months, the median survival of the 30 enrolled pts was 15 months, 
while 1-y PFS and OS were 23% and 52%, respectively. In the group 
of pts who completed the chemoradiotherapy, 1-y PFS was 37% and 
1-y OS was 65%.
Conclusions: It appears, from these preliminary data, that an induc-
tion chemotherapy with CG for 2 cycles, followed by weekly G and 
concurrent TRT, is a reasonable treatment option for locally advanced 
NSCLC, with acceptable clinical activity, tolerability, and survival.
P3.007 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Concurrent chemoradiation with pemetrexed and cisplatin 
followed by consolidation pemetrexed for patients with 
unresectable stage III non-small cell lung cancer (NSCLC): 
preliminary results of a phase I study
Cardenal, Felipe1; Arnaiz, Ma Dolores1; Moran, Teresa 4; Jové, 
Josep2; Solé, Josep Ma1; Porta, Ruth5; Nadal, Ernest1; Brao, Isabel 1; 
Palmero, Ramón1; Fuentes, Rafael 5; Nuñez, Inmaculada3; Cassinello, 
Alejo3
1 Institut Català d’Oncologia, Barcelona, Spain; 2 Institut Català 
d’Oncologia, Hospital Germans trias i Pujol, Badalona, Spain; 3 
Elli Lilly and Company, Medical Department, Alcobendas (Madrid), 
Spain; 4 Institut Català d’Oncologia, Badalona, Badalona, Spain; 5 
Institut Català d’Oncologia, Girona, Spain
Background: Concurrent chemotherapy and radiation is the standard 
of care for patients with unresectable stage III non-small cell lung 
cancer. The integration of third generation chemotherapy agents with 
radiation has been disappointing probably because they need to be 
used in low weekly doses. Pemetrexed with carboplatin at full doses 
along with radiation therapy has shown to be feasible. This phase I 
study was implemented to test the feasibility of full dose pemetrexed 
and cisplatin with thoracic radiation therapy.
Methods: Eligibility: Unresectable stage III NSCLC, ECOG PS 0 or 
1, FEV1>1500 ml, DLCO>50%. Adequate organ function. PTV<2 
liters, V20<35%. Patients received a fixed dose of pemetrexed (P): 
500 mg/m2 and cisplatin (C) at three dose levels: 60-75 mg/m2 q21 
days for three cycles concurrent with RT (66 Gy in 6.5 weeks). Three 
cycles of consolidation P 500 mg/m2 q 21 days were also planned. 
Dose-limiting toxicities (DLT) were G3/4 neutropenia, thrombocyto-
penia, dysphagia/esophagitis, dermatitis, or grade 4 fatigue delaying 
RT more than 1 week, PC more than 2 weeks, or the first cycle of 
consolidation P more than 5 weeks.
Results: From February 06 to April 08, 12 eligible patients were re-
cruited on two dose levels cohorts (9 on level 1, 3 on level 2). Male/
female: 10/2. Median age: 57 years (range 40 to 70 y). Squamous cell 
carcinoma/NOS/adeno: 5/4/3. Stage IIIA/IIIB 3/9. ECOG PS 0/1: 5/7.
Nine of the twelve patients completed all three cycles of concurrent 
chemotherapy. Two (on dose level 1) discontinued due to DLT (pro-
longed grade 3 esophagitis following 2 cycles) and 1 (on dose level 
2) due to investigator decision. Two patients (1 on level 1, 1 on level 
2) had the third dose delayed. Six patients completed consolidation 
chemotherapy (one of them with dose delays due to odinophagia). 
The other 6 discontinued consolidation due to adverse events (3 pts), 
progression (2 pts) and death (1 pt).
Asthenia, odinophagia, and dysphagia, were the most common non-
hematologic adverse events (in 9, 9 and 8 pts respectively). Grade 
3/4 toxicities were esophagitis (5 pts),febrile neutropenia (2 pts), 
lymphopenia (4 pts), neutropenia (6 pts), anemia (3 pts) and thrombo-
cytopenia (1 pt). 
While still recruiting patients at the third cohort preliminary effi-
cacy data show that with a median follow-up time of 23 months the 
median time to progression has not been reached (six patients are 
alive without progression from +11 to +32 months) 
Conclusions: Chemoradiotherapy is feasible with manageable tox-
icity in this trial. Updated results will be presented at the upcoming 
meeting. 
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P3.008 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Induction docetaxel (D) and cisplatin (C) plus concurrent 
thoracic radiotherapy (TRT) and biweekly D and C for 
stage III non-small cell lung cancer (NSCLC): a Galician 
Lung Cancer Group study
Casal, Joaquin1; Vazquez, Sergio2; Campos, Begoña2; Lazaro, 
Martin3; Leon, Luis4; Villanueva, Maria Jose3; Mel, Jose Ramon2; 
Carnero, Beatriz3; Lopez, Rafael 4; Gomez, Antonio5; Caeiro, 
Manuel6; Firvida, Jose Luis7; Amenedo, Margarita8
1 Xefe de Seccion Oncoloxia Medica, Vigo, Spain; 2 Oncoloxia 
Medica, Complexo Xeral-Calde, Lugo, Spain; 3 Oncoloxia Medica, 
Complexo hospitalario Universitario, Vigo, Spain; 4 Oncoloxia 
Médica, Complexo Hospitalario Universitario, Santiago, Spain; 5 
Oncoloxia Radioterápica, Complexo Hospitalario Universitario, 
Santiago, Spain; 6 Oncoloxia Radioterapica, Complexo Hospitalario 
Universitario, Vigo, Spain; 7 Oncoloxia Medica, Complexo 
Hospitalario, Ourense, Spain; 8 Oncoloxia Medica, Centro 
Oncoloxico de Galiza, A’Coruña, Spain
Background: Standard treatment of stage III NSCLC remains con-
current chemoradiation, although a clearly superior regimen has not 
been identified. D has been shown to possess good single agent activ-
ity against NSCLC as well as radiosensiziting properties, both alone 
and sinergisitically with C. The aim of our study is to evaluate the 
feasibility of induction chemotherapy with D-C followed by biweekly 
D-C and concurrent TRT.
Methods: 65 patients (p) with inoperable locally advanced NSCLC, 
stage IIIAN2/IIIB (no pleural T4), were included in a phase II study 
with induction chemotherapy consisting of three cycles of D 75 
mg/m2 on day 1 and C 40 mg/m2 days 1-2 every 3 weeks and, if no 
surgery, then underwent concurrent TRT with D 30 mg/m2 and C 30 
mg/m2 every 2 weeks for four courses, during conformal TRT (60-66 
Gys, 180 cGy/day). The primary 
Objective: overall survival (OS); secondary: progression free sur-
vival (PFS), response rate (RR) and toxicity. Median follow-up: 8.8 
months.
Results: The p characteristics were: mean age 61,6 years (44-75); 
male/female 61/4; ECOG PS 0/1 in 15/50 p; squamous/adeno/large 
cell carcinoma: 53.8%/23.1%/23.1%; stage IIIAN2 16 p (24.7%) and 
stage IIIB 49 p (75.3%). 60 p were evaluables for response and 62 
p for toxicity. Induction D-C response: 33 PR (RR 55%; CI95%:43-
77), 18 SD (30%) and 9 PD (15%). 4 p went to surgery: 3 pPR and 1 
pPD (unresectable). 40 p completed CChRT (5 p in treatment) with 
5 CR, 23 PR, 4 SD and 8 PD (RR 70%; CI95%:56-84). The median 
to PFS was 11 months (CI95%:7-15) and median OS was 12 months 
(CI95%:8-16) . The PFS and OS at 1 year was 44.5%/48.1% re-
spectively. A total of 175 cycles of D-C were given (2.8 per p); main 
toxicity (NCI-CTC 3.0) per p Grade (g) 1-2/3-4 (%) was as follows: 
neutropenia 11.3/29; anemia 30.6/0.5; nausea/vomiting 30.6/4.8; 
fatigue 27.4/0; diarrhea 14.5/11.2; there were nine episodes of febrile 
neutropenia and there was one treatment-related death. Main toxici-
ties per p in CChRT (D-C doses: 143, 3.5 per p) were: g1-2 neutro-
penia/anemia 13/34.7%; g1-2/3 esophagitis in 45.6/2.1% and g1-2 
pneumonitis in 26 %; there was one treatment-related death.
Conclusions: Induction chemotherapy with D-C plus concurrent TRT 
and biweekly D-C is a feasible treatment option for locally advanced 
NSCLC, showing good clinical activity and tolerability with promis-
ing survival.
P3.009 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Erlotinib as maintenance therapy after concurrent chemo-
radiotherapy in patients (P) with stage III non small cell 
lung cancer (NSCLC): a Galician Lung Cancer Group 
phase II study
Casal, Joaquín2; Villanueva, María José2; Vázquez, Sergio3; Campos, 
Begoña3; Barón, Francisco Javier4; Fírvida, José Luis5; Lázaro, 
Martín6; Amenedo, Margarita8; Alonso, Guillermo7; Santomé, 
Lucía10; Cardona, José Vicente1; Afonso, Francisco Javier9
1 Roche Farma, S.A., Madrid, Spain; 2 Complejo Hospitalario de 
Vigo - Hospital do Meixoeiro, Vigo, Spain; 3 Complejo Hospitalario 
Xeral Calde, Lugo, Spain; 4 Complejo Hospitalario Universitario de 
Santiago, Santiago de Compostela, Spain; 5 Complejo Hospitalario 
Universitario de Ourense, Ourense, Spain; 6 Complejo Hospitalario 
de Vigo - Hospital Xeral Cíes, Vigo, Spain; 7 Complejo Hospitalario 
Universitario A Coruña, A Coruña, Spain; 8 Centro Oncológico 
de Galicia, A Coruña, Spain; 9 Complejo Hospitalario Arquitecto 
Marcide - Novoa Santos, Ferrol, Spain; 10 Hospital POVISA, Vigo, 
Spain
Background: Combination of platinum-based chemotherapy and 
radiotherapy is the standard treatment for p with unresectable stage 
III NSCLC, but considering the high rates of recurrence, it is neces-
sary to improve these results. Erlotinib is an EGFR TKI that prolongs 
survival in p with recurrent and metastatic NSCLC. In this study, we 
aim to evaluate the role of erlotinib as maintenance therapy after a 
standard concurrent chemo-radiotherapy regimen in p with stage III 
NSCLC.
Methods: P with unresectable stage IIIA/IIIB -without malignant 
effusions- NSCLC who had received a standard concurrent chemo-
radiotherapy regimen and had no evidence of tumor progression were 
enrolled in this single arm, open-label phase II study and received 
erlotinib 150 mg/day po for 6 months. Main elegibility criteria were: 
PS 0-2, adequate bone marrow, hepatic and renal function and meas-
urable disease by RECIST criteria. Primary endpoint was the percent-
age of p without evidence of disease progression after 6 months of 
elotinib therapy and secondary endpoints were: PFS, OS, ORR and 
safety profile.
Results: 52 p have been included in the study and data from 37 p 
are presented in this analysis. Baseline characteristics: median age 
62 years (range 41-76); male 94.6%; caucasian 100%; smokers/
never smokers (%) 97.3/2.7; ECOG PS 0/1/2 (%) 18.9/75.7/2.7; 
adenocarcinoma/squamous cell carcinoma/large cell carcinoma (%) 
16.2/75.7/5.4; stage IIIA/IIIB (%) 16.2/83.8. Most common previ-
ous chemo-radiotheapy regimen is cisplatin/docetaxel/RT (83.8%). 
27 p were evaluable for tumor response: CR 22.2%; PR 12.8%; SD 
55.6%; PD 7.4%. Median TTP was 7.3 months (95% CI 5.8-16.9) 
and median OS was 18.7 months (95% CI 11.8-NA). Most common 
adverse events related to erlotinib were rash 30.6% (3 p gr. 3) and 
diarrhea 16.7%.
Conclusions: Erlotinib as maintenance therapy is an active and well 
tolerated treatment after concurrent chemo-radiotherapy in p with 
stage III NSCLC. In spite of the majority of patients are cauca-
sian, males, smokers with squamous cell carcinoma, maintenance 
with single agent erlotinib reached a promising median OS of 18.7 
months. Updated data will be presented.
Copyright © 2009 by the International Association for the Study of Lung Cancer S851
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
P3.010 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Improvement in performance status and specific survival 
after alfa-erythropoietin
Casas, Francesc1; Viñolas, Núria 2; Marrades, Ramon2; Gimferrer, 
Josep Maria3; Sanchez, Marcelo3; Arguis, Pedro3; Lomeña, Paco3
1 Radiation Oncology Department, Hospital Clinico y Provincial de 
Barcelona, Barcelona, Spain; 2 Medical Oncology, Hospital Clinico 
y Provincial de Barcelona, Barcelona, Spain; 3 Hospital Clinico y 
Provincial de Barcelona, Barcelona, Spain
Background: Update of a phase II prospective study published 
in “Red Journal” in 2003 about role of r-Huepo administration to 
maintain KPS and Hemoglobine (Hb) in patients with lung cancer 
undergoing concurrent CH-RT. This update was made in order to 
analyze causes of death in this selected patients group with a longer 
follow-up.
Material: A total of 51 patients (11 with LD-SCLC and 40 NSCLC 
IIIA and IIIB) were treated with neoadjuvant CT and concur-
rent CT-RT both based in cisplatin doublets (CDPP). We analyzed 
baselineKPS and baselineHb at the diagnosis, after the neoadjuvant 
CT (nadir KPS and nadir Hb) and finally after concurrent CT-RT 
(finalKPS and finalHb). The r-Huepo supportive treatment was begun 
previously to concurrent CT-RT if nadirHb was < 11 g/dl (Catalan 
Health System rules).
Results: Median bKPS and bHb were respectively 80% and 12.2 
+ 1.76. Median nadir KPS and nadirHb were respectively 60% and 
9.98+0.67. And median finalKPS and finalHb were respectively 80% 
and 11.33 + 1.59. It was a significant improvement on finalKPS and 
finalHb (p< 0,001) from nadir KPS and nadir HB. With an updated 
median follow–up of 72 months (3.5-115 m) the median overall 
survival was 17 months and overall and specific survival was 16% 
and 22% respectively. SCLC histology (p<0.02), absence of weight 
lost (p<0.001) and finalHb (p<0.035) were positive prognostic 
factors of Overall Survival in the multivariate analysis. FinalHb 
improvement had a strong tendency to significance (p<0.056). On a 
multivariate analysis of Specific survival had coincidence on SCLC 
histology (p<0.002), absence of weight lost (p<0.004) but at this 
occasion finalhb improvement was significant (p<0.022). In March 
2009, 6 patients are free of illness but 4 patients died after 4 years of 
follow-up without any evidence of progression. Two for myocardial 
infarction (two LD-SCLC), one for CO2 intoxication and another one 
for toxicity (esophageal broke after stenosis dilatation).
Conclusions: r-Huepo as a supportive treatment in a group of se-
lected lung cancer patients heavily treated with neoadjuvant CT and 
concurrent CT-RT based in CDPP doublets had a positive impact on 
maintenance of Hb, KPS and in specific survival. An Hb level of < 
11g/dl, always after neoadjuvant CT, seems safe to avoid published 
morbi-morbidity associated to r-Huepo administration.
P3.011 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Clinical outcome of chemoradiotherapy in elderly veterans 
with locally advanced unresectable non-small cell lung 
cancer (NSCLC)
Choong, Nicholas W.1; Choi, Minsig2, 3; Dembla, Vikas2; May, 
Warren 2; Chan, Wayne 3; Khansur, Tawfiq3
1 Medical College of Wisconsin, Milwaukee, WI, USA; 2 University 
of Mississippi, Jackson, MS, USA; 3 Montgomery VA Medical Center, 
Jackson, MS, USA
Background: The majority of lung cancer patients are elderly. Data 
on the optimal chemoradiotherapy schedule in the elderly is limited. 
Methods: Medical records of NSCLC patients treated at the Veterans 
Affairs Medical Center in Jackson, MS and Milwaukee, WI between 
Jan 2000 to Dec 2007 were abstracted. Patients were included if 
they were ≥ 65 years and received both chemotherapy and thoracic 
radiotherapy as definitive treatment for locally advanced unresectable 
NSCLC. Patients who only received palliative radiation therapy were 
excluded. 
Results: Eighty seven patients ≥ 65 years with locally advanced 
unresectable NSCLC were included. Sequential chemoradiotherapy 
was delivered in 26 patients and concurrent chemoradiotherapy in 
61 patients. All patients were male. Demographics of the patients 
receiving sequential and concurrent chemoradiotherapy were: age 
74 and 72 years, African-American race 23% and 20%, Stage IIIB 
23% and 36%. Median radiotherapy dose delivered with sequential 
regimen was 6230Gy and 6300Gy with concurrent regimen. Patients 
receiving sequential chemoradiotherapy received systemic doses of 
carboplatin-taxane while patients receiving concurrent chemoradio-
therapy received weekly doses of carboplatin-taxane. There was only 
1 treatment related death. 12 patients (7 concurrent, 5 sequential) 
survived less than 6 months. Survival among the two groups did not 
differ statistically (median survival-20 months (sequential) vs. 17 
months (concurrent), p=0.97). 
Conclusions: Both sequential and concurrent chemoradiotherapy are 
feasible in elderly patients with lung cancer. Sequential treatments 
may be as effective as concurrent chemoradiotherapy in elderly VA 
patient population.
P3.012 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Radio-chemotherapy in locally advanced (LA) non small 
cell lung cancer (NSCLC): a concomitant regimen with low 
dose fractionated schedule of oral vinorelbine (NVBo) and 
cisplatin (CDDP) with radiotherapy (RT) after induction 
chemotherapy (CT)
Dansin, Eric1; Madelaine, Jeannick2; Dujon, Cécile3; Chouaïd, 
Christos4; Schott, Roland5; Prêcheur, Bénédicte6; Piolat, Viviane6; 
Rivière, Alain7; Zalcman, Gérard2; Lartigau, Eric1
1 Centre Oscar Lambret, Lille, France; 2 Centre Hospitalier de 
Caen, Caen, France; 3 Hôpital André Mignot, Le Chesnay, France; 
4 Hôpital Saint Antoine, Paris, France; 5 Centre Paul Strauss, 
Strasbourg, France; 6 Institut de Recherche Pierre Fabre, Boulogne 
Billancourt, France; 7 Centre François Baclesse, Caen, France
Introduction: NVB+CDDP administrated concomitantly with RT 
is a recognized treatment in LA NSCLC (Vokes, JCO 2002). The 
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introduction of the oral form of NVBo has demonstrated to be safe 
and efficient in combination with CDDP, especially as concomitant 
treatment with RT (Krzakowski JTO 2008). This new fractionated 
schedule is proposed to possibly improve the results of CT-RT.
Materials and Methods: Non operable stage IIIA-IIIB NSCLC 
patients received an induction CT with 2 cycles of NVBiv 25 mg/m² 
+ CDDP 80 mg/m² on D1 and NVBo 60 mg/m² on D8 every 3 weeks. 
Non progressive pts received 2 additional cycles of fixed dose NVBo 
of 20 mg on D1, D3 and D5, + CDDP 80 mg/m² on D1 every 3 
weeks, combined with a conformal RT (66 Gy total dose, 5 fractions 
of 1.8 to 2 Gy per week).
Results: Between October 05 and May 08, 70 pts were enrolled: 68 
pts evaluable for safety, 64 for response. Patient and disease charac-
teristics were: median age 61 years [range 41-73], male 85%, stage 
IIIA 28%, IIIB 72%; Squamous carcinoma 44%, Adenocarcinoma 
30%; median KPS 90%.
After 2 cycles of induction chemotherapy, the Objective Response 
(OR) was 42% (PR) and Disease Control (DC) was 87%. 4 pts were 
down-staged and underwent surgery. After completion of the chemo-
radiotherapy, the OR was 55% (CR=7%), DC= 88%.
With a median follow up of 2 years, 48 progression events occurred 
with: distant metastasis 51% (including brain 48%, bone 20%, other 
32%), loco-regional relapse 30% and clinical progression 19%.
Overall safety (G3-4, % of pts) was: neutropenia 19%, N/V 1%, post 
radiation pneumonitis 1%, anorexia 7%. Oesophagitis G1-2 was 
recorded in 42% of pts (no G3-4).
Conclusion: This new fractionated schedule provides Objective 
Response in 55% of pts and Disease Control in 88% of pts. Given 
the optimal tolerance profile of this new administration schedule of 
NVBo+CDDP, 72% of pts could complete the planned treatment. 
Furthermore, the at home-intake of the oral formulation of NVB on 
D3 and D5 reduces organizational constraints related to the concur-
rent CT-RT. This combination of chemo-radiotherapy offers a well 
tolerated and efficient therapeutic option for the treatment of non 
operable stage IIIA-IIIB NSCLC. The final results will be presented 
during the congress.
P3.013 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Improvement in efficacy and tolerability over carboplatin 
and paclitaxel standard of care with the triple combination 
of carboplatin, ASA404 and patupilone (EPO906) in the in 
vivo A549 NSCLC model
Ferretti, Stephane; Berger, Marjorie; Cozens, R.; McSheehy, Paul MJ; 
Evans, Dean B.
Novartis Pharma AG, Basel, Switzerland
Patients with advanced non-small cell lung carcinomas (NSCLCs) 
have a poor prognosis. One of the currently recognised standard of 
care (SoC) approaches involves carboplatin (CBP) and paclitaxel 
(PTX) and this offers some clinical benefit. ASA404 (ASA) is a 
small molecule tumour-vascular disrupting agent (Tumour-VDA) 
that selectively disrupts established tumour blood vessels. Patupil-
one (PAT) is a novel non-taxane microtubule stabilizing macrolide 
that binds to β-tubulin with a higher affinity than taxanes leading to 
stabilized microtubules that subsequently results in cell cycle arrest 
and apoptosis. PAT and ASA are currently in phase II and phase III 
clinical development trials for NSCLC respectively. The aim of this 
study was to evaluate the potential benefit of adding ASA to the cur-
rent SoC and also to examine the possibility for replacing PTX with 
PAT in the current SoC.
An experimental model of NSCLC was established using human 
A549 cells which were grown as subcutaneous (s.c.) xenografts in 
nude mice. Treatments were administered intraveneously (i.v.) either 
weekly (qw) with PAT (2 mg/kg) or CBP (30-70 mg/kg) or 2-3qw 
with PTX (8-10 mg/kg). ASA (10-20 mg/kg) was given intraperiton-
eally (i.p.) on days 0, 4 and 8 of a 2 week study. Efficacy and toler-
ability were assessed by changes in tumour volume (TVol) and body 
weight (BW) respectively. Data were calculated as the mean ratio of 
tumour volume in treated divided by vehicle control mice (T/C) and 
of the analogous body weight ratio (T/CBW), but are expressed as 
the maximum observed value from at least 2 individual studies, with 
significance levels set at p<0.05.
A549 tumour growth was inhibited dose-dependently by CBP (max 
T/CTVol=0.53), ASA (max T/CTVol=0.36) and PTX (max T/CTVol=0.07). 
PAT alone at a relatively low dose of 2 mg/kg had a weak effect on 
tumour growth (T/CTVol=0.8). Combination of PTX (10 mg/kg 2qw) 
and CBP (50-70 mg/kg qw) resulted in 50% mortality, so the dose of 
PTX in the combination was decreased to 8 mg/kg (T/CTVol=0.69). 
A comparable significant magnitude in potency was observed when 
CBP was given either in combination with PTX (max T/CTVol=0.42) 
or PAT (max T/CTVol=0.32). Both of these combinations showed 
non-significant signs of some toxicity (max T/CBW=0.91 for PTX and 
0.87 for PAT). The addition of ASA (15-18 mg/kg) to CBP and PTX 
significantly improved the efficacy (max T/CTVol= -0.04) but this was 
also associated with some increased mortality (survival=60-85%) 
as well as BW loss (max T/CBW=0.84). However, replacing PTX by 
PAT in the triple combination with CBP and ASA slightly increased 
the efficacy (max T/CTVol= -0.11) whilst significantly increasing BW 
loss (max T/CBW = 0.76) but this was not associated with an increased 
mortality.
These preclinical data using the A549 in vivo NSCLC model sug-
gest that the current SoC chemotherapy combination of CBP and 
PTX used for the treatment of NSCLC could be markedly improved 
upon by the addition of ASA404 and that the replacement of PTX 
by patupilone was associated with an improvement in efficacy and 
tolerability.
P3.014 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Phase II study of combined modality therapy with 
concurrent docetaxel and carboplatin plus radiation 
therapy followed by consolidation pemetrexed 
chemotherapy for unresectable stage III non-small-cell-
lung cancer
Gauden, Stan1; Haug, Greg2; Markos, James2; Parkes, Scott2
1 WP Holman Clinic, Launceston, TAS, Australia; 2 Launceston 
General Hospital, Launceston, TAS, Australia
Background: Concurrent chemoradiotherapy is emerging as standard 
treatment for patients with inoperable stage III non-small-cell lung 
cancer (NSCLC).
However, the optimal combination of chemotherapy and radiation 
therapy (RT), as well as the role of consolidation chemotherapy in 
patients with locally advanced NSCLC remains unknown. Docetaxel 
and carboplatin have demonstrated activity as radiation senstisers in 
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pre-clinical studies. Both drugs are active against NSCLC and can 
safely be combined with RT at effective systemic doses, making them 
attractive study agents against locally advanced NSCLC. Moreover, 
the antifolate agent pemetrexed has demonstrated efficacy and toler-
ability in the treatment of locally advanced and metastatic NSCLC.
The objective of this phase II study was to document the activity and 
to evaluate the toxicity of concurrent docetaxel and carboplatin with 
thoracic radiation followed by consolidation pemetrexed chemother-
apy in locally advanced stage III NSCLC.
Methods: Eligible patients had stage IIIA or IIIB NSCLC, baseline 
performance status of 0 to 1, forced expiratory volume in 1 second 
≥1 L, and less than 5% weight loss. Carboplatin was administered at 
an AUC of 4 on days 1 and 29. Patients received docetaxel 30 mg/m2 
intravenously (IV) on days 1, 8, 22, and 29 concurrently with three 
dimensional conformal thoracic RT to 60 Gy in 30 fractions (2 Gy/
fraction 5 fractions per week). Patients who did not experience pro-
gression were assigned to pemetrexed 500 mg/m2 IV every 21 days 
for four cycles. The primary end point was to determine the overall 
response rate, the secondary endpoint was to evaluate survival and 
the safety profile.
Results: Patient characteristics (n = 25) were as follows: 48% 
female; median age, 66 years; 48% stage IIIA; and 52% stage IIIB. 
The overall response rate was 76%. The median survival rate for 
all patients was 22 months, and the 1-year survival rate was 68%. 
Toxicity was moderate: grade 2 neutropenia was seen in 6 patients, 
and grade 3 neutropenia in 1 patient. Grade 2 thrombocytopenia was 
seen in 2 patients, and grade 3 thrombocytopenia was not observed. 
Nonhaematological toxicities were moderate: grade 3 oesophagitis 
occurred in 1 patient. Grade 1 asthenia/fatigue was observed in 5 
patients, and grade 2 asthenia/fatigue in 3 patients. Grade 3 pulmon-
ary toxicity occurred in 1 patient.
Conclusion: We have identified a well-tolerated and active chemor-
adiotherapy regimen in the treatment of patients with unresectable 
Stage III NSCLC. Concurrent docetaxel and carboplatin along with 
thoracic radiation therapy followed by consolidation single agent 
pemetrexed is feasible and tolerable. Survival results are promising 
and warrant further study in large randomised studies to document 
and confirm the effectiveness of this regimen.
P3.015 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
A randomized multicenter phase II study of concurrent 
pemetrexed and radiotherapy with induction or adjuvant 
cisplatin/pemetrexed in patients with unresectable stage III 
non-small cell lung cancer (NSCLC)
Germonpré, Paul R.1, 2; Janssens, Annelies1; Galdermans, Danny3, 2; 
Ortmanns, Paul4, 2; Deschepper, Koen6, 2; Devogelaere, Roger7, 2; De 
Droogh, Els3, 2; De Pooter, Christel5, 2; Goor, Chris3, 2
1 Antwerp University Hospital, Edegem, Belgium; 2 Thoracic 
Oncology Group Antwerp (TOGA) - Antwerp University, Antwerp, 
Belgium; 3 ZNA Middelheim, Antwerp, Belgium; 4 AZ Heilige 
Familie, Reet, Belgium; 5 Sint Augustinus, Wilrijk, Belgium; 6 AZ 
Nikolaas, Sint Niklaas, Belgium; 7 AZ Damiaan, Oostende, Belgium
Background: Concurrent chemoradiation (CRT) is the standard 
of care for unresectable stage III NSCLC, however no standard 
chemoradiation regimen or schedule has been established. Cisplatin/
pemetrexed has shown excellent efficacy and tolerability in patients 
with advanced NSCLC. Phase I/II data indicated that pemetrexed at 
full dose can be combined with radiotherapy 
Aim: To evaluate the efficacy and toxicity of concurrent pemetrexed 
and radiotherapy with induction or adjuvant cisplatin/pemetrexed 
for unresectable stage III NSCLC. The primary endpoint is overall 
response rate.
Methods: Between 01/2006 and 12/2008, 30 patients were random-
ized to induction combination chemotherapy followed by CRT (arm 
A) or CRT followed by adjuvant combination chemotherapy (arm 
B). The CRT and combination chemotherapy schedules (including 
vitamin supplementation) are identical in both arms. Combination 
chemotherapy consists of cisplatin 75 mg/m2 and pemetrexed 500 
mg/m2 on day 1 every 21 days for 3 cycles. CRT consists of 60 Gy 
of thoracic conformal radiotherapy (2 Gy/fraction, 5 fractions/week) 
combined with 3-weekly pemetrexed 500 mg/m2 (starting on day 1 or 
2 of RT) for a total of 6 weeks. Eligibility criteria included: PS 0-2, 
weight loss <10%, FEV1 >1.2L or 45%, DLCO >50% and adequate 
organ function.
Results: As of 01/2009 13 patients in each arm were evaluable: 
median age 66y (range 39 – 82y), male/female 21/5, squamous/non-
squamous 8/18, IIIA/IIIB 13/13, PS 0-1/2 22/4. The grade ≥3 toxicity 
data (%) by arms (A/B) for 26 patients: anemia 0/15, neutropenia 
46/62, febrile neutropenia 0/15, neutropenic infection 8/23, radiation 
pneumonitis 23/15, radiation esophagitis 0/15, fatigue 15/23, and 
anorexia 8/23. Two treatment-related deaths occurred in arm B: 1 due 
to sepsis and 1 due to pneumonia. The best overall response rate was 
69% in both arms. The 1-year progression-free and overall survivals 
are 40% and 58% in arm A, and 34% and 54% in arm B. Updated 
data on treatment delivery, toxicity, response rate and survival will be 
available in August 2009.
Conclusion: Our preliminary data indicate that the combination of 
full dose pemetrexed and concurrent radiotherapy with induction or 
adjuvant cisplatin/pemetrexed appears feasible and results in encour-
aging response rates.
This trial was supported by an unrestricted grant from Eli Lilly
P3.016 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Phase I/II trial of a COX-2 inhibitor with limited field 
radiation for intermediate prognosis patients with locally 
advanced non-small cell lung cancer: Radiation Therapy 
Oncology Group (RTOG) 0213
Gore, Elizabeth M.1; Bae, Kyounghwa2; Langer, Corey3; Extermann, 
Martine4; Movsas, Benjamin5; Okunieff, Paul6; Videtic, Gregory7; 
Choy, Hak8
1 Medical College of Wisconsin, Milwaukee, WI, USA; 2 Department 
of Statistics, Radiation Therapy Oncology Group, Philadelphia, PA, 
USA; 3 Division of Hematology-Oncology, University of Pennsylvania 
Health System, Philadelphia, PA, USA; 4 Senior Adult Oncology, 
H. Lee Moffitt Cancer Center, Tampa, FL, USA; 5 Department of 
Radiation Oncology, Henry Ford Hospital, Detroit, MI, USA; 6 
Department of Radiation Oncology, University of Rochester Medical 
Center, Rochester, NY, USA; 7 Department of Radiation Oncology, 
Cleveland Clinic, Cleveland, OH, USA; 8 Department of Radiation 
Oncology, UT Southwestern Medical Center, Dallas, TX, USA
Background: There is no standard of care for patients with poor risk 
factors and locally advanced lung cancer. Concurrent chemotherapy 
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is effective but results in significant toxicity. Cooperative group 
trials have not been uniformly successful in accruing patients with 
advanced age, poor performance status (PS), weight loss (WL), and 
multiple co-morbid conditions. This study was conducted to test a 
treatment regimen with anticipated low toxicity and evaluate patient 
factors that may better define this diverse patient population. 
Methods: This phase I/II study employed concurrent celecoxib, a 
COX-2 inhibitor, and hypo-fractionated radiation therapy (45 Gy in 
15 fractions). Eligible patients had inoperable or unresectable stage 
IIB, IIIA/B NSCLC, PS 2 and/or > 5% weight loss. The phase I 
portion of the study featured celecoxib at a starting dose of 200mg 
BID with one dose escalation to 400mg BID. 400mg BID was well 
tolerated and was chosen for the phase II component of the study. All 
patients had functional and psychological status, QOL and co-mor-
bidity assessments to further define prognostic factors.
Results: The phase I portion of the study accrued 8 patients each 
at 200mg BID and 400mg BID. The Phase II portion of the study 
accrued only 5 patients and was closed June 30, 2005 due to poor 
accrual, slowed by reported cardiac toxicity with this class of drug. 
One patient withdrew consent and 2 were ineligible. Eighteen pa-
tients were analyzable for this report. PS was 0, 1, and 2 in 7, 7 and 
4 patients. Median age was 72. WL >5% was noted in 10 patients 
(56%). Four out of the 10 had WL ≥ 20%. Treatment was well toler-
ated and toxicities matched those expected with TRT alone. Median 
follow up and survival was 10 months. Overall survival at 1 and 2 
years were 44.4% (95% CI: 21.6, 65.1) and 22.2% (95% CI: 6.9, 
42.9). Progression free survival at 1 year was 33.3% (95% CI: 13.7, 
54.5). One patient was alive and 6 died without tumor progression. 
Three patients had loco-regional progression only, and 8 patients had 
distant only failures. At baseline, 8 patients were dependent and 10 
patients independent in Assessment of Daily Living Scale. Based on 
the Geriatric Depression Scale, one patient was mildly depressed; 17 
were not depressed. Mean score for Cumulative Illness Rating Scale 
for Geriatrics was 10.1 and for Charlson Comorbidity Index was 1.8.
Conclusions: Results of this study are similar to other studies evalu-
ating LA-NSCLC patients with unfavorable prognostic factors. Of 
interest, median age was higher than similar studies evaluating more 
aggressive therapy, including studies targeting patients with unfavor-
able prognostic factors. Comorbidity scores were high compared to 
the general lung cancer population. More effective regimens with low 
anticipated toxicity need to be studied in this challenging population.
P3.017 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Weekly paclitaxel and carboplatin concurrent with 
radiotherapy for locally advanced inoperable NSCLC in a 
tertiary referral centre
Islam, Mohammed2; Dauth, Margaret2; Lehman, Margot2; Murphy, 
Michelle2; Horwood, Keith2; Tao Mai, Gang2; McCaffrey, Elizabeth2; 
Guminski, Alexander David1
1 Royal North Shore Hospital, Sydney, New S Wales, Australia; 2 
Princess Alexandra Hospital, Brisbane, QLD, Australia
Background: Weekly paclitaxel (P) and carboplatin (C) given with 
radiotherapy is an attractive treatment for locally advanced NSCLC 
due to its convenience, patient tolerability and low incidence of 
haematological toxicity. Belani et al (JCO 2005 23:5883-91) tested 
three regimens of sequential or concurrent PC with radiotherapy (RT) 
with either induction or consolidation three weekly PC. The best 
outcome, but greatest toxicity, was seen in weekly PC concurrent 
with RT followed by 2 cycles of consolidation PC. In view of these 
results and toxicity data our lung cancer service adopted the concur-
rent component of therapy as a pragmatic treatment for locally ad-
vanced inoperable NSCLC patients. More recently a report of weekly 
chemoRT with PC has been compared with induction PC followed 
by chemoRT with PC. No benefit from induction treatment was seen 
and the median survivals in both groups were considered low, casting 
doubt on the effectiveness of weekly PC chemoRT (Vokes et al JCO 
2007 25:1698-704). We therefore have reviewed our experience with 
unselected patients referred to a tertiary referral centre.
Methods: All patients with NSCLC referred to Princess Alexandra 
Hospital are reviewed in a multidisciplinary meeting with dedicated 
respiratory physicians, radiologists, medical and radiation oncolo-
gists. All patients with apparently localised disease are staged with 
PET and CT. Since June 2003 patients with inoperable non-metastatic 
NSCLC, not participating in clinical trials, have been routinely 
treated in our centre with P (45mg/m2) and C (AUC=2) given weekly 
concurrent with radiotherapy. Radiotherapy is given over 6 weeks to 
60Gy by standard techniques. Forty-six patients were identified who 
commenced PC chemoRT. Characteristics of the patients were 29 
male, 17 female, median age 67 (range 36-79), ECOG performance 
status ECOG 0/1/2-22/23/1 patients respectively, 25 with >5% weight 
loss. Stage distribution was 2A-3, 2B-6, 3A-17, 3B-20. 
Results: The median number of cycles of chemotherapy received 
was 6. All patients experienced some grade 1 or 2 toxicity espe-
cially nausea and fatigue. One patient experienced a major allergic 
reaction after his 2nd cycle of P precluding further P. Three patients 
experienced Grade 3 neutropenia. One patient developed significant 
radiation pneumonitis following treatment. Forty of 46 patients were 
considered to have a partial or minor radiological response. One 
complete response was observed. One patient had stable disease, one 
patient had progressive disease and three were not assessable. The 
median progression free survival was 7 months and 7 patients remain 
progression free with follow-up between 9 and 60 months.
Conclusion: Weekly PC chemoRT is a pragmatic treatment with 
good tolerability and high response rate. Novel strategies to consoli-
date this treatment are required however to improve patient out-
comes.
P3.018 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Concurrent chemoradiotherapy using cisplatin and 
vinorelbine for locally advanced non-small cell lung 
cancer (NSCLC) in the era of 3D radiotherapy planning: a 
retrospective analysis of clinical practice data
Hayakawa, Kazushige; Mitsufuji, Hisasi; Niibe, Yuzuru; Ishiyama, 
Hiromichi; Kotani, Shouko; Ryuge, Shinichiro; Katagiri, Masato; 
Kubota, Masaru; Satoh, Yukitoshi; Masuda, Noriyuki
Kitasato University School of Medicine, Sagamihara, Japan
Purpose: To evaluate the feasibility and efficacy of concurrent 
chemoradiotherapy using cisplatin and vinorelbine for unresectable 
stage III non-small cell lung cancer (NSCLC) by the retrospective 
analysis of our clinical practice. 
Patients and Methods: The eligibility criteria included unresect-
able stage III NSCLC, no previous treatment, age between 20 and 71 
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years, and performance status 0 or 1. Treatment consisted of cisplatin 
(80 mg/m2 on days 1, 29), vinorelbine (20 mg/m2 on days 1, 8, 29, 
36), and thoracic radiotherapy (TRT) (60 Gy/30 fractions over 6 
weeks starting on day 1), followed by consolidation two courses of 
same regimen (vinorelbine 25 mg/m2). Inhomogeneous dose distribu-
tions in the target volume and the surrounding organs-at-risk were 
evaluated by using 3D RT planning system, although the given dose 
was calculated at the central axis without any inhomogeneity correc-
tion. A V20 (the percent volume of the normal lung receiving 20 Gy or 
more) was calculated on a dose-volume histogram in the majority of 
patients, and as a rule V20 was planed less than 35%.
Results: Sixty-one patients (50 males and 11 females with a median 
age of 61) were treated with this protocol between September 2000 
and October 2008 in our hospital. There were 23 patients in stage 
IIIA and 38 in IIIB. Chemoradiotherapy was well tolerated; three or 
more cycles of chemotherapy and 60 Gy of TRT were administered in 
54 (90%) and 56 (93%) patients, respectively. Grade 3 or 4 neutro-
penia was often seen and resulted in discontinuation of the protocol 
therapy. There were few patients who had esophagitis and pneumon-
itis necessitating a rest of the treatment. The median progression-free 
survival was 12.5 months, and median survival was 22.2 months. The 
1-, 2-, and 3-year survival rates were 95, 68, and 55%, respectively. 
Only 8 patients needed a medical care for radiation pneumonitis.
Conclusion: This regimen produced promising overall survival in 
patients with stage III NSCLC by 3D RT planning with a V20<35%.
P3.019 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
A phase I trial of cisplatin, pemetrexed and radiation in 
patients with stage III non-small cell lung cancer 
Hensing, Thomas A.2; Patel, Jyoti1; Marymont, Maryanne1; Shaikh, 
Arif2; Nash, Therese1; Neale, Marie2; Rademaker, Alfred W.1
1 Northwestern University, Chicago, IL, USA; 2 NorthShore 
University HealthSystem, Evanston, IL, USA
Background: Concurrent cisplatin (C)-based chemotherapy (CH) 
and thoracic radiation (TRT) remains the standard treatment of 
patients (pts) with unresectable stage III non-small cell lung can-
cer (NSCLC). Recent trials have demonstrated the importance of 
delivering CH at full dose with TRT. The antifolate pemetrexed (P) 
has been evaluated in combination with TRT and can be delivered 
at full dose with a reasonable toxicity profile. The combination of 
PC has been shown to have comparable activity when compared to 
other platinum-based doublets in the treatment of pts with advanced 
NSCLC. Given this background, we conducted a phase I/II trial to 
determine the maximum tolerated dose (MTD), dose-limiting toxici-
ties (DLT) and overall response rate of PC with concomitant TRT in 
pts with unresectable stage III NSCLC. 
Methods: Newly diagnosed unresectable stage III pts (age > 18, 
ECOG PS 0-1, no pleural effusion) with acceptable bone marrow, 
liver and renal function were eligible. All pts received folic acid and 
vitamin B12 supplementation. Treatment consisted of 2 cycles of CH 
with PC administered concurrently with TRT (60 – 66 Gy) followed 
by consolidation with 2 additional cycles. P 500 mg/m2 was admin-
istered on day (d) 1 every 21 d to all pts with C at the following dose 
levels: (1) 30 mg/m2 d 1, 8; (2) 60 mg/m2 d 1; and (3) 75 mg/m2 d 1.
DLT was defined as grade IV hematological toxicity, grade IV 
gastrointestinal toxicity, grade III dermatological toxicity or grade 
III fatigue lasting greater than 1 week. At least 3 pts were accrued to 
each level. If a DLT was observed, an additional 3 pts were accrued 
at that dose level. If 2 or more pts experienced a DLT, accrual was 
continued at the next lower dose level. The MTD was defined as the 
highest dose where not more than 1 of a 6 pt cohort developed a DLT. 
Results: Between 1/4/06 and 12/2/08, 17 pts were enrolled (4 
male/13 female; 10 stage IIIA/7 IIIB). No DLT was observed on 
dose level 1 (5 pts) or 2 (4 pts). One pt on level 3 experienced a DLT 
with grade III fatigue and dehydration. Three additional pts were 
accrued to this dose level (total 8 pts) without further DLT. The most 
common adverse events (n>3 events, G I/II/III) included fatigue 
(5/4/1), nausea (7/2/1), vomiting (4/1/0), skin (2/2/0), anemia (3/3/0), 
leucopenia (1/0/2), and thrombocytopenia (3/2/0). Notably, the rate 
of esophagitis was low (3 G II). Overall 14 pts are evaluable for re-
sponse. Partial response was achieved by 8 pts (1 dose level I, 2 dose 
level 2, 5 dose level 3).
Conclusion: In this phase I trial, the MTD of C combined with full 
dose P (500 mg/m2) and TRT was defined to be 75 mg/m2. Overall, 
this combination was tolerable and antitumor activity was observed. 
We would recommend further testing of this regimen against the 
standard regimen of cisplatin, etoposide and radiation in pts with 
stage III NSCLC. 
P3.020 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
A phase I trial of concurrent chemoradiotherapy (cCRT) 
with the conventional administration of decetaxel (D) and 
cisplatin (P) for dry-stage III non-small cell lung cancer 
(NSCLC) (JCOG9901DI)
Hida, Naoya; Tsujimura, Shuko; Tomiki, Fujii; Naoki, Katsuhiko; 
Okamoto, Hiroaki; Shimizu, Teppei; Watanabe, Koshiro
Yokohama Municipal Citizens' Hospital, Yokohama, Knagawa, Japan
Background: In cCRT for locally advanced NSCLC, the full dose 
chemotherapy with new agent plus platinum doublet is considered 
to have inacceptable toxicities. Weekly chemotherapy is often used. 
However, the conventional administration regimens are expected to 
emphasize not only radiosensitizing but also systemic effect. This 
study aimed to establish the MTD of cCRT with the conventional 
administration DP (conv-DP) regimen.
Methods: Unresectable dry-stage III NSCLC patients(pts) (<70 
years) with ECOG performance status 0-1 and adequate organ 
function were eligible. Pts received 60Gy in 30 fractions once daily 
radiotherapy. Concurrent P (day1; 60mg/m2 at level 1-3, 80mg/m2 at 
level 4) and D (day1; 30mg/m2 at level 1, 40mg/m2 at level 2, 50mg/
m2 at level 3-4) given every 4 weeks at least 2, up to 4 courses. The 
DLT was defined as Gr 3 febrile neutropenia, Gr4 thrombocytopenia, 
Gr2 pneumonitis and any Gr3 non-hematological event.
Results: Eighteen pts (six pts in level 2 and 4, three pts in level 1 
and 4) were enrolled from 06/1999 to 05/2006; 13 males, median 
age 60 years old (range 43-70), stage IIIA/IIIB 5/13, histology Ad/
Sq/Large 9/7/2. The three DLTs were observed in level 2 (D40/P60); 
unrecovered Gr4 pneumonitis, in level 3(D50/P60); Gr3 cerebral 
infarction and Gr3 atrial fibrillation. In these levels, three cases were 
added, and the tolerability was cleared (DLTs two or less). The 60Gy 
radiotherapy completed in 15 pts. Seventeen pts were received more 
than two courses of chemotherapy. The Gr3/4 esophagitis and severe 
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hematologic event were not observed. The MTD is D50/P80. The 
objective response rate is 89%.
Conclusions: The CRT with non split DP (50/80 every 4 weeks) 
regimen were tolerable. The esopagitis and hematologic toxicity were 
minimal in this small patients trial. A phase II trial is being planned to 
evaluate the efficacy and toxicity of this cCRT with conv-DP therapy.
P3.021 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
MM-121, a first in class anti-ErbB3 antibody, shows 
efficacy in preclinical models of lung cancer: a potentially 
new treatment modality for human lung cancer
Kalra, Ashish; Linggi, Bryan; Kopsiaftis, Stavros; Burenkova, Olga; 
Fulgham, Aaron; Onsum, Matt; Garcia, Gabriela; Schoeberl, Birgit; 
Kubasek, Bill; Nielsen, Ulrik
Merrimack Pharmaceuticals, Cambridge, MA, USA
Lung cancer remains one of the leading causes of death in the United 
States. Currently available treatments for this disease have shown 
only modest benefits, and thus, there remains a need for improved 
therapeutics.
Using a combination of computational and experimental biology, 
we identified ErbB3 as a critical signal transducer in several cancer 
indications, including lung cancer. Based on this information, we 
developed a human monoclonal IgG2 antibody (MM-121) against 
ErbB3 and tested it in multiple assays for its ability to inhibit onco-
genic signaling. 
Previously, we demonstrated that MM-121, used as a single agent, 
inhibited heregulin-induced signaling events in human cancer cell 
lines. Additionally, MM-121 caused dose-dependent inhibition of 
tumor growth in multiple xenograft models of human cancer, includ-
ing ovarian, renal cell, pancreatic, lung, and prostate cancer. 
In this study we investigated the efficacy of MM-121 given in com-
bination with either chemotherapy or targeted therapeutics in lung 
cancer cell lines treated in vitro and in lung cancer xenografts. The 
current data is highly promising as it supports that MM-121 when 
used as a single therapeutic agent or in combination could have sig-
nificant clinical benefit for the treatment of lung cancer.
P3.022 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
A phase I/II study of nab-paclitaxel and carboplatin with 
concurrent radiation therapy for unresectable stage III 
non-small-cell lung cancer (NSCLC)
Keedy, Vicki1; Horn, Leora 1; Carbone, David1; Nagle, Lawrence2; 
Johnson, David1; Sandler, Alan1
1 Vanderbit University Medical Center, Nashville, TN, USA; 2 
University Oncology/Hematology Associates, Chattanooga, TN, USA
One third of patients (pts) with NSCLC present with localized, but 
unresectable disease. Concurrent chemoradiotherapy is well estab-
lished with weekly paclitaxel and carboplatin with median survivals 
of ~14 months. Nab-paclitaxel is a cremophor-free formulation of 
nanopartical paclitaxel designed to improve solubility and intra-tumor 
delivery. We designed a Phase I/II trial using weekly nab-paclitaxel 
with carboplatin and thoracic radiation in patients with unresectable 
stage III NSCLC, and present results of the Phase I study here.
Methods: Pts entered escalating dose cohorts in a 3+3 design of nab-
paclitaxel weekly, beginning at 40 mg/m2 and increasing by 20 mg/
m2 in each cohort, in combination with carboplatin (AUC 2) weekly 
for seven weeks and concurrent radiation therapy in 33 fractions. Pts 
then received 2 cycles of consolidation therapy with full dose nab-
paclitaxel (100 mg/m2 weekly for 3 weeks) and carboplatin (AUC 6 
on day one of each cycle) every 21days. 
Results: Five patients have been treated at 2 dose levels of nab-pa-
clitaxel, 40mg/m2 and 60mg/m2. One patient signed consent and then 
withdrew. To date, 4 patients have completed all cycles of therapy 
and 1 remains on treatment without dose reductions or DLT. During 
concurrent treatment grade 2 (G2) or greater toxicities possibly/prob-
ably related were G2 thrombocytopenia (1), anemia (2), esophagitis 
(1) and fatigue (2), and G3 hypoxia (1). During consolidation or 
follow-up, toxicities included G2 anemia (1), and G3 hypotension (1) 
and hypophosphatemia (1). 4 pts are evaluable for response with 2 
PRs and 2 SD. 2 patients have progressed 5 and 7 months after begin-
ning treatment, and 2 patients remain stable 8 and 10 months after 
beginning treatment.
Conclusion: Weekly nab-paclitaxel appears to be safe and well toler-
ated at 60mg/m2 when used in combination with weekly carboplatin 
and thoracic radiation. Enrollment in the phase I study continues, and 
updated results will be provided.
P3.023 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Concurrent three-dimensional conformal radiotherapy 
with different dose fractionation in combination with 
cisplatin-based systemic chemotherapy for stage III non-
small cell lung cancer: a randomized trial study
Fan, Tingyong; Li, Ji-bin
Shandong Cancer Hospital and Institute, Jinan, China
Objective: To compare the treatment effects and toxicity of con-
ventional-dose fractionation, hypofractionation three-dimensional 
conformal radiotherapy (3D-CRT) plus concurrent cisplatin-based 
systemic chemotherapy and conventional-dose fractionation 3D-CRT 
alone on the patients with Stage III non-small cell lung cancer. 
Methods: From August 2000 to June 2003, 90 patients with unresect-
able Stage III NSCLC were selected for the study and had completed 
the treatment. They were divided randomly into 3 groups. Group 1: 
Conventional-dose fractionation 3D-CRT plus concurrent cisplatin-
based systemic chemotherapy, group 2: Conventional-dose frac-
tionation 3D-CRT alone, group 3: hypofractionation 3D-CRT plus 
concurrent cisplatin-based systemic chemotherapy. Conventional-
dose fractionation schedule 3D-CRT was given to a total dose of 
66-66.6 Gy (1.8-2Gy/fraction, 5 fraction/week) and hypofractionation 
schedule was given to a total dose of 45Gy (4.5-5Gy/fraction, 5 frac-
tion/week). 
Results: The 3-year overall survival rate and disease-free survival 
rate in Group 1, Group 2 and Group 3 were 33.3%,20.0%,36.6% 
and 23.3%,16.6%,23.3% respectively. The median survival time 
were 31months, 20months and 32months respectively, with ob-
vious better results in group 1 and group 3 (Group 1 vs Group 
2:χ2=3.87,P=0.0492; Group 2 vs Group 3: χ2=4.28, P=0.0387), 
though without statistical difference between these two groups. Using 
Kaplan—Meier methods to analyze the metastasis: The median 
metastasis time of group 2 (22 months) is lower than that of group 1 
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(31.5 months) and group 3 (30.5 months), with significant statistical 
difference (Group 1 vs Group 2: χ2=4.71, P=0.0301; Group 2 vs 
Group 3:χ2=4.02, P=0.0449), while there were no difference between 
group 1 and group 3. The median recurrent time of group 1, group 2 
and group 3 were 27.5, 32 and 28 months respectively. There were no 
significant statistical difference in regional recurrence among three 
groups. The incidence of radiation induced esophagitis in these 3 
groups were 46.7%, 43.3% and 63.3% respectively. The incidence in 
group 3 were higher than the other two groups. The patients number 
of radiation induced pneumonitis in these 3 groups were similar 
(P=0.487), which mainly is grade Ⅰ response. More patients with 
grade Ⅱ radiation induced pneumonitis cases were found in group 3. 
Conclusion: 3D-CRT combined with concurrent chemotherapy re-
duced the distant metastasis incidence and increased the over survival 
and disease-free survival. Patients could tolerante the whole chemo-
therapy, without significant blood toxicity. The acute and late radia-
tion injury of hypofractionation radiotherapy were more severe com-
pared with conventional dose fractionation schedule. Small-sized and 
isolated tumors are fit for hypofractionated schedule, which should 
reduce the treating time and increase the local control rate,but no 
obvious increase of normal tissue complication probability. While to 
big-sized or late-response-tissue surrounded tumors,hypofractionated 
radiotherapy should not be suitable.
P3.024 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Impact of age in stage IIIb NSCLCC patients treated with 
concurrent radio chemotherapy
Tardieu, Mathilde1; Des Guetz, Gaetan1; Bouillet, Thierry1; Escure, 
Paul1; Etessami, Reza1; Diana, Christian2; Hamond, Karim2; Spano, 
Jean Philippe2; Sebbane, Georges2; Morere, Jean Francois2, 1
1 Department of Oncology, Assistance Publique - Hôpitaux de 
Paris, Bobigny, France; 2 GNOM (Groupe Nord Oncologie 
Multidisciplinaire) Hôpital Avicenne, Bobigny, France
Background: Concurrent radiochemotherapy has been shown to 
improve overall survival in stage IIIb NSCLC, but these beneficial re-
sults may not be extrapolated to older patients. In a randomized phase 
2 study we have evaluated the impact of age comparing of two radi-
osensitizing regimens ( cisplatine VP16 vs carboplatine paclitaxel). 
Patients / Methods: patients with confirmed stage IIIb NSCLC, 
PS 0 to 2 were randomized to receive either cisplatin 20 mg/m2 
and etoposide 60 mg/m2 Day 1 to 5 every three weeks, 3 courses or 
paclitaxel 40mg/m2 and carboplatine AUC2 day 1 weekly, 7 courses. 
The concurrent radiotherapy (31.2Gy) delivered (34 fractions 1,8Gy 
per fraction, 7 weeks). 
Results: 45 patients were enrolled between 01/2000 and 03/2004. 
The characteristics of the population were:15 patients > 65 years 
(mean age 70) and 30 < 65 years(mean age 54). There were no dif-
ference in both groups considering overall response rate: 60% partial 
response, 20% stable disease in the elderly group vs 18% and 20% 
progressive disease in the elderly group vs 18%. Median overall 
survival was 274 days in older patients vs 466. Incidence of Grade 4 
haematological toxicities were more frequently observed in elderly 
patients ( 1 grade 4 thrombopenia, 1 grade 4 neutropenia). Incidence 
of non haematological toxicities was similar in both groups. Most 
frequent ones were asthenia and oesophagitis ( 8% grade 3 4). 
Conclusion: Concurrent radio chemotherapy with Paclitaxel/Carbo-
platine as well as Cisplatine VP16 is feasible in older patients. Hema-
tological risks is the major risk to be considered for these patients
P3.025 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Treatment and survival in patients with postoperative 
recurrence of non-small cell lung cancer
Nakajima, Ryu; Izumi, Nobuhiro; Takahama, Makoto; Yamamoto, 
Ryoji; Tada, Hirohito
Thoracic Surgery, Osaka City General Hospital, Osaka, Japan
Background: New generation of chemotherapeutic agents were inte-
grated in the treatment of non-small cell lung cancer (NSCLC) since 
the late 1990s and early 2000s in JAPAN, and the treatment after 
postoperative recurrence has changed since 2000s.
Methods: We retrospectively reviewed surgically resected patients 
in our institution (1994-2004), and recurrence cases were extracted. 
These patients were grouped between 1990s group (1994-1999) and 
2000s group (2000-2004), patients characteristics, treatment and 
survival data were compared between the groups. χ2-test and log-rank 
test were used for statistically analysis. 
Results: Of the 1329 patients (90s: 706; 2000s: 623) who underwent 
surgery during both periods, 472 relapsed. Medical records and 
survival data were complete for 384 (90s: 219; 2000s: 165). Patient 
characteristics (gender, age, smoking history, PS, histology and stage) 
and pattern of recurrence were well-balanced. Relapse-free survival 
was not differ (MST (90s vs. 2000s: 13 vs. 17 months, p = 0.6153), 
but survival after recurrence (MST: 11 vs. 18 months, p = 0.007) and 
overall survival (MST: 24 vs. 35 months, p = 0.048) were improved. 
Patients who received any therapy (includes chemotherapy, radio-
therapy, chemo-radiotherapy, and surgical resection) after recurrence 
tended to increase in the 2000s group (90s: 138/219; 2000s: 119/165: 
p = 0.063), and those who received chemotherapy (at least once) 
was significantly increased (54/138 vs. 77/119, p < 0.001). The total 
number of chemotherapy was significantly increased in 2000s group 
(table1), and the total number of EGFR-TKIs therapy was signifi-
cantly increased (table2). 
Conclusions: The survival of patients with postoperative NSCLC 
recurrence has improved and is driven by increased access to therapy 
after recurrence. The increased use of EGFR-TKIs might have con-
tributed to these outcomes.
Table1
  Chemoradiotherapy Chemotherapy Radiotherapy Surgical total 
     resection
 90s group (%) 6 (2) 96 (36) 136 (50) 32 (12) 270 
 2000s group (%) 4 (2) 162 (62) 74 (28) 20 (8) 260
Table2
  Platinum  non-palatinum EGFR-TKIs Total 
  based regimen based regimen
 90s group (%) 31 (32) 48 (50) 17 (18) 96
 2000s group (%) 47 (29) 66 (41) 49 (30) 162
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P3.026 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Chemoradiation in older patients with stage III non-small 
cell lung cancer (NSCLC)
Ng, Dawn M.1, 2; Sun, Alex3, 2; Coate, Linda1, 2; Ma, Clement4; 
Bezjak, Andrea3, 2; Brade, Anthony3, 2; Burkes, Ronald L.5, 2; Cho, 
John3, 2; Feld, Ronald1, 2; Liu, Geoff5, 2; Shepherd, Frances1, 2; Leighl, 
Natasha B.1, 2
1 Division of Medical Oncology/Hematology, Princess Margaret 
Hospital/University Health Network, Toronto, ON, Canada; 2 
University of Toronto, Toronto, ON, Canada; 3 Department of 
Radiation Oncology, Princess Margaret Hospital/University Health 
Network, Toronto, ON, Canada; 4 Department of Biostatistics, 
Princess Margaret Hospital/University Health Network, Toronto, ON, 
Canada; 5 Division of Medical Oncology/Hematology, Mount Sinai 
Hospital, Toronto, ON, Canada
Background: Despite the prevalence of lung cancer in the elderly, 
there is little consensus on stage III NSCLC treatment for older 
patients, with few older patients included in clinical trials. In this 
retrospective analysis, we reviewed patients aged 70 or older with 
stage III NSCLC that received chemoradiation or radiation alone, and 
explored the impact of age, comorbidity, and performance status on 
outcomes. 
Methods: An institutional radiation database was used to identify 
135 patients, age 70 years or older, with stage III NSCLC diagnosed 
between 1999-2007. Demographics, treatment and survival informa-
tion, Charlson comorbidity index (CCI), and ECOG performance 
status (PS) were recorded. Patients were categorized by radiation 
dose prescribed, (RT ≥ 45 Gy versus less), and by whether they 
received combined modality therapy (CMT) with concurrent or se-
quential chemotherapy. Summary statistics were used, and univariate 
and multivariate predictors of outcome were explored. 
Results: Median age of the sample was 74, (range 70-88), with 38% 
≥ 75 years; 33% were female, and 61% had stage IIIA NSCLC. 
Eighty-five percent of the sample received higher dose RT; the main 
reasons for using lower dose RT included disease extent (65%), age 
(35%), and comorbid illness (35%). Many (78%) received chemo-
therapy, 71% concurrent and 7% sequential. Two-thirds of patients 
(65%) completed all planned chemotherapy cycles, while 78% 
completed at least ¾ of planned chemotherapy cycles. Severe toxicity 
(estimated grade 3 or 4) was recorded in 34% of patients, including 
febrile neutropenia (5%), esophagitis (10%), and pneumonitis (10%). 
Patients treated with higher dose RT were more likely to have severe 
toxicity, (39% versus 5%, univariate p=0.02). Patients receiving 
concurrent CMT were more likely to have severe toxicity, while those 
treated with RT alone were least likely to have toxicity, (59% and 
3%; p<0.0001). Those selected for higher dose RT had longer pro-
gression-free survival (PFS) and overall survival (OS) than patients 
treated with lower dose RT, (p=0.001, p=0.04 respectively); this is 
confounded by the effect of patient selection for higher dose RT. Nei-
ther increasing age nor comorbidity was associated with outcomes. 
Worse performance status was associated with poorer OS, even when 
controlled for treatment received, (p=0.04). Performance status was 
also associated with completion of all planned chemotherapy cycles 
(OR 0.19; 95% CI 0.07 to 0.52 for PS >0 patients, p=0.001). 
Conclusions: In this descriptive analysis, while many older patients 
received high dose radiation and chemotherapy, increasing age and 
comorbidity did not demonstrate a strong association with outcome. 
Performance status appeared most important in predicting survival 
and completion of chemotherapy treatment. Age alone should not be 
a barrier to offering curative treatment for stage III NSCLC. In the 
absence of randomized trial data, the impact of age on treatment se-
lection and outcome requires comparison to a younger control group. 
This analysis is currently ongoing, (Coate et al.), and will allow more 
definitive conclusions regarding treatment selection and outcome by 
age in stage III NSCLC. 
P3.027 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Early weight loss is not caused by dysphagia in non-
small cell lung cancer patients treated with concurrent 
chemoradiotherapy
Op den Kamp, Céline M.1; de Ruysscher, Dirk K.2; Houben, Ruud 
M.2; Dehing-Oberije, Cary2; Langen, Ramon C.1; Wouters, Emiel F.1; 
Schols, Annemie M.1; Dingemans, Anne-Marie C.1
1 Department of Respiratory Medicine, Maastricht University 
Medical Centre +, Maastricht, Netherlands; 2 Department of 
Radiation Oncology (Maastro Clinic), Maastricht University Medical 
Centre +, Maastricht, Netherlands
Background: Concurrent chemoradiotherapy (chemo-RT) is the 
treatment of choice for patients with locally advanced non-small 
cell lung cancer (NSCLC). Despite the beneficial effect on survival, 
increases in acute oesophageal toxicity are observed. It is therefore a 
tempting hypothesis that body weight loss during chemo-RT would 
only be due to reduced nutritional intake provoked by treatment-
induced dysphagia. However, alternative hypotheses include inflam-
mation induced by chemo-RT. We therefore investigated body weight 
changes during concurrent chemo-RT in relation to the onset of 
dysphagia. 
Methods: Fifty-one consecutive patients with NSCLC treated with 
concurrent chemoradiotherapy from January 1, 2006 till December 
31, 2007, were included. Body weight was measured at diagnosis, be-
fore chemo-RT, and at week 1, 2 and 3 during concurrent chemo-RT. 
Toxicity was scored according to the Common Terminology Criteria 
for Adverse Events (version 3.0). According to this system, dysphagia 
grade 0-1 does not affect, whereas grade 2 or more influences nutri-
tional intake. Associations between body weight loss and relevant 
predictive variables (age, gender, Charlson comorbidity index, WHO 
performance status, dysphagia grade, mean lung dose and mean 
esophageal dose) were analyzed in a longitudinal data analysis by 
means of a linear mixed regression model. Stepwise reduction was 
performed until only significant predictors remained, with exception 
of dysphagia grade which remained in the model. Data were analyzed 
using SPSS (version 15.0). Significance was set at p<0.05. Results 
are expressed as mean ± 1 standard deviation, unless otherwise 
stated. 
Results: Mean age of patients was 62 ± 9 years (range 41-80). Thirty-
six patients (70.6%) were men, 15 (29.4%) were women. Histology: 
adenocarcinoma: 27.5%, squamous cell carcinoma: 21.6%, large cell 
carcinoma: 19.6%, NSCLC without further specification: 31.4%. Sta-
ging: IIIB: 66.7%, IIIA: 29.4%, IIB: 3.9%. Patients received a total 
dose of 61.5 ± 7.5 Gy (range 45-79 Gy). Concurrent chemotherapy 
consisted of 2 cycles cisplatin-vinorelbine in all patients. Induction 
chemotherapy was administered in 80.4% of patients. The median 
survival for all patients was 22 months (95% CI 16-28). 
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Between diagnosis and start of chemo-RT, patients lost 0.34% ± 3.4% 
of body weight (p=0.57). During concurrent chemo-RT, patients 
lost 1.4% ± 2.2% (p<0.001), 3.3% ± 3.1% (p<0.001), 4.3% ± 3.9% 
(p<0.001) of body weight in week 1, 2, 3, respectively. Body weight 
decreased in 51%, 84%, 86% of patients at week 1, 2 and 3, respect-
ively. In contrast, only 4% of patients had dysphagia grade > 1 before 
start chemo-RT and only 7%, 19%, 31% of patients had grade > 1 
dysphagia at week 1, 2 and 3, respectively. In a linear mixed model 
a significant association was found between body weight loss across 
time (p<0.001). None of the other predictors were significantly as-
sociated with body weight loss, including the grade of dysphagia. 
Conclusions: In this study we show that body weight loss already 
occurs during the first 3 weeks of concurrent chemo-RT, and is not 
associated with dysphagia. Induction chemotherapy did not lead to 
significant body weight loss. Further research is ongoing to eluci-
date the mechanisms underlying this observation. Understanding the 
mechanisms of weight loss would allow for intervention strategies. 
P3.028 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Postoperative complications in pneumonectomy after 
chemoradiation - a single-institutional experience
Osoegawa, Atsushi1; Kometani, Takuro1; Fukuyama, Sei-ichi1; Hirai, 
Fumihiko1; Nosaki, Kaname1; Ondo, Kaoru1; Shinotoh, Makoto2; 
Seto, Takashi1; Sasaki, Tomonari2; Ichinose, Yukito1
1 Department of Thoracic Oncology, National Kyushu Cancer Center, 
Fukuoka, Japan; 2 Department of Radiation Oncology, National 
Kyushu Cancer Center, Fukuoka, Japan
Background: Induction chemoradiotherapy (CRT) followed by sur-
gery for locally advanced non-small cell lung cancer is not regarded 
as a standard therapy following the results from two randomized 
phase III studies (INT0139, GLCCG). The reason why they have 
shown no improvements in survival is probably due to the relatively 
high motality rates, especially among the pneumonectomy cases 
(26% and 14%, respectively). On the other hand, some single-insti-
tutional phase II studies have shown favorable outcomes. We had no 
treatment related death among eleven pneumonectomies after induc-
tion CRT (Ann Thorac Surg 2003).
Methods: From 1995 to 2008, 28 pneumonectomies (23 males and 
5 females, median age of 58 (34-72), Ad/Sq/Others=12/9/7) have 
undergone after induction CRT in our institution. We retrospectively 
reviewed the clinical features and postoperative complications com-
pared with the control group (consecutive cases who underwent pneu-
monectomy as the first therapy during the same time period, n=85).
Results: Concurrent radiation was performed in 27 cases. Median 
dose of radiation was 40 (38-60) Gy. The regimens used for chemo-
therapy were CDDP/UFT in 19 cases, CDDP/TS-1 in 7 cases, CDDP/
VDS and CBDCA/GEM in one case each. Combined resection was 
required in 21 cases including carinal resection in 7 cases, and SVC 
reconstruction in 5 cases. The 30-day mortality was none (same 
with control), and the 100-day mortality was one (4%, compared 
with 6 cases (7%) in control, p=N.S.). There were 13 morbidities 
(46%), pleural effusion required re-drainage in 5 cases, pyrothorax 
in 3 cases, paroxysmal atrial fibrillation in 2 cases, bleeding required 
re-thoracotomy, broncho-pleural fistula, and pneumonia in one case 
each.
Conclusions: Although pneumonectomy after CRT resulted in 
relatively high morbidity because of high incidence of combined re-
section, the mortality rate was modest in our institution. Clinical trials 
among selected institutions should be planned for further investiga-
tions.
P3.029 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Hipofractionated radiotherapy for locally-advanced
Karakoyun Celik, Omur1, 2; Parvizi, Mortaza2; Ozkok, Serdar2; 
Yalman, Deniz 2; Cok, Gursel 3
1 Celal Bayar University, Faculty of Medicine, Department of 
Radiation Oncology, Manisa, Turkey; 2 Ege University, Faculty of 
Medicine, Department of Radation Oncology, Izmir, Turkey; 3 Ege 
University, Faculty of Medicine, Department of Chest Disease, Izmir, 
Turkey
Background: Lung cancer is the leading cause of cancer death in 
the world and majority of patients have advanced disease. Hypofrac-
tionated radiotherapy (HRT) for the treatment of locally-advanced 
non-small cell lung cancer (NSCLC) offers some advantages includ-
ing decreased accelerated repopulation of the tumor clonogenic cells, 
reduced over all treatment time and reduced cost of treatment as well 
due to the fewer fractionation. In this prospective consecutive follow-
up study, we report the clinical outcomes of symptomatic response, 
and overall survival (OAS) in conjunction with acute and late toxici-
ties in patients with locally advanced NSCLC who were treated with 
curative-intend HRT. 
Methods: Twenty-four patients with inoperable NSCLC were treated 
with HRT. The patients were treated using 12 fractions of 4 Gy each, 
Monday through Friday. Initial field consisted of primary tumor and 
lymphatics using AP/PA fields for the first 7 fractions followed-by 
off-cord oblique fields and then cone-down fields for the last 4 frac-
tions. None of the patients received chemotherapy due to the medical 
comorbidities. 
Results: All patients were male with a median age of 72.5 years 
old (range 46-79). Median KPS was 80% (range 60%-90%). There 
were 12 stage IIIA and 12 stage IIIB patients. Fifteen (62.5%) had 
squamous cell carcinoma, 14 (58%) had weight loss more than 10 % 
of their pre-illness weight. Symptomatic improvement was obtained 
in 100 % of patients with hemoptysis, 73% of patients with pain, 60% 
of patients with dyspnea. Radiological tumor response evaluation was 
conducted one month after the completion of HRT on 21 patients. 
There were 14 (67 %) patients with partial response, 1 (5%) patient 
with complete response and 6 (25%) patients with stable disease. All 
patients had died at the time of analysis. The median survival time 
was 11.4 months (range 6-30 months). OAS rates after 12 and 24 
months were 34.8% and 8.7% respectively. In univariate analyses, 
tumor stage (p=0.01), nodal stage (p=0.003), squamous cell histol-
ogy (p=0.02), pre-treatment forced expiratory volume in first second 
(FEV1) (p=0.001), pretreatment DLCO (p=0.045), hemoglobin 
(p<0.0001) values were significant prognostic factors for OAS. In 
multivariate analysis however, only hemoglobin level (p=0.029) and 
squamous histology (p=0.022) were significant prognostic factors 
for OAS. Acute grade I; II esophageal and pulmonary toxicities were 
observed in 6; 12 and 9; 2 patients respectively. Late toxicity was 
evaluated in 20 patients. There were 6 grade II and 1 grade 3 radia-
tion fibrosis and 1 grade 1 esophageal fibrosis. 
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Conclusions: Symptomatic response and OAS rates using HRT in 
patients with locally advanced NSCLC were comparable with other 
fractionation schemas and can be offered in daily routine practices in 
selected patients. 
P3.030 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Patient compliance with prolonged erlotinib (E) treatment: 
experience from a phase I/II trial of perioperative 
concurrent chemoradiotherapy (CRT) and E followed by 
2 years of maintenance E for stage III non-small cell lung 
cancer (NSCLC)
Pennell, Nathan A.; Videtic, Gregory M.; Murthy, Sudish; Mason, 
David; Rice, Thomas W.; Mazzone, Peter; Samsa, Julia; Rich, Tara; 
Shapiro, Marc; Mekhail, Tarek
Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
Background: Prolonged treatment with E for up to 2 years is being 
tested as part of several major adjuvant and maintenance trials in 
NSCLC, but data to support the tolerability of this regimen is lacking. 
We report our single institution experience with maintenance (m) E 
as part of a phase I/II trial of E added to perioperative CRT for resect-
able stage III NSCLC patients (pts).
Methods: As part of an open-label phase I/II trial, pts with poten-
tially resectable stage IIIA/B NSCLC and PS 0-1 received weekly pa-
clitaxel (50 mg/m2), and carboplatin (AUC 2) with daily oral E for 28 
days concurrent with twice daily thoracic radiation (1.5 Gy/fraction) 
to 30 Gy, followed by restaging. Non-progressors underwent resec-
tion followed by the same CRT regimen and 2 years of mE (150mg). 
Results: Of the 32 pts enrolled in both phases of the trial, 20 pts 
(63%) began treatment with mE. 12 pts (38%) did not receive mE 
due to: disease progression prior to the mE phase (42%), prior grade 
3 toxicity with perioperative E (25%), complicated post-operative 
courses that precluded mE (25%), and 1 pt refused treatment. The 
median duration of mE was 5.1 months (range 0.9-25.6 months), 
with 6 (30%) completing the full 2 year course and 2 pts remain-
ing on treatment to date. Of the 12 pts discontinuing mE prior to 2 
years, 6 (43%) experienced disease progression and the remaining 6 
self discontinued after a median duration of treatment of 3.3 months 
(range 0.9-5.8). 30% of pts experienced grade 3 toxicity (1 each: rash, 
diarrhea, fatigue, anorexia, elevated lipase, and encephalopathy) and 
there was no grade 4 toxicity with mE. The most common toxicities 
were grade 1/2 diarrhea (75%), rash (65%), fatigue (50%), nausea 
(20%), and dry eyes (15%).
Conclusions: Of the pts who began up to 2 years of maintenance 
E, 30% completed the full 2 year course and 30% self discontinued 
mE without disease progression. Patients experienced a moderate 
rate of grade 3 and a high rate of persistent grade 1/2 toxicity, which 
may have contributed to the lower than expected rate of compliance. 
Current and future clinical trials utilizing prolonged treatment with 
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors 
should closely monitor and treat pts for toxicity in order to ensure 
adequate pt compliance.
P3.031 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Evaluation of a treatment strategy for optimizing pre-
operative chemoradiotherapy in stage III non-small-cell 
lung cancer
Phernambucq, Erik CJ1; Spoelstra, Femke OB2; Paul, Marinus A.2; 
Senan, Suresh2; Melissant, Christian F.3; Postmus, Pieter E.2; Smit, 
Egbert F.2
1 VU Medical Center, Amsterdam, The Netherlands; 2 VU University 
Medical Center, Amsterdam, Netherlands; 3 Spaarne Hospital, 
Hoofddorp, Netherlands
Background: Concurrent chemoradiotherapy is standard of care 
in stage III non-small-cell lung cancer, although surgery may 
be beneficial in selected patients in whom induction therapy has 
achieved ‘downstaging’ of mediastinal nodal disease. Previous stud-
ies incorporated treatment ‘splits’ for re-evaluation, and such gaps 
lead to poorer survival in patients undergoing chemoradiotherapy. We 
describe the outcome of a treatment strategy to limit the duration of 
treatment splits. 
Methods: A prospective database (2003-2007) of stage III non-small-
cell lung cancer patients treated with concurrent chemoradiotherapy 
outwith clinical trials at our center was reviewed. Pre-operative 
chemoradiotherapy consisted of one induction course of cisplatin-
gemcitabine, followed by two courses of cisplatin-etoposide with 
once-daily thoracic radiotherapy using 4-dimensional involved-field 
treatment planning. After a dose of 46-50 Gy, potentially resectable 
patients without disease progression underwent immediate planned 
mediastinal restaging, and patients with persistent N2-disease or who 
were unfit for surgery continued to full-dose radiotherapy. 
Results: A total of 34 patients had potentially resectable disease at 
start of treatment. Toxicity of chemoradiotherapy was predomin-
antly leucocytopenia grade III/IV in 38% of courses and grade III 
esophagitis in 5 patients (15%), but was manageable and reversible. 
After restaging using mainly mediastinoscopy, 24 patients (71%) 
proceeded to surgery. A radical resection was achieved in 23 patients, 
9 had a complete pathological response. Restaging was accurate with 
only 1 false-negative mediastinoscopy. One patient died 10 days after 
surgery. Median time from end of induction treatment to restaging 
or surgery was 12 days (range 0-51) and 35 (range 18-63) days, re-
spectively. Median survival for resected patients was not reached. Six 
patients had persisting N2-disease, of which 2 continued radiotherapy 
after a split of 3 and 4 days. 
Conclusions: Image-guided, involved-field pre-operative chemor-
adiotherapy can be performed with acceptable toxicity, and the 
present strategy achieves the goal of limiting splits in treatment deliv-
ery that may adversely affect survival in patients who do not undergo 
downstaging with induction therapy.
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Concomitant chemo-radiotherapy with oral vinorelbine 
and cisplatin after induction chemotherapy with cisplatin-
docetaxel in patients with locally advanced non-small cell 
lung cancer: a multicenter phase II trial. GFPC study 05-
03 (French cooperative group of thoracic oncology)
Robinet, Gilles1; Fournel, Pierre2; Berard, Henri 3; Falchero, Lionel 6; 
Kahlout, Sana 7; Monnet, Isabelle4; Chouabe, Stéphane 8; Geriniere, 
Laurence 5; Bota, Suzanna9; Locher, Chrystèle 10; Thomas, Pascal11; 
Chajara, Abdesslam1
1 CHU Brest, Institut Cancérologie et Hématologie, Brest, France; 
2 Institut de Cancérologie de La Loire, Saint-Priest en Jarez, 
France; 3 Hôpital d’Instruction des Armées Toulon, Toulon, France; 
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Background: The most satisfactory treatment for patients with 
inoperable locally advanced NSCLC is chemotherapy-radiotherapy 
(CT-RT). However, the optimal interval between RT and CT and the 
most effective CT protocol remain to be defined. Cisplatin-docetaxel 
induction-CT showed previously an interesting activity with good 
tolerance. Intravenous vinorelbine-cisplatin used with concomitant 
RT provided also a good activity/tolerance ratio. Oral vinorelbine 
presents a similar activity profile as intravenous vinorelbine and 
could simplify the administration of CT during RT.
Material and Methods: Patients between 18 and 70 years with 
histologically or cytologically confirmed inoperable stage IIIA and 
IIIB previously untreated, PS≤ 1, and weight loss ≤ 10 %, received 
two cycles of induction-CT cisplatin (75 mg/m2) and docetaxel (75 
mg/m2) every three weeks. Patients with response or stable disease 
continued with cisplatin (80 mg/m2) and oral vinorelbine (40 mg/
m2) day 1 and 8 for two cycles during thoracic RT (2 Gy/day, 5 days/
week, total dose of 66 Gy). The main endpoint was the objective 
response rate.
Results: Sixty patients were enrolled, initial characteristics were: 
mean age 57.3±7.7 years, males 51, PS 0 65%, weight loss 2.4±4.2% 
(95% IC: 1.31-3.42), stage IIIB 63.3%, squamous carcinoma 30%, 
adenocarcinoma 51.7% and large cells 18.3%. Nine patients were 
not assessable for induction-CT response. Thirteen patients did not 
continued with CT-RT at end of induction-CT (progression disease: 7 
patients, operable: 1 patient, toxicity: 1 patient and protocol devia-
tion: 4 patients). Thirty eight patients underwent CT-RT and all of 
them were eligible for tumor response. Dose intensity received was 
for induction-CT: cisplatin 98.3±5.12%, docetaxel 99.0±2.45% and 
for CT-RT: cisplatin 94.3±13.75%, oral vinorelbine 95.3±14.4%. 
Cycles received: induction-CT 1.8 ± 0.40, concomitant CT-RT 1.9± 
0.27. Radiation delivered was: mean dose 67.1 ±12.08 Gy (95% IC: 
63.3-70.9), mean dose intensity 102±18.3% (95% IC: 95.9-107.5), 
fractions 34.4±5.71 (95% IC: 32.6-36.3). The most frequent toxicity 
in induction-CT was grade 3-4 neutopenia (28.4%), the main others 
toxicities were: grade 3-4 renal failure (2 patients), grade 3 cardiac 
insufficiency (1 patient), grade 3 sigmoiditis (1 patient), grade 3 
phlebitis (1 patient) and grade 2 lower respiratory tract infection 
(LRTI, 5 patients). Five patients stopped treatment due to toxicities. 
RT-CT related toxicities were: grade 3-4 neutropenia (4 patients), 
grade 2 pulmonary toxicity (1 patient), grade 2 (13 patients) and 
grade 3 (2 patients) esophageal toxicity and grade 3 peripheral neur-
opathy (1 patient). No treatment related death occurred. Persistent 
toxicities of RT were: 2 grade 3-4 esophagus stenosis, 1 grade 4 vena 
cava stenosis and 1 grade 2 pneumonitis. No complete response was 
observed. Response rate was 39.2% (95%CI: 25.8-53.9) for patients 
eligible to induction-CT, 60.5% (95%CI: 43.4-76.0) for those eligible 
to CT-RT and 38.3% (95%CI: 26.1-51.8) for the ITT analysis. Six pa-
tients had progression disease at end of induction-CT: 2 loco-region-
al, 1 lung metastasis, 1 adrenal, 1 liver and 1 bone. Seven patients 
progressed at end of RT-CT: 1 loco-regional, 2 cerebral, 1 adrenal, 1 
adrenal and bone, 1 neoplasic pericarditis and 1 meningeal carcin-
omatosis. Median survival time for patients assessable for CT-RT was 
23.7 months and median time to progression was 13.9 month.
Conclusion: These results demonstrate that the tested combined 
treatment modality is feasible and presents a good efficacy/tolerabil-
ity ratio.
P3.033 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Dose escalation using three-dimensional conformal 
radiotherapy (3D-CRT) in concurrent setting with 
vinorelbine and a platinum compound, preceeded by 
induction chemotherapy and followed by consolidation 
chemotherapy in locally advanced non-small cell lung 
cancer (NSCLC) - a preliminary report of a modified 
phase I-II study
Rusu, Petronela; Ciuleanu, Tudor E.; Todor, Nicolae; Ghilezan, 
Nicolae
Institute of Oncology, Cluj, Romania
Background and Purpose: local and distant control are poor in 
locally advanced NSCLC. In order to improve them we aimed to 
evaluate the maximum-tolerated dose (MTD) and efficacy of dose 
escalation using 3D-CRT in concurrent setting with vinorelbine and 
a platinum compound, preceeded by induction chemotherapy (ChT) 
and followed by consolidation ChT with the same drugs, in locally 
advanced NSCLC.
Patients and Methods: Forty-nine patients (pts) were included from 
14.02.2005 to 23.07.2008: median age 56(41–73), M/F=4/45, PS 
1/2=32/17, stage IIIA/IIIB=10/39, squamous cell cc 36, large cell 
cc 2, adenocc 7, „non-small” carcinoma 4. Treatment consisted of 2 
cycles of induction ChT, followed by concurrent chemoradiotherapy 
and consolidation ChT. When given as induction or consolidation 
chemotherapy, drugs were given in full doses: Vrb (25 mg/sqm, d1, 
8, q21) and Cis (100 mg/sqm, d1, q21), or Carbo (AUC 5, d1, q21), 
in concurrent setting, doses were reduced: Vrb 15 mg/sqm, d1, 8, 
q21, Cis 80 mg/sqm, d1, q21 or Carbo AUC 4, d1, q21. Pre and 
post-induction ChT computed tomography defined the target volumes 
for radiotherapy. Patients who fulfilled the dose-volume histogram 
constraints, underwent dose escalation of radiotherapy, in cohorts of 
7 pts, if no more than two grade 3 or one grade 4 toxicities occurred, 
until MTD. If one grade 3 and one grade 4 toxicities occurred, further 
expansion continued by 5 more pts.
Results: Forty pts underwent dose escalation in five cohorts: 64Gy, 
66Gy, 68Gy, 70Gy, 72Gy, without dose-limiting toxicity. For each 
dose level up to 7 pts were enrolled, with further expansion by five 
pts at 70 Gy dose level.
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Acute toxicities, in the 49 evaluable pts, were preponderantly mild, 
of grade 1 and 2. Severe grade 3 and 4 toxicities were: esophagitis in 
4(10%), pulmonary toxicity in 7(14%), neutropenia in 8(16%) pts. 
There were 43% CR, 41% PR, 8% SD, 8%PD. RR .was 84%. With a 
median follow-up of 15.9 months, the 1-year survival rate was 83% 
(95%CI: 70-91). The mS has not been reached yet.
Conclusions: As no MTD was reached during dose escalation this 
strategy has to be continued.
P3.034 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Adjuvant chemotherapy following pneumonectomy for 
non small cell lung cancer: a multivariate survival analysis 
on a multicentric series of 61 patients
Spaggiari, Lorenzo1; Pardolesi, Alessandro1; Petrella, Francesco1; 
De Pas, Martino 1; Toffalorio, Francesca1; Margaritora, Stefano1; 
Mezzetti, Maurizio2; Facciolo, Francesco3; Sacco, Rocco1; Gotti, 
Giuseppe4; Cardillo, Giuseppe5; Alloisio, Marco6; Carbognani, Paolo7
1 Euoropean Institute of Oncology, Milan, Italy; 2 Università 
di Milano, Milan, Italy; 3 Istituto Regina Elena, Roma, Italy; 4 
Università di Siena, Siena, Italy; 5 S. Camillo - Forlanini, Roma, 
Italy; 6 Istituto Clinico Humanitas, Milan, Italy; 7 Università di 
Parma, Parma, Italy
Background: the role of adjuvant chemotherapy after major pulmon-
ary resection is still unclear.The aim of this study is to asses the role 
of post operative chemotherapy in patient submitted to pneumonec-
tomy for primary non small cell lung cancer.
Material and Methods: Sixty – one patients were enrolled from 9 
Italian centers in the present retrospective study; 51 were males ( 
83.6%) Twenty patients (32.8%) were operated on the right side. 29 
patients ( 47.5%) were younger than 61; 10 patients (16.4%) were 
classified as ASA I; 31 (50.8%) patients were classified as ASA II; 
20 patients ( 32.8%) were classified as ASA III. Pathological stages 
were: stage I: 3 patients (4.9%); stage II 24 patients ( 39.3%); stage 
III 31 patients (50.8%); stage IV 3 patients (4.9%). 59 out of the 61 
enrolled patients completed at least 2 cycles of post operative chemo-
therapy.
Results: among the 59 patients completing at least 2 cycles of post 
operative chemotherapy, 12 patients ( 20.3%) interrupted the planned 
chemotherapy. Median number of post operative chemotherapy 
cycles was 4. 
1 patient ( 1.6%) had pulmonary complication; 7 patients ( 11.5%) 
had cardiac complications; 7 patients ( 11.5%) had other complica-
tions (neurological, renal or abdominal complicatons).
Median overall survival was 30.4 months; multivariate survival 
analysis showed no difference related to age, gender, pathological 
stage, ASA score, side of the operation; Cox regression hazard ratio 
disclosed that only chemotherapy discontinuation affected overall 
survival ( p =0.0317).
Conclusions: post operative chemotherapy discontinuation after 
pneumonectomy affects overall survival. Adjuvant chemotherapy, 
even after a major surgical procedure like pneumonectomy, is worth-
while in order to offer the best long – term survival results
P3.035 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Feasibility trial of adjuvant chemotherapy with docetaxel 
after surgical resection with non-small cell lung cancer: 
report of the Kurume Surgical Oncology Group (KSCOG) 
protocol L001
Terazaki, Yasuhiro1; Mitsuoka, Masahiro2; Iwasaki, Yasunori1; Nishi, 
Tatsusya1; Kashihara, Masaki1; Muta, Fumihiko1; Matsuo, Toshihiro1; 
Takamori, Shinzo1; Shirouzu, Kazuo1
1 Department of Surgery, Kurume University, Faculty of Medicine, 
Kurume, Japan; 2 Department of Thoracic and Cardiovascular 
Surgery, Saga University Faculty of Medicine, Saga, Japan
Background: In non-small-cell lung cancer (NSCLC) patients, 
adjuvant doublet chemotherapy with a platinum compound and a 
new chemotherapy agent (vinorelbine) has been shown to improve 
survival. However, chemotherapy compliance has been difficult. A 
new single-agent chemotherapy regimen may improve chemotherapy 
compliance. This study investigated the feasibility of chemotherapy 
with docetaxel, which is one of the new chemotherapy agents admin-
istered after surgical resection of non-small cell lung cancer.
Methods: The primary endpoint of this trial was the completion rate 
of four cycles. All patients were required to be between 20 and 80 
years old, with an Eastern Cooperative Oncology Group (ECOG) 
performance status (PS) of 0 to 1, and without uncontrolled cardiac or 
hepatic disease. Eligible patients had pathologically confirmed stage 
IB-IIIB NSCLC and had undergone lobectomy or pneumonectomy. 
All patients gave written informed consent and the protocol was ap-
proved by the institutional review board at each center. Adjuvant ther-
apy was initiated between 4 and 8 weeks after surgery, and consisted 
of docetaxel 60mg/m2 every 21 days for four cycles.
Results: Between July 2006 and November 2008, 24 patients who 
had undergone surgical resection were enrolled in a multi-institution-
al trial of docetaxel. Patient characteristics were: median age 64 years 
old (range 49-77), gender male/female 12 (50%)/12 (50%), stage IB: 
1 (4%), IIA: 3 (12%), IIB: 9 (38%), IIIA: 10 (42%), IIIB: 1 (4%), 
Eastern Cooperative Oncology Group (ECOG) performance status 
(PS) 0/1= 22 (92%)/2 (8%), and the two most common histologies 
were adenocarcinoma in 18 (75%) and squamous cell carcinoma in 6 
(25%). The completion rate of four cycles was 96%. The reason for 
incomplete cycles was patient refusal in one case. There were only 
3 patients with a 25% dose reduction of docetaxel. There were no 
treatment related deaths and the primary toxicities were hematologic 
(grade 4 neutropenia 42% and febrile neutropenia 13% of patients). 
There were no severe nonhematological toxicities.
Conclusion: Single chemotherapy with docetaxel has an acceptable 
toxicity profile and the majority of the patients were able to complete 
four cycles of therapy after surgical resection for NSCLC. 
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P3.036 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Phase I/II trial of the addition of erlotinib to pre- 
and postoperative chemotherapy/hyperfractionated 
radiotherapy, and as maintenance, for resectable 
mediastinoscopy-defined stage III non-small cell lung 
cancer (NSCLC): report on the phase II component
Videtic, Gregory M.; Rice, Thomas W.; Murthy, Sudish; Mason, 
David; Mazzone, Peter; Shapiro, Marc; Pennell, Nathan; Samsa, 
Julia; Reddy, Chandana; Mekhail, Tarek
Cleveland Clinic, Cleveland, OH, USA
Purpose: To report on phase II trial results testing the addition of 
erlotinitb (E) to an institutional regimen of pre-and postoperative 
chemoradiotherapy (CRT) for potentially resectable stage III NSCLC.
Methods: Eligible patients (pts) had stage IIIA/B NSCLC as 
determined by mediastinoscopy and PET, PS 0-1, and were judged 
surgically resectable. Preoperative (and postoperative) CRT consisted 
of weekly P (50 mg/m2), and C (AUC 2) and concurrent hyperfrac-
tionated radiotherapy (30 Gy/1.5 Gy per fraction BID, > 6 hours 
between fractions), with daily oral E (150 mg) for 28 days. Following 
restaging, non-progressors underwent resection. Four to 6 weeks fol-
lowing surgery, CRT with E was re-administered, followed by 2 years 
of maintenance E. Unresectable pts received a second course of CRT 
followed by maintenance E. We report patient, tumor and treatment 
characteristics for the phase II cohort with current outcomes.
Results: From 6/04 to 10/08, 25 pts were enrolled. Median follow-
up was 30.3 months (range 3.3-25). 60% pts were alive at analysis. 
Median age was 60 years (range 32-76). 16 pts (64%) were female. 
16% were never-smokers. Median baseline %-predicted FEV1 and 
DLCO were 85 and 86.5, respectively. 23 pts (92%) had stage IIIA 
disease, 76% had right-sided tumors, 64% had adenocarcinoma, 
median primary PET SUV maximum was 8.19 (range 2.4-34). 
Percent of pts completing preop CRT, surgery and postop CRT were 
100, 88 and 84, respectively. There were no pre- and postoperative 
esophageal and respiratory toxicities above grade 2: 24% and 4%; 
and 12% and 8%, respectively. Concerning radiation, median pre- 
and postoperative V20 and mean lung doses were: 15% and 6.5 Gy; 
and 8% and 3.6 Gy, respectively. 8 pts (32%) had pneumonectomy. 
Downstaging to N0-1 was seen in 50%. Median post-therapy %-pre-
dicted FEV1 and DLCO were 61 and 65, respectively. Surgery was 
the only significant factor accounting for changes in pulmonary func-
tion (p <0.0001). Median duration of maintenance E was 6.9 months 
(range 0.97-25.6). Median, 3-year overall and relapse-free survivals 
were: 41.39 months, 58.8% and 43.6%, respectively. For downstaged 
pts, median, 3-year overall and relapse-free survivals were: not yet 
reached, 70% and 59.5%, respectively. Non-downstaged pts had 
median overall and relapse-free survivals of 37.6 and 19.4 months, 
respectively. Multivariable analysis showed receiving surgery as the 
most significant factor influencing survival (p=0.0016, HR=18.8, 
95% CI: 3.0, 116.1).
Conclusions: Addition of E to pre- and postoperative CRT produced 
minimal toxicity and resulted in notable downstaging, resulting in 
improved survival for this cohort. Further testing of this regimen is 
warranted.
P3.037 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Randomised phase II trial of induction chemotherapy 
with gemcitabin in brief vs. long infusion, both combined 
with cisplatin prior to radical chemo-radiotherapy for 
inoperable NSCLC
Vrankar, Martina; Zwitter, Matjaz
Institut of Oncology, Ljubljana, Slovenia
Background: The value of induction chemotherapy prior to defin-
itive chemo-irradiation for inoperable NSCLC is not clear. In many 
trials, a long interval between induction chemotherapy and definitive 
chemo-irradiation might allow early tumor repopulation. We believe 
that optimal regimen for induction chemotherapy and a brief interval 
to definitive chemo-irradiation are crucial in our efforts to improve 
tumor control. On the basis of favourable experience with gem-
citabine in long infusion in combination with cisplatin for advanced 
NSCLC, we here present experience from a randomised clinical trial, 
comparing standard brief infusion of gemcitabine to the low-dose 
prolonged infusion, both in combination with cisplatin prior to radical 
chemoradiotherapy for inoperable NSCLC.
Methods: Eligible patients had biopsy-proven NSCLC; performance 
status 0 or 1; inoperable stage IIB or III; tumor volume within limits 
for radical radiotherapy; and adequate hematological, liver and renal 
function. Patients were randomised betwen two schedules of induc-
tion chemotherapy. On days 1 and 8, patients received gemcitabine 
1250mg/m2/30 min (arm A) or 250 mg/m2/6 hours (arm B). On day 2, 
all patients received cisplatin 75mg/m2. Radiotherapy started within 
15 to 22 days after the last aplication of the third cycle of induction 
chemotherapy. Parameters of irradiation: 3-D planning for linear ac-
celerator, 6-10 MeV, 60 to 66 Gy in 30 to 33 fractions in 6.5 weeks. 
During 1st and 5th week of radiotherapy, patients received concomi-
tant cisplatin (50 mg/m2 on days 1 and 8) and etoposide (50 mg/m2 
on days 1 – 5). 
Results: Between December 2005 and May 2008, 60 patients (49 
men and 11 women, median age 56 years) were recruited into the 
trial. All 3 cycles of induction chemotherapy were given to 43 
patients. Full dose of radiotherapy (56 Gy and more) was given to 
57 patients, and a reduced dose to 3 patients. During radiotherapy, 
two cycles of concomitant chemotherapy were given to 43 patients, 
one cycle to 14 patients, while 3 patients received no concomitant 
chemotherapy. Grade 3 or 4 toxicity included anemia (3 patients), 
thrombocytopenia (4 patients), febrile neutropenia (4 patients) and 
esophagitis (8 patients). There were no treatment related deaths. At 
completion of treatment, only three patients had clearly progres-
sive disease. Complete response was observed in 16 patients, and 
partial response or stable disease in 39 patients. No patient was lost 
to follow-up. Median time to progression was 14 months and 22 
months, and median overall survival was 26 months and 29 months 
for arms A and B, respectively. 
Conclusion: In both treatment arms, induction chemotherapy im-
mediately followed by chemo-radiotherapy has acceptable tox-
icity and leads to promising progression-free and overall survival. 
Gemcitabine in low dose in prolonged infusion is clearly not inferior 
and may be superior to standard gemcitabine, and should be further 
investigated. 
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P3.038 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Unexpected high lung toxicity from radiation pneumonitis 
in a phase I/II trial of concurrent erlotinib with limited 
field radiation for intermediate prognosis patients with 
stage III or inoperable stage IIB non-small cell lung cancer 
(NSCLC)
Wan, Jonathan1; Cohen, Victor2, 4; Agulnik, Jason2, 4; Faria, Sergio3, 
4; Portelance, Lorraine3, 4; Ofiara, Linda3, 4; Sultanem, Khalil2, 4; 
Souhami, Luis3, 4; Hirsh, Vera3, 4
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University, Montreal, QC, Canada
Background: Combination chemotherapy and radiation in carefully 
selected patients with locally advanced non-small cell lung cancer 
(NSCLC) remains standard of care. Retrospective analyses of RTOG 
studies have shown that patients with weight loss, poor performance 
status and advanced age do not benefit from aggressive multimodal-
ity therapy. Radiotherapy alone provides a low likelihood of local 
control for these patients. Erlotinib, an inhibitor of epidermal growth 
factor receptor (EGFR), is effective in locally advanced and meta-
static NSCLC. Randomized trials have shown promising results with 
concurrent EGFR inhibitors and radiation in head and neck cancers. 
We initiated a phase I/II trial to determine the toxicity of concurrent 
erlotinib with limited field radiation treatment for intermediate prog-
nosis NSCLC patients. 
Methods: Eligibility Criteria: Stage IIIA-IIIB or inoperable IIB 
NSCLC; ECOG 2 or ECOG 0-1 with >5% weight loss. Treatment: 
Erlotinib given 10-30 days prior to radiotherapy, concurrently with 
radiotherapy and following radiotherapy until progressive disease or 
unacceptable toxicity. The first 3 patients were treated with erlotinib 
100mg PO QD during the concurrent radiation phase of treatment 
and 150mg PO QD prior and post radiation. After an initial toxicity 
assessment, the second phase was opened in which patients received 
erlotinib at a dose of 150mg PO QD throughout treatment. Radio-
therapy dose was 60Gy/30 fractions or 45Gy/15 fractions to involved 
regions only. Primary endpoint was toxicity and secondary endpoint 
was tumor response on CT at 30days post radiation.
Results: 8 patients were enrolled between January,2006 and De-
cember,2008. No dose limiting toxicities were seen in the initial 
3 patients at Erlotinib 100mg PO QD during RT. The remaining 5 
patients were treated with Erlotinib 150mg PO QD during RT. Demo-
graphics: Male 5/8( 62.5%) Female 3/8(37.5%); Caucasian 6/8(75%) 
Asian 2/8(25%); Stage IIIA 6/8(75%) IIIB 2/8(25%); ECOG 2 7/8( 
87.5%) ECOG 0 with weight loss 1/8(12.5%); median age 72years. 
7/8(87.5%) patients received 60Gy/30#. 1/8(12.5%) patients received 
45Gy/15#. Median follow-up time 12.5months. All patients com-
pleted concurrent erlotinib and radiotherapy. 
Toxicities: 4/8(50%) patients developed rash and fatigue ≤grade II; 
3/8(37.5%) of patients had diarrhea ≤grade II; 1/8(12.5%) patient 
developed a grade III foot abscess thought unrelated to therapy and 
due to pre-existing diabetes; 2/5(40%) patients at dose level 150mg 
PO QD developed radiation pneumonitis( 1 grade III with V20=15%, 
1 grade V withV20=36%). Both patients received 60Gy/30#. Another 
patient with progressive lung disease died within 6 weeks post-radia-
tion from respiratory distress. 
Response: At one month after concurrent erlotinib and radiation, 
5/8(62.5%) patients had a partial response. No patients had a com-
plete response. 3/8(37.5%) of patients had progressive disease.
Conclusion: After an initially well-tolerated dose of concurrent RT 
and erlotinib at 100mg daily, we encountered unexpected high lung 
toxicity in patients treated with concurrent RT and erlotinib at 150mg 
daily. 2/5(40%) treated patients at this dose level developed radiation 
pneumonitis with one fatal outcome. This trial was closed due to high 
lung toxicity. The safety of a dose of Erlotinib 150mg PO QD given 
concurrently with RT in this population must be questioned.
P3.039 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
CRP predicts tolerance of treatment and overall survival 
with weekly carboplatin-paclitaxel and concomitant 
irradiation for locally advanced non-small cell lung cancer
Webber, Kate1; Fontela, Antoinette1; Bonner, Nina1; Bell, Janet1; 
Bucci, Joseph1; Lewis, Craig2; de Souza, Paul1; Graham, Peter1; 
Links, Matthew1
1 St George Hospital, Kogarah, NSW, Australia; 2 Prince of Wales 
Hospital, Randwick, NSW, Australia
Background: Concurrent chemotherapy and irradiation is the stan-
dard of care for locally advanced NSCLC, but selection of appropri-
ate patients is critical. Inflammation has been shown to be a prognos-
tic factor for NSCLC and a predictive factor for toxicity of docetaxel. 
We therefore sought to prospectively explore the significance of 
baseline CRP, ESR and IL-6 with other potential predictive markers 
in predicting treatment tolerance of concurrent chemoradiation. 
Methods: 21 patients with stage IIIA or IIIB NSCLC were treated 
with concurrent weekly carboplatin/paclitaxel and irradiation. 2 
additional cycles of carboplatin/paclitaxel were planned and given as 
either induction or consolidation at the discretion of the treating team. 
Our primary end point was the composite endpoint of Tolerable 
Treatment Delivery (TTD) defined as completion of full radiother-
apy dose within radiotherapy protocol duration ± 5% and absence of 
grade 3 or 4 non-haematological toxicity lasting more than 3 weeks. 
TTD was correlated with potential pre-treatment predictive factors of 
age, sex, ECOG status, weight loss to diagnosis, albumin, ESR, CRP, 
IL-6, CA 15-3, planned radiation volume and baseline FEV1. Given 
small numbers, univariate analysis only was undertaken. Second-
ary analysis was to correlate these factors with progression free and 
overall survival. 
Results: In addition to concurrent chemoradiation, 6 patients re-
ceived induction chemotherapy and 15 consolidation. 
Median baseline C-Reactive Protein was lower in the group tolerat-
ing treatment (8 mg/L vs 31 mg/L, p=0.0197), as was ESR (20mm/
hr vs 81 mm/hr, p=0.0279) but not IL-6. Higher Serum Albumin also 
predicted TTD (36 g/L vs 33 g/L, p=0.0385). Age, baseline FEV1, % 
weight loss to baseline, planned radiation volume and CA 15.3 did 
not impact on TTD. 
Patients receiving induction chemotherapy were more likely to toler-
ate treatment than those who commenced with concurrent chemor-
adiation (100% vs 53%), but at the price of poorer outcomes in terms 
of both PFS and OS (median PFS 9 months vs 22 months, 95% CI 
0.039 - 0.779, and OS 19.97 months vs 32.18 months, 95% CI 0.320 
– 0.922). 
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Lower inflammatory markers at baseline were also predictive of 
survival. Baseline CRP < 20 mg/L was correlated with increased PFS 
of 19 vs 8 months (95% CI 0.046-0.79), and OS (median survival not 
yet reached v 17.5 months, 95% CI 1.75 – 20.1). There was a similar 
non-significant trend for ESR and survival. Normal baseline CA 15.3 
was also correlated with PFS (21 vs 8) and OS (32 vs 19) months 
(95% CI 1.31 – 1.96). There was a non-significant trend for baseline 
IL-6 but other variables including age, sex, planned treatment vol-
ume, baseline FEV1 and weight loss to baseline were not significant 
for survival. 
Conclusions: Within the limitations of a small study, we have pro-
spectively confirmed previous data on the effect of CRP on treatment 
tolerance and survival. Combined with previous data this suggests 
that inflammation is both a prognostic and predictive factor in pa-
tients with locally advanced NSCLC treated with chemo-radiation. 
P3.040 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Phase II trial of combined modality treatment with 
induction chemotherapy followed by concurrent 
chemoradiation using cisplatin and vinorelbine or 
carboplatin and vinorelbine for locally-advanced non-
small-cell lung cancer
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3 Leicester Royal Infirmary, Leicester, UK; 4 Royal Devon & Exeter 
Hospital, Exeter, UK; 5 Royal Marsden Hospital, London, UK; 6 
Pierre-Fabre Oncology, Winchester, UK
Aim: To assess the effectiveness and safety of the use of concur-
rent chemoradiotherapy for locally advanced Non-Small-Cell Lung 
Cancer (NSCLC) in routine practice in the UK.
Methods: 32 patients from five centres with locally-advanced or 
inoperable NSCLC were treated between 2002-2004 with two cycles 
of induction chemotherapy followed by two cycles of dose reduced 
concomitant chemotherapy and radical 3 –d conformal radiother-
apy (2Gy per fraction, 5days per week). Nineteen patients received 
cisplatin 80mg/m2; 60mg/m2 d1 and vinorelbine 25mg/m2; 15mg/
m2 d1 +8 and thirteen received carboplatin AUC 5 d1; AUC 2 max 
200mg d1 +d8 and vinorelbine 25mg/m2; 15mg/m2 d1 + 8 according 
to centre preference and patient characteristics, in a non-randomised 
trial (induction;concomitant doses).
Results: Thirty-two patients were recruited, with a median age of 
62. Fourteen (44%) of patients had stage IIIa NSCLC, fourteen 
(44%) had stage IIIb, and four patients with stages I-II and inoper-
able disease were treated. All patients had a performance status of 
0-1. One early death occurred on day 52 of the treatment protocol 
from complications of bowel obstruction. Twenty-one patients (66%) 
had a complete or partial response to treatment, six (19%) had stable 
disease and four patients (13%) progressed during treatment. Twenty 
patients (63%) completed all cycles of chemotherapy and twenty-
seven (84%) completed radical radiotherapy (median 62Gy range 
54-66). Median follow up all patients was 23 months (range 1.7-65 
months). Median progression-free survival and overall survival were 
15.4 and 23 months respectively. The 1-year, 2-year, and 5-year 
progression-free survival was 73%, 43% and 31% respectively. The 
1-year, 2-year and 5-year overall survival was 70%, 47% and 32% 
respectively. Median progression-free survival in patients treated 
with carboplatin and vinorelbine, and cisplatin and vinorelbine, was 
10.9 and 17.9 months respectively. Grade 4 haematological toxicity 
occurred in nine (28%) of patients. Grade 3 oesophagitis occurred in 
four patients. No pneumonitis of grade 3 or higher was recorded.
Conclusion: This treatment regimen has been confirmed to be effect-
ive, well tolerated and suitable for use in routine practice in the UK 
for treatment of locally advanced NSCLC.
P3.041 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Studies on the relationship of objective response by 
chemotherapy and senescence induced in vitro for non-
small cells lung cancer
Li, Hong; Zheng, Shi Ying; Jiang, Dong; ge, Jin Feng
Department of Thoracocardiac Surgery, The First Affiliated Hospital 
of Suzhou University, Suzhou, China
Background: To investigate the relationship between the objective 
response to combination chemotherapy of taxanes plus cisplat/n jn 
non-small celI lung cancer (NSCLC) and docetaxel plus cisplatin 
(DC regime1 jnduced senescence of tumor cells in vitro. And its rela-
tion to mutant P53 protein (m, P53)was also to be evaluated.
Methods: Sixty seven specimen obtained from NSCLC patients 
from January 1, 2003 to June 30, 2006. The patients consisted of 
48 males and 19 females, ranging in age from 54 to 82 years(mean, 
67.5 years), 41 cases were diagnosed as pathological stage IIIb, 26 
cases were diagnosed as stage IV. Thirty-nine tumors were confirmed 
to be adenocarcinomas. 28 were confirmed to be squamous cell 
carcinomas. All patients accepted 2-6 cycles combination chemo-
therapy of Taxanes(docetaxel 40 mg/m2 .d1; d8.or paclitaxel 175 
mg/m2, d1)plus cisplatin (CDDP, 25 mg/m2, d2-4). Patients were 
divided into chemoresponsive (CR+PR)and chemoresistant (SD+PD) 
groups according to objective response status which was evaluated 
by RECIST system. Tumor cells from specimens of bronchoscopic 
surgical biopsy and pleural effusion cell collection had been cultured 
and treated with DC in vitro. The m-P53 of culture supernatant was 
measured by ABC. ELISA kit before DC treatment. The telomerase 
activity was determined by the telomeric repeat amplification proto-
col (TRAP) based PCR-ELISA kit and apoptosis was determined by 
TdT-mediated d-UTP-X nick-end labeling (TUNEL) assay. Data rep-
resent as both actual detected and positive value. The senescence of 
tumor cells defined as that, apoptosis rate increased more than 50%to 
contro1, and telomerase activity decreased less than 50% to contro1. 
Results: There was no significant diference between clinical treat-
ment response and sex, pathological type, specimen origin, or 
m-P53 status in cultured cell supematant. TeIomerase activity and 
apoptosis rate was positive in 61.1% (41/67) and 25.4%(17/67) of 
all samples respectively. A significant difference of senescence of 
tumor cells treated by DC, was existed between chemoresponsive 
and chemoresistant patients groups(P<O.05). Multinomial logistic 
regression analyses shew that teIomerase activity decreased less than 
50% in vitro may be an indicator of clinical response for taxanes plus 
cisplatin chemotherapy. Odds ratio was 4.226, P<0.05.
Conclusions: For NSCLC, DC induce lung cancer tumor cells sen-
esce in vitro may be a promising predicator for clinical chemotherapy 
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and detectable m-P53 or DC induced apoptosis response, but the 
relationship between objective response by is still obscure.
P3.042 Combined Modality Therapy, Mon Aug 3 – Tue Aug 4 
Toxicity report of a dose escalation study in inoperable 
locally advanced NSCLC with helical tomotherapy and 
concurrent chemotherapy
Bral, Samuel; Duchateau, Michael; Schallier, Denis; Everaert, 
Hendrik; Storme, Guy; De Grève, Jacques L.
UZ Brussel, Brussels, Belgium
Purpose: To evaluate the feasibility and toxicity of radiation dose 
escalation using helical tomotherapy (TT) in patients with inoperable 
stage III non-small cell lung cancer (LANSCLC) with concurrent 
chemotherapy. 
Patients and Methods: This phase I/II study was designed to deter-
mine the maximum tolerated dose (MTD) of radiotherapy in patients 
with LANSCLC, concurrently with docetaxel and cisplatin. Radio-
therapy was delivered using TT. A dose per fraction escalation was 
applied starting at 2Gy, with an increase of 6% per dose cohort (DC). 
The RTOG acute radiation morbidity score was used to monitor 
pulmonary, esophageal and cardiac toxicity. All other adverse events 
were scored using the NCI CTC version 3.0. 
Results: Dose escalation was performed in 34 patients over 5 DCs 
to a dose per fraction of 2.48Gy. No differences were found in acute 
toxicity between the different DCs, but a significant increase in late 
lung toxicity in DC IV, using a fraction size of 2.36Gy, necessitated a 
halt in further dose escalation with the MTD being defined as 2.24Gy 
per fraction. The overall incidence of acute ≥grade 3 esophageal and 
pulmonary toxicity is 24% and 3% respectively. Overall late lung 
toxicity was 21%, but an acceptable 13% in DC I-III. Local response 
rate was 61% on computed tomography.
Conclusion: The use of helical tomotherapy to 67.2Gy with concur-
rent cisplatin/docetaxel is feasible and resulted in acceptable toxicity. 
A full phase II study has been initiated to establish the true local 
response rate at the MTD of 2.24Gy per fraction.
Early Detection and Chemoprevention
P3.043 Early Detection and Chemoprevention, Mon Aug 3 – Tue Aug 4 
Autofluorescence bronchoscopy (AFB)-guided biopsy and 
brush smears increase detection rate of pre-malignant 
changes and early cancer lesions in central airways
Adamek, Mariusz4, 1; Niepsuj, Grzegorz1, 4; Unger, Michael2; 
Kozielski, Jerzy3; Ziora, Dariusz1; Zielinska-Les, Izabela1; Stoltny-
Sieron, Karolina4; Sieron, Aleksander4
1 Dept. of Pulmonary Diseases, Silesian Medical Univ., Zabrze, 
Poland; 2 Fox Chase Cancer Center, Philadelphia, USA; 3 Dept. 
of Pulmonary Diseases, Silesian Medical Univ., Zabrze, Poland; 
4 Center for Laser Diagnostics and Therapy, Dept. of Internal 
Diseases, Angiology and Physical Medicine, Silesian Medical 
University, Bytom, Poland
Background: It has been widely evidenced that the individual prog-
nosis strongly depends on the stage in which lung cancer is detected. 
Mounting data have recently demonstrated that autofluorescence 
bronchoscopy (AFB) is able to improve the detection rate of early 
pre-malignant and malignant lesions in bronchial tree. This finding 
has been reflected in ACCP guidelines, pointing out the potential role 
of this modality. In this study we present the results of early (pre)
malignant lesion detection by means of AFB. 
Patients and Methods: A total of 255 patients (65 females, 190 
males) with the symptoms and/or signs suggestive for lung cancer 
underwent white-light bronchoscopy (WLB) and AFB. AFB was per-
formed by means OncoLIFE lung system (Xillix Corp., Richmond, 
BC, Canada). yielding fluorescence images in real time. Implementa-
tion of AFB into clinical examination stems from the observation that 
normal and cancerous tissues tend to have distinct emission spectra 
when excited with blue light. Normal bronchial mucosa was viewed 
as shades of green, while pathological areas were represented as red-
brown areas. Indications for AFB were x-rays findings, haemoptysis 
or other signs suggestive of lung cancer, staging procedure in patients 
with previously diagnosed lung cancer. Exclusion criteria were as 
follows: severe inflammation, excessive mucus secretion, bleeding 
and bulky, bronchus-obturating tumour mass. All areas exhibiting 
pathological fluorescence were sampled (298 biopsies and 319 brush 
smears) and histopathologically verified. The tissue specimen were 
regarded as positive when at least one of the following pathological 
alterations were revealed: metaplasia, dysplasia, carcinoma.
Results: Positive biopsies were obtained from 102 patients. Among 
them 16 were diagnosed as metaplasias, 15 as low-grade dysplasias 
(LGD), 20 as high-grade dysplasias (HGD) and 51 as carcinomas. In 
these individuals 104 brush smears were identified as metaplasias, 19 
as LGD, 29 as HGD and 13 as carcinomas. The biopsies and smears 
in 95 patients were taken under autofluorescence guidance, i.e. the 
pathological areas would not be identified in WLB. In 7 patients 
biopsies were taken from tumour mass which did not display altered 
fluorescence. The cumulative AFB sensitivity for biopsies and smears 
equaled 86.4%, whereas specificity was 39.8%. Positive predictive 
value (PPV) and negative predictive value (NPV) were 54.5% and 
77.9%, respectively. 
However, it is worth noting that sensitivity, specificity, PPV and NPV 
calculated solely on the basis of biopsies were 84.3%, 64.9%, 65.8% 
and 83.8%, respectively.
“Falsely negative” results were due to bulky tumour mass which 
entailed the loss of red-brown fluorescence. Yet in these cases the 
diseased tissue could easily be localized with conventional WLB. 
“Falsely positive” samples resulted from mucosal bleeding or local 
inflammation.
Keeping in mind the role of early diagnosis for a long-term survival, 
the significance of AFB in patients at risk becomes unquestionable. 
Moreover AFB enables to include a patient at risk into a chemo-
prevention arm in clinical trial with accurate monitoring of its 
outcome.
Conclusion: Based on the obtained data it may be concluded that 
autofluorescence bronchoscopy may substantially increase the detec-
tion rate of (pre)malignant alterations within bronchial mucosa.
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Low-dose CT screening for lung cancer in Australia: 
QLCSS project interim report
Marshall, Henry M.; Bowman, Rayleen V.; Crossin, Jane; Fuentes, 
Melanie; Slaughter, Richard; Zimmerman, Paul; Yang, Ian; Passmore, 
Linda; McCaul, Elizabeth; Redmond, Stanley; Fong, Kwun 
The Prince Charles Hospital, Brisbane, QLD, Australia
Introduction: LDCT is more sensitive than CXR for imaging. RCTs 
of effectiveness are awaited. Local data on Australian nodules in high 
risk smokers are not known. The Queensland Lung Cancer Screening 
Project (QLCSS) is screening volunteer smokers ± asbestos exposure 
for lung cancer by LDCT. 
Study design: A prospective observational cohort study of LDCT to 
assess: disease detection rates and work-up of screen detected lung 
nodules; economic analysis of screening; quality of life issues; smok-
ing cessation outcomes; feasibility of collection of biomarkers (blood 
and breath analysis). 
Methods: Participants have a prevalence screen followed by inci-
dence screens at 1 and 2 years. LDCTs are reported by 2 independ-
ent radiologists and the final report ratified by a consensus panel of 
radiologists and clinicians. Nodules are managed according to the 
NLST/ACRIN protocol. Potential asbestos-related abnormalities are 
recorded (eg pleural disease, fibrosis). Detailed occupational history 
is obtained for all participants to be analysed by job exposure matrix.
Results (to be updated prior to WCLC): See Table 1 for summary. 
Forty-two participants have been screened. Nodules were categorised 
according to longest diameter, attenuation and margin characteris-
tics. No scans were determined ‘high’ suspicion for cancer. Twenty 
participants had no nodules. Seventeen participants had suspicious 
nodule(s) and are due for interval scan at 6 months, one had 2 interval 
scans (3 and 6 months), another had a PET scan and limited CT. 
None of the four incidence or nine interval scans have shown pro-
gression of nodules. Seventeen participants had pleural abnormalities, 
nine have known asbestos exposure.
A variety of incidental abnormalities have been found such as coron-
ary artery calcification, emphysema and thyroid goitre. Eighteen 
participants have required further assessment for nodules and/or other 
potentially significant abnormality
Conclusions: In the pilot phase of this study, the protocol was refined 
and found to be feasible. LDCT frequently identifies lung and other 
organ abnormalities in a high-risk population. Insufficient numbers 
have been screened so far, but the international experience of a high 
rate of detection of “benign” or “incidental” abnormalities is likely 
to be replicated in Australia. Public response to the project has been 
high.
Table 1. Results   
    n (mean ± SD)
 Screenee characteristics  
  Screenees  42
  Males/ females  26/16
  Age (years)  65 ±4
  FEV1 (% predicted)   FEV1 92±19 
  Pack-year smoking history 54± 21
    
 Scan findings Scans with suspicious nodules 17
  Interval scans performed/scheduled 9/8
  Micronodules <4mm diameter 115 (2.9 ± 0.6mm)
  Nodules 4-10mm diameter 42 (5.5 ± 1.5 mm)
  Nodules > 10mm  1 (11.8mm)
   
 4-10mm Nodule characteristics (n=42) 
  Margin Smooth 27
   Poorly defined 12
   Spiculated 3
  Attenuation Soft tissue 36
  Ground glass  3
  Mixed  2
  Other  1
   
 Index of suspicion for lung cancer 
  None  17
  Low  20
  Intermediate  4
  Moderately high  1
  High  0
  
 Pleural abnormalities 
  Plaques  11
  Localised thickening 8
  Diffuse thickening  0
  
 Other abnormalities 
  Coronary artery calcification 25
  Emphysema  19
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Analysis of potential diagnostic markers in bronchial fluid 
of patients with non small cell lung cancer (NSCLC)
Carrera, Sergio1; López Vivanco, Guillermo1; Muñoz, Alberto1; 
Zalacain, Rafael2; Gomez, Ainhoa2; Algorta, Jaime3; Simón, 
Laureano3; Uribarri, Maria3; Calvo, Begoña4; Jangi, Muhialdin4; 
Rubio, Itziar1; Azkona, Eider1; Mañe, Joan Manel1; Sancho, 
Aintzane1; Fernandez, Ricardo1; Martínez, Alejandro1; Ferreiro, 
Josefa1
1 Hospital de Cruces Oncology Department, Baracaldo, Spain; 2 
Neumology Department Hospital de Cruces, Baracaldo, Spain; 3 
Progenika, Zamudio, Spain; 4 Hospital de Cruces Molecular Biology 
Department - Medical Oncology, Baracaldo, Spain
Background: Lung cancer ranks among the most common and most 
lethal malignancies worldwide. Given the fact that survival of lung 
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cancer patients is very poor, it is logical to speculate that early detec-
tion might result in more favourable outcomes for these individuals. 
New proteomic techniques can identify potential diagnostic and 
prognostic markers. The aim of this study was to find protein markers 
in bronchial fluid which could enable early diagnosis in NSCLC.
Methods: We have included 96 patients with NSCLC diagnosed 
using bronchoscopy (64 squamous/29 adenocarcinoma/3 others) 
and 49 consecutive patients with non pathological bronchoscopy. 
Bronchial fluid was obtained from each patient and potential protein 
markers were studied. Bronchial fluid was centrifuged and super-
natant proteins were analysed using bidimensional electrophoresis 
with poliacrilamid gel stained with silver nitrate. Gel was scanned 
and analysed with Progenesis PG6220 program, which measures 
intensity of each spot. Resultant intensities in each group of patients 
(NSCLC/non pathological bronchoscopy) were compared using T-
Student method. We selected as potential markers those spots with a 
p value of less than 0.05. We calculated “fold change” of each spot as 
the ratio between mean intensity in NSCLC bronchoscopies samples 
and non pathological bronchoscopies samples. 
Results: We analysed 300 spots in each sample and we found 31 
potential markers whose fold-change ranges from 1.49 to 7.41; 15 of 
the markers were expressed in a higher level in NSCLC samples and 
the other 16 were expressed in a lower level. 
Conclusions: We have identified 31 potential protein markers in 
bronchial fluid among our patients,that could be used as an early 
diagnostic test. Anyway, these results must be validated by appropri-
ate and well-designed randomized studies.
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Common Medical Error: 20% of Lung Cancer Cases 
Misdiagnosed as Tuberculosis
Chandra, Subhash; Singh, Vikas; Mohan, Anant; Guleria, Randeep; 
Agarwal, Dipti
Department of Medicine, All India Institute of Medical Sciences, New 
Delhi, India
Objective: To emphasize the delay in diagnosis of lung cancer 
caused by wrong diagnosis of tuberculosis (TB) in India. This is of 
concern as early-diagnosis increases tumor resectability and may 
provide better quality of life.
Methods: Newly diagnosed lung cancer patients, who had received 
antitubercular treatment (ATT) since the onset of current symptoms, 
were studied retrospectively during the period of Nov-2007 to Nov-
2008. 
Data-source: Patient interview and medical records.
Results: 14 out of 70 patients (20%) had received ATT [male-12, 
female-2; mean age-58.07±6.81; Non Small Cell Lung Cancer-12, 
Small Cell Lung Cancer-2], 12 were smokers with median smok-
ing pack-years of 44 (15 to 112). Initial sputum for Acid Fast Bacilli 
(AFB) was done only in 3 out of 14 patients and it was negative. 
Bronchoalvealar Lavage for AFB was negative in 6 patients. Mean 
duration of ATT taken was 4.46±3.15 months. Delay in diagnosis 
was significantly high in patients who had received ATT for current 
symptoms (p=0.002) and the mean difference was 65.55 days (95% 
confidence interval of difference was 24.46 to 106.64).
Conclusion: Wrong interpretation of chest radiograph and lack of 
follow up of suspicious opacities with Computed Tomography scan 
and bronchoscopy is the main source of error leading to this delay. 
Further, clinicians associate lung cancer with inevitable mortality and 
start ATT without detailed investigation in suspicious cases.
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Promoter demethylation of WIF-1 by epigallocatechin-3-
gallate in lung cancer cells
Gao, Zhi2; You, Liang1; Xu, Zhidong 1; Hung, Ming-Szu1; Lin, Yu-
Ching1; Jablons, David M.1
1 University of California San Francisco, San Francisco, CA, USA; 2 
Beijing Friendship Hospital, Beijing, China
Background: The Wingless-type (Wnt) family is extensively 
involved in oncogenesis. Wnt inhibitory factor-1 (WIF-1) is a Wnt 
antagonist, WIF-1 silencing due to promoter hypermethylation in 
lung cancer was reported by our group. Re-expression of WIF-1 can 
downregulate the Wnt pathway and inhibit lung cancer cell growth. 
Epigallocatechin-3-gallate (EGCG) is a chemo-preventive agent and 
an inhibitor of DNA methyltransferase (DNMT). We hypothesize that 
EGCG can be used as an effective and nontoxic demethylating agent 
of WIF-1 promoter in lung cancer. 
Methods: Lung cancer cell lines, H460 and A549, H1703 and a colon 
cancer cell line, HCT116, were treated with EGCG. After incuba-
tion for 72 hours, cellular proliferation was measured using the MTS 
assay. Total RNA from H460, A549, HCT116 and H1703 cell lines 
was isolated. Reverse transcription-PCR (RT-PCR) was performed 
using a RT-PCR kit. Bisulfite-treated genomic DNA was amplified 
using either a methylation-specific or an unmethylation-specific 
primer set. Bisulfite-treated genomic DNA was amplified, the PCR 
products were extracted and subsequently sequenced. The HCT116 
cells were transfected with TOP-flash plasmid. Cells were treated 
with EGCG after transfection. Luciferase activity was assayed 24 
hours after treatment. Cytosolic proteins were bound with the primary 
antibodies of b-catenin. Antigen-antibody complexes were detected 
by ECL blotting analysis system. 
Results: The WIF-1 transcript was silenced in H460, A549 and 
HCT116 cell lines. Results from cell proliferation assay showed that 
compared with that of controls, the remaining cell viability was not 
altered at a concentration up to 50 μM. Promoter methylation was 
found by using methylation-specific PCR (MSP) in H460 and A549 
cell lines. The CpG islands in H460 and A549 cell lines were densely 
methylated by using sequencing technique. Sequence analysis of the 
WIF-1 promoter region revealed concentration-dependent demethyla-
tion after incubation with EGCG, The sequencing results showed that 
the WIF-1 promoter methylation level decreased after treatment with 
EGCG in H460 and A549 cell line. Results from RT-PCR showed 
that WIF-1 expression can be restored and reactivated after treatment 
by EGCG. Concentration-dependent decrease of TOP flash luciferase 
activity with no change in the mutated control (FOP flash) would be 
expected to correlate with down-regulation of b-catenin-induced Tcf/
Lef transcriptional activity. H460 and A549 cells treated by EGCG 
had decreased expression of b-catenin by western blot analysis.
Conclusion: EGCG can reactivate WIF-1 gene expression from a 
previous state of silencing by a mechanism of promoter demethyla-
tion. EGCG can also down-regulates the canonical Wnt signaling 
pathway. Our study indicated that EGCG can be used for the restora-
tion of WIF-1 expression by reversal of WIF-1 promoter methyla-
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tion. This may suggest a potential preventive usage of EGCG in lung 
cancer patients. 
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Relationship between the expressions of CDK2, p27kip1 
proteins and non-small cell lung cancer of XuanWei
Huang, Yunchao; Li, Xiaoming; Yang, Kaiyun; Zhao, Guangqiang; 
Gao, Jia; Wang, Kun; Ye, Lianhua; Lei, Yujie
Yunnan Tumor Hospital, Kunming, China
Objective: To study the expressions of CDK2 and p27kip1 protein in 
non-small cell lung cancer of Xuanwei. To explore their relationship 
and biological behavior of lung cancer of Xuanwei. 
Method: 30 cases non-small cell lung cancer tissues and normal 
pulmonary tissues of Xuanwei were selected as the experimental 
group. 30 cases non-small cell lung cancer tissues and normal pul-
monary tissues of other regions were selected as the control group. 
Immuneohistochemical metXuanweid was used to detect the expres-
sions of CDK2 and p27kip1 protein in lung cancer tissues and normal 
pulmonary tissues. SPSS12.0 statistic package was applied to analyze 
the data(χ2test and Pearson Correlatons). 
Results: The positive expression of CDK2 protein was 73.33% in 
lung cancer tissues and 10% in normal pulmonary tissue of experi-
mental group. There was a significant difference between lung cancer 
tissues and normal pulmonary tissues of experimental group(P<0.05). 
The positive expression of CDK2 protein was 53.33% in lung cancer 
tissues and 3.33% in normal pulmonary tissues of the control group. 
There was a significant difference between lung cancer tissues and 
normal pulmonary tissues of control group(P<0.05). The expressions 
of CDK2 protein in lung cancer tissues had not significant difference 
between the experimental group and the control group (P>0.05). 
The expressions of CDK2 protein had significant difference between 
adenocarcinomas of the experimental group and adenocarcinomas 
of the control group (P<0.05). The expressions of p27kip1 protein 
in normal lung tissues were more than Xuanweise in lung cancer tis-
sues. The positive expression of p27kip1 protein was 36.67% in lung 
cancer tissues and 90.00% in normal pulmonary tissues of the experi-
mental group. There was a significant difference between lung cancer 
tissues and normal pulmonary tissues of experimental group(P<0.05). 
The positive expression of p27kip1 protein was 43.33% in lung 
cancer tissues and 93.33% in normal pulmonary tissues of the control 
group. There was a significant difference between lung cancer tissues 
and normal pulmonary tissues of control group(P<0.05). There was 
negative correlation between the expressions of CDK2 and p27kip1 
protein (P<0.05, r=-0.484, r=-0.530). 
Conclusions: The high expression of CDK2 protein and the low ex-
pression of p27kip1 protein in non-small cell lung cancer might play 
an important role in carcinogenesis of lung carcinoma of Xuanwei. 
The expressions of CDK2 protein had correlation with histopatX-
uanweilogy type of Xuanwei. The expressions of CDK2 protein in 
adenocarcinomas tissues had significant difference between Xuanwei 
and the other regions. The expressions of CDK2 and p27kip1 proteins 
had correlation with lymph node metastasis. There was negative cor-
relation between the expressions of CDK2 and p27kip1 proteins in 
lung cancer tissues.
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The effects of multiple COX pathway manipulations on 
murine lung tumorigenesis
Hudish, Tyler M.; Mozer, Anthony B.; Opincariu, Laura I.; Boten, 
Jessica A.; Crossno, Joseph T.; Keith, Robert L.
Denver VA Medical Center, Denver, CO, USA
Introduction: Our laboratory has focused on prostacyclin (PGI2) 
as a chemopreventive agent in murine lung carcinogenesis. We have 
genetically modified mice to overexpress the enzyme that synthesizes 
PGI2, prostacyclin synthase (PGIS). When PGIS-overexpressing 
mice (PGISOE) are given a single dose of urethane (resulting in K-
Ras mutations predominantly of codon 61), they develop significantly 
fewer tumors after 18 weeks than do wildtype littermates given the 
same treatment. We also have shown that an oral synthetic analogue 
of PGI2, iloprost, has similar effects in the same tumor model. More 
recent studies from our lab suggest PGI2 is chemopreventive in-
dependently of the IP receptor as a PPAR-γ agonist. As an extension 
of these results, we chose to evaluate the chemopreventive effects of 
two additional COX pathway effectors, indomethacin, a nonspecific 
COX inhibitor, and rosiglitazone, a PPAR-γ agonist.
Methods: Iloprost (Schering AG) was fed to mice at 175mg/kg 
antioxidant-free chow (AIN-76A, TestDiet). Rosiglitazone was 
administered similarly at 150mg/kg. Indomethacin was given to 
mice in drinking water (2mg/L 0.1% EtOH). One week following the 
administration of each of these agents singly or in combination to 
wildtype FVB/N mice, and the latter two agents singly to PGISOE/
FVB/N transgenic mice (20 mice per experimental group), adeno-
carcinomas were induced with a single intraperitoneal injection of 
urethane (1mg/g body weight) and enumerated 18 weeks later. We 
were able to confirm the effects of the transgene and pharmacologic 
agents by measuring selected prostaglandin levels (EIA analysis of 
6-keto prostaglandin F1α).
Results: As illustrated in figure 1, PGIS overexpression as well as 
iloprost or rosiglitazone administration significantly reduced tumor 
incidence following urethane injection compared to wt controls, 
while indomethacin failed to show change. The PGISOE/indometha-
cin and PGISOE/rosiglitazone combinations also reduced tumor 
incidence (p<0.01), while the iloprost/indomethacin and iloprost/rosi-
glitazone combinations did not (p>0.05). While PGISOE/indometha-
cin was no more effective in decreasing tumor incidence than was 
PGISOE alone (p>0.05), PGISOE/rosiglitazone was more effective 
than PGISOE alone (p=0.02).
Discussion: These results demonstrate the chemoprotective effects 
of PGIS overexpression, iloprost, and rosiglitazone as single-agent 
interventions, but only show a clear advantage to combinatorial 
chemoprevention in the PGISOE/rosiglitazone group, where tumor 
incidence reduction was enhanced to 80.1% (vs 69.6% in PGISOE 
alone and 30.4% in rosiglitazone alone). Oral administration of 
either iloprost or rosiglitazone was not as chemopreventive as PGI2 
overexpression. The lack of chemoprotection observed with indo-
methacin may be explained by its inhibition of hydroxyprostaglandin 
dehydrogenase (PGDH) and subsequent inactivation of pro-oncogen-
ic prostaglandin E2 (PGE2). Whether combinatorial prostaglandin 
manipulation will prove to be more effective than PGI2 manipulation 
remains to be determined.
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Total antioxidant status and its response amongst lung 
cancer patients
Joshi, Shambhu D.1; Kumar, A2; Pandit, N2
1 DPHO, Dhangadhi, Nepal; 2 NMC teaching hospital, ktm, Nepal
Introduction: Lung cancer is one of the leading cause of death.The 
incidence of lung cancer is up cropping even in the under developing 
country like Nepal (2), where the changing life style, addiction, oc-
cupation hazards, social and epidemiological factors are the major 
cause of cancer in Nepal. scientific research work claimed that p53 
is detected as a significance role to cause the cancer (3). Our present 
study encourage us due to the number of patient who are provision 
diagnose as cancer. Our research work is mainly focused on the total 
antioxidant status amongst the subjects provisionally diagnosed of 
lung cancer.
Method: The study was conducted in lung cancer patients reports 
attending at Medicine and Surgery out patient department,different 
hospitals. This study was a form of pilot studies to asses the anti-
oxidant status in cancer patients. A total of 108 subjects (male: 58, 
female 50) were chosen and an age-sex matched healthy controls 
of 108 subjects (male: 55, female 53). A four-day dietary recall was 
established to check the differences in dietary antioxidants intake 
in both groups. 5 ml of blood sample was collected after a written 
consent from the subjects and was stored at -22°C for further analy-
sis. The total antioxidant, super oxide dismutase, and glutathione 
peroxidase was measured adopting a ready-made kit procured from 
RANDOX, Germany.
Results: Among the cancer patients the total antioxidant was rela-
tively lowered and falling in lower borderline range to those observed 
in controls subjects. The results are shown in Table. No. I which is 
given below.
Discussion: In the present study carried out on lung problem patients 
showed that the total antioxidants was lower in cancer patients com-
pared to the control groups. This establishes the fact that lowering 
of antioxidants could be the most probable cause of lung cancer. The 
dietary antioxidants intake in the study subjects were similar to that 
of control group stating the fact that dietary antioxidants does not 
play a major role in prevention of cancer but it delays the cancer pro-
gression as confirmed and stated by the research conducted elsewhere 
(5). Our study concludes that in changing lifestyle cancer is one of 
the major community health problems and it can only be prevented 
with regular intake of antioxidant vitamins and advocating healthy 
habits by saying to avoid smoking, tobacco, drinking, roasted food, 
air pollution environment etc. Nepal being a poor developing country 
with scientific research and molecular biochemistry is in grass-root 
stage, the authors feels that this current study would show some light 
for the future research and encourage the habit of doing original 
work and contribute to the developing nation in the field of molecular 
biochemistry.
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Potential diagnostic markers in bronchial fluid of small cell 
lung cancer (SCLC)
López-Vivanco, Guillermo1; Carrera, Sergio1; Calvo, Begoña 
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Muhialdin1; Ruiz de Lobera, Abigail2; Ballesteros, David2; Fuente, 
Natalia2; Casas, Raquel2; López de Argumedo, Gonzalo2; Iruarrizaga, 
Eluska2
1 Molecular Biology Department-Medical Oncology, Hospital 
of Cruces, Barakaldo, Spain; 2 Medical Oncology Departement, 
Hospital of Cruces, Barakaldo, Spain; 3 Neumology Department, 
Hospital of Cruces, Barakaldo, Spain; 4 Progenika, Zamudio, 
Zamudio, Spain
Background: Lung cancer is a major cause of mortality worldwide 
and overall survival rate has not improved significantly over the past 
20 years. Although the incidence of SCLC is declining, it remains a 
worldwide public health problem. An early diagnosis could improve 
prognosis and survival among these patients. The aim of this study 
was to identify protein markers obtained from bronchial fluids of 
SCLC patients which may differ from non-pathological bronchos-
copy samples.
Methods: We have included 43 patients with SCLC diagnosed using 
bronchoscopy and 49 consecutive patients with non pathological 
bronchoscopy. Bronchial fluid was obtained from each patient and 
potential protein markers were studied. After being centrifuged, 
supernatant proteins were analysed using bidimensional electro-
phoresis with poliacrilamid gel stained with silver nitrate. Gel was 
scanned and analysed with Progenesis PG6220 program, which 
measures intensity of each spot. Resultant intensities in each group 
of patients (SCLC/non pathological bronchoscopy) were compared 
using T-Student method. We selected as potential markers those spots 
with a p value of less than 0.05. We calculated “fold change” of each 
spot as the ratio between mean intensity in SCLC samples and non 
pathological samples.
Results: Optimal bidimensional gels of each sample were obtained. 
Among 300 comparable spots, 10 of them were expressed with a 
different intensity in both groups of patients; 6 of these potential 
markers were over expressed in SCLC samples, whereas 4 of them 
were under expressed. The “fold change” of these 10 spots ranges 
from 1.5 to 8.67.
Conclusions: Different protein markers can be detected in bron-
chial fluid obtained from SCLC samples. Significant differences in 
expression of these biomarkers were detected between SCLC patients 
and non pathological bronchoscopy patients. The development of an 
early diagnostic test using these proteins must be validated in future 
studies. 
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Spectral biopsy of lung cancer by auto fluorescence of 
urine
Trinka, Vijmasi2; Salhi, Mohamad Al3; Elangovan, Masilamani4; 
Masilamani, Vadivel1; Diab, Abdulrahman Al3; Hajjar, Waseem 3; 
Ainia, Mohamad3; Mustapha, Abdullah Al3
1 Physics Dept, College of Science, King Saud University, KSA, 
Riyadh, Saudi Arabia; 2 Masila’s Cancer Diagnostics, Chennai, 
India; 3 King Saud University, Riyadh, Saudi Arabia; 4 Thendrel Inc, 
Fairfax, VA, USA
There are very limited methods for detection, diagnosis and prognosis 
of lung cancer, based on biomarkers of urine. This paper, we present 
results of a study done on auto fluorescence of urine to detect lung 
cancers with a sensitivity of 90%.
Methods: For this study, normal controls (N=2100) in the age group 
of 30-60 and lung cancer patients (N=40) were recruited. 5ml of fast-
ing urine samples from each persons was collected and taken in quart 
curette and Fluorescence Emission Spectra (FES) was obtained for 
each with an excitation at 400nm. 
Results and Discussion: Fig 1(a) gives the typical FES of nor-
mal urine. There are three bands, one at 450nm due to pyridoxine, 
490nm due to the combinations of reduced nicotinamide dinucleotide 
(NADH), and flavin adenine dinucleohide (FAD) and 615nm due to 
porphyrin. In this spectrum, the dominance is by NADH(490nm). 
In contrast, as shown in fig 1(b), there is a dramatic shift of the peak 
from 490 to 510nm due to the elevation of FAD. This is the indication 
of early lung cancer. Fig 1(c) shows typical FES of urine of advanced 
lung cancer patient. Here the band gets shifted to 525nm (due to 
FAD) and the band at 490nm due to NADH is swamped.
We define the intensity ratios, R1=I555/ I 450 and R2= I 615/ I 450.
For normal, R1<0.5; and R2<0.3; for early lung cancer 0.5<R1<2 and 
0.3 <R2<0.8; for advanced lung cancer R1>2; and R2>0.8.
More importantly, the peak shifts from 490nm to 510nm for early 
carcinoma and to 525nm for advanced laser.
A multivariate statistics was developed; involving these parameters 
which showed a sensitivity of 90% for advanced carcinoma and 77% 
for early cancer, always in comparison to the histopathology.
Conclusion: Based on our study involving and fasting urine samples 
of a few thousand normals and 40 lung cancer patients, detection and 
diagnosis are possible for lung cancer with a sensitivity of 90%. All 
these because bio fluorophores, porphyrin, and flavins are elevated 
two to four times in the body fluids of the diseased. The cell prolif-
eration and cell degeneration (due to cancer), change the metabolic 
activities, leading to elevation of many bimolecules. Out of these 
porphyrin and flavin released in urine are reliable spectral cancer 
biomarkers.
Based on the above work a patent has been submitted to Indian and 
US patent office. 
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Non Intrusive and extremely early detection of lung cancer 
using TCPP (Biomoda Lab Cultured Lung Cancer Data)
Mukkamala, Srinivas
Biomoda, CAaNES, New Mexico Tech, Albuquerque, NM, USA
In this study, we introduce a method of functionally classifying lung 
cancer cells from normal cells by using Tetrakis Carboxy Phenyl Por-
phine (TCPP) and well-known computational intelligent techniques. 
Tetrakis Carboxy Phenyl Porphine (TCPP) is a porphyrin that is able 
to label cancer cells due to the increased numbers of low density 
lipoproteins coating the surface of cancer cells and the porous nature 
of the cancer cell membrane.
We study the performance of kernel methods in the context of clas-
sification accuracy on lung sputum dataset (Biomoda Laboratory). 
We use a Library for Support Vector Machines (LIBSVM) for model 
selection. Through a variety of comparative experiments, it is found 
that SVMs perform the best for detecting lung cancer. Results show 
that all 79 features we use give the best accuracy to identify lung 
cancer cells. Our results thus demonstrate the potential of using TCPP 
and learning machines in detecting and classifying lung cancer cells 
from normal cells.
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SLaptamer-based proteomic arrays for serum biomarker 
discovery in lung cancer
Ostroff, Rachel M.1; Brody, Edward N.1; Zichi, Dom A.1; Stewart, 
Alex1; Stanton, Marty1; Muley, Thomas2; Meister, Michael2
1 SomaLogic, Inc, Boulder, CO, USA; 2 Thoraxklinik, University of 
Heidelberg, Heidelberg, Germany
Background: Most lung cancer cases are diagnosed at an advanced 
stage of disease, where five year survival is less than 20%. A blood 
test that identifies early stage lung cancer would provide an avenue 
for early detection and treatment, which would improve survival and 
reduce the cost of treating this deadly disease. 
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Methods: SomaLogic has identified a potential set of protein bio-
markers and constructed a preliminary classifier to distinguish lung 
cancer from both smokers and patients with identified pulmonary 
nodules or other benign pulmonary conditions. These biomarkers 
were discovered by analyzing two separate archived sample collec-
tions with the SLaptamer biomarker discovery array. 
Results: Over six hundred serum proteins were measured with the 
SLaptamer assay, and significant differential expression was observed 
for multiple proteins between the lung cancer samples and control 
groups. A classifier was constructed with a subclass of these pro-
teins, with an estimated sensitivity and specificity of 80% for both 
the training and test sets derived from these two sample collections. 
These results were verified by applying the classifier algorithm to 
an independent sample set of lung cancer and smoker control serum 
samples collected from a third site. In this set, a sensitivity of greater 
than 85% and a specificity of 80% were achieved for identification of 
lung cancer compared to smokers. 
Conclusions: These results present the potential for early detection 
and diagnosis of lung cancer using the biomarkers and classifier 
discovered with the SLaptamer assay. Refinement and validation of 
these biomarkers are essential steps for advancing these discoveries 
to the clinic for early detection of lung cancer.
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Breathing analysis by electronic nose in lung cancer 
detection
Bonarini, Andrea1; Blatt, Rossella1; Calabrò, Elisa2; Matteucci, 
Matteo1; Randi, Giorgia3; Verdirosa, Mauro1; Trameri, Claudio1; La 
Vecchia, Carlo3; Pastorino, Ugo2
1 Politecnico di Milano, Milan, Italy; 2 National Cancer Institute, 
Milan, Italy; 3 Mario Negri Institute, Milan, Italy
Early detection is a major challenge to decrease lung cancer mortal-
ity, and efforts are now focused on radiological imaging. We tested 
the ability of breathing analysis by electronic nose (e-nose), based on 
an array of metal oxide semiconductor sensors, to detect lung cancer. 
From June 2007 to September 2008 we analysed 306 breath samples 
from 153 subjects, 73 lung cancers and 80 age- and smoking-matched 
healthy subjects. We implemented a genetic algorithm to discriminate 
‘lung cancer’ from ‘healthy’ subjects, using Fisher’s Linear Dis-
criminant Analysis (LDA) and a classification based on the k-Nearest 
Neighbours (k-NN) method. In a first pilot study on 202 samples 
from 101 subjects (43 cancers and 58 controls), sensitivity was 95% 
and specificity 90%. Positive predictive value was 88%, and negative 
predictive value 96%. To test reproducibility, we performed a second 
study on 104 samples from 52 subjects (30 cancers and 22 controls). 
Sensitivity was 93% and specificity 100% overall, and 75% and 98% 
respectively in a subset of stage I lung cancer. All results were based 
on a leave-one-subject out cross-validation. These findings, though 
based on small samples and on a methodology requiring standardisa-
tion, indicate a potential scope of breathing analysis by e-nose for 
lung cancer diagnosis in high risk individuals. 
Oncology Nursing
P3.056 Oncology Nursing, Mon Aug 3 – Tue Aug 4 
A review of key roles of Scottish lung cancer nurses
Borthwick, Diana C.1; McPhelim, John2; Irvine, Lynn2; Downer, 
Penny3; Mencnarowski, Julie1; Stevens, Liz4
1 NHS Lothian, Edinburgh, UK; 2 NHS Lanarkshire, East Kilbride, 
UK; 3 NHS Greater Glasgow & Clyde, Glasgow, UK; 4 NHS 
Grampian, Aberdeen, UK
The role of the lung cancer nurse specialist in the UK is a relatively 
recent development in response to improving the quality, co-ordina-
tion and delivery of lung cancer services (Standing Medical Advisory 
Committee1994, Calman &Hine 1995). However despite the lung 
cancer nurse being integral to the MDT, there has been little strategic 
planning as well as training and evaluation of the role (Moore et al. 
2002, Department of Health 2004a). This poster describes the results 
of a survey of Scottish nurses, their key roles and activities. 
Methods: The group used a questionnaire developed in 2005 to 
audit lung cancer nurse specialists in the UK on behalf of the BTS 
Lung cancer and Mesothelioma working party. The survey addresses 
caseload, grading, working practices and identifies clinical and non-
clinical activities in order of priority. There were twenty-eight posts 
across Scotland at the time of the survey with two posts vacant so 
twenty-six questionnaires were distributed. Twenty were returned 
(77%). 
Results: Key themes from the survey included delivering care, edu-
cation, multidisciplinary working, professional and servcie develop-
ment as well as research and audit.
Conclusions: The survey demonstrates key components of the clin-
ical nurse specialist role in Scotland and highlights the high number 
of single-handed practitioners as well the disparity in caseload. This 
paper supports previous research into the lung cnacer nurse speciliast 
role. 
P3.057 Oncology Nursing, Mon Aug 3 – Tue Aug 4 
Skin related quality of life in lung cancer patients receiving 
targeted therapy
Lai, Yeur-Hur; Lin, Ru-Yu
College of Medicine, National Taiwan University, Taipei, Taiwan
Background: Targeted therapy is one of new treatments for lung 
cancer currently. The major side effect of EGFR inhibitors is related 
to its skin toxicities. It may further influence patients’ quality of life. 
However, limited studies have explored these problems. Therefore, 
the purposes of this study were to examine (1) patients’ experiences 
related to dermatologic toxicities; and its impact on quality of life and 
body image; and (2) patients’ strategies used to cope with side effects 
related to targeted therapy. 
Methods: A cross-sectional study with purposive sampling was 
conducted. Data were collected by (1) Symptom Severity Scale (NCI 
CTC v3.0---dermatology/skin); (2) Skindex -29 to measure skin 
related quality of life, (3) Hospital Anxiety and Depression Scale 
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(HADS) to measure mood status, (4) Coping strategies scale, and (5) 
Background Information Form. 
Results: A total of 94 lung cancer patients were recruited from a 
medical center in Taipei. The results showed that 91.5% of patients 
had dermatological toxicities and 70.2% of patients had multi-sites 
of skin change. Incidences of these side effects as their descending 
order were (1) skin rash, (2) pruritus, and (3) dry skin. The severity of 
these symptoms as their ranking order was (1) pruritus, (2) dry skin, 
and (3) skin rash. The most frequently used coping strategies were 
(1) using prescription by doctor, (2) using lotion, (3) using antiseptic 
before nail change. Pruritus was found to be the most significant 
side effect to affect patients’ life. There were significant correlations 
among NIC CTC v3---dermatology/skin skindex-29. ECOGE PS and 
depression. The results also showed that Tarceva had severer side 
effects than Iressa..
Conclusion: Skin toxicities have been found to be significantly 
related to lung cancer patients’ quality of life. Longitudinal studies 
would be necessary to further examine the changes of dermatologic 
toxicity and related quality of life across time. 
P3.058 Oncology Nursing, Mon Aug 3 – Tue Aug 4 
YES WE CAN implement a minimal contact intervention 
for smoking cessation in 3 minutes or less!
Martelli-Reid, Lorraine1, 2; Zywine, Christine1, 2; Matone, Jean1, 2; 
Mitton, Jennifer3; Rand, Carol1, 2
1 Juravinski Cancer Centre, Hamilton, ON, Canada; 2 McMaster 
University, Hamilton, ON, Canada; 3 Public Health Department, 
Hamilton, ON, Canada
Background: Tobacco use and smoking has been linked to the de-
velopment of 15 different cancers and accounts for 30% of all cancer 
deaths. It is important for oncology nurses to be aware of the infor-
mation that links continued smoking to worse treatment outcomes 
and the increased risk of second primaries, as well as the strategies 
that can lead smokers to smoking cessation whether they have a diag-
nosis of cancer or are close friends and family of the cancer patients. 
As valued health care professionals, oncology nurses can be effective 
tobacco cessation interventionists. The 5A model of minimal contact 
tobacco intervention is recognized internationally as a best practice in 
smoking cessation and is advocated for in many clinical best practice 
guidelines. In a busy practice setting, this evidence-based approach 
can be implemented in three minutes or less. 
Methods: A retrospective chart review was completed over a 1 
month period to look at documentation of the intervention delivered. 
Results: This presentation will review the effects of smoking on ones 
health and of continued smoking during treatment for cancer. It will 
also highlight how one regional oncology centre implemented the 5A 
model as part of ongoing surveillance for all oncology patients and a 
review of the outcomes to date via a retrospective chart review.
P3.059 Oncology Nursing, Mon Aug 3 – Tue Aug 4 
Strength in numbers - bringing lung cancer patients 
together through an information fair
Martelli-Reid, Lorraine; Hapke, Sally; Ellis, Peter
Juravinski Cancer Centre, Hamilton, ON, Canada
The Juravinski Cancer Centre in Hamilton, Ontario hosted their 1st 
biennial Lung Cancer Information Fair to reach out to those who are 
touched by lung cancer-patients, families and caregivers. The goals of 
this unique event were to promote lung cancer awareness in the com-
munity, enhance knowledge and care and to provide an opportunity 
for peer and community resource networking. Successful partnering 
with Hamilton Health Sciences, McMaster University, Industry, and 
Lung Cancer Canada, provided an unprecedented day with over 100 
attendees. Those who attended had access to over 25 exhibitors who 
provided information on physical and psychological resources relat-
ing to all aspects of care along the illness trajectory. One highlight 
of the event was a Peer Support Table hosted by patients and family 
members affected by lung cancer including Mr. Walter Gretzky and 
his daughter Kim. This free event also included short supportive care 
presentations, a wellness room and the feelings of support, encour-
agement and hope. This poster will highlight the organizational 
planning, components of the program and evaluation of the event that 
was a huge success. 
P3.060 Oncology Nursing, Mon Aug 3 – Tue Aug 4 
Economics of oncology care: Initiatives NGO nurses in 
resource poor settings
Sankpal, P D.1; Vaishali, P S.2; Salgokar, R N.1
1 Health Alert Organization Of India [Ngo], Dhule, India; 2 Public 
Health BMC, Mumbai, India
Introduction: Qualifies oncologists are rarity in developing nations. 
Access to care poorly addressed issue. To evaluate role of nursing 
personal of resource-poor-nations. Our NGO enrolled 534 Respira-
tory-cancer-patients. 56% tobacco-induced. 68% taken treatment in 
city returned back to villages. 27% under palliation. 27% treatment 
dropouts, 5% on chemo. Our NGO provides economical home care in 
rural-India. 
Aims: Determine strategies to reduce cost of oncology care in rural 
India by training of nurses, its benefits to rural-community. NGO 
team trained 11 nurses in rural India.
Method: 18 NGO training workshops conducted between Dec2003 
to April 2008 to assess current oncology-nursing-services & modify 
them to reduce sot to patients. To evaluate role of Nurse in rural 
areas. To determine psychosocial needs of lung caner patients. 
Modify nurse training module for better care of elderly-population. 
A multicentre-survey at 5 rural health centers conducted. Traditional 
faith healers, patients undertaken to identify needs & train nurses. 
Nurses work with multidisciplinary-NGO-team. Nurses available 
to patient and family for psychosocial needs with home-based-care. 
Nurses also increased public awareness on Respiratory-cancer issues 
like crude-tobacco-smoking in elderly through community programs.
Results: 118 lung cancer patients opinions of nursing-care analyzed 
two years. NGO functioning in operational stages graphically shown 
to IASLC congress participants.
Conclusion: our nursing design works as link between medical 
team patient. Benefits: Reduce depression, Manage patients needs. 
Improved QOL in elderly. Economical care for respiratory diseases of 
rural tribal communities.
Recommendation: our approach reduces treatment-cost burden . 
we Plan to integrate our approach with European experts at IASLC-
2009-conference venue. Need to share experiences at 13th WCLC to 
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break barriers in providing accessible home-based Oncology nursing-
care in developing nations like India. Involving NGO’s in resource 
poor settings is must to solve economic issues of oncology care.
P3.061 Oncology Nursing, Mon Aug 3 – Tue Aug 4 
The role of a dietician in the evaluation of nutritional 
status in stage I lung cancer patients referred for 
stereotactic radiotherapy
Wisman, Lilian; Vogel, Jeanne; van Miert, Lisette; Koppe, Friederike; 
van de Pol, Marjan
Institute Verbeeten, Tilburg, Netherlands
Background: The majority of cancer patients develop clinical mal-
nutrition, which negatively affects response to therapy, increases the 
frequency of treatment-related side effects and decreases survival.
The purpose of the present study was to evaluate the nutritional status 
of stage I lung cancer patients treated with stereotactic radiotherapy 
(SRT). These patients are presumed to be at risk being malnourished, 
because of the presence of various risk factors such as higher age and 
COPD.
Methods: Prospectively, 57 patients with stage I lung cancer referred 
for SRT were included. Nutritional status was evaluated by an in-
depth nutritional assessment by a dietician. The assessment includes 
extensive dietary history, anthropometry and the short nutritional 
assessment questionnaire (SNAQ).
Patients were considered to be malnourished if their diet did not pro-
vide adequate calories and protein for growth and maintenance.
Results: The median age of patients referred for SRT was 73 years 
(range 48 - 90). The vast majority was medically inoperable, mainly 
due to COPD.
Moderate COPD (GOLD stage II) was seen in 45% and severe COPD 
(GOLD stage III or IV) in 33% of the patients.
At the onset of SRT, 7 out of 57 patients (12%) were malnourished. 
These patients could successfully be treated by nutritional support. 
Five of them were known to have GOLD-stage III COPD. 
Only 2 of these 7 patients were identified to be at risk for malnutri-
tion by the SNAQ screening tool (score > 2).
In the malnourished patients, the mean body mass index (BMI) was 
30.8, ranging from 26.5 – 34.7, suggesting no underweight. The mean 
BMI in the other patients was 26.8 (17.6-42.7). 
Four patients, all with adequate intake and a normal scoring at the 
SNAQ, were underweighted (BMI < 20).
Five normally weighted patients were identified by the SNAQ to be at 
risk for malnutrition, three of them had a sufficient nutritional intake.
Conclusion: This study showed that malnutrition in stage I lung 
cancer patients referred for stereotactic radiotherapy occurs relatively 
infrequently.
Nevertheless, recognition and treatment of malnourished patients 
remains important. Easily applicable screening tools, including the 
SNAQ and the BMI, seemed to be not very accurate in identifying 
these patients. Therefore, standard assessment by a dietician is rec-
ommended for this patient group.
Pathology
P3.062 Pathology, Mon Aug 3 – Tue Aug 4 
Pathology of rare malignant anterior mediastinal thymic 
tumors: a retrospective study
Asuncion, Bernadette R.; Gadingan, Donaldson M.
Philippine Heart Center, Quezon City, Philippines
Background: Malignant tumors of the thymus are rare, representing 
about 0.2 to 1.5% of all malignancies. Thymic carcinomas represent 
0.06% of all thymic neoplasms. A logical approach is necessary to 
classify and to predict the behavior of these aggressive tumors. 
Methods: To present a series of immunohistochemically confirmed 
cases of thymic malignancies seen in the Philippine Heart Center 
such as:
1) Thymic Carcinoid with Oncocytic Differentiation. A case of 
an assymptomatic 48 year old male, on routine annual medical 
examination revealed an incidental finding of an anterior medi-
astinal mass measuring 9 cms in widest diameter. A year after 
the mass increased in size from 9 cms to 14 cms in its widest 
diameter. Surgical resection was done and revealed positivity to 
chromogranin, synaptophysin and neuron specific enolase. LCA, 
cytokeratin 7, cytokeratin 20, thyroglobulin and calcitonin were 
negative.
2) Composite Hodgkins and Non Hodgkin’s Lymphoma arising 
from an epithelial – containing lesion of the thymus. This is a 
case of a 19 year old female with a rapidly enlarging supracla-
vicular mass. CT scan revealed a large lobulated anterosuperior 
mediastinal mass measuring 13.5 cms in widest diameter. 
Immunohistochemical staining with CD3, CD15, CD20, CD30, 
CD68, S100 and Actin was done.
3) Composite Thymoma and Thymic carcinoma. A case of a 51 
year old female presenting with right eye ptosis and right sided 
weakness of face and upper extremities. A CT-scan revealed an 
anterior mediastinal mass. Fine needle aspiration biopsy was 
suggestive of Thymoma. Open thoracotomy revealed a mass 
measuring 7.5 cms in widest diameter and histopathology showed 
Combined Thymoma Type B2 and Thymic Carcinoma.
Results: Thymic malignancies are difficult to diagnose on routine 
Hematoxylin and Eosin slides. These lesions must be properly evalu-
ated and confirmed with immunohistochemical analysis. A retrospect-
ive review of 26 cases seen in the last five years revealed 26 cases, 7 
cases of thymic carcinoma ( 3 males and 4 females ), 10 cases of non 
Hodgkin’s lymphoma ( 4 males and 6 females), 4 cases of Hodgkin’s 
lymphoma ( 4 males ), 2 cases of teratocarcinoma ( 2 males ) and 3 
cases of carcinoid ( 2 males and 1 female ).
Conclusion: Thymic neoplasms harbor a definite malignant poten-
tial and are capable of following an aggressive behavior. The degree 
of invasion, histology and staging of thymic malignancies remain 
to be the prognostic indicators after complete resection. Immuno-
histochemical studies, both in cytology and tissue preparations have 
tremendously paved the way for the pathologist to arrive at a defin-
itive diagnosis, and eventually aiding in the administration of proper 
treatment.
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Immunohistochemistry (IHC) In Primary Lung 
Lymphoma(PLL) and Diffuse Large B-Cell (DLBC) 
Histology
Avilés, Agustin
Oncology research Unit,Oncology Hospital,IMSS, México, Mexico
Objective: PLL is rare presentation of DLBL, for this reason prog-
nostic factors and treatment remain unsolved.Recently, the use IHC 
as surrogate of microarray techniques has been demonstrated that 
can divided in two prognostic groups: germinal-Bcell(GBB): good 
prognosis and non-GCB: poor prognosis.
Methods: We performed an retrospective analysis of 92 cases of PLL 
and DLBC histology diagnosed between 1989 to 2004.In all cases 
were CD20 +,and the IHC were CD10, BCL-6, and MUM1.Addition-
ally we performed an analysis of the levels of BCL-2.All were treated 
with chemotherapy: CHOP (cyclophosphamide,doxorubicin,vincristi
ne and prednisone).
Results: 72 cases were GCB (78%) and 20 were non-GCB (21%). 
Complete response event-free survival and overall survival in GCB 
group were: 87%,91% and 87%, that were not statistical significant 
when compared to no-GCB: 80%,87% and 75% . The 14 patients that 
were positive to BCL-2 die secondary to tumor progression.
Conclusions: We confirmed that PLL is a rare presentation of ma-
lignant lymphoma (<1% in our institution) but we can confirm the 
efficacy of IHC studies to define prognosis, because the non-GCB 
that is considered an worse prognostic factors did no showed any 
significance in our patients. BLC-2 demonstrated that was the only 
prognostic factor that influence overall survival.
P3.064 Pathology, Mon Aug 3 – Tue Aug 4 
Comparison of the expression of TTF1 and p63 using a 
low-cost tissue microarray and conventional sections of 
lung cancer
Latorre, Gabriel; Saieg, Mauro A.; Rosalino, Ulisses; Amary, Maria 
Fernanda; Bernardi, Fabiola D.
Faculdade de Ciências Médicas da Santa Casa de São Paulo, São 
Paulo, Brazil
Background: Pulmonary carcinomas are the most prevalent cancer 
in the world and the leading cause of cancer death. The pathologic 
diagnosis of lung cancer can be established by histology or cytology. 
The most frequent histological evaluation for lung cancer is made 
on transbronchial or needle biopsies with a small amount of tissue, 
being generally divided into small cell lung carcinomas (SCLC) and 
non-small cell lung carcinomas (NSCLC). This small amount of 
tissue is many times the only available material for analysis, since 
two thirds of the patients present at the time of a diagnosis with an 
inoperable mass. However, the advent of novel therapies based on the 
discovery of molecule targeted neoplasic markers seems to provide 
an additional need for an exact definition of the tumor histological 
subtype in the NSCLC. The present work compares the results of an 
immunohistochemical (IHC) panel of TTF1 and p63 between tissue 
microarray (TMA) build with cylinder paraffin punches (simulating 
transbronchial biopsies) and conventional sections of selected cases. 
Methods: 36 selected cases, being 15 adenocarcinomas (AC),15 
squamous cell carcinomas (SCC), 5 large cell carcinomas (LCC) and 
1 SCLC had IHC study of TTF1 and p63 in conventional sections 
and in a low-cost method TMA, using tissue punches and transferring 
these cylinders to a receptor block. 
Results: Three cases (8,33%), two SCC and one AC, showed 
discordant results between TMA and conventional sections. Two 
cases had their diagnosis changed due to IHC results (a previously 
diagnosed AC with positive p63 and negative TTF1 marking and a 
previous SCC showing positive staining for TTF1 and negative mark-
ers of p63-cases 35 and 36).All LCC were negative for both markers 
in the two methods, as well as the SCLC (table 1). 
 Case  Primary p63 p63 TMA TTF-1 TTF-1 TMA 
  Diagnosis conventional conventional 
   sections sections
 1 AC negative negative positive negative
 2 AC negative negative positive positive
 3 AC positive positive positive positive
 4 AC negative negative positive positive
 5 AC negative negative positive positive
 6 AC negative negative positive positive
 7 AC negative negative positive positive
 8 AC negative negative negative negative
 9 AC negative negative positive positive
 10 AC negative negative positive positive
 11 AC negative negative positive positive
 12 AC negative negative negative negative
 13 AC negative negative positive positive
 14 LCC negative negative negative negative
 15 LCC negative negative negative negative
 16 LCC negative negative negative negative
 17 LCC negative negative negative negative
 18 SCLC negative negative negative negative
 19 SCC positive negative negative negative
 20 SCC positive positive negative negative
 21 SCC positive positive negative negative
 23 SCC positive positive negative negative
 24 SCC positive positive negative negative
 25 SCC positive positive negative negative
 26 SCC positive positive negative negative
 27 SCC positive positive negative negative
 28 SCC positive positive negative negative
 29 SCC positive positive negative negative
 30 SCC positive positive negative negative
 31 SCC positive negative negative negative
 32 SCC positive positive negative negative
 33 AC negative negative negative negative
 34 LCC negative negative negative negative
 35 SCC negative negative positive positive
 36 AC positive positive negative negative
Conclusions: Our results show the use of a low-cost TMA method as 
an efficient tool in simulating the limited sampling of a transbronchial 
biopsy, being representative of the total mass. We can also imply 
that in cases with a small amount of tissue, the use of p63 and TTF1 
is helpful in distinguishing the two main types of NSCLC (AC and 
SCC), what is useful for a distinct approach to inoperable cases.
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P3.065 Pathology, Mon Aug 3 – Tue Aug 4 
Histopathologic changes due to neo-adjuvant 
chemoradiotherapy in resected NSCLC
Blaauwgeers, Hans1; Belderbos, José2; Kappers, Ingrid2; Dijksman, 
Lea1; Smit, Egbert3; Phernambucq, Erik3; Paul, Rick3; Oosterhuis, 
Wolter3; Senan, Suresh3; Postmus, Piet3; Thunnissen, Erik3
1 Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands; 2 
Netherlands Cancer Institute-Antonie van Leeuwenhoek Hospital, 
Amsterdam, Netherlands; 3 Vrije Universiteit medical center, 
Amsterdam, Netherlands
Background: Neo-adjuvant chemoradiotherapy is standard care in 
advanced Non-Small Cell Lung Cancer (NSCLC). Limited informa-
tion is available about the histopathologic changes of pretreatment 
on tumor and adjacent lung parenchyma. The aim of this study was 
to describe these histopathologic changes in resection specimens of 
NSCLC.
Methods: A retrospective analysis was performed on a consecutive 
series of patients treated with neo-adjuvant chemoradiotherapy for a 
pancoast tumor in the period 1997-2007. Irresectibility was deter-
mined by the invasion of the chest wall, the vertebral bones or lymph 
node metastases. Subsequent surgical resection was performed in 
the Vrije Universiteit Medical Center (VUmc) and the Netherlands 
Cancer Institute (NCI), Amsterdam in 27 and 19 cases, respectively. 
Follow-up was taken from the reviewed archives.
Histology slides together with the pathology reports of the resection 
specimens were retrospectively reviewed. Post-treatment tumor size, 
regression, fibrotic changes, vasculopathy, peritumorous inflamma-
tory reaction and reactive parenchymal changes divided in a total 
of 20 items were semi quantitatively scored. There were no differ-
ences between the two hospitals (p>0.05). Correlations between all 
histological items were calculated using the Pearson’s R test with a 
significant level <0,05. 
Results: Clinical analysis revealed 34 males and 12 females with 
a mean age of 56 years (31-78). All but one of the 19 NCI patients 
received a radiation dose of 66 Gy and most of them (n=15) had a 
single agent chemotherapy scheme of Cisplatin. The radiation scheme 
in the VUmc varied between 39 and 50 Gy (mean 44) along with 
cisplatinum-etoposide based chemotherapy. 
The absence of vital tumor cells (i.e. complete regression, CR) was 
found in 20 cases. Tumor size was taken from gross pathological 
exam. A smaller tumor diameter was associated with higher chance 
on absence of vital tumor (i.e. CR), [r= -0,35, p<0,02]. The chance to 
detect residual tumor was dependent of number of tumor blocks taken 
for histological exam (r=-0,31, p<0,04), but seemed to correlate with 
tumor size, i.e. larger tumors had more blocks and also more residual 
tumour.
In case of residual tumor, vital tumor cells were more frequently 
found in the periphery than in the center (value 0,66, p<0,001). More 
prominent cytonuclear atypia was present in cases with necrosis com-
pared to cases with mainly fibrosis (value 0,66, p<0,01)
Several stromal reactions correlated, such as fibrosis and dyselastosis 
and the presence of extensive foamy macrophages and cholesterol 
clefts. 
In addition, correlations (P<0.05) were found between obliterative 
and inflammatory vascular changes and reactive changes in adjacent 
lung parenchyma.
Conclusion: The chance of complete regression was higher in 
patients with smaller post treatment tumor size. Residual vital tumor 
is more frequently found peripherally in the remaining mass with 
more cytonuclear atypia in cases with predominant necrosis. Reactive 
changes in adjacent lung parenchyma seems to be due to vascular 
changes.
P3.066 Pathology, Mon Aug 3 – Tue Aug 4 
Measure of S-Phase dysfunction in the adenomatous 
neoplasia spectrum
Black, Candice
Dartmouth, Lebanon, NH, USA
Background: Our current understanding of pulmonary adenocarcin-
oma (ADC) is one of a spectrum of pneumocyte centered disease that 
is recognized at its earliest morphologic state as atypical adenoma-
tous hyperplasia (AAH). Bronchoalveolar carcinoma (BAC) is a pure 
in-situ carcinoma that may be mixed with invasive ADC of various 
architectural growth patterns. A microinvasive ADC (up to 0.6 cm) 
with a prognosis close to pure BAC has been recently described. To 
better understand the progressive molecular changes associated with 
recognizable morphologic changes in the ADC family of neoplasia, 
a cocktail of monoclonal antibodies targeted against proteins DNA 
topoisomerase 2-alpha and minichromosome maintenance protein 
2 (TOP2A-MCM2), markers of aberrant S-phase dysfunction, were 
selected for study in a variety of ADC tumors. This antibody cocktail 
has been of diagnostic use in recognizing true pre-neoplasia in other 
organ systems including uterine cervix. This is the first study TOP2A-
MCM2 in progressive adenomatous neoplasia in lung.
Methods: Fourteen cases of ADC, ADC with BAC features (AD-
CWBACF) and cases with separate areas of AAH were selected and 
reviewed. Two patients with initial resections for ADCWBACF with 
tumor recurrence two years later were also included. One case of pure 
invasive ADC and five control cases of inflammation and fibrosis 
(mimicking tumors radiographically) were stained against TOP2A-
MCM2 (ProExC, BD Diagnostics-Tripath, Burlington NC) using 
appropriate negative and positive (cervix) controls. The ICH scoring 
was counted as the percent nuclear stain in 100 nuclei in areas of 
greatest staining.
Results: The TOP2A-MCM2 stain percent increased as the neoplasia 
progressed. It was increased the greatest in solid pattern invasive 
tumors (>70 %) and was least in the surrounding benign lung (1%). 
1 The mean range of positive pneumocyte stain in the control group 
was 10-20%.
2 The mean range of positive AAH was 20-25%.
3 The BAC component in ADCWBAC features averaged 30-35% 
positive stain. 
4 The mean of positive stain for the invasive component in ADC 
(pure), microinvasive ADC, and ADC WBACF was 50-90% with 
no differences noted with the exception of one microinvasive mu-
cinous BAC, which was low in both the BAC and microinvasive 
components (20-25%).
5 All invasive ADC was greater than all AAH for a given case by a 
factor of 2 or greater .
There appeared to be an increase in stain in tumor infiltrating lymph-
ocytes as well as adjacent alveolar macrophages, although these were 
not the focus of this study. 
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Conclusion: The theory that an S-phase dysfunction could be 
detected in pneumocyte neoplasia and that it would increase with 
progressive neoplasia was demonstrated. Unexpected was how well 
it defined each category of ADC, and that invasive ADC showed the 
same percent of S-phase dysfunction in each case regardless of the 
quantity of invasion. Tumor s-phase did not increase in recurrent 
ADCWBACF but was the same as the initial tumors. Only the mucin-
ous BAC was an outlier, which is consistent with other studies that 
demonstrate IHC profile differences. 
P3.067 Pathology, Mon Aug 3 – Tue Aug 4 
Telomere attrition, telomeric protein TRF1 and TRF2 
expression and DNA damage response activation during 
bronchial and bronchiolo-alveolar carcinogenesis
Lantuejoul, Sylvie1; Raynaud, Christophe2; Gazzeri, Sylvie3; 
Salameire, Dimitri1; Moro-Sibilot, Denis3; Soria, Jean-Charles4; 
Brambilla, Elisabeth1, 3
1 Department of Pathology, CHU Michallon; University J Fourier, 
Grenoble, France; 2 Radiology and Oncology Laboratory, CEA, 
Fontenay aux Roses, France; 3 Lung Cancer Research Group- 
INSERM U 823, Institut A Bonniot; University J Fourier, Grenoble, 
France; 4 Department of Medicine, Phase I unit (SITEP), Institut 
Gustave Roussy; University Paris XI, villejuif, France
Purpose: Telomere shortening is an early event in bronchial car-
cinogenesis, preceding P53/Rb pathway inactivation and telomerase 
reactivation. It is perceived as double strand breaks, leading to DNA 
damage responses (DDR), inactivated in cancer to overcome G1 
arrest or apoptosis, and to promote malignant progression through 
genetic instability. 
Experimental design: To establish the chronology of these abnor-
malities in bronchial and bronchiolo-alveolar carcinogenesis, we 
have evaluated telomere length by FISH and analysed by immuno-
histochemistry DDR phosphorylated proteins (p)-CHK2, p-ATM and 
p-H2AX expression in 109 bronchial preneoplastic lesions, including 
15 mild dysplasia, 19 moderate dysplasia, 31 severe dysplasia, and 
44 in situ carcinoma, and in 35 normal or metaplastic epithelium, 
and 32 squamous invasive carcinoma (SCC); the same analyses were 
performed in normal alveolar epithelium, 27 atypical alveolar hyper-
plasia (AAH), 6 bronchiolo-alveolar carcinoma (BAC), 6 stage I 
mixed adenocarcinoma (ADC), and 11 stage II -IV mixed- type ADC. 
We have analysed concomitantly the expression of telomeric proteins 
TRF1 and TRF2, involved in telomere stabilization and potentially in 
DDR inactivation. 
Results: During bronchial carcinogenesis, telomeres critically short-
en at bronchial metaplasia stage, to increase from mild to moderate 
and severe dysplasia to invasive carcinoma (p= 0.03); in bronchiolo-
alveolar lesions, telomere length decreased from normal to AAH to 
BAC, to increase at ADC stage. In response, TRF1 and TRF2 were 
increasingly expressed along with the severity of the lesions, to reach 
a plateau in invasive carcinoma; in contrast, p-H2AX, p-CHK2 and 
p-ATM activation, already observed at metaplasia and AAH stages, 
increased significantly in low-grade to high-grade bronchial dysplasia 
(p< 0.0001 for p-CHK2 and p-ATM, and p=0.0002 for p-H2AX), and 
in AAH to BAC and stage I ADC (p=0.001 for p-CHK2, p=0.0044 
for p-ATM, and p=0.01 for p-H2AX, respectively); interestingly, 
p-CHK2 and p-H2AX expressions, which were highly correlated, sig-
nificantly decreased in SCC and in stage II-IV ADC, whereas p-ATM 
expression was maintained.
Conclusion: Telomere attrition is associated with DDR activation at 
the earliest stage of bronchial and bronchiolo-alveolar carcinogenesis, 
and precedes TRF1 and TRF2 over-expression, favoring telomere 
length stabilization. On the other hand, DDR inactivation represents 
a later event, occurring in SCC and advanced stage ADC in order to 
promote their progression despite genetic instability.
P3.068 Pathology, Mon Aug 3 – Tue Aug 4 
Sancomatoid Carcinoma (SC) associated to Hypertrophic 
Pulmonary Osteoarthropathy (HPO)
Guachalla, Jaime U.1; Rodriguez, Patricio1; Meneses, Manuel 2; 
Robinson, Maria I.1; Campos, Monica M.1
1 Insituto Nacional del Torax, Santiago, Chile; 2 Anatomia Patologica 
Universidad de Chile, Santiago, Chile
Background: Prymary Pulmonary Sarcoma (PPS) represents less 
than 1% of lung cancer Sarcomatoid Carcinoma and Hypertrophic-
Ppulmonary Osteoarthropathy HPOA are very rare pathologies. 
The asssociation of lung cancer patients lwith HPO occurs in 5%. 
Complete tumor resection relieves symtoms and bone lesions of the 
HPOA. We report a 59 tear-old male with edema, pain and varices in 
the lower limbs treated six months with vein esclerosis, then an Xray 
and CT scan for dorsalgia revealed a 3 x 4 cm tumor in the left upper 
lobe and lymph nodes less than 1cm.. Bone scyntigraphy demostrated 
marked only accumulation of 99mTc-MDP along the cortex of long 
bones He was treated with lobectomy and linfadenectomy. The histo-
logic and inmunoprofile diagnosis was Carcinoma Sarcomatoide. Fig 
1. Pain and swelling rapidly alleviatedplus reduction of scintigraphic 
bone uptake. However alter five months the tumor relapsed and 
the patient died after 15 months from initial symptoms and after 8 
months of lobectomy.
Comentary Resecability for PPS depends on site, diameter and tumor 
contact to other structures. This patient had a 5 cm in diameter per-
ipheric tumor, staged localized but and short survival 
Etiene-Mastroianni B. he reported from 12 patients with complete 
resection 4(33%) relapsed and died: 3 at 3 months and one at 4 
months. I and Regnrd JF report 83% of patients that relapsed, had 
incomplete resection. The best prognosis had localizad endobronchial 
sarcomas . Moreover high grade sarcomas have bad prognosis, Grade 
is evaluated with tumor diferenciation, mitotic count and necrosis. 
This patient had 16 mitosis x 10 fields and intermediate grade 2. In 
summary prognosis of PPS depends on tumor size, contact to other 
structures, complete resection and grade. PPS should be staged with 
different staging system. Fig 2. Clinical diagnosis of HPOA is easy 
but requires discard pulmonary pathology
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Figure 2: TNM staging for Sarcomas according to grade and size of tumors
 Histologic Grades 
	 •	 G1	similar	to	normal	tissue	-	grows	slow
	 •	 	G2	Less	similar	to	normal	tissue	-	grows	faster	
	 •	 	G3	minimal	appearance	of	normal	tissue	-	grows	much	faster
	 •	 	G4	No	normal	tissue	-	grows	very	fast
 Tumor Size and Stages 
  T1 Sarcoma less than 5 cms
  T2 Tumor 5cm or more 
   a. Tumor es superfitial
   b. Ttumor deep in the organ 
 Stage I G1-2 T1ab, N0,M0 Tumor of any size but lymphnodes negative 
 Stage II G 3-4 T1 a-b, or T2a, N0, M0 High mitotic count (mitosis) . Tumor of any size If less than 
     5 cm. may be superficial or deep- If more than 5cm must 
    be superficial. No positive lymphnodes nor metastasis 
 Stage III G3-4 T2b,N0M0 Tumor has many mitotic cells and tumor i dep and larger 
    than 5cm.. No positive lymphnodes nor metastasis
 Stage IV    Any histologic grade any T, N1, M0 or Any H G, any T, any N, 
     M1: Tumor any size or any feature but positive lymphnodes 
     near the turmor or metastasis
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Potential increase in the prognostic value of P53 mutation 
by Pro72 allele in stage I Non-Small Cell Lung Cancer
Cheng, Ya-Wen1; Wu, Ming-Fang 1; Chien, Wen-Pin 1; Chen, Chih-Yi 
2; Chou, Ming-Chih 1; Lee, Huei1
1 Chung Shan Medical university, Taichung, Taiwan; 2 China Medical 
University Hospital, Taichung, Taiwan
Purpose: Accumulated evidence suggests that p53 function altered 
by its gene mutation or genetic polymorphism contributes to tumor 
malignancy. Association of p53 mutation and its codon 72 poly-
morphism with lung cancer prognosis has been extensively studied. 
However, the joint effect of p53 mutation and p53 codon 72 poly-
morphism on lung cancer prognosis remains uncertain. 
Methods: In the present study, 266 primary lung cancer patients 
were included and overall survival was calculated. Genomic DNA 
prepared from adjacent normal lung and lung tumor tissues was used 
to determine p53 codon 72 genotype and p53 mutation by PCR-RFLP 
and direct sequencing, respectively. 
Results: Our results showed that for all stages neither p53 codon 72 
genotype nor p53 mutation is associated with lung cancer prognosis. 
However, stage I patients with p53 mutation had a 1.79 fold hazard 
ratio (95% CI, 1.04-3.10) for overall survival when compared with 
p53 wild-type patients. Notably, stage I patients with p53 mutation 
and p53 codon 72 Pro/Pro genotype experienced a 2.31-fold hazard 
ratio (95% CI, 1.08-4.95) for overall survival when compared with 
those with p53 wild-type and Arg/Arg genotype. An increased prog-
nostic value was not observed in stage I patients with p53 wild-type 
and p53 Pro72 allele or in those with p53 mutation and p53 codon 72 
Arg/Arg genotype. 
Conclusions: We therefore suggest that p53 codon 72 Pro allele 
potentially increases the prognostic value of p53 mutation in stage I 
non-small cell lung cancer. 
P3.070 Pathology, Mon Aug 3 – Tue Aug 4 
Value of P63 in distinguishing squamous cell carcinoma 
from adenocarcinoma of the lung
Conde, Esther1; Angulo, Bárbara1; Redondo, Pilar1; García-García, 
Elena1; Suárez-Gauthier, Ana1; García Luján, Ricardo2; López-
Encuentra, Angel2; Paz-Ares, Luis3; López-Ríos, Fernando1
1 Laboratorio de Dianas Terapéuticas, Madrid, Spain; 2 Hospital 
Universitario 12 de Octubre, Madrid, Spain; 3 Hospital Universitario 
Virgen del Rocío, Madrid, Spain
Background: The importance of lung cancer histology has increased 
during the last few years. The main reason is that most target-specific 
agents are only or preferentially administered in certain histologic 
subtypes: tyrosine kinase inhibitors of EGFR-adenocarcinoma, 
bevacizumab-nonsquamous histology, pemetrexed-nonsquamous 
histology, anti-IGFR-squamous cell carcinoma, etc… However, dif-
ferentiating adenocarcinoma from squamous cell carcinoma can be 
difficult by morphology alone in small biopsies or core-needle biop-
sies. P63 has been used as a marker of squamous differentiation, but 
is not currently considered to distinguish squamous cell carcinoma 
from adenocarcinoma of the lung.
Methods: Tumor samples were collected from 146 consecutive 
patients who underwent resection of staged I-II lung carcinoma. All 
tumors were reclassified by 2 pathologists according to the 2004 
WHO classification. Three TMAs containing duplicate 1-mm cores 
carefully selected from tumor areas of the lung carcinoma blocks 
were constructed using a tissue arrayer. Immunohistochemical stain-
ing (IHC) for P63 (clone 4A4, Dako) was performed. IHC reactions 
on TMAs were evaluated by 2 pathologists, who semiquantitatively 
recorded for each core the intensity of nuclear protein expression. 
Frequencies were compared either by Fisher’s exact test or the 2 con-
tingency test, as appropriate. Differences of p<0.05 were considered 
statistically significant. 
Results: P63 expression was detected in 7% of adenocarcinomas and 
52 % of squamous cell carcinomas, the difference being statistically 
significant (p<0.0001). These results are being validated prospect-
ively in a series of bronchoscopic biopsies and core-needle biopsies, 
in which the histologic subtype was not clear by morphology alone.
Conclusions: P63 immunohistochemical staining appears to be use-
ful in accurately subclassifying lung carcinomas. The prospective 
validation of this work will be presented.
Acknowledgment: This work is partially funded by Fundacion Mutua 
Madrileña.
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Limited copy number - high resolution melting for the 
detection of low frequency mutations
Do, Hongdo1, 2; Dobrovic, Alexander1, 2
1 Peter MacCallum Cancer Centre, Melbourne, Australia; 2 
Department of Pathology, University of Melbourne, Melbourne, VIC, 
Australia
Background: Mutation detection in clinical tumour samples is chal-
lenging when the proportion of tumour cells, and thus mutant alleles, 
is low. Recently a number of highly sensitive techniques have been 
developed but they can not be validated by sequencing due to its lim-
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ited sensitivity. In addition, it is important to discriminate false posi-
tives due to PCR errors or template degradation from true mutations.
Methods: We developed an adaptation of high resolution melting 
(HRM), limited copy number HRM (LCN-HRM) which utilises the 
ability of HRM to detect heteroduplexes when variant sequences are 
present. Multiple replicate reactions with a limited number of target 
sequences per reaction readily allow low frequency mutations to be 
detected by their aberrant melting patterns The dilutions used are 
chosen such that mutations if present can be detected well within the 
analytic sensitivity of conventional sequencing. 
Results: When using a cell line heterozygous for a KRAS mutation, 
the mutation was not detected below 10% of mutant alleles (20% tu-
mour cells) by sequencing whereas it was readily detectable down to 
less than 5% mutant alleles by HRM. LCN-HRM is capable of even 
greater sensitivity if more replicates are analysed.
LCN-HRM followed by sequencing was used to review formalin-
fixed paraffin-embedded (FFPE) clinical samples showing discord-
ant findings between sequencing and HRM for KRAS exon 2 and 
EGFR exons 19 and 21. Both true mutations present at low levels and 
sequence changes due to PCR artefacts were detected in the samples. 
The use of high fidelity polymerases showed that the majority of 
artefacts derived from the damaged template rather than replication 
errors during amplification.
Conclusions: LCN-HRM is an effective and rapid single step method 
to enable levels of sequence variation below the normal sensitivity 
of dideoxynucleotide sequencing to be detected in a way that then 
allows ready identification by sequencing.
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Primary mediastinal malignant teratomas: A report of 2 
cases
Gadingan, Donaldson m.; Asuncion, Bernadette R.
Division of Laboratory Medicine, Philippine Heart Center, Quezon 
City, Philippines
Background: Extragonadal germ cell tumors are uncommon none-
theless the anterior mediastinum is the most common extragonadal 
site. Most mediastinal teratomas are benign, and have equal incidence 
in men and women, but 90% of malignant tumors are seen in men.
Methodology: We present 2 cases of primary mediastinal malignant 
teratomas seen at our center.
1. Case 1: A 20-year-old male presented with cough and dyspnea for 
several months duration and an anterior mediastinal mass was seen 
on CT scan. Open thoracotomy was performed and the specimen 
was submitted for histopathologic examination which consisted of 2 
previously dissected, partially encapsulated, tan, rubbery to firm tis-
sues altogether measuring 5 x 5 x 4 cm. with multiloculated cysts and 
tan-white poorly circumscribed nodules. 
2. Case 2: A 37-year-old male presenting with chest pain, cough, and 
progressive dyspnea. On chest CT scan, a large anterior mediastinal 
mass measuring was identified. The patient underwent open thora-
cotomy and the specimen submitted for histopathologic examination 
consisted of a well-encapsulated, gray, ovoid, soft to moderately firm 
tissue measuring 16 x 6 x 4 cm and weighing 663 grams. Serial sec-
tions revealed numerous well-delineated cystic structures containing 
green viscous fluid and white mucoid material.
Results: Microscopic examination of the specimen from our first pa-
tient revealed abundant areas of fibrosis and solid areas with immature 
neural tissues, cartilage, several cysts lined by flattened to cuboidal, 
gastrointestinal glands of mucinous type, bronchial epithelium, and 
focal sarcomatous and carcinomatous areas. For our second patient, 
the microscopic examination disclosed varied array of tissues from the 
3 germ cell layers with most of the areas showing mature compon-
ents and occasional mucous and serous glands displaying a papillary 
arrangement encompassing fibrohyalinized and fibrofatty tissues. In 
some areas of the tumor, solid sheets of immature ovoid to squamoid 
cells invading the stroma and surrounded by areas of necrosis and 
hemorrhage were noted. The histopathologic examination of the 
specimens from our two patients revealed malignant teratoma with 
non-germinal tumor pattern. Our two patients had uneventful post-
operative courses, discharged improved but were lost to follow-up.
Conclusion: We have presented 2 cases of primary mediastinal ma-
lignant teratoma with non-germinal tumor pattern. These lesions may 
be asymptomatic or present with symptoms referable to compression 
of the mediastinal structures. Malignant teratomas may be indistin-
guishable from mature teratomas on imaging studies. The presence of 
frank cytologic atypia and invasiveness distinguishes these neoplasms 
from their benign counterpart thus warranting the need for careful 
histolopathologic evaluation and adequate sampling. The approach 
to these tumors warrants careful judgment and multidisciplinary ap-
proach with the surgeons, radiologists, oncologists, and pathologists. 
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Immunohistochemistry analysis-based recursive 
partitioning decision tree model for predicting lymphatic 
metastasis in squamous cell carcinomas of lung
Gao, Yanning1; Liu, Yu1; Lin, Dongmei2; Xiao, Ting1; Cheng, Shujun1
1 Department of Etiology and Carcinogenesis, Cancer Institute & 
Hospital, Chinese Academy of Medical Sciences, Beijing, China; 
2 Department of Pathology, Cancer Institute & Hospital, Chinese 
Academy of Medical Sciences, Beijing, China
Background: Lymphatic metastasis is highly associated with 
cancer patients’ survival time. The clinical diagnosis nowadays is 
mainly based on histopathological morphology of hematoxylin-
eosin stained, formalin-fixed and parrffin-embedded (FFPE) tissue 
section of tumors and lymph nodes resected by surgery. This could 
be problematic because of failing to collect the informative lymph 
node or failing to catch the micro-metastasis during the FFPE section 
preparation of lymph nodes. We present here a new approach to help 
decision making on lymph node status of the patients with squamous 
cell carcinoma (SCC) in lung. 
Methods: Tissue microarrays containing FFPE primary tumor tissue 
specimens derived from 319 patients with SCC in lung were used for 
the immunohistochemistry (IHC) analysis. Totally 24 proteins were 
involved in this investigation. IHC staining was examined and scored 
by experienced pathologists. The patients were separated into training 
or test group for the subsequent study. Briefly, 34 patients diagnosed 
as lymph node metastasis-negative but died during a 56-month 
follow-up period together with other 30 randomly selected patients 
were assigned to test group, while the other 255 patients formed the 
training set. Recursive partitioning decision tree was chosen as the 
algorithm for molecular classification in this study, and was used to 
construct the prediction tree model in the training set, and then the 
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model was applied to the test group. Survival analysis was carried on 
to inspect the difference between survival time of the patients esti-
mated by the prediction tree model as lymph node metastasis-nega-
tive or -positive in the test group. All statistic analysis was conducted 
with the R software. 
Results: Among the 24 proteins 8 were selected to build the recur-
sive partitioning decision tree model, including Cathepsin-D, Fascin, 
IQGAP1, MMP1, PIGR/SC, TIMP1, TPX2, and uPA. The accuracy 
of the tree model in training set is 78.0%, with sensitivity and specifi-
city 83.0% and 70.3%, respectively. When applying the model to test 
group, the accuracy is 76.6% while the sensitivity and specificity is 
76.0% and 76.9%, respectively. Among those 34 patients who were 
diagnosed pathologically as lymph node-negative but died during a 
56-month follow-up period in the test group, 8 cases were predicted 
as lymph node metastasis-positive by the prediction tree model, and 
these 8 patients had remarkable shorter survival time compared with 
the other 26 who are predicted as lymph node metastasis-negative (p 
= 0.024). 
Conclusions: We proposed here a recursive partitioning based 
decision tree model (with the 8 protein markers) to help diagnosing 
lymph node status of metastasis of SCC in lung. The tree model takes 
IHC analysis data of surgically dissected primary tumor tissues as 
input so that it may be easily build up and practical in clinic. 
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The prognostic significance and clinicopathological 
associations of Cyclooxygenase-2 (COX2) Single 
Nucleotide Polymorphisms in patients with non-small cell 
lung cancer (NSCLC)
Grimminger, Peter P.3; Stöhlmacher, Jan 2; Vallböhmer, Daniel3; 
Schneider, Paul M.4; Hölscher, Arnulf H.3; Danenberg, Peter V.1; 
Metzger, Ralf3; Brabender, Jan3
1 DGCH (Deutsche Gesellschaft für Chirurgie); BDC (Bund 
Deutscher Chirurgen); Faculty of Biochemistry and Molecular 
Biology, University of Southern California, Los Angeles, CA, USA; 
2 Internal medicine clinic I, University Dresden, Dresden, Germany; 
3 Departmet of General, Visceral and Tumor Surgery, University 
of Cologne, Cologne, Germany; 4 Departmet of Visceral- and 
Transplant Surgery, University Spital, Zürich, Switzerland
Background: To further improve the screening, diagnosis and 
therapy of patients with non-small cell lung cancer (NCLC) addi-
tional diagnostic tools are desperately warranted. Gene expression of 
Cyclooxygenase-2 (COX2) has been linked to prognosis in patients 
with non-small cell lung cancer (NSCLC)1. The role of the COX2 
Single Nucleotide Polymorphism (SNP) in the promoter 926 (G→C) 
in patients with NSCLC remains unclear. Aim of this study was to 
investigate the potential of the COX2 926 SNP as a molecular marker 
in this disease. 
Material and Methods: COX2 926 SNP was analyzed in tumor tis-
sue of 85 patients with NSCLC using a PCR-based RFLP technique. 
Tumor stages were as follows: Stage I: 42 (49%) patients, Stage II: 
18 (21%), Stage IIIA 25 (30%). 39 (46%) patients had squamous cell 
carcinoma and 31 (36%) had adenocarcinoma and 15 (18%) had large 
cell carcinoma. All tumors were R0 resected.
Results: The COX2 926 SNP genotypes were detected with the 
following frequencies: GG n=62 (73%), GC n=20 (23%), CC n=3 
(4%). There were no associations between COX2 SNP genotype and 
histology, grading or gender detectable. COX2 SNP was signifi-
cantly associated with tumor stage (p=0.032) and lymph node status 
(p=0.016, Chi-square test). A borderline significant association was 
found between non-smoker and COX2 926SNP (p=0.042, Pearson 
Chi-square; p=0.55 Fisher’s Exact Test). With a median follow-up 
of 85.9 months the median survival was 59.7 months. There were no 
associations between the COX2 SNP genotype and patients prognosis 
observable. 
Conclusion: The COX2 926 SNP is detectable at a high frequency in 
patients with NSCLC. The COX2 926 SNP genotype is no prognostic 
molecular marker in this disease. A possible association with between 
non-smoker and the COX2 926 SNP was seen. However, patients 
with the GC or CC genotype seem more susceptible to lymph node 
metastases and higher tumor stage than patients with the GG geno-
type and suggest COX2 926 SNP as a molecular marker for lymph 
node involvement in this disease. 
Literature: 
1) Brabender J, Park J, Metzger R, Schneider PM, Lord RV, Hölscher AH, Danenberg 
KD, Danenberg PV. Prognostic significance of cyclooxygenase 2 mRNA expression 
in non-small cell lung cancer. Ann Surg. 2002 Mar;235(3):440-3. 
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Vascular Endothelial Growth Factor A and its receptor 
Vascular Endothelial Growth Factor Receptor 2 expression 
in non-small cell lung cancer patients: Relation to 
prognosis
Guldhammer Skov, Birgit1; Bonnesen, Barbara1; Holmstav, Jullie G.1; 
Pappot, Helle2
1 KAS Herlev, Dept. of Pathology, Division Gentofte, Copenhagen 
(Hellerup), Denmark; 2 Depart. of Oncology, Rigshospitalet, 
Copenhagen, Denmark
Background: The majority of patients with Non-Small Cell Lung 
Cancer (NSCLC) are diagnosed with advanced inoperable disease. 
While treatment with conventional chemotherapy has improved dur-
ing the last decade the 5-years survival is still modest. Novel drugs, 
which selectively target aberrant elements in neoplastic cells and their 
microenvironment, have recently been and are continuous developed 
including drugs inhibiting the angiogenetic system. Angiogenic factor 
Vascular Endothelial Growth Factor A (VEGF-A) and its receptor 
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) seem to 
play key roles in tumour-induced angiogenesis. Previous studies have 
been inconclusive on the topic of a role for VEGF-A and its receptor 
as prognostic factors in NSCLC.
Methods: Paraffin- embedded histological material from 102 patients 
operated for NSCLC was included and a representative block with 
lung cancer tissue was selected from each patient for immunohisto-
chemical studies. The sections were incubated with primary mono-
clonal antibodies to VEGF-A and VEGFR2. The expression of the 
immunohistochemical staining was assessed semi-quantitatively by 
estimating the percentage and the intensity of tumour cells stained on 
whole tumour slides. Kaplan-Meier survival curves were generated 
to evaluate the significance of immunohistochemical VEGF-A and 
VEGFR expression for the prognosis. 
Results: VEGF-A and VEGFR2 expression was observed in the 
majority of NSCLC patients. VEGF-A expression showed a correla-
tion to histological type with significantly increased expression in 
adenocarcinomas and large cell carcinomas as compared to squamous 
cell carcinomas (p=0.002). There was no statistically significant cor-
relation between VEGF-A and VEGFR2 expression and age, gender 
or stage at diagnosis. Finally, there was no relation between expres-
sion of VEGF-A and VEGFR2, nor an effect of high expression of 
both VEGF-A and VEGFR2 on survival
Conclusions: VEGF-A and VEGFR2 are expressed in NSCLC, but 
the immunohistochemical expression of VEGF-A and VEGFR2 had 
no have a prognostic impact in NSCLC in this study. We showed 
that the histological subgroups of NSCLC express VEGF-A differ-
ently, with adenocarcinomas having the highest amount. Whether 
these markers might be useful as clinically reliable predictive marker 
remains to be solved. 
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Comparison of two antibodies for immunohistochemical 
evaluation of epidermal growth factor receptor expression 
in Non Small Cell Lung Cancer
Guldhammer Skov, Birgit1; Pappot, Helle2
1 KAS Herlev, Dept. of Pathology, Division Gentofte, Copenhagen 
(Hellerup), Denmark; 2 Depart. of Oncology, Rigshospitalet, 
Copenhagen, Denmark
Background: Immunohistochemical staining for epidermal growth 
factor receptor (EGFR) might be a criterion for the selection of 
patients with non small cell lung cancer (NSCLC) for anti-EGFR 
therapy. However, lack of association between the degree of EGFR 
protein expression and the effectiveness of EGFR inhibitors has been 
demonstrated. Two different commercially available EGFR anti-
bodies were tested using different scoring systems and cut-off points 
to evaluate 1) the relation between percentage of positive tumours 
using the two antibodies and 2) the prognostic value of the anti-
bodies. Furthermore the influence of time of fixation and the size of 
the specimens for EGFR expression were analyzed. 
Methods: Paraffin embedded, histological material was collected 
from 102 Danish patients (70 men and 32 women), operated in the 
period 1989-1992 for NSCLC (54 squamous cell carcinomas, 40 
adenocarcinomas and 8 large cell carcinomas) with more than 17 
years of follow up. The influence of the tissue size and the time of 
formalin fixation for EGFR expression were evaluated in 11 test 
samples with NSCLC. EGFR were immunohistochemically analysed 
using DAKO EGFR PharmDx kit (Dako) and Zymid EGFR antibody, 
clone 31G7 (Zymid). The expression of EGFR was assessed semi 
quantitatively by estimating the percentage of positive tumour cells 
with subcellular location of the staining (1) positive, complete or 
incomplete, circumferential membranous staining only, (2) positive, 
complete or incomplete, circumferential membranous staining and 
staining in the adjacent cytoplasm or (3) coarsely granular cytoplas-
mic staining with no staining of the membranes. The staining inten-
sity was also evaluated semi quantitatively (no reaction, any very 
weak reaction above any background level, weak reaction, moderate 
reaction, and strong reaction).
Results: Using a definition of a positive tumour according to the 
manufacturer, 81% were positive with Dako as compared to 58% 
with Zymid. Using the number of tumours having >= 10% positive 
cells with >= 1 in intensity as a definition for positivity 74% were 
positive with Dako as compared to 34% with Zymid. Using the num-
ber of tumours with staining index above the middle point as a defin-
ition for positivity 61% were positive with Dako as compared to 15% 
with Zymid. Thus, the Dako was more sensitive than the Zymid and 
this was true for the intensity as well as for the percentage of positive 
tumour cells. All tested definition of positivity with both antibodies 
had no impact on survival. Overall, good correlation was observed 
between the expression of EGFR in small tissue samples (“biopsies”) 
as compared to corresponding larger (“resections”), although tumours 
with low number of positive cells and tumours with a heterogeneous 
staining pattern tend to have different score. Time of formalin fixation 
seems to have no influence on the number of positive cells.
Conclusion: We showed high variation in the number of positive 
cases using two different antibodies against EGFR. None of the 
tested definitions for positivity had impact on survival for either of 
the antibody. Size of the tested specimens influenced the test results 
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whereas time of fixation had no impact on staining reaction. Further 
standardization of the immunohistochemical evaluation of different 
frequently used antibodies against EGFR is urgent needed. Multiple 
biopsies from different areas of the tumour, in order to get a more 
representative section of the whole tumour, especially in inoperable 
cases, should be emphasized.
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Expression of vascular endothelial growth factor correlates 
with a poor prognosis based on analysis of prognostic 
factors in 705 patients with non-small cell lung cancer
Huang, Jun1; He, Jianxing1; Wang, Daoyuan1; Zhong, Baoliang1; 
Tucker, Steven J.2
1 First Affiliated Hospital of Guangzhou Medical College, 
Guangzhou, China; 2 Pacific Cancer Centre, Singapore, Singapore
Objective: To analyze the factors affecting the prognosis of com-
pletely resected non-small cell lung cancer (NSCLC), and to assess 
the impact of vascular endothelial growth factor (VEGF) on progno-
sis.
Methods: Between January 2002 and December 2007, a total of 
705 pathologically confirmed NSCLC patients were enrolled in this 
study. The major clinical and pathological features were analyzed, 
and the impact of VEGF on prognosis was investigated. The median 
clinical follow-up was 38.4 months (range, 12-61 months). Paraffin-
embedded tumor specimens were stained with VEGF using immuno-
histochemical methods. VEGF staining was evaluated, by combining 
both percentage of positive tumor cells and staining intensity, as low 
(negative and <20% of tumor cells showing weak positivity), or high 
(>20% of tumor cells showing strong positivity). Statistical analy-
sis was performed with SPSS software. Survival was analyzed by 
Kaplan-Meier method and Cox regression.
Results: There were 146 patients with stage IA, 166 patients with IB, 
47 patients with IIA, 124 patients with IIB, 157 patients with IIIA and 
65 patients with IIIB, according to the American Joint Committee on 
Cancer (AJCC). Low VEGF expression was seen in 329 (46.7%) pa-
tients, and high VEGF expression was seen in 376 (53.3%) patients. 
The median overall survival was 42 months (95% CI, 33.89-50.11). 
The median overall survival in patients with lower VEGF expression 
was 53 months (95% CI, 44.87-61.13), which was higher than with 
high VEGF expression 35 months (95% CI, 24.33-45.67). The overall 
1-, 3-, and 5-year survival rate were 80.7%, 59.4%, and 19.7%, 
respectively. The 1-, 3-, and 5-year survival rate in patients with low 
VEGF expression was 88.5%, 68.6%, and 29.2%, respectively, all of 
which were significantly higher than that in those with high VEGF 
expression (77.1%, 56.4%, and 10.7%, the P values were 0.004, 
0.003 and 0.005, respectively). Univariate analysis revealed that the 
following factors were significantly correlate with overall survival: 
histological type, differentiated status, TNM stage, VEGF expres-
sion and lymph nodes metastasis, whereas multivariate analysis 
showed that patients with stage I/II (RR=1.409, 95% CI, 1.105-2.591, 
P<0.001), with lower VEGF expression (RR=1.309, 95% CI, 1.120-
2.679, P<0.05), and without lymph nodes metastasis (RR=2.422, 
95% CI, 1.809-3.412, P<0.001) had significantly increased overall 
survival.
Conclusion: TNM stage, VEGF expression and lymph nodes metas-
tasis were the significant prognostic factors in NSCLC. High VEGF 
expression within NSCLC is closely associated with poor prognosis. 
Immunohistochemical evaluation of VEGF expression along with 
examination of angiolymphatic invasion perioperatively may aid in 
predicting prognosis.
P3.078 Pathology, Mon Aug 3 – Tue Aug 4 
Expression pattern of PRL (phosphatase of regenerating 
liver) family in non small cell lung cancer
Hwang, Jung Joo1, 2; Min, Sang Hyun2; Lee, Seung Hyo2; Kim, Do 
Hyung1; Kim, Kil Dong1
1 Department of thoracic cardiovascular surgery, Eulji University 
Hospital, Daejeon, Korea; 2 Laboratory of Molecular Biology, 
Biomedical Research Center, Korea Academy Institute of Science and 
Technology, Daejeon, Korea
Background: Protein tyrosine phophatases (PTPs) are implicated in 
the tumorigenesis and metastasis of human cancer. PRL (phosphatase 
of regenerating liver) family, a subgroup of PTPs is also linked to 
these processes. PRLs are consisted of three subtypes such as PRL-
1,-2, and -3. In colorectal and breast cancer, high level of PRL-3 ex-
pression is related with metastasis and poor prognosis. But ironically 
it has been known that in metastatic lung cancer, expression levels of 
PRL-3 are decreased. The expression patterns of PRL-1 and -2 were 
not explored in lung cancer yet. Therefore we investigated the expres-
sion levels of PRL-1 and -2 in the tissues of lung cancer patients. 
Materials and methods: Eleven lung cancer and normal samples 
from non small cell lung cancer patients were obtained at the Eulji 
University Hospital (Daejeon, Korea) . Those were composed of 
seven cases of adenocarcinoma, three cases of squamous cell carcin-
oma, and other pleomorphic carcinoma. The number of patients in 
each stage was 5 in stage I, 2 in stage II and 4 in stage IIIa. The RNA 
and protein expression were evaluated by real time PCR and western 
blot, respectively. We also observed the expression pattern of several 
cancer markers by PRL-2 over-expression using immunofluorescence 
method in cell line.
Results: In the cancer tissues of all patients, the protein expression 
levels of PRL-2 were increased compared to normal tissues, but 
expression of PRL-1 and -3 in cancer tissues showed low level. There 
was no correlation between mRNA and protein expression levels. 
Immunofluorescence results showed that pERK, pAKT, and pSTAT3 
were activated by all PRLs.
Discussion: The pattern of lung cancer in the expression of PRLs is 
different from other cancers. In our study, the levels of PRL-1, and 3 
expression were decreased, in contrast, PRL-2 protein level was in-
creased in lung cancer. Furthermore, functional downstream proteins 
in cancers such as ERK, AKT and STAT3 were all activated by PRLs 
over-expression in cancer cell line. These results suggest that PRL-2 
may have an important role in lung cancer and can be a marker of 
lung cancer, substituting for function of other PRLs. 
Copyright © 2009 by the International Association for the Study of Lung Cancer S883
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
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Towards an evidence based proposal for the best 
minimal immunohistohistochemical panel to infer lung 
adenocarcinoma metastatic to supraclavicular lymph node
Jambhekar, Nirmala A.1; Kumar, Rajiv1; Marchevsky, Alberto M.2; 
Dikshit, Rajesh1; Pramesh, CS3
1 Tata Memorial Hospital., Mumbai, India; 2 Department of 
Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, 
Los Angeles, CA, USA; 3 Dept of Surgery, Tata Memorial Hospital, 
Mumbai, India
Background: Supraclavicular lymph node (SCLN) metastasis is 
frequent in various malignancies. A biopsy, with the use of immuno-
histohistochemistry (IHC), is of immense value to infer the origin 
of metastatic disease. Several IHC markers with varying degrees of 
sensitivity and specificity are available. In such a situation it becomes 
imperative to judiciously choose an IHC panel which is most accurate 
in inferring lung carcinoma and yet be cost-effective. This study aims 
to deduce the best minimal cost-effective IHC panel to recognise 
lung cancer as primary in metastatic SCLN using statistical analytical 
methods. 
Methods: A total of 135 metastatic SCLN biopsies were divided into 
two groups: Category I: 110 cases wherein, the primary site was in 
the lung as judged by biopsy, cytology or radiology and Category II: 
25 cases wherein, the primary was in sites other than lung. An IHC 
panel comprising cytokeratin 7(CK7),cytokeratin 20(CK20),epithelial 
membrane antigen(EMA), carcino embryonic antigen (CEA), thyroid 
transcription factor 1(TTF1),surfactant protein B (SPB) and vimentin 
was performed on all cases. The results were statistically analysed 
using SPSS14.0 and STATA software to discriminate between 
carcinoma arising from lung and carcinoma arising from sites other 
than the lung as gauged by the IHC markers taken, either singly or in 
combination. 
Results: The overall immunoreactivity for CK7, TTF1, SPB and 
Vimentin in adenocarcinomas was significantly more than in 
squamous carcinomas (p value <0.05). In Category I the expres-
sion of CK7, TTF1 and SPB positivity and CK20 negativity was 
more than Category II (p-value<0.05). As an individual, non-lineage 
specific marker CK20 negativity [odds ratio (OR)-37] scored higher 
than CK7 positivity (OR-11.5). As a lineage specific marker TTF-1 
positivity (OR-43.3) scored higher than SPB (OR-16.7). The best 
minimal panel comprising two markers was CK20 and TTF-1 and a 
panel comprising four markers was CK7, CK20, TTF1 and SPB. The 
binomial probability for diagnosing lung cancer using the four marker 
panel was high (0.8) than a panel of two markers (0.61). 
Conclusion: SCLN biopsy is a simple and rapid method to confirm 
metastatic disease. However, establishing metastasis from lung as 
opposed to other glandular sites requires further work-up. This study 
revealed that a panel comprising two sensitive markers (CK7 and 
CK20) and two lung specific markers (TTF and SPB) proved very 
useful to establish primary in the lung. This IHC panel would result 
in a higher cost benefit ratio, since it is much less expensive to test 
for four antibodies on paraffin block in contrast to most imaging 
modalities to establish a final tissue diagnosis. In this study, we have 
tried to apply the evidence based medicine (EBM) concept to work 
out a dependable and cost effective panel to infer lung adenocarcin-
oma in metastatic SCLN.
P3.080 Pathology, Mon Aug 3 – Tue Aug 4 
Podoplanin expression by cancer associated fibroblasts in 
pulmonary adenocarcinoma
Kawase, Akikazu1, 2; Ishii, Genichiro2; Nagai, Kanji1; Yoshida, Junji1; 
Nishimura, Mitsuyo1; Hishida, Tomoyuki1; Ochiai, Atsushi2
1 Department of Thoracic Oncology, National Cancer Center 
Hospital East, Kashiwa-shi, Chiba, Japan; 2 Pathology Division, 
Research Center for Innovative Oncology, National Cancer Center 
Hospital East, Kashiwa-shi, Chiba, Japan
Background: Podoplanin is known as a specific marker for lymph-
atic endothelium. Its increased expression in cancer cells and stromal 
cells has recently been reported. Although podoplanin expression has 
been reported to be biologically significant in pulmonary squamous 
cell carcinoma, its significance in pulmonary adenocarcinoma has not 
been clarified.
Methods: We examined podoplanin expression by both cancer and 
stromal cells in 177 consecutive pulmonary adenocarcinoma patients 
and analyzed its relationships with clinicopathologic factors and 
outcome. 
Results: Podoplanin expression was observed on cancer cell apical 
membrane in only 9 (5.1%) of the 177 patients. In contrast, stromal 
cancer-associated fibroblasts (CAF) expressed podoplanin in the 
cytoplasm in 54 (30.5%) patients. Podoplanin-positive CAF was 
observed only in invasive adenocarcinomas and none were found in 
noninvasive adenocarcinomas (pure bronchioloalveolar carcinomas). 
Podoplanin expression in CAF was significantly associated with 
smoking history (p = 0.003), tumor size (p = 0.021), pathological 
lymph node involvement (p = 0.033), pathological stage (p < 0.001), 
tumor differentiation (p < 0.001), vascular invasion (p < 0.001) and 
pleural invasion (p = 0.002). Univariate analyses and log-rank test 
showed that CAF podoplanin expression was significantly associated 
with poorer survival (p < 0.001). However, a multivariate analy-
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sis showed CAF podoplanin expression was a marginally, but not 
significantly independent prognostic factor (p = 0.091). When the 
177 patients were categorized into 3-grade groups according to CAF 
podoplanin expression proportion (grade 0 (n = 123); podoplanin-
positive CAF area/stromal area (P/S ratio) ≤ 0.1, grade 1 (n = 36); 0.1 
< P/S ratio ≤ 0.5, and grade 2 (n = 18); P/S ratio > 0.5), the results of 
Spearman’s rank correlation coefficient showed that smoking history 
(p = 0.003), tumor size (p = 0.007), pathological lymph node involve-
ment (p = 0.008), pathological stage (p < 0.001), tumor differentia-
tion (p < 0.001), vascular invasion (p < 0.001), lymphatic permeation 
(p = 0.026) and pleural invasion (p <0.001) were significantly correl-
ated with the grade of CAF podoplanin expression.
Conclusion: Although podoplanin expression in CAF was signifi-
cantly associated with poorer survival, it did not prove to be a signifi-
cant independent prognostic factor. The analyses showed CAF podo-
planin expression was significantly associated with advanced and 
aggressive tumor status. Identifying the mechanism behind elevated 
podoplanin expression in CAF will help understand the biological 
significance of podoplanin and CAF in pulmonary adenocarcinoma.
P3.081 Pathology, Mon Aug 3 – Tue Aug 4 
The role of minichromosome maintenance (MCM) protein 
4 in proliferation and its clinicopathological significance in 
non-small cell lung cancers (NSCLCs)
Kinoshita, Ichiro1; Kikuchi, Junko2; Shimizu, Yasushi1; Kikuchi, 
Eiki2; Konishi, Jun2; Aburatani, Hiroyuki3; Oizumi, Satoshi2; 
Nishimura, Masaharu2; Akita, Hirotoshi1
1 Department of Medical Oncology, Hokkaido University Graduate 
School of Medicine, Sapporo, Japan; 2 First Department of Medicine, 
Hokkaido University School of Medicine, Sapporo, Japan; 3 Genome 
Science Devision, Research Center for Advanced Science and 
Technology, University of Tokyo, Tokyo, Japan
Background: We have previously shown that blocking AP-1 tran-
scription factor by a cJun dominant negative mutant, TAM67, inhibits 
growth of non-small cell lung cancer (NSCLC) cells including NCI-
H1299 (H1299) cells. We performed microarray analysis to identify 
downstream effectors relevant to the growth inhibition and found that 
TAM67 decreased mRNA of minichromosome maintenance (MCM) 
4 in H1299 cells. MCM4 is one of the six MCM family members 
that form a prereplicative complex essential for the initiation of DNA 
replication. Although some MCMs were assessed in human cancers, 
the role of MCM4 has not been determined in lung cancer.
Methods: We downregulated the expression of MCM4 by small 
interfering RNA (siRNA) in three NSCLC cell lines, H1299, A549 
and PC-3, and evaluated effects on cell growth by MTT-based assay. 
We then analyzed MCM4 expression by immunohistochemistry 
in 156 surgically resected NSCLCs to correlate clinicopathologic 
characteristics. The percentage of cells showing nuclear staining was 
measured as MCM4 labeling indices (LIs).
Results: The decreased expression of MCM4 by TAM67 was con-
firmed by real-time quantitative PCR and Western blotting analysis. 
Inhibition of MCM4 expression by siRNA reduced cell proliferation 
in H1299 and A549 cells but not PC-3 cells. Immunohistochemistry 
analysis demonstrated that Mcm4 expression was significantly higher 
in cancer cells than in the adjacent normal bronchial epithelial cells 
(p < 0.001 by Wilcoxon matched pairs signed ranks test). With a cut-
off level of 50%, high and low MCM4 expression was found in 118 
(75.6%) and 38 (24.4%) NSCLCs, respectively. High MCM4 expres-
sion was significantly correlated with male gender, heavy smoking, 
poorer differentiation and non-adenocarcinoma histology (p < 0.001 
by qui-square test), while the association with non-adenocarcinoma 
histology only remained significant after multivariate adjustment (p = 
0.004). Among biological characteristics of tumors studied previously 
in this cohort, high MCM4 expression was significantly correlated 
with higher Ki-67 LI (p < 0.001). MCM4 expression was not associ-
ated with survival.
Conclusions: These results suggest that MCM4 plays an essential 
role for the proliferation of some NSCLC cells and is a new prolif-
erative marker of NSCLCs. Taken together with higher expression 
in NSCLCs and its correlation with non-adenocarcinoma histology, 
MCM4 may have potential as a therapeutic target in some population 
with NSCLCs.
P3.082 Pathology, Mon Aug 3 – Tue Aug 4 
Immunohistochemical differential diagnosis between 
thymic carcinomas and type B3 thymomas: diagnostic 
utility of GLUT-1 in thymic epithelial neoplasms
Kojika, Masakazu1, 2; Ishii, Genichiro 1; Yoshida, Junji 2; Nishimura, 
Mituyo 2; Hishida, Tomoyuki 2; Nagai, Kanji 2; Ochiai, Atsushi1
1 Pathology Division, Research Center for Innovative Oncology, 
National Cancer Center Hospital East, Chiba, Japan; 2 Division of 
Thoracic Surgery, National Cancer Center Hospital East, Chiba, 
Japan
Background: It is sometimes difficult to histologically differenti-
ate thymic carcinomas (type C) from type B3 thymomas, especially 
when the biopsy specimen is small. There are only a few immuno-
histochemical markers that are useful in differentiating thymic 
carcinomas from type B3 thymomas. The purpose of this study was 
to establish better markers in differentiating thymic carcinomas from 
type B3 thymomas.
Methods: We performed tissue microarray analyses of surgically re-
sected thymic epithelial neoplasm specimens. There were 12 thymic 
carcinomas and 7 type B3 thymomas. Staining scores were calculated 
by multiplying the percentage of positive-staining cells per slide (0 
- 100%) by the predominant level of staining intensity: 0 = negative, 
1 = weak, 2 = intermediate, 3 = strong. Possible scores ranged from 
0 to 300. The scores of two slides for a tumor were determined, and 
their average was registered as the staining score for the tumor.
Results: Significant difference in staining scores between thymic 
carcinomas and type B3 thymomas was observed in 7 marker pro-
teins: GLUT-1 (average staining score for the 12 thymic carcinomas/
average staining score for the 7 type B3 thymomas; 167/4), CA-9 
(110/15), C-kit (162/44), CD5 (33/0), MUC1 (54/0), CEA (42/0), 
and CK18 (110/42). Sensitivity and specificity of these antibodies for 
thymic carcinomas were 72% and 100% in GLUT-1; 58% and 71% 
in CA-9; 72% and 85% in C-Kit; 33% and 100% in CD5; 58% and 
71% in CK18; 25% and 100% in MUC-1; 33% and 100% in CEA, 
respectively. GLUT-1, with the highest sensitivity and specificity, 
proved to be the best thymic carcinoma marker. When the other 
two 100%-specificity markers, CD5 and CEA were combined with 
GLUT-1, thymic carcinomas were differentiated from type B3 thymo-
mas with a 91.6% sensitivity and 100% specificity.
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Conclusion: We identified GLUT-1 as an additional marker to differ-
entiate thymic carcinomas from type B3 thymomas. Its combination 
with CD5 and CEA was highly reliable in differentiating these two 
thymic epithelial neoplasms.
P3.083 Pathology, Mon Aug 3 – Tue Aug 4 
Cytodiagnosis of lymphocytic- rich pleural effusion . A 
study of 137 cases
Kumar, Perikala V.; Adeli, Omid ali; Tabibi, Narges; Youssefi, Babak
Dept. of Pathology, Shiraz Medical School, Shiraz, Iran
Background: Lymphocytic- rich pleural effusion can be caused by 
many diseases. So the exact diagnosis of the disease is necessary 
for proper treatment. Cytomorphologic and ancillary studies help to 
detect the cause of lymphicytic – rich pleural effusion. This study 
analyses the diagnostic efficacy of cytomorphologic findings, with 
special emphasis on ancillary studies, such as special stains, Molecu-
lar study (PCR), Flow-cytometry, Immunocytochemistry (ICC) and 
gene rearrangement.
Materials and Methods: A total of 137 cases of lymphocytic – rich 
pleural effusion (101 bilateral and 36 unilateral) with subsequent 
histopathologic follow-up were analyzed. The cytologic diagnoses 
were divided into different categories: Viral infection, tuberculosis, 
autoimmune disease, lymphoma, leukemia and small-cell carcinomas 
(lymphocytic-like)
Results: No disease was diagnosed by cytomorphology alone. Ten 
cases of 137 cases were diagnosed as leukemia with the help of 
clinical history and special staining. The rest of cases were diagnosed 
by the help of PCR, flow-cytometry and ICC; Viral infection: 11, Tu-
berculosis: 69, Auto-immune diseases: 9, Lymphoma: 32, Leukemia: 
10, Small-cell carcinoma: 6
Conclusion: Cytomorphologic study alone is not enough to detect 
the cause of lymphocytic-rich pleural effusion, ancillary studies are 
also necessary.
Clinical history, special stains; Periodic acid-schiff (PAS), Sudan 
black B, Tartarate resistant acid phosphatase (TRAP) and flow-
cytometry are useful for the diagnosis of leukemic infiltration.
ICC helped to detect small cell and oat cell carcinomas and to differ-
entiate them from other causes of lymphocytic -rich effusion.
P3.084 Pathology, Mon Aug 3 – Tue Aug 4 
Significance of periostin expression in non small cell lung 
carcinoma
Lee, Min Ki1; Lee, Chang Hun1; Jeong, Yeon Joo1; Lee, Young-Min 2
1 Pusan National University Hospital, Busan, Korea; 2 Busan Paik 
Hospital, Inje University, Busan, Korea
Background: Periostin is a recently identified gene that is prefer-
entially expressed in periosteum, indicating a potential role in bone 
formation and maintenance of structure. In tumorigenesis, there 
have been controversies about its role for invasion and metastasis of 
human malignancies. We attempted to determine clinicopathologic 
significance of periostin expression in non-small cell lung carcinoma 
(NSCLC). 
Methods: Immunohistochemical staining with rabbit polyclonal anti-
body to periostin was performed on tissue microarray blocks from 91 
cases of NSCLCs. The result was correlated with clinicopathologic 
parameters. 
Results: Positive reaction to periostin was predominantly noted in the 
tumor stroma. The strongest reaction was present as band-like pattern 
just around tumor nests. Non-neoplastic lung and most of in situ 
carcinomas did not show positivity in their stroma. Regarding tumor 
differentiation, moderately to poorly differentiated tumors (47/77) re-
vealed even higher periostin expression than well-differentiated ones 
(4/14) (p=0.024). High periostin expression was positively correlated 
with E-cadherin and p53 expression, but was not related with patient 
age, sex, tumor type, PCNA index, b-catenin, cyclin D1, pTNM-T, 
pTNM-N, stage, and patient survival (p>0.05).
Conclusions: These results suggest that periostin might plays an 
important role in the tumor cell adhesion of NSCLC, and partly con-
tribute its aggressive behavior.
P3.085 Pathology, Mon Aug 3 – Tue Aug 4 
Epigenetic inactivation of retinoid X receptor genes in non-
small cell lung cancer and its relationship with clinicopathological 
features
Lee, Su Man2; Kim, Mi Jin2; Lee, Ji Yun2; Lee, Shin Yup1; Han, Sung 
beom3; Kim, Dong Sun2; Park, Jae Yong1
1 Departement of Internal Medicine, Kyungpook National University 
Hospital, Daegu, Korea; 2 Department of Anatomy, School of 
Medicine, Kyungpook National University, Daegu, Korea; 3 
Department of Internal Medicine, School of Medicine, Keimyung 
University, Daegu, Korea
Lung cancer is the leading cause of cancer deaths worldwide and 
is usually associated with a late diagnosis and a poor prognosis. 
Retinoids exert the anti-proliferative and pro-apoptotic activity 
against some cancers via interacting with retinoid X receptor (RXR) 
α, β and γ. Deregulation of RXRs expression have been reported 
in non-small cell lung cancer (NSCLC), however, the mechanism 
leading to impaired expression of RXRs in lung cancer development 
is not yet known. Aberrant methylation of promoter CpG islands is 
known to be a major inactivation mechanism of tumor suppressor 
and tumor-related genes. Here, the methylation status of the promoter 
region of human RXR α, β and γ genes was investigated in primary 
NSCLC using a methylation-specific PCR (MSP) and the correlation 
of their methylation with clinicopathologic features was studied. The 
methylation frequencies of RXRs genes were 8 of 139 (5.7%) for α, 
6 of 139 (4.3%) for β, 32 of 139 (23.0%) for γ in NSCLCs. RT-PCR 
analysis showed that RXR γ methylation correlates with its mRNA 
expression. RXR γ hypermethylation was significantly associated 
with pathological stage, whereas no correlation was found between 
its hypermethylation and other clinicopathological factors. There was 
no significant difference in the overall survival of patients according 
to methylation status of RXR γ gene. However, when the patients 
were categorized according to smoking status, RXR γ methylation 
was significantly associated with a worse survival in never-smokers, 
whereas it was significantly associated with a better survival in ever-
smokers.
These results suggest that methylation-associated down-regulation 
of RXR γ expression might play a different role in pathogenesis of 
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NSCLC between men and never-smokers, but further studies are 
needed to confirm this.
P3.086 Pathology, Mon Aug 3 – Tue Aug 4 
Hemoglobin level is a good prognostic factor in Chinese 
lung cancer patients
Lu, Shun; Gu, Linping; Zheng, Yin; Yu, Yongfeng; Xu, Yunhua; Ye, 
Xiangyun; Li, Ziming
Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai 
Jiao Tong University, Shanghai, China
Objective: To investigate the correlation between pre-treatment 
hemoglobin (Hb) levels and survival time in Chinese patients with 
lung cancer. 
Methods: This was a retrospective analysis of 614 patients treated at 
the Shanghai Chest Hospital between January 2003 and March 2005. 
Hb levels were obtained at the initial visit to the hospital. Survival an-
alysis was evaluated by Kaplan–Meier and Log rank tests. Multivari-
ate analysis was performed by the Cox Stepwise Regression model. 
Results: The median survival time for all patients (n = 614) was 
21.92months with a 3-year survival rate of 32.25%. A total of 207 
(33.71%) patients had anemia at the initial visit. The proportion of 
patients experiencing anemia increased with each cycle of chemo-
therapy and was greatest after the fourth cycle (occurring in 92.59%). 
The median survival time was 18.83 months for patients with anemia 
vs. 23.34 months for patients without anemia. The 3-year survival 
rate was significantly lower in patients with anemia than those with-
out anemia (27.13% vs. 34.87%, p = 0.016). Cox Stepwise Regres-
sion analysis showed that anemia was an independent prognostic 
factor for survival. 
Conclusions: This study confirmed that anemia is common in 
Chinese patients with lung cancer and is an independent prognostic 
factor for survival.
P3.087 Pathology, Mon Aug 3 – Tue Aug 4 
Clinical significance of XAGE-1b expression in Non-Small 
Cell Lung Cancer 
Maeda, Ai; Shimizu, Katsuhiko; Yukawa, Takuro; Hirami, Yuji; 
Nakata, Masao 
Kawasaki Medical School, Okayama, Japan
Background: It has been demonstrated that various cancer antigens 
are expressed in human cancers, and that cancer patients mount the 
immune responses to these antigens. Cancer/testis (CT) antigens 
represent a unique class of tumor antigens which are expressed in a 
variety of cancerous tissues and remain silent in all normal tissues, 
except for the testes. Because of their high immunogenicity, CT 
antigens are the most attractive targets for cancer immunotherapy and 
candidates for serum biomarkers. XAGE-1b is one of the members of 
CT antigens. Recent studies demonstrated that XAGE-1b protein and 
XAGE-1b m-RNA were expressed at a high frequency in lung cancer 
tissue. We here examined the expression of XAGE-1b protein in 
non-small cell lung cancer (NSCLC) tissue by immunohistochemistry 
(IHC), and investigated the relationship between XAGE-1b expres-
sion and several clinicopathological factors. The expression of COX-
2 (in adenocarcinoma) and EGFR (in squamous cell carcinoma), 
which have been reported as prognostic factors, was also examined 
for comparison.
Material and Methods: The expressions of intratumoral XAGE-1b, 
COX-2, and EGER were retrospectively examined by IHC in paraf-
fin-embedded samples of 100 NSCLC patients who had undergone 
complete resection between June 2003 and December 2006. Cumula-
tive survival rates were calculated by the Kaplan-Meier method and 
analyzed using log-rank test. A multivariate analysis was carried out 
using Cox’s proportional hazards regression model.
Results: The expression rate of XAGE-1b, COX-2 and EGFR 
were 30%, 68%, 20%, respectively. The XAGE-1b expression rate 
was significantly higher in adenocarcinoma compared with that in 
other histologic types (p=0.004), but there were no differences in 
the XAGE-1b expressions among other clinicopathological factors 
including age, gender, and disease stage. In the univariate analysis, 
patients showing XAGE-1b expression showed a significantly poorer 
relapse-free survival (RFS) rate than patients without XAGE-1b 
expression (p=0.037). COX-2 expression was also a significant pre-
dictor of a poor RFS (p=0.035), whereas EGFR expression had no in-
fluences on RFS (p=0.580). However, multivariate analysis revealed 
that XAGE-1b expression was not an independent predictor of a poor 
RFS (p=0.513), and that the disease stage was an only significant 
prognostic factor (p=0.011).
Conclusion: XAGE-1b protein was expressed in 30% of specimens 
of NSCLC. The rate of recurrence tended to be higher, but not signifi-
cantly, in the patients showing XAGE-1b expression.
P3.088 Pathology, Mon Aug 3 – Tue Aug 4 
Molecular follow-up of non-small cell lung cancer in 
BAL: which specimen and which technique for mutation 
detection? A case report
Beau-Faller, Michele1; Stenger, Rodolphe 2; Voegeli, Anne-Claire1; 
Legrain, Michele1; Neuville, Agnès3; Lavaux, Thomas1; Mennecier, 
Bertrand2; Oudet, Pierre2; Gaub, Marie-Pierre1; Quoix, Elisabeth2
1 Molecular laboratory, Strasbourg, France; 2 Service de 
Pneumologie, Pôle de Pathologie Thoracique, Strasbourg, France; 3 
Laboratoire d’anatomie pathologique, Strasbourg, France
The epidermal growth factor receptor tyrosine kinase inhibitor 
(EGFR-TKI, gefitinib or erlotinib), results in a partial or complete re-
sponse in a high proportion of patients in case of sensitivity mutation 
of EGFR. Nevertheless, after sometimes a prolonged disease control, 
a relapse occurs, related in some cases to an acquired resistance 
mutation of EGFR. The present study reports the case of a 76-yr-old 
non-smoking male presenting a multifocal bronchiolo-alveolar lung 
adenocarcinoma. After failure of a first line chemotherapy by vinorel-
bine and a second line by docetaxel, gefitinib (250 mg/day) resulted 
in a prolonged disease control. After 46 months a slow progres-
sive disease was observed.. A broncho-fiberoscopy was performed 
with bronchial biopsies and bronchiolo-alveolar lavage (BAL). The 
paraffin-embedded bronchial biopsies contained 5% of tumor cells 
and no EGFR mutation was detected by classical direct sequencing. 
The BAL contained tumor cells corresponding to bronchiolo-alveolar 
carcinoma cells. The BAL was centrifugated and the spelled cells 
were extracted. Direct sequencing of BAL revealed a sensitive EGFR 
L858R mutation associated with an EGFR T790M mutation related 
to resistance of EGFR-TKI. Thus, mutational analysis by direct 
sequencing could be successfully realised on BAL with detection of 
Copyright © 2009 by the International Association for the Study of Lung Cancer S887
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
the mutations which could not be evidenced in the bronchial biopsy 
by the same technical approach probably due to the low sensitivity 
of the technique. On the other hand, we developed a more sensitive 
mutational analysis using PNA-mediated PCR clamping for T790M 
mutation detection. Clamped PCR analysis confirmed the presence 
of the EGFR T790M mutation in BAL and also detected the same 
T790M mutation in the paired bronchial biopsy. These molecular 
results correspond to a cellular sub-clone with T790M mutation 
which could explain the slow clinical progression of the patient under 
EGFR-TKI treatment. No K-Ras mutation was detected in BAL and 
in bronchial biopsy, by direct sequencing as well as by clamped PCR. 
The present report underscores the interest of molecular analysis 
of all the biological specimens available for a same patient, and the 
potential interest of adapting molecular analysis to the tumor cel-
lularity of routine specimen, especially to detect EGFR-TKI resistant 
mutations. 
P3.089 Pathology, Mon Aug 3 – Tue Aug 4 
Remote evaluation of 3D cell morphology for lung cancer 
screening and research
Steinhauer, David E.; Patten, Florence W.; Meyer, Michael G.; 
Nelson, Alan C.
VisionGate, Inc., Seattle, WA, USA
Background: VisionGate, Inc. (Gig Harbor, WA, USA) in col-
laboration with the University of Washington (Seattle, WA, USA) 
has developed the Cell-CT platform which produces 3D volumetric 
representations of cells based on computed tomography. We report 
on new software developed to view and evaluate 3D cell morphol-
ogy and assign cell diagnoses. With this software, cell data can be 
transmitted electronically to a remote location, opening up new pos-
sibilities for diagnosis and research. 
Methods: VisionGate’s Cell-CT system is used for computed tomog-
raphy of individual cells at submicron resolution at optical wave-
lengths. Data from the Cell-CT are stored in a computer file system, 
and are read by VisionGate’s data visualization software, potentially 
over the internet, for viewing in 3D. Diagnoses or 3D cellular charac-
teristics are entered by a cytotechnologist or pathologist and transmit-
ted back to the computer file system.
Results: VisionGate’s cell visualization software provides multiple 
viewing methods, starting with a stack of traditional 2D images for 
consistency with standard methods. In 3D, data can be viewed as 
slices in three orthogonal planes of equal resolution. The 3D cell can 
be rendered in a maximum intensity projection and rotated to any 
viewing angle. Finally, alpha composite rendering shows the texture 
of the nuclear wall and makes shape readily apparent. The cell can be 
rotated and sliced at will in order to examine sub-cellular detail. 
The figure shows two views of an adenocarcinoma cell from the same 
perspective. On the left is a maximum intensity projection. On the 
right is an alpha composite view showing the surface and interior of 
the highly active nucleus; nucleoli are red, the nuclear wall is opaque 
blue, and the cytoplasm is gray.
Conclusions: The ability to view 3D cell volumetric data opens up 
new possibilities both for 3D morphology research and for disease 
screening and diagnosis. Three dimensionality allows a more compre-
hensive evaluation, while the electronic format permits human review 
to occur in a location far removed from data acquisition. 
As a lung cancer screening device, the Cell-CT captures many 
hundreds of cells obtained from a sputum. The 3D reconstructions 
are processed to compute VisionGate’s lung cell evaluation device 
(LuCED) score, which correlates to degree of cell abnormality. A 
small number of cells ranked by degree of abnormality are transmit-
ted for diagnosis by human review. This scheme combines the best 
of both worlds: 3D volumetric processing algorithms to provide high 
sensitivity, and human review of a small number of cells to achieve 
high specificity.
P3.090 Pathology, Mon Aug 3 – Tue Aug 4 
3D cytology in lung cancer: imaging of nuclear 
features and distribution of heterogeneous nuclear 
ribonucleoprotein A2/B1 (hnRNP A2/B1)
Neumann, Thomas1, 2; Yu, Julia1; Tourovskaia, Anna 1, 2; Meyer, 
Michael G.1, 2; Tauler, Jordi 3; Mulshine, James L.3; Nelson, Alan C.1, 
2
1 VisionGate Inc., Seattle, WA, USA; 2 University of Washinton, 
Seattle, WA, USA; 3 Rush University Medical Center, Chicago, IL, 
USA
Background: The transformation of cells during carcinogenesis cor-
relates with well-characterized changes in morphology. These include 
changes in nuclear size and shape, number and size of nucleoli, and 
chromatin distribution. Cell transformation has also been linked to 
changes in the distribution and expression levels of nuclear proteins. 
There is an increasing need for accurate analysis of nuclear protein 
distribution to understand the relationships between nuclear structure 
and cell phenotype. VisionGate in collaboration with the University 
of Washington has developed the Cell-CT platform which produces 
3D volumetric representations of cells based on computed tomog-
raphy. We used the Cell-CT to study the 3D distribution pattern of 
hnRNP A2/B1 –a nuclear protein that is up-regulated in lung cancer.
Methods: Standard cytological nuclear staining with hematoxylin 
and immunochemistry, using monoclonal antibodies against hnRNP 
A2/B1, were carried out to study hnRNP A2/B1 distribution in human 
lung adenocarcinoma cells (A549). Labeled A549 cells were then em-
bedded in optical gel and imaged in a rotating capillary tube in trans-
mission mode using filtered white light. Each image set consisted 
of 500 pseudo-projections (shadowgrams), spaced evenly across a 
360-degree rotation. The images were subsequently 3D-reconstructed 
using filtered back projections, similar to X-ray CT. 
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Results: ematoxylin staining revealed large oddly-shaped nucleoli 
and numerous clumps of chromatin of various sizes. hnRNP A2/B1 
was localized throughout the nucleoplasm. Most of the protein was 
distributed in a punctuated pattern with foci of different sizes. Figure 
1A shows hematoxylin-stained nuclear features and Figure 1B shows 
the distribution of hnRNP A2/B1 within the nucleus of an A549 cell.
Conclusions: Our study demonstrates the ability of the Cell-CT 
system to image both nuclear structure and distribution of a cancer 
marker in 3D. We are currently developing techniques for simultan-
eous localization of 3D nuclear features with several biomarkers. We 
are also developing morphometric methods that allow for quantifi-
cation of protein expression in 3D. The ability to correlate nuclear 
morphology with expression level and localization of proteins might 
help to identify more reliable biomarkers for the early detection of 
lung cancer. 
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Carcinoembryonic antigen staining pattern as 
prognostic indicator for pathological stage IA pulmonary 
adenocarcinoma
Nakagiri, Tomoyuki1; Sawabata, Noriyoshi1; Morii, Eiichi2; Oda, 
Tomofumi1; Minami, Masato1; Inoue, Masayoshi1; Utsumi, Tomoki1; 
Kadota, Yoshihisa1; Shigemura, Norihisa1; Tokunaga, Toshiteru1; 
Funaki, Souichirou1; Okumura, Meinoshin1
1 Department of General Thoracic Surgery, Osaka University 
Graguate School of Medicine, Suita-City Osaka, Japan; 2 Department 
of Pathology, Osaka University Graduate School of Medicine, Suita-
City Osaka, Japan
Background: For small-sized non-small cell pulmonary carcinoma 
patients, the serum level of carcinoembryonic antigen (CEA) is a 
prognostic indicator as well as predictor of nodal involvement. In 
addition, several studies of colorectal carcinoma reported that the 
CEA immunohistopathological staining pattern was correlated with 
patient prognosis, with similar findings reported for clinical stage I 
pulmonary adenocarcinoma. We conducted an observational study of 
CEA staining patterns in patients with pathological stage IA pulmon-
ary adenocarcinoma. 
Patients and Methods: We assessed 147 consecutive patients treated 
for pathological stage IA lung adenocarcinoma by complete resection 
at Osaka University Graduate School of Medicine from January 1993 
to December 2002. CEA staining patterns were classified as apico-
luminal, diffuse-cytoplasmic, or negative, and patient survival among 
the groups was compared. 
Result: An apico-luminal staining pattern was observed in 63 pa-
tients and diffuse-cytoplasmic staining in 44, while negative staining 
was seen in 43, and they had 5-year survival rates of 95.0%, 85.5%, 
and 83.1%, respectively (apico-luminal vs. diffuse-cytoplasmic, 
p=0.0443). 
Conclusion: CEA staining pattern may be an important prognostic 
factor for pathological stage IA pulmonary adenocarcinoma patients.
P3.092 Pathology, Mon Aug 3 – Tue Aug 4 
Does elevated pre-operative C-reactive protein predict 
poor survival in those undergoing resection for non-small 
cell lung cancer?
O’Dowd, Caroline A.1, 2; McCrae, Laura 2; McMillan, Donald C.3; 
Kirk, Alan4; Milroy, Robert 2
1 Southern General Hospital, Glasgow, UK; 2 Stobhill Hospital, 
Glasgow, UK; 3 University Department, Glasgow Royal Infirmary, 
Glasgow, UK; 4 Department of Cardiothoracic Surgery Golden 
Jubilee National Hospital, Glasgow, UK
Introduction: Non-small cell lung cancer (NSCLC) is the com-
monest cause of cancer death worldwide. Only the minority of 
patients are suitable for surgical resection, which offers the best pos-
sibility of cure. We examined the relationship between clinicopatho-
logical stage, pre- operative systemic inflammatory response (SIR) 
and survival in patients undergoing potentially curative resection 
for NSCLC, to investigate if evidence of a systemic inflammatory 
response pre-operatively, was an adverse prognostic factor. 
Methods: All patients who underwent resection of lung cancer, from 
one hospital serving a population of 200,000, between 2000 and 
2006 were included (n=96). Pre-operative staging in the conventional 
manner and routine bloods including C-reactive protein (CRP), White 
Cell Count (WCC) and serum albumin were measured. Patients were 
followed up for a minimum of 19 months. The median follow up 
for the survivors was 63 months. Details of adjuvant therapy were 
recorded. Date and cause of death was documented in those who had 
died. (57/96). 
Results: Most patients were over the age of 60 years (71%), male 
(57%), underwent a lobectomy (65%) and had TNM stage I dis-
ease (66%). Of the markers of the systemic inflammatory response, 
only an elevated CRP (>10mg/l) was associated with poorer cancer 
specific survival. On multivariate analysis, only TNM stage (hazard 
ratio (HR) 1.70, 95% confidence interval (CI) 1.21–3.89, p<0.01) and 
pre-operative CRP (HR 1.74, 95% CI 1.01–3.00, p<0.05) retained 
independent significance. Patients with a pre-operative CRP >10mg/l 
had a median survival of 27.3 months compared with 72.5 months in 
those patients with a normal CRP <10mg/l (p<0.05). 
Conclusion: The results of the present study indicate that, in patients 
who have undergone potentially curative resection for lung cancer, 
the presence of a systemic inflammatory response pre-operatively 
predicts poor outcome. This study requires verification in larger 
prospective cohorts.
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Cell-CT provides 3D cytologic analysis in combined 
brightfield and fluorescence mode 
Seibel, Eric J.1; Miao, Qin1; Tourovskaia, Anna2; Rahn, J. R.2; Meyer, 
Michael G.2; Neumann, Thomas2; Patten, Florence W.2; Nelson, Alan 
C.2, 3
1 University of Washington, Seattle, WA, USA; 2 VisionGate, Inc., Gig 
Harbor, WA, USA; 3 Arizona State University, Tempe, AZ, USA
Background: Typically, optical microscopes for cytopathology use 
absorptive stain, while research microscopes for biomarker studies 
use fluorescent probes. Optical microscopes rely on stacks of 2D 
fluorescence images, but true 3D volumes cannot be measured accur-
ately due to low resolution along the optical axis. By rotating the cell 
within a capillary tube in an optical microscope, the high 2D lateral 
resolution can be used to compensate for this shortcoming. The Cell-
CT microscope utilizes a rotating cell mechanism with tomographic 
reconstruction to produce isotropic-resolution, true 3D images of 
cells for more accurate quantitative measurement of features. Imaging 
a cell in the Cell-CT equipped for dual labeling of both fluorescence 
and absorbance allows for exact registration of volumetric images of 
isometric resolution. 
Methods: Chemically fixed and labeled cells are embedded in optical 
gel and flowed through a rotating capillary tube within the Cell-CT 
microscope. The same objective lens is used to image the cell in 
transmission-mode, using filtered white-light, followed by imaging 
in epi-illumination-mode using filtered arc-lamp light. Each image 
set consists of 500 image pseudo-projections, spaced evenly across a 
single 360-degree rotation (every 0.72 degrees). A pseudo-projection 
image is the result of rapidly scanning the sub-micron depth-of-focus 
of the objective lens through the cell and integrating the optical 
information at the CCD camera. To generate a 3D reconstruction of 
the cell, the 500 pseudo-projections are processed tomographically in 
the same manner as x-ray projections are used to generate X-ray CT 
images. To illustrate the Cell-CT instrument performance, fluorescent 
microspheres (100 nm diameter) and dual-labeled female muntjac 
cells (arrested in metaphase and labeled with hematoxylin and Sytox 
Green) were imaged.
Results: The 0.35 micron resolution of the Cell-CT was equal in 
lateral and axial directions when measuring the point-source of fluor-
escence in the 3D reconstructed images. The six large chromosomes 
of the female muntjac cell are clearly visible in the figure showing 
a series of absorbance and fluorescence views from the 3D recon-
structions. Co-registration of images is within a rotational unit (0.72 
degrees). Non-specific and sparse distribution of hematoxylin allows 
the cytoplasm boundary to be distinguished in the absorption images.
Conclusions: Isometric 3D resolution has been demonstrated in the 
Cell-CT instrument for fluorescence imaging which registers exactly 
with absorption imaging. Future work will provide 3D localization of 
biomarkers onto diagnostic cells with standard cytological classifica-
tion. Within single cells, more quantitative protein expressions, Q-dot 
localizations, and 3D fluorescence in-situ hybridizations (3D-FISH) 
are now possible. 
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Immunohistochemical examination of CD21+CD35 and 
anti-follicular dendritic cell antibody in three cases of 
primary pulmonary sarcomatoid carcinoma
Seki, Erina1, 2; Nakazato, Yoshimasa1; Tanaka, Ryota1; Yoshida, 
Tsutomu1; Iijima, Misa1; Kojima, Masaru1; Goya, Tomoyuki2
1 Gunma Prefectural Cancer Center, Gunma, Japan; 2 Department of 
Surgery, School of Medicine, Kyorin University, Tokyo, Japan
Background: Follicular dendritic cell (FDC) sarcoma is a rare 
neoplasm that may occur in both nodal and extra nodal sites. Among 
case of FDC sarcoma, primary pulmonary FDC sarcoma appears very 
rarely. According to the World Health Organization Classification of 
Tumors, FDC sarcoma occurs in histiocytic and dendritic cell tumors 
of the thymus. Its diagnostic criteria as primary lung cancer are not 
mentioned. We regarded it as primary pulmonary sarcomatoid carcin-
oma with FDC differentiation. We evaluated the features of primary 
pulmonary sarcomatoid carcinoma including the spindle cells which 
differentiated to FDCs. The purpose of our study was to review the 
differentiated FDCs by immunohistochemistry in cases of resected 
primary pulmonary sarcomatoid carcinoma.
Methods: We examined 179 cases of resected primary pulmonary 
carcinoma during the period from January 2005 to December 2008. 
These patients underwent surgical tumor resection with mediastinal 
and pulmonary hilar lymph node dissection at the Gunma Prefectural 
Cancer Center in Japan. Three of these patients (1.7%) had primary 
pulmonary sarcomatoid carcinoma. The three cases of primary pul-
monary sarcomatoid carcinoma, including a case shown to have FDC 
differentiation by immunohistochemistry, were collected from surgical 
pathology files. For immunohistochemistry, a panel of an antibody 
cocktail of 2G9 (CD21; Novocastra ) and RB L25( CD35; Novocas-
tra), 1B12 (CD23; Novocastra), and anti-FDC antibody (CNA.42; 
Dako) were used. The primary antibodies were replaced with normal 
rabbit- and mouse-serum for use as a negative control. The histologic 
and immunohistochemical features and outcome were analyzed.
Results: The first case was a 58-year-old woman, the second case 
a 54-year-old man, and the third case a 63-year-old woman. As 
for the diagnosis, two cases were sarcomatoid carcinoma, and one 
case was squamous cell carcinoma with a spindle cell feature. All 
patients presented with a tumor in extranodal sites. The most com-
mon histologic feature was a storiform or fascicular array of spindle, 
ovoid, or polygonal cells with oval nuclei, delicate nuclear mem-
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brane, vesicular or granular chromatin, distinct nucleoli, indistinct 
cell borders, and frequently fibrillary cytoplasm. There were often 
scattered multinucleated forms. The tumor cells sometimes formed 
sheets, circular whorls, follicle-like structures, and trabeculae. There 
was a sprinkling of small lymphocytes, with or without cuffing 
around blood vessels. The neoplastic cells with a spindle cell feature 
were immunoreactive for anti-FDC antibody (3 of 3 cases) and, a 
cocktail of CD21+CD35 (1 of 3 cases). Among the three patients 
with a median follow-up of 2 years, only one patient survived with no 
recurrence, and two died of disease.
Conclusions: Recently, a number of studies on FDC carcinoma have 
been reported. Most of them have described lymph node diseases 
which frequently involve extra nodal sites, such as intraabdominal 
organs and tonsils. As for other sites, few studies have reported 
occurrence in the lung. Sarcomatoid carcinoma of the lung exhibits 
distinctive histologic features that permit its presumptive recognition, 
and we think that some of these carcinomas have a tendency to differ-
entiate to FDC sarcoma. However, firm diagnosis requires confirma-
tion with in-depth examination.
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Tumor infiltrating Foxp3+ regulatory T cells are correlated 
with cyclooxygenese-2 expression and associated with 
recurrence in resected Non-Small Cell Lung Cancer
Shimizu, Katsuhiko; Hirami, Yuji; Yukawa, Takuro; Maeda, Ai; 
Nakata, Masao
Kawasaki Medical School, Kurashiki, Japan
Background: Cyclooxygenese-2 (COX-2) is constitutively over-
expressed in a variety of epithelial malignancies and usually is as-
sociated with poor prognosis or short survival. COX-2 and its product 
prostaglandin (PG) E2 underlie an immunosuppressive network, and 
COX-2-derived PGE2 transformed CD4+CD25+ T regulatory (Treg) 
cells. Tregs are thought to moderate the antitumor immune response. 
We here investigate the prognostic value of tumor infiltrating Treg 
cells and its correlation with COX-2 expression in resected non-small 
cell lung cancer (NSCLC). 
Material and Methods: Intratumoral COX-2 and Treg expression 
were retrospectively assessed by immunohistochemistry in paraffin-
embedded samples from 100 patients who underwent complete 
resection for NSCLC. The most specific Treg cell marker identified 
to date is nuclear transcription factor known as Foxp3. Therefore, 
the expressions of COX-2 and Foxp3+ Treg were compared with 
the clinicopathlogical variables, and the correlation between Foxp3+ 
Treg and COX-2 expression was analyzed. Prognostic value of 
COX-2 and Foxp3+ Treg expression were evaluated by Kaplan-Meier 
analysis and analyzed using COX’s regression model.
Results: The elevated COX-2 expression was associated with nodal 
involvement (p=0.03), but was not associated with age, gender, 
histology, and tumor size. The relapse free survival (RFS) of patients 
with elevated COX-2 expression was significantly worse than that 
of patients with no COX-2 expression. (p=0.010). Tumor Infiltrating 
Foxp3-positive lymphocytes were positively correlated with COX-2 
expression. The median count of the Foxp3-positive lymphocytes 
was 3 (minimum-maximum, 0-24) in 10 HPF. The RFS of patients 
with tumors containing >=3 Foxp3-positive cells (Foxp3 expres-
sion group) was significantly worse than that of patients with tumors 
containing <3 Foxp3-positive cells. (p=0.003) Foxp3 expression was 
not associated with other clinical features. Using multivariate analy-
sis, only nodal status was an independent predictor for significantly 
shorter RFS (p=0.004), and COX-2 expression (p=0.287) and Foxp3 
expression (p=0.114) were not independent predictors. However, 
in node-negative NSCLC, Foxp3 expression was an independent 
predictor for significantly shorter RFS (p=0.018), whereas COX-2 
expression was not an independent predictor (p=0.329).
Conclusions: Tumor infiltrating Foxp3+ Treg was positively correl-
ated with intratumoral COX-2 expression, and associated with worse 
prognosis in RFS, especially in node-negative NSCLC. These results 
suggested that the COX-2 expression might suppress the antitumor 
activity by inducing tumor infiltrating Treg cells.
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Epidermal growth factor receptor protein expression and 
gene amplification in Caucasian patients with malignant 
pleural mesothelioma (MPM)
Surmont, Veerle1; Praet, Marleen1; Rottiers, Isabelle1; Beerens, 
Elisabeth1; Matthys, Bart1; Pauwels, Patrick1; van Meerbeeck, Jan2
1 Department of Pathology/University Hospital Ghent, Gent, 
Belgium; 2 Department of Respiratory Medicine/University Hospital 
Ghent, Ghent, Belgium
Background: Malignant Pleural Mesothelioma (MPM) is a fatal 
tumour which is related to asbestos exposure and highly resistant to 
therapeutic modalities. Epidermal Growth Factor Receptor (EGFR) is 
overexpressed in a variety of epithelial malignancies. In lung cancer 
cases, EGFR gene mutation at the kinase domain and EGFR gene 
amplification are reported predictors of the response to EGFR inhib-
ition. Determining EGFR amplification in MPM patients may give 
important therapeutic information. (1)
Methods: We used the Zymed-kit for EGFR immunohistochemistry 
(IHC). Gene copy number per cell was investigated using fluores-
cence in situ hybridization (FISH) with the LSI EGFR SpectrumOr-
ange/CEP7 SpectrumGreen probe (Vysis,Abott Laboratories,IL, 
USA).(2) Patients were classified according to published criteria.(3 )
Results:: We evaluated EGFR amplification and protein expression 
in archival specimens of 17 patients with MPM: 14 males and 3 
females with a median age of 71 years; 16 epithelial and 1 biphasic 
mesothelioma. Using IHC 17/17 (100 %) were stongly positive for 
the EGFR protein. Disomy (≤ 2 copies in >90% of cells) was present 
in 16 patients and low polysomy (≥ 4 copies in 10-40% of cells) in 1 
case. All were considered FISH negative. 
Conclusions: This is a first report on EGFR FISH in Caucasian 
MPM patients. EGFR protein overexpression is seen in patients with 
epithelial type of MPM, but in our analysis there was no EGFR gene 
amplification. These findings suggest that only a small number of 
MPM patients may profit from anti-EGFR treatment. 
References:
1. Okuda K, Sasaki H, Kawano O et al. Epidermal growth factor receptor gene muta-
tion, amplification and protein expression in malignant pleural mesothelioma. J 
Cancer Res Clin Oncol 2008; 134:1105-1111.
2. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al. Epidermal growth-factor receptor in 
non-small cell lung carcinomas: correlation between gene copy number and protein 
expression and impact on prognosis. J Clin Oncol 2003;3798-3807.
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Prognostic evaluation of “the Nodal Zone” proposed in the 
revised TNM staging system for lung cancer 
Takamochi, Kazuya; Oh, Shiaki; Sakuraba, Motoi; Takahashi, 
Nobumasa; Miyasaka, Yoshikazu; Banno, Takamitsu; Matsunaga, 
Takeshi; Suzuki, Kenji
Juntendo University School of Medicine, Tokyo, Japan
Background: The IASLC has proposed a new TNM staging system 
for the next revision scheduled in 2009. Although T and M com-
ponents were newly subclassified based on differences in survival, 
there was no change in the N component. However, the anatomic 
location of lymph nodes was defined by “zone” instead of “station” 
to reconcile the difference in nomenclature between the Naruke and 
the Mountain-Dresler lymph node map. The purposes of this study 
were to evaluate the proposed “Nodal Zone” map from the point of 
prognosis, and to identify the significant prognostic factors in each 
pathologic N stage. 
Methods: We reviewed 647 consecutive patients with surgically re-
sected non-small cell lung cancers. We analyzed the following prog-
nostic factors in each pathologic N stage: location of involved zone, 
number of involved lymph nodes, stations and zones, and presence 
of skip metastases. Univariate survival rate analyses were estimated 
using the Kaplan and Meier method, with comparisons made between 
groups by the log-rank test. Multivariate analyses were performed 
using the Cox proportional hazards model. 
Results:
1) Pathologic N stage / Number of patients / Median survival time / 
5-year survival rate: N0 / 427 / Not Reached / 84%, N1 / 91 / 62 
months / 52%, N2 / 101 / 36 months / 36%, N3 / 28 / 22 months / 
20%
2) There was no significant difference in survival among the loca-
tion of involved zone in each pathologic N stage. 
3) N1 stage: No significant prognostic factor was identified. 
4) N2 stage: The number of involved stations and zones, and the 
presence of skip metastases were significant prognostic factors in 
univariate analyses. Multivariate analyses showed the presence of 
skip metastases as significant. 
5) N3 stage: Lymph nodes were involved in multiple stations and 
zones in almost all of N3 patient, and there was no patient with 
skip metastases. Therefore, no significant prognostic factor was 
identified statistically.
Conclusions: “The Nodal Zone” was a useful anatomic mapping 
from the point of prognosis. Patients with N2 disease could be strati-
fied according to the number of involved stations and zones, and 
presence of skip metastases.
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Lymphatic vessels in lymph node-positive lung 
adenocarcinoma
Takizawa, Hiromitsu; Kondo, Kazuya; Toba, Hiroaki; Nagao, Taeko; 
Nakagawa, Yasushi; Kenzaki, Koichiro; Sakiyama, Shoji; Tangoku, 
Akira
Department of Thoracic, Endocrine Surgery and Oncology, Institute 
of Health Bioscience, The University of Tokushima Graduate School, 
Tokushima, Japan
Background: With increasing opportunity to encounter small periph-
eral non-small cell lung cancer, radical sublober resection, alterna-
tive to lobectomy, has become a topic for discussion. The sublober 
resection leads to limited exploration of hilar and mediastinal lymph 
nodes, which may disturb accurate nodal staging. Therefore, to 
collect information on risk of lymph node metastasis from primary 
tumors is important. The monoclonal antibody D2-40 is a select-
ive marker for lymphatic endothelium. This study was conducted 
to reveal characteristics of lymphangiogenesis and risk factors of 
lymphatic spread in lymph node-positive lung adenocarcinoma. We 
also performed three-dimensional reconstructions of the lymphatic 
vessels in several typical lung adenocarcinomas using computerized 
image analysis.
Methods: Primary tumors of 36 patients with lymph node-positive 
lung adenocarcinoma who underwent curative operation without 
preoperative therapy were selected for immunohistochemical study 
of D2-40. Four factors, lymphatic vessel invasion, shape of lymph-
atic vessels, lymphatic vessel density, and area of lymphatic vessels, 
were evaluated in the immunohistochemical specimen of D2-40. We 
defined two subgroups according to extent of lymph node metasta-
sis: n1 and single n2 disease group (n = 20), and multiple n2 disease 
group (n = 16). For three-dimensional reconstructions of lymphatic 
vessels, 20 to 54 serial sections were prepared. Serial tissue sections 
were stained for D2-40 and corresponding images were selected and 
aligned. Three-dimensional reconstructions were produced using an 
image analysis software.
Results: Lymphatic vessel invasion was observed in 9 (45.0%) in n1 
and single n2 disease group and 13 (81.3%) in multiple n2 disease 
group (p = 0.029). There was no correlation between the extent of 
lymph node metastasis and other clinicopathologic factors includ-
ing factors evaluated in D2-40 immunostaining specimens. Three-
dimensional visualization of microscopic structures of lymphatic 
vessels revealed the various patterns of lymphangiogenesis.
Conclusion: Lymphatic vessel invasion was a risk factor of multiple 
mediastinal lymph node metastases. Three-dimensional visualization 
of microscopic structures of lymphatic vessels provides useful infor-
mation about the exact three-dimensional configuration.
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Genomic predictors of lymph node metastases and survival 
for bronchopulmonary carcinoid tumors
Thomas, Jr., Charles F.; Rickman, Otis B.; Aubry, Marie Christine; 
Sun, Zhifu; Wigle, Dennis A.
Mayo Clinic, Rochester, MN, USA
Background: Bronchopulmonary carcinoid tumors are rare malig-
nant neoplasms that comprise 1-2% of all lung cancers. Classified 
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histologically as typical and atypical subtypes, these neuroendocrine 
tumors are poorly responsive to chemotherapy and radiation treat-
ments. The current treatment for these tumors is complete surgical 
excision, which may not be possible in extensive or metastatic spread 
of the tumor. Little is known about the biology of these tumors, due 
in part to their scarcity, and to the lack of reagents such as well estab-
lished cell lines. 
Methods: To better understand the biology of these rare tumors, we 
performed whole genome mRNA expression analysis of surgically 
resected samples which included 31 typical carcinoids, 11 atypical 
carcinoids, 10 normal lung, and 12 small cell lung cancers using 
the Illumina Human WG-6_v2 BeadArray Chips that profile 48,701 
transcripts. Complete clinical data and follow-up was available for all 
patient samples and was correlated to gene expression. 
Results: Unsupervised clustering showed the 10 normal lung and 
12 small cell lung cancers formed distinct molecular subgroups. The 
typical and atypical carcinoids for the most part formed individual 
clusters, however there was some mixing of several typical and atyp-
ical tumors. Supervised clustering was performed based on histol-
ogy, the presence or absence of lymph node metastases, and clinical 
outcomes such as disease-free and overall survival. All analyses were 
conducted by T test or one way ANOVA. We found 63 highly varied 
genes (p<0.01 with log2 fold-change > 3 standard deviations) that 
appeared to distinguish typical and atypical carcinoid tumors. Further, 
195 unique genes (p<0.05 with log2 fold-change> 3 SD) identified 
typical or atypical carcinoids with lymph node metastases (n=9) com-
pared to those without. The expression of 212 unique genes (p<0.05 
with log2 fold-change> 3 SD) were found in patients who died from 
their disease (n=11).
Conclusions: Gene expression analysis of bronchopulmonary car-
cinoid tumors can identify unique molecular signatures for histology, 
lymph node involvement, and overall survival. This information 
provides exciting insights into the biology of bronchopulmonary car-
cinoid tumors. These initial gene signatures are currently being valid-
ated on an independent series of well characterized bronchopulmon-
ary carcinoid tumors with 10 year or more follow-up and complete 
clinical data. The information from this series will identify molecular 
prognostic markers for clinical utility and will provide the necessary 
foundation to investigate the biology of these rare tumors.
P3.100 Pathology, Mon Aug 3 – Tue Aug 4 
Regenerating gene 1α (REG 1α) expression may give the 
new treatment strategy in early non-small cell lung cancer
Tojo, Takashi; Naito, Hiroshi; Kimura, Michitaka; Taniguchi, 
Shigeki; Takasawa, Shin; Dohi, Yoshiko; Nagata, Yoko 
Nara Medical University, Kashihara-city, Nara, Japan
Background/Aims: Regenerating gene (REG) I was originally 
isolated as an endogenous growth factor from pancreatic islet β cells. 
REG Iα protein is suggested to be involved in carcinogenesis in vari-
ous gastroenterologic tissues. In the present study, to elucidate roles 
for REG Iα in non-small cell lung cancer (NSCLC), we investigated 
REG Iα expression in NSCLCs, focusing especially on its relation-
ship with prognosis.
Methods: We enrolled 70 NSCLCs (adenocarcinoma (AC)(n=48) 
and squamous cell carcinoma (SCC)(n=22)) who received surgery 
at Nara Medical University Hospital. Total RNA was extracted from 
each tumor tissue and corresponding normal lung tissue (NL)(n=70), 
cDNA was then reverse-transcribed from total RNA, and quantita-
tive real-time reverse transcriptase-polymerase chain reaction was 
then carried out. The expression level of REG Iα in each sample was 
normalized with respect to that of β-actin, and the cutoff level was 
set at average+3SD expression of the 70 NLs. We also examined the 
relationship between REG 1α expression in the tumor tissue and the 
prognosis.
Results: Six (12.5%) of the 48 ACs and 5 (22.7%) of the 22 SCCs 
were positive for REG Iα gene, and which is higher than that of NLs 
(2 of 70: 2.9%). After median follow-up of 26.2 months, 12 patients 
died due to disease progression. The survival rate among the REG 
1α positive patients was significantly worse than among the REG 1α 
negative patients in ACs (P<0.05), and not significantly but worse in 
SCCs (P=0.07). In case of stage I, none of REG 1α negative patient 
died in both ACs and SCCs compared with 4 patients died of positive 
patients (AC:2, SCC:2), and also the survival rate among the REG 
1α positive patients was significantly worse than among the negative 
patients in ACs (P<0.01) and SCCs (P<0.05). Disease free survival 
of REG 1α positive patients was also worse than negative patients in 
ACs (P<0.05) and SCCs (P=0.16).
Conclusion: REG Iα expression in NSCLCs may be the risk factor 
for poor prognosis, and we anticipate that it will enable us to provide 
more appropriate and individualized treatment to patients of early 
NSCLC.
P3.101 Pathology, Mon Aug 3 – Tue Aug 4 
Clinicopathological examination of pulmonary 
Pleomorphic carcinoma
Yamamoto, Satoshi1; Kawahara, Katsunobu1; Yamamshita, Shinichi1; 
Miyawaki, Michiyo1; Iwasaki, Akinori2
1 Yufu-city, Japan; 2 Fukuoka-city, Japan
Background: Pleomorphic carcinoma is an uncommon malignant 
tumor of the lung. As there are few large scale studies of patients with 
pleomorphic carcinoma, the clinical characteristics and behavior of 
the disease has been unclear until now. In this study, we investigated 
the clinicopathological findings and prognosis of 21 patients with 
pleomorphic carcinoma.
Patients and Methods: We identified 930 cases of pulmonary carcin-
oma in which the patient underwent a lung resection in our institutes. 
Of those patients, 21 (2.6%) were diagnosed with pleomorphic car-
cinoma as determined by the three pathologists in our institute. 
Results: The 21 study subjects consisted 18 male and 3 female 
patients. The locations of the lesions were as follows, 13 cases, right 
upper lobe, 5 cases, left upper lobe, 2 cases, right lower lobe, and 1 
case, left lower lobe. The mean diameter of the tumor in this series 
was 55.2mm (17mm-100mm). As for the pathological stage, 4 cases 
were stage IA, 7 cases were stage IB, 5 cases were stage IIB, 2 cases 
were stage IIIA, and 3 cases were Stage IIIB. The over-all five-
year survival rate was 80.0%. There were no significant differences 
between the symptomatic group, and the asymptomatic group, or be-
tween the p-factor positive group and the p-factor negative group. On 
the other hand, there was a significant difference in the disease-free 
survival rate between the node negative group and the node positive 
group, and there was also a significant difference in the over-all sur-
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vival rate between the curative operation group and the non-curative 
operation group.
Conclusions: In this clinical study, the presence of lymph node 
metastasis and the treatment by a curative resection of the tumor were 
the most important prognostic factors for the pulmonary pleomorphic 
carcinoma. However, further investigation of a large number of cases 
is needed in order to gain a more clear understanding of the clinical 
characteristics and behaviors of pleomorphic carcinoma
P3.102 Pathology, Mon Aug 3 – Tue Aug 4 
Clinicopathological significance of E-cadherin and PCNA 
expression in human Non-small Cell Lung Cancer
Zheng, Shi Ying; Li, Hong; Jiang, Dong
First Affiliated Hospital of Suzhou University, Suzhou, China
Background: Lung cancer is the leading cause of cancer deaths in 
both women and men, and its incidence has increased markedly in 
the past decade, Epithelial tumors, which present the majority of lung 
tumors, are classifted primarily into two subgroups: small cell lung 
cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC is 
composed of squamous cell, adenocarcinoma, large cell and adeno-
squamous carcinoma. As the 5-year survival for lung cancer patients 
is currently 13%. Mainly due to metastasis, the devastation caused 
by this single cancer type deserves special attention. Cell adhesion 
is a key process because it is directly related to the differentiation, 
architecture and normal tissue development. E-cadherin (E-cad) is the 
most important protein. E-cad, a l20-kDa transmembrane glycopro-
tein, is a calcium, dependent cell adhesion molecule that is expressed 
in epithelial tissues involved in formation and maintenance of the 
histoarchitecture. Reduced/absent expression of E-cad has been found 
in a variety of human carcinoma. This study was designed to assess 
E-cadherin (E-cad) and proliferating cell nuclear antigen (PCNA) 
expression as well as their clinicopatholocal significance in human 
nonsmall cell lung cancers (NSCLCs). Possible molecular mechan-
isms of differentiation and metastasis of NSCLCs are discussed.
Methods: Sixty-eight primary NSCLCs patients underwent surgical 
resection between 2004 and 2006 Department of Cardio-Thoracic 
Surgery, The First Affiliated Hospital of Suzhou University. 
Immunostaining for the PCNA antigen was performed in a similar 
manner. Mouse PCNA antibody ( 1:1000) was used. For fluorescence 
immunohistochemistry double staining, rabbit E-cad antibody (1:200) 
and mouse PCNA antibodlV (1:1000) were mixed and used as the 
primary antibodies, then mixed secondary antibodies (anti-mouse and 
anti- rabbit) labeled with Alexa594 (red) and Alexa488 (green) were 
applied. Finally the sections were mounted with glycerin. After the 
immunohistochemical reaction. Images were captured using identical 
exposure times and camera settings, ve measured the sum of staining 
intensity in 5 fields of view for each sample for each antibody using 
on Image J Plus system, and the values used for statistical analysis. 
The independent t- test, Spearman correlation and Person’s correla-
tion were determined by SPSS II.5 soflware package. Results were 
considered statistically significant at a P value of 0.05 or less.
Results: The positive signal of E-cad expression in adenocarcinomas 
was stronger than that in squamous cell carcinomas. However, the 
difference between these two types was not significant (P=0.34). On 
the other hand, it was observed that E-cad expression had a positive 
correlation with pathological differentiation of NSCLC. In other 
words, the expression of E-cad in well differentiated tumors was 
significantly stronger compared to poorly differentiated (P=0.003). 
The E-cad expression in the non-metastastic group was significantly 
stronger than that in the metastatic group (P=0.002). The results 
showed no significant difference in PCNA expression between 
NSCLCS squam ous cell carcinomas and adenocarcinomas. Further-
more, it was found that the expression of PCNA in well differenti-
ated tumors was weaker,but stronger in poorly differentiated tumors 
(p=0018). It also was found that the PCNA expression in the metas-
tastic group was significantly stronger compared to the non-metastas-
tic group (p=0.001, Table 3). The E-cad and the PCNA expressions 
showed an Inverse correlation (r=0.51, P =0.002). The E—cad and 
PCNA expression presented a reverse correlation.
Conclusion: The results of our present study indicate that the 
expression of E-cad has no significant correlation with the NSCLC 
histological type, but has a significant relationship with the differenti-
ated grade and lymph node metastasis. Low expression of E-cad is 
associated with tumor cell proliferation. Conjoint analysis of E-cad 
and PCNA expression is a good way to evaluate tumor biological 
behavior. Further studies are necessary to elucidate the mechanism 
by which the down-regulation of E-cad expression is induced in lung 
cancer.
Patient Advocacy
P3.103 Patient Advocacy, Mon Aug 3 – Tue Aug 4 
Lung cancer awareness month in Slovakia - success and 
challenge
Berzinec, Peter1; Bellova, Beata2; Cerna, Maria3; Kasan, Peter3; 
Steinerova, Andrea2; Utesena, Martina2; Zimanova, Erika4
1 Specialised Hospital of St Zoerardus Zobor, Nitra, Slovak Republic; 
2 Roche, Bratislava, Slovak Republic; 3 Faculty Hospital of Comenius 
University, Bratislava, Slovak Republic; 4 Accelerate, Bratislava, 
Slovak Republic
Background: For the first time Slovakia joined many other coun-
tries worldwide and during November 2008 several organizations, 
including Slovak Oncological Society, Ministry of Health, Ministry 
of Education, Ministry of Agriculture, Roche Slovakia, leading lung 
cancer centers, and many others helped to raise awareness about all 
aspects of lung cancer. 
Methods: A nation-wide campaign Lung Cancer Awareness Month 
(LCAM) was divided into 4 weeks: Week 1 under the logo GREEN 
with a tree as a symbol for lung, reflecting the role of trees in oxygen 
production, Week 2 under the logo AIR to stress the role of clean air 
for lungs, Week 3 under the logo EARTH as a symbol for roots of life 
and hope for future, Week 4 under the logo WATER as a symbol of 
possibility to swim over the waters of uncertainty together. The main 
activities during the Week 1 were: introductory press conference and 
planting of saplings at the secondary school by VIPs representing 
Slovak political, cultural, and medical organizations. During the 
Week 2 free lung function tests and leaflets containing information 
about lung cancer were provided in three largest shopping centers in 
the western, central and eastern parts of Slovakia. The highlights of 
the Week 3 were educational activities at secondary schools with the 
main purpose to give information about lung cancer in general, and 
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how to help family members and others affected by this disease. The 
introductory lecture given by lung cancer expert Dr. Maria Cerna 
was supported by the Deputy Prime Minister of the Slovak Republic 
Government and Education Minister of the Slovak Republic Prof. Jan 
Mikolaj. Week 4 was devoted to patients suffering from lung cancer 
and to their families. Health Minister of the Slovak Republic Dr. 
Richard Rasi and the First Lady of the Slovak Republic Silvia Gaspa-
rovicova visited lung cancer patients at the Department of Pneumoon-
cology, Faculty Hospital of Comenius University, Bratislava. Small 
gifts and information containing leaflets were given to patients with 
lung cancer in all oncology centers and also in others health care 
facilities caring for these patients in Slovakia to show solidarity and 
support. Also a special web site (www.rakovinapluc.sk - www.lung-
cancer.sk) was introduced offering information, advice and help. 
Results: there was excellent mass media coverage of LCAM. The 
main public TV channels STV1 and STV2 devoted altogether about 
three hours to the expert discussion and to the information about 
LCAM. By the end of 2008 there were more than 1500 web sites 
which noticed LCAM and activities done during the LCAM. 
Conclusion: The first LCAM in Slovakia was a great success. The 
main challenge is to continue in what LCAM 2008 started. 
P3.104 Patient Advocacy, Mon Aug 3 – Tue Aug 4 
UK Media coverage of lung cancer increases with less 
attention on smoking/tobacco use, and less negative 
messages
Blum, Diane; Boerckel, Winfield A.
CancerCare, New York, NY, USA
Background: Following up on a survey conducted in 2005 on how 
UK media reported on lung cancer, relative to other major cancers 
over two periods (August, 1999-July, 2000 and August, 2003-July, 
2004), a new survey analyzed a random sample of UK media cover-
age on lung cancer, breast cancer, prostate cancer and colorectal 
cancer between August, 2007 – July, 2008. The survey was commis-
sioned to determine whether trends in volume and favorability/nega-
tivity, noted earlier, had persisted. 
Method: Research firm Carma International analyzed a systematic 
random sample of 300 stories from U.K. media, including print, 
broadcast and web based sources (August, 2007-July, 2008). Cover-
age was analyzed by volume, story type, topics, awareness events 
and celebrity outreach. Topics and messages from this period were 
matched to those used in previous periods (August 1999 - July 2000, 
August 2003 - July 2004). Project parameters were held consist-
ent between time periods to enable an accurate comparison of each 
cancer over time.
Results: Breast Cancer continued to receive the most coverage (187 
stories), with lung cancer experiencing a 25% increase in coverage 
volume (67 to 83 stories). In the earlier survey, 61% of lung cancer 
stories discussed smoking/tobacco use in comparison to only 37% of 
2007-2008 stories. While lung cancer led all 4 cancers in the number 
of negative messages (47), penetration of negative message for lung 
cancer decreased by 9%, and positive lung cancer messages were 
present in 34% of the stories in the current period vs. 25% in the 
prior period. One third of lung cancer articles mentioned treatment 
of the disease and increase of 15% and contributed to overall posi-
tive content and favorability in lung cancer coverage. Detection and 
screening of lung cancer while noted in 15% of articles previously, 
received mention in only 6% or current period articles. Research-
driven reports, an important source of positive lung cancer reports 
increased from 11 articles in the 2003-2004 survey to 23 articles in 
the latest period. Few opinion leaders commented on lung cancer, 
and no politicians/celebrities were featured speaking out about lung 
cancer in the current sample analyzed. 
Conclusions: While the results give cause for guarded optimism that 
media coverage of lung cancer is increasing in volume and positiv-
ism, and a shift away from smoking/tobacco dominance, they also 
clearly indicate that a great deal more improvement is needed. Given 
the UK’s toll of lung cancer, results such as these should serve to mo-
bilize its physicians, healthcare professionals and lung care advocacy 
groups in an effort to generate even greater positive media cover-
age on the disease. The additional involvement of opinion leaders, 
politicians, and celebrities in speaking out for advancement in lung 
cancer prevention, screening, research and treatment may also gener-
ate greater positive media notice of a disease sometimes described as 
the “invisible” cancer. 
P3.105 Patient Advocacy, Mon Aug 3 – Tue Aug 4 
The lung cancer clinical nurse specialist: the true advocate
Bell, Nicola; Guerin, Maria
National Lung Cancer Forum for Nurses, Leeds, UK
Clinical nurse specialist (CNS) roles have been developing in oncol-
ogy since 1980’s. These roles are defined as “an expert practitioner in 
nursing with considerable knowledge, a high degree of skill and ex-
tensive experience in the care of patients in the speciality concerned”.
Lung Cancer CNS roles in the UK began to emerge in the late 1990’s 
after several national reports highlighted an area of need in the care 
and treatment for lung cancer patients. This role was defined by the 
National Lung Cancer Forum for Nurses (NLCFN) in 2003 as
A first level nurse locally recognised a part of the lung MDT and 
designated as a specialist in lung cancer. The nurse should spend at 
least 50% of their time caring for Lung cancer patients”
There are many aspects of the lung CNS’s role which have continued 
to evolve. The shared objective for all aspects is the improvement of 
the overall quality of care available to each individual diagnosed with 
lung cancer. 
This poster will show examples of how the authors have continued 
to strive to achieve such improvements. These range from service 
developments within the local multidisciplinary team, working in 
partnership with national lung cancer organisations to lobbying of 
government ministers raising the profile and highlighting the inequal-
ity within the lung cancer pathway. 
These initiatives have driven significant change, demonstrating that 
the Lung cancer CNS is a true advocate for one of the most neglected 
patient tumour groups. 
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P3.106 Patient Advocacy, Mon Aug 3 – Tue Aug 4 
Effectiveness of Epidermal Growth Factor containing 
Moisture Cream for treatment of Epidermal Growth 
Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI)-
induced cutaneous toxicities.
Lee, Sung Yong1; Moon, Jae Young1; Lee, Sang Yeub 2; Kim, Je 
Hyeong 2; Shin, Chol2; Shim, Jae Jeong 1; In, Kwang Ho 2; Yoo, Se 
Hwa 2; Kang, Kyung Ho 1; Kim, Jun Suk 1; Song, Hae Jun3
1 Department of Internal Medcine, Guro Hospital, Korea University, 
Seoul, Korea; 2 Department of Internal Medicine, Anam Hospital, 
Korea University, Seoul, Korea; 3 Department of Dermatology, Guro 
Hospital, Korea University, Seoul, Korea
Background: EGFR TKIs (gefitinib, erlotinib) have proven effect-
ive in some patients with advanced NSCLC. However, their use is 
associated with dermatologic reactions of varying severity. The most 
commonly reported toxicity is a papulopustular reaction. This usually 
develops on the face and/or upper trunk. Mechanisms that underlie 
EGFR TKI associated cutaneous toxicities remain incompletely char-
acterized; however, interference with the follicular and interfollicular 
epidermal growth signaling pathway is considered critical. Drug-
induced inhibition of EGFR is thought to alter keratinocyte prolifera-
tion, differentiation, migration, and attachment, and this may help 
to explain the papulopustular reaction and xerosis. EGF containing 
Moisture Cream (Easy dew®; dae woong, Korea) has nano-liposome 
that contains the hEGF and is a commercially available lotion. This 
study was to evaluate efficacy of EGF containing Moisture Cream. 
Methods: This study was an open-label, single-arm, single center 
trial between May 2008 and February 2009. Inclusion criteria were: 
informed consent, age >= 35yrs, on-going chemotherapy and cuta-
neous toxicities (acneiform or popular eruption greater than grade 1). 
Treatment was administered three times/day for at least 7 days. We 
checked the improvement of symptoms and signs (itching sensation, 
pain and secondary infection). Symptoms were assessed weekly 
through the functional assessment of symptom index that is a scaled 
from 0 (not at all) to 4 (very much).
Results: In total, 10 pts (consisting of 6 with adenocarcinoma, 4 with 
squamous cell carcinoma, median age 61 years, M/F 7/3) with EGFR 
TIK-induced cutaneous toxicity were treated with EGF containing 
Moisture Cream, and have been monitored clinically. There were 
statistically significant differences in symptom score (improvement 
of itching sensation, p=0.026, Wilcoxon test) and grade of toxicity 
(p=0.023, Wilcoxon test) between before and after Easy dew® treat-
ment. 
Conclusion: EGF containing Moisture Cream is effective for allevi-
ating EGFR TKI-induced cutaneuous toxicities. 
Prognostic and Predictive Markers
P3.107 Prognostic and Predictive Markers, Mon Aug 3 – Tue Aug 4 
Clinical variants along with several pharmacogenomic 
markers impact the outcome of advanced non small cell 
lung cancer (NSCLC)
Abdel Karim, Nagla F.1; Bui, Hai X.2; Patherson, Peter1; Patil, 
Ninad1; Mostafa, Ahmed3; Rao, M B.1; Mehta, Apurva1; Anderson, 
Marshall1
1 The university of Cincinnati, Cincinnati, OH, USA; 2 VA medical 
Center, Cincinnati, OH, USA; 3 Mercy Hospital system, Cincinnati, 
OH, USA
Background: Performance status is the only known clinical predictor 
to affect the outcome of patients with advanced NSCLC. Several 
other pharmacogenomic markers were studied.ERCC1 is a useful 
marker of resistance to cisplatin and its analogues. Longer survival 
was noted in patients with ERCC1 negative expression when treated 
with platinum. VEGF and its receptor-KDR previously indicated poor 
prognosis with high tumor cell expression, however, they indicated 
better outcome with overexpression in the tumor stroma. Previous 
studies have shown that 14-3-3 protein levels are higher in human 
lung cancers as compared to normal tissues. 
Patients and Methods: From 1998-2008, a retrospective study 
included 50 patients with stage III or IV NSCLC, where clinical 
variants as well as the levels of expression of VEGFR using rabbit 
monoclonal Ab (VEGFR: 55B11, 1:250, cell signaling), IHC for 
ERCC1 (Mouse monoclonal ab-8F1, Thermo Scientific, 1:200) and 
levels of expression of 14-3-3 sigma (Clone N-14: 1:500 SCBT) were 
measured and co-related to the overall survival of those patients using 
cox proportional hazards model.
Results: Of the 50 patients, forty received platinum based regimens, 
while ten received non-platinum based regimens. Median age was 65 
(42-84), where ECOG performance status (PS) was 0 in 8 patients 
(16%), I in 29 patients (58%), II in 7 patients (14%) and III in 6 pa-
tients (14%). ECOG PS of 0 and I were significantly associated with 
higher overall survival (p=0.004), where age was not significantly 
associated with survival (p=0.24). Females had a longer survival 
compared to males with a median survival of 31.7 months versus 
12.5 months (p=0.04). Caucasians had better overall survival in com-
parison to African Americans with median survival of 14.8 months 
versus 10.4 months, however this did not reach statistical significance 
(p=0.1). 
Patients treated with gemcitabine therapy had improved survival 
of 19 months versus 13 months in non-gemcitabine therapy group 
(p=0.003). Patients treated with platinum based therapy had better 
survival of 15.3 months versus 8.4 months, but did not reach statis-
tical significance. However, in patients treated with platinum, ERCC1 
negativity was strongly associated with longer survival (p=0.007).
High expression of the VEGF stromal receptor showed improved 
overall survival of 14 months versus 9.7 months with the lower 
expression, but this did not reach statistical significance (0.1). Also 
14-3-3 sigma tissue expression did not correlate with survival. 
Conclusion: Platinum therapy in patients with ERCC1 negative 
expression was significantly associated with prolonged survival. Pa-
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tients who received gemcitabine therapy also had prolonged survival. 
In addition, good performance status and female gender were associ-
ated with improved overall survival.
 Variant Median survival p value
 Females (n=8) 31.7 months 0.04
 Males (n=42) 12.5 months 
 Caucasians (n=45) 14.8 months 0.1
 African Americans (n=5) 10.4 months 
 PS (0,I) (n=37) 15 months 0.007
 PS (II,III) (n=13) 6.3 months 
 Gemcitabine therapy (n=12) 19 months 0.003
 None-Gemcitabine therapy (n=38)  13 months 
 Platinum therapy (n=40) 15.3 months 0.1
 Non-Platinum therapy (n=10) 8.4 months 
 Platinum treated ERCC1 negative (n=14) 36 months 
 Platinum treated ERCC1 positive (n=12) 15 months 0.035
 Platinum treated ERCC1 strongly positive (n=14) 12 months 0.007
 Platinum and non-platnum treated ERCC1 negative (n=19) 15 months 
 Platinum and non-platinum treated ERCC1 positive (n=14) 14.6 months 0.38
 Platinum and non-platinum treated ERCC1 strongly positive (n=17) 12.5 months 0.0008
 VEGFR stromal Low expression (n=23/49 evaluable patients) 9.7 months 0.1
 VEGFR stromal high expression (n=26/49 evaluable patients) 14 months 
 14-3-3 sigma high expression (n=7/48 evaluable patients) 13.5 months 
 14-3-3 sigma low expression (n=41/48 evaluable patients) 13 months 
P3.108 Prognostic and Predictive Markers, Mon Aug 3 – Tue Aug 4 
The assessment of Ki-67 cell proliferation marker in 
forceps biopsy specimen obtained under autofluorescence 
bronchoscopy guidance
Adamek, Mariusz3, 1; Niepsuj, Grzegorz1, 3; Unger, Michael2; 
Kozielski, Jerzy1; Ziora, Dariusz1; Zielinska-Les, Izabela1; Stoltny-
Sieron, Karolina3; Sieron, Aleksander3
1 Dept. of Pulmonary Diseases, Silesian Medical Univ., Zabrze, 
Poland; 2 Fox Chase Cancer Center, Philadelphia, USA; 3 Center for 
Laser Diagnostics and Therapy, Dept. of Internal Diseases Angiology 
and Physical Medicine, Silesian Medical Univ., Bytom, Poland
Background: Ki-67 constitutes a growth fraction proliferation 
marker and has been demonstrated to have a prognostic value even 
in in situ cancers. Autofluorescence bronchoscopy (AFB) is believed 
to yield information on biochemical composition and metabolic state 
of bronchial tissue, as opposed to structural information provided by 
white-light bronchoscopy (WLB). Therefore it is interesting to try 
correlating Ki67 index with bronchial tissue fluorescence in various 
pathologically identified lesions.
Patients and Methods: A total of 255 patients (65 females, 190 
males) with the symptoms and/or signs suggestive for lung cancer 
underwent WLB and AFB. AFB was performed by means OncoLIFE 
lung system (Xillix Corp., Richmond, BC, Canada) yielding fluores-
cence images in real time. Indications for AFB were x-rays findings, 
haemoptysis or other signs suggestive of lung cancer, staging pro-
cedure in patients with previously diagnosed lung cancer. All areas 
exhibiting pathological fluorescence were sampled (298 biopsies) 
and pathologically verified. A total of 141 biopsy specimen were 
immunostained to assess Ki-67 in epithelial cells. Ki-67 antigen was 
evaluated with the use of Dako Monoclonal Mouse Anti-Human p53 
protein, clone DO-7, Code N1581, DakoCytomation. In each sample 
at least 50 stained cells were counted.
Results: Ki-67 index equalled 15.9% in samples determined as 
inflammation. In case of metaplasia it was 9.8%, low-grade dysplasia 
14.7%, high-grade dysplasia 14.3% and carcinoma 27.1%. Addition-
ally in bronchial epithelium classified as exhibiting no changes Ki-67 
index was 6.1%. It is apparent Ki-67 may allow to distinguish normal 
epithelium from cancer. On the other hand inflamed bronchial mu-
cosa exhibits similar Ki-67 index in comparison with pre-malignant 
lesion including metaplasia and dysplasia of different grades.
In general the biopsies taken from the spots displaying negative 
fluorescence have Ki-67 index 8.1%, whereas these originating from 
fluorescence positive areas are characterized by an average index 
equal to 14.2%.
Conclusion: Although there is no discriminative value of Ki-67 
index permitting to differentiate between pre-cancerous changes, 
fluorescent-positive specimens taken under AFB guidance tend to 
have higher index especially with regard to cancer lesions.
P3.109 Prognostic and Predictive Markers, Mon Aug 3 – Tue Aug 4 
Assessment of biologic individual prognosis after surgery 
in patients with non small lung cancer I stage
Laktionov, Konstantin2; Polotsky, Boris2; Allakhverdiyev, Arif 
2; Ardzinba, Merab2; Zborovskaya, Irina2; Bogatirev, Vladimir2; 
Gotsadze, Ilya2
1 Kashirskoye sh.24, Moscow, Russia; 2 N.N.Blokhin Cancer 
Research Center, Moscow, Russia
Methods: Between 1997-2005, 106 patients were operated on 
radically, with systematic mediastinal lymph node dissection, for 
stage I non small cell lung cancer. Biologic prognostic factors such 
as: expression of р53 mutation, BCL-2, BAX and VEGF, tumor cell 
ploidy, S-phase cell fraction, allelic imbalance and instability of 
microsatellite 32-36th loci on chromosome 1p were examined in the 
resected specimens. The patients were retrospectively divided into 
2 groups: first group included 46 patients, in progression of disease 
were detected within 3 years after surgery (unfavorable prognosis) 
and second group, which consisted of 60 patients, who survived the 5 
years without any evidence of disease (favorable prognosis).
Results: As statistical monfactorial analysis showed (p <0.05), 
unfavorable prognosis was associated with the presence expression 
of р53 mutation and VEGF, absence of expression BCL-2 and BAX, 
tumor cell aneuploidy, S-phase cell fraction of more than 10%, allelic 
imbalance and instability of microsatellite 32-36th loci on chromo-
some 1p.
Survival calculated by multifactorial regression analysis taking into 
account above-mention factors of prognosis, coincided with retro-
spectively assessed survival fo the same patients. 
Conclusion: Multifactorial regression biologic prognostic factors 
may be used for individual prognosis of survival after surgery in 
patients with stage I non small cell lung cancer and for indidvidual 
planning of treatment tactics. 
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Comparison of direct sequencing and a commercial real-
time PCR kit for detection of mutation in EGFR
Angulo, Bárbara; Conde, Esther; Martínez, Rebeca; Suárez-Gauthier, 
Ana; García-García, Elena; Rubio-Viqueira, Belén; López-Ríos, 
Fernando
Laboratorio de Dianas Terapéuticas, Madrid, Spain
Background: EGFR mutation testing is part of standard lung adeno-
carcinoma management. Therefore, it is very important to evaluate the 
performance of genetic testing in the “real” world because there are 
many facts that influence the pre-analytical, analytical and post-ana-
lytical aspects of the procedure. For morphology-based methods (ie., 
immunohistochemistry, FISH) this is self evident, but for assays based 
on DNA extraction, there is a worrisome lack of standardization.
At the present time, EGFR mutation detection is most commonly 
done by direct DNA sequencing. Conventional DNA sequencing is 
time-consuming and labor-intensive and is subject to significant vari-
ability. Recent advancements in molecular technology have enabled 
the design of sensitive detection assays for genetic alterations. For ex-
ample, real-time PCR is a very fast method for quantification, without 
the need of any post-PCR sample manipulation. 
Among the real-time PCR approaches, we have chosen to determine 
the sensitivity and clinical applicability of the TheraScreen EGFR29 
mutation test kit (DxS, Manchester, UK) in a series of lung carcin-
oma samples.
Methods: We assayed DNA extracted form paraffin blocks to 
determine the presence of EGFR mutations by direct sequencing in 
92 lung carcinomas. Macrodisecction was performed on all surgical 
resection specimens. We reported mutations in 9 (10%) of them. The 
lung cancer samples positive for EGFR mutations were also con-
firmed by the kit. 
To assess the sensitivity of both assays, we diluted mutant DNA in 
various concentrations of genomic DNA, to give final percentages of 
mutant DNA relative to wild-type DNA of 1%, 3% or 5% (kit) and 
10% or 20% (direct sequencing).
Results: Sequencing was only able to detect the presence of the 
EGFR mutant in one sample (11%) when present at < 20% of the 
total mixture. Interestingly, this case had the highest percentage of 
tumor cells on the whole series (90%).
The TheraScreen kit was able to detect the presence of a mutant at 
1% of the total DNA in 5 cases (55%). The only two samples that 
were not identified at the 5% dilution had a percentage of tumor cells 
below 40%.
Conclusions: The TheraScreen assay is more sensitive than sequen-
cing for detecting EGFR mutations. This assay offers ease of scoring 
and gives a very rapid result (<1 week). Nonetheless, pathology 
assessment is essential before DNA extraction to ensure optimal 
sensitivity, and macrodissection is strongly recommended.
In summary, the TheraScreen EGFR29 kit is a robust method for 
the screening of EGFR mutations in lung cancer patients. From a 
practical standpoint it appears to be an attractive alternative to direct 
sequencing for mutation analysis. 
Acknowledgment: This work is partially funded by Fundación 
Mutua Madrileña.
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Transactivation of HER2 by phosphorylated HER3 and 
EGFR correlates with clinicopathological end points in 
HER2 negative NSCLC
Mohan, Kamlesh1; Dodson, Andrew2; Gosney, John2; Carr, Martin1; 
Thomas, Andrew3; Womack, Chris3; Jenkins, Martin3; McGuire, Joe1; 
Walshaw, Martin1; Armour, Alison3
1 The Liverpool Heart and Chest Hospital, Liverpool, UK; 2 Royal 
Liverpool University Hospital, Liverpool, UK; 3 Astra Zeneca, 
Macclesfield, UK
Introduction: Contrary to preclinical studies, trastuzumab (directed 
against the extracellular domain of the receptor) treatment based on 
HER2 receptor expression and gene amplification failed to demon-
strate clinical benefit in non small cell lung cancer (NSCLC). It is 
well known that HER2 activation results from receptor overexpres-
sion (secondary to gene amplification) or heterodimerization with 
other ErbB members. In a prospective study, using formalin fixed 
tissue samples from resected surgical specimens, we have recently 
shown no evidence of HER2 receptor overexpression (Hercep test) 
or gene amplification in 104 patients undergoing attempted curative 
resection for NSCLC. However the role of phosphorylated HER2 
(pHER2) as a dimerisation partner has not been investigated before 
in NSCLC. We therefore investigated the expression of pHER2 at 
two sites (Tyr 1248, Tyr 1221/1222) and its correlation with pHER3, 
pEGFR, and clinicopathological (18 F-FDG PET scan and Ki-67) 
endpoints.
Methods: Tissue samples were collected from lung resection speci-
mens using standard operating procedures, specifically designed to 
minimise cold ischaemia times in order to preserve protein phos-
phorylation status. IHC staining using technically validated methods 
was undertaken, following which analysis of markers were performed 
on formalin fixed paraffin wax embedded tissue micro array lung 
samples from the same study population (N = 104, mean age 70 years 
[range 46-84], 100 [96%] smokers, and 55 [53%] male) with NSCLC 
(60 [58%] adenocarcinoma, 41 [39%] squamous cell carcinoma, 2 
[2%] bronchioalveolar carcinoma and 1 [1%] mixed; 35 [34%] stage 
1A, 42 [40%] 1B, 2 [2%] 2A, 16 [15%] 2B and 9 [9%] stage 3A). 
As there are no well-defined scoring methods or cut off points to 
evaluate phosphorylated receptor expression, we used the H scoring 
method (the percentage of positive tumour cells multiplied by the 
membrane staining intensity on a 4 point scale) and dichotomised the 
data to positive or negative expression based on the median values of 
expression. Ki 67 was scored semi quantitatively by determining the 
percentage of positive nuclear staining. 
Results: pHER2 (Tyr 1221/1222) expression, above a H-score of 15, 
was seen in 51 % (53/104) of patients with HER2 negative NSCLC. 
None of the tumours showed expression with pHER2 at site Tyr 
1248 (cytoplasmic staining in the absence of membrane staining was 
considered negative). We found pHER2 (1221/1222) expression cor-
related strongly with pHER3 (p <0.001) and pEGFR (p<0.001). Only 
5 patients (9%) with pHER2 showed no co expression with other 
pErbB members. pHER2 alone and in combination with pHER3 and 
pEGFR showed significant correlation with PET SUV (p<0.05) and 
Ki67 (p<0.05). Data on relapse and survival is ongoing and will be 
reported at a future date.
Conclusions: This is the first study to investigate the role of pHER2 
at Tyr site 1221/1222. Our results show that pHER2 expression oc-
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curs in many patients with HER2 negative NSCLC and may represent 
a heterodimerization marker of the receptor. This could be used as 
a new therapeutic target and a predictor of response to future anti 
HER2 therapy in various cancers. 
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A prospective study of CYFRA 21-1 (C21) in 750 patients 
(pts) with advanced non-small-cell lung cancer (NSCLC); 
a useful tool to detect early chemotherapeutic (CT) failures 
and take therapeutic decisions
Barradas, Pedro; Melo, Maria Jose; Costa, Agostinho; Cristovao, 
Margarida; Alves, Paula; Fragoso, Ana
Hospital Pulido Valente, Lisboa, Portugal
Objectives: Our aims were to test the prognostic implications of both 
the pre-treatment level and change in serum C21 after two cycles of 
CT in 750 NSCLC pts with advanced disease and to compare these 
variables with clinical stage and OOR. As second objective we also 
tried to verify the importance of an earlier 2nd line CT change based 
on the absence of marker response on overall survival.
Patients and Methods: Our pts consisted of 750 advanced NSCLC 
submitted to CT. Samples were collected before CT and before 2nd 
cycle and C21 levels were measured by immunoradiometric ELSA-
CYFRA 21-1 kit. We express changes in C21 in terms of ratio and 
natural logarithm ratio of pos-treatment to pre-treatment C21. 
Results: C21 baseline values were strongly related with survival 
(p<.000001); C21 baseline levels along with PS were, in a multivari-
ate analysis including 26 prognostic factors, the strongest prognostic 
factors to survival. Clinical stage is not a significant factor on this 
analysis and OOR is just slightly significant (p=.041). C21 decline ≥ 
30% (or log 2/1 <=-.0175) after 2nd cycle was strongly related with 
non-progression (NP), defined as the sum of objective response (OR) 
+ stable disease (p=.00011) and survival (p<.00001). When a hazard 
survival (HS) was used, including baseline C21 and % change after 
two cycles, the survival differences strongly expands (p<.0000001). 
Although numbers are small (116 pts), it seems also that an early 
change in therapy after marker response failure, produces a signifi-
cant survival gain when compared with a delayed 2nd line treatment 
(p=.0023).
Conclusions: In advanced NSCLC, the initial level of C21 provides 
more prognostic information than clinical stage. Furthermore drops 
≥30% after 2nd cycle of chemotherapy adds more prognostic and ear-
lier information than ORR. A HS, using both pre-treatment and post-
treatment values of C21, provide additional prognostic information 
and may be a very useful tool to decide whether to continue the same 
chemotherapy treatment, to make an early change or to stop therapy. 
P3.113 Prognostic and Predictive Markers, Mon Aug 3 – Tue Aug 4 
Prognostic factors in stage IV NSCLC: A RPA method to 
help therapeutic strategies
Barradas, Pedro; Melo, Maria Jose; Cristovao, Margarida; Costa, 
Agostinho; Alves, Paula
Hospital Pulido Valente, Lisboa, Portugal
Objectives: To evaluate the importance of some pre-therapeutic and 
early post-therapeutic prognostic factors in the survival of stage IV 
NSCL patients (pts) submitted to chemotherapy(CT)
Patients and Methods: Our population included 513 stage IV 
NSCLC chemo-naïve pts submitted to CT over a decade (98-07). 
Twenty-six clinical and biological potential prognostic factors were 
included in a univariate analysis and those with significance were 
retained for multivariate analysis. Using a RPA method, a regression 
tree was built (the entire group is partitioned into 2 sub-groups ac-
cordingly to the variable, determined by Cox’s multivariate analysis, 
that produces the most significant survival difference and the process 
is stopped when no variable produces a further significant difference 
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in survival. An amalgamation process combines then these terminal 
sub-groups of pts whose survival does not differ from each other by a 
log-rank test, producing the final sub-groups. 
Results: Sex, performance status (PS), weigh loss > 10%, multiple 
liver and metastasis, baseline values of hemoglobin, LDH, CEA and 
Cyfra 21-1 (C21) were in a univariate analysis the pre-treatment 
factors with prognostic importance. After a multivariate analysis only 
C21, PS and multiple liver and brain metastasis retained signifi-
cance. Using a RPA method 3 sub-groups with significantly different 
survival potentials were defined. Among them, patients with normal 
baseline C21, PS=0 and no multiple liver metastasis were found to 
obtain the most favorable survival results (MS – 16.9 months; 2-year 
survival rate 18.9%) whereas survival of pts with higher baseline C21 
values, PS=2 and liver or brain metastasis was extremely short (MS 
3.9 months and 2-year survival rate 0%). In 363 pts we were able to 
measure C21 after 2 cycles of CT. A drop of 30% in C21 was the only 
significant independent early post-therapeutic prognostic factor. A 
survival tree including also HS (baseline C21 + %drop in C21 after 
2nd cycle) was then built and we were able to identify 5 subgroups 
with even more pronounced different survival prognosis. (very poor 
33 pts – MS 2.9 months 2-year 0%, poor 50 pts – MS – 5.4 months 
2-year 1.3%, intermediate 188 pts – MS 8.4 mo 2-year 3.1%, good 
61 pts – MS 14.6 mo 2-year 19.8% and very good 31 pts – MS – 23.2 
mo 2-year 48.2%) 
Conclusions: As survival in stage IV NSCLC pts is short (median 
survival in this study – 8 months) quality of life is of great import-
ance. The results of our study suggest that some important prognostic 
factors are not only useful for predicting survival but permit the 
building of a regression-tree that makes possible to decide an initial 
more or less aggressive chemotherapeutic option. An early readjust-
ment after two cycles of CT based on C21 response permits a more 
accurate subdivision and consequently more appropriate therapeutic 
choice. 
P3.114 Prognostic and Predictive Markers, Mon Aug 3 
Treatment with motesanib or bevacizumab results 
in differential changes in levels of several serum 
proteins including placental growth factor (PlGF) and 
soluble kinase domain receptor (sKDR): results from 
a randomized, open-label, phase 2 study of motesanib 
or bevacizumab with paclitaxel and carboplatin (p/c) 
for advanced nonsquamous non-small cell lung cancer 
(NSCLC)
Bass, Michael B.1; Hamic, Kim2; Khoo, Mei2; Kivman, Lisa2; Davis, 
Michael2; Blumenschein, Jr, George3; Schwartzberg, Lee4; Sikorski, 
Robert5; Hei, Yong-jiang5
1 Computational Biology, Amgen Inc., Thousand Oaks, CA, USA; 2 
Molecular Sciences, Amgen Inc., Thousand Oaks, CA, USA; 3 M.D. 
Anderson Cancer Center, Houston, TX, USA; 4 The West Clinic, 
Memphis, TN, USA; 5 Oncology Development, Amgen Inc., Thousand 
Oaks, CA, USA
Background: Motesanib is a potent inhibitor of vascular endothelial 
growth factor receptors (VEGFR) 1, 2, and 3; platelet-derived growth 
factor receptor, and Kit that is under investigation for its antiangio-
genic and antitumor properties. In the motesanib first-in-human study, 
PlGF was found to increase within one day of initiation of treatment, 
whereas serum KDR was found to be a more slowly responding 
biomarker (Rosen et al, J Clin Oncol 2007;25:2369). An explora-
tory analysis of the effects of motesanib on a panel of proangiogenic 
cytokines was performed in patients with NSCLC.
Methods: Patients with advanced NSCLC were randomized (1:1:1) 
to receive P/C every three weeks (Q3W) plus motesanib at either 125 
mg once daily (QD) (Arm A) or 75 mg twice daily (BID) for 5 days 
followed by a 2-day treatment-free period (BID-5/2) (Arm B); or 
bevacizumab at 15 mg/kg Q3W (Arm C). Serum samples were col-
lected predose on day 1 of cycles 1, 2, 3 and on day 1 of every second 
cycle thereafter. Samples were analyzed utilizing the Meso Scale 
Discovery® (MSD) multiplexed sandwich immunoassay technique 
using electrochemiluminescent (ECL) detection. Separate assays 
were performed to detect human soluble VEGFR-1 (sFlt-1), PlGF, 
and VEGF (3-plex) and human c-Kit and soluble VEGFR-2 (sKDR) 
(2-plex). No adjustments have been made for multiple comparisons; 
P-values are considered to be descriptive.
Results: Treatment with motesanib 125 mg QD and 75 mg BID-5/2 
were associated with an increase from baseline in levels of PlGF by 
2.5-fold (P < 0.0001)and 1.3-fold (P = 0.002), respectively, by week 
4 of treatment. Bevacizumab administration led to a 1.4-fold increase 
(P = 0.0002) in PlGF over the same time period. The difference in 
changes between Arms A and B could be due to the interrupted dos-
ing in Arm B or the lower overall area under the concentration-time 
curve (AUC) of motesanib in the blood. Levels of sKDR decreased 
from baseline 1.4-fold at 4 weeks in Arms A and B (P < 0.0001), but 
increased only slightly in patients receiving bevacizumab (P = 0.008). 
Neither dosing regimen of motesanib caused a significant change 
from baseline in sFlt-1; however, bevacizumab induced a decrease 
in sFlt-1 of 2.3-fold. Serum cKit levels decreased from baseline by 
1.2-fold after 13 weeks of both dosing regimens of motesanib (P < 
0.004), whereas bevacizumab therapy resulted in a 1.2-fold increase 
(P = 0.0009) in cKit. No significant change was observed in VEGF 
with any treatment in this study.
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Conclusions: Treatment with motesanib was associated with signifi-
cant changes in a number of proangiogenic cytokines and receptors. 
These changes provide evidence for different mechanisms of action 
between the antiangiogenic compounds bevacizumab and motesanib. 
Further research is warranted to understand the biological implica-
tions of these differences.
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Peripheral blood Ercc1 gene expression level in non-
small cell lung cancer patients treated with cisplatin 
chemotherapy
Schena, Marina1; Buffoni, Lucio1; Consito, Lorena1; Cristiano, 
Carmen1; Pivetta, Emanuele2; Dongiovanni, Diego1; Barone, Carla 1; 
Grillo, Raffaella1; Gaspari, Fabio1; Salvadori, Angelica1; Ciuffreda, 
Libero1
1 MEDICAL ONCOLOGY S. Giovanni Battista Hospital, Turin, Italy; 
2 Unit of Cancer Epidemiology CPO Piedmont AOU S. Giovanni 
Battista, Turin, Italy
Background: Excision repair cross-complementation group 1 
(ERCC1) overexpression is a potential negative predictive marker in 
non small-cell lung cancer (NSCLC) patients treated with cisplatin-
based chemotherapy. Intratumoral ERCC1 levels is usually detected 
from paraffin-embedded tumor specimens or fresh tumor specimen 
by real time reverse transcriptase polymerase chain reaction (RT-
PCR) or immunocitochemistry. However the availability of tumor tis-
sue is limited in most patients and the development of a more feasible 
evaluation is warranted. 
Methods: From September 2007 to December 2008 44 NSCLC pa-
tients were enrolled; median age was 64 (range 52-72), male/female 
33/11; PS was 0/1 in 26 (59%) and 18 (41%) of patients respectively; 
24 patients were stage III, 20 stage IV; squamous cell carcinoma 
were 11 (25%), non-squamous cell carcinoma 33 (75%). 25 patients 
(57%) received cisplatin 80 mg/m2 day 1 and gemcitabine 1250 mg/
m2 day 1 and 8 q21 while 19 (43%) received cisplatin 75 mg/m2 and 
docetaxel 75 mg/m2 day 1 q21; three to six cycles were administrated 
as first line treatment. A peripheral blood sample was collected before 
chemotherapy, after informed consent. Using RT-PCR we determined 
ERCC1 mRNA levels in peripheral blood cells samples. Response 
rate was assessed after three and six cycles.
Results: We observed 21 (48%) partial response (PR) to chemother-
apy, 16 (36%) stable disease (SD) and 7 (16%) progressive disease 
(PD). ERCC1 expression was detectable in 43/44 cases. Mean 
ERCC1 expression was 0,16 in responsive patients (PR) and 0,27 in 
unresponsive patients (SD+PD) and this difference shows a trend to 
statistical significance (p=0,07). Patients were grouped by the median 
of gene expression in a low-espression (LE) and in a high espression 
(HE) group (24 and 19 patients respectively). In the LE group we ob-
served 15 (62%) PR and 9 (38%) SD+PD, while 6 (32%) PR and 13 
(68%) SD+PD occurred in the HE group with a trend to statistically 
significant difference (p=0,06). No significant difference in ERCC1 
levels was present by gender, performance status, tumor stage and 
histotype.
Conclusions: ERCC1 analysis from peripheral blood is feasible and 
could be easily implemented in clinical practice. Our datas suggest 
that peripheral blood ERCC1 expression may predict response to 
platinum based chemotherapy in NSCLC but a greater number of 
patients observed is necessary in order to confirm these results. 
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Roles of natural killer-cell Immunoglobulin-like receptors 
(KIR) in immune escape and cancer metastasis
Chan, Daniel C.1; Zheng, Di2; Zhang, Zhiyong2; Sui, Xiaomei2; Chan, 
Tiffany T.2; Sugita, Michio3; Bunn, Jr, Paul A.3
1 University of Colorado Cancer Center, Aurora, CO, USA; 2 
University of Colorado Boulder, Boulder, CO, USA; 3 University of 
Colorado Denver, Aurora, CO, USA
Background: The aim of this study is to investigate the mechanism 
of immune-escape and cancer metastasis through an aberrant expres-
sion of the natural killer (NK) cell immunoglobulin-like receptors 
(KIRs) on human lung cancer cells. The concept of immuno-editing 
suggests that the immune system not only protects the host against 
development of primary nonviral cancer but also sculpts tumor 
immunogenicity for increasingly aggressive growth and further 
resistance to immune destruction as they progress. In this report, we 
provide evidence supporting and expanding the concept of immuno-
editing and immune escape leading to the development of metastases.
Methods: Human lung cancer cell line H2122 adenocarcinoma was 
tagged with green fluorescent protein (GFP) and in vivo imaging 
was used to track metastasis in an orthotopic lung cancer model 
in athymic nude rats. Primary tumors and distant metastases were 
aseptically isolated and grew in tissue culture. RNAs were extracted 
for gene expression profiling using Affymetrix Hu-133 plus 2 and 
were analyzed with the GeneSpring. Expression of KIR proteins was 
verified with antibodies using flow cytometry and by ihc in human 
tissue microarray consisting of advanced lung tumors and lymph 
node metastases. 
Results: We have detected that a whole family of human KIR recep-
tors were aberrantly expressed on the surface of H2122 cancer cells 
after orthotopic implantation in nude rats. KIR expression levels 
increase progressively in metastases in direct relationship to their dis-
tance from the primary tumor, and correlates strongly with aggressive 
and metastatic behavior. In contrast, KIR was very low or not detect-
able in the parental lung cancer cell line in vitro. Interestingly, except 
for KIR genes, other NK cell markers were barely detectable, and 
they failed to change progressively from primary to metastatic cancer 
cells. KIR expression was also up-regulated in metastases isolated 
from other non-small cell lung cancer cell lines A549 and H157 after 
implanted orthotopically in the lungs of nude rats or in metastases 
from Mia-PaCa pancreatic tumor after implanted orthotopically in 
the pancreas of nude mice. Using anti-proliferative assays, we have 
demonstrated that metastatic cancer cells with high KIR expression 
levels are more resistant than parental cells to cytolytic killing by hu-
man or rodent NK cells in vitro. Furthermore, continuous co-culture 
of parental lung cancer cells with cytolytic human or rodent NK cells 
results in the selection of resistant cancer cell subpopulations with 
significantly elevated expression of surface KIRs that are immuno-re-
sistant. Finally, we demonstrated by ihc strong positive KIR staining 
on human lung cancer cells in human tissue microarray consisting of 
advanced human lung tumors with lymph node metastases.
Conclusions: We conclude that exposure of human cancer cells to 
NK cells either in vitro or in vivo results in the selection of immuno-
resistant cancers due to elevated expressions of KIR on their surfaces. 
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We hypothesize that cancer metastases with elevated KIR expression 
levels acquire features that can fool the immune system into thinking 
of the cancer as “self” that allows them to escape immuno-surveil-
lance and metastasize to distant organs. 
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Colocalization of AP-2β with hTERT suggests AP-2β is a 
novel tumor marker in NSCLC
Chen, Ying; Kim, Min P.; Khanna, Abha; Chen, Jie Qing; Fernandez, 
Ricardo L.; Zaidi, Tanweer M.; Zhang, Hua-Zhong; Bekele, B 
Nebiyou; Caraway, Nancy P.; Ji, Lin; Roth, Jack; Katz, Ruth L.
M. D. Anderson Cancer Center, Houston, TX, USA
Background: Activating enhancer-binding protein-2β (AP-2β) was 
recently identified as a cancer-specific activator of telomerase. We 
determined the expression level and expression pattern of AP-2β 
and human telomerase reverse transcriptase (hTERT) in NSCLC 
and correlated these with biomarkers associated with prognosis and 
differentiation, namely a proliferation indicator (Ki67), expression of 
epidermal growth factor receptor (EGFR), thyroid transcription fac-
tor-1 (TTF1) and surfactant protein A.
Methods: A total of 224 tumor samples of patients (116 male; 108 
female) who underwent lung cancer resection from 2002 to 2008 
were included in the study (mean age: 66 years; 64 squamous cell 
carcinomas, 134 adenocarcinomas, 8 adenosquamous carcinoma, 5 
neuroendocrine cancer, 2 pleomorphic cancer, 1 sarcomatoid cancer 
and 10 NSCLC not otherwise specified; stage: I: 145, II: 34, III: 33, 
IV: 12). Immunohistochemistry (IHC) for Ap-2β, hTERT, Ki67, 
EGFR,TTF1 and surfactant protein A was performed on tissue micro-
array slides; results were reported as “IHC score” = intensity of the 
signal (1-4) ×percentage of stained tumor cells. 
Results: AP-2β and hTERT were expressed predominantly in nuclei 
of tumor cells. We found two distinct expression patterns: (1) diffuse 
pattern (DNS, diffuse nuclear staining without evidence of nucleolar) 
and (2) nucleolar pattern (NP, nucleolar staining with or without 
diffuse nuclear staining). There were a higher number of cases with 
AP-2β NP (n = 165) compared to AP-2β DNS (n = 53). hTERT also 
showed a higher number of cases with NP (n = 119) compared to 
DNS (n = 51). AP-2β IHC score had a significant correlation with 
hTERT IHC score (p = 0.016). However, it had no correlation with 
TTF1 IHC score and an insignificant correlation with surfactant pro-
tein A IHC score (p = 0.53), EGFR IHC score (p = 0.052) and Ki67 
IHC score (p=0.12).
AP-2β DNS correlated with hTERT DNS whereas AP-2β NP correl-
ated with hTERT NP (p<0.001). TTF1 and surfactant protein A IHC 
scores were significantly higher in patients with AP-2β DNS com-
pared to patients with AP-2β NP (p = 0.01, p=0.016). Ki67 IHC score 
was lower in patients with AP-2β DNS compared to patients with 
AP-2β NP (p = 0.052). There no relationship between AP-2β pattern 
and EGFR IHC score (p = 0.499).
Conclusions: AP-2β is significantly associated with hTERT in 
NSCLS in both location and expression. This suggests that AP-2β 
plays a major role in regulating the expression of hTERT and hence 
in tumorigenesis in NSCLS. We also showed that the AP-2β DNS 
expression pattern correlated with higher levels of TTF1 and surfact-
ant protein A and lower levels of Ki67. Higher levels of TTF1 and 
surfactant protein A are associated with favorable survival and lower 
levels of Ki67 indicate less proliferation. Overall these findings sup-
port the role of AP-2β as a novel tumor marker and the potential use 
of the expression pattern as an indicator for the aggressiveness of the 
tumor. 
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Effect of genetic polymorphisms on survival and toxicity 
in advanced non-small cell lung cancer (NSCLC) patients 
(pts) treated with Carboplatin (CBDCA) and Alimta 
regimen
Ludovini, Vienna1; Chiari, Rita1; Pistola, Lorenza 1; Floriani, Irene2; 
Meacci, Marialuisa1; Minotti, Vincenzo1; Garavaglia, Daniela2; 
Tofanetti, Francesca R.1; Flacco, Antonella1; Mare, Marzia3; 
Giuffrida, Dario3; Crinò, Lucio1
1 Department of Medical Oncology, S Maria della Misericordia 
Hospital, Perugia, Italy; 2 Oncology Department, Ist. di Ricerche 
Farmacologiche M.Negri, Milan, Italy; 3 Medical Oncology, Istituto 
Oncologico del Mediterraneo, Catania, Italy
Background: Identification of genetic polymorphisms which influ-
ence chemotherapy outcome may help towards individually opti-
mized therapy. We investigated the influence of ten single nucleotide 
polymorphisms (SNPs) of 7 genes (P53 Arg72Pro (G/C); XRCC3 
Thr241Met (C/T); XPD Lys751Gln (A/C); ERCC1 Asn118Asn 
(C/T); GARFT C/G, GARFT C/T, DHFR C/G, DHFR A/G, TS 
5’UTR, TS 3’UTR involved with metabolism of CBDCA and Alimta 
regimen in pts with advanced NSCLC. 
Methods: Genomic DNA was extracted from whole blood samples 
using the QIAamp DNA estraction kit on Biorobot EZ1 (Qiagen). 
Polymorphisms were detected with TaqMan-probe based assays using 
the 7300 Real-Time PCR system (Applied Biosystems, Foster City, 
CA) or PCR followed by RFLP. The results of SNPs were assessed 
by Cox model for survival/PFS & logistics regression for response/
toxicity. 
Results: We performed a retrospective analysis in 57 advanced 
NSCLC pts treated with CBDCA(AUC=5) + Alimta (500 mg/
m2) after failure of two or three lines of chemotherapy. Median 
age was 59 years (range 26-79), M/F:63/37%; Adeno/Squa/other 
Ca:65/20/15%; ECOG PS:0-1/2-3:96/4%. Overall response rate was 
38.6%, stable disease 38.6% and disease progression 21.1%. At medi-
an follow-up of 7.9 months, 10 pts (17.5%) died, 47 pts (82.5%) are 
alive. The median progression free survival (PFS) was 7.4 months, 
the median survival time not reached. P53 Pro72Pro was significantly 
associated with shorter survival (HR 5.5, 95%CI 1.01-30.5, p=0.04) 
when compared to P53 Arg72Arg and P53 Arg72Pro. None of the 
analyzed polymorphisms was related to response to therapy. No 
associations were found between the analyzed polymorphisms and 
toxicity considered either as the maximum observed grade, or as sum 
of each toxicity pattern grade, probably due to low number of events 
observed for toxicity within this data set. 
Conclusions: P53 Pro72Pro may be associated with shorter survival 
in pts with advanced NSCLC. Further studies are warranted to valid-
ate this finding. Genotype-related differences in common toxicities 
and in response to therapy were not observed. The small sample size 
limits interpretation of these data. 
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P3.119 Prognostic and Predictive Markers, Mon Aug 3 – Tue Aug 4 
Polymorphisms in the FAS and FASL genes and survival of 
early stage non-small cell lung cancer
Choi, Jin Eun2; Lee, Shin Yup1; Yoo, Seung Soo1; Lee, Eung Bae4; 
Park, Tae In5; Cha, Sung Ick5; Kim, Chang Ho5; Jung, Tae Hoon5; 
Jheon, Sanghoon3; Park, Jae Yong1
1 Departement of Internal Medicine, Kyungpook National University 
Hospital, Daegu, Korea; 2 Department of Biochemistry, School 
of Medicine, Kyungpook National University, Daegu, Korea; 
3 Department of Thoracic and Cardiovascular Surgery, Seoul 
National University School of Medicine, Seoul, Korea; 4 Department 
of Thoracic Surgery, School of Medicine, Kyungpook National 
University, Daegu, Korea; 5 Department of Pathology, School of 
Medicine, Kyungpook National University, Daegu, Korea
Purpose: This study was conducted to investigate the impact of 
functional polymorphisms in the FAS and FASL genes on the survival 
of early stage non-small cell lung cancer (NSCLC) patients.
Experimental Design: Three hundred and thirty-eight consecu-
tive patients with surgically resected NSCLC were enrolled. The 
FAS -1377G>A (rs2234767) and -670A>G (rs1800682) and FASL 
-844C>T (rs763110) polymorphisms were investigated. Immuno-
histochemistry was used to assess FAS protein expression in tumors. 
The genotype and haplotype associations with survival were analyzed 
using Cox proportional hazards model, Kaplan-Meier method and the 
log-rank test. 
Results: Patients with the GG and combined AG + GG genotypes of 
the FAS -670A>G locus had a significantly decreased survival when 
compared to patients with the AA genotype [adjusted HR (aHR) = 
1.71, 95% confidence interval (CI) = 1.06-2.77, P = 0.03; and aHR 
= 1.48, 95% CI = 1.01-2.20, P = 0.047, respectively]. In addition, 
the FAS -1377G/-670G and -1377A/-670G haplotypes exhibited 
a significantly lower survival compared with the -1377G/-670A 
haplotype (aHR = 1.87, 95% CI = 1.20-2.91, P = 0.006; and aHR = 
1.31, 95% CI = 1.05-1.65, P = 0.02, respectively). Strongly positive 
FAS immunostaining was significantly less frequent in patients with 
the FAS -670 AG + GG genotype than in patients with the -670 AA 
genotype (4.5% vs 10.8%, P = 0.04). 
Conclusion: The FAS -670A>G polymorphism may affect survival in 
early-stage NSCLC. The analysis of the FAS -670A>G polymorphism 
can help identify patients at high risk of a poor disease outcome.
P3.120 Prognostic and Predictive Markers, Mon Aug 3 – Tue Aug 4 
Expression of VEGF and Ki67 in non-small cell lung 
carcinoma and their correlation with clinic significance
Cui, Youbin; Fu, Xianming; Cui, Yu; Chen, Yulong; Wang, Yongxin; 
Liu, Guojin; Deslauriers, Jean 
First Hospital of Jilin University, Changchun, China
Background: Vascular endothelial growth factor VEGF is considered 
the most important angiogenic factors in the induction factors of 
tumor angiogenesis and Ki67 is currently the most representative 
indicator of tumor cell proliferation and activity. The purpose of this 
study was to investigate expression of VEGF and Ki67 in NSCLC 
and the correlation with clinical significances.
Methods: We immunohistochemically examined 118 specimens of 
surgically resected NSCLC to evaluate the expression of the biologic-
al markers Ki-67,and vascular endothelial growth factor (VEGF).
The survival curves were plated using the method of Kaplan-Meier. 
The relationship between two markers,clinical characteristic date and 
prognostic significance was evaluated.
Results:
1. The expression of VEGF and Ki67 had correlation with clinical 
TNM stage and the metastasis of lymph nodes (P<0.05). The 
positive expression rates of the two markers in NSCLC with 
metastasis of lymph nodes were higher than that without metas-
tasis and positive expression of VEGF and Ki67 with III stages 
were higher that with I~II stages(P<0.05) but didn’t correlate to 
age,sex, and pathological type (P>0.05).
2. Survival analysis showed that the two markers correlated poor 
survival (P<0.05). 
Conclusion: VEGF and Ki67 have correlation with clinical stages 
and the metastasis of lymph nodes in NSCLC and indicate an un-
favorable prognosis 
P3.121 Prognostic and Predictive Markers, Mon Aug 3 – Tue Aug 4 
Potential diagnostic and prognostic role of serum levels 
of cytokeratin 18, in both its intact and caspase-cleaved 
forms, in patients with NSCLC
De Petris, Luigi1; Branden, Eva2; Pernemalm, Maria1; Koyi, Hirsh2; 
Herrmann, Richard3; Lewensohn, Rolf1; Linder, Stig4; Lehtiö, Janne1
1 Karolinska Biomics Center, Karolinska Institutet, Stockholm, 
Sweden; 2 Dpt Pulmonary Medicine and Allergy, Karolinska 
University Hospital Solna, Stockholm, Sweden; 3 Peviva AB, 
Stockholm, Sweden; 4 Dpt Oncology and Pathology, Karolinska 
Institutet, Stockholm, Sweden
Background: Serum level of uncleaved cytokeratin-18, a marker of 
carcinoma total cell death, and of caspase-cleaved cytokeratin-18, 
an indicator of carcinoma apoptosis, can be measured using sand-
wich ELISA assays (M65® ELISA and M30-Apoptosense® ELISA, 
respectively). We aimed to explore the potential of baseline serum 
levels of serum cytokeratins as diagnostic or prognostic markers for 
NSCLC. 
Methods: Using ELISA we measured plasma/serum levels of of total 
cytokeratin-18 (“M65”) and caspase-cleaved cytokeratin-18 (“M30”) 
in 200 healthy blood donors (HBD), in 107 patients with benign lung 
diseases (BLD) and in 180 NSCLC cases. In the latter group, com-
prised of 82 cases with stage I-IIIA and 98 cases with stage IIIB-IV 
NSCLC, blood samples were obtained prior to any treatment. 
Results: The levels of M30 and M65 showed wide ranges of con-
centration in all the three subject groups. M30 and M65 levels were 
similar between the HBD and the BLD groups, but were significantly 
higher in the NSCLC group (t-test p<0.0001). Mean (SD) levels of 
M30 were 55(32) U/L, 44(33) U/L and 78(73) U/L in the HBD, BLD 
and NSCLC groups, respectively. Mean (SD) levels of M65 were 
41(34) U/L, 55(38) U/L and 134(170) U/L in the HBD, BLD and 
NSCLC groups, respectively. In the NSCLC group, mean (SD) M30 
and M65 levels significantly increased with stage, being 64(51) U/L 
and 96(107) in early stage, respectively, and 89(86) U/L and 166(204) 
U/L in advanced stage, respectively. 
Using the HBD group as a reference training set we found that a cut 
off >104 U/L corresponded to 95% specificity for both the M30 and 
M65 analyses. Using the BLD and NSCLC groups as test set, the cut 
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off of 104 U/L maintained an excellent specificity (>90% for both 
M30 and M65) but at a disappointing low sensitivity (18% for M30 
and 35% for M65). 
We finally explored the possible prognostic role of plasma levels 
of M30 and M65 in 57 patients with advanced NSCLC for whom 
survival data was available. Of these, 42 cases received first-line 
chemotherapy, while 15 cases received only palliative radiother-
apy or best supportive care. M65, but not M30, showed prognostic 
implications in this group of patients. Dichotomized at the cut off of 
104 U/L, patients with M65 <cut off (n=30) had a significant shorter 
median survival time compared to patients with M65 levels >cut off 
(n=27) (5 months vs 11 months, log-rank p=0.0001). In the multivari-
ate analysis model that included also patient age, smoking status, 
stage (IIIB vs IV) and chemotherapy (yes vs no), M65 (>104 U/L vs 
<104 U/L) maintained its negative prognostic impact (HR 1.67, 95% 
CI 1.24-2.28; p=0.0007). 
Conclusions: Our results suggest that intact or caspase-cleaved 
cytokeratin18 cannot be used as accurate biomarkers of NSCLC. 
Nevertheless, intact cytokeratin 18 (M65) shows promising poten-
tials as a prognostic marker in patients with advanced stage NSCLC, 
independently on the therapeutical intervention. 
P3.122 Prognostic and Predictive Markers, Mon Aug 3 – Tue Aug 4 
Circulating plasma DNA in non-small cell lung cancer 
patients is not influenced by inflammatory pulmonary 
conditions
van der Drift, M.A.1; Hol, Bernard E.A.2, 3; Klaassen, Corne H.W.2; 
Prinsen, Clemens F.M.2; Aarssen, Yvonne A.W.G. v.2; Dekhuijzen, 
P.N.Richard1; van der Stappen, Jos W.J.2; Thunnissen, Frederik 
B.J.M.2
1 Radboud University Nijmegen Medical Centre, Nijmegen, 
Netherlands; 2 Canisius-Wilhelmina Hospital, Nijmegen, 
Netherlands; 3 Albert Schweitzer Hospital, Dordrecht, Netherlands
Aim of the study: Free or circulating DNA in plasma of non-small 
cell lung cancer (NSCLC) patients is under investigation as a diag-
nostic or prognostic biomarker. Elevated concentrations of circulating 
DNA may arise from lytic cells in cancer, inflammatory and other 
damaging processes from most organ sites of the body. In a previous 
study we found that the amount of free DNA in sputum was related to 
the amount of inflammatory cells1. The aim of this study was to ana-
lyse if inflammatory pulmonary conditions like chronic obstructive 
pulmonary disease (COPD) and smoking influence circulating DNA 
concentration in plasma of NSCLC patients.
Patients and Methods: Plasma DNA concentration of 46 NSCLC 
patients was determined by a real-time quantitative polymerase 
chain reaction targeting the human ß-globin gene. Classification of 
COPD in GOLD stages was performed according to the guidelines 
of the Global Initiative for Chronic Obstructive Lung Disease (stages 
GOLD 1 to 4). Smoking status was retrieved from patient files. For 
statistic analysis a nonparametric Mann-Whitney U or Kruskal-Wallis 
test were used. 
Results: For the 46 patients the mean FEV1 (forced expiratory 
volume in one second) (% predicted) was 70.7% (range 36.2 – 112.4) 
and 65% of the patients had COPD. The median DNA concentration 
according to pulmonary function and smoking is presented in Table 
1. Neither GOLD stage nor smoking were related to the circulating 
DNA concentration (p = 0.83 and p = 0.85, respectively). 
Conclusion: The circulating plasma DNA concentration in NSCLC 
patients is not influenced by frequently occurring pulmonary inflam-
matory conditions.
1 van der Drift MA et a. Lung Cancer 2008;61:385-390
 Clinical % (no.) DNA ng/ml p-value 
 characteristics  (interquartile range)
 Overall (46) 52 (64) 
 COPD   0.83
  absent 35 (16) 53 (67) 
  GOLD 1 13 (6) 60 (57) 
  GOLD 2 41 (19) 49 (64) 
  GOLD 3 11 (5) 27 (83) 
 Smoking   0.85
  current 65 (30) 52 (72) 
  former 33 (15) 49 (29) 
  never 2 (1) 777 (-) 
P3.123 Prognostic and Predictive Markers, Mon Aug 3 – Tue Aug 4 
Prognostic significance of serum iron, iron-binding 
capacity, ferritin and bronchoalveolar lavage ferritin levels 
in primary lung cancer
Erbaycu, Ahmet E.1; Ucar, Hayriye1; Uslu, Ozgur1; Tuksavul, 
Fevziye1; Kazanci, Melik N.1; Batum, Ozgur1; Kalenci, Dilek2; 
Guclu, Salih Z.1
1 The Department of Chest Diseases, Izmir Dr. Suat Seren Chest 
Disease and Thoracic Surgery Training Hospital, Izmir, Turkey; 2 The 
Department of Biochemistry, Izmir Dr Suat Seren Thoracic Diseases 
and Surgery Training and Research Hospital, Izmir, Turkey
Tumor markers are being investigated in order to predict the progno-
sis of lung cancer (LC). It was aimed to uncover the prognostic value 
of serum parameters, which reflect iron metabolism, and of bron-
choalveolar lavage (BAL) ferritin measurement in LC patients.
The age, gender, tumor cell type, stage of the disease, serum ferritin 
levels at diagnosis, BAL ferritin, serum iron, and serum iron-binding 
capacities (SIBC) of the patients diagnosed with LC were recorded.
A total of 37 (90.2%) male and 4 (9.8%) female patients, with a 
mean age of 60.6 years, were included in the study. Mean follow-
up period was 11.9 months. During this period, 32 patients (78.0%) 
died. Levels of serum iron (p=0.175), SIBC (p=0.577), serum ferritin 
(p=0.426) and BAL ferritin (p=0.073) did not reveal a difference 
regarding tumor cell type.
Although the mean BAL ferritin and SIBC levels of deceased 
patients were not statistically different, their mean serum iron level 
(42.1±28.0) was lower (74.7±26.3) than that of survivors (p=0.003). 
Serum ferritin levels of deceased patients were higher (395.3±437.7), 
and statistically significant compared to survivors (72.9±46.3) 
(p=0.006).
A weak positive correlation (p=0.025, r:0.349) between serum iron 
levels and survival, and a weak negative correlation (p=0.034, r:-
0.332) between serum ferritin levels and survival were detected.
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Although SIBC and BAL ferritin levels at diagnosis are not correlated 
with the survival period in patients with LC, lower serum iron and 
higher ferritin levels are correlated with poor prognosis. 
P3.124 Prognostic and Predictive Markers, Mon Aug 3 – Tue Aug 4 
Prognostic and predictive role of K-RAS and EGFR 
Mutational and FISH analyses in advanced NSCLC 
patients
Favaretto, Adolfo G.1; Bonanno, Laura1; Schiavon, Marco2; Pasello, 
Giulia1; Indraccolo, Stefano3; Bonaldi, Laura3; Bertorelle, Roberta 
3; Nardo, Giorgia3; Galligioni, Alessandra4; Stragliotto, Silvia1; Rea, 
Federico2
1 Istituto Oncologico Veneto Oncologia Medica 2, PADOVA, Italy; 
2 Thoracic Surgery Dept., University of Padua, Padua, Italy; 3 
Immunology and Molecular Diagnostic, Padua, Italy; 4 Pathology 
Dept. Istituto Oncologico Veneto, Padua, Italy
Background: Gefitinib and erlotinib are small-molecule tyrosine 
kinase inhibitors (TKIs), which seem to be more effective in a subset 
of NSCLC patients defined by clinical and molecular features. EGFR 
tyrosine kinase domain mutation and gain of gene copy number have 
been associated with increased response rate to TKIs, whereas effects 
on survival are controversial. The aim of the study was to investigate 
the prognostic and predictive role of these molecular markers in 
advanced NSCLC patients.
Methods: Patients were selected for this study according to the pres-
ence of at least one of these characteristics: non-squamous histol-
ogy, female sex, non-smoker status. Tumor biopsies were analyzed 
from 58 patients who underwent diagnostic or resective surgery for 
advanced NSCLC from May 2005 to December 2008. FISH analysis 
(according to UCCC score system) and PCR-DNA sequencing of 
EGFR exons 18 to 21 and K-RAS codons 12-13 were performed to 
evaluate the presence of EGFR amplification and EGFR and K-RAS 
mutation.
Results: The analysed cohort consists of 29 female and 29 male pa-
tients, 32 never-smokers, 17 former smokers and 9 current smokers. 
Histological subtypes were: 43 adenocarcinoma, 9 adenocarcinoma 
with BAC features and 3 pure BAC, 2 squamous and one adenosqua-
mous carcinoma. Median age was 62 yrs (range 26-81). 46 patients 
had stage IV disease, 12 stage IIIb. Surgical resection was performed 
in 29 patients and 9 of them received preoperative chemotherapy. The 
first-line treatment was chemotherapy for 33 patients, while Erlotinib 
was administered in 4 cases without any previous chemotherapy. 
As second-line treatment, 33 patients received chemotherapy, and 
9 Erlotinib. As third-line treatment 2 patients received TKIs and 4 
chemotherapy.
Mutation analysis was performed in 47 patients and EGFR mutations 
were present in 13 of them (28%). 2 patients carried insertion of exon 
20, that has been associated with TKI resistance. So far 39 biopsies 
were analysed with FISH method, showing increase in gene copy 
number in 17 patients (43%). 7 cases were positive for both analysis.
Both mutations and amplifications showed no significant correla-
tion with survival, although mutational analysis showed a trend in 
increased survival for mutated patients treated with erlotinib [Median 
Survival (MSv) = 99 weeks] vs non-mutated patients not treated 
with erlotinib (MSv = 86 weeks) or mutated patients treated without 
erlotinib (MSv = 30 weeks) (p=0.06).
The group of FISH-positive patients treated with TKIs showed an 
increased survival (MSv = 112 weeks) compared to FISH-negative 
patients not treated with TKI (MSv= 64 weeks), or FISH-positive 
patients not treated with TKIs (MSv= 40 weeks) (p=n.s.).
Mutational analysis of K-RAS was performed in 43 patients with 11 
positive cases (26%). Patients with K-RAS-negative had a MSv of 99 
weeks vs. K-RAS-positive patients (MSV= 47 weeks; p= 0.08).
Conclusion: In a group of patients selected according to clinical fea-
tures, mutational and FISH analyses can identify a subset of patients 
most likely to benefit from TKIs. Even though these data are limited 
by the sample size they are consistent with emerging evidence of a 
role of molecular analysis in the clinical practise.
P3.125 Prognostic and Predictive Markers, Mon Aug 3 – Tue Aug 4 
Feasibility of semiquantitative p53 expression 
determination by immunohistochemical staining in small 
bronchial biopsies
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3 Anatomopathology Department, Hospital São João/ Faculty of 
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P53 tumour suppressor is one of the fundamental mechanisms in-
volved in protecting the integrity of nuclear DNA. Overexpression of 
the p53 protein has been observed in many tumours, including lung 
cancer. The influence of the accumulation of the mutated protein has 
controversial effects on prognosis, with conflicting results between 
studies. P53 has also been associated with resistance to cisplatin-
based chemotherapy in patients with NSCLC.
Aim: This study was conducted to determine the feasibility of 
performing immunohistochemical analysis in small biopsies such as 
those obtained by flexible bronchoscopy. The purpose of this evalua-
tion is to use this marker in prospective studies as prognostic and 
predictive factor to chemotherapy.
Material and Methods: Patients with clinical lung cancer suspicion 
that underwent a flexible bronchoscopy with diagnostic purpose 
were firstly included. All of them signed informed consent. Of 42 
preselected patients only 17 consecutive patients were included 
(those with positive biopsies for lung cancer). Immunochemistry 
staining was performed with a monoclonal antibody against p53 
protein (DO7), positivity was considered if at least 5% of neoplastic 
cells contain reaction product in the nucleus. A scoring system based 
on intensity and percentage of stained cells was applied.
Results: Regarding histological type, 10 were adenocarcinomas, 4 
squamous cell carcinoma, 2 classified as non small cell carcinomas 
NOS and 1 small cell carcinoma. Immunohistochemical staining 
was possible to perform in all patients. In all, except one, different 
degrees of positivity were detected. Among adenocarcinomas, half 
(5) showed ++++ positivity for p53 accumulation, as also 2 of the 
squamous cell carcinomas.
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Conclusion: Most patients with lung cancer need to perform a 
bronchoscopy to achieve lung cancer diagnosis. Small fragments 
obtained through flexible bronchoscopy can provide enough material 
to analyse p53 protein accumulation with a semiquantitative immuno-
histochemical staining. This technique has shown a good feasibility 
and can be included in the routine clinical setting.
P3.126 Prognostic and Predictive Markers, Mon Aug 3 – Tue Aug 4 
Xanthine oxidoreductase as a marker for prognosis and 
chemosensitivity in non-small cell lung cancer (NSCLC)
Myint, Ronald; Batus, Marta; Liptay, Michael J.; Bonomi, Philip; 
Fidler, Mary; Leslie, William T.; Warren, William H.; Faber, L. P.; 
Gattuso, Paolo; Basu, Sanjib; Xu, Xiulong; Kim, Anthony W.
Rush University Medical Center, Chicago, IL, USA
Background: Xanthine oxidoreductase (XOR) is an enzyme in-
volved in both the degradation of purines into uric acid and react-
ive oxygen species and the activation of the MAP kinase pathway 
involved in apoptosis. Decreased XOR expression was shown to be 
associated with more aggressive disease in breast(1) and gastric(2) 
cancers. The goal of our study was to see if there was a relationship 
between XOR expression and prognosis and chemosensitivity in non-
small cell lung cancer.
Methods: Tissue specimens from 82 newly diagnosed patients (pts) 
with NSCLC were stained using a XOR specific antibody. XOR 
staining intensity was measured on a scale of 0 through 4. XOR 
intensity was correlated with clinical characteristics and outcomes 
using log rank and COX PH regression analysis.
Results: Of the 82 pts: 36 male & 46 female, age range from 40 to 92 
years, 25 stage 1, 21 stage 2, 15 stage 3A, 21 stage 3B/4, 41 adeno-
carcinoma, 31 squamous cell, 8 poorly/moderately differentiated, and 
2 bronchioloalveolar. 29 of the 82 pts had low XOR expression (XOR 
intensity 0-1), and 53 pts had high XOR expression (XOR intensity 
2-4). Pts with low XOR had a shorter median survival of 592 days 
(95% CI 492 – 692), compared to 3053 days in the high XOR group 
(95% CI 2190 – 3916, p=0.0089, HR (independent of stage)=0.47). 
Also, of the 82 total pts, 34 (stage 2B and up) received chemotherapy 
(chemo), and of these, 15 pts had low XOR. These 15 pts with low 
XOR expression that received chemo had a shortened median surviv-
al of 543 days compared with the median survival of 2023 days for 
the 19 pts with high XOR that received chemo (p=0.007, HR=0.33).
Conclusions: In this retrospective study, we found that low XOR 
expression was associated with decreased survival in NSCLC. Also, 
we found that pts who received chemo had a longer survival if their 
tumors expressed high levels of XOR. XOR could be a potential 
predictor for responsiveness to chemo. Further studies of XOR in 
NSCLC pts are warranted as pts with low XOR expression may bene-
fit from earlier use of alternative therapies. 
  Number Median survival (days)  Median survival P-value Hazard 
  pts for low XOR(N) for high XOR (Log-rank) ratio
 Total 82 592 (29) 3053 (53) 0.0089 0.47
 Stage 1 25 1867 (7) NA (18) 0.07 0.3
 Stage 2 21 943.5 (6) 2465 (15) 0.53 0.7
 Stage 3A 15 275 (7) 3402 (8) 0.06 0.24
 Stage 3B/4 21 215 (9) 424.5 (12) 0.7 0.82
 Chemo (+) 34 543 (15) 2023 (19) 0.007 0.33
 Chemo (-) 48 1577 (14) NA (34) 0.29 0.58
References:
1.  Linder et al. Down-regulated xanthine oxidoreductase is a feature of aggressive 
breast cancer. Clin Cancer Res 2005; 11:4372-4381.
2.  Linder et al. Decreased xanthine oxidoreductase is a predictor of poor prognosis in 
early-stage gastric cancer. J Clin Pathol 2006; 59:965-971.
P3.127 Prognostic and Predictive Markers, Mon Aug 3 – Tue Aug 4 
Proteomics-based identification of anti-tumor 
autoantibodies in patients with non-small-cell lung cancers
Fujimoto, Minoru1; He, Ping2; Serada, Satoshi1; Iwahori, Kota2; 
Naka, Tetsuji1
1 National Institute of Biomedical Innovation, Osaka, Japan; 2 Osaka 
University, Suita, Japan
Background: Anti-tumor antibodies are found in patients bear-
ing cancers, indicating that immune systems can recognize tumor-
associated self-antigens and elicit immune responses. These immune 
responses, although insufficient to eradicate tumors, often precede the 
manifestation of clinical symptoms, as in the case of paraneoplastic 
symptoms caused by a subset of these antibodies before the detection 
of original tumors. Thus, anti-tumor antibodies are potential markers 
for the diagnosis and also their antigens are possible candidates for 
immunotherapy. To identify novel anti-tumor antibodies in patients 
with non-small-cell lung cancer (NSCLC), we screened antibodies in 
sera of NSLC patients by the usage of proteomic approach. 
Methods: Proteins from NSCLC tumor tissues were separated by 
2-D gel electrophoresis and transferred onto membranes. These mem-
branes were incubated with sera from NSCLC patients and proteins 
recognized by serum antibodies were visualized by HRP-conjugated 
anti-human IgG. To identify these proteins, protein spots were 
harvested and analyzed with mass spectrometry. The reactivity of 
serum antibodies to these proteins were further evaluated by Western 
blotting and ELISA using recombinant proteins.
Results: Initial proteomic screening by the usage of NSCLC sera 
revealed 8 possible autoantigens in NSCLC tissues. Further analysis 
by immunohistochemical staining, Western blotting and ELISA re-
vealed that the expression of alpha-enolase, one of these candidates, 
is increased in NSCLC tissues and antibodies against alpha-enolase 
is highly prevalent in patients with NSCLC (27.7%). In contrast, 
anti-alpha-enolase antibodies were detected only in 1.7% of healthy 
controls and hardly detected in patients with small-cell lung cancer 
and pulmonary mycobacterial infection. In addition, combined meas-
urements of anti-alpha-enolase antibody with CEA and CYFRA 21-1 
improved the detection of NSCLC. 
Conclusions: Our findings indicate that anti-alpha-enolase antibody 
is a novel marker for NSCLC. This study also suggests that proteom-
ics-based analysis is a powerful tool to screen clinical samples and is 
a promising strategy to detect novel markers and/or autoantigens that 
are useful for the diagnosis of lung cancers and the development of 
immunotherapy. 
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Increase of activated/memory and decrease of naive T cells 
with unchanged frequency of regulatory T cells in blood of 
lung cancer patients
Galffy, Gabrieella1; Bartusek, Dora1; Cseh, Aron2; Komlosi, Zsolt1; 
Szarvas, Zsuzsanna1; Horvath, Rita1; Vásárhelyi, Barna2; Losonczy, 
Gyorgy1
1 Departmetn of Pulmonology Semmelweis University, Budapest, 
Hungary; 2 1st Department of Pediatric, Budapest, Hungary
Few data are available on how effector T, NK cells and various regu-
latory subsets like Treg-s (foxp3+), or NK T-s respond to lung cancer 
(LC) or cancer treatment.
Blood was drawn from 28 pts (age 44 to 82, males12, females 16) 
suffering from non-small cell lung cancer (NSCLC, n=22) or small 
cell lung cancer (SCLC, n=6). Since 60% of LC pts also suffered 
from chronic obstructive pulmonary disease (COPD), one control 
group was formed from COPD pts (n=12) and an other one from 
healthy individuals (n=16). Peripheral blood mononuclear cells 
were separated and analysised by FACS using labeled monoclonal 
antibodies. 
Counts of measured cell fractions of COPD pts did not differ sig-
nificantly from healthy individuals and there was also no difference 
between FACS data of NSCLC and SCLC pts. Before treatment, 
LC pts had significantly higher neutrophil (p<0,01), but unchanged 
total lymphocyte (Ly) counts. Within Ly-s, the CD4+CD45RO and 
the CD8+CD45RO subsets – the mature, effector/memory frac-
tions – were more than 50% higher in LC versus healthy individuals 
(p<0.01). At the same time CD4+CD45RA and CD8+CD45RA 
cells – naive, immature subsets – became diminished in cancer pts as 
compared to the healthy group (p<0.01). The frequency of the two 
Treg populations (CD4+foxp3+, CD8+foxp3+) remained unchanged. 
No changes were detected either in the number of NK and NK T 
counts. After cancer treatments, no changes could be observed in any 
of the above Ly. 
LC is a strong stimulus for T cell mediated immune response. Greater 
fraction of effector/memory and smaller fraction of immature T cells 
characterize LC pts both prior to and 6 months after cancer treatment.
P3.129 Prognostic and Predictive Markers, Mon Aug 3 – Tue Aug 4 
Can the epidermal growth factor receptor (EGFR) 
expression predict survival in surgically resected non-small 
cell lung cancer (NSCLC) patients? 
Gately, Kathy A.; Coate, Linda; Cuffe, Sinead; Pidgeon, Graham; 
O’Byrne, Kenneth
St James Hospital, Dublin, Ireland
Background: An increased understanding of the molecular biol-
ogy of EGFR in NSCLC has led to the introduction of novel EGFR 
targeted therapies including EGFR tyrosine kinase inhibitors (TKIs) 
erlotinib and gefitinib and the monoclonal antibody cetuximab. 
Several studies have shown that patients with somatic mutations in 
the EGFR TK domain are more sensitive to treatment with the TKIs. 
Patients with amplified EGFR and EGFR overexpression have also 
been shown to benefit from TKIs. 
Aim of Study: To examine EGFR expression, copy number and 
mutation status in a cohort of 197 patients who underwent resection 
for NSCLC between 2002-2004 in St James’s Hospital prior to the 
introduction of EGFR targeted therapies and to correlate these results 
to patient clinico-pathological data and prognosis.   
Methods: EGFR expression was examined in 197 patients (92 
- squamous, 87 - adenocarcinoma, 18 - other) using immunohisto-
chemistry (IHC) and the results were scored by a pathologist. The 
DNA from the same cohort of patients was examined for mutations in 
exons 19 and 21 of the EGFR tyrosine kinase domain using sequen-
cing analysis. EGFR copy number is being determined by FISH using 
the Vysis probe set.  
Results: 47% of patients had 3+ (strong) levels of EGFR expression, 
29% had 2+ (moderate) expression, 16% had 1+ (weak) expression 
and 6% had no expression. Patients with squamous cell carcin-
oma had higher EGFR expression than those with adenocarcinoma 
(p=0.002). EGFR expression was not-prognostic in this patient series. 
EGFR mutations were identified in 8% of patients being seen pre-
dominantly in adenocarcinomas. All patients with mutations had 2+ 
(moderate) or 3+ (high) levels of EGFR expression. The EGFR gene 
was amplified in 15% of the 70 patients analysed to date and these 
patients also have high levels of EGFR expression. 
Conclusion: EGFR expression levels are high in our population with 
47% (3+) and 29% (2+). 15% of patients had amplified EGFR and 
high levels of EGFR expression. These data indicate that FISH an-
alysis in combination with EGFR expression by IHC would identify 
patients in our population who may benefit from EGFR TKIs. 
P3.130 Prognostic and Predictive Markers, Mon Aug 3 – Tue Aug 4 
EphA2 expression and brain relapse in resected non-small 
cell lung cancer
Goodgame, Boone1; Brantley-Sieders, Dana2; Waqar, Atif1; Zhang, 
Jean1; Chen, Jin2; Watson, Mark1; Govindan, Ramaswamy1
1 Washington University School of Medicine, St Louis, MO, USA; 2 
Vanderbilt University, Nashville, TN, USA
Background: Brain metastasis occurs in up to 40% of patients with 
non-small cell lung cancer (NSCLC), leading to significant morbid-
ity and mortality. If patients at high risk of brain metastasis could 
be identified, preventative treatments such as prophylactic cranial 
irradiation could improve outcomes. EphA2 is a receptor tyrosine 
kinase which has been associated with brain metastasis and poor 
prognosis in NSCLC (Clin Ca Res, 9:613-618, 2003). We conducted 
a case-control study of EphA2 expression in patients with resected 
NSCLC to determine if there was an association with brain relapse.
Methods: In a large cohort of patients with resected NSCLC at 
Washington University/Barnes-Jewish Hospital, we identified patients 
who had eventual relapse in the brain. For each case, two controls 
were identified: one with no relapse and one with relapse outside 
the brain. Controls were matched based on stage and histology. A 
tissue microarray (TMA) was constructed using two 0.8 mm cores 
per case from the original paraffin tumor block. Expression levels of 
EphA2 were evaluated by immunohistochemistry and scored as 0 (no 
expression), 1 (weak expression), 2 (expression), or 3 (strong expres-
sion). Fisher’s exact and Chi-squared tests were used to compare the 
cohorts. 
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Results: The study included 69 patients with resected stage I 
NSCLC, of which 28 had a recurrence in the brain, 22 had recurrence 
outside the brain, and 19 had no recurrence. The brain metastasis and 
control cohorts were similar with respect to age, gender, T classifica-
tion, and histologic subtype. EphA2 staining could not be performed 
in 4 cases. There was a trend towards higher levels of EphA2 in 
patients with brain metastasis but this did not reach statistical signifi-
cance (p=0.19, see table). EphA2 expression did not correlate with 
any other pathologic characteristics.
 EphA2 Staining All Patients Brain Recurrence
  N N (%)
 0 4 2 (50%)
 1 16 4 (16%)
 2 45 19 (42%)
 3 2 2 (100%)
Conclusion: EphA2 expression did not show a statistically signifi-
cant correlation with brain metastasis in this dataset.
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The identification of tumor antigens associated with 
asbestos-related lung cancer
Hanagiri, Takeshi; Yasuda, Manabu; Kuroda, Koji; Shigematsu, 
Yoshiki; Baba, Tetsurou; So, Tetsuya; Ono, Kenji; Uramoto, 
Hidetaka; So, Tomoko; Takenoyama, Mitsuhiro; Yasumoto, Kosei
2nd Department of Surgery, University of Occupational and 
Environmental Health, Kitakyushu, Japan
Background: Asbestos is a well-known lung cancer carcinogen, 
and several studies have shown that risk of lung cancer increased 
with cumulative exposure to asbestos. It is therefore predicted that 
asbestos-related lung cancer will increase in industrial countries. 
Although numerous studies have previously reported the carcino-
genicity of asbestos for lung cancer, the immunological responses 
of asbestos exposure in lung cancer patients have not yet been fully 
discussed. To investigate new tumor antigens in lung cancer patients 
with asbestos exposure, we analyzed the humoral immune response 
in asbestos-exposed lung cancer patients. 
Patients and Methods: The current study was retrospectively con-
ducted by reviewing the medical records of 27 lung cancer patients, 
all of whom had undergone surgery and a histopathological diagnosis 
of lung cancer was confirmed in our department between 2001 and 
2007. Asbestos exposure was estimated based on the occupational 
history and the presence of pleural plaque. The counts of asbestos 
bodies in lung tissue were measured by a light microscopic analysis. 
Surgically resected tumor tissue specimens and patient sera samples 
were frozen and kept at –80°C and –20°C, respectively. A cDNA 
library was constructed in a lambda ZAP Express vector using mRNA 
extracted from a mesothelioma cell line, which has previously been 
established in our laboratory. Tumor associated antigen was identi-
fied by the SEREX (serological analysis of recombinantly expressed 
cDNA clones) method using lung cancer patients with asbestos 
exposure. 
Results: Among the lung cancer patients with asbestos exposure, 
more than 1,000 asbestos bodies per gram of dry weight of the 
lung tissue specimens were detected in 15 of 27 cases. To identify 
immuno-reactive antigens, the humoral immune response in lung 
cancer patients with asbestos exposure was investigated by the 
SEREX method, and 5 antigen-coding genes were isolated. RT-
PCR, and immunohistochemical staining indicated annexin A2 to 
be overexpressed in asbestos-exposed lung cancer tissue specimens. 
The antibody titers against annexin A2 were higher in the asbestos-
exposed lung cancer patients that in those of the lung cancer patients 
without asbestos-exposure. Furthermore, the antibody titer against 
annexin A2 was also observed to decrease after surgery. 
Conclusion: Because annexin A2 was overexpressed in lung cancer 
associated with asbestos-exposure and annexin A2 elicited a humoral 
response, the antibody titer against annexin A2 might therefore be 
potentially useful as a new diagnostic surrogate marker for asbestos-
related lung cancer.
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Detections of CEA mRNA, p53, ae1/ae3 in HE-negative 
lymph nodes may improve veracity of N staging and 
predict its prognosis in patients with NSCLC
Qiu, Yuan; Yang, Haihong; He, Jianxing; Chen, Hanzhang; Ge, 
Linhu; Wang, Daoyuan; Xu, Xin; Xiong, Xinguo
First Affiliated Hospital of Guangzhou Medical College, Guangzhou, 
China
Objectives: Although the surgical-pathological classification can be 
considered the ‘gold standard’ of T-N staging, it could not provide 
satisfactory and accurate estimation of survival rates in resectable 
non-small cell lung cancer (NSCLC). Several studies have reported 
that immunohistochemistry or quantitative polimerase chain reac-
tion (PCR) detection in lymph nodes metastases could upstage N 
staging and indicate suvival in NSCLC patients. The expression of 
carcinoembryonic antigen (CEA), P53 and AE1/AE3 in hematoxylin-
eosin (HE)-staining-negative lymph nodes from patients with resect-
able non-small cell lung cancer (NSCLC) were analyzed by fluor-
escent quantitation reverse transcription-polymerase chain reaction 
(RT-PCR) and immunohistochemistry, in order to improve veracity of 
N staging and develop sensitive molecular bio-markers.
Methods: Fluoresce quantitation reverse transcription-polymerase 
chain reaction (FQ-PCR) for CEAmRNA was performed on hema-
toxylin-eosin negative lymph nodes from 28 patients undergoing 
radical resection for NSCLC. Immunohistochemistry was applied 
in evaluating P53 and AE1/AE3 in lymph nodes metastases. And 10 
control lymph nodes were from 5 patients without malignancy. The 
primary end point of this study was tumor recurrence. All patients 
were followed 60 months. 
Results: 193 lymph nodes were analyzed. 2 patients staged as I 
up-staged to II; and 3 patients staged as II up-staged to III. 42, 19 
and 36 lymph nodes were positive respectively for CEAmRNA 
(42/193, 21.76%), P53 (19/193, 9.84%) and AE1/AE3 (36/193, 
18.65%) compared with control lymph nodes. Only FQ-PCR test for 
CEAmRNA could detect micrometastases in stage I NSCLC patients 
with N0 lymph nodes (2/13, 15.4%). Disease-free time in patients 
with CEAmRNA (P=0.001), P53 protein (P=0.027) and AE1/AE3 
(p=0.029) positive were significantly inferior to those with microme-
tastases negative. Moreover the results demonstrated that the positive 
lymph nodes for CEAmRNA (P=0.028), P53 protein (P=0.048) and 
AE1/AE3 (P=0.007) were associated with the relapse time, respect-
ively. However, Cox proportional hazards test showed only clinical 
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stage was the independent risk factor of relapse, and denied the cor-
relation between micrometastases in LNs and recurrence.
Conclusions: Detections of CEA mRNA, P53, AE1/AE3 in HE-
negative lymph nodes may improve veracity of N staging and predict 
its prognosis in patients with NSCLC. Furthermore micrometasta-
ses in stage I may be performed by FQ-PCR more sensitive than 
immunohistochemistry.
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Prediction of the chemotherapeutic effect on postoperative 
recurrence based on an in vitro anticancer drug sensitivity 
testing in non-small cell lung cancer 
Higashiyama, Masahiko 1; Oda, Kazuyuki1; Okami, Jiro1; Maeda, 
Jun1; Kodama, Ken1; Kobayashi, Hisayuki2; Minamigawa, 
Kazuhiko2; Takano, Toshikazu2; Yoneima, Eri1
1 Department of Thoracic Surgery, Osaka Medical Center for Cancer 
and Cardiovascular Diseases, Osaka, Japan; 2 Research Laboratory 
Division, Nitta Gealtin Inc., Yao, Osaka, Japan
Background and aims: The Collagen gel droplet embedded culture 
drug test (CD-DST) is an in vitro anticancer drug sensitivity test. 
The test has been used with various types of malignant tumors, but 
the significance of clinical application remains unknown. The aim of 
the present study is to evaluate the ability of this test to predict the 
response to chemotherapy in non-small cell lung cancer (NSCLC) 
patients. 
Methods: From January 2000 through March 2007, the CD-DST 
data using the primary tumor specimens to cisplatin (CDDP), car-
boplatin (CBDCA), and such “new generation” drugs as paclitaxel 
(PAC), docetaxel (TXT), gemcitabine (GEM), and vinorelbine 
(VNR), were successfully obtained from 382 patients that underwent 
radical resections for NSCLC. Eighty-one of the patients received 1st 
line chemotherapy using such drugs for postoperative recurrence. The 
chemotherapy regimen included a CDDP (or CBDCA)-based com-
bination (N=41), non-CDDP-based combination (N=1) and single 
agent (N=39). The predictability of the chemotherapeutic effect of the 
CD-DST data was analyzed retrospectively. 
Results: A partial response (PR) was obtained in 24 (30%) patients 
(Response rate=30%), stable disease (SD) in 33 (41%) and pro-
gressive disease (PD) in 24 (30%). Forty-two patients underwent 
chemotherapy with one or more CD-DST-sensitive drugs, 21 (50%) 
of whom showed PR (RR=50%), whereas only 3 (8%) patients 
showed PR in response to chemotherapy with no CD-DST-sensitive 
drugs. Good predictability was obtained, showing a 50 % of positive 
predictive value (PPV) for PR and a 92% of negative predictive value 
(NPV) by CD-DST. The predictive accuracy was 70%. Interestingly, 
based on a subset analysis according to the recurrent site, the predict-
ive accuracy was highest (89%) for CD-DST-based chemotherapy for 
recurrence in the lymph nodes. 
Conclusions: The application of the CD-DST for the “new gen-
eration” anticancer drugs using surgically resected specimens of 
the primary lesion in NSCLC patients may be clinically useful for 
predicting the response to chemotherapy for postoperative recurrence, 
especially in the lymph nodes.
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Application of kinase activity profiles to predict survival 
and therapeutic strategies in early stage non small cell lung 
cancer
Hilhorst, Riet1; Thijssen, Victor2; van Suylen, Robert-Jan 2; Houkes, 
Liesbeth1; de Wijn, Rik1; Dingemans, Anne-Marie C.3; Ruijtenbeek, 
Rob1
1 PamGene International BV, ‘s-Hertogenbosch, Netherlands; 2 
Department of Pathology, Maastricht University Medical Center, 
Maastricht, Netherlands; 3 Department of Pulmonology, Maastricht 
University Medical Centre, Maastricht, Netherlands
Background: The prognosis of patients with non-small cell lung 
cancer (NSCLC) is poor, even in early stage disease. At present, no 
good diagnostic tests are available to identify early stage NSCLC 
patients with poor survival or to select patients that might benefit 
from specific adjuvant therapy. The aim of the current study was to 
evaluate the prognostic value of kinase activity profiles in early stage 
NSCLC patients.
Methods: A retrospective study was performed using frozen tumor 
tissue from 14 NSCLC patients (stage IA-IIIA) who underwent a 
complete surgical resection. Patients were grouped based on their 
overall survival, i.e. short survival (<24 months, n=6) and long 
survival (>48 months, n=8). Tissue cryosections were lysed in 
M-Per buffer supplemented with phosphatase and protease inhib-
itors. Phosphorylation profiles of the lysates were generated in the 
presence and absence of the protein tyrosine kinase inhibitor gefitinib 
on PamChip® arrays comprising 144 tyrosine containing peptides 
derived from known human protein phosphorylation sites.
Results: Re-evaluation of hematoxilin/eosin stained cryosections 
confirmed that all tissue samples contained at least 50% tumor area. 
A clear phosphorylation profile could be obtained from all samples. 
In the absence of gefitinib, no differential phosphorylation profile 
could be detected between patients with short survival and long 
survival. Interestingly, the inhibitory effects of gefitinib were stronger 
in patients with short survival as compared to patients with long 
survival. Univariate analysis identified 19 peptides that showed a 
significantly altered level of phosphorylation (p<0.05) between both 
groups. Multivariate unsupervised analysis was performed using PCA 
where a clustering of long term survivors vs. short term survivors was 
observed.
Conclusions: Kinase activity profiles in combination with kinase 
targeting drugs can be used to identify early stage NSCLC patients 
with poor prognosis. The present study introduces a new biomarker 
discovery platform, which can be applied in drug development and 
personalized therapy of NSCLC.
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Immunohistochemical evaluation of the oncofetal isoforms 
of fibronectin and tenascin-C in fresh frozen lung cancer 
specimens
Pedretti, Marta2; Neri, Dario2; Arni, Stephan1; Soltermann, Alex3; 
Weder, Walter1; Hillinger, Sven1
1 Division of Thoracic Surgery, University Hospital, Zurich, 
Switzerland; 2 Institute of Pharmaceutical Sciences, Department 
of Chemistry and Applied Biosciences, Swiss Federal Institute 
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Switzerland
One avenue towards the development of more selective, better anti-
cancer drugs consists in the targeted delivery of bioactive molecules 
(drugs, cytokines, procoagulant factors, photosensitizers, radionu-
clides, etc.) to the tumor environment by means of binding molecules 
(e.g., human antibodies) specific for tumor-associated markers. The 
targeted delivery of pharmaceutical agents to new blood vessels ap-
pears to be particularly attractive, because of their accessibility for 
agents coming from the bloodstream, and because new blood vessels 
are different from the mature ones at a molecular, anatomical and 
patho-physiological level. Furthermore, angiogenesis, i.e. the prolif-
eration of new blood vessels from pre-existing ones, is an underlying 
process not only in cancer, but also in many human diseases, includ-
ing blinding ocular disorders and chronic inflammatory conditions.
The alternatively spliced EDB domain of fibronectin and A1 domain 
of tenascin-C are some of the best-characterized markers of tumor 
angiogenesis, which are virtually undetectable in normal adult tissues 
but abundantly expressed in the neo-vasculature and stroma of most 
aggressive cancer types [Neri & Bicknell, 2005]. In this study, we 
have performed an immunohistochemical analysis of 110 freshly fro-
zen lung specimens (59 tumors and 51 normal lung specimens), using 
the human monoclonal antibodies L19 [Pini et al., 1998] and F16 
[Brack et al., 2005], specific to the EDB domain of fibronectin and 
A1 domain of tenascin-C, respectively. The use of freshly frozen tis-
sue samples was necessary, since the two antibodies do not recognize 
their cognate antigen in formalin-fixed paraffin-embedded samples. 
Therapeutic derivatives of both antibodies are currently being used in 
clinical trials.
All normal lung samples tested were found to be negative or only 
weakly positive for the antibody reaction, without striking differences 
between F16 and L19. For more than half of the tumor specimens 
tested, F16 revealed a stronger staining of the tumor stroma and 
neo-vasculature, compared to L19. Only in one case [one small cell 
carcinoma], a slightly stronger reaction was observed for L19.
The results of this study confirm that both L19 and F16 appear to be 
promising vehicles for the targeted delivery of therapeutics against 
a broad variety of lung cancer types, with an apparent superiority 
for F16. The immunoscintigraphy clinical trials, which are on-going 
with radioiodinated versions of the two antibodies, will shed light on 
whether these immunohistochemical differences are mirrored at the 
level of absolute antibody uptake in the neoplastic lesions.
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Alterations of systemic antioxidants and 8-isoprostane 
during chemotherapy for lung cancer
Ho, James C.; Ho, S.P.; Mak, Judith C.; Wong, Matthew K.; Ip, Mary 
S.; Lam, W.K.
Dept of Medicine, The University of Hong Kong, Queen Mary 
Hospital, Hong Kong, China
Introduction: Our previous studies have demonstrated a distinct 
antioxidant profile in lung cancer cells and erythrocytes from subjects 
with non-small cell lung cancer (NSCLC). This observational study 
aimed to investigate the longitudinal profile of erythrocyte anti-
oxidants during chemotherapy for advanced NSCLC. 
Methods: Fifty-two subjects with advanced NSCLC undergoing 
chemotherapy (mainly platinum-based) were recruited into the study, 
in which 54% were “responders” to treatment. Serial blood samples 
were collected at baseline (pre-chemotherapy) and prior to each cycle 
of chemotherapy. Erythrocyte antioxidants (catalase, superoxide 
dismutase [SOD], glutathione peroxidase [GPx] and total glutathione 
[tGSH]) and plasma 8-isoprostane were measured. Data were com-
pared between “responders” (disease control) and “non-responders” 
(progressive disease). 
Results: The baseline erythrocyte antioxidants and 8-isoprostane 
were similar between “responders” and “non-responders”. During 
chemotherapy, there were significant increasing trends of erythro-
cyte catalase and SOD, but decreasing trends of erythrocyte GPx, 
tGSH and plasma 8-isoprostane, irrespective of treatment response. 
Erythrocyte tGSH levels were significantly higher in “responders” 
compared to “non-responders” from second chemotherapy cycle 
onwards, in which the level before third chemotherapy cycle was an 
independent predictor of response to chemotherapy.
Conclusion: There was a distinct systemic antioxidant profile during 
chemotherapy for NSCLC. The predicting role of erythrocyte tGSH 
for treatment response warrants further investigation.
  Chemotherapy cycle Responders Non-responders  p-value
 Catalase (mU/g Hb) Pre-cycle 1 7.13 ± 2.49 6.30 ± 1.43 0.14
  Pre-cycle 2 10.58 ± 1.44 10.32 ± 1.12 0.47
 SOD (U/g Hb) Pre-cycle 1 15.21 ± 2.66 15.31 ± 2.64 0.89
  Pre-cycle 2 16.30 ± 2.82 17.82 ± 3.12 0.07
 GPx (mU/g Hb) Pre-cycle 1 195.62 ± 10.94 194.21 ± 11.28 0.65
  Pre-cycle 2 188.77 ± 21.98 192.09 ± 19.09 0.56
 tGSH (microM) Pre-cycle 1 163.66 ± 7.46 162.37 ± 8.54 0.57
  Pre-cycle 2 164.14 ± 29.29 146.70 ± 25.64 0.03
 8-isoprostane (pg/ml) Pre-cycle 1 34.37 ± 4.34 35.94 ± 5.64 0.27
  Pre-cycle 2 32.88 ± 4.21 34.92 ± 5.19 0.13
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α1,6-fucosyltransferase (α1,6-FT) in non-small cell lung 
cancers (NSCLCs): its decreased expression in squamous 
cell carcinomas by immunohistochemistry
Honma, Rio1; Kinoshita, Ichiro1; Miyoshi, Eiji2; Matsuno, Yoshihiro3; 
Shimizu, Yasushi1; Kaga, Kichizo1; Taniguchi, Naoyuki4; Dosaka-
Akita, Hirotoshi1
1 Hokkaido University Graduate School of Medicine, Sapporo, 
Japan; 2 Osaka University Graduate School of Medicine, Suita, 
Japan; 3 Hokkaido University Hospital, Sapporo, Japan; 4 Osaka 
University Research Institute for Microbial Diseases, Suita, Japan
Background: α1,6-FT, an enzyme for the core fucosylation of 
N-glycans, has been shown to be needed for the function of EGF 
receptor and TGF-β1 receptor. α1,6-FT expression is found in human 
normal bronchial epithelial cells, bronchial gland cells, and alveolar 
pneumocytes. However, α1,6-FT expression has not been previously 
examined in human lung cancers.
Methods: In the present study, we examined α1,6-FT expression by 
immunohistochemistry in 156 surgically resected NSCLCs.
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Results: High, moderate and low expression of α1,6-FT was found 
in 25 (16.0%), 35 (22.4%) and 96 (61.6%) NSCLCs, respectively. 
Low α1,6-FT expression was significantly more prevalent in tumors 
from men than in those from women (p < 0.0001), in tumors from 
smokers compared with nonsmokers (p = 0.0002), and in squamous 
cell carcinomas compared with non-squamous cell carcinomas (p < 
0.0001) by the χ2 test. Multivariate logistic regression analysis for the 
correlation between α1,6-FT expression and various characteristics 
revealed a significant association between low α1,6-FT expression 
and squamous cell carcinomas, as compared with non-squamous cell 
carcinomas (low vs. moderate, p = 0.0005; low vs. high, p = 0.005). 
Among biological characteristics of tumors studied previously in this 
cohort of NSCLCs, Ki-67 labeling index was significantly higher 
in tumors with low α1,6-FT expression than in those with moder-
ate or high α1,6-FT expression (low vs. moderate, p = 0.01; low vs. 
high, p = 0.001). Low expression of GalNAc-T3 and GnT-V was 
more prevalent in tumors with low α1,6-FT expression than in those 
with moderate or high α1,6-FT expression (p = 0.006 and p = 0.005, 
respectively). α1,6-FT expression was not associated with survival.
Conclusions: These results indicate that α1,6-FT may be a new 
marker of NSCLCs with specificity for histology.
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Urine PGE-M to assess prostaglandin E2 (PGE2) levels in 
non-small cell lung cancer (NSCLC)
Horn, Leora1; Milne, Ginger1; Sandler, Alan2; Morrow, Jason1; 
Carbone, David1; Shyr, Yu1; Hayes, Amy1; Campbell, Norma1; 
Johnson, David H.1
1 Vanderbilt Ingram Cancer Center, Nashville, TN, USA; 2 Oregon 
Health & Science University, Portland, OR, USA
Background: COX-2 is often overexpressed in NSCLC leading 
to high systemic PGE2 levels that in turn play a role in NSCLC 
pathogenesis. Changes in urine PGE-M (the major PGE2 metabolite) 
reflect changes in systemic & intratumoral PGE2 [Csiki et al. Clin 
Cancer Res 11:6634, 2005]. A ≥70% decline in PGE-M in NSCLC 
patients (pts) treated with celecoxib (C) (400 mg bid) + docetaxel 
(D) was associated with an apparent survival benefit [Ibid]. To effect 
maximum COX-2 inhibition we tested a higher C dose in a subse-
quent phase II trial. 
Methods: Eligibility: previously treated NSCLC, PS 0-2, evaluable/
measurable disease, adequate marrow, renal & hepatic function, no 
current NSAID or sulfa allergy. Urine PGE-M measured prior to & 
5-10 days after C 600 mg PO bid. Pts with ≥70% decline in PGE-M 
continued on C + D 75 mg/m2 or pemetrexed 500 mg/m2 q3wk x 4 
cycles followed by maintenance C 400 mg PO bid until PD or drug 
intolerance. 
Results: 23 pts enrolled; F=8, M=15; 2 ineligible (1 carcinoid; 1 
elevated LFT); 2 stopped C early (1 ARF; 1 pruritus). Mean PGE-M 
levels decreased from 39.2 to 10.6 ng/mg Cr pre- & post-C (mean 
change = 73%; P=0.005). The mean decline was greater in current 
& former smokers (73.8%; P=0.004) compared to never smokers 
(46.2%; P=0.19). Males had higher pre-treatment PGE-M compare 
to females (46.8 vs. 28.8 ng/mg Cr; P=0.39). Males had a significant 
decrease in mean PGE-M levels after C (70%; P=0.02); a similar al-
beit not significant change occurred in females (P=0.11). 10 screened 
pts (53%) had a ≥70% decline in PGE-M & received treatment with 
C + chemotherapy; 8 pts are evaluable for response; SD = 6; PD = 2. 
Treatment was well tolerated with no cardiac toxicities noted. 
Conclusions: These preliminary data indicate C 600 mg bid ef-
fectively inhibits intratumoral COX-2 in >50% NSCLC pts, a higher 
percentage than our previous trial using C 400 mg bid. The effect 
is greatest in former & current smokers & males compared to never 
smokers & females. Toxicities are acceptable. Accrual is ongoing. 
[Funding: VICC Lung Cancer SPORE CA90949].
P3.139 Prognostic and Predictive Markers, Mon Aug 3 – Tue Aug 4 
Prognostic sgnificance of biomarkers in lung tumors of 
patients with NSCLC
Hudish, Tyler M.1; Keith, Robert L.1; Byers, Tim2; Levinson, Arnold 
H.3; Bucher-Bartelson, Becki4; Merrick, Daniel T.1; Franklin, Wilbur 
A.5
1 Denver VA Medical Center, Denver, CO, USA; 2 Colorado School 
of Public Health, Aurora, CO, USA; 3 University of Colorado Denver 
Cancer Center, Aurora, CO, USA; 4 Colorado Prevention Center, 
Denver, CO, USA; 5 University of Colorado Denver and Health 
Sciences Center, Aurora, CO, USA
Introduction: In order to improve prognosis of patients with non-
small cell lung cancer (NSCLC), it is important to improve diagnostic 
strategies for early detection and to develop more effective treat-
ments. A better understanding of tumor cell biology and prognostic 
markers may result in earlier detection and better methods of iden-
tifying appropriate therapies through individual marker profiling in 
patients with NSCLC.
Through the use of tissue microarray (TMA) analysis, correlations 
can be made between a large number of potential prognostic markers 
and survival data from large cohorts of lung cancer patients. Mem-
bers of the COX, ErbB, and E-cadherin families play critical roles 
in cell cycle regulation, apoptosis, and cell-to-cell adhesion in the 
development of NSCLC. This study aims to evaluate several of the 
proteins in these pathways, many of which have yet to be systematic-
ally examined as prognostic markers in NSCLC.
Methods: Using TMAs and clinical follow-up data, associations 
were examined between levels of tumor expression of 18 proteins 
implicated in tumorigenesis and survival data in 93 patients with 
NSCLC. The TMAs were stained with antibodies against CD10, 
EGFR, HER2, HER3, MAPK, AKT, cPLA2, COX-2, PGES, PGIS, 
E-cadherin, N-cadherin, α-catenin, β-catenin, γ-catenin, p120, p27, 
and APC. Patients were followed for a median period of 40 months, 
and multivariate proportional hazards analyses adjusted for age, 
stage, and histologic subtype of cancer were performed to assess the 
relationship between biomarker expression and survival.
Results: Biomarkers that showed significant associations with 
survival, after adjusting for age, stage, and histologic subtype, were 
HER2, MAP-kinase, and E-cadherin. In multivariate analysis with 
expression scores divided into quartiles (0-100, 101-200, 201-300, 
301-400), higher levels of HER2 expression were associated with 
improved survival (HR 0.606, P<0.01), while higher levels of MAP-
kinase were associated with reduced survival (HR 1.491, P=0.05, 
table 1).
Discussion: Tumor expression of both HER2 and MAP-kinase are 
significantly associated with survival in NSCLC patients. Multivari-
ate analyses revealed that an increase in HER2 expression level 
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results in a 39% decreased hazard of death, and that of MAP-kinase 
results in a 49% increased hazard of death. 
These results warrant further investigation of potential biological 
mechanisms that could possibly explain this contradictory association 
with the otherwise proto-oncogenic effects seen in HER2-positive 
breast cancers. While future studies will need to be directed toward a 
better fundamental understanding of the ErbB family, a larger sample 
size could provide the power to test the hypothesis of variable rela-
tionships between the expression of these biomarkers and different 
histologic subtypes. It would also follow from these results that the 
question of those relationships should be evenly explored in differing 
cancer types throughout the body.
Table 1. Results of Cox Regression Analysis
  Hazard Ratio (p-value)
 Covariate Crude Modestly Adjusted   Fully Adjusted
 Age (<65 vs ≥65) 1.412 (0.18) 1.782 (0.03) 1.567 (0.10) 1.581 (0.09) 1.797 (0.03)
 Stage 1.354 (0.01) 1.415 (<0.01) 1.409 (0.01) 1.382 (0.01) 1.383 (0.01)
 HER2 0.670 (0.01) 0.670 (<0.01)   0.606 (<0.01)
 Map kinase 1.491 (0.05)  1.349 (0.14)  1.491 (0.05)
 E-cadherin 0.740 (0.05)   0.905 (0.51) 0.905 (0.67)
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Expression of Bcl-2 predicts outcome in locally advanced 
non-small cell lung cancer patients treated with cisplatin-
based concurrent chemoradiotherapy
Jeong, Seong Hyun; Jung, Jae Ho; Han, Jae Ho; Choi, Yong Won; 
Lee, Hyun Woo; Kang, Seok Yun; Choi, Jin Hyuk; Oh, Young Taek; 
Sheen, Seung Soo; Ahn, Mi Sun; Hwang, Yun Ho
Ajou University Hospital, Suwon, Korea
Background: Platinum-based concurrent chemoradiotherapy (CCRT) 
is a standard treatment for locally advanced unresectable NSCLC. 
The determination of parameters that may predict the result of the 
treatment has strong clinical implications. 
Patients and Methods: Pretreatment tumor biopsy specimens from 
39 patients with locally advanced NSCLC (stage IIIA: 5, stage IIIB: 
34) were analyzed for p53, Bcl-2, Bax and ERCC1 expression by 
immunohistochemistry. All patients were treated with cisplatin-based 
CCRT. Twenty-four patients received induction chemotherapy fol-
lowed by CCRT (60 Gy/30 fractions, 6 mg/m2 of cisplatin daily). The 
most commonly administered induction chemotherapy regimen was 
VIP (etoposide, ifosfamide, cisplatin; 20 patients). Fifteen patients 
received the same CCRT without induction chemotherapy. 
Results: High expression of p53, Bcl-2, Bax and ERCC1 was 
observed in 15 (38%), 19 (49%), 17 (44%) and 12 (31%) patients, 
respectively. High expression of Bcl-2 was significantly associated 
with longer survival duration (20 months vs. 9 months, P=0.0008) 
and better response to the treatment (74% vs. 30%, P=0.01). In multi-
variate analysis, Bcl-2 expression was the only significant independ-
ent predictor of overall survival (P=0.007) among the pretreatment 
patients characteristics.
Conclusions: High expression of Bcl-2 may be a useful predictor of 
outcome in locally advanced NSCLC patients treated with cisplatin-
based CCRT.
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Intron 1 CA repeat polymorphism is associated with the 
sensitivity to EGFR TKIs in NSCLC patients with wild 
type EGFR
Shin, Jung-Young; Kim, Jeong Oh; Zhang, Xiang-Hua; Yoon, Seong-
Ae; Choi, Jung-Ran; Kang, Jin-Hyoung
The Catholic university of Korea, Seoul, Korea
Background: The epidermal growth factor receptor (EGFR) plays 
a key role in carcinogenesis and progression in various solid tumors 
by its activation by over-expression, mutation, and autocrine ligand 
production etc. Clinical outcome of EGFR TKIs is mainly affected by 
the mutation status of EGFR TK domain, histology, gender, smoking 
status and ethnicity. Recently, it has been reported that some genetic 
variants of EGFR gene including CA repeat polymorphism in intron 1 
modulate its transcriptional activity. 
We investigated the allelic frequency of three genetic variants on 
EGFR gene in Korean population and analyzed the genetic variants, 
EGFR mutations, and the sensitivity to EGFR TK inhibitors in vitro 
and NSCLC patients. 
Methods: Genomic DNA was extracted from peripheral blood in 
221 healthy volunteers and 20 NSCLC patients receiving EGFR TK 
inhibitors. PCR products that were amplified for promoter region, 
intron 1, and exon 18~21 were sequenced in a 3730XL DNA analyzer 
and GeneScan. For in vitro experiment, thirteen NSCLC cells and 
A431 epidermoid carcinoma cells (as control) were used to measure 
the drug sensitivity to gefitinib using the SRB assay. 
Results: In healthy Koreans, the most frequent EGFR CA repeat 
genotype was 20/20 (32.6%) repeats followed by 16/20 (22.1%), 
15/20 (8.6%) and the allelic frequencies of -216G>T and -191C>A 
were 95% and 99%, respectively. Among thirteen NSCLC cell 
lines, the most sensitive cells to gefitinib were PC9 and HCC-827 
(IC50: <0.1 and <0.03 uM) which had an in-frame deletion in exon 
19 (E746-A750). H1975 cells having T790M in exon 20 as well 
as L858R mutation in exon 21 were relatively resistant to gefitinib 
(IC50: 12.2 uM). There was a tendency that drug sensitivity has an 
inverse correlation with the sum of CA repeats in the five cells with 
wild type EGFR and wild type K-RAS (PC14, Calu-3, H1666, H520, 
A431). In 20 NSCLC patients, mean age was 62.7(40~81) and M:F 
ratio was 5:15. Tumor responses to EGFR TKIs were 12 PRs, 5 SDs, 
and 3 PDs. All five patients with in-frame deletion in exon 19 dis-
played partial response irrespective of sum of CA repeats. However, 
in 3 PDs and 4 SDs with short TTP (< 5 months), the sum of CA 
repeats was 39~40 with no mutations in EGFR. 
Conclusion: Not only the distribution of CA repeat genotype but also 
the allelic frequency of -216G>T and -191C>A in Korean popula-
tion were quite different from those of Caucasian. It is obvious that 
the mutations in tyrosine kinase domain of EGFR gene are the major 
determinant to anti-tumor efficacy of EGFR TKIs. Our results sug-
gest that CA repeat polymorphism in intron 1 be another predictive 
biomarker of EGFR TKIs in NSCLC patients with wild type EGFR. 
Further study using sufficient human tumor samples is underway to 
support this preliminary results.
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The association of BCL-2 expression with 
clinicopathological parameters and prognosis in non-small 
cell lung cancer
Kervankaya Aktas, Selma; Mutluay, Neslihan; Demirag, Funda; 
Koksal, Deniz; Basay, Nihal; Bayiz, Hulya; Berktas, Bahadir; 
Berkoglu, Mine 
Ataturk Chest Diseases and Chest Surgery Education and Research 
Hospital, Ankara, Turkey
Background and Aim: Bcl-2 is an oncoprotein that prevents cells 
from apoptosis. It is expressed in lymphoproliferative disorders and 
also in non-hematopoietic malignancies such as breast carcinoma, 
adenocarcinoma of prostat and gastrointestinal tract, nasopharangeal 
carcinoma, and lung cancer. In this study, we aimed to investigate 
the association of Bcl-2 expression with clinicopathological param-
eters and prognosis in non-small cell lung cancer (NSCLC). Median 
follow-up time was 20.5 (range:1-77) months. 
Methods: The study comprised of 100 NSCLC (50 adenocarcinoma, 
50 squamous cell carcinoma) patients with a mean age of 61±10 
years (range: 38-78). Patients underwent lobectomy or pneumon-
ectomy with hilar and mediastinal lymph node sampling. Paraffin 
embedded tumor sections were retrieved for expression of Bcl-2 
oncoprotein. Clinicopathological data and survival of patients were 
all determined. 
Results: Bcl-2 expression was positive in 47 (47%) and negative in 
53 (53%) patients. Bcl-2 positive and negative groups were similar 
for age, sex, smoking history, tumor diameter, lymph node involve-
ment, tumoral differentiation, histologic subtype, and stage. Relaps 
was significantly high (p=0.014) in Bcl-2 negative group. Bcl-2 was 
not found to be related with overall survival. While median overall 
survival was 29 months (%95CI: 22.3-35.7) in the whole study group 
it was 45.1 months (%95CI: 34.4-55.8) in Bcl-2 positive group and 
33.5 months (%95CI: 27.3-39.6) in Bcl-2 negative group. Median 
overall survival was not significantly different between the groups 
(p=0.44). In multivariate survival analysis using cox regression, 
squamous histology (p<0.001) and presence of metastasis (p=0.006) 
was determined as independent prognostic factors.
Conclusion: Bcl-2 expression is not found to be related with overall 
survival. But relapses are more frequent in the absence of Bcl-2 ex-
pression which finally causes a shorter median survival time. 
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Heterozygous CT genotype of TGFβ1 at T869C was 
associated with a worse outcome in patients with non-
small-cell lung cancer treated with definitive radiotherapy
Yuan, Xianglin1; Liao, Zhongxing2; Komaki, Ritsuko 2; Liu, 
Zhensheng 2; Tuker, Susan L2; Li, Mao2; Martal, Mary2; Cox, James 
D2; Milas, Luka2; Wei, Qingyi2
1 Department of Oncology, Tongji Hospital, Huazhong University 
of Science and Techlogy, Wuhan, China; 2 Departments of 
Epidemiology, The University of Texas, M.D. Anderson Cancer 
Center, Houston, TX, USA
Purpose: To investigate the associations between single nucleo-
tide polymorphisms (SNPs) of the TGFβ1 gene and the outcome 
in patients with non-small-cell lung cancer (NSCLC) treated with 
definitive radiotherapy.
Methods and Materials: We genotyped three SNPs of the TGFβ1 
gene: rs1800469:C-509T, rs1800471:G915C, and rs1982073:T869C, 
as determined by the polymerase chain reaction-restriction fragment 
length polymorphism method in 217 patients with NSCLC. These 
patients were treated with definitive radiation at The University of 
Texas M. D. Anderson Cancer Center between November 1998 and 
January 2005.
Results: The median follow-up time for the entire group was 
17 (range, 1-97) months and 39 months for living patients. The 
median overall survival (OS) time, the progression free survival 
(PFS) time and the median distant metastasis free (DMFS) time 
were 17 months, 8 months and 10 months, respectively. Multivari-
ate analysis showed that heterozygous CT genotype in TGFβ1 
rs1982073 was significant prognostic predictors for PFS (HR =1.603, 
CI=1.117-2.301, P=0.010).Heterozygous CT genotype in TGFβ1 
rs1982073 and TGFβ1 rs1800469 were associated with a reduced 
DMFS (HR=1.823, 95%CI=1.157-2.874, P=0.010; HR=1.569, 95% 
CI=1.040-2.367, P=0.032, respectively). And this significant differ-
ence could further be seen in the populations with brain metastasis 
rather than with bone and lung metastasis. However, the difference 
of associations between genotypes in TGFβ1 rs1982073, rs1800469, 
rs1800471 and OS did not reach statistical significance in multivari-
ate analysis.
In conclusion The heterozygous CT genotype of TGFβ1 rs1982073 
could play as a prognostic marker predicting the clinical outcome 
and the predisposition of metastasis in NSCLC patients treated with 
definitive radiotherapy. 
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Predictive value of CEA plasma levels in response and 
survival rates in patients suffering from lung cancer
Komurcuoglu, Berna E.1; Ulusoy, Sadik2; Cirak, A.Kadri1
1 Izmir Training and Resarch Hospital for Chest Disease, Izmir, 
Turkey; 2 Biochemistry, izmir, Turkey
High levels of CEA plasma levels are considered a negative pre-
dictive factor in lung cancer. The aim of the study is to detect the 
CEA plasma levels in advanced stage lung cancer patients before the 
therapy and to investigate the relation with responce rate, disease rec-
curance, and survival times with it. 60 nonsmall cell lung carsinoma 
(NSCLC) patients and 20 healty control were included the study; all 
of the patients were advanced stage. Median plasma CEA level was 
36,2 ng/ml.in NSCLC patient and it was statistically significant high 
from healty control group (median 3,6ng/ml in control group).There 
was no statistically differences was detected between smooker and 
nonsmooker lung cancer patients. Patients evaluated according to the 
responce rates; 23 patient were partial responce (PR) (38%), 19 pa-
tients were stable disease (SD)(32%) and 18 patient were progresive 
disease (PD)(30%). Patient with progresive disease plasma CEA 
leves were higher and statisticaly significant from the PR and SD 
groups. As a result we conclueded that CEA could be a predictive role 
to evaluate the responce the therapy and survival in NSCLC patients.
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A qPCR-based assay applicable to a prognostic genomic 
signature in early stage lung adenocarcinoma using 
formalin-fixed paraffin-embedded tissues.
Kratz, Johannes R.; Ray, Roshni; Raz, Dan J.; He, Biao; Jablons, 
David M.
UCSF, San Francisco, CA, USA
Background: Patients with early stage lung cancer demonstrate sig-
nificant recurrence rates and lower-than-expected survival rates after 
surgical resection, indicating that our current staging methods do not 
adequately predict outcome. A number of microarray and qPCR-
based models have been proposed which more accurately predict 
prognosis in patients with early stage lung cancer. For example, our 
group has published a 4-gene qPCR signature that is prognostic of 
survival in patients with early-stage lung adenocarcinoma. To date, 
these studies have been based on genomic analysis of fresh frozen 
tissue which is impractical in the clinical setting. To address this, we 
have developed qPCR based technology which allows us to extract 
and analyze RNA expression from formalin-fixed, paraffin-embedded 
(FFPE) lung tissues. This technology is being used to develop a FFPE 
qPCR prognostic signature in early stage lung adenocarcinoma wich 
may impact both the use of adjuvant therapy as well as the choice of 
surgical procedure in patients with early-stage lung cancer. 
Methods: Formalin-fixed paraffin-embedded tissues from patients 
who underwent complete surgical resection of lung adenocarcinoma 
without preoperative chemotherapy or radiation treatment were used 
in the study. RNA was extracted from FFPE samples using a protocol 
based on Qiagen’s FFPE RNA extraction kit. Multiple gene-specific 
reverse transcription primers, PCR primers, and TaqMan probes for 
each gene were developed and tested using SYBR-green and Taqman 
PCR assays. After cross-validation was used to determine model size, 
a risk score was generated for each patient based on model coeffi-
cients; these predicted risk scores were dichotomized (at the median) 
and corresponding Kaplan-Meier survival curves were generated and 
compared via the log-rank statistic. 
Results: RNA was successfully extracted from 10uM slices of 
formalin-fixed paraffin-embedded tissues. Concentration and purity 
were assessed using both Nanodrop and Agilent Bioanalyzer assays, 
yielding values that were comparable to previously published values 
for RNA extracted from FFPE tissues. FFPE specific qPCR assays 
were developed for 14 cancer-related genes and 2 housekeeping 
genes previously identified from published microarray and PCR-
based studies of prognosis in early stage lung cancer. SYBR green 
assays demonstrated product amplification and specificity. Dilution 
curves demonstrated good curve-fit (R2) and efficiency values for 
each assay. These assays were tested on early-stage lung adenocarcin-
oma FFPE samples in patients for whom 5-year follow-up informa-
tion was available and predictive risk scores were generated.
Conclusion: A clinically-applicable genomic prognostic assay based 
on information extracted from formalin-fixed paraffin-embedded 
tissues has the best chance of impacting both the use of adjuvant ther-
apy as well as the choice of surgical procedure in patients with early-
stage lung cancer. To our knowledge, this is the first demonstration 
of the successful development of a clinically practical FFPE-based 
qPCR based assay that is applicable to a genomic signature prognos-
tic in early stage lung cancer. Such a FFPE-based qPCR prognostic 
signature is already in widespread use in the field of breast oncology. 
It is hoped that this study will have a similar impact in the field of 
thoracic oncology.
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Reverse-hybridization assay for the simultaneous detection 
of 10 mutations in codons 12 and 13 of the KRAS gene 
Kriegshaeuser, Gernot; Kury, Fritz; Oberkanins, Christian
ViennaLab Diagnostics GmbH, Vienna, Austria
Background: Somatic mutations in the gene for the epidermal 
growth factor receptor (EGFR) are found in adenocarcinomas of the 
lung and are associated with sensitivity to small-molecule EGFR 
tyrosine kinase inhibitors (gefitinib and erlotinib). Approximately 
33% of non-small cell lung carcinomas (NSCLC) harbour activating 
mutations in the KRAS gene and these mutations have a mutually ex-
clusive relationship with EGFR mutations. In contrast to EGFR muta-
tions, NSCLC patients that have mutations in KRAS do not respond 
to small-molecule EGFR tyrosine kinase inhibitors. Furthermore, 
NSCLC patients with KRAS mutations seem to have poor prognosis. 
Therefore, treatment decisions with respect to the use of these kinase 
inhibitors might be improved by determining the mutational status of 
KRAS.
Methods: We have developed a reverse-hybridization (RH) assay for 
the simultaneous detection of 10 mutations (Ala12, Arg12, Asp12, 
Cys12, Ile12, Leu12, Ser12, Val12, Asp13, Cys13) in codons 12 and 
13 of the KRAS gene. This assay combines mutant-enriched PCR 
based on peptide nucleic acid (PNA) clamping and RH of biotinyl-
ated amplification products to nitrocellulose test strips containing a 
parallel array of oligonucleotide probes specific for each mutation 
covered by the RH assay. Bound sequences are visualized using 
streptavidin-alkaline phosphatase conjungate and colour substrates.
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Results: Genomic DNA isolated from 8 tumor cell lines containing 
a KRAS mutation was used to generate recombinant plasmid clones. 
After confirming the presence of mutations by DNA sequencing, 
plasmid clones served as reference DNA templates to control for 
specificity. The assay´s limit for detecting KRAS mutations was de-
termined using different amounts of tumor cell line DNA mixed with 
wild-type DNA. All KRAS mutations in cell lines were unambigu-
ously identified by the RH assay with 1% of each cell line DNA 
diluted in normal DNA.
Conclusions: The RH assay to be presented is a sensitive tool for 
the simultaneous detection of 10 mutations in codons 12 and 13 of 
the KRAS gene. The procedure is relatively fast (< 6 hours exclud-
ing DNA isolation) and follows a simple protocol using ready to use 
test strips and visible colour detection. The method requires standard 
laboratory equipment only and, for increased sample throughput, 
hybridization/detection may be fully automated by means of com-
mercially available instrumentation. Therefore, this approach appears 
to be a good alternative to methods currently in use for the detection 
of KRAS mutations.
P3.147 Prognostic and Predictive Markers, Mon Aug 3 – Tue Aug 4 
Serum proteomic analysis of lung squamous cell carcinoma 
patients
Kuribayashi, Hidehiko; Seike, Masahiro; Okano, Tetsuya; Soeno, 
Chie; Yoshimura, Akinobu; Kudoh, Shoji; Gemma, Akihiko
Nippon Medical School, Tokyo, Japan
Cigarette smoking is one of the most important risk factor for lung 
squamous cell carcinoma, however, the underlying mechanisms 
of carcinogenesis had not been apparent. The understanding of the 
proteomic signature of lung squamous cell carcinoma patients and 
smokers will facilitate the establishment of novel tumor marker for 
diagnosis of lung squamous cell carcinoma. 
We conducted proteomic analysis using serum samples. We compared 
the proteomic profiles of serum from six primary lung squamous cell 
carcinoma patients and three current smokers. High-abundance serum 
proteins were depleted by use of an immuno-affinity column, and the 
resulting serum samples profiles were generated by two-dimensional 
difference gel electrophoresis (2D-DIGE), and the intensity of ap-
proximately 2,400 spots was converted to the numerical data for the 
expression study. 
We found that 72 protein spots were differently expressed between 
cancer patients and smokers. Mass spectrometry and database search-
ing allowed the identification of the proteins corresponding to the gel 
spots. These proteins may be good candidates for tumor markers for 
diagnosis and clinicophysiological targets.
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The overexpression of ribonucleotide reductase regulatory 
subunit M1 (RRM1) protein is a predictor of shorter 
survival to gemcitabine-based chemotherapy in advanced 
non-small cell lung cancer (NSCLC)
Lee, Jae Jin; Kim, Gou Young; Choi, Cheon Woong; Maeng, Chi 
Hoon; Baek, Seon Kyung; Kim, Yee Hyuong; Yoo, Jee-Hong; Kim, 
Si-Young 
Kyung Hee University School of Medicine, Seoul, Korea
Background: RRM1, the regulatory subunit of ribonucleotide 
reductase, is associated with resistant to gemcitabine. There are few 
studies to analyze the prognosis according to RRM1 protein expres-
sion by immunohistochemical (IHC) stain. We evaluated whether 
RRM1 protein expression is predictor to survival and response in 
gemcitabine-treated, advanced NSCLC.
Methods: We retrospectively collected 40 formalin-fixed paraffin-
embedded tumor tissues of NSCLC to investigate the protein expres-
sion of RRM1 by IHC stain. Purified rabbit anti-human RRM1 poly-
clonal antibody (ProteinTech Group, Chicago, IL, USA) was used for 
IHC stain of RRM1. It was defined as RRM1-positive tumor to be 
grade 3 of intensity scale and more than half of proportion score out 
of the tumor tissue. Survival rate was analyzed with Kaplan-Meier 
method and the response with RECIST criteria.
Results: Among 40 tumors, RRM1 expression was positive in 14 
(35%) and negative in 26 (65%). All forty patients were treated with 
gemcitabine-based combination therapy as first-line for 10 (25%) pa-
tients or second-line for 30 (75%) patients. The therapeutic regimens 
were gemcitabine/platinum or gemcitabine/vinorelbine. As first-line 
therapy, gemcitabine/platinum was administered to 7 patients and 
gemcitabine/vinorelbine to 3 patients. All previous treated patients 
were refractory to paclitaxel/platinum and received gemcitabine/
vinorelbine as second-line therapy. Median age was 61 years and M/F 
was 31/9. Stage IIIB/IV was 7/33 and adenocarcinoma/squamous cell 
carcinoma/other cell type was 20/16/4. Any characteristics including 
age, gender, stage, cell type and first/second-line were not statistic-
ally different between RRM-positive and RRM-negative groups. 
Overall survival of RRM1-positive groups was significantly shorter 
than that of RRM-negative groups (20.3 weeks vs. 51.7 weeks, 
p=0.022). Progression-free survival of RRM1-positive groups was 
significantly shorter than that of RRM-negative groups (6.4 weeks vs. 
10.4 weeks, p=0.022). The response rates of 38 patients out of all 40 
patients were assessable. Among RRM1-positive groups, PR was 1 
(7.7%) patients, SD 2 (15.4%) and PD 10 (76.9%). Among RRM1-
negative groups, PR was 6 (24.0%) patients, SD 8 (32.0%) and PD 
11 (44.0%). Disease control rate (PR+SD) of RRM1-positive groups 
was significantly lower than that of RRM1-negative groups (23.1% 
vs. 56%, p=0.05) but the response rate was not different between two 
groups (p=0.149). 
Conclusions: In patients with gemcitabine-based treated, advanced 
NSCLC, patients with RRM1-positive tumors were worse in overall 
survival, progression-free survival and disease control rate than 
patients with RRM1-negaitive tumors. These results strongly sug-
gest that IHC overexpression of RRM1is a significant predictor of 
survival and disease stabilization to gemcitabine-based chemotherapy 
in advanced NSCLC.
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Epigenetic inactivation of checkpoint kinase 2 gene in non-
small cell lung cancer and its relationship with clinicopathological 
features
Kim, Dong Sun2; Kim, Mi Jin2; Lee, Ji Yun2; Lee, Su Man2; Choi, Jin 
Eun3; Lee, Shin Yup1; Hyun, Dae Sung4; Park, Jae Yong1
1 Departement of Internal Medicine, Kyungpook National University 
Hospital, Daegu, Korea; 2 Department of Anatomy, School of 
Medicine, Kyungpook National University, Daegu, Korea; 3 
Department of Biochemistry, School of Medicine, Kyungpook 
National University, Daegu, Korea; 4 Department of Internal 
Medicine, Catholic Medical University of Daegu, Daegu, Korea
Lung cancer is the leading cause of cancer deaths worldwide and is 
usually associated with late diagnosis and poor prognosis. Tumor-
acquired methylation of the promoter CpG islands (CGIs) is an 
important mechanism for silencing tumor suppressor genes. The 
checkpoint kinase 2 (CHK2) is a tumor suppressor that plays a 
crucial role in regulating cell-cycle checkpoints and apoptosis fol-
lowing DNA damage. The methylation status of two CGIs, distal and 
proximal, of human CHK2 gene were determined in non-small cell 
lung cancers (NSCLCs) using a nested methylation-specific PCR and 
bisulfite sequencing. The methylation of distal CHK2 CGI was found 
in 39 (28.1%) of the 139 NSCLCs. Its frequency was significantly 
more frequent in squamous cell carcinomas than in adenocarcinomas 
(40.0% vs 19.0%, p=0.006) and was also higher in ever-smokers than 
in never-smokers with a borderline significance (31.7% vs 17.1%, p 
= 0.071). RT-PCR analysis showed that the distal CGI methylation 
correlated with CHK2 mRNA expression. However, the methylation 
of the proximal CHK2 CGI is not specific to tumors and not related 
to gene expression. These results suggest that the down-regulation of 
CHK2 gene via distal CGI methylation may play a role in the patho-
genesis of NSCLC, particularly squamous cell carcinoma. However, 
further studies with large numbers of patients are needed to confirm 
our findings.
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Expression of ERCC-1,RRM-1, survivin and VEGFR in 
non-small cell lung cancer in Thai patients
Lertprasertsuke, Nirush; Phattana, Naritchaya; Suksombooncharoen, 
Thatthan; Sae-tang, Somcharoen; Thongprasert., Sumitra 
Departments of Pathology, Internal Medicine Oncology Unit and 
Thoracic Surgery, Chiangmai University, Chiangmai, Thailand
A cross sectional study of protein expression in resectable non-small 
cell lung cancer has been conducted in Maharaj Nakorn Chiang Mai 
Hospital Thailand retrospectively. 
Twenty cases diagnosed as non-small cell lung cancer who had been 
resected in 2005 were recruited. There were 12 men and 8 women. 
The mean age was 61.5 and ranged 21-75 years old. Thirteen patients 
still alive and regulary follow up at the outpatient clinic up to present. 
Histologically there were 11 cases of adenocarcinoma ( 55% includ-
ing bronchioloalveolar cell type), 7 cases of squamous cell carcinoma 
and 2 cases of undifferentiated large cell carcinoma. Immunohisto-
chemically, the expression of RRM-1 and VEGFR is universally 
found in all cases irrespective to the cell type or the staging whereas 
the expression of EGFR and survivin are 90% and 70% respectively. 
6 cases express ERCC-1 . Two cases are squamous cell type and one 
patient died at 2 years interval. Four positive cases are adenocarcin-
oma and all of them still alive at the lattest follow up.
Conclusion: This is a small study about non-small cell lung cancer in 
Thai patient which has never been documented before. 
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Lower osteopontin and galectin-3 plasma levels are 
associated with sub-clinical micrometastasis in advanced 
non-small-cell lung cancer
Li, Hui; Liang, Yong; Hou, Sheng-cai; Hu, Bin; Miao, Jin-bai,  Zhou, 
Caicun
Department of Thoracic Surgery, Beijing Chaoyang Hospital, Capital 
Medical University, Beijing, China
Background: To study the relationship between expression of galec-
tin-3 and osteopontin and sub-clinical micrometastasis in non-small 
cell lung cancer and explore their clinical significance. 
Methods: The expression of galectin-3 and osteopontin were as-
sessed in lung cancer specimens using RT-PCR technique, and the 
level of plasma were measured by ELISA. 
Results: In 46 NSCLC patients, the expression of galectin-3mRNA 
and osteopontin mRNA were significantly lower than that in normal 
lung tissues. The expression of galectin-3 and osteopontin correl-
ated with pathological stage, but has no relationship with age, sex, 
smoking and pathology. Plasma levels of galectin-3 and osteopontin 
and the expressions of galectin-3 mRNA and osteopontin mRNA in 
metastasis group were higher than non-metastasis group(p<0.05) . 
Conclusions: Higher plasma levels of galectin-3 and osteopontin 
and higher expressions of galectin-3 mRNA and osteopontin mRNA 
in NSCLC patients are significantly associated with postoperative 
occurrence and metastasis, which may play the important roles in 
prognosis of NSCLC. Galectin-3 and osteopontin levels in the plasma 
may serve as biomarker for evaluating the sub-clinical micrometasta-
sis of NSCLC.
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RRM1 and BRCA1 mRNA expression levels and clinical 
outcome of advanced NSCLC patients treated with 
cisplatin –based chemotherapy
Li, Zhanxia; Zhou, Songwen; Zhang, Ling; Ren, Shengxiang; Zhou, 
Caicun
Dept of Medical Oncology, Shanghai Pulmonary Hospital, Tongji 
University, Shanghai, China
Background: Platinum-based chemotherapy is the standard treat-
ment for advanced NSCLC patients. RRM1 and BRCA1 are import-
ant regulators of chemosensitivity of NSCLC. 
Methods: Stage IIIb/IV NSCLC patients were given cisplatin-based 
chemotherapy based upon expression levels of RRM1 and BRCA1 
mRNA in the tumor. Expression levels of the two genes were de-
termined by real-time PCR and cut-off points were reported in our 
previous study. The patients with low expression of RRM1 were 
treated with gemcitabine/cisplatin up to 4 cycles. The others were 
treated with vinorelbine or paclitaxel plus cisplatin up to 4 cycles. 
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
Copyright © 2009 by the International Association for the Study of Lung CancerS916
After the chemotherapy, the patients were followed every 6 weeks up 
to disease progression and then every 3 months up to death.
Results: 90 chemonaive, stage IIIB/IV, PS 0-1 NSCLC patients 
were enrolled. Age 60 (40-78) yrs old, male/female: 73/27%; 
adenocarcinoma/squamous/adeno-squamous/undefined NSCLC: 
49/33/11/7%;,stage IIIb/IV: 13/87%. Overall response rate was 
41.1%, stable disease 42.2%, progressive disease 16.7%. Disease was 
not progressive in 33 patients. Median TTP was 5 months. Response 
rate and TTP were better in those with low RRM1 expression (table 
1). Toxicity of the chemotherapy was acceptable. Overall survival 
will be reported in the conference.
Conclusions: RRM1 and BRCA1 mRNA expression levels in non-
small cell lung cancer are associated with clinical outcome to cisplat-
in-based chemotherapy. Prospective studies are ongoing to evaluate 
the role of the two genes in tailoring chemotherapy in our center.
 Gene expression  Case Number ORR SD PD TTP
 Overall 90 41.1% 42.2% 16.7% 5months
 Low RRM1 24 54.2% 29.2% 16.7% 6.15months
 High RRM1+ any BRCA1 66 39.4% 43.9% 16.7% 5months
 High RRM1+Low BRCA1 33 35.4% 46.4% 18.2% 5months
 High RRM1+ High BRCA1 33 42.4% 42.4% 15.2% 5months
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EGFR mutation and p-EGFR expression in resected Non-
Small Cell Lung Cancer 
Liu, Wei2; McMillen, Elizabeth1; Ye, Fei1; Li, Guanghu2; Wu, Yong2; 
Yin, Guanghao2
1 Mount Sinai School of Medicine, New York, NY, USA; 2 First 
Hospital of Jilin University, Changchun, China
Background: Lung cancer, specifically NSCLC, is a leading cause 
of mortality worldwide. In China, where two-thirds of adult Chinese 
men are smokers, a dramatic increase in the incidence of NSCLC 
is expected in the next 20 years. As newer, more expensive thera-
peutic agents become available; it grows increasingly important to 
predict which patients may benefit from treatment and which will 
not. In NSCLC, positive response to treatment with tyrosine kinase 
inhibitors (TKIs), such as gefitinib and erlotinib, has been correlated 
with EGFR mutations. Different patterns of autophosphorylation in 
wild-type and mutated EGFR may allow for immunohistochemical 
analysis of p-EGFR to substitute for genetic mutation analysis in 
resected NSCLC as a marker for predicted clinical response. 
Methods: In this study, mutation analysis of EGFR in 218 cases 
of NSCLC was performed. 130 tissue samples were examined via 
immunohistochemistry of EGFR at two phosphorylation sites (p1045 
and p1068). 
Results: Mutations were seen in 29% of patients. A total of 13 
types of mutations were found, with 37 patients having deletions on 
exon 19 and 18 having substitutions on exon 21. Phosphorylation 
at tyrosine 1045 was noted in 52% of all cases, but in 74% of cases 
with EGFR mutation (p=.001). Phosphorylation of tyrosine 1068 was 
seen in 55% of all cases but in 74% of cases with EGFR mutation 
(p=.007). Mutated EGFR was correlated with female sex, non-smok-
ing history, and adenocarcinoma histology. 
Conclusions: This study of EGFR mutation and p-EGFR expres-
sion in resected NSCLC from Chinese patients is one of the largest 
to date. As a developing country, most patients could not afford TKI 
treatment so response could not be adequately assessed. The data 
show that, among Chinese patients, p1045 and p1068 expression are 
correlated with EGFR mutations. Immunohistochemical analysis of 
p-EGFR may be useful to more accurately predict responses to TKI 
therapy. Further study of the role of TKI therapy in patients with p-
EGFR expression is needed. 
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Expression of cyclic AMP response element-binding 
protein in non-small cell lung cancer
Wu, Yong1; Liu, Wei1; Li, Guanghu1; Ye, Fei2; Xue, Menghua1; Zhu, 
Dongshan1; Zhang, David Y.2
1 First Hospital of Jilin University, Changchun, China; 2 Mount Sinai 
School of Medicine, New York, NY, USA
Background: Lung cancer is the leading cause of cancer death 
worldwide. In recent years, the advances of targeted therapy has 
brought new promising therapeutic methods for lung cancer by 
targeting specific molecules in the signal transduction pathway. 
Dramatic responses to inhibitors of the EGF and VEGF signaling 
pathway have been noted in the treatment of certain subsets of lung 
cancer. Identifying new molecular targets for treatment and preven-
tion of NSCLC will improve the control of this deadly disease.
The cyclic AMP response element (CRE)-binding protein (CREB) is 
an intracellular effector for a variety of receptors, including EGF sig-
naling pathway, insulin signaling pathway, and cAMP/Ca2+ signaling 
pathway. It is closely related to apoptosis, cell proliferation and tumor 
metastasis. However, there are very few reports about the roles of 
CREB in lung cancer carcinogenesis.
Methods: NSCLC tissue specimens and TMA construction 
Ninety-four paraffin-embedded tumor tissue specimens resected from 
patients who underwent operation between January, 1998—Decem-
ber, 2003 for primary NSCLC were obtained. Tumor tissue micro-
arrays (TMAs) were constructed using two tissue cores per tumor that 
were 1 mm in diameter to obtain tissue from central and intermediate 
tumor areas.
Immunohistochemical analysis The intensity of CREB immunos-
taining was graded on a scale of 0 to 3. The extent of positive 
immunoreactivity for CREB (0–1; 1 = 100%) was calculated as the 
percentage of cells that had nuclear staining for CREB. Scoring of 
immunohistochemical staining in each specimen was determined as 
the product of positive immunostaining intensity (0–3) and positive 
immunoreactivity extent (0–1).
Data Analysis and Statistics The statistical significance of clinico-
pathologic characteristics and CREB expression were determined 
with chi-square test and survival curves were determined using the 
Kaplan- Meier product limit estimates. Differences in probability of 
survival between groups were assessed using the log-rank test.
Results: CREB was positively expressed in 56 of 94 (59.57%) 
specimens of NSCLC tumor tissues, and the expression of CREB 
was significantly related to histological types (p=0.000) and smoking 
status (p=0.013), but not related to gender (p=0.268), age (p=0.234), 
PTNM stage(p=0.667), tumor size (p=0.774), nodal status(p=0.452). 
The immunostaining scores of CREB were significantly higher in 
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the squamous cell carcinoma specimens than in the adenocarcinoma 
specimens (45/57 vs 11/37, p=0.000) and also significantly higher in 
smokers than in non-smokers (42/61 vs 14/33, p=0.013). The Kaplan-
Meier survival curves showed that only in adenocarcinoma the 
overexpression of CREB was related to lower probability of survival 
(p=0.034).
Conclusion: CREB is highly expressed in NSCLC and closely re-
lated to the carcinogenesis associated with squamous carcinoma and 
smoking. The relationship to NSCLC survival needs further investi-
gation.
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Prognostic significance of hepatitis B Virus to non-small 
cell lung cancer patients in China
Lu, Shun1; Ye, Xiangyun1; Li, Ziming1; Yang, Yi1; Yu, Yongfeng1; 
Chen, Zhiwei1; Wu, Chunxiao2; Zheng, Ying2; Liao, Meilin1
1 Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai 
Jiao Tong University, Shanghai, China; 2 Shanghai Municipal Center 
for Disease Control and Prevention, Shanghai, China
Background: Hepatitis B virus (HBV) is considered to be a major 
cause of hepatocellular carcinoma. However, little is known about the 
role of chronic HBV infection in other malignancies. We aimed to de-
termine HBV infection with other well established prognostic factors 
and performed multivariate survival analyses to evaluate its value in 
Chinese non-small cell lung cancer (NSCLC) patients.
Methods: It is a retrospective evaluation of the impact of HBV 
infection status in 248 patients who underwent complete surgical 
resection for stage IB NSCLC and 166 stage IV NSCLC patients in 
Shanghai Chest Hospital from 1998 to 2008. All the patients were 
Shanghai Niece and all the stage IB NSCLC patients didn’t receive 
adjuvant chemotherapy. The patients’ blood samples were tested with 
chemiluminescent immunoassay for the presence of HBV surface 
antigen (HBsAg), antibodies against HBV core antigen (anti-HBc), 
and antibodies against HBsAg (anti-HBs) before operation. Other 
variables in the analysis included age, gender, history of smoking and 
pathologic type.
Results: 36 HBV infection cases (14.52%) were positive in stage 
IB NSCLC. The 5-year overall survival of patients with or with-
out chronic HBV infection were 72.12% and 51.85 %( P=0.034) 
(image1). 86 HBV infection cases (51.81%) were positive in stage 
IV NSCLC. The 1-year overall survival of patients with or with-
out chronic HBV infection were 74.68% and 32.56 % (P=0.034) 
(image2). Multivariate analyses revealed that gender, chronic HBV 
infection were significant predictive factors for overall survival (P< 
0.05).
Conclusions: The chronic HBV infection is a significant independ-
ent prognostic factors in stage IB and stage IV non-small cell lung 
cancer.
P3.156 Prognostic and Predictive Markers, Mon Aug 3 – Tue Aug 4 
Consecutive measurement of YKL-40 in patients with non 
small cell lung cancer is predictive for overall survival and 
response to chemotherapy
Lykkegaard Andersen, Jon1; Juhler-Nøttrup, Trine1; Johansen, Julia2; 
Pappot, Helle3; Jarle, Ib4; Mellemgaard, Anders1
1 Dpt of Oncology University Hospital Herlev, Herlev, Denmark; 2 
Dpt of Rheumatology, University Hospital Herlev, Herlev, Denmark; 
3 National Board of Health, Copenhagen, Denmark; 4 Finsen 
Laboratory, Copenhagen, Denmark
Background: YKL-40 (CHI3L1, HC-gp39) is a 40 kDa-heparin-
binding glycoprotein that belongs to the family of mammalian 
chitinase-like proteins. The gene coding for this protein is situated on 
1q32.1 and the complete structure of the protein is known. YKL-40 
is produced by macrophages, neutrophil granolocytes, fibroblast-
like synovial cells, chrondrocytes, vascular smooth muscle cells, 
endothelial cells, and by cancer cells in different solid tumours [1]. 
Elevated serum levels of YKL-40 have shown to be an independent 
negative prognostic marker for glioblastoma, malignant melanoma, 
small cell lung cancer and cancers originating from breast, ovary, 
kidney, prostate, head and neck, and colon [1, 2, 3]. YKL-40 has until 
now not been tested for non small cell lung cancer (NSCLC). This 
study evaluates the prognostic and predictive value of YKL-40 for 
patients with NSCLC treated with chemotherapy.
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Methods: The study is a retrospective longitudinal evaluation of 
serum YKL-40 levels in 48 patients with NSCLC during treatment. 
All patients were included in a prospective phase II study from 
January 1995 [ref 4] designed to evaluate the toxicity of bi-weekly 
administered cisplatin and paclitaxel. All patients gave written in-
formed consent according to the Helsinki declaration. Blood samples 
from each patient were collected biweekly and stored in a biobank 
at a temperature of minus 80 degrees Celsius. The patient charac-
teristics, number of chemotherapy cycles, best response and overall 
survival were extracted form the initial database. Serum YKL-40 was 
measured in all the blood samples with the commercially available 
ELISA test (Quidel). To evaluate the predictive and prognostic of 
YKL-40, the levels were correlated to best response to chemotherapy, 
duration of response, and overall survival. All YKL-40 values were 
compared with YKL-40 levels in an age and sex matched group of 
healthy individuals. 
Results: At the World conference we will be presenting results of the 
measurements of YKL-40 in above mentioned population. This will 
be correlated to pretreatment serum YKL-40, age, sex, PS, histology, 
stage and response to treatment and demonstrate that YKL-40 is an 
independent prognostic and predictive variable of overall survival 
and response to chemotherapy in non small cell lung cancer.
References cited:
1 Johansen JS, Jensen BV, Roslind A, et al: Serum YKL-40: A new prognostic bio-
marker in cancer patients? Cancer Epidemiol Biomarkers Prev 15:194-202, 2006
2 Johansen JS, Bojesen SE, Mylin AK, Frikke-Schmidt R, Price PA, Nordestgaard 
BG: Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and 
decreased survival after any cancer diagnosis in the general population. J Clin Oncol. 
2009 Feb 1;27(4):572-8. 
3 Johansen JS, Drivsholm L, Price PA, Christensen IJ: High serum YKL-40 level in 
patients with small cell lung cancer is related to early death.. Lung Cancer. 2004 
Dec;46(3):333-40.
4 Sørensen JB, Wedervang K, Dombernowsky P: Preliminary results of a phase II 
study of paclitaxel and cisplatin in patients with non-small cell lung cancer. Semin 
Oncol. 1997 Aug;24(4 Suppl 12):S12-18-S12-20.
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A new unique lung cancer spectral biomarker
Masilamani, Vadivel4; Salhi, Mohamad Al2; Elangovan, Masilamani3; 
Trinka, Vijmasi1; Diab, Abdulrahman Al2; Hajjar, Waseem 2; Ainia, 
Mohamad2; Mustapha, Abdullah Al2
1 Masila’s Cancer Diagnostics, Chennai, India; 2 King Saud 
University, Riyadh, Saudi Arabia; 3 Thendrel Inc, Fairfax, VA, USA; 4 
University, Riyadh, Saudi Arabia
This paper present results of a new unique biomarker obtained from 
the native fluorescence of blood plasma of lung cancer patients. 
Methods: Normal Volunteers (N=2100) and cancer patients 
(N=3100) of different etiology inclusive of lung cancer (N=40) were 
recruited. 
Exactly 5 ml of fasting blood from each of them was drawn into 
EDTA vial then centrifuged at 4000 rpm for 15 minutes. The super-
natant plasma was subjected to Synchronous Excitation Spectra 
[SES].
Results: All SES were obtained with an off-set of 70nm. Fig.1 (a) 
shows a typical SES of blood plasma of a normal control. This spec-
trum has peaks at 285nm (excitation bands of tryptophan); 350 nm 
(NADPH ); and 440nm (flavin); 
Fig.1 (b) shows SES of a breast cancer patient. Here the 285 nm band 
gets shifted to 295nm; 350nm to 365nm, but 440nm band remains 
largely unchanged.
Fig.1 (c) shows similar SES of a lung cancer patient. There is a clear 
distinct band at 327nm and the 350nm bands get shifted to 365nm 
leaving 440nm band unaffected.
Fig.1 a, b and c are representative figures of each category (Nor-
mal=2100, Ca diseased =3060 and lung Ca=40) each with unique 
set of spectral features. This band with excitation band at 327nm 
is exclusive to plasma of lung cancer patients only. Though only 
77 % of lung cancer patients have this biomarker it is found nei-
ther in the plasma of normal nor in those of Ca patients of other 
etiology(specificity is 100%). We have observed the 327nm band in 
the SES of lung cancer tissues also (Not shown).
The SES and emission for pure bovine elastin have spectral peaks at 
327nm (Fig 1d) and 400 nm (not shown here) coinciding to that of 
lung cancer plasma and tissue. This shows that the exclusive spectral 
biomarker for lung cancer is the structural protein elastin. Note that 
collagen, another protein, has spectra similar to that of elastin. With 
bands at 327- 400 and this too may have some contribution. 
Conclusion: In this report on auto fluorescence of plasma of few 
thousand normal controls and cancers of different etiology, a new 
unique spectral biomarker has been identified for lung cancer, with 
specificity about 100 % and with sensitivity of 77%. The results pre-
sented here appears to be the first of this kind indicating that elastin 
(and collagen) could be taken as totally new spectral biomarker for 
lung cancer exclusively. 
Based on the above work a patent has been submitted to Indian and 
US patent office. 
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Classification of lymph node metastasis for NSCLC: The 
ratio of metastatic lymph nodes to examined lymph nodes 
(N ratio) is a better prognostic indicator than the number 
or location of metastatic lymph nodes
Matsuguma, Haruhisa3; Nakahara, Rie3; Ishikawa, Yoshinori3; 
Suzuki, Haruko3; Ui, Akiko1; Kamiyama, Yukari3; Mori, Kiyoshi3; 
Kodama, Tetsuro3; Igarashi, Seiji3; Yokoi, Kohei2
1 Division of Thoracic Surgery, Utsunomiya, Japan; 2 Nagoya 
University Graduate School of Medicine, Nagoya, Japan; 3 Tochigi 
Cancer Center, Utsunomiya, Japan
Objective: The staging system is critically important to make a 
prognosis and determine a treatment strategy for cancer patients. The 
current nodal classification employed for lung cancer is based on the 
location of metastatic lymph nodes. The number of metastatic lymph 
nodes is included in the nodal staging in several major carcinomas 
due to its better prognostic ability. However, the number of meta-
static lymph nodes could be influenced by the method of lymph node 
removal or pathologic examination. The ratio of metastatic lymph 
nodes to examined lymph nodes (N ratio) has been proven to be a 
powerful and reproducible prognostic indicator in some malignan-
cies. This study has been conducted in order to investigate whether 
the N ratio is a more useful prognostic factor than the current nodal 
classification based on the location of metastatic lymph nodes or a 
staging system based on the number of metastatic nodes in NSCLC. 
Methods: Between 1987 and 2003, 675 patients with T1-3 NSCLC 
underwent the complete resection of lung tumors without any pre-
operative treatment. The number of lymph nodes removed ranged 
from 1 to 66, and the average was 19.5. Eighteen patients had less 
than 5 lymph nodes removed, and we excluded them from further 
analysis. The number of metastatic lymph nodes ranged from 1 to 24, 
and the average was 3.6. The N ratio in node-positive patients ranged 
from 0.02 to 0.72, and the average was 0.16. The median follow-up 
period of surviving patients was 82 months. In order to compare the 
prognosis in each category, all of the new nodal categories based on 
the number or ratio of the metastatic lymph nodes were defined so 
that the numbers corresponded with paired categories within the cur-
rent N classification. 
Results: Table 1 shows the numbers of patients and 5-year overall 
survival rates for each nodal status stratified according to the nodal 
classifications based on the location, number of metastatic lymph 
nodes, or N ratio. The survival difference between each nodal status 
using the new classification based on the N ratio was the most sig-
nificant. The second most effective classification was based on the 
number of LN metastases. 
Table 1
 Current No.  5-yOS Number of No.  5-yOS N No.  5-yOS 
 classification  of pts.  metastatic LN of pts.  ratio of pts.
 N0 443 75% 0 443 75% 0 443 75%
 N1 113 51% 1-2 116 53% <0.12 114 58%
 N2 101 42% ≥ 3 98 39% ≥ 0.12 100 34%
  Single station  60  49%  3-5  57  45%  0.12-0.26  60  39%
  Multiple stations  41  37%  ≥ 6  41  31%  ≥ 0.26  40  26%
When the patients were divided into two groups according to whether 
the numbers of lymph nodes examined were less than (Table 2) or 
equal to or more than 15 (Table 3), the N ratio could be used to clas-
sify the patients into the prognostic subgroups more reproducibly 
than the number of metastatic lymph nodes.
Table 2 LN < 15
 Number of No.. 5-yOS N No. 5-yOSS 
 Metastatic LN of pts.  ratio of pts.
 0 145 73% 0 145 73%%
 1-2 26 38% <0.12 18 50%
 ≥ 3 13 46% ≥ 0.12 21 33%
Table 3 LN≥15     
 Number of No.. 5-yOS N No. 5-yOSS 
 Metastatic LN of pts.  ratio of pts.
 0 298 77% 0 298 77
 1-2 90 58% <0.12 96 60%
 ≥ 3 85 46% ≥ 0.12 79 35%
Conclusion: Lymph node classification based on N ratio may be the 
most effective method for the discrimination of prognostic groups.
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Gene copy number gains are associated with prognosis in 
a comprehensive molecular profile of non-small cell lung 
cancer
Micke, Patrick1; Edlund, Karolina1; Göransson, Hanna2; Ekman, 
Simon3; Bergqvist, Michael3; Scheibenflug, Lena1; Lamberg, 
Kristina7; Ståhle, Elisabeth 5; Berglund, Anders 3; Lambe, Mats 3; 
Nyberg, Fredrik6; Thomas, Andrew4; Isaksson, Anders2; Holmberg, 
Lars8; Botling, Johan 1
1 Uppsala University Hospital, Pathology, Uppsala, Sweden; 2 
Uppsala University Hospital, Medical Science, Uppsala, Sweden; 3 
Uppsala University Hospital, Regional Oncology Centre, Uppsala, 
Sweden; 4 Astra Zeneca, Alderley Park, Macclesfield, UK; 5 
Uppsala University Hospital, Thoracic and Cardiovascular Surgery, 
Uppsala, Sweden; 6 Astra Zeneca R&D, Mölndal, Sweden; 7 Uppsala 
University Hospital, Pulmonary Division, Uppsala, Sweden; 8 
King's College London, Medical School, Division of Cancer Studies, 
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Background: The present classification of non-small cell lung cancer 
(NSCLC) is principally based on histopathological parameters. To 
date, no molecular signature with a major prognostic impact has been 
established. To maximise the chance of identifying molecular events 
that are associated with survival we applied a comprehensive analysis 
strategy involving two prognostically extreme patient groups.
Methods: From a clinically and histopathologically well-charac-
terised group of 382 operated NSCLC patients with available fresh 
frozen tumour biobank samples, 30 short (<20 months) and 30 long 
term survivors (>58 months) were selected. On each tumour sample 
global high-resolution gene expression arrays, genome-wide SNP 
arrays, mutation analysis (p53, exon 4-9; KRAS, exon 1-2; EGFR, 
exon 19-21) and EGFR-FISH were performed. 
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
Copyright © 2009 by the International Association for the Study of Lung CancerS920
Results: By comparing gene copy number alterations we identified 
two candidate regions encompassing 75 genes on chromosome 1q 
and 11q that were more frequently amplified in the long-term survival 
group. In contrast, the global gene expression profiles did not reveal 
any expression pattern that correlated with clinical outcome. Muta-
tions of p53, KRAS and EGFR were detected in 68%, 24% and 13% 
of all samples, respectively, and were not associated with survival or 
subgroups generated by genomic or expression profiles.
Conclusion: Our results highlight the complexity but also the 
potential of comprehensive molecular analysis strategies in NSCLC. 
The genomic regions that were associated with survival may serve as 
a starting point for more specific studies and functional analysis of 
candidate genes.
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Treatment response and outcomes of non-small-cell lung 
cancer with EGFR gene mutations in exon 20
Miyanaga, Akihiko1; Akagi, Kiwamu2; Takeuchi, Susumu1; 
Toyokawa, Masaru1; Sudo, Junko1; Kurimoto, Futoshi 1; Yoshino, 
Naoyuki3; Mikami, Iwao3; Akiyama, Hirohiko3; Sakai, Hiroshi 1
1 Division of Thoracic Oncology, Saitama Cancer Center, 
Saitama, Japan; 2 Division of Molecular Diagnosis and Cancer 
Prevention,Saitama Cancer Center, Saitama, Japan; 3 Division of 
Thoracic Surgery, Saitama Cancer Center, Saitama, Japan
Background: Several studies have reported that the epidermal 
growth factor receptor (EGFR) gene mutations, such as exon 19 
deletions or the replacement of leucine with arginine at codon 858 
(L858R) in exon 21, can predict the sensitivity of non-small-cell lung 
cancer to EGFR-tyrosine kinase inhibitors (TKI), whereas exon 20 
insertions and the replacement of threonine with methionine at codon 
790 (T790M) are related to resistance. 
Methods: We studied 1421 patients in whom EGFR gene mutations 
were examined at our hospital from March 2005 through February 
2009. 1079 patients had non-small-cell lung cancer and 370 patients 
had EGFR gene mutations. We retrospectively studied treatment 
response and outcomes in 30 patients who had EGFR gene mutations 
in exon 20.
Results: Overall, 19 patients (1.8%) had exon 20 insertions (or de-
letions), and 11 (1.1%) had T790M. Four of the patients with exon 20 
insertions received initial chemotherapy, 1 naïve EGFR-TKI therapy, 
12 underwent surgery, and 2 best supportive care; 1 received second-
line EGFR-TKI therapy. But none who received chemotherapy and 
EGRF-TKI had response. T790M was present before treatment in 5 
patients (0.5%) and T790M appeared in 4 patients after resistance 
developed to gefitinib. Among 5 patients whom T790M was present 
before treatment, one patient who received gefitinib as second-line 
treatment had progressive disease, and another who received chemo-
therapy had stable disease. 
Conclusions: Since the presence of exon 20 mutations might result in 
clinical resistance and some patients may have acquired T790M be-
fore treatment, exon 20 mutations should also be routinely examined. 
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Adjustment of creatinine (Cr) is needed to avoid severe 
thrombocytopenia of carboplatin (C) plus gemcitabine (G) 
in non-small cell lung cancer (NSCLC)
Miyauchi, Eisaku; Horiike, Atsushi; Motokawa, Ikuyo; Kudo, Keita; 
Ohyanagi, Fumiyoshi; Mun, Mingyon; Sakao, Yukinori; Okumura, 
Sakae; Nakagawa, Ken; Horai, Takeshi; Nishio, Makoto
Japanese Foundation For Cancer Reserch, Cancer Institute Hospital, 
Tokyo, Japan
Background: Carboplatin plus gemcitabine (CG) is a standard regi-
men for advanced NSCLC. Although the dose of C is calculated from 
Cr clearance (CCr) by Calvert`s formula, severe thrombocytopenia 
sometimes occurs in the CG regimen. Severe thrombocytopenia 
might arise from differences in the methods of measuring Cr values. 
We have used two different techniques, the Jaffé method and the 
enzymatic method. When the enzymatic method was used, CCr over-
estimated the glomerular filtration rate and the dose of C calculated 
by Calvert`s formula leads to overdosing.The aim of this study was 
to clarify whether severe thrombocytopenia could be avoided by 
adjusting the CCr in the CG regimen when Cr is measured by the 
enzymatic method. 
Methods: All patients (pts) were treated with CG (C, AUC = 5 on 
day 1; G, 1,000 mg/m2 on days 1 and 8) every 3 weeks for 4 cycles. 
Serum Cr values were measured by the enzymatic method and CCr 
was estimated by the Cockcroft-Gault formula for all patients. In the 
non-adjusted group, the dose of C was calculated by Calvert`s for-
mula without adjustment of CCr. In the adjusted group, the dose of C 
was calculated by Calvert`s formula, adjusting Cr as follows: (serum 
Cr +0.2). We compared the correlations between Cr values and the 
nadir of thrombocytes, and the frequencies of severe thrombocyto-
penia in both groups. 
Results: 32 pts were enrolled both in the non-adjusted and the 
adjusted groups, respectively. Grade 3/4 thrombocytopenia was 
observed in 19 pts (60%) and these pts had low levels of serum Cr 
values. On the other hand, significantly fewer cases of grade 3/4 
thrombocytopenia were observed in the adjusted group (9 pts; 28%, 
p = 0.0006). In addition, there was a significant correlation between 
Cr values and the nadir of thrombocytes in the non-adjusted group 
(R= 0.442, p= 0.0105), but no significant correlation was observed in 
the adjusted group (R= -0.165, p= 0.3691). These results suggest that 
adjustment of CCr can reduce the variable nadir of thrombocytes in 
the CG regimen when Cr is measured by the enzymatic method. 
Conclusions: If Cr is measured by the enzymatic method, adjustment 
of Cr is needed to avoid severe thrombocytopenia in the CG regimen. 
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Tumor Marker Index (TMI) based on CYFRA 21-1 and 
CEA predicts recurrence-free survival in P-Stage I NSCLC
Muley, Thomas R.; Traschütz, Christa; Hoffmann, Hans; Dienemann, 
Hendrik; Thomas, Michael; Herth, Felix J.; Meister, Michael
Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, 
Germany
Background: Tumor markers such as CEA and CYFRA 21-1 have 
been shown to provide prognostic information in non-small cell lung 
cancer (NSCLC). In addition, a combination of the two markers 
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might considerably improve the prognostic value. We recently intro-
duced an algorithm successfully combining CEA and CYFRA 21-1 
for the new parameter TMI. TMI was shown to be a valuable tool for 
risk evaluation in early stage NSCLC (Muley et al, Lung Cancer 60, 
408-415, 2008).
Methods: The purpose of the prospective study was to analyse the 
value of TMI to predict recurrence in 113 completely resected stage 
I NSCLC patients (72 male/ 41 female). There were 37 squamous 
cell carcinomas, 60 adenocarcinomas, and 16 other NSCLC types. 
The mean age was 64 years. Sixteen patients experienced recurrence 
within the observation period. Tumor markers were measured in pre-
operatively collected serum specimens by immunoassays on Elecsys 
Bioanalyzer 2010 (Roche, Mannheim, Germany). TMI is defined as 
the geometric mean of normalized tumor marker data [TMI=Square 
root of (CYFRA 21-1/diagnostic cut-off (=3.3ng/ml) x CEA/diag-
nostic cut-off (=5.0)]. Statistical analysis was done with SPSS 15.0 
(Chicago, Illinois, USA) and ADAM (DKFZ, Heidelberg, Germany).
Results: The median follow-up period was 14.3 months and the 
overall 1-year recurrence-free survival rate was 87%. TMI at a cut-
off-point of 0.58 differentiated significantly between patients with 
low and high rate of recurrence in univariate (p=0.004) and multivari-
ate (p=0.013) analysis. The hazard ratio was found to be 6.6 (95%CI 
1.5-28.9) (Figure).
Conclusions: Combining CYFRA 21-1 and CEA by the TMI algo-
rithm proved to be a useful tool for prognostic evaluation in NSCLC. 
Stage I Patients with elevated TMI levels were shown to be at higher 
risk of recurrence and might therefore be appropriate candidates for 
adjuvant therapy. 
P3.163 Prognostic and Predictive Markers, Mon Aug 3 – Tue Aug 4 
The derivation and validation of the rule for estimating 
short-term mortality risk during gefitinib treatment of 
non-small-cell lung cancer
Naito, Tateaki; Ono, Akira; Takahashi, Toshiaki; Murakami, 
Haruyasu; Endo, Masahiro; Tsuya, Asuka; Nakamura, Yukiko; Kaira, 
kyoichi; Yamamoto, Nobuyuki
Thoracic Oncology Division, Shizuoka Cancer Center, Sunto-gun, 
Japan
Rationale: Gefitinib has a therapeutic effect on patients with non-
small cell lung cancer (NSCLC) with relatively mild toxicities as 
compared with cytotoxic chemotherapy. However, little is known 
about the risk assessment of short-term mortality during the treat-
ment. The aims of this study are to elucidate the predictive factors for 
short-term mortality and to establish the risk-assessment rule. 
Method: We retrospectively reviewed consecutive 238 patients (der-
ivation cohort, n = 167, and validation cohort, n = 71) with pretreated 
NSCLC who had received gefitinib treatment. The short-term mortal-
ity was defined as death within 28 days from starting gefitinib. 
Results: In the derivation cohort, median age was 62 (31 - 83) 
and the overall 28-day mortality was 6.1%. The classification and 
regression tree analysis identified 3 risk-groups including high-risk 
group (Male with hypoalbuminemia [<3.75 g/dl] and poor perform-
ance status [grade 3 or 4], 28-day mortality of 70.0%), moderate-risk 
group (Male with hypoalbuminemia and recent weight loss [> 1.1 kg/
month], 20.0%), and low-risk group (others, 0.0%). Hazard ratio was 
12.8 (6.1 - 24.4) in high-risk group and 6.9 (3.5 - 12.7) in moderate-
risk group (reference, low-risk group). The major cause of death was 
caner progression in high-risk group. When this rule was applied to 
the validation cohort, median survival time was 1.5 months in high-
risk group, 4.4 months in moderate-risk group, and 11.4 months in 
low-risk group (log-rank test P < 0.001). 
Conclusion: Male gender and nutritional status (hypoalbuminemia 
and recent weight loss) were strongly associated with 28-day mortal-
ity during gefitinib treatment. The short-term mortality risk assess-
ment might reduce the unnecessary or possibly harmful treatment 
decision in the treatment of advanced NSCLC.
P3.164 Prognostic and Predictive Markers, Mon Aug 3 – Tue Aug 4 
Female gender is a prognostic factor in lung cancer 
patients after surgery
Nakamura, Haruhiko1; Ando, Koji1; Tagaya, Rie1; Shinmyo, Takuo1; 
Morita, Katsuhiko1; Mochizuki, Atsushi1; Kurimoto, Noriaki1; 
Yokote, Kumio1; Osada, Hiroaki2
1 Chest Surgery, St. Marianna University School of Medicine, 
Kawasaki, Japan; 2 Sho-nan Chu-oh Hospital, Fujisawa, Japan
Background: The international TNM staging system is the most reli-
able predictor of outcome for patients with lung cancer. Besides the 
disease stage, various clinico-pathologic factors have been reported 
to be useful for prediction of survival from a biological or epidemio-
logical perspective. However, it is still unclear if basic clinical factors 
such as gender and age affect survival after surgery for lung cancer. 
Methods: A search of the patient database of St. Marianna Univer-
sity School of Medicine identified 936 consecutive patients who 
underwent surgery for lung cancer. These patients were analyzed to 
determine possible prognostic factors. The patients included 648 men 
and 288 women, and had a mean age of 64.7 years old. Histologic 
types included adenocarcinoma in 56% of the patients, squamous 
cell carcinoma in 31%, adenosquamous cell carcinoma in 4%, large 
cell carcinoma in 2%, and miscellaneous types in 7%. The pathologic 
stage was IA in 30%, IB in 27%, IIA in 2%, IIB in 10%, IIIA in 20%, 
IIIB in 5% and IV in 6%. The mean follow-up period was 40 months. 
The postoperative survival rate was calculated by the Kaplan-Meier 
method and the survival difference between the two groups was 
tested by Log rank test. Multivariate analysis was performed using a 
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Cox proportional hazards model. A p-value below 0.05 was con-
sidered significant.
Results: The overall postoperative survival rate (5-year survival 
rate) in women was significantly higher than that in men (55.1% 
vs. 37.2%, p<0.0001). Adenocarcinoma, younger age, and earlier 
stage were also identified as factors indicating a better prognosis, but 
multivariate analysis revealed that disease stage and gender were in-
dependent significant prognostic factors. The survival rates in women 
were higher than those in men for p-stages IA (p<0.05) and IB 
(p<0.001), but survival was similar for more advanced stages. A sig-
nificant survival difference between men and women was also found 
for adenocarcinoma (p<0.0001), but not for squamous cell carcinoma 
(p=0.3508). A survival benefit for women with adenocarcinoma was 
found only for p-stage IB. Survival rates for adenocarcinoma and 
squamous cell carcinoma were similar in men (p=0.8849), whereas 
in women survival for adenocarcinoma tended to be higher compared 
with squamous cell carcinoma. Operation time, intraoperative blood 
loss, and surgical curability were all significantly associated with 
survival after surgery, which indicates the importance of appropriate 
surgery for advanced-stage lung cancer.
Conclusions: Women have a postoperative survival benefit after 
surgery for lung cancer, especially for cases in p-stages IA and 
IB. The overall survival advantage was also detectable in cases of 
adenocarcinoma only. Specific adenocarcinoma subtypes such as 
focal bronchioloalveolar carcinoma or well-differentiated papillary 
adenocarcinoma may contribute to the better outcome in women be-
cause of the slow-growing, non-aggressive features of these cancers. 
Differences in smoking habits between men and women may also af-
fect the postoperative course, and a further study is needed to clarify 
these issues.
P3.165 Prognostic and Predictive Markers, Mon Aug 3 – Tue Aug 4 
Sex-linked hormone receptor expression in lung cancer 
patients: pilot study in a consecutive group of patients with 
advanced Lung Cancer
Monica, Valentina1; Novello, Silvia1; Longo, Marina1; Cappia, 
Susanna2; Pandiscia, Saverio1; Crida, Benedetta1; Giaj Levra, 
Matteo1; Rapetti, Simonetta G.1; Capelletto, Enrica1; Papotti, Mauro1
1 University of Turin_Department of Clinical and Biological 
Sciences, Orbassano, Italy; 2 Division of Pathology, San Luigi 
Hospital, Orbassano (Torino), Italy
Background: Lung cancer in women has some different characteris-
tics than men, with more adenocarcinoma, higher risk in never smok-
ers, differences in DNA repair machinery and more frequent EGFR 
mutations in women. Epidemiologic evidence supporting a role for 
reproductive and hormonal status in lung cancer has been some-
what inconsistent, mainly in retrospective and surgical cohorts of 
patients, and the mechanism modulating the expression and function 
of hormonal receptors in lung cancer still remain unclear. We aimed 
to assess possible correlation between sex-linked hormone receptor 
expression and the activation of specific growth factor signalling and 
DNA repair pathways. 
Methods: In this first part of the study, we collected a pilot series of 
66 chemotherapy-treated consecutive patients (46 men, 20 women), 
referred to the Thoracic Oncology Unit of San Luigi Hospital from 
January to November 2008, with advanced non-small cell lung cancer 
(NSCLC), including 27 adenocarcinoma (ADC), 19 squamous carcin-
oma (SCC), 10 carcinomas not otherwise specified and 10 small cell 
lung cancer (SCLC). The immunohistochemical (IHC) expression 
of estrogen receptors (ER α/β), progesterone receptor (PR), EGFR 
and ERCC1 was assessed as percentage of positive cells; aromatase 
reactivity was scored 0 (totally negative) or score 1 (presence of any 
cytoplasmic IHC signal). All markers were preliminarily tested on 16 
(8 women and 8 men) surgically resected NSCLC and their reactivity 
in lung tissues validated and compared with corresponding biopsy 
specimens. 
Results: ERβ nuclear expression was found in both men and women 
at high levels (median expression level=80%), while ERα and PR 
had a weak, preferentially in women, or null expression. By adopt-
ing cut-off value according to median expression level, no significant 
correlation was found between age, sex, stage of disease, response to 
chemotherapy, histology and ERβ, aromatase and EGFR expression, 
respectively. Cytoplasmic immunoreactivity for aromatase was found 
in 40% of cases. A linear correlation was found between ERCC1 
levels and aromatase staining (p=0.03) and between ERCC1 and 
ERβ, this latter only in women (p=0.01) compared to men (p=0.27). 
ERCC1 was differentially expressed among histotypes, with signifi-
cantly higher levels in SCC compared to ADC (p= 0.003) and SCLC 
(p=0.02). 
Conclusions & Perspectives: The small number of currently inves-
tigated lung cancer patients showed: a) a significant association be-
tween ERβ status and ERCC1 in women; b) higher ERCC1 levels in 
SCC compared to ADC and SCLC histotypes; c) a linear correlation 
between aromatase and ERCC1 expression levels. The above markers 
will be assessed at both protein and mRNA levels in a larger series of 
advanced NSCLC, in order to better define the prognostic / predictive 
value of these factors and further understand some peculiarities of 
lung cancer in women. 
P3.166 Prognostic and Predictive Markers, Mon Aug 3 – Tue Aug 4 
Immunohistochemical expression of nuclear receptors 
PPARγ, LXR-β and LRH-1 in NSCLC and correlation 
with clinicopathologic features
Raso, Maria Gabriela1; Xie, Yang4; Behrens, Carmen1; Woods, 
Denise5; Jeon, Yang4; Mehran, Reza5; Mangelsdorf, David4; Moran, 
Cesar1; Minna, John4; Wistuba, Ignacio I.1
1 University of Texas MD Anderson Cancer Center, Houston, TX, 
USA; 2 UT Southwester, Dallas, TX, USA; 3 UT MD Anderson Cance 
Center, Houston, USA; 4 University of Texas Southwestern Medical 
Center, Dallas, USA; 5 UT MD Anderson Cancer Center, Houston, 
USA; 6 UT Soutwestern, Dallas, USA; 7 MD Anderson CC, Houston, 
USA
Background: Peroxisome proliferator activated receptor gamma 
(PPAR γ), Liver X Receptor β (LXR-β), and Liver Receptor Homo-
log-1 (LRH-1), are members of the nuclear receptor (NR) super 
family of ligand dependent transcription factors that regulate the 
expression of genes controlling physiological processes. These NRs 
have been involved in cancer development, but not well character-
ized in lung cancer. Recently, we developed a prognostic signature 
based on mRNA expression analysis of NR in NSCLC tumors (Jeong 
et al, unpublished data). Our goal was to investigate in a large set of 
NSCLCs the immunohistochemical (IHC) expression of three NRs 
and correlate the expression with tumors’ characteristics and patients’ 
clinicopathologic data. 
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Methods: Tumor tissue from 309 NSCLCs in tissue microarrays, in-
cluding 196 adenocarcinomas (AC) and 113 squamous cell carcinoma 
(SCC), were analyzed for protein expression by IHC of NRs PPAR γ, 
LXR-β and LRH-1. Protein expression was quantified using a semi 
quantitative score (range 0-300), combining intensity and extension 
of the immunostaining. 
Results: Protein expression of all three NR was present in the 
nucleus and cytoplasm of malignant NSCLC cells. Different levels 
of expression of these receptors were detected by NSCLC histol-
ogy: adenocarcinomas expressed significantly higher expression of 
nuclear PPAR γ (mean score AC 35.7; SSC 16.7; P<0.001), while 
squamous cell carcinomas showed significantly higher expression of 
cytoplasmic PPAR γ (mean score AC 4.3; SCC 33.3; P< 0.001) and 
nuclear LXR-β (mean score AC 127.2; SCC 147.2; P=0.0226). LRH-
1 was expressed only in the nucleus of squamous cell carcinomas at 
very low levels. Correlative analysis of the NRs expression with the 
clinicopathologic features showed significant differences according to 
gender and smoking: a) while cytoplasmic expression of PPAR γwas 
significantly higher in males (P=0.0095), nuclear expression was 
higher in females (P=0.0489); b) cytoplasmic PPAR γ (P=0.0005) 
and LRH-1 (P=0.0255) were significantly higher in ever smokers 
compared with never smokers. In stages I/II tumors, multivariate 
analysis of the marker expression scores as continuous variables 
showed that higher levels of cytoplasmic (HR 1.31; P=0.0123) and 
nuclear (HR 1.42; P=0.0061) LXR-β expression significantly correl-
ated with worse disease free survival, and higher cytoplasmic (HR 
1.2; P=0.0117) expression correlated with worse overall survival.
Conclusions: Our study confirms that PPAR γ, LXR-βand LRH-1 
proteins are expressed in NSCLC tissue specimens. The expression 
of these NRs correlated with NSCLC patients’ clinicopathologic 
features, and LXR-βexpression correlates with patients’ outcome. 
The molecular characterization of NRs may aid in the development 
of prognostic biomarkers and in the identification of new therapeutic 
targets for prevention and treatment of NSCLCs. Supported by grants 
DoD W81XWH-04-1-0142 and UT-Lung SPORE P50CA70907.
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Does expression of Betatubulin 3 correlate between 
primary non small cells lung cancer tumor and 
metastases?
Roseau, Jean-Baptiste1; Tasei, Anne-Marie2; Souraud, Jean-Baptiste3; 
Figarella-Branger, Dominique2; Astoul, Philippe4
1 Service de Pneumologie, Toulon Armees, France; 2 Service 
d’Anatomopathologie, Hôpital de la Timone, Marseille, France; 3 
Service d’Anatomopathologie, HIA Sainte Anne, Toulon Armees, 
France; 4 Service d’Oncologie Thoracique, Hôpital Sainte 
Marguerite, Marseille, France
Background: Chemotherapy is the cornerstone of the treatment of 
metastatic lung cancer. Betatubulin 3 is a component of the micro-
tubules involved during cell proliferation. It is a target for some drugs 
of chemotherapy like taxanes and vinca-alcaloides. Over-expression 
of betatubulin 3 could be associated with resistance to those drugs. 
Little is known about the biology of this protein. In particular there is 
no data about the conservation of its expression during the metastatic 
process.
Aims and Objectives: The aim of this study was to determinate if 
expression of betatubulin 3 is correlate between primary non small 
cells lung cancer (NSCLC) tumors and matched metastasis. 
Methods: Twenty-eight patients with metastatic NSCLC were 
included. Primary tumor and metastases were operated or biopsied 
for each patient. The expression of Betatubulin 3 in each tumor was 
evaluated with immunohistochemistry.
Results: Betatubulin 3 was over-expressed in 12 (48%) primary 
tumors and 16 (57%) metastases. Expression of Betatubulin 3 was 
discordant between primary tumors and metastases in 5 (20%) pairs 
of tumors. Expression of Betatubulin 3 is correlated (Spearman’s 
correlation coefficient = 0.62, p < 0.001) and concordant (Kendall’s 
tau B test = 0.62, p < 0.001) between primary tumor and metastases 
in NSCLC.
Conclusions: Betatubulin 3 expression is correlated between primary 
tumor and metastases in NSCLC. It is not necessary to evaluate every 
site of the disease for this marker before discussing a treatment with 
taxanes or vinca-alcaloides.
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Does expression of Excision repair cross-complementation 
group 1 correlate between primary non small cells lung 
cancer tumor and metastases?
Roseau, Jean-Baptiste1; Tasei, Anne-Marie2; Pradel, Vincent3; 
Figarella-Branger, Dominique2; Astoul, Philippe4
1 Service de Pneumologie, Toulon Armees, France; 2 Service 
d’Anatomopathologie, Höpital de la Timone, Marseille, France; 
3 Service d’information médicale, Hôpital Sainte Marguerite, 
Marseille, France; 4 Service d’Oncologie Thoracique, Höpital Sainte 
Marguerite, Marseille, France
Background: Chemotherapy is the cornerstone of the treatment of 
metastatic lung cancer. Excision repair cross-complementation group 
1 (ERCC1) is a protein involved in the DNA repairing process. It is 
responsible of a resistance to platinium-based chemotherapy while 
removing DNA-adducts. Over-expression of ERCC1 is associated 
with resistance to cisplatin. Little is known about the biology of this 
protein. In particular there is no data about the conservation of its 
expression during the metastatic process.
Aims and objectives: The aim of this study was to determinate if 
expression of ERCC 1 is correlate between primary non small cells 
lung cancer (NSCLC) tumors and matched metastasis. 
Methods: Twenty-eight patients with metastatic NSCLC were in-
cluded. Primary tumor and metastases were operated or biopsied for 
each patient. The expression of ERCC 1 in each tumor was evaluated 
with immunohistochemistry.
Results: ERCC 1 was over-expressed in 9 (39%) primary tumors and 
16 (64%) metastases. Expression ERCC 1 was discordant between 
primary tumors and metastases in 9 (39%) pairs of tumors. Expres-
sion ERCC 1 is neither correlated (Spearman’s correlation coefficient 
= 0.34, p = 0.116) nor concordant (Kendall’s tau B test = 0.34 p = 
0.06) between primary tumor and metastases in NSCLC.
Conclusions: ERCC 1 expression is not correlated between primary 
tumor and metastases in NSCLC. Decision of using cisplatin, or not, 
cannot be based only on the expression of ERCC1 in the primary 
tumor.
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
Copyright © 2009 by the International Association for the Study of Lung CancerS924
P3.169 Prognostic and Predictive Markers, Mon Aug 3 – Tue Aug 4 
Effect of genes related to gemcitabine pathway (RRM1, 
DCK, UMPK) on outcome to gemcitabine- and taxane-
doublets
Ryu, Jeong-Seon1; Nam, Hae Sung1; Cho, Jae Hwa1; Kim, DoJin2; 
Kim, Hyun Jung1
1 INHA University Hospital, Incheon, Korea; 2 Division of 
Pulmonology, Soonchunhyang University Bucheon Hospital, 
Bucheon, Korea
Purpose: To determine whether germline variations in genes related 
to gemcitabine pathway can be guide to differentially affect outcome 
in non–small-cell lung cancer patients treated with platinum com-
bination chemotherapy. 
Patients and Methods: We evaluated the associations of seventeen 
tagging SNPs (-756T/C, -269C/A, IVS1-2374T/C, IVS4+80G/A, 
IVS7+25A/C, IVS7-1246C/T, IVS7-425A/G, IVS8+287T/C, R284R, 
IVS9-242T/C for RRM1; -201C/T, IVS2+9846G/A, IVS6+1392T/C 
for DCK; IVS1+1057C/A, IVS1-928C/A, IVS5+592C/T, 1047C/T 
for UMPK), gene-gene interaction with treatment outcome in 298 
NSCLC patients. 
Results: As a first-line regimen, 159 patients (53%) received taxane 
doublets, and 139 patients (46%) received gemcitabine doublet. 
In Cox’ model, wild genotype of IVS1+1057 was associated with 
shorter survival in group of gemcitabine doublet (adjusted HR=1.70, 
P=.0026) whereas this effect was not observed in taxane-doublets 
(adjusted HR=1.03, P=.8865). In analysis of combined effect of 
RRM1 and UMPK, patients with wild genotypes of RRM1 and 
UMPK were shown to have statistically significant shorter survival 
in group of gemcitabine doublet (adjusted HR=2.15, P=.00002 for 
IVS1-2374T/T of RRM1 + IVS1+1057C/C of UMPK; adjusted 
HR=2.10, P=.00004 for IVS7+25A/A of RRM1 + IVS1+1057C/C 
of UMPK; adjusted HR=2.26, P=.00002 for IVS7-425A/A of RRM1 
+ IVS1+1057C/C of UMPK; adjusted HR=2.15, P=.00002 for 
IVS8+287T/T of RRM1 + IVS1+1057C/C of UMPK). However 
these effects were not observed in taxane-doublets. 
Conclusion: These findings suggest that the combination of RRM1 
and UMPK is helpful in clinician’s assignment of choosing patients 
to be more or less beneficial from gemcitabine- and taxane-doublets 
as the first-line regimen. 
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Prognostic impact of gene expression profile in early stage 
Non-small Cell Lung Cancer
Saji, Hisashi; Tsuboi, Masahiro; Usuda, Jitsuo; Kajiwara, Naohiro; 
Usuda, Osamu; Ohira, Tatsuo; Ikeda, Norihiro
Tokyo Medical University, Tokyo, Japan
Background: Lung cancer is the first leading cancer-related death 
in all over the world. Even in early stage lung cancer, approximately 
50% of patients with stage I and II non-small cell lung cancer 
(NSCLC) will die due to recurrent disease despite completely sur-
gical resection. Because no reliable clinical or molecular predictors 
are currently available, it is unable to select those who have poor 
prognosis for more aggressive therapies including adjuvant chemo-
therapy.
Materials and Methods: Gene expression profiling using Affymetrix 
gene chip (HG-133 plus 2.0 Array) on tumor tissues from a total of 
30 patients with stage I (n=26) and II (n=4) NSCLC known clinical 
follow-up information were assessed. Statistical analysis and clus-
tering approaches were used to determine patterns of gene expression 
segregating with clinical outcome (GeneSpring GX, Agilient). 
Results: We found 850 genes expression elevated in early relapse pa-
tients using moderated t test of empirical Bayes’ method. Moreover, 
24 gene profiles predicting prognosis of our series were identified 
using leave-one-out cross-validation method. Of the 24 genes, BCR, 
BAG1, TEGT, MTDH, and CADM1 are listed to be correlated with 
cancer apoptosis and metastasis.
Conclusion: The results suggested that molecular subtyping of 
NSCLC can identify distinct profiles of gene expression correlating 
with disease-free survival.
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A novel algorithm for the EGFR fluorescence in situ 
hybridization (FISH) assay in non-small cell lung cancer: 
an analysis of the NCIC Clinical Trials Group Study BR.21
Santos, Gilda C.1; Ding, Keyue2; Cutz, Jean-Claude3, 4; Le Maitre, 
Aurélie 2; Squire, Jeremy A.1; Shepherd, Frances A.1; Tsao, Ming S.1; 
Seymour, Lesley2
1 University Health Network, University of Toronto, Toronto, ON, 
Canada; 2 NCIC Clinical Trials Group, Kingston, ON, Canada; 3 
Department of Pathology and Molecular Medicine, Faculty of Health 
Sciences, McMaster University, Hamilton, ON, Canada; 4 Hamilton 
Regional Laboratory Program and St Joseph’s Healthcare Hamilton, 
Hamilton, ON, Canada
Background: Exploratory analysis on BR 21 addressed chromo-
some 7 polysomy as a contributing prognostic or predictive factor for 
survival (OS) benefit from erlotinib in non-small cell lung carcinoma 
(NSCLC), and to detect a new algorithm for EGFR FISH interpreta-
tion. 
Methods: The mean EGFR gene copy number (CN)/nuclei (EGFR-
CN) and mean centromere 7 (CEP-7) CN/nuclei were calculated. A 
graphic method based on Martingale residuals from Cox regression 
model was used to determine the cutoff points that correlate to clinic-
al characteristics and outcomes. Cutoff points and analyses for CEP-7 
and EGFR-CN used either three categories (primary): <2.5 (low), 2.5 
-3.5 (intermediate) and ≥ 3.5 (high) or two categories (exploratory): < 
3.5 (low + intermediate) and ≥3.5 (high). 
Results: FISH results were available in 159 patients. Compared to 
patients without FISH results, this cohort experienced similar benefit 
from erlotinib (HR 0.63, 95% C.I. 00.43 – 0.91, p= 0.01, interaction 
p = 0.23) but were more likely to have had progression as the best 
response to prior therapy (43% vs. 30% p = 0.03), ≥ 2 prior therapies 
(60% vs. 48%, p = 0.007), but were less likely to be East Asian (6 vs. 
14%, p = 0.008). At baseline, age ≥ 60 and EGFR expression (IHC) 
were associated with high EGFR- CN (p = 0.024 and p = 0.019 re-
spectively). High polysomy and amplification using Colorado criteria 
were highly associated with high EGFR-CN (p < 0.001). Three-cat-
egory analyses: Both EGFR and CEP-7 CN were not prognostic but 
showed trends for being predictive for treatment effect (interaction 
p=0.09 and p=0.08, respectively). Fifty-four, 51 and 54 patients had 
high EGFR-CN, intermediate or low respectively. For 54 patients 
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with high EGFR-CN, median OS was 10.7 months on erlotinib 
versus 3.0 months for 21 on placebo (HR 0.39, 95% C.I. 0.21 to 0.73, 
p=0.0025). CEP-7 and EGFR-CN were highly correlated. For CEP-7 
CN, 47, 56 and 56 patients fell into the high, intermediate and low 
groups. For 47 patients with high CEP-7 CN, median survival was 
10.7 months for 32 patients on erlotinib and 3.0 months for 15 pla-
cebo patients (HR 0.41, 95% C.I. 0.21 to 0.83, p=0.01). Two category 
analyses: Neither EGFR-CN nor CEP-7 CN was predictive for OS 
(interaction p = NS) using two categories. 
Conclusions: This exploratory study proposes a new algorithm for 
FISH analysis and shows that both high EGFR and CEP-7 CN (≥ 3.5) 
appear to be predictive markers for better survival in NSCLC patients 
treated with erlotinib. The applicability of this algorithm requires 
additional validation.
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Clinical impact of intraoperative detection of 
carcinoembryonic antigen (CEA) mRNA in pleural lavage 
specimens from patients with non-small cell lung cancer
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Background: A positive finding on intraoperative pleural lavage 
cytology (PLC) is considered as a possible prognostic factor for 
patients with non-small cell lung cancers (NSCLCs). However, even 
with negative cancer cells by PLC recurrence may occasionally be 
encountered after surgery. Recently, rapid genetic diagnosis with the 
transcription reverse transcription concerted reaction (TRC) method 
based on RNA polymerase amplification system for detection of 
carcinoembryonic antigen CEA mRNA (mCEA) has been introduced 
for pleural lavage diagnosis. We here evaluated the significance of 
rapid intraoperative detection of mCEA in pleural lavage in NSCLC 
patients. 
Methods: From January 2006 to August 2008, pleural lavage was 
performed before any manipulation or resection of the lung for 437 
consecutive patients who had no macroscopic pleural effusion, dis-
semination or diffuse adhesions and who subsequently underwent 
resection for primary lung cancer at the Cancer Institute Hospital. 
Out the total, 383 NSCLC patients underwent analysis as follows. 
Immediately after thoracotomy, the pleural cavity was washed with 
100 ml of physiological saline, and as much lavage fluid as possible 
was recovered and divided into two portions, analyzed for PLC and 
mCEA expression in the cell fraction. Results of mCEA detection 
by the TRC method and for PLC were analyzed with reference to 
clinicopathologic characteristics, recurrence patterns and patient 
survival. According to the dynamic range with the TRC method, a 
copy number of at least 11 (in the quantitative range) was regarded as 
mCEA expression-positive. 
Results: The patients were 162 women and 221 men, with a median 
age of 65 years (range, 25 to 85 years). For every case, TRC analysis 
was completed within 90 minutes. One hundred and nineteen (31%) 
were mCEA-positive, and 8 (2.1%) were PLC-positive, all of which 
were also mCEA-positive. Positive mCEA results were observed 
much more frequently for adenocarcinoma patients (n=89), followed 
by those with a squamous cell carcinoma (n=14), large cell carcinoma 
(n=6), pleomorphic carcinoma (n=3), adenosquamous carcinoma 
(n=2), and others (n=5). The positive mCEA rates were not associ-
ated with cancer histology or serum CEA level. Overall follow-up 
ranged from 5 to 33 months, with a median of 14 months. The overall 
32-month survival rate was 79% in patients with positive mCEA 
findings and 92% in patients with negative results, the difference 
being statistically significant (P=0.004). Thirty seven cases developed 
recurrence at 3 to 24 months after surgery: 31 with distant metastasis, 
4 with intrapulmonary and 2 with pleural recurrence. Among 37 pa-
tients with recurrence, 18 were mCEA-positive and 3 were PLC-posi-
tive. In the mCEA-positive group, 13 patients had distant metastasis, 
3 pleural involvement and 2 local recurrence. Moreover, 3 out of 14 
patients with both recurrence and positive mCEA results were all 
PLC-positive. Recurrence occurred more frequently in mCEA-posi-
tive (n=18; 15%) than negative patients (n=19; 7%) (p<0.015). Out of 
the 19 patients with negative mCEA and recurrence, 11 had adeno-
carcinomas, 4 large cell carcinomas, and 3 squamous cell carcinomas 
and one a pleomorphic carcinoma. 
Conclusions: Intraoperative mCEA analysis by the TRC method 
should be considered as a sensitive aid to assessing microscopic 
spread of malignant cells into the pleural cavity, associated with 
recurrence and a poor prognosis. Further studies of individual patient 
data with long term outcomes are clearly warranted.
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Expression pattern of p53 family N-terminal isoforms in 
Non-Small Cell Lung Cancer
Lo Iacono, Marco; Ceppi, Paolo; Saviozzi, Silvia; Monica, Valentina; 
Pandiscia, Saverio; Billè, Andrea; Bracco, Enrico; Papotti, Mauro; 
Scagliotti, Giorgio V.
Dep. of Clinical and Biological Sciences, Orbassano, Italy
Background: The p53 family (p53, p63 and p73) is involved in 
many cellular biological processes such as morphogenesis, tissue 
differentiation, development and homeostasis, playing a key-role in 
the regulation of several molecular pathways. p63 and p73 proteins 
share structural and functional similarities with p53 even though 
they exhibit unique properties. The wide range of biological effects 
mediated in cancer cells by the p53 family members p63 and p73 
could be explained by the existence of multiple isoforms expressed 
by the TP63 and TP73 genes. The N-terminal isoforms of p53 family 
can be subdivided in two categories: TA isoforms, which contain 
a transactivation domain (TA), and can mediate apoptosis and cell 
growth suppression, and ∆N isoforms, without the TA domain, which 
can inhibit the activity of TA isoforms acting as putative oncogenes. 
Recent studies suggest the hypothesis that the pathogenesis of many 
diseases, including cancer, an altered ∆N/TA expression ratio more 
than an isoform overexpression may play a role.
Methods: We performed an isoform-specific real-time PCR analy-
sis on matched tumoral and corresponding normal tissues from 46 
surgically resected non-small cell lung cancer (NSCLC) patients in 
order to quantify the expression levels of each p63 and p73 N-termin-
al isoforms (TAp63, ∆Np63, TAp73, D2p73, D2/3p73, ∆Np73 and 
∆N’p73). Expression levels of all p53 family isoforms and ß-actin 
reference genes were evaluated via SYBR technology with ABI 
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PRISM 7900HT Sequence Detection System using isoforms specific 
primers. Melting curve analysis was performed for all the amplicons 
to test primers specificity.
Result: Altered expression of ∆Np63 and TAp73 isoforms was 
significantly associated with squamous differentiation (all p<<0.01) 
whereas high TAp63 (p=0.05), ∆Np63, TAp73, D2p73 (all p<<0.01) 
levels with proliferation rate of the tumors. TAp63 isoform was 
down-regulated (p=0.01) and the ∆Np63 isoform was up-regulated 
(p=0.02) in tumor tissue. The mRNA expression pattern of p73 
mRNA showed a similar pattern of expression: D2p73, D2/3p73 
isoforms were up-regulated and ∆Np73 and ∆N’p73 isoforms were 
down-regulated (all p<0.001), respectively. We identified a significant 
correlations between the high expression level of TAp63 (p<<0.01) 
and ∆N’p73 (p<<0.01) isoforms and reduced patients’ survival.
Conclusion: A intensive cross-talk between TP73 and TP63 N-
terminal isoforms and de-regulation of ∆N/TA expression ratio was 
detected in early NSCLC. These results highlight the relevance of 
the evaluation, in future studies, of all p63 and p73 mRNA isoforms. 
Further studies are necessary to confirm if the evaluation of expres-
sion of these isoforms in normal tissues from healthy individuals at 
high-risk of cancer (i.e. sputum or serum) may be used for screening 
purposes.
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Prognostic significance of eukaryotic initiation factor 
4E and 4E binding protein 1 expression in patients with 
pathological stage I invasive lung adenocarcinoma
Seki, Nobuhiko1; Takasu, Tasaburo 2; Sawada, Shigeki 3; Nakata, 
Masao 4; Nishimura, Rieko 3; Segawa, Yoshihiko 3; Seki, Reishi 5; 
Hanafusa, Toshiaki 2; Eguchi, Kenji 1
1 Teikyo University School of Medicine, Tokyo, Japan; 2 Osaka 
Medical College, Osaka, Japan; 3 National Hospital Organization 
Shikoku Cancer Center, Ehime, Japan; 4 Kawasaki Medical School, 
Okayama, Japan; 5 Isehara Kyodo Hospital, Kanagawa, Japan
Background: The expression of eukaryotic initiation factor 4E 
(eIF4E; key regulator of protein synthesis) and 4E-binding protein 1 
(4E-BP1; suppressor of eIF4E) is involved in the malignant pro-
gression of various human cancers. However, the role of eIF4E and 
4E-BP1 expression as prognostic markers has not been evaluated 
concurrently in any human cancers. 
Methods: The expression of eIF4E and 4E-BP1 was semiquantified 
immunohistochemically in 80 patients with pathological stage I inva-
sive lung adenocarcinoma to evaluate their prognostic significance.
Results: Thirty-six of 80 patients (45%) were determined to have 
high eIF4E expression (4E high group), and 32 (40%) were deter-
mined to have high 4E-BP1 expression (4E-BP1 high group). The 
10-year survival rates of 4E low and 4E high group were 89.9% and 
64.0%, respectively (P = 0.024), whereas the 10-year survival rates of 
4E-BP1 low and 4E-BP1 high group were 70.8% and 85.8%, respect-
ively (P = 0.308). Among 4E low group, the 10-year survival rates of 
4E-BP1 high and 4E-BP1 low subgroup were 100% and 87.6%, re-
spectively (P, not evaluable), whereas among 4E high group, the 10-
year survival rates of 4E-BP1 high and 4E-BP1 low subgroup were 
85.2% and 39.0%, respectively (P = 0.036). By multivariate analysis, 
significantly unfavorable prognostic factors were age over 65 years (P 
= 0.015), pathological stage IB (P = 0.045), high eIF4E expression (P 
= 0.008), and low 4E-BP1 expression (P = 0.007).
Conclusions: Both eIF4E and 4E-BP1 are potential new prognostic 
factors for survival of lung adenocarcinoma and may provide a new 
paradigm for individualized therapy.
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2D-DIGE as a strategy to identify plasma markers for the 
early detection of NSCLC
Sha, Huifang; Sun, Qiangling; Yang, Xiaohua; Feng, Jiuxian
Basic Research Laboratory, Chest Hospital, Shanghai Jiaotong 
University, Shanghai, China
Background: Lung cancer is the leading cause of cancer death in 
China and is the most common cause of cancer mortality in the 
world. Owing to the difficulty in diagnosing the disease at an early 
stage, there is an urgent need for additional markers to improve the 
diagnostic accuracy for early diagnosis and detection. Among the 
many possible types of samples, blood is thought to be ideal for 
this discovery as it can be collected easily in a minimally invasive 
manner. Therefore, proteomic analysis of serum has the potential to 
identify biomarkers related to early detection.
Methods: Blood samples (4-ml Heparin tubes) were collected from 
20 patients (10 with newly diagnosed stage Ⅰ NSCLC and 10 with 
benign lung diseases) and 10 health volunteers under the same condi-
tions. Written informed consent was obtained from all persons. Ar-
chival formalin-fixed, paraffin-embedded tissue blocks were collected 
from 315 patients from the Departments of Pathology of our hospital. 
The three groups were matched with respect to gender, smoking 
habits, number. Plasma samples were subjected to immunoaffinity 
depletion and protein expression analysis using two-dimensional dif-
ferential gel electrophoresis(2D-DIGE). Images were analyzed using 
Decyder 6.5 software(GE company). Proteins associated with lung 
cancer were identified by matrix-assisted laser desorption/ionization 
time-of-flight tandem mass spectrometry (MALDI-TOF-MS/MS) and 
analyzed according gene ontology. Some key molecules were valu-
ated by tissue microarray.
Results: Among 1237 matched protein spots, 72 significantly dif-
ferentially expressed protein spots were screened ratio (chemoresist-
ance/chemosensitive)≥2 or ratio (chemoresistance/chemosensi-
tive≤2), p≤0.01; ). 14 proteins which highly expressed in cancer 
were successfully identified via peptide mass print (PMF) using 
MALDI-TOF- MS/MS. Among them, seven proteins have been 
reported to be related to cancer, such as acyl-CoA synthetase family 
member 3(ACF3), platelet membrane glycoprotein Ib (GPIb) specific 
antibody, serum amyloid A4(SAA4), gelsolin, complement factor 
H(CFH), fibrinogen gamma chain(FGG)and Apolipoprotein A-I(apo 
A1). Among them, SAA4 and gelsolin were further confirmed by 
Western blot analysis. These two proteins were highly expressed in 
NSCLC biopsies(n=225), but not expressed in benign lung diseases’ 
tissues(n=90). 
Conclusions: These results suggest that SAA4 and gelsolin were 
characteristic proteins and might serve as potential biomarkers for 
early detection and targets to lung cancer therapy. We are confident 
that proteomics-based approaches have the potential to provide more 
insight into the underlying molecular mechanisms of the disease and 
also hold great promise for biomarker discovery in lung cancer.
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High expression of VEGF and VEGFR1 is a prognostic 
marker in resectable non-small cell lung cancer (NSCLC)
Cabrera Pastor, Andrea1; Jantus Lewintre, Eloisa1; Sirera, Rafael1, 
2; Honguero, Antonio3; Blasco, Ana1; Sanmartin, Elena1; Gallach, 
Sandra1; Guijarro, Ricardo3; Camps, Carlos1
1 Molecular Oncology Laboratory, Medical Oncology Department, 
General University Hospital of Valencia, Valencia, Spain; 2 
Departamento de Biotecnología, Universidad Politécnica de 
Valencia, Valencia, Spain; 3 Surgery Department, General University 
Hospital of Valencia, Valencia, Spain
Background: NSCLC is a major cause of cancer-related death world-
wide. The prognosis for lung cancer patients is poor with 5-years 
survival rates being less than 15%. It is known that angiogenesis is an 
essential event for solid tumour growth. Vascular endothelial growth 
factor (VEGF) family of ligand and receptors (VEGFR) are described 
as powerful angiogenic factors. VEGF ligands bound to their recep-
tors at the membrane levels, gathering a cascade of intracellular 
events. Our objective was to evaluate the expression and prognostic 
significance of VEGFA and VEGFR1 determined by real-time PCR 
(RTqPCR) in resectable NSCLC patients. 
Methods: We performed RT-qPCR analysis to assess the expression 
of VEGFA and VEGFR1 (FTL1) in 151 frozen lung cancer speci-
mens from untreated NSCLC patients who had undergone surgical 
resection. For this purpose, RNA was extracted using Trizol® and 
RTqPCR was performed using TaqMan® probes. Relative quantifica-
tion was calculated by Pfaffl formulae, using GUS-B (endogenous 
control gene) for normalization. We correlate the expression of both 
angiogenic genes between them and with survival variables. All sta-
tistical analysis were done using the SPSS 13.0 software.
Results: Our results show a strong correlation between the expres-
sion of VEGF and VEGFR1 in tumour samples (p<0.0001, Spear-
man’s test). We used the median as a cut-off value for both variables, 
therefore, cases were scored as high (H) or low (L) according to this 
criteria. There were 71.5% (108/151) of concordant results (both 
variables H or L). Kaplan Meier plots (Figure 1) show that the group 
of patients expressing high levels of VEGFA and VEGFR1 (HH) has 
a significant worse prognosis (p=0.038, log-rank test) than the other 
groups (HL or LL). The median OS for the HH group was 24.27 
months, compared with the 38.03 months for the HL + LL group.
Conclusion: Our results reveal that, in NSCLC tumour samples, 
there is a correlation between the expression of VEGFA and VEGFR1 
mRNA. In addition, determination of these two genes by RTqPCR 
would be a useful clinical test to assess prognosis in NSCLC, due to 
the fact that higher levels of expression of both genes correlates with 
shorter OS. 
Supported by Instituto de Salud Carlos III (Grant PI061041).
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Vascular Endothelial Growth Factor Receptor 2: New 
soluble biomarker in advanced non-small cell lung cancer? 
Sanmartin, Elena1; Sirera, Rafael1; Jantus Lewintre, Eloisa1; Miñana, 
Maria D.3; Navarro, Amparo3; Cabrera Pastor, Andrea1; Rosell, 
Rafael2; Camps, Carlos1
1 Molecular Oncology Laboratory, Medical Oncology Department, 
General University Hospital of Valencia, Valencia, Spain; 2 Catalan 
Institute of Oncology, Badalona, Spain; 3 General University 
Hospital Research Foundation, Valencia, Spain
Background: An increase in VEGF expression in tumour or some 
blood compartments (i.e. serum or plasma) has been found in solid 
tumours of various origins. Several studies have suggested that the 
VEGF ligands and receptors play an important role in tumour growth 
and are associated with metastasis and poor prognosis. The aim of 
our study was to investigate the usefulness of plasmatic VEGF-R2 
quantification as a new biomarker in advanced NSCLC.
Methods: We studied blood samples from 106 healthy controls (c) 
and 467 advanced NSCLC patients (p) (stage IIIB and IV). Whole 
blood samples were collected before chemotherapy and the plasmatic 
levels of the VEGF-R2 were determined by ELISA.
Results: In the NSCLC group, the median age was 59.9, range (31-
80); 82% were males. The histological subtypes were: 31.4% squa-
mous, 49.8% adenocarcinoma, 15.3% large cell and undifferentiated 
and 3.5% other. There was a significant difference in the plasmatic 
levels of VEGF-R2 between c and p (mean+ SEM): 6318+152 ng/
ml and 8141+ 119 ng/ml, respectively (p<0.0001). The area under 
the ROC curve was 0.743 indicating that VEGF-R2 is an adequate 
biomarker for the discrimination between c and p. On the other hand, 
we found no statistical differences in the levels of soluble VEGF-R2 
according to sex, histology, or stage. Dividing the cohort in two sub-
groups according to VEGF-R2 levels: high (>9473,9 ng/ml) and low 
(< 9473,9 ng/ml), we found significant difference in terms of Time 
to Progression (TTP). Patients with higher levels of VEGF-R2 had a 
median TTP of 204 days whereas in the group with lower expression 
the median was 164 days, (p= 0.039). 
Conclusion: In advanced NSCLC, we found higher levels of soluble 
VEGF-R2 in p than in c. There was a correlation between higher ex-
pression of soluble VEGF-R2 with better prognosis, in terms of TTP, 
therefore a more thorough understanding in the role of the plasmatic 
quantification of this angiogenic receptor in advanced NSCLC p 
seems to be an important task.
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Prognostic value of vascular endothelial growth factor 
expression in patients with lung cancer: a systematic 
review and meta-analysis
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Background: It is thought that vascular endothelial growth factor 
(VEGF) was implicated in tumorigenesis and metastasis by mediating 
the proliferation of endothelial cells and promoting vascular perme-
ability. However, the prognostic value of VEGF overexpression in 
patients with lung cancer remains controversial. 
Methods: Published studies were identified with the objective to 
aggregate the available survival results after a methodological assess-
ment using a scale specifically designed by the European Lung Can-
cer Working Party (ELCWP). A meta-analysis of eligible studies was 
performed to quantitatively review the effects of VEGF overexpres-
sion on survival in patients with lung cancer.
Results: Fifty-one studies including 5386 patients were subjected 
to final analysis. The studies were categorized by histology, disease 
stages, race of patients, isoforms of VEGF, laboratory technique. 
Combined hazard ratios (HR) suggested that VEGF overexpres-
sion had an unfavorable impact on survival of patients with NSCLC 
and SCLC. But, VEGF-C and VEGFR3/flt-1 overexpression were 
not shown significant impact on survival for NSCLC: in stage I-III 
NSCLC with VEGF the HR(95%CI) was 1.47 (1.39-1.55), 1.36(1.25-
1.47) in Asian, 1.61(1.49-1.73) in non-Asian, 1.41(1.17-1.65) in 
SCLC, 1.27(1.06-1.47) in Adenocarcinoma, 1.57(1.43-1.70) in stage 
I NSCLC, 1.46(1.38-1.55) in NSCLC by IHC, 1.52(1.23-1.81) in 
NSCLC by RT-PCR, 1.22(0.96-1.48) in NSCLC with VEGF-C, 
1.58(0.96-2.20) in NSCLC with VEGFR3/flt-1. Data were insuffi-
cient to determine the prognostic value of VEGF in squamous cell 
carcinoma of lung.
Conclusion: VEGF overexpression was a poor prognostic factor 
in patients with NSCLC and SCLC, VEGF-C and VEGFR3/flt-1 
overexpression were not shown significant impact on survival for 
NSCLC.
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EGFR mutation analysis in circulating tumor cells and 
matched tumor of patients with non-small cell lung cancer
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Background: Mutations in the epidermal growth factor receptor 
(EGFR) tyrosine kinase (TK) domain are useful indicators of sensi-
tivity to EGFR TK inhibitors. Methods for detecting EGFR mutations 
in non-invasive samples such as blood are desirable as tumor samples 
are often unavailable in routine clinical practice. We sought to deter-
mine the response rate (RR) and time to progression (TTP) according 
to EGFR mutation status in circulating tumor cells (CTC) and tumor 
of patients with non-small cell lung cancer (NSCLC) treated with an 
EGFR TK inhibitor. 
Methods: Blood samples from patients with NSCLC were pro-
spectively collected prior to treatment with EGFR TK inhibitors and 
enriched for CTCs using immunomagnetic cell separation. DNA 
was extracted from these and matched paraffin-embedded diagnostic 
tumor samples and analyzed for EGFR mutation by direct sequen-
cing. Response was determined using RECIST criteria.
Results: Of 22 patients enrolled, all were Asians, 15 were female, 
17 never smokers, and 17 had adenocarcinoma histological subtype. 
Nineteen patients were treated with gefitinib. Assessment of response 
was available in 21 patients. Adequate tumor samples was available 
for EGFR analysis in 13/22 (60%) patients. Mutation analysis was 
successful from blood and tumor samples in 20/22 (91%) and 9/13 
(69%) cases respectively. EGFR wild-type, activating and resistance-
conferring T790M mutations were detected in blood in 7 (35%), 9 
(45%) and 4 (20%) patients and tumor in 3 (33%), 6 (67%) and 0 
patients respectively. The RR for patients with wild-type EGFR, acti-
vating and resistance mutations was 57%, 63% and 25% respectively 
in blood and 33%, 40% and not available (NA) respectively in tumor. 
The corresponding TTP was 8.0, 4.1 and 1.0 month respectively in 
blood and 1.0, 5.4 and (NA) months in tumour.
Conclusions: EGFR mutations are detectable in blood, and blood 
analysis is feasible and could provide results more frequently than 
tumor analysis. Blood analysis also yielded similar trends in RR and 
TTP according to EGFR mutation status as analysis of tumour, with 
the addition of information on T790M mutations. A larger study is 
required to confirm if blood-based mutation analysis could be used as 
an alternative to tumor mutation analysis.
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Study of molecular changes in epidermal growth factor 
receptor (EGFR) and K-ras in non-small cell lung cancer 
(NSCLC) biopsies at time of progression compared to 
initial biopsy
Speranza, Giovanna1; Cohen, Victor1; Agulnik, Jason S.1; Chong, 
George2; Meilleur, Francine2; Brandao, Guilherme2; Kasymjanova, 
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Background: EGFR mutations predict sensitivity and clinical out-
come to tyrosine kinase inhibitors (TKIs) in NSCLC. The two most 
commonly described mutations are Exon 19 deletions and Exon 21 
L858R point mutations. K-ras mutations have been shown to predict 
resistance to TKIs. Genetic alterations over time have been described 
in other tumor types, but studies assessing genotypic changes with 
lung cancer progression are lacking. We seek to compare EGFR and 
K-ras mutational status from lung tumors at time of recurrence or 
progression with that of the primary tumor.
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Methods: Using the Jewish General Hospital lung cancer database of 
all patients diagnosed with NSCLC since 1999, those with biopsies at 
two different points in time were identified. All tumour samples will 
be genotyped for EGFR exons 19 and 21 mutations using denatur-
ing high performance liquid chromatography and for K-ras mutation 
using high resolution melting analysis.
Results: 29 patients were identified. Data for EGFR mutational status 
of 12 patients, whose time of recurrence or progression varied be-
tween 4 months and 6 years, are available at this time. Of 12 patients, 
one had EGFR exon 19 mutation at time of diagnosis and continued 
to express this in the second biopsy. One patient who initially dis-
played no EGFR mutation was found to have an exon 19 deletion at 
time of recurrence. K-ras testing is ongoing and further results are 
pending. 
Conclusions: To our knowledge, this is the only study assessing 
changes in molecular genotype between primary and recurrent or 
progressive lung cancer biopsy specimens. Although sample size is 
small, it is evident that changes in mutational status can occur. Final 
results will be presented at the 13th World Conference on Lung 
Cancer. Further prospective studies are required to determine how 
commonly molecular changes occur.
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Analyses of clinical or biological factors for predicting 
benefit of gefitinib in patients with recurrent non-small 
cell lung cancer with EGFR mutation after pulmonary 
resection
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Background: Somatic mutations in the epidermal growth factor re-
ceptor (EGFR) gene are associated with significant clinical responses 
to the treatment with gefitinib in non-small cell lung cancer (NSCLC) 
patients. Although about 70-80% of the patients harboring EGFR 
mutations respond to gefitinib, acquired resistance develops in almost 
all patients sooner or later. However, predictive factors associated 
with initial response or time to treatment failure (TTF) of gefitinib 
in NSCLC patients with EGFR mutation is unclear. We previously 
reported the positive correlation of EGFR mutation and effectiveness 
of gefitinib in 59 patients (Mitsudomi et al, JCO, 2005). Here, we 
report the results of updated analysis of clinical or biological factors 
for predicting response to gefitinib based on 83 patients restricted to 
EGFR mutation positives.
Methods: In 133 patients treated with gefitinib for their recurrent 
NSCLC after pulmonary resection, 83 patients were revealed to 
harbor EGFR mutation from direct sequencing using total RNA ex-
tracted from the tumors. Clinico-pathological records were examined 
for age, gender, smoking status, pathological stage, and differentia-
tion. Detailed information of recurrence free survival (RFS), prior 
chemotherapy, response to gefitinib, and TTF was also gathered. 
Mutational status of TP53 that had been previously determined by 
direct sequencing were used for analysis or analyzed in addition for 
newer cases. TTF was calculated using the Kaplan-Meier method and 
a multivariate analysis was performed according to the Cox propor-
tional hazards model.
Results: In 83 patients with EGFR mutation, 51 had evaluable le-
sion in imaging studies and 34 patients were evaluated as effective 
(response rate (RR): 67%). Contingency table analysis using various 
factors (age, gender, smoking status, pathological stage, differentia-
tion, RFS, prior chemotherapy, type of EGFR mutation (exon 19 de-
letions, L858R, or others), and TP53 mutation) showed no significant 
relationship with RR. The 1-year TTF rate was 51% in 83 patients 
with EGFR mutation. Smoking history (p<0.01) and shorter RFS 
(under 1 year) after initial pulmonary resection (p<0.05) were the 
risk factors for shorter TTF in univariate and multivariate analyses. 
Smoking history was not related to adverse effect that resulted in 
treatment failure (p=0.76). Type of EGFR mutation or presence of 
TP53 mutation was not significantly related to shorter TTF. Details of 
the results are shown in Table 1. 
 Univariate analysis Multivariate analysis
  HR 95% CI HR 95% CI p-value
 Age 1.00  0.97-1.03 1.02  0.98-1.07 0.26 
 Gender (female / male) 0.95  0.53-1.70 2.02  0.84-4.82 0.11 
 Smoking (ever / never) 1.90  1.04-3.50 3.68  1.48-9.14 <0.01
 Pathological stage (I-II / III-IV) 0.98  0.54-1.77 1.22  0.55-2.72 0.63 
 Differentiation (poorly / well-modelate) 1.15  0.60-2.20 1.19  0.47-2.97 0.71 
 Type of EGFR mutation     
  L858R / del 1.31  0.71-2.42 2.00  0.91-4.42 0.09 
  others / del 1.55  0.62-3.88 2.78  0.86-9.07 0.09 
 TP53 mutation (mutant / wild type) 1.33  0.73-2.41 1.03  0.44-2.42 0.94 
 RFS     
  under 1 year / over 3 years 2.60  1.21-5.61 3.34  1.26-8.91 <0.05
  1-2 years / over 3 years 1.92  0.77-4.79 1.88  0.65-5.43 0.24 
 Prior chemotherapy (yes / no) 1.13  0.63-2.05 1.23  0.57-2.65 0.60 
Conclusions: We conclude that smoking history and shorter RFS are 
risk factors for shorter TTF, although no factor was related to initial 
response to gefitinib in NSCLC patients with EGFR mutation.
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Malignant cells in pleural lavage cytology before and after 
curative lung resection as a predictor of local recurrence 
in patients with pathological stage I non-small cell lung 
cancer
Tantraworasin, Apichat
Department of Pathology, Faculty of Medicine, Chiangmai 
University, Thailand, Thailand
Background: Intraoperative pleural lavage cytology (PLC) in pa-
tients with non-small cell lung cancer (NSCLC) has been considered 
as a possible aid to assess the prognosis of lung cancer, and it was 
reported to be useful in detecting sub-clinical pleural dissemination in 
addition to local and systemic recurrence. However, PLC in patients 
with stage I NSCLC is controversial.
Objective: To conduct a prospective study to explore any possible 
association of malignant cells in PLC before and after lung resection 
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with radical mediastinal lymph node dissection and local recurrence 
in patients with pathological stage I non-small cell lung cancer.
Material and Methods: From 1st August 2004 to 31th December 
2008, PLC was performed before and after lung resection with medi-
astinal lymph node dissection in 40 consecutive pathological stage I 
non-small cell lung cancer patients who had no macroscopic pleural 
effusion, dissemination, or diffuse adhesion. The operations were 
performed by only one surgeon and the results of PLC with reference 
to clinicopathologic characteristics were evaluated and reported by 
only one pathologist. Local recurrence was analyzed.
PLC consisted of the cytological analysis of 50 mL of saline irrig-
ated over the lung surface immediately after thoracotomy and after 
complete curative lung resection with radical mediastinal lymph node 
dissection.
Results and Discussion: Twelve (30.0%) of 40 patients had a posi-
tive cytological finding, which was observed more frequently in male 
patients with well differentiated squamous cell carcinoma.
Eight (66.67%) of these 12 patients had a positive cytological find-
ing before curative lung resection, three (25.0%) after curative lung 
resection and one patient (8.3%) both before and after curative lung 
resection. 
Univariate and multivariate prognostic predictor was positive 
cytologic finding before curative lung resection (risk ratio = 5.17, 
95%CI=1.85-14.39, p = 0.003 and risk ratio = 5.41, 95%CI=1.20-
24.38, p=0.028, respectively).
Conclusions: If malignant cells were found in PLC before curative 
lung resection, the risk of local recurrence would increase by 5 times, 
which was statistically significant. We suggest PLC as a predictor for 
local recurrence and it should be performed routinely before curative 
lung resection with mediastinal lymph node dissection, especially in 
patients with stage I NSCLC.
Table 1
 Characteristics Recurrent status Recurrent status Total (n=40) p-value 
   Yes (n=10) No (n=30) 
 Gender    
  Male 7 (35.0) 13 (65.0) 20 0.273
  Female 3 (15.0) 17 (85.0) 20 
 Age (year)    
  Below 60 5 (27.8) 13 (72.2) 18 0.731
  60 and over 5 (22.7)  17 (77.3) 22 
  Median (range) 60 (43-72) 61 (46-75)  
 Cell types of NSCLCs    
  Squamous cell carcinoma 4 (25.0) 12 (75.0) 16 0.941
  Adenocarcinoma 5 (27.8) 13 (72.2) 18 
  Bronchoalveolar carcinoma 1 (33.3) 2 (66.7) 3 
  Large cell carcinoma 0 (0) 3 (100) 3 
 Cell Differentiation    
  Well-differentiation 5 (31.2) 11 (68.8) 16 0.770
  Moderate-differentiation 2 (25.0) 6 (75) 8 
  Poorly differentiation 3 (25.0) 9 (75) 12 
  Undifferentiation 0 (0) 4 (100) 4 
 Organ invasion    
 Pleura    
  No 9 (24.3) 28 (75.7) 37 1.000
  Yes 1 (33.3) 2 (66.7) 3 
 Lymphnodes    
  No 1 (11.1) 8 (88.5) 9 0.404
  Yes 9 (30.0) 22 (70.0) 31 
 Vessels    
  No 6 (18.7) 26 (81.3) 32 0.089
  Yes 4 (50.0) 4 (50.0) 8 
 Pleural larvage cytology    
 Pre-curative lung resection    
  Negative 4 (12.9) 27 (87.1) 31 0.003
  Positive 6 (66.7) 3 (33.3) 9 
 Post-curative lung resection    
  Negative 9 (25.0) 27 (75.0) 36 1.000
  Positive 1 (25.0) 3 (75.0) 4 
Table 2
 Determinant Unfavorable Favorable Risk Ratio 95%CI p-value
 Gender Male Female 2.33 0.70-7.76 0.273
 Age 60 or more  less than 60 0.82 0.28-2.39 0.731
 Cell type Adeno CA Others 1.59 0.24-10.35 1.000
 Cell differentiation III or IV I or II 0.64 0.19-2.12 0.711
 Pleural invasion Yes No 1.37 0.25-7.49 1.000
 LymphaticÂ invasion Yes No 2.61 0.38-17.97 0.404
 Vascular invasion Yes No 2.67 0.98-7.25 0.089
 Pleural larvage cytology     
  Pre-curative lung resection Yes No 5.17 1.85-14.39 0.003
  Post-curative lung resection Yes No 1.00 0.17-5.98 1.000
Table 3
 Determinant Risk Ratio 95%CI p-value
 Gender 0.62 0.09-3.95 0.612
 Age  0.73 0.19-2.81 0.650
 Cell type 5.11 0.00 0.995
 Cell Differentiation 0.82 0.17-3.82 0.810
 Pleural invasion 1.10 0.03-31.3 0.955
 Lymphatic invasion  2.26 0.00 0.995
 Vascular invasion 2.69 0.58-12.3 0.203
 Pleural larvage cytology  
  Pre-curative lung resection 5.41 1.20-24.4 0.028
  Post-curative lung resection 1.40 0.04-47.3 0.848
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Evaluation of the optimal time interval for dCK and 
hENT1 gene expression induction following administration 
of pemetrexed in patients with advanced non-small cell 
lung cancer (NSCLC): Final results from a pilot study
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Danesi, Romano3; De Braud, Filippo2
1 Eli Lilly Italia, Sesto F.no, Italy; 2 Unit of Medical Oncology of 
Respiratory Tract and Sarcomas, New Drugs Development Division, 
European Institute of Oncology, Milan, Italy; 3 Department Internal 
Medicine, Division Pharmacology and Chemotherapy, University of 
Pisa, Pisa, Italy
Copyright © 2009 by the International Association for the Study of Lung Cancer S931
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
Background: Clinical evidence support the association of pe-
metrexed and gemcitabine for the treatment of a number of malig-
nancies, including NSCLC(Adjei et al, Ann Oncol 2006). A ran-
domized trial of different sequences has identified the sequence of 
pemetrexed followed by gemcitabine as an efficacious and less toxic 
sequence(Ma et al, J Clin Oncol 2005), but the molecular mechan-
isms underlying the optimal sequence of administration in individual 
patients remained unsettled. Preclinical data in different cancer cell 
lines, including NSCLC cells(Giovannetti et al, Mol Pharmacol 
2006), suggest that this synergistic activity might result from the in-
duction of human equilibrative nucleoside transporter-1(hENT1) and 
deoxycytidine kinase(dCK), two key determinants for the transport 
and activation of gemcitabine, following pemetrexed administration. 
This pharmacogenetic pilot study aims to better evaluate the modula-
tion of expression of these two critical genes(dCK and hENT1)for 
gemcitabine activation, following pemetrexed administration, in 
NSCLC patients. 
Patients and Methods: The expression of dCK and hENT1 was 
examined by quantitative real-time PCR(qRT-PCR)on RNA extracted 
from peripheral blood mononuclear cells from patients with locally 
advanced(stage IIIb)and advanced(stage IV)NSCLC, before and 
after administration of pemetrexed(3 cycles of 500mg/m2, q2wks). 
Patients were not pre-treated with pemetrexed or gemcitabine and 
were not amenable to combined-modality therapy. The gene expres-
sion levels of dCK and hENT1 were measured during each cycle at 
various intervals(1, 2, 4, 6, 24 and 48h)after pemetrexed administra-
tion. Statistics were calculated for original dCK and hENT1 values, 
for the relative differences from baseline to each planned time, for 
peak-values and for the relative-difference-at-peak, by cycle. The 
95% CI for the mean peak value and for the relative difference at 
mean peak were calculated for the three cycles, as well as the 95% CI 
for each category. Multivariate repeated-measures ANOVA on dCK 
and hENT1 values was performed using two-repeated within-subjects 
factors:cycle and time. 
Results: Nineteen patients(11 males/8 females; ECOG PS0=5, 
PS1=11, PS2=3 patients, respectively; not pre-treated patients=6, 
pre-treated patients=13)were enrolled. Patients experienced grade 3 
and/or 4 haematological toxicities (15.8% neutropenia, 15.8% leuko-
penia) and non-haematological toxicities (15.8% gastrointestinal 
disorders, 26.4% general disorders, 10.5% transaminases increase 
and 26.3% respiratory, thoracic and mediastinal disorders). Levels 
of dCK and hENT1 mRNA were successfully measured in the large 
majority of samples(>90%). The mean(± standard deviation)dCK 
and hENT1 peak values were at cycle 1(0.98±0.04; 0.91±0.04), at 
cycle 2(0.98±0.03; 0.93±0.04) and cycle 3(0.98±0.02, 0.92±0.02), 
respectively, while the relative difference at dCK and hENT1 peak 
were at the three cycle 6.65±2.33, 6.68±2.25, 6.93±1.26 and 5.63± 
2.45, 7.31± 3.12, 6.56± 1.66, respectively.
qRT-PCR analysis revealed a statistically significant(p<0.001)bi-
phasic increase(confirmed by standard curve or the 2ΔΔCT method)
in both hENT1 and dCK genes, at early(1-2 hours)and late(24-48 
hours)time points(irrespective of cycle), following pemetrexed 
administration. Compared to baseline levels, dCK and hENT1 gene 
expression were increased approximately 4-fold and 3-fold at both 
early and late time points, respectively.
Conclusion: This is the first evidence of dCK and hENT induction 
by pemetrexed in humans. The kinetics of gene expression induc-
tion points out a peak at both early and late time points, suggesting a 
suitable administration time for gemcitabine at 1-2 hours following 
pemetrexed administration.
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ERCC1 protein expression as a prognostic and predictive 
marker in patients with advanced Non-Small-Cell-Lung-
Cancer (NSCLC) treated with platinum-based first-line 
chemotherapy
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Background: Excision repair cross-complementing group 1 gene 
(ERCC1) is essential for the platinum-induced DNA adduct repair. 
ERCC1 protein expression has been correlated with resistance to 
platinum drugs. ERCC1 has a well-known prognostic and predict-
ive value in patients with early stage NSCLC but its significance in 
advanced disease remains unclear. We investigated the impact of the 
ERCC1 protein expression on the outcome of patients with advanced 
NSCLC treated with platinum-based first-line chemotherapy. 
Patients and Methods: 97 patients with advanced NSCLC, stage 
IIIB & IV, treated with platinum-based first-line chemotherapy, were 
included in the study. Tumor samples were collected before treatment 
and evaluated for ERCC1 protein expression using immunohisto-
chemistry. For each patient, a semi-quantitative H-score was calcu-
lated on the basis of both the percentage of positive tumor cells and 
staining intensity. Response to treatment (RR), time to tumor progres-
sion (TTP), and overall survival (OS) were correlated with patients’ 
clinicopathological characteristics and ERCC1 protein expression. 
Results: The median age of patients was 59 years, 84 patients 
(86.6%) were male, 67 (69.1%) presented with non-squamous 
histology and 86 (88.7%) had ECOG of PS 0-1. 27 (27.8%) patients 
responded to treatment (CR, PR), 26 (26.8%) had stable disease (SD) 
and 44 (45.4%) had disease progression (PD). No significant correla-
tions were found between ERCC1 protein expression and patients’ 
clinicopathological characteristics. ERCC1 protein over-expression 
was detected in 55 patients (56.7%) and was associated with a signifi-
cantly shorter TTP (2.93 months vs. 5.07 months; p= 0.023), shorter 
OS (9.9 months vs. 19.4 months; p= 0.015), and a trend for lack of 
objective response (30 vs. 14; p=0.061). In multivariate analysis, 
ERCC1 protein expression was an independent prognostic factor for 
TTP and OS (HR: 0.556; CI: 0.348- 0.890; p= 0.014 and HR: 0.458; 
CI: 0.273- 0.767; p= 0.003, respectively), along with PS (HR: 0.450; 
CI: 0.222- 0.913; p= 0.027 and HR: 0.381; CI: 0.181- 0.787; p= 
0.009). 
Conclusions: These results indicate that ERCC1 protein expression 
is a prognostic and predictive marker in patients with advanced stage 
IIIB and IV NSCLC treated with platinum-based first-line chemother-
apy. This information could be used for individualizing treatment in 
NSCLC patients.
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Parallel comparison of NSCLC CNV, survival and gene 
expression profiles in Estonian population
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Background: Histology has been the best method to discriminate the 
different cancer types but is inapplicable for survival prediction and 
therefore application of more sophisticated methods are needed to 
elucidate the molecular backgrounds of the disease. Hereby we have 
used the gene expression and copy number variation analysis together 
with genotyping and survival data to study the non-small cell lung 
cancer. 
Methods: Non-Small Cell Lung Cancer (NSCLC) tumor specimens, 
control and blood samples were collected by the surgeon at the Clinic 
of Cardiovascular and Thoracic Surgery of Tartu University Hospital, 
Estonia from 28.11.2002 to 31.12.2006. There were 146 samples 
gathered altogether.
For microarray gene expression experiments the Illumina platform 
and corresponding Human-6 Expression Whole-Genome BeadChips 
of more than 48 000 transcript probes were used. There were 81 
samples with the sufficient quality and quantity available. These 
cancer samples were compared against 21 control samples. For data 
consistency and quality control of the hybridization the Illumina and 
its internal controls and BeadStudio software was used. The compari-
son between gene groups was done using t - test on significance level 
0.01 after Bonferroni correction for multiple testing. 
DNA for the genotyping analysis was extracted from the blood and Il-
lumina platform with corresponding Sentrix HumanHap300 Genotyp-
ing BeadChip was used. 106 samples were used for the genotyping.
CNV from the Illumina genotyping data were studied in silico by 
using two programs, PennCNV and QuantiSNP in parallel. 
Results: Using cluster analysis we can divide the patients into two 
distinct classes. One with expression profiles close to normal samples 
and other with distinct patterns. With this classification we can 
predict survival more accurately than using histological profiles. We 
were able to detect several copy number gains and corresponding 
up-regulation of gene expression (CDT1) as well as losses of hetero-
zygosities and corresponding down-regulations of gene expressions 
(MSR1, CAT, DRAM, EDNRB) simultaneously.
From the genotyping analysis we were not able to detect any statistic-
ally relevant genomic positions that could predict the survival.
Conclusions: 
• We were able to match different NSCLC types and gene expres-
sion profiles
• Adenocarcinoma profiles were more similar to controls than squa-
mocellular carcinomas
• Current cohort is insufficient for association studies.
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Detection of autoantibodies to a panel of recombinant 
tumor-associated antigens in the sera of untreated patients 
with lung cancer
Yang, Jin-ji 
Guangdong General Hospital,P.R.China, Guangzhou, China
Background: Autoantibodies have been detected in sera of lung 
cancer patients using the SEREX approach and will have a promising 
application for screening and early diagnosis of lung cancer. But this 
approach fails to detect post-translational modifications.
Methods: Here, we report the application of the wheat germ cell-free 
system for the successful production of tumor-associated antigens 
(TAAs). Those TAAs comprised full-length recombinant proteins 
expressed from cDNAs encoding p53, c-myc, 14-3-3 theta antigen, 
annexin Ⅰ, survivin and livin. The sera of 144 untreated lung cancer 
patients(128 with non-small cell lung cancer and 16 with small cell 
lung cancer) were tested for ELISA analyses to detect the presence 
of autoantibodies to those TAAs, and the control sera were from 95 
cases(50 healthy volunteers and 45 with benign pulmonary diseases).
Results: Serum autoantibodies to p53, c-myc, 14-3-3 theta anti-
gens, annexin Ⅰ, survivin and livin were found respectively in 67.4% 
(97/144), 53.5% (77/144), 47.2% (68/144), 8.3% (12/144), 42.4% 
(61/144) and 41.7% (60/144) of lung cancer patients, whereas the 
positive rates of these autoantibodies were ranging from 0%~2.1%. 
Profiling 6 serum autoantibodies had a sensitivity of 78.5% and a 
specificity of 94.7% in the diagnosis of untreated lung cancer. 
Conclusions: Detection of serum autoantibodies to recombinant 
TAAs produced by the wheat germ cell-free system might contribute 
a clinically useful noninvasive approach to lung cancer detection and 
diagnosis.
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Promoter hypermethylation of p16 and Wif-1 genes as an 
independent prognostic marker in stage IA non-small cell 
lung cancers
Yoshino, Mitsuru; Suzuki, Makoto; Moriya, Yasumitsu; Hoshino, 
Hidehisa; Motohashi, Shinichiro; Yoshida, Shigetoshi; Shibuya, 
Kiyoshi; Yoshino, Ichiro
Department of Thoracic Surgery, Graduate School of Medicine, 
Chiba University, Chiba, Japan
Background: Aberrant methylation of promoter CpG islands is 
known to be a major inactivation mechanism of tumor suppressor 
genes, some of which are suggested to be related with the progno-
sis of patients with non-small cell lung cancer (NSCLC); therefore 
hypermethylation of the specific genes may be expected to serve as 
a prognostic biomarker for NSCLC. In this study, we investigated 
the relationship between the methylation status of tumor suppressor 
genes and the prognostic characteristics to identify a useful prognos-
tic biologic and molecular marker in patients with stage IA NSCLC. 
Methods: A total of 44 NSCLCs were surgically resected and 
histologically diagnosed at stage IA. Methylation status of 14 genes 
(PTGER2, DRM/Gremlin, sFRP-2, IL-12Rβ2, Reprimo, APC, 
CXCL12, HPP1, SPARC, sFRP-5, p16, RUNX3, sFRP-1 and Wif-1) 
were analyzed by means of methylation specific PCR. The patients 
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included 22 males and 22 females who ranged in age from 44 to 
90 years (average, 63.2 years) at the time of diagnosis. The histo-
logic subtypes included 30 adenocarcinomas, and 11 squamous cell 
carcinomas, and 3 large cell carcinomas. Twenty-three patients were 
smokers (including both current and former smokers), and 21 patients 
had never smoked. A follow-up evaluation was ranged from 16.0 to 
147.2 months after surgery (median, 77.4 months).
Results: The relapse-free and overall 5-year survival rates of all 
patients were 83.2% and 87.5% respectively. The aberrant methyla-
tion was detected in 70% of the cases for PTGER2, 66% for DRM/
Gremlin, 57% for sFRP-2, 48% for IL-12Rβ2, 41% for Reprimo, 
39% for APC, 39% for CXCL12, 30% for HPP1, 30% for SPARC, 
27% for sFRP-5, 25% for p16, 20% for RUNX3, 20% for sFRP-1, 
and 16% for Wif-1. The patients who had p16, sFRP-5, Wif-1 or 
CXCL12 methylation were found to have a significantly shorter 
duration of relapse-free survival, as compared with the counterparts 
with unmethylation for each gene (p16:P = 0.011, sFRP-5:P = 0.030, 
Wif-1:P = 0.036, CXCL12:P = 0.026). Also in overall survival, HPP1, 
p16 or Wif-1 methylation status were found to have a significantly 
shorter duration of overall survival (HPP1: P = 0.031, p16: P = 0.026, 
Wif-1: P = 0.008). Multivariate analysis which include other clinical 
factors revealed that p16 methylation in relapse-free survival and 
Wif-1 methylation in overall survival were all found to be strongest 
independent prognostic factors (p16: P = 0.036, Wif-1: P=0.035). In 
other words, Wif-1 methylation is strong prognostic marker, whereas a 
case of p16 methylation can predict a recurrence and lung metastasis. 
Conclusions: The hypermethylation of p16 and Wif-1 genes may be 
useful biomarker to predict the prognosis of stage IA NSCLC. This 
result may come to help adaptation of the treatment of post operative 
adjuvant-therapy in stage IA disease. 
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Plasma TGF-β1 level during radiotherapy is correlated 
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pulmonary function in patients with non-small cell lung 
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Background: Pulmonary function reduction remains a problem after 
RT in patients with non-small cell lung cancer (NSCLC). TGF-β1 is 
a key molecule associated with radiation induced lung damage. The 
aim of this study was to investigate the correlation between circulat-
ing TGF-β1 during-RT and pulmonary function after RT. 
Methods and Materials: Patients with stage I-III NSCLC under-
going RT based therapy were eligible. Patients were treated with 
conventionally fractionated (10 Gy per week) conformal RT of more 
than 60Gy, + chemotherapy based on stage of disease. Ventilation/
perfusion (V/Q) SPECT-CT and global pulmonary function tests 
(PFTs) including carbon monoxide diffusing capacity (DLCO), 
forced expiratory volume at the first second (FEV1), and forced vital 
capacity(FVC) were performed at pre-RT, during-RT, 3 months and 
1 year post-RT. Plasma TGF ß1 levels were measured at pre-RT, 2, 
4, and 6 weeks from the start of RT. Ventilation and perfusion were 
interpreted by experienced nuclear medicine physicians (KF and 
MG) and measured by a semi-quantitative score of V/Q scanning. We 
used Pearson correlation (PC) to determine the relationship between 
TGF-β1 during-RT and local lung function scores on V/Q SPECT 
and PFTs after RT. 
Results: A total 38 patients with stage I-III NSCLC were enrolled. 
Plasma TGF-ß1 levels were 10.7+ 9.5, 8.5+ 9.5, 7.8+ 7.8, 6.4+ 6.7 
ng/ml at pre-RT, 2, 4, and 6 weeks during-RT, respectively. TGF-ß1 
levels pre-RT (PC=-0.541, p=0.006) and TGF-ß1 ratios over the 
pre-RT level at 4 weeks(PC=0.455, p=0.025), 6 weeks(PC=0.419, 
p=0.047) during-RT all were significantly correlated with DLCO at 
3-month post-RT. TGF-β1 at 2 weeks during-RT were correlated with 
FEV1 at 12 months post-RT (PC=0.754, p=0.031). Plasma TGF-ß1 
levels at 4 weeks (PC=-0.387, p=0.056) and 6 weeks (PC=-0.372, 
p=0.074) during-RT were borderline significant for their correlation 
with the V-SPECT scores of both lungs 3 months post-RT. TGF-ß1 
levels at 6 weeks during-RT were significantly correlated with the 
Q-SPECT scores of both lungs at 3 months post-RT (PC=-0.427, 
p=0.038). No significant correlations were observed between TGF-β1 
during-RT and FVC post-RT. 
Conclusions: TGF-ß1 levels during-RT and their ratios (over the 
pre-RT level) may be predictive of pulmonary function post-RT in 
patients with NSCLC.
Table 1. Lung V/Q SPECT image score system as a mean of evaluating lung function
Largest localized V/Q defect score (DS) in each lung as seen on SPECT
 0 = No defect
 1 =Defect <25% of one lung
 2 =Defect 25–49% of one lung
 3 = Defect 50–74% of one lung
 4 =Defect 75–100% of one lung
 Remaining lung function score (RLFS) as seen on SPECT images
 1 = Homogeneous
 2= Mild heterogeneity
 3 =Moderate heterogeneity
 4 = Marked heterogeneity
 Total lung function score (LFS) = right lung DS + left lung DS+ RLFS=1–12
 SPECT, single photon emission computed tomography.
 V/Q, Ventilation/Perfusion
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P53 autoantibodies in NSCLC serum bind to commen 
linner epitope
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Serum autoantibody is significant for the early diagnosis and progno-
sis of cancer. p53 autoantibodies were found in sera of patients with a 
variety of different cancers. So our objective is to synthesize peptide 
array to analyse p53 autoantibodies in the sera of patients with non 
small cell lung cancer(NSCLC). To evaluate its role in lung cancer 
progression, we analyzed p53 autoantibodies from patients with non 
small cell lung cancer by peptide library, ELISA and Western blot of 
p53. The peptide library consisted of 12 amino acids long peptides 
with nine amino acids overlapping with the adjacent peptides im-
mobilised on a cellulose membrane. The membrane was incubated 
with 1/400 dilutions of p53 monoclonal antibody (DO-2) whose 
epitopes are already known to establish a new approach to detect 
p53 antibody. Then, we analysed the p53 autoantibodies from the 
87 sera of NSCLC and controls by ELISA, Western blot and peptide 
array. It was found that 16.1% of the patients developed antibodies 
against p53. Furthermore, p53 autoantibodies recognized three com-
mon epitopes which were also recognized by well-known mouse 
monoclonal antibodies against p53. Common epitopes are located in 
regions which are functionally important for the role of p53 in growth 
control. This three epitope peptides were artificial synthesized and 
used successfully for analysis of serum sample of NSCLC. Taken 
together, the peptide array could be applied not only to detect the 
autoantibodies in the sera of patients with lung cancer, but also to 
map the epitopes of the autoantibodies. Further more, these findings 
suggest that p53 autoantibodies is involved in lung cancer progres-
sion and the epitopes might offer a novel therapeutic target. 
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Comparison between Epidermal Growth Factor Receptor 
(EGFR) Gene Expression in Primary Non-small Cell Lung 
Cancer (NSCLC) and in the corresponding recurrent 
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Zhang, Peng; Jiang, Gening 
The General Thoracic Department of the Pulmonary Disease Hosptal 
of Tongji University, Shanghai, China
Background: Epidermal growth factor receptor (EGFR) gene copy 
number obtained by fluorescence in situ hybridization (FISH) has 
been recently found to predict treatment outcome in non-small cell 
lung cancer (NSCLC) patients receiving EGFR tyrosine kinase in-
hibitors. However, it is still unknown whether EGFR status differs in 
the corresponding recurrent tumor of the lung compared with primary 
NSCLC. 
Methods: EGFR gene copy number was analyzed by FISH on 
Paraffin Sections of 26 patients with the recurrent tumor of the lung 
after the operation for the primary lung cancer and the results were 
compared with those obtained on corresponding paraffin histologic 
sections from the primary tumor.
Results: 7 of the 26 cases (27%) were EGFR positive on both pri-
mary tumor and and the corresponding recurrent tumor of the lung 
.10 (38%) were negative on both primary tumor and recurrence . Nine 
of the 26 cases (35%) showed discordance of primary tumor versus 
recurrence (Fisher’s Exact Test, P=0.036).
Conclusions: EGFR gene copy number is discordant between pri-
mary NSCLC and the corresponding recurrent tumor of the lung in a 
significant proportion of cases. These findings should be considered 
in future studies designed to elucidate the predictive role of EGFR 
FISH in NSCLC.
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Predictive values of intratumoral microvascular density 
(MVD) in the patients (pts) with advanced NSCLC 
and metastatic colorectal cancer (mCRC) receiving 
chemotherapy plus Bevacizumab 
Zhang, Li 1; Jiang, Wei1; Zhang, Yang1; Xu, Ruihua1; Qian, 
Chaonan2; Resau, James H.3; VandenBeldt, Kristin4
1 Department of Medical Oncology, Cancer Center of Sun Yat-Sen, 
Guangzhou, China; 2 State Key Laborotary of Oncology in South 
China, Sun Yat-sen University Cancer Center, Guangzhou, China; 
3 Division of Quantitative Sciences, Van Andel Research Institute, 
Grand Rapids, USA; 4 Laboratory of Analytical, Cellular, and 
Molecular Microscopy, Van Andel Research Institute, Grand Rapids, 
USA
Background: The using of Bevacizumab (VEGFR inhibitor) com-
bined with chemotherapy represents a most noticeable recent advance 
in clinical oncology for significantly improving pts’ survival in 
several tumor types. There is an unmet need for seeking biomarker(s) 
to predict the treatment response of Bevacizumab and identify the 
pts sensitive to the treatment. Our study was designed to investigate 
the predictive value of intratumoral MVD in NSCLC and mCRC pts 
treated with Bevacizumab.
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Method: Sixteen NSCLC (stage IIIB/IV) and 15 mCRC pts who 
underwent chemotherapy (Taxol+Carbo for NSCLC and IFL for 
CRC, respectively) combined with Bevacizumab were included into 
this study. The paraffin-embedded tumor samples (13/16 NSCLC and 
all CRC samples were collected from primary tumor) were sectioned 
and stained immunohistochemically for blood vessel markers (CD34 
and CD31) to identify the characteristics of intratumoral vasculature. 
A computerized image analysis program was used to quantitatively 
calculate the intratumoral MVD (Yao et al., Clin Cancer Res 2007). 
Treatment response was evaluated by computed tomography scanning.
Results: Two types of blood vessel, undifferentiated (CD31+/CD34-) 
and differentiated (CD34+), were identified. For the 16 NSCLC pts, 
a positive correlation was found between the largest tumor shrinkage 
percentage (evaluate in the primary tumors and metastases) and the 
total (CD31+) MVD as well as the undifferentiated (CD31+/CD34-
) MVD, with Spearman’s correlation coefficients equaled to 0.567 
(p=0.022) and 0.576 (p=0.019), respectively. However, no significant 
correlation between tumor shrinkage and MVD was found in CRC 
pts, in which the treatment response was evaluated in metastatic le-
sions while the MVD was calculated in primary tumor.
Conclusion: This exploratory analysis suggests higher total ves-
sel and undifferentiated vessel MVD appeared to be predictive of 
Bevacizumab treatment advantage for advance NSCLC pts.Our study 
also indicated that the MVD of primary lesions did not correlate with 
the treatment response of metastatic lesions in CRC pts. Further stud-
ies are needed to verify the predictive role of MVD in the treatment 
of Bevacizumab in NSCLC. 
Radiotherapy
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A pilot study to investigate the use of 4-dimensional 
Computed Tomography (4D CT) for patients with Non-
small cell lung cancer (NSCLC) undergoing Radiotherapy
Aarons, Yolanda1; Campeau, Marie Pierre1, 2; David, Steven1; Kron, 
Tomas1; Rolfo, Aldo1; Nguyen, Eric1; Herschtal, Alan1; Wheeler, 
Greg1; MacManus, Michael1; Ball, David1
1 Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; 2 
CHUM - Notre-Dame Hospital, Montreal, QC, Canada
Background: For the purposes of radiotherapy (RT) planning of lung 
tumors, both FDG PET/CT and 4D CT produce images which take 
into account tumor motion. This study was undertaken to determine 
the feasibility of 4D CT, as compared to PET/CT, in defining the 
internal target volume (ITV) in patients with Non-small cell lung 
cancer (NSCLC). The study also looked at detecting significant 
change in the ITV over a 6 week course of RT using serial 4D CT’s. 
In addition, we aimed to explore the potential benefit of respiratory 
gating by developing a gated plan for each patient using the planning 
4D CT.
Method: Nine patients planned to undergo radical radiotherapy (60 
Gy in 30 fractions) were recruited to this study. All underwent a PET/
CT for RT planning, a planning 4D CT and three additional 4D CT’s 
at week 1, 3 and 5 of RT using a Philips Brilliance 16-multislice CT 
scanner. 4D CT would be determined feasible if ITV’s could be gen-
erated from the Maximum Intensity Projection (MIP) and subsequent 
plans produced. In total, each patient had three plans including a 
PET/CT, 4D CT and a gated plan.
Significant change in the ITV was evaluated by assessing the inci-
dence of grade 1 and 2 geographic misses when comparing the plan-
ning ITV to subsequent ITV’s on 4D CT’s at week 1, 3 and 5 of RT. 
A grade 1 miss was defined as part of the serial 4D CT gross tumor 
volume (GTV) outside the planning 4D CT planning target volume 
(PTV), and a grade 2 miss as <90% of the serial 4D CT PTV receiv-
ing ≥95% of the prescribed dose.
Gated plans were created on the maximum expiratory (EXP) phase 
of the planning 4D CT. Dose volume histograms (DVH) from gated 
and PET/CT plans were compared to determine if respiratory gating 
significantly reduces dose to organs at risk including the lungs (V20, 
V30 & mean), spinal cord (max), esophagus (V45 & V50) and heart 
(V40).
Results: 4D CT proved feasible in all nine patients recruited.
We found there to be no significant change to the planning ITV on 
serial 4D CT’s as defined by grade 1 and 2 geographic misses. A 
grade 1 miss was recorded for one patient on 4D CT’s at weeks 1 and 
3, however this was clarified by PET/CT to be atelectasis as opposed 
to GTV.
DVH analysis of gated plans showed a statistically significant reduc-
tion in dose to the esophagus (p=0.032 for both the V45 and V50) 
for the gated plan, but no significant reduction to lung, spinal cord or 
heart dose was detected.
Conclusions: We determined that 4D CT was feasible in defining 
the ITV, and found no significant change in the planning ITV that 
resulted in a true geographic miss over the six week course of RT. 
However, 4D CT should be used in combination with PET/CT, in 
order to correctly identify tumor from atelectasis.
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Brain metastases in non small cell lung cancer-- univariate 
& multivariate analyses
Agarwal, Jai Prakash; Chadha, Pranav; Apsani, Rajiv; Ghosh Laskar, 
Sarbani; CS, Pramesh; Menon, Hari; Kumar, Prabhas; Jambhekar, 
Nirmala
Tata Memorial Hospital, Mumbai, India
Purpose: To study the prognostic factors in particular to brain me-
tastases of lung cancers and validation of RTOG – RPA (Recursive 
partitioning analysis) score.
Methods & Materials: A retrospective study was carried out at our 
institution on consecutive 59 patients diagnosed as Non small cell 
lung cancer (NSCLC) with brain metastases, treated by palliative 
Whole brain Radiotherapy (WBRT) with short course radiotherapy 
to a dose of 20Gy/ 5fx. An analysis of various patient factors (Age, 
Performance status, gender, symptoms, smoking habits), tumor re-
lated factors (histology, clinical stage, extracranial disease, supra v/s 
infratentorial metastases, oligo v/s multiple metastases) and disease-
free interval (DFI) were done in addition to validation of RPA score. 
Survival analysis was done by Kaplan Meier/log rank method and 
multivariate cox regression analysis used to study the significance 
of prognostic factors. An attempt was made to determine correla-
tion between DFI and Overall survival (OS) (Pearson’s correlation 
coefficient) and to predict OS from DFI (linear regression), in each 
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RPA class. Statistical package software SPSS version 14 was used for 
statistical analysis.
Results: The mean survival of the cohort group was 12.3 months 
(95% CI 1.45-12.23). Among patient related factors, KPS at the time 
of presentation of brain metastases had a significant impact on overall 
survival,KPS ≥ 70 versus KPS < 70, 10 months and 4 months re-
spectively (p=0.008).Of the tumor related factors, presence of extrac-
ranial component showed a significant impact on mean survival being 
35 months for no extracranial disease versus 6.8 months in presence 
of extracranial disease {p=0.0001}; DFI greater than 12 months had 
a mean survival of 33.4 months versus 10.5 months (DFI<12 months)
{p=0.001}.Recursive partitioning analysis (RPA) class II had a 
median survival of 10 months compared to 4 months in RPA class III 
{p=0.015} corroborating the significant impact of RTOG-RPA. 
Validation by multivariate analyses of the aforementioned factors, 
DFI and presence/absence of extracranial disease had significant 
impact on the overall survival.
In terms of correlation, there was a strong association between DFI 
and OS (r=0.786) for the cohort. In terms of correlation with RPA 
class, DFI and RPA class II correlation was stronger (r=0.861) com-
pared to a weak association between DFI and RPA class III (r=0.499). 
Overall DFI was modestly predictive for OS (r2=0.62). There was a 
strong prediction of OS from DFI in RPA class II (r2=0.74), however 
it was offset by a paltry prediction for RPA class III (r2=0.25) sug-
gesting other confounding factors in this class of patients. 
Conclusions: DFI of at least 1 year after the completion of curative 
therapy for NSCLC and no extracranial disease translates into greater 
overall survival. There is a strong association between DFI and OS 
overall, and especially for RPA class II. Therefore an attempt should 
be made to incorporate DFI in the RTOG-RPA scoring system as a 
factor, and this needs to be validated further in a larger prospective 
cohort study.
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Excellent Negative Predictive Value (NPV) of early 
PET-CT in the follow-up of pts treated with Stereotactic 
Radiation Therapy (SRT)
Paravati, Anthony J.2; Johnstone, David W.1; Aitken, Candice L.1, 2
1 Dartmouth Hitchcock Medical Center, Lebanon, NH, USA; 2 
Dartmouth Medical School, Hanover, NH, USA
Purpose/Objective: SRT is increasingly used for pts with medically 
inoperable lung cancer. The role of PET-CT in following such pts is 
not clear. We therefore reviewed our experience in this area.
Materials and Methods: 45 lesions in 39 pts with newly diagnosed 
node-negative (29) or oligometastatic (lung only) (4) or locally 
recurrent (4) lung cancer were treated with 4-dimensional linac-
based stereotactic radiation therapy. 37 pts had at least 1 follow-up 
PET-CT. 28 pts had 2 or more follow-up PET-CT scans. Pts received 
3750 cGy in 3 fractions (peripheral tumors) or 3-6 fractions (central/
hilar tumors). Dose was prescribed to the 65-87% isodose line. Pts 
were followed with PET-CT every 3-6 mo for the first year and then 
every 6 mo, unless there was no FDG uptake in the index lesion(s). 
A negative PET-CT was defined as no residual activity greater than 
mediastinal blood pool activity. Median follow-up was 8 months, 
with a range of 2-25 mo.
Results: There was a complete metabolic response (CMR) in 28 
lesions, a partial metabolic response (PMR) in 12 and progressive 
metabolic disease (PMD) in 12. (median 2.9 mo after SRT) All 28 le-
sions with CMR, remained locally controlled. Of the 15 lesions with 
PMR or progression, FDG activity resolved in 10 and persisted in 5. 
28 pts had 2 or more PET-CT scans. The accuracy, NPV and positive 
predictive values (PPV), sensitivity and specificity of the first PET for 
subsequent local failure were 80%, 100% and 33%, 100% and 74%, 
respectively. 1 year overall survival was 76% (95% CI 58-93%) and 1 
year local control rate was 90% (95% CI 78-98%).
Conclusions: These early results suggest that early PET-CT fol-
lowing SRT predicts outcome at the treated site. Additional pts and 
further follow-up are needed to confirm this finding.
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Stereotactic body radiation therapy is tolerable in patients 
who have undergone previous lung surgery
Ashton, Spencer N.1; Hicks, Aaron1; Shah, Hemangini1; Kohman, 
Leslie2; Dexter, Elisabeth2; Bogart, Jeffrey1
1 Department of Radiation Oncology, State University of New 
York - Upstate, Syracuse, NY, USA; 2 Department of Surgery, State 
University of New York - Upstate, Syracuse, NY, USA
Background: Patients successfully treated for early stage non-small 
cell lung cancer remain at risk for developing new primary lesions. 
The purpose of this study was to evaluate the tolerability of stereo-
tactic body radiation therapy (SBRT) in patients who have undergone 
previous anatomic lung resection.
Methods: Retrospective review of patients treated with SBRT for 
primary NSCLC that had a history of lobectomy or pneumonectomy. 
SBRT toxicity was graded according to the NCI common terminol-
ogy criteria version 3.0. 
Results: Seventeen patients (median age 67 years, 9 male / 8 female) 
were identified with a history of prior resection (15 lobectomy, 2 
pneumonectomy). Three patients also had a history of prior lung 
radiotherapy. The mean interval between initial surgery and SBRT 
was 40 months, and the most common SBRT regimen was 60 Gy in 3 
fractions. The average planning target volume (PTV) was 14.53 cm3 
(4.02 – 27 cm3), and the average lung V20 was 2.43% (0.5 – 3.4%). 
All patients were assessed one month after completion of SBRT and 
then every 3 months thereafter (including chest CT). With median 
follow-up of 6 months, grade 3 or greater toxicity has not been 
observed. Grade 1 toxicity (asymptomatic radiographic change) was 
noted in most (11/17) patients, while 3 patients experienced transi-
ent grade 2 pneumonitis. Local recurrence has not been detected on 
follow-up imaging.
Conclusion: This preliminary data suggests SBRT is tolerable in 
patients who have undergone previous pulmonary resection. Further 
follow-up is necessary to assess potential late effects of SBRT and 
long-term tumor control.
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A model for the introduction of 4DCT into a District 
General Hospital (DGH)
Ford, Victoria A.; Moloney, Stephen; Laurence, Virginia; Bayne, Mike
Poole Hospital NHS Foundation Trust, Poole, UK
Background: The routine use of sophisticated image-guided treat-
ment techniques are emerging as the new paradigm in radiother-
apy. In radical radiotherapy for lung cancer 4DCT (4 dimensional 
computed tomography) may be used to define the target volume, 
accurately accounting for respiratory motion, and cone-beam CT may 
be used to verify accurate treatment delivery. Such imaging reduces 
the risk of geographic miss and enables the use of narrower CTV 
to PTV margins offering the potential for greater sparing of normal 
tissues and aiding safe dose escalation. These technologies have 
become part of routine practice in a number of large centres, but they 
have often used bespoke in-house software and equipment which is 
out of reach of most UK centres. Recent investment in radiotherapy 
technology in the UK has made the equipment required for 4DCT 
available to smaller centres, yet there is no model within the literature 
for the introduction of these new technologies into clinical practice. 
The objective of this project is to establish and evaluate protocols and 
procedures for the routine use of 4DCT in radical lung radiotherapy 
treatment planning and on-treatment verification of positioning using 
cone-beam CT within a UK radiotherapy centre. 
Methods: Quality assurance of 4DCT image acquisition was per-
formed using a respiratory motion phantom (Modus Medical Devices 
Inc.) with a custom-made moving insert. The insert consisted of a 
wooden cylinder containing three acrylic spheres of varying diameter. 
Images of the phantom moving at 20, 15, and 10 breaths per minute 
and 1 and 2 cm amplitude were acquired using the RPM (real time 
position management) gating system and Philips Brilliance Big Bore 
CT scanner. A retrospectively gated helical scan protocol was used. 
Images were analyzed to determine the accuracy of the depicted 
tumor motion and tumor volume. A system performance phantom 
was also scanned using normal and 4D techniques to compare various 
measures of image quality.
A series of three clinical 4DCTs were then imported into Prosoma 
planning software and the reported methods of acquiring the ITV 
(Internal Target Volume) compared: ITV = MIP (maximum intensity 
projection); ITV = summation of 10 phases contoured independ-
ently; ITV = mid inspiratory phase with standard margin applied. The 
merits of the different methods will be discussed and illustrated by 
clinical cases.
Results: Results from the quality assurance aspect of the work 
indicate that the 4D images obtained are accurate and suitable for use 
in radiotherapy treatment planning. The experience gained from this 
work suggests that the range of tests carried out is appropriate and 
presents a workload that would be manageable in most UK centres. 
We have demonstrated that the 4DCT data set can be imported into 
the planning soft ware and effectively used for contouring the ITV.
Conclusion: 4DCT can be introduced into the planning of radiother-
apy for lung cancer in a DGH following a straight forward quality 
assurance program that is achievable without excessive investment in 
time or equipment. 
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Adjuvant radiotherapy for completely resected stage II 
thymoma
Berman, Abigail T.1; Singhal, Sunil4; Su, Stacey4; Kucharczuk, John 
C.4; Cooper, Joel D.1; Shrager, Joseph2; Kaiser, Larry R.7; Friedberg, 
Joseph S.4; Faerber, Jennifer5; Evans, Tracey L.6; Stevenson, James 
P.6; Langer, Corey J.6; Metz, James M.3; Glatstein, Eli1; Hahn, 
Stephen M.1; Rengan, Ramesh1
1 Department of Radiation Oncology, University of Pennsylvania, 
Philadelphia, PA, USA; 2 Division of Thoracic Surgery, Stanford 
University, Palo Alto, CA, USA; 3 Department of Radiation 
Oncology, University of Pennsylvania, Phiadelphia, PA, USA; 4 
Division of Thoracic Surgery, Department of Surgery, University 
of Pennsylvania, Philadelphia, PA, USA; 5 Center for Clinical 
Epidemiology and Biostatistics, University of Pennsylvania, 
Philadelphia, PA, USA; 6 Division of Hematology and Oncology, 
Department of Medicine, University of Pennsylvania, Philadelphia, 
PA, USA; 7 The University of Texas Health Science Center at 
Houston, Houston, TX, USA
Background: The clinical benefit of post-operative mediastinal 
radiation for patients with completely resected Masaoka Stage II 
thymoma remains controversial. Due to the indolent nature and infre-
quent recurrences of this tumor, no study has definitively determined 
the optimal approach. The purpose of this analysis was to determine 
the role of adjuvant radiation therapy in Stage II thymomas.
Method: We retrospectively reviewed 175 consecutive patients who 
underwent thymic resection from January 1990 to July 2008 at the 
University of Pennsylvania. We compared outcomes of patients with 
Stage II thymomas treated by resection alone versus resection plus 
radiation. The decision to irradiate postoperatively was based primar-
ily upon the surgeon’s perception of a complete resection at the time 
of surgery. Patients with high recurrence risk were routinely referred 
for adjuvant radiotherapy. Lower risk patients were observed without 
adjuvant radiotherapy.
Results: Seventy-four Masaoka stage II patients were resected; 62 
underwent complete resections with adequate post-surgical follow-
up data. Myasthenia gravis was present in 32.3% (20/62). Thirty-
eight patients received adjuvant radiotherapy and 24 patients were 
observed without intervention. The median radiation dose was 5040 
cGy. Mean tumor size was 5.8 cm. The median tumor size in patients 
undergoing observation was 5.3 cm and was 6.1 cm for those receiv-
ing adjuvant radiation (p=0.49). The median follow-up of all patients 
was 34.2 months. Local recurrence was defined as recurrence within 
the surgical bed. The overall local recurrence rate was 3.2% (2/62). 
The proportion of recurrences in patients observed after surgery was 
8.3% (2/24) and 0% (0/38) in those who received adjuvant radiother-
apy (p=0.15, Fisher’s Exact test). One recurrence was treated with 
surgery, chemotherapy, and radiation and the other recurrence was 
treated with surgery and radiation only. Cox regression modeling 
demonstrated that size (p= 0.81) was not an independent predictor 
of recurrence. The tumor-related death rate was 0%, and the overall 
death rate was 4.8% (3/62). Two deaths occurred in the observation 
group and one in the radiation group.
Conclusions: These results suggest that recurrence rates are low 
following complete resection of patients with Stage II thymoma 
either with or without adjuvant radiotherapy. Additionally, these data 
suggest that adjuvant radiotherapy may decrease the local relapse 
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rate in a subset of these patients who are potentially at higher risk for 
recurrence.
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Survival advantage of three-dimensional conformal 
radiotherapy over two-dimensional radiotherapy for 
patients with stage III non–small-cell lung cancer
Cao, Jianzhong; Wang, Luhua; Zhang, Hongxing; Chen, Dongfu; 
Xiao, Zefen; Feng, Qinfu; Zhou, Zongmei; Liang, Jun; Ou, Guangfei; 
Lv, Jima; Yin, Weibo
Department of Radiation Therapy, Cancer Institute and Hospital, 
Chinese Academy of Medical Sciences and Peking Union Medical 
College, Beijing, China
Purpose: This retrospective analysis was performed to assess the 
outcomes of three-dimensional (3D) conformal radiotherapy and two-
dimensional (2D) planning.
Methods and Materials: Between 2000 and 2006,527 patients were 
analyzed who met the following criterias:histologically or cyto-
logically documented locally advanced NSCLC, definitive thoracic 
radiotherapy alone or chemoradiotherapy and a total dose of at 
least 50 Gy. Among them, 274 were treated with two-dimensional 
radiotherapy and 253 with 3D conformal radiotherapy. Overall 
survival (OS),disease-specific survival (DSS),disease-free survival 
(DFS),locoregional control (LRC),and distant metastasis-free survival 
(DMFS) rates were analyzed.
Results: The OS,DSS,DFS,DMFS and LRC rates were significantly 
higher in patients who were treated by 3D conformal radiother-
apy. 1-,3-,5-year OS rates and median survival in the 3D group 
were 73.3%,26.1%,14.4% and 20.1 months, respectively,and 
61.0%,13.8%,8.0% and 15.6 months in the 2D group (P=0.002). 
DSS at 1-,3-,5-year for the 3D group were 79.0%, 33.3%, 20.8%, 
respectively, vs. 65.1%,16.7%,11.2% in the 2D group(P=0.000).1-
,3-,5-year DFS rates were 53.5%,19.5%,16.9%,respectively,for the 
3D group and 39.9%,9.6%,7.6% for the 2D group (p=0.005). DMSF 
at 1-,3-,5-year were 67.8%,36.3%,32.9%,respectively, for patients 
who received 3D radiotherapy vs. 55.0%, 23.9,20.5% for the 2D 
group (p=0.015). LRC rates at 1-,3-,and 5-year for patients in the 3D 
group were 71.6%, 34.3% and 31.0% and 57.3%, 22.1% and 19.2% 
in the 2D treatment ( P=0.002). On univariate analysis,the survival 
statistical difference for both OS and DSS was significant for the fol-
lowing variables: radiotherapy technique, performance status, tumor 
response, stage, pretreatment haemoglobin level. Gender, age, weight 
loss, smoking history, pathology, chemotherapy did not show the sig-
nificant difference. On multivariate analysis, 2D radiotherapy was as-
sociated with decreased OS (hazards ratio:1.332, P=0.006),decreased 
DSS (hazards ratio:1.491, P=0.001). In addition,performance 
status,tumor response,pretreatment haemoglobin level also were the 
independent prognostic factors on OS and DSS.
Conclusions: This study demonstrates that 3D conformal radiother-
apy improves outcomes in patients with locally advanced NSCLC 
compared with 2D treatment.
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Excellent early local control with tumor volume adapted 
dosing of stereotactic body radiation therapy for 
pulmonary tumors
Chang, Christine N.; Zhou, Lisa Y.; MacFarlane, Gillian; Tran, 
Phuoc; Rao, Aarti; Chapman, Chris; Le, Quynh-Thu; Wakelee, 
Heather; Colevas, A. Dimitrios; Whyte, Richard; Hristov, Dimitre; 
Dieterich, Sonja; Maxim, Peter; Loo, Billy W.
Stanford Cancer Center, Stanford, CA, USA
Background: Stereotactic Body Radiation Therapy (SBRT) has 
demonstrated promising local control of pulmonary tumors. We 
previously reported that when treating with single fraction SBRT, 
tumor volume has a profound negative impact on local control. Here 
we present a retrospective analysis of a more recent cohort of patients 
with pulmonary tumors treated by SBRT. The use of single fraction 
SBRT was restricted to smaller tumors (< 10 mL), whereas larger 
tumors were treated with more dose intensive fractionated regimens. 
Methods: We retrospectively reviewed the records of patients treated 
with SBRT for lung tumors at Stanford Cancer Center since August 
2005 who had at least 3 months of follow up by serial imaging (CT 
and/or PET-CT). Local, nodal, and distant progressions were scored 
if biopsy proven, or if progressive imaging abnormalities or clinical 
findings were sufficient to prompt a change in management, and were 
dated back to the first imaging demonstrating progression that was 
ultimately scored.
Results: Fifty patients treated between August 2005 and November 
2008 met the inclusion criteria. 12 patients received a single fraction 
(25-30 Gy), 20 patients received three fractions (60 Gy total), and 18 
received 4 fractions (40-50 Gy total). 32 patients had early stage lung 
cancer, 14 had limited pulmonary metastasis from another site, and 4 
had locally recurrent lung cancer. At the time of analysis, 5 patients 
had died and 10 patients had progression at any site. Median time to 
progression was 7 months. Median follow-up was 11 months.
There was a single local progression at 12 months in a patient treated 
with 50 Gy in 4 fractions (tumor volume 36.7 mL). The main mode 
of progression in the cohort was distant metastasis. Progressors did 
not significantly differ from non-progressors in tumor volume, histol-
ogy, or location. 
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Table: pattern of progression and median tumor volumes by fractiona-
tion schedule.
 Fractions Total #  Nodal Local Distant Tumor volume Tumor volume 
  progressed (# pts)    median (range) in progressors
 Single (12) 3 0 0 3 2.2 mL (0.2-7) 2.0 mL
 Three (20) 4 2 0 2 10 mL (2-43) 10.9 mL
 Four 18) 3 0 1 2 23 mL (2-47) 13.2 mL
Conclusions: Our previous series of single fraction SBRT demon-
strated a 1 year local control rate of 68% overall (100% for tumor 
volume < 6 mL, 85% for 6-12 mL, and 37% for > 12 mL). In the cur-
rent patient cohort, tumor volume adapted dosing of SBRT achieved 
excellent early local control with a single local progression at one 
year. Longer follow up of more patients is required to substantiate 
this finding. Distant metastasis is the main mode of progression, and 
future work to integrate effective systemic therapy safely with SBRT 
is needed.
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Mid-treatment PET predicts progression in 
hypofractionated accelerated radiation therapy for lung 
tumors
Chang, Christine N.1; Fillion, Edith2; Chapman, Chris1; Rao, Aarti1; 
Wakelee, Heather2; Ganjoo, Kristen2; Le, Quynh-Thu1; Maxim, 
Peter1; Quon, Andrew2; Graves, Edward E.2; Loo, Billy W.1
1 Stanford Hospital, Stanford, CA, USA; 2 Stanford Cancer Center, 
Stanford, CA, USA
Background: Stereotactic body radiotherapy (SBRT) has emerged as 
a promising treatment of limited lung cancer or pulmonary metas-
tases, but is feasible only for small tumors that are not too centrally 
located or involve lymph nodes. More modestly hypofractionated 
accelerated radiotherapy (HypoART) has potential advantages for 
treating intermediate volume/stage or very centrally located tumors, 
delivering a high biologically effective dose in a short time frame to 
compensate for accelerated repopulation, with tolerable normal tissue 
toxicity. We analyzed the outcomes of patients treated with HypoART 
as a single modality for intermediate volume or centrally located 
tumors. We also analyzed PET scans acquired pre- and mid-treatment 
as a potential predictor of progression.
Methods: Patient Characteristics: We retrospectively identified 14 
patients with lung tumors treated with HypoART at Stanford Cancer 
Center from 8/2006 to 1/2008. All had fine-needle aspiration biopsy 
confirmed malignancy; 10 had primary lung cancer and 4 had limited 
lung metastasis from other primary sites.
Treatment: 12 patients received 66 Gy, and 2 patients received 60 Gy, 
all in 3 Gy fractions, administered once daily, 5 days per week. None 
of the patients received concurrent or adjuvant chemotherapy.
PET-CT: All patients underwent pre-treatment PET-CT at the time of 
treatment simulation, and all but one underwent PET-CT mid-way 
through treatment.
Results: The median follow-up time was 13 months. At the time 
of analysis, 2 patients had died, 1 of cancer progression and 1 of 
other comorbidities. A total of 7 of the 14 patients have progressed: 
2 in field, 4 out of field, 1 both in and out of field. Of the patients 
progressing out of field, 2 progressed elsewhere in the lungs and 3 
developed brain metastasis. The median time to progression was 180 
days (194 days for in field, and 172 for out of field). Kaplan-Meier 
disease-free survival was 48%, and local control was 75% at 13 
months. Toxicities were mild, with 2 patients developing symptom-
atic grade 2 pneumonitis.
Pre-treatment PET SUVs were not significantly different between 
progressors and non-progressors, but mid-treatment SUVs were 
significantly different (p = 0.01).
Conclusions: The early (13 
month) local control rate with 
HypoART in this series com-
pares favorably to historical re-
sults with radiation therapy. We 
found mid-treatment PET to be a 
significant predictor of progres-
sion, and thus potentially useful 
for selecting those who will 
benefit from adjuvant systemic 
therapy and/or dose escalation. 
Confirmation in a larger cohort 
with longer follow up is needed.
P3.201 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Docetaxel plus cisplatin concurrent chemoradiotherapy 
followed by the same regimen consolidation in 
unresectable stage III non-small-cell lung cancer - Result 
of a phase I Trial
Bao, Yong; Zhuang, Ting-ting; Hu, Xiao; Wang, Wei-hua; Gao, Jian-
ming; He, Han; Sun, Zong-wen; Wang, Yan; Paudle, Shivoji; Chen, 
Ming
Sun Yat-sen University Cancer Center, Guangzhou, China
Purpose: To determine the maximum tolerable dose (MTD) and dose-
limiting toxicity (DLT) of docetaxel and cisplatin currently with thor-
acic radiation for Stage III non-small-cell lung cancer (NSCLC); and 
to test the suitable timing schedule for consolidation chemotherapy. 
Materials and methods: Patients with histologically proven and un-
resectable Stage III NSCLC were the subjects of this dose escalating 
study. The primary tumor and regional lymph nodes were irradiated 
to 60~70Gy/30~35Fx/6~7W using three dimensional conformal 
radiation therapy. Two cycles of Docetaxel and cisplatin (four 
weeks repeated) were administered concurrently with radiotherapy. 
The starting dose of docetaxel and cisplatin was 65 mg/m2, with a 
subsequent dose escalation of 10 mg/m2 in cohorts of 3 new patients. 
Two cycles of consolidation chemotherapy every three weeks using 
the same regimen as concurrent chemotherapy was administered. 
The starting time of consolidation chemotherapy was four weeks 
after concurrent chemoradiation, with a subsequent prolonged time 
of 1 week in cohorts of 3 new patients. Toxicity was graded accord-
ing to CTCAE 3.0. MTD was defined when two out of six patients 
developed DLT. 
Results: Twelve patients with unresectable stage III NSCLC without 
prior treatment were enrolled. All patients received concurrent 
chemotherapy. On the first and second dose levels (55mg/m2, 65mg/
m2) no patient experienced DLT; on the third level (75mg/m2) all of 
three patients developed grade 4 neutropenia, that caused interruption 
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of radiotherapy in two patients. Six patients were administered two 
cycles consolidation 4 weeks after radiotherapy, and none of them 
experienced DLT. 
Conclusions: We recommend a dose of 65mg/m2 for phase II study 
on the use of docetaxel plus cisplatin in stage III NSCLC CCRT 
(2 cycles, 4 weeks repeated) and consolidation (2 cycles, 3 weeks 
repeated). 
P3.202 Radiotherapy, Mon Aug 3 – Tue Aug 4 
The study of lung volume and respiratory movement based 
on four-dimensional CT
Sun, Zong-wen; Huang, Xiao-Yan; Chen, Yuan-Yuan; Bao, Yong; 
Zhang, Li; Huang, Shao-min; Gao, Jian-ming; Wang, Wei-hua; He, 
Han; Hu, Xiao; Fan, Wei; Chen, Ming
Sun Yat-sen University Cancer Center, Guangzhou, China
Purpose: To evaluate the respiratory movement of both lungs with 
four-dimensional CT (4D-CT), and determine the optimal respiratory 
phase series CT images for radiation dose calculation. 
Materials and methods: From November 2005 to November 2006, 
thirty patients with lung cancer who received 4D-CT scan in SYSU 
cancer center were enrolled. There were 15 left and right lung cancer 
cases respectively. Twenty-five were male and 5 were female. Media 
age was 55 years old with a range of 35-78. After 4D-CT scanning, 
the image was treated with Advantage 4D workstation GE, and 
then transmitted into Pinnacle station, Adac 7.4. Both lungs were 
automatically outlined using Pinnacle station, and auto outlined CT 
recognition value is (-900Hu, -200Hu). After auto contouring of both 
lungs, the same physician examined the unreasonable parts and then 
revised them. After the contouring of both lungs was completed, the 
volume of 10 respiratory phases of lung was obtained. 
Results: The average respiratory phase of the tumor located lung in 
inspiratory and expiratory phase is 78.87%±2.71%, 26.32%±3.17% 
respectively; as for the healthy lung 77.55%±2.81%, 24.73%±2.55% 
respectively. The maximum, minimum mean volume of tumor 
located lung is 106.48%±3.00%, 94.23%±2.78% respectively; as for 
the healthy lung 107.47%±2.43%, 93.65%±2.32% respectively. The 
volume of the end of inspiratory and expiratory of tumor located lung 
is 106.43%±3.07%, 94.63%±2.71% respectively; as for the healthy 
lung 107.37%±4.62%, 93.98%±2.34% respectively. 
Conclusions: The series CT images scan on 20%, 30% or 80% 
respiratory phases are reasonable for radiation dose calculation. The 
maximum and minimum average lung volumes are nearly equal to 
the volumes at the end of inspiratory and expiratory with a very slight 
difference.
P3.203 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Four-dimensional computed tomography based assessment 
and analysis of lung tumor mobility during free breathing 
respiration
Wang, Yan; Bao, Yong; He, Han; Zhang, Li; Fan, Wei; Yu, Hong-bo; 
Deng, Xiao-Wu; Chen, Ming
Sun Yat-sen University Cancer Center, Guangzhou, China
Purpose: To quantify the amount of lung tumor motion during free-
breathing measured using four-dimensional computed tomography 
(4D-CT). 
Methods and Materials: Respiratory-induced tumor motion was 
analyzed for 44 tumors from 42 lung cancer patients and 1 NPC 
patient. All patients underwent 4D-CT during free breathing before 
treatment. Gross tumor volumes (GTV) on ten respiratory phases 
were contoured by the same doctor. The centroids of GTVs were 
autoplaced by the soft of ADAC Pinnacle 7.4f, and then the ampli-
tudes of tumors motion were assessed. The association of GTV 
motion with various clinical and anatomic factors was analyzed 
statistically. The characteristics of tumors which need respiratory 
management (Tumor motion is greater than 5mm in any direction) 
were reviewed. 
Results: The tumor motion was found to be associated with T stage, 
GTV size, the superior-inferior (SI) tumor location in the lung, and 
the attachment to rigid structures such as chest wall, vertebrae or 
mediastinum. For a total of 44 tumors, ten cases need respiratory 
management .All were located in the lower or posterior half of the 
lung, and exceed 5mm in SI direction, in which the greatest was 
14.4mm. There is a tendency that the closer to diaphragm the greater 
amplitude of tumor motion. The motion of unfixed small lesion in the 
right upper lobe posterior segment was great, which ranged from 5.1 
to 6.3mm. 
Conclusions: Tumor motion due to breathing was associated with 
tumor location, volume, and attachment to rigid structures. The mo-
tion was greatest in the SI direction for lower-lobe unfixed tumor, and 
upper-lobe posterior-segment tumor ranked secondly.
P3.204 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Prediction of acute radiation pneumonitis after concurrent 
chemoradiotherapy in non-small-cell lung cancer patients
Zhuang, Ting-ting; Bao, Yong; Huang, Shao-min; Yu, Hong-bo; 
Wang, Wei-hua; Hu, Xiao; Wang, Yan; Deng, Xiao-Wu; Chen, Ming
Sun Yat-sen University Cancer Center, Guangzhou, China
Objective: This study attempted to identify clinical and dosimetric 
parameters from dose-volume histogram (DVH) which related with 
the incidence of radiation pneumonitis (RP) in patients with non-
small cell lung cancer (NSCLC) who underwent three-dimensional 
conformal radiotherapy with concurrent chemotherapy. 
Methods: Records about clinical information and treatment plan 
parameters from DVH of 90 NSCLC patients treated with concur-
rent chemoradiotherapy from January 2006 to October 2008 were 
retrospectively reviewed to assess the correlation to RP. 
Results: There were 32.2% patients developed grade1 RP, grade 2 
in 30% patients, grade 3 in 5.6% patients, grade 4 in 0% patients and 
grade 5 in 1.1% patients. Tumor location was the only correlated clin-
ical factor on univariate analysis. And when MLD was divided into 
two groups by 17Gy, V5, V10, V20, V30, V40 were divided into two 
groups by 47%, 36%, 24%, 23%, 22% separately, there were statistics 
different. Multivariate analysis showed the tumor location was the 
only independent predictive factor associated with RP.
Conclusion: The incidence and development of RP contributes to 
many factors. We recommended MLD < 17Gy for three-dimension 
conformal radiation plan especially when the tumor located on the 
lower lobe. 
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Dose ventilation-weighted and density-weighted volume 
histogram using 4DCT data, a new model for risk 
assessment of pneumonitis in thoracic radiotherapy
Choi, Noah C.; Gansemer, Cornelia; Yock, Adam D.; Vrancic, 
Christian; Bortfeld, Thomas; Trofimov, Alexie
Massachusetts General Hospital, Harvard Medical School, Boston, 
MA, USA
Purpose: Current guide for risk assessment of radiation pneumonitis 
(RP) is based on dose-volume-histogram (DVH) of the lung that is 
generated from planning 3DCT data without consideration for the 
differences in regional lung function among individual patients. How-
ever, it is well known that the distribution of emphysematous lung 
varies greatly among patients with chronic obstructive pulmonary 
disease (COPD).
We investigated the utility of weighting dose distributions by surro-
gate metrics of the lung function (parenchyma density and ventilation 
distribution) as complementary information for assessing the risk of 
RP, and for further individualizing thoracic radiation therapy. 
Methods: Partners Protocol 2008P000651 has been approved by 
Partners IRB for the use of anonymized patient data (CT scans, IMRT 
plans) for development of the analysis methods and software.
An in-house soft ware was used to co-register the inhalation and ex-
halation images from 4DCT with the CT sets used for treatment plan-
ning. The relative local increase in the air volume due to ventilation, 
or specific volume expansion was estimated using the differences in 
Hounsfield numbers from co-registered points in the exhalation and 
inhalation images of 4DCT. 
The tissue density and the distribution of ventilatory function in the 
lung were estimated from respiration-correlated 4DCT data of 19 
patients. 
Dose distributions of IMRT (N=17) and proton (N=2) plans were 
reevaluated by applying importance of weighting for parenchymal 
density and ventilation to all 1-cc volume elements in the lung, ac-
cordingly with their estimated relative functional load. 
The dose-histogram metrics were compared between various dose-
weighting 
Methods: mean lung dose (MLD), share of the 5-Gy isodose (V5), 
etc. Regions characterized by high ventilatory activity were seg-
mented, and used to define objectives aiming to maximize sparing of 
lung function in optimization of study IMRT plans. 
Results: Substantial differences were observed between the metrics 
of DVH and ventilation-weighted histograms. Change of over 5% in 
MLD and relative increase of V20 over 10% were observed in 8 of 19 
(42%) and 3 of 19 patients (16%) respectively. 
The correlation between the density- and ventilation-weighted met-
rics was insignificant. The use of additional optimization constraints 
for highly-ventilated lung subvolumes allowed to achieve reduction 
in the ventilation-weighted MLD, without compromising the target 
coverage, or causing deterioration in the standard DVH. 
Conclusions: Ventilation-weighted DVH of the lung may provide a 
better indicator for the risk of RP than that which is available from 
the current standard DVH. 
The use of ventilation distribution maps can potentially reduce the 
risk of RP without compromising the coverage of target volume by 
proper selection of beam numbers, their angles and the load of radia-
tion dose to spare regions with good ventilatory function. 
P3.206 Radiotherapy, Mon Aug 3 – Tue Aug 4 
A retrospective analysis comparing PORT with 3DCRT 
versus conventional radiotherapy technique for non-small 
cell lung cancer
Dai, Honghai1; Ji, Wei1; Tang, Yu1; He, Jie2; Wang, Luhua1; Ou, 
Guangfei1; Liang, Jun1; Feng, Qinfu 1; XIao, Zefen 1; Chen, Dongfu 
1; Lv, Jima 1; Zhou, Zongmei1; Zhang, Hongxing1; Yin, Weibo1
1 Department of Radiation Oncology, Cancer Institute (Hospital), 
Chinese Academy of Medical Sciences and Peking Union Medical 
College, Beijing, China; 2 Department of Thoracic Surgery,Cancer 
Institute (Hospital), Chinese Academy of Medical Sciences and 
Peking Union Medical College, Beijing, China
Objective: To retrospectively analysis treatment result of postopera-
tive three-dimensional conformal radiotherapy (3DCRT) and conven-
tional radiotherapy(CR) in patients with non-small cell lung cancer 
(NSCLC). 
Methods: 162 patients with pathological stageIB-IIIB NSCLC 
received postoperative radiotherapy from Nov. 2002 to Mar. 2006 in 
Cancer Hospital of China Peking Union Medical College, 86 cases 
was treated with 3DCRT technique, and 76 with conventional radio-
therapy.The survival outcome, pattern of failure and treatment-related 
side effects in both groups were retrospectively analyzed. The median 
radiation dose was both 60Gy in the two group. 71 patients(43.8%) 
received median 3 cycles of adjuvant chemotherapy. The median 
follow-up was 29.4 months in the 3DCRT group and 24 months in the 
CR group.
Results: The 1-, 2- and 3-years overall survival rates was 87.2%, 
69.4%, 56.2% for 3DCRT group vesus 81.6%, 61.8%, 53.6% 
for CR group (P=0.904 ). there was no difference in the rates of 
disease-free survival rate(DFS) and distant metastasis-free survival 
rate(DMFS) between the two groups. 1-, 2- and 3-years local-
regional free survival rate(LRFS) was 97.5%, 83.2%, 83.2% for 
3DCRT group and 84.3%, 76.0%,65.6% for CR group respectively 
(P=0.019). local-regional failure rate was 14.5% and for 3DCRT 
and 33.3% for CR group(P=0.006). Intercurrent death rate was 4.7% 
in 3DCRT group and 7.9% in CR group (P= 0.518). According to 
NCI CTC 3.0 criteria,≥grade 2 radiation pneumonitis occurred in 28 
patients(17.3%), with 10 patients (11.6%) in 3DCRT group and 18 
patients (23.7%) in CR group, P=0.043.
Conclusions: Postoperative radiotherapy with 3DCRT could improve 
local-regional control and reduce the incidence of radiation pneumon-
itis compared with conventional radiotherapy in NSCLC.
P3.207 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Complexities of lung stereotactic radiotherapy planning 
target volumes
Dawood, Omar1; Chang, Joe Y.2; Balter, Peter A.2; Komaki, Ritsuko2; 
Roth, Jack A.2
1 Accuray Incorporated, Sunnyvale, CA, USA; 2 The University of 
Texas MD Anderson Cancer Center, Houston, TX, USA
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During the last decade the field of lung stereotactic radiotherapy 
(SRT) has evolved into one dominated by technical sophistication 
and diverse methods of motion management. Nevertheless, there 
remains a lack of consistency in target and margin delineation, i.e., 
construction of the planning treatment volume (PTV). This inconsis-
tency reflects variation in methods of respiratory compensation and 
tracking and lack of consensus about how to account for microscopic 
extension. In addition, the collaboration of surgeons and radiation 
oncologists in treatment planning has further evolved target iden-
tification, shaping clinical tumor volume (CTV) margins to match 
predicted tumor drainage and spread patterns in a manner that is con-
sistent with surgical pathology. These trends have complicated what 
was once thought of as a simple concept, the ideal PTV.
The past decade’s experience (reflected in the work of Onishi et 
al.) has shown that a biologically effective dose (BED) > 100 Gy, 
delivered in 3-4 fractions of 12-20 Gy, is required to achieve high 
rates of local control in lung SRT. This finding serves as the basis of 
many single-PTV prescription plans, which are focused on the high-
est density of cells within the macroscopic tumor. Some have argued, 
however, that effective treatment of macroscopic and microscopic 
disease requires two unique PTV margins that address different rela-
tive densities of cells comprising the disease. Recent research has 
demonstrated that effective treatment of low density clonogenic cell 
extension beyond the gross tumor volume (GTV) requires these cells 
to be covered by at least 38-40 Gy in 3-4 fractions to achieve high 
local control rates and minimize marginal failures, especially for the 
adenocarcinoma tumor variants. These findings were the underpin-
nings of the target delineation and margin scheme used in the recently 
launched Phase III STARS study randomizing operable early stage 
lung cancer patients to surgery vs. SRT, a comparison that leave no 
room for diminished efficacy in the SRT arm due to marginal recur-
rence stemming from inappropriate PTV construction.
In this presentation we describe various approaches to constructing 
the ideal lung SRT PTV, and the variables that must be taken into 
account given different technologies employed in lung SRT. The 
concept of the dual PTV, with differential dosing of macroscopic and 
microscopic disease, will be described. We will also provide a sense 
of the continued evolution of PTV identification stemming from sur-
geons and radiation oncologists providing joint input into delineation 
of tumor spread and microscopic extension. 
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PET is useful in differentiating cancer from fibrosis after 
curative radiotherapy for non-small cell lung cancer 
(NSCLC)
Faria, Sergio L.; Lisbona, Robert; Souhami, Luis; Freeman, Carolyn 
R.
McGill University Health Centre (MUHC) and the Jewish General 
Hospital, Montreal, QC, Canada
Introduction: Curative radiotherapy in NSCLC generally causes 
lung fibrosis. With CT scan is often difficult to distinguish fibrosis 
from active cancer. FDG-PET/CT is a functional imaging method 
that could be effective for early assessment in this group of patients. 
We report an experience on the value of PET/CT in assessing tumor 
response, differentiating active cancer from fibrosis, after curative 
radiotherapy alone for NSCLC.
Material/Methods: Early stage NSCLC patients, medically inoper-
able, treated with radiation alone to a dose of 52.5Gy/15 fractions 
with 3-D planning. All had PET/CT performed before and after 
radiotherapy. Post-treatment PET/CT was performed 7-8 months 
after radiotherapy. Follow-up was every 3-6 months and included at 
least physical examination and chest x-ray (CXR). The primary lung 
tumor treated with radiation had the post-treatment PET/CT meta-
bolic response scored as “negative” when there was a complete or 
almost complete response, or “positive” (partial, stable or increased 
hypermetabolic disease) when compared to the pre-treatment PET/
CT. Evaluation of the interpretation of the post-treatment PET/CT 
(local tumor control or progression) was done with long term follow-
up with physical examination and imaging including CXR, CT, bone 
and additional PET scans whenever necessary. Fifteen cases are the 
subject of this analysis. Median follow-up time after radiotherapy 
was 40 months (range: 11-51), and after the post-treatment PET was 
29 months (range:6-40). Median age 76 was years. Stages: T1=5, 
T2=8, T3=1, T4=1 patient. Median PTV = 142 cc. 
Results: Post-treatment PET/CT (in the irradiated area) was con-
sidered “positive” in 4 and “negative” in 11 patients. All of the latter 
11 “negative” cases still had local control at the last follow-up, al-
though 7 of them showed new lesions within a median of 15 months 
after the post-treatment PET/CT. Of the 4 cases with “positive” PET/
CT, 2 had confirmed local relapse with new lesions during further 
follow-up, while the remaining 2 cases showed non-evidence of dis-
ease in subsequent follow-up 34 and 39 months after post-treatment 
PET/CT. Figure shows a T3N0 right lung tumor. Pre (above) and post 
(below) treatment PET and CT (7 months after RT). 
Conclusion: There is paucity on data dealing with the value of PET/
CT to determine absence of active tumor after radiotherapy alone in 
NSCLC, particularly after radiotherapy alone and with a long follow 
up after the post-treatment PET. This study shows that post-treatment 
PET/CT is very useful in differentiating active cancer from lung 
fibrosis after curative radiation treatment for NSCLC.
Copyright © 2009 by the International Association for the Study of Lung Cancer S943
Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 1, September 2009  13th World Conference on Lung Cancer
P3.209 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Final report of a phase I Dose Escalation Trial of 
Stereotactic Body Radiotherapy (SBRT) for lung tumors
Feigenberg, Steven Joel1; Sharma, Navesh1; Yu, Jian Q.1; 
Buyyounouski, Mark1; Borghaei, Hossein1; Scott, Walter1; Simon, 
George1; Unger, Michael1; Movsas, Benjamin2
1 Fox Chase Cancer Center, philadelphia, PA, USA; 2 Henry Ford 
UNiversity Hospital, Detroit, MI, USA
Purpose: To determine the maximum tolerated dose of SBRT for 
lung tumors.
Materials/Methods: Eligible patients had biopsy proven cancer (any 
histology) with a greatest dimension < 5 cm and a KPS > 50. Patients 
were allowed to have up to 2 sites of involvement. Patients with 
central tumors were included. Total doses were escalated in 8 Gy(i.e. 
2 Gy per fraction) increments from 40 Gy to 56 Gy, delivered in 4 
equal fractions administered 2 to 3 times per week on an Institutional 
Review Board approved protocol at Fox Chase Cancer Center. SBRT 
was administered using 7 to 9 fixed coplanar and/or non-coplanar 
beam arrangements with CT localization performed prior to each 
treatment. Treatment Volumes (ITV) were individualized using 
4D simulation or slow CT. There was no expansion to account for 
subclinical disease. The planning target volume (PTV) was defined 
as the ITV with a uniform 5 mm expansion in all directions. The dose 
was prescribed at the 90% isodose line which specifically covered 
100% of the PTV. PET scans 1 month prior to and 3 months follow-
ing SBRT to acccess response for patients treated definitively. Dose 
limiting toxicity was defined as any grade 3 or higher toxicity using 
the RTOG common toxicity version 3.
Results: Between 4/04 and 2/08 accrual was completed with 18 
patients receiving the prescribed treatment (40 Gy n=6, 48. Gy n=7, 
56 Gy n=5). Seventeen of 18 patients had non-small cell lung cancer 
(1 with rectal cancer), four of whom were treated for an oligometas-
tasis. The mean tumor size was 2.6 cm ( range 0.9 to 4.5 cm). Three 
patients developed grade 2 or higher symptoms following SBRT, with 
only one (48 Gy) that was grade 3. This patient developed a bacterial 
pneumonia 2 days after treatment with a fever of 103 that responded 
to intravenous antibiotics which was assumed radiation related. No 
late pulmonary complications have occurred with a median follow 
up of 18 months (range 12 months to 48 months). PET scans were 
obtained pre and post SBRT in 15 patients. PET response (ratio of 
pre-PET versus post PET) was higher in each cohort (-7% for 40 Gy, 
48% for 48 Gy and 58% for 56 Gy). No patient had a decrease in 
FEV1 or DLCO by one month after treatment.
Conclusions: The maximum tolerated dose of SBRT to lung lesions 
less than 5 cm has not been reached and doses of up to 56 Gy admin-
istered in 4 equal fraction delivered in 2 to 3 fractions is safe.
P3.210 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Respiratory gated proton beam therapy for early stage 
lung cancer
Fuji, Hiroshi; Murayama, Shigeyuki; Yamashita, Haruo; Harada, 
Hideyuki; Asakura, Hirofumi; Nishimura, Tetsuo
Shizuoka Cancer Cneter, Nagaizumi-cho, Shizuoka-pref., Japan
Background: Proton beam with Bragg-peak enables to decrease 
doses to normal tissue proximal and distant of tumor. Although the 
proton beam with the unique dose distribution supposed to be effect-
ive technique for stereotactic treatment of early stage non-small cell 
lung cancer (NSCLC), the fluctuations of tumor localization and of 
beam pass by respiration compromise the advantage of proton beam. 
Shizuoka Cancer Center has been performed respiratory gated proton 
beam therapy since 2003. Outcomes in patients underwent respira-
tory gated proton beam therapy (RPBT) for primary early stage lung 
cancers were analyzed.
Methods: A retrospective data of patients identified 39 patients 
underwent RPBT for primary early stage lung cancer. Stage IA and 
IB disease were 26 and 13, respectively. Subjects included 33 patients 
(85%) with pre-treatment histological confirmation of malignancy 
and 21 patients (53%) diagnosed medically inoperable. Median size 
of tumor was 25 mm (13 - 62 mm). Clinical target volumes (CTV) 
were defined on images from respiratory gated computed tomog-
raphy. Two-phases (inhale and exhale) computed tomography or 
fluoloscopy were used for measurement of normal respiratory motion 
and margins regarding with the respiratory tumor motion data were 
added for internal target volumes (ITV). Margins for set-up error of 
5 mm were added to ITV. Window width of 5 – 10% were introduced 
for respiratory gated beam delivery. Mostly hypofractionated treat-
ment of 80 GyE / 20 fr. (n=18) or 60 GyE / 10 fr (n=18) were applied. 
Others were treated larger fraction number (70 GyE / 25 fr. for one 
patient, 78 GyE / 28 fr, for two patients). 
Results: Median respiratory tumor motion was 8 mm (0-30 mm). 
Introduced margins added ITV for respiratory gate treatment were 0 
-4 mm (median 4 mm). The median follow up times was 28 months. 
Actuarial overall survivals of this cohort were 84% and 56% at 2 and 
5 years, respectively. The overall survival of stage IA and IB disease 
at 2 years were 95% and 62%. There were no cases with local failure 
among the patients with stage IA but three cases (23%) in stage IB. 
No grade 3 to 5 radiation pneumonitis was observed. Four patients 
developed costal bone fracture in CTV after 16 – 26 months of 
RPBT.
Conclusion: Respiratory gated proton beam therapy provides excel-
lent local control and overall survival rate for patients with stage IA 
disease. Relatively lower control rate and survival rate in stage IB 
disease indicated that different treatment strategy is needed to be 
explored for this stage of disease. Although respiratory gating proton 
beam therapy appears to be least toxic, reasonable decrease of dose to 
normal tissues in clinical target should be established.
P3.211 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Impact of Lung Stereotactic Body Radiotherapy (SBRT) 
on Pulmonary Function
Grills, Inga S.; Kestin, Larry L.; McInerney, Erika; Galerani, Ana 
Paula; Ye, Hong; Seidman, Joel; Welsh, Robert
William Beaumont Hospital, Royal Oak, MI, USA
Background: Multiple studies report changes in pulmonary func-
tion occurring after surgical resection for lung cancer. Medically 
inoperable patients with early stage disease are typically treated 
with radiotherapy, often due to the concern for surgical pulmonary 
morbidity. Minimal data are available, however, regarding the impact 
of radiation, specifically stereotactic body radiotherapy (SBRT) on 
pulmonary function. This study quantifies changes in lung function 
after SBRT.
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Materials/Methods: Thirty-nine patients with Stage I non-small cell 
lung cancer or a solitary metastasis were treated with cone-beam CT 
image-guided lung SBRT as part of a single institution phase II trial. 
Patients received 48 (T1) – 60 (T2, metastatic) Gy in 4-5 fractions 
delivered to the planning target volume with heterogeneity correc-
tion. PFT’s were performed at baseline and then 6, 12, 24, 36, and 52 
weeks after completion of SBRT. Multiple factors were analyzed for 
association with change in PFT’s, including baseline patient charac-
teristics and lung dose volume parameters. 
Results: The mean FEV1, %predicted FEV1(FEV1%), DLCO, 
%predicted DLCO(DLCO%), DLCO/VA, corrected DLCO, and Total 
lung capacity(TLC) at baseline were 1.57L, 67%, 12.43ml/min, 50%, 
3.05ml/min, 11.12ml/min, and 5.32L, respectively. Reductions in 
FEV1 and FEV1% occurred early and remained stable with rela-
tive reductions from baseline of -8% (FEV1) and -6 (FEV1%) at 52 
weeks. Relative reductions in DLCO were -9%, -1%, -8%, -10% and 
-15 % at 6, 12, 24, 36 and 52 weeks. DLCO/VA was mildly affected 
(-4 % 52 weeks), suggesting the DLCO reduction is related to alveo-
lar RT damage (not apparent with DLCO corrected for alveolar vol-
ume). At 12 mos, Lung V10 and V12.5 correlated with absolute and 
relative reduction in DLCO (p<0.001 V10 and V12.5) and DLCO/VA 
(p=0.03 V10, p=0.02 V12.5). Reduction in FEV1 (12 mos) was asso-
ciated with mean lung dose (p=0.03). Rates of pneumonitis (8%, 5%, 
and 3% grades 1-3) and dyspnea (21%, 5%, and 3% grades 1-3) were 
minimal. Declines in pulmonary function over time were recorded 
using the RTOG SBRT Pulmonary Toxicity Scale as defined in RTOG 
0813 and are outlined in Table 1.
 Toxicity Grade 0 Grade 1 Grade 2 Grade 3
 FEV1    
 6 weeks 78% 19% 3% 0%
 12 weeks 87% 13% 0% 0%
 6 mos 58% 32% 11% 0%
 9 mos 71% 24% 6% 0%
 12 mos 59% 35% 6% 0%
 Forced Vital Capacity    
 6 weeks 84% 9% 6% 0%
 12 weeks 87% 13% 0% 0%
 6 mos 67% 18% 5% 0%
 9 mos 63% 38% 0% 0%
 12 mos 59% 29% 12% 0%
 DLCO*    
 6 weeks 58% 27% 12% 0%
 12 weeks 61% 28% 11% 0%
 6 mos 53% 33% 6% 6%
 9 mos 44% 31% 19% 6%
 12 mos 47% 24% 29% 0%
(*single patient grade 4 reduction at 6 weeks). 
Conclusion: Lung SBRT is well-tolerated in patients with poor 
baseline pulmonary function. FEV1 reductions of 6-8% and largely 
asymptomatic DLCO reductions of 15-18% occurred 1 year after 
RT, correlating with mean lung dose, Lung V10 and V12.5. DLCO 
reduction appears to be primarily related to alveolar damage. Nearly 
all declines in pulmonary function after SBRT were grade 1 or 2, 
with 6%, 12% and 29% having grade 2 declines in FEV1, FVC, and 
DLCO, respectively at 1 year. 
P3.212 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Toxicity profile for concurrent chemo-radiation (CRT) of 
locally advanced NSCLC using weekly docetaxel
Hansen, Olfred; Schytte, Tine; Hansen, Karin H.; Sørensen, Peter; 
Brink, Carsten 
Odense University Hospital, Odense, Denmark
Background: From 2001 to 2006 patient with locally advanced 
NSCLC were treated as part of a phase III trial using weekly 
docetaxel in CRT. After the termination of the trial we continued 
using this regimen for fit patient. In this study we report the toxicity 
experienced with this regimen compared with patient treated with 
radiotherapy (RT) without concurrent chemotherapy (CT) treated at 
our institution
Methods and Material: Data from patient files of 113 patients 
treated with RT in planned doses of 60-66 Gy without CT 183 
patients treated with neoadjuvant CT followed by RT 60-66 Gy, and 
37 patients treated with neoadjuvant CT followed by concurrent do-
cetaxel CRT 60 Gy. All RT was applied as 3-D RT in 2 Gy/F without 
elective nodal irradiation from 1995-2008
Results: The median survival in the 3 groups was 16.3, 15.6, and 
20.5 months. The 1 year survival was 60%, 61%, and 79%. How-
ever, the differences were not statistically significant. Dyspnoe 
grade 3+ was not significant more prevalent in the CRT group, while 
esophagitis grade 3+ was. In a logistic regression analyses using 
dyspnoe grade 3+ as endpoint, only PS 2+ was a statistically sig-
nificant factor, while analyzing esophagitis grade 3+ CRT and stage 
were. 
Conclusion: Use of concurrent docetaxel with RT resulted in an 
increased frequency of esophagitis grade 3-4 while the risk of 
pneumonitis did not change significantly. Although a trend for bet-
ter survival with CRT was demonstrated, this was not statistically 
significant.
  N Dyspnoe g3+ Dysphagia g3+ Treatment related death
 RT alone 113 17.6% 1.9% 8
 Neoadjvuant CT 183 22.8% 0.6% 5
 CRT 37 27.8% 8.3% 3
 p value CRT vs no-CRT  ns <0.02 ns
P3.213 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Stereotactic body radiotherapy for peripheral stage I Non-
small Cell Lung Cancer: A single institution experience by 
respiratory gating and tumor-tracking methods
Hayakawa, Kazushige; Kotani, Shouko; Katagiri, Masato; Mitsufuji, 
Hisasi; Yanase, Nobuo; Niibe, Yuzuru; Ishiyama, Hiromichi; Kubota, 
Masaru; Satoh, Yukitoshi; Masuda, Noriyuki
Kitasato University School of Medicine, Sagamihara, Japan
Purpose: To evaluate the clinical outcomes of stereotactic body 
radiotherapy (SBRT) for peripheral stage I non–small-cell lung can-
cer (NSCLC) in a single institution.
Patients and Methods: From September 2000 to March 2008, 61 pa-
tients with peripheral stage I NSCLC were treated in our hospital and 
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were followed for > 12 months. Forty-nine patients had T1 tumors 
and 12 had T2 tumors. One patient had two T1 tumors. The size of 
T1 tumors ranged from 15 to 30 mm in diameter and T2 tumors were 
less than 45 mm in diameter. 25 patients were treated with a standard 
fractionation of 30 Gy / 10 fractions or 40 Gy / 20 fractions and a 
single high-dose boost of 20 Gy using 3D non-coplanar SBRT. A 
spiro-analyzer was adopted for gaiting respiratory tumor motion. The 
other 36 patients were treated with a total dose of 48 Gy/ 4 fractions 
by real-time tumor-tracking radiotherapy. 3D treatment planning was 
performed to maintain the target dose homogeneity within 10-20 
%. The overall actuarial survival (OAS) and cause-specific survival 
(CSS) rates were calculated from the first day of treatment using the 
Kaplan-Meier method.
Results: Of the 62 tumors, 51 tumors (82%) decreased in size by 
50% or more after treatment. No radiation pneumonitis greater than 
National Cancer Institute-Common Toxicity Criteria Grade 1 was 
noted except one patient had grade 2 pneumonitis. The cumulative 
in-field progression rates at 2 years were 4 % in T1 and 64% in T2, 
respectively (P<0.05). Only two patients developed isolated regional 
nodal failure. Six patients had distant failures. Nine patients died 
of primary lung cancer. Seven patients died of intercurrent disease, 
and one patient died of secondary lung cancer within 5 years after 
the treatment. The 3-year and 5-year OAS rates for all patients were 
62% and 46%, and the CSS rates were 75% and 64%, respectively. 
By the substage, the OAS and CSS rate at 3 years was 71% and 88% 
for those with stage IA and 30% and 33% for those with stage IB, 
respectively. There was not a statistically significant difference in sur-
vival curves between adenocarcinoma and squamous cell carcinoma.
Conclusions: Our methods of SBRT are safe and effective treatments 
for patients with peripherally located stage IA NSCLC who are not 
sufficiently fit for or decline surgery.
P3.214 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Association of ATM and P53 Single Nucleotide 
polymorphisms with radiation-induced pneumonitis
Iqbal, Kashif1; Zhang, Li 2, 1
1 Nuclear Medicine, Oncology and Radiotherapy Institute, 
Islamabad, Pakistan; 2 Chinese Academy of Medical Sciences and 
Peking Union Medical College, Beijing, China
Purpose: To explore the possible relationship between single nu-
cleotide polymorphisms (SNPs) in candidate genes encoding DNA 
repair, apoptosis, and inflammatory cytokines with radiation-induced 
pneumonitis (RP) in patients with lung cancer.
Patients and Methods: One hundred and twenty-seven non-small 
cell lung cancer patients and forty-three small cell lung cancer 
patients who were inoperable and underwent thoracic radiother-
apy at Cancer Hospital of Peking Union Medical College (PUMC) 
and Chinese Academy of Medical Sciences between January 2004 
and August 2006, were evaluated. All of them consented for blood 
sampling, SNP analysis and follow up. The primary endpoint was 
≥ grade 2 radiation pneumonitis. We analyzed 37 SNPs in 20 DNA 
repair, apoptosis and inflammatory Cytokines genes, including 
ATM, TP53, ERCC1, XRCC1, XRCC3, XPD, XPC, XPG, NBS1, 
STK15, ZNF350, ADPRT, FAS, FASL, CYP2D6*4, CASP8, COX-2, 
TGF-β1, CD14 and ACE genes, using PCR-based restricted fragment 
length polymorphism (RFLP). 
Results: One hundred and seventy patients with a median follow-up 
of 22 months were evaluated. Twenty-nine patients (17.1%) experi-
enced ≥ grade 2 pneumonitis and the median occurrence time was 
59 days from the first day of irradiation. ATM –111GA and –111AA 
genotypes were independently associated with the risk of RP (Haz-
ards ratio (HR) = 3.27, 95% confidence interval (CI) = 1.09-9.78, P 
= .034) and TP53 72Arg/Pro and 72Pro/Pro genotypes had a trend to 
decrease the risk of RP (HR = 0.43, 95% CI = 0.17-1.12, P = .084). 
The presence of two risk genotypes (ATM –111A allele combined 
with TP53 72Arg/Arg genotype) showed an independent role for high 
risk for RP with HR of 4.75 (95% CI = 1.33-17.04, P = .017).
Conclusion: Genetic polymorphisms in ATM gene and TP53 gene 
contribute to the risk of radiation-induced pneumonitis. These could 
be used as putative predictive biomarkers for radiotherapy in the 
future.
P3.215 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Radiotherapy quality assurance (QA) in a multi-center 
stereotactic body radiation therapy (SBRT) trial for stage 
IA non-small cell lung cancer: the Japan Clinical Oncology 
Group (JCOG) Trial 0403
Ishikura, Satoshi1, 2; Sanuki-Fujimoto, Naoko1, 2; Hiraoka, Masahiro3; 
Bosch, Walter4; Purdy, James5
1 Center for Cancer Control and Information Services, National 
Cancer Center, Tokyo, Japan; 2 Radiotherapy Support Center, Tokyo, 
Japan; 3 Kyoto University Graduate School of Medicine, Kyoto, 
Japan; 4 Washington University, St. Louis, MO, USA; 5 UC Davis 
Medical Center, Sacramento, CA, USA
Background: The JCOG has introduced a radiotherapy QA program 
for SBRT including credentialing, digital data submission, and a 
protocol compliance QA review using a web-based remote review 
tool supported by the Advanced Technology QA Consortium (ATC). 
JCOG 0403 was the first trial to apply this QA program in Japan. The 
purpose of this study was to analyze the quality of this trial. 
Methods: JCOG 0403 was a single arm phase II study. This study 
was designed to confirm whether SBRT was superior to conventional 
radiotherapy in medically inoperable patients, and to explore whether 
SBRT could achieve comparable survival to surgery in operable 
patients with clinical stage IA NSCLC. The primary endpoint was 
3-year overall survival, and the target accrual was 100 inoperable and 
65 operable patients. Radiotherapy requirements included a total dose 
of 48 Gy in 4 fx with heterogeneity correction using pencil-beam 
algorithms; overall treatment time (OTT), 4 to 8 days; and a homo-
geneity index (HI) < 1.6. Dose constraints to normal tissues were also 
defined. Chemotherapy was not allowed until any disease progres-
sion. The following radiotherapy parameters were reviewed by a 
responsible radiation oncologist (S.I.): PTV, maximum and minimum 
doses, HI, and D95; the lung, mean dose, V15, and V20; and doses 
to other normal tissues. The differences between doses calculated by 
a pencil-beam algorithm and a convolution-superposition algorithm 
were also reviewed when comparative data were available. 
Results: A total of 169 cases were accrued, and 164 were available 
for analysis. The OTT ranged from 4 to 8 days (median: 4 days) 
except 1 case of 9 days due to a national holiday. The PTV ranged 
from 8.2 to 103.7 cc (median: 33.7 cc). The maximum and minimum 
doses, HI, and D95 of the PTV were: 48.2 to 54.0 Gy (median: 49.9 
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Gy); 29.4 to 46.7 Gy (median: 43.5 Gy); 1.01 to 1.73 (median: 1.15); 
and 41.3 to 48.1 Gy (median: 46.2 Gy), respectively. The mean lung 
dose, V15, and V20 of the “Total Lung minus PTV” were: 1.1 to 
7.0 Gy (median: 3.1 Gy); 2.1 to 16.7% (median: 6.1%); and 1.4 to 
12.2% (median: 4.1%), respectively. In 123 of 164 cases, recalculated 
doses to the PTV using the convolution-superposition algorithm were 
available. These maximum and minimum doses, HI, and D95 were: 
39.9 to 50.3 Gy (median: 46.6 Gy); 22.0 to 43.4 Gy (median: 33.6 
Gy); 1.15 to 2.02 (median: 1.37); and 27.4 to 46.0 Gy (median: 38.5 
Gy), respectively. There were 8 protocol deviations: dose constraints 
to normal tissues, the spinal cord (1), the pulmonary artery (1); dose 
prescription (4); H.I. > 1.6 (1); and administration of chemotherapy 
prior to SBRT (1). Otherwise, 161 of 169 cases (95.3%) followed the 
protocol guidelines.
Conclusions: Radiotherapy compliance in JCOG 0403 was satisfac-
tory for providing scientifically reliable results. Analyses of these 
radiotherapy parameters regarding the long-term clinical outcome 
will provide meaningful findings, and are thus awaited.
P3.216 Radiotherapy, Mon Aug 3 – Tue Aug 4 
The impact of pulmonary emphysema on radiation 
pneumonitis in patients with lung and mediastinal tumors 
Kimura, Tomoki1; Togami, Taro2; Nishiyama, Yoshihiro2; Takashima, 
Hitoshi2
Hiroshima, Japan; 2 Takamatsu, Japan
Purpose: To evaluate whether pulmonary emphysema (PE) is related 
to the incidence and grade of radiation pneumonitis (RP) in patients 
with lung and mediastinal tumors. 
Methods and Materials: Ninety-two patients with lung and medias-
tinal tumors who had received definitive radiation therapy at Kagawa 
University were enrolled. The median age was 72 years (range 52 to 
93 years). Pathologic diagnoses of thelung tumors were non-small 
cell carcinoma (NSCLC) in 64 patients (stage I in two patients, stage 
II in 8 patients, stage III in 46 patients, and stage IV in 8 patients), 
and small cell carcinoma (SCLC) in 23 patients (all patients were 
diagnosed withlimited-disease). Five patients were diagnosed with 
mediastinal tumors. All patients were performed FDG- PET for 
staging. Radiation therapy for patients with NSCLC and mediastinal 
tumors was performed by involved-field, and the total dose ranged 
from 54 to 80Gy (median 70Gy). Radiation therapy for patients with 
SCLC was performed by accelerated hyperfractionation (45Gy/30fr, 
bid) including elective nodal regions. Seventy-three patients (79.3%) 
were administered chemotherapy (sequential: 10 patients, concurrent: 
63 patients). We evaluated RP using CTCAE ver. 3.0 and the relation-
ship with V20 (the percentage of pulmonary volume irradiated to 
>20Gy) and PE. 
Results: The follow-up time ranged from 3 to 83 months (median 16 
months).
1) The incidence of RP was Grade 1 in 32 patients, Grade 2 in 49 
patients, Grade 3 in 10 patients and Grade 5 in 1 patient.
2) The relationship with RP and V20: V20 values ranged from 1.0 to 
38.1% (median 19.4%). The 6-month cumulative incidence of RP 
greater than Grade 3 was 7.7% and 34.1% in patients with a V20 
of <25% and 25%≥, respectively (p=0.017).
3) The relationship with RP and PE: PE was diagnosed by the pres-
ence of low-attenuation area (LAAs) on CT scans. According 
to the extent of LAAs in the lung fields, the CT findings were 
classified into the five grades: grade 0 (no LAAs) to grade 4 (ab-
sence of normal lung parenchyma). A PE grade of 0, 1, 2, 3 and 
4 was observed in 33, 23, 25, 10 and 1 patient, respectively. The 
6-month cumulative incidence of RP greater than Grade 2 was 
63.9%, 76.7%, 82.2% and 90.9% in patients with a PE grade of 0, 
1, 2, 3 and 4, respectively (p=0.0058).
Conclusions: The incidence and grade of RP are significantly related 
to not only the V20 values but also PE grade.
P3.217 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Oral vinorelbine (NVBo) at three weekly flat-dose intakes 
concomitantly with Thoracic Radiotherapy (TRT) in 
locally advanced or inoperable stage III Non-Small Cell 
Lung Cancer (NSCLC): results of a phase I dose escalation 
trial
Krzakowski, Maciej2; Gridelli, Cesare3; Paccagnella, Adriano4; 
Aslanis, Vassili1; Perraud, Kevin1; Lucas, Christel1
1 Institut de Recherche Pierre Fabre, Boulogne Billancourt, France; 2 
Centrum Onkologii Instytut, Warswa, Poland; 3 Azienda Ospedaleria 
S. Giuseppe Moscati, Avellino, Italy; 4 Ospedale Civile di Venezia, 
Venice, Italy
Background: In vitro, vinorelbine (NVB) has shown to be a power-
ful radiosensitizer. Based on the bioavailability of NVBo and the 
available marketed dosages (20-30 mg), a feasibility study has been 
implemented in patients (pts) with untreated locally advanced or 
inoperable stage III NSCLC with continuous administration of NVBo 
during the RT period through flat-dose intakes 3 times a week (w). 
Material and Methods: 3 pts between 18 and 70 years, with stage 
IIIAN2/IIIB (no supraclavicular lymph nodes / pleural effusion) 
NSCLC, adequate bone marrow, hepatic and renal function, KPS 
≥80%, were expected at each dose-level (L) with 3 additional pts 
in case of dose-limiting toxicity (DLT). NVBo was given concomi-
tantly with 60 Gy RT (2 Gy/day; 5 days/w) from 20 mg up to 60 mg 
total-doses on days (D) 1, 3 and 5, each week during 6 w. We report 
the maximal tolerated dose (MTD) defined as 2 DLT in a L and the 
recommended dose (RD). 
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Results: Between 06/02 and 10/07, 21 men and 5 women were 
enrolled with stages IIIA N2 (6 pts) or IIIB (20 pts); median age 
60.6 years [39.5-70.3], median KPS 100% [80-100%]. No DLT 
occurred in the first 5 L. MTD was reached at L7 with 3 Grade(G)3 
oesophagitis and 1 G3 pneumonia as DLT out of 5 pts: 60 mg D1, 50 
mg D3,5. In the RD level (L6; 50mg D1, 3, 5), only 1/6 pts experi-
enced a DLT: a febrile neutropenia with G4 thrombopenia and G3 fa-
tigue. 18 pts received 100% of the planned NVBo dose, 4 pts missed 
only one intake for TRT planning reasons, 1 had 1 w-doses cancel-
lation for haematological toxicity (L6) and 3 pts had a premature 
withdrawal related to a DLT (1L6, 2L7). Objective Response (R) was 
observed in 11 pts (42%) and 1 out of 4 additional partial R during 
follow-up was confirmed. Pharmacokinetics on the 1st w confirmed 
a dose-proportional increase of drug exposure and its reproducibil-
ity between administrations with low intra-pt variability and without 
accumulation. 
Conclusion: NVBo with this original schedule of 3 times a week 
intake concomitantly with RT for 6 w is well tolerated. The RD as 
single chemotherapy agent is 50 mg D1,3 and 5. Additional evalua-
tion of dose-escalation is ongoing in combination with cisplatin at 
the dose of 80 mg/m2 D1 every 3 weeks: to date 4 patients received 
NVBo 50 mg D1, 40 mg D3 and 5 (first level with combination 
chemotherapy).
P3.218 Radiotherapy, Mon Aug 3 – Tue Aug 4 
A Phase I trial of radiation dose escalation using 
accelerated concomitant boost radiotherapy concurrently 
with weekly carboplatin/paclitaxel in patients with good 
performance status and Stage IIB/ IIIA/B non-small cell 
lung cancer (NSCLC)
Lehman, Helen M.
Princess Alexandra Hospital, Brisbane, QLD, Australia
Background: The median survival for Stage IIB- IIIB NSCLC 
treated with concurrent platinum-based chemotherapy and radiation 
therapy (60Gy/30f) is 12-16 months. Local failure occurs in a sig-
nificant proportion of patients and evidence of a relationship between 
local control and survival exists. A radiation dose-response relation-
ship exists but prolongation of overall treatment time is detrimental to 
tumour control and survival. Accelerated radiation using concomitant 
boost allows dose escalation while maintaining overall treatment 
duration, delivers a significant proportion of the dose when tumour 
clonogens are regenerating, and should not result in an increase in 
late effects. This study was conducted to determine the safety and 
tolerability of accelerated concomitant boost radiotherapy given 
concurrently with weekly carboplatin and paclitaxel.
Methods: Patients with Stage IIB-IIIB NSCLC fit for radical therapy 
were prospectively entered into a dose escalation protocol.
 Day 1-28:  40Gy/20f (2Gy/f), 5 days/week.
 Day 29-40:  Radiation delivered twice daily 
 Dose Level 1: 30Gy/10f (1.5Gy bd, 6 hour interfraction inter-
val), 5 days/week
 Dose Level 2:  32Gy/10f (1.6Gy bd)
 Dose Level 3:  34Gy/10f (1.7Gy bd)
 Dose Level 4:  36Gy/10f (1.8Gy bd)
Three patients entered at each dose level. Acute dose-limiting toxici-
ties (DLT) experienced during and after chemo-radiotherapy defined 
according to NCI CTC v3.0. The maximum tolerated dose defined 
as the highest safely tolerated dose level where at most one of six 
patients experienced a DLT.
Carboplatin AUC 2, Paclitaxel 45mg/m2 delivered on Days 
1,8,15,22,29,36.
Results: Between 11/05 and 11/08, 8 patients accrued: 4 dose level 1, 
3 dose level 2, and 1 dose level 3. 50% SCC, 25% Adenocarcinoma, 
25% large cell carcinoma. 25% Stage IIB, 75% Stage IIIA/B.
No patient has experienced a dose limiting toxicity.
Disease recurred in 6 (75%) of patients. 6 (75%) of patients main-
tained local control, 4(50%) of patients failed distantly with 75% of 
distant failures occurring in the brain.
7 (88%) of patients have died, 6 (86%) due to NSCLC, 5 (71%) 
locally controlled at the time of death.
Median Survival 8.3months.
Conclusions: Radiation dose escalation using accelerated con-
comitant boost radiotherapy concurrently with weekly carboplatin/
paclitaxel has proven tolerable to a dose level of 74Gy/40f. Local 
control is maintained in a significant proportion of patients while 
intracereberal failure remains a significant site of failure.
P3.219 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Tomotherapy in the radical treatment of stage 3 NSCLC
Lewanski, Conrad R.1, 2; Keggin, Emma2; Turner, Elizabeth 2; 
Aldridge, Emma 2; Thompson, Anna C.1
1 Charing Cross Hospital, London, UK; 2 Cromwell Hospital, 
London, UK
Background: Tomotherapy combines CT scanning capabilities with 
a linear accelerator mounted on a rotating gantry, thereby allowing 
the integration of image guidance and helical delivery to provide 
precision radiation to a thoracic target. We review the plans of 11 
cases treated radically with tomotherapy between Sept 2006 and Sept 
2008 and assess each against conventional 3D-conformal radiother-
apy (3DCRT).
Methods: 11 consecutive patients receiving radical tomotherapy as 
part of combined modality treatment were assessed ( Stage 3A: 4 
cases, Stage 3B: 7 cases). All patients received 66Gy in 33 fractions 
over 6.5 weeks in 2 phases of treatment. Plans were reviewed to as-
certain whether an equal radical dose using 3DCRT could have been 
delivered and whether the use of megavoltage CT image guidance 
throughout tomotherapy to verify the actual position of the tumour 
prior to each fraction of treatment would necessitate re-planning in 
any instance.
Results: Number %
• Radical treatment could be satisfactorily achieved with either 
tomotherapy or 3DCRT 6 54.5
• Radical plan could NOT be accomplished satisfactorily using 
3DCRT 3 27.3 (spinal cord proximity 2 cases, pacemaker 1 case)
• Radiation edema during treatment causing lobar collapse and 
necessitating re-planning 1 9.0
• Resolution of lobar collapse during treatment necessitating re-
planning 1 9.0
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Conclusions: Tomotherapy in the radical treatment of stage 3 
NSCLC offers advantages over conventional 3DCRT. In our series, 
3DCRT would offer suboptimal therapy in 45.5% of the cases either 
as a result of dose limitation due to critical organ constraints or 
significant target volume movement during therapy as a consequence 
of lobar collapse or re-aeration. Survival data will be presented at the 
conference. 
P3.220 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Study on the dosimetric of different parameter of 
simultaneous integrated boost intensity-modulated 
radiotherapy and sequentially conformal radiotherapy for 
multiple brain metastases
Shao, Qian; Sun, Tao; Li, Ji-bin; Liang, Chao-qian; Liu, Tong-hai; 
Tian, Shi-yu; Xu, Min; Xing, Jun; Fan, Ting-yong; Yu, Jin-ming
Department of Radiation Oncology, Shandong Tumor Hospital, 
Jinan, China
Objective: To compare the dosimetric of different parameter of 
simultaneous integrated boost intensity-modulated radiotherapy(SIB) 
and sequentially conformal radiotherapy(CRT) for multiple brain 
metastases. 
Methods: Nine patients with multiple brain metastases form lung 
adenocarcinoma were selected to study. The metastatic lesion was 
defined as gross tumor volume (GTV) and the whole brain was 
defined as clinical target volume (CTV). The plans of simultaneous 
integrated boost intensity-modulated radiotherapy and sequentially 
conformal radiotherapy were respectively designed for every patient 
using VARIAN Eclipse planning system and the dosimetric of differ-
ent parameter was compared. The prescribe dose of whole brain and 
metastatic lesion in SIB plane was DT39.6Gy/22f, DT55.0Gy/22f 
respectively. The prescribe dose of whole brain and metastatic disease 
in CRT plane was DT40.0Gy/20f, DT60.0Gy/22f respectively. 
Result: The mean dose and maximum
Dose of GTV, CTV,brainstem and optic nerve were significant differ-
ence (p<0.05) in two plans.But The mean dose and maximum dose 
lens were not significant difference (p>0.05.) 
Conclusion: The SIB plan is better than the CRT plan. At the same 
time, it can preserve the important organs such as brainstem and optic 
nerve,and shorten the period of therapy time.
P3.221 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Three-dimensional conformal radiotherapy for 
mediastinal lympha node recurrence of esophageal cancer 
after postoperativ radiotherapy 
Shao, Qian; Sun, Tao; Liang, Chao-qian; Zhang, Ying-jie; Xu, Min; 
Li, Ji-bin; Yu, Jin-ming
Department of Radiation Oncology, Shandong Tumor Hospital, 
Jinan, China
Objective: To evaluate the feasibility,therapeutic effects and nomal 
tissue complications of three-dimensional conformal radiotherapy 
(3DCRT) for mediastinal lympha node recurrence of esophageal 
cancer after postoperative radiotherapy. 
Methods: Twenty-six patients with mediastinal lympha node recur-
rence of postoperative middle esophageal cancer were treated with 
three-dimensional conformal radiotherapy after innitial radiotherapy. 
Radiotherapy was delivered at 2.0Gy per fraction,once a day and five 
days a week.The median dose was 52Gy. The median follow-up was 
16.5 months. Treatment results and nomal tissue complications were 
assessed with WHO and RTOG criteria. 
Results: Twenty-three patients (88.5%) comleted the planned 
3DCRT treatment. Their clinical symptom relief rate was 77.3% and 
the response rate was 57.7%. The overall 1- and 2-year survival rate 
were 46.1% and 15.4% respectively with a median survival time of 
9 months. Grade 1 to 2 acute radiation esophagitis developed in 12 
patients,and grade 3 and 4 were 10 and 1 patients respectively. Grade 
1 to 2,grade 3,and grade 4 acute radiation pneumonitis developed in 
13, 9 and 1 patients. 
Conclusion: 3DCRT is feasible and advisable for mediastinal lympha 
node recurrence of esophageal cancer after postoperative radiother-
apy.It gives a good clinical and effective response and acceptable 
normal tissue complications. 
P3.222 Radiotherapy, Mon Aug 3 – Tue Aug 4 
The necessarity to change treatment plans of NSCLC 
during radiotherapy 
Zhang, Ying-jie; Li, Ji-bin
Shandong Tumor Hospital, Jinan, China
Background: Local control rate of NSCLC can be increased by 
irradiation dose boost, but pulmonary irradiation damage is another 
challenge. Target position and volume may change in different grade 
during radiotherapy inter-fraction, so target may be irradiated more 
exactly if radiotherapy plan modified in proper occasion, and irradia-
tion dose of pulmonary may be decreased.
Objective: To analyze the change of target volume during radiother-
apy inter-fraction and the inference of plan modification for pulmon-
ary DVH parameters.
Method: 124 patients with NSCLC treated by 3D-CRT were retro-
spectively analyzed. In Pinnacle3 treatment plan system, lung volume 
which got by ipsilateral lung volume and total lung volume minus 
GTV was calculated as prescribed dose in modified plan, then DVH 
parameters related to lung injury were collected respectively. Target 
volumes and pulmonary DVH parameters of the primary and modi-
fied plan were compared by paired T-test.
Results: The time of plans modification was fraction of 21.0±6.2. 
GTV decreased 46.3%±37.9% (t =4.31, p<0.01), and the grade of 
target volume shrinkage was correlated with irradiation fractions 
before treatment plan modification (r =0.434, P=0.005). Compared to 
the primary plan, total mean lung dose decreased 3.9%±9.6%(t =2.40, 
p=0.02), ipsilateral mean lung dose decreased 4.1%±11.0% (t =2.57, 
p=0.01) of the modified plan.
Conclusion: Treatment plan modification can decrease pulmonary 
DVH parameters, so which may contribute to protect pulmonary from 
severe irradiation damage and to boost irradiation dose. 
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P3.223 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Can elective nodal irradiation be omitted in limited-
disease small cell lung cancer? Retrospective analysis of 
concurrent involved field radiochemotherapy
Lievens, Yolande N.1; Pelgrims, Ans1; Vandenbroucke, Elke2; 
Vanstraelen, Bianca1; Moons, Johnny4; Nackaerts, Kristiaan2, 3
1 Radiation Oncology Department UZ Leuven, Leuven, Belgium; 2 
Respiratory Oncology Department UZ Leuven, Leuven, Belgium; 3 
Leuven Lung Cancer Group, Leuven, Belgium; 4 Thoracic Surgery 
Department, Leuven, Belgium
Background: Prospective outcome data regarding the optimal irradi-
ation volume in limited-disease small cell lung cancer (LD-SCLC) 
are lacking, leading to controversy about target volume definition. In 
this study, the outcome of LD-SCLC patients treated with concurrent 
involved field radiochemotherapy was analyzed, as well as the impact 
of incidental nodal irradiation. 
Materials and Methods: Patients with LD-SCLC treated between 
1-2003 and 1-2007 within the Leuven Lung Cancer Group were 
retrospectively reviewed. 
Chemotherapy consisted of 4 cycles of Cisplatin (60mg/
m²,d1,Q3wks) and Etoposide (120mg/m²IV,d1-3,Q3wks). Concur-
rent 3D conformal radiotherapy to a dose of 50Gy/2Gy over 5 
weeks started with the second cycle. Prophylactic cranial irradiation 
(30Gy/2Gy/3wks) followed if patients were in complete remission. 
Clinical target volume (CTV) included the involved lymph node re-
gions, defined as PET-positive and/or suspect on CT scan (short-axis 
diameter >1cm). 
The other lymph node regions were defined as elective nodes (EN) 
and retrospectively contoured on the original treatment plans accord-
ing to the definition of the Michigan atlas (except level 3p and 8). 
Overall survival was calculated from the initiation of treatment. 
Elective nodal failure was analyzed and compared to the dose deliv-
ered to the EN. 
Results: Twenty patients (13 males, median age 58 years, 11 right-
sided tumors) with a minimum and median follow-up of 24 and 34 
months respectively, were reviewed. In 14 patients diagnostic FDG-
PET data were available. 
After termination of the concurrent radiochemotherapy, a complete 
remission was obtained in 13 patients, based on CT scan. Partial 
remission was scored in 5 patients (2 of these never progressed); 
metastatic disease in 2 patients.
During follow-up 4 patients developed a local recurrence: 1 simultan-
eously in-field and out-of-field (at 21 months) and 3 in-field concur-
rently with distant progression (at 12, 18 and 22 months). 
The table shows the number of patients (total and per tumor side) 
with EN irradiation per region and the mean percentile incidental 
dose delivered in these EN regions. The incidental dose in the out-of-
field local recurrence is shown separately. 
Overall survival for all patients was 75%, 60% and 40.1% at 1, 2 and 
5 years respectively.
total patient 
number 
(n=20)
1-2R 1-2L 3 4R 4L 5 6 7 10R 10L
patient number 
per EN 11 16 18 4 6 9 12 1 8 8
° left-sided 
tumors 6 7 8 4 4 2 3 1 8 0
° right-sided 
tumors 5 9 10 0 2 7 9 0 0 8
mean incidental 
dose (in%) 18.7 46.6 63.4 60.5 87.2 78.6 88 58.5 30.2 28.2
° left-sided 
tumors 11.2 38.8 59.6 60.5 86 94.5 81.9 58.5 30.2 0
° right-sided 
tumors 27.8 43.1 66.5 0 89.5 74.1 90 0 0 28.2
mean incidental 
dose out-of-
field recurrence 
(in%)
10.5 92.8
Conclusion: Our survival data for LD-SCLC patients compare favor-
ably to reported literature results. Although a retrospective analysis 
of a small series, it suggests that the omission of elective nodal ir-
radiation in PET-CT-planned LD-SCLC patients does not result in an 
unacceptable local failure rate. Higher doses may however be needed 
to improve local control. Larger prospective studies on this subject 
are warranted.
P3.224 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Dose intensification with intensity modulated radiotherapy 
in locally advanced non-small cell lung cancer: where is 
the bottleneck?
Nulens, An 1; Mousa, Amr G.3; Defraene, Gilles1; Stroobants, Sigrid5; 
De Wever, Walter4, 2; Van den Heuvel, Frank1; Lievens, Yolande N.1
1 Radiation Oncology Department, UZ Leuven, Leuven, Belgium; 2 
Leuven Lung Cancer Group, Leuven, Belgium; 3 Radiation Oncology 
Department, National Cancer Institute, Cairo, Egypt; 4 Radiology 
Department, UZ Leuven, Leuven, Belgium; 5 Nuclear Medicine 
Department, UZA, Antwerp, Belgium
Background: The potential of dose escalation with intensity modu-
lated radiotherapy (IMRT) compared to 3D-conformal radiotherapy 
(3D-CRT) in locally-advanced non-small cell lung cancer (LA-
NSCLC) patients is analyzed as well as the associated normal-tissue 
complication probability (NTCP) for lung and esophagus.
Materials and Methods: CT scans of 35 LA-NSCLC patients with 
pathology-proven mediastinal involvement were retrospectively 
retrieved from the Leuven Lung Cancer Group database. Involved 
nodes were re-defined on CT and PET scan using visual correlation, 
target definition was restricted to PET-positive regions only. 
The 3D-CRT plans used at least 3 coplanar static 10MV beams. The 
IMRT plans consisted of 6 coplanar 10MV beams, delivered using a 
sliding window technique.
The baseline prescribed dose (PD) was 66Gy/2Gy for the 3D-CRT 
plans, except in case of endpoint (EP) violation. The baseline IMRT 
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plan was defined as the plan delivering the same mean lung dose 
(MLD) as the baseline 3D-CRT plan. 
The primary EP was planning target volume (PTV) cover-
age (V95%>95%). Secondary EP were dose to the spinal 
cord (Dmax<50Gy), lung (MLD<19Gy; V20<37%) and heart 
(V40<100%; V50<67%; V60<33%). Esophagus tolerance was 
defined as Dmax<66Gy and D2cm³≤60Gy, but not considered as 
secondary EP.
Baseline plans were escalated to reach maximal PD based on second-
ary EP constraints and de-escalated to remain within esophageal 
tolerance.
All plans were calculated using Eclipse (Varian) software with a pen-
cil beam (PB) algorithm. Afterwards, IMRT plans were recalculated 
using a collapsed cone algorithm (AAA).
NTCPs were calculated for lung (grade 2 pneumonitits, Seppen-
woolde et al.) using the relative seriality model and for esophagus 
(late toxicity, Chapet et al.) using the Lyman-Kutcher-Burman model. 
Results: The table shows the mean values for PD, MLD, Dmax 
esophagus and correlating NTCP’s for the 3 dose-levels and the 3 
different calculation approaches. p-values for IMRT-PB versus 3D-
CRT and for IMRT-AAA versus IMRT-PB are shown in the rows in 
between the mean values. 
  PD MLD NTCP lung Dmax NTCP 
     esophagus esophagus
 Baseline     
  3D-CRT 64.3Gy 13.7Gy 4.7% 63.7Gy 0.44%
  p-value 3D-CRT vs. IMRT-PB <0.0001  <0.0001  <0.0001
  IMRT-PB 72.9Gy 13.6Gy 3.6% 72.5Gy 4.00%
  p-value IMRT-PB vs. IMRT-AAA   <0.0001  <0.0001
  IMRT-AAA 72.9Gy 13.6Gy 3.3% 72.2Gy 2.99%
 Escalated     
  3D-CRT 80.7Gy 16.4Gy 6.9% 79.1Gy 14.9%
  p-value 3D-CRT vs. IMRT-PB <0.0001  <0.0001  <0.0001
  IMRT-PB 94.9Gy 16.6Gy 5.5% 93.1Gy 30.9%
  p-value IMRT-PB vs. IMRT-AAA   <0.0001  <0.0001
  IMRT-AAA 94.9Gy 16.2Gy 5.1% 89.8Gy 23.0%
 De-escalated     
  3D-CRT 62.3Gy 13.2Gy 4.3% 60.9Gy 0.06%
  p-value 3D-CRT vs. IMRT-PB 0.16  <0.0001  0.53
  IMRT-PB 63.8Gy 11.8Gy 2.4% 61.9Gy 0.07%
  p-value IMRT-PB vs. IMRT-AAA   <0.0001  0.008
  IMRT-AAA 63.8Gy 11.9Gy 2.1% 61.8Gy 0.05%
Conclusion: In this group of LA-NSCLC patients, IMRT offers the 
potential to significantly escalate the dose based on lung tolerance. 
However, in parallel with the higher target doses, a drastic increase 
in esophageal late complication probability is observed, even when 
using a more accurate dose calculation algorithm (AAA). It therefore 
seems that sparing the esophagus remains a real challenge in this 
patient population. These findings are important to consider in the 
context of concomitant chemo-radiotherapy. 
P3.225 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Outcomes of Continous Hyperfractionated Accelerated 
Radiotherapy (CHART) for Non-Small Cell Lung Cancer 
(NSCLC) in routine practice
Williams, Matt; Khan, Atia; Lyn, B E.; Dickson, Jeanette; Mawdsley, 
Suzannah; Williams, Joy
Mount Vernon Cancer Centre, Northwood, UK
Background: Only a minority of patients with non-small cell lung 
cancer are suitable for radical surgery. Some with locally advanced 
disease may be suitable for radical radiotherapy. A phase III trial 
showed improvement in 2 year survival in those treated with CHART 
(54Gy in 36 fractions treating 3 times per day) compared with 
conventional daily radiotherapy (60Gy in 30 daily fractions); 29% 
vs 20%. Since the trial, there has been one review of outcomes for 
CHART used in the non-trial setting between 1998 – 2003 from 5 UK 
centres (this centre was not one) and two year survival was 34%.
Methods: Patients with inoperable NSCLC who received primary 
treatment with CHART between the 1st September 2005 and the 31st 
August 2005 were analysed. All had a histological or cytological 
diagnosis and had PET/CT scans in addition to other staging investi-
gations. Date of last follow-up or death were extracted from hospital 
notes or obtained from the Office of National Statistics. All follow up 
was censored on the 31st December 2008, 2 months before analysis, 
to allow notifications of deaths to be recorded. Survival was calculat-
ed from the date of treatment, and estimated using the Kaplan-Meier 
method. Differences in survival between groups were tested using the 
log-rank test, and differences in patient characteristics using the t-test 
and chi-squared in SPSS.
Results Eighty three patients were identified, of whom 57 (69%) 
were male. Median age was 66.8 years (range 41 - 84). Twenty seven 
(32%) had stage 1 or 2 disease, inoperable due to co-morbidity, and 
were older than those with Stage III disease (p <0.004). All patients 
received the prescribed dose.
Median follow-up was 20.8 months, and estimated median survival 
was 16.9 months (95% CI: 12.3 – 34.4). Estimated overall survival 
at 2 years was 40% (see figure). Median survival by stage was I or II: 
28.5, IIIa: 22.5, IIIb: 11.3 months (p = 0.06).
Discussion: Although patient numbers are small and follow-up rela-
tively short, median and 2 year survival are comparable, if not better, 
than other reported results, and CHART in the non-trial setting would 
appear an effective treatment. 
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Long term results of concurrent accelerated 
hypofractionated radiotherapy and chemotherapy with 
cisplatinum ± vinorelbine in non-small cell lung cancer
Maguire, Joseph; Kelly, Veronica; Page, Richard; Ledson, Martin; 
Smyth, Colin; Walshaw, Martin
Liverpool Heart and Chest Hospital, Liverpool, UK
Background: Concurrent chemoradiotherapy is the most effect-
ive form of treatment for inoperable non-small cell lung cancer 
(NSCLC). Accelerated repopulation of tumour cells after 21-28 days 
of radiation and chemotherapy is recognised as an important possible 
cause of local treatment failure. Chemoradiation treatment schedules 
designed to minimise or avoid the effect of accelerated repopulation 
might improve local control rates and hence survival.
Methods: Between 1998-2005 we treated 88 patients with acceler-
ated hypofractionated radiotherapy to a dose of 52.5-55 Gy in 20 
fractions over four weeks concurrent with cisplatinum (51 Patients) 
or cisplatinum and vinorelbine (37 patients). 57 patients were male, 
31 female. Median age was 59 years (range 39-80). 73 patients 
had stage III disease, 13 had bulky stage IIB disease and 2 patients 
had metastatic disease at the time of starting treatment. 68 patients 
(77.2%) were PS 0-1, 17 patients PS 2 and 3 patients were PS 3. 59 
patients had 2-4 cycles of chemotherapy after completing concurrent 
treatment.
Results: The median survival of the whole group of patients is 22.1 
months. Survival at one, two, three, five and eight years is 75.6%, 
47.7%, 40.7%, 30.1% and 20.3% respectively. No treatment – related 
deaths were identified. Patients who received adjuvant chemotherapy 
after concurrent treatment did not live longer than patients who did 
not, although this was not a randomised comparison. Long term local 
control was observed in 66 patients (75%).
Conclusion: Accelerated hypofractionated radiotherapy to a dose of 
52.5-55 Gy in 20 fractions over four weeks concurrent with cisplat-
inum or cisplatinum/vinorelbine results in high levels of local tumour 
control and significant long term survival for patients with inoperable 
NSCLC. The high local control rates observed with this regimen 
provides evidence for the importance of accelerated repopulation in 
the treatment of NSCLC.
P3.227 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Postoperative radiotherapy for patients with completely 
resected pathological N2 non small cell lung cancer: a 
retrospective analysis
Mantovani, Cristina; Todisco, Liana; Giaj Levra, Niccolo; Filippi, 
Andrea; Guarneri, Alessia; Ciammella, Patrizia; Iftode, Cristina; 
Botticella, Angela; Ragona, Riccardo; Ricardi, Umberto
Ospedale San Giovanni Battista, Torino, Italy
Background and Purpose: The effectiveness of radiotherapy as 
adjuvant treatment for patients with lung cancer is controversial. 
Postoperative radiation therapy (PORT) meta-analysis reported an 
overall decrease in survival for patients treated with PORT despite 
improvement in local disease control. This detrimental effect was 
more marked for patients with pN0 or pN1 disease; otherwise in pa-
tients with stage III and pN2 survival was slightly better but the effect 
was not statistically significant. 
Purpose of the study is to evaluate retrospectively the role of the 
PORT in terms of local control and survival in patients with patho-
logical N2 disease. 
Materials and Methods: From January 2003 to December 2008, 66 
patients (male 42, female 14; median age 63 years) with pathological 
N2 non small cell lung cancer (NSCLC) underwent PORT in our 
Institution. Overall, 54 patients had a lobectomy, 12 a pneumonec-
tomy; the definitive histological analysis demonstrated 56 stage IIIA 
disease, 10 stage IIIB disease. Fourteen patients underwent preopera-
tive chemotherapy, 23 adjuvant chemotherapy. Mediastinal lymph 
node metastasis were classified into two categories: single station or 
multiple station metastasis when two or more lymph node stations 
were involved. The first group included 12 patients, the second one 
54 patients. 
All the patients received a three-dimensional conformal radiation 
therapy through linear accelerator with photon regimen of nominal 
energy 6-10 MV with median total dose of 50.4 Gy (1.8-2 Gy daily). 
The target volume included the bronchial stump, omolateral hilum 
and all pathological involved lymph node regions. The nodal site 
progression was defined as in-field or out of field.
Survival and time to recurrence were calculated using Kaplan-Meier 
method from the last day of radiotherapy to death or recurrence 
respectively. Multivariate analyses with the log-rank test was used 
to estimate the effect of prognostic factors (age, gender, stage, type 
of surgery, number of pathological involved lymph node stations, 
histological findings, chemotherapy, radiation dose). 
Results: Median follow up time was 26.8 months (range 3.5–62.8 
months). Local control was 80% at 12 months, 77.2% at 24 months, 
72% at 36 months. Pattern of failure was local in 3 patients (1 out of 
field and 2 in-field), distant in 25 patients, and 12 patients presented 
loco-regional and distant disease. Cancer specific survival at 12, 24, 
36 months was 80%, 62%, 48% respectively. Median survival time 
was 34 months and median disease-free survival was 16 months. 
On multivariate analysis the number of pathological involved 
lymph node stations was a prognostic factor for local tumor control 
(p=0.05), cancer specific survival (p=0.04), disease-free survival 
(p=0.04). There was a trend of significance for stage regarding cancer 
specific survival. 
Conclusion: Adjuvant radiotherapy obtained good results in term 
of local control and overall survival in patients with completely 
resected pN2 NSCLC. The number of mediastinal lymph nodes with 
metastasis represents a powerful prognostic factor in this subgroup of 
patients. 
P3.228 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Role of dose volume histogram in the evaluation of 
radiation-induced esophageal and lung toxicity in patients 
with locally advanced Non Small Cell Lung Cancer 
(NSCLC): a retrospective analysis
Mantovani, Cristina; Todisco, Liana; Giaj Levra, Niccolo; Filippi, 
Andrea; Guarneri, Alessia; Ciammella, Patrizia; Iftode, Cristina; 
Ragona, Riccardo; Botticella, Angela; Ricardi, Umberto
Ospedale San Giovanni Battista, Torino, Italy
Background and Purpose: Esophageal toxicity and radiation 
pneumonitis (RP) are the most common dose-limiting complication 
of thoracic radiotherapy, which can have a considerable impact on 
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patient morbidity (quality-of-life and respiratory function), tumor 
control and survival. The incidence of severe acute esophagitis in 
patients treated for lung cancer with standard (once daily) radia-
tion therapy alone is 1.3%, induction chemotherapy increase the 
risk of acute esophagitis, finally concurrently chemo-radiotherapy 
is associated with an increase of severe esophagitis of 14% to 49%. 
About lung irradiation clinically significant RP usually develops in 
13–37% of patients receiving radical dose for lung cancer. Since 
three dimensional conformal radiation therapy (3D-CRT) planning 
have been generated, it can provide both a graphical and mathemat-
ical representation of the cumulative organs dose–volume relation-
ship. Several Dose Volume Histogram (DVH) parameters have been 
developed in order to reduce the complex nature of the DVH into a 
single parameter that can then be used to prevent esophageal toxicity 
and RP risk.
Purpose of the study is to evaluate retrospectively some predictor fac-
tors of esophageal toxicity and radiation-induced lung injury.
Materials and Methods: From January 2003 to December 2007, 304 
patients (173 stage IIIA,131 Stage IIIB) underwent radical thoracic 
radiation therapy in our Institution and were rewied. The patients 
characteristics (age, gender, performance status, pretreatment weight 
loss, respiratory co-morbidity, previous surgery, chemotherapy, dis-
ease localization (lung and lymph nodal)) and treatment parameters 
(total dose, Mean Lung Dose (MLD), V20, V35, D15, D35) were 
studied in multivariate regression analyses. Acute esophageal and 
lung toxicities were evaluated with RTOG score, late lung toxicity 
was graded by LENT-SOMA score. Patients characteristics and 
volumetric/dosimetric parameters coded were correlated with acute 
esophageal toxicity and acute, late lung toxicity of Grade ≥ 2 using 
multivariate regression analyses. 
Results: 54/304 enrolled patients developed an acute esophagitis 
Grade 2, no one had a toxicity >Grade 2. 57/304 had a late lung tox-
icity (31 patients Grade 2, 19 patients Grade 3, 7 patients Grade 4).
In multivariate analysis D15 evidence a statistical significant as prog-
nostic factor (p-value 0.034, Odds Ratio 1.04, C.I 1.003 – 1.091) for 
acute esophageal toxicity. V20 was the only prognostic factor with 
a trend of statical significant for lung toxicity (p-value 0.062, Odds 
Ratio 1.04, C.I 0.998 – 1.085)
Conclusion: The D15 is a useful parameter easily obtained from 
most 3D treatment planning systems. The D15 may be useful in 
comparing competing treatment plans to evaluate the risk of acute 
esophagitis for our individual patient treatments. We confirm the 
importance of V20 as predictor factor of lung toxicity. 
P3.229 Radiotherapy, Mon Aug 3 – Tue Aug 4 
The ExacTrac Snap Verification contribution during the 
intra-fraction verification of the lung tumors treated by 
SBRT: a new tool for ensuring the quality control for 
SBRT
Mornex, Francoise; Udrescu, Corina; Sotton, Marie-Pierre; De Bari, 
Berardino; Michel-Amadry, Geraldine; Chapet, Olivier
Centre Hospitalier Lyon Sud - Radiotherapy-Oncology Dpt, Lyon 
Pierre Benite, France
Background: The intra-fraction patient imaging and verification pro-
vided by ExacTrac® Snap Verification (SV) allows tracking possible 
target motion throughout treatment and realigning targeting during 
the treatment fraction if intra-fraction tumor displacement is detected. 
The purpose of this study was (1) to measure the deviations between 
the patient isocenter and the accelerator isocenter, (2) to correct these 
potential deviations, (3) to study the evolution of these deviations 
function of the fraction duration and (4) to evaluate the eventual 
impact of the table movement on the patient positioning, using 
ExacTrac® Snap Verification.
Methods: ExacTrac® Snap Verification uses X-ray real-time im-
ages acquired at any moment during treatment delivery or between 
fields to instantly detect and visualize internal tumor displacement. 
The ExacTrac® design allows SV images to be taken whether the 
treatment beam is on or off and for any gantry and couch position. 
The corrections can be made using the fusion of the bony structures, 
or the implanted markers, between the DRRs and the radiographic 
images. A tolerance margin indicates if the patient setup correction is 
needed or not. The tolerance is a virtual area (a circle), where the ac-
celerator isocenter and the patient isocenter should gather (or, if using 
the implanted markers, these should be in the tolerance circle).
We already evaluated 5 patients (number of beams between 4 and 
14, with a mean of 7.8) that were treated with the ExacTrac® X-ray 
6D, for inoperable or relapsing T1-T2 lung (NSCLC) lesions, using 
SBRT (Stereotactic Body Radiation Therapy). The patients had a SV 
at each fraction, before each treatment beam. We also measured the 
time from the moment the patients were installed on the table, until 
the end of the last beam. 
Results: The observed deviations were between 1 and 8 mm per 
beam, with a mean deviation of all the beams and all the fractions 
of 2.37 mm. The total mean time of one fraction was 22 minutes 
(between 9- 36 minutes). At the end of one fraction, the reasons for 
the deviations were analyzed. In a few situations, the patients ex-
perienced arm or chest pain, caught or talked, which may explain the 
observed deviations. Another reason for the major deviations was the 
sudden movement of the couch, or the long duration of the treatment. 
At the time of the meeting results for 25 patients will be available. 
Conclusions: Snap Verification makes possible and highly suitable 
the intra-fraction verification for the SBRT, including the patient 
condition (cough, pain, fatigue…) but also the detection of mechan-
ical inaccuracies from couch rotation. With high-quality images at 
low X-ray doses, this method gives an accurate targeting from the 
beginning to the end of each fraction, inducing confidence to escalate 
the dose and reduce the safety margins. Snap Verification appears to 
be an important tool for ensuring the quality control for SBRT.
P3.230 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Quality of life in patients receiving optimal supportive care 
(including dexamethasone) plus whole brain radiotherapy 
in the treatment of inoperable brain metastases from non-
small cell lung cancer: the MRC Quartz randomised trial
Mulvenna, Paula2; Barton, Rachel3; Wilson, Paula4; Faivre-Finn, 
Corinne5; Courtney, Cheryl1; Pugh, Cheryl1; Stephens, Richard1; 
Nankivell, Matthew G.1
1 Medical Research Council, London, UK; 2 Newcastle General 
Hospital, Newcastle, UK; 3 Castle Hill Hospital, Hull, UK; 4 
University Hospital Bristol, Bristol, UK; 5 The Christie Hospital, 
Manchester, UK
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Background: Up to one third of patients with non-small cell lung 
cancer (NSCLC) will present with or develop brain metastases. Such 
patients have a poor prognosis, and a tendency to experience rapid 
deterioration in both neurological function and performance status 
with survival generally measured in weeks rather than months.
Historically, standard treatment for patients with NSCLC and inoper-
able brain metastases has been steroids plus whole brain radiotherapy 
(WBRT) for but there are no randomised trials to show that WBRT 
can improve quality or length of life in this setting. In the absence 
of randomised data, justification for the use of WBRT is based on 
non-randomised populations selected to receive WBRT or no radio-
therapy. It remains unclear whether any potential benefits of WBRT 
outweigh the known toxicity.
Methods: The QUARTZ trial has been designed to address whether 
WBRT should remain a standard therapy for patients with inoperable 
brain metastases from NSCLC. Patients are randomised between a 
standard arm which comprises dexamethasone, optimal supportive 
care and WBRT and an experimental arm comprising dexametha-
sone and optimal supportive care alone. In each arm, the dose of 
dexamethasone is titrated to the lowest effective dose. The primary 
endpoint of quality of life years (QALYs) reflects the fact that both 
quality and duration of survival are important.
The trial has been designed pragmatically. All patients with inoper-
able brain metastases from NSCLC are eligible whether presenting 
with, or subsequently developing brain metastases. Inclusion is based 
on the clinician and patient being uncertain of the value of WBRT 
and we have demonstrated that patients are willing to be randomised.
Results: Data on symptoms, side effects and quality of life are col-
lected via weekly telephone calls from a nurse who may be a research 
nurse or a clinical nurse specialist. This method has proved feasible 
and effective with 96% overall data compliance to date.
QUARTZ is open to recruitment at 72 centres in the UK and Aus-
tralia with 72 patients randomised so far.
Conclusion: We have shown that patients are willing to be random-
ised into this trial, and that data collection via weekly phone calls is 
feasible, and we are now looking to recruit more centres worldwide 
in order to increase accrual.
P3.231 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Proton therapy for non-small cell lung cancer
Nichols, Romaine C.; Hoppe, Bradford H.; Henderson, Randal H.; 
Huh, Soon; Flampouri, Stella; Li, Zuofeng; Mendenhall, Nancy P.
University of Florida Proton Therapy Institute, Jacksonville, FL, 
USA
Introduction: A preliminary review of the University of Florida 
Proton Therapy Institute (UFPTI) experience in the treatment of non-
small cell lung cancer (NSCLC).
Methods and Materials: From March, 2008 to December, 2008, 11 
adult patients with NSCLC were treated with protons at the UFPTI. 
Median follow up is 5 months and minimum follow up is 2 months 
post completion. 8 patients were treated with protons alone and 3 
were treated with a combination of protons and x-rays. 7 patients re-
ceived weekly chemotherapy (Paclitaxel 50mg/m2, Carboplatin AUC 
2) concomitantly with radiotherapy. 4 were treated with radiotherapy 
alone. 6 patients were treated for newly diagnosed stage III NSCLC; 
2 were treated for T1N0 NSCLC; 2 were treated for mediastinal/hilar 
recurrence of NSCLC after surgery; and 1 was treated for bilateral 
synchronous T2N0 NSCLC. 
Results: Grade 3 toxicities were limited to one episode of transi-
ent acute pneumonitis which responded to a short course of steroids 
and one episode of grade 3 fatigue by NCI criteria. Doses, treatment 
volumes, toxicities and preliminary outcomes are summarized in 
Table #1.
Conclusion: Based on our favorable initial experience, we have 
opened 2 prospective phase II protocols for patients with NSCLC. 
LU02, for patients with Stage III disease, offers dose escalation to 
80 Cobalt Gray Equivalent (CGE) to gross disease with elective 
nodal irradiation to 40CGE and concomitant chemotherapy. LU03, 
for patients with T1N0 and T2N0 disease, offers stereotactic proton 
doses of 48CGE in 4 fractions for peripheral tumors and 60CGE in 
10 fractions for central tumors.
Patient Diagno-
sis
Proton 
Dose
X-Ray 
Dose
Chemo Toxicity Outcome
#1 Bilateral 
T2N0 
75.6CGE yes Grade 2 skin No progression
#2 T2N2 25.2CGE 50.40Gy 
to nodes
yes Grade 1 
esophagitis, 
Grade 2 skin
No progression
#3 T4N2 72CGE 
(44CGE to 
nodes)
yes Grade 3 
fatigue (NCI), 
Grade 2 skin
died of inter-
current disease 
without local 
progression
#4 T1N2 80CGE 
(40CGE to 
nodes)
yes Grade 3 lung, 
Grade 1 
esophagitis
No progression
#5 T1N0 78CGE no Grade 1 skin No progression
#6 T4N2 25.2CGE 50.4Gy to 
nodes
yes Grade 2 
esophagitis, 
Grade 2 skin
died of meta-
static disease 
without local 
progression
#7 Recurrent 
TxN1
76CGE 
(40CGE to 
nodes)
no Grade 1 skin No progression
#8 T1N0 50CGE no none No progression
#9 T3N2 62CGE yes Grade 2 
esophagitis
No progression
#10 T2N1 74CGE no none No progression
#11 Recurrent 
TXN2
23.4CGE 45Gy to 
nodes
yes none Malignant 
pleural effusion
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Particle radiotherapy for patients with T3T4 lung cancer 
- in the Hyogo Ion Beam Medical Center (HIBMC) 
experience
Niwa, Yasue; Murakami, Masao; Arimura, Takeshi; Terashima, 
Kazuki; Miyawaki, Daisuke; Demizu, Yusuke; Hishikawa, Yoshio
Department of Radiology,Hyogo Ion Beam Medical Center, Hyogo, 
Japan
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Background: Particle radiotherapy including proton (PRT) and 
carbon-ion radiotherapy (CRT) is sophisticated treatment modality 
for patients with early stage cancer. Efficacy of particle radiotherapy 
for locally advanced lung cancer is unknown. The purpose of this 
study is to examine clinical results of T3T4 non-small cell lung can-
cer treated with PRT or CRT.
Materials and Methods: From Nov 2004 to Sep 2007, 17 patients 
aged 46-89 (median 72) with histologically-proven cT3-4 lung cancer 
(1997 UICC TNM) received PRT in 17 or CRT in 2 at the HIBMC. 
Thirteen was male and four was female. Eight patients was classi-
fied as clinical stage of IIIA and nine as stage IIIB. Six patients had 
adenocarcinoma, 7 squamous cell carcinoma, 3 large cell carcin-
oma and 1 sarcoma. Initial WHO performance status was good 
(PS0/1/2/=2/12/3). Overall and progression-free survivals, and local 
control were evaluated using the Kaplan-Meier method. Acute and 
late morbidities were assessed based on the Common Terminology 
Criteria for Adverse Events (CTCAE) v3.0. The median follow-up 
was 12 months. Prescribed dose was 52.8-80GyE/4-40Fr (median 
80GyE/20Fr). No patient received concurrent chemotherapy. 
Results: The 1-year overall survival, progression-free survival, 
and local control rates were 100%, 62%, 94%, respectively. Three 
patients experienced local recurrence. Seven patients experienced 
distant metastases (bone, lung, etc.). Interruption of the treatment due 
to Grade 3 acute reactions was observed in 1 patients (pleural effu-
sion); however, no patients experienced severe (Grade 3 or more) late 
adverse effects.
Conclusions: Proton or Carbon-ion radiotherapy showed excellent 
local control rates without combined chemotherapy. We suggest that 
concurrent chemotherapy may be not indispensable in the treatment 
of particle radiotherapy.
P3.233 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Evaluation of dose-volume histograms and related 
pulmonary side effects in lung cancer patients treated with 
3-D conformal radiotherapy
Kamer, Serra; Cok, Gursel; Yalman, Deniz; Sengul, Adem; Eren, 
Hakan; Olacak, Nezahat; Ozkok, Serdar
Ege University Faculty of Medicine Dept. of Pulmonology, Izmir, 
Turkey
Purpose: To determine the treatment related early and late side 
effects, changes in pulmonary function, and related factors in lung 
cancer patients treated with 3-D conformal radiotherapy.
Materials and Methods: Seventeen patients with lung cancer, who 
completed radical radiotherapy at least 6 months before, without any 
local or regional recurrence were evaluated. Pre and post-treatment 
respiratory function tests (FVC, FEV1, FEV1/FVC), pre and post-
treatment radiological findings, and the complaints of the patients 
during or after treatment were evaluated. Mean lung dose (MLD), the 
volume of lung that received 20 Gy (V20), the volume of lung that 
received 10 Gy (V10), the volume of lung which did not receive 5 
Gy (SV5Gy) were determined as dosimetric parameters influencing 
pulmonary toxicity. Spearman’s and Pearson’s correlation tests were 
used for statistical analysis.
Results: Median age of the patients was 65 (range: 48-78). Fifteen 
patients received concomitant radiochemotherapy. Total radiotherapy 
dose was 66-74 Gy, with 2 Gy-daily fractions. Mean values for MLD, 
V20, V10, and SV5Gy were 17 Gy (range: 8- 20 Gy), 25% (range: 
9%-33%), 28% (range: 9%-37%), 67% (range: 54%-88%) respect-
ively. Mean pre-radiotherapy FVC was 96% (range: 73%-112%), 
while it was 77% (range: 55%-97%) during the sixth month. Mean 
pre-radiotherapy, and post-radiotherapy FEV1 values were 85% 
(range: 59%-112%), and 66% (range: 48%-84%) respectively. There 
was a significant difference among the pre and post-radiotherapy 
respiratory function tests (p<0.01). Grade 2 or 3 pulmonary event 
was recorded in 7 patients either during or after treatment. Although 
there was a significant correlation between the decrease in FVC, and 
FEV1, SV5Gy, and pulmonary events, no significant correlation was 
detected with other dosimetric parameters (V20, V10, MLD).
Conclusion: There is a need for new dose-volume constraints for the 
prediction of treatment related complications in 3-D conformal radio-
therapy planning for lung cancer. Respiratory function tests should 
be done before treatment in order to establish subclinical pulmonary 
toxicity, and suspected patients should be followed and treated during 
the early period. 
P3.234 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Hyperfractionated accelerated radiotherapy with doze 
escalation in non-small cell lung cancer
Zolotkov, Alexey G.; Mardynsky, Yury S.; Ragulin, Yury A.; 
Medvedev, Victor N.
Medical Radiological Research Center RAMS, Obninsk, Kaluga 
region, Russia
Background: Results of the treatment of inoperable non-small cell 
lung cancer are unsatisfactory. The aim of study is to compare of ef-
ficiency nonconventional (hyperfractionated accelerated radiotherapy 
with doze escalation) with traditional (conventional) radiotherapy. 
Materials and Methods: Between 1995 and 2003 two groups of 
patients (87 person in everyone) with non-small-cell lung cancer 
stage I-IIIB received radiotherapy. Patients with resectable stage 
I or II NSCLC are high-risk operative candidates because of poor 
cardiopulmonary function or other medical problems. Patient demo-
graphics, tumor characteristics, treatment details, and survival were 
recorded retrospectively. All patients earlier did not spend any special 
anticancer treatment. Group A (hyperfractionated, accelerated radio-
therapy with doze escalation): patients received two daily fractions of 
1.3 Gy with an interval 5-6 hours during 3 weeks, further two daily 
fractions of 1.6 Gy to a total dose of 68-72 Gy. Group B (conven-
tional radiotherapy): 2 Gy daily to a total dose of 64-72 Gy. Radio-
therapy was carried on the linear accelerator Clinac 2100C. Patients 
with stage III prevail in both groups: Group A – 44 (50.6%); Group 
B – 38 (43.7%), stage I were at 22 (25.3%) in each group, stage II at 
21 (24.1%) and 27 (31%), respectively. 
Results: Complete response was observed in 18 (24%) patients 
Group A and in 8 (9%) patients Group B. Five-year overall survival 
was 19% and 8%, respectively. In both groups five years’ term was 
gone through only by those patients at who had complete regress of 
a tumor. Toxicity: acute radiation pneumonitis end esophagitis ob-
served in 39 (45%), 48 (50%) patients Group A and in 26 (30%), 24 
(28%) patients Group B respectively. Tardive toxicity: post-radiation 
esophagitis, post-radiation pneumofibrosis, pericarditis expanded 
in 18 (21%), 22 (25%), 2 (2,4%) patients Group A and in 6 (7%), 
8 (9%), 1 (1,2%) patients Group B. Duration of hyperfractionated, 
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accelerated radiotherapy with doze escalation course was 47 days and 
duration of traditional course was 32 days.
Conclusions: Hyperfractionated, accelerated radiotherapy with doze 
escalation is more effective then traditional radiotherapy in non-small 
cell lung cancer with low levels of toxicity. Improvement of thera-
peutic results will be achieved by combination hyperfractionated, 
accelerated radiotherapy with doze escalation with new chemother-
apy regimens.
P3.235 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Continuous hyperfractionated accelerated radiotherapy in 
non-small cell lung cancer
Ivanova, Irina N.; Gulidov, Igor A.; Kudrjavtsev, Dmitry V.; 
Zolotkov, Alexey G.; Kursova, Larisa V.; Ragulin, Yury A.
Medical Radiological Research Center RAMS, Obninsk, Kaluga 
region, Russia
Background: The aim of study is to compare efficiency of a radical 
course of remote radiotherapy in the mode hyperfractionated acceler-
ated radiotherapy (HART) to a traditional (conventional radiotherapy) 
mode (CR) at patients with inoperable non-small cell lung cancer 
(NSCLC). 
Materials and methods: Results of radiotherapy 174 patients with 
inoperable non-small cell lung cancer have been studied from 2000 
to 2005. A radical course of radiotherapy by a method HART with 
non-uniform crushing of a day dose (two daily fractions 1+1.5 Gy) 
to a total dose 60 -70 Gy have received 96 patients and a traditional 
course CR, the daily dose 2 Gy to a total dose 60 – 70 Gy have 
received 78 patients with NSCLC. About 20 % of patients from them 
had II stage of disease and 80 % - IIIA and IIIB stage. The most of 
patients have received chemotherapy in EP regimen. 
Results: Three - and the five years’ survival rate were accordingly 
in patients treated by a method HART 19 % and 10 %, and in group 
CR – 12.5 % and 5 %, respectively. The given distinctions are 
statistically significant (р=0.31 Log-rank test). The relative risk (RR) 
in two groups was 0.68 at 95 % a confidential interval 0.65 – 1.32. 
Radiotherapy in both groups has been well transferred. Acute radia-
tion reactions (on scale LENT SOMA RTOG/EORTC) have been 
presented by pneumonitis and esophagitis in the moderate severity 
level, not leading to the compelled breaks in treatment. Radiation-
induced esophagitis II degrees are noted at 83.1% in patients treated 
by a method HART and 67.5 % of patients treated with a traditional 
method. Esophagitis III degrees (5.1 %) has been revealed only in 
patients treated by a method HART. It is necessary to notice that in 
both groups acute reactions was not at the bottom of not planned 
break in radiotherapy. 
Conclusion: A radical course of hyperfractionated accelerated 
radiotherapy with non-uniform crushing of a day dose 1+1.5 Gy to a 
total dose 60 -70 Gy improves the results of treatment patients with 
NSCLC in comparison with a traditional Method: three- and the five 
years’ survival rate has made 19 % and 10 %, against 12.5 % and 5 
%, respectively. The mode of crushing of a day dose is well trans-
ferred by patients and reduces time to stay of the patient in a hospital. 
Preliminary results are comparable with the data represented in the 
literature.
P3.236 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Predictive role of 18F-FDG-PET/CT 1 month before and 
after hypofractionated stereotactic body radiation therapy 
for stage I non-small cell lung cancer
Song, Si Yeol1; Ryu, Jin Sook2; Yoon, Sang Min1; Lee, Sang-wook1; 
Ahn, Seung Do1; Kim, Jong Hoon1; Lee, Jung Shin3; Choi, Eun 
Kyung1
1 Dept. of Radiation Oncology, Asan Medical Center, Seoul, Korea; 
2 Nuclear Medicine, Asan Medical Center, Seoul, Korea; 3 Medical 
Oncology, Asan Medical Center, Seoul, Korea
Purpose: To know the predictive role of 18F-FDG-PET/CT 1month 
before and after stereotactic body radiation therapy (SBRT) to stage I 
non-small cell lung cancer (NSCLC)
Methods and Materials: Between 2004 and 2007, 20 patients 
received SBRT with 48 Gy for 4 consecutive days and checked two 
times of FDG-PET/CT and chest CT with contrast-enhancement at 1 
month before and after SBRT. Change of maximal SUV (SUVmax) 
on FDG-PET/CT and the longest tumor diameter on chest CT before 
and after SBRT was measured. Patients only with high FDG uptake, 
SUVmax 3.0 or above, on FDG-PET/CT before SBRT and tumor 
diameter below 5 cm were analyzed in this study. Change of tumor 
diameter was classified to PR (partial response), SD (stable disease), 
and DP (disease progression) as RECIST criteria and change of SU-
Vmax was described as % change. Chest CT was checked at every 3 
or 6 months during follow-up.
Results: Mean time intervals from SBRT to FDG-PET/CT and chest 
CT were 32 and 30 days respectively. Mean longest tumor diameter 
was changed from 2.59 cm (1.36-3.93) to 2.17 cm (1.18-3.41), and 
its reduction rate was -16.2%. By RECIST criteria, 4 patients showed 
PR, 15 patients showed SD, and other 1 patient showed DP. Mean 
decrease rate of SUVmax on 18F-FDG-PET/CT was -52.1% and its 
mean value was changed from 7.1 (3.2-13.1) to 3.4 (0.3-9.8). Median 
follow-up time was 16 months. Local tumor progression developed in 
2 (10%) patients and time to progression was 3.4, 6.1 months. Tumor 
responses on post-SBRT chest CT were PR in 1 and SD in the other 1 
patient, and SUVmax changes were -31.9%, -25.5% in each. Most of 
patients showing no response, SD or DP, didn’t recur after SBRT, and 
so chest CT at 1 month could not predict actuarial tumor response. 
On the contrary to chest CT, no patients showing SUVmax decreases 
over 40% experienced tumor progression after SBRT. High decrease 
rate of SUVmax over 40% decrease on FDG-PET/CT 1 month after 
SBRT could warrant good actuarial local tumor control earlier.
Conclusion: Change of SUVmax on FDG-PET/CT 1 month before 
and after SBRT could predict actuarial local tumor control of stage 
I NSCLC earlier and 1 month after SBRT was adequate time for the 
earlier evaluation of tumor response
P3.237 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Radiation therapy for primary tracheal adenoid cystic 
carcinoma
Song, Si Yeol1; Je, Hyoung Uk1; Park, Seung-Il3; Kim, Dong Kwan3; 
Kim, Yong hui3; Kim, Woo-sung4; Lee, Sang-wook1; Ahn, Seung 
Do1; Kim, Jong Hoon1; Lee, Jung Shin1; Choi, Eun Kyung1
1 Dept. of Radiation Oncology, Asan Medical Center, Seoul, Korea; 
2 Thoracic Surgery, Seoul, Korea; 3 Thoracic Surgery, Asan Medical 
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Center, Seoul, Korea; 4 Pulmonology, Asan Medical Center, Seoul, 
Korea
Purpose: To know the outcome of radiation therapy (RT) for primary 
tracheal adenoid cystic carcinoma (ACC).
Patients and Methods: Retrospective chart review was performed 
for all patients found to have a pathologic diagnosis of primary 
tracheal ACC and received RT. Since November 1994, 21 patients 
received postoperative or definitive RT for primary tracheal ACC.
Results: Median age was 44 years and 13 (61.9%) patients were 
female. Sixteen (76.2%) patients suffered from dyspnea, and other 
main presenting symptom was cough in 3 (14.3%) and hoarseness 
in 1 (4.8%). Tumor was located at upper trachea in 7 (33.3%), lower 
trachea in 7 (33.3%), and carina with main bronchus involvement 
in 7 (33.3%). Thirteen (61.9%) received surgery and adjuvant RT, 
7 (33.3%) received RT alone, and 1 (4.8%) patient received defin-
itive concurrent chemoradiation therapy (CCRT). Median RT dose 
was 59.4Gy for adjuvant RT and 74.4Gy for definitive RT. RT field 
encompassed tumor and regional lymph node area in 20 (95.2%) 
except 1 (4.8%) patient. Fifteen (71.4%) patients received external 
beam radiation therapy (EBRT) alone, and 6 (28.6%) received EBRT 
with intraluminal brachytherapy. During follow-up period 3 patients 
had local recurrence and 13 patients had distant metastasis. Major site 
of distant failure was lung parenchyma in 12 patients. 5-year local 
tumor control rate was 89.9% and 5-year disease free survival rate 
was 51.6%. And 5-year overall survival (5y-OS) rate was 89.4% for 
all patients. Patients who received surgery and postoperative RT had 
better 5y-OS than who received RT alone (100% vs. 75%, respective-
ly), but the difference was not statistically significant (p=0.058). Most 
patients experienced tolerable respiratory or esophageal discomfort 
during or after radiation therapy.
Conclusions: Surgery with postoperative radiation therapy in 
primary tracheal adenoid cystic carcinoma showed good local tumor 
control and survival rate. Definitive radiation therapy alone in 
patients who was ineligible to surgery showed also good treatment 
results. Major pattern of failure was lung metastasis, but long-term 
survival was observed despite multiple lung metastasis.
P3.238 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Salvage Extracranial Stereotactic Radiotherapy for 
Locally Relapsed, Previously Radically Irradiated Non-
Small Cell Lung Cancer
Talbot, Toby L.1; Wurm, Reinhard2; Dubey, Sidarth1; Plowman, 
Nick3; Yiannakis, Dennis1
1 Derriford Hospital, Plymouth, Devon, UK, Tavistock, UK; 
2 Charité-Universitätsmedizin Berlin, Berlin, Germany; 3 St 
Bartholomew’s Hospital, London, UK
Background: Radical chemo-radiotherapy is standard treatment in 
patients with locally advanced inoperable non small cell lung cancer. 
Local relapse remains a problem. In such patients treatment is often 
with palliative systemic therapy and best supportive care. We report 
two cases of patients with local in-field inoperable relapse after 
radical concurrent chemo-radiotherapy who were re-irradiated using 
extracranial stereotactic radiotherapy (SRT) as salvage treatment.
Methods and Results: Patient 1: A 58 year old otherwise fit female 
was diagnosed in October 2004 with T4 N2 (stage IIIb) NSCLC 
with a right upper lobe primary. She underwent thoracotomy but was 
found to be inoperable and the procedure was abandoned. She then 
went on to have induction chemotherapy using weekly carboplatin/
paclitaxel x12 to which she had a partial response and then went on 
to receive radical (CT planned 3-D) concurrent chemoradiotherapy 
with dose reduced carboplatin/paclitaxel to 60Gy/30# with a further 
response. She relapsed in the area of the primary tumour 9 months 
later with a tumour mass measuring 2.2x1.8cm. Staging investi-
gations including PET scan revealed no distant disease. She was 
referred for SRT in June 2006. Adapted real-time gated, image guided 
radiotherapy was employed to deliver 78Gy in12 fractions using 
6MV photons in 3 dynamic arcs and the target was encompassed by 
the 80% isodose. Treatment was well tolerated and she remains well 
and disease free to date. Consequences of SRT include fibrosis of the 
anterior chest wall and a benign pericardial effusion that has required 
drainage.
Patient 2: A 66 year old male was diagnosed in May 2006 with T4 
N0 left upper lobe squamous cell carcinoma with a left hilar mass 
encircling the aorta. His disease was inoperable. He received concur-
rent chemoradiotherapy using cisplatin/vinorelbine as induction 
for 2 cycles and CT planned 3-D radiotherapy concurrently with a 
further 2 (dose reduced) cycles to 60Gy in 30 fractions, completed in 
September 2006, with a good partial response. He progressed in May 
2007 in the primary site and remained inoperable due to proximity 
to the aorta. He was treated with cisplatin/docetaxel chemotherapy 
x6 with a good partial response. He progressed in November 2007 
and received pemetrexed chemotherapy to which he showed stable 
disease. He went on to receive erlotinib with marked skin toxicity. 
His disease remained localised and he was referred for SRT delivered 
in September 2008 using IGRT to deliver 60Gy in 24 fractions with 
2 fractions per day and an interfraction interval of >6hours, with the 
80% isodose covering the target defined on CT and PET scans. Treat-
ment was well tolerated and he remains well, asymptomatic with a 
partial response on CT 6 months post treatment.
Conclusions: Our small series shows that salvage potentially curative 
radiotherapy is possible in patients previously irradiated radically. 
Patients were highly selected. The current developments in SRT /
SRS as primary radical treatment for non- small cell lung cancer, will 
allow more experience and expertise to accumulate in the relapse 
salvage setting.
P3.239 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Outcomes following stereotactic radiosurgery for intra-
cranial NSCLC metastases at a single UK centre
Lewanski, Conrad R.; Thompson, Anna C.; Coles, Ian; Lovell, Doris; 
Glaser, Mark
Charing Cross Hospital, London, UK
Introduction: Stereotactic radiosurgery (SRS) is an accepted treat-
ment modality for small volume brain metastases with or without 
additional whole brain radiotherapy (WBRT). We report a series of 
18 patients with primary non-small cell lung cancer (NSCLC) with 
brain metastases treated with SRS at a single centre.
Methods: Data from all patients treated with intracranial SRS for 
metastatic NSCLC was collected retrospectively from patient charts 
and radiotherapy records. Data included patient demographics, age 
at time of SRS, number of lesions treated, the use of WBRT and the 
number of extra-cranial sites of disease at presentation. A Kaplan-
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Meier survival curve was used to calculate median survival from the 
date of brain metastasis diagnosis.
Results: Between Feb 2002 and Feb 2009, 18 patients (6 male, 12 
female) diagnosed with brain metastases secondary to NSCLC have 
been treated with intracranial SRS. Median and mean age at time of 
SRS was 58 years (range 34 – 82 years). Patients were staged using 
Magnetic Resonance (MRI) brain imaging. Nine patients were found 
to have brain metastases at time of presentation, the remainder de-
veloped brain metastases subsequent to initial diagnosis of NSCLC. 
The lesion size was recorded in 17 cases where the median diameter 
equaled 15mm (range 5-25mm). No patients had any other sites of 
extracranial metastatic disease. Four patients had 2 brain metastases 
treated simultaneously with SRS and the remainder had a solitary 
metastasis only. Three patients went on to receive further SRS for 
new brain metastases at a later date (3-12 months post initial SRS). 
Nine patients (50%) received additional whole brain radiotherapy 
(WBRT) either before or after SRS. The WBRT dose ranged form 20 
– 35Gy in 2-3Gy daily fractions. The SRS dose ranged from 12-20Gy 
delivered in a single fraction prescribed to the 80% isodose. Median 
follow up is 11.5 months (range 2-72 months). Median survival is 16 
months.
Conclusion: SRS is an effective treatment for brain metastasis in 
an appropriately selected group of patients. Our series shows a good 
median survival rate of 16 months which compares favourably with 
previously published data using SRS, although no large series solely 
assessing NSCLC solitary metastases has been published to date. We 
believe patient selection to include solitary metastases, small tumour 
size (≤ 25mm) and the absence of any other site of extracranial 
disease other than their primary tumour, to be paramount in achieving 
this outcome.
P3.240 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Use of quantitative SPECT imaging to assess changes in 
lung perfusion following radiation therapy of lung cancer
Thompson, Anna C.1; Yin, Lingshu1; Moiseenko, Vitali1; Fua, Tsein-
Fei1; Shcherbinin, Sergey2; Gill, Bradford1; Liu, Mitchell1; Celler, 
Anna2; Duzenli, Cheryl1; Worsley, Daniel2; Powe, John2; Finbar, 
Sheehan1
1 British Columbia Cancer Agency, Vancouver, BC, Canada; 2 
Vancouver General Hospital, Vancouver, BC, Canada
Background: Lung radiation therapy (RT) is associated with radia-
tion pneumonitis and fibrosis. Traditionally, lung volume is used as 
a surrogate of lung function in RT plan optimization. Quantitative 
single-photon emission tomography (qSPECT) is a novel functional 
imaging-based technique that provides the most accurate quantitative 
data on lung perfusion and therefore lung function. We used qSPECT 
to assess and compare lung function distribution pre-and post- lung 
RT.
Methods: Five lung cancer patients treated with RT (dose range: 
30-60Gy in 2-3Gy daily fractions) were SPECT-scanned prior to 
and approximately 3 months after RT. Patients were injected with 
intravenous 185 MBq of 99mTc-labelled macro-aggregated albumin 
immediately prior to SPECT scanning and scans were performed 
in the RT treatment position. Ipsilateral and contralateral lung was 
compartmentalized using a threshold of 30% maximum uptake in the 
pre-RT SPECT scan and a dose threshold of 10 Gy from RT.
Results: The most marked changes in tracer uptake were observed in 
the ipsilateral lung. Regions exhibiting <30% perfusion pre RT and 
receiving >10 Gy showed an 8 - 20% increase in uptake, indicative of 
re-perfusion as shown in patient#1.
Regions of ipsilateral lung receiving less than 10 Gy demonstrated a 
0 - 15% decrease in uptake, which may be due to tracer re-distribu-
tion rather than decreased perfusion. In the contralateral lung changes 
in uptake were small and any decrease in uptake was noted for doses 
>30 Gy only. 
Conclusions: Accurate tracer uptake data can be obtained using 
qSPECT. This data can be used to evaluate lung perfusion both 
pre- and post- lung RT. Observed increase in uptake demonstrates 
re-perfusion following RT. Decrease in uptake was minimal in both 
ipsilateral and contralateral lung except for doses in excess of 30 Gy.
P3.241 Radiotherapy, Mon Aug 3 – Tue Aug 4 
A c-Met receptor tyrosine kinase inhibitor offers increased 
radiosensitization in NSCLC after pretreatment with 
Erlotinib
Welsh, James1; Ellsworth, Ron2; Mahadevan, Daruka2; Bearss, 
David3; Komaki, Ritsuko1; Stea, Baldassarre 2
1 U.T. MD Anderson, Houston, TX, USA; 2 University of Arizona 
Health Sciences Ctr., Tucson, AZ, USA; 3 SuperGen, Inc., Dublin, CA, 
USA
Background: Non Small Cell Lung Cancer (NSCLC) continues to 
be a challenging malignancy to treat. Targeted therapies to EGFR 
have been used to treat NSCLC for several years now and while 
some patients develop impressive response, durable responses remain 
elusive and resistant pathways rapidly develop. Recently we have 
learned that anti-EGFR treated tumors overexpress various pathways 
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of resistance with c-Met upregulation being implicated. Furthermore 
c-Met is also overexpressed in lung tumors with Ras mutations and 
anti-c-Met therapies appear to be effective in selectively killing these 
cells (1). c-Met is a receptor tryosine kinase shown to confers protec-
tion from cytotoxic response triggered by DNA damage; consequent-
ly inhibiting c-Met may radiosensitize resistant tumor types such 
as NSCLC. Furthermore tumors having already been treated with 
anti-EGFR targeted therapies such as Erlotinib may have additional 
radiosensitization.
Methods: Human A549 NSCLC cells were used in colony assays 
to demonstrate inhibition of clonogenic potential. A549 cells were 
grown in 1um Erlotinib for 3 days before being used in colony assay 
as described above. These same Erlotinib pre-treated cell were col-
lecting and evaluated for c-Met levels with Western blots, using the 
c-Met antibody (Met (C-28):SC-161). Intrathoracic xenograft models 
were developed by injecting 6 x105 A549 cells into the left thoracic 
cavity of nude mice. Eight animals were in each arm consisting of:
Control
• 2) MP470 alone-starting on day 15 at 50mg/kg/d orally for a total 
of 12 days. 
• 3) XRT alone-starting on day 15 XRT was delivery every other 
day for a total of 5 fraction at 4Gy each to the entire left thoracic 
cavity only
• 4)MP470 + XRT
Results: A549 NSCLC cells grown in low level Erlotinib are shown 
to rapidly over express c-Met with a 41 fold induction. Using colony 
assays MP470 was shown to act as a radiation sensitizer and this ef-
fect was increased with pretreatment of an EGFR inhibitor (Erlotinib) 
from 72% to 96% cell kill. Xenograft models were used to evaluate 
the in vivo response, and we compared the total number of tumors 
present at 5 weeks after implantation. Control animals had an average 
of 12 tumors, both the MP470 and XRT alone had 15 tumors, while 
the combination of MP470 + XRT had 6 tumors (p=0.13).
Conclusions: C-Met is a pro survival gene providing resistance to 
various cytotoxic therapies and is upregulated in response to anti-
EGFR based therapies. The small molecule inhibitor, MP470, has 
been shown to inhibit the tyrosine kinase activity of c-Met. MP470 
reduced clonogenic potential which is enhanced when used concur-
rently with radiation. Cells pre-treated with Erlotinib before MP470 
demonstrated further radiosensitization compared to native cells. 
Animal studies have confirmed radiosensitization in vivo and MP470 
appears to be very well tolerated in animals, at doses up to 800mg/kg. 
Based on these preliminary results Phase I human trials were started. 
1. Yang Y, Wislez M, Fujimoto N, et al. A selective small molecule inhibitor of c-Met, 
PHA-665752, reverses lung premalignancy induced by mutant K-ras. Mol Cancer 
Ther 2008;7:952-960.
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Non-resected NSCLC: Primary tumor size - radiation dose 
related, accelerated, twice daily radiotherapy, preceded by 
2 cycles of chemotherapy: Update of a prospective study
Wurstbauer, Karl1; Deutschmann, Heinz1; Kopp, Peter1; Kranzinger, 
Manfred1; Merz, Florian1; Schöller, Helmut1; Studnicka, Michael2; 
Sedlmayer, Felix1
1 University Clinic of Radiation Oncology, Salzburg, Austria; 2 
University Clinic of Pneumology, Salzburg, Austria
Background: Besides raising the treatment dose a short overall treat-
ment time seems to be crucial for a successful radiation therapy of 
patients with non-resected NSCLC.
Ensuing a phase I trial of accelerated, twice daily high dose radio-
therapy showing good tolerability, in order to determine the required 
dose, a prospective study relating primary tumor size with radiation 
dose was started.
Methods: From 1/2004 until 12/2008 131 patients with 134 histo-
logically/ cytologically proven tumors were enrolled: Stage I: 32 
patients.; II: 7 pts.; IIIA: 54 pts.; IIIB: 38 pts. Weight loss >5%/3 
months: 32 patients. M/f = 99/32. Squamous cell carcinomas, 
adenocarcinomas and NSC-not otherwise specified in 86, 33 and 15 
patients, respectively. 
We formed 4 groups with primary tumor sizes (mean number of 3 
perpendicular diameters) <2,5; 2,5-4,5; 4,5-6,0; >6,0 cm (n = 23 / 
74 / 25 / 12, respectively); tumor doses of 73,8, 79,2, 84,6 and 90,0 
Gy (ICRU) were applied to the primary tumors of the patients in the 
respective groups. Single doses 1,8 Gy, twice daily, interval 11h; 5 
days/week; duration 32 days median (range 29-42). To macroscop-
ically involved nodes 59,4 Gy median (range 54,0-75,6 Gy) were 
given, to nodes electively 45,0 Gy (to sites about 6 cm cranial to 
apparently involved nodes). 
For the majority of patients the conformal target splitting technique 
has been employed. In order to reduce internal margins slow planning 
CTs (4 sec./slice) were used, patients freely breathing, with 7 mm 
margins from GTV to PTV. 
In 82 patients in median 2 cycles chemotherapy before radiotherapy 
were given, concurrent chemotherapy was not applied.
Median follow-up of all patients 16,5 months (2,5-64), of patients 
alive 16,8 months.
Results: To 96% of the patients the intended dose has been applied. 
Until now 19 local recurrences occurred (0/23, 11/74, 5/25, 3/12 in 
the respective groups) with an actuarial local tumor control rate at 3 
years of 74%. 7 regional recurrences were observed (4 in previously 
therapeutically treated sites, 3 in previously not treated areas). 
The actuarial overall survival rate at 2 / 3 years is 54% / 39%, 
respectively, the median overall survival time 26,0 months. For IIIA-
N2 patients (n=51) the median survival amounts to 46,3 months.
2 treatment-related deaths occurred 5 and 6 months after the end of 
radiotherapy, respectively: pulmonary fibrosis (in the pretherapeutic 
CT scans of both patients clear signs of existing pulmonary fibrosis 
were visible). Pneumonitis grade 3: 5 patients. Esophagitis grade 1, 2, 
3 in 32, 9 and 7 patients, respectively. No late toxicity >grade 1 was 
observed. Most of the patients show local fibrotic pulmonal altera-
tions, which in no patient surpassed scoring grade 1 (mild symp-
toms).
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Conclusions: Accelerated, twice daily applied radiotherapy using the 
technique of target splitting, relating the dose (73,8 – 90,0 Gy) to the 
primary tumor volume seems to be highly efficient in regard of loco-
regional tumor control and survival. Generally it is well tolerated, but 
patients with preexisting pulmonary fibrosis must be excluded. Nodes 
need not to be treated with doses as high as primary tumors.
P3.243 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Serial radiographic changes on CT for long survivors after 
carbon ion radiotherapy
Yamamoto, Naoyoshi; Baba, Masayuki; Nakajima, Mio; Miyamoto, 
Tadaaki; Kandatsu, Susumu; Yoshikawa, Kyosan; Mizoe, Jun-etsu; 
Kamada, Tadashi; Tsujii, Hirohiko
National Institute of Radiological Sciences, Chiba, Japan
Background: Concerning the change of tumor shadow and the 
pulmonary response after radiotherapy for non-small cell lung cancer, 
a number of studies have been reported, but only few studies have 
been conducted base on long-term observation after radiotherapy. In 
order to evaluate the characteristics of changes in tumor shadow on 
CT images and the pulmonary response after carbon ion radiotherapy 
(CIRT) for non-small cell lung cancer, we examined the CT images 
for those with long-term local control and evaluated if there were any 
changes in the shadow at the tumor site on CT before and after CIRT.
Methods: In our institute, 69 patients received CIRT more than 8 
years ago with a total dose of 72.0 GyE given in 9 fractions. Among 
them, we selected 27 cases who survived 5 years or longer and were 
judged as free of local recurrence, for whom changes in the shadows 
at the tumor site were analyzed on CT scans before and after CIRT. 
CT images were taken immediately after CIRT or up to 1 month, after 
3–4 months, after 6–8 months, after 12 months, and every 6 months 
thereafter. The CT scans were performed with the slice thickness of 
3 mm, the slice interval of 3 mm, the window width of 1600, and the 
window level of -600 to -550.
Results: The change of the shadow was categorized into four pat-
terns: A) those in which a shadow on CT immediately after irradia-
tion was larger than before the irradiation, thereafter continued to 
enlarge, and then fixed (3.7%); B) those in which the shadow became 
smaller on CT immediately after the irradiation and then fixed in 
an unchanged form (11.1%); C) those in which the shadow became 
smaller on CT immediately after the irradiation, then the shadow 
temporarily enlarged, and again the shadow became smaller and 
fixed (18.5%); and D) those in which the shadow became smaller on 
CT immediately after the irradiation, then the shadow temporarily 
enlarged, thereafter fixed in an unchanged form (66.7%).
Regarding the aforementioned changes of the shadow, it was an aver-
age of 11.2 months (2.0–36.5 months) after CIRT when the tumor 
shadow and a pneumonitis shadow merged to form a larger shadow. 
Furthermore, the period until the shadow became smaller or the 
period until shadow enlargement was no longer found averaged 15.4 
months (4.7–46.7 months) after the CIRT. In 23 of 27 cases (85.2%), 
the shadow was fixed within 2 years; while in the remaining 4 cases, 
the shadow was fixed within 2 to 4 years. In 18 cases (66.7%), the 
size of the fixed shadow was larger than that of the tumor before 
CIRT.
Conclusions: In most cases examined, the changes in the shadows 
on CT tended to fix within 2 years after CIRT. This finding appeared 
useful for estimating the local control in the follow-up after CIRT.
P3.244 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Four-dimensional computed tomography-based 
pulmonary ventilation imaging for adaptive functional 
guidance in radiotherapy
Yamamoto, Tokihiro1; Kabus, Sven3; von Berg, Jens3; Lorenz, 
Cristian3; Mittra, Erik S.2; Quon, Andrew2; Loo, Billy W.1; Keall, 
Paul J.1
1 Department of Radiation Oncology, Stanford University School of 
Medicine, Stanford, CA, USA; 2 Department of Radiology, Stanford 
University School of Medicine, Stanford, CA, USA; 3 Department of 
Digital Imaging, Philips Research Europe, Hamburg, Germany
Background: It is theoretically advantageous to include information 
of pulmonary function, i.e., ventilation (the subject of this study) or 
perfusion, during radiotherapy treatment planning for lung cancer to 
preserve the lung function. The purpose of this study is to develop 
and investigate adaptive radiotherapy using an emerging ventilation 
assessment technique based on four-dimensional computed tomog-
raphy (4D-CT).
Methods: Adaptive radiotherapy based on 4D-CT-derived ventila-
tion images begins with a routine acquisition of 4D-CT scans for 
treatment planning purposes. A ventilation image is derived by a 
deformable image registration (DIR) algorithm for calculating a 
displacement vector field (DVF), and the subsequent analysis of a 
DVF to compute local volume change (i.e., ventilation). In this study, 
we determine the appropriate class of DIR algorithm and metric by 
comparison with the ground truth ventilation image acquired by the 
single photon emission CT (SPECT) ventilation/perfusion (V/Q) 
scan. Treatment plans are created using original 4D-CT images along 
with ventilation images so that doses to functional lungs are reduced. 
Additional 4D-CT scans are acquired during treatment to observe the 
temporal change in ventilation and to adapt radiation treatment deliv-
ery throughout the course of treatment. Thus, we also investigate the 
temporal change in ventilation and ventilation image-based adaptive 
radiotherapy based on multiple 4D-CT scans.
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Results: Preliminary results demonstrated that different classes of 
DIR algorithms yielded DVFs resulting in spatially variant ventila-
tion images. Validation studies against SPECT V/Q scans are ongoing 
on ten patients with lung cancer under IRB-approval. We created 
intensity-modulated radiotherapy (IMRT) and volumetric modulated 
arc therapy (VMAT) treatment plans with and without 4D-CT-derived 
ventilation information. Ventilation image-based treatment plans 
showed reduction in doses to functional lungs whilst keeping a good 
target coverage and low doses to other critical organs.
Conclusions: The 4D-CT-based approach potentially can yield venti-
lation images more quickly, cheaply, with higher spatial and temporal 
resolution, and with more availability than nuclear medicine or mag-
netic resonance techniques. However, our preliminary results clearly 
indicated the need for the further studies to validate its physiological 
accuracy. An appropriate class of DIR algorithm and metric will be 
determined through comparison between ventilation images derived 
from 4D-CT and SPECT V/Q scans. Based on multiple 4D-CT 
studies, we will also test the hypotheses: (1) ventilation significantly 
changes in association with tumor regression and (2) ventilation 
image-based adaptive radiotherapy significantly reduces doses to 
functional lungs compared to other radiotherapy schemes.
P3.245 Radiotherapy, Mon Aug 3 – Tue Aug 4 
The registration of diagnostic versus planning FDG PET-
CT in radiotherapy planning for Non- Small Cell Lung 
Cancer
Yap, Mei Ling 1; Vinod, Shalini1, 2; Ho-Shon, Ivan3; Fowler, Allan 1; 
Lin, Michael3; Gabriel, Gabriel2; Holloway, Lois1
1 Cancer Therapy Centre, Liverpool Hospital, Sydney, NSW, 
Australia; 2 University of New South Wales, Sydney, NSW, Australia; 
3 Department of Nuclear Medicine, Liverpool Hospital, Sydney, NSW, 
Australia
Background: The use of FDG PET-CT fusion in the radiotherapy 
planning process for non-small cell lung cancer (NSCLC) is becom-
ing more prevalent. However, there are a number of controversies 
regarding its application, including the accuracy of registration of the 
FDG PET-CT scan to the radiotherapy planning CT scan. Further-
more, it remains unknown as to whether the incorporation of a plan-
ning FDG PET-CT scan conducted in the treatment position results in 
more accurate registration than with a diagnostic FDG PET-CT scan. 
This study aims to quantify the degree of misregistration of the CT 
component of the planning FDG PET-CT (pCT) and CT component 
of the diagnostic FDG PET-CT (dCT) to the radiotherapy planning 
CT (rCT).
Methods: This study included patients with stage I to III NSCLC 
(based on conventional imaging and FDG PET-CT) who underwent 
a radiotherapy planning CT scan (rCT). Immediately following this 
they underwent a FDG PET-CT (pCT) in the radiotherapy treatment 
position. All patients had previously undergone a diagnostic FDG 
PET-CT (dCT) at their original time of presentation. The dCT and 
pCT were registered to the rCT using a rigid body mutual informa-
tion algorithm, with manual adjustment performed if required. Four 
blinded observers (2 radiation oncologists and 2 nuclear medicine 
physicians) identified a series of anatomical points on each scan and 
differences in the absolute location of these points was analysed 
using the rCT as the reference standard. T-test and comparison of the 
means were used to examine the differences between the registrations 
and calculate the p value. SPSS version 17 was used in the analysis.
Results: At the carina, there was a smaller mean absolute error 
(MAE) for pCT-rCT compared to dCT-rCT, 4.37 vs 5.73mm respect-
ively (p=0.028). Comparison of other anatomical points revealed sim-
ilar small differences although these were not statistically significant. 
The MAE for pCT-rCT compared to dCT-rCT, for all points, was 4.11 
vs 4.15mm and RMSE was 4.40 vs 4.48 mm. (p=NS). Inter-observer 
variability was minimal, with the range of mean MAE for pCT-rCT 
being 0.64mm across the four observers.
Conclusions: The degree of misregistration between fused PET-CT 
and planning CT images, on average 4mm, must be taken into con-
sideration when defining target volumes for radiotherapy treatment 
using PET-CT planning. The registration of dCT to rCT and pCT 
to rCT is not significantly different, suggesting the usefulness of 
diagnostic PET-CT in radiotherapy planning, particularly for centres 
without access to onsite PET-CT machines.
P3.246 Radiotherapy, Mon Aug 3 – Tue Aug 4 
Accelerated hypofractionated radiotherapy for Non Small 
Cell Lung Cancer: pooled results from 4 UK centres
Din, Omar S.1; Harden, SV2; Hudson, E.3; Mohammed, N.4; 
Pemberton, L.1; Lester, JF3; Biswas, D.2; Magee, L.2; Tufail, A.4; 
Carruthers, R.4; Sheikh, G.4; Gilligan, D.2; Hatton, MQ1
1 Dept. of Clinical Oncology, Weston Park Hospital, Sheffield, UK; 2 
Dept of Oncology, Addenbrookes Hospital, Cambridge, UK; 3 Dept. 
of Clinical Oncology, Velindre Hospital, Cardiff, UK; 4 Beatson West 
of Scotland Cancer Centre, Glasgow, UK
Introduction: A variety of radical radiotherapy regimens are in use 
for non-small cell lung cancer with the accelerated hypofractionated 
regimen of 55Gy in 20 daily fractions over 4 weeks being the most 
commonly used in the UK (Price). This regimen has not been valid-
ated through randomised phase III trials and the purpose of this audit 
was to pool together existing data from 4 UK centres producing the 
largest series documenting the use of this schedule in routine practice.
Methods: 4 UK centres (Cambridge, Cardiff, Glasgow and Shef-
field) has used a common database to combine experience for this 
retrospective review. Anonymous patient demographics, tumour, 
radiotherapy and survival data were collected from the case notes 
and radiotherapy records of radically treated patients between 1999 
and 2007. Statistical analysis for survival was performed using 
Kaplan Meier methodology. Univariate and multivariate analyses 
were performed with the log rank test and the Cox regression model 
respectively.
Results: 609 patients were identified of whom 98% received the 
prescribed dose of 55/20. 62% were male with a median age of 71.3 
years (range 33-89). 90% had histologically confirmed NSCLC, 40% 
being squamous cell. 49% were treated for stage I disease and 27% 
had received a combined chemo-radiotherapy treatment. The median 
overall survival from time of diagnosis was 24.0 months with a 2 
year overall survival of 50%. 
Conclusions: These data shows an encouraging survival, for NSCLC 
patients treated with this accelerated hypofractionated radiotherapy 
regimen in routine practice. However, further improvements are 
needed to gain better local control and outcomes for various (chemo-) 
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radiotherapy fractionations need to be directly compared in the set-
ting of a randomised controlled trials. 
Price A. Results of a survey of UK clinical oncologists. Presented at 
the Medical Research council; 2001.
Supportive and Palliative Care
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Patients’ preferences and expectations for follow-up after 
lung cancer treatment.
Duffy, Mary1; Carey, M2; Dryden, T1; Ugalde, A1; Krishnasamy, M1
1 Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; 2 
The Cancer Council Victoria, Carlton, VIC, Australia
Background: There is no robust evidence to indicate the most ap-
propriate models of follow up care for patients who have completed 
treatment for lung cancer.
Aims: The aim of this pilot study was to assess lung cancer patients’ 
expectations and preferences for follow-up care in order to inform 
future service delivery.
Method: An exploratory, descriptive study. Thirty-one patients who 
had completed treatment for primary lung cancer were recruited at a 
specialist cancer centre. An 18 item self-report survey was developed 
from relevant literature and multidisciplinary review to elicit patient’s 
preferences and expectations for follow up. Participants completed 
the 18 item survey and the EORTC QLQ30 questionnaire and lung 
cancer add-on module.
Results: The most important factors, scored as extremely important 
by over 80% of respondents, focused on care coordination. These 
included, 1) being able to see the same doctor or health care profes-
sional at each visit (24/83%); 2) knowing which doctor or nurse to 
contact if queries arise between visits (23/82%); and knowing the 
patient can book an appointment or contact a health care profes-
sional involved in their care regarding health concerns between visits 
(25/89%). Patients were supportive of nurse-led (21/78%) follow 
up when offered in the context of a model of shared care with their 
cancer specialist.
Conclusion: This study offers new insight into the expectations and 
preferences for follow up of patients with lung cancer. This pilot 
will inform the development of a larger study on the coordination of 
follow-up care.
P3.248 Supportive and Palliative Care, Mon Aug 3 – Tue Aug 4 
The efficacy of integrated psycho-educational group 
intervention in preventing depression in progressive lung 
cancer patients
Futamura, Yohei; Sawa, Toshiyuki; Ishiguro, Takashi; Horiba, Akane; 
Yoshida, Tsutomu; Nagase, Tatsuya; Kanbe, Makoto; Sugimoto, 
Yaeko
Gifu Municipal Hospital, Gifu City, Japan
Background: It is reported that depression and anxiety in lung 
cancer patients tend to aggravate in spite of cancer treatment. There 
is evidence regarding the use of psychosocial intervention to improve 
health related quality of life (HRQOL) in patients with breast or colo-
rectal cancer. To evaluate the efficacy of structured group intervention 
in an acute cancer care setting, a comparative study was performed in 
Japanese patients with progressive lung cancer.
Patients and Methods: Stage III and IV lung cancer inpatients were 
given the opportunity to participate in an educational group interven-
tion lasting 2 weeks (consisting of four 30 minute sessions). The 
intervention had four major components: 1) management of pain 
by oncology pharmacologists, 2) disease profile / health education 
by oncology nurses 3) psycho-oncology / medication by oncology 
psychiatrists and 4) psychological coping skills by psychotherapists. 
Participating patients (intervention group; n =17) and non-partici-
pants (control group; n = 10) were evaluated before and after inter-
vention by means of standardized questionnaires (HADS, L-FACT).
Results: Thirteen of 17 patients completed four course of pro-
grammed intervention. We compared the depression and anxiety 
scores of patients who completed the intervention (n=13), and those 
who did not (dropout patients and the control group) (n=14). In re-
gard to the depression score, there was almost no change in the group 
that completed the program (mean+SD: 7.9+4.3 to 7.5+4.5), whereas 
there was a significant increase (6.7+5.0 to 8.5+5.3, p<0.05) in the 
dropout/control group. Changes in the anxiety scores were insignifi-
cant in the completed group (6.0+3.3 to 5.3+4.6) while there was in-
crease in the dropout/control group (6.7+3.1 to 7.6+4.4). Progression 
of anxiety and depression were high in some particular individuals in 
the control group.
Conclusion: The possibility that interdisciplinary psycho-educational 
group intervention may prevent progression of depression in end-
stage lung cancer patients. The importance of delivering care to 
prevent depression and anxiety in high-risk patients should be further 
investigated.
P3.249 Supportive and Palliative Care, Mon Aug 3 – Tue Aug 4 
Initial Characterization of Menadione Topical Lotion for 
the Prevention and Treatment of Skin Toxicities Associated 
with Epidermal Growth Factor Receptor (EGFR) 
Inhibitor Therapy
Imperiale, S. Michael; Hagey, Anne E.; Silverman, Jeffrey A.; 
Deitcher, Steven R.
Hana Biosciences, San Francisco, CA, USA
Background: Acneform rash is a pervasive, painful, and treatment-
limiting complication of EGFR inhibitor therapy with reported 
incidence rates ranging from 50-100%. Menadione Topical Lotion 
(MTL) is being developed as a targeted treatment for this side effect 
of EGFR inhibitors, of which there are 4 approved agents (erlotinib, 
gefitinib, panitumumab and cetuximab). Menadione has been shown 
to have direct EGF activating activity as well as EGFR and other 
growth factor-related phosphatase inhibitory activity. 
Methods: This Phase 1, placebo-controlled, open-label, modified 
dose-escalation study assessed the bioavailability, safety and toler-
ability of three concentrations (0.05%, 0.1%, 0.2%) of MTL and 
placebo administered BID on face, neck, upper chest and upper arms 
of subjects for 3.5 days in a 7 day cycle over a 28 day period. The 
pharmacokinetic parameters of MTL were assessed in blood and tis-
sue and the major metabolites menaquinone-4 and thiodione were as-
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sessed in blood. Potential response biomarkers p27, p63 and pEGFR, 
were measured in skin.
Results: Twelve normal subjects, 6 male and 6 female, with a 
median age of 43 years (range, 30-52) were entered into the study. 
Plasma drug levels were analyzed and negligible plasma menadione 
concentrations near the lower limit of quantification were observed in 
a small sample of patients. This confirms that topical menadione has 
no meaningful systemic absorption. The most frequent adverse events 
(AEs) potentially related to MTL included skin toxicities of erythema 
and a burning sensation. All AEs were CTC Grade 1 or 2. Immuno-
histochemical analysis of p27, p63 and pEGFR suggest that normal 
skin structure and signaling was not adversely affected by MTL. 
Conclusions: Pharmacokinetic analysis of plasma from MTL treated 
subjects demonstrated no meaningful systemic levels of menadione 
and its major metabolites menaquinone-4 and thiodione. MTL is 
being developed for EGFR inhibitor therapy-associated skin toxicity 
(rash) and is currently under investigation in a Phase 1 study in can-
cer patients receiving EGFR inhibitor therapy. Early data from this 
clinical trial will be presented.
P3.250 Supportive and Palliative Care, Mon Aug 3 – Tue Aug 4 
Risk factors for severe anaemia: a prospective, 
multicentric, observational survey of 645 patients treated 
with first-line chemotherapy (INDEX study)
Hennequin, Christophe5; Asselain, Bernard1; Goldwasser, Francois2; 
Leblond, Veronique3; Casadevall, Nicole4
1 Institut Curie, Paris, France; 2 Hopital Cochin, Paris, France; 
3 Hopital la Pitie Salpetriere, Paris, France; 4 Hotel Dieu, Paris, 
France; 5 Höpital Saint Louis, Paris, France
Aim of the study: To describe clinical, therapeutical and biological 
factors associated to the occurrence of chemotherapy-induced 
anaemia (haemoglobin (Hb) level < 10 g/dl). 
Methods: A French prospective, multicentric, observational survey 
was conducted between November 2007 and March 2008, includ-
ing patients (pts) with lung (n=299), breast (n=114), ovarian (n=68) 
cancer and lymphomas (n=164) treated with first-line chemotherapy 
(CT). All pts were followed during 24 weeks or until prescription of 
erythropoietin-stimulating agents (ESA). Risk factors for anaemia 
were studied by multivariate logistic regression.
Results: In the whole population, 151 pts (23,4%) developed an 
anaemia during the survey; ESA prescription or blood transfusion 
were performed in 340 pts (56,7%) and 73 pts (11,3%) respectively. 
Regarding pts with lung cancer, 66 (22,1%) were females, median 
age was 62 yrs; stage IIIB or IV were 18% and 82% respectively; 
93% received a platinum-based CT. In this group of pts, anaemia oc-
curred in 81 cases (27,1%), ESA was prescribed in 150 pts (56%) and 
39 pts (13%) received blood transfusion. For the whole population, 
risk factors for anaemia were age ≥ 62 yrs, CT including cisplatin and 
initial Hb level < 12 g/dl. 
Conclusion: Occurrence of anaemia, prescription of ESA or blood 
transfusion was roughly identical in the whole population and for pts 
with lung cancer.
Risk factors for CT-induced anaemia in pts with lung cancer will be 
presented during the meeting.
P3.251 Supportive and Palliative Care, Mon Aug 3 – Tue Aug 4 
Palliative care and KAP study among patients and 
Healthcare workers towards Lung cancer in developing 
country
Joshi, Shambhu D.1; Pandit, N2
1 DPHO, Dhangadhi, Nepal; 2 NMC Teaching Hospital, Ktm, Nepal
Background: Nepal is one of the least developing country where the 
prevalence of cancer is increasing.This study shows the knowledge, 
attitude, social support,coping strategies and practices of end-of-life 
care issues of terminally ill lung cancer patients in our region.
Methods: A cross-sectional qualitative study using case studies, 
focus group discussions on providers and recipients of palliative care, 
an open-ended, interviewer administered questionnaire on nurses, 
patients and healthcare professionals.
Results: Most of the nurses could enumerate more than 3 important 
technical elements of end-of-life care. The explanations and counsel-
ling provided by nurses were mostly satisfy the patients and their 
relatives. Of the cancer patients, 19 (95%) desired to use special 
services but were unaware of such facilities.
Conclusion: The knowledge and practices of nurses and healthcare 
professionals were not up to the expectations and requirements of 
terminally ill cancer patients. Curriculum-based learning or organized 
teaching of end-of-life care issues should be updated. Capacity build-
ing for the care of terminally ill cancer patients is urgently required 
in developing country like India and Nepal. This result implies that 
families have important roles for patients and should be educated and 
supported by healthcare professionals especially nurses in approach-
ing patients in a knowing way. In addition to the results, this study 
could be used to help develop nursing interventions and efficient 
coping strategies. Patients may then be able to use the latter to solve 
symptom-associated distresses, consequently enhancing their quality 
of life.
P3.252 Supportive and Palliative Care, Mon Aug 3 – Tue Aug 4 
Exploring The Impacts of Pain on Patients with Lung 
Cancer
Lai, Yeur-Hur; Liao, Yu-Chien
Yuanpei University, Shinshu, Taiwan
Background: Pain is one of the major problems faced by cancer 
patients. However, limited research has explored the different experi-
ences between lung cancer with and without pain. Therefore, the 
purposes of this study were to examine the differences in fatigue 
severity, fatigue interferences, pain catastrophizing thoughts, anxiety 
and depression between lung cancer patients with or without pain.
Methods: A cross-sectional survey study was conducted to recruit 
eligible patients from a medical center in Northern Taiwan. For study 
purpose, we excluded those patients suffered from post-operative 
acute pain. Cancer patients with pain and without pain were recruited 
by trained research nurses. Instruments used to assess patients’ pain 
related experiences included (1) Pain intensity at its worst and in 
average, (2) Brief Fatigue Inventory (BFI), (3) Pain Catastrophiz-
ing Scale (from CSQ), (4) Hospital Anxiety and Depression Scale 
(HADS) and Background information. Data were analyzed by de-
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scriptive statistics, t-test, and correlation analysis. IRB approval and 
patients’ consent were received before data collection. 
Results: A total of 167 lung cancer patients were recruited with 74 
patients (44.3%) having no pain and 93 patients (55.7%) having vari-
ous levels of pain. The major results showed that patients with cancer 
pain had significantly higher average fatigue, worst fatigue, fatigue 
interference, catastrophic thinking, anxiety and depression. However, 
patients in both group had similar and high levels in negative beliefs 
about using opioid analgesics and had beliefs to endure cancer pain. 
Conclusion: Our results showed that lung cancer patients with pain 
had worse experiences in many aspects of pain related experience 
than those without pain. It suggests that cancer pain is still a problem 
having impacts on lung cancer patients’ life. More active interven-
tions to manage cancer pain and build up a more positive belief about 
using opioid analgesics are necessary. 
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Correlation between pain and the Hospital Anxiety and 
Depression Scale (HADs) with emotional symptoms in lung 
cancer patients referred to a Psycho-Oncology Unit.
Leon-Pizarro, Concepcion1; Jovell, Esther1; Blanco, Remei1; Dalmau, 
Elsa2; Garcia, Yolanda2
1 Hospital de Terrassa, Terrassa (Barcelona), Spain; 2 Hospital Parc 
Tauli, Sabadell (Barcelona), Spain
Background: It is well known that pain contributes to increase 
emotional distress in cancer patients, but rarely are assessed in a 
systematic manner. 
Purpose: The main goal of the study is to systematically asses the 
pain and emotional problems experienced by lung cancer patients, 
referred to a Psychooncology Unit to receive psychotherapeutic sup-
port.
Methods: Forty-nine lung cancer patients (37 males, 12 females), 
from three Catalan public hospitals were assessed during the first 
visit to the Psychooncology Unit, in relation to different symptoms 
(pain, mood, anxiety, worry, sadness and fatigue), from January 2005 
until December 2006. The measurement of symptoms was performed 
using a 0-10 scale, and the Hospital and Depression scale (HADs) 
was given at the first visit. The association between “pain” and HADs 
subscales with the same symptoms were evaluated. The level of 
significance for the Pearson’s correlation coefficients analysis were 
set at 5% (0.05).
Results: We found a positive significant moderate association be-
tween “pain” and “fatigue” (r=0.659, p=0.000). A positive signifi-
cant low association was found, also, between “pain” and “mood” 
(r=0.448, p=0.015), and “pain” and “sadness” (r=0.435, p=0.018). 
We have not found significant association between “pain” and 
“anxiety”, “worry” (0-10 scale) nor the HADs subscales ( “Depres-
sion” and “Anxiety”) . Concerning to the HADs subscales we found 
a positive significant moderate association between HAD-Anxiety 
and “anxiety” (0-10 scale) (r=0.555, p=0.009), and HAD-Anxiety 
and “sadness” (r=0.619, p=0.002). We found a positive significant 
low association between HADs-Depression and “worry” (r=0.486, 
p=0.022). The association was moderate between HADs-Depression 
and: “sadness” (r=0.629, p=0.002), or “mood” (r=0.653, p=0.001)
Conclusions: In our study we can conclude that: a) Positive significa-
tive correlation between “pain” and “mood”, “sadness” and “fatigue” 
are shown, and b) We can detect levels of anxiety or depression 
using the HADs indiscriminately both as sadness or mood for HAD-
Depression and HAD-Anxiety or “anxiety (0-10 scale) in the lung 
cancer patients referred to our Psychooncology Unit
Clinical Implication: Reduced emotional distress can impair pa-
tient’s ability to cope with pain. We can use indiscriminately HADs 
or 0-10 scales to detect sadness and anxiety.
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Symptoms, Psychological Distress and Unmet Supportive 
Care Needs in Patients with Lung Cancer
Liao, Yu-Chien; Lai, Yeur-Hur
Institute and gratuate school of Nursing, College of Medicine, 
National Taiwan University, Taipei, Taiwan
Background: Lung cancer is the most life threatened disease world-
wide. Due to the innovation in associated treatment, physical and 
psychological impacts and supportive care needs from the disease 
and the treatment will continue to occur. The aims of this study were 
to examine the symptomology profile, psychological distress and 
supportive care needs by treatment regimens and to identify the deter-
minants of unmet supportive care needs for lung cancer patients.
Methods: A cross-sectional survey was conducted. Valid question-
naires including Symptom Severity Scale, Hospital Anxiety and 
Depression Scale and short form of Supportive Care Needs Surveys 
were applied to assess symptoms, depression, anxiety and five do-
mains of supportive care needs in 156 NSCLC or SCLC patients.
Results: High prevalence of multiple symptoms, psychological 
distress and unmet supportive care needs were found across treatment 
subgroups. Patients receiving chemoradiotherapy and chemotherapy 
had greater symptom severity than the target therapy and follow-up 
without active treatment patients in several specific symptoms. 25.0% 
and 14.2% of subjects achieved clinical depression and anxiety 
criteria, respectively. The highest unmet needs in information and 
health care system and psychological needs were revealed. Logistic 
regression analysis addressed that anxiety (OR= from 1.16 to 1.31, 
95% CI= from 1.03-1.32 to 1.04-1.65) consistently significantly pre-
dicted five domains of unmet care needs. Likewise, symptom severity 
(OR=1.96, 95%CI=1.18-3.27) and depression (OR= .73, 95% CI= 
.59-.91), age (OR=.95, 95%CI=.91-.99), educational level (OR=1.12, 
95%CI =1.018-1.24) and symptom severity (OR=1.54, 95%CI=1.12-
2.13), length since diagnosed (OR=2.95, 95%CI=1.14-7.62) were 
revealed as the significantly determinants of information and health 
care needs, psychological needs, physical and daily care needs, and 
interpersonal and communication need, respectively.
Conclusion: The results suggest that the multidisciplinary care 
model for lung cancer patients should focus on managing the most 
frequent symptoms and psychological distress in terms of treatment, 
and multi-facet supportive cares should be provided to the specific 
subgroups. 
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Psychosocial Oncology and the Care of Lung Cancer 
Patients
Marcus, Joel D.
Cancer Therapy and Research Center at the University of Texas 
Health Science Center San Antonio, San Antonio, TX, USA
Background: Psychosocial Oncology is inclusive of a wide a range 
of services including pain and symptom management, psychological, 
assessment and treatment and assistance with social and financial dif-
ficulties. [1]. Lung cancer has been identified as an oncological dis-
order that results in some of the highest level of distress in compared 
with other cancer patients[2]. Psychosocial interventions have proven 
efficacious for helping patients and families confront the many issues 
that arise during this difficult time[3]. A main goal of the program 
is to provide an infrastructure to deliver better emotional care to 
patients and their families who are dealing with cancer. The Institute 
of medicine report “Cancer Care for the Whole Patient” describes 
the psychosocial needs of patients and families. A recent Mandate for 
Change” from a coalition of European Cancer specialists states: “The 
emotional trauma of being diagnosed with lung cancer and going 
through treatment can be a potentially harmful for the patient as the 
disease itself”.
Methods: Comprehensive care of the cancer patient necessitates the 
integration of psychosocial aspects of care into the overall assessment 
and management plan. A growing body of scientific evidence demon-
strates that the psychological and social (“psychosocial”) problems 
created or exacerbated by cancer (e.g., depression, other emotional 
problems, or a lack of information or skills needed to manage illness) 
can be effectively addressed by a number of services and interven-
tions[4-8].
Results: Cancer care today often provides state-of-the-science bio-
medical treatment, but fails to address the psychological and social 
(psychosocial) problems associated with the illness. These problems 
including patients’ lack of information or skills needed to manage 
the illness; anxiety, depression or other emotional problems; lack of 
transportation or other resources; and disruptions in work, school, 
and family life can cause additional suffering, weaken adherence to 
prescribed treatments, and threaten patients’ return to health. Today, it 
is not possible to deliver good-quality cancer care without addressing 
patients’ psychosocial health needs. All patients with cancer and their 
families should expect and receive cancer care that ensures the provi-
sion of appropriate psychosocial health services. Specific recommen-
dations regarding screening assessment and psychosocial treatment of 
lung cancer patients are reviewed.
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Palliative Care Needs in Patients with Lung Cancer - The 
Importance of Symptom Assessment
Milroy, Robert1; Buchanan, Deans 2; Thompson, Alastair3; Levack, 
Pamela4
1 Consultant Respiratory Physician, Glasgow, UK; 2 SpR in Palliative 
Medicine, Dundee, UK; 3 Consultant Surgeon, Dundee, UK; 4 
Consultant Palliative Care Physician, Dundee, UK
Introduction: Lung cancer is the commonest cause of cancer related 
deaths worldwide. In Britain it accounts for 25% of all cancer deaths. 
The prognosis remains poor with an overall five year survival of 
around 7%. Symptom distress is higher than other cancers and there 
is a large psychosocial burden. Palliative care is now considered to be 
an integral part of lung cancer management. The palliative outcome 
scale (POS) has been developed and validated in several clinical 
settings as a tool to identify and quantify palliative needs. Elevated 
C-reactive protein (CRP) and reduced albumin are associated with 
shorter survival. This study compared respiratory symptoms, CRP, 
albumin and POS in lung cancer patients attending an out-patient 
clinic. 
Methods: 115 patients attending a lung cancer clinic completed a 
questionnaire containing the POS and 3 questions rating the sever-
ity of dyspnoea, cough and haemoptysis. CRP and albumin of each 
patient was measured. 
Results: The presence and severity of dyspnoea, cough and haemop-
tysis were associated with increased palliative needs as measured by 
POS. (POS 0-4 Vs 5-9, p=0.002, POS 5-9 Vs 10-14, p<0.001, POS 
10-14 Vs 15+, p=0.042). Albumin and CRP were not associated with 
POS. 
Conclusion: The symptoms of dyspnoea, cough and haemopty-
sis in lung cancer out-patients are associated with their palliative 
needs. There was no association with albumin or CRP. These results 
emphasise the importance of identifying the presence and severity of 
physical symptoms. This simple approach may allow early identifi-
cation of patients who are likely to benefit from specialist palliative 
care services. 
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The different correlation of Performance Status scale 
with survival time among the main histological types in 
advanced lung cancer patients
Mylonaki, Efrosyni J.2; Voutsas, Vasileios2; Kapetagiorgis, 
Athanasios2; Iordanidis, Fotios3; Antoniou, Dimitrios2; Kontakiotis, 
Theodoros1; Tsara, Venetia2
1 Aristotelian Univercity Pulmonary Clinik, General Hospital ‘G. 
Papanikolaou’, Exohi, Thessaloniki, Greece; 2 2nd Dpt of Chest 
Medicine, General Hospital ‘G. Papanikolaou’, Thessaloniki, 
Greece; 3 Dpt of Pathology, General Hospital ‘G. Papanikolaou’, 
Thessaloniki, Thessaloniki, Greece
Background: The Eastern Cooperative Oncology Group (ECOG) 
score is a well known predictor of survival which impacts on treat-
ment decisions. We correlated the different Performance Status 
(PS) scores with the survival time among the histological types of 
advanced lung cancer patients (pts).
Patients and Methods: 119 pts were involved with newly diagnosed 
advanced Lung Cancer (stage IIIB – IV): 84 NSCLC (35 squamous 
cell and 49 adenocarcinoma) and 35 SCLC, of median age 63,00, 
62,00 and 62,50 years respectivelly and in good Performance Status 
0-1 (WHO).
Median survival time was evaluated for patients with PS 0 and 1 
in the three main histological types and the statistic evaluation was 
performed with Caplan Mayer curves and Breslow test. 
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Results: 
    MEDIAN SURVIVAL TIME
   Patients 95% Confid. Interval BRESLOW TEST
 HISTOLOGICAL TYPE No Estimate St. Error Lower Upper  significance 
     band band
 Sqamous cell carcinoma 0 10 423,00 29,25 365,66 480,33 0,046
  1 25 241,00 54,95 133,28 348,71 p<0,05
  overall 35 360,00 79,24 204,68 515,31 
 Adenocarcinoma 0 14 230,00 56,12 119,99 340,00 0,308
  1 35 200,00 21,28 158,27 241,72 
  overall 49 210,00 20,99 168,84 251,15 
 Small Cell Lung Cancer 0 6 249,00 33,68 182,98 315,01 0,224
  1 29 353,00 41,26 272,12 433,87 
  overall 35 310,00 36,07 239,27 380,70 
It was observed a statistically significant increase of median survival 
time in patients with better PS:0 than those with PS:1 only in the 
histological type of sqamous cell lung cancer. In contrast, for the 
SCLC pts there was a survival benefit of 120 days in PS:1 versus 
PS:0, without any statistically significant difference, obviously be-
cause of the small number of cases with PS:0 (6 pts). 
Conclusions: The better PS, as it was appeared in this group of pts, 
would be a predictive marker for the longer survival of squamous cell 
lung cancer among the other histological types, but there is certainly 
the need of confirmation with a greater number of pts.
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The incidence of hypomagnesaemia comparing two 
magnesium supplement regimens in patients receiving 
cisplatinum-based chemotherapy: an observational study.
Ootes, L. E.1; van der Drift, M. A.1; van den Hurk, D1; Dekhuijzen, P. 
N.2; Timmer-Bonte, J. N.2
1 Radboud University Nijmegen Medical Centre, Groesbeek, 
Netherlands; 2 Radboud University Nijmegen Medical Centre, 
Nijmegen, Netherlands
Background: Cisplatinum-based chemotherapy is frequently applied 
in thoracic oncology. The reported incidence of cisplatinum- induced 
hypomagnesaemia in patients (pts), due to decreased re-absorption 
of magnesium in the kidneys, varies from 29 up to 100%. Supple-
menting magnesium during pre- and posthydration of cisplatinum 
chemotherapy is standard practice, however, the optimal magnesium 
dose is not clear. We observed several cases of hypomagnesaemia in 
our clinic with a standard dose of 15 mmol intravenously (i.v.). We 
postulated that the incidence of hypomagnesaemia might decrease 
with increased suppletion of magnesium. The aim of this pilot study 
was to assess the effect of higher magnesium supplements on the 
incidence of hypomagnesaemia in pts with thoracic cancer receiving 
cisplatinum-based chemotherapy. 
Methods: An observational study comparing 2 magnesium supple-
ment regimens in thoracic cancer pts receiving cisplatinum-based 
chemotherapy was performed. Consecutive pts were assessed, 16 
received 15 mmol magnesium i.v. (group A) and the next 17 received 
60 mmol (group B). After prehydration (1 liter NaCL 0.9% in 3 
hours), cisplatinum was infused (80 mg/m2 in 1 hour) followed by 
2 liters NaCl 0.9% posthydration in 6 hours. Electrolytes and renal 
functions were assessed at least 3 weekly before start of the next 
cycle. Adverse events were assessed according to CTC criteria.
Results: Of the pts included 23 suffered from non-small cell lung 
cancer, 7 from small cell lung cancer and 3 pts from mesothelioma. 
The incidence of CTC grade 1 hypomagnesaemia (i.e. <0.70 mmol/l) 
was 8/16 (50%) and 7/17 (42%) in group A and B, respectively. 
Median magnesium levels were 0.75 mmol/l (range 0.43-0.96) and 
0.80 mmol/l (range 0.53-0.95) in group A and B, respectively. In 
group A, hypomagnesaemia was observed after the first cycle in 5 out 
of 7 pts, while in group B hypomagnesaemia after cycle 1 occurred 
only in 2 out of 7 pts and after cycle 2 in 4 out of 7 pts. The number 
of patients receiving magnesium supplements, either orally or i.v., at 
any point during chemotherapy was comparable in both groups.
Conclusion: This pilot study demonstrates that the incidence of 
cisplatinum-induced hypomagnesaemia is comparable, despite an 
increase of routine magnesium suppletion from 15 mmol to 60 mmol. 
The clinical benefit of a higher magnesium dose during hyperhy-
dration seems limited as the incidence of hypomagnesaemia was 
comparable. However, our data suggest that a higher magnesium dose 
during hyperhydration might postpone the occurrence of hypomagne-
saemia during chemotherapy. 
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Lung cancer sufferers issues: Lethargy/Fatigue 
Assessment/management by Indian cancer NGO
Sankpal, P D.1; Salgokar, R N.1; Vaishali, P S.2
1 Health Alert Organization Of India [Ngo], Dhule, India; 2 Public 
Health BMC, Mumbai, India
Objective: Lethargy poorly understood in Lung-cancer-sufferers. 
Our Non-Govt-Organization determined frequency/severity of 
fatigue in lung-ca-cases & analyzed role of complimentary-system-
medicine[CAM] to reduce fatigue in lung cancer sufferers. 
Methods: 162 Patients with lung-ca who returning to villages after 
Rx in city-hospitals evaluated for fatigue, mean period 18 wks. 76% 
males, 24% females. 143 completed study of 36 weeks by question-
naires for QOL. 
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Results: QOL in advanced lung-ca significantly-better after addition 
of anabolics. patients three groups: [A]43%those with advanced-
lung-cancer diagnosed for >1 year[B]27% on active therapy. [C] 
diagnosed with metastasis & on palliative care. During survey seven 
psychotherapy-camps conducted by our NGO for better QOL guid-
ance/follow-up. 82% suffered fatigue. 69% patients experienced 
more fatigue after chemo than surgery alone. CAM gave relief but 
needs evaluation for scientific benefits. Lung cancer patients received 
Hypnotherapy [34%], Bach flower remedy [11%], acupressure/
acupuncture [69%] . 11 patients didn’t take any recourse suffered 
more from fatigue/muscle-lethargy. The duration of therapy had no 
influence on incidence, severity of fatigue. Significant reduction in 
fatigue, weakness, willpower with CAM-Rx.. 
Lessons learned: Lung-Ca sufferers from developing-nations 
neglected due to poor prognosis & poor socio-economics with no pal-
liative/supportive care to speak of. Resources permit we plan to bring 
more data of use of CAM in reducing fatigue Still We have taken lead 
on this supportive care issue of lung cancer sufferers. We share find-
ings with researchers from western nations at 13th WCLC-congress. 
We carry back IASLC-2009 congress knowledge back in our country 
to improve QOL of lung-ca-sufferers
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Lung Cancer- support services in resource poor 
nations: recommendations by Indian NGO. [Non-Govt-
Organizations]
Sankpal, P D.1; Salgokar, R N.1; Vaishali, P S.2
1 Health Alert Organization Of India [Ngo], Dhule, India; 2 Public 
Health BMC, Mumbai, India
Background of current Project: Counseling & pain management 
as part of supportive care service for lung cancer-sufferers facili-
ties limited to Indian city hospitals. Especially cancer-sufferers who 
return to villages after chemotherapy needed this assistance. Nurses 
with volunteers from NGO’s play key role in psychosocial-support/
pain-management. Our NGO Project aimed to organize nursing 
personals to give better & cost-effective palliative-support-services in 
rural India.
Methods: We mobilized training resources from local Indian Health-
centers. Primary Training in supportive care imparted to nurses. 
Team consisted social worker & nurses trained by physician. Local 
traditional faith-healers & nurses involved for more community ac-
ceptance/participation. Seven nurses & 10 volunteers trained till now. 
Aim to provide physical-comfort to patient, improve relationship 
with family members. for terminal cancer diseases, gradually we pre-
pared patient/family for death with dignity. Psychologists managed 
pain & broke bad news of lung cancer status to family. Discomfort/
anxiety due to diagnosis decreases overall treatment efficacy. Patients 
enrolled during community out-reach-programs. Data collected on 
feedback-questionnaire. Most difficult tasks is discussing end of life 
issues” [telling diagnosis/its outcome, managing respiratory distress 
& pain in terminal cases]. 
Results: Supportive care be made more accessible in rural-areas of 
resource poor nations.. Our NGO approach of in-house training is 
also very cost-effective. Due to non-availability of trained-oncol-
ogists in rural areas this approach helps. We noted 95% responded 
favorably to counseling/nursing care, 60 % showed willingness to 
motivate fellow lung cancer-patients to facilitate supportive-care-
program of NGO-volunteers. Infact 8 patients themselves became 
regular active facilitators in our NGO’s cancer-care workshops. 
Our Holistic approach helped overcome hopelessness/fear depres-
sion. Pain management/supportive care emerged very serious issue 
affecting QOL. Cancer-NGO’s need Improved access to specialized 
training/CME’s to improve supportive care services.
Recommendations/Conclusion: In no extra cost nurses perform 
good job of Counseling & pain-management. Restricted resource-
limitations didnot permit us to take study large-sample-size, but 
we can collaborate with seniors at 13th WCLC congress 2009 for 
expanding such efforts. Our approach most suitable to resource-poor-
settings. Our Projects step-wise functioning showed graphically at 
IASLC-congress-venue.
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The role of caregivers during lung cancer diagnostics and 
treatment
Schook, Romane M.1; Hoek, van, Rosalinda C.2; Stegenga, Marije2; 
Lammers, Ernst3; Weenink, Carla4; Linssen, Cilia2; Postmus, Pieter 
E.1
1 VU University Medical Center, Amsterdam, Netherlands; 2 Lung 
Cancer Information Center: Longkanker Informatiecentrum, 
Baarn, Netherlands; 3 Gelre Ziekenhuizen, Zutphen, Netherlands; 4 
Kennemer Gasthuis, Haarlem, Netherlands
Background: It is known that patients’ caregivers play an important 
role in the life of chronically ill patients. The specific roles played by 
lung cancer patients’ caregivers have not been investigated yet.
Study Aim: The objective of this study was to acquire more insight 
in the role of caregivers of lung cancer patients during lung cancer 
procedure by means of combined points of view of patients, pulmon-
ary physicians and caregivers themselves.
Methods: Newly diagnosed lung cancer patients and their families 
from 3 different hospitals in the Netherlands were included in this 
study. Patients and caregivers have been -after consent- interviewed 3 
times and pulmonary physicians once or twice at different time points 
during lung cancer procedure (at diagnosis, one month after diagnosis 
and 3 months after diagnosis). The used semi-structured interviews 
contained questions concerning decision making, caregivers’ roles 
and information seeking behaviour.
Results: Sixteen patients have been approached for this study, 2 
patients dropped out early. Twenty seven caregivers have been 
interviewed and 22 interviews of health care providers have been 
collected.
The most important role played by caregivers is to be present for 
patients. They show interest, they support and take care of them. The 
contact becomes more intensive during illness. It is the most intense 
directly after diagnosis and decreases in time. At time of diagnosis, 
the role of caregivers becomes clear and remains the same during 
procedure.
Life partners fulfil a specific role as they take over all duties patients 
are not able to do anymore. This seems to be a compensation behav-
iour. Relatives feel urged to be useful, expressing their powerlessness 
dealing with cancer, as they can not control it. This urge can have 
advantages (caregivers alert the physicians earlier) and disadvantages 
(patients or physicians experience this behaviour as excessive).
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Caregivers look more often for information than patients. If a patient 
asks relatives to look for information, usually one person is desig-
nated. This person is frequently someone working in healthcare. The 
information need is the highest at diagnosis and decreases during pro-
cedure, as patients and caregivers become familiar with the hospital 
and treatment, and receive or look for information themselves.
Patients and caregivers do not feel they have a choice once a diag-
nosis is made. Therapy is the only option to them. The option not to 
treat is also not often being discussed by physicians, although they 
think they do list all different treatment and non-treatment options.
Patients and caregivers state that the most influent person on treat-
ment decisions is the patient himself. However, most of them say to 
follow their physician’s advice and to discuss the decision together. 
Caregivers influence patients’ decisions by means of emotional pres-
sure.
Physicians usually encourage the presence of caregivers during con-
sultations but do not always know their identity and role. This is often 
due to inadequate communication. 
Conclusions: A patient is not alone during lung cancer treatment. 
Caregivers play in important role in patient care. Health care pro-
viders are not used to caregivers and should take them more into 
account. 
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Quality of Life during chemotherapy in Elderly (> 75 
years) versus younger NSCLC Patients 
Sorensen, Jens B.; Talibi, Monica; Jensen, Soren A.
Dept. Oncology, Finsen Centre/National University Hospital, 
Copenhagen, Denmark
Purpose: To examine the quality of life (QoL) changes in very 
elderly patiens (age>75 years) with advanced Non-Small-cell-Lung-
Cancer (NSCLC) when treated with first line palliative chemotherapy 
compared to that of younger patients.
Methods: The patients where divided into three groups, group A 
were <70 years, group B were between 70-75 years and group C were 
>75 years. Treatment consisted was carboplatin and vinorelbine for 4 
to 6 courses dependent on response to treatment.
The QoL were assessed using the European Organisation for Re-
search and treatment of Cancer (EORTC) Quality of Life-Core 30 
questionnaire (QLQ-C30) module and the Lung Cancer specific 13 
item questionnaire (LC-13). The questionnaires were collected at 
baseline and after each treatment course. The focus were on the ques-
tions concerning QoL, role and emotional functioning (anxiety and 
feeling depressed), fatigue, dyspnoe, cough and chest pain.
Results: A total of 53 patients (group A=26 patients, B=15 patients 
and CE=12 patients) participated. There were no differences in 
pre-treatment characteristics such as gender, histologic subtype, 
performance status, weight loss or stage. Analyses on all 53 patients 
revealed no statistic significant variation between baseline and after 
2-4 courses of chemotherapy except for the scores on emotional 
functioning (p=0.0001) which increased and cough (p=0.0001) which 
decreased.
Comparison of the EORTC questionnaires at baseline within the three 
age groups discovered that a significant difference appeared only for 
overall QoL (p=0.04), fatigue (p=0.004) and chest pain (p=0.04). 
The effect on chemotherapy among the A, B, and C groups differed 
significantly with respect to QoL (p=0.0001), fatigue (p=0.004) and 
cough (p=0.04). QoL increased for group A and declined for group C 
during treatment. No change appeared for group B. Especially group 
C experienced increased fatigue during treatment, while group B also 
reported on more fatigue though to a lesser degree. The opposite were 
the case for the group A. Cough decreased during treatment for the A 
and B group, while no change occurred in the C group.
Conclusion: The elderly patients above 75 years with inoperable 
NSCLC tolerate palliative chemotherapy less good than younger 
patients below 70 years of age and also a little less then patients aged 
70-75 years. It is however known from other studies that the elderly 
has similar or better outcome with respect to response rate and sur-
vival.
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Targeted therapy at the end of life of lung cancer patients
Wong, Alvin S.1; Teo, Catherine1; Lim, Siew-Woon2; Chan, Noreen1
1 Department of Haematology Oncology, National University 
Hospital, Singapore; 2 Pharmacy Department, National University 
Hospital, Singapore
Background: Targeted therapy with Epidermal Growth Factor 
Receptor (EGFR) tyrosine kinase inhibitors (TKIs) has become stan-
dard treatment in a variety of settings in non-small cell lung cancer 
(NSCLC), particularly in Asians. We wanted to characterize the use 
targeted therapies in relation to the end of life in our NSCLC patients. 
Methods: Data of NSCLC patients was extracted from an ongoing 
retrospective study on “aggressiveness of care at the end of life” 
involving adult patients with advanced solid tumors who died as 
inpatients under the Department of Hematology Oncology, National 
University Hospital, Singapore. Information on patients’ diagnoses, 
investigations and treatments in the 3 months before death was ob-
tained from hospital records. 
Results: Among patients who died between July 2007 and September 
2008 we identified 53 NSCLC patients for inclusion in this analysis. 
Patient characteristics: Median age 67 (44-90), Chinese/Malay/Indian 
47/4/2, male/female 38/15, smokers/non-smokers/unknown 27/13/13. 
Histology: adenocarcinoma 35 (including 3 with bronchioloalveo-
lar carcinoma component), squamous-cell carcinoma 6, NSCLC 
unspecified 6, others 4, not available 2. 22 patients (42%) were 
receiving at least one systemic anti-cancer drug in the last 3 months 
of life, of which 21 patients (40%) were receiving targeted agents. 
Of these 21 patients receiving targeted drugs: 17 received 1 drug, 3 
received 2 drugs, and 1 received 3 drugs. Gefitinib was prescribed 
in 12 patients and erlotinib 6 (including 2 receiving gefitinib then 
erlotinib, 1 erlotinib with sorafenib, 1 gefitinib with rapamycin). 6 
patients received investigational agents on clinical trial. 1 patient was 
receiving gefitinib rechallenge followed by erlotinib rechallenge. 13 
patients had at least 1 line of targeted therapy initiated within the last 
3 months of life, including 5 as 1st line, 7 as 2nd line, and 1 each as 
6th, 7th and 8th line systemic therapies. The median time from the 
last prescription of targeted agent to death was 21 days (range 5-89 
days). Targeted therapy was the last line of treatment before demise 
in 20 patients. 
Conclusion: We found a high number of NSCLC patients receiv-
ing targeted agents close to the end of life. The convenience of oral 
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EGFR TKIs coupled with their low toxicity, are factors which may 
promote a ‘last gasp’ attempt at disease control, despite the cost.
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A simple versus complicated analysis of quality of life 
(QOL) data for non-small cell lung cancer (NSCLC)
Zee, Benny C.; Mo, Frankie; Mok, Tony
Chinese University of Hong Kong, Shatin, Hong Kong
This study is to evaluate two different approaches to analyze qual-
ity of life data in a randomized Phase II trial setting for patients 
with stage IIIB or IV NSCLC. Eligible patients were randomized 
to receive gemcitabine plus cisplatin (GP) or gemcitabine plus oral 
etoposide (GE). We used the official translated Chinese version 
of European Organization for Research and Treatment of Cancer 
(EORTC) Quality of Life Core Questionnaire (QLQ-C30) as well as 
Lung Cancer Modules (QLQ-LC13) in Chinese patient population. 
The simple statistical approach called the QOL Response method was 
used and a more complicated approach was the modified generalized 
estimating equation (GEE) under the pattern mixture model (PMM). 
The QOL Response method summarized the longitudinal QOL data 
into a QOL response variable. This approach takes into account longi-
tudinal nature of the data by defining change scores along time and 
a pre-specified clinically significant difference “D” for the change 
score. It summarizes the longitudinal data into a single variable. The 
complicated approach involves using GEE incorporating in a pat-
tern mixture model framework to deal with non-ignorable missing 
data problem. We have carried out simulation study to examine the 
performance of these models for different types of data. The results of 
the simple and complicated approaches will be compared. 
The results show that the GEE is better than GEE-PMM if the data 
have missing values that are missing at random, and GEE-PMM 
is a better choice for non-ignorable missing data. The simple QOL 
Response method also shows similar results as compared to the GEE 
and GEE-PMM approaches. In conclusion, the simple approach is 
sufficient in normal circumstances under randomized trial setting.
